<SEC-DOCUMENT>0001410578-24-000531.txt : 20240425
<SEC-HEADER>0001410578-24-000531.hdr.sgml : 20240425
<ACCEPTANCE-DATETIME>20240424173955
ACCESSION NUMBER:		0001410578-24-000531
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		171
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240425
DATE AS OF CHANGE:		20240424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		24872107

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>cvac-20231231x20f.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 4/24/2024 9:34:48 PM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: 33a3b396-0f14-446b-a4af-305eb2f5253b -->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:cvac="http://www.curevac.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:CurrentFiscalYearEndDate" id="Tc_hFpLeDz9YUK4KnNE2nA8hQ_15_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentFiscalYearFocus" id="Tc_RtpAsUGZL0mr7w4j7TxIAg_16_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentFiscalPeriodFocus" id="Tc_TZKVgll6zESCgS2c-SADCw_17_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityCentralIndexKey" id="Tc_j4caA6F4FU2syRaCZNgrFw_18_1">0001809122</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:AmendmentFlag" id="Tc_wHclw8sDgk-56K3JdLdgEA_19_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tGMjQ13Y6kWsrsTpWJqw_Q" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Hidden_QbGLvVS5SkqjgHf0Brd8Fg">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tieFmpdel06r1eZXxqI5EQ" name="cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" id="Hidden__sfsWKiKEkycy4zRfN1NDQ">P10D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" name="cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" id="Hidden_YzcivET66UycOOg4x0ArdA">P10D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MWzGNMmG1E6v3rQ9gBnpSg" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" id="Hidden_tznxVCWtS0SW9reUKePQUQ">25000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_ZqrduP_DhU-c-0DXXjhxKw" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" id="Hidden_-FWGuI_NEUqdXYeZrX373g">25000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_Cfres-mG-kGSfXOFxQdxag" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" id="Hidden_hL-cJYxbn0-tJ6X_juFSYQ">25000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_xeuiIWVNGkapjrX-CNiEZQ" decimals="4" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_XU_t8pnL4UiX_Hi9qILQtw">0.0033</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_xeuiIWVNGkapjrX-CNiEZQ" decimals="4" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_QYgdAo6NHkmI49zrX7zMAA">0.0033</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="4" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_11RqQzGybUSMAflcteDxJA">0.0033</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="4" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_lI9qMg_ZoEa59Vg_AMB8SQ">0.0033</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvac-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_IVeKC3yvOEugAiflyH3c3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WHDQrxvJz065lEPIjGIWuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_wEcN7ca8EkmDto9rHIMXqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_4y9Rq2Ban029PexLw4uVTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_SzFXrlYIYkGJv5pgzyKXhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_yHk0L5C8gEyXoJw8KYw3Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_dLLTUG3nUkmNAeblyIfEfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_h5bEzTVa3EyxXxcQh-dg1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_n816zTthhUCd928-Xo9B2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WdwXgqTk-0Gz8-5HXgSqZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IF3SAFyRDkmSY9vIIRwRsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_TechnologyMember_hH9UPyIPlEOolWMJj-UurA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember__BM_BXDhyESvodEXrE5DVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember_ihjeHuLIPk2tQ0IJ5csIrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_7ob2rXhv0ECk61hyXNe7kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR__hXio1aUh0yPowZRVEGPEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_OFTLAOtsqkSihsTZpVXK2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tiOKflb2S0qu7_rAt0WFJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_UfCOEGrffUq3abl-fRhxig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DxjsavysM0WLv8Lp8ri1eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_XId6JMRHbEi7pWfMUdRyfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_4BI6yad6zEGqAQHMGJ0Ssw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_sFnkjvJ1RUWEpsQY3dM6qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryLiabilitiesInForeignCurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_1QMTkTTsdkCGavOTm0os4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryAssetsInForeignCurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_Ju4vpITtT02dIgHA1CnNWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_utQHB3ubf0qCXWhEgF-buQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_kxVp_wCgNE6FvnLLR-syMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:CashAndCashEquivalentsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_yLPRccYMQ0WEes48TIb4Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:CashAndCashEquivalentsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DolE5C86p0ekLVQ3PMh3_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_bODM9rD0EUC2RC277AOZlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_ov6PyZWWUUy6kIErGoPNSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_w0ZgcmzTPkCXLtNWBXC5iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_RmJ2ciRZdEmmfIdFfjBrGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_xdnpZEJ2mEWa4sCfDXRnOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_uhnmPrBIeEi3fuQMts_BCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryLiabilitiesInForeignCurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_qzSBjM_s00e_a6TyWqLnUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryAssetsInForeignCurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_2hwJbQ3UHEG7HHhakH5QdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryAssetsInForeignCurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_lmEX-wi5LEW5VEf6oyObmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_XKseGYdQ5U21PwXtFPcggA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_rxt_fxShG0i6GkUMgTzphQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FHdyYMNB7Eq_o5tMRVitmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_k9Skiw6h_kq4wMDfbW6Y1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_BptK40MzA0KOKdTRAaFA1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_v2qH86-io02_ESJqX83O4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_4U9TKa-8kku0qyyWYuN66g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_8jM0YpsBR0yMEEEdxZY0HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_kyYUjNgs7UmP0QeRDTa87w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_MqFywxdSdU-VC2yfCNoI7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_VRui_vZPnUujh6ZiBB2PSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_BjoLbqhzlEu6HrZ0ubsedQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_yBPoJBQs-0OaTLvr_QnFFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_dQAt4xUTeEa7rdqV3nh2dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8UvD_28teUGxzHNuaZqFzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_BtRutl2rT0KKDhuHIfebvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_EJnK4qeQukWwruVzej1OHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3-k7Yjy3h0SK1bXLY0SdIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_zGcglSxVGUO78S8LUIsdFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_EHc6gwQXD0SOYI6THi9OXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_q_oIdOGpA0Sek6pDPz5Now"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_M57Dz1YMN0mNMaEnjl265w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_a1WmAXnod02XXfLywgY6XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BundesministeriumFurBildungUndForschungMember_Bwm_0zYqGkqkxhjgUSGCYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BundesministeriumFurBildungUndForschungMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_pZPakGLA-kuhoS52uwEr1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:GlaxosmithklineCovidAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_ifrs-full_MajorCustomersAxis_cvac_OtherCustomersMember_1iVbqSw630CraOQMAg_n6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">cvac:CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_SxzE48-JZ0GVSklXpGPGZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_7Ew6bGtW7U-tbNE2PXrHEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_oqWek3tQ0kWMDoro7ubGQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_5-Lg5t6vPU2ChcpJcmCALQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_RMBBdxirVU2J7HBkSJTreA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_d3CfPh5Ro06AwvuG4ee_dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_axX3OEHMmkqd9Ok2GiGCCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ETMXkobFKEy02hSV09o2aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Z1OBdDkToEK9908Tmo7-Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_eY2mumkXxUm95YVOlQS_oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:GlaxosmithklineCovidAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_Fzr32Hw5zkuxkQLHVRVGAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_iy1v_ExV0UmIJE_JDCu52A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_9-AN-Kf0kE-sEE04nCFBVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ye3SzgaAhUuYYFA2QScpkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_BNdhSUOAIEaFWRVUEBmbrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_0BY17joY10aei1gwG_rArQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WsnVoqdta0SqDA9Z3Yh5sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_LlIbA19tekq2L6F9XYlTsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_aZBsDHmyoEK9afaiu5dSRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_MM2GgEv-80-KyXB__YMNuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_rZxpRnG9XUK0LeJgU3D9Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8zx9Bh4e0kKH3oVw23ubCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_5WdzkEBG3U2RD2KTauKIHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_8MAty4A8qE6RjZSge37rBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_tqNpKUkXKE2OcFOuv70evw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_beG4kI-_-EObUq60yy9jHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WxiupYvXpUCZcGSWCISs4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_b7TNjQEttE2_PmjG1h3w9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Oxw0JrIpY0G78r49kJmAPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember__cAQp-UsNEC2DWQx2cXz0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_wkd5UtMjWEm5jn5jyWXGGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_8_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ImmaticsBiotechnologiesGmbhMember_8VKq2e-Yh0aBVCNKzz4EmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_H9754yeGbUCITGZy_i1eNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_KF0KEZ_P60OBG3llY8c9rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_vx00BKTjL0C1MH6pWcVznA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_kHeRSiduSE-H2FthCmMR7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GxtzQ5W2qkKKhXTjunpSVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__0Fq4xEc5USvdYA7uwb9kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_5cbrQ8MBFkim2wo7LQxZVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_EGzp-xjlD0SJrQdKTR20uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GVJksEcFyUyKzVpP3nSNNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_K5vleFi0skqHLv2sbuvs-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_swVr7XTCQEqhZkjBon9n_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3YEDZJEcNUCF-BbD2Iw3ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w6XdbSqlp06NSNtoVAqCkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_XfOC2qeC50iUajLNfhbYcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iLzT9AM5F0Gv_MXd0N7WwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GJ80BNA4w02YFSPV325rWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_gVeKYMrm2kqPAEgtA4ctgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ES83sXGGEUiud1LCNDkpvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_SWfFNmCXQkGxOp1OayMWRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3hNl2cG_e0iw0IDtLwg0sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_3Ozy5OoM_EqCMGWp5kzLAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ySJm0_yzS0O5WbckJbrJig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_6hwBOOLcHk-K1sLFoc-0rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GttWyC5eVEu0a5D8x-ZKVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_jiGBndkblk6uSV1cNASR2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4bLJEBum0UGcpDQCcpC3iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_K_aG3SZaKUW1mCYhFvnDYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_8byNOjFo4ki3TRAVrcpw_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_uEHNJFwr3EmVaCzLXcE2lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_i7EfMlh5iUKmaxl0vc-mog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iEt59g_0hEWUB6Yz9rNI_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OXWs40hPgkKqkaLy0hyWrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_HKdVFHQkxEmgyjhDxX2T9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ADqOKH8jt0KB1nbIrPKgoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_yqlv57v0OEG1_brdVqLq1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_vIgFICzC7UiHO-GUZ0v4Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_SHbUU420-U6-wZvoecLRCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_vuDrG59udk6_pmg0jdRl8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_17_2021_To_9_17_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_jUlavD3NjEy-jk37WZ7FiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_npuKWKdpoUWvxgvLp2wwtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Xs37kP1MXEWQ-qdRg_8D7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_Sw6Kjo1tDE-BHe-dTLqX0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_H5V7XcidSEeqvZO0kZROGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_x6s2vBxPH0OH-sUVuKrR1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_uxFGoa7hQEWcuDdN_uz3Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LegacyPlanMember_RGbEltV_HESu23rxrqMUeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LegacyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_ZqrduP_DhU-c-0DXXjhxKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_QddTv344JkOsFwJFGAPjQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_s1OUV32MXEmc3KvzrvgpIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MWzGNMmG1E6v3rQ9gBnpSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_Cfres-mG-kGSfXOFxQdxag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_jh1w8gRbgEipnv2Kd3Q7zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_QqhHzWTUTUWo9mtYyqyW5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ExecutiveBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_uKCC8GofE0G_GEmvlAEeTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_NUSNjsD8UEOnZi8loJYDVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_ExerciseOfOptionsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wMo5XPBJDEWL4EzQFfN9nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:ExerciseOfOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WpDGmX1BBk-irWX_MsZINg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_Emv5VFNkOkeu9n01IcUiDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_xxYCQu-d0kOvAqnbd6uzjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_15_2023_To_12_15_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_zcNwztHf20yUPCFfBpK37A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-15</xbrli:startDate><xbrli:endDate>2023-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_30_2023_To_9_30_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_hmgAXRtQi0mLk9qz8iijtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_HaxPqM7xIEqQzOqccUnD3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_30_2022_To_11_30_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_YaepVSyZlU2heFMGLS9PMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-30</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_ixs-47BeUUyl1kn1TalbNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_EaL8v88MnEKSvl3GFfmHuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_Fl_UlTw2MEicwzSFEfSNiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hcC_vpIE1k--3Sn_jsbP0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_MQ4SgOseWki-M9I2hpt9zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_Ufa1a3hx1k2ehDCG8MEN5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_I9QppcopR0ywsK2v4mo-QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_uxxE4wcx60S5_hvy1sXzRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_ObBmT6n8TkOKFE0nU935Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_IedADyrcS0Sk1puAhMSxsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ExecutiveBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_x7oTzwEM40qM38yhmGMObg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_hizFCmgkaE2aderOvs1LNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_kk4sEIFbXE6LU2RSZnpNkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_b9BiLH-CyUWgD-n-MYvg5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_ZF2N9tkLFEaK095giq-KlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_eimyXQngAkWRK3ARVfDZJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_-yi3-Too5kCsgm19jUEi9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3uG-xQGBjk2UUp8qg_geog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_cDlmM3W2jEmSkYOD4grJhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_SNfgVOPHpkOAwFRDrPaxfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_tEkPhB01qkqTdfn3O75Wzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_syES-Ei1DUW-SeNDoWBa7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_TsCUi_lxRUSo6j60ua4lmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_amLMRVfn1Ee2t3F85rOj6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_Auk54leS0kegyMpOaw5bEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Fo_xNC8x2E2Nw6expsmq5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CxYy2LPXFkaLHvgdxKLbYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_taOkSa3SjUyVQqMwIn0Hjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_smPSOhfL00esXI2_6xMXmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_TpCSNwbGR06S0oUDZgjo1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_e3XuayV2tk6ysYr-TQ-BSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hlhg1JNAsESzQBLYmwp6xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1FJQlhWUMk6KNwscC81P8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_lxNwvrDKd0-QyYtez9i4Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3xb5m9-bNEqJh9Hoo7pWKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_4a0nsTyeT0WWO6mJkY9WFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1teDHrsx_kWaav_Zvx6nuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_9EPi2cugF02lQJNpQpyZfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_-ENPqM9es0SNp-ig-Xj1tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_2Z6ov_rV6UGba_ri3U2OrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_t4-RJZpgr0CDzvIjX0yH7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_jb5qNe6RhUGF9vZAO08FkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_pTI2ycYZxUCgYp1XaojMCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JTWgO7w8WUSANCdQPMb8Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hhtxzsBDiUKB449PVvTqJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JgayIPr0HUqHcsGqQ4Msdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_t4jMo4Sp2U27gxThk2CyYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_AZk_qPQ4MUWJzWTnl1YlfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_glkxLuCSRUCQqGxSgDm4sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nbvH9kC4i0CT5CljgxvX-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8G-l7cSohE2wypqHd_nGtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_rK-mQvhP6k6rDG5s_W9Crw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_Pu91BJKoY0yyQ7jXhJKbDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_jspXe4LQ_UyibQFOKeFBYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Oueb9u3QfkWqN8BPX_v-xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_xc2cFeX11U6brkADl8elRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_AvgaG-0jnkaft9oN3wJb5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_cyOGw2ND4EOXxVCS45Rnhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_xwxmUcynR0KOedEqXVH6mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_ZRIYWuzzT0SCY6jmM6q8Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_Z4th35GQN0yb98iIcO_pdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_lt3cWNU5H0SMaF3fADwXfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_41JFXgAYbU-2g4bnHFwsiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_mT3WIF4M9k-HrxxK03IB1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RsuSupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_uMKK0Q6dEUmdlqOP5j56rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_jRMpo2_Z7EeshW9iq1ZxOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_D1vacamOH0G3JMpcUfj14g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_8rng1PMUlky5RzxNm--ypw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RsuSupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_hGO4w4NtCUa_4_aoaCmHzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_-tPgLvVPd0iGi29T4BoBUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_bAEfKq92c0ycQbava4HefQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RsuSupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_8RFzGrzUeE6P9-Pt00WG7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_NkdF9lVGbUq5xwUCOH7yAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_jpnt_Qkh80SEH5rLvclaIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_WZMCwy54QUmI6ryK9Caqbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_FRvDHd6gz0-TIgKz3l7NTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_UBWp1OUhsESfo0wo4zeF7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_eThCk2awTUa5-6f7LEuCSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_bx2x9QVGwUKRwb9RkD06sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_LeF6mzlRgUqn4uUTYSSTkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_-_-inCxASkiTTlbNRKnG9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember__tOhjBnh-k-Pzhm_-oubRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_wHx_7Z9Dg0my8RqwuxGOxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_nrIihK8t60Kg6c5Z8quIzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_rkGlJwdXYkifsZbvBkjdoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MlAIV3j9EESYEfc4Yj76xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember__36EPFnJpUGaQzWSL7tMWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_-SG7NEQ-8E-ah1y5uSU_bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8C3Nwu6XF0Oi2St2MLlLAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_RpHUMDrg-UiGjsQj8CQEXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_b_PVXi45TkWmP1ML_7DnkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_2d_godOeNkaEasgWMSZ_jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_WR0SFBa4b0qDmHaXvC4SwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_whZRjt-4FU-yl6yGweVnzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_0VcWnDDzFUyC5BwrczrKvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_dzqCRSdTaUyCKSftygGc5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lwBDHWf6DkiDBz3u8cOGuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_s8xXd8c1h0mpJ1IehtKt5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3ZjP9sOEAEuMEnQiZZAC6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_HPKAQE4Je0CJX_Y06wwKhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_KQB5gpktAESb-bTOPIdFnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_Jd9TaF_3MUmPThwO_m8oKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AnQeJoI56kuDvOssY92e1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_S1JWhNByVkO_gfsU5FZiQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_47DGLZoJlUGG58WY5poswg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_N9GQJX-VN0-QtPUbM25Rww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_KyV7Slh2JkqGlclN0ZugPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_rkeQ49L4e06MJK-fI2BJhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_PZFJd68wgkCqXp4YW2TkiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_vwFy4tKujEGvLRYO8xC60g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_sopM0fRxjEGXBD4cfhAb-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_x2jtrAGjukm-Q3NjjwN9zA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_RPtNKWdi7kep-OWhPRdbZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_YQ7OFau-40655Qsd3p7mHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_KQcN-T4_jUa6vvQqtTmIxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Y2yquS5opE-ddUHuqsYCSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_C0Yd0VHbrESYa5VTH7JK-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_5g69MJCNR0qupo7-cCBilg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_YWA7IRvytUCV0dt4jLtEeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_nwphsrqbPkGFkMezYtJrvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_z3m9cMNGJkyyuC_pOxiLYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xyqNnfW_P0-d5WX8yyxmQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hjZQJLPupkuissku-yiCaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_2nV73AJ870mDjh_tkOBisg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_BR9esw-0g0WSTYUwmmFSEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_b0HAzOV390aY5p51-Rkqhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_VWLXKKbGpUq7QH7ui7XDUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_uqcVVb-EwESwn3lB6wxn9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w8rxm3hBy0y_-Ae1ZVWKlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_t-iXQatkZ0KzkyWEc3dpwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_-ZhyaL6E9kaT3dKgQLND6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_budjsnBG90KFg41r2z8BQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_N2Zm5geGpE2tjfPniK-XXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_MKSIOOU_xkyo8xpkv2OyHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_8o2ZYCj_7EKP52vUoSck2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_XS4wMvPP1k64ztgaiLo9AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_qNgj2Z_Q3k6Magi__mK2Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_RcuGyuNGcUqdgPvzwcxZHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_8V8uLdfk1k6k9TaP2157vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_bMA8T5tG6ES2FAnIC7DkfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_WlD6qYqQ-UChT6kij1OauQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_dPvTMfFzZkqhDReqmruC2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_Ay6fLSJ51ketqazQXPf5hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_ZZaNrVakd0WQ7KvFCMu6Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_2NV8EZlD8UGXJFNTR3SpMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_vPbCsfbl10GjVuhXwSETZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_xceMST2sskiZALYanrkx6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_HeRhz1br2kW9XGBq3W35TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_2z_v-2cIV0GPSwrqAp-RhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_0jknVHupLEyMHv6EAT-P4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_KOCTqYugQU-Xp2Dma3UX4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_FgRE2Czx-0e3kuw6SVMj_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_brACGjFlf0yYmlE-IZbkqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_BxdZ_fqI90qVPvPxCxQ8Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_N6uLOUQcWEa4CDo-FoW1jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_AdgiqRdnnUCyfzTbCUw3EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_WoU5OY8q9UmNGItiCh3wFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_q0E1iqjsuEivVAPEk_0CQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_K70FGvuxREqsUGGoFXb3Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WJuDdMd_AEOjhVaYyZzKtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_sPUZgy8alUm9DrExIlqZxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_NwLw6YbSN0CNCMJtsJh-lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__QCZpl7FCECVWYoHf5mRiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_q7WO6vvez0OVGaUlPRtXNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_AMhqZjayEkyLFJUXTSfqhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_y_Uiw0kSbEuybbOsAdT54w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_nNMExjPVFE-feDhtK4OSgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServicesGmbhTuebingenGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_bZP5vsKUxUWOPhfDrg8I3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_dpBYHdH2n0euqcNEgHxmzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_Fr_u4k8C4EyZbX93eTH8iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_6IbdDCUU1k2phHbdFhwJZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_J-pJWtADOEeUxcm-wYpInA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_8P9AJYdqkUuBYi1IlF81dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_5ly2YlnqS0GPhMxtaYcLWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WbbYak-BQUGFoFXANHb7Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_mdiFR6M0iEGRWxBYIMdEcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_iav8T9jxJ02hwX0kprs5wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__OUzUplfMke4OyytxLopmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_TXI_swpSqEWRqNR403cl4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_XYmGcuw_GUu29m7J0DC8FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_LXDETgWXhUW-6PMmcfMtQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_RRVoksyfikayCq6qHVsupQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_1Cz5tMIDUE64OdcnvtgS2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_CL_42NO980yFn3bMpoksBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_3qNBdkGOC0S9Pb4g2-0A6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_tiHq0sjs80K57XqBzMQLJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_bOuXDQXtgECvVjIJJiEBBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_fOnOhohTI0aH7chs7hxlhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_VwP1ZgmTKEqT0Qondxniqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_USje2-QFJEy2AJRt3OvR5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pgKJujKGq0Gc4IGKg7SH9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_5Z0-f_Nn2Uep_e7zqZA6_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZFq3H-aADUWbi48lz1-J3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_2n8B9LUx5UueVjJYl4z0CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dj_kuij1ukqB0BZd5Wb8cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_y1C8YKr28UeNst5nGOjNFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_a0Kr79sWk0Obs3Ohp5ui0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_2doude3lg0OUQmpYjlR9-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_ep4tnexH0kyFY8VzHHJmYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_lFP2_XAYDUudX-fY-YAD1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_GrkJ0r-6s0aI6oLGR4t78A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_tg5uf0hf90mOvis2DMD5YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_WuUc_xWmdUqMzpKJ1_OlaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_D4XaHP_XzUyH3j-sKKjh5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_cqxmGMVGW0W7n02ag0EpUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_xFpumxL9VU6TqcyTi7LMRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_j_FuUitGzU-WI673yfsjoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">cvac:OnerousContractProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_51kbfHiK10CFR5dmzP024Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_8YeTvYg7kUKynLYBgt67GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_oC7hV09GIUK4KIsK7e8ZoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_B2bOhJ54KEOrUvEAltnJrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:OtherEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_vnP_GndeskmGccGmbmXP2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:OtherEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_BsheSwtJGU-hU30WhGx3GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:LandBuildingsAndSupplyInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_Q9fMN7T-y0m13lblbattaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:LandBuildingsAndSupplyInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_HfoXp3Ph3E6zl6AvXTfb-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_Uqq6tqDywUKR7NfMQRtxqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:GlaxosmithklineCovidAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember__SZm_EveFkuat9TplxJ75w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2017_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_HShGdT13tU-b1m7Ylf054A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_IkXEAQpU6E-CCqDrHRQ4QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b8EFZRIMq0WCtvwfKe4gIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_nC4KCpY88UGym-D27dL6Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_fV8dgKI9A0qDluOP4s-fcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_VDgvtxQGnUWTC1YHHYEPSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_UNDEvAgHeEiRXFi1vbQ4Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_1VRD647OiE6jHdJLTQ7IRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_Zy-68Enju0iBz6gYRoHmDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2I2dxZFv7Eyci3--WSWO7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2023_To_8_14_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_c7I5rda9O0unxghjuyCeYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2022_To_8_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_vhVPWZE6FE-yd2_OHphj6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-14</xbrli:startDate><xbrli:endDate>2022-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2020_To_8_14_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_WwopKLYhAkmX30Ihq8HcEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fUKrlVf3Qk6qjGa7_xKIlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-MBxnDM6-U6QBuGgHl5BEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_gLfbS6LG906Sox56_2muhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WckCf34PZUGzza4sNjwFMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4ms1oi7d0EywO8ZNbgPv5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_tDcuRfOZHUis6pxE_-4Qjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_f2yWNH0RhECkx-pihStCXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:RittershausRechtsanwaelteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_RnuhJALUXEW6OjzFID5ePg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_qPHpyi8B6kOFRUh0cCyRZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:MariolaFotinMleczekMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CurevacPrinterGmbhMember_gCs4iaZl0UyakTfPuIOiJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:CurevacPrinterGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_QN5vMskJz0SjqLv-t82qVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_adrBhWYBcUKP4xl56ZYvMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:MariolaFotinMleczekMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_3YpDQRUP7U-XcUYi-sII5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_xCV0b46ewUWBBkAiRGRUnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:RittershausRechtsanwaelteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember__huxDT93sUCUvh-o5CwH7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DieviniHoppBiotechHoldingGmbhCo.KgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_AeWpyZ9BY0qX-7I4dJeLCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DieviniHoppBiotechHoldingGmbhCo.KgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_lDAMCnCC90O3RpaIsg3kZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_6nW0xhgNC0mT9D42Qi4zog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_rNMx4zueSkOBF5WSJkSlXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_wxgIcShrNEKq5nN0HbJ7vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_5b14ql9RFEezFsOggnD0RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_GFLhPP5AWUCAjFvKMkszFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_I_69X6Df9k6Te3sWPj6hwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_Wh8p0VKIT0O3NgVdxK2fOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2016_To_11_30_2016_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_WgEgi6NaVEWkMFit_-JGNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_HRF1MwVKgUu89NEIRuzDvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_z_oev7deRk-jsRWTlzMzkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_lBS-kbj340mK__LFAXyYQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_34HbkgDTrEKqkuExas5krQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_s0o811r3yEWWO5MCpwlyaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_PqOHXw2W70SLtVHUTZnIIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2019_To_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_v2GiAszp-UioMADTqx2Ctg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_nQQb4IPGNkaNHOnRJ9HnPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_cieCTs_Zuk2PWdYu7Wy6ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mZrACg5Qy0atlIzvQ-sFZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_WiesbadenMember_qqZmF0WHQk-CQHfo53QZ7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvac:WiesbadenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_TbingenMember_qUeXimjzQ0KjqUiReUdC4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvac:TbingenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b2Vp5VUFV0ur7dOqZSCNYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_dBuLkJzR8UGZKxJeLbvRJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tieFmpdel06r1eZXxqI5EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_L61lR4DVa0KvyH4imXbLGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_CwZYI28sy0a1k2hv3Y76Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_XKUaAnV49EWl3jd-hAE8eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_UkHTlmAHJkSss_TraYDEdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2020_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zETrLnvnJU-bFHQhtWzRHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_wT00lKBxs0KIgm-oIxqE4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_0NzIZ6BiH0K-Yg0H0gY9Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:ClosingOfPublicOfferingOfCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_IfrsOverAllotmentOptionMember_riZy2Z4KG0Gk8otdZzKN2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:IfrsOverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:ClosingOfPublicOfferingOfCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_pq40A99Zy0-J899Hpgyiuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">cvac:ContractTerminationProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_TsjaEu7n40i6mOR_moJurg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:MariolaFotinMleczekMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FlorianVonDerMlbeMember_SIwLkqeJIE-s7t_ZN4MKdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:FlorianVonDerMlbeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_Dr.IngmarHrrMember_wYrvLaDbgEqiqWSPHKS2gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:Dr.IngmarHrrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_21_2022_To_3_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_M7yeLt7eC0yDiQxH3rlo7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-21</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_PublicOfferingOfCommonSharesMember_aEkH7sfkH02lkeyEWiOvdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:PublicOfferingOfCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_bhT-Hm2SaEu5uUt9fXRzGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_29_2023_To_12_29_2023_SuqeE38xXUK8RRKDLZ3EOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_xeuiIWVNGkapjrX-CNiEZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_y1_WCcSI20-05QOkXbljog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_qO3ooGZGqE-1SoyY1Zy6eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JtGHYH8FrEKyyYF5zBuS5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tGMjQ13Y6kWsrsTpWJqw_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_38uXsNcfl0e1xpuxCmbyTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_cvac_IfrsIncomeStatementLocationAxis_cvac_MiscellaneousOtherOperatingIncomeMember_cpxyNogu7kOQwMXm7EojUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:MiscellaneousOtherOperatingIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_qyWBhjwBlkKQHtJUuv5N4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_q_UBt-6xnEai2whg5OLb5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_mp2AzJFe_U2GzM3aVT9NMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_A6it69ifLUeKRgdoAQT4iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2024_To_3_22_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LzXStsEX10Sllgbp-IfhBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_YmO0AmylMUGXyDkvXeCLlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:NewVsopPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_12_2022_To_12_12_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_RQ8a6WZN30er9veT-GsPsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_sAMF0EDzsUqQ8PpTkE7KMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:NewVsopPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_18_2021_To_10_18_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_NU3QWXFiZkS0exKI1Z5L4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-18</xbrli:startDate><xbrli:endDate>2021-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2021_To_3_10_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_D2yuVO9FDUOmQ5j1k8A3bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-10</xbrli:startDate><xbrli:endDate>2021-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_3vgagNoi6kSQIXzMaP-lig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wK1DnDLSIkWj7Emo6TjbNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_Tj5GLbNT3kSBwyxRAfJfVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_2ruopNpg1EOnMxTf_GiPBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanysLargestPrivateBankMember_TPfvCFqo80y0z7BFfC2YKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">cvac:GermanysLargestPrivateBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanLandesbankMember_x_lULUcrc0GPG1twEsc5vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">cvac:GermanLandesbankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_EuropeSLargestPrivateBankMember_grNAnpFTY0ubOJ1E3t9yiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">cvac:EuropeSLargestPrivateBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_UoCEidhqNkCfZfezQJra6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_AlexanderZehnderMember_mQ65pe5XS02CILSpyMNi-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:AlexanderZehnderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_GridEuropeMember_6WJlWjlo_kuCilFMPK6nQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:GridEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FranzWernerHaasMember_3KoWd6cW3kiWfRndyVReUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:FranzWernerHaasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_FnDpFAjGGkeAyPEcOA6zCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:CraigToomanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_1aQ3jbYg70uyuJDLyM2Akw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_03V4AWHHaUicJNVRIZQgJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BarkerBiomedicalGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_LRyErr-s70-iTcECgyji4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_WZbR2KdIsEWpAKkVfjG6Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_8DK6e_LQPUG6vKafYfDvgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dzLDR4-bwEyHrc4xbtFT-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ao6gXG47qEqwSYLU3wAumQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_26_2024_To_3_26_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8MhaP9inOEWOlUmUTvRFIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_26_2024_To_3_26_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_rczlzRLESEmjal2oPh8nsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_14_2022_To_12_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_AYQqGHS96EG_31uhHqhopg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-19</xbrli:startDate><xbrli:endDate>2021-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-11</xbrli:startDate><xbrli:endDate>2021-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_UJYAD019cUGBDnGIwVIvFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_m_1pv_Rp7ES0m0oWmWkw9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_oFHjPsrbYU-V2V22lqobCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_lgx14Yi8EUGXWrkRb0K3Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember___lz1oR3-k2v1ISygb7bPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_oXIlxEKLg0uXPK0YY9JWaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2014_To_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_uR8Rb-zZ-0W5xnOW1rqrfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_pfMi8wn3EkWe1O0Rx8uvnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_tranche_maOPN1bXI0mZlNy5N3Q2hA"><xbrli:measure>cvac:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_loan_B2W9DgI1ukyKELWFZzXYow"><xbrli:measure>cvac:loan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA"><xbrli:measure>cvac:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag"><xbrli:measure>cvac:Option</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_GBP_NKJzu3jWTEavxop33-TfZw"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Milestone_ymq4eXsZYUanqqY0KpCtNg"><xbrli:measure>cvac:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw"><xbrli:measure>cvac:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_thtYd9HVPUa-ZcLIAcALtA"><xbrli:measure>cvac:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><a id="_27069480_ab18_4963_bad4_fd72bee758cd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentType" id="Narr_ybuNXXrT9UOk6OXd2dsi_Q"><b style="font-weight:bold;">20-F</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Mark One)</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentRegistrationStatement" id="Narr_IwnvCfL0YkSpfXnShCK-Zw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentAnnualReport" id="Narr_YlWjtI7jKUSr8IoLX4p1wA"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentPeriodEndDate" id="Narr_Z7G6Kdq08EuJgwjGMd_puw"><b style="font-weight:bold;">December 31, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentTransitionReport" id="Narr_trOVu1PZHUGpuEe_XRwb5w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b><br/><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentShellCompanyReport" id="Narr_kAdnupYkmU2rqzfd8ilIAA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4pt;margin-top:0pt;"><b style="font-weight:bold;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b><br/><b style="font-weight:bold;">Date of event requiring this shell company report </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Commission file number: <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityFileNumber" id="Narr_ZrwE2YLXiEmtsQBgsgdDMQ"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-39446</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityRegistrantName" id="Narr_OHSVBaGvUE6LWX4wh3biOQ"><b style="font-weight:bold;">CureVac N.V.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of Registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The </b><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityIncorporationStateCountryCode" id="Narr_2xu4sUNWtkeBP476uf2xPA"><b style="font-weight:bold;">Netherlands</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Jurisdiction of incorporation or organization)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityAddressAddressLine1" id="Narr_2rgnb3k-8UmIlYs6kJGFPA"><b style="font-weight:bold;">Friedrich-Miescher-Strasse 15</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityAddressPostalZipCode" id="Narr_YOWqhw9o3U6Z_ksq1Gkrwg"><b style="font-weight:bold;">72076</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityAddressCityOrTown" id="Narr_ef4N5_vd7U-_dHRjYCdkXg"><b style="font-weight:bold;">T&#252;bingen</b></ix:nonNumeric><b style="font-weight:bold;">,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityAddressCountry" id="Narr_GNPaswCR8U2jn_JwCH6Jhg"><b style="font-weight:bold;">Germany</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">+49 7071 9883 0</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw" name="dei:ContactPersonnelName" id="Narr_z9t65RzvSEmUL0V2R3J3DQ"><b style="font-weight:bold;">Alexander Zehnder</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw" name="dei:EntityAddressAddressLine1" id="Narr_EcH_PFQJd0eBkv-7QCVy-Q"><b style="font-weight:bold;">Friedrich-Miescher-Strasse 15</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw" name="dei:EntityAddressPostalZipCode" id="Narr_kaK4mYmsSUaK7Ur5DeTMcQ"><b style="font-weight:bold;">72076</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw" name="dei:EntityAddressCityOrTown" id="Narr_N8Hu0-KN_EathUAY8WtHEQ"><b style="font-weight:bold;">T&#252;bingen</b></ix:nonNumeric><b style="font-weight:bold;">,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw" name="dei:EntityAddressCountry" id="Narr_6eXDHTo9M06_DVYdyfq5Zw"><b style="font-weight:bold;">Germany</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw" name="dei:ContactPersonnelEmailAddress" id="Narr_UgEWRO1qBEeO4jiaC5qa0g"><b style="font-weight:bold;">info@curevac.com</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_6d0354da_e863_4b89_b5bb_710cce53bc04"></a><a id="Tc_VxA6ypMzgkCOfSVXL9sTrw_0_0"></a><a id="Tc_TjGfMKe2zUWFU8aDljzpqw_0_2"></a><a id="Tc_zrCUDWBHlU67iKeVwAmDmA_0_4"></a><a id="Tc__WAFIJydskmZH0w_gbYSKw_1_2"></a><a id="Tc_8rxWrT6_-E2kTYhPpOr46Q_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:38.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:Security12bTitle" id="Tc_8wfEsfmrx0Gh2WZYkePIOg_1_0">Common shares, par value &#8364;0.12 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8220;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:TradingSymbol" id="Narr_6oJFeWDCc0ixwHw9vthxjA">CVAC</ix:nonNumeric>&#8221;</p></td><td style="vertical-align:top;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The <ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:SecurityExchangeName" id="Narr_M7f3xFBqhU66sGfXIIDs-A">NASDAQ</ix:nonNumeric> Global Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The number of outstanding shares as of December 31, 2023 was:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_bddc2c33_8251_4953_a407_fd88fa14c3ce"></a><a id="Tc_NJ1c-7oOLEO9xyfqlZCFeg_0_0"></a><a id="Tc_ed34s5moMkGFs3_IAWsiyA_0_2"></a><a id="Tc_dEaKQpMhWkq4aJNGZCiNDA_1_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Class</b></p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Common shares, par value &#8364;0.12 per share</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Tc_NNbkZggg50mmX96y96Y13Q_1_2">223,988,675</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Yes&#160;<span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_Tpi7U8EepEm3rCNUd6y9Lw">No</ix:nonNumeric> <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">Yes <span style="font-family:'Segoe UI Symbol';">&#9744;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityVoluntaryFilers" id="Narr_RroQN4RTkUSxGkdAHXHLPw">No</ix:nonNumeric> <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Note</b> &#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityCurrentReportingStatus" id="Narr_yk-lY5OtB0eMsu5jBIu-pg">Yes</ix:nonNumeric> <span style="font-family:'Segoe UI Symbol';">&#9746;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span>No <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:EntityInteractiveDataCurrent" id="Narr_VQrU2lU0o0WYqRG3VHQe7g">Yes</ix:nonNumeric> <span style="font-family:'Segoe UI Symbol';">&#9746;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span>No <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &#8220;accelerated filer and large accelerated filer&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="Narr__8dygCuLoESknhMn3rGG0A">Large Accelerated Filer </ix:nonNumeric>&#8199;<span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Accelerated Filer &#8199;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Non-accelerated Filer &#8199;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Emerging growth company &#8199;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_PUUtPRNycUKXJVFxhib19A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="Narr_IAg3E86dY0KyLtk8nrg7zQ"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_EHPvzg6mtk2jk0unaG5iHw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">U.S. GAAP</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:DocumentAccountingStandard" id="Narr_pfyRfD9wfU-Ps-OYNjduMw">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Other</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span> Item&#160;17<span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#9744;</span> Item&#160;18</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Yes <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="Narr_b3g3PMa-skSPvBSoS-0BeA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span>No <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:18pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_373f0c25_67dd_460a_8d99_49cafe566d12"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTI_178936"><span style="font-style:normal;font-weight:normal;">Part I</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1IDENTITYOFDIRECTORSSENIOR_103248"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM1IDENTITYOFDIRECTORSSENIOR_103248"><span style="font-style:normal;font-weight:normal;">Identity of Directors, Senior Management and Advisers</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM2OFFERSTATISTICSAND_160207"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM2OFFERSTATISTICSAND_160207"><span style="font-style:normal;font-weight:normal;">Offer Statistics and Expected Timetable</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM3KEYINFORMATION_787899"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM3KEYINFORMATION_787899"><span style="font-style:normal;font-weight:normal;">Key Information</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM4INFORMATIONONTHE_612098"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM4INFORMATIONONTHE_612098"><span style="font-style:normal;font-weight:normal;">Information on the Company</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM4AUNRESOLVEDSTAFF_538213"><span style="font-style:normal;font-weight:normal;">Item 4A.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM4AUNRESOLVEDSTAFF_538213"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">153</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM5OPERATINGANDFINANCIAL_980402"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM5OPERATINGANDFINANCIAL_980402"><span style="font-style:normal;font-weight:normal;">Operating and Financial Review and Prospects</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">154</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM6DIRECTORSSENIORMANAGEMENT_816845"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM6DIRECTORSSENIORMANAGEMENT_816845"><span style="font-style:normal;font-weight:normal;">Directors, Senior Management and Employees</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">175</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM7MAJORSHAREHOLDERSANDRELATED_593176"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM7MAJORSHAREHOLDERSANDRELATED_593176"><span style="font-style:normal;font-weight:normal;">Major Shareholders and Related Party Transactions</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">189</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM8FINANCIALINFORMATION_151512"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM8FINANCIALINFORMATION_151512"><span style="font-style:normal;font-weight:normal;">Financial Information</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">197</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9THEOFFERANDLISTING_784381"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM9THEOFFERANDLISTING_784381"><span style="font-style:normal;font-weight:normal;">The Offer and Listing</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">199</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM10ADDITIONALINFORMATION_673584"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM10ADDITIONALINFORMATION_673584"><span style="font-style:normal;font-weight:normal;">Additional Information</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">199</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">217</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM12DESCRIPTIONOFSECURITIES_166212"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM12DESCRIPTIONOFSECURITIES_166212"><span style="font-style:normal;font-weight:normal;">Description of Securities Other Than Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">218</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTII_487458"><span style="font-style:normal;font-weight:normal;">Part II</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">219</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM13DEFAULTSDIVIDENDARREARAGES_143929"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM13DEFAULTSDIVIDENDARREARAGES_143929"><span style="font-style:normal;font-weight:normal;">Defaults, Dividend Arrearages and Delinquencies</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">219</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM14MATERIALMODIFICATIONSTOTHERIGHTS_8"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM14MATERIALMODIFICATIONSTOTHERIGHTS_8"><span style="font-style:normal;font-weight:normal;">Material Modifications to the Rights of Security Holders and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">219</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM15CONTROLSANDPROCEDURE_71419"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM15CONTROLSANDPROCEDURE_71419"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">219</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16Reserved_143062"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16Reserved_143062"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">221</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16AAuditCommitteeFinancialExpert_495"><span style="font-style:normal;font-weight:normal;">Item 16A.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16AAuditCommitteeFinancialExpert_495"><span style="font-style:normal;font-weight:normal;">Audit Committee Financial Expert</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">221</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16BCodeofConduct_487362"><span style="font-style:normal;font-weight:normal;">Item 16B.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16BCodeofConduct_487362"><span style="font-style:normal;font-weight:normal;">Code of Conduct</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">221</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16CPrincipalAccountantFees_604803"><span style="font-style:normal;font-weight:normal;">Item 16C.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16CPrincipalAccountantFees_604803"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">221</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16DExemptionsfromtheListing_19416"><span style="font-style:normal;font-weight:normal;">Item 16D.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16DExemptionsfromtheListing_19416"><span style="font-style:normal;font-weight:normal;">Exemptions from the Listing Standards for Audit Committees</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">222</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16EPurchasesofEquitySecurities_95956"><span style="font-style:normal;font-weight:normal;">Item 16E.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16EPurchasesofEquitySecurities_95956"><span style="font-style:normal;font-weight:normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">222</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16FChangeinRegistrant_263042"><span style="font-style:normal;font-weight:normal;">Item 16F.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16FChangeinRegistrant_263042"><span style="font-style:normal;font-weight:normal;">Change in Registrant&#8217;s Certifying Accountant</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">222</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16GCorporateGovernance_898522"><span style="font-style:normal;font-weight:normal;">Item 16G.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16GCorporateGovernance_898522"><span style="font-style:normal;font-weight:normal;">Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">222</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16HMineSafetyDisclosure_10468"><span style="font-style:normal;font-weight:normal;">Item 16H.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16HMineSafetyDisclosure_10468"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosure</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">235</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16KCybersecurity_314098"><span style="font-style:normal;font-weight:normal;">Item 16K.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM16KCybersecurity_314098"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">235</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIII_702996"><span style="font-style:normal;font-weight:normal;">PART III</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">236</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM17FinancialStatements_982680"><span style="font-style:normal;font-weight:normal;">ITEM 17.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM17FinancialStatements_982680"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">236</p></td></tr><tr><td style="vertical-align:top;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM18FinancialStatements_475615"><span style="font-style:normal;font-weight:normal;">ITEM 18.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM18FinancialStatements_475615"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">236</p></td></tr><tr><td style="vertical-align:top;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM19Exhibits_127428"><span style="font-style:normal;font-weight:normal;">ITEM 19.</span></a></p></td><td style="vertical-align:bottom;width:82.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ITEM19Exhibits_127428"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">238</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:1pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1</td><td style="padding:0pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 1.1pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3bba7d81_bc48_4c67_87e5_a36eb5dd3e55"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PRESENTATION OF FINANCIAL AND OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the IASB. We have made rounding adjustments to some of the figures included in this Annual Report. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial statements included in this Annual Report are presented in euro and, unless otherwise specified, all monetary amounts are in euro. All references in this Annual Report to &#8220;$,&#8221; &#8220;U.S. dollars&#8221; and &#8220;dollars&#8221; mean U.S. dollars and all references to &#8220;&#8364;&#8221; and &#8220;euro&#8221; mean euro, unless otherwise noted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In this Annual Report, unless otherwise indicated, some euro amounts have been translated into U.S. dollars at the rate of $1.105 to &#8364;1.00, the official exchange rate quoted as of December 31, 2023 by the European Central Bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dedbb5fa_a6e7_427a_8b17_666ff8ae971c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CERTAIN REFERENCES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated or the context otherwise requires, all references in this Annual Report to &#8220;CureVac&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;ourselves,&#8221; &#8220;us&#8221; or similar terms refer to: (1)&#160;on or following the consummation of the Corporate Reorganization, CureVac N.V. together with its subsidiaries, including CureVac SE (formerly known as CureVac AG), and (2)&#160;prior to the consummation of the Corporate Reorganization, CureVac AG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a holding company and our sole asset is the capital stock of our wholly owned subsidiaries, including CureVac SE. CureVac N.V. operates and controls all of the business and affairs and consolidates the financial results of CureVac SE. We are incorporated in the Netherlands, and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the U.S. Securities and Exchange Commission, or the SEC, we are currently eligible for treatment as a &#8220;foreign private issuer.&#8221; As a foreign private issuer, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;letter-spacing:0.2pt;">We own or have rights to various trademarks and trade names, including CureVac</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;letter-spacing:0.2pt;"> and the CureVac logo, that we use in connection with the operation of our business. This Annual Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. We do not intend our use or display of other entities&#8217; trademarks, trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. Solely for convenience, the trademarks, trade names and service marks in this Annual Report are referred to without the symbols </span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;letter-spacing:0.2pt;"> and &#8482;, or&#160;</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">SM</span><span style="font-size:10pt;letter-spacing:0.2pt;">, but the omission of such references should not be construed as any indication that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_87b52a65_dd14_471b_9f7e_1811ca517123"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use of forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate&#8221; and &#8220;potential,&#8221; or other similar expressions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Forward-looking statements appear in a number of places in this Annual Report and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section entitled &#8220;Risk Factors&#8221; in this Annual Report. These risks and uncertainties include factors relating to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and our ability to obtain and maintain regulatory approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates and cost associated with the cancellation of manufacture and supply agreements in the event of termination of our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the exercise by the Bill &amp; Melinda Gates Foundation of withdrawal rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our and our collaborators&#8217; ability to obtain, maintain, defend and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to commercialize our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability and the potential to successfully manufacture our drug substances and delivery vehicles for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, political, demographic and business conditions in the United States and Europe;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of unstable market and economic conditions such as rising inflation and interest rates and the conflict involving Russia and Ukraine on our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to implement our growth strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete and conduct our business in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enroll patients for our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of qualified personnel and the ability to retain such personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments and changes in the United States, Europe and countries outside of Europe including tax matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to overcome the challenges posed by pandemics (such as COVID-19), to the conduct of our business;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to implement, maintain and improve effective internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates of our expenses, future revenue and capital requirements and our needs for or ability to obtain additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other factors that may affect our financial condition, liquidity and results of operations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risk factors discussed under &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Item 3. Key Information &#8212; D. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Risk Factors.&#8221;</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should read this Annual Report carefully with the understanding that our actual future results may be materially different from and worse than what we expect. If our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Other sections of this Annual Report include additional factors which could adversely impact our business and financial performance. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Moreover, we operate in an evolving environment. Thus, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events or otherwise, except as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 7.55pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1484d598_4e4c_4243_a2d4_198a787485b1"></a><a id="PARTI_178936"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I</p><a id="ITEM1IDENTITYOFDIRECTORSSENIOR_103248"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_a1669b3d_4396_474f_9cd0_20ac44daff68"></a><a id="ITEM2OFFERSTATISTICSAND_160207"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_f7b9f54d_f285_42e6_9a47_2b9a857b3a79"></a><a id="ITEM3KEYINFORMATION_787899"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 3. KEY INFORMATION</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">A.</span>[Reserved]</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;font-weight:bold;min-width:18pt;white-space:nowrap;">B.</span><b style="font-weight:bold;">Capitalization and Indebtedness</b></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;font-weight:bold;min-width:18pt;white-space:nowrap;">C.</span><b style="font-weight:bold;">Reasons for the Offer and Use of Proceeds</b></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;font-weight:bold;min-width:18pt;white-space:nowrap;">D.</span><b style="font-weight:bold;">Risk Factors</b></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Summary of Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the risk factors our business faces. The list below is not exhaustive, and investors should read this &#8220;Risk Factors&#8221; section in full. Some of the risks we face include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may face residual business disruption and related risks resulting from inflationary pressures, supply chain issues, labor shortages and increases in commodity prices (including as result of the war in Ukraine) and the lingering effects of the COVID-19 pandemic, which could have a material adverse effect on our business plan or clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cyberattacks or other failures in our or our third-party vendors&#8217;, contractors&#8217; or consultants&#8217; telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain, maintain and enforce intellectual property protection for our products or product candidates, or if the scope of our intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be materially adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on strategic partnerships with other companies to assist in the research, development and commercialization of our platform and product candidates. If our existing or future partners do not perform as expected, if we fail to maintain any of these collaborations or if these collaborations are not successful, our ability to commercialize our product candidates successfully and to generate revenues through technology licensing or otherwise may be materially adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results. If clinical trials of our product candidates or production of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our proprietary product candidates are still in preclinical or clinical development. We cannot give any assurance that any of our product candidates will receive regulatory approval, and if we are unable to obtain regulatory approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following regulatory approval, if any. Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials, delay or prevent regulatory approval or market acceptance of any of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To date, a limited number of products that utilize mRNA as a prophylactic vaccine against COVID-19 have been approved in the United States, Europe and other countries, subject to certain limitations. In addition, no product that utilizes mRNA as a therapeutic vaccine has been approved in the United States or Europe. As such, mRNA drug development has substantial clinical development and regulatory risks due to the novel nature of this new category of medicines.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA and comparable authorities are lengthy, time consuming and inherently unpredictable and if we fail to obtain regulatory approval in any jurisdiction, we will not be able to commercialize our products in that jurisdiction and our business, results of operations, financial condition and prospects, may be materially adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A potential breakthrough therapy designation by the FDA for a product candidate may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive marketing approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The manufacture of mRNA-based medicines is complex and manufacturers often encounter difficulties in production, especially in the field of biologics. If we or any of our third-party manufacturers encounter difficulties, our ability to provide product candidates for clinical trials or products, if approved, to patients or future customers could be delayed or halted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Undetected errors or defects in our production could harm our reputation or expose us to product liability claims.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our nonclinical and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we or any third-party manufacturer of our product candidates is unable to increase the scale of production of our product candidates, and/or increase the product yield of manufacturing, then our costs to manufacture the product may increase and commercialization may be delayed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">At the start of the COVID-19 pandemic, we entered into contractual engagements with third-party manufacturers to have access to additional capacity. The remaining wind-down of these contracts entails risks of financial penalties and litigation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to comply with our obligations under any license, collaboration or other intellectual property agreements, disagree over contract interpretation, or otherwise experience disruptions to our business relationships with our collaborators or licensors, we could lose intellectual property rights that are necessary to our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Some of our product candidates are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that products similar to our product candidates will be reviewed within its Center for Biologics Evaluation and Research, or CBER. Even though our mRNA product candidates are designed to have a different mechanism of action from gene therapies, the association of our product candidates with gene therapies could result in increased regulatory burdens, impair the reputation of our product candidates, or negatively impact our platform or our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We cannot assure you of the adequacy of our capital resources to successfully complete the development and commercialization of our product candidates, and a failure to obtain additional capital, if needed, could force us to delay, limit, reduce or terminate one or more of our product development programs or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had cash and cash equivalents amounting to &#8364;402 million. We believe that we will continue to expend substantial resources for the foreseeable future developing our proprietary product candidates. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, seeking regulatory approvals, as well as launching and commercializing products approved for sale, if any, and costs associated with manufacturing products and maintaining manufacturing facilities. In addition, other unanticipated costs may arise. Because the outcomes of our anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our proprietary product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements will depend on many factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the numerous risks and uncertainties associated with developing product candidates and maintaining our mRNA technology platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of enrollment, progress, cost and outcomes of our clinical trials, which may or may not meet their primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and cost involved in, conducting nonclinical studies that are regulatory prerequisites to conducting clinical trials of sufficient duration for successful product registration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing clinical supply and establishing commercial supply of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and costs involved in, conducting post-approval studies that may be required by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of commercialization activities for our product candidates, if any of our product candidates are approved for sale, including product manufacturing, marketing and distribution of product candidates generated from our mRNA technology platform and any other product opportunity for which we receive marketing approval in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaborative, licensing and other arrangements that we are currently party to or may establish, including any required milestone and royalty payments thereunder and any nondilutive funding that we may receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs, if any, and the outcome of any such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt, and amount of sales of, or royalties or milestones on, our future products, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5.44pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs to recruit and build the organization, including key executives needed to transform to a commercial organization; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company, including hiring additional personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our operating plan may change as a result of many factors currently unknown to us. As a result of these factors, we may need additional funds sooner than planned. We expect to finance future cash needs primarily through a combination of public or private equity offerings, strategic collaborations, revenues from future product sales, if any, and debt financing. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, limit, reduce or terminate one or more of our product development programs or commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have incurred significant losses since our inception. Our consolidated net loss for the years ended December 31, 2023 and 2022 were &#8364;260.1 million and &#8364;249.1 million, respectively. As of December 31, 2023, our accumulated deficit was &#8364;1,566.0 million. We expect to continue to incur losses in the future as we continue our research and development of, and seek regulatory approvals for, our product candidates and maintain and develop new technology platforms, prepare for and begin to commercialize any approved product candidates and add infrastructure and personnel to support our product development efforts and operations as a public company in the United States. We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials and development of our manufacturing technology. The net losses and negative cash flows from operations incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials, the partnering process for our proprietary product candidates or the development of any of our proprietary product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue to date has been primarily revenue from the license of our technology platform and from milestone payments for the development of product candidates against targets provided<span style="font-size:12pt;"> </span>by our collaborators. Our ability to generate revenue and achieve profitability in the future depends in large part on our ability, alone or with our collaborators, to achieve milestones and to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize, our product candidates and technology platform. This will require us to be successful in a range of challenging activities, including developing product candidates, obtaining regulatory approval for such product candidates, and manufacturing, marketing and selling those product candidates for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable could depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We require substantial financing, which may not be available on acceptable terms, or at all. Raising capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technology or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To the extent that we raise capital through the sale of common shares, convertible securities or other equity securities, the ownership interests of our shareholders may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect rights of our common shareholders. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring debt, making capital expenditures, creating liens, redeeming shares or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we raise funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that funding will be available on acceptable terms, or at all. If we are unable to raise capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our current or future license agreements may also be terminated if we are unable to meet the payment or other obligations under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited financial and managerial resources, and therefore we intend to focus on developing product candidates for specific indications that we believe are most likely to succeed, in terms of both their potential for marketing approval and potential for successful commercialization, if approved. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to<span style="font-size:12pt;"> </span>capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on strategic partnerships with other companies to assist in the research, development and commercialization of our platform and product candidates. If our existing or future partners do not perform as expected, if we fail to maintain any of these collaborations or if these collaborations are not successful, our ability to commercialize our product candidates successfully and to generate revenues through technology licensing or otherwise may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have established strategic partnerships and intend to continue to establish strategic partnerships with third parties to research, develop and commercialize our platform and existing and future product candidates. We have entered into strategic partnerships with Genmab, Acuitas, CRISPR Therapeutics, GlaxoSmithKline Biologicals SA (&#8220;GSK&#8221;), the Bill &amp; Melinda Gates Foundation, CEPI and Tesla Automation (formerly trading under the name of Tesla Grohmann Automation) and myNEO NV (&#8220;myNEO&#8221;), among others. For certain of these programs, including our collaborations with Genmab, CRISPR Therapeutics and GSK, we will depend on our partners to design and conduct their clinical studies. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. While we have certain contractual rights to information about preclinical and clinical developments and results under certain of our collaboration agreements, including our agreements with Genmab, CRISPR Therapeutics and GSK, we cannot be certain that clinical trials conducted in connection with such collaboration programs will be conducted in a manner consistent with the best interests of our business. In addition, if any of these partners withdraw support for these programs or proposed products or otherwise impair their development, our business could be negatively affected. Also, our inability to find a partner for any of our product candidates may result in our termination of that specific product candidate program or evaluation of a product candidate in a particular indication. Even if we found a partner for one or more of our product candidates, there is no assurance that upon the approval of one or more of such product candidates we will be able to successfully co-commercialize such products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our existing licenses and collaboration agreements, including our agreements with Genmab, Acuitas, the Bill &amp; Melinda Gates Foundation, CRISPR Therapeutics, GSK, CEPI and myNEO, impose, and any future licenses, collaborations or other intellectual property agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. Furthermore, our licenses and collaboration agreements impose, and any future agreement we enter into may also impose, restrictions on our ability to license certain of our intellectual property to third parties or to develop or commercialize certain product candidates or technologies. In spite of our best efforts, our collaborators may conclude that we have breached our obligations under our agreements, in which case, we may be required to pay damages and the collaborator may have the right to terminate the agreement. Any of the foregoing could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology, enable a competitor to gain access to the licensed technology or disrupt our right to receive funding or milestone or royalty payments. See &#8220;Item&#160;4. Information on the Company&#8201;&#8212;&#8201;B.&#160;Business Overview&#8201;&#8212;&#8201;&#8201;Collaborations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under certain of our collaboration agreements, including our collaborations with Genmab, CRISPR Therapeutics and GSK, we grant our partners an exclusive license to develop and commercialize certain classes of products containing our mRNA technology for specific targets and receive license fees, research and development funding, milestone payments and/or, if a product is approved for marketing, sales royalties in return. Following the discovery and preclinical testing phase, in certain cases, our partners are solely responsible for the further development of the product candidate and therefore exercise full control over its further development and potential commercialization. In certain cases, including under our collaboration with Genmab, we have a limited right to co-commercialize collaboration products. While certain of our existing licenses and collaboration<span style="font-size:12pt;"> </span>agreements, including our agreements with Genmab, CRISPR Therapeutics and GSK, impose development or commercialization obligations on our collaborators, we cannot be certain that our collaboration partners will allocate sufficient resources or attention to our collaboration programs or that they will progress our collaboration programs consistent with the best interests of our business. Our existing collaborations, and any future collaborations we enter into, therefore, may pose a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected by us or by health authorities, such as the FDA, the EMA or comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may dissolve, merge, be bought or may otherwise become unwilling to fulfill the initial terms of the collaboration with us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may fail to perform their obligations under the collaboration agreements or may be slow in performing their obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities or change the actual or perceived competitive situation in a specific indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or may require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, licensors or licensees, including disagreements over proprietary rights, contract interpretation and breach of contract claims, payment obligations or the preferred course of development, might cause delays or termination of the research, development or commercialization of products or product candidates, might lead to additional responsibilities, including financial obligations for us with respect to products or product candidates, or delays or withholding of any payments due or might result in litigation or arbitration, any of which would be time-consuming and expensive, and could limit our ability to execute on our strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly obtain, maintain, enforce or defend our intellectual property or may use our proprietary information in such a way that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe, misappropriate or otherwise violate the intellectual property of third parties, which may expose us to litigation and potential liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our collaborations on research and development candidates do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement<span style="font-size:12pt;"> </span>with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our proprietary product candidates. Moreover, our relationships with our partners may divert significant time and effort of our scientific staff and management team and require effective allocation of our resources to multiple internal and collaborative projects. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report also apply to the activities of our program collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the future, we may enter into additional collaborations to fund our development programs or to gain access to sales, marketing or distribution capabilities. Our ability to establish additional strategic alliances will depend, among other things, on our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed strategic alliance and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or similar regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to trial participants, the potential of competing drugs, the existence of uncertainty with respect to our or the proposed collaborator&#8217;s ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions<span style="font-size:12pt;"> generally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators in a timely manner. For more information on our current collaboration agreements, see &#8220;Item&#160;4. Information on the Company&#8201;&#8212;&#8201;B. Business Overview&#8201;&#8212; Collaborations.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm the business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a public company, we incur significant legal, accounting and other expenses. The U.S. federal securities laws, including the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and the Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on public companies, including requirements to file annual and event-driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations result in substantial legal and financial compliance costs and have made some activities time-consuming and costly. We may not be able to produce reliable financial statements or file these financial statements as part of periodic report in a timely manner with the SEC or comply with Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting, including the attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To maintain compliance with Section 404, we document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we have needed to continue to dedicate internal resources, have engaged outside consultants, and have adopted a detailed work plan to assess and document the adequacy of internal control over financial reporting. We will continue to implement steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting financial institutions, companies in the financial service industry or the financial service industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect our operations and liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Development, Clinical Testing and Commercialization of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our approach to the discovery and development of product candidates based on mRNA is unproven, and we do not know whether we will be able to successfully develop any products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We focus on delivering mRNA encoding functional versions of proteins into cells without altering the underlying DNA. Our future success depends on the successful development of this novel therapeutic or vaccine approach. Relatively few mRNA-based product candidates have been tested in animals or humans, and the data underlying the feasibility of developing mRNA-based products are both preliminary and limited. To date, a limited number of products that utilize mRNA as a prophylactic vaccine against COVID-19 have been approved in the United States and Europe, subject to certain limitations. In addition, no product that utilizes mRNA as a therapeutic vaccine has been approved in the United States or Europe. We have not yet succeeded and may not succeed in demonstrating to the FDA or EMA the efficacy and safety of any of our product candidates in clinical trials or in obtaining marketing approval thereafter.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results. If clinical trials of our product candidates or production of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our technology platform. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates, our business would be significantly harmed. Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is<span style="font-size:12pt;"> </span>expensive, time-consuming and uncertain, and we may not be able to obtain approvals for the commercialization of any product candidates we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective in humans. Clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. For example, our Phase&#160;2b clinical trial with CV9104, one of our first-generation vaccines based on protamine formulation that was designed to evaluate the investigational mRNA-based cancer vaccine in patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer, failed to meet the primary endpoint of improving overall survival despite proceeding through preclinical and Phase&#160;1 studies. While we have assessed the results of past trials and these have informed our approach going forward, we can provide no assurance that future clinical trials will not be discontinued or fail to meet their specified endpoints. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to significant regulatory oversight with respect to manufacturing and developing our product candidates. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet GMP requirements set forth in regulations promulgated by the FDA, the EMA and other comparable regulatory authorities could result in significant delays in and costs of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials must be conducted in accordance with the FDA, EMA and comparable foreign regulatory authorities&#8217; legal requirements, regulations or guidelines and are subject to oversight by these governmental agencies and Institutional Review Boards, or IRBs, at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our product candidates produced in accordance with current good manufacturing practices, or cGMPs, and other requirements. We depend on medical institutions and clinical research organizations, or CROs, to conduct our clinical trials in compliance with good clinical practice, or GCP, standards. Failure to follow and document adherence to such regulations or other regulatory requirements may lead to significant delays in the availability of a product for our clinical trials, result in the termination of, or a clinical hold being placed on, one or more of our clinical trials, or delay or prevent submission or approval of marketing applications for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent our CROs fail to enroll participants for our clinical trials, fail to conduct the trial in accordance with GCP requirements or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. Our product candidates, CV2CoV (SARS-CoV-2), CV0501 (modified nucleotides, SARS - CoV - 2), CV0601/0701 (modified nucleotides, SARS-CoV-2), CVSQIV (multivalent seasonal influenza), Flu SV mRNA (modified nucleotides, single antigen seasonal influenza), CV7202 (rabies), CV8102 (melanoma, adenoidcystic carcinoma, squamous cell cancer of skin and head and neck), CVGBM (cancer), Cas9 gene - editing, are in early clinical development. All other of our research programs are in the preclinical development stage.</p><a id="_431560"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The completion of clinical trials for our clinical product candidates may be delayed, suspended or terminated as a result of many factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shortage of materials required for the production of our product candidates including due to inflationary pressures, supply chain issues, labor shortages and increases in commodity prices (including as result of the war in Ukraine) and the lingering effects of COVID-19;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability of our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers to meet regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfer of manufacturing processes to larger-scale facilities operated by a CMO or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or refusal of regulators or IRBs to authorize us to commence a clinical trial at a prospective trial site and changes in regulatory requirements, policies and guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to enroll a sufficient number of patients in trials to ensure adequate statistical power to detect statistically significant treatment effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or inconclusive results, which may require us to conduct additional preclinical or clinical trials or to abandon projects that we expect to be promising;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety or tolerability concerns causing us to suspend or terminate a trial if it is determined that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or safety concerns, among others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lower than anticipated retention rates of patients and volunteers in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our CROs or clinical trial sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays relating to adding new clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in maintaining contact with patients after treatment, resulting in incomplete data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in establishing the appropriate dosage levels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality or stability of the product candidate falling below acceptable standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to produce or obtain sufficient quantities of the product candidate to complete clinical trials on time, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exceeding budgeted costs due to difficulty in accurately predicting costs associated with clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments observed in trials conducted by competitors for related technology that raise general FDA or foreign regulatory authority concerns about risk to patients of gene therapy technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination that the product will not be producible at the manufacturing stage; and</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disruptions caused by the inflationary pressures, supply chain issues, labor shortages and increases in commodity prices (including result of the war in Ukraine) and the lingering effects of the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. The FDA, the EMA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other testing of our product candidates that we develop beyond the trials and testing that we contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are unfavorable or are only modestly favorable, or if there are safety concerns associated with our other product candidates, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing or other requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">remove the product from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product development costs will also increase if we experience delays in testing or receiving marketing approvals and we may be required to obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which may harm our business and results of operations. In addition, some of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of regulatory approval of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed and result in increased costs and longer development periods or otherwise be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will be required to identify and enroll a sufficient number of patients for our planned clinical trials. Trial participant enrollment could be limited in future trials given that many potential participants may be ineligible because of preexisting conditions, medical treatments or other reasons. We may not be able to initiate or continue clinical trials required by the FDA, EMA or other foreign regulatory agencies or any of our other product candidates that we pursue if we are unable to locate and enroll a sufficient number of eligible patients or volunteers to participate in these clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patient enrollment is affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of the clinical trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eligibility criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of the product candidate under trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived safety and tolerability of the product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of competing therapies and clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including standard-of-care and any new drugs that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to monitor patients adequately during and after treatment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also may encounter difficulties in identifying and enrolling such patients with a stage of disease appropriate for our ongoing or future clinical trials. In addition, the process of finding and diagnosing patients may prove costly. Our inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may face continued business disruption and related risks resulting from inflationary pressures, supply chain issues, labor shortages and increases in commodity prices (including as result of the war in Ukraine) and the lingering effects of the COVID-19 pandemic, which could have a material adverse effect on our business plan or clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, higher interest rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, the ongoing military conflict between Russia and Ukraine has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, if COVID-19 would restart, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving authorization from local regulatory authorities to initiate our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions in preclinical studies due to restricted or limited operations at our research and development laboratory facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to accept data from clinical trials in affected geographies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays to our sourced discovery and clinical activities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, quarantines, travel restrictions, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities upon which we rely, or the availability or cost of materials, which could disrupt the supply chain for our product candidates. We have taken a series of actions aimed at safeguarding our employees and business associates, including regular PCR-based COVID-19 testing, implementing a work-from-home policy for employees except for those related to our production and laboratory operations, and these arrangements may cause reduced productivity of our employees and/or delays or disruptions of our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our suppliers, licensors or collaborators could also be disrupted by conditions related to COVID-19, possibly resulting in disruption to our supply chain, clinical trials, partnerships or operations. If our suppliers, licensors, CMOs, CROs or collaborators are unable or fail to fulfill their obligations to us for any reason, our ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our proprietary product candidates are still in preclinical or clinical development. We cannot give any assurance that any of our product candidates will receive regulatory approval, and if we are unable to obtain regulatory approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our proprietary product candidates are still in preclinical or clinical development. Although we may receive certain payments from our collaboration partners, including upfront payments, payments for achieving certain development, regulatory or commercial milestones and royalties, our ability to generate revenue from our product candidates&#8217; sales is dependent on receipt of regulatory approval for, and successful commercialization of, such product candidates, which may never occur. Our business and future success is in particular dependent on our ability to develop, either alone or in partnership, successfully, receive regulatory approval for and then successfully commercialize our proprietary product candidates. Each of our product candidates will require additional preclinical and/or clinical development, regulatory approval in multiple jurisdictions, manufacturing supply, substantial investment and significant marketing efforts before we generate any revenue from product sales or royalties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities. The success of our product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical and/or clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or inconclusive results from our clinical trials, the clinical trials of our collaborators or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment of patients in, and completion of, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic commitment to particular product candidates and indications by us and our collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of regulatory authorizations from applicable regulatory authorities for future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of product approvals, including marketing approvals, from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of all safety studies required to obtain regulatory approval in the United States, the European Union and other jurisdictions for our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining coverage and adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining, maintaining, enforcing and defending intellectual property and intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety and quality profile of the product candidates following approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued, sufficient supply of drug substance in acceptable quality.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we do not achieve one or more of these factors in a complete and timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially adversely affect our business, financial condition, results of operations and prospects and, in case of product candidates, technologies and licenses we have acquired, which may result in a significant impairment of assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we expect to submit biologics license applications, or BLAs, for our mRNA-based product candidates in the United States, and in the European Union, mRNA-based medicines have been classified as gene therapy medicinal products, other jurisdictions may consider our mRNA-based product candidates to be new drugs, not biologics or gene therapy medicinal products, and require different marketing applications. In addition, we have not previously submitted a BLA to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to seek regulatory approval to commercialize our product candidates both in the United States and the EU, and potentially in additional foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We commenced operations in 2000 and have a long track record of performing clinical trials with multiple product candidates since 2008. Our operations to date have been limited to establishing our company, raising capital, developing our proprietary mRNA technology platform, identifying and testing potential product candidates and conducting clinical trials. We have not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek to enter into agreements with others to utilize their marketing and distribution capabilities, but we may be unable to enter into agreements on favorable terms, if at all. If we rely on others to commercialize our products if we receive the necessary approvals, our revenues may be lower than if we commercialized these products ourselves. In addition, we may have little or no control over such third parties&#8217; sales efforts. If our partners commit insufficient resources to commercialize our products, and we cannot independently develop necessary marketing capabilities, we may be unable to generate sufficient product revenue to sustain our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following regulatory approval, if any. Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials, delay or prevent regulatory approval or market acceptance of any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Undesirable side effects that may be caused by our product candidates could cause us, our collaboration partners or the regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or comparable foreign regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our trials could be suspended or terminated and the FDA, EMA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials assess a sample of the potential patient population. With a limited number of patients and duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive regulatory approval and we or others identify undesirable side effects caused by such product candidates (or any other similar products) after such approval, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw or limit their approval of such product candidates and require us to take our approved product(s) off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication, or submission of field alerts to physicians and pharmacies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or potential drug-related side effects could negatively affect patient recruitment or the ability of enrolled patients to complete a trial for our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance of our products, if any, by patients and physicians may be reduced and sales of the product, if any, may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require a Risk Evaluation and Mitigation Strategy, or a REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to regulatory investigations and government enforcement actions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may decide or be required to remove such product candidates from clinical trials, or if approved, from the marketplace;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and potentially held liable for injury caused to individuals exposed to or taking our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if any product candidates are approved, sales of the product(s) may decrease substantially; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and therefore could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">To date, a limited number of products that utilize mRNA as a prophylactic vaccine against COVID-19 have been approved in the United States, Europe and other countries, subject to certain limitations. In addition, no product that utilizes mRNA as a therapeutic vaccine has been approved in the United States or Europe. As such, mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No product that utilizes mRNA as a therapeutic vaccine has been approved in the United States or Europe. In addition, a limited number of products that utilize mRNA as a prophylactic vaccine against COVID-19 have been approved by the FDA, EMA and other regulatory agencies. Such approvals were provided after parallelized clinical trials, and certain of the products may be subject to ongoing review by the FDA, EMA or other regulatory agencies, and in some cases may be canceled, expire or subject to lengthy renewal. Successful discovery, development and continued market presence of mRNA-based (and other) products by either us or our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our or their control. Our product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic or clinical holds, or fail to reach the market or stay in the market for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discovery efforts aimed at identifying potential immunotherapies may not be successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nonclinical or preclinical study results may show product candidates to be less effective than desired or have harmful or problematic side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial results may show the product candidates to be less effective than expected, including a failure to meet one or more endpoints or have unacceptable side effects or toxicities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing failures, insufficient supply of GMP materials for clinical trials, or higher than expected cost could delay or set back clinical trials, or make our product candidates commercially unattractive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our improvements in the manufacturing processes may not be sufficient to satisfy the clinical or commercial demand of our product candidates or regulatory requirements for clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes that we make to optimize our manufacturing, testing or formulating of GMP materials could impact the safety, tolerability and efficacy of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing or reimbursement issues or other factors could delay clinical trials or make any immunotherapy uneconomical or noncompetitive with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to timely advance our programs or receive the necessary regulatory approvals, or a delay in receiving such approvals, due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, BLA, MAA or the equivalent application, discussions with the FDA or the EMA, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proprietary rights, products and technologies of our competitors may prevent our immunotherapies from being commercialized.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we expect to submit biologics license applications, or BLAs, for our mRNA-based product candidates in the United States and in the European Union, mRNA-based medicines have been classified as gene therapy medicinal products. Unlike certain gene therapies that irreversibly alter cell DNA and may cause certain side effects, mRNA-based medicines are designed not to irreversibly change cell DNA. Side effects observed in other gene therapies, however, could negatively impact the perception of immunotherapies despite the differences in mechanism. Due to the circumstances surrounding the approval of mRNA-based vaccines against COVID-19, the regulatory pathway for future mRNA products in the United States and other jurisdictions for approval is uncertain. The length of time necessary to complete clinical trials and submit an application for marketing approval by a regulatory authority varies significantly from one pharmaceutical product to the next and may be difficult to predict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA and comparable authorities are lengthy, time-consuming and inherently unpredictable and if we fail to obtain regulatory approval in any jurisdiction, we will not be able to commercialize our products in that jurisdiction and our business, results of operations, financial condition and prospects, may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA, EMA and comparable authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval laws, regulations, policies or the type and amount of clinical data or other information necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the designs or our execution of clinical trials might not be considered adequate, or the results of clinical trials may not meet the level of statistical significance required, by the FDA, EMA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected may not be sufficient to support the submission of a BLA or other submission, or to obtain regulatory approval in the United States, the European Union or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or those of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the laws, regulations or policies of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data or other regulatory submissions insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to commercialize our products in more than one jurisdiction, we will be required to obtain separate regulatory approvals in each market and to comply with numerous and varying regulatory requirements. The approval procedures vary from country to country and may require additional testing, administrative review periods, agreements with pricing authorities or other steps. Satisfying these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. In addition, in many countries outside the United States and in particular in many of the Member States of the European Union, a product must undergo health economic assessments to agree on pricing and/or be approved for reimbursement before it can be approved for sale in that country, or before it becomes commercially viable. The FDA and the EMA may come to different conclusions regarding approval of a marketing application. Approval by the FDA or EMA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA or EMA. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. We may not obtain regulatory approvals on a timely basis, if at all. We may not be able to submit applications for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. We may be required to conduct additional preclinical studies or clinical trials, which would be costly and time-consuming. If we or any future partner are unable to obtain regulatory approval for our product candidates in one or more significant jurisdictions, then the commercial opportunity for our product candidates, and our business, results of operations, financial condition and prospects, may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory landscape that will govern our product candidates is uncertain. Regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulatory requirements to which our product candidates will be subject are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and authorizes its initiation. Conversely, the FDA can place an Investigational New Drug Application, or an IND, on clinical hold even if such other entities have provided a favorable review. Furthermore, gene therapy clinical trials may also require evaluation and assessment by an institutional biosafety committee, or an IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such assessment may result in some delay before initiation of a clinical trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union a special committee called the Committee for Advanced Therapies, or the CAT, was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue-engineered products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As the regulatory landscape for our product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product sales revenue to maintain our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may materially adversely affect our business, prospects, financial condition and results of operations. We have not previously submitted a BLA to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate and never received regulatory approval for any of our product candidates. Even if the FDA, EMA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, product sampling, adverse event reporting, storage, advertising, marketing, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. There also are continuing, annual program user fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance to monitor the safety and efficacy of the product. For example, the FDA has the authority to require a REMS as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved product, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, untitled letters or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA, EMA or a comparable foreign regulatory authority to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct additional clinical trials, change our product labeling or submit additional applications or application supplements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, regulatory policies may change or additional government regulations or legislation may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we fail to comply with existing requirements, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained or face regulatory or enforcement actions, which may materially adversely affect our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, the policies of FDA, EMA and other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or to adopt new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. It is difficult to predict how current and future legislation, executive actions, and litigation, including the executive orders, will be implemented, and the extent to which they will impact our business, our clinical development, and the FDA&#8217;s and other agencies&#8217; ability to exercise their regulatory authority, including the FDA&#8217;s pre-approval inspections and timely review of any regulatory filings or applications we submit to the FDA. To the extent any executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A breakthrough therapy designation by the FDA for a product candidate may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may in the future seek a breakthrough therapy designation for one or more product candidates. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we are developing product candidates for the treatment or prevention of diseases in which there is little clinical experience using new technologies, there is increased risk that the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As we are developing novel treatments and preventative measures for diseases in which we believe there is limited clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, EMA or comparable foreign regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the European Union or other jurisdictions, if ever. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the regulatory review process, we will need to identify success criteria and endpoints such that the FDA, the EMA or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates we may develop. Because our initial focus is to identify and develop product candidates to treat or prevent diseases in which there is little clinical experience using new technologies, there is heightened risk that the FDA, the EMA or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA determines that our success criteria is sufficiently validated and clinically meaningful, we may not achieve the prespecified endpoints to a sufficient degree of statistical significance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This may be a particularly significant risk for many of the genetically defined diseases for which we plan to develop product candidates because many of these diseases have small patient populations, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations. Further, even if we do achieve the prespecified criteria, the results may be unpredictable or inconsistent with the results of the non-primary endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. The EMA and other regulatory authorities may make similar comments with respect to these endpoints and data. Any product candidate we may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We and our collaboration partners have conducted and intend to conduct additional clinical trials for selected product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations or may require additional U.S.-based trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and our collaboration partners have conducted, currently are conducting and intend in the future to conduct, clinical trials outside the United States, particularly in the European Union where we are headquartered. In addition, CureVac and its partner GSK are running the Phase 2 study with CV0601 (monovalent mRNA vaccine candidate encoding the Omicron BA.4-5 variant) and CV0701 (encoding the Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus) in Australia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be conducted by qualified investigators in accordance with GCPs, and the FDA must be able to validate the trial data through an on-site inspection, if necessary. Generally, the patient population for any clinical trial conducted outside of the United States must be representative of the population for which we intend to seek approval in the United States. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any clinical trials that we or our collaboration partners conduct outside the United States, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our ability to develop and market these or other product candidates in the United States. In other jurisdictions, for instance, in Japan, there is a similar risk regarding the acceptability of clinical trial data conducted outside of that jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the United States, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign exchange fluctuations;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, customs, shipment and storage requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cultural differences in medical practice and clinical research; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If any of our product candidates receive regulatory approval, the approved products may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The commercial success of our product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the approved labeling for a product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in the approved clinical indications for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrated clinical safety and efficacy compared to other products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of significant adverse side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales, marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of coverage and extent of reimbursement from managed care plans and other third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market introduction and perceived effectiveness of competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree of cost-effectiveness of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second-or third-line therapy for particular diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the product can be used effectively with other therapies to achieve higher response rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity about our product candidates or favorable publicity about competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">convenience and ease of administration of our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates for which we may seek approval as biologic products may face competition sooner than anticipated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act, signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent any of our product candidates approved as a biological product under a BLA qualifies for a 12-year period of exclusivity, for which we make no assurances, there is a risk that such exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for nonbiological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any approved products are subject to biosimilar competition sooner than we expect, we will face significant pricing pressure and our commercial opportunity will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other government agencies caused by inflation, funding shortages, labor shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, inflation, labor shortages, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent&#160;years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for our product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market opportunities for our product candidates may be smaller than we believe, or we may be unable to successfully identify clinical trial participants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our estimates of addressable patient populations are based on our beliefs, and have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may be lower than expected and potential clinical trial participants or patients may not be otherwise amenable to treatment with our product candidates or any products, or new clinical trial participants or patients may become increasingly difficult to identify or gain access to. Even if we obtain significant market share for our product candidates, if approved, because the potential target populations are small, these medicines may never be profitable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are not successful in discovering, developing and commercializing additional products, our ability to expand our business and achieve our strategic objectives would be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An element of our strategy is to discover, develop and commercialize products beyond our current product candidates to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our drug discovery efforts, exploring potential strategic alliances for the development of new products and in-licensing technologies. Identifying new product candidates requires substantial technical, financial and human resources. We may fail to identify promising candidates or to successfully develop and commercialize products for many reasons, which would impair our potential for growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We could be adversely affected by outbreaks of epidemic, pandemic or other contagious diseases.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a future epidemic or pandemic, our clinical trials could be paused or delayed due to restrictions (such as quarantines or travel limitations) or reprioritization of resources. Travel limitations could also create challenges and potential delays in our development and production activities, increasing the expense and timelines for producing our products and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We utilize third parties to, among other things, manufacture raw materials, components, parts and consumables. If these third parties were to experience delays or disruptions in providing their services in response to an epidemic or pandemic, our supply chain could be disrupted, limiting our ability to manufacture product candidates for our clinical trials, as well as negatively impacting our research and development operations. Such delays or disruptions could adversely impact our strategic collaborators&#8217; ability to fulfill their obligations, which could affect the clinical development or regulatory approvals of product candidates under joint development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, during a global health crisis, one or more government entities could take actions (such as via the Defense Production Act in the U.S.) that diminish our rights or economic opportunities with respect to our potential products. Our third-party service providers could be impacted by government-imposed restrictions on services they might otherwise offer. Any such action could cause us to experience delays in the development, production, distribution or export of our product candidates and increased expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The increasing use of social media platforms presents risks and challenges.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Social media is increasingly being used to communicate about our research, product candidates, commercial products and the diseases our product candidates are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This uncertainty creates risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, subjects may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations or we may be unable to defend our business in the face of political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Manufacturing of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The manufacture of mRNA-based medicines is complex and manufacturers often encounter difficulties in production, especially in the field of biologics. If we or any of our third-party manufacturers encounter difficulties, our ability to provide product candidates for clinical trials or products, if approved, to patients or future customers could be delayed or halted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The manufacture of mRNA-based medicines is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and analytics. We and our third-party manufacturers must comply with cGMP, regulations and guidelines for the manufacturing of our product candidates used in preclinical studies and clinical trials and, if approved, marketed products. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up and validating initial production. Large-scale mRNA vaccine production requires a high level of (i)&#160;equipment to build and run new facilities and (ii)&#160;raw materials to produce mRNA and to formulate the drug substance in the required volumes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities where our product candidates are made, such manufacturing facilities may be closed for an extended period of time to investigate and remedy the contamination. Shortages of raw materials may also extend the period of time required to develop our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Manufacturing these products requires facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, there are risks associated with large-scale manufacturing for clinical trials or commercial-scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that we or our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. If we or our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that any disruptions or other issues relating to the manufacture of any of our product candidates will not occur in the future. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could delay or impede the development and commercialization of any of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We and our third-party manufacturers and suppliers could be subject to liabilities, fines, penalties or other sanctions under federal, state, local and foreign environmental, health and safety laws and regulations if we or they fail to comply with such laws or regulations or otherwise incur costs that could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We manufacture and produce mRNA-based active ingredients for our product pipeline. We also currently rely on and expect to continue to rely on third parties for the manufacturing and supply of active pharmaceutical ingredients, or API, and drug products of our product candidates. We and these third parties are subject to various federal, state, local and foreign environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, labeling, transportation, use, manufacture, storage, treatment and disposal of hazardous materials and wastes and worker health and safety. We do not have control over a manufacturer&#8217;s or supplier&#8217;s compliance with environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or, in certain circumstances, an interruption in operations, any of which could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With respect to any hazardous materials or waste which we are currently, or in the future will be, generating, handling, transporting, using, manufacturing, storing, treating or disposing of, we cannot eliminate the risk of contamination or injury from these materials or waste, including at third-party disposal sites. In the event of such contamination or injury, we could be held liable for any resulting damages and liability. We also could be subject to significant civil or criminal fines and penalties, cessation of operations, investigation or remedial costs or other sanctions for failure to comply with applicable environmental, health and safety laws. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts or otherwise have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the start of the COVID-19 pandemic, we had entered in contractual engagements with third-party manufacturer to have access to additional capacity. The wind-down of these contracts entail risks of financial penalties and risk of litigation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Undetected errors or defects in our production, misconduct from our business partners and negative media reports could harm our reputation or expose us to product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Defects in the cGMP materials we produce may damage the third parties&#8217; businesses we work with and could harm their and our reputation. If that occurs, we may incur significant costs, the attention of our key personnel could be diverted, or other significant problems may arise. We may also be subject to warranty and liability claims for damages related to errors or defects in products made with our cGMP materials. In addition, if we do not meet industry or quality standards, if applicable, such products may be subject to recall. A material liability claim, recall or other occurrence that harms our reputation or decreases market acceptance of such products could harm our business and operating results. In addition, misconduct by our business partners or unfavorable publicity regarding our industry, our business partners or us can lead to reputational damage that adversely affects our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to operational risks associated with the physical and digital infrastructure at our manufacturing facilities and those of our external service providers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our manufacturing facilities incorporate a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. The digitization of our facilities exposes us to the risk of process equipment malfunctions. These risks include potential system failures or shutdowns due to internal or external factors including, design issues, system compatibility or potential cybersecurity compromises, incidents or breaches. Upgrades or changes to our systems, infrastructure or the software that we implement, use, or upon which our business relies, may result in the introduction of new cybersecurity vulnerabilities and risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our facilities and infrastructure or those of our contract manufacturers or other third-party providers may also be subject to attacks or acts of sabotage by outside actors, contractors or employees. Any disruption in our or our contract manufacturers&#8217; manufacturing capabilities could cause delays in production capacity for our drug substances or product candidates or a shutdown of facilities, could impose additional costs, cause us to fail to meet certain product candidate volume or delivery timing obligations, or may require us to identify, qualify and establish an alternative manufacturing site, the occurrence of which could adversely affect our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Collaborators and Other Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our nonclinical and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical and clinical studies and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with cGMP, GCP, Good Laboratory Practice, or GLP, and other regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Union and comparable foreign regulatory authorities for all of our product candidates in nonclinical and clinical development. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, trial sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the data generated in our nonclinical and clinical trials may be deemed unreliable and the EMA, FDA, or other regulatory authorities may require us to perform additional nonclinical and clinical trials before approving our marketing applications. In addition, even if, for example, the EMA finds our data generated in our nonclinical and clinical trials reliable for approving a marketing application, there is no assurance that other regulatory authorities like the FDA will find such data reliable and sufficient for approving a similar market application. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that all of our clinical trials comply with cGCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations, meet expected deadlines, conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we or any third-party manufacturer of our product candidates is unable to increase the scale of production of our product candidates, and/or increase the product yield of manufacturing, then our costs to manufacture the product may increase and commercialization may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates in our pipeline or that we may develop, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger-scale and more robust production could prove difficult or costly. Further, any claims in our manufacturing process as a result of scaling up or optimization of the manufacturing, supply and fill and finish process may result in the need to obtain regulatory approvals. If we or our third-party manufacturers are not able to optimize the manufacturing process to increase the product yield for our product candidates or the cGMP production requirement for clinical studies, or if we or our third-party manufacturers are unable to produce increased amounts of our product candidates while maintaining the quality of the product or generally unable to produce the right quality, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits. Difficulty in achieving commercial scale-up production or production optimization or the need for additional regulatory approvals as a result could have a material adverse impact on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain, maintain and enforce intellectual property protection for our products or product candidates, or if the scope of our intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our current and future proprietary product candidates. We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our technology, manufacturing processes, products and product candidates. We and our collaborators have primarily sought to protect our proprietary positions by filing patent applications in the United States and abroad related to our proprietary technology, manufacturing processes, and product candidates that are important to our business. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In addition, we or our collaborators, may only pursue, obtain or maintain patent protection in a limited number of countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. We may be unaware of prior art that could be used to invalidate or narrow the scope of an issued patent or prevent our pending patent applications from issuing as patents. Because patent applications in the United States, Europe and many other non-U.S. jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or any in-licensed issued patents or pending patent applications, or that we or our licensors were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Even if patents do successfully issue, our owned or in-licensed patents may not adequately protect our intellectual property, provide exclusivity for our products or product candidates, prevent others from designing around our claims or otherwise provide us with a competitive advantage. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents or whether any issued patents will be found invalid or unenforceable or will be threatened by third parties. In addition, third parties may challenge the validity, enforceability, ownership, inventorship or scope of any of our patents. Any successful challenge to any of our patents could deprive us of rights necessary for the successful commercialization of any product candidate that we may develop and could impair or eliminate our ability to collect future revenues and royalties with respect to such products or product candidates. If any of our patent applications with respect to our product candidates fail to issue as patents, if their breadth or strength of protection is narrowed or threatened, or if they fail to provide meaningful exclusivity or competitive position, it could dissuade companies from collaborating with us or otherwise adversely affect our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent position of pharmaceutical companies is generally uncertain because it involves complex legal, scientific and factual considerations for which legal principles remain unsolved. Further, mRNA medicines are a relatively new scientific field and, as the field continues to mature, patent applications are being processed by national patent offices globally. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. The standards applied by the United States Patent and Trademark Office, or the USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably, and can change. Additionally, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property rights, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement, misappropriation, or other violation of our patents or other intellectual property, including the unauthorized reproduction of our manufacturing or other know-how or the marketing of competing products in violation of our intellectual property rights generally. Any of these outcomes could impair our ability to prevent competition from third parties, which may have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, the existence of issued patents does not guarantee our right to practice the patented technology or commercialize the patented product candidate. Third parties may have or obtain rights to patents which they may use to prevent or attempt to prevent us from practicing our patented technology or commercializing any of our patented product candidates. If any of these other parties are successful in obtaining valid and enforceable patents, and establishing our infringement of those patents, we could be prevented from selling our products unless we were able to obtain a license under such third-party patents, which may not be available on commercially reasonable terms or at all. In addition, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency of competent jurisdiction may find our patents invalid or unenforceable. Our competitors and other third parties may also be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing manner. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, competitors may use our technologies in jurisdictions where we have not obtained or are unable to adequately enforce patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States and Europe. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing with us. Proceedings to enforce our patent rights, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or held unenforceable, or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop, acquire or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our patents and technology, including patents and technology relating to our yellow fever product candidate, was funded in part by the U.S. government. As a result, the U.S. government has certain rights to such patent rights and technology, which include march-in rights. When new technologies are developed with government funding, in order to secure ownership of such patent rights, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. Additionally, the U.S. government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention or to have others use the invention on its behalf. Accordingly, we have granted the U.S. government a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States, the inventions described in the patents and patent applications relating to our technology or one or more of our product candidates. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The government&#8217;s rights may also permit it to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use such government-funded technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. If we fail to comply with those requirements, we could lose our ownership of, or other rights to, any patents subject to such regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Germany, the German federal government, and the Federal Ministry of Health and downstream authorities, in the event of a national epidemic, have the right to order the use of our owned and in-licensed patents in the interest of the public welfare or the security of the Federal Republic. The German government may issue such an order with respect to our owned or in-licensed patents and we may lose exclusivity with respect to the technologies and product candidates covered by such patents. We would be entitled to compensation in the event a use order is issued with respect to our owned or in-licensed patents; however, such compensation may be less than what we could otherwise receive and any such use order could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Russia, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in a partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, it is uncertain whether the World Trade Organization, or the WTO, will waive certain intellectual property protections now or in the future on certain technologies related to COVID-19 or other future pandemics. We cannot be certain that any of our current or future product candidates or technologies would not be subject to an intellectual property waiver by the WTO. We also cannot be certain that any of our current or future intellectual property rights, whether patents, trade secrets, or other confidential information would be eliminated, narrowed, or weakened by such a waiver. Given the uncertain future actions by the WTO and other countries and jurisdictions around the world, including the United States, it is unpredictable how our current or future intellectual property rights or how our current or future business would be impacted.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the research resulting in certain of our patents and technology was funded in part by the German Ministry of Education and Research, or the BMBF. Results of such government-funded research projects must, subject to certain conditions, be made available free of charge for academic research and teaching in Germany and must be published in half-yearly interim reports and a final report following completion of the funded work. Information relating to intellectual property generated, commercial expectations, scientific chances of success and next steps and certain additional information must be disclosed to the German government and must be disclosed to third parties for academic research and teaching upon request under a written confidentiality agreement. The BMBF additionally has, in the case of a special public interest, a nonexclusive and transferable right to use intellectual property generated as part of the funded work. Contracts with third parties relating the exploitation of the results of the funded work must be disclosed to the BMBF and any such contracts with parties outside of the European Union require the prior consent of the BMBF to the extent they deviate from an exploitation plan previously approved by the BMBF. Additionally, if we fail to use or commercialize the results of the funded work we may be required to grant third parties licenses to use such results. In certain scenarios, including if we come under the decisive influence of foreign investors, the funded results are exclusively or predominantly used outside Germany without the prior consent of the BMBF or if we are in breach of our obligations under the grant, the grant funding, including funding already received, can be revoked.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, certain of our patents and technology, including patents and technology relating to our rotavirus, malaria, Lassa virus and SARS-CoV-2 projects, were funded in part by grants from nonprofit third parties, including the Bill &amp; Melinda Gates Foundation and CEPI. We are required to fulfill certain contractual obligations with respect to products created using such grant funding, including making certain products available at an affordable price in a list of clearly defined low- and lower-middle income countries and ensuring that certain products are available in geographic regions where there has been an outbreak of an infectious disease at certain reduced economic rates. See &#8220;Item&#160;4. Information on the Company &#8212; B. Business Overview &#8212; Collaborations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after its effective filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing, regulatory review and approval of new product candidates, our patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we encounter delays in obtaining regulatory approvals, the period of time during which we could market a product under patent protection could be further reduced. Even if patents covering our product candidates are obtained, once such patents expire, we may be vulnerable to competition from similar or biosimilar products. The launch of a similar or biosimilar version of one of our products would likely result in an immediate and substantial reduction in the demand for our product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to comply with our obligations under any license, collaboration or other intellectual property agreements, disagree over contract interpretation, or otherwise experience disruptions to our business relationships with our collaborators or licensors, we could lose intellectual property rights that are necessary to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely, in part, on license, collaboration and other intellectual property agreements. These may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our product candidates in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our existing licenses and collaboration agreements, including our agreements with Genmab, Acuitas, GSK, the Bill &amp; Melinda Gates Foundation, CRISPR Therapeutics, CEPI and myNEO, impose, and any future licenses, collaborations or other intellectual property agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. Our licenses and collaboration agreements, including our agreement with Genmab, impose, and any future agreement we enter into may also impose, restrictions on our ability to license certain of our intellectual property to third parties or to develop or commercialize certain product candidates or technologies. In spite of our best efforts, our licensors, licensees and collaborators may conclude that we have breached our obligations under our agreements, or that we have used the intellectual property licensed to us in an unauthorized manner, in which case, we may be required to pay damages and the licensor, licensee or collaborator may have the right to terminate the agreement. Any of the foregoing could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology, enable a competitor to gain access to the licensed technology or disrupt our right to milestone or royalty payments. We might not have the necessary rights or the financial resources to develop, manufacture or market our current or future product candidates without the rights granted under our licenses, and the loss of sales or potential sales in such product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Disputes have arisen and may in the future arise regarding intellectual property subject to licensing, collaboration or other intellectual property agreements, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial obligations under the license agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the agreements under which we currently license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or expand the rights of our licensors or partners to the relevant intellectual property or technology, including their ability to use or license such intellectual property or technology to third parties. In addition, such resolution may also increase what we believe to be our financial or other obligations under the relevant agreement. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some circumstances, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. We cannot be certain that these patents and applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such intellectual property, or lose rights to such intellectual property, the rights we have licensed and our exclusivity may be reduced or eliminated and our right to develop and commercialize any of our products that are subject to such licensed rights could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, our rights to our in-licensed patents and patent applications may depend, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. In addition, the development of certain of our product candidates is funded by grants that impose certain pricing limitations on such product candidates and limit our ability to commercialize such product candidates and to achieve or maintain profitability. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have on reasonable terms or at all, we may have to abandon development of the relevant program or product candidate and our business, financial condition, results of operations and prospects could suffer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are and may in the future become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful and could result in a court or administrative body finding our patents to be invalid or unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if the patent applications we own or license are issued, third parties may infringe our patents. To counter infringement, we have been and may in the future be required to file infringement claims, which can be expensive and time-consuming. If we initiate legal proceedings against a third-party to enforce a patent covering any of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including novelty, nonobviousness (or inventive step), written description or enablement. In addition, patent validity challenges may, under certain circumstances, be based upon nonstatutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. In an infringement proceeding, a court may decide that one or more of our patents is not valid, is unenforceable or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, post-grant review, <i style="font-style:italic;">inter partes</i> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings, revocation actions, nullity actions or cancellation actions). Such proceedings could result in the revocation or cancellation of, or amendment to, our patents or other intellectual property rights such as utility models, in such a way that they no longer cover our product candidates or provide any competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Litigation is ongoing over the underlying technology to mRNA medicines between many mRNA market participants. It is likely that there will continue to be significant litigation and patent office proceedings in various patent offices relating to patent rights in the mRNA field. For example, one of our manufacturing related U.S. patents was invalidated in an <i style="font-style:italic;">inter partes</i> review proceeding and certain of our European patents relating to RNA-based adjuvants/immunostimulants, RNA-coded antibodies, mRNA vaccination of the elderly, intratumoral (m)RNA treatments, polyvalent mRNA production, optimized in vitro transcription, and mRNA vaccination in combination with an anti-PD1 or anti-PD-L1 antibody have been revoked in European opposition proceedings. Further European patents have been amended after opposition proceedings. For example, European patents related to an mRNA injection solution, mRNA vaccination of newborns and infants, combination of mRNA-based vaccination and agonistic OX40 antibodies and method of RNA analysis have been amended. Further European patents have been maintained after opposition proceedings. One of these patents relates to an mRNA injection solution and the other relates to sequence optimization of a coding sequence. Some of these decisions are currently on appeal and continuation or divisional applications of certain of the maintained, revoked and amended patents have been filed and are currently under examination, although there can be no assurance that any such appeal will be successful or that any such patent applications will issue as patents that provide us with any competitive advantage. Additionally, several of our European and Australian patents relating to intratumoral treatment, mRNA vaccination in combination with an anti-PD1/PD-L1 antibody, prime-boost regimens, lyophilization of RNA, spray-drying of RNA, spray-freeze-drying of RNA, an mRNA comprising a split poly(A) sequence, mRNA production comprising tangential flow filtration, and an improved method for plasmid production for in vitro transcription of mRNA are currently subject to opposition proceedings. The outcome following legal assertions of invalidity and unenforceability is unpredictable. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose part or all of the patent protection on one or more of our product candidates, which could result in our competitors and other third parties using our technology to compete with us. Such a loss of patent protection could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interference proceedings, or other similar enforcement and revocation proceedings, provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications. We may not be able to prevent, alone or with our licensors, infringement, misappropriation or other violation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2022, we filed a lawsuit against BioNTech SE and its wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH (collectively, &#8220;BioNTech&#8221;), in the D&#252;sseldorf Regional Court, for infringement of one European patent, EP1857122B1, (&#8220;EP&#8217;122 Patent&#8221;), and three utility models, DE202015009961U1, DE202015009974U1, and DE202021003575U1, as a result of the manufacture, use and sale of Comirnaty, BioNTech and Pfizer&#8217;s mRNA COVID-19 vaccine.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2022, we added European Patent EP3708668B1 (&#8220;EP&#8217;688 Patent&#8221;) to the German lawsuit. In July 2023, we added European Patent EP4023755B1 (&#8220;EP&#8217;755 Patent&#8221;) and two further utility models, DE202021004123U1 and DE 202021004130U1, to the German lawsuit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2022, BioNTech filed a nullity action in the Federal Patent Court of Germany seeking a declaration that the EP&#8217;122 Patent is invalid. In December 2023, the Federal Patent Court in Germany revoked this patent in the first instance. The formal reasons for the decision of the court have not yet been provided. CureVac intends to appeal this decision before the German Federal Court of Justice. Subsequently, the Dusseldorf Court decided to suspend the infringement proceedings until a final decision on validity from the German Federal Court of Justice is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2022, BioNTech filed cancellation actions seeking the cancellation of three German utility models DE202015009961U1, DE202015009974U1, and DE202021003575U1 in the German Patent and Trademark Office, and we are defending these actions.In September 2023 the Dusseldorf Court decided to suspend the infringement proceedings for these three utility models until the cancellation division of the German Patent and Trademark Office (DPMA) has reached a decision in the first instance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2023, BioNTech and Pfizer, among others, filed oppositions against the EP&#8217;668 Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, BioNTech filed cancellation actions against the two utility models, DE202021004123U1 and DE 202021004130U1 in the German Patent and Trademark Office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2023 and January 2024, BioNTech and Pfizer, among others, filed oppositions against the EP&#8217;755 Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2022, BioNTech and Pfizer filed a declaration of non-infringement and revocation action against the EP&#8217;122 Patent and the EP&#8217;668 Patent in the Patents Court of the Business and Property Courts of England and Wales. In October 2022, we counterclaimed seeking an order that the EP &#8216;122 Patent and EP &#8216;688 Patent are infringed and are valid (the &#8220;UK Proceedings&#8221;). In February 2024 we added the EP&#8217;755 Patent to our infringement claim. The trial is currently scheduled for July 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2022, BioNTech and Pfizer filed a complaint for a declaratory judgment in the U.S. District Court for the District of Massachusetts, seeking a judgment of non-infringement by Comirnaty of U.S. Patent Nos. 11,135,312, 11,149,278 and 11,241,493. Subsequently we filed a motion to have the case transferred to the Eastern District of Virginia, and such motion was granted in May 2023. Subsequently,we filed our counterclaim claiming infringement of ten U.S. patents, U.S. Patent No. 11,135,312; U.S. Patent No. 11,149,278; U.S. Patent No. 11,286,492; U.S. Patent No. 11,345,920; U.S. Patent No. 10,760,070; U.S. Patent No. 11,667,910; U.S. Patent No. 11,241,493; U.S. Patent No. 11,471,525; U.S. Patent No. 11,576,966; and U.S. Patent No. 11,596,686. The jury trial is currently scheduled for January 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, Acuitas filed a Motion to Intervene, a Motion to Sever and Stay and a Complaint for Declaratory Judgement of Inventorship to seek correction of inventorship regarding four United States patents, U.S. Patent No. 11,241,493; U.S. Patent No. 11,471,525; U.S. Patent No. 11,576,966; and U.S. Patent No. 11,596,686 which are part of the litigation against BioNTech and Pfizer. In April 2024, Acuitas' motion was granted, with the judge recommending to stay litigation of all ten patents before the District Court of the Eastern District of Virginia until the Acuitas claim is resolved. CureVac is preparing objections to this recommendation and anticipates a decision within the next two months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2023, Acuitas filed a Request of Arbitration to resolve a dispute between Acuitas and CureVac regarding the ownership and licensing rights with regard to the patent family WO2021/156267 which is part of the litigation against BioNTech and Pfizer in Germany and the United States. CureVac is defending itself against these claims. The possible outcome of this dispute cannot be predicted at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of such proceedings are currently pending. In the course of pursuing our case for infringement and defending against the challenges to our patent estate from Pfizer and BioNTech, should we ultimately not be successful, we will be liable for our own and may be liable for BioNTech and Pfizer&#8217;s legal costs in at least Germany and the UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">An unfavorable outcome could also require us to cease using the related technology or attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">In many cases, the possibility of appeal exists for any party, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. We cannot be certain that any patent will survive or that the claims will remain in the current form. Even if our rights are not directly challenged, disputes could lead to the weakening of our IP rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Additionally, an adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are sued for infringing, misappropriating, or otherwise violating intellectual property rights of third parties, such litigation could be costly and time-consuming and could prevent or delay us from developing or commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing, misappropriating, or otherwise violating the intellectual property and other proprietary rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights of third parties with respect to our product candidates, including interference and post-grant proceedings before the USPTO. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, formulation, use or manufacture of our product candidates. Because patent applications can take many&#160;years to issue, there may be currently pending patent applications that we may or may not be aware of which may later result in issued patents that our product candidates may be accused of infringing. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction based on interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform. If we<span style="font-size:12pt;"> </span>are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims at issue are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us, especially as we gain greater visibility and market exposure as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Third parties have, and may in the future have, U.S. and non-U.S. issued patents and pending patent applications relating to compounds, methods of manufacturing compounds or methods of use for the treatment of the disease indications for which we are developing our product candidates that may cover our product candidates. For example, we are aware of certain third-party U.S. and non-U.S. issued patents and patent applications, including those of our competitors, that relate to mRNA production, mRNA optimization, modification of mRNA, LNP technology, RNA-based tumor vaccination, LNP formulation, LNP-based mRNA delivery to the eye, lung or liver, mRNA encoding gene-editing enzymes, RNA-encoded antibodies or antigens in LNPs and LNP-formulated RNA that may be construed to cover the LNP-formulated RNA technology used in our vaccines and protein and antibody therapies. We are also aware of certain third-party U.S. and non-U.S. patents and patent applications, including those of our competitors, that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">relate to coronavirus vaccines, influenza virus vaccines, Respiratory Syncytial Virus (RSV) vaccines and treatments and vaccines against other infectious diseases and we expect such third parties to have filed additional patent applications, which have not yet been published, and to file additional patent applications in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that any of these patent rights were asserted against us, we believe that we have defenses against any such action, including that such patents would not be infringed by our product candidates and/or that such patents are not valid. However, if any such patent rights were to be asserted against us and our defenses to such assertion were unsuccessful, unless we obtain a license to such patents, we could be liable for damages, which could be significant and include treble damages and attorneys&#8217; fees if we are found to willfully infringe such patents, and we could be precluded from commercializing any product candidates that were ultimately held to infringe such patents, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are required to obtain a license from any third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate, we may not be able to obtain such required license on commercially reasonable terms or at all. In particular, any of our competitors that control intellectual property that we are found to infringe may be unwilling to provide us a license under any terms. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. Further, if a patent infringement suit is brought against us or our third-party service providers and if we are unable to successfully obtain rights to required third-party intellectual property, we may be required to expend significant time and resources to redesign our product candidates, or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis, and may delay or require us to abandon our development, manufacturing or sales activities relating to our product candidates. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property litigation and other proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, intellectual property litigation or other legal proceedings relating to our, our licensor&#8217;s or other third parties&#8217; intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. Patent litigation and other proceedings may also absorb significant management time. If not resolved in our favor, litigation may require us to pay any portion of our opponents&#8217; legal fees. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Our competitors or other third parties may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from our participation in patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in certain jurisdictions in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the perceived value of our product candidates or intellectual property could be diminished. Accordingly, the market price of our common shares may decline. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes to the patent law in the United States and other jurisdictions could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, thereby impairing our ability to protect our technologies and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, the Leahy-Smith America Invents Act, or the America Invents Act, was signed into law on September&#160;16, 2011, and many of the substantive changes became effective on March&#160;16, 2013. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Specifically, the America Invents Act reforms United States patent law in part by changing the U.S. patent system from a &#8220;first to invent&#8221; system to a &#8220;first inventor to file&#8221; system. Under a &#8220;first inventor to file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor was the first to invent the invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications. Circumstances may arise that could prevent us from promptly filing patent applications on our inventions and allow third parties to file patents claiming our inventions before we are able to do so. The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by the USPTO administered post-grant proceedings, including reexamination proceedings, <i style="font-style:italic;">inter partes</i> review, post-grant review and derivation proceedings. These adversarial proceedings at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant review or <i style="font-style:italic;">inter partes</i> review proceeding than in a litigation in a U.S. federal court. One of our manufacturing-related patents has been invalidated in an <i style="font-style:italic;">inter partes</i> proceeding and if any of our other patents are challenged by a third-party in a USPTO proceeding, there is no guarantee that we or our licensors or collaborators will be successful in defending the patent, which would result in a loss or narrowing of the challenged patent right to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways. In addition, the complexity and uncertainty of European patent laws have also increased in recent&#160;years. Complying with these laws and regulations could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims by third parties asserting that our employees, consultants, independent contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property and proprietary technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of our current and former employees, consultants, and independent contractors including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees, consultants or independent contractors have used or disclosed intellectual property, including trade secrets or other proprietary information, of such individual&#8217;s current or former employers, or that patents and applications we have filed to protect inventions of these individuals, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize our technology or products. Such a license may not be available on an exclusive basis or on commercially reasonable terms, or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, while we typically require our employees, consultants and independent contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, or such agreements may be breached or alleged to be ineffective, and the assignment may not be self-executing, which may result in claims by or against us related to the ownership of such intellectual property or may result in such intellectual property becoming assigned to third parties. If we fail in enforcing or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection, including patents licensed from third parties, depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and patent applications will be due to be paid to the USPTO and various government patent agencies outside the United States over the lifetime of our patents and patent applications and any patent rights we may own or license in the future. Additionally, the USPTO and various government patent agencies outside the United States require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we or our licensors fail to maintain the patents and patent applications covering or otherwise protecting our product candidates, it could have a material adverse effect on our business. In addition, to the extent that we have responsibility for taking any action related to the prosecution or maintenance of patents or patent applications in-licensed from a third party, any failure on our part to maintain the in-licensed intellectual property could jeopardize our rights under the relevant license and may have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extensions and data exclusivity for each of our product candidates, our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. In the European Union, a maximum of five and a half&#160;years of supplementary protection can be achieved for an active ingredient or combinations of active ingredients of a medicinal product protected by a basic patent, if a valid marketing authorization exists (which must be the first authorization to place the product on the market as a medicinal product) and if the product has not already been the subject of supplementary protection. However, we may not receive an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or if the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Certain employees and patents are subject to German law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A significant number of our personnel work in Germany and are subject to German employment law. Inventions which may be the subject of a patent or of protection as a utility model as well as technical improvement proposals for other technical innovations that may not be the subject of a patent or of protection as a utility model made by such employees are subject to the provisions of the German Act on Employees&#8217; Inventions (<i style="font-style:italic;">Gesetz &#252;ber Arbeitnehmererfindungen</i>), which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes may occur between us and our current or former employees pertaining to the sufficiency of compensation paid by us, allocation of rights to inventions under this act, or alleged nonadherence to the provisions of this act, any of which may be costly to resolve and take up our management&#8217;s time and efforts whether we prevail or fail in such dispute. In addition, under the German Act on Employees&#8217; Inventions, certain employees retain rights to patents they invented or co-invented and disclosed to us prior to October&#160;1, 2009 if the employee inventions were not actively claimed by us after notification by the employee inventors. While we believe that all of our current and past German employee inventors have assigned to us their interest in inventions and patents they invented or co-invented, there can be no assurance that all such assignments are fully effective. Therefore, there can be no assurance that present or former employees do not hold rights to intellectual property used by us or that such employees will not demand the registration of intellectual property rights in their name or demand damages pursuant to the German Act on Employees&#8217; Inventions or other applicable laws. Even if we lawfully own all inventions of our employee inventors who are subject to the German Act on Employees&#8217; Inventions, we are required under German law to reasonably compensate such employees for the use of the inventions. If we are required to pay increased compensation or face other disputes under the German Act on Employees&#8217; Inventions, our business, financial condition, results of operations and prospects could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The German Act on Employees&#8217; Inventions does not generally apply to managing directors, supervisory directors, freelancers or agents who are not employees under German labor law. Unless the German Act on Employees&#8217; Inventions has been referred to in the respective services agreements, inventions and intellectual property rights created by such inventors must be assigned to us by contract. While we believe that all of our managing directors, supervisory directors, freelancers or agents which are not employees have assigned to us their interest in inventions and patents required for our course of business, there can be no assurance that all such assignments are fully effective. If any of our current or past employees, managing directors, supervisory directors, freelancers or agents obtain or retain ownership of any inventions or related intellectual property rights that we believe we own, we may lose valuable intellectual property rights and be required to obtain and maintain licenses from such persons to such inventions or intellectual property rights, which may not be available on commercially reasonable terms or at all, or may be nonexclusive. If we are unable to obtain and maintain a license to any such person&#8217;s interest in such inventions or intellectual property rights, we may need to cease the development, manufacture, and commercialization of one or more of our product candidates or the product candidates we may develop. In addition, any loss of exclusivity of our intellectual property rights could limit our ability to stop others from using or commercializing similar or identical technologies and products. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to patent protection, we also rely on trade secrets and confidentiality agreements to protect other proprietary information that is not patentable or that we elect not to patent. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, independent contractors, collaborators, CMOs, CROs and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or entity or made known to the individual or entity by us during the course of the individual&#8217;s or entity&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees as well as our personnel policies also generally provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property (to the extent not covered by the German Act on Employees&#8217; Inventions) or that we may obtain full rights to such inventions at our election. However, we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes and cannot guarantee that individuals with whom we have these agreements will comply with their terms. We also face the risk that present or former employees could continue to hold rights to intellectual property used by us, may demand the registration of intellectual property rights in their name and demand damages pursuant to the Patent Act. In addition, present or former employees may demand damages due to violation of obligations under the German Act on Employees&#8217; Invention. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not have adequate remedies in the event of unauthorized use or disclosure of our proprietary information in the case of a breach of any such agreements and our trade secrets and other proprietary information could be disclosed to third parties, including our competitors. Many of our partners also collaborate with our competitors and other third parties. The disclosure of our trade secrets to our competitors, or more broadly, would impair our competitive position and may materially harm our business, financial condition, results of operations and prospects. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Courts outside the United States are sometimes less willing to protect proprietary information, technology and know-how. In addition, others may independently discover or develop substantially equivalent or superior proprietary information and techniques, and the existence of our own trade secrets affords no protection against such independent discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in obtaining necessary intellectual property rights to product candidates for our development pipeline through acquisitions and in-licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we intend to develop product candidates through our own internal research, we may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates and it is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. However, we may be unable to acquire or in-license intellectual property rights relating to, or necessary for, any product candidates from third parties on an exclusive basis or commercially reasonable terms or at all. In that event, we may be unable to develop or commercialize such product candidates. We may also be unable to identify product candidates that we believe are an appropriate strategic fit for our company and intellectual property relating to, or necessary for, such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The in-licensing and acquisition of third-party intellectual property is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of Europe or the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside of Europe and the United States, or from selling or importing products made using our inventions in and into those countries or other jurisdictions. Third parties may use our technologies in jurisdictions where we have not obtained or are unable to adequately enforce patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in Europe or the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business, financial condition, results of operations and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names or marks which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business, financial condition, results of operations and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our proprietary and intellectual property rights is uncertain because such rights offer only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to develop products that are similar to, or better than, our product candidates in a way that is not covered by the claims of the patents we license or may own currently or in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our licensing partners or current or future collaborators, might not have been the first to make the inventions covered by issued patents or pending patent applications that we license or may own currently or in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our licensing partners or current or future collaborators, might not have been the first to file patent applications for certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our pending owned or in-licensed patent applications may not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found not to be owned by us, invalid or unenforceable; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business, financial conditions, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our current and future relationships with third-party payors, healthcare professionals and customers in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency and other healthcare laws and regulations, which could expose us to significant penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal civil False Claims Act, that may constrain the business or financial arrangements and relationships through which we conduct clinical research, sell, market and distribute any products for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. Further, several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of a federal healthcare-covered business, the Anti-Kickback Statute has been violated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including, without limitation, the federal civil False Claims Act (that can be enforced through civil whistleblower or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">qui tam </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions), and the civil monetary penalties law, which impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Public Health Service Act, or the PHSA, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Physician Payments Sunshine Act, created under Section&#160;6002 of the Affordable Care Act, and its implementing regulations, which requires specified manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or the CMS, information related to payments or other &#8220;transfers of value&#8221; made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and certain other healthcare providers beginning in 2022, and which requires teaching hospitals and applicable manufacturers to report annually to CMS ownership and investment interests held by physicians and their immediate family members by the 90th day of each calendar year. All such reported information is publicly available; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; and state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom may recommend, purchase or prescribe our product candidate, if approved, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement. The insurance coverage and reimbursement status of newly approved products for orphan diseases is particularly uncertain and failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to generate revenue. Third-party payors may not view our product candidates, if approved, as cost-effective, and coverage and reimbursement may not be available to our customers or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. If coverage and reimbursement are not available, or reimbursement is available only to limited levels, we, or any future collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. Cost-control initiatives could also cause us to decrease any price we might establish for our product candidates, which could result in lower than anticipated product revenues. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including our costs related to research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. If the prices for our product candidates, if approved, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our business, prospects, operating results and financial condition will suffer, perhaps materially.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products, including genetic treatments. In the United States, the Centers for Medicare &amp; Medicaid Services, or the CMS, the federal agency responsible for administering the Medicare program, make the principal decisions about coverage and reimbursement for new treatments under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours. In addition, certain Affordable Care Act marketplace and other private payor plans are required to include coverage for certain preventative services, including vaccinations recommended by the U.S. Centers for Disease Control&#8217;s, or the CDC&#8217;s, Advisory Committee on Immunization Practices, or ACIP, without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members. For Medicare beneficiaries, vaccines may be covered for reimbursement under either the Part&#160;B program or Part&#160;D depending on several criteria, including the type of vaccine and the beneficiary&#8217;s coverage eligibility. If our vaccine candidates, once approved, are reimbursed only under the Part&#160;D program, physicians may be less willing to use our products because of the claims adjudication costs and time related to the claims adjudication process and collection of co-payment associated with the Part&#160;D program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, certain countries, including a number of Member States of the European Union, set prices and reimbursement for pharmaceutical products, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues from sales by us or our collaborators, and the potential profitability of our product candidates, in those countries would be negatively affected. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, an increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run healthcare systems. These international price control efforts have impacted all regions of the world, but have been most drastic in the European Union. In some countries, in particular, in many Member States of the European Union, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. In addition, publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially adversely affected. Cost-control initiatives could cause us, or any future collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenues. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we, or any future collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Price controls may be imposed in certain markets, which may adversely affect our future profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some countries, particularly Member States of the European Union, the pricing of prescription drugs is subject to governmental control or control by associations of health insurers. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost-containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. In some countries, in particular, in many Member States of the European Union, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exchange rate fluctuations or abandonment of the euro currency may materially affect our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Potential future expense and revenue may be incurred or derived from outside the European Union, particularly the United States. As a result, our business and share price may be affected by fluctuations in foreign exchange rates between the euro and other currencies, particularly the U.S. dollar, which may also have a significant impact on our reported results of operations and cash flows from period to period. In addition, the abandonment of the euro by one or more members of the European Union could lead to the re-introduction of individual currencies in one or more European Union Member States, or in more extreme circumstances, the dissolution of the European Union. The effects on our business of the abandonment of the euro as a currency, the exit of one or more European Union Member States from the European Union (such as Brexit) or a potential dissolution of the European Union, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">More generally, shifts in geopolitical balance, political crisis or wars may affect foreign exchange rates between the euro and other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We could be subject to strict restrictions on the movement of cash and the exchange of foreign currencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some countries, we could be subject to strict restrictions on the movement of cash and the exchange of foreign currencies, which would limit our ability to use this cash across our global operations. This risk could increase as we continue our geographic expansion, and in particular if we seek to expand into emerging markets, which are more likely to impose these restrictions than more established markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, President Obama signed the Affordable Care Act into law. Among the provisions of the Affordable Care Act of potential importance to our business and our product candidates are the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription products and biologic products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of manufacturers&#8217; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that certain Affordable Care Act marketplace and other private payor plans include coverage for preventative services, including vaccinations recommended by the ACIP without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Independent Payment Advisory Board, or an IPAB, which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the establishment of the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial and congressional challenges to numerous aspects of the Affordable Care Act. We are continuing to monitor any changes to the Affordable Care Act that, in turn, may potentially impact our business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021. In addition, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our product candidates, if approved, and, accordingly, the results of our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which has resulted in several congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The policies of the FDA or similar regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. It is difficult to predict how current and future legislation, executive actions, and litigation, including the executive orders, will be implemented, and the extent to which they will impact our business, our clinical development, and the FDA&#8217;s and other agencies&#8217; ability to exercise their regulatory authority, including FDA&#8217;s preapproval inspections and timely review of any regulatory filings or applications we submit to the FDA. To the extent any executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot predict whether future healthcare legislative or policy changes will be implemented at the federal or state level or in countries outside the United States in which we may do business, or the effect any future legislation or regulation will have on us, but we expect there will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of healthcare.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cyberattacks or other failures in our or our third-party vendors&#8217;, contractors&#8217; or consultants&#8217; telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We utilize information technology, or IT, systems and networks and cloud computing services to process, transmit and store electronic information in connection with our business activities. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data centers and cloud-based data centers. We utilize external security and infrastructure vendors to manage our information technology systems and data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information, and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data. Despite the implementation of cybersecurity measures, given the size and complexity of our internal IT systems and those of our third-party vendors, contractors and consultants, and the increasing amounts of confidential information that they maintain, such IT systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, and telecommunication and electrical failures. Such IT systems are additionally vulnerable to cybersecurity breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners, and/or other third parties, or from cyberattacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information). These threats pose a risk to the cybersecurity of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cybersecurity threats are persistent and constantly evolving. Such threats have increased in frequency, scope and potential impact in recent years, which increase the difficulty of detecting and successfully defending against them. We may not be able to anticipate all types of cybersecurity threats, and we may not be able to implement preventive measures effective against all such cybersecurity threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies. There can be no assurance that we or our third-party service providers, contractors or consultants will be successful in preventing cyberattacks or successfully mitigating their effects. Similarly, there can be no assurance that such third-party service providers, contractors or consultants will be successful in protecting our clinical and other data that is stored on their systems. If the IT systems of our third-party vendors and other contractors and consultants become subject to disruptions or cybersecurity breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. Any cyberattack or destruction or loss of data could have a material adverse effect on our business, financial condition, results of operations and prospects. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party vendors and other contractors and consultants, it could result in a material disruption or delay of the development of our product candidates. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyberattacks or other data security breaches and may incur significant additional expense to implement further data protection measures. As cybersecurity threats continue to evolve, we may be required to incur material additional expenses in order to enhance our protective measures or to remediate any information security vulnerability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">O</span>ur business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are in the early stages of developing disaster recovery, business continuity plans and document retention plans designed to allow us to be operational despite unforeseen events,&#160;including natural disasters such as an earthquake, fire, hurricane, tornado, flood or significant power outage; political crises, such as terrorist attacks, war and other political instability, including the ongoing geopolitical tensions related to Russia&#8217;s actions in Ukraine and associated international sanctions in response to such sanctions; or other catastrophic events. Without disaster recovery, business continuity and document retention plans, if we encounter difficulties or disasters with our manufacturing facilities, affiliates, corporate headquarters or those of third parties we rely on, our critical systems, operations and information may not be restored in a timely manner, or at all, and our business activities could be materially disrupted. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may experience growth in the number of our employees and the scope of our operations in the areas of clinical development and regulatory affairs. We are currently constructing a new facility, designed for the development of a cGMP production process on a large industrial scale for market supply. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these activities. Moreover, our growth could require us to relocate to a different geographic area of the country. We may not be able to effectively manage any expansion or relocation of our operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, and give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful development and commercialization of our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Engaging in acquisitions, joint ventures or collaborations may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numerous risks, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating expenses and cash requirements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assumption of additional indebtedness or contingent liabilities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk in the retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have an adverse effect on the results of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators and consultants, despite our robust efforts to prevent such misconduct through sponsor oversight. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and cybersecurity and changes in such laws, regulations, policies and contractual obligations could adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Additionally, if we are unable to properly protect the privacy and security of personal information, including protected health information, we could be found to have breached our contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. If we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. The HHS has the discretion to impose penalties without attempting to first resolve violations. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. Even when HIPAA does not apply, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce and be construed as a violation of Section&#160;5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C &#167;&#160;45(a). The Federal Trade Commission, or the FTC, expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards and the FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, many states in which we operate have laws that protect the privacy and security of personal information. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act, or the CCPA, increases privacy rights for California residents and imposes obligations on companies that process their personal information. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. The CCPA also creates a new state agency that will be vested with authority to implement and enforce the CCPA. State laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we would become subject if it is enacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Internationally, laws, regulations and standards in many jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal information. For example, in the European Union, the collection and use of personal data is governed by the provisions of the General Data Protection Regulation, or the GDPR, in addition to other applicable laws and regulations. The GDPR came into effect in May 2018, repealing and replacing the European Union Data Protection Directive, and imposing revised data privacy and security requirements on companies in relation to the processing of personal data of European Union and United Kingdom data subjects. The GDPR, together with national legislation, regulations and guidelines of the European Union Member States and the United Kingdom governing the processing of personal data, impose strict obligations with respect to, and restrictions on, the collection, use, retention, protection, disclosure, transfer and processing of personal data. The GDPR imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States. For example, in 2016, the European Union and United States agreed to a transfer framework for data transferred from the European Union to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. The standard contractual clauses issued by the European Commission, or the EC, for the transfer of personal data may be similarly invalidated by the Court of Justice of the European Union. On June 4, 2021, the EC adopted new standard contractual clauses, which impose on companies&#8217; additional obligations relating to data transfers, including the obligation to conduct a transfer impact assessment and, depending on a party&#8217;s role in the transfer, to implement additional security measures and to update internal privacy practices. If we elect to rely on the new standard contractual clauses for data transfers, we may be required to incur significant time and resources to update our contractual arrangements and to comply with new obligations. If we are unable to implement a valid mechanism for personal data transfers from the EU, we will face increased exposure to regulatory actions, substantial fines and injunctions against processing personal data from the EU. It remains to be seen whether these standard contractual clauses will remain available and whether additional means for lawful data transfers will become available. The GDPR authorizes fines for certain violations of up to 4% of the total global annual turnover of the preceding financial year or &#8364;20 million, whichever is greater. Such fines are in addition to any civil litigation claims by data subjects. Separately, Brexit could also lead to further legislative and regulatory changes and increase our compliance costs. As of January 1, 2021, and the expiry of transitional arrangements agreed to between the United Kingdom and the European Union, data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June 28, 2021, the European Commission adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from European Union member states to the United Kingdom without additional safeguards. However, the United Kingdom adequacy decision will automatically expire in June 2025 unless the European Commission reassesses and renews or extends that decision. Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations, which could increase our compliance costs and the risks associated with noncompliance. We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with federal, state and international laws regarding privacy and security of personal information could expose us to penalties under such laws, orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face and will continue to face competition from third parties that use mRNA, gene editing or gene therapy development platforms and from third parties focused on other therapeutic modalities, such as small molecules, antibodies, biologics and nucleic acid-based therapies. The competition is likely to come from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even greater concentration of resources among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approvals for their products faster or earlier than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For example, some of our competitors have already received approval from the FDA and other regulatory agencies for their mRNA-based COVID-19 vaccines. Additionally, technologies developed by our competitors may render our product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors&#8217; products. In addition, the availability of our competitors&#8217; products could limit the demand and the prices we are able to charge for any products that we may develop and commercialize.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend heavily on our executive officers and managing directors, and the loss of their services would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends, and will likely continue to depend, upon our ability to retain the services of our current executive officers, managing directors, principal consultants and other service providers, and our ability to hire new highly qualified personnel. We are highly dependent on the management, development, clinical, financial and business development expertise of our executive officers, managing directors, principal consultants and other service providers. In addition, we have established relationships with universities and research institutions which have historically provided, and continue to provide, us with access to research laboratories, clinical trials, facilities and patients. Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In most cases, our personnel may only terminate their employment upon first providing notice. A limited number of agreements provide for at-will termination. If we lose one or more of our executive officers or other key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may be unable to hire, train, retain or motivate these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees, independent contractors, consultants, collaborators and contract research organizations may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates (i)&#160;FDA regulations or similar regulations of comparable non-U.S. regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii)&#160;manufacturing and clinical trial conduct standards, (iii)&#160;federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities and (iv)&#160;laws that require the reporting of financial information or data accurately. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As a result of our geographically diverse operations, we are more susceptible to certain risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have offices and operations in six cities and in five countries. If we are unable to manage the risks of our global operations, including fluctuations in foreign exchange and inflation rates, international hostilities, natural disasters, security breaches, failure to maintain compliance with our clients&#8217; control requirements and multiple legal and regulatory systems, our results of operations and ability to grow could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in our level of taxes, and audits, investigations and tax proceedings, could have a material adverse effect on our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although limited in terms of magnitude due to ongoing losses incurred so far, we are subject to income taxes in Germany and the United States. We calculate and provide for income taxes in each tax jurisdiction in which we operate. Tax accounting often involves complex matters and judgment is required in determining our worldwide provision for income taxes and other tax liabilities. We are subject to ongoing tax audits in Germany. In the future, tax authorities may disagree with our judgments or may take increasingly aggressive positions with respect to the judgments we make. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax liabilities. However, our judgments might not be sustained as a result of these audits, and the amounts ultimately paid could be different from the amounts previously recorded. In addition, our effective tax rate in the future could be adversely affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities and changes in tax laws. Tax rates in the jurisdictions in which we operate may change as a result of macroeconomic or other factors outside of our control. Increases in the tax rate in any of the jurisdictions in which we operate could have a negative impact on our profitability. In addition, changes in tax laws, treaties or regulations, or their interpretation or enforcement, may be unpredictable, particularly in less developed markets, and could become more stringent, which could materially adversely affect our tax position. Any of these occurrences could have a material adverse effect on our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 20, 2021 the OECD published the Global Anti-Base Erosion Model Rules (the &#8220;GloBE Rules&#8221;), also known as Pillar II. The GloBE Rules aim to impose a global minimum tax of 15% on multinational enterprises with a revenue in excess of &#8364;750 million. On December 22, 2021, the European Commission published a legislative proposal for Pillar II (the &#8220;EU Pillar II Directive&#8221;). The EU Pillar II Directive is largely aligned with the GloBE Rules. Some deviations were introduced to ensure compliance with EU treaties. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2022, the Council of the European Union formally adopted the EU Pillar II Directive. The EU Pillar II Directive aims at consistently implementing among all 27 member states the GloBE Rules. EU Member States will have to transpose the EU Pillar II Directive into their national laws and will have to apply the Pillar II measures in respect of the fiscal years beginning on or after December 31, 2023. The Netherlands has transposed the EU Pillar II Directive into its national legislation with effect from December 31, 2023 pursuant to the Dutch Minimum Tax Act 2024 (<i style="font-style:italic;">Wet minimumbelasting 2024</i>). Germany has transposed the EU Pillar II Directive into its national legislation with effect from December 28, 2023 pursuant to the German Minimum Tax Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not yet meet the revenue threshold of &#8364;750 million for Pillar II but (i) should this threshold be reduced or (ii) should our revenue increase, then the application of Pillar II could have a material adverse effect on our business, financial position and results of operations. We will continue to monitor the impact of Pillar II going forward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Uninsured losses arising from third-party claims brought against us could result in payment of substantial damages, which would decrease our cash reserves and could harm our profit and cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our products are used in applications where the failure to use our products properly or their malfunction could result in serious bodily injury or death. We may not have adequate insurance to cover the payment of any potential claim related to such injuries or deaths. Insurance coverage may not continue to be available to us or, if available, may be at a significantly higher cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The use of our investigational medicinal products in clinical trials and the sale of any approved products in the future may expose us to liability claims. These claims might be made by patients who use the product, healthcare providers, pharmaceutical companies or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a product, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we cannot maintain our corporate culture, we could lose the innovation, teamwork and passion that we believe contribute to our success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We invest substantial time and resources in building and maintaining our culture and developing our personnel; however, it may be increasingly difficult to maintain our culture. Recent shifts in workplace and workstyle, increase the risk of our ability to maintain culture. Any failure to preserve our culture could negatively affect our future success, including our ability to retain and recruit personnel and to effectively pursue our strategic plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To cover such liability claims, we purchase clinical trial insurance in the conduct of each of our clinical trials. It is possible that our liabilities could exceed our insurance coverage or that our insurance will not cover all situations in which a claim against us could be made. We also intend to expand our insurance coverage to include the sale of commercial products if we receive marketing approval for any of our proprietary products. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity and injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compensation in response to a liability claim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our products or product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our business, financial condition, results of operations or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Some of our product candidates are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that products similar to our product candidates will be reviewed within its Center for Biologics Evaluation and Research, or CBER. Even though our mRNA product candidates are designed to have a different mechanism of action from gene therapies, the association of our product candidates with gene therapies could result in increased regulatory burdens, impair the reputation of our product candidates or negatively impact our platform or our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been few approvals of gene therapy products in the United States and other jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Gene therapy products have the effect of introducing new DNA and potentially irreversibly changing the DNA in a cell. In contrast, mRNA is highly unlikely to localize to the nucleus, integrate into cell DNA or otherwise make any permanent changes to cell DNA. Consequently, we expect that our product candidates will have a different potential side effect profile from gene therapies because they lack risks associated with altering cell DNA irreversibly. Further, we may avail ourselves of ways of mitigating side effects in developing our product candidates to address safety concerns that are not available to all gene therapies, such as lowering the dose of our product candidates during repeat dosing or stopping treatment to potentially ameliorate undesirable side effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future, and the implications for mRNA-based medicines is unknown. For example, the FDA has established the Office of Tissues and Advanced Therapies within CBER to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the European Union, mRNA has been characterized as a Gene Therapy Medicinal Product. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us. Specifically, in Japan, the Pharmaceuticals and Medical Devices Agency has not taken a position on the regulatory classification. Notwithstanding the differences between our mRNA product candidates and gene therapies, the classification of some of our mRNA product candidates as gene therapies in the United States, the European Union and potentially other countries could adversely impact our ability to develop our product candidates, and could negatively impact our platform and our business. For instance, a clinical hold on gene therapy products across the field due to risks associated with altering cell DNA irreversibly may apply to our mRNA product candidates irrespective of the mechanistic differences between gene therapies and mRNA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adverse events reported with respect to gene therapies or genome-editing therapies could adversely impact one or more of our programs. Although our mRNA product candidates are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapy products caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our mRNA investigational therapies, and as a result, may delay one or more of our trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory review agencies may have a negative effect on our business by lengthening the regulatory review process, requiring us to perform additional or larger studies, or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">An active trading market for our common shares may not be sustainable. If an active trading market is not maintained, investors may not be able to resell their shares at or above the purchase price and our ability to raise capital in the future may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although our common shares are listed and trade on Nasdaq, an active trading market for our shares may not be maintained. If an active market for our common shares is not maintained, it may be difficult for you to sell shares you purchase without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. In addition to the risks described above, the market price of our common shares may be influenced by many factors, some of which are beyond our control, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of financial analysts to continue to cover our common shares or changes in financial estimates by analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates by financial analysts, or any failure by us to meet or exceed any of these estimates, or changes in the recommendations of any financial analysts that elect to follow our common shares or the shares of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant contracts or acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future sales of our shares; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investor perceptions of us and the industries in which we operate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These and other factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, the stock market in general has from time to time experienced extreme price and volume fluctuations, including in recent&#160;months, that have often been unrelated or disproportionate to the operating performance of particular companies affected. These broad market and industry factors may materially harm the market price of our common shares, regardless of our operating performance. In the past, following periods of volatility in the market price of certain companies&#8217; securities, securities class action litigation has been instituted against these companies. This litigation, if instituted against us, could adversely affect our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of substantial amounts of our common shares in the public market, or the perception that these sales may occur, could cause the market price of our common shares to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of substantial amounts of our common shares in the public market, or the perception that these sales may occur, could cause the market price of our common shares to decline. This could also impair our ability to raise additional capital through the sale of our equity securities. We cannot predict the size of future issuances of our shares or the effect, if any, that future sales and issuances of shares would have on the market price of our common shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Considerable amounts of common shares are available for issuance under our equity incentive plans, and significant issuances in the future may adversely impact the market price of our common shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had 386,250,000 authorized common shares, of which 224,305,680 shares were outstanding. In addition, 33,598,301 common shares were reserved for issuance pursuant to our equity incentive plans. The availability of substantial amounts of our common shares resulting from the exercise or settlement of equity awards outstanding under our equity incentive plans, which would be dilutive to existing stockholders, could adversely affect the prevailing market price of our common shares and could impair our ability to raise additional capital through the sale of equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have broad discretion in the use of our cash on hand and may invest or spend it in ways with which you do not agree and in ways that may not yield a return on your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had cash and cash equivalents amounting to &#8364; 402.4 million. Our management will have broad discretion in the use of such cash and could spend it in ways that do not improve our results of operations or enhance the value of our common shares. You will not have the opportunity to influence our decisions on how to use our cash on hand. The failure by our management to apply these funds effectively could result in financial losses that could harm our business, cause the price of our common shares to decline and delay the development of our product candidates. Pending its use, we may invest our cash on hand in a manner that does not produce income or that loses value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of ownership by our principal shareholders may conflict with your interest and may prevent you from influencing significant corporate decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 15, 2024, our principal shareholder, dievini Hopp BioTech holding GmbH &amp; Co. KG, or dievini, and its related parties, beneficially owned approximately 37% of our common shares and Kreditanstalt f&#252;r Wiederaufbau, or KfW, beneficially owns approximately 13% of our common shares. See &#8220;Item 7. Major Shareholders and Related Party Transactions.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) has the right under our articles of association to make a binding nomination for the following number of supervisory directors until dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates as defined by our articles of association and ultimate beneficiaries as defined by our articles of association (individually or collectively) cease to own at least 10% of our issued share capital or an earlier change of control over dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) as defined by our articles of association, which period we refer to as the initial nomination period for dievini:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four (4)&#160;supervisory directors for as long as dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates (as defined by our articles of association) and ultimate beneficiaries (as defined by our articles of association) (individually or collectively) own at least 70% of our issued share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three (3)&#160;supervisory directors for as long as dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates (as defined by our articles of association) and ultimate beneficiaries (as defined by our articles of association) (individually or collectively) own at least 50% (but less than 70%) of our issued share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two (2)&#160;supervisory directors for as long as dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates (as defined by our articles of association) and ultimate beneficiaries (as defined by our articles of association) (individually or collectively) own at least 30% (but less than 50%) of our issued share capital; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one (1)&#160;supervisory director for as long as dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates (as defined by our articles of association) and ultimate beneficiaries (as defined by our articles of association) (individually or collectively) own at least 10% (but less than 30%) of our issued share capital.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Dievini and Mr.&#160;Dietmar Hopp may be able to significantly influence all matters requiring shareholder approval. Even when dievini ceases to own common shares representing a majority of the total voting power, for so long as dievini continues to own a significant&#160;percentage of our common shares, dievini will still be able to significantly influence the composition of our supervisory board and the approval of actions requiring shareholder approval. Accordingly, for such period of time, dievini will continue to have significant influence with respect to our management, business plans and policies, including the appointment and removal of our managing directors, decisions on whether to raise future capital and any amending of our organizational documents, which govern the rights attached to our common shares. In particular, for so long as dievini continues to own a significant&#160;percentage of common shares, it will be able to cause or prevent a change of control of us or a change in the composition of our supervisory board and could preclude any unsolicited acquisition of us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In addition, KfW (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) has the right, and has exercised the right under our articles of association, the KfW dievini Shareholders&#8217; Agreement and the ISA to make a binding nomination for one (1)&#160;supervisory director until KfW or any KfW affiliates as defined by our articles of association (individually or together with any other KfW affiliate) cease to own at least 10% of our issued share capital, which period we refer to as the initial nomination period for KfW. Certain decisions require, and cannot be taken without, a resolution of our supervisory board that the KfW nominee, and a dievini nominee, have approved. These relate in particular to the location within the European Union of certain of our activities. The KfW dievini Shareholders&#8217; Agreement includes provisions relating to voting together and in a coordinated fashion on certain specified matters as further described under &#8220;Item&#160;7. Major Shareholders and Related Party Transactions&#8201;&#8212;&#8201;B. Related Party Transactions.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The concentration of ownership and these nomination rights could deprive you of an opportunity to receive a premium for your common shares as part of a sale of us and ultimately might affect the market price of our common shares. In addition, the concentration of voting power and these nomination rights could delay or prevent an acquisition of our company on terms that other shareholders may desire or result in the management of our company in ways with which other shareholders disagree.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be required to redeem for cash all, or to facilitate the purchase by a third-party of all, the shares of us held by the Bill &amp; Melinda Gates Foundation as per the date of the ISA if we default under the Global Access Agreement, which could have an adverse impact on us and limit our ability to make distributions to our shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into a Global Access Agreement with our shareholder, the Bill &amp; Melinda Gates Foundation, in February&#160;2015 pursuant to which we are required to take certain actions to support the Bill &amp; Melinda Gates Foundation&#8217;s mission. In the event that we commit a material breach of the Global Access Agreement or certain provisions of the ISA, following a cure period, we may be required to redeem for cash all, or to facilitate the purchase by a third-party of all, the shares of our company held by the Bill &amp; Melinda Gates Foundation as per the date of the ISA at certain terms that may not be favorable to us. If this occurs, cash used for this purpose may adversely affect our liquidity, cause us to reduce expenditures in other areas of our business, or curtail our growth plans. If we do not have sufficient cash on hand to purchase the shares, we would have to seek financing alternatives in order to meet our obligations, and there is no certainty that financing would be available on reasonable terms or at all. For the period that we are unable to redeem the shares held by the Bill &amp; Melinda Gates Foundation or arrange for a third-party to purchase such shares, we will generally not be allowed to pay dividends, redeem the shares of any other shareholder or otherwise make any other distribution to any of our shareholders in connection with their shares. Therefore, meeting this purchase obligation, if necessary, could have a material adverse effect on our business and financial results. For more information on the Bill &amp; Melinda Gates Foundation&#8217;s withdrawal rights, see &#8220;Item&#160;7. Major Shareholders and Related Party Transactions&#8201;&#8212;&#8201;B. Related Party Transactions&#8201;&#8212;&#8201;Investment and Shareholders&#8217; Agreement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Being a public company may continue to increase our costs and disrupt the regular operations of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In August&#160;2020, we completed our initial public offering. After the completion of our initial public offering we incurred and expect to continue to incur costs and expenses, including, but not limited to, managing directors&#8217; and supervisory directors&#8217; fees, increased directors and officers insurance, investor relations, and various other costs of a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We also anticipate that we will continue to incur significant costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. We expect these rules and regulations to continue to increase our legal and financial compliance costs and make some management and corporate governance activities more time-consuming and costly. These rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. This could have an adverse impact on our ability to retain, recruit and bring on a qualified independent supervisory board.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The additional demands associated with being a public company may disrupt regular operations of our business by diverting the attention of some of our senior management team away from revenue producing activities to management and administrative oversight, adversely affecting our ability to attract and complete business opportunities and increasing the difficulty in both retaining professionals and managing and growing our businesses. Any of these effects could harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">We are a foreign private issuer and, as a result, we are not subject to U.S. proxy rules and are subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&#160;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act, (ii)&#160;the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time and (iii)&#160;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four&#160;months after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75&#160;days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation&#160;Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. If in the future we are not a foreign private issuer as of the last day of the second fiscal quarter in any fiscal year, we would be required to comply with all of the periodic disclosure, current reporting requirements and proxy solicitation rules of the Exchange Act applicable to U.S. domestic issuers. In order to maintain our current status as a foreign private issuer, either (a)&#160;a majority of our common shares must be either directly or indirectly owned of record by nonresidents of the United States or (b) (i) a majority of our managing directors, supervisory directors and executive officers may not be United States citizens or residents, (ii)&#160;more than 50% of our assets cannot be located in the United States and (iii)&#160;our business must be administered principally outside the United States. If we were to lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the costs we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time-consuming and costly. These rules and regulations could also make it more difficult for us to attract and retain qualified managing directors and supervisory directors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As a foreign private issuer and as permitted by the listing requirements of Nasdaq, we follow certain home country governance practices rather than the corporate governance requirements of Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a foreign private issuer. As a result, in accordance with the listing requirements of Nasdaq, we rely on home country governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of Nasdaq. In accordance with Dutch law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings. To this extent, our practice varies from the requirement of Nasdaq Listing Rule&#160;5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares. Although we must provide shareholders with an agenda and other relevant documents for the general meeting, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice varies from the requirement of Nasdaq Listing Rule&#160;5620(b). As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule&#160;5605(d), which requires, among other things, an issuer to have a compensation committee that consists entirely of independent directors, Nasdaq Listing Rule&#160;5605(e), which requires independent director oversight of director nominations, and Nasdaq Listing Rule&#160;5605(b)(1), which requires an issuer to have a majority of independent directors on its board. These rules require that a majority of our supervisory directors must be independent. In addition, we have opted out of shareholder approval requirements, as included in the Nasdaq Listing Rules, for the issuance of securities in connection with certain events such as the acquisition of shares or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of our company and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Rule&#160;5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. Accordingly, you may not have the same protections afforded to shareholders of companies that are subject to these Nasdaq requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Although we do not believe that we were a &#8220;passive foreign investment company,&#8221; or a PFIC, for U.S. federal income tax purposes for our 2023 taxable year, we may be a PFIC for 2024 or one or more future taxable&#160;years. A U.S. holder of common shares may suffer adverse U.S. federal income tax consequences if we are a PFIC for any taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Internal Revenue Code of 1986, as amended, or the Code, we will generally be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries, either (i)&#160;75% or more of our gross income consists of &#8220;passive income,&#8221; or (ii)&#160;50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, &#8220;passive income.&#8221; Passive income generally includes dividends, interest, certain nonactive rents and royalties, and capital gains. The value of a non-U.S. corporation&#8217;s goodwill that is associated with activities that produce or are intended to produce active income is generally an active asset for purposes of the asset test unless, for U.S. federal income tax purposes, the non-U.S. corporation is a &#8220;controlled foreign corporation,&#8221; or a CFC, that is not publicly traded &#8220;for the taxable year.&#8221; If a non-U.S. corporation is a CFC that is not publicly traded for the taxable year, its PFIC status under the asset test is determined by using the U.S. tax basis of its assets rather than their fair market value and therefore the market value of its goodwill is generally disregarded. Generally, a non-U.S. corporation is a CFC if more than 50% of its shares&#8217; voting power or value is owned, directly, indirectly or constructively, by &#8220;United States shareholders&#8221; (as defined in Section&#160;951(b) of the Code). Although it is not certain, we may be or may have been a CFC in the 2023 taxable year. However, under Treasury regulations promulgated in 2020, the fair market value of our assets (including goodwill) can be used for purposes of the asset test provided that (i)&#160;we are publicly traded on the majority of days during our taxable year or (ii)&#160;we would not be a CFC if certain constructive ownership rules were not applied. We believe, and the remainder of this discussion assumes, that we are eligible to use the fair market value of our assets for purposes of the asset test for our 2023 taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the composition of our income and assets during 2023, we do not believe that we were a PFIC for our 2023 taxable year. However, there can be no assurance that the Internal Revenue Service, or the &#8220;IRS,&#8221; will agree with our conclusion. Whether we will be a PFIC in 2024 or any future year is uncertain because, among other things, (i) we currently own a substantial amount of passive assets, including cash, (ii) the valuation of our assets that generate nonpassive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time, (iii) the treatment of grants as income for U.S. federal income tax purposes is unclear, and (iv) the composition of our income may vary substantially over time. Accordingly, there can be no assurance that we will not be a PFIC in 2024 or any future taxable year.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are a PFIC for any taxable year during which a U.S. investor holds common shares, we generally would continue to be treated as a PFIC with respect to that U.S. investor for all succeeding&#160;years during which the U.S. investor holds common shares, even if we ceased to meet the threshold requirements for PFIC status. Such a U.S. investor may be subject to adverse U.S. federal income tax consequences, including (i)&#160;the treatment of all or a portion of any gain on disposition as ordinary income, (ii)&#160;the application of a deferred interest charge on such gain and the receipt of certain dividends and (iii)&#160;compliance with certain reporting requirements. There is no assurance that we will provide information that will enable investors to make a qualified electing fund election, also known as a QEF Election, that could mitigate the adverse U.S.&#160;federal income tax consequences should we be classified as a PFIC. See &#8220;Item&#160;10. Additional Information &#8212; E.&#160;Taxation&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Considerations to U.S. Holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Insiders have substantial control over us and could limit your ability to influence the outcome of key transactions, including a change of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 15, 2024, our principal shareholders, managing directors, supervisory directors and executive officers and entities affiliated with them own 58% of the outstanding common shares. As a result, these shareholders, if acting together, would be able to influence or control matters requiring approval by our general meeting, including the appointment of managing directors and supervisory directors, changes to our articles of association and approval of mergers or other extraordinary transactions. They may also have interests that differ from yours and may vote in a way with which you disagree and which may be adverse to your interests. The concentration of ownership may have the effect of delaying, preventing or deterring a change of control of our company, could deprive our shareholders of an opportunity to receive a premium for their common shares as part of a sale of our company and might ultimately affect the market price of our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common shares depends in part on the research and reports that securities or industry analysts publish about us or our business. If securities or industry analysts do not continue to cover our company, the market price for our common shares would likely be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, our share price may decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our shares could decrease, which might cause our share price and trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not anticipate paying any cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently intend to retain our future earnings, if any, for the foreseeable future, to fund the development and growth of our business. We do not intend to pay any dividends to holders of our common shares. As a result, capital appreciation in the price of our common shares, if any, will be your only source of gain on an investment in our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do pay dividends, we may need to withhold tax on such dividends payable to holders of our shares in both Germany and the Netherlands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not intend to pay any dividends to holders of our common shares. See &#8220;&#8212;&#8201;We do not anticipate paying any cash dividends in the foreseeable future.&#8221; However, if we do pay dividends, we may need to withhold tax on such dividends both in Germany and the Netherlands.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an entity incorporated under Dutch law, any dividends distributed by us are subject to Dutch dividend withholding tax on the basis of Dutch domestic law. However, on the basis of the 2012 Convention between the Federal Republic of Germany and the Kingdom of the Netherlands for the avoidance of double taxation with respect to taxes on income, or the &#8220;double tax treaty between Germany and the Netherlands,&#8221; the Netherlands will be restricted in imposing these taxes if we are also a tax resident of Germany and our effective management is located in Germany, or the &#8220;withholding tax restriction.&#8221; See also &#8220;&#8212; We may become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us.&#8221; The withholding tax restriction does, however, not apply, and Dutch dividend withholding tax is still required to be withheld from dividends, if and when paid to Dutch resident holders of our common shares (and non-Dutch resident holders of our common shares that have a permanent establishment in the Netherlands to which their shareholding is attributable). As a result, upon a payment of dividends, we will be required to identify our shareholders in order to assess whether there are Dutch residents (or non-Dutch residents with a permanent establishment in the Netherlands to which the common shares are attributable) in respect of which Dutch dividend withholding tax has to be withheld. Such identification may not always be possible in practice. If the identity of our shareholders cannot be determined, withholding of both German and Dutch dividend withholding tax may occur upon a payment of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the withholding tax restriction referred to above is based on the current reservation made by Germany under the Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting, or the MLI, with respect to the tie-breaker provision included in Article&#160;4(3) of the double tax treaty between Germany and the Netherlands, or the &#8220;MLI tie-breaker reservation.&#8221; If Germany changes its MLI tie-breaker reservation, we will not be entitled to any benefits of the double tax treaty between Germany and the Netherlands, including the withholding tax restriction, as long as Germany and the Netherlands do not reach an agreement on our tax residency for purposes of the double tax treaty between Germany and the Netherlands, and, as a result, any dividends distributed by us during the period no such agreement has been reached between Germany and the Netherlands, may be subject to dividend withholding tax both in Germany and the Netherlands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to utilize our net operating losses, or NOLs, is currently limited, and may be limited further, under Section&#160;8c of the German Corporation Income Tax Act (<i style="font-style:italic;">Korperschaftsteuergesetz</i>, or KStG) and Section&#160;10a of the German Trade Tax Act (<i style="font-style:italic;">Gewerbesteuergesetz</i>, or GewStG). These limitations apply if a qualified ownership change, as defined by Section&#160;8c KStG, occurs and no exemption is applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, a qualified ownership change occurs if more than 50% of the share capital or the voting rights are directly or indirectly transferred to an acquirer or a party related to the acquirer or a group of acquirers with aligned interests within a period of five years. A qualified ownership change may also occur in case of a transaction comparable to a transfer of shares or voting rights or in case of an increase in capital leading to a respective change in the shareholding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of such a qualified ownership change, current year tax losses, tax loss carryforwards and interest carryforwards (together &#8216;tax loss carryforwards&#8217;) expire in full. To the extent that the tax loss carryforwards do not exceed the built-in gains (<i style="font-style:italic;">stille Reserven</i>) in the qualifying assets and liabilities taxable in Germany, they may be further utilized despite a qualified ownership change. In case of a qualified ownership change within a group, tax loss carryforwards will be preserved if certain conditions are satisfied. In addition, in case of a qualified ownership change due to a share acquisition in order to restructure business operations, tax loss carryforwards are preserved if certain conditions are met. Further, tax loss carry forwards will be preserved (in the form of a &#8220;<i style="font-style:italic;">fortfuhrungsgebundener Verlustvortrag</i>&#8221;) in case of a qualified ownership change if the business operations have not been changed and will not be changed within the meaning of Section 8d KStG and a corresponding application is filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to an appeal filed by the fiscal court of Hamburg dated August 29, 2017, Section 8c, paragraph 1, sentence 1 KStG is not in line with the German Constitution. The appeal is still pending. It is unclear when the Federal Constitutional Court will decide this case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, there are NOLs available for the German entities of CureVac for German corporate income tax purposes of &#8364; 1,700 million: &#8364; 1,242 million for CureVac SE, &#8364; 376 million for CureVac Manufacturing GmbH, &#8364; 37 million for CureVac N.V., &#8364; 44 million for CureVac RNA Printer GmbH and a NOL for CureVac Netherlands B.V. for Dutch Corporate income tax of &#8364; 1 million. For German entities there are NOLs for German trade tax purposes of &#8364; 1,685 million: &#8364; 1,234 million for CureVac SE, &#8364; 370 million for CureVac Manufacturing GmbH, &#8364; 37 million for CureVac N.V. and &#8364; 44 million for CureVac RNA Printer GmbH available as of December 31, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future changes in share ownership may also trigger an ownership change and, consequently, a Section&#160;8c KStG or a Section&#160;10a GewStG limitation. Any limitation may result in the expiration of a portion or the complete tax operating loss carryforwards before they can be utilized. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to reduce German income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shareholders may not be able to exercise preemptive rights and, as a result, may experience substantial dilution upon future issuances of common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of an issuance of common shares or a grant of rights to subscribe for common shares, subject to certain exceptions, each shareholder will have a pro rata preemptive right in proportion to the aggregate nominal value of the common shares held by such holder. These preemptive rights may be restricted or excluded by a resolution of the general meeting or by another corporate body designated by the general meeting. Our management board, subject to approval of our supervisory board, has been authorized, for a period of five years from our initial public offering, to issue shares or grant rights to subscribe for shares up to our authorized share capital from time to time and to limit or exclude preemptive rights in connection therewith. This could cause existing shareholders to experience substantial dilution of their interest in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our incorporation, we have had, on a continuous basis, our place of &#8220;effective management&#8221; in Germany. We will therefore qualify as a tax resident of Germany on the basis of German domestic law. As an entity incorporated under Dutch law, however, we also qualify as a tax resident of the Netherlands on the basis of Dutch domestic law. However, based on our current management structure and the current tax laws of the United States, Germany and the Netherlands, as well as applicable income tax treaties, and current interpretations thereof, we should qualify solely as a tax resident of Germany for the purposes of the double tax treaty between Germany and the Netherlands due to the &#8220;effective management&#8221; tie-breaker included in Article&#160;4(3) of the double tax treaty between Germany and the Netherlands and the current MLI tie-breaker reservation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The test of &#8220;effective management&#8221; is largely a question of fact and degree based on all the circumstances, rather than a question of law. Nevertheless, the relevant case law and OECD guidance suggest that our company is likely to be regarded as having become a German tax resident from incorporation and remaining so if, as our company intends, (i)&#160;most meetings of its management board are prepared and held in Germany (and none will be held in the Netherlands) with a majority of managing directors present in Germany for those meetings; (ii)&#160;at those meetings there are full discussions of, and decisions are made regarding, the key strategic issues affecting our company and its subsidiaries; (iii)&#160;those meetings are properly minuted; (iv)&#160;a majority of our managing directors, together with supporting staff, are based in Germany; and (v)&#160;our company has permanent staffed office premises in Germany. We may, however, become subject to limited income tax liability in other countries with regard to the income generated in the respective other country, for example, due to the existence of a permanent establishment or a permanent representative in such other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The applicable tax laws or interpretations thereof may change, including the MLI tie-breaker reservation. Furthermore, whether we have our place of effective management in Germany and are as such tax resident in Germany is largely a question of fact and degree based on all the circumstances, rather than a question of law, which facts and degree may also change. Changes to applicable laws or interpretations thereof, changes to applicable facts and circumstances (for example, a change of directors or the place where board meetings take place), or changes to applicable income tax treaties, including a change to the MLI tie-breaker reservation, may result in us becoming (also) a tax resident of the Netherlands or another jurisdiction. See &#8220;&#8212; If we do pay dividends, we may need to withhold tax on such dividends payable to holders of our shares in both Germany and the Netherlands.&#8221; As a consequence, our overall effective income tax rate and income tax expense could materially increase, which could have a material adverse effect on our business, results of operations, financial condition and prospects, which could cause our share price and trading volume to decline. In addition, as a consequence, dividends distributed by us, and interest or royalty payments made by us, if any, may become subject to withholding taxes in more than one jurisdiction. The double taxation of income and the double withholding tax on dividends, interest and/or royalties may be reduced or avoided entirely under the double tax treaty between Germany and the Netherlands or under a double tax treaty between the Netherlands and the respective other country.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Claims of U.S. civil liabilities may not be enforceable against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are organized and existing under the laws of the Netherlands. As such, under Dutch private international law, the rights and obligations of our shareholders vis-&#224;-vis the company originating from Dutch corporate law and our articles of association, as well as the civil liability of our officers (<i style="font-style:italic;">functionarissen</i>) (including our managing directors, supervisory directors and executive officers) are governed in certain respects by the laws of the Netherlands. Our headquarters is located in Germany. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are not a resident of the United States and our officers may also not all be residents of the United States. As a result, depending on the subject matter of the action brought against us and/or our officers, United States courts may not have jurisdiction. If a Dutch court has jurisdiction with respect to such action, that court will apply Dutch procedural law and Dutch private international law to determine the law applicable to that action. Depending on the subject matter of the relevant action, a competent Dutch court may apply another law than the laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also, service of process against non-residents of the United States can in principle (absent, for example, a valid choice of domicile) not be effected in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, most of our assets are located outside the United States. On the date of this Annual Report, (i) there is no treaty in force between the United States and the Netherlands for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters and (ii) both the Hague Convention on Choice of Court Agreements (2005) and the Hague Judgments Convention (2019) have entered into force for the Netherlands, but have not entered into force for the United States. Consequently, a judgment rendered by a court in the United States will not automatically be recognized and enforced by the competent Dutch courts. However, if a person has obtained a judgment rendered by a court in the United States that is enforceable under the laws of the United States and files a claim with the competent Dutch court, the Dutch court will in principle give binding effect to that United States judgment if (i) the jurisdiction of the United States court was based on a ground of jurisdiction that is generally acceptable according to international standards, (ii) the judgment by the United States court was rendered in legal proceedings that comply with the Dutch standards of proper administration of justice including sufficient safeguards (<i style="font-style:italic;">behoorlijke rechtspleging</i>), (iii) binding effect of such United States judgment is not contrary to Dutch public order (<i style="font-style:italic;">openbare orde</i>) and (iv) the judgment by the United States court is not incompatible with a decision rendered between the same parties by a Dutch court, or with a previous decision rendered between the same parties by a foreign court in a dispute that concerns the same subject and is based on the same cause, provided that the previous decision qualifies for recognition in the Netherlands. Even if such a United States judgment is given binding effect, a claim based thereon may, however, still be rejected if the United States judgment is not or no longer formally enforceable. Moreover, if the United States judgment is not final (for instance when appeal is possible or pending) a competent Dutch court may postpone recognition until the United States judgment will have become final, refuse recognition under the understanding that recognition can be asked again once the United States judgment will have become final, or impose as a condition for recognition that security is posted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A competent Dutch court may deny the recognition and enforcement of punitive damages or other awards. Moreover, a competent Dutch court may reduce the amount of damages granted by a United States court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Thus, United States investors may not be able, or experience difficulty, to enforce a judgment obtained in a United States court against us or our officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States and Germany currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, in civil and commercial matters. Consequently, a final judgment for payment or declaratory judgments given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in Germany. German courts may deny the recognition and enforcement of a judgment rendered by a U.S. court if they consider the U.S. court not to be competent or the decision to be in violation of German public policy principles. For example, judgments awarding punitive damages are generally not enforceable in Germany. A German court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, actions brought in a German court against us, our managing directors, our supervisory directors, our senior management and the experts named herein to enforce liabilities based on U.S. federal securities laws may be subject to certain restrictions. In particular, German courts generally do not award punitive damages. Litigation in Germany is also subject to rules of procedure that differ from the U.S. rules, including with respect to the taking and admissibility of evidence, the conduct of the proceedings and the allocation of costs. German procedural law does not provide for pre-trial discovery of documents, nor does Germany support pre-trial discovery of documents under the 1970 Hague Evidence Convention. Proceedings in Germany would have to be conducted in the German language and all documents submitted to the court would, in principle, have to be translated into German. For these reasons, it may be difficult for a U.S. investor to bring an original action in a German court predicated upon the civil liability provisions of the U.S. federal securities laws against us, our managing directors, our supervisory directors, our senior management and the experts named in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the lack of a treaty as described above, there can be no assurance that U.S. investors will be able to enforce against us or managing directors, supervisory directors, executive officers or certain experts named herein who are residents of or possessing assets in the Netherlands, Germany, or other countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions and may not protect investors in a similar fashion afforded by incorporation in a U.S. jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a public company (<i style="font-style:italic;">naamloze vennootschap</i>) organized under the laws of the Netherlands. Our corporate affairs are governed by our articles of association, the rules of our management board and those of our supervisory board and by the laws governing companies incorporated in the Netherlands. However, there can be no assurance that Dutch law will not change in the future or that it will serve to protect investors in a similar fashion afforded under corporate law principles in the United States, which could adversely affect the rights of investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rights of shareholders and the responsibilities of managing directors and supervisory directors may be different from the rights and obligations of shareholders and directors in companies governed by the laws of U.S. jurisdictions. In the performance of their duties, our managing directors and supervisory directors are required by Dutch law to consider the interests of our company, its shareholders, its employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For more information on relevant provisions of Dutch corporation law and of our articles of association, see &#8220;Item&#160;10. Additional Information &#8212; B. Memorandum and Articles of Association.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The ability for our shareholders to alter the members of our management board or supervisory board may be limited by the Dutch cooling-off period in face of shareholder activism or hostile take-over</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management board, with the approval of our supervisory board, can invoke a cooling-off period of up to 250 days when shareholders, using their right to have items added to the agenda for a general meeting or their right to request a general meeting, propose an agenda item for our general meeting to dismiss, suspend or appoint one or more managing directors or supervisory directors (or to amend any provision in our articles of association dealing with those matters) or when a public offer for our company is made or announced without our support, provided, in each case, that our management board believes that such proposal or offer materially conflicts with the interests of our company and its business. During a cooling-off period, our general meeting cannot dismiss, suspend or appoint managing directors and supervisory directors (or amend the provisions in our articles of association dealing with those matters) except at the proposal of our management board. During a cooling-off period, our management board must gather all relevant information necessary for a careful decision-making process and at least consult with shareholders representing 3% or more of our issued share capital at the time the cooling-off period was invoked, as well as with our Dutch works council (if we or, under certain circumstances, any of our subsidiaries would have one). Formal statements expressed by these stakeholders during such consultations must be published on our website to the extent these stakeholders have approved that publication. Ultimately one week following the last day of the cooling-off period, our management board must publish a report in respect of its policy and conduct of affairs during the cooling-off period on our website. This report must remain available for inspection by shareholders and others with meeting rights under Dutch law at our office and must be tabled for discussion at the next general meeting. Shareholders representing at least 3% of our issued share capital may request the Enterprise Chamber of the Amsterdam Court of Appeal, or the Enterprise Chamber (<i style="font-style:italic;">Ondernemingskamer</i>), for early termination of the cooling-off period. The Enterprise Chamber must rule in favor of the request if the shareholders can demonstrate that:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our management board, in light of the circumstances at hand when the cooling-off period was invoked, could not reasonably have concluded that the relevant proposal or hostile offer constituted a material conflict with the interests of our company and its business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our management board cannot reasonably believe that a continuation of the cooling-off period would contribute to careful policy-making; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other defensive measures, having the same purpose, nature and scope as the cooling-off period, have been activated during the cooling-off period and have not since been terminated or suspended within a reasonable period at the relevant shareholders&#8217; request (i.e., no &#8220;stacking&#8221; of defensive measures).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions of our articles of association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent, delay or frustrate any attempt to replace or remove our managing directors or supervisory directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. In this respect, our general meeting shall authorize our management board, subject to the approval by our supervisory board, to grant a call option to an independent foundation under Dutch law (if and when incorporated), or protective foundation, to acquire preferred shares pursuant to a call option agreement, or the call option agreement, that may be entered into between us and such protective foundation after the later of (a)&#160;dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates as defined by our articles of association and ultimate beneficiaries as defined by our articles of association (individually or collectively) no longer holding at least 25% of our issued share capital (or an earlier change of control over dievini, as defined in our articles of association), which we refer to as the initial period, or (b)&#160;the termination or expiry of the KfW dievini Shareholders&#8217; Agreement (see &#8220;Item&#160;7. Major Shareholders and Related Party Transactions &#8212; B. Related Party Transactions &#8201;&#8212;&#8201;Shareholders&#8217; Agreement Among KfW, dievini and Mr.&#160;Hopp&#8221; for further information on that agreement), which we refer to as the initial approval period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This call option, if and when granted, shall be continuous in nature and can be exercised repeatedly on multiple occasions. If the protective foundation, if and when incorporated, would exercise such call option, if and when granted, a number of preferred shares up to 100% of our issued share capital held by others than the protective foundation, minus one share, will be issued to the protective foundation. These preferred shares would then be issued to the protective foundation under the obligation to pay 25% of their nominal value upon issuance. In order for the protective foundation to finance the issue price in relation to the preferred shares, the protective foundation may enter into a finance arrangement with a bank or other financial institution. As an alternative to securing this external financing, subject to applicable restrictions under Dutch law, the call option agreement, if and when entered into, will provide that the protective foundation may request us to provide, or cause our subsidiaries to provide, sufficient funding to the protective foundation to enable it to satisfy the payment obligation (or part thereof) in cash and/or to charge an amount equal to the payment obligation (or part thereof) against our profits and/or reserves in satisfaction of such payment obligation. The articles of association of the protective foundation, if and when incorporated, will provide that it will promote and protect the interests of the company, the business connected with the company and the company&#8217;s stakeholders from time to time, and repress possible influences which could threaten the strategy, continuity, independence and/or identity of the company or the business connected with it, to such an extent that it could be considered to be damaging to the aforementioned interests. These influences may include a third-party acquiring a significant&#160;percentage of our common shares, the announcement of an unsolicited public offer for our common shares, shareholder activism, other concentration of control over our common shares or any other form of undue pressure on us to alter our strategic policies. The protective foundation, if and when incorporated, shall be structured to operate independently of us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The voting rights of our shares are based on nominal value and, as we expect our common shares to trade substantially in excess of their nominal value, preferred shares issued at 25% of their nominal value can carry significant voting power for a substantially reduced price compared to the price of our common shares and thus can be used as a defensive measure. These preferred shares, if and when issued, will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a fixed rate calculated over the amount paid-up on those preferred shares <i style="font-style:italic;">pro&#160;rata tempore</i> for the period during which they were outstanding. The protective foundation would be expected to require us to cancel its preferred shares, if and when issued to the protective foundation, once the perceived threat to the company and its stakeholders has been removed or sufficiently mitigated or neutralized. However, subject to the same limitations described above, the protective foundation would, in that case, continue to have the right to exercise the call option in the future in response to a new threat to the interests of us, our business and our stakeholders from time to time.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain provisions of our articles of association may make it more difficult for a third party to acquire control of us or effect a change in the composition of our management board and supervisory board. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that our managing directors and supervisory directors are appointed on the basis of a binding nomination, the binding nature of which can only be overruled by a simple majority of votes cast representing at least one-third of our issued share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that our managing directors and supervisory directors may only be dismissed by the general meeting by a two-thirds majority of votes cast representing more than 50% of our issued share capital (unless the dismissal is proposed by the supervisory board or, with respect to supervisory directors nominated by dievini or KfW, by dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) during the nomination period for dievini or by KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) during the nomination period for KfW, respectively, in which case a simple majority of the votes would be sufficient);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that certain provisions of our articles of association can only be amended with the affirmative vote of (i)&#160;during the nomination period for dievini, dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and (ii)&#160;during the nomination period for KfW, KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that if a supervisory director is no longer in office or is unable to act, he or she may be replaced temporarily by a person who the supervisory board has designated for that purpose and, where a supervisory director who has been appointed upon a nomination of dievini or KfW, as applicable, is no longer in office or unable to act, such supervisory director may only be temporarily replaced by a person designated for such purposes by dievini or KfW, as applicable. Such person shall become a full member of the supervisory board with the rights of the relevant supervisory director appointed upon a nomination of dievini or KfW, as applicable, as soon as a written designation to that effect has been received by the chairman or vice-chairman of our supervisory board, subject to limitations, under applicable law regarding dievini&#8217;s rights under this provision;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision allowing, among other matters, a former chairman of our supervisory board, a former nominee of dievini, and a former nominee of KfW to jointly take on the supervisory functions, which persons jointly may designate one or more other persons to be charged with the supervision of our company (instead of or together with the former chairman of our supervisory board), as applicable, to supervise our affairs if all of our supervisory directors are removed from office and to appoint others to be charged with the supervision of our affairs, until new supervisory directors are appointed by the general meeting on the basis of a binding nomination discussed above;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision allowing the management board to temporarily replace a managing director who is no longer in office or unable to act, with another person or persons designated for this purpose by the management board and attributing the management of the company to the supervisory board in case all managing directors are no longer in office or unable to act; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that certain matters, including an amendment of our articles of association, may only be brought to our shareholders for a vote upon a proposal by our management board with the approval of our supervisory board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Dutch law allows for staggered multiyear terms of our managing directors and supervisory directors, as a result of which only part of our managing directors and supervisory directors may be subject to appointment or reappointment in any one year.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are not obligated to, and do not, comply with all best practice provisions of the Dutch Corporate Governance Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the Dutch Corporate Governance Code, or the DCGC. The DCGC contains both principles and best practice provisions on corporate governance that regulate relations between the management board, the supervisory board and the general meeting and matters in respect of financial reporting, auditors, disclosure, compliance and enforcement standards. The DCGC is based on a &#8220;comply or explain&#8221; principle. Accordingly, companies are required to disclose in their annual reports, filed in the Netherlands, whether they comply with the provisions of the DCGC. If they do not comply with those provisions (for example, because of a conflicting Nasdaq requirement), the company is required to give the reasons for such noncompliance. The DCGC applies to Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or elsewhere, including Nasdaq. We do not comply with all best practice provisions of the DCGC. See &#8220;Item&#160;10. Additional Information &#8212; B. Memorandum and Articles of Association.&#8221; This may affect your rights as a shareholder and you may not have the same level of protection as a shareholder in a Dutch company that fully complies with the DCGC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have identified a material weakness in our internal control over financial reporting related to (i) lack of sufficient accounting and supervisory personnel, (ii) lack of appropriate level of technical accounting training; and (iii) lack of consistent performance of controls over financial reporting which, if not remediated appropriately or timely, could result in loss of investor confidence and adversely impact our stock price. If we are unable to remediate the material weakness, or if other material weaknesses are identified, we may not be able to report our financial results accurately, prevent fraud or file our periodic reports as a public company in a timely manner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining internal control over financial reporting, disclosure controls, and compliance with the other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC thereunder. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with international financial reporting standards. A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We reported in our Annual Report 20-F for the year ended December 31, 2022, a material weakness in internal control over financial reporting primarily related to an IT system&#8217;s functionalities that were not configured to support segregation of duties in the recording of manual journal entries as well as in the authorization of purchase orders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2023, we implemented measures to remediate this material weakness, and even though progress was made to strengthen our control environment, management concluded that at December 31, 2023, there was a material weakness in internal control related to (i) lack of sufficient accounting and supervisory personnel, (ii) lack of appropriate level of technical accounting training; and (iii) lack of consistent performance of controls over financial reporting. As a result, management concluded that our internal control over financial reporting was not effective as of December 31, 2023. While we are working to remediate the weakness as quickly and efficiently as possible, we cannot at this time provide an estimate of the time frame we expect in connection with implementing our plan to remediate this material weakness. These remediation measures may be time consuming, costly and might place significant demands on our financial and operational resources. If we are unable to remediate the material weakness, or are otherwise unable to maintain effective internal control over financial reporting or disclosure controls and procedures, our ability to record, process and report financial information accurately, and to prepare financial statements within required time periods, could be adversely affected, which could subject us to litigation or investigations requiring management resources and payment of legal and other expenses, result in material misstatements in our financial statements that could require a restatement of financial statements, negatively affect investor confidence in our financial statements and adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the material weakness identified as of December 31, 2023, we have concluded that the financial statements and other financial information included in this Annual Report on Form 20-F, fairly present in all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management has and continues to take measures to remediate this material weakness, as discussed in more detail under &#8220;Item 15. Controls and Procedures&#8221; of this Report and is committed to continue investing significant time and resources and taking actions to remediate the material weakness in training and hiring staff as well as supervisory personnel to further strengthen our internal control over financial reporting. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in additional significant deficiencies or material weaknesses, and result in material misstatements in our financial statements that could result in a restatement of financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Risks Related to ESG</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance, or &#8220;ESG,&#8221; matters, including related social expectations and concerns, may impose unexpected costs or result in reputational or other harm that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There are rapid and ongoing developments and changing expectations relating to ESG matters and factors such as the impact of our operations on the environment, corporate governance, management of business ethics, human rights diligence in our supply chain, and human resource development, which may result in increased regulatory, social or other scrutiny on us. Regarding climate risks, we are expected to address climate risks due to our own contribution to climate change (inside-out perspective), risks due to physical effects of climate change as well as transition risks (outside-in perspective), and interactions between both perspectives (&#8220;dual materiality&#8221;). If we are unable to adequately recognize and respond to such developments and governmental, societal, investor and NGO expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional scrutiny, incur unexpected costs or experience damage to our reputation or our various brands. If any of these events were to occur, there may be a material adverse effect on our business, financial condition, cash flows and results of operations and the market value of our common shares may decline. We have observed that in addition to the importance of their financial performance, companies are increasingly being judged by their performance on ESG matters. A variety of organizations measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. We may not comply with some or all of the standards or best practices put forth by such organizations or by governmental or regulatory bodies. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures to their investment decisions. In light of investors&#8217; increased focus on ESG matters, there can be no certainty that we will manage such issues successfully. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability of our business over time. We are committed to taking actions to manage ESG - related risks. Therefore, in 2023, we initiated a project focused on addressing ESG - related matters based on relevant legal requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we or our third-party suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><a id="_0cc59dbd_4371_4d46_9443_74e986fd02e8"></a><a id="ITEM4INFORMATIONONTHE_612098"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 4. INFORMATION ON THE COMPANY</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">A.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">History and Development of the Company</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;7, 2020, CureVac B.V. was incorporated under the laws of the Netherlands and became the holding company of CureVac AG in connection with our initial public offering on August&#160;14, 2020, as part of a corporate reorganization (the &#8220;Corporate Reorganization&#8221;), in which the legal form of CureVac B.V. was converted from a Dutch private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) to a Dutch public company (<i style="font-style:italic;">naamloze vennootschap</i>), and the articles of association of CureVac N.V. became effective. Following the Corporate Reorganization, CureVac N.V. became the holding company of CureVac AG. On September 26, 2022, CureVac AG entered into a plan of merger with CureVac Beteiligungsverwaltungs AG, with CureVac SE as the surviving entity and both CureVac AG and CureVac Beteiligungsverwaltungs AG as disappearing entities. The historical consolidated financial statements of CureVac AG included in this Annual Report became part of the historical consolidated financial statements of CureVac N.V. Our legal and commercial name is CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 T&#252;bingen, Germany, and our telephone number at this address is +49 7071 9883 0. Our additional offices are in Wiesbaden (Germany), Louvain La Neuve (Belgium), Amsterdam (Netherlands), Basel (Switzerland), and Boston (Massachusetts, United States).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since August&#160;14, 2020, our common shares are trading on Nasdaq under the symbol &#8220;CVAC.&#8221; Our agent for service of process in the United States is CureVac Inc., located at 250 Summer St. 3rd Fl., Boston, Massachusetts 02210.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SEC maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov. Our website can be found at www.curevac.com. The information on our website is not incorporated by reference into this Annual Report, and you should not consider information contained on our website or any websites mentioned in this Annual Report to be part of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span>Business Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a global biopharmaceutical company that is developing a new class of transformative medicines based on messenger ribonucleic acid, or mRNA, which has the potential to improve the lives of people. mRNA plays a central role in cellular biology in the production of proteins in every living cell. Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. We are pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Our technology platform is based on a targeted approach to optimize mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell&#8217;s intrinsic translation machinery. Our current product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Prophylactic Vaccines</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In prophylactic vaccines, we are advancing our second-generation mRNA backbone against coronavirus (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our improved second-generation mRNA backbone features targeted optimizations designed to improve intracellular mRNA stability and translation for increased and extended protein expression. These optimizations potentially allow for strong and early immune responses at low doses. This supports the development of multivalent vaccines to target spreading COVID-19 variants or different influenza strains as well as combination vaccines against different viral diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">COVID-19 Program in collaboration with GSK (second-generation mRNA backbone)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The collaboration on COVID-19 vaccine candidates with GSK, initiated in April 2021, aims to research, develop, and manufacture mRNA vaccines targeting relevant SARS-CoV-2 variants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On January 5, 2024, CureVac announced positive data from a formal interim analysis in the ongoing Phase 2 clinical study assessing monovalent and bivalent modified COVID-19 vaccine candidates in direct comparison to a licensed bivalent mRNA-based COVID-19 comparator vaccine. The monovalent mRNA vaccine candidate, CV0601, encodes the Omicron BA.4-5 variant; the bivalent candidate, CV0701, encodes the Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus. Both vaccine candidates apply CureVac&#8217;s proprietary second-generation mRNA backbone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Initiation of the Phase 2 study with CV0601 and CV0701 was announced on August 1, 2023. The study is being conducted in Australia and is fully enrolled with 427 healthy adult participants, as announced on November 1, 2023. It assesses the safety and immunogenicity of different single booster doses of CV0601 and CV0701. While the monovalent candidate CV0601 was tested at a single medium dose level, the bivalent candidate CV0701 was tested at low, medium, and high dose levels. All tested dose levels were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Results from the formal interim analysis showed that both candidates exhibited a favorable reactogenicity profile across all tested doses and were generally well tolerated with a lower or similar proportion of participants reporting solicited adverse events when compared to comparator vaccine participants within seven days of dosing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Both candidates produced meaningful immune responses beginning at the lowest tested dose. Interim immunogenicity data showed meaningful titers of neutralizing antibodies for both candidates, which matched or numerically exceeded the titers induced by the licensed comparator vaccine at all tested doses except for the low dose level of CV0701. At the medium dose level tested for CV0601, neutralizing antibody titers against the Omicron BA.4-5 variant on day 29 following the booster vaccination were 5.0 times the pre-boosting titers, numerically exceeding the 3.6-fold ratio generated by the licensed comparator vaccine. At the low, medium, and high dose levels tested for CV0701, neutralizing antibody titers against BA.4-5 on day 29 following the booster vaccination were 2.7-fold, 3.7-fold, and 4.6-fold the titers before the booster, compared to a 3.6-fold ratio for the comparator vaccine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Phase 2 study was based on a Phase 1 study with the modified COVID-19 mRNA construct CV0501 also applying our second-generation backbone and encoding the Omicron BA.1 variant. CV0501 was the first vaccine candidate in the COVID-19 program to apply modified mRNA. Vaccination of the first participant in the Phase 1 study with CV0501 was announced on August 18, 2022. The study was conducted at clinical sites in the United States, Australia, and the Philippines to evaluate the safety, reactogenicity, and immunogenicity of a booster vaccination of CV0501 in 180 participants. Positive preliminary data from the Phase 1 study were reported in January and April 2023 and led to the selection of modified mRNA as the preferred technology for further clinical development in the COVID-19 program. The study was completed in August 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The first representative of our joint COVID-19 vaccine program with GSK based on our second-generation backbone was CV2CoV, an unmodified mRNA construct, encoding the original SARS-CoV-2 virus. A Phase 1 clinical study with CV2CoV was announced on March 30, 2022, to evaluate the safety, reactogenicity, and immunogenicity of a booster vaccination of CV2CoV in 98 participants at clinical sites in the United States. The study was completed in March, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Seasonal Flu Program in collaboration with GSK (second-generation mRNA backbone)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Seasonal flu was disclosed as the first indication from the initial collaboration we started with GSK in July 2020. The collaboration focuses on the development of new products for different targets in the field of infectious diseases, excluding COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 4, 2024, we announced promising interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of a seasonal influenza vaccine candidate. The multivalent candidate was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains. Results from the planned interim analysis showed that the multivalent vaccine candidate boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose. The vaccine candidate was shown to have an acceptable safety and tolerability profile, with the majority of solicited adverse events reported as either mild or moderate. Among younger and older adults, geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across all tested dose levels. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across both age groups and tested dose levels, in line with expectations and other initial mRNA-based clinical flu development programs. Further optimizations to enhance immune responses against influenza B strains will be tested in an additional Phase 2 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Initiation of the combined Phase 1/2 for seasonal flu was announced on May 8, 2023. The initial Phase 1 part compared a comprehensive series of multivalent, modified mRNA seasonal flu vaccine candidates with up to eight separate mRNA constructs per candidate, addressing all four WHO-recommended flu strains. Candidates were tested at different dose levels in 270 healthy younger adults (age 18-50). Positive data from an interim analysis of the Phase 1 part was reported on September 12, 2023. Interim safety data showed no safety concerns across all tested dose levels for the multivalent candidates. Immunogenicity of all candidates was assessed in parallel with a licensed seasonal flu vaccine comparator vaccine. The humoral responses observed supported the selection of the preferred vaccine candidate, which is currently being tested in the Phase 2 part of the study. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined Phase 1/2 study is based on a Phase 1 study with a modified, monovalent influenza vaccine candidate, Flu-SV-mRNA, announced on August 18, 2022. The vaccine candidate expresses an H1N1 hemagglutinin antigen (subtype of influenza A). The Phase 1 dose-escalation study is being conducted in Canada, Spain, and Belgium to evaluate the safety, reactogenicity, and immunogenicity of Flu-SV-mRNA in younger adults aged 18-45 and older adults aged 60-80. Preliminary safety and reactogenicity data in younger adults showed that the monovalent Flu-SV-mRNA candidate was generally well tolerated with no safety concerns observed to date across all tested dose levels. For older adults, a single dose of Flu-SV-mRNA (dose level undisclosed) was assessed for safety and reactogenicity and was also observed to be safe and well tolerated with no grade 3 adverse events in the 32 subjects who were administered the mRNA construct. Immunogenicity of Flu-SV-mRNA was assessed in parallel with a licensed seasonal flu vaccine comparator in both age groups. In younger adults, adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA increased up to approximately 3.3 times those elicited by the licensed flu vaccine comparator in younger adults. In older adults, adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA were approximately 2.3 times those elicited by the licensed flu vaccine comparator. In the same age group, the percentage of subjects achieving seroconversion was 89.7% for Flu-SV-mRNA and 56.2% for the licensed flu vaccine comparator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The first vaccine candidate within the broader infectious disease program applying our second-generation backbone we tested in collaboration with GSK was the flu candidate, CVSQIV, a multivalent vaccine candidate featuring multiple unmodified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. On February 10, 2022, we announced the start of a Phase 1 dose-escalation study in Panama evaluating the safety, reactogenicity, and immunogenicity of CVSQIV. Preliminary safety data reported on April 28, 2022, showed a benign reactogenicity profile across the tested dose groups. The study was completed in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Avian Influenza in collaboration with GSK (second-generation mRNA backbone)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Avian influenza was disclosed as the latest program progressing to clinical trials under the initial collaboration we started with GSK in July 2020. The collaboration focuses on the development of new products for different targets in the field of infectious diseases, excluding COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 24, 2024, the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate was announced. The study assesses a monovalent vaccine candidate encoding an influenza A H5-antigen. The H5N1 avian flu virus is considered a potential future pandemic threat, able to sporadically cross species from its original bird host to other animal hosts to humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Oncology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In oncology, we plan to build a meaningful portfolio and create long-term value to accelerate growth beyond the recent progress in prophylactic vaccines. Within our oncology strategy, we follow two approaches: (1) the development of off-the-shelf cancer vaccines based on tumor antigens shared across different cancer indications and (2) the development of fully personalized cancer vaccines based on a patient&#8217;s individual tumor genomic profile. Developing new cancer vaccine candidates is characterized by similar medical challenges as in infectious diseases, including selection and accessibility of disease-relevant antigens, enhancing antigen-induced immune activation, and triggering immune responses led by a strong induction of tumor-killing T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A key component to deliver on the development of new cancer vaccines is the build-up of a powerful antigen discovery engine. To complement existing in-house expertise to identify and validate promising antigens for mRNA cancer vaccine candidates and gain access to state-of-the-art antigen discovery technologies, we announced a partnership with Belgium-based company myNEO Therapeutics (&#8220;myNEO&#8221;) on May 25, 2022, and the acquisition of Netherlands-based Frame Cancer Therapeutics (&#8220;Frame&#8221;) on June 8, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Together with immunotherapy company myNEO, we aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation is expected to allow for selection of antigens with the highest confidence of success for potential clinical testing. On November 22, 2023, both companies announced that CureVac exercised two exclusive options on selected sets of potential cancer vaccine shared antigen targets. The shared antigen targets identified by my NEO within the collaboration demonstrated strong immunogenicity in undisclosed preclinical studies. The most promising targets will be considered for validation for the design of potential mRNA cancer vaccine candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the acquisition of Frame, a private company focused on advanced genomics and bioinformatics, we added sophisticated methods to identify unique neoantigens across different cancer types. The former Frame site was inaugurated as CureVac Netherlands and will further develop the proprietary technology platform, which has the potential to identify a broad panel of neoantigens and tumor-associated antigens that go beyond conventional approaches. This could strongly increase the likelihood of developing highly effective cancer vaccines that activate the human immune system against cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The field of immunotherapy has advanced with the progression of available technologies, such as next-generation sequencing, to extract data from patient samples. Conventional approaches have so far focused on the exome, the protein-coding part of the genome, which represents only about 1.5% of the total genetic information. More recently, breakthrough developments in sequencing capacity have enabled the extraction of vastly larger amounts of data that allows us to utilize the remaining 98.5% of genetic information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The technologies brought in house with the acquisition of Frame are based on whole-genome-sequencing for every patient sample combined with short as well as long-range RNA sequencing to map the full inventory of genomic changes. More specifically, downstream of the sequencing, a software package integrates all the data to retrieve the exact changes in the DNA of the tumor cells compared to healthy cells. Correlation of this data with changes in the RNA transcription of the tumor results in entirely new and potentially antigenic tumor antigens that we plan to test as targets for a portfolio of new cancer vaccine candidates. These new antigens are not only entirely foreign to the body but are also uniquely expressed in the tumor and not in healthy tissue. In their foreignness, these constructs are expected to raise stronger immune responses than antigens derived from exome-based conventional approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">We recently extended our capabilities in oncology with a co-development and licensing agreement with The University of Texas MD Anderson (&#8220;M.D. Anderson&#8221;) Cancer Center, announced on April 16, 2024. The collaboration creates strong synergies between CureVac&#8217;s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and M.D. Anderson&#8217;s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The focus of the collaboration is on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need. Identification of differentiated cancer antigens via whole genome sequencing, combined with long- and short-read RNA-sequencing and cutting-edge bioinformatics will be followed by joint preclinical validation of the highest-quality cancer antigens and selection of the most promising clinical-lead candidates for conducting initial Phase 1/2 studies in appropriate clinical indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the collaboration agreement with M.D. Anderson, we are granted an exclusive, fee-bearing, sublicensable license under certain intellectual property to develop, manufacture and commercialize (i) products containing certain RNA-based cancer vaccine candidate(s) developed under the agreement, or M.D. Anderson Cancer Center (MDACC) Program Products, for any and all uses for cancer in humans throughout the world and (ii) certain other products that target one or more antigens identified under the agreement throughout the world and M.D. Anderson is granted an exclusive, fee-bearing, sublicensable license under certain intellectual property jointly created under the agreement to develop, manufacture and commercialize certain non-MDACC Program Products that target one or more antigens identified under the agreement throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, we are solely responsible for the commercialization and commercial manufacturing of the MDACC Program Products for any and all uses related to cancer in humans worldwide. On a program-by-program basis upon completion of the first Phase I/II or Phase I clinical trial, as applicable, for a program, the parties agree to decide on a commercialization strategy through the joint steering committee, including whether such commercialization will be done by us or a third party via a partnership. On a program-by-program basis, each party will fund a specific percentage of all development costs incurred under the agreement. On a program-by-program basis, we will initially receive a percentage of the commercialization proceeds which is equal to our percentage of development costs, subject to certain assumptions and adjustments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investigational cancer vaccine CVGBM for surgically resected glioblastoma</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To assess the safety and immunogenicity of our second-generation backbone in an oncology setting, we initiated a proof-of-principle Phase 1 study in patients with newly diagnosed surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma on June 20, 2023. The open-label study evaluates the safety and tolerability of CVGBM, a cancer vaccine candidate featuring a single unmodified mRNA encoding eight epitopes derived from known tumor-associated antigens with demonstrated immunogenicity in glioblastoma. On April 24, 2024, we announced that the dose-escalation Part A of the study completed recruitment of all four dose levels. Following review of the safety data, the Data Safety Monitoring Board (DSMB) confirmed no dose limiting toxicities and gave a dose recommendation for 100 &#181;g for the dose-confirmation Part B of the study. Part B is expected to start enrollment mid-2024. A first study data readout is expected in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">The multiepitope design of CVGBM was supported by preclinical studies assessing the potency of a multiepitope mRNA cancer vaccine construct targeting tumors in a murine melanoma model. The data was presented at the 11th International mRNA Health Conference, hosted by CureVac from October 31 to November 2, 2023, in Berlin, Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">The preclinical mRNA construct encoding ten epitopes derived from the murine B.16.F10 melanoma cell line was tested in mice. The study applied three 5 &#181;g doses of LNP-formulated B.16 mRNA, administered intramuscularly at weekly intervals. Data obtained on day 21 confirmed prominent induction of CD8+ and CD4+ T cell responses recognizing epitopes across the full multiepitope construct. Median survival of the animals increased to 30.9 days for treated mice compared to 23.2 days for a group vaccinated with formulated control mRNA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Strong T cell activation is particularly encouraging and relevant, as the B16-F10 tumor model is characterized as a cytokine deficient &#8220;cold&#8221; tumor model that exhibits very little immune cell infiltration and resistance to check-point inhibitors. The data suggest that single-agent application of the multiepitope B.16 mRNA construct generated robust T cell activation in the tumor microenvironment, thereby inhibiting tumor growth and extending survival in the applied preclinical model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The RNA Printer</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">In addition to our GMP manufacturing facilities, we are developing a novel downsized, integrated, and automated process for manufacturing of mRNA vaccines and therapeutics, which we refer to as The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is CureVac&#8217;s automated end-to-end manufacturing solution for GMP-grade mRNA vaccines and therapeutics and an integral part of our oncology strategy. The highly standardized system is expected to allow for rapid and highly flexible availability of mRNA to screen new targets and transition promising mRNA product candidates more efficiently into the clinic. Designed for small-scale quantities, the automated GMP-grade output of The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is designed to open avenues for personalized mRNA-based cancer therapies. On November 14, 2023, we announced that the system has successfully achieved the first regulatory milestone by obtaining a manufacturing license from the regional authority in Baden-W&#252;rttemberg for an mRNA in our cancer vaccine development program to support CureVac&#8217;s oncology strategy. The second regulatory milestone was achieved on December 12, 2023, when The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> received a drug substance framework manufacturing license from the regional authority in Baden-W&#252;rttemberg. The regulatory review process is ongoing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Molecular Therapies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our development efforts for molecular therapy are based on delivering optimized mRNAs to trigger production of antibodies or therapeutic proteins. Using our technology, we can instruct human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, cell membrane. Based on this &#8220;healthy&#8221; information delivered by mRNA, our cells can produce proteins, which are required to treat the disease caused by missing or inactive proteins. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our mRNA optimization process, which is a core pillar of our RNA optimizer platform, is designed to increase protein expression with the aim to reach therapeutic levels. In preclinical studies in non-human primates, we have demonstrated that antibodies encoded by mRNA can be produced in hepatocytes very rapidly and can reach therapeutic levels in the blood stream. We are currently advancing undisclosed programs in preclinical studies across eye disorders as well as delivering therapeutic antibodies. Our work in eye disorders is carried out in collaboration with the Schepens Eye Research Institute. We expect to publish data from our collaboration in 2024.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our approach seeks to mitigate clinical and developmental risk across multiple levels to advance and expand our broad product portfolio. We have made advances in utilizing the potential of our technology platform through rational disease selection. We consider a number of factors in our disease selection process including unmet medical need, immune response, duration of expression, dosing requirements, delivery, and targeted tissue types, among other factors. Our programs target the underlying modes of action of the disease that play a critical role in the pathology of the disease. We are initially targeting diseases that require an active immune response (such as prophylactic vaccines and cancer vaccines) and require transient expression of mRNA in tissue types that are more easily accessible. We believe these indications are amenable to localized delivery using a lipid nanoparticle, or LNP, delivery system. Following the encouraging results from our current prophylactic vaccines program in clinical studies and based on our advanced understanding of mRNA biology and immune stimulation control, we have expanded our product portfolio to also target indications that require an immune silent approach (such as protein delivery), given the need for higher doses, repeated dosing and longer expression of the protein. These initial indications are using LNP delivery systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">We consider our manufacturing process an important part of our strategy that allows us to match our flexible and versatile technology platform with equally flexible and versatile manufacturing setups. In house, we currently operate three GMP-certified suites, with the capacity to supply our clinical programs and support potential early commercialization activities. We are in the process of building a fourth GMP large-scale production facility at CureVac&#8217;s headquarters in T&#252;bingen, which is being designed to cover all manufacturing steps from starting material to formulation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial Position</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Our capital expenditures for 2023, 2022, and 2021 amounted to &#8364; 57.8 million, &#8364; 101.6 million, and &#8364;135.4 million, respectively. These expenditures were primarily for equipment and intangibles used in our research and development activities, as well as for the development of a GMP production process on a large scale (GMP IV).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">To date, our revenues have consisted of upfront licensing payments, product sales, and compensation for research and development services, the majority of which relate to our license and collaboration agreements. For the years ended December 31, 2021, 2022, and 2023, &#8364;103.0 million, &#8364;67.4 million, and &#8364;53.8 million, respectively, or 100%, of our total revenue, in each respective year, was derived through our collaborations. Since our founding in 2000, we have raised &#8364;1.94 billion in gross proceeds from equity financings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of revenue by geographic area. Revenue is attributed to geographic region based on the location of our license and collaboration partner:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">North America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Rest of the World</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have built an intellectual property portfolio in the United States, Europe, and other major geographies. As of March 19, 2024, we own approximately 624 issued patents worldwide, including 103 issued U.S. patents, 43 issued European patents (which have been validated in various European countries resulting in a total of approximately 395 national patents in European countries) and including two European patents with unitary effect, one German national patent, and 126 issued patents in other foreign countries, 116 pending U.S. patent applications, 74 pending European patent applications, 311 pending patent applications in other foreign countries, and 18 pending PCT patent applications. Our patent portfolio includes claims relating to our RNA technology platform, our proprietary LNP technology, and our Influenza and SARS-CoV-2 product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are led by a team of experts with extensive experience in the biopharmaceutical industry, including in nucleic acid therapy, oncology, rare and infectious diseases, and antibodies. Our management team as well as our supervisory board members have broad expertise in the clinical, regulatory, and commercialization aspects of prophylactic vaccines, oncology and molecular therapy, as well as in drug development, process development, and manufacturing for mRNA therapies. As the result of our organic growth, our workforce has increased from an approximate average workforce of 440 in fiscal 2019 to 1,126 as of December 31, 2023, including 301 employees with advanced scientific degrees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Product Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our differentiated mRNA technology platform is designed to address a broad range of diseases across multiple therapeutic areas. Given the strengths of our platform, the broad potential of mRNA-based medicines and our rational approach to disease selection, we have chosen to leverage our platform to initially focus on advancing our product candidates in the areas of prophylactic vaccines, oncology and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A disease indication may require an approach that triggers an immune response (immune active) or that does not require immune activation (immune silent). Each of the disease indications that we are targeting require different levels of immune activation for the mRNA-based medicines to be effective. For the immune active side of our technology, we focus on mRNA-based medicines in prophylactic vaccines and oncology. For the immune silent side of our technology, we have expanded our preclinical product portfolio to include mRNA therapies based on the expression of therapeutic proteins (including ocular, liver and lung applications).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our lead programs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our vaccine candidates CV0601 (monovalent) and CV0701 (bivalent) against SARS-CoV-2, applying our second-generation mRNA backbone and modified mRNA, are being developed in collaboration with GSK. We initiated a Phase 2 study in August 2023, which provided positive interim results in January 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our multivalent vaccine candidate against influenza, applying our second-generation mRNA backbone and modified mRNA, is being developed in collaboration with GSK. We initiated a combined Phase 1/2 study in May 2023 testing a comprehensive series of multivalent vaccine candidates. The preferred candidate selected from the Phase 1 part was advanced to the Phase 2 part in November 2023. The Phase 2 part provided interim results in April 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our cancer vaccine candidate CVGBM is tested in patients with surgically resected Glioblastoma Multiforme. It applies our second-generation mRNA backbone and unmodified mRNA. It encodes eight epitopes derived from known tumor-associated antigens with demonstrated immunogenicity in glioblastoma. A Phase 1 study initiated in June 2023 is expected to provide data in the second half of 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our key partnered programs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have partnered with GSK for the development of COVID-19 vaccine candidates based on our second-generation mRNA backbone and vaccine candidates against other infectious diseases, including seasonal influenza, also based on our second-generation mRNA backbone.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have partnered with the immunotherapy company myNEO to identify specific antigens on the surface of tumors for the development of novel mRNA-based cancer vaccine candidates. The partnership leverages myNEO&#8217;s biological datasets and integrated machine learning and bioinformatics platform to identify and validate specific tumor antigens predicted to elicit a strong immune response.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have partnered with CRISPR Therapeutics for the development of novel Cas9 mRNA constructs for use in gene editing therapeutics, with improved properties such as increased potency, decreased duration of expression and reduced potential for immunogenicity. CRISPR Therapeutics has an exclusive license to the improved constructs in three of their </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> gene editing programs.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:231.69pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a broad strategic partnership with Genmab to leverage our mRNA technology platform to develop up to four mRNA-based novel therapeutic antibodies. This represents the first publicly announced strategic partnership focused on differentiated mRNA-based antibodies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We also have several academic collaborations, including with SERI for target discovery research in mRNA-based eye therapy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.7pt 0pt;"><img src="cvac-20231231x20f002.jpg" alt="Graphic" style="display:inline-block;height:231.69pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:493.14pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:4.55pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Unidentified indication.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9pt;">**</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">For further details on our collaboration agreements, see &#8220;Business&#8201;&#8212;&#8201;Collaborations&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8201;&#8212;&#8201;Our Collaborations and Related License Agreements.&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strengths</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are developing a broad portfolio of product candidates currently in preclinical or clinical development stages that we believe position us at the forefront of targeted immune active and immune silent mRNA medicines. Our key strengths include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have a differentiated mRNA technology platform that has the potential to address a wide range of diseases. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As the pioneers in the field of mRNA-based medicines, we have a deep understanding of mRNA biology, its interaction with the cellular translation machinery as well as the immune system. We have built our differentiated RNA optimizer platform to incorporate these insights over the past 23 years. We optimize mRNA to preserve critical protein-RNA interactions. Given the potential advantages of the mRNA-based medicines over existing treatment modalities, such as potential for broad application, wide range of activity, flexibility, design versatility, transient expression and a single manufacturing process, we believe that we have the potential to address a broad range of diseases across multiple therapeutic areas. Our technology platform has been validated in clinical and preclinical studies in selected disease indications.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have an optimized second-generation mRNA backbone, which catalyzes the expansion of our clinical development pipeline in prophylactic vaccines as well as oncology</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Our proprietary second-generation mRNA backbone targets improved intracellular mRNA translation for increased and extended protein expression, resulting in early and strong immune responses. The second-generation mRNA backbone broadly spans unmodified and modified mRNA, as well as monovalent and multivalent vaccine formats to diversify and advance our product development pipeline. We aim to be at the forefront of delivering mRNA-based vaccines against a range of relevant infectious diseases and are executing on a broad mRNA vaccine program in collaboration with GSK. Second-generation backbone-based vaccines are expected to allow for flexible protection against one or more emerging COVID-19 variants and to enable new mRNA vaccines against other infectious diseases, such as influenza, as well as potential combination vaccines against different viruses. Alongside our recent progress in COVID-19 and flu we are also broadening our foundation in oncology and aim to build a meaningful portfolio of cancer vaccine candidates based on the second-generation mRNA backbone in combination with promising new tumor antigens predicted to elicit strong immune responses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have a broad portfolio of mRNA-based medicines in preclinical and clinical development stages being designed for efficacy, safety and protein expression at relatively low doses.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The potential of our technology optimized for immune activation in prophylactic vaccines and oncology has been observed in multiple clinical studies. We are developing our product candidates, have conducted preclinical studies and initiated Phase 1 and Phase 2 trials of vaccine candidates based on our second-generation mRNA backbone for COVID-19 and influenza. In oncology, we plan to build a meaningful portfolio of novel cancer vaccines based on our second-generation mRNA backbone to create long-term value and accelerate growth beyond the recent progress in prophylactic vaccines. A key component to deliver on this strategy is the buildup of a powerful antigen discovery engine. In the immune silent area molecular therapy, our approaches optimized for protein therapies have been evaluated in multiple preclinical disease models.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have a strong clinical development pipeline driven by the technological advantages of our versatile second-generation mRNA backbone. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our development focus in the immune activation area is on our second-generation mRNA backbone. In infectious diseases, we leverage this backbone to advance COVID-19 and flu vaccine candidates jointly developed with GSK. On January 5, 2024, we announced positive data from a formal interim analysis in the ongoing COVID-19 Phase 2 clinical study assessing the monovalent mRNA vaccine candidate, CV0601, encoding the Omicron BA.4-5 variant and the bivalent mRNA candidate, CV0701, encoding the Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus. All tested dose levels were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU. Results from the formal interim analysis showed that both candidates exhibited a favorable reactogenicity profile across all tested doses and were generally well tolerated with a lower or similar proportion of participants reporting solicited adverse events compared to a licensed comparator. Both candidates produced meaningful immune responses beginning at the lowest tested dose with neutralizing antibody titers matching or numerically exceeding the titers induced by the licensed comparator vaccine at all tested doses except for the low dose level of CV0701. In seasonal influenza, we announced promising interim data on April 4, 2024 from the Phase 2 part of the combined Phase 1/2 study of a multivalent candidate, encoding antigens matched to all four WHO-recommended flu strains. Results showed that the multivalent vaccine candidate boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, and exhibited an acceptable safety and tolerability profile, with the majority of solicited adverse events reported as either mild or moderate. Among younger and older adults, geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across all tested dose levels. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across both age groups and tested dose levels. Further optimizations to enhance immune responses against influenza B strains will be tested in an additional Phase 2 study. On April 24, 2024, we announced the start of a combined Phase 1/2 study in avian influenza (H5N1).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">In oncology, we leverage our second-generation mRNA backbone in a Phase 1 study in patients with newly diagnosed resected glioblastoma, initiated in June 2023. The study evaluates the safety and tolerability of CVGBM, a cancer vaccine candidate featuring a single unmodified mRNA encoding eight epitopes derived from known tumor-associated antigens with demonstrated immunogenicity in glioblastoma. On April 24, 2024, we announced that the dose-escalation Part A of the study completed recruitment of all four dose levels. Following review of the safety data, the Data Safety Monitoring Board (DSMB) confirmed no dose limiting toxicities and gave a dose recommendation for 100 &#181;g for the dose-confirmation Part B of the study. Part B is expected to start enrollment toward mid-2024.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have the ability to target different tissue types based on our delivery systems. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have access to a number of mRNA delivery systems, including third-party and our proprietary systems, which allow us to target distinct tissues in an optimal way. Our current clinical prophylactic vaccine and cancer vaccine programs rely on LNP-based delivery systems administered intramuscularly and providing access to the immune cells. Moreover, LNP-based systems deliver mRNA efficiently to the hepatocytes in the liver, if administered intravenously. Protein expressed in the liver may either restore a specific function in the liver itself or produce secreted proteins for release into circulation. We rely on third-party state-of-the-art LNP delivery systems for our current clinical programs, but we are also developing our own proprietary LNP delivery system. In our proprietary LNP programs, we demonstrated that changes to the ratio and/or composition of the LNP constituents can be applied to fine tune LNP physico-chemical properties and steer immune responses as well as overall biological activity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have invested in building our in-house manufacturing infrastructure, capabilities and expertise to rapidly, efficiently and cost-effectively produce mRNA-based medicines. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have continued to invest in our manufacturing platform since 2000 and have manufactured thousands of mRNAs. We consider our manufacturing process an important part of our strategy that allows us to continuously improve our technology platform and maintain flexibility in clinical development. Our manufacturing setup allows us to drive innovation and to maintain flexibility as well as to pivot quickly in clinical development and potential commercialization. In house, we currently operate three GMP-certified suites, with the capacity to supply our clinical programs and support potential early commercialization activities. We are in the process of building a fourth GMP large-scale production facility at CureVac&#8217;s headquarters in T&#252;bingen, which is being designed to cover all manufacturing steps from starting material to formulation. All our mRNA-based active ingredients for various fields of application originate from a common technology platform and are based on standardized source materials, which enables us to produce mRNA-based medicines using a platform process concept.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have entered into strategic partnerships with leading biopharmaceutical companies and research and nonprofit institutions to expand the applications of our technology platform.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We have a history of partnering with leading biopharmaceutical companies such as GSK, myNEO, CRISPR Therapeutics, Genmab, and Bayer. We also have received research grants from the Bill &amp; Melinda Gates Foundation and CEPI for the development of several prophylactic vaccines. Our academic collaborations are focused on identifying and evaluating novel targets in selected therapeutics areas such as our collaboration with the M.D. Anderson Cancer Centre in selected hematological and solid tumor indications with high unmet medical need. These partnerships and collaborations allow us to expand the application of our platform and bring in external expertise and capabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have built an intellectual property portfolio in a variety of markets for our platform and product candidates.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> As pioneers in the field of mRNA therapies, we have built an intellectual property portfolio in the United States and other major geographies, which is one of the broadest and most diverse intellectual property portfolios in the field. As of March 19, 2024, we own approximately 624 issued patents worldwide, including 103 issued U.S. patents, 43 issued European patents (which have been validated in various European countries resulting in a total of approximately 395 national patents in European countries) and including two European patents with unitary effect, and 126 issued patents in other foreign countries, 116 pending U.S. patent applications, 74 pending European patent applications and 311 pending patent applications in other foreign countries and 18 pending PCT patent applications. These patents include claims relating to our mRNA technology platform, our proprietary LNP technology and other product candidates. We believe our patent applications and other patents are the most cited among mRNA companies&#8217; intellectual property.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">We have a long history of mRNA research and development and are led by an experienced management team.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are led by veterans of the biopharmaceutical industry with extensive experience in nucleic acid therapy, oncology, rare and infectious diseases and antibodies. Our management team as well as our supervisory board members have broad expertise in the clinical, regulatory and commercialization aspects of oncology, prophylactic vaccines and rare diseases as well as in drug development, process development and manufacturing for mRNA-based medicines. Members of our management team have held senior positions at Novartis, Ipsen, Sanofi, Roche, Roche/Genentech, Merck KGaA, Schering Plough, Pixium Vision and other companies. As of December 31, 2023, our broader team included 294 individuals with advanced scientific degrees working on advancing our mRNA platform.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our goal is to build a leading, fully integrated mRNA-based medicines company that can transform the lives of people. The key components of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to invest in our proprietary technology platform to be the leading mRNA platform company. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We intend to invest in our proprietary technology platform to broaden its potential across therapeutic areas, in addition to broadening our pipeline in existing therapeutic areas. We believe our continued investment will enable us to further optimize the three core pillars of our technology platform&#8201;&#8212;&#8201;protein design, mRNA optimization and mRNA delivery&#8201;&#8212;&#8201;and to further enhance our treatment approaches by offering higher selectivity, greater protein expression, potential combination therapies and reduced or flexible dosing. We are continuing to build on our deep expertise in mRNA-based medicines based on what we have learned from our current programs to apply to our future programs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Utilize a rational disease selection approach to minimize clinical and commercial risk for our programs and broader platform.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our strategy is to maximize the potential of our technology platform through our rational disease selection approach to clinical development. We are initially targeting diseases that require an active immune response (such as prophylactic vaccines and cancer vaccines) and require transient expression of mRNA in tissue types that are more easily accessible. We are also developing a product portfolio targeting diseases that require an immune silent approach (such as molecular therapy).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Rapidly advance our lead product candidates through clinical development and regulatory approval. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates are currently in preclinical or clinical development stages. In COVID-19, we are currently conducting a Phase 2 clinical study assessing the monovalent mRNA vaccine candidate, CV0601, which encodes the Omicron BA.4-5 variant and the bivalent mRNA candidate, CV0701, which encodes the Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus. The candidates are tested in direct comparison to a licensed bivalent mRNA-based COVID-19 comparator vaccine. Results from a formal interim analysis were announced on January 5, 2024, and showed that both candidates exhibited a favorable reactogenicity profile across all tested doses and were generally well tolerated. Both candidates produced meaningful immune responses beginning at the lowest tested dose. Interim immunogenicity data showed titers of neutralizing antibodies for both candidates, which matched or numerically exceeded the titers induced by the licensed comparator vaccine at all tested doses except for the low dose level of CV0701. In seasonal influenza, within the broader second-generation infectious disease program we are developing in collaboration with GSK, we are conducting a combined Phase 1/2 study. The currently ongoing Phase 2 part of the study assesses a multivalent candidate, which was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains. In oncology, we are conducting a Phase 1 study in patients with newly diagnosed surgically resected glioblastoma, initiated in June 2023. The study evaluates the safety and tolerability of CVGBM, a cancer vaccine candidate featuring a single unmodified mRNA encoding eight epitopes derived from known tumor-associated antigens with demonstrated immunogenicity in glioblastoma. A first data readout is expected in the second half of 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">We believe that by initially targeting diseases with high unmet medical need, we will be able to rapidly advance our programs through clinical development. We intend to pursue the appropriate regulatory pathways available to further accelerate our development efforts.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to invest in our manufacturing capabilities across all manufacturing steps from starting material to formulation to further add scale and flexibility.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We believe that our manufacturing capabilities are a key strategic advantage that offer us flexibility, scalability, versatility and reliability in discovery and development. We are currently building our GMP IV facility, which is being designed to cover all manufacturing steps from starting material to formulation. In addition, we are developing a new integrated and automated process for manufacturing of mRNA vaccines and therapeutics, The RNA Printer&#174;. The RNA Printer&#174; is CureVac&#8217;s end-to-end solution for integrated and automated manufacturing of small-scale quantities of GMP-grade mRNA vaccines and therapeutics. On April 24, 2024, we announced that the system achieved an important milestone in an ongoing regulatory review process. The system was granted a framework license that significantly broadens its regulatory freedom and flexibility to manufacture different mRNA vaccine candidates in support CureVac&#8217;s oncology strategy. The framework license represents an extension of the initial manufacturing license CureVac announced on November 14, 2023.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Selectively seek strategic partners to develop and commercialize product candidates in certain therapeutic areas and geographies.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We plan to continue to seek additional partnerships with other leading biopharmaceutical companies with specialized capabilities, including development and commercialization expertise in selected therapeutic areas and geographies. We may pursue partnerships that allow us to expedite the discovery and development of product candidates, complement our internal development expertise, broaden the breadth of our technology platform, and provide us with non-dilutive financing, while allowing us to retain economic rights to our product candidates that we view as strategically important. Our approach of partnering with biopharmaceutical companies allows us to execute on a broad range of programs simultaneously, while mitigating our drug development risk.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Seek strategic acquisitions or in-licenses of technology or assets that are complementary to our programs and technology platform.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNA-based medicines is an emerging field with ongoing advancements and discoveries. As the pioneers in the field, we have made significant strides in advancing and optimizing our technology platform over the past 23 years. We may seek acquisitions and in-licensing opportunities that can augment our internal expertise, expand our competitive differentiation and further enhance our mRNA technology platform. In June 2022, we announced the acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics, to identify both shared and unique neoantigens across different cancer types. The acquisition complements existing in-house expertise to identify and validate promising antigens for mRNA cancer vaccine candidates. The acquired technologies will support the development of a strong antigen discovery engine, which has the potential to identify a broad panel of neoantigens and tumor-associated antigens that go beyond conventional approaches and could strongly increase the likelihood of developing highly effective cancer vaccines that activate the human immune system against cancer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Strengthen and expand our intellectual property portfolio to protect our scientific and technical know-how.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We intend to continue to strengthen and expand our intellectual property to protect our advances in scientific and technical know-how. Our intellectual property strategy is focused on covering advancements in our technology platform, manufacturing processes, and product candidates. In addition to patent protection, we also rely on trade secrets and confidentiality agreements to protect other proprietary information that is not patentable or that we elect not to patent.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview of mRNA Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The Role of mRNA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">mRNA-based medicines represent a novel class of medicine that have the potential to address limitations of conventional treatment modalities. We believe the modular nature of mRNA has the potential for higher efficacy, greater speed and lower cost of production as compared to conventional treatment modalities. mRNA delivery enables direct production of any protein (secreted, membrane and intracellular) in the body and has shown a wide range of activity. The flexible chemical structure of mRNA, utilizing only four nucleotide buildings blocks, allows us to encode for a broad range of proteins with simple sequence changes, offering design versatility, specificity and limited off-target effects. Transient expression of mRNA limits the risk of irreversible changes to the cells&#8217; DNA and allows for flexible dosing based on a patient&#8217;s needs as well as the opportunity for repeat dosing. We are leveraging these inherent advantages of mRNA-based medicines in the development of our mRNA technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have built an extensive expertise in the fields of mRNA biology, optimization and production. We have continued to invest in developing our technology platform, which we refer to as the RNAoptimizer, over the past 23 years. Our differentiated technology platform is designed to optimize each component of the mRNA-based medicine. Our RNAoptimizer platform is built on three core pillars:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Protein design:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;optimizing the specific properties of encoded protein;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">mRNA optimization:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;optimizing characteristics such as half-life and translation efficacy of the mRNA molecule; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">mRNA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">delivery:&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selecting the best-suited delivery system from our diverse portfolio of proprietary and third-party delivery systems.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:180.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">mRNA is a molecule instructing the translation of genetic information encoded in DNA by cells into proteins, which carry out essential cellular functions. As depicted in the figure below, genetic information stored in DNA is transferred to mRNA in a process called transcription in the cell nucleus. In transcription, double-stranded DNA is temporarily unwound and copied into single-stranded mRNA by the enzyme RNA polymerase. mRNA is then transported to the cytoplasm where it instructs synthesis of proteins through a process called translation. In translation, cellular structures called ribosomes decode mRNA bases in groups of three (called codons) as amino acids. Each codon specifies a particular amino acid, and amino acids are the building blocks of protein molecules which perform distinct functions within the body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cvac-20231231x20f004.jpg" alt="Graphic" style="display:inline-block;height:179.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:434.17pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitations of Existing Treatment Modalities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are several existing treatment modalities that seek to address the underlying cause of absent or defective proteins associated with diseases, including protein replacement therapy, gene therapy, gene editing, RNA interference and small molecule therapies. Other treatment modalities seek to harness the immune system, including antibody therapies and traditional prophylactic vaccines. Each of these treatment modalities have certain limitations as discussed below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Protein Replacement Therapy:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> While this approach has been successfully used to treat a subset of protein-based disorders, it is mostly limited to proteins that function outside of the cell.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Antibody Therapy:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Antibody therapeutics are largely administered intravenously and, being proteins themselves, have applications largely limited to surface molecules. In addition, antibodies have historically faced challenges due to their relatively large size, inadequate pharmacokinetics and tissue accessibility as well as unwanted interactions with the immune system.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Gene Therapy:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Gene therapy is usually a one-time intervention meant to provide lasting levels of therapeutic protein. While expected to be a one-time treatment, the duration of treatment efficacy is still largely unknown and it may not be amenable to repeat dosing due to neutralizing antibodies against the gene therapy vehicle. In addition, large-scale manufacturing is costly, time consuming and complex.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Gene Editing:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Despite its promise, gene editing is still in the early-stages of development and has potential risks related to unwanted on and off-target DNA modifications, incomplete targeting or mosaicism that hinder intended modifications. Similar to gene therapies, manufacturing complexities and costs for gene editing are also challenging.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RNA Interference:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RNA interference has potential in silencing certain genes but has limitations in replacing defective or missing proteins, as well as highly expressed proteins. Most of the current efforts in this treatment modality are focused on genes expressed in the liver, with limited evidence of applications in extra-hepatic tissues.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Small Molecule:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> While small molecules offer advantages over other treatment modalities in terms of biodistribution, tolerability, and delivery, they do not directly address specific gene defects and have a high potential to cause off-target toxicities.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:204.72pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Traditional Prophylactic Vaccines:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> While traditional prophylactic vaccines are one of the most successful and cost-effective global health interventions, their complex development and costly production processes create a high barrier to entry, long development cycle and limitation in developing vaccines with high serotype coverage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">mRNA as a Novel Treatment Modality</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">mRNA, as the universal template for protein synthesis, can direct the synthesis of any protein in the body. To treat a medical condition, we identify a target protein and encode the information required to synthesize this protein on the mRNA. The mRNA, optimized using our platform, carries this code to give a patient&#8217;s body the information to produce its own, custom-tailored protein as medicine. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">mRNAs are typically characterized by their rate of translation into protein and their short and predictable, yet steerable half-life. We optimize these mRNA properties for specific therapeutic needs to provide the most efficacious mRNA-based medicine. mRNAs provide the flexibility to deliver medicines that are required for a limited time as well as the opportunity to deliver repeated doses that can be adjusted to patient needs. The development and manufacturing of mRNA-based medicines can also proceed much more quickly than traditional protein-based therapies, including antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5.44pt 0pt;"><img src="cvac-20231231x20f005.jpg" alt="Graphic" style="display:inline-block;height:204.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:467.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key potential advantages of mRNA therapies that could position it as a novel treatment modality include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Broad application:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNA has the ability to produce all types of proteins, including secreted, membrane and intracellular proteins. This enables broad applicability across a variety of diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Natural biology:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNAs mimic human biology to produce proteins in the body in contrast to recombinant proteins that are manufactured using processes that are foreign to the body.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wide range of activity:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNAs can be used to create therapies that can be applied as an agonist, an antagonist or for vaccines.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Flexibility:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A large number of alternative mRNA candidates can be generated in a short time and tested to optimize both the mRNA and protein format.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Design versatility:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Therapeutic protein expressed from mRNA </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in situ</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> can be designed for efficacy without being limited by the constraints which recombinant proteins are subject to.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Specificity:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNA-based medicines encode proteins which offer much higher specificity of interactions compared to small molecule drugs, which limits any potential off-target effects.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Repeat dosing:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNA-based medicines can be dosed repeatedly given their low immunogenicity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Transient expression:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Short-lived expression of mRNA limits the risk of unforeseen adverse effects of lasting protein expression (as seen in gene therapy and gene editing) and allows for modified dosing schedules adjusted based on a patient&#8217;s needs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Manufacturing:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNA production process is largely independent of the encoded protein as changes to the mRNA sequence do not affect its chemical and physical properties, allowing for higher efficiency, greater speed and lower cost of production.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Historical Challenges with Developing mRNA Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Using mRNA as a treatment has long been of interest given its potential to address limitations of existing treatment modalities. However, mRNA has historically been limited by the following theoretical and practical hurdles:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Stability:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Naked mRNA is rapidly degraded by RNase enzymes present throughout the body which limits the duration of its therapeutic effect. An effective mRNA would need to be masked from these enzymes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Uptake by cells:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Uptake of naked mRNA into cells is relatively inefficient. A more effective mRNA-based medicine would need a delivery system that delivers mRNA efficiently into cells.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expression level:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Protein expression levels from synthetic mRNA obtained by </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> production have been considered too low historically for therapeutic purposes, which underlines the need for an optimized mRNA construct.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Immunogenicity:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Non-optimized mRNA in the body rapidly activates receptors on immune cells which triggers the innate immune response and can lead to shut down of protein translation in cells. An effective mRNA-based medicine needs to modulate the immune system according to the disease indication being targeted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Tissue targeting:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Each indication requires delivery to a specific tissue. An effective mRNA-based medicine would need a delivery system that efficiently delivers mRNA to a specific target tissue with low off-target delivery and toxicity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Manufacturing:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> mRNA manufacturing technology must be scalable and cost-effective to enable large production for multiple clinical trials and commercialization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Technology Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The therapeutic potential of mRNAs was discovered by our co-founders in 2000. As the pioneers in the field of mRNA, we have built extensive expertise in mRNA biology, optimization and production. We have developed our technology platform, called RNAoptimizer, through continued investments over the past 23&#160;years. We believe that we have created the broadest and most versatile platform to develop optimized mRNA-based medicines that has potential to offer differentiated profile in terms of safety, stability and expression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our optimization approach covers three pillars: protein design, mRNA optimization and mRNA delivery. Our approach is based on the extensive data libraries we have generated to date. To improve protein expression from <i style="font-style:italic;">in vitro</i> produced mRNA, we isolated high numbers of human natural mRNAs from different cells and identified elements which stabilize mRNA and improve their interaction with the cellular translation machinery. Our technology platform broadly spans unmodified and modified mRNA, as well as monovalent and multivalent formats. We continue to invest in all levels of optimization to improve the methods we currently employ and continue advancing mRNA-based medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a long track record of performing clinical trials with multiple product candidates since 2008. The data generated in these clinical trials has allowed us to better understand the biology of mRNA and to further accelerate development in new therapeutic areas and approaches. We were the first company to demonstrate that mRNA vaccines can induce protective antibody titers in na&#239;ve human subjects with a previous version of our current rabies vaccine product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:193.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates consist of two major components: the protein-coding mRNA and a delivery vehicle. Once we have established delivery capability to a target tissue, we can design new product candidates that vary only in the mRNA component, which we expect will allow for rapid target and development candidate identification. We believe that this will enable our platform to be flexible and scalable as we develop additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5.94pt 0pt;"><img src="cvac-20231231x20f006.jpg" alt="Graphic" style="display:inline-block;height:193.41pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:440.34pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our process for creating novel mRNA therapies comprises the following three pillars:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Protein Design:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our goal is to define the amino acid sequence to optimize specific properties of the encoded protein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">mRNA Optimization:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our goal is to define the nucleotide sequence of the mRNA encoding the optimized protein to improve the properties of the mRNA molecule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">mRNA Delivery:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our goal is to define mRNA encapsulation and delivery to select the optimal formulation for each specific indication and tissue.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">First Pillar: Protein Design</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Proteins play a central role in biology, including formation of the structural framework of the body, aiding in intra- and extracellular transport, biological catalysts (such as enzymes), controlling the activity of cells, and enabling signal transduction throughout the body. Accordingly, mutations that alter the function of a protein that plays a critical role inside the body can disrupt normal development and cause disease. Diseases could be caused by low expression, over expression, or abnormal structures for specific proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We target diseases that are caused by these abnormal or missing proteins. Once our team identifies the protein of interest for a specific vaccine or therapeutic target with a defined target product profile, protein design further improves the potential efficacy by adaptation of the amino acid sequence. Protein design is based on modulation of beneficial protein characteristics that are not present in the naturally occurring protein. We have a library of validated protein domains that can be leveraged using a combinatorial approach to optimize the properties of the target protein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our protein design process considers multiple factors before the protein is encoded in the mRNA, including half-life, stabilization of tertiary structure, oligomerization, secretion, and immunogenicity. We have the ability to modify each of these parameters while ensuring that these modifications work in harmony with the required function of the target protein.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:204.48pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Protein design always depends on the function of the individual protein of interest. The protein can serve as a therapeutic protein without any activation of the immune system or the protein can serve as an antigen with the goal of inducing strong immune responses against it. We employ different optimization strategies to support these distinct functions and requirements. For example, we can enhance certain parameters to extend the half-life or localization of a protein in the case of therapeutic proteins while making sure that RNA sensors remain muted to avoid activation of the immune system. For vaccines, our goal is to induce an optimal immune response mimicking response induced by bacterial or viral infections. Therefore, protein design is always bespoke and multi-factorial to support distinct functions and requirements of the specific target protein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below are several specific examples of protein modifications by which we designed a protein&#8217;s properties relative to the wild-type protein:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Extended Half-Life of Secreted Protein</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This approach relies on the addition of supplementary short domains to the coding sequence of the protein of interest. Although this fusion increases protein size, the additional domains recruit binding proteins already present in blood which promote stabilization of the target protein by preventing proteolytic degradation. To support the efficient persistence of a secreted protein in the bloodstream, we can improve the half-life of this protein by adding specific, endogenous domains. By tailoring the pharmacokinetic profile of secreted proteins, we have the ability to reduce the frequency of dosing, generating a better therapeutic window, and using less material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, wild-type erythropoietin (Epo) is a protein that has a very short half-life of three to four hours in the bloodstream. In a preclinical model, mice were dosed with mouse Epo and protein engineered mouse Epo, both encoded with our optimized mRNA. Dosing with the engineered mouse Epo protein showed an increase in serum titers and pharmacokinetic profile. We were able to increase the half-life and availability of functional Epo in blood from four days to two weeks by fusing endogenous Epo to a selected domain. Notably, both mRNA-encoded Epo proteins showed significantly higher protein expression levels than the injected recombinant Epo, which was cleared from the bloodstream after a single day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.34pt 0pt;"><img src="cvac-20231231x20f007.jpg" alt="Graphic" style="display:inline-block;height:204.48pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:314.64pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Mice received a single injection in the tail vein of recombinant protein (control) or mRNA encoding proteins. Mice received 2.8 &#956;g of recombinant mouse Epo protein. Wild-type Epo encoded by our optimized mRNA and engineered Epo protein encoded by our optimized mRNA were administered at a dose of 0.4 mg/kg giving rise to relevant serum titers of functional Epo and different pharmacokinetic profiles.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:224.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Extended Half-Life of Intracellular Protein</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar approaches can also be applied to intracellular proteins, promoting the half-life of functional target proteins. In the example below, protein variant 1 represents the fusion of a protein of interest with a selected protein domain, while variant 2 represents a construct with a single point mutation within the protein of interest. In contrast to the wild-type protein, both engineered protein variants enabled the detection of protein even one week after mRNA delivery to hepatocyte cells in culture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><img src="cvac-20231231x20f009.jpg" alt="Graphic" style="display:inline-block;height:224.22pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:268.39pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Intracellular abundance of engineered protein variants in comparison to unmodified wild-type protein. Protein levels were determined by whole cell Western Blot analysis in human hepatocytes, followed by normalization to signals from a cytosolic loading control and relative to the wild-type protein. Same doses used in wild-type and engineered protein variants.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:241.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Increased Oligomerization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Protein oligomerization is a process that converts monomers to macromolecular complexes through polymerization. We can engineer protein oligomerization by adding domains capable to perform this process to the target protein. As antigens need to be secreted and build clusters to form virus-like particles, or VLPs, this oligomerization process is beneficial in boosting the immune response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.34pt 0pt;"><img src="cvac-20231231x20f011.jpg" alt="Graphic" style="display:inline-block;height:241.44pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:373.45pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Protein sequence of viral antigen was optimized (design 2) by adding an element promoting secretion and clustering of antigen. In the left-hand side of the graphic, secretion of antigen in form of clusters was confirmed by Western Blot analysis of supernatants from transfected human cells. In the right-hand side of the graphic, vaccination of mice with an mRNA vaccine based on this improved protein design resulted in higher immunogenicity, measured by induction of virus neutralizing antibodies.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Improved Secretion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The potency of secreted target proteins can be improved by using alternative, more powerful signal peptides. These signal peptides are responsible for transporting the target protein from the cytoplasm to the outside of the cell, where the secreted protein fulfills its primary function. We screen large libraries of signal peptides to optimize secretion of any given target protein and in any cell type of choice.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:221.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, we selected a set of 87 verified signal peptides to maximize secretion. These were combined with the novel target protein via automated cloning to enable facile screening and selection of the most potent product candidate. In the figure below, the top hit from this screen increased the secreted protein levels in primary human muscle cells by three-fold relative to the native signal peptide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5.55pt 0pt;"><img src="cvac-20231231x20f013.jpg" alt="Graphic" style="display:inline-block;height:221.04pt;width:414pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Modified Immunogenicity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the target protein serves as a therapeutic agent, it is important to curb the protein&#8217;s natural immunogenicity. Our protein design process analyzes and replaces immunogenic epitopes, masking immunogenic epitopes and thereby rendering the target protein more immunosilent. In contrast, we also have the ability to improve immunogenicity for certain applications (for example in a cancer vaccine) by protein design. These protein sequence adaptations promote immunogenicity and suppress tumor growth in mouse models, as shown in the below example.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.05pt 0pt;"><img src="cvac-20231231x20f014.jpg" alt="Graphic" style="display:inline-block;height:182.16pt;width:316.8pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Therapeutic vaccination with mRNA vaccine encoding optimized Trp2 cell antigen inhibited tumor growth in murine melanoma model. Syngeneic mice were challenged subcutaneously with melanoma cells. When tumors were palpable, mice were vaccinated intradermally twice a week with LNP-formulated mRNA encoding either wild-type murine antigen Trp2 or Trp2 designed to improve antigen presentation. Mice vaccinated with LNP-formulated irrelevant mRNA (PpLuc) served as control.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:131.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Second Pillar: mRNA Optimization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Overview of mRNA Biology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">mRNA is a linear polymer comprising four monomers called nucleotides: adenosine (A), guanosine (G), cytidine (C), and uridine (U). The sequence at any mRNA&#8217;s center instructing the synthesis of the protein encoded by it is the open reading frame (ORF, also known as coding sequence). The ORF is a continuous stretch of groups of three nucleotides (called codons) that is decoded and translated into protein by the ribosome. The process of translation begins at the first codon of the ORF, always an AUG (the start codon). The start codon signals to the ribosome where to start protein synthesis. The ribosome then progresses along the ORF one codon at a time, adding the amino acid to the protein chain fitting to the codon. A stop codon at the end of the ORF (UAA, UAG, or UGA) signals to the ribosome to terminate protein synthesis. In every cell, hundreds of thousands of mRNAs are translated into hundreds of millions of proteins every day. A typical protein contains 200-600&#160;amino acids; therefore, a typical mRNA coding region ranges from 600-1,800 nucleotides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5.15pt 0pt;"><img src="cvac-20231231x20f016.jpg" alt="Graphic" style="display:inline-block;height:131.01pt;width:449.19pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the coding sequence, mRNAs contain the following elements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Untranslated regions, or UTRs&#8201;&#8212;&#8201;UTRs are sequences that are not translated into protein. The 5&#8217; UTR precedes the start codon, the 3&#8217; UTR follows the stop codon. These regions play important roles in gene expression, including mRNA stability, mRNA localization and translational efficiency via protein-RNA interactions. Some of the elements in the UTRs form characteristic secondary structures that are involved in mRNA regulation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5&#8217; cap&#8201;&#8212;&#8201;The cap structure is required to recruit ribosomes and additional proteins involved in translation to the mRNA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3&#8217; polyadenosine, or poly-A, tail&#8201;&#8212;&#8201;The 3&#8217; poly-A tail is a long sequence of adenosine nucleotides (often several hundred) at the 3&#8217; end of mRNA. This tail promotes mRNA export from the nucleus and translation and protects mRNA from degradation. In addition, the 3&#8217; end of the mRNA can include a stretch or sequence of nucleotides following the 3&#8217; poly-A tail.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Approach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our mRNA optimization process is designed to generate the most efficacious mRNA for any particular target and indication by optimizing translation, stability and immunogenicity. Each of these parameters can be modified by changing individual mRNA elements and their interplay guided by the envisaged application. Our mRNA molecule contains six elements that can be optimized to improve the potential efficacy of the mRNA construct. These elements include 5&#8217; cap, 5&#8217; UTR, ORF, 3&#8217; UTR, and 3&#8217; poly-A tail and 3&#8217; end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending on the target and indication, the required pharmacokinetics of protein expression might be different. Some applications may require the highest possible protein expression but only for a limited time, as is the case for gene editing approaches. For other applications, for example some protein replacement therapies, long-lasting protein expression might be key. Peak level and duration of protein expression can be adjusted by the choice or design of enhancer and stabilizing elements in untranslated regions of mRNA. Each of the mRNA elements together in combination with the overall sequence influence the degree of activation of the immune system by any particular mRNA. Therefore, our approach to RNA optimization always considers multiple factors as well as the whole construct to generate the optimal mRNA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:192.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">UTRs contribute decisively to the potential efficacy of therapeutic mRNAs. Natural mRNAs contain several different 5&#8217; and 3&#8217; UTRs, setting the individual level of translation and stability for each message. We have tapped this natural wealth of regulatory sequences and identified a large set of UTRs that confer translation or mRNA stability via diverse protein-RNA interactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, one factor limiting the use of mRNA as a treatment has been the observation that <i style="font-style:italic;">in vitro</i> produced synthetic mRNA activated the innate immune system, resulting in a fast shutdown of protein translation in cells. An effective mRNA therapy would need to evade recognition by the immune system to avoid shut down of protein translation. We have accumulated significant knowledge about the signatures recognized by the innate immune system over the past few&#160;years. With the insights we have gained, we are able to avoid signatures activating the immune system in elements at our disposal or eliminate them from mRNA constructs. This is demonstrated by the following example where formulated mRNA was injected intradermally in mice and both B cells and T cells were activated in the draining lymph node. In contrast, unformulated mRNA injected intradermally had limited immunostimulatory capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><img src="cvac-20231231x20f017.jpg" alt="Graphic" style="display:inline-block;height:191.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:467.94pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">10 &#956;g of mRNA, either free or formulated, was administered intradermally to the back of mice. Twenty-four hours post treatment, draining lymph nodes were isolated, and the activation status of immune cells was analyzed by flow cytometry. A higher CD69 signal indicates activation of the respective immune cells.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cap Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The cap structure influences translation as it recruits the translational machinery, including initiation factors and the ribosome. The cap structure also affects mRNA stability due to its influence on the various proteins recruited to mRNA. Further, the cap structure is a determinant of activation of the innate immune system as different cap structures are differentially recognized by several innate immune sensors. In addition, different cap structures are incorporated during <i style="font-style:italic;">in vitro</i> production of mRNA with different capping efficiency, resulting in varying proportion of mRNA lacking a cap, which is an mRNA species which is recognized by yet other sensors of the innate immune system. Accordingly, there is great potential to improve protein expression and immunosilence in mRNA by optimizing the cap structure. We have access to several cap structures, including those we have developed and commercially available ones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5&#8217; and 3&#8217; UTRs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have identified high numbers of naturally occurring 5&#8217; and 3&#8217; UTRs. Using bioinformatics analysis to identify patterns of increased expression, duration of expression, and reduced immunogenicity, we have catalogued more than one million 5&#8217; and 3&#8217; UTRs. From these, we selected a large set of potential enhancer elements (improving the rate of protein expression) and stabilizer elements (improving half-life of protein expression). By running a high throughput combinatorial approach, we identify and create optimized UTR combinations for a specific construct. Further, we have created UTR sub-libraries because we discovered that different UTRs perform differently in various tissue types.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below is an example of the effectiveness of our UTR library to optimize protein expression as part of our collaboration with CRISPR Therapeutics. An open reading frame coding for an optimized Cas9 protein was combined with 83 UTR combinations via automated cloning. This target-specific UTR screening increased Cas9 protein levels in HepG2 cells five-fold compared to an already optimized construct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.34pt 0pt;"><img src="cvac-20231231x20f019.jpg" alt="Graphic" style="display:inline-block;height:272.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:354.51pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">To maximize expression of the target protein a set of 83 combinations of untranslated regions (UTR) was selected from screens identifying stable or highly translated endogenous transcripts. These UTR combinations were combined with the target open reading frame (ORF) via automated cloning to enable facile screening and selection of the most potent product candidates. Target-specific UTR screening led to a five-fold increase in protein levels in HepG2 cells compared to an already optimized construct.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Open reading frame (ORF)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ORF instructs the synthesis of the protein it encodes by the ribosome. The ORF is a continuous stretch of groups of three nucleotides called codons. Ribosomes decode each codon as an amino acid to be added to the nascent protein. Each codon specifies a particular amino acid, however, many amino acids are specified by more than one codon. Due to this multiplicity of codons that specify an amino acid, any protein can be encoded by a myriad of coding sequences differing in their codon composition. These various ORFs differ largely in their properties and for any particular protein a top-performing ORF needs to be identified or designed to make an efficacious mRNA-based medicine. We currently optimize the ORF in a broad, holistic approach that includes multiple parameters taking into account codon optimality. Our algorithms also take into account that, similar to UTRs, different codons are optimal for different tissues. Furthermore, these algorithms also analyze and consider secondary structure. For example, as certain elements are known to drive immune stimulation by secondary structure, our algorithms avoid generation of sequences that may give rise to such immune stimulations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:287.21pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the following example, protein expressed from our mRNA containing a wild-type coding sequence was abundant in the livers of mice injected intravenously with LNP-encapsulated mRNA. However, protein levels were higher from our mRNA containing a coding sequence engineered for maximal protein expression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.34pt 0pt;"><img src="cvac-20231231x20f021.jpg" alt="Graphic" style="display:inline-block;height:287.21pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:244.46pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Abundance of a therapeutic protein in mouse liver expressed from an engineered open reading frame (ORF) in comparison to the wild ORF. mRNAs containing ORF variants were formulated in LNPs and injected intravenously into mice (called engineered ORF). Protein levels were determined by Western Blot analysis of liver lysates, followed by normalization to the signal from a loading control.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:240.27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Poly(A) tail and 3&#8217; end</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 3&#8217; end of the mRNA molecule, prone to degradation by nucleases, is another form of optimization. The 3&#8217; end can be sealed using different stabilizing elements, including secondary structure or specific nucleotide sequences, to inhibit RNA nucleases degrading RNA from the 3&#8217; end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><img src="cvac-20231231x20f023.jpg" alt="Graphic" style="display:inline-block;height:240.27pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:247.46pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impact of different mRNA 3&#8217; end on serum levels of a therapeutic protein. mRNAs containing different vector-encoded 3&#8217; end variants were formulated in LNPs and injected intravenously at a dose of 20 &#956;g into female Balb/c mice. Six hours after injection, serum levels of secreted protein were determined by an enzyme-linked immunosorbent assay test, also referred to as ELISA, to measure antibodies in blood.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, we analyze the structure of the optimized mRNA as a whole, including ORF and UTRs, to predict its recognition by RNA sensors and immune activating potential and modify any inappropriate elements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third Pillar: mRNA Delivery</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The potency of the administered mRNA drug product is the combination of the potential efficacy of the mRNA that encodes the protein and the delivery system that transports the mRNA to the cells. Protein levels are highly correlated with the number of transfected cells which requires optimized delivery systems. While it is possible to deliver mRNA directly into the target tissue without delivery systems in certain cases, the presence of RNA degrading enzymes in blood and interstitial fluids rapidly regrade any extracellular mRNA. Additionally, cell membranes act as a significant barrier to entry of large molecules such as mRNA. These delivery technologies enable us to deliver large quantities of mRNA to the target cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have access to a diverse portfolio of third-party and proprietary delivery systems that allow us to target a range of diseases. Access to this broad range of delivery technologies allows us to select the best-suited technology for development of each of our product candidates. We choose the most suited delivery system based on a number of factors, including immunogenicity, duration of treatment, dose levels, mode of administration and targeted tissue type.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The key delivery systems that we currently employ include lipid-based delivery systems. We employ lipid nanoparticles, or LNPs, to deliver our mRNA-based prophylactic and cancer vaccines locally. For protein and antibody therapeutic candidates, we apply LNP-formulated mRNA systemically. We have relied on third-party state-of-the-art LNP delivery systems for our initial clinical programs, and we are developing our proprietary LNP delivery systems for our future clinical programs. With these delivery modalities at hand, we are currently expanding our development pipeline and plan to bring new mRNA therapies to different organs and applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lipid Nanoparticles (LNPs)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A variety of nanoparticles have been developed over the years for use in drug delivery. LNPs represent the most clinically advanced non-viral delivery systems. Encapsulation of the mRNA within LNPs enables delivery to the site of action within the cell. LNPs protect the mRNA from degradation, rapid excretion and liver clearance, enabling higher bioavailability and longer half-life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">LNPs consist of different lipids that form together a lipid nanoparticle with a solid core. The four primary LNP components include cationic lipids, pegylated lipids, phospholipids, and cholesterols. LNPs mimic low-density lipoproteins, which allows them to be taken up by an endogenous cellular transport pathway to deliver the mRNA cargo to cells. When LNPs are injected into biological systems, they attach to natural transport proteins, apolipoproteins, to facilitate the transport of lipids within the bloodstream and throughout the body. Following intravenous administration, the apolipoprotein binding enables efficient transport of the mRNA cargo to the liver. Once internalized in endosomes within cells, the LNPs are designed to escape the endosome and release their mRNA cargo into the cytoplasm, where the mRNA can be translated. Any mRNA and LNP components that do not escape the endosome are typically delivered to lysosomes where they are degraded by the natural process of cellular digestion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The properties of each LNP system can be customized based on altering each component or overall composition. All of the LNPs we employ in our projects are designed to be biodegradable. We have extensively tested over 40 different delivery solutions and have selected the ones we use based on comparative data for the most efficient LNPs available from third parties for licensure. Having access to these technologies enables us to develop fast powerful solutions for vaccines and protein therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Besides the licensed LNP technology from our partners, we are also developing our own LNP technology. We have established two ionizable lipid families and are developing those LNPs for application in local vaccination and systemic delivery to the liver. We conducted a systematic screening of LNP components and compositions for local vaccination in skin and muscle. Those optimized LNP formulations incorporating our own lipids helped to raise significant levels of immune response comparable with those of approved vaccine formulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:183.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The graphs below demonstrate comparable immunogenicity of CV LNP against a commercial PEG LNP in a vaccination trial with the rabies antigen in mice at same mRNA dose. On the left panel, the virus neutralization titer seven days post the second vaccination is shown, whereas on the right panel the induced T cell response is assessed by EliSpot of peptide library stimulated spleenocytes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6.09pt 0pt;"><img src="cvac-20231231x20f025.jpg" alt="Graphic" style="display:inline-block;height:183.72pt;width:353.06pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Approach to Disease Selection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our approach seeks to mitigate risk across multiple levels to advance and expand our broad product portfolio. While mRNA is still an emerging treatment modality, we believe that we have made advances towards utilizing the potential of our technology platform through rational disease selection. Our approach for selecting new programs is based on the following key factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Target diseases with high unmet medical needs that are not effectively addressed using the current standard of care.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Target areas where the underlying mode of action of the disease is understood or hypothesized which allows us to identify the required protein(s) or antigen(s).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify areas where mRNA therapies have potential to have differentiated profiles compared to the conventional treatment modalities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assess the likelihood of being able to address the disease using our technology platform and seek to continuously improve and expand the capabilities of our platform to address an even broader range of diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seek to build on our deep understanding of mRNA biology, data derived from our technology platform and previous clinical and preclinical studies to apply to new indications.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In building our product portfolio, we have considered a number of factors including immune response, duration of expression, dosing requirements, delivery technology, target tissue type, potential for responsiveness to mRNA-based medicine and target disease profile, among other factors. A disease indication may require an mRNA-based medicine that triggers an immune response, or that is immune active, or an mRNA-based medicine that requires no immune activation, or that is immune silent. Each of the disease indications that we are targeting require different levels of immune activation for the mRNA-based medicine to be effective. Our approach is to initially target indications that require an immune active approach (such as prophylactic vaccines or cancer vaccines), given the need for lower doses and transient expression of the antigen. These initial indications are amenable to localized delivery using an LNP delivery system. Based on the clinical validation of our prophylactic vaccines program and our advanced understanding of mRNA biology and immune stimulation modulation, we are also further expanding our product portfolio to target indications that require an immune silent approach (such as protein delivery). Targeting diseases amenable to the immune silent approach requires higher doses and longer expression of the protein, with potential for long-term repeat dosing for chronic diseases.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Immune active.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> For indications that require immune stimulation such as prophylactic and therapeutic vaccines, our technology optimizes the combination of mRNA molecules encoding specific antigens and selected delivery modalities to provide the desired immunostimulatory capacity. This allows us to design vaccines with high immunogenic effect. The goal is to induce an immune response against the encoded antigen. The mRNA is taken up by cells, including dendritic cells, at the injection site. Expressed antigens are then presented to the adaptive immune system leading to selective activation of T cells and B cells that recognize these antigens. These activated adaptive immune cells can then recognize and attack similar antigens that are found on tumors or pathogens.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Immune silent.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> For indications that require no immune stimulation such as protein delivery, our technology can also design product candidates to be immunosilent and to express encoded proteins over an extended period of time. These product candidates can be expressed either locally (eye, liver or lung) or systemically, using the liver as a bioreactor for production of the therapeutic proteins (enzymes and antibodies).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prophylactic Vaccines</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Infectious disease-related proteins, such as viral surface proteins, specific targets for the body&#8217;s immune defense system, can be expressed by injected mRNA and then presented to B and differentiated T cells, activating a specific immune response. We believe that our mRNA technology offers a platform for the development and production of prophylactic vaccines against infectious diseases. We believe our mRNA vaccines offer many potential advantages over existing vaccine technologies, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNA vaccines mimic several aspects of a natural viral infection and has the potential to offer improved and balanced immune response.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNAs allow us to encode for specific protein antigens of choice, offering potential for the development against known and yet unidentified pathogenic threats.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNAs allow production of multivalent vaccines with the potential to either demonstrate a broader efficacy by including additional target pathogens, or to strengthen potential efficacy by better targeting a specific pathogen, for example by adding of immunogenic epitopes, or by addressing different pathogen variants, or both.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNA vaccines are generally expected to be safer than live or attenuated vaccines since no living virus is injected. As they do not interact with the host-cell DNA, they avoid the potential risk of genomic integration posed by DNA-based vaccines.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNA binds to pattern recognition receptors and mRNA vaccines are thereby self-adjuvanting, a property which peptide- and protein-based vaccines lack.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rapid speed of development from knowing the sequence of the virus to progressing programs in clinical development given our ability to produce antigens without dedicated cell cultures and fermentation-based manufacturing processes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Commercial-scale production of mRNA is fast, cost-effective and, in contrast to traditional vaccine approaches, does not require cell culture or the use of live pathogens, and as a result, multiple vaccines can be produced in the same plant.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Our current approach to the development of potential prophylactic vaccines is focused on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">CV0601/CV0701 for SARS-CoV-2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: A Phase 2 clinical study was initiated on August 1, 2023, with two modified mRNA COVID-19 vaccine candidates: the monovalent candidate, CV0601, encoding the spike protein of the omicron BA.4-5 variant and the bivalent candidate, CV0701, encoding the spike protein of the omicron BA.4-5 variant as well as the original SARS-CoV-2 strain. The study is being conducted in Australia and fully enrolled with 427 participants. Interim Phase 2 data was announced on January 5, 2024. The data showed that both candidates exhibited a favorable reactogenicity profile across all tested doses and were generally well tolerated with a lower or similar proportion of participants reporting solicited adverse events when compared to comparator vaccine participants. Both candidates produced meaningful immune responses beginning at the lowest tested dose. Interim immunogenicity data showed meaningful titers of neutralizing antibodies for both candidates, which matched or numerically exceeded the titers induced by the licensed comparator vaccine at all tested doses except for the low dose level of CV0701.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Multivalent candidate for seasonal influenza</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: A combined Phase 1/2 clinical study was initiated on May 8, 2023, comparing a comprehensive series of multivalent, modified mRNA seasonal influenza vaccine candidates with up to eight separate mRNA constructs per candidate addressing all four WHO-recommended flu strains. Positive data from an interim analysis of the Phase 1 part was reported on September 12, 2023, and enabled selection of a preferred candidate to be advanced to the Phase 2 part. Promising interim data from the Phase 2 part was announced on April 4, 2024, confirming an acceptable safety profile and boosted antibody titers against all encoded flu strains across age groups and tested dose levels. Geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across tested dose levels and age groups. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across age groups and tested dose levels. Targeted optimizations to further improve immune responses against influenza B strains will be tested in an additional Phase 2 study.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Monovalent candidate for avian influenza (H5N1):</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A combined Phase 1/2 clinical study was initiated on April 24, 2024, with a monovalent, modified mRNA vaccine candidate, encoding an influenza A H5 antigen. The Phase 1 part of the study will assess the safety, reactogenicity and immunogenicity of the vaccine candidate in healthy younger and older adults against a placebo control.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Oncology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">mRNA is a versatile platform for cancer vaccine development allowing to encode a wide range of antigens from full length tumor associated antigens to neoepitopes. We are taking multiple approaches in oncology to induce tumor-specific immune responses in patients:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Novel cancer vaccines: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We focus on building a meaningful portfolio of novel cancer vaccine candidates based on differentiated antigen discovery technologies and bioinformatics to target antigens that are overexpressed in tumor tissues with no or little expression on healthy tissues, using our LNP formulations. Within this strategy, we follow two approaches. (1) the development of off-the-shelf cancer vaccines based on tumor antigens shared across different cancer indications and (2) the development of fully personalized cancer vaccines based on a patient&#8217;s individual tumor genomic profile.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Multi-epitope cancer vaccine candidate CVGBM:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A proof-of-principle Phase 1 study was initiated on June 20, 2023 with CVGBM in patients with newly diagnosed surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. The study evaluates the safety and tolerability of CVGBM, a cancer vaccine candidate featuring a single unmodified mRNA encoding eight epitopes derived from known tumor-associated antigens with demonstrated immunogenicity in glioblastoma. On April 24, 2024, we announced that the dose-escalation Part A of the study completed recruitment of all four dose levels. Following review of the safety data, the Data Safety Monitoring Board (DSMB) confirmed no dose limiting toxicities and gave a dose recommendation for 100 &#181;g for the dose-confirmation Part B of the study. Part B is expected to start enrollment mid-2024. A first study data readout is expected in the second half of 2024.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Molecular Therapy: Deliver mRNA to express the right protein wherever needed</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We are seeking to optimize mRNA molecules to trigger production of antibodies. Our antibody work has potential to protect against viruses, bacteria, and toxins and can be applied to many disease indications including </span>cancer, <span style="font-size:10pt;">cardiovascular diseases, infectious diseases and autoimmune diseases. In preclinical studies in non-human primates, we have demonstrated that antibodies encoded by mRNA can be produced in hepatocytes very rapidly and can reach the blood stream at relevant therapeutic levels.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With our technology, we can instruct human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles or cell membrane. Based on this &#8220;healthy&#8221; information delivered by mRNA, our cells are designed to produce proteins, which are required to treat the disease caused by missing or inactive proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe there are several advantages of our technology applied to development of molecular therapy, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNA encoded proteins can function within or outside of cells as well as inside cell membranes, allowing us to address intracellular protein deficiencies that are not addressed by recombinant proteins.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNAs can enable production of complex proteins that are challenging to make using recombinant technologies due to their folding requirements and complexity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Administered mRNAs encode proteins using natural pathways allowing for post-translational modifications such as glycosylation whereas recombinant proteins use non-human post-translational modifications which may lead to lower effectiveness and increased immunogenicity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNA constructs can be optimized to produce proteins that offer desirable pharmacology relative to the wild-type protein, such as increased half-life.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNA allows for dosing flexibility to meet patient needs without causing irreversible changes to the genome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mRNA can be delivered repeatedly, creating the opportunity to provide long-term benefit for treatment of chronic diseases.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have collaborations focused on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Therapeutic antibodies:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are also developing mRNA therapies to produce antibodies systemically using the liver as a bioreactor for subsequent secretion and systemic distribution of the antibodies to primary organs affected by a disease. Our collaboration with Genmab, a global leader in antibody discovery and design, will allow us to work with novel antibodies produced using our mRNA technology. This partnership represents the first-ever publicly disclosed mRNA antibody-focused deal and will allow us to optimize and manufacture mRNA-encoded antibodies for Genmab.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Liver diseases:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are working on mRNA therapies targeted for the liver, including designing and producing intracellular targets such as transcription factors. Our collaboration with the Hannover Medical School aims to design treatments for liver diseases such as NAFLD, NASH and liver cirrhosis, with the potential to treat or reverse liver fibrosis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Eye diseases:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are investigating development of mRNA-based treatments for undisclosed ophthalmic indications. We have a collaboration with SERI for our discovery efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our Key Pipeline Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">RNA-Based Therapeutics in Oncology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Discovery of new therapeutic cancer vaccine candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A key component to the development of new therapeutic cancer vaccine candidates is the build-up of a powerful antigen discovery engine. To gain access to state-of-the-art antigen discovery technologies, we announced a partnership with Belgium-based company myNEO Therapeutics on May 25, 2022, and the acquisition of Netherland-based Frame Cancer Therapeutics on June 8, 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Together with immunotherapy company myNEO, we aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation is expected to allow for selection of antigens with the highest confidence of success for potential clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">With the acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics, to identify both shared and unique neoantigens across different cancer types, we complement existing in-house expertise to identify and validate promising antigens for mRNA cancer vaccine candidates. Our technology platform has the potential to identify a broad panel of neoantigens and tumor-associated antigens that go beyond conventional approaches and could strongly increase the likelihood of developing highly effective cancer vaccines that activate the human immune system against cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The field of immuno-therapy has advanced with the progression of available technologies to extract data from patient samples, such as next-generation sequencing. Conventional approaches have so far focused on the exome, the protein-coding part of the genome, which represents only about 1.5% of the total genetic information. More recently, breakthrough developments in sequencing capacity have enabled the extraction of vastly larger amounts of data that allows us to utilize the remaining 98.5% of genetic information. The technologies brought in-house with the acquisition of Frame Cancer Therapeutics are based on whole-genome-sequencing for every patient sample and combine it with short as well as long-range RNA sequencing to map the full inventory of genomic changes. More specifically, downstream of the sequencing, a software package integrates all the data to retrieve the exact changes in the DNA of the tumor cells compared to healthy cells. Correlation of this data with changes in the RNA transcription of the tumor results in entirely new and potentially antigenic tumor antigens that we plan to test as targets for a portfolio of new cancer vaccine candidates. These new antigens are not only entirely foreign to the body but are also uniquely expressed in the tumor and not in healthy tissue. In their foreignness, these constructs are expected to raise stronger immune responses than antigens derived from exome-based conventional approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The highly synergistic antigen discovery technologies of Frame Cancer Therapeutics and myNEO are expected to significantly accelerate CureVac&#8217;s oncology strategy to build a meaningful portfolio of new cancer vaccine candidates. Within this strategy, we follow two approaches. The first approach assesses tumor antigens shared by different cancer patients for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy. We plan to advance new antigens for both approaches based on our second-generation mRNA backbone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">CVGBM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To assess the safety and immunogenicity of our second-generation backbone in an oncology setting, we initiated a proof-of-principle Phase 1 study in patients with newly diagnosed surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma on June 20, 2023. The open-label study evaluates the safety and tolerability of CVGBM, a cancer vaccine candidate featuring a single unmodified mRNA encoding eight epitopes derived from known tumor-associated antigens with demonstrated immunogenicity in glioblastoma. On April 24, 2024, we announced that the dose-escalation Part A of the study completed recruitment of all four dose levels. Following review of the safety data, the Data Safety Monitoring Board (DSMB) confirmed no dose limiting toxicities and gave a dose recommendation for 100 &#181;g for the dose-confirmation Part B of the study. Part B is expected to start enrollment mid-2024. A first study data readout is expected in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The multiepitope design of CVGBM was supported by preclinical studies assessing the potency of a multiepitope mRNA cancer vaccine construct targeting tumors in a murine melanoma model. The data was presented at the 11th International mRNA Health Conference, hosted by CureVac from October 31 to November 2, 2023, in Berlin, Germany.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:156.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preclinical mRNA construct encoding ten epitopes derived from the murine B.16.F10 melanoma cell line was tested in mice. The study applied three 5 &#181;g doses of LNP-formulated B.16 mRNA, administered intramuscularly at weekly intervals. Data obtained on day 21 can be seen below and confirmed prominent induction of CD8+ and CD4+ T cell responses (left and middle graph) recognizing epitopes across the full multiepitope construct. Median survival (right graph) of the animals increased to 30.9 days for treated mice compared to 23.2 days for a group vaccinated with formulated control mRNA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f026.jpg" alt="Graphic" style="display:inline-block;height:155.94pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:512.93pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Strong T cell activation is particularly encouraging and relevant, as the B16-F10 tumor model is characterized as a cytokine deficient &#8220;cold&#8221; tumor model that exhibits very little immune cell infiltration and resistance to check-point inhibitors. The data suggest that single-agent application of the multiepitope B.16 mRNA construct generated robust T cell activation in the tumor microenvironment, thereby inhibiting tumor growth and extending survival in the applied preclinical model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">mRNA-Based Prophylactic Vaccine Programs Jointly Developed With GSK: Second-Generation mRNA Backbone</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">COVID-19: Disease Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome, or MERS-CoV, and Severe Acute Respiratory Syndrome, or SARS-CoV. Coronaviruses are transmitted between animals and people and can evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (2019-nCoV) was identified as the cause of pneumonia cases and deaths in Wuhan, China and an exponentially increasing number of cases have since then been found worldwide. On March 11, 2020, the World Health Organization (&#8220;WHO&#8221;) designated COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, an international pandemic. As of January 21, 2024, there have been 774,395,593 confirmed cases of COVID-19 globally, including 7,023,271 deaths, reported to WHO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical COVID-19 Vaccines Program (second-generation mRNA backbone)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2021, we announced a collaboration with GSK for our COVID-19 vaccine program, which went into effect in April 2021 pursuant to which we are collaborating with GSK to research, develop and manufacture mRNA vaccines based on our second-generation mRNA backbone targeting relevant SARS-CoV-2 variants. The second-generation mRNA backbone can flexibly encode for different COVID-19 variants and features targeted optimizations designed to improve intracellular mRNA stability and translation for increased and extended protein expression. The optimizations potentially allow for strong and early immune responses at low doses, which also supports the development of multivalent vaccines and combination vaccine approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interim Phase 2 Data of the Monovalent mRNA Vaccine Candidate, CV0601 and Bivalent Vaccine Candidate, CV0701</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Phase 2 study evaluates safety, reactogenicity, and immune responses of single booster doses of the monovalent mRNA vaccine candidate, CV0601, encoding the Omicron BA.4-5 variant and the bivalent candidate, CV0701, encoding the Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus. It is active-controlled, featuring a licensed bivalent mRNA-based COVID-19 comparator vaccine. The study is being conducted in Australia and completion of enrollment at 427 healthy adult participants was announced on November 1, 2023. Interim Phase 2 data were presented on January 5, 2024.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:184.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Results from the formal interim analysis showed that both vaccine candidates using CureVac&#8217;s proprietary second-generation mRNA backbone produced meaningful immune responses and favorable reactogenicity profiles across all tested doses, including the lowest tested dose. All three of the dose levels tested were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU. The candidates were shown to be generally well tolerated with a lower or similar proportion of participants reporting solicited adverse events when compared to comparator vaccine participants within seven days of dosing. Interim immunogenicity data showed meaningful titers of neutralizing antibodies for both candidates at all dose levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The graphs below illustrate the reactogenicity (left graph) and immunogenicity (right graph) data reported for the monovalent candidate, CV0601, in comparison to the licensed bivalent comparator vaccine. CV0601 was tested at a medium dose level. The immunogenicity data show that it elicits neutralizing antibody titers against the Omicron BA.4-5 variant on day 29 following the booster vaccination that were 5.0 times the pre-boosting titers, numerically exceeding the 3.6-fold ratio generated by the licensed comparator vaccine. Antibody titers against the original SARS-CoV-2 virus on day 29 following the booster vaccination were 3.1 times the pre-boosting titers, numerically exceeding the 2.8-fold ratio generated by the comparator vaccine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f027.jpg" alt="Graphic" style="display:inline-block;height:184.5pt;width:450.46pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">1)&#160;GMR and confidence intervals are adjusted for baseline titer, age at baseline (&lt;65 or &#8805;65) and prior SARS-CoV-2 infection </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2)&#160;Licensed bivalent, mRNA-based comparator vaccine</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:176.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The bivalent candidate CV0701 was tested at a low, medium, and high dose level. The graphs below illustrate the reported reactogenicity (left graph) and immunogenicity (right graph) data. The immunogenicity data show neutralizing antibody titers against BA.4-5 on day 29 following the booster vaccination that were 2.7-fold, 3.7-fold, and 4.6-fold the titers before the booster, compared to a 3.6-fold ratio of post- to pre-booster titers for the comparator vaccine. Antibody titers against the original SARS-CoV-2 virus on day 29 following the booster vaccination were 2.1-fold, 2.7-fold, and 3.1-fold the titers before the booster, compared to a 2.8-fold ratio of post- to pre-booster titers for the comparator vaccine, matching or numerically exceeded the titers induced by the licensed comparator, except for the low dose level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f028.jpg" alt="Graphic" style="display:inline-block;height:176.22pt;width:441.04pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">1) GMR and confidence intervals are adjusted for baseline titer, age at baseline (&lt;65 or &#8805;65) and prior SARS-CoV-2 infection </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2) Licensed bivalent, mRNA-based comparator vaccine</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Influenza: Disease Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Influenza is a highly contagious virus that causes mild to severe respiratory virus that can lead to death. During the 2022-2023 influenza season, influenza was associated with 31 million illnesses, 14 million medical visits, 360,000 hospitalizations and 21,000 deaths in the United States. Preliminary in-season burden estimates for the U.S. in the 2023-2024 flu season showed 32-59 million flu illnesses, 15-27 million flu medical visits, 360,000-730,000 flu hospitalizations and 22,000-65,000 flu deaths. The WHO reports that globally there are around a billion cases of seasonal influenza annually, including three to five million cases of severe influenza, leading to as many as 290,000 to 650,000 deaths.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Influenza viral infections can be prevented by vaccination although there are several limitations associated with current flu vaccines. Flu vaccines are not always effective, primarily because the influenza virus and its associated antigens undergo mutations or changes in its sequence over short periods of time, which is called antigenic drift. Vaccines that are developed for the predominant strain infecting people can be rendered ineffective as the virus mutates as it passes from person to person. The process of developing a standard traditional vaccine typically takes approximately eight months from strain identification to doctor&#8217;s office availability, increasing the likelihood that a significant pool of viruses circulating will be poorly recognized by antibodies in vaccinated individuals. Additionally, vaccine efficacy tends to wane over time. For these reasons, vaccination of the target population needs to be repeated every year before the start of the next influenza season, putting a significant burden on the health system. Furthermore, only a part of the population targeted to get the yearly shot is vaccinated each year, leaving many individuals unprotected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Influenza Vaccines Program (second-generation mRNA backbone)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Influenza is the first indication from the initial collaboration we started with GSK in July 2020, which focuses on the development of new products for different targets in the field of infectious diseases. The jointly developed influenza vaccine candidates are based on our second-generation mRNA backbone, which can flexibly encode for different influenza strains and which features targeted optimizations designed to improve intracellular mRNA stability and translation for increased and extended protein expression. The optimizations potentially allow for strong and early immune responses at low doses, which will also support the state-of-the-art multivalent format of influenza vaccines as well as combination vaccine approaches. The second-generation mRNA backbone differs significantly from the mRNA backbone for our first-generation. The first candidate from the second-generation backbone influenza program was the non-chemically modified mRNA construct CVSQIV, a differentiated multivalent vaccine candidate featuring multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. On February 10, 2022, we announced the start of a Phase 1 dose-escalation study in Panama evaluating the safety, reactogenicity and immunogenicity of CVSQIV in the dose range of 3&#181;g to 28&#181;g. Preliminary safety data reported on April 28, 2022, showed a benign reactogenicity profile across the tested dose groups. Within the jointly developed COVID-19 vaccine program, we also extended our technology platform to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We announced the start of a Phase 1 dose-escalation study with a chemically modified influenza vaccine candidate, Flu SV mRNA, on August 18, 2022. The candidate is a monovalent candidate. The Phase 1 dose-escalation study is being conducted in Canada, Spain and Belgium to evaluate the safety, reactogenicity and immunogenicity of Flu SV mRNA. On January 6, 2023 we announced that the second-generation mRNA backbone using modified mRNA was selected as the preferred technology for further clinical development in the influenza program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Flu SV mRNA: Preliminary Phase 1 Data of the Chemically Modified Construct Expressing an H1N1 hemagglutinin antigen</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Influenza Vaccine Programs (second-generation mRNA backbone)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Seasonal influenza and avian influenza (H5N1) are the first two indications from the collaboration we started with GSK in July 2020, which focuses on the development of new products for different targets in the field of infectious diseases. The jointly developed influenza vaccine candidates are based on our second-generation mRNA backbone, which can flexibly encode for different influenza strains, and which features targeted optimizations designed to improve intracellular mRNA stability and translation for increased and extended protein expression. The optimizations potentially allow for strong and early immune responses at low doses, which will also support the state-of-the-art multivalent format of influenza vaccines as well as combination vaccine approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Combined Phase 1/2 Study Start in Avian Influenza</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 24, 2024, the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate was announced. The study assesses a monovalent vaccine candidate encoding an influenza A H5-antigen. The H5N1 avian flu virus is considered a potential future pandemic threat, able to sporadically cross species from its original bird host to other animal hosts to humans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interim Phase 2 Data of the Multivalent Seasonal Influenza Vaccine Candidate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A combined Phase 1/2 clinical study was initiated on May 8, 2023. The initial Phase 1 part compared a comprehensive series of multivalent, modified mRNA seasonal flu vaccine candidates with up to eight separate mRNA constructs per candidate, addressing all four WHO-recommended flu strains. Candidates were tested at different dose levels in 270 healthy younger adults (age 18-50). On September 12, 2023, we announced selection of a promising vaccine candidate for continued Phase 2 clinical development based on positive data from an interim analysis of the Phase 1 part. Interim safety data showed no safety concerns across all tested dose levels for the multivalent candidates. Immunogenicity of all candidates was assessed in parallel with a licensed seasonal flu vaccine comparator. The humoral responses observed supported the selection of the preferred vaccine candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:146.84pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We announced dosing of the first participant with the preferred vaccine candidate in the Phase 2 part of the study on November 1, 2023. The potentially differentiated, multivalent candidate encodes antigens matched to all WHO-recommended flu strains. In the Phase 2 part, the selected candidate is being tested in younger (age 18-64) and older (age 65-85) adults at different dose levels compared to age-appropriate licensed seasonal flu comparator vaccines. On April 4, 2024, we announced that the selected candidate boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose. The vaccine candidate was shown to have an acceptable safety and tolerability profile, with the majority of solicited adverse events reported as either grade 1 (mild) or grade 2 (moderate) within seven days of dosing. The results confirm previous findings that the platform elicits strong overall antibody titers at well-tolerated dose levels. Among younger and older adults, geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across all tested dose levels. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across both age groups and tested dose levels. Targeted optimizations to further improve immune responses against influenza B strains will be tested in an additional Phase 2 study. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preliminary Phase 1 Data of Monovalent Seasonal Influenza Construct Flu SV mRNA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 6, 2023, the second-generation mRNA backbone using modified mRNA was selected as the preferred technology for further clinical development in the seasonal flu vaccine program. In the Phase 1 study of the monovalent Flu-SV-mRNA, expressing an H1N1 hemagglutinin antigen (subtype of influenza A), five doses ranging from 2 to 54&#956;g with up to 25 subjects per dose cohort were evaluated in younger adults (age 18-45). This dose range takes into account that the candidate is a monovalent construct. Correspondingly, the applied doses reflect doses for a single mRNA construct, which would later be multiplied for a state-of-the-art multivalent flu vaccine. In the younger adult age group, the preliminary safety and reactogenicity data shown below demonstrate that the monovalent Flu-SV-mRNA candidate was generally well tolerated with no safety concerns observed to date across all tested dose levels. A single dose of Flu-SV-mRNA (dose level undisclosed) was assessed for safety and reactogenicity in older adults (age 60-80) and was also observed to be safe and well tolerated with no grade 3 adverse events in the 32 subjects who were administered the mRNA construct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f029.jpg" alt="Graphic" style="display:inline-block;height:146.84pt;width:490.43pt;"/></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:160.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immunogenicity of the monovalent Flu-SV-mRNA construct was assessed in parallel with a licensed seasonal flu vaccine comparator in both age groups, shown as the orange bar to the right in the figures below. The data illustrate the ratio of post- to pre-boost geometric mean hemagglutinin inhibition antibody titers. In younger adults, Flu-SV-mRNA achieved comparable antibody increases to the licensed vaccine, boosting geometric mean titers at least about 14-fold beginning at the lowest dose of 2&#181;g. In older adults a comparable ratio of post- to pre-boost titers of 14.5 was achieved at the undisclosed dose, which compares to a ratio of 6.2 for the flu vaccine comparator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f030.jpg" alt="Graphic" style="display:inline-block;height:154.82pt;width:459.21pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The robust preliminary ratios of post- to pre-boost geometric mean hemagglutinin inhibition antibody titers were shown to result in seroconversion rates that are substantially higher for the modified mRNA candidate. Specifically in the older adults age group, the percentage of subjects achieving seroconversion was 89.7% for Flu-SV-mRNA and 56.2% for the licensed flu vaccine comparator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f031.jpg" alt="Graphic" style="display:inline-block;height:160.24pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:498.95pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interim data supported the progression of the modified second-generation mRNA technology for the development of a multivalent mRNA flu vaccine as it is tested in the currently ongoing Phase 2 part of the combined Phase 1/2 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">RNA-Based Therapeutics in Molecular Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">mRNA-based protein supplementation offers a therapeutic approach to compensate for lack of proteins in monogenetic diseases caused by loss-of-function mutations. It offers a potentially curative treatment option, especially in diseases in which the protein is expressed predominantly in organs that can be reached by intravenous delivery (such as the liver). Despite the success of classical enzyme-replacement therapy in several metabolic disorders, this therapeutic approach is not well suited for treatment of diseases caused by the lack of functional intracellular proteins, especially if the proteins are located in or on intracellular compartments. Additionally, as therapeutic proteins are conventionally manufactured by using human, animal or even plant cells, the pharmacological and biochemical properties of such recombinant proteins may differ from endogenously expressed enzymes. Cellular localization, folding and post-translational modifications can especially be critical for the correct function of a therapeutic protein. Delivery of mRNA can overcome these limitations and is likely to result in expression of a functional protein at a physiological cellular location. An example of our rare disease approach is for the potential treatment of hereditary spastic paraplegia, or HSP.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:116.14pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Hereditary Spastic Paraplegia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">HSP is a group of inherited disorders that are characterized by progressive weakness and spasticity of the legs due to axonal degeneration of the corticospinal tract. Hereditary spastic paraplegia type 5, or SPG5, is caused by autosomal recessive loss-of-function mutations in CYP7B1, a gene encoding for the cytochrome P-450 oxysterol 7-&#945;-hydroxylase, essential for the alternative pathway of bile acid synthesis in the liver. Mutations causing SPG5 lead to decreased enzyme activity of CYP7B1 and accumulation of oxysterols in the serum, the liver and then the central nervous system. The accumulation of hydroxyl cholesterol, or HC, in the brain is what is believed to be the pathologic correlate of this particular disease, which leads to spasms and paraplegia as symptoms. To date, no curative treatment for SPG5 is available. Current clinical treatment strategies for SPG5 are based on the reduction of cholesterol by applying cholesterol-lowering drugs (statins), which consequently lead to a reduction of oxysterols.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f032.jpg" alt="Graphic" style="display:inline-block;height:116.14pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:239.96pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our approach is based on replacement of CYP7B1 by administration of mRNA. We have studied the intravenous application of formulated CYP7B1 mRNA in mice lacking the endogenous&#160;<i style="font-style:italic;">Cyp7b1&#160;</i>gene. Comparable to the human situation in SPG5 patients, a drastic increase of these oxysterols was detected in all three compartments (serum, liver and brain) of knockout mice. Using this&#160;<i style="font-style:italic;">in vivo&#160;</i>model, we were able to demonstrate that a therapeutic approach with mRNA can restore human CYP7B1 protein that exhibits physiological function and eliminates abnormal cholesterol metabolites<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As shown below, we investigated the safety and efficiency of repeated dosing with four consecutive doses of 40 &#956;g LNP-encoded mRNA of CYP7B1 administered intravenously every five&#160;days. LNP loaded with a non-translating mRNA were applied as control (vehicle). Prior to the administration, serum samples were taken to determine basal oxysterol levels. Two days after the last injection (17&#160;days of treatment), animals were sacrificed, and serum, liver and brain samples were analyzed. Oxysterol analysis of these samples demonstrated a significant decrease of 25 hydroxy cholesterol, or 25 HC, in the serum and liver. mRNA expression of the human CYP7B1 in the liver led to a reduction of 25 HC in the liver by 8-fold and in serum by approximately 88%. These effects are accompanied by a reduction of the accumulation of 25 HC in the brain by more than 50%. Additionally, repetitive treatment resulted in a significant decrease of 27-HC and 3&#946;-HCA in livers of treated compared to vehicle animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, repeat intravenous delivery of CYP7B1 mRNA was found to be well tolerated in this study. Neither the CYP7B1 mRNA nor the restored protein nor the LNP induced liver toxicity. None of the treated animals presented signs of toxic or adverse effects. LNP particles encapsulating non-coding mRNA led to a temporary increase in oxysterol levels (25-HC and 27-HC) in liver and serum in the vehicle group, which is expected given cholesterol is an essential component of LNPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f033.jpg" alt="Graphic" style="display:inline-block;height:99.73pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:392.71pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Lysosomal Storage Disorders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lysosomal storage diseases are well-defined, single-gene disorders that are amenable to correction by systemic mRNA therapy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:251.14pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have conducted preclinical studies in an undisclosed lysosomal storage disease, or LSD, to evaluate LNP delivery of mRNA encoding the deficient enzyme to the liver, production of the enzyme by the liver and subsequent secretion and systemic distribution of the enzyme to the primary organs affected by the disease. In this specific LSD, the enzyme deficiency results in a progressive accumulation of lipid in cellular lysosomes, which ultimately affect the functioning of the heart and kidneys. Enzyme replacement therapy, or ERT, which involves intravenous administration of recombinant enzyme, has been the standard of care for this specific LSD. In contrast to ERTs, our LNP mRNA technology specifically and efficiently targets the liver to naturally produce the missing enzyme, which is subsequently secreted into the bloodstream and distributed to the affected organs. In this specific LSD, the liver is not the target organ, but is used to produce the endogenous native enzyme.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As shown below, LNP delivered mRNA therapy produces a high and homogenous expression of the missing enzyme in the livers of knockout mice (Figure A, brownish stain). The endogenously produced enzyme is then secreted into the bloodstream with a better pharmacokinetic profile than the injected recombinant protein. The enzyme is then taken up by the target organs. In this example, the enzyme is taken up by the heart (Figure B) and kidney (Figure C) and localized into the lysosomes. Our mRNA therapy, through prolonged synthesis and secretion by the liver, led to higher enzyme activity in the organs compared to the infused recombinant enzyme (Figures B and C). This higher enzyme activity leads to a significant and prolonged reduction of accumulated lipids in the organs of mRNA-treated animals (Figure D).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f034.jpg" alt="Graphic" style="display:inline-block;height:251.14pt;width:395.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Liver-Specific Metabolic Diseases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are applying a similar approach to inherited liver-specific metabolic disorders of amino acids, nitrogen and essential nutrients. The goal of these studies is to restore the specific enzyme or protein that is deficient in the liver by LNP-mediated delivery of mRNA to the liver. As such, the target organ for correction is the liver, and secretion and systemic distribution of the enzyme or protein to other organs is not required for a therapeutic effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our ability to optimize mRNA stability and translation, in combination with optimization of the expressed protein, is an important part of our technical expertise. Using a process of mRNA and protein optimization, we believe that we are able to extend the duration of protein expression to meet a defined target product profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">One example of this technology is the mRNA that we are developing for a metabolic amino acid disorder. In this inherited disorder, a liver-specific intracellular enzyme is deficient resulting in decreased metabolism of the amino acid. As a result, there is a toxic build-up of the amino acid in the blood, which leads to severe consequences for the central nervous system.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:274.97pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A single intravenous injection of a liver-targeted LNP formulation containing the therapeutic mRNA leads to a marked decrease in the level of the amino acid in the sera of knockdown animals (Figure A), but also in the brain (Figure B). Several rounds of mRNA and protein optimization were subsequently performed. Improving the mRNA molecular structure during the first round of optimization prolonged the protein and its therapeutic effect (Figure A) compared to the reference mRNA. Protein optimization (Figures C and D) of the expressed target enzyme increased its expression/stability and/or activity&#160;<i style="font-style:italic;">in vitro</i>. The combination of both optimization programs resulted in a candidate with improved characteristics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f035.jpg" alt="Graphic" style="display:inline-block;height:274.97pt;width:293.21pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Fibrotic Liver Diseases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">According to published literature, chronic liver diseases cause two&#160;million deaths a year worldwide. We have shown that the delivery of liver-specific protein factors, which are down regulated in fibrosis, can resolve liver fibrosis, a key pathological feature of NAFLD, NASH, cirrhosis and hepatocellular carcinoma. Protein factor treatment of liver diseases is uniquely suited to mRNA medicines enabling the expression of intracellular proteins. Moreover, we believe that in this particular case, the LNP technology allows us to deliver mRNA almost exclusively to the target cells, hepatocytes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In a CCL4 chemically induced mouse model of liver fibrosis, we delivered eight doses of LNP-mRNA at an interval of five&#160;days at 2 mg/kg. The figure below illustrates the ability of an mRNA-delivered protein factor to reduce collagen, the main fibrotic material deposited in fibrosis, and eliminate activated stellate cells, the source of collagen (stained red). To confirm the potential activity of this mRNA therapy, we obtained similar data in two other unrelated murine models: a diet-induced model and a knockout mouse model of liver fibrosis. These findings offer preclinical proof of concept for this therapeutic concept to treat acute and chronic liver diseases, as well as diseases of other organs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:151.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are currently focused on significantly lowering the dose by employing two parallel strategies &#8211; mRNA sequence optimization to improve expression and optimization of the protein sequence for higher and sustained activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f036.jpg" alt="Graphic" style="display:inline-block;height:151.48pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:284.74pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">mRNA has the potential to promote expression without inducing an adverse immune response against the encoded protein. We have tested various antibodies using different designs to evaluate our platform&#8217;s potential for prophylactic and therapeutic antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We evaluated the use of mRNA for passive immunization in two indications, rabies and botulism, that can be considered prototypes for anti-pathogen and anti-toxin therapies, respectively. Single injections of mRNA-LNPs were sufficient to establish rapid, strong and long-lasting serum antibody titers&#160;<i style="font-style:italic;">in vivo</i>, thereby enabling both prophylactic and therapeutic protection against lethal rabies infection or botulinum intoxication. In both models, the high levels of&#160;<i style="font-style:italic;">in vivo&#160;</i>serum expression conferred full protection in pre- and post-exposure scenarios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The left side of the graphic below shows that mice expressing the anti-rabies mAb survived, whereas the majority of control animals which received anti-influenza mAb mRNA succumbed to the rabies infection. The right side of the graphic below shows that mice treated post-intoxication with VNA-BoNTA mRNA or recombinant VNA-BoNTA also survived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f037.jpg" alt="Graphic" style="display:inline-block;height:125.23pt;width:428pt;"/></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:189.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, we have demonstrated that mRNA-mediated antibody expression may be effective in the field of cancer immunotherapy, where mAbs are widely used in medical practice. In a preclinical study conducted in mice, we compared the efficacy of rituximab-encoding mRNAs to recombinant rituximab. We inoculated mice intravenously with luciferase expressing Raji lymphoma cells and started treatment with 50 &#956;g of mRNA-LNP encoding rituximab and 200 &#956;g of recombinant rituximab at various time points. mRNA-LNPs coding for an irrelevant antibody were used as further control. Control animals revealed strong tumor cell proliferation and had to be euthanized 17&#160;days after inoculation due to severe symptoms. As shown in the picture below, repeated administration of mRNA-LNP for rituximab strongly decelerated or even abolished tumor cell growth compared to continued tumor growth for recombinant rituximab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="cvac-20231231x20f038.jpg" alt="Graphic" style="display:inline-block;height:188.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:201.44pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 21.3pt;"><i style="font-style:italic;">Therapeutic HNF4A mRNA to Attenuate Liver Fibrosis in Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 21.3pt;"><span style="font-style:italic;font-weight:bold;">On August 25, 2021, we published first preclinical data on the restoration of hepatocyte functions and attenuation of liver fibrosis and cirrhosis in multiple mouse models via an HNF4A encoding mRNA in the Journal of Hepatology. Owing to the extensive amount of data featured in the scientific publication, the following data excerpts represent only a selection of important findings of the preclinical studies. Full data can be accessed via the corresponding publication.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a first step within the study, existing clinical data was collected that confirmed reduced endogenous HNF4A mRNA levels in patients with liver fibrosis, graded by the Ishak score. In two cohorts from Hannover Medical School, Germany, and Shanghai Zhongshan Hospital, China, liver tissues showed fibrosis stage-dependent reduction in HNF4A mRNA. Subsequently, it was examined whether in vitro synthesized <i style="font-style:italic;">HNF4A</i> mRNA produces functionally active HNF4A protein. The wild-type (non-codon-optimized) or codon-optimized HNF4A mRNA were transfected into the human cervical carcinoma cell line (HeLa) cells as these lack endogenous HNF4A expression. Codon-optimized <i style="font-style:italic;">HNF4A</i> mRNA-transfected cells showed higher HNF4A protein levels than those transfected with wild-type <i style="font-style:italic;">HNF4A</i> mRNA. ZsGreen mRNA-transfected HeLa cells served as a control.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:238.84pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Human HNF4A mRNA restoration improves function of fibrotic hepatocytes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f039.jpg" alt="Graphic" style="display:inline-block;height:238.84pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:259.46pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Figure. (A) qPCR analyses of human HNF4A mRNA in patients with fibrosis; 0 (n = 9), 1 (n = 3), 2 (n = 3), 3 (n = 3) and 4 (n = 3) from MHH, Germany and 0 (n = 6), 2 (n = 4) 3 (n = 3), 4 (n = 5), 5 (n = 4), 6 (n = 5) from Zhongshan Hospital, China. (C) Western blot and its quantification for wild-type (non-codon-optimized) and codon-optimized HNF4A mRNA in HeLa cells, 6 hours after HNF4A mRNA delivery.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Efficient Lipid Nanoparticle (LNP)-mediated mRNA delivery into hepatocytes of murine fibrotic livers was established. LNPs interact with apolipoprotein E at the surface of hepatocytes and are subsequently internalized via endocytosis. However, whether LNP-formulated mRNA reaches hepatocytes of fibrotic livers efficiently has remained unknown. LNP carrying mRNA encoding for Photinus pyralis luciferase (Luc/LNP) or ZsGreen (ZsGreen/LNP) were injected into CCl4-induced fibrotic and non-fibrotic control (wild-type) mice i.v. In-vivo imaging revealed robust bioluminescence exclusively in the liver from 8 hours to 120 hours after Luc/LNP injection in both groups (graphic shown below). Co-localization studies showed robust ZsGreen protein expression specifically in hepatocytes of fibrotic and control mice, but not in other hepatic cells. Our results demonstrated that LNP-formulated mRNA technology could specifically and efficiently target hepatocytes in murine fibrotic livers (data not shown below).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:298.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Targeted delivery of LNP-encapsulated mRNA into hepatocytes of fibrotic livers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f041.jpg" alt="Graphic" style="display:inline-block;height:298.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:234.64pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Figure. Successful mRNA delivery into hepatocytes of fibrotic BALB/c mice by LNP. Bioluminescence analyses at 8&#160;h, 24 h and 48 h in wild type control and CCl4-induced fibrotic mice (n = 3 mice per group) injected i.v. with 40&#181;g luciferase mRNA-encapsulated LNP (Luc/LNP).</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To address whether systemic administration of <i style="font-style:italic;">HNF4A</i> mRNA inhibits liver fibrosis, mice with toxin- (repeated CCl4 injection, data shown below) or cholestasis-induced fibrosis (induced via 3,5-diethoxycarbonyl-1,4-dihydrocollidine DDC-containing diet, data not shown) were used. <i style="font-style:italic;">HNF4A</i> mRNA levels significantly decreased in fibrotic livers from both models. <i style="font-style:italic;">HNF4A</i>/LNP or ZsGreen/LNP (henceforth referred to as control) were injected i.v. into fibrotic mice at 2 mg/kg per injection. HNF4A protein expression was confirmed in <i style="font-style:italic;">HNF4A</i>/LNP-injected mouse livers and was absent in control mice, since the HNF4A antibody was only specific to human but not mouse HNF4A. <i style="font-style:italic;">HNF4A</i>/LNP-injected mice showed significantly reduced alanine aminotransferase (ALT) and bilirubin indicating improved liver function, and significantly reduced levels of collagen (hydroxyproline assay), suggesting decreased fibrosis in both CCl4 and DDC models. Histological analyses, desmin (profibrogenic activated stellate cell marker) and Sirius red (collagen marker) staining further con&#64257;rmed reduced &#64257;brosis in CCl4 (Fig. F, N). Our data together provide evidence that HNF4A mRNA delivery attenuates fibrosis in mouse models of toxin as well as cholestasis-induced fibrosis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:169.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Therapeutic HNF4A/LNP delivery inhibits toxin induced liver fibrosis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:0pt;"><img src="cvac-20231231x20f043.jpg" alt="Graphic" style="display:inline-block;height:146.98pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:98.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvac-20231231x20f044.jpg" alt="Graphic" style="display:inline-block;height:110.23pt;width:268.88pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Figure. Therapeutic HNF4A/LNP delivery inhibits toxin induced liver fibrosis. CCl4-induced liver fibrosis (n = 6 mice per CCl4 model). (B) Hnf4a qPCRs after CCl4 injection. (D) Liver function tests for ALT shows reduced injury upon HNF4A/LNP administration. (E) Hydroxyproline assay shows reduced collagen content.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="cvac-20231231x20f046.jpg" alt="Graphic" style="display:inline-block;height:169.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:398.95pt;"/></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:137.18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="cvac-20231231x20f047.jpg" alt="Graphic" style="display:inline-block;height:135.73pt;width:132.37pt;"/><img src="cvac-20231231x20f048.jpg" alt="Graphic" style="display:inline-block;height:137.18pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:106.48pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Figure. Therapeutic HNF4A/LNP delivery inhibits toxin induced liver fibrosis. CCl4-induced liver fibrosis (n = 6 mice per CCl4 model). (F) Immunohistochemical images of H&amp;E, desmin and Sirius red stainings. Scale bars, 100 lm. (G) Quanti&#64257;cation of Sirius red and desmin stainings.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In summary, the preclinical work shown here provides the first evidence that therapeutic mRNA delivery restores intracellular HNF4A transcription factor levels, induces endogenous Hnf4a expression, and improves metabolic activity of targeted hepatocytes. The data show that hepatocyte-specific delivery of HNF4A mRNA in injured livers attenuates fibrosis and cirrhosis in multiple independent mouse models of liver diseases. The shown data represents only a selection of important findings of the comprehensive preclinical studies. Full data can be accessed via the corresponding publication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eye Diseases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are exploring the treatment of eye diseases with mRNA therapy. We have strategic collaborations with SERI for the development of mRNA-based treatments for currently undisclosed eye indications. We believe that the treatment of eye diseases with mRNA therapy represents an excellent opportunity for the mRNA approach for the following reasons:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Therapeutic protein can be produced directly and locally within the target tissue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Local treatment in the eye requires lower mRNA doses, thereby minimizing systemic exposure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enables production of endogenous proteins to stop or prevent pathological processes locally in the eye, such as neo-vascularization or apoptosis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enables expression of multi-domain intracellular or transmembrane proteins in key cells within the eye overcoming limitations of recombinant proteins;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No concern with potential side effects typical for viral gene vector;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No mRNA construct size restrictions as with viral gene vectors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The eye is an immune-privileged organ.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Based on positive preclinical data the agreement and collaboration with SERI moved ahead. We believe that the clinical and research expertise in eye diseases at SERI would allow us to fully leverage our mRNA in the discovery and validation of eye disease targets amenable to mRNA treatment. In collaboration with SERI, a high-priority rare eye condition has been identified for development. Multiple therapeutic targets have been identified for this condition and mRNAs have been generated and are currently being tested in preclinical studies, including models of disease.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Significant Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Collaborations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have entered into various licensing and commercialization agreements, including the following agreements with respect to product candidates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Collaboration and License Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">2020 GlaxoSmithKline Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In July&#160;2020, we entered into a Collaboration and License Agreement with GSK, which we refer to as the 2020 GSK Agreement, pursuant to which we are collaborating with GSK to research, develop and commercialize prophylactic and therapeutic non-replicating mRNA-based vaccines and antibodies targeting infectious disease pathogens. Under the terms of the 2020 GSK Agreement, we granted GSK a worldwide exclusive, sublicensable (subject to certain conditions) license under certain of our intellectual property relating to vaccines and antibodies encoded by our proprietary mRNA targeting certain selected pathogens, or GSK Program Products, and a non-exclusive license under certain LNP technology to develop, manufacture and commercialize a certain number of such GSK Program Products for use in connection with the infectious diseases targeted under the 2020 GSK Agreement. We additionally granted GSK an exclusive option for a certain period to add additional products in the field of infectious diseases as GSK Program Products. If such additional product targets a coronavirus other than SARS-CoV-2, at our election such product will be developed and commercialized on a cost and profit split basis under the GSK COVID Agreement. GSK is permitted for a certain period to replace any of the GSK Program Products with an alternative product, up to a certain number of times, and to exchange any antigen or antibody for which we have granted GSK a license under LNP technology for an alternative antigen or antibody, up to a certain number of times. In April 2023, GSK exercised its replacement right to replace one product. In the event we obtain rights to any intellectual property controlled by a third party that is useful for the development, manufacture or commercialization of the GSK Program Products, but which is not necessary to obtain freedom to operate with respect to the use or exploitation of our technology or know-how, we must, at GSK&#8217;s election, use commercially reasonable efforts to obtain a sublicense to such rights on behalf of GSK. Under the terms of the 2020 GSK Agreement, GSK granted us a royalty-free, non-exclusive license under certain GSK-controlled technology to perform certain development and manufacturing activities under the 2020 GSK Agreement. The 2020 GSK Agreement was amended and restated in April 2021, September 2021, February 2022 and March 2022. Under the September 2021 Amendment, each party also granted the other party a royalty-free, perpetual, worldwide, non-exclusive, sublicensable license under certain inventions created by such party to freely practice, use and exploit such inventions in any field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For a certain period after the effective date, GSK has the right to reserve up to a certain number of antigens and we and our affiliates will be prohibited from granting any rights to a third party with respect to any such antigen for use in connection with infectious diseases. Under the terms of the 2020 GSK Agreement, GSK and its affiliates and sublicensees and we and our affiliates are additionally prohibited from developing, manufacturing or commercializing, directly or indirectly, any prophylactic or therapeutic mRNA-based vaccine or mRNA-based antibody targeting a pathogen targeted by a GSK Program Product, other than as contemplated under the 2020 GSK Agreement. Such exclusivity obligation will continue on a pathogen-by-pathogen basis for the duration of the 2020 GSK Agreement, so long as such pathogen is targeted by a GSK Program Product. We are additionally prohibited from granting any third party any license under the licensed LNP technology, or using such LNP technology ourselves, in connection with any GSK Program Product for so long as such GSK Program Product is being developed or commercialized under the 2020 GSK Agreement, except as contemplated under the 2020 GSK Agreement. We are additionally prohibited, for the period during which GSK&#8217;s option to license additional GSK Program Products remains outstanding, from commercializing or granting any third-party the right to develop or commercialize any prophylactic or therapeutic mRNA-based vaccine or mRNA-based antibody targeting certain pathogens for use in connection with infectious diseases.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We and GSK are required to complete certain development activities with respect to the GSK Program Products set forth in various development plans. Among other development responsibilities, we are required to provide clinical supply and will in principle be responsible for sponsoring Phase&#160;1 clinical trials for the GSK Program Products. We and GSK agree to decide whether the products required for clinical studies will be manufactured by us, GSK or jointly. At GSK&#8217;s request, we are required to transfer to GSK all know-how necessary for GSK&#8217;s development activities under the 2020 GSK Agreement and all know-how necessary for the manufacture of the GSK Program Products. GSK is generally responsible for development activities following completion of Phase&#160;1 clinical trials and is required to use diligent efforts to secure marketing authorization following completion of all necessary clinical trials. GSK is responsible for the commercialization of approved GSK Program Products in all countries other than Austria, Germany and Switzerland and is required to use diligent efforts to commercialize approved GSK Program Products in certain major market countries. At our request, we and GSK will negotiate and agree in good faith to a distribution agreement pursuant to which we will have the exclusive right to commercialize GSK Program Products in Austria, Germany and Switzerland, and we will pay GSK royalties at the rate set out below. We and GSK are required to provide development data to the other party thorough a joint steering committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">GSK paid us an upfront payment of &#8364;120&#160;million and is required to pay us a manufacturing capacity reservation fee of &#8364;30&#160;million following a certain regulatory milestone event, which is creditable against future milestone payments. We are eligible to receive up to between &#8364;28&#160;million to &#8364;45&#160;million in development milestone payments, &#8364;32&#160;million to &#8364;35&#160;million in regulatory milestone payments and &#8364;70 to &#8364;100&#160;million in commercial milestone payments, depending on the GSK Program Product. Upon each exercise of its option to add additional products as GSK Program Products, GSK is required to compensate us for certain development costs and pay any accrued milestone payments. If GSK exercises its right to replace a GSK Program Product and if the replacement product was already under development by us, GSK must compensate us for certain development costs and pay any accrued milestone payments. We are eligible to receive tiered royalty payments ranging from a single-digit&#160;percentage to a low teens&#160;percentage on net sales, subject to certain customary reductions. GSK&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of (i)&#160;the expiration of the last to expire valid claim covering such product in such country, (ii)&#160;the earlier of expiration of regulatory exclusivity for such product in such country or 12&#160;years following the first commercial sale of such product in such country or (iii)&#160;ten&#160;years following the first commercial sale of such product in such country provided our proprietary know-how is required for such product. In any event, GSK&#8217;s royalty obligations with respect to a product will expire in all countries no later than 20&#160;years following the first commercial sale of such product in any country in which GSK is responsible for the commercialization of approved GSK Program Products. GSK is required to compensate us for certain development and regulatory costs we may incur in connection with our performance of our obligations under the 2020 GSK Agreement and we are eligible to receive up to &#8364;20,000 in reimbursements for expenses incurred recording or registering the licenses granted under the 2020 GSK Agreement. Under any distribution agreement entered into between us and GSK in connection with our distribution of a GSK Program Product in Austria, Germany and Switzerland, we will be required to purchase supply from GSK and pay GSK a low thirties&#160;percentage royalty on net sales. Under the March 2022 amendment, GSK and CureVac agreed on certain changes to the manufacturing strategy for the products developed under the collaboration, as a part of which GSK agreed to reimburse us for certain manufacturing expenses amounting to &#8364;42 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The term of the 2020 GSK Agreement will continue until the expiration of the last-to-expire royalty term, unless terminated earlier by either party. GSK has the right to terminate the 2020 GSK Agreement in its entirety or on a program-by-program basis for convenience following a certain notice period. We and GSK both have the right to terminate the 2020 GSK Agreement on a program-by-program basis before the first commercial sale of a GSK Program Product under such program in the event of the other party&#8217;s material breach following a cure period or after the first commercial sale of a GSK Program Product under such program if the other party fails to make any payments due, commits any willful and material breach of the restrictions on any license granted to such party, commits a material breach of its non-compete obligations or commits a persistent and material breach of its confidentiality obligations following a cure period. We additionally have the right to terminate on a program-by-program basis after the first commercial sale of a GSK Program Product under such program if GSK commits a material breach of its commercialization diligence obligations following a cure period.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon expiration, the licenses granted to GSK under the 2020 GSK Agreement will become fully paid-up, perpetual and non-exclusive. In the event GSK terminates the 2020 GSK Agreement or a program under the 2020 GSK Agreement for convenience or we terminate a program under the 2020 GSK Agreement for cause, we will have the right to elect to continue with the development and commercialization of such program ourselves. If we decline to continue with the development and commercialization of a terminated program, all licenses granted under the 2020 GSK Agreement will terminate. If we elect to continue with the development and commercialization of a terminated program, all licenses granted by us to GSK will terminate and GSK must grant us an exclusive license under any intellectual property developed under the 2020 GSK Agreement and, at our election, a non-exclusive license under technology, which was used by GSK for the development, manufacture or commercialization of such terminated product. In the case of termination for GSK&#8217;s convenience and if we elect to obtain such nonexclusive license, we will be required to pay GSK a single-digit&#160;percentage royalty on net sales. In the case of our termination for cause, the grant of rights and transition of the assets from GSK will be subject to a payment to GSK to be mutually agreed by the parties. In the event GSK terminates a program under the 2020 GSK Agreement for cause, GSK will have the right to elect to continue the development and commercialization of such program. If GSK declines to continue with the development and commercialization of a terminated program, all licenses granted under the 2020 GSK Agreement will terminate. If GSK elects to continue development and commercialization, all licenses granted to GSK under the 2020 GSK Agreement will survive termination and all payment obligations will remain in effect except that GSK will have the right to suspend payments until the amount of damages suffered by GSK has been agreed and set off against such payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">GlaxoSmithKline COVID Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April 2021, we entered into a collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as our second-generation COVID-19 vaccine candidates, CV0601 or CV0701. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the GSK COVID Agreement, we granted GSK a worldwide, exclusive, sublicensable (subject to certain conditions) license under certain of our intellectual property relating to mRNA-based vaccines targeting SARS-CoV-2 and a non-exclusive license under certain LNP technology to develop, manufacture and commercialize certain SARS-CoV-2 pathogen vaccine products, or the GSK COVID Products, for use in connection with the prevention or treatment of diseases caused by the SARS-CoV-2 pathogen. The GSK COVID Products consist of (i) next-generation SARS-CoV-2 pathogen vaccine products (other than CVnCoV), (ii) vaccine products targeting coronaviruses other than SARS-CoV-2 for which GSK exercises its exclusive option pursuant to the 2020 GSK Agreement and where we elect to develop and commercialize such product on a cost and profit split basis under the GSK COVID Agreement and (iii) next-generation SARS-CoV-2 pathogen vaccine products (other than CVnCoV) that also target one or more pathogens that the parties are targeting under the 2020 GSK Agreement, which we refer to as Combination Products. In the event we obtain rights to any intellectual property controlled by a third-party that is useful for the development, manufacture or commercialization of the GSK COVID Products, but which is not necessary to obtain freedom to operate with respect to the use or exploitation of our technology or know-how, we must, at GSK&#8217;s election, use commercially reasonable efforts to obtain a sublicense to such rights on behalf of GSK. Under the terms of the GSK COVID Agreement, GSK granted us a royalty-free, non-exclusive license under certain GSK-controlled technology to perform certain development and manufacturing activities under the GSK COVID Agreement. Under the September 2021 Amendment, each party also granted the other party a royalty-free, perpetual, worldwide, non-exclusive, sublicensable license under certain inventions created by such party to freely practice, use and exploit such inventions in any field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">GSK and its affiliates and sublicensees and we and our affiliates are prohibited from, subject to certain exceptions, developing, manufacturing or commercializing, directly or indirectly, any mRNA-based vaccine or mRNA-based antibody products targeting the SARS-CoV-2 pathogen, other than a GSK COVID Product as contemplated under the GSK COVID Agreement or CVnCoV. The exclusivity obligations remain in effect until the expiration or termination of the GSK COVID Agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in various development plans. The GSK COVID Agreement was amended and restated in September 2021, February 2022 and March 2022, as described below, and further amended in August 2022 to reflect conforming updates to the development plans. Pursuant to the amendment in September 2021, we and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. We and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by us, GSK or jointly. Once a manufacturing and supply strategy for a given GSK COVID Product has been agreed upon between the parties, we must negotiate and agree in good faith on a commercial supply agreement pursuant to which we may be required to reserve certain manufacturing capacity for GSK. At GSK&#8217;s request, we are required to transfer to GSK all know-how necessary for GSK&#8217;s development activities under the GSK COVID Agreement and all know-how necessary for the manufacture of the GSK COVID Products. GSK is responsible for the commercialization of GSK COVID Products in all countries other than Austria, Germany and Switzerland and is required to use diligent efforts to commercialize approved GSK COVID Products in certain major market countries. At our request, we and GSK will negotiate and agree in good faith to a distribution agreement pursuant to which we will have the exclusive right to commercialize GSK COVID Products in Austria, Germany and Switzerland. We and GSK are required to provide development data to the other party thorough a joint steering committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the GSK COVID Agreement, GSK paid us an upfront payment of &#8364;75&#160;million. Upon GSK&#8217;s exercise of its option to add CVnCoV and boosters for such vaccine as GSK COVID Products, GSK is required to compensate us for certain development costs. We and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. We and GSK will share all net profits generated from sales of GSK COVID Products, other than Combination Products, under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. We are eligible to receive tiered royalty payments ranging from a sub-teen percentage to a mid-teens&#160;percentage on net sales of Combination Products, subject to certain customary reductions. We will pay GSK a high-teen percentage royalty on net sales of all Combination Products in Austria, Germany and Switzerland. All royalty obligations continue on a product-by-product and country-by-country basis until the later of (i)&#160;the expiration of the last to expire valid claim covering such product in such country (ii)&#160;the earlier of expiration of regulatory exclusivity for such product in such country or 12&#160;years following the first commercial sale of such product in such country, or (iii)&#160;10&#160;years following the first commercial sale of such product in such country provided our proprietary know-how is required for such product. In any event, GSK&#8217;s royalty obligations with respect to a product will expire in all countries no later than 20&#160;years following the first commercial sale of such product in the respective party&#8217;s territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The term of the GSK COVID Agreement will continue until the expiration of all applicable payment obligations, unless terminated earlier by either party. GSK has the right to terminate the GSK COVID Agreement in its entirety for convenience following a certain notice period, and we have the right to opt out of the funding of the development, manufacture and commercialization of a GSK COVID Products on a product-by-product basis. In the event we opt out of funding the development of a GSK COVID Product, GSK can elect to cease the development and commercialization of the relevant product, or to continue it on the terms of the 2020 GSK Agreement. If GSK declines to continue with the development and commercialization, the agreement terminates in connection with that GSK COVID Product and all licenses granted under the GSK COVID Agreement will terminate. We and GSK both have the right to terminate the GSK COVID Agreement before the first commercial sale of a GSK COVID Product in the event of the other party&#8217;s material breach following a cure period or after the first commercial sale of a GSK COVID Product if the other party fails to make any payments due, commits any willful and material breach of the restrictions on any license granted to such party, commits a material breach of its non-compete obligations or commits a persistent and material breach of its confidentiality obligations following a cure period. We additionally have the right to terminate after the first commercial sale of a GSK COVID Product if GSK commits a material breach of its commercialization diligence obligations following a cure period.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon expiration, the licenses granted to GSK under the GSK COVID Agreement will become fully paid-up, perpetual and non-exclusive. In the event GSK terminates the GSK COVID Agreement for convenience or we terminate the GSK COVID Agreement for cause, all licenses granted to GSK under the GSK COVID Agreement will terminate and we will have the right to elect to continue with the development and commercialization of the GSK COVID Products ourselves. If we elect to continue with the development and commercialization of the COVID Products, GSK must grant us an exclusive license under any intellectual property developed under the GSK COVID Agreement and, at our election, a non-exclusive license under technology which was used by GSK for the development, manufacture or commercialization of the GSK COVID Products. In the case of termination for GSK&#8217;s convenience and if we elect to obtain such non-exclusive license, we will be required to pay GSK a royalty ranging from a sub-single-digit percentage to a low single-digit percentage on net sales. In the case of our termination for cause, the grant of rights and transition of the assets from GSK will be subject to a payment to GSK to be mutually agreed by the parties. In the event GSK terminates the GSK COVID Agreement for cause, GSK will have the right to elect to continue the development and commercialization of the GSK COVID Products. If GSK declines to continue with the development and commercialization of the GSK COVID Products, all licenses granted under the GSK COVID Agreement will terminate. If GSK elects to continue development and commercialization, all licenses granted to GSK under the GSK COVID Agreement will survive termination, provided that for GSK COVID Products other than Combination Products a one-time payment from GSK to Curevac (in replacement of a continuous profit sharing mechanism) will be mutually agreed upon by the parties. All payment obligations for Combination Products will remain in effect. In each case, GSK will have the right to suspend payments until the amount of damages suffered by GSK has been agreed and set off against such payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">CureVac-GSK Consortium Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Federal Republic of Germany, represented by the Vaccine Production Taskforce on behalf of the Federal Ministry of Health, called for tenders relating to pandemic preparedness, which we refer to as the Tender Procedure. The Tender Procedure resulted in framework agreements for the provision to the Federal Republic of Germany of production capacities and, upon demand, the production and supply of mRNA vaccines (referred to as lot 1) and vector- or protein-based vaccines (referred to as lot 2). Because neither we nor GSK were alone in a position to provide the full range of services requested by the Federal Republic of Germany under the Tender Procedure, we established a consortium with GSK (referred to as the CureVac-GSK Consortium) for the purpose of participating in the Tender Procedure, entering into a framework agreement for the provision of production capacities and, upon demand, the production and supply of mRNA vaccines (lot 1), which we refer to as a Pandemic Preparedness Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The CureVac-GSK Consortium submitted an application and offer under the Tender Procedure for the award of a Pandemic Preparedness Agreement. On April 8, 2022, the Federal Republic of Germany sent a letter confirming that the CureVac-GSK Consortium had been awarded a Pandemic Preparedness Agreement. Following a qualification phase of a maximum of two years from the award date, the Pandemic Preparedness Agreement grants the government access to a manufacturing capacity of 80 million doses of mRNA-based vaccine per year until 2029, subject to extension. Under the contract, after successful achievement of pandemic preparedness by the end of the qualification phase, the contract will enter into a stand-by phase during which the government will pay the CureVac-GSK Consortium an annual stand-by fee. During the stand-by phase, the CureVac-GSK Consortium is required to maintain a manufacturing capacity of 80 million doses of mRNA-based vaccine per year at constant readiness. The Pandemic Preparedness Agreement is subject to termination by the Federal Republic of Germany or the CureVac-GSK Consortium if, among other things, by the end of the qualification phase the CureVac-GSK Consortium does not have an mRNA-based vaccine for which a marketing authorization (which may be temporary) for the German market has been granted. On April 9, 2024, the CureVac-GSK Consortium terminated the Pandemic Preparedness Agreement, effective as of May 31, 2024.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 18pt;"><i style="font-style:italic;">Genmab Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2019, we entered into a Collaboration and License Agreement with Genmab, which we refer to as the Genmab Agreement, to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#8217;s proprietary antibody technology for the treatment of human diseases. The Genmab Agreement was amended in July 2020, December 2020 and June 2021. Pursuant to the Genmab Agreement we granted Genmab an exclusive, worldwide, sublicensable (subject to certain conditions) license under our mRNA technology for the development, manufacture and commercialization of an mRNA antibody product designed to express a certain Genmab proprietary antibody, which we refer to as the Genmab First Program. However, in June 2023 Genmab notified us of its intent to terminate the Genmab First Program under the Genmab Agreement effective in September 2023. Such termination did not terminate the Genmab Agreement in its entirety, but rather only with respect to certain license and exclusivity provisions related to the Genmab First Program. We additionally granted Genmab an exclusive, worldwide, sublicensable license under our mRNA technology for the research and preclinical development of up to four additional mRNA antibody product concepts and an option to obtain an exclusive, worldwide, sublicensable (subject to certain conditions) license to develop, manufacture and commercialize product candidates for up to three of such product concepts. We have the option to share in the costs and profits in connection with the development, manufacture and commercialization of one of the additional mRNA antibody product concepts under predefined terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may not, directly or indirectly, offer any rights to a third party under the technology we license to Genmab for the additional product concepts and targets being developed under the Genmab Agreement or conduct or participate in the development, manufacture or commercialization of any antibody product that is directed at a target being developed under the Genmab Agreement for certain periods of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In partial consideration for entering into the Genmab Agreement, Genmab paid us an upfront fee of $10 million and made a &#8364;20 million equity investment. Genmab is additionally required to pay us up to $30 million in option exercise fees. If Genmab exercises any of its options to obtain commercial licenses for the additional mRNA antibody concepts, Genmab would fund all research and would develop and commercialize any resulting product candidates. We are additionally eligible to receive up to between $25 million and $43 million in development milestone payments, $100 million and $125 million in regulatory milestone payments and $150 million and $200 million in commercial milestone payments for each product, depending on the specific product concept. In addition, we are eligible to receive a mid-single-digit to low teens percentage tiered royalty on aggregate net sales of licensed products, on a per product basis and subject to certain customary reductions. Genmab&#8217;s royalty obligation continues on a country-by-country and product-by-product basis until the later of the expiration of the last-to-expire valid claim in the licensed patents in such country covering such licensed product, expiration of regulatory exclusivity for such product in such country or 10 years from the date of the first commercial sale of such product. In the event we exercise our right to share in the development, manufacture and commercialization of a product, we must pay Genmab a one-time payment of $3 million and refund any option fee paid by Genmab with respect to such product. As of December 31, 2023, we have received $1 million in development cost reimbursements, and we have not received any reservation, product selection, option exercise or sublicense fees or milestone or royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are required to use commercially reasonable efforts to perform our obligations under the research and development plans established in connection with the Genmab Agreement. Genmab is required to use commercially reasonable efforts to identify and develop each additional product Genmab adds to the development program under the Genmab Agreement, and to further develop each optioned product to marketing authorization and to commercialize each product for which it obtains regulatory approval. We and Genmab are required to make available to the other party all preclinical development data for each program under development under the Genmab Agreement until filing of an IND for such program. Following IND filing for a product, we and Genmab will establish a collaboration committee where Genmab will share the status, progress and results of the development of the respective product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The term of the Genmab Agreement will continue until the expiration of the royalty term, unless terminated earlier by either party. The Genmab Agreement may be terminated upon written notice by either party upon the other party&#8217;s material breach or default of any of its obligations following a cure period. Genmab may terminate the Genmab Agreement for convenience after a certain notice period. Upon expiration of the Genmab Agreement, the license rights we granted to Genmab under the Genmab Agreement will become fully paid-up, perpetual and non-exclusive. In the event of termination for our material breach, we will grant Genmab an exclusive (even to us), worldwide and sublicensable license to exploit any product identified prior to termination, subject to Genmab&#8217;s continued milestone and royalty obligations. In the event of termination by us for Genmab&#8217;s material breach, or Genmab&#8217;s termination for convenience, the licenses granted to Genmab will automatically terminate. Additionally, at our request, Genmab will grant us a non-exclusive, royalty-free, sublicensable, perpetual and worldwide license under certain Genmab intellectual property that is created under the Genmab Agreement and that is required to develop, manufacture and commercialize our own mRNA antibody products targeting the collaboration targets under the Genmab Agreement prior to termination. Such license would not include any license to Genmab background intellectual property or the specific products or antibodies developed by Genmab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Arcturus Development and Option Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In January 2018, we entered into a Development and Option Agreement with Arcturus, which we refer to as the Arcturus Agreement, pursuant to which Arcturus granted us the right to reserve a certain number of targets and an irrevocable offer to obtain a license to a certain number of such reserved targets to develop, manufacture and commercialize products containing Arcturus&#8217;s LNP technology (LMD technology) and mRNA constructs intended to express such targets. The Arcturus Agreement expired in July 2023. We did not accept the offer with respect to any targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, we made payments totaling $5.6 million to Arcturus reimbursing Arcturus for development costs and in connection with our FTE funding obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Acuitas Development and Option Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April 2016, we entered into a Development and Option Agreement with Acuitas, which as amended we refer to as the Acuitas Agreement, pursuant to which Acuitas granted us the right to reserve a certain number of vaccine and other targets and an option to obtain a license to a certain number of such reserved targets to develop, manufacture and commercialize products containing Acuitas&#8217;s LNP technology and mRNA constructs intended to express such targets. With respect to a certain number of nonexclusive licenses to vaccine targets that we obtain under the Acuitas Agreement, Acuitas additionally granted us an option to exchange each vaccine target licensed under such nonexclusive license for an alternate vaccine target for a certain period. As of December 31, 2023, we have exercised our option to obtain a nonexclusive license to 18 targets, and have not exercised our option to exchange a vaccine target licensed under any nonexclusive license. In connection with an amendment to the Acuitas Agreement dated February 13, 2024, Acuitas also granted us the right to evaluate, and an option to obtain a license to, certain of Acuitas&#8217;s LNP technology for personalized cancer vaccine products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Acuitas Agreement, Acuitas is responsible for the LNP chemistry and formulation and characterization work, and we are responsible for mRNA construct development. Both parties will undertake certain allocated preclinical studies. Each party is required to use diligent efforts to perform its obligations under the work plans established in connection with the Acuitas Agreement. Acuitas is further required to use diligent efforts to manufacture and supply us with certain formulated products. The Acuitas Agreement provides for the establishment of a joint development committee for the discussion of development efforts under the Acuitas Agreement. We are required to reimburse Acuitas for certain costs incurred in connection with development activities and certain FTE costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are further required to pay Acuitas annual target reservation and maintenance fees of up to $1.4 million if we reserve the maximum number of targets permitted under the Acuitas Agreement. We are additionally required to pay an option exercise fee ranging from $50,000 to $2 million upon each exercise of our option under the Acuitas Agreement, subject to certain additional fees ranging from $10,000 to $200,000 for the exercise of our option for certain other vaccine targets. We paid Acuitas a $5 million upfront fee in connection with an amendment to the Acuitas Agreement dated July 2020 and, upon each exercise of our option to exchange a vaccine target licensed under any non-exclusive license, we paid an exchange fee of $3 million. We paid Acuitas a $3 million upfront fee in connection with an amendment to the Acuitas Agreement dated December 2020 and paid two annual payments of an additional $250,000 per option to extend certain options. Under each license agreement we enter into in connection with our exercise of our option, we will additionally be required to make low single-digit percentage tiered royalty payments, subject to certain customary reductions, on a country-by-country and a product-by-product basis until the later of the expiration of the last-to-expire licensed patent in such country covering such licensed product, expiration of regulatory exclusivity for such product in such country or 10 years from the date of the first commercial sale of such product in such country. Under each such license we additionally must pay up to between $1.1 million and $9 million in development milestone payments, $1.3 million and $7 million in regulatory milestone payments and $1.3 million and $7 million in commercial milestone payments, depending on whether the license is exclusive or non-exclusive and the number of options exercised to date. As of December 31, 2023, we have exercised our option to obtain a non-exclusive license to 18 targets. As of December 31, 2023, we have paid Acuitas $9.7 million in reservation and option exercise fees, $0.6 million in license maintenance fees and $1.75 million for certain options not yet exercised and have made payments totaling $9.0 million reimbursing Acuitas for development costs and LNP batches and in connection with our FTE funding obligations. Payments made under the license agreements entered into in connection with our exercise of our option under the Acuitas Agreement are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Acuitas Agreement, Acuitas granted us a worldwide, non-exclusive license under its LNP technology for us to perform development activities, and we granted Acuitas a worldwide, non-exclusive license under our mRNA technology solely to enable Acuitas to perform development activities in connection with the Acuitas Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Acuitas Agreement will expire in April&#160;2025 unless earlier terminated or extended. Both parties have the right to terminate the Acuitas Agreement in whole or on a program-by-program basis in the event of a material breach by the other party following a cure period. We additionally have the right to terminate the Acuitas Agreement for convenience following a certain notice period or for Acuitas&#8217;s change of control. In the event of termination for any reason, Acuitas will transfer all deliverables created under the Acuitas Agreement to us and in the event we terminate for reasons other than for Acuitas&#8217;s material breach, we must make any payments owed to Acuitas up to the time of termination. In the event we terminate for Acuitas&#8217;s material breach or for Acuitas&#8217;s change of control, Acuitas will transfer any technology and provide licenses as reasonably necessary for us to complete work contemplated under the Acuitas Agreement and, in the case of termination for Acuitas&#8217;s material breach, Acuitas must refund to us any target reservation and maintenance fees for the remainder of the contract year in which such termination is effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Acuitas Non-exclusive License Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For each option we have exercised under the Acuitas Agreement, we have entered into a non-exclusive license agreement with Acuitas with respect to such optioned product, all based on the same form agreement, which we collectively refer to as the Acuitas License Agreements. Under the Acuitas License Agreements, Acuitas grants us a non-exclusive, non-transferable, sublicensable (subject to certain conditions) worldwide license under Acuitas&#8217;s LNP technology to develop, manufacture and commercialize licensed products directed to the optioned targets. We may convert the non-exclusive licenses to exclusive licenses subject to certain additional financial obligations. As of December 31, 2023, we have not converted any non-exclusive license to an exclusive license.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We must pay Acuitas up to between $1.1 million and $1.6 million in development milestone payments, $1.3 million and $1.8 million in regulatory milestone payments and $1.3 million and $1.8 million in commercial milestone payments under each Acuitas License Agreement upon the occurrence of certain milestone events. We additionally are obligated to pay Acuitas annual fees ranging from $5,000 to $10,000 for any additional protein targeted by a vaccine product licensed under an Acuitas License Agreement after a certain milestone event. We are further required to pay Acuitas a low single-digit tiered percentage royalty on net sales of licensed products, subject to certain potential customary reductions. Our royalty obligations continue under each Acuitas License Agreement on a country-by-country and product-by-product basis until the later of the expiration of the last-to-expire licensed patent claim covering such licensed product in such country, expiration of any regulatory exclusivity period for such product in such country and 10 years following the first commercial sale of such product in such country. As of December 31, 2023, we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to Rabies RAV-G, $1.4 million in development milestone payments (Phase I, Phase II and Phase III milestone payments) to Acuitas with respect to the license agreement relating to the SARS-CoV-2 Spike protein S, $350,000 in development milestone payments to Acuitas with respect to the license agreement relating to the Influenza hemagglutinin (HA) antigen, $1.0 million in development milestone payments to Acuitas with respect to the license agreement relating to CVGBM, and have not made any royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each Acuitas License Agreement will continue on a product-by-product and a country-by-country basis until there are no more payments owed to Acuitas for such product in such country. Either party may terminate an Acuitas License Agreement in the event of a material breach by the other party following a cure period. We additionally have the right to terminate the Acuitas License Agreements for convenience following a certain notice period. Upon expiration of an Acuitas License Agreement, the licenses granted to us under such Acuitas License Agreement will become fully paid-up and will remain in effect. In the event of our termination of an Acuitas License Agreement for Acuitas&#8217;s material breach, the rights and licenses granted to us under such agreement will become perpetual and irrevocable. Alternatively, instead of exercising our right to terminate in the event of Acuitas&#8217;s material breach, we may elect to instead continue the license but reduce our milestone and royalty payment obligations to Acuitas by a certain&#160;percentage. In the event of termination of an Acuitas License Agreement by us for convenience or by Acuitas for our material breach, the licenses granted under such agreement will terminate, except that we will have the right to sell off any remaining inventories of licensed products for a certain period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">CRISPR Therapeutics Development and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2017, we entered into a Development and License Agreement with CRISPR Therapeutics, which as amended by a first amendment entered into in June 2020 and a second amendment entered into in October 2023, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. Under the terms of the CRISPR Therapeutics Agreement, we granted CRISPR Therapeutics a worldwide, exclusive (even to us), sublicensable (subject to certain conditions) license under certain intellectual property rights that are reasonably necessary or useful to develop, manufacture or commercialize products comprising Cas9 mRNA constructs, and under any patents controlled by us that arise from inventions discovered under the CRISPR Therapeutics Agreement to develop, manufacture and commercialize three of CRISPR Therapeutics&#8217; <i style="font-style:italic;">in vivo</i> gene-editing programs for certain diseases. CRISPR Therapeutics granted us an exclusive (even as to CRISPR Therapeutics), worldwide, cost-free sublicense to manufacture products comprising Cas9 mRNA constructs for CRISPR Therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">CRISPR Therapeutics has paid us an upfront one-time technology access fee of $3 million and we are eligible to receive up to $28 million in development milestone payments, $52 million in regulatory milestone payments and $260 million in commercial milestone payments, as well as mid single-digit percentage royalties from CRISPR Therapeutics on the net sales of licensed products on a product-by-product and country-by-country basis, subject to certain potential customary reductions. CRISPR Therapeutics&#8217; royalty obligations continue on a product-by-product and country-by-country basis until the later of the date when there are no valid patent claims under our licensed patents covering such licensed product in such country, the date when regulatory exclusivity for such licensed product in such country expires and 10 years following the date of first commercial sale of such licensed product in such country. CRISPR Therapeutics is additionally required to reimburse us for our FTE costs and reasonable out-of-pocket expenses incurred performing development activities under the CRISPR Therapeutics Agreement. In the event CRISPR Therapeutics exercises its right to sublicense under the agreement, CRISPR Therapeutics must pay us a low teens to mid-twenties percentage of any non-royalty sublicense income, depending on the timing of the sublicense and whether the sublicense is granted through an affiliate of CRISPR Therapeutics. As of December 31, 2023, we have received &#8364;8.4 million in payments, for the supply of materials and FTE cost, development reimbursements and upfront one-time technology access fee and no milestone, royalty or sublicense fee payments. Additionally, as of December 31, 2023, we have invoiced CRISPR Therapeutics for certain amounts under the agreement in connection with the second amendment, which confirmed the parties&#8217; intention to stop work on two programs under the CRISPR Therapeutics Agreement, terminated all licenses granted by CureVac to CRISPR Therapeutics with respect to such programs and added three new programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are required to use commercially reasonable efforts to perform our development obligations under the CRISPR Therapeutics Agreement and to supply certain materials to CRISPR Therapeutics. CRISPR Therapeutics is required to use commercially reasonable efforts to perform its obligations under the development plan and to develop and commercialize licensed products. We and CRISPR are required to keep the other party informed regarding the progress and results of performance of all development activities under the CRISPR Therapeutics Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The term of the CRISPR Therapeutics Agreement will continue on a product-by-product and country-by-country basis, until the last-to-expire royalty term expires in such country for such product, unless terminated earlier by either party. The CRISPR Therapeutics Agreement may be terminated (i)&#160;by CRISPR Therapeutics for convenience following a certain notice period, (ii)&#160;by us if CRISPR Therapeutics or any of its affiliates, either directly or indirectly, challenges or assists a third party to challenge the licensed patent rights or in the event CRISPR Therapeutics undergoes a change of control, or (iii)&#160;by either party in the event of the other party&#8217;s material breach following a cure period (including on a program-by-program basis) or in the event of the other party&#8217;s insolvency. Upon expiration, the license granted to CRISPR Therapeutics converts into a fully paid-up, royalty-free, perpetual and irrevocable license. Upon termination, the licenses granted to CRISPR Therapeutics will terminate and, in the case of termination for CRISPR Therapeutics&#8217; material breach or insolvency or for convenience by CRISPR Therapeutics, CRISPR Therapeutics must transfer all Cas9 mRNA constructs and related data to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Boehringer Ingelheim Exclusive Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In August&#160;2014, we entered into an Exclusive Collaboration and License Agreement with Boehringer Ingelheim, which we refer to as the Boehringer Agreement, whereby we granted Boehringer Ingelheim exclusive global rights for development and commercialization of our investigational therapeutic mRNA vaccine BI 1361849 (formerly CV9202) formulated with our protamine technology, and products containing such vaccine for all uses for cancer in humans. We received an upfront payment of &#8364;30&#160;million, as well as an option fee payment of &#8364;5&#160;million and an additional &#8364;7&#160;million in development milestone payments. As of December 31, 2021, we received &#8364;7.6&#160;million for the supply of materials and reimbursing us for development costs. In June 2021, Boehringer Ingelheim provided notice of its intention to terminate the Boehringer Agreement, with such termination becoming effective on November 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Bill &amp; Melinda Gates Foundation Partnership</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In May 2014, we entered into a contract agreement with the Bill &amp; Melinda Gates Foundation for the development of a vaccine for rotaviruses. Under the terms of the contract grant, as amended by an amendment entered into November 2020, the Bill &amp; Melinda Gates Foundation will provide up to $3.0 million in funding, and we are required to perform certain activities specified in a project collaboration plan. As of December 31, 2023, we have received $3.0 million in funding under the agreement. We own all intellectual property created using contract funding; however, we must make any Bill &amp; Melinda Gates Foundation-funded products available at an affordable price in a list of clearly defined low and lower middle-income countries. The term of the rotavirus agreement expired in June 2022. Our global access commitments survive termination or expiration of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In March 2015, the Bill &amp; Melinda Gates Foundation made an equity investment of $40 million to support continued development of our RNA technology platform and the construction of an industrial-scale cGMP production facility, and we entered into the Global Access Commitments Agreement with the Bill &amp; Melinda Gates Foundation in February 2015 pursuant to which we are required to take certain actions to support the Bill &amp; Melinda Gates Foundation&#8217;s mission. In particular, we are required to conduct development activities for up to three concurrent projects to be proposed by the Bill &amp; Melinda Gates Foundation, subject to our right to reject proposed projects where we believe there is a reasonable likelihood of a material adverse effect on us. The costs of such projects will be allocated on a project-by-project basis in proportion to the allocation of the expected benefits. All intellectual property developed in connection with such projects will be owned by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Global Access Commitments Agreement, any Bill &amp; Melinda Gates Foundation-funded products will be made available by us at an affordable price in a list of clearly defined low and lower middle-income countries, while we will be able to market such products in developed countries on our own or through licensees. In addition, the new manufacturing facility will have dedicated capacity to focus on products resulting from Bill &amp; Melinda Gates Foundation-related projects for distribution in such low and lower middle-income countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our global access commitments are perpetual, however, our obligation to commence new development programs expires in February&#160;2025. In the event that we commit a material breach of the Global Access Agreement, following a cure period, we must grant the Bill &amp; Melinda Gates Foundation a non-exclusive, perpetual, irrevocable, fully paid-up, royalty-free license under any intellectual property controlled by us covering any Bill &amp; Melinda Gates Foundation-funded products to develop, manufacture and commercialize such products in low and lower middle-income countries, and the Bill &amp; Melinda Gates Foundation will have certain withdrawal rights with respect to its equity investment in us. For more information on the Bill &amp; Melinda Gates Foundation&#8217;s withdrawal rights, see &#8220;Item 7. Major Shareholders and Related Party Transactions &#8212; B. Related Party Transactions&#8201;&#8212;&#8201;Investment and Shareholders&#8217; Agreement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2016 in connection with and subject to the terms of the Global Access Agreement, we were awarded a grant for up to $0.9 million in funding from the Bill &amp; Melinda Gates Foundation for the development of a vaccine for picornaviruses. As of December 31, 2023, we have received $0.7 million in funding under the grant agreement. We granted the Bill &amp; Melinda Gates Foundation a non-exclusive, perpetual, irrevocable, worldwide, royalty-free, fully paid-up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display any products developed using grant funding; however, in the event we demonstrate to the satisfaction of the Bill &amp; Melinda Gates Foundation that we are able to meet its global access requirements, such license will be modified or terminated. The term of the picornavirus grant expired in June 2022; however, our global access commitments survive. Following the completion of the project, the Bill &amp; Melinda Gates Foundation requested a reimbursement for unspent funds. As of December 31, 2023, we have paid unspent funds of $0.2 million back to the Bill &amp; Melinda Gates Foundation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2017, also in connection with and subject to the terms of the Global Access Agreement, we were awarded two additional grants for up to $1.9 million and $1.5 million from the Bill &amp; Melinda Gates Foundation for the development of a universal influenza vaccine and a malaria vaccine, respectively. By an amendment entered into November 2020, our grant for the development of a malaria vaccine was increased by an additional $0.8 million. As of December 31, 2023, we have received $1.9 million and $2.2 million, respectively, in funding under each grant agreement. The programs will leverage our advanced RNActive<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> prophylactic vaccine technology to develop mRNA-based universal influenza and malaria vaccines. The malaria grant agreement expired in December 2022 and the universal influenza grant agreement expired in March 2022; however, our global access commitments survive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In July&#160;2020, we amended the Global Access Agreement and entered into a Letter Agreement with GSK and the Bill &amp; Melinda Gates Foundation. Pursuant to this letter agreement, the Bill &amp; Melinda Gates Foundation released us of our global access commitments with respect to certain prophylactic and therapeutic vaccines based on our mRNA technology platform to be developed under the 2020 GSK Agreement. This release will remain in effect for a vaccine or medicine only for so long as it is in development or being commercialized under the 2020 GSK Agreement. The letter agreement does not release us from any of our obligations to initiate or continue projects under the Global Access Agreement or related grant agreements and GSK granted to us and the Bill &amp; Melinda Gates Foundation a non-exclusive, royalty-free, perpetual license under intellectual property arising from certain activities under the 2020 GSK Agreement to make vaccines arising from those projects available in low and lower middle-income countries as set forth in the Global Access Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Coalition for Epidemic Preparedness Innovations Framework Partnering Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February&#160;2019, we entered into a framework partnership agreement with CEPI, which as amended we refer to as the CEPI Agreement, to develop our RNA Printer using certain intellectual property controlled by us covering the development and manufacture of mRNA products as well as certain additional intellectual property licensed to us. In connection with the CEPI Agreement we have entered into work orders for the preclinical development of a Lassa virus vaccine, a yellow fever vaccine and our rabies virus vaccine. In addition, we entered into a work package for the preclinical development and a Phase&#160;1 clinical trial for our first-generation SARS-CoV-2 vaccine, CVnCoV.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are required to use reasonable efforts to achieve certain development milestones and are responsible for conducting certain clinical trials. We are required to share clinical trial data with CEPI, subject to the terms of specific work packages entered into in connection with the CEPI Agreement. In the event of an infectious disease outbreak, where such outbreak can be addressed by a Lassa virus, SARS-CoV-2 or future vaccine developed under the CEPI Agreement, we must manufacture such vaccine for use in the area affected by the outbreak on economic terms that satisfy CEPI&#8217;s equitable access guidelines or otherwise allow CEPI or a third-party to supply such vaccine in the affected area. For the initial term of the CEPI Agreement and for a certain period thereafter, in the event of an outbreak that cannot be addressed by a vaccine already developed under the CEPI Agreement, CEPI may request, and we may agree, that we will develop a product targeted against such outbreak, or we will assist CEPI to develop a candidate product against such outbreak. In the event we decline to enter into such a development agreement, we will grant CEPI the right to develop and stockpile such vaccines under certain of our background intellectual property and intellectual property developed under the CEPI Agreement. We are additionally required to use reasonable efforts, at CEPI&#8217;s request, to submit certain optimized antigen nucleotide sequences for up to three specified pathogens in order for CEPI to start its own product development program. We have a right of first refusal to manufacture any pharmaceutical products developed by CEPI using the antigen nucleotide sequences we provide. In certain scenarios, including if we fail to provide Lassa virus, SARS-CoV-2 or future vaccines developed under the CEPI Agreement at prices that comply with CEPI&#8217;s equitable access guidelines, we must grant CEPI a license under certain of our background intellectual property and intellectual property developed under the CEPI Agreement to, among other things, develop our automation solution for use in treating such infectious diseases and to develop, manufacture and market such pharmaceutical products for use in geographic areas where there is a disease outbreak.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with a December 2020 amendment to the CEPI Agreement, we agreed to provide CVnCoV to organizations operating under the COVAX Facility, a global collaboration to accelerate the development, production and equitable access to SARS-CoV-2 tests, treatments and vaccines. Under this amendment, we agreed to supply a certain percentage of our total capacity for distribution of CVnCoV to organizations participating in the COVAX Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are required to grant certain approved manufacturers all necessary rights to use certain of our preexisting intellectual property and intellectual property developed under the CEPI Agreement to further develop our automation solution and manufacture products for the treatment of certain diseases in geographic areas where there is an outbreak on economic terms that satisfy CEPI&#8217;s equitable access guidelines. We must provide all necessary commercially reasonable support to such approved manufacturers to facilitate such efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">CEPI agreed to contribute up to $34&#160;million in funding for projects undertaken under the CEPI Agreement and an additional $15.3&#160;million in connection with development of CVnCoV. In the event of our commercial use of the pharmaceutical products developed under the CEPI Agreement, other than CVnCoV, we must notify CEPI and agree in good faith how such commercial benefits are to be equitably managed between the parties. As of December 31, 2023, we have received &#8364;27.1&#160;million in funding for projects undertaken under the CEPI Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We solely own all intellectual property developed under the CEPI Agreement but are required to obtain CEPI&#8217;s consent prior to exploiting any intellectual property developed under the CEPI Agreement if such exploitation is in conflict with or goes against CEPI&#8217;s mission or policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The CEPI Agreement terminated in February 2022, except with respect to certain ongoing projects, which are contemplated to be completed in March 2024. Following the completion of the CEPI Agreement, CEPI requested a partial reimbursement of $1.0 million for unspent funds. As of December 31, 2023 we have paid these unspent funds back to CEPI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Tesla Automation Development and Intellectual Property Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2015, we entered into a development and intellectual property agreement with Tesla Automation, formerly trading under the name of Tesla Grohmann Automation, which we refer to as the Tesla Automation Agreement, pursuant to which Tesla Automation agreed to design, develop and manufacture certain automated manufacturing machines on our behalf. We are obligated to pay Tesla Automation a fee for each machine delivered by Tesla Automation and up to $50 million to $60 million in commercial milestone payments as well as certain development costs under each associated work order. As of December 31, 2023, we have paid Tesla Automation &#8364;22 million to &#8364;23 million in development costs under various work orders, and we have not paid any fees for machines provided under the Tesla Automation Agreement or made any milestone payments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The parties jointly own any intellectual property developed under the Tesla Automation Agreement, and Tesla Automation granted us a non-exclusive, royalty-free, perpetual, irrevocable as to existing machines, worldwide license to use, sublicense and distribute Tesla Automation background intellectual property that is incorporated into any machine developed under the Tesla Automation Agreement and an exclusive (only with respect to the machines, and until a certain period after the first commercial use of a machine, after which the license shall be non-exclusive), royalty-free, perpetual, irrevocable as to existing machines, worldwide license under Tesla Automation&#8217;s interest in any jointly owned intellectual property. We granted Tesla Automation a non-exclusive, nontransferable, no-charge license during the term of the Tesla Automation Agreement under our background intellectual property for Tesla Automation&#8217;s performance of its obligations under the Tesla Automation Agreement and a non-exclusive, royalty-free, perpetual, irrevocable as to existing machines, worldwide license under our interest in any jointly owned intellectual property to perform its obligations under the Tesla Automation Agreement and for applications and uses unrelated to the machines developed under the Tesla Automation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Tesla Automation Agreement continues on a machine-by-machine basis until 10 years after the first commercial use of such machine. Either party may terminate any work order entered into in connection with the Tesla Automation Agreement for convenience upon written notice to the other party, and either party may terminate a work order for the other party&#8217;s material breach following a cure period, or for the other party&#8217;s insolvency. In the event Tesla Automation terminates a work order for convenience or we terminate for Tesla Automation&#8217;s material breach or insolvency, Tesla Automation must grant us a non-exclusive, fully paid-up, worldwide, irrevocable, perpetual, transferable and sublicensable license under Tesla Automation background intellectual property and Tesla Automation&#8217;s interest in intellectual property developed under the Tesla Automation Agreement for us to complete, either on our own or with another supplier, the work under such terminated work order. In the event we terminate for convenience, we must pay Tesla Automation a termination fee. In the event Tesla Automation terminates for our material breach or insolvency, we must pay Tesla Automation a termination fee and grant Tesla Automation a non-exclusive, fully paid-up, sublicensable, worldwide irrevocable and perpetual license under our background intellectual property and our interest in the intellectual property developed under the Tesla Automation Agreement to manufacture machines relevant to the applicable work order.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Research and Option Agreement with myNEO</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On May 12, 2022, we entered into a Research and Option Agreement (&#8220;R&amp;O&#8221;) with myNEO, pursuant to which, as amended in January 2023, we will collaborate to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets, its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response. Under the R&amp;O, we aim to develop and commercialize at least two new medicinal products for the treatment of non-small cell lung cancer and melanoma (the &#8220;Main Indications&#8221;) and potentially other indications. We are required to use commercially reasonable efforts to develop at least one product for each of the Main Indications, to file marketing approval applications for such products and commercialize such products in at least one of certain countries. Under the R&amp;O, myNEO will own all intellectual property rights generated solely by myNEO or jointly with us during the first three phases of the R&amp;D plan (the &#8220;R&amp;D Project IP&#8221;). We received a non-exclusive, royalty-free, non-assignable, sublicensable, worldwide license under certain patents and know-how owned by myNEO and R&amp;D Project IP to the extent required to perform our research and development obligations under the agreement until the completion of a certain phase of the R&amp;D plan. We were also granted with an exclusive option to acquire all of myNEO&#8217;s rights under certain R&amp;D Project IP relating to certain target lists, which we exercised on April 12, 2023. In connection with our exercise of such option, we granted myNEO a non-exclusive, royalty-free, perpetual license back to such IP to make, use or sell certain targets in the field of patient-specific vaccines. Under the R&amp;O, myNEO agrees to work exclusively with us to develop and validate shared antigens for the Main Indications until the earlier of the date of the first phase I clinical trial for either Main Indication or 24 months after we exercised our option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the R&amp;O, we paid myNEO an upfront one-time technology access fee of &#8364;138,000 and myNEO is eligible to receive up to &#8364;17.5 million in research and development milestone payments with respect to the Main Indications, up to &#8364;175,000 in research and development milestones payments with respect to indications other than the Main Indications, up to &#8364;30 million in commercial milestone payments with respect to the Main Indications and up to &#8364;7.5 million in commercial milestone payments with respect to indications other than the Main Indications, as well as low single-digit percentage royalties on the net sales of licensed products in the Main Indications and sub single-digit percentage royalties on the net sales of licensed products for indications other than the Main Indications. Our royalty obligations continue on a product-by-product and country-by-country basis until the earlier of the date when there are no valid patent claims covering such licensed product in such country and 10 years following the date of first commercial sale of such licensed product in such country. On October 9, 2023, we notified myNEO that we reached a research and development milestone where we selected four antigens for further development, which we intend to use in a clinical candidate for the indication head and neck squamous-cell carcinoma, which is an indication other than the Main Indication.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The term of the R&amp;O will continue until (i) the expiration of the option period if we do not exercise any of our exclusive options or (ii) the expiry of all applicable royalty payment obligations to myNEO, unless terminated earlier by either party. We have the right to terminate the R&amp;O if certain milestones or if provisions of certain reports are delayed by a certain period, for convenience or in the case of a change of control of myNEO. We and myNEO both have the right to terminate the R&amp;O in the event of the other party&#8217;s material breach following a cure period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Sponsored Collaboration Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Schepens Institute Research Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In March 2019, we entered into a sponsored research agreement, as amended in April 2020, July 2021, September 2021, August 2022, January 2023, June 2023 and February 2024 (as amended, the &#8220;Schepens Agreement&#8221;), with The Schepens Eye Research Institute, Inc. (&#8220;SERI&#8221;) and Massachusetts Eye and Ear Infirmary (&#8220;MEEI&#8221;), pursuant to which SERI and MEEI agreed to perform certain research activities for mRNA-based eye therapy candidates. Under the Schepens Agreement, SERI and MEEI granted us an exclusive option to initiate negotiations for an exclusive or non-exclusive license to SERI&#8217;s interest in any inventions developed under the Schepens Agreement. SERI and MEEI additionally granted us an exclusive option to negotiate an exclusive license to certain background intellectual property. Upon the exercise of such option and upon execution of the contemplated license, we would be required to pay SERI a $30,000 upfront payment, up to $0.8 million in development milestone payments and $1.8 million in regulatory milestone payments, and a low single-digit percentage royalty on net sales subject to certain minimum annual payments. We are required to provide $1.7 million in funding to SERI and MEEI in multiple payments during the term of the Schepens Agreement. As of December 31, 2023, we have provided $2.0 million in funding to SERI and MEEI under the Schepens Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each party will solely own inventions it solely develops and will jointly own jointly developed inventions. We are responsible for all patent prosecution costs regarding intellectual property developed under the Schepens Agreement, and if we elect not to cover the prosecution costs for such intellectual property, SERI and MEEI will have the right to license such intellectual property to third parties, and we will have no rights in such intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 7pt 0pt;">The Schepens Agreement continues until June 2024, unless extended by mutual agreement or earlier terminated. Both parties have the right to terminate the Schepens Agreement for the other party&#8217;s material breach following a cure period, and SERI has the right to terminate in the event of our insolvency. We additionally have the right to terminate the Schepens Agreement for convenience following a notice period. In the event SERI terminates for our material breach or insolvency or we terminate for convenience, we must reimburse SERI for all costs incurred to date and provide certain additional funding for a three-month period. In the event we terminate for SERI&#8217;s material breach, we must reimburse SERI for all noncancellable commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">Advance Purchase Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">European Commission&#8201;&#8212;&#8201;COVID-19 Vaccine Candidate</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 18pt;"><i style="font-style:italic;">Advance Purchase Agreement for our COVID-19 Vaccine Candidate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 7pt 0pt;">On November 30, 2020, we entered into an APA with the EC, acting on behalf and in the name of all Member States of the European Union, which provided for the advance purchase by the Member States of 225 million doses of the vaccine to be allocated among the Member States, and the option to purchase up to an additional 180 million doses. Pursuant to the APA, we received an upfront payment of &#8364;450 million. Such upfront payment had to be used solely for the development and commercial supply of CVnCoV. We were required to return any unspent amounts of the upfront payment if, among others, we failed to successfully develop CVnCoV, or if we successfully develop CVnCoV without receiving EU marketing authorization, or if we failed to supply any doses of CVnCoV to any of the Member States by late 2021 (unless we and the EC mutually agree to a later date). In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, we would only be required to return any unspent amount of the upfront payment. In the context of the APA, &#8220;spent&#8221; means either costs incurred or commitments made in connection with the purposes set forth in the APA. On March 8, 2022, we received a letter signed by the EC acknowledging and outlining that we will not be required to return any portion of the upfront payment. Due to the termination of the APA, we will not receive any further payments related to the APA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In other respects, upon the EC&#8217;s request, we will transfer any raw materials and/or primary components paid for with the upfront payment that were not used as of the termination date. Additionally, should the EC request, or should we successfully sell, any raw materials and/or primary components, then an applicable portion of such raw materials, primary components or proceeds, as the case may be, will be remitted to the EC. This repayment agreement expired at the end of 2022 and an amount of &#8364;4.1 million was paid to the EC as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">Pandemic Preparedness Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 7pt 9.35pt;">Federal Republic of Germany</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 7pt 0pt;"><i style="font-style:italic;">Pandemic Preparedness Agreement with the Federal Republic of Germany</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 7pt 0pt;">On February 20, 2022, the CureVac-GSK Consortium submitted its best and final offer in the Tender Procedure for the conclusion of framework agreements for the provision of production capacities and, on demand, for the production and supply of mRNA vaccines (lot 1). On April 8, 2022, the CureVac-GSK Consortium received a letter from the Federal Republic of Germany&#8217;s counsel confirming that the CureVac-GSK Consortium had been awarded a Pandemic Preparedness Agreement. Pursuant to the Pandemic Preparedness Agreement, the CureVac-GSK Consortium will have to achieve, within a two years&#8217; time frame beginning from the award of the Pandemic Preparedness Agreement, a state in which it is considered qualified to provide manufacturing capacities in Germany for 160 million doses of mRNA vaccine per year, including procurement of the required nonproduct specific manufacturing licenses and insurances and to have achieved &#8220;pandemic preparedness,&#8221; which means, inter alia, that we maintain the GMP IV facility in a stand-by mode that can be activated for manufacture of a so-called selected vaccine at any time and that the CureVac-GSK Consortium is complying with the material requirements set out in the Pandemic Preparedness Plan (in particular with the requirements regarding the assurance of a supplier network and the availability of the critical supplier products).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If qualification and pandemic preparedness is achieved by the end of the two years&#8217; time frame beginning from the award of the Pandemic Preparedness Agreement (and if the Pandemic Preparedness Agreement is not terminated because the CureVac-GSK Consortium does not have an mRNA-based vaccine for which a marketing authorization for the (at least temporary) placing on the German market has been granted at this time), the CureVac-GSK Consortium will receive a stand-by fee which will be shared between us and GSK in accordance with the agreement governing the CureVac-GSK Consortium. The phase following the qualification phase (stand-by phase) during which pandemic preparedness is to be maintained is for five years, it being understood that this term may be extended by mutual agreement up to three times for a subsequent one-year renewal term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At any time during the stand-by phase, in case there is a public health emergency, the Federal Republic of Germany may exercise its preferred purchase right and/or its preferred manufacturing right. If the preferred purchase right is exercised the CureVac-GSK Consortium will have to deliver up to 80 million doses of the mRNA vaccine of the CureVac-GSK Consortium, and if the preferred manufacturing right is exercised the CureVac-GSK Consortium will have to act as a contract manufacturer and manufacture a third party&#8217;s mRNA vaccine in our GMP IV facility. However, there are strict and narrow requirements to be fulfilled before the Federal Republic of Germany may exercise the preferred manufacturing right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 9, 2024, the CureVac-GSK Consortium notified the Federal Republic of Germany of its termination of the Pandemic Preparedness Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates, and our core technologies and other know-how, defend and enforce our patents, preserve the confidentiality of our trade secrets, operate our business without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties and prevent third parties from infringing, misappropriating or otherwise violating our proprietary or intellectual property rights. We seek to protect our proprietary and intellectual property position by, among other methods, seeking and maintaining patents in the United States and other major markets. We also rely on trade secrets and know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, which we generally seek to protect through contractual obligations with third parties.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Patents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 19 2024, we own approximately 103 issued U.S. patents, 116 pending U.S. patent applications, 170 issued foreign patents (including 43 European patents, which have been validated in various European countries resulting in a total of approximately 395 national patents in European countries and including two European patents with unitary effect), 410 pending foreign patent applications (including 74 pending European patent applications) and 18 pending Patent Cooperation Treaty, or PCT, patent applications, including several patent families that are jointly owned with third parties. These patents include claims relating to our RNAoptimizer technology platform, and our COVID-19 and Influenza vaccine candidates, and our proprietary LNP technology, as described further below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">RNAoptimizer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 19, 2024, we own 23 issued U.S. patents, 20 pending U.S. patent applications, 92 issued foreign patents, including in Europe, Canada, China, India, Israel, Japan, the Republic of Korea, Singapore, Mexico and Australia, and 90 pending foreign patent applications and three PCT patent applications relating to our RNAoptimizer technology, including patents and patent applications relating to ORF optimization, UTR optimization, novel CAP analogs, protein optimization and formulation. Our RNAoptimizer technology is used in our Influenza and SARS-CoV-2 product candidates. The issued patents are expected to expire between 2025 and 2037, excluding any additional term for patent term adjustments or patent term extensions. If granted, the pending patent applications would be expected to expire between 2022 and 2044, excluding any additional term for patent term adjustments or patent term extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Influenza Vaccine candidates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 19, 2024, we own 11 issued U.S. patents, 17 pending U.S. patent applications, 49 issued foreign patents, including in Europe, Canada, China, India, Israel, Japan, the Republic of Korea, Singapore, Mexico and Australia and 49 pending foreign patent applications and one PCT patent application relating to our Influenza product candidates. The issued patents are expected to expire between 2022 and 2038, excluding any additional term for patent term adjustments or patent term extensions. If granted, the pending patent applications would be expected to expire between 2022 and 2043, excluding any additional term for patent term adjustments or patent term extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">COVID-19 Vaccine Candidates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 19, 2024, we own 14 issued U.S. patents, 17 pending U.S. patent applications, 47 issued foreign patents, including in Europe, Canada, China, India, Japan, the Republic of Korea, Singapore, Russia, Mexico and Australia, 80 pending foreign patent applications and one PCT patent application relating to our COVID-19 product candidates. The issued patents are expected to expire between 2022 and 2041, excluding any additional term for patent term adjustments or patent term extensions. If granted, the pending patent applications would be expected to expire between 2022 and 2043, excluding any additional term for patent term adjustments or patent term extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we have filed patent applications, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted for a portion of the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations and provided statutory and regulatory requirements are met. For more information on patent term extension, see &#8220;&#8212; Government Regulation&#8201;&#8212;&#8201;Patent Term Restoration and Extension.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our owned and licensed pending patent applications, and any patent applications that we may in the future file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive in the future may be challenged, invalidated, narrowed, held unenforceable, infringed or circumvented. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. See &#8220;Item 3. Key Information &#8212; D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property Rights.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Trademarks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of April 2, 2024, we own trademark registrations or registration applications for CureVac, and the CureVac logo in the United States and in certain foreign jurisdictions including Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Trade Secrets and Proprietary Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and know-how can be difficult to protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality, and invention assignment agreements with our employees, consultants, and independent contractors. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee, however, that we have executed such agreements with all applicable counterparties, such agreements will not be breached, or that these agreements will afford us adequate protection of our intellectual property and proprietary rights. See &#8220;Item 3. Key Information &#8212; D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property Rights.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, in other countries and jurisdictions and in the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological products. In addition, some jurisdictions regulate the pricing of pharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other requirements of regulatory authorities, require the expenditure of substantial time and financial resources.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Patent Term Restoration and Extension</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of FDA approval of product candidates, some of a sponsor&#8217;s U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period generally is one-half the time between the effective date of an IND and the submission date of a BLA less any time the sponsor did not act with due diligence during the period, plus the time between the submission date of a BLA and the approval of that application less any time the sponsor did not act with due diligence during the period. Only one patent applicable to an approved biologic product is eligible for the extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended, and the application for the extension must be submitted prior to the expiration of the patent. Moreover, a given patent may only be extended once based on a single product. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. For more information regarding the risks related to our intellectual property, see &#8220;Item 3. Key Information &#8212; D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property Rights.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Regulation and Procedures Governing Approval of Biological Products in the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, we expect our product candidates will be regulated as biological products, or biologics, under the Public Health Service Act, or PHSA, and the Federal Food, Drug, and Cosmetic Act, or FDCA, and their implementing regulations, and other federal, state, local and foreign statutes and regulations. The failure to comply with the applicable U.S. requirements at any time during the product development process, including during nonclinical testing, clinical testing, the approval process or post-approval process, may subject an applicant to delays in the conduct of a study or regulatory review and approval, and/or to administrative or judicial sanctions and adverse publicity. Sanctions may include, but are not limited to, the U.S. Food and Drug Administration, or FDA&#8217;s, refusal to allow an applicant to proceed with clinical testing, refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, debarment, disgorgement of profits and civil or criminal investigations and penalties brought by the FDA or the Department of Justice or other governmental entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nonclinical laboratory tests, animal studies and formulation studies all performed in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an Institutional Review Board, or IRB, or ethics committee representing each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance with applicable regulations, including with GCP regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">after completion of all pivotal clinical trials, preparation and submission to the FDA of a BLA requesting authorization to market the product candidate for one or more proposed indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, safety, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of any FDA audits of the clinical study sites to assure compliance with GCPs, and the integrity of clinical data in support of the BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees and securing FDA approval of the BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including the potential requirement to implement a REMS and to conduct any post approval studies required by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Nonclinical Studies and Investigational New Drug Application</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before testing any biologic product candidate in humans, the product candidate must undergo nonclinical testing. Nonclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as animal studies to evaluate the potential for activity and toxicity. The conduct of the nonclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the nonclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, are submitted to the FDA as part of an IND or similar application in other jurisdictions. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and&#160;<i style="font-style:italic;">in vitro</i>&#160;studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless within the 30-day time period, the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and places the trial on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, submission of the IND may result in the FDA not allowing the trial to commence or not be conducted on the terms originally specified by the sponsor in the IND. In addition, the FDA may raise concerns or questions at any time after the IND has become effective, and may impose a clinical hold even after clinical studies have initiated. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. A clinical hold issued by the FDA may therefore delay either a proposed clinical study or cause suspension of an ongoing study, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigation may proceed. This could cause significant difficulties in completing planned clinical trials in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Human Clinical Trials in Support of a BLA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, dosing procedures and the effectiveness criteria to be evaluated. A separate protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of the BLA so long as the clinical trial is well-designed and well-conducted in accordance with GCP, including review and approval by an independent ethics committee, and the FDA is able to validate the study data through an onsite inspection, if necessary.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of human subjects. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements, the trial is unlikely to meet its stated objectives or that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules, including the requirements for informed consent. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated check points based on access to certain data from the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;1 clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as in the case of some products for severe or life-threatening diseases as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase&#160;2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger Phase&#160;3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;3 clinical trials proceed if the Phase&#160;2 clinical trials demonstrate that a certain dose or dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase&#160;3 clinical trials are undertaken within an expanded patient population, often at geographically dispersed clinical trial sites, to gather additional information about safety and effectiveness necessary to evaluate the overall benefit-risk relationship of the investigational product and to provide an adequate basis for physician labeling and product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase&#160;4 clinical trials, or Phase 4. These studies may be used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting required Phase&#160;4 clinical trials could result in withdrawal of approval for products. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or&#160;<i style="font-style:italic;">in vitro</i>&#160;testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological candidate has been associated with unexpected serious harm to patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Review and Approval of a BLA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results of product candidate development, nonclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting a license to market the product for one or more indications. The BLA must contain extensive chemistry manufacturing and controls information and detailed information on the composition of the product and proposed labeling. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a substantial user fee to the FDA, and the sponsor of an approved BLA is also subject to annual program fees. The FDA adjusts the Prescription Drug User Fee Act, or PDUFA, user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act, or FDASIA, requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days after an end-of-Phase&#160;2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has 60&#160;days after submission of the application to conduct an initial review to determine whether the BLA is sufficient to accept for filing based on the agency&#8217;s threshold determination that it is substantially complete so as to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to complete its initial review of a standard application and respond to the applicant within 10&#160;months of the 60-day filing date, and for a priority review application within six&#160;months. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and its review goals are subject to change from time to time. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may also be extended by three&#160;months if the FDA requests or if the applicant otherwise provides additional information or clarification regarding information already provided in the submission within the last three&#160;months before the PDUFA goal date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA reviews a BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP requirements to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the application is not approved, the FDA may issue a complete response letter indicating that the review cycle is complete and the application is not ready for approval. A complete response letter will describe the deficiencies that must be addressed in order to secure final approval of the application, and when possible, will outline recommended actions the sponsor might take to obtain approval of the application. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. The FDA may also request additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sponsors that receive a complete response letter who elect to address the deficiencies may submit to the FDA information that represents a complete response to the issues identified by the FDA in the response letter. Such resubmissions are classified under PDUFA as either Class&#160;1 or Class&#160;2, based on the information submitted by an applicant in response to an action letter. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to review and act on a Class&#160;1 resubmission with two&#160;months of receipt and, with respect to a Class&#160;2 resubmission, within six&#160;months of receipt. The FDA will not approve an application until issues identified in the complete response letter have been addressed. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the FDA approves a new product, it may limit the approved indications for use of the product, or limit the approval to specific dosages. It may also require development of adequate controls or specifications and that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase&#160;4 clinical trials, to further assess the product&#8217;s safety after approval and may limit further marketing of the product based on the results of these post-marketing studies. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. Once approved, the FDA may withdraw the product approval if compliance with pre-and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Expedited Development and Review Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has a number of programs intended to expedite the development and/or review of new products intended for serious or life-threatening diseases or conditions. These programs include fast track designation, breakthrough therapy designation, priority review and accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may issue a fast track designation to a product candidate if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic may request that the FDA designate the biologic as a fast track product at any time during the clinical development of the product. For fast track products, sponsors may have greater interactions with the FDA during product development. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. However, the FDA&#8217;s PDUFA goal for reviewing a BLA fast track application does not begin until the last section of the application is submitted. Fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to facilitate the design of clinical trials in an efficient manner. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase&#160;1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes and evidence of safety and effectiveness in a new subpopulation. A priority review is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on an original BLA from 10&#160;months to six&#160;months from the 60-day filing date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has stated that although it has limited experience with accelerated approvals based on intermediate clinical endpoints, such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, may lead the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fast track designation, priority review, accelerated approval, and breakthrough therapy designation may expedite the development or approval process, but do not change the standards for approval. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Post-Approval Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval for marketing of a product or for a new indication for an existing product is obtained, the sponsor will be required to comply with rigorous and extensive post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed on the particular product as part of the approval process. The sponsor will be required, among other things, to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising, promotional labeling, product sampling and distribution. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the BLA-holder and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we or our partners may decide to use. In addition, changes to the manufacturing process or facility are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market study requirements or clinical trial requirements to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, untitled letters or warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions, fines, debarment, disgorgement of profits or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates marketing, labeling, advertising and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict marketing authorization holders&#8217; communications on the subject of off-label use of their products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a disease or condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making available the product for the disease or condition will be recovered from sales of the product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation qualifies a company for certain financial incentives, including tax advantages, waiver of the BLA application user fee and, if the product receives the first FDA approval for the indication for which it has orphan designation, market exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven&#160;years from the approval of the BLA, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first product. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor, the manufacturer makes a showing of clinical superiority over the product with orphan exclusivity, or the sponsor is unable to provide sufficient quantities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An orphan-designated product may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan exclusivity in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Biosimilars and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The BPCIA (under the Affordable Care Act) created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approve of biosimilars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product, and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Regulation and Procedures Governing Approval of Medicinal Products in the European Union</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In order to market any product outside the United States, a company also must comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can initiate clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical development, nonclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the medicinal product for each proposed indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt 0pt 11pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Clinical Trial Approval</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 31, 2022, the new Clinical Trial Regulation (EU) No 536/2014 became effective, replacing Clinical Trials Directive 2001/20/EC (which can still be applied for new clinical studies during a transition period until January 2023). This new legislation, which is directly applicable in all Member States, aims at simplifying and streamlining the approval of clinical trials in the European Union by allowing for a streamlined application procedure via a single-entry point and strictly defined deadlines for the assessment of clinical trial applications. The Clinical Trial Regulation harmonizes the assessment and supervision processes for clinical trials throughout the European Union, via a Clinical Trials Information System, or CTIS, which contains the centralized European Union portal and database for clinical trials foreseen by the Regulation. The EMA sets up and maintains CTIS, in collaboration with the competent national authority of each European Union Member Sate and the EC.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Marketing Authorization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must obtain Marketing Authorization, or MA. There are two types of MAs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Community MA, which is issued by the EC through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy medicinal products (such as gene therapies, somatic cell therapies and tissue engineered products), and medicinal products that contain a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the Centralized Procedure the maximum time frame for the evaluation of a marketing authorization application is 210&#160;days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when the authorization of a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. Under the accelerated procedure the standard 210-day review period is reduced to 150&#160;days.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in other Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An MA may be granted only to an applicant established in the European Union. Regulation&#160;1901/2006 on Medicinal Products for Pediatric Use provides that prior to obtaining a marketing authorization in the European Union in the centralized procedure, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a deferral for one or more of the measures included in the Pediatric Investigation Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The European Union also provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, new chemical entities generally receive eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic or biosimilar application. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Periods of Authorization and Renewals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A marketing authorization is valid for five&#160;years, in principle, and it may be renewed after five&#160;years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing Member State. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the EC or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the product on the European Union market (in the case of the centralized procedure) or on the market of the authorizing Member State within three&#160;years after authorization ceases to be valid.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Requirements After Marketing Authorization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s cGMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of products to assure their safety and identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the European Union under Directive 2001/83.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulation&#160;141/2000 and Regulation&#160;847/2000 provide that a product can be designated as an orphan drug by the EC if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1)&#160;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2)&#160;a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the product in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the product has to be of significant benefit compared to products available for the condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Orphan drugs also benefit from a 10-year period of market exclusivity. During this market exclusivity period, neither the EMA nor the EC or the Member States can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six&#160;years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior, the applicant consents to a second orphan medicinal product application, or applicant cannot supply enough orphan medicinal product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coverage, Pricing and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. Even if our product candidates are approved for marketing, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States (such as Medicare and Medicaid), commercial health insurers, and managed care organizations, provide coverage and establish adequate reimbursement levels for such product candidates. In the United States, the Member States of the European Union and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Reimbursement rules and levels are not harmonized in the European Union and therefore differ from Member State to Member State. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the price and examining the medical necessity and cost effectiveness of medical products and services and imposing controls to manage costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, and the cost of these studies would be in addition to the costs required to obtain FDA or other comparable marketing approvals. Even after pharmacogenomic studies are conducted, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. For example, the payor may require co-payments that patients find unacceptably high. Further, one payor&#8217;s determination to provide coverage for a product does not assure that such coverage will continue or that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be adequate to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. The insurance coverage and reimbursement status of newly approved products for orphan diseases is particularly uncertain, and failure to obtain or maintain adequate coverage and reimbursement for any such product candidates could limit a company&#8217;s ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The containment of healthcare costs also has become a priority of federal, state and foreign governments as well as other third-party payors such as statutory health insurance funds and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented or coverage may be ended in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, we will face challenges in ensuring obtaining adequate coverage and payment for any product candidates we may develop. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities or other third-party payors such as statutory health insurance funds can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular product candidate to currently available therapies (so-called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union Member States may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union Member States and parallel trade (arbitrage between low-priced and high-priced Member States) can further reduce prices. Special pricing and reimbursement rules may apply to orphan drugs. Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any product. Acceptance of any medicinal product for reimbursement may come with cost, use and often volume restrictions, which again can vary by country. In addition, results based rules of reimbursement may apply. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Laws and Regulations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Our current and future arrangements with providers, researchers, consultants, third-party payors and customers are subject to broadly applicable federal and state fraud and abuse, anti-kickback, false claims, physician payment transparency and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations include, without limitation, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in cash or in-kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to be made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government. Moreover, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the CMS, within the HHS, information related to payments and other transfers of value made by that entity to physicians (as defined by statute), certain other healthcare providers beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs and which may be used in the calculation of reimbursement and/or discounts on marketed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Violations of these laws can subject us to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, reputational harm, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Data Privacy and Cybersecurity Laws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We may be subject to, or our marketing activities may be limited by, HIPAA and its implementing regulations, which established uniform standards for certain covered entities (healthcare providers, health plans and healthcare clearinghouses) governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of protected health information, including, among other requirements, mandatory contractual terms and technical safeguards to protect the privacy, security and transmission of protected health information and notification to affected individuals and regulatory authorities in the event of certain breaches of security of protected health information. The American Recovery and Reinvestment Act of 2009, commonly referred to as the economic stimulus package, included sweeping expansion of HIPAA&#8217;s privacy and security standards called the Health Information Technology for Economic and Clinical Health Act, or HITECH, which became effective on February&#160;17, 2010. Among other things, the HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, or independent contractors or agents of covered entities, that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Even when HIPAA does not apply, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce and be construed as a violation of Section&#160;5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C &#167;&#160;45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards and the FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">State laws may be more stringent, broader in scope or offer greater individual rights with respect to protected health information, or PHI, than HIPAA, and state laws may differ from each other, which may complicate compliance efforts. By way of example, the California Consumer Privacy Act as amended by the California Privacy Rights Act, or CCPA, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. The CCPA also creates a new state agency that will be vested with authority to implement and enforce the CCPA. In addition, other states may choose to adopt more stringent privacy legislation, which could increase our potential liability and compliance costs and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, we may be subject to strict data protection regulations, in particular with regard to health data of individuals pursuant to Art. 4 Nr. 15 of the GDPR, effective since May&#160;25, 2018. The GDPR, together with national legislation, regulations and guidelines of the European Union Member States and the United Kingdom governing the processing of personal data, impose strict obligations with respect to, and restrictions on, the collection, use, retention, protection, disclosure, transfer and processing of personal data. In particular, the GDPR includes obligations and restrictions concerning the consent and rights of data subjects, the transfer of personal data to countries outside the European Union, security breach notifications, and other requirements concerning the security and confidentiality of personal data. For example, in 2016, the European Union and United States agreed to a transfer framework for data transferred from the European Union to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July&#160;2020 by the Court of Justice of the European Union. The standard contractual clauses issued by the European Commission for the transfer of personal data may be similarly invalidated by the Court of Justice of the European Union. On June 4, 2021, the European Commission adopted new standard contractual clauses, which impose on companies additional obligations relating to data transfers, including the obligation to conduct a transfer impact assessment and, depending on a party&#8217;s role in the transfer, to implement additional security measures and to update internal privacy practices. It remains to be seen whether these standard contractual clauses will remain available and whether additional means for lawful data transfers will become available. The GDPR imposes special requirements concerning the protection of special categories of personal data which include health and genetic information of data subjects. These special categories of data may only be processed under certain circumstances, including if the data subject consented to such processing or if (i)&#160;processing is necessary in order to protect vital interests of the data subject or of another natural person, insofar as the data subject is unable to provide consent for physical or legal reasons; (ii)&#160;the data concerned have manifestly been made public by the data subject; (iii)&#160;processing is necessary in order to assert, exercise or defend legal claims; or (iv)&#160;processing is necessary for the purposes of scientific research and to ensure that any additional requirements under applicable data protection laws, including national legislation, regulations and guidelines, are met.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Therefore, we may be subject to and our marketing activities may be limited by the regulations regarding the data protection of individuals according to the GDPR, the German Federal Data Protection Act and other applicable data protection laws. These regulations could also restrict the transfer of data from European Union member states to the United States. The general transfer of personal data outside of the European Union is prohibited unless the conditions laid out in Art. 44 et. seq. of the GDPR are fulfilled and an adequate level of data protection can be ensured. Currently the United States is not considered to be a country with an adequate level of data protection, and further contractual arrangements must be adopted to permit the international transfer of personal data to the United States. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the European Union. Guidance on implementation and compliance practices is regularly updated or otherwise revised. The GDPR has increased our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the relevant data protection regimes. Separately, Brexit could also lead to further legislative and regulatory changes and increase our compliance costs. As of January 1, 2021, and the expiry of transitional arrangements agreed to between the United Kingdom and the European Union, data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June 28, 2021, the European Commission adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from European Union member states to the United Kingdom without additional safeguards. However, the United Kingdom adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or extends that decision. For more information regarding the risks related to data security and privacy, see &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Business and Industry.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We participate in an industry that is characterized by a rapidly growing understanding of disease biology, quickly changing technologies, strong emphasis on proprietary products, and a multitude of companies involved in the creation, development and commercialization of novel therapeutics. These companies are highly sophisticated and often collaborate strategically with each other.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We are developing a broad portfolio of product candidates that, coupled with our capabilities across mRNA technology, development and manufacturing, we believe position us at the forefront of targeted immune active and immune silent mRNA-based medicines. However, we compete with a wide range of pharmaceutical companies, biotechnology companies, academic institutions and other research organizations for novel therapeutic targets, new technologies, talent, financial resources, intellectual property rights and collaboration opportunities. As such, many of our competitors and potential competitors have substantially greater scientific, research and product development capabilities as well as greater financial, manufacturing, marketing and human resources than we do. In addition, there is intense competition to establish clinical trial sites and register patients for clinical trials. Many specialized biotechnology firms have formed collaborations with large, established companies to support the research, development and commercialization of products that may be competitive with ours. Accordingly, our competitors may be more successful than we may be in developing, commercializing and achieving widespread market acceptance. In addition, our competitors&#8217; products may be more effective or more effectively marketed and sold than any treatment we or our development partners may commercialize and may render our product candidates obsolete or noncompetitive before we can recover the expenses related to developing and commercializing any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are additional companies that are working on potential mRNA medicines. Companies with clinical programs with mRNA include BioNTech/Pfizer, Moderna, eTheRNA Immunotherapies, Translate Bio, GlaxoSmithKline Sanofi, AstraZeneca, Merck &amp; Co. and Arcturus Therapeutics and those programs include, Ethris and Genevant Sciences. In COVID-19, our monovalent vaccine candidate, CV0601, and in seasonal influenza our multivalent vaccine candidate are currently the main focus of other pharmaceutical companies, some with more considerable capital resources than ours. For example, a limited number of products that utilize mRNA as a prophylactic vaccine against COVID-19 have been approved by the FDA, EMA and other regulatory agencies.. For influenza, no mRNA-based vaccine has been approved so far with the current standard-of-care being well-established protein-based vaccines. Thus, we expect intense competition for our vaccine candidates from other pharmaceutical companies not limited to the field of mRNA medicines. In addition, the oncology therapeutics landscape in general is highly competitive and includes large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. It includes both competition from marketed therapies as well as potential new therapeutics in development. We may compete with products with different mechanisms of action as well as against established standards of care. We expect our intratumoral immunotherapy candidates for the treatment of solid tumors to face direct competition from companies such as Moderna and BioNTech in collaboration with Sanofi in addition to several non-mRNA-based approaches.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:159.73pt;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">C.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Organizational Structure</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a holding company, and our sole asset is the capital stock of our wholly owned subsidiaries. Our major subsidiaries are listed under Exhibit 8.1 filed herewith.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">D.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Property, Plant and Equipment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Manufacturing Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an integrated biopharmaceutical company with in-house manufacturing capabilities and expertise. We consider our manufacturing process an important part of our strategy that allows us to continuously improve our technology platform and maintain flexibility in clinical development and allow us to manufacture potential future commercial products. The close interaction of our technical development and research teams enables us to rapidly implement innovations and robustness to the manufacturing process. We control the critical steps of manufacturing in-house and also collaborate with manufacturing organization partners. Both of which allow us to drive innovation and to maintain flexibility, and in turn allows us to pivot quickly in pandemic settings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of our mRNA-based active ingredients for various fields of application originate from a common technology platform and are based on identical source materials. This enables us to produce all mRNA therapies using a platform process concept. Given the differences in the encoded protein only require alterations of the sequence of the mRNA molecule, leaving its physicochemical characteristics largely unaffected, we can use the same mRNA production strategy applying the same unit operations for diverse products. This allows us to save time and reduce costs compared to other manufacturing processes. Our approach supports a seamless production concept based on our experience and know-how in mRNA manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Our GMP Manufacturing Facilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f050.jpg" alt="Graphic" style="display:inline-block;height:159.73pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:428.82pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:171.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have continued to invest significantly in building and expanding our manufacturing capabilities since 2006. We currently have the capacity to produce early and late-stage clinical trial RNA material and potential future commercial lots. Since 2006, we have manufactured thousands of mRNA constructs, from high throughput and small amounts for discovery and preclinical development to GMP compliant products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are currently operating three GMP-certified suites. Our GMP I and II facilities were designed to run up to 14 different products in parallel, using a lab-scale process. The facilities cover all steps from starting material pDNA, through mRNA manufacturing to formulated bulk. Our GMP I and II facilities are dedicated to providing supplies for early clinical development (Phase 1 and 2), with capacity to produce multiple batches per year. In 2019, we expanded our production capacity to meet the increasing demands for clinical studies and potential future initial commercial supply by adding a GMP III facility. Our GMP III facility allows us to achieve additional scale and reduce manufacturing process time. This facility focuses on the production of mRNA, and formulated bulk. We currently use our GMP/II facility and CMOs for starting material plasmid DNA (pDNA). The GMP III facility is intended to provide supply for early to late-stage clinical studies and initial potential market supply and is based on a new scalable process design compared to our GMP I and II facilities. We are currently in the process of certifying a GMP IV facility (shown in the picture below), which is being designed to cover all manufacturing steps from starting material (pDNA) to formulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f051.jpg" alt="Graphic" style="display:inline-block;height:171.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:250.39pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">GMP IV facility</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">The RNA Printer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to our GMP I-IV manufacturing facilities, we are operating an integrated and highly automated production unit, The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is a GMP-grade end-to-end system that is being designed to downscale, accelerate and automate the manufacturing process. The fully synthetic production process allows us to have rapid manufacturing of products and offer reproducibility and high standardization. It includes automated cleaning and sanitization in place procedures and continuous process verification. The current setup covers DNA and RNA production for automated downstream and upstream production up to drug substance. We have obtained a Manufacturing License for a mRNA in the cancer vaccine development program to support CureVac&#8217;s oncology strategy from the regional authority in Baden-W&#252;rttemberg as announced in November 2023. In April 2024, we announced that the system was also granted a Framework License from the same authority that significantly broadens its regulatory freedom and flexibility to manufacture different mRNA vaccine candidates. The regulatory approval process for the formulation Module is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvac-20231231x20f052.jpg" alt="Graphic" style="display:inline-block;height:236.79pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:335.1pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The RNA Printer</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The key characteristics of The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> are rapid throughput, easy operator access to equipment, sophisticated precision control software and data capture, and the small footprint that allows for easy decentralization. We view The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> as complementary to our manufacturing strategy. With its modular design and decentralized concept, we believe The RNA Printer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> could be used to facilitate broad access to mRNA technology and enable mRNA product developments, e.g. for patient access to advanced and personalized mRNA-based therapies in oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our objective is to cover the entire production stream, and we believe efficient accompanying analytics will help to rapidly produce high-quality material. All data generated during production would be collected to further improve production processes and product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our headquarters are in T&#252;bingen, Germany, Friedrich-Miescher-Strasse 15, where we occupy approximately 123,000 square feet of office and laboratory space under a sublease agreement entered into with CureVac Real Estate GmbH that started on June&#160;6, 2018. The fixed-term 15-year lease payment period began on March&#160;1, 2020. We also occupy approximately 53,000 square feet of additional office and laboratory space in T&#252;bingen, Germany, Paul-Ehrlich-Strasse 15, under sublease agreements also entered into with CureVac Real Estate GmbH, that started on February&#160;1, 2018.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since 2006, we have operated a manufacturing facility in T&#252;bingen, Germany, the first worldwide GMP-compliant mRNA production plant with two multi-product suites (GMP I and II). These facilities contain approximately 16,145 square feet of laboratory space, including 2,800 square feet of GMP facilities, and are dedicated to providing supplies for early clinical development (Phases 1 and 2 of clinical trials). In addition, we have established a third in-house production suit (GMP III) with an upscaled manufacturing process, which was certified in December 2019. We currently occupy 2,800 square feet of GMP III facility for the production of mRNA. Our GMP III facility is intended to provide supplies for our late-stage clinical studies and anticipated early market supply. These manufacturing facilities are located in T&#252;bingen, Germany, Paul-Ehrlich-Strasse 15 and are leased via the abovementioned sublease agreements entered into with CureVacManufacturing GmbH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have also constructed a new CureVac owned manufacturing facility, for a GMP production process at large scale, from starting material to formulation(GMP IV). This facility is expected to be approximately 128,000 square feet. The expected cost of completion is &#8364;171.1 million, and as of December 31, 2023, we have spent &#8364;170.6 million on completing the GMP IV facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">In addition, we lease land and small- to mid-scale buildings for our offices and laboratories in T&#252;bingen approximately 111,000 sq. feet. We occupy approximately 27,000 square feet of additional offices and laboratories in T&#252;bingen, Germany, Rosentalstrasse 15 for research and development (or Technology Department). The agreement started on March 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We lease an aggregate of approximately 337,300 square feet, in Germany, Europe and the United States. The following table summarizes information with respect to the principal facilities leased by us:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Area&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Approximate&#160;Sq.&#160;Feet)</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Germany:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">T&#252;bingen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 287,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Frankfurt am Main</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,600</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Wiesbaden</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,800</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">310,400</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Belgium:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Louvain La Neuve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,200</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,200</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Netherlands:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Amsterdam</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,800</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 8,800</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">United States:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Boston</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,900</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,900</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 337,300</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our leases expire on various dates from 2021 to 2035. The lease in Boston, United States, is held by our U.S. subsidiary, CureVac Inc. The Lease in Louvain La Neuve, Belgium, is held by our Belgian subsidiary, CureVac Belgium SA. The lease in Amsterdam, Netherlands, is held by our Dutch subsidiary, CureVac Netherlands B.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Environmental Issues</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the best of our knowledge, currently there are no foreign, federal, state or local environmental laws, rules or regulations that will materially affect our results of operations or our position with respect to our competitors. However, we can provide no assurance of the effect that any possible future environmental laws will have on our operating results.</p><a id="_117fae72_561c_4cde_ab64_1da4567d4856"></a><a id="ITEM4AUNRESOLVEDSTAFF_538213"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 4A. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0e581366_3371_4c97_b47a_d6385532d634"></a><a id="ITEM5OPERATINGANDFINANCIAL_980402"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">A.&#160;&#160;&#160;Operating Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with CureVac&#8217;s audited consolidated financial statements as of December 31, 2022 and 2023, and for the years ended December 31, 2021, 2022 and 2023, and the notes thereto, included elsewhere in this Annual Report. Financial information presented in the consolidated financial statements for periods prior to the completion of our corporate reorganization is that of CureVac AG (currently CureVac SE), our wholly owned subsidiary. The consolidated financial statements of CureVac N.V. are a continuation of the historical consolidated financial statements of CureVac AG (currently CureVac SE). CureVac AG (currently CureVac SE) was acquired by CureVac B.V., which subsequently converted into CureVac N.V. on August 14, 2020, as part of our corporate reorganization. CureVac B.V. had no assets, liabilities or contingent liabilities until the completion of our corporate reorganization. Following the corporate reorganization, CureVac N.V. became the holding company of CureVac AG (currently CureVac SE) and the historical consolidated financial statements of CureVac AG (currently CureVac SE) included in this Annual Report became the historical consolidated financial statements of CureVac N.V. The following discussion is based on our financial information prepared in accordance with IFRS as issued by the IASB, which may differ in material respects from generally accepted accounting principles in the United States and other jurisdictions. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under &#8220;Item 3. Key Information &#8212; D. Risk Factors&#8221; and elsewhere in this Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Key Factors Affecting Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that the most significant factors affecting our results of operations include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our ability to successfully pioneer a robust mRNA technology platform and develop innovative product candidates will be the primary factor affecting our future growth and development. Our approach to the discovery and development of product candidates based on mRNA technology is still being demonstrated. As such, we do not know whether we will be able to successfully develop any products. Developing novel product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. We have chosen to leverage our platform to initially focus on advancing our product candidates in the areas of prophylactic vaccines, oncology and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For more information on our proprietary technology and clinical development pipeline, see &#8220;Item 4. Information on the Company &#8212; B. Business Overview &#8212; Our Product Portfolio.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the product candidates are still in development, and we have incurred and will continue to incur significant research and development costs for preclinical studies and clinical trials. We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates. Due to our accelerated efforts to develop our first-generation backbone COVID-19 vaccine candidate, CVnCoV, we incurred research and development expenses that significantly exceeded our historical levels of research and developments expenses. Additionally, our October 2021 notification to the European Commission, or EC, of the withdrawal of our regulatory approval application for CVnCoV resulted in our recognition of several expenses, which have contributed to our increased expense levels, but which we do not expect to recur in future periods. In April 2021, we entered into a collaboration agreement with GSK for the development of a broad COVID-19 vaccine program based on our second-generation backbone. CV2CoV, a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within LNPs, is the first representative of our COVID-19 vaccine program based on the second-generation backbone and presently in the Phase 1 clinical trial, as announced on March 30, 2022. Within this COVID-19 vaccine program, we plan to extend our technology platform also to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We expect to incur significant expenses related to such second-generation backbone vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID Products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation backbone vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generation backbone for our COVID-19 vaccine candidates, such as for our second-generation backbone COVID-19 vaccine candidates or may pursue new indications with our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically funded the research and development expenses primarily through public offerings of our common stock, private placements of equity securities, convertible loans, grants from government agencies and similar bodies and payments for collaborative research and development services with strategic partners. In addition, we signed an advance purchase agreement, or APA, with the EC that provided substantial support for our efforts to advance our first-generation backbone vaccine candidate, CVnCoV. In October 2021, we notified the European Commission of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:11pt;margin:0pt 0pt 10pt 18pt;">Our and Our Collaborators&#8217; Ability to Commercialize Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our ability to generate revenue from our product candidates depends on our and our collaborators&#8217; ability to successfully advance clinical trials for our product candidates and receive regulatory approval, particularly in the United States, Europe, and other major markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that our broad portfolio of product candidates with both novel and validated targets enhances the likelihood that our research and development efforts will yield successful product candidates. Nonetheless, we cannot be certain if any of our product candidates will receive regulatory approvals. Even if such approvals are granted, we will thereafter need to maintain manufacturing and supply arrangements and engage in extensive marketing prior to generating any revenue from such products, and the ultimate commercial success of our products will depend on their acceptance by patients, the medical community and third-party payors and their ability to compete effectively with other therapies on the market. See &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to the Development, Clinical Testing and Commercialization of Our Product Candidates.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The competitive environment is also an important factor with the commercial success of our product candidates, and our ability to successfully commercialize a product candidate will depend on whether there are competing product candidates being developed or already marketed by other companies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently do not have any product candidates that have received regulatory approval. As such, we have not incurred any material commercialization expenses in connection with an approved product candidate. In February 2021, we initiated a rolling submission for our first generation COVID-19 vaccine candidate, CVnCoV, with the EMA, which was designed to allow the EMA to assess CVnCoV&#8217;s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, EMA informed us that the EMA would not start reviewing our submission for CVnCoV before the beginning of 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. Data on the efficacy of CVnCoV was generated and published in June 2021. This efficacy data did not live up to our pre-trial expectations and fell behind the efficacy of competing COVID-19 vaccine products. The application for the marketing authorization for CVnCoV was withdrawn in early October 2021, as a necessary reaction to the efficacy data as well as the concerns and uncertainties resulting from such data on the granting of a marketing authorization and the expected concerns of prescribers and patients about using a COVID-19 vaccine with a lower efficacy compared to the vaccines already available on the market. After the withdrawal of the application for a marketing authorization for CVnCoV, we have focused our efforts on second-generation mRNA vaccines. The decision is aligned with the evolving dynamics of the pandemic response toward greater need for differentiated vaccines with the gradual transition from an acute pandemic to an endemic SARS-CoV-2 environment. In connection with the regulatory approval process, and in preparation for the commercialization of a second-generation COVID-19 vaccine, we expect our expenses related to commercialization to significantly decrease in the short-term due to our past commercialization efforts for CVnCoV. However, we expect that our expenses related to commercialization will significantly increase in the long term if a second-generation COVID-19 vaccine candidate reaches late clinical stages, but we expect that this increase in expenses will be mitigated by the GSK COVID Agreement, as described below. As part of the commercialization process of CVnCoV, we also entered into strategic partnerships with Bayer for the development, production and distribution of CVnCoV. In addition, pursuant to a preliminary agreement regarding the secondary manufacturing of CVnCoV we entered into with GSK, GSK would have supported the secondary manufacturing of up to 100 million doses of CVnCoV in 2021. Additionally, we also set up an integrated European manufacturing and supply network. After our decision to withdraw CVnCoV from the regulatory approval process, we have restructured this network to focus our efforts on the second-generation mRNA vaccine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:11pt;margin:0pt 0pt 10pt 18pt;">Our Collaborations, Related License Agreements and Advance Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our results of operations have been, and we expect them to continue to be, affected by our contractual collaborations with third parties for the development and commercialization of certain of our product candidates. In addition, our future results of operation may be affected by future advance purchase agreements for our COVID-19 vaccine candidates. To date, our revenues have been recognized pursuant to license and collaboration agreements, which include upfront payments for licenses or options to obtain licenses, milestone payments, payments for product sales and payments for research and development services. Grants from government agencies or similar bodies are recognized as other operating income or as a reduction to depreciation and amortization expense recognized from assets purchased under the associated arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into strategic collaborations and license agreements with third parties. In addition, on November 30, 2020, we entered into an advance purchase agreement, or APA, with the European Commission, or EC, which provided for the advance purchase by the commission of our first-generation vaccine candidate, CVnCoV. In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA. As part of our business development strategy, we aim to increase the number of our strategic collaborations in order to derive further value from our platform and more fully exploit the potential of our collaboration and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On April 8, 2022, we received a letter from the Federal Republic of Germany&#8217;s counsel confirming that the CureVac-GSK Consortium, was awarded with the Pandemic Preparedness Agreement. On April 9, 2024, the CureVac-GSK Consortium notified the Federal Republic of Germany of its termination of the Pandemic Preparedness Agreement, effective as of May 31, 2024.  For further details on our Pandemic Preparedness Agreement, see &#8220;Item 4. Information on the Company &#8212; B. Business Overview &#8212; Pandemic Preparedness Agreement&#8221;.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain key terms of our current material collaboration and license agreements, as well as our advance purchase agreement with the EC are summarized below. For further details on our collaboration agreements, see &#8220;Item 4. Information on the Company &#8212; B. Business Overview &#8212; Collaborations&#8221; and &#8220;Item 4. Information on the Company &#8212; B. Business Overview &#8212; Advance Purchase Agreements,&#8221; respectively.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">GlaxoSmithKline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In July 2020, we entered into a Collaboration and License Agreement with GSK, which we refer to as the 2020 GSK Agreement, pursuant to which we are collaborating with GSK to research, develop and commercialize prophylactic and therapeutic non-replicating mRNA-based vaccines and antibodies targeting infectious disease pathogens. The 2020 GSK Agreement was amended and restated in April 2021, September 2021, February 2022 and March 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">GSK paid us an upfront payment of &#8364;120 million and is required to pay us a manufacturing capacity reservation fee of &#8364;30 million following a certain regulatory milestone event, which is creditable against future milestone payments. We are eligible to receive up to between &#8364;28 million to &#8364;45 million in development milestone payments, &#8364;32 million to &#8364;35 million in regulatory milestone payments and &#8364;70 million to &#8364;100 million in commercial milestone payments, depending on the product. Under the 2020 GSK Agreement, we granted GSK an exclusive option to add additional products in the field of infectious diseases to the license granted under the 2020 GSK Agreement and, upon each exercise of such option, GSK is required to compensate us for certain development costs and pay any accrued milestone payments. Additionally, GSK has the right to replace products licensed under the 2020 GSK Agreement and, if the replacement product was already under development by us, GSK must compensate us for certain development costs and pay any accrued milestone payments. We are additionally eligible to receive tiered royalty payments ranging from single-digit to low - teens percentages on net sales, subject to certain customary reductions. GSK is required to compensate us for certain development and regulatory costs we may incur in connection with performing our obligations under the 2020 GSK Agreement, and we are eligible to receive up to &#8364;20,000 in reimbursements for expenses incurred by recording or registering the licenses granted under the 2020 GSK Agreement. We retain the right to commercialize products developed under the 2020 GSK Agreement in Germany, Austria and Switzerland, as GSK&#8217;s exclusive distributor in these markets. Under any such distribution agreement to be entered into between us and GSK, we will be required to purchase supply from GSK and pay GSK a low thirties percentage royalty on net sales. Pursuant to the amendment in September 2021, we and GSK are required to complete certain development activities set forth in updated development plans. We and GSK agree to decide whether the products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Additionally, in April 2021, we entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as our second-generation COVID 19 vaccine candidates, CV0601 and CV0701. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September 2021, February 2022 and March 2022, and further amended to update the research and development plan in August 2022. Pursuant to the amendment in September 2021, we and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. We and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Under the GSK COVID Agreement, GSK paid us an upfront payment of &#8364;75 million. We and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. We and GSK will share all net profits generated from sales of GSK COVID Products, other than Combination Products (as defined therein), under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. We are eligible to receive tiered royalty payments ranging from sub-teen to mid-teen percentages on net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement we have the right to commercialize GSK COVID Products in Austria, Germany and Switzerland and if we exercise such right, our sales of GSK COVID Products, other than Combination Products will be subject to the profit share and we will be required to pay GSK a high-teen percentage royalty on net sales of all Combination Products in such countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Genmab</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2019, we entered into a Collaboration and License Agreement, which we refer to as the Genmab Agreement, with Genmab to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#8217;s proprietary antibody technology for the treatment of human diseases. We collaborated on research to identify an initial product candidate designed to express a certain Genmab proprietary antibody, and we contributed a portion of the overall costs for the development of such product candidate. In June 2023, Genmab notified us of its intent to terminate the Genmab First Program under the Genmab Agreement effective in September 2023. Such termination did not terminate the Genmab Agreement in its entirety, but rather only with respect to certain license and exclusivity provisions related to the Genmab First Program. Under the Genmab Agreement, we further grant Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under our mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Genmab Agreement, Genmab paid us a $10 million upfront fee and made a &#8364;20 million equity investment in March 2020. Genmab is additionally required to pay us up to $30 million in option exercise fees. If Genmab exercises any of its options to obtain commercial licenses for the additional mRNA antibody concepts, Genmab would fund all research and would develop and commercialize any resulting product candidates. We are additionally eligible to receive up to between $25 million and $43 million in development milestone payments, $100 million and $125 million in regulatory milestone payments and $150 million and $200 million in commercial milestone payments for each product, depending on the specific product concept. In addition, we are eligible to receive a mid single-digit to low teens percentage tiered royalty on aggregate net sales of licensed products, on a per-product basis and subject to certain customary reductions. We retain an option to participate in development and commercialization of one of the potential additional mRNA antibody product concepts under predefined terms and conditions. In the event we exercise such right, we must pay Genmab a one-time payment of $3 million and refund any option fee paid by Genmab with respect to such product. As of December 31, 2023, we have received $1 million in development cost reimbursements and we have not received any reservation, product selection, option exercise or sublicense fees or milestone or royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Arcturus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2018, we entered into a Development and Option Agreement, which we refer to as the Arcturus Agreement, with Arcturus, which provided us with access to Arcturus LNP formulation technology which we used in combination with our mRNA technology. Such agreement expired in July 2023. As of December 31, 2023, we made payments totaling $5.6 million to Arcturus reimbursing Arcturus for development costs and in connection with our FTE funding obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Acuitas</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2016, we entered into a Development and Option Agreement, which as amended we refer to as the Acuitas Agreement, with Acuitas, which provides us with access to Acuitas LNP formulation technology that we use in combination with our mRNA technology. We are required to pay Acuitas annual target reservation and maintenance fees of up to $1.4 million if we reserve the maximum number of targets permitted under the Acuitas Agreement and to reimburse Acuitas for certain costs incurred in connection with development activities and certain FTE costs. We are additionally required to pay an option exercise fee ranging from $50,000 to $2 million upon each exercise of our option to obtain a license for further development and commercialization with respect to a selected target, subject to certain additional fees ranging from $10,000 to $200,000 for the exercise of our option for certain other vaccine targets. We paid Acuitas a $5 million upfront fee in connection with an amendment to the Acuitas Agreement dated July 2020 and, upon each exercise of our option to exchange a vaccine target licensed under any non-exclusive license, we are required to pay an exchange fee of $3 million. We additionally paid Acuitas a $3 million upfront fee in connection with an amendment to the Acuitas Agreement dated December 2020 and paid two annual payments of an additional $250,000 per option to extend certain options. Under each license agreement in connection with our exercise of our option, we will additionally be required to make low single-digit percentage tiered royalty payments and must pay up to between $1.1 million and $9 million in development milestone payments, $1.3 million and $7 million in regulatory milestone payments and $1.3 million and $7 million in commercial milestone payments, depending on whether the license is exclusive or non-exclusive and the number of options exercised to date. As of December 31, 2023, we have exercised our option to obtain a non-exclusive license to 18 targets, subject to customary closing conditions. As of December 31, 2023, we have paid Acuitas $9.7 million in reservation and option exercise fees, $0.6 million in license maintenance fees and $1.75 million for certain options not yet exercised and have made payments totaling $9.0 million reimbursing Acuitas for development costs and LNP batches and in connection with our FTE funding obligations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For each option that we have exercised under the Acuitas Agreement, we have entered into a non-exclusive license agreement with Acuitas with respect to such optioned target, all based on the same form agreement, which we refer to as the Acuitas License Agreements. We are required to pay Acuitas up to between $1.1 million and $1.6 million in development milestone payments, $1.3 million and $1.8 million in regulatory milestone payments and between $1.3 million and $1.8 million in commercial milestone payments under each Acuitas License Agreement. We must pay Acuitas annual fees ranging from $5,000 to $10,000 for any additional protein targeted by a vaccine product licensed under each Acuitas License Agreement after a certain milestone event. Additionally, we are obligated to pay Acuitas a low single-digit percentage royalty on net sales of licensed products. As of December 31, 2023, we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to Rabies RAV-G, $1.4 million in development milestone payments (Phase I, Phase II and Phase III milestone payments) to Acuitas with respect to the license agreement relating to the SARS-CoV-2 Spike protein S, $350,000 in development milestone payments to Acuitas with respect to the license agreement relating to the Influenza hemagglutinin (HA) antigen, $1.0 million in development milestone payments to Acuitas with respect to the license agreement relating to CVGBM, and have not made any royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CRISPR Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2017, we entered into a Development and License Agreement with CRISPR Therapeutics, which, as amended by the first amendment entered into in June 2020 and the second amendment entered into in October 2023, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. Under the CRISPR Therapeutics Agreement, we granted CRISPR Therapeutics an exclusive worldwide license to use our improved Cas9 constructs for the development and commercialization of three of its in vivo gene-editing programs for certain diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CRISPR Therapeutics has paid us an upfront one-time technology access fee of $3 million and we are eligible to receive up to $28 million in development milestone payments, $52 million in regulatory milestone payments and $260 million in commercial milestone payments, as well as mid-single-digit percentage royalties from CRISPR Therapeutics on the net sales of licensed products on a product-by-product and country-by-country basis, subject to certain potential customary reductions. Additionally, CRISPR Therapeutics will make payments to us for services provided by us in conjunction with research programs under the CRISPR Therapeutics Agreement. In the event CRISPR Therapeutics exercises its right to sublicense under the CRISPR Therapeutics Agreement, CRISPR Therapeutics must pay us a low-teens to mid-twenties percentage of any non-royalty sublicense income, depending on the timing of the sublicense and whether the sublicense is granted through an affiliate of CRISPR Therapeutics. As of December 31, 2023, we have received &#8364;8.4 million in payments for the supply of materials and FTE cost, development reimbursements and upfront one-time technology access fee and no milestone, royalty or sublicense fee payments. Additionally, as of December 31, 2023, we have invoiced CRISPR Therapeutics for certain amounts under the agreement in connection with the second amendment, which confirmed the parties&#8217; intention to stop work on two programs under the CRISPR Therapeutics Agreement and added three new programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Bill &amp; Melinda Gates Foundation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May 2014, we were awarded a contract from the Bill &amp; Melinda Gates Foundation for the development of a vaccine for rotaviruses, as amended in November 2020, for up to $3.0 million in funding. As of December 31, 2023, we have received $3.0 million in funding under the agreement. In March 2015, the Bill &amp; Melinda Gates Foundation made an equity investment of $40 million to support continued development of our RNA technology platform and the construction of an industrial-scale cGMP production facility. We entered into a Global Access Commitments Agreement with the Bill &amp; Melinda Gates Foundation in February 2015 pursuant to which we are required to take certain actions to support the Bill &amp; Melinda Gates Foundation mission. In connection with the investment by the Bill &amp; Melinda Gates Foundation, we are required to conduct development activities for up to three concurrent projects to be proposed by the Bill &amp; Melinda Gates Foundation. The costs of such projects will be allocated on a project-by-project basis in proportion to the allocation of the expected benefits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2016, in connection with the Global Access Commitments Agreement, we were awarded a grant for up to $0.9 million in funding from the Bill &amp; Melinda Gates Foundation for the development of a vaccine for picornaviruses. As of December 31, 2023, we have received $0.7 million in funding under the picornaviruses grant agreement. The term of the picornavirus grant expired in June 2022; however, our global access commitments survive. Following the completion of the project, the Bill &amp; Melinda Gates Foundation requested a reimbursement for unspent funds. As of December 31, 2023, we have paid unspent funds of $0.2 million back to the Bill &amp; Melinda Gates Foundation. In November 2017, we were awarded two additional grants each for up to $1.9 million and $1.5 million in funding from the Bill &amp; Melinda Gates Foundation for the development of a universal influenza and a malaria vaccine, respectively. By an amendment entered into November 2020, our grant for the development of a malaria vaccine was increased by an additional $0.8 million. As of December 31, 2023, we have received $1.9 million and $2.2 million, respectively, in funding under each grant agreement. The malaria grant agreement expired in December 2022 and the universal influenza grant agreement expired in March 2022; however, our global access commitments survive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Coalition for Epidemic Preparedness Innovations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2019, we entered into a framework partnership agreement, which as amended we refer to as the CEPI Agreement, with the Coalition for Epidemic Preparedness, or CEPI, to develop our RNA Printer using certain intellectual property controlled by us covering the development and manufacture of mRNA products, as well as certain additional intellectual property licensed to us. In connection with the CEPI Agreement we have entered into work orders for the preclinical development of a Lassa virus vaccine, a yellow fever vaccine and our rabies virus vaccine. In addition, we entered into a work package for the preclinical development and a Phase 1 clinical trial for our first-generation COVID-19 vaccine candidate, CVnCoV. The CEPI Agreement terminated in February 2022, except with respect to certain ongoing projects, which are contemplated to be completed in March 2024. CEPI agreed to contribute up to $34 million in funding for projects undertaken under the CEPI Agreement and an additional $15.3 million in connection with development of CVnCoV. As of December 31, 2023, we have received &#8364;27.1 million in funding for projects undertaken under the CEPI Agreement. Following the completion of the CEPI Agreement, CEPI requested a partial reimbursement of $1.0 million for unspent funds. As of December 31, 2023 we have paid these unspent funds back to CEPI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tesla Automation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2015, we entered into a development and intellectual property agreement with Tesla Automation, formerly trading under the name of Tesla Grohmann Automation, which we refer to as the Tesla Automation Agreement, pursuant to which Tesla Automation agreed to design, develop and manufacture certain automated manufacturing machines on our behalf. We are obligated to pay Tesla Automation a fee for each machine delivered by Tesla Automation and up to $50 million to $60 million in commercial milestone payments as well as certain development costs under each associated work order. As of December 31, 2023, we have paid Tesla Automation &#8364;22 million to &#8364;23 million in development costs under various work orders, and we have not paid any fees for machines provided under the Tesla Automation Agreement or made any milestone payments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and Option Agreement with myNEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2022, we entered into a Research and Option Agreement (&#8220;R&amp;O&#8221;) with myNEO, pursuant to which, as amended in January 2023, we will both collaborate to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets, its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response. Under the R&amp;O, we aim to develop and commercialize at least two new medicinal products for the treatment of non-small cell lung cancer and melanoma (the &#8220;Main Indications&#8221;) and potentially other indications. We are required to use commercially reasonable efforts to develop at least one product for each of the Main Indications, to file marketing approval applications for such products and commercialize such products in at least one of certain countries. Under the R&amp;O, myNEO will own all intellectual property rights generated solely by myNEO or jointly with us during the first three phases of the R&amp;D plan (the &#8220;R&amp;D Project IP&#8221;). We receive a non-exclusive, royalty-free, non-assignable, sublicensable, worldwide license under certain patents and know-how owned by myNEO and R&amp;D Project IP to the extent required to perform our research and development obligations under the agreement until the completion of a certain phase of the R&amp;D plan. We were also granted an exclusive option to acquire all of myNEO&#8217;s rights under certain R&amp;D Project IP relating to certain target lists, which we exercised on April 12, 2023. myNEO receives a non-exclusive, royalty-free, perpetual license back to such IP to make, use or sell certain targets in the field of patient-specific vaccines. Under the R&amp;O, myNEO agrees to work exclusively with us to develop and validate shared antigens for the Main Indications until the earlier of the date of the first phase I clinical trial for either Main Indication or 24 months after we exercised our option. On October 9, 2023, we notified myNEO that we reached a research and development milestone where we selected four antigens for further development, which we intend to use in a clinical candidate for the indication head and neck squamous-cell carcinoma, which is an indication other than the Main Indication. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the R&amp;O, we paid myNEO an upfront one-time technology access fee of &#8364;138,000 and myNEO is eligible to receive up to &#8364;17.5 million in research and development milestone payments with respect to the Main Indications, up to &#8364;175,000 in research and development milestone payments with respect to indications other than the Main Indications, up to &#8364;30 million in commercial milestone payments with respect to the Main Indications and up to &#8364;7.5 million in commercial milestone payments with respect to indications other than the Main Indications, as well as low single-digit percentage royalties on the net sales of licensed products in the Main Indications and sub single-digit percentage royalties on the net sales of licensed products for indications other than the Main Indications. Our royalty obligations continue on a product-by-product and country-by-country basis until the earlier of the date when there are no valid patent claims covering such licensed product in such country and 10 years following the date of first commercial sale of such licensed product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Advance Purchase Agreement for our First-Generation COVID-19 Vaccine Candidate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 30, 2020, we entered into an APA with the EC, acting on behalf and in the name of all Member States of the European Union, which provided for the advance purchase by the Member States of 225 million doses of the vaccine to be allocated among the Member States and the option to purchase up to an additional 180 million doses. Pursuant to the APA, we received an upfront payment of &#8364;450 million. Such upfront payment had to be used solely for the development and commercial supply of CVnCoV. We are required to return any unspent amounts of the upfront payment if, among others, we fail to successfully develop CVnCoV or if we successfully develop CVnCoV, but we do not receive EU marketing authorization or fail to supply any doses of CVnCoV to any of the Member States by late 2021, unless we and the EC mutually agree to a later date. In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would only return the unspent amount of the upfront payment. In the context of the APA, &#8220;spent&#8221; means either costs incurred or commitments made in connection with the purposes set forth in the APA. On March 8, 2022, we received a letter signed by the EC acknowledging and outlining that we will not be required to return any portion of the upfront payment. Due to the termination of the APA, we will not receive any further payments related to the APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In other respects, upon the EC&#8217;s request, we will transfer any raw materials and/or primary components paid for with the upfront payment that were not used as of the termination date. Additionally, should the EC request, or should we successfully sell, any raw materials and/or primary components, then an applicable portion of such raw materials, primary components or proceeds, as the case may be, will be remitted to the EC. This repayment agreement expired at the end of 2022 and an amount of &#8364;4.1 million was paid to the EC as of December 31, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Acquisition of Frame Pharmaceuticals</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On June 8, 2022, we entered into a Share Purchase Agreement (&#8220;SPA&#8221;), to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., domiciled in Amsterdam, the Netherlands, a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>), organized and existing under the laws of the Netherlands, focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. Under the SPA, the total consideration for the purchase was &#8364;34 million, conditioned on certain development milestone payments, as described therein. This acquisition serves to complement and strengthen our discovery capabilities to identify and validate promising neoantigens for our mRNA cancer vaccine programs and could strongly increase the likelihood of developing highly effective cancer vaccines for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Year Ended December 31, 2022 Compared to Year Ended December 31, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have based the following discussion of our financial condition and results of operations on our audited consolidated financial statements as of and for the years ended December 31, 2022 and 2023, and the notes thereto, included elsewhere in this Annual Report and which have been retrospectively adjusted to reflect the impact of the share split resulting from the Corporate Reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following is a discussion of our consolidated results of operations for each of the years ended December 31, 2022 and December 31, 2023. This information is derived from our accompanying consolidated financial statements prepared in accordance with IFRS as issued by IASB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes our results of operations for the fiscal year ended December 31, 2022 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros,&#160;except</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;share&#160;data)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Statement of Operations and Comprehensive Income (Loss) Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67,420</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,758</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (183,993)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (124,366)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,817)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,912)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (62,550)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (115,724)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (104,178)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (91,758)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from release of governmental contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,932</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,151</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,271)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,356)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,457)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (274,207)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,009</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,731</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,707)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,493)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,155)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (259,969)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 126</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (198)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (260,167)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income/loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Items that may be subsequently reclassified to profit or loss</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (105)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,134)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (260,095)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1.32)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1.18)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Revenue was &#8364;53.8 million for the year ended December 31, 2023, representing a decrease of &#8364;13.7 million, or 20%, from &#8364;67.4 million for the year ended December 31, 2022. The decrease was primarily driven by lower revenues recognized from collaborations with GSK due to changes in the timeline of certain projects. For the full year ended December 31, 2023 and 2022, &#8364;47.1 million and &#8364;62.3 million, respectively, in revenue was recognized through the collaborations with GSK.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of Sales</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cost of sales was &#8364;124.4 million for the year ended December 31, 2023, representing a decrease of &#8364;59.6 million, or 32%, from &#8364;184.0 million for the year ended December 31, 2022. The decrease was primarily attributable to decrease in write-offs of raw materials, which were in prior periods procured for manufacturing products to sell to GSK and due to a change of contract termination provisions. Additionally, prior year period was impacted by a higher impairment of CMO equipment identified for sale. Personnel expenses increased mainly due to increased workforce. We recognize in Cost of Sales costs related to all R&amp;D-services that we provide to GSK and all other collaboration partners as well as costs from set-up and quality assurance activities for our production processes, including those relating to pharmaceutical products which are under development in our collaboration agreements and for which we have not yet generated revenues.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,185)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (37,734)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (88,891)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (59,641)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,331)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,398)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,425)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,672)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,295)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,850)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,948)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,085)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,918)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,986)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (183,993)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (124,366)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling and Distribution Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses were &#8364;3.9 million for the year ended December 31, 2023, representing an increase of &#8364;1.1 million, or 39%, from &#8364;2.8 million in the year ended December 31, 2022. The increase was primarily attributable to higher personnel expenses related to the satellite offices in Belgium and the United States.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,029)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,425)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (45)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (336)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (417)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (424)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,817)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (3,912)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs were &#8364;115.7 million for the year ended December 31, 2023, representing an increase of &#8364;53.1 million, or 85%, from &#8364;62.6 million in the year ended December 31, 2022. The increase was primarily attributable to prior year impacts caused by (i) the reversal of provision for onerous contracts in the amount of &#8364;38.5 million as a result of more participants leaving the clinical trials, prior to completion, than originally estimated; and (ii) renegotiations of contracts with CROs. Additionally, in the prior year period, GSK took over the Group&#8217;s committed capacity at a CMO which resulted in a reduction in the estimated contract termination provisions in the amount of &#8364;25.1 million The net effect of these two events resulted in an overall gain within the Third-party services category. Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period. Materials decreased due to prior years impact of further write-off and scrap related to our first generation COVID-program, CVnCoV.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,982)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,126)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33,944)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (43,267)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,650)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,539)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,813)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,666)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,499</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,587)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,069)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,287)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,591)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,252)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (62,550)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (115,724)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table reflects our research and development costs for each of our programs for the year ended December 31, 2022 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Key Programs (CV8102, CVGBM, SARS-CoV-2 and CVnCoV)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">CV8102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,781)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,773)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">CVGBM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,062)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,821)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Second Generation COVID (CV0601, CV0701 and CV0501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,983)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,233)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">CVnCoV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 39,458</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,002</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other Research and Development Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,106)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,848)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unallocated costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (60,076)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (84,051)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (62,550)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (115,724)</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unallocated costs primarily consist of costs associated with personnel expenses, patents and fees to register a legal right, amortization and depreciation, maintenance and lease expenses, certain third-party service expenses and certain material expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Considering that, our research and development expenses primarily relate to the following key programs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For SARS-CoV-2, we are developing our modified mRNA vaccine candidates CV0601 (monovalent) and CV0701 (bivalent) in collaboration with GSK. While CV0601, encodes the Omicron BA.4-5 variant; CV0701, encodes the Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus. Both candidates are currently tested in a Phase 2 study, comparing both candidates to a licensed bivalent mRNA-based COVID-19 comparator vaccine initiated on August 1, 2023. Positive data from a formal interim analysis were announced on January 5, 2024. Both vaccine candidates, CV0601 and CV0701, apply CureVac&#8217;s proprietary second-generation mRNA backbone.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In our oncology therapeutic area, we work on novel cancer vaccine candidates based on differentiated antigen discovery technologies and bioinformatics to target antigens that are overexpressed in tumor tissues with no or little expression in healthy tissues. Within this strategy, we follow two approaches: (1) the development of off-the-shelf cancer vaccines based on tumor antigens shared across different cancer indications and (2) the development of fully personalized cancer vaccines based on a patient&#8217;s individual tumor genomic profile. We plan to advance new antigens for both approaches based on our second-generation mRNA backbone.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our oncology program, CVGBM, is a single mRNA construct based on our second-generation mRNA backbone, encoding eight epitopes from known tumor associated antigens with demonstrated relevance in glioblastoma. It is currently being tested in a Phase 1 study to assess safety and tolerability as a monotherapy in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. The study consists of two parts, a dose-escalation part (Part A) and a dose-expansion part (Part B). In the currently ongoing Part A, patients receive a total of seven intramuscular administrations of CVGBM at escalating doses in the range of 12&#181;g to 100&#181;g.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our oncology program, CV8102, has completed a Phase 1 dose escalating clinical trial for four types of solid tumors as a monotherapy and in combination with anti-PD-1 and an expansion of the Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600&#956;g dose. In the context of our strategic focus on the development of novel mRNA-based cancer vaccines, current and upcoming clinical developments will provide the basis for any potential integration of CV8102 into this priority program as a strong immune-modulatory adjunct. Clinical development of CV8102 will only be considered in combination with a defined mRNA cancer vaccine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were &#8364;91.8 million for the year ended December 31, 2023, representing a decrease of &#8364;12.4 million, or 12%, from &#8364;104.2 million in the year ended December 31, 2022. The decrease was primarily attributable to less personnel expenses due to lower workforce in the corporate service functions and due to lower other expenses.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,765)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,996)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,853)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,353)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,669)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29,920)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,394)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,160)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,360)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,821)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,137)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,508)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (104,178)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (91,758)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Operating Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating income was &#8364;9.2 million in the year ended December 31, 2023, representing a decrease of &#8364;28.8 million or 76%, from &#8364;37.9 million for the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decrease was primarily attributable to the impacts of the amendments to the 2020 GSK Agreement and the GSK COVID Agreement, under which CureVac was entitled to further compensation by GSK for set-up activities undertaken by CureVac (&#8364;20.5 million) and for reimbursement of prepayments (&#8364;12.0 million) in prior year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, we have been granted the positive research allowance notice by the German Federal Ministry of Education and Research for the years 2020-2026. The Group recognized EUR &#8364;3.1 million as other operating income for the year ended December 31, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Operating Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating expense was &#8364;1.4 million in the year ended December 31, 2023 representing an increase of &#8364;0.1 million, or 7%, from &#8364;1.3 million for the year ended December 31, 2022. Other operating expense related primarily to compensation expense of our supervisory board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Finance Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance income was &#8364;16.7 million for the year ended December 31, 2023, representing an increase of &#8364;12.7 million, or 317%, from &#8364;4.0 million for the year ended December 31, 2022. The increase was primarily attributable to interest income on cash investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Finance Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance expenses were &#8364;2.5 million for the year ended December 31, 2023, representing a decrease of &#8364;1.2 million, or 33%, from &#8364;3.7 million for the year ended December 31, 2022. The decrease was mainly related to prior year impacted by negative interest on cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Tax Benefit (Expense)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An income tax expense of &#8364;0.2 million was generated for the year ended December 31, 2023, representing an increase of &#8364;0.3 million, from an income tax benefit of &#8364;0.1 million generated for the year ended December 31, 2022. The increase to an expense was primarily attributable to income tax expense of CureVac Belgium S.A. and release of DTA at CureVac Corporate Services GmbH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Year Ended December 31, 2021 Compared to Year Ended December 31, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have based the following discussion of our financial condition and results of operations on our audited consolidated financial statements for the years ended December 31, 2021 and 2022, and the notes thereto, included elsewhere in this Annual Report and which have been retrospectively adjusted to reflect the impact of the share split resulting from the Corporate Reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a discussion of our consolidated results of operations for each of the years ended December 31, 2021 and December 31, 2022. This information is derived from our accompanying consolidated financial statements prepared in accordance with IFRS as issued by IASB.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the fiscal year ended December 31, 2021 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;Years&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros,&#160;except&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;share&#160;data)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Statement of Operations and Comprehensive Income (Loss) Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 102,990</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67,420</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (238,195)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (183,993)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,743)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,817)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (815,907)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (62,550)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (100,402)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (104,178)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income from release of governmental contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 574,502</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67,702</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,932</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,210)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,271)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (412,263)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,457)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,103</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,009</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,338)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,707)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (412,498)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,155)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 126</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (411,716)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,029)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income/loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Items that may be subsequently reclassified to profit or loss</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">  </i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (91)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (105)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (411,807)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (249,134)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2.21)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1.32)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Revenue was &#8364;67.4 million for the year ended December 31, 2022, representing a decrease of &#8364;35.6 million, or 35%, from &#8364;103.0 million for the year ended December 31, 2021. The decrease was primarily driven by the termination of the Boehringer Agreement in 2021, which led to a recognition of the remaining contract liability, option fee payment and development milestone in revenue amounting to &#8364;26.0 million for the full year ended December 31, 2021. For the full year ended December 31, 2022 and 2021, &#8364;62.3 million and &#8364;74.3 million, respectively, in revenue was recognized under the collaboration agreements with GSK, for both the 2020 GSK Agreement and the GSK COVID Agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of Sales</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cost of sales was &#8364;184.0 million for the year ended December 31, 2022, representing a decrease of &#8364;54.2 million, or 23%, from &#8364;238.2 million for the year ended December 31, 2021. The decrease was primarily attributable to less expenses on CMO services (fiscal year 2021 was highly impacted by significant expenses for the set-up of a CMO network), partially offset by increased write-offs and scrap of raw materials amounting to &#8364;80.0 million in 2022, which were procured for manufacturing of products to sell to GSK that are no longer expected to be sold to them or were determined to be excess materials on hand. We recognize in Cost of Sales costs related to all R&amp;D-services that we provide to GSK and all other collaboration partners as well as costs from set-up and quality assurance activities for our production processes, including those relating to pharmaceutical products which are under development in our collaboration agreements and for which we have not yet generated revenues.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,159)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,185)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46,250)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (88,891)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (139,975)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,331)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,874)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,425)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization, depreciation and derecognition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,992)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,295)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,810)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,948)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (135)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,918)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (238,195)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (183,993)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling and Distribution Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses were &#8364;2.8 million for the year ended December 31, 2022, representing an increase of &#8364;1.1 million, or 65%, from &#8364;1.7 million in the year ended December 31, 2021. The increase was primarily attributable to higher personnel expenses due to an increase in headcount.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,369)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,029)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (86)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (371)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (288)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (417)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1,743)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,817)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs were &#8364;62.6 million for the year ended December 31, 2022, representing a decrease of &#8364;753.3 million, or 92%, from &#8364;815.9 million in the year ended December 31, 2021. The decrease was primarily attributable to significantly lower research and development costs. Fiscal year 2021 was highly impacted from the start of our Phase 2/3 clinical trial for CVnCoV. As of December 2021, we had recognized a provision for all remaining costs related to the CVnCoV clinical trials. During 2022, we were able to renegotiate the existing contracts such that our estimated remaining costs decreased, and more participants exited the trials earlier than originally estimated. As a result of these changes, we recognized a gain from the reversal of &#8364;38.5 million of the provision. Additionally, during this period, we recognized a net gain of &#8364;25.1 million for a change of estimate in the contract termination provisions as a result of GSK taking over our committed capacity at a CMO. As a result of these gains, we experienced a net gain in third-party services costs.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (232,292)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,982)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33,733)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33,944)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,259)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,650)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,157)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,813)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (531,827)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,499</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (347)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,069)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,292)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,591)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (815,907)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (62,550)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table reflects our research and development costs for each of our programs for the year ended December 31, 2021 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Key Programs (CV8102, CV7202, CV2CoV and CVnCoV)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CV8102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,591)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,781)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CV7202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (518)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (219)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CV2CoV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,782)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (24,983)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CVnCoV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (753,627)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 39,458</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other Research and Development Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,610)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,949)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unallocated costs(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (44,779)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (60,076)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (815,907)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (62,550)</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Unallocated costs primarily consist of costs associated with personnel expenses, patents and fees to register a legal right, amortization and depreciation, maintenance and lease expenses, certain third-party service expenses and certain material expenses.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates. Considering that, our research and development expenses primarily relate to the following key programs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our modified mRNA vaccine candidate against SARS-CoV-2, CV0501, a monovalent construct, developed in collaboration with GSK. A Phase 1 study was initiated in August 2022. We reported positive preliminary data in early 2023. A Phase 2 clinical study, expected to start later in 2023, will assess monovalent and/or bivalent vaccine candidates designed to target clinically relevant variants. Novel cancer vaccine candidates based on differentiated antigen discovery technologies and bioinformatics to target antigens that are overexpressed in tumor tissues with no or little expression on healthy tissues. Within this strategy, we follow two approaches. The first approach assesses tumor antigens shared by different cancer patients for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy. We plan to advance new antigens for both approaches based on our second-generation mRNA backbone. To assess the safety and immunogenicity of our second-generation backbone in an oncology setting, we expect to initiate a proof-of-principle study in the second quarter of 2023, assessing an mRNA construct encoding eight epitopes from tumor associated antigens in patients with surgically resected Glioblastoma Multiforme.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:17.85pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our oncology program, CV8102, which is currently in a Phase 1 dose escalating clinical trial for four types of solid tumors as a monotherapy and in combination with anti-PD1 and an expansion of the Phase 1 study to evaluate the safety, tolerability and efficacy of CV8102 at a 600&#956;g dose in patients with PD-1 refractory melanoma &#8211; also as a monotherapy and in combinations with anti-PD-1 antibodies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:17.85pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our vaccine program, CV7202, which is currently in a Phase 1 clinical trial as a vaccine candidate for rabies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were &#8364;104.2 million for the year ended December 31, 2022, representing an increase of &#8364;3.8 million, or 4%, from &#8364;100.4 million in the year ended December 31, 2021. The increase was primarily attributable to increased amortization and depreciation expenses due to increased depreciation expense of right-of-use assets.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (37,393)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,765)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,306)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,853)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,875)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,669)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,230)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,394)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,895)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,360)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,703)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,137)</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (100,402)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (104,178)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income from release of governmental contract liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the withdrawal of the EMA regulatory approval application for CVnCoV in October 2021, CureVac recorded in 2021 an &#8220;Income from release of governmental contract liabilities&#8221; amounting to &#8364;574.5 million (refer to the &#8220;Year Ended December 31, 2020 Compared to Year Ended December 31, 2021&#8221; section for additional information regarding this prior year event). There was no such event occurring in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Operating Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating income was &#8364;37.9 million in the year ended December 31, 2022, representing a decrease of &#8364;29.8 million or 44%, from &#8364;67.7 million for the year ended December 31, 2021. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac SE (as the surviving entity from the merger of CureVac AG and CureVac Beteiligungsverwaltungs AG) and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK Agreement and the GSK COVID Agreement in connection with GSK entering into a direct Agreement with Novartis relating to the use of Novartis as CMO at the same time as CureVac exits its CMO agreement with Novartis and is released from its pre-existing capacity commitments under the agreement. As a result, the Company avoided an outflow of resources. Additionally, under the restated agreement, CureVac was entitled to further compensation by GSK. The compensation mainly consists of consideration for set-up activities undertaken by CureVac (&#8364;20.5 million) and for reimbursement of prepayments (&#8364;12.0 million).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021 the other operating income was primarily attributable to amounts recognized from grants from government agencies and similar bodies, primarily the German Federal Ministry of Education and Research, or BMBF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Operating Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating expense was &#8364;1.3 million in the year ended December 31, 2022 representing an increase of &#8364;0.1 million, or 8%, from &#8364;1.2 million for the year ended December 31, 2021. Other operating expense related primarily to compensation expense of our supervisory board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Finance Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance income was &#8364;4.0 million for the year ended December 31, 2022, representing an decrease of &#8364;6.1 million, or 60%, from &#8364;10.1 million for the year ended December 31, 2021. The decrease was mainly attributable to less foreign exchange gains partially compensated by positive interest on cash investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Finance Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance expenses were &#8364;3.7 million for the year ended December 31, 2022, representing an decrease of &#8364;6.6 million, or 64%, from &#8364;10.3 million for the year ended December 31, 2021. The decrease was mainly related to less foreign exchange losses and less negative interest on cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Tax Benefit (Expense)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An income tax benefit of &#8364;0.1 million for the year ended December 31, 2022, representing a decrease of &#8364;0.7 million, or 88%, from &#8364;0.8 million for the year ended December 31, 2021. The change was primarily attributable to decreased deferred tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.&#160;&#160;&#160;Liquidity and Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. For the year ended December 31, 2022 and 2023, we incurred net losses of &#8364;249.0 million and &#8364;260.2 million, respectively. To date, we have financed our operations primarily through the IPO in August 2020, follow-on public offerings, private placements of equity securities, issuance of convertible debt, grants from government agencies and similar bodies and payments for collaborative research and development services. Our cash and cash equivalents as of December 31, 2023, were &#8364;402.5 million. Our primary cash needs are to fund our non-clinical and clinical development programs, for working capital requirements and for capital expenditures. The expected cost of completion for GMP IV is &#8364;171.1 million, and as of December 31, 2023, we have spent &#8364;170.6 million on completing the GMP IV facility. We believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements at least through the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2023, we sold an additional 27,027,028 common shares in an underwritten public offering at an offering price of $9.25 per share raising $234.2 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses payable by us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market offering (ATM) program, pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600 million. As of December 31, 2023, we had issued 8,656,711 common shares through the ATM program, resulting in $87 million in gross proceeds to us. Following these issuances, the remaining value authorized for sale under the at-the-market program is $513 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial condition and liquidity is and will continue to be influenced by a variety of factors, including our ability to generate cash flows from our operations, future indebtedness and the interest we are obligated to pay on this indebtedness, the availability of public and private debt and equity financing, changes in exchange rates which will impact our generation of cash flows from operations when measured in euros and our capital expenditure requirements, which are described in more detail at &#8220;Item 3. Key Information &#8212;&#8201;D. Property, Plant and Equipment.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our contractual obligations as of December 31, 2023, and the effects, including estimated interest payments, that such obligations are expected to have on our liquidity and cash flows in future periods:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands of euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2027</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2028</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Contractual commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,269</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,269</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 53,656</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,254</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,096</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,977</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,821</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 56,925</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 10,523</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 7,096</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,977</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,633</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,875</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 22,821</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into various agreements with collaborators, including licensing agreements. These agreements provide for us to make milestone and royalty payments that are conditional on the achievement of certain development, regulatory and commercial milestones and certain of these agreements provide us an option to obtain further licenses which could additionally require us to make such milestone and royalty payments. As of December 31, 2023, the aggregate amount of such potential milestone payments, including those relating to licenses acquired from exercised options, under all such collaboration agreements, was up to $192.4 million. The timing of these payments, and whether they become due, is conditional on achieving the applicable milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not included milestone or royalty payments or other contractual payment obligations in the table above if the timing and amount of such obligations are unknown or uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">European Investment Bank Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2020, we signed a financing arrangement with the European Investment Bank, or EIB, under which EIB agreed to provide us with a line of credit in an amount of up to &#8364;75 million for the partial financing of our clinical developments and large-scale production of our infectious diseases vaccine candidates including our vaccine against SARS-CoV-2, or the Investment, provided that the amount of financing does not exceed 50% of the cost of the Investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had drawn &#8364;25 million under the first of the three tranches. In November 2020, a land charge (mortgage) amounting to &#8364;75 million was registered in favor of the EIB to secure the loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2021, we issued a prepayment request and cancellation notice to the EIB, pursuant to which we voluntarily repaid the &#8364;25 million in principal in addition to accrued interest in December 2021 and canceled the remaining &#8364;50 million available under the EIB loan. The mortgage was deleted from the land register in 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BMBF Grant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We received from BMBF a grant to support the development of our first-generation COVID-19 vaccine candidate, CVnCoV of up to &#8364;252 million. In July 2020, we had applied to that grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2. In addition to the further development of our first-generation COVID-19 vaccine candidate, CVnCoV, against COVID-19, the grant was used for the rapid expansion of the vaccine production. Payments were contingent on reaching predefined milestones. Amounts incurred in 2020 and 2021 were eligible for reimbursement through the grant. Due to the withdrawal of the regulatory approval application for CVnCoV, we were not able to reach all predefined milestones for 2021 under the grant. We received funding of &#8364;103 million in 2020 and funding of &#8364;93 million in 2021. As of December 31, 2021, we had drawn &#8364;196 million of the grant. In November 2021, we notified BMG of our inability to supply CVnCoV, thereby triggering automatic termination of the supply arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Advance Purchase Agreement for our First-Generation COVID-19 Vaccine Candidate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2020, we entered into an APA with the EC, acting on behalf and in the name of all Member States of the European Union, which provides for the advance purchase by the Member States of 225 million doses of the vaccine to be allocated among the Member States, and the option to purchase up to an additional 180 million doses. Pursuant to the APA, we received an upfront payment of &#8364;450 million. Such upfront payment had to be used solely for the development and commercial supply of CVnCoV. We are required to return any unspent amounts of the upfront payment if, among others, we fail to successfully develop CVnCoV or if we successfully develop CVnCoV, but we do not receive EU marketing authorization or fail to supply any doses of CVnCoV to any of the Member States by late 2021, unless we and the EC mutually agree to a later date. In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, we would only return the unspent amount of the upfront payment. In the context of the APA, &#8220;spent&#8221; means either costs occurred, or commitments made in relation to the purpose as set out in the APA. We were able to demonstrate that the upfront payment was used in accordance with the contract and no repayment was required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Comparative Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comparison of the years ended December 31, 2022 and 2023</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash flow provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (286,177)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (267,887)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (93,499)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (55,200)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 63,173</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 230,893</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Effect of currency translation gains on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 836</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,151)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Overall cash inflow/(outflow)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (315,667)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (93,345)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2023, was &#8364;267.9 million as compared to net cash used by operating activities of &#8364;286.2 million for the year ended December 31, 2022. The decrease in net cash used in operating activities was primarily attributable to less payments for service agreements with contract manufacturing organizations and raw material suppliers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the year ended December 31, 2023, was &#8364;55.2 million as compared to net cash used in investing activities of &#8364;93.5 million for the year ended December 31, 2022. The change in cash flows used in investing activities was primarily attributable to decreased purchases of property, plant and equipment for manufacturing facilities and intangible assets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was &#8364;230.9 million for the year ended December 31, 2023, as compared to &#8364;63.2 million for the year ended December 31, 2022. The increase in cash flows provided by financing activities was mainly attributable to the raising of cash in the follow-on underwritten public offering conducted in February 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Comparison of the years ended December 31, 2021 and 2022</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash flow provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (733,128)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (286,177)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (127,901)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (93,499)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 344,964</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 63,173</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Effect of currency translation gains on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,936</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 836</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Overall cash inflow/(outflow)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (511,129)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (315,667)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2022, was &#8364;286.2 million as compared to net cash provided by operating activities of &#8364;733.1 million for the year ended December 31, 2021. The decrease in net cash used in operating activities was primarily attributable to less payments for service agreements with contract research organizations and contract manufacturing organizations, including related settlements which were driving the cash outflows in the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the year ended December 31, 2022, was &#8364;93.5 million as compared to net cash used in investing activities of &#8364;127.9 million for the year ended December 31, 2021. The change in cash flows used in investing activities was primarily attributable to decreased purchases of property, plant and equipment for use in contract manufacturing facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was &#8364;63.2 million for the year ended December 31, 2022, as compared to &#8364;345.0 million for the year ended December 31, 2021. The decrease in cash flows provided by financing activities was mainly attributable to the proceeds in 2022 from the at-the-market offering program being lesser than those from the follow-on public offering, which closed in February 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">C.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Research and Development, Patents and Licenses, etc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research and preclinical and clinical development activities, including our product discovery efforts and certain activities relating to the design of GMP-manufacturing facilities. Research and development expenses contain wages and salaries, share-based compensation, fringe benefits and other personnel costs, the costs of clinical testing and the associated clinical production costs, research material production costs, fees for contractual partners, consultants and other third parties, fees to register legal rights, amortization of licensed software and intellectual property as well as costs for plant and facilities. Research and development expenses contain costs for independent research and development work as well as work carried out in the context of collaboration and licensing agreements; such expenses include all costs related to research and development services delivered under our collaboration arrangements. Additionally, prior to initial regulatory approval, if any, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin as the underlying costs will not be included in cost of sales as they will have been recognized in research and development expense in the period incurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also have partnered programs as further described under &#8220;Item 4. Information on the Company&#8201;&#8212;&#8201; B. Business Overview&#8201;&#8212;&#8201;Collaborations&#8221; and &#8220;Item 4. Information on the Company&#8201;&#8212;&#8201;B. Business Overview&#8201;&#8212;&#8201;Advance Purchase Agreements,&#8221; for which we incur additional expenses. In addition, our research and development expenses relate to our preclinical studies of further product candidates and discovery activities. These expenses mainly consist of salaries, share based-compensation, costs for production of preclinical compounds and costs paid to contract research organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense research and development expenses as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as patient enrollment or clinical site activations for services received and efforts expended. We expect research and development costs, including manufacturing, to support these activities, to increase significantly for the foreseeable future as our current development programs progress and new programs are added.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">D.&#160;&#160;&#160;Trend Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of trend information, see &#8220;Item 5. Operating and Financial Review and Prospects.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">E.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for those noncancellable contractual obligations from certain of our arrangements with contract manufacturing organizations disclosed in &#8220;Item 5. Operating and Financial Review and Prospects&#8201;&#8212;&#8201;B. Liquidity and Capital Resources.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">F.&#160;&#160;&#160;Safe Harbor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Forward-Looking Statements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">G.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with IFRS as issued by the IASB. Some of the accounting methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the circumstances concerned. The actual value of our assets, liabilities and shareholders&#8217; equity and of our earnings could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies that we believe to be critical to the judgments and estimates used in the preparation of our financial statements are included in &#8220;note 2&#8201;&#8212;&#8201;Significant accounting policies&#8221; and &#8220;note 10&#8201;&#8212;&#8201;Share-based payments&#8221; to our consolidated financial statements included elsewhere in this Annual Report.</p><a id="_8e8e6318_b5db_4ccd_9bf6_6bec6ee7edf0"></a><a id="ITEM6DIRECTORSSENIORMANAGEMENT_816845"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.&#160;&#160;&#160;Directors and Senior Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Board Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a two-tier board structure consisting of a management board (<i style="font-style:italic;">bestuur</i>) and a separate supervisory board (<i style="font-style:italic;">raad van commissarissen</i>). There are no family relationships among any of our managing directors and supervisory directors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management Board</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management board is composed of four members, who we refer to as our managing directors and who we consider to be our executive officers. Each managing director of CureVac N.V. holds office for the term set by our general meeting (as set forth in the table below), except in the case of his or her earlier death, resignation or removal. Our managing directors do not have a retirement age requirement under our articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our managing directors are responsible for the management and representation of our company. Our senior management has an average of 25 years of experience in the biopharmaceutical industry. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table lists our current managing directors who are also executive officers, as well as their ages, term served, the year of expiration of their term as managing directors of CureVac N.V. and position:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;in&#160;which</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;Served</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;Expires</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexander Zehnder, MD, MBA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 54</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4/2023&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pierre Kemula, B.Sc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/2016&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:28.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Myriam Mendila, MD<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 58</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2/2023&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Development Officer</p></td></tr><tr><td style="vertical-align:bottom;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Malte Greune, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7/2021&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Zehnder was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Mendila joined the executive team as Chief Development Officer on February 1, 2023. She was formally appointed as a managing director of CureVac N.V. on March 28, 2023. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the lapse of his term in office as managing director on October 31, 2023 and with effect from November 1, 2023, Pierre Kemula was appointed as a managing director in the event of absence or inability to act of a managing director until the end of the AGM 2024 and his date of initial appointment includes the term of office served as managing director of CureVac SE (at that time named: CureVac AG).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The above table does not include Dr. Antony Blanc and Dr. Igor Splawski, who each resigned as a managing director of CureVac N.V. on November 30, 2023 and July 14, 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a brief summary of the prior business experience and principal business activities performed outside of CureVac of our managing directors. Unless otherwise indicated, the current business addresses for each managing director is Friedrich-Miescher-Strasse 15, 72076 T&#252;bingen, Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Alexander Zehnder, MD, MBA </b>became our chief executive officer in April 2023. Dr. Zehnder earned his degree as a Medical Doctor from the University of Bern, Switzerland, and completed an MBA at IMD Business School in Lausanne, Switzerland. He has held roles of increasing complexity and responsibility in the pharmaceutical industry for more than 20 years, across multiple business units and functional areas in Europe, the United States and Japan. Prior to joining CureVac, Dr. Zehnder was the Global Head of Oncology at Sanofi and previously held leadership positions at Sanofi at both the headquarter and country level since 2014. Prior to Sanofi, Dr. Zehnder worked at Roche/Genentech where he served as Vice President, Global Product Strategy and Global Franchise Head Avastin, the company&#8217;s blockbuster oncology drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pierre Kemula, B.Sc.</b> has been our chief financial officer since 2016. Previously, he was the chief financial officer of Pixium Vision from 2014 until 2016, where he successfully contributed to the listing of the company on Euronext in Paris, and Vice President of Corporate Finance, Treasury and Financial Markets,<span style="font-size:12pt;"> </span>as well as Director of Investor Relations, Vice President of Investor Relations and Investor Relations Officer at lpsen from 2008 until 2014. Earlier in his career, Mr.&#160;Kemula worked with major strategy consulting firms (Roland Berger, Bossard Consultants and Gemini Consulting). He holds a Bachelor of Science in Management Sciences from the London School of Economics, or LSE, in the United Kingdom.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Myriam Mendila, MD </b>has been our chief development officer since February 2023. She has more than 20 years of global experience in product development, medical affairs, pharmacovigilance and healthcare compliance as well as global product strategy, including commercial strategy at Roche, Genentech and Novartis. Over the last 5 years, she has held the position of Worldwide Head of Medical Affairs and Chief Medical Officer Oncology at Novartis Pharma AG, Switzerland where she drives and oversees the development and cross-functional execution of the long-range global medical affairs vision and strategy for the Novartis oncology portfolio. Myriam earned her medical degree and subsequently doctoral degree from the Medical University of Hanover, Germany. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Malte Greune, Ph.D. </b>has been our chief operating officer since July 2021. Dr. Greune joins CureVac from Sanofi-Aventis Deutschland GmbH, where he held various management positions for almost ten years. As General Manager and Vice President Cartridges, Devices &amp; Insulin Technology Group, he was responsible for several manufacturing sites in Frankfurt. Under his leadership, six isolator filling lines for insulins, oncology drugs and biologics were set up including one for a COVID-19 vaccine. Prior to his position as Head of Diabetes, Oncology and Devices at Sanofi, he worked as the Senior Vice President of Animal Health Manufacturing for the Merck Manufacturing Division, USA, where he led an international network of 28 sites, including 18 integrated vaccine sites. Furthermore, he held various leadership roles at the pharmaceutical companies Schering-Plough and Intervet International B.V. Dr. Greune started his career at Hoechst AG in Corporate Planning. Dr. Greune received his Ph.D. in Economics from the University of Cologne, Germany, graduated from the University of Trier, Germany, and completed a Master of Business Administration at Clark University in Worcester, USA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Supervisory Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our supervisory board is composed of seven current members, who we refer to as our supervisory directors. Each supervisory director holds office for the term set by our general meeting (as set forth in the table below), except in the case of his or her earlier death, resignation or removal. Our supervisory directors do not have a retirement age requirement under our articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the names and functions of our current supervisory directors, their ages, term served and the year of expiration of their term as supervisory director of CureVac N.V.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;in&#160;which</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;Served</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;Expires</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Functions</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baron Jean St&#233;phenne, MSc, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 74</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/2015&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman and Supervisory Director</p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mathias Hothum, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 57</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/2015&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supervisory Director</p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Craig A. Tooman, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 58</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/2019&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supervisory Director</p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Viola Bronsema, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/2020&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supervisory Director</p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Debra Barker, MD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/2022&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supervisory Director</p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Klaus Schollmeier Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 67</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/2022&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supervisory Director</p></td></tr><tr><td style="vertical-align:bottom;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Brosnan BSc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 69</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/2023&#8201;&#8211;&#8201;Present</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supervisory Director</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Mr. Brosnan joined the Supervisory Board on June 19, 2023.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The above table does not include Dr. Hans Christoph Tanner and Dr. Ralf Clemens, who each resigned from the Supervisory Board on June 19, 2023 and September 30, 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a brief summary of the prior business experience and principal business activities performed outside of CureVac of our supervisory directors. Unless otherwise indicated, the current business addresses for each of our supervisory directors is Friedrich-Miescher-Strasse 15, 72076 T&#252;bingen, Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Baron Jean St&#233;phenne, MSc, MBA</b> has served as a supervisory director since 2015. Mr. St&#233;phenne was the CEO of GSK Biologicals from 1989 until 2012 and the President of GSK Biologicals from 2002 until 2012, where he was instrumental in building one of the world&#8217;s leading vaccine companies. In 1974, Mr. St&#233;phenne joined SmithKline-Rit, as engineer in biology in research and development. He also served as the President of UWE (Union Wallonne des Entreprises) from 1997 until 2000. Mr. St&#233;phenne was the chairman of BESIX Group S.A./N.V. and TiGenix N.V., IBA Wallonia Foreign Trade and Investment Agency, Henogen S.A., Aseptic Technologies and Bone Therapeutics (now BioSenic SA). He was also a director of Fortis bank, GBL and Bone Therapeutics.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Mathias Hothum, Ph.D. </b>has served as a supervisory director since 2015. Dr. Hothum is the managing director of dievini Hopp BioTech holding GmbH &amp; Co. KG, or dievini. dievini manages the biotech investments of SAP co-founder Dietmar Hopp. For the past 25 years, Dr. Hothum has worked as a health economist in the healthcare, health services and life sciences sectors. Dr. Hothum specializes in financing, pricing, reimbursement and in the evaluation of mid-sized companies as well as of publicly owned/market-listed companies. He is the owner and founder of HMM-Consulting. Furthermore, Dr. Hothum serves as a supervisory director of a few biotech companies, including Heidelberg Pharma AG, Apogenix AG, Weinheim 216 GmbH, Novaliq GmbH, Molecular Health GmbH and Joimax GmbH. He received his Ph.D. in economics from the University of Magdeburg and degree in economics from the University of Mannheim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Craig A. Tooman, MBA </b>has served as a supervisory director since 2019. Mr. Tooman has experience in the biopharmaceutical industry spanning more than 30 years, including more than 15 years of such experience as the Chief Executive Officer and Chief Financial Officer at several public companies. Mr. Tooman currently serves as the President, Chief Executive Officer and as a member of the board of directors of Silence Therapeutics. He was previously the Chief Financial Officer of Silence. Prior to joining Silence, from September 2019 to January 2021, he served as CFO and COO at Vyome Therapeutics, Inc. and prior to his tenure at Vyome, from November 2013 to July 2019, Mr. Tooman served as CFO, and then subsequently as CEO and Board Director of Aratana Therapeutics, where he successfully negotiated a merger with Elanco. Before Aratana, from 2005 to 2010, Mr. Tooman served as the CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau, and prior to that led the $1.1 billion M&amp;A initiative and integration of ILEX Oncology and Genzyme Corporation. Mr. Tooman has also held key positions at Pharmacia, and Upjohn. Mr. Tooman also serves on the Board of Directors of Ondine Biomedical Inc. Mr. Tooman earned his MBA in finance from the University of Chicago and a Bachelor of Arts degree in economics from Kalamazoo College.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Viola Bronsema, Ph.D.</b> has served as a supervisory director since August 2020. Dr. Bronsema has been Secretary General and CEO of BIO Deutschland, Germany&#8217;s Biotechnology Industry Association, since 2006. With its 390 corporate members, the sector association represents the interests of Germany&#8217;s biotechnology industry nationally and internationally. Currently, she is member of the Advisory Boards of the German Federal Government (Bioeconomy Advisory Board, Council for technological Sovereignty), and one of the oldest German economic policy associations (WPCD e.V.). Previously, Dr. Bronsema was Head of Communications of Roche Diagnostics GmbH and of Roche Diagnostics Europe, Middle East, Africa, and before that, of Lilly Pharma Holding GmbH. She earned her Ph.D. at the Centre for Molecular Biology (ZMBH) at the University of Heidelberg, Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Debra Barker, MD</b> has served as a supervisory director since June 2022. Dr. Barker is a seasoned pharmaceutical executive with more than 25 years of experience in drug development and commercialization from Novartis, Roche, SmithKline Beecham and Knall in Europe, the Americas and Asia. She currently serves as a Non-Executive Director for two additional public companies including BergenBio ASA, a Norwegian Oncology company, and Destiny Pharma PLC, a late-stage British Anti-infective company. Previously, Dr. Barker led as Chief Medical and Development Officer at Polyphor LTD for two years. From 2006 to 2017 she held various leadership positions at Novartis, where she most recently served as Vice President, Medical Affairs Franchise Head for Ophthalmology as well as interim Franchise Head for Neuroscience. In addition, she held the role of Regional Medical Director, Asia Pacific for Novartis where she led teams to develop and execute medical communication, clinical trial and opinion leader development activities across the franchises. Dr. Barker holds a degree in pharmaceutical medicine and received a master&#8217;s degree in immunology from King&#8217;s College in London and a medical degree from Queens&#8217; College, Cambridge, UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Klaus Schollmeier, Ph.D</b> has served as a supervisory director since June 2022. Dr. Schollmeier is an advisor to the Pharma/Biotech industry. He was Chief Executive Officer of SuppreMol in Munich from 2013 until 2015, when the company was sold to Baxalta. From 2004 to 2011, he served as CEO of Santhera in Basel, and as Chairman of the Board of Santhera until 2013. Dr. Schollmeier joined Graffinity Pharmaceuticals AG in Heidelberg, Germany as CEO in 2003 and merged the company with MyoContract AG, Basel in 2004 to form Santhera. Prior to joining the biotechnology industry in 2003, he was managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Before that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. Dr. Schollmeier is member of the board and chairman of several biotech companies including Tacalyx (Germany), Modra Pharmaceuticals (Netherlands), Affiris Pharma (Austria) and Eternygen (Germany).He holds a Ph.D. in biology from the University of D&#252;sseldorf, Germany, and is currently an adjunct research associate professor at the Boston University Medical School, Massachusetts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Michael Brosnan, BSc</b> has served as a supervisory director since June 2023. Mr. Brosnan currently serves as chairman of the audit committee and member of the supervisory board at MorphoSys AG, a biotechnology company. He also is chairman of the audit committee and member of the supervisory board of Daimler Truck AG. Until his retirement in 2019, he was the CFO of Fresenius Medical Care (&#8220;FMC&#8221;), headquartered in Germany, a worldwide leader in dialysis products and services. FMC is dual listed in New York and Frankfurt. Prior to taking over management roles in financial departments at FMC in 2003, he was an audit partner at KPMG. Mr. Brosnan holds a degree in business administration and accounting from Northeastern University, Boston.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Diversity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below provides certain information regarding the diversity of our supervisory board members as of the date of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0046310425%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="5" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory Board Diversity Matrix</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Country of Principal Executive Officers</b></p></td><td style="vertical-align:top;width:17.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Germany</p></td><td style="vertical-align:top;width:21.23%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.84%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Foreign Private Issuer</b></p></td><td style="vertical-align:top;width:17.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Yes</p></td><td style="vertical-align:top;width:21.23%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.84%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Disclosure Prohibited under Home Country Law</b></p></td><td style="vertical-align:top;width:17.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Yes</p></td><td style="vertical-align:top;width:21.23%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.84%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Total Number of Supervisory Board Members</b></p></td><td style="vertical-align:top;width:17.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">7</p></td><td style="vertical-align:top;width:21.23%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.84%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.49%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Female</b></p></td><td style="vertical-align:top;width:21.23%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Male</b></p></td><td style="vertical-align:top;width:19.08%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Non-Binary</b></p></td><td style="vertical-align:top;width:13.84%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Did not Disclose</b></p></td></tr><tr><td colspan="5" style="vertical-align:bottom;width:100%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Part I: Gender Identity</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Supervisory Board Members</p></td><td style="vertical-align:bottom;width:17.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">2</p></td><td style="vertical-align:bottom;width:21.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">5</p></td><td style="vertical-align:bottom;width:19.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">-</p></td><td style="vertical-align:bottom;width:13.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">-</p></td></tr><tr><td colspan="5" style="vertical-align:bottom;width:100%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Part II: Demographic Background</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Underrepresented individual in Germany</b></p></td><td colspan="4" style="vertical-align:bottom;width:71.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">LGBTQ+</b></p></td><td colspan="4" style="vertical-align:bottom;width:71.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:28.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Did Not Disclose Demographic Background</b></p></td><td style="vertical-align:bottom;width:17.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">-</p></td><td style="vertical-align:bottom;width:21.23%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.84%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have diversity objectives with respect to the composition of our management board and supervisory board as part of our diversity policy. We are committed to supporting, valuing and leveraging diversity and we recognize and welcome diversity with respect to gender, age, race, ethnicity, nationality, sexual orientation and other important cultural differences. In its evaluation of new candidates, the nomination and corporate governance committee may consider race or ethnicity, nationality, gender, sexual orientation, age, background, education skills and experience, as well as the restrictions, requirements and recommendations concerning those matters under applicable law, Nasdaq rules or best practice provisions of the Dutch Corporate Governance Code in relation to the full our management board, supervisory board and/or individual directors or director candidates. However, we also believe that there is a fine line between diversity and unintentional discrimination. For that reason, the importance of diversity, in and of itself, should not set aside the overriding principle that someone should be recommended, nominated and appointed for being &#8220;the right person for the job.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we have not yet set specific targets with respect to certain elements of diversity (other than with regard to gender as required by section 2:166(2) of the Dutch Civil Code), we believe that it is important for the management board, supervisory board and our senior management to represent a diverse composite mix of personal backgrounds, experiences, qualifications, knowledge, abilities and viewpoints, consistent with the principles outlined above. We also seek to combine the skills and experience of long-standing members of the management board, supervisory board and our senior management with the fresh perspectives, insights, skills and experiences of new candidates from time to time. To further increase the range of viewpoints, perspectives, talents and experience, we strive for a mix of experience among the management board, supervisory board and its senior management, but we have not set a specific target in this respect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Three of our managing directors are male and one is female. We<span style="letter-spacing:-0.1pt;"> </span>believe<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> we are on a trajectory to achieve </span>our diversity objectives with respect to the management board.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Five of our supervisory directors are male and two are female. We<span style="letter-spacing:-0.1pt;"> </span>believe<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> we are on a trajectory to achieve </span>our diversity objectives with respect to the supervisory board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our diversity objectives, we have defined our senior management as employees at the vice president position and above. Seven out of our thirty-four senior management members are female. We believe that we are on a trajectory to achieve our diversity objectives with respect to our senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have taken the following activities and measures for a more balanced gender ratio within the organization: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing policies that support equal opportunities for employees, senior management and applicants for employment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">encouraging and enforcing respectful communication and cooperation among all employees and senior management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fostering a corporate culture where employees and senior management are treated with dignity, respect and understanding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actively encouraging employees and officers who feel that they have been subjected to discrimination or harassment to report this to their supervisor, to our human resources department or via our Speak-Up tool; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regularly review our corporate policies to ensure equal treatment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Given the gender ratios both in the management board, supervisory board and as well as senior management, we are satisfied overall with our efforts towards improving gender diversity and we believe that our activities, training, mentoring and programs will continue to enhance our diversity objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Remuneration and Other Benefits to Supervisory and Managing Directors as of December 31, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a foreign private issuer, in accordance with Nasdaq listing requirements, we must comply with home country compensation requirements and certain exemptions thereunder rather than complying with Nasdaq compensation requirements. Dutch law does not provide for limitations with respect to the aggregate annual compensation paid to our managing directors or supervisory directors, provided that such compensation is consistent with our compensation policy. Such compensation policy requires approval by the general meeting. The supervisory board, in conjunction with our compensation committee, determines the remuneration of individual managing directors with due observance of the compensation policy. A proposal with respect to remuneration schemes in the form of shares or rights to shares in which managing directors may participate is subject to approval by our general meeting. Such a proposal must set out at least the maximum number of shares or rights to subscribe for shares to be granted to the managing directors and the criteria for granting or amendment. The compensation for our supervisory directors is set by the general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation policy authorizes our supervisory board to determine the amount, level and structure of the compensation packages of our managing directors at the recommendation of our compensation committee. These compensation packages may consist of a mix of fixed and variable compensation components, including base salary, short-term incentives, long-term incentives, fringe benefits, severance pay and pension arrangements, as determined by our supervisory board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not provide pension, retirement or similar benefits to our managing directors and supervisory directors in the year ended December 31, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Supervisory Board</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Compensation of Supervisory Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, the cash compensation paid to our supervisory directors for services in all capacities was &#8364;673,742. The following table sets forth the aggregate compensation and benefits provided to our supervisory board members for services in the year ended December 31, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(&#8364;)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baron Jean St&#233;phenne, MSc, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 123,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 194,500</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ralf Clemens, MD, PhD <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 94,400</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mathias Hothum, PhD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 128,598</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Hans Christoph Tanner, PhD <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,216</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,942</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Craig A. Tooman, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 116,741</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Viola Bronsema, PhD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,750</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Debra Barker, MD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,140</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Klaus Schollmeier PhD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 73,002</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Brosnan BSc. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,026</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,026</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Dr. Clemens resigned from the Supervisory Board of CureVac N.V. on September 30, 2023.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Dr. Tanner resigned from the Supervisory Board of CureVac N.V. on June 19, 2023.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Mr. Brosnan joined the Supervisory Board of CureVac on June 19, 2023.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This column represents the cash compensation and value of shares delivered in 2023 and does not include RSUs held by certain of the supervisory board members, as described in the share ownership section below.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management Board</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Compensation of Managing Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, the aggregate compensation accrued or paid to our managing directors for services in all capacities was &#8364;5,627,583. The following table sets forth the compensation and benefits provided to our management board for services in the year ended December 31, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">All&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Bonus</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(&#8364;)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexander Zehnder, MD, MBA <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 250,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,831</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 818,831</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Franz-Werner Haas, LLD, LLM <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 107,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,043</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 880,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,046,543</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pierre Kemula, B.Sc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 355,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 179,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119,550</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 654,175</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Antony Blanc, Ph.D. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 313,834</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 175,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 557,607</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,047,316</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Igor Splawski, Ph.D., MSc <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 176,556</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,803</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 573,115</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 839,474</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Myriam Mendila, MD <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 359,239</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 184,175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,381</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 581,795</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Malte Greune Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 355,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 179,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 600,736</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Senta Ulrike Gnad-Vogt MD <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,312</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,041</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,360</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,713</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This amount represents the annual variable amount accrued in full in 2023 for the year 2023 based on a percentage of yearly gross remuneration for reaching certain targets agreed upon with the supervisory board, as described further below. These amounts may differ from actual amounts that will be paid in 2024 as the Compensation Committee assesses the performance of the management team.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All other compensation includes other monetary benefits and contributions to social security insurance, if any.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This column does not include the virtual shares, options or RSUs held by certain of the management board members, as described in the &#8220;Virtual Share Ownership of Managing Directors&#8221; table below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Zehnder was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Haas resigned as a managing director of CureVac N.V. on March 31, 2023.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Blanc resigned as a managing director of CureVac N.V. on November 30, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Splawski resigned as a managing director of CureVac N.V. on July 14, 2023. Amounts in USD (Conv.rate 1,1058).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Mendila joined the executive team as Chief Development Officer on February 1, 2023. She was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Gnad-Vogt served as our interim Chief Development Officer from July 1, 2022 until January 31, 2023.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Bonus Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain and implement a management bonus plan for our managing directors. Under the management bonus plan, we provide a variable bonus payment as a component of management compensation that ranges from 50% to 55% of the individual&#8217;s annual base salary, depending on management level. We agree upon the respective individual target bonus amount with each employee on an individual contractual basis. The annual performance review is used to measure the achievement of objectives. The Supervisory Board finally decides on the goal achievement of the Managing Directors. The bonus payment is calculated based on the individual&#8217;s degree of target bonus achievement, which is then calculated as a percentage of annual base salary, and is generally paid out in March of the following year. The bonus is calculated on a pro rata basis if the individual joins or leaves CureVac during the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain a virtual share plan (the &#8220;Prior VSOP&#8221;) for members of the management board and the supervisory board. As of December 31, 2023, there are 5,603,155 virtual shares outstanding and no awards are available for issuance under the Prior VSOP. Ten percent (10%) of each award under the Prior VSOP became exercisable upon expiration of the 180-day lock-up period following the closing of CureVac&#8217;s IPO, which occurred on February 9, 2021. The exercise case &#8220;Liquidity after IPO&#8221; which relates to certain minimum trading volumes of the CureVac N.V. shares and liquidity levels being reached led to a second 10% portion of the (vested) virtual shares becoming exercisable on the first anniversary after the IPO on August 14, 2021, a third 10% portion of the (vested) virtual shares becoming exercisable on the second anniversary of the IPO on August 14, 2022 and a fourth 10% portion of the (vested) virtual shares becoming exercisable on the third anniversary of the IPO on August 14, 2023. The remaining portion of each award may be exercised (in whole or in part) upon the occurrence of certain defined triggering events, including, but not limited to, drug approval or the sale by a majority shareholder of 5% of our outstanding shares, in each case subject to the terms and conditions of the Prior VSOP. All rights under the Prior VSOP will terminate following the ninth calendar year of our listing on Nasdaq. The Prior VSOP was restructured upon the completion of our Corporate Reorganization. Following this restructuring, upon vesting of virtual shares, the holder will be able to exchange his or her virtual shares (in whole or in part) for cash or common shares of CureVac N.V. (instead of shares of CureVac SE) on a 1 to 133.0778 basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the increase in value of CureVac prior to our Corporate Reorganization, we modified our incentive program to allow members of the supervisory board, management board and other employees to participate in the value-increased business based on CureVac&#8217;s valuation at the time of the Corporate Reorganization subject to the occurrence of certain enumerated exercise cases reflecting such value-increase (the &#8220;New VSOP&#8221;). Each virtual share awarded under the New VSOP tracked one underlying series A share of CureVac SE (formerly CureVac AG). The New VSOP provides a cash-claim against CureVac in the amount of the positive difference between the value of CureVac per virtual share at the grant date (as determined by CureVac when the New VSOP was established) and the value per virtual share at the time of exercise of such virtual share (such value to be derived from the valuation of CureVac in the relevant triggering event), subject to CureVac&#8217;s discretion to provide tradable shares against payment of the value of CureVac per virtual share at the grant date. Such awards provided under the New VSOP have a term of ten years from the date of grant and vest over four years, where 25% vest after the first anniversary of the individual&#8217;s hire date and the remainder vesting monthly. These virtual shares were assumed by CureVac N.V. upon the completion of our Corporate Reorganization, and were converted into options, exercisable for common shares of CureVac N.V. on a 1 to 133.0778 basis. Following this conversion, subject to the same vesting, exercise and expiration terms discussed above, these option awards are governed by the Plan (as defined below).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our initial public offering, we established the Long Term Incentive Plan &#8220;LTIP&#8221; (the &#8220;Plan&#8221;) pursuant to which we may grant options, restricted stock, restricted stock units, share appreciation rights and other equity and equity-based awards to our employees, managing directors and supervisory directors, consultants or other advisors. As of December 31, 2023, there are 7,391,361 awards outstanding and 26,206,940 shares remained available for issuance under the Plan. The maximum number of common shares underlying awards granted pursuant to the Plan, including the awards granted under the New VSOP and the common shares underlying outstanding awards under the Prior VSOP, will not exceed an equivalent of 15% of our issued share capital from time to time. The Plan is administered jointly by our management board, supervisory board and compensation committee. Awards under the Plan may be granted to our employees, managing directors and supervisory directors, consultants or other advisors. Awards under the Plan may be conditioned upon the achievement or satisfaction of certain performance criteria. The vesting conditions for awards under the Plan are determined by the Committee and will be set forth in the applicable award documentation. The Plan provides for special provisions for good leavers and bad leavers as well as for a change in control of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">C.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Board Practices</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Committees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audit committee consists of Michael Brosnan (as chairman), Craig A. Tooman and Klaus Schollmeier. The audit committee assists the supervisory board in overseeing our accounting and financial reporting processes and the audits of our financial statements. In addition, the audit committee is responsible for the appointment, compensation, retention and oversight of the work of our independent registered public accounting firm. Our supervisory board has determined that Michael Brosnan, Craig A. Tooman and Klaus Schollmeier satisfy the &#8220;independence&#8221; requirements set forth in Rule 10A-3 under the Exchange Act and qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in the rules of the SEC. The composition of our audit committee is consistent with the best practice provisions of the DCGC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audit committee is governed by a charter that complies with applicable Nasdaq rules, which charter has been posted on our website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The compensation committee consists of Craig A. Tooman (as chairman), Michael Brosnan, Mathias Hothum and Viola Bronsema. The compensation committee assists the supervisory board in determining compensation for our management and supervisory board members. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The composition of our compensation committee deviates from the best practice provisions of the DCGC, because half of its members are not independent within the meaning of the DCGC because of their affiliation with dievini. Under SEC and Nasdaq rules, there are heightened independence standards for members of the Committee, including a prohibition against the receipt of any compensation from us other than standard director fees. As permitted by the listing requirements of Nasdaq, we opted out of Nasdaq Listing Rule 5605(d), which requires that a compensation committee consist entirely of independent supervisory directors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The compensation committee is governed by a charter that complies with applicable Nasdaq rules, which has been posted on our website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Nomination and Corporate Governance Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nomination and corporate governance committee consists of Craig Tooman (as chairman), Mathias Hothum, Michael Brosnan and Viola Bronsema. The nomination and corporate governance committee assists our supervisory board in identifying individuals qualified to become our managing directors or supervisory directors consistent with criteria established by us and in developing our code of business conduct and ethics. The composition of our nomination and corporate governance committee deviates from the best practice provisions of the DCGC, because more than half of its members are not independent within the meaning of the DCGC because of their affiliation with dievini or KfW. As permitted by the listing requirements of Nasdaq, we opted out of Nasdaq Listing Rule 5605(e), which requires independent director oversight of director nominations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nominating and corporate governance committee is governed by a charter that complies with applicable Nasdaq rules, which has been posted on our website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Special Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Resolutions of our supervisory board to approve a resolution of our management board to exclude or limit pre-emption rights (except in connection with the ordinary operation of our equity incentive plans), or to issue shares against non-cash contribution, require approval by a special committee consisting of one supervisory director nominated by dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement, as defined below) (during the initial nomination period for dievini), one supervisory director nominated by KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for KfW) and, if applicable, one supervisory director nominated by a nomination concert. In this special committee, the affirmative votes of one supervisory director nominated by dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for dievini) and the supervisory director nominated by KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for KfW) are required. See &#8220;Item 16G. Corporate Governance&#8201;&#8212;&#8201;Duties of Managing and Supervisory Directors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Service Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Consulting Agreement with Craig Tooman</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the approval of the supervisory board, we entered into a consulting agreement with Craig Tooman, a current member of our supervisory board in January 2023 (the &#8220;Tooman Consulting Agreement&#8221;), whereby Mr. Tooman agreed to provide consulting services and to advise on the strategic and operative planning of CureVac&#180;s organization. The Tooman Consulting Agreement was concluded for a term of one year, payment of certain travel and out-of-pocket expenses in addition to his consulting fee and restrictive covenants (including covenants related to confidentiality and proprietary information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Consulting Agreement with Debra Barker</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the approval of the supervisory board, we entered into a consulting agreement with Debra Barker, a current member of our supervisory board in January 2023 (the &#8220;Barker Consulting Agreement&#8221;), whereby Ms. Barker agreed to provide consulting services and to advise on the strategic and operative planning of the fast-track build-up of state-of-the-art oncology clinical pipeline. The Barker Consulting Agreement was concluded for a term of one year, payment of certain travel and out-of-pocket expenses in addition to her consulting fee and restrictive covenants (including covenants related to confidentiality and proprietary information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Consulting Agreement with Ralf Clemens</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the approval of the supervisory board, we entered into a consulting agreement with Dr. Clemens, a former member of our supervisory directors in March 2013 (the &#8220;Clemens Consulting Agreement&#8221;), whereby Dr. Clemens agreed to provide consulting services and agreed to act as a member of our scientific advisory board for an indefinite period. The Clemens Consulting Agreement provides for a notice of termination period of four weeks, payment of certain travel and out-of-pocket expenses in addition to his consulting fee and restrictive covenants (including covenants related to confidentiality and proprietary information). In addition, we entered with the approval of the supervisory board into a consulting agreement with GRID EUROPE in June 2023 (the &#8220;GRID Consulting Agreement&#8221;). The consulting services were provided by Dr. Clemens. The Grid Consulting Agreement included the information of the Scientific Committee of the Supervisory Board on latest mRNA based clinical activities and global policies. The Grid Consulting Agreement was concluded for a term of six months, payment of certain travel and out-of-pocket expenses in addition to his consulting fee and restrictive covenants (including covenants related to confidentiality and proprietary information).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Management Board Service Contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into management board service agreements (the &#8220;Management Contracts&#8221;) with the following current or former managing directors: Dr. Gnad-Vogt, Dr. Haas, Mr. Kemula, Dr. Splawski, Dr. Greune, Dr. Blanc, Dr. Mendila and Dr. Zehnder. The Management Contracts generally provide for an initial term of three years, a 12-month notice period thereafter, a base salary, certain administrative allowances, an annual variable payment expressed as a percentage of annual base salary that is dependent on the achievement of certain objectives agreed to by the supervisory board and a severance payment upon termination of the Management Contracts. The supervisory board is entitled to grant managing directors additional compensation at its discretion. The managing directors are also eligible to participate in a virtual stock plan or equivalent plan that is established in a manner substantially similar to other of the executive officers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Management Contracts provide for the following restrictive covenants: (i) a non-compete during employment and for 12 months after termination; (ii) a non-solicit of employees during employment and for two years after termination; and (iii) a perpetual confidentiality covenant. Under the Management Contracts, we are obligated to pay the managing directors compensation for the duration of their post-employment non-compete period in monthly installments that are equal to half of the total compensation they received prior to their termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Employment Contract with Senta Ulrike Gnad-Vogt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into an employment contract with Dr. Gnad-Vogt in July 2011, as amended in September 2019, (the &#8220;Gnad-Vogt Employment Contract&#8221;), whereby Dr. Gnad-Vogt is employed for an indefinite period of time. The Gnad-Vogt Employment Contract provides for a notice of termination period of six months, which can be initiated in writing by either party, and restrictive covenants, including non-compete and non-solicitation covenants and a covenant related to confidentiality. Dr. Gnad-Vogt resigned as our interim chief development officer on July 31, 2021. Dr. Gnad-Vogt also served as our interim Chief Development Officer from July 1, 2022 until January 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Contract with Franz-Werner Haas</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into an addendum to the employment contract with Franz-Werner Haas in April 2022 (the &#8220;Haas Addendum&#8221;) pursuant to which Dr. Haas agreed to extend his service on the management board until March 31, 2023. Under Dr. Haas&#8217;s addendum, we awarded him 36,000 RSUs under the Plan on April 1, 2022, which vested immediately and became exercisable on or after January 1, 2023. The Haas Addendum also provides that Dr. Haas be entitled to the reimbursement of certain costs. On March 31, 2023, Dr. Haas stepped down as CureVac&#8217;s Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Contract with Pierre Kemula</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into an addendum to the employment contract with Pierre Kemula in April 2022 (the &#8220;Kemula Addendum&#8221;) pursuant to which Mr. Kemula agreed to an indefinite extension of his service on the management board, subject to a notice period of 9 months, but in any case not before October 4, 2024. The Kemula Addendum also provides that Mr. Kemula be entitled to the reimbursement of certain administrative costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Contract with Igor Splawski</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into an addendum to the employment contract with Igor Splawski in April 2022 (the &#8220;1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> Splawski Addendum&#8221;) pursuant to which Dr. Splawski is entitled to the reimbursement of certain administrative costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into another addendum to the employment contract with Igor Splawski in July 2022 (the &#8220;2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup> Splawski Addendum&#8221;) pursuant to which Dr. Splawksi agreed to relocate his place of work to the U.S. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2023, Dr. Splawski stepped down as CureVac&#8217;s Chief Scientific Officer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Contract with Malte Greune</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into an addendum to the employment contract with Malte Greune in April 2022 (the &#8220;Greune Addendum&#8221;) pursuant to which Dr. Greune agreed to an indefinite extension of his service on the management board, subject to a notice period of 12 months, but in any case not before July 31, 2024. The Greune Addendum also provides that Dr. Greune be entitled to the reimbursement of certain administrative costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Contract with Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into an addendum to the employment contract with Antony Blanc in April 2022 (the &#8220;Blanc Addendum&#8221;) pursuant to which Dr. Blanc agreed to an indefinite extension of his service on the management board, subject to a notice period of 12 months, but in any case not before November 30, 2023. The Blanc Addendum also provides that Dr. Blanc be entitled to the reimbursement of certain administrative costs. Dr. Blanc stepped down as CureVac&#8217;s Chief Business Officer on November 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Contract with Myriam Mendila</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into an employment contract with Myriam Mendila in June 2022 (the &#8220;Mendila Employment Contract&#8221;), pursuant to which Dr. Mendila agreed to serve on the management board with an indefinite term, subject to a notice period of 12 months. The Mendila Employment Contract also provides that Dr. Mendila be entitled to the reimbursement of certain administrative costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Contact with Alexander Zehnder</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into a future service agreement with Alexander Zehnder on January 6, 2023, and Dr. Zehnder became our CEO on April 1, 2023. On February 28, 2023, we entered into an addendum to the future service agreement with Dr. Zehnder (the &#8220;Zehnder addendum&#8221;) pursuant to which Dr. Zehnder agreed to an earlier start date into his new role already as of March 1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">D.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we employed 1,172 total employees worldwide, 999 of whom were full-time, 294 of whom hold Ph.D. or M.D. degrees, 466 of whom were engaged directly or indirectly in production, 523 of whom were engaged in research and development activities, 48 of whom were engaged in clinical and regulatory activities, 15 of whom were engaged in marketing and sales activities, and 120 of whom were engaged in management, business development or marketing, finance, human resources or administrative support. Of our 1,172 total employees, 1,129 work in Germany, 13 work in Belgium, 22 work in the Netherlands and 8 work in the United States. We are not subject to collective bargaining agreements or similar labor contracts and have a workers&#8217; council established since November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">E.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Share Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Share Ownership of Supervisory Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the share ownership of our supervisory directors as of March 15, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Voting&#160;Rights</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baron Jean St&#233;phenne, MSc, MBA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,758</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.01</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,758</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mathias Hothum, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 106,349</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.05</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 106,349</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Craig A. Tooman, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,653</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,653</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Viola Bronsema, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Debra Barker, MD.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,125</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Klaus Schollmeier, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,032</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Brosnan BSc. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,186</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,186</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><span style="font-style:normal;">Mr. Brosnan joined the Supervisory Board of CureVac on June 19, 2023.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Restricted Stock Unit Ownership of Supervisory Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the restricted stock unit (RSU) ownership of our supervisory directors as of March 15, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baron Jean St&#233;phenne</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,370</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2022 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec 31, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:31.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baron Jean St&#233;phenne</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,481</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:31.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mathias Hothum, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,843</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2022 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec 31, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:31.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mathias Hothum, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,485</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:31.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Craig A. Tooman, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,521</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2022 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec 31, 2024</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Craig A. Tooman, MBA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,485</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Viola Bronsema, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Debra Barker, MD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2022 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/2 on Dec 31, 2024</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Debra Barker, MD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Klaus Schollmeier, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 695</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2022 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec 31, 2024</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Klaus Schollmeier, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,490</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Brosnan BSc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,373</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">CureVac LTIP 2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Mr. Brosnan joined the Supervisory Board of CureVac on June 19, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">RSU awards which have vested and have been delivered as shares are not included in the table above. The RSUs included in the table above which have not yet vested or been settled (delivered as shares) are not included in the fully diluted shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Share Ownership of Managing Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the share ownership of our managing directors as of March 15, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Voting&#160;Rights</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexander Zehnder, MD, MBA <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,374</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pierre Kemula, B.Sc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,013</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.04</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,013</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Myriam Mendila, MD <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,752</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,752</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Malte Greune, Ph.D </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,523</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,523</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;font-style:normal;min-width:18pt;white-space:nowrap;">(1)</span><span style="font-style:normal;">Dr. Zehnder was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Mendila joined the executive team as Chief Development Officer on February 1, 2023. She was formally appointed as a managing director of CureVac N.V. on March 28, 2023. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Option Ownership of Managing Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the option ownership of our managing directors as of March 15, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in USD)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexander Zehnder <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144,379</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">LTIP Option Award 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6.66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">April 1, 2033</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pierre Kemula</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">LTIP Option Award 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19.35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">March 1, 2032</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Myriam Mendila <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Malte Greune</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">LTIP Option Award 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 84.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">LTIP Option Award 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19.35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">March 1, 2032</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Zehnder was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Mendila joined the executive team as Chief Development Officer on February 1, 2023. She was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Restricted Stock Unit Ownership of Managing Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the restricted stock unit (RSU) ownership of our managing directors as of March 15, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vesting&#160;Date</b></p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Alexander Zehnder <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27,233</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/> 2023 RSUs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Pierre Kemula</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,203</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/>2022 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Dec 31, 2024</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,063</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/>2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Myriam Mendila <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,472</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/>2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Malte Greune</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,203</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/>2022 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Dec 31, 2024</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/>2022<br/>supplemental RSUs - with performance criteria</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1/2 on Dec 31, 2022 &amp; 1/2 on Dec 31, 2023</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,063</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/>2023 RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1/2 on Dec 31, 2024 &amp; 1/2 on Dec 31, 2025</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">CureVac LTIP<br/>2023<br/>supplemental RSUs - without performance criteria</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1/33 on Dec 31, 2023,1/3 on Dec 31, 2024 &amp; 1/3 on Dec 31, 2025</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Zehnder was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Mendila joined the executive team as Chief Development Officer on February 1, 2023. She was formally appointed as a managing director of CureVac N.V. on March 28, 2023.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Please note: RSU awards which have vested and have been delivered as shares are not included in the table above. The RSUs included in the table above which have not yet vested or been settled (delivered as shares) are not included in the fully diluted shares outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Virtual Share, or VS, Ownership of Management Board Members from VSOP Programs as of March 15, 2024.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Start of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant date </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Max</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Date of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VS Points</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Only for New</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Points</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Participants)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Letter)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VSOP Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Valid until</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pierre Kemula</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">VS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 465,779</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 465,779</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01.10.2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18.04.2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aug 13, 2029</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">F.&#160;&#160;&#160;Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_260f5619_c471_4e5e_9369_7c694e6c4d07"></a><a id="ITEM7MAJORSHAREHOLDERSANDRELATED_593176"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Major Shareholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents information relating to the beneficial ownership of our common shares as of March 15, 2024 by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each managing director and supervisory director; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all managing directors and supervisory directors as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of common shares beneficially owned by each entity, person, supervisory director or managing director is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any common shares over which the individual has sole or shared voting power or investment power as well as any common shares that the individual has the right to acquire within 60 days of March 15, 2024, through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all common shares held by that person. The table is based on information supplied by our managing directors and supervisory directors and by Schedules 13D and Schedules 13G, if any, filed with the SEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The percentage of outstanding common shares is computed on the basis of 224,305,680 common shares outstanding as of March 15, 2024. Common shares that a person has the right to acquire within 60 days of March 15, 2024 are also deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all members of the supervisory board and management board as a group. Unless otherwise indicated below, the address for each beneficial owner is CureVac SE, Friedrich-Miescher-Strasse 15, 72076 T&#252;bingen, Germany.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Beneficially&#160;Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Shareholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">5% Shareholders:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dietmar Hopp<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83,880,935</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Kreditanstalt f&#252;r Wiederaufbau<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,871,441</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Glaxo Group Limited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,591,937</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Managing Directors:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexander Zehnder, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pierre Kemula, BSc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,013</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Myriam Mendila, MD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,752</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Malte Greune, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,523</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Supervisory Directors:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mathias Hothum, Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,288,109</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baron Jean Stephenne, MSc, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,758</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Brosnan, BSc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,186</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Debra Barker, MD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Viola Bronsema, MD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Klaus Schollmeier, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Craig A. Tooman, MBA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,653</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">All Managing Directors and Supervisory Directors as a Group:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 70,475,339</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 31.4</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">*</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Represents beneficial ownership of less than 1%.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This information is based on a Schedule 13D filed with the SEC on February 24, 2023 by dievini Hopp BioTech holding GmbH &amp; Co. KG (&#8220;dievini&#8221;), DH-LT-Investments GmbH (&#8220;DH-LT-Investments&#8221;), DH-Capital GmbH &amp; Co. KG (&#8220;DH-Capital&#8221;), OH Beteiligungen GmbH &amp; Co. KG (&#8220;OH Beteiligungen&#8221;), Dietmar Hopp, Oliver Hopp, Daniel Hopp, DHFS II Holding GmbH &amp; Co. KG (&#8220;DHFS II Holding&#8221;) and Zweite DH Verwaltungs GmbH (&#8220;Zweite DH&#8221;). dievini is the record holder of 70,181,760 shares and DH-LT Investments is the record holder of 10,102,286 shares. Mr. Hopp is the record holder of 158,700 shares and is the sole shareholder of a company that is the record holder of 33,517 shares. Zweite DH is the record holder of 3,404,672 shares. DH-Capital and OH Beteiligungen, are collectively the holders of 100% of the limited partner interest in dievini. DH-Capital and OH Beteiligungen each hold a 50% limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini. The sole general partner of dievini with the authorization to represent are dievini Verwaltungs GmbH and Dr. Hothum; however, 100% of the shares of dievini Verwaltungs GmbH are held by dievini so dievini Verwaltungs GmbH is not considered to have control over dievini. The managing directors of dievini Verwaltungs GmbH are Dietmar Hopp and Dr. Hothum. Voting and dispositive decisions made within dievini Verwaltungs GmbH regarding the securities held by dievini are made by at least two managing directors acting together; however, Dietmar Hopp is entitled to represent dievini Verwaltungs GmbH solely. Therefore, in their capacity as managing directors, Dietmar Hopp and Dr. Hothum share voting and dispositive power over the shares held by dievini, and may be deemed to beneficially own such shares held by dievini; however, each of Dietmar Hopp and Dr. Hothum disclaims beneficial ownership of the shares held by dievini except to the extent of their pecuniary interests therein. The address for dievini, DH-LT Investments and Dietmar Hopp is c/o dievini Hopp BioTech holding GmbH &amp; Co. KG, Johann-Jakob-Astor Str. 57, 69190 Walldorf, Germany, the address for DH-Capital and OH Beteilungen is Heidelberger Stra&#223;e 43, 69168 Wiesloch, Germany, the address for Oliver Hopp, Daniel Hopp, DHFS II Holding and Zweite DH is Johann-Jakob-Astor Stra&#223;e 57, 69190 Walldorf, Germany.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This amount includes the amount of 672,875 shares which was delivered to the Company to fulfil dievini&#8217;s prior VSOP obligation end of March 2024. As of March 31, 2024 the amount has to be reduced by 672,875. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This information is based on a Schedule 13D filed with the SEC on February 24, 2023 by KfW, or Kreditanstalt f&#252;r Wiederaufbau, an institution (Anstalt des &#246;ffentlichen Rechts) organized under public law of the Federal Republic of Germany. The Federal Republic of Germany holds 80% of KfW&#8217;s subscribed capital, and the German federal states (L&#228;nder) hold the remaining 20%. The address for KfW is Palmengartenstrasse 5-9, 60325 Frankfurt am Main, Germany.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 70,181,760 shares held by dievini Hopp BioTech holding GmbH &amp; Co. KG that may also be deemed beneficially owned by Dr. Mathias Hothum, 95,504 shares held by MH-LT-Investments GmbH and 10,845 shares held by Dr. Mathias Hothum.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each of our shareholders is entitled to one vote per common share. None of the holders of our shares will have different voting rights from other holders of shares. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a number of our shares are held in book-entry form, we are not aware of the identity of all of our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.&#160;&#160;&#160;Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a description of related party transactions we have entered into since January&#160;1, 2021, with any of our management and supervisory directors and the holders of more than 5% of our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">dievini Hopp BioTech holding GmbH &amp; Co. KG, Walldorf</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, dievini holds the majority of our capital stock and is the controlling shareholder. Molecular Health GmbH, or Molecular Health, is a subsidiary of dievini. In December 2017, we concluded a contract with Molecular Health, according to which Molecular Health provides services in conjunction with the Modeling of the biological and clinical effects of Toll-like receptor 7 and 8 agonists in cancer and immune cells. In fiscal years 2021, 2022 and 2023, payments to Molecular Health with respect to research and development amounted to &#8364;0. In 2023 a total of EUR 1k (2022: EUR 58k) was paid to dievini Hopp BioTech Holding GmbH &amp; Co. KG as a reimbursement of travel cost.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Convertible Loans with Mr. Hopp</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We entered into a convertible loan agreement on May 3, 2019 with Mr. Dietmar Hopp, managing director of dievini, under which Mr. Hopp disbursed to us the amount of EUR 50,000k, or Convertible Loan I. On October 24, 2019, we entered into an additional convertible loan agreement with Mr. Hopp, as amended, under which we have the right to call for disbursements in two tranches of EUR 20,000k and a final tranche of &#8364;23,927k, until December 31, 2021, or Convertible Loan II, and together with Convertible Loan I, or the Convertible Loans. The Convertible Loans bear an interest rate of 8.00% per annum. We repaid the Convertible Loans on August 7, 2020, and as of December 31, 2020, no Convertible Loans were outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Immatics Biotechnologies GmbH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, a purchase agreement between CureVac Manufacturing GmbH and Immatics Biotechnologies GmbH was entered into. CureVac purchased technical equipment of containers which CureVac will use as a facility in the future. dievini held 16,7% of the shares in Immatics N.V. (Immatics) as of December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup>, 2023 per the Form 20-F of Immatics filed in March 2024. CureVac paid EUR 178k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BePharBel Manufacturing S.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2020, CureVac Manufacturing GmbH (formerly CureVac Real Estate GmbH) and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#8217;s first concentrated COVID-19 vaccine candidate, CVnCoV. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Manufacturing GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021, CureVac Manufacturing GmbH terminated the commercial and supply agreement with BePharBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k. In total an amount of EUR 4,016k was paid. Baron Jean St&#233;phenne, our supervisory board member, holds directly and indirectly 15.61% of BePharBel Manufacturing&#8217;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#233;phenne&#8217;s son, Vincent St&#233;phenne, holds 1.43% of BePharBel Manufacturing&#8217;s equity and is a managing director of BePharBel Manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rittershaus law firm, Mannheim</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A consulting agreement dated December 15, 2005, was in place for an indefinite term with the law firm Rittershaus Rechtsanw&#228;lte Partnerschaftsgesellschaft mbB, Mannheim (Rittershaus). The agreement was replaced by a new consulting agreement dated January 1, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The agreement can be terminated without notice by us and with notice of three months to the end of the quarter by Rittershaus. In fiscal years 2021, 2022 and 2023, consulting fees of EUR 757k, EUR 518k and EUR 212k were paid to Rittershaus, respectively. Prof. Dr. Christof Hettich, who was one of the managing directors of dievini until June 2022, is a partner of Rittershaus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Ingmar H&#246;rr</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2018, an advisory agreement was implemented between Dr. Ingmar Hoerr and CureVac. Dr. Hoerr received EUR 0k, EUR 0k and EUR 0k for consulting services in fiscal years 2021, 2022 and 2023, respectively. The advisory agreement with Dr. Ingmar Hoerr was terminated in March 2020. Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 573k as per year-end 2022 for the income tax and social security liability. CureVac has received the money in February 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Antony Blanc</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In July 2020, a consulting agreement was implemented between CureVac AG (currently CureVac SE) and Clarentis SRL, which is wholly owned by Antony Blanc, our chief business officer. The consulting agreement was further amended in September 2020. The consulting agreement was terminated in February 2021 upon Antony Blanc&#8217;s appointment as our chief business officer. The consulting agreement provided for payments that were contingent upon the achievement of certain milestones. Clarentis SRL received EUR 150k and EUR100k in fiscal years 2020 and 2021, respectively. In addition to his Management Board position at CureVac NV, Antony Blanc also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services in 2023, CureVac paid EUR 85k in 2023 (2022: EUR 69k, 2021: EUR 0k). The amounts invoiced for these function/services are offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V. As Antony Blanc has left the company as of November 30, 2023, CureVac and Antony Blanc signed a settlement agreement as of September 26, 2023. Under this agreement CureVac incurred cost of EUR 107k for Clarentis SRL entity in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Dr. Mariola Fotin-Mleczek</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 131k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2022, a consulting agreement between CureVac N.V. and Mariola Fotin-Mleczek was made. In 2022 and 2023, a total of EUR 20k and EUR 2k were paid, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Dr. Florian von der M&#252;lbe</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 559k as per year-end 2022 for the income tax and social security liability. CureVac has received the money in February 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Consulting agreements between CureVac Printer GmbH and Florian von der M&#252;lbe related to the years 2022 to 2024 have been executed. In 2023 CureVac paid EUR 146k under such agreement related to 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Franz-Werner Haas</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was executed. In 2023 CureVac paid EUR 65k under this agreement. The payment was partially compensated by Franz-Werner Haas taking over his former company car for EUR 40k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Alexander Zehnder</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR 51k during the month of March.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Barker BioMedical GmbH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was executed. Barker BioMedical GmBH is a wholly owned consulting company of Debra Barker, Supervisory Board member of CureVac N.V. In 2023 CureVac paid EUR 14k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Craig Tooman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Craig Tooman was executed. In 2023, CureVac paid EUR 5k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Ralf Clemens</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In Q3 2023, a consulting agreement between CureVac N.V. and GRID EUROPE was executed. GRID EUROPE is a wholly owned consulting company of Ralf Clemens, who was a member of the supervisory board up to September 30, 2023. CureVac incurred EUR 23k under this agreement in 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2020 Private Investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On July 17, 2020, we entered into a binding agreement with KfW, Glaxo Group Limited, or GSK, QIA and other investors, pursuant to which we agreed to issue new Series B shares in CureVac AG (currently CureVac SE), representing approximately 36% of the shares in CureVac SE in exchange for an aggregate investment of &#8364;560 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">According to the mandate of KfW by the Federal Republic of Germany pursuant to and in accordance with Article 2 paragraph 4 of the KfW Law (<i style="font-style:italic;">Zuweisungsgesch&#228;ft</i>) KfW, acquired approximately 19% shareholding in CureVac AG (currently CureVac SE), for an aggregate investment of &#8364;300 million. In addition, GSK acquired approximately a 9% shareholding in CureVac SE for an investment of &#8364;150 million and QIA acquired approximately 4% shareholding in CureVac SE for an investment of &#8364;60 million. We refer to the investment of KfW as the KfW Investment and to the investment by GSK as the GSK Investment. In addition, the other several shareholders purchased an aggregate 3% shareholding in CureVac SE for an aggregate investment of &#8364;50 million. As part of our Corporate Reorganization, outstanding shares of all series in CureVac SE have been exchanged for common shares in CureVac B.V., which subsequently were converted into shares of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the 2020 Private Investment those investors who have subscribed for our Series&#160;A, B and C shares, or the pre-IPO shareholders, became parties to an Investment and Shareholders&#8217; Agreement, as amended, pursuant to which certain of our pre-IPO shareholders holding at least 10% of our shares have entered into a Registration Right Agreement, as further described below. In addition, KfW has become a party to a Relationship Agreement and entered into a separate Shareholders&#8217; Agreement with dievini and Mr.&#160;Hopp as further described below. As part of the GSK Investment, we also entered into a collaboration agreement with GSK pursuant to which we are collaborating with GSK to research, develop and commercialize prophylactic and therapeutic non-replicating mRNA-based vaccines and antibodies targeting infectious disease pathogens. For further information regarding our collaboration agreement with GSK please refer to &#8220;Item 4. Information on the Company &#8212;&#8201; B. Business Overview &#8212;&#8201;Collaborations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are obligated to use the funds raised in the 2020 Private Investment solely to fund the (i)&#160;development of our proprietary pipeline, including earlier stage assets currently in preclinical development, (ii)&#160;research and development activities to expand our mRNA platform technology, in particular with respect to our vaccine candidate against SARS-CoV-2 and other infectious diseases and (iii)&#160;manufacturing capacities for mRNA-based drug product candidates and future approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shareholders&#8217; Agreement among KfW, dievini, DH-LT Investments GmbH and Mr.&#160;Hopp</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the KfW Investment, KfW, dievini and Mr.&#160;Hopp entered into a shareholders&#8217; agreement on June&#160;16, 2020, or the KfW dievini Shareholders&#8217; Agreement, agreeing to certain transfer restrictions and rights of first refusal relating to their interests in our company, nomination rights as provided elsewhere in this Annual Report, and a voting agreement relating to certain specified actions. In particular, dievini and Mr. Hopp agree to vote a specified number of their shares as directed by KfW on certain specified actions, subject to certain exceptions. These specified actions include,&#160;<i style="font-style:italic;">inter alia</i>: (1)&#160;transferring the tax domicile of CureVac N.V. and/or the approval of the transfer of the corporate or administrative seat of CureVac AG (currently CureVac SE); (2)&#160;relocating or ceasing activities in specified areas to a state outside the European Union to the extent (in particular in the area of the development of vaccines) material for the protection of the health of the population of the European Union; (3)&#160;entering into material mergers and acquisitions; and (4)&#160;amendments to the articles of association of CureVac AG (currently CureVac SE) which would affect the foregoing matters. Under the terms of KfW dievini Shareholders&#8217; Agreement, Mr.&#160;Hopp agreed to purchase an aggregate of &#8364;100&#160;million of our common shares in a private placement that took place with our initial public offering, in August 2020, at a price per share equal to our initial public offering price concurrently. Mr. Hopp effected this purchase through DH-LT-Investments GmbH, an affiliated entity. In connection with such concurrent private placement DH-LT-Investments GmbH has become a party to the KfW dievini Shareholders&#8217; Agreement. The KfW dievini Shareholders&#8217; Agreement has been extended to December 31, 2024. The Shareholders&#8217; Agreement may be terminated after December 31, 2024, by either party subject to six months&#8217; notice prior the end of the applicable calendar year. In addition, the Shareholders&#8217; Agreement shall automatically terminate if KfW sells all or a part of its interest in the Issuer to a third party, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investment and Shareholders&#8217; Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We and our pre-IPO shareholders, entered into an investment and shareholders&#8217; agreement July&#160;17, 2020, or the ISA. The ISA provides for certain particular shareholders&#8217; rights and also envisages restrictions on the shareholders party thereto, including the obligation to enter into a registration rights agreement, restrictions on transfer, as well as certain tag-along rights, drag-along rights, demand rights, rights of first offer and rights of first refusal.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the listing of our shares on Nasdaq, only certain limited provisions of the ISA survived the Corporate Reorganization. Pursuant to such surviving provisions, we and/or our pre-IPO shareholders are subject to certain obligations, as listed below.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5.3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We agreed to prepare and provide KfW our interim financials not later than 30&#160;days after the end of each quarter. In addition, not later than 30&#160;days prior to the start of each fiscal year we agreed to prepare and provide KfW our operating plans that shall include certain projections regarding our financials, our business plan relating to the succeeding fiscal year including our development plans, financial and investment plans, budgeted and projected figures and other information and forecasts. Our supervisory board needs to approve the planning by a simple majority vote. In addition, subject to certain limitations, the member of our supervisory board designated (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">nominiert</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) by KfW shall, to the extent not prohibited by any mandatory law and/or Nasdaq rules, be entitled to pass on and discuss any information received in his or her capacity as a member of the supervisory board with KfW and certain governmental agencies and offices of the federal government of the federal republic of Germany, however, restricted to the extent required for KfW and any of the aforementioned institutions to comply with their respective obligations. We are obligated to also provide to KfW upon its request such information that is reasonably requested by KfW for the management and the controlling of KfW&#8217;s shareholding in us in order for KfW and certain other institutions as of the Federal Republic of Germany to comply with their respective obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">KfW has the right to designate (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">nominieren</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) one member of our supervisory board for appointment by the general meeting (and to prompt the recall of such member of the supervisory board at its sole discretion) as long as KfW&#8217;s shareholding in our share capital is at least 10% in accordance with the arrangements included in our articles of association. Furthermore, our pre-IPO shareholders shall, to the extent legally permissible, ensure that any established advisory board or any other comparable panel of our subsidiaries or affiliate shall also provide KfW the right, upon its discretion, to include a member to be designated (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">nominieren</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We need to reasonably cooperate with each of our pre-IPO shareholders to provide them with information that is mandatory for their tax obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to withhold taxes on certain amounts paid to a pre-IPO shareholder, its affiliates and certain related persons of such pre-IPO shareholder (excluding a shareholder that was not our shareholder prior to the 2020 Private Investment), and such certain amounts are reimbursable or creditable to such pre-IPO shareholder, its affiliates and certain related persons of such pre-IPO shareholder, then such pre-IPO shareholder needs to use his or her best efforts in order to obtain a credit or reimbursement from the applicable tax authority and such credit or reimbursement shall be paid to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are obligated to use the funds raised in the 2020 Private Investment solely to fund the (i)&#160;development of our proprietary pipeline, including earlier stage assets currently in preclinical development, (ii)&#160;research and development activities to expand our mRNA platform technology, in particular with respect to our vaccine candidate against SARS-CoV-2 and other infectious diseases and (iii)&#160;manufacturing capacities for mRNA-based drug product candidates and future approved products;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We entered into a Global Access Agreement with the Bill &amp; Melinda Gates Foundation in February&#160;2015 pursuant to which we are required to take certain actions to support the Bill &amp; Melinda Gates Foundation&#8217;s mission. We may be required to redeem all, or to facilitate the purchase by a third party of all, the shares held in us by the Bill &amp; Melinda Gates Foundation as per the date of the ISA on certain terms that may not be favorable to us, if we receive from the Bill &amp; Melinda Gates Foundation a notification that we have (a)&#160;committed a material breach of certain commitments under the Global Access Agreement, (b)&#160;used the funds received from the Bill &amp; Melinda Gates Foundation for purposes other than those described in the Global Access Agreement, including not for the (i)&#160;finance of our facility to be used </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">inter alia</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to manufacture vaccines and drugs in support of the Bill &amp; Melinda Gates Foundation&#8217;s charitable purpose, (ii)&#160;continued development of technology for prophylactic and therapeutic mRNA vaccines and drugs against infectious diseases and vaccine adjuvants, comprised of long, non-coding RNA molecules and formulation/delivery technology necessary to develop the mRNA vaccines and drugs, or the Platform Technology, (iii)&#160;the use of the Platform Technology to advance vaccine and drug candidates in support of the Bill &amp; Melinda Gates Foundation charitable purpose and/or (c)&#160;failed to comply with certain U.S. regulatory and tax obligations, or together the BMGF Default, and the BMGF Default continues to exist following a cure period. In addition, if we are required but fail to purchase all of the shares held in us by the Bill &amp; Melinda Gates Foundation as per the date of the ISA, we shall not be allowed to pay dividends, redeem the shares of any other shareholder (other than repurchases at cost of shares from our employees, officers, directors, consultants or other persons performing services for us pursuant to agreements under which we have the option to repurchase our shares upon the occurrence of the termination of employment or service) or otherwise make any other distribution to any of our shareholders in connection with their shares. In addition, if within 12&#160;months after such redemption or sale, we close an underwritten public financing or a change of control occurs and the valuation used for such underwritten public financing or a change of control, as the case may be, is in excess of 200% of the valuation used for the redemption or the sale of the shares held by the Bill &amp; Melinda Gates Foundation, we will need to pay the Bill &amp; Melinda Gates Foundation compensation equal to the excess of what it would have received in such transaction if it still held its shares at the time of such underwritten public financing or a change of control over what it received in the sale or redemption of its shares had the BMGF Default not occurred. For further information regarding the Global Access Agreement see &#8220;Item 4. Information on the Company &#8212;&#8201; B. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Business Overview</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;&#8201;Collaborations &#8212; Bill &amp; Melinda Gates Foundation Partnership;&#8221;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upon the consummation of our initial public offering, we agreed to file, and filed, an application for continuation of tax book value (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Antrag auf Buchwertfortf&#252;hrung&#160;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acc. to Sec. 21 par. 1 second and third sentences of the German Tax Conversion Act&#8201;&#8212;&#8201;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">UmwStG</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) regarding the shares of CureVac AG (currently CureVac SE) that has been transferred as part of our initial public offering, as set out above, with the respectively competent tax authorities within four (4)&#160;months after the date of the ISA at the latest; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We agreed to provide pre-IPO shareholders holding at least 10% of our share capital certain information required to facilitate the disposition of our shares held by any such pre-IPO shareholder, or in some circumstances to provide information that we intend to file with the SEC and in such case we may be required to take into account the input of such pre-IPO shareholder holding prior to the filing with the SEC. In addition, we agreed that upon a written request of such a pre-IPO shareholder, we will add such pre-IPO shareholder holding to our liability insurance as a named insured in connection with the consummation of a registered offering, but any related premium shall be borne by such pre-IPO shareholder holding at least 10% of our share capital; and dievini and certain other limited pre-IPO shareholders agreed to bear the economics with respect to the Prior VSOP for a total of up to 60,175 participation rights corresponding with 10% of our share capital as of February&#160;1, 2015, in the amount of altogether &#8364;601,750,000. In case of an exercise event under the Prior VSOP, dievini and such other limited pre-IPO shareholders agreed to transfer common shares up to a pre-determined amount to allow us to fulfill any claims of the beneficiaries under the Prior VSOP.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Registration Rights Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We entered into a registration rights agreement upon the consummation off our initial public offering, pursuant to which each holder of at least 10% of our common shares and certain other holders of our common shares is entitled to various rights with respect to the registration of their common shares under the Securities Act. Each holder party to the registration rights agreement or an Eligible Shareholder shall continue to have various rights with respect to the registration of its common shares under the Securities Act, until 90&#160;days after such shareholder, including its affiliates, cease to hold at least 10% of our common shares, or any other future class of shares. The registration of these common shares under the Securities Act would result in these common shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. We are not required to register such common shares if an exemption from the registration requirements of the U.S. Securities Act is available with respect to the number of our common shares desired to be sold.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Form F-1 Registration Statement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">As of February&#160;9, 2021, any Eligible Shareholder or group of Eligible Shareholders, is entitled to demand in writing that we effect the registration under the Securities Act of the sale or other transfer of such shareholder or shareholders&#8217; common shares, provided that we are not required to effect more than three such registrations and that the aggregate anticipated offering price from the sale of such shares equals at least $35&#160;million, subject to certain exemptions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Form F-3 Registration Statement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">As of August&#160;13, 2021, each Eligible Shareholder or group of Eligible Shareholders may request in writing, not more than three times within 12-month period, that we effect a registration of the sale or other transfer of such shares, provided that the aggregate anticipated offering price from the sale of such shares equals at least $15&#160;million, subject to certain exemptions. We will not be obligated to file a registration statement on Form F-3 in certain customary cases, subject to certain exemptions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Piggyback Registration Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The registration rights agreement provides our Eligible Shareholders with &#8220;piggy back&#8221; registration rights in the event that we determine to register the sale of any of our securities. With respect to such registration rights, we are committed to use our reasonable best efforts to include in a registration statement a prospectus relating to the resale of certain securities held by certain of our Eligible Shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Relationship Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the KfW Investment, KfW, dievini and CureVac B.V. entered into a relationship agreement on July&#160;17, 2020, or the KfW dievini Relationship Agreement. Pursuant the KfW dievini Relationship Agreement the parties provide for our agreed form of the articles of association, the supervisory board rules and the management board rules. In addition, the KfW dievini Relationship Agreement establishes that if at any time during the effectiveness of the KfW dievini Shareholders&#8217; Agreement any of our shareholders other than KfW or dievini is granted a nomination right to our supervisory board or the supervisory board of any of our subsidiaries, then all of the parties to the KfW dievini Relationship Agreement shall use best efforts to exercise their shareholder rights to ensure that KfW and dievini shall each be given a nomination right as well. We also agreed not to procure, not to propose or implement during the terms of the KfW dievini Shareholders&#8217; Agreement and the ISA, any amendment to the corporate documents of CureVac AG (currently CureVac SE) or CureVac B.V. or CureVac N.V., which would violate or not observe the Relationship Agreement, the ISA or other agreements concluded with us and KfW in connection with KfW&#8217;s investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our articles of association require us to indemnify our current and former managing directors and supervisory directors to the fullest extent permitted by law, subject to certain exceptions. We entered into indemnification agreements with all our managing directors and supervisory directors and may enter into additional indemnification agreements with future managing directors and supervisory directors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of our managing directors and supervisory directors have entered into service agreements with us as discussed in more detail within &#8220;Item 6. Directors, Senior Management and Employees &#8212; C. Board Practices &#8212; Service Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer of Shares from Prior Shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 10, 2021, October 18, 2021, and December 12, 2022, the holders of the virtual shares under the Prior VSOP plan exercised all of their exercisable virtual shares. See note 10 to our audited consolidated financial statements contained elsewhere in this Annual Report for further information on the exercise of the virtual shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">C.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Interests of Experts and Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_aac669f1_0f9a_4c4b_b0cb_c1a63e50859f"></a><a id="ITEM8FINANCIALINFORMATION_151512"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 8. FINANCIAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Consolidated Statements and<span style="font-weight:normal;"> </span>Other Financial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 18. Financial Statements,&#8221; which contains our audited financial statements prepared in accordance with IFRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities including proceedings initiated by former employees and directors. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report, we do not believe such claims and proceedings, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. If and to the extent necessary, we have formed appropriate accruals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In connection with our adjustment of our external European manufacturing network after the withdrawal of our EMA dossier for our vaccine candidate, CvnCoV, we are involved in disputes with three former contract manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In February 2022, we were served with a request for arbitration filed with the German Arbitration Institute by Wacker Biotech B.V. seeking payments based on a terminated agreement with us. In April 2022, Celonic Deutschland GmbH &amp; Co.KG initiated arbitration proceedings according to the procedural rules of the German Arbitration Institute against us also requesting payments based on a terminated agreement. The agreements with Wacker and Celonic were terminated in connection with the withdrawal of our EMA dossier for our drug candidate CVnCoV. We have defended ourselves vigorously against Wacker&#8217;s and Celonic&#8217;s claims in written submission and the oral hearings. The taking of evidence has concluded in both proceedings, and we are awaiting the final awards of the arbitration tribunals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In August 2022, Rentschler Biopharma SE initiated arbitration proceedings according to the procedural rules of the German Arbitration Institute against us. Rentschler's claims are based on the assumption that certain agreements between Rentschler and CureVac Manufacturing GmbH (then: CureVac Real Estate GmbH) have been terminated due to the withdrawal of our EMA dossier for CVnCoV or alternatively that CureVac would have been obliged to terminate these agreements. CureVac's position always was that the agreements had ended upon expiration of their term. We did not believe that there was a legal basis for Rentschler's claims and therefore defended ourselves vigorously against these claims in written submissions and the oral hearing in October 2023. In its final award rendered in April 2024, the arbitration tribunal followed CureVac's arguments and dismissed Rentschler's claims in their entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In addition, we are involved in several intellectual property related legal proceedings.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In June 2022, we filed a lawsuit against BioNTech in the D&#252;sseldorf Regional Court for infringement of several of CureVac&#8217;s patents and utility models as a result of the manufacture, use and sale of Comirnaty. Additionally, certain of our patents and utility models are part of infringement claims in Germany filed by BioNTech. For all patents and utility models parallel invalidity claims (nullity action, oppositions and cancellation actions) were filed by BioNTech. In December 2023, the Federal Patent Court in Germany revoked one patent which is part of the infringement claim. The formal reasons for the decision of the court have not yet been provided. CureVac intends to appeal this decision before the German Federal Court of Justice. The proceedings before the D&#252;sseldorf Regional Court regarding the remaining intellectual property rights are still ongoing and will be decided individually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In November 2022, BioNTech filed cancellation actions seeking the cancellation of three of CureVac&#8217;s German utility models in the German Patent and Trademark Office. In November 2023, BioNTech filed cancellation actions against two additional utility models in the German Patent and Trademark Office. In December 2023, BioNTech filed an opposition against a European patent at the European Patent Office. CureVac is defending against these actions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In September 2022, BioNTech and Pfizer filed a declaration of non-infringement and revocation action against two of CureVac&#8217;s patents in the Patents Court of the Business and Property Courts of England and Wales. We counterclaimed that such patents are valid and infringed by Comirnaty and subsequently added a third patent to our counterclaim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In July 2022, BioNTech and Pfizer filed a complaint in the U.S. District Court for the District of Massachusetts seeking declaratory judgment of non-infringement of several of CureVac&#8217;s patents by Comirnaty. Subsequently we successfully filed a motion to have the case transferred to the Eastern District of Virginia. In May 2023, CureVac filed a counterclaim alleging infringement of several of our U.S. patents by the manufacture and sale of Comirnaty. Pfizer and BioNTech filed a counterclaim alleging non-infringement and validity of the asserted rights. In November 2023, Acuitas filed a motion to intervene and a motion to sever and stay in the U.S. proceedings regarding four U.S. patents. Simultaneously, Acuitas filed a separate case in the Eastern District of Virginia (Norfolk) claiming co-inventorship for the same patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In October 2023, Acuitas initiated arbitration proceedings against CureVac. Acuitas requests a declaration of the tribunal that Acuitas co-owns a patent family which is part of CureVac&#8217;s litigation against BioNTech and Pfizer in Germany and the United States and asserts consequential claims. CureVac will defend itself against these claims. The possible outcome of this dispute cannot be predicted at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">For more information, see also &#8220;Item 3. Key Information &#8212; D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property Rights.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Legal disputes, arbitration and litigation are inherently unpredictable. While we do not believe that any of these matters will have a material adverse effect on our financial position, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our financial condition or on our results of operations and/or our cash flows in the period in which any such amounts are accrued or paid. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends and Dividend Policy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We have never paid or declared any cash dividends on our common shares, and we do not anticipate paying any cash dividends on our common shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Under Dutch law, we may only pay dividends to the extent our shareholders&#8217; equity (<i style="font-style:italic;">eigen vermogen</i>) exceeds the sum of the paid-in and called-up share capital plus the reserves required to be maintained by Dutch law or by our articles of association and (if it concerns a distribution of profits) after adoption of the annual accounts by the general meeting from which it appears that such dividend distribution is allowed. Subject to such restrictions, any future determination to pay dividends will be at the discretion of our management board with the approval of our supervisory board and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our management board and supervisory board deem relevant.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under our articles of association, our management board may decide that all or part of the profits are added to our reserves. Before reservation of any profit, to the extent that preferred shares have been canceled and preferred distributions on those canceled shares are outstanding, the profits are first to be used to satisfy the outstanding claim to those who held those preferred shares at the moment of such cancellation becoming effective and subsequently if any preferred shares are outstanding, a dividend is paid out of the remaining profit on the preferred shares in accordance with our articles of association. This dividend, or preferred dividend, shall be calculated on the basis of a fixed rate over the amount paid-up on the outstanding preferred shares pro&#160;rata tempore for the period during which they were outstanding during the financial year concerned, and shall include any arrears in payment of prior&#160;years&#8217; preferred dividends (if any). The remaining profit will be at the disposal of the general meeting at the proposal of the management board for distribution on the common shares, subject to restrictions of Dutch law and approval by our supervisory board of such proposal of our management board. Our management board is permitted, subject to certain requirements, to declare interim dividends without the approval of the general meeting, but only with the approval of the supervisory board. Dividends and other distributions shall be made payable not later than the date determined by the management board. Claims to dividends and other distributions not made within five&#160;years from the date that such dividends or distributions became payable will lapse and any such amounts will be considered to have been forfeited to us (<i style="font-style:italic;">verjaring</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Significant Changes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_56dd11f9_61b1_4b54_930f_3eb1253f8029"></a><a id="ITEM9THEOFFERANDLISTING_784381"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9. THE OFFER AND LISTING</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Offering and Listing Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our common shares, with a par value of &#8364;0.12 per share, have traded on Nasdaq under the symbol &#8220;CVAC&#8221; since August 14, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Plan of Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">C.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Markets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a description of our publicly traded common shares, see &#8220;Item 9. The Offering and Listing &#8212; A. Offer and Listing Details.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">D.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Selling Shareholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">E.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Dilution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">F.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Expenses of the Issue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_1c54e69f_6f3c_4e49_8fc8_8f695447fb52"></a><a id="ITEM10ADDITIONALINFORMATION_673584"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 10. ADDITIONAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Share Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Memorandum and Articles of Association</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our shareholders adopted the Articles of Association included as Exhibit 3.1 to our revised registration statement on Form F-1 (File No. 333-240076) filed with the SEC on August 7, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We incorporate by reference into this Annual Report on Form 20-F the description of our Articles of Association effective upon the closing of our last public offering contained in our Registration Statement on Form F-3 (File No. 333-259613), under &#8220;Description of Share Capital and Articles of Association&#8221; filed with the SEC on September 17, 2021. Such description sets forth a summary of certain provisions of our articles of association, and certain descriptions of applicable German and Dutch law, each as currently in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">C.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Material Contracts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 4. Information on the Company &#8212; B. Business Overview &#8212; Significant Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">D.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Exchange Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Dutch law, there are no exchange controls applicable to the transfer to persons outside of the Netherlands of dividends or other distributions with respect to, or of the proceeds from the sale of, shares of a Dutch company, subject to applicable restrictions under sanctions and measures, including those concerning export control, pursuant to European Union regulations, the Sanctions Act 1977 (<i style="font-style:italic;">Sanctiewet 1977</i>) or other legislation, applicable anti-boycott regulations and similar rules. There are no special restrictions in the articles of association or Dutch law that limit the right of shareholders who are not citizens or residents of the Netherlands to hold or vote shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">E.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following summary contains a description of certain Dutch, German and U.S. federal income tax consequences of the acquisition, ownership and disposition of common shares, but it does not purport to be a comprehensive description of all the tax considerations that may be relevant to a decision to purchase common shares. The summary is based upon the tax laws of the Netherlands and regulations thereunder, the tax laws of Germany and regulations thereunder and the tax laws of the United States and regulations thereunder as of the date hereof, which are subject to change. You should consult your tax advisor regarding the applicable tax consequences to you of investing in our common shares.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Material Dutch Tax Considerations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a general summary of certain material Dutch tax consequences of the acquisition, holding and disposal of our common shares. This summary does not purport to set forth all possible tax considerations or consequences that may be relevant to a holder or prospective holder of our common shares and does not purport to deal with the tax consequences applicable to all categories of investors, some of which (such as trusts or similar arrangements) may be subject to special rules. In view of its general nature, it should be treated with corresponding caution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary is based on the tax laws of the Netherlands, published regulations thereunder and published authoritative case law, all as in effect on the date hereof, including, for the avoidance of doubt, the tax rates applicable on the date hereof, and all of which are subject to change, possibly with retroactive effect. Any such change may invalidate the contents of this summary, which will not be updated to reflect such change. Where the summary refers to &#8220;the Netherlands&#8221; or &#8220;Dutch&#8221; it refers only to the part of the Kingdom of the Netherlands located in Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is for general information purposes and is not Dutch tax advice or a complete description of all Dutch tax consequences relating to the acquisition, holding and disposal of our common shares. Holders or prospective holders of our common shares should consult their own tax advisor regarding the Dutch tax consequences relating to the acquisition, holding and disposal of our common shares in light of their particular circumstances.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please note that this section does not set forth the Dutch tax considerations for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">holders of common shares if such holders have a substantial interest (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">aanmerkelijk belang</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) or deemed substantial interest (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">fictief aanmerkelijk belang</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) under the Dutch Income Tax Act 2001 (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wet inkomstenbelasting 2001</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). Generally, a holder of securities in a company is considered to hold a substantial interest in such company if such holder alone or, in the case of individuals, together with such holder&#8217;s partner for Dutch income tax purposes, or any relatives by blood or marriage in the direct line (including foster children), directly or indirectly holds (i)&#160;an interest of 5% or more of the total issued and outstanding capital of that company or of 5% or more of the issued and outstanding capital of a certain class of shares of that company; or (ii)&#160;rights to acquire, directly or indirectly, such interest; or (iii)&#160;certain profit sharing rights in that company that relate to 5% or more of the company&#8217;s annual profits and/or to 5% or more of the company&#8217;s liquidation proceeds. A deemed substantial interest exists if a substantial interest (or part thereof) in a company has been disposed of, or is deemed to have been disposed of, on a non-recognition basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">holders of common shares for which the common shares qualify or qualified as a participation (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">deelneming</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) for purposes of the Dutch Corporate Income Tax Act 1969 (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wet op de vennootschapsbelasting 1969</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). Generally, a holder&#8217;s shareholding of 5% or more in a company&#8217;s nominal paid-up share capital qualifies as a participation. A holder may also have a participation if (a) such holder does not have a shareholding of 5% or more but a related entity (statutorily defined term) has a participation or (b) the company in which the shares are held is a related entity (statutorily defined term);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">holder of common shares which are or who are entitled to the dividend withholding tax exemption (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">inhoudingsvrijstelling</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) with respect to any income (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">opbrengst</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) derived from the common shares (as defined in Article 4 of the Dutch Dividend Withholding Tax Act 1965 (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wet op de dividendbelasting 1965</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). Generally, a holder of common shares may be entitled or required to apply, subject to certain other requirements, the dividend withholding tax exemption if it is an entity and holds and interest of 5% or more in our nominal paid-up share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pension funds, investment institutions (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">fiscale beleggingsinstellingen</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">), tax exempt investment institutions (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">vrijgestelde beleggingsinstellingen</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) (each as defined in the Dutch Corporate Income Tax Act 1969) and other entities that are, in whole or in part, not subject to or exempt from Dutch corporate income tax, entities that have a function comparable to an investment institution or a tax exempt investment institution, as well as entities that are exempt from corporate income tax in their country of residence, such country of residence being another state of the European Union, Norway, Liechtenstein, Iceland or any other state with which the Netherlands has agreed to exchange information in line with international standards; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">holders of common shares who are individuals and for whom the common shares or any benefit derived from the common shares are a remuneration or deemed to be a remuneration for (employment) activities performed by such holders or certain individuals related to such holders (as defined in the Dutch Income Tax Act 2001).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Dividend Withholding Tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends distributed by us generally are subject to Dutch dividend withholding tax at a rate of 15%. Generally, we are responsible for the withholding of such dividend withholding tax at source; the Dutch dividend withholding tax is for the account of the holder of our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expression &#8220;dividends distributed&#8221; includes, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distributions in cash or in kind, deemed and constructive distributions and repayments of paid-in capital not recognized for Dutch dividend withholding tax purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liquidation proceeds, proceeds from the redemption of common shares, or proceeds from the repurchase of common shares (other than as temporary portfolio investment; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">tijdelijke belegging</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) by us or one of our subsidiaries or other affiliated entities to the extent such proceeds exceed the average paid-in capital of those common shares as recognized for Dutch dividend withholding tax purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an amount equal to the par value of common shares issued or an increase of the par value of common shares, to the extent that it does not appear that a contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partial repayment of the paid-in capital, recognized for Dutch dividend withholding tax purposes, if and to the extent that we have net profits (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">zuivere winst</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">), unless (i) the general meeting has resolved in advance to make such repayment and (ii) the par value of the common shares concerned has been reduced by an equal amount by way of an amendment of our articles of association. The term &#8220;net profits&#8221; includes anticipated profits that have yet to be realized.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.1pt 62.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Corporate legal entities that are resident or deemed to be resident of the Netherlands for Dutch corporate income tax purposes (&#8220;Dutch Resident Entities&#8221;) generally are entitled to an exemption from, or a credit for, any Dutch dividend withholding tax against their Dutch corporate income tax liability. The credit in any given year is, however, limited to the amount of Dutch corporate income tax payable in respect of the relevant year with an indefinite carry forward of any excess amount. Individuals who are resident or deemed to be resident of the Netherlands for Dutch personal income tax purposes (&#8220;Dutch Resident Individuals&#8221;) generally are entitled to a credit for any Dutch dividend withholding tax against their Dutch personal income tax liability and to a refund of any residual Dutch dividend withholding tax. The above generally also applies to holders of our common shares that are neither resident nor deemed to be resident of the Netherlands (&#8220;Non-Resident Holders&#8221;) if the common shares are attributable to a Dutch permanent establishment of such Non-Resident Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A holder of common shares resident of a country other than the Netherlands may, depending on such holder&#8217;s specific circumstances, be entitled to exemptions from, reduction of, or full or partial refund of, Dutch dividend withholding tax under Dutch domestic tax law, EU law, or treaties for the avoidance of double taxation in effect between the Netherlands and such other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividend Stripping</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to Dutch domestic anti-dividend stripping rules, no credit against Dutch tax, exemption from, reduction, or refund of Dutch dividend withholding tax will be granted if the recipient of the dividends we paid is not considered the beneficial owner (<i style="font-style:italic;">uiteindelijk gerechtigde</i>; as described in the Dutch Dividend Withholding Tax Act 1965) of those dividends. This legislation generally targets situations in which a shareholder retains its economic interest in shares but reduces the withholding tax costs on dividends by a transaction with another party. It is not required that the recipient of the dividends is aware that a dividend stripping transaction took place for these rules to apply. The Dutch State Secretary of Finance takes the position that the definition of beneficial ownership introduced by this legislation will also be applied in the context of a double taxation convention. As from January 1, 2024, more stringent rules apply to the setoff, exemption from, and reduction or refund of Dutch dividend withholding tax to address situations where a claim for setoff, exemption, reduction or refund may align with the letter of Dutch tax law or a double taxation convention but goes against the underlying intention or spirit of the dividend stripping rules, as perceived by the legislator. The burden of proof with respect to beneficial ownership of dividends distributed by us rests on the Dutch tax authorities. If, however, a shareholder would receive dividends, including dividends on the common shares, in a calendar year in respect of which an aggregate amount of &#8364;1,000 in Dutch dividend withholding tax would otherwise be due based on the rate of 15%, the burden of proof with respect to beneficial ownership of such dividends lies with the shareholder. Furthermore, for shares traded on a regulated market, including the common shares, it has been codified that the record date is used when determining the person who is entitled to the dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditional withholding tax on dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the regular Dutch dividend withholding tax as described above, a Dutch conditional withholding tax will be imposed on dividends distributed by us to entities related (<i style="font-style:italic;">gelieerd</i>) to us (within the meaning of the Dutch Withholding Tax Act 2021; Wet bronbelasting 2021), if such related entity:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is considered to be resident (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">gevestigd</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) in a jurisdiction that is listed in the yearly updated Dutch Regulation on low-taxing states and non-cooperative jurisdictions for tax purposes (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Regeling laagbelastende staten en niet-co&#246;peratieve rechtsgebieden voor belastingdoeleinden</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) (a &#8220;Listed Jurisdiction&#8221;); or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">has a permanent establishment located in a Listed Jurisdiction to which the common shares are attributable; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">holds the common shares for the main purpose or one of the main purposes to avoid taxation for another person or entity and there is an artificial arrangement or transaction or a series of artificial arrangements or transactions; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> is not considered to be the beneficial owner of the common shares in its jurisdiction of residence because such jurisdiction treats another entity as the beneficial owner of the common shares (a hybrid mismatch); or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">202</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is not resident in any jurisdiction (also a hybrid mismatch); or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is a reverse hybrid (within the meaning of Article 2(12) of the Dutch Corporate Income Tax Act 1969), if and to the extent (x) there is a participant in the reverse hybrid which is related (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">gelieerd</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) to the reverse hybrid, (y) the jurisdiction of residence of such participant treats the reverse hybrid as transparent for tax purposes and (z) such participant would have been subject to the Dutch conditional withholding tax in respect of dividends distributed by us without the interposition of the reverse hybrid, all within the meaning of the Dutch Withholding Tax Act 2021.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Dutch conditional withholding tax on dividends will be imposed at the highest Dutch corporate income tax rate in effect at the time of the distribution 2024: 25.8%). The Dutch conditional withholding tax on dividends will be reduced, but not below zero, by any regular Dutch dividend withholding tax withheld in respect of the same dividend distribution. As such, based on the currently applicable rates, the overall effective tax rate of withholding the regular Dutch dividend withholding tax (as described above) and the Dutch conditional withholding tax on dividends will not exceed the highest corporate income tax rate in effect at the time of the distribution (2024: 25.8%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dual Tax Residency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are incorporated under the laws of the Netherlands, and we are therefore a Dutch tax resident for Dutch domestic tax law purposes, including the Dutch Dividend Withholding Tax Act 1969. We are also treated as a German tax resident for German domestic tax law purposes, since our place of effective management is located in Germany. Based on the so-called tie-breaker provision (the &#8220;Tie-Breaker Provision&#8221;) included in Section 4(3) of the 2012 Convention between the Federal Republic of Germany and the Kingdom of the Netherlands for the avoidance of double taxation with respect to taxes on income (the &#8220;double tax treaty between Germany and the Netherlands&#8221;) as in effect on the date hereof, our tax residence in either the Netherlands or Germany for the purposes of the double tax treaty between Germany and the Netherlands should be determined on our place of effective management. As long as our place of effective management is in Germany, and the Tie-Breaker Provision and the reservation made by Germany with respect to the Tie-Breaker Provision as part of the Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting are not changed, we should exclusively be a tax resident of Germany for purposes of the double tax treaty between Germany and the Netherlands. As a consequence, the Netherlands will be restricted from imposing Dutch dividend withholding tax on dividends distributed by us pursuant to Section 10(5) of the double tax treaty between Germany and the Netherlands, except for dividends distributed to Dutch Resident Entities, Dutch Resident Individuals and Non-Resident Holders if the common shares are attributable to a permanent establishment in the Netherlands of such Non-Resident Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Taxes on Income and Capital Gains</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dutch Resident Entities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally speaking, if the holder of common shares is a Dutch Resident Entity, any benefits derived or deemed to be derived from the common shares or any capital gains realized on the disposal or deemed disposal of the common shares is subject to Dutch corporate income tax at a rate of 19% with respect to taxable profits up to &#8364;200,000 and 25.8% with respect to taxable profits in excess of that amount (rates and brackets for 2024).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dutch Resident Individuals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the holder of common shares is a Dutch Resident Individual, any benefits derived or deemed to be derived from the common shares or any capital gains realized on the disposal or deemed disposal of the common shares is taxable at the progressive Dutch income tax rates (with a maximum of 49.5% in 2024), if:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the common shares are attributable to an enterprise from which the holder of common shares derives a share of the profit, whether as an entrepreneur (<i style="font-style:italic;">ondernemer</i>) or as a person who has a co-entitlement to the net worth (<i style="font-style:italic;">medegerechtigd tot het vermogen</i>) of such enterprise without being a shareholder (as defined in the Dutch Income Tax Act 2001); or</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1pt;margin-top:0pt;">the holder of common shares is considered to perform activities with respect to the common shares that go beyond ordinary asset management (<i style="font-style:italic;">normaal, actief vermogensbeheer</i>) or otherwise derives benefits from the common shares that are taxable as benefits from miscellaneous activities (<i style="font-style:italic;">resultaat uit overige werkzaamheden</i>).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.1pt 62.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">203</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Taxation of savings and investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">If the above-mentioned conditions (i) and (ii) do not apply to the Dutch Resident Individual, the common shares will be subject to an annual Dutch income tax under the regime for savings and investments (</span>inkomen uit sparen en beleggen<span style="font-style:normal;">). Taxation only occurs insofar the Dutch Resident Individual&#8217;s net investment assets for the year exceed a statutory threshold (</span>heffingvrij vermogen<span style="font-style:normal;">). The net investment assets for the year are the fair market value of the investment assets less the fair market value of the liabilities on January 1 of the relevant calendar year (reference date;</span> peildatum<span style="font-style:normal;">). Actual income or capital gains realized in respect of the common shares are as such not subject to Dutch income tax.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Dutch Resident Individual&#8217;s assets and liabilities taxed under this regime, including the common shares, are allocated over the following three categories: (a) bank savings (</span>banktegoeden<span style="font-style:normal;">), (b) other investments (</span>overige bezittingen<span style="font-style:normal;">), including the common shares, and (c) liabilities (</span>schulden<span style="font-style:normal;">). The taxable benefit for the year (</span>voordeel uit sparen en beleggen<span style="font-style:normal;">) is equal to the product of (x) the total deemed return divided by the sum of bank savings, other investments and liabilities and (b) the sum of bank savings, other investments and liabilities minus the statutory threshold, and is taxed at a flat rate of 36% (rate for 2024).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The deemed return applicable to other investments, including the common shares, is set at 6.04% for the calendar year 2024. Transactions in the three-month period before and after January 1 of the relevant calendar year implemented to arbitrate between the deemed return percentages applicable to bank savings, other investments and liabilities will for this purpose be ignored if the holder of common shares cannot sufficiently demonstrate that such transactions are implemented for other than tax reasons.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The current Dutch income tax regime for savings and investments was implemented in Dutch tax law following the decision of the Dutch Supreme Court (Hoge Raad) of 24 December 2021 (ECLI:NL:2021:1963) (the &#8220;Decision&#8221;). In the Decision, the Dutch Supreme Court ruled that the (old) system of taxation for savings and investments based on a deemed return may under specific circumstances contravene with Section 1 of the First Protocol to the European Convention on Human Rights in combination with Section 14 of the European Convention on Human Rights (the &#8220;EC-Human Rights&#8221;). A new court procedure is pending before the Dutch Supreme Court questioning whether the current tax system for savings and investments is in line with the Decision. On 18 September 2023 (ECLI:NL:PHR:2023:655) the Attorney General Wattel concluded that the new tax system is not in line with the Decision, except for the taxation of bank savings, as the system is, in short, still based on a deemed return rather than actual returns, and as a result, the regime contravenes with the EC-Human Rights. The decision of the Dutch Supreme Court is expected mid-2024. In addition, on 8 September 2023, the former cabinet published a law proposal for a new tax system for savings and investments on the basis of actual returns according to an asset accumulation system, the &#8216;Actual Return Box 3 Act&#8217; (Wet werkelijk rendement box 3). The proposed system is expected to come into effect on 1 January 2027 at the earliest. However, it is up to the new cabinet to submit a final law proposal to the Dutch parliament.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of common shares are advised to consult their own tax advisor to ensure that the tax in respect of the common shares is levied in accordance with the applicable Dutch tax rules at the relevant time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-residents of the Netherlands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A holder of common shares that is neither a Dutch Resident Entity nor a Dutch Resident Individual will not be subject to Dutch (corporate) income tax in respect of income derived or deemed to be derived from the common shares or in respect of capital gains realized on the disposal or deemed disposal of the common shares, provided that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such holder does not have an interest in an enterprise or deemed enterprise (as defined in the Dutch Income Tax Act 2001 and the Dutch Corporate Income Tax Act 1969) which, in whole or in part, is either effectively managed in the Netherlands or carried on through a permanent establishment, a deemed permanent establishment or a permanent representative in the Netherlands and to which enterprise or part of an enterprise the common shares are attributable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event the holder is an individual, such holder does not carry out any activities in the Netherlands with respect to the common shares that go beyond ordinary asset management and does not otherwise derive benefits from the common shares that are taxable as benefits from miscellaneous activities in the Netherlands.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">204</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Gift and Inheritance Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Residents of the Netherlands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Gift or inheritance taxes will arise in the Netherlands with respect to a transfer of common shares by way of a gift by, or on the death of, a holder of such common shares who is resident or deemed resident of the Netherlands at the time of the gift or the holder&#8217;s death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-residents of the Netherlands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No gift or inheritance taxes will arise in the Netherlands with respect to a transfer of common shares by way of gift by, or on the death of, a holder of common shares who is neither resident nor deemed to be resident of the Netherlands, unless:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a gift of common shares by an individual who at the date of the gift was neither resident nor deemed to be resident of the Netherlands, such individual dies within 180&#160;days after the date of the gift, while being resident or deemed to be resident of the Netherlands; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a gift of common shares is made under a condition precedent, the holder of common shares is resident or is deemed to be resident of the Netherlands at the time the condition is fulfilled; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the transfer is otherwise construed as a gift or inheritance made by, or on behalf of, a person who, at the time of the gift or death, is or is deemed to be resident of the Netherlands.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of Dutch gift and inheritance taxes, among others, a person that holds the Dutch nationality will be deemed to be resident of the Netherlands if such person has been resident in the Netherlands at any time during the ten (10) years preceding the date of the gift or such person&#8217;s death. Additionally, for purposes of Dutch gift tax, amongst others, a person not holding the Dutch nationality will be deemed to be resident of the Netherlands if such person has been resident in the Netherlands at any time during the twelve (12) months preceding the date of the gift. Applicable tax treaties may override deemed residency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Value Added Tax (VAT)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No Dutch VAT will be payable by a holder of common shares in respect of any payment in consideration for the holding or disposal of the common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stamp Duties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No Dutch documentation taxes (commonly referred to as stamp duties) will be payable by a holder of common shares in respect of any payment in consideration for the holding or disposal of the common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Material German Tax Considerations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following section is a description of the material German tax considerations that become relevant when purchasing, holding or transferring the company&#8217;s shares. The section is based on the German tax law applicable as of the date of this Annual Report. It should be noted that the law may change following the issuance of this Annual Report and that such changes may have retroactive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The material German tax principles of purchasing, owning and transferring of shares are set forth in the following. This section does not purport to be a comprehensive or complete analysis or listing of all potential tax effects of the purchase, ownership or disposition of shares and does not set forth all tax considerations that may be relevant to a particular person&#8217;s decision to acquire common shares. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">205</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section is intended as general information only and does not purport to be a comprehensive or complete description of all potential German tax effects of the acquisition, ownership or transfer of ordinary shares and does not set forth all German tax considerations that may be relevant to a particular person&#8217;s decision to acquire ordinary shares. It does not constitute particular German tax advice and potential purchasers of CureVac&#8217;s ordinary shares are urged to consult their own tax advisors regarding the tax consequences of the acquisition, ownership and transfer of ordinary shares in light of their particular circumstances with regard to the application of German tax law to their particular situations, in particular with respect to the procedure to be complied with to obtain a relief of withholding tax on dividends and on capital gains (<i style="font-style:italic;">Kapitalertragsteuer</i>) and with respect to the influence of double tax treaty provisions, as well as any tax consequences arising under the laws of any state, local or other non-German jurisdiction. For German tax purposes, a shareholder may include an individual who or an entity that does not have the legal title to the ordinary shares, but to whom nevertheless the ordinary shares are attributed, based either on such individual or entity owning a beneficial interest in the ordinary shares or based on specific statutory provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the following is subject to change. Such changes could apply retroactively and could affect the consequences set forth below. This section does not refer to any U.S. Foreign Account Tax Compliance Act aspects (FACTA).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">CureVac&#8217;s Tax Residency Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac has its statutory seat in the Netherlands and its sole place of management in Germany and is therefore tax resident in Germany (for purposes of the German-Dutch tax treaty). Thus, CureVac qualifies as a corporation subject to German unlimited liability for corporate income tax purposes. However, because CureVac&#8217;s tax residency depends on future facts regarding its place of management the German unlimited liability for corporate income tax purposes may change in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Dividends Tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Withholding Tax on Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends distributed from a company to its shareholders are subject to withholding tax, subject to certain exemptions (for example, repayments of capital from the tax equity account (<i style="font-style:italic;">steuerliches Einlagekonto</i>)), as described in the following. The withholding tax rate is 25% plus 5.5% solidarity surcharge (<i style="font-style:italic;">Solidarit&#228;tszuschlag</i>) thereon (in total 26.375%) of the gross dividend approved by the ordinary shareholders&#8217; meeting. Withholding tax is to be withheld and passed on for the account of the shareholders by a domestic branch of a domestic or foreign credit or financial services institution (<i style="font-style:italic;">Kredit-und Finanzdienstleistungsinstitut</i>), by the domestic securities trading company (<i style="font-style:italic;">inl&#228;ndisches Wertpapierhandelsunternehmen</i>) or a domestic securities trading bank (<i style="font-style:italic;">inl&#228;ndische Wertpapierhandelsbank</i>) which keeps and administers the shares and disburses or credits the dividends or disburses the dividends to a foreign agent, or by the securities custodian bank (<i style="font-style:italic;">Wertpapiersammelbank</i>) to which the shares were entrusted for collective custody if the dividends are distributed to a foreign agent by such securities custodian bank (which is referred to as the &#8220;Dividend Paying Agent&#8221;). In case the shares are not held in collective deposit with a Dividend Paying Agent, the company is responsible for withholding and remitting the tax to the competent tax office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Such withholding tax is levied and withheld irrespective of whether, and to what extent, the dividend distribution is taxable at the level of the shareholder, and whether the shareholder is a person residing in Germany or in a foreign country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of dividends distributed to a company within the meaning of Art. 2 of the amended EU Directive 2011/96/EU of the Council of November&#160;30, 2011, or the EU Parent Subsidiary Directive, domiciled in another Member State of the European Union, an exemption from withholding tax will be granted upon request if further prerequisites are satisfied (<i style="font-style:italic;">Freistellung im Steuerabzugsverfahren</i>). This also applies to dividends distributed to a permanent establishment located in another Member State of the European Union of such a parent company or of a parent company tax resident in Germany if the participation in the company is effectively connected with this permanent establishment. The key prerequisite for the application of the EU Parent Subsidiary Directive is that the shareholder has held a direct participation in the share capital of the company of at least 10% for at least one year.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">206</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The withholding tax on distributions to other foreign resident shareholders is reduced in accordance with a double taxation treaty (e.g., to 15%, 5% or 0% depending on certain prerequisites) if Germany has concluded such double taxation treaty with the country of residence of the shareholder and if the shareholder does not hold his shares either as part of the assets of a permanent establishment or a fixed place of business in Germany or as business assets for which a permanent representative has been appointed in Germany. The reduction of the withholding tax is procedurally granted in such a manner that the difference between the total amount withheld, including the solidarity surcharge, and the tax liability determined on the basis of the tax rate set forth in the applicable double taxation treaty (15% unless further qualifications are met) is refunded by the German tax administration upon request (Federal Central Office for Taxes (<i style="font-style:italic;">Bundeszentralamt f&#252;r Steuern</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of dividends received by corporations whose statutory seat and effective place of management are not located in Germany and who are therefore not tax resident in Germany, two-fifths of the withholding tax deducted and remitted are refunded without the need to fulfill all prerequisites required for such refund under the EU Parent Subsidiary Directive or under a double taxation treaty or if no double taxation treaty has been concluded between the state of residence of the shareholder. However, such refund is subject to the German anti-directive/treaty shopping provision of Section 50d paragraph 3 of the German Income Tax Act (<i style="font-style:italic;">Einkommensteuergesetz</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to receive a refund pursuant to a double taxation treaty or the aforementioned option for foreign corporations, the shareholder has to electronically submit a n application via the Federal Central Tax Office&#8217;s online portal (www.elster.de/bportal) and upload certain documents during the application, i.a. a withholding tax certificate (<i style="font-style:italic;">Kapitalertragsteuerbescheinigung</i>) issued by the institution that withheld the tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The exemption from withholding tax in accordance with the EU Parent Subsidiary Directive or a double tax treaty and the aforementioned options for a refund of the withholding tax (with or without protection under a double taxation treaty) depend on whether certain additional prerequisites (in particular so-called substance requirements) are fulfilled. The applicable withholding tax relief will only be granted if the preconditions of the German anti avoidance rules (so called Directive Override or Treaty Override), in particular Section 50d, paragraph 3, German Income Tax Act (<i style="font-style:italic;">Einkommensteuergesetz</i>) are fulfilled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aforementioned reductions of (or exemptions from) withholding tax are further restricted if (i)&#160;the applicable double taxation treaty provides for a tax reduction resulting in an applicable tax rate of less than 15% and (ii)&#160;the shareholder is not a corporation that directly holds at least 10% in the equity capital of the company and is subject to tax on its income and profits in its state of residence without being exempt. In this case, the reduction of (or exemption from) withholding tax is subject to the following three cumulative prerequisites: (i)&#160;the shareholder must qualify as beneficial owner of the shares in the company for a minimum holding period of 45 consecutive days occurring within a period of 45&#160;days prior and 45&#160;days after the due date of the dividends, (ii)&#160;the shareholder has to bear at least 70% of the change in value risk related to the shares in the company during the minimum holding period without being directly or indirectly hedged and (iii)&#160;the shareholder must not be required to fully or largely compensate directly or indirectly the dividends to third parties. However, these further prerequisites do not apply if the shareholder has been the beneficial owner of the shares in the company for at least one uninterrupted year upon receipt of the dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Absent the fulfillment of all of the three prerequisites, three-fifths of the withholding tax imposed on the dividends must not be credited against the shareholder&#8217;s (corporate) income tax liability, but may, upon application, be deducted from the shareholder&#8217;s tax base for the relevant assessment period. A shareholder that has received gross dividends without any deduction of withholding tax due to a tax exemption without qualifying for a full tax credit has to notify the competent local tax office accordingly and has to make a payment in the amount of the omitted withholding tax deduction. The special rules on the restriction of withholding tax credit do not apply to a shareholder whose overall dividend earnings within an assessment period do not exceed &#8364;20,000 or that has been the beneficial owner of the shares in the company for at least one uninterrupted year upon receipt of the dividends.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">207</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">For individual or corporate shareholders tax resident outside Germany not holding the shares through a permanent establishment (Betriebsst&#228;tte) in Germany or as business assets (Betriebsverm&#246;gen) for which a permanent representative (st&#228;ndiger Vertreter) has been appointed in Germany, the remaining and paid withholding tax (if any) is final (i.e., not refundable) and settles the shareholder&#8217;s limited tax liability in Germany. For individual or corporate shareholders tax resident in Germany (that are, for example, shareholders whose residence, domicile, registered office or place of management is located in Germany) holding their shares as business assets, as well as for shareholders tax resident outside of Germany holding their shares through a permanent establishment in Germany or as business assets for which a permanent representative has been appointed in Germany, the withholding tax withheld (including solidarity surcharge) can be credited against the shareholder&#8217;s personal income tax or corporate income tax liability in Germany. Any withholding tax (including solidarity surcharge) in excess of such tax liability is refunded. For individual shareholders tax resident in Germany holding the company&#8217;s shares as private assets, the withholding tax is a final tax (Abgeltungsteuer), subject to the exceptions described in the following section. Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding the Company&#8217;s Shares as Private Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For individual shareholders (individuals) resident in Germany holding the company&#8217;s shares as private assets, dividends are subject to a flat tax rate which is satisfied by the withholding tax actually withheld (<i style="font-style:italic;">Abgeltungsteuer</i>). Accordingly, dividend income will be taxed at a flat tax rate of 25% plus 5.5% solidarity surcharge thereon (in total 26.375%) and church tax (<i style="font-style:italic;">Kirchensteuer</i>) in case the shareholder is subject to church tax because of his individual circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless the shareholder has filed a blocking notice (<i style="font-style:italic;">Sperrvermerk</i>) with the German Federal Tax Office (details related to the computation of the concrete tax rate including church tax are to be discussed with the individual tax adviser of the relevant shareholder). Except for an annual lump sum savings allowance (<i style="font-style:italic;">Sparer-Pauschbetrag</i>) of up to &#8364; 1.000 (for individual filers) or up to &#8364; 2.000 (for married couples and for partners in accordance with the registered partnership law (<i style="font-style:italic;">Gesetz &#252;ber die Eingetragene Lebenspartnerschaft</i>) filing jointly), private individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from their dividend income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax owed for the dividend income is satisfied by the withholding tax withheld by the Dividend Paying Agent. However, if the flat tax results in a higher tax burden as opposed to the private shareholder&#8217;s individual tax rate, the private shareholder can opt for taxation at his individual personal income tax rate. In that case, the final withholding tax will be credited against the income tax. However, private shareholders are nevertheless not entitled to deduct expenses incurred in connection with the capital investment from their income. The option can be exercised only for all capital income from capital investments received in the relevant assessment period uniformly, and married couples as well as partners in accordance with the registered partnership law filing jointly may only jointly exercise the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Exceptions from the flat tax rate (satisfied by withholding at source) (<i style="font-style:italic;">Abgeltungsteuer</i>) may apply&#8201;&#8212;&#8201;that is, only upon application&#8201;&#8212;&#8201;for shareholders who have a shareholding of at least 25% in CureVac or for shareholders who have a shareholding of at least 1% in CureVac and work for the company in a professional capacity. In such a case, the same rules apply as for sole proprietors holding the shares as business assets. See &#8220;&#8212; Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding the Company&#8217;s shares as Business Assets &#8201;&#8212;&#8201;Sole Proprietors.&#8221; Further, the flat rate tax does not apply if and to the extent dividends reduced CureVac taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding the Company&#8217;s shares as Business Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a shareholder holds the company&#8217;s shares as business assets, the taxation of the dividend income depends on whether the respective shareholder is a corporation, a sole proprietor or a partnership.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">208</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Corporations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividend income of corporate shareholders is exempt from corporate income tax, provided that the incorporated entity holds a direct participation of at least 10% in the share capital of a company at the beginning of the calendar year in which the dividends are paid. The acquisition of a participation of at least 10% in the course of a calendar year is deemed to have occurred at the beginning of such calendar year for the purpose of this rule. Participations in the share capital of the company which a corporate shareholder holds through a partnership, including co-entrepreneurships (<i style="font-style:italic;">Mitunternehmerschaften</i>), are attributable to such corporate shareholder only on a pro rata basis at the ratio of the interest share of the corporate shareholder in the assets of the relevant partnership. However, 5% of the tax-exempt dividends are deemed to be non-deductible business expenses for tax purposes and therefore are subject to corporate income tax (plus solidarity surcharge) and trade tax, i.e., tax exemption of 95%. Business expenses incurred in connection with the dividends received are entirely tax-deductible. The participation exemption does not apply if and to the extent dividends reduced CureVac&#8217;s taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For trade tax purposes the entire dividend income is subject to trade tax (i.e., the tax-exempt dividends must be added back when determining the trade taxable income), unless the corporation shareholder holds at least 15% of the company&#8217;s registered share capital at the beginning of the relevant tax assessment period (<i style="font-style:italic;">Erhebungszeitraum</i>). In case of an indirect participation via a partnership please refer to the section &#8220;Partnerships&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the shareholding is below 10% in the share capital, dividends are taxable at the applicable corporate income tax rate of 15% plus 5.5% solidarity surcharge thereon and trade tax (the rate of which depends on the municipalities the corporate shareholder resides in).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Special regulations apply which abolish the 95% tax exemption if the company&#8217;s shares are held as trading portfolio assets in the meaning of Section&#160;340e of the German commercial code (<i style="font-style:italic;">Handelsgesetzbuch</i>) by (i)&#160;a credit institution (<i style="font-style:italic;">Kreditinstitut</i>), (ii)&#160;a financial service institution (<i style="font-style:italic;">Finanzdienstleistungsinstitut</i>) or (iii)&#160;a financial enterprise within the meaning of the German Banking Act (<i style="font-style:italic;">Kreditwesengesetz</i>), in cases where more than 50% of the shares of such financial enterprise are held directly or indirectly by a credit institution or a financial service institution, as well as by a life insurance company, a health insurance company or a pension fund in case the shares are attributable to the capital investments, resulting in fully taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sole Proprietors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For sole proprietors (individuals) resident in Germany holding shares as business assets dividends are subject to the partial income rule (<i style="font-style:italic;">Teileink&#252;nfteverfahren</i>). Accordingly, only (i) 60% of the dividend income will be taxed at his/her individual personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the dividend income are deductible for tax purposes. In addition, the dividend income is entirely subject to trade tax if the shares are held as business assets of a permanent establishment in Germany within the meaning of the German Trade Tax Act (<i style="font-style:italic;">Gewerbesteuergesetz</i>), unless the shareholder holds at least 15% of the company&#8217;s registered share capital at the beginning of the relevant assessment period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, if a partner is an individual, depending on the applicable municipal trade tax rate and the individual tax situation, the trade tax paid at the level of the partnership is credited against the partner&#8217;s personal income tax liability up to four times of the trade measurement amount (Gewerbesteuer-Messbetrag) depending on the applicable municipal trade tax levy rate and the personal tax situation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Partnerships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In case shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax. In this regard, corporate income tax or personal income tax (and church tax, if applicable) as well as solidarity surcharge, are levied only at the level of the partner with respect to their relevant part of the profit and depending on their individual circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the partner is a corporation, the dividend income will be subject to corporate income tax plus solidarity surcharge. See &#8220;&#8212; Corporations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the partner is a sole proprietor, the dividend income will be subject to the partial income rule. See &#8220;&#8212; Sole Proprietors.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">209</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the partner is a private individual, the dividend income will be subject to the flat tax rate. See &#8220;Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding the Company&#8217;s Shares as Private Assets&#8221; above; unless the partnership is a (operative or deemed) commercial partnership in which case the partial income rule applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If a partner is an individual, depending on the applicable municipal trade tax rate and the individual tax situation, the trade tax paid at the level of the partnership is partly or entirely be credited against the partner&#8217;s personal income tax liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In case the partnership is a (operative or deemed) commercial partnership with its place of management in Germany, the dividend income is subject to German trade tax at the level of the partnership, unless the partnership holds at least 15% of a company&#8217;s registered share capital at the beginning of the relevant assessment period, in which case the dividend income is exempt from trade tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Taxation of Dividend Income of Shareholders Tax Resident Outside of Germany</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For foreign individual or corporate shareholders tax resident outside of Germany not holding the shares through a permanent establishment in Germany or as business assets for which a permanent representative has been appointed in Germany, the deducted withholding tax (possibly reduced by way of a tax relief under a double tax treaty or domestic tax law, such as in connection with the EU Parent Subsidiary Directive) is final (that is, not refundable) and settles the shareholder&#8217;s limited tax liability in Germany, unless the shareholder is entitled to apply for a withholding tax refund or exemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In contrast, individual or corporate shareholders tax resident outside of Germany holding the company&#8217;s shares through a permanent establishment in Germany or as business assets for which a permanent representative has been appointed in Germany are subject to the same rules as applicable (and described above) to shareholders resident in Germany holding the shares as business assets. The withholding tax withheld (including solidarity surcharge) is credited against the shareholder&#8217;s personal income tax or corporate income tax liability in Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Taxation of Capital Gains</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Withholding Tax on Capital Gains</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Capital gains realized on the disposal of shares are only subject to withholding tax if a German branch of a German or foreign credit or financial institution, a German securities trading company or a German securities trading bank stores or administrates or carries out the sale of the shares and pays or credits the capital gains. In those cases, the institution (and not the company) is required to deduct the withholding tax at the time of payment for the account of the shareholder and has to pay the withholding tax to the competent tax authority. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case that the shares in CureVac N.V. are held (i) as business assets by a sole proprietor, a partnership or a corporation and such shares are attributable to a German business or (ii) in the case of a corporation being subject to unlimited corporate income tax liability in Germany, the capital gains are not subject to withholding tax. In the case of clause (i), the withholding tax exemption is subject to the condition that the paying agent has been notified by the beneficiary (<i style="font-style:italic;">Gl&#228;ubiger</i>) that the capital gains are exempt from withholding tax. The respective notification has to be filed by using the officially prescribed form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Taxation of Capital Gains Realized by Shareholders Tax Resident in Germany Holding Shares as Private Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For individual shareholders (individuals) resident in Germany holding shares as private assets, capital gains realized on the disposal of shares are subject to final withholding tax. Accordingly, capital gains will be taxed at a flat tax rate of 25% plus a 5.5% solidarity surcharge thereon (in total 26.375%) and church tax, in case the shareholder is subject to church tax because of his individual circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless the shareholder has filed a blocking notice (<i style="font-style:italic;">Sperrvermerk</i>) with the German Federal Tax Office (details related to the computation of the concrete tax rate including church tax are to be discussed with the individual tax adviser of the relevant shareholder). The taxable capital gain is calculated by deducting the acquisition costs of the shares and the expenses directly related to the disposal from the proceeds of the disposal. Apart from that, except for an annual lump sum savings allowance (<i style="font-style:italic;">Sparer-Pauschbetrag</i>) of up to &#8364;1,000 (for individual filers) or up to &#8364;2,000 (for married couples and for partners in accordance with the registered partnership law (<i style="font-style:italic;">Gesetz &#252;ber die Eingetragene Lebenspartnerschaft</i>) filing jointly), private individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from their capital gain.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">210</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In case the flat tax results in a higher tax burden as opposed to the private shareholder&#8217;s individual tax rate, the private shareholder can opt for taxation at his or her individual personal income tax rate. In that case, the withholding tax (including solidarity surcharge) withheld will be credited against the income tax. However, the private shareholders are nevertheless not entitled to deduct expenses incurred in connection with the capital investment from their income. The option can be exercised only for all capital income from capital investments received in the relevant assessment period uniformly, and married couples as well as for partners in accordance with the registered partnership law filing jointly may only jointly exercise the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Capital losses arising from the sale of the shares can only be offset against other capital gains resulting from the disposition of the shares or shares in other stock corporations during the same calendar year. Offsetting of overall losses with other income (such as business or rental income) and other capital income is not possible. Such losses are to be carried forward and to be offset against positive capital gains deriving from the sale of shares in stock corporations in future years. In case of a derecognition or transfer of worthless shares (or other capital assets), the utilization of such loss is further restricted and can only be offset up to the amount of &#8364;20,000 per calendar year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The final withholding tax will not apply if the seller of the shares or, in the case of gratuitous transfer, its legal predecessor has held, directly or indirectly, at least 1% of the company&#8217;s registered share capital at any time during the five years prior to the disposal. In that case capital gains are subject to the partial income rule. Accordingly, only (i) 60% of the capital gains will be taxed at his individual personal income tax rate plus a 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the capital gains are deductible for tax purposes. The withholding tax withheld (including solidarity surcharge) will be credited against the shareholder&#8217;s personal income tax liability in Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Taxation of Capital Gains Realized by Shareholders Tax Resident in Germany Holding the Company&#8217;s Shares as Business Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a shareholder holds shares as business assets, the taxation of capital gains realized on the disposal of such shares depends on whether the respective shareholder is a corporation, a sole proprietor or a partnership:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Corporations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Capital gains realized on the disposal of shares by a corporate shareholder are generally exempt from corporate income tax and trade tax. However, 5% of the tax-exempt capital gains are deemed to be non-deductible business expenses for tax purposes and therefore are subject to corporate income tax (plus solidarity surcharge) and trade tax, i.e., tax exemption of 95%. Business expenses incurred in connection with the capital gains are entirely tax-deductible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Capital losses incurred upon the disposal of shares or other impairments of the share value are not tax deductible. A reduction of profit is also defined as any losses incurred in connection with a loan or security in the event the loan or the security is granted by a shareholder or by a related party thereto or by a third person with the right of recourse against the aforementioned persons, and the shareholder holds directly or indirectly more than 25% of the company&#8217;s registered share capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Special regulations apply if the shares are held as trading portfolio assets by a credit institution, a financial service institution or a financial enterprise within the meaning of the German Banking Act (<i style="font-style:italic;">Kreditwesengesetz</i>) as well as by a life insurance company, a health insurance company or a pension fund. See &#8220;&#8212; Taxation of Dividend Income of Shareholders Tax Resident in Germany Holding the Company&#8217;s shares as Business Assets &#8201;&#8212;&#8201;Corporations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sole Proprietors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the shares are held by a sole proprietor, capital gains realized on the disposal of the shares are subject to the partial income rule. Accordingly, only (i)&#160;60% of the capital gains will be taxed at his/her individual personal income tax rate plus a 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii)&#160;60% of the business expenses related to the dividend income are deductible for tax purposes. In addition, 60% of the capital gains are subject to trade tax if the shares are held as business assets of a permanent establishment in Germany within the meaning of the German Trade Tax Act (<i style="font-style:italic;">Gewerbesteuergesetz</i>). The trade tax levied, depending on the applicable municipal trade tax rate and the individual tax situation, is partly or entirely credited against the shareholder&#8217;s personal income tax liability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">211</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Partnerships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In case the shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax as well as a solidarity surcharge (and church tax) since partnerships qualify as transparent for German tax purposes. In this regard, corporate income tax or personal income tax as well as a solidarity surcharge (and church tax, if applicable), are levied only at the level of the partner with respect to their relevant part of the profit and depending on their individual circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the partner is a corporation, the capital gains will be subject to corporate income tax plus a solidarity surcharge. See &#8220;&#8212; Corporations.&#8221; Trade tax will be levied additionally at the level of the partner insofar as the relevant profit of the partnership is not subject to trade tax at the level of the partnership. However, with respect to both corporate income and trade tax, the 95% exemption rule as described above applies. With regard to corporate partners, special regulations apply if they are held as trading portfolio assets by credit institutions, financial service institutions or financial enterprises within the meaning of the German Banking Act or life insurance companies, health insurance companies or pension funds, as described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the partner is a sole proprietor (individual), the capital gains are subject to the partial income rule. See &#8220;&#8212; Sole Proprietors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if the partnership is liable to trade tax, 60% of the capital gains are subject to trade tax at the level of the partnership, to the extent the partners are individuals, and 5% of the capital gains are subject to trade tax, to the extent the partners are corporations. However, if a partner is an individual, depending on the applicable municipal trade tax rate and the individual tax situation, the trade tax paid at the level of the partnership is credited against the partner&#8217;s personal income tax liability up to four times of the trade tax measurement amount (Gewerbesteuer-Messbetrag) depending on the applicable municipal trade tax levy rate and the personal tax situation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A new tax regime enables certain partnerships to be taxed as a corporation and their partners to be taxed like shareholders of a corporation. The election is available for fiscal years ending in 2022 or later years. See &#8220;&#8212; Corporations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Taxation of Capital Gains Realized by Shareholders Tax Resident Outside of Germany</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Capital gains realized on the disposal of the shares by a shareholder tax resident outside of Germany are subject to German taxation provided that (i) the company&#8217;s shares are held as business assets of a permanent establishment or as business assets for which a permanent representative has been appointed in Germany, or (ii) the shareholder or, in case of a gratuitous transfer, its legal predecessor has held, directly or indirectly, at least 1% of the company&#8217;s shares capital at any time during a five-year period prior to the disposal. In these cases, capital gains are generally subject to the same rules as described above for shareholders resident in Germany. However, except for the cases referred to in (i) above, most double tax treaties concluded by Germany provide for a full exemption from German taxation unless the company is considered a real estate holding entity for treaty purposes. Further, in case of non-German corporations, the participation exemption applies in full resulting in a tax exemption of 100% (i.e., no deemed non-tax-deductible business expenses).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Inheritance and Gift Tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transfer of the company&#8217;s shares to another person by way of succession or donation is subject to German inheritance and gift tax (<i style="font-style:italic;">Erbschaft-und Schenkungsteuer</i>) if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the decedent, the donor, the heir, the donee or any other beneficiary has his/her/its residence, domicile, registered office or place of management in Germany at the time of the transfer, or is a German citizen who has not stayed abroad for more than five consecutive&#160;years without having a residence in Germany; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(irrespective of the personal circumstances) the shares are held by the decedent or donor as business assets for which a permanent establishment in Germany is maintained or a permanent representative is appointed in Germany; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(irrespective of the personal circumstances) at least 10% of the shares are held, directly or indirectly by, the decedent or person making the gift, himself or together with a related party in terms of Section&#160;1, paragraph 2 of the Foreign Tax Act (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Au&#223;ensteuergesetz</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">).</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">212</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Special regulations apply to qualified German citizens who maintain neither a residence nor their domicile in Germany but in a low tax jurisdiction, and to former German citizens, also resulting in inheritance and gift tax. The few double tax treaties on inheritance and gift tax which Germany has entered into provide that German inheritance and gift tax is levied only in the case of (i)&#160;and, with certain restrictions, in the case of (ii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Other Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No German capital transfer tax (<i style="font-style:italic;">Kapitalverkehrsteuer</i>), value added tax (<i style="font-style:italic;">Umsatzsteuer</i>), stamp duty (<i style="font-style:italic;">Stempelgeb&#252;hr</i>) or similar taxes are levied when acquiring, holding or transferring the company&#8217;s shares. No value added tax will be levied unless the shareholder validly opts for it. Net wealth tax (<i style="font-style:italic;">Verm&#246;gensteuer</i>) is currently not levied in Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;22, 2013, the Council of the European Union approved the resolution of the ministers of finance from 11 European Union member states (including Germany) to introduce a Financial Transaction Tax, or FTT, within the framework of enhanced cooperation. On February&#160;14, 2013, the EC published a proposal for a Council Directive implementing enhanced cooperation in the area of financial transaction tax. The plan focuses on levying a tax of 0.1% (0.01% for derivatives) on the purchase and sale of financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A joint statement issued by 10 of the 11 participating European Union member states in October 2016 reaffirmed the intention to introduce FTT. However, at the moment not many details are available. Thus, it is not known to what extent the elements of the European Commission&#8217;s proposal outlined in the preceding paragraph will be followed in relation to the taxation of shares. The FTT proposal remains subject to negotiation between the participating member states and is subject to political discussion. It may, therefore, be altered prior to the implementation, the timing of which remains unclear. Additional European Union member states may decide to participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prospective holders of the shares are advised to seek their own professional advice in relation to FTT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Material U.S. Federal Income Tax Considerations to U.S. Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders, as defined below, of owning and disposing of our common shares. It does not describe all tax considerations that may be relevant to a particular person&#8217;s decision to invest in common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion applies only to a U.S. Holder that holds common shares as capital assets for U.S. federal income tax purposes. In addition, it does not describe all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder&#8217;s particular circumstances, including alternative minimum tax consequences, the potential application of the provisions of the Code known as the Medicare contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dealers or traders in securities who use a mark-to-market method of tax accounting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the common shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entities classified as partnerships for U.S. federal income tax purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt entities, including an &#8220;individual retirement account&#8221; or &#8220;Roth IRA&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that own or are deemed to own ten&#160;percent or more of our common shares (by vote or value); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding common shares in connection with a trade or business conducted outside of the United States.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">213</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal income tax consequences of owning and disposing of the common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between the Federal Republic of Germany and the United States, or the Treaty, all as of the date hereof, any of which is subject to change or differing interpretations, possibly with retroactive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our common shares, who is eligible for the benefits of the Treaty and who is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate or trust, the income of which is subject to U.S. federal income taxation regardless of its source.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Treasury regulations that apply to taxable years beginning on or after December 28, 2021, may in some circumstances prohibit a U.S. person from claiming a foreign tax credit with respect to certain non-U.S. taxes that are not creditable under applicable income tax treaties. Accordingly, U.S. investors that are not eligible for Treaty benefits should consult their tax advisers regarding the creditability or deductibility of any non-U.S. taxes imposed on them. This discussion does not apply to investors in this special situation. U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing of our common shares in their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Taxation of Distributions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed above under &#8220;Item 8. Financial Information &#8212; A. Consolidated statements and other financial information &#8212; Dividends and dividend policy&#8221; we have never paid or declared any cash dividends on our common shares, and we do not anticipate paying any cash dividends on our common shares in the foreseeable future. In the event that we do make distributions of cash or other property, subject to the passive foreign investment company rules described below, distributions paid on common shares, other than certain pro&#160;rata distributions of common shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. For so long as our common shares are listed on the Nasdaq or another established securities market in the United States or we are eligible for benefits under the Treaty, dividends paid to certain non-corporate U.S. Holders may be eligible for taxation as &#8220;qualified dividend income&#8221; and therefore, subject to applicable limitations, taxable at rates not in excess of the long-term capital gain rate applicable to such U.S. Holders. U.S. Holders should consult their tax advisers regarding the availability of the reduced tax rate on dividends in their particular circumstances. The amount of a dividend will include any amounts withheld by us in respect of German income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in a U.S. Holder&#8217;s income on the date of the U.S. Holder&#8217;s receipt of the dividend. The amount of any dividend income paid in euros will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#8217;s particular circumstances, German income taxes withheld from dividends on common shares at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">214</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">German taxes withheld in excess of the rate applicable under the Treaty will not be eligible for credit against a U.S. Holder&#8217;s federal income tax liability. The rules governing foreign tax credits are complex, and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any German income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 18pt;">Sale or Other Disposition of Common Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Subject to the passive foreign investment company rules described below, gain or loss realized on the sale or other disposition of common shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the common shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to various limitations. The Treaty generally exempts a U.S. Holder from German tax on capital gains realized on the sale or other disposition of common shares and, accordingly, no such tax will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 18pt;">Passive Foreign Investment Company Rules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Under the Code, we will generally be a &#8220;passive foreign investment company,&#8221; or a PFIC, for any taxable year in which, after the application of certain &#8220;look-through&#8221; rules with respect to subsidiaries, either (i)&#160;75% or more of our gross income consists of &#8220;passive income,&#8221; or (ii)&#160;50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of, &#8220;passive income.&#8221; For purposes of the above calculations, we will be treated as if we hold our proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which we directly or indirectly own at least 25%, by value, of the shares of such corporation. Passive income generally includes dividends, interest, rents, certain non-active royalties and capital gains. The value of a non-U.S. corporation&#8217;s goodwill that is associated with activities that produce, or are intended to produce, active income is generally an active asset for purposes of the asset test unless, for U.S. federal income tax purposes, the non-U.S. corporation is a &#8220;controlled foreign corporation,&#8221; or CFC, that is not publicly traded &#8220;for the taxable year.&#8221; If a non-U.S. corporation is a CFC that is not publicly traded for the taxable year, its PFIC status under the asset test is determined by using the U.S. tax basis of its assets rather than their fair market value and therefore the market value of its goodwill is generally disregarded. Generally, a non-U.S. corporation is a CFC if more than 50% of its shares&#8217; voting power or value is owned, directly, indirectly or constructively, by &#8220;United States shareholders&#8221; (as defined in Section&#160;951(b) of the Code). Although it is not certain, we may be or may have been a CFC in our 2023 taxable year. However, under Treasury regulations promulgated in 2020, the fair market value of our assets (including goodwill) can be used for purposes of the asset test provided that (i) we are publicly traded on the majority of days during our taxable year or (ii) we would not be a CFC if certain constructive ownership rules were not applied. We believe, and the remainder of this discussion assumes, that we are eligible to use the fair market value of our assets for purposes of the asset test, for our 2023 taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the composition of our income and assets during 2023, we do not believe that we were a PFIC for our 2023 taxable year. However, there can be no assurance that the IRS will agree with our conclusion. Whether we will be a PFIC in 2024 or any future year is uncertain because, among other things, (i) we currently own a substantial amount of passive assets, including cash, (ii) the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time, (iii) the treatment of grants as income for U.S. federal income tax purposes is unclear, and (iv) the composition of our income may vary substantially over time. Accordingly, there can be no assurance that we will not be a PFIC in 2024 or any future taxable year. If we are a PFIC for any year during which a U.S. Holder holds common shares, we generally would continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds common shares, even if we ceased to meet the threshold requirements for PFIC status. In addition, we may, directly or indirectly, have held or hold equity interests in other PFICs, collectively referred to as Lower-Tier PFICs. Under attribution rules, if we are a PFIC, U.S. Holders will be deemed to own their proportionate shares of the stock of Lower-Tier PFICs and will be subject to U.S. federal income tax according to the rules described in the following paragraphs on (i) certain distributions by a Lower-Tier PFIC and (ii) a disposition of shares of a Lower-Tier PFIC, in each case as if the U.S. Holder held such shares directly, even though holders have not received the proceeds of those distributions or dispositions directly. U.S. Holders should consult their tax advisors about the consequences to them of our investment in one or more Lower-Tier PFICs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">215</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we were a PFIC for any taxable year during which a U.S. Holder held common shares (assuming such U.S. Holder has not made a timely mark-to-market election, as described below), gain recognized by a U.S. Holder on a sale or other disposition (including certain pledges) of the common shares would be allocated ratably over the U.S. Holder&#8217;s holding period for the common shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Further, to the extent that any distribution received by a U.S. Holder on its common shares exceeds 125% of the average of the annual distributions on the common shares received during the preceding three&#160;years or the U.S. Holder&#8217;s holding period, whichever is shorter, that distribution would be subject to taxation in the same manner as gain, described immediately above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A U.S. Holder can avoid certain of the adverse rules described above by making a mark-to-market election with respect to its common shares, provided that the common shares are &#8220;marketable.&#8221; Common shares will be marketable if they are &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; or other market within the meaning of applicable Treasury regulations. If a U.S. Holder makes the mark-to-market election, it generally will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in our common shares will be adjusted to reflect the income or loss amounts recognized. Any gain recognized on the sale or other disposition of common shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). A mark-to-market election generally cannot be made for equity interests in any Lower-Tier PFIC unless shares of such Lower-Tier PFIC are themselves &#8220;marketable.&#8221; As a result, if a U.S. Holder makes a mark-to-market election with respect to our common shares, the U.S. Holder would nevertheless be subject to the PFIC rules described above with respect to its indirect interest in any Lower-Tier PFIC unless the U.S. Holder makes a qualified electing fund election, also known as a QEF Election, with respect to such Lower-Tier PFIC, as discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in order to avoid the application of the foregoing rules, a U.S. Holder that owns stock in a PFIC for U.S. federal income tax purposes may make a QEF Election with respect to such PFIC if the PFIC provides the information necessary for such election to be made. If a U.S. Holder makes a QEF Election with respect to a PFIC, the U.S. Holder will be currently taxable on its pro&#160;rata share of the PFIC&#8217;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for each taxable year that the entity is classified as a PFIC and will not be required to include such amounts in income when actually distributed by the PFIC. There is no assurance that we will provide information necessary for U.S. Holders to make QEF Elections. A QEF Election with respect to us will not apply to any Lower-tier PFIC. If we determine that any of our subsidiaries is a Lower-Tier PFIC for any taxable year, there is no assurance that we will provide information necessary for U.S. Holders to make a QEF Election with respect to such Lower-Tier PFIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, if we were a PFIC or, with respect to a particular U.S. Holder, were treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would not apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If a U.S. Holder owns common shares during any year in which we are a PFIC, the U.S. Holder generally must file annual reports, containing such information as the U.S. Treasury may require on IRS Form 8621 (or any successor form) with respect to us, generally with the U.S. Holder&#8217;s federal income tax return for that year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">U.S. Holders should consult their tax advisers concerning our potential PFIC status and the potential application of the PFIC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Information Reporting and Backup Withholding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&#160;the U.S. Holder is a corporation or other exempt recipient, or (ii)&#160;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder&#8217;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">216</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">F.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Dividends and Paying Agents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">G.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Statement by Experts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">H.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Documents on Display</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the informational requirements of the Exchange Act. Accordingly, are required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. The SEC maintains an Internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">I.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Subsidiary Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7e9a7eb7_fbe3_4623_915c_4597cc2dbe31"></a><a id="ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business activities, we are exposed to various market risks that are beyond our control, including fluctuations in foreign exchange rates, which may have an adverse effect on the value of our financial assets and liabilities, future cash flows and profit. As a result of these market risks, we could suffer a loss due to adverse changes in foreign exchange rates in the countries in which we operate. Our policy with respect to these market risks is to assess the potential of experiencing losses and the consolidated impact thereof and to mitigate these market risks. We are not currently exposed to significant interest rate risk because we do not currently hold long-term debt that is exposed to market rates. See note 16 to our financial statements contained elsewhere in this Annual Report for further information on our risk management policies and exposure to market risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our credit risk arises primarily from cash and cash equivalents and other financial assets, including deposits with banks and financial institutions, as well as credit exposures to customers, including outstanding receivables and contract assets. These financial instruments approximate fair value due to short-term maturities. We maintain our cash and cash equivalents and short-term investments with high credit quality financial institutions. We believe that our credit policies reflect normal industry terms and business risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Foreign Currency Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. Our exposure to the risk of changes in foreign exchange rates relates primarily to our operating activities (when revenue or expense is denominated in a foreign currency) and the amounts held as cash and cash equivalents. Our consolidated financial statements are reported in euros. We generate a significant portion of our revenue and incur a significant portion of our expenditures in certain non-euro currencies, principally U.S. dollars. We are exposed to fluctuations in foreign currency exchange rates primarily on revenue generated from sales in these foreign currencies. Our results of operations can be affected if the U.S. dollar appreciates or depreciates against the euro. As of December 31, 2023, if the euro had weakened 10% against the U.S. dollar with all other variables held constant, pre-tax loss for the year would have been &#8364;8.0 million (2022: &#8364;8.6 million) lower and post-tax loss would have been &#8364;5.6 million lower (2022: &#8364;6.1 million). Conversely, if the euro had strengthened 10% against the U.S. dollar with all other variables held constant, pre-tax loss would have been &#8364;6.6 million (2022: &#8364;7.1 million) higher and post-tax loss would have been &#8364;4.6 million (2022: &#8364;5.0 million) higher. The effects on pre- and post-tax loss and (accumulated) other comprehensive income due to fact that our subsidiary CureVac Inc.&#8217;s functional currency is the U.S. dollar would still have been immaterial at December 31, 2022 and 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">217</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that we need to convert U.S. dollars into foreign currencies for our operations, appreciation of such foreign currencies against the U.S. dollar would adversely affect the amount of such foreign currencies we receive from the conversion. Sensitivity analysis is used as a primary tool in evaluating the effects of changes in foreign currency exchange rates on our business operations. The analysis quantifies the impact of potential changes in these rates on our earnings, cash flows and fair values of assets and liabilities during the forecast period, most commonly within a one-year period. The ranges of changes used for the purpose of this analysis reflect our view of changes that are reasonably possible over the forecast period. Fair values are the present value of projected future cash flows based on market rates and chosen prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Interest Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Our exposure to the risk of changes in market interest rates relates primarily to our cash and cash equivalents with floating interest rates. Due to persistent low interest rates we may be exposed to the risk of being charged negative interest rates on our bank deposits. If interest rates as of December 31, 2022 and 2023, had been 1% higher while all other variables had remained the same, the net loss for the year (before and after tax) would have been &#8364;4.0 million (2022: &#8364;5.0 million) lower, because the higher interest income would have been generated from floating rates on invested cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7ef76319_8665_4543_b302_ba209dd40534"></a><a id="ITEM12DESCRIPTIONOFSECURITIES_166212"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Warrants and Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">C.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Other Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">D.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>American Depositary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">218</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_63fb3bc4_3dc9_473f_a734_6cf149c6e8f3"></a><a id="PARTII_487458"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="ITEM13DEFAULTSDIVIDENDARREARAGES_143929"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Defaults</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No matters to report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Arrears and Delinquencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">No matters to report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ca33eb31_f56f_4d9f_989d_64c763589582"></a><a id="ITEM14MATERIALMODIFICATIONSTOTHERIGHTS_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Material Modifications to Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">B.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Material Modifications to Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">C.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Withdrawal or Submission of Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">D.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Changes in Trustees or Paying Agents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">E.<b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</b>Use of Proceeds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 62.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_51e77f98_4b06_4adb_a100_9b3acabb8e3d"></a><a id="ITEM15CONTROLSANDPROCEDURE_71419"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 15. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A.&#160;&#160;&#160;Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, including our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), has performed an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2023. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitations, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding our required disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the foregoing, our Chief Executive Officer and our Chief Financial Officer, together with our other members of management, have concluded that, as of December 31, 2023, due to a material weakness in internal control over financial reporting described below, our disclosure controls and procedures were not effective.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">219</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">B.&#160;&#160;&#160;Management&#8217;s Annual Report on Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act). Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS as issued by IASB and includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS as issued by IASB, and that receipts and expenditures of our Company are being made only in accordance with authorizations of management and directors of our Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our Company&#8217;s assets that could have a material effect on the financial statements. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any internal control system, no matter how well designed, has inherent limitations, including the possibility of human error and the circumvention or overriding of the controls and procedures, which may not prevent or detect misstatements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, our management used the updated criteria set forth in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in &#8220;Internal Control &#8211; Integrated Framework&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management has concluded, based on its assessment, that our internal control over financial reporting was not effective as of December 31, 2023 due to a material weakness resulting from (i) lack of sufficient accounting and supervisory personnel, (ii) lack of appropriate level of technical accounting training; and (iii) lack of consistent performance of controls over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the material weakness identified as of December 31, 2023, our management has concluded that the consolidated financial statements included in this Annual Report on Form 20-F, present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with IFRS as issued by IASB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Remediation plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As previously disclosed, we reported in our Annual Report 20-F for the year ended December 31, 2022, a material weakness in internal control over financial reporting primarily related to an IT system&#8217;s functionalities that were not configured to support segregation of duties in the recording of manual journal entries as well as in the authorization of purchase orders. During 2023, we implemented measures to successfully remediate this material weakness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s planned remediation measures for the material weakness identified as of December 31, 2023 include (i) training and hiring additional qualified staff; (ii) implementing, streamlining, and/or replacing certain IT systems to increase automation in accounting processes and procedures; and (iii) engaging third parties, as required, to assist with technical expertise, integration and streamlining of business controls. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes the foregoing plans will effectively remediate the deficiencies constituting the material weakness. However, there is no assurance as to when such remediation will be successful. As the remediation plans are implemented, management may take additional measures or modify the plan described above. See <i style="font-style:italic;">&#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; We have identified a material weakness in our internal control related (i) lack of sufficient accounting and supervisory personnel, (ii) lack of appropriate level of technical accounting training; and (iii) lack of consistent performance of controls over financial reporting which, if not remediated appropriately or timely, could result in loss of investor confidence and adversely impact our stock price. If we are unable to remediate the material weakness, or if other material weaknesses are identified, we may not be able to report our financial results accurately, prevent fraud or file our periodic reports as a public company in a timely manner.&#8221;</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">220</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">C.&#160;&#160;&#160;Attestation Report of the Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">KPMG AG Wirtschaftspr&#252;fungsgesellschaft, an independent registered public accounting firm who audited the consolidated financial statements as of and for the year ended December 31, 2023, has also audited the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2023.  Their reports are included in this Annual Report on Form 20-F beginning on page F-3.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">D.&#160;&#160;&#160;Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Other than the changes described above there were no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act of 1934), which occurred during the period covered by this Form 20-F that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3529c93e_02f9_495f_989f_947690d11058"></a><a id="ITEM16Reserved_143062"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM 16. [Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2a080b0c_b6e4_4ef8_b394_137b7683231f"></a><a id="ITEM16AAuditCommitteeFinancialExpert_495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 16A. Audit Committee Financial Expert</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our supervisory board has determined that Michael Brosnan, Craig A. Tooman, Klaus Schollmeier, Hans Christoph Tanner and Ralf Clemens satisfy the &#8220;independence&#8221; requirements set forth in Rule 10A-3 under the Exchange Act and each qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in the rules of the SEC. Hans Christoph Tanner resigned from the Supervisory Board on June 19, 2023 and Ralf Clemens resigned from the Supervisory Board on September 30, 2023. For more information see &#8220;Item 6. Directors, Senior Management and Employees &#8212; C. Board Practices &#8212; Committees &#8212; Audit Committee.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9b267295_d009_4f39_8923_d70d8b43e4c3"></a><a id="ITEM16BCodeofConduct_487362"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 16B. Code of Conduct</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We adopted a written code of business conduct and ethics, or code of conduct, which outlines the principles of legal and ethical business conduct under which we do business, and is a code of ethics as defined in Item 16B of Form 20-F promulgated by the SEC. The code of conduct applies to all of our management board and supervisory directors and employees. The full text of the code of conduct is available on our website at www.curevac.com. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report and is not incorporated by reference herein. If we make any amendment to the code of conduct or grant any waivers, including any implicit waiver, from a provision of the code of conduct, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, we have implemented a compliance management policy which describes the compliance management system implemented at CureVac SE, which is designed to ensure compliance with all legal requirements, while at the same time implementing high ethical standards that are mandatory for both management and each employee. The overall responsibility for the compliance management system lies with the management board, which reports regularly to the audit committee. In the performance of its compliance responsibilities, the management board has delegated the corresponding tasks to various functions at CureVac SE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_57825c83_b4ac_486d_b5eb_1dd23ec3b272"></a><a id="ITEM16CPrincipalAccountantFees_604803"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 16C. Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial statements have been prepared in accordance with IFRS as issued by the IASB and are audited by KPMG. KPMG has acted as our independent registered public accounting firm registered with the Public Company Accounting Oversight Board in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">KPMG has served as our independent registered public accounting firm for the year ended December 31, 2023, for which audited financial statements appear in this Annual Report. EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft (&#8220;EY&#8221;) served as our independent registered public accounting firm for the years ended December 31, 2021 and 2022, for which audited financial statements appear in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Audit Fees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We incurred fees of &#8364;1.2 million to KPMG for audit services for fiscal 2023 and &#8364;1.8 million to EY for audit services for fiscal 2022, respectively, including fees associated with the annual audit, consultations on various accounting issues, performance of local statutory audits and comfort letters and review of offering documents filed with the SEC.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">221</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Audit-Related Fees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No audit-related services fees were incurred for fiscal 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Tax Fees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">We incurred &#8364;0.1 million to KPMG for tax fees for fiscal 2023 and &#8364;0.5 million for tax fees to EY for fiscal 2022, including fees associated with tax compliance, tax advice and tax planning services for fiscal 2023 and 2022, respectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">All Other Fees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">No fees for services other than those categorized in Audit Fees, Audit-Related Fees and Tax Fees described above incurred to KPMG in 2023.We incurred &#8364;0.1 million for services other than those categorized in Audit Fees, Audit-Related Fees and Tax Fees described above to EY in 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Pre-Approval Policies and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Audit Committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm. These policies generally provide that we will not engage our independent registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by the Audit Committee or the engagement is entered into pursuant to the pre-approval procedure described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, the Audit Committee may pre-approve specified types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months. Any such pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum dollar amount. In fiscal 2023, our Audit Committee approved all of the services provided by KPMG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_506f3cad_c870_4a32_a47f_96d459626d22"></a><a id="ITEM16DExemptionsfromtheListing_19416"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 16D. Exemptions from the Listing Standards for Audit Committees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_42ae6b67_c0b1_4d94_8cae_5d617c8366bc"></a><a id="ITEM16EPurchasesofEquitySecurities_95956"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ef3e77f3_5eba_42d9_b2a9_73e734552169"></a><a id="ITEM16FChangeinRegistrant_263042"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 16F. Change in Registrant&#8217;s Certifying Accountant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2b1d3dd0_6be5_4706_8250_382fa572ee8c"></a><a id="ITEM16GCorporateGovernance_898522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">ITEM 16G. Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following comparison between Dutch corporate law, which applies to us, and Delaware corporation law, the law under which many publicly listed corporations in the United States are incorporated, discusses additional matters not otherwise described in this Annual Report. Although we believe this summary is materially accurate, the summary is subject to Dutch law, including Book 2 of the Dutch Civil Code and the DCGC and Delaware corporation law, including the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Duties of Managing and Supervisory Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> In the Netherlands, a listed company typically has a two-tier board structure with a management board comprised of the managing directors (executive directors) and a supervisory board comprised of the supervisory directors (non-executive directors). We have a two-tier board structure consisting of our management board (<i style="font-style:italic;">bestuur</i>) and a separate supervisory board (<i style="font-style:italic;">raad van commissarissen</i>).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">222</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under Dutch law, the management board is charged with the management of the company, subject to the restrictions contained in our articles of association, and the supervisory board is charged with the supervision of the policy of the management board and the general course of affairs of the company and of the business connected with it. The managing directors may divide their tasks among themselves in or pursuant to the internal rules applicable to the management board. Each managing director and supervisory director has a statutory duty to act in the corporate interest of the company and its business. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of the company also applies in the event of a proposed sale or breakup of the company, provided that the circumstances generally dictate how such duty is to be applied and how the respective interests of various groups of stakeholders should be weighed. Any resolution of the management board regarding a material change in our identity or character requires approval of the general meeting. In addition, during the initial approval period, the following additional resolutions of the management board will require approval of the general meeting and our supervisory board:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transferring the tax domicile of CureVac N.V. and/or the approval of the transfer of the corporate or administrative seat of CureVac SE;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relocating or ceasing (including by way of disposal, demerger or similar transactions) activities in specified areas in or to a state outside the European Union, except to the extent our supervisory board considers such activities (in particular in the area of the development of vaccines) not to be material for the protection of the health of the population of the European Union;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entering into mergers, demergers and similar reorganizations and entering into acquisitions or businesses or participations, except to the extent our supervisory board considers such transactions not to be material;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amendments to the articles of association of CureVac SE which would affect these approval rights during the initial approval period; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the exercise of voting rights in CureVac SE approving, directing or causing any of the foregoing matters.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under our articles of association, the approval of our supervisory board is also required for resolutions of the management board, including concerning the following matters:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the making of certain proposals to the general meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issue of shares or the granting of rights to subscribe for shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limitation or exclusion of pre-emption rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the establishment of new activities of us or our direct or indirect subsidiaries in the areas of research, development, production and administration and/or the approval to establish activities of CureVac SE or its subsidiaries in these areas, in each case in a state outside the European Union;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acquisition of shares by us in our own capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drawing up or amendment of our management board rules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of legal acts relating to non-cash contributions on shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material changes to the identity or the character of the company or its business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the charging of amounts to be paid up on shares against the company&#8217;s reserves;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the making of an interim distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designating a current or former officer or employee as indemnitees under our articles of association;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">223</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the stipulation of additional terms, conditions and restrictions in relation to the indemnification offered under our articles of association;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and such other resolutions as the supervisory board shall have specified in a resolution to that effect and notified to the management board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the internal rules applicable to our management board, certain additional resolutions are subject to the approval of our supervisory board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the internal rules applicable to our supervisory board, resolutions of our supervisory board to approve a resolution of our management board to exclude or limit pre-emption rights (except in connection with the ordinary operation of our equity incentive plans) or to issue shares against non-cash contribution, shall require the approval of a special committee consisting of one supervisory director nominated by dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for dievini), the supervisory director nominated by KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for KfW) and, if applicable, one supervisory director nominated by a nomination concert. In this special committee, the affirmative votes of one supervisory director nominated by dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for dievini) and the supervisory director nominated by KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for KfW) shall be required. Similarly, the affirmative votes of at least one supervisory director nominated by dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for dievini) and the supervisory director nominated by KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) (during the initial nomination period for KfW) shall be required for certain resolutions of the supervisory board specified by our articles of association and the internal rules applicable to our supervisory board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The absence of the approval of the supervisory board shall result in the relevant resolution being null and void but shall not affect the powers of representation of the management board or of the managing directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management board is entitled to represent us. The power to represent us also vests in the chief executive officer individually, as well as in any other two managing directors acting jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware. </i>The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or breakup of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Director Terms</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> The DCGC provides the following best practice recommendations on the terms for tenure of managing directors and supervisory directors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Managing directors should be appointed for a maximum period of four&#160;years, without limiting the number of consecutive terms managing directors may serve.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Supervisory directors should be appointed for two consecutive periods of no more than four&#160;years. Thereafter, supervisory directors may be reappointed for a maximum of two consecutive periods of no more than two&#160;years, provided that any reappointment after an eight-year term of office should be disclosed in the company&#8217;s annual report.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">224</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The general meeting shall at all times be entitled to suspend or dismiss a managing director or supervisory director. Under our articles of association, the general meeting may only adopt a resolution to suspend or dismiss such director by at least a two-thirds majority of the votes cast, provided that such majority represents more than half of the issued share capital, unless the resolution is passed at the proposal of the supervisory board or, with respect to supervisory directors nominated by dievini or KfW, by dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) during the nomination period for dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) or by KfW (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) during the nomination period for KfW, respectively, in which case a simple majority of the votes cast is sufficient. In addition, the supervisory board may at any time suspend a managing director. A suspension by the supervisory board can at any time be lifted by the general meeting. If a managing director is suspended and the general meeting does not resolve to dismiss him or her within three&#160;months from the date of such suspension, the suspension shall lapse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Delaware.</i> The Delaware General Corporation Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes with up to three-year terms, with the&#160;years for each class expiring in different&#160;years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the stockholders. A director elected to serve a term on a &#8220;classified&#8221; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Director Vacancies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under Dutch law, managing directors and supervisory directors of a company like ours are appointed and reappointed by the general meeting. Under our articles of association, managing directors and supervisory directors are appointed by the general meeting upon the binding nomination by our supervisory board. During the periods specified below, dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement), KfW (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement), and any nomination concert have the right to make a binding nomination for one or more supervisory directors as specified below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">during the initial nomination period for dievini, dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) will have the right under our articles of association to make a binding nomination for the following number of supervisory directors:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four (4)&#160;supervisory directors for as long as dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates, as defined by our articles of association, and ultimate beneficiaries, as defined by our articles of association (individually or collectively) owns at least 70% of our issued share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three (3)&#160;supervisory directors for as long as dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates, as defined by our articles of association, and ultimate beneficiaries, as defined by our articles of association (individually or collectively) owns at least 50% (but less than 70%) of our issued share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two (2)&#160;supervisory directors for as long as dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates, as defined by our articles of association, and ultimate beneficiaries, as defined by our articles of association (individually or collectively) owns at least 30% (but less than 50%) of our issued share capital; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one (1)&#160;supervisory director for as long as dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and its affiliates, as defined by our articles of association, and ultimate beneficiaries, as defined by our articles of association (individually or collectively) owns at least 10% (but less than 30%) of our issued share capital.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">during the initial nomination period for KfW, KfW (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) will have the right under our articles of association to make a binding nomination for one supervisory director; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">225</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at any time, each nomination concert (excluding dievini, its affiliates and its ultimate beneficiaries and excluding KfW and its affiliates for as long as dievini and KfW, respectively, have the nomination rights discussed above) will have the right under our articles of association to make a binding nomination for one supervisory director for each 20% of our issued share capital represented by that nomination concert, provided such nominee is independent from the nomination concert and CureVac N.V. under the DCGC and applicable U.S. securities laws and Nasdaq rules.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The general meeting may at all times overrule the binding nomination by a resolution adopted by a simple majority of the votes cast, provided that such majority represents at least one-third of the issued share capital. If the general meeting overrules the binding nature of a binding nomination, a new nomination shall be prepared by whoever made the overruled nomination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If dievini, KfW and/or a nomination concert loses the right to nominate one or more of our supervisory directors, as applicable, the supervisory director(s) so nominated must promptly resign. A supervisory director nominated by a nomination concert must also promptly resign once that supervisory director is no longer independent from the nomination concert or our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Dutch law, when nominating a person for appointment or reappointment as a supervisory director, the nomination must be supported by reasons (if it concerns a reappointment, past performance must be taken into consideration) and the following information about such person must be provided: (i)&#160;age and profession; (ii)&#160;the aggregate nominal value of the shares held in the company&#8217;s capital; (iii)&#160;present and past positions, to the extent relevant for the performance of the tasks of a supervisory director; and (iv)&#160;the name of each entity where such person already holds a position as supervisory director or non-executive director (in case of multiple entities within the same group, the name of the group shall suffice).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware.</i> The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (i)&#160;otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii)&#160;the certificate of incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conflict-of-Interest Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under Dutch law and our articles of association, our managing directors and supervisory directors shall not take part in any discussion or decision-making that involves a subject or transaction in relation to which he or she has a direct or indirect personal conflict of interest with us. Such a conflict of interest would generally arise if the managing director or supervisory director concerned is unable to serve our interests and the business connected with it with the required level of integrity and objectivity due to the existence of the conflicting personal interest. Our articles of association provide that if as a result of conflicts of interests no resolution of the management board can be adopted, the resolution may be passed by the supervisory board and that, if as a result of conflicts of interests no resolution of the supervisory board can be adopted, the resolution may nonetheless be adopted by the supervisory board as if none of the supervisory directors had a conflict of interest. In that case, each supervisory director is entitled to participate in the discussion and decision-making process and to cast a vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DCGC provides the following best practice recommendations in relation to conflicts of interests in respect of managing directors or supervisory directors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A managing director should report any potential conflict of interest in a transaction that is of material significance to the company and/or to such person to the chairman of the supervisory board and to the other members of the management board without delay. The managing director should provide all relevant information in that regard, including the information relevant to the situation concerning his or her spouse, registered partner or other life companion, foster child and relatives by blood or marriage up to the second degree;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A supervisory director should report any conflict of interest or potential conflict of interest in a transaction that is of material significance to the company and/or to such person to the chairman of the supervisory board without delay and should provide all relevant information in that regard, including the relevant information pertaining to his or her spouse, registered partner or other life companion, foster child and relatives by blood or marriage up to the second degree. If the chairman of the supervisory board has a conflict of interest or potential conflict of interest, he or she should report this to the vice-chairman of the supervisory board without delay;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">226</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The supervisory board should decide, outside the presence of the managing director or supervisory director concerned, whether there is a conflict of interest;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All transactions in which there are conflicts of interest with managing directors or supervisory directors should be agreed on terms that are customary in the market; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decisions to enter into transactions in which there are conflicts of interest with managing directors or supervisory directors that are of material significance to the company and/or to the relevant managing directors or supervisory directors should require the approval of the supervisory board. Such transactions should be published in the annual report, together with a description of the conflict of interest and a declaration that the relevant best practice provisions of the DCGC have been complied with.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Delaware.</i> The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the material facts as to the director&#8217;s relationship or interest are disclosed and a majority of disinterested directors consent;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the material facts are disclosed as to the director&#8217;s relationship or interest and a majority of shares entitled to vote thereon consent; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the stockholders.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Proxy Voting by Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> An absent managing director may issue a proxy for a specific management board meeting but only to another managing director in writing or by electronic means. An absent supervisory director may issue a proxy for a specific supervisory board meeting but only to another supervisory director in writing or by electronic means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Delaware.</i> A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Shareholder Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Voting Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands</i>. In accordance with Dutch law and our articles of association, each issued common share confers the right to cast one vote at the general meeting. Each holder of shares may cast as many votes as it holds shares. No votes may be cast on shares that are held by us or our direct or indirect subsidiaries or on shares for which we or our subsidiaries hold depository receipts. Nonetheless, the holders of a right of use and enjoyment (<i style="font-style:italic;">vruchtgebruik</i>) and the holders of a right of pledge (<i style="font-style:italic;">pandrecht</i>) in respect of shares held by us or our subsidiaries in our share capital are not excluded from the right to vote on such shares, if the right of use and enjoyment (<i style="font-style:italic;">vruchtgebruik</i>) or the right of pledge (<i style="font-style:italic;">pandrecht</i>) was granted prior to the time such shares were acquired by us or any of our subsidiaries. Neither we nor any of our subsidiaries may cast votes in respect of a share on which we or such subsidiary holds a right of use and enjoyment (<i style="font-style:italic;">vruchtgebruik</i>) or a right of pledge (<i style="font-style:italic;">pandrecht</i>). Shares which are not entitled to voting rights pursuant to the preceding sentences will not be taken into account for the purpose of determining the number of shareholders that vote and that are present or represented, or the amount of the share capital that is provided or that is represented at a general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In accordance with our articles of association, for each general meeting, the management board may determine that a record date will be applied in order to establish which shareholders are entitled to attend and vote at the general meeting. Such record date shall be the 28th day prior to the day of the general meeting. The record date and the manner in which shareholders can register and exercise their rights will be set out in the notice of the meeting which must be published in a Dutch daily newspaper with national distribution at least 15&#160;days prior to the meeting (and such notice may therefore be published after the record date for such meeting). Under our articles of association, shareholders and others with meeting rights under Dutch law must notify us in writing or by electronic means of their identity and intention to attend the general meeting. This notice must be received by us ultimately on the seventh day prior to the general meeting, unless indicated otherwise when such meeting is convened.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">227</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event will a quorum consist of less than one-third of the shares entitled to vote at a meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than 10&#160;days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shareholder Proposals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Pursuant to our articles of association, extraordinary general meetings will be held whenever required under Dutch law or whenever our management board or supervisory board deems such to be appropriate or necessary. Pursuant to Dutch law, one or more shareholders or others with meeting rights under Dutch law representing at least one-tenth of the issued share capital may request us to convene a general meeting, setting out in detail the matters to be discussed. If we have not taken the steps necessary to ensure that such meeting can be held within six weeks after the request, the requesting party or parties may, on their application, be authorized by the competent Dutch court in preliminary relief proceedings to convene a general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also, the agenda for a general meeting shall include such items requested by one or more shareholders, and others entitled to attend general meetings, representing at least 3% of the issued share capital, except where the articles of association state a lower&#160;percentage. Our articles of association do not state such lower&#160;percentage. Requests must be made in writing or by electronic means and received by us at least 60&#160;days before the day of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with the DCGC and our articles of association, a shareholder shall exercise the right of putting an item on the agenda only after consulting the management board in that respect. If one or more shareholders intend to request that an item be put on the agenda that may result in a change in the company&#8217;s strategy (for example, the removal of managing directors or supervisory directors), the management board must be given the opportunity to invoke a reasonable period to respond to such intention. Such period shall not exceed 180&#160;days (or such other period as may be stipulated for such purpose by Dutch law and/or the DCGC from time to time). If invoked, the management board must use such response period for further deliberation and constructive consultation, in any event with the shareholders(s) concerned, and shall explore the alternatives. At the end of the response time, the management board shall report on this consultation and the exploration of alternatives to the general meeting. This shall be supervised by our supervisory board. The response period may be invoked only once for any given general meeting and shall not apply: (a)&#160;in respect of a matter for which a response period has been previously invoked; or (b)&#160;if a shareholder holds at least 75% of the company&#8217;s issued share capital as a consequence of a successful public bid. The response period may also be invoked in response to shareholders or others with meeting rights under Dutch law requesting that a general meeting be convened, as described above.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">228</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Moreover, our management board, with the approval of our supervisory board, can invoke a cooling-off period of up to 250 days when shareholders, using their right to have items added to the agenda for a general meeting or their right to request a general meeting, propose an agenda item for our general meeting to dismiss, suspend or appoint one or more managing directors or supervisory directors (or to amend any provision in our articles of association dealing with those matters) or when a public offer for our company is made or announced without our support, provided, in each case, that our management board believes that such proposal or offer materially conflicts with the interests of our company and its business. During a cooling-off period, our general meeting cannot dismiss, suspend or appoint managing directors and supervisory directors (or amend the provisions in our articles of association dealing with those matters) except at the proposal of our management board. During a cooling-off period, our management board must gather all relevant information necessary for a careful decision-making process and at least consult with shareholders representing 3% or more of our issued share capital at the time the cooling-off period was invoked, as well as with our Dutch works council (if we or, under certain circumstances, any of our subsidiaries would have one). Formal statements expressed by these stakeholders during such consultations must be published on our website to the extent these stakeholders have approved that publication. Ultimately one week following the last day of the cooling-off period, our management board must publish a report in respect of its policy and conduct of affairs during the cooling-off period on our website. This report must remain available for inspection by shareholders and others with meeting rights under Dutch law at our office and must be tabled for discussion at the next general meeting. Shareholders representing at least 3% of our issued share capital may request the Enterprise Chamber for early termination of the cooling-off period. The Enterprise Chamber must rule in favor of the request if the shareholders can demonstrate that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our management board, in light of the circumstances at hand when the cooling-off period was invoked, could not reasonably have concluded that the relevant proposal or hostile offer constituted a material conflict with the interests of our company and its business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our management board cannot reasonably believe that a continuation of the cooling-off period would contribute to careful policy-making; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other defensive measures, having the same purpose, nature and scope as the cooling-off period, have been activated during the cooling-off period and have not since been terminated or suspended within a reasonable period at the relevant shareholders&#8217; request (i.e., no &#8216;stacking&#8217; of defensive measures).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Delaware.</i> Delaware law does not specifically grant stockholders the right to bring business before an annual or special meeting. However, if a Delaware corporation is subject to the SEC&#8217;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#8217;s securities entitled to vote, may propose a matter for a vote at an annual or special meeting in accordance with those rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Action by Written Consent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under Dutch law, shareholders&#8217; resolutions may be adopted in writing without holding a meeting of shareholders, provided that (i)&#160;the articles of association allow such action by written consent, (ii)&#160;the company has not issued bearer shares or, with its cooperation, depository receipts for shares in its capital, and (iii)&#160;the resolution is adopted unanimously by all shareholders that are entitled to vote. Although our articles of association allow for shareholders&#8217; resolutions to be adopted in writing, the requirement of unanimity renders the adoption of shareholder resolutions without holding a meeting not feasible for us as a publicly traded company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Delaware.</i> Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take action by written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Appraisal Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Subject to certain exceptions, Dutch law does not recognize the concept of appraisal or dissenters&#8217; rights. However, Dutch law does provide for squeeze-out procedures. Also, Dutch law provides for cash exit rights in certain situations for dissenting shareholders of a company organized under Dutch law entering into certain types of mergers. In those situations, a dissenting shareholder may file a claim with the Dutch company for compensation. Such compensation shall then be determined by one or more independent experts. The shares of such shareholder that are subject to such claim will cease to exist as of the moment of entry into effect of the merger.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">229</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Delaware.</i> The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder&#8217;s shares, in connection with certain mergers and consolidations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Shareholder Suits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> In the event a third-party is liable to a Dutch company, only the company itself can bring a civil action against that party. The individual shareholders do not have the right to bring an action on behalf of the company. Only in the event that the cause for the liability of a third-party to the company also constitutes a tortious act directly against a shareholder does that shareholder have an individual right of action against such third-party in its own name. Dutch law provides for the possibility to initiate such actions collectively, in which a foundation or an association can act as a class representative and has standing to commence proceedings and claim damages if certain criteria are met. The court will first determine if those criteria are met. If so, the case will go forward as a class action on the merits after a period allowing class members to opt out from the case has lapsed. All members of the class who are residents of the Netherlands and who did not opt out will be bound to the outcome of the case. Residents of other countries must actively opt in in order to be able to benefit from the class action. The defendant is not required to file defenses on the merits prior to the merits phase having commenced. It is possible for the parties to reach a settlement during the merits phase. Such a settlement can be approved by the court, which approval will then bind the members of the class, subject to a second opt out. This new regime applies to claims brought after January&#160;1, 2020, and which relate to certain events that occurred prior to that date. For other matters, the old Dutch class actions regime will apply. Under the old regime, no monetary damages can be sought. Also, a judgment rendered under the old regime will not bind individual class members. Even though Dutch law does not provide for derivative suits, directors and officers can still be subject to liability under U.S. securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Repurchase of Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under Dutch law, when issuing shares, a public company such as ours may not subscribe for newly issued shares in its own capital. Such company may, however, subject to certain restrictions of Dutch law and its articles of association, acquire shares in its own capital. A listed public company such as ours may acquire fully paid shares in its own capital at any time for no valuable consideration. Furthermore, subject to certain provisions of Dutch law and its articles of association, such company may repurchase fully paid shares in its own capital if (i)&#160;the company&#8217;s shareholders&#8217; equity less the payment required to make the acquisition does not fall below the sum of paid-in and called-up share capital plus any reserves required by Dutch law or its articles of association and (ii)&#160;the aggregate nominal value of shares of the company which the company acquires, holds or on which the company holds a pledge (<i style="font-style:italic;">pandrecht</i>) or which are held by a subsidiary of the company, would not exceed 50% of its then-current issued share capital. Such company may only acquire its own shares if its general meeting has granted the management board the authority to effect such acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">An acquisition of common shares for a consideration must be authorized by our general meeting. Such authorization may be granted for a maximum period of 18&#160;months and must specify the number of common shares that may be acquired, the manner in which common shares may be acquired and the price limits within which common shares may be acquired. The actual acquisition may only be effected pursuant to a resolution of our management board, with the approval of our supervisory board. Our management board, subject to approval of our supervisory board, has been authorized, for a period of 18&#160;months following the completion of our initial public offering, to cause the repurchase of common shares by us of up to 20% of our issued share capital, for a price per share not exceeding 110% of the average market price of our common shares on Nasdaq (such average market price being the average of the closing prices on each of the five consecutive trading days preceding the date the acquisition is agreed upon by us). These shares may be used to deliver shares underlying awards granted pursuant to our equity-based compensation plans.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">230</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management board, subject to approval by our supervisory board, has also been authorized for a period of 18&#160;months following the completion of our initial public offering to cause the repurchase of preferred shares, for a price which is higher than nil and does not exceed the nominal value thereof. No authorization of the general meeting is required if fully paid common shares are acquired by us with the intention of transferring such common shares to our employees under an applicable employee share purchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Anti-Takeover Provisions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. In this respect, certain provisions of our articles of association may make it more difficult for a third-party to acquire control of us or effect a change in our management board and supervisory board. These provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authorization of a class of preferred shares that, after the expiration of the later of the initial period or the initial approval period, may be issued to a protective foundation pursuant to a call option to that effect, see &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Item 3. Key Information &#8212; D. Risk Factors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;&#8212;&#8201;Provisions of our articles of association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent, delay or frustrate any attempt to replace or remove the members of our managing directors or supervisory directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that our managing directors and supervisory directors are appointed on the basis of a binding nomination, the binding nature of which can only be overruled by a simple majority of votes cast representing at least one-third of our issued share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that our managing directors and supervisory directors may only be dismissed by the general meeting by a two-thirds majority of votes cast representing more than 50% of our issued share capital (unless the dismissal is proposed by the supervisory board or, with respect to supervisory directors nominated by dievini or KfW, by dievini (or its legal successor) or permitted assigns under the KfW dievini Shareholders&#8217; Agreement during the nomination period for dievini or by KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) during the nomination period for KfW, respectively, in which case a simple majority of the votes would be sufficient);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that where a supervisory director is no longer in office or is unable to act, he or she may be replaced temporarily by a person whom the supervisory board has designated for that purpose and, where a supervisory director who has been appointed upon a nomination of dievini or KfW, as applicable, is no longer in office or unable to act, such supervisory director may only be temporarily replaced by a person designated for such purposes by dievini or KfW, as applicable. Such person shall become a full member of the supervisory board with the rights of the relevant supervisory director appointed upon a nomination of dievini or KfW, as applicable, as soon as a written designation to that effect has been received by the chairman or vice-chairman of our supervisory board, subject to limitations, under applicable law regarding dievini&#8217;s rights under this provision;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision allowing, among other matters, a former chairman of our supervisory board, a former nominee of dievini, and a former nominee of KfW, to jointly take on the supervisory functions, which persons jointly may designate one or more other persons to be charged with the supervision of our company (instead of or together with the former chairman of our supervisory board), as applicable, to manage our affairs if all of our managing directors and supervisory directors are removed from office and to appoint others to be charged with the management and supervision of our affairs, until new managing directors and supervisory directors are appointed by the general meeting on the basis of a binding nomination discussed above;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision allowing the management board to temporarily replace a managing director who is no longer in office or unable to act, by another person or persons designated for this purpose by the management board and attributing the management of the company to the supervisory board in case all managing directors are no longer in office or unable to act;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">231</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a provision that certain provisions of our articles of association can only be amended with the affirmative vote of (i)&#160;during the nomination period for dievini, dievini (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) and (ii)&#160;during the nomination period for KfW, KfW (or its legal successors or permitted assigns under the KfW dievini Shareholders&#8217; Agreement); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that certain matters, including an amendment of our articles of association, may only be brought to our shareholders for a vote upon a proposal by our management board.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In addition, Dutch law allows for staggered multi-year terms of our managing directors and supervisory directors, as a result of which only part of our managing directors and supervisory directors may be subject to appointment or reappointment in any one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Furthermore, our management board may, under certain circumstances invoke a reasonable period of up to 180 days to respond to certain shareholder proposals or a statutory cooling-off period of up to 250 days to respond to certain shareholder proposals or a hostile bid. See above under &#8220;Shareholder Proposals.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Delaware.</i> In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Section&#160;203 of the Delaware General Corporation Law prohibits &#8220;business combinations,&#8221; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation&#8217;s voting stock, within three&#160;years after the person becomes an interested stockholder, unless:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the transaction that will cause the person to become an interested stockholder is approved by the board of directors of the target prior to the transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">after the completion of the transaction in which the person becomes an interested stockholder, the interested stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">after the person becomes an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">A Delaware corporation may elect not to be governed by Section&#160;203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. Such an amendment is not effective until 12&#160;months following its adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Inspection of Books and Records</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> The management board and the supervisory board provide the general meeting, within a reasonable amount of time, all information that the shareholders require for the exercise of their powers, unless this would be contrary to an overriding interest of our company. If the management board or supervisory board invokes such an overriding interest, it must give reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, any stockholder may inspect for any proper purpose certain of the corporation&#8217;s books and records during the corporation&#8217;s usual hours of business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">232</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Dismissal of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under our articles of association, the general meeting shall at all times be entitled to dismiss a managing director or supervisory director. The general meeting may only adopt a resolution to suspend or dismiss a managing director or supervisory director by at least a two-thirds majority of the votes cast, provided that such majority represents more than half of the issued share capital, unless the proposal was made by the supervisory board or, with respect to supervisory directors nominated by dievini or KfW, by dievini (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) during the nomination period for dievini or by KfW (or its legal successor or permitted assigns under the KfW dievini Shareholders&#8217; Agreement) during the nomination period for KfW, respectively, in which latter case a simple majority is sufficient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i)&#160;unless the certificate of incorporation provides otherwise, in the case of a corporation whose board is classified, stockholders may effect such removal only for cause, or (ii)&#160;in the case of a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he or she is a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Issuance of Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under Dutch law, a company&#8217;s general meeting is the corporate body authorized to resolve on the issuance of shares and the granting of rights to subscribe for shares. The general meeting can delegate such authority to another corporate body of the company, such as the management board, for a period not exceeding five&#160;years; this authorization may only be extended from time to time for a maximum period of five&#160;years. In order for a resolution of the general meeting on an issuance or an authorization as discussed in the previous sentence to be valid, a prior or simultaneous approval shall be required from each meeting of holders of a certain class of shares whose rights are prejudiced by the issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management board, subject to approval of our supervisory board, has been authorized, for a period of five&#160;years from the completion of our initial public offering, to issue shares or grant rights to subscribe for shares up to our authorized share capital from time to time. We may not subscribe for our own shares on issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware.</i> All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company&#8217;s certificate of incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preemptive Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i>&#160;Under Dutch law, in the event of an issuance of common shares, each shareholder will have a pro&#160;rata preemptive right in proportion to the aggregate nominal value of the common shares held by such holder (with the exception of common shares to be issued to employees or common shares issued against a contribution other than in cash or pursuant to the exercise of a previously acquired right to subscribe for shares). Our preferred shares carry no preemptive rights. Under our articles of association, the preemptive rights in respect of newly issued common shares may be restricted or excluded by a resolution of the general meeting. Another corporate body, such as the management board, may restrict or exclude the preemptive rights in respect of newly issued common shares if it has been designated as the authorized body to do so by the general meeting. Such designation can be granted for a period not exceeding five&#160;years. A resolution of the general meeting to restrict or exclude the preemptive rights or to designate another corporate body as the authorized body to do so requires a majority of not less than two-thirds of the votes cast, if less than one-half of our issued share capital is represented at the meeting. Our management board, subject to approval of our supervisory board, has been authorized, for a period of five&#160;years from the completion of our initial public offering, to limit or exclude preemptive rights in relation to an issuance of shares or a grant of rights to subscribe for shares that the management board is authorized to resolve upon. See &#8220;&#8212;Issuance of Shares.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, stockholders have no preemptive rights to subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">233</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Dutch law provides that dividends (if it concerns a distribution of profits) may be distributed after adoption of the annual accounts by the general meeting from which it appears that such dividend distribution is allowed. Moreover, dividends may be distributed, whether as a distribution of profits or of freely distributable reserves, only to the extent the shareholders&#8217; equity exceeds the amount of the paid-in and called-up issued share capital and the reserves that must be maintained under the law or the articles of association. Interim dividends may be declared as provided in the articles of association and may be distributed to the extent that the shareholders&#8217; equity exceeds the amount of the paid-in and called-up issued share capital plus any reserves as described above as apparent from our interim financial statements prepared under Dutch law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under our articles of association, our management board, with the approval of our supervisory board, may decide that all or part of the profits are carried to reserves. Before reservation of any profit, to the extent that preferred shares have been canceled and preferred distributions on those canceled shares are outstanding, the profits are first to be used to satisfy the outstanding claim to those who held those preferred shares at the moment of such cancellation becoming effective and subsequently if any preferred shares are outstanding, the preferred dividend is paid out of the remaining profit on the preferred shares in accordance with our articles of association. The remaining profit will be at the disposal of the general meeting at the proposal of the management board for distribution on the common shares, subject to restrictions of Dutch law and approval by our supervisory board of such proposal of our management board. Our management board is permitted, subject to certain requirements, to declare interim dividends without the approval of the general meeting, but only with the approval of the supervisory board. Dividends and other distributions shall be made payable not later than the date determined by the management board. Claims to dividends and other distributions not made within five&#160;years from the date that such dividends or distributions became payable will lapse and any such amounts will be considered to have been forfeited to us (<i style="font-style:italic;">verjaring</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of common stock, property or cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Shareholder Vote on Certain Reorganizations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> Under Dutch law, the general meeting must approve resolutions of the management board relating to a significant change in the identity or the character of the company or the business of the company, which includes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a transfer of the business or virtually the entire business to a third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the entry into or termination of a long-term cooperation of the company or a subsidiary with another legal entity or company or as a fully liable partner in a limited partnership or general partnership, if such cooperation or termination is of a far-reaching significance for the company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acquisition or divestment by the company or a subsidiary of a participating interest in the capital of a company having a value of at least one-third of the amount of its assets according to its balance sheet and explanatory notes or, if the company prepares a consolidated balance sheet, according to its consolidated balance sheet and explanatory notes in the last adopted annual accounts of the company.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">234</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, however, unless required by the certificate of incorporation, if (i)&#160;the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (ii)&#160;the shares of stock of the surviving corporation are not changed in the merger and (iii)&#160;the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#8217;s common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the stockholders will be entitled to appraisal rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 18pt;">Remuneration of Managing Directors and Supervisory Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">The Netherlands.</i> The supervisory board determines the remuneration of individual managing directors with due observance of the compensation policy at the recommendation of our compensation committee. A proposal with respect to remuneration schemes in the form of shares or rights to shares in which managing directors may participate is subject to approval by our general meeting. Such a proposal must set out at least the maximum number of shares or rights to subscribe for shares to be granted to the managing directors and the criteria for granting or amendment. The compensation for our supervisory directors is set by the general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Delaware.</i> Under the Delaware General Corporation Law, the stockholders do not generally have the right to approve the compensation policy for directors or the senior management of the corporation, although certain aspects of the compensation policy may be subject to stockholder vote due to the provisions of U.S. federal securities and tax law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9de4e1b5_5f18_49da_be51_344bbf5d6114"></a><a id="ITEM16HMineSafetyDisclosure_10468"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">ITEM 16H. Mine Safety Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f46ab0b4_51fc_4e43_8d54_55f6c61c3e0d"></a><a id="ITEM16KCybersecurity_314098"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">ITEM 16K. Cybersecurity</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Protecting the security and integrity of CureVac&#8217;s IT systems and safeguarding the privacy of our business partners, patients and employees along with our intellectual property is a key priority for us. Cybersecurity risks are among the core risks evaluated through our enterprise risk management program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Our IT security team is responsible for assessing and maintaining our cybersecurity risk management program. Our Head of IT oversees our cybersecurity program and is supported by our Manager of Information Security, the Senior Director of Infrastructure &amp; Operations, the IT Leadership Team and other business leaders. Our cybersecurity program is designed to enable the Company to respond to the threat of security breaches and cyberattacks and to protect and preserve the confidentiality, integrity, and continued availability of information assets processed by the Company. Our Manager of Information Security and his team are experienced subject matter experts in the field of information security. The Senior Director of Infrastructure &amp; Operations has over 25 years of international experience in information security, IT strategy and IT management, including security consulting. Similarly, our Head of IT has over 25 years of experience in various senior international IT leadership roles. Our internal IT security team is augmented by third parties, who provide additional information security expertise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">To address cybersecurity threats and in an effort to prevent IT system interruptions, we are developing enterprise-wide policies, procedures, and practices based on and audited against industry standards, including the ISO 27001 Standard and &#8220;BSI-Grundschutz&#8221;. CureVac&#8217;s systems are regularly patched and updated with supported software releases. We conduct regular internal vulnerability analyses (including simulated hacking) as well as external penetration testing utilizing third parties to verify and ensure the effectiveness of our cybersecurity controls. Our employees are required to participate in our cybersecurity awareness program, which includes access to specific cybersecurity and information security training sessions and content and periodic phishing attack simulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">CureVac requires employees to report IT security incidents to the IT security team via CureVac&#8217;s internal service management platform. Additionally, we have implemented a 24/7/365 Cyber Security Operations Center (CSOC) operated by an external third party. The CSOC provides active monitoring and is responsible for investigating any security incidents and alerts on our platforms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Where appropriate, threats or incidents are escalated to our Head of IT, who informs our CEO, management board and/or Data Protection Officer of any such threats or incidents. Any breaches related to personal data are managed by the Data Protection Officer in consultation with CureVac&#8217;s IT security team.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">235</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Head of IT updates the status of the cybersecurity program quarterly within the enterprise risk management program. The management board provides oversight over the enterprise risk management program, reviews the risk portfolio on a quarterly basis and is responsible for ensuring that we have implemented an appropriate and effective risk management system and process. The supervisory board reviews the enterprise risk management program on an annual basis. In addition, the Head of IT provides regular updates on the status of the cybersecurity program, and emerging cybersecurity threats and incidents to the management board. At least once each year, the Audit Committee discusses our approach to cybersecurity risk management with the Head of IT and, as necessary, to the full supervisory board, based on management&#8217;s assessment of risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In 2023, we did not identify any cybersecurity threats or incidents that have materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats or incidents or provide assurances that we have not experienced an undetected cybersecurity incident. For more information about these risks, please see &#8220;Risk Factors&#8211;Risks Related to Our Business and Industry&#8221; in this Annual Report on Form 20-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a5463f68_7b01_4ddf_a9c9_5f9cadf37f0a"></a><a id="PARTIII_702996"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">PART III</p><a id="ITEM17FinancialStatements_982680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">ITEM 17. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have responded to Item&#160;18 in lieu of this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9f9e5597_384b_4dc5_89f7_d5600adf3a37"></a><a id="ITEM18FinancialStatements_475615"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">ITEM 18. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our audited consolidated financial statements are included in this Annual Report beginning at Page&#160;F-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 4.5pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">236</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9cf4f92d_988c_404e_aa9d_64f4e553c3be"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">CureVac N.V.</p></td></tr><tr><td style="vertical-align:bottom;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">/s/ Alexander Zehnder</p></td></tr><tr><td style="vertical-align:bottom;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">Name:&#160;&#160;Alexander Zehnder</p></td></tr><tr><td style="vertical-align:bottom;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">Title:&#160;&#160;<i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">Date: April 24, 2024</p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">237</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3277046d_e0b1_49f4_95f2_f0f4cd33ff83"></a><a id="ITEM19Exhibits_127428"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ITEM 19. Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920091817/tm2016252d8_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Articles of Association of CureVac N.V. (translated into English) (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920089179/tm2016252d8_ex3-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investment and Shareholders&#8217; Agreement among several shareholders and CureVac AG (incorporated by reference to Exhibit&#160;3.5 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.2</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex3-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shareholders&#8217; Agreement among Kreditanstalt f&#252;r Wiederaufbau, dievini Hopp BioTechholding GmbH &amp; Co KG and Mr. Dietmar Hopp, dated June&#160;16, 2020 (incorporated by reference to Exhibit&#160;3.6 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.3</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex3-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Relationship Agreement among Kreditanstalt fur Wiederaufbau, dievini Hopp BioTechholding GmbH &amp; Co KG and Mr. Dietmar Hopp, dated July&#160;17, 2020 (incorporated by reference to Exhibit&#160;3.7 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.4</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921116930/tm2127619d2_ex4-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Form F-3 (File No. 333-259613) filed on September 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.5</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057823000793/cvac-20221231xex2d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the rights of each class of securities registered under Section&#160;12 of the Securities Exchange Act of 1934 as of December 31, 2021.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920089179/tm2016252d8_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement by and between CureVac AG and Genmab B.V., dated December&#160;19, 2019 (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920089179/tm2016252d8_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Development and License Agreement by and between CureVac AG and CRISPR Therapeutics AG, dated November&#160;9, 2017 (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920089179/tm2016252d8_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Global Access Commitments Agreement, by and between Bill &amp; Melinda Gates Foundation and CureVac GmbH, dated February&#160;13, 2015 (incorporated by reference to Exhibit&#160;10.7 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Definitive Agreement and Project Collaboration Plan for Assessment of RNA Vaccine Technology for Non-live Rotavirus Vaccines in Pre-clinical Models by and between Bill &amp; Melinda Gates Foundation and CureVac GmbH, dated May&#160;15, 2014 (incorporated by reference to Exhibit&#160;10.8 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Framework Partnering Agreement between Coalition for Epidemic Preparedness Innovations and CureVac AG, dated February&#160;15, 2019 (incorporated by reference to Exhibit&#160;10.9 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Workpackage Statement (Development of CureVac Outbreak Response To Novel Coronavirus (2019-nCoV)) between Coalition for Epidemic Preparedness Innovations and CureVac AG, dated January&#160;27, 2020 (incorporated by reference to Exhibit&#160;10.10 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Development and Option Agreement, between CureVac AG and Acuitas Therapeutics Inc., dated April&#160;29, 2016 (incorporated by reference to Exhibit&#160;10.11 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920089179/tm2016252d8_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Side Agreement and Amendment Number One to the Development and Option Agreement, between CureVac AG and Acuitas Therapeutics Inc., dated December&#160;1, 2016 (incorporated by reference to Exhibit&#160;10.12 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Development and Intellectual Property Agreement, between CureVac AG and Tesla Grohmann Automation GmbH, dated November&#160;24, 2015 (incorporated by reference to Exhibit&#160;10.13 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">238</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated March&#160;15, 2019 (incorporated by reference to Exhibit&#160;10.19 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.11</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated May&#160;19, 2019 (incorporated by reference to Exhibit&#160;10.20 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.12</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Rental contract for commercial premises, between CureVac Real Estate GmbH and Technologieparks T&#252;bingen-Reutlingen GmbH, dated January&#160;31, 2018 (incorporated by reference to Exhibit&#160;10.21 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.13</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Rental Contract between CureVac Real Estate GmbH and Fr&#228;nkel Immobilien-Service GmbH, dated June&#160;6, 2018 (incorporated by reference to Exhibit&#160;10.22 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.14</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Supplement to the rental contract, between CureVac Real Estate GmbH and Fr&#228;nkel Immobilien-Service GmbH, dated July&#160;23, 2018 (incorporated by reference to Exhibit&#160;10.23 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.15</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Supplement to the rental contract, between CureVac Real Estate GmbH and Fr&#228;nkel Immobilien-Service GmbH, dated August&#160;20, 2018 (incorporated by reference to Exhibit&#160;10.24 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.16</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Supplement to the rental contract, between CureVac Real Estate GmbH and HSB Vermietungs-und Verpachtungs-GmbH &amp; Co. KG, dated November&#160;5, 2018 (incorporated by reference to Exhibit&#160;10.25 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.17</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Supplement to the rental contract, between CureVac Real Estate GmbH and HSB Vermietungs-und Verpachtungs-GmbH &amp; Co. KG, dated October&#160;22, 2019 (incorporated by reference to Exhibit&#160;10.26 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.18</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of indemnification agreement between CureVac N.V. and members of the Supervisory Board or Management Board (incorporated by reference to Exhibit&#160;10.27 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.19</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">CureVac N.V. Long-Term Incentive Plan (incorporated by reference to Exhibit&#160;10.28 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.20</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">CureVac Virtual Share Plan (incorporated by reference to Exhibit&#160;10.29 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.21</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Collaboration and License Agreement by and between CureVac AG and Genmab B.V., dated July&#160;2, 2020 (incorporated by reference to Exhibit&#160;10.32 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.22</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated July&#160;15, 2020 (incorporated by reference to Exhibit&#160;10.33 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.23</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex10-34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment Two to the Development and Option Agreement, between CureVac AG and Acuitas Therapeutics Inc., dated July&#160;10, 2020 (incorporated by reference to Exhibit&#160;10.34 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.24</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920091817/tm2016252d17_ex10-38.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement regarding the alignment between the Global Access Commitments Agreement, between CureVac AG and the Bill &amp; Melinda Gates Foundation and the Collaboration and License Agreement between CureVac AG and Glaxosmithkline Biologicals&#160;SA, dated July&#160;15, 2020 (incorporated by reference to Exhibit&#160;10.38 to the Company&#8217;s Form&#160;F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">239</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.25</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920091817/tm2016252d17_ex10-39.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment and Joinder to Global Access Commitments Agreement, between CureVac AG, CureVac B.V. and the Bill &amp; Melinda Gates Foundation, dated July&#160;15, 2020 (incorporated by reference to Exhibit&#160;10.39 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.26</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920091817/tm2016252d17_ex10-40.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Global Access Commitments Agreement, between the Bill &amp; Melinda Gates Foundation and CureVac AG, dated July&#160;15, 2020 (incorporated by reference to Exhibit&#160;10.40 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.27</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920092289/tm2016252d19_ex10-41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Long Term Incentive Plan of CureVac N.V. (incorporated by reference to Exhibit&#160;10.41 to the Company&#8217;s Form F-1 (File No. 333-240076) filed on August&#160;10, 2020).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.28</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921007168/tm2036979d3_ex10-42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">1st Amendment to the Development and License Agreement, effective as of November&#160;9, 2017, between CureVac AG and CRISPR Therapeutics, AG (incorporated by reference to Exhibit&#160;10.42 to the Company&#8217;s Form F-1 (File No. 333-252391) filed on January&#160;25, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.29</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921007168/tm2036979d3_ex10-43.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment 4 to Definitive Agreement 1 between the Bill &amp; Melinda Gates Foundation and CureVac AG, effective November&#160;3, 2020 (incorporated by reference to Exhibit&#160;10.43 to the Company&#8217;s Form F-1 (File No. 333-252391) filed on January&#160;25, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.30</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921007168/tm2036979d3_ex10-44.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Addendum to Investment and Shareholders&#8217; Agreement among several shareholders and CureVac N.V., dated June&#160;16, 2020 (incorporated by reference to Exhibit&#160;10.44 to the Company&#8217;s Form F-1 (File No. 333-252391) filed on January&#160;25, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.31</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921007168/tm2036979d3_ex10-46.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Collaboration and License Agreement between Genmab B.V. and CureVac AG, dated December&#160;19, 2019 (incorporated by reference to Exhibit&#160;10.46 to the Company&#8217;s Form F-1 (File No. 333-252391) filed on January&#160;25, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.32</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921007168/tm2036979d3_ex10-47.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment Three to Development and Option Agreement between Acuitas Therapeutics Inc. and CureVac AG, dated December&#160;24, 2020 (incorporated by reference to Exhibit&#160;10.47 to the Company&#8217;s Form F-1 (File No. 333-252391) filed on January&#160;25, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.33</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921007168/tm2036979d3_ex10-48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment Number One to the Framework Partnering Agreement between Coalition for Epidemic Preparedness Innovations and CureVac AG, dated December&#160;11, 2020 (incorporated by reference to Exhibit&#160;10.48 to the Company&#8217;s Form F-1 (File No. 333-252391) filed on January&#160;25, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.34</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921055619/tm215958d3_ex4-49.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated April&#160;2, 2021 (incorporated by reference to Exhibit 4.49 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filled on April 27, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.35</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465921055619/tm215958d3_ex4-50.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">COVID Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated April&#160;2, 2021 (incorporated by reference to Exhibit 4.50 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filled on April 27, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.36</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057821000557/cvac-20210930xex99d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to the Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated September 29, 2021 (incorporated by reference to Exhibit 99.3 to the Company&#8217;s Form 6-K (File No. 001-39446) filed on December 17, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.37</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057821000557/cvac-20210930xex99d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the COVID Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated September 29, 2021 (incorporated by reference to Exhibit 99.4 to the Company&#8217;s Form 6-K (File No. 001-39446) filed on December 17, 2021).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.38</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000110465922004038/tm2136618d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to the Shareholders&#8217; Agreement among Kreditanstalt f&#252;r Wiederaufbau, dievini Hopp BioTechholding GmbH &amp; Co KG and Mr. Dietmar Hopp, dated January 13, 2022 (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Form 6-K (File No. 001-39446) filed on January 13, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">240</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.39</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057822001070/cvac-20211231xex4d56.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Collaboration and License Agreement between Genmab B.V. and CureVac AG, dated December 19, 2019, effective June 30, 2021 (incorporated by reference to Exhibit 4.56 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 28, 2022).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.40</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057822001070/cvac-20211231xex4d57.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consortium Agreement between CureVac AG, CureVac Real Estate GMBH and Glaxosmithkline Biologicals SA, dated February 20, 2022 (incorporated by reference to Exhibit 4.57 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 28, 2022).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.41</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057822001070/cvac-20211231xex4d58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to the Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated March 4, 2022 (incorporated by reference to Exhibit 4.58 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 28, 2022).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.42</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057822001070/cvac-20211231xex4d59.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to the COVID Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated March 4, 2022 (incorporated by reference to Exhibit 4.59 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 28, 2022).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.43</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057822001070/cvac-20211231xex4d60.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated July 29, 2021 (incorporated by reference to Exhibit 4.60 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 28, 2022).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.44</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057822001070/cvac-20211231xex4d61.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated September 1, 2021 (incorporated by reference to Exhibit 4.61 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 28, 2022).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.45</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057822001070/cvac-20211231xex4d62.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the Collaborative Research Agreement between CureVac AG and Yale University (incorporated by reference to Exhibit 4.62 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 28, 2022).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.46</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057823000793/cvac-20221231xex4d61.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Research and Option Agreement, by and between CureVac AG and myNEO NV, dated May 12, 2022 (incorporated by reference to Exhibit 4.61 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 25, 2023).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.47</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057823000793/cvac-20221231xex4d62.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to the COVID Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, dated August 25, 2022 (incorporated by reference to Exhibit 4.62 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 25, 2023).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.48</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057823000793/cvac-20221231xex4d63.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated August 31, 2022 (incorporated by reference to Exhibit 4.63 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 25, 2023).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.49</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1809122/000141057823000793/cvac-20221231xex4d64.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated January 1, 2023 (incorporated by reference to Exhibit 4.64 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-39446) filed on April 25, 2023).&#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.50*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex4d50.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">CureVac N.V. Long-Term Incentive Plan (Amended and Restated as of 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.51*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex4d51.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">1st Amendment of the Research and Option Agreement, by and between CureVac AG and myNEO NV, dated January 12, 2023. &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.52*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex4d52.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to the Development and License Agreement between CureVac SE and CRISPR Therapeutics AG, dated October 27, 2023. &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.53*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex4d53.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment Four to Development and Option Agreement between Acuitas Therapeutics Inc. and CureVac AG, dated February 13, 2024. &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.54*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex4d54.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sixth Amendment to Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated June 29, 2023. &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">241</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.55*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex4d55.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Seventh Amendment to Sponsored Research Agreement, between CureVac AG and The Schepens Eye Research Institute, Inc., dated February 23, 2024. &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8.1*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex8d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of subsidiaries.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12.1**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex12d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12.2**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex12d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13.1**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex13d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13.2**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex13d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15.1*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex15d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG AG Wirtschaftspr&#252;fungsgesellschaft.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15.2*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex15d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97.1*</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">CureVac N.V. Compensation Recoupment Policy</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104**</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Certain information has been excluded from the exhibit because it both (i)&#160;is not material and (ii)&#160;would likely cause competitive harm to the Registrant if publicly disclosed.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Filed with this Annual Report on Form 20-F.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">In accordance with Rule 402 of Regulation S-T, the information in these exhibits shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">242</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:75.74pt;"><a id="_39a19cfd_080b_4b36_8578_09dadd988e99"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><img src="cvac-20231231x20f066.jpg" alt="Graphic" style="display:inline-block;height:75.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:217.47pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:17pt;font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:17pt;font-weight:bold;">Consolidated Financial</b><b style="font-size:17pt;font-weight:bold;"><br/></b><b style="font-size:17pt;font-weight:bold;">Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">As of December 31, 2023 and 2022</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">and for the years ended December 31, 2023, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Audited Annual Consolidated Financial Statements</b></p></td><td style="vertical-align:bottom;width:2.17%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Reports of Independent Registered Public Accounting Firm</span></a> (<i style="font-style:italic;">PCAOB ID </i><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:AuditorFirmId" id="Narr_CO7TZPt7bki__iE1IHrCYw"><i style="font-style:italic;">1021</i></ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:2.17%;background:#cceeff;border-top:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:86.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><a href="#ReportofIndependentRegistere_2"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> <i style="font-style:italic;">(PCAOB ID 01251)</i></p></td><td style="vertical-align:bottom;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:bottom;width:86.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperationsandOth"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Income (Loss) for the Fiscal Years Ended December 31, 2023, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-8 </p></td></tr><tr><td style="vertical-align:bottom;width:86.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofFinancialPositio"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Financial Position as of December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-9</p></td></tr><tr><td style="vertical-align:bottom;width:86.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><a href="#ConsolidatedStatementsofChangesinShareho"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Shareholders&#8217; Equity for the Fiscal Years Ended December 31, 2023, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-10</p></td></tr><tr><td style="vertical-align:bottom;width:86.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_959663"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the Fiscal Years ended December 31, 2023, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-11 </p></td></tr><tr><td style="vertical-align:bottom;width:86.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a1CorporateInformation_486713"><span style="font-style:normal;font-weight:normal;">Notes to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-12</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f480b62d_8f50_435f_82da_f25bb467a029"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac N.V.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Opinion on the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the accompanying consolidated statement of financial position of CureVac N.V. and subsidiaries (the Company) as of December 31, 2023, the related consolidated statements of operations and comprehensive income (loss), changes in shareholders&#8217; equity, and cash flows for the year ended December 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in <i style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated April 24, 2024 expressed an adverse opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basis for Opinion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Critical Audit Matters</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Identification of distinct performance obligations and determining the over-time revenue recognition method under the GSK collaboration agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As discussed in Notes 2 and 3.1 to the consolidated financial statements, the Company entered into collaboration and license agreements with GlaxoSmithKline Biologicals SA (&#8220;GSK&#8221;) in July 2020, as amended and restated through March 2022. Under these arrangements, the Company recognized revenue in 2023 of EUR 38.3 million. These agreements contain multiple performance obligations and include licenses for the Company&#8217;s technology or programs, research and development services, and services or obligations in connection with participation in research or steering committees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As part of our initial audit, we identified the evaluation of the distinct performance obligations identified by the Company and the determination of the appropriate method for measuring progress as a critical audit matter. Complex auditor judgment was required in evaluating the terms and conditions in the agreements to assess the identification of distinct performance obligations and to assess the most appropriate method to measure progress towards complete satisfaction of the identified performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design of a certain internal control related to the identification of distinct performance obligations and the determination of the appropriate method to measure progress. We obtained and read the amended and restated collaboration and license agreements and evaluated the terms and conditions of the agreements to assess that the performance obligations within the agreements were completely and accurately identified in accordance with the relevant accounting guidance, and an appropriate measure of progress has been selected that best depicts the transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Provisions for contract termination costs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">As discussed in Note 2 to the consolidated financial statements, the Company recognizes provisions for contract termination costs when it is probable that an outflow of resources will be required to settle a present obligation and when the outflow can be reliably estimated. As described in Note 12 to the consolidated financial statements, as of December 31, 2023, the Company recorded provisions in the amount of EUR 37.4 million for the estimated costs that are expected to be required to settle the termination of  arrangements that had been concluded with contract manufacturing organizations (CMOs) in prior years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have identified the evaluation of the provisions for terminated CMO contracts as a critical audit matter as the assessment required significant auditor judgment, due to the significant measurement uncertainty in the amount that will ultimately be required to be paid to release the Company from its remaining obligations under the CMO contracts, in particular considering the impact of future arbitration decisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of a certain internal control related to the evaluation of legal proceedings, including the evaluation of information from external and internal legal counsels. We evaluated the competence of the external legal counsel of the Company. We assessed the provisions by: (1) Inspecting confirmation letters received directly from the Company&#8217;s external legal counsels that assessed the likelihood of loss and the amounts that would be paid in the event of loss of the arbitration proceedings, and comparing these assessments and estimates to those made by the Company; (2) Inquiring of the Company&#8217;s in-house legal counsel; and (3) Inspecting the latest correspondence between the Company and the CMOs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:AuditorName" id="Narr_Dp4uzXDHnUePGZv6D5HpqA">KPMG AG Wirtschaftspr&#252;fungsgesellschaft</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="dei:AuditorLocation" id="Narr_EFiAjEe_jUChj3VhrFYnPw">Mannheim, Germany</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 24, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac N.V.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Opinion on Internal Control Over Financial Reporting </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited CureVac N.V.&#8217;s and subsidiaries (the Company) internal control over financial reporting as of December 31, 2023, based on criteria established in <i style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness, described below, on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2023, based on criteria established in <i style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statement of financial position of the Company as of December 31, 2023, the related consolidated statements of operations and comprehensive income (loss), changes in shareholders&#8217; equity, and cash flows for the year ended December 31, 2023, and the related notes (collectively, the consolidated financial statements), and our report dated April 24, 2024 expressed an unqualified opinion on those consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. A material weakness related to (i) lack of sufficient accounting and supervisory personnel, (ii) lack of appropriate level of technical accounting training; and (iii) lack of consistent performance of controls over financial reporting has been identified and included in management&#8217;s assessment. The material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2023 consolidated financial statements, and this report does not affect our report on those consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basis for Opinion </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Definition and Limitations of Internal Control Over Financial Reporting </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ KPMG AG Wirtschaftspr&#252;fungsgesellschaft</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mannheim, Germany </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 24, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_966f69bd_daaf_446f_8a8e_a6c849697cb6"></a><a id="ReportofIndependentRegistere_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">To the Shareholders and the Audit Committee of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated statement of financial position of CureVac N.V. (the Company) as of December 31, 2022, the related consolidated statements of operations and other comprehensive income (loss), changes in shareholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">/s/ EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We served as the Company&#8217;s auditor from 2015 to 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Stuttgart, Germany</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">April 25, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9e4c92d2_de70_4b10_a5d2_be964e24b279"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><a id="ConsolidatedStatementsofOperationsandOth"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations and </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Other Comprehensive Income (Loss)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e5e58f2d_4dfe_451f_a3f9_2c1d89f7a6a1"></a><a id="_da8fe3b7_3ba5_4de4_a879_147f3c3a2419"></a><a id="Tc_hE7s6vWV0E2tec2CQFjV4Q_1_4"></a><a id="Tc_mlOc-_K7E0qPOqPVakOO1A_2_0"></a><a id="Tc_A_D4ihTK2UevT6C1-1BmSQ_2_2"></a><a id="Tc_Kr9caGBJsEOYIjvo9arOYg_2_4"></a><a id="Tc_ifNcyLQwtkGKAVboTIVWgw_2_6"></a><a id="Tc_TIWulo93q0mID_gONJd9Zg_2_8"></a><a id="Tc_s4wd9OXBJkyKS7Z6Y-xrrA_4_0"></a><a id="Tc_yW2SzPr75E2fZ6Kn00XPZA_4_2"></a><a id="Tc_6MvP10algkWDOp4VApSEXw_5_0"></a><a id="Tc_8nXXra3y2kWTXb1KJrdqyg_5_2"></a><a id="Tc_-E-kXOHZm0WxgXrkvRUVFg_6_0"></a><a id="Tc_M3F7QDqvyE-Or1nIOKG_PQ_6_2"></a><a id="Tc_FiRacpdxAEONSccMdzMyBw_7_0"></a><a id="Tc_xDdmskomJECYnaTuVtsxxQ_7_2"></a><a id="Tc_IGxFrFYKAEep71dSJ-zHGQ_8_0"></a><a id="Tc_uezqNMrOf02RrX0XE6LeDA_8_2"></a><a id="Tc_uEQTYhsxlUqJsGuaG_iL6Q_9_0"></a><a id="Tc_NvAcbTJhrEG0QS3vV0-8NQ_9_2"></a><a id="Tc_zG5ESqU2kEOzNr1wZvcPmQ_9_6"></a><a id="Tc_7ILAJBTOpU-0FGFfVa8D7Q_9_8"></a><a id="Tc_OrF1J94Vk0mHpj2oldOtEA_10_0"></a><a id="Tc_QTW-THZGKUia4fbDL99tZA_10_2"></a><a id="Tc_Tpyof5-530iCZmrg5DWrug_11_0"></a><a id="Tc_i_YOXGslLk691Ltpltgrbg_12_0"></a><a id="Tc_CQio94Byw0enUX8MWHJd2g_13_0"></a><a id="Tc_dy6odJvD1UKMPnwCOp73Ig_13_2"></a><a id="Tc_mCEHHepsF0WNL16fjwiGZg_14_0"></a><a id="Tc_fvHQTgVTHkODtiurStZaLQ_14_2"></a><a id="Tc_-K7h7Ey2nUeUEI0ngOfPQQ_15_0"></a><a id="Tc_IX9HpklLXEWS8zzdDVTCQw_16_0"></a><a id="Tc_wNDg8Ojmx0qpOpXrgs-d0w_16_2"></a><a id="Tc_BQRMmoBK_EiaVoqp_4gzHw_17_0"></a><a id="Tc_jAFFglcSLEq1UCL_U1UGSg_18_0"></a><a id="Tc_Nx_xP2w20kGvsbFCHDDrNA_19_0"></a><a id="Tc_HDXge2dTwEeKAwpHWqjikQ_20_0"></a><a id="Tc_-lXuv901hUaXnW5l4PryQA_21_0"></a><a id="Tc_sHfjIab_VEWw7BJ-MfCdTg_22_0"></a><a id="Tc_srGLk8K6tkCjAWZQXwmZxA_22_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR, except per share amounts)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_PMS8uamPG06EoJ4i5QL5fQ_4_4">102,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_reLhFVtv106EzvYF47r0pg_4_6">67,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_rJGTOvl97EuA2OKBclUQhQ_4_8">53,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_0IRPlnx7mU-QjKSib0DdUg_5_4">238,195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_Am3D5S6ll0iyzJaKBM7iVA_5_6">183,993</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_BWFnkJEaWkSy0_TgUw0dbg_5_8">124,366</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_1y4s9Xc0gESZtTY4yZbDOA_6_4">1,743</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_fv9vmVHQRUaxcXIkEj6mPA_6_6">2,817</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_NZ0ht4cNUU-pAi2eOpjEWA_6_8">3,912</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_cdpnFo5IcUyspkJHm6MhGw_7_4">815,907</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_aqryNoanm0OMnZwvLWZrBQ_7_6">62,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_YJjE3piWuEG9kGxL7d6jFQ_7_8">115,724</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_X396aTzMyk-On4jv4vNnPQ_8_4">100,402</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_7pwAhBgEn0y1dNvf3ovgEA_8_6">104,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_6R1sUeZ--kWGapIhBGLA4Q_8_8">91,758</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from release of governmental contract liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Tc_HO9RkhdWcUeLONaf_je2MA_9_4">574,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_5Xt12yclvkim0sPLK6PU2w_10_4">67,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_jmPqkaWTcUWsEAzG0Y84gw_10_6">37,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_4AtDkLRK-0atJt3Yx4-0uQ_10_8">9,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_qVgt5m3djU67kXRHqSGINg_11_4">1,210</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_B4Un2win1kCDSFpEKuMU8w_11_6">1,271</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_F7zJdHCf3kqDA7Wjq9h86Q_11_8">1,356</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating loss </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_UxHVVikYFEep3pe4b9cU2w_12_4">412,263</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_JYGE8h6U80OfoAsLb4y71Q_12_6">249,457</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_zDuEkeVsOE2B7vj07UZlow_12_8">274,207</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_Q58WronV2UuuTxPDqVIXnA_13_4">10,103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_ETShN1oNNEayX_FLvsWnRA_13_6">4,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_A7dn9cGWKE2Rscy8gaI4-Q_13_8">16,731</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_kyXdp46UZ02FpeUDqyVo9Q_14_4">10,338</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_wcBz17VrJ0GtHHQvLVOpfg_14_6">3,707</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_t1nGyJawS0aS25NrBbeDfQ_14_8">2,493</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_kBiMC_FR40iVLxC18iaSCQ_15_4">412,498</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_mS6DSOIN0U-SWRe08HDdfQ_15_6">249,155</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_ogeDG7jPFkeYc-H8_xCiFA_15_8">259,969</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit/ (expense) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_JtfNjGy_10OvL00rntWLeg_16_4">782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc__gX0Qn66RU2B3UGfJxlHPA_16_6">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_XL_JdU_zD0q0fvkBUGo8fQ_16_8">198</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_mTs3OizpeEeyaBeCCJmyQg_17_4">411,716</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_8fIk3_0MZ0C7YTPvzX3GZw_17_6">249,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_lS8WLy39vkemu58vQelhSQ_17_8">260,167</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Items that may be subsequently reclassified to profit or loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_valqUtf2N0qcBg_90UW8CA_20_4">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_YE4Ju4rmmES5UEMxyuhbHw_20_6">105</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="Tc_1hGwZoUfyU2FloBW_hc_hw_20_8">72</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive loss for the period </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_ia5rT6QyK0qAHnTSH1C18A_21_4">411,807</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_8Wje0eJ9NkaFbW1U6mVvDg_21_6">249,134</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_b1Zwj6X-r0ita4rxK7wrQw_21_8">260,095</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_aB0cfEG2iE2T2L3bx3aQ3Q_22_4"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_aB0cfEG2iE2T2L3bx3aQ3Q_22_4_2">2.21</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_i-hchxS41kaEeZ_w71gJRg_22_6"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_i-hchxS41kaEeZ_w71gJRg_22_6_2">1.32</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_aUetIiLEOEiEjaI5jMbnVw_22_8"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_aUetIiLEOEiEjaI5jMbnVw_22_8_2">1.18</ix:nonFraction></ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_354eb2f2_ea26_4fe5_bc9a_142e35387f55"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><a id="ConsolidatedStatementsofFinancialPositio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Financial Position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6e74aabb_0b12_4803_9703_0900f19ee9c2"></a><a id="Tc_8O4OEPOJ6UG3GWpdGBPiPw_1_4"></a><a id="Tc_JUjv6SJPKUG9pvf6-W7xrA_1_6"></a><a id="Tc_80MRg9kvYEGzlNjN-7RjQg_2_0"></a><a id="Tc_4d9k335LrUCq86GGHiC5YA_2_2"></a><a id="Tc_uzCx6QNDzUeur9twk7VShA_2_4"></a><a id="Tc_hy7c3XUWq0eMJTbxOKX-Pw_2_6"></a><a id="Tc_vAUEmwQjZ0C06vCKDpVUSQ_3_0"></a><a id="Tc_-Pb6yISyAky06crrj1FpuQ_4_0"></a><a id="Tc_EBjTPUezuUqg18deoVO8RQ_5_0"></a><a id="Tc_TepZz01za02C50gJ450e1g_5_2"></a><a id="Tc_uKUcbb72zEKi_1hkv1VNmA_6_0"></a><a id="Tc_G7DPricxzUmsALXo2WQ2oA_6_2"></a><a id="Tc_jYogyMfiF0q8qdP4cnaItQ_7_0"></a><a id="Tc_FbuBNgiVoUWtifR5iH7HMA_7_2"></a><a id="Tc_xIkIIKNkYEmlmlJaI7MZqQ_8_0"></a><a id="Tc_x6LoAlEGB0u91xbUi_1nnw_9_0"></a><a id="Tc_KxqJC_T_EUSPYaXULXfp5A_9_2"></a><a id="Tc_feBioTHdaEiqPjhGtV8DpA_10_0"></a><a id="Tc_LICDHP_9iEGJLvRtzy8JXA_11_0"></a><a id="Tc_weE35GWL8USr9l7mOBuPjQ_12_0"></a><a id="Tc_SoqRebT5QE65M50CyN17iw_12_2"></a><a id="Tc_YdskulFuVU2N3ZP--Ul8fQ_13_0"></a><a id="Tc_WeUHF7G020eOKTFp9Hve0A_13_2"></a><a id="Tc_-pz4J2t3YEaPka2D8YeCXQ_14_0"></a><a id="Tc_HQ4smtiBg0mwZx3w73KZYg_15_0"></a><a id="Tc_wnWXoAZuykyidLQCvfvbJQ_15_2"></a><a id="Tc_xNX0el2fwESnAppg3RXUgA_16_0"></a><a id="Tc_Asz3tXeuKkSYvd2nmNbZ8g_16_2"></a><a id="Tc_ccdeXQBgzkOm7do7xgxUvg_17_0"></a><a id="Tc_mTCLirs5SEyvsDb9YcqkYQ_17_2"></a><a id="Tc_ZCL9gyxnOU2HR3ovRe-N7w_18_0"></a><a id="Tc_WbiQ0hH9R0KhZIO4kOhvGQ_18_2"></a><a id="Tc_kmCCEIJQXEqOPZzjwBisfQ_19_0"></a><a id="Tc_h2oD8zeaIkyiCWqeWOouNw_20_0"></a><a id="Tc_GPoqvXICgU-M2x-gsqH6JA_21_0"></a><a id="Tc_wF83udrZr0qzxECRv70Alw_22_0"></a><a id="Tc_TCf5z4VxuEydDBxYYBB4vA_23_0"></a><a id="Tc_1riDQoOPeEmnHi7vnv5ElQ_24_0"></a><a id="Tc_Yiyu5n_kIUay0VNureSWMg_24_2"></a><a id="Tc_BlHihhDJPkyVfJB7sYB3YQ_25_0"></a><a id="Tc_1rBdOmHXk0a75EvPeYZPOw_26_0"></a><a id="Tc_31hJfnTfD0-C8Eim1ScXVg_26_6"></a><a id="Tc_uHeoURSwAEONLhwc7TXMrA_27_0"></a><a id="Tc_AonWqtAnU064s_zMlXghBw_28_0"></a><a id="Tc_jR4n6ac7KEGjYq6shFX5hw_29_0"></a><a id="Tc_caRO0jh0tkGwTgH1Mngc3A_30_0"></a><a id="Tc_VltA9kzS5UKOlwjg93kaww_31_0"></a><a id="Tc_ZLKlu1428kq7T00A516Oyg_31_2"></a><a id="Tc_M3OY8FDjgkqOHrtSH66tWQ_32_0"></a><a id="Tc_OxLF90j7jEWIqXTtNLbQlA_32_2"></a><a id="Tc__goyWo-LhEOdVdDeH60Cng_33_0"></a><a id="Tc_YYe-c3BWcE6NJij_Tut1YQ_33_2"></a><a id="Tc_dyR9OitJk0KnYCbc-2_ScQ_33_6"></a><a id="Tc_4MotzWSqX0yLsyHx0so2Aw_34_0"></a><a id="Tc_pKKgvVQR6kejd5GdcMPBww_34_2"></a><a id="Tc_gI9C_yIcMkignnUEiJ67VA_34_6"></a><a id="Tc_YfJQHnt7XEWj1vKiahdnqw_35_0"></a><a id="Tc_p2Hcs67YTUqvSG-mcFaVzw_36_0"></a><a id="Tc_pzQKLrN9Ykq-E40Wjrhetg_37_0"></a><a id="Tc_JxezNgv0vUCAt9r3RDfB2w_37_2"></a><a id="Tc_ord-_qFU1E66npJkTMd1pA_38_0"></a><a id="Tc_X2R5STeJh0WCmhU6m6iZ6w_38_2"></a><a id="Tc_R8R4J7S5hU-pT0n_T6ppsA_39_0"></a><a id="Tc_wY8vTJADKkeZBSWml_6R4Q_39_2"></a><a id="Tc_wWdtI5jhx0Ko9HtT2apIFA_40_0"></a><a id="Tc_bXousMt25kq2XR4WmyUmNQ_40_2"></a><a id="Tc_WDmlb95LU0iU7ptO9Tpf2Q_41_0"></a><a id="Tc_8Uv-7YkFwECtbyQTPeIZyw_41_2"></a><a id="Tc_jfU2DTwUjUqjWHnpBa9jUA_42_0"></a><a id="Tc_dCa3dXb9GkqMTEMS2RssXA_42_2"></a><a id="Tc_QOUDb0uqe0es5ueq7H8rPw_43_0"></a><a id="Tc_S4k8nOiVG0mWU9CN2UIitA_44_0"></a><a id="Tc_dBRDyc4w0U6kUnvFVeeOAw_45_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets and goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" id="Tc_qveFr0uNSUWNHMtVfdDs4g_5_4">31,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" id="Tc_6kWiX3pez069iWibHb9JIg_5_6">28,347</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_EfAbT2QkqkiEexreMViNYw_6_4">197,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_5duFXUHQwk6Ptli7eAWrmg_6_6">236,782</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_fzUQZ1vG7EmM199QG6pJbA_7_4">43,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_S_U70h3woEqvNFL9kdREbw_7_6">41,843</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_uRXFUgfUH0CUXPieEHylfg_8_4">1,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_S0kKSzWcmUG9-e5siprYDg_8_6">1,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:DeferredTaxAsset" scale="3" id="Tc_WvqPxDJsjEWLqabeQBJCUg_9_4">1,297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:DeferredTaxAsset" scale="3" id="Tc_R_08S60Dc0eL5FUZd5vvXg_9_6">1,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_IlhFo9NaT0-TPFGIw9CESg_10_4">276,443</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_WFjKRxGlGEWY9OpKW5TBsA_10_6">309,868</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_5T4-Zl0JZEmGLqo0AwHm0g_12_4">10,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_tO4VR4OPGUqOdXXiM3WZ7Q_12_6">2,419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventories </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_2IG0qMJPPkOdajtVudfvyA_13_4">23,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_xZmrDIp3IESPmtR6u8Ep7w_13_6">24,801</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Trade receivables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_eysxGcbZTkew3Z4LafriZQ_14_4">6,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_2-lCK-o9-0-zaL0XrVDETQ_14_6">14,326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc_FNnQoJq9T0K0i2jrE4HS5Q_15_4">2,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc_0MzB2Mu_JEe1LxW7nnE1yQ_15_6">2,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_fPcEEZSq8kmN9o0G4Tr5eQ_16_4">4,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_KE_XNKb6pE-ogXboyaXSzA_16_6">2,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_AWheY8DEFkKcUGTn7394gg_17_4">40,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_DkqQAxcREUuiHTxm8qD3bQ_17_6">23,763</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="3" id="Tc_IB7eUCR0bUuMlpXhwFWmoA_18_4">285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="3" id="Tc_ucGF63shjEKbSF4_evBUZg_18_6">5,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_YMvaCzcUIUiqMUiYGkWV5w_19_4">495,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_L-DQLaKiTUKtM5undoIk7A_19_6">402,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_KZ6MJgrVF0i9Nm7ZZAFzHQ_20_4">584,029</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_yczDW4XdVEumIEzPtm-ZxA_20_6">478,381</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_qB0zI89hh0-4wMWppRfwjg_21_4">860,472</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_ybfJ7raVY0-cp6KMuPLPlw_21_6">788,249</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity and liabilities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issued capital </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_gPFe1f6IVkWqyaCJ45uh1A_24_4">23,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_YqwAT2YThUiyJ_1_SMiZwg_24_6">26,879</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capital reserve </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_cTnt3KqAm0-WxFD5PyY-sw_25_4">1,817,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_SQzOlhHWPkuPRwThXLLpsg_25_6">2,056,110</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Treasury Shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TreasuryShares" scale="3" id="Tc_S6fkH6WNv0aZhgCSMGBWXg_26_4">1,481</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_WNAtm_AU1kWFS5tIhiG3yw_27_4">1,305,814</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_8sZRgDKS_UCTPlNc6rLqfA_27_6">1,565,981</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_91XGuBfbh0-5UMfgrIYcpw_28_4">139</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_KPyYK-ChME2gkW8cI1M_2Q_28_6">67</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_wPc7XFXYzEOCgUK7CnOjkw_29_4">533,253</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_oyJ83VTBokqcM19cQmrsRw_29_6">516,941</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current liabilities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_SxbsKgGDD0eE9Z3Lsk_0sw_31_4">37,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_PJfnJtFv1Uii9ZPQCeG8_Q_31_6">36,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_azwS-B66tEmnBN29Ep8bww_32_4">72,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_YhnjxlSE4kOOEyN5pMgbyw_32_6">48,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisions" scale="3" id="Tc_mzrsfQ_shkuxnq_EhD0jSA_33_4">61,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_oDcyPSLMLkqnWQP3CmY6yA_34_4">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current liabilities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_3Klj9LBq_0qlrSWzXAE6Dw_35_4">170,994</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_yAgXqvCTU06bs-kx7C6zuw_35_6">84,919</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_iVRA3-if8U2PNRkWyWK1UQ_37_4">4,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_IGc-WXcnREaVVEU-tlJrdQ_37_6">5,005</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Trade and other payables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_5tZWFicCtkO5eIP6mUj6yA_38_4">73,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_bdudxceiz0iAa-xIkK0rVA_38_6">48,033</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="3" id="Tc_1AP1DMVzKkefuRk3tXmpSw_39_4">1,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="3" id="Tc_0QDMmchsK0mIdI711TC65g_39_6">37,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_ny9lbsULyU-NpFA-0aFBeQ_40_4">40,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_ulIlTRZ4T0SCowIXbyiQGg_40_6">50,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Income taxes payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_OhG77VIolEqWhwLgN3Uofg_41_4">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_KUDqzC_-tUq2OZ5ptSroDQ_41_6">654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_E1nA8fWkwUGSxJHbFgpLPA_42_4">34,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_Q9xAfL-LdUug4DQa2FW3DQ_42_6">44,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_T1XNDZJBJEGtcqilcAbNPg_43_4">156,225</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_p1hg4aFLQU2NHwA6zRN3mw_43_6">186,389</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_IgKe89Y4WkCYuqQzWBwa4g_44_4">327,219</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_KcgJUUuZgUyixGt5U3SxgA_44_6">271,308</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_THE32kqrT0SpWCXRbgTRlQ_45_4">860,472</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_oa6Y0zx5xU6NmPob6OLRcA_45_6">788,249</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0e60c603_3b1c_46e0_93e4_1989604abac4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><a id="ConsolidatedStatementsofChangesinShareho"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Changes in Shareholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_53791026_d2a8_485c_af8f_0dafa30aee62"></a><a id="Tc_yB26HZKsS0CqACj-SGvWXA_1_10"></a><a id="Tc_dhWNaNlqeUKQaG9qIW1LYA_2_2"></a><a id="Tc_QlfdZSRl1k6S6x9z-CwYhQ_2_4"></a><a id="Tc_9yi4nf6Qd0KJDOCZoF9c-A_2_6"></a><a id="Tc_lSoJB-xmmE6Tl_ELSRyLFA_2_8"></a><a id="Tc_WUvwKHamE0mZO95EG1n1jA_2_10"></a><a id="Tc_r_MQ4mUsyEyoBo6mkgvPBw_2_12"></a><a id="Tc_LnEEuFy8VE-zwnwZu3RGYA_3_0"></a><a id="Tc_dMbpKiMBkEWwdaEqwIWXsw_3_2"></a><a id="Tc_CVOjEyhqg0qVxRFImwLFwg_3_4"></a><a id="Tc_OtbrdVo_HUCavh5nPiGjVw_3_6"></a><a id="Tc_V34WjeUez0KUVegsDGBB9A_3_8"></a><a id="Tc_cN2U0tNyEEmtfYjD_iwh5A_3_10"></a><a id="Tc_Yj_xE0l1qkC0mK7fPH-fGw_3_12"></a><a id="Tc_no4fbgMnA062QNOV3up4AA_4_0"></a><a id="Tc_XN0tnpnQukGtgzXSox7d9A_4_6"></a><a id="Tc_LpEd0tVNoE2ctXiFmjiXgg_5_0"></a><a id="Tc_h30eS7fg8EmWwTGKn8HevA_5_2"></a><a id="Tc_ZX--vPkL1USQOn2zKudzZA_5_4"></a><a id="Tc_DqTLPrdYXUqVlfz63Z7nng_5_6"></a><a id="Tc_kyT4nhgosESaJLIzfe1heA_5_10"></a><a id="Tc_Ezx8Hq6BbUW1tnhSJ9loZA_6_0"></a><a id="Tc_bxK7ECCbrEaJgpjJnvTJmQ_6_2"></a><a id="Tc_fPv9M7cVJ0-_T3mgBvVXQg_6_4"></a><a id="Tc_cj4oo0wjl0aQXb-9r4UCOQ_6_6"></a><a id="Tc_15UhAWL3T0qY1HDg0maVLw_6_8"></a><a id="Tc_--b5iryuR0yRzXe4E-nHyA_7_0"></a><a id="Tc_ylu1uci6206ksrVJXEeVhg_7_2"></a><a id="Tc_IxLMcLju1kKHwO1Y0-g4fw_7_4"></a><a id="Tc_5bvvbvejlEC8urW7faqx0w_7_6"></a><a id="Tc_oMl6u4ol6U-ripIKwqYx-w_8_0"></a><a id="Tc_2h2W7-d0eE-bhAD_lXbCdQ_8_2"></a><a id="Tc_kHBJJz3saEejj0EXvdby7Q_8_6"></a><a id="Tc_I6mtwPGVhkWXx0g94fbb5g_8_8"></a><a id="Tc_mLjPVPczxEmt-QkBV1LHGA_8_10"></a><a id="Tc_JwpIWl_hDEqnO9KA4HZ9Bg_9_0"></a><a id="Tc_3K-1qdpqmka5KvvK4DsvZg_9_6"></a><a id="Tc_1EVln3KqYUOZJYLCWw5sIg_9_8"></a><a id="Tc_vTOI9_CK3kGvVgmU_KhaRw_9_10"></a><a id="Tc__wdYTi4Ea0uWEM-n6ZGfdw_10_0"></a><a id="Tc_Z6bVRaEz4EqTHJ80q8otmg_10_6"></a><a id="Tc_Sx6ZTLZvO0KJfJvKiKEm7A_10_8"></a><a id="Tc_A9nDlMeGa0KEIj09X5W5uQ_10_10"></a><a id="Tc_HU9evA44UUihtvTr6LB1nQ_11_0"></a><a id="Tc_5AqIuVK59E6CvVB2rfiCCQ_11_2"></a><a id="Tc_h6WP1IPNj0SpTDJ04W5j1w_11_8"></a><a id="Tc_3A1DQUq4d0Sgspv7sFWuJQ_11_10"></a><a id="Tc_NEpd5Jk7vEyNa9Syb-060g_12_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Currency&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Treasury </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AnQeJoI56kuDvOssY92e1Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_nTmagA4fCk-8HzNSdc8q4g_4_2">21,655</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_S1JWhNByVkO_gfsU5FZiQQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_aRKmPq40tESqJ0LdIGEjjQ_4_4">1,334,704</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_KQB5gpktAESb-bTOPIdFnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_39_xq3hImE2KjeMs2mqnAg_4_8">645,069</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_Jd9TaF_3MUmPThwO_m8oKg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_6CEs8VKSL0GIYG-cdHSoGg_4_10">57</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_uca6GGCvaE-73Oc8sX-Ofw_4_12">711,347</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dj_kuij1ukqB0BZd5Wb8cQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_D4m-tnnKbEqTwtUz2u5hag_5_8">411,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_8Uy90qnIOUCPOjSt63hyXA_5_12">411,716</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_y1C8YKr28UeNst5nGOjNFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_Cp2amuh_RkSfYbrIL7N1aw_6_10">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_8KrI9re5B0KjKZfv8Z7xRg_6_12">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dj_kuij1ukqB0BZd5Wb8cQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_7ocGcS014EGGNLGc2cktfQ_7_8">411,716</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_y1C8YKr28UeNst5nGOjNFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_ffxC9zVc-EGyzZ3DBUAk6g_7_10">91</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_UKBxZKPvCUexd13tBrEiPQ_7_12">411,807</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_Bu06EDd-7keB-Ej3HnMOJA_8_4">15,789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc__Iodufop9kWdL29nPDQQ7w_8_12">15,789</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8G-l7cSohE2wypqHd_nGtQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_huj4j_QbpUGU5DAQRcjznQ_9_2">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc__2SXce2MT0yHF1aqAXA0Zg_9_4">3,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_A9bmgF8rA02Jnne_48vjZg_9_12">3,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8G-l7cSohE2wypqHd_nGtQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_G_lEsrXDsE2BJwBQmlZImA_10_2">690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_qDlbXw-DT0mVGVxZlmSLKQ_10_4">403,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_62rfI4MKJ0eT3J7IsBgKtg_10_12">404,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Repurchase of common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_-SjBWjjos0GkZprnzbGh0A_11_4">28,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nbvH9kC4i0CT5CljgxvX-A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_Rdj2DX7jjU6VxB1q1IAolg_11_6">5,817</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_WvZ0jLZ3E0WsKTs3DPuktQ_11_12">34,101</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3ZjP9sOEAEuMEnQiZZAC6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_TwOSEiFYEEOON1jF4fTPSw_12_2">22,454</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_HPKAQE4Je0CJX_Y06wwKhA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_nq32YJsZvEeRNOQzXQzRbA_12_4">1,728,658</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_dzqCRSdTaUyCKSftygGc5A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_zy0DQHqof0mPSFGeVpmMSw_12_6">5,817</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lwBDHWf6DkiDBz3u8cOGuQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_XxiBZO-fpUePAqI8cGcEcQ_12_8">1,056,785</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_s8xXd8c1h0mpJ1IehtKt5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_HZZaSHuWxkaUOTWJhO0lLQ_12_10">34</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_aRUugoQ9EUS8Z0S3GkLS6w_12_12">688,476</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7f8dfb30_4334_4e2d_9015_a16e41281a52"></a><a id="Tc_MvCKQGfjaUO2Dy2nFACXUw_1_10"></a><a id="Tc_WAu3xnx-V0uNYvHEQPbxig_2_2"></a><a id="Tc_j_07vmNfNkem2Ss0SoOTlA_2_4"></a><a id="Tc_5lb3AOgJIEmUhAVPdnSk7g_2_6"></a><a id="Tc_zQ_ZunUnVUS-Vl83QpWcRQ_2_8"></a><a id="Tc_XzTz2wVQ7U-7NrDgwhCwCg_2_10"></a><a id="Tc_6W-kt3sFLkSzS456zATZmg_2_12"></a><a id="Tc_CieHxcex6kCp_0eTchyL7w_3_0"></a><a id="Tc__S9qo8_UbUCKTPDUwja1Pw_3_2"></a><a id="Tc_QuijoVrqbUqBN1d3YU3o1Q_3_4"></a><a id="Tc_MFI8CzdN5USSycnsKp-HdA_3_6"></a><a id="Tc_soolIrf6REuFllGQnp6nOg_3_8"></a><a id="Tc_QOc4eao5_UCo7Hp5bqdBxg_3_10"></a><a id="Tc_aBOKNTsIh0q8GpT97BfBDg_3_12"></a><a id="Tc_v2yjQ_lDbk-TP5PkJCV7Ow_4_0"></a><a id="Tc_X5g7V42MrUa2zmihTDz1HQ_5_0"></a><a id="Tc_mT6LUG09Rkq_ksEsuVYy3Q_5_2"></a><a id="Tc_4Lqc500soUiEKGiK_X_3DQ_5_4"></a><a id="Tc_qZseGn3bNkSKQ3Y3dvuomg_5_6"></a><a id="Tc_W8knEecxpUa-LBeEtSWvTQ_5_10"></a><a id="Tc_CbUKEVgYi0e0zXvwcfpqGg_6_0"></a><a id="Tc_-dOUmC9XRUyHHt6raKsDHw_6_2"></a><a id="Tc_Y-_qgENA0kGV3ZaWpg8rGQ_6_4"></a><a id="Tc_xghBCwv04UO7hVH0_ItbUw_6_6"></a><a id="Tc_1MVrLl5yf02wHh19otJMzA_6_8"></a><a id="Tc_8WwVZRr9zUm2K1t1K9-TMA_7_0"></a><a id="Tc_W5jZHDe0t022hpvBckNcQA_7_2"></a><a id="Tc_1051spexYkepfBCyNW4m6w_7_4"></a><a id="Tc_kPjudevoV0GOSZb8U9tRSQ_7_6"></a><a id="Tc_2FH96RmZi0CD5T7NE4F0Ew_8_0"></a><a id="Tc_HCQm6vXbqEGEeFA1P02usw_8_2"></a><a id="Tc_dsaiA1zsX0mmAcPu3flNTA_8_6"></a><a id="Tc_cNO0G4wSYk-X8nN5Xr77AQ_8_8"></a><a id="Tc_GauACNHsUE-ebUOwfQ83Xw_8_10"></a><a id="Tc_aO-B83vGkUmDfK_jkThfZA_9_0"></a><a id="Tc_S9VlZ8iP0U-yjsYJn1lQGQ_9_6"></a><a id="Tc_s1mAMrjgfEOzYF8Ey9j8Yg_9_8"></a><a id="Tc_Vz50DZvRHkiwWlUNw1KZYA_9_10"></a><a id="Tc_vEwWE1dM7Ea4ArqZ4HewEA_10_0"></a><a id="Tc_zIFrNZvRxk6K4QcxGSzQug_10_6"></a><a id="Tc_KWgWUVchv0KosNx29_9_eA_10_8"></a><a id="Tc_f7ogaxSwf0i6x9xKC6GmEg_10_10"></a><a id="Tc_H5IXHAjIYkiMV95N_KsCWA_11_0"></a><a id="Tc_TpISDH-8l0WhrKVwfc3r5Q_11_8"></a><a id="Tc_apQQUVg8u0-xoJ3sOv5lUw_11_10"></a><a id="Tc_DGZQ-rULckGBbhg3bk02lA_12_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Treasury </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3ZjP9sOEAEuMEnQiZZAC6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_RCapSEntkUGH8s8NCLpFVg_4_2">22,454</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_HPKAQE4Je0CJX_Y06wwKhA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_ffP-QT4qFkWXlNm9NthJkQ_4_4">1,728,658</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_dzqCRSdTaUyCKSftygGc5A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_UAC9baOxk0qdPHDrp-13sw_4_6">5,817</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lwBDHWf6DkiDBz3u8cOGuQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_Ejh97SeXu0C-WbdimDfydg_4_8">1,056,785</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_s8xXd8c1h0mpJ1IehtKt5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_h7EeRslB5UqQfUTDQ0e9Xw_4_10">34</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_wQaelAA7mUCgJxNxylryNQ_4_12">688,476</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZFq3H-aADUWbi48lz1-J3Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_MTysRwZYlkiO1F5B4OvwOA_5_8">249,029</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_NgEh7jAGpEW-J_tuIB3GDA_5_12">249,029</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_2n8B9LUx5UueVjJYl4z0CA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_xG_pHMfmIE2Ji7MZIyni4w_6_10">105</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_xFQpWFnYhEigEoqtqz0-RA_6_12">105</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZFq3H-aADUWbi48lz1-J3Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_kP4qgA8ztEKyypqRPDkvsQ_7_8">249,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_2n8B9LUx5UueVjJYl4z0CA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_kZJlBz33h0aTmXjmV2dBbA_7_10">105</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_pR_9vRy3YEKmIB1KalouGQ_7_12">249,134</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Share-based payment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_N-6MazUpCUaGmpOWi7tSwA_8_4">7,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_VhRiBo0xDUaNjtNxIJGJsA_8_12">7,539</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_DspC-OT87k2c2opT7g8iag_9_2">829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_ahW3V1LTKUyiWib3ckBhXw_9_4">65,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_luWN4X-bOUCWRmZCFhnPUA_9_12">66,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Share issuances and contingent consideration from business combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" sign="-" scale="3" id="Tc_3HjxkBQ2b02_Ji5uZlNdHw_10_2">103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" sign="-" scale="3" id="Tc_Zzz6RixDAkuA0zpzIC97gQ_10_4">18,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" sign="-" scale="3" id="Tc_eimAMolq402H2XrIPLAs0A_10_12">19,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise of options / Settlement of share-based payment awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_mKOr-W7rIUuGob7LUKMxWw_11_2">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" sign="-" scale="3" id="Tc_a0_ADO5P4k6thtu3KFPSVg_11_4">3,440</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_8DK6e_LQPUG6vKafYfDvgw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_C-GGBfkEG06u4JvUNJ6rjA_11_6">4,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_j0mFzwI4rUaXw62scsee1w_11_12">910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_whZRjt-4FU-yl6yGweVnzQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_SZb65vP3JEut5_H0vXZgmg_12_2">23,400</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_0VcWnDDzFUyC5BwrczrKvA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_xwC5ff8oOECbPe-FvFwGmg_12_4">1,817,287</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_b_PVXi45TkWmP1ML_7DnkQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_Hh1n4mRorky-D55oXzCrEw_12_6">1,481</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_2d_godOeNkaEasgWMSZ_jg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_d7xT-_IdDUWcld37HgpPLA_12_8">1,305,814</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_WR0SFBa4b0qDmHaXvC4SwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_szF7QLNjUkODlfnn9bQIpw_12_10">139</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_g7KZNHop-UG5CA0dDXVi6w_12_12">533,253</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f9de9a6b_7dfd_4eb6_b540_b1aeeb0b9e7e"></a><a id="Tc_ESdADoaOXEujamzhpv1YUw_1_10"></a><a id="Tc_fCLOkurFOEq0S5vLIkqDqw_2_2"></a><a id="Tc_J65yY168j064kYpd0husEg_2_4"></a><a id="Tc_--okSdxtxkG_b-4yCPCYvQ_2_6"></a><a id="Tc_829iUYomKUO9w_DX640nug_2_8"></a><a id="Tc_dAp5wVA3BE6Rt5Yi2XKz_w_2_10"></a><a id="Tc_s4bHh--aGUqt7ItxcR-dPA_2_12"></a><a id="Tc_BTnsU5evvUmUC3OuwXhdcA_3_0"></a><a id="Tc_yXpjoJ14q0ufPT6N92tIrQ_3_2"></a><a id="Tc_61ESLenxGEefWvtuLcjr4Q_3_4"></a><a id="Tc_hEqq4e486kukOkHjSxoNrw_3_6"></a><a id="Tc_-Oh7NHyzJ0qiX73lJn7Frw_3_8"></a><a id="Tc_vj-gGEol3kqRux7_yZYS8g_3_10"></a><a id="Tc_DtYLhMnsZ0KlgGgmy6pHFg_3_12"></a><a id="Tc_tv_pziZ730mUASgZ73GC9g_4_0"></a><a id="Tc_Nw-oCr5i0Eqw_y7iyVbfiA_5_0"></a><a id="Tc_yQx5toueRU686uiIBcwliw_5_2"></a><a id="Tc_KdnvLD2ea0u98xOMsR9Uvg_5_4"></a><a id="Tc_s5gAM4u4mU6ynjhU81gqmA_5_6"></a><a id="Tc_9VlN-uTQy0uoUIu5nFrWRQ_5_10"></a><a id="Tc_thmvAjFHr0eEZAD89BACJw_6_0"></a><a id="Tc_uLDaflIBD0q8JRqVUm3cDg_6_2"></a><a id="Tc_YT_sSFEI00mvhZTvANLA7g_6_4"></a><a id="Tc_f-2AbwCl7Ua_a7wnQ431lw_6_6"></a><a id="Tc_Ohs9ezMaNkqWyBrYDdJCwQ_6_8"></a><a id="Tc_tmhOvCSR00CEpE5gj7OSWA_7_0"></a><a id="Tc_TueE6hs1106zIVb0hb8a_Q_7_2"></a><a id="Tc_mva-nzl3IU-UD3KP7vZhAQ_7_4"></a><a id="Tc_yYqVf-e6FUGSbp1nz4TZSw_7_6"></a><a id="Tc_34QaWlNsO029h_U-l-RY6g_8_0"></a><a id="Tc_O92hKHHjF0yb35ipCpgofA_8_2"></a><a id="Tc_nwZ9Xsp9dUG-KIsKkEdbFA_8_6"></a><a id="Tc_mccdqinFFkqQKUjPk-QfQA_8_8"></a><a id="Tc_R5KsiKMOwkC8YiGM0v625A_8_10"></a><a id="Tc_kqJf7mQNC0KfzHs8Fn5gBQ_9_0"></a><a id="Tc_ZMjAi25_gUCvbdjns70Tbw_9_6"></a><a id="Tc_fT97XrOU30ivKQczauh_Cw_9_8"></a><a id="Tc_6kBsddfdgk6HNtGCewReKg_9_10"></a><a id="Tc_EP0xXvNeT0iE4bvEqb7rbw_10_0"></a><a id="Tc_F3X6mRROeUyAmb3KEbI1JQ_10_8"></a><a id="Tc_s5qMSYufFkSmYmL_ZA54Ew_10_10"></a><a id="Tc_RaOD6Wfe2U-pRw6y5imGpQ_11_0"></a><a id="Tc_GOC0dmW0A0WosU9d-MkDCQ_11_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Treasury </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_whZRjt-4FU-yl6yGweVnzQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_jnrA-bZJu0K12ysP_T2a8Q_4_2">23,400</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_0VcWnDDzFUyC5BwrczrKvA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_L0vcWxcuhkujN9EMf0D-BQ_4_4">1,817,287</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_b_PVXi45TkWmP1ML_7DnkQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_-ekGiXXPhU2_FFEzwENU3w_4_6">1,481</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_2d_godOeNkaEasgWMSZ_jg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_fp7Cs407mUmRbbYkqIH6kQ_4_8">1,305,814</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_WR0SFBa4b0qDmHaXvC4SwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_QKvEFsRVcE21zFrA3K4zAA_4_10">139</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_c2IyADG6hUC-EKRUubOtBg_4_12">533,253</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pgKJujKGq0Gc4IGKg7SH9Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_x2l3AVnpZkqwutibTDs7Yw_5_8">260,167</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_PajIgtHbmEWAaKWMkcyxzQ_5_12">260,167</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive income (loss) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_5Z0-f_Nn2Uep_e7zqZA6_g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="Tc_N_H4SuSR9EmkuUl97YjwrA_6_10">72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="Tc_yBqHrCL4rEmoR3a88GZAwQ_6_12">72</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income (loss) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pgKJujKGq0Gc4IGKg7SH9Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc__Mgbyt1mgE-jikbab5SX5A_7_8">260,167</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_5Z0-f_Nn2Uep_e7zqZA6_g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="3" id="Tc_3tr56iUuy0CkaxPeuEe8Gw_7_10">72</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_4DZ77CT-yEaWkf_cksgduA_7_12">260,095</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payment expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_yb-6NXkPNUGRfxIiw4TB6g_8_4">7,697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_QdOylNGhrk-vE6GsLj3RZA_8_12">7,697</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2I2dxZFv7Eyci3--WSWO7Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_Sq6IPGlhB06QnMTkQXjRrg_9_2">3,453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_nvPSmkYKPEGQFVspwXmm3A_9_4">232,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_TqmgG5kogkqB8FyWCAl8oQ_9_12">235,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlement of share-based payment awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2I2dxZFv7Eyci3--WSWO7Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_OpFQgrT3Hk2qOmh9DtfL4A_10_2">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" sign="-" scale="3" id="Tc_X3v1S6lK2Ua6EisMhRgc-Q_10_4">1,261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_Zy-68Enju0iBz6gYRoHmDw" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_DbP0M_PSrkGxUBNUqB5wZA_10_6">1,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_JOZzjq-t4kqUncnBXNEJzw_10_12">246</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8C3Nwu6XF0Oi2St2MLlLAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_JhbpO-WBWUqGjLCgoPnGmg_11_2">26,879</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_RpHUMDrg-UiGjsQj8CQEXQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_fyS1zHn3_kuE2BUNQ8_yeQ_11_4">2,056,110</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember__36EPFnJpUGaQzWSL7tMWg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_OnCJR6I7q0mRrAUR4A-Sig_11_8">1,565,981</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_-SG7NEQ-8E-ah1y5uSU_bQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_w126yYUOak6jvlOTia5AgA_11_10">67</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_UYsFzaHNlEyUXx2BIsKVnQ_11_12">516,941</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c4052fc6_d56c_4e74_8ed9_ba5c5aa26e44"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><a id="ConsolidatedStatementsofCashFlows_959663"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c0e2a4b1_ab2f_4c85_b08c_3a239209dafc"></a><a id="Tc_S2I30hv_WE6JrlUd_Wlf4w_1_4"></a><a id="Tc_QdoSNm3WfkGgCy-M8nnbBA_2_0"></a><a id="Tc_5BPnNhWzwESfoc1YM2aUTg_2_2"></a><a id="Tc_gmytGidzME2wYXcMiTmDnA_2_4"></a><a id="Tc_NC6DfIwPCEqY9t9VaKuh7w_2_6"></a><a id="Tc_sHuD6usPu0aiB5Hnt_qKhQ_2_8"></a><a id="Tc_1-gPRLQ4xE2JriSkPEMv8A_3_0"></a><a id="Tc_J_VlMpjeyEqmR8q9uWYnIw_4_0"></a><a id="Tc__I3fjzkCp0O9GSQjbWYl0A_5_0"></a><a id="Tc_huHiEBn3VUejx3cRq1wG5Q_6_0"></a><a id="Tc_qF4QQOuBEkitam2Zit9Qzw_7_0"></a><a id="Tc_6eak-A1EkUG0ARG7rufjbw_8_0"></a><a id="Tc_P9dfNVLKTEeA6gdLfIKt8w_8_2"></a><a id="Tc_5IWwn8FwW06oocCXUw1ELQ_9_0"></a><a id="Tc_CIu0wg2UjU6K_Ler4PnUtA_9_2"></a><a id="Tc_O13chBKc-ESuqltFFnI78A_10_0"></a><a id="Tc_7dl_StLbh0OXFaqP9CRdww_10_2"></a><a id="Tc_F6dw9uoKU0GJiTcDkrWgFw_11_0"></a><a id="Tc_bDqYRU5fREajn4DBTLD1Zg_11_2"></a><a id="Tc_2l0QH56K70mU_u1wLPzgyQ_11_4"></a><a id="Tc_NTDmXiBgWEWO7pOryL90Kg_12_0"></a><a id="Tc_PMW7MGjIE0Kqn4OTJ_2Ktg_12_2"></a><a id="Tc_fSNc5_eigU-CwF2cawU1Eg_13_0"></a><a id="Tc_EzKlkPESIUKlR9tSzov1Uw_14_0"></a><a id="Tc__ASXIQazQUS1hLriHIxJJw_14_2"></a><a id="Tc_SAze0JwKI0y7OgiCFT1oUw_14_6"></a><a id="Tc__17POBUhIU2h5r9sAprbPg_14_8"></a><a id="Tc_Lv8YxFttD02tbToFue-QcA_15_0"></a><a id="Tc_NKhiI7USH0Gncf568QbAsw_15_2"></a><a id="Tc_M5N2srbaT0K_EanRBoQ5Zw_15_4"></a><a id="Tc_90ET-_YEHUK8IczpVm5Frw_16_0"></a><a id="Tc_bQdZxGaSzkSx7BMMvXv1aw_17_0"></a><a id="Tc_7iW_-f7Q6kiuMUpGKAYgZQ_17_4"></a><a id="Tc_Q3EzFVL3SUujOZNG-ov8GA_17_6"></a><a id="Tc_n4fPeOX4nUu-hZqy9ENsQw_18_0"></a><a id="Tc_5xxxsqVuPESEtuBEfhPBtw_19_0"></a><a id="Tc_8Gihj4uUmE2UyDVjZQHnEg_19_2"></a><a id="Tc_r8bY6N-JsUeGUrYiDbVR9g_20_0"></a><a id="Tc_DzCEKKk1qUG19M8v75GV6Q_21_0"></a><a id="Tc_DscUA6Hbv0WQe2ELr2QzMA_21_6"></a><a id="Tc_FC68yeq1bk6Lch_qgnRK6w_21_8"></a><a id="Tc_EniyidJTeUGqLfGZGau-Fw_22_0"></a><a id="Tc_GNu0-w3b7k-mdsr37cBxLw_23_0"></a><a id="Tc_H6pe9-ga-kyWNm8oJ1YGRg_23_6"></a><a id="Tc_f89qO6qxVk2suU9UZrzaWQ_23_8"></a><a id="Tc_fimr8cihE0i8RHmfp0ItEA_24_0"></a><a id="Tc_ZGdafa_8Bk6yw9guvYBb2A_25_0"></a><a id="Tc_dDPE8no6CUaGmBtSrJnJUA_26_0"></a><a id="Tc_Ks7CquLgkEmHN4P9ei1kdw_27_0"></a><a id="Tc_6HhkrDMfR0-yhpBmM21fMw_28_0"></a><a id="Tc_T5pKR9be_kqIfCDLsZvstQ_29_0"></a><a id="Tc_iPKy0CgbbkmVLg_-uMDHYw_30_0"></a><a id="Tc_EEaZhFSLukCCzgkk96XohQ_31_0"></a><a id="Tc_thNf9zgUWEmHH87devUmYA_32_0"></a><a id="Tc_UdcktFcex0GBHo5zyl_PSQ_32_2"></a><a id="Tc_TADolS6nAkq7QhSJpFGr5A_32_4"></a><a id="Tc_MvsBrb7G602ZYZ2vrlKMqw_32_8"></a><a id="Tc_UQpw1TrhGUam1fV8KSB12g_33_0"></a><a id="Tc_AbjElZwvT0mLjVmQo-Nu1Q_34_0"></a><a id="Tc_90WT88psikGAc6zR5FNgig_35_0"></a><a id="Tc_HMd23hPtoE-oSCgMu7xYyg_36_0"></a><a id="Tc_hHBj2HLOf0SRY-PAjv6xqQ_36_6"></a><a id="Tc_eMQ8UCw_6EGqtUG5cFSWIQ_37_0"></a><a id="Tc_0sv2Eu03j0m_sDBobGwq8g_38_0"></a><a id="Tc_AwDsv5psqkewTMezCQkZpw_38_4"></a><a id="Tc_gXLi2YWUHEWAOpaBgzr__A_38_8"></a><a id="Tc_H_IOjKgq9kmmgQ3vgw8LsA_39_0"></a><a id="Tc_U36jxVgXTEuaV_h84F6qIQ_39_6"></a><a id="Tc_YdKeyOg7uUis1skenPy1Qg_39_8"></a><a id="Tc_cTstFXwbtUawykCAnfKfVQ_40_0"></a><a id="Tc_L7LCErCWTESmE1Wdoar54w_41_0"></a><a id="Tc_ww_738XZQE-pOOiHsN2VSg_42_0"></a><a id="Tc_TPuAHej4Wkaeek-lwtxxdA_43_0"></a><a id="Tc_UrbJSDtB2km-_y8qAkLJ5g_44_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_LyYhAbnB_EmN3e7hbWZ5xQ_4_4">412,498</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_XqWe2NObZUqc_Dt4WDNQFw_4_6">249,155</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_T4Wd2JbzfkWM2f9scCcG9w_4_8">259,969</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile loss before tax to net cash flows </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc__oX1-de53EKzygiwFZRoBw_6_4">10,103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_HI0EcCs2y0OFOAe3jua5mg_6_6">4,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_IFjyBx5BqUSzHLmH47Af0Q_6_8">16,731</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_Ew0q2opSpESl5FcHKVZ49g_7_4">10,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_H_f062Kfa0G9NKkZSlazzg_7_6">3,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_i-n6hMsok0WGYilX4W_UsA_7_8">2,493</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_x5tVQNxOxUymq7LjHcqaaA_8_4">15,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_eVxD_2FTc0S6z6ya95Lhww_8_6">23,741</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_S-YXnd-ljUOUjH5q4ukBHQ_8_8">23,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_bQ-0JaNeYEGDmFuR_Y0dQg_9_4">22,810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_QEijHxhs_0-3JzYUYU6KTQ_9_6">6,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_tqgyKTRD_UKmWjxf3CPVnA_9_8">2,466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss on disposal of fixed assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_c955qYQ6e0aIyr7RnB53qQ_10_4">587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_OowYQf7isE6ft8OLbmO_SA_10_6">11,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_v2yBT_SezEiFeEnMs7t9Bw_10_8">3,477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsTransferToAssetHeldForSale" scale="3" id="Tc_urj-z1ZHlUKuEEQMRZC5Gw_11_6">19,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsTransferToAssetHeldForSale" scale="3" id="Tc_9mY0yGxlQUuqvgLc_Wh_Ig_11_8">6,711</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoryWritedown2011" scale="3" id="Tc_SjTgmL5mq0e0VbvpvUvQmw_12_4">185,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoryWritedown2011" scale="3" id="Tc_ZUqowEjIKkSeCSnBiOceDg_12_6">80,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoryWritedown2011" scale="3" id="Tc_c5I_zKU160GF9bwJdjieGw_12_8">47,129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based payment expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_3PF-HCx4B0GRvM1yScH6zw_13_4">14,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_JftGZ_pd7kCPUcAgM6DJvA_13_6">9,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_pRQpLx1YLE6VUZYjFQWajg_13_8">7,697</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Income from release of governmental contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Tc_4E220jxI2Ue_YSr79eDiSA_14_4">574,502</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes of provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForProvisions" sign="-" scale="3" id="Tc_mR-SimIklkK3aCJzbya6kg_15_6">58,799</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForProvisions" sign="-" scale="3" id="Tc_0xJw-SaI5UOpG7iQ0bz1_g_15_8">25,842</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Working capital changes </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decrease / (increase) in asset held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_EctPo7J6qEioZEhsXItKIg_17_8">1,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decrease / (increase) in trade receivables and contract assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" sign="-" scale="3" id="Tc_TjVhIxalI0O6phqVFLE95w_18_4">16,682</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="Tc_03r99611NEWSHgA9iu_7LQ_18_6">9,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" sign="-" scale="3" id="Tc_YBsBOvCeSkCLJhfdhfrbiw_18_8">8,082</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decrease / (increase) in inventory </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" sign="-" scale="3" id="Tc_oOrboWaJSkmhNshBTEmUQQ_19_4">227,460</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" sign="-" scale="3" id="Tc_YAkFYk50iEOZIu70m_7l7A_19_6">47,851</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" sign="-" scale="3" id="Tc_I9e1lz1ffUSUJhIQfXeVpg_19_8">47,940</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decrease / (increase) in prepaid expenses and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" scale="3" id="Tc_Qlp4xMXUdE2jg8_BL14iEw_20_4">3,118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" sign="-" scale="3" id="Tc_E7BCNk_7jk2dyLEtV2mW7Q_20_6">8,968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" sign="-" scale="3" id="Tc_RQ1RkG63jUataoieYjw4ow_20_8">16,494</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipts from grants from government agencies and similar bodies </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Tc_pftm3WOFKka8oY_K6r-nwg_21_4">93,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Decrease) / increase in trade and other payables and contract liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="Tc_yhbfgoq26k2c5O-JBRM9KQ_22_4">179,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" sign="-" scale="3" id="Tc_ZBpc8DwJ-kSQm66W8yZkpQ_22_6">96,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" sign="-" scale="3" id="Tc_hQ5s6GF8ykiFsdyCHBUfKQ_22_8">29,984</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Decrease) / increase in other current financial and other liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" sign="-" scale="3" id="Tc_8lcjMh-jSEiNwls6B93S1A_23_4">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decrease / (increase) in deferred taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" sign="-" scale="3" id="Tc_zNGGebl9fEao3h0jSj9NTw_24_4">1,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="3" id="Tc_XyvBxxRYKEm2_NbDHMr1hA_24_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" sign="-" scale="3" id="Tc_rFRUct6dDkaFX3q4kLJWAw_24_8">115</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Income taxes paid </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="Tc_WTZxt9mwo0KaGhkFP_oZvA_25_4">502</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="Tc_-_WljoKblkO2vG4KgpK28Q_25_6">128</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="Tc_c-E4JY6OBkGtSxdlqdD5uw_25_8">3,891</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest received </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_ldA7zHyQwECPpD4J-aU95Q_26_4">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_dmGYOGY9qEGJhoKBt1OCpw_26_6">1,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_jxAjHgPGYkehrfgffNczMA_26_8">15,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest paid </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_ZCSDhjbESEWHncxg2NtN1Q_27_4">9,785</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_ZlhkJuCd1kmk7lqiH6L39A_27_6">4,606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_00pWYmSxskCrA_WEU4fCqw_27_8">2,375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash flow provided by (used in) operating activities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_k5OnnA-5o0iK4T7mvUc01w_28_4">733,128</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_S4fRvgKaakWWUe51PCNZoQ_28_6">286,177</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_-tVWhck-CUylY95_TkGt6g_28_8">267,887</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investing activities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of property, plant and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_gM8WIj5jVUu4epsm1PZt1A_30_4">124,222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_ife3ndJ8a0Sy8CaDWz0fdw_30_6">88,023</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_jqdAOKZEfUOqD5nCxpD8tQ_30_8">52,320</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_qk_4JWkU102W8EOWFbALjQ_31_4">3,679</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_3R-ZvL2ECEi84BKOGhw-Tg_31_6">5,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_-fJdItPEz0ir69hQ_Vh2Cw_31_8">2,880</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition of subsidiary, net of cash acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="3" id="Tc_2fwzt6sdfUql2hryeYgkYw_32_6">277</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash flow provided by (used in) investing activities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_Gf7VzDdzXkCT42ll0yX2Gw_33_4">127,901</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_6gGvmbXrcUK7nG0Wuq-ixg_33_6">93,499</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_mUH6kvmPyUyJXGHNNEQBeQ_33_8">55,200</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financing activities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments on lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_fgltxFxSrU-Fr8Q2-BnocQ_35_4">3,183</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_uNDmo-J1a0OtQR74EuevLQ_35_6">4,221</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_SuqcbZS6IkmKx6fO9mj8jg_35_8">5,193</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from the issuance of shares (net of transaction costs) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Tc_WOVUaOY4XUiNioU9lxQnEQ_36_4">404,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Tc_wgJFKbo0okKlGksiFKA81Q_36_8">235,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment on / proceeds from treasury shares/exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" sign="-" scale="3" id="Tc_cxNY5ZWoqEKZ1gvDQ3YNtw_37_4">30,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" scale="3" id="Tc_rtuxeRaVHkm6Z2VdbNH0oA_37_6">910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" scale="3" id="Tc_CSo9zvDPv0ur5v7h1xG-MQ_37_8">246</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from at-the-market offering program (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodValueNewIssues" sign="-" scale="3" id="Tc_1lXhpmscT0uJlv7MHbiB5w_38_6">66,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Repayment of the EIB loan </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="Tc_nBKuAzDGo0GTYvxvEuV-UQ_39_4">25,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash flow provided by financing activities </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_AGXHXceAU0aoXScBTWxS8A_40_4">344,964</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_Uee74yd6tUqYvrEts4TLAA_40_6">63,173</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_JXTESQjRbkK0SsILPgIllQ_40_8">230,893</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_LLuCTJHcfka_Q553bKY-Cw_41_4">516,065</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_07Vp8bvN_Ee8Q1HZZ_WNyg_41_6">316,503</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_0rbSUXPywkGfZHToiIzKCA_41_8">92,194</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of currency translation gains on cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_uMb3CHO-50GD4R57sJsotA_42_4">4,936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_13ysMu2grEu1KO1LLGr7jQ_42_6">836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_s43hpS4xskSAGLouCCqiQQ_42_8">1,151</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_HUtZNR6aQk-ZpDWiS4ynjQ_43_4">1,322,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_uNIdDPv7H0GHQEdT8tqG2A_43_6">811,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_zPChOYLzukWLbingWmx2Bg_43_8">495,797</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_dY7U1g8B70KZceoxis-tDA_44_4">811,464</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_05jq1wle50m1tptOgknKPg_44_6">495,797</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_ZXVYYIoxA0GClws4uC_dMA_44_8">402,452</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="a1CorporateInformation_486713"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:CorporateInformationTextBlock" id="Tb_r6PH5N7q1UGBeCKzNjZrdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (CureVac or CV or the Company) is the parent company of CureVac Group (Group) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With in - house manufacturing capabilities and expertise we are an integrated biopharmaceutical company. We consider our manufacturing process an important part of our strategy that allows us to continuously improve our technology platform and maintain flexibility in clinical development and allow us to manufacture potential future commercial products. The close interaction of our technical development and research teams enables us to rapidly implement innovations and robustness to the manufacturing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were incorporated pursuant to the laws of the Netherlands as CureVac B.V. on April 7, 2020 to become a holding company for CureVac AG prior to our initial public offering. Pursuant to the terms of a corporate reorganization (the &#8220;Corporate Reorganization&#8221;), all of the outstanding shares in CureVac AG were contributed and transferred to CureVac B.V. in a capital increase in exchange for common shares of CureVac B.V. and, as a result, CureVac AG became a wholly-owned subsidiary of CureVac B.V. and then current shareholders of CureVac AG became the shareholders of CureVac B.V. Immediately following such exchange, and prior to the listing of our common shares on Nasdaq, we converted into a public company (naamloze vennootschap) under Dutch law pursuant to a Dutch notarial deed of amendment and conversion, following which our legal name became CureVac N.V. As part of our Corporate Reorganization, outstanding shares of all series in CureVac AG were exchanged for common shares in CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are registered in the commercial register at the Netherlands Chamber of Commerce under company number 77798031 (RSIN 861149336). Our principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 T&#252;bingen, Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During fiscal 2023, dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, was the largest shareholder of CureVac. Together with its related parties, dievini held shares and voting rights in CureVac between appr. <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_lBS-kbj340mK__LFAXyYQg" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfVotingInterestsHeld" scale="-2" id="Narr_QBgYVnBMuECGp0asCcJ__w">37</ix:nonFraction> &#8211; <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_z_oev7deRk-jsRWTlzMzkA" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfVotingInterestsHeld" scale="-2" id="Narr_q5yOOdqvsEyZzjbYvZv5rQ">43</ix:nonFraction> % (prior year: <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_s0o811r3yEWWO5MCpwlyaw" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfVotingInterestsHeld" scale="-2" id="Narr_AZpmYp3tJkai7DvO97_slQ">43</ix:nonFraction> &#8211; <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_34HbkgDTrEKqkuExas5krQ" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfVotingInterestsHeld" scale="-2" id="Narr_JUz8QWspwkaJmKR2lqDw1Q">46</ix:nonFraction> %) during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="Tb_z08GPT4NXkK0SYqRGX7bXw" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_WtQh0Wnqs0uMcjH5wAO1hg" continuedAt="Tb_WtQh0Wnqs0uMcjH5wAO1hg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of preparation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and were authorized by the Management Board for presentation to the Supervisory Board on April 23, 2024. The Group&#8217;s consolidated financial statements are presented in Euros (EUR), which is also the parent company&#8217;s functional currency. Unless otherwise stated, the numbers are rounded to thousands of Euros, except per share amounts.Due to rounding, differences may arise when individual amounts or percentages are added together.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has prepared the consolidated financial statements on the basis that it will continue to operate as a going concern. No commercial products have been marketed yet as CureVac is still in the development phase. Hence, the Group is raising capital to perform research &amp; development activities and to advance its technologies up to a successful development and regulatory approval of its products. To reach its development and commercialization objectives, the Group will seek additional funding through collaboration or licensing agreements or other financing activities. While the Group&#8217;s business projections could be unfavorably affected by being unable to obtain funding or enter into collaboration or license agreements on acceptable terms, CureVac&#8217;s cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the financial statements. This anticipates, that for the foreseeable future the Group will continue to operate. Thus, no adjustments to the consolidated financial statements have been made related to the Group not being able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Details of the Group&#8217;s accounting policies, including changes thereto are described below. The accounting policies have been consistently applied to all years presented unless otherwise stated.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont1" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont2"><ix:continuation id="Tb_WtQh0Wnqs0uMcjH5wAO1hg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory" id="Tb_T5lc3F2RTkSxzEUgiHRJkw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of consolidation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsidiaries are entities controlled by the Group. The Group &#8220;controls&#8221; an entity when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The consolidated financial statements include the Company&#8217;s wholly-owned subsidiaries CureVac SE (until September 26, 2022: CureVac AG, Tuebingen, Germany), CureVac Inc. (Boston, Massachusetts, USA), CureVac Manufacturing GmbH (prior years: CureVac Real Estate GmbH, Tuebingen, Germany), CureVac Corporate Services GmbH (Tuebingen, Germany), CureVac RNA Printer GmbH (Tuebingen, Germany), CureVac Swiss AG (Basel, Switzerland &#8211; incorporated in 2021) and CureVac Belgium SA (Ottignies-Louvain-la-Neuve, Belgium &#8211; incorporated in 2022). Effective July 1, 2022, we acquired Frame Pharmaceuticals B.V., Amsterdam, Netherlands (Frame Pharmaceuticals), which was renamed to CureVac Netherlands B.V.; refer to Note 20 for additional information about this business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The fiscal year of all Group entities corresponds to the calendar year ending December&#160;31.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Material accounting policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" id="Tb_6kU3LzyZHkKMry3gtG2jOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business combinations and goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Group determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Any contingent consideration to be transferred by the acquirer is recognized at fair value at the acquisition date. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of IFRS 9 Financial Instruments, is measured at fair value with the changes in fair value recognized in the statement of operations in accordance with IFRS 9. Other contingent consideration that is not within the scope of IFRS 9 is measured at fair value at each reporting date with changes in fair value recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred over the fair value of net identifiable assets acquired and liabilities assumed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;">After initial recognition, goodwill is measured at cost less any accumulated impairment losses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="Tb_5gbQSr8_Dk6pkr98gj0OEA" continuedAt="Tb_5gbQSr8_Dk6pkr98gj0OEA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Revenue from the sale of products and services is recognized when the Group transfers control to the customer. Control generally transfers when the customer gains the ability to direct the use of and obtain substantially all of the remaining benefits from the good or service. If the contract contains more than one performance obligation, the consideration which the Group expects to receive is allocated to each of the performance obligations, using the relative stand-along selling price method. Revenue is recognized at the amount of consideration that the Group is expected to receive in exchange for these goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group primarily generates revenue from its licensing and development agreements with its customers, which include collaboration partners for the development of mRNA medicines against a variety of targets in diseases and conditions. These arrangements contain multiple contractual promises, including (i) licenses, or options to obtain licenses to the Group&#8217;s mRNA technology, as well as related research and development technology services, (ii) delivery of products, and (iii) research and development services. Such arrangements provide for various types of payments to the Group, including upfront fees, funding of research and development services, payment for delivered products, development, regulatory and commercial milestone payments, license fees, and royalties on product sales, all of which may be satisfied at different points in time. Outlicensing agreements may be entered into with or without any further significant contractual obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Goods or services promised in collaborative arrangements are accounted for as separate performance obligations if such promises are distinct (i.e., if the customer can benefit from the good or service on its own or together with other resources readily available to it and if the promise is separately identifiable from other promises in the contract).</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont2" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont3"><ix:continuation id="Tb_5gbQSr8_Dk6pkr98gj0OEA_cont1" continuedAt="Tb_5gbQSr8_Dk6pkr98gj0OEA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In determining whether contractual promises are separately identifiable, the Group considers whether:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It provides a significant service of integrating the goods or services with other goods or services that represent the combined output or outputs for which the other party has contracted.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One or more of the goods or services significantly modifies or customizes one or more of the other goods or services promised in the agreement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The goods or services the Group promised to transfer or to provide are highly interdependent or highly interrelated.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Based on these criteria, management evaluates whether the intellectual property (IP) licenses granted, and to which further research and development activities may apply under the terms of a collaboration agreement, are distinct from the unperformed obligations to the collaboration partner, considering the relevant facts and circumstances of each arrangement. Factors considered in this determination include the nature of the IP license, the stage of development of the IP license granted, the research capabilities of the partner, and the availability of mRNA technology research expertise in the general marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When an IP license is not considered to be distinct from research services, the Group generally recognizes revenue, including any upfront payment, attributable to the license on a straight-line basis, which reflects the performance of services by the Group towards satisfaction of the obligation, over the contractual or estimated performance period, which is typically from the effective date of the related collaboration agreement through to the estimated date of Marketing Authorization Application (MAA) or Biologics License Application (BLA) for a product developed under the agreement. The determination of the estimated date of MAA or BLA is a significant estimate given the uncertainty inherent in developing innovative pharmaceutical products and is based upon development plans with the customer, which are subject to change, clinical trials, and approval of regulatory authorities Changes in the estimated date of market entry could have a material impact on the amount and timing of revenue the Group records in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Sometimes an IP license is granted together with research and development services relating to the technology. In this case, the services are not considered distinct from the licenses and form a bundle for which revenue is recognized on a straight line basis over the time of services, as the services are determined predominant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When an IP license is considered to be distinct, the Group determines whether it provides the customer with either (1) a right to access the IP throughout the license period (for which revenue is recognized over the license period) or (2) a right to use the IP as it exists at the point in time that the license is granted (for which revenue is recognized at a point in time where the customer can first use and benefit from the license).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Some of the collaboration arrangements include rights and obligations that are considered outside the scope of a customer-vendor relationship as they are more akin to the activities that joint operators perform. CureVac decided that the nature of these types of activities is best reflected by applying joint arrangements accounting which, as the main effect, usually leads to revenue recognition at a later point in time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">If the transaction price in an agreement includes a variable amount, the Group estimates the amount of consideration to which the Group will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated deferred contract liability is updated at each reporting date to reflect the current facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Collaboration agreements may also provide a customer with the option to acquire additional goods or services. In these cases, the Group determines as to whether the customer was granted a material right.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont3" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont4"><ix:continuation id="Tb_5gbQSr8_Dk6pkr98gj0OEA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Product sales related to collaboration agreements include RNA products and are recognized over time as goods are produced because such goods have no alternative use. Otherwise, revenue for product sales is recognized at a point in time. In 2023 revenue for produced LNP batches were recognized on a point-in-time basis. No product revenue was recognized in 2022 and 2021. Revenue from certain research and development services, delivered as a distinct performance obligation under the collaboration agreements, are recognized over time as the services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A receivable is recognized when the consideration is unconditional and only the passage of time is required before payment is due. Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liability in the statements of financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group may present the following contract balances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contract assets&#8201;&#8212;&#8201;Represents the Group&#8217;s right to consideration in exchange for goods or services that the Group has transferred to the customer when that right is conditioned on something other than the passage of time</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trade receivables&#8201;&#8212;&#8201;Represents the Group&#8217;s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contract liabilities&#8201;&#8212;&#8201;Represents the Group&#8217;s obligations to transfer goods or services to a customer for which the Group has received consideration (or consideration is due) from the customer</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes revenue from contracts with customers relating to its core business. All other operating proceeds are presented as other operating income in the statements of operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants" id="Tb_MbE6eT_jhUqN_qgDGJR4FA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants from government agencies and similar bodies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects. Each grant agreement is assessed to determine whether there are elements of the supply of products from the group to the grantor that are recognized separately from the grant. For the supply of products, the standalone selling price is determined by reference to observed prices with other customers. The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If grant funds are received prior to qualifying expenses being incurred or assets purchased, they are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other operating income on a systematic basis over the period in which the corresponding expenses are incurred. If the funds reimburse purchased assets, the liability is reduced with a corresponding amount deducted from the asset&#8217;s carrying amount upon recording of the qualified asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="Tb_1gpPUxi8nEmejdyh6IK5yQ" continuedAt="Tb_1gpPUxi8nEmejdyh6IK5yQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">i) Financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial recognition and measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The classification of financial assets at initial recognition depends on the financial asset&#8217;s contractual cash flow characteristics and the Group&#8217;s business model for managing them. The Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component are measured at the transaction price determined under IFRS 15.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont4" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont5"><ix:continuation id="Tb_1gpPUxi8nEmejdyh6IK5yQ_cont1" continuedAt="Tb_1gpPUxi8nEmejdyh6IK5yQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subsequent measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For purposes of subsequent measurement, financial assets are classified into four categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at amortized cost (debt instruments);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at fair value through other comprehensive income with recycling of cumulative gains and losses (debt instruments);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets designated at fair value through other comprehensive income with no recycling of cumulative gains and losses upon derecognition (equity instruments); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at fair value through profit or loss.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2021, 2022, and 2023, the Group only had the following financial assets to be measured at amortized cost:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash and cash equivalents</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trade receivables</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other financial assets</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in the statement of operations when the asset is derecognized, modified, or impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An allowance for expected credit losses (ECLs) is recognized for all debt instruments not held at fair value through profit or loss including contract assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12- months (a 12- month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For financial assets being due more than 30 days, a significant increase in credit risk is assumed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk but instead recognizes a loss allowance based on lifetime ECLs at each reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group considers a financial asset in default when contractual payments are 180&#160;days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ii) Financial liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s material financial liabilities consists of lease liabilities and trade payables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade payables at initial recognition are accounted for at fair value and subsequently at amortized costs. The material accounting policy information regarding accounting of leases is described below.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_3QULTqtBPkqjvxBKrv8v6Q_1_0"></a><a id="Tc_k2PbrYGJVkK9cPV5lpSQYQ_1_2"></a><a id="Tc_QCNsjR4IPk2b-Bp_SOjXFw_2_0"></a><a id="Tc_o4FYIhYxo02o5NoFdkEm7A_2_2"></a><a id="Tc_MmPggCPQ-kSTQY-bVTDpnw_3_0"></a><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont5" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont6"><ix:continuation id="Tb_1gpPUxi8nEmejdyh6IK5yQ_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="Tb_kKiOgBSCg02kvzakYWmvMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquired intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Acquired intangible assets are mainly comprised of software and licenses. Regarding the acquired intangible assets (i.e., technology and goodwill) in the business combination with Frame Pharmaceuticals, refer to Note 20.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated useful lives for each intangible asset class are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory" id="Tb_U8a8-hZsxUeUeGC3VXjqvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Software</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IF3SAFyRDkmSY9vIIRwRsA" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="Narr_BE7o92UqtECHAT-k2uksLA">3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WdwXgqTk-0Gz8-5HXgSqZg" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="Narr_JSJ3wbQxQkOGF7gzt3FmCA">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_n816zTthhUCd928-Xo9B2w" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="Narr_7XnC16SbgkyPm4UMR8ekzA">8</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_h5bEzTVa3EyxXxcQh-dg1Q" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="Narr__0YCT1SI80C9xrb5bu7w4A">20 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_TechnologyMember_hH9UPyIPlEOolWMJj-UurA" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="Tc_eZQzr3udf0mwpEfDhLYuEA_3_2">8 years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the exception of goodwill, the Group does not have any intangible assets with indefinite useful lives.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory" id="Tb_gPK-zIfPBEKYFJjcmPjYlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and development costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research costs are expensed as incurred. Since our own development projects are mostly subject to regulatory approval and all studies are at an early phase, where the outcome of reaching the next phases is uncertain, the conditions for the capitalization of expenditures incurred prior to approval are not met.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="Tb_Pbtkyp1Us020Fy5DJmRwrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairments. These costs also comprise the costs for replacement parts, which are recognized at the time they are incurred, providing they meet the recognition criteria. All other repair and maintenance costs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" id="Tb_gHPvM-qNlEeYHjEjWplc8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Leasehold improvements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_SzFXrlYIYkGJv5pgzyKXhQ" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="Narr_Oi1qwRFM4ESiy7nsxyDC4Q">1</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_4y9Rq2Ban029PexLw4uVTQ" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="Narr_coYQpGkBeUiypJowebydVQ">15 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technical equipment and machines:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_dLLTUG3nUkmNAeblyIfEfQ" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="Narr_JIxID085CUOvOikV0BAVvw">3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_yHk0L5C8gEyXoJw8KYw3Kg" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="Narr_comUzR9oDk6HS16WNty7Fg">14 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment, furniture and fixtures:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_wEcN7ca8EkmDto9rHIMXqw" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="Narr_XdVCH1o3XEKu09tl16AeDw">3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WHDQrxvJz065lEPIjGIWuQ" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="Narr_IVbAIYVrIkajB2XTdVLtJg">14 years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated useful lives are reviewed regularly and revised if necessary. The depreciation method remained unchanged from 2021 through 2023. The residual values of the assets are generally considered to be <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="0" format="ixt-sec:numwordsen" name="cvac:IfrsPropertyPlantAndEquipmentSalvageValue" scale="0" id="Narr_f0gSpQlpPkKdJVtSkfRoPw">zero</ix:nonFraction>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="Tb_DRKo6uCtjES-vPEOqH_BOA" continuedAt="Tb_DRKo6uCtjES-vPEOqH_BOA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of non-financial non-current assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At each reporting date, the Group assesses whether there is an indication that a non-financial asset may be impaired. If there is any indication of impairment (triggering event) or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of the asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case it is determined at the level of the cash-generating unit (CGU). If the carrying amount of an asset or CGU exceeds its recoverable amount, the asset or CGU is impaired and written down to its recoverable amount. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In principle, the recoverable amount has to be determined for each individual asset where such asset generates cash flows that are largely independent of those generated by other assets. Where it is not possible, the recoverable amount has been determined on the basis of a group of assets representing a cash generating unit.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont6" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont7"><ix:continuation id="Tb_DRKo6uCtjES-vPEOqH_BOA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In assessing whether the cash flows are largely independent, CureVac considers various factors, including how management manages the company activities and how the CureVac companies are linked in business operations. As management decisions are centralized on group level and the CureVac companies are closely linked in business operations, the Group operates as one cash-generating unit. Therefore, for the purpose of annual goodwill impairment testing in 2022 and 2023, goodwill was allocated at Group level. The recoverable amount for the Company&#8217;s cash-generating unit based on fair values less costs of disposal using market capitalization derived from public quotations of CureVac stock. Management believes that no reasonably foreseeable change in the price of CureVac stock would cause the carrying amount of our one cash-generating unit to exceed its recoverable amount.Impairment losses of continuing operations are recognized in the statement of operations in expense categories consistent with the function of the impaired asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal year 2021, impairment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Narr_AheVyckymEeU2JcsgEPfJw">22,810</ix:nonFraction>k were recognized. These pertained largely to machinery and technical equipment recorded as assets under construction and resulted from the partial impairment of production lines which were obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV, see Note 4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beginning in year 2022, goodwill is tested for impairment annually as of December 31 and when circumstances indicate that the carrying value may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For 2023, impairment was evaluated for goodwill by assessing the recoverable amount on Group level. Impairment losses relating to goodwill cannot be reversed in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There was <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" scale="3" id="Narr_FPullIuzD0GPTaPm66gk2A">no</ix:nonFraction> impairment of goodwill in 2023. However, there were impairments of technical equipment amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Narr_245TIN92bECXts4LlGOaEQ">1,374</ix:nonFraction>k; refer to Note 4.1 for additional information.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" id="Tb_TlLiOCP7IUGGRzrOnJSYKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-current assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group classifies non-current assets as held for sale if their carrying amount is expected to be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expenses. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management is committed to the plan to sell the assets. Property, plant and equipment are not depreciated or amortized once classified as held for sale.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory" id="Tb_oEdZSYxJ_02Qvz05S10_NA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Right-of-use assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received as well as any estimated costs to be incurred by the lessee for dismantling and removing the underlying asset. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life, indicated below, and the lease term. Right-of-use assets are subject to impairment. Refer to the section above &#8220;Impairment of non-financial assets&#8221;.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory" id="Tb_SBTZDvsbgkyOw4Avjm5m5w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Land, Buildings and supply installations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_Q9fMN7T-y0m13lblbattaw" format="ixt-sec:duryear" name="cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" id="Narr_m8s-LClxc0Gt5WpF-qU2pw">1</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_BsheSwtJGU-hU30WhGx3GA" format="ixt-sec:durwordsen" name="cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" id="Narr_GyGIs8_7PUynBxco2YFf0Q">15 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_oC7hV09GIUK4KIsK7e8ZoA" format="ixt-sec:duryear" name="cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" id="Narr_EvV5pTxQ6ECgDtw54FlHuA">3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_8YeTvYg7kUKynLYBgt67GA" format="ixt-sec:durwordsen" name="cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" id="Narr_M8eRbLuj90m7H8iq7rVvlg">4 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_vnP_GndeskmGccGmbmXP2A" format="ixt-sec:duryear" name="cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" id="Narr_N_N5PZlCLkyMtPkr-LO6qw">2</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_B2bOhJ54KEOrUvEAltnJrA" format="ixt-sec:durwordsen" name="cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" id="Narr_FroxxU0WlEeBsEYv3B5OdA">5 years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="Tb_1hRDglRq30mHpVOSkvhDuA" continuedAt="Tb_1hRDglRq30mHpVOSkvhDuA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Lease liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in- substance fixed payments) less any lease incentives receivable and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont7" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont8"><ix:continuation id="Tb_1hRDglRq30mHpVOSkvhDuA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments, or a change in the assessment to purchase the underlying asset. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount for the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Short-term leases and leases of low-value assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group applies the short-term lease recognition exemption to its short-term leases (i.e., leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption. Lease payments on short-term leases and leases of low-value assets are recognized as expenses on a straight-line basis over the lease term.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="Tb_Tnd53Csth0q6t2_forfrtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventories are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Inventories are comprised of raw materials, work in progress, and finished goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in bringing each product to its present location and condition are accounted for, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raw materials: purchase cost on a first-in/first-out basis</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overhead based on normal operating capacity, but excluding borrowing costs</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="Tb_chk7Wx3lJUqegCZz_JM_ww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and cash equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash on hand, bank balances on-demand, and short-term deposits with original maturities of three months or less.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="Tb_STlyy1tmbEyK6DbWMAMl5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Onerous contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An onerous contract is a contract under which the unavoidable costs (i.e., the costs that the Group cannot avoid because it has the contract) of meeting the obligations under the contract exceed the economic benefits expected to be received under it. The unavoidable costs under a contract reflect the least net cost of exiting from the contract, which is the lower of the cost of fulfilling it and any compensation or penalties arising from failure to fulfil it. The cost of fulfilling a contract comprises the costs that relate directly to the contract (i.e., both incremental costs and an allocation of costs directly related to contract activities).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Group has a contract that is onerous, the present obligation under the contract is recognized and measured as a provision. However, before a separate provision for an onerous contract is established, the Group recognizes any impairment loss that has occurred on assets dedicated to that contract.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="Tb_UHxHXHGJwkaENdD2YZROWw" continuedAt="Tb_UHxHXHGJwkaENdD2YZROWw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share-based payment awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Group operates several share-based payment programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">An equity-settled share-based payment award is accounted for by recognizing the related expense over the vesting period of the award, with a corresponding increase recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont8" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont9"><ix:continuation id="Tb_UHxHXHGJwkaENdD2YZROWw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When a share-based payment award provides for different ways of settlement (i.e. cash versus shares) depending on the occurrence of contingent events, CureVac has the right to choose the manner of settlement and accounts the award based on this.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The related share-based payment expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="Group_uD0V0ZAsJ0Gp9x0Gos3Icg" continuedAt="Group_uD0V0ZAsJ0Gp9x0Gos3Icg_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Tax loss carryforwards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Tax loss carryforwards are examined by the German taxation authorities and may be adjusted. Furthermore, significant changes in the shareholder and company structure can lead to a reduction in the loss carryforwards under the current provisions of German tax law, which can be used to calculate the annual amount for offsetting against the future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. The amount of the expected tax liability or tax receivable reflects the amount, which represents the best estimation taken into account tax uncertainties. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Deferred income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Deferred tax assets are recognized for deductible temporary differences, the carry forward of unused tax credits and any unused tax losses to the extent that it is probable that future taxable income will allow the deferred tax asset to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="Tb_MWDWGZhnPUOjwmjP1FXNVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">An operating segment is defined as a component of an entity for which discrete financial information is available and whose operating results are regularly reviewed by our Management Board as the Chief Operating Decision Maker (CODM). The Group operates as a single segment dedicated to the discovery and development of biotechnological applications and the CODM makes decisions about allocating resources and assessing performance based on the Group as a whole. Accordingly, the Group has determined it operates in <ix:nonFraction unitRef="Unit_Standard_segment_thtYd9HVPUa-ZcLIAcALtA" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:IfrsNumberOfReportableSegments" scale="0" id="Narr_SCapgVV-sUG_d4zRl0p-dQ"><ix:nonFraction unitRef="Unit_Standard_segment_thtYd9HVPUa-ZcLIAcALtA" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:IfrsNumberOfOperatingSegments" scale="0" id="Narr_HK7q48A2PEGZm82kl5c7bQ">one</ix:nonFraction></ix:nonFraction> operating and reportable segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="Tb_cm7pzYxFaEyUwjOjIa21wA" continuedAt="Tb_cm7pzYxFaEyUwjOjIa21wA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Significant accounting judgments, estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates, and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments and estimates in relation to assets, liabilities, contingent liabilities, uncertain tax position, revenues, and expenses. Management bases its judgments and estimates on historical experience and other various factors, which it believes to be reasonable under the circumstances, the result of which forms the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for. Actual results may differ from these estimates under different assumptions and conditions and may materially affect the financial results or the financial position reported in future periods.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont9" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont10"><ix:continuation id="Tb_cm7pzYxFaEyUwjOjIa21wA_cont1" continuedAt="Tb_cm7pzYxFaEyUwjOjIa21wA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Judgments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the process of applying the accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition and collaboration agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group applied the following judgments in determining the amount and timing of revenue from collaboration agreements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification and determination of the nature of performance obligations in collaboration and license agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group generates revenues from collaboration and license agreements under which the Group grants licenses to use, research, develop, manufacture, and commercialize candidates and products. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. If these promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in the Group accounting for all goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For these combined performance obligations, it must be assessed which of these promises is the predominant promise to determine the nature of the performance obligation. The Group determined that the research and development technology services for the grant of the license is the predominant promise within the (combined) performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Group shares the risks and benefits of a development project in such a way that the nature of the arrangement is not considered to be purely a customer-vendor-relationship, activities that are determined to be outside of a customer-vendor-relationship are accounted for in consideration of the principles of a joint operation accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, the promise of the research and development technology services for granting a license is accounted for as a performance obligation satisfied over time as the Group&#8217;s customer simultaneously receives and consumes the benefits from the Group&#8217;s performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition and collaboration agreements</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimation of variable consideration and assessment of the constraint when determining the amount of revenue of which to defer recognition</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s collaboration and license agreements comprise variable considerations which are contingent on the occurrence or non-occurrence of a future event (i.e., reaching a certain milestone). When determining the deferral of revenue in a collaboration and license agreement, the Group is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As there are usually only two possible outcomes (i.e., a milestone is reached or not), the Group has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which the Group will be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The most likely amount of these milestone payments (i.e., the full milestone payment) is only included in the transaction price if the occurrence of reaching a future milestone is highly probable. The Group has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has concluded that future milestone payments are fully constrained at each of the fiscal years. Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, regulatory approval, or achievement of a sales milestone.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont10" continuedAt="Tb_z08GPT4NXkK0SYqRGX7bXw_cont11"><ix:continuation id="Tb_cm7pzYxFaEyUwjOjIa21wA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>Estimation of determination of date of market authorization application for revenue release over-time</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A significant amount of judgment given the uncertainty inherent in developing innovative pharmaceutical products is being used in the determination of the estimated date of the Marketing Authorization Application or Biologics License Applications. The group regularly reviews the timelines and changes are reflected in the release of revenue amount when they become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for non - current assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-current assets are classified as asset held for sale if their carrying amount will be recovered through a sale transaction rather than through continued use; the carrying value of such assets is measured at the lower of their previous carrying value and their fair value less costs to sell. In evaluating whether the criterion, for classification as assets held for sale, of a sale being highly probable, the Group considered that a plan to sell the assets was committed to and an active program to locate a buyer was initiated with an equipment reseller. By estimating the fair value less costs to sell the Group considered various indicative prices of expected auction proceeds quoted by the equipment reseller. Additionally, the Group estimated, whether the plan to sell the assets could be completed within one year from the date of classification and whether actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has multiple share-based payment programs. Significant estimates are included in the determination of the grant date fair value of the awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for onerous contract provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has entered into binding legal agreements for the supply of services by contract research organizations (CROs) to the Group for clinical trials of its first-generation COVID-19 vaccine candidate, CVnCoV. Such services are generally associated with the ongoing monitoring and care for enrolled participants in the clinical trials. Due to the discontinuation of the CVnCoV program, the remaining services, which the Group is obligated to procure, do not have a value for the Group anymore. In estimating the cost of the remaining services, judgment is required, particularly in estimating the number of participants completing the clinical trials, when measuring provisions for such contracts with clinical research organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for contract termination provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Contract termination provisions are established under certain conditions in the case of legal risks. Settlement and legal proceedings often raise complex issues and are subject to many uncertainties and complexities including, but not limited to, the facts and circumstances of each particular case. The outcome of any current or future proceedings cannot normally be predicted. The Group considers the need for accounting measures in respect of pending or future settlements for terminated contracts on the basis of the information available to its legal department and in close consultation with legal counsel acting for the Group. Where it is more likely than not that such settlement will result in an outflow of resources that is already reasonably estimable, a provision for settling terminated contracts is recorded in the amount of the present value of the expected cash outflows.</p></ix:continuation><ix:continuation id="Group_uD0V0ZAsJ0Gp9x0Gos3Icg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for. The risk for the assessment regarding i) the deferral of upfront payments, ii) the cooperation between CureVac and GlaxoSmithKline Biologicals SA (GSK), and iii) the transfer pricing setup not to be accepted by the tax authorities is estimated to be between <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ao6gXG47qEqwSYLU3wAumQ" decimals="2" format="ixt:numdotdecimal" name="cvac:EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" scale="-2" id="Narr_m4RGqbUNAEWU585W7NAwdA">10</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dzLDR4-bwEyHrc4xbtFT-A" decimals="2" format="ixt:numdotdecimal" name="cvac:EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" scale="-2" id="Narr_2lV3L7R4VUS42M-Kr6EGTQ">50</ix:nonFraction>%.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" id="Tb_ddOKYpbuRUKe48w28s-akQ" continuedAt="Tb_ddOKYpbuRUKe48w28s-akQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in accounting policies and disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New and amended standards and interpretations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has not early adopted any standards, interpretations, or amendments that have been issued but are not yet effective.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk157782873"></a><ix:continuation id="Tb_z08GPT4NXkK0SYqRGX7bXw_cont11"><ix:continuation id="Tb_ddOKYpbuRUKe48w28s-akQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Standards issued but not yet effective</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following amendments will be adopted effective January 1, 2024, or at a later effective date:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 1: Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 7 and IFRS 7: Supplier Finance Arrangements</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IFRS 16: Lease Liability in a Sale and Leaseback</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 21: Lack of Exchangeability</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CureVac does not expect these standards to have an impact on the Group&#180;s consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_NK8AJaBvDU-499UCf2NeLg_1_2"></a><a id="Tc_M17bcujvvEyQFAbR1OkXNA_2_2"></a><a id="Tc_jDprhNNSdEO2lZfwFMdMiA_2_4"></a><a id="Tc_5NPG_u27gUygoA-BJ7sV2w_2_6"></a><a id="Tc_vv4suK9pakOVikrohV_8QA_3_2"></a><a id="Tc_FeaUQgXP3U6awHcsJpntYA_3_4"></a><a id="Tc_PzhhEtzWv0yWo_Z5moFA-A_3_6"></a><a id="Tc__EcZFEPuZEut7wbCnLv2Rg_4_0"></a><a id="Tc_VsWUY7AxU0eLE7hkarpBQg_5_0"></a><a id="Tc_vi7zO06yHEiODX5AeKLg7w_6_0"></a><a id="Tc_bX-hOgnV-0uLCsxqWeFLbw_7_0"></a><a id="Tc_inRhRez3okqmRGfLyGMbAg_7_4"></a><a id="Tc_1Bpg2k4BBUaryv9SqBk3EA_7_6"></a><a id="Tc_ggn6Wsiq0UqcI_4IpKI2oQ_8_0"></a><a id="Tc_5si1cWW58UCrfr1sHejeyg_9_0"></a><a id="Tc_WW8EsZn1qUCU-253PLvXyQ_10_0"></a><a id="Tc_dSdkAQPVX0qN952rhzQ4MA_11_0"></a><a id="Tc_iYuLxr08AkqzEdPG4ayInQ_12_0"></a><a id="Tc_FKCx-MtsiUCJDeck6D_Nsg_13_0"></a><a id="Tc_jRu2aKqLPke0rlEnIt2T6g_13_2"></a><a id="Tc_Rei-Ipl7jUCiTL3A6MCYdA_13_4"></a><a id="Tc_B7r5fD70ZUSDBIWNUijfsA_14_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock" id="Tb_eXNajj7K5E23MRE8ailPlQ" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the consolidated financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">The Group recognized the following revenues in 2021, 2022 and 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="Tb_IFouQAZpqUiqSovtbYyINQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_tqNpKUkXKE2OcFOuv70evw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_MfLAw8co30G2QMnTBe6N2w_5_2">74,298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_BNdhSUOAIEaFWRVUEBmbrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_vSKntqhg60mpA8GaHYuJFw_5_4">62,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_RMBBdxirVU2J7HBkSJTreA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_xI1A3gnE4U6Pys6DY-LXfQ_5_6">47,128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_5WdzkEBG3U2RD2KTauKIHw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_e2ARdi8dGU2_VsThKeYUVg_7_2">26,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8zx9Bh4e0kKH3oVw23ubCw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_oqTVUh85CkixmDMjmSQpfw_9_2">1,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_9-AN-Kf0kE-sEE04nCFBVw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_5w8qB93B9EKtiHLdqxSBTw_9_4">1,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_oqWek3tQ0kWMDoro7ubGQA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_LSKQVQPwXUOhvgXjkrhNWQ_9_6">1,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_8MAty4A8qE6RjZSge37rBg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_hXJRYo4nmES-2cA46TxdPA_11_2">919</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ye3SzgaAhUuYYFA2QScpkg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_NPkGfcboU0iCycUoUA-mlA_11_4">3,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_5-Lg5t6vPU2ChcpJcmCALQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_ZhrMfn34rU68kbVvsSJUPw_11_6">5,425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_ifrs-full_MajorCustomersAxis_cvac_OtherCustomersMember_1iVbqSw630CraOQMAg_n6w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_OQ8fMuYHM02FdpdWtbCelg_13_6">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_F67rk625S0CKRXA0xBDoAQ_14_2">102,990</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_mSngo5i0R0ystLIGl-9Eeg_14_4">67,420</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_m9ws-S-hF0mwDHySRDzybQ_14_6">53,758</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended December 31, 2023, the Company recognized revenues over-time (i) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_axX3OEHMmkqd9Ok2GiGCCw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_iagVXZ_M8UaS63dLTvwmOw">31,051</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WsnVoqdta0SqDA9Z3Yh5sQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_Rlkn2Lm3TUGA3EcHs-zFjw">44,787</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WxiupYvXpUCZcGSWCISs4A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_WCTCSylmFkufPyggQ82HpA">79,827</ix:nonFraction>k) related to delivery of research and development services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below) and (ii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ETMXkobFKEy02hSV09o2aw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_L6kawoZOiEuOtrNhHYJLtw">11,395</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_LlIbA19tekq2L6F9XYlTsg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_DzuYELJ08EOuQJnIY5mIHA">19,571</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_b7TNjQEttE2_PmjG1h3w9Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_1PIUHvpDUkSoNiWR3LRvaA">22,706</ix:nonFraction>k) from those research and development services considered distinct within the agreements and recognized revenues at point-in-time (iii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_d3CfPh5Ro06AwvuG4ee_dw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_AUCoNEXAj0uTx6VBJ9I4Ag">11,312</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_0BY17joY10aei1gwG_rArQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_i8xgRSJ5u06M6rJNcw9kMQ">3,062</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_beG4kI-_-EObUq60yy9jHQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_y3hesRd2iEyhqLiKALKzfw">457</ix:nonFraction>k) related to delivery of products.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont1" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlaxoSmithKline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2020, the Group entered a collaboration with GSK for the research, development, manufacture and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. In addition to an equity investment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_7_1_2020_To_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b2Vp5VUFV0ur7dOqZSCNYg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Narr_uuvTrs27rk-LLTfspUgh_w">150,000</ix:nonFraction>k as part of the 2020 Private Investment, GSK made a non-refundable upfront cash payment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_PzMUYFjEa0eknV1Blk-RFQ">120,000</ix:nonFraction>k which was deferred upon receipt and recognized as a contract liability. Additionally, the Group is eligible to receive a one-time reimbursable payment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" scale="3" id="Narr_fdngwfUmh0CNDro7LTF4YQ">30,000</ix:nonFraction>k for manufacturing capacity reservation, upon certification of CureVac&#8217;s commercial scale manufacturing facility currently under construction in Germany as well as to receive development and regulatory milestone payments of up to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" scale="3" id="Narr_bIEvY7SyIUKrSCjXcOufNg">320,000</ix:nonFraction>k, commercial milestone payments of up to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AmountEligibleToReceiveAsCommercialMilestonePayments" scale="3" id="Narr_JmJ9A_lldEutp8qN5DrWnw">380,000</ix:nonFraction>k and tiered royalties on product sales. GSK will fund R&amp;D activities incurred by CureVac related to the development projects covered by the collaboration. CureVac will be responsible for the research and development in collaboration with GSK up to the submission to authorities, after which GSK will be responsible, including commercialization. CureVac will be responsible for the manufacturing of the product candidates, including for commercialization, and will retain commercialization rights for selected countries for all product candidates. This contract consists of <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_7_1_2020_To_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b2Vp5VUFV0ur7dOqZSCNYg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfPerformanceObligations" scale="0" id="Narr_MxT3sbVLpUeBcUSNAKaRKw">two</ix:nonFraction> performance obligations. Performance obligation one consists of a combined performance where CureVac grants its customer a license which is bundled with research and development services relating to the technology. The group accounts for this as a single obligation overtime. The second performance obligation consists of research and development project work which is recognized over-time. The upfront payment, attributable to the IP license, is being recognized straight-line from the effective date of the collaboration agreement through to the agreed estimated submission date for authority approval. In the year ended December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_7Ew6bGtW7U-tbNE2PXrHEQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_TEW_0r7Ll0GoJydnNBMytw">27,740</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_iy1v_ExV0UmIJE_JDCu52A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_9CSGCp0ATkeX8C3c4rMEhw">41,379</ix:nonFraction>k) in revenue was recognized under the collaboration agreement with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. In 2023, less revenue was released than originally anticipated, due to changes of the estimated project timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, in April 2021, the Group entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches (&#8220;GSK COVID Products&#8221;), such as the CureVac&#8217;s second-generation COVID-19 vaccine candidate, CV2CoV. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September 2021. Pursuant to the amendment in September 2021, CureVac and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. CureVac and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by CureVac, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the GSK COVID Agreement, GSK has paid CureVac an upfront payment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_4_30_2021_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_Uqq6tqDywUKR7NfMQRtxqw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_3IyDDuom3UqZW9jxcOWhTg">75,000</ix:nonFraction>k in 2021. Under the terms of the 2020 GSK Agreement, CureVac granted GSK a worldwide exclusive, sublicensable (subject to certain conditions) license under certain of our intellectual property relating to vaccines and antibodies encoded by our proprietary mRNA targeting certain selected pathogens, or GSK Program Products, and a non-exclusive license under certain LNP technology to develop, manufacture and commercialize a certain number of such GSK Program Products for use in connection with the infectious diseases targeted under the 2020 GSK Agreement. CureVac also granted GSK an exclusive option, after a certain date, to obtain exclusive licenses to develop, manufacture and commercialize CVnCoV and boosters for such vaccine. CureVac and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. CureVac and GSK will share all net profits generated from sales of GSK COVID Products, other than certain products defined in the agreement as &#8220;Combination Products&#8221;, under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. This contract consists of a bundled performance obligation where CureVac grants its customer a license which is bundle with research and development services relating to the technology. The group accounts for this as a single obligation overtime. For the equally shared development costs CureVac accounts for the GSK share as a research and development expense and reimbursements from GSK for CureVac&#8217;s share are offset against research and development expense. CureVac is eligible to receive tiered royalty payments ranging from a low-teen percentage to a mid-teen percentage of net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement, CureVac has the right to commercialize GSK COVID Products in Austria, Germany and Switzerland and if CureVac exercises such right, CureVac&#8217;s sales of GSK COVID Products, other than Combination Products will be subject to the profit share and CureVac will be required to pay GSK a high-teen percentage royalty on net sales of all Combination Products in such countries. In the year ended December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_pZPakGLA-kuhoS52uwEr1w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_9xYep9YZNkexvUVeOm2ZOg">10,530</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_eY2mumkXxUm95YVOlQS_oA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_pLTM9EMEKk27lcixsaSLfQ">20,884</ix:nonFraction>k) in revenue was recognized under the GSK COVID Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont2" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Boehringer Ingelheim</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2014, the Group entered into an Exclusive Collaboration and License Agreement, which it refers to as the Boehringer Agreement, with Boehringer Ingelheim, whereby it granted Boehringer Ingelheim exclusive global rights for development and commercialization of its investigational therapeutic mRNA vaccine BI 1361849 (formerly CV9202) formulated with a legacy protamine technology. The Group received, in 2014, an upfront payment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_IkXEAQpU6E-CCqDrHRQ4QA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_SDILTMEiNEqDvYOBK3S3Lg">30,000</ix:nonFraction>K, as well as, an option fee payment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_8_1_2014_To_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_uR8Rb-zZ-0W5xnOW1rqrfQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OptionFeePayment" scale="3" id="Narr_zILOH24IYkWuZVPamMAv8w">5,000</ix:nonFraction>K and in 2018 an additional EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_8_1_2014_To_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_uR8Rb-zZ-0W5xnOW1rqrfQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionalDevelopmentMilestonePaymentsReceived" scale="3" id="Narr_YllUD57LXU2PiHFcbHkC5A">7,000</ix:nonFraction>K in development milestone payments, all of which are non-refundable and non-creditable in the event of expiry or termination of the agreement. In June 2021, Boehringer Ingelheim provided notice of its intention to terminate the Boehringer Agreement, with such termination to become effective on November 17, 2021. Upon termination of the Boehringer Agreement, the rights and licenses granted by the Group to Boehringer Ingelheim reverted back to the Group, provided that Boehringer Ingelheim has the right to sell off existing inventory of BI 1361849 for a certain period. In addition, Boehringer Ingelheim assigned to us all regulatory approvals or applications and grant us a non-exclusive, cost-free, perpetual and worldwide license to intellectual property held by Boehringer Ingelheim that has been used in the development, manufacture or commercialization of BI 1361849 or any other product developed under the Boehringer Agreement. As a result of the termination in 2021, the remaining contract liability, related to the upfront payment, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_UNDEvAgHeEiRXFi1vbQ4Ng" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" scale="3" id="Narr_W4oC6MSCRUWzENHzETA5YA">14,003</ix:nonFraction>k was recognized over a shorter period through the termination date. In addition, the option fee payment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_Tj5GLbNT3kSBwyxRAfJfVQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsOptionFeePaymentIncludedInContractLiabilities" scale="3" id="Narr_pl7tj6eUa0iWxx8kWzgv_w">5,000</ix:nonFraction>k and the additional EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_Tj5GLbNT3kSBwyxRAfJfVQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" scale="3" id="Narr_nUKwOW_36U-o56PWWtdyrg">7,000</ix:nonFraction>k development milestone were recognized in 2021. Therefore, for the year ended December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_UNDEvAgHeEiRXFi1vbQ4Ng" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_icw2KySuYUWzh0gDxkKmHw">0</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_MM2GgEv-80-KyXB__YMNuw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_tyH57qhOoUSaNhEGO1HtAg">0</ix:nonFraction>k, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember__cAQp-UsNEC2DWQx2cXz0Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_bHjSIs94fkqCsSjNEbdpuw">26,003</ix:nonFraction>k) was recognized related to this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRISPR Therapeutics Development and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2017, we entered into a Development and License Agreement with CRISPR Therapeutics, which, as amended by amendments entered into in June 2020 and in October 2023, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. CureVac and CRISPR confirmed to stop working on two programs under the CRISPR Therapeutics Agreement and added three new programs. CRISPR Therapeutics has paid us an upfront one-time technology access fee of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_11_30_2017_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_HShGdT13tU-b1m7Ylf054A" decimals="-6" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="6" id="Narr_J7nF-EGGJk-RELzBRU1CEQ">3</ix:nonFraction> million and certain additional amounts under the second amendment, which are recognized straight-line from the effective date of the collaboration agreement through to the date of market entry of a product developed under the agreement. In the year ended December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Z1OBdDkToEK9908Tmo7-Sg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_SS726DfhHECc_cWEZHz_vg">5,425</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_aZBsDHmyoEK9afaiu5dSRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_3-7XsUXtYUKaglSubymL6A">3,370</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Oxw0JrIpY0G78r49kJmAPQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_kiNyD8U8w0GLIHpmveC20g">919</ix:nonFraction>k) in revenue was recognized under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Genmab Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the Group entered into a Collaboration and License Agreement with Genmab, which we refer to as the Genmab Agreement, to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#8217;s proprietary antibody technology for the treatment of human diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, Genmab notified the Group of its intent to terminate the Genmab First Program under the Genmab Agreement effective in September 2023. Such termination did not terminate the Genmab Agreement in its entirety, but rather only with respect to certain license and exclusivity provisions related to the Genmab First Program. Under the Genmab Agreement, the Group further grants Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under CureVac&#8217;s mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In partial consideration for entering into the Genmab Agreement, in 2019 Genmab made a USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2019_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember__SZm_EveFkuat9TplxJ75w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr_jtFgZqe1ykaEpbrjmq2srw">20</ix:nonFraction> million equity investment and paid us an upfront fee of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2019_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember__SZm_EveFkuat9TplxJ75w" decimals="-6" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="6" id="Narr_IEZNVC1L_UCyaP6zPMZHiA">10</ix:nonFraction> million, which was recognized through the date of market entry of a product developed under the agreement until August 2023 (no recognition from September 2023 onwards). In the year ended December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_SxzE48-JZ0GVSklXpGPGZA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_ME4ZQmrmIkiMgfKgSPIXdA">1,197</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_Fzr32Hw5zkuxkQLHVRVGAQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_-aRb6CDx3kyROKzo4Slv5A">1,787</ix:nonFraction>k, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_rZxpRnG9XUK0LeJgU3D9Fg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_ZSHT778WSEG9aK2KFusIlg">1,770</ix:nonFraction>k) in revenue was recognized under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_3a66ma-IxUmlGRlKm6-NxA_1_4"></a><a id="Tc_5J1ODpIdN0ir4ZCEDojROA_2_2"></a><a id="Tc_ieHF9-02QkO8lsiKGdp9Nw_2_4"></a><a id="Tc_VIaHDcfKb02I4j4VuKl6Lw_2_8"></a><a id="Tc_kZkSrjd7ZUSCj9lWarTGuA_3_0"></a><a id="Tc_i5nFGhLwS06mk9Sbp3h3qQ_3_4"></a><a id="Tc_e6lFhOdc2Ey-yiWZ529ioA_3_6"></a><a id="Tc_LXG8tpRFl0y6JVcU1cODXQ_3_8"></a><a id="Tc_WLfZNZJbrEOgJfnCTW7zyg_3_10"></a><a id="Tc_rxZYNR4AjUWwc0VIdwilnQ_3_12"></a><a id="Tc_UowoA4_7pE-zL56eUEU6Tw_4_2"></a><a id="Tc_H_5WsDvJakmHtcJxtI0vaA_4_4"></a><a id="Tc_gde-nz67b0GumCYdlwJ3CQ_4_6"></a><a id="Tc_VERud3nl5EGJiY2ziZBnMQ_4_8"></a><a id="Tc_2C_g_b4qCk2-P5YClS4AWw_5_0"></a><a id="Tc_DU0CrLfG4UaguuvxBz9SsQ_5_2"></a><a id="Tc_RLYKj5Oa8E-cJq2h165VVw_6_0"></a><a id="Tc_nz9jkhsvM0Ww9ssuU3xEwg_6_2"></a><a id="Tc_BLe_9TQlK0e-gWoYuCuhzA_6_4"></a><a id="Tc_W0p6sVYeJ0GWB0Z6jkohtw_6_6"></a><a id="Tc_JKHPAv7lCE-fkH6UQPtIsw_6_10"></a><a id="Tc_sNss-Q7hzEKetfdK3-YdOg_6_12"></a><a id="Tc_l1JphlRqd0S4836vnngkWQ_7_0"></a><a id="Tc_X_cNOyuLGkCyZpZnZhOK-w_7_2"></a><a id="Tc_bkz-UL-Lc06lknhs4Ms52Q_8_0"></a><a id="Tc_uloPrx_pRE-NVB7YqK9iPg_8_2"></a><a id="Tc_21gnO15ubEaNd1Ic9v3r4w_9_0"></a><a id="Tc_UizE-y7MpUKIXBaBCza5Ug_1_2"></a><a id="Tc_RAhmCE_VOkqoGBfsZ0ki2g_1_4"></a><a id="Tc_uygY_RxUEkCQi07BYwJb9g_2_2"></a><a id="Tc_wRQ-MeapI0qT88LKU75LOw_2_4"></a><a id="Tc_b0L_t57eWUip_H4Ik1_9Tg_3_2"></a><a id="Tc_C7zJUVAwHkGnaKr6ALzwhg_3_4"></a><a id="Tc_QgFssZcoLE6byBLZlLqo5g_4_0"></a><a id="Tc_1V8HlKf1xEGnbWTjE5wa7Q_5_0"></a><a id="Tc_SZ_g7wCA30qwRl4G6v8m9A_6_0"></a><a id="Tc_RfDOyvbdB0m91JXxf7xhIg_1_2"></a><a id="Tc_6k9bo9kWlUi8_oDXo36jzQ_2_2"></a><a id="Tc_3mmoMwF9OUOoiqUhGAK7JA_2_4"></a><a id="Tc_wJfsMqp5i0OMzdnEwA9wwQ_3_2"></a><a id="Tc_5UlmIavetUuX3h8DfHPJew_3_4"></a><a id="Tc_gYfupDm_XU2LRo3RIlbxYA_4_0"></a><a id="Tc_fdavgkVDE0OSz5LgQgplww_5_0"></a><a id="Tc_hirHQpQapEG0yKL15Te9yw_6_0"></a><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont3" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period or upon termination of the agreement, when no services are provided anymore. Below is a summary of such payments and the related revenues recognized over-time:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="Tb_5G8AUmQg2kqy96_P5DvqdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:24.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract liabilities at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized&#160;from&#160;upfront and milestone&#160;payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b8EFZRIMq0WCtvwfKe4gIw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_8n30FeBV-EKPRLu-GV8-BA">220,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_nC4KCpY88UGym-D27dL6Fg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_TFYUABimN0WR_S4T6DsQcA_5_4">102,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b8EFZRIMq0WCtvwfKe4gIw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_SPhex_Xng0m0N-iv_UJe_g_5_6">88,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_EJnK4qeQukWwruVzej1OHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_2iTA2fTVBUa1vC1LrnwrBQ_5_8">51,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_dQAt4xUTeEa7rdqV3nh2dg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_2JbZeDN3V0GcCE8S3VGaCQ_5_10">42,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_VRui_vZPnUujh6ZiBB2PSA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_QUfYT1XL8UOS-IqeFG8vDg_5_12">29,089</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_HfoXp3Ph3E6zl6AvXTfb-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_Jea8Tf89BUqdf9jfS757JA">30,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_EHc6gwQXD0SOYI6THi9OXg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_jIpFMdlLX0CiF-artEZ46A_6_8">14,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_GOB91vcpXU60qIB1IbdNXA">10,000</ix:nonFraction> (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_SQaYkG7SAkWa54auJh-xfw">8,937</ix:nonFraction>) *</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_fV8dgKI9A0qDluOP4s-fcA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_q_M8ZNPLWkGLIvorktvXTA_7_4">3,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_yPsef0xOl06x0UOtN1k8ew_7_6">2,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3-k7Yjy3h0SK1bXLY0SdIA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_dyGE6rJmW0KyCAwVC-VjaA_7_8">1,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8UvD_28teUGxzHNuaZqFzg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_0G8_ZuPu60GwOPleEE7F3w_7_10">1,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_BjoLbqhzlEu6HrZ0ubsedQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_yeTzfgfWuEySAgySEKwCXw_7_12">1,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_Ti2oxCceIk2jNDXC_Dyqpw">4,500</ix:nonFraction> (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_nVQuKS3dhUGXU-dqJ0Bh4g">3,947</ix:nonFraction>)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_VDgvtxQGnUWTC1YHHYEPSQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_ohGi8gH3w0KRpXbjOSzsVg_8_4">929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_x6s7J1jJFkmBzTLtEKaZRw_8_6">1,582</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_zGcglSxVGUO78S8LUIsdFQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_9fw2a9G7iEKeYqXx6vuowA_8_8">310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_BtRutl2rT0KKDhuHIfebvQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_4-ocebYaq0-Oalfiv4X5sw_8_10">310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_yBPoJBQs-0OaTLvr_QnFFA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_1rIUZLdnmkeCwtH3CnaGyg_8_12">770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_CZ3BRhpvpkWS9sN4DW6Ouw_9_4">107,308</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_B3BM_VrsykqZYqVcKKY7Wg_9_6">92,680</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_XgEoocaX10WVhK_ij38Ukg_9_8">67,828</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_EkrAfLMm8U6WQAf-xp4HVA_9_10">44,787</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_LNHYLl-S3kex0CdpJvhlCA_9_12">31,051</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">*Translated at the currency exchange rate prevailing on the transaction date</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Contract balances:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="Tb_pI19jb36WEeXKFp6cO4Z0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_UYAdhzzVOkidkySM2ifOww_4_2">6,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_2MRNU2V98kiGS9GrKvlgWw_4_4">14,326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc__4lSMT49EU2aw08C6j2iZA_5_2">2,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc_aFdMNsq-WkyNBJs-Wv9Pgw_5_4">2,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_Pnq1UKNXgEq2oxeAv812xA_6_2">107,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_Aib7YnxJIkS19i4BRdNvzQ_6_4">92,680</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Contract liabilities include advances received from the Group&#8217;s license and collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" id="Tb_R0lLaepF4k6jPR9KKZ-ltA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" scale="3" id="Tc_oLj14qB7LUuJUwNg2cTxoA_4_2">34,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" scale="3" id="Tc_kApRhjcUtEapWTqmt1_mTQ_4_4">44,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">More than one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember_ihjeHuLIPk2tQ0IJ5csIrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" scale="3" id="Tc_R4BOCE7ZkkK9P5UuzlLiMA_5_2">72,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember__BM_BXDhyESvodEXrE5DVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" scale="3" id="Tc_F2t6KzOWY0KQnkQlZ5iaHA_5_4">48,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" scale="3" id="Tc_yzdTvQcjp0KWAzIjoSHZ6w_6_2">107,308</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" scale="3" id="Tc_5CoyuMfTqkagHzjWc9XRIg_6_4">92,680</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are non-interest bearing and are generally settled within 30 to 45 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Group had <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" scale="0" id="Narr_5pMKwyxcI0auW7EOH382Mw">two</ix:nonFraction> collaboration partners (2022: <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" scale="0" id="Narr_CrBxiFaFGkaxkxS2WE2llw">two</ix:nonFraction>) that owed 100% (2022: 100)% of all the receivables and contract assets outstanding. There were <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" scale="0" id="Narr_BQA5YNBJ8UyHts5cnsMzLQ">two</ix:nonFraction> collaboration partners (2022: <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" scale="0" id="Narr_UbrmoUbpGkqBEwVv-aubUw">one</ix:nonFraction>) with balances greater than 10% of the total amounts of receivable and contract assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a57e6c2d_85a8_49ce_b083_2cd0093d1b8c"></a><a id="Tc_MLNeqPICNUumB8e5WhpB1w_1_2"></a><a id="Tc_F4wTBH4SfkSfSSNeMe8fLA_1_4"></a><a id="Tc_-Dnk8_Ag3kuj-EaxJ0T6Uw_1_6"></a><a id="Tc_fKo9CdJs9UeoZXe7371Axw_2_2"></a><a id="Tc_mxE4nCAdEE2cAjNkLRdxkg_2_4"></a><a id="Tc_W1BIdfgjdEuNxJGVo6jjsw_2_6"></a><a id="Tc_6w5iLmjGeUark27evA_SNQ_3_0"></a><a id="Tc_tbjbqmSHaEKXMDmBH8GWRw_4_0"></a><a id="Tc_bkByOIhFGE6M_1iFFabHOA_5_0"></a><a id="Tc_Z_NejPEWOUiETBaSJOJXMA_6_0"></a><a id="Tc_UNWViEbPBEiYyQLi6bM3aA_7_0"></a><a id="Tc_VaEmu6lmaESJ5j_izBzC8Q_8_0"></a><a id="Tc_d6v0kYUkc0Kgdex5zWXMoQ_9_0"></a><a id="Tc_YGf_zkj-VkefCBLJF6Dlaw_10_0"></a><a id="_b8cc9470_7330_458c_a4e5_9e6eb4e16312"></a><a id="Tc_5bzzjT8h_UOXRglUMU-8Jg_1_2"></a><a id="Tc_Yfo2LaWLrUOKVrtxk2hn3w_1_4"></a><a id="Tc_z0IxnBmKj0qgKYiFyGNLrQ_1_6"></a><a id="Tc_kSS--AOJ-02tsFFGHcXsww_2_2"></a><a id="Tc_47eIQ3761UOSgOLR-IhyVg_2_4"></a><a id="Tc_lxYGYPfZhkeLYFerTXzB0Q_2_6"></a><a id="Tc_7SPrJ0m4DU2_1_2LtGs-cA_3_0"></a><a id="Tc_N4SHcSIb2U-Czf3Cfyeq0A_4_0"></a><a id="Tc_3ApWUbYVb0WcRhZGA1gv3g_5_0"></a><a id="Tc_SXaFv_9Ne0O_OORT30gp5Q_6_0"></a><a id="Tc_zeOY6XvpT0m130lu8vFl2g_7_0"></a><a id="_7ed042bf_5bb6_4c25_90ed_255d0d66ff45"></a><a id="Tc_5EgGlAnPf0idqT5HszYkhQ_1_2"></a><a id="Tc_T1BL54tPOUW8x67ITKxIbA_1_4"></a><a id="Tc_sE8MT0-g6EKlf5UXDfb9Mw_1_6"></a><a id="Tc_o3cF-Rl2YEiF71hFEfpJUQ_2_2"></a><a id="Tc_tONuKlNl-kuY0uX_X1pm6Q_2_4"></a><a id="Tc_PnAzY_O-HEmUwg4VUwyyaA_2_6"></a><a id="Tc_GmJnt0_tUkC8c7FrJSrbMw_3_0"></a><a id="Tc_IHOvvsKXXE-DAig0iZWXAQ_4_0"></a><a id="Tc_wm1j6uUJhkC6ZzEoAWLCXQ_5_0"></a><a id="Tc_zTujUIgfjUyNGbV2UUFw5A_6_0"></a><a id="Tc_s8HNDSwyTkecIgYsS1tf_g_7_0"></a><a id="Tc_wbdNZh_sLESMqOOOB-Bxzw_8_0"></a><a id="Tc_bAzmKRKZHU-mTDpT1BEUyw_9_0"></a><a id="Tc_Wp_x4JZhCEOS1I5SEb-ROA_10_0"></a><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont4" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The nature of expenses recognized in the functional categories of the statement of operations are as follows:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="Group_LwtXsnMciUCqqZu7eH8ELA" continuedAt="Group_LwtXsnMciUCqqZu7eH8ELA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_AZx7f0emFUmAlTMe7BpaQQ_3_2">22,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_p7cNWxPmbUS6D3PGZRNRBg_3_4">27,185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_IlzhbjJXTkGcRCGiEN7Xsg_3_6">37,734</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_4saV7DxKHE6sWyvvr993IQ_4_2">46,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_RF8t3Y-6qUOIl0E2HtXDtg_4_4">88,891</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_W5rjb2KIJECdVfpA9Ud2Aw_4_6">59,641</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_BGnS-DlM2EyNRIpSiUmOww_5_2">139,975</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_03If7Ooh4ky4M9X_PUKENw_5_4">32,331</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_o047g8-oBkGbaVQhjfXFsw_5_6">9,398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_F9jq5mRFNUe02PjgRV8Wng_6_2">2,874</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_vSUKL9_58E68pajVbA0W_A_6_4">2,425</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_-pI5_S3ZXkS2ulDnzHBB2A_6_6">2,672</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_9NmwIXdgGk21ogzLnOYYlQ_7_2">3,992</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_fm6XkLBMJUi0l27pUSLsAA_7_4">6,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_iygTgcCf_0Snh0OaxqiL3w_7_6">4,850</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" id="Tc_1eS2IU-2XkuLIasgJcNFtw_8_2">22,810</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" id="Tc_VLgX9Ofvnk2a3kdIBSi4Xg_8_4">24,948</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" id="Tc_WV0KiE6EnEKHW8ORkIXTsQ_8_6">8,085</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_I07WFhKOLUKxJGTK4O7Ugg_9_2">135</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_6G9f-nKiEkyoBuNJqly0KQ_9_4">1,918</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_106ZB72Uxkmu6_Sz90_8iA_9_6">1,986</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_sK45siVg8k6wHgZtG39mHA_10_2">238,195</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_-SWgJ1H93Eqp7ICrg9iZXg_10_4">183,993</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_vu9F9QdDf06aN0kl7AbBWg_10_6">124,366</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, cost of sales mainly decreased compared to the same period of 2022 due to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them (refer to Note 6 for further information). Additionally, in the prior year, the Company recognized a higher impairment of assets held for sale (refer to Note 5 for further information). Personnel expenses increased mainly due to increased workforce in the manufacturing organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><ix:continuation id="Group_LwtXsnMciUCqqZu7eH8ELA_2" continuedAt="Group_LwtXsnMciUCqqZu7eH8ELA_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_u8f3oop4gkK5wg-yKu7eWw_3_2">1,369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_nTfaK9gE-U6e5BaRSAEePg_3_4">2,029</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_l6nxgMwJvku-xQ2AmbB4tA_3_6">3,425</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_CbArIvCJ_Ua7iicCP_QzZg_4_2">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_JOaPzJwhhki4k7Y1dFNa4w_4_4">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_qxKgvTw4qk-QFBJQ1omslw_4_6">45</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_wO7LDLIUd0yHgwPjd8piGQ_5_2">86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_BhOEKn3zzUyUJn8aX-o-BA_5_4">336</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_FQ0B8lZ5jUOEdPEsfucRog_5_6">18</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_QhCU2O_hCkOjrJm-0jV57w_6_2">287</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_TTaggNPNXUWGt1Q7DUX4cQ_6_4">417</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_yt_h6PlfIUmq-IUmnUm-Fg_6_6">424</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_zo8uAdR31UeV74ht0elIaQ_7_2">1,743</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_GYx-XZTPwUqJFoSVLJXQaA_7_4">2,817</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_ZBWBgebFnUmd1-Q6ebA4fQ_7_6">3,912</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, selling and distribution expenses increased compared to the same period of 2022. The increase was primarily attributable to higher personnel expenses mainly related to the satellite offices in Belgium and the US.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development (R&amp;D) expenses</span></p><ix:continuation id="Group_LwtXsnMciUCqqZu7eH8ELA_3" continuedAt="Group_LwtXsnMciUCqqZu7eH8ELA_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">R&amp;D expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_azF26qTB5UC_8NloPoffuw_3_2">232,292</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_L0KUjZutm0KXgt62OfwMdA_3_4">32,982</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_nMF-ghd2Tk6eyKlphKxW7A_3_6">19,126</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_Lyi0gi4KOUm1iLFDb9Fg2g_4_2">33,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_rmfwUYiSzUSBZeqabWpcjw_4_4">33,944</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_PpIjBu49XEmVYG-wlW2zgA_4_6">43,267</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_oJHFW2AIWEGk1zsxyluPkg_5_2">4,259</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_wVjFChlyekCC1-Z09jYNsw_5_4">8,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_hXSIdjyqREe2-9YDxTtGdg_5_6">8,539</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_UYP3sLnd5EGwQq9Mv6lIqA_6_2">3,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_EyMCn0TbPE2k_pNePMF_GA_6_4">3,813</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_Cq42S9HAQ02nJdYNRS4F2w_6_6">6,666</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_56-eW5OweE2we8jUCgvVRw_7_2">539,786</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" sign="-" scale="3" id="Tc_eKPKasBx0Eir8uJTe_mm_g_7_4">20,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_y6A9fMvhBkiwtMIvWIkGyw_7_6">28,587</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_jOFTo8LWeEaSkhpXF2hhLg_8_2">347</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_cSGilp7fZ0u9TwLuKpeujA_8_4">1,069</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_p7uu8uYXhkKieoyHYsZwSw_8_6">7,287</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_5m5SjAbIMk68lAcJSXZyjg_9_2">2,291</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_6Xhu7MUdAE6bQeroHwoJxA_9_4">2,591</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_pkMlKGlvkEaIdF9HB5jrnQ_9_6">2,252</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_bpmQaEVHoEuy4B9ylzKivA_10_2">815,907</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_MH85bdyhlU6rgljqapbGdg_10_4">62,550</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_9Kusb-6P0EKeIVIq7NGMgQ_10_6">115,724</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During the year ended December 31, 2023, research and development expenses increased significantly in comparison to the same period of 2022, as the prior period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4327f95d_500a_46c4_8df7_d7cca2e714e3"></a><a id="Tc_3Olu0_0RIU6VRRFvsezsBw_1_2"></a><a id="Tc_6R0JlXkY9kS5BnTYcrYu_g_1_4"></a><a id="Tc_6H0IM30OREiieRbmmsXvAg_1_6"></a><a id="Tc_fsPV_JEa_UOrqM2mlt7Wgg_2_2"></a><a id="Tc_FrTl22uRy0q2H7JFaM_cXA_2_4"></a><a id="Tc_LPM2i-Lxn0KiGgXRo4DZ2Q_2_6"></a><a id="Tc_3Ry5sfdzpEKL_596FdHFVg_3_0"></a><a id="Tc__40tlZe9GkW28Qd-er2AFQ_4_0"></a><a id="Tc_OROifwtIBEKBNO0rmDVt6w_5_0"></a><a id="Tc_jfq9VUr0GkqFJR8qISEnfw_6_0"></a><a id="Tc_ek1IEj9fAEeNAP7UzqK04g_7_0"></a><a id="Tc_J4HA4Ktq1k2PWRtKDbUTrA_8_0"></a><a id="Tc_7dD6SzH5MkqvinpY7Jz9fA_9_0"></a><a id="_05e3b312_fa76_44c9_a018_49e1d2bfdc9d"></a><a id="Tc_LAG16KwEVkWzwvnv3fXM9Q_1_2"></a><a id="Tc_vxVeugFRu0SGI23B-Phq9A_1_4"></a><a id="Tc_Jqlm2Ta2VE-3RnzP3b9wqg_1_6"></a><a id="Tc_F6ioukdinEC-WiTGwdVqZw_2_2"></a><a id="Tc_Oc9yVeyViUGFHbb8dm5_rA_2_4"></a><a id="Tc_Q2yzityXZ0SJJ7YkVkOeCg_2_6"></a><a id="Tc_40PN-JZ_1k26glq2pZtzOQ_3_0"></a><a id="Tc_Ix0pP77UMUmTwesXwj_0iA_4_0"></a><a id="Tc_do0lkjvxoUyShuPff2cnUw_5_0"></a><a id="Tc_Ky1TFbuN-EGDRpeDcrW9NA_6_0"></a><a id="Tc_gGJjP_hQWke6OiBat6EFaQ_7_0"></a><a id="Tc_7OhHEsj5hkqK9KJZJg-FhQ_8_0"></a><a id="Tc_pC5Dk4MbLUe6oevkaWl9Hg_9_0"></a><a id="Tc_hl-3_Cppv0yZB5DHGnSzfw_10_0"></a><a id="Tc_f7SES7gMAUq-PZ0cSYGcBA_11_0"></a><a id="Tc_T3GYmXkJn06zLsw-fdJ6tQ_12_0"></a><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont5" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_q_UBt-6xnEai2whg5OLb5Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReversalOfProvisionForOnerousContracts" scale="3" id="Narr_rYFdEAaVb0iAU2YWonnK-Q">38,533</ix:nonFraction>k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group&#8217;s committed capacity at Novartis (see Note 3.8 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_q_UBt-6xnEai2whg5OLb5Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsProvisionForLossOnContracts" scale="3" id="Narr_IFjl0-Z5T0ygIFKEfeH27Q">25,059</ix:nonFraction>k. The net effect of these two events resulted in an overall gain within the Third-party services category. The period of 2021 was largely impacted by the Group&#180;s CVnCoV program. These expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception through December 31, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from the German Federal Ministry of Education and Research (Bundesministerium f&#252;r Bildung und Forschung, or BMBF), the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.7 for more information on amounts recognized from this grant in the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period (refer to Note 10 for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><ix:continuation id="Group_LwtXsnMciUCqqZu7eH8ELA_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">General and administrative expenses include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_hi6H4x8qcEWNpm88c_zgjg_3_2">37,393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_2U94WxfzXkOxfZgFfJUnpQ_3_4">36,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_fBz_rxHR70yVnpbn6DW-NQ_3_6">28,996</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_iZwMiiQ5vUKKT7IptitUGQ_4_2">4,306</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_89pAP-qyckyIg3Vy_jddyQ_4_4">5,853</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_K2KE8VCH7kaJfKO89ydS-g_4_6">5,353</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_m3YKzqePK0KIJYPpwQceLA_5_2">28,875</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_Dk2DFw4AS0Ckvqqz3M84aQ_5_4">27,669</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_yU-Cgxr74EOEdd8_XVpI8Q_5_6">29,920</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_dpZrGQXa60-vehf6LlP3Xw_6_2">9,230</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_jSdeSrmaSUS9rV8zSzVLiA_6_4">10,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_nCC26czCQkeylT0-VCfqag_6_6">10,160</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_ODHCc5e1wEiIf25qJ0q9Wg_7_2">8,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_PEs2DO2gzEq0VhHO2MN1Zw_7_4">11,360</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_d1AYXowyVkmESXxVn4DvnA_7_6">13,821</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_Qzzp5FH0sEWfGl7IfWkRiQ_8_2">11,703</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_hksEAnwwKEWllkoq1ee_0Q_8_4">12,137</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_L0cmU6urDEmmBZcU8ZUnPg_8_6">3,508</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_dRZcSZVDTE-LC5W7s58r7A_9_2">100,402</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_8rOy2b5Mn0arFRa9IWBxzQ_9_4">104,178</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_0IoZLKxL2kGP79LsvGlD8A_9_6">91,758</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, general and administrative expenses decreased in comparison to the same period of 2022. The decrease was primarily attributable to less personnel expenses due to lower workforce in the corporate service functions. Others include mainly expenses for D&amp;O insurance and allocations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Expenses by nature</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="Tb_PCXqPT01rk6y5AkVera5AA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nature of the expenses is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_WQo6Cuk8CUahC9gcyQOCBw_3_2">94,655</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_F6CmkqMOjkOOQFicKoVijw_3_4">99,924</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_eVPjcw9weEW8f4s_AkFkAA_3_6">113,422</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_VkGXgeYV7kChGe9OHGNqeQ_4_2">278,542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_AlrSSCNVhkazwvu3fNUEUQ_4_4">121,873</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_E2hEHGk8V0y09hhdIHgoGw_4_6">78,767</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_YpvUnJ3_wE-J9-1I-j-_kA_5_2">708,636</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_3VV9FxPCZUSQOjwcf493eA_5_4">39,501</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_kvYSCbak3UKHPmhHseOJGw_5_6">67,905</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_khvHydw370aLuJ0Uh0GZqg_6_2">7,528</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_Sxs49JphN0OOLoRnHsRXSg_6_4">9,381</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_Q-g_7cZEwEKDxtuuHXSbzg_6_6">15,356</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_LmlkFQP-yUOR9aHwmNg6sA_7_2">17,232</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_7peIeNcsjEWf56Rnh882Qw_7_4">26,641</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_AJW1N4tuzUOV-vwzklXFKg_7_6">27,229</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" id="Tc_Qs0amL_q3keSxjcGnku_fg_8_2">22,810</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" id="Tc_KyKQV6TeB0uQ1YK3NpIjQg_8_4">24,948</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" id="Tc_8p1NvQxugkixIj7XiD7BzQ_8_6">8,085</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_3YWQxAw4IUO0HHsau5uyHA_9_2">3,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_ypzOqwA8okuo11-Un9hIwg_9_4">3,813</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_czdBMFL0yEumePBdZ8Kvww_9_6">6,666</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_2NF2FQQ4_kuHTRbElTwt1A_10_2">9,230</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_gyWyTx4PNk2geGeQ1JNlwA_10_4">10,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_VshZIlK4LEmscIvHRCVkAw_10_6">10,160</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_QhH9Dj3meUCTPSnLqOOpFw_11_2">14,415</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_Z7oUGLYve0WkIMg1tJTVUg_11_4">17,064</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_KvF54vMtNU-UT9cr3mpeYg_11_6">8,170</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_2-ObkWeYYkapvdaWNYN31A_12_2">1,156,247</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_PXV4gpBCyEG20X5V0ADLqQ_12_4">353,539</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_a10nLrmj-EeUuGT_uGk8-g_12_6">335,760</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We refer to Notes 3.2 - 3.5 for additional information.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont6" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.7. Income from release of governmental contract liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the withdrawal of the EMA regulatory approval application for CVnCoV, in October 2021, CureVac recorded in 2021 &#8220;Income from release of governmental contract liabilities&#8221; amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_10_1_2021_To_10_31_2021_a1WmAXnod02XXfLywgY6XA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_REjB00mQYUulfd5skFLFtQ">574,502</ix:nonFraction>k, which is explained further below. There was no such event in 2022 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Advance Purchase Agreement with European Commission </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2020, CureVac entered into an Advance Purchase Agreement (APA) with the European Commission (EC), acting on behalf and in the name of all Member States of the European Union. The APA provided for the advance purchase by the Member States of <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_11_1_2020_To_11_30_2020_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_dBuLkJzR8UGZKxJeLbvRJQ" decimals="-6" format="ixt:numdotdecimal" name="cvac:NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" scale="6" id="Narr_LYy43hTYyku8fyvAtBAKyg">225</ix:nonFraction> million doses of our SARS-CoV-2 vaccine. In order to support our accelerated efforts to develop a safe and effective vaccine, the APA provided support to our operations in the form of up-front payments. The first up-front payment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_11_1_2020_To_11_30_2020_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_dBuLkJzR8UGZKxJeLbvRJQ" decimals="-6" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentReceived" scale="6" id="Narr_NPIhA8vyQUONkAwqLstrpA">450</ix:nonFraction> million was paid by the EC on behalf of the Member States and was included in contract liabilities as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The second up-front payment would have had been due after the submission of the interim data package to the EMA in view of obtaining EC marketing authorization for CVnCoV. The up-front payments were designed to support the development and prepare the commercial supply of the vaccine. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would return the unspent amount of the up-front payment. In the context of the APA, &#8220;spent&#8221; means either costs occurred, or commitments made in relation to the purpose as set out in the APA. CureVac demonstrated that the up-front payment was used in accordance with the contract and <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_UkHTlmAHJkSss_TraYDEdw" decimals="-3" format="ixt-sec:numwordsen" name="cvac:MaximumGrantToBeReceived" scale="3" id="Narr_7myTAuk3-EOfwfR_CWUYUA">no</ix:nonFraction> repayment was required. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described above, CureVac recognized the consideration related to its delivery obligations, existing at the outset of the arrangement, as contract liabilities. Upon the automatic termination of the APA, the ability for CureVac to satisfy the contractual performance obligations of the arrangement ceased and the EC ceased to have the ability to exercise its rights for performance by the CureVac. As such, the substance of the arrangement changed from a revenue contract to that of a government grant. Due to the material magnitude of the amount, its non-recurring nature and to better enable comparability to past performance and predictability of future performance, CureVac recognized the EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_1VRD647OiE6jHdJLTQ7IRQ" decimals="-6" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentReceived" scale="6" id="Narr_Dhj0Uix9hUKHEe6D0DQu9w">450</ix:nonFraction> million into income in an additional line item &#8220;Income from release of governmental contract liabilities&#8221; in the 2021 statement of operations. The &#8220;spent&#8221; amounts incurred by CureVac, and which demonstrate use of the up-front payment, have been included in &#8220;Research and development expenses&#8221; (refer to Note 3.4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, CureVac was required to transfer, upon EC&#8217;s request any raw material and primary components paid for with the up-front payment and not used as of the termination date. Should the EC request any raw material and primary components or should CureVac successfully sell some of these, an applicable portion of raw material, primary components or proceeds would be remitted to the EC. This agreement expired at the end of 2022 and an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_pfMi8wn3EkWe1O0Rx8uvnQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:AccruedOtherLiabilityForUpFrontPayment" scale="3" id="Narr_D47IKXH8SkGfHxIKCbJP9g">4,114</ix:nonFraction>k was accrued as &#8216;other liabilities&#8217; as of December 31, 2022 for the related amount due to be remitted to the EC. As of December 31, 2023, the accrued amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_PqOHXw2W70SLtVHUTZnIIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" scale="3" id="Narr_9MAI3pvdoU-QHSMEqJRh_w">4,114</ix:nonFraction>k was paid to the EC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">German Federal Ministry of Education and Research </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company announced that the German Federal Ministry of Education and Research (Bundesministerium f&#252;r Bildung und Forschung), or BMBF, a German government-related entity,had established a grant to support the development and production of its COVID-19 vaccine candidates. In July 2020, CureVac applied for this grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2. The grant amounted up to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_7_31_2020_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zETrLnvnJU-bFHQhtWzRHA" decimals="-6" format="ixt:numdotdecimal" name="cvac:MaximumGrantToBeReceived" scale="6" id="Narr_IzPzINZXL0y7Y633SC2xXA">252</ix:nonFraction> million and the payments were contingent to reaching predefined milestones. Based on the terms and conditions of the arrangement, the Company assessed the arrangement as having two components: a grant component and a supply component which were separated. The amount attributed to the supply of future deliveries was determined based on the relative stand-alone selling price of the vaccine observed in similar arrangements and is presented in contract liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company reached all the predefined milestones for 2020. Due to the withdrawal of the EMA regulatory approval application for CVnCoV in October 2021, CureVac was not able to reach all predefined milestones in 2021. From 2020 to December 2021, CureVac received a total of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2020_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_3vgagNoi6kSQIXzMaP-lig" decimals="-5" format="ixt:numdotdecimal" name="cvac:IfrsMilestonePaymentReceived" scale="6" id="Narr_RJ3w0sTvwEWACEJ7xD5ulQ">196.3</ix:nonFraction> million. In November 2021, CureVac notified BMG of the inability to supply CVnCoV, triggering the automatic termination of the supply agreement. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_qgnbrxqzAUqknbvbbC3w3A_1_2"></a><a id="Tc_-3mKnJKYTUCG3s6wBvgsVg_1_4"></a><a id="Tc_LgXSNoibsUeQQfd8Yvjl3Q_1_6"></a><a id="Tc_No0Ai40kpkeFOaGjkPRfsg_2_2"></a><a id="Tc_k9WU1JURCkmVNpEVVYLMWQ_2_4"></a><a id="Tc_ApDGq2P_dkmRtCdQj_vlgg_2_6"></a><a id="Tc_EM9HgsRpT0uZkzBlZzRdFw_3_0"></a><a id="Tc_TH6g2FLNGkGaOeeYVGHJ5w_3_2"></a><a id="Tc_iw-GBSyTI0CiVEqLXg8Ewg_4_0"></a><a id="Tc_MyDM49ry7UWJxlJPZzgVlQ_4_2"></a><a id="Tc_aNa5mrSG_Ee6L8ybTW_8nQ_5_0"></a><a id="Tc__jVX5Jo-r0yvhBdqMF9v5g_5_2"></a><a id="Tc_lzMA-HKNIEutcy3QfpsXKQ_6_0"></a><a id="Tc_E9uypH_NHEaZ-Ip8abGPAw_7_0"></a><a id="Tc_rvuK20KHKEyxp7I4R7A6-A_8_0"></a><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont7" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with the rationale and treatment described above under the APA with the EC, the substance of the supply component of the BMBF arrangement changed from a revenue contract to that of a government grant and thus, consistent with the presentation of the contract liabilities under the APA, CureVac recognized the EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BundesministeriumFurBildungUndForschungMember_Bwm_0zYqGkqkxhjgUSGCYQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="6" id="Narr_DJ4uyUegi0m-d-7qEMA5CQ">124</ix:nonFraction> million in 2021 from the BMBF agreement as income in the line item &#8220;Income from release of governmental contract liabilities&#8221; and the corresponding expenses have been included in research and development expenses. The remaining amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_qyWBhjwBlkKQHtJUuv5N4g" decimals="-6" format="ixt:numdotdecimal" name="cvac:IfrsRemainingGrantIncome" scale="6" id="Narr_yrerR5t5lkin5m2AtUTkrw">65</ix:nonFraction> million, not related to the supply component, was reflected as grant income in &#8220;other operating income&#8221; in 2021. (Refer to Note 3.8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.8 Other operating income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Other operating income relates to:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="Tb_TqJ5BJYuh06EybXTGE1AUQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation for CMO/Materials transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_vjBdfCmUCkaI8cxojxWGzQ_3_4">35,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_yQI4W9EsgUi8EB4mpWS2lQ_3_6">2,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:CostOfReimbursementClaim" scale="3" id="Tc_rhX8xOI5U0eMp132Wqnl5w_4_4">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CostOfReimbursementClaim" scale="3" id="Tc_EEu1yMFiPk6VKQxjG1zlEQ_4_6">860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:SaleOfEquipment" scale="3" id="Tc_sr6lXJFDOESpwShIqyW8lw_5_4">785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:SaleOfEquipment" scale="3" id="Tc_UOO3uVGb8kGj7FVD60MG0A_5_6">1,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grants and other reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_SIRG2U9QAU-3TTZtjrWEag_6_2">66,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_c0bARPuaeEKCaxpq6xx-Sw_6_4">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_7QEfF3onkE-MYbLTilEHXw_6_6">3,566</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_6aJQSjirSkeU2YRo3jEPhA_7_2">1,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_YpZj_x17Y02-zzujkleRrg_7_4">704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_fwuP64Es1k-31ZEsuk7jqg_7_6">1,101</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_WIaGeK5hhE-ZqX6mp4QZxw_8_2">67,702</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_yX9--gqDpkucuflsmvgUXw_8_4">37,932</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_7an2u6XyL0uqXHuVQSIwdQ_8_6">9,151</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac AG and GSK amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exited its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensation mainly consists of consideration for set-up activities undertaken by CureVac (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_UJYAD019cUGBDnGIwVIvFQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" scale="3" id="Narr_mnRmtZIAJEK3c-QBlrsPVg">20,500</ix:nonFraction>k) and for reimbursement of prepayments (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_UJYAD019cUGBDnGIwVIvFQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" scale="3" id="Narr_rqBSUa2raUu1duZTq94tEg">12,000</ix:nonFraction>k), which were recognized in &#8216;Compensation for CMO/Materials transfer&#8217; in other operating income during the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2023, 2022 and 2021 income from grants with government agencies and similar bodies resulted from the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">German Federal Ministry of Education and Research</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 3.7, in 2020 the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The Group recognized grant income of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_qyWBhjwBlkKQHtJUuv5N4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_bozyeBVIf0i9y2AAYiha3g">65,218</ix:nonFraction>k from this grant. As the grant ended in 2021, <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_M57Dz1YMN0mNMaEnjl265w" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_W8r3ht3CfUeqTnGv2eo7xw"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_q_oIdOGpA0Sek6pDPz5Now" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_5pJfqLjp30SPF0FHYg9X5Q">no</ix:nonFraction></ix:nonFraction> such income was recognized in 2022 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, CureVac has been granted the positive research allowance notice by the German Federal Ministry of Education and Research for the years 2020 - 2026. The research allowance is an instrument that provides tax relief for research expenditure by companies subject to tax in Germany - regardless of size, legal form and sector - and is intended to create incentives to invest in R&amp;D. During the year ended December 31, 2023 the Group recognized EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_cvac_IfrsIncomeStatementLocationAxis_cvac_MiscellaneousOtherOperatingIncomeMember_cpxyNogu7kOQwMXm7EojUQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsRemainingGrantIncome" scale="3" id="Narr_iGKXWq3_oU2oUyZfpIJXyw">3,064</ix:nonFraction>k for R&amp;D projects as other operating income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coalition for Epidemic Preparedness Innovations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Coalition for Epidemic Preparedness Innovations (CEPI) is an innovative partnership between public, private, philanthropic, and civil organizations, launched at the World Economic Forum in Davos in 2017, to develop vaccines to stop future epidemics. CEPI&#8217;s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (i.e., Disease X).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, CureVac entered into a partnership agreement worth up to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_nQQb4IPGNkaNHOnRJ9HnPw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PartnershipAgreementMaximumAmount" scale="3" id="Narr_fS33VVTaAES9Rog0arsmBA">34,000</ix:nonFraction>k with CEPI to further develop CureVac&#8217;s The RNA Printer&#8482; prototype. Under the <ix:nonNumeric contextRef="Duration_2_1_2019_To_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_v2GiAszp-UioMADTqx2Ctg" format="ixt-sec:durwordsen" name="cvac:PartnershipAgreementTerm" id="Narr_d5codZSJVEuJevyvPmV23g">three-year </ix:nonNumeric>partnership agreement, CureVac used its mRNA platform for the preclinical development of a Lassa virus vaccine (a high-priority disease on the World Health Organization R&amp;D list), a yellow fever vaccine and CureVac&#8217;s rabies virus vaccine. Funds are received semi-annually in advance, to cover costs for the next <ix:nonNumeric contextRef="Duration_2_1_2019_To_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_v2GiAszp-UioMADTqx2Ctg" format="ixt-sec:durwordsen" name="cvac:PartnershipAgreementPeriodOfCostsToBeCovered" id="Narr_Eujj5ZQ7oUahUnQFXuSjmg">six&#160;months</ix:nonNumeric>. These payments are allocated to the agreed and signed statements of work. Management concluded that the arrangement should be accounted for by analogy to IAS 20.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont8" continuedAt="Tb_eXNajj7K5E23MRE8ailPlQ_cont9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is required to use reasonable efforts to achieve certain development milestones and is responsible for conducting certain clinical trials. In the event of an infectious disease outbreak, where such outbreak can be addressed by a Lassa virus, SARS-CoV-2 or future vaccine developed under the agreement, CureVac must manufacture such vaccine for use in the area affected by the outbreak on economic terms that satisfy CEPI&#8217;s equitable access guidelines or otherwise allow CEPI or a third party to supply such vaccine in the affected area.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is required to grant certain approved manufacturers all necessary rights to use certain of CureVac&#8217;s pre-existing IP and IP developed under the CEPI Agreement to further develop CureVac&#8217;s automation solution and manufacture products for the treatment of certain diseases in geographic areas where there is an outbreak on economic terms that satisfy CEPI&#8217;s equitable access guidelines. CureVac must provide all necessary commercially reasonable support to such approved manufacturers to facilitate such efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac solely owns all IP developed under the CEPI Agreement but is required to obtain CEPI&#8217;s consent prior to exploiting any IP developed under the CEPI Agreement if such exploitation is in conflict with or goes against CEPI&#180;s mission or policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that CEPI terminates the agreement, CureVac will grant CEPI a license under CureVac&#8217;s background IP and IP developed under the agreement to, among other things, develop and use CureVac&#8217;s RNA Printer for use in treating certain infectious diseases and to manufacture products developed under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2020, CureVac and CEPI entered a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_0NzIZ6BiH0K-Yg0H0gY9Ww" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaximumGrantToBeReceived" scale="3" id="Narr_NCxt92rpR0emRnPc1Sy8Sg">8,300</ix:nonFraction>k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_wT00lKBxs0KIgm-oIxqE4Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaximumGrantToBeReceived" scale="3" id="Narr_8oH0Ff4arUqkWoPPgoaREg">15,300</ix:nonFraction>k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, CureVac recognized the reimbursement of approved expenses of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_XKUaAnV49EWl3jd-hAE8eg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReimbursementOfApprovedExpenses" scale="3" id="Narr_GPY91mQyJ0-i7IqRvCawjg">3</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_lDAMCnCC90O3RpaIsg3kZA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReimbursementOfApprovedExpenses" scale="3" id="Narr_0uw8oEE9akWllHdagmjDxA">42</ix:nonFraction>k; 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_6nW0xhgNC0mT9D42Qi4zog" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReimbursementOfApprovedExpenses" scale="3" id="Narr_CMMrhNAy4kG2s5bZqU_XwQ">688</ix:nonFraction>k) as &#8220;other operating income&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_xc2cFeX11U6brkADl8elRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_DjFKcta51EWAbhra_CQfqA">305</ix:nonFraction>k in grant funds received have been deferred and are presented within other liabilities (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_cyOGw2ND4EOXxVCS45Rnhg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_d2OMUwwOUkWi5q6cy-E6jw">309</ix:nonFraction>k). Following the completion of the partnership agreement of February 2019 between CureVac and CEPI in May 2022, CEPI requested a partial reimbursement of the unspent funds up to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_XKUaAnV49EWl3jd-hAE8eg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaximumUnspentFundsReimbursable" scale="3" id="Narr_UTWdvUU6-06ePQn_ncMHCA">1,000</ix:nonFraction>k. Those were reclassified from other liabilities to trade and other payables as of December 31, 2022. As of December 31, 2023, these unspent funds were repaid to CEPI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bill &amp; Melinda Gates Foundation (BMGF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BMGF finances, in the form of grants, various programs that CureVac operates for the development of vaccines, hence promoting and accelerating the development of CureVac&#8217;s technology platform. Through its equity investment, BMGF supports mainly the development of CureVac&#8217;s technology platform including the construction of a production plant in accordance with the GMP (Good Manufacturing Practice) standard on an industrial scale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2015, CureVac entered into a Global Access Commitments Agreement with the Bill &amp; Melinda Gates Foundation pursuant to which the Company is required to take certain actions to support the Bill &amp; Melinda Gates Foundation&#8217;s mission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2016, in connection with the Global Access Agreement, CureVac received a grant of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_11_1_2016_To_11_30_2016_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_WgEgi6NaVEWkMFit_-JGNA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_ifvjgCscVkGo-G2wEGAbrA">653</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_11_1_2016_To_11_30_2016_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_WgEgi6NaVEWkMFit_-JGNA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_iIvGBN9mD0Sh60DRVYlbGQ">614</ix:nonFraction>k) in funding for the development of a vaccine for picornaviruses. In November&#160;2017, also in connection with the Global Access Agreement, the company received <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_L61lR4DVa0KvyH4imXbLGw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfAdditionalGrantsReceived" scale="0" id="Narr_I5xQNzNyaUylZldsj4l5pg">two</ix:nonFraction> additional grants: an amount of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_Wh8p0VKIT0O3NgVdxK2fOQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_3gfLb3JJe0up5TEge1mOrg">1,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_Wh8p0VKIT0O3NgVdxK2fOQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_jS3NemFyUU2vvAueOq8obQ">852</ix:nonFraction>k) was received for the development of a universal influenza vaccine and an amount of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_I_69X6Df9k6Te3sWPj6hwQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_6xfdq14eg0OKwY_EIZCG6g">800</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_I_69X6Df9k6Te3sWPj6hwQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_RF-okWMCPUibcxPTPS21Mg">673</ix:nonFraction>k) was received for a malaria vaccine. In August&#160;2019, the Company received a second payment for the universal influenza program amounting to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_8_1_2019_To_8_31_2019_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_GFLhPP5AWUCAjFvKMkszFg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_juJxEznQnUeJAMbluDJ6jA">540</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_8_1_2019_To_8_31_2019_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_GFLhPP5AWUCAjFvKMkszFg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_Ryd3yDNaKU672xjXf1FOEA">486</ix:nonFraction>k). In November 2020, the Company received a third payment for the universal influenza program amounting to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_5b14ql9RFEezFsOggnD0RA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_DRaMBpxOZEyHBTF6km8JDg">322</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_5b14ql9RFEezFsOggnD0RA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_gJ_cKfJ1ekqzrzPnVUs6Ow">280</ix:nonFraction>k). In November and December 2020, the Company received further payment for the malaria program amounting to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_wxgIcShrNEKq5nN0HbJ7vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_NA6PMqOAC0ybdP8CPHpBDw"><ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_12_1_2020_To_12_31_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_rNMx4zueSkOBF5WSJkSlXw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_QzGK2hxdO0WBX2wUHrnRnQ">1,449</ix:nonFraction></ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_wxgIcShrNEKq5nN0HbJ7vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_pP8G009jmE2AJXTINrJ-vw"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_12_1_2020_To_12_31_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_rNMx4zueSkOBF5WSJkSlXw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Narr_J9bGcpowuk2dhdQNuBhYVw">1,208</ix:nonFraction></ix:nonFraction>k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023 CureVac recognized EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_m_1pv_Rp7ES0m0oWmWkw9w" decimals="-3" format="ixt:numdotdecimal" name="cvac:AmortizationOfGovernmentGrants" scale="3" id="Narr_VoLHP6S57kqqd9bDSdjimg">66</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_oFHjPsrbYU-V2V22lqobCg" decimals="-3" format="ixt:numdotdecimal" name="cvac:AmortizationOfGovernmentGrants" scale="3" id="Narr_UdsAS8e9uE2ZOCZl8XLt5w">167</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_lgx14Yi8EUGXWrkRb0K3Jg" decimals="-3" format="ixt:numdotdecimal" name="cvac:AmortizationOfGovernmentGrants" scale="3" id="Narr_VoHRdi_yFUmXpXphf5TorQ">488</ix:nonFraction>k) for services as other operating income. In addition, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fUKrlVf3Qk6qjGa7_xKIlw" decimals="-3" format="ixt:numdotdecimal" name="cvac:RepaymentOfGrantReceivedFromGovernment" scale="3" id="Narr_Y2NM2JudgkmG-krjFZIC1Q">217</ix:nonFraction>k were repaid in 2023 to the Bill &amp; Melinda Gates Foundation due to the closure of one project. The grant is released on a cost occurred basis.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eXNajj7K5E23MRE8ailPlQ_cont9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_AvgaG-0jnkaft9oN3wJb5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_iMn1Xi5bp0KGEEGSDtQ-cQ">1,430</ix:nonFraction>k in grant funds received have been deferred and presented within other liabilities (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_xwxmUcynR0KOedEqXVH6mg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_qQpATKjZikeEsKsMBqHlww">1,712</ix:nonFraction>k).</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_-uphlJF8BkW5IO4uXjOHLw_1_10"></a><a id="Tc_7ag7DNtuBUesYLok10Scmg_2_0"></a><a id="Tc_DC1YSp7O3EONBX6FKE4D1w_2_2"></a><a id="Tc_ju0gJylRmUuJ66vH4tN3dg_2_4"></a><a id="Tc_vr6cKFR-mUi5AEvxtWwP8g_2_6"></a><a id="Tc_b2WnbjWKKE2HKArv6Qk6Jw_2_8"></a><a id="Tc_kPERvac_oEC1DtlB5W15JQ_2_10"></a><a id="Tc_zqnBgq2Vy0qrt428C-RvbA_2_12"></a><a id="Tc_0NooV1xCZEOYJKBZo6Gl7Q_3_0"></a><a id="Tc_rvlgQWqSCEqkXE9-0vCAkg_4_0"></a><a id="Tc_RsBHXcOOQUic301w4eu68g_4_6"></a><a id="Tc_Gul_fBQfEUyiCYNacjUhzw_4_8"></a><a id="Tc_45gwu_pss06WdyDxKU2QyQ_5_0"></a><a id="Tc_BZ_btQLFgEKBUy2CFxCaRA_5_10"></a><a id="Tc_UKCixxUolE6QLfVHfq0pNw_6_0"></a><a id="Tc_cW3HbMTuGEC2fPietu5KOg_6_6"></a><a id="Tc_M7BzdJCH7UeXTtWKKoKTIA_6_8"></a><a id="Tc_awQcAE4FaEKtW-_-jY_UtA_7_0"></a><a id="Tc_yc_eKzrWgEuzue88f_BYmg_7_4"></a><a id="Tc_UE9Nhrd06kOYbuQKW0xhPw_7_6"></a><a id="Tc_HL3xNGcVuU65mAQue71rKQ_7_8"></a><a id="Tc_FlcRfzTu60u7ZM3KDtfo9g_7_12"></a><a id="Tc_n27k_oNh6kuMha7Z6CbN7g_8_0"></a><a id="Tc_w_-bixRrJ0i3Tc3iicKzMA_8_4"></a><a id="Tc_5OZEPyWZ80adswJg2HScSA_8_6"></a><a id="Tc_mPvZYdx6tUiUWGwu5o6UTw_8_8"></a><a id="Tc_zrfrol2KiEWqAz5k2MrbYA_8_10"></a><a id="Tc_eyrMBdWo40qSSWIiMoCpRA_9_0"></a><a id="Tc_CalOj4Pfu02kF-JM0gpYcQ_10_0"></a><a id="Tc_H04LZF58EUKz6kg1ryqHEA_11_0"></a><a id="Tc_3rlk6we5LU6hB4Cb0EX2bw_11_6"></a><a id="Tc_pkOTITH_8EaMutknIeey4Q_11_8"></a><a id="Tc_cS7ISCkWP0qLiln9K2pNmg_11_10"></a><a id="Tc_fEKeIiapNUitOzPc8DH9Mw_12_0"></a><a id="Tc_6N2Id2qgykG9npPb6kOdGA_12_8"></a><a id="Tc_QIuB8YyWbUC9FXGOdujD1w_12_10"></a><a id="Tc_b3Wo2GF-xE6RQEzhe12eIg_13_0"></a><a id="Tc_pKjbKzbFhUO86odW9veqEA_13_6"></a><a id="Tc_xLX0vSncIEKkIoFZkg2OWg_13_8"></a><a id="Tc_4r3tWfnLlEeZAenFvvyCVQ_13_10"></a><a id="Tc_xBlfGcLZakW_0eZv9FC_UQ_14_0"></a><a id="Tc_X0Q_kYUMg0qx4gLtbsQNOg_14_4"></a><a id="Tc_wjU0HRWlkUiHOhTP6ZrVBg_14_6"></a><a id="Tc_hPHhzq9PO0iKkhetxvCQ0w_14_8"></a><a id="Tc__5LxZQudkkiJ2uQaX9Eskw_14_10"></a><a id="Tc_mPDjEB7HdU2YMCcL-UAANA_15_0"></a><a id="Tc_Z2f3l0t_uUWjduoY9FKBOg_15_8"></a><a id="Tc_IuQaH9TaGUK9MNpqWogIrQ_15_10"></a><a id="Tc_Y61eVFRFcEeJjFsAMcZFBw_16_0"></a><a id="Tc_niEoj1Yk6k-YKB3PCtL2BQ_17_0"></a><a id="Tc_Vvtq4TtP40KURc7jg74mAg_18_0"></a><a id="Tc_lyZKzqNyzEuJknyozu2wWQ_18_6"></a><a id="Tc_yHvdbufztE6QcMCh5vz0Qw_18_8"></a><a id="Tc_EfvW0QqMR0qpIWg-KmJlyQ_18_10"></a><a id="Tc_kyXfyzlSnk6LDssknUnedA_19_0"></a><a id="Tc_9j8QyoJ0vkqGQJv0JqUiag_19_6"></a><a id="Tc_ttrjz86Ur0CVRL5A_N99lw_19_8"></a><a id="Tc_2EEul8xqQkSEH_R6kjqyHQ_20_0"></a><a id="Tc_PwR2Crsge0eqnFOeRVpqyQ_20_6"></a><a id="Tc_1R5cixTtrkuXQ0YnFVLhpQ_20_8"></a><a id="Tc_BwTgOuQPP0OKnPPS9whZ4Q_20_10"></a><a id="Tc_kqsL-yjApUi2daV2kGlhGg_20_12"></a><a id="Tc_N9f6a47E7Uic4QJX3rZ_9w_21_0"></a><a id="Tc_R3X84ktsV06nvMq2h1lggg_21_2"></a><a id="Tc_1F99y24yMEG3Q55AEBgDlg_21_4"></a><a id="Tc_Os7LxzHHAE2B58p-wZhjiQ_21_6"></a><a id="Tc_0X3jdsn43U679vxidBIplg_21_8"></a><a id="Tc_tELQ1_6Gu0iEgeVi9KSbAQ_21_10"></a><a id="Tc_c51gMPjzZEiGzGVgNpMTEw_21_12"></a><a id="Tc_WZ90Oc-M1EGxOk50JyoImw_22_0"></a><a id="Tc_f-bULar2ak-_0tFBXVUIQw_22_10"></a><a id="Tc_11HZ9p-mD02mLuSEoutQ5g_23_0"></a><a id="Tc_mZb9Ks93d0mbkhVSgWmLdw_24_0"></a><a id="Tc_VRGq8EPrI06MOGWV-3lSkA_24_8"></a><a id="Tc_asypxheSZUGV4_gPFPs1mg_24_10"></a><a id="Tc_73bC-v2iD0iTrc9uxOSzGQ_25_0"></a><a id="Tc_SP_1R8sXj0e8Rt8GUNOvRQ_25_8"></a><a id="Tc_v7g3SVhqkUqq5xDYkanG4A_25_10"></a><a id="Tc_Ko7549S-9UKS68WsXH7Vyw_26_0"></a><a id="Tc_Jh2CPvibOUWuktlDB53eag_26_6"></a><a id="Tc_GpEoPEf9o0CsI7Fjq8WP4Q_26_8"></a><a id="Tc_kaoEft3oikq_ES1MsmNhJw_26_10"></a><a id="Tc_kJrS0MRE2UWVRdiTW_sesQ_27_0"></a><a id="Tc_keqrN3_cokqoDmDAteGPrg_27_6"></a><a id="Tc__a1OXJ997ke7AmIGXZY9Gw_27_8"></a><a id="Tc_6Q1cUBgTBkKWn3Jh4IdqGg_27_10"></a><a id="Tc_O-GuyvqWdUW5jo99D02Y9g_27_12"></a><a id="Tc_xRraBmFwR0OlXlZB-hagmw_28_0"></a><a id="Tc_66OThQOul0e0FjcwDhWIwg_28_2"></a><a id="Tc_rGw0-blzy0envGNgzghYrw_28_4"></a><a id="Tc_6I-7NJZqREyn1fXkUX-WDw_28_6"></a><a id="Tc_3TaqitPlLkG1P5ZAxHlE2g_28_8"></a><a id="Tc_PmrHY8mGzE-xYECi62mIdQ_28_10"></a><a id="Tc_j5-IFxHjt0mc8-5ke7Juxg_28_12"></a><a id="Tc_t8SxQuPTqkCHs6ugPOrURg_29_0"></a><a id="Tc_9GaKmRtmUUmgOWW7h9wd-Q_29_8"></a><a id="Tc_IQFlt7bJ9k-NQhYvw4tPzg_29_10"></a><a id="Tc_o2y6Wj3ReUWY77JAdoW0Qw_30_0"></a><a id="Tc_wjkdBbDo8kGfndL74zwFqg_31_0"></a><a id="Tc_t7Awuaih5USjE8U-sgXJAg_31_6"></a><a id="Tc_Db0OjXFZp0e-OfN7tAO9yw_31_8"></a><a id="Tc_FPV07ArikUuGxKlPyUCUFw_32_0"></a><a id="Tc_TfSbaxUh5k2ioMGttNrNZA_33_0"></a><a id="Tc_bA9rEJ-UN0eo6VkP9GuODw_33_10"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfFixedAssetsExplanatory" id="Tb_K7CDab1xZUKNrx9PJs0WAw" continuedAt="Tb_K7CDab1xZUKNrx9PJs0WAw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Fixed Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4.1 Development of intangible assets and property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development of intangible assets and property, plant and equipment for the years ended December 31, 2023 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="Tb_Afz_EtJO3UiQomhevLL_Sw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Advance</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Software</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Technology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_t4-RJZpgr0CDzvIjX0yH7g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_L5cslTEFdkOP9jzMHY9Rvg_4_2">12,626</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_2Z6ov_rV6UGba_ri3U2OrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_-VBfMnqT00m6f1lGqMchnw_4_4">10,259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_jb5qNe6RhUGF9vZAO08FkA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_3k6ZDRvSrkGu_UYPOt39Rg_4_10">965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_t4jMo4Sp2U27gxThk2CyYA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_hYWYp5U9mEGPoTOlvVrwaA_4_12">23,850</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_3MlEL--7f0OshY_BIiblKg_5_2">1,433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_cqxmGMVGW0W7n02ag0EpUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_8eiBPmgqqE6hL-7ZXtUZfQ_5_4">4,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_j_FuUitGzU-WI673yfsjoQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_zespjVYuSEekWM9VEit3Ow_5_6">6,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_xFpumxL9VU6TqcyTi7LMRA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_SMPLlWZUEEy_lu-_O2WFew_5_8">12,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc__bk3CqRCYkyR6gByoqEyGg_5_12">24,454</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_Jf18aG6NnkWLRCK045nW3w_6_2">2,331</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_cqxmGMVGW0W7n02ag0EpUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_fl68pil5PUKdgEhXSVDq9A_6_4">1,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_PZFJd68wgkCqXp4YW2TkiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_uqFPoTbaVEOCbDRhqJkzvw_6_10">298</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_mNgkY1lBVEKWxEpiTJ4Ajw_6_12">4,166</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_RuZMKOBcl0u8ZQBJ_Zs7qg_7_2">656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_PZFJd68wgkCqXp4YW2TkiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" sign="-" scale="3" id="Tc_xJdBcPKerE6x5aY360cLAw_7_10">656</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_ZOTQ6l9j3k-YZnCW-W4Dhg_8_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_ZbWrFIkIFEKSe32Vj_Sr7Q_8_12">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_TpCSNwbGR06S0oUDZgjo1Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_oGbjXU6ZvESKh9ytemUbAQ_9_2">12,385</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CxYy2LPXFkaLHvgdxKLbYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_FJLPTyDBH0WVpGTX4f7sDw_9_4">12,930</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_smPSOhfL00esXI2_6xMXmQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_h3gdipHc3kip6Kz7DbHBZw_9_6">6,350</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_taOkSa3SjUyVQqMwIn0Hjg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_z7tk5W3ApkG_fby_eGnWVQ_9_8">12,463</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_e3XuayV2tk6ysYr-TQ-BSQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_LFVzitZwSUawlNz2MXK9QQ_9_10">11</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_e4LNke4W5kqBcsPw7Fegaw_9_12">44,139</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated amortization and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JTWgO7w8WUSANCdQPMb8Hg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_jTddt-ro9Ei7tawMJ7ITTQ_11_2">5,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_pTI2ycYZxUCgYp1XaojMCQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_BsYDlqpbKEamsFkg5KeNNQ_11_4">4,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_AZk_qPQ4MUWJzWTnl1YlfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_Gzy04IE11E-ixDk4o2Qrow_11_12">10,612</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_pFS0HzUiV0GvDtcfoPaEbA_12_2">1,730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_ep4tnexH0kyFY8VzHHJmYA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_rbkmOUosnkK_xD0X5KXZxA_12_4">2,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_lFP2_XAYDUudX-fY-YAD1Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_9mmDMD57qEq3qtSkgqWpaA_12_6">484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_O_5DKtVHs0KQJkUSKP9CbQ_12_12">5,079</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_mmkmFqthLUeARqOZAz3F7w_13_2">2,217</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_ep4tnexH0kyFY8VzHHJmYA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_1-55wJwJ10mS-p9l2AXVow_13_4">1,114</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_Hh2LmsjcyUaHo6pzrOoLAg_13_12">3,331</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_wo0UAi3tZkaKj81PY7Cn_w_14_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_8TUmMGeMuUakThxoyCaZgA_14_12">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_lxNwvrDKd0-QyYtez9i4Cw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_CQkOlmxj_0upn5Y9v6jjcw_15_2">5,479</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hlhg1JNAsESzQBLYmwp6xQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_oJRhpEL70UOD7C1D7TX7lQ_15_4">6,398</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1FJQlhWUMk6KNwscC81P8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_cxsyoLBlmUu442x-F0Rftw_15_6">484</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_8Z9rItWJHEOMsrod-Zvovw_15_12">12,361</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_TpCSNwbGR06S0oUDZgjo1Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_7sqJXsXOm0KLyrOFpP1Dsw_17_2">12,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CxYy2LPXFkaLHvgdxKLbYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_TjCQM1JVKEu2RWNZH_lrVQ_17_4">12,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_smPSOhfL00esXI2_6xMXmQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_hSYAuuLHUkG2q1-VxuLmuA_17_6">6,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_taOkSa3SjUyVQqMwIn0Hjg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_HXdBWAHuzkmkgb583KCRdA_17_8">12,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_e3XuayV2tk6ysYr-TQ-BSQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_kAxRiwRqsEywC3w43nUU_g_17_10">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_RS4qR934BkmkkcGdV4oZ3w_17_12">44,139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_kdAR8QIep0ePDXZusmjS3A_18_2">201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_v08ySrrQo0WRSZMzc1oKNg_18_4">2,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_snYCQPo_UU2S7j5Eqa87OQ_18_12">2,880</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_LvEvVlD5IE6hjTf4SE_HDQ_19_2">1,946</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_KblfovmMrUeHFZRuwWkqrg_19_4">4,432</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_rkeQ49L4e06MJK-fI2BJhg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_4o3BhRHAfUyAN2seQr4B_g_19_10">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_1LEEBU619EWgs84-LNC08g_19_12">6,388</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" sign="-" scale="3" id="Tc_FEcZHi5jNE6ISXikqXxMbA_20_2">6,797</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_ov8njsUfV0OnkiZaYYfIsQ_20_4">6,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_-yi3-Too5kCsgm19jUEi9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_J_e_vPWT30KLui-E39QE1w_22_2">3,843</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_b9BiLH-CyUWgD-n-MYvg5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_t2N3Rvv8rkuqHUa_6Mfb1Q_22_4">17,974</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_eimyXQngAkWRK3ARVfDZJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_YPJL8bwPFUa6bhtuYftqCg_22_6">6,350</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_ZF2N9tkLFEaK095giq-KlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_tPIuTE8D9UiyCGlOTVZQRQ_22_8">12,463</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_Auk54leS0kegyMpOaw5bEw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_EF17ec9RW0S0E_X4wQjERw_22_12">40,630</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated amortization and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_lxNwvrDKd0-QyYtez9i4Cw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_545aXI1Fd0mTyvjoDjESHA_24_2">5,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hlhg1JNAsESzQBLYmwp6xQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_-y7_HM61Lkq4oODC_bYC5Q_24_4">6,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1FJQlhWUMk6KNwscC81P8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_ry6j5JtVFEWTct9F3GXrzg_24_6">484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_sBsNqlkV_USWGISarRkHVA_24_12">12,361</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_x1ysCY7z40OBHKJkKAzXKw_25_2">820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_FgaOzuFwr0mdhs6fb_xdqg_25_4">3,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_2doude3lg0OUQmpYjlR9-w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_460X-bu7xEOEaVFomClVxQ_25_6">782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_BlOG_bENfkCtrJ6V88PujQ_25_12">5,059</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_EthjrErtS0ShP1ybmIkgIA_26_2">1,841</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_hEd47oA77E-Oc0_7ILTTfQ_26_4">3,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_SqZ9nd9RpUCv0monSnYz_g_26_12">5,135</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" sign="-" scale="3" id="Tc_kIKNsVTxNU-i2m76MzW1cA_27_2">2,493</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_6Ceq3j8CbUKN1RzHO6g7WA_27_4">2,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_SNfgVOPHpkOAwFRDrPaxfw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_x3GEdjGaFk6NqNX9wCRPvw_29_2">1,965</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3uG-xQGBjk2UUp8qg_geog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_HT31obYvYUi3OcJataAbGw_29_4">9,054</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_cDlmM3W2jEmSkYOD4grJhw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_UbfYH_kJPkCAbwx1mUfSmg_29_6">1,266</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Fo_xNC8x2E2Nw6expsmq5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_CsKxUJe6o0OpYhNfSUz5CA_29_12">12,285</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Carrying amount</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JgayIPr0HUqHcsGqQ4Msdg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_l-YkUhOwfEeBNTUGRNgJdQ_31_2">6,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hhtxzsBDiUKB449PVvTqJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_ABZ63v2ZKka42wnxfGapbA_31_4">5,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_glkxLuCSRUCQqGxSgDm4sQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_XL3JVUYV_0KQknsnhh_LHw_31_10">965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_tV7LRNl6G0-jNcJUCe8hUA_31_12">13,238</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_9EPi2cugF02lQJNpQpyZfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_sCvoMGO_1k2VTiicsV8o6g_32_2">6,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3xb5m9-bNEqJh9Hoo7pWKQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_2R6aVxsIXE-pPBQlu_Ieag_32_4">6,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1teDHrsx_kWaav_Zvx6nuA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_O1iIeUjkN0KysOk9z5IE6g_32_6">5,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_4a0nsTyeT0WWO6mJkY9WFA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_p4h6VMRzmE2SaOeqAftmxA_32_8">12,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_-ENPqM9es0SNp-ig-Xj1tA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_hnQP-cWVeEWUBu_b661AAg_32_10">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_coJkUiG4PUqqUXLUpGLlkA_32_12">31,778</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_amLMRVfn1Ee2t3F85rOj6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_1ZfIvnc91U2u0q7Zblh9MQ_33_2">1,878</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_tEkPhB01qkqTdfn3O75Wzw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_SSt2DGno30SQRznrZEZW9g_33_4">8,920</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_TsCUi_lxRUSo6j60ua4lmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_E3p_LfZjqUCJXLk0ZUUYQQ_33_6">5,084</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_syES-Ei1DUW-SeNDoWBa7Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_ZXcyXMHR7E6XJor_OWsc6g_33_8">12,463</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_rVrenyNaq0-Dru8yqPUgrQ_33_12">28,347</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As the Group operates as one cash-generating unit, for the purpose of impairment testing in 2023, goodwill was allocated at Group level. For the impairment test the market capitalization was compared to the Group&#8217;s equity; the Goodwill was covered by the exceeding amount. The market capitalization derived from public quotations of CureVac stock (Nasdaq Dec 29, 2023: USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_12_29_2023_To_12_29_2023_SuqeE38xXUK8RRKDLZ3EOw" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsSharePrice" scale="0" id="Narr_IIEGWwHHZE2Z9px7uktwdA">4.21</ix:nonFraction>). Based on this, CureVac has concluded, that there are no indications of potential impairment in the goodwill of its one cash-generating unit.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_j5oNy6ZyXUWHp2vs8TPxgQ_1_6"></a><a id="Tc_BhR3rKEWT0WuRszGFcCAug_2_6"></a><a id="Tc_lhGJV5hsB0Co7SOOB9Aukw_3_4"></a><a id="Tc_OCRs6WS06ECinPhBtfCGiw_3_6"></a><a id="Tc_iBxHTuHZw0WwpDzjWCq3OQ_3_8"></a><a id="Tc_WKkBFpPSHU6GPQ-6wlhTxw_4_4"></a><a id="Tc_DZvRZZzmYUeGc38boQ8SEQ_4_6"></a><a id="Tc_M0KHpQfMY0K9YHf_2_KFwA_4_8"></a><a id="Tc_Rtkx3i7rykqDGMb2lShvig_5_0"></a><a id="Tc_Yzs4WyBMOEaqOHj6NMbAlQ_5_2"></a><a id="Tc_pBMwJ8wb-kKBmtIMwxai1Q_5_4"></a><a id="Tc_fNbdHJJP0UWKnGF4abyqdw_5_6"></a><a id="Tc_lFToi2nY_EqYASlSJt1-OQ_5_8"></a><a id="Tc_iqVXQ5BaFkOzJotyzPp0CQ_5_10"></a><a id="Tc_bVtyAKW_9Ui00WeJ6Mq7Lw_6_0"></a><a id="Tc_fU507AXbq0KPupDWyd-YZQ_7_0"></a><a id="Tc_PHasGH-_qkOXIN1WZEQowA_8_0"></a><a id="Tc_tB1MxpPAvk6QHyL80veG-Q_9_0"></a><a id="Tc_8seYMAV8nkC5c1sIjpi8Pw_9_2"></a><a id="Tc_K9NUBHr7r0q3Q9MTMZTqcQ_9_6"></a><a id="Tc_aCCduvmaLUCc1KXu-0a3LA_10_0"></a><a id="Tc_RPDA8A6Q80OhvbOxAa0tuA_11_0"></a><a id="Tc_1_N9BpY2PEy8FZMRBMcXRg_11_2"></a><a id="Tc_98f37qLayUOyBLJffwRESQ_11_6"></a><a id="Tc_JbVvQE6nlUGqXB9Uw1cueg_11_10"></a><a id="Tc_7r5lzhEBf02ODiKchgcBuw_12_0"></a><a id="Tc_tBaxHJicDUyYmav3_FMSsw_12_2"></a><a id="Tc_UJrvq9ISq0CxvBTcdkbzmQ_12_4"></a><a id="Tc_DK_FvAk6mUmaRUmRUR6V1g_12_8"></a><a id="Tc_tTI_PZuDJEGlre6EQVRAGA_13_0"></a><a id="Tc_9T1yyoJZO0e2NuxVuc6ShQ_14_0"></a><a id="Tc_1Lv_95OLkEeuGPlwV5D-Rg_15_0"></a><a id="Tc_ZAAezWOCrUmpuJdr8kfWqg_16_0"></a><a id="Tc_PPKa7Vcdu0iK2QI7-6uJEQ_16_8"></a><a id="Tc_nmjfNlY3fEquaW2iAxoKNQ_17_0"></a><a id="Tc_hZX48zGRf0yRMBX7d7qLGg_17_2"></a><a id="Tc_J7ee7FOIVkmt4_JYRAzf8Q_17_6"></a><a id="Tc_1zrCdxRPD0GTFy0qE-65qg_18_0"></a><a id="Tc_-5a54jLvIE21zCeFopIuVQ_19_0"></a><a id="Tc_kWrp4YcaQEiyU-2lA5a6qA_19_2"></a><a id="Tc_nw7X5F8r0UyPAIekCznsRQ_19_4"></a><a id="Tc_9rLEBNsoxkOkR_-B61h3Lg_19_8"></a><a id="Tc_X2I3-lQoZUuPfi2RuZICVw_20_0"></a><a id="Tc_ARSBmAiJ30SyEWvhxoN5eA_21_0"></a><a id="Tc_O0t_V-tz60qvCrJTXmS3Ig_22_0"></a><a id="Tc_HcPEGeQMwEWy1jdZ2OCMJw_23_0"></a><a id="Tc_tmFbicFPPU2ITR-PhJZJ-A_24_0"></a><a id="Tc_OPFm-7-LRUKmkbYBiKGjug_25_0"></a><a id="Tc_JmPYMvde1UmCQK1Kg48KAQ_26_0"></a><a id="Tc_sV2JG5zAZkegtMFAhaACmA_26_2"></a><a id="Tc_9bODXdi5eEOwxJuY1y7H1Q_26_4"></a><a id="Tc_g6ysEKige0yqRpmHo1adRg_26_8"></a><a id="Tc_yeh9Vp9zdk24KGb2HEtH5g_27_0"></a><a id="Tc_z5OtNxefxE6lOmve3bPHBw_28_0"></a><a id="Tc_AGD3XeuizkKgxX8ftmj0wA_29_0"></a><a id="Tc_3YziuHvjPk-3iQAchR7MSA_30_0"></a><a id="Tc_VDB5bfriNEqMItB1UAI_cQ_30_8"></a><a id="Tc_mMn9M2tD7U2KdubKt-yfPQ_31_0"></a><a id="Tc_jzVyItEjkEaA9zgad6_e7Q_31_2"></a><a id="Tc_3jNprTaxx0CGP1KyvHPBRw_31_4"></a><a id="Tc_g3Ty2nmUfkiUDGQ14w9iJw_31_6"></a><a id="Tc_vo70fihOOEqst_uHHDBytw_32_0"></a><a id="Tc_JMaHJMFUaUyBGTYVKDMOjA_32_8"></a><a id="Tc_RD0Tlm0gu0CrnFpHf8H6WA_33_0"></a><a id="Tc_7o1Yux1Ip0K8jOaLH4I3UQ_33_2"></a><a id="Tc_xvpwjQkldEe6e3rgAjqS7g_33_4"></a><a id="Tc_lVgseXfFU0ObxRfnIsyZhA_33_8"></a><a id="Tc_EHb2KSJqG0KZBLMloJDs9w_34_0"></a><a id="Tc_mAQRUCQCFEGIXRVqEZ2QDw_35_0"></a><a id="Tc_X1Ic16ds4Um5bY_iYHnyLQ_36_0"></a><a id="Tc_UnAi6-dGCkOMX4NzKwVicQ_37_0"></a><a id="Tc_ygRH4RGtBU2ASGlYjH5Q4A_38_0"></a><ix:continuation id="Tb_K7CDab1xZUKNrx9PJs0WAw_cont1" continuedAt="Tb_K7CDab1xZUKNrx9PJs0WAw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property, plant and equipment</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="Tb_bBuAwn4bMkOcWuJEkePdCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Other</b><span style="font-family:'Times New Roman Bold';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment,</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Technical</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">furniture</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">under</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and&#160;machines</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;fixtures</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">construction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_uEHNJFwr3EmVaCzLXcE2lw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_nenA90_L6kei_WhtarYJyQ_7_2">27,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_i7EfMlh5iUKmaxl0vc-mog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_UtOq34qT9U6008IsYbTEDg_7_4">51,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_K_aG3SZaKUW1mCYhFvnDYQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_2DQnKFAGO02KLGhNvHOOiA_7_6">11,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_8byNOjFo4ki3TRAVrcpw_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_rdeeu3VnkU2AbmWP7D4SBg_7_8">124,543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_t4jMo4Sp2U27gxThk2CyYA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc__X0woYbgVkKxz3hGocgjFQ_7_10">215,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_D4XaHP_XzUyH3j-sKKjh5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_Id52pnkK70C-UIC4vBUzXQ_8_2">377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_XE77jBDk7UKL6xMTJ8bjHA_8_4">9,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_u2R1mWc9_0m4mZUAVCSOQw_8_6">2,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_be4_3SWRgUmNjKWgeCCTjA_8_8">76,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_hoJy0ZR2B0KqreNXc7zTtQ_8_10">89,620</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" scale="3" id="Tc_706B2hmMTk2k0HaDGMU0Bg_9_4">6,719</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" scale="3" id="Tc__xInh29lxEWaTfA_gcN6ow_9_8">50,851</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" scale="3" id="Tc_wAjE5VDjgk-Z99KA7M9NTw_9_10">57,570</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_D4XaHP_XzUyH3j-sKKjh5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_ztQpjlnduUqVbB8UERD2lg_10_2">1,182</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_E3TGg10ftUOrI1w89HCu3A_10_4">12,584</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_HPupaWEhIkGuWhhNoZ5XYg_10_6">1,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_HazolbTDTUWu_rZdP0Co7Q_10_8">4,356</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_Uk1ugIcj0kqAw870WRMXdg_10_10">19,854</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" scale="3" id="Tc_EocEEdwK-UisVi3dUk8nsw_11_4">7,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_GfQCft9wp0CCZG5CdTEYNg_11_8">7,652</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="Tc_61Tvt6QwrE24IGC3iZfegg_12_6">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="Tc_tfAg6_Jpj0a2e2iylQZHZQ_12_10">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_gVeKYMrm2kqPAEgtA4ctgQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_9BXCnuT4kkiIHXGvEpQjgg_13_2">26,467</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ES83sXGGEUiud1LCNDkpvg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_ifPH1kekYk-syNcnY_JZrw_13_4">50,033</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iLzT9AM5F0Gv_MXd0N7WwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_V9Ksjuqjy0acFSGu3EwNyQ_13_6">12,552</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GJ80BNA4w02YFSPV325rWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_gs9BE6F1ak6VnY83kK6dvQ_13_8">138,457</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_9dYTS8W3w0ihiFFL0qavXw_13_10">227,509</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated depreciation and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_HKdVFHQkxEmgyjhDxX2T9w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_9ZwVuu3R70SupCl4S6B4Dg_15_2">5,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ADqOKH8jt0KB1nbIrPKgoQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_8vETB6DiQ0a5lcXhoqJshw_15_4">11,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iEt59g_0hEWUB6Yz9rNI_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_0ztXiYOyiUO7fB89Oh1hOg_15_6">7,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OXWs40hPgkKqkaLy0hyWrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_3noCiUIrnEiFzbsPmri65A_15_8">22,810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_AZk_qPQ4MUWJzWTnl1YlfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_G5Ro4lgJJEeLNba6oQcDOA_15_10">47,019</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_-ZhyaL6E9kaT3dKgQLND6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_KdA4KCB_Z0Wac2tb5fp5uQ_16_2">4,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_-YR3Kzf6lU2fL-o7HJUmcQ_16_4">6,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_Om6Fe6UL00KWc46l4ArpHQ_16_6">1,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_kM2GgivrKEKeJKORilUWaA_16_10">13,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_dhDt2PAgSUG4l88aMvIuzA_17_4">3,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_KyV7Slh2JkqGlclN0ZugPw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_fQSMY6AYy0mkybNX33MuuQ_17_8">2,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_HsIR71IE9UmZIZ9vYs_EzQ_17_10">5,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_-ZhyaL6E9kaT3dKgQLND6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_qMW0AUDaUkeP2bs-uK6nPA_18_2">1,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_q1XUMTjaFUCNnfy70lcV1A_18_4">9,938</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_y1rgOMALeEK_WYiB7lWNhA_18_6">1,688</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_KyV7Slh2JkqGlclN0ZugPw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_AVTzeUE0wUyDdEjuaRPCUw_18_8">24,038</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_eDy-LaiRLUOgLvHOhbJ_NQ_18_10">36,747</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="Tc_nURPv1RED0u17kMitmiteg_19_6">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="Tc_mmr-GHt6c0-VpAueOgpwjw_19_10">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_3Ozy5OoM_EqCMGWp5kzLAw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_sd5EMkE-_EWgPKUqnmlrWw_20_2">8,710</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ySJm0_yzS0O5WbckJbrJig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_HsdVYo8HTEyyscDhgayLNQ_20_4">12,617</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_SWfFNmCXQkGxOp1OayMWRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_f45mx64RJUanP-lcnNUQLg_20_6">7,415</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3hNl2cG_e0iw0IDtLwg0sQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_VYmg_Gv-9E2wTbyYv_tp3A_20_8">826</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_h_spDiQBp0awd8yci3y2-Q_20_10">29,568</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_gVeKYMrm2kqPAEgtA4ctgQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_5bazr96yM06WLKl0LXNZIg_22_2">26,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ES83sXGGEUiud1LCNDkpvg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_e7mwakJ9W0KLLlA8mHNU5Q_22_4">50,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iLzT9AM5F0Gv_MXd0N7WwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_FEkg6vSA9kq9uFBZppZd1g_22_6">12,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GJ80BNA4w02YFSPV325rWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_Daac6lEC8UyQWbgR0HZuMQ_22_8">138,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_ZOgY9DXfhkSatg6p8-oJHA_22_10">227,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_HPDnJo6RIkyIQ8oRpyyWKw_23_2">551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_BJJbuNOEvEWf8Nz_KG6e1g_23_4">9,171</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_gs_IPERVlU2u17t__6_Iyw_23_6">2,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc__jC1P-0rF064ygwc0geVRA_23_8">43,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Tc_YAXN26kWfEaqiBOslxcUuQ_23_10">54,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_LPLCfcLlp0yYJVg8VW4EEQ_24_2">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_JUAhG310cEKQoeNWn0RnmA_24_4">5,090</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_w8wbRSkIvkS1v9SN6ihPvg_24_6">1,825</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_a6xqg04ztUOhXHJsPv1faw_24_8">1,235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_zHRWUbcWKk-mH9Xqal8s7g_24_10">8,165</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" scale="3" id="Tc_jLPu9bk6402u5CR6_GXavw_25_2">533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" scale="3" id="Tc_1z7400w0DkGzQy1l9Js9Mg_25_4">828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_7U4-JsCdhkGlC3w4NiTkKg_25_6">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_eu4HYNbb1k24H58DfR4Qcw_25_8">1,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" scale="3" id="Tc_TzOUsagG7Em_VcseaCgYkw_25_10">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_9HWgJ_9Z70uFswDKmoiU7w_26_6">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_iI40Di00bkud7GOjd4B_Cw_26_10">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GxtzQ5W2qkKKhXTjunpSVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_FxWYuYb1oUWpfyuAaeZLhA_27_2">27,537</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__0Fq4xEc5USvdYA7uwb9kQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_1_ma4fnE_0egmkbK-Rl1bA_27_4">54,941</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_vx00BKTjL0C1MH6pWcVznA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_wYgfOw3Kek-ODgG-yIcFiQ_27_6">12,736</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_kHeRSiduSE-H2FthCmMR7g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_AtSq9UIs00-i-KvOppZRdQ_27_8">178,990</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_Auk54leS0kegyMpOaw5bEw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_QkP4mgSteUO9T8kSF3aDPg_27_10">274,205</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated depreciation and impairment charges </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_3Ozy5OoM_EqCMGWp5kzLAw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_EWnTihw260SDGsAWtfxlYA_29_2">8,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ySJm0_yzS0O5WbckJbrJig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_ivCx4ZyfPUuxnQfUtiBlDA_29_4">12,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_SWfFNmCXQkGxOp1OayMWRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc__ymnm_jYJUCTPh4g9RtsUg_29_6">7,415</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3hNl2cG_e0iw0IDtLwg0sQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_MolQQ4L0sE6BsVh4kSWPNw_29_8">826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_Q-bjCoNIwEqrnmSEYKisBw_29_10">29,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w8rxm3hBy0y_-Ae1ZVWKlw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_mgukVP1FjEKmRztclechSQ_30_2">4,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_t-iXQatkZ0KzkyWEc3dpwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_sYlrktFIwUqjdyGFEwy2Uw_30_4">5,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_aI-OvPO5ZEm2oOZ_cy79pA_30_6">2,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="Tc_iJcw_NKwZ0yBz_ubdtCbtQ_30_10">12,432</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_Pu91BJKoY0yyQ7jXhJKbDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_iCr6K8Cx7UaMb2FrKL70mg_31_8">1,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Tc_IO-YXLS-70WulqjBtuQPlg_31_10">1,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w8rxm3hBy0y_-Ae1ZVWKlw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_QUuIREGAO0aaF-vH9MZzOA_32_2">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_t-iXQatkZ0KzkyWEc3dpwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_Ti6ijNGHjUKFge0AxF-cAw_32_4">4,270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_jXrz4-YYlkGY06VI7LOl5A_32_6">1,659</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="Tc_VXeb-YSb8kCXqpsEXV_57Q_32_10">5,941</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_-dHEBPACV0-6DstWeNZK5g_33_6">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" sign="-" scale="3" id="Tc_B-KMtuDzOE-eMphQb6P3fg_33_10">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GVJksEcFyUyKzVpP3nSNNg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_4MeS1rbuzE2sNdqN0QJ0Pg_34_2">12,914</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_K5vleFi0skqHLv2sbuvs-Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_iiKEAeZtlkWHeHVxAIaPBw_34_4">14,272</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_5cbrQ8MBFkim2wo7LQxZVQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_wd-QIAuWDkqgEKIxgM4ddA_34_6">8,038</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_EGzp-xjlD0SJrQdKTR20uA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_HaKIM4lkQkWpINY4JlE7BA_34_8">2,200</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Fo_xNC8x2E2Nw6expsmq5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_X5BCPoH2xkSKvJZlCCJbEg_34_10">37,424</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Carrying amount</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_SHbUU420-U6-wZvoecLRCQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_Pl89EomiJU2b7EMXxiXWeg_36_2">21,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_vuDrG59udk6_pmg0jdRl8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_d2gyu5UFXUm9hBGlxVZFSA_36_4">40,248</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_yqlv57v0OEG1_brdVqLq1g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_Cpp-r0e_ekS129Mb3vZIMQ_36_6">4,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_vIgFICzC7UiHO-GUZ0v4Yw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_pPKzviZ4Wki44THc8ekNxw_36_8">101,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_ySv7TR-XWk-Cxd0dN4skjw_36_10">168,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_jiGBndkblk6uSV1cNASR2w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_NZGnuP43GUCFtbEw_uTECQ_37_2">17,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4bLJEBum0UGcpDQCcpC3iw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_gR1Y4nQ1fUW27xTaFqzHiA_37_4">37,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_6hwBOOLcHk-K1sLFoc-0rg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_atwa1wtUmkeVMiCkgmGH0Q_37_6">5,137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GttWyC5eVEu0a5D8x-ZKVg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_meyVqMAjeUeg-4meNh4KdQ_37_8">137,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_AZdOFkzTW0mMeMPZSsqJ1Q_37_10">197,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w6XdbSqlp06NSNtoVAqCkQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_3e84q4QgikKiSW_RgEV5NQ_38_2">14,623</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_XfOC2qeC50iUajLNfhbYcw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_FtRAWbU5eEmGBoWLAKQneg_38_4">40,669</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_swVr7XTCQEqhZkjBon9n_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_JFXv6bFyrU6fE8hUeePu0A_38_6">4,698</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3YEDZJEcNUCF-BbD2Iw3ZQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_MUI9-bBsbUqX05FKqhVvvg_38_8">176,790</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_stfUbYdH7EyIcb5h6vlkHg_38_10">236,782</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2023, impairments of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Narr_EzBd-ekZi0OsfkAxI02hxw">1,374</ix:nonFraction>k were recognized (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="Narr_EmPNglP7DkqhCWe6zfGUAw">5,884</ix:nonFraction>k). These were recognized in cost of sales as they pertained to machinery and technical equipment recorded under assets under construction and resulted from the partial impairment of equipment which are obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV. In fiscal 2022, assets were reclassified as &#8216;assets held for sale&#8217; (Refer to Note 5 for additional information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group capitalized EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:BorrowingCostsCapitalised" scale="3" id="Narr_tLqpl06ifEqjoknfMF7JQg">2,375</ix:nonFraction>k borrowing costs during fiscal 2023 (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:BorrowingCostsCapitalised" scale="3" id="Narr_r2HkDQDj9ky3gH_GTv5c0w">2,291</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:BorrowingCostsCapitalised" scale="3" id="Narr_l69cvjsb4Ui1DHCgfvme0A">2,932</ix:nonFraction>k). The capitalization rate used to determine the amount of the borrowing costs eligible for capitalization during fiscal 2023 was a weighted average of <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" scale="-2" id="Narr_CaSxa7frHUi3H5se354k3w">5.76</ix:nonFraction>% (2022: <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" scale="-2" id="Narr_r5iHAfOtDU2pWZoXepGsgA">5.78</ix:nonFraction>%, 2021: <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" scale="-2" id="Narr_6uh9EQp9lEmHHmdsdstEzA">7.17</ix:nonFraction>%).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_FK4KRtz9tUm7sdkS-MHbtQ_1_2"></a><a id="Tc_HF2dW25usE21DiodK3Pa2Q_2_2"></a><a id="Tc_9fQFiYRaOEObuUXWFrA43g_2_6"></a><a id="Tc_XKzxR8fqZEqzcFQf9Ojicw_3_2"></a><a id="Tc_IGQUmjeLNU-EfrP7T9xgnw_3_4"></a><a id="Tc_HQuVruzKPEOmOJljb4Jz6A_3_6"></a><a id="Tc_VcH82Fp_okuVU6QIxv7Wrw_3_8"></a><a id="Tc_ygm1_SYp1EKy4FYjB2KG4A_4_2"></a><a id="Tc_u7YnWvQuwU-sKwbLyGP6aw_4_4"></a><a id="Tc_d0wLouDyJ0SerupFwhKAiA_4_6"></a><a id="Tc_SareO1uO_0iGIi3b6QmJAA_4_8"></a><a id="Tc_nlJVPSqUmEG-xh_9RwjCtw_5_0"></a><a id="Tc_pYE7sUxxok638AR_8uWDmg_6_0"></a><a id="Tc_3EhzJdvMgEuzHaBCFBfSQQ_6_6"></a><a id="Tc_Et76HfL5jkCTvO8yc3u-kw_7_0"></a><a id="Tc_81e-5j7jjkKJLrxuBp5bjQ_8_0"></a><a id="Tc_5a7o26FbykCv-ETYNDC-nA_8_4"></a><a id="Tc_ColtAiuAnEadSeYX8n2DbQ_8_6"></a><a id="Tc_fFYJ7YkHtEOHfgbeM0p6vA_9_0"></a><a id="Tc_GK_u3Bn5LEOVqFhGp7ryZw_9_4"></a><a id="Tc_dRom2B4g60GbhUfmODuwqw_9_6"></a><a id="Tc_IQFSBzoxKU64-AOp-XYKJw_10_0"></a><a id="Tc_QR52XcJy-UiOmfQcajpqgg_1_2"></a><a id="Tc_kRmLuKuvf0KQn_z0EoITbQ_3_0"></a><a id="Tc_qlZdw4BsbEO8voqWQ5v7ow_4_0"></a><a id="Tc_nCWyfvBp1UulQii4dVG5YQ_5_0"></a><a id="Tc_kQ0XaEbGZEqI0aYnQzr1IQ_6_0"></a><a id="Tc_Q_eE0-bq9E2U2tYYtr_GDg_7_0"></a><a id="Tc_AD4pCQ0zjU-TzKb2UcOE1w_8_0"></a><a id="Tc_wmuWmamGTk-a2I9XVz341A_9_0"></a><a id="Tc_SrGEGdeelkGoqbFMU5O_Zg_10_0"></a><a id="Tc_NJQ1w_DK-kmr3XXsCjJiGw_1_2"></a><a id="Tc_Jy3JitHHrE-FuUAaPcP57w_1_4"></a><a id="Tc_ze7mnf6qC0Gc-pK5darUog_1_6"></a><a id="Tc_gCKam2vXE0exh_a6kcnrYw_2_2"></a><a id="Tc_Yy_e4WVuSEKYVUPpjvAuEA_2_4"></a><a id="Tc_nurwKABDrU-4CEb6KAzzjw_2_6"></a><a id="Tc_LmFiVcb8PUqulEA76vDKsg_3_0"></a><a id="Tc_2aFSrvNNk0G4X5z5BkBbWg_4_0"></a><a id="Tc_ND14JkMHkUKnDJMEZceuFQ_4_2"></a><a id="Tc_MB0z5zpi4EegoRTVQFTTRw_5_0"></a><a id="Tc_Au8PPgToAkuwSLBfl1-2VQ_6_0"></a><a id="Tc_D2w5HT8oUE2OdGgH_lnS9w_7_0"></a><a id="Tc_o-P1vm9Vgk-leYnOwL40fw_8_0"></a><a id="Tc_WJcpOKY4TUWYmUdBe2ad_w_8_2"></a><a id="Tc_cPe3CpJCWE25POs-9NIMOA_8_4"></a><ix:continuation id="Tb_K7CDab1xZUKNrx9PJs0WAw_cont2" continuedAt="Tb_K7CDab1xZUKNrx9PJs0WAw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">4.2 Right-of-use assets and lease liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Set out below, are the carrying amounts of the Group&#8217;s right-of-use assets and the movements during the period:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="Group_XSLMR1ibY0-eyZ6TabHjQA" continuedAt="Group_XSLMR1ibY0-eyZ6TabHjQA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-use&#160;assets</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Land&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_4U9TKa-8kku0qyyWYuN66g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_dQeFQ67kkEeMl05cirZPsQ_5_2">41,183</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_BptK40MzA0KOKdTRAaFA1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_3NQA7XzyFEmIoiVEatnrYg_5_4">275</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_v2qH86-io02_ESJqX83O4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_C79Iq8pqYk6F9Ci8cqqQCw_5_6">2,303</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_DEOhZkV1u0-QMW_pRle9gw_5_8">43,761</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions (new leases and reassessment of existing leases)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Tc_tvY4SeTApUWlw8eTqTFYGQ_6_2">4,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_GrkJ0r-6s0aI6oLGR4t78A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Tc_w1Wr-q3OTEqQcNIVN0ocLw_6_4">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Tc_8W-lpVPKrkihHgLwAsUEmQ_6_8">4,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_SS_7ToHoakCNjUHxIAz2aA_7_2">5,264</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_GrkJ0r-6s0aI6oLGR4t78A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_W0ynrP5zjE-LgtQJ10wWug_7_4">156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_uqcVVb-EwESwn3lB6wxn9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_JxqrUNsaeEyEmnHr4PQD0Q_7_6">352</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_Uq5XlrxptUKTpr2hcU58Ug_7_8">5,772</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOnRightOfUseAssets" scale="3" id="Tc_8Nxs3i9MEEmnnM_HbJI5hg_8_2">1,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOnRightOfUseAssets" scale="3" id="Tc_NP20IlEmKEuISiECbUvUdg_8_8">1,100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg" decimals="-3" format="ixt:numdotdecimal" name="cvac:Foreigncurrencytranslationrightofuseassets" sign="-" scale="3" id="Tc_Er0Gs9gWfkK9lqsH6p01cg_9_2">33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:Foreigncurrencytranslationrightofuseassets" sign="-" scale="3" id="Tc_PIyfSL9apUyk2UeT_euRfA_9_8">34</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_k9Skiw6h_kq4wMDfbW6Y1g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_BRy5XP5AOU-zFu7T8skkYg_10_2">39,574</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_rxt_fxShG0i6GkUMgTzphQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_abijlBpnxUuc7VYIQvk4xg_10_4">319</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FHdyYMNB7Eq_o5tMRVitmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_LSM08_2yl0Cgw1c7ZvI-OA_10_6">1,950</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_fiL3NgYYI0im8HnGKmbjIw_10_8">41,843</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The most significant lease agreements that have been initiated relate to several buildings in T&#252;bingen, a building in Wiesbaden and Frankfurt am Main, a building in Amsterdam/Netherlands and a building in Boston/USA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The additions mainly relate to <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_TbingenMember_qUeXimjzQ0KjqUiReUdC4g" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfRentalAgreements" scale="0" id="Narr_ym8pQkDDsUORmsWRm7pQWA">six</ix:nonFraction> rental agreements in T&#252;bingen (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_TbingenMember_qUeXimjzQ0KjqUiReUdC4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Narr_XzNqqoPbzka9HDTZ7BuAfg">2,452</ix:nonFraction>k) and <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_WiesbadenMember_qqZmF0WHQk-CQHfo53QZ7w" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfRentalAgreements" scale="0" id="Narr_uAhMI4K9bkuJFxJNltGa0A">one</ix:nonFraction> rental agreement in Wiesbaden (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_WiesbadenMember_qqZmF0WHQk-CQHfo53QZ7w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Narr_D0VAkyMhrU2YOOTaiN-qSw">510</ix:nonFraction>k). In addition, CureVac assessed <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="INF" format="ixt-sec:numwordsen" name="cvac:RightOfUseAssetsNumberOfExtensionOption" scale="0" id="Narr_7soaQe8Eq0iGN-wHPFgTBQ">one</ix:nonFraction> extension option of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" format="ixt-sec:durwordsen" name="cvac:IfrsLesseeOperatingLeaseRenewalTerm" id="Narr_iKUsxr25qkmIgMu1FiI4qA">5 years</ix:nonNumeric> to be reasonably certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Below are the carrying amounts of lease liabilities and the movements during the period:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" id="Group_gh1fkl4ob0yAPF6hUC3i7Q" continuedAt="Group_gh1fkl4ob0yAPF6hUC3i7Q_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_J1a4onlnpUujgNXlytBGKg_3_2">42,086</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions (new leases and reassessment of existing leases)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionsLeaseLiabilities" scale="3" id="Tc_pIsM3246TEax4q6vh87iRA_4_2">4,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="Tc_hpXhLicIi0CXK7JjgAJfRQ_5_2">2,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashOutflowForLeases" scale="3" id="Tc_TvJVd9_ue0GGTrp_Tuobiw_6_2">7,568</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ForeignCurrencyTranslationLeaseLiabilities" sign="-" scale="3" id="Tc_odjw9CjepE2AdQxHpThgcQ_7_2">57</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_GIeiOjaA60GWCxoD4XZXtQ_8_2">41,824</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_D6_KFjQ1I0CuCSzG9uye0A_9_2">5,005</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_-Uw8ENdE00e3TG4rhi_C-g_10_2">36,819</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A maturity analysis of lease liabilities is disclosed in Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following are the amounts recognized in the statement of operations:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock" id="Group_SzcK8yTu-Eu0JN95XYaWSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_gVVxjInyP0mTEIJFmXm51A_3_2">3,901</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_oRPcB5yavUmkEchwQ5mL2g_3_4">5,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_0jbpkJOEWEK1LJ-JPPUALw_3_6">5,772</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment expense / reversal of impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOnRightOfUseAssets" scale="3" id="Tc_6PuldUUywECf40lNm7ib9Q_4_4">710</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOnRightOfUseAssets" scale="3" id="Tc_ICI1r5dlhkmEoQZy4--PfA_4_6">1,100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="Tc_CqToswRjJEOUKXmzZH-ZgA_5_2">1,729</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="Tc_kc5C3gGtwkWd9Gb-R9Jdaw_5_4">2,218</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="Tc_sk_BXk05-U6WYOQVnEL7RQ_5_6">2,375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense relating to short-term leases (included in cost of sales)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="3" id="Tc_KgTHMeDWI0KauqPWvPswQw_6_2">119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="3" id="Tc_gGGuIPkuTUmzMzZvwIUZUQ_6_4">76</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="3" id="Tc_zJmtIxH1bEe9ixEUtL1tMg_6_6">70</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense relating to leases of low-value assets (included in general and administrative expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" id="Tc_KBs_FuR1ik6m8ZUwxh2KmA_7_2">39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" id="Tc_ca6Bvm5FtEixoAurWJVx2w_7_4">66</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" id="Tc_LRiDL5ebs0-Ms4A9HRSR8w_7_6">55</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from sub-leasing right-of-use assets presented in &#8220;other operating income&#8221;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeFromSubleasingRightofuseAssets" scale="3" id="Tc_3jtruc42_UqPyf4AmRB_gA_8_6">51</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_awsQ1J0-cEquuN-ktICd0A_1_2"></a><a id="Tc_cNiVAI0D8UqILSN0nJ-2Rw_2_2"></a><a id="Tc_dElIMf1mcUS7DhyUFO_hZg_2_6"></a><a id="Tc_ILGXainwNk2T5QbYxGG8bw_3_2"></a><a id="Tc_ZWQeDyDYL0CldwKUrgQAcA_3_4"></a><a id="Tc_VrHWCtHUB0eldLwARLBJ_A_3_6"></a><a id="Tc_bHTu5OOX4U-qlddABcNx4A_3_8"></a><a id="Tc_dqM0ihRyUkyhW9UMXEdkdA_4_2"></a><a id="Tc_5EOZbiDkMUyNOiNN8kEcIw_4_4"></a><a id="Tc_6k99NFQ3M0e96YXqbp7qCg_4_6"></a><a id="Tc_-NLlrvLzXkelaUh_q3hv7A_4_8"></a><a id="Tc_GkUSH5zkLke9Ha6Asbtfog_5_0"></a><a id="Tc_-VfAE_S6yUe549L59Ultgg_6_0"></a><a id="Tc_tkaVbrvSy0quOsS3oLD9Zg_7_0"></a><a id="Tc_OP8rCJ1_AESEdJUS1dao2g_8_0"></a><a id="Tc_r0JGbPADoUiglRdERQjPPQ_8_4"></a><a id="Tc_n8JC7FDLEU62FBnfK1ybTA_8_6"></a><a id="Tc_P4Kjt_8-H0WMNQ5SFVUHEQ_9_0"></a><a id="Tc_fD8cNuvx40S9tbgmbjGtlg_9_4"></a><a id="Tc_wyf93FZKrU6TOY175qq_DQ_9_6"></a><a id="Tc_-6hMgkqBiEK5wVO4ZXdaVw_10_0"></a><a id="Tc_-p1boLT_bUedxp0K8rCXFA_1_2"></a><a id="Tc_h-Y5nwj-l0eYIYaFupcN3A_3_0"></a><a id="Tc_WccGECsFUkiNvDOXwT65NQ_4_0"></a><a id="Tc_1DSvJbLel0ii1vpUnarKpA_5_0"></a><a id="Tc_xO-TFd7p-0ijtyW9U_czzA_6_0"></a><a id="Tc_kWJPTTzF0EeN2weJgwys0g_7_0"></a><a id="Tc_zYXlKRzEdUyFHm2O_RMDTA_8_0"></a><a id="Tc_g0Omt8PMZkC0zNciGhPaEA_9_0"></a><a id="Tc_dTjavH0gbUCjc0gJnvEnMw_10_0"></a><ix:continuation id="Tb_K7CDab1xZUKNrx9PJs0WAw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Set out below, are the carrying amounts of the Group&#8217;s right-of-use assets and the movements of prior period:</p><ix:continuation id="Group_XSLMR1ibY0-eyZ6TabHjQA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-use&#160;assets</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Land&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_MqFywxdSdU-VC2yfCNoI7A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_tnk8O1cVkkqzuFQpHb6SDg_5_2">31,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_8jM0YpsBR0yMEEEdxZY0HQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_yKzAtP5pWUeiqEXTBLOzjA_5_4">142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_kyYUjNgs7UmP0QeRDTa87w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_4IJ3hJU5J0aUi9XW9gCqGQ_5_6">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_Q6eBG0sst0-hvpVaNsQquA_5_8">32,129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Tc_WnH4T6xNC0mstKjM7uFCcA_6_2">14,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_tg5uf0hf90mOvis2DMD5YQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Tc_v2cmyOiyk0aY8bqXDaJptw_6_4">231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_WuUc_xWmdUqMzpKJ1_OlaA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Tc_lUxCPRu8uEOv3_NdfxLJxg_6_6">2,179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="Tc_EM3ERRevWEWekDrsaor9vQ_6_8">17,244</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_Y3ymH2bGfUa9f1t713BkGw_7_2">4,639</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_tg5uf0hf90mOvis2DMD5YQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_X_YyEkJUxEi-Hlbrp0EjGw_7_4">98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_WuUc_xWmdUqMzpKJ1_OlaA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_IiXOstB73kmFPUKpAFjKkQ_7_6">316</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="Tc_llc9wDtYWUux_KDb_JPM3w_7_8">5,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOnRightOfUseAssets" scale="3" id="Tc_J_XQSJR_OkCMPEtEQ27f1A_8_2">710</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOnRightOfUseAssets" scale="3" id="Tc__4alOeP6sUqEf8LtcrYQgg_8_8">710</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:Foreigncurrencytranslationrightofuseassets" scale="3" id="Tc_CQ78heJICUqioSo4uibCaw_9_2">151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:Foreigncurrencytranslationrightofuseassets" scale="3" id="Tc_VaJFntROA0KmtLMgJHcDlw_9_8">151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_4U9TKa-8kku0qyyWYuN66g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_JjJwxlqAk0as_a9YrTZVPA_10_2">41,183</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_BptK40MzA0KOKdTRAaFA1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_bWGzgD1YLkeAMYaVfIvt2g_10_4">275</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_v2qH86-io02_ESJqX83O4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_0XpPhKViukaaYGlNQt3IHA_10_6">2,303</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_tIjQQstunEi-sc5-yp30Iw_10_8">43,761</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below are the carrying amounts of lease liabilities and the movements during the period 2022:</p><ix:continuation id="Group_gh1fkl4ob0yAPF6hUC3i7Q_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_EvvBnjQSs0apuSh_tMEeGQ_3_2">28,892</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionsLeaseLiabilities" scale="3" id="Tc_fcpt0K-wpUG6ZZkgzgRRHw_4_2">17,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="Tc_i-H-m9M3A0W-7F_cB-8VIw_5_2">2,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashOutflowForLeases" scale="3" id="Tc_5opMwmMCA0SEg84r3eFQ9A_6_2">6,439</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ForeignCurrencyTranslationLeaseLiabilities" scale="3" id="Tc_4p2laoScQUe4StJ-B7PD7w_7_2">174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_RRKA-wnmqES1B-bqsoe0rA_8_2">42,086</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_Q2My9glY8EOklv9ZThUohA_9_2">4,980</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_anomI2d0xkyQqHEBcf07aw_10_2">37,106</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A maturity analysis of lease liabilities is disclosed in Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There are no commitments for leases not yet commenced as of December 31, 2023. Commitments for leases not yet commenced as of December 31, 2022, related to two lease agreements of buildings in T&#252;bingen, Germany that have been signed in 2021 and one lease agreement of a building in Wiesbaden, Germany that has been signed in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Optional lease payments from using extension options not included in the measurement of the lease liability exist in a gross amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OptionalLeasePaymentsUponUsingExtensionOptions" scale="3" id="Narr_hCGaaRXo8UCfSx1QCESCEQ">39,325</ix:nonFraction>k.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" id="Tb_zFHSCHcR3EqjgHJ6VMxADw" continuedAt="Tb_zFHSCHcR3EqjgHJ6VMxADw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">5. Assets held for sale</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO Equipment identified for sale had a gross book value of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:NetBookValueOfCmoEquipmentHeldForSale" scale="3" id="Narr_bYVRs52Zrk6qygZx760DZQ">29,531</ix:nonFraction>k and was written down by EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOfAssetsHeldForSale" scale="3" id="Narr_t4__rOb4ZU-rL0vqWseViw">19,064</ix:nonFraction>k (with the corresponding expense recognized in cost of sales) to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Narr_IGXR47s-4U2C3UlCo9UDEQ">10,467</ix:nonFraction>k, the fair value less anticipated costs to sell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">During fiscal year 2023 assets with a net book value of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AssetsHeldForSaleNetBookValueSold" scale="3" id="Narr__eKq45xxCk238LCLr86iGQ">167</ix:nonFraction>k were classified as assets held for sale and assets held for sale with a net book value of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AssetsHeldForSaleNetBookValueDirectSold" scale="3" id="Narr_I8b5FigfGEOk6Udj_G4tlQ">1,505</ix:nonFraction>k were sold through direct sales and an external service provider, indicating the remaining assets held for sale&#8217;s carrying value might be further impaired. Based on fair value less costs of disposal calculations, and taking into account the most recent sales projections, including Q1 of 2024, the external service provider&#8217;s market expertise, and an assessment to date as prepared by management, the fair value at December 31, 2023 was lowered to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Narr_DhlSAVI5SUOJVVvz_4_hfg">2,419</ix:nonFraction>k by a decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:DecreaseThroughClassifiedAsHeldForSale" scale="3" id="Narr_EVGSrCZB8keY-6uGamX2dA">6,711</ix:nonFraction>k (with the corresponding expense recognized in cost of sales). The assets held for sale have been valued taking into account the current market circumstances and demand for secondhand equipment for assets outside of warranty periods. Criteria for the determination of the fair value were defined based on certain sales scenarios and considering different sales campaigns, where valuation techniques applied have remained consistent to the prior year.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zFHSCHcR3EqjgHJ6VMxADw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="Tb_Xi-9GfONZUibh_cN9Lc1LA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">6. Inventories</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials and supplies amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterials" scale="3" id="Narr_FmEUobXRK02A1nGn7EhvEg">24,801</ix:nonFraction>k (December 31, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterials" scale="3" id="Narr_u81tq42gZ0CfA5NH9PFj0g">23,989</ix:nonFraction>k), which are recoverable under the Company&#8217;s agreements with its collaboration partners. During the year ended December 31, 2023, the increase in inventory of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseInInventory" scale="3" id="Narr_c8pdUV0rRESLef5YQ4IorQ">811</ix:nonFraction>k is primarily due to purchases of raw material for R&amp;D collaborations and for stockpiling towards the PPA of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:InventoryPilingForPandemicPreparednessAgreement" scale="3" id="Narr_gjh5EOdvdEmhq9ek037-pw">62,082</ix:nonFraction>k. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Timelines related to the Pandemic Preparedness Agreement were ambitious with the aim of providing acute pandemic preparedness in Germany in the context of emerging COVID-19 variants. In 2023, CureVac identified a risk that necessary regulatory approvals needed to meet these timelines may not be achieved within the contractually agreed timeframe. After consultation with ZEPAI, CureVac applied for a timeline extension as foreseen under the agreement to avoid procurement of further substantial amounts of raw material at risk. As of December 31, 2023, it was considered unlikely that the extension would be granted. Additionally, a rapidly changing epidemiological environment did no longer prompt an acute pandemic threat. Accordingly, inventories which had been stockpiled as required by the PPA, were written down to their net realizable value. Ultimately, the extension was not granted, whereupon CureVac and GSK jointly decided to terminate the agreement. For more detailed information we refer to Note 21. In total, inventory in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoryWritedown2011" scale="3" id="Narr_PBDqY4e5cUmEFLEhP9XVBg">47,129</ix:nonFraction>k was written - off as of year-end including write-off of materials received as part of Gen1 commitments. The residual amount was consumed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expense recognized related to the write-offs, scraps and consumption are mainly included in &#8216;Cost of Sales&#8217;. In the year 2022 EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoryWritedown2011" scale="3" id="Narr_5PFOZzZ_30C9wzZtjbpx0w">80,021</ix:nonFraction>k were written off.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfOtherFinancialAssetsExplanatory" id="Tb_1l3f0tk1LEax9mz8LmGlNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">7. Other financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Other financial assets as of December 31, 2023 amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentInvestments" scale="3" id="Narr_dJLKcsFwf0eUfyd88IceUA">2,661</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentInvestments" scale="3" id="Narr_qwutj0HrnkadKls2H43Rog">4,487</ix:nonFraction>k) mainly include deposits held by third parties in amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:DepositsHeldByThirdParties" scale="3" id="Narr_nSRslSY3CkWIlGnt8qqnlQ">1,936</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:DepositsHeldByThirdParties" scale="3" id="Narr_PBxm_UIZxUqup4BdVGWqrA">1,936</ix:nonFraction>k) and other receivables in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherReceivables" scale="3" id="Narr_RfZYMPzsJk6bWmQw6xc0Tw">726</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherReceivables" scale="3" id="Narr_nsvzKBJZXkec23qgKoX9Og">2,551</ix:nonFraction>k).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="Tb_PkekTGcw90WmfP8xLLJt1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Prepaid expenses and other current assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_1ZgqOPnfCUWUfMD-aiRdWQ">23,763</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_0Qo9BdI0pUWrLviHOD8hhg">40,002</ix:nonFraction>k) include prepayments for future service agreements and material in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAdvancesToSuppliers" scale="3" id="Narr_gtwcvPuseEqCpoI0DjGlbw">1,075</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAdvancesToSuppliers" scale="3" id="Narr_OLe-LwdHsECOUJO088-QFA">4,507</ix:nonFraction>k), deferred charges of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" id="Narr_vZum8BI7DE-m8ZkfJY9Okg">5,463</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" id="Narr_g91rDLrGQ0Kf2UqPNc7Mfg">5,345</ix:nonFraction>k) and receivables of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_qpUmqYWcEkej_TFR1rGkJA">4,344</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_DhaRRmjPZUSjgSH7p1wVbg">5,595</ix:nonFraction>k). For more details, refer to Note 3.8. As of December 31, 2023, we had tax receivables, mainly VAT refund claims, of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_yF6HE7k0sUSMv_jrKLycYg">12,881</ix:nonFraction>k in other current assets (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_zUw7NXPoVkaimEkknwDgwQ">24,555</ix:nonFraction>k).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="Tb_ImtZU1CtokaCkFhKtxxaDg" continuedAt="Tb_ImtZU1CtokaCkFhKtxxaDg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">9. Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">According to the Company&#8217;s articles of association, the Company&#8217;s authorized shares are divided into <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_EPtB9tP-TEK2-HT_DhqQMA">386,250,000</ix:nonFraction> common shares and <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_Sw6Kjo1tDE-BHe-dTLqX0g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_dihUyWBzmU66FxqenRAbZA">386,250,000</ix:nonFraction> preferred shares, each having a nominal value of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_MPWn6Yhb9k2MaUaT36kptg">0.12</ix:nonFraction>. As of December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_Sw6Kjo1tDE-BHe-dTLqX0g" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_7_l2rU1GWkiYSJzNRPqkBQ">no</ix:nonFraction> preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#8217; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#8217;s articles of association.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_UjdpslkXFkmtQs68Li1nMQ_1_0"></a><a id="Tc_yrewXullLEmGj6RGAS9K1w_2_0"></a><a id="Tc_1MYv0inm9k-R1g4htm0zGw_3_0"></a><a id="Tc_UO8utOwqZUCILL-x9IWj-A_4_0"></a><a id="Tc_-3TIi3A2nkuVmTb1Ds-8Uw_5_0"></a><a id="Tc_-cvZUrMqeUGmlMiVhWIxLQ_6_0"></a><a id="Tc_PCmMvQU6-E6x6y3Lgjet4A_7_0"></a><a id="Tc_pdoPT3AS0EWU9evS-SyiUg_8_0"></a><a id="Tc_O_x2NGnF4USp-9gfRT1XMw_9_0"></a><a id="Tc_R-COD1AzH0GTMjV0CWDB5Q_10_0"></a><a id="Tc_n69jM_vfH0OnKNA96E9cIw_11_0"></a><a id="Tc_dUI3_SQ680-MPJZwOA933g_12_0"></a><ix:continuation id="Tb_ImtZU1CtokaCkFhKtxxaDg_cont1" continuedAt="Tb_ImtZU1CtokaCkFhKtxxaDg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding in fiscal 2023 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="Tb_5ouEwXM_v0yAlU6QCx9kkA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2020</b></p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_ecwrKnXM6UOEVpuUwd4Ixg_1_2">180,460,565</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Follow-on public offering, incl. Greenshoe </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_pq40A99Zy0-J899Hpgyiuw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IncreaseInNumberOfSharesOutstanding" scale="0" id="Tc_uVpFMSvKLEq3ym5R9Y2_xA_2_2">5,750,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="INF" format="ixt:numdotdecimal" name="cvac:ShareOptionExercises" scale="0" id="Tc_VMAl3pVhM0ukg4-u0TlPSA_3_2">910,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_N_Y6BK8HR0anqbp5EaDwuQ_4_2">187,120,728</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the at-the-market offering program </p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_bhT-Hm2SaEu5uUt9fXRzGw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_YWd0pTw-A0WWw8KZfgP_iQ_5_2">6,908,493</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued to former shareholders of Frame Pharmaceuticals</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="INF" format="ixt:numdotdecimal" name="cvac:StockIssuanceDuringPeriodForExistingShareholders" scale="0" id="Tc_IpNLY7l1WUqkSKSuGb6qRw_6_2">858,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued for LTIP option exercises and RSU deliveries </p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" scale="0" id="Tc_lpB0PwKwzkC43WBCMggF5A_7_2">109,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2022 </b></p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_zkohPBrMUkitW6zdsKie5g_8_2">194,997,091</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the at-the-market offering program</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember___lz1oR3-k2v1ISygb7bPw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_RhcHOzaSPUGImQymEnKqzw_9_2">1,748,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the public offering</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_PublicOfferingOfCommonSharesMember_aEkH7sfkH02lkeyEWiOvdA" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc__Hu1v7rGg0ifiIVdq1Ag-Q_10_2">27,027,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued for LTIP option exercises and RSU releases</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" scale="0" id="Tc_DntSvQSQyUqGnYuS1kQ8kg_11_2">216,338</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_4MstNagF2kSEXS-EWEtL5A_12_2">223,988,675</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Refer to Note 21 for additional information on share transactions occurring after December 31, 2023. The share transactions which occurred in 2021, 2022 and 2023 are as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Follow-on public offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Company completed a follow-on public offering whereby it sold <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA" decimals="INF" format="ixt:numdotdecimal" name="cvac:IncreaseInNumberOfSharesOutstanding" scale="0" id="Narr_msG4CyzzpUiuEcyQXuOe8Q">5,000,000</ix:nonFraction> common shares at a price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Narr_c2_rpLggUk-Ogu1bsF6tFA">90.00</ix:nonFraction> per share. In addition, the underwriters exercised their option to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_IfrsOverAllotmentOptionMember_riZy2Z4KG0Gk8otdZzKN2A" decimals="INF" format="ixt:numdotdecimal" name="cvac:IncreaseInNumberOfSharesOutstanding" scale="0" id="Narr_e-1NQF7HqU6qunenEzLEyA">750,000</ix:nonFraction> common shares at this same price less the underwriting discount. The aggregate proceeds, net of underwriting discounts, received by the Company from these transactions were EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Narr_Jwf8ve0PCEyaqek2Gf1j4g">426,652</ix:nonFraction>k. Offering costs for legal, accounting, printing and registration fees of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="Narr_IvEActDn40WsolN3Y7oTQg">22,590</ix:nonFraction>k were recognized as reduction to capital reserve against the proceeds from the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">At-the-market offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 17, 2021, CureVac filed a prospectus for an &#8220;at-the-market&#8221; (ATM) offering program to raise additional cash of up to USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_9_17_2021_To_9_17_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_jUlavD3NjEy-jk37WZ7FiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Narr_SiRJkB_PSECYRkcQLMRzkA">600</ix:nonFraction> million. The program was activated in June 2022. Through December 31, 2022, CureVac has issued <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_H5V7XcidSEeqvZO0kZROGA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_jl3xvkbAGkCXEIyH48LshA">6,908,493</ix:nonFraction> shares and raised gross proceeds of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember___lz1oR3-k2v1ISygb7bPw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AggregateGrossProceedsReceivableFromIssuingShares" scale="3" id="Narr_IZhw5NN2TkCfXSh75lTAyQ">69,139</ix:nonFraction>k. In the first quarter of 2023, <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_npuKWKdpoUWvxgvLp2wwtg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_vijVmn-d1UaWMgNRPXbpgA">1,748,218</ix:nonFraction> shares were issued under the ATM program, raising USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_oXIlxEKLg0uXPK0YY9JWaA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AggregateGrossProceedsReceivableFromIssuingShares" scale="3" id="Narr_hASuyzGA1EKMxo6NKNEXdw">18,023</ix:nonFraction>k million in gross proceeds. Offering costs for legal, accounting, printing and registration fees were recognized as reduction to capital reserve against the proceeds from the offering. Following these issuances, the remaining value authorized for sale under the at - the - market program amounts to USD <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_H5V7XcidSEeqvZO0kZROGA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="6" id="Narr_KCWcMkJjAkuU9m4bhIDyFg">513</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Follow-on public offering 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2023, the Company completed a follow - on public offering whereby it sold <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IncreaseInNumberOfSharesOutstanding" scale="0" id="Narr_eFrsjEwNLESB8ZVDxwUSwQ">27,027,028</ix:nonFraction> common shares at a price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Narr_cpFEG4eZI0q8WHgm-aL9mA">9.25</ix:nonFraction> per share. The aggregate proceeds, net of underwriting discounts, received by the Company from these transactions were EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Narr_98eSE-NCqEaPj5Biv9aRSw">219,832</ix:nonFraction>k. Offering costs for legal, accounting, printing and registration fees of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="Narr_siLudS2s3U-UTn8Ksx79jg">14,580</ix:nonFraction>k were recognized as reduction to capital reserve against the proceeds from the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Frame Pharmaceuticals acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2022, CureVac entered into a Share Purchase Agreement (SPA) to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., a research company focused on advanced genomics and bioinformatics, based in Amsterdam, Netherlands. Under the SPA, the total consideration for the the purchase was up to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_51kbfHiK10CFR5dmzP024Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" scale="6" id="Narr_jN0WXyusnUe-gxohsK03mw">34</ix:nonFraction> million, conditioned on the meeting of certain development milestone payments. On the date of acquisition, July 1, 2022, CureVac issued <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_ObBmT6n8TkOKFE0nU935Fw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" scale="0" id="Narr_qojuy7XPBk2pMpvjUuCjjw">858,496</ix:nonFraction> shares to the former shareholders of Frame Pharmaceuticals. Refer to Note 20 for additional information.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ImtZU1CtokaCkFhKtxxaDg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercises of share options under the prior VSOP plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IPO in August 2020 triggered an exercise event under the set terms of the prior VSOP plan (see Note 10). In March 2021, CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_wByHZDzoG0GTHomAjnaf6Q">759,677</ix:nonFraction> shares from the old shareholders and transferred <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesHeldForTaxLiabilities" scale="0" id="Narr_KW2WAiknn0-YHD2pCGlULw">390,023</ix:nonFraction> shares to the participants of the old VSOP plan. CureVac withheld <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_mYHyPgsZbESvV7bZ-VPFLw">369,654</ix:nonFraction> shares equaling the amount to be paid for income tax and social security tax. A second triggering event, &#8220;liquidity after IPO&#8221; was met one year after IPO. In October 2021, CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_RmxXIpiDL06445m3dhykeA">765,223</ix:nonFraction> shares from the old shareholders and transferred <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesHeldForTaxLiabilities" scale="0" id="Narr_p3i5A57COkmA12KOJ5HuRg">523,897</ix:nonFraction> shares to the participants of the VSOP plan. CureVac withheld <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_3KoZgMH9dkOnwPu4vNuwww">241,326</ix:nonFraction> shares equaling the amount to be paid for income tax and social security tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third triggering event, again &#8220;liquidity after IPO&#8221;, was met on the second anniversary of the IPO. In December 2022, CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_mp2AzJFe_U2GzM3aVT9NMA" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_FKRXcqkAsEeoJBAex4m-XQ">777,260</ix:nonFraction> shares from the old shareholders. All shares were transferred to the participants of the prior VSOP plan and the portion of shares equaling the amount to be paid for income tax and social security tax were sold to pay for these taxes and social security amounts. In 2022, CureVac recorded a receivable for income tax and social security tax for former employees and received these amounts in Q1 2023. A fourth triggering event, again &#8220;liquidity after IPO&#8221;, was met on the third anniversary of the IPO. CureVac will receive <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_A6it69ifLUeKRgdoAQT4iw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_7mzT7Z3t_kKDfxgnzL0KtA">786,746</ix:nonFraction> shares from the old shareholders and will transfer these to the participants of the old VSOP plan in March 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercises of share options under the new VSOP plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Participants of the new VSOP plan (see Note 10) were able to continue to exercise their options throughout the year of 2023. In 2023 <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_YmO0AmylMUGXyDkvXeCLlQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_tw-5GpP8E0a4K0EVID-T8g">69,246</ix:nonFraction> shares (2022: <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_sAMF0EDzsUqQ8PpTkE7KMQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_388rQvlhukikNAD8SsuzFA">147,620</ix:nonFraction> shares) were issued upon exercise of options and <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LegacyPlanMember_RGbEltV_HESu23rxrqMUeQ" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_g0fMmOmDNEuEi4qwrxf08w">no</ix:nonFraction> options were forfeited (2022: <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_sAMF0EDzsUqQ8PpTkE7KMQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="Narr_Nkz6eCfxX0-XhHDX12bTzQ">96,785</ix:nonFraction>).</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_32eb8a0c_a5a5_4316_a321_87be417ed026"></a><a id="Tc_9gm21BCIXkydFUoBaHaZ-Q_1_2"></a><a id="Tc_X3AXHh0hGEimweXqY5SAgw_1_4"></a><a id="Tc_dJnX9v2u_UqA1d9kqO5MFg_1_6"></a><a id="Tc_dPEW2MnyJU6-Vbh8HD6HAQ_2_2"></a><a id="Tc_cCCZRkukAUqA6bgDjj7g8g_2_4"></a><a id="Tc_0pztJ0A12ku9xMN7jB6Zvw_2_6"></a><a id="Tc_kIYCJQrBvUiHYNOr4uKVIg_3_0"></a><a id="Tc_8VVWFDv-CUqmTIU00ne8Ig_4_0"></a><a id="Tc_oX9sOuGXG0yLidrT2Pl7JA_5_0"></a><a id="Tc_yknwMzDHPUqM3HtgwtRU6w_6_0"></a><a id="Tc_tI2OVsTmYEyRUcx7BZXJQw_7_0"></a><a id="Tc_HDbAxJYXHUi7gZbqk9MlvA_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_J15S6nmpgk-KhQe7Sn3GBA" continuedAt="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2023, 2022, and 2021, the Group operated the following share-based plans for members of management and other key employees of the Group, as well as members of the supervisory board:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prior VSOP</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New VSOP &#8201;&#8212;&#8201;for US employees (from 2019 onwards)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">LTIP Stock Options </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">LTIP RSUs (from 2021 onwards)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">All programs were accounted for as equity-settled share-based payment awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Measurement of the grant date fair value is based on valuation techniques appropriate in the circumstances, such as Black Scholes option pricing models or a Monte Carlo simulation. Expected volatility, a key input to such models, was based on an evaluation of the historical volatilities of comparable listed biotech-companies over the historical period commensurate with the expected option life. Regarding the expected option life of the stock option programs, this was based on the assumptions that the beneficiary would exercise his option in equal installments from the date of the first time possible (taking into account lock-up and potential trading windows restrictions) until maturity. The risk-free interest was derived from German or US-Government bonds, as appropriate.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="Tb_9XtP8dJCpU2E-YcSdhOx_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expense recognized for share-based payments during the years ended December 31 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_CP6B1xyrnkSGKe2rhIwnWQ_3_2">624</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_JCQaoDu4VUyX6LjZCAZZdA_3_4">131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_LSl8AWp13kq_JcXdQCvoAQ_3_6">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_WFIMLitrLk6lL-4HmapGcw_4_2">572</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_o-OArYcutke-xTbroFZp7Q_4_4">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_jevRmbynI02QUNFA-u51vA_4_6">19</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LTIP Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_8RFzGrzUeE6P9-Pt00WG7A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_launymV-mUqixCr99NYOyg_5_2">12,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_hGO4w4NtCUa_4_aoaCmHzQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_NmWC_zU6L02hPl1gjr_wog_5_4">5,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_uMKK0Q6dEUmdlqOP5j56rQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_4etbebEOUkei8tnDbWXJxA_5_6">2,944</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LTIP RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_NkdF9lVGbUq5xwUCOH7yAQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_Vyd4qoK9Okud5b7C2kFY9Q_6_2">705</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_-tPgLvVPd0iGi29T4BoBUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_jVa7eFZVX0GiQO4oL2BIKw_6_4">3,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_jRMpo2_Z7EeshW9iq1ZxOg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_hRPWMHm-X0iJ6boDElGEGQ_6_6">4,072</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU Supervisory board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_bAEfKq92c0ycQbava4HefQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_f-e3aEnWT0SAo08gDW2chg_7_2">566</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_8rng1PMUlky5RzxNm--ypw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_XijTHvCNDkerWr_iIdotDA_7_4">478</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_mT3WIF4M9k-HrxxK03IB1g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_LO3WFeQPxEuBiBDGOIzXSw_7_6">652</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_rBynXPefr0-TTNX-hIKBfQ_8_2">14,939</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_chfMwEhaH0upj8G8WG8IOg_8_4">9,184</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" sign="-" scale="3" id="Tc_POC5MCkDGk6UT-QveXnuSQ_8_6">7,697</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_HqAYdYbTGkm8Hx083er1gg_1_2"></a><a id="Tc_URDJzuWnUES9t1_hGXD8ew_1_4"></a><a id="Tc_UyYCrvNXK0SObxVADL3aZQ_1_6"></a><a id="Tc_vNJieXCIjkq8n_SXW0LbRw_2_0"></a><a id="Tc_NUe2pagz9UOgXTCdT1BPiw_3_0"></a><a id="Tc_UHRG_yh76EqCzQb4NK_7Fg_3_2"></a><a id="Tc_k5w87zpCmkGjsnWT6OJdRw_3_4"></a><a id="Tc_FNlcwPGij0q1h59Q_lXwXw_3_6"></a><a id="Tc_51dIPJs1VU6k2UaTqaF3zw_4_0"></a><a id="Tc_89g4asR6z0mCAJZ0MP7dpw_4_2"></a><a id="Tc_0VSf-RR7hUaJ5VHiI94gag_5_0"></a><a id="Tc_sWUSilJW4US1zk1pZAhMtg_5_6"></a><a id="Tc_UcZqV0IcOE6hyu3HOM1Szg_6_0"></a><a id="Tc_by0m0d0RzkuM-OhLnG4IUA_7_0"></a><a id="Tc_rAqGlzVF9Ua5t9miRh2Kfg_8_0"></a><a id="_e34343db_5281_44b1_80eb_b0196c412d5d"></a><a id="Tc_RjlfZSRavUCyUv6C1Xrb_g_1_2"></a><a id="Tc_-vKfVfBTsEuFrEwujlpDEQ_1_4"></a><a id="Tc_FmxAa6jS0k21b1nz05sjEQ_1_6"></a><a id="Tc_dvtkScdZY0yyV423Fw_2Hw_2_2"></a><a id="Tc_euFyoystg02BHssz7cEspQ_2_4"></a><a id="Tc_NNY9pqRUIk2HQKA7-B0yFA_2_6"></a><a id="Tc_94s6oGNEmUq8IW2sPvHDWw_3_0"></a><a id="Tc_W9qcz5lQL0uB8exgiHgwOw_3_2"></a><a id="Tc_ZMyCbDVBg0Ojs3r4EzOf6Q_3_4"></a><a id="Tc_ZCyHSL1XlkWZmi5dNld2Gg_4_0"></a><a id="Tc_7T6HLglrVki8_8RinQ_vkw_5_0"></a><a id="Tc_t64zx9vOdUGvhCWC7wZOmw_6_0"></a><a id="Tc_vbh_82odhUWviWZOBr3tsw_7_0"></a><ix:continuation id="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont1" continuedAt="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Prior VSOP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The development of the virtual shares in the Prior VSOP program granted to management and key employees was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="Tb_QjrzYGqHlkGfLHoUfpv-cA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the beginning of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_xxYCQu-d0kOvAqnbd6uzjQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="Tc_fsgDMNEHoEK579HDQ6QXmA_2_2">7,951,265</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="Tc_XU0Ppm6wx0G8TaaxaukyAg_2_4">6,426,365</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="Tc_TdyxG_YNRU-pyxU4jkr7xQ_2_6">5,614,246</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="Tc_6rT1jUnMVEKAypHqjmZOoA_4_4">34,859</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="Tc_2unfQMZ6d0yGw6Q6YC9uKQ_4_6">11,091</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised during the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mZrACg5Qy0atlIzvQ-sFZQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Tc_lpdeRRf71Ema_1ca-9i5BA_5_2">1,524,900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Tc_KRrmOkaIkEiTyfXst6ihEQ_5_4">777,260</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="Tc_F0PjmSFj_EOZrH8ZKbgx_g_6_2">6,426,365</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="Tc_4k2l7c70t0ig_G0hwJ_xsw_6_4">5,614,246</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_Emv5VFNkOkeu9n01IcUiDw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="Tc_JSuAj5usSUmXKB0LlkVsjA_6_6">5,603,155</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mZrACg5Qy0atlIzvQ-sFZQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" scale="0" id="Tc_dEjZEUGuf0GFGDQ4IuQc3w_7_2">6,365,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" scale="0" id="Tc_thvIox4v6kGP9wR4JXA0Bg_7_4">5,509,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" scale="0" id="Tc_pCMzmjCmdUWBumXr7y7b2w_7_6">5,588,513</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_j55KzHHTV0-9M7XId1miLg_8_2">none</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_3sBGapBm2ky2h1GaTaWUBg_8_4">none</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_Emv5VFNkOkeu9n01IcUiDw" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_9-zMHHrBAU6_Uk7tqSRzkQ_8_6">none</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IPO on August 14, 2020, triggered the right to exercise <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_14_2020_To_8_14_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_WwopKLYhAkmX30Ihq8HcEQ" decimals="2" format="ixt:numdotdecimal" name="cvac:RightToExercisePercentageOfVestedVirtualShares" scale="-2" id="Narr_9M5wl4zBDkicbvlZw40ntw">10</ix:nonFraction> % of the vested virtual shares at the end of the lock-up period, which ended on February 10, 2021. By March 10, 2021, the beneficiaries declared the exercise of all their exercisable <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_10_2021_To_3_10_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_D2yuVO9FDUOmQ5j1k8A3bw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_YhU7i224S0O0ki-5IMeMnA">759,677</ix:nonFraction> virtual shares and CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_10_2021_To_3_10_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_D2yuVO9FDUOmQ5j1k8A3bw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_NfQe9hJwpESu5dI3IuACkA">759,677</ix:nonFraction> shares from their former major shareholders as of 2015, on that day. On March 11, 2021, CureVac transferred <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_pTbohJf3ZkqciuC17uKyxg">390,023</ix:nonFraction> shares to the exercising beneficiaries and withheld <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA" decimals="INF" format="ixt:numdotdecimal" name="cvac:TreasurySharesTransferred" scale="0" id="Narr_A16k_AHwrUCcntAX9iZfng">369,654</ix:nonFraction> (treasury) shares equal to the monetary value (approximately EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA" decimals="-6" format="ixt:numdotdecimal" name="cvac:ProvisionForEmployerTaxes" scale="6" id="Narr_omatLzW7mUiDHg8DC2chGg">26</ix:nonFraction> million) of the beneficiaries (wage) tax and social security obligations, which CureVac transferred to the relevant authorities on the exercising employee&#8217;s behalf in cash. The share price of CureVac on March 11, 2021, was EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_H6GkULc44UOUqsJ4VqJkQQ">69.69</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A second <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="2" format="ixt:numdotdecimal" name="cvac:RightToExercisePercentageOfVestedVirtualShares" scale="-2" id="Narr_eWLu5D1hGUqhU8yWun2YBQ">10</ix:nonFraction> % portion of the (vested) virtual shares became exercisable on the first anniversary after IPO i. e., on August 14, 2021, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were reached. The beneficiaries declared the exercise of their exercisable <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_10_18_2021_To_10_18_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_NU3QWXFiZkS0exKI1Z5L4Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_FuYfUxQfcU2vcP-zwkU9pQ">765,223</ix:nonFraction> virtual shares by October 18, 2021 and CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_10_18_2021_To_10_18_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_NU3QWXFiZkS0exKI1Z5L4Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_k6b-9FmKl0un43IjSYkPCQ">765,223</ix:nonFraction> shares from the old shareholders on that day. On October 19, 2021, CureVac transferred <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_6-utdyqKG0SBGykuUrHY9A">523,897</ix:nonFraction> shares to the exercising beneficiaries and withheld <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:TreasurySharesTransferred" scale="0" id="Narr_tkhoMmNAY0q3j9KSpkZmVQ">241,326</ix:nonFraction> (treasury) shares equal to the monetary value (approximately EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ" decimals="-6" format="ixt:numdotdecimal" name="cvac:ProvisionForEmployerTaxes" scale="6" id="Narr_mUFnJCYMp0qxSaUXXb0FyQ">8</ix:nonFraction> million) of the beneficiaries (wage) tax and social security obligations, which CureVac transferred to the relevant authorities on the exercising employee&#180;s behalf in cash. The share price of CureVac on October 19, 2021, was EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_N4QMIaWPBUaAN89Kon5uwA">34.56</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_14_2022_To_8_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_vhVPWZE6FE-yd2_OHphj6g" decimals="2" format="ixt:numdotdecimal" name="cvac:RightToExercisePercentageOfVestedVirtualShares" scale="-2" id="Narr_ImwhryUaE0me2T1tW0vZtw">10</ix:nonFraction> % portion of the (vested) virtual shares became exercisable on the second anniversary after IPO i. e., on August 14, 2022, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were again reached. The beneficiaries declared the exercise of their then exercisable <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_12_12_2022_To_12_12_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_RQ8a6WZN30er9veT-GsPsQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_5W9TPOeXnkW0asZsNjJ_fg">777,260</ix:nonFraction> virtual shares by December 12, 2022 and CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_12_12_2022_To_12_12_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_RQ8a6WZN30er9veT-GsPsQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_3PwT5mTBgUyCJZlS-rm9FQ">777,260</ix:nonFraction> shares from the old shareholders on that day. On December 14, 2022, CureVac transferred <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_12_14_2022_To_12_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_AYQqGHS96EG_31uhHqhopg" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_BhopSudEKEas_r6_tdNb6A">777,260</ix:nonFraction> shares to the exercising beneficiaries. The portion of shares equaling the amount to be paid for (wage) tax and social security obligations were sold to pay for these amounts. For former employees CureVac shows a receivable position equaling the amount to be paid for (wage) tax and social security obligations. The share price of CureVac on December 14, 2022, was EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_14_2022_To_12_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_AYQqGHS96EG_31uhHqhopg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_vR1itbL7w0ys4aygLwWyVg">6.96</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A fourth <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_14_2023_To_8_14_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_c7I5rda9O0unxghjuyCeYA" decimals="2" format="ixt:numdotdecimal" name="cvac:RightToExercisePercentageOfVestedVirtualShares" scale="-2" id="Narr_-uAKCvE2AkyEcfjY8ahBHQ">10</ix:nonFraction>% portion of the (vested) virtual shares became exercisable on the third anniversary after IPO i. e., on August 14, 2023, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were again reached. The beneficiaries declared the exercise of their then exercisable <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LzXStsEX10Sllgbp-IfhBQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_sYQgY0fzWk2OJbbKjGzubQ">786,746</ix:nonFraction> virtual shares by March 22, 2024 and CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LzXStsEX10Sllgbp-IfhBQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_mYHrzEz3rUi9fazlDbkDxA">786,746</ix:nonFraction> shares from the old shareholders on that day. On March 26, 2024, CureVac transferred <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_26_2024_To_3_26_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8MhaP9inOEWOlUmUTvRFIA" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_5d64Y9qUQECcEX2QBrEDnQ">786,746</ix:nonFraction> shares to the exercising beneficiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Expense recognized in the statement of operations and other comprehensive income (loss)</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" name="cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="Tb_uG-GhwUd6kOYYjaHviKQZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The expense recognized for this share-based payment plan during the years ended December 31 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of Sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" sign="-" scale="3" id="Tc_cTjLrkVNi0OpqStaGl5tnA_3_6">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" sign="-" scale="3" id="Tc_W4YqFMq5CU2xl-hpjHyaAQ_4_2">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" sign="-" scale="3" id="Tc_8qpqSs47CEaopfDxtZlKOw_4_4">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" sign="-" scale="3" id="Tc_a28D1l3e-0-tGg1G7PXCJg_4_6">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_uXqkn4zr4EmWb0mHxG_MUA_5_2">369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_J9Q8Kd-7BES9PfpA6l5W7w_5_4">45</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_CFuJ5wyyv0KbpQIhXMTe0w_5_6">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" sign="-" scale="3" id="Tc_T9WnR8-NG06kpvfuL-nWcw_6_2">230</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" sign="-" scale="3" id="Tc_5BYIKpaYkUS7l8FKi0LMmg_6_4">78</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" sign="-" scale="3" id="Tc_G6yQnD6wY0-03xouuemkPg_6_6">41</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" sign="-" scale="3" id="Tc_FXBIsrLGzUGCwDgq2WYgcA_7_2">624</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" sign="-" scale="3" id="Tc_xMMLigGLw0iMkT_IQaISHw_7_4">131</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" sign="-" scale="3" id="Tc_liI6GQajSEKZrhVnYX4bMg_7_6">10</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3abf0353_fdeb_45f9_88e5_72c70aa14878"></a><a id="Tc_XdLtjWN9DEaOxnPf-E_ztg_1_2"></a><a id="Tc_vbWrXsvavk2_ubO90g2o1A_1_4"></a><a id="Tc_6fESDVCgK0qR9tzHx7yYUQ_1_6"></a><a id="Tc_G2NQQ9IS0E2T9NCZ4pwcwg_2_0"></a><a id="Tc_isrgGdZzd0eXwwjo6rc-kQ_3_0"></a><a id="Tc_tDX6LAiEDEKDcE111iwi7Q_3_2"></a><a id="Tc_5GU4qLYtA0qBfrlxFXMrnQ_3_4"></a><a id="Tc_Lvx_g6WQ2EaIwM9_38mDXw_3_6"></a><a id="Tc_73YRyYyFakmbRg13HxS0uA_4_0"></a><a id="Tc_E1yxBgQTR06tCz6fIrJYZQ_4_6"></a><a id="Tc_-cmdeH3uRkCQS_tR_ESy5Q_5_0"></a><a id="Tc_OaKQUHCfTUW8ty-_cyA8fQ_6_0"></a><a id="Tc_nF0hPUhMLEmHo9HkOlbuaA_7_0"></a><a id="Tc_5DW__xTD0UyZlhlPDxz70w_9_0"></a><a id="Tc_LF7JGxmtGUqdP0nb-k9teQ_9_6"></a><a id="_03bf7b14_b737_4a4d_8eba_4fe934d6b53f"></a><a id="Tc_PdiThy__AkefGvxRFJQd3A_1_2"></a><a id="Tc_Y8kFVF4dH0qYDyYZkt0zZQ_1_4"></a><a id="Tc_oqP7NbspUUq5WYVYXYYsNQ_1_6"></a><a id="Tc_CGGTYbmH-kejQW-vNP4hqQ_2_2"></a><a id="Tc_ltXmgDO6U0GXJGQcNKEmZA_2_4"></a><a id="Tc_u0AXJAVRPk-occ8wtUmc9A_2_6"></a><a id="Tc_igcfDZPs_0u6Pra3up8XdQ_3_0"></a><a id="Tc_O2SNX3qqnUq0s1KFWsC1Pw_4_0"></a><a id="Tc_Jr5XrudNGEOi-BZeXiN5_g_4_6"></a><a id="Tc_CVKDPidHi0qwIhdNNMOmMg_5_0"></a><a id="Tc_y5ls6GzMDkedSRqo6DRvkA_6_0"></a><ix:continuation id="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont2" continuedAt="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New VSOP</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="Tb_AzBlJU1_QUSjRuQGqZtlKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The number of awards in the New VSOP program granted to key employees developed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the beginning of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wK1DnDLSIkWj7Emo6TjbNQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" id="Tc_2kBCMk-0-0CbAqm-Pl9sbA_2_2">906,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" id="Tc_osjBFV12302d5-TdTmHvAg_2_4">349,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" id="Tc_UbIbZL01-kWDpZz1HBxJ9w_2_6">102,108</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="3" id="Tc_BFFANs7Q-EKSXYD2JUbJag_4_4">99,696</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised during the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="3" id="Tc_Rl-zrsjFXUC-FLMzPjZVIg_5_2">557,171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="3" id="Tc_v6SGIvuLW0CPKXvfiQYkAg_5_4">147,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="3" id="Tc_Pt4SBMdLl0OvuGwN4ESB-g_5_6">69,246</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" id="Tc_JqeNwy5dikyntOsmImiw9A_6_2">349,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" id="Tc_xzbRd6cOr0GvwxvIHwE99A_6_4">102,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WpDGmX1BBk-irWX_MsZINg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" id="Tc_HBqugzxp3EmjhGyoZ9NjrQ_6_6">32,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" scale="3" id="Tc_z5HO9-ToHkWL7bOP1HRO4w_7_2">88,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" scale="3" id="Tc_lXYhJHiB_Ei5crTVJ954eQ_7_4">59,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" scale="3" id="Tc_P2oWZ_UvXEO5MeDbMICPkw_7_6">32,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof exercisable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="3" id="Tc_2F-xqv1vxEGMlgLwhGJXRQ_9_2">88,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="3" id="Tc_McmpJLenCkaqginp6UKoBQ_9_4">59,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The remaining life of the option awards as of December 31, 2023 is between <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_gLfbS6LG906Sox56_2muhw" format="ixt-sec:duryear" name="cvac:RemainingOptionLifeShareOptionsAwardsGranted" id="Narr_4jsS4tnEAEqoX2R2bbhAFw">4.5</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-MBxnDM6-U6QBuGgHl5BEw" format="ixt-sec:duryear" name="cvac:RemainingOptionLifeShareOptionsAwardsGranted" id="Narr_gcnuXv-tU0uQWai1OKWdOA">5.7</ix:nonNumeric> years (2022: range between <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4ms1oi7d0EywO8ZNbgPv5w" format="ixt-sec:duryear" name="cvac:RemainingOptionLifeShareOptionsAwardsGranted" id="Narr_CVw7fXMgT0ercfpu8Ieudw">5.5</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WckCf34PZUGzza4sNjwFMA" format="ixt-sec:duryear" name="cvac:RemainingOptionLifeShareOptionsAwardsGranted" id="Narr_US-wqnMHyU-vontMCcaqog">6.9</ix:nonNumeric> years).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021 multiple exercises happened throughout the year. In total <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_I4_IhLTJjEKaN-zyEKLfgg">557,171</ix:nonFraction> options were exercised with an average share price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_fYpSGSXe_EW_x7HdBzRySQ">61.28</ix:nonFraction>. These exercises led to CureVac having to pay an amount of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wK1DnDLSIkWj7Emo6TjbNQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsEmployerTaxesPayable" scale="3" id="Narr_g1J6ROoH2Ua78p6OabgtRA">493</ix:nonFraction>k employer taxes and to use USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_HRF1MwVKgUu89NEIRuzDvg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProvisionForEmployerTaxes" scale="3" id="Narr_LVO04ktNbUO8fR8RDCLToQ">981</ix:nonFraction>k of the provision recorded in 2020.In 2022, a number of exercises were carried out throughout the year. In total, <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_ExerciseOfOptionsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wMo5XPBJDEWL4EzQFfN9nw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_S7bh73hnaUG8Sp8dqgovkw">147,620</ix:nonFraction> options were exercised with an average share price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_mZpZEQWy1E-9M2n-X2WSGQ">16.81</ix:nonFraction>. These exercises led to CureVac having to pay an amount of USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsEmployerTaxesPayable" scale="3" id="Narr_3Zx4ikUQg0id_j8NWxEyLw">45</ix:nonFraction>k employer taxes and to use USD <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsEmployerTaxesPayable" scale="3" id="Narr_jujo1AjepEKC9ncC5XYxoQ">51</ix:nonFraction>k of the provision recorded in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2023, a number of exercises were carried out throughout the year. In total, <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_qHL-5b_bCkS0eMvp0NdGnQ">69,246</ix:nonFraction> options were exercised with an average share price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_FY3J1kO0l0CHze4DE0AITQ">9.90</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Expense recognized in the statement of operations and other comprehensive income (loss)</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" name="cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="Tb_EJwBl2mMkkmiFQFtP9dPng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The expense recognized for employee services received during the years ended December 31, 2023, 2022, and 2021 is shown in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_e9VapVmxfUe-bMNFWlE1rQ_3_2">349</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_97nhJiWWC06aceyWZ9WYQw_3_4">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_1lJGYMJq4EqZZtnidqZJRw_3_6">31</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" sign="-" scale="3" id="Tc_f5nBCOdxJk6t7wtuROZBNw_4_2">188</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" scale="3" id="Tc_XHgZxRYnXUmtm6y3TY7vmw_4_4">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" sign="-" scale="3" id="Tc_GQQYlu8se0G7E-xghrRQzQ_5_2">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_NJgEZ4KejECGqsKASjI9dg_5_4">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_ILNCNmma7kukm7cA83LCNA_5_6">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_XUP_WKL3vEey-rluHP07pQ_6_2">572</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_CFqlMoXZwk2ERvdpijW5hw_6_4">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_SAyS3_rHVE28CAc3ra2OgA_6_6">19</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Term Incentive Plan (LTIP) - Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_h16zoZEEs0mNQJ4RroRV_A">266,155</ix:nonFraction> options to the former Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_jh1w8gRbgEipnv2Kd3Q7zQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_a9aAf_EQ1kSIcUNdlEdbaQ">266,156</ix:nonFraction> options (in 3 tranches) to the company`s former Chief Business Officer (CBO) / Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan put in place by CureVac.Options will be settled in shares of CureVac.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the former CSO have an exercise price of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MlAIV3j9EESYEfc4Yj76xA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_wRHSsvcvU0SoGpte1oqG3A">10.04</ix:nonFraction> per share option and an expiration date of July 14, 2030. The exercise price was based on value of the shares at entry date of the former CSO. The award vests over a period of <ix:nonNumeric contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_EkzMI72F9UOQTzkYFTeOhQ">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_5LhJWmRmf06i8Wocj-zjXQ">25</ix:nonFraction>% vesting after 12 months and the rest in 1/36 monthly installments thereafter . Exercise is contingent upon the stock price increasing by +<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" scale="-2" id="Narr_fEk7n5xOn0izN5uZ4CSe7Q">20</ix:nonFraction>% from the grant date to the date of exercise, based on the <ix:nonNumeric contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" format="ixt-sec:durday" name="cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="Narr_g5-JDbCT3UOQbnuzdEfc6g">10</ix:nonNumeric>-day VWAP at time of exercise.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_f6-XxxL7yUWBH47PiuFwyg_1_0"></a><a id="Tc_pAcbhpMnXEuNLcYKGPf9tw_1_2"></a><a id="Tc_qvnRXwIGtU2sll3BJ5PBnA_2_0"></a><a id="Tc_MZc60RIv-Ee-7Kl4sbY6DQ_2_2"></a><a id="Tc_TpFRw_mwikiipo-gsPh9HA_3_0"></a><a id="Tc_YQUQOpPml0iqN9lCUg-XqA_3_2"></a><a id="Tc_eeZ-p3eYzEiypxhQwnstYg_4_0"></a><a id="Tc_tF4VrwOVEEOBE_PYPAkHMA_4_3"></a><a id="Tc_QNUfd_A9gUKa5dupcd6SGA_5_0"></a><a id="Tc_N36t8NeixUaeErYEdPO5oA_6_0"></a><a id="Tc_IXNwIhLvvUWQXIBOqUD-mg_6_2"></a><a id="Tc_gLw4eVN_bkOb1Ceuxb06ow_6_3"></a><a id="_6e4ac3e8_553b_4670_a039_5e921045cea1"></a><a id="Tc_VEd8oQS2e0mLhcpTpZq80g_1_0"></a><a id="Tc_SeYLJAn7U0yhvauj_uEkZg_1_2"></a><a id="Tc_slJhLcY8QUGMdhXnzd-iBQ_2_0"></a><a id="Tc_KEwWR-82hkGbB5_J_0oZig_2_2"></a><a id="Tc_HDRgbxW3sk6ArVTOqbtAvQ_3_0"></a><a id="Tc_p-vS1cITPUW7bt-HBoXcJw_3_2"></a><a id="Tc_aflHD1Za2kG1-f8612jWYQ_4_0"></a><a id="Tc_KukpKCMyEEmstuc0EQyxKA_4_3"></a><a id="Tc_B6I5Xl0EV0a9paSCNR811Q_5_0"></a><a id="Tc_-KGwKPRQsE-GDDs3wOenPg_6_0"></a><a id="Tc_jV-0Rp94z0q-mbA3ZKKlDA_6_2"></a><a id="Tc_bE8fYyKsYEixc8s59VtAWw_6_3"></a><a id="_32ed3e1c_6d80_4a1f_8f90_9e3f3be55490"></a><a id="Tc_Mq4OWvGbb0G-BVDRFwOeFg_1_0"></a><a id="Tc_hemb5jLJlUaevLijceOxcw_1_2"></a><a id="Tc_fA8QgHTSPEanhzRX9LRsJQ_2_0"></a><a id="Tc_JDKMW1MJpk6kisLcuE51TQ_2_2"></a><a id="Tc_5Ig1KG0XFEG4zvZPD9jOqg_3_0"></a><a id="Tc_Be_Kh-7q70yvdqYPEO10EA_3_2"></a><a id="Tc_2ZkyMUOAMUyjXBSq4C29xw_4_0"></a><a id="Tc_pQwj-cgrKE6TIy7UQjsqeg_4_3"></a><a id="Tc_xHZVOdzspU-1enD2Wa9NnQ_5_0"></a><a id="Tc_N4copnDKR0S1pIoCppAyIA_6_0"></a><a id="Tc_arYCMBD0LkOcd-QnAwSdtw_6_2"></a><a id="Tc_5mdttJClh0SO_OQPSIErpQ_6_3"></a><a id="_75262cc9_08e9_4c75_8874_7c993231211b"></a><a id="Tc_3NVtWHwNDUqfeZNT2V-jww_1_0"></a><a id="Tc_Rb89d7WcjkWqSsrsCzFO4w_1_2"></a><a id="Tc_NGy-u-TY6kafCtqpZPFUKg_2_0"></a><a id="Tc_6WbBOLIQbkufOs0QI1BnMA_2_2"></a><a id="Tc_BcQc3sb2H0mJF4FcC6B9Dw_3_0"></a><a id="Tc_Q0-G_EaEWkmNxpL_hqg1DA_3_2"></a><a id="Tc_NDOufuKKLkCA_9h2_N8jmg_4_0"></a><a id="Tc_d8ex-5lEpk-d8UZsdhzqTg_4_3"></a><a id="Tc_Ezs220yOrUiR7nsN3P3DBQ_5_0"></a><a id="Tc_Jze7WEi-tkCe4OJBaOuMhA_6_0"></a><a id="Tc_iH-2IDd70UaK_HDl_G-1sg_6_2"></a><a id="Tc_8JUpI2na2U-d9GoePu5axA_6_3"></a><ix:continuation id="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont3" continuedAt="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the former CSO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="Group_dDIDNyJK5kiORGNPsPB6Og" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_369zwdq-PUCU0HZwexOHZw">57.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_B2dUjzvbTUalYcUHWHSCIA">50.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_YRbyjLezhUWJWFgH1Qiewg">11.90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_sDD8AvQSzE6AExUdKaAvew">10.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_EAMHzSVkO0uDlBeJHVKTmA_4_2">62.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_JCjPXm9avUqmHiemGSCR-w_5_2">1.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_BR9esw-0g0WSTYUwmmFSEQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_ElEAflM0ekSJz0hw1HkykQ">0.07</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_2nV73AJ870mDjh_tkOBisg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_N1qmRgh3AUCVEEo1Bj5tVw">1.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_NUSNjsD8UEOnZi8loJYDVg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_2DCtRqW_5k-ZQmRy5SBDIw">6,303</ix:nonFraction> options granted to the former CSO had been exercised. <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_uKCC8GofE0G_GEmvlAEeTw" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_ToCipSMftUeHAtX_GZACng">No</ix:nonFraction> options granted to the former CSO had been exercised in 2023. As the former CSO left the Group as of July 14, 2023, all remaining unvested awards were subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the former CBO / CCO have been granted in 3 tranches vesting over <span style="-sec-ix-hidden:Hidden_QbGLvVS5SkqjgHf0Brd8Fg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span> to <ix:nonNumeric contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JtGHYH8FrEKyyYF5zBuS5w" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_ZxvFr5Ih50iGQSzDehMyzA">3 years</ix:nonNumeric>, with exercise prices applicable to future tranches being estimated. The exercise price of the first tranche is EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_11_16_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_rkGlJwdXYkifsZbvBkjdoA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_rsVxgJiktEGcAnmhiwvOpA">43.87</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_11_16_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_rkGlJwdXYkifsZbvBkjdoA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_gGpdQCG2vkOvGOcdqfwOOg">52.96</ix:nonFraction>), The exercise prices for future installments, 2021 and 2022, were estimated to be EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_-_-inCxASkiTTlbNRKnG9Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_mA5QK1NMSk2kLf5wK7rlow">81.48</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_-_-inCxASkiTTlbNRKnG9Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_u4Anla7Vw0eIzF3Z7XWeYg">98.36</ix:nonFraction>) and EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_UBWp1OUhsESfo0wo4zeF7Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_AIb0kT8rFUeJKymzlWMtLw">81.65</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_UBWp1OUhsESfo0wo4zeF7Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_kCxnAwJo8ky1Y-Y2RsT2iA">98.57</ix:nonFraction>). For the second tranche the actual exercise price in fiscal year 2021 was determined to be EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_LeF6mzlRgUqn4uUTYSSTkQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_3RcrAYNd10mfj0aHIm46uQ">33.07</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_LeF6mzlRgUqn4uUTYSSTkQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_TFKwhclE5EascV1QZ2g0-w">39.92</ix:nonFraction>) and of the third tranche the actual exercise price in fiscal year 2022 was determined to be EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_FRvDHd6gz0-TIgKz3l7NTQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_1BP2-PXc7kCYCQeIVbnU1A">7.35</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_FRvDHd6gz0-TIgKz3l7NTQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_GPeestl6Ek2pGX7V6tDbWg">7.68</ix:nonFraction>). The tranches each have a term of <ix:nonNumeric contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_38uXsNcfl0e1xpuxCmbyTw" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_ApkSzU33MEmnG0IGPdE5IQ">10 years</ix:nonNumeric>. Exercise of all three tranches is contingent on a share price increase of <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_38uXsNcfl0e1xpuxCmbyTw" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" scale="-2" id="Narr_oJPZcUixoE2Eufsg4phvXw">10</ix:nonFraction> %, based on a <span style="-sec-ix-hidden:Hidden__sfsWKiKEkycy4zRfN1NDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span> - day VWAP at the time of each exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the former CBO/CCO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_2" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">First tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_X6L3rcVVzUqdnRUUpwy7Tg">48.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (actual 10-days VWAP before grant date, USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_O8_PkiFMdkWdom8WATp9bQ">81.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_ztR6cezj7kmokW41YQSh2Q">67.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_q57cW_DNZ0-CsT6kz8SWGw">52.96</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_vmHUsr8K00ycxPzcoGo8bg">43.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_1KCppi_b_0qS2rCvHgTm7Q_4_2">62.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_7YzNj3ODMUyjPDjCQj-V6w_5_2">1.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hjZQJLPupkuissku-yiCaw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_osF9Sv57rkyt0OJfcOJYBg">0.07</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xyqNnfW_P0-d5WX8yyxmQQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_eU5yzCMTMUiF2uFsLoxU_w">1.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">Second tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_IVuRYcqWFEOVxundSn42_g">24.36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (estimated by Monte Carlo simulation to be USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_i61Gn-lTQ0GB3__zizp0BQ">98.36</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_OyOfPtvWZE64M0Scm_0cFg">81.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (estimated by Monte Carlo simulation to be USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_WtrSNIWy2EGJ0cj0x-b9TQ">98.36</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_vG3rFbzUskSwnxYRYuwAzQ">81.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_qVqflbKpwE-43nxqvWcH_w_4_2">62.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_m0IpS_AVEUuD5g7zMLEHVg_5_2">2.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_YWA7IRvytUCV0dt4jLtEeg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_Q8n_BjGdfUOpnlF63uAOqw">0.07</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_5g69MJCNR0qupo7-cCBilg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_QrF3rh67lkqa3I-8vaAfgg">1.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">Third tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_U8Trx90CLkeI0srANloX_Q">20.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (estimated by Monte Carlo simulation to be USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_Omi6ezzaDkW18NdD3o3G4w">98.57</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr__QaqIqNtfkqrX7V61lE-Wg">81.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (estimated by Monte Carlo simulation to be USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_YQdOesAmN0KOIyTIAEoMUg">98.57</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_NPSdz2MrAE25cyPN4dmTOw">81.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_A5Trh88OOkiovL1aAduaRg_4_2">62.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_5-31TNWgx0GF5oFxE5DtGA_5_2">2.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_z3m9cMNGJkyyuC_pOxiLYw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_ybVj_TW9_E-nGP9AnmPraw">0.07</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_nwphsrqbPkGFkMezYtJrvw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_dFDCFmj6xUCG-eH5enzUaA">1.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As the former CBO/CCO left the Company as of November 30, 2023, all remaining unvested awards were subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ZcGedA06eE61healMwKwRA_1_0"></a><a id="Tc_l9dPdDAdGUO4ELifOHzgpA_1_2"></a><a id="Tc_8tf6auodc0GQfi9iQIuAew_2_0"></a><a id="Tc_Xgy-_mswDkCRMlrv76nSOQ_2_2"></a><a id="Tc_qZuEYddF-kCbgK7b9bzxLg_3_0"></a><a id="Tc_8jJKpnIhu02UG4vu55MbFA_3_2"></a><a id="Tc_HkTyQK9AkES0ocTI1GOlrg_4_0"></a><a id="Tc_PmmA7_T57kiVv8QLCcEHHg_4_3"></a><a id="Tc_qLBdPxswUka_Yj7b4Blb6Q_5_0"></a><a id="Tc_-rQ4-TwGF0imEhyhZHAcwQ_6_0"></a><a id="Tc_gaKN6VW4ekmpXVnBkjopOw_6_2"></a><a id="Tc_WziQB-DEgEis0VE4kGqOGA_6_3"></a><a id="Tc_qGZx5MY270WE-K63XWw1kw_1_0"></a><a id="Tc_KqFDxopl4km_a8z3-0AUbA_1_2"></a><a id="Tc_prJRXfcONEyL7TWEYLUK5Q_2_0"></a><a id="Tc_pNhSw9biiE2J3dV0OiG6KQ_2_2"></a><a id="Tc_4c_Tc3IGXEmj2-_shYBHRw_3_0"></a><a id="Tc_64e3MjjAkUGFK9_GhLPbJg_3_2"></a><a id="Tc_1XK22_kIMEaTT9dHHqI2iQ_4_0"></a><a id="Tc_7NxyORzHFkCJuGWmnLRHHw_4_3"></a><a id="Tc_BCgsTQLMP0-wpQ15wXi7rg_5_0"></a><a id="Tc_bsENvA2e8k6ujzKxGBx5yQ_6_0"></a><a id="Tc_h7MJy_04yUKN_4sWznY4xQ_6_2"></a><a id="Tc_d6l7oyolTEaBvSPw0VpG-A_6_3"></a><a id="Tc_2cy_3lQJ-ESOLMNXkMSCeA_1_0"></a><a id="Tc_EOd3YCrYtEu-NeXfPAj7Pw_1_2"></a><a id="Tc_e3rwc0-I80eGLume8t3aFA_2_0"></a><a id="Tc__bmbS4nfCEiPkxQKOHpTAw_2_2"></a><a id="Tc_QkwnPsMAUEyHSnPsgsrJPw_3_0"></a><a id="Tc_KirS_9wJWUW9JpNVm4QayA_3_2"></a><a id="Tc_OMBan9aQpUW1i4AF7a2Hsw_4_0"></a><a id="Tc_r2cQOwfK4Eaje2u1XIzb_Q_4_3"></a><a id="Tc_WSkKjHVyhU2M0JDWqVq-2A_5_0"></a><a id="Tc_DHvkrgBIsE2x57HA_9_nKA_6_0"></a><a id="Tc_xtX3ip7n7kuYaXgnxWRxUw_6_2"></a><a id="Tc_E77jMxMPUUeQdXWmLurw1A_6_3"></a><ix:continuation id="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont4" continuedAt="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_rYFLjLEep0ajcFxkKpskoQ">2,000</ix:nonFraction> options to a key employee. Options granted to this key employee have an exercise price of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_nrIihK8t60Kg6c5Z8quIzg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_-aUg33L_iUSTCbEh8DvdJA">77.73</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_nrIihK8t60Kg6c5Z8quIzg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_3cX4XtnJz0-zjIWdzSbekw">88.16</ix:nonFraction>) per share option and an expiration date of February 28, 2031. The exercise price was based on the 30 - day volume - weighted average price (VWAP) of March 1 &#8211; March 31, 2021 of the shares. The award vests over a period of <ix:nonNumeric contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_kPwskKesd0eRPws3VYVPYg">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_KeZjZq0dPEKk-S2BuqjkYA">25</ix:nonFraction>% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" scale="-2" id="Narr_asNgyZMOCEaxMNu8TtCE9Q">10</ix:nonFraction>%, based on the <ix:nonNumeric contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" format="ixt-sec:durday" name="cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="Narr_CyYR27D2SEa-YVLqt3vV_Q">10</ix:nonNumeric> - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_3" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_yU8axQyL70K_HnE_L-1hWg">0.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (30-days VWAP after grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_t1-DTzm6gkaw31MYefYwJw">77.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_jpnt_Qkh80SEH5rLvclaIw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_jLW-f9VTcUCX4VR85lsekg">88.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_tSlGKro8UUm74KlhEncu0g">77.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_q7u8NnfRe0OiOEQYPA5D7w_4_2">73.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_0I393VrhUkumkgwfOezwpw_5_2">2.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_C0Yd0VHbrESYa5VTH7JK-g" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_jKtfYAKFGEudS1y923_Oug">0.08</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Y2yquS5opE-ddUHuqsYCSg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_H8KxpSdgVU2pg3OfWktz6A">0.49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_T-9SDwhe_0qq4opfNtgg1g">20,000</ix:nonFraction> options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_TpUKYadcSE27PjnOUAUk2A">30,000</ix:nonFraction> options to the former Chief Development Officer (CDO). Both grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the COO have an exercise price of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember__tOhjBnh-k-Pzhm_-oubRQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_6BDFBdrJJ0uNgGMXxx4LIA">70.92</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember__tOhjBnh-k-Pzhm_-oubRQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_vVzcP8OPw0WzAjdaqOE3jQ">84.03</ix:nonFraction>) per share option and an expiration date of July 2, 2026. The exercise price was based on the <ix:nonNumeric contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" format="ixt-sec:durday" name="cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="Narr_AHBJh6qi_0uyd1NReDR74A">20</ix:nonNumeric> - day VWAP of the shares at entry date of the COO. The award vests over a period of <ix:nonNumeric contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_Aay5oHzcHUS2URL02r0akw">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_xXMoj0lcWUi48BrKUsZnig">25</ix:nonFraction>% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" scale="-2" id="Narr_yqZBMJ3O8EiP_kIojdezMw">20</ix:nonFraction>%, based on the <span style="-sec-ix-hidden:Hidden_YzcivET66UycOOg4x0ArdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span> - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the COO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_4" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_oFGBD5Zew0Gn_IfmFgO6AA">17.56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (20-day VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_s9wFEIJqc0yHWlZZFfOyug">56.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_EsUIaWOf4UGzgm4lHifDlg">84.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_YgaaedEW90-mqhgEirKunA">70.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_DV1IWoU_zEKpgy6CYm-e7w_4_2">70.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" decimals="1" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_8Bm4c_7-5Ua7hctyfB0LMw_5_2">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_KQcN-T4_jUa6vvQqtTmIxA" decimals="5" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_S0otEMl0mE2nXUlF5hHS0Q">0.099</ix:nonFraction> &#8201;&#8211;&#8201; <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_YQ7OFau-40655Qsd3p7mHw" decimals="5" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_4awXyc402kW2cRs1qisyOw">0.903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the former CDO have an exercise price: EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_wHx_7Z9Dg0my8RqwuxGOxw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_X9grP2K-Vk684IparK5YHQ">46.16</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_wHx_7Z9Dg0my8RqwuxGOxw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_v3KSA-lvqESvFhb1pmkDHg">54.79</ix:nonFraction>) per share option and an expiration date: August 2,2026. The exercise price was based on the <ix:nonNumeric contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g" format="ixt-sec:durday" name="cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="Narr_RQlzUfn4BUyK1AiBCvmsIg">20</ix:nonNumeric> - days VWAP of the shares at entry date of the former CDO. The award vests over a period of <ix:nonNumeric contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_31wR9Hup6kCIEvqLNfd-8g">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_c5ATAxYFsUOXPzCkF_mjIQ">25</ix:nonFraction>% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" scale="-2" id="Narr_ICz8EX16CEqHE9MizkrzSA">20</ix:nonFraction>%, based on the <ix:nonNumeric contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw" format="ixt-sec:durday" name="cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" id="Narr_HzOBr8O3DUCcTFj7lAy3fQ">10</ix:nonNumeric> - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the former CDO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_5" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_pw0dN1j2Z0qjUXKpZQ-R1Q">17.56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (20-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_RFp3cXF90UW4_vV6TRBVQQ">41.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_WMpccKMsX0y6nuVh_7B5GQ">84.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_5lrCU29RcUaN1FqB3r5raQ">46.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_7jPIY9CzfE2A8y8dld47rg_4_2">75.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg" decimals="1" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_VnxJ2NL_Tkuxja3Dkt-oMQ_5_2">4.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_RPtNKWdi7kep-OWhPRdbZw" decimals="5" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_j7zyaVp3O0q4hKr73u2JYw">0.075</ix:nonFraction> &#8201;&#8211; &#8201;<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_x2jtrAGjukm-Q3NjjwN9zA" decimals="5" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_BaP1BUFie0O63LR9FqoYmQ">0.704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The former CDO has since left the company and, under the terms of his LTIP agreement, his options had expired as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_BDrLM9I0okeajcmmXx0_dQ_1_0"></a><a id="Tc_qWlXESPnBkK7fw31CGGOXQ_1_2"></a><a id="Tc_sUjHiUVld0iHvWoFdc4NDQ_2_0"></a><a id="Tc_RB1Y18ZEjEeJ01XSAMsxDQ_2_2"></a><a id="Tc_6FbiuyiI_EuuO0BzgITJfQ_3_0"></a><a id="Tc_YoJzn4SvrUij7Nco_p9_Hw_3_2"></a><a id="Tc_zpAFRKQeJUiWOPpFBLYz8A_4_0"></a><a id="Tc_iURnqTpEWk29B2u1VLGOXw_4_3"></a><a id="Tc_WSSrhj9aoUmtox4dbRZSeg_5_0"></a><a id="Tc_AT1xczXZdEaqVHAh2oVXQw_6_0"></a><a id="Tc_kth17U4CUEehFP6hpeYZfA_6_2"></a><a id="Tc_GT3pg4YYdk6nYCQ1DDD0kg_6_3"></a><a id="Tc_XxfoIkUNjEKZWwXiLM_a1w_1_0"></a><a id="Tc_1nLtHeD2IkqW1AMlKK8r7g_1_2"></a><a id="Tc_iEY9QJccLkmYXqCV936a1Q_2_0"></a><a id="Tc_AqiceAOKLkS1JxF8eq5d9g_2_2"></a><a id="Tc_Lghn1JkgJ0qOap24ChHN7g_3_0"></a><a id="Tc_p4lyJMXhEk6xyY25w-STSg_3_2"></a><a id="Tc_PPrZP5debkqt7ttdOVi2Lg_4_0"></a><a id="Tc_AHsQ14xiKUC8lYibshJolw_4_2"></a><a id="Tc_vZKYWZ1Ji0CIYWVOQzF1pQ_4_3"></a><a id="Tc_8bhquqFvskewcSakmKLW_Q_5_0"></a><a id="Tc_yb0RrKV9p0aWNHS_UOs4Hg_6_0"></a><a id="Tc_bAJJ7Orm402f6vnZcpP-9g_6_2"></a><a id="Tc_eGxCXuYAX0mG9jq-dwshVg_6_3"></a><ix:continuation id="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont5" continuedAt="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_eVmliQYuVk2ddZB68jYp8w">9,500</ix:nonFraction> options to a key employee. Options granted to this key employee have an exercise price of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_bx2x9QVGwUKRwb9RkD06sQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_lnA15SsAwUyzGKrfV1yyMw">30.67</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_bx2x9QVGwUKRwb9RkD06sQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_KdKhkB2gW0mwuCVY3c3wRA">33.87</ix:nonFraction>) per share option and an expiration date of December 31, 2031. The exercise price was based on the <ix:nonNumeric contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" format="ixt-sec:durday" name="cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="Narr_8Rao5uNpfky_StQRFzHjTw">30</ix:nonNumeric> - day VWAP of January 1 &#8211; January 31, 2022 of the shares. The award vests over a period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_sXpDll66UEiwkgljfYD57Q">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_6vpNUKaYNUyYwC_sxM5LIg">25</ix:nonFraction>% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" scale="-2" id="Narr_UfQoDjX4-kST-wbpW8O7gQ">20</ix:nonFraction>%, based on the <ix:nonNumeric contextRef="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA" format="ixt-sec:durday" name="cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" id="Narr_3be-ebFnb0mpPTsVBvjU_A">10</ix:nonNumeric> - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_6" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_BXgOwAY-8kWiag28J9nqRQ">14.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (30-days VWAP after grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_xaYKmDlzV0yEBhLEIYwDkw">30.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_dKZF2Y60cUSLk0zjHaZ5dQ">34.87</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2022_To_1_1_2022_WZMCwy54QUmI6ryK9Caqbw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_83JwmovxXEK6yK3jAiZy1w">30.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_-S5QYpKRKU21Ww-8z6Pi_Q_4_2">72.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_Qzbj6XHK0kqu1lBa1Dgi_w_5_2">2.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_sopM0fRxjEGXBD4cfhAb-w" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_yHKmwLjkTkWSOIezlyxWaw">0.40</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_vwFy4tKujEGvLRYO8xC60g" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_jmCGxEB5fESM9vJOnynRbw">1.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The key employee has left the company and, under the terms of his LTIP agreement, his unvested options have been forfeited as of January 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_9rNAShnTckS6xPeeQAhFeg">130,000</ix:nonFraction> supplemental options to the Company&#8217;s management board. <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_s1OUV32MXEmc3KvzrvgpIg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_cQ7Rq9fcGEGXXZKtvzBaZg">30,000</ix:nonFraction> options were granted to the former CEO, and <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_QddTv344JkOsFwJFGAPjQA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_eTmVhE_FhkaGQSZfuFYMgw">25,000</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_tznxVCWtS0SW9reUKePQUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">options</span></span> <span style="-sec-ix-hidden:Hidden_-FWGuI_NEUqdXYeZrX373g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">were</span></span> <span style="-sec-ix-hidden:Hidden_hL-cJYxbn0-tJ6X_juFSYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">granted</span></span> to each of the CFO, former CSO, COO and former CBO/CCO. All grants were made at no cost under the terms of a new long-term incentive plan put in place by CureVac. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options granted to the management board have an exercise price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_3LoLbhctnUiC8qf9ru6Lyg">19.35</ix:nonFraction> per share option and an expiration date of March 1, 2032. The exercise price was based on the <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" format="ixt-sec:durday" name="cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" id="Narr_WmqWPFe6HUe-IAlC8oZlcQ">10</ix:nonNumeric>day VWAP as of March 1, 2022 + a performance criteria of 15%. The award has a vesting of <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_y1_WCcSI20-05QOkXbljog" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_tITvYS2EmUCkboizACqnXQ">25</ix:nonFraction>% on each of Dec 31, 2022, Dec 31, 2023, Dec 31, 2024, Dec 31, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grants to the management board, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_7" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_a3H4BQ8LREarvhbs3Aw7zw">4.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10 - day VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_-LJPHGTHEkKDRDexexsv1A">15.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_GozJjRpBK0iF9S5NPbZxJA">19.35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_-MopLh2Nv0uvjq1qh1t-Wg">18.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_VWLXKKbGpUq7QH7ui7XDUQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Narr_8SdagxVS2UyMbHDgjI-Wvg">73.87</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_b0HAzOV390aY5p51-Rkqhg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Narr_delOaki8fUe68UFu6K54dw">86.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA" contextRef="Duration_3_1_2022_To_3_1_2022_y1_WCcSI20-05QOkXbljog" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_27y6XM7HKESQnE5HaIJO6g_5_2">2.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_VWLXKKbGpUq7QH7ui7XDUQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_OopRCwL34UaNJUW43Ld-Vg">2.34</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_b0HAzOV390aY5p51-Rkqhg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Narr_HHobAb-DBEm5Ob4UaH8Rfw">3.21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As the former CEO, former CSO and former CBO/CCO left the Group, in 2023, all of their remaining unvested awards were subject to accelerated vesting. As of December 31, 2023 none of these options had been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_P5vdUy0dhku-gGRouu-6bQ">700</ix:nonFraction> options to a key employee. Options granted to this key employee have an exercise price of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_eThCk2awTUa5-6f7LEuCSQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_1e9U2qIijU2RHkegkJtg7w">17.45</ix:nonFraction> (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_eThCk2awTUa5-6f7LEuCSQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="Narr_e-VB75OwwU6UpXXxXLYVPw">19.28</ix:nonFraction>) per share option and an expiration date of March 31, 2032. The exercise price was based on the <ix:nonNumeric contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" format="ixt-sec:durday" name="cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="Narr_zChIeXXb-0mcL27gLW7dTw">10</ix:nonNumeric> - day VWAP of March 21 &#8211; March 31, 2022 of the shares. The award vests over a period of <ix:nonNumeric contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_k027aOwVFEuoQBBDrIb2Zw">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_9lv_Fy3DC0-Uh4G66BAr9A">25</ix:nonFraction>% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" scale="-2" id="Narr_b1HRsXyGmkGURTrHtOU5eg">20</ix:nonFraction>%, based on the <ix:nonNumeric contextRef="Duration_3_21_2022_To_3_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_M7yeLt7eC0yDiQxH3rlo7g" format="ixt-sec:duryear" name="cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="Narr_8I_0SlUleEeyaLzjLJrGBA">10</ix:nonNumeric> - day VWAP at time of exercise.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_5l37RMm9c0Cbl8yogVTfgw_1_0"></a><a id="Tc_tYK5yo9Ah0ykha89DMbC1g_1_2"></a><a id="Tc_AH6Hnjif706CoWTcac2Cbw_2_0"></a><a id="Tc_d0AJwiO9CEWtbjpIrMqvTA_2_2"></a><a id="Tc_NobB0ExIKUOG8awxnzIUpw_3_0"></a><a id="Tc_XZgRJq1ZaESYHoYGjDyRsQ_3_2"></a><a id="Tc_zAkPlL0UUU6zeg_BVEioBg_4_0"></a><a id="Tc_L4nK1QWaO0mGqeFYlKLNFg_4_3"></a><a id="Tc_xxVQBPZmNUOCCyzGIc6tUQ_5_0"></a><a id="Tc_oE_0nELdu0aUYxBU0RHtaA_6_0"></a><a id="Tc_v9w2oczROUaJYxGzxCMv2g_6_3"></a><a id="Tc_g75ihqi4XkaZYNKxPoRwZw_1_0"></a><a id="Tc_4k_gnOSvF0ahYxH7ExVc3Q_1_2"></a><a id="Tc_oomLzUCE9kesblMGKHJ-Fg_2_0"></a><a id="Tc_bYXIz24uW0u7clPmsYlfPg_2_2"></a><a id="Tc_Af3yLktc002wEQzMU6RyUg_3_0"></a><a id="Tc_uhT-8KouR0uLjDc1JqYaAA_3_2"></a><a id="Tc_tjQ-q9ZGt0yf_rLpOpMB9g_4_0"></a><a id="Tc_-b0jAJFcvE-mwCgaKdmgAQ_4_3"></a><a id="Tc_rOtvKfDrk0iHXfVb_xqEwA_5_0"></a><a id="Tc_shS2daYrhUyL-huDpEvaVA_6_0"></a><a id="Tc_EzcRb8jIj0SMgF6PZGMM_w_6_3"></a><ix:continuation id="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont6" continuedAt="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_8" continuedAt="Group_dDIDNyJK5kiORGNPsPB6Og_9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_o2EjXR-fXkaDTOugOR24lw">6.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_UDNqozGWgky3bz16pvDKiQ">17.45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_0BmescjZ10Ox2hP97DumgQ">19.28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_eBp1e2f40kmaVcj2Z6iVrg">17.45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_5P1nCs914kOoB_6G_BPAKg_4_2">50.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_VtRckBWZ_EqapG9ND2AOvw_5_2">2.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Tc_4Y8Yq20QiUm1NqGpx54z8w_6_2">2.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On April 1, 2023, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_x6s2vBxPH0OH-sUVuKrR1A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_jOy9_rjqek-NH9Mt49PuBw">144,379</ix:nonFraction> options to the current CEO. All grants were made under the terms of the new long - term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of December 31, 2023, none of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the CEO, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><ix:continuation id="Group_dDIDNyJK5kiORGNPsPB6Og_9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Weighted average fair value per option</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw" decimals="2" format="ixt:numdotdecimal" name="cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" scale="0" id="Narr_PgsECSJe6UCC2D-lST2xrw">3.55</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Weighted average share price (10-day VWAP before grant date)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="Narr_0AiGZDlnjUS1RpfDUpGVXA">6.12</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Exercise price (USD </span><span style="font-family:'timesew Roman';"><ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr_vfe1RGIl0kSToLxyGyNTXQ">6.66</ix:nonFraction></span><span style="font-family:'timesew Roman';">)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="Narr__nWntDouvUii0Wp0uNnBuw">6.12</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Expected volatility (%)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="Tc_i_FytkJlFUayP0mAdBwdSg_4_2">75.0</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Expected life (years)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> <ix:nonFraction unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="Tc_YZm-QqwN20S4VUi2laqzSg_5_2">3.39</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Risk-free interest rate (%)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="Tc_9KmWe_JYG0iSYBi451ijXQ_6_2">3.70</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">%</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expense recognized for employee services received under the LTIP &#8211; options during the year ended December 31, 2023, in an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_LRyErr-s70-iTcECgyji4w" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Narr_IppPB7oDA0aFsJwLeZ6r7Q">2,944</ix:nonFraction>k (2022:EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_WZbR2KdIsEWpAKkVfjG6Ow" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Narr_SCLfYLE88UexUdF4u5RwIw">5,564</ix:nonFraction>k) is mainly included in general and administration expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units (RSUs)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 24, 2021, the group awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_I9QppcopR0ywsK2v4mo-QQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_zFvdutR8T0mMyYmQbcfQAw">10,956</ix:nonFraction> RSUs to supervisory board members and on December 23, 2021, the group awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_uxxE4wcx60S5_hvy1sXzRQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_VvUk99Oro0SWdPJmg-FXvA">63,095</ix:nonFraction> RSUs to the executive board and various key employees. These RSU awards vest over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_qO3ooGZGqE-1SoyY1Zy6eA" format="ixt-sec:durwordsen" name="cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="Narr_nF9SOqGbV0qKgV0ws_tPOQ">3 years</ix:nonNumeric> with <span style="-sec-ix-hidden:Hidden_XU_t8pnL4UiX_Hi9qILQtw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> vesting taking place each year on December 31. All RSU awards from 2021 had vested as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, on July 1, 2021, the group also awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_7_1_2021_To_7_1_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_Ufa1a3hx1k2ehDCG8MEN5w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_I7lgL7lPN0SpC56yzrLVFg">4,691</ix:nonFraction> special RSU awards. These special RSU awards vest over 12 months and are fully vested as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, as part of the LTIP program, the group awarded RSUs (RSU Award 2022) to senior executives as well as supervisory board members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022 the group awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_6_22_2022_To_6_22_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_EaL8v88MnEKSvl3GFfmHuw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_kCxm3ygW2UmcYldQMISGPA">225,888</ix:nonFraction> RSU awards as part of the &#8220;LTIP - RSU Award 2022&#8221; to members of the supervisory board, executive board and various key employees. On November 30, 2022, the group awarded a further <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_11_30_2022_To_11_30_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_YaepVSyZlU2heFMGLS9PMw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_wctcBEvMfke8O3yOYP3kdw">7,633</ix:nonFraction> RSU awards to key employees who joined the company during fiscal 2022. These RSU awards vest with one third vesting taking place each year on December 31, 2022, December 31, 2023 and December 31, 2024. <span style="-sec-ix-hidden:Hidden_QYgdAo6NHkmI49zrX7zMAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One third</span></span> of these RSU awards had vested as of December 31, 2022, one further third as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, on January 1, 2022, the group awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_1_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_MQ4SgOseWki-M9I2hpt9zg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_YGCoDLh9WE2iQF7YcsR-Fg">36,000</ix:nonFraction> supplemental RSU awards to the former CEO. This RSU award vests over 12 months and is fully vested as of December 31, 2022.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ow7SIGAT7U6voobuM5hPbA_1_2"></a><a id="Tc_9FkbJE6ydkOfh7GQoRfX-Q_1_4"></a><a id="Tc_rArrtndOQkukn-Qf5_Mcwg_1_6"></a><a id="Tc_Ct7Ql8UmlUugz8pJvXvDow_2_2"></a><a id="Tc_TogElQe2aUu3fOcKf5G5lg_2_4"></a><a id="Tc_yr9PY6mCvk6KpTniCL4imw_2_6"></a><a id="Tc_d9ge0aXSCkWkBLVRp0uf0g_3_0"></a><a id="Tc_VwN9ZIEWKUqO_usKvKGYFQ_3_2"></a><a id="Tc_0H2FRtLuMkqfLunELjkzPw_3_4"></a><a id="Tc_t-AA6bzvBkqb1DlCPkoWBA_4_0"></a><a id="Tc_LoqhlIKp6UenVybLbZxWfQ_5_0"></a><a id="Tc_p27_HmE0HEO6MHKXfONZ9w_6_0"></a><a id="Tc_b_DJSvRvF0ei1aPoaI3cMg_7_0"></a><ix:continuation id="Tb_J15S6nmpgk-KhQe7Sn3GBA_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 31, 2022, the group also awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_Fl_UlTw2MEicwzSFEfSNiw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_ZPPOlHCItESKIV40wEnwFQ">5,000</ix:nonFraction> supplemental RSU awards to the COO and <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hcC_vpIE1k--3Sn_jsbP0g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_I6szy2ow8EuFNDfalTKPoA">30,000</ix:nonFraction> supplemental RSU awards to the former CBO/CCO. These RSU awards vest in <ix:nonFraction unitRef="Unit_Standard_tranche_maOPN1bXI0mZlNy5N3Q2hA" contextRef="Duration_1_1_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_cieCTs_Zuk2PWdYu7Wy6ag" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="Narr_MW7TvQk7Ck-jMeeri2-Txw">2</ix:nonFraction> tranches (50% on December 31 2022 and 50% on December 31, 2023). In order for the RSUs to settle and be delivered, the share price must reach <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="As_Of_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_CwZYI28sy0a1k2hv3Y76Ig" decimals="2" format="ixt:numdotdecimal" name="cvac:MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" scale="0" id="Narr_wso67wc1q0WQbEP5tHBsiQ">19.16</ix:nonFraction> USD on or after vesting. As of December 31, 2023, all of these RSUs had vested but had not been settled or delivered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2022, the group awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_7_1_2022_To_7_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_ixs-47BeUUyl1kn1TalbNg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_9Gs_rqTwwUmFNscaIfn6Ew">89,655</ix:nonFraction> RSU awards to former Frame employees to replace existing share-based payment awards of Frame Pharmaceuticals. These RSU awards vest with one third vesting taking place each year on June 30, 2023, June 30, 2024 and June 30, 2025. The RSU program is accounted for by recognizing the related expense over the vesting period of the award, with corresponding increases recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Group awarded <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_uxFGoa7hQEWcuDdN_uz3Xg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_g58-LWWsD0q18b_FV1MNdw">92,701</ix:nonFraction> RSUs to the Supervisory Board members and <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_HaxPqM7xIEqQzOqccUnD3A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_3nRu5tIMwUiS0N9tGUYw5A">646,914</ix:nonFraction> RSUs to the Executive Board and various key employees. On December 15, 2023, the group awarded a further <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_12_15_2023_To_12_15_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_zcNwztHf20yUPCFfBpK37A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_cnJaDD47702be_4rBgwRoQ">32,783</ix:nonFraction> RSU awards to Supervisory Board members and key employees who joined the company during fiscal 2023. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified. <span style="-sec-ix-hidden:Hidden_11RqQzGybUSMAflcteDxJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One third</span></span> of these RSU awards had vested as of December 31, 2023. The RSU expense related to Supervisory Board members recognized during the year ended December 31, 2023, in an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_41JFXgAYbU-2g4bnHFwsiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr_BysEvyepH0yqwdj_B0valQ">652</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_D1vacamOH0G3JMpcUfj14g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr_1QQMrx1jAU26D3Z5jSP4sQ">478</ix:nonFraction>k) is included in other operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2023 the group also awarded <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="Duration_9_30_2023_To_9_30_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_hmgAXRtQi0mLk9qz8iijtg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_KI3KjUeuUUqk47_k_SzIAA">25,000</ix:nonFraction> supplemental RSU awards to the COO. This RSU award vests with one third vesting taking place each year on December 31, 2023, December 31, 2024 and December 31, 2025. <span style="-sec-ix-hidden:Hidden_lI9qMg_ZoEa59Vg_AMB8SQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One third</span></span> of these RSU awards had vested as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the former CEO, former CSO and former CBO/CCO left the Group in 2023, all of their remaining unvested awards were subject to accelerated vesting. As a Supervisory Board member left the Group as of June 19, 2023, all remaining unvested awards were subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenses for employer taxes arising upon the delivery of RSUs are recognized in profit or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" name="cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="Tb_UoYjbvyDbUemgRI65xRhBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of Sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" sign="-" scale="3" id="Tc_Q13KPV2ooUOE1A6QcBLm_g_3_6">331</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_-Lu2Ow567kSiSXJs508Cjw_4_2">240</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_xkx-ryDNlkmIA_c6c-ZV5Q_4_4">909</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_OnS5ak8XSEiYjo1goFapFQ_4_6">1,719</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" sign="-" scale="3" id="Tc_4I4oyb7y80SnLyXZXs6Fyw_5_2">82</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" sign="-" scale="3" id="Tc_PuaYSOdjRk2aUbOZKIZeEg_5_4">199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" sign="-" scale="3" id="Tc_Jaegf7xXQUa9vX5VldI2uw_5_6">269</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" sign="-" scale="3" id="Tc_MnqoTnZFIkmMnTYNhPk1Ug_6_2">383</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" sign="-" scale="3" id="Tc_gujyzJavtEmhHo8zE4UwKQ_6_4">2,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" sign="-" scale="3" id="Tc_3Ohex6btI0aufJdFtFkVAQ_6_6">1,753</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" sign="-" scale="3" id="Tc_GFflu1pChkShp2Z3TtAj_g_7_2">705</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" sign="-" scale="3" id="Tc_s-mIsUgGf0mxm0rfXhy6xQ_7_4">3,108</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" sign="-" scale="3" id="Tc_ZXLBgR_fPUmRwcbYRh70xQ_7_6">4,072</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_8Z-kbpTgnk-OQBxIVShI6A_1_2"></a><a id="Tc_E8ufbmsIFEuaxn68koIGGQ_1_4"></a><a id="Tc_p9J8trnyY0OAAVffhHE7DA_2_2"></a><a id="Tc_Xnpoh5YDQEqjyF7__IvlPQ_2_4"></a><a id="Tc_dTuSiJy7eEGw-lLozyP1xw_3_0"></a><a id="Tc_H6PzQkkM-0GKCiF7o8ZOWQ_4_0"></a><a id="Tc_7rlXrBhdh0a1Fxl-zqKSIg_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="Tb_BxkQ6wnpR0G5UgzDinbS-g" continuedAt="Tb_BxkQ6wnpR0G5UgzDinbS-g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11. Trade and other payables</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Trade payables and other payables are all due within one year and include the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfTradeAndOtherPayablesTableTextBlock" id="Tb_4k_uzUssxEu1DY9TU_UmPQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_YbKTwu6NNUWDGuGbpcC0Ag_3_2">68,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_UeY6hxWKd0yQNCHxlV0FxQ_3_4">46,365</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Miscellaneous liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="3" id="Tc_tnThSGeJO0aepNDegKiG-Q_4_2">5,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="3" id="Tc_2m7NFnOSA0S5-uBtEBhpvg_4_4">1,668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_dQ53-KDsckeKzMHNf7EguQ_5_2">73,463</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_fPJz1a8szUqnUWrdi9wFCA_5_4">48,033</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade and other payables are all due within one year. The prior year was highly impacted by received invoices of raw material suppliers before December 31, 2022. Thus, during the year ended December 31, 2023, Trade and other payables decreased by EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ChangeInTradeAndOtherPayables" scale="3" id="Narr_bV5YICbYvEuA5tCteUUqOw">25,430</ix:nonFraction>k. Miscellaneous liabilities consist mainly of payroll-related taxes and social security liabilities of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="3" id="Narr_TNWY1EaHbkea1syO-l9t2Q">1,496</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="3" id="Narr_jB38XwHcIE-xW81yyf0HWQ">5,027</ix:nonFraction>k).</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BxkQ6wnpR0G5UgzDinbS-g_cont1"></ix:continuation><a id="Tc_GX4kWdXc00GwW7SivHe3Qw_1_2"></a><a id="Tc_q0u7xrSvZEqnzKx13wQujg_1_4"></a><a id="Tc_Qi1S1na8aUCiF8XXZjXEJw_2_2"></a><a id="Tc_X8MXQP51Ik2wZ9hsE4Po4Q_2_4"></a><a id="Tc_-UlcTO9jMUaJYyf-j-tO5A_3_0"></a><a id="Tc_mtklJlKe4EqtMqLThuWGjA_3_4"></a><a id="Tc_cTePVmLu90-lGSCk5YMmkA_4_0"></a><a id="Tc_Jw3T-CpQRU6Hlzej3glxiw_4_4"></a><a id="Tc_Sk9B7Hw84EyJAcNeWRqyoA_5_0"></a><a id="Tc_3lnwGpx0l0mSf8Mudi-khA_6_0"></a><a id="Tc_0bvZYjI-EUGRaPetKvZ7GA_6_2"></a><a id="Tc_vMICb0NbDkW8u9NzKDIdZw_7_0"></a><a id="Tc_vmeNxpj-ZUqA677LmJPR0w_8_0"></a><a id="Tc_V8zhIe16jEaEJnyTN3nswA_1_2"></a><a id="Tc_z6z1k5XQZ0qxpW3jNwH2UA_3_0"></a><a id="Tc_xiOikub82kiVmcU-_Cd0LA_4_0"></a><a id="Tc_z8flPuPWf0yBk_uw6yejEQ_5_0"></a><a id="Tc_FXzggIxCj0O7W-reQSUyQw_6_0"></a><a id="Tc_JgAtA_Af7k-cNWF0GIRUyw_7_0"></a><a id="Tc_9erYlX25xk2MGm6HiKuyRA_8_0"></a><a id="Tc_X46tONQ7N02jTLYy8IF-uA_9_0"></a><a id="Tc_qpekozdYzUSh409dQsooxA_9_2"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:OtherLiabilitiesAndProvisionsTextBlock" id="Tb_KZnpuMa2tUG5iJzIf4yN7A" continuedAt="Tb_KZnpuMa2tUG5iJzIf4yN7A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12. Other liabilities and provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions include the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" id="Tb_5NFprLLw802xJLWot5sLlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract termination provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ContractTerminationProvisionsCurrent" scale="3" id="Tc_7zSoasSnRUqX8G6ig702wQ_3_2">61,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions (non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisions" scale="3" id="Tc_cSsXIc1oFkSbLDqola5WTA_4_2">61,320</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for onerous contracts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermOnerousContractsProvision" scale="3" id="Tc_yiuhcPMNREupVwIq22dCYg_5_2">1,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermOnerousContractsProvision" scale="3" id="Tc_wF-8G13dgkSNs-R-fQd43g_5_4">184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract termination provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ContractTerminationProvisions" scale="3" id="Tc_K-YP1CCuRUG03rPmfNPCvw_6_4">37,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions (current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="3" id="Tc_LeieRS1Ft0-x2paVBUZquQ_7_2">1,922</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="3" id="Tc_ZE6VJhwNUkC7mhRlES6A5A_7_4">37,400</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Provisions (current &amp; non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Provisions" scale="3" id="Tc_B6zfYGqJYkO-7LRfOA0uIQ_8_2">63,242</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Provisions" scale="3" id="Tc_4H-3ni08cE-Sa9tD_KaWtw_8_4">37,400</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below are movements during the period:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfOtherProvisionsExplanatory" id="Tb_zR41z5k6yk25vV23X4xT4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Provisions" scale="3" id="Tc_Ce4_svI3M0Ci7jnIZI6qow_3_2">63,242</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="Tc_Ww8tvodn6UKAyGKYVSNfwg_4_2">980</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">used (amounts charged against the provision)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Tc_IcmMRzk_zEyntWJEO7HKmA_5_2">1,174</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">unused amounts reversed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="3" id="Tc_55FuOOfKKEGoTnuXhk5teQ_6_2">25,648</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Provisions" scale="3" id="Tc_FZnaaLmqV0GbyUebBQERLA_7_2">37,400</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="3" id="Tc_p6qQ604R9EGyspC-d91ZOA_8_2">37,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for onerous contracts relates to CRO agreements and are expected to be settled within one year from December 31, 2023. All amounts recognized as of December 31, 2022 arose during 2021. During the year ended December 31, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="Narr_Qgqbk_I0rEe0L7pXNWXXVA">184</ix:nonFraction>k additional provisions were made, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Narr_k9OGrU3M4U2cE9gQNdnRDw">1,174</ix:nonFraction>k were utilized and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="3" id="Narr_ixpy8e5v2E2cFxsZ_eC07A">748</ix:nonFraction>k were reversed. As described in Note 2, when initially measuring onerous contract provisions relating to CRO agreements, judgment was required in estimating the cost of the remaining services, particularly in estimating the number of participants completing the clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Contract termination provisions relate to amounts which the Company expects to pay out to settle its obligations under certain CMO contracts which it has terminated. All amounts recognized as of December 31, 2023 arose during 2021 and 2022 except for EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="Narr_JTYmlz3t2kumUt9Rtzqq0A">646</ix:nonFraction>k in additional provisions made in 2023 and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="3" id="Narr_J6eooGg_GU2hhDaoBXWPUw">18,000</ix:nonFraction>k reversed during the year. As described in Note 2, judgment is required in estimating these amounts. The amount of the outflow of resources to settle the obligations to which these provisions relate may vary from the provision amount recognized as of December 31, 2023 due to potential variability in the amount required to be paid to ultimately release the company from its remaining obligations under the CMO contracts, including as a result of arbitration decisions. In its final award rendered, the arbitration tribunal followed CureVac&#8217;s arguments and dismissed Rentschler&#8217;s claims in their entirety. The totality of Rentschler Biopharma SE related provision of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseThroughReclassificationsProvisions" scale="3" id="Narr_Y0dIN6ublU6i4_3oItTeAA">6,900</ix:nonFraction>k was reversed as of December 31, 2023. Contract terminations provisions were reclassed from Provisions (non-current) into Provisions (current) due to an expected settlement within one year.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_2EowEec8yUqtVQ0YMHbn0Q_1_2"></a><a id="Tc_VxnvnVlnMUaBZfUsMxIShw_1_4"></a><a id="Tc_pq0T8v83P0-eeTMEwgvdgw_2_2"></a><a id="Tc_8XjNSwScc0KAOIiV4gfeCA_2_4"></a><a id="Tc_13LrbkXrLUKe1X4hUOLI1Q_3_0"></a><a id="Tc_M2MZvrcXvUuCBIzzZasZvg_3_4"></a><a id="Tc_0LlFym9Ub0Womyhd4FaChw_4_0"></a><a id="Tc_wcmN_5pGmkuHfONuDLZq7g_4_4"></a><a id="Tc_hYevH4xwq0S5RZ416mDaoA_5_0"></a><a id="Tc_-qwIXKhRN0qkgHAvcZUQZA_6_0"></a><a id="Tc_TOZ3nUL3mU6UVgnXkha2ag_7_0"></a><a id="Tc_sgtEGubvOUenGi1qCWoIhw_8_0"></a><a id="Tc_OAxvW-7AREasG4JdQ4LkRQ_9_0"></a><a id="Tc_Qg4kuzHUXkOtsp0l1hJqBw_10_0"></a><a id="Tc_ixWTbhbnFUKe3BC7JGhmpw_11_0"></a><a id="Tc_lwuvN_v9BkC9bqv5ezChMQ_12_0"></a><ix:continuation id="Tb_KZnpuMa2tUG5iJzIf4yN7A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other liabilities include the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfOtherLiabilitiesTableTextBlock" id="Tb_Awl0GECeHEmDZQnnmT7Cqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherMiscellaneousNonCurrentLiabilities" scale="3" id="Tc_FbsOtnjieE2zHlpKj4YKuw_3_2">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other liabilities (non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_3pPp_GkXRUGVDrBacpaKFg_4_2">19</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel accrued liabilities (e.g. bonus, vacation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelAccruedLiabilities" scale="3" id="Tc_5G45pjHFKUibigb9xOMtRQ_5_2">7,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelAccruedLiabilities" scale="3" id="Tc_wWlDzoKaA0a7_01vGXnVAQ_5_4">10,543</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grants from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentGovernmentGrants" scale="3" id="Tc_iD0N48eiVEqhrVHv74mUDA_6_2">2,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentGovernmentGrants" scale="3" id="Tc_4VtJ3vBzMU6VUSGXzg-XjQ_6_4">1,735</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding invoices</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OutstandingInvoicesCurrent" scale="3" id="Tc__gtfi-j7-UaCHbTPFJOcTA_7_2">28,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OutstandingInvoicesCurrent" scale="3" id="Tc_k5X2t1C3M060I99XEKMz_Q_7_4">36,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfessionalFessCurrent" scale="3" id="Tc_2wrlMw2EwkWsgzrkFpVVJQ_8_2">1,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfessionalFessCurrent" scale="3" id="Tc_lSTRCV6Uy0qaZZD06jcwEQ_8_4">1,116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:CurrentValueAddedTaxAndOtherTaxesPayables" scale="3" id="Tc_uWNXrtgUJUCnaK4dIdAS-g_9_2">924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:CurrentValueAddedTaxAndOtherTaxesPayables" scale="3" id="Tc_WxVowDD47E6VgW2LsKvAAQ_9_4">1,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilityCurrent" scale="3" id="Tc_Jn_s1Bz5JUOiP6SUWbLwwg_10_2">278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilityCurrent" scale="3" id="Tc_h65ZqFJWiUKP_OJFde9HmQ_10_4">200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other liabilities (current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_SXpkMGYwXkessy2IzqMnWg_11_2">40,491</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_J6QAYPjcjkGFUG9NmhH1gw_11_4">50,717</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total other liabilities (current &amp; non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherLiabilities" scale="3" id="Tc_hwFPeHW9KkC7K8iIoDa_Zg_12_2">40,510</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherLiabilities" scale="3" id="Tc_-tUQSlOStU-7GI9Wx5vCdA_12_4">50,717</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_TxukEMyIMEOUWFLWY4c7Bw_1_2"></a><a id="Tc_UHSJRaCh102peZYHehG0wg_1_4"></a><a id="Tc_X3pl16v_XE65-5DBYYzEow_1_6"></a><a id="Tc_J4MW5gkcE0ipHZVQAOc6Hg_2_2"></a><a id="Tc_wQc5CuNpGEeKsPX-1Bd2YQ_2_4"></a><a id="Tc_Xuz4GCAM9kq7kHO2ENDdwA_2_6"></a><a id="Tc_0WYZkUX6i0WrhFBh1xg0SA_3_0"></a><a id="Tc_21Vx3KBL-ECFng1SL3ncbA_4_0"></a><a id="Tc_E2ejkczSxESYkKbxRGGAVw_5_0"></a><a id="Tc_lNBCn_27I0STCSb8Th4PYQ_5_2"></a><a id="Tc_Q8t5tg-Be0WO89l8Sa2HCg_5_6"></a><a id="Tc_Xn7Uc_Uoe0yIKznRqBhuGA_6_0"></a><a id="Tc_Wi-DMOugzU2zruK6Oxbf1w_7_0"></a><a id="Tc_93ih29tA-0WiIxFjUitl1g_8_0"></a><a id="Tc_qLN-c3Q57kCh4--06606Eg_8_6"></a><a id="Tc_GcF_dRk4J0CV-ezr41yk_g_9_0"></a><a id="Tc_1d7tyGzwVkOgcvqxwv-_4Q_9_2"></a><a id="Tc_iK08TZXHvUaiZCvgYWRg_A_9_4"></a><a id="Tc_a1-e2sft2kiTFAtaFmp9DQ_10_0"></a><a id="Tc_ffBx5524AUG5j_gcUmseCQ_10_2"></a><a id="Tc_x2Fl4pnYykqpoKeS8hv6jg_11_0"></a><a id="Tc_1Ib-mRL9uEiEQ-m0u5lebA_11_6"></a><a id="Tc_aQ5UTKWyjk64qhPH9YI9KA_12_0"></a><a id="Tc_TR2MmPuGX0yK9Myz4WM2KA_12_4"></a><a id="Tc_da90oLEgZ0GJwL2DGjIUOA_12_6"></a><a id="Tc_NXJex1DeHUiWqqOoftVV5g_13_0"></a><a id="Tc_UrC1LmSNpUGNfXgMTxAKUg_14_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="Tb_JwKNKbgjW0uda0xjj62bwA" continuedAt="Tb_JwKNKbgjW0uda0xjj62bwA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13. Income tax</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2023, the Group recorded a consolidated income tax expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Narr_CYuX-KDHa0yXKLdWAAhtvw">198</ix:nonFraction>k, in fiscal 2022 and 2021, the Group recorded a consolidated income tax benefit of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Narr_GLDgm4iSfEqzBgb4BJ7Iog">126</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Narr_YBExezxE4kaKAa9awPtlzQ">782</ix:nonFraction>k, respectively. The income tax expense in fiscal 2023 results from current income tax expenses (2022 income and 2021 expenses) of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="3" id="Narr_UyM4V6Oemk67lfDXjSTW-Q">118</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="3" id="Narr_F65YYHxI_EGBSubJDj-x1g">106</ix:nonFraction>k and 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="3" id="Narr_vXo0clyk2USGWUa2h97Hfg">1,033</ix:nonFraction>k) and deferred tax expenses (2022 income and 2021 income) of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncome" scale="3" id="Narr_7cshXY1gi0CuX_wzpCH3lw">80</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncome" scale="3" id="Narr_Dfx5OG1KC0yft28CVFJGDw">20</ix:nonFraction>k and 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncome" scale="3" id="Narr_Qm0CgcRdWUanO8hJ7iQ4Zg">1,815</ix:nonFraction>k), thereof from taxable temporary differences EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" scale="3" id="Narr_fK39PEa-L0mkYUh1iI5mhg">3,225</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" scale="3" id="Narr_19EJwW9op0aCuoNdSi4z5w">1,090</ix:nonFraction>k and 2021: EUR (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" sign="-" scale="3" id="Narr_oMXmNGc_VkCpdlI7poWB1A">1,540</ix:nonFraction>)k). In fiscal 2023, the Group further recorded deferred tax liabilities of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" scale="3" id="Narr_m6mcYE1wik6R-MZ657lhZg">0</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" scale="3" id="Narr_HsgfifTM1kS5ZeyqsTeVUg">20</ix:nonFraction>k and 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" scale="3" id="Narr_Dq1t8OpDmECS1OrurREgjg">0</ix:nonFraction>k). In fiscal 2023 and 2022 an amount of EUR (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" sign="-" scale="3" id="Narr_LpIB_RSxJkuLIRO9ZZ1ztg">2,094</ix:nonFraction>)k was accounted in equity. The basis for outside basis differences is EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" scale="3" id="Narr_3uRyM8yf5kiwwjXQjBSK_g">168</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" scale="3" id="Narr_yf9neI0GC02UyG0zEG-gAg">1,120</ix:nonFraction>k and 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" scale="3" id="Narr_ERqr_-n3EkCxH6dLm4r1gg">3,713</ix:nonFraction>k), which create a taxable outside base difference of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_2NV8EZlD8UGXJFNTR3SpMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Narr_s7mG9lDdxEevUqcOBkDmEw">8</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_KOCTqYugQU-Xp2Dma3UX4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Narr_4pM1MgZN-EWW_O7_LewleA">56</ix:nonFraction>k and 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_FgRE2Czx-0e3kuw6SVMj_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Narr_lnWvcLORy02Fkk5Y1LwWKA">186</ix:nonFraction>k), which are indefinitely reinvested and associated with investments in subsidiaries, deferred tax liabilities have not been recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A reconciliation between actual income taxes and the expected tax benefit from the loss before tax multiplied by the Group&#8217;s applicable tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ApplicableTaxRate" scale="-2" id="Narr_fQ-Y_q9KcUin2CP9AkjCsw">29.48</ix:nonFraction>% (<ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="Narr_y7jt-S6rg02Zd8TvQpa3Iw">15.0</ix:nonFraction>% corporate income tax, <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="5" format="ixt:numdotdecimal" name="cvac:PercentageOfSolidarySurcharge" scale="-2" id="Narr_z-AfO1xMMkmih1jr2Os9YQ">0.825</ix:nonFraction>% solidary surcharge and <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="4" format="ixt:numdotdecimal" name="cvac:PercentageOfTradeTax" scale="-2" id="Narr_cHa4AYCQT0agGwBkkNDtfg">13.65</ix:nonFraction>% trade tax) is presented below for the years ended December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_eGJ8cKQLUkq_dYm4ygwGMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" sign="-" scale="3" id="Tc_A4LRjFnFVkqvVodRAQT9_w_3_2">412,498</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" sign="-" scale="3" id="Tc_hvArTo27xku77frvgUdVCw_3_4">249,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" sign="-" scale="3" id="Tc_V49kepUc00asC-BBDHnshg_3_6">259,969</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected tax benefit (based on statutory tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ApplicableTaxRate" scale="-2" id="Narr_dPnm3jY-rUWvA7Yel6TVZQ"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ApplicableTaxRate" scale="-2" id="Narr_9ecVc0Gv6UuLawAgzapIEg"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ApplicableTaxRate" scale="-2" id="Narr_c2K8spcK00qOJEbVVSNLUw">29.48</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2023, 2022 and 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" sign="-" scale="3" id="Tc_NLr2nwCrT027oagj_mDsnQ_4_2">121,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" sign="-" scale="3" id="Tc_pQlryqhp3EKoEHrEGhFmkQ_4_4">73,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" sign="-" scale="3" id="Tc_Q05T3l8X-E2BNp300-mZzQ_4_6">76,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Recognition of tax loss carryforwards recognized in prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" sign="-" scale="3" id="Tc_vtVdSnR0RESg8U_U_GXXSg_5_4">327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effects from differences between Group and local tax rates </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="3" id="Tc_K4kD0-n-lkW8aqzofqMm_g_6_2">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="3" id="Tc_72XekMyJ3EKdaqPGHdSEnA_6_4">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="3" id="Tc_YOSxZQNSD0ajSuttcOZLOQ_6_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-recognition of tax loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards" sign="-" scale="3" id="Tc_OXFopvAAJ0m2_IYVfpLMng_7_2">114,999</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards" sign="-" scale="3" id="Tc_0IJgoHRY_UGCbnh0aaeVsw_7_4">69,724</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards" sign="-" scale="3" id="Tc_An9cXz3LZUyn-8viQAqSkw_7_6">81,392</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-recognition of deferred tax assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" sign="-" scale="3" id="Tc_SfGDrS4370uyRfYlM72gTQ_8_2">7,363</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" sign="-" scale="3" id="Tc_Jd3qxAEXt06hSl_Nusd7Rw_8_4">626</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Recognition of deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" scale="3" id="Tc_aGHvjTfdg0erO4tdUcgouQ_9_6">3,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-deductible expenses for tax purposes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOnNonDeductibleExpensesForTaxPurposes" scale="3" id="Tc_h4wr7EH6qk67Ft_D67DENw_10_4">119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOnNonDeductibleExpensesForTaxPurposes" scale="3" id="Tc_dWgOQwt7VE2unAtlZMryew_10_6">706</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additions for local trade taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" scale="3" id="Tc_TLxQBNB8r0KxXQXdfIA0ig_11_2">176</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" scale="3" id="Tc_5YQyPpRivkOMVlDgfZ9w-Q_11_4">330</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="3" id="Tc_bRHwNIxrNE-UiH2fCbyEsg_12_2">101</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other effects</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" sign="-" scale="3" id="Tc_xNmdZnpgf0KpYlLnaLtHVw_13_2">1,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="Tc_Vji-1JxwCUqA0Ot6GesrIg_13_4">2,826</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" sign="-" scale="3" id="Tc_Rc-RDly9mU6mzrnCeGtokg_13_6">1,599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Effective tax benefit / (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_N_5SmR1VykeJXQ7ysOzBug_14_2">782</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_LZ6SRiO52k-SVMhky7NMQQ_14_4">126</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_DSAAuKLrZ0yFdi8kAz74hA_14_6">198</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c230dcba_e75d_4297_8e71_6a16d303d4e5"></a><a id="Tc_dxVNq5sij0yjkwGury4pKA_1_2"></a><a id="Tc_-QMUr1nO6k2nfCo92jWOsA_1_4"></a><a id="Tc_t-8qijVEFEGo2P4aaMAmxQ_1_8"></a><a id="Tc_HZtf13FzYUWwsl1bta_46w_1_10"></a><a id="Tc_i8AZZGd2ik-uF5BZtM9zKA_2_2"></a><a id="Tc_pPh18PKWA0uU1ZJj2BGQ9A_2_4"></a><a id="Tc_rI7oYQqBkkCx0MA3Q5a6hQ_2_6"></a><a id="Tc_8Mh7TTJf40uRAMHppOV92A_2_8"></a><a id="Tc_qsNe6I2bWUScifdkj6H9hQ_2_10"></a><a id="Tc_vZKsJgWMaEqQgD623cSybA_2_12"></a><a id="Tc_JfJJG6x1jEWMojqF5PFQyA_2_14"></a><a id="Tc_XzEodyZJw0iA0lzFSxhuxA_3_2"></a><a id="Tc_Ath7nDsipEiUOr3GpRfbIA_3_4"></a><a id="Tc_twBOrHwyz0y8LpAnyBDSjg_3_6"></a><a id="Tc_dXE0ULIsq06Oh36dPb8SBg_3_8"></a><a id="Tc_RbAZ3CqG4EWsNU_DcrnQXg_3_10"></a><a id="Tc_y0qDbaKoFUSWgw3aiwG-Jg_3_12"></a><a id="Tc_CiA_hPAcoUKHrpUIcI9BDA_3_14"></a><a id="Tc_20zIORsvJEChLREE96CyNw_4_0"></a><a id="Tc_qDl_te6xZkKxyi676Yx_zg_5_0"></a><a id="Tc_VXw5ST8890eVohYlOQ0d8w_5_6"></a><a id="Tc_xrF-PTXB8ESJlHV6I4ogZw_5_8"></a><a id="Tc_Ks0Y8PXEREqapsubze9IUQ_5_12"></a><a id="Tc_-vTg1qkpF029xsdT7067Fw_6_0"></a><a id="Tc_gkZDFfNLUky2UD6yH8ZV7A_6_6"></a><a id="Tc_uljzu100fkWQgp16nMV3vw_6_8"></a><a id="Tc_X4BaivUdeEGb5GkcmSGvBg_6_12"></a><a id="Tc_fgWTxuabzkeB5-bpicFEuQ_7_0"></a><a id="Tc_I2-nNYzX6U2MeNBM7rxgZg_7_6"></a><a id="Tc_87BP5N7AdU-CFoqJQnqb8w_7_8"></a><a id="Tc_qhDl28lj8UaWHxPWD5G6NA_7_12"></a><a id="Tc_YXvqXn9QRUmCsPsGQRIZMw_8_0"></a><a id="Tc_muXeWdCHukiAPWbTdN5m0Q_8_6"></a><a id="Tc_7fJkiSQMy0apJXCoFUaVOA_8_8"></a><a id="Tc_L5-b-axSpUG9u37B8H3-ug_8_10"></a><a id="Tc_OnuQqqLFh0GP2hnYTgl7Mg_8_12"></a><a id="Tc_wXGa4Lek5EmJHmNoSVFhaQ_8_14"></a><a id="Tc_AaW4TwQUR0OYBebATJdp2A_10_0"></a><a id="Tc_0V-OS7j4Rketsm33eHIh2g_11_0"></a><a id="Tc__FQnkoRP8USzan5Vt7h3rQ_11_2"></a><a id="Tc_lev8KyilFE2sdQBWSZNkiA_11_6"></a><a id="Tc_mRwiJkrwckaWyeu0naSQ7w_11_8"></a><a id="Tc_bKVHFm68WE-ORSie3FBEOA_11_14"></a><a id="Tc_XYJzPkxDPE6Ftt2koASULA_12_0"></a><a id="Tc_-oO54SJk10eJcGBs2BHJrQ_12_6"></a><a id="Tc_ffTCsTAP-U2tu-uozGWnLw_12_8"></a><a id="Tc__Can9vdgAE-XmmTECauq1A_12_14"></a><a id="Tc_gFZwynuBh0W3NOmzpT9cdg_13_0"></a><a id="Tc_oJqJNHMZ9UCge0-oQuCdjQ_13_4"></a><a id="Tc_Gw3amXS_rkevfXCRyytu7w_13_6"></a><a id="Tc_VvaqwoIzKUKAj6NSX56fWA_13_8"></a><a id="Tc_LYoIL51e5UirvdtOo30JEQ_13_14"></a><a id="Tc_NPuabZZwtESd1CTEm2LFDA_14_0"></a><a id="Tc_ejZkOyN6d0aEYYIK-KSlHg_14_6"></a><a id="Tc_2GLxeAwwqE6pQcWptURtpg_14_8"></a><a id="Tc_l64MsJ5z8kKtO1VDYFaejQ_16_0"></a><a id="Tc_uiGPM49wEUeuEDXgEX0cEA_17_0"></a><a id="Tc_UT7-wAy2t0ineX3H_NWOJQ_17_6"></a><a id="Tc_I0xErEnulkKi-nay4N435g_17_8"></a><a id="Tc_DvBXqusqB0m5fqwinkz6rg_17_14"></a><a id="Tc_g_GtyrO2BEqAQraJagdkfA_18_0"></a><a id="Tc_NHvERNb_nkGLvaoAsbnNVA_18_6"></a><a id="Tc_h1jJk3LNoke7iK9d7lIhAA_18_8"></a><a id="Tc_iU4mHD9lNUKNlWZNs5vhww_18_12"></a><a id="Tc_8BFj08XTyUCIEI0VX0Wf_A_20_0"></a><a id="Tc_vXiT5Yhc1ECQFes19aKGJA_21_0"></a><a id="Tc_7RS_G8xNRk2ILlW8TOfw4w_21_6"></a><a id="Tc_M03cgIkD2k-LmdgbLmnPVw_21_8"></a><a id="Tc_HhjUUqS0N0-Izo1S5SdCyw_21_14"></a><a id="Tc_l4DHtWMKx06qXR_H1cZQlg_22_0"></a><a id="Tc_YFSPTiiRFEiD_bJIwFt23w_22_6"></a><a id="Tc_xWroy0KZR0yD-wXmEM8CDw_22_8"></a><a id="Tc_822VlRoDmUyOHxMCBH48Ag_22_12"></a><a id="Tc_LNOjjIyXdEqydLukrRGA_A_23_0"></a><a id="Tc_HDJhsUrwbESJnLyEAlvJaA_23_6"></a><a id="Tc_LiwXLvNgCE2jE3kSQjIOjA_23_8"></a><a id="Tc_K7k26fMGgkiuwxynFjhDzw_24_0"></a><a id="Tc_v7b6eVjZ5UqlowAE_Ql1mA_24_6"></a><a id="Tc_HZEn4f5fYUKkCyZzzrDfHA_24_8"></a><a id="Tc_mJhiwXbZQU-jYjEU-BU0gQ_24_14"></a><a id="Tc_lASGVPA7p028yMlZfwkYBg_25_0"></a><a id="Tc_wwlrA4SAyUumG8UVEyzQ5g_25_6"></a><a id="Tc_ERMC_-cF9EmrvCvt_SFKtg_25_8"></a><a id="Tc_ik60_xe3zUas9pchn6Ggdg_25_14"></a><a id="Tc_m-swyI7tUEWfhveMHWCNGw_26_0"></a><a id="Tc_0-ZA7KYV8U-oUVedcrjILA_26_2"></a><a id="Tc_ZP_0pBslCkuG5uLAgHso-Q_26_4"></a><a id="Tc_oyyUP6VT9kalkMiR2QBleg_26_6"></a><a id="Tc_8bvtAXj0REuWSwl3H7O1-w_26_8"></a><a id="Tc_9P90XacQXkOTjYblICSRvQ_26_10"></a><a id="Tc_jM5ZFAzmAUurS6rFgASK6w_27_0"></a><a id="Tc_hCYaBPEh0E-IaLaomswHlQ_27_6"></a><a id="Tc__GZUJNM57EWDcMiqcnbSXA_27_8"></a><ix:continuation id="Tb_JwKNKbgjW0uda0xjj62bwA_cont1" continuedAt="Tb_JwKNKbgjW0uda0xjj62bwA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Deferred tax assets and deferred tax liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfDeferredTaxesExplanatory" id="Tb_9c7kfuKhX0-XhHK3Dk9PVQ" continuedAt="Tb_9c7kfuKhX0-XhHK3Dk9PVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;01,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Recognized&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquired&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit&#160;and&#160;loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business&#160;combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTL</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_aBG681UXeUit3EpdZXEbgg_5_2">1,412</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_sPUZgy8alUm9DrExIlqZxg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_nHmw2OvuG0G5252dnobdOg_5_4">188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_2z_v-2cIV0GPSwrqAp-RhA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_maDql4I2tUCR_gGRHRSVtg_5_10">1,224</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_2z_v-2cIV0GPSwrqAp-RhA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_zT7B8iRQXkWhDCE6gswrpA_5_14">1,224</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_6lVkhXH0AUGAqskpK7YXDA_6_2">2,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_N6uLOUQcWEa4CDo-FoW1jw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_uUdj737wQkyJqC-AfieZXQ_6_4">665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_xceMST2sskiZALYanrkx6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_R1WPxsd4gESfKtYgskGT_Q_6_10">3,439</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_xceMST2sskiZALYanrkx6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_Rc67bcVCH0aQHVc2nEPx2Q_6_14">3,439</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_Y3FLMGSOCE6QrgdNOIuEIQ_7_2">12,364</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_BxdZ_fqI90qVPvPxCxQ8Cw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_19xjbz_hWUidIeyGaMOk2A_7_4">312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_vPbCsfbl10GjVuhXwSETZQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_CjPL3y0g7kevrFoS4KZhkw_7_10">12,052</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_vPbCsfbl10GjVuhXwSETZQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_OWAg_vuVZkiYVHW-tseERQ_7_14">12,052</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_az5nhTyJi02zSv6Cgsy7Dg_8_2">90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_AdgiqRdnnUCyfzTbCUw3EA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_1aWuBP4USUe3-wfp3HKyFA_8_4">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_q7WO6vvez0OVGaUlPRtXNw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_zO0hXKKnV0OJSNp1O7fJ0g_11_4">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_bOuXDQXtgECvVjIJJiEBBQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_7KQV_fSxMEefU8vWTgj28g_11_10">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_bOuXDQXtgECvVjIJJiEBBQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_m4c0yEjC0kWZpkyAFATn7A_11_12">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_g799CB7bWESmkku-wVT9AQ_12_2">47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_brACGjFlf0yYmlE-IZbkqQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_PeLz3dbJVEa-TFUQD48yfg_12_4">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_RRVoksyfikayCq6qHVsupQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_qZN_9MtWwUSZ02XbpmgsQA_12_10">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_RRVoksyfikayCq6qHVsupQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_TY4Lxq1sAkqaYiFplQHUpg_12_12">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_SNFag8xaYkSVrMiB8WVT-Q_13_2">1,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_tiHq0sjs80K57XqBzMQLJg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_I8dfQ_l3x0S0w9bLSFyBFg_13_10">1,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_tiHq0sjs80K57XqBzMQLJg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_u1H0dTX5GkujsLJX_VTV5Q_13_12">1,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_sJvMehruh0SL3_MLiyScng_14_2">1,014</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_AMhqZjayEkyLFJUXTSfqhA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_Syx4YD-n10KdNAWbbLoDng_14_4">1,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_bnz7AYEHyU66rCbG225deA_14_10">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_L1XtKWWlkEmHy2VJe5XHrQ_14_12">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_eMJndYy13UWuF0Q__Cz_rA_14_14">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non - current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Non-current )</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_HeUHViCqcEiCL7EXrzetuQ_17_2">10,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WJuDdMd_AEOjhVaYyZzKtA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_o5ZLIsoKEU2Z9pdVSe-iKw_17_4">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_3qNBdkGOC0S9Pb4g2-0A6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_S1esw5hi5km1fJjkZuy3-w_17_10">10,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_3qNBdkGOC0S9Pb4g2-0A6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_vPM9xWB9jUmfdY0LR5r4ug_17_12">10,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_GUklFo36YUCYkB35N7CWMg_18_2">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_NwLw6YbSN0CNCMJtsJh-lA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_bhxfP_Oa7Ei3wQ8Zp8PA4g_18_4">118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_0jknVHupLEyMHv6EAT-P4w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_p2bD1EeK_0O45T_Q2ZxVBQ_18_10">67</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_0jknVHupLEyMHv6EAT-P4w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_717-RIpFyEKSYlmmyt-Nmw_18_14">67</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_v2vEahXnjUqhd1aGHdJDiQ_21_2">1,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_y_Uiw0kSbEuybbOsAdT54w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_pFuStwutKkSpMX2XwrpktQ_21_4">152</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_VwP1ZgmTKEqT0Qondxniqg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_W8VgMS8LBkqMJ3r7-jtDqg_21_10">1,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_VwP1ZgmTKEqT0Qondxniqg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_wR7uNE2_D06rU6ARoXuiMQ_21_12">1,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_0wtAWnvcw0WlzLd57QizqQ_22_2">184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_WoU5OY8q9UmNGItiCh3wFQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_FDd8Mbr5uUCLjarTe7RJhQ_22_4">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_HeRhz1br2kW9XGBq3W35TQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_zLTEQU9PmEOx6yyjxFlyMQ_22_10">142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_HeRhz1br2kW9XGBq3W35TQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_B-qfygeQ5kaXB7Q5rpda8A_22_14">142</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_Y4VXeJc9MkigIsAoXuQ77g_23_2">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__QCZpl7FCECVWYoHf5mRiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_XyTYU04LGEmFZ9_VqLUqSQ_23_4">508</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_Mm9ehNdpE0OuLujHkIN2Og_23_10">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_djAGZJtGdEeyXMTRYLA4aA_23_12">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_caltuI94p0S_QK0MGbfUUw_23_14">137</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_4S99_2fWfUiFYQaG3cC3Mg_24_2">1,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_q0E1iqjsuEivVAPEk_0CQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_4MvYj5HoaUSunVKszngY4g_24_4">3,122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_1Cz5tMIDUE64OdcnvtgS2A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_9g-BDp7MP0u2uAhfIQ_S-g_24_10">4,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_1Cz5tMIDUE64OdcnvtgS2A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_NhiPu_ukME2MRAh2ixO0Vg_24_12">4,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_nx_b9xX9tUyULXIg9s1bsg_25_2">3,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_K70FGvuxREqsUGGoFXb3Ig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_9-CABrykQEewZKF9FjhAew_25_4">3,498</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_CL_42NO980yFn3bMpoksBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_zL51qIckkEikVkSyYnvJGg_25_10">496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_CL_42NO980yFn3bMpoksBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_kBflKx_nYE6IJN2ORLvxLg_25_12">496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_fOnOhohTI0aH7chs7hxlhQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_e4ig74cwX0emHn9pjbqHig_26_12">10,490</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_fOnOhohTI0aH7chs7hxlhQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_vRcJQTkuJkqs4BMppOilBg_26_14">10,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Taxes Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_euQ-jIMNi0KZo2kyvKCy6g_27_2">1,278</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_kXS-c1vXzkKVzLSVSQVA7A_27_4">84</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_jGtf0-VXTU23h3mNoGimeg_27_10">1,194</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_3SG-4mBhX0qC6CRILOQ4sA_27_12">7,777</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_GqVqFoG6RE2Ou6FLjQheUg_27_14">6,583</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1a8d407e_cc80_4a4d_ad15_a8d95a835692"></a><a id="Tc_g_-XReTZNEqKNbrxr-GI8g_1_2"></a><a id="Tc_alrzmbI30kCyZ9Vebo2Otw_1_4"></a><a id="Tc_QxgcqLmnck-ER-qZzilEsQ_1_9"></a><a id="Tc_fuWzIYIv50ykfv9Tymzweg_1_12"></a><a id="Tc_ADbajFty70KYxcSbARxX7g_2_2"></a><a id="Tc_hXRTMvhyXk6v6BCgtEtjpQ_2_4"></a><a id="Tc_tvAxnMXXkEuO6g4svvPgvw_2_7"></a><a id="Tc_6JX2aYy2XEujUC3WqmKrRw_2_9"></a><a id="Tc_SpHfUmXAgUGhFy8UwqRDhw_2_12"></a><a id="Tc_nZQ8YRzfU0SxjVMazu6LhQ_2_14"></a><a id="Tc_u-oO-Kz26kiXyOAsBqfZJw_2_16"></a><a id="Tc_qsEp1vCGdU2c3JtWI8M0Cw_3_2"></a><a id="Tc_gnjtDB1VUE63PJ2TBwTT0g_3_4"></a><a id="Tc_pE9RSxnSSkavhjdbQdyV2w_3_7"></a><a id="Tc_yIFzLX69FkaJ2qjN8Y6fAg_3_9"></a><a id="Tc_auoYiCljbUuciAqg8Vo2Gw_3_12"></a><a id="Tc_Ua2e2xC7WEyeCZqO257YCw_3_14"></a><a id="Tc_DqatFCe6SUirVYDmTXe-mg_3_16"></a><a id="Tc_xtuSAgmcokGNcfZOOgxAQg_4_0"></a><a id="Tc_PKgeQX-TbECtMgcHJ--xow_5_0"></a><a id="Tc_y4pOqh3qz0yjDMC000pQVw_5_2"></a><a id="Tc_MWsQdtBv2UOxfSMR-kdqhw_5_4"></a><a id="Tc_Lk2_NabCKESECrChJUOq1w_5_7"></a><a id="Tc_Rnl_93ySG0-QkiN_PuRqXg_5_14"></a><a id="Tc_FdMpc8cMzk26oPNRRE8nNg_6_0"></a><a id="Tc_8uOpAiBH5UqOldqqzpVyEw_6_7"></a><a id="Tc_Cen-8cp52kSk1Bz3nPkZ1A_6_9"></a><a id="Tc_d2Gx4fGUSkaBWNtPZXeQBw_7_0"></a><a id="Tc_dc52_F9daEmLDIlPE9_Pgg_7_7"></a><a id="Tc_FbXpcleBrE6OEFKeXGUTdw_7_9"></a><a id="Tc_RN4xRPkCik-5YPr7KEVjaw_7_14"></a><a id="Tc_rTDtjj0YRE-NJo6-qn459Q_8_0"></a><a id="Tc_5ZxF4inxAU6cwf7ZkbNoDg_8_2"></a><a id="Tc_kP4pbGW5c0yz1jLUaRlOVg_8_7"></a><a id="Tc_9jtAo0DvN0SQadKe7vTGDg_8_9"></a><a id="Tc_Luqj19xbvE2UKbaCZtPIGg_8_14"></a><a id="Tc_AIx5Ba_rpk2SwjMWH3KIQA_10_0"></a><a id="Tc_KgL2KIFv4UKysPVb-E2n9Q_11_0"></a><a id="Tc_cAzqOQMsXUqUYbEksB4aWw_11_7"></a><a id="Tc_G49S2ks_0EKoc1xmLgz27A_11_9"></a><a id="Tc_s0pcyVog7EOgXq56yf7a5Q_11_12"></a><a id="Tc_JmDQvZGM8kKWkzUxR_NdXw_11_14"></a><a id="Tc_TJDMXNGEQEiaANCraHS4rw_11_16"></a><a id="Tc_FCDfR2YAbE6Jv9rzxOtdow_12_0"></a><a id="Tc_4s8m1s6fg06fFnq9pboV8g_12_7"></a><a id="Tc_H01cgfNdSEKTU3KbUUbOcw_12_9"></a><a id="Tc_SJjiDOz5YkaX7s1Whs7VgQ_12_14"></a><a id="Tc_X8dsMUiT-0OD_q1sK67CVg_13_0"></a><a id="Tc_iE1uYirUVkWI91V4S9ho5A_13_7"></a><a id="Tc_jBiOaUQRu0CuzoUPrjBgHw_13_9"></a><a id="Tc_NhjhU6kiRkyfCLtbLdfVaw_13_16"></a><a id="Tc_8efYKKMGnEWUT9Of2upu_Q_14_0"></a><a id="Tc_jKtLIK1tiEqap3EnVAmBiQ_14_7"></a><a id="Tc_IwesPf4gMEKkYpDZvcYUWA_14_9"></a><a id="Tc_VdKpLug2Tky4HJksqil2Mw_14_14"></a><a id="Tc_-rIdSbOny0GbUia0zLrewQ_16_0"></a><a id="Tc_HyyoXoHWwUCbcIfzVe84mw_17_0"></a><a id="Tc_QUF8fayc7UiHyVxxQ7uWag_17_7"></a><a id="Tc_xwFwx9fJf06wx18qf6c35w_17_9"></a><a id="Tc_xNJ82AYR40mRoINZPh2wqA_17_16"></a><a id="Tc_w6YoVMxLGUePxfcAfAj6Jw_18_0"></a><a id="Tc_dcPFsTa3AkiEQ4Pt2S2vyA_18_7"></a><a id="Tc_yfxfrJ5mWEKNBOYiF4lg_w_18_9"></a><a id="Tc_jAlHEhe5HECVAPxXGDESIg_20_0"></a><a id="Tc_bZj_vCVwLkClS7qZKtKY7g_21_0"></a><a id="Tc_JnTaHzTZekKfaHpICNc0Jg_21_7"></a><a id="Tc_ftKROpPRIUe3qdJbbGOJeA_21_9"></a><a id="Tc_UymM8YpftUSe23DdWQhIYQ_21_16"></a><a id="Tc_Caeh1GIXX0K-s_0nyTeLKA_22_0"></a><a id="Tc_42d_FWOFHkySzhVz34BB7g_22_7"></a><a id="Tc_bgy4EKOnGUS1DoHyMZp2Kg_22_9"></a><a id="Tc_x6nUq8JsR0m886o19X_CFA_22_14"></a><a id="Tc_n-CC_bIO7E6RvYZ9gNNzNw_23_0"></a><a id="Tc_hhfRExNY3EWwXECLOzdbhw_23_7"></a><a id="Tc_k3evuO7Dwk6-nHSMgLf3zw_23_9"></a><a id="Tc_W_t3eddeYU-OTVcOBBUTuw_24_0"></a><a id="Tc_eNixzpkWKU2Ol-Wu6I9zjg_24_7"></a><a id="Tc_k7llk0mJ7U-4ph36fM3cJA_24_16"></a><a id="Tc_bgWYft609Ui4c6tSRoEBOQ_25_0"></a><a id="Tc_Nixd1nrbq0GCFpVInwrRvQ_25_9"></a><a id="Tc_CeM0RNLpG0-0zNlX97MQ1Q_25_16"></a><a id="Tc_YIiS5WHN9UOGhpERMIyoXQ_26_0"></a><a id="Tc_z9gczl-VvUGJRT0hMOFg4w_26_2"></a><a id="Tc_9UKSVftVnkCNUtq3l82uiA_26_4"></a><a id="Tc_6ppR4FJqQUa_qG4G2wswWA_26_7"></a><a id="Tc_sIhCUPenaUewbOfJzlT2_g_26_9"></a><a id="Tc_JoEq9uG_YkGcD6EYmTVzxQ_26_12"></a><a id="Tc_j2Fdsq2OJkC_Ekyr7D0a9Q_27_0"></a><a id="Tc_MSF1PyAaD0yjwG-CbbBzmw_1_0"></a><a id="Tc_JAM4mkOd-EWd448-QUtG0g_1_2"></a><a id="Tc_7FD_cXJeC0qivS4DKc1gdg_1_4"></a><a id="Tc_ObFEH48sBEGAQP2VjTIUVw_1_6"></a><a id="Tc_RwayIpKKwkWHpjmW-9Bk5g_2_2"></a><a id="Tc_3gimtgWYB06LIGNsr2YK4A_2_4"></a><a id="Tc_daQku2ROyUi5YHV8FIWpvg_2_6"></a><a id="Tc_3KDaY5TsvEWY0Mry6p5NVA_3_0"></a><a id="Tc_XHTc6Qbt0kyTdBaq4ZPILA_4_0"></a><a id="Tc__DpSKWiEmUqjvb2ezR3xxw_5_0"></a><a id="Tc_S1zt6Bl0GE25acXs-NLdkA_5_4"></a><a id="Tc_VsEPTYPtj0qIP_AyLs3vNg_5_6"></a><ix:continuation id="Tb_JwKNKbgjW0uda0xjj62bwA_cont2"><ix:continuation id="Tb_9c7kfuKhX0-XhHK3Dk9PVQ_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 01,2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Recognized in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquired in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit and loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTL</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_rK-mQvhP6k6rDG5s_W9Crw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_6LE4-bXb1UGMMMPEftTYcg_5_9">1,412</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_zUEeNR6WFU2pLVv7QktXNw_5_12">1,412</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_EL5ADEy70k2i9pak6v69dA_5_16">1,412</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_MKSIOOU_xkyo8xpkv2OyHQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_8VOH0Hf_5E2KDjLd4irViw_6_2">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_Fr_u4k8C4EyZbX93eTH8iw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_k2d5fPdIZ0OTKM7A_l4Eyw_6_4">2,769</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_ahlA9G0TskG04DtZMQkQDg_6_12">2,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_uKkjmoVZ4Em1OZr_jGxnlQ_6_14">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_6G5Abu0ehkyobH1jsIp2FQ_6_16">2,808</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_N2Zm5geGpE2tjfPniK-XXA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_cYe4Hl3MdUeHxgbmskOYSw_7_2">663</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_dpBYHdH2n0euqcNEgHxmzg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_Y2EkUzGh00KqUQlbJxHdFA_7_4">11,701</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc__5stfYUXvEittEDiT1V4Xw_7_12">12,364</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_MjVnQdYGqEyHRRz3nU7Gfg_7_16">12,364</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_6IbdDCUU1k2phHbdFhwJZQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_iVadYp7zC0CgfYswDhP1MQ_8_4">90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_GyDtQsdK8kGqKj0zNE4SxA_8_12">90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_LC7oNLC9jU-2d1HHC2jgYg_8_16">90</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_dPvTMfFzZkqhDReqmruC2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_-kz0CeTWZUKvb7STf4j8_A_11_2">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_TXI_swpSqEWRqNR403cl4w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_pRI76V4HqkKZNzUzlYYRCA_11_4">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_budjsnBG90KFg41r2z8BQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_l5MaQ60PCkO0UulrbXfQKQ_12_2">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_bZP5vsKUxUWOPhfDrg8I3A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_XTGVNz_XW0aTi8TnTnQB_g_12_4">144</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_Ny-a0vEd20qI0RO22TRa9w_12_12">47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_7NJpBg9Kc0O4-6K1ejqDxw_12_16">47</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_8V8uLdfk1k6k9TaP2157vA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_9dJPVEDb-UWuasQrVH9aag_13_2">181</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_mdiFR6M0iEGRWxBYIMdEcQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_Af7TIcysAkmv6IrqXTlP5Q_13_4">1,609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_M3Z_ABpQikazBC4xgzgLaQ_13_12">1,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_OIDkh8L0IU6vV2PJ-q8pCg_13_14">1,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_Ay6fLSJ51ketqazQXPf5hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_rtBBnxXW4ku0j9eeSd9A-g_14_2">87</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_XYmGcuw_GUu29m7J0DC8FQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_aYwlpGxYqU-wujWDHJs3Ug_14_4">927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_oQ6Pk-kPXE2SRPpogo15Lg_14_12">1,014</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_uZLSH8TvxE-NxIKYy-MJyw_14_16">1,014</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non - current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_RcuGyuNGcUqdgPvzwcxZHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_RHJJ5KuxIEusTHRy4oZPdg_17_2">622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WbbYak-BQUGFoFXANHb7Vw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_DBn-xSsn5ki6k1ltpJsNow_17_4">9,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_GSJYiQ3oWkOlUaqLY4gc2Q_17_12">10,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_VSV4phClr0CNajtNqsfSvA_17_14">10,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_bMA8T5tG6ES2FAnIC7DkfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_07UgCtJOikmM55_TJ0vsbA_18_2">129</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_iav8T9jxJ02hwX0kprs5wA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_jJn35ow6SE2-ziK-uHM57w_18_4">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_-vsG7nA7d0e7-sB5rwws0A_18_12">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_JFL86pOiJk-ZUIBub6xmeg_18_14">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_M64GEFe8502eGYrwDO224Q_18_16">33</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_ZZaNrVakd0WQ7KvFCMu6Bw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_6lkjWB1h00atfLOFoCd60g_21_2">156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_LXDETgWXhUW-6PMmcfMtQA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_M-jNIYNgCUaaGOeC38tgNQ_21_4">1,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_D1bWb9__jUy_cOTLWYeUQA_21_12">1,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_WQQ2nZrwt0mDU2T8xwPFzg_21_14">1,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_8o2ZYCj_7EKP52vUoSck2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_Es74sqshZUOElU2pJ-AS_w_22_2">23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_J-pJWtADOEeUxcm-wYpInA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_nDkJ6bU_Tk-4L9gop5ixAQ_22_4">161</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_7Gpinpnejkmj88LbkzbxuA_22_12">184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_zvgztu9BHkuDOwBWCilFWw_22_16">184</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_WlD6qYqQ-UChT6kij1OauQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_WT0qkSOMWUGfUq1R4UO-Cw_23_2">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__OUzUplfMke4OyytxLopmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_aeQIn7e78UaiiW55FdQA-w_23_4">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_KfWV61s1vEmILIThCzm8kw_23_12">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_PU4MWpM08Eq6LsHBJBw-Yg_23_14">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_i8nxbOo0Q0-EvFKMYyVsyQ_23_16">205</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_XS4wMvPP1k64ztgaiLo9AQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_4RDt93HpTUeOka25FdJvxg_24_2">294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_8P9AJYdqkUuBYi1IlF81dg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" sign="-" scale="3" id="Tc_2meTWX1mFUyBJK8TZvNLHw_24_4">276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_8P9AJYdqkUuBYi1IlF81dg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" scale="3" id="Tc_3xlBOA8M0k6mHck2vFvoGg_24_9">1,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_bH7upELfKk-xnDKipQZyqg_24_12">1,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_sAouS4o4gkiO7kuVn5RjTA_24_14">1,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_qNgj2Z_Q3k6Magi__mK2Lw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_E0yH-85SmEiCeTLX87P0jA_25_2">2,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_5ly2YlnqS0GPhMxtaYcLWg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_HlpiEtKXDEeBocc_ioVyaA_25_4">2,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_5ly2YlnqS0GPhMxtaYcLWg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" sign="-" scale="3" id="Tc_V0G7I3odoky9FdglKHx58w_25_7">1,590</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilityAsset" scale="3" id="Tc_2otOJbDo2UutJnKuunSk0Q_25_12">3,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_tVvC7oSkSEytAeBxRJmXwA_25_14">3,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_USje2-QFJEy2AJRt3OvR5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_FqG5Mzg2TU6cmE66aiOgJQ_26_14">11,466</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_USje2-QFJEy2AJRt3OvR5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_fhOsJ9nxyUaE2saQ-XV_FA_26_16">11,466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Taxes Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_gecJPuZG2UCLwesvxNB8zg_27_2">2,861</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Tc_4kp1ibTytEKBjM1xCJBHyA_27_4">26</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" sign="-" scale="3" id="Tc_IyA2RBVQykOSxPKhdGDv-w_27_7">1,590</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" sign="-" scale="3" id="Tc_1SxUq2DcvUWQ5XGPcvgZaA_27_9">19</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_T8ozrOdIpkGU-g27PVPzIw_27_12">1,278</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_cJtg9Wp8AUCLtK-xe1pW9g_27_14">7,969</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="Tc_F6HwetmY4k2AybMRkZpPUA_27_16">6,691</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Deferred Tax Assets for CureVac Corporate Services, which incurred a tax loss in the current or prior year, are recognized in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_nNMExjPVFE-feDhtK4OSgg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="Narr_1cnf2f6c5kWwTQWfoRTADQ">1,172</ix:nonFraction>k as the company is expected to generate taxable profits due to its support function remuneration in the group (IAS 12.82).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following unused tax losses for which <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt-sec:numwordsen" name="cvac:TemporaryDifferencesValuationOfDeferredTaxAssets" scale="3" id="Narr_zn4N7cMQEkm6MFBOLe8HSQ"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt-sec:numwordsen" name="cvac:TemporaryDifferencesValuationOfDeferredTaxAssets" scale="3" id="Narr_rL38fYZXlE6LZhadPNvtHw"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt-sec:numwordsen" name="cvac:TemporaryDifferencesValuationOfDeferredTaxAssets" scale="3" id="Narr_IbmP5sHOuEOtkTDVtlpP3g">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> deferred tax asset is recognized in the statement of financial position had been carried forward as of the end of the reporting periods:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock" id="Tb_IUYQ3_9DmE-0Zg2CsWJxlA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Tax loss carryforwards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused tax losses for corporate income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UnusedTaxLossesForCorporateIncomeTax" scale="3" id="Tc_1wffuUWj202H4CxdVqSAtQ_3_2">1,180,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UnusedTaxLossesForCorporateIncomeTax" scale="3" id="Tc_bqJe-g-xk0iUECTxolOy1g_3_4">1,427,735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UnusedTaxLossesForCorporateIncomeTax" scale="3" id="Tc_T-u2V5vokEqt9hnLeEiZPw_3_6">1,700,475</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused tax losses for trade tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UnusedTaxLossesForTradeTax" scale="3" id="Tc_gvXerF_-RUyiPsm0hz-01A_4_2">1,175,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UnusedTaxLossesForTradeTax" scale="3" id="Tc_UDCyKT7nRUKZz4PpA87Qog_4_4">1,419,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UnusedTaxLossesForTradeTax" scale="3" id="Tc_xIvrk90mC0K_OL5lfurTfw_4_6">1,685,517</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused interest carryforward ("Zinsschranke")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UnusedInterestCarryforward" scale="3" id="Tc_LDbmcQd9W02yVBCQv2rnhg_5_2">2,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac has tax losses in Germany and Netherlands that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose. In Germany and Netherlands tax losses carryforwards are unlimited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">DTA&#8217;s for temporary differences in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="6" id="Narr_r1L4jVPZFk6YJRdH-XNiHw">20.9</ix:nonFraction> million (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="6" id="Narr_GYqeEENL1kSoVjRcYDOs1g">21.8</ix:nonFraction> million) are not capitalized at year end 2023 because they are not recoverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pillar Two legislation has been enacted or substantively enacted in certain jurisdictions in which the Group operates. However, this legislation does not apply to the Group as its consolidated revenue is lower than EUR 750 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Current tax assets of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssets" scale="3" id="Narr_FucMfEB2yk2pmf4_u2lugg">5,201</ix:nonFraction>k (2022: <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssets" scale="3" id="Narr_o7_8aWiw7kOOYVj0gTyp6g">285</ix:nonFraction>k) consists of withholding tax receivables.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:EarningsPerShareExplanatory" id="Tb_BsrR9_z2mEG7DAW2ckhbSA" continuedAt="Tb_BsrR9_z2mEG7DAW2ckhbSA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. Earnings per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated by dividing the consolidated net loss of CureVac by the weighted average number of shares outstanding in the fiscal period.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_lm4yXOekn0WKNvend9UWBA"></a><ix:continuation id="Tb_BsrR9_z2mEG7DAW2ckhbSA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted average number of shares outstanding in fiscal 2021, 2022 and 2023 was <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_ft4879ykCUqauc4AzVDwtg">186,012,586</ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_SwvtTWN3HkGONDNZharf1w">189,074,911</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_hiswsaqsOEWTgEBMOuWNoQ">220,833,271</ix:nonFraction>, respectively. This has led to basic loss per share of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_SzfnR9XRMUez2eIXMJcsDg">2.21</ix:nonFraction>, EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_sz2BzUCnXEC8GIvVc6oIXA">1.32</ix:nonFraction> and EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_XGL7312URUSXiJTmUIqY-w">1.18</ix:nonFraction> for fiscal 2021, 2022 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Diluted earnings per share is calculated using CureVac&#8217;s weighted-average outstanding common shares including the dilutive effect of share-based payment awards as determined under the treasury stock method. In periods when CureVac has a net loss, share-based payment awards are excluded from the calculation of earnings per share as their inclusion would have an antidilutive effect. Share options and RSUs of 1.217.526 and <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" scale="0" id="Narr_1s4mB-Y7bEiZmIqNewuyog">1,788,206</ix:nonFraction> as of December 31,2022 and 2023 respectively, were excluded from the computation of diluted weighted average number of shares because their effect would have been antidilutive.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="Tb_v_SZS6UNNEWzHvoUyGwcJw" continuedAt="Tb_v_SZS6UNNEWzHvoUyGwcJw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. Disclosure of financial instruments and management of financial risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is exposed to certain financial risks with respect to its assets and liabilities and the transactions associated with its business model. These risks generally relate to credit risks, liquidity risks and market risks (including currency risk, interest rate risk and price risk).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aim of risk management is to limit the potential negative impact on expected cash flows and take advantage of any opportunities that arise. As a result, the management of CureVac assesses at least once a year whether risks have changed and whether the measures in place to limit risk are still sufficient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Finance Income / Finance Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, finance income was EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Narr_pz3Jr-vqtkOKPwSSl1SJDQ">16,731</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Narr_E7zxk3vWYk-PzY-i1BJ4Jg">4,009</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Narr_yWv3w5MAq0-0xDHpNqjVrg">10,103</ix:nonFraction>k) and related mainly to interest income on cash investments EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="Narr_F50yBYMc1kyJUxkGOfo91Q">15,411</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="Narr_qPeH84va106jwu0SFkcf7g">1,733</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="Narr_kMcivfaNWUephxMLb8IIMQ">81</ix:nonFraction>k) and foreign exchange gains EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeGain" scale="3" id="Narr_tLiizCrtvUKVlJrcVYbBBQ">1,062</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeGain" scale="3" id="Narr_iUcPuSdU2k6IMdvIJp1qFA">2,188</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeGain" scale="3" id="Narr_iUsed17LYkC22Hq5bEZIPA">10,092</ix:nonFraction>k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, finance expenses were EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Narr_sHWWQX4V7EiZo19NoBIUqw">2,493</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Narr_EEGXNoRzgkqumyrwPmm2cw">3,707</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Narr_RU4h1i8GiEeVHgbFQnFQ1g">10,338</ix:nonFraction>k) and related mainly to foreign exchange losses EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeLoss" scale="3" id="Narr_R14YZ7bQKEOmpHpDXm3nmg">2,272</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeLoss" scale="3" id="Narr_Zcn3UL__F0msx69D2bdCew">1,319</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeLoss" scale="3" id="Narr_3o8L-oNFxk2E5tYRpLrLUw">3,939</ix:nonFraction>k) and negative interest on cash of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:InterestExpenseOnCash" scale="3" id="Narr_ms8od68D9UGegXsXn7XoSA">0</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:InterestExpenseOnCash" scale="3" id="Narr_8VyP733vLUeO4H46LfvFZQ">2,299</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:InterestExpenseOnCash" scale="3" id="Narr_mh04dIMVSUCNdkQnsliOQw">6,793</ix:nonFraction>k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk is managed by CureVac&#8217;s finance department. Credit risk arises from cash and cash equivalents and other financial assets, including deposits with banks and financial institutions, as well as credit exposures to customers, including outstanding receivables and contract assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is exposed to bank default and concentration risk as its cash is concentrated at few financial institutions. Management distributed the cash to decrease concentration risk as of December 31, 2023, deciding to allocate <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_EuropeSLargestPrivateBankMember_grNAnpFTY0ubOJ1E3t9yiQ" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsConcentrationRiskPercentage" scale="-2" id="Narr_xtKvVBruI0Otzgxpja2SxQ">12</ix:nonFraction>% of the cash at one of Europe&#8217;s largest private bank, <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanysLargestPrivateBankMember_TPfvCFqo80y0z7BFfC2YKQ" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsConcentrationRiskPercentage" scale="-2" id="Narr_F412yhw3r0u5IpWF9sK7sA">7</ix:nonFraction>% at Germany&#8217;s largest private bank and <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanLandesbankMember_x_lULUcrc0GPG1twEsc5vQ" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsConcentrationRiskPercentage" scale="-2" id="Narr_bKOnzGh4XEa4EVsuTxdrzA">71</ix:nonFraction>% at a major German Landesbank; the remaining cash balance is maintained at other banks. The focused cash management structure with few banks allows enhanced bank risk supervision. The market capitalization of all banks mentioned above is regularly reviewed. Credit risk is further limited by investing only in liquid instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is also exposed to a credit risk for its receivables and contract assets. The risk of default is considered to be low because the structure of customers consists of reputable collaborating parties and government grantors. Receivables management and financial accounting incorporates monitoring of payments received and any overdue receivables. The risk of counterparty nonperformance is not material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amount of other financial assets recognized determines the maximum theoretical credit risk. As of the end of fiscal 2023, available funds are deposited at three reputable financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the loss allowance for the &#8220;expected credit losses&#8221; totaled to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:AllowanceForExpectedCreditLossOnFinancialAssets" scale="3" id="Narr_nCEC00hXPUmd6-yvWqc29w">71</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AllowanceForExpectedCreditLossOnFinancialAssets" scale="3" id="Narr_uSMywn47P0ypBK663mGdUA">99</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AllowanceForExpectedCreditLossOnFinancialAssets" scale="3" id="Narr_qIQKPVWNNEGgmRZIRbHX8A">105</ix:nonFraction>k), resulting in an effect recognized in fiscal 2023 in finance income EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_ZRIYWuzzT0SCY6jmM6q8Kw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Narr_13V-evk5UUWmTfWBH07TuQ">248</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_Z4th35GQN0yb98iIcO_pdA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Narr_NgOIMiyUqkmQSFPVj_F7_Q">57</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_lt3cWNU5H0SMaF3fADwXfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Narr_NTFHSqvWsU-mcpbtDR_IdA">149</ix:nonFraction>k) and finance expense EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_ZRIYWuzzT0SCY6jmM6q8Kw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Narr_HXm85k2lXEOPM4XESYpvZg">220</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_Z4th35GQN0yb98iIcO_pdA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Narr_39SSm4aqcEWeNjTQF5seaQ">51</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_lt3cWNU5H0SMaF3fADwXfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Narr_HBCvGcYmb0mth1Z9vLkpCQ">71</ix:nonFraction>k).</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e650e532_9012_43bc_9f4c_61cfb9c8eb21"></a><a id="Tc_Kwk9AiG9xkmEFqW_I1b3Yg_1_2"></a><a id="Tc_C3iZmpQfK0OFwLdE_kFFng_1_4"></a><a id="Tc_4HwX2mWLMU2Lza5IOwueaQ_1_6"></a><a id="Tc_wDVg8dGkRUiSYU8UC-4oSA_1_8"></a><a id="Tc_byzpMEdwckCfyLk0K3PCkQ_2_0"></a><a id="Tc_u0nmEtWPTUaxe3c1FJmQHg_2_2"></a><a id="Tc_vw8U77q-lkODKaaKrp_HGg_2_4"></a><a id="Tc_hnwHQRnXwE-jZY5LknBhkg_2_6"></a><a id="Tc_EZG_0Are4kOZGKb8vFPx-Q_2_8"></a><a id="Tc_EMtg-2_2Zkm383jdEQh-sA_3_0"></a><a id="Tc_uk__UDjCqkOtb8bLs4VL-A_3_4"></a><a id="Tc_AooMHIDRnUS5BxSc-TzJqg_3_6"></a><a id="Tc_7UNjxZ_aE0SJn07bIB3EPg_4_0"></a><a id="Tc_d-u59al5okyf5fT0e5YjvQ_5_0"></a><a id="Tc_aokE7vrwIEm4LsXcVJVqdg_5_4"></a><a id="Tc_g5sMjf9bIk-z7IUccLTLRw_5_6"></a><a id="Tc_6_3bsEu8BUa658cseqWZhA_6_0"></a><a id="Tc_-xHwnFYNtUKEDVh5JZDtNA_6_4"></a><a id="Tc_qoxNk_W-ZkaK588KIWlxQw_6_6"></a><a id="Tc_nzQJMRGll0Cp3Q7gaU136A_7_0"></a><ix:continuation id="Tb_v_SZS6UNNEWzHvoUyGwcJw_cont1" continuedAt="Tb_v_SZS6UNNEWzHvoUyGwcJw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity risk</span> <span style="font-style:italic;font-weight:bold;">/ Capital management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of CureVac&#8217;s capital management, capital includes share capital and all other equity reserves attributable to the equity holders. The primary objective of CureVac&#8217;s capital management is to maximize the shareholder value through investment in the development activities of the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its business as an active research group, CureVac has historically relied almost exclusively on equity funding by its shareholders and lenders as a means of financing itself prior to successful development and sales of a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s finance department reviews the total amount of cash of the Group on a weekly basis. As part of this review, the finance department considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In meeting its financing objectives, the Group negotiates and enters into research cooperation agreements. In general, the aim is to maximize the financial resources available for further research and development projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is not subject to externally imposed capital requirements. However, certain grant funds received may be required to be returned if qualifying costs are not incurred or are not incurred in accordance with the grant terms (see also Note 3.7. and Note 3.8.). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in Note 9, the Group has an at-the-market offering program through which, from time to time, may be able to raise additional capital through the issuance of common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No changes were made in the objectives, policies or processes for managing cash during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to safeguard liquidity, the Group invests funds not required immediately for operating purposes in call-deposit accounts with original maturities up to three months. Liquidity risks are therefore expected to be low. The Group does not enter into trading of financial instruments and monitors its risk of a shortage of funds using a liquidity planning tool.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, CureVac has relied on financing from shareholders, grant income and collaborators in order to ensure sufficient liquidity. Lack of external financial support could pose a risk of going concern. The liquidity management of CureVac ensures the availability of cash and cash equivalents for operational activities and further investments through appropriate budget planning.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ultimately, the responsibility for liquidity risk management lies with management, who has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. CureVac manages liquidity risks by holding appropriate reserves, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the maturity profile of the Group&#8217;s liabilities based on contractual undiscounted payments:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" id="Tb_CHUGFXssIUGHettfIcO9RA" continuedAt="Tb_CHUGFXssIUGHettfIcO9RA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt;1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual commitments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ContractualCommitmentsUndiscountedCashFlows" scale="3" id="Tc_2Se7KjZlpUWrP5YuIVGLYA_3_2">3,269</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ContractualCommitmentsUndiscountedCashFlows" scale="3" id="Tc_9UozcO8T2UKMY66eT1OZkw_3_8">3,269</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Note 4.2) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_7QKTV9_1VE2imjYpwyE6MA_4_2">7,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_jspXe4LQ_UyibQFOKeFBYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_NpZT_jsWrEeuigng9fygCA_4_4">23,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Oueb9u3QfkWqN8BPX_v-xw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_YS_3TWNiOEaPAm2s8k9OhA_4_6">22,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_-a4Hab1Y8k6Ja-fZzIx6iQ_4_8">53,656</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities and provisions (Note 12) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_SpniZedu60ei_EIIdj90lA_5_2">88,117</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_xLjdGP0CY066_OK1nh4qUg_5_8">88,117</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables (Note 11) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" scale="3" id="Tc_rigUll7b-kCpB7ex5HFA8A_6_2">48,033</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" scale="3" id="Tc_lo-9Mn0G70qMqkE4HWbwMw_6_8">48,033</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_xzyFvo5Py0q3jvuXCMoVHg_7_2">146,673</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_jspXe4LQ_UyibQFOKeFBYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_sFaFU-F-D0i9bhsKFbVz1Q_7_4">23,581</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Oueb9u3QfkWqN8BPX_v-xw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_z2Mpz2pcMUWLx58s-0UJuA_7_6">22,821</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_7022TWiyUUS-wqwLn3_zfQ_7_8">193,075</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ca96588e_9bd8_470e_bc5b_c615e5fe9907"></a><a id="Tc_YawwlpXkBkS7mRExOUM8PQ_1_2"></a><a id="Tc_PM7KoLmkP0OhxYx7l-q0BA_1_4"></a><a id="Tc_TVLz110NxEWFiu662AYmHg_1_6"></a><a id="Tc_GtTbddy8uEqcahkIlAFA8Q_1_8"></a><a id="Tc_xvv9lwbHMEOm98MqEdu5Qg_2_0"></a><a id="Tc_Gq677IPkREevCjtcj8TAeQ_2_2"></a><a id="Tc_xX7WBHXdTUWge7rRdA3EhQ_2_4"></a><a id="Tc_HDLiHtmXe0WQ2yM9uXMvUA_2_6"></a><a id="Tc_AMwXzT1oMUSLreT48zyB_A_2_8"></a><a id="Tc_3mjXZzTFyE-87aMKbGUg2Q_3_0"></a><a id="Tc_b3lgiIXmM0mVLF6Woo2qEA_3_6"></a><a id="Tc_VSFKcVUijEag_0PgXRfB1w_4_0"></a><a id="Tc_tgp878_6e0awW4Ig1ZuwLg_5_0"></a><a id="Tc_8prkDuYcKEWBlPg5IKxaEQ_6_0"></a><a id="Tc_RKDsFGspHk6y3C8sw-0q4g_6_4"></a><a id="Tc_Xe16girppkm7gl5EjZHRkQ_6_6"></a><a id="Tc_DeyoxUbN-kq2KlcfQE4f4A_7_0"></a><a id="_a30d14ef_cbc0_4d91_be6d_5dc1bbe464dd"></a><a id="Tc_AF7o6BD2WUaroP6uYscA4Q_1_2"></a><a id="Tc_HElALpteW0u2TjAgZ7Tueg_2_0"></a><a id="Tc_rLHKFieKP0e0Ag7x7_cXTw_2_3"></a><a id="Tc_DGWsEySRBUSeUwKIESm2pA_2_5"></a><a id="Tc_c33VGDrC-0eEgrbmUqHGfg_3_3"></a><a id="Tc_oEpgsPvFTUuSfXxrg3piCw_3_5"></a><a id="Tc_s1DuPpk0ck2uih5tSumtTA_4_0"></a><a id="Tc_j03QhYKXUkiKxXo18BJ9QQ_4_3"></a><a id="Tc_xPK8of4drkqANx1AvZbFYQ_4_5"></a><a id="Tc_7p7olPFWLEGHB_SGMsxFSw_5_0"></a><a id="Tc_IyifriXCCEOLO4Kkj3q2mA_5_3"></a><a id="Tc_VtRPUg4hvkiyY8p3QzPovw_6_0"></a><a id="Tc_5TkgUVdyYUGc09dZfWvAow_6_3"></a><a id="Tc_oit4RDrBSk-NDF2zQ6HD0A_6_5"></a><a id="Tc_rhNzKf1-AUOdo5PKX0xmZQ_7_3"></a><a id="Tc_GHg6uTJInEanHt5-7a1w7g_7_5"></a><a id="Tc_fgXCFcYk90S_dhQX47ACWA_8_3"></a><a id="Tc_b52F9rrOS0O6aK7j1-irjw_8_5"></a><a id="Tc_eRzZW8pym06_gL8k1vWokg_9_0"></a><a id="Tc_IJ4Jq6uFhk6Re-6OIX4q-Q_9_3"></a><a id="_081c49ca_fe22_40dd_9c6c_a55bd96354f0"></a><a id="Tc_qqffbj4NX02GzRF98EXMcg_1_2"></a><a id="Tc_-GC4cPsjxEiUOAftM2A55Q_2_0"></a><a id="Tc_0b3ccQkFIEuVz1FRkE2LWQ_2_3"></a><a id="Tc_2qGxiRADe0qUv6J15kZNdg_2_5"></a><a id="Tc_yms_p0Cl5kanFCsc75OqVg_3_0"></a><a id="Tc_-jHZVBhBmkWvouYChfYgBg_3_2"></a><a id="Tc_xkwVFWffb0mOLgpUYIcEUw_3_3"></a><a id="Tc_S3FfRM9DFECEaWw48nXKww_3_4"></a><a id="Tc_6Htxaja8tkKms3klXYQgDw_3_5"></a><a id="Tc_TUHpKCRnZkKQVwFo4tuZiQ_4_0"></a><a id="Tc_W-kyPKAfT0OzHlWc87xc6A_4_3"></a><a id="Tc_GLFYL2Kz7EqDpGef55QtYw_4_5"></a><a id="Tc_mLVgjOpzTUm7wK7zNGW_1A_5_0"></a><a id="Tc_JLWU6RuX70-20Wa334kIrg_5_3"></a><a id="Tc_ULx20ouPBECPiU5Wcc4FkQ_5_5"></a><a id="Tc_CKwP7X-JjUiMrHolGFw4KQ_6_3"></a><a id="Tc_eSzKyAn8i0iXjJo6f0CW1Q_6_5"></a><a id="Tc_o7LlZsxfGUevgnx8N2ziMQ_7_3"></a><a id="Tc_2g57PumXmEuPz-eDF5bR3Q_7_5"></a><a id="Tc_PUzR9z_JN0aamDCP9AcCZQ_8_0"></a><a id="Tc_ifBljxXlkEKXuF8_exkCgg_8_3"></a><a id="Tc_c_xo-Mu8gUibdA4pBXj39w_1_2"></a><a id="Tc_sK1rkFxmW0iaC5N6h7Oq4w_1_6"></a><a id="Tc_zug0Y5Jc8UeUWHTRA_QO0g_2_2"></a><a id="Tc_fbu_hcAvx023uPB-ZOiKVQ_2_4"></a><a id="Tc_t7aNM1nV9UqO0E0ibZowDQ_2_6"></a><a id="Tc_T-_eRCDTaUmLu8yYdKWoXg_2_8"></a><a id="Tc_EJQYBzeaK0qzo1kuB06VFw_3_0"></a><a id="Tc_h96Np_wt0kmTcGlFNnOqGw_4_0"></a><ix:continuation id="Tb_v_SZS6UNNEWzHvoUyGwcJw_cont2" continuedAt="Tb_v_SZS6UNNEWzHvoUyGwcJw_cont3"><ix:continuation id="Tb_CHUGFXssIUGHettfIcO9RA_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt; 1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;5years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ContractualCommitmentsUndiscountedCashFlows" scale="3" id="Tc_839Rhr_pPEGJ8JDsz-Ip3w_3_2">49,923</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ContractualCommitmentsUndiscountedCashFlows" scale="3" id="Tc_YQGCEr6qhkm-UlW2gPticQ_3_4">24,377</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ContractualCommitmentsUndiscountedCashFlows" scale="3" id="Tc_WTFXdwvym0qOtBlHvmn7Zg_3_8">74,300</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Note 4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_RpU8fU_6VEqCS7QuVjk7pg_4_2">7,247</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_IXuA-Gzrukqoy0NJxSkMkw_4_4">25,693</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_fT4Z_TcfzEG4vk6M40CnZw_4_6">21,783</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="Tc_mJCM3b9-d0-KTOUhkOTTwQ_4_8">54,723</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities and provisions (Note 12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_qPhHsNzcz0q64vYLMeKCvQ_5_2">41,447</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_KG5Y9pqYXk6K28K8e-wvJA_5_4">62,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilitiesUndiscountedCashFlows" scale="3" id="Tc__qPITBnQAE2htWYLHF0Erg_5_6">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_NvLW3HkD6EaKwCptCK-8rg_5_8">103,753</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" scale="3" id="Tc_e5Ap34FcJ02r3zbUXprakw_6_2">73,463</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" scale="3" id="Tc_I6CEAnNlg0ifs_GWB0O2mw_6_8">73,463</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_4z_ZHDoIYEWyQOK61-cuDg_7_2">172,080</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_okUiJFp5ZUKFow8VkI54qQ_7_4">112,356</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_VwSV_qmMHUiLDIjoyMe6QA_7_6">21,803</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="Tc_byD--wYXpUWNiiPpphP24w_7_8">306,239</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign currency risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. CureVac&#8217;s exposure to the risk of changes in foreign exchange rates relates primarily to the Group&#8217;s operating activities (when revenue or expense is denominated in a foreign currency) and the amounts held as cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For all CureVac entities except of CureVac Inc. and CureVac Swiss AG the functional currency is EUR. The functional currency of CureVac Inc. is the USD and of CureVac Swiss AG the CHF. CureVac SE&#8217;s exposure in foreign currency at the end of 2023 and 2022 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfExposureToForeignCurrenciesTableTextBlock" id="Group_wdgJQwWiiECmTvPfPoUEXA" continuedAt="Group_wdgJQwWiiECmTvPfPoUEXA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b>&#160;<b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_utQHB3ubf0qCXWhEgF-buQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_KCQxwyi6jUeSlh9Q9xzBnA_2_2">57,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_Ju4vpITtT02dIgHA1CnNWQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_lLt-Bxh5I0SXbSrGjzUsKQ_2_4">63,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_kxVp_wCgNE6FvnLLR-syMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_WlLEHM9g_0ylGQxbOjpgkA_3_2">221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_yLPRccYMQ0WEes48TIb4Rw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_ENcMfIYU0kqMo2kSxP7rXQ_3_4">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR__hXio1aUh0yPowZRVEGPEA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_C4CiCyQZpEi3HeUVbBFXGA_4_2">1,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_7ob2rXhv0ECk61hyXNe7kg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_00Iay9-ZwEmqmqtgjtJZEA_4_4">1,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total monetary assets in foreign currency </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_1QMTkTTsdkCGavOTm0os4w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_oiC9sB1wK0OBJIHqy7Kb9w_5_2">58,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_4BI6yad6zEGqAQHMGJ0Ssw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_MeQo9WLIr0itY7sMe992dw_6_2">13,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_XId6JMRHbEi7pWfMUdRyfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_CTUrolPpgE2nLjjLurOx7w_6_4">15,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DxjsavysM0WLv8Lp8ri1eA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_euJedYaO0kKGsaRDB3HOIA_7_2">54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_GBP_NKJzu3jWTEavxop33-TfZw" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_UfCOEGrffUq3abl-fRhxig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_6oZ8eix5_ES-PtXVCNROXw_7_4">47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">GBP</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_OFTLAOtsqkSihsTZpVXK2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_gzy3ty5nMEq935jHf2xDEA_8_2">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tiOKflb2S0qu7_rAt0WFJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_8sWRw-_b9EytFcpnr5esVQ_8_4">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total monetary liabilities in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_sFnkjvJ1RUWEpsQY3dM6qA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_72yQ24f1IkSf9nIgaJWITg_9_2">14,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b>&#160;<b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_XKseGYdQ5U21PwXtFPcggA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_sXMff2AeC0mhqvKTxf1G2A_2_2">106,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_lmEX-wi5LEW5VEf6oyObmA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_nIkRMBd18EGZGEIid3oYjw_2_4">113,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total monetary assets in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_2hwJbQ3UHEG7HHhakH5QdQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_a_dAXYySYkmW2iGLcYh7AQ_4_2">106,566</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_qzSBjM_s00e_a6TyWqLnUg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_3yz1cdfOXU2W6H03sd14wg_4_4">113,664</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_xdnpZEJ2mEWa4sCfDXRnOg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_o6W21ydoFEerwhNWtQtvFQ_5_2">26,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_RmJ2ciRZdEmmfIdFfjBrGQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_1KMniw3nhEaCpRC5bm5nNg_5_4">27,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_w0ZgcmzTPkCXLtNWBXC5iA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_Bu_eSotEUUumWaXdkZzpNA_6_2">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_GBP_NKJzu3jWTEavxop33-TfZw" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_ov6PyZWWUUy6kIErGoPNSw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_nJCM5PDKGku9Z4YG11QFrQ_6_4">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GBP</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DolE5C86p0ekLVQ3PMh3_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_s1ViKmr4PE-rXKB0cq40nw_7_2">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_bODM9rD0EUC2RC277AOZlA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_0HWZzV5t80qJ8tsTwWLtBA_7_4">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total monetary liabilities in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_uhnmPrBIeEi3fuQMts_BCw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Tc_OkaYH6KGkk2nBcaQCIi7nA_8_2">26,332</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the tables above, CureVac N.V. is exposed to a currency risk only in relation to the USD. Therefore, a foreign currency sensitivity analysis is only presented in respect to the net exposure in USD at fiscal year ends. CureVac&#8217;s net exposure in USD is the difference between monetary assets in USD and monetary liabilities in USD and developed as follows:</p><ix:continuation id="Group_wdgJQwWiiECmTvPfPoUEXA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net exposure in USD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:53.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2022 (1 EUR= <ix:nonFraction unitRef="Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Narr_SD6GWYEa6kqVgXC7B6n-Lw">1.0666</ix:nonFraction> USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (1 EUR = <ix:nonFraction unitRef="Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Narr_gO_RbTvFbEekmzUsYLJkVA">1.1050</ix:nonFraction> USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">EUR </b><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExchangeRateCurrencyNetExposure" scale="3" id="Narr_iNqmiClWrU27XIAFllNQdg">77,649</ix:nonFraction></b><b style="font-weight:bold;">k from USD </b><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExchangeRateCurrencyNetExposure" scale="3" id="Narr__yF4axFIbUCKlAKu8xMhLQ">82,822</ix:nonFraction></b><b style="font-weight:bold;">k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR </b><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExchangeRateCurrencyNetExposure" scale="3" id="Narr_b-OFVU3nk0evnVaeLfjvAA">72,015</ix:nonFraction></b><b style="font-weight:bold;">k from USD </b><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExchangeRateCurrencyNetExposure" scale="3" id="Narr_l_CVOOeLvUus_FakGnKS4Q">79,576</ix:nonFraction></b><b style="font-weight:bold;">k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2023, if the EUR had weakened and conversely, had strengthened, <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfEurStrengthened" scale="-2" id="Narr_T40oVljj4E6jb5tZRXI61Q">10</ix:nonFraction> per cent against the US dollar, with all other variables held constant, pre-tax loss and post-tax loss would have been affected as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfMarketRiskExplanatory" id="Tb_MCKV3MNf0E630oM7VQjMpA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effect&#160;on&#160;pre-tax&#160;profit&#160;or&#160;loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effect&#160;on&#160;post-tax&#160;profit&#160;or&#160;loss</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strengthening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weakening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strengthening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weakening</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">31.12.2023 EUR against USD </b><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfEurWeakened" scale="-2" id="Narr_xNQfTjLM5Uyi64er3FuUyw">10</ix:nonFraction></b><b style="font-weight:bold;">% movement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossBeforeTaxIfEurStrengthened" scale="3" id="Tc_b6Kkxebps0mrd9ALragGfA_3_2">6,547</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossBeforeTaxIfEurWeakened" sign="-" scale="3" id="Tc_sslkHezKa0OjIpPBUHYCNw_3_4">8,002</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossAfterTaxIfEurStrengthened" scale="3" id="Tc_l4Ih2-7If0uiiPwpW9eSbg_3_6">4,617</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossAfterTaxIfEurWeakened" sign="-" scale="3" id="Tc_306OphxVTUyfcj5YdTzItA_3_8">5,644</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">31.12.2022 EUR against USD <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfEurWeakened" scale="-2" id="Narr_6HFJNXlyHE6M7607-ApDgw">10</ix:nonFraction>% movement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossBeforeTaxIfEurStrengthened" scale="3" id="Tc_QqMLUpk61EaHa1ko_9EHfg_4_2">7,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossBeforeTaxIfEurWeakened" sign="-" scale="3" id="Tc_ZgFhi9eUAk-bdPLAt_2adw_4_4">8,628</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossAfterTaxIfEurStrengthened" scale="3" id="Tc_oCmnbmzi_kiZOb5sZ2Wbbw_4_6">4,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProfitLossAfterTaxIfEurWeakened" sign="-" scale="3" id="Tc_2Z3lTGwlnE-uOD-d3Leu3w_4_8">6,085</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac did not have derivatives in 2023 and 2022.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_v_SZS6UNNEWzHvoUyGwcJw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest rate risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. CureVac&#8217;s exposure to the risk of changes in market interest rates relates primarily to CureVac&#8217;s cash and cash equivalents with floating interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If interest rates as of December 31, 2023 had been <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfInterestHigher" scale="-2" id="Narr_XPGHdeZ4ZUiw2s8dW_dF3w">1</ix:nonFraction>% higher while all other variables had remained the same, the net loss for the year (before and after tax) would have been EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:NetLossBeforeTax" scale="3" id="Narr_Osj5sG5c5Ue1WHWRxYi3oQ">4,025</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:NetLossBeforeTax" scale="3" id="Narr_-5EBMiOBvECjF7b_NbSoow">4,959</ix:nonFraction>k) lower because the higher interest income would have been generated from floating rates on invested cash and cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair value measurement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized with the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Inputs use quoted prices in active markets for identical assets or liabilities</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs are inputs, other than quoted prices included in Level&#160;1, which are directly or indirectly observable</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs for the asset or liability that are not based on observable market data (unobservable inputs)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All financial instruments are measured at amortized cost at December 31, 2023 and December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The group measures assets held for sale at fair value less cost of disposals. For all short term liabilities and receivables the book value approximates the fair value.</p></ix:continuation><a id="_5accdb52_5c11_40a9_b19c_bd9c3fa665ee"></a><a id="Tc_7NeO8AtlCk6B0w8jDmKHIA_1_16"></a><a id="Tc_RyWRSwxFkkSlauthfQXu7A_2_2"></a><a id="Tc_Ji3uS7YrL0ezLiZ1dZKdiQ_2_10"></a><a id="Tc_rus51-t0dUyNg9csLSy23A_2_12"></a><a id="Tc_2j6B7U7m1EGODPyQZdRmfg_2_14"></a><a id="Tc_QvIB_FIwgk-fXdTkrjESBA_2_16"></a><a id="Tc_M9Z8o6eknUez4eUBw0PgZw_2_18"></a><a id="Tc_J6C4gEJkp0mOIbq5cc4mKg_3_0"></a><a id="Tc_lwVYindW4EmdLukA3SyUqQ_3_2"></a><a id="Tc_T0q0GrH_-EidlO5JbwaOTw_3_4"></a><a id="Tc__6AyUUk2AECqxsVJd5zjOA_3_6"></a><a id="Tc_oSlfFN1ElUiICf_2jutyuQ_3_8"></a><a id="Tc_BJVn4NqEmkG3dEi3Os0vog_3_10"></a><a id="Tc_Yk-xP_iMAESeFdlLQy3c2w_3_12"></a><a id="Tc_NyI-k4Qc3EG5RebuhOjrcQ_3_14"></a><a id="Tc_Cv_MQuX2pEWzO1edliAPPA_3_16"></a><a id="Tc_hOPa0izXKEiQG5P8ksbdMQ_3_18"></a><a id="Tc_h4JS9_KNYUOcwQp1Q_L9jw_4_0"></a><a id="Tc_IPWOQuYkW0-4y9hyR9ijxw_4_6"></a><a id="Tc_TX6kNcSMjUOlJMeoz7HhNg_4_12"></a><a id="Tc_3xQI7XeENEmp-b1jzcOXow_5_0"></a><a id="Tc_Rxiz1x0WzUaAA0NCVKLqng_5_6"></a><a id="Tc_0Ar-2jKhAEen1qWPgKwmoQ_5_12"></a><a id="_31f1a381_3556_4fd4_ad9f_8c97b7ee9640"></a><a id="Tc_zfIvfqQlAU2si7emBb-lCA_1_16"></a><a id="Tc_O4ZvS-ARbkm4RR8nbTCvig_2_2"></a><a id="Tc_XVpTkc3Hq0m3m5j7TfRDOw_2_10"></a><a id="Tc_yaOIppxp0EalJj-uaWADdQ_2_12"></a><a id="Tc_aQ_1m8fVWkOAxWqyDHIhBA_2_14"></a><a id="Tc_SZ22U4ZhHEasQPhIvTUwxQ_2_16"></a><a id="Tc_swgq_m3z_EKryS_811FZAw_2_18"></a><a id="Tc_7tSy26Z3YkiflCiQRGLhTg_3_0"></a><a id="Tc_0__F_Eq3hEmwyKNVgeM77Q_3_2"></a><a id="Tc_5nPaWtn-bEyJRzsrzH--2g_3_4"></a><a id="Tc_W3xnojy4X0KOpvvKxrfZKQ_3_6"></a><a id="Tc_QyBWvpgyskOdchEGuy-YhA_3_8"></a><a id="Tc_SSXvM0Zn0UKkyaUb1fV4Uw_3_10"></a><a id="Tc_qwCZpbKFh02k1BT-Uq0VVQ_3_12"></a><a id="Tc_vC2EqV9Gx0alWKZ8-NgWqg_3_14"></a><a id="Tc_04zsNjaSjE-pNhKMdWXwng_3_16"></a><a id="Tc_De22zUdiFEurPgg81I13HQ_3_18"></a><a id="Tc_T1ANrv1x6EKO5b5SxkOGUA_4_0"></a><a id="Tc_VCMInggR9kKKBJ_h1lSZJg_4_6"></a><a id="Tc_cL0j_-JCk0SXVX6PI2BDew_4_8"></a><a id="Tc_eL3Xof0ASkCfcFBZFiqDQw_4_12"></a><a id="Tc_1jiWLbGWbkafZFtJOvjP8Q_5_0"></a><a id="Tc_PhLd0NHjV0K8Wfi7E0pz-Q_5_6"></a><a id="Tc_5yEVKNuvHUKaOiM_0b8Ecg_5_8"></a><a id="Tc_upNZGN79RkCBwk9uPXlWQg_5_12"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="Tb_H_McRjxbqkS0qjikrZc6JA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16. Notes to the consolidated statements of cash flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in liabilities arising from financing activities</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" id="Tb_4y9DAroZA0C5BTsFw-B73g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;1,</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accrued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">in thousands of EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reclassification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Disposals</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Changes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Movements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Payment of lease liabilities (Note 4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_hizFCmgkaE2aderOvs1LNA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_FiwMgrqXjUCHs-ydxFi88g_4_2">42,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc_I81JXTvP8kqygWoMimy83A_4_4">7,568</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc_gjOg5HWSZkWvVxS86RONBA_4_8">2,998</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_LCsXa9Y-DEGYcMqMZXJFVw_4_10">7,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_NCEnravM60efnt5pNZBNMQ_4_14">2,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc_uwpGJVjj602fZZC1hbpihw_4_16">57</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_x7oTzwEM40qM38yhmGMObg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_gFXbW3cEFU6UATPdHMNomQ_4_18">41,824</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_M5CqQ8hh20yA64xT9tcP7Q_5_2">42,086</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc_UlPkuYIzLkGGuMJ2xBq4TQ_5_4">7,568</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc_gj4LqbjpykeVKMwhyyTtwg_5_8">2,998</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_RuhHknfuc0-jO8qFNeB9DA_5_10">7,986</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_x5ThmmEL9Ee0bVIRryAvcw_5_14">2,375</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc_V31nMpzuIEG-vqmcS1rf6Q_5_16">57</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_kscN7SiN9kWKMoZwvQOhAg_5_18">41,824</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accrued</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">Exchange</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">in thousands of EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reclassification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Disposals</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Changes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Movements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Payment of lease liabilities (Note 4. 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_kk4sEIFbXE6LU2RSZnpNkA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc__xEWceRYVUiKDd_Bw_C0zw_4_2">28,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc__ikjHTqvOkCgQ8ZthBDs9Q_4_4">6,439</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_C6hbZsufx0K3rluNtalXyg_4_10">17,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_N6y0aErfEk6bXd8ChRcY5Q_4_14">2,218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_K8VYr3ixY0W8XIoGGK8NsA_4_16">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_hizFCmgkaE2aderOvs1LNA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_IUG-q3xwzUuCIx3KJXrmRw_4_18">42,086</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities from financing</b> <b style="font-weight:bold;">activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_cMd4QQCAdEqNCxYhLOPitw_5_2">28,892</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" sign="-" scale="3" id="Tc_BBVlGjIQmUO9yOCeHDdyhA_5_4">6,439</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_IPOevQtd_EiS69_lh5jv7w_5_10">17,241</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_Q7ByCKxmIEuGONnKdt2cMg_5_14">2,218</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_3uKAnydQ-06lzw0FLe1Vpg_5_16">174</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="Tc_hcg-Ff8Vdkmy_I3NgScuXQ_5_18">42,086</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The cash flow includes an interest component which is presented separately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="Tb_95QJp9J70ES68En72T3r7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17. Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">No material contingent liabilities resulting from claims and legal proceedings exist as of December 31, 2023. Refer to Note 12 for provisions recognized for contract terminations. For contractual commitments, refer to Note 15.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_5Or92Vhdfk2NRxntA2ZxBw_1_2"></a><a id="Tc_V1nGfOnur0aG3dByuxIY1Q_1_6"></a><a id="Tc_C5oQS1rgSkuMQp4M_yqluw_1_10"></a><a id="Tc_kJyyM2Hzs0uJJBd7Cm_2Qw_2_2"></a><a id="Tc_oD1NuURDz0OqSlIH1HLqsA_2_4"></a><a id="Tc_mDIiiybgC0CXV0TpoQgSSw_2_6"></a><a id="Tc_ekO0V8qayE2q2bPTk6lknQ_2_8"></a><a id="Tc_HDczcdEbG0WiSS78VFRsCA_2_10"></a><a id="Tc_rebRZeGfZUCORJRVLENJjA_2_12"></a><a id="Tc_BpfS-KuW8USbTj6SvspasA_3_0"></a><a id="Tc_Tch18udDrkypH6Ce6o70_A_3_2"></a><a id="Tc_FhRTLGmUlkmG6ZkE2Z2-8A_3_4"></a><a id="Tc_-wtUDRIEu0OIW7rZCCtoQw_3_6"></a><a id="Tc_cWGCy8pAzEiEoN1DSWJgmQ_3_8"></a><a id="Tc_4RUMejzqB0u8GJ2gKTx5IA_3_10"></a><a id="Tc_yktPW5_DOU-imRke1UxUuQ_3_12"></a><a id="Tc_lxo3ZxfjzU2kTigC2corWg_4_2"></a><a id="Tc_16X_vizsEEOA6rV2qHk5FA_4_4"></a><a id="Tc_01LDWJgBN0mZ6cEYRXnd5g_4_6"></a><a id="Tc_QnYAgF98o0W18w6FaDsYbw_4_8"></a><a id="Tc_32FbgZcvBUuAZ--mmwc6rQ_4_10"></a><a id="Tc_O9RBlmP7pk69wavQKLfbFw_4_12"></a><a id="Tc_P4baYRJbXEiUCaH1nYgVBQ_5_0"></a><a id="Tc_EczeMMKF1km32W-JEldaXQ_6_0"></a><a id="Tc_IJjHMPA5FUOqtTP7FdGnSg_6_2"></a><a id="Tc_dFMG40W890a-e0b4hA06_g_6_4"></a><a id="Tc_q8Yle-7N0EmhJgC44AagBA_6_6"></a><a id="Tc_l4B7COjySk-qDpCr1Odwcw_6_8"></a><a id="Tc_TAvfcMOMA0yaEpcDgo6zZA_6_12"></a><a id="Tc_Cqs3omurcECpG-qCNphw9g_7_0"></a><a id="Tc_fj3qhiwB0ESF8lF10L9eYQ_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="Tb_r3T8_NBaX0mvJgA4k41atQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18. Remuneration of the Company&#8217;s key management personnel</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Total remuneration of key management personnel</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Remuneration of the Company&#8217;s key management personnel was as follows :</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock" id="Group_-a-3UIxTKk2FWG9kg4Ly3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Remuneration of key management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="Tc_OO-hWAHxu0SNEKVRZ1QhsQ_5_2">3,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="Tc_VxFwEkAUKkmjAkTU1bQw2w_5_4">646</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="Tc_fe7JJkDgC0edR069D8-Jnw_5_6">3,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="Tc_BVjLNn0VaU-vj0tNHyV1ag_5_8">669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="Tc__7OH19kh2Umz7-UCS9lA2g_5_10">3,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="Tc_4k59ujFy7UG5G1OHW2Ar4A_5_12">674</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Termination benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="Tc_UQNQr6Yd5UCgrxa-6zRcPA_6_10">1,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="Tc_c58OF2ZO7E-cPN9a4fQ5fQ_7_2">12,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="Tc_w7bQH5HaE0mAXo0MnHHeBg_7_4">566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="Tc_9CyuiImoc0Gk_0WUdA-FrA_7_6">6,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="Tc_-1rtvMPqfU-bqyMJNsaX9g_7_8">478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="Tc_3R6tikYJvE2TbXBqDtWciw_7_10">4,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="Tc_Q-bfxwxDTkq_CxH_AyQuPg_7_12">652</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" id="Tc_XjzwaPWBhECBBpjfdRdplw_8_2">15,771</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" id="Tc_6TpFB3uAEkSWTI9MYftznA_8_4">1,212</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" id="Tc_xKmeCuozTkGHPeJOAer2JA_8_6">9,756</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" id="Tc_G895cncFfUOAMARpcDvFqQ_8_8">1,147</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" id="Tc_6er4xNP91U2cySh1Ioc48w_8_10">9,928</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" id="Tc_2EFtBplQ-USBSup9ngJrJw_8_12">1,326</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Out of the total remuneration, for Management Board EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AuditorsRemuneration" scale="3" id="Narr_niXGamqBm0-a9Vdbx2Vnng">1,551</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AuditorsRemuneration" scale="3" id="Narr_y3syXisTUEKnprp-mi5PFg">852</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AuditorsRemuneration" scale="3" id="Narr_AV7dqeQ8REKEIbpqHike4w">1,323</ix:nonFraction>k) and for the Supervisory Board EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AuditorsRemuneration" scale="3" id="Narr_7TJvrAG9xU6PZtoivNJiSA">158</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AuditorsRemuneration" scale="3" id="Narr_AwAHbmuhzk2WB3APtNbzYw">0</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AuditorsRemuneration" scale="3" id="Narr_0kw7PI2ErUKiWf043596JA">0</ix:nonFraction>k) are outstanding, as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In 2023, <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_vCYEDODVKUutm04bE5jrPw">105,260</ix:nonFraction> RSUs were granted to the Supervisory Board and <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_JpslkfIHHEOCHkx9kfTGsg">207,481</ix:nonFraction> RSUs and <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_IedADyrcS0Sk1puAhMSxsg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_xxPedGY5xEKwgStoqvIydA">144,379</ix:nonFraction> options were granted to the Executive Board. During the year, <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="Narr_VxpWvh8P3069gCX5dbuJrQ">21,413</ix:nonFraction> RSUs were transferred to the Supervisory Board and <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_QqhHzWTUTUWo9mtYyqyW5g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="Narr_uZE8ygBMqEiWZ5Jz-6mF2g">139,027</ix:nonFraction> RSUs were transferred to the Executive Board. No options were exercised from the Key Management Personnel. For more detailed information we refer to Note 10.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_RYpbc8X8-k6bGuF8wrTcQA" continuedAt="Tb_RYpbc8X8-k6bGuF8wrTcQA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">19. Related party disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parent and ultimate controlling party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As disclosed in Note 1, during fiscal 2023, dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, was the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between approximately 37-43 % during that period. dievini is thus the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer of shares from the former major shareholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 10, due to certain virtual share exercises under the Prior VSOP during the year 2023: <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_I1KYRHnhw0WZTuj1LeOczA">0</ix:nonFraction> (2022:<ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_w-w0xzFDaEur6OVFAS3oTA">777,260</ix:nonFraction>) common shares were transferred to the Company by the former major shareholders, with no consideration paid in exchange, and all of these shares were subsequently transferred to fulfill obligations from option exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the majority shareholder of the Group, granted <ix:nonFraction unitRef="Unit_Standard_loan_B2W9DgI1ukyKELWFZzXYow" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_tDcuRfOZHUis6pxE_-4Qjg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:RelatedPartyTransactionNumberOfLoansReceived" scale="0" id="Narr_8hO_LvvrW0WFtASBwzBKYA">two</ix:nonFraction> convertible loans to the Group which were terminated in July 2020 and fully repaid in August 2020. Additionally, in 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Groups largest shareholder, purchased EUR <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Xs37kP1MXEWQ-qdRg_8D7g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="3" id="Narr_1Y9jhRAQ6EKe7R4amvBWTg">100,000</ix:nonFraction>k of the Group&#8217;s common shares at the price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_IVeKC3yvOEugAiflyH3c3g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Narr_DYv6rOnDOEWsO0EVAgb--A">16</ix:nonFraction> per share. In 2023 a total of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember__huxDT93sUCUvh-o5CwH7Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReimbursementOfTravelCost" scale="3" id="Narr_fhvBkN_MoE6PaUaeLm2G5A">1</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_AeWpyZ9BY0qX-7I4dJeLCg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReimbursementOfTravelCost" scale="3" id="Narr_ySmgoNc5mUOModUxmppQRg">58</ix:nonFraction>k) was paid to dievini Hopp BioTech Holding GmbH &amp; Co. KG as a reimbursement of travel cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immatics Biotechnologies GmbH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, a purchase agreement between CureVac Manufacturing GmbH and Immatics Biotechnologies GmbH was entered into. CureVac purchased technical equipment of containers which CureVac will use as a facility in the future. dievini held <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_8_1_2023_To_8_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ImmaticsBiotechnologiesGmbhMember_8VKq2e-Yh0aBVCNKzz4EmA" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_HqCM5ywRz0m3n3X4oscagg">16.7</ix:nonFraction>% of the shares in Immatics N.V. (Immatics) as of December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup>, 2023 per the Form 20-F of Immatics filed in March 2024. CureVac paid EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_8_1_2023_To_8_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ImmaticsBiotechnologiesGmbhMember_8VKq2e-Yh0aBVCNKzz4EmA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="3" id="Narr_MOiPKfvHO06hmtDEHiifMw">178</ix:nonFraction>k under this agreement.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_RYpbc8X8-k6bGuF8wrTcQA_cont1" continuedAt="Tb_RYpbc8X8-k6bGuF8wrTcQA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key management personnel compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Referring to key management personnel compensation we refer to Note 18.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key management personnel transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Franz-Werner Haas</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was executed. In 2023 CureVac paid EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FranzWernerHaasMember_3KoWd6cW3kiWfRndyVReUQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedFromRelatedPartyTransaction" scale="3" id="Narr_-3fnveGJLkOzR23jJNKVDQ">65</ix:nonFraction>k under this agreement. The payment was partially compensated by Franz-Werner Haas taking over his former company car for EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FranzWernerHaasMember_3KoWd6cW3kiWfRndyVReUQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" scale="3" id="Narr_qyaw_PqfpE-V9CS_Pzc2rA">40</ix:nonFraction>k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alexander Zehnder</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_3_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_AlexanderZehnderMember_mQ65pe5XS02CILSpyMNi-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpensesToHandleFutureServiceAgreement" scale="3" id="Narr_du9paQ0b_0mmXyWQ72A5Xw">51</ix:nonFraction>k during the month of March.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_2ruopNpg1EOnMxTf_GiPBQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsContractualObligation" scale="3" id="Narr_yvJoA-2fCkuSFxP9bHDPcg">100</ix:nonFraction>k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac, Antony also took over the role as Management Director at CureVac Belgium SA. He executed this function by using Clarentis SRL. As it relates to these services in 2023, CureVac paid EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_RnuhJALUXEW6OjzFID5ePg" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_l5LUDwlm8kKxuOPW608qsA">85</ix:nonFraction>k in 2023 (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_QN5vMskJz0SjqLv-t82qVw" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_FwO46RM0R0OMK-sL6CUiTw">69</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_3YpDQRUP7U-XcUYi-sII5w" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_ZLIIalEtTkO3d2t1E0XDKg">0</ix:nonFraction>k). The amounts invoiced for this function/services are offset/deducted from his base compensation for his function on the Board of Management of CureVac. As Antony Blanc has left the company as of November 30, 2023, CureVac and Antony Blanc signed a settlement agreement as of September 26, 2023. Under this agreement CureVac incurred cost of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_1aQ3jbYg70uyuJDLyM2Akw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedFromRelatedPartyTransaction" scale="3" id="Narr_11MyD1_Gu0WEq7bkHfRplQ">107</ix:nonFraction>k for Clarentis SRL entity in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr. Ingmar H&#246;rr</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_Dr.IngmarHrrMember_wYrvLaDbgEqiqWSPHKS2gQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncomeTaxAndSocialSecurityLiabilityReceivable" scale="3" id="Narr_egSxEuuFY0-yHgenvJK5yA">573</ix:nonFraction>k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Florian von der M&#252;lbe</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FlorianVonDerMlbeMember_SIwLkqeJIE-s7t_ZN4MKdg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncomeTaxAndSocialSecurityLiabilityReceivable" scale="3" id="Narr_a-KZYOo5HEqojlp3znF-9A">559</ix:nonFraction>k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consulting agreements between CureVac Printer GmbH and Florian von der M&#252;lbe related to the years 2022 to 2024 have been executed. In 2023 CureVac paid EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CurevacPrinterGmbhMember_gCs4iaZl0UyakTfPuIOiJg" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_UZb0KeXSYk6o6mnGJ4oD6g">146</ix:nonFraction>k under such agreement related to 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mariola Fotin-Mleczek</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, a consulting agreement between CureVac and Mariola Fotin-Mleczek was made. In 2023 a total amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_qPHpyi8B6kOFRUh0cCyRZA" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_mtYXMgOr_kyLCqChPFvgWQ">2</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_adrBhWYBcUKP4xl56ZYvMQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_J0SmsFg6XUeabMdCAF3wOw">20</ix:nonFraction>k) was paid. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_TsjaEu7n40i6mOR_moJurg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncomeTaxAndSocialSecurityLiabilityReceivable" scale="3" id="Narr_nCO9sjlrq0a0zwN0Hzwy_g">131</ix:nonFraction>k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_RYpbc8X8-k6bGuF8wrTcQA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barker BioMedical GmbH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was executed. Barker BioMedical GmBH is a wholly owned consulting company of Debra Barker, Supervisory Board member of CureVac. In 2023 CureVac paid EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_03V4AWHHaUicJNVRIZQgJw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedFromRelatedPartyTransaction" scale="3" id="Narr_k347H2oRwkuKisaEis1FDQ">14</ix:nonFraction>k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Craig Tooman</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Craig Tooman was executed. In 2023, CureVac paid EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_FnDpFAjGGkeAyPEcOA6zCA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedFromRelatedPartyTransaction" scale="3" id="Narr_4iVY8UCZB0eg86yPQ5huVQ">5</ix:nonFraction>k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ralf Clemens</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q3 2023, a consulting agreement between CureVac and GRID EUROPE was executed. GRID EUROPE is a wholly owned consulting company of Ralf Clemens, who was a member of the supervisory board up to September 30, 2023. CureVac incurred EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_GridEuropeMember_6WJlWjlo_kuCilFMPK6nQQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedFromRelatedPartyTransaction" scale="3" id="Narr_i5Ibjpt7OEmsJyjsDS-brQ">23</ix:nonFraction>k under this agreement in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Indemnification Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s articles of association require it to indemnify its current and former managing directors and supervisory directors in relation to acts or omissions in the performance of their duties to the fullest extent permitted by law, subject to certain exceptions. We entered into indemnification agreements with all our managing directors and supervisory directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other related party transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Rittershaus Rechtsanwaelte</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since December 15, 2005, a consultant agreement is in place for an indefinite term with Rittershaus. The agreement can be terminated without notice by CureVac and with notice of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_f2yWNH0RhECkx-pihStCXQ" format="ixt-sec:durwordsen" name="cvac:RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" id="Narr_XMIbW1dn8k6ZXNxGBDrGng">three months</ix:nonNumeric> to the end of the quarter by Rittershaus. In fiscal 2023, consulting fees of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_t1fcjJzHB0K519JIqIdErA">212</ix:nonFraction>k (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_Rfz9PcKAJ0ubf4ddBIHdcQ">518</ix:nonFraction>k, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_xCV0b46ewUWBBkAiRGRUnA" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_Ib6KHvz3U0C4QUz6WRrpCQ">757</ix:nonFraction>k) were paid to the Rittershaus. Additionally, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_f2yWNH0RhECkx-pihStCXQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ServiceRenderedIssue" scale="3" id="Narr_YhdHwVMiX0WzCKDZ-9arlQ">16</ix:nonFraction>k were owed for services rendered in 2023 and paid in 2024. Prof. Dr. Christof Hettich is managing director of Rittershaus and was managing director at dievini until June 2022 as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2020, CureVac Manufacturing GmbH (formerly CureVac Real Estate GmbH) and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#8217;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Manufacturing GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Manufacturing GmbH terminated the commercial and supply agreement with BePharBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_a0Kr79sWk0Obs3Ohp5ui0Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" scale="3" id="Narr_QA0FMMAlrUuLE7f449L35Q">3,900</ix:nonFraction>k, which had been recognized in provisions, based on estimate, as of December 31, 2021. In total an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_wkd5UtMjWEm5jn5jyWXGGw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="Narr_xntuBxmgGUe3p6YqLiCeMQ">4,016</ix:nonFraction>k was paid. Baron Jean St&#233;phenne, our Supervisory Board member, holds directly and indirectly <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_KF0KEZ_P60OBG3llY8c9rg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_lusTJ-qd8UyPyTSS21HoOw">15.61</ix:nonFraction>% of BePharBel Manufacturing&#8217;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#233;phenne&#8217;s son, Vincent St&#233;phenne, holds <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_H9754yeGbUCITGZy_i1eNA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_Asr66n9NO0uSDDpOu93w7w">1.43</ix:nonFraction>% of BePharBel Manufacturing&#8217;s equity and is a managing director of BePharBel Manufacturing.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory" id="Tb_Eq0m47RIC0uxVd61vji5GQ" continuedAt="Tb_Eq0m47RIC0uxVd61vji5GQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">20. Business Combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination and Goodwill &#8211; Frame Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022 (&#8216;closing date&#8217;), CureVac acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#8216;Frame Pharmaceuticals&#8217; or &#8216;Frame&#8217;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling the identification of structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. In July 2022, Frame Pharmaceuticals was renamed CureVac Netherlands B.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the purchase price agreement (&#8216;SPA&#8217;) dated June 8, 2022, total consideration of up to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_UoCEidhqNkCfZfezQJra6Q" decimals="-5" format="ixt:numdotdecimal" name="cvac:FairValueOfTotalConsiderationTransferred" scale="6" id="Narr_LeiY5vaFi0e701OYEAxVJw">32.0</ix:nonFraction> million, subject to certain adjustments for vested and non-vested employee options of the acquiree plus an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_51kbfHiK10CFR5dmzP024Q" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesIncurred" scale="6" id="Narr_GGb9KepAXESDue24OJdb7g">1.56</ix:nonFraction> million for the assumption of an outstanding obligation resulting from advisory services, was agreed. The consideration consisted of the transfer of shares in CureVac (&#8216;CureVac Shares&#8217;) and minor cash payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total consideration is split into <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" scale="0" id="Narr_KoHRjwbtFEaJntckzVMOGA">three</ix:nonFraction> payments, <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt-sec:numwordsen" name="cvac:ContingentConsiderationNumberOfPaymentsConsidered" scale="0" id="Narr_1iRoVbDjdkCIFIL9EC7cow">two</ix:nonFraction> of which are contingent upon the achievement of defined milestones (contingent consideration). At the closing date, the consideration transferred was comprised of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" scale="0" id="Narr_i4ln780I5U-4gh7uupmnmQ">810,242</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" scale="3" id="Narr_EVWlMrQqWEG-cS5DMIEzbQ">11,040</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k) to former Frame shareholders. The respective share price of one CureVac Share was EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsBusinessAcquisitionSharePrice" scale="0" id="Narr_vg-R52tGukqmL-KuWMri5Q">13.63</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (&#8216;Closing Share Price&#8217;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" scale="0" id="Narr_36BnKWdw60e5OIUvgE090Q">48,254</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" scale="3" id="Narr_t8oTBwODcEGb5q4HomBFJg">658</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k, valued at the Closing Share Price) as consideration for discharging the contractual obligations for the outstanding advisory agreements of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesIncurred" scale="3" id="Narr_r-lDNK_Z7EKS69C8MfSRRA">1,560</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k before deducting strike prices. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashTransferred" scale="3" id="Narr_kOvhu3NQ4EC5hRxMNXojNA">585</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, consisting of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:CashTransferredForSettlementOfVestedEmployeeOptions" scale="3" id="Narr_0prpt2NFjEORdLWkPM2orA">335</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k being the consideration for the settlement of the vested employee options, and an additional EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionalCashTransferred" scale="3" id="Narr_eKkWz0lefE-OD2FK4bwccw">250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment of the remaining <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="2" format="ixt:numdotdecimal" name="cvac:ContingentConsiderationPercentageOfTotalConsideration" scale="-2" id="Narr_nSlDWdg540afEAaJ2f8ssA">50</ix:nonFraction>% of the total consideration is contingent upon the achievement of <ix:nonFraction unitRef="Unit_Standard_Milestone_ymq4eXsZYUanqqY0KpCtNg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt-sec:numwordsen" name="cvac:ContingentConsiderationNumberOfMilestones" scale="0" id="Narr_1-K2Jv-rgE20RIJwRGGLdA">two</ix:nonFraction> milestones. A further <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" scale="0" id="Narr_cAMt0_cBgEazjnK1xhLx_Q">194,644</ix:nonFraction> shares (representing <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" scale="-2" id="Narr_4Nd-9IIVwk-IJt_zBveaQg">10</ix:nonFraction>% of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-5" format="ixt:numdotdecimal" name="cvac:SigningSharePriceRepresenting10" scale="6" id="Narr_ChLSc1topkCOE5RpIu3VQw">32.0</ix:nonFraction> million divided by the Signing Share Price) are issuable upon the achievement of a successful investigational new drug application filing for a product candidate of the Group that consists of at least one antigen based on frameshift-mutation identified by Frame&#8217;s algorithms; (&#8220;Milestone 1&#8221;) and a further <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" scale="0" id="Narr_XDnYsWQ33U-Gko46DWZd6Q">778,575</ix:nonFraction> shares (representing <ix:nonFraction unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" scale="-2" id="Narr_D3YdVmoJakuWLYNbv1CK-g">40</ix:nonFraction>% of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-5" format="ixt:numdotdecimal" name="cvac:SigningSharePriceRepresenting40" scale="6" id="Narr_oZzj0kEPfkmEqkOKrPOZ_g">32.0</ix:nonFraction> million divided by the Signing Share Price) are issuable upon successful proof of mechanism in humans of that or another product candidate (&#8220;Milestone 2&#8221;). The fair value of these contingent payments was determined by considering the likelihood of the events occurring and totaled, based on the Closing Share Price, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" scale="3" id="Narr_yS9uf8lyiUCgIWwEnISIWA">7,198</ix:nonFraction>k (Milestone 1: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" scale="3" id="Narr_IXQquHZp_ECOHzj3BYOuug">1,831</ix:nonFraction>k and Milestone 2: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" scale="3" id="Narr_Icy752qzfEWNWxHLQAfRWA">5,367</ix:nonFraction>k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consequently, the total consideration transferred for the business combination was determined to be EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" scale="3" id="Narr_WOmRTa_dyUK5D_dyIOQ-UA">19,481</ix:nonFraction>k, consisting of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" scale="0" id="Narr_WgzxfFLPA0-IjyNOF344wQ">858,496</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityInterestsOfAcquirer" scale="3" id="Narr_acnFPAZU30yLk0IJDC8OCw">11,697</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashTransferred" scale="3" id="Narr_vg6issjmnkuj7EwferReXg">585</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contingent consideration, classified as equity, with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" scale="3" id="Narr_JIPcVTZIuk-WSz-V02-MpQ">7,198</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k. The contingent consideration will be settled by the issuance of a maximum of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="INF" format="ixt:numdotdecimal" name="cvac:ContingentConsiderationMaximumSharesIssuable" scale="0" id="Narr_13vjUuDPAki3VoTyz4l_dQ">973,236</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The contingent consideration of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" scale="3" id="Narr_tTX7QFa9xUm4GIc-w2KycA">7,198</ix:nonFraction>k was valued by applying an estimated probability of the milestone being achieved to the payments due upon achievement. These probabilities were derived from third-party clinical development success rate studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, <ix:nonFraction unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_MnOYZiqEr0KsvgTz-N9SVA">89,655</ix:nonFraction> restricted stock unit awards (RSUs) were issued to certain employees to replace existing share-based payment awards of Frame Pharmaceuticals. This element is accounted for as a separately from the business combination as an equity-settled share-based transaction according to IFRS 2 (see Note 10). The total fair value of the grant was determined to be EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" id="Narr_KgVEiehWnEWOZoyirZ1Ljg">1,218</ix:nonFraction>k and will be expensed in the functional cost category to which the award recipient&#8217;s costs are allocated (i.e., general and administrative expenses or research and development expenses) over the individual vesting periods for the <ix:nonFraction unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="Narr_5zzRLWvlGEiR-otWjys62A">3</ix:nonFraction> tranches, which run through June 30, 2023, June 30, 2024, and June 30, 2025.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_fZ3_LUN09k-IkRxZv9vMCw_1_0"></a><a id="Tc_jftVa9EsHUOQUgrKCaY8YQ_1_2"></a><a id="Tc_TyaTaB9aVUiGs9yXCwaxwQ_2_0"></a><a id="Tc_VUBP-MQ9R0Kp0JyNjyULiQ_3_0"></a><a id="Tc_z_LWszuU3kimrGH2Rfznrw_4_0"></a><a id="Tc_tllgNwtQdkyWLe6Tb2H7zQ_5_0"></a><a id="Tc_DRHqGmN9AE-rOMtXfHibYA_6_0"></a><a id="Tc_3Lg6R9I_VkuUvl7VcykVqw_7_0"></a><a id="Tc_0qfWM7_CRkip89r-Y7PMVQ_8_0"></a><a id="Tc_4y0bIGHi2kq58zx22eRrJg_9_0"></a><a id="Tc_MT_3PXvKSEi79yJM8bZz3Q_10_0"></a><a id="Tc_aJykzxZkKECCU2fIxXEigQ_11_0"></a><a id="Tc__MYmjjc2xEWmUFZFi1pLXQ_12_0"></a><a id="Tc_h8FbckkvYUmE81puDp2s0Q_13_0"></a><a id="Tc_JgEzA20QvEeX68CFx_i73A_14_0"></a><a id="Tc_ARltcAunIEe5f06PXTGDdw_15_0"></a><a id="Tc_0EIZQH2u1kG23nNxRU6_2w_16_0"></a><a id="Tc_MX1Tp7kiGkKqDOya788a3A_17_0"></a><a id="Tc_ipY1s8Sv30ithucKTbtXLg_18_0"></a><a id="Tc_aLkqde_weUePEJSroGltTQ_1_0"></a><a id="Tc_Ag7aZXAgFUikvvb0f2Zbxw_2_0"></a><a id="Tc_m1ZjXQqj0EiOq2fLlgtenw_3_0"></a><a id="Tc_2X8hSy2SME2iSFAa9BLn9Q_4_0"></a><ix:continuation id="Tb_Eq0m47RIC0uxVd61vji5GQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The final fair values in accordance with IFRS 3 of the identifiable net assets as of the date of acquisition were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" id="Tb_lUJnAt2aY0aamtuvJ_ZDTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EUR thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;recognized&#160;on&#160;acquisition</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_ZV8XFX30gE2zx-8KHvOqwQ_2_2">6,592</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" scale="3" id="Tc_FscUwDYRWUiapOTTr6jLQg_3_2">206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:RightOfUseAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_5ySFNnJMuUSlwGAwkHKL-g_4_2">170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset (Technology)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_ctLPmAPk9UC2Z_IMchS5hw_5_2">6,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_tyRSZr-FH0mUeHGGkavK3w_6_2">966</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FairValueOfAcquiredReceivables" scale="3" id="Tc_d8mKHYW_U0SUm6j4cI4WwA_7_2">658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_5ReQH2ch1EmZm1dyEpPFrQ_8_2">308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:TotalAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_dhbfXmt5MESJJZQzRLuMSA_9_2">7,558</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_pDOBroCb0EmGyMOHSkwOiQ_10_2">134</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_c9Qt3N_QQUKgLJOQnBoptQ_11_2">114</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities (net of deferred tax assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_clcjuMqwHE-YfIM8b7Ro_Q_12_2">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_5p0ta-cnWkOPqhs-FKF6Lg_13_2">406</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_JtZfU3GvrkKwAXDwr9UtAA_14_2">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts Payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_zvjmJ0Rmm0uNscUaFZ-aFw_15_2">346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_QJ2wUXdMv0ivVdHA9GJBlQ_16_2">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:LiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_Anh3NQPTBk2LQfCI314T-w_17_2">540</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="3" id="Tc_uEPYEXBd-E6fCYYN3YPOEw_18_2">7,018</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The technology intangible asset consists of a bioinformatical platform for cancer antigen discovery and validation for off-the-shelf and personalized cancer vaccines. The fair value of the technology of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProvisionalFairValue" scale="3" id="Narr_BRXyGN0sL0C6vD_O6NKf_Q">6,216</ix:nonFraction>k was determined by applying the replacement cost approach due to its early stage. The replacement cost was derived from historical costs incurred to create the technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Goodwill was recognized as a result of the acquisition as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" id="Tb_YcHTLay7Q0e9Nx5VuGYKkQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consideration transferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" scale="3" id="Tc_OHl-7PvemU6b3WgMDvrINA_2_2">19,481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="3" id="Tc_0jnWuxKx6EGJRjxeqkiRTw_3_2">7,018</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" sign="-" scale="3" id="Tc__E5QqePD6EyinQqB-hdTSw_4_2">12,463</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The goodwill is mainly attributable to the synergies and an assembled workforce as well as the strategic benefits to the Group. The goodwill is not deductible for tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions costs in relation to the business combination amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" scale="3" id="Narr_4iNtlskymUGO_wSfO9VN7A">500</ix:nonFraction>k were expensed and recognized within general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated statements of profit or loss include the results of Frame Pharmaceuticals (meanwhile: CureVac Netherlands B.V.) since the acquisition date. From the date of acquisition through December 31, 2022 Frame Pharmaceuticals did not have any significant impact on the operating income or revenues of the Group. The same applies if the transaction had occurred at the beginning of the reporting period.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_gnt0-eXtRk-DvEqev9br2Q" continuedAt="Tb_gnt0-eXtRk-DvEqev9br2Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">21. Subsequent events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, positive interim data from the ongoing Phase 2 clinical program assessing monovalent and bivalent modified vaccine candidates against COVID-19 in comparison with a licensed bivalent mRNA-based comparator vaccine were published. The tested vaccine candidates are being developed in collaboration with GSK. Results from the interim analysis showed that both vaccine candidates using CureVac&#8217;s proprietary second-generation mRNA backbone produced meaningful immune responses and favorable tolerability profiles across all tested doses, including the lowest tested dose. All three tested dose levels were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gnt0-eXtRk-DvEqev9br2Q_cont1" continuedAt="Tb_gnt0-eXtRk-DvEqev9br2Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2024, the beneficiaries of the Prior VSOP plan declared their intent to exercise their exercisable shares. The shares became exercisable on the third anniversary after IPO (August 14, 2023), because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels had been reached. <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions" scale="0" id="Narr_7BR5f491zkm7yjFb9roCow">786,746</ix:nonFraction> virtual shares were exercised by March 22, 2024 and CureVac received <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_8rzB9Zr0pEytPy0ZICOGBg">786,746</ix:nonFraction> shares from the Prior VSOP holders on that day. On March 26, 2024, CureVac transferred <ix:nonFraction unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA" contextRef="Duration_3_26_2024_To_3_26_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_rczlzRLESEmjal2oPh8nsg" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" scale="0" id="Narr_1jcJ-T8F_kCOd9AY9GHGYw">786,746</ix:nonFraction> shares to the exercising beneficiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2024, the Company started a voluntary leaver program intended to align the workforce to the Company&#8217;s business scope and priorities. The business goal is to reduce 150 positions by year-end, including natural attrition. Unnecessary residual pandemic infrastructure is being adapted to significantly increase efficiency and performance while maintaining a strong focus on innovation and R&amp;D activities. For this program we anticipate costs in a range between EUR <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_N9GQJX-VN0-QtPUbM25Rww" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DistributionCosts" scale="6" id="Narr_U95KUzJTZU-q4h_XWwwcqA">2</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg" contextRef="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_47DGLZoJlUGG58WY5poswg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DistributionCosts" scale="6" id="Narr_lfSyw8acX0eoliCOzU7ISw">3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, promising interim data from the ongoing Phase 2 part of the combined Phase 1/2 study of a seasonal influenza vaccine candidate were reported. The multivalent candidate was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains. Results from the planned interim analysis showed that the multivalent vaccine candidate boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose. The vaccine candidate was shown to have an acceptable safety and tolerability profile, with the majority of solicited adverse events reported as either grade 1 (mild) or grade 2 (moderate) within seven days of dosing. Among younger and older adults, geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across all tested dose levels. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across both age groups and tested dose levels. Targeted optimizations to further improve immune responses against influenza B strains will be assessed in an additional Phase 2 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, the Company entered into a co-development and licensing agreement with The University of Texas MD Anderson Cancer Center for the development of novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac&#8217;s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson&#8217;s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need. Both parties will contribute to the identification of differentiated cancer antigens based on whole genome sequencing, combined with long- and short-read RNA sequencing and cutting-edge bioinformatics followed by joint preclinical validation of the highest-quality cancer antigens and selection of the most promising clinical-lead candidates for conducting initial Phase 1/2 studies in appropriate clinical indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, Curevac and GSK entered into a Pandemic Preparedness Agreement with the Federal Republic of Germany. Timelines related to the Pandemic Preparedness Agreement were ambitious with the aim of providing acute pandemic preparedness in Germany in the context of emerging COVID-19 variants. In 2023, CureVac identified a risk that necessary regulatory approvals needed to meet these timelines may not be achieved within the contractually agreed timeframe. After consultation with ZEPAI, CureVac applied for a timeline extension as foreseen under the agreement to avoid procurement of further substantial amounts of raw material at risk. As of December 31, 2023, it was considered unlikely that the extension would be granted. Additionally, a rapidly changing epidemiological environment did no longer prompt an acute pandemic threat. Accordingly, inventories which had been stockpiled as required by the PPA, were written down to their net realizable value. Ultimately, the extension was not granted, whereupon CureVac and GSK jointly decided to terminate the agreement. Despite the termination, CureVac&#8217;s GMP IV manufacturing plant for the large-scale production of mRNA-based vaccines will be completed. Contingent upon regulatory approval, the facility is expected to be certified mid-2024.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gnt0-eXtRk-DvEqev9br2Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, the Company announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate developed in collaboration with GSK. The H5N1 avian influenza virus is considered a potential future pandemic threat, able to cross species from its original bird host to humans. The monovalent vaccine candidate is based on CureVac&#8217;s proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen. Avian influenza represents latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, the Company had the first ruling in one of its CMO arbitration. In August 2022, Rentschler Biopharma SE initiated arbitration proceedings according to the procedural rules of the German Arbitration Institute against the Company. Rentschler&#8217;s claims are based on the assumption that certain agreements between Rentschler and CureVac Manufacturing GmbH (then: CureVac Real Estate GmbH) have been terminated due to the withdrawal of the EMA dossier for CVnCoV or alternatively that CureVac would have been obliged to terminate these agreements. CureVac&#8217;s position always was that the agreements had ended upon expiration of their term. We did not believe that there was a legal basis for Rentschler&#8217;s claims and therefore defended ourselves against these claims in written submissions and the oral hearing in October 2023. In its final award rendered, the arbitration tribunal followed CureVac&#8217;s arguments and dismissed Rentschler&#8217;s claims in their entirety. The totality of Rentschler Biopharma SE related provision was reversed as of December 31, 2023.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.50
<SEQUENCE>2
<FILENAME>cvac-20231231xex4d50.htm
<DESCRIPTION>EX-4.50
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:34:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;4.50</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LONG-TERM INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CUREVAC N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Amended and Restated as of March 14, 2024)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTRODUCTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 1</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This document sets out the Company&#8217;s long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The main purposes of this Plan are:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">to attract, retain and motivate Participants with the qualities, skills and experience needed to support and promote the growth and sustainable success of the Company and its business;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">to incentivise Participants to perform at the highest level and to further the best interests of the Company, its business and its stakeholders; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">to align the compensation incentives of Participants with the interests and considerations of Company shareholders and other stakeholders.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Plan is effective as of the consummation of the IPO.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINITIONS AND INTERPRETATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 2</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In this Plan the following definitions shall apply:</p></td></tr></table><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Article</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">An article of this Plan.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A grant under this Plan in the form of one or more Options, SARs, Shares of Restricted Stock, RSUs, Other Awards, or a combination of the foregoing.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award Agreement</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A written agreement between the Company and a Participant, substantially in the form of Annex A to this Plan, evidencing the grant of an Award to such Participant and containing such terms as the Committee may determine, consistent with and subject to the terms of this Plan.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Bad Leaver</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A Participant who ceases to be an Eligible Participant for Cause, including a situation where the Participant resigns and the Committee determines that an event has occurred with respect to that Participant which constitutes Cause.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Cause</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">With respect to a Participant, &#8220;cause&#8221; as defined in such Participant&#8217;s employment, service or consulting agreement with the Company or a Subsidiary, or if not so defined (and unless determined otherwise in the applicable Award Agreement or by the Committee):</p><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">such Participant&#8217;s indictment for any crime which (i) constitutes a felony, (ii) has, or could reasonably be expected to have, an adverse impact on the performance of such Participant&#8217;s services to the Company and/or any Subsidiary or (iii) has, or could reasonably be expected to have, an adverse impact on the business and/or reputation of the Company and/or any Subsidiary;</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">such Participant having been the subject of any order, judicial or administrative, obtained or issued by any governmental or regulatory body for any securities laws violation involving fraud, market manipulation, insider trading and/or unlawful dissemination of non-public price- sensitive information;</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">such Participant&#8217;s wilful violation of the Company&#8217;s code of conduct, insider trading policy or other internal policies and regulations established by the Company and/or any Subsidiary, in each case to the extent applicable to the Participant concerned;</p></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">d.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">gross negligence or wilful misconduct in the performance of such Participant&#8217;s duties for the Company and/or any Subsidiary or wilful or repeated failure or refusal to perform such duties;</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">e.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">material breach by such Participant of any employment, service, consulting or other agreement entered into between such Participant on the one hand and the Company and/or any Subsidiary on the other;</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">f.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">conduct by such Participant which should be considered as an urgent cause within the meaning of Section 7:678 DCC, irrespective of whether that provision applies to such Participant&#8217;s relationship with the Company and/or any Subsidiary; and</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">g.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">such other acts or omissions to act by such Participant as reasonably determined by the Committee, provided that the occurrence of an event described in paragraphs c. through e. above shall only constitute Cause if and when such event has not been cured or remedied by the relevant Participant within thirty days after the Company has provided written notice to such Participant.</p></div></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Change of Control</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">The occurrence of any one or more of the following events:</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">the direct or indirect change in ownership or control of the Company effected through one transaction, or a series of related transactions within a twelve-month period, as a result of which any Person or group of Persons acting in concert, directly or indirectly acquires (i) beneficial ownership of</p></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">more than half of the Company&#8217;s issued share capital and/or (ii) the ability to cast more than half of the voting rights in the General Meeting;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">at any time during a period of twelve consecutive months, individuals who at the beginning of such period constituted the Management Board and/or the Supervisory Board cease to constitute a majority of members of the Management Board and/or the Supervisory Board, as applicable, provided that any new member of the Management Board or the Supervisory Board who was nominated for appointment by the Supervisory Board by a vote of at least a majority of the Supervisory Directors who either were Supervisory Directors at the beginning of such twelve-month period or whose nomination for appointment was so approved, shall be considered as though such individual were a member of the Management Board or the Supervisory Board, as applicable, at the beginning of such twelve-month period;</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">the consummation of a merger, demerger or business combination of the Company or any Subsidiary with another Person, unless such transaction results in the shares in the Company&#8217;s capital outstanding immediately prior to the consummation of such transaction continuing to represent (either by remaining outstanding or by being converted into, or exchanged for, voting securities of the surviving or acquiring Person or a parent thereof) at least half of the voting rights in the General Meeting or in the shareholders&#8217; meeting of such</p></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">surviving or acquiring Person or parent outstanding immediately after the consummation of such transaction;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">d.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">the consummation of any sale, lease, exchange or other transfer to any Person or group of Persons acting in concert, not being Subsidiaries, in one transaction or a series of related transactions within a twelve-month period, of all or substantially all of the business of the Company and its Subsidiaries; or</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">e.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">subject to Article 10, such other event which the Committee determines to constitute a change of control in respect of the Company.</p></div></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Committee</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">Any of the following bodies, as applicable:</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">the Management Board, to the extent the administration or operation of this Plan relates to the grant of Awards to Eligible Participants who are not Managing Directors or Supervisory Directors, as well as any other matter relating to such Awards;</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">the Supervisory Board, to the extent the administration or operation of this Plan relates to the grant of Awards to Eligible Participants who are Managing Directors or members of the compensation committee established by the Supervisory Board, as well as any other matter relating to such Awards; or</p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">the compensation committee established by the Supervisory Board for all other matters relating to the administration or operation of the Plan.</p></div></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Company</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">CureVac N.V.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consultant</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Any Person, other than a Managing Director, Supervisory Director, or Employee, who is an adviser or consultant engaged by the Company and/or a Subsidiary to render bona fide services to the Company and/or a Subsidiary.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">DCC</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Dutch Civil Code.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Eligible Participant</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Any Managing Director, Supervisory Director, Employee or Consultant.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Employee</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Any Person, other than a Managing Director or a Supervisory Director, who is an employee or officer of the Company and/or a Subsidiary.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercise Date</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The date on which an Award is duly exercised by or on behalf of the Participant concerned.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The exercise price applicable to an Award.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">FMV</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The closing price of a Share on the relevant date (or, if there is no reported sale of Shares on such date, on the last preceding date on which any such reported sale occurred) on the principal stock exchange where Shares have been admitted for trading, unless determined otherwise by the Committee.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">General Meeting</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s general meeting of shareholders.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Good Leaver</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A Participant who ceases to be an Eligible Participant and who is not a Bad Leaver.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The date on which the Committee decides to grant an Award, or such later effective date applicable to such Award as may be determined by the Committee.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">IPO</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s initial public offering of its Shares.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">IPO Replacement Options</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Options granted with effect from or after the Company&#8217;s conversion into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) in substitution and exchange for:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">a.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">any options for series A shares in CureVac AG under the CureVac AG legacy management stock option plan that was in place prior to the consummation of the IPO; and</p></div></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">b.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">any virtual shares (Beteiligungspunkte) under the modified CureVac AG virtual share plan (which, for the avoidance of doubt, shall not include the Prior VSOP Virtual Shares) that was in place prior to the consummation of the IPO.</p></div></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Management Board</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s management board.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Managing Director</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A member of the Management Board.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The right to subscribe for, or otherwise acquire, Plan Shares.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Award</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">An Award which does not take the form of an Option, SAR, Share of Restricted Stock or RSU, and which may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to Shares or factors which may influence the value of Shares, including cash-settled financial instruments and financial instruments which are convertible into or exchangeable for Plan Shares.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Participant</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The holder of an Award, including, as the context may require, the rightful heir(s) of a previous holder of such Award having acquired such Award as a result of the death of such previous holder.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Performance Criteria</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The performance criteria applicable to an Award.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Person</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A natural person, partnership, company, association, cooperative, mutual insurance society, foundation or any other entity or body which operates externally as an independent unit or organisation.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Plan</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">This long-term incentive plan (as amended and restated as of [&#8226;] 2024).</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Plan Share</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A Share underlying an Award.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Prior VSOP Virtual Shares</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The virtual shares (<i style="font-style:italic;">Beteiligungspunkte</i>) outstanding immediately prior to the consummation of the IPO under the CureVac AG virtual share plan that was in place prior to the consummation of the IPO.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Prior VSOP Virtual Shares (Adjusted)</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The number of Prior VSOP Virtual Shares multiplied by the ratio for exchanging series A shares in CureVac AG for Shares in connection with the corporate reorganization of the Company and CureVac AG that was implemented immediately prior the IPO.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Replacement Award</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Except for IPO Replacement Options, an Award granted in assumption of, or in substitution or exchange for, long-term incentive awards previously granted by a Person acquired (or whose business is acquired) by the Company or a Subsidiary or with which the Company or a Subsidiary merges or forms a business combination, as reasonably determined by the Committee.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Restricted Stock</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Plan Shares subject to such restrictions as the Committee may impose, including with respect to voting rights and the right to receive dividends or other distributions made by the Company.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Retirement</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Participant&#8217;s termination of employment with the Company with the intention of retiring upon reaching a statutory retirement age; <i style="font-style:italic;">provided </i>that, in connection with their intention to retire, the Participant must certify to the Company, in a manner that is satisfactory to the Company and, if applicable, sufficient to comply with local law, that the Participant is retiring.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RSU</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The right to receive, in cash, in assets, in the form of Plan Shares valued at FMV, or a combination thereof, the FMV of one Share on</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">the Exercise Date.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">SAR</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The right to receive, in cash, in assets, in the form of Plan Shares valued at FMV, or a combination thereof, the excess of the FMV of one Share on the applicable Exercise Date over the applicable Exercise Price.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Section 409A IRC</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Section 409A of the United States Internal Revenue Code of 1986, as amended, and the rules, regulations and guidance promulgated pursuant thereto; any reference to a provision in this Code shall include any successor provision thereto.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Section 457A IRC</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Section 457A of the United States Internal Revenue Code of 1986, as amended, and the rules, regulations and guidance promulgated pursuant thereto; any reference to a provision in this Code shall include any successor provision thereto.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">An ordinary share in the Company&#8217;s capital.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Subsidiary</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A subsidiary of the Company within the meaning of Section 2:24a DCC.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supervisory Board</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s supervisory board.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supervisory Director</b></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">A member of the Supervisory Board.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">References to statutory provisions are to those provisions as they are in force from time to time.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Terms that are defined in the singular have a corresponding meaning in the plural.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Words denoting a gender include each other gender.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as otherwise required by law, the terms &#8220;written&#8221; and &#8220;in writing&#8221; include the use of electronic means of communication.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADMINISTRATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 3</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Plan shall be administered by the Committee. The Committee&#8217;s powers and authorities under this Plan include the authority to perform the following matters, in each case consistent with and subject to the terms of this Plan:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 1.5pt 5.59pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">designating Persons to whom Awards are granted;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">deciding to grant Awards;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">determining the form(s) and type(s) of Awards being granted and setting the terms and conditions applicable to such Awards, including:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">i.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of Plan Shares underlying Awards;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">ii.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the time(s) when Awards may be exercised or settled in whole or in part;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">iii.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">whether, to which extent, and under which circumstances Awards may be exercised or settled in cash or assets (including other Awards), or a combination thereof, in lieu of Plan Shares and vice versa;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">iv.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">whether, to which extent and under which circumstances Awards may be cancelled or suspended;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">v.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">whether, to which extent and under which circumstances a Participant may designate another Person owned or controlled by him as recipient or beneficiary of his Awards;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">vi.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">whether and to which extent Awards are subject to Performance Criteria and/or restrictive covenants (including non-competition, non-solicitation, confidentiality and/or Share ownership requirements);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">vii.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the method(s) by which Awards may be exercised, settled or cancelled;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">viii.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">whether, to which extent and under which circumstances, the exercise, settlement or cancellation of Awards may be deferred or suspended;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">amending or waiving the terms applicable to outstanding Awards (including Performance Criteria), subject to the restrictions imposed by Article 9 and provided that no such amendment shall take effect without the consent of the affected Participant(s), if such amendment would materially and adversely affect the rights of the Participant(s) under such Awards, except to the extent that any such amendment is made to cause this Plan or the Awards concerned to comply with applicable law, stock exchange rules, accounting principles or tax rules and regulations;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">making any determination under, and interpreting the terms of, this Plan, any rules or regulations issued pursuant to this Plan and any Award Agreement;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">f.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">correcting any defect, supplying any omission or reconciling any inconsistency in the Plan or any Award Agreement;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">g.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">settling any dispute between the Company and any Participant (including any beneficiary of his Awards) regarding the administration and operation of this Plan, any rules or regulations issued pursuant to this Plan, and any Award Agreement entered into with such Participant; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">h.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">making any other determination or taking any other action which the Committee considers to be necessary, useful or desirable in connection with the administration or operation of this Plan.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Committee may issue further rules and regulations for the administration and operation of this Plan, consistent with and subject to the terms of this Plan.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All decisions of the Committee shall be final, conclusive and binding upon the Company and the Participants (including beneficiaries of Awards).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AWARDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 4</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Awards can only be granted to:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Eligible Participants; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">any other Person who has been extended an offer of employment or other service, as a result of which the Committee reasonably expects such Person to become an Eligible Participant within twelve months after the Grant Date, provided that Awards granted to any such Person shall be treated as Awards held by a Bad Leaver if and when he has not become an Eligible Participant within such twelve- month period.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">No Award is intended to confer any rights on the relevant Participant except as set forth in the applicable Award Agreement. In particular, no Award should be construed as giving any Participant the right to remain employed by or to continue to provide services for the Company or any Subsidiary.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Awards shall be granted for no consideration or for such minimal cash consideration as may be required by applicable law.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Awards may be granted alone or in addition or in tandem with any other Award and/or any award under any other plan of the Company or any Subsidiary. Awards granted in addition or in tandem with any other Award</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">and/or any award under any other plan of the Company or any Subsidiary may be granted simultaneously or at different times.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Each Award shall be evidenced by an Award Agreement entered into between the Company and the Participant concerned. Until an Award Agreement has been entered into between the Company and the relevant Participant, no rights can be derived from the Awards concerned by such Participant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Plan Shares, including Awards in the form of Shares of Restricted Stock, shall be delivered in such form(s) as may be determined by the Committee and shall be subject to such stop transfer orders and other restrictions as the Committee may deem required or advisable. Furthermore, the Committee may determine that certificates for such Shares shall bear an appropriate legend referring to the terms, conditions and restrictions applicable thereto.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The terms and conditions applicable to Awards, including the time(s) when Awards vest in whole or in part and any applicable Performance Criteria, shall be set by the Committee and may vary between Awards and between Participants, as the Committee deems appropriate. The Committee may also determine whether and under which circumstances Awards shall be settled automatically upon vesting, without being exercised by the Participant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The term of an Award shall be determined by the Committee, but shall not exceed ten years from the applicable Grant Date. Unless determined otherwise by the Committee, if the exercise of an Award is prohibited by applicable law or the Company&#8217;s insider trading policy on the last business day of the term of such Award, such term shall be extended for a period of one month following the end of such prohibition.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Unless determined otherwise by the Committee, Awards cannot be transferred, pledged or otherwise encumbered, except by testament or hereditary law as a result of death of the Participant concerned.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If, as a result of changes in applicable law, accounting principles or tax rules and regulations, or due to a variation of the composition of the Company&#8217;s issued share capital (including a share split, reverse share split, redenomination of the nominal value, or as a result of a dividend or other distribution, reorganization, acquisition, merger, demerger, business combination or other transaction involving the Company or a Subsidiary), an adjustment to this Plan, any Award Agreement and/or outstanding Awards is necessary to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under this Plan, the Committee may adjust equitably any or all of:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 5.25pt 5.59pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of Plan Shares available under this Plan;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of Plan Shares underlying outstanding Awards; and/or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the Exercise Price or other terms applicable to outstanding Awards.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.11</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Any rights, payments and benefits under any Award shall be subject to repayment and/or recoupment by the Company in accordance with applicable law, stock exchange rules and such policies and procedures as the Company may adopt from time to time.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.12</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company may withhold from any outstanding Award, any payment, issuance or transfer to be made under such Award, or any other compensation or amount owed by the Company to the Participant holding such Award, an amount (in cash, in assets, in the form of Shares or other Awards, or a combination thereof) equal to the withholding taxes and other costs due, or to be withheld, by the Company or any Subsidiary in respect of the grant, exercise or settlement of such Award.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TYPES OF AWARDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 5</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Committee may grant Awards in the form of Options, SARs, Shares of Restricted Stock, RSUs, Other Awards or a combination of the foregoing.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon the exercise or settlement of vested Options, the Company shall be obliged to deliver to the Participant concerned (or the beneficiary of such Options, as applicable), the Plan Shares underlying such Options (unless otherwise set forth in the Award Agreement).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon the exercise or settlement of vested SARs, the Company shall be obliged to pay to the Participant concerned (or the beneficiary of such SARs, as applicable) an amount equal to the number of Plan Shares underlying such SARs multiplied by the excess, if any, of the FMV of one Share on the applicable Exercise Date over the applicable Exercise Price. The Company may satisfy such payment obligation in cash, in assets, in the form of Shares valued at FMV, or a combination thereof, at the discretion of the Committee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The exercise by a Participant of his rights attached to Shares of Restricted Stock shall be subject to such restrictions as the Committee may impose, including with respect to voting rights and the right to receive dividends or other distributions made by the Company. Upon the vesting of Shares</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 5.59pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">of Restricted Stock, any such restrictions and conditions shall lapse with respect to those Shares. If an Award in the form of Shares of Restricted Stock is cancelled or otherwise terminated, the Participant shall be obliged to transfer all of his unvested Shares of Restricted Stock to the Company promptly and for no consideration.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon the exercise or settlement of vested RSUs, the Company shall be obliged to pay to the Participant concerned (or the beneficiary of such RSUs, as applicable) an amount equal to the number of Plan Shares underlying such RSUs multiplied by the FMV of one Share on the applicable Exercise Date. The Company may satisfy such payment obligation in cash, in assets, in the form of Shares valued at FMV, or a combination thereof, at the discretion of the Committee (unless otherwise set forth in the Award Agreement).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Committee may determine that a Participant holding one or more RSUs is entitled to receive dividends and other distributions made by the Company on the Shares, as if such Participant held the Plan Shares underlying such RSUs. The Committee may impose restrictions with respect to such entitlement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PERFORMANCE CRITERIA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 6</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Committee may condition the right of a Participant to exercise one or more of his Awards, and the timing thereof, upon the achievement or satisfaction of such Performance Criteria as may be determined by the Committee, within periods specified by the Committee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If an Award is subject to Performance Criteria which must be achieved or satisfied within a period specified by the Committee for that purpose, such Award can only be exercised or settled at or after the end of that period.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Performance Criteria may be measured on an absolute or relative basis and may be established on a Company-wide basis or with respect to one or more business units, divisions, Subsidiaries and/or business segments. Relative performance may be measured against a group of peer companies determined by the Committee, financial market indices and/or other objective and quantifiable indices. Performance Criteria may relate to performance by the Company and/or by the Participant concerned.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If the Committee determines that a change in the business, operations, group structure or capital structure of the Company, or other events or circumstances, render certain Performance Criteria applicable to</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 5.59pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">outstanding Awards unsuitable or inappropriate, the Committee may amend or waive such Performance Criteria, in whole or in part, as the Committee deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PLAN SHARES AVAILABLE FOR AWARDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 7</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Subject to Articles 4.10 and 7.2, the Plan Shares underlying Awards (including, for the avoidance of doubt, Plan Shares underlying IPO Replacement Awards) which are not Replacement Awards, irrespective of whether such Awards have been exercised or settled, together with any Prior VSOP Virtual Shares (Adjusted) which have not yet been exercised or settled, shall not represent more than 15% of the Company&#8217;s issued share capital from time to time.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Plan Shares underlying Awards, except for Replacement Awards, which expire, which are cancelled or otherwise terminated, or which are exercised or settled in cash or assets in lieu of Plan Shares, shall again be available under this Plan and shall not be counted towards the limit imposed by Article 7.1.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">VESTING, EXERCISE AND SETTLEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 8</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Each Award Agreement shall contain the vesting schedule and, where relevant, delivery schedule (which may include deferred delivery later than the vesting dates) for the relevant Awards.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Only vested Awards may be exercised or settled in accordance with their terms. An Award can only be exercised (to the extent it is not settled automatically) by or on behalf of the Participant holding such Award.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">An Award can only be exercised through the use of an electronic system or platform to be designated by the Committee (if and when such system or platform has been set up by the Company), or otherwise by delivering written notice to the Company in a form approved by the Committee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Subject to Article 9.1, the Committee shall determine the Exercise Price, provided that the Exercise Price for an Award which can be exercised or settled in the form of Plan Shares shall not be less than the aggregate nominal value of such Plan Shares.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon the exercise of an Award, the applicable Exercise Price must immediately be paid in cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 5.25pt 5.59pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Committee, subject to applicable law, may allow that such Exercise Price is satisfied on a cashless or net settlement basis, applying any of the following methods:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">by means of an immediate sale of Plan Shares underlying the Award concerned, with sale proceeds equal to the Exercise Price being paid to the Company on behalf of the relevant Participant and any remaining sale proceeds (less applicable costs and taxes, if any) being paid to such Participant;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">by means of the relevant Participant forfeiting his entitlement to receive part of the Plan Shares underlying the Award concerned at FMV on the Exercise Date and charging the aggregate nominal value of the remaining Plan Shares underlying such Award against the Company&#8217;s reserves;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">by means of the relevant Participant surrendering his entitlement to receive part of the Plan Shares underlying the Award concerned at FMV on the Exercise Date, against the Company becoming due an equivalent amount to such Participant and setting off that obligation against the Company&#8217;s receivable with respect to payment of the applicable Exercise Price; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">by means of the relevant Participant surrendering and transferring Shares to the Company (which may include Plan Shares underlying the Award concerned) at FMV on the Exercise Date.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company is authorized to withhold from any Award granted or any payment due or transfer made under any Award or under the Plan or from any compensation or other amount owing to a Participant the amount (in cash, Shares, other Awards, other property, net settlement or any combination thereof) of applicable withholding taxes due in respect of an Award, its exercise or settlement or any payment or transfer under such Award or under the Plan and to take such other action (including providing for elective payment of such amounts in cash or Shares by the Participant) as may be necessary in the option of the Company to satisfy all obligations for the payment of such taxes</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">When an Award is exercised or settled in the form of Plan Shares, the Company shall, at the discretion of the Committee, subject to applicable law and the Company&#8217;s insider trading policy:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">issue new Plan Shares to the relevant Participant; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">transfer existing Plan Shares held by the Company to the relevant Participant,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">provided, in each case, that Plan Shares may be delivered in the form of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">book-entry securities representing those Plan Shares (or beneficial ownership of those Plan Shares entitling the holder to exercise or direct the exercise of voting rights attached thereto) credited to the securities account designated by the relevant Participant. Furthermore, Plan Shares may be delivered as described in the previous sentence to a Person designated by the relevant Participant, with the prior approval of the Committee, as beneficiary of his Award.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If an Award is exercised or settled in the form of Plan Shares and such Award does not relate to a whole number of Plan Shares, the number of Plan Shares underlying such Award shall be rounded down to the nearest integer.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRICING RESTRICTIONS FOR OPTIONS AND SARS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 9</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except for Replacement Awards, the Exercise Price for an Option or SAR shall not be less than the higher of:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the FMV of a Plan Share on the applicable Grant Date and, in case of a SAR being granted in connection with an Option, on the Grant Date of such Option; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the nominal value of the Plan Share(s) underlying the Option.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as provided in Article 4.10, the Committee may not, without prior approval of the General Meeting, seek to effect any re-pricing of any outstanding &#8220;underwater&#8221; Option or SAR by:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">amending or modifying the terms of such Option or SAR to lower the Exercise Price;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">cancelling such Option or SAR and granting in exchange either (i) replacement Options or SARs having a lower Exercise Price, or (ii) Restricted Stock, RSUs or Other Awards; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">cancelling or repurchasing such Award for cash, assets or other securities.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Options and SARs will be considered to be &#8220;underwater&#8221; within the meaning of Article 9.2 at any time when the FMV of the Plan Shares underlying such Awards is less than the applicable Exercise Price.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. PARTICIPANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">With respect to any Award subject to Section 409A IRC and Section 457A IRC, this Plan and the applicable Award Agreement are intended to comply with the requirements of Section 409A IRC and Section 457A IRC, the provisions of this Plan and such Award Agreement shall be interpreted in a manner that satisfies the requirements of Section 409A IRC and Section 457A IRC, and this Plan shall be operated accordingly. If any provision of this Plan or any term or condition of any Award subject to Section 409A IRC and Section 457A IRC would otherwise frustrate or conflict with this intent, the provision, term or condition will be interpreted and deemed amended so as to avoid this conflict.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Notwithstanding any provision of this Plan to the contrary or any Award Agreement, a termination of employment shall not deemed to have occurred for purposes of any provision of an Award that is subject to Section 409A IRC providing for payment upon or following a termination of a Participant&#8217;s employment unless such termination is also a &#8220;separation from service&#8221; and, for purposes of any such provision of such Award, references to a &#8220;termination&#8221;, &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service&#8221;.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">No Awards will be eligible for the payment of dividends or dividend equivalents, to the extent such Option or SAR is subject to Section 409A IRC and Section 457A IRC.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If all or part of any payments made, or other benefits conferred, under any Award subject to Section 409A IRC constitutes deferred compensation for purposes of Section 409A IRC as a result of a &#8220;separation from service&#8221; of the relevant Participant (other than due to his death) within the meaning of Section 409A IRC while such Participant is a &#8220;specified employee&#8221; under Section 409A IRC, then such payment or benefit shall not be made or conferred until six months and one business day have elapsed after the date of such &#8220;separation from service&#8221;, except as permitted under Section 409A IRC.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If an Award subject to Section 409A IRC includes a &#8220;series of installment payments&#8221; within the meaning of Section 1.409A-2(b)(2)(iii) of the United States Treasury Regulations, the right of the relevant Participant to such series of installment payments shall be treated as a right to a series of separate payments and not as a right to a single payment, and if such an Award includes &#8220;dividend equivalents&#8221; within the meaning of Section 1.409A-3(e) of the United States Treasury Regulations, the right of the relevant Participant to such dividend equivalents shall be treated separately from the right to other amounts or other benefits under such Award.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For any Award subject to Section 409A IRC or Section 457A IRC that</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-indent:-35.45pt;margin:0pt 0pt 6pt 5.59pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">provides for accelerated distribution on a Change of Control of amounts that constitute &#8220;deferred compensation&#8221; as defined in Section 409A IRC and Section 457A IRC, if the event that constitutes such Change of Control does not also constitute a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets (in either case, as defined in Section 409A IRC), such amount shall not be distributed on such Change of Control but instead shall vest as of the date of such Change of Control and shall be paid on the scheduled payment date specified in the applicable Award Agreement, except to the extent that earlier distribution would not result in the relevant Participant incurring any additional tax, penalty, interest or other expense under Section 409A IRC and Section 457A IRC.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Notwithstanding the foregoing in this Article 10, the tax treatment of the benefits provided under this Plan or any Award Agreement is not warranted or guaranteed, and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by a U.S. Participant on account of non-compliance with Section 409A IRC and Section 457A IRC.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Notwithstanding any provision of this Plan to the contrary or any Award Agreement, in the event the Committee determines that any Award may be subject to Section 409A IRC or Section 457A IRC, the Committee may adopt such amendments to this Plan and the applicable Award Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determined are necessary or appropriate to:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">exempt the Award from Section 409A IRC or Section 457A IRC and/or preserve the intended tax treatment of the benefits provided with respect to the Award; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">comply with the requirements of Section 409A IRC or Section 457A IRC and thereby avoid the application of any adverse tax consequences under such Sections.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LEAVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 11</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">11.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If a Participant becomes a Good Leaver, unless otherwise determined by the Committee or set forth in an Award Agreement:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">all vested Awards that have not yet been exercised or settled must be exercised or settled in accordance with their terms within a period specified by the Committee and, if such Awards are not</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">exercised or (through no fault of the Participant concerned) not settled within such period, they shall be cancelled automatically without compensation for the loss of such Awards; and</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">all unvested Awards of such Participant shall be cancelled automatically without compensation for the loss of such Awards, unless the Committee decides otherwise.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">11.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If a Participant becomes a Bad Leaver, all vested Awards of such Participant which have not been exercised or settled, as well as all unvested Awards of such Participant, shall be cancelled automatically without compensation for the loss of such Awards.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">11.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If a Participant terminates employment with the Company due to their Retirement:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All unvested Awards of such Participant shall become vested pro rata based on the portion of the applicable vesting schedule completed through the date of the Participant&#8217;s Retirement (for example, if an Award&#8217;s 12 month vesting schedule completes as of December 31 and the date of the Participant&#8217;s Retirement is October 31, then 10/12 of the Award would vest). Upon the date of their Retirement, the Participant shall be entitled to exercise any vested Options and SARs, receive delivery of any Plan Shares underlying vested Awards, and enjoy all other rights and benefits associated with the vested Awards as specified in the Plan or in the applicable Award Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">At the sole discretion of the Committee, all unvested Awards of a Participant shall automatically accelerate and become fully vested (and, with respect to Options and SARs, the time when such Awards may be exercised) as of the date of the Participant&#8217;s Retirement. Upon the date of their Retirement, such Participant shall be entitled to exercise any Options and SARs, receive delivery of any Plan Shares underlying vested Awards, and enjoy all other rights and benefits associated with the vested Awards as specified in the Plan or in the applicable Award Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon the date of the Participant&#8217;s Retirement, the Company will assess (i) the Participant&#8217;s Insider status and (ii) whether the Participant is aware of material non-public information (in each case, pursuant to the Company&#8217;s Insider Trading Policy) and, if applicable under the Company&#8217;s Insider Trading Policy, a waiting cooling period for 90 days may apply.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.5pt;text-indent:-35.5pt;margin:0pt 0pt 0pt 41.05pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CHANGE OF CONTROL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 12</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If long-term incentive awards are granted in assumption of, or in substitution or exchange for, outstanding Awards in connection with a Change of Control and the Committee has determined that such awards are sufficiently equivalent to the outstanding Awards concerned, then such outstanding Awards shall be cancelled and terminated upon the replacement awards being granted to the Participants concerned.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If, in connection with a Change of Control, outstanding Awards are not replaced by long-term incentive awards as described in Article 12.1, or are replaced by long-term incentive awards which the Committee does not consider to be sufficiently equivalent to such outstanding Awards, then such Awards shall immediately vest and, where relevant, settle in full, unless the Committee decides otherwise.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For purposes of this Article 12, awards shall not be considered to be &#8220;sufficiently equivalent&#8221; to outstanding Awards, if the underlying securities are not widely held and publicly traded on a regulated national stock exchange.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LOCK-UP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 13</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">13.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In connection with any registration of the Company&#8217;s securities, to the extent requested by the Company or the underwriters managing any public offering of the Company&#8217;s securities, and except (a) as otherwise approved by the Committee, or (b) pursuant to any exceptions approved by the underwriters, Shares acquired by a Participant pursuant to the issuance, vesting, exercise, or settlement of any Award granted under the Plan may not be sold, transferred, or otherwise disposed of prior to such period following the effective date of such registration as designated by the underwriters, not to exceed 180 days following such registration.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">13.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company may impose stop-transfer instructions with respect to the Shares subject to the restriction stipulated by Article 13.1 until the end of the lock-up period referred to in that provision.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DATA PROTECTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 14</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company may process personal data relating to the Participants in connection with the administration and operation of this Plan. &#160;The</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 1.5pt 5.59pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">personal data of the Participants which may be processed in this respect may include a copy of an identification document, contact details and bank and securities account numbers. Each Participant&#8217;s personal data shall be stored by the Company for such time period as is necessary to administer such Participant&#8217;s participation in the Plan or as otherwise permitted under applicable law.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Each Participant&#8217;s personal data shall be handled by the Company in a proper and careful manner in accordance with applicable law, including the General Data Protection Regulation (GDPR) and the rules and regulations promulgated pursuant thereto. Participants have the right to lodge complaints with an applicable supervisory authority regarding the Company&#8217;s processing of personal data pursuant to this Plan.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company shall implement technical and organisational measures designed to protect personal data processed pursuant to Article 14.1. Personnel or third parties that have access to such personal data shall be bound by confidentiality obligations.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company shall abide by any statutory rights the Participants may have regarding their respective personal data processed pursuant to Article 14.1, which includes the right to access, rectification, erasure, restriction of processing, objection to processing and portability of such personal data.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In connection with the administration and operation of this Plan, the Company may transfer personal data processed pursuant to Article 14.1 to one or more third parties, provided that there is a legitimate interest in doing so. Where such third parties are located outside the European Economic Area in countries that are not considered to provide for an adequate level of data protection, the Company shall ensure that sufficient data protection safeguards are put in place, failing which explicit consent for such transfer shall be obtained from the Participant(s) concerned.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The contact details of the Company&#8217;s data protection officer can be found on the Company&#8217;s intranet or otherwise can be obtained from the Company&#8217;s General Counsel.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company may establish one or more privacy policies providing further information on data protection and applying to the processing of personal data of the Participants by the Company in connection with the administration and operation of this Plan.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 15</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">15.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except to the extent prohibited by applicable law and unless otherwise expressly provided in an Award Agreement or in this Plan, pursuant to a resolution to that effect, the Supervisory Board may amend, alter, suspend, supplement or terminate this Plan or any portion thereof, provided that no such amendment, alteration, suspension, supplementation or termination shall take effect without:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">approval of the General Meeting, if such approval is required by applicable law or stock exchange rules; and/or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the consent of the affected Participant(s), if such action would materially and adversely affect the rights of such Participant(s) under any outstanding Award, except to the extent that any such amendment, supplement or termination is made to cause this Plan to comply with applicable law, stock exchange rules, accounting principles or tax rules and regulations.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">15.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Notwithstanding anything to the contrary in the Plan, the Committee may amend the Plan or any Award Agreement in such manner as may be necessary or desirable to enable the Plan or such Award Agreement to achieve its stated purposes in any jurisdiction in a tax-efficient manner and in compliance with local laws, rules and regulations to recognize differences in local law, tax policy or custom. The Committee also may impose conditions on the exercise or vesting of Awards in order to minimize the Company&#8217;s obligation with respect to tax equalization for Participants on assignments outside their home country.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GOVERNING LAW AND JURISDICTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Article 16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Plan shall be governed by and shall be construed in accordance with the laws of the Netherlands. Subject to Article 3.1 paragraph g., any dispute arising in connection with these rules shall be submitted to the exclusive jurisdiction of the competent court in Amsterdam, the Netherlands.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.51
<SEQUENCE>3
<FILENAME>cvac-20231231xex4d51.htm
<DESCRIPTION>EX-4.51
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:34:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.51</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REDACTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">ST</sup><b style="font-weight:bold;"> AMENDMENT OF THE RESEARCH AND OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This 1<sup style="font-size:7.5pt;vertical-align:top;">st</sup> Amendment (&#8220;<b style="font-weight:bold;">Amendment</b>&#8221;) to the Research and Option Agreement (&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is made and entered into effective as of 12 January 2023 (the &#8220;<b style="font-weight:bold;">Effective Amendment Date</b>&#8221;) by and between CureVac SE, Friedrich-Miescher-Str. 15, 72076 T&#252;bingen, Germany, and myNEO NV, Ottergemsesteenweg Zuid 808 box 511, 9000 Ghent, Belgium.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Parties have entered into a joint research and option agreement in May 2022 under which myNEO identifies new antigen targets that can be used by CureVac to develop and commercialize new medicinal products for the treatment of non-small cell lung cancer, melanoma and potentially other indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the First Research Milestone has been reached and the Parties now intend to amend the requirements of the Second Research Milestone as well as the order of work packages to be provided by myNeo to CureVac.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, the Parties agree to amend the Agreement as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise specifically provided herein, the definitions as set out in the Agreement shall apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 2.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of the Effective Amendment Date, the Parties agree to amend the Agreement as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The definition of [*****] in column one (1) of row two (2) of the table provided in Sec. 8.4.1 shall read as follows</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[*****]</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Exhibit 1.71: R&amp;D Plan of the Agreement is replaced by Exhibit 1.71: Amended R&amp;D Plan (December 2022) provided as an attachment to this Amendment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 3.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REMAINING PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other than as expressly specified above, all provisions of the Agreement shall remain unchanged and fully applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">This Amendment is executed by the authorized representatives of the Parties as of the Effective Amendment Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><b style="font-weight:bold;">CUREVAC SE</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><b style="font-weight:bold;">myNEO NV</b></p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">By:</p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">[*****]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">By:</p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Name:</p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Dr. Franz-Werner Haas</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Name:</p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Cedric Bogaert</p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Title:</p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">CEO</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Title:</p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">CEO</p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">By:</p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">[*****]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">By:</p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Name:</p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Antony Blanc, Ph.D.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Name:</p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Jan Van den Berghe</p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Title:</p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">CBO &amp; CCO </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Title:</p></td><td style="vertical-align:top;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.64pt 0pt;">Director </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit 1.71</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amended R&amp;D Plan (December 2022)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 0.64pt 0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 0.64pt 0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[******]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[******]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[******]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[******]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.52
<SEQUENCE>4
<FILENAME>cvac-20231231xex4d52.htm
<DESCRIPTION>EX-4.52
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:34:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.52</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REDACTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2nd Amendment to the</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEVELOPMENT AND LICENSE AGREEMENT (&#8220;Agreement&#8221;),</b><b style="font-weight:bold;text-decoration-line:none;"><br></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">effective as of November 9, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CureVac SE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Friedrich-Miescher-Stra&#223;e 15, 72076 T&#252;bingen, Germany<br>(hereinafter called &#8220;CureVac&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CRISPR Therapeutics AG</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Baarerstrasse 14, 6300 Zug, Switzerland<br>(hereinafter called &#8220;CRISPR&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">WHEREAS, CRISPR and CUREVAC entered into the Agreement, as first amended June 22, 2020 (&#8220;Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">WHEREAS, CRISPR has decided to stop work under Program 1 and the [*****] Program, and suspended them under the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">WHEREAS, The Parties wish to amend the Agreement, as amended, by adding the [*****] Program, Program 3 and Program 4 (each defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">THEREFORE, the Parties agreed that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of the effective date of signature of this 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment, all licenses granted by CureVac to CRISPR for Program 1 and the [*****] Program - which CRISPR suspended under the Agreement - shall terminate, and the Licensed Intellectual Property relating to Program 1 and the [*****] Program shall automatically revert back to CureVac.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 1 of 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Parties consent and mutually agree to further amend the Agreement as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Definition of FTE in Section 1.38 shall be amended to read:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">&#8220;<b style="font-weight:bold;">FTE</b>&#8221; means one employee working full-time for one year, or more than one person working the equivalent of a full-time person, working directly on performing activities under the Development Program, as applicable, where &#8220;full-time&#8221; is considered [*****] hours for one Calendar Year. No additional payment will be made with respect to any individual who works more than [*****] hours per Calendar Year and any individual who devotes less than [*****] hours per Calendar Year will be treated as an FTE on a pro rata basis based upon the actual number of hours worked divided by [*****].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Definition of FTE Rate in Section 1.40 shall be amended to read:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">&#8220;<b style="font-weight:bold;">FTE Rate</b>&#8221; means [*****]. CureVac may increase the FTE Rate for inflation on an annual basis based upon the percentage increase in the Consumer Price Index for Germany.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Definition of Program in Section 1.68 shall be amended to read (and account for the suspension of Program 1 and the [*****] Program by CRISPR, which for clarity shall have the effect stipulated in the Agreement):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">&#8220;<b style="font-weight:bold;">Program</b>&#8221; means applying the CRISPR System and using a Cas9 mRNA Construct for the following programs: (i) [*****] in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3</u> (&#8220;<b style="font-weight:bold;">[*****] Program</b>&#8221;), or (ii) [*****] (&#8220;[*****]<b style="font-weight:bold;"> Program</b>&#8221;), or (iii) Program 3, or (iv) Program 4.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Into Section 4, a new subsection 4.5 shall be added:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Program Selection. CRISPR shall have [*****] from the signing of this 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment for Program 3, and [*****] from the signing of this 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment for Program 4 by both Parties to indicate the target gene for Program 3 and Program 4, respectively.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 2 of 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Program Naming Process. CRISPR shall provide CureVac written notice of the target gene for each of Program 3 and Program 4 using the procedures set forth in Section 4.6(c).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Into Section 4, a new subsection 4.6 shall be added:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Program Substitution: During the first [*****] following the signing of this 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment by both Parties, CRISPR shall be permitted to substitute an alternative program for the [*****] Program, Program 3 or Program 4, using the procedures set forth in Section 4.6(b) and 4.6(c). The substitution is subject to the substitution fee set forth in Section 4.6(d), and the milestones set forth in Section 5.4(c) of this 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment shall not be adjusted for any Program Substitution. For clarity, even if the Program(s) had already achieved milestones, the substitution program would have to pay those milestones again.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Program Substitution Process. CRISPR shall provide CureVac written notice of its request to substitute a target for the [*****] Program, Program 3 or Program 4 using the procedure set forth in Section 4.6(c). Each Program is eligible for up to [*****] substitutions prior to IND submission.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Target Selection Process for Program Selection or Program Substitution. CRISPR shall provide CureVac written notice of its request to (1) indicate a target gene for Program 3 or Program 4; or (2) substitute a target for the [*****] Program, Program 3 or Program 4. If CureVac provides CRISPR notice that a proposed target is a Reserved Program, CureVac shall notify CRISPR within [*****] after the date on which CureVac receives notice of the proposed target if such proposed target is a Reserved Program. CureVac shall, if requested by CRISPR in writing, provide CRISPR with such evidence to support that such proposed target is a Reserved Program. If after providing such evidence, CRISPR concludes that such a target is not a Reserved Program, CRISPR will so notify CureVac, CureVac will provide such evidence as CureVac believes is reasonably required to establish that such target is a Reserved Program to an independent attorney or other expert with experience that is relevant to the dispute and reasonably acceptable to both Parties. Such independent expert will review and make a determination in accordance with this Agreement regarding whether such proposed target is a Reserved Program. The independent expert shall promptly notify the Parties of its determination as to whether a proposed target is a Reserved Program, but shall not disclose to CRISPR information provided by</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 3 of 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">CureVac in connection with such determination. The independent expert&#8217;s determination shall be binding on the Parties, absent a manifest error of such expert&#39;s determination. If the independent expert determines such proposed target is a Reserved Program, CRISPR shall be permitted to select another target; if the independent expert determines such proposed target is not a Reserved Program, such proposed target shall become the target for the [*****] Program, Program 3 or Program 4.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Substitution Fee. In the event CRISPR chooses to substitute the [*****] Program, Program 3 or Program 4, a Substitution Fee of [*****] is due within [*****] of confirmation of the new target by CureVac, or once the target is confirmed not to be a Reserved Program. For clarity, each substitution event is subject to the Substitution Fee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Into Section 4, a new subsection 4.7 shall be added:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Program Addition Fee. The addition of [*****] Program, Program 3 and Program 4 triggers &#160;an addition fee of [*****] per added Program and shall be due and payable within [*****] of signing of this 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment by both Parties. For clarity, both Parties agreed on the addition of [*****] Program, Program 3, and Program 4 (resulting in [*****] in Program Addition Fee).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Section 5.4 (c) shall be amended to read as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The first achievement of any of the following milestones by a Licensed Product Developed by or on behalf of CRISPR, any of its Affiliates or any Sublicensee in connection with the [*****] Program, or the [*****] Program, or Program 3, or Program&#160;4, or any Program resulting from a Program Substitution:</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Milestone</b></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Payment</b></p></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 4 of 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[*****]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In Article 6 &#8220;Confidentiality&#8221;, the following shall be deleted at the end of Section 6.1 of the 1<sup style="font-size:7.5pt;vertical-align:top;">st</sup> Amendment to the Development and License Agreement effective as of June 22, 2020:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">For the purposes of this Article 6 and its Sections 6.1-6.5 and 6.7, Casebia may be a Receiving Party or a Disclosing Party, as the case may be, to allow exchange of Confidential Information amongst CureVac, CRISPR and Casebia.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In Article 15.2 &#8220;Notices&#8221; CureVac&#180;s address shall be changed at the end of Section 15.2 of the 1st Amendment to the Development and License Agreement effective as of June 22, 2020 to:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">CureVac SE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Friedrich-Miescher-Str. 15</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">72076 T&#252;bingen</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Germany</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Attention: CEO and General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 5 of 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment shall enter into force upon signature by both Parties. The remaining terms and conditions of the Agreement shall apply and remain in full force and effect. Capitalized terms used in this 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> Amendment shall have the same meaning as defined in the Agreement.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">a</p></div></div></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CUREVAC SE</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRISPR Therapeutics AG</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:6.5pt;"><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:43.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Accounting Manager</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">27-Oct-2023</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:6.5pt;"><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[******]</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:43.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[******]</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[******]</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26-Oct-2003</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 6 of 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.53
<SEQUENCE>5
<FILENAME>cvac-20231231xex4d53.htm
<DESCRIPTION>EX-4.53
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:34:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.53</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">REDACTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amendment Four to Development and Option Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;">This Amendment Four to the Development and Option Agreement (this &quot;Amendment&quot;), dated as of February 13, 2024 (the &quot;Amendment Four Effective Date&quot;), is made by and between CureVac SE, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 T&#252;bingen, Germany (&quot;CureVac&quot;), and Acuitas Therapeutics Inc., a British Columbia corporation with offices at 6190 Agronomy Road, Suite 405, Vancouver, British Columbia, V6T 1Z3, Canada (&quot;Acuitas&quot;) and amends the Development and Option Agreement dated April 29, 2016, as amended by Side Agreement and Amendment Number One dated December 1, 2016, Amendment Two to the Development and Option Agreement dated July 10, 2020, and Amendment Three dated December 24, 2020 by and between CureVac and Acuitas (collectively as amended, the &#8220;D&amp;O Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;">Each of CureVac and Acuitas may be referred to herein as a &quot;Party&quot; or together as the &quot;Parties.&quot;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Acuitas and CureVac entered into the D&amp;O Agreement to provide for CureVac&#8217;s evaluation of, and option to license, Acuitas LNP Technology for the research, development, manufacture and/or commercialization of products incorporating Acuitas LNP Technology and CureVac Technology;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Acuitas and CureVac desire to amend the D&amp;O Agreement to provide for CureVac&#8217;s evaluation of, and option to license, Acuitas LNP Technology for Personalized Cancer Vaccine (PCV) Products (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the mutual covenants and representations contained herein, and for other good and valuable consideration, the amount and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Defined Terms</b>. &#160;Capitalized terms not otherwise defined herein will have the definitions set forth in the D&amp;O Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">New Defined Terms.</b> &#160;The following defined terms will be added to the D&amp;O Agreement and Exhibit 1.54 (Form of Non-Exclusive License) of the D&amp;O Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Licensed Service&#8221;</b> means a service, pursuant to which a Personalized Cancer Vaccine (PCV) Product is prepared for a specific Third Party to whom CureVac, its Affiliates and its Sublicensees sells such Personalized Cancer Vaccine (PCV) Product for such Third Party&#8217;s use in the Field of Use.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;</b><b style="font-weight:bold;">Personalized Cancer Vaccine (PCV) Product&#8221;</b> means any product manufactured on a patient-by-patient basis comprising Lipid Nanoparticles (LNP(s)) containing [*****] mRNA Constructs encoding at least [*****] PTA, where such a product utilizes or incorporates any Acuitas LNP Technology. For clarity, (i) any additional strengths, pharmaceutical forms, administration routes, presentations, indications or variations/extensions for or to a Personalized Cancer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccine (PCV) Product under clinical development or subject to a regulatory approval shall be considered as being the same Personalized Cancer Vaccine (PCV) Product; and (ii) different products manufactured on a patient-by-patient basis encoding different PTAs according to the same process and directly resulting from a Personalized Cancer Vaccine (PCV) Product, which are under the same regulatory approval in the relevant jurisdiction, shall be considered the same Personalized Cancer Vaccine (PCV) Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Personalized Tumor Antigen (PTA)&#8221;</b> means any polypeptide(s) that are expressed in a tumor cell in an individual patient.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Amendment of D&amp;O Agreement</b>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The definition of Licensed Product in the D&amp;O Agreement is hereby removed and replaced with this text:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 71.25pt;"><b style="font-weight:bold;">&#8220;Licensed Product&#8221;</b> means (i) [*****] product comprised of Lipid Nanoparticles (LNP) containing [*****] mRNA Constructs intended [*****] Target where the Target is selected from the Targets available to CureVac on the Reserved Target List and where such product is derived from, is based on, or utilizes any Acuitas LNP Technology; (ii) [*****] Licensed Vaccine Product; and/or (iii) [*****] Personalized Cancer Vaccine (PCV) Product. &#160;If a given protein, e.g. an antibody comprises separate amino acid chains, or a given Vaccine comprises multiple antigens or antibodies, which may be delivered as separate mRNA Constructs (combined in one LNP or delivered in separate LNPs), such product would be considered as one Licensed Product. &#160;For the avoidance of doubt, the term Licensed Product in respect of a given Target encompasses all variants of such Target, including wild types, naturally occurring &#160;variants, engineered variants wherein modifications to the native amino acid sequence have been made (for example, mutated versions, derivatives or fragments) and species homologs or orthologs thereof, provided, however, that any such naturally occurring variant, engineered variant or species homolog or ortholog possesses [*****] to such Target(s) (for example [*****]).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The definition of Licensed Product in Exhibit 1.54 (Form of Non-Exclusive License) of the D&amp;O Agreement is hereby removed and replaced with this text:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 71.25pt;">&quot;<b style="font-weight:bold;">Licensed Product</b>&quot; means: (i) [*****] product comprised of Lipid Nanoparticles (LNP) containing [*****] mRNA Constructs intended to express the Target and where such product is derived from, is based on, or utilizes any Acuitas LNP Technology; (ii) [*****] Licensed Vaccine Product; and/or (iii) [*****] Personalized Cancer Vaccine (PCV) Product. If a given protein, e.g., an antibody comprises separated amino acid-chains, or a given Vaccine comprises multiple antigens or antibodies, which might be delivered as separated mRNA Constructs (combined in one LNP or delivered in separated LNPs), such product would be considered as one Licensed Product For the avoidance of doubt, the term &#8220;Licensed Product&#8221; in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 71.25pt;">respect of the Target encompasses all variants of such Target, including the wild types, naturally occurring variants, engineered variants wherein modifications to the native amino acid sequence have been made (for example, mutated versions, derivatives or fragments) and species homologs and orthologs thereof, provided however that any such naturally occurring variant, engineered variant or species homolog or ortholog possesses [*****] to such Target(s) (for example [*****]), in all cases in accordance with the definition of Target.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Section 4.1 of the D&amp;O Agreement is hereby removed and replaced in its entirety with the following amended Section 4.1:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><b style="font-weight:bold;">4.1</b> &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</b><b style="font-weight:bold;">.</b> &#160;CureVac will select the Targets that will be the subject of the work performed as part of the Program from the Reserved Target List. CureVac shall have the right, but not the obligation, to reserve Targets (or replace a Reserved Target with a new Target) in accordance with this Article 4. In the case of Targets for Personalized Cancer Vaccine (PCV) Products, other than Section 4.2(d)(iv), none of the Target Reservation and Target pre-clearance mechanisms according to Sections 4.2 and 4.3 will be applicable.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Section 4.2 (d) of the D&amp;O Agreement is hereby amended to add the following text:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">&#8220;(iv) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personalized Cancer Vaccine (PCV) Products</u>. &#160;In the case of Targets for Personalized Cancer Vaccine (PCV) Products, all Targets of all such Personalized Cancer Vaccine (PCV) Products will count as [*****] Reserved Target on the Reserved Target List and will be treated as [*****] Reserved Target for the purposes of Sections 5.1 and 5.2.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">e.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Section 4.4 of the D&amp;O Agreement is hereby amended to add the following text:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">&#8220;(d) <font style="font-style:italic;font-weight:bold;">Personalized Cancer Vaccine (PCV) Products</font>. &#160;In the case of Targets for Personalized Cancer Vaccine (PCV) Products, no Target Reservation or Target Reservation Maintenance Fees will be payable by CureVac to Acuitas.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Amended Form of Non-Exclusive License Defined Term</b>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The first sentence of the definition of &#8220;Net Sales&#8221; set forth on Exhibit 1.54 (Form of Non-Exclusive License) of the D&amp;O Agreement is hereby amended to read as set forth below:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 71.25pt;">&quot;<b style="font-weight:bold;">Net Sales</b>&quot; means, with respect to any Licensed Product or Licensed Service, the amount received by CureVac and its Affiliates and Sublicensees for <i style="font-style:italic;">bona fide</i> sales of such Licensed Product or provision of such Licensed Service to a Third Party (other than Affiliates and Sublicensees, but including distributors for resale) less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The bullet points (b)-(d) of the definition of &#8220;Net Sales&#8221; set forth on Exhibit 1.54 (Form of Non-Exclusive License) of the D&amp;O Agreement are hereby amended to read as set forth below:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">credits or allowances actually granted upon claims, damaged goods, rejections or returns of, and for uncollectable amounts on, such Licensed Product or Licensed Service, including such Licensed Product or Licensed Service returned in connection with recalls or withdrawals;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">freight out, postage, shipping and insurance charges for delivery of such</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 71.25pt;">Licensed Product or Licensed Service;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">taxes or duties levied on, absorbed or otherwise imposed on the sale of such Licensed Product or Licensed Service, including value-added taxes, or other governmental charges otherwise imposed upon the billed amount, as adjusted for rebates and refunds;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">No Other Amendment</b>. &#160;Except as amended hereby, all other provisions of the Agreement shall remain unchanged and in full force and effect in accordance with their terms.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Conflict</b>. &#160;In the event of a conflict between the terms and conditions of this Amendment Four and the terms and conditions of the Agreement, the terms and conditions of this Amendment Four shall control.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Counterparts</b>. &#160;This Amendment Four may be executed simultaneously in two or more counterparts, and by PDF or other electronic transmission, each of which counterparts shall be deemed an original, but all of which together shall constitute one and the same instrument, provided that all such counterparts, in the aggregate, shall contain the signatures of all parties hereto.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature page to follow]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Parties have duly executed this Amendment Four as of the Amendment Four Effective Date.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CEO</p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Acuitas Therapeutics Inc.</b></p></td></tr><tr style="height:19.35pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and CEO</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CureVac SE</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CEO</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CDO</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.54
<SEQUENCE>6
<FILENAME>cvac-20231231xex4d54.htm
<DESCRIPTION>EX-4.54
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:07 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.54</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REDACTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIXTH AMENDMENT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SPONSORED RESEARCH AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">MEE Agreement No. 2019A009504</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">This sixth amendment to Agreement (the &#8220;Sixth Amendment&#8221;), is effective as of June 29, 2023 (&#8220;Sixth Amendment Effective Date&#8221;), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (&#8220;SERI&#8221;), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (&#8220;MEEI&#8221;) (collectively, SERI and MEEI shall be referred to herein as &#8220;Hospitals&#8221;), and CureVac SE, a European Company, having a principal place of business at Friedrich-Miescher-Stra&#223;e 15, 72076 T&#252;bingen, Germany (&#8220;Sponsor&#8221;), each herein referred to as a &#8220;Party&#8221; and collectively as the &#8220;Parties&#8221;.  Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Hospitals and Sponsor are Parties to sponsored research agreement, MEE Agreement No. 2019A009504 (formerly, 2019-0112), effective as of March 15, 2019, as previously amended effective as of May 19, 2020, July 29, 2021, September 1, 2021, August 31, 2022 and January 1, 2023 (the &#8220;Agreement&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 42pt;">WHEREAS, the Parties desire to extend the Term until December 31, 2023;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 6pt;">WHEREAS, Sponsor and Hospital acknowledge that as of [*****], payments (a) through (m) described in Section 5.1 of the Agreement and totaling US [*****] have been paid in full; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 6pt;">In consideration of the promises made herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Hospital and Sponsor hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. AMENDMENT</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.95pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by deleting Section 2 in its entirety and inserting the following language in its place:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 42pt;"><font style="display:inline-block;text-indent:0pt;width:35.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term.</u> The term of this Agreement shall be from the Effective Date until December 31, 2023 (the &#8220;Term&#8221;), unless earlier terminated by either Party as set forth in Section 11 or extended in a writing signed by authorized representatives of both Parties.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as herein provided, the Agreement and all of its terms, covenants and conditions are hereby ratified and confirmed in all respects and remain in full force and effect. The Agreement shall, together with this Sixth Amendment, be read and construed as a single agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Sixth Amendment may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Sixth Amendment may be executed electronically/digitally in compliance with the Massachusetts Uniform Electronic Transactions Act (MUETA) Mass. Gen. Laws ch. 110G and/or The Electronic Signatures In Global And National Commerce Act (ESIGN) 15 USC ch. 96. Persons signing this Sixth Amendment agree that, if used, electronic/digital signatures are intended to authenticate this writing and to have the same force and effect as the use of manual signatures.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">The remainder of this page is intentionally left blank.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 2 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Parties have caused this Sixth Amendment to Agreement to be executed and delivered by their duly authorized representatives as of the Sixth Amendment Effective Date.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CUREVAC SE</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">THE SCHEPENS EYE RESEARCH INSTITUTE, INC.</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 13, 2023</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MASSACHUSETTS EYE AND EAR INFIRMARY</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 13, 2023</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I have read the terms of the foregoing Sixth Amendment and agree with Hospital (but without incurring any personal liability to Sponsor) to comply with the obligations of the Hospital Principal Investigator stated therein.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Signature of Hospital Principal Investigator)</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NAME:</p></td><td style="vertical-align:top;width:43.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DATE:</p></td><td style="vertical-align:top;width:43.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">The remainder of this page is intentionally left blank.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.55
<SEQUENCE>7
<FILENAME>cvac-20231231xex4d55.htm
<DESCRIPTION>EX-4.55
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:08 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.55</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REDACTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SEVENTH AMENDMENT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SPONSORED RESEARCH AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">SERI Agreement No. 2019A009504</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">This seventh amendment to Agreement (the &#8220;Seventh Amendment&#8221;), is effective as of February 23, 2024 (&#8220;Seventh Amendment Effective Date&#8221;), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (&#8220;SERI&#8221;), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (&#8220;MEEI&#8221;) (collectively, SERI and MEEI shall be referred to herein as &#8220;Hospitals&#8221;), and CureVac SE, a European Company, having a principal place of business at Friedrich-Miescher-Stra&#223;e 15, 72076 T&#252;bingen, Germany (&#8220;Sponsor&#8221;), each herein referred to as a &#8220;Party&#8221; and collectively as the &#8220;Parties&#8221;.  Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Hospitals and Sponsor are Parties to sponsored research agreement, MEE Agreement No. 2019A009504 (formerly, 2019-0112), effective as of March 15, 2019, as previously amended effective as of May 19, 2020, July 29, 2021, September 1, 2021, August 31, 2022, January 1, 2023, and June 29, 2023 (the &quot;Agreement&quot;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sponsor and Hospital acknowledge that as of the Seventh Amendment Effective Date the Agreement is expired and the Parties desire to reinstate the Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">WHEREAS, the Parties desire to extend the Term until June 30, 2024;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">WHEREAS, the Parties desire to amend the plan of research;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Sponsor desires to provide [*****] additional funding to Hospital; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.5pt;margin:0pt 0pt 12pt 0.5pt;">WHEREAS, Sponsor and Hospital acknowledge that as of [*****] payments (a) through (m) described in Section 5.1 of the Agreement and totaling [*****] have been paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In consideration of the promises made herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Hospital and Sponsor hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.&#160;&#160;&#160;AMENDMENT</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRB</u><font style="white-space:pre-wrap;">.  The Parties agree and acknowledge that as of the Seventh Amendment Effective Date Hospital has not obtained the requisite IRB review or approval, as applicable for Sponsor&#8217;s use of Hospital Human Materials to perform Goal 1 Task 3 and Goal 1 Task 4 of the Research Plan under Appendix A2 attached hereto as Exhibit I. The Parties agree that Hospital needs</font></p></td></tr></table><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">to obtain such IRB review prior to Hospital transferring the Hospital Human Materials for Sponsor&#8217;s use.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by deleting Section 2 in its entirety and inserting the following language in its place:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&quot;2. Term. &#160;The term of this Agreement shall be from the Effective Date until June 30, 2024 (the &quot;Term&quot;), unless earlier terminated by either Party as set forth in Section 11 or extended in a writing signed by authorized representatives of both Parties.&quot;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by deleting &#8220;two million seventy-four thousand two hundred forty in United States dollars (US $2,074,240)&#8221; in the first sentence of Section 5 and replacing it with the following: &#8220;two million three hundred seven thousand five hundred fifty-two in United States dollars (US $2,307, 552)&#8221;.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by inserting the following payments [*****] immediately following payment [*****] in Section 5.1:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">(n) [*****]</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.5 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by inserting the following Section 6.2, immediately following Section 6.1.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:46.61pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;6.2 </font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hospital Human Materials</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">6.2.1 Hospital shall provide to Sponsor and/or preapproved subcontractors of Sponsor the following materials: [****] which together with any derivatives thereof shall hereinafter be referred to as the &#8220;Hospital Human Materials&#8221;, solely to perform the Sponsor responsibilities to be carried out under the direction of Sponsor Principal Investigator as set forth in the Research Plan. Sponsor warrants that it will not (a) use the Hospital Human Materials for any purpose other than Sponsored Research or (b) transfer the Hospital Human Materials to a third party without prior written permission from Hospital. Hospital acknowledges and agrees that [*****] is a preapproved subcontractor. Sponsor warrants that it will comply with all federal, state and local laws and regulations concerning the storage, labeling, handling, testing, use and disposal of Hospital Human Materials and shall not use the Hospital Human Materials in human subjects, in clinical trials, or for diagnostic purposes involving human subjects. Sponsor shall not derive whole genome or exome data from the Hospital Human Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">6.2.2 Notwithstanding anything express or implied to the contrary herein, all rights, title and interest in and to the Hospital Human Materials shall be owned by Hospital. Sponsor agrees that nothing herein shall create or imply any license in such rights except to use the Hospital Human Materials solely in accordance with Section 6.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">6.2.3 For clarity, Sponsor shall not have access to any patient or clinical information relating to the Hospital Human Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">6.2.4 Sponsor agrees to use the Hospital Human Materials in a safe manner and shall treat the Hospital Human Materials as infectious, biomedical and biohazardous. THE HOSPITAL HUMAN MATERIALS ARE PROVIDED &#8220;AS IS&#8221; AND WITHOUT ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY INCLUDING SAFETY OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS. THE HOSPITAL HUMAN MATERIALS HAVE NOT BEEN ANALYZED OR TESTED BY HOSPITAL AND MAY, THEREFORE, CONTAIN VIRUSES, BACTERIA OR OTHER POTENTIALLY DANGEROUS COMPONENTS AND MAY CARRY TRANSMITABLE INFECTIOUS AGENTS. SPONSOR ACKNOWLEDGES AND ACCEPTS THE RISKS OF SUCH VIRUSES, BACTERIA OR OTHER POTENTIALLY DANGEROUS COMPONENTS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">6.2.5 Upon termination or expiration of this Agreement, Sponsor shall discontinue all use of the Hospital Human Materials and return all remaining Hospital Human Materials to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">Hospital or, at Hospital&#8217;s election, lawfully dispose of the remaining Hospital Human Materials and provide Hospital with certification of same.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.6 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by deleting Section 12, paragraph (b) in its entirety and inserting the following paragraph in its place.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">&quot;(b) Sponsor shall further defend, indemnify and hold harmless Institute and its trustees, directors, officers, medical and professional staff, employees and agents (&quot;Institute Indemnitees&quot;) against any and all third party actions, suits, claims, investigations, inquiries, demands, judgments and/or prosecutions that may be brough or instituted against Institute and Institute Indemnitees based on or arising out of, any use by Sponsor, its Affiliates or licensees or subcontractors of any Invention, Research Information (and/or material or thing embodying such Invention or Research Information), Institute material, Project Material, or Hospital Human Material, including but not limited to any such use in the manufacture, use, sale importation or other distribution of any product or process by Sponsor, its Affiliates, licensees or subcontractors, excepting to the extent Sponsor can demonstrate by clear and convincing evidence that it is directly resulting from the gross negligence or intentional misconduct of Institute and/or Institute Indemnitees in the use of any such product or process.&quot;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.7 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by deleting Section 13 in its entirety and replacing it with the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">&quot;13. DISCLAIMER OF WARRANTIES. NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, CONCERNING THE SPONSORED RESEARCH, PATENT RIGHTS, ANY OTHER INTELLECTUAL PROPERTY RIGHTS, INSTITUTE MATERIAL, PROJECT MATERIAL, HOSPITAL HUMAN MATERIAL OR ANY RESEARCH INFORMATION, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF ANY PATENT RIGHTS CLAIMS OR</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.25pt;">OTHER INTELLECTUAL PROPERTY RIGHTS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, AND EXPRESSLY DISCLAIMS THE SAME. Specifically, and not to limit the foregoing, Institute makes no warranty or representation (i) regarding the validity or scope of the Sponsored Research, any Patent Rights or any intellectual property rights optioned or granted hereunder, whether issued or pending; and (ii) that the exploitation of the Sponsored Research, the use of Institute material, Project Material, Hospital Human Material, Research Information, Patent Rights or any other intellectual property rights will not infringe any patents or other intellectual property rights of Institute or third party.&quot;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.8 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Section 17.2 of the Agreement is hereby amended to provide that the notice and contact addresses for Hospital shall be as follows:</p></td></tr></table><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:49.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #808080;border-right:1px solid #808080;border-top:1px solid #808080;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #808080;border-right:1px solid #808080;border-top:1px solid #808080;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Hospital Contacts for Notices</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-right:1px solid #808080;border-top:1px solid #808080;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Innovation Officer, Innovation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Schepens Eye Research Institute, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MGB Innovation STE 999</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">399 Revolution Drive STE 999</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Somerville, MA 02145</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.9 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by appending Appendix A of the Agreement with Appendix A2 attached hereto as Exhibit I.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.10 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Agreement is hereby amended by appending Appendix B of the Agreement with Appendix B2 attached hereto as Exhibit II.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.11 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="white-space:pre-wrap;">Except as herein provided, the Agreement and all of its terms, covenants and conditions are hereby ratified and confirmed in all respects and remain in full force and effect.  The Agreement shall, together with this Seventh Amendment, be read and construed as a single agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.12 </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Seventh Amendment may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Seventh Amendment may be executed electronically/digitally in compliance with the Massachusetts Uniform Electronic Transactions Act (MUETA) Mass. Gen. Laws ch. 110G and/or The Electronic Signatures In Global And National Commerce Act (ESIGN) 15 USC ch. 96. Persons signing this Seventh Amendment agree that, if used, electronic/digital signatures are intended to authenticate this writing and to have the same force and effect as the use of manual signatures.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">The remainder of this page is intentionally left blank.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.5pt;margin:0pt 0pt 12pt 0.5pt;">IN WITNESS WHEREOF, the Parties have caused this Seventh Amendment to Agreement to be executed and delivered by their duly authorized representatives as of the Seventh Amendment Effective Date.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">CUREVAC SE</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">THE SCHEPENS EYE RESEARCH INSTITUTE, INC.</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fabio Montrasio, Ph,D.</p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">VP, Area Head Molecular Therapy/Rare Diseases</p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">February 26, 2024</p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">February 23, 2024</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">CUREVAC SE</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">MASSACHUSETTS EYE AND EAR INFIRMARY</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:8.34%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[*****]</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:36.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">February 23, 2024</p></td></tr><tr><td style="vertical-align:top;width:8.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I have read the terms of the foregoing Seventh Amendment and agree with Hospital (but without incurring any personal liability to Sponsor) to comply with the obligations of the Hospital Principal Investigator stated therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Signature of Hospital Principal Investigator)</i></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NAME:</p></td><td style="vertical-align:top;width:39.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DATE:</p></td><td style="vertical-align:top;width:39.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-style:italic;font-weight:bold;">The remainder of this page is intentionally left blank.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Appendix A2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RESEARCH PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-6-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[*****]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-8-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">EXHIBIT II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Appendix A2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:center;text-indent:-0.5pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADDITIONAL BUDGET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 0.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 0.5pt 0pt;">[*****]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-9-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[*****]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-10-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>8
<FILENAME>cvac-20231231xex8d1.htm
<DESCRIPTION>EX-8.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:11 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.55pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;8.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;"><b style="font-weight:bold;">Subsidiaries of the Registrant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Place of </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Incorporation</b></p></td></tr><tr><td style="vertical-align:bottom;width:63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac SE</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Germany</p></td></tr><tr><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac Inc.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">United States of America</p></td></tr><tr><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac Belgium SA</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Belgium</p></td></tr><tr><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac Swiss AG</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Switzerland</p></td></tr><tr><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac Corporate Services GmbH</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Germany</p></td></tr><tr><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac Netherlands BV</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Netherlands</p></td></tr><tr><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac RNA Printer GmbH</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Germany</p></td></tr><tr><td style="vertical-align:bottom;width:63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CureVac Manufacturing GmbH</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Germany</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>9
<FILENAME>cvac-20231231xex12d1.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:12 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:394.5pt;margin:0pt 0pt 0.1pt 6.7pt;"><b style="font-weight:bold;">Exhibit&#160;12.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.34pt 0pt;"><b style="font-weight:bold;">CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 0pt;">I, Alexander Zehnder, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">I have reviewed this annual report on Form 20-F of CureVac N.V.&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;text-align:justify;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: April 24, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Alexander Zehnder</p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Alexander Zehnder</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>10
<FILENAME>cvac-20231231xex12d2.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:394.5pt;margin:0pt 0pt 0.1pt 6.7pt;"><b style="font-weight:bold;">Exhibit 12.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 6.05pt;">I, Pierre Kemula, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">I have reviewed this annual report on Form 20-F of CureVac N.V.&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#894;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;text-align:justify;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:21.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: April 24, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Kemula </p></td><td style="vertical-align:bottom;width:51.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Kemula</p></td><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>11
<FILENAME>cvac-20231231xex13d1.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:374.3pt;margin:0pt 0pt 0.1pt 26.9pt;"><b style="font-weight:bold;">Exhibit&#160;13.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:374.3pt;margin:0pt 0pt 0.1pt 26.9pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.7pt;text-align:center;text-indent:-67.7pt;margin:0pt 0pt 0.34pt 0pt;"><b style="font-weight:bold;">CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:30.25pt;margin:0pt 0pt 0.34pt 5.75pt;">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 36pt;">I, Alexander Zehnder, the Chief Executive Officer of CureVac N.V., certify that, to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of CureVac N.V.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.15pt;text-indent:-15.15pt;margin:0pt 0pt 0.25pt 36.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Date: April 24, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.05pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:52.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Alexander Zehnder</p></td></tr><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:52.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Alexander Zehnder</p></td></tr><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>12
<FILENAME>cvac-20231231xex13d2.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:31 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:374.3pt;margin:0pt 0pt 0.1pt 26.9pt;"><b style="font-weight:bold;">Exhibit 13.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.7pt;text-align:center;text-indent:-67.7pt;margin:0pt 0pt 0.34pt 0pt;"><b style="font-weight:bold;">CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:30.3pt;margin:0pt 0pt 0.34pt 6.05pt;">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 36.35pt;">I, Pierre Kemula, the Chief Financial Officer of CureVac N.V., certify that, to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#894; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of CureVac N.V.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.15pt;text-indent:-15.15pt;margin:0pt 0pt 0.25pt 36.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.05pt;">Date: April 24, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Kemula</p></td></tr><tr><td style="vertical-align:bottom;width:49.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Pierre Kemula</p></td></tr><tr><td style="vertical-align:bottom;width:49.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>13
<FILENAME>cvac-20231231xex15d1.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;15.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We consent to the incorporation by reference in the registration statements (No. 333-259613) on Form F-3 and (No. 333-246197) on Form S-8 of our reports dated April 24, 2024, with respect to the consolidated financial statements of CureVac N.V. and the effectiveness of internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">/s/ KPMG AG Wirtschaftspr&#252;fungsgesellschaft</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mannheim, Germany</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">April 24, 2024</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>14
<FILENAME>cvac-20231231xex15d2.htm
<DESCRIPTION>EX-15.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;15.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">Consent of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We consent to the incorporation by reference in the following Registration Statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(1) Registration Statement (Form F-3 No. 333-259613) of CureVac N.V., and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(2) Registration Statement (Form S-8 No. 333-246197) as amended, pertaining to the CureVac N.V. Long-Term Incentive Plan, CureVac Virtual Share Plan, and Employment Agreement between CureVac AG and a Former Employee;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of our report dated April 25, 2023, with respect to the consolidated financial statements of CureVac N.V. included in this Annual Report (Form 20-F) of CureVac N.V. for the year ended December 31, 2023.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:85%;"><tr><td style="vertical-align:bottom;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stuttgart, Germany</p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 24, 2024</p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>15
<FILENAME>cvac-20231231xex97d1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/24/2024 09:35:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;97.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.2pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">CUREVAC N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">COMPENSATION RECOUPMENT POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;">This CureVac N.V. Compensation Recoupment Policy (the &#8220;<b style="font-weight:bold;">Policy</b>&#8221;) has been adopted by supervisory board (the &#8220;<b style="font-weight:bold;">Supervisory Board</b>&#8221;) of CureVac N.V. (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;). This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under U.S. federal securities laws in accordance with the terms and conditions set forth herein. This Policy is intended to comply with the requirements of Section 10D of the Exchange Act (as defined below) and Section 5608 of the Nasdaq Listing Rules (the &#8220;<b style="font-weight:bold;">Listing Rule</b>&#8221;). This Policy also reflects certain Dutch legal provisions relating to the recoupment and/or adjustment of a Bonus from members of the Company&#39;s management board under certain circumstances defined by Dutch law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. For the purposes of this Policy, the following terms shall have the meanings set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.65pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:13.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>&#8220;<b style="font-weight:bold;">Bonus</b>&#8221; means any variable compensation of a member of the Company&#39;s management board that is partly or entirely conditional on the achievement of certain targets or the occurrence of certain events (e.g., signing bonuses, severance pay, cash bonuses, performance awards and contributions to pension funds).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>&#8220;<b style="font-weight:bold;">Covered Compensation</b>&#8221; means any Incentive-based Compensation &#8220;received&#8221; by a Covered Executive during the applicable Recoupment Period; <i style="font-style:italic;">provided </i>that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">such Incentive-based Compensation was received by such Covered Executive (A) on or after the Effective Date, (B) after he or she commenced service as an Executive Officer and (C) while the Company had a class of securities publicly listed on a United States national securities exchange; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">such Covered Executive served as an Executive Officer at any time during the performance period applicable to such Incentive-based Compensation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.25pt 5pt;">For purposes of this Policy, Incentive-based Compensation is &#8220;<b style="font-weight:bold;">received</b>&#8221; by a Covered Executive during the fiscal period in which the Financial Reporting Measure applicable to such Incentive-based Compensation (or portion thereof) is attained, even if the payment or grant of such Incentive-based Compensation is made thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:13.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Covered Executive</b>&#8221; means any current or former Executive Officer.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221; means October 2, 2023.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:13.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Exchange Act</b>&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:12.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Executive Officer</b>&#8221; means, with respect to the Company, (i) its president, (ii) its principal financial officer,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.25pt 5pt;">(iii) its principal accounting officer (or if there is no such accounting officer, its controller), (iv) any vice-president in charge of a principal business unit, division or function (such as sales, administration or finance), (v) any other officer who performs a policy-making function for the Company (including any officer of the Company&#8217;s parent(s) or subsidiaries if they perform policy-making functions for the Company) and (vi) any other person who performs similar policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. The determination as to an individual&#8217;s status as an Executive Officer shall be made by the compensation committee of the Supervisory Board (the &#8220;<b style="font-weight:bold;">Committee</b>&#8221;) or the Supervisory Board and such determination shall be final, conclusive and binding on such individual and all other interested persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>&#8220;<b style="font-weight:bold;">Financial Reporting Measure</b>&#8221; means any (i) measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, (ii) stock price measure or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;">(iii) total shareholder return measure (and any measures that are derived wholly or in part from any measure referenced in clause (i), (ii) or (iii) above). For the avoidance of doubt, any such measure does not need to be presented within the Company&#8217;s financial statements or included in a filing with the U.S. Securities and Exchange Commission to constitute a Financial Reporting Measure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>&#8220;<b style="font-weight:bold;">Financial Restatement</b>&#8221; means a restatement of the Company&#8217;s financial statements due to the Company&#8217;s material noncompliance with any financial reporting requirement under U.S. federal securities laws that is required in order to correct:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">an error in previously issued financial statements that is material to the previously issued financial statements; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">an error that would result in a material misstatement if the error were (A) corrected in the current period or (B) left uncorrected in the current period.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;">For purposes of this Policy, a Financial Restatement shall not be deemed to occur in the event of a revision of the Company&#8217;s financial statements due to an out-of-period adjustment (i.e., when the error is immaterial to the previously issued financial statements and the correction of the error is also immaterial to the current period) or a retrospective (1) application of a change in accounting principles; (2) revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization; (3) reclassification due to a discontinued operation; (4) application of a change in reporting entity, such as from a reorganization of entities under common control; (5) revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure; or (6) adjustment to provisional amounts in connection with a prior business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:12.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>&#8220;<b style="font-weight:bold;">Incentive-based Compensation&#8221; </b>means any compensation (including, for the avoidance of doubt, any cash or equity or equity-based compensation, whether deferred or current) that is granted, earned and/or vested based wholly or in part upon the achievement of a Financial Reporting Measure. For purposes of this Policy, &#8220;Incentive- based Compensation&#8221; shall also be deemed to include any amounts which were determined based on (or were otherwise calculated by reference to) Incentive-based Compensation (including, without limitation, any amounts under any long-term disability, life insurance or supplemental retirement or severance plan or agreement or any notional account that is based on Incentive-based Compensation, as well as any earnings accrued thereon).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:12.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(j)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Nasdaq</b>&#8221; means the NASDAQ Global Select Market, or any successor thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.25pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</font></font>&#8220;<b style="font-weight:bold;">Recoupment Period</b>&#8221; means the three (3) fiscal years completed immediately preceding the date of any applicable Recoupment Trigger Date. Notwithstanding the foregoing, the Recoupment Period additionally includes any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following those three (3) completed fiscal years, provided that a transition period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine (9) to twelve (12) months would be deemed a completed fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:12.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</font></font>&#8220;<b style="font-weight:bold;">Recoupment Trigger Date</b>&#8221; means the earlier of (i) the date that the Supervisory Board (or a committee thereof or the officer(s) of the Company authorized to take such action if Supervisory Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement, and (ii) the date on which a court, regulator or other legally authorized body directs the Company to prepare a Financial Restatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recoupment of Erroneously Awarded Compensation</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.65pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.25pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:13.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>In the event of a Financial Restatement, if the amount of any Covered Compensation received by a Covered Executive (the &#8220;<b style="font-weight:bold;">Awarded Compensation</b>&#8221;) exceeds the amount of such Covered Compensation that would have otherwise been received by such Covered Executive if calculated based on the Financial Restatement (the &#8220;<b style="font-weight:bold;">Adjusted Compensation</b>&#8221;), the Company shall reasonably promptly recover from such Covered Executive an amount equal to the excess of the Awarded Compensation over the Adjusted Compensation, each calculated on a pre-tax basis (such excess amount, the &#8220;<b style="font-weight:bold;">Erroneously Awarded Compensation</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If (i) the Financial Reporting Measure applicable to the relevant Covered Compensation is stock price or total shareholder return (or any measure derived wholly or in part from either of such measures) and (ii) the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the amount of Erroneously Awarded Compensation shall be determined (on a pre- tax basis) based on the Company&#8217;s reasonable estimate of the effect of the Financial Restatement on the Company&#8217;s stock price or total shareholder return (or the derivative measure thereof) upon which such Covered Compensation was received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:13.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>For the avoidance of doubt, the Company&#8217;s obligation to recover Erroneously Awarded Compensation is not dependent on (i) if or when the restated financial statements are filed or (ii) any fault of any Covered Executive for the accounting errors or other actions leading to a Financial Restatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Notwithstanding anything to the contrary in Sections 2(a) through (c) hereof, the Company shall not be required to recover any Erroneously Awarded Compensation if both (x) the conditions set forth in either of the following clauses (i), (ii), or (iii) are satisfied and (y) the Supervisory Board&#8217;s committee of independent supervisory directors responsible for executive compensation decisions (or, in the absence of such a committee, a majority of the independent supervisory directors serving on the Supervisory Board) has determined that recovery of the Erroneously Awarded Compensation would be impracticable:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">the direct expense paid to a third party to assist in enforcing the recovery of the Erroneously Awarded Compensation under this Policy would exceed the amount of such Erroneously Awarded Compensation to be recovered; <i style="font-style:italic;">provided </i>that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation pursuant to this Section 2(d), the Company shall have first made a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to make such recovery and provide that documentation to the Nasdaq;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;">recovery of the Erroneously Awarded Compensation would violate the laws of the Netherlands to the extent such law was adopted prior to November 28, 2022 (<i style="font-style:italic;">provided </i>that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation pursuant to this Section 2(d)), the Company shall have first obtained an opinion of home country counsel authorized to practice in the Netherlands that is acceptable to the Nasdaq, that recovery would result in such a violation, and the Company must provide such opinion to the Nasdaq; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;">recovery of the Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Sections 401(a)(13) or 411(a) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<b style="font-weight:bold;">Code</b>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:13.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Company shall not indemnify any Covered Executive, directly or indirectly, for any losses that such Covered Executive may incur in connection with the recovery of Erroneously Awarded Compensation pursuant to this Policy, including through the payment of insurance premiums or gross-up payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:12.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>The Committee shall determine, in its sole discretion, the manner and timing in which any Erroneously Awarded Compensation shall be recovered from a Covered Executive in accordance with applicable law, including, without limitation, by (i) requiring reimbursement of Covered Compensation previously paid in cash; (ii) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity or equity-based awards; (iii) offsetting the Erroneously Awarded Compensation amount from any compensation otherwise owed by the Company or any of its affiliates to the Covered Executive; (iv) cancelling outstanding vested or unvested equity or equity-based awards; and/or (v) taking any other remedial and recovery action permitted by applicable law. For the avoidance of doubt, except as set forth in Section 2(d), in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation; <i style="font-style:italic;">provided </i>that, to the extent necessary to avoid any adverse tax consequences to the Covered Executive pursuant to Section 409A of the Code, any offsets against amounts under any nonqualified deferred compensation plans (as defined under Section 409A of the Code) shall be made in compliance with Section 409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</u>. This Policy shall be administered by the Committee. All decisions of the Committee shall be final, conclusive and binding upon the Company and the Covered Executives, their beneficiaries, heirs, executors, administrators and any other legal representative. The Committee shall have full power and authority to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;">(i) administer and interpret this Policy; (ii) correct any defect, supply any omission and reconcile any inconsistency in this Policy; and (iii) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of this Policy and to comply with applicable law (including Section 10D of the Exchange Act) and applicable stock market or exchange rules and regulations. Notwithstanding anything to the contrary contained herein, to the extent permitted by Section 10D of the Exchange Act and the Listing Rule, the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;">Supervisory Board may, in its sole discretion, at any time and from time to time, administer this Policy in the same manner as the Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment/Termination</u>. Subject to Section 10D of the Exchange Act and the Listing Rule, this Policy may be amended or terminated by the Committee at any time. To the extent that any applicable law, or stock market or exchange rules or regulations require recovery of Erroneously Awarded Compensation in circumstances in addition to those specified herein, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Erroneously Awarded Compensation to the fullest extent required by such applicable law, stock market or exchange rules and regulations. Unless otherwise required by applicable law, this Policy shall no longer be effective from and after the date that the Company no longer has a class of securities publicly listed on a United States national securities exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u>. Notwithstanding anything to the contrary herein, this Policy is intended to comply with the requirements of Section 10D of the Exchange Act and the Listing Rule (and any applicable regulations, administrative interpretations or stock market or exchange rules and regulations adopted in connection therewith). The provisions of this Policy shall be interpreted in a manner that satisfies such requirements and this Policy shall be operated accordingly. If any provision of this Policy would otherwise frustrate or conflict with this intent, the provision shall be interpreted and deemed amended so as to avoid such conflict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Compensation Clawback/Recoupment Rights</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.65pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.25pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:13.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="white-space:pre-wrap;">Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies, rights or requirements with respect to the clawback or recoupment of any compensation that may be available to the  Company pursuant to the terms of any other recoupment or clawback policy of the Company (or any of its affiliates) that may be in effect from time to time, any provisions in any employment agreement, offer letter, equity plan, equity award agreement or similar plan or agreement, and any other legal remedies available to the Company, as well        as applicable law, stock market or exchange rules, listing standards or regulations; </font><i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that any amounts recouped or clawed back under any other policy that would be recoupable under this Policy shall count toward any required clawback or recoupment under this Policy and vice versa. To the extent that any other recoupment or clawback policy of the Company (or any of its affiliates) conflict with this Policy, the terms of this Policy shall control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Without prejudice to the foregoing provisions of this Policy, the Company may and, if so directed by the Supervisory Board at the recommendation of the Committee shall, recoup all or part of a Bonus that has already been paid to a member of the Company&#39;s management board, to the extent payment of such Bonus was based on inaccurate information as to the achievement of targets or the occurrence of events on which the Bonus was based (as determined by the Supervisory Board acting in good faith at the recommendation of the Committee). The claim for recoupment of a Bonus will expire after a period of five years has elapsed after the Company became aware that the Bonus was based on inaccurate information. In addition, the Supervisory Board may (but is not required to) adjust an entitlement of a member of the Company&#39;s management board to a Bonus that has not yet been paid to an appropriate amount, if payment of the (unadjusted) Bonus would be unacceptable according to standards of reasonableness and fairness (as determined by the Supervisory Board acting in good faith at the recommendation of the Committee).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exempt Compensation</u>. Notwithstanding anything to the contrary herein, the Company has no obligation under this Policy to seek recoupment of amounts paid to a Covered Executive which are granted, vested or earned based solely upon the occurrence or non-occurrence of nonfinancial events. Such exempt compensation includes, without limitation, base salary, time-vesting awards, compensation awarded on the basis of the achievement of metrics that are not Financial Reporting Measures or compensation awarded solely at the discretion of the Committee or the Supervisory Board, <i style="font-style:italic;">provided </i>that such amounts are in no way contingent on, and were not in any way granted on the basis of, the achievement of any Financial Reporting Measure performance goal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous.</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.65pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3.65pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:13.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Any applicable award agreement or other document setting forth the terms and conditions of any compensation covered by this Policy shall be deemed to include the restrictions imposed herein and incorporate this Policy by reference and, in the event of any inconsistency, the terms of this Policy will govern. For the avoidance of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3.65pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 5pt;">doubt, this Policy applies to all compensation that is received on or after the Effective Date, regardless of the date on which the award agreement or other document setting forth the terms and conditions of the Covered Executive&#8217;s compensation became effective, including, without limitation, compensation received under the Company&#8217;s Long- Term Incentive Plan and any successor plan thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0.2pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:13.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>This Policy shall be governed by and shall be construed in accordance with the laws of the Netherlands. Any dispute arising in connection with this Policy shall be submitted to the exclusive jurisdiction of the competent court in Amsterdam, the Netherlands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:14.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>If any provision of this Policy is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cvac-20231231x20f002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '0 ]L# 2(  A$! Q$!_\0
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M([?W'V*H*'IMP!4US\+K"37[S5+;4]5T\7L@EN[*TN0MO<.%V[F4J2,C@A2
M<#.: ./\/?M P2:'83:CI=Y=3QVL=SJUWI\2?9[!'=E1G#/N(.TG"AB ":V;
M/XYZ3=:Q]D.DZK#9/<3V<6I211^3-/$NYD4!R_0<,5 /3-'_  H/PXL$%O%<
MZG!:B&.WN;>*ZVI>QHQ9%F^7)P2>A'!P>*J>$_@7;Z7>W=WJ^JW>HLU]=7=I
M:I)MMK;SAMW*NW)<+D9)(&>!0!')^T)9P/)YGA77XHHHHKN65XX,1VLAPLQ
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MJOS*IX]P*T"H(P1FEH 3 ]*,#TI:* "BBB@ HHHH Y;S?&7_ #ZZ%_X%3?\
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M^,O^?70O_ J;_P"-T>;XR_Y]="_\"IO_ (W73JX=0RD%2,@CD&DDF2%0SNJ
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MJ:BBNE:'(W=W,G6GUQ7B_LF'3Y$P?,^VRR(0>V-JFLSS?&7_ #ZZ%_X%3?\
MQNNIHK&5)R=^9K^O0Z(5E&*7(GZW_P SEO-\9?\ /KH7_@5-_P#&Z/-\9?\
M/KH7_@5-_P#&ZZFBH]@_YW^'^1?UA?\ /N/X_P"9RWF^,O\ GUT+_P "IO\
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M--V'_0%NO^_B_P"-'_#3=A_T!;K_ +^+_C7@O]GW?_/I<_\ ?E_\*/[/N_\
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MLL__ #PE_P"_;?X46"Z.M_X6%_TY_P#CU:.G>*)=3B:2.!$"G&&8UP/V6?\
MYX2_]^V_PKI_"T$JV4N8I!\_=#2"Z.A_M:Y_YYQ?]]&C^UKG_GG%_P!]&J_E
M2?\ /-_^^31Y4G_/-_\ ODT!=%C^UKG_ )YQ?]]&C^UKG_GG%_WT:K^5)_SS
M?_ODT>5)_P \W_[Y- 718_M:Y_YYQ?\ ?1H_M:Y_YYQ?]]&J_E2?\\W_ .^3
M1Y4G_/-_^^30%T6/[6N?^><7_?1H_M:Y_P"><7_?1JOY4G_/-_\ ODT>5)_S
MS?\ [Y- 718_M:Y_YYQ?]]&C^UKG_GG%_P!]&J_E2?\ /-_^^31Y4G_/-_\
MODT!=%C^UKG_ )YQ?]]&E75;EB!Y<7/^T:K&-U&2C*/4J11'_K%^M S3#:B1
MG9;?]]M_A1G4?[EK_P!]M_A5U?NCZ4M %'.H_P!RU_[[;_"C.H_W+7_OMO\
M"KU% %'.H_W+7_OMO\*,ZC_<M?\ OMO\*O44 4<ZC_<M?^^V_P *,ZC_ '+7
M_OMO\*O44 4<ZC_<M?\ OMO\*,ZC_<M?^^V_PJ]10!4B-]Y@\Q+<)WVNQ/\
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M HYU'^Y:_P#?;?X4X&_QREOGV=O\*N44 %%%% !1110 4444 %%%% !1110
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M??\ @5)_\51_;NI_]!.^_P# J3_XJJ-%'/+N'LX=D7O[=U/_ *"=]_X%2?\
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MH<-:O[907*ERJVE]?O;_  "BBBMSF"BBB@ HHHH **** "BBB@ I",C!I:*
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M!-#_ .AFF_\ !4W_ ,<J6BO(_P!6\L_Y]_\ DTO\SWO];\Y_Y_?^2Q_R(O\
MA!-#_P"AFF_\%3?_ !RC_A!-#_Z&:;_P5-_\<J6BC_5O+/\ GW_Y-+_,/];\
MY_Y_?^2Q_P B+_A!-#_Z&:;_ ,%3?_'*/^$$T/\ Z&:;_P %3?\ QRI:*/\
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M;\Y_Y_?^2Q_R/(?^&<X_^AIC_P#!<_\ \75ZP_9;DU&)I(O%4&T'!W:>X_\
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M0O+RTE9+B:(%HF%OD X;D[AR3R:L#XDWFJZ7<W,4CVR01Q64@MXD,@OW?:R
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MI%_W]3_&OCCRT_N+_P!\BCRT_N)_WR*/]<)_\^%_X%_P _XA_3_Z"7_X#_\
M;'V/N7_GI%_W]3_&C<O_ #TB_P"_J?XU\<>6G]Q/^^11Y:?W$_[Y%'^N$_\
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M1'_\51_:EE_S^VG_ ($1_P#Q5?G]Y4?_ #S3_OD4>5'_ ,\T_P"^11_KA/\
MY\+_ ,"_X ?\0_I_]!+_ / ?_MC] ?[4LO\ G]M/_ B/_P"*H_M2R_Y_;3_P
M(C_^*K\_O*C_ .>:?]\BCRH_^>:?]\BC_7"?_/A?^!?\ /\ B']/_H)?_@/_
M -L?H)#>6]PQ6&X@F8#)6.56./H#5B/_ %B_6O@/0=:O/#&JV^I:9,;2\@;<
MDB#'X'U!]*^POA/\5+'XDZ<N-MMJ\ 'VFTS_ ./IZJ?TKZ#*>(*693=*<>2?
M17O?\M?(^4SWA6OE%-5Z<O:4^KM9KU5WIYGK2_='TI:1?NCZ4M?6'PP4444
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M^2R_R.'HKN/^$2\-_P#01UC_ ,!8?_BZ/^$2\-_]!'6/_ 6'_P"+H_U;S/\
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M/-<_\&_"OB+PEH-U;:_<0R%YMUK DBSR018QM>81Q^:?<H#C@D]:] H P8/
M7AJUU"ZOX?#^EQ7MTACGN$LXP\JD8*L<9(/H:C3X=>%8S8%/#>DJ; YM"+*/
M_1^<_)Q\O/I7144 4/[!TWS(W^P6V^.5IT;RERLAZN..">YK';X7^#WAO8F\
M+:,8[UP]RAL(L3,.A8;>373T4 5M.TVTTBRBL[&VAL[2%=L<%O&$1!Z!1P*L
MT44 %%%% "5Y/>_&.^TC3/%T=Y8V_P#;FD7T=I:VL1;;<"4CR6P3GD9)QZ5Z
MS7 >(O@_IWB+XA:;XIFN9(WM ADLP@*3NF=C,<]1D=NU>9CHXF48O"O79^C5
MK_\ ;KL_P/8RR>#C.2QJ]VUUONFG;3I)77E=,EU;XIVGA2YMK37;*ZMYCY4<
MUW#&IMQ(X'W<MO*@G&X*1GO4L_Q0TA_$,^C16>H7RP3"VNKRWM"]K;N?X9'[
M>_! [UA^)O@?%XCUK5[YM6\H:A+#,5:RCDDC,>,!9#\P4XZ#'7\].W^%T^F:
MYJ=QINNS6>E:I<_:KS3?LR.)&/WPLAY4-W_2N+FS+G:Y?=OY-VU\UIM?KJ]S
MT>3*/9J7.^>VOQ)7]WR>NLK='97L59?B]IUYI&I2Z3;7UO;06\LEOJL]@QLI
M/+Z[2""<<\<9P:-1^-6CZ#"+>^AOK^\ALX;JZ:PLRT:HZ@[^3\J\CJ>^.:98
M_"&\L/#UUX>3Q/</H+P300V;6D>8Q)R,N#EMI)(Z=:?=_!J&Z?66.J2K_:6D
MQ:4P\D?($51OZ\D[>GO6=\TY4XQ5[:[6O9[+FVO9)[VW-DLE4FI2;C?2U[VN
MDKOEWM=M+2^Q9UKXQ>&/##0P+YLZFU2]<6<:[887P5=@2.N<[5R<<XJQ_P +
M;T:?63IUA;WVJNB0R2RV4(=8UE *$@L&(P03M!P.M8EW\#HA>6MY8:JEM=)8
M16$[7.GQ722^6H59 K_<; '3CC\S4O@@NL:Q:7MWK ;[/)"ZR1:?%%<XC4#8
M)EP0IP3C'&<#H*;GFB;M!;KMMKUOZ7T].Z4:>2M*]1WL[WYM].BCZV][M?L_
M4:,44M?1GR(F*6BB@ HHJ&[NH[*UEN)F"11(7=CV &2:3=E=C2;=D345R?AS
MXB66LZ0;V\ADTEUN4MF@N/F*M)M,1) X#!U//3/-:%WXMLX-6M]/BD2:=KH6
MLHW%?+8Q-*!T^8[5S@'H<USQQ-&45)2T?Z^6YU2PE>$W"4'=7_#SV_X==S;Q
M17.0_$30)H[MS>20"U@-S*+FVEA(B!P7 = 6 /<9ZCUJYH/BW2O$LES'IUT9
MI+?:9$>)XV ;.TX8#(.#@C@XJHUZ,VHQFFWYHF6%KPBY3IM);Z/0U\48I:*W
M.8**** "BBB@ I,9I:YOQ%XU@\-ZYH]A<6[M%J#,K7*L L&"H!8>A9E&>V:S
MJ5(4H\TW9?YZ&U*E.O+DIJ[U_!7.CQ2UQFG?%'3+J76C<J]E::=-'"D[Y<W)
M8L 4106/S*0 ,DU>D^(WAZ.SMKDZANCN'>.)4@D:1G3[R[ NX,/0C-81Q="2
MNIK[[=;?F=$L#BHOE=-_)7Z7Z=;:V.DQ1BN=N?B)X>M+.SNGU$-#>(983'%)
M(2@^\Q"J2H'<L !WJVWB[1UM[V<WT?DV2H\[@$A0R[E(X^8$'C&<UHL11>BF
MOO7K^6ID\+76KIO[GWM^>GKH:^*,5A#QOI+:F=.$TJ7I+(B36TL:.RKN*J[*
M%8X]":SK+XEZ4-'TZ[U*86<]W!YYAC2281)G&YBJG:O^TV!4O$T4[.:^_P!/
M\T6L'B&KJF^G1WUOT[:/4Z^BN=G^(&@6VJ'3WU ?:A(D1"Q.R*S@% 7"[1D$
M8R><TWPGX[T_Q?<:C;VJ3QS64[PNLL+J#M.-P8@#GTSFFL11<E!35WTOV$\)
MB%!U'3:BK.]GL]F=)11170<@4444 %%%% !1110 4444 %%1M<1(V&D13Z%@
M*>K!U!4@@]P:5QV8M%,::-3@NH/H2*7S%"@[A@]#FBZ"S'44A8*,D@#U- 8,
M,@@CU%,0M%%% !1110 5\L?'W_DH,W_7%*^IZ^3_ (Y>+M"B^(^H6U[IVIR7
M%NJ(9+>YB5&^7/ 9"1U]:XL7C:&!@JF(ERINW5_E<]' Y=BLRJ.EA(<TDK[I
M:?-HX&BC_A+_  O_ - S6O\ P,@_^-T?\)?X7_Z!FM?^!D'_ ,;KRO\ 6'+/
M^?WX2_R/<_U4SG_GQ_Y-'_Y(**/^$O\ "_\ T#-:_P# R#_XW1_PE_A?_H&:
MU_X&0?\ QNC_ %ARS_G]^$O\@_U4SG_GQ_Y-'_Y(**/^$O\ "_\ T#-:_P#
MR#_XW1_PE_A?_H&:U_X&0?\ QNC_ %ARS_G]^$O\@_U4SG_GQ_Y-'_Y(**/^
M$O\ "_\ T#-:_P# R#_XW1_PE_A?_H&:U_X&0?\ QNC_ %ARS_G]^$O\@_U4
MSG_GQ_Y-'_Y(**/^$O\ "_\ T#-:_P# R#_XW1_PE_A?_H&:U_X&0?\ QNC_
M %ARS_G]^$O\@_U4SG_GQ_Y-'_Y([CX4?\AB[_ZX?U%>H5X;X;^*7AWPS=23
MP:-JTS2)L(DO(< 9SV2NA_X:'T?_ *%[4/\ P-B_^(H_UARS_G]^$O\ (/\
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MBC_6'+/^?WX2_P @_P!5,Y_Y\?\ DT?_ )(]1HKR[_AH?1_^A>U#_P #8O\
MXBC_ (:'T?\ Z%[4/_ V+_XBC_6'+/\ G]^$O\A?ZJ9S_P ^/_)H_P#R1ZC7
M4>%/^/*7_?K@O"_BG3O&.E"_TUVV [9K>0CS(&]&Q^A'!KO?"G_'E+_OU[M*
MK3KP52D[Q>S/FJ]"KAJDJ-:/+*.C3-NBBBM3 **** "BBB@ HHHH **** "G
M1_ZQ?K3:='_K%^M '0+]T?2EI%^Z/I2T %%%% !1110 4444 %%%% !1110
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MX[#PPN)G0IS4U%VNMG_7W=FPHHHKJ.$**** "BBB@ HHHH **** "NH\*?\
M'E+_ +]<O74>%/\ CRE_WZ -NBBB@ HHHH **** "BBB@ HHHH *='_K%^M-
MIT?^L7ZT = OW1]*6D7[H^E+0 4444 %%%% !1110 4444 %%%% !2'I2T4
M>!K+=ZI\9O$J37R2065U;+##<>);BS,8,>2$MD!23)YYZU@Z9\6]7\/PJ_G_
M &JZ>P4"[U"ZD>&$R7C1^9(FX+A0.O!Z#.*]EU!/A]>^-5M[V'PY<>*D"R 7
M$4#7BX&0<D;A@=*COYO!?BO3-8TVTU?3(#%;[+R;3IH/,@BSN.XD$!<Y^\".
MN: /+]6^)NL:E8:I!+J=O<SV#:C;1:EI,KP))Y=OO5R@=E)!/J<=JB\,?$K7
M[W3=*TVZUVQU9EBTZZ-YII99%\SAH93O8,3C.<@GTKO_ (0IX'N].U72_#/E
MZK;6%P1<7L@BD2:21<L5*@+@C@@ #VK;AUGX?>&-.NV@O/#FF65O*KW A>"-
M(Y.@+!>C?7F@#C?A7\5?$OCCQ,JW=M81Z1.L_P"[22)9K=HV(48$S.^<<YC3
M%<UKOC7Q3H7C[Q=J9U.Q>S@U&TTBT6Y$PCLA*N3*ZB41L!CNH))'S 5[1IL7
MA.*\N-9L$T=+N6-9)[^W6$2.C?=9I!R0>Q)YK.U/QAX*9->M7N=*U*>"%IM1
MT^$Q2RR*JY.]/XCCUH X[PO\3/%/B?4;#2K*?0IY%N;F&YU,1R-%.D+ ;X45
M^ISCEB ?6MOXG^--?T'4XK+19=/M@NGW&H2RWD#REO*&0B@.N >Y.<=JL:1\
M1?!R(UKHT-LUUIXAC.G6B0Q2VZ2@$84LH"@$9Q^IK?E\4>%;S5KRPEU/29M1
MM(6-Q \T9DBC_BW G(7US^- 'DT_Q,\1N@M]5FLKCS#IUW"^G>;:E%F;#1M\
MY+ >^,]Q7+^&OC+XMM+&TTRRDCO;G%S=FZU-XW%QBX9!"'DGCVA0.HW$<<5]
M"Z%=^&O%ED+W27TS5;4$1B>U\N504Z+D>G8=JL7GA#0M0@AANM%TZYA@<RQ1
MS6D;K&Y.2R@C@Y[B@#PWQ3\8_%,4OB*S:]L=&N/L<\FF_9X4NXR453N,R3$A
MADY5XU'3!-22_&GQ)I4$0GUGPY<O865G<2A8V5M3:9E!6+]X=NW/4;LL#P!7
MM\/A+1+>^N+V+1]/BO+E-DUPEK&))5]&;&6'L:8G@SP_$;(IH>FH;(DVNVSC
M'D$]=GR_+^&* /*;[XP>)-*U-+V:'3[G2YKV\L8M/@A=;C,,9=6,A8@L2,%0
MM8>E?&OQUJGAR748K32'2X2&6-FEMXW@W$[T6,W1\U@ ,;S&2<^E?0']E60=
M&^QV^Y)#*C>4N5<]6''!/K6:_@3PU)'=QOX>TIX[QM]RK6,1$[>KC;\Q]S0!
M4^&OB=O&'@W3]4>Y2[DF4AY8[8VX)!P04+-@_1B/0UU%0V=G;Z?;1VUK!';6
M\2[4BA0(B#T ' %34 %%%% !17-_VOXG_P"A>LO_  :'_P"-4?VMXG_Z%ZR_
M\&A_^-5S?6(=G_X#+_(Z_JM3O'_P*/\ F=)17-_VMXG_ .A>LO\ P:'_ .-4
M?VMXG_Z%ZR_\&A_^-4?6(=G_ . R_P @^JU.\?\ P*/^9TE%<W_:WB?_ *%Z
MR_\ !H?_ (U1_:WB?_H7K+_P:'_XU1]8AV?_ (#+_(/JM3O'_P "C_F=)17-
M_P!K>)_^A>LO_!H?_C5']K>)_P#H7K+_ ,&A_P#C5'UB'9_^ R_R#ZK4[Q_\
M"C_F=)17-_VMXG_Z%ZR_\&A_^-4?VMXG_P"A>LO_  :'_P"-4?6(=G_X#+_(
M/JM3O'_P*/\ F=)17-_VMXG_ .A>LO\ P:'_ .-4?VMXG_Z%ZR_\&A_^-4?6
M(=G_ . R_P @^JU.\?\ P*/^9TE<W\0-,N]6\,SP6</VI_,B>2U#!?M$:NI>
M/)X^901SQS1_:WB?_H7K+_P:'_XU1_:WB?\ Z%ZR_P#!H?\ XU6=6I3JPE3=
M[-6^&7^1M1I5:-2-6+C=-/XH]/\ MXXF/PKJ%Q)=SV>@/I%M+K>GW<=H?*0K
M%'L\QR$8@=#QUK._X0C6YK+6[#3M*ELH9K=OWU]';K<,YF5FB69"3(KJ'&9!
M_=R37H_]K>)O^A>LO_!I_P#:J/[6\3?]"]9?^#3_ .U5Y;P>'ENY=?LM;W_N
M^9[4<?BH[*'3>2>UK;R\C@/^$4U"+2+G[)HU^D-S>0M=036=B) BHPW0Q F(
M-DJ"S<XZ=*K-X)U&'PYI@;1KZ2^MI[UH(7AM;B)$DDW*)8V8*,@#E,;>1WKT
MC^UO$W_0O67_ (-/_M5']K>)O^A>LO\ P:?_ &JD\%AWUEM;9][]NY2S#%+:
M,-[_ !1[-?S=F<!/X)U:3Q T]_874D\\UM/%/ID=L8[?:J#8))/WB*K*W"\$
M'U)K8\'>';[2?&=Q)%I+PZ<S3O)<:A!!YRLSY'E31L7=3D\..!CGBNG_ +6\
M3?\ 0O67_@T_^U4?VMXF_P"A>LO_  :?_:JTAA:$)J:<KIWV?^1C4QF)J4W3
M:A9JWQ1[6_FW.DHKF_[6\3_]"]9?^#0__&J/[6\3_P#0O67_ (-#_P#&J]7Z
MQ#L__ 9?Y'A_5:G>/_@4?\SI**YO^UO$_P#T+UE_X-#_ /&J/[6\3_\ 0O67
M_@T/_P :H^L0[/\ \!E_D'U6IWC_ .!1_P SI*X7Q=H#2^-]%U@Z(NL6\-M-
M;/M2-FB=FC9'(<C@;6Y'(S[UK?VMXG_Z%ZR_\&A_^-4?VMXF_P"A>LO_  :?
M_:JPK2IUX\LK[I_"^COV.G#PK8>?/%QV:^./56Z2/-H?!^OW&IRW$FDSPW4E
MM>QW3I';16[NZD((]GSL"<'+Y/KS6AK.B:=X1M?#LEYI%C-;)8M%-92R0Q[9
M]B9E(<A7( 8$Y)&<C-=S_:WB;_H7K+_P:?\ VJF2ZAXBF $GAJP?!R-VIYP?
M^_->8L'0C%\KE=]7%OMY>1[+Q^)G*+FHJ*Z*:7?^]YGEUEX)U&[T;1YKC3[R
MYLI=+2&.&S@MI7MVWNQXFQMR&7#+S\OTK?F\&O%+XCMY_#]Y<M?)$\>H6I@\
MYE$:*REV(RQ*DD$;6_&NU_M;Q-_T+UE_X-/_ +51_:WB;_H7K+_P:?\ VJB.
M"P\5:\O_  %]FOY?,)YCBYRO:"_[>7=/I)=EZF!X9\%+K?AJZL-?TF.W@-R6
MA401V\CKM WR)$2@;.1] #@5WEC8PZ=:QVUNGEP1C")DG ].:PO[6\3?]"]9
M?^#3_P"U4?VMXG_Z%ZR_\&A_^-5Z-'V-!)13O:U^5W_(\G$?6,3)N4HI7O;G
MC9/TYCI**YO^UO$__0O67_@T/_QJC^UO$_\ T+UE_P"#0_\ QJNGZQ#L_P#P
M&7^1Q_5:G>/_ (%'_,Z2BN;_ +6\3_\ 0O67_@T/_P :H_M;Q/\ ]"]9?^#0
M_P#QJCZQ#L__  &7^0?5:G>/_@4?\SI**YO^UO$__0O67_@T/_QJC^U_$_\
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M^]]__ #_ %VS;^[_ . _\$\5_P"%<?\ 4RZ'_P!_)O\ XU1_PKC_ *F70_\
MOY-_\:KVK_AFW7O^@A9?FW^%'_#-NO?]!"R_-O\ "C_5;+_[WW_\ /\ 7;-O
M[O\ X#_P3Q7_ (5Q_P!3+H?_ '\F_P#C5'_"N/\ J9=#_P"_DW_QJO:O^&;=
M>_Z"%E^;?X4?\,VZ]_T$++\V_P */]5LO_O??_P _P!=LV_N_P#@/_!/%?\
MA7'_ %,NA_\ ?R;_ .-5HZ5H]IX2)GCN[?5-5/$<]N&,-L/5=P!+^^,#ZUZS
M_P ,VZ]_T$++\V_PI/\ AFS7O^@A9?FW^%=6&X>P&%JJK&+;6UW='%C.+,TQ
MM&5"<DE+>RL[=KW.:^%)+:U>$DDF'))ZD[A7J%5?!GP/UCPU?33S7=I*KQ[
M$)SUSZ5U_P#P@=__ ,](?^^C_A7TI\<<U172_P#"!W__ #TA_P"^C_A1_P (
M'?\ _/2'_OH_X4 <U172_P#"!W__ #TA_P"^C_A1_P ('?\ _/2'_OH_X4 <
MU172_P#"!W__ #TA_P"^C_A1_P ('?\ _/2'_OH_X4 <U172_P#"!W__ #TA
M_P"^C_A1_P ('?\ _/2'_OH_X4 <U172_P#"!W__ #TA_P"^C_A1_P ('?\
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M .*H_P"%I>#/^AMT/_P8P_\ Q5;/]A:;_P ^%K_WX7_"C^PM-_Y\+7_OPO\
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M!G_0VZ'_ .#&'_XJMG^PM-_Y\+7_ +\+_A1_86F_\^%K_P!^%_PHO2[/[_\
M@!;%_P T?N?^9C?\+2\&?]#;H?\ X,8?_BJ/^%I>#/\ H;=#_P#!C#_\56S_
M &%IO_/A:_\ ?A?\*J:K!H&A:?/?ZC%I]C90+OEN+A$1$'J21@4+V3=DG_7R
M%+ZS%.4I127D_P#,H_\ "TO!G_0VZ'_X,8?_ (JC_A:7@S_H;=#_ /!C#_\
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MS_86F_\ /A:_]^%_PH_L+3?^?"U_[\+_ (47I=G]_P#P MB_YH_<_P#,QO\
MA:7@S_H;=#_\&,/_ ,51_P +2\&?]#;H?_@QA_\ BJV?["TW_GPM?^_"_P"%
M']A:;_SX6O\ WX7_  HO2[/[_P#@!;%_S1^Y_P"9C?\ "TO!G_0VZ'_X,8?_
M (JC_A:7@S_H;=#_ /!C#_\ %5L_V%IO_/A:_P#?A?\ "C^PM-_Y\+7_ +\+
M_A1>EV?W_P# "V+_ )H_<_\ ,QO^%I>#/^AMT/\ \&,/_P 51_PM+P9_T-NA
M_P#@QA_^*K9_L+3?^?"U_P"_"_X4?V%IO_/A:_\ ?A?\*+TNS^__ ( 6Q?\
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M_&C_ (2+2O\ H)V?_?\ 7_&OB'[?9_\ 0;TG_P &UO\ _%T?;[/_ *#>D_\
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M>$O^ALT+_P &</\ \51_PL;PE_T-FA?^#.'_ .*H]A5_D?W,/K^$_P"?T?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?/C$C1LLB*Q ;F/! .>0><5I2C&4K2_R.?%U*E*ES4][KI>R;U=EO9&YX?\
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M?J@4444 %%%% !1110 4444 %.C_ -8OUIM.C_UB_6@#H%^Z/I2TB_='TI:
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M#_XFC_AD+PG_ -!O7/R@_P#B:]RHH_M3&?\ /Q_A_D'^JV3?] R^]_YGAO\
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M&[QG:2&C9F+?*200!\W'2NPTGX7Z=IILYI;R^OK^'4#J<MY<2*7N)S$8LN
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M=7AW_H$ZQ_X$0?\ Q%>,45]7_8^"_D_%_P"9^2?ZZ9W_ ,_5_P" Q_R/9_\
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M_P!8OUIM.C_UB_6@#H%^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH
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M5]"5@D]Q$3"YZ"13N3/MD"NRI,5I3J2I352&Z=SGQ%"GB:,Z%57C)-/T>A\
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MY%&17UM_PF&M_P#04N/_ !W_  H_X3#6_P#H*7'_ ([_ (4?ZP+_ )]?C_P
M_P"(=R_Z"O\ R3_[8^2<BNV^'7PZD\73M>WK/::';MB6<#YI6_YYQYZL>YZ
M<FOH#_A,-;_Z"EQ_X[_A5&_U2\U217O+F2Y=1A3(>@]JQK9]*<'&G"S[WO\
MH=F#\/Z5*O&IB:_/!;QY;7^?,]#L?A4T::E);6T"6EE;VVR"VC^[&NX?F3U)
MZDUZ;7E_PH_Y#%W_ -</ZBO4*^5;<G=[GZS"$:<5""LEL@HHHI%A1110 444
M4 %%%% !1110 5U'A3_CRE_WZY>NH\*?\>4O^_0!MT444 %%%% !1110 444
M4 %%%% !3H_]8OUIM.C_ -8OUH Z!?NCZ4M(OW1]*6@ HHHH **** "BBB@
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M@S\H4\$^X]:;9_&71[FZ99[#5M/L?M362ZG=VFVT>57*8WJ3@%A@%@![UO\
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MX6?QGX3O]'CN%M7N0H$K+N"X=6Z?A6E-1<TI[7U.?$.I&C-T5>5G;UMH5O\
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MS[G!->M5S5:;I2Y&>IA,3'%TE5@FD^^X4445B=@4444 %%%% !1110 4444
M%%%% !1110 4444 (>E?FG^UA_R7CQ+_ +T7_HL5^EAZ5^=?[4?@SQ!J?QO\
M17-GH6IW=L[1;)H+.1T;Y!T(&#7T>1R4<1)R=M/U1^:\>4YU,NIJ";?.MO1G
MA-%=!_PKSQ5_T+.L?^ $O_Q-'_"O/%7_ $+.L?\ @!+_ /$U]Q[6G_,OO/PC
MZK7_ .?;^YG/T5T'_"O/%7_0LZQ_X 2__$T?\*\\5?\ 0LZQ_P" $O\ \31[
M6G_,OO#ZK7_Y]O[F<_170?\ "O/%7_0LZQ_X 2__ !-'_"O/%7_0LZQ_X 2_
M_$T>UI_S+[P^JU_^?;^YG/T5T'_"O/%7_0LZQ_X 2_\ Q-'_  KSQ5_T+.L?
M^ $O_P 31[6G_,OO#ZK7_P"?;^YG/TZ*5X9%DC9D=2&5E."".X-;W_"O/%7_
M $+.L?\ @!+_ /$UVG@#X2RB4:IXILIK2SB;]SILZ&.6Z<?W@>5C'<]^@K&M
MBJ-"#J3EHCNP64XW'5XT*--W?=-)>;?D>X_L\ZOJ/B72'U36+<V]Z8_+BN"<
M&^0$9D*]B.A;HWUS7L%>:?#&Y>[UZ[D?:/\ 1PJJ@VJB@@!5'8 =!7I=?F->
MI&K5E.,>5/H?U)@,/4PF&IT*M1SE%6<GU_K[^X4445@=X4444 %%%% !1110
M 4444 %=1X4_X\I?]^N7KJ/"G_'E+_OT ;=%%% !1110 4444 %%%% !1110
M 4Z/_6+]:;3H_P#6+]: .@7[H^E+2+]T?2EH **** "BBB@ HHHH **** "B
MBB@ I#2T4 ?.GCKQIXFTCQ5JVC6VL7<9TJ[_ +=D*8R;  'RB>?ESNZCM1I7
MQH\0V>G7.IVYLM0M)86UQQJ5RZN;1Y=D<5NH P0.<MD9.*]]DT33IKN>ZDL;
M9[F>'[/+,T2EY(_[C'&2OMTJE=>"?#U]_9_VC0].G_L_'V/S+5&^SXZ>7D?+
M^% 'AGB#XT^);76](U>1+:#2VEO(X+"&9U\X*B!&N"1@8+9.WIS22_'#Q1X,
MFUHZE%IFMW4UXUK:16=T[0B<1ADB3@D!@2>_(KWR7PUI$Y!ETRSDQOQO@4_?
M&'[?Q#KZU6T_P-X<TFVCM[+0=,LX(Y1.D4%I&BK)TW@ <-[]: /&#^T#?Z@D
M&K6-A$8[M/L]D)+EUMRQE"&208^Z&R,CTQ61I'QS\7Z0]]8&SMM>U)+ZZFGD
M25GMUA1PHBB;*[?JQ(7N#7T(WA+1'LVM&TBQ:U:,PF VZ%"A.2N,8P3SBJ1^
M&_A-K*VLSX9T<VEM)YL-N;"+RXG[LJ[< ^XH VM.NFOM/MKEHC"TT:R&,L&V
MDC.,C@X]15FFHBHH50%4#  & !3J "BBB@ HHHH **** "BBB@ HHHH X;_A
M=G@K_H.Q?]^9?_B*/^%V>"O^@[%_WZE_^(KN,CU_6C(]?UK>]+^5_?\ \ X.
M3%_\_(_^ O\ ^3.'_P"%V>"O^@[%_P!^I?\ XBC_ (79X*_Z#L7_ 'ZE_P#B
M*[C(]?UHR/7]:+TOY7]__ #DQ?\ S\C_ . O_P"3.'_X79X*_P"@[%_WZE_^
M(H_X79X*_P"@[%_WZE_^(KN,CU_6C(]?UHO2_E?W_P# #DQ?_/R/_@+_ /DS
MA_\ A=G@K_H.Q?\ ?J7_ .(H_P"%V>"O^@[%_P!^I?\ XBNXR/7]:,CU_6B]
M+^5_?_P Y,7_ ,_(_P#@+_\ DSA_^%V>"O\ H.Q?]^I?_B*/^%V>"O\ H.Q?
M]^I?_B*[C(]?UHR/7]:+TOY7]_\ P Y,7_S\C_X"_P#Y,X?_ (79X*_Z#L7_
M 'ZE_P#B*/\ A=G@K_H.Q?\ ?J7_ .(KN,CU_6C(]?UHO2_E?W_\ .3%_P#/
MR/\ X"__ ),X?_A=G@K_ *#L7_?J7_XBF3_&7P-<Q-'-K-O+&W5'@D(/X%*[
MO(]?UHR/7]:.:E_*_O\ ^ ')BWHZD?\ P!__ "9P!^+W@$@@ZM:D&02D?9I/
MO_WON=>!SUJ*/XI_#N&[>Z34+%+ESEIEM'#L<8R6V9->B9'K^M&1Z_K3YZ?9
M_?\ \ GV.)>\X_\ @#_^3/.9_BA\.;H6XFOK"46_^I#V;-Y?3[N4XZ#IZ4Z+
MXI_#N"[>ZCU"QCN78LTRVCAV)&"2VS.<5Z)D>OZT9'K^M'/3[/[_ /@"]CB;
MWYH?^ /_ .3/.[7XJ?#NQ;=;ZA8P-N9\Q6CJ=QZGA.I[FB#XI?#JUBECAO[&
M*.5M\B):.H=O4@)R?>O1,CU_6C(]?UHYZ?9_?_P 5'$K[</_  !__)GGEW\5
M/AW?K(MSJ%E<+(0SB6T=@Q'0G*<XJQ!\9? UM"D4.M6\42#:J)!(%4>@ 3BN
M[R/7]:,CU_6ES4]K/[_^ 4J6*3NIQO\ X'_\F</_ ,+L\%?]!V+_ +]2_P#Q
M%'_"[/!7_0=B_P"_4O\ \17<9'K^M&1Z_K1>E_*_O_X ^3%_\_(_^ O_ .3.
M'_X79X*_Z#L7_?J7_P"(JM?_ !9^'VJQ+%>ZG9W<:G<$GM7< ^N"AKT'(]?U
MHR/7]:%*DMHO[_\ @"=/%25G./\ X __ ),\Z_X6A\.?M2W/VZP^T* !+]C;
M> .G.S/':IU^+_@)/+VZM:KY;%DQ;2?*3G)'R<9R?SKOLCU_6C(]?UI\]/L_
MO_X E1Q*VG#_ , ?_P F><Q_%#X<Q/<LE]8(UR")V6S8&4'KN^3YOQI]I\5/
MAY81QQVVHV5ND;%T6*T=0K$8) "<''>O0\CU_6C(]?UHYZ?9_?\ \ 2HXE:J
M4/\ P!__ "9PLGQH\#S1LDFMP.C#!5H9""/<;*KW?Q6^'M_'$ESJ5E<)$08U
MEM78(?8%.*]"R/7]:,CU_6DI4ULG]_\ P"G2Q4MYQ_\  '_\F>=3_%#X<W0@
M$U_82B#_ %6^S9O+_P!W*<?A0WQ1^'37<MT;^Q-S*NV28V;;W&,8+;,D8]:]
M%R/7]:,CU_6GST^S^_\ X!/L,3_-#_P!_P#R9P+?%[P$X<-JUJP=@S VTGS$
M8P3\G)&!^50O\4_AV]]]M;4+%KS&/M!M',GI][9FO1,CU_6C(]?UHYZ?9_?_
M , ;HXE[SC_X _\ Y,\\L/BM\/-*$@LM1LK02'+^1:.FX^^$&:M_\+L\%?\
M0=B_[]2__$5W&1Z_K1D>OZTG*D]6G]__  !JGBHJRG'_ , ?_P F0:??P:I8
MP7EK();>=!)&X!&Y3T/-6*04M8>AWJ]M3 \2^/-"\(2P1ZOJ"63S M&&1VW
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MQZT >0?8Y_\ GB__ 'R:/L<__/%_^^37K_'K1QZT >0?8Y_^>+_]\FC['/\
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M-UZ!16OM9]SO^O8C^;\%_D>?_P#"I9?^AX\7_P#@R3_XW1_PJ67_ *'CQ?\
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M]K/N'U[$?S?@O\CS_P#X5++_ -#QXO\ _!DG_P ;H_X5++_T/'B__P &2?\
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MIB/Y']QZW^K><?\ 0+/_ ,!9[A_PNSQC_P!!7_R$M'_"[/&/_05_\A+7A_\
MPOGX;?\ 0PZA_P""9_\ XNC_ (7S\-O^AAU#_P $S_\ Q='U3$?R/[@_U;SC
M_H%G_P" L]P_X79XQ_Z"O_D):/\ A=GC'_H*_P#D):\/_P"%\_#;_H8=0_\
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M_P#QRCZGB/Y']P?ZMYS_ - L_P#P%GT1_P )5JG_ #]-1_PE6J?\_35\[_\
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M)_T.X,\77'#%5/X%01Z5NT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS7Q^;SH2J)0^+J?SQXA5\LJ8J,*"OB%\36UNB?>7Y+?H=%1117SY^0A1110
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M+.,R2,JEV/8*JCDL20 !U)%-)MV1<(2J24(*[>B1K8HKA?#?Q535=>BT?6-
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M> HXZM4<<O4W.VO)>]OET.+_ .$2\-?]"GX=_P#!1!_\31_PB7AK_H4_#O\
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M'PW\$+7PKXP;6+&]@^RR3-<O;2Z9 \WFL,$K<$;U7C./UKTZ@ HHHH ****
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MU8?%8C"2<\/4<&]+Q;3_  /'O^%<^ O^A!T+_P F?_CU'_"N? 7_ $(.A?\
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M4 %%%% !1110 4444 %%%% !3H_]8OUIM.C_ -8OUH Z!?NCZ4M(OW1]*6@
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M?^!1_P SK**Y/_A,=8_Z$G6_^_\ 9?\ R11_PF.L?]"3K?\ W_LO_DBCD?\
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M@0DR&,N#ACD#@$@5]!?\)AK'_0DZW_W_ ++_ .2*/^$PUC_H2=;_ ._]E_\
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M,=8_Z$G6_P#O_9?_ "11_P )CK'_ $).M_\ ?^R_^2*.1_TT'U:IW7_@4?\
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MA;_P:_\ V%?;/_#/7BSTL_\ O_\ _6H_X9Z\6>EG_P!__P#ZU']KXGR^X/\
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(*/Q7_&@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cvac-20231231x20f004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %H V4# 2(  A$! Q$!_\0
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M 4444 %%%% '/W__ ".ND_\ 7M/_ #6N@KG[_P#Y'72?^O:?^:UT% !1110
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M 4444 <_?_\ (ZZ3_P!>T_\ -:Z"N?O_ /D==)_Z]I_YK704 %%%% !1110
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MRV1^L2QN&K8&5"JFG:WFGYGT%\%_%=AXA_9WTJ7Q)JUO,IM3:WMQ=3 ;<,0
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M_P"&_B:QMOV@M1_X7MITO_"32NOV&:_8&SM"3E5"?=V\@*W(_'FND^#GQO\
M#OB;XUZEXG\<7Z64KH(-%><YMX Q.[<W1&Q@ G'?FOH3XU_ OPY\>/#:)<^7
M'J")NL=5@PS+GD<C[R'TKR%)XQ*M2EHGMW]?T/LU3IY-4>#QD&N=:S6ZO_+Y
M+9]7^!D?M1_"6U^*OPDN_L<2'5-*C-]ITD0SG"_,@QV9<CZXK\U/A?KVM7G[
M8W@BZU)_M4.I7EK$967#,8DV -[@*/RK[%^$?QRUW]GOQ.WPW^*:RC3$(2PU
M9LL(T)PI)_BC/KU7H:\IL=$T7Q'^V_#:^'5MYK"TUM;F*2V(=%(CWN5(XQDG
M\ZQJU(NI"K#=NS1ZV!P]:AAJV$K:Q47.$UM:VMGY]NY^DM?,_P :?VP+SX3?
M$"]\-Q>%X=32W2-Q</>F,MN7/W=A_G7TQ7YP?MC?\EYUG_KC!_Z *^YRG#TL
M37<*JNK?Y'\]\7YCBLLP$:V$GRR<DKV3TL^Z9Z;_ ,/"=0_Z$BV_\&3?_&J/
M^'A.H?\ 0D6W_@R;_P"-5\C45]=_9."_Y]_B_P#,_'/];L[_ .@C_P EC_\
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M\1AS*UJ^X65UW(*C_5D^JC'J*^5KK]BKXS:AXNBLQX1.G1Q+M6>VO8OLK'&
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M_+:BOTP_X93^%W_0JV__ 'V_^-'_  RG\+O^A5M_^^W_ ,:^F_M[#_RO\/\
M,_,?^(?YC_S]A^/^1^9]=S\(=>T_P9X]T77M1NE6UM)"\D: E\8(Z5][_P##
M*?PN_P"A5M_^^W_QI?\ AE3X7?\ 0JV__?;_ .-8ULZH58."35_)?YG=@N",
M=A*T:TI0ERV:UDM4[_RGPYX)\5Z1X=E\?-<WJL->TBYL;;RU)VR22*REO08!
MKI/ _P 1=!TGX:0^&YO$^K>%[J&[DN)KCP^,-?HP ".V5(QC Y(YZ5]?_P##
M*GPN_P"A5M_^^W_QH_X94^%W_0JV_P#WV_\ C7%/,J,]V^G1=-.Y[M'AK%T+
M<L(:)KXY;-W>T;[GR;XQ^+'AK7[_ ,6W-I=3(FL>&K7284N,NZ31NI.]NXPO
MWNY-8/ASQOX7L?"'A#1]7#:C'I>I75U=Q0RO"=DB@(T;K@[U(W#Z"OM#_AE3
MX7?]"K;_ /?;_P"-'_#*GPN_Z%6W_P"^W_QJ5F%",>5.5O1=K=^QI/A[&U*C
MJRA"[T^*5M9<VW);?\-#Y:U+XXZ=I6AV%G9>)=1\97EKJ4-];W?B&,*]FD9Y
MC1OF9BPX))QQTKD]?OOAA(^N:O8O?:CJ^IAC;V5Z/+AT^1V!:3>IS(5Z*",<
M\U]H_P##*GPN_P"A5M_^^W_QK'3]F+X:'Q?-9'PQ;_9UL4F";W^\9'!/7T I
M0S"A#6+DODM?Q_(JKP_C*ZM4ITVNEY2=NFEXO\;].R/EB3XFZ WQNU7Q>+L_
MV9<V4ENB[#YFYK<1C(^M:6MCP)=> ?A@/$U]J-G=6.G2LDEG"'2ZC^TN?+YQ
MCG^(9ZGVKZM_X94^%W_0JV__ 'V_^->=:E\$?!EPZV\NCB6"U+101O*Y6)-Q
M.U1G@9YKY_-^*L'DZI2J\^NBLH]%;K)=ST,'PGC,4JT73IOFN]9RM>4HR?V?
M[IX)?_$[0?&.E_$"SUJ\;31KDD%Q8FU3S1&T((CC?.."-N6^M7-4^*GA;Q)?
MZ]INIW,R>'=8L;&)I[=?W]O<6\84.%/#+G/&:]C_ .%">!/^@!#_ -]M_C1_
MPH3P)_T (?\ OMO\:^=_XB+E*VA4_P# 8^7][R1V?ZDYJU[RIOO[\M;\VC]S
M;WI?>>0^&OBGX1\$WWA'2M(N[B?P[HUU=:A=7ES'MGNKB6%H@5C&0JJ"!C->
M?Z%XBTS2/ 7C32);Q'NM7:!K?8"1\DA8Y/;@\5]/?\*$\"?] "'_ +[;_&C_
M (4)X$_Z $/_ 'VW^-7'Q(RJ.O)4UM]F/1W_ )NYC4X#S.HDK4U922]^6BE%
M1_D[)?F?#]%?;_\ PH/P'_T+\/\ WVW^-'_"@_ ?_0OP_P#?;?XUZ?\ Q%3*
M/^?-3[H__)'RG_$*,W_Y_4_OE_\ (GQ!17V__P *#\!_]"_#_P!]M_C5/5/A
M1\.?"=N-1NM%MXA$=R EF+,.0 ,\T?\ $4\J>D:%1OTC_P#)%P\)<XJ2456I
MZ]N;_P"1/*O@1\!_[6,/B/Q+!MT],26UG*,"7T9P?X?;O7NNM?%/PSH!:.74
M$ED3CR[8;R/;CBO*KGQ+K'Q>\2_V!:ZA%X;TX(6B@<$M*H^G4X[9Q4OC+X #
M1?"EW>Z?J=U?ZA /,9'4*K*/O8 [_C7X=GV<XG/\9]8QLK?RQ6T5V_S?7[C^
MHN&>#\KX8P\,%.3YY6YFEJWW;VMV2T7WG07/[2OA^)B(;"^F [[57^M0+^TW
MHI/S:3>J/4%3_6LWX1_#_P &>.O"L=W/82-J,#>3=H9VX<=& ST(YJ*W_9^E
M3XD.9;6.3PB0SJ!-AA\O"]<Y![UX')ATW&2V/KG3RN$YTYQDG'N_RU)[C]J"
M!=;5(=#DDTG8,S-*!-N[_+TP/K5#XA?%/P7XZTAHV@OK;450B&Z6 $J?[K#/
MS+ZC\J[]_@#X,8?\@^5?I</_ (U6/[.W@XMGR+L>PN34QJ8>+4HIJQG3KY93
MDIP4XM=5_P .>0_#_P".FK>"M-^PW,*ZG:JO[F-Y"#"?0-UV^W:NI\#_  [E
M^*7B:X\7Z]I\6FZ?*P9;2!2HN6'\1SV]3WKTS1O@QX0T299H=)2:53D-<L9,
M?@>*[546-0JJ%4# 4#  I5,3&[=)6;ZF>)S&BG*6$ARREO+K\E^HB(L2*B*$
M10%55&  .@%.HHKSCYX**** "BBB@#Y&_:M_Y*1:_P#8/C_]#>O&*^]O$_PO
M\,^,M06^UC2X[VZ6,1"1F(.T$D#@^YK(_P"%!^ _^A?A_P"^V_QK^ALB\1<L
MRO+*&"JTIN4(I-I1M\O>/YSS[PXS/-<TKXVE5@HU)-I-RO\ /0^(**^W_P#A
M0?@/_H7X?^^V_P :/^%!^ _^A?A_[[;_ !KWO^(J91_SYJ?='_Y(\'_B%&;_
M //ZG]\O_D3X@KMO@UXRL? 'Q$TS7-165[.V$@<0KN;YD(&!^-?5/_"@_ ?_
M $+\/_?;?XT?\*#\!_\ 0OP_]]M_C6<_%')ZD7"5&I9^4?\ Y(WH>%V=8:K&
MM"M3O%IK66Z_[=/EKP3XVL/#UGX\BN4E9M<TJ6RMMBYP[2JXW>@PIKK/!OQ7
MT?3OAI9^'9M9\0>%KFUN99IY/#X"G4%;&%=PRD$8P,Y'/2O>?^%!^ _^A?A_
M[[;_ !H_X4'X#_Z%^'_OMO\ &L9^)>2U-Z-3>^T>BM_,=]#P[S[#VY:U+1-?
M:V;N]E??_(\3\=_&O0/$USXKGLX+V(:OH5GIT,<XW-'+$1N#-GD8'WN]<]HW
MQ&\.6_ASP!IFJZ?=W\.B7-])>QPR&%@)BOEO$ZD'>A7=]0*^C?\ A0?@/_H7
MX?\ OMO\:/\ A0?@/_H 0_\ ?;?XU,?$G)(Q451J_P#DO:W\W8TJ>'_$%6HZ
MLJU*[TZV^)3VY;;K[M#R.\^/&CP6>@6$NKZYXN6RUBWU#^T-:A036L49YCC.
M2S$]\GM5;1/C!HMUH&J:-%J>M>&[B[URYU'S]+0#^T(Y3\D4Q# C;TZD<]*^
MJM&_9;^&-WI5K-+X7MVD>,,QWOR?SI-;_9B^&FEZ1>7=MX8MX[B")I(W#OPP
M'!ZU]O3S3 UZ*G",O>5^G77T.%<.9W3K7G5IV6GVMO7?\?+;0^7-3^-'A?5?
M&>L27<>I6NEZIX;&A3NB"6:WD7 W#)&\?+[=:RM.^,VAZ=9>'-*EMKN\TF'1
M;C1M2V )(4>8NKQ^XX./PKZ^T_\ 9<^&5Y86T\OA>W>66)7=B[\D@$GK4_\
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MD[]B)8BC"G[64TH][JV]M]M]/4Z>BD5@P!!!!Y!%+69T!1110 4444 %%%%
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M?06.DHJSW)!=LS2'MT'/ [5X-3$1J4*;O[\-/ET^X^^PV75,/CL2K)T*JO\
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M,(#E1_.O5%4*  , = *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J6LZ+8>(M,N-.U.TAOK&X79+!.@9''N#5VBC83
M2:LSR'X+?L]VOP:\3^)]5M-7FO8=89=EJR!$A522.G4\XSZ5ZZ5!() )'0^E
M+16M6K.M+GJ.[.7"X6C@Z2HT(\L5?3U=PKGX_P#D?Y_^P9'_ .C7KH*Y^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX1&E->BX3:9EE7"]<Y(&:W?VBM.N-8\&:5;6:++.NMV%P4,BJ?+296=OF(X
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MP[\=OXYT^]:ZT:\T'4K"Y:TN[&\PVUP <HX^5U(((85X=J]_%XI\(>$HM?\
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MW^'/&7B#Q"GA#1/$/BH:=I-S?:I$VK:=J*.\X@*^1!)<J ID +ABOWC%]:]
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M,C_]&O705S\?_(_S_P#8,C_]&O2&=!7C5[_Q^W'_ %T;^9KV6O&KW_C]N/\
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MQJ7.,LQPH'N3Q7B^LWVKZ!>^-]!M/$LD45M%IT]K<ZM=$%&F9Q)&)L$IOV
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MREU#1_B3XQ\-3:O?:MIUE%:W%N=1E\V2-I%.\!CSC(SB@+GJE%%%(9A^./\
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M7Y. <+P/2NJHH<$R8XBI%67Y+_(XB]^$FBZEIMKIUVHNM/M0!;VLUO"\<('
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M8V=K;VT!\FVMY!-##'!$JQN.C* O#<GGKS2W7@VSOH[I+ES<)=$&=9(8F$I
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M"=V0<?4YJSF/HJBBBD,P_''_ "*6J_\ 7 UKVW_'M%_N#^59'CC_ )%+5?\
MK@:U[;_CVB_W!_*@74EHHHH&%%%% !1110!S]_\ \CKI/_7M/_-:Z"N?O_\
MD==)_P"O:?\ FM=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^?.3_P "IO\ XNC_ (5[H/\ SYR?^!4W_P 771T4 <Y_PKW0?^?.3_P*F_\
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M_P# J;_XNNCHH YS_A7N@_\ /G)_X%3?_%T?\*]T'_GSD_\  J;_ .+KHZ*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5>XL+:[!$T$<@/]Y0:**B<(U%RS
M5UYC3<7=,QKSP-IMSDHC0,>Z'C\JR)/AR_FC9>#RN^Y.1117SV(X=RO$OFG1
M2?E=?E8[X8_$TU93^_4T;/P#808,S27#>YP/TK;M-'LK( 0VT:8[A>:**]##
M97@<'_ I13[VU^]ZF%3$UJOQR;+E%%%>H<P4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cvac-20231231x20f005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &! W # 2(  A$! Q$!_\0
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MCL93@YY!#=JKV'Q<\<?$B[UB^\&R>%](\/V%U):6K:\\C3Z@\9PS (P\M">
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M^;J4:4%I%<OO:WUT;M;7TMW%A\9BJTKN<_:_NK1L^76,'.^EENV[M6Z69O\
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M+A/=MMZM[^<FV_72_9!1117*>H%(>E+2'I0 VBBBH+"BBC.* "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M25K;I:6T,$?"1($4>P&*\W^"^C0K9W6I9)F+>2!V P#7IM0RD%%%%2,****
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M(>BIXAT6 2:]IL9$D*CFZ@ZX'JR\D>O(]*^'+A8]0NMVIQF[NE;#2W>9)..
MOS= *]2</K454CNMSR,LC3PN*>"Q,^6,M8OIZ7Z?UW/O']J[QQ-8_ [48O#
MM=4U/6G&FV=R"LL-N[YW2DC(RJ@D=\XKY$T2Q\0:#I,2ZQJ4\DD<8WSF,)G
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M#+&[L=0\0W.I>-=0M26 UB;=;,Q'.8NAKV*WT.WM;:.%(UBAB0)'#"H5$4#
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MJ"]M;:\4+=1QR#L9.&'T/4?A4.$6=$,35AUOZ_YGM0YHKR+2M>UG0@/L-_\
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M<)YEN3A+A.5;Z^AK\]Q."G0U6L>_^9^R83'T\5[KTEV_R,:BBBO./4"BBB@
MHHJOJ5V+#3[JZ(SY,328^@HO;4:3;LCFIVTCQQXZMO"^K:TNBZ-&-UQ*6V&Z
ME[0J_0'')S7M/PL^&NM?##5KO2[/4+?4?!$RM/;I,H^TPR$_=W ?.ON:\G^#
MWBOPAK_@JV\->+]%G+:M=RRP7TT!:*>1VP-D@Y4C 'X5]*>$O#%IX-T"UT>Q
M>9[6V!5#<2%WP3GDGZUZV5T(5&JVC>]TW=?W6NQY.>8BI13PSNEM9I.+M]N+
MWO?[MK]#750O2EHHKZD^'"BBB@ HHHH *S=?U^T\.:>UW=R84<(@^\Y]!3?$
M/B*T\-6#75VWLD8/S2-Z#_&O"/$?B2[\37[7-T_RCB.(?=0>@IB8OB;Q)=>*
M-2:ZN3A0-L<8Z(OH*3PYX;N_$^H+;6J\#F24_=C7U-/\,^&+OQ1?BWMEQ&.9
M)C]U!_GM7NV@Z!:>'+!+6T0*HY=R/F<^IIB%T#1(/#VEPV-N69(QRSG)8]S6
MC114E!1110 5'/\ ZIJDIDWW#0!XWX\>X.LV(U<W:^#C)<&[-B6#>=O&P3;?
MF\K'IWZT_1K_ .S0:M;^$K.VEM))8/L,VFHC1*,#S/,.<Y'S?>YKN;F98=K$
MA%9Y"??YJJV*VEE-,]K:0V[3'=*T,80N>Q;'4UP2PLG4<U+?[UI:R?;K;OJ>
MK'&Q5%4G';I]EZWNUWZ7OJM+'(7#>/XK!W7+3/%D@%&VMYP[8X_=Y]:;JS>.
M386HTV0RF]1[.Z$R!7LF)XN4[L-N1M/?;73>-=3O+/25:SM[J>4L<?9#@AL?
M*#[$\5R]_J.K_8+EX(->DFMVB'D/.(S*&&6VD#^'IFNBA0]C/FYV_)ZG!B\0
M\33]FH*.M[QT?H4]&LO&OAWP]-IL.D-;6&8VLQ"\<LEO&' D5@1R[)E\G/S%
MO:K'B$:5:Z2\EE+>1>*OG-DMJBK>/)GY0\:?*4SC.[C&:GMYEUC64M[CPYKE
MQ:O(JM=7EVWEQC;U*[AGGC SD<U/;^+8-&5TT_PA?6ELV52[CCC6.1LE5!.<
M\G'6NYS5[GDQP\DN6^GGK;TT1SWQ :\EO?";Z@(UOS:,;E8?N++N7<%]LYKU
M[P;QID?TKP_Q9J>KZKX@T:2_L!86ZP,J1R#$K.),,Q&>%/4#TKW'P<N-,C^@
MK)G<M#H****DH**** "BBB@ HHHH ***AO;R'3[62XN)%B@C&YG8\ 4 %W=P
MV-M)<7$BQ0QC<SL> *\2\=^.Y?%$YMX,Q:;&V44]7/\ >/\ A3/''CJ;Q3<F
M&'=#IT;?)'W<_P!YO\*YW3M/N-5O([6UB::>0X55_P ]*HD+"PN-3NXK6UC,
MLTAPJK7N7@CP9%X3LF+-YE[,!YKYX'^R*/!?@JW\*6>3B:^D'[V;'3_97VKI
MJ38)!1112*"BBB@ HHKEO%GCJVT!Q9V\7V_5W7<EHC8"#^](W\*_J>U4DY.R
M,YSC37-)FYJVL6>AV,EW?7,=K;IUDD/?T [GV%>=:SXXU7Q#F/30^C:>?^7B
M0#[3*/\ 97I&/<Y/TK'FCN=4OA?ZM<?;KT?<&,0P#TC3M_O'DU8R<YSSZUT1
M@H[GDU<1.IHM%^)6LK&"R5F@7+.27F8[GD/<LQY)JSUZ5R%QIR^'_&FDFPGF
MAM]2:;[5:,Y:%B%W;U!^ZV?2M#Q)H-UXCN+:UDNC;:,O[RX2!RLT[#[J;AT3
MN>YK4XD]'9&^01UX-59M3L[:YCMY;N".XD^[$\@#-]!6+;>#6T]PMEK.H6]F
M%PMJ\GF*G^Z6Y%68O!NDK!)'+:K=22X,MQ<?/*Y[$MUX[8Z5C-SO:"^\ZJ:I
MM7J-^B_X-OZ[%C7]?M_#MO;3W*.T4]Q';;UP%1G. 6/89K3(VL0>O2O+_'=E
M?W-F_A'3=1;5;V]4'[-/&&,$(.0\DG\(&.#U)K:U2RU7PKI*7']J7FHV2(J7
M@(#3(A&#)&<=5]/2A2D[7@U]W^9,HPCS-5$[>3^[;<[1G2-D,K&.(G#28SM'
MK]*SM?U@^'/^/F W"MS%-:D.D@]O2LW2]+T+4K7R[&[:XMF0;H1<%@1ZLI.>
M>]9>DZ4-7UN;2W:6VCMW\LI;OM1O?'8X]*BI*I!WBM#KPL*-:-IO4@TJ275O
M&0OKR\L["*6$(89IUC:+'W3SUSFO4C\,=+UNW$L-W%=RXSOAD5A^AJSI7@"W
MTMEMKK2K76]*EQB2]56EMN.02P^9?3N*S]7^ G@37'>334E\/ZA_#=:)=M Z
MGL< X/TQ23C+XM&=#52G=4DFEWNOT93U?PSJFBV,EO&[M PP4/-<]!XI%C(M
MOJL;6S]%FVDHWU]*Z'X9^!/'7@D>)G\1>(D\36DD9;3DN,M,I0'86/09&,@=
MZ^7_  =X_P!>\&?$*?5O&5WJ.L^&-0B8W")%YPBEY(**.% /'TKDKXNEA*D:
M<Y?%UZ'?AL!6S*A*K&%N7===;_Y'TJ;JQO[<AI8)X'&TJQ# @]L5A:S\-[74
M;>*\L8_[/DA8F*8Q;HMQZ'![^X]*]#T2Y\*VNC6FL16L96ZB6:$/%AR&&1QV
M-4-3UNYUN0/,ODPK_J[=>B#W]Z[HS<]CQJM&-!:O7L>41-XK\$G?<M+K%N."
MV2XX' 4#D9YZ]\5>N]1\/7VER:KJ&F&SN3+Y9B('FR,,-@$=NF:[34=3M](L
MY+J[E$,*#);N?8>]>,ZGJ4GB?4I;Z3Y4)(BB P$7/''J>YK4Y5KJR?5/$6JZ
M]>&[>YDM0/\ 5Q0.5"#^IK-D6[N)-]Q<37##G,CDUF:IXG&G7#6MI"MQ*G$C
MM]U3Z>].TSQ>9)TAU"!(5<[5ECZ ^XI\K(=2QU?ACQ7/X8O&$BO/I\I_>1@Y
M*'^\O]17J5M=6'B+3PT;17MJ_P#"PR!]1V->4/;A,DCM5KP;JJ:+XI0.WEVU
MTOE-SA0W\)/\OQI;#NIH]AT?Q!J_A?:MI(VJ:>.MC=/^\0?],Y#_ .@M^=>B
M>'/%FG^*(6>SE(EC_P!=;2C;+$?1E_KTKS7VJ">T$LT5Q%+):7L7^JNH#MD3
MV]Q['BIE!2-J5>=+1:KM_D>U45R/@#Q1?Z]%?VVH0QFZL)$C:Z@XCGW+N!"_
MPD#&1[UUU<S7*[,]BG-5(J40HHHJ30**** "BBB@ HHHH *<.E-IPZ4T)BT4
M451(T]:2E/6DJ2@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** *NIZ=;:M
MIUU97<*SVMS&T,L;#AE88(_*OS,^+?P_N?AAX^U/0Y=QBBD\RUEZ>9"W*$?A
MQ]0:_3TC-?/?[87PL'B_P2OB*QAWZIH@+N%&3);G[P_X"?F_.N_!U?9SY7LS
MPLWPOMZ/M(KWH_EU_P SIOV9/BD/B3\.+<74N_6-+Q:78)^9L#Y)/^!+^H->
MLW-M%=V[PRQK+$XPR,,@BOSG_9T^*#?"_P"(UG<SR%-(OB+2^7L$)^5_^ GG
MZ9K]&T=752K!E(!!!R"/6HQ='V<_)FN5XOZQ12;]Z.G^3/,/%?PRDM=]UI ,
ML7WFM2<LO^Z>X]JX!@58JP*L#@@\$&OH_ SFN9\5>!;+Q$#*@^RWN.)D'#>S
M#O7R^)RY2]^C]Q]W@\U<;0Q&J[_YGBU%7]9T*]T"[,%[%Y9_A<<JX]0:H5\]
M*+@^62U/J(RC-*47=,*S/%"&3PUJJCJ;63_T$UIUGZU/;&TELI;E(9KF*18U
M+ ,_RG.*B6L6;4])IHW_ -CW5[S7_A?96UUID;:382.+/4),;I7WL6 0\KM)
MZ]Z^@>E?/O[$I2/X036T3N\,&JW'E[SG:K$' ]LYKZ"K[#+TOJM.SOI_7W'P
MF:M_7JMU;5[7^_6^^X4445Z!Y(4444 %9'B7Q+:>&=/:ZN6RQXCB!^:1O0?X
MUJ2OY<3OC.U2<?2OG3Q!KUWXBU&2[NWRV<*@^ZB^@IH3%\0^(;OQ+J#75V^3
MT2,?=0>@J;POX6N_%-^(( 4A7F68CY4'^/M3O"OA6[\57XA@!2!>99R.$']3
M[5[MHFB6N@6$=I:1A(UY)[L?4^],0FAZ%:>'[!+2TC"H.68_><^IK0HHJ2@H
MHHH **** "F3?='U%/J.?[GXB@#SK6+L@6JYR^Z4\_[YZTZ&[\L#S'5&89!)
MQG\*R=56030S1'(:-B0>QW-5>VD1F&593QRW-6(Z0WLDL0(XR1T.*)(I;F,J
MK @MCEN@JA(4$.1,$5>22< #U-8^E^(8]4UV[M;2XAN;&U@C9KF([@9&)^0'
MH< 9X]:+"<E%I/J=7<PSI#& 2^T80Y_G6?;ZQ-9V\L$T*S(""JX&%Y]/UKG?
M$OC2[O;.\TS0[*2^G:)H#=AQ'#"Y!'WNI(ST%7+>ZBBT:PLO+<W%M!'"9/[[
M  $Y/KUI*TE= VU)Q:V,/X@7PN_$FBH <BV#[C[N:]A\'_\ (,C_ -T5X?XL
MC=/%>D^8VYVLU<^W[P\5[CX2&--C_P!T4F,W:***0PHHHH **** "BB@T 5[
MZ_@TRTEN;F188(QN9V[5X?XW\;S^*KKRXMT.GQG]W%GEO]IO>KWQ2\07=]KT
MVG,^VTMB L:]&. <GWKD],TNYUB]CM+2(RS2'  [>Y]!5(D33=-N-7O8K2TB
M:6:0X"K_ #/H*]S\&>"[?PI9_P ,U](/WL^/_'5]!2^#O!MMX4L\#$MY(!YL
M^.O^R/:NCZ4FQI!1112&%%%% !03BBO.O&?C274+ZYT'1KCRGA.V_O(S\\61
MGRX_]LCJ>P/K5QBY.R,:M6-*-Y%CQ?X[E-S+I6A.K7:';<WQ&Z.V_P!E1_%)
M[=!W]*Y*SLX[%'"%GDD;?)+(VZ25N[,>YI]M:Q6<"001B.%!A5'Z_4^IK#UK
M2_$EY<RG3==MM.MC@QQM:"1\XY!8GI^%=48I:(\.I4E-\TM?T.@HK#\(Z_+K
M>G.EZ$BU:TE:WO(4X"NIZ@>A&"/K6YFFU8F+YE=&;KFF2W\,4EJZ17MN_F0L
MXRI/=3[$4:#K UNP6X\DV\@9HI8F.=CJ<,,]ZO7#.D$C1\R!&*CWQQ65X/$8
M\.63(PD+J7=Q_$Y)+$^^<US[55;JG?Y6.OXJ#<NC27SO?\C9I1R125B:OXJM
MM.N?L4,<M_J;+E+2V3<WL6/11[FM9SC35Y,QA3G5?+!7?]?U<J>#8Q<R:IJ,
MD6RZFNI(7)'.$; &?3I73 _-@*S'^ZJDG\A7/^"M&NM(TZY>]58[N]N7NY85
M;<(RV/ESWZ5T<,\MM,LT$K02KT=#S65!25*-]_,WQ/(Z\K/2_3]"M8^$+@7,
ML^DZ"MO<S#$EPT0C!^OK6_X3^'<FAW3W-TWFW,C;W<]SZU);>/-4M0!-!%>J
M/XE.QO\ "I5^)D4UTD4T#6S-T$@QGZ&E-R>YV4(T8KW&7=>OGO=5-@&*V\ &
MX XWL>>:MV^GPI#T ..HX-<]KDS0:G_:<8+VEP!N8<[& QS[&K">)X"BA7#'
MH IR369UFEK^B3>./!VKZ%]LDLI9XC#]IB8A@#[CGGH<5Y;X>_9NTGP7H(@U
M.[FUAT.Y;=79($ _AQU;\:]IT"&2ULI+BX'EO,=^P]0.V:Q?$'B*U$IC9QZ5
MR5<+1KS4ZD;M=]ONV.VCC:^'ING2ERI[VW^_>WD>(^+O&G]C74Y-O<B41&*T
MDCVB&)P. XQD#'3'I7GGQ8^*OBWPI9S+I<8B47MN$OH ;J,J4SY:8'SEVX([
M5]'7?A*#4XS?Z=+&+P#_ %38Q*/[IS61:6ELD 2.TC@"ON,/E@;'[\=C[UW)
M.37+*UG]_D>-6FH*7/!2NK)ZZ/OIV^X^4(_VA?%GC6^_LG7O"AL$0^8&A@DC
M*G'W3G(/XUVOA?4#JUM(ZP26_EL4"R<$G'6O7_B!H4NN:"_V?FXMV\Y5 _UF
M!R/RKS#175U#'@MS76VGLCR;-0W.$L4VR2K+D2"1MV>N<\U/J(3R2!R<<5U^
MK^$8-5N&N+:7[)<'[_&58^I'K2:3X+ALKA+B\N/M;H<J@7"@^I]:NYRMFS!&
MZZ;:B7_6")=V?7%9UY$#$^>@&<^E:MS-D&L#4KC<ICSD-P1ZBLWN;4DSU[P-
M?SZEX9M)KC)8957/\:CH:WBRH"SG"*,L3V ZU6TQ433K58T\N,1*%3&-HP.*
M9JL3W=H+.+_77LB6J>V\X)_ ;C0BY/JCT+X8V1@\)074BXFOY'O'S_MGY1_W
MR%KK:BM8$M;:*",!8XE"*!V &!4M<<G=W/?IP]G!1[!1114FH4444 %%%% !
M1110 4X=*;3ATIH3%HHHJB1IZTE*>M)4E!1112&%%%% !1110 4444 %%%%
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M<9X8^"W@;P@ZR:5X7TZUF7I,80[_ /?39-=KM'ITI:*XVW)W9[$(1IKE@K(
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M6/%OB[1+0)&VCW.+5U;/VJW'RF4?\#!_!EKO_%^B7'B7PQJ>E6NHR:3/>P-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Y7PE\;="\->-/B'IOB[Q;;64EOKA2QMK^?!C@\B(X0'HNXM^.:]RKSCX=>
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ME/H^OZ%>:K>2V5I!K.FO;/*\<!F9@#_!M4_-ZC%<_P#M<$#]G;QD3P/)A_\
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M:IJ^KZ=';W<4NF21QRRSV[1Q2EXPX,3D8D #8)7H00>16I7RGXAGUZ"_\?\
MB87UW<ZGX,U?1=:EAA:1$FA73H1>QB(GA6B>9MA'W@O&17,^+=4U[6?"WASQ
M;<WRV?ACQWXDN+^^DU6[N+:SBL! 8],AGDB^:*)PB.<84NX#'!H ^TJ*^)9'
MDG^'K6S^/]"/A]/%1CL;:>XU'^Q)%%K\]D^H'#>4)"9$?<8PXV<X 'O7[,.L
M1>(/A?/$EM<PVMIJ5W9)YNIMJ-O(BOUM;EE5I+?YBJ%LD!2,G&: .LM/B[X;
MU#^PS:W,UPFLZI<Z/9R) P5KBW\[S0<@8 ,$HW="1[UVE?#_ (!\%^'+[0_
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MI.)K5]0G69U9UAEVL6\G:64KD9W$#K0!]5T444 %%%% !1110 4444 %%%%
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M?&_BCPCH6F^([;2$U34?$D5U?)I\<SB&RN5C@$:M\N[#!23G(R>N* /1M-^
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MS)XE^-_Q(U3Q)XWN/"VGZG-;>&M4ETRTTNVT:*>TOC"J-)]HNFE5HBY8@;0
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M'VJ>,SKESKU[)$VFVT<CQ-!IL0<&6&((H.3(@+%RS94#( Q7S7/XP\6_$Y/
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MQR/$CR1YV.R@E<\'![5)10 4444 %%%% !1110 4444 %%%% !1110 4444
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MFF:'XI_M'PVUMXIT35;72$T&.]$AO);KROLS1R[!\K^8>=O'EOZ4 ;]]\ /
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MKDHF[ ZCL* /;-!^!'@CP_#JD<6CM??VG9_V==/JMW-?.]KS_HX:9W*Q\GY
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M;MV..F.]=-X7^'Z^&O''C/Q&+YKAO$<MK*;8Q;1;^3 (L!LG=G&>@QTKKJ*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M4\:_#'7]9U?XR7-G:0N/$GA:#2M,<S*IEG6*Z5D;^Z,RIR>.3Z5SGC[X!^(?
M'%EHVE1BWT^V7P!=^'9KEI05@NY#:E%VKR4/DL"5[?45]'44 ?-'AOX.^(M3
MOVN=5\%+!/9Z'>6$3>(_%MUJL,\T\:QF*.,.0D#!?F9@'QMPHP:S_#OP<\='
M3_$&GMH#1>%I]#:R7PGXJ\0G4[>>Y+H56WG4&6"$*KCELY*':-N:^IZ* /ES
M3OAM\7-/\/\ BE="DU'2+66"RCT_2M?UJ'4[Y'2?=<&"[9'$0,7RQ^87P_S8
M6N3\5?"CQ3I:>+?%7B!GT/3?[.TIK6X\3Z^=09[FUU$3B*Z=05CC<D+\@*+G
M<3G(K[/J.YMHKRWD@GB2>"52CQ2*&5U/!!!X(/I0!\=^)]*UW]I3Q_XWT^"Q
MT_1;D>$+*&/R=32\43+J/VA(IYH,A-_E' 4EE4[N,@5ZQ\(_AWJ]I\0Y?$NL
M>%[O1&M],:QAN-7\4SZQ=NSR*[H@+F-(OD!R?F)QP!FO7]#\.:3X8M&M='TN
MRTFU9BY@L;=(4+>NU0!GWK1H \8UKP_XU\#_ !/\8>(_#?ANT\6V?BFSM$\N
M6_2U>RN+='C DWCYX6#AOERP.[Y3FJ'P=^"6L_#6_6"Z,%Y#;^"[#1$O8G #
MW23W<DR(IY6,>='MSVQZ5[M10!Y1X!\ :UH/[,VG^#KRWCCU^'PZ^GO LJL@
MF,+*%WCC&2.>E<!#\'?%UBUW:R>&M,UZRU7P%IN@W$%_?;+>.ZM1+OAEV_.5
M?S<+)'G:1DU]+44 >'_ CP/XT\,>*M5N-435-+\*/8106ND:[K*:O=1W <EF
MCG ++"$PH1G8D\X7O'X\^%/B'7?^%Z&SLX9'\5Z):V.EEIU4S2);3(RMG[@#
M2#D\<FO=** /GKXF?![Q1XCDU(Z;90.LWPVOO#D>;A4_TV0Q[(_93M/S=!4O
MB7X MX3_ .$.\9?#KPYI&G>-M"$,-[8V\45M%JMHP5;B%WV[0XY=)#R"N,X8
MU] 44 >#/\!]1\2Z=\2H-0<:/J&H>*!X@\.:I#('DM)TMK=89\#IAXW5E/52
MPZ-7&>#/V?O'FO\ A[X;:!XMN)?#-KH,NIZ[J-WH-['YC:G-=RFW6+*MA5CF
MD?)'\0'45]644 >">#_ASXU^"7BGQ[)X<AN/'&C:U;PZM;?VSJ<<5PVJ B*:
M-W" !7B$;[MN,QD'DU[RA)12PVL1R,YP:=10 4444 %%%% !1110 4444 %%
M%% 'R7\-O#OB_P"(GPVTCPS#H%E9^'(_&%UJC^(Q?*6\FWUB:<JL(&\3L\>S
M/W0ISG/%=9;?!?Q3!\'-,L(;2R7Q)HWBZ7Q-!I\\X$%XHOY9UC:10=I>.0$$
M@[6VYZ5] V5C;:;;B"TMXK6 ,S"*% B@LQ9C@<9)))]22:GH ^:O%_PG\=?$
MWQ!JGC6XT:R\.ZI9II2Z7H-S?+-]L-G=M=/]IEC!5=Y<HF-VW&3UQ4'B_P"&
M?Q#^)MY\0-6N?#5EX=N-0TW2(]+L[C4DF:>6SO'N&29XP0F[(4$9 !!/<#Z<
MHH ^:O&/PQ^('Q7U7Q;JU[H=CX;>ZTC28=,LKJ_6XWSV5^]V8[@Q@@*Y(7*[
M@ <]<BKOQ*\#_$7XT:/)->^'K'PTNE7=A?V&E'4_],OI8)6>4-=P_P"I0JV(
M\9(<;CCI7T110!X[\%/A_J.A>*O$/B+5/#MQH<U[;6]E$^I^(9M7OIDC+L?,
M9G:-$#2':%)/WB3R!7.?$3X3>+-3UWQMJ^F:=#>F;Q'X?UJPMC=I$UY'9"$S
M(&/"-E& W<'BOH6B@#YEU[X5^/)?B#>:GX;T27PK=WVKP7TVIV6O!]+N(=T9
MD-WI[A@]QL5D)C !8*P<8KT[XT^#-;U^?P=K_AZV@U/4O#&KC4AI=S,(5O(V
MADA=5<@A9 )=REN,K@D9S7IE% 'S=KOPJ\=^)K?Q[XVBTJST;QG>7&FWOA_1
MGO%E$4MB'V&>51LW2B61#C("%02>:K?"_P#9SU_P+\1]$9U@_P"$1L=,AU20
M"8,\FO?9C:RL5]"A>3=_>;VKZ:HH ^?]"^$'B33OAS\$-'>Q@CO?"VLPWNJ1
MK.FV*-;>Y1BIZ.=TJ<#KDUUWQ1\*^(D^('@[QQX<TR+Q!-HD-[97.D27*V[R
M17 C_>1._P H=6B7(8C*L><CGU*B@#YM\%?"7QK_ ,)5X6UO6M&L]/>#QEK&
MO7D$%XDRV\%S;.D14X&YMS ' ]3TJOXZ^&7Q#.B?%/PGHOAZRU&P\6:L=6M=
M9DU)(EB1U@$D+Q$;O,'DL%(^4[@21@@_35% 'Q7\8?$5UX2\$_'#PAIJ:-KL
M>MZG<3_:)-22*YMI[I(@;9[5AYDDF<>4R JP9.1M-?6V@7NM2:OJ5E?:1'9Z
M3:QVXL+];H2/=DIF4-&!F/8P Y)W9SQ5FY\)Z'>:U#K%QHVGSZM" (K^2U1I
MT Z;9"-P_ UJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XK\
M8O"_CW6/'NEW.BIJ%YX7%@8I;71=7CTJX%UYF=TTQ4NT.P@;8SD$$X.17F&C
M_ CQGX?\">#+.Y\,3W.MZ5;WT#:EX:\3-I^H6KR7<DJJ)6.R>!U920X+!ADJ
M<FOKFB@#S6R\)>*I/V>Y_#>N75MJGB^;0)[*:: +'%+</"RJ,@*!R0"V #@G
M Z5C>&_AKK>F?$/X:ZI-9PII^A>#Y](NF6528KEC:;54=QB&3YAQP/6O8Z*
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cvac-20231231x20f006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %; Q8# 2(  A$! Q$!_\0
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M,R =/>KC3G).44VD83Q%&G.-.<TI/9-I-^BZG94445!N%%%% !1110 4444
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M=5Y)I6.[+,!+ 4Y0E/FOUM;I:[\WU?4****XSV HHHH **** "BBB@ HHHH
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MND8'<3R><@^]>\7.F6=[+')<6D$\D6=CRQJQ3Z$CBI(;*WMRAB@BC*)Y:%$
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MVT41 =P5Y8]R!6DNLZ1XDU7PU_PL769+71Y?"UK=V9GO'M8+BZ8GSG+JR[I
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M_P!_;7_X]1_PDVI?]"KJO_?VU_\ CU=#167LI_\ /Q_A_D;>VI_\^E_Y-_\
M)'/?\)-J7_0JZK_W]M?_ (]1_P )-J7_ $*NJ_\ ?VU_^/5T-%'LI_\ /Q_A
M_D'MJ?\ SZ7_ )-_\D<]_P )-J7_ $*NJ_\ ?VU_^/4?\)-J7_0JZK_W]M?_
M (]70T4>RG_S\?X?Y![:G_SZ7_DW_P D<]_PDVI?]"KJO_?VU_\ CU'_  DV
MI?\ 0JZK_P!_;7_X]70T4>RG_P _'^'^0>VI_P#/I?\ DW_R1SW_  DVI?\
M0JZK_P!_;7_X]1_PDVI?]"KJO_?VU_\ CU=#11[*?_/Q_A_D'MJ?_/I?^3?_
M "1SW_"3:E_T*NJ_]_;7_P"/4?\ "3:E_P!"KJO_ ']M?_CU=#11[*?_ #\?
MX?Y![:G_ ,^E_P"3?_)'/?\ "3:E_P!"KJO_ ']M?_CU'_"3:E_T*NJ_]_;7
M_P"/5T-%'LI_\_'^'^0>VI_\^E_Y-_\ )'/?\)-J7_0JZK_W]M?_ (]1_P )
M-J7_ $*NJ_\ ?VU_^/5T-%'LI_\ /Q_A_D'MJ?\ SZ7_ )-_\D<]_P )-J7_
M $*NJ_\ ?VU_^/4?\)-J7_0JZK_W]M?_ (]70T4>RG_S\?X?Y![:G_SZ7_DW
M_P D<]_PDVI?]"KJO_?VU_\ CU'_  DVI?\ 0JZK_P!_;7_X]70T4>RG_P _
M'^'^0>VI_P#/I?\ DW_R1SW_  DVI?\ 0JZK_P!_;7_X]1_PDVI?]"KJO_?V
MU_\ CU=#11[*?_/Q_A_D'MJ?_/I?^3?_ "1SW_"3:E_T*NJ_]_;7_P"/4?\
M"3:E_P!"KJO_ ']M?_CU=#11[*?_ #\?X?Y![:G_ ,^E_P"3?_)'/?\ "3:E
M_P!"KJO_ ']M?_CU'_"3:E_T*NJ_]_;7_P"/5T-%'LI_\_'^'^0>VI_\^E_Y
M-_\ )'/?\)-J7_0JZK_W]M?_ (]1_P )-J7_ $*NJ_\ ?VU_^/5T-%'LI_\
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MA_D'MJ?_ #Z7_DW_ ,D7_P#A)M2_Z%75?^_MK_\ 'J/^$FU+_H5=5_[^VO\
M\>JA_:5U_P _$G_?5']I77_/Q)_WU1[*?_/Q_A_D'MJ?_/I?^3?_ "1?_P"$
MFU+_ *%75?\ O[:__'J/^$FU+_H5=5_[^VO_ ,>JA_:5U_S\2?\ ?5']I77_
M #\2?]]4>RG_ ,_'^'^0>VI_\^E_Y-_\D7_^$FU+_H5=5_[^VO\ \>H_X2;4
MO^A5U7_O[:__ !ZJ']I77_/Q)_WU1_:5U_S\2?\ ?5'LI_\ /Q_A_D'MJ?\
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ME=?\_$G_ 'U1[*?_ #\?X?Y![:G_ ,^E_P"3?_)%_P#X2;4O^A5U7_O[:_\
MQZC_ (2;4O\ H5=5_P"_MK_\>JA_:5U_S\2?]]4?VE=?\_$G_?5'LI_\_'^'
M^0>VI_\ /I?^3?\ R1?_ .$FU+_H5=5_[^VO_P >H_X2;4O^A5U7_O[:_P#Q
MZJ']I77_ #\2?]]4?VE=?\_$G_?5'LI_\_'^'^0>VI_\^E_Y-_\ )%__ (2;
M4O\ H5=5_P"_MK_\>H_X2;4O^A5U7_O[:_\ QZJ']I77_/Q)_P!]4?VE=?\
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MU7_O[:__ !ZNAHH]E/\ Y^/\/\@]M3_Y]+_R;_Y(Y[_A)M2_Z%75?^_MK_\
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M]]&F44 =K#S#'_NC^5/J.#_41_[H_E4E !1110 4444 %%%% !1110 4444
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M^9K[3Q&_Y)R/^*'Y,_E%_P"\S]7^9Q=%%%?R@= 4444 %%%% !1110 4444
M=3\,_P#D<;/_ '7_ /037MM>)?#/_D<;/_=?_P!!->VU_5?A=_R)*G_7R7_I
M,#@K_$%=/H/_ "#4^I_G7,5T^@_\@U/J?YU^P',?+_[?7@[6/'UG\.]!T&R>
M_P!4O-3G2*).@_=C+,?X5 Y)/2O5/V<_V>=(^ GA06\6R]\0WBJVHZF5YD;_
M )YIZ1KV'?J?;UEH(WE25HU:5 0CE1E0>N#VS@?E4E.XK:W"N=\2?\?<7^Y_
M6NBKG?$G_'W%_N?UI#,FBBB@ HHHH **** (Q;1"X:<1()V4(90HW%1T&>N/
M:A+>**:25(D263&^15 9\=,GOBI** ,76?!^EZSH.M:5]FCLH=7@D@NI;2-8
MY'#J06) Y//4U+H_A?2]#TB/3;6QMDM1"D,BB%1YP50H+X'S$@<YK5HH K7-
MC'/'+LQ;SO"T"W,:CS(U(_A/L>0.F:S_  YX2TWPOX9TW0K6$26-@BK%YX#L
M6!SO8GJQ8DY]36S10!2_L73OMK7G]GVGVMV#M<>0OF%AT);&<CUIZ:38Q7DU
MXEC;)=S+MEN%A422#T9L9(^M6J* *EGI%AIVS[)8VUKL#*GD0JFT$Y8# XR>
M3ZTMCI5CIGF_8[*WL_-;?)]GA6/>WJ<#DU:HH ADL[>:XAN)((GGASY4K("\
M>>#M/49]J@?1=.EO&NWT^T>[;:6N&@4R';]W+8SQVJ[10!5&EV2Z@U^+.W%^
MR[#=")?-(]-^,X_&HX="TRV,AATVSB,D@E<QVZ+O<<AC@<D>M7J* *_]GVNP
M)]FAV"3S@OEC DSG?_O9YSUIATBP.H?;S8VQO]NW[5Y*^;CTWXS^M6Z* *EC
MI%AI;3-96-M9M,VZ0V\*QESZM@#/XU;HHH **** "BBB@#M(/]1'_NC^525'
M!_J(_P#='\JDH **** "BBB@ HHHH **** "OG[]J#XL2:)9#PGI4VR\NX]U
M[*AYBB/1/8MW]OK7M'C'Q/;>#?#&HZS=D"&TA,FW^\W\*CW)P/QK\^]=UN[\
M2:S>:I?R&6\NY3+(Q]3V'L!P/I7Q7$V9O"T%AJ3]Z>_DO^#M]Y^B\&Y.L=B7
MC*RO"GMYRZ?=O]Q1 P*OZ%H5]XFU>UTS3;=KJ]N7V1QK^I/H!U)JA^OL*^S/
MV>/A(G@/P^NK:A$/[=U&,,^X<V\1Y$8]^Y]^.U?GV4Y9/,\1[-:16K?9?YOH
M?JV>YQ3R;"NL]9O2*[O_ "77[NIM_"+X-Z9\+],#@+>:U.@%S>L/_'$]%_GW
MKT2BF2RI!$\LKK'&BEF=S@*!U)/85^W8?#TL+35&C&T4?S=B\76QM:6(Q$N:
M3W?]=!]<WXR^(_AGX?6GVCQ#K=II2$959I/G?_=0?,WX"OF#X\?MJ/;SW.A?
M#YD8KF.;6W7<,]"(5/!_WS^ [U\AZOK%_K^H2W^IWD^H7LIR]Q<R%W;\37UN
M#R6I62G7?*NW7_@'Y/G''&'P4G1P4?:277[*_P _E9>9]S^)?V\O!6F2-'I&
MEZGK9'_+0JMO&?H6RWYJ*XV;_@H/*9/W7@M0F>CWV3^B5\?45]##)\'%6<;^
MK9^=U>-,YJRO&HH^2BOU3?XGVQH__!0/1YI%75/"5[:IGF2UN4EX_P!TA?YU
M[!X%_:9^'GQ DC@L=>CL[UR MIJ*_9Y"?0;OE8_0FOS'HQFL:N286:]R\7]_
MYG7A..LUH27MN6HO-6?WJWY,_8H$, 0<@\@BEK\VO@Y^U+XM^%4\-I/</KWA
M\$!["\D+-&O_ $R<\J?;D>U??7PV^)V@_%;PY'K.@78GA)VRPOQ+ _\ <=>Q
M_0]J^3QN75L$[RUCW_K8_7,EXDP>=+EIOEJ+>+W^7=?TT;FMZ'8^(]+N-.U*
MV2[LIUVR12#((_H?>OB_XU?!JZ^%^JK-;&2ZT"Y;]Q<,,F)O^>;GU]#WK[?K
M,\2>';'Q7HEYI.I0B>SND*.IZCT(]"#R#7QF;Y32S.E;::V?Z/R/U/(<]K9-
M7OO3?Q1_5>:_'8_.>N\^#GQ.N/ACXKCNBS/I-R1%>P#H4SPX']Y>OTR*R/B+
MX%O/AUXKN]&NR9%C.^"?&!-$?NM]>Q]Q7-5^-0E6P&(YE[LX/\4?T-.&&S3"
M\K]ZG47WI_U\F?I-:W45[;17$$BRP2H'213D,I&01^%2UX%^RE\0FUC0KGPQ
M>2[[G3AYEJ6/+0$_=_X"?T(KWVOW3 8R&/PT,1#K^#ZH_F;-,!4RS%SPM3[+
MT?==']P4445Z!Y04444 %%%% !1110!SWB7_ (^8?]P_SK(K7\2_\?,/^X?Y
MUD4 <Y\2/^2?>)/^O"7_ -!KXO'2OM#XD?\ )/O$G_7A+_Z#7Q>.E?EO%_\
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MG7[ <QHT444 %86O6LT]U&T<3R )@E1GO6[10!Q_]G77_/O)_P!\T?V==?\
M/O)_WS7844 <?_9UU_S[R?\ ?-']G77_ #[R?]\UV%% ''_V==?\^\G_ 'S1
M_9UU_P ^\G_?-=A10!Q_]G77_/O)_P!\T?V==?\ /O)_WS7844 <?_9UU_S[
MR?\ ?-']G77_ #[R?]\UV%% ''_V==?\^\G_ 'S1_9UU_P ^\G_?-=A10!Q_
M]G77_/O)_P!\T?V==?\ /O)_WS7844 <?_9UU_S[R?\ ?-']G77_ #[R?]\U
MV%% ''_V==?\^\G_ 'S1_9UU_P ^\G_?-=A10!Q_]G77_/O)_P!\T?V==?\
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M:_X22'_GD_YBC_A)(?\ GD_YBN?HH Z#_A)(?^>3_F*/^$DA_P">3_I7/T4
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M!**/[!PW\TOO7^0?Z_YI_P ^Z?W2_P#DC[[_ .&I_AE_T,,G_@#/_P#$4?\
M#4_PR_Z&&3_P!G_^(KX$HH_L'#?S2^]?Y!_K_FG_ #[I_=+_ .2/OO\ X:G^
M&7_0PR?^ ,__ ,11_P -3_#+_H89/_ &?_XBO@2BC^P<-_-+[U_D'^O^:?\
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M#(T<BLCJ2K*PP0?0BFU\LTT[,T.I^&?_ ".-G_NO_P"@FO;:\2^&?_(XV?\
MNO\ ^@FO;:_JKPN_Y$E3_KY+_P!)@<%?X@KI]!_Y!J?4_P ZYBNGT'_D&I]3
M_.OV YCY%_X*5_\ (G^"?^PA/_Z+%>4?LB?LH2_%2]@\6>*;=XO"%O)F"V<$
M'47!_P#10/4_Q=!WK[-^-_P'L/CEJ'A*+69RNBZ/=R7=U:ID-=94!8\]ER.>
M^.!UKTVPL+;2K&"SLX([6T@0110Q*%1% P  .@ JKZ$VU'VUM#96\5O;Q)!!
M$H2.*-0JHH&  !T %87B3_C[B_W/ZUT5<[XD_P"/N+_<_K4E&31110 4444
M%%%% !1110 4444 -DC66-XW7=&ZE&7U!&"/RKQ(?!GQHOA _#U?$6DCP"28
M?M/V63^TQ9;]WV4?-Y><?+YF,X[9KV^B@#RO7/@_>ZCX?^(FFVUY;0CQ)>V]
MQ:[E.($B2)=K^I_=G&/458L_ 7BO1?$.OVNGZCH\OA#Q!?2WUXMS#*+Z RIM
ME2-E.ULGD,PR.G->F44 >+Z)\'/%7EZ)I^MZSI$VD^&=.NK#1S8VSI/.98#
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M137!6'/_ #S7Y4_0"OJS]H_X@CP9X#FL[:79JFJYMH0I^94Q^\?\N/J:^+
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M^>S_ )"@#GZ*Z#_A&XO^>S_D*/\ A&XO^>S_ )"@#GZ*Z#_A&XO^>S_D*/\
MA&XO^>S_ )"@#GZ*Z#_A&XO^>S_D*/\ A&XO^>S_ )"@#GZ*Z#_A&XO^>S_D
M*/\ A&XO^>S_ )"@#GZ*Z#_A&XO^>S_D*/\ A&XO^>S_ )"@#GZ*Z#_A&XO^
M>S_D*/\ A&XO^>S_ )"@#GZ*Z#_A&XO^>S_D*/\ A&XO^>S_ )"@#GZ*Z#_A
M&XO^>S_D*/\ A&XO^>S_ )"@#GZ*Z#_A&XO^>S_D*/\ A&XO^>S_ )"@#GZ*
MZ#_A&XO^>S_D*/\ A&XO^>S_ )"@#4@_U$?^Z/Y5)3478BKZ#%.H **** "B
MBB@ HHHH **** ,#QWX3M_''A+4M%N0 MU$51S_ XY5OP(!K\_=5TNZT/4[K
M3KZ(PWEK(T4L;#HP.#7Z0U\X_M2_"E[R,>,=+@W20H$U"-!RR#[LN/;H?;'I
M7Q'$^6O$T5BJ2]Z&_G'_ (&_I<_2>#,X6#Q#P59VA4V\I?\ !V];'S&"5(92
M58'(8'!!]17VO\ _BQ'\1?#2VEY(!KVGH$N%)YE7HLH^O?T/UKXGK5\+^)]1
M\':Y:ZMI4YM[RW;(/\+CNK#N#W%?!Y/F<LLQ'/O!Z27Z^J/T_/\ )H9SA?9[
M3CK%^?9^3Z_?T/T6IDT,=Q$\4J++$ZE61QE6!Z@CN*XKX6?%?2?BAHXGM&%O
MJ,*C[58N?GB/J/53V-=Q7[90KT\1356E*\7LS^;\3AJN$JRH5X\LENF?'/QX
M_8KDEGN==^'R)AB9)M#=MN#U)A8\?\ /X'M7R+JNDWVA7\MCJ5G/87D1VO!<
MQE'4^X-?L!7,^,_AKX7^(5KY'B'1+35% PKS1_O$_P!UQ\P_ U];@\ZJ44H5
MUS+OU_X)^49SP/A\9)UL#+V<GT^R_P#+Y77D?DU17WCXE_8+\&ZE*TFCZOJ>
MBY_Y9L5N(Q] V&_-C7&3?\$^+@2?NO&<;1YZO8D''X/7T$,XP<E=RMZIGYW5
MX,SJE*RI*7FI+]6G^!\@T$XK[5T;_@GWI43JVJ^+KRY7/,=I:K%Q_O$M_*O8
M? O[,7P[\ 2QW%EH27UZA!%WJ3?:'!]0#\H_ "L:N=X6"]R\GZ?YG9A.!LUK
MR7MN6FO-W?W*_P":/BSX.?LO>+?BO/#=26[Z'H!8%]0O$*EU[^4AY8^_ ]Z^
M^_AI\+] ^$_AR/1]!M?)BSNFG?F6X?\ ONW<_H.U=8JA0   !P .U+7RF-S&
MMC7:6D>W^?<_7,DX;P>2KFI^]4>\GO\ +LOZN%4M:UFS\/:5=:EJ$ZV]G;1F
M261N@ _K[5)J.I6ND6,][>W$=K:0(7DFE;"JH[DU\;?'3XVS?$F__L[36D@\
M.V[953\K7+C^-AZ>@_&OCLUS6EEE'FEK-[+O_P  _4,CR2MG.(4(Z4U\4NWD
MO-]/O.3^*/Q!N?B5XNN=7F#16X_=6L!/^JB!X'U/4^YKDJ*[+X4?#B[^)GBN
M#3HE9+&(B6]N!TCBST_WCT'_ -:OQ=*MC\1_-.;_ !?]?(_HEO#Y9A?Y:=-?
M<E_7S9[E^R;\/FL-,N_%=Y#MEO!Y%GN'(B!^9A_O$8^BU]#U7L+"WTNQM[.U
MB6&V@18XXU& J@8 JQ7[GE^#C@,-##QZ;^;ZL_F?-<PGFF,GBI]=EV2V7]=0
MHHHKT3R0HHHH **** "BBB@#GO$O_'S#_N'^=9%:_B7_ (^8?]P_SK(H X[X
MR_\ )(_&7_8*G_\ 0:_-T=*_2+XR_P#)(_&7_8*G_P#0:_-T=*^WR#^#/U_0
M_"_$+_?*'^%_FPHHHKZD_* K4\,:79ZUXAT^QU'4H]'L9Y0D]_,I98$[L0.M
M9=!.*35U9%P:C)-JZ73N>M_$/3]+NY?#NAZ9XJT&+PM;7!M[=+::6:2'>1YE
MU<$QKDM@9V]   .*\INHEM[J:))5G1'95E3[K@' 8>QZU#D8SGBES65*G[-<
MM[G5BL0L3-SY4GY7VM9+T70**,T5L<04'I10>E S]-_ O_(D>'?^P=;_ /HM
M:\Y^+/\ R-$?_7NG\S7HW@7_ )$CP[_V#K?_ -%K7G/Q9_Y&B/\ Z]T_F:_D
MSQ0_Y$<O^OD?U/[*R_\ AP_PK\D<71117\CGL!1110 4444 %%%% !1110!U
M/PS_ .1QL_\ =?\ ]!->VUXE\,_^1QL_]U__ $$U[;7]5^%W_(DJ?]?)?^DP
M."O\05T^@_\ (-3ZG^=<Q73Z#_R#4^I_G7[ <QHT444 %%%86O7<UO=1K'*R
M IDA3[T ;M%<?_:5U_S\2?\ ?5']I77_ #\2?]]4 =A17'_VE=?\_$G_ 'U1
M_:5U_P _$G_?5 '845Q_]I77_/Q)_P!]4?VE=?\ /Q)_WU0!V%%<?_:5U_S\
M2?\ ?5']I77_ #\2?]]4 =A17'_VE=?\_$G_ 'U1_:5U_P _$G_?5 '845Q_
M]I77_/Q)_P!]4?VE=?\ /Q)_WU0!V%%<?_:5U_S\2?\ ?5']I77_ #\2?]]4
M =A17'_VE=?\_$G_ 'U1_:5U_P _$G_?5 '845Q_]I77_/Q)_P!]4?VE=?\
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M]WY=E\WY%%%%?6GP84444 %%%% !1110 4444 <]XE_X^8?]P_SK(K7\2_\
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M* "BBB@ HHHH **** / ?CYHT.O?%GP3:3^#3X[C.E:@PTK[4EN VZ+$A=V
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MI,(IUW*'1@R-CU5@"/<4V70].FU&?4)+&![Z>V^QRW!3YW@R3Y9/]W))Q[T
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M_P#@,_\ A0?#>KX/_$JO?_ 9_P#"CGCW#V-3^5_<?I-X%_Y$CP[_ -@ZW_\
M1:UYS\6?^1HC_P"O=/YFO2/!"-'X*\/JRE673[<%6&"#Y:\&O-_BS_R-$?\
MU[I_,U_)WBA_R(Y?]?(_J?V+E_\ #A_A7Y(XNBBBOY'/8"BBB@ HHHH ****
M "BBB@#J?AG_ ,CC9_[K_P#H)KVVO$OAG_R.-G_NO_Z":]MK^J_"[_D25/\
MKY+_ -)@<%?X@KI]!_Y!J?4_SKF*Z?0?^0:GU/\ .OV YC/\1^ M$\6:UH6J
M:M9K>W.B2O<60EY2.5E"[]O<@#CTSFNAHHH *YWQ)_Q]Q?[G]:Z*N>\1(S7<
M9"DC9V'O0!D44[RI/[C?]\FCR9/^>;?]\F@!M%.\J3^XW_?)H\F3_GF__?)H
M ;13O)D_YYM_WR:/*D_N-_WR: &T4[R9/^>;?]\FCRI/[C?]\F@!M%.\J3^X
MW_?)H\I_[C?]\F@!M%.\J3^XW_?)H\J3^XW_ 'R: &T4[RI/[C?]\FCR9/\
MGFW_ 'R: &T4[RI/[C?]\FCR9/\ GFW_ 'R: &T4[RI/[C?]\FCRI/[C?]\F
M@!M%.\F3_GFW_?)H\J3^XW_?)H ;13O*D_N-_P!\FCRI/[C?]\F@!M%.\J3^
MXW_?)H\J3^XW_?)H ;13O*D_N-_WR:/*D_N-_P!\F@!M%.\J3^XW_?)H\J3^
MXW_?)H [*#_41_[H_E4E,@XAC_W1_*GT %%%% !1110 4444 %%%% !1110
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MT45K&$8*T%805T^@_P#(-3ZG^=<Q73Z#_P @U/J?YU8&C1110 4444 %%%%
M!1110 4444 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO8Z**0PHHHH **** "BBB@ KY]^$_P"S?%I?Q.\2>//$D"37T^I3RZ7:-AA
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MK34/L>HZN+K[4L(((\P1@(<' X.<#-=YXYT74?%GPXU#38[:*WU.[@C'V?S
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cvac-20231231x20f007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &9 G8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ I#2TA&: .&\8_&WP5X!UVRT;7]?M=-U*\($%O*V&
M?)P,?C7;0S)<1))&P9'&58=Q7Q)_P4Q\":(_A?P;XH-A'_;L&O6<"7HSO"&9
M,K]*^RO#)QX<TXGC]PG\A0(U:*:3D=0*0-C^+]*!CZ*8,EOO9'IBG Y)YH 6
MBBB@ HHHH **** "BBB@ HHHH **** "BBF/G;QS0 ^BL'Q%XLL?#<*&ZE+3
M/]R",9=OH*Y_P5XW?Q!>^()9G:&SLVC"+,FTJ"I)S6#KPC/D;U-XT)R@ZEM$
M=]17&Z;\2=-U'45M@TL*N=L<LR;4D/H#WIVH_$K3-/U1[/;/</&0LC01[E0^
MYH5:F^HW0JIV<3L*2N2'B<W/BBWMX;I5MFM_.,3+@_6J=U\6=&M97R\I@C.U
M[@1YC!SC[U)UX*^NPE1J/9'=45RNJ?$'2M,^SJTS2O<KOC2)2S,,9Z59TKQK
MINJZ9+?),88H<B191M9,>HJE6@^HG2J)7L=!FEKC+3XH:1>Z@EEYCVTDO^JD
MF7:C_P"Z>]1>*_B38Z)'=00O)<7<:$_N$W;#CO4^WIVO<I8>JWR\IW%%<G\-
M=?NO$GA*WO[IR\TA;DKCO4NN^.+#P]?0VES(WVF6,ND2+N9L>E5&K"4.>^A+
MI24W!:M'3T5P47Q;TA[-Y@T\C1L1)&D9+QCU8=JV[GQCI]MHD>JM/FWD V;1
MEF)[ 4E7IRV8Y4*D?BB=%17,Z!XZL/$*W B\V"> ;GAN$V,%]<5/)XSTN+07
MU=[E19(=ID]\XI^VA:]R?93[&]17*ZY\0],T.:.)W:>:10ZPP+N<@\YQ4Z^.
M--_LA-0EF:"%N LB88GTQ1[:G=IO8?LJEDTMSHZ6N8\.^.]/\1WKVD'G0W"#
M=Y<\>TD>HIGQ"UZY\/>%;Z^M7"2Q[0K,.!DXH=:"@YWND$:,W.-.UF_U.JHK
MRCPYX@UK49;&:7Q%8LCD%X0PW'VKI;GXFZ);7TEHUT?M*/L>-4+%364,52G%
M2O:YK/"U(2<;7:WLGIT.RI*Q['Q7IVH6TT\5PNR$%I-QP5 ]:XGQ%\8X-,U7
M1HK6)KBSO9"&F /"CTJYXBG!)M[D0H5*DN5+4].I:\Z\0?$!M'\2:3GS'L;J
M)V,2QG<3C(K8M?B'ILV@S:R\C16L+%)5D7#(0<<U,<33E?6UAO#U$HNVYUM)
M7(:=\3]#U5)I;>Y9H8DWM(4(7'L:=HOQ'TO6;Q;7>]M*XW1^<NT2C_9JU7I/
M:2)="JDVXO0ZVBN*OOBAI%A<W<7G-/):N$F2-"=F>YJ\_C[28-"CU1KD/;R_
M<"<LQ] /6A5H.^H.C470ZBBN;\/>.M/\1+*(C);RQ#+Q7"[6 ]:HGXGZ2-0-
MLWG11;_+%TT9\HGZTW6IJUY"5&H[VB=C2UYE>_%Q+#XCR: \+M:BW65940DD
MFM^+Q:D&HZF;B[7[/;(K[-O* CO6<<32E>SV=C26%JQM=;JYUU%<;:?$W2KZ
M^AMT:1!,/W<TB;4;Z&NI$Y"%V.%QGGTK6%2,[V>QA*$HVNBS17#W7Q8T:U:5
M1)++Y;['>.,E8S[FI['XCZ;?:I;V2F8-.#Y4KQX1^.QK..(IRV9L\/56\6=C
M17ENL^(_$=YXQO+#3+B*&TMHPV)!@D^E3^'_ (A:CK'A/7KJ6!8;S3MR@CE6
M('6H^M4N;E;-/JE3E4O3\3TK-+7COA/XL:E>>&-4;4T2/5[6W:>-%& Z@<&N
MHTSQC<S_  \76IY%6Y\KS,8ZG' _.BGBZ-17B^EPJ8.M2;4EL[?,[JBO-_A7
MXRUKQ!)=VNMQK%=1XD0 8^0]*]'%;4JL:T>:.QE7HRP]1TY[H6BBBMCG"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#Y _P""EO\ R2?PK_V,=E_Z.2OJ
MKPVN[PYIH/\ S[I_(5\J_P#!2[_DD_A7_L8[+_T<E?5GAK_D7=._Z]T_]!%&
MXB])A1Z8YK$F\7Z3%*\;:G '0X9=XR*V6&]2#SD'.:\/^*'A'1X?'7A94T^!
M!=S_ .D*JX$O/\7K7GXVM/#PYX'I8##TL55]G4;6C>GDKGN%K<1W,*RQ.)$8
M9#*<@U*% .1WJI96,.G6XM[:)884X5$& !5Q?NBNU7MKN>>[7]W86BBBK$%%
M%% !1110 4444 %%%% !1110 4USA:=2$9H \F\;[M&^*>C:O=1NVF+:F(R
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M:VC%H;>*)CW10*DEMHIU*R1JZGJ&&<UO#"*%"5&^YA+%RG7C7?1K\#QCP?\
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M&Y.S.>OTKU*;XC:]<>-YO#FD:9 X@A69KB<DC!.,'%7.C;8PPV-5>*EW[?\
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MM7&M726-U8W!^602#/FCGMC]:Z?X:^)=2O\ 5_BDMQ>.Z64\BP!SQ& O;TH
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M235K=DWW85=J[0O(R!F@#'+>*OBC:>)?B7:>*;G15T.^DB@TR*1O):*(X96
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #9'6-&9B%4#))["J5I?6.J+OMKBWN@.\;*]6IX!-&Z'D,""#R*
M^2OB=^QWXHL-<N/$WPD\9W/AW6I)#+)97,SBVD)Y(P#Q0!];1JH'RJ%SUP*D
MKYA^&WQI^)O@75-*\)?%+P7J%]J-RP1=>T1//L\$X!<CD?C7TVIW8/\ .@!]
M%%% !1110 4444 %(1FEHH ^/?\ @I<H'PG\*#L/$=ET_P"NR5]7>&>/#FF_
M]>Z?R%?*?_!2[_DD_A7_ +&2Q_\ 1R5]6>&O^1=T[_KW3^5 B^YWC'XUX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUB["@!YU2..4@W2D[1< ;3_J_2IGO%>0Q+<X>11(F%SA1UJ+[5B5E:>(DXD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!OU%9OB32WU;2Y+9[59@LGG0KGD/U!7UD![46YUROJ#<J<E5ANC[#6>>1
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M'K7TA<6-O=M&T\$<S1MN0R(&*GU&>E2[0*.4+GS'!XL_:/58O-\&:6Y"G?\
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M2HBGX7Z*2$(8BYC'S>M>?_%G4?B+\*O NI>+?$?P[L8-,TZ+=<-:WJ;LDX!
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M.K"YM+#5HU73B[>1\._!Z[^(NEZC<7/A:P?5I0GS6]S-L0^^6XKUQ?'7[0!
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MK/QSX%CBU"P^(MV9K^]2WM=.DMH]GS-TSC. *]X\.17L>A:>FI3">_6%?/D
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M "D(!I:* $V@=J ,4M% !1110 4444 %%%% "%01CM0!BEHH **** "BBB@
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cvac-20231231x20f009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '! AD# 2(  A$! Q$!_\0
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MX6\.RZ8="L]'O5O)+FZ?8SL&^Z,U^@%I&(K2WCSNV(JY]<"@"S1110 4444
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MIG!IP.17HGC"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGU'&V68?K4E=BOU/,"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !113#*J]3B@!]%5-2U6TT>PGO;R=+>U@0O)*YPJJ.YKQC1OVUO@[KOBO\
MX1VU\963:F6*",M@$CMF@#W*BH+6\AO;:.X@D66&10R.AR"#WJ;- "T4PRJ
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M4[6^HWBPRZG(A,04D?K6C^U_\2_$OPX^'EE?>&+N.QOKF9$::5<J : /H4G
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M]=OO&EUJ%P=^K2M+:D=8V(ZT ><:]<^.]?\ '/PD\0^([FU%KJ<YE2TA!#Q
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M>M? ]A.L>E2I=SW\MJ\3  CY,D5]TV:&.V@1N66-0?KB@18I,XI:3% SY/\
MVP?BIX?TO6O"^DS-,U[9WZ7$HBCR%3(ZFO2O&GC;X>>-/A];:AKZFZT-RH_>
M(<@^]>B:O\.O#>OWC76H:/:W=PPVF26,$XJ:3P/H,VF+ISZ7;-9+T@*#;^5
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M"XP "I&"*M4W:!GCK4M7T>P'@_Q#\'WO@OQ)%XFT-"MO&H^TV\?1N>3BO3_
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M^J/9:*0,",Y%&:]0\(6BBB@ HHHH **** "BBB@ HHHH ***:[B-69CP.30
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MR#^R%KGB"T^*WC3PPWB&_P#%'A:R1)+:_OGWD2'[R!O:OKV@!:*** "BBB@
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ME;:1NYP:\$_:,_9^\*?#'XB?#Z[T5+D7!NU&)9-P^\* /ONS_P"/2#_KFO\
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MFJ)%HHI,T +1110 4444 %%%% !5._L(KY<31AUQT(JY5>ZO;>T \^>.'/\
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M:H;/_CT@_P!Q?Y5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPZ*^+/@MXV_: ^-'@NV\1:;JVC6EI. R).#N(/-=Y_PC/[2/_0P:!_WRW^%
M7/I>BOFC_A&?VD?^A@T#_OD_X4O_  C7[2'_ $,&@?\ ?+?X4!<^EJ*^:?\
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M/-"BJ2/88KUGO7FGPO\ '?BOQ/=W,7B+P\-&6,91U?<']J]*#9.,4 .HHHH
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M7XR>./%4[P+;:YI,EI$H;)$C*1S0(\HMOB!XXTK]G;X9>-]''EV-G>3R:O'
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M%FC+@+D\8_"@#[RT.&XM=(L8KD[KE(E64_[6.:T:9LSU/Y4^@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cvac-20231231x20f011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'C NL# 2(  A$! Q$!_\0
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M3[.[(1;BSD+ 'MUK%^*LNH'Q/X8\=V>CS7-I!<EKBUCC/FA2.N*J>-_'5_\
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ML_Z='J$)DFBG24PH,-U!P!6AXQ^.C^-_!5OX?TGPUJDEU/$L3/-$0HX SG%
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MWQZU'5KV\T+Q)I8TGQ!!&T@B0Y5]HYQ7$^'?CQ\4/'MAJESH7A.SDM["X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8S7V'!'Y4*(.BJ!0!)1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MMV96'TKCYOCE:)K%C:1P_N[F[%NK>M>;^,?&K?#C6=5T*/<IU.8K$@[9K/\
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M>*-%M=2M&+13J' '8^E &S12"EH **** "BBB@ HHHH **** "BBB@ HHHH
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M[&K8MRXYV_6O0:CA38B#). !S4E !1110 4444 %%%% !1110 4444 %%%%
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*,T
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M4?AF O@31<=/LR?RKIZYCX:?\B'HG_7LG\JZ>@ HHHH **** "BBB@ HHHH
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M71HE8^N? Z[?#5F/]@5OU@>!SGPU9Y_N"M^H>I04444 %%%% !1110 4444
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M\Q$; GKA:5V"*WPS_: UKQ;XF@CG38&<+A2<5^BOPCO#>:$&<'?T%?&OPI^
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M'&O2>&/#5]J,%NLTUO'O52F<FN \->/_ !'=_P!FWMT]G+;7S*!;QKATS[4
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MI?X4 Z4E*.E)7DH]KH%*.E)2BM([B8N*8GWZ?3$^_40^(1ZI^QG_ ,EEU_\
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MM0,]>^&C;O NBD$,#;)R/I73US/PTQ_P@FB8&/\ 1DZ?2NFH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z4R;[AI[=*9
M/]RD]AK<_./QY_R4#Q+_ -?K_P ZR.XK7\>'_BX'B;_K]?\ G6.O:OQS-?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)B]:8GWZ>.*8GWZF'Q"Z'JG[&G_)9=?_ .O8?SK[AZ'\*^'OV-#_ ,7EU_\
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M>5XATW5-5AG6Y>6YG4W+98"-">?RK<URPLK#5[:#1;B6?1) !>R>83M/<]:
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MGS\9=>_Z]A_.ON,_>_"OAW]C0;?C+KW_ %[#^=?<1^]^%?LF6?[M$_G7._\
MD8UO7]$"=33Z8G4T^O5/$"BBB@ HHHH **** "BBB@!#R*XWQ#X*;7)21JKP
M\\ ,.*[(C((]:^9/CFMQX=\1QV>F2:B;FZ42&5';RTR: /H3PUI7]B::EI]H
M-U@DF0UJ,N\CV/->>? RZNKWP)']LD,UPDSH9"<DX->BJ,"@#*G\,V%T+EIK
M:-Y)\AVV]:HV?P^T*QLI;6/2[812C$BA/O'U-=+10!PGBKPWIGASPC>I96<<
M*%<$J.<5M^ QL\+6,8^ZB8!]JK_$C_D4;WZ58\"_\BQ9?[E '04444 %%%%
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M$OT2OKQ.]?LV5?[LO0_G7/?]^D2#I2T@Z4M>N> %%%% !1110 4444 %%%%
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M>+TU 7DCZ))'ET498-GIBOH&O /CO8^(;OQ;IQTJ7S(1&";5& 9N>N* ._\
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MFD1OJANRZ:CI5U\LD08\NH[X- AOQ&T+5K_QN=532KW6-$U6198IM/8R"(
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MU+8JWXCU/5?"GB*PT6WU5YH-0QOF'1!0!]"_$&1;GPA>[64@C@@Y%6/ C_\
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M5]>IWKY"_8U_Y&CQ+]$KZ^3O7[/E?^[1]#^=<]_WZ0\=*6D'2EKUCP HHHH
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MM/ GP2T_Q->V&K"X'V:S_=O$J_ZR0=3GTKZ(M[5;6**)%"J@QA1VH XOX/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKPSXSRMI_C?3KZV8PW<<("RKU S110!Z7\/-0N=3T%9KJ5II2W+-UKIQTHHH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>cvac-20231231x20f013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &[ SP# 2(  A$! Q$!_\0
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MW!LXQ KF41ABI/?FJ?PR^)?C/PE\2'\&>.M2.JW$\1F@N/+"''X4#/I4'UI
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MWKA/CEJN@V=_96^O>%Y]:MVC)%S!%N,7/3/:O8P,#@8QVJ*:VCG7$L:2CT8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13%E5
MLX/([4NX8![&@!U%1/<QID%AD=L\T\.&H%<=13!,C,5!!(IVX4#%HIN_!Q@_
M6D$@)/:D ^D.::)5+8!Y]*4N!3 =13#,BL%+ ,>@S2&=%8J6 8#.,T["NB2D
M-1_:8\X+8/I3A(&7(/% 73V'T4@/%!;%(84M-W"C<,9H =13!*K<@@CU%+N!
MH =13/-4'!X_K1Y@SCF@!QS11D4F\#O0 ZBHI+F*)E#R(A;@!F S3PP/J/K0
M ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML,L<%R9HGC;)X<8KB=9\&3^(?B6Y:2]MH%B8N8>$?GH:]Q22$'"%,^@-(LD
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M:"[N[>9[%9R&B*G%>YZG-8VJM-<+#A.A8#BI;5K/5;1'C\N6W89"X&*/K/\
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M0>(%T];=B8SB4)'U_&NP'CZ'<\3VDZRK'N.4^7\ZCO/AO!/JWVVWNG@=S^\
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M:!"A0*,"FI()%#+R#W%.SS0,, T8XQ11^- "%0>M 4 8IU% :B;11M'I2T4
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M4"F1.WF&VFB5';[LCC!_.MCF2:W=R-0;)MP@:2V?HSCH*?.5M(U:"7Y)#\Z
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M1W\LT^']H)+BTBN5T:\$<BA@?+.,5RGQ1\8>$Y_ATRIJ^GO<!%SMF&2:M?\
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MP]J9MFTW6;*.>)OEV3C#5=\;^+/##?#4)+JNGM=[4WJLPSFCFCV%?R.^T_\
M:+M]1LQ<QZ1=B,@D$H>:F'[04$@;R](NY"O]V,UYQHOBGPW+\)EAL]8L([]D
M8+^^7(YI/@UXKTS3M.GBU[6M/9P6*N\RY(HYH]@OY'>V?[2EG?W,L$&D7;R1
M#Y@(SP:LC]HJR-P\)TN[#KCC8<Y]*\X\">,O",?B[6F;5K!8R<@F8<\U635_
M#U]\2XKIM7LXM-B4NQ^T+AV[#K1S1[#375'H]_\ M*V>FW%O#/H]XKSG"CRS
MS5R;]H*VMX]\ND7:#/&8^M>:?$OQCX3D\3>'WCU:P9%?YMLRX K-^.7B/3-6
MTVR&A:W9QD(=Q2=>O;O1>+V';FT1ZU-^T+;16TEP-'O&A09+"/M45E^T;:W]
MH+F'1[QHCT;RS7!^%_%?A^T^$IAU+6;$ZD+5Q*K3KG...]3>#?%GA.3X;"$:
MO8Q3M$P!\Y<@TN:.PG'EW.\C_:%M97*KI-VP&.1&3R:A7]HNV;4A8_V->?:-
MH<KY9X%>1_!#5;#1M7UF77/$%G-:N0;?S)U//YUV,GC+P@/B=<2?VU8&,Z>/
MF$RXW>@IKD[BOY'92_M!6T08MI5T IPQV<"H-0_:/M-,M5N)M(O!"Y 5A&><
MUX%J_B2WNM*U6WAUBV97E9HQYZYZ\=ZZK4/%7A^W^&FDVM[K-E)>B6,MF8$C
MGZTFET87MJT>LC]H2#"DZ1= . 5RAR<TYOV@8 7VZ5<G9]["'BO.O&_CC0O[
M9\/SV6L61CC"B;9*N-N!4?@;QOX<@U7Q)]LU2T-O*VZ+S)EQC':AV74EW3VT
M/H3P'XS@\<Z+_:$$30J'*%'Z@BNDKRW]G^\LKWPSJ$EA,D]L;QRKQMD8KU*I
M*W"BBB@ HHHH **** "BBB@ HHHH 3\:6BB@!*6BB@!**6B@!,<T;>*6B@!
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M'Q!\9D\[L?[XK.>,JP=N8N.#=17C Q/BM^SUX9TK4]$6"&1?,?GYC5U?V?\
MPUM&Z&0G'=S7(?$;QAXNU#4]'\S((?C+BM@:YXQP.O3^^*SJ8NMRIJ9T4<$E
M+WH%K6_@)X;31[W;#+\L98'>>M:WP^_9V\,7WA:SFFMY&=UR<,>*Y;6-=\8?
MV1>!^$,9S\XK3\!>(O&4?ABT$9.T#^\*N.,JN&LB:V$BY7C [E?V:O"@.?L\
M@)XQN-<M<?LX^%1\06M2DHC2T#@[SUK1;Q)XU9<#.<_WQ7.OK7C"X\?EP3O^
MR*#\X]:<<5.2?O&,L*H_8.M7]FWPH4'[AP>XW&N?\9?L\>%[2RM6CBD.Z900
M7/K6K_:OC//4_P#?8K \7ZCXO-G:DDY\]?XQZTJ6*JRER\Q5;#0]GL>G6_[,
M'@\Q1;K9_P#5J<ECZ53U[]E_PA;Z/>.D+J1&S ACZ4^/4_' BB^;CRQ_&/2J
M.NZEXX.AWP)ZQ-G+CTK>GB:GM$W(XIX:/*U8]%_8/LX],^%FI6<;$Q0ZE*B;
MCDXKZ5# U\L_L'-=-\+-3-TQ^T'49-^3GFOI17=68@U]O3U@F?,STDT:=%9Z
MW#J<T[[8]:V)N7J*J?;3_=J07:XYI!<GHJ,3H1G.*42H?XA0,?12 @]*6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ IK '%.I#0!SOCR5[7PCJ4D6=XC.*_)OQG9SS>,;ZY65B[73$IGWK]?-3M
M8[^PG@E4,DBE2#7Y=?M.?#S5OAI\3KE_)*Z5<,)EF'3)[5\WG-.4X)Q1]CPY
MB(4:SC(\_P#B)JZVUC922J49" Q%=II.O6EWHD#1RK@Q\Y^E>/?$_P 413:&
ML9D#,>.E2^%M'EGT9)8[IE7R@<$^U?*2PUZ*;T9]_'&N.)Y$KZ7-IHY]0\2S
M)IMP%3!+C/%?2/[!EA)I_P 2]4WN)7>/YB.W-?'OA^ZFT75]0E+M)D'[IK[L
M_P""<^@"[L]9\0R*VZ5MB;J]O+J36(BUV_0^9SFNI824NK?ZGW"!R:=3$!Y)
M[T^OM#\U$/2FNBR##*"/0BGT4 ,2-8UVJH4>@%.%+10 4444 %%%% !1110
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M9VP#CUJ*5-1BTC6I-U)*[-O_ (7/8GC^RM0&?]BO-OB-\7+.X\3Z9(--O51
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M):[X8\6Z5XRT[?#;[V P _O4TH5+W;.FM7HJ/NK4]%_X53H!_P"6;_\ ?9K
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M+92<.:US<>,MK8L[?./^>M<GJ&J>*[7QNV;2 RFV&1YE*DYV>I4K3=FCM?\
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M-MON'[R/\Q6%XLBA^S6X#H,S+T(]:5'V//N/$>U]GL0Q_$FU6",'3]0^Z/\
MEW;TJIJWQ)MFTNZ"Z?? E",F ^E>GHEOY$0^4_(/XO:JVM"W71;M=Z(#&W4C
MTK6BJ7M8ZF%657V4M#TC_@GW<B\^#M[, RA[^0@,,&OI[L?>OFK]@U0OPJU
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MFT^ZV2'Y?W9K9_X67:D?\@^['_ #7Z3CX*> U/'A>P_[]TI^"W@0CCPO8?\
M?%0^'L/)WN./$F)C&W]?F?E_JOQ!@GU?3[A=/NS'"<M^[-=H/C#II4?Z#=_]
M^Z_0K_A2?@0_\RO88_ZYTO\ PI3P)_T*]A_WQ6DN'\.TE<S7$6)O<_.O4OBU
MIUSI]U$EA>%VC(7]V<5C>&_B1:6>DQ12Z?=AAGC97Z6_\*5\"9S_ ,(O8="/
M]721_!/P(B ?\(Q8G'<I1+(,/R<MS2/$>(3YK'YS'XIV2C/V"[QT/[LU+X>^
M*VGZ?XGENIK&[6%H N1&>M?HHWP4\"D8'ABQZ_W*#\%/ I()\,6' Q_JZ<,A
MP\5N95.(,1/='PY_PO70\?\ 'M>_]^S6#XP^,NEZEI\$5O:WCL) 3^[-?H#_
M ,*5\"_]"Q8?]^Z#\%/ A!_XI>P'TCJED=%.Z9@\[KM6:/AB'XYZ*L,2FUO=
MRJ ?W9]*JZU\<=%DTVX7[+>@.A&1&>3BOO(?!?P+CGPO8?\ ?NE/P6\##./"
M^G@$<_NZ%D5"$U*Y<\\K5(.-CQW]@5Y)O@_<W$D4D2RWTC()!@XKZ6*D8)K.
MT'PYIOA>P%EI=JEG; Y$<8P!6BS;B/2OHJ<%3BHKH?.RDYMR>[+=ET:K55;+
MHU6J8D%%%% PIDAPC$=0*?3)CB)_I0!SG@Z]FNYM565]RQW!5?88KI20HR>!
M7*^!UVW.M?\ 7T?Y5U+<J><>] %5M6LTG$+7$8E)P$)YJY7A7Q@T632-6L=:
MM]1N!*9E#!7^11GN*]BT.[^T:7;-),LLK1AB5- B>[U:TL"/M%Q'#G@;SC-6
M8Y4FC#HP=#R".]>%?&W1]3U#Q)%)++<?V.D>[;;OM8'O65K/QSD\,V6D:/HF
M^\E>$.))3SC.,'WH&?0[W<2S+$9%$AY"YYI^_ .3R*^>M6^)EW;76G:_+#(C
MI:N6B'0MFH/#?[1.KW,MW/>6/^C,H6)AV)Z9H$?18D P"PR>F:<6P,]J^:/&
M7B;QU>66EW,=Q%;BYE_=X;'%2ZG\<O$.CZG:Z1%;K<36\8,S YW>M 'T?-<Q
MVZ,\CA$7JQZ"GQR+*BNA#*PR".XKYU\3_$KQ#XQT74O[/1+6ULU4W&\X8Y]*
M]+U'Q9+X4^&>GZA&/-N&AC1=WJ10!Z!FC/.*\1U[XC>)/#/A])-5GMX[N]RU
MJ$YR.M8&D_'O7-:\,6\EM;*;YI3"6<8Y!H&?1C-M^E58M4MIBVR="%;8>>_I
M7CT_Q?U9]&%H;>-=:D)CW#[HQWKCO!OB+48=-,^HSDW"ZDVX*>#@=*=@/I>>
M]AMMOFR+'N.!GN:E\P;<YR/:OF_Q7\0-9\2ZQ:RQ,MOI5K<JC@G!)IVL_';4
M=(\1"UMBMW8R*(E*CHQ%%@/HU7#KE2&'J*56S]?2OG32/B+XE\)>"[G5+Z6.
MZ,\K>0H;)7G&,4^#XX^)Y_#HF>Q2*0LV^;NH'?%(1]$@@G%(7"J6)  ZFO._
M"GC._P!>\ R:I"RSW* DX&,USEO\4KCQ9!>6UH#&+6(B=NX?TH&>S)('Y!##
ML14*WT+736XE4S!=VP'G%?.M_P#';5='_L[2M,MC/.J!YF?N":V)/'-U9>+I
MM2(*ROIXVQ=?F)H ]T:ZC698C(HE;D)WJ85X?X(U7Q!J7Q'M7UB2,H\!94C.
M:]QH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:SA%R
MW ID-PDX)1@P!QD&EIL'2Y+12#I2TP"BBB@ I"0HR>!2U#=!#;2"1MD94[FS
MT% $-MJ]G>7$D$,Z22Q_>4'D5:#@C/:O'-&M[.?XE'^P=19HHT)N,R9#'TKU
MN*]@FAD:*5)/+R&VG.#[T $>I6\]R]O'())4&64=JLYKYZU[Q;K5SJ<MMH\B
MV]Y<3E&FZ<"N[^#NL:[J4&I0:Q,)WMGV)-_>H ])W<9P15;^U;;S'02@NA 8
M>E>,7GQ,UB'Q)?Z2LI>57^0!>BUQVMZEKOB3Q#9VL.M_V6LS,7=1][![T ?4
M'F#('.3TI3(.?45X VI>+;:UNM2_M[-A;'R5^3AR.^:N^"/$GB&#X@65C>:J
MFIV5[#Y[&+D1G^Z?0T >Y!@1FES7A_Q"\:ZUHWQ$AM9=1&FZ4 I 4;M_U]*B
MT?Q?KGC"\U&\AUJ/3;:PS&L#]9L?Q4 >ZDXI-WL:^:-4^(_BK1?"MQKSWS7"
M&8PI&B<CWQ61#\=?%-EX6G></)([*([EDY7-.P'U?N_*F23I$!O8+GIFOF+P
M]\1/&OB*RM=/6\,%Q-* +EEP2#6TGBGQ!:+=:=J-Y]IN+:<H)!QTIV ^A=X]
MZ-P&/>OGZ]\0^+T$VM1ZILL()A']FVYSQ5*;QWXDU=FU6#6X[*&&=(C9M]YP
M3SQ1RL#Z.9MO8F@N%!). !DFO/OB9XMOO"^A6%[;G:S@!AUR2*\^\%_$GQ+K
MU]/9WK;0RO)]W'R[>*D#WL7]NX^616] #UIUO=172%HF#J#C(]:^8X+G7-:U
M;19(M>;3XC,RM&W\8&:T-*N/%7AM(M4CUDS::;P1M 5ZY;%*PCZ*FO8()$C=
MPLCG"J>IJ1KA$<(Q 8C('K7D/QE;5+O4_#Z:3=FQNW^82=JR]#\8:T\-O'?7
M/GW=K/)&S 8W8HLF,]UWCZ5%!>0W._RG#[#M;'8U\W7WQ$\2S:Y:7J:O'%:3
MW9@-CW  ZU7L]8\5Z3<W6J6^IG[#+>^6UN><9IVL!],V][!=[_)D638<'!Z4
M]P)"5*]NM>$VWBR^\,:9?:O%*3;0R[K@-Z&NX^$_B74_%UM=:E<L?L,C?N%8
M8..QI =C/#Y)Z9!]*B[9K590PP1FJ<UKMY7FJ$RM2\4;3Z4E,5P-%%%%@#'-
M*#2446!NXI.: <4E%%@N+FC-)12L@N*"*4D8IM%+E07"BBBK$+1GBDHI6L,6
MD]***8BY9=&JU56RZ-5JH*045E:GXITC1IEAOM1M[65NB2R $_A6E%*DT:R1
ML'1AD,.A% Q)9"D;E1N8#(%>9Z)\7X=2\4:QHVHQ?84LTR)F^ZWTKTV1=RLN
M.HZBN6/PVT(7=U=26F^:X'SLQS0!#\.;R&_35IX)1+$]R2K#Z5V+#*FN+^&E
ME%IT6K6\*".-+HA5';BNSDXC;Z4M@. U[X4P^(]2\^ZU6X^S!][6H VM[&NE
MTWPY;:3=FX@ED$9C$8A/( %<?JWB&^L)+S[(29@VU5<\5GGQQK>D030WBJUT
MV/+(/ S7"\93B[,[XX*I-71TGC#X?2>++Q9X]9GT\ ;3'&@8,/QK$U#X#Z'<
M06BV\KVMU;KC[0JABWKP>E5[CQ3XCTY+.!]CRW#XW!N@K/U'XEZY!K'V*.+)
MA(64J,YIO&4T6L!6EM8ZR?X2Z/J%O#'=232^5$8L] <]\5DZ1\"-)TM;J(W<
MT]I,,")E VGUS5;4/B'?0ZI:B%P\;L!(@Y(-3P^/-276IC,/+MD4D*P^]]*S
M>/I(IY9B$3CX)6$FG&UDU.ZF .8&<#,/TJK=_ ?3I;Z"==6F@N(P 7" EQ[U
M4TWXJ:C<:A,[PLUJ,[2HZ5%::_K%_P")+*YFF M9#Q&IYI/'4W9H?]G58_$:
M5[\!]-O;R5XM2NK6&8 SQ(.)2/6NTUCP;8ZWX830YRPMDC5$D'WACH:YWQ=X
MGU:VOUMM/"J-N69_I5"/QSJVH2P0V^Q2@_>YK1XRFI69C# U91YB#4/V?['5
M+2VAO=:O)GMF+02, =@]*MZ%\"=&T6PBM_M,TY23S/,/&35.7QUK DFFVH;6
M(E6!.#D55L/&>L:7IEY>SR><C-F-<YQFLWF%./0V66UGU1TNJ?"#2=3M)(_.
MEMIF8L)DY853T'X(Z/HVG?9#<3W0$YGWR<$DBJ7A_P <ZEK-E,;N-XBC#:PX
MI?\ A-]=%R\\:(;**0(W.3S5QQT)O1&,\#5AN3W/P&TF?6EOA>W*0[]YM1]P
MG%49_P!G70I=36[^UW"HD@D$"C@$>]=1XQ\3:C8:1;2V:?O) -Q]*XS5_BAJ
M=A:VL< $URP&]E&:N>-IT]RJ. K5U>!MO\%--N8KVWDO9O(F;,:%0?+]Q1_P
MI&W?1%T\ZO/MP0\OEC<0>U5[7QOKFK"V@MXUBF/+M(<5*_BK71+=RL4\BU7Y
M@.>:A8ZDU=!+ 582Y);G3^$/ ]EX(T$Z=:,]PG\3RG[WX5SO@;X8VVF6FN-<
MH$DU"X9\QGHO:N;A^)&MZS;77E(8U ^1\<5K>&=<U*WTVW>^E:63+-\IZC-9
MQQ\'*QK/+*T%KN6]3^!FD:A/:3V]U-93PC#2H =X]#6M=?";2M0F>:XDD:9H
M/LY9>,#UK"D\<:U;RR73+&UFS;40-R*73_%WB&2[AN)50632A2,\X-;+&4Y.
MR,7@*L8\S-3P9\)+7P3JC:E_:-Q?3*A1!/T ->@Q.)$##H:YCQ;?R"UMXHF*
MO+(!QU-=!IUN;6SBC+%B!U-=,:BD[(XG'E5RU1116I 4444 %%%% !1110 4
M444 %%%% !1110 A.* <TM)0(0L!36F5%!/&:)WV)G( ]Z\.^)WBR_M?%-K#
M9WK+ ZDD(>#6M.G*IL<U>O&A&[/4O$'B"""REB$FV:1#LKFOA%J-S?:?>FXD
M,A$IQGM7F:ZC=W=SH_FS-(S%\DGCZ5Z'\&?^0;>Y_P">K?SKDQ-.5'%1ATL=
M. Q"Q6%J3ML['IZ'*BG4V/[@IU;#"BBB@ JO>VJWMI+;OPDBE2?K5BJ>JW M
M+">8_P "$TF[*XTKNQPWACX,Z3X5U>2^M99-[DD@MUKK-(\-VVC17B0DD73E
MWR?6O*=(\9ZE;ZS>2F9Y[>1"45CG;BM.VUG4K6REO'N6G,W"1AO]77F+'P>R
M/3>75([L[6+P)ID5U'<+"N]23GW-;&EZ7;Z3"8X$5,GDCO7GL>L:AHUO9R2W
M8G$KY;YNE5K[Q-J.HVL\-I<!&:9421>V>M7]=AU1"P,WU.W7P3IB:O-J7DH;
MB52I8^]8U[\+=&U&>"0!5D@S]T\\FN/\4ZSJ.BR011WDLTL; R*&QFHM.U'4
MTDO=4-VY# ,+<=>E93S",79(VCELI*_,>H?\(9IQ\/R:0T8:U?.1[GO5?PA\
M/M+\'(WV2,,Y/^L?DC\:Y'X9^(]6U.]F%Y&WDLN]2S9P/I57QOXKNX=>C^Q7
M,F(V&Z(' KH^N4U#G9A]2J>T]FF==K_PVTOQ-K4>HW:;I(B,*QR#BH]3^%NC
MZEJ4-X(Q;LB;"D7 8>XKE;OQ+J(UFWFDG\B @853PQ]Z/^$FO;?6YI+ZY,<+
MJ?+5#GMUK".84WT-WEM1/<[X>"-+&BR:6T"&UDR<$9Y]:R;/X4Z/::1-8,OG
MQR=Y!]WZ5Q>C>+K]]9FMUGDFB==Z,QKJ?"_BFZ\2:O'"@*0P;EF]S6E/'0J2
MY48U<#4I)MFAH?PUTW0%B,1,KQMN!?M5I_"&DR7TK,D9GF8R%3U-<OXTU74H
M]9FBMKP6L4?S;6/WJAAUN1I8+J=B)%@QO'>E+%\LN5H<,#.<.=,[6X\+:8+"
M2VE1$MW?S&^M>.>)/A#JNL^/+:>SC2'2%97RAX.#2_\ "1:GJL&I6/VAR%0R
M1RLW(!XJW-K^KZ=9:9803R7#[ 6E#8!]JS_M*'8WEEDXK<]BU70+77-.AM+Q
M%DC3:<'U%0VWA'3;2Y,T5ND<K1&$D#^&O.=2U[61>V<LDOD6X(W -R:U_BQX
MG_LCP.EQ%=2VLTF-CIPQ-=6'Q*Q#:2L<&(P\L.DV[E[6_AYX=CBL%N72U,$I
M>-BV"Q/45K6GA_1+_3AI]LT<R0.&8*<X(.>:^=M$\6:IX@TJ&VU=WFE@NE,3
MR-N)!KH['Q3=>&],U\V>8YKBZ6'SO[F>,UV'*>]:CX>L]1EMY)D!:'[A/:J4
M?@S3H<ND"EM[2?4FO%].^(^L^&4FMKRZ.II:D%KD-D$&K'A3XG^(];UV:RE4
M(LY::W/0&/M1< U'X,:GJOQ,74%A6VTR*42^QKUIO FG/9_9Q&-AE$IX[BO+
M/"'BW6H_B7/#JU^X@F&(K<-E:]Y0[E!]:=Q'%>)O D-WX9O=,M(5)NB-X([5
MT?AW1X]"TBTLHD6-8HE0A1Z"M2BD,**** *EQ;DY9:JG/<8-:M03P;\D=:=Q
M6*%%/D0H<&F4R0HHHI@%%%% !1110 4444 %%%% !1110 4444 7++HU6JJV
M71JLM]TXZXJ"D?*/[1,4>G_%/3=0EU*"+E%^SRG(QGKBOIWP[)YNA6#!E?,*
MG<G0\=J^7_V@]+M=?\>VS3VD+2PE?,9F&2,^E?3?A,1#PYIH@79$(5 7\*;5
MD,UZ9-_JG^AI],F_U3_0T@.5\"_\?.L_]?)_E76,,J0:Y/P+_P ?.L_]?)_E
M752G;&Q] 32?F","?PG:SW$TCGEV#5#?^#+/4_,,O5EV@^GO7(:IXOUJ74;I
MK81I#  =K?6H;OXBZCH5J1=Q+)*XS'M[9KQYUZ$9VE$]F.'Q'*G%G2Z3\.+?
M3EC$MS)<.C;P7.<4FM?#NUU/4/M,<IMWSERIZURUKX_U:71KF>2 )*!\K'WH
ML_%NO7 E!$6R!@)".IXS4.OAWT-EA\3%_$;;?#+3YM:%P),NF"PW<Y]<5<B^
M'=LNKK>22%D"[0N<UR5KXBU"WU_4[U,- NPLN>2,=!6U;^-+Z\U-S&@M[9(
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M,TJ;-_JG^AI6;8K,>0/2N=TWQQI>LZC=Z=#.%N( =X<@ 5(%;P+_ ,?.L_\
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M,****8!1110 4444 %%%% #70.I!&:H2VYB;/:M&D8!E(/2@1E458GMMG*U
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MZ_SJCIXQK%P?^G$U>'_'K<_]>Z_SJEI__(8N/^O$T1W-9[(2\YO-*_Z]I?\
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M<E,T'_CW/_7!OY4WNQQV'0?\?>@?[C_R-%U_QYVO_ J6#_C[T#_<?^M)=?\
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MX*=38_N"G4':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU L=, &%^S2G'_ JT])YCL1_T[3?^@UUQBHQL>54K2G45V5_#X ;1/\ >?\
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MW-]:_P#79ZLZ!][0?J_]:K-Q?6O_ %V>K@*O\,33'70?^NKT:;SI$0]=2?\
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M_OI_2M"P^]J?_7$?R%..QK/XC"U3BRU7_<C_ *5;ON-4N?\ KSC_ )54U/\
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MY?\ LM<YK?,][C_GT;^5='%C_A$DQ_SY?^RUX>:_%2]49Y<OC.7T5A]@M_\
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MA-7^(K%F_P#]5X@'_31/Z5?L3AM2_P"N(_D*H7^/*\0?]=$/\JT;'!;4^/\
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MTJYZX->BX%%%P.!L?A#IEC*S(S$GN3FH6^"VDF2X?S)"9CN89[UZ)BC')IW
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MT%+1<#C8/AG80VZ0[V*(, 4-\,M/>=96D=F7@ ]!7944K@<#J/PETZ_>4L6
MD&#@XHA^$FG00>6'8CT-=]28IW \[7X-::+L3"212HP,&I$^$5DMPC&X<HK;
MMN:] Q2T7$<7=_#'3[N<2NQW*, BJUQ\)]/G"Y<Y7H0<5WA&11@$"BXS@K'X
M3:?:ONSN/)Y/K4DWPITZ9 IR,# P:[G %+1<#S:T^#&GVL@<2.?FW$$UU_AK
=PQ;^&;9X8.0QR36N><4X]*+B '-+34^[3J0S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cvac-20231231x20f014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %M GH# 2(  A$! Q$!_\0
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MA<LZEE^[W->@_ /PHWAG]I+QXMKIS6&FNP,81"L9^E?5CVD$DJRO#&TB]'*
MD?C2I:01RM*D,:RMU<* 3]30!\X?MP>$M:\2^!=*ETVWEO;2SO%FN[6+),B
M\UXGIFD'XH_&[PY>^!?#<_A^RL;-$OY6C*+( /F4^M??SQK*A5U#J>H89!J&
MVL+:SR8+>* GKY:!<_E0!\G_ ++O@B.Q^-_Q(NKK2!$$N%-M,\>,>NTUZ/\
MMEV%SJ7P)UJ"U@>XF8KB.,9)KVR*UA@=WCACC=_O,J@$_6EF@CN8RDL:RH>J
MNH(/X4 ?EA9Z(&\.^#5\+6.LR^,K>Y0NERA,,:Y&< ]*^L/VP/&WV;X+S^%Y
MK"YNM:O[&(@PQE@&P,_KFOI>'1K"WD#Q6-M$XZ,D2@_GBGW.FVEZP-Q:PSD=
M#)&&Q^= 'Q]X,GN/BO\ L?WW@G3+*ZMM;T_35C=)D*[V'85\\6/AB:+P'H&@
MZ)H&L:?\0[6]17G7<(P@//M7ZDVVGVMEN^SVT,&[KY487/Y4BZ99K/YPM8!-
M_P ]!&-WYXH \6U;X(>)?%4FGZBWC;4-)D%I$DMK#]T.%&3^=>)_M!_#.;Q!
M^T3\,M)U&&YU734A\JZN0#\WN2*^WJADLX)IEE>"-Y4^Z[("P^AH X7P[X!\
M,_!30M4N](LI8K8KYLR!B[-@=LU\A?!OXG6^B_M+>*=?N-)OX]/U93;P-Y)'
MS%N_%??;QK*A5U#J>"K#(-4UT+358,-/M00<@B%>/TH ^()Y=4_9Z_:8\3^*
M=2T:[O\ 1M:LMEO-;(6PQ&<&O1/V)?"6L6EYXY\6:G8R:?;^(+T3VT4HPVWZ
M5]0W-A;7@ N+>*<#H)$#8_.I8HDA0)&BQH.BJ, 4 ?'W[=GA6675_!WB)-(?
M4K2SN5%SY4>YBN1P:X3]H-S?^+_A?XUT3P]<KH-A-&98HH2"F.O%??5Q:PW<
M>R>))D_NR*&'ZU&VG6C0B$VL)B'1#&-H_"@#X7\+W=YXV_:!^(>OPZ3=VEE=
MZ$R1&:,@L=M>;_#CX8&?]E+XE37F@.VL#5&-NSQ'S-N[^&OTPCTZTA8M':PH
MS#:2L8!(]*$TRSCA>%;6!8G.601@*Q]QB@#X,\3?#IM/M?@E=:=HSV]]LB^T
MS1H=P/'WC2>); _#SX^^.M2\:^'+CQ!9ZM8"+3IQ&757QV]*^]FL;9A&#;Q$
M1_<R@^7Z>E)<Z?:WA!GMH9R.GF1AL?G0!^:VL_#GQ)9?LS,MSIERL%WJS36U
MB5):.,].*^]_@WX4T[PW\/\ 0/LFG16-Q)80^=L3#%M@SFNSDL;>:(1201/$
M.B,@*C\*F50BA5 51P !P* /B3]J30KK2_C[X?\ $NMZ7-K7A.(J&MD&X;OI
M7,_##4+#Q-\3_BG=:'I;6%I-I9$5L%P1QZ5]2_&SX(WOQ5^S-9Z_/H[PMNP@
MRK#'I57X#_LW6'P8EU&]?49M8U._XFFG QCT H \?_9]^%C7'P,\3+#I"VWB
M"9&$$SIB0'!Z5X%=:9';_""?P3/X-NYO' ORQO?*.3\W7=7Z@0VT5LNV*)(E
M]$4 ?I4)TNS,QF-I 93_ ,M/+&[\\4 ?!'Q>\ >*/AKX&^'_ (KALY[O7[*%
M;:9(P6=0PQ@_3-<=XF\-^*?A-I,#:7IMU,WC:W7[9L4DQN3DYK]+)[2&Z39/
M#',O7:ZAA^M-ET^UG">9;0R;/N[T!V_3TH ^"_CE\)SX(\!_"^[BT1KV*S=9
M+X11;FYP3FMOXMP6'Q!\7?#&XTC0)8M($Z+- 82JCIG(K[<GM(+F/RYH8Y8_
M[KJ"/R-1KIMHNS;:PC9]W$8^7Z>E 'RS\*O!X\,?M=>+S8:8;#3'M4V^6A$9
M/M7U?42VL*S-,L,8E88,@4;C^-2T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !129H!R.AH 6BF[L'V]:7- "T4F<G%+0 4444
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M9\#:OXL\:2ZD?":^#K**RE@901F=F& ,#M0(MZ%\2O&=H="U_69K630M8N3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY'3CI0!YUXDT1A\1_";PVH:W@@D5W"\+TQ7HP&!@<"@J"02 2.AI: "BBB@
MHHHH **** "BBB@ KRG]H+XTM\&_#,5Y;6!U+4+B0106^< D^]>K5X9^UK+X
M#3X>[?'5[<:?:M*OD3VBDRJ_;% %'X(?M%W_ ,3O%%GI=[8Q6WVC3Q=_NVR4
M;<05/Y5] U\9_L7?\*KL/%NH6_A'5=5UC6W@^>748BH2/).%-?9E !1110 4
M444 >,_M??\ )O\ XJ_Z]S6U^S5_R0KP9_V#X_Y5B_M??\D \4_]>YK:_9K_
M .2%^#/^P?'_ "H ],HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:,B@#QK]KW_D@'BK_KW-;7[-?_)"_!G_ &#X_P"58G[7I!_9_P#%/O;FMO\
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M[1OBKJNOWLNCVYEM%A6TTZ16Z'K@5]E5\9_L9WWA2[\;:I!;>']1\/\ B&&
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MB.PUC]F[7+N*ZA075D)4C:0!B",]*Z_]FLY^!?@S_L'1_P J\6_:J^ NBQ?
M>[O[J6Y.I:9IZ0@QS$(Q4>E>T_LU#_BQ7@OVTZ,?I0!Z91110 4444 %%%%
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M;7[-?_)"O!G_ &#H_P"5 'IE%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %(>12UD>*]?A\,^'K[4IV"I!$6Y.,G'%
M'F.N ^/_ (SV&GJ?-TK1T,LXZJ9.P->R*,# & .E>7? 31)8= O-<NP3>:O.
MUP68<[2>!7J5 !1110 4444 %%%)F@#GO%WC[1?!%LLVK7:P*QP!W)JUX:\5
MZ;XNT\7NF7"W$!.,CM7SE^T=IDWCCQ?;Z9HS/>WL8&^%#E5'K7IO[//@'4/
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MMRSN%RH] <5[1^S3Q\"?!?.?^)='_*@9Z;1110 4444 %%%% !1110 4444
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MA*-ZU7XY;^7D=>-Q$9VH4?X<=O-]7\Q:***](\L**** "BBB@ HHHH ****
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M3X%BAC&,X^9O<FM>BBO8C&,%RQ5D>'*4IMRD[MA1115$A1110 4444 %%%%
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M_P!J#Q+_ &!Y=[H=QK,B-@7,8ZUV/+JRI*KH>2N(L&\2\-K==;,^NZ*^>O\
MAIO6<?\ (FWGY&C_ (:<UG_H3;W\JYOJM3R^\]#^UL+W?W/_ "/H6BOGG_AI
MS6>W@R]/X5GZ_P#M0:[%I%TT?A&[MY AVR,#A3ZU2PE63MI]Y$\XPL(N3;T\
MG_D?2N:6OB+X(_M ^+-:^)4%I?3O>6UTQ!A/\%?;:-N4'U&:6)PL\+)1GU+R
MS,Z6:4G5HII)VU'4445QGL!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 AKXP^/'[-'Q5^)7Q"NM1L==C;0L_
MN;&9_D_$5]GD9HQ0!\Z?LW_#3XF_#S4WM?$M]9'P\L>(K6U&-K^M?1E)BEH
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M*XK_ (8D\"?\_&I_^!%<S\0OV'?#$GA'41H<VI-JQ3]P&GXSFCEQW\T?N?\
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M+2*3_GK-(&;Z\UO6_B[Q]J'#7T21'^!+A4 KTC_AA7P*#QJ.M#Z79I?^&%_
MXZ:GK@^EX:ZEA</]N+EZM_I8\MU\;>].KR?X4OU3/%/B*-;3P_+>Z@\,L<?+
M.;L.0/I6+\%Y[W7;ZYN=,73I(X@ QO) !GVKZ"F_82\"3Q-')J.M21MP5:[)
M!J.T_8)^'U@I6VO-8@4]1'=%<_E36!RY5%6^KKG6VK:_%D/%YTZ;PWUV7LGJ
MU9)_)I*R*%LWC.( 6^J:!9_[KK5U)/B!(@'_  F6DPCT65>*YSXH_L+Z(W@V
M\'AS4M;;5LKY0-XQ'7G]*Z/3/V&?!KZ9:?:-3UO[1Y*>9B\;[VT9_6N^-2,?
M@@E\CA>#<W>=63]62QZ9XTN,>=\0;"//7;*M6$\+:[,/WWQ+MU)_NS"HQ^PO
MX''_ #$]<_\  QJ/^&%_ _\ T$]<_P# QJT6*J+:WW&;RR@_B;?S9:C\!7$@
M/G_$[D_W)Q5+Q#\*;74]"O+;_A8S7$DD9"I)<+M8^AI__#"_@?\ Z">N?^!C
M4G_#"W@?_H)ZY_X&-5+&5D[W_!&,LEP<DTXO7^]+_,\3^'/[/]Y#XPB?4]<L
M]/LH6R;B&X&YOI7OP^$OA9N)?&\KKZ?:Q_C6<?V%_ Y_YB>N?^!K4?\ #"_@
M?_H)ZY_X&-6M7'UJSNV<^#R#!8*+C%-W[O\ R-/_ (4_X+;A_%\C+Z&['^-'
M_"F_ 7\7BAR/>\'^-9G_  POX'_Z">N?^!C5PWQI_85TMOAUJH\(ZEK1U_:O
MV8/>-@G<,Y_#-<WUFJ^IZ2R_#+['YGIW_"F?AYGGQ$2/0W8_QIX^#GPX[ZVA
M'I]K'^-<MX=_87\)?V#IPO\ 4]<^VB!/.Q>-]_ W?K6C_P ,+^!_^@GKG_@:
MU+ZQ5[E?4,-_(C:?X-_#-T9?[4AR1C/VH?XUY'J/[+.@2^+!+!XGLAHS-N=3
M,-P]A7H/_#"_@?\ Z">N?^!K4I_87\#G_F*:Y_X&-6M/&5Z5^61R8G)L#BTE
M5IK0[/3?A[\,-.MHHMVFRE%"Y>8$G ^M:D/ASX:0?<BT<'WD4_UKS@?L+^!Q
M_P Q/7/_  ,:C_AA?P.?^8GKG_@8U8.M4?VF=ZP>&2M[-?<CU6.U^'\/W/['
M7Z,E6XKWP5!]R?25^C)7CW_#"W@?_H)ZY_X&M1_PPMX'_P"@GKG_ (&M4.I-
M[MFL:%*.T$ODCT?QAX?^'_CBQ%IJ-QIK1@[@4D4$&KOA:U\#>#],2PTZZTV*
M!>>95)->'^-?V%O#)\+ZB-'U/6SJ?DMY&;QL%L<4_P &?L+^&1X4TL:QJ6MC
M4_(7[0!>-@/CFG[2;CRWT$L/14_:*"YN]CZ%_P"$C\+?\_\ IO\ W\2C_A(_
M"W_/_IO_ '\2O$_^&%O _P#T$]<_\#6H_P"&%O __03US_P-:HNS;E78]L_X
M2/PM_P _^F_]_$J&\U?PE?VTD$U[IKQ2#:RF1>17C/\ PPMX'_Z">N?^!K4?
M\,+>!_\ H)ZY_P"!K47?<3A%Z-'<>%? _P -_!^MRZKIUS81W;DG<9E^7Z<U
MWO\ PFF@_P#08LO^_P O^->%?\,+>!_^@GKG_@:U'_#"_@?_ *">N?\ @:U5
M.<IN\G<SI4:=!<M**2\CW7_A--!_Z#%E_P!_E_QI5\9:$S #5[(DG 'G+_C7
MA/\ PPMX'_Z">N?^!K5R_P 2OV'=&M_"5S+X8U'6FUJ-XW@5[QB"0PSG\*@W
M/K5'$B!E(92,@CO3JQ_"%C/IGA;2;2Z)-Q!;1QR$G)W!0#6Q0 4444 %%%%
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MVH Z:BL[1?$&G>(K;[1IMY%>0_WXFR!65JGQ(\-:+J#65[K%K;70.#'(X!%
M'34F*\)^,O[1D?@GQ-X>\.Z(;>ZO]6;(FD8>6B^I-:G@;]I7PUXH\4:CX9GN
M5M]5TYECE8D;)'/]V@#V+ ]!1@>E<Y/\1/#=MJ2V$NLVJ73$ 1F09SZ4M_\
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MNP&FVX2:9#L9@H_6OK633K6:99I+:)Y1T=D!(_&G+:PK,9EB02D8+A1D_C3
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L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cvac-20231231x20f016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $' X,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4CFD:0*"
M2>E#$]J\O^.7B"^T71[,6%R+1YI=K2'TH ]-,Z#;\PR>.M*LR.[(KJ67JH/(
MKQ[PIH6JZE-:S1>*H;H\.\*-DBMW3= U?1?B7/>-.\^FW:\J3PAH ](HI!2T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^'>@S^3=Z_!'*1D)GDUZ%''86N^6E4C)^33)=2$=6SU;.*-P]17C\G[4_@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCFGU6M;A+I5>-@R%<Y'O5FO UZGZZFFKH****!A1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD#M3#<=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;\P-.K[!;'G!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 0@'K00#2T4K7 8848$$<&L?6O#&EZ[:26E_:I<P
M-P4>MNF% 7R:F<8SCRR5T5&3A)33LT?)'QB_8TAUAY[KPT1:,QR(!T->$^)?
MA#\1? 6C&RU&VDGT=3]V,Y7/J:_2MT9N]4M2T6SU*W:.YMH[A#U5QFOG\3DM
M*I%^R?+?ML?;Y=Q=C,)**KKVB7\VK^39^;GP ^(FD_"KQA=ZKXA@E>7&U %^
M[7U/;_MJ>"9HLM!<*?08J_\ %7]E#PUX_=;B)&L)P<D6_P H->$:Y^Q+XATZ
M5I=*F29/[C'G%>5%9CE\?94(77H?22Q60Y[6^LYA*49>O_#E']ISX_:?\5[&
MTT_2]\=NAW2;Z\6\!?&^Y^"&N1W5GI2:E,1E&;^&O3[C]D[QXK%19*^>I%.@
M_8K\:ZHR%H8X67N]<,8XZ>(5:K!MGTDL3P[A\']1H5[1?W_-V,36?VR/'WC&
MWE-I+_96<X6+M^=>:7OCWQ!XE!&LZC->2;L@=Z^GO"W[!MT94_MN[*Q_Q&W;
M::]G\"_LC>$/"$XG:V-V^.?M/S5W/"8[&-^T;4?4\.&<9-D[7U1*;2WLKW^Y
M'YK:U\%_B1\6]1M[?0M#GELHSN>7L17L/@']@/QU>JB:F5L;8CG'5:_2W1_#
M&FZ!%Y>G64-HI&#Y2XS6BL1#=>!7NTLKI1IJ$NA\1B.),55K2JQZGYI^-?V5
M=0^!EM&]C+<:R;X_.Y'"&OI#]D3X=M:>'[C4-8TE(KN0[5>5<G;7TCJ6CV6J
M1B.[MH[E<Y"N,@5+:V$-E$D=O"D,8XVJ,8J*65TZ6*==&F*XEQ&,R]8":6CW
MZ_>4[FV33;<M&%C0= !@"OSJ_:!U\Z_X\U2W$GG>7=&->>G-?H]J]@-1LGMR
MQ"N,&OCO7_V0-;NOB--JD<Z2Z?+.92"><9K'.,-6Q/LXT]DSMX.S##9?BZE7
M%-6<=+][GT%^S[X/_P"$3^'EA 4"M-$DA([Y%=CXQU2+P_X=OK^1MJ11DYJ_
MX=L#I>B65H>L$2Q_D*\U_:5U672OA;J!17)E&SY1G%>H^;#X5]TCY:G%8W,$
MI/24M_*Y\+:J]S\1/B9/' 3,9KHE ?[N:_0GP1X,MK;P/IVF7%LCQ",*\9''
M3FOAG]EC0I]>^,5N\L#^7 "SDC@>]?HW!&BQ*%X4<<5\_DU%5?:RJKJ?<\9U
MH4*U/!X=Z06Z/D+]I']FZSTS3;SQ/HD:60MSEXNS U\Q>%?%FH>%-36\TZ[-
MO<QGEUZ'UK[<_;)\8IH?PRN+!)0+N[;:%SV]:^+_ (/?"N_^*-Y>6UB7W6Z;
MG;L37CYI1C+%J.$5I+L?7<+8ZI4RNI/,G>DM/>U6Z[GU+\%OVM;/4[V#3/$$
MSI/+A%F8<9KZAL+^.^@$\$RRPMRKKTK\I_$W@_6_ FK/#J%M+;-$_P"[D8<'
M'<&OH?\ 9A_:-ETS4$T#Q+=_Z)(<1ROT7\:]7+\WG&:H8K3S/GN(.%Z52F\?
MENJ[(^VPV.K4JAB<[LBJUKJ=M?6R3VSK-$_1D.15B-]PW#I7V2DI*Z/R-JSY
M7N/ .X\Y'I3J8H^8FGT)W ****8!1110 4444 %%%% !1110 4SS "033ZKM
M)\S?N\X/6@"3<">&_"L[Q#/?P:5.^G0K/>*,QQOT8U>#C&=NVE,R*/F(4>IH
MN%CR?Q/HNN^-;"WLKC2(+6?S$DDE7^'![5?U'POJ^F>(=%OK*-;I;>)HYL^]
M>C&XC ($JG\:1+F(MDRIG'/-*Z[A9[6/,E\.:[X;UV]O[*U2>&]B974=48UR
MVH^$M5\+>'M-:2))-1DO QC'3&<U[N;F%AQ(N1[U7NK"WU$*)2LA0[E]C27D
MP5X;(X==)U[Q'XJTZ[O[9+:TM5)R#U->C<\X--0[0HR, 8I^1CCD52N+<=11
M24#%HHHH **** "BBB@ HHHH ***3^+VQ0 9%#?=-(1@9S7*^.?'^G>#-%NK
MN\F6(QH2JEN6-4HN6B,JM6%&#G-V2)_%WC33O!FE->7\WE(/S->!^(OVH+/5
M'-I8R,JOE=Y%>0_$_P"*>J_$/>(I2;,$LJU5^ ?PCU/QUK\=W?P&#3X2'8L?
MO\]JSS/)UB\%*$9N+\G8^#H\35\1F$8X.*=.YZ[H-G>Z\&O;BWDDM!RTAZ$5
MW_PVL-/L=8EC>W7,GS12'^5>D1^%;2UT)K"! D>S: ![5Y68[GP_?F.12/(?
M<C?WAZ5_.>895/AG&T,5-<\9/WF];'[=3Q;QM-TEIZ'N%O&(TVYX-</\5]*6
MZ\-2R@9=&!S[5T?AO6H=7L4=&RV.1GD4GBJP;4?#]S .693BOV3,H4,UR>JZ
M%FG%V^X\"A>AB8J7?4\I^"VIK!JLMJYXD^[FO:U#F08/ KY_\&6=YI7BZW!M
M9-JMM;"\5]"0#]V/4CK7S7 5:O++I4*ZMRR?Z';FU."KJ4.IY%\:E_<H"2 3
MTJU\(-.6XT8>:BN&!^\*ZCQKX$A\4QJ)'92ISD&K?A+PQ'X8TY8$.[;QN/>B
MADE>6?5<5B(7I.UON'+%1^J*FMSDOC!X,6\\$:@='LU;5=O[IE'(->'>"?A[
MXJU6RA@O+=H[C&'9NF:^O=BMP<'VIL5C#&25C4$^@KT\VX4PN9U$U%07DDOT
M,\-F=?#+1W/F/4?@OXCL5,@B6= /X37+:KX2O]/C)O;!E4?WER*^Q_*WG!'R
MCM56_P!#M=0B,<L,;J1CE:\#%<!T5&^%J-/U_P" >A3SVK)_O8IKT/DGPQXH
MO_"\Z/:RE%'5.V*]#G^,5KKVDS6&K6Y*3+M..E=;X@^!.FZC))-;N\,K= I^
M45Y[JOP-UNR#/!MF7T[U\C/+L^RURIQ4I1?G=?F>@J^ Q34I:-?(XGP[?W^E
MZS-%]H632RY>+/6,U[7H'Q;T^/2VAU"0R2HI )_BKS!/A?XB1]@L6Y[UTGAS
MX&:GJ%RDFI,88Q_"AP<5AEE//,-7?U:E;FW5M/FKA7C@91?-/\3C=3O+CQ-X
MFFFL+8F%SA57O7H'@'X6:E=:M;W^I1B.WA.Y4/K7J/A?X<Z7X84&&$._J_)S
M74F,(F!A1Z"ONLKX0C*NL9F'QWO9;'DU\TDH>RH[=Q\<2+&J@< <4X*!T%*O
MW12U^JI)+E6Q\[YA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#QVI:* $Z]J:X(' S[4^B@"
M$J6ZKBE"$#[H'TJ6BCH&I"P<YP,<>M(%D1,CD^E3T4(=^A$H9E!8?-UI=A'(
M /M4E%!(P;L=*8N\L<C J:B@9" P3[O-'SX7Y?K4U% =+#"#QBD9>.%&:DHH
M C 8'VQ6?X@T*V\1Z=)8WD(FMY!AE-:E%3)*2LQQ;B[IG ^#?@[H/@;4I[_3
M+?R[B889L]J[H#8H4=!3R<#-,#AZ4:<8+W4:5:LZTN>H[L^)/VS= \3^(/$T
M:V6G7%S9+@*Z+D5Z/^QG\-KOP=X4N;O4+5H+NY<_*ZX.VOH75M+35(!&VW@Y
M!(S4VGV0LHP@(P!V%>-3R^$,5]8N?2UL[J5<MC@$DDNW4\J_:!^%NG^/_!EX
M9TCM[FWC)CDZ?K7YTZMI\NB:K)9&<.83\KH>XK]0/C+%<O\ #?71:(9)_L[;
M%'<U^8VG^%/$&L:_+;)I\SW#;F8%#Q7BYYAN:2G".I]OP1F$:5.=+$2]T^C_
M -EK]H/^R;H:#XBN\6[\0.YX!K[4LM1MKNRCG@F66%_NNIX-?DE/#=Z/J82>
M Q3P.#M88)K[$^!7[4'AO3O"@LM?G%@;4A!(YX8FKR7,-?857Z&/%V0Q_P"1
MA@X[[I;'UDLRD]>*=YBX)S7/^&?%NE^,-/6]TFYCN[4D#?&P(KH% QTZ^M?8
MI]S\E::T>X+*K9P:7<*8Z#''%.7D4V["0I< XSS3J3 /:F_=.>M,!](3B@'(
M]*0MCM2N H8$\&EI <]J,T70"TTR 42?=K"\3^*-/\*:5+=7TRK&@_O $U,Y
MQIQ<I/0NG"522A%7;->[U"VL8'FN)DBC099F. *\M\8?M!>$/"#R/)JL5P^?
M]7&V:^>OCC^U'I.JP7&EZ3#<!CP\DC87\,5\MZE<R^()MT(>65_NH,L37R>+
MSIQER4-?,_3,HX05>$:^.;47TV/MKQ#^V=ID\;0:5:F24]&W5Y?J'[2WB_Q!
M>-:::7>8G_4QKDUXQX7^&7B.$)K=Y9O:V<9Q\X(W5[)^R_IL&H_%^XADPI\K
M>I(SGFO#^MXJOB(TY.USZ_\ LG*,%@:F)ITE)P[MEZSU[XUZQ\UK;SQJ>ADB
MP*R_&GC+XQ>!;%;O5[A8(W.,A:^\;.T^SQ;/DV@\8%?-O[;JE?"%J.!\U>[B
M<%5H4)554=T?$Y;FM+&XZ%"5&*C)VZGS]HGQQ^)>KEGL99;P1\N(H\XKIM%_
M:G\6>&;T'5T:4=/+==I!K8_8CL4N[_6HW*ONCQR,XKU;XF?LOIXMB\^PO(X[
MH,6 D3BN;!8?$U8QK*3.S/<QP.'JU<'"BKI:/K<C\)?M76.LQQG4;;[*/[P-
M>K^&?B]X9U]MEOJ,8?\ NLW-?$_C'X<ZO\.)%&I&&:,-M!B'%9-CK2Z5<I=6
MYR3@[0<5^FTL$G2BVW>Q_*\N)L50QLZ56*LF?I)!>PW(S%(''L:E5@02#7R=
M\*/VA+*"\%KJ<,RNW D5OD'YU]+Z!XIL-=M4EM)DD#=@P-<56A*F_(^[P&:4
M,?"\&K]C;!!HS2*P;D4IQFN8]D6BFL=HSBA6W"@5QU)D49S1WZ4##-!8+UHI
M& .,T"%W#&>U-,JCJ:C&R,D%OSJM>W<,,+,[ 1JI+/G@ >].UP;4=69/CSQK
MIO@KP]>:A?W*0)$A/S'&:_/#XQ_M"0_$/5"D%S^X0X2,'[U>C_M9?$M?B%(/
M"VAC+2<-<,?D4].<5\[>%?V==3;Q]H.F3:G:L))T,C1Y.!FO9P]/V,7.2/S7
M-\?''5UA8R]V]M#U'X<_#/QAXDTN[U(6$J6:)NCRN-]=Y\,_B/>?#CQ''#J1
M=+1B$DB;C;7U_P"%_#"Z!X=M]+5E*0QB,,!C/'6O ?C!^SQJWBC6XKG3;F%4
MWY8,,&H^L>T]V1-7(9X!PQ&$;YNJZ'T;X:\0V7B;3DN;"431, <BL#Q_X:N-
M3@CEL4!G4U8^%GA"3P7X9@T^:19)54;BM=>RX-?*YOE]#,*<J%36+/TO!5JL
M(1G+21Y_\.?"NIZ'(\UX<*Y^YZ5W\Z;X6 'X5)VH'2IP& I9?AEAZ>L?,Z*M
M656?.]RE#811*&$2A_7'-65R,>E/(K'UG7[?19(Q/GYSP!6M26'P%'VDVHQ6
M[_ 4>:H[;FBKL2P;I3WVJF,]:Q[#Q/9:B_EQ,=YZ!N*U)V\R/:, U5+%4Z\'
M*@^:Q+@UHR<$ 4+("<=*IW]XNG6LDS@E4'-)I5]'J%NLZ=&[5I[9>T]EU%:Z
MN7@P)P*&)QP,TT2*7V]Z?VXK=.ZT)&_-C!&/I3 <@Y.:6698D9F.%49)K%TW
MQ+97][)!$^YUZBN6MB:="485'\1:@Y:HV5"@%B,4+PV>U)(P; J*YO8K0HCG
MEN!70Y0IQYGHB$G)V1/YJE@..:2:4*IX!QUHXP3Q[5"HS(>^:;U5DRHJ^Y9C
MD#1JW8BEWCUK.FU".WE6%E8ECCCM52TUN&?5GL5SYBKN-<3QD(RC!O5NQ2A?
M4W<TM,4C=3Z]!.Z,PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !2;0.U+28/K0 ;1Z4<4M(1DCF@".:)+B)HW4.IX*G
MH:S(?"FD64S3PZ;;),>KK&,FM41X.=U./(-2TGNAQE)*R=CY>_:C^ 4'B/1'
MUO1+18]0@^9DB7EAWKX4U?23(LUA>0F)@3NCD&"".]?L*8!)&R.H*D8((S7R
MQ^UA\!(K_1)O$&BVJ?;(1F5(TP6%?)YMEUU]9HJS6Y^I<,<2N@EE^*UC+1-^
M9QO[ WB$:1>:CX>GNOE*^9&DC<$^@S7V+K.K-8:5>W)1C]G0MP<9Q7Y1Z#K>
MH>%M9M[^RFDM;J%@2%.#D=17VC\.?VA;+XB^ =;T^[E^SW]O:,Q+M]\@5GE6
M9KV3HU7[W0VXIX?FL0L?AE>EIS)+;_,;'^UN3XKCT^339#;-*(M^\5]+Z7J/
MVZS2Y'"N 0#[BORWT'4TU#QQ9C+$-=ANN<<U^G?AM#)H-HOW,(OX\5W95B:E
M6I4C5=VK'@\2Y?A<#"B\/&SDO\BUJNMVVCQ"6[FCA0\ R.%%1Z5K5EJLI>UO
M(;CC[D4@;%?,_P"W1J4UKX8L+>*XDA+R?P-@UQ'[#POYO&5S+)=SRVXMV&UV
M)&<UI4S7EQ<<,H[NS,:'#L:V42S.52SBF[6W/N5B0O7%56OK>*3RWNXA)_<+
M@'\JK:QJ)LM.N9B,+$N[<:_.?XF_$;6-8^)&H'3=2N%D^TE8XTD..M=..S&.
M"M%J[9YF3Y+/-N>49<L8[L_2HN&CR#GW%5W=8,R22!$ YWG KS;3OB1IOPY^
M%^GZGXHU*.*1+5&<;PSL<>GK7S!\5?VM5\:KY>CM-:Z<K',A.TN*O$9A3PM-
M2EN^A.79'B,SQ#I4=D]_^'/7OVA_VMM"^&VFR6%C.+G57;8!$X^6OAKQ3\?=
M<\;WY.H7\[P/)Q#OKE_'^B:I\3=7BL] @>\U.ZE&QNN/J>U?8W[,G[#?_"+0
M6NM>-%@N;_:&%HW[Q0:^=FJV9P]I;3L?;PJX+AB<J;2G/3I_PY\WZ=H$'BO5
M;2PEN19Q3N 9G'*BOO#X)_LX>%O!6C6EXL<&KSNN[[0R[LY%>"_M._!K4O#O
MB:"]T&Q)M97^5+=,;/RKZ,_97M=>L_AM#'KD3QS"0[%D/(7M4Y3@W2Q#A4C>
MQU<5YG]?PM'%X2I:+23BNCL[FG\;]'M/^%5ZLMO;)#Y$>X!5QBOE+]GF]_LW
MXX>'V)VI<0%&&>IK[;\>Z _B#PAJFGQ'][<1%1]:^//AK\"_'.E?%O3-1N+&
M)+"RE)#"3EEKT,PPTYXNG4IJUCP<CQU.&58G#5I:RO8^Y5'F -TKYE_;?/\
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M0RCGZ5^;?B3PIK7A6^,5Y"]K(IXE0D8/UKC/&DGBC6I;*[LM?O8[JQ<%$$I
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MV7RK7S*BV$2)L"X3&,5'8Z/::8[M:P+%YARQ ZU?HH;;&HI;(****104444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cvac-20231231x20f017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &  Z@# 2(  A$! Q$!_\0
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M:_.7XT:FEM^V]-'J6E7WB/3?).=/M6)S^% C])?"GQ%T'QNKG1M0ANRGW@C
MD?A72 \#M7YN?LCZU;:1^U)XA%V+WPM8W48%EH]ZY!8^P-?H=XEUM/#OAZ_U
M65=T=I TNT=\#- &J3CT_&ES7YV>"?B)\?\ ]HCQ%K&K>$]0MM-T2SN"(HY#
MRX#8Q^E;/Q__ &C?B7X)U'P]X%M)H[?Q'<1AKJY49 SZ4#/O:281J6/W0"2?
M0"N,T#XR^%_$K:HMA?I,=-+"XQ_!CK7R!^SY\=/BI:_$>X\)>+[:ZU73+J)R
MNI>20B?*>,UPG[*<\KW_ ,;09WD5)+K'S=.&H _0GP1\2-$^(EK-<:'=K=11
M,49AV(KI\]LC-?FC^S_\3/$OPO\ V6_%>N^'K635=76]<1QH-Q4;CS5'X-?M
M&_%/Q9K>D7NI^+;/3GN;@)-I=Y\C;<]!GO0!^GU%4])G>YTNUED96D>-2S+T
M)Q5R@ HHHH **** "BBB@ HHHH **** "BBDH 6N9\0_$70/"MU;V^JZA%9S
M3G;&LC %C72%@JEB0 !DFOR"_:Q^($WQ5^/'B&)-?;3K'P_(S0CS=H<KS@?E
M0!^O4$Z7,22QL&C<;E8="*>S8Z8)]*^//A-^UI;I^RH_BAY1<:AIEMY(0G+%
ME& 37#_!_7/VB?BY:VWC:QU&UBTBYEREHQ_@S_A0!]UQ:_8SZC+8QW,;7<0R
M\(8;A^%<_9_%CP]?^+W\,PW>[5D7)BQ7YO6MY\7;O]M77[#1]5VWBLAGB=_W
M07C.!7K5G\0-=7]J2_\ #UM86ZZQ'IS2_: .3(!_C0(^]\G'3FC<?I7Y_P#A
M7]M;Q1H7@WXD6OBW;#XGTB0I8P'AG.>,"NBU+XM?$+5O@)H^M7?B6R\-ZWJ+
M!D2X(#LIZ8% S[=#''K[BLZ3Q-IL6I+I[WD*7S<+;EAO/X5^<?P8_:I^)Z_&
M4_#S5KU-2DO$(MKHKCYNQKS[XE7/Q:B_;3TS2H=6/]OF5#$H?]UCMD?2@#]2
M;SXBZ-8^+K?PU-<%=6N$WQQ8ZBNFW>O%?'-UXZU?1?VJO!NA^(+:&?43IGFW
M5S'V;'.*Y/QA\0_C)\:?BCXHL_AYJ<.EZ+HB\"7@N1U_E0(^\R3G@4;O7K7P
MWH7[5_BV?]G'Q#J4X7_A+-"N?LDTG\+$'&:XO4?B[\>/#6F>%?&VKZA;-H&H
MSI&UO'UP2.M 'Z,9R,BC/X5F^'M2.JZ#87K#F>!9#]2,U\6_$SXH?%GXN?&7
M6/"OPXOH=(LM$4_:'F_C(&?Z4#/MO4-0ATJSFN[J18K>)=S.QP *X?PA\=?"
M7CO6Y=)T74DN[Z+.Y%Z?G7PSK/[1_C?XD?LW^--%NYA!XET2=[6ZN(SC>JY&
M0:Z[_@FK\.]=C\/)XGU.*)K6<$1W&<R,?>@#[,\6_%+P[X%N(8-;OX[*27E0
MYZUDV_Q]\$W-Y':QZU"TTA"HH8<DUF_'+X2^&_'?AW4-2UBU::YM;9C$RMC:
M0.*^5OV&OA#X=\7:AXJN]6CFO;C3K\BV:20G8 >* /OJ.<2HK+R&&1]*>21Z
M?2N<\<^((_ G@75]8*[DTZT>4+Z[1P*^"_A5\4/C]^TS=W_B3PK?VVEZ+:W7
ME+;RGEE#?X4 ?HQG!]O6LWQ!X@L_#.E3ZEJ$HALX%W/(>PKX#^.O[3/Q)_X6
MA'\/O#EV+*YL;=1=W"KN+28YQ46D?&_QWXR^!'C[0/&FGW275DC+#?M&5$BX
MH ^U1\</";>#_P#A)QJ"_P!C[_+^T=MU=?H>MVOB'2;;4;*026MPH>-_45^8
M\,\I_P"">MD1.^_^TN6W<GYJ[;XP?'CQY\-/A;\,-%\*Q2PVE_8(;C4]A98N
M.YH _1'- .:^5OV._B)XI\7RW<.O>)+37HD3<ODL-ZGT(KZH!R: '4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2UR?Q,\>
MP_#;PC>:]/;2W<=N,^5$,L: .KSF@'-<+\(_BC!\5O#$>L16,VGH_2.<8-=Q
MYJ XWKGTS0!Y1^T]X+\1_$'X3:IH'AC9]OO<1MO.!L/6OGCPU_P3;\-V?PEN
MM,OD!\13PL0RGY5D(_QK[?W@'G\Z;+*L:%F8* ,\G% 'Y\?#']@WQBOP0\3>
M ?$UW%%OF\W3KA&S@@\9KH?AM\*?VB_!6GZ/X5^T68T2QD"?;!(=QC!_PKZ,
M\!_M'Z'X]^).K^#;2&1=0TXG>YY4XKUO>/[P_.@#X"O/V2OBKX&_:5E^(GA6
M>UNH+Z4-<B1L$# W?UKMD_9G\;7/[5&F?$*;R!IJ1KYY#?-N[U]BFXC7@R*#
MGH6%<]\0O&T7@'PE?:[);27L=LFXQ0\LWTH ^)?VW?V+_'WQD^+-EXD\%74=
MO;7%OY%[N8J<?UKTGQ1^R/JU_P#LGZ!\.]/NUM]6TV$-(5.!+)UY->Z_!?XM
MP?&+PD-<@L)]-C+E/*N!AN*[_P Y 0I=0WIGF@#\U]8_9#^,_BW2?!^EWMII
MMG::+=QR,T;?,ZJ>IKVC]JO]FWQSX[U'X?>(_!DD!UKPW&JM'*V 2,=*]U\=
M_&ZV\#^-=*\.R:7=74E^0%N(U^1/K7I$;J5#E\;@#@F@#X+^-/[,?Q9^,MEX
M1O\ 44M1J]A-&UP-Q( !!XK7^+_[&7BV3Q7H7CWP7>1)XELH426W<X4D#UK[
M@617&58-]#2-*B-@NH8]B: /C;X!?LT?$ ?%K5_B)\19X!J<]J;:&WB;<*Z#
M]GK]GKQ9\-_'7Q:U/5C"+7Q&[-8E#SSTS7U6'##Y3GZ&O(?V@/VD-$_9[L=*
MN=;ADF74)O)C$?8T".*_9#^!?B/X.R^)GU\1+]OO'FA\LYX)XK=_;$^ 5Y^T
M)\*WT33+E;75;>9;FW=NA93D _E7L'A3Q);^+/#UAJ]O\L-W$)45CS@BM8L
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MXC KXK^&'_!/2VU!?$6J>/E6;5M2=W38<["2<5]T;O>FRRK$C.Q "C/)H$?
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M9^,OCCXW?M2R?#^VULZ#HEI&SLT;;&.#7W=X!\,?\(9X+TC0MPE%E;K 6/?
MQ7SA\9?V';;QO\1XO&7AK5)-!U,C$SPL5+#\* /%/V8]-NO"'[0'Q,A6]-_=
M6MK*R7+')) /.:[']FZ[^(OQU&HWMQXKEL[2TO778I[*W2O0O@9^QM/\)O$7
MB/5;G6'U"XU:W>%I';)RPQ7?_LZ_ (_ _3=5MOM/V@7D[R]>FXY_K0(^7?CY
M\3+2Q\5ZUI6F>-]0FUJQ!4VUH255@.]<9\#OVFO&_C+X)?$:/5[W[5)I4;_9
MI9.6XSUKV?QS_P $]?[6^)^L>*]"U@V!U1F>9&.22>M6/AM^P'_P@7@SQ;H@
MU(3MKJ,K2%NA- 'BGACX^>,+#]@Z7Q;9W@MM:346C$B<#;4'B_QI\2=$^"_P
MV^)2>+)Y;K5W0SP;CMQGD5[]:_L)&V_9ID^%XU/&ZY-P90:Z+Q-^Q[_PD/P,
M\%> ?MOEKH)4F3/WL&@#A_B[\4-;_P"$Y^%+(ZJFII$9LCDD@9JG\7O'OC'6
M/VI?#/@32]:ETS3=0C DV'VKU_QI^R[_ ,)/K?@B_6\V#P\J+C^]MJ?6?V:6
MU3]H#0/B)]JQ_9H"^5ZT >&?"?XI>+_AW^T/XR\$:EJLVM:=IL,DT9F.6R 3
M7'>$O$GQ!^+.F^/_ !O<>+I=.BTII3:V:28&%S@8KZ?TS]EZ.P^/NN_$2>[\
MV+48V5X#Z$=*^*/C%\.].\'ZWXT'AC7+VW6]D?=I$(<[V/H.E SZK_X)Y_$_
MQ#\3_AC>W_B*\:\NH[EXU=CG@'%>=?\ !51@FB>!LC@Z@/YUW?\ P38\!:UX
M*^"A.M6$NG37$S.L<PPS G@UWW[5G[- _:+T_0X/M8MCILXFY/6@1\S_ !7^
M)7CKX()\+M<LKZ0>$[R.*.XB_A P*Z3X3?M"^+OCA^TI=VFFW3KX1TRQ>5FC
M^XSA3@$UZ5^UCX%TC2_V8!H.HPM>W=G;K%:;5);>!CC%0_L&_!!/AW\''N[B
MV:WU'5XR6,J_. 10!\Z_#+X@_$;XU:W\4K6;Q//8P^'XY9H%B8@\,<#]*O?"
M'6?B+\4?@9XD\07/BZ>"XT%G\L*QR^WU_*OH/X+_ +'3_"W4_B!>M?\ FGQ-
M&\>W/W-Q)_K6O\*OV4_^%>?"[Q1X4^V[SK!<B0'[N[- 'B^K?M!^,+G]C.P\
M51WK0ZYYA@:X!ZX;&:YSXJ^,/'GPH\!?#WQ_;^+9=1N-6:,3V9?(.<9XKJ/V
M@O@M>_"G]DX^#+-9=1E#E]\2EB,MFG_!+]B>^\5:1X-UKQCKD^H:5:VZ2PZ:
M['$;=N#0,X+X_7-Y\2/VA_A5<1W#:=J-[;J3*."AQ72?#3XG^-O '[7EQX'U
M#7)=7T>2#<!*<X.:^A/'_P"RU#XJ^+_A3Q=:SK;0:&@181QD"LZX_9*\_P#:
M)/Q)^V[?W>SR<T >T_%+4Y]%^'6NW]JY2X@M'D1AU! K\\/A%XM^(GQF^&OC
M77IO%ES9R:+YLL*(QYVYP*_1[QIX=_X2OPEJ>C[MGVJ!H=WU&*^??@O^Q^?A
M=X!\7: ;[S3KB2("#]S=F@#Y@\,?MG^.]+_9=O=3DF-SKGGFVCO&YV#=MR:Z
M?QT/'_PN^%_A/XAP>.);R\U#RIKBT>7*G=@D 5[9\,?V&="\,_!_6/ ^NN-0
MCOI&D2;/,9)R,5Q&G?\ !/;5+J_TZTUSQ7<W_AW3Y@\%DTI(" \#% &)XY^.
M_B[XO?$?P1X(T_47\/VVHVRS7-PAVL3CG!K!T/PK/\.?VXU@N-7EUR:'3/,:
M>4Y;Z5]"?'#]CK3_ (CSZ)?^'KMM U;2D$4-Q"2IVCZ5A?"K]B[4/!'Q=C\<
M:QKSZU<_9_(D$S$EA0(^:?&?[0_C7X@?%;QO8)J=_9V^E2&.RMK,'DCIFN[^
M'OQZ^,6H_ +Q:U[:RC6;!"+>5UP[+_C7J?Q-_8;;6?'U[XJ\(:N=#NM08M=)
MV)K<T+]DK5--\"ZEI,_B*:74KL<7 8X!H ^8O@!\9[[5O$.DQ>(O%^H:3K5P
MXWVUYE4<YZ"OTXLVW6L)SORBG=Z\=:^,/!'_  3\%OXPL-:\5ZJ-4%BX>$)P
M<@YYK[/M(Q! D0&%10H'L!B@9/1110 4444 %%%% !5;424L+EQU$3']#5FH
M;N/S[:6+O(A3/U% 'YL?"KXS>)9?'WQ>5K@*=-CE:VV#&",XKC?#'Q.^)WC;
M]GOQ!\0W\5SPW>CWFR. ,<,-W>OJCP?^Q*WACQ#XXU(ZB'_X2)74C/W=V?\
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M[M^JKG&2:I^//'WQ$^&'P^\ ^(_^$OFOKO7KE1/$),A02.*]OU;]D'0OAO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 1N1BLB;P?H<]W]JDTFSDN,Y\QH5)S6Q24 -CB2&,(B*B#HJC %/HHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44QGVGG@>IKF]8^)OA;0+HVVH:Y9VTXZH
M\H!% '3T5FZ/XCTSQ!;^?IM]!>1_WH7#5?#DCI0 ^BO*_BM\?M+^%6MZ+I=Y
M97%Q/J<ZP(T:_*I/<FMWXA^,-=\/Z'%=>']#?6[N10PA5L8!&: .VI:\E^$?
MQS;X@:G>:/JFDR:+K%F,S02,"!^->II=Q2G$<B28Z[6!H GHI <BEH ****
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M.,$YZUP>C_\ )P&L?]<U_E0,]G P*6BB@ HHHH **** "BBB@ HHHH ****
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MJ$<$"O./@-\<-'^/7@W^W]'1HH5D,3QOU4UZ2$P>M QU%%% !7C&D?\ )?\
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M5S&J?$OPMHVI?8+W7;*VNP<&&24!A]16I>^)=*TW31J-UJ%O!8MTN'<!#^-
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M ">QXV_Z]!_*OJWTKY3^'/\ R>SXV_Z]!_*@#ZMHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH YWXA_P#(CZY_UZ2?RK\I=&_X^;[_ *ZO_,U^K7Q$_P"1
M&US_ *])/Y5^4NC'_2;[_KL__H1KX_B7_=T?JG '^_2-&BE[4E?FA^^#U[5G
M:Q_K;/\ Z[K_ #K17M6=J_\ K;/_ *[K_.NO"_QH>OZG%C/]VGZ,_4/X,_\
M).-&_P"N(_E7;5Q/P:_Y)QHO_7%?Y5VU?MZV/XZCL%%%%,H**** "BBB@ HH
MHH **** "BBB@"O>7<-C"T\\BPPH,M(YP *^"_B]JGQ&^$_QJU_Q5X)T"7Q%
MHVOQ[!<0#>O3'%?6O[0S21_!SQ4T;^4PLG._..U?&_P5_:P\;>&_ACI>G0>$
M+C4XK8,J7!B9MXSZT"/?OV)/ 'B3PEX$U2_\4P26>IZK?/=FW?\ A#5](UY-
M^S_\5-9^*?AZ6_UG1I-'G20H(G4KQ7K- PJK?ZA:Z9;M-=SI;PKU>1L"K5>
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M'X?\-6.CJY>&UMU@#'J0!BO!/&O['5IXGU+5WM_$.H65AJCA[BTA?",0<]*
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M/U$^#7_).-%_ZXK_ "KMJXGX-?\ ).-&_P"N(_E7;5^X'\=QV"BBB@H****
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M%*$ &,56@U&WNV9(+F*9P<$1N#BN:^(7Q*TCX;^'[C5=3N5,<) ,2,-V3[4
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MKO'V5W.4P_ VU]A>#O@5H?@W5FO[8O*^"%C<Y50>V*RM;_9D\):]JEW>7%L
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MORGT3_7ZA_UV?^9KXWB7_=T?J7 /^_2-(4M(*,^QK\T/WX4=:SM7_P!;9_\
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M\/\ V-MS?!JQWR/)M<KESDD5[A(-N?K7SU2/(W&^Q]M3FJL%-*US\^?VQ?\
MDOB?]>@KR4]:]:_;%_Y+XG_7H*\E/!-?D6?_ ._2]$?T]P7_ ,B:'JPI#2TA
MKYT^W>S,+QS_ ,BS??05^F'[,/\ R0SPI_UZK_*OS/\ '/\ R+-]]!7Z8?LP
M_P#)#/"G_7JO\J_1>&?X4S\+\0?]YH^AZK2T45]NMC\D"BBBF!GZWH-AXCTZ
M6PU*V2\LY1AX9!E2*X _LS?# MD^#-,/_;.O3Z* /,?^&9_A?_T)>F?]^_\
MZ]=QX=\*Z5X2TY;#1[*+3[-3D0PKA:UJ* $ Q2T44 )2T44 %%%% !1110 4
MF,TM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 55U*>.ULYYICMB1"SMZ#%6JKWUK'?6LMM*,Q2J58>QH
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M]6HHHK[=;'Y&%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N"^+?@;3O%/ANXDN;9)98!YGF-U ')KO:IZG;QWEE/;3?ZJ9"C'T!H
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M^*,N_P Z7_AYC'@?\47=_G0!]TT5\/1_\%+[,J=W@Z]S[&O6/V=/VO+'X_\
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M,****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OB&VD
MO-%O8(FV2R0LJ-Z$CBM*HI]JJ78X51DYZ8H _*?XH^,]9^';^(_ OC2VUE](
MU6^$INX Q!B[@&NZ_8SM_#MM\<+6/X96VL6WAXV__$P.HAMK2=R,UWO[3_Q_
M_P"$J\6MX*\%^#8_%FKVX_?3>4&$7MG%=-^Q]\7R==F\%>)/"D?A3Q'L\Q%$
M84RCZXH$?7]+29I:!GD'[2'BOQ=X5\&)+X.L6O;R5]DNP99%[D5PGP#O;C5-
M/U#1;W0;VVNKU"]S?W28WL1TS7TL8@WW@&'H12>0B?<1$/LM CY*EM/'-A!/
M\.8-%#:?)=[UU  [/++9KH_''@37OA9XNT_QCX=LCJS-;"UNX!R5XZBOI,1
M'.U=WKCFE,8.00"#V(H&>#? SX;ZC>Q>(-2\7V<3?VO)O6V(R A[$5YW\%O#
M>F^$OVQO&FGZ1;)9V8M ?*08&<5]?*@7H !Z"OE3X<\_ML>-O^O0?RH$<?\
M\%#E&W2,\\K_ #KY**#(SZ5];?\ !0W[ND?4?SKY*/\ 2@8WRE]*4* ,4O-
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MK_\ N_UH ^ZWZBOSQ_X* ''Q=\,U^AS<D5^>/_!0'_DKOAFNW!?[Q$\C-_\
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M:'JPW49S3:!UKY^Q]O+9F'XX_P"19OOH*_3']F'_ )(;X4_Z]5_E7YG>./\
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M*7^P--_Y\8/^^!7NK.*RTL?$/A/"RU<G<_+8Z+XB_P"A<U#_ +]TG]B^(O\
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MT3;3[=GW&%,_[HI_V6'&/*3'^Z*TIU)4Y<T3FKT(XBE*E/9GY:-X0\8ER?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>cvac-20231231x20f019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (B L8# 2(  A$! Q$!_\0
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MY4=30I#(2#QZTUJ $8HI%.1ZTM @HI 03C(SZ4[:<XH&)0!D4H'- 4L<@9%
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MS:GH,C&:;X'^ -A\+_&.J^+[O4WN8+K<9(2,A0?:O;.')#<@]C3+FW2> PN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&:Y*ZY;[IW^\WS#K7V5X>YT+3_\ KW3^0K!ZR;6Q=.+C!*6YI4444C4****
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MJY@ZU-24;ZL[6BHXVR",Y-.)&<9Q4&XZBDW"EH **** "BBB@ HHHH ****
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M,9KW,)'ZQ1]K/3J?C7%=2GP]BWA\._:V:C=:*[=CZ<^-GQ2;X::!!?(H>=V
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MCIIY]V4;6$PPE$78@7"J!@ 58C&Q%#=:FHK4^;$5@>E*.]%+0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 444F: %HIA)SCBFJ[G.0/:AZ M26HKC.P8ZYIDL[0H68A5'4FN
M!^(7QH\/>!=->6\U"$3]%B##<3Z8I-I*[.BA0K8F:A1@Y-G:7TRV["6680Q
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M44 %%,:158 GDT[<* %HJ-ID5MI/-/# ]Z %HHHH ***0L!UH 6BD# T9S0
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MCIHW_7PG\Q6K^%^A\]AU^^CZQ_,^K?VI_P#DG5E_UVC_ *5W7PC_ .16M?\
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M6_B&?^+6^'Z\I;E17JOQ%X^%OA^O*F^X*YZ'VCZG._XD%_<C^0@X(K0\*?\
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M;K2=6G&/PR-,/E3;?UC32Z/K9)U=%;/!&>:>)%(SFO%] ^*5UIWVVSU@C[3
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MPQS6MPPV",]!4+,:'.ES::E4,BQF*C%TX_$KKNSZ&^)OCV3P'HDM_'&)=H)
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M3^=9PZBM#PI_R.FC?]?"?S%:_9?H>!A_X\?6/YGU?^U/S\.K+_KM'7=?"/\
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MI[5V7BI6;PEX>/?R>37H*E&DD?(0S:MF->O5J72Y-OF<I&,)UJ-SN;UH0G8
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M*DIWOJ-*RL%%%% SY%_X*(<>%?!'_8=@_P#0A7U3X>_Y 6G?]<$_]!%?*O\
MP41_Y%7P1_V';?\ ]"%?57A__D Z=_UP3_T$4 :-%%% !1110 4444 5&D$4
MAW=ZY3QO\4M(\"1AM1=N>BQC)-=<T"R9)Y:OFKQQ'!<?&RUBU5R+ H?EDY4U
MSU:C@TDCT<!1A7JM5;M>1[7X=^)&C^)M);4;27]PHW,&X*CW%<S_ ,-%>%_[
M4>Q_?[E;8)-GRD_6N#\8)X7T[0=77PI<L9SC[2J$X7Z5>DLO#(^&MO+LA\[R
M<F3C?NKE>)E&;1Z\<NHMW<96;^:]3TOQ!\6M$\+V\4UX[%95W*5&<UG>'?CE
MX=\47WV2V:2&XQD+*N 17C6HVD>IVNA07F94RNP'N,]ZTO&FDZ9H_CG2@H^R
MP>1^\:,8(%92Q<U'F:ZV-/[.PR]R5[L])U;]H+PSHVLG3)?/>X#;2R)E1^-4
M_BU\7U\->#(]0TURTDS@+(HR%%>57NC6D,&I7>E7Z:K"%+-'*HW8^O6IWU&V
MUKX(I<?81"%N-I5SN[]>:WG5FN6+T?Z'6\IPL'3:3=W9W/2O#_Q]T?\ X1FW
MO;\RM)M 8[,%C[5N^'/C=H'B#48[.V\Y)9?N^:N*\OCT73M1NO#-N\4?DNR$
MJN,'BM[Q_8Z?X8^(V@F.-+:#:!E1C)JJM2=-.3VO^!A7P&$=14X)\TDVOD>J
MZSXXL-"U*VT^X<FXN.4QTKGO%GQOT'P=<QVU\TCS.0-L0SCZUPOCW6K35O'N
MCQ0SJTL8/W.:P_#-IHMY\1M;3Q&Z/$(^#+T QVJYU6HIKJ<$,NC&DY33O:]C
MJ?BE\<TT"STRYT^5GM[KDE!DBO1?AQXN3QCX<@O(U<$CDN,$UX5XVMO"']G:
M>?#LZW=JLY#ALD ^@S7N7P^>WA\,6PM%0':/E6JA*4JEC3&4:$,%"<(N_70[
M!>@IU0P,[Q R+M;NHJ:ND^93N%%%% PHI#31)@988H ?13%DW=.:;)-L7)XH
M EJ&X?RTSM+?2JM_K5MIUHUS/*D42\EF. *^<OBQ^V3I.BF73/",T&KZV&V"
M$9.&]*ERC'5GI8++L3F$N7#QOY]%ZOH?0^H^(;+2(?,O+B.W7UD;%0Z;XITW
M62/L5Q'<C/6-@:^1-)^'_P 3_CY*K^,[JYT;2),/Y-N-N1Z9KZ.^&7P1T/X8
M6B)IDER[X&7FD+9_.IC)R>VAVX[ 8? QY9U.:?EM]YZ1FEI *6K/ (I -W/'
M%(54X.*>\0?OBFI#L!!8G/>F  #=US3FC![4U(=ASN)J6CT$1E1C&"*:L?R$
M'I4A4D_>XI0,#'6C;8"-5"C %-,67!''M4I7T.*-OO0 QTX('4TV.,A3N.?:
MI-AW[MQ^E.H\@ZW(UB"CH/:F-"6.0:F92RD9Q2+&0N"Q-";06OH,\D @\YIX
M&#TI=I_O&E QWS0"5A/XO:G4F.:"2.G- Q:*;N.>F*,G/2@!U%-WC%1+.<D,
M #V% KV)Z9(H9>:&<A<C%4=4U:+2K&:ZNR(;>%=SR'H!1N%[:E/Q5EO#&J?]
M<&_E7YTZ@@&IWG .96_G7W)+\6O#'BS1M4M-,U)+BY,#_(/I7PWJ(/\ :=YC
MIYK?SKW<NBX\R:/QWCRM3G"BXNZ=]A416_#TIQ.T8 I@^49]:,\@U[=WL?D=
M[02CN)=9^S\>E=IXG/\ Q27A_P#ZXUQ=VVZ#IC%=IXG_ .12\/?]<:Y:RM8^
MDRNR^L)._N+\SC,\"BC^$45U+9'S741N :[7X/\ _(V)_P!<V_E7%-]TUVOP
M?_Y&U/\ KFW\JPK_  'T/#W_ ",8>C_(YOQ"<:]J'_75OYU0;[J^]7O$'&NW
M_P#UU;^=46Z+6B^&)Y%7^)4_KJ->D'4?6E?E:0=1]:LY#UOXB?\ )+?#]>4$
MY2O5OB)_R2WP_7E1&$KFH?:/J\[_ (D/\$?R&KU%:/A3_D<]&_Z^$_F*SUZB
MM#PI_P CIHW_ %\I_,5K]A^A\_A_X\?6/YGU=^U/_P DYLO^NT?]*[KX1_\
M(JVO_7-?Y5PO[4__ "3FR_Z[1_TKNOA'_P BK:_]<U_E7YY3_P!XF?V>_P#D
M7Q]3MAT_&B@=/QHKO/(0^BBB@D*1NE+2-TH ^1/VD)!X=\<1ZGJFCGQ#HI*[
MK9QE%'<D5)\*O&GPN\2>)[1=$\!:?87NX8NHX@"AK3^,LC^-OB-_PBNHSFPT
M4@;IQ\I;/4 USFJ?"'P_\!_$6B:AX3OY+ZZGG4/:N^\%2>366#N[)]V/%/5^
MB/L5,!  , #BGU#:N9;6%R,,R D>A(J:M1!1110!\B?\%$?^15\$?]AVW_\
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MOQ?^.FJXB272/#\C8!"%7*FO;/"/[(/@O07@O[RU?4-2&'>6<[COZUDY2EI
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M^+6^'Z\J;[@KU7XB?\DL\/UY4WW*YL/]H^KSO^)#_!'\A%^\*T/"O_(Z:/\
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MUD9E25"C%>N#6LM=BH*T4CY)^)%I OB75;71YY4TKR]TERDF0S9Y&:YS6/\
M1-<T#18KZ9-,N8EFDS(1\WN:]^\/_LP>'-"LM1M$O;VXAO9#(_G/DJ2<\5.O
M[,WA9=*DLW>YE9GW+.[9=!Z ^E=&'J*G&TC'$4Y5(VB?(/[6GBB\MX_ GAB.
MQGN=+_M>%QJ).44AAA<U^A?A_C0M._ZX)_Z"*^//VX_"UEX-^'?@+3K,N8H]
M<MQO;EC\PZU]B>'O^0%I_IY"?^@BLIR4I71I2BX046:-%%%0:A1110 4444
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MF^Y"D)5LDY-2!<4ZB@R"BBB@!"<"D#9[8I33%SR6XH DIN_G&#2[A29R>#0
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MM0=I?<0'SZUT1R?&PH^S^L_^2GC/Q R*6/I8UY;[D-.7G\K7^$R-2U&9+96
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M4J]TW>]NQP87CS(WBJ*J9:^51Y;>TOJ]$]NA]5_M1<?#JQ'WOWL?-=]\)/\
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M$//BR/':-OY5Q9Z5VOP>&?%B_P#7-OY5A7^ ^AX?US&'H_R.9U[_ )#FH?\
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M_DJ6L_\ 785\)Q3M1]3^ROH\?'F7_7O_ #/5S_QX6G_7)?Y4@Z4$_P"@6?\
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M/RP-HX%:JRA;J1&+3UD_P/E3X)_'SPYJGPSG\'V_AN^T;0XX'MXWO%(9@<C
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M7J<;;KQ4&TR@=1CO6GIWCGX516B2V6C2&YE^64E02WU%1%)PYC*G)\SC*3_
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>cvac-20231231x20f021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (_ >D# 2(  A$! Q$!_\0
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M0,^97D^J?'_P+I%])83Z[;+>QS_9WMP_SA\XQBN_CFCGLQ/$P9'C\Q6]L9%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YKQWXU
MB\"Z0+^6TN+]FD$4=M:KEW8] *YKP+\<=)\;^(;C0FL[S1=9@3S'LK]-K[?4
M4 >E453CU*VN'=(KA'D0?,H/(^M$6I03!S'.DH3.XJ<XQUS0!<HKRO1/VD_
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M1110 4444 %%%% !1110 4444 %%%% !1110 44F>,TM !1249H 6BD!S2T
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MZ+_9-X^ GA+G</LB\_A0,]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFD)J3V9;TQ!_:]GG_GH/YU^GG@CGPUI'_7LG\J_,/3#_ ,3BS'_30?SK]0O
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MC_D5-)_Z]T_E7Z!PSM,_"?$;;#>C-ZBBBOO3\3"BBB@ HHHH **** "BBB@
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MV&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJO\
MR#;K_KFW\J_+KQK_ ,C;JO\ U\O_ #K]1M5_Y!MU_P!<V_E7Y<^-?^1MU7_K
MY?\ G7Q'$_\ "AZG[!X=?[Q7]%^9BC[U-+<T[^*D(YK\Z/W_ /R <BDH/2@4
MBD6],_Y#-E_UT7^=?J'X(_Y%32?^O=/Y"OR\TW_D,V7_ %T7^=?J'X(_Y%32
M?^O=/Y"OT#AG:9^%>(VV%]&;U%%%?>GXF%%%% @HHHH&%%%% !1110 4444
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M#^Q;\;/"OC_[-\.;.+5O#T\QG6XW!6B9FR0<_6OUC9@JDD\"O"_'W[:/PO\
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M([^U>E?LE?\ ) _"8SS]D7CTH ]AHHHH **** "BBB@ HHHH **** "BBB@
MHHIDLT<*[I'6-?5C@4 /HJJ-3M#TNH#_ -M!0-2MC_R\P?\ ?P4 6J*KQWL,
MW"312-Z(X-3@Y - "T444 5-5_Y!MS_US;^5?EUXV_Y&W5?^OE_YU^HNJ_\
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M*LR!T.5/<4^K)*FJ_P#(-NO^N;?RK\N_&W_(VZK_ -?+_P Z_435?^0;<_\
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M;7C/FYF<\\DP$N:/LEJ?IA\%]5N=9^'NEW5VYEG=,LY[UW->?? ?_DF&C?\
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MY5Y'^UK\>X;[P1XJ\&6OA36=0OY(C%'+!;,4)]0<5B? C]JZ'P)\+M!T2_\
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M[=_!?B#?%"J-_HK=0/I7VG#^&JX=251'X_QUF6&S&.&>&J*5D^Q]6T5\R_\
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MX%1Z;J%OJUE#=VLJS6\J[DD7HP]:LT"(OL5O_P \(O\ O@4GV*W_ .>$7_?
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M.F:/8:QJFG1VOBB>U2.]E'+,<=3[YKT% 0.: &K'M?<?2I*** "BBDS0 TR
M9[D=17B7[7NO:QH'P8U.]T)I$O Z!C&,G8>OZ5T_Q1^//@_X07=I!XFU$Z>U
MUG9(8R4XZ GU-='I6H:;\0_#4%TUL+G3+V(2HDR_>4]\4"/!_@Q\&OAU\2O@
M'# +6*^:^B9[JZ=OWL<Y')SU&#7D7P6\#R_$^_\ &WP:U[4GU*U\,PB?3-84
MY>-V? PW?''Y5ZAXM_90\56GB*XG^'OB]_"VA7;%IM.B!P<_>_K7L/P=^"^E
M_"73]MM$LVJ3KMNK_P#CE[\_C0,Z'X;^%+WP9X/TW1K[47U.:SB$7VF3[S >
MM=1CFEHH **** $)Q2,^T<@TCG:1WSUKP_XS_'E/@QX_T :])';>%;\>7)<L
M>8W['% C#_;?\1:EHWPTTV*S$JV-WJ<$%^\?58&;YL^V*U?%G[//@7X@?"FV
MM-/M;>!$M5>TOH&"LCX^\6'6O2)?^$:^,W@IA$T.L:+>J0)!RI/K^%?.Y_9%
M\>V&I2V6F_$*XM_";.0--!.0A[9H&<Y\(?ALWQV\+7?ASQ!?/-K/@/4?LFG:
MW$>9%'.<]QCBOL_1;&33-(M+268SR0Q+&TC=6(&,US7PT^&NF_#'PU!I.FQ*
MK8S-/CYI6[L:[.@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DF
M0AQUKY _:Q_9FU_Q)J<GB[P-<_9WF4_VQIR2>7'>H.F1_$:^PJ:R*RE2H*^A
M'% 'YY>,O$/P^\0> /"%KH&G+H_Q TNYAMGCMK?$@93AU+#J#7VQX,^'?AW2
MX;'5X] L+369($,MS% JR%B.<FH],^"_@[2O%5WXAM]"M5U6Y.YYBH//J!V-
M=T      /2@!%Z4ZBB@ HHHH *R?$?B33_"6F2:AJ4WD6L?+2'M6M7S!^TCJ
MWC/2K[4;6[T=]:\#:A#Y12S&9HF]:!'%?';Q!H?QD\9:-X?U=K:?PIK:%+._
M7!:-QT)]#FNE\":O\7_ %E#X'AT2'4K>V(BL-6>7I;CH3ZG%>-_"7X":'\=?
M!FJ:?I.H:GH6J:5=@PPSAAL4'(Y/0_2OOOPGI$NB>&]+L+J7[3<VMND+S'DL
M0,9H&7=*\\Z?;FZ %UY:^:%Z;L<U;HHH **** "BBN+^)GQ,TGX8:%+J>JS;
M>T4"$>9*WHH[F@!WQ!^*?AWX:VRW&NW+0(PR B[B?PKY9\0ZQX;\4?M&65SX
MO,>K^$=7LB=/6['F0H<=QT4UP/QK^*6HW_C>"^U#1+T6>M1!;"6]C/DVQ/!+
M@=.*]+^&>@>%/%6JZ/X$M--;Q!HR6QFU#4WW+Y4Q&=J-V&?2@#:^ WG>!?CE
MK7A7P@9-4\#20+<22,^4M9#V0>E?6 -<G\/OAIX>^&MA)9^'[$6D,C;I&9BS
ML?<FNMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M3 I:** "BBB@ HHHH *C>".52KHKJ>S#(J2B@#/L]"L-.N9I[6UBMY)CF1HD
M"[OKBK_2EHH **** "BD)P*X_P"*/Q$@^&7@V]UVXB^T&$8C@!P78]!0!#\4
M_B;8_"[PS)JM\V2Q\N"/O)(>%4?C7R/XRO-6_:E\6V_A'5X%TCQ#HJKJUE<1
M$A$(Y"./4TSQ/\7-8_::EN_ >L^&)/#VIVB'4;&]BEWIN R@)['I5+X8:#\1
M/$CV?AV/PK<^'-2:X#ZIXLED+O=1@]%] 10(^@O@KK=_X^TK4/"?CC1(VO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>cvac-20231231x20f023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'A >\# 2(  A$! Q$!_\0
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MG[._@3PIXMUKQU=>)3%>RKJ,X*RSA< 'T)KZ?T#X26_@VXU";1+86B7.2\2
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MOSZ^(_PYT+X>_MJ>%#H[S>;J$J/.)Y2XSGMZ4"/T-C^[US3Z9'TI] PHHHH
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M;X;W]HG&&=3SFOIC2;N2_P!,M;B:$V\LL8=HFZJ2.E RW1110 4444 %%%%
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M!&12T4 1F"/_ )YK^5?'?[(:*?C?\2 54C[3)U'^T:^QS7QS^R%_R7#XD?\
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MHH **** "BBB@ HHHH 0U\<_LA?\EP^)'_7S)_Z$:^QCTKXY_9"_Y+A\2/\
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MGQAX!UWPI^VOX<GU35FU);F9)(EZB-<]*!'Z/1C"TZF1]*?0,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!*6F; >>]+P.,T>@A3T-?'/[(7_)</B1_U\R?^A&OL7 '?K7QS^R$/^+X
M_$@_]/,G_H1H ^R**2FD!N*!CZ*;@ 8I0: %HHHH **** "BBB@ HHHH ***
M* "D-+10!\X?M4_"CXB>-)=*U+X?:S]@O+%23;.?DE;.1G^5<!I'QH_:?TS1
M%L+KX3P7FI1+Y:W*S81P!@,:^QY66*.21B0B L2.V*Y7X??%'P_\4K74)_#U
M[]KCL+EK2X(X*2#J*!'SK^SW\/OC=J_Q&F\7?$NY32[?&8M)MGW1KGL:^N5S
MCFFH,-UIX&*!BT444 %%%% !1110!6NTD-O*(L>;M.S/K7YU^,](\66/[;7A
MY_$ERDD;RHUL(B?N9Z&OT6G#>2QC^:3!*@],U^?OQ/N?%4W[:WA$Z_;PP1+(
M@MO).<KGO0(_0:/I3Z:GW:=0,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S/QW\?/"?PYU./3M9U#[
M/=R L%([5@?\-;?#HD$ZH2?7::^9OVU(Q)\7],+_ # 6K<'ZUX@NWIM'Y5\'
MC\]Q&&K.E32T/VK(N",)F>!CB:LW=]G_ , _0;_AKGX>G<!J?8X^4U\X?LZ?
M%KP[X$^*/C/6M6NFM['4IG>!BOWLMFO!HX^3D#&?2GNN[KR!T!KSGQ'BKZ)'
MTO\ Q#G+EHIR^_\ X!^@O_#77P\_Z"A_[Y-!_:W^'B@D:K^.TU^>YB _A7\J
M8(-Y/( ]A1_K'B_+[A?\0XRZZ;G+[_\ @'ZA^ ?BIH/Q,@EDT2[^T+$<,<8K
MLU.37R1^PY@0:FH&#C.:^M('W@FON<MQ,\7AU5GU/Q#/<OAE>85,+3=TB6BB
MBO4/ "BBB@ HHHH **** "BBB@ HHHH JWR[[2X11AFC8#ZXK\Q/!7A7XO?!
MWQAXNT_PIX@LHHK[4GOY+=B"1N8U^FNJL_\ 9=ZT(_?+#(4S_>VG%?B-_P +
MJM/ _P 4O$%UJOB"]DU>9I89[=MP"R;B  #^% C]A_@E>ZY?^!;*?Q'<I=:J
M<^;)#]TUVFK:U8Z'9/>7]S':VR?>DD. *\-_8DN]7U#X(6%WJY<O<2-)"9,[
MBAZ9S7J/Q*\#Z7XZT![35YW@L83YKLC;1@>M S9T3Q7I'B1'?2[^&^5/O&%P
MV*U X.:^0_V>+*VA^.6KQ>#I[B7PE;0[)MY)7S<^M:/QL_:OU#X$>*;O2M7@
MA+7O_(+63DNQ]<=!0!]5-(%&<&J]OJEI=221PSI(\;;753G!KD?AMJFM>)/A
MU87NM 6^K7ENTIV<B/<./YU\W?LIZEKMEX]^(UEJ&JRZF+6^FVF7G  ) % '
MUAJ?C+1-&O([6]U*WM[F0X6)W 8UH7.I6]I9O=2R*L"(9"Y/ 4#K7P7+H4_Q
M'\/_ !3\9ZCJMR=0T:-Y+)%; B9.AKTCX5W/BSXV_LSQ6XO7CU55"F=6YD0K
MR* /HCPC\2=%\?Z1>WGA^]COUMF9&\HY^8=J^$?&OBCQ'KW[;/AG^V]*?3TA
ME1+=G&-ZYZUZI\!+/Q9^S_\ #;7YM0TE[N9KDF*$(?FYZ\5XSJ?Q5U#XI?M<
M>#[F_P!+_LN>WD2-(I%9<\^] C]+$Z4ZF1 @'-/H&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^?W[
M:0_XN[IW_7JW\Z\-7[QKW/\ ;2_Y*YIW_7LW\Z\,7J:_'\W_ -[F?UCP=_R*
M:8J\9H)H!Y-+BO%/N!"<T1]#2XI$ZO1T ^N?V'?NZI_NU]96OW*^3?V'?N:G
M_NU]8VOW:_7<C_W&!_)?&7_([K%BBBBO=/B@HHHH **** "BBB@ HHHH ***
M* /-/C?\9M+^"G@^ZUK559@(V$:J,\XXS7Y?:-^T/\%?'.DZYXA\7>$(;CQ=
M)=R-;30P\=]F1ZYQ7WY^U1XNO-+O=*TAO#,6OZ9=PLTWFH"%.<8KX<N=>UGP
MIKE[9Z/\#(Y+59]R2M:[MWN#B@#[\_8Z\7ZKXV^#&FZAJEFMB22L$2Q[ (_X
M>/I70?M$^!/$OQ&\!OHWAG4O[-GFD G8'!=.XJU^SUJ^H:W\--+N=1TE=%N&
M3FS"[=GMBO3  #GO0(\"^ 7PN\8?"YI+&[^P0Z41N<PI^\D;U)K6\5_LQ>%/
MB)KE[J_B>.;5)YQB(S-GR1VV^E>S;1G..?6E  H Y?POX5D\'>#XM%L9WN/L
M\;)"]PVX@?P@FOGGX0? OXA^ _'VOZU<W5L]EJ]VTL\6.2A]/PKZNP*,"@9\
MB^,?V=O&>FZYKNF>$KU(O#'B;*7\$YRR*?O%?2O?_@_\+K'X1^"K30K#+B)0
M'=CDDXKNMBYS@9I0H% %6[,45I+)+&KH@+E2H-?GMX_^(FD^./VUO"T>G0>3
M]BE2.3*;<G-?H;,52&0RD"( EL],5^?OQ+U'PM>?MJ^%/[!$!=9$%P85Q\^>
M] C]!DZ=/QI],C.1]*?0,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#\_\ ]M+GXN:;_P!>S?SKPQ?O
MFO<_VTO^2N:;_P!>S?SKPQ?OFOR#./\ ?)G]8\'?\BFF.'>EI!U-+7AGVXUJ
M2/HWTI],C/+T^@SZZ_8=^YJ?^[7UE:?<KY,_8=^YJG^[7UG:_=K]=R/_ '"!
M_)?&7_([K$]%%%>Z?%!1110 4444 %%%% !1110 4444 ?$/_!3OQ=JGA#X>
M6%YI5XUI<*RDLIP2 XKF] _;^U:+1=*23P#-,PMXU:3[,V7.T#=T[U]/?M$_
MLZZ9^T#HL%AJ<NQ(64A?7# _TKT;2_!NCZ7I=E9IIMJR6L*0J3$N<* /3VH$
M8GP>\:O\0_!=GK<MB=.DGY\AEV[?PKN:KVUI#;*J0Q+$B]%08%6*!A1110 4
M444 %%%% $-PD;P.L@!B(.[/3%?GY\4-.\,V?[:?A-M 6'S&EC-P+?GYL]Z_
M0*=4:WD68@1%2&)XXK\_/B/X9\.:%^VIX6?0[L223R(\T<4NX!L]Z /T'CQB
MGTR/@$9S3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH _/_P#;1Y^+FG?]>S?SKPQ?OFO<_P!M'CXN
M:=_U[-_.O#!]\U^09Q_ODS^L>#O^133'#J:/I2#J:4UXA]P'--C'+>]+DBB/
MDMZT= Z'US^P]PNJ?[M?6-K]VOD[]A[[NJ?[M?6-I]ROUW(_]P@?R7QG_P C
MNL6****]T^*"BBB@ HHHH **** "BBB@ HHHH IZA-]FM+B?!?RHF?:.^!FO
M@GPY^V-\9OB/J6MW?A;X<"YTVROWL_,:?'*G'3\*^]-6#+IMVR<N(7(!Z$[3
M7Y#_  BT#Q'X@U'QC=6GQ(L_"X;7)@]B]QLP=QY S0!^J'PDU_7?$O@ZSOO$
MFGC3-6?(DMP<[:[:O.?@'97.G_#?3H+O5DUN=!\U[&VX/[YKT:@ HHHH ***
M* "BBB@"K?6XO+26#=M$JE<^F:_.CQI\*8?A]^VOX9ECU)K];^5)&#<%#GH*
M_1JYC,]O)&I*[U*[AU'O7Y]?$?P-=>$_VTO#$D^IR7XNY(W42G[@ST% C]"8
MQ@<4^F1_=ZT^@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (2!UXK,E\4Z/#*T<FIVJ2+P5:4 BKE_;_ &JUDA\QH]ZE=R]1FOE'
MQE^P1!XOU^[U-O'FN6IN'W>7%+@+[#F@#Z@'BW16&1JMH1_UV%">+-%D=475
M+1F8[0!*"2:_,74_V;M2L_VE+/X?Q^.]9&FO;&3S/.^8\_6OI+PY_P $_H/#
MVNZ?J"^/]<G%K,LWE22DAL'.#0!]>@AAD'(I:AM(C#;I&7+[ %W'J:FH ***
M* /S_P#VTO\ DKFG?]>S?SKPQ?O&O<_VT_\ DKFG?]>S?SKPQ?O&OQ_./]\F
M?UCP;_R*:8X=Z6D'>@]*\0^X$:DBX9J7WH3G<:?0?0^N?V'?NZI_NU]96GW*
M^3/V'?NZG_NFOK.T^Y7Z[D?^X0/Y*XS_ .1W6)Z***]T^*"BBB@ HHHH ***
M* "BBB@ HHHH IZBP73KML;P(GRHZ]#7XG>.+#X,VWC_ ,02366MI*;YS.Z,
MR#?N.?PK]L[MO+M9V4 LJ,0OKP:_)KXD?&CQ)KNL>)='M/A593@W$D(OHX-S
M')(#<#K0(_0?]DIM%;X,:+_8!F;3MG[LSG+8^M>T5X-^Q;X6U?PA\"]&L=;C
M>"\.9/*==I4'G%>\T#"BBB@ HHHH **** (Y0[1,(VVN0=I/0&OS_P#BO9ZW
M8?MJ^%#K-VERCR1FW"KC S7W[<^8;>0(=KE3M([&OST^(MIXEM_VVO"_]O7I
MO(6E0VY$878N>E C]#XQA?K3Z9'G'/3M3Z!A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !140<[CSTK)\0>*+/PS;+/J%PEO&S;5+'&34\
MR2NRHQ<VHQ5VS;I,"N&C^,/ALG+:E$!CIN%/_P"%P^&.VI1'_@0K'ZQ2_F1U
M_4L3M[-_<?*>NC_C/?3/^O%O_0J^XL CD5^?VM>,]*F_;;L=2CNQ]GCM"#+_
M  ]>F:^S!\7O#( SJ47_ 'T*GZS2O;F&\#B8[TV=J  ,#@4M<-_PN'PUO_Y"
M46/]X5L^&_&NE^*)I$T^Z6XV#)VG.*TC6IS=HR,ZF%KTES3@TCH****V.4_/
M_P#;2_Y*]IW_ %ZM_.O#%^^:]S_;2Y^+NF_]>K?SKPP??-?D&<?[Y,_K'@[_
M )%-,<.]!H'>EKPS[<3&::G 84^FKU>GT&?7'[#OW-4_W:^L[3[E?)G[#OW-
M4_W:^L[3[E?KN1_[A _DOC+_ )'=8GHHHKW3XH**** "BBB@ HHHH **** "
MBBB@"GJ#@65T "?W+G(^AK\A_A9^V%XI^!?B;QOHS^#9-:@GUN69)KJS=F52
MQ  ..E?KMJ$[6VG7DRC>8XG< >H4FOR TC]H/Q3<?%KQ%>ZYK6EVMC(9?L]L
MR*"A5B ",=>*!'ZD_ KXB7/Q2^'VGZ_=V)TV><<VQ0KM_ UZ"\JQJ6=@BCJ6
M. *\/_8_\9:CXY^$=KJ6HC,K3.%?;M#+V(]J[?XV>%[OQ;\.-8L;*^ETZX\A
MW6:%L,,*>] ':6U_;7J,UO/%.JG!,3A@#^%2F3'8D>M?'O\ P3;;44^'7B6V
MU+49]2FM]4DC\V=RQX)[UT?Q/_:=O?@=XJU33=;MCJBW/-@UL>(L]-] SZ?,
MF!G%0P:C:W3.L-Q%,R'#"-PVT^^*XSX>7FJ>*?AO:WNIS(+V_@>0R0GA P.W
M'T!KYA_8_M-5\.>-OB/IU]JUUJ36U].R&:0MM') ^E C[*N-?TVTE$4]_;0R
M$X"/,H;/TS4\VH06UH]S-(D4* LSLPP!ZYKX&MO"P^('A_XO>+=3U&ZEU+3X
M'-FJ2E1"R="!7?\ PJT[Q;\:_P!ERWTJRUA[354*B2[N"7\Q-OW: /J#0_&>
MG^)],N;S2KB.Z2$E0R,&!(^E?!WC_P 8:WXC_;7\+0ZE8);QP2HL3(I!<9Z\
MUZ=\ -$\<?LW_#K79M:TA]<D:X8P6UFA#$9ZX]Z\:U+XJ:E\4_VN?!][J7AJ
MZ\-R0NB+%=C!89ZT ?I2@P*=38S\M.H&%%%% !1110 44F1ZT9H 6BDR,XI:
M "BBB@ HHHH **** "BBB@ HHHH B88(P.M?+?[=L\L7A+0]DC(#>@'82.U?
M4499G?(X!XKY8_;R)/A/01C_ )?1_*O'S7F^J3<6?3<-QY\TH+S/D WMR#_K
MY,=OG-'V^Y_Y[R?]]FH@69<&@"OR!SE?5G]>^PI=8+[AIW&Y$^?WHX$G\7YU
M.;ZZ_P">\O\ WV:CQ2L0.*.>7</84OY%]R)%O;AL?OY<]#\YKZD_8?N9Y-7U
M%'D9T$1ZG/>OE49!_&OJC]AL?\3?4C_TS/\ .O<R64GCJ>O4^$XTI4XY16DH
MK;]3[*HI!2U^MG\KGY__ +:7_)7-._Z]F_G7AB_>->Y_MH\?%W3O^O9OYUX8
M/O&OR#./]\F?UCP=_P BFF*#@FEW4W'-+CFO#/N1<TU.=U.(XI$XW4^@CZX_
M8=^YJG^[7UG:?<KY-_8=^YJG^[7UE:_<K]=R/_<('\E\9_\ ([K$]%%%>Z?%
M!1110 4444 %%%% !1110 4444 >1_'C]H#PY\#=,@?6S)-+>?)%;Q=7R=O]
M:_+K]IWX=?!_1/C7%,NM7\=WJ"QWMSIMO#O$&XAB"?7!K[?_ &_O@IXE^).B
M:7K'AFT&H7NEC/V8=6PP;^E?,7P:_9O\:>/?$GC+XC>.O#4EM*UJUO;VCKEM
MRI@<?A0(_0_]G"X\-3_"70O^$4E\_24A"HY&#G'.:U_C'HOB#Q#X#U"P\-3K
M!J<Z%%=C@8(P:\\_8L\'ZMX*^"MC8:S:M9W)E>1(6ZJI/%>^4 ?*7[&W[//C
M7X#'5[;7-02[LK^9KDJIR1(37I^H?L[Z)XBU;6[_ %\_VH^HKM577_4CMBO7
MJ*!G&^#?!DO@GP.N@VMV]QY$;I!*XY4$':/PKY>^#?[-/Q-\!?$;7->O=3BG
MMM5NFDE3?_ 3_A7VG10!\>^+_P!EWQA;:[XF@\-ZF!HGB11%=1N=OEJ>I%?0
M?P;^&EM\)O 6G:! _F&W0+))_>/K7?TF!CI0(AF?RX7<Y8*,G ZBO@CXK^,[
M3Q3^VGX/BM[6:!K1T5O-3;NY[5]Z7=PMK:R3.0(T!9CC/%?GOX^^(7A[QS^V
MQX9CT1#OM)$CN',90[L^] S]#XQ@4^F1XQ3Z "BBB@ KPOX^>*_BSH.HVR>
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M %U3^=>@? 3_ )(_X3_Z\$KS_P#;?_Y(5J/_ %U3^=>@? 7_ )(_X2_Z\$H
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MFLLB*Y  '3FJO_#1WCXN=FMMCZ5\F^(\/&4HN+T/U*EX=YE6@IQG%)J^M_\
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MOK.T_P!7SUK]<R/_ '"!_)?&7_([K$]%%%>\?%!1110 4444 %%%% !1110
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M,<D9^M=+^TM\;]#^(WCZUU31+:[>U2$J6:,@YS7F/_":6^<FVNO^_9K\MS/
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M/_?L5W=% '"Q_!3P/"ZNGARR1E.0PC&0:[2TMHK2WCAA01Q(-JJ.@%2X%+0
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M+7Q1=)=^&;R!6LK<#Y[<8X#'UKZ.L]3\,_$/S8(9K;5Q9NK,%(=4;L0:Z2*
M1X&%*KPO'04@)1^E+2 8I:!A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 445%=,4MY&7J%)&: '2,%0DL%&.
MIZ5Y%\;O'CR_#W7=.\(ZY9?\)6]NRVD/G#>7[X'TS7-:]\5'U=M:\*:EJL.F
M7VHQO;V$H; W=,9[&OCGXB^$8] \6+HB:I+97MC:&]6^>1MT\ZM@*K=3GTH
M[[X5_#2;XH?#&]^RZK<Z7\3+"=IB)&,<LK+SM)/52:]^^#OP=B\5Z98ZSXX\
M-V=MX@MCB8"//FL/XCZU6_9C\(WWBS1[;Q9XKTJ73]?MP((W(V>;&!PQ ZYK
MZ4A&$H$1VL"V\:QHJI&@VJJC  [58HHH&%%%)F@ SBHKFXCMD+2NL:CDLQP!
M6?XDNY;#2;RZA!,D4+,N/7%> 7/B]_C#X4N?#-SKMOI>M.K*R>;L=E[%2.M
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M5E!:(<%FA7;O^M=)2 8%+0,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M:?#=Q[)HTE&<X=<TZ.V,3($(6-?X!0 6UFEK$D: !$ 50!T'I5BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>cvac-20231231x20f025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %P L,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHKY?_;$^.?Q!^%OBKX:^'OA\-*_M'Q3J#V3'5D)
MC'R\'(Y&* /J"J-SKNG6>HV]A/?6\-]< F&W>0"23'7:O4U\._M&?M2?$SX-
M?V3X?@\5Z%=>.[+13J&K:59:6TXE<,3OR2/+CVX&>M>=>+?BGXI^-/Q8_9P\
M9:--IV@^)]5TF[DW7N6M8G PQ*YY'% 'Z2ZMX@TS0?LW]HW]O8_:9!##]HD"
M>8YZ*N>I]JT*_./4?VK?%/C+P7X'/B;1/#FLZY9_$./P]/>M;>9;.,X$\'/R
MN/7FI/&O[>/Q8U3XJ>,[+P-X?AET7PIJZZ9)IL]KNDND5L22/*2/+]L T ?H
MQ44]S#:IOFE2%,XW2,%&?QKX%^+'[:/Q'\+_ !;CT^YFT[P-X/*VWD7UY9?;
M([AW +(\BG]V><=*^D_VG_AY)\;/V9_$FE6MRRZE/IOVVRNK5V0B=%$BE2,'
MG&/QH ]GENH(-GFS1Q[SA-[ ;CZ#UIJ7UM*LC)<1.L?WRK@A?KZ5^:'P4^*=
MW^V+\6_@MI3370LOAWH#ZAX@0,RXU) 84#^N=@/XFO&=(\7>+?@QX-^*7CI[
MR]U?P3XLU'4M"O[9)6+6%P&/DRCG@=LT ?L?)K6GPLHDOK9"PW -,HR/7K4U
MK>V]\A>VGBN$!P6B<, ?PK\N?V@/AMX?O/V!?A_XYN+61O%BII]E_:BW$BRF
M%GP5)#<Y!K]!?@;\,_#'PE^&]C:^&-,&FVES;QWDT:R,Y>0Q@EB6)Y- '>:I
MK-AH=L+C4+R"R@+!1)<2!%R>@R:>VHVB-&K74*M+R@:0 M]/6ORS_:&^._Q
M^/\ \./$&N37VC:/X&TSQ9#I=OHP4_V@[1R@%V?.1GTQ7J/[;/@[X<)X*L)T
MCOM4^,GB"TM;3P_;6E^XEMY0%VRJ@("(.I)ZT ??US=P6<>^XFC@3IND<*/S
M-2*ZNH92&4\@@Y!K\POVF-,\3:I\2/@UX+O1_P +)\0Z7X1,FL^%+G4&M+>X
ME$9S<>:"-TF>G^Z*^DO^":VN#6/V<8HWU>_U.[L]2N+>X@OV+&Q=6_X]T8D[
ME4=#0!]6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?,_P"W_KGB?P;\![WQ/X4\2W?AW4M-FC(:V"D2AF"D-GZU],5YE\>/V??#
M7[1/AF+P_P"*KC5$TM)/,:'3KLP>81TW8'(H ^,/C;\1?B9X=\>_ [P7H_B3
MQ+K":YX<EU#4%T<1"]NI1EMP+#: /Y"K7QD^+'QA^''C7X46'A?4=3N&AT6;
M6-8T?6 AN[F-''F(^T8W!<]*^LO#W[+7@SP[XK\$>)(I-4N]8\'V$NFZ9<7=
MX9"(),@A^/FX) ]*Z37O@KX9\2?$[2/'E]!/)KVF6DME 1+B+RI/O!D[T ?,
M?[./[8\'B:U^)GC76K[4]5\)0:I##IMO9V;3S6ZLF2FQ1G@Y!-=EX]_;ETGX
M>>*--;5M*FL_!^L^'[K5M,U2\1H))+B $FV=&Z,P' [UZS\(/V=?!7P-F\0/
MX3L)+--<NS>W4,DF^,2$Y.P$?*.>E>>?MI_LSW?[2/AOP5IVG06#/HVO0:A/
M]L.T&W!_>JN.Y7C% '6Z)\3/$7BS]F*;QQJ&G#PUKEWHLVH1V@.XVWR,T><]
M\8/XU\E?LB_$#XF?$#P)-XN\1ZGXON$?2+Z;[?<&$:8[JK;2H W@\<5^@.J>
M&+'6?"UQH%S$1IUQ:FS>.,[<1E=I /;BO%_AE^Q;X*^$R_9M"UKQ3_9'V>6V
M&D7.K-)9JD@(;$9&,\F@#YZ^!_QE\0:IJGP(L;J[O]6\1ZUX?U:YBFFNRMO)
M+'OV"5?XN0!GM6+\(?CE\0M/^*&BV/Q9\3>+O!OBN]U&2-=.O=-0Z+J" G;%
M!(HR. ,-FOK+1?V0?AWH-WX3N+:TOO,\,Z?=Z9I^^Z)"PW (E#<<GDX/:LKP
MU^Q-X \+ZYIVKBXU[7KC22\FE6VNZH]W;V4C _-&K#@C/'- 'E6B_MY^*FUG
M2K[6/ EM:^"K_P 0R^'AJ4-Z&G656(#^7UQQ4H_;_P!5_M:#Q!_PA /PMF\1
MCPPFLB\7[7]H+[!)Y/79N_&M'X!_L$Z3X4UB3Q'X\DN=8UVVUNYU2PM$OF:Q
MAWL2K^3C&_!ZUW\G[#/PIE^(">*WTR^9TU :LND&\;^SA> Y$_D=-V>: //O
MV7/BQ\6/&7[1OQ=T'Q#%977A31]6:"-Q.-]H-N8T1>X(P3Z&K'[4/[4'BC2M
M?\7?#KX?>'UO]6TO0)=3U+59[H0"SC*G:8P?O-WKV;P[^S;X1\)_&+6?B3I+
MZE9:]K(_T^WCO"+2X;  =HL8W8'6L?XO_L@_#[XU^)3K^N1:G9ZI):M97$^D
MWS6QN83_  2X'S"@#Y\M_$OB34OV,/ _C_5?BUJ'@Y+30FFG>%$DGU&]/^J7
M+ EB3QM'7-<M\2OCM\;;3X+?!"'4[F_T_P 5^($FEUO3M$A0ZM-$N3'(D;<#
MY=I;ZU]&^,/V$/AIXU\-^"M!O'URWTSPA!Y.E06FHM&$P<AV&,,X[$UH^(?V
M,/ OBOP_H6GZMJ'B*[U#1)'DL->.J,-1AW_>43 9V^V* ,[]A?XFZ_\ %#X-
M-?>)M;&LZM;7TUL_FQB.Y@56PJ3J. X'6OHNN&^$/P8\+? _PP="\*V;VUK)
M*T\\T\ADFGE;J\CGEF/K7<T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,DE2( NZH"<#<
M<9/I0 ^BH%O;=YY(5GB::(9>,.-RCW':G6UU#>1^9!-'/'G&Z-@PS]10!+11
M10 5QOC;X1^%_B'KWAW6==TX7FH>'[@W6GREB/)DQC/'6NRHH \G^)?[+GPY
M^+?B9?$'B/0S<:N+8V;W4$[PM+"?X'VD;A[&LC6_V,_A3K^B^'M+N= =;70(
M7M].\BY>-X$;[P# YYKV^B@#R2+]E7X9P>%_#OAZ'PY%%I6@WZZI8PHY!2Y'
M(D)ZL?K47B_]D[X:>-O%ESXCU#1)(M4NF5KI[.Y>!;DKT,BJ0&Z=Z]@HH \9
MUS]D/X7^(_$HUO4= :ZN Z2&![ES;LR?=)CSM)&/2O88K:*"W2".-5A10BQ@
M<!<8QCTJ6B@#S;X8_L[^ ?@[K'B+5/">A1:7?>()3-J$J,292221ST&23@57
MB_9H^'<7@+7/!AT"*3P[K5R]W>VCL2))7.6;/8YKU&B@#S;7OV>? OB3X8V'
MP_U#1Q-X6L3$T%EYA&PQG*<]>#7H5E90Z?906D";((8UB1/10, ?E4]% 'A7
MB']B;X0>)_$%[K%]X8!N[RY6\F6*=TB:93D/L!QG/M4OCC]C3X7?$/Q>/%&L
M:/<2:XL*VZ7D-Y)&\:*, +@\<>E>X44 >-^*OV2?AIXTTS0K35M%EGDT2$V]
ME?+=2+=)&>JF4'<P^IKO_A[\./#GPL\-0:#X7TN'2=+B)80PCJQZLQZDGU-=
M+10 4444 %%%% !1110 4444 %%%% !1110 445Q/Q;^*.F?"?PH^J7\T27$
MS_9[**9]BS3E254MV'')H [:BOE+0OVH?%_C3PGHMYH5MH<FH+IT^JZH3(SP
M;(Y=ABB(_B/J:VM._:1\2ZQK]IJ=MIM@GA#[?#I=Q%(S?:_.=<EU[;03B@#Z
M3HKD;GXI:!9:JFGW,T]O.TPMPTD#!-YZ#=C%==UH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF[]H
M?P5\2O$7CKPSJ.D166H>'-/U6REAM1.\<L3>8/,E8#A@!Z]J^D:* /BA?A_X
MFF\2:_'IV@:M9^*Q]N?6M7>1O*U&)W4HD;9P<J"%P!BO3/V>/#.JV&F^(I/#
M6F7/A#2)Y(1:V>KHSXD50)6"EB1D^]?1=% '(>"M7UJXU?6],UF:VNI;%X]D
MUO&4#!ESR,FNOKCO"_\ R/GB[_>M_P#T778T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:YX>TW
MQ+8M9ZI8P7]NP/R3QAP,C&1D<'GK6C10!XY<_LH> I-%TO2[2WOM*M=/\Q4&
MGW/E&6-VW/'(0/F0GM6G_P ,Y>#1XRL_$207<4EJ4D2PCN"+1I$7:LC1XY8#
MOFO4** .%^+T2#PS;'8N?M]OS@?WJ[B/[B_05Q/Q?_Y%BU_Z_P"W_P#0J[:/
M[B_04 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ\Z4R']:UJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI!86C)O4QH SXQM&3[<U[[10!Y]\/-+GTGQ?XM@GU*YU1P\!\Z[V[_\ 5].
M!7H-<=X7_P"1\\7?[UO_ .BZ[&@ HHKA/&GCG7/#OC7PSI&G>')]5T[4G9;N
M_C/RVH'0FKC!S=D95:L:4>:6VGGN=W17E,/Q3\4R2^/%;P9=(NA_\@XEO^0A
MQ_#7:^ ?$&H>*/"6G:GJFER:-?7$8:6RE.6C/H:N=*4%=_G\S&EB:=67+&]]
M>C6SL=#1116)UA1110 45Y3\?OBIXI^%UAX>G\+^#+KQC)J&HI:W,=J<&VB/
M60^U>I6\C2P1NZ&-F4,4/\)(Z4 24444 %%%% !1110 4444 %%%% !1110
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ME^%.NI%K]WXBL(/"<FH&%([#1[A2%$:A=Y90!SCTZ4 >@^& 1X\\6Y'\5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$_9F_P"2*^'/^N;_ /H9K\^Y/N-]#7Z"?LS?\D5\.?\ 7-__ $,T >HT444
M%%%% !1110 4444 %%%% !1110!\V_M+:(/%7B[2;30]5TA?%$$#.MCJ\BB+
MR\@E@<Y5OPKKOV98[=?#.LO_ &E!J6J2:C(;][0?N$F[HA[@>M>:?M0Z+X?T
M3Q]I&J_V!HXU"[7-WJNK.X\R($ Q1X.-Q'K7JG[.&KV>I>%M4@TS3+'3])M-
M0EAM6T]-L4R _>SW/J: ,S]IZSUI-#T;5K/Q;;^&M+TV^CN)XI+,W#W;\A(U
M4'G.?NUG? +4+CQ-X^U[5]8U^YN=<CLX[;^R)[#['Y$.[<)-F3NR>,UT_P"T
MN^DP_#F.?4KR^L;N&_@DTR7381-/]L!/EA4/#9^8'/&,URO[/E[<:UX[UR^\
M576I?\)PEFD36-]:+ D5KNRK1[0 ^6ZGMTH ^@J*** $Q2T44 </\7_^18M?
M^O\ M_\ T*NVC^XOT%<3\7_^18M?^O\ M_\ T*NVC^XOT% 'PI^W'_R5+3?^
MO$?SKYVKZ)_;C_Y*EIO_ %XC^=?.U?IV6_[I3]#^9>(_^1OB/\7Z(**HZVVH
M)ILQTM(WO?\ EFLGW:GL3<-9PFZ"K<[1Y@3IN[XKT;ZV/GN7W>:_^9/7UQ^P
M/][Q;_O1?R-?(]?7'[ _WO%O^]%_(UY&;_[E/Y?FCZSA/_D<T?G_ .DL^OJ*
M1F"J2>@&37F5[^TC\/["\GM9]=1)X',<B^6W# X(Z5^;G]'GIU%>5_\ #3GP
MZ_Z#Z?\ ?MO\*\D^)G[7Z:7\5?!-AX;U[1#X7NY&&K?;0PGV]O+% 'U?17E?
M_#3GPZ'_ #'T_P"_;?X4A_:=^'*@DZ^F!_TS;_"@#U6BLWP[XBL/%>CV^J:9
M.+FRN!NCD QN%:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\2?[:_X0+7O
M^$=;;K8M'-H>.),<=:\=^#OBCQYXC^(%MJNHRRCP]JEO.%TZ8H?LJ1%5C<D'
M[[DL2/I7J?Q>-O=> =9TN36(]$N+^TEA@NI&*[3MR3D>U?/_ .S7I=W<>/K$
M2WNEV%GI$-V(+#3KYKAK@2LIW'(X5=OZT ?6E%%<EK_Q/T+PWXX\/>$KR:5=
M9UT2M9QI&2I$:[F);H.!0!UM%>46_P"TKX0FUG5+%FO(8+%9BM_) 1;W)B($
MBQ-_$02!6_\ #OXNZ)\1[*\GM$N=-DM'"S6VI1^3(H895L$]".10!/X7_P"1
M\\7?[UO_ .BZ9\9?^27>)?\ KRD_E1X2FCN/'/BUXI$E0M;_ #(P8?ZOVH^,
MO_)+O$O_ %Y2?RK:A_%CZK\SBQW^ZU?\+_(_+J#_ %2T^F0?ZI:?7ZT?R<MB
M""\2XFEC4,#&<$D5/0% )( !-% W;H>E_LU_\ET\*?\ 79O_ $$U^E=?FI^S
M7_R73PI_UV;_ -!-?I77PN?_ ,>'I^K/W'@/_<*O^/\ ]M1\)_M<_P#)7Y?^
MO5*\8KV?]KG_ )*_+_UZI7C%?,GZ8%%%% #9/N-]#7Z"?LS?\D5\.?\ 7-__
M $,U^?<GW&^AK]!/V9O^2*^'/^N;_P#H9H ]1HHHH **** "BBB@ HHHH **
M** "BBB@#POX_:=?ZEXK\/6\GA5/&WA^6.476D,4#*X'RR+D@G'M7H/PHO8+
MKPE#%;>'AX8@MF,*Z<&4^7C_ '37F'[1FMMX&\:>%?$NF:K;Q:\!)90Z;=1L
M\<JOP6./NX]:ZG]G6U2#P[K$DNIIJ&JS:C*]^L*E8X9B>44'L/7O0 G[2UOI
M=]X&TZRU26]MEN=5MXX+JPD$<L$OS$2;CT  ->4?!/1[;QI\3[O58_$?BF*_
MMHL037LZM%J%HDI7( '"EP:^@OB):^#_ !)H\_A_Q9=6 M;E0S6]U<+$Q'9A
MD@CZBHO _A_P7I]YY_AEK&2>"T2RS:3K(4A4Y52 3CF@#M**** "BBB@#A_B
M_P#\BQ:_]?\ ;_\ H5=M']Q?H*XGXO\ _(L6O_7_ &__ *%7;1_<7Z"@#X4_
M;C_Y*EIO_7B/YU\[5]$_MQ_\E2TW_KQ'\Z^=J_3LM_W2GZ'\R\1_\C?$?XOT
M0R>XBM8FDFD6*->K,< 4Y)%E171@RL,AAT-5M4TNWUBRDM+I-\$GWE!Q4MI:
MQV5M%;Q#;%&NU1Z"O1UOY'SWN\OG^A+7UQ^P/][Q;_O1?R-?(]?7'[ _WO%O
M^]%_(UY&;_[E/Y?FCZSA/_D<T?G_ .DL^NI_]1)_NG^5?F-XR1?^$RUWY1_Q
M^R]O]HU^G,_^HD_W3_*OS'\9?\CEKO\ U^R_^A&OS<_H\Q]B_P!U?RJC>:!I
MNHWMM>7-G%-=6QS#*R\I]*OT?B/IF@!-B_W1^5-D1?+;Y1T]*?39/]6WTH _
M0O\ 9U&/@_X?QQ^Z_K7I5>;?LZ_\D?\ #_\ UR_K7I- !1110 4444 %%%%
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MPDG^]6Y4<ES#%(D;RHDC_<1FP6^E $A.3FFR?ZMOI3J;)_JV^E 'Z&?LZ_\
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M;2[/2/&?BV"RMHK6$/ =D2X&?+ZU/\9?^27>)?\ KRD_E6U#^+'U7YG%CO\
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M34D:Y-R-2MWP;ABF=W]W.*]43[B_2N)^+_\ R+%K_P!?]O\ ^A5VT?W%^@H
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M /(L6O\ U_V__H5=M']Q?H*XGXO_ /(L6O\ U_V__H5=M']Q?H* /A3]N/\
MY*EIO_7B/YU\[5]$_MQ_\E2TW_KQ'\Z^=J_3LM_W2GZ'\R\1_P#(WQ'^+]$%
M%%%>D?.!7UQ^P/\ >\6_[T7\C7R/7UQ^P/\ >\6_[T7\C7CYO_N4_E^:/KN$
M_P#D<T?G_P"DL^NI_P#42?[I_E7YC^,O^1RUW_K]E_\ 0C7Z<3_ZB3_=/\J_
M,?QE_P CEKO_ %^R_P#H1K\W/Z/,BBBB@ ILG^K;Z4ZFR?ZMOI0!^AG[.O\
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M?7AOPQT[Q);_ !+N)[Z.\^Q.MP9//! C.5V GHV0#C'3FO<J "BBB@ HHHH
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M*DU#0;PW$$3^7(LB&-T/NIY&1R*C^*O@V;Q_X"U;0[:=+>XN8QY4D@RNY2&
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MUI96+W-A<$_:+CS#^ZKV)?V9_BH% _X1FWX'_/V*</V:?BK_ -"U;_\ @6*
M/(+[PS93V>IPVT26D]^A26XC'S-D=3ZTGA30/^$7\/6FEBY>X%NN/,SMS^ K
MU*R^ /Q+U"]O+2'PS%YUHP67==*!DC(Q5W_AFCXJ?]"S;_\ @6* .3\!Y_X3
MKP]\S_\ ']%_$?[U?II%_JD^@KX)\,_L]?%#1O$FE:A/X8A:&UN4F<)=KN(!
MR<5]F:'XJUJ_OX+:Z\+W>GP,,-<22(57CV- '6T444 %%%% !1110 4444 %
M>"_MD7SZ?\+X)4+ _;$'RG'7->]5Y!^U/X(N?'?PEO;*QD$-_'/#)#(W1?G
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MX1 GG2=V(% &]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 >7I\,_&<:*B_$:^VJ,#-G#_A3O^%;>-/\ HHU]_P" </\ \37IU% 'F/\
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MMX\LSNVYY7/WG8]R3R:VU7 &>6QR?6G4 %%%% !1110 4444 %%%% !1110
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MW9@<@GU%>Z !0 . .*   *  , =A2T44 %%%% !1110 4444 %%%% !1110
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M8E61<'*QO+U9%["O8 H4    =A0   # X%+110 4444 %%%% !1110 4444
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M*Z+::5IL7D6-JGEPQYSM7L,^E:5 !1110 4444 %%%% !1110 4444 %%%%
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E?)C5,D^@JAX?\)6VA227!=[N^E^_<S'+'V'H*W: "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>cvac-20231231x20f026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $X! (# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZCEN(H
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MX>-BI'[Q>XKQ'Q+H2?!R+X6>(/">M7Z:QK%W;07FF2W;3)<QR*"[;">F>/\
M@0KTJ&#5>FI<UFVTM.RON?,X_.98'$2I>SYHQ49-WL[2DXZ*VOWH^S**^3/B
MI^T/XM\*^(==N=!U>UU?2M,O!!+;1::QCAY *//G&[.>@KK?$_[0.J> ?%$I
MUTP1Z%J.@?VEIC!,,+@("8B>^2:?]GUK)JVO_ _S$N(L%S3C*ZY6DWI;6Z3N
MF]+JWJ?0U0&_MA/Y)N(A-_SSWC=^5<G\(-4U_7?AWHVI>)O+&KWD7VB1(DV!
M%8Y1<>H4C-?/GQO\ ^'Y/&5EI?@M[V[^(5[J0O+BXBNW86D1;<^\YPJ^BUE1
MPRJ572E*UNJU6GW:'5C,RGA\+#%4J=U*VC=GKLDK.\O(^LY)4B7<[JB],L<"
MGU\T?M?:-?67A'P_JZZW?1/'?6MK)9PR[89"2<N<<D\5ZA\4]7\6:5H?A]_"
M4FGI/+=Q)='4)%13#MYVY/+9Q2^K7A"2E\5_E8?]I\M6O3G3?[M1>FK?-?IY
M6/1Z3I6)XWU>_P!!\):MJ&EV?]H:C;V[206W_/1P.!7S'X9^,_C/QCI?B#3-
M0\0V=CJSZ/=3_P!FSZ9);S0%5).QB?FXR,_0T4,+.O%SBU9#QV;4<!4C1G%N
M4DVK6MZ7;6ODKL^MP0PR""/44M?(?@7Q[XW\ _LJ2>+/[6MM0&Z)-/CN(V>6
M/==%)/,8GYLYX]*[3Q?\4?B'X7T_PSIEQ)I">(/%%Z([6XCC)@M8=@/()^9L
MFMI8":DXQDGJU]VK^XXJ?$%"5*-2=.2;C&5K)V4FU%7OU:T_&Q]$45\R7/QT
M\9^'/#/Q-L-3EL+O7_"BPO%?P0[8Y0[@<IGMS5CPS\8O'FF_$GP9IOB.;3;[
M2_$VDR:@D5G"4>#9"TF,D\D[?_'O:E]0JV;NM/QTOI\BEQ!A7.,.66MEMLW)
MPUU_F5M+GTG17R%)\??B3/X'MO'4=]I$.CW^K+8PZ8+<M+$A<+DMGK7T!\9?
M$FH^&_@[XBUC3"PU&&PWQL@Y4G +#Z D_A45,'4I2C"36KM\_P"F;X?.L/BJ
M52K",K0CS:K=--IK7K8[87]L9_)%Q$9O^>>\;ORI?MEOYFSSX]^<;=XS^5?-
M_P (?@CX0UCX>>&_%EYK-W+KUP8KZ;6/MS*QEW F(Y.,9^4K7%>%/ .E>/\
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MN(()8^ 6#1G(Z$8SFNF\2? GPUXEU6]O)3?6D6HA!J-E9W3Q6]\$X7S4!PW
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M3_'OAB]T/4@_V6Y4#?$VUXV!RKJ>Q! (^E<==_!S4-;\/ZKHVN>--3U:RO\
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MDMK>ZV;I8<;AM8,,9^E5;7X<V=KX]NO%2W,QNY]-CTQH3C8$1B0WU^:NMHH
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M&!US7U/10!X]/^SQ ?A1X6\%Z7X@O_#<>BQ(K3Z>$/VAMN'$BL"&#,2>:O?
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M/I0 M%)D^E&3Z4 +129/I1D^E "T4F3Z49/I0 M%)D^E&3Z4 +129/I1D^E
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MOX@_]"%I_P#X4 _^1ZX?XS_\G(? ?_KIK/\ Z3PU[O0!P'_"5_$'_H0M/_\
M"@'_ ,CT?\)7\0?^A"T__P * ?\ R/7?T4 >=7GC?QSIUI-=7?@G2[6VA4O)
M--XC5$11R2S&#  ]34H\6?$!@"/ >GD'D$>(!_\ (]=;XG1I/#NI(F\NUNX7
M9;B=LX[1GA_]WO6A#_J4SG.T=1C].U '!_\ "5_$'_H0M/\ _"@'_P CT?\
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M25P?K7H->(_M#_&W4?@QX@\%36^EZEKFGW\MS'=Z;I%KY]S+MC!4J.N >N*
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M?S\M@HHHKB/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\4^.W@;QM<^-?!GC
MGP';Z=JNKZ$EW9RZ7JDICBDAN F75AG:RF,?4,:]KKYE\7?M6ZA\-OB_XW\-
MWOA'Q+XML;.2T:R;P_IQG2V5[9'=)&'\18D\]C0!Z5^SS\/];^'_ ((O(_$9
MM%US5M4N=7NK>P_U%N\Q!\M/4#:.>Y)KU"N*^$GQ+7XK^$EUU= U?PV#.\'V
M+6K<P7'RX^;:>QSP?8UVM !7*_$CXB:=\,_#O]JZ@DDYDE2W@MX2 \TK'"J"
M2 /J3@5U5<-\6_AG'\3M$T^U\^&WNM.OX=1MS<P^="TD;9"R)D;E/0C(H K:
MUXRM?%OP8UO5UBDT];K2+HK!=,H<'RF'4$@CW!P:V?A9_P DU\+?]@VW_P#1
M8KRKQ5^S=X87X+ZG8>)[.V\1WFG6=_=03M$8DA9U=]L:!CM4'&!D]*]5^%8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\L?W'9067Z'M75AZL*,W*<>96:L>5F.$K8RBJ="JZ;33NE?9WMJ</J/Q,O\
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MV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH&5DNT7:<QR J2V!@\T >P?L_P#C^U^-8O=<U+2M$_MWP]<O81ZEH-U]JLY
MZ*S&&7 SP<$=B*]MK@_@[X;UWPEX9;2]971#'#)FTFT2R^Q++$0#NDA'RI)G
MKMX^G2N\H **** /"/C/_P G(? ?_KIK/_I/#7N]>$?&?_DY#X#_ /736?\
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MS>O_  #\:]WKP?\ :[:'_A3'Q-7?!Y__  AM\=GVL^;MQU\C&"N?X\Y!X[T
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M9>\.^./#/@"6T\=^)+?Q'J)N"T#03"8VT6.(FD'WB/6O8Z "BBB@#PCXS_\
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M6F\3W,TNAN9.))-T)Y^3RE_A'3IVZ\T >ZT444 %%%% !1110 4444 %<?\
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MBFH]+G)@88J&'A'&R4JG5I63_I!1116!WA1110 4444 %%%% !1110 4444
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MV-><R?"_QCXE\#>.])UF+2]/O_&D5Q%-)8SL\>G#[(D$.,JIE)V98C;C/&:
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M9TG6PD^:*=KZ[KU"BBBN<]$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M:DB:"-\LN.#6M>$*=1QIRYDNIR8&M6Q&&A5Q%/V<WO&][?,VJ***P.\****
M"BBB@ HHHH **** "BBB@ KR+67\8Z?\>-(DE\1Z39^&;JQF2*QGC97F(EA+
M( 9 &EVYPX& "1CFO7:^;?VO?#Z?$*#0O#VGV_AB75(WFD;5-:U06TVCY5-K
MQA6#%F!X[?*#0!](YSBEKQ7]G#X9Z_X!TDG4OB?/\0;$P""-#L>&"0')*R D
MGCC!->U4 %%>;?&?Q7K.B/X.T70[N+3+SQ)K(TQM1EC#BVC%M/.Q53P7/D;0
M#_>]JJZ3XX\3ZW\"9_$%BNGR^)HH+M/,DR+9I()9(S)@<X/E[L>^* -7X[^#
M=+\<_";Q/IVKQW$EHMA/<!;:[EMFWI$Q7YXF5L9[9P>X-:GPK 7X:>%@.@TR
MW'_D-:\J\??')/#OP'L;K7-)UK6-1UWP_*[RZ)IK3Q)(T!W%\'Y!D_E7#?&[
M2?C%JWPH^&H^%URD5JNGQF_C4$2E_+3RSD$?+C=GWQ6U&G[6:A>U^IQ8S$O"
M4)5E!RMT6[/K=E# @@$'@@]ZQM!\%Z%X7N+JXTG2K73YKIMTTD$84N??_"O,
M_P!F>/Q_X?\ A2[_ !4O(#J<4\DB2'@QV^!C>2>N=WX5W'A?XL^$O&>I2:?H
MVMVU[>("QA0D,0.N,]:FI#V<W&][&N&K?6*,:KBXW5[/='74445F= 5S/Q+\
M&P_$/X?>(?#-PTB0ZK8RVK-%(8V&Y2!AAR.?2NFJOJ N#87(M"HNC&WE%_NA
M\<9]LU46TTT9U(J<'%[-'Q7^QG^RQJ'PP^).H:YK6@WMBUI"T5O<7>H7#_.3
M@[5,A5P1GD@^U?;E?/7[-VG?%>R\4>(&\=2S-IK [!<L&W2[NL>.BXS^E>R:
MQX_\/:!K=II&H:K;VNHW1 B@=N3GI],^]>AF#YL0W==/AV/G>'8*&7Q24UJ_
MXGQ;]?T.AHI.M+7FGTP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 AZ57N=-L[RYM[BXM8)Y[8DPRR1AFB)&"5)&1GVJP>E+0!5L-+LM*C
M>.RM(+.-W,CI;Q*@9CU8@#DGUJU110!D>*]1U/2M!NKG1]-75M27:(;1YQ"C
M$L!EG/W5 )8G!. < FO%5_::U6XTR:2U\+V]Q>:<+R;4B+_%N8+9U1Y+=]F9
M,E^,A>58$\5ZY\1O!K?$'P9J?AX:K>:*+Y!&U[8-MF1=P+!3VW %3[$UPM[^
MSK9W^BZ=I[Z_>VXM+:33V:SBCA$MFY4F J!@#*@Y'/6@#A/'OQ#\/^,OVE_@
M7:Z5JEM=:A#'JES<622 S6Z26L)3>O5<U]-5\Y_$WPKH_A[]I/X$2:=IEI:3
ML-6ADN(H5661$MH0H=P,M@>M?1E !7->/_(N?#MS8323PFY0[9H+9IS&5(;.
MT?08KI:Y[X@1^;X.U-?M:V1\L$3L2 I# @''.">./6N?$ZT9^C.O".V(I^J_
M/YG':/KVJ7EKJD=WK-Q?Q)8R,(Y-,DTO!&.?/+';^'KGM7I\/,*?[H[Y_7O7
MFNISZMJFH$ZE#'I<L>E72PVT/^E-<YV98(<*P7 ^4\G/IFO2H?\ 5)V^4=L?
MI6&#O[-IMNSZWOT[MM'1F"7M4TDKKI:V[_E23^7IT'TR:5((GDD;:B LQ/84
M^D(R*[SS5YGDPETW2M=U!67P]>BZNOM"R7Q8W"[@O!/EG\.>*]#\-2"2TN".
M@N) ,7)G'7L3]W_=[=*X?4]0UBUM_$-@+2>YNYKDFVU"*1!%"I"[03GY=O<5
MV?A"*6'39EG8M+Y[[F, BW'/)&/O#_:[UY6"TE**_*UM7IYGMYCK"$F_QO?1
M:^1N4445ZIX9Y;XBDTVU\576I,VBWL=Y$B[-4+%D*97Y/D; ]O6NNTN=9->L
M/+6-$;2]X6WO&\H#>N-L' (]),9 X[UDZMJ-_H_BC5'>QGU:RFMH_(BM&7,)
M .X,">,GG=4O@RUOK>XT?^T93=78T@"6X6!60GS <>=U)Q_#T.,UY6&]VM./
MKTMU[];[H]S&>]AX2OM9;WNK=NEK69VM(S!5))P ,DFEJGK-S+9:1?7$%N;N
M>&"22.W'65@I(7\3Q^->J>&?/_[-WQ4\.:SX_P#BMI-O>_Z5>>++BZMMZ[5F
M06UK&=I]<H>/3FOHROR6_8P^+WCCQ+\<-?DU'X83VQ;Q ;WS(%:V%K*Z,#:_
MO.#D(&]1L]Z_1#7_ (YWW@^XT;_A(/!FH:9::IJ,.F17(N8Y LLIPF0.<9H
M]9HHHH *\)^.WQ8\.>"OB/X M]4NVBDL[V2ZN-J%A%&\+QJQ_%A^%>[5P7CG
MX(>$/B-KMCJ^NZ;]JO;0 *0Y57 .0''<5UX6=*%2]:]K/;S5CQ\UHXNOAN3!
M.//>+]Z]M&GT]#07XM^"VQCQ/I?/3_25_P :ZF">.Z@CFA=9(I%#HZG(92,@
M@UPWQ%\&Z!;^ /$4D6AZ;'(FGS%72TC!4A#@@XK=^'G_ "('AG_L&6W_ **6
MIG"GR<\+[VU-J-6O[=T:UMKZ7[VZG04445S'I!1110 4444 %%%% !1110 4
M444 %?+W[=^IQ6/@S081X"'C2]N;EXX+B2QEO$TWY?FE,48)8XZ#(Z5]0UX#
M^U)XJ\4^"[SPMJGAS2=>UJ()>V]Q;:&6W!GAVQ.X! (5N1GIVH \V_85\,>
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M]3IPMO;P;=M5UM^+T/-]-U:/4H;N[U>XU"94TR[-K<:T(K2W2-2$FRT1+ Y
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M=%%% !1110!P?QQ\5Z9X1^%^OW6J7(MXIK62VBXR7D=2%4#U_P #4?PF\?\
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M* 2-]U#G^(]AU- '<?\ "SO!W_0V:'_X,H?_ (JC_A9W@[_H;-#_ /!E#_\
M%5RX_9D^$Q&1\/?#Q'_7BG^%'_#,?PG_ .B>^'O_  !3_"@#J/\ A9W@[_H;
M-#_\&4/_ ,51_P +.\'?]#9H?_@RA_\ BJY?_AF/X3_]$]\/?^ *?X54G_9[
M^#%K#---X*\+0Q0R"*622VB58W) "L3T)++@'U'K0!V?_"SO!W_0V:'_ .#*
M'_XJJI\<> 3?B]/B#PY]L VBX^VV_F8]-V[-<FOP!^"CW$<"^#O"AGD1I$C%
MO%N95.&8#J0#P3VI9O@!\%;>>SAE\&^%(IKS(MHWMX@T^!D[!_%QSQ0!VO\
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M\@>!Y;:$12H&4J2CK@JPSP1R#6QSG::EXX\.VFGW4TFN:>(XXV9L7*$@ <\
MYKXO^-G[1'P]\,?#/X6Z9J?B2WM;^/Q9;74ENP)=(4N'9I".R@,.?>OJ"/\
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MM#?LX_#!@1_P@NB<_P#3HM '8'QAH*G!UO3@?0W<?^-)_P )CH'_ $'--_\
M N/_ !KS[PW^RI\*O#&A6.E6_@O3;F"TB$237L?GS.!W=VR6/N36E_PSE\,/
M^A$T/_P$6@#K_P#A,= _Z#FF_P#@7'_C2GQAH(ZZWIP^MW'_ (UP6M_ [X/^
M&]*N-3U;PEX;TW3K==TUU=P1QQQC.,LQX') _&N*\"? ?X+>"[YO!-]'X>US
MQ-/=7>HQV]ZD7VH13S23I&%Z[41MJCKL0'H* /<?^$QT#_H.:;_X%Q_XT?\
M"8Z!_P!!S3?_  +C_P :Y#_AG+X8?]")H?\ X"+1_P ,Y?##_H1-#_\  1:
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M^(>NC1K/4O$7B==)FURW>Z8P36MQ#&MC<M*C32_.8VF%OD  !N%.#Q]1T44
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M T4 +1244 +1244 >&_M6?"OQ;\5?!<]AH$NFW5I#:RO_9%]$Y^TW7'E.&#
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ML;C7IFG<.ZG>%D(''L.!0!]&\T"EI/6@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I*6D- !S69XB\3Z1X0TM]2UW5++1M.1E5[N_G6&)23@
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MM% "#I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10
ME!&1@\BEHH P;WP/HNH^+M.\3W%BDFMZ?!);6UT?O1QR8WJ/K@5NE01@\TM%
M "$9&#R*,4M% #=@(Q@8],4N*6B@!",C!Y%&,4M% "4$9ZTM% #=H( QP*4J
M#C/..E+10 E%+10 F,4$9Z\TM% "%01@\CWHQ2T4 (!@8' HI:* $I:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HI:* $Q6'XR\$
M:+X_T&71M=LDO]-D=)&@?@%E;<I_ BMVB@!D42PQK&@VHHP![4X*%&!P/:EH
MH 0#'2C: 2?6EHH 0*%&!P/:BEHH 0*!TXHI:* $HV@9XZTM% ";1C';TH Q
MTI:* $HQSFEHH 3% &!CM2T4 (%"]./I0% )/<TM% "44M% "4M%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAL(V4B&*1\H/EX!QV'2@#T.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "FLBO]Y0WU%%% ">3'_P \U_*G  # &!110*PM%%% PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *@-C;$DFWB)/\ L"BB@!T=K!$VY(8T;U50
M#4M%% !1110 4444 %%%% !1110 4444 %(0",$9%%% #/L\7_/)/^^13DC1
M/NJ%^@Q110 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>cvac-20231231x20f027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Q X4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSNJM\3+2SM;?X@2_$#2;K4/$[V%O_8UVUL\J1((5W^4R\1D2;B3P>E3?2_\
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MVQ>5_<P-OY5P/_"E= _Y\8_^_C__ !5'_"E= _Y\8_\ OX__ ,51:EW?W?\
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M8_\ OX__ ,51:G_,_N_X(<V*_DC_ .!/_P"1/0O,3^\OYTQ%AC+%1&I8Y8C
MR?>N _X4KH'_ #XQ_P#?Q_\ XJC_ (4KH'_/C'_W\?\ ^*HM2[O[O^"'/BOY
M(_\ @3_^1.^ECAE.6V;\$!^-PSZ&LKPGX6TOP5I TW2U,=OYKS,7?<SN[%F9
MCW))KEO^%*Z!_P ^,?\ W\?_ .*H_P"%*Z!_SXQ_]_'_ /BJ+4N[^[_@AS8K
M^2/_ ($__D3IKCPCI%WXLA\1S1"34XK,V*NS97RBX<C;ZY'6MSS$_O+^=>>_
M\*5T#_GQC_[^/_\ %4?\*5T#_GQC_P"_C_\ Q5%J6UW]W_!#FQ6_)'_P)_\
MR)W["%G5R$+KT8XR*=YB?WE_.O/O^%*Z!_SXQ_\ ?Q__ (JC_A2N@?\ /C'_
M -_'_P#BJ+4N[^[_ ((<^*_DC_X$_P#Y$]!\Q/[R_G38UAASL$:9.3MP,FN
M_P"%*Z!_SXQ_]_'_ /BJ/^%*Z!_SXQ_]_'_^*HM2[O[O^"'-BOY(_P#@3_\
MD3T+S$_O+^='F)_>7\Z\]_X4KH'_ #XQ_P#?Q_\ XJC_ (4KH'_/C'_W\?\
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M[O[E_F'-BOY(_P#@3_\ D3T#SXO^>B?]]"CSXO\ GHG_ 'T*\_\ ^%*^'O\
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MN_N7^8<V*_DC_P"!/_Y$[YFMV=7)C+KT8XR*1S;R.C/Y3,ARK'!*_3TK@O\
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M3MA\GIY>!M_*GK+"BA5=%4<  C K@/\ A2OA[_H&V_YM_C1_PI7P]_T#;?\
M-O\ &BU+N_N7^8<V*_DC_P"!/_Y$[T&W61I!Y0D88+C&3^-!-N91(3$9 ,!^
M,@>F:X+_ (4KX>_Z!MO^;?XT?\*5\/?] VW_ #;_ !HM2[O[E_F'-BOY(_\
M@3_^1.]3[-&[.GE*[_>88!/UI96MYXRDACD0]5;!!_"N!_X4KX>_Z!MO^;?X
MT?\ "E?#W_0-M_S;_&BU+N_N7^8<V*_DC_X$_P#Y$] 66)0 '0 <  CBCSX_
M^>B?]]"O/_\ A2OA[_H&V_YM_C1_PI7P]_T#;?\ -O\ &BU+N_N7^8<V*_DC
M_P"!/_Y$] \^/_GHG_?0IZL&&001ZBO//^%*^'O^@;;_ )M_C75^&_#L/ANR
M2SM56*U0DK$O09.34R4+>ZW]W_!-:<JS?[R*2\FW^B-FBBBLSH"BBB@ HHHH
M 0=*6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"O&.D3>
M,_VB[C0[KQ%K6D:5:^$XKZ./2]0>U59FNY$,A X8[0!SGI7&6GQ\\5:1X)AM
M;6_MM;UNVO=0MXI)K&2>;4+:V;"S8BPJ^C/TR.E>Y^,/@[X4\=:Y'K&L:<T^
MHI;?8_/CG>,M#N+;&VD9&XDX/K4>N?!/P=K]KIEM/I"00Z;$T%LMH[0[(F^]
M'\I&5/<'K4I-1MZ_FW?]"G9ROZ?E;_@GE9_:AU.+2+1Y]&@CU/7M+M;KP]:[
MS_I5S*_EO$Q_V&.XX_AKV;QQ;V-SX*NO[?U6?1;-(EENKRQNFMF3;@L!(.0#
MC''.*Y^X^"ND/XK\$W\$4-OI7A.&9=/L!'DI+( H?<><!01CWS73^./ FB?$
M?P_+HGB&R&H:9*Z2/ S%065@RG((Z$"JEJM._P"%]"(W35_Z?]?J?.MG;^-[
MGP MS:2>)KGPA<Z_YL<$=R[:L-+V@#$A/F89_FZ[MIKT;]F7Q-?^(?#OB.&Y
MEU*XL-.UF>SL)-7):Z\A<$*['EB"2,GGCFNMM_@]X<M/#UWHL"7L-C=.LD@2
M]EWY'3#;L@>PKH_#?AG3/".D0:7I%HEE90YVQ)ZGDDGJ23U)JD[7_KM_E^+#
M>W]=_P#/\$>"6_[0GBZRMK;Q%J5AI+^&I_$%]H2VEJ9/M@\F69$ER?E.?*Y4
M=CG-6M-^.GC>*UL)[O1M+U237]&FU;2+/39'$D90!EBE+<,2&'(QR"*ZWX=_
ML[>'O!=W/J%XIU?4WU&]OXY9F8QQ&XF=SMC)VA@K[=V/7UK8TGX$>"]%^W_9
M-)*"\A:W8&9SY4;')2/GY!GG"XJ%\-GO;]/\]2G\6G?]?\CQ&^^-'CSQ39^%
MH]*UK1[/6F\36]C>VC6EQ T226\CB*:-_FQE<Y'7 Q7T+H'C&XU'79]%NM'U
M""XM8QYNH-;%+29P!GRW/4$DX^E88^ '@H:'<Z8VFR21W%Q'=/<O<.UQYL8Q
M&XE)W J,@<]":[^TM4LK2&WBW>7"BQKN))P!@9)ZU6FO]=%^I.O]>K/"_%/C
M[Q?X8^-'BN2.\L[CPIH_A]-2DTYU;S6(+9V$<!B0!D\8K8^&WQ1\3ZGXRTO1
M/$UOI;+K>CMK5C+I;/\ N$5T5HI-W4_O%PPX.#Q7<ZW\-/#_ (@\2V^O7MD7
MU*&$V_F+(RB6(YRCJ#AEY/!JOX+^$OACP!?W%[HNG^1=31B'S))&D,<0.1&F
MXG:F><"E'3?^M_\ @?<.6NW];?\ !^\\_P#B1\6?&.A^+_%EEH5OHW]F>&]*
MMM4G:_:3S;@.TFZ-=O"\1\$]STK#F_:(\5C1_%_BA-'TT>&=!" 0L\AO)WDC
M1D& , !GY]AQ7=ZY\ =$\5_$K5/%.MM)?17=I;6JV =DC'E,[?. <.#O'!]*
M[)/ 'A^.RUBS&EP&UU=MU]"1E9CM"\CZ ?E25^7S_P"#_D-VYO+_ ('^9Y=\
M.?C7XIU*VUR3Q!X8OKJ*SCMYK:?3-.FB,_F$AHQ')R2F 2PX((K#\6>./&"_
M%>^U#PXT%E;0>$4U&;3M=\Q0N)VR-B\*Y QN/3WKV3P7\-M$\ FY.D1W"FX"
MAC<7+S85<X5=Q. ,]JI>,?@YX5\>:PFJ:QI[3WJP"V:2.9X_,A#;O+<*1N7/
M.#3>Z:_K1H2V:?\ 6J9Y-;_M'>)=:TJ\\4Z=INFP>&M*DLX;VSNF?[9*TP3<
M8R. %WC (^;':M+_ (7QXE-_'KHL--/@]_$J^&A:;G^W[VE\D39^[CS,'9C.
MWG->AZA\$O!NIZ];:O-H\?VF#R\1H[+$YC_U9:,':Q7 QD<4\_!GPB?%W_"2
M'2E_M+S_ +5CS&\KS\;?.\O.W?C^+&::M=/^NG_!]+B=[/\ KO\ \#UL>!^)
MOCWX[U/P?XM@>XT[POXCMK9KBWTR6VF2Y@59@NX.WR2KM(.Y>/F%>T>,]4\4
MZ1\!-?U&2]LX_$UOH\UPEW:JPB5Q&6# 'G/]:LV/P%\%6*ZBO]EM<K?0/:R"
MZG>79$QRR)N)V@D \>@KIM)\&:5I'A;_ (1V.%Y]*,+0-#<R-*61A@J2W)&#
MBH:O!QZ_\.6G::?3_ACYF\:_$;QYI'@JZ\S4[>/Q+_P@4^L17]K)((5(G@4$
MQ'@R88_/^'0UT?BWXZ^.O"NJV/AJ'3[/5->ATI=4NI;2QN)XYPS;4B0+RI.#
MEFXSVKU?2_@CX.TK3Y+)-*\^"2QFTPBYE:4_99&#/%DG[N57CMBJUQ\!/!]S
M8:?;/:70-BC10W"WDBS>63DHS@Y9?8U;=W=?UJ_\U]Q"T2_KM_D_O.&/QC^(
M>LZGXB_L3PWIK6^B6,%U+8W<KK>32R0;_)4 8!#8&2:ZKX$_$W4/B)::PFK7
M=@^I6$D2RV=M:S6TUMO3.V6.7GL<$<'!KK1\./#RVVJP+IX5-4A2"[*NP:54
M7:N6SG( ZTG@GX<:#\/DO/['M7CFO&5KBXGE:667:,*&=B20HX [4*VH:V1T
M]%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 @Z4M(.E+0 4444 %%%% !1110 45Q'Q>^,7AOX)>%4U[Q-
M<R0VTMQ'9V\,$9DEN)WSLC11R6.#5'X=?&_2/B%!JKMIVJ^&WTP(US'KUHUH
M55@2&!;@CCUH6M[= >EKGHM%><_$GX]>%?AKX&3Q7<70U?26O8+ /I;K-^\E
M<(O0XQD\UH>%_BMIOB34_%5K);7&DP^'KA+>>\U#;'#+N7=N1L_=^N*/Z_+_
M #0';45P6K?&70K#6?#UE:%M8MM9EDB74-/=);>W*+N)D8'@8I?A[\</!?Q0
MT6_U70-=MKBSL9I(+EY'$?E,C%6)!Z#(Z]#1N!WE%9%OXOT.\TB358-8L)M,
MCSOO$N4,2X]6S@5R?PS^.'AWXL>(O%FDZ$TDS^'+E+6YN.#%*S+N!C8$[ACO
M1UL&RN>AT5Y5\0/VEO!'PT^)_AKP%K=])#KVOE1:HD99%+,57>W1<D8&:WOB
MO\8/#?P=\*:CKFO7T2)96[7/V-)%^T3*O78A.6/TI77+S=/\AV;?+U.WHKG/
M#7C_ $3Q1X>M=7M[Z&*":SBO7CFD57@CD4,ID&?EX/>K5SXST"SFM(9]:T^&
M6[ -NDERBF8'H5!//X5333LR4TU=&S16:_B328KYK)]3LTO%94-NTZB0,1D#
M;G.2.:@L?&6@ZI<W-O9ZUI]U/; F:.&Y1FB ZE@#Q^-(9LT5FZ-XETGQ&DKZ
M5J=IJ2Q-M<VDZR!3Z':3BO)/B'^UIX1^'7Q&NO!%SIVMZIKUK:Q7DL.EV#SA
M(I,[6)'THZI!YGMM%86E^-='U/1_[1%]#;PK&DDRW$BHUON (60$_*>>AJ:;
MQ=H=OJ-OI\NL6,=]< &&V>Y022 ]-JYR:=M;"O=7->BL:;QEH%O?"SEUK3XK
MLR^3Y#W*!_,_N[<YS[5SOAKXW^#/%OB_Q#X9T[6[>36-!D$=] [!=AQG@G[P
M ZD=*6XSNZ*R]%\4Z-XD,PTG5;+4C"<2?9)UEV'WVDXK4H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YCXE_$
M/2?A1X'U;Q7KC2KI6F1&:<PH7?;[ =:3:2NQI-NR.GHKQ_X3_M1^#OB]XEF\
M/:8FI:=K26:WZV>J6;0/);MTD7/5:M_"?]I?P1\9_&/BGPSX:OI;C5/#LFR[
M62(HKC<4W1D_>7<I&156=[$W5K_UJ>JT5@^.?'&C?#GPM?\ B'7KQ;+3+*,R
M2RMR?H!W)[ 5E_"/XK:'\:? UCXL\.M,VE7A81&XC,;_ "G!RIZ<TEK>W0;T
M.RHKQ'Q]^UKX3\ _$2_\%3:9KNK:[8V\5S<1:5I[W 2.090DK7LVG7JZEI]K
M=HCQI<1+*J2KM90P!P1V//2A:JZ!Z.S+%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45F>)?$FF^#]!O]:U>[CL=,L8FGN+
MB4X5$ R2:\;\ ?ME> ?B!XJTS0H%U72IM7W'2KG5+%[>#4,?\\G88;CFA:NR
MW!Z*[/=Z*XGQU\6]#\$^%=0UI)/[<-F-S6.F2)+</\ZHVU<]BPSZ5LW'CC0=
M/%JNH:M9:;/<Q+,EO=W"1R;2,]":-P-VBN)T[XKZ9?>+]=T.6">RBTF"*>34
M[DJMK(LG3:^?YUO6WC#0KR*\E@UFPFCLAFY>.Y1A"/5R#\OXT>8>1L45Y]X\
M^.7A3P+\/=7\8MJ$6L:5I:AI_P"RY4G<9(&.#[UH^)_BOX=\%_#63QUKEW_9
MV@16B7;S2+EE5P-HP.I.0,>M)NR;?0=KM+N=A17E7PQ_:(T7XGZI)8V^BZ]H
ML@L_[0BEU?3W@CG@R!O1SP>H..M0_"?]J#P+\9QXJ_X1J]FN#X;=UO!)$4)"
M[OG3/WE^4\BF]-_42UV]#UNBOG[P1^VY\._'&O:%ID"ZMI_]NW#VFF7E_8O%
M;W4RD@HCG@G@U;L_VP_!>K>([K3M)L-=UBPM=0_LN?6K'3GELH[@,%*&0>A/
M)Z4TF[)=?Z_5!M<]VHK)\5^*M+\$>'-0UW6[R.PTJPB:>XN)#A40=37E_P +
M/VJ/"WQ:UZ+3-,TW7;%;B![JTOM2TZ2"VN8UQEDD88[@TEJ[('HKL]FHKB/%
MGQC\+^%?!NN^)?[1BU:PT6(S7BZ6ZW$D:CJ=JDGC^E8\G[1/@_\ M#P%96]Q
M/>7'C6/SM*2WB+;H]NXN_P#= ]^]"U=E_5P>FK_JQZ?17*?$KXB67PP\,MK-
M]8ZAJ,?G) EMIELUQ.[MT 1>>W6L7X+_ !W\-?'32]4NO#YNX+C2KHV6H6&H
M0&&XM9@,[70].*%K>W0'I:YZ+1110 4444 %%%% !1110 4444 %%%% "#I2
MU%-<16R!II$B4D %V &?2H&UBP2_-DUY +P)YAMS(-X7UV]<>] %RBLQ/$VD
M26JW*ZI9M;-)Y*RB==I?^[G/7VK0CFCE9U1U<H=K!3G:>N#0 ^BBB@ HHHH
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M3.]@$^XJ\ #T-?2%%"T;??0;U278****0!1110 4444 %%%% !1110 4444
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MI7'@[7K[X@Q7C:.\0FUFVU7^TFD0^1 D&QX#SNR6R, 8.[-"UL#TN>T4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY9\=_"NI^)K706T^UGN$M+B5Y6M4225-T+(I$<GRL"6YST[5ZG12:YE9C3L[
MG-_#W2;S1? &@:;?1):WUM8Q0RQQ-O5&5 " 3UZ5MV#N\+"1M[*Y7=C&:LU5
MT_\ U<O_ %T:J;YFV2E96+5%%%(84444 %%%% !1110 4444 %%%% !1110
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M^'.B>'_$$VL6,$D-S(A01>:3#'D*&*)T4D(F?I5:7\B=;>9LWTR"XMH\_.9
M<8]C5ZJE]]^V_P"NH_D:MTAA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%>17.J7@N9@+N< 2-QYK>I]ZVITW4OJ4E<]=HKQ[^U+W_G\N/^_K
M?XT?VI>_\_EQ_P!_6_QK;ZL^Y7(>PT5X]_:E[_S^7'_?UO\ &C^U+W_G\N/^
M_K?XT?5GW#D/8:*\T\*:A=3>(+-)+F:1"6RK2$@_*>V:]+K"I#V;L2U8****
MR)"BBB@ HHHH **** "BBB@ HHHH **** *NG_ZE_P#KHW\ZM55T_P#U+_\
M71OYU:H **** "BLWQ-JS:!X<U74UB$S65I+<B(G <HA;&>V<5\>#_@H1J9
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MU,;1'=6T=Q\AW ;E#<$=>M2Z7(LL$C*<J9&QQBJ::=F2G=71<HHHI#"BBB@
MKQS2M7ATCXJ:I=VT]]<:,EDS7*KY\@2;S /F5^,\\!.U>QT@4 D@ 9Z\4+1W
M#I8\YT?5_P#B]VLV8O+V2VFTBWD6"57\A)1))N"<8!VE">:]'I,#.<4M'1+^
MMPZM_P!;!1110 4444 %%%% !1110 4444 %%(W"GG''7TKS?P1XJNKSQ5K@
M?7$U3PY;XC6]N/+C47.[!CC*XW*!@9/?C-'6P=+GI-%>*^ ?B1KNM?$U["]N
M=^DW37JVV%0QR>3(JC8!\Z$ G=OX/&*]JH6J3[AU:[!1110 4444 %%%% !1
M110 4444 %%%% "#I5.76K""_2QDO($O'4NL#. Y4=3CTJX.E>#^(/AYXNF\
M;>(I-/\ ,":JS_Z9(R&$0&$J(QQN5@WH<4FQI'L2>+]#DM?M*ZM9M;^;Y'FB
M9=OF?W<YZ^U:<5Q%.T@CD5S&VUPISM.,X/YBO ;7X.WOB#3M8N;O2I-',=M%
M#:Z?$R?OY%@:.1CV&_< &ZC&:Z_X9>'_ !=X9\37MGJ3";2&5YFN"!B65MAW
M ]<YW@Y[!:JVMB>ESTB^^_;?]=1_(U;JC?(WVBV;>=OF#Y,>QJ]2&%%%% #9
M/]6WT->0^M>O2?ZMOH:\A]:[,/U/%S'['S_0****[#Q@HHHH V_!G_(P0_[C
M_P J]%KSKP9_R,$/^X_\J]%KSZ_QGT. _A/U"BBBN<](**** "BBB@ KQBY_
MX^I_^NC?S->SUXQ<_P#'U/\ ]=&_F:[<-NS2!'1117<:!1110!L>$/\ D8[+
MZM_Z":]3KRSPA_R,=E]6_P#037J=>=B/B1E/<****Y2 HHHH **** "BBB@
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M_)5/N+]*^TX?^"IZH_$O$/\ C8?TE^:%HHHKZP_(0K]'?V-_^2$:/_UVF_\
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M)055T_\ U<O_ %T:K55=/_U<O_71J0RU1110 5!?WB:=8W%U("8X(VE8+U(
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M^I?_ *Z-_.K5 !1110!SOQ%_Y)]XG_[!=U_Z*:OR53[B_2OUJ^(O_)/O$_\
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M(N8LLWF@C;@DDG&.,= .*LV/@[1=,UNXUBUTZ&#4KA0DDZ Y(P!TZ#A5Z#G
MK9HH\P*E]]^V_P"NH_D:MU4OOOVW_74?R-6Z "BBB@!LG^K;Z&O(?6O7I/\
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M ,+/\*_]!NU_[ZH_X6?X5_Z#=K_WU7H^RJ?RO[C6S.HHKE_^%G^%?^@W:_\
M?5'_  L_PK_T&[7_ +ZH]E4_E?W!9GH'A#_D8[+ZM_Z":]3KPWX?>/?#^K^,
M=-L[/58+BYE9]D:'EL(Q/Z"O<J\O%1<9I25M#*>C"BBBN,S"BBB@ HHHH **
M** "BBB@ HHHH **** *NG_ZE_\ KHW\ZM55T_\ U+_]=&_G5J@ HHHH YWX
MB_\ )/O$_P#V"[K_ -%-7Y*I]Q?I7ZU?$7_DGWB?_L%W7_HIJ_)5/N+]*^TX
M?^"IZH_$O$/^-A_27YH6BBBOK#\A"OT=_8W_ .2$:/\ ]=IO_0J_.*OT=_8W
M_P"2$:/_ -=IO_0J^<SW_=EZ_HS]*X!_Y&<_\#_-'MU%%%?!'] A1110 444
M4 %%%% 'G_Q\_P"2/>*/^O8?^AK7P(.E???Q\_Y(]XH_Z]A_Z&M? @Z5]?DW
M\&7K^B.VA\+"BBBO>.@0]#7Z#?!7_DE'A?\ Z\4K\^3T-?H-\%?^24>%_P#K
MQ2OG\Y_A1]?T.:OLCMJ***^2.,**** "BBB@ HHHH **** "JNG_ .KE_P"N
MC5:JKI_^KE_ZZ-0!:HHHH *R_%'_ "+.K?\ 7I+_ .@&M2LOQ1_R+.K?]>DO
M_H!JH_$C*K_#EZ,_(=/N+]*6D3[B_2EK]>/XZ"BBB@1^B/[%'_)"['_K\N/_
M $*O>J\%_8H_Y(78_P#7Y<?^A5[U7Y=C_P#>JGJS^K,@_P"13AO\$?R"BBBN
M ]\**** "BBB@ KA_C=_R23Q7_UX2?RKN*X?XW?\DD\5_P#7A)_*MZ'\:'JO
MS*C\2/S\HHHK]&/3"@]**#TH ^_O@/\ \DB\,?\ 7K_[,:[VN"^ _P#R2+PQ
M_P!>O_LQKO:_.<1_&GZO\SS)?$PHHHK D**** "BBB@ HHHH **** $'2O'O
M&_A77?&'C.ZC.ABTL(+::.RU"&1 9)I(RN^3^+ Z ?C7L(Z4M)JXT['@-K\'
M+[7]/UBZO]+;2I5MHH+2PAE7$SI T<A8@8 ?=C/48S75_#/PUXM\+>)KRTU"
M43Z,5>5IR5Q+*VP[AWSN\S.>P7%>IT55];DVTL4;Z-OM%L_F-M\P#9VZ&KU5
M+[[]M_UU'\C5ND,**** &3$+$Y/ "DUX ?B%X=!/_$UAZ^C?X5[Y=_\ 'I-_
MN-_*OS[;[S?4U]#E.$ABN?F;5K?J?G/%^<5LJ=#V44^;FWOTY>S7<^B/^%A>
M'?\ H*P_DW^%'_"PO#O_ $%8?R;_  KYVHKW_P"RJ7\S_ _.O];\7_S[C^/^
M9]$_\+"\._\ 05A_)O\ "C_A87AW_H*P_DW^%?.U%']E4OYG^ ?ZWXO_ )]Q
M_'_,^KOAUXOT?5_%4%M9W\=Q.T<A$:YR0!SVKUVOD']G'_DJUC_U[S_^@5]?
M5\MF>'CAJZA%WT_S/UKA7,:F9X&5>JDFI-:>B_S"BBBO(/L0HHHH **** "O
MS0UL?\3S4_\ K[F_]&-7Z7U^:&M_\AS4_P#K[F_]&-7TN2[U/E^IU4.I3Q1B
MHY[B*UB:2:1(HUZN[  ?B:A.J60\G-W /._U?[P?/].>:^GNEI<ZRUBC%0K>
MV[/(HGB+1G:X#C*GT/I4U--/8#TC]G/_ )+3X:_WYO\ T2]?>=?!G[.?_):?
M#7^_-_Z)>OO.OD,X_CQ]/U9Q5_B04445X)SA1110 4444 %%%% !1110 444
M4 %%%% %73_]2_\ UT;^=6JJZ?\ ZE_^NC?SJU0 4444 <[\1?\ DGWB?_L%
MW7_HIJ_)5/N+]*_6KXB_\D^\3_\ 8+NO_135^2J?<7Z5]IP_\%3U1^)>(?\
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MOOVW_74?R-6ZJ7WW[;_KJ/Y&K= !1110!#=_\>DW^XW\J_/MOO-]37Z"7?\
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M[5]NM_\ GLGYU-@&C ]!7S=>JZ]251JUW<_2L#A8X'#4\-%W4$E?T(?MUO\
M\]D_.C[=;_\ /9/SJ; ]!1@>@K$[B'[=;_\ /9/SH^W6_P#SV3\ZFP/048'H
M* (?MUO_ ,]D_.C[=;_\]D_.IL#T%&!Z"@"'[=;_ //9/SKC_C #J?PO\36M
MF#<W,ME(D<,0W,YQT '4UVV!Z"C ]*N$N22DN@T[.Y^<O_"O/%/_ $+NI_\
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M.XQ-AT#<?-ST&:Z+2M''PTTH:K+%>3:M>P1PRW-TPF6QB7&U&;C*J3CU-7O
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M[)7E1@"$3I*H; *'KVKTGX?_  _C\/O)JM_;V9UJX+,TEFCI&BM@D*C$A2<
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M#=< FLCX5?"J[2[FU+68X/LDL[R26=Q;J\LQ&X1K(_*NBEV=6'))!/3%>V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M@Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>cvac-20231231x20f028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %A W,# 2(  A$! Q$!_\0
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M+&6Q'MQDOA3G'&:T+7X_>#+GP;>>)3?RP65I=G3Y[>>W=;E+GC$/E8W;SN7
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M>G>EU#]H3P+IOBJY\.S:N3JMK(D=Q'';R.L :,2*[N!M5=I!W$XH ]'HKAO
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M]GXR>%V!!GN2#P0;.7_XFHK;XM>$;-"MN9H%)R5CL9%!/X+2]A4ZQ=M?QO\
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MO_B:/^%R>&_[]]_X 3?_ !-"H5$DN5_U;_('CL,W?VB^]?UU//-?^"OB"^\
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M*VTM_**OYD"J?,);Y@>?0XKV_P#X7)X;_OWW_@!-_P#$T?\ "Y/#?]^^_P#
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MRZDG@BO2_P#A<GAO^_??^ $W_P 31_PN3PW_ '[[_P  )O\ XFI]A4;ORO\
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MA_.C^QK?T/YU?HH H?V-;^A_.C^QK?T/YU?HH H?V-;^A_.C^QK?T/YU?HH
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M^T7.FG7'P_U.XM+NZT^QU])KIK2SENC$GE2#<4C5FQDCG'>EV]5^8^_S._\
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M5*=TG_7_  WZZ%-6=OZ_K]-3[A_L:V]#^=5GATR/48K!IT6]EC:9+<O\[(I
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M 4444 %9VG>'M-TG4-1OK.TCM[O4)%ENI4SF9@NT$_@ *T:* "BBB@ HHHH
M*SE\/:<FO/K8M(QJKP"U:ZYWF($L%^F23^-:-% !1110 45\W?'7]KV7X/\
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MW5T@O;=+B-9!A@K*& (]>:OU333LR4TU=!1112&%%%% !1110 4444 %%%%
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ML2!PJ@D C) &3S7I-%%.3YG<25E8****D84444 %%%% !1110 4444 %%%%
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M1>./$#^&])GU.TCLH]"\'V\D-@@4Y\Q@_)<_2OI>BE'W7=>@Y>\K/U"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY3:V><;2Q+XQP:I>9+/0=0^Y%_UU6K=4=2A1C!(5RXD4 U>I#"BBB@ HHHH
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MP<XJK8_$>.Y\8Q>'+C0M6T^[F226*:X2(Q.B=6RDC$ Y&,@=:.M@\SL****
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M27,<C2C8&W$'CK54*,L145..[.Z,7)V1] 5YW\%O^/'Q;_V,M_\ ^ABOE/\
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M "O'/C'\#=9\<^(;?Q#X6\40^'-6^R_8;N.^T];ZUNH=VY=T;$896Y!KV.O
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M6PN[V_@NKFXNOM5[9?8S*SR%BR1?PH2?E]J]>KD?A5X.U/P!X(T_P_JFM_\
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MFK)6_(_;.',76QV5TL1B)7F[W?S85ROQ5_Y)EXK_ .P7<_\ HIJZJN5^*O\
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M^ZHW'&/6FZ3\,]!T/6H-4LK>2&>")8HT$A,8PFP-M_O;>,UU5% %34/N0_\
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M^R/^"?7^H\8?[\'\C7V'7QY_P3Z_U'C#_?@_D:^PZ_.LV_WR?R_)'])<(?\
M(EH?/_TIA7*_%7_DF7BO_L%W/_HIJZJN5^*O_),O%?\ V"[G_P!%-7FTOXD?
M5'T^+_W>I_A?Y'Y/4445^MG\?A7Z(_L2_P#)"++_ *_KG_T.OSNK]$?V)?\
MDA%E_P!?US_Z'7SV>_[JO5?J?HW ?_(UE_@?YH]ZHHHKX _H0\,_;._Y(5JG
M_7>#_P!#%?G/7Z,?MG?\D*U3_KO!_P"ABOSGK[[(O]U?J_T/Y\X]_P"1K'_
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M3Z9#_J8_]T4^O'/L5L%%%% SB_B!_KK+_=?^E<G76?$#_767^Z_]*Y.O2H_
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M\EK?Q9>K/Z^P7^ZTO\*_)!7RM^VA_P A3PS_ -<I?YBOJFOE;]M#_D*>&?\
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MKPY_V$K;_P!&K7I2BH4W&*TL?,4ZDZN(C.H[MM'ZW4445^2G]?A7Y^?MS_\
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M?05\KGK3=-KS_0_7> (2IPQ,9JSO'\F/HHHKY4_6@KY(_;-_Y'#P[_UY2?\
MH8KZWKY%_;3GCM_%GAZ2618D%C)EG. /G'>O6RO3%1^?Y&U'XSY^HJ#[?:YC
M'VB+,GW!O'S?3UIR7<$A8+-&Q5MA 8'#>GUK[:Z.\^J_V+?^0;XJ_P"NUO\
M^@O7TK7S5^Q;_P @WQ5_UVM__07KZ5KX7,?]ZG\OR1Y]7XV%%%%>:9!1110
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M\^<>_P#(UC_@7YL*#10:^B/S@_5KX/?\DL\+?]@^'_T$5V-<=\'O^26>%O\
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MR5\>5^D91_N4/G^;/YFXP_Y'=?\ [=_])05N^ _^1Z\.?]A*V_\ 1JUA5N^
M_P#D>O#G_82MO_1JUZE3X'Z'RN'_ (T/5?F?K=1117Y&?V&%?GY^W/\ \EE@
M_P"P9%_Z$]?H'7Y^?MS_ /)98/\ L&1?^A/7OY)_O?R9^>\=?\BC_MZ/ZGSO
M1117Z"?SL>M?LJ_\EW\,?]=6_P#037Z8U^9W[*O_ "7?PQ_UU;_T$U^F-?"9
M]_O$?3]6?OO '_(MJ?XW^2"BBBOFC]./S[^-O_)6/$__ %]M_(5Q%=O\;?\
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M246/2_$:(H5%FA 4#  VM4YG"4,'.[NM/S1KPK7I5LWH<L.62YMMG[CZ'O\
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MY?DCAJ?&PHHHKS3(**** "BBB@ HHHH *JV__']=_P# /Y5:JK;_ /']=_\
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MVEJ;L!K55*D,P/)+9X!Z#KS7NO%4T['P4,JQ$H\VBUMOY7/OCX/?\DL\+?\
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MP]_UXP_^@"OSRU7X:Z18:+XOG1X)+RT+/!"+L$VJ!P &7J20?P^M?H;\./\
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MUI1117PQYX4444 %%%% !1110 55U2\.G:9>7:IYC00O*$'\6U2<?I5JD(#
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M6UALK:*WMXEA@B4(D:# 51P !4M !1110 4444 %%%% !1110 4444 %%%%
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MOGFMKP!X>LO VD:GXBN-0U&.VOXUNIH=3<,UN%7') R21C.>:[F_6RV1O>K
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M>^'+&ZM='EUN$WDH,*L7R=P^7YF'"MGL<<TWQEXDM? NF7%S':1PRSHWE3%
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MS$;N57 \D2Y&S:,-@')^@->F51UFPT^_LG&I6T-U;1_O"LT8<#'.<8H \_\
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M?/MUC4E0[D_OH)<[C#( 2$;ICC(Q0!T?PP^%"Z'=S7^K:39VC1,JV%FK^?\
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MH **** "JBZ39+J!OQ:0B]*[#<",;R/3/6K=% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>cvac-20231231x20f029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $F ]4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH *@GOK:U8+-<11,>0'<*3^=3U^9?_!0G4H$_;!\ 6>K:=XC\0: =
M N)[K1_#EV\,\NUB=PVGMC)H _3&.5)D#QNKH>C*<@T^OR[_ &9?CYKWP!_8
MX^*_Q9CN;C7M .LB'PSH.IWYNI[ M((@L[GE<%@2O?;Q]ZO5?@!^U=\7M9^)
M%IIGC+3SJ'A+4=)FOI=?;0)M-@TJ=8S(%9G)$D?&-W&<T ?=]%?FWX<_;J^)
MEC\4_ <<NK:?XS\%^)]7_LLW=OX?EL+<9. 8)W8^9CZ=J]-\*?'7XX?M$^-?
MB5-\-M0\,>&/#W@O57TJ*RUNU::;4)$&6+N"/*4C'..,^U 'VL&4L5!&X=1G
MFEK\\O FM_%U?^"A_P 7H(?$^FG2M,TZUOKVPN$EDA^P8B98X$W;4FV%07Q@
MG)[UGR_MM?&8_"NY^.T;>'!\.X/$)TG_ (1@V[?;6@$FS?YV?O\ ?&* /T=H
MKX-\3_M8_%GQU\0?C O@*\\/>'/#7PQT8ZC<V^KVS3W&I/Y#R[5P1L'[MAGW
M7UK#\4?M]^/!\)O@8NFVEM!XQ^(-I<WEWJ$.G/=QVL<,I3]U;J<NQXXSQ@T
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MX  X& ,5/<_L.?"^[^#?_"L9++4/^$6_M<ZWY0OI!+]I+,V=^<XRQXKZ"HH
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MS72444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 45X?\ %CX_>(/A/K*SW_@F6;PG]MAL?[52[7S':0@!ECZD9/Z5
MZKXE\:Z+X-\.MKNNZA%I6E($WW-QD*N\@*#]20* -NBN6U3XH>%-%NM8MK[7
M+2UGT>W6ZOXY'P;>)ONLWUR,55\"_&+P=\2;J:U\.:Y!J5U#$L\D"JRNB,<*
MQ# <&@#LZKZ>[26,#,2S% 23WXJQ7BNI_%'6M+OY[2!H1# WEKNCR<#\: /:
MJ*\+_P"%OZ__ '[?_OU_]>C_ (6_K_\ ?M_^_7_UZ /=**\+_P"%OZ__ '[?
M_OU_]>C_ (6_K_\ ?M_^_7_UZ /=**\+_P"%OZ__ '[?_OU_]>C_ (6_K_\
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M-O[%OO\ GUF_[]M_A1_8M]_SZS?]^V_PKU.BCZP^P?V='^8\L_L6^_Y]9O\
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M,T4J\Y^5UY!X[5QNC?!72-$U6UOX=8\132VT@D6.YUF>6-B.S*6PP]C7H-%
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MB@ HHHH *0]#2TAZ&@"MIG_'A!_NU:JKIG_'A!_NU:H **** "BBB@ HHHH
M**** "BBB@ HHHH **^7O&W[75U:?%R]\'Z'+X:TVUTNZBM+N]\1W$R&>1L%
MEB$:D# /5R!FO>?'OQ&T3X8^#YO$OB*Z-MI4!C$DT*&7EV"K@+R<DB@#J**\
M_P#$/QW\&>%;_P 1V>IZH;6?P_:QWE^&A8A$DQLVG'S$Y  '.347PW^/'A?X
MI:Q=Z3I(U*UU2UMDNY;/4[&2VD6)SA'PPY![$4 >BU6TW_D'VW_7-?Y59KPS
M5OB'K6GZE<VT-P5BB<HH] * /<Z*\!_X6?KW_/T:/^%GZ]_S]&@#WZBO ?\
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M])9WLJD37SVYB!F4?PQ$RX4_Q8)Z$5[;0 4444 %%%% !1110 4444 %%%%
M!1110 5\-ZYKNG+\0=>\6CP'X>_X1:7Q1;Z=J+K?E=3N9H[M$2;R0>@E*OLQ
MSM!/2OLWQ;<ZS9^'+^;P_:6]]K21YM;>[D*12/D<,PY QFOA9=;U:;Q8WQ)U
M3X:^#(WM/$$6GWES'J4A*71N5@\WR=V"P9@V[&<?-C% 'WW<?\>\G^Z:+;_C
MVB_W!_*BX_X]Y/\ =-%M_P >T7^X/Y4 2T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 55?_D)1_P#7)OYBK557_P"0E'_UR;^8H M4444
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M;_"OHRB@#YS_ .$#UW_H&7/_ 'Z;_"C_ (0/7?\ H&7/_?IO\*^C** /G/\
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M  C>H?\ /O)_WPW^%'_"-ZA_S[R?]\-_A7IM%'UB78/[/A_,SS+_ (1O4/\
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MXGQ__$/\%_S^G^'^1\I_"?X;^)=&\>:5=WNC7EO;1R@O))"RA1[DBOJ/3_\
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M%6Q4:$N5H]*HKS7_ (2B_P#^>K?]]M_C1_PE%_\ \]6_[[;_ !K3ZO+N<_\
M:$/Y6>E45YK_ ,)1?_\ /5O^^V_QH_X2B_\ ^>K?]]M_C1]7EW#^T(?RL]*J
MMIW_ !Y0_P"[7GW_  D]_P#\]F_[[;_&FQ^)+Z) JRM@?[;?XT?5Y=P_M"'\
MK/3**\U_X2B__P">K?\ ?;?XT?\ "47_ /SU;_OMO\:/J\NX?VA#^5GI5%>:
M_P#"47__ #U;_OMO\:/^$HO_ /GJW_?;?XT?5Y=P_M"'\K/2J*\U_P"$HO\
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MR"K;_<J]7K1^%'R-7XY>K"BBBJ,@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \!^*?\ R.U]]$_E7)5UOQ3_ .1VOOHG\JY*ONL-_ AZ+\C\ S3_ 'ZO
M_BE^84445TGF!1110 4444"/O7PE_P BMI'_ %Z1?^@BL^#X?Z7%XPUGQ$PD
MFN]6M([*YBD(,31IG VX[[CFM#PE_P BMI'_ %Z1?^@BM:OR>?QOU/Z_P_\
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MAZBO@W_A,=>_Z#6H?^!4G^-'_"8Z]_T&M0_\"I/\:/[!G_S\7W!_Q$&A_P!
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MG",/9[+O_P  ^!Q7 :Q->=;ZS;F;=N7O_P!O'Y__ -G77_/O)_WR:/[.NO\
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M7:W]M,]WH>R.17.+M\X!S_SSK]%O#\#6NB6,#XWQ0K&V.F0,'^57STJOI_\
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M (]HO]P?RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6O!/M5RO+;V]G2Y=5E8*,  'V%:TX<[L<F(K^P2=KW/3_.C_ .>B_G1YT?\
MST7\Z\J_M"Y_Y[/^=']H7/\ SV?\ZW^K^9P?VC_=_$]5\Z/_ )Z+^='G1_\
M/1?SKRK^T+G_ )[/^=']H7/_ #V?\Z/J_F']H_W?Q/5?.C_YZ+^='G1_\]%_
M.O*O[0N?^>S_ )T?VA<_\]G_ #H^K^8?VC_=_$]5\Z/_ )Z+^8JMI\T8LX@7
M7[OK7F?]H7/_ #V;\Z1;ZX4 "5@![T?5_,/[1_N_B>K>='_ST7\Z/.C_ .>B
M_G7E7]H7/_/9_P Z/[0N?^>S_G1]7\P_M'^[^)ZKYT?_ #T7\Z/.C_YZ+^=>
M5?VA<_\ /9_SH_M"Y_Y[/^='U?S#^T?[OXGJOG1_\]%_.F27D$6-\\:9Z;G
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MX(?\1"?_ $#?^3?_ &I][?VC:?\ /U#_ -_!1_:-I_S]0_\ ?P5\$_VQ??\
M/W-_WV:/[8OO^?N;_OLT?V"O^?GX?\$/^(A/_H&_\F_^U/O;^T;3_GZA_P"_
M@H_M&T_Y^H?^_@KX)_MB^_Y^YO\ OLT?VQ??\_<W_?9H_L%?\_/P_P""'_$0
MG_T#?^3?_:GWM_:-I_S]0_\ ?P56T[4+5;1 ;F$')_Y:#U^M?"7]L7W_ #]S
M?]]FD75KU1@74P'^^:/[!7_/S\/^"'_$0G_T#?\ DW_VI][_ -HVG_/U#_W\
M%']HVG_/U#_W\%?!/]L7W_/W-_WV:/[8OO\ G[F_[[-']@K_ )^?A_P0_P"(
MA/\ Z!O_ ";_ .U/O;^T;3_GZA_[^"C^T;3_ )^H?^_@KX)_MB^_Y^YO^^S1
M_;%]_P _<W_?9H_L%?\ /S\/^"'_ !$)_P#0-_Y-_P#:GWM_:-I_S]0_]_!1
M_:-I_P _4/\ W\%?!/\ ;%]_S]S?]]FC^V+[_G[F_P"^S1_8*_Y^?A_P0_XB
M$_\ H&_\F_\ M3[V.HVF/^/J'_OX*33F#V:%2""201]37P4-8OL_\?<W_?9K
M[6^%S%_A]H3,2S&V4DGOR:\S'Y;]2A&7->[['U7#_$SSRM.C[+DY5?>_6W9'
M4T5POQO\>WWPQ^%^M>)--MH+R_L_)6&"Y)$;-)/'%\Q'./GS^%<OI/QUN=6T
M[P*XTZ*WU#5M9DT/6+.1B6L;F*.0RJOK\R @GJK ]Z\0^Z/8J*IZOJ]CH&FS
MZAJ5W#86,"[I;FX<)'&,XR6/ ZUS&E_&CP%K>HV]AI_C+1+V]N'$<-O!?QN\
MC'HJ@'))H [.BJ6M-J"Z3=G2D@?41&?LZW1(B+]MV.<?2O,_"WCSQ=IOQ-C\
M&^*AI6H376FOJ45WI,;QB#:VTI(K,>N>#WP: /6:*^>_@7\8?$OQ9DL+J7Q7
MX20O)(USX?MXR;Z.-79<?ZS(. #G;WKZ$H **** "BBB@ HHHH **** "BBB
M@ HHHH R_%$6K3>'M0CT*:"WUAH6%I+=*6B63L6 Y(KY[NOA#\;?B+)8Z3X^
M\6>&V\*K>V]Y=P:39R+/,(95E5 S' RR+S7TQ10!%<_\>\G^Z:+;_CVB_P!P
M?RHN?^/>3_=-%M_Q[1?[@_E0!+1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !55_P#D)1_]<F_F*M55?_D)1_\ 7)OYB@"U1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2'H:6D/0T 5M,_X\(/\ =JU5
M73/^/"#_ ':M4 %%%% !1110 4444 %%%% !1110 5Y3<_LO?#B]\:/XIN="
MDNM3>\:_*3WL[V_V@G)D\DOLSGGIBO5J* .0\9_"?PMX_.GG6M*CN&L+M+V!
MD)C(E4Y!)7&X>QR*Q?VB/A3=?&CX/ZWX-L;Z'3+C4/(V7,Z%D0),DAR!SR$Q
M^->DT4 >)M^RKX1TGPUXDM]$L$DUC6M-%A-<:Y=7-]"X7!3<K2[L @8VL",#
M!K+_ &=OV9+SX/\ BO5_$FKZO:WVH7MI%8Q6NGK/Y$$2'(^:>21V/;&< =*^
M@** "N.'@W[<JW'FX\Q0V-WM]*[&H+&-H;.!'&&5 "/PJXS<-C&K1A624SEO
M^$#_ .FW_CW_ -C1_P ('_TV_P#'O_L:["BM/;3[G-]2H=OQ./\ ^$#_ .FW
M_CW_ -C1_P ('_TV_P#'O_L:["BCVT^X?4J';\3C_P#A _\ IM_X]_\ 8T?\
M('_TV_\ 'O\ [&NPHH]M/N'U*AV_$X__ (0/_IM_X]_]C45MX(\^!)/.^\,_
M>_\ L:[6H+*-HK6-&&& Y%'MI]Q_4J';\3EO^$#_ .FW_CW_ -C1_P ('_TV
M_P#'O_L:["BCVT^XOJ5#M^)Q_P#P@?\ TV_\>_\ L:/^$#_Z;?\ CW_V-=A1
M1[:?</J5#M^)Q_\ P@?_ $V_\>_^QKCOB%\"[CQD+$0:A%;?9]^?,R<YQZ#V
MKV&BM:6+JT9J<'JCEQ6483&494*T;Q>^K76Y\V_\,IZA_P!!JV_[Y;_"HX/V
M5]0FB#_VU:\Y_@;U^E?2IY!J*SC:*W56&",\?C7=_;&,_F7W(\#_ %+R7_GT
M_P#P*7^9\Y_\,I:A_P!!JV_[Y;_"C_AE+4/^@U;?]\M_A7TE11_;&,_F7W(/
M]2\E_P"?3_\  I?YGS;_ ,,I:A_T&K;_ +Y;_"C_ (92U#_H-6W_ 'RW^%?2
M5%']L8S^9?<@_P!2\E_Y]/\ \"E_F?-O_#*6H?\ 0:MO^^6_PH_X92U#_H-6
MW_?+?X5])44?VQC/YE]R#_4O)?\ GT__  *7^9\V_P##*>H?]!JV_P"^6_PJ
M.W_98U">%7_MJUY]$;_"OI4U#8QM%:QHXPPSD?C1_;&,_F_!!_J7DO\ SZ?_
M (%+_,^=/^&4M0_Z#5M_WRW^%'_#*6H?]!JV_P"^6_PKZ2HH_MC&?S+[D'^I
M>2_\^G_X%+_,^;?^&4M0_P"@U;?]\M_A1_PREJ'_ $&K;_OEO\*^DJ*/[8QG
M\R^Y!_J7DO\ SZ?_ (%+_,^;?^&4M0_Z#5M_WRW^%'_#*6H?]!JV_P"^6_PK
MZ2HH_MC&?S+[D'^I>2_\^G_X%+_,^;?^&4M0_P"@U;?]\M_A4=O^RQJ$\0?^
MVK7G_8;_  KZ6JO8QM%;*KC# GC\:/[8QG\WX(/]2\E_Y]/_ ,"E_F?.O_#*
M6H?]!JV_[Y;_  H_X92U#_H-6W_?+?X5])44?VQC/YE]R#_4O)?^?3_\"E_F
M?-O_  REJ'_0:MO^^6_PH_X92U#_ *#5M_WRW^%?25%']L8S^9?<@_U+R7_G
MT_\ P*7^9\V_\,I:A_T&K;_OEO\ "C_AE+4/^@U;?]\M_A7TE11_;&,_F7W(
M/]2\E_Y]/_P*7^9\V_\ #*>H#_F-6W_?+?X5[OX*TEM!\+:;ISR+*]M%Y9=1
M@'!-;1J*SC:*W56&#D_SKDQ&.KXJ*C5=TO(]?+<AP&4U)5,)!IR5GJWI\V<!
M^T'X,U7X@_"/6] T2*.?4[I[4Q1RR"-2$N8I&RQX'RHU<;XP^"NNO\>?#?BK
M0F@_X1R6\6_UFU=PK)<QQ-$DR ]2R/M8#^XE>[T5P'T)G>(=)DUW1;NPBOI]
M,DG3:+NV6-I(^<Y42*RD_537"Z%\'=0T76+.^D\?^(-12WD60VMQ;:<L<H!^
MZQ2U5@#_ ++ ^]>ET4 8_B^ZUFR\,:G/X>L8=2UM(&-G:7$OE1RRX^4,W89K
MR/X,:-XRT'5=0O/$?@B;^WM40RW_ (ANM8MI1(ZCY(4CCR8XAT '3J<FO=**
M / K[PIXH^(GC;P3-/X B\"0^'M5_M.ZU<W]M,\R+'(OV>$0Y8K(7!8N$&%Z
M$XKWVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN?^/>3_=-%M_Q
M[1?[@_E4A 8$$9![4 !0 !@#@"@!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *JM_R$H_^N3?S%6J;L&[=@;L8S0 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D/0TM% %73?^/"#_=JU3418U"J
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MI]Q9:^\$2$3S1%IX-\2JK;6'3&5Z&OIB@84444 %%%% !1110 4444 %%%%
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MM;B6+F-5.57 X8*>0"" >E=G110 4444 %8/C3P+H'Q$T8:3XDTR'5].$R7
MMY\[?,0Y5N".0:WJ* .$\:_ KX??$;7K/6_$WA'2]:U:T 6&[NH S@ Y )_B
M ). <CFNF\0>%=)\4^'[C0M5L8KS2+B,12V; B-T&,*0,<<#BM6B@#BO$'P6
M\#>*M<TK6-6\+Z??ZEI:HEI/+%S&J'<BD=&"GD!@0#R*[6BB@ HHHH *X/QI
M\"/A]\1=?M-;\2^$=,UG5;7 BNKJ'+X!R W]X#T;(KO** .!\:? /X=?$75[
M+5/$O@[2=8O[)%C@GN;<$J@Z*>S*/0Y%=5KWAG2_$^@7.B:I91W>DW,7DS6C
M9".G]T@8X]JU** .)U_X*^!?%.JZ3J6J^%].O;W242.REDB_U2IC8N!P0N!@
M$'&.*[4    8 ["EHH **** "O/O&?[/WPX^(?B*+7O$?@[2M7UB,*!=W$/S
ML%^Z'QC>!_M9KT&B@#@?&/P#^'7Q U+3[_Q#X-TG5;NP18[:6>W&8T7[JX&
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M#X4^$?A;;7=OX4T&TT..[=7G^S*<R%1A<DDG ' &< =,5UE% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5;4-,L]6MC;WUI!>0$@F*X
MC$BY'0X(Q5FB@!D,$=M"D4,:Q1(-JHB@*H] !TI%MXD5U6)%5\[@%&&^OK4E
M% %73],L])@,-C:06<)8L8[>-8UR>IP!UJU110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>cvac-20231231x20f030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $V Y<# 2(  A$! Q$!_\0
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M7-7\9Z?J%O<7$6@?9IF=1&\ 4RQ09PQ!)P.W:@#[E219,[6#8X.#G%<_X?\
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M:I^S;81^*1<2>*+OQ+:Q^&VN8Q'>R8NU,$CJ.C^6')QVZT ?75%%% !1110
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MA2  "#7IG[5_PD^)E]\(K>TU_6[OX@-_PD-E<K'HM@()[6W1R9"NTY)QW]J
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M5^B@!JHJ* H  &!]*Y[1OAUX9\/:Y=:QINB6=GJEUGSKN*("1\G)Y]S71T4
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M1]I?_GVE_P#'?\: +%%5_M+_ //M+_X[_C1]I?\ Y]I?_'?\: +%%5_M+_\
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M ,^TO_CO^-'VE_\ GVE_\=_QH L457^TO_S[2_\ CO\ C1]I?_GVE_\ '?\
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M!!';0I#$BQQ1J%1$& H'0 5)110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!XW^UW_R0+Q'];?\ ]')7KMC_ ,>5
MO_US7^5>1?M=_P#) O$?UM__ $<E>NV/_'E;_P#7-?Y4 3T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **\!^.?[4Q^#_ ,1-'\(6_AS^U[W4K1KM)IK^*TB4!MNW=)QF
MLGXA?M?W?@W5[G3K'P5<:U/H^DPZSK_DWL:BQ@D/ 4])&ZGCCB@#Z4HK,\,>
M(;3Q9X=TW6K%BUGJ%NES"2.=K*"/YUI%@O4@?4T +13?,3^\OYT>8G]Y?SH
M=13?,3^\OYT>8G]Y?SH =13?,3^\OYT>8G]Y?SH =13?,3^\OYT>8G]Y?SH
M=13?,3^\OYT>8G]Y?SH =13?,3^\OYT>8G]Y?SH =13?,3^\OYT>8G]Y?SH
M=13?,3^\OYT>8G]Y?SH =13?,3^\OYT>8G]Y?SH =13?,3^\OYT>8G]Y?SH
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MF)_>7\Z/,3^\OYT .HIOF)_>7\Z/,3^\OYT .HIOF)_>7\Z/,3^\OYT .HI
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M\8_]BM8?^CY:]KH A^UQ^K?]\FC[7'ZM_P!\FIJ* (?M<?JW_?)H^UQ^K?\
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MAW_D[OQC_P!BM8?^CY:]KH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )ZQ_P#?'_UZ-ES_ ,]8_P#OC_Z]6** *^RY_P">L?\ WQ_]>C9<_P#/6/\
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M-WK_ 'A^=&]?[P_.@#Q;P[_R=WXQ_P"Q6L/_ $?+7M=>)^'2/^&NO&)R,?\
M"+6'_H^6O:MZ_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0
MZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0
MZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0
MZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0
MZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0
MZBD!!Z'-+0 4444 %%%% !7CO[6.O:?X:^#&I:AJ.CQ:XL5Q;^1:SRF*(3&5
M?+=W'W55L$GVKV*O*_VG$UB7X,:]'H>C_P!OW[B-1IOD1S"X0N-ZE7XP5SSV
M[4 >._L2ZIH%_P"(O%;:5HMM97MU;07M[<6EXUQ$DKL^Z!2>% () 'K7UM7A
MG[+9TVST?5=/TOX3WOPM@CD61X+P1@W+$=?E.>/>O<Z "BBB@ HHHH ****
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M61D.5/S,2,'TKT:B@#A?#'P2\'>#I[J;2M*:![F$V\N^YED#1GJN&8BH-8^
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MEX91FO5J^8OV.UGU34_%>NZMKOB3Q#K]T(89[O7-)&FQ^6@.Q4C7@GU-?3M
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M*_\ ^O6W_P#18K]$:_.[]M;_ )+E?_\ 7K;_ /HL5]%D7^]/_"_S1^<<>_\
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M,O\ ]\H_XX_FC]2Z***_)C^NPI&^Z?I2TC?=/TH _*[XX?\ )6?$_P#U^O\
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M<+S5O.M_M;:)' 3Y(QM$K'I7>?\ #47C7_GO:_\ ?@5K4XFP-.W,I:I/;O\
M,PI<&YE6YG%QT;6[W7R/LVBOC+_AJ+QK_P ][7_OP*]-^ ?QD\1?$'Q9<6&J
MRPO;I;-*!'&%.X,H'\S6F&XCP>*K1H4U*\G;;_@F6,X1S'!8>>)JN/+%7=F[
M_D?0%%%%?4GQ(4444 %%%% !1110 4444 %%%% !1110 4444 17%W!:*&GF
MCA5B%!D8*"3T'/>JNH:]IFDS6\-]J-K9RW#;84N)E1I#Z*">3]*^2OV^I=(M
MM3^'-W-+JCZM::Q#<?9[7SG@%LK@R.\:Y4D<8)YKS;]IZ+3]9^)WCO4_$.F7
M.JVNK>%;4>#9?LKR%;HOD^5@?(^2I/0T ?H9UI:Y3X4V^J6GPS\+P:T7.KQZ
M; MT9#EO,"#=GWS73RF7(\L*?7<: )*^8/V^O^2<>'_^PG_[2>OI?-UZ1?F:
M^9/V]3+_ ,*YT#S @_XF?\)/_/)Z]3+/]\I^OZ'RO%/_ ")L3Z?JCX7HHHK]
M,/Y>,BX_Y&ZR_P"O.7_T(5KU@7-Z@\8VHV2$) \)8(=NYB".:WZY,/).52W\
MWZ(]C,(2A##\RM[B_P#2I!7VE_P3[_Y!'C+_ *ZVO\I:^+:^SO\ @G_YO]D^
M,?+"?ZVU^\?:2N'./]RG\OS1[O!O_([H_P#;W_I+/KVBJ^;KTB_,T9NO2+\S
M7YP?TL6*\L_:>_Y(9XJ_Z]OZBO2\W7I%^9KR_P#:;,__  H[Q5O$>/LW8GU%
M=6$_WBGZK\SRLV_Y%^(_P2_)GYF'K10>M%?JQ_))D>(/]=I/_7VO\C6N>M96
MM:;>:A-:-;30Q) _F$2*22?PK5&<#/7O7-3356;:TT_(]3$R@\+049)M*5UV
MUOJ%?0?[$/\ R69/^O.;_P!!KY\KZ!_8DW_\+D39MS]CF^]_NUCC_P#=*OHS
MMX>_Y&V&_P :_,_0JBJ^;KTB_,T9NO2+\S7Y<?U46*S/$_\ R+6J_P#7I+_Z
M :MYNO2+\S6;XE-Q_P (YJN1%C[)+W/]PU4?B1E5_AR]&?DI>?\ 'W-_OG^=
M0U+=Y^U39Z[S_.HJ_7C^.0HHHH *] ^ '_)9O"'_ &$8OYUY_7?_  "S_P +
ME\(8QG^T8NOUK#$?P9^C_(]#+_\ ?*/^./YH_4RBJ^;GTB_,T9NO2+\S7Y,?
MUV6*1ONGZ5!FZ](OS-!-SCD18^IH _+7XX?\E9\3_P#7Z_\ .N&KN/C=N_X6
MQXGW8S]MDZ?6N'K]:H_PH>B_(_D'&_[U5_Q2_-A1116QQ!5O2?\ D)VO_71?
MYU4JUI6?[2M<=?,7^=)[%+='ZY:!_P @+3?^O:/_ -!%7ZR="-Q_8>G8$>/L
MT?4G^Z*O9NO2+\S7Y%+=G]BT_@CZ%BBJ^;KTB_,T9NO2+\S4FAX_\4/VAW^'
M7B>321HZW@10WFF8KG(STP:Y#_AL-_\ H78__ D__$UPW[3F_P#X67/O"C]T
MG3Z"O)*_(<PSS,*&+JTJ=6R4FEHN_H?O64\-95B<!1K5:-Y2BFW>6[7J?2J_
MMAN2!_PCJ?\ @2?_ (FO-/@E^TVWAB+QBHT-)OM?B"YN>9R-N[''W?:O-D^^
MOUKDOA]]WQ!_V%9OZ5G3S[,94:DW5U5K:+J_0WK<,93'$T8*CI+FOK+HM.I]
M@?\ #8;_ /0NQ_\ @2?_ (FE7]L)V8#_ (1V/DX_X^3_ /$U\U4Y/OK]17)_
MK#F?_/W\(_Y'?_JGDW_/C_R:7^9^AW@OQ&?%OAC3]7,'V8W4>_R@V[;^-;=<
M)\'#/_PK30-HCQ]G'4FNSS=>D7YFOV/"SE4P].<GJTF_N/Y\QU.-+%5:<%9*
M32]$RQ13(]^WYPH;_9I]=1Q!1110 4444 %%%% !1110!^?W[9T-EHWQ<UKQ
M9<^*M$U:.QLK.W/@6?5[JSU"5BPRT"PL-S,&]"/6ON_PS<"[\.:5.+>2T$EI
M$XMYCEX@4!VL3U(Z&J]_X*\/ZKK$&K7NAZ==ZI!CRKV>U1YH\=-KD9'YUM4
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M,O\ ]\H_XX_FC]2Z***_)C^NPI&^Z?I2TC?=/TH _*[XX?\ )6?$_P#U^O\
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M_P#WQ7ZE1Q%%4XIS6RZKL?RCC,NQLL35:H3MS2^R^[\CSNBO1/\ AGOXB?\
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M'_ODT 3T5!]MB_O'_ODT?;8O[Q_[Y- $]%1QS)-G:2<>HQ4E !1110 4444
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MKZS8.EW#<W<;1R20R#.,, <*V10!]/8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>cvac-20231231x20f031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f031.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %! ^8# 2(  A$! Q$!_\0
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M]5\*_LN6.F:)XPUGP_KT.J.FK:?>I.B(JNQ$2NJ$Q;AW&<U]D_LA>)-5\3?
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M\U=DPZ3!5)S_ +)J_P"$/'?B3X3:)\%OMAUK3O#<OA>^AN(+>UD<?;#GR@R
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MN+K41:1B$D  ?(V3R*]3\(W^LZEH-M<:_ID.CZJ^?-L[>Y^T(G/&'VKGCVH
MV:*\E^(OQ6\;^!I=6NK?X>QZEH%A&9CJ;ZU'!N0+DG84)'YUVOPX\8/X_P#
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M+OP=TOXR:!!HVJS26FGO=V\^H1VR)NOX(G#_ &61R,^4S!=P') ([FO.+O\
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MOYT?;(?^>B_G0!/UKXQ^,OAVV\.7?C'PAX!\;ZU'J/B2=Y)O!=CI\<Z_:)@
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M,?=].*]<^ 'QFC^-O@F75VT]M*U&SNY;"^LB^\13QMA@&[CN* /3**0D 9/
MIOG1_P!]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/^^OYT>='_ 'U_.@!]%,\Z
M/^^OYT>='_?7\Z 'T4SSH_[Z_G1YT?\ ?7\Z /&?VP?L,WP)UJRO99HI+V:W
MMK00J&WW+3+Y2N&XV%L!L]LUY##H7BN_^+ZZ'XRMM)\.>*]2\)7.GZ-?^&23
M:W!QB0RY 92O&%(('.#7U3XR\):)X_\ #EYH6NVT5]IETNV2)FQT.001R""
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M=QB6)I(V1BIZ95@"/QH O>4G]Q?RH\I/[B_E3Z* &>4G]Q?RH\I/[B_E3Z*
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MQ;WDE_+YG[(8A_V/THQ#_L?I7Y%_\)+JW_01NO\ O\W^-'_"2ZM_T$;K_O\
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M-?RH^R0_\\U_*IJ* ./^)^OWO@GP1JFN:3HL6M7-A$UP]H\PA!C4%G.X@\@
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M]+UW3M<@>;3KZWOH4.UI+>574'T)!HT_7=-U::>&RO[:[E@.)4@E5RGU /%
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M'V6IV]G/[E_F?H'\1O\ D0?$7_8/G_\ 0#7(?LP?\D!\#_\ 8/7^9KX>UO\
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M)/\ OFC[+#_SR3_OFO&/M1^]?[P_.JFKNO\ 95Y\P_U+]_8U8^RP_P#/)/\
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M *YI7DU?JN$_W>G_ (5^1_)>;_\ (QQ/^.?_ *4P'6L?0O\ D(Z[_P!?:_\
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M_GDG_?-'V6'_ )Y)_P!\T /WK_>'YT;U_O#\Z9]EA_YY)_WS1]EA_P">2?\
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M>HJ#[#!_<'YT?88/[@_.@"?</44;AZBH/L,']P?G1]A@_N#\Z )]P]17Y?\
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MF'_T,5MO]]OK6)XQ_P"0(/\ KYA_]#%;;_?;ZURP_CS](_\ MQZU;_D7T/\
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M_7TW\Z^HR#^-/T_4_*_$'_<J/^/]&>:T445]P?A!3UF:.#2+UY76-?)9=S'
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M110 4444 %%%% !1110 45X'\0OVK;3PS\3Y_ GA_1$\0:S9+$U^]QJ,5E%
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M .1HU'_KW/\ ,5]69K]EX8_Y%L?5_F?SUQG_ ,C>?I'\A:*3-+7U9\.%%%%
M!1110 4444 %%%% !117FGQK^.ND?!6QTH7=K-JFKZO.;;3M,MG5'G<#))9B
M%10.K&@#TNBO"?$O[4#^%O"OA&XN?!U[<>*_%$\D&G>';2[AE:38,L_G [-N
MWG-=U\&/B_I?QJ\&KKVFV\]B\<\EI=65SCS+>9#AT;'!Y[T =Y1110 4444
M%%%% !1110 5^7W[1G_)9?$__7TW\Z_4&OR^_:-&/C-XG_Z^F_G7U&0?QI^G
MZGY7X@_[E1_Q_HSS6BBBON#\("BBB@ HHHH [3X,_P#)5/"W_81@_P#0Q7ZK
MU^5'P9_Y*IX6_P"PC!_Z&*_5>OB<_P#XM/T/W+P\_P!UQ'^)?D%%%%?*GZR%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X>?\ D\L?]B9_[=U[
MA7AY_P"3RQ_V)G_MW0![A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\9?'7]BWQ-X[\>^.-0\/GPO<:=XT6U\^_UJ.3[=HTD1&Y[
M;:I#%AGJ5[5+X_\ V0/'L^N^-K+PMK>C3>&_'5GI]KK-UK#2B\MS;1K$SQA0
M5<NJD\D8)K[(HH S/#.AQ>&?#FEZ1 YDAL+6*U1VZL$4*"?RJ_+;QSXWKNQT
MJ2B@"O\ 8+?_ )YBOE#]OJWCA\.^%]B!?](E_P#017UO7R9^W_\ \B[X7_Z^
M)?\ T$5ZV5?[Y3^?Y'R/%G_(EQ'HO_2D?$]%%%?I1_,09HHHH *]^_8HB27X
MRQAUW#['-_2O :^@?V)/^2S1_P#7G-_2N#'_ .ZU/1GT'#__ "-L-_C1^@7V
M"W_YYBC[!;_\\Q5BBORX_JLK_8+?_GF*\J_:BLX8_@7XG*H!^[C_ /1BUZ[7
ME'[4O_)"_$W_ %SC_P#1BUUX/_>:?^)?F>/G/_(MQ/\ @E_Z2S\RSUHH/6BO
MU4_DPP_&3JNBJ"P4FXBQDX_C%;I8,25(8$\$'(-5;W3;34E07=NEP$SM#C.*
MFAA2WB2*)0D:#"J.@%<\825:4WLTOPO_ )GI5:]*6#I48WYHN3>UO>Y=M;_9
M[=1]=/\ #!0_Q"\.AAD?;H>/^!BN8KJ/A=_R43P[_P!?T/\ Z&*TJ?!+T9RX
M?^-#U7YGZMFP@)),8S1]@M_^>8JQ17Y&?V&5_L%O_P \Q535K&!=+O"(Q_J7
M_P#036G5/5_^03>?]<7_ )&FMT1/X6?DAXB 77]2 Z?:)/\ T(UGUH^(_P#D
M8-2_Z^9/_0C6=7Z\MC^.I_$PHHHID!2H,L*2G)]]?K0#/U-^#%G#)\*?"I9
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M-/\ QP_]*1UM%%%>>>H>]_LEP)+XHU'>N?\ 1S_,5]4?8+?_ )YBOEK]D?\
MY&C4?^O<_P Q7U;7[+PQ_P BV/J_S/YZXS_Y&\_2/Y$45M%"<H@4U+117U9\
M.%%%% !1110 4444 %%%% !7SY^U'\ M4^*VM>"O$FBV&DZ[>>&[F1Y="UUR
MEK>Q.N"I8*V&'49!%?0=% 'Q7X?_ &1?B!X$\*?#[5M)N-%U#Q9X8UJ_U/\
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M]7_[[-6** *_V*/U?_OLT?8H_5_^^S5BB@"O]BC]7_[[-'V*/U?_ +[-6**
M*_V*/U?_ +[-'V*/U?\ [[-6** *_P!BC]7_ .^S1]BC]7_[[-6** *_V*/U
M?_OLT?8H_5_^^S5BB@"O]BC]7_[[-'V*/U?_ +[-6*\N_:-UJ^T'X=&ZT^ZE
ML[C[7&OF0L5;!#9&17+BL0L+0G7DKJ*N=V!PLL=B:>&B[.;2OZGI/V*/U?\
M[[-'V*/U?_OLU\$?\+6\6_\ 0?O_ /O^W^-'_"UO%O\ T'[_ /[_ +?XU\5_
MK?0_Y]2^]'Z)_J#BO^?\?N9][_8H_5_^^S7B7V5!^V3MRV/^$,_O'_G[KYU_
MX6MXM_Z#]_\ ]_V_QKB1\1/$G_"YOMW]LWGVO^Q?*\[S3NV^;G&?3-;TN*J%
M7FM2>B;W70YJW!&)H\MZT?>:6SZGZ6_8H_5_^^S1]BC]7_[[-?!'_"UO%O\
MT'[_ /[_ +?XT?\ "UO%O_0?O_\ O^W^-8?ZWT/^?4OO1T_Z@XK_ )_Q^YGW
MO]BC]7_[[-'V*/U?_OLU\$?\+6\6_P#0?O\ _O\ M_C7U/\ LV:[J'B#P#)<
MZC=RWD_VIU\R9BQQQQDUZN6\04LRK^PA!IV;UMT/$S?A6OD^&^LU*JDKI62?
M4]0^Q1^K_P#?9H^Q1^K_ /?9JQ17U1\05_L4?J__ 'V:/L4?J_\ WV:L44 5
M_L4?J_\ WV:/L4?J_P#WV:L44 5_L4?J_P#WV:=':I&VX;L^[$U-10 4444
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M*IZO_P @F\_ZXO\ R-7*IZO_ ,@F\_ZXO_(TUNB)_"S\D?$?_(P:E_U\R?\
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M*#UHK@/3/?OV1_\ D:-1_P"O<_S%?5M?*7[(_P#R-&H_]>Y_F*^K:_9>&/\
MD6Q]7^9_/7&?_(WGZ1_(****^K/APHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *_+[]HS_DLOB?_ *^F_G7Z@U^7W[1G_)9?$_\
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M]_(/^1KAO\:_,^.****_!S^G@KDQ_P E6/\ V"/_ &I765R8_P"2K'_L$?\
MM2N_"?\ +S_"_P!#R\?_ ,N?\<?U.LHHHK@/4"OL3]E/_DFTG_7V_P#(5\=U
M]?\ [+%N)?AO(=[K_I;]#]*^OX6_Y&/_ &Z_T/@>-O\ D5?]O1_4]LHJM]B'
M_/23_OJC[$/^>DG_ 'U7["?@!9HJM]B'_/23_OJC[$/^>DG_ 'U0!9HJM]B'
M_/23_OJC[$/^>DG_ 'U0!9HJM]B'_/23_OJGQVPC;<'<^Q:@":BBB@ HHHH
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M_P"1@U+_ *^9/_0C6=7Z\MC^.I?$PHHHID!3D^^OUIM.3[Z_6@'L?JG\%?\
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M+7Q,<3A:_*ME^AZN!RNIEF;8'VDKN;3TZ:VMY^I^@?V5_P#GYE_3_"C[*_\
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MU?\ O =JRJ*^V<(MW:/PY5JD8\JD[>O?<D-Q,P(,TA![%S786GQG\<6'AM-
MMO$M[!I*1>2MNC ;8^FT-C('MFN+HJ94X3^))E4L16H-NE-QOH[-K0Z_P_\
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MSGDMKF*ZD:.:)MK*=QY!J&+Q+JT$.H0QZC<I%J'-VBRD"?\ WQ_%U[TGB/\
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M[!5<QRZKA:-N:5K7VW3/RVHK]!/^&'/AYZZE_P"!'_UJ/^&'/AYZZE_X$?\
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MK/)G_P"?C_QP5\7C*L:^(G4ALV?MV382I@,OHX:K\48I.Q8HJOY,_P#S\?\
MC@H\F?\ Y^/_ !P5QGLGS3^U]_R$-&_ZYM_,5\Y5]X>/?A!I'Q'EMY-8EG9H
M%*IY+;.#7)?\,H^#O[]]_P!_O_K5^:9KP_C<9C*E>E;E?=^2\C]BR/BK+\OR
M^EAJW-S1O>RTW;[GQY17V'_PRCX._OWW_?[_ .M1_P ,H^#O[]]_W^_^M7E?
MZJYA_=^__@'N_P"N^5?WO_ ?^"?'E%?8?_#*/@[^_??]_O\ ZU'_  RCX._O
MWW_?[_ZU'^JN8?W?O_X ?Z[Y5_>_\!_X)YU^R/\ \C1J/_7N?YBOJVO/_ GP
M7T7X=7LMUI$MPLLJ;&\Y]PQ7<>3/_P _'_C@K]#R7!5<!@U0K6YDWMYGY-Q%
MF%'-,?+$X>_*TEKILBQ1444<BGYY=_X 5+7NGS(4444 %%%% !1110 4444
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M#QU'$5?AC)-V\C\^:*^Q_P#AE?P=ZWO_ ']'^%'_  ROX.];W_OZ/\*_+O\
M5;,?[OW_ / /VK_7;*O[W_@/_!/CBBOL?_AE?P=ZWO\ W]'^%'_#*_@[UO?^
M_H_PH_U6S'^[]_\ P _UWRK^]_X#_P $^.**^Q_^&5_!WK>_]_1_A1_PROX.
M];W_ +^C_"C_ %6S'^[]_P#P _UWRK^]_P" _P#!/CBOL3]E/_DFTG_7V_\
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M,_"1]9'BASN'%V$P(\>F[FOM4   #@"@!:*** "BBB@ HHHH **** "BBB@
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M "MOY8\K;D@@D_C7UW)96\L\<SP1/-']R1D!9?H>U-2PM8YI)EMH5FD^_($
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M>IXH ^7=.\:>-] \*Z!K%OK.H:YJ>N>%[G4);:[0,B7"",J44+\N-S<=ZU?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>cvac-20231231x20f032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f032.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #I > # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MF-(%('K3Z $!!I:B+!2<#+>E<M\0/BEX:^%VAMJGB?58-+M1P/-;YF/H!WH#
M<ZPNJ]2*-XQG.!ZFOE#Q+^U[K_B!4'P\\'SZA9R\+J5_^[3Z@'J*X_Q=J7Q:
M\>V,4=_XKCT.,C]Y#IZ;3@]LUC.K&&YTT\/4J;(^R-0\9:%I(8WFL65L%Z^;
M.JX_6L:7XQ^"81EO$VG8]IU-? \7[.>DQW#SZIK>KZU(YW2"YN6*D_2MRS^&
MGAS3<+%I*,@[.2U<DL;!=#T(Y94ENS[67XV^!F8 >)M/R?\ IL*O6?Q3\(:A
M,L4'B/39)6Z(+A<G]:^(Y/!'A]T8'1K9<]P#7-ZQ\&/#.IQLSV]Q97'\$]K*
M59:E8^'5%O*JO1GZ2PW,5S$)(I%EC/(9#D&GAU;H<U^=/@34?B#\&HY&\.^*
MI]8LE'R:?JC%\^V3TKU_PI^W3;Z?9#_A._#-WHMU'Q)-;*9(L?WLUU4\13J;
M,X*N#K4?B1]<;@.]!8#O7)?#_P"*'ACXI:+'J?AO5;?4[9QD^6XW*?0CM72^
M:LC%5&2.HKH33.)IHL9I:K"8*2,<^E31ON'/%58FX^BBF[P/6D4.HI"V!FFE
M_:@5QV:6HP<\T>81VHLPN24FX>M1>?[4H ?M0%R0'-+3=NT8%**!BT444 %%
M%% !1110 44E+0 @.:"0.]!P 34)Q(I(.!2=P)1(I.,BE)Q7.>)?&FC^#+$W
M.K74=JG;<>3^%<3-^TCX2AR?.DE3U5:QE6IP^.2+4)/9'K.X>M(7 [UY"/VE
M_"VPLJ3[1_L5O^%?C+X;\8W"VL%R(;ESA8Y.":E8FC)V4@Y)+='=S7<-NN99
M4C'J[8JO'KFGRR>6E[ S_P!T2#-?)G[0'B_5;_X@3Z>EY+;VMIQ''$V 3[^M
M>?->:I:O'<27%Q;R+R&#GFO+KYK"A4<+7.J&&E./,?H!YB\?,.:&D5.I KQ+
MX"?%.?QE:R:7J"YOK=?W<O\ >6H/BU\>7\%:VNB:="EQ<A-TDK<A?:N_ZY35
M+VLM$<_LI.?(CW4,",]J1I%7J0*^.+CXY^,[NX2<7&R",Y"HO#?6O4/ _P"T
M39WFB74WB#;%<VXRB+UD]JPHYEAZTN5,VGA:D%=H]W\Q3W%*#FO&=!_:5\/:
MOJ$%I+%);&8[1(P^45Z]#=1W4,<D+AXFY!'0UW4ZT*OPLYY0E'XD6:0G% 8-
MT.:&7<*W( '-+2 8%+0 4444 %%%% !1110 4A.*6D/:@!" 3R.:C:4APO0G
MI0TI27GA?6O'/VC/V@[3X):#$;.U_MOQ/?L(;'2X6!<L?XB.H I-J.K$DY.R
M,GX[_M-6?@#41X2\-V[:UXXNT(AMT&4MR>CR'L*\;\.?!.\\2D:O\2-0?Q3K
MDK^:T$S9MX#U 5>G%+\+_AI>0:O>^+/$L_V[Q=JS^?-*_/V93R(E^E>Y:7IH
MFC49Y'YUY\ZDI.R/6IT%35Y&)9>'#:626T02.W082)!A5'L*I7VG&V&"F:]#
M&A.(P>:S[_0]X.X9-82@SJC5L[(\JO\ 3<ACC\*YV>(QO@UZ+K6GF NN*XC4
M(@)#QS7#--'ITIWW,>X 1"<<U4$A)YY%7[A25^Z<5G.-GKS7*^9GH*5B.Z"L
M2V,5E7<?VV-HI8XYHGX9)%R"*T) ['@<56E#)U0X]:S2ML:NSW.)F\&:CX0O
M5U/X?ZK)X9UM7$GDQL?L\WLR].:]JT+]N;5?"5O:V_C_ ,)RQ7"@+<:AIOSQ
MX_O5P,X(PZC?)G /I7F'Q8\9W,>?"6FP"]UF_7&<96!3W:O0PN)FM#R\9@J4
MX<R6I^C/@_XV>!_'6EP:EI/B*TFAE .TOAD)['WKO4FCN(4DC</&W*NIR#7X
M^>!/@/J'AR!T;Q?J$#R_,Z6KX17]J]G^&OQ$^+OP:F=;7Q&/%VACD6>J\R#V
M4BO66,IMVN> \MKI72/T=\\(0O4U,#N%?'/A7_@H+IL.KV^G^./"E_H#R' O
M85+PCZXYKZ#T7X^> /$-HEQ:>*;$(XR!)*$;\0:ZU-2V/.E3E3=I*QZ$6 '-
M)D$9KDHOB;X1E; \4:8<]/\ 24_QK2M_%NA7@_T?6[&7_<N%/]:ILS29N*P/
M2G5D)JMIG*ZA;'_MJ*M+JEHV +N$GVD%)7'H62$4\\4X$$<8J#=%<C*R+(/]
ME@:5!L.<$#WH5^H6)><YIR]*C\T]1R*1Y&W849'K5(5T/>3;QWI4;<N:AR3U
MJ6(@IQ0 ^BBB@84444 ,#9;&*?28&<T'I0Q##("&QVKG_&?B9?"GA>\U)AGR
MD.T>I[5O1 Y?(ZUY#^TSJ\NE^ 4CA7<)YU1_85S5Y\E.4O(T@KR2/FWQ%K^I
M>/=8>\OIGN7))2$GY /I2V/A&XD/S*JY_A["F^$D1]6W#ICI7H2%<#"\^M?F
MN)Q#;/I:=./8Y%/ <[<-<!5/85E:EHMWX6N(KBUE$9W#$@/(YKT5D).X,<>E
M<]XRC^T:2_RG,?.:PIUIJ2-I4XM/0Y:YUBY\6^(IKJ\(:9"JEO7'>N]O=*BO
M-(VR*"0O#8Z5YCX21I[Z><$MYDFW:.V*]<G_ .088RI!(IXR;E43ON94=(F%
M\)?%EE\//&$MYJ4ACL5B*#;U)K!U/4],\2>.]0FB:2>">0R(\O4>P]JP_$L2
MDN&. LH!SW%;WAGPRMPZ7BR *O '<UZE7$-854F<\(+VSD==]AMH;(*L2XQZ
M5Y;XIQ9ZG"-H3,N!Z&O6U4>4$/:N'\4^$IM9OH652H1]^:\FA/EO<[*GO&.V
MD.MFLX; SD ?SKZ3^"_Q-L+7P&K:W>"W$,AB624]17ANOVHL-)MD4Y)^6N57
M5KEH)K"0;K*-CMC_ -H]37M9?BWAVY2.+$4U*T3[G\-^-M#\0R/%I-\EZ1RQ
M0YQ711,S#YA7Q1\%?$\OA/QII]G$^([N38X[8K[5$C!U4+\I&<U]EA,4L5'F
M1XM6G[.5B:F.Q'2G4C#-=YB /'-(,EO:E S0" <4 .HHHH **** "FN,BG4R
M4D+QUH Y_P ;^*[7P9X4U;7+S @T^!ICGN0.!^=?"OP^L[CQWXBO?B1KZ2R:
M]JLC&U6<Y6U@S\JJIZ&O2/VX?'FJ:IJ?ASX8:'E'U607.I7"'_5P*>A^M9.C
M1_8[>"%2 D2A !QT&*\[&5>6T4>SE^'YKU&=]H-UYKQQORP/6O4?#]G")$=N
MN*\MT.6%-C<;J[[3M2 P0>!7/"1TXB+9Z6EK$\.0 0!VKC/%>L6&B0237=U#
M9PJ"3),P5:E'B,VUG(3)M4*6)/8 5\,^/O%NM_M#>-+R75!)8>$='G:WM+6)
MRIN6!Y=O45T3JQA&[."C1J5*G*CU3Q1^TM\/H9IXCK1N'1BK&%"PS]:\_OOV
MB_ LTF8KZX/_ &R-4['P?H=IA5TNVP..8QS6;XP.F^%]!N-0@T*VN98L!8Q"
M,<GK7D_6(U':Q]"L+*DKW+\WQ^\)!-QO)RIZ 1&JA^.WA&52?M5P!_UR->4K
MXYDTZ:^OI-'MKJ/*"*&.#Y3GKCBI]-^++2:/JMZWA&W6:U8;8C!U7U'%7R)D
M>UBG9R_!GHK?';PF7P+N?;V_='-1?\+S\*ON'VJX/TB/%>?Z1XTMY9'N9='@
MCAN6WH\L&%08Z#BFQ>-EUG7]/MK'188K872I+*+?AE)Z=*APCO8I5VW9-?<=
M/XM^.^@:=X9O9-+-Q=:@5VPKY1X8]ZXWX=>,=$T6Q:ZU*XN+[7+MB]S.T1+9
M/\(]A7M;:!I4%W*3IMOL8\?NA6SX1\/:3/XITX#2[7891G,0J%.G;E[F\J59
M?O.QYO!\3]!C./L]\I]3;FKL?Q5T#(9EO6"]O(:OO1/!^A01H&T#3W! P3 O
M/Z5RWQ6N= ^'7@F?6X_"]C+/&X01BV#9S[8KNC@Z4EN>2\UKJRL?'5U\3/"]
M]9LSVEU*G?=;$_TKE-6UWP'J,8WZ1<H3_%';LI->CZO\==>T/Q>U^O@VUET2
M=-_V3[%]TX[<5VFD_'&]US3+B\MOA]IZ)"FX>9:\L?IBMXX**^&3,GF,WO!'
MS7/'X";!%AJ:$=U5ZI7B^&U)-G=^(;,CIY)<8KZ3/Q\GU72H%B\!6=KK,VZ,
MQ?9/E&/XNE8OP^_:!O\ 0VO+G7_!<&KQ3YBB2*RQY4H/ Z5:PR7VV0\<WO31
M\]I?I"=D7B+Q2#V.YZEM?%$RSF+_ (2_7;68?=%Q*R@_B:^U/V=OBQ%\8-=U
MFTU;X?6VBK9L5_>V@7G\17K/B;X2>"/'.FW=CJGAZR198S&LL,05QGN"*ET]
M;*;''$Q>KIH_/>S\8>.-"(ETWQQJB1D9YG+ UTGA;]KWXQ_#_4HWN;RW\4:1
MN!D@G&)=OL?6N9^+'PV;]FWQU_PC6IW[S^&[Q#<:?J-Q_#D_ZLGVKA9O&>@R
MSGR]5A)'09KF=6M2E;='J1HX/%4^9KE9^D?P7_;.\"_%Z0:8US_8.MJH,EG?
M'8"?]DGK7O=I-@  AT(W*P.017XE:I_9&MOYR7T<=VO*W$$FUU/;D5]&?L]?
MMSZ[\+UT[PYXS']O: 7$,>K!LRP+T&_V%=]'$J:]X\C%Y=*CK2?,C],'(9>.
MM+""%YK \)^+M'\6Z)%JFBZC!JMC+@K+;ON ]CZ5OQ2K*FY3D5W+4\2UMR2B
MBB@8444QGVD"@!]1ABKG/ IX.1FJMS+O4A3C'4FIW&C%\9>-K'P7HMQJ-\^$
MC'R)W8^@KP&^_:#L/',-QIFMZ(8]/DR$E4Y9?0UJ_M1ZQ9:MH.GVUC?PSRP3
MGSHT?D"O(]"\-Q:E8AED^8<&OE\RS"5"?)#;J>EAJ*DKLR-2F70-8=M.S/;,
MV4D!YQ[BNQ\-ZP=4A<N0&099B< "L[_A Y')Q)M6N1^+4,V@^#X-*MKA[6;5
MIUM3/&<,%)YQ^%?+SG'$248JQZZ4H+4Z?4OC?X)T2^DLKS5PTZ=1"N\#\163
MJGQW\ W]E+ NJ2*7&,F(UK^&?AAX<\-:-;:=#I$%UY"#=<7"!WD;N236L/">
M@R+\V@60/_7$5E*6&A+E5VR[3:OW/+/#/Q8\"Z!=N\FJ.R%L\1FNUN/VB/ $
ML ":E+S_ -,C6X/"&@*1G0+$_P#;$5Y_X[UK3O!VO+;P>#[6^L5C#R,D ))]
M!Q6T8TJ\E[KOZHR:E!:'->(OC'X1NOM!2]F93(&7$1YKI_!GQY\%6FF!)]0E
MC<'H8C7%>$OC+I'B"_OK>Z\#PV4,.?*EEML \_=Z=:;XN^*UCX;T:]U#_A#+
M64PW'DQ0I;9,@QUZ5Z+H*4>1Q?WHRNT[GJK?M > E_>'4Y=N>OE&D?\ :-\!
MD_\ (3D ]XC5'X3VNE^*O!L6LW^@VB7%RVX0- !L'8=*[/\ X1/P]+'@Z!8_
MA"M>3.-&G+E<7]Z.A*4EH>2^)OCUX6O+AO)OI7B0%E/E'K6K\*-3TWQ]'--;
M7*W(5BSIT<?A7>GP+X>#%QHUH/4>4,5Y3\8[&+X2ZUX=\8>'XDL#/=I9W=K$
M,)*K''2NBG.A57L8W4F9S4HOGEL>B^(M*&EWUIJ%F/+\D@[QU!%?6_PT\91>
M,?"=G=+(K7"H$E7/.17SU=6$>MZ6R[?+26(-^)&:Y"WU36? ][#_ &7/+$L3
M9^4G#_45U97CUA9<D]C#%4/:QYHGVZ&=3P<^M2*_F=*\G^%'QF7QUFSOD2TU
M&,<J#PXKUB%T<?+7WM*M&LN:#T/"E!P>H[;[T;>:=2=ZV(%HHHI@%%%% !4%
MRXAB>5B J L2>V*GKQO]K7Q_<?#KX&>(M1LCB_EB-O!SSO;CBDW8:5W8^6=%
MU6]\:_$SQKXMU&82B6[-G9@<A8E)! _*NK4D2\'Y?2N$^&6ES:/X%TF*9F-S
M)&)Y]W7>W)S^==G%,7;/>OF:M7VE1L^VP]+V=)1.BTW4#"1D\5U>G^( @&6_
M6O/DF(Q5J&\*MUJHS%.ES'2?$GQ'+#\//$D\,IC=+-RK*>1P:^=?A/<O/X#T
MR:0[WD0L6/4DGK7IOQ%U0O\ #GQ*F[K:./T->9?"8?\ %O-#(_YXT8B5Z8L+
M3Y*ITH1V8L20*3:')5T$BGJ&&0:MEQC&!5<9W5Y^VQZ[6HPV4 <%;:$8Z#8,
M"E:&$$#[-"0.P05:;[F>]5A(%E&:?-+N9A]DM&*@V<+XZ+L&*=<V*Q*%6UBM
MUZ@+& :Y+XK:_>^'O#;7&G*T<LDBQ&<#_5*3RU>8^)O%FM>&5T9-*\3C7W9S
M)(YY!'=2:Z(0E-;G-4K*E*S1[Y;&,L/,;)%;7@^1#XPTU5X/FC Q7S7+^T1J
M-Y+/%'ID<21@HV3AV;'WE'I5_P"#_P ==8AUK1%EM1>7:R%WW_?<9XQ36'E=
M,YYXF'(S]3$):)8]N6 'X5#+:K.A29$F0\[9%##\C7Q9K_[9?B:9KA+-;>&6
MUODBEA5<OL[K]:O^%?VW/$WB]KRTLO#B&\+^5;JW!0@X^?T)KZ'E;L?)-VLC
MZ]CTBSG(S8VSJ#PK0K_A5A-.M8G*K8V\>.#B)0#^&*^*_%W[8WBZ"TU73FT]
M+*XAD:S"Q_ZY) N?,Q_=KZN^&.HWVK_"WPUJ%Y,;B]NK5))I#U+'K3Y6M6P3
M3T-J73+.*;>+*W5P<AA$O'Z5,-+L7QG3[7D[O]2O7UZ5,_[Q!GJ*57V@"I<N
MP<@T6L5I&TB0PQ%C\QC0*3]<4(\17.W'UJ5HRR#O45]&(XQM'S4XMW&N9:'R
MG_P4,\.66K^%/!<EY:I<A[]D^8<@8Z5\?W?PP\.H-O\ 9,0],9K[;_;L?S_!
MG@@+@D:BV?\ OFOEW45 RN#G%>=C*CC*-CZ/*H*=.7-&YY/>_#C08I"8[5HV
M/7:QKGK[P#;6S,EE=W$*/RR,<J:]3U",9Q@UA7D)&3U%<2KU+W/;^KTW[THV
M*7P7^,WQ!_9FUJ6Y\/:B-1T:=PUQIER2RL.^WT-?K#^SU\<M#^//@"W\0Z-F
M*0?)=VK?>AD[BOR(U%M@9V7*KUK[T_X)>Z6T'PP\27X0K#=ZAF+TP!SBO5PE
M:=1VD?,YIA:5"$9P6K/M<'(I:0<"@'->F?. 2!4,J&1UP:?,,XH?(( Z4G<#
MGO&OBVS\%Z.U[>2;4' 4'YF/H*\@U;]I33M9TV^L[6SN+"8Q$+-,1@FI/VI[
M74);'39[>-Y+.//F%>@/8U\_6FBW-S8%PZ2B3@C/-?,X_&3HRY.AZ5"A&<>;
MJ93N;V2X<S,1*QPY))S5_P ">(9K?5?L4[$%&"G/1O>M'0_",J&6*X!:$*2K
M8Z5SURR6/B6T<84#*GWQ7S<ZBK.QZ-.'L]3VN96D?$;<8KR3]H&+9:>$<]?[
M17G\17J6AS&\M5GSVQ7FW[1/_'AX3;N-17^8K@P_N5K'34E>)Z7N"X4#G8/Y
M4K1F% SY /?%96K7]SI^EWEW;IYD\-MOC0C[Q KQ:V\8ZW_8LFH6GB-=8U*X
MEYTPK_J#_=/I44\-*OS27<T=1044SWII(\?>XJ&7!7:$1@><LH->%Z[^T1J6
MCQ0V;Z$JWJ K<NYPK-CHGJ:PO!'[1>K7FVUN;+SK@R.0K##$=@*Z/J%?>*(=
M:#/HU+"SP"]E;D?]<P,FF3V-G,P$EI!)W :,$5\[M^U#KTEG]H32H5,-V8IH
MB,D(/ZUL^&?CUKGBRQ6:RTF-[@R,&Y^4(.?SHE@L3NW^)*JT^Q[O:QB)=BHL
M:=E1<"IFRAZ8S7SROQYUW6/$6D:6+1(?-NU1I8>0%ST;T-?1%P/WFT]17)6P
M\J"]_=FL)J6D2(L-IKPW]KE6_P"$&\. -R=6@/\ X]7N+< @>E>(?M=?\B+X
M<)Z_VM!_Z%6^!5L137G^@5E:#3/>K0E+'3P#_P N\>??Y1236<,I+. 2>V*2
MW)&G6!_Z=X__ $$5!J<C16KR#^Z:YGK(:^$XJ2[F\,^,;2ZM)3&_G*,KZ9Z5
M]M:1(;C3+290?WL:LWXBOFSX!>!+3Q=JMSJNIJ)TMV^2-N>?6NM^*'QKN_ ?
MC"UT>UB462@>8V.0/2OO<N_V6C[2H]&?/8A^TGRKH>[K@# .:6LGPWK=IXCT
MN&^LIEFAD4'*GH>XK4#9.*^CBU))HX&K:#J***H04444 %?-/[<QCN? >AV4
MP)BN-3B!'XU]+5\T_MRA(O F@W4C;4AU.(DGZUG4^%FM+XT>10QB*/9T5 %
M]A34EVOC-0P77F[F[,,CWII)#9KY38^[:VMY&I'/T[U)'+EJSDFY%2B1@PQS
M3'U,OQ_)_P 4)XD_Z]7_ )5R'PD7=\.=#_ZX5T_Q"G"^ /$7/S&U;C\#7,_"
M G_A6VAMTS!53?[LBFG[5>ATYCSG%(L1;V/I3D/R,3Z]17.:YXKN+/7190Q)
M&$CSNE'+_2N1<ST1U.2B[LZ'<W*GM4;VI<;P>!7"Q?$#59M5@AATX-:L#ND9
M3GBI;CXA:A9WEE%-IY9)'(E9 2$7MFM52?<R>(AV.VGCMKRS:WN8A/;OPT;#
M(-<J=&T2PUB'3++185C&9&8*"$!K0C\0.-"N[^YB%K-"Q7RCW]*;X0TFXL8G
MN[R3S;N]_>-G^!>PK172O<BH^:<>4F;PAH4UXERNFP;T& X09%:WAOPQHFDZ
M[9:G#I$4\]FWF1HJ $CN*?!;L';GCTK9\%DR>+]/@<XBDDV,/8]:(U&Y(J5.
M,82T/HCPOX%\$ZUIT.N0^&K**6^832AH@6$@]36[;>!?">CW%U=6F@V=M/<N
M&DD2(#+#O7DMEXYU3X:W/B;PZ\2R"UE%Q8RSC*>6WK["IF_:"U9?"]S<RZ1"
M]Y'((TN%0^001UKZ6]TCXB=F]#T]OAYX5U#4[C4[G0K&2^F789FB&7'O5'PO
MXZT^;6KOPM]C_LF]L!B"W/"21]BM>;P_M":M]HAC?1HYXC;"8&!"3(Q."%KI
MY=$3XU>$(=9"2:#KUK,?LEQ%\K@CHK>H-2PB>IB,0QY;[Y[4V-PLGS"O(++X
MWZA9Z%)IVL6":=XLM9?L[Q7'W98Q_P ME]144GQ:\9V=X]N=(M+FV2W-P+R,
M$HP[#ZTN6Y7-8]MDE#+A>#VJNL@9RLHRRUX%:_M"^)KFV1+O2K:PU.1"\,#H
M?G7^]6AI?Q^U$:Q<Z=?Z+LNX[,RHZ(?+DEZA<_2K2%<QOVS?#VI^([/P-9:+
M9"_O)]0<1VQ. ?EZUXK>_LT_%Z^.(-!LH/0M)7TOXFU^X\3:W\']2:$6SW-[
M*[Q#C:=O2OH9TW'()_.H="-369<,75H>[!GYHR?L?_&R[.%M-+C [M)56;]A
M+XSZBX1[G3+9#U97S7Z7W%U#8KON+B.&,_Q2OM'ZUA^$?B)X=\?2ZC'H6I1W
M[Z=,;>Y$9_U;CL::PU+L4\PQ+5G,_/2R_P""9GQ"U&[A_M7QE:V]F6'G1PKD
ME>X%??WPA^&&D?"+P-I_AK1HO+M;5 &?O(_=C77E!G&>3ZT^*/8O7-;1IP@_
M=1RU*U2MK.5R2FJ,"G4A8+U.*U, (R*86"J<\ =Z?D$9K/UF[6STJ[N9&VK%
M&S?I4R=DV"U/%_B_\<+'1KJX\.Q6 OY2N'9^5&:^:$U.ZM-6:Z ")(_R01]
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M0QX#X]*[\'E;KIS;V.:KB/9Z'ET7CJVDP6V@YQQ7#?M 7*W6E^$77^+4%/\
M*MCP+HT$\EU'>1;9896#(W8YK,_:$BBCL/"2PCIJ"\?E7/"/+B.4T;YX'I"+
ME5'^P/Y4J_(,"EC& N[KL'\J%ZY/2O,GJWZG?#X4(5XS7#_%'*:18E3M_P!*
M09_&N\F(9,"O,_B[XDTO1]'LX=1OXK>X-RCK$YP2N>M;8:+=561G4LDV2?\
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MY&A*^2<=*9'("*J+XAT&7_F-Z>#_ -?*?XTIUW0\8_MK3Q_V\I_C31#=RZ6
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M8HQFEHH **** $Q2T44 %%%% !1110 A&:,4M% !1110 F*, '-+10 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>cvac-20231231x20f033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f033.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #( Q(# 2(  A$! Q$!_\0
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M%L&H+65Y8XV<;2RAL'M[5\=?M#_&CQ1X$^*][;VUW,MA]G*P10*6*MW8CT%
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MP*]P\/JHT/3O:W3D_P"Z*\<_:_VK\+[0'G_B9VW7_?%>QZ0=NAV _P"F"?\
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M;Z=9Z#'8HB2AY;FY7,D6/[I[5\_>-OV/O&_B&]8VMS:*D+[V9R3]K)'(?Z4
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MT;2[QDQ]O<8.015&70=4B4F+5'R22=W/7I0,\GM/BK\4;:#8/AIY2J/ECC?
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MBKX.5>?$^F,?7[2O^-#?%?P;_P!#/I@_[>5_QI@=60^[J,4ZN07XJ^#@<_\
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MMM(0/,/\3>U '5:;^QSX?U:W\^U\>:W=P'Y0T5X3S^=3G]AG27.?^$S\0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>cvac-20231231x20f034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'W Q<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,CJ* +9;! IU,W=SU]*1)!("002.,9H$244BY(YZTM PHHHH **** "BBB@
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M4SCFG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4%MIGB%&CN5^470^ZP]37;2K=)''5I:WB>ZE<L#3JR]-\1:?K"*UE>17 89
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M110 44UC@5%D^M(">BD7[HI:8!1110 4444 %%%% !1110 F<4M%% !1110
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MW\4HXZUF:6FIJY^VO&Z]M@Q6DW6M$[D-6 'FG4@%+0)!1110,**** "BBB@
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MN;:ZBB">:0>3Q7T%\0%U*?P=J*Z0^R^:(JC#J/4CWQ7SI^SD8=3^,'B+4,0
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M@ HHHH **** "BBB@ HHHH **** "BD. <TP@AR3R.P% $E%,$BDXSR*=N%
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M@[OXW^#;7[.HUA)I+@,8TA1G8[>N0!Q^->?Q_M:>&]4^SG2ED;=>_8Y/M*E
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M.[]E#56M_P!I>Q=V6;1IX7'4%LTO;0[A[.78]NS1G->,W'[2%C"FY=*F<D9
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M"/RUW$;!@]3CK3O+7&-H ^E.HH I7VEVFHB-+FVCN%5@X$B@@$=#5L(%7"C
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M+TI::I '6E+ 4#%HINX>M&X4 .HIN\9ZTN10 M%)N%(7 [T .HI P/>D+@4
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MR5]*Y;QU_P PO;P?M KJXVR/0T /HHHH&%%%% !1110 4444 %%%% !1110
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M'TOQDFDV:W>I6C78B42D*<%L<U;\?H/L>G_]?:?SKJXQ\BY]* .4&G^*L?\
M(1M/^^30NG^*AUU&T/\ P$UUA ]* /:@9R9L/%)_YB-H#_NFO'_V@] ^)^H3
M^%U\-ZK9PLMZIE8@Y([U]%E1@\5Q/CQ]EYH6#_R\TAHGMK#Q:MI LVHV9G"
M2$*<$U*+#Q3_ -!&T_[Y-=2/F)!'%.VCT%,1R36'BK/&HV@_X":46/BGOJ-I
M_P!\FNLVCTI-BYZ"@-3YX_:.T+XDWNA:/_86K6<2I>H;C((RN:]3T[3?%PTV
MS$FI6GF")0Y"GDXK0\8>"HO&$,4,]Q+#'&X?$;8R16]:1?9X8X,EEC4*"W4X
MI SG?L7B8#_D(VF?]TTT6/B@_P#,1M/^^375%0>HHV =J .5:P\4X.-1M/\
MODUXU^T)H/Q2O;CPLV@ZQ9PVL=_&;A<'YN>,U]'GY>@KC_B4P%CI/'6_B'ZT
M#0L&F>+3!&)-2M#)M&["GKWJ9=/\4KUU"U/_  $UU(&.:4'(IB.7%CXG[W]I
M_P!\FD>P\4,,#4+0?\!-=3@'M28 (XH ^=_CWH?Q0N7\,KX=U.S5%O5,Y((.
MW/->_:7',MC;_:B&NEC42,O0MCG%<]X[C,BZ:%X_T@9KJHR-H&>0* 'T444
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MMC)KHK.V^RVZ1;B^T ;FZFILX'- YI7L M%%%, HHHH **** "BBB@ HHHH
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M.5 5650P!KFC5C.I*">J-YT90IQJ-:2V+E%(HP!2UTF 4444 %%%% !1110
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M8\FT@#O7G]W\65MSK_\ Q*;MFTC!("_Z_/\ =KT%P".>E0E+<9!6,%NH('-
MRCX;UAM?TBUU'RGMUN$#B*089<]C6J2!49=((\G;&@[] *P[KQ#-<NT.F6_V
MI\X\T\*O^-*X)&Q>W\&GPF6>18D'<]36&U[?Z\^+13:V9ZS/]YOI4EIX<>69
M;C5)#=W&<JO\"?05OA %  P!V%#5T5I%G!>)]'LK+[ CV37SK*&:5EW$>]=M
M;@2PHRC:N!@>E3F-3U /UI0,#%9J"3;13FVDNP"EHHK4S"BBB@ HHHH *0D"
MEI",T !Z4R.82%@.HJ&_N5MH2S' QQ6=H%R;B6?)S@T=!7U-NBBDH&+1110
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M\2-).HWC(5>2/RJG)XGGN6*6-C+*1_$W (I.44"BV;Q 9NIS3+BX2WB8NZJ
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MI'.:=10 W!I>:6B@04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/$-QXWT>RU"$I8W\8>-(UR0&&06]*]O5<KAL4"'*23GM13J* "BBB@ HHHH
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MV 7YK_3P%D _VA7N?F .J]Z 9Q_Q1@2V^'>KQQHL:"$X"# K7\$#/@_1L_\
M/K'_ "%9?Q9'_%O]8Y_Y9&M3P0?^*1T;_KUC_P#0: -VBBB@ HHHH ****0#
M2@)S3J**8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 50UJZN;2PEDLX/M-P =L?J:O9YQ00#0!X-\&_'GQ1U[Q;KUOXK\.)9:7%
M<;;653_#7H_Q \:/X.@CF^S-.DB-M"KGYP.!78JH6F3VL-T )HDD .0'&<4
M?/4WQ3\=WNGV]Y_9D5C&TRY78<^7W!K9_P"%I^*;>]T\OI4"V]PK.S!3P!T
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MK&]6_@$J*R@]F&#5FJ)"BD[FEH%<****!A1110 4444 %%%% !1110 4444
M%%%% !1110 A&32T44 %%%% !28I:* $(YS12T4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU-C4J@!ZTK9QQ6I M%- ;//2G4( HHHI@%%%% !1110 4444 %%%% !1110
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M#%W]*F'2F).XM%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &21+)]X4")0,8HHIW%9#@,#
MBEHHI#&A &W=Z4@&BB@ "A>E!&1BBB@ "A1@48&,=J** #:,8IJQ*O0444 .
M P*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>cvac-20231231x20f035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f035.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (F DL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2T %%%% !1249!H 6BDI: "BBDR,XSS0 M%%% !1110 4444 %%%% !1110
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M]CGPM$]S/>W=S?W=P$\R:5LD[3Q70:O^S/X7U6R:V8.JM/'<$X&<ITKV"DH
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M$VBP22>=(BLK2'^(Y/->E4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/B3PIKT2RFU>*W;(G^7(QVK'UKX':AXA\:3:Q/?I:6[*1Y=N<>82/XJRM3^
MBKX9U^?Q!="ZS;L(4@)4!0.,T =W\ Y5F^%^E2(P=6W$,.XW&O1:\W_9\LX[
M#X5:/;0C$<895![#)KT<4#%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^+PKX8T[28)VN8+2$1I*YR6'8YH VZ*** /.O&X_XN3X0_WW_E7HM><^-O\
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M81WVI6ZYB1ER3]*;\/-=O_$GA>TO]4LVL;V3(D@;JIH,UH['44444&@4444
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M;I"V6).2RYSBO9Z0\B@#R?Q'X=L-)^(_@IH8%6:/='Y@') %>L ')KSKQO\
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M)X*^'7C31_"NMZK';ZQJIQ!"3S^- 'IV:6JUO<0RJKI*KAAD$'M4P9>QS]*
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M+WQ;^(]WHUA!X+O9+-DE4R.S'E/3\J]H\(?M5Z_I/ARRMKVR6:[2$"61CRS
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M/MO_ -![4?\ OZ:]<HH \B_X9\M_^@]J'_?TTO\ PSY;?]!W4/\ OZ:]<HH
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ME"C!4X*R1X4/!'Q?QC_A+;7_ +\T?\(1\7_^AMM?^_->ZT5)J>%?\(3\8/\
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M%)D>M)N&,T .HI,YH+!1DD >IH 6BD5@PR#FEH **** "BBB@ HHHH ****
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M&*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HII;'O1OYQC% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#TH K7VIV
MFF0F6[N8K:/^]*X4?K18ZE:ZG$);2XCN(S_%&P85\P_M56FHM\0/"%W?B[?P
M=%)F]6VR1_P("O:OA/<>'+S2GG\,I-'8L<!9%*C\,T =]1110 4444 %%%%
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MGR0N/YUM^ ?@[\1/#_CKPOK=Q=:E+(UTQU".6<F,+GTH ^UZ6D'2EH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH7[/$J87IP*U* .=L/ 6AZ9J7V^WT^*.X ^4@<)]!VKC?AXJCXF^+,*%^9>
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M;+87<9]XS2]M#N+V,^B.\S1FN.M_BMX>FX>Y,#=Q(,5IVOCC0KT@0ZC$V?\
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M;JYU&:TEU",F+,2@%C7UO7PK^S9XSTOXD_'&XU.STG[%=DL9RQ. <]A7W70
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MN\$GVS[DBMC'N*_:KP'>W.@?LVZ$+*0QW26<<<;CL<5^(\OQSFNFBB  +2J
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M^A!/0%L&M*.^MYQF.=&!]&I69NIQELRQD^E+3%<'HP/XTNZD4.HHHH&%%%%
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MBB@ KGOB!X<D\7^"M9T6&402WUL\"R$?=)&,UT-% 'Y#77_!&CQ?<ZA=3?\
M"76H625G!\L]"2:7_AS/XM5N/&=N/^V9K]=VZ5X'\</$_BC1_'>D0:%(S))$
MP>%1^M 'P9'_ ,$;?%\:''C:#)[".J<__!&3Q?N)'B^U8>ICK](_V?\ 6-8U
M71]476KE[BZBN-H9AT'H*ZKXJ:C=Z5X'U*XLG9;E5^0KUI6$?E</^",OBU@"
MOBZU/K^[I'_X(S>+4(#>,+-<] 4YK[7\+?&S6_"6GDWL4ES-.X18IP<IGO\
M2NF\.^*]>^(/C_3OM:BULX@6V(3AJ8'P&W_!&7Q:H'_%76N3V,= _P"",?C
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M^(-#NIM4E$DRSL% ZJ,]#7EOQ:\:>(--^++V=G/-'910JVY0=J<]Z /A<?\
M!&+Q?DY\76O_ '[-(/\ @C-XK?/E^,K-P.I"=#7W_/\ 'G599WTZSL1)Y<&&
MG?(+-CJ*U8KW4]#^$<E]YKI?74OSR@DE030!^=B?\$9/%K=/%]H?HF:4?\$8
M?%Q/_(W6H'_7,U]Z:E\0M2^&VKQ16-T=;M+B%&E>4\1,?>G?\+D\0Z_JNGPV
MZQ6L:W2QR2KG:X)]: /@N#_@C+XNBNH7/BVUPCAB?+/8U^J'PJ\'R^ ?A]H?
MA^>83RV%LL+2#HQ ZUU49)C4DY) R13J!A1110 4444 %%%% !1110 4444
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MM<]E&]QG)?'+?6L[3/AIH>F:Q=:FEJKW$YSAONK]!7644 4K#1[33#)]EA6
M2'<P48R?6J]YX8TR_FFEN+.*:65=KNR\D>E:M% &$O@G1%E21=/B5T&T$+VK
M0ETBSFL39O;HUL1@Q$<5=HH Y34?AGH.H:7-8?8UBBE.6*]:N:?X&T33M.AL
MHK"+RHL%<CG([UOT4 -10BA0, # IU%% !1110 4444 %%%% !1110 4444
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MN+EKBXLIU"M"$/R-BNJ^#GBKQ/K6L:Q!X@M)88A(6MG<<;<UZL;:)L9B0_\
M :<L2+T4#Z"@8X=*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $I:** $ I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>cvac-20231231x20f036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f036.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O CH# 2(  A$! Q$!_\0
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MPNGP8?\ F,0_G7P)Y*'M^M'E(.WZT?ZS8C^2(_\ 4C"_\_9?<C[Z/QH\&?\
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MG2#XT^##_P QF#\Z^ Q$I/W?UIQB4#[OZU"XFQ'\D3?_ %(PO_/V7W(^^_\
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M\=KZ?/7O2@D4?V!E_P#)^+%_K1FG_/S\$?,/_#&QS_R&C_WS1_PQL<\ZT?\
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M_/O\1_ZTYK_S]_!'S$/V-L?\QH_]\TO_  QO_P!1H_\ ?-?3HR3S2_G1_86
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M-JSS,%C.PX8T?ZH4'_RZ_$?_ !$^HG;VS_\  #MO^&.6_P"@T?RI#^QR^/\
MD-G_ +YKB;S]MKQ997K6UQH<$$R<,C=0:B/[</B@9_XD]N:?^I]'_GU^(?\
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M_P"$V\/_ /0:L?\ P(7_ !H VZ*Q5\:: YP-9L2?^OA?\:D_X2S1?^@O8_\
M@0G^- &M162?%FB_]!>Q_P# A?\ &@>*]%/_ #%['_P(7_&@#6HK,'B;2/\
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ME<#.;:XS_P!<S43Z=<%@5M;@$?\ 3,U^IO\ PCGA;_GRTW_OE*7_ (1WPO\
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M9K]2_P#A%/#A_P"8;8?]^UH_X1/PYT&FV'_?M:O^VH_R?B9?ZFS_ .?WX?\
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M['%O':^*/B&D:!%-XI('TKS3P]H5KJGBKX@/,NZ0:U)BO3?V.C)_PE/Q#$P
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MGSW1V4C$#^M$3C&2P-4/[06ZB#H<*?X338$6V#%2Q#')R<XJ6R'#D99OY)!
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MO&NFB7R2N OK[U>A2=\%94CLE/\ JUK-0YD=47&#ON10>([?1;:*6_8YE/)
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MDPHZFOHO]G3X3>*/AU<^)=3\6WMO>:GK%P)F-M]T<5Y#XX_8A\8:QX_US7M
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M*^MY]4U.*V3!BB&Y6[_2M#0+O4AJ7D:AIS(3Q',HRN*YZS_8@^)]B[O#\4I
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9&* #-!Q0 !01F@8#!I:0 "EH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>cvac-20231231x20f037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f037.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #[ UD# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>:]T'P_\/[LG3HORK;#U858MM:GGYAA<;0JJ-&I&S2>SZG*?\-&>%S_#=_\
M?HT?\-%^%_[MW_WZ-=</ 7A[_H'1?]\T?\(%X>_Z!T/_ 'S73>GV/+]EFG_/
MR/\ X"_\SD?^&C/"X_AN_P#OT:3_ (:-\+_W;O\ []&NO_X0+P]_T#X?^^:/
M^$"\/?\ 0.A_[YHO3[![+-/^?D?_  %_YG(#]HWPN?X;O_OT:7_AHSPO_=N_
M^_1KKO\ A O#W_0/A_[YH_X0+P]_T#X?^^:+T^P>RS3_ )^1_P# 7_F<C_PT
M9X6]+O\ []&@_M&^%AVN_P#OT:Z__A /#W_0.A_[YH_X0#P]_P! Z'_OFB](
M/99I_P _(_\ @+_S.0_X:-\+?W;O_OT:/^&C?"W]V[_[]&NO_P"$ \/?] Z'
M_OFC_A /#W_0.A_[YIWI"]EFG_/R/_@+_P SD/\ AHSPM_=N_P#OT:;_ ,-'
M>%L$[;OKC_5&NP;P!X?[:=%^5-'P^\/=].A_[YJ?<*5/,[ZSC]S_ ,S8T368
M=?TR"^M]PAF7<NX8-.U758M'L9KJ8$QQ+N(7DU/96D-C;)# @CB0851T%%S:
MQW<;1R*'1A@J>]9JUSU_?Y-=SR]/VC_"Y=D*7:LIP1Y1KM_#/C6P\5V8N;+S
M-GHZX-4I/AQH!D#'3HL^H%;.GZ+:Z/%LM(EB7^Z!5OEZ'%2CBU-NK*/+Z:EY
MI@O/;J?:O@+XV_%NSU+XRR^($OM0BF\/W(@AAMP3$ZYYW8XK[TN[5[ZPN(%8
MPO(I4..HSWKSS2/V>O"^G>'-2TRXLX[R34"S37$BY8D]\UEUU/1Z:'G?C3XT
M>*O$5WX?C\$2VZP7UIY\TDHSM(&2!7CWBCXO>//'][I$EC>):M83-#=HG24K
MUKZ>\'? #2_"#6JP7+RQVT;1QJW8&N>N/V4M)B@D6PU"6TFDN&G+CW/(KIA*
M"W,[,R_"O[1FC^!? UC)X@@NC<W$C*HMHBXR/6N9TCXR?$'7]%\0^*Q=6UIX
M?MY"EK"R_O-O;/O7O7ACX3Z/H/AN/29X(M0$>2)9D!.36/=? G2CX-U/P_;2
MM#'>3>?N_N-_A64G%HI7OJ?./A[]I;7_ !?::_X=N6D>=H"\$SQE"#71:%\1
MO&WPU\%:<OBF6+4;+4K=Q;[/O1GG&:]#TC]EFQLYY;R[U%IKZ2+R?,50 !5_
M3?V<X6M_LNMZO+JEI!&8K2-Q_JL]ZOFBH)):BFFW[IY)XV_:EU'PWI'AW1=)
MMY(KZZM_->2.,R$>V*E\0?M)^,E^&>FZM!;F%Y'*SSB/+J!WVUZYK_[.6FW5
MC8/IDXL=5LXQ"EVRALIZ4NH_L_K/X8MM.M]4:.Z3/F2,@*R9Z\5+<6)<W4O?
MLZ_$:[^)?@5=2O9TN)Q)L+*,?F*]6%<'\(OA/8_"?09+"SD,K3.9)'/0D^@K
MO:A^1:OU"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH *3O2T4 0S6Z3(4
MD570]5<9!JNFCV:0O"MK L#=8Q&,&KU)2 BMX$M8A'&H2,<!5& *D6N,^+/Q
M%7X9>#[W6C9RWSPH2D,(R2:\ST7]IB75_A18^)4TTKJVHR&&UL&ZELXYJM]1
M;:'T!G%'0UX#IG[15_H6EZI#XPTQ=/UZV :"V0\3;ONXK2^%GQE\1:[XA32_
M%.BC2WO$,UFZGADI\C>PSVVDS[5F:[KD/A[1[O4;I@MO;1F1LD#@5XKX/_;<
M^%OBV*]<:VMDUI,8728<Y%9WTN.Q[[NHSFO(1^UC\+O^AHM_R-)_PUG\+LX_
MX2>W_(T:BNCU_/M1D^E>0_\ #6/PO_Z&>W_(T?\ #6/PO_Z&BV_(U5F!Z]D^
ME&3Z5Y#_ ,-8_"__ *&>W_(T?\-8_"__ *&BV_(T68'KV3Z49/I7D/\ PUC\
M+_\ H:+;\C1_PUC\+_\ H:+;]:+,#U[\*,GTKR'_ (:Q^%__ $-%M^M'_#6/
MPO\ ^AHMOUHLP/7LGTHR?2O(?^&L?A?_ -#1;?K1_P -8_"__H:+;\C19@>O
M9/I1D^E>0_\ #6/PO_Z&BV_(T?\ #6/PO_Z&BV_(T68'KV3Z49/I7D/_  UC
M\+_^AHMOR-'_  UC\+_^AHMOR-%F!Z]D^E'/I7D/_#67PO\ ^AGM_P C2']K
M/X7#_F:+;]:+,#V"BN;\&_$'0_']@;W0KY+^V!P73I71,X12Q.%')-(!U%<1
M>_&GP5IUY+:W/B&SBGC.'1GY!K4\-_$+P]XO>1-'U6"_:/[PA;.*ODFE>P'0
MLVTBHX[A)2P5P2IP0#T-/'S&O!Y-7U'X<_&^X;5M09?#VIQ-)&)#\JL!4CWV
M/=O/CWE=Z[O[I/-)).D0!=PN3CFOCOXH^(/%GB/P5KOB?P_K<EG+=:BMM8;>
M@4'^M4+[XV>*%\)>&]'UZ[.G>)H+Z-)MW'GQ_P!ZJ<;:,B;Y(J7<^U?.48RP
M&?>E\P#KQFO@SXH?M'7EI\3/[7M?$8ATW19$MYM.7.)B<9-?3VM_'?PI;^&;
M9IM<@M-2U"Q\ZWB;.2Q7C%-P=DRE\7*>EC5K1YS MQ&9A_ &&:L^9QZ5^?Z>
M*M4@\*S>(8GUW^UOM9Q>A,V^W=USZ8KVZ\^/?B34;C3](\(Z6GB&\@L4N;RZ
M#84<<U'IT!Z,^D3, 0,X/8$TPW<:JQ=PH'4DU\,?%_XV^-?'GBKPE+X-NWTR
MYL')U.Q'(DVGYEKT^+XJK\3_ !UX?TZQU)K9)X"EY;(<,KC@Y'UJG!J*EW%=
M'TB-;L?E_P!*B()P/G'6K0F5NC GT!KXSTCP,T?[1NK:-/XCU#^QM/LQ>B)G
MXW Y-<[IOQZND^-\6KKXJ_XIN.?[&VEG)R<X#9JN2SL*^ES[R4Y%+5>SN4O+
M>*>(AHI5#J1Z$58K,:"BBB@84444 %%%% !1110 F.<TFWDGUIU5;O4;>PBW
MW,\=NG]Z1L4 3[,$D=30B$=>:JMJUHMK]I:ZB6VZ^;O&W\Z?9ZA;ZA#YEK.D
MZ'^*-LB@#RS]K'C]GGQM_P!>+UQG_!/_ )_9M\/_ / OYUV?[6/_ ";SXU_Z
M\7KC/^"?_P#R;9X?_P"!?SH$?1^!1@4M% Q-HIDD8="*DI&Z&@5CQ'2T_P"+
M]RC_ *=S7M(7<^#T%>,::?\ B_LO_7N?YU[2G^L->?A-5)^;/9S1^_3_ ,,?
MR%V#%'EC_(I]%=YXXSRQ_D4>6/\ (I]% #/+%'EBGT4 -\L4;!3J*8#=@]*-
M@]*=10 F!Z"@@'M2TAH  <<4M)ZU&91NP>E&XAS-@]*4C>*H7.V68,LP '4;
MJM6XP/O;OH:-.X:DJ+M[YIK2!3C!)IV>:\ ^)O[0VH^$?BOI.@6-@MSHK.([
MZ[)_U3$]*:U'ZGOR8],4,P4=*X#Q]\</#'PU:TCU:>027*!XEA3<2#WXK@O'
M_P"UQX:\)RZ0EN);M=1^ZRH3M^M.,')I(5SWP."3QC%+@$=*Y#P#XO\ ^$K\
M+KJOF( ^2,\<5S,WQXT?PWH]YJ.NW&R"*<PQ^4N2V.U)H$[GJ;L%'2D#AB01
MTKP/QY^UMX;TGX<7?B/2UGN&C/EK&\9!#'ID5SO[/'[4UQXT@U ^+52S>.0+
M RKC<#T%-1;OY!-\J5^I]0C!QQ2X%<5=?%_PU8ZO)ID]\J7<</GLA_N8SFN9
MM_VH/ L]C>7?]H-'':G#[UP3]/6E9H;T/6\8I:\K\-_M&^$?%D=X]A/.QM8C
M,Z/&0S)ZJ.]4?"?[4_@CQEK,FEV,]RMVBEV26$K@#K1RL1[#36D"M@UYQX/^
M/OA;QQXDN-#T^:5;V$D8D3:&QZ'O67^T;\1]9^'7A2QGT,VZW]Y="W1KDX1<
M^M*S^\I:GK9D -/KP+X,_&G6]>\7W7A3Q$EM+?P1K+Y]F=R$&O?!FFTUN3U%
MHHHI#"BBB@ HHHH **** "BBB@ HHHH *3'-+10!R/Q2T]]1\!:Y!%%YTSVS
MA$ R2<=J^8?#G@?6=-^#WAO4[G3Y_M.D7AGDM OS,N[TK[*9 W4 _6HC &&T
MHOE]TQP:%HK"\SX^\=Z'J/QHO=0\4V.FW%K;V*1;89%(>7;UQ^5=Q\/-=NOB
M-X\T6ZCTNYT^WTBV\F4W"D M[5]$PVD4"%(XTC0G)55 %)%910EO+BCCW<G8
MH&::DX[ U='SU^W'X \8?$'X,:A;>#]3_LRZA0R2MN(W(!R*^.OV'/@9#XF\
M!ZLVJ:<M_?0731S3XSN8'FOTB^+.5^&OB+:<'[')_*OF;_@FRN? ?BDGDG4Y
M.OUKSL=A'C:/LN9Q\UNC6$N5W:+2_LSZ2"1_82Y_W:FTS]FKPY/JT=A>:1'#
MO&02M?6AC#$<#\JX_6=O_":6)[A:^'Q.2U,&Z=18F3]Y+?IV.^G5A44HN'0\
MK'[&GA';G[+#]-M _8V\('_ETA_[YKZ&7.!3NM?8_P!GT]/>?WL\OE78^>!^
MQKX1_P"?6'_OFD_X8V\)?\^L/_?-?1-%/^SJ?\S^]BY5V/G;_AC;PE_SZ0_]
M\T?\,:>$?^?6'_OFOHFDQ1_9U/\ F?WL.5=CYW_X8T\(_P#/K"?^ TG_  QK
MX1_Y](?^^:^BJ*/[.I_S/[V'+'L?.W_#&OA'_GTA_P"^:/\ AC7PC_SZP_\
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M>%+>[Q_9\R3O.1S(R]?SKC?V@_V2H_C+K'A_6++4CI.HZ5CYEX#\8YQ7T:2
M:<IX]*J[>H=+=#PGPK^R;X6TSP9+I>K6T6I:G,"9+UURS,>AK<T3]G[1K7PI
M'I>I6\-]>6ZLEM=NN60'H/PKUD'G)%#GC/6CF8EIL?-R? 3QVOAF;PD-=M$T
M"5V+-L^<(3G%6[+]F_5O 6IQWO@_5%B9[06LXG)Y]2*^AMP(Z@GTH5@:+[^8
M-'SWX9_963P[XJTS6QJ.^:)VENE[2,W6I="_93M/#?QSG^(%AJ+113 [K#^
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M*3EN M%%%0,**** "BBB@ HHHH **** "BBD- "T4T$FC=U]: '4PL >3BG
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M,]I;7B6UK&O.\@_-5^Y_:.U#Q!X%\,7EIFRUB2\CMK^W?@C/6N@E^$6JZ?\
M!70-&C7SM5%W'=7A/=LY:O/?VD?V?_$]YJWA[6?!,?E>2RO=VJCAVQ]ZM+1N
M1+X$^IL_$;]H37]!^+E@MBR'PG9[(=1EW#Y'..M?26I:Y'+X4FU&TF0%[4S1
M'<.?ER*^8="_8ZA\7>![^Z\2ZC>QZW?YGG@C?">8/N_TKLO#_P "KW7/!=J-
M8U&_MK_38F@@BCD(210,+D=Z';E&FV]3P:/XQ>*+&0^(#\1K5IUO#&=#(.]A
MNQMKZNO?CWI&AP:?;W4$]UJTMJEQ-;6R[C&I'4U\L+\//%,FF3^&O^$ L7NC
M<-MU9HSYF"W#9]:[^3P3XT^#?B"'4[.R'B%KO3UM96G7>R-Z"LX)6=PEH]!G
MQ]_:>UC1/&7@N7P63J.E7$G_ !,H4^]&N><_2O1/%?Q'U/Q3XJT+3?#E^D5M
MJ5MO\T'A&QTKS?PA^SMK&G^,-)U.\MR]M?L\MW%VCW=A6OX.^ OB7P3^T$E]
M#<R3^$8P6@1SGRR>U7.,7!6W%=V.*T;1_B]<_'FZ\*R^.8Q96B+>NP[IGE?R
MKJ],^.'BV+X[PV<]PD_@E6^S/<J1CS>F/SK=\4^ O%%A\7?%GB+2[8R)>Z9]
ME@?T<^E<K9_LA7%E\-H[\ZC?-XH\P7+P%_D,F<TTHW293TC=;GU/XO\ &FG>
M"M EUC49"ME&-Q9><CM7G\?[2OA^ZMHI+>TNI))!O6(J VS^]]*B\9^'=8\7
M?!FWTR: /J81%DCQU(ZUXU\9/@[K%A?>'-7L+6>Y$=B+:6*WR,-CT%1UL#VT
M/H&\^.WANVT6TOX))+M[LE8K:$;I"1U&*ZSPIXMM?%VF"\MDDBP<-%*N&4^]
M?+6D_#/Q%\/O"_AWQ'8Z7]JU"VD=Y;*0%L;O:O7_  1XC\8M!:7%WI$,!OI<
MRQJN!&M-I="$WU/80<TM-3[H^E.J2PJ.7[CD\* <FI*CF(\IQC=P>/6@#X^\
M8^,+I_%^KZ1I6I3W6GW+F*2*8DIO/85T?[-'@JV\,>*+TZF\\.O;<+"P.S8>
MF#535K?PAX3^(EQJOB&[.F6:3>889$."WK7J&C?'/P!XEU*)=#G74;Z3$:O!
M$<CZG%5'38B2/68GW CN#S3B/4U%;!O*4N,$\UD>*_&^B>";);K6;Z.RA8X!
M<]:DI&[CG-)MYSFN5_X6GX7'AAO$!U: :2IP;C/ /I5[PIXWT7QM8?;=%OH[
MVWS@LAZ&@#@/VL^/V>/&W_7B]<9_P3^_Y-L\/_\  OYUV?[61S^SQXVP?^7!
MZXO_ ()_G/[-?A\C_:_G0,^D:*** "D/0TM-<X7IF@#PZVO(;+X]R/-((U-N
M<%C7LEMJEM<RXBF5R> %.:\H^)GP@O?%OB.+4]/E^RR*NTN&P:X/X+0:OH/Q
MQU?1;^]DN8H8LA&8D"O*IRE0GR-:-_F?35:%/'TG5A*TH03MZ:'U"#2TG>EK
MU3YD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
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M:_\ 7B]<9_P3_P#^3;/#_P#P+^==G^UCS^SQXVQ_SX/7&?\ !/\ X_9K\/\
M_ OYU)1](4444 %(1D4M% %<G;,2>E?/7C?X/^+)_B=?^)?#FHK9_:%VY-?1
MA4'L#3'0!#P*PK4E6C9[G;A,74P4I2IV]Y6=^QX?\#M>\33ZWJ^F>(;[[7+:
M-@$5[<H+ $'K7C/PE /Q(\69Y_?5[*_#@=*RPDW*DK_U8[,WC%8GW5;1;>A/
M11178>,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVJ?<7Z4ZFQ_<7Z4ZO;CJD<@44458!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(S!5))P!R32U%<Q^=!)&3C>I7(H ^</B_P#$'1O&ZZO81Z[J&A0Z0"T]_9\
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M***^F.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!T"\#%2UQ/P=U2YUCX;Z)<WDC2SM" TC=6QWKMJ&K#6H4444AA1110 4444
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M]XCMQ/;NIV$_P'UKY\^&_P#P2^^$O@ZPN8-5L1KDLLA9)9<@H/2I&O,[@?\
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M^_KG'>M@V%NR%&@C*$Y*[1@FIE0(  , = *J4^96&D.HHHK,H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I*6D8[: (+R>*TMY)IG$<* L[GL*\]L_C[X%N-1^
MQ1:RAD5_*WD?(#Z9K=^*;E?A[KI4[3]F;!_"OFOX,>'O#5W^SUX@N-0BM&O5
MDF83,1Y@8?=YZ]:J%I;@UI<^N(+V&X@26.9'C895E;@U*7&, C=7YX6WQ?\
M%6D>!(XHYKR6:RW.L<0)(4'@GVKUKPM^T%K.G>&]%\4ZY,B:?>6K1E?27H/Q
MJE3<DY1)NSZS$RC@G;CKGI3RX'0@U\5_$[XG^/K+P[HVIK<,UA=EI2D S($Z
M@FO>/ GCN;Q#\$)-=BN1/=);,1)T(8#O4.+2N--,];\P<@$$TPRX"@D!C_">
MM?%FF?$[QGI7A'_A-9M=BNY%N6A73EY.T>U7+'XD>,/%O@2^^(@UF.RGLI2J
M:8W&Y1[46 ^R?-"X!8 GL356/5[2>[>T2>-[E!EX@WS+]:^(M:^./C%O$&DZ
MM?W+0Z7.D9#P#Y8R>S5Z1\"[>[U;XX:_J\FL-<036ZLMN3^N*?+:31-_=4CZ
M035[.346LUFW7,8R4]*L75_;V%LT]Q,D42_><G@?6OC_ ..?Q3\1>&?B5<:?
MH\T=L\TXA$I'(!JOXHE\51Z/KWA>_P!>:82V\=R)QD%2>2*.1^R]H5]KE/LN
M*]BG@259%:)QE7!X(I5?<3CH.E?*^F:KK^MW.D^![;5_L5O!8K.U\QY<XZ9J
MAXJ^+_BGPU\-[S7H=0CFOM%N39B$<_:1TW4YQY96N3"7,MCZKN=>L["\AM;B
M8)<3'$:'JU7VE Z$$]QZ5\)^*?C9XET[P_X9\0RW,5SJ5^2P7&?*_P ,5Z_X
M=U+6_#7AL^(]1\6P2O?6QE^S2M]TXSQ244XWN+FUL?137$<<;N67"\M@]/K6
M5!XJTN:[6WM[I)Y'.%$9SS7Q3X4^-'BJ3Q\NC-+.+/6X)?W\X^48!Y6JO@7Q
MOK/PTN;QQ=C5#%)+(F?F8G-:>R=[%W3CS'WP90/0GOS1N4L 2-W89KX]F^(G
MBW1/"]GXW;78[HZ@6SIH_@_"N8T_XE^.H_!B>/9-9W[-1$"V9'!0GH:7)K:Y
M"FFC[J15P=H[\YJ2LKPQJ4FL>'M/OI0%EN(5D8#L2*U:R- HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *2EHH *3&:6B@!*6BB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D(SBEHH J:GIUOJ]C/9W*"2WF
M4JZGN*\LM/V9?"-A<$P13+;-+YKVWFD(Q]Q7KU%.+<-@>IY?KW[/OA?6KX7"
MVYM5*>7)'"<*Z^AKC?BK^SRGBG1="\*Z/:1VF@6EP+ASGG(/2OH$]14?>B+<
M=%ZAT://=>^">A^(]/T^VG5H_LD8C 0X!&,$5H3?#NST?P'?:!HD*VL<L#(J
M#H6(ZUVBCI3B,BIYFT))(^>/@W^S!9^&+-Y/$(^US&9I%@+$H">^*[F[_9\\
M*7.HB<6K16Q.Y[1&Q&Q]<5Z=@'![TAZ?C57'N>8:Q^SWX6U>]BE:U\NW3!-L
M#\A(Z<5NZ/\ "K0_#WB'^V-.M_LUUY8C.T\$"NS-&*5^HK:6.&\0?!KPOXGU
M;^T[_3UEO=X?S,]Q5S4OAAH.JSW$]Q:*TT\(@9O]D5UN*,4[NW+T'UN><ZI\
M#M U*RMX )+>2#A)XVP^WTS4R_ [PJ;:WMY+$30P\['.0Y]3ZUZ!T-&!0VV[
ML226QYM/^S[X,NMBR:8K1QDE(R?E4GTJ&R_9]\,V_P!H2>)[N&12J1RL2(P?
M2O3\44NEA63=SR_0OV?/"^B:A:WAA:YGM=P@,ASL4]A5G3?@)X1TO5+B^CL
M\LQ)97.1SUKT? H'4U7,[W&E96/,;/\ 9\\*6M^UP;9I(<DI;LQ*)GK@5I2_
M!3PI)X=;1!IZKIQF\\Q#^_ZUW@H[BE=WN+E2*^GV46F64%K"-L,*!$'H!5FD
MQ2TB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>cvac-20231231x20f038.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f038.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z 9,# 2(  A$! Q$!_\0
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MEP #7O;0EG!)''2I-HSTJ7.4KW&E9W/F>W^!'B75] UUYDT[0KN_C'E06*;
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MAZTFVP"EI,@#-)O&<9H =129%% "T444 %%%% !1110 4444 %%%% !1110
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M5JB_*K6RY3/K7F=O\/\ ]H?]H34S-K>N3^%O#9.^.U4>6Y![$BOJ+X8_LU>
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MQ#.]BFB:[HX/FP2'<#QFO0/A%XAU?Q5X.L-5UF,1W$\>< 8[^E#5A)W/$/\
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MW'$JI)&1RK#(-8UJ2K4Y4WU1TX:LL/6A5:O9WL?"GP>U;X@7FIW'V6T(P?\
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M:-_Z-^U;_ODT!<_1&DK\[S^W)^T;_P!&_:M_WR:3_AN3]HW/_)O^K?\ ?)H
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M-<T;2=%M?'>V+[/J"ZBDK%,Y WCD_A7;^./%^F^(_C!X*ATN]-YLT6;=Y1.
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>cvac-20231231x20f039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f039.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> @<# 2(  A$! Q$!_\0
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MG]@O.C-:3M-N\T@GC\J /N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.?FEQUQ7Y]:>FOGP7HBVTMB/%/\ PF<N9'!^S^9CGCTKV'Q!#X[B_:-^&?\
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MX\U_Q'?^.]#UJ^NKV/1+Y(;4W\HEN$1ESM=AP:^C:.B?<GJUV"BBB@84444
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M_D[-,0>5>F_3VF/5JV]8\$:1KFN:=K%W:K)J&G*ZVTIZQ[A@UOT4!N<K\.O
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MBKI\]YX>OENXH7*.,88>^/2C<-CL*Y;Q!\3_  OX7U2'3M4UJTM+V4@+#)(
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MQU ->FTQ%#6=631;,W$D<DJ@XVQKDUA?\+#M?^?*[_[]&NK.,<XQ[TW"?[-
M'+?\+#M?^?*[_P"_1H_X6':_\^5W_P!^C74X3_9HPG^S0!RW_"P[7_GRN_\
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M_='\J!DE4VT>Q=BS6D))ZDH*ML-RD9QD=1VKDY/!>H/(S#Q+J*@DD*'&![4
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M8MA_SYP?]^Q7._\ "$ZC_P!#-J7_ 'W1_P (3J/_ $,VI?\ ?= '1?V+8?\
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MC:$N,[&ZBK% '(_\( ?^@O=_]]5T.CZ;_95BEL9GN-O_ "TD/)J[10 4444
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M?RU/1 >^*]UH Y;2-5\1W%_''>Z7'!;'[T@?)%=3110 4444 %%%% !1110
M4444 %%%% !1110 4444 ,FA2XB>.10R.-K*>XKYT\ :#I_A?]J7Q/;Z9IZ:
M=9#3%D81)A68G))/<U]'54&E6:WDEV+:(7,B['EVC<P]":5M4RD[)H^??CQ>
M> ?B#?\ A236]=U#3;6WNW6"]L25C64#D.V.*M_LN:]K5^_BW3VU2ZUWPW8W
M6S2M2O1\\@YRN>X''->S77@C0+[39-/N-(M)K)VWM \0*EO7'K6AI.CV.@V4
M=GIUI%96J?=BA4*H_"G'2_\ 78EZGR]X^N?B!-\:/ANGB>WTV/1QK!^SO:@^
M9T.,_A7U;7AGQY_Y*?\ "G_L+?T->YT 5K[4+?3(/.N95BCSC<QXK&U#Q-HN
MH6-Q;-J$0$J%,ANF17COQ6^/NO>"=8BT^[\ RZE87-VMI:S;_ED<G"\5Z3\/
MHAXGT,7>L>%XM$N]Q7[,PW<>M&X;'DGP(^!VG_!GQIKVOW/C-M974W,B6\LA
M(A8GMSZ5[]'XNTB6146^B+,< 9ZFI/\ A%])_P"@?;_]\4J>&M*C=76P@5E.
M00G0T=$NP=6S2!R,TM(!@4M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>>_'/PWXR\4^ +RR\"ZXN@:^2&CN77(('5?Q
MKT*N)^,.G>+]1\#WJ^!M0@T_Q'&-]N]RNZ-R/X2/>IEL5'<^([;38;OXJ^&/
M#/Q*U'Q+H]W,'%\;^5H[2Y<?=*.IP ?<U^@.D6%GH^AV]K9#?900A8P&WY4#
MCGO7PGXB^*_Q*\97>A>%O%WAG0O$L\\IAOM&">3<;E/WD)Y]\BON'PE9C2?"
M=A;QV+V(@@"K9N^YH\#[F>_I6GV#/[1\C?%;5?AEXQEU>/4/ 7B/2)(V83ZC
MIZ&!#C^,X(!_&O0OV+OB%9^-O#FJV^D>(-2U_1--D%O;2:G!Y;Q@<;0<8('K
M7F/CKQ/\3_B;XUU&S\4^!]3L/ UI*5@TS3)E$NH*#UE./NG'2OH[X#>([;4=
M$FTRT\&GP7;V&$2R8KDCUP/ZU,/AN5/>QZG1110 4444 >&_M/\ ^I\(?]A6
M/^8KVHV\5W8^1,BRQ21[71AD,".0:\5_:?\ ]3X0_P"PK'_,5[=!_J(_]T?R
MH ^>+GP5\+/V6_%=QX@T'P'+'J^KJ\EQ=Z="7(&<MGT_"NB^&_[4N@?%#4+.
MWTC2-5\BZ8HEW+ 1&".N37<_%KQWH/PS^'NM^)/$=REII5C;.TLKKG'&  .]
M>'?L#_&[PC\6OA4UIH%RLM[ID\@N(60*Z!F)4_0@T ?4-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X9\>?^2G_  I_["W]
M#7N=>&?'G_DI_P *?^PM_0U[G0!XI^TD[+/X# ) _MZW_G7M0Z"O%/VD_P#C
MX\!?]AZW_G7M8Z"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O'_VC_'-_X$T30[RROEL$EU&**:5NFPL,
M@U[!7GOQR\-7WBOP)=6-AH5AXAG+ BRU!BJ-CT(Z&D]+/T*1PWAF/0OB+\>M
M8O+NTLKBZT""%K&_@8;SO'S D=:]RU*9K?3KJ5/OQQ.R_4 FOSV\46_ACX17
M"W^O>&?$GP[U*=U1KS0[H7*R'/'R$EL?A7WEX(N(=5\%Z5,EQ/>P3VJ$372[
M9)%*]6'8TTO<TZ$7M+4^&;O6M8TSPYI'CG1?'TJ>,]:U1[6X@O+G=;PQ%BN!
M&>F!S7UE\"?A_IO@K3+R:'Q'+XGU>]827U[+/YF7]%'\(]J\/^+OPF\):7X_
MM_#?A?X=6.IZG=1F_GN=1NVBMT!)^[S][/I7KG[-_@J]\':?JD=YX?TW0C*X
M*KIUVTX?W)).*<?A_KR_4);_ -?UL>T5\\_M$_%#Q[X.\5>&;30;2"T\/SWD
M<=[?RG+N"0-BK_6OH:O+/CQ\.-6^(NGZ%#I3Q(UG?QW,OFG&44@G'O4]4_-%
M+9^C-[XL^.)/A_\ #75M?A02W5O;[HE;H7/3->-^#?&GC;P/X\\%0>(]:77=
M,\8P[O+\O8;29AD >HQ7IGQ'\):]\0M+UGPM+!;0:+=66R&]R?,6;MD>F:\]
M\#_##QYXD\<>%KWQG;V>GZ9X2A\JU%JQ+7<@X5^>@Q1&_-_6P.W+_6^AJ?M-
M:I9S'PE!'=PO.NK1@QK("W4=J]QGO8--TUKJYE6&WABWR2.<!5 Y)KYD_:$^
M$'A;P_X@\,>(;.PDCU:?5T=IC.[ DGGY2<5ZI^TC="S_ &?_ !G,\CPPII<A
ME>/[P3;SCWIB/+-2^-_P;_;-T7QG\*H-6%Y*MM()HR=A;9_$A[X-9_\ P3W_
M &??"WP5^&,^HZ5*9=2U69_M$TCC.U6(48_"OAC]@;PA\%/'WQ8URPTVX\1V
M_B'^SI9;22X<(C +^\Y4Y_.O0_C5\,_'G@_]F/PYKWPIN-;N=2;4)DU'[+*S
M,D>X@87/K0!^JRNKC*L&'L<TZOB__@F-KGCC5/A?K$/CVYO9=9ANN([\_O$4
M]*^SR<#- "T5F2>)-+A<))?0H[' 5G )/H/6KMM=PWD>^&02)TRM6X2BKM&C
MISBKR31-1114&84444 %%%% !1110 4444 %%%% !1110!%<RM#;R2(AD95)
M"CN?2O ?A+\3?'?B/X\^*-"\4V]OINEV]N)+"RA.Y@N<;F/J:^@Z\HTGX;ZQ
MI_QWUSQ@S0MIMU8+;Q)GY]X]?:I^TOG^1:M9F=\;_&.O-XM\+^"/#E^-)O-:
M=S-?E-QB11G@>IJ3]G_QYK>M7/B/PSXBN%OM3T&Y\K[:J[?.C/W21Z\5C>/O
M!7CS7-0T/QG96%@/$NAW$@CL"Y\NXA88'/K70_ GX:ZSX737M<\3&)-=UZ?S
MIH+<Y2%?X5SZ\U4.M_ZVL3*VEOZ[F-\=I8Y?B=\*MDB/C5\$*P)'![5[D\J1
MXW.JYZ9.*^6_B)\(M"\#?&OX::KI[W9NKK5SY@GG9UYR3@$\5\+_ /!2[XT?
M&SP/\>)8H[_4=$\+0!6TU[7*Q2#N68<9]J!'Z+_M3ZQ8Z)8^#]4O[N&TT^SU
MJ"6>XD<!8U!Y)K6^$G[67PS^-?B.^T'PMXB@O=4M"<P9P9 ."R^HK\[[/XM>
M ?VU/A)X9^'+:OJ.F>/[F>&&Y:>0[97_ (G7GD5U/P"_X)N^)/V9/BEIWCC7
M/%-O<16M\(K2#3RP:93T\S/\J /U)HID3^9$C'^( T^@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR[]HV[UNU^
M&E[_ &!XHMO"&I.RJFIW:[D3GI['WKU&N+^+&N^&?#_A.6Y\6VB7FC[@LB21
M>8O/<BIEJBH[GRI\.SJ'@RX74]4\(6'Q)U8$,^N1:C')*Q]0AS_*OL_0+\ZI
MHUG=M:M9-+&&-N_6/(Z5\1_#?PS\'_'WQ5\8BTUG^Q[;,1LEM+IK< ]]HK[=
MT&PBTO1[2T@G>YAAC")+(^YF '!)[U:=XILAJTM#Y9_:FT>"Z^+7AVZU_3-<
MU/0([4B,Z+N!AFR<L^.HQVKT?]F:'P]#IVJ_V!9:W9QEQY@UG=N)_P!G-;WQ
M>^/.B_">>TM;JRNM5O[@K_H]G'O,2$XWMZ"MCX<_%;2?B)+?6]E!/9WEF5\Z
MWN$VM@]&'L:4=FD.6ZN=Q1110 4444 >&_M/_P"I\(?]A6/^8KI/VB8TF^!G
MB>*10\4MB4=#T93@$5S?[3_^I\(?]A6/^8K?_:4G>T_9_P#&-S&AEE@TUY4C
M'\3 9 H \3\'_!'X-?L=?#+4_BS!I(TZY;2 9[G[S+O095!VR36A_P $^?C]
MX6^,WPLGTW1RZW^F3R&YMYADX9B5;Z<U\?\ [/\ \?/B_P#MF76L?"'7-+MX
M?#,^GF*6:6U*^0B@ <GO6SX]^%WQ5_X)P_"7S/APT6M'5;O;>ZA':[Y8AU7(
M].U 'W!\ _\ DI'Q'XQB]   QZU[J1D8KXR_X)K>./$GQ)\%>(_$7BZ(PZ_=
M70\X-'L)'8[:^PKS5[/3Y%2XN$B=AD*QY(JHQ<G:*N5&,INT5=GQK^U[\+/C
M!XQ^,O@.]\ P6EOX>TBX%Q(&FV-/(3\P8=QMK[&T*!H-*MA+;K:SM&IEC3H'
MQS^M?&_[77B'XN:A\9/ ,GP]M1+X<TF=;F[E60CSR3AD(],5]>:5XKLKNPM)
M+B>."YE12\1/W6(Y'YUO*%5I)I_B=4H5Y12:E^)N44@((R.12US'&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!X9\>?^2G_"G_ +"W]#5?]K?X
M3Z-\;O"VF>#=;79::E.5^T(H\R-@."#5CX\_\E/^%/\ V%OZ&NL^*7_(P>$_
M^OS^E 'P7HO[!'A;]B[Q!H'Q"U?Q,=1-KJL>V:1=D<$.>2V>IQ7T4O[8GPM^
M/VI6OA[PCX@6\U:TU!/W$B%/- )R4SU%;7[=7P\@^+?PVT7P==3/:V^KZG#;
MF>/JA)X-?*_P6_X)IW'[-_Q,TSQMK'B(:@MGJ"I8V\*XW@]&;_"@#].[<$01
M@\':/Y5)3(G+Q(QZE0:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 57O;"VU*!H+N".YA;K'*H93^!JQ10!YUXF
M_9[^'_BT[K_PU9A\Y\RW7RF_-<5W.D:5;Z'IEM86BE+:W01QJ220HZ<FKE,E
MD$4;N<D*"QQ1L@/E;]KK2;FWUZQU#3;F\T6YNX!;W&J& RVHC#9"O@$CFNZ_
M9D\-VL.GWNOR>+;/Q?K%ZB0SW-D1LC1/NKCJ/QKG/C=X]/B"32HUUW5]#\/W
M 83P6&GL]S+@X/.#M%=%^R[H7P]T'2=5B\#Z=?V3R2[[V748F269S_$=U$-F
M$]T>YUROB3XH^%?"&KVFEZQK=K8W]T0(H)&^8Y.!GT_&NJKY!?0M$\2:K\=K
MWQ%%#<ZC9RNEJ]PWS0QJN4V>G/I4MV_,=CZXENX8;5KEY46W5=YD)^4+ZYKD
M/#?QE\&>+]:.DZ/KUM?WXS^YBR3QP><8K@_#KW>N?LKVUM-J$5EJ%SHWEBYN
MGP$R,!F/I7FOPOM]4^!/C;P'X>U2VT#6;/7HS##?Z5#MGADQG<Q_B4^M7:TW
M%DWO%-'I/[3_ /J?"'_85C_F*Z;]H4X^"7B/_KT_PKQ[]H'XNZ?KWB?PSX?B
MTW48KB'6$0SRV[+$<'J&Z5[!^T+_ ,D2\1_]>G^%(9M_"WPYI6E>#]&N[+3;
M6TN9[&$RRP0JC/\ (.I YKJKVPMM2@,-W!'<PGK'*H93^!K&^'G_ "(?A[_K
MPA_] %=#0!X-^SY#';_$/XBQ0QI#$EX J1J%4#GH!7JLUO%<>- )8UD M3@,
M,]Z\L^ 7_)2/B/\ ]?H_K7JQ./&F?^G4_P ZZJ&CE;LSLPS:<VOY61Z_96\>
MHZ4JPHJF4Y &.U+XMT^VCTK>L$:L)%((7!KRWXP?M(>&?AGXT\'Z-KVZVO=7
MNS#;(6')[$^U>G:Y?G4?#QF,30Y=<*W>NN"FI4[O;?7S.^"J*5*[VWU\SHK/
M_CUA_P!P?RI\LJ01M)(ZQQJ,EG. ![FF6?\ QZP_[@_E6/XUT";Q3X>O=)CD
M2.&\A>"4N#G:PQQBO-MS2M<\=J\K&C9:WIVI.4M+^UNG'589E<C\C5VOC?\
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MHW#B;4+M,M'SS&&[*/2M53G*/,EH6H2:YDM#ZGHHHK(@**** "BBB@ HHHH
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M6O/?AY^T3+XG\6V.BZYH$^@_VM$;C2IY3D7"9X!]"1SBJMKR]2;Z7(/VG_\
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M(=5CTV6[B.)(HVR6*GL>*QOA%#J'PX^-.L> ?[8O=9T9M.34(&OY-\D3EL,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.JGT)Q7B_CO]F3PA\0/BEIGCO4)2-6T\@Q*DF$8#^\,\T=4N@=&^IU>F^+/
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M.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR2+#&SNP1%&2QZ 4
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MQC1LY(% $2_";XD@<_$7)_ZX&E_X5-\2/^BBG_OP:RD^ _Q'*+_Q=V_.0/\
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M(&.E?,/[0+:5J4_PLU33;>V$5UJ,<J2PQJ,@C/45].0_ZE/]T5LG<!]%%%,
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MZ"O*_P!E'_DD-O\ ]?\ =_\ HUJ]:U'_ )!]S_UR;^1KR7]E'_DD%O\ ]?\
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M?@SZ/_*O&CUKVGXT?!SXS_%[Q!H^IO8:%8'3@<()V._-<=_PRU\9O^>>A?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;/IEU;-OTJ^S\LL;$8VYY.*RP6'FY*K)/7:WX^C['U-E"/+_ %;^MSVJ_P#
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M;ZK8WT/FQ/O!_>Q>AZU]!?##X?6GPQ\&66@6<C3)"6DDE;J\C'<[>V237/\
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M%U/9R=%JZLM.S\GV_!CWN%%%%>04%%%% !1110 4444 %%%% !1110 4444
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1BH&%%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>cvac-20231231x20f041.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f041.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )5 =8# 2(  A$! Q$!_\0
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M04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT_.E_P"'@?P/(_Y'2T_.OP"2QLR@+.F?:K%O9Z=MVLT>?4T<H<Q^^Q_X* _
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M\+?VI/AQ\9=<DTCPGXA@U2_CC,K11GD+ZUZS7XP?\$?[:WC_ &A]6:*17/\
M9S  =J_9^H:L-$<LR0(7D8(H[GI2+=0OC;(K9Z8/6N6^*NM3^'/ FJZA:QI+
M<0Q[D23H34G@!AK7A/1]4N85CNYX%D<(3@$]:SYUS\G7<W]E+V7MNE[?.USJ
M>M+115F(4444 %%0M>0)$\K3QB-/O.7&%^I[5 ^LV")$QO(-LO\ JVWC#?0T
M 7:*J:?JUGJR.]G<QW*(Q5FC.0#Z5;H **** "BBB@ HHHH **** "BBB@ H
MHHH **** /R;_P""U4)/B+P&^/EV2#-?FI;VL<L$V1\WFJH-?J'_ ,%D],_M
M+5O!"[MI42&OS^^ GPLOOBU\2K?0;8'[*DHEN) /NJ*M=R;E_5_@Q)#X,DU@
M3%FCC$C1=P#7E36B*3MZ!.OK7Z\V/[,UEXU\#Z_HFGP@W#V9BBD [JO_ -:O
MRQ\0>!;[P9KVL:/JBF.[L7>)E/L>M4G<G8L>!_!<7BK7!:;_ "5\L,3Z5;^)
M/P['@K5K*"1C+%,I>-CW%?0'[$OP8G\56NJ>*]1CQ;+_ */;[APQKT/]MG]G
MR^N_AQI/B_0;4L-))BNE5?X<=:=];"/SZ,2^:!T!R,5Z%X'^#=QXJT*XU99C
M#;QY"ENC&N0M-%N-5:SMK52]Y<2"-4 Y))Q7Z@>$_P!E<>%?@QX<T>]C:+4I
M8A<RD#U&<&E\(V?EMJ6GK86UU$>9(YRF:_>;_@FHFS]E#PN/]ZOQK_:B^$=]
M\)/',ENREM-U _:(9,=^XK]G?^"<<0B_98\,@=PQJ64CZ>KD=?TN"[\7Z9+.
MJNFPIM/>NNKD?$#^?XMTZT+%2\;$,.H]Z\G'J3A#E_FC^:-Z=;V+;[IK[]#I
MQ"EO:&.-0B*A"J.PQ7\X?[6,93]HKQ\&'/\ :$G_ *%7]'<4)M[(1ES(53!9
MNIK^=;]L#3MG[0/CRY#\?;W&/QKU$KF+/-O"/AM/$&N6]FAV;X\DU:\=>!)/
M"&JI;SY967<C=F%>P?LI_"N3Q2UWKUX"+2("&,XQDU[9^UA^SG<Z[\.-/\3Z
M# 3)IB[;A0.2GK6J[$/<^$+2!&D3<,C#8%>B^!_A4/%6BM<I,4EYV*!UQS7#
MW&GRPPVJ0_-/(VP*!R237Z _ GX.Q>&O"VAVUY"&NWB$DRD<C=_^NC8&?GWJ
MNFI837D)7]Y%)M.>W-9L-J)V">KXXKZ&_:T_9]U7X1^,I-0.UM%U63S8F[J3
MVKC_ -G[X-ZA\6?B78Z=:QE[&&02W#@<!12ZW'?0YC6?AC>Z+X=CU*X&Q) '
M"GJ!ZT?"^-5^+/A$(,#^T;?_ -#%?;'[0?P.AU30[N+3@R?9(/+$0'!*C_ZU
M?%WP@MY#\8?#5O<#;)%J<*$>F'%)Z@C^E7P__P @+3_^N"?^@BM"J&@#;H=@
M/2!/_015^LRPKYY_;ZC,G[*OCH 9_P!#-?0U>!_MT1B7]F#QNC<!K-A0!_/!
MIX22YA1P",G(-=7HO@ZXU+19+Z&WDEA20AF49Q7.2Z>UC?P(C@L_>OLG]C/P
MM8^)[6]T:[Q()#M QQDUJM"&SXXU&PBMC(J@YW=^U.TZT6;9'_$TP7-?2'[3
MO[+&H_#O7YKK33YEE(Q=HOXE^E> :%I-QJ'BNQTV!"\DDZY4#D>M/?45]#K?
M%?PIO/#6F17TL1>RFCW"51P#CH:\[U"!(_+"KM^3/UK]2='^"=A\1?A"_A]H
M\3K ")2.0<5^>/Q-^%&H?#SQ/=Z==R">W@)195[?6EN@3L<QX5\'S^,-6%E:
M_P"M*Y ]:36O#,GAW5ELKN-HYTR&1Z]K_9+^'4^O^,'U9BPLK=@@X^^:]K_;
M&_9SDO\ P]!XQT&VQ/;K^_B4<D8HVT'?4=_P1X7'[1>K8Z#3W_G7[55^+?\
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ME,C@&NM^#VDVTUAJ6NZY+9[]9N3/';>8&" =![FBGL[>7Y+\]?N1=6W-O?\
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M)CA"0KGE<=.:[#QS^V[J\7Q%M='L;@1Z'$#%/)CE3C&:.4+GTY\)O'EOJ_Q
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M5US4+]?&UD@N9"X78W _*OIT_P#!4SX"#_F9)?\ OPU _P""IGP#/_,R2_\
M?AJ+L+(^55_X(Y>,P1GQU9D#ML;'\JZ7P5_P2:\5^&QJRW'C&SN$O;<PC"'Y
M2>_2OH7_ (>F? /&?^$DE_[\-3A_P5(^ A&?^$DDQ_UP-%V%D?*S_P#!'/Q@
MT;*/&]EDY .QO\*_0K]E_P"#MY\"?A!I/A"_ODU"YLP=T\8P&S7C[?\ !4?X
M"J.?$DG_ 'X-?0OPC^+GAWXV>#K?Q/X7NC>:3.Q5)2NW)'7BD[]1I+H=I6-X
MA\,6OB-$6X497HPZCZ5LT5(S \/>$8/#IN3!(S></F#>M?G3\8?^"5'BOXD_
M$S7_ !)!XQM;:VU&Y:9('5B4!.<=*_31CM!)Z"OGGQ5^WA\)/!OB&^T74]<:
M&_LY#',@B)VD4U?H)VZGQ$G_  1T\9131NOCBS 5@W"-V/TK4\8_\$B?%WB3
M5TO(O&EG"!$J,"C9)'?I7U;+_P %(?@E",MXA?\ [\FJ,G_!3GX%1G#>(W'_
M &Q-5=BLCY+OO^"/7CS4C']H\?6<OEKM3*-P/RK5_P"'1'BU/!/]B1^,[)9G
MN/.DEV'D>G2OIB3_ (*C? 6+KXDD_" U'_P]-^ ?_0R2_P#?AJ+L+(^36_X(
MT^-",#QS9#_@#?X4J_\ !&OQIQN\=63<CDHW^%?6/_#TWX!X_P"1DE_[\-0/
M^"IGP#S_ ,C)+_WX:B["R/FKQ'_P2*\9:P\"1>.+5+:.,+Y3*V,^O2CP-_P2
M+\9>$?&&CZP/&]HT=E=1SNBJP+A3G'2OI?\ X>D? 3./^$DD_P"_#5=T3_@I
ME\#?$&L66F6?B*22ZNY5AB7R3RS' %%V%D?4NG6QL["W@8[FBC5"?7 Q5BHK
M:=+JWCFC.4D4,I]C4M04%><_M!?#*Z^,'PGU[PG9W:6-QJ,)B2=QPI]:]&KG
M_'?CC2OASX7OO$&MS_9]-LTWS2 9P* /RZ7_ ((Y>,0@'_";V61_L-_A3'_X
M(X>,V!'_  G%D,C^XW^%?8W_  \?^"04$^(GP?\ IB:K3_\ !2_X&V^=_B-Q
MC_IB:N[)LCY:UK_@D3XNU+0=+TZ+QI9I]DSN8H>2?PK!'_!&KQH/^9YL?^^&
M_P *^MV_X*A_ 9>OB23_ +\FHS_P5,^ 8//B27_OPU%Y(+(^;O#7_!)#QAX?
MTC5[=?&EDUS>H(UD"-\H[]JYP?\ !&?QD!C_ (3BR_[X;_"OK/\ X>F_ /\
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M_P"]=_\ H)KL?@C_ ,DNT#_KW% "_%O_ )%^W_Z^$_G4'C[_ (^O"W_75_\
MT"I_BW_R+]O_ -?"?SJ#Q]_Q]>%O^NK_ /H%>C2^&'_;WY')/>7R_,J>&_\
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MYKWBTZZ]Y(LT9\M$)R-H/0BOU6\-?\$H/ASX8U%[NWU;4G=HS&0TG&#64_\
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M+CJ*_03_ ()_?\FN>$,_\\*^0?\ @IE-!>? C0YULQ#>K=>5,R+P<#J:^O\
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MG)ZYI15X.WH.6DE<^;+47FD?#272;O5[NZT]O$[V]]?2N=_EY'!/85V?PO\
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M\0_%NOW=K:S7]Q>W;%-@R<9XKZ0^+O[0S^*_A3<QZ:)(4NK@VX<MU4=:^?\
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M!OC'\+=<\(K>?8&U*$Q?: ,[/>O0*Q_%GBS2_!&@W>LZQ<K9Z=:KOEF;HHH
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M!^V/^S%H]_JMCJZB6SO+A,,T/  QWKZ>_8G&G^*_@[8ZO-90S:QY89IU4;F
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ME#FO#IWNVV[GY3?\%F;8WGBCP!;J,F5BOYD5]"_#K4(M+^"?ACPK;HMLKV:
ME1R#M&2:\0_X*RPK=?&#X36TG^IEN,-^8KWG2+>.W\.:9''&!)%$H&1R1BN8
M[C-M->NOA]X<U^[6-WNHK250W4R*5/-?EK\%/#;?$K]I;1XI,XFU-KEP>V&S
MS7["Q:;:ZYH&HQ20[Y&M73D< ;37P+^Q1\/K.Y_;0U>QVA?LGF,BGMSVJD]V
M2?I1J?AMKC6=&F;8MI81!56(8W$#O7R9_P %#?$FI^'/@WK5C#*1:ZE*OFJA
MZ#/>OL_6-/GT5'3?Y@!X)ZBOE;]N;P9_:GP%\2ZC<MYK1A70>E1'<IG@_P#P
M3<^((G\$ZKX7:S$TUO<"1)BO(![9K[KO[*)=1LY9T$T;IAX7&0!7R)_P3D\
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M]>_3Q&!JX^662PKBVKQFFVG&WQ/YGYZ\XQ]+$*%1+XK-==_QTU/C7]EF:_\
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M;>W0U^=O[.-U!9?&'2+NZR8H92QQUK]6?AA\-];^+U]'J%TZZ;X3AE#&%O\
M6W..Q]J]C+\36PU6ZA#V=FW*6K3Z1BN[^X^6S:&-K5H4<))QNM6MM^K\NQ\R
M_%C1/$.M_ #5M4U^2>YLX+G%G/= [G'J,]J^>/V1;KQ)%\5YQX;?]^$#NC'Y
M6P>]?IC_ ,%#;"TLOV>+J**..T@MP$AAC    KX%_8+\,7?B+Q3JKZ7<K:ZJ
M6$<3N/E_&G]9IXC&?6*D4HM[=/*]OQ/5K4J]+"2IX>5ZB6C?<^GO$W[0OQA\
M17%YIE[J:Z3!9)N?R4&, <#/>OF#]KC2M6GT;0]?U]#_ &C>0-^\==K.O8FO
MT9\!_LCZY'XFEU_QQJ%M>6$9$AL[3I*1R-WM7R%_P5(O(FU71[>.%8 L?[N-
M1@*HZ "O2S7%X.<(T,)"/=M+\$<.64<<KU<=+5Z)?FS2_96U'XG:5\#+./0K
MZ/3[6Z4J&<?.%]JZF^^'<&F:%<WE]X@N?[6'[SSGD.UY#U '>J?[/?B_5'^%
M_AVU_L2XNBL($$MK]U_]ZO<-'^"][J 7Q!XLC"3(,VFF Y5?]IO>OF:.,SE5
MY4JD84*$6FIPLYU$MHV=_B^TVE8YZ^%JUZU-PJRD]>9-.,8.^EFOBTU7XGSI
M_P $][";3OVS=46X39-)9N[<8SGO7ZZU^8G[,%FMC_P4$U>- !_Q+B2!VK].
MZ522G-R2M<^HAI&S.:^(Z[O!.K#UA-4OAWI,$WA#2I)E$P\E2$<9"D=Q5WXD
M2B'P3JSGHL))IGPTF2?P1I#KC#0@XK/V6GMOE^IS<W^T\O\ =_4Z<# P.!2T
M44CL"BBB@ KDOB-\0;+P!H<MU,RR73#]S;YY<^N!SBMG5O$=AHT%P]Q<QJ\*
M;C%N&[VX]Z^6_%WCMO%?C'3-2U<1:=&URUK82Q_,8QG#+.OHWK2U;444M$VR
M6'3_ !5\5_$EWI.K76G?V>"MY]KC?+6\?4JA[\=0:N_$GXBW$EMIFD^#':UT
M:RWHTTJ_NKLJ.53UQW!K8\4QZ!I?VCP_<6DG@VY5?M-EK%L3Y-R^.03Z'T-<
MGI^F/X5\-6'CN\5FT.%GCFT1QB%Y&^7SH\]-U&EM-E_7_ #K?J=%\&HM)\0>
M$]:E\.WFGCQS)&6:(]8&/0CTS[5%\// VK:QXEGO_'EE%Y>E#BY8<3/_ '?]
MH5A?"/X8Z7K.O2ZUX>OIO#T<DQGN4W_OXB3D*IZ%#7LOC;7?MD,MHP$NG6H7
MS),XE=A_&OK790H.M-=/T]#@Q6*CAJ<GN^G_  2*]UO4M<N;.*R2UCL;D-#'
M:MP !_?'\/M4]Y./"6B2Z5I[F34S@W%PHRL>>Q-65DT^QTVUNKFS\^WOH]LF
MIP @H>Q([5D6^AR7[7[VM\TD=H%<W2C(N8_[C>I%>Q'DM9JT5^.O7^KGS4G4
MOS)\TY?@FNGKW6BVW'^#+C3[S6R^KS0+J&0D*M_RU-3:KH&O:CXD6TOHTN;2
M67>KH.$2LJTT[3_&.N&YLX/LMV0%*L<JP'\2XZ&O7]'T]],L(H)+B2Z=!CS9
M?O&HQ%94)*:W:V?3T-,'0>*@Z;^%._,NOD[DMA80Z;;)! BHBC'RC&:LT45X
M#;;NSZU)15EL%%%%(84444 %%%% 'Y;?\%9+LP_&GX2$#.R?./\ @0KZ>%BM
MM8>'Y&P!/;(S#T^45\J_\%>)Y-.^*OPTU$)NCMF,C?@0:]T\(^.;;QMX.\-:
ME9W*R"6!5(#?=P.13Z$L];,L&@^&=3O)&528V6-?7BO@G]CEY8?V]-=O6!6%
M879E'O7U3XJ\30PV-Q93SD21Q^9EC\N*^-/@9\0%^'/[6%_XKO7@71+T_9RV
MX%L]B!32T$?JAXB6358YKJ([D+?=)Z"OG#]M.^#? /Q1I<,BRW)C#%5YP*]2
MO/BUH5_X6U&2VO@+AE+*@/)';%?(7Q[\9+I/PJ\2S370N[F>/(1FRZ@GTI)
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M2-SL&>U? WQS\-7'AS]O?PBUPI"74EM)&WJ,U]P7'B:/4M3M"MPIM%ER^3@
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M0DX..H-7M'UV_P##=VUUI]PT4C*5.#U%?J>G_!'CP$B;?^$DU(CZTC?\$=O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_FR$NK,W&IW>/^NY_P :F U7'RZI=D_]=S_C1R,.9'])'_"X_ __ $->D_\
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M_P"-?S?74U^N0-4N\_\ 7PQ_K5 W.K;SC5+LK_UW;_&CD'S']*/_  N/P/\
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M3PO+X=U&YM)W830-L92>]?:?[(/P+NO[*TS7+QRHN9!,(@,Y6JW[<W[(FO\
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MO]P?RJ6HK;_CWB_W!_*I:S+"O-_VCU#? GQP#T.ES?RKTBO.OVB8S+\#O&R
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M[+GAT?[3U^=7_!0Y+&T\;>&;73[=;>,VAE8(.,U^BO\ P3C.?V7?#O\ O/\
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MD6UWX.TF*6/*1H' !QS7)ROV_-Y?J8W_ 'UO+]3J0=P!'2DD<1QLS<J!DTH
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MX>*E)I]G^1S8J+E&*3M[R_,]4F_U,G^Z:_ +X_>%9?&W[5^I:)"</<ZNW)]
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M)=.URSLIB\T%K)N!& 1L/(]:SO@+_P DIT+_ *YM_P"AF@75E+]H#_D2X/\
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MD X%>@>/O^/KPM_UU?\ ] KAKNV:WM]4C:,0.L\ :(N#L.!Q^%=SX\^:[\+
M$9\U^X_N5Z2;:IM]O_;4<%1)3J);7_\ ;BIX;_Y)OK/^_/73?#S_ )%#3_\
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MS7S'_P $[/""3?#O6[LL599C&V.X!KZ=OVCN;(VS+M*M\OOBK>XD?FS_ ,%
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M'T*[T?7M%L=6BC\=-&6WSJ!Y6>A4_P"'2K'P_P#@EJJ>*9]6\;,7M-/7"M*
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M% J>BBI;;=V6DHJRV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>cvac-20231231x20f043.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f043.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $F ,8# 2(  A$! Q$!_\0
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MLXD1,>6@8$_GBI_&/P#O?$&K)<VNIK:P6VD+IMK%CB-NCO\ B*6O+]_Z_P#
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MG[,/CO0/#.I:/>:G<:EM=Y(!Q&A;''J: /<A\,+4#_D*:E_W_-+_ ,*QM?\
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M_P"$9)9-&TBUTUYAB1K=-I8>];U !1110 4444 %%%% !1110 4444 %%%%
M!1110!\C_%;Q9K1\5^+O$EAX;T2\\/>%F5-0AN( US?9QP#CWKO?@!HGB76-
M9F\7:AH6G^$M#O+=18Z3;1!9]IYW2GU]JX7]HGX56'AN[U?4;CQGKEA9>*)T
MC;1-,&XW$HZ <>U=/^S7>:PVNW-I>ZKXFO+2&V58H=94"-0.!MX'-%+;7?\
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MO R3V\7AZWL(DLI\'SA<HV[+?[.:Q_ 7PD\6ZQXK@UKX@36,JZ?9FPMK:S!
ME4C!9OJ*]YHJKZW_ *_K4FVEOZ_K0\U_X9P^&WG/+_PB=D)7^\XW9/U.:=_P
MSI\.?^A6M/\ OI__ (JO2*1F"*68@*!DD]J0SSC_ (9T^'(_YE:T_P"^G_\
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M[]"DNYX[\6/$UG\7=5TGQCJ&BWFAZ!:3E=#\8V$OF*'!P//1>3&2,5Z=\"?
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M;S2O-(B_>D.2/:M*BBOKX05.*@MD?-3FYR<GNPHHHJR HHHH **** "BBB@
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M?4XZGZFKM>M0P48QO72E-N[]>GW;(\ZKBI7M1;44K?Y_?U"BBBO4//"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ&F6NJVY@NX
M$GB/\+BHM*T*PT.-DL;9+=6.3MZFBBLO94^?VG*N;O;7[S3VDU'DN[=NA?HH
>HK4S"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>cvac-20231231x20f044.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f044.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #= AH# 2(  A$! Q$!_\0
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MPIKEQ\/TOVEU?4&@DT:8IR+<KEOKCI7%>-+S7/'?A.;7=8\7^2UIK,%HVC'
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MZ?%=:4R!/L[CY0!TQ]*'K%I G[R;/D;P?\3?&EKX@\1Z!;:Q-$TFD"]M7UC
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M1B"1[5ZA13N!0T?49=3M?-EM9+1LX\N3K5^BBD 4444 %%%% !1110 4444
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MSH?A*WL]2U YN9E?ES7;P:SXA>>-9-)C2,G#-OZ"NHHHZ6#K<09(&>#2T44
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MFA27@)@6X;!<#KBOE[]L[]O6R\%_![2_$7PD\2Z?J^H7-ZL3",>8?+QR<=J
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M6GCDU/\ L^,S&(87=CM7HE>>?L^:E?ZO\%_"%YJ5K]BO)M/C9X,YV<=*]#H
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M?BBH4 *-/P .U?.7QSN+*V_9?^+$E_?7>G6PU%LW-B"9$.1CIVKZ(L[N&_\
MB3'<6\BS02:?E)%Z,/45X1\3/$D/AGX&?$![JR@O;*YU62&<W)Q%$#C#-^-=
M5/XGZL,1_ _[=A^;-7X=RP3_  S^"SVT\]U ;>,K-<C$C\=37U'7S!X'UH:]
MX+^%5PMHEG%'MBC2,Y1E'0K[5]/UT1^)GG5OX5+T?YA1116AQA1110 4444
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M\7ZF3\,KV+3?A?IEU.VV&&WWN?0"OFC]LKXO2_$KX'^(=.^%GB&'^VK.:/\
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M2M9NI[:QU"WNYX#B6.*0,R'W%:= !1110 4444 %%%% !1110 4444 %</\
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M%QZ5^DVA:W9^)-'L]4T^9;BRNXQ+%*O1E/>LS0OT444 %%%% !1110 4444
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M2=;B8&2V@42P]]X8<X^M:)7E;Y?.[7Z$/X;KU^5DSUCXV_\ )0/AM_V$F_\
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MJW^]O_%^IRGAS_DA\/\ UYFNU\'_ /(KZ7_U[I_*N*\.?\D/A_Z\S7:^#_\
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M0YX._P"P@/Y5ST/XB^?Y'1/X3TT=!2T@Z"EKG- HHHH **** "BBB@ HHHH
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>cvac-20231231x20f046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f046.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 QX# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXED\EGC/-O;_ ,;GTXS6'^QT9?"&G^,?!]S=RW?]@WS@2SL68CKG)KBOA?\
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M:PRG^)0,U\JV'[/%M=6Y'_"2^)!*G+$Z@W/M4]A\!=$6Y-I<^)O$OF,N0_\
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M-.*"U^51QUWC[I-5&7470TK"X<K 7*&,D'8.N?6DU 1FYN%^=C]YCWQ44,Z
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M5ZWN)$M9G&)HU(&3U-)KJC)Q2:<2M!<IS;M )'!R2QXQ5B:UR5!0&-AE=O\
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M*E?EV'D*:J:KIO\ :GDQ"WBBXQO7C=6RJJ29=/%.,K2_#0XGS3?V4=O'$7:
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M9,T0SYF1U/M69]OT>^T6X@N/$=JM_"ZR+F=-OX<U OB#2O#VO1F\UBUNX)%
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M/[7H?RL?U*M92N=^O[-?P-4_+X9T8?2X?_XNG']F_P"!Y;)\-Z.6'<W+Y_\
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MP0.LNM'_ +?FK/ZQ$?/<W_\ AFGX%YS_ ,(OHN?7[0W_ ,71_P ,T? K.?\
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M)8K^[MI,/$]O,O'/*FLG0KR?Q#:^1/Y2%S\TR#.*W)M'MYK:*W66=WB;E@<
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MSCO5,[IT('[L#H!4Z2O;C+$$=FK-Q*;3V)9) D>Y2>/SH.]PDBC(/7/>F^:
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M.#%_B3\52PP?[2CX_P" 5D^/FV_M?^'.W_$G;^9K0_9CW'X@_%(LVYCJ4?\
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M_+J\R\#\ZJ*3V-*LG)II:,T#=(S$Y._&.:?;3G=&%;)'K6=J4-QHTL45U/:
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MMH$+R2-T4#J:M57U#3[?5+.:TNX5GMIE*21N,A@>QI.]M-QJU]3RP_M6_"M
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M_CPNCGH?M!J)OV=? T2_-I]T??SS_C6']LX?^1_@4LNJ=)(TO^&5_A,5*_\
M"676WT_M4?XTL?[*OPFC4A/%ETH/4#51_C6*W[._@C )LKKD\XG/%97B/]FW
MPB\)FLX+U)8E)""X;#5<<WP\OLO\#2&5SF^5S2.R'[+?PJ48'BZ[ ]/[5'^-
M-C_96^%$9)C\67:D]2-5'^->8Z+\$?"NI:(;Q;6\W1.1<!K@_*!7$>+_  )X
M*NM6L[/3HM0MH2V99A<-^5="S"D[^YMZ'J4>&,57FX0DM-_(^@Y/V5/A+*P,
MGBNZ9ASDZJ/\:23]E7X2R@;_ !7=-CUU0?XUP_ASX%^#);5?,LKUTXP\D[9:
MMX? #P*"H^P71+<?Z\XKGEFU"+MR/\#S:F45:<N5R1T,'[,GPNM5*P>,[V)?
M1=5'^-)_PS!\+"Q<^,+LL>K?VHN3^M8H_9W\#!<?8+IB/^G@U6_X9[\$";>U
ME=%,8VB=JE9U0O9Q9"RNH_M(Z,_LM_"N>)K9_%MW+;R\/ =4&UQZ$9KZ+\-:
M#I_AWPW8:3IBA--M8%A@53D! ,#FOA?XK_L_>'M$\%ZS<:4]U;W<<)FA=KDA
MEQSQ7UW\#YI9O@AX4DEE>68Z5&6D<Y8G;U)KU<+BHXJ+E!62.+$X9X:2BW>Y
MY#XB_9#^#%WXBU*_GU$Z?>WDIEN(X]0" N3R<9K-'['GP367S!KT@DQC<-3'
M3\ZX#X3?"_PKXQ?Q?K7B9+_4K]=5F5<3M@*&. *Z/4/@]X/EE@6PT*=1(<8>
MX.:'B:$7RR:O>UNHJ6&Q-9_NXNW=NR.@'[(GP9"E1XBF"GJ!J8_QH3]D+X,1
MYV>(9ESUQJ8Y_6LJU^"O@EQ^\T*YSG:2+@]:%_9Z\%EG+V%T 3D8N#Q7-5S#
M#T_A]Y^1I'"8C7VGN_/?[C7'[(WP;'3Q'./^XF/\:C_X8\^"OFF7^WY1*>KC
M4QD_K60?V?O!$S[!972J._GGFJ=U^S_X+C=@+2[X_P"GAJY7FU!?8?X&L<)5
MO92_,Z3_ (8^^"YE$O\ PD$WFCH_]J#/\ZLC]D_X1A=H\47.WT_M0?XUP$OP
M'\&H26AO%[<7#<5S^L_ _P )PS*ENE])*PZ+<M@5<,TH3VC^1U4LKK5I*//^
M9Z__ ,,H?"0?\S3=?^#0?XT-^RC\(SPWBFY(]#J@_P :\)@^$&A6]Z5EAO7A
M;Y<FX;Y37>_#7X">"[ZTN1=VU[<RHY!=KAB *]/#U88B5HHC,<LJY;AY8BI-
M-*VB\SNO^&5_A* !_P )9=8]/[4'^-*?V5?A,1_R-=UC_L*#_&JZ_L[^ ,?\
M@ZY_[_FO.?'G[/7AWPM<B_MH+V;39#\Z&X;Y*ZJU/V,.>USP<OJPS&M[",N6
M3VOU?;U/3E_94^$RC \5W0'MJ@_QH'[*OPF#9'BNZSZ_VH/\:\;L_@OX;UUD
MDB@O(+8'M<MEJZ%/@1X/"JK07A<=Q<-7ARS.C#1P?X'O5<JJ4FE*:OV['H0_
M95^$N>/%=UD_]10?XU8;]F?X8O'Y;>-+UH^FTZJ,?SK@W_9_\&_9\_9KO?\
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M3K^R_P#"M/N^,+P?]Q4?XTH_9@^%BYQXQO!G_J*C_&N>_P"&?? V['V*Z_\
M @_XT?\ #/?@4  65V3W_P!(-/\ MBC_ "/\#/\ LVI_,CI8OV:/AC I6/QK
M?(IZ@:J/\:C'[,'PK!8CQA=@MU/]J+S^M<Y+^SSX%8J19W8 _P"G@T]/V?\
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M'6HWCV.&5=F!T]:T<;V6/;E ,9)IT-NDUPL+,#SU-9)N3&JO+JRYX5S/J4>
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M8K*A\QC\Q/4^]<_XJU+^PKB&6&XLS!(=LO[]#@?G79:3J%I<6<,\=[9["O\
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)% ' HHJ!H__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>cvac-20231231x20f047.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f047.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $0 0D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]*?B9\2]!
M^$OA"^\2>(KQ+/3K1"S,QY8]@/4FOS/^(W_!4_X@>--?GT_X:>&O+LPY$4C1
M-),X]2!TK3_X*[?%&]GU_P -^!+:5DLPGVJ9%/#L3@ U],_L%?LV^'?AI\'-
M&UJ;38+G7M5A%S+=3(&90>0!GI448NLI56_=3LO,TJ-4N6"5Y/4^*;3_ (*-
M_M _#W4(I_%6B)):L?\ 5W5LR*P] <5^A'[)_P"UOX>_:@\+R7%DAT[7+, 7
MFG2'YD/]X>U=C\9O@[X.^,?@O4?#FMVUB/M$12.?"B2%NS"O#/V5?V#]"_9N
M\9OXAL?%<VIW\T9B> . CKVR,\XK:G*[<9K3HS*HM%*#UZH^OJ***@84444
M%%%% !1110 4444 %%%% !1110 4444 %%,,J*<%U!]S3@<C(Y% "T444 %%
M%% !12$XZ\4 Y&1R* %HHHH **** "BBB@#\A?\ @K/X?N=*^..A:P\;&TN;
M1=KGID-R*_1W]E/Q59>,/@!X0O+&5942Q2%MISM91@BN-_;>_9<3]I;X9&UL
M62'Q%IQ,]C(P^\<<H?K7YO?"']H/XR_L.ZI=^'M2\.W5QI D.^PN(F9 <_>1
MAZU&'DH0G0GIK=?U\S6O%U)0K1ULK/\ KY'N7Q__ &0_VAO$_P 4_%'B'0/$
MLEMH,TC300K=NNU "< 9KQC]AWQSXPN/VL="T;5_$FHWL4,LL,T$T[,A9>#P
M377?$G_@J/\ $SXCZ/)HOA7PQ)H4UTIC>>.%WEP>"%XXK0_X)]?LK_$:;XRZ
M?\1]=TV32-(MV>1WO!B2X=NX%:X2+A42?PI=3+%2YZ<OYF?K/1114@%%%% !
M1110 4444 %%%% !1110 4444 %,E.(W(Z@&GTR7_5/_ +II/8:W/B;X=_#C
M6OCM\1?B'/?^.-8TQ--U(V]O;VDA"*OYUVGPT\5>+?@I\<Q\-/%6NOXCT#4[
M5KO2M2NAB6/;RR-]*X[X$?&SPC\*OB/\4K3Q-J#Z9<3:L9(UD@<AEQU! IU_
M<WO[3_QHU+Q)X9L[F/PWH&CSVUIJ$T9C^TW#J1A,\XJ*;<84W'5<MW_X#_G8
MNHKSJ*6GO:?^!+]+GKVH?M@^%;/5+E(M,U6\T6UG^SW&N00$VD;YP<MZ"N@^
M('[2/ASP1<Z196MO=^(]3U2(7%K8Z4GF2/'_ '\>E?&7A$66E?!G4?#_ (@^
M(.LZ5<1RR07?AN*W!>1BW1>,G/K7H'BOP[X0TI/ -G)K&N^!/$MKI@_LSQ(5
MW H>?+D/K6G1?+YZ-^G_  /,G2[^?X-?,^@%_:J\')\.+[QE=+>65CI]R+6\
MMKB$K-!)G&&!KGK?]MSP2=3BL[VQU73OM4?F6$MQ;D+>^@C]2:^>M=\8>(_&
MWP1\5:5KD<6N6=AK5O'#KMK;;/[0&_DL,<GWKU7XP:3;M\1_@=&-/5XHF3 $
M.0GRCKQQ32O+R;2^]7%:R?DI/[GL=W9_M(^&?B;X5\96135/#=]I%H\MU!<1
M[+A(L?ZQ!WJ*W_:5\(?#/P?X'L;JYU'5Y]:L1-I[>7NFN0/7WKS'XN6Q3XX?
M% QVK@-X0(W)'PW7CCJ:S/ 6GK<^/_V<S/9-((O#\F#)%D1G'?(X-*G[]NE[
M7^Z?^0YKDO?6U_RC_F?2/PB_:$\/_%[4-2TRSM[S2=9T\_O].U"/9*H[-CTK
MU&OF?PO;"']M/Q&Z6YC5]+7=(J85CQW[U],4TTXQDNO^;7Z$M<LY1[6_%)_J
M%%%%( HHHH *Q=?\%Z#XI4+J^D6>H@=/M$(:MJB@#C=+^#?@?1)Q-8^%M,MY
M@<ATMUR#781QK$@5%"*.BJ, 4ZB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *.M%% '-7_ ,-/"NJ7;W5WX?L+BX<Y:62 %F/N:VM-TJST>U6VL;6*
MTMUZ1PH%4?@*MT4;:!N<]>?#[PU?ZLNJ7.AV,VH*<BX>$%\_6K>O>$]&\46J
M6VK:9;:A G*I/&&"_2H[_P 8Z-IFKVNF7.H017MUGRHF<9;%+KWC#1_#*V[:
ME?PVHN)!%'O<?,Q[46T2'U'V_A/1K32TTV'3+:.P0[EMUC&P'UQ5F?1K&YEM
MY9;2*22W_P!4S("4^GI4&M>)M+\/:;)?W][#;VB#)D9QBGCQ!IQTH:E]LA^Q
M&/S?-WC&W&<T7W8DNB'3Z%IUS<33RV4,DTR>7)(R EE]"?2DBT#389;62.Q@
M1[5=D#!!F-?1?2FZ#XBT[Q-I\5]IMU'=VTHRKQL#FM*C8-RHFE6<=^UZMM$M
MVPVM.%&\CTS5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $
M9@BEB< #)-?/6N_M?:*GQMT3X>Z%:OJDMW(4NKX*1%"1_"#W-?0DB"1&1AE6
M&"*^6?C=X;TKPU\<OA?'I=A!8B:\=Y/)0 NQ/4^M*/\ %@GLW8<M*<VMTCOO
MCO\ '+6OAWXA\.^'/"V@KX@U_5W.V!GVK&@ZL36_\(/%GC[Q*]^/&GAF'P^L
M>/L[12[_ #/7O7GWQ>^"VC_%;XX:/>2>-9M%U/3[(J--M'V3.A/W@:Q/@KXA
MU_X;_&GQA\.[K6KGQ9HMA8KJ%K-.WF3PD_\ +,FBEKH]W>WR_P" @JZ*ZV5K
M_/\ X+/J>BO)? W[05GXO\;)X7N=$U'1]1EA>>'[7$5615.#@UZU3$4I=9L(
M9&22\@1U."K2 $4W^WM-_P"?ZW_[^"J]SX2T>[G>:;3X9)7.6=AR34?_  A6
MA?\ 0,@_*@"Y_;VF_P#/];_]_!0==TTC_C^M_P#OX*I_\(5H7_0,@_*C_A"M
M"_Z!D'Y4 ?)WQ:_9AU3QI\9(/%FD^(1;:3;RJ\EE]J_U_.6(YXK0_:1_9LO_
M (MZEHDOAWQ"-)2PC5IF^T\2D?P8S^M?4/\ PA>AC_F&P?D:/^$+T,?\PV#\
MC4I6BHKH[E<S<G+JU8^;OC+^S]<_$7X3^'?#6CZU_9>JVR@3W1NL^7Q\V>><
MT_\ X4)<+^SR?!8U?_BH=V!>?:^XX#]>F.U?1W_"%Z'_ - V#\C7G7Q)^(OP
MX^&%Y:6FKBRBNYY5B\ICAE!_B/M3E:7,G]IBC=<K7V4<O^RG\(9/@;X?O;'7
M-<34KXOM2[>XRKIUX&>.:]Y_M[3?^?ZW_P"_@KR_QK\1?AKX*\*Q:[=M8O:S
M*&@ ;_6@GM4W_"=_#3_A"O\ A*/,T_\ LWR]_F9XW8^[GUJI2O=OH3&-K)=3
MTK^WM-_Y_K?_ +^"C^WM-_Y_K?\ [^"O+_!OQ#^&GC7PO+KEHUBMM"I:;)_U
M8'K3/AM\1?AO\4+NZM-(6RENX)6C\D'+,!_$/:BSOR]0Z7/6+;4[2\?9!<Q3
M-UPC@FK59NG^'=-TJ8RVEG%;R$8+(.:TJ0PHHHH **** "BBB@ HHHH ****
M "BBLW7O$6F^&-.DOM5O8;&UC!+23,%%)NVXTKZ(TJ*^>-:_;:\%V=ZT&E:?
MJ^OHIPTUE:.4'XD<UUOP]_:>\#?$.\6QM[]]-U,];/4(S"^?0%N#5)<VPG[N
MYZU7"^-/A)I/CCQ=X>\07KR+>:*YDMPAX)/K7<@A@"#D'H12TNJ?8-TUW/*O
MBS^S[I'Q.UFPUV.]N=$\162[(M2LVP^S^Z1W%7OA'\#M%^$JW]S;2S:EK.H-
MOO-2NVW2RGTSV'M7H]%$?=T0/WMSQ?Q2?^,G/"([#2KCC\17M%>+^*?^3GO"
M/_8)N/YBO:* "BBB@ I <UY9^TCXO\3^!_AG?ZMX6A@N+R-2C12J69MPP-F.
M^:\I^ /Q6^)OB'X(ZQJNL65K:ZMI496."\1O-++DMO\ 7VQ4J2:D_P"4IQMR
M^>A]4@YZ49KY%_96^+GQ1\<3>)(-?L(;%;<R3PB\1@SYY7;_ +-9_P $OC7\
M5/%7QVUC2-5TZ&UT>61MD\L;B)E7_GE_]>M%%N2CW5R&[)R[.Q]5:IXGNM/O
M7@CT:\NE4?ZV( J:\%^/'P(LOCWJ]C?:GH]_9FR7,9CB&YI,\%CW'M7$ZY\<
M?BQ:?M+IH4.G6YT19/LOVKRW^S $]&_VJ^S;?S/(C\['F[1OV],]\5"2G&-3
M[BVW"3@?-OQ-^"5I\5/A_HWA+4M$O+>SL %DE@A"LX P I[<\T]?@S"/@Q_P
MKLZ+=&U!V_:O(&[9_CCO7TG13>JDGUW)3Y>6W38^:?AG\$;7X7> M8\*:?HM
MW<6E\I6.2:$%DR.<GO47P(^!-E\!-9U"_P!,T>_O/MJ[G\R(;DD)R2I[#VKZ
M;HIW?-S=;6^0K:<O3<YW3?%-U?7B02:+>VRMUED7Y171444AA1110 4444 %
M%%% !1110 4444 %<7\1/"GA7Q9+I=MXH>*2-9=T%K/)M25O0CO7:5Y/^T2W
M@F+PG%)XRDFC42?Z(;0D7'F?[&.<U,G:S*BKNQ#\4?'.G?!^QTK2_#_AVUO-
M5U%_*L[1%6-#]6KD_!]SH7QLUK4/#WC3P?:Z/XJTP+,6MV!(&>&5UKRJ*6\\
M<Z&UK9R77C?0=/<.;2?,&JV0]5[FO;?V:X? $4&H'PP;P:R3_IT>J,S72>S$
M]JTBM6Y?\'R_X?4F3T27]=_^&/:[*T6QLX;="S)$@0%CDX%3T45.X;!1110!
MXOXI_P"3GO"/_8)N/YBO9G!*, <$C@^E>,^*?^3GO"/_ &";C^8KVB@#DWT'
MQ&9&*ZU&%)R!Y?04G]@>)/\ H-Q_]^JZVB@#CYO#&O7*[)]5@G3.=LD.1FF?
M\(GK*B0#4;55E_U@$& _UKLB< D]!7/S^.M"1Y87OT#*2K#!X/Y4 <PRR6FM
MQZ6->L(=2DC++&L0!*#M1J,+:#>6%O<ZYI]I<W#F.V'D@-NQDXKYC\1? Z_U
M'X[1^,+7Q%,F@1W !L3.^YD)RQ![#/:KG[0OP8O?B5\0M.UOPYXBDL;&P5)'
MA:9QY[9 91Z<=Z47=0;ZO7R*:2<DGLM/,^D=;M7\/6@NM2UK3X(7D7]X\(RS
MD\'/K5N_&J:9ILE_<^);>.S1-[2E>,5\[?M%_"-_BIH/AK3_  WK\NF2V4*B
MXE>9R/D'RJ1W).>:L^/OABWBKX%:3X3L-;FM-<0!)KAIW(7U8^M)W496W3M_
MP1*S<;[-7?EY'T+IMKK.L6<5U9^(8)X)%W*Z)G(K<T/3=6LIY&O]02[C(^55
M3&*\7_9ET:V^$G@8:5K>L-=ZDC[6G>1G#CL0#TKW/2=>L=<1WLIQ.J'#$ \5
MK-).T7<B+;6J-"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "O(_C[X!A
M\:1:)+;>((/#WB"QF:73YKG!C=B,%2#UKURN5^(7PVT3XF:-_9^LP%U4[HIH
MV*R1-_>4]C4R6S70J+[G#?!KX,:MX0U[4/$WB;6XM9UV^01EK2/RX50=, =:
M]&O(_#WABXEU6X6RTV:0;7N6VQE_8GO7@=Y^S5\2-&F\GPQ\5[ZVTT?=AOE,
MK*/3-;?A;]EEY=1@U+QWXKU'QA=1,&6VFD*VP([[:TOS6Z)$6M?K<]ZM[B.Z
M@2:)@\;C<K#H14E1P01VT*11($C0!54= !VJ2D_(%YA1112&>+^*?^3GO"/_
M &";C^8KVBO%_%/_ "<]X1_[!-Q_,5[10 4444 <Q\2?&\7PZ\%ZEXAGMVNH
MK)-[1(<%N<5P?P&^.6D?':+4Y;71?L!LR WFJIW9KT[Q/X:L/%^B76DZG")[
M&Y7;)&>XK$^'_P */#GPQCNDT"Q6S6Y(,@7OBN&<<2\3&4)+V=M5UN>_0JY8
MLMJTZM-O$MKEE?1+2]U?UZ'4_8+;_GWB_P"^!37L[2)"[00JJC))08 JS7F?
M[0^L>*-(^&&IGP?IK:IKLZ^5#"#P,]2?;%=DGRIL\:C2=:I&FG:[MKL=1IOB
MGPKK%^+&PU'3;R[()\B"1'?CKD"MS[!;9S]GB_[X%?G)^RI\(-8U_P".5UXK
MEU.'P3XETUA!>>'@2WV@#[S@9X!K](AT&>M13FYIMJQU8S#0PLHQC-2=M;;)
MWZ/JO-$!T^U/6VB/_ !4D5O% "(HTC!Z[5 J2BM3SPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *9+(L,3R,<*H))]J?3)8UFC=&&58$&D[VT&O,^0_&
M/[77Q 77Y5\+>!X;S06OSIMM?7,I7SI@<5Z=^SC\6?&?Q'N_$-KXTT>VT#4=
M-F\K[#$^6Q_>/M7COCGPMIGA.\UOP2?B!8PW]Y?_ -J:#9$$R6UQG=M<CH":
M](_94\.:[>7_ (@\8^*-?TW6-;OF%L\6ED^7"$XPP/.[BJHZQUUT_P OQO="
MJZ/3O_G^GXGT1+((8G=NB@DXKY-\0?M*>,]5_:!\,>'M/T2?1O!\UPT$MY>)
MM>Z8''RCTKZT(R,'I7S/^T05B^.OPHC&%7[4V%'%3'^+3OLVD.7\.=M[&K\8
M/B'XL\0_%K2_AEX+O4TBXDMC>7^J%=QACS@!1ZU;^ GQ)\32^.?%'P[\9SQW
MVLZ*%F@U"-=OVF!CA21ZUS.L7UKX"_;,@U#6)5LK'6=)\FWNICMC,@;[NX\
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MIL#UW/%_%/\ R<]X1_[!-Q_,5[17B_BG_DY[PC_V";C^8KVB@ HHHH ****
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M%G[,VAZEXY\;6^KVVJ-IUM=;+'SIW"A/]GFO4/\ ADKP#_SZW?\ X$O_ (T
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M>X_LAWNI7OPGC:]FDN+1;J5+&:4Y9H WR\_2O?QM&G&BXTUI'EZ=UT?7SO\
4(3;]IKW:^[]/ZZGM]%%%?.&Y_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>cvac-20231231x20f048.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f048.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $3 -4# 2(  A$! Q$!_\0
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MN5R[*_XM?H%FYJ/=I?@G^I]!T5\9>*_VEO&(\#?#-S?0: /$<+27WB"6'=!
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MW]:NG'2EH Y<_#C1B/N3?]_6KH+"QBTVUCMX01&@P-QR:L44 %%%% !1110
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M/J13N4$=",TM(HVJ!Z#%+7MGPIY5K'[-7@G7?B/%XYN[*5_$<3!DNA*PVX[
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ML$]:^O00>AS6D+*"E'S6O2VG]>1,[N3B_)^M_P#@_B+1114@%%%% '@>H_\
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MWX'_ !9M?C)X#M=>A@-I<;C#=6K=8I5.&6B/O1YEZ_)[,)>Z[/T^?8X/4?\
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M2;Q1^25Z;X(BM;3PMIMG:7BWL=K D/G*?O8&*W:J,E)*47="E%Q=I*S/%?\
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>cvac-20231231x20f050.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f050.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %  UH# 2(  A$! Q$!_\0
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MY5E%3W7@'6/$'AY+75;F(7 F$H\I<  &O2:* (+*W^RVD,).2BA<_2N)\>>
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M3^XU [GM=%<;X?\ B);:@%CNQY$A[GI7707$=S&'B<.I[@TQDE%%% !1110
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MTUN19H=1112$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2T4#(B.<4RI7'.>YIC"I ;111BD(2DSCI3N*:>#3 ",TQA@U(32>M4 T&EI
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MZUF;N/2N95L3A*L:==\T)=>WJ=;P^&QE&57#+EG'5KNNZ/H"D+ =:0NJ#YF
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M[+2=-OK.&?5K]1(6=02M?*.@WL>D:Q:WLT7VB."0.8_6O:OA'XKNO'_Q>AU
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MI.M3:V?<5+ XFD]))Z)=>]S#^"6AW>@?#^QM[Q3%*V7"'^$'M7?CI2*H50H
M '0"E'2N)OF=SW81Y(J/88_WA7@/[7W_ "*-G_UTKWZ3J#7@'[7Y_P"*2LA_
MTTKP\[_Y%]5>1]-P[_R-:%^Y\E#[JT4!3M7@_E00?0G\*_"N5]C^F.>'="4M
M(0<?=/Y4N#_=/Y4<LNP<\>Z"BC!_NG\J,'^Z?RHY9=@YX]T%%&#_ '3^5&#_
M '3^5'++L'/'N@IK_=-.P<_=/Y4CJVPG:?RHY96V#G@NJ/LG]E X^'[?]=*]
M9T_PQI^FWUY=P0*L]WS*<?>KR7]D\Y^'[?\ 72O<:_>,F;6 I6['\OY\E+,Z
M]_YF>?W/P8T"XU;[>(6C??O*(<*3]*O^*?AEHOBT0?:XBLD(VJZ'!QZ5V!Z5
MQ/Q?UN\\/^!;V]L)1#=)@(Y[9KW8RE*5KZL^8JTZ-*G*3CHM2]I'P[T?16M7
M@@^>U_U;'DU?N/"FG75W<7#P*99TV.WJ*\2TOQ=XM\+77AVZO]8@U:VU)E5[
M:,Y9<]Z]IM/&5A=ZS+I:,?M42;V!Z8JZD9Q=[W,J%6C45N6P]_".FR:.NEF
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M'^5'_"/V'_/K'^57\GUHJOJ6$_Y\Q_\  4']JYC_ -!,_P#P)_YE#^P+ ?\
M+K'^5)_8%A_SZ)^5:&:,TG@<)_SYC_X"@_M3,?\ H)G_ .!/_,H?V!IX/_'K
M'^5._L/3]K?Z(AX]*NT['[M_I6=3 X3V<OW,=G]E&E+-<P]I&^(F]5]I_P"9
MW'[+\:QS:PB#:BOP!VKZ%'2OG[]F _Z3K0_VZ^@J^-RY<M"R[L_8\PN\0VW?
M1?D@J*XN8K6(R32+%&.K,<"I:\F^/T]W!I^BMODCTK[6OVQX^H7W]J],\X]%
MB\3:7,NY;Z'&=O+ <UH1SQRKN1U9?4&OFWXQZIH-WI6CMX9N1)(MRGF?9R>G
MO63-XG\17VMVFD6E]-90-$TC.H/) H ^JO,4OMW#=UQ1O7'WA^=?-9^('B*S
M\*7-XADGNXU$32X/RC^]4&N>+H]+\*645OXFN+N\O/WCRJ#B)L9VFE<#Z7:[
MA6=83*HE89"$\D5-7S!\'?%^J^+O'.F2W\TDODJT8?G# =Z^GZ8!7/\ CH_\
M4CJG_7!OY5T%8'C7_D4M5S_SP;^585_X4O0UI?Q(^J/C7PEI%E<V4TDMNKN9
MFRQ'O6T= T__ )]4_*J'@O']G3?]=F_G6]FO6RK"866"IN5*+=NJ3ZGPF?YC
MCJ>:5X0KS23Z2?9>90_X1^P_Y]8_RH_L"P/_ "ZI^57R31S7J_4L)_SYC_X"
MCY_^U,Q_Z"9_^!/_ #*!T"P(_P"/5/RI!H%AWM$_*M')HS2^I83_ )\P_P#
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MNSCV>OW=C7/Q6\=J,_VN:GLOB5\0]2N4M[;47FE<X4*,UU_@WX":OKXCGO\
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MTN,+;PJN.^.:O4QHIZ?I%KID82WA5/?'-7***!A1110 4444 %%%% !1110
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M0?5346><'Y3[UJFGU.9Q:T8M% ..]+@XID"8HHQ10 4444 %%':B@044&B@
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M0KIB45HB?2NB./@]T>=4X>KQ^"29\_YR/:DW#UKUO4_@.P8FSNOE[!JYR_\
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M^ =/TEUD8&>4=WZ5TRJ$ "@ #L*"EL8.C^#-.TD*5B$DH_B:MX *, 8%+13
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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,J4KW'4445R'MG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>cvac-20231231x20f051.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f051.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %8 ?4# 2(  A$! Q$!_\0
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MTMU]Q]OC]N_PD1G^RK[]*/\ AN_PEC/]E7WZ5\1  4IQCI^E']@X'^5_>/\
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M.6Y2VA,LK!%49Y[UWO[*$DGB'XU6%[AO*M%8K@9KPS6=9EUFX\J$8A6OJ/\
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M*% '2G 9I%,:%YIX&*-N#3U7/6@D-I-.0;1S2[3ZB@ ]ZD8O4U)BFJ*>!FD
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M=).&C0[&>M*>*;EO2GJAZGI5)F8HZ#-.7I2A1FG8R<5+-HZ"  YIVT \4X<
M"EVY;FIN4U<94R#FA$VY[TX#-.]S*PH%+0.!3\Y%(I(1:D09XI%3&:G7@5#9
M:0T#&..*4#%.ZTNW/I2N-JX@YI>?2EVFG*":0P5:D Q2A>*=00WT$ [U+;?\
M?MK_ -=5_G3-N13[6/\ TVUY_P"6J_SH;)BKGZ!Z%_R!;#_K@G_H(HI="_Y
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M96R ;HB,+(/4&N^A5IT$XU*?/*;\[W\SFG"4]8RM%'7 @\I@CU%.!S@4B1)
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M-/:^)/"]U'O540C<.F2:^8]>\#R^,M*MK2XF^SQ, [$<<^@KZ2_X*(V5_?\
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M=\FMJ6PE'BF*Y91Y$,(5/K7V$*4*$.6"[7/#G4E6DW)]S'M;9SXZGD<!ECC
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MY+WEM<V$I2ZM)X&SUDC('ZU1NI%,,F2.A-?HC^TGH^E7O@=C)IMLCB0 2+&
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MZH3> 73_ %4FX'N>U*UAJ1SXU*)S^]MASW6I;9K*6Z@ +QOO&":N3>#K^ <
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M/;LBYDFC)(S[5\I^2O91FJ/B2U27P_>KM&2F!43P5/E;1=/&RE))H^\_#?\
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MKH21P!H)Y8L= #4>LZ-=3:#J$7VPN# Q._G/%:FF$RV2YZ@FI;R/_B67_?\
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MHO\ HTI4=MU15P[JS<^;<<)N$5%HY&*< Y#H>.S U\H_M S"6]&.%>\1<?\
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M[ _G.>K'BF+!*Z;E",/9Q2_9Y,<[1]&%3H59HGM[B=!F557_ '33A?W*R;)
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M\!CP,5%97#3V3R.@4$XQ[U(\UM>Q-#= %T^[SUKQHMPDI+HSMISM?S1X;?\
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MO#ODNI)HWY[[&UX7^*/@KQ-8)"+I-/E<XC27@D_6ND&A65Y;X@N5OHSWCD!
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M"C%)]@MO^?>/_O@444P%^PVW_/"/_OD4?8;8?\L(_P#OD444 'V&W_YX1_\
M?(H^Q6__ #PC_P"^1110 ?8;?_GA'_WR*/L-O_SPC_[Y%%% !]@MO^>$?_?
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>cvac-20231231x20f052.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f052.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &+ B\# 2(  A$! Q$!_\0
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MYR!T&[=CV K>FTZWDY*8;^\O!K*473DXW",E))HCMHEM;>*!&.R-0BAN3@#
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M"5[>3S$.2",=N.H]JQ:92M?4U7XW5'N7UITS<L3P<U S>O I"%8*<\9%0M&
MPVY'L*D:/:,X('K4;9_O9JP&,SKZ'ZTV2[6+[XV_C2LQ]*YGQ_J!TOPGK&H"
M-)9K&RGNXUD^[O2,L,^W% '2QW4<G1OPI^[_ &J_-?X$_MD?$CXB?%_P98ZM
MK=G:Z-J=ZEO/8V]LJ0[&!XR23G(&#FOT1M;AIHS);7%O>1 E-T,G&5ZCODCT
MIZ[M%;&QN]ZR]9T>W\011Q77F&*-]X5)&0$^^.3]*7^T6CXDC=?]Y<C\Q3X=
M0CD88P<'H"/Y47%<P-7\*300R2:'//IVIMS&RW#"//3+H<@\5TWA];^VTNWC
MU2\6^OU&)+B./RPQ[#':L7PUIESI,FI"YU%KU;FY::$2YW1(?X"3_2N@1CN.
M*JR'<UK?4I8?X\@?WCQ6A:Z_'-P0&]=A# UR.IVT>HVKV<^3!,-KA25R/J.E
M86I>$;6336@T[%C=*FR">.1QY9S]X@'D?6HL*YZPJV-[_=5O;Y30VFSQ\VUQ
MO']V2N(\-VMUI.DQ6MYJ,VJW"DYN9P S>W';]:W8=2FA("R$>W45!1H37<]K
MQ<6[ ?WDY%5VOH9E^209_NMP:MP>('VXECWCOMILRZ7JGWXQ&_\ >'RFGL5J
M9-PW<USEQI9M$N6L7$5U,?\ 739D_#D_I7477AR95)LKO>O]R3I^=8EXEY9Y
M%Q:N!_?096FI$LS;*W-C9"/S&ED+%GD88+,3R?;FG>%]:MSXF>[20&UABV-*
M>%W9.0/4TOGI(/D8?C3K715U^<6!D, FX9E7<1CGI5W,V=)-XZTRWE+?:T8^
MB9/\JSM0^+,4*XB2>3\=H_6N \'^"9-?\76@:_G%C87+?:($(7[0IR &X[$9
MKW>V\%Z'91L(M,MV#<MYB[B?;FES7,^6R/+V^)&I:@Q6WM,,W0 %V(]>*I:Q
MXIU33=-74=6GETRQ;(\R11&/PSS7KNL:I:>&=)O=0>)(X+:(RE85"EL= ,#J
M3@5^;WQS^-VN>-[K6;NZF;RWF%M#"O,<>,G"CZ8YI2;BM#6G!2>NQ] :_P#&
M[P]IMQ;PI>C4))6'$SL,Y]!6YX7^)7@7Q)JHLKG5IM"N4(62.2)2&8]/G["O
MSXBEN9K4RO+NN=VZ*9WX&.<Y/Y5TS:W%<VZW<[^3)% &2Z@)7N!M8'[PYKGO
M+N=O+3VL?IPFC>!;#6H=&O\ 5I9M1E194M[B[QO5NA^3 Y]*ZN;X;Z%'^]L;
M."RG XDV!P?J&S7PS^SC8Z7XDO+>]UC5KNXU*S"?9_WQ:.?:<CYCSP>!TXXK
MZ]O-:\Y(I!+(P=?NAC\OX5I%RD]3EJ)15T/U[25+QQ:@L'[L_NFA(VM]!VKB
M_A*RIX=U,+T&KW87Z>8:L>)]295M]BF,9;/O6#X#NIM)T>XAE7;YE]<3#\7I
M[2U,])1T/19)!5>2;WK(_M;S,'-(U\&SWJKBL:+39--\T=-U9KR"="FYER,;
MD."*U_"?B"#0=EMJ5C'>VV>+O9F5/]X=_P *EL=AJAYB J,Q/]U2:XKXJV\]
MN-.:6&2,,'Y<8]*]R7Q]HD/^I+'CCRXL5X_\?_$,.O-HGV97 C\S=N]]M1.6
MAI%:EOX)^'[[4M'U.XB11$]Y@,[^D:CI7H^H>&+RQM3,OEW&WEE7.X#OBO/_
M ('^+)-,\+W]J(@76^;#$^JJ:] E\7WL@^5E0>RYJJ=^4F>YBM,LR@J<GITQ
MSZ&J\C%?IW%3R[I9GE"'S'.2<=??%4[AF*M@#>!QDXS6QGJ5KF91D]*R[BX^
M;CFO-/&OQJU'P7XFMK+5]&CL](N"(EU(N6\F7/"R#& #V;H:Z.+69KY4(F^5
M^?W>,'C.1[5FY(=CZ6U!Q# 78JB("Y)Z  51TCQ'8:D\,4$_FS2(7VJ/N@>O
MI7C/B;]J?PU=Z#J4&G1W2:D;:3[.T\7[OS-I*[N>A(J/]GOXLKX]UR>+5([6
MRUN*U69XK<$*8V PW/OQ^%:TTJD')/8TK4:N'FHU(M-]SZ(HIJMN7(IU8DA5
M2^^['_OBK=5;[I%_OBF@/);,8_:BOS_U+\8_\BFN<\ _\CU\5Q_U&(O_ $4*
MZ"U)'[4MZ,\'P\G_ *-KGO 3?\5]\5O0:O%U_P"N0KKEL_1'@47^]C_B?Y'I
M?I]*Y_4Y M_*N%+8!Y^E=!Z?2N$\51R?V](5# ;5Z?2E0^,]V6QE>*KLO+I5
MBB$FYN [[3V4C _$XKH)+?S,JT98=P1D5Y[K4.I7&M:7<V=L0EL6+-<D@=1U
M'4CBNZTS6+B]_>2R>6"-C)C"_4"O1L1<HWVBV<TCL]K"7(QGRQN_.LIO!=G"
M0]J]S9MUW6UPZ_IG!J]<:L_VJ56 ;YB ?QIZZPN.8R?H:;"Y6N-!U:2(-!K=
MRJG*B.XBCN$4^HW#^9[US\&B7]P;A9K/1=3,)>-W,+0DL1GC!P.O/:NWDU>)
M=-CDRRG<0,US?@NY>YTV\89E+SLY.*4=RBKHNBQZ&_E+IJZ8[QR,1%/YJMB-
MN<GIC-=?\-_^1/T3!S_HY_G6)?3BXU:V3(PL4WU^X>#6Q\-/^1/T5<8Q P_4
MUP8C^(RX_"=3J"&2QE3CYEQ\QQ7E'BZ]UE//M8=+DDL(5"M);X<$CGMVKU#5
MFD^S.@BWQ%&W/N&!QWKRN[\.V4<=U-;J]K(8VR8)63/'IG%717NL#%U+6KC2
M=<L_LP9WFT^WP5''\1Y/:NY\+WWB.\59VU&*"V!YC+%\^V"2*Y73[K[+K4$I
MG\J-=+M_D,2R*YR<!@1_*C4?B)=&_-L-*LYH=I_>H#$Y^FTXJJ7-**C%&EH[
MMGH>M:39ZFNV_L-,OD?^&>S .,8X*X(^M8^D_"&T.H->:/HUO8.0"Q^TR,A(
MZ84FK_A_4EU+2[65+2;[N2OF[C^O/%5])GCA\=?;/[3U!;EV%N+-U(A1,=0!
MWSWJFY0=A<O,M#<TGPW<V]\DEU=^9Y.?W(7"\5H_>F3FNBGA4&9L<[37-_\
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MPJC^O2LFSU9FM62,KM4$[JG>9IH4&XE2,L-M:06HI/0MZ7,TGB2$'YAY4O\
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M21VZL>W'8=:]I4W431PU:\**U>IBVWAA9/*DO'Q9P#>+1> 3ZL>_TI)62ZO
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M=?AAMFA$,91PR!,YV=*PQ"BY73/3IMQARM&_\-M6_MC5(K":%VM9;)3',J@
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M9I44[F?U-36]GNV,.3G_ #BN9:,Z97DM#W/X*WBVWA'4G8?NK>7S,^HVY/\
M*J%S>K-;W[J<HPD(/L:?\(V=O"OB>VA5GD5/,1,9/*$=/J*Q%5+.UNX(T\I$
M20;03QQS7SE56K39];AG^XB+H5UYD^I@'Y/L=K_Z :[/X:W7D0:LI.!YR_\
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MO&'Q"MO"EU]C=6EN[D PJ!\@(8=:]'N5W6*'/\6*\@\=>#9==\2PWD493R
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MQNFT]['RKG4(1OCA=5\M%(SGY@?SKTSP5KEAX@U#7WT^;[3%!?FUE91@"5%
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M;.2,Y22.+YE/L3WK3EM8)YH7>))&0Y#, 2._%-72G/,EU)(?]XXJQ%:Q6H)
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M7$H7/7)KSO:/H>CR+J<]IV@/]H+3W$MV3@A3PO3L!5'XA6[Z==:7&J*@:)B
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M[O4%"LS<8]>:"VW)/;K3%?.<_+S22,&4YZ8YI@>/VNK#3/VP'G89C3PRI/\
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M9B,N6-0L.?>I&?%0-EFP!DGM0:(IW9P<YZ"N*\?1M<^&+M5CED(SPB$L>X
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M,99&Y;?TS5;R4_>$'(!^[G^5="6EF>>FVSL/@?I,7B+XAZ<MR"T<$<DK =V
MQC]:^I(?#=@F?*CFB/\ LN17R]\ ;YM/^*%K".MS#)$GUP#_ $KZKBN+I Q9
M&('7%?*9A?VUO(^ORRWL;^9YM\5?!.KZU<6)TRV>^MXD8-OD 8,3[UXKXO\
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MO\(H B$=.\O\ZEIV!021K'Q3A'Z"GK3J &;2.HHVM4G\-"]: &A:7!]:?3*
M$VTOXTO\(H]: &_A2;/7BG44 -Y]Z7;2T?QT (O2DP:D]*;5@-*FDVX]Z?2=
MQ0!'13Z* &_Q4['%(WWA2T &/:C;]*5:6@!-M)MQS3J*=P$VT;:5?OT[_&D
MY!WJTN<577^M3IT% "3]*KL#@59F^[59NM $3"HV6I6[U&U $+)3=HJ>DVCT
MH 2,5+CVID?4U(M2P$J1$SBHU_K5BW^\OUI 6!;_ +NJUPFW&16HJC'2J=X.
M!4=33H588@PS3VC.:?;CY!4K#Y:LBQ5^[33SS3F^\:2@1$XW-[4FVG_Q&D7I
$04?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>cvac-20231231x20f066.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20231231x20f066.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E 2(# 2(  A$! Q$!_\0
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M6VNO4K%0RW#8B=!8:;Y6U?FWL_0XOP+^T?X;\=:VFE)%=:==RG;$MTBCS#Z
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M2_:J^&6F(Q_X21+AUXVVT$LA/TPN*Y/4?VW_  +:DBTMM4U!L' CMU0$_P#
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:U)"1U'!69J** /HNBBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>55
<FILENAME>cvac-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/24/2024 9:35:19 PM-->
<!--Modified on: 4/24/2024 9:35:19 PM-->
<xsd:schema targetNamespace="http://www.curevac.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cvac="http://www.curevac.com/20231231" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:us-types="http://fasb.org/us-types/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" id="StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss">
        <link:definition>00100 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition" id="StatementConsolidatedStatementsOfFinancialPosition">
        <link:definition>00200 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails">
        <link:definition>40310 - Disclosure - Notes to the consolidated financial statements - Operative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" id="DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails">
        <link:definition>40312 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails" id="DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails">
        <link:definition>40405 - Disclosure - Fixed Assets - Amounts recognized in the statement of operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails" id="DisclosureShareBasedPaymentsPriorVsopExpensesDetails">
        <link:definition>41003 - Disclosure - Share-based payments - Prior VSOP - Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" id="DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails">
        <link:definition>41005 - Disclosure - Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" id="DisclosureTradeAndOtherPayablesDetails">
        <link:definition>41101 - Disclosure - Trade and other payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" id="DisclosureOtherLiabilitiesAndProvisionsDetails">
        <link:definition>41201 - Disclosure - Other liabilities and provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails" id="DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails">
        <link:definition>41203 - Disclosure - Other liabilities and provisions - Current and Non Current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails" id="DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails">
        <link:definition>41302 - Disclosure - Income tax - Schedule of tax reconciliations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" id="DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails">
        <link:definition>41502 - Disclosure - Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" id="DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails">
        <link:definition>41801 - Disclosure - Remuneration of the Company's key management personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" id="DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails">
        <link:definition>42002 - Disclosure - Business Combinations - Fair value recognized on acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" id="DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails">
        <link:definition>42003 - Disclosure - Business Combinations - Goodwill recognized as a result of the acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" id="StatementConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" id="DisclosureShareBasedPaymentsTables">
        <link:definition>31003 - Disclosure - Share-based payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" id="DisclosureCorporateInformationDetails">
        <link:definition>40101 - Disclosure - Corporate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails" id="DisclosureAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40201 - Disclosure - Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails" id="DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails">
        <link:definition>40202 - Disclosure - Accounting Policies - Estimated useful lives Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails" id="DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails">
        <link:definition>40203 - Disclosure - Accounting Policies - Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails" id="DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails">
        <link:definition>40204 - Disclosure - Accounting Policies - Estimated useful life of right-of-use assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails">
        <link:definition>40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" id="DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" id="DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails">
        <link:definition>40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails">
        <link:definition>40304 - Disclosure - Notes to the consolidated financial statements - Contract balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" id="DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails">
        <link:definition>40305 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails">
        <link:definition>40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails">
        <link:definition>40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails">
        <link:definition>40308 - Disclosure - Notes to the consolidated financial statements - Research and development (R&amp;D) expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails">
        <link:definition>40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails">
        <link:definition>40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" id="DisclosureFixedAssetsIntangibleAssetsDetails">
        <link:definition>40401 - Disclosure - Fixed Assets - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" id="DisclosureFixedAssetsPropertyPlantAndEquipmentDetails">
        <link:definition>40402 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails" id="DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails">
        <link:definition>40403 - Disclosure - Fixed Assets - Right-of-use assets and lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40601 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40801 - Disclosure - Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails" id="DisclosureEquityOverviewAndGeneralRemarksDetails">
        <link:definition>40901 - Disclosure - Equity - Overview and General Remarks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails" id="DisclosureEquityImpactOfShareSplitDetails">
        <link:definition>40902 - Disclosure - Equity - Impact of share split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails" id="DisclosureEquityFollowOnPublicOfferingDetails">
        <link:definition>40903 - Disclosure - Equity - Follow-on public offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails" id="DisclosureEquityAtMarketOfferingDetails">
        <link:definition>40904 - Disclosure - Equity - At-the-market offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails" id="DisclosureEquityFrameAcquisitionDetails">
        <link:definition>40905 - Disclosure - Equity - Frame acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails" id="DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails">
        <link:definition>40906 - Disclosure - Equity - Exercises of share options under the VSOP plan and legacy program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails" id="DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails">
        <link:definition>41001 - Disclosure - Share-based payments - Expense recognized for the share-based payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails" id="DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails">
        <link:definition>41002 - Disclosure - Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails" id="DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails">
        <link:definition>41004 - Disclosure - Share-based payments - New VSOP - Reconciliation of outstanding awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails" id="DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails">
        <link:definition>41006 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails" id="DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails">
        <link:definition>41007 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails" id="DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails">
        <link:definition>41008 - Disclosure - Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails" id="DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails">
        <link:definition>41009 - Disclosure - Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails" id="DisclosureShareBasedPaymentsRestrictedStockUnitsDetails">
        <link:definition>41010 - Disclosure - Share-based payments - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails" id="DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails">
        <link:definition>41011 - Disclosure - Share-based payments - Restricted Stock Units expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails" id="DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails">
        <link:definition>41204 - Disclosure - Other liabilities and provisions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" id="DisclosureIncomeTaxDetails">
        <link:definition>41301 - Disclosure - Income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails" id="DisclosureIncomeTaxScheduleOfDeferredTaxesDetails">
        <link:definition>41303 - Disclosure - Income tax - Schedule of deferred taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails" id="DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails">
        <link:definition>41501 - Disclosure - Disclosure of financial instruments and management of financial risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" id="DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails">
        <link:definition>41503 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails" id="DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails">
        <link:definition>41504 - Disclosure - Disclosure of financial instruments and management of financial risks - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails" id="DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails">
        <link:definition>41601 - Disclosure - Notes to the consolidated statements of cash flows - Financing activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails" id="DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails">
        <link:definition>41802 - Disclosure - Remuneration of the Company's key management personnel - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" id="DisclosureRelatedPartyDisclosuresDetails">
        <link:definition>41901 - Disclosure - Related party disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsDetails" id="DisclosureBusinessCombinationsDetails">
        <link:definition>42001 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>42101 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" id="DisclosureCorporateInformation">
        <link:definition>10101 - Disclosure - Corporate Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAccountingPolicies" id="DisclosureAccountingPolicies">
        <link:definition>10201 - Disclosure - Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" id="DisclosureNotesToConsolidatedFinancialStatements">
        <link:definition>10301 - Disclosure - Notes to the consolidated financial statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>10401 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" id="DisclosureAssetsHeldForSale">
        <link:definition>10501 - Disclosure - Assets held for sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10601 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherFinancialAssets" id="DisclosureOtherFinancialAssets">
        <link:definition>10701 - Disclosure - Other financial assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10801 - Disclosure - Prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquity" id="DisclosureEquity">
        <link:definition>10901 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" id="DisclosureShareBasedPayments">
        <link:definition>11001 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" id="DisclosureTradeAndOtherPayables">
        <link:definition>11101 - Disclosure - Trade and other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions" id="DisclosureOtherLiabilitiesAndProvisions">
        <link:definition>11201 - Disclosure - Other liabilities and provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTax" id="DisclosureIncomeTax">
        <link:definition>11301 - Disclosure - Income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" id="DisclosureEarningsPerShare">
        <link:definition>11401 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks" id="DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks">
        <link:definition>11501 - Disclosure - Disclosure of financial instruments and management of financial risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlows" id="DisclosureNotesToConsolidatedStatementsOfCashFlows">
        <link:definition>11601 - Disclosure - Notes to the consolidated statements of cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11701 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnel" id="DisclosureRemunerationOfCompanySKeyManagementPersonnel">
        <link:definition>11801 - Disclosure - Remuneration of the Company's key management personnel</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" id="DisclosureRelatedPartyDisclosures">
        <link:definition>11901 - Disclosure - Related party disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBusinessCombinations" id="DisclosureBusinessCombinations">
        <link:definition>12001 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>12101 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies" id="DisclosureAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesTables" id="DisclosureAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" id="DisclosureNotesToConsolidatedFinancialStatementsTables">
        <link:definition>30303 - Disclosure - Notes to the consolidated financial statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsTables" id="DisclosureFixedAssetsTables">
        <link:definition>30403 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEquityTables" id="DisclosureEquityTables">
        <link:definition>30903 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesTables" id="DisclosureTradeAndOtherPayablesTables">
        <link:definition>31103 - Disclosure - Trade and other payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables" id="DisclosureOtherLiabilitiesAndProvisionsTables">
        <link:definition>31203 - Disclosure - Other liabilities and provisions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxTables" id="DisclosureIncomeTaxTables">
        <link:definition>31303 - Disclosure - Income tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables" id="DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables">
        <link:definition>31503 - Disclosure - Disclosure of financial instruments and management of financial risks (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsTables" id="DisclosureNotesToConsolidatedStatementsOfCashFlowsTables">
        <link:definition>31603 - Disclosure - Notes to the consolidated statements of cash flows (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelTables" id="DisclosureRemunerationOfCompanySKeyManagementPersonnelTables">
        <link:definition>31803 - Disclosure - Remuneration of the Company's key management personnel (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsTables" id="DisclosureBusinessCombinationsTables">
        <link:definition>32003 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails" id="DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails">
        <link:definition>40404 - Disclosure - Fixed Assets - Carrying amounts of lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" id="DisclosureAssetsHeldForSaleDetails">
        <link:definition>40501 - Disclosure - Assets held for sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails" id="DisclosureOtherFinancialAssetsDetails">
        <link:definition>40701 - Disclosure - Other financial assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails" id="DisclosureOtherLiabilitiesAndProvisionsMovementsDetails">
        <link:definition>41202 - Disclosure - Other liabilities and provisions - Movements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails" id="DisclosureIncomeTaxScheduleOfTaxReconciliationDetails">
        <link:definition>41302 - Disclosure - Income tax - Schedule of tax reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails" id="DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails">
        <link:definition>41304 - Disclosure - Income tax - Schedule of unused tax losses carried forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" id="DisclosureEarningsPerShareDetails">
        <link:definition>41401 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20231231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd" />
  <xsd:element name="CorporateInformationAbstract" id="cvac_CorporateInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateInformationTextBlock" id="cvac_CorporateInformationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangesInWorkingCapitalAbstract" id="cvac_ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" id="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesAbstract" id="cvac_SignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory" id="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" id="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory" id="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsProductMember" id="cvac_IfrsProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsPropertyPlantAndEquipmentSalvageValue" id="cvac_IfrsPropertyPlantAndEquipmentSalvageValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IfrsNumberOfOperatingSegments" id="cvac_IfrsNumberOfOperatingSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsNumberOfReportableSegments" id="cvac_IfrsNumberOfReportableSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TechnicalEquipmentAndMachinesMember" id="cvac_TechnicalEquipmentAndMachinesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherEquipmentMember" id="cvac_OtherEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" id="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoehringerIngelheimMember" id="cvac_BoehringerIngelheimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherCustomersMember" id="cvac_OtherCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CrisprMember" id="cvac_CrisprMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentServicesMember" id="cvac_ResearchAndDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GenmabMember" id="cvac_GenmabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontPaymentsReceivedOrReceivable" id="cvac_UpfrontPaymentsReceivedOrReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentsIncludedInContractLiabilities" id="cvac_UpfrontPaymentsIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IfrsIncomeStatementLocationAxis" id="cvac_IfrsIncomeStatementLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncomeStatementLocationDomain" id="cvac_IfrsIncomeStatementLocationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCostOfSalesMember" id="cvac_IfrsCostOfSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PersonnelExpenses" id="cvac_PersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ThirdPartyServiceExpenses" id="cvac_ThirdPartyServiceExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaintenanceAndLeaseExpenses" id="cvac_MaintenanceAndLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SellingAndDistributionExpensesMember" id="cvac_SellingAndDistributionExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsResearchAndDevelopmentExpenseMember" id="cvac_IfrsResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentsAndFeesToRegisterLegalRight" id="cvac_PatentsAndFeesToRegisterLegalRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsGeneralAndAdministrativeExpenseMember" id="cvac_IfrsGeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MiscellaneousOtherOperatingIncomeOther" id="cvac_MiscellaneousOtherOperatingIncomeOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsTable" id="cvac_DisclosureOfGovernmentGrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsAxis" id="cvac_GovernmentGrantsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsDomain" id="cvac_GovernmentGrantsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CoalitionForEpidemicPreparednessInnovationsMember" id="cvac_CoalitionForEpidemicPreparednessInnovationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillAndMelindaGatesFoundationBmgfMember" id="cvac_BillAndMelindaGatesFoundationBmgfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsLineItems" id="cvac_DisclosureOfGovernmentGrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementMaximumAmount" id="cvac_PartnershipAgreementMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PartnershipAgreementTerm" id="cvac_PartnershipAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementPeriodOfCostsToBeCovered" id="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfAdditionalGrantsReceived" id="cvac_NumberOfAdditionalGrantsReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsAbstract" id="cvac_DisclosureOfFixedAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsExplanatory" id="cvac_DisclosureOfFixedAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfOtherFinancialAssetsExplanatory" id="cvac_DisclosureOfOtherFinancialAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIMember" id="cvac_VirtualSharesProgramIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIiMember" id="cvac_VirtualSharesProgramIiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsGrantedToThenChiefExecutiveOfficerMember" id="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" id="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" id="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" id="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingAxis" id="cvac_IfrsVestingAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingDomain" id="cvac_IfrsVestingDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedPaymentArrangementTrancheOneMember" id="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedPaymentArrangementTrancheTwoMember" id="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" id="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" id="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseRecognizedForEmployeeServices" id="cvac_ExpenseRecognizedForEmployeeServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RittershausRechtsanwaelteMember" id="cvac_RittershausRechtsanwaelteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DietmarHoppMember" id="cvac_DietmarHoppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" id="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionConsultingFees" id="cvac_RelatedPartyTransactionConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNumberOfLoansReceived" id="cvac_RelatedPartyTransactionNumberOfLoansReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfKeyManagementPersonnelAbstract" id="cvac_DisclosureOfKeyManagementPersonnelAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock" id="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManagementBoardMember" id="cvac_ManagementBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SupervisoryBoardMember" id="cvac_SupervisoryBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfCommitmentsAndContingenciesAbstract" id="cvac_DisclosureOfCommitmentsAndContingenciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfTradeAndOtherPayablesTableTextBlock" id="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfOtherLiabilitiesTableTextBlock" id="cvac_DisclosureOfOtherLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherOperatingIncomeGovernmentGrants" id="cvac_OtherOperatingIncomeGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock" id="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TaxEffectOfNonRecognitionOfTaxLossCarryforwards" id="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" id="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NonDeductibleExpensesForTaxPurposes" id="cvac_NonDeductibleExpensesForTaxPurposes" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" id="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="UnusedTaxLossesForCorporateIncomeTax" id="cvac_UnusedTaxLossesForCorporateIncomeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UnusedTaxLossesForTradeTax" id="cvac_UnusedTaxLossesForTradeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="FinancialInstrumentsAndRiskManagementAbstract" id="cvac_FinancialInstrumentsAndRiskManagementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExposureToForeignCurrenciesTableTextBlock" id="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherLiabilitiesUndiscountedCashFlows" id="cvac_OtherLiabilitiesUndiscountedCashFlows" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NotesToConsolidatedStatementsOfCashFlowsAbstract" id="cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCashAndCashEquivalentsMember" id="cvac_IfrsCashAndCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeAndOtherPayablesMember" id="cvac_TradeAndOtherPayablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExchangeRateCurrencyNetExposure" id="cvac_ExchangeRateCurrencyNetExposure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfEurWeakened" id="cvac_PercentageOfEurWeakened" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProfitLossBeforeTaxIfEurWeakened" id="cvac_ProfitLossBeforeTaxIfEurWeakened" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfEurStrengthened" id="cvac_PercentageOfEurStrengthened" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProfitLossBeforeTaxIfEurStrengthened" id="cvac_ProfitLossBeforeTaxIfEurStrengthened" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfInterestHigher" id="cvac_PercentageOfInterestHigher" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetLossBeforeTax" id="cvac_NetLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ProfitLossAfterTaxIfEurWeakened" id="cvac_ProfitLossAfterTaxIfEurWeakened" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ProfitLossAfterTaxIfEurStrengthened" id="cvac_ProfitLossAfterTaxIfEurStrengthened" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OtherExpense" id="cvac_OtherExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsOtherLiabilitiesAbstract" id="cvac_IfrsOtherLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GlaxosmithklineMember" id="cvac_GlaxosmithklineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GermanFederalMinistryOfEducationAndResearchMember" id="cvac_GermanFederalMinistryOfEducationAndResearchMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" id="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" id="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock" id="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdditionsLeaseLiabilities" id="cvac_AdditionsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ForeignCurrencyTranslationLeaseLiabilities" id="cvac_ForeignCurrencyTranslationLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="LeasesExpenseRecognizedInProfitOrLoss" id="cvac_LeasesExpenseRecognizedInProfitOrLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaximumGrantToBeReceived" id="cvac_MaximumGrantToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IfrsSaleOfStockAxis" id="cvac_IfrsSaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockDomain" id="cvac_IfrsSaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClosingOfPublicOfferingOfCommonSharesMember" id="cvac_ClosingOfPublicOfferingOfCommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExerciseOfOptionsMember" id="cvac_ExerciseOfOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInNumberOfSharesOutstanding" id="cvac_IncreaseInNumberOfSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" id="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsOverAllotmentOptionMember" id="cvac_IfrsOverAllotmentOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GermanysLargestPrivateBankMember" id="cvac_GermanysLargestPrivateBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GermanLandesbankMember" id="cvac_GermanLandesbankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsConcentrationRiskPercentage" id="cvac_IfrsConcentrationRiskPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractualCommitmentsUndiscountedCashFlows" id="cvac_ContractualCommitmentsUndiscountedCashFlows" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="BepharbelManufacturingS.aMember" id="cvac_BepharbelManufacturingS.aMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BaronJeanStephenneMember" id="cvac_BaronJeanStephenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VincentStphenneMember" id="cvac_VincentStphenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PublicOfferingOfCommonSharesMember" id="cvac_PublicOfferingOfCommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RightToExercisePercentageOfVestedVirtualShares" id="cvac_RightToExercisePercentageOfVestedVirtualShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionForEmployerTaxes" id="cvac_ProvisionForEmployerTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LongTermIncentivePlanMember" id="cvac_LongTermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefScientificOfficerMember" id="cvac_ChiefScientificOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefBusinessOfficerAndChiefCommercialOfficerMember" id="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ThenChiefExecutiveOfficerMember" id="cvac_ThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LegacyPlanMember" id="cvac_LegacyPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedPaymentArrangementTrancheThreeMember" id="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RemainingOptionLifeShareOptionsAwardsGranted" id="cvac_RemainingOptionLifeShareOptionsAwardsGranted" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SoftwareMember" id="cvac_SoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonSharesIssuedAndOutstanding" id="cvac_CommonSharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareOptionExercises" id="cvac_ShareOptionExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" id="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IntangibleAssetsMember" id="cvac_IntangibleAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentsMember" id="cvac_ShareBasedPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonCurrentLeaseLiabilitiesMember" id="cvac_NonCurrentLeaseLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurrentLeaseLiabilitiesMember" id="cvac_CurrentLeaseLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsOtherLiabilitiesMember" id="cvac_IfrsOtherLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UnusedInterestCarryforward" id="cvac_UnusedInterestCarryforward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IfrsOtherNoncurrentLiabilitiesMember" id="cvac_IfrsOtherNoncurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" id="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FollowOnPublicOfferingMember" id="cvac_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentExpenseIncl.DeferredTaxes" id="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangeInTradeAndOtherPayables" id="cvac_ChangeInTradeAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TechnicalEquipmentAndMachinesAndOtherEquipmentMember" id="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DepositsHeldByThirdParties" id="cvac_DepositsHeldByThirdParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentReceived" id="cvac_UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OptionFeePayment" id="cvac_OptionFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AdditionalDevelopmentMilestonePaymentsReceived" id="cvac_AdditionalDevelopmentMilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" id="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" id="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Foreigncurrencytranslationrightofuseassets" id="cvac_Foreigncurrencytranslationrightofuseassets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ClarentisSrlMember" id="cvac_ClarentisSrlMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StatementsTable" id="cvac_StatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StatementsLineItems" id="cvac_StatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OldVsopPlanMember" id="cvac_OldVsopPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewVsopPlanMember" id="cvac_NewVsopPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" id="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsNumberOfSharesHeldForTaxLiabilities" id="cvac_IfrsNumberOfSharesHeldForTaxLiabilities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsNumberOfSharesIssuedForExerciseOfStockOptions" id="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsEmployerTaxesPayable" id="cvac_IfrsEmployerTaxesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ChiefDevelopmentOfficerMember" id="cvac_ChiefDevelopmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" id="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsThresholdDurationOfVolumeWeightedAveragePrice" id="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsContractualObligation" id="cvac_IfrsContractualObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisclosureOfOtherLiabilitiesTable" id="cvac_DisclosureOfOtherLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfOtherLiabilitiesLineItems" id="cvac_DisclosureOfOtherLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsMember" id="cvac_RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MembersOfExecutiveBoardAndVariousKeyEmployeesMember" id="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CrisprTherapeuticsMember" id="cvac_CrisprTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" id="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdvancedPurchaseAgreementWithEuropeanCommissionMember" id="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsMilestonePaymentReceived" id="cvac_IfrsMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsRemainingGrantIncome" id="cvac_IfrsRemainingGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory" id="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryDifferencesValuationOfDeferredTaxAssets" id="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PrepaidCompensationForContractManufacturingOrganizationsTransfer" id="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransfer" id="cvac_CompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" id="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" id="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SettlementOfShareBasedPaymentAwardsAmount" id="cvac_SettlementOfShareBasedPaymentAwardsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CostOfReimbursementClaim" id="cvac_CostOfReimbursementClaim" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SaleOfEquipment" id="cvac_SaleOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AntonyBlancMember" id="cvac_AntonyBlancMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoriesTable" id="cvac_InventoriesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoriesLineItem" id="cvac_InventoriesLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInInventory" id="cvac_IncreaseDecreaseInInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtMarketOfferingProgramMember" id="cvac_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AggregateGrossProceedsReceivableFromIssuingShares" id="cvac_AggregateGrossProceedsReceivableFromIssuingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesNewIssues" id="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="KeyEmployeesMember" id="cvac_KeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" id="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetsHeldForSaleAxis" id="cvac_AssetsHeldForSaleAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetsHeldForSaleDomain" id="cvac_AssetsHeldForSaleDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" id="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" id="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ContingentConsiderationNumberOfPaymentsConsidered" id="cvac_ContingentConsiderationNumberOfPaymentsConsidered" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsBusinessAcquisitionSharePrice" id="cvac_IfrsBusinessAcquisitionSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CashTransferredForSettlementOfVestedEmployeeOptions" id="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdditionalCashTransferred" id="cvac_AdditionalCashTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContingentConsiderationPercentageOfTotalConsideration" id="cvac_ContingentConsiderationPercentageOfTotalConsideration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ContingentConsiderationNumberOfMilestones" id="cvac_ContingentConsiderationNumberOfMilestones" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" id="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" id="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContingentConsiderationMaximumSharesIssuable" id="cvac_ContingentConsiderationMaximumSharesIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" id="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RightOfUseAssetsRecognisedAsOfAcquisitionDate" id="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TotalAssetsRecognisedAsOfAcquisitionDate" id="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FormerFrameEmployeesMember" id="cvac_FormerFrameEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsTable" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SigningSharePriceRepresenting10" id="cvac_SigningSharePriceRepresenting10" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SigningSharePriceRepresenting40" id="cvac_SigningSharePriceRepresenting40" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueOfTotalConsiderationTransferred" id="cvac_FairValueOfTotalConsiderationTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProvisionalFairValue" id="cvac_ProvisionalFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuanceDuringPeriodForExistingShareholders" id="cvac_StockIssuanceDuringPeriodForExistingShareholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" id="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GlaxosmithklineCovidAgreementMember" id="cvac_GlaxosmithklineCovidAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BundesministeriumFurBildungUndForschungMember" id="cvac_BundesministeriumFurBildungUndForschungMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CumulativeAmortizationAndImpairmentMember" id="cvac_CumulativeAmortizationAndImpairmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrossCarryingAmountOfAcquisitionCostMember" id="cvac_GrossCarryingAmountOfAcquisitionCostMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdvancePaymentsIntangibleAssetMember" id="cvac_AdvancePaymentsIntangibleAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PersonnelAccruedLiabilities" id="cvac_PersonnelAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OutstandingInvoicesCurrent" id="cvac_OutstandingInvoicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProfessionalFessCurrent" id="cvac_ProfessionalFessCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CurrentValueAddedTaxAndOtherTaxesPayables" id="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractTerminationProvisions" id="cvac_ContractTerminationProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherLiabilityCurrent" id="cvac_OtherLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TradeAndOtherReceivablesMember" id="cvac_TradeAndOtherReceivablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MonetaryLiabilitiesInForeignCurrencyMember" id="cvac_MonetaryLiabilitiesInForeignCurrencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MonetaryAssetsInForeignCurrencyMember" id="cvac_MonetaryAssetsInForeignCurrencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TradeAndOtherPayablesTwoMember" id="cvac_TradeAndOtherPayablesTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" id="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TechnologyMember" id="cvac_TechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncomeTaxTable" id="cvac_IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncomeTaxLineItems" id="cvac_IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImpairmentOnRightOfUseAssets" id="cvac_ImpairmentOnRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SignificantAccountingPolicyTable" id="cvac_SignificantAccountingPolicyTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SignificantAccountingPolicyLineItems" id="cvac_SignificantAccountingPolicyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImpairmentOfAssetsHeldForSale" id="cvac_ImpairmentOfAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedOtherLiabilityForUpFrontPayment" id="cvac_AccruedOtherLiabilityForUpFrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumUnspentFundsReimbursable" id="cvac_MaximumUnspentFundsReimbursable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" id="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LongTermIncentivePlanStockOptionsMember" id="cvac_LongTermIncentivePlanStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermIncentivePlanRsusMember" id="cvac_LongTermIncentivePlanRsusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RsuSupervisoryBoardMember" id="cvac_RsuSupervisoryBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TreasurySharesTransferred" id="cvac_TreasurySharesTransferred" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContractTerminationProvisionsCurrent" id="cvac_ContractTerminationProvisionsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherMiscellaneousNonCurrentLiabilities" id="cvac_OtherMiscellaneousNonCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" id="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" id="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AmortizationOfGovernmentGrants" id="cvac_AmortizationOfGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReimbursementOfApprovedExpenses" id="cvac_ReimbursementOfApprovedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TbingenMember" id="cvac_TbingenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WiesbadenMember" id="cvac_WiesbadenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherLiabilitiesAndProvisionsAbstract" id="cvac_OtherLiabilitiesAndProvisionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseThroughReclassificationsProvisions" id="cvac_IncreaseDecreaseThroughReclassificationsProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DieviniHoppBiotechHoldingGmbhCo.KgMember" id="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MariolaFotinMleczekMember" id="cvac_MariolaFotinMleczekMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FlorianVonDerMlbeMember" id="cvac_FlorianVonDerMlbeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Dr.IngmarHrrMember" id="cvac_Dr.IngmarHrrMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncomeTaxAndSocialSecurityLiabilityReceivable" id="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborationAndLicenseAgreementMember" id="cvac_CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsTypeOfArrangementAxis" id="cvac_IfrsTypeOfArrangementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArrangementsAndNonArrangementTransactionsDomain" id="cvac_ArrangementsAndNonArrangementTransactionsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsPlanNameAxis" id="cvac_IfrsPlanNameAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsPlanNameDomain" id="cvac_IfrsPlanNameDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractTerminationProvisionsMember" id="cvac_ContractTerminationProvisionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TradeAndOtherPayablesOneMember" id="cvac_TradeAndOtherPayablesOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OnerousContractProvisionsMember" id="cvac_OnerousContractProvisionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherLiabilitiesAndProvisionsTextBlock" id="cvac_OtherLiabilitiesAndProvisionsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsProvisionForLossOnContracts" id="cvac_IfrsProvisionForLossOnContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" id="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" id="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AssetsHeldForSaleNetBookValueSold" id="cvac_AssetsHeldForSaleNetBookValueSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExpensesToHandleFutureServiceAgreement" id="cvac_ExpensesToHandleFutureServiceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BarkerBiomedicalGmbhMember" id="cvac_BarkerBiomedicalGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpenseRecognizedFromRelatedPartyTransaction" id="cvac_ExpenseRecognizedFromRelatedPartyTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CraigToomanMember" id="cvac_CraigToomanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfVotingInterestsHeld" id="cvac_PercentageOfVotingInterestsHeld" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LargestShareholderMember" id="cvac_LargestShareholderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" id="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FranzWernerHaasMember" id="cvac_FranzWernerHaasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImmaticsBiotechnologiesGmbhMember" id="cvac_ImmaticsBiotechnologiesGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" id="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsStockIssuedDuringPeriodValueNewIssues" id="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" id="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentsTransferToAssetHeldForSale" id="cvac_AdjustmentsTransferToAssetHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" id="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" id="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmountEligibleToReceiveAsCommercialMilestonePayments" id="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" id="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" id="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsOptionFeePaymentIncludedInContractLiabilities" id="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NetBookValueOfCmoEquipmentHeldForSale" id="cvac_NetBookValueOfCmoEquipmentHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReversalOfProvisionForOnerousContracts" id="cvac_ReversalOfProvisionForOnerousContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" id="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" id="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperativeExpensesMember" id="cvac_OperativeExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfRentalAgreements" id="cvac_NumberOfRentalAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MiscellaneousOtherOperatingIncomeMember" id="cvac_MiscellaneousOtherOperatingIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RepaymentOfGrantReceivedFromGovernment" id="cvac_RepaymentOfGrantReceivedFromGovernment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" id="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LandBuildingsAndSupplyInstallationsMember" id="cvac_LandBuildingsAndSupplyInstallationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" id="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DecreaseThroughClassifiedAsHeldForSale" id="cvac_DecreaseThroughClassifiedAsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" id="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" id="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EuropeSLargestPrivateBankMember" id="cvac_EuropeSLargestPrivateBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashAndCashEquivalentsOneMember" id="cvac_CashAndCashEquivalentsOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CurevacPrinterGmbhMember" id="cvac_CurevacPrinterGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AlexanderZehnderMember" id="cvac_AlexanderZehnderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TaxEffectOnNonDeductibleExpensesForTaxPurposes" id="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfPerformanceObligations" id="cvac_NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" id="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InventoryPilingForPandemicPreparednessAgreement" id="cvac_InventoryPilingForPandemicPreparednessAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AssetsHeldForSaleNetBookValueDirectSold" id="cvac_AssetsHeldForSaleNetBookValueDirectSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsSharePrice" id="cvac_IfrsSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RightOfUseAssetsNumberOfExtensionOption" id="cvac_RightOfUseAssetsNumberOfExtensionOption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsLesseeOperatingLeaseRenewalTerm" id="cvac_IfrsLesseeOperatingLeaseRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OptionalLeasePaymentsUponUsingExtensionOptions" id="cvac_OptionalLeasePaymentsUponUsingExtensionOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfSolidarySurcharge" id="cvac_PercentageOfSolidarySurcharge" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfTradeTax" id="cvac_PercentageOfTradeTax" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsinventoriesMember" id="cvac_IfrsinventoriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsprepaidExpensesAndOtherAssetsMember" id="cvac_IfrsprepaidExpensesAndOtherAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TaxLossesCarriedForwardsMember" id="cvac_TaxLossesCarriedForwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExecutiveBoardMember" id="cvac_ExecutiveBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CurevacCorporateServicesGmbhTuebingenGermanyMember" id="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VirtualShareOptionPlanMember" id="cvac_VirtualShareOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GridEuropeMember" id="cvac_GridEuropeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ServiceRenderedIssue" id="cvac_ServiceRenderedIssue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReimbursementOfTravelCost" id="cvac_ReimbursementOfTravelCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AllowanceForExpectedCreditLossOnFinancialAssets" id="cvac_AllowanceForExpectedCreditLossOnFinancialAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" id="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InterestExpenseOnCash" id="cvac_InterestExpenseOnCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAsset" id="cvac_DeferredTaxAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>56
<FILENAME>cvac-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/24/2024 9:35:19 PM-->
<!--Modified on: 4/24/2024 9:35:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsPriorVsopExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureTradeAndOtherPayablesDetails" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638495913128906326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638495913128906326" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_638495913128916324" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638495913128916324" xlink:to="ifrs-full_ProfitLossBeforeTax_638495913128916324" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638495913128916324" xlink:to="ifrs-full_FinanceIncome_638495913128916324" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638495913128916324" xlink:to="ifrs-full_FinanceCosts_638495913128916324" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638495913128916324" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638495913128916324" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_CostOfSales_638495913128916324" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638495913128916324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_SalesAndMarketingExpense_638495913128916324" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638495913128926323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638495913128926323" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638495913128926323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638495913128926323" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638495913128926323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638495913128926323" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638495913128926323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638495913128926323" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638495913128926323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638495913128916324" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638495913128926323" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913128926323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638495913128916324" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913128926323" order="2" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_NoncurrentAssets_638495913128936321" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638495913128936321" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_638495913128936321" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638495913128936321" xlink:to="ifrs-full_PropertyPlantAndEquipment_638495913128936321" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638495913128936321" xlink:to="ifrs-full_OtherNoncurrentAssets_638495913128936321" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DeferredTaxAsset" xlink:label="cvac_DeferredTaxAsset_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638495913128936321" xlink:to="cvac_DeferredTaxAsset_638495913128936321" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638495913128936321" xlink:to="ifrs-full_RightofuseAssets_638495913128936321" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_CurrentAssets_638495913128936321" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_Inventories_638495913128936321" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638495913128936321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_CurrentTradeReceivables_638495913128936321" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638495913128946319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_CurrentContractAssets_638495913128946319" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638495913128946319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638495913128946319" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_638495913128946319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_OtherCurrentFinancialAssets_638495913128946319" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638495913128946319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_CashAndCashEquivalents_638495913128946319" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_638495913128946319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_638495913128946319" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913128946319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638495913128936321" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913128946319" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638495913128946319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Equity_638495913128946319" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638495913128956319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638495913128946319" xlink:to="ifrs-full_IssuedCapital_638495913128956319" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_638495913128956319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638495913128946319" xlink:to="ifrs-full_TreasuryShares_638495913128956319" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_638495913128956319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638495913128946319" xlink:to="ifrs-full_CapitalReserve_638495913128956319" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638495913128956319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638495913128946319" xlink:to="ifrs-full_RetainedEarnings_638495913128956319" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_638495913128956319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638495913128946319" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_638495913128956319" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638495913128956319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_638495913128956319" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638495913128956319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638495913128956319" xlink:to="ifrs-full_NoncurrentLiabilities_638495913128956319" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638495913128966319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638495913128956319" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638495913128966319" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638495913128966319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638495913128956319" xlink:to="ifrs-full_NoncurrentContractLiabilities_638495913128966319" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638495913128966319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638495913128956319" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638495913128966319" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_638495913128966319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638495913128956319" xlink:to="ifrs-full_NoncurrentProvisions_638495913128966319" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638495913128966319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638495913128956319" xlink:to="ifrs-full_CurrentLiabilities_638495913128966319" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638495913128966319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638495913128966319" xlink:to="ifrs-full_CurrentLeaseLiabilities_638495913128966319" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638495913128976319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638495913128966319" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638495913128976319" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638495913128976319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638495913128966319" xlink:to="ifrs-full_OtherCurrentLiabilities_638495913128976319" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_638495913128976319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638495913128966319" xlink:to="ifrs-full_CurrentTaxLiabilities_638495913128976319" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638495913128976319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638495913128966319" xlink:to="ifrs-full_CurrentContractLiabilities_638495913128976319" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_638495913128976319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638495913128966319" xlink:to="ifrs-full_CurrentProvisions_638495913128976319" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638495913128986320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_ProfitLossBeforeTax_638495913128986320" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_638495913128986320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_638495913128986320" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_638495913128986320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_638495913128986320" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638495913128986320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638495913128986320" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions_638495913128986320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForProvisions_638495913128986320" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011_638495913128986320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_InventoryWritedown2011_638495913128986320" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638495913128996322" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913128996322" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638495913128996322" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsTransferToAssetHeldForSale" xlink:label="cvac_AdjustmentsTransferToAssetHeldForSale_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="cvac_AdjustmentsTransferToAssetHeldForSale_638495913128996322" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638495913128996322" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638495913128996322" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638495913128996322" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638495913128996322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638495913128996322" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638495913129006322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638495913129006322" order="15" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638495913129006322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638495913129006322" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638495913129006322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638495913129006322" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638495913129006322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638495913129006322" order="18" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638495913129006322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638495913129006322" order="19" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_638495913129006322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_638495913129006322" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913129016320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913129016320" order="21" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638495913129016320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913128986320" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638495913129016320" order="22" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638495913129016320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638495913129016320" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638495913129016320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638495913129016320" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638495913129016320" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638495913129016320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638495913129016320" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638495913129016320" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638495913129016320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638495913129016320" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638495913129016320" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913129016320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913129016320" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638495913129026323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913129016320" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638495913129026323" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638495913129026323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913129016320" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638495913129026323" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638495913129026323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913129016320" xlink:to="ifrs-full_ProceedsFromIssuingShares_638495913129026323" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638495913129026323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913129016320" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638495913129026323" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638495913129026323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913129016320" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638495913129026323" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" xlink:type="extended" xlink:title="40310 - Disclosure - Notes to the consolidated financial statements - Operative Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638495913129036321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="cvac_PersonnelExpenses_638495913129036321" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638495913129036321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638495913129036321" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638495913129036321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="cvac_ThirdPartyServiceExpenses_638495913129036321" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638495913129036321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="cvac_MaintenanceAndLeaseExpenses_638495913129036321" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638495913129036321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638495913129036321" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_638495913129036321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_638495913129036321" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_638495913129036321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_638495913129036321" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638495913129046321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ProfessionalFeesExpense_638495913129046321" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638495913129046321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="cvac_OtherExpense_638495913129046321" order="9" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40312 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="MiscellaneousOtherOperatingIncome" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_638495913129046321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_SaleOfEquipment_638495913129046321" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_638495913129046321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CostOfReimbursementClaim_638495913129046321" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_638495913129046321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_638495913129046321" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_638495913129046321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_638495913129046321" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_638495913129046321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_638495913129046321" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Fixed Assets - Amounts recognized in the statement of operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LeasesExpenseRecognizedInProfitOrLoss" xlink:label="LeasesExpenseRecognizedInProfitOrLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets_638495913129056323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeasesExpenseRecognizedInProfitOrLoss" xlink:to="ifrs-full_DepreciationRightofuseAssets_638495913129056323" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImpairmentOnRightOfUseAssets" xlink:label="cvac_ImpairmentOnRightOfUseAssets_638495913129056323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeasesExpenseRecognizedInProfitOrLoss" xlink:to="cvac_ImpairmentOnRightOfUseAssets_638495913129056323" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_638495913129056323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeasesExpenseRecognizedInProfitOrLoss" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_638495913129056323" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_638495913129056323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeasesExpenseRecognizedInProfitOrLoss" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_638495913129056323" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_638495913129056323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeasesExpenseRecognizedInProfitOrLoss" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_638495913129056323" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Share-based payments - Prior VSOP - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638495913129056323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638495913129056323" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913129056323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913129056323" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913129066321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913129066321" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913129066321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913129066321" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="ExpenseRecognizedForEmployeeServices" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913129066321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseRecognizedForEmployeeServices" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913129066321" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913129066321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseRecognizedForEmployeeServices" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913129066321" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913129066321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseRecognizedForEmployeeServices" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913129066321" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Trade and other payables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638495913129066321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638495913129066321" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_638495913129066321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_638495913129066321" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities and provisions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_638495913129076321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_CurrentProvisions_638495913129076321" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision" xlink:label="ifrs-full_ShorttermOnerousContractsProvision_638495913129076321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentProvisions_638495913129076321" xlink:to="ifrs-full_ShorttermOnerousContractsProvision_638495913129076321" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisions" xlink:label="cvac_ContractTerminationProvisions_638495913129076321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentProvisions_638495913129076321" xlink:to="cvac_ContractTerminationProvisions_638495913129076321" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_638495913129076321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_NoncurrentProvisions_638495913129076321" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisionsCurrent" xlink:label="cvac_ContractTerminationProvisionsCurrent_638495913129076321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentProvisions_638495913129076321" xlink:to="cvac_ContractTerminationProvisionsCurrent_638495913129076321" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Other liabilities and provisions - Current and Non Current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities" xlink:label="ifrs-full_OtherLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638495913129076321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_638495913129076321" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilityCurrent" xlink:label="cvac_OtherLiabilityCurrent_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentLiabilities_638495913129076321" xlink:to="cvac_OtherLiabilityCurrent_638495913129086323" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentLiabilities_638495913129076321" xlink:to="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_638495913129086323" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfessionalFessCurrent" xlink:label="cvac_ProfessionalFessCurrent_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentLiabilities_638495913129076321" xlink:to="cvac_ProfessionalFessCurrent_638495913129086323" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OutstandingInvoicesCurrent" xlink:label="cvac_OutstandingInvoicesCurrent_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentLiabilities_638495913129076321" xlink:to="cvac_OutstandingInvoicesCurrent_638495913129086323" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants" xlink:label="ifrs-full_CurrentGovernmentGrants_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentLiabilities_638495913129076321" xlink:to="ifrs-full_CurrentGovernmentGrants_638495913129086323" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelAccruedLiabilities" xlink:label="cvac_PersonnelAccruedLiabilities_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentLiabilities_638495913129076321" xlink:to="cvac_PersonnelAccruedLiabilities_638495913129086323" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638495913129086323" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_638495913129086323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherNoncurrentLiabilities_638495913129086323" xlink:to="cvac_OtherMiscellaneousNonCurrentLiabilities_638495913129086323" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income tax - Schedule of tax reconciliations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638495913129096323" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_638495913129096323" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_638495913129096323" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_638495913129096323" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:label="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913129096323" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:label="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913129096323" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes" xlink:label="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_638495913129096323" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" xlink:label="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_638495913129096323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_638495913129096323" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_638495913129106332" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_638495913129106332" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_638495913129106332" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_638495913129106332" order="10" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractualCommitmentsUndiscountedCashFlows" xlink:label="cvac_ContractualCommitmentsUndiscountedCashFlows_638495913129106332" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="cvac_ContractualCommitmentsUndiscountedCashFlows_638495913129106332" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities_638495913129106332" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_GrossLeaseLiabilities_638495913129106332" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesUndiscountedCashFlows" xlink:label="cvac_OtherLiabilitiesUndiscountedCashFlows_638495913129106332" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="cvac_OtherLiabilitiesUndiscountedCashFlows_638495913129106332" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_638495913129106332" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_638495913129106332" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Remuneration of the Company's key management personnel (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="KeyManagementPersonnelCompensation" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638495913129116323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638495913129116323" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_638495913129116323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_638495913129116323" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638495913129116323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638495913129116323" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" xlink:type="extended" xlink:title="42002 - Disclosure - Business Combinations - Fair value recognized on acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638495913129116323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638495913129116323" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638495913129116323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638495913129116323" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638495913129116323" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638495913129116323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638495913129116323" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638495913129116323" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638495913129116323" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638495913129116323" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638495913129116323" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638495913129116323" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638495913129126402" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638495913129116323" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638495913129126402" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638495913129126402" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638495913129126402" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638495913129126402" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_638495913129126402" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638495913129126402" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638495913129126402" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638495913129136322" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" xlink:type="extended" xlink:title="42003 - Disclosure - Business Combinations - Goodwill recognized as a result of the acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913129136322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913129136322" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638495913129136322" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638495913129136322" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>57
<FILENAME>cvac-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/24/2024 9:35:19 PM-->
<!--Modified on: 4/24/2024 9:35:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityFollowOnPublicOfferingDetails" roleURI="http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityAtMarketOfferingDetails" roleURI="http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails" roleURI="http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsPriorVsopExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsRestrictedStockUnitsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxScheduleOfDeferredTaxesDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="EntityAddressesAddressTypeAxis" xlink:title="EntityAddressesAddressTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="AddressTypeDomain" xlink:title="AddressTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EntityAddressesAddressTypeAxis" xlink:to="AddressTypeDomain" xlink:title="definition: EntityAddressesAddressTypeAxis to AddressTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:title="RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="RestatedMember" xlink:title="RestatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="RestatedMember" xlink:title="definition: RetrospectiveApplicationAndRetrospectiveRestatementAxis to RestatedMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="definition: ComponentsOfEquityAxis to EquityMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="IfrsSaleOfStockAxis" xlink:title="IfrsSaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="IfrsSaleOfStockDomain" xlink:title="IfrsSaleOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsSaleOfStockAxis" xlink:to="IfrsSaleOfStockDomain" xlink:title="definition: IfrsSaleOfStockAxis to IfrsSaleOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingAxis" xlink:label="IfrsVestingAxis" xlink:title="IfrsVestingAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="IfrsVestingDomain" xlink:title="IfrsVestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsVestingAxis" xlink:to="IfrsVestingDomain" xlink:title="definition: IfrsVestingAxis to IfrsVestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember" xlink:title="definition: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="BusinessCombinationsAxis" xlink:title="BusinessCombinationsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="EntitysTotalForBusinessCombinationsMember" xlink:title="EntitysTotalForBusinessCombinationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessCombinationsAxis" xlink:to="EntitysTotalForBusinessCombinationsMember" xlink:title="definition: BusinessCombinationsAxis to EntitysTotalForBusinessCombinationsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="TimingOfTransferOfGoodsOrServicesAxis" xlink:title="TimingOfTransferOfGoodsOrServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="TimingOfTransferOfGoodsOrServicesMember" xlink:title="TimingOfTransferOfGoodsOrServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TimingOfTransferOfGoodsOrServicesAxis" xlink:to="TimingOfTransferOfGoodsOrServicesMember" xlink:title="definition: TimingOfTransferOfGoodsOrServicesAxis to TimingOfTransferOfGoodsOrServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember" xlink:title="definition: ClassesOfAssetsAxis to ClassesOfAssetsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="InitiallyAppliedIFRSsAxis" xlink:title="InitiallyAppliedIFRSsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="InitiallyAppliedIFRSsMember" xlink:title="InitiallyAppliedIFRSsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InitiallyAppliedIFRSsAxis" xlink:to="InitiallyAppliedIFRSsMember" xlink:title="definition: InitiallyAppliedIFRSsAxis to InitiallyAppliedIFRSsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskAxis" xlink:label="ConcentrationsOfRiskAxis" xlink:title="ConcentrationsOfRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ConcentrationsOfRiskMember" xlink:title="ConcentrationsOfRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationsOfRiskAxis" xlink:to="ConcentrationsOfRiskMember" xlink:title="definition: ConcentrationsOfRiskAxis to ConcentrationsOfRiskMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:title="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="IntangibleAssetsOtherThanGoodwillMember" xlink:title="IntangibleAssetsOtherThanGoodwillMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IntangibleAssetsOtherThanGoodwillMember" xlink:title="definition: ClassesOfIntangibleAssetsOtherThanGoodwillAxis to IntangibleAssetsOtherThanGoodwillMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember" xlink:title="definition: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="GeographicalAreasAxis" xlink:title="GeographicalAreasAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="GeographicalAreasMember" xlink:title="GeographicalAreasMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GeographicalAreasAxis" xlink:to="GeographicalAreasMember" xlink:title="definition: GeographicalAreasAxis to GeographicalAreasMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="MajorCustomersMember" xlink:title="MajorCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="MajorCustomersMember" xlink:title="definition: MajorCustomersAxis to MajorCustomersMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsAxis" xlink:label="GovernmentGrantsAxis" xlink:title="GovernmentGrantsAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="GovernmentGrantsDomain" xlink:title="GovernmentGrantsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GovernmentGrantsAxis" xlink:to="GovernmentGrantsDomain" xlink:title="definition: GovernmentGrantsAxis to GovernmentGrantsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="IfrsIncomeStatementLocationAxis" xlink:title="IfrsIncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="IfrsIncomeStatementLocationDomain" xlink:title="IfrsIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsIncomeStatementLocationAxis" xlink:to="IfrsIncomeStatementLocationDomain" xlink:title="definition: IfrsIncomeStatementLocationAxis to IfrsIncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain" xlink:title="definition: CurrencyAxis to AllCurrenciesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ClassesOfFinancialInstrumentsAxis" xlink:title="ClassesOfFinancialInstrumentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ClassesOfFinancialInstrumentsMember" xlink:title="ClassesOfFinancialInstrumentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfFinancialInstrumentsAxis" xlink:to="ClassesOfFinancialInstrumentsMember" xlink:title="definition: ClassesOfFinancialInstrumentsAxis to ClassesOfFinancialInstrumentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="LevelsOfFairValueHierarchyAxis" xlink:title="LevelsOfFairValueHierarchyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="AllLevelsOfFairValueHierarchyMember" xlink:title="AllLevelsOfFairValueHierarchyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LevelsOfFairValueHierarchyAxis" xlink:to="AllLevelsOfFairValueHierarchyMember" xlink:title="definition: LevelsOfFairValueHierarchyAxis to AllLevelsOfFairValueHierarchyMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:title="LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="definition: LiabilitiesArisingFromFinancingActivitiesAxis to LiabilitiesArisingFromFinancingActivitiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis_1" xlink:title="ifrs-full_TypesOfContractsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_1" xlink:title="ifrs-full_TypesOfContractsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfContractsAxis_1" xlink:to="ifrs-full_TypesOfContractsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfContractsAxis_1 To ifrs-full_TypesOfContractsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis" xlink:title="cvac_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:title="cvac_ArrangementsAndNonArrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_IfrsTypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_TypeOfArrangementAxis_1 To cvac_ArrangementsAndNonArrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1 To cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_1" xlink:title="ifrs-full_CounterpartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_1" xlink:title="ifrs-full_CounterpartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CounterpartiesAxis_1" xlink:to="ifrs-full_CounterpartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CounterpartiesAxis_1 To ifrs-full_CounterpartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:title="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" xlink:title="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:to="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1 To ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_1" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1 To ifrs-full_EntitysTotalForSubsidiariesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember_1" xlink:title="ifrs-full_ContingentLiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:to="ifrs-full_ContingentLiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfContingentLiabilitiesAxis_1 To ifrs-full_ContingentLiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AssetsHeldForSaleAxis" xlink:label="cvac_AssetsHeldForSaleAxis_1" xlink:title="cvac_AssetsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AssetsHeldForSaleDomain" xlink:label="cvac_AssetsHeldForSaleDomain_1" xlink:title="cvac_AssetsHeldForSaleDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_AssetsHeldForSaleAxis_1" xlink:to="cvac_AssetsHeldForSaleDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_AssetsHeldForSaleAxis_1 To cvac_AssetsHeldForSaleDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" xlink:title="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_1" xlink:title="ifrs-full_IntangibleAssetsAndGoodwillMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1 To ifrs-full_IntangibleAssetsAndGoodwillMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis" xlink:label="ifrs-full_ReclassifiedItemsAxis_1" xlink:title="ifrs-full_ReclassifiedItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember" xlink:label="ifrs-full_ReclassifiedItemsMember_1" xlink:title="ifrs-full_ReclassifiedItemsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ReclassifiedItemsAxis_1" xlink:to="ifrs-full_ReclassifiedItemsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ReclassifiedItemsAxis_1 To ifrs-full_ReclassifiedItemsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis_1" xlink:title="cvac_IfrsTypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_1" xlink:title="cvac_ArrangementsAndNonArrangementTransactionsDomain_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis_1" xlink:title="cvac_IfrsPlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_1" xlink:title="cvac_IfrsPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_IfrsPlanNameAxis_1" xlink:to="cvac_IfrsPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_IfrsPlanNameAxis_1 To cvac_IfrsPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis_1" xlink:title="ifrs-full_ClassesOfProvisionsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember_1" xlink:title="ifrs-full_OtherProvisionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfProvisionsAxis_1" xlink:to="ifrs-full_OtherProvisionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfProvisionsAxis_1 To ifrs-full_OtherProvisionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_1" xlink:title="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_1" xlink:title="ifrs-full_LineItemsByFunctionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_1" xlink:to="ifrs-full_LineItemsByFunctionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_1 To ifrs-full_LineItemsByFunctionMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_638495913129146321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_638495913129146321" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638495913129236324" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_638495913129236324" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:label="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="31003 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913129266329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913129266329" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913129276408" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913129276408" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913129496331" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913129496331" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LargestShareholderMember" xlink:label="cvac_LargestShareholderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_LargestShareholderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfVotingInterestsHeld" xlink:label="cvac_PercentageOfVotingInterestsHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PercentageOfVotingInterestsHeld" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPolicyTable" xlink:label="cvac_SignificantAccountingPolicyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_SignificantAccountingPolicyTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638495913129506330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember_638495913129506330" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_IfrsProductMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_SignificantAccountingPolicyTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913129506330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913129506330" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPolicyLineItems" xlink:label="cvac_SignificantAccountingPolicyLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="cvac_SignificantAccountingPolicyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPropertyPlantAndEquipmentSalvageValue" xlink:label="cvac_IfrsPropertyPlantAndEquipmentSalvageValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="cvac_IfrsPropertyPlantAndEquipmentSalvageValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisions" xlink:label="cvac_ContractTerminationProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="cvac_ContractTerminationProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision" xlink:label="ifrs-full_ShorttermOnerousContractsProvision" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="ifrs-full_ShorttermOnerousContractsProvision" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="ifrs-full_BorrowingCostsCapitalised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="ifrs-full_BorrowingCostsCapitalised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfOperatingSegments" xlink:label="cvac_IfrsNumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="cvac_IfrsNumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfReportableSegments" xlink:label="cvac_IfrsNumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="cvac_IfrsNumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" xlink:label="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Accounting Policies - Estimated useful lives Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638495913129536333" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638495913129536333" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="cvac_SoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_LicencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="cvac_TechnologyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913129546330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913129546330" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Accounting Policies - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638495913129556332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638495913129556332" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnicalEquipmentAndMachinesMember" xlink:label="cvac_TechnicalEquipmentAndMachinesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913129556332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913129556332" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Accounting Policies - Estimated useful life of right-of-use assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_638495913129566332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_638495913129566332" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LandBuildingsAndSupplyInstallationsMember" xlink:label="cvac_LandBuildingsAndSupplyInstallationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_LandBuildingsAndSupplyInstallationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember" xlink:label="ifrs-full_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherEquipmentMember" xlink:label="cvac_OtherEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_OtherEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913129576328" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913129576328" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:label="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638495913129586331" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_638495913129586331" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_BE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH" xlink:label="country_CH" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CH" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="country_NL" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" xlink:label="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638495913129596329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember_638495913129596329" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_OtherCustomersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638495913129606331" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember_638495913129606331" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638495913129616330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638495913129616330" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_CrisprTherapeuticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GenmabMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="cvac_IfrsTypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsTypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913129616330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsTypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913129616330" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:to="cvac_GlaxosmithklineCovidAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:to="cvac_CollaborationAndLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638495913129626329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember_638495913129626329" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" xlink:to="cvac_IfrsProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638495913129636332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_638495913129636332" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_BE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionFeePayment" xlink:label="cvac_OptionFeePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_OptionFeePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfPerformanceObligations" xlink:label="cvac_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" xlink:label="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638495913129686334" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember_638495913129686334" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638495913129696322" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_638495913129696322" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913129706324" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913129706324" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsCostOfSalesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913129716328" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913129716328" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="cvac_OperativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913129726320" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913129726320" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_SellingAndDistributionExpensesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913129736325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913129736325" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="cvac_OperativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the consolidated financial statements - Research and development (R&amp;D) expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913129746316" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913129746316" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913129746316" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913129746316" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="cvac_OperativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ReversalOfProvisionForOnerousContracts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProvisionForLossOnContracts" xlink:label="cvac_IfrsProvisionForLossOnContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_IfrsProvisionForLossOnContracts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913129776325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913129776325" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913129776325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913129776325" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="cvac_OperativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" xlink:type="extended" xlink:title="40310 - Disclosure - Notes to the consolidated financial statements - Operative Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913129796321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913129796321" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="cvac_OperativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_GovernmentGrantsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_638495913129816325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain_638495913129816325" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638495913129826325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638495913129826325" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_IfrsTypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsTypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913129826325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsTypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913129826325" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913129836319" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913129836319" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MiscellaneousOtherOperatingIncomeMember" xlink:label="cvac_MiscellaneousOtherOperatingIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_MiscellaneousOtherOperatingIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsRemainingGrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_RevenueFromGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_UpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" xlink:label="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_MaximumGrantToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementMaximumAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfApprovedExpenses" xlink:label="cvac_ReimbursementOfApprovedExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReimbursementOfApprovedExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfAdditionalGrantsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmortizationOfGovernmentGrants" xlink:label="cvac_AmortizationOfGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_AmortizationOfGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RepaymentOfGrantReceivedFromGovernment" xlink:label="cvac_RepaymentOfGrantReceivedFromGovernment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_RepaymentOfGrantReceivedFromGovernment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_GovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_MaximumUnspentFundsReimbursable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913129876319" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913129876319" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913129886329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913129886329" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="cvac_SoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_LicencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="cvac_TechnologyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdvancePaymentsIntangibleAssetMember" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="cvac_AdvancePaymentsIntangibleAssetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_GoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSharePrice" xlink:label="cvac_IfrsSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="cvac_IfrsSharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913129906318" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913129906318" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638495913129916329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638495913129916329" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_BuildingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="ifrs-full_BorrowingCostsCapitalised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_BorrowingCostsCapitalised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fixed Assets - Right-of-use assets and lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsTable" xlink:label="cvac_StatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_StatementsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_638495913130036332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_638495913130036332" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="ifrs-full_LandAndBuildingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_LandAndBuildingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember" xlink:label="ifrs-full_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_StatementsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638495913130036332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_638495913130036332" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TbingenMember" xlink:label="cvac_TbingenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cvac_TbingenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_WiesbadenMember" xlink:label="cvac_WiesbadenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cvac_WiesbadenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsLineItems" xlink:label="cvac_StatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_StatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_StatementsLineItems" xlink:to="ifrs-full_RightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_StatementsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_StatementsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImpairmentOnRightOfUseAssets" xlink:label="cvac_ImpairmentOnRightOfUseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_ImpairmentOnRightOfUseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Foreigncurrencytranslationrightofuseassets" xlink:label="cvac_Foreigncurrencytranslationrightofuseassets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_Foreigncurrencytranslationrightofuseassets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfRentalAgreements" xlink:label="cvac_NumberOfRentalAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_NumberOfRentalAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightOfUseAssetsNumberOfExtensionOption" xlink:label="cvac_RightOfUseAssetsNumberOfExtensionOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_RightOfUseAssetsNumberOfExtensionOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsLesseeOperatingLeaseRenewalTerm" xlink:label="cvac_IfrsLesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_IfrsLesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Equity - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638495913130056320" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638495913130056320" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_PreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Equity - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913130066329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain_638495913130066329" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_AtMarketOfferingProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PublicOfferingOfCommonSharesMember" xlink:label="cvac_PublicOfferingOfCommonSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_PublicOfferingOfCommonSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_CommonSharesIssuedAndOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_ShareOptionExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Equity - Follow-on public offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913130086322" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain_638495913130086322" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ClosingOfPublicOfferingOfCommonSharesMember" xlink:label="cvac_ClosingOfPublicOfferingOfCommonSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ClosingOfPublicOfferingOfCommonSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsOverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Equity - At-the-market offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913130096325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain_638495913130096325" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_AtMarketOfferingProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Equity - Frame acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130106323" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130106323" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_BusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Equity - Exercises of share options under the VSOP plan and legacy program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsTable" xlink:label="cvac_StatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_StatementsTable" xlink:to="cvac_IfrsPlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913130116325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain_638495913130116325" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OldVsopPlanMember" xlink:label="cvac_OldVsopPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsPlanNameDomain" xlink:to="cvac_OldVsopPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NewVsopPlanMember" xlink:label="cvac_NewVsopPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsPlanNameDomain" xlink:to="cvac_NewVsopPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LegacyPlanMember" xlink:label="cvac_LegacyPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IfrsPlanNameDomain" xlink:to="cvac_LegacyPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsLineItems" xlink:label="cvac_StatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_StatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesHeldForTaxLiabilities" xlink:label="cvac_IfrsNumberOfSharesHeldForTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_IfrsNumberOfSharesHeldForTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_StatementsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_StatementsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Share-based payments - Expense recognized for the share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130126327" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130126327" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanStockOptionsMember" xlink:label="cvac_LongTermIncentivePlanStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanRsusMember" xlink:label="cvac_LongTermIncentivePlanRsusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanRsusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RsuSupervisoryBoardMember" xlink:label="cvac_RsuSupervisoryBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RsuSupervisoryBoardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130146325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130146325" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TreasurySharesTransferred" xlink:label="cvac_TreasurySharesTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_TreasurySharesTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ProvisionForEmployerTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Share-based payments - Prior VSOP - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130166320" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130166320" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Share-based payments - New VSOP - Reconciliation of outstanding awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130176330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130176330" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913130186327" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain_638495913130186327" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913130186327" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913130186327" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ProvisionForEmployerTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RemainingOptionLifeShareOptionsAwardsGranted" xlink:label="cvac_RemainingOptionLifeShareOptionsAwardsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_RemainingOptionLifeShareOptionsAwardsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsEmployerTaxesPayable" xlink:label="cvac_IfrsEmployerTaxesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsEmployerTaxesPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130206318" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130206318" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913130216326" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain_638495913130216326" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsEmployerTaxesPayable" xlink:label="cvac_IfrsEmployerTaxesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsEmployerTaxesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ProvisionForEmployerTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseRecognizedForEmployeeServices" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130236326" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130236326" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefScientificOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefDevelopmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_KeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsVestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain_638495913130246321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingDomain_638495913130246321" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913130246321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913130246321" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130256320" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130256320" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" xlink:label="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsVestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain_638495913130276321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingDomain_638495913130276321" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsPlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913130286330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain_638495913130286330" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsPlanNameDomain" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130286330" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130286330" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130296321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130296321" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefScientificOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefDevelopmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_KeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913130306321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913130306321" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" xlink:label="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" xlink:label="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130336320" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130336320" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsPlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913130346326" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain_638495913130346326" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsPlanNameDomain" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130346326" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130346326" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_KeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_FormerFrameEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" xlink:label="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ProvisionForEmployerTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsEmployerTaxesPayable" xlink:label="cvac_IfrsEmployerTaxesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsEmployerTaxesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130416352" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130416352" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41010 - Disclosure - Share-based payments - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130426331" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130426331" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsPlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913130426331" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameDomain_638495913130426331" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsPlanNameDomain" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130436338" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130436338" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails" xlink:type="extended" xlink:title="41011 - Disclosure - Share-based payments - Restricted Stock Units expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130446324" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130446324" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Other liabilities and provisions - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_OtherProvisionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember_638495913130466333" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_OtherProvisionsMember_638495913130466333" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OnerousContractProvisionsMember" xlink:label="cvac_OnerousContractProvisionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="cvac_OnerousContractProvisionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisionsMember" xlink:label="cvac_ContractTerminationProvisionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="cvac_ContractTerminationProvisionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="cvac_GovernmentGrantsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_638495913130466333" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain_638495913130466333" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="ifrs-full_UnusedProvisionReversedOtherProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="ifrs-full_UnusedProvisionReversedOtherProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="ifrs-full_ProvisionUsedOtherProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="ifrs-full_ProvisionUsedOtherProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughReclassificationsProvisions" xlink:label="cvac_IncreaseDecreaseThroughReclassificationsProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_IncreaseDecreaseThroughReclassificationsProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_MaximumUnspentFundsReimbursable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxTable" xlink:label="cvac_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_IncomeTaxTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130486331" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130486331" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubsidiariesMember" xlink:label="ifrs-full_SubsidiariesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_SubsidiariesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxLineItems" xlink:label="cvac_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_IncomeTaxLineItems" xlink:to="cvac_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" xlink:label="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_IncomeTaxLineItems" xlink:to="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" xlink:label="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_IncomeTaxLineItems" xlink:to="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_DeferredTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_ApplicableTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="ifrs-full_AverageEffectiveTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_IncomeTaxLineItems" xlink:to="ifrs-full_AverageEffectiveTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfSolidarySurcharge" xlink:label="cvac_PercentageOfSolidarySurcharge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_IncomeTaxLineItems" xlink:to="cvac_PercentageOfSolidarySurcharge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfTradeTax" xlink:label="cvac_PercentageOfTradeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_IncomeTaxLineItems" xlink:to="cvac_PercentageOfTradeTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income tax - Schedule of deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913130506334" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913130506334" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IntangibleAssetsMember" xlink:label="cvac_IntangibleAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_IntangibleAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_RightofuseAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember" xlink:label="ifrs-full_OtherAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_OtherAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsinventoriesMember" xlink:label="cvac_IfrsinventoriesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_IfrsinventoriesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsprepaidExpensesAndOtherAssetsMember" xlink:label="cvac_IfrsprepaidExpensesAndOtherAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_IfrsprepaidExpensesAndOtherAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TradeReceivablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareBasedPaymentsMember" xlink:label="cvac_ShareBasedPaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_ShareBasedPaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NonCurrentLeaseLiabilitiesMember" xlink:label="cvac_NonCurrentLeaseLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_NonCurrentLeaseLiabilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherNoncurrentLiabilitiesMember" xlink:label="cvac_IfrsOtherNoncurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_IfrsOtherNoncurrentLiabilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_TradeAndOtherPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentLeaseLiabilitiesMember" xlink:label="cvac_CurrentLeaseLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_CurrentLeaseLiabilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherLiabilitiesMember" xlink:label="cvac_IfrsOtherLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_IfrsOtherLiabilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxLossesCarriedForwardsMember" xlink:label="cvac_TaxLossesCarriedForwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_TaxLossesCarriedForwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" xlink:label="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_638495913130526323" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_638495913130526323" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" xlink:label="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_NetDeferredTaxAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Disclosure of financial instruments and management of financial risks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskAxis" xlink:label="ifrs-full_ConcentrationsOfRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_ConcentrationsOfRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ifrs-full_ConcentrationsOfRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ConcentrationsOfRiskAxis" xlink:to="ifrs-full_ConcentrationsOfRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ifrs-full_ConcentrationsOfRiskMember_638495913130546323" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ConcentrationsOfRiskAxis" xlink:to="ifrs-full_ConcentrationsOfRiskMember_638495913130546323" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanysLargestPrivateBankMember" xlink:label="cvac_GermanysLargestPrivateBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ConcentrationsOfRiskMember" xlink:to="cvac_GermanysLargestPrivateBankMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanLandesbankMember" xlink:label="cvac_GermanLandesbankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_GermanysLargestPrivateBankMember" xlink:to="cvac_GermanLandesbankMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_EuropeSLargestPrivateBankMember" xlink:label="cvac_EuropeSLargestPrivateBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ConcentrationsOfRiskMember" xlink:to="cvac_EuropeSLargestPrivateBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_638495913130556334" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember_638495913130556334" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_FinanceIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_InterestIncomeOnCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain" xlink:label="ifrs-full_ForeignExchangeGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ForeignExchangeGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_FinanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="ifrs-full_ForeignExchangeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ForeignExchangeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InterestExpenseOnCash" xlink:label="cvac_InterestExpenseOnCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="cvac_InterestExpenseOnCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsConcentrationRiskPercentage" xlink:label="cvac_IfrsConcentrationRiskPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="cvac_IfrsConcentrationRiskPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AllowanceForExpectedCreditLossOnFinancialAssets" xlink:label="cvac_AllowanceForExpectedCreditLossOnFinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="cvac_AllowanceForExpectedCreditLossOnFinancialAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638495913130576326" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_638495913130576326" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanFiveYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractualCommitmentsUndiscountedCashFlows" xlink:label="cvac_ContractualCommitmentsUndiscountedCashFlows" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="cvac_ContractualCommitmentsUndiscountedCashFlows" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesUndiscountedCashFlows" xlink:label="cvac_OtherLiabilitiesUndiscountedCashFlows" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="cvac_OtherLiabilitiesUndiscountedCashFlows" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_638495913130586328" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_638495913130586328" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF" xlink:label="currency_CHF" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CHF" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="currency_EUR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP" xlink:label="currency_GBP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_638495913130596333" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_638495913130596333" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913130606324" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913130606324" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CashAndCashEquivalentsOneMember" xlink:label="cvac_CashAndCashEquivalentsOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_CashAndCashEquivalentsOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherReceivablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Notes to the consolidated statements of cash flows - Financing activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_638495913130626339" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_638495913130626339" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" xlink:label="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" xlink:label="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Remuneration of the Company's key management personnel (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130636328" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130636328" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ManagementBoardMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SupervisoryBoardMember" xlink:label="cvac_SupervisoryBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_SupervisoryBoardMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Remuneration of the Company's key management personnel - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130646328" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130646328" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ManagementBoardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SupervisoryBoardMember" xlink:label="cvac_SupervisoryBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_SupervisoryBoardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExecutiveBoardMember" xlink:label="cvac_ExecutiveBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ExecutiveBoardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130656332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130656332" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration" xlink:label="ifrs-full_AuditorsRemuneration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_AuditorsRemuneration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130666326" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913130666326" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_BaronJeanStephenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_VincentStphenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_AntonyBlancMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130676338" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913130676338" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_RittershausRechtsanwaelteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_DietmarHoppMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_BepharbelManufacturingS.aMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FranzWernerHaasMember" xlink:label="cvac_FranzWernerHaasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_FranzWernerHaasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AlexanderZehnderMember" xlink:label="cvac_AlexanderZehnderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_AlexanderZehnderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BarkerBiomedicalGmbhMember" xlink:label="cvac_BarkerBiomedicalGmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_BarkerBiomedicalGmbhMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CraigToomanMember" xlink:label="cvac_CraigToomanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_CraigToomanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ClarentisSrlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MariolaFotinMleczekMember" xlink:label="cvac_MariolaFotinMleczekMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_MariolaFotinMleczekMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FlorianVonDerMlbeMember" xlink:label="cvac_FlorianVonDerMlbeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_FlorianVonDerMlbeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Dr.IngmarHrrMember" xlink:label="cvac_Dr.IngmarHrrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_Dr.IngmarHrrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImmaticsBiotechnologiesGmbhMember" xlink:label="cvac_ImmaticsBiotechnologiesGmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ImmaticsBiotechnologiesGmbhMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurevacPrinterGmbhMember" xlink:label="cvac_CurevacPrinterGmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_CurevacPrinterGmbhMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GridEuropeMember" xlink:label="cvac_GridEuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_GridEuropeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913130696342" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913130696342" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638495913130706329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638495913130706329" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionConsultingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfTravelCost" xlink:label="cvac_ReimbursementOfTravelCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_ReimbursementOfTravelCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_ExpenseRecognizedFromRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" xlink:label="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpensesToHandleFutureServiceAgreement" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_ExpensesToHandleFutureServiceAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ServiceRenderedIssue" xlink:label="cvac_ServiceRenderedIssue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_ServiceRenderedIssue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Business Combinations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130756331" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130756331" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FairValueOfTotalConsiderationTransferred" xlink:label="cvac_FairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_FairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_LiabilitiesIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationNumberOfPaymentsConsidered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsBusinessAcquisitionSharePrice" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_IfrsBusinessAcquisitionSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionalCashTransferred" xlink:label="cvac_AdditionalCashTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_AdditionalCashTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationPercentageOfTotalConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationNumberOfMilestones" xlink:label="cvac_ContingentConsiderationNumberOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationNumberOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_EquityInterestsOfAcquirer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationMaximumSharesIssuable" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationMaximumSharesIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionalFairValue" xlink:label="cvac_ProvisionalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ProvisionalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SigningSharePriceRepresenting10" xlink:label="cvac_SigningSharePriceRepresenting10" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_SigningSharePriceRepresenting10" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SigningSharePriceRepresenting40" xlink:label="cvac_SigningSharePriceRepresenting40" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_SigningSharePriceRepresenting40" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" xlink:type="extended" xlink:title="42002 - Disclosure - Business Combinations - Fair value recognized on acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130866334" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130866334" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_FairValueOfAcquiredReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" xlink:type="extended" xlink:title="42003 - Disclosure - Business Combinations - Goodwill recognized as a result of the acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130896328" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913130896328" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638495913130906339" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_638495913130906339" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualShareOptionPlanMember" xlink:label="cvac_VirtualShareOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="cvac_VirtualShareOptionPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913130916338" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_638495913130916338" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DistributionCosts" xlink:label="ifrs-full_DistributionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DistributionCosts" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>58
<FILENAME>cvac-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/24/2024 9:35:19 PM-->
<!--Modified on: 4/24/2024 9:35:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Email Address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations and Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from release of governmental contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from release of governmental contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit/ (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax benefit / (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DeferredTaxAsset" xlink:label="cvac_DeferredTaxAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DeferredTaxAsset" xlink:to="cvac_DeferredTaxAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DeferredTaxAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of deferred tax assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DeferredTaxAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DeferredTaxAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Assets Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets or disposal groups classified as held for sale or as held for distribution to owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value less anticipated costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current prepayments and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax assets, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity And Liabilities Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current Liabilities Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisions" xlink:to="ifrs-full_NoncurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions (non-current)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities (non-current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions (current)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities (current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Changes in Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserveMember" xlink:to="ifrs-full_CapitalReserveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued on exercise of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of share capital (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:label="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:to="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in contingent consideration asset (liability)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuances and contingent consideration from business combination</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" xlink:to="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of exercise of options or share based payment awards settled in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of Options Settlement Of Share Based Payment Awards Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options / Settlement of share-based payment awards</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of share based payment awards settled in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Of Share Based Payment Awards , Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement of share-based payment awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through treasury share transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase of common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile loss before tax to net cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceCosts" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for gain (loss) on disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsTransferToAssetHeldForSale" xlink:label="cvac_AdjustmentsTransferToAssetHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsTransferToAssetHeldForSale" xlink:to="cvac_AdjustmentsTransferToAssetHeldForSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsTransferToAssetHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfer to assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsTransferToAssetHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments Transfer To Asset Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdjustmentsTransferToAssetHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryWritedown2011" xlink:to="ifrs-full_InventoryWritedown2011_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials write-off</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes of provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangesInWorkingCapitalAbstract" xlink:to="cvac_ChangesInWorkingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Working Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital changes</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Decrease (Increase) In Non-current Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in asset held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in trade receivables and contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in inventory</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in prepaid expenses, and assets classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Increase Decrease In Prepaid Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from government grants and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from Government Grants Classified as Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from grants from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) / increase in trade and other payables and contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Increase Decrease In Other Current Financial And Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) / increase in other current financial and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for deferred tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow provided by (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of subsidiary, net of cash acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of shares (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of proceed from issuing other equity instrument or exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceed From Issuing Other Equity Instrument Or Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on / proceeds from treasury shares/exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accrued other liability for up-front payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from at-the-market offering program (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of the EIB loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of currency translation gains on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CorporateInformationAbstract" xlink:label="cvac_CorporateInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationAbstract" xlink:to="cvac_CorporateInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationTextBlock" xlink:to="cvac_CorporateInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on corporate information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="cvac_SignificantAccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SignificantAccountingPoliciesAbstract" xlink:to="cvac_SignificantAccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of material accounting policy information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of notes to consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Notes to Consolidated Financial Statements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="cvac_DisclosureOfFixedAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsExplanatory" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for fixed assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Fixed Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-current assets held for sale and discontinued operations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of inventories [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherFinancialAssetsExplanatory" xlink:label="cvac_DisclosureOfOtherFinancialAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherFinancialAssetsExplanatory" xlink:to="cvac_DisclosureOfOtherFinancialAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherFinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for other financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherFinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Other Financial Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfOtherFinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of trade and other payables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="cvac_OtherLiabilitiesAndProvisionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesAndProvisionsTextBlock" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherLiabilitiesAndProvisionsTextBlock" xlink:to="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of other liabilities and provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities and Provisions [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and management of financial risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial risk management [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and management of financial risks</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:label="cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:to="cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="ifrs-full_DisclosureOfCashFlowStatementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of cash flow statement [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfCommitmentsAndContingenciesAbstract" xlink:label="cvac_DisclosureOfCommitmentsAndContingenciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfCommitmentsAndContingenciesAbstract" xlink:to="cvac_DisclosureOfCommitmentsAndContingenciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfCommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfCommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of commitments and contingent liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfKeyManagementPersonnelAbstract" xlink:label="cvac_DisclosureOfKeyManagementPersonnelAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfKeyManagementPersonnelAbstract" xlink:to="cvac_DisclosureOfKeyManagementPersonnelAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfKeyManagementPersonnelAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfKeyManagementPersonnelAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remuneration of the Company's key management personnel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about key management personnel [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remuneration of the Company's key management personnel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of business combinations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of consolidation [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for business combinations and goodwill [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations and goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for recognition of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for government grants [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of non-financial non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-current assets or disposal groups classified as held for sale [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets held for sale</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory" xlink:to="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for right of use assets.]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description Of Accounting Policy For Right Of Use Assets Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for measuring inventories [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of cash and cash equivalents [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for provisions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Onerous contracts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for share-based payment transactions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for segment reporting [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting judgements and estimates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant accounting judgments, estimates and assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of changes in accounting policies, accounting estimates and errors [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in accounting policies and disclosures</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory" xlink:to="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information about estimated useful lives of intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Detailed Information About Estimated Useful Lives Of Intangible Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful lives for intangible asset class</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xlink:to="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information about estimated useful lives of property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Detailed Information About Estimated Useful Lives Of Property, Plant And Equipment, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful lives for property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory" xlink:to="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information about estimated useful lives of right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Detailed Information About Estimated Useful Lives Of Right Of Use Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful lives for right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenue from contract with customers recognized</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about upfront payments and related revenues recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of upfront payments and related revenues recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Explanation of significant changes in contract assets and contract liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transaction price allocated to remaining performance obligations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expenses by nature [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of nature of expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of development of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of development of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of carrying amounts of the Group's right-of-use assets and the movements during the period</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:label="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:to="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of carrying amounts of lease liabilities and the movements during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Quantitative Information About Lease Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of carrying amounts of lease liabilities and the movements during the period</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock" xlink:label="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock" xlink:to="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of lease expense recognized in the statement of operations related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Leases Expense Recognized In Profit Or Loss [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of amounts recognized in the statement of operations related to leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIMember" xlink:to="cvac_VirtualSharesProgramIMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program I.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIiMember" xlink:to="cvac_VirtualSharesProgramIiMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program II (New VSOP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Chief Executive Officer Grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RestrictedStockUnitsMember" xlink:to="cvac_RestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Restricted stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of expense recognized for the programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Expense Recognized for the Programs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule for expense recognized for the equity-settled programs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of outstanding awards</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expense recognized for employee services explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Expense Recognized For Employee Services Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based payments expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inputs used in the measurement of the fair value at grant date</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock" xlink:label="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock" xlink:to="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular information pertaining to trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Trade And Other Payables [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of trade and other payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherProvisionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherProvisionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other provisions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movements in provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesTableTextBlock" xlink:label="cvac_DisclosureOfOtherLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesTableTextBlock" xlink:to="cvac_DisclosureOfOtherLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular information pertaining to other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Other Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfOtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of tax reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:to="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of deferred taxes [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred taxes</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock" xlink:label="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock" xlink:to="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unused tax losses carried forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturity profile of the financial liabilities based on contractual undiscounted payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock" xlink:label="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock" xlink:to="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information about exposure to foreign currencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Exposure To Foreign Currencies [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of exposure in (foreign) currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:to="ifrs-full_DisclosureOfMarketRiskExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of market risk [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other variables held constant, pre-tax loss and post-tax loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of reconciliation of liabilities arising from financing activities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in liabilities arising from financing activities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock" xlink:label="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock" xlink:to="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of detailed information about remuneration of key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Detailed Information of Remuneration of Key Management Personnel [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of remuneration of company's key management personnel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value recognized on acquisition</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xlink:to="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information pertaining to goodwill recognized as a result of the acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Goodwill Recognized As A Result Of Acquisition, Explanatory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of goodwill recognized as a result of the acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LargestShareholderMember" xlink:label="cvac_LargestShareholderMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LargestShareholderMember" xlink:to="cvac_LargestShareholderMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LargestShareholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LargestShareholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Largest Shareholder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LargestShareholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dievini</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfVotingInterestsHeld" xlink:label="cvac_PercentageOfVotingInterestsHeld" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfVotingInterestsHeld" xlink:to="cvac_PercentageOfVotingInterestsHeld_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfVotingInterestsHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of voting equity interests held in the Entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfVotingInterestsHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Voting Interests Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfVotingInterestsHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting interests held</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPolicyTable" xlink:label="cvac_SignificantAccountingPolicyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SignificantAccountingPolicyTable" xlink:to="cvac_SignificantAccountingPolicyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SignificantAccountingPolicyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SignificantAccountingPolicyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policy [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsProductMember" xlink:to="cvac_IfrsProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Article or substance produced by nature, labor or machinery.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPolicyLineItems" xlink:label="cvac_SignificantAccountingPolicyLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SignificantAccountingPolicyLineItems" xlink:to="cvac_SignificantAccountingPolicyLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SignificantAccountingPolicyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SignificantAccountingPolicyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policy [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_SignificantAccountingPolicyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPropertyPlantAndEquipmentSalvageValue" xlink:label="cvac_IfrsPropertyPlantAndEquipmentSalvageValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsPropertyPlantAndEquipmentSalvageValue" xlink:to="cvac_IfrsPropertyPlantAndEquipmentSalvageValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsPropertyPlantAndEquipmentSalvageValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsPropertyPlantAndEquipmentSalvageValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Property, Plant, and Equipment, Salvage Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsPropertyPlantAndEquipmentSalvageValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Residual values</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisions" xlink:label="cvac_ContractTerminationProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractTerminationProvisions" xlink:to="cvac_ContractTerminationProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractTerminationProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contract termination provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractTerminationProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Termination Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContractTerminationProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract termination provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ContractTerminationProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract termination provisions in prior year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision" xlink:label="ifrs-full_ShorttermOnerousContractsProvision" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermOnerousContractsProvision" xlink:to="ifrs-full_ShorttermOnerousContractsProvision_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermOnerousContractsProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current onerous contracts provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermOnerousContractsProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for onerous contracts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life measured as period of time, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="ifrs-full_BorrowingCostsCapitalised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingCostsCapitalised" xlink:to="ifrs-full_BorrowingCostsCapitalised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingCostsCapitalised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing costs capitalised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingCostsCapitalised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing costs capitalized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:to="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalisation rate of borrowing costs eligible for capitalisation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average borrowing costs (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss recognised in profit or loss, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment to property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss recognised in profit or loss, goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No impairment of goodwill</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfOperatingSegments" xlink:label="cvac_IfrsNumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfOperatingSegments" xlink:to="cvac_IfrsNumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfReportableSegments" xlink:label="cvac_IfrsNumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfReportableSegments" xlink:to="cvac_IfrsNumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" xlink:label="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" xlink:to="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of risk estimated for not accepting the transfer pricing setup.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Risk Percentage For Not Accepting The Transfer Pricing Set Up</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated risk percentage for not accepting the transfer pricing set up</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of intangible assets other than goodwill [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SoftwareMember" xlink:to="cvac_SoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The member stands for software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicencesMember" xlink:to="ifrs-full_LicencesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LicencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licence [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LicencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TechnologyMember" xlink:to="cvac_TechnologyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnicalEquipmentAndMachinesMember" xlink:label="cvac_TechnicalEquipmentAndMachinesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TechnicalEquipmentAndMachinesMember" xlink:to="cvac_TechnicalEquipmentAndMachinesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TechnicalEquipmentAndMachinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for technical equipment and machines.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TechnicalEquipmentAndMachinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical equipment and machines:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other property, plant and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other equipment, furniture and fixtures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other equipment, furniture and fixtures:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life measured as period of time, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of assets [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LandBuildingsAndSupplyInstallationsMember" xlink:label="cvac_LandBuildingsAndSupplyInstallationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LandBuildingsAndSupplyInstallationsMember" xlink:to="cvac_LandBuildingsAndSupplyInstallationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LandBuildingsAndSupplyInstallationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for land, buildings and supply installations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LandBuildingsAndSupplyInstallationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land, Buildings And Supply Installations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LandBuildingsAndSupplyInstallationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land, Buildings and supply installations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember" xlink:label="ifrs-full_VehiclesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_VehiclesMember" xlink:to="ifrs-full_VehiclesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_VehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vehicles [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_VehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vehicles</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherEquipmentMember" xlink:label="cvac_OtherEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherEquipmentMember" xlink:to="cvac_OtherEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other equipment :</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:label="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:to="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The useful life, measured as period of time, used for right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful Life Measured As Period Of Time, Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives of right-of-use assets (in years)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of notes to the consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Notes To The Consolidated Financial Statements [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BE" xlink:to="country_BE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Belgium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Belgium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH" xlink:label="country_CH" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Switzerland</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Switzerland</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="country_NL" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Netherlands</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_NL_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Netherlands</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" xlink:label="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" xlink:to="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for countries other than Belgium, Germany, Netherlands and Switzerland.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Countries Other Than Belgium, Germany, Netherlands and Switzerland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Countries other than Belgium, Germany, Netherlands and Switzerland</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major customers [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customers [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customers</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GlaxosmithklineMember" xlink:to="cvac_GlaxosmithklineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GlaxoSmithKline.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprMember" xlink:to="cvac_CrisprMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GenmabMember" xlink:to="cvac_GenmabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Genmab.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BoehringerIngelheimMember" xlink:to="cvac_BoehringerIngelheimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Boehringer Ingelheim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Boehringer Ingelheim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Boehringer Ingelheim</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherCustomersMember" xlink:to="cvac_OtherCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Other customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents of disclosure of notes to the consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Notes To The Consolidated Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprTherapeuticsMember" xlink:to="cvac_CrisprTherapeuticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR Therapeutics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR Therapeutics</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsTypeOfArrangementAxis" xlink:to="cvac_IfrsTypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsTypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsTypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GlaxosmithklineCovidAgreementMember" xlink:to="cvac_GlaxosmithklineCovidAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Collaboration Agreement With GlaxoSmithKline COVID Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GlaxoSmithKline COVID Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAndLicenseAgreementMember" xlink:to="cvac_CollaborationAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for termination of exclusive collobaration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" xlink:to="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research and development services combined with Ip license.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Services Combined With Ip License Member</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchAndDevelopmentServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsReceivedOrReceivable" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments received or receivable by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Received Or Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Received Or Receivable</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:to="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Eligible To Receive As One Time Reimbursable Payment For Manufacturing Capacity Reservation</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:to="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount eligible to receive development and regulatory milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Eligible To Receive As Development And Regulatory Milestone Payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:to="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount eligible to receive commercial milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Eligible To Receive As Commercial Milestone Payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionFeePayment" xlink:label="cvac_OptionFeePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionFeePayment" xlink:to="cvac_OptionFeePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionFeePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of Option fee Payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionFeePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Fee payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfPerformanceObligations" xlink:label="cvac_NumberOfPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfPerformanceObligations" xlink:to="cvac_NumberOfPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additional development milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Development Milestone Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional development milestone payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" xlink:label="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" xlink:to="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront payment revenue recognized from termination of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment Revenue Recognized From Termination Of Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:to="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of Option fee payment included in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Option Fee Payment Included In Contract Liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development milestone payment included in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Development Milestone Payment Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone payment included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:to="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Collaboration Partners That Owed Hundred Percent Of All Receivables And Contract Assets Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:to="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Collaboration Partners With Balances Greater Than Ten Percent Of All Receivables And Contract Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments of the company included in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestones payments included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue that was included in contract liability balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from upfront and milestones payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transaction price allocated to remaining performance obligations [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated time bands [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within one year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within one year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less than 1 year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearMember" xlink:to="ifrs-full_LaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">More than one year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">More than one year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transaction price allocated to remaining performance obligations [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities allocated to the remaining performance obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction price allocated to remaining performance obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsIncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCostOfSalesMember" xlink:to="cvac_IfrsCostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attribution of expenses by nature to their function [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrs-full_LineItemsByFunctionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LineItemsByFunctionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items by function [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OperativeExpensesMember" xlink:to="cvac_OperativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OperativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for operating expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OperativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OperativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operative expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PersonnelExpenses" xlink:to="cvac_PersonnelExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterialsAndConsumablesUsed" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials and consumables used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThirdPartyServiceExpenses" xlink:to="cvac_ThirdPartyServiceExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for third party services during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Service Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third-party services</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaintenanceAndLeaseExpenses" xlink:to="cvac_MaintenanceAndLeaseExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maintenance and lease expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance And Lease Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance and lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherExpense" xlink:to="cvac_OtherExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ExpenseByNature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses, by nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SellingAndDistributionExpensesMember" xlink:to="cvac_SellingAndDistributionExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for selling and distribution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption in which the reported facts about research and development expense have been included.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PatentsAndFeesToRegisterLegalRight" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for registering a legal right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents And Fees To Register Legal Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents and fees to register a legal right</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionForOnerousContracts" xlink:to="cvac_ReversalOfProvisionForOnerousContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Provision For Onerous Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of provision for onerous contracts</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProvisionForLossOnContracts" xlink:label="cvac_IfrsProvisionForLossOnContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsProvisionForLossOnContracts" xlink:to="cvac_IfrsProvisionForLossOnContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of provision for loss on contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Provision For Loss on Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated contract termination provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and other professional services</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accrued other liability for up-front payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Other Liability for Up-front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other liability for up-front payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GovernmentGrantsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for German Federal Ministry of Education and Research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">German Federal Ministry of Education and Research</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants related to Coalition for Epidemic Preparedness Innovations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coalition for Epidemic Preparedness Innovations</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BundesministeriumFurBildungUndForschungMember" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Bundesministerium fr Bildung und Forschung.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bundesministerium fr Bildung und Forschung</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Advance Purchase Agreement with European Commission</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance Purchase Agreement with European Commission</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MiscellaneousOtherOperatingIncomeMember" xlink:label="cvac_MiscellaneousOtherOperatingIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MiscellaneousOtherOperatingIncomeMember" xlink:to="cvac_MiscellaneousOtherOperatingIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MiscellaneousOtherOperatingIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for other miscellaneous operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MiscellaneousOtherOperatingIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous Other Operating Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MiscellaneousOtherOperatingIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating income</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRemainingGrantIncome" xlink:to="cvac_IfrsRemainingGrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of remaining grant income classified as other operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Remaining Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining grant income</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentReceived" xlink:to="cvac_UpfrontPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment Received</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" xlink:label="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" xlink:to="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payment of accrued other liabilities of upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Accrued Other Liabilities Of Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of accrued other liabilities of upfront payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaximumGrantToBeReceived" xlink:to="cvac_MaximumGrantToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum grant receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Grant To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsMilestonePaymentReceived" xlink:to="cvac_IfrsMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation consist for set-up activities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of prepayments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementMaximumAmount" xlink:to="cvac_PartnershipAgreementMaximumAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount agreed under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Maximum Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount under the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementTerm" xlink:to="cvac_PartnershipAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered by the funds received under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Period Of Costs To Be Covered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfApprovedExpenses" xlink:label="cvac_ReimbursementOfApprovedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReimbursementOfApprovedExpenses" xlink:to="cvac_ReimbursementOfApprovedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReimbursementOfApprovedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of reimbursement of approved expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReimbursementOfApprovedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of Approved Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReimbursementOfApprovedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of approved expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfAdditionalGrantsReceived" xlink:to="cvac_NumberOfAdditionalGrantsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Additional Grants Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmortizationOfGovernmentGrants" xlink:label="cvac_AmortizationOfGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmortizationOfGovernmentGrants" xlink:to="cvac_AmortizationOfGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmortizationOfGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of amortization of the grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmortizationOfGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of the Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmortizationOfGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of the grants</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RepaymentOfGrantReceivedFromGovernment" xlink:label="cvac_RepaymentOfGrantReceivedFromGovernment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RepaymentOfGrantReceivedFromGovernment" xlink:to="cvac_RepaymentOfGrantReceivedFromGovernment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RepaymentOfGrantReceivedFromGovernment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for repayment of received government grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RepaymentOfGrantReceivedFromGovernment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of Grant Received From Government</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RepaymentOfGrantReceivedFromGovernment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of grant received from government</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants received and deferred</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaximumUnspentFundsReimbursable" xlink:to="cvac_MaximumUnspentFundsReimbursable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaximumUnspentFundsReimbursable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum unspent funds reimbursable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaximumUnspentFundsReimbursable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Unspent Funds Reimbursable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaximumUnspentFundsReimbursable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum unspent funds reimbursable</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for CMO/Materials transfer</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CostOfReimbursementClaim" xlink:to="cvac_CostOfReimbursementClaim_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cost of reimbursement claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of reimbursement claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement claim</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SaleOfEquipment" xlink:to="cvac_SaleOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sale of equipment in operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherOperatingIncomeGovernmentGrants" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other operating income recognized in relation to government agencies and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Operating Income, Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants and other reimbursements from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MiscellaneousOtherOperatingIncomeOther" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of miscellaneous other operating income, classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous Other Operating Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CumulativeAmortizationAndImpairmentMember" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for accumulated depreciation, amortization and impairment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Amortization And Impairment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Amortization And Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative amortization and impairment charges</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Carrying Amount of Acquisition Cost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of intangible assets and goodwill [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillMember" xlink:to="ifrs-full_GoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwil</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdvancePaymentsIntangibleAssetMember" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdvancePaymentsIntangibleAssetMember" xlink:to="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for advance payments, intangible asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortisation, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through transfers, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through net exchange differences, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSharePrice" xlink:label="cvac_IfrsSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSharePrice" xlink:to="cvac_IfrsSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of a single share of a number of saleable stocks of a company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for technical equipment and machines and other equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical equipment and machines [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical equipment and machines</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConstructionInProgressMember" xlink:to="ifrs-full_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets under construction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease through classified as held for sale, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through transfers from construction in progress, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through net exchange differences, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsTable" xlink:label="cvac_StatementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StatementsTable" xlink:to="cvac_StatementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements Table</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="ifrs-full_LandAndBuildingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LandAndBuildingsMember" xlink:to="ifrs-full_LandAndBuildingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LandAndBuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land and buildings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LandAndBuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land and Buildings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TbingenMember" xlink:label="cvac_TbingenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TbingenMember" xlink:to="cvac_TbingenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TbingenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Tbingen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TbingenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tbingen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TbingenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tbingen</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_WiesbadenMember" xlink:label="cvac_WiesbadenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_WiesbadenMember" xlink:to="cvac_WiesbadenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_WiesbadenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Wiesbaden.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_WiesbadenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wiesbaden [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_WiesbadenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wiesbaden</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsLineItems" xlink:label="cvac_StatementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StatementsLineItems" xlink:to="cvac_StatementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements Line Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_StatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImpairmentOnRightOfUseAssets" xlink:label="cvac_ImpairmentOnRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ImpairmentOnRightOfUseAssets" xlink:to="cvac_ImpairmentOnRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ImpairmentOnRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of impairment on right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ImpairmentOnRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment on Right-of-use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ImpairmentOnRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment expense / reversal of impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="cvac_ImpairmentOnRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Foreigncurrencytranslationrightofuseassets" xlink:label="cvac_Foreigncurrencytranslationrightofuseassets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Foreigncurrencytranslationrightofuseassets" xlink:to="cvac_Foreigncurrencytranslationrightofuseassets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Foreigncurrencytranslationrightofuseassets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in right of use assets due to foreign currency translation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Foreigncurrencytranslationrightofuseassets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ForeignCurrencyTranslationRightOfUseAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Foreigncurrencytranslationrightofuseassets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfRentalAgreements" xlink:label="cvac_NumberOfRentalAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfRentalAgreements" xlink:to="cvac_NumberOfRentalAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfRentalAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of rental agreements entered during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfRentalAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Rental Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfRentalAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of rental agreements</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightOfUseAssetsNumberOfExtensionOption" xlink:label="cvac_RightOfUseAssetsNumberOfExtensionOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RightOfUseAssetsNumberOfExtensionOption" xlink:to="cvac_RightOfUseAssetsNumberOfExtensionOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RightOfUseAssetsNumberOfExtensionOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of extension option  under the right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RightOfUseAssetsNumberOfExtensionOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right Of Use Assets, Number Of Extension Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RightOfUseAssetsNumberOfExtensionOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets, number of extension option</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsLesseeOperatingLeaseRenewalTerm" xlink:label="cvac_IfrsLesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsLesseeOperatingLeaseRenewalTerm" xlink:to="cvac_IfrsLesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsLesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsLesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsLesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, operating lease, renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionsLeaseLiabilities" xlink:label="cvac_AdditionsLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionsLeaseLiabilities" xlink:to="cvac_AdditionsLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionsLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of addition of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionsLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions, Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionsLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash outflow for leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ForeignCurrencyTranslationLeaseLiabilities" xlink:label="cvac_ForeignCurrencyTranslationLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ForeignCurrencyTranslationLeaseLiabilities" xlink:to="cvac_ForeignCurrencyTranslationLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ForeignCurrencyTranslationLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in lease Liabilities due to foreign currency translation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ForeignCurrencyTranslationLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation, Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ForeignCurrencyTranslationLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionalLeasePaymentsUponUsingExtensionOptions" xlink:label="cvac_OptionalLeasePaymentsUponUsingExtensionOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionalLeasePaymentsUponUsingExtensionOptions" xlink:to="cvac_OptionalLeasePaymentsUponUsingExtensionOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionalLeasePaymentsUponUsingExtensionOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of optional lease payments arising upon exercise of extension options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionalLeasePaymentsUponUsingExtensionOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Optional Lease Payments Upon Using Extension Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OptionalLeasePaymentsUponUsingExtensionOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Optional lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to short-term leases for which recognition exemption has been used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to short-term leases (included in cost of sales)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to leases of low-value assets for which recognition exemption has been used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to leases of low-value assets (included in general and administrative expenses)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeFromSubleasingRightofuseAssets" xlink:label="ifrs-full_IncomeFromSubleasingRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeFromSubleasingRightofuseAssets" xlink:to="ifrs-full_IncomeFromSubleasingRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeFromSubleasingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from subleasing right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeFromSubleasingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from sub-leasing right-of-use assets presented in "other operating income"</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LeasesExpenseRecognizedInProfitOrLoss" xlink:label="cvac_LeasesExpenseRecognizedInProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LeasesExpenseRecognizedInProfitOrLoss" xlink:to="cvac_LeasesExpenseRecognizedInProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LeasesExpenseRecognizedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of lease expense recognized in profit or loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LeasesExpenseRecognizedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases Expense Recognized In Profit Or Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="cvac_LeasesExpenseRecognizedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total amount recognized in profit or loss</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetBookValueOfCmoEquipmentHeldForSale" xlink:label="cvac_NetBookValueOfCmoEquipmentHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetBookValueOfCmoEquipmentHeldForSale" xlink:to="cvac_NetBookValueOfCmoEquipmentHeldForSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetBookValueOfCmoEquipmentHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of net book value of CMO-Equipment held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetBookValueOfCmoEquipmentHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Book Value Of Cmo Equipment Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetBookValueOfCmoEquipmentHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net book value Of CMO-Equipment held for sale</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImpairmentOfAssetsHeldForSale" xlink:label="cvac_ImpairmentOfAssetsHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ImpairmentOfAssetsHeldForSale" xlink:to="cvac_ImpairmentOfAssetsHeldForSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of impairment loss on assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Assets Held for Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of assets held for sale</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AssetsHeldForSaleNetBookValueSold" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AssetsHeldForSaleNetBookValueSold" xlink:to="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net book value sold of assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held for Sale, Net Book Value Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale with a net book value sold</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AssetsHeldForSaleNetBookValueDirectSold" xlink:label="cvac_AssetsHeldForSaleNetBookValueDirectSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AssetsHeldForSaleNetBookValueDirectSold" xlink:to="cvac_AssetsHeldForSaleNetBookValueDirectSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AssetsHeldForSaleNetBookValueDirectSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net book value sold of assets held for direct sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AssetsHeldForSaleNetBookValueDirectSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held for Sale, Net Book Value Direct Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AssetsHeldForSaleNetBookValueDirectSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale, net book value direct sold</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DecreaseThroughClassifiedAsHeldForSale" xlink:label="cvac_DecreaseThroughClassifiedAsHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DecreaseThroughClassifiedAsHeldForSale" xlink:to="cvac_DecreaseThroughClassifiedAsHeldForSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DecreaseThroughClassifiedAsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The decrease in assets through classification as held for sale or inclusion in a disposal group classified as held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DecreaseThroughClassifiedAsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease Through Classified As Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DecreaseThroughClassifiedAsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease through classified as held for sale</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesTable" xlink:to="cvac_InventoriesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesLineItem_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Line item</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials" xlink:label="ifrs-full_RawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterials" xlink:to="ifrs-full_RawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current raw materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseDecreaseInInventory" xlink:to="cvac_IncreaseDecreaseInInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in inventory during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in inventory</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoryPilingForPandemicPreparednessAgreement" xlink:label="cvac_InventoryPilingForPandemicPreparednessAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoryPilingForPandemicPreparednessAgreement" xlink:to="cvac_InventoryPilingForPandemicPreparednessAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoryPilingForPandemicPreparednessAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of inventory piling for the pandemic preparedness agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoryPilingForPandemicPreparednessAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Piling For Pandemic Preparedness Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_InventoryPilingForPandemicPreparednessAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory piling for pandemic preparedness agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInvestments" xlink:label="ifrs-full_CurrentInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DepositsHeldByThirdParties" xlink:label="cvac_DepositsHeldByThirdParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DepositsHeldByThirdParties" xlink:to="cvac_DepositsHeldByThirdParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DepositsHeldByThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of deposits held by third parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DepositsHeldByThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Held By Third Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_DepositsHeldByThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits held by third parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current advances to suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for future service agreements and goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables from taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax claims</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by type of sale of the entity's stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsSaleOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FollowOnPublicOfferingMember" xlink:to="cvac_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to follow on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on public offering, incl. Greenshoe</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AtMarketOfferingProgramMember" xlink:to="cvac_AtMarketOfferingProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to at the market offering program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Offering Program</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PublicOfferingOfCommonSharesMember" xlink:label="cvac_PublicOfferingOfCommonSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PublicOfferingOfCommonSharesMember" xlink:to="cvac_PublicOfferingOfCommonSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for public offering of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering of common shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CommonSharesIssuedAndOutstanding" xlink:to="cvac_CommonSharesIssuedAndOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued and outstanding for during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares Issued And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding beginning</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInNumberOfSharesOutstanding" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in the number of shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Number Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital increase (in shares)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareOptionExercises" xlink:to="cvac_ShareOptionExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share option exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Option Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share option exercises</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period for existing shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance During Period For Existing Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued to former shareholders of Frame Pharmaceuticals</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:to="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued for RSU deliveries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Issued on Exercise of Options and RSU Deliveries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for LTIP option exercises and RSU deliveries</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ClosingOfPublicOfferingOfCommonSharesMember" xlink:label="cvac_ClosingOfPublicOfferingOfCommonSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ClosingOfPublicOfferingOfCommonSharesMember" xlink:to="cvac_ClosingOfPublicOfferingOfCommonSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ClosingOfPublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for closing of public offering of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ClosingOfPublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing of public offering of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ClosingOfPublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing of public offering of common shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOverAllotmentOptionMember" xlink:to="cvac_IfrsOverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right given to the underwriter to sell additional shares over the initial allotment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue related cost</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of aggregate gross proceeds receivable from issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Gross Proceeds Receivable From Issuing Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for business combinations [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsMember" xlink:to="ifrs-full_BusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Frame Pharmaceuticals B.V., Amsterdam, Netherlands.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frame Pharmaceuticals B.V., Amsterdam, Netherlands</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frame Pharmaceuticals B.v.Amsterdam Netherlands</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration transferred, acquisition-date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration transferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments or interests issued or issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate consideration in shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsPlanNameAxis" xlink:to="cvac_IfrsPlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsPlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by plan name for share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsPlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsPlanNameDomain" xlink:to="cvac_IfrsPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan name for share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OldVsopPlanMember" xlink:label="cvac_OldVsopPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OldVsopPlanMember" xlink:to="cvac_OldVsopPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OldVsopPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Old VSOP Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OldVsopPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Old VSOP Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OldVsopPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Old VSOP Plan</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NewVsopPlanMember" xlink:label="cvac_NewVsopPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NewVsopPlanMember" xlink:to="cvac_NewVsopPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NewVsopPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for New VSOP Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NewVsopPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NewVsopPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP Plan</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LegacyPlanMember" xlink:label="cvac_LegacyPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LegacyPlanMember" xlink:to="cvac_LegacyPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LegacyPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for legacy plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LegacyPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legacy plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LegacyPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legacy plan</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received from the participants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesHeldForTaxLiabilities" xlink:label="cvac_IfrsNumberOfSharesHeldForTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfSharesHeldForTaxLiabilities" xlink:to="cvac_IfrsNumberOfSharesHeldForTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfSharesHeldForTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares held for payable of tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfSharesHeldForTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Number Of Shares Held For Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfSharesHeldForTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares held for payable of tax liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:to="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRs Number Of Shares Issued For Exercise Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiteded during the period</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanStockOptionsMember" xlink:label="cvac_LongTermIncentivePlanStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LongTermIncentivePlanStockOptionsMember" xlink:to="cvac_LongTermIncentivePlanStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LongTermIncentivePlanStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for long term incentive plan stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LongTermIncentivePlanStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Incentive Plan Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LongTermIncentivePlanStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP Stock Options</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanRsusMember" xlink:label="cvac_LongTermIncentivePlanRsusMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LongTermIncentivePlanRsusMember" xlink:to="cvac_LongTermIncentivePlanRsusMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LongTermIncentivePlanRsusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for long term incentive plan RSU.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LongTermIncentivePlanRsusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Incentive Plan RSUs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LongTermIncentivePlanRsusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP RSUs</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RsuSupervisoryBoardMember" xlink:label="cvac_RsuSupervisoryBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RsuSupervisoryBoardMember" xlink:to="cvac_RsuSupervisoryBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RsuSupervisoryBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for RSU supervisory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RsuSupervisoryBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU Supervisory Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RsuSupervisoryBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU Supervisory board</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses from share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested share-options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options exercised</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share options vested and expensed thereof in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Share Options, Vested And Expensed Thereof, In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of awards exercisable</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the right to exercise percentage of vested virtual shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right To Exercise Percentage Of Vested Virtual Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to exercise percentage of vested virtual shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:to="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The decrease in the number of shares outstanding through transfer from shareholders to entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Number Of Shares Outstanding Through Transfer From Shareholders to Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from shareholders to company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beneficiaries declared the exercise of all their exercisable</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TreasurySharesTransferred" xlink:label="cvac_TreasurySharesTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TreasurySharesTransferred" xlink:to="cvac_TreasurySharesTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TreasurySharesTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of treasury shares transferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TreasurySharesTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TreasurySharesTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares transferred</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProvisionForEmployerTaxes" xlink:to="cvac_ProvisionForEmployerTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of provision for employer taxes arising according to US regulations for future exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for Employer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for employer taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets, In Cost of Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Sales</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Selling And Distribution Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfOptionsMember" xlink:to="cvac_ExerciseOfOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share options vested thereof in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Share Options, Vested Thereof, In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof vested</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RemainingOptionLifeShareOptionsAwardsGranted" xlink:label="cvac_RemainingOptionLifeShareOptionsAwardsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RemainingOptionLifeShareOptionsAwardsGranted" xlink:to="cvac_RemainingOptionLifeShareOptionsAwardsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RemainingOptionLifeShareOptionsAwardsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The remaining option life of share options awards granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RemainingOptionLifeShareOptionsAwardsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Option Life Share Options Awards Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RemainingOptionLifeShareOptionsAwardsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining life of the options</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsEmployerTaxesPayable" xlink:label="cvac_IfrsEmployerTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsEmployerTaxesPayable" xlink:to="cvac_IfrsEmployerTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsEmployerTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of employer taxes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsEmployerTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Employer Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsEmployerTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer taxes payable</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseRecognizedForEmployeeServices" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense recognized for employee services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized For Employee Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LongTermIncentivePlanMember" xlink:to="cvac_LongTermIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Long-Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP Stock Options</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefScientificOfficerMember" xlink:to="cvac_ChiefScientificOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Scientific Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Scientific Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Business Officer and Chief Commercial Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer and Chief Commercial Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_KeyEmployeesMember" xlink:to="cvac_KeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COO</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefDevelopmentOfficerMember" xlink:to="cvac_ChiefDevelopmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Development Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsVestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First tranche</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second tranche</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third tranche</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" xlink:label="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" xlink:to="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value per share of share options granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Fair Value Per Share At Measurement Date, Share Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value per option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (%)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option life, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (%)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Financial Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThenChiefExecutiveOfficerMember" xlink:to="cvac_ThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dan Menichella, then Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">the Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members of supervisory board</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of outstanding share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of options granted</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" xlink:label="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" xlink:to="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold duration of volume weighted average price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Threshold Duration Of Volume Weighted Average Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold duration of volume weighted average price</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of vesting of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of increase in share price under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Share-based Compensation Arrangement By Share-based Payment Award, Increase In Share Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of increase in share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" xlink:label="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" xlink:to="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of days of VWAP based on which percentage of stock price increase is calculated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Days Of Vwap Calculate Percentage Of Stock Price Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days increase related to percentage of stock price</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for person or persons designated as part of Executive board and various key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members of executive board and various key employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CEO</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FormerFrameEmployeesMember" xlink:to="cvac_FormerFrameEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame employee's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSU's awarded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs issued to certain former employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of tranches for vesting of instruments granted in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Tranches For Vesting Of Instruments Granted In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches for vesting of RSUs granted</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" xlink:label="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" xlink:to="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum share price on or after vesting to settle and deliver the RSUs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Share Price on or After Vesting to Settle and Deliver the RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum share price on or after vesting to settle and deliver the RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInTradeAndOtherPayables" xlink:to="cvac_ChangeInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of change in trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Trade and Other Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in trade and other payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables on social security and taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll-related taxes and social-security liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="cvac_IfrsOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="cvac_IfrsOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions.</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisionsCurrent" xlink:label="cvac_ContractTerminationProvisionsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractTerminationProvisionsCurrent" xlink:to="cvac_ContractTerminationProvisionsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractTerminationProvisionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contract termination provisions, current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractTerminationProvisionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Termination Provisions, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContractTerminationProvisionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract termination provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Provisions (current &amp; non-current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional provisions, other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="ifrs-full_ProvisionUsedOtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProvisionUsedOtherProvisions" xlink:to="ifrs-full_ProvisionUsedOtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision used, other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">used (amounts charged against the provision)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions utilized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="ifrs-full_UnusedProvisionReversedOtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:to="ifrs-full_UnusedProvisionReversedOtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedProvisionReversedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused provision reversed, other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_UnusedProvisionReversedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">unused amounts reversed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_UnusedProvisionReversedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversed</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughReclassificationsProvisions" xlink:label="cvac_IncreaseDecreaseThroughReclassificationsProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseDecreaseThroughReclassificationsProvisions" xlink:to="cvac_IncreaseDecreaseThroughReclassificationsProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseDecreaseThroughReclassificationsProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in provisions through reclassifications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseDecreaseThroughReclassificationsProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through Reclassifications, Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseDecreaseThroughReclassificationsProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">reclassified from accounts payable</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:to="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other miscellaneous non-current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Miscellaneous Non-current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (e.g. license liabilities, Deferred Tax Liability)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelAccruedLiabilities" xlink:label="cvac_PersonnelAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PersonnelAccruedLiabilities" xlink:to="cvac_PersonnelAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PersonnelAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PersonnelAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PersonnelAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel accrued liabilities (e.g. bonus, vacation)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants" xlink:label="ifrs-full_CurrentGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OutstandingInvoicesCurrent" xlink:label="cvac_OutstandingInvoicesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OutstandingInvoicesCurrent" xlink:to="cvac_OutstandingInvoicesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OutstandingInvoicesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current outstanding invoices.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OutstandingInvoicesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Invoices, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OutstandingInvoicesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding invoices</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfessionalFessCurrent" xlink:label="cvac_ProfessionalFessCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProfessionalFessCurrent" xlink:to="cvac_ProfessionalFessCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProfessionalFessCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProfessionalFessCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional Fess, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProfessionalFessCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:to="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current value added tax and other taxes payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Value Added Tax And Other Taxes Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VAT and other taxes (real estate transfer taxes)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilityCurrent" xlink:label="cvac_OtherLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherLiabilityCurrent" xlink:to="cvac_OtherLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities" xlink:label="ifrs-full_OtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other liabilities (current &amp; non-current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfProvisionsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfProvisionsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of other provisions [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="ifrs-full_OtherProvisionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other provisions [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OnerousContractProvisionsMember" xlink:label="cvac_OnerousContractProvisionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OnerousContractProvisionsMember" xlink:to="cvac_OnerousContractProvisionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OnerousContractProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for onerous contracts provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OnerousContractProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Onerous Contract Provisions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OnerousContractProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Onerous Contract Provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisionsMember" xlink:label="cvac_ContractTerminationProvisionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractTerminationProvisionsMember" xlink:to="cvac_ContractTerminationProvisionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractTerminationProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for contract termination provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractTerminationProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Termination Provisions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContractTerminationProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Termination Provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxTable" xlink:label="cvac_IncomeTaxTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxTable" xlink:to="cvac_IncomeTaxTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of Income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubsidiariesMember" xlink:label="ifrs-full_SubsidiariesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubsidiariesMember" xlink:to="ifrs-full_SubsidiariesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SubsidiariesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SubsidiariesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxLineItems" xlink:label="cvac_IncomeTaxLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxLineItems" xlink:to="cvac_IncomeTaxLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax [line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax benefits (expense) from net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax expense (income) and adjustments for current tax of prior periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense (income) relating to origination and reversal of temporary differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax (income) expenses on taxable temporary differences</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" xlink:label="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" xlink:to="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of deferred tax assets related to items credited (charged) directly to equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DeferredTaxAssetsRelatingToItemsChargedOrCreditedDirectlyToEquity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of deferred tax assets related to items credited (charged) directly to equity</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" xlink:label="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" xlink:to="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVenture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinetly reinvested and associated with invested in subsadiries, deferred tax liabilities have not been recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Applicable tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="ifrs-full_AverageEffectiveTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageEffectiveTaxRate" xlink:to="ifrs-full_AverageEffectiveTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average effective tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate income tax</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfSolidarySurcharge" xlink:label="cvac_PercentageOfSolidarySurcharge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfSolidarySurcharge" xlink:to="cvac_PercentageOfSolidarySurcharge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfSolidarySurcharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of solidary surcharge.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfSolidarySurcharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Solidary Surcharge</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfSolidarySurcharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of solidary surcharge</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfTradeTax" xlink:label="cvac_PercentageOfTradeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfTradeTax" xlink:to="cvac_PercentageOfTradeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfTradeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of trade tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfTradeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Trade Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfTradeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of trade tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of accounting profit multiplied by applicable tax rates [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccountingProfit" xlink:to="ifrs-full_AccountingProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccountingProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccountingProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income) at applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected tax benefit (based on statutory tax rate of 29.48% in 2023, 2022 and 2021)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" xlink:to="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of tax loss carryforwards of prior year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect Of Non Recognition Of Tax Loss Carryforwards Prior Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of tax loss carryforwards recognized in prior years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax effect of foreign tax rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effects from differences between Group and local tax rates</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards" xlink:to="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of tax loss carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect Of Non-Recognition Of Tax Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-recognition of tax loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:label="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:to="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of deferred tax assets or deferred tax liabilities (DTA/DTL).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect Of Non-Recognition Of Deferred Tax Assets And Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-recognition of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:label="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:to="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to recognition of deferred tax assets or deferred tax liabilities (DTA/DTL).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect On Recognition Of Deferred Tax Assets And Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes" xlink:label="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes" xlink:to="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-deductible expenses for tax purposes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect On Non-Deductible Expenses For Tax Purposes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible expenses for tax purposes</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NonDeductibleExpensesForTaxPurposes" xlink:label="cvac_NonDeductibleExpensesForTaxPurposes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NonDeductibleExpensesForTaxPurposes" xlink:to="cvac_NonDeductibleExpensesForTaxPurposes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NonDeductibleExpensesForTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible expenses for tax purposes abstract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NonDeductibleExpensesForTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Deductible Expenses For Tax Purposes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NonDeductibleExpensesForTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible expences for tax purposes</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" xlink:label="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" xlink:to="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to additions or deductions for local trade taxes not deductible in determining taxable profit (tax loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect Of Expense Not Deductible In Determining Profit Loss Related To Additions Or Deductions For Local Trade Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions for local trade taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax effect of expense not deductible in determining taxable profit (tax loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-deductible expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other tax effects for reconciliation between accounting profit and tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other effects</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IntangibleAssetsMember" xlink:label="cvac_IntangibleAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IntangibleAssetsMember" xlink:to="cvac_IntangibleAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IntangibleAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IntangibleAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssetsMember" xlink:to="ifrs-full_RightofuseAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use-assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember" xlink:label="ifrs-full_OtherAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssetsMember" xlink:to="ifrs-full_OtherAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsinventoriesMember" xlink:label="cvac_IfrsinventoriesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsinventoriesMember" xlink:to="cvac_IfrsinventoriesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsinventoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for inventories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsinventoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRSInventories [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsinventoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsprepaidExpensesAndOtherAssetsMember" xlink:label="cvac_IfrsprepaidExpensesAndOtherAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsprepaidExpensesAndOtherAssetsMember" xlink:to="cvac_IfrsprepaidExpensesAndOtherAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsprepaidExpensesAndOtherAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for prepaid expenses and other expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsprepaidExpensesAndOtherAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRSPrepaid Expenses And Other Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsprepaidExpensesAndOtherAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivablesMember" xlink:to="ifrs-full_TradeReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCashAndCashEquivalentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareBasedPaymentsMember" xlink:label="cvac_ShareBasedPaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareBasedPaymentsMember" xlink:to="cvac_ShareBasedPaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareBasedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for share-based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareBasedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareBasedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NonCurrentLeaseLiabilitiesMember" xlink:label="cvac_NonCurrentLeaseLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NonCurrentLeaseLiabilitiesMember" xlink:to="cvac_NonCurrentLeaseLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NonCurrentLeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for lease liabilities (non-current portion).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NonCurrentLeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities (Non-current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherNoncurrentLiabilitiesMember" xlink:label="cvac_IfrsOtherNoncurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOtherNoncurrentLiabilitiesMember" xlink:to="cvac_IfrsOtherNoncurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for other non-current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities (Non-current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesMember" xlink:to="cvac_TradeAndOtherPayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentLeaseLiabilitiesMember" xlink:label="cvac_CurrentLeaseLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurrentLeaseLiabilitiesMember" xlink:to="cvac_CurrentLeaseLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurrentLeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Lease liabilities (current portion).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurrentLeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities (Current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherLiabilitiesMember" xlink:label="cvac_IfrsOtherLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOtherLiabilitiesMember" xlink:to="cvac_IfrsOtherLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOtherLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOtherLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsOtherLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities (Current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxLossesCarriedForwardsMember" xlink:label="cvac_TaxLossesCarriedForwardsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TaxLossesCarriedForwardsMember" xlink:to="cvac_TaxLossesCarriedForwardsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TaxLossesCarriedForwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for tax losses carried forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TaxLossesCarriedForwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Losses Carried Forwards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TaxLossesCarriedForwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax losses carried forward</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" xlink:label="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" xlink:to="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to netting of tax in the DTA and DTL.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets and Deferred Tax Liability, Netting [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Netting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for subsidiaries [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" xlink:label="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" xlink:to="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to CureVac Corporate Services GmbH (Tuebingen, Germany).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Corporate Services GmbH (Tuebingen, Germany) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Corporate Services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilityAsset" xlink:to="ifrs-full_DeferredTaxLiabilityAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability (asset)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense (income) recognised in profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized profit and loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax relating to items credited (charged) directly to equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through business combinations, deferred tax liability (asset)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in Business combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DeferredTaxAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Taxes Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UnusedTaxLossesForCorporateIncomeTax" xlink:label="cvac_UnusedTaxLossesForCorporateIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UnusedTaxLossesForCorporateIncomeTax" xlink:to="cvac_UnusedTaxLossesForCorporateIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UnusedTaxLossesForCorporateIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of unused tax losses of corporate income tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UnusedTaxLossesForCorporateIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused Tax Losses For Corporate Income Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UnusedTaxLossesForCorporateIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused tax losses for corporate income tax</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UnusedTaxLossesForTradeTax" xlink:label="cvac_UnusedTaxLossesForTradeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UnusedTaxLossesForTradeTax" xlink:to="cvac_UnusedTaxLossesForTradeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UnusedTaxLossesForTradeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of unused tax losses of trade tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UnusedTaxLossesForTradeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused Tax Losses For Trade Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UnusedTaxLossesForTradeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused tax losses for trade tax</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UnusedInterestCarryforward" xlink:label="cvac_UnusedInterestCarryforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UnusedInterestCarryforward" xlink:to="cvac_UnusedInterestCarryforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UnusedInterestCarryforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of unused interest carryforward.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UnusedInterestCarryforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused Interest Carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UnusedInterestCarryforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused interest carryforward ("Zinsschranke")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused tax credits for which no deferred tax asset recognised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets, temporary differences</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TemporaryDifferencesValuationOfDeferredTaxAssets" xlink:label="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets" xlink:to="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of temporary differences valuation of deferred tax assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Differences Valuation Of Deferred Tax Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary differences valuation of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssets" xlink:label="ifrs-full_CurrentTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssets" xlink:to="ifrs-full_CurrentTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive effect of all instruments on weighted average number of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive share-based payment awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial assets [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskAxis" xlink:label="ifrs-full_ConcentrationsOfRiskAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConcentrationsOfRiskAxis" xlink:to="ifrs-full_ConcentrationsOfRiskAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConcentrationsOfRiskAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of risk [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ifrs-full_ConcentrationsOfRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConcentrationsOfRiskMember" xlink:to="ifrs-full_ConcentrationsOfRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConcentrationsOfRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of risk [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanysLargestPrivateBankMember" xlink:label="cvac_GermanysLargestPrivateBankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GermanysLargestPrivateBankMember" xlink:to="cvac_GermanysLargestPrivateBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GermanysLargestPrivateBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Germany's largest private bank.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GermanysLargestPrivateBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany's largest private bank</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanLandesbankMember" xlink:label="cvac_GermanLandesbankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GermanLandesbankMember" xlink:to="cvac_GermanLandesbankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GermanLandesbankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for German Landesbank.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GermanLandesbankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">German Landesbank</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_EuropeSLargestPrivateBankMember" xlink:label="cvac_EuropeSLargestPrivateBankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EuropeSLargestPrivateBankMember" xlink:to="cvac_EuropeSLargestPrivateBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EuropeSLargestPrivateBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Europe's largest private bank.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EuropeSLargestPrivateBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe's Largest Private Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_EuropeSLargestPrivateBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe's largest private bank</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedImpairmentMember" xlink:to="ifrs-full_AccumulatedImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated impairment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and management of financial risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="ifrs-full_InterestIncomeOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income on cash investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain" xlink:label="ifrs-full_ForeignExchangeGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeGain" xlink:to="ifrs-full_ForeignExchangeGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="ifrs-full_ForeignExchangeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange losses</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InterestExpenseOnCash" xlink:label="cvac_InterestExpenseOnCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InterestExpenseOnCash" xlink:to="cvac_InterestExpenseOnCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InterestExpenseOnCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of interest expense on cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InterestExpenseOnCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_InterestExpenseOnCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on cash</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsConcentrationRiskPercentage" xlink:label="cvac_IfrsConcentrationRiskPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsConcentrationRiskPercentage" xlink:to="cvac_IfrsConcentrationRiskPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsConcentrationRiskPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsConcentrationRiskPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsConcentrationRiskPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of risk</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AllowanceForExpectedCreditLossOnFinancialAssets" xlink:label="cvac_AllowanceForExpectedCreditLossOnFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AllowanceForExpectedCreditLossOnFinancialAssets" xlink:to="cvac_AllowanceForExpectedCreditLossOnFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AllowanceForExpectedCreditLossOnFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allowance for expected credit loss on financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AllowanceForExpectedCreditLossOnFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance For Expected Credit Loss On Financial Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AllowanceForExpectedCreditLossOnFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for expected credit losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">1 to 5 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanFiveYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">&gt; 5 years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Greater than 5 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and management of financial risks</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractualCommitmentsUndiscountedCashFlows" xlink:label="cvac_ContractualCommitmentsUndiscountedCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractualCommitmentsUndiscountedCashFlows" xlink:to="cvac_ContractualCommitmentsUndiscountedCashFlows_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractualCommitmentsUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contractual undiscounted cash flows in relation to contractual commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractualCommitmentsUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Commitments, Undiscounted Cash Flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ContractualCommitmentsUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesUndiscountedCashFlows" xlink:label="cvac_OtherLiabilitiesUndiscountedCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherLiabilitiesUndiscountedCashFlows" xlink:to="cvac_OtherLiabilitiesUndiscountedCashFlows_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contractual undiscounted cash flows in relation to other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Undiscounted Cash Flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_OtherLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables, undiscounted cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-derivative financial liabilities, undiscounted cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="currency_EUR" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EUR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF" xlink:label="currency_CHF" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CHF" xlink:to="currency_CHF_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CHF_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP" xlink:label="currency_GBP" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_GBP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GBP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of risks [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial instruments [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments, class [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CashAndCashEquivalentsOneMember" xlink:label="cvac_CashAndCashEquivalentsOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CashAndCashEquivalentsOneMember" xlink:to="cvac_CashAndCashEquivalentsOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CashAndCashEquivalentsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for cash and cash equivalents, one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CashAndCashEquivalentsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents, One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CashAndCashEquivalentsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents, One</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherReceivablesMember" xlink:to="cvac_TradeAndOtherReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MonetaryAssetsInForeignCurrencyMember" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total monetary assets in foreign currency</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesOneMember" xlink:to="cvac_TradeAndOtherPayablesOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables, One</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesTwoMember" xlink:to="cvac_TradeAndOtherPayablesTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables, Two</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">"This member stands for a type
 of market risk representing the
 risk that the fair value or future
 cash flows of a financial
 instrument will fluctuate
 because of changes in foreign
 exchange rates."</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total monetary liabilities in foreign currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk exposure associated with instruments sharing characteristic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exposure in (foreign) currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average foreign exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange rate</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExchangeRateCurrencyNetExposure" xlink:label="cvac_ExchangeRateCurrencyNetExposure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExchangeRateCurrencyNetExposure" xlink:to="cvac_ExchangeRateCurrencyNetExposure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExchangeRateCurrencyNetExposure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents exchange rate net exposure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExchangeRateCurrencyNetExposure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange Rate Currency Net Exposure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExchangeRateCurrencyNetExposure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net exposure</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossBeforeTaxIfEurWeakened" xlink:label="cvac_ProfitLossBeforeTaxIfEurWeakened" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProfitLossBeforeTaxIfEurWeakened" xlink:to="cvac_ProfitLossBeforeTaxIfEurWeakened_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProfitLossBeforeTaxIfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the profit (loss) before tax expense or income if EUR weakened.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProfitLossBeforeTaxIfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss Before Tax If EUR Weakened</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProfitLossBeforeTaxIfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-tax loss if EUR weakened</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfEurWeakened" xlink:label="cvac_PercentageOfEurWeakened" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfEurWeakened" xlink:to="cvac_PercentageOfEurWeakened_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents the Percentage of EUR weakened.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of EUR Weakened</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of EUR weakened</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossAfterTaxIfEurWeakened" xlink:label="cvac_ProfitLossAfterTaxIfEurWeakened" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProfitLossAfterTaxIfEurWeakened" xlink:to="cvac_ProfitLossAfterTaxIfEurWeakened_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProfitLossAfterTaxIfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the profit (loss) after tax expense or income if EUR weakened.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProfitLossAfterTaxIfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss After Tax If EUR Weakened</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProfitLossAfterTaxIfEurWeakened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-tax loss if EUR weakened</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfEurStrengthened" xlink:label="cvac_PercentageOfEurStrengthened" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfEurStrengthened" xlink:to="cvac_PercentageOfEurStrengthened_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents the Percentage of EUR strengthened.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of EUR Strengthened</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of EUR strengthened</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossBeforeTaxIfEurStrengthened" xlink:label="cvac_ProfitLossBeforeTaxIfEurStrengthened" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProfitLossBeforeTaxIfEurStrengthened" xlink:to="cvac_ProfitLossBeforeTaxIfEurStrengthened_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProfitLossBeforeTaxIfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the profit (loss) before tax expense or income if EUR strengthened.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProfitLossBeforeTaxIfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss Before Tax If EUR Strengthened</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProfitLossBeforeTaxIfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-tax loss if EUR strengthened</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossAfterTaxIfEurStrengthened" xlink:label="cvac_ProfitLossAfterTaxIfEurStrengthened" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProfitLossAfterTaxIfEurStrengthened" xlink:to="cvac_ProfitLossAfterTaxIfEurStrengthened_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProfitLossAfterTaxIfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the profit (loss) after tax expense or income if EUR strengthened.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProfitLossAfterTaxIfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss after Tax If EUR Strengthened</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProfitLossAfterTaxIfEurStrengthened_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-tax loss if EUR strengthened</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfInterestHigher" xlink:label="cvac_PercentageOfInterestHigher" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfInterestHigher" xlink:to="cvac_PercentageOfInterestHigher_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfInterestHigher_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents percentage of Interest higher.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfInterestHigher_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Interest Higher</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfInterestHigher_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Interest higher</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetLossBeforeTax" xlink:label="cvac_NetLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetLossBeforeTax" xlink:to="cvac_NetLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent amount of Net loss before tax if interest rate 1% higher while all other variables had remained the same.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of reconciliation of liabilities arising from financing activities [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities arising from financing activities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities arising from financing activities [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of reconciliation of liabilities arising from financing activities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through financing cash flows, liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" xlink:label="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" xlink:to="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in liabilities arising from financing activities resulting from disposals that the entity does not separately disclose in the same statement or note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Through Disposals Liabilities Arising from Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase through new leases, liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New leases</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" xlink:label="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" xlink:to="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in liabilities arising from financing activities resulting from interest that the entity does not separately disclose in the same statement or note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Through Interest Liabilities Arising from Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Exchange Movements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ManagementBoardMember" xlink:to="cvac_ManagementBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for management board of the entity's key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management Board</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SupervisoryBoardMember" xlink:label="cvac_SupervisoryBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SupervisoryBoardMember" xlink:to="cvac_SupervisoryBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SupervisoryBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for supervisory board of the entity's key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SupervisoryBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supervisory Board</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remuneration of the Company's key management personnel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation, short-term employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation, termination benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation, share-based payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExecutiveBoardMember" xlink:label="cvac_ExecutiveBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExecutiveBoardMember" xlink:to="cvac_ExecutiveBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExecutiveBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for executive board of the entity's key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExecutiveBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExecutiveBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Board</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration" xlink:label="ifrs-full_AuditorsRemuneration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemuneration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemuneration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor's remuneration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AuditorsRemuneration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total remuneration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments granted</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BaronJeanStephenneMember" xlink:to="cvac_BaronJeanStephenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Baron Jean Stephenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baron Jean Stephenne [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baron Jean Stephenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VincentStphenneMember" xlink:to="cvac_VincentStphenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Vincent Stphenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vincent Stephenne [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vincent Stephenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AntonyBlancMember" xlink:to="cvac_AntonyBlancMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Antony Blanc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antony Blanc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antony Blanc</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DietmarHoppMember" xlink:to="cvac_DietmarHoppMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dietmar Hopp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dietmar Hopp</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:to="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dievini Hopp BioTech holding GmbH &amp; Co. KG [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dievini Hopp BioTech holding GmbH &amp; Co. KG</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ClarentisSrlMember" xlink:to="cvac_ClarentisSrlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarentis SRL [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarentis SRL</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BepharbelManufacturingS.aMember" xlink:to="cvac_BepharbelManufacturingS.aMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BePharBel Manufacturing S.A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BePharBel Manufacturing S.A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BePharBel Manufacturing S.A</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FranzWernerHaasMember" xlink:label="cvac_FranzWernerHaasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FranzWernerHaasMember" xlink:to="cvac_FranzWernerHaasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FranzWernerHaasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Franz-Werner Haas.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FranzWernerHaasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Franz-Werner Haas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FranzWernerHaasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Franz-Werner Haas</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AlexanderZehnderMember" xlink:label="cvac_AlexanderZehnderMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AlexanderZehnderMember" xlink:to="cvac_AlexanderZehnderMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AlexanderZehnderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Alexander Zehnder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AlexanderZehnderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alexander Zehnder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AlexanderZehnderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alexander Zehnder</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BarkerBiomedicalGmbhMember" xlink:label="cvac_BarkerBiomedicalGmbhMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BarkerBiomedicalGmbhMember" xlink:to="cvac_BarkerBiomedicalGmbhMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BarkerBiomedicalGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for barker biomedical GmbH member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BarkerBiomedicalGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Barker BioMedical GmbH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BarkerBiomedicalGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Barker BioMedical GmbH</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CraigToomanMember" xlink:label="cvac_CraigToomanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CraigToomanMember" xlink:to="cvac_CraigToomanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CraigToomanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for craig tooman.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CraigToomanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Craig Tooman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CraigToomanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Craig Tooman</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RittershausRechtsanwaelteMember" xlink:to="cvac_RittershausRechtsanwaelteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Rittershaus Rechtsanwaelte , a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rittershaus Rechtsanwaelte [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rittershaus Rechtsanwaelte</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MariolaFotinMleczekMember" xlink:label="cvac_MariolaFotinMleczekMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MariolaFotinMleczekMember" xlink:to="cvac_MariolaFotinMleczekMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MariolaFotinMleczekMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Mariola Fotin-Mleczek.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MariolaFotinMleczekMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mariola Fotin-Mleczek [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MariolaFotinMleczekMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mariola Fotin-Mleczek</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FlorianVonDerMlbeMember" xlink:label="cvac_FlorianVonDerMlbeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FlorianVonDerMlbeMember" xlink:to="cvac_FlorianVonDerMlbeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FlorianVonDerMlbeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Florian von der Mlbe.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FlorianVonDerMlbeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Florian von der Mlbe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FlorianVonDerMlbeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Florian von der Mlbe</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Dr.IngmarHrrMember" xlink:label="cvac_Dr.IngmarHrrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Dr.IngmarHrrMember" xlink:to="cvac_Dr.IngmarHrrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Dr.IngmarHrrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dr. Ingmar Hrr.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Dr.IngmarHrrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ingmar Hrr [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Dr.IngmarHrrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ingmar Hrr</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImmaticsBiotechnologiesGmbhMember" xlink:label="cvac_ImmaticsBiotechnologiesGmbhMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ImmaticsBiotechnologiesGmbhMember" xlink:to="cvac_ImmaticsBiotechnologiesGmbhMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ImmaticsBiotechnologiesGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Immatics Biotechnologies Gmbh.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ImmaticsBiotechnologiesGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immatics Biotechnologies Gmbh [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ImmaticsBiotechnologiesGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immatics Biotechnologies GmbH</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurevacPrinterGmbhMember" xlink:label="cvac_CurevacPrinterGmbhMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacPrinterGmbhMember" xlink:to="cvac_CurevacPrinterGmbhMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacPrinterGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CureVac Printer Gmbh.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacPrinterGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Printer GmbH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurevacPrinterGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Printer GmbH</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GridEuropeMember" xlink:label="cvac_GridEuropeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GridEuropeMember" xlink:to="cvac_GridEuropeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GridEuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for related party Grid Europe, which is a wholly owned consulting company of Ralf Clemens, who was a member of the supervisory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GridEuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grid Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_GridEuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grid Europe</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of notice for termination of the agreement at the option of the party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Notice Period for Termination of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for termination at the option</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionConsultingFees" xlink:to="cvac_RelatedPartyTransactionConsultingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consulting fees incurred as a part of related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of loans received from a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Number of Loans Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible loans</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsContractualObligation" xlink:to="cvac_IfrsContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual obligation amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments made by entity, related party transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement amount</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfTravelCost" xlink:label="cvac_ReimbursementOfTravelCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReimbursementOfTravelCost" xlink:to="cvac_ReimbursementOfTravelCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReimbursementOfTravelCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reimbursement of travel cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReimbursementOfTravelCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement Of Travel Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReimbursementOfTravelCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of travel cost</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:to="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of income tax and social security liability receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax and Social Security Liability Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax and social security liability receivable</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:to="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense recognized during the period from related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized From Related Party Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense recognized from related party transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity interest held</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of goods, related party transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of related party</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" xlink:label="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" xlink:to="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount reimbursed to the company in the form of kind from related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of Expense In The Form of Kind From Related Party Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment compensated</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpensesToHandleFutureServiceAgreement" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpensesToHandleFutureServiceAgreement" xlink:to="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expenses to handle future service agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses To Handle Future Service Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses to handle future service agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ServiceRenderedIssue" xlink:label="cvac_ServiceRenderedIssue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ServiceRenderedIssue" xlink:to="cvac_ServiceRenderedIssue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ServiceRenderedIssue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of service rendered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ServiceRenderedIssue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service Rendered Issue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ServiceRenderedIssue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service rendered issue</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FairValueOfTotalConsiderationTransferred" xlink:label="cvac_FairValueOfTotalConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FairValueOfTotalConsiderationTransferred" xlink:to="cvac_FairValueOfTotalConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fair value of total consideration transferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Of Total Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesIncurred" xlink:to="ifrs-full_LiabilitiesIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net amount of discharging contractual obligations</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:to="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of payments in which the total consideration is to be paid under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Payments In Which The Total Consideration Is To Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of payments in which the total consideration is to be paid</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:to="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of payments of total consideration under the business combination arrangement, that are subject to the achievement of defined milestones (contingent considerations).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Number Of Payments Considered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, Number of payments considered</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance and transfer of shares to former Frame shareholders</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued to former Frame shareholders</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsBusinessAcquisitionSharePrice" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsBusinessAcquisitionSharePrice" xlink:to="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Business Acquisition, Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Share Price</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashTransferred" xlink:to="ifrs-full_CashTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:to="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash transferred in a business combination for the settlement of the vested employee options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Transferred For The Settlement Of The Vested Employee Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration paid in cash for the settlement of the vested employee options</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionalCashTransferred" xlink:label="cvac_AdditionalCashTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionalCashTransferred" xlink:to="cvac_AdditionalCashTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionalCashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value, at acquisition date, of additional cash transferred as consideration in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionalCashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Cash Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionalCashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional cash consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:to="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total consideration transferred under the business combination, that are subject to the achievement of defined milestones (contingent considerations).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Percentage Of Total Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, Percentage of total consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationNumberOfMilestones" xlink:label="cvac_ContingentConsiderationNumberOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationNumberOfMilestones" xlink:to="cvac_ContingentConsiderationNumberOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones to be achieved under the contingent consideration arrangement under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Number Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, Number of milestones</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon the achievement of the successful investigational new drug application filing</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total consideration transferred under the business combination, upon the achievement of first milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Consideration Transferred Upon Achievement Of First Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued upon the achievement of the successful investigational new drug application filing</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon successful proof of mechanism in humans</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total consideration transferred under the business combination, upon the achievement of second milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Consideration Transferred Upon Achievement Of Second Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of consideration transferred upon successful proof of mechanism in humans</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued upon successful proof of mechanism in humans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityInterestsOfAcquirer" xlink:to="ifrs-full_EquityInterestsOfAcquirer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityInterestsOfAcquirer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity interests of acquirer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityInterestsOfAcquirer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued to former Frame shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_EquityInterestsOfAcquirer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of aggregate consideration in shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationMaximumSharesIssuable" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationMaximumSharesIssuable" xlink:to="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares issuable as contingent consideration in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Maximum Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Maximum shares issuable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value at measurement date, other equity instruments granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of the RSU grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionalFairValue" xlink:label="cvac_ProvisionalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProvisionalFairValue" xlink:to="cvac_ProvisionalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProvisionalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of provisional fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProvisionalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisional Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProvisionalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisional fair value</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SigningSharePriceRepresenting10" xlink:label="cvac_SigningSharePriceRepresenting10" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SigningSharePriceRepresenting10" xlink:to="cvac_SigningSharePriceRepresenting10_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SigningSharePriceRepresenting10_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents of signing share price representing 10%.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SigningSharePriceRepresenting10_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing Share Price Representing 10%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SigningSharePriceRepresenting10_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing share price representing 10%</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SigningSharePriceRepresenting40" xlink:label="cvac_SigningSharePriceRepresenting40" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SigningSharePriceRepresenting40" xlink:to="cvac_SigningSharePriceRepresenting40_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SigningSharePriceRepresenting40_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents of signing share price representing 40%.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SigningSharePriceRepresenting40_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing Share Price Representing 40%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SigningSharePriceRepresenting40_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing share price representing 40%</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for deferred tax liabilities net of deferred tax assets assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Deferred Tax Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities (net of deferred tax assets)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">net deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for right-of-use assets assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right Of Use Assets Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology-based intangible assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets (Technology)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FairValueOfAcquiredReceivables" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of acquired receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for total assets assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Assets Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for non-current lease liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent Lease Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for current lease liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Lease Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for other liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for total liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Identifiable assets acquired (liabilities assumed)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net assets acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-adjusting events after reporting period [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualShareOptionPlanMember" xlink:label="cvac_VirtualShareOptionPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualShareOptionPlanMember" xlink:to="cvac_VirtualShareOptionPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualShareOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for virtual share option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualShareOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Virtual Share Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VirtualShareOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VSOP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-adjusting events after reporting period [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DistributionCosts" xlink:label="ifrs-full_DistributionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DistributionCosts" xlink:to="ifrs-full_DistributionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DistributionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Distribution costs</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>59
<FILENAME>cvac-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/24/2024 9:35:19 PM-->
<!--Modified on: 4/24/2024 9:35:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureCorporateInformation" roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPolicies" roleURI="http://www.curevac.com/role/DisclosureAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatements" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssets" roleURI="http://www.curevac.com/role/DisclosureFixedAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAssetsHeldForSale" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureInventories" roleURI="http://www.curevac.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherFinancialAssets" roleURI="http://www.curevac.com/role/DisclosureOtherFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquity" roleURI="http://www.curevac.com/role/DisclosureEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPayments" roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureTradeAndOtherPayables" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisions" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTax" roleURI="http://www.curevac.com/role/DisclosureIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEarningsPerShare" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.curevac.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRemunerationOfCompanySKeyManagementPersonnel" roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRelatedPartyDisclosures" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinations" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesPolicies" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesTables" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsTables" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsTables" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityTables" roleURI="http://www.curevac.com/role/DisclosureEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureTradeAndOtherPayablesTables" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsTables" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxTables" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedStatementsOfCashFlowsTables" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRemunerationOfCompanySKeyManagementPersonnelTables" roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsTables" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureAssetsHeldForSaleDetails" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureInventoriesDetails" roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherFinancialAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityFollowOnPublicOfferingDetails" roleURI="http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityAtMarketOfferingDetails" roleURI="http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails" roleURI="http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsPriorVsopExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsRestrictedStockUnitsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureTradeAndOtherPayablesDetails" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsMovementsDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxScheduleOfTaxReconciliationDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxScheduleOfDeferredTaxesDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureEarningsPerShareDetails" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638495913130926331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentInformationTable_638495913130926331" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638495913130926331" xlink:to="dei_EntityAddressesAddressTypeAxis_638495913130936357" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_638495913130936357" xlink:to="dei_AddressTypeDomain_638495913130936357" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_638495913130936357" xlink:to="dei_BusinessContactMember_638495913130936357" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638495913130926331" xlink:to="dei_DocumentInformationLineItems_638495913130936357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentType_638495913130936357" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentRegistrationStatement_638495913130936357" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentAnnualReport_638495913130936357" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentTransitionReport_638495913130936357" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentShellCompanyReport_638495913130936357" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityRegistrantName_638495913130936357" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638495913130936357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentPeriodEndDate_638495913130936357" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityIncorporationStateCountryCode_638495913130946333" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityAddressAddressLine1_638495913130946333" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityAddressCityOrTown_638495913130946333" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityAddressCountry_638495913130946333" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityAddressPostalZipCode_638495913130946333" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_ContactPersonnelName_638495913130946333" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_ContactPersonnelEmailAddress_638495913130946333" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_Security12bTitle_638495913130946333" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_TradingSymbol_638495913130946333" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638495913130946333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_SecurityExchangeName_638495913130946333" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityFileNumber_638495913130956328" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityWellKnownSeasonedIssuer_638495913130956328" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityCurrentReportingStatus_638495913130956328" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityFilerCategory_638495913130956328" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityInteractiveDataCurrent_638495913130956328" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityEmergingGrowthCompany_638495913130956328" order="23" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentAccountingStandard_638495913130956328" order="24" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638495913130956328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityShellCompany_638495913130956328" order="25" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638495913130966326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityCommonStockSharesOutstanding_638495913130966326" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638495913130966326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_CurrentFiscalYearEndDate_638495913130966326" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638495913130966326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentFiscalYearFocus_638495913130966326" order="28" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638495913130966326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentFiscalPeriodFocus_638495913130966326" order="29" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638495913130966326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityCentralIndexKey_638495913130966326" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638495913130966326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_AmendmentFlag_638495913130966326" order="31" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638495913130966326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_IcfrAuditorAttestationFlag_638495913130966326" order="32" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638495913130976326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638495913130976326" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638495913130976326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_EntityVoluntaryFilers_638495913130976326" order="34" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638495913130976326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_AuditorName_638495913130976326" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638495913130976326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_AuditorFirmId_638495913130976326" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638495913130976326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638495913130936357" xlink:to="dei_AuditorLocation_638495913130976326" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638495913130986328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_CostOfSales_638495913130986328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense_638495913130986328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638495913130986328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638495913130986328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638495913130986328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638495913130986328" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638495913130986328" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638495913130986328" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceIncome_638495913130986328" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638495913130986328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceCosts_638495913130986328" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax_638495913130996333" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913130996333" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss_638495913130996333" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_638495913130996333" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_638495913130996333" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638495913130996333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_638495913130996333" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638495913130996333" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638495913130996333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638495913130996333" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_638495913131006334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638495913131006334" xlink:to="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_638495913131006334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_PropertyPlantAndEquipment_638495913131006334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_RightofuseAssets_638495913131006334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_OtherNoncurrentAssets_638495913131006334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DeferredTaxAsset" xlink:label="cvac_DeferredTaxAsset_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" xlink:to="cvac_DeferredTaxAsset_638495913131006334" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_NoncurrentAssets_638495913131006334" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638495913131006334" xlink:to="ifrs-full_CurrentAssetsAbstract_638495913131006334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913131006334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_Inventories_638495913131006334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638495913131006334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_CurrentTradeReceivables_638495913131006334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_CurrentContractAssets_638495913131016333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_OtherCurrentFinancialAssets_638495913131016333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638495913131016333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_638495913131016333" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_CashAndCashEquivalents_638495913131016333" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638495913131006334" xlink:to="ifrs-full_CurrentAssets_638495913131016333" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638495913131006334" xlink:to="ifrs-full_Assets_638495913131016333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_638495913131016333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638495913131016333" xlink:to="ifrs-full_EquityAbstract_638495913131016333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638495913131016333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638495913131016333" xlink:to="ifrs-full_IssuedCapital_638495913131016333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638495913131016333" xlink:to="ifrs-full_CapitalReserve_638495913131026328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638495913131016333" xlink:to="ifrs-full_TreasuryShares_638495913131026328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638495913131016333" xlink:to="ifrs-full_RetainedEarnings_638495913131026328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638495913131016333" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_638495913131026328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638495913131016333" xlink:to="ifrs-full_Equity_638495913131026328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638495913131016333" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_638495913131026328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638495913131026328" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638495913131026328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638495913131026328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638495913131026328" xlink:to="ifrs-full_NoncurrentContractLiabilities_638495913131026328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_638495913131036330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638495913131026328" xlink:to="ifrs-full_NoncurrentProvisions_638495913131036330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638495913131036330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638495913131026328" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638495913131036330" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638495913131036330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638495913131026328" xlink:to="ifrs-full_NoncurrentLiabilities_638495913131036330" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638495913131016333" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638495913131036330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" xlink:to="ifrs-full_CurrentLeaseLiabilities_638495913131036330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638495913131036330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638495913131036330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_638495913131036330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" xlink:to="ifrs-full_CurrentProvisions_638495913131036330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638495913131046332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" xlink:to="ifrs-full_OtherCurrentLiabilities_638495913131046332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_638495913131046332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" xlink:to="ifrs-full_CurrentTaxLiabilities_638495913131046332" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638495913131046332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" xlink:to="ifrs-full_CurrentContractLiabilities_638495913131046332" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638495913131046332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638495913131036330" xlink:to="ifrs-full_CurrentLiabilities_638495913131046332" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638495913131046332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638495913131016333" xlink:to="ifrs-full_Liabilities_638495913131046332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638495913131046332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638495913131016333" xlink:to="ifrs-full_EquityAndLiabilities_638495913131046332" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638495913131056327" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638495913131056327" xlink:to="ifrs-full_ComponentsOfEquityAxis_638495913131056327" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638495913131056327" xlink:to="ifrs-full_IssuedCapitalMember_638495913131056327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638495913131056327" xlink:to="ifrs-full_CapitalReserveMember_638495913131056327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638495913131056327" xlink:to="ifrs-full_TreasurySharesMember_638495913131056327" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638495913131056327" xlink:to="ifrs-full_RetainedEarningsMember_638495913131056327" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638495913131056327" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638495913131056327" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638495913131056327" xlink:to="ifrs-full_EquityMember_638495913131056327" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638495913131056327" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638495913131056327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_Equity_638495913131056327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_ProfitLoss_638495913131066333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_OtherComprehensiveIncome_638495913131066333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_ComprehensiveIncome_638495913131066333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_638495913131066333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638495913131066333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_IssueOfEquity_638495913131066333" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:label="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_638495913131066333" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount_638495913131066333" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_638495913131066333" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638495913131066333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638495913131066333" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638495913131056327" xlink:to="ifrs-full_Equity_638495913131076331" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638495913131076331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638495913131076331" xlink:to="ifrs-full_ProfitLossBeforeTax_638495913131076331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_638495913131076331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_638495913131076331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638495913131076331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913131076331" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638495913131076331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638495913131076331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsTransferToAssetHeldForSale" xlink:label="cvac_AdjustmentsTransferToAssetHeldForSale_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="cvac_AdjustmentsTransferToAssetHeldForSale_638495913131086335" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_InventoryWritedown2011_638495913131086335" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638495913131086335" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638495913131086335" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638495913131076331" xlink:to="ifrs-full_AdjustmentsForProvisions_638495913131086335" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638495913131076331" xlink:to="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913131086335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638495913131086335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638495913131086335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638495913131086335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638495913131086335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638495913131086335" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638495913131096330" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638495913131096330" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_638495913131096330" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638495913131096330" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638495913131096330" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638495913131096330" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638495913131086335" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638495913131096330" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638495913131096330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638495913131096330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638495913131096330" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638495913131106330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638495913131096330" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638495913131106330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638495913131096330" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638495913131106330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638495913131096330" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638495913131106330" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638495913131106330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" xlink:to="ifrs-full_ProceedsFromIssuingShares_638495913131106330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638495913131106330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638495913131106330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638495913131116329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638495913131116329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638495913131116329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638495913131116329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913131116329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638495913131106330" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638495913131116329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638495913131116329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638495913131116329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638495913131116329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638495913131116329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638495913131116329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_638495913131116329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638495913131126330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_638495913131126330" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformation" xlink:type="extended" xlink:title="10101 - Disclosure - Corporate Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock_638495913131126330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="cvac_CorporateInformationTextBlock_638495913131126330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="cvac_SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638495913131126330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638495913131126330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" xlink:type="extended" xlink:title="10301 - Disclosure - Notes to the consolidated financial statements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock_638495913131136342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock_638495913131136342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="10401 - Disclosure - Fixed Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_638495913131136342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_638495913131136342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xlink:type="extended" xlink:title="10501 - Disclosure - Assets held for sale" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_638495913131136342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_638495913131136342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10601 - Disclosure - Inventories" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_638495913131146332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_638495913131146332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherFinancialAssets" xlink:type="extended" xlink:title="10701 - Disclosure - Other financial assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="DisclosureOfFinancialAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherFinancialAssetsExplanatory" xlink:label="cvac_DisclosureOfOtherFinancialAssetsExplanatory_638495913131146332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="cvac_DisclosureOfOtherFinancialAssetsExplanatory_638495913131146332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10801 - Disclosure - Prepaid expenses and other current assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_638495913131146332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_638495913131146332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquity" xlink:type="extended" xlink:title="10901 - Disclosure - Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638495913131146332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638495913131146332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPayments" xlink:type="extended" xlink:title="11001 - Disclosure - Share-based payments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638495913131156336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638495913131156336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xlink:type="extended" xlink:title="11101 - Disclosure - Trade and other payables" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638495913131156336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638495913131156336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions" xlink:type="extended" xlink:title="11201 - Disclosure - Other liabilities and provisions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract_2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesAndProvisionsTextBlock" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_638495913131156336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract_2" xlink:to="cvac_OtherLiabilitiesAndProvisionsTextBlock_638495913131156336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTax" xlink:type="extended" xlink:title="11301 - Disclosure - Income tax" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_638495913131166335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_638495913131166335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShare" xlink:type="extended" xlink:title="11401 - Disclosure - Earnings per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory_638495913131166335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory_638495913131166335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks" xlink:type="extended" xlink:title="11501 - Disclosure - Disclosure of financial instruments and management of financial risks" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638495913131166335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638495913131166335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="11601 - Disclosure - Notes to the consolidated statements of cash flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:label="NotesToConsolidatedStatementsOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory_638495913131176337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:to="ifrs-full_DisclosureOfCashFlowStatementExplanatory_638495913131176337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11701 - Disclosure - Commitments and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfCommitmentsAndContingenciesAbstract" xlink:label="DisclosureOfCommitmentsAndContingenciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_638495913131176337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCommitmentsAndContingenciesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_638495913131176337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnel" xlink:type="extended" xlink:title="11801 - Disclosure - Remuneration of the Company's key management personnel" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfKeyManagementPersonnelAbstract" xlink:label="DisclosureOfKeyManagementPersonnelAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_638495913131176337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfKeyManagementPersonnelAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_638495913131176337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xlink:type="extended" xlink:title="11901 - Disclosure - Related party disclosures" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_638495913131186336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_638495913131186336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinations" xlink:type="extended" xlink:title="12001 - Disclosure - Business Combinations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_638495913131186336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_638495913131186336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="12101 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638495913131186336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638495913131186336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638495913131196334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_638495913131196334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_638495913131196334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_638495913131196334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_638495913131196334" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_638495913131196334" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_638495913131196334" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_638495913131196334" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_638495913131196334" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_638495913131196334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_638495913131196334" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_638495913131206335" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory_638495913131206335" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_638495913131206335" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_638495913131206335" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_638495913131206335" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_638495913131206335" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_638495913131206335" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_638495913131206335" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_638495913131206335" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638495913131206335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638495913131206335" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_638495913131216331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_638495913131216331" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory_638495913131216331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory_638495913131216331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_638495913131216331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_638495913131216331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory" xlink:label="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory_638495913131216331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory_638495913131216331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Notes to the consolidated financial statements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638495913131226338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_638495913131226338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_638495913131226338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_638495913131226338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_638495913131226338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_638495913131226338" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638495913131226338" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fixed Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_638495913131226338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_638495913131226338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_638495913131226338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_638495913131236335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_638495913131236335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:label="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_638495913131236335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_638495913131236335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock" xlink:label="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock_638495913131236335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock_638495913131236335" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638495913131236335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638495913131236335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="31003 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131236335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131236335" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131236335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131236335" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131236335" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131236335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131236335" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131236335" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131236335" xlink:to="cvac_VirtualSharesProgramIMember_638495913131246336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131236335" xlink:to="cvac_VirtualSharesProgramIiMember_638495913131246336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131236335" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913131246336" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131236335" xlink:to="cvac_RestrictedStockUnitsMember_638495913131246336" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131236335" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131246336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131246336" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_638495913131246336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131246336" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_638495913131246336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131246336" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_638495913131246336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_638495913131246336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131246336" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_638495913131246336" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Trade and other payables (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock" xlink:label="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock_638495913131256342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock_638495913131256342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Other liabilities and provisions (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_638495913131256342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract_1" xlink:to="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_638495913131256342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherProvisionsExplanatory_638495913131256342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract_1" xlink:to="ifrs-full_DisclosureOfOtherProvisionsExplanatory_638495913131256342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesTableTextBlock" xlink:label="cvac_DisclosureOfOtherLiabilitiesTableTextBlock_638495913131256342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract_1" xlink:to="cvac_DisclosureOfOtherLiabilitiesTableTextBlock_638495913131256342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxTables" xlink:type="extended" xlink:title="31303 - Disclosure - Income tax (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638495913131256342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638495913131256342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_638495913131266336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfDeferredTaxesExplanatory_638495913131266336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock" xlink:label="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock_638495913131266336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock_638495913131266336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables" xlink:type="extended" xlink:title="31503 - Disclosure - Disclosure of financial instruments and management of financial risks (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_638495913131266336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_638495913131266336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock" xlink:label="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock_638495913131266336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock_638495913131266336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory_638495913131266336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfMarketRiskExplanatory_638495913131266336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsTables" xlink:type="extended" xlink:title="31603 - Disclosure - Notes to the consolidated statements of cash flows (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:label="NotesToConsolidatedStatementsOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_638495913131276339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_638495913131276339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelTables" xlink:type="extended" xlink:title="31803 - Disclosure - Remuneration of the Company's key management personnel (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfKeyManagementPersonnelAbstract" xlink:label="DisclosureOfKeyManagementPersonnelAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock" xlink:label="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock_638495913131276339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfKeyManagementPersonnelAbstract" xlink:to="cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock_638495913131276339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsTables" xlink:type="extended" xlink:title="32003 - Disclosure - Business Combinations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_638495913131276339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_1" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_638495913131276339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_638495913131276339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_1" xlink:to="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_638495913131276339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913131286338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913131286338" xlink:to="ifrs-full_RangeAxis_638495913131286338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131286338" xlink:to="ifrs-full_RangesMember_638495913131286338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131286338" xlink:to="ifrs-full_BottomOfRangeMember_638495913131286338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131286338" xlink:to="ifrs-full_TopOfRangeMember_638495913131286338" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913131286338" xlink:to="srt_TitleOfIndividualAxis_638495913131286338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638495913131286338" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131286338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LargestShareholderMember" xlink:label="cvac_LargestShareholderMember_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131286338" xlink:to="cvac_LargestShareholderMember_638495913131286338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913131286338" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913131286338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfVotingInterestsHeld" xlink:label="cvac_PercentageOfVotingInterestsHeld_638495913131286338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913131286338" xlink:to="cvac_PercentageOfVotingInterestsHeld_638495913131286338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPolicyTable" xlink:label="cvac_SignificantAccountingPolicyTable_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="cvac_SignificantAccountingPolicyTable_638495913131296340" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyTable_638495913131296340" xlink:to="ifrs-full_ProductsAndServicesAxis_638495913131296340" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638495913131296340" xlink:to="ifrs-full_ProductsAndServicesMember_638495913131296340" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638495913131296340" xlink:to="cvac_IfrsProductMember_638495913131296340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyTable_638495913131296340" xlink:to="ifrs-full_RangeAxis_638495913131296340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131296340" xlink:to="ifrs-full_RangesMember_638495913131296340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131296340" xlink:to="ifrs-full_BottomOfRangeMember_638495913131296340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131296340" xlink:to="ifrs-full_TopOfRangeMember_638495913131296340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPolicyLineItems" xlink:label="cvac_SignificantAccountingPolicyLineItems_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyTable_638495913131296340" xlink:to="cvac_SignificantAccountingPolicyLineItems_638495913131296340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638495913131296340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638495913131296340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPropertyPlantAndEquipmentSalvageValue" xlink:label="cvac_IfrsPropertyPlantAndEquipmentSalvageValue_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="cvac_IfrsPropertyPlantAndEquipmentSalvageValue_638495913131306342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisions" xlink:label="cvac_ContractTerminationProvisions_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="cvac_ContractTerminationProvisions_638495913131306342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision" xlink:label="ifrs-full_ShorttermOnerousContractsProvision_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="ifrs-full_ShorttermOnerousContractsProvision_638495913131306342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_638495913131306342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="ifrs-full_BorrowingCostsCapitalised_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="ifrs-full_BorrowingCostsCapitalised_638495913131306342" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_638495913131306342" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913131306342" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_638495913131306342" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfOperatingSegments" xlink:label="cvac_IfrsNumberOfOperatingSegments_638495913131306342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="cvac_IfrsNumberOfOperatingSegments_638495913131306342" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfReportableSegments" xlink:label="cvac_IfrsNumberOfReportableSegments_638495913131316336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="cvac_IfrsNumberOfReportableSegments_638495913131316336" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp" xlink:label="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp_638495913131386356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_SignificantAccountingPolicyLineItems_638495913131296340" xlink:to="cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp_638495913131386356" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Accounting Policies - Estimated useful lives Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131386356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131386356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_638495913131386356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131386356" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_638495913131386356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638495913131386356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_638495913131386356" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638495913131386356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638495913131386356" xlink:to="cvac_SoftwareMember_638495913131396360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638495913131386356" xlink:to="ifrs-full_LicencesMember_638495913131396360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638495913131386356" xlink:to="cvac_TechnologyMember_638495913131396360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131386356" xlink:to="ifrs-full_RangeAxis_638495913131396360" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131396360" xlink:to="ifrs-full_RangesMember_638495913131396360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131396360" xlink:to="ifrs-full_BottomOfRangeMember_638495913131396360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131396360" xlink:to="ifrs-full_TopOfRangeMember_638495913131396360" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131386356" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131396360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131396360" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_638495913131396360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Accounting Policies - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131396360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131396360" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131396360" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638495913131406348" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638495913131406348" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638495913131406348" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131406348" xlink:to="ifrs-full_LeaseholdImprovementsMember_638495913131406348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnicalEquipmentAndMachinesMember" xlink:label="cvac_TechnicalEquipmentAndMachinesMember_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131406348" xlink:to="cvac_TechnicalEquipmentAndMachinesMember_638495913131406348" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131406348" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_638495913131406348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131396360" xlink:to="ifrs-full_RangeAxis_638495913131406348" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131406348" xlink:to="ifrs-full_RangesMember_638495913131406348" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131406348" xlink:to="ifrs-full_BottomOfRangeMember_638495913131406348" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131406348" xlink:to="ifrs-full_TopOfRangeMember_638495913131406348" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131396360" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131406348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_638495913131406348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131406348" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_638495913131406348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Accounting Policies - Estimated useful life of right-of-use assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SignificantAccountingPoliciesAbstract" xlink:label="SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638495913131416338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638495913131416338" xlink:to="ifrs-full_ClassesOfAssetsAxis_638495913131416338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_638495913131416338" xlink:to="ifrs-full_ClassesOfAssetsMember_638495913131416338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_638495913131416338" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638495913131416338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LandBuildingsAndSupplyInstallationsMember" xlink:label="cvac_LandBuildingsAndSupplyInstallationsMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131416338" xlink:to="cvac_LandBuildingsAndSupplyInstallationsMember_638495913131416338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember" xlink:label="ifrs-full_VehiclesMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131416338" xlink:to="ifrs-full_VehiclesMember_638495913131416338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherEquipmentMember" xlink:label="cvac_OtherEquipmentMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131416338" xlink:to="cvac_OtherEquipmentMember_638495913131416338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638495913131416338" xlink:to="ifrs-full_RangeAxis_638495913131416338" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131416338" xlink:to="ifrs-full_RangesMember_638495913131416338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131416338" xlink:to="ifrs-full_BottomOfRangeMember_638495913131416338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131416338" xlink:to="ifrs-full_TopOfRangeMember_638495913131416338" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638495913131416338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638495913131416338" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638495913131416338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:label="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638495913131416338" xlink:to="cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_638495913131426337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131426337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131426337" xlink:to="ifrs-full_GeographicalAreasAxis_638495913131426337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638495913131426337" xlink:to="ifrs-full_GeographicalAreasMember_638495913131426337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638495913131426337" xlink:to="country_BE_638495913131426337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH" xlink:label="country_CH_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638495913131426337" xlink:to="country_CH_638495913131426337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="country_NL_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638495913131426337" xlink:to="country_NL_638495913131426337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638495913131426337" xlink:to="country_DE_638495913131426337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember" xlink:label="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638495913131426337" xlink:to="cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_638495913131426337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638495913131426337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131426337" xlink:to="ifrs-full_MajorCustomersAxis_638495913131426337" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638495913131426337" xlink:to="ifrs-full_MajorCustomersMember_638495913131436338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131436338" xlink:to="cvac_GlaxosmithklineMember_638495913131436338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131436338" xlink:to="cvac_CrisprMember_638495913131436338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131436338" xlink:to="cvac_GenmabMember_638495913131436338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131436338" xlink:to="cvac_BoehringerIngelheimMember_638495913131436338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131436338" xlink:to="cvac_OtherCustomersMember_638495913131436338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131426337" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131436338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638495913131436338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131436338" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638495913131436338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" xlink:to="ifrs-full_MajorCustomersAxis_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638495913131446338" xlink:to="ifrs-full_MajorCustomersMember_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131446338" xlink:to="cvac_GlaxosmithklineMember_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" xlink:to="ifrs-full_GeographicalAreasAxis_638495913131446338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638495913131446338" xlink:to="ifrs-full_GeographicalAreasMember_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638495913131446338" xlink:to="country_BE_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" xlink:to="srt_CounterpartyNameAxis_638495913131446338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638495913131446338" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131446338" xlink:to="cvac_BoehringerIngelheimMember_638495913131446338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131446338" xlink:to="cvac_CrisprTherapeuticsMember_638495913131446338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638495913131446338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131446338" xlink:to="cvac_GenmabMember_638495913131446338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_6384959131314463381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131446338" xlink:to="cvac_GlaxosmithklineMember_6384959131314463381" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" xlink:to="cvac_IfrsTypeOfArrangementAxis_638495913131456336" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsTypeOfArrangementAxis_638495913131456336" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131456336" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131456336" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_638495913131456336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131456336" xlink:to="cvac_GlaxosmithklineCovidAgreementMember_638495913131456336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131456336" xlink:to="cvac_CollaborationAndLicenseAgreementMember_638495913131456336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" xlink:to="ifrs-full_ProductsAndServicesAxis_638495913131456336" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638495913131456336" xlink:to="ifrs-full_ProductsAndServicesMember_638495913131456336" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638495913131456336" xlink:to="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_638495913131456336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_638495913131456336" xlink:to="cvac_IfrsProductMember_638495913131456336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember_638495913131456336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_638495913131456336" xlink:to="cvac_ResearchAndDevelopmentServicesMember_638495913131456336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638495913131446338" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638495913131466335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="ifrs-full_ProceedsFromIssuingShares_638495913131466335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_638495913131466335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_638495913131466335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_638495913131466335" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_638495913131466335" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionFeePayment" xlink:label="cvac_OptionFeePayment_638495913131466335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_OptionFeePayment_638495913131466335" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfPerformanceObligations" xlink:label="cvac_NumberOfPerformanceObligations_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_NumberOfPerformanceObligations_638495913131476335" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_638495913131476335" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement" xlink:label="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement_638495913131476335" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_638495913131476335" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_638495913131476335" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_638495913131476335" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_638495913131476335" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_638495913131476335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638495913131466335" xlink:to="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_638495913131476335" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131486335" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131486335" xlink:to="ifrs-full_MajorCustomersAxis_638495913131486335" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638495913131486335" xlink:to="ifrs-full_MajorCustomersMember_638495913131486335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131486335" xlink:to="cvac_GlaxosmithklineMember_638495913131486335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131486335" xlink:to="cvac_BoehringerIngelheimMember_638495913131486335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131486335" xlink:to="cvac_GenmabMember_638495913131486335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638495913131486335" xlink:to="cvac_CrisprMember_638495913131486335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131486335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131486335" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131486335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131486335" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_638495913131496344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131486335" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_638495913131496344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131486335" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_638495913131496344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the consolidated financial statements - Contract balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CurrentTradeReceivables_638495913131496344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CurrentContractAssets_638495913131496344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ContractLiabilities_638495913131496344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_638495913131496344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638495913131496344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_638495913131496344" xlink:to="ifrs-full_MaturityAxis_638495913131496344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638495913131496344" xlink:to="ifrs-full_AggregatedTimeBandsMember_638495913131506337" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638495913131506337" xlink:to="ifrs-full_NotLaterThanOneYearMember_638495913131506337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638495913131506337" xlink:to="ifrs-full_LaterThanOneYearMember_638495913131506337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_638495913131496344" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_638495913131506337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_638495913131506337" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_638495913131506337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131506337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131506337" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638495913131506337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638495913131506337" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913131506337" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638495913131506337" xlink:to="cvac_IfrsCostOfSalesMember_638495913131506337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131506337" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131506337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913131506337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131506337" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913131506337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638495913131506337" xlink:to="cvac_OperativeExpensesMember_638495913131516340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131506337" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="cvac_PersonnelExpenses_638495913131516340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638495913131516340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="cvac_ThirdPartyServiceExpenses_638495913131516340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="cvac_MaintenanceAndLeaseExpenses_638495913131516340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638495913131516340" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_638495913131516340" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="cvac_OtherExpense_638495913131516340" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638495913131516340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131516340" xlink:to="ifrs-full_ExpenseByNature_638495913131516340" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131526339" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131526339" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638495913131526339" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638495913131526339" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913131526339" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638495913131526339" xlink:to="cvac_SellingAndDistributionExpensesMember_638495913131526339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131526339" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131526339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131526339" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913131526339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638495913131526339" xlink:to="cvac_OperativeExpensesMember_638495913131526339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131526339" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131526339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131526339" xlink:to="cvac_PersonnelExpenses_638495913131526339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131526339" xlink:to="cvac_MaintenanceAndLeaseExpenses_638495913131526339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131526339" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638495913131526339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131526339" xlink:to="cvac_OtherExpense_638495913131526339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638495913131526339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131526339" xlink:to="ifrs-full_ExpenseByNature_638495913131526339" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the consolidated financial statements - Research and development (R&amp;D) expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131536339" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131536339" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638495913131536339" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638495913131536339" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913131536339" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638495913131536339" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_638495913131536339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131536339" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131536339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131536339" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913131536339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638495913131536339" xlink:to="cvac_OperativeExpensesMember_638495913131536339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131536339" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638495913131536339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="cvac_PersonnelExpenses_638495913131536339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638495913131536339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638495913131536339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_638495913131546338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="cvac_ThirdPartyServiceExpenses_638495913131546338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="cvac_MaintenanceAndLeaseExpenses_638495913131546338" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="cvac_OtherExpense_638495913131546338" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="ifrs-full_ExpenseByNature_638495913131546338" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="cvac_ReversalOfProvisionForOnerousContracts_638495913131546338" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsProvisionForLossOnContracts" xlink:label="cvac_IfrsProvisionForLossOnContracts_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131536339" xlink:to="cvac_IfrsProvisionForLossOnContracts_638495913131546338" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131546338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131546338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131546338" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638495913131556337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638495913131556337" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913131556337" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638495913131556337" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_638495913131556337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131546338" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131556337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131556337" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913131556337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638495913131556337" xlink:to="cvac_OperativeExpensesMember_638495913131556337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131546338" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="cvac_PersonnelExpenses_638495913131556337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="cvac_MaintenanceAndLeaseExpenses_638495913131556337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="cvac_ThirdPartyServiceExpenses_638495913131556337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="ifrs-full_ProfessionalFeesExpense_638495913131556337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638495913131556337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="cvac_OtherExpense_638495913131556337" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638495913131556337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="ifrs-full_ExpenseByNature_638495913131556337" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131556337" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment_638495913131566338" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails" xlink:type="extended" xlink:title="40310 - Disclosure - Notes to the consolidated financial statements - Operative Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_1" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131566338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131566338" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131566338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638495913131566338" xlink:to="ifrs-full_LineItemsByFunctionMember_638495913131566338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OperativeExpensesMember" xlink:label="cvac_OperativeExpensesMember_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638495913131566338" xlink:to="cvac_OperativeExpensesMember_638495913131566338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638495913131566338" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="cvac_PersonnelExpenses_638495913131566338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638495913131566338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="cvac_ThirdPartyServiceExpenses_638495913131566338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638495913131566338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="cvac_MaintenanceAndLeaseExpenses_638495913131566338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638495913131576338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_638495913131576338" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_638495913131576338" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="ifrs-full_ProfessionalFeesExpense_638495913131576338" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="cvac_OtherExpense_638495913131576338" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638495913131566338" xlink:to="ifrs-full_ExpenseByNature_638495913131576338" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_638495913131576338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638495913131576338" xlink:to="cvac_GovernmentGrantsAxis_638495913131576338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsAxis_638495913131576338" xlink:to="cvac_GovernmentGrantsDomain_638495913131576338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_638495913131576338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638495913131576338" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_638495913131576338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638495913131576338" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638495913131586338" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638495913131576338" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_638495913131586338" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638495913131586338" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_638495913131586338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638495913131586338" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_638495913131586338" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638495913131586338" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember_638495913131586338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638495913131576338" xlink:to="srt_CounterpartyNameAxis_638495913131586338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638495913131586338" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131586338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638495913131586338" xlink:to="cvac_GlaxosmithklineMember_638495913131586338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638495913131576338" xlink:to="cvac_IfrsTypeOfArrangementAxis_638495913131586338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsTypeOfArrangementAxis_638495913131586338" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131586338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsDomain_638495913131586338" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_638495913131586338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638495913131576338" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638495913131586338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638495913131586338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638495913131586338" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638495913131586338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MiscellaneousOtherOperatingIncomeMember" xlink:label="cvac_MiscellaneousOtherOperatingIncomeMember_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638495913131586338" xlink:to="cvac_MiscellaneousOtherOperatingIncomeMember_638495913131596337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638495913131576338" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_IfrsRemainingGrantIncome_638495913131596337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638495913131596337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_638495913131596337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_UpfrontPaymentReceived_638495913131596337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment" xlink:label="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment_638495913131596337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_MaximumGrantToBeReceived_638495913131596337" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_638495913131596337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment_638495913131596337" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_IfrsMilestonePaymentReceived_638495913131606335" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_638495913131606335" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_638495913131606335" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_PartnershipAgreementMaximumAmount_638495913131606335" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_PartnershipAgreementTerm_638495913131606335" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_638495913131606335" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfApprovedExpenses" xlink:label="cvac_ReimbursementOfApprovedExpenses_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_ReimbursementOfApprovedExpenses_638495913131606335" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638495913131606335" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived_638495913131606335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_NumberOfAdditionalGrantsReceived_638495913131606335" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AmortizationOfGovernmentGrants" xlink:label="cvac_AmortizationOfGovernmentGrants_638495913131616335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_AmortizationOfGovernmentGrants_638495913131616335" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RepaymentOfGrantReceivedFromGovernment" xlink:label="cvac_RepaymentOfGrantReceivedFromGovernment_638495913131616335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_RepaymentOfGrantReceivedFromGovernment_638495913131616335" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants_638495913131616335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="ifrs-full_GovernmentGrants_638495913131616335" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable_638495913131616335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638495913131596337" xlink:to="cvac_MaximumUnspentFundsReimbursable_638495913131616335" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40312 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_638495913131616335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_638495913131616335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_CostOfReimbursementClaim_638495913131626341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_SaleOfEquipment_638495913131626341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_638495913131626341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_638495913131626341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638495913131626341" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131626341" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131626341" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638495913131626341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638495913131626341" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131626341" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131626341" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_638495913131626341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131626341" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_638495913131626341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_638495913131626341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131626341" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_638495913131626341" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_638495913131626341" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913131636339" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913131636339" xlink:to="cvac_SoftwareMember_638495913131636339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913131636339" xlink:to="ifrs-full_LicencesMember_638495913131636339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913131636339" xlink:to="cvac_TechnologyMember_638495913131636339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913131636339" xlink:to="ifrs-full_GoodwillMember_638495913131636339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdvancePaymentsIntangibleAssetMember" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638495913131636339" xlink:to="cvac_AdvancePaymentsIntangibleAssetMember_638495913131636339" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638495913131626341" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638495913131636339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_638495913131636339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_638495913131636339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_638495913131636339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_638495913131636339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_638495913131646336" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_638495913131646336" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638495913131646336" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSharePrice" xlink:label="cvac_IfrsSharePrice_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638495913131636339" xlink:to="cvac_IfrsSharePrice_638495913131646336" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131646336" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131646336" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638495913131646336" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638495913131646336" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131646336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131646336" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_638495913131646336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_638495913131646336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638495913131646336" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_638495913131646336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131646336" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638495913131656340" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638495913131656340" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638495913131656340" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131656340" xlink:to="ifrs-full_BuildingsMember_638495913131656340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131656340" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_638495913131656340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131656340" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_638495913131656340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638495913131656340" xlink:to="ifrs-full_ConstructionInProgressMember_638495913131656340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638495913131646336" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_PropertyPlantAndEquipment_638495913131656340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638495913131656340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_638495913131656340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_638495913131656340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_638495913131656340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_638495913131666337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_638495913131666337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913131666337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638495913131666337" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_638495913131666337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_638495913131666337" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_638495913131666337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_638495913131666337" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638495913131666337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_PropertyPlantAndEquipment_638495913131666337" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="ifrs-full_BorrowingCostsCapitalised_638495913131666337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_BorrowingCostsCapitalised_638495913131666337" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_638495913131666337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638495913131656340" xlink:to="ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_638495913131666337" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fixed Assets - Right-of-use assets and lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsTable" xlink:label="cvac_StatementsTable_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_StatementsTable_638495913131676341" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsTable_638495913131676341" xlink:to="ifrs-full_ClassesOfAssetsAxis_638495913131676341" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_638495913131676341" xlink:to="ifrs-full_ClassesOfAssetsMember_638495913131676341" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="ifrs-full_LandAndBuildingsMember_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_638495913131676341" xlink:to="ifrs-full_LandAndBuildingsMember_638495913131676341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember" xlink:label="ifrs-full_VehiclesMember_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_638495913131676341" xlink:to="ifrs-full_VehiclesMember_638495913131676341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_638495913131676341" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_638495913131676341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsTable_638495913131676341" xlink:to="srt_StatementGeographicalAxis_638495913131676341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638495913131676341" xlink:to="srt_SegmentGeographicalDomain_638495913131676341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TbingenMember" xlink:label="cvac_TbingenMember_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638495913131676341" xlink:to="cvac_TbingenMember_638495913131676341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_WiesbadenMember" xlink:label="cvac_WiesbadenMember_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638495913131676341" xlink:to="cvac_WiesbadenMember_638495913131676341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsLineItems" xlink:label="cvac_StatementsLineItems_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsTable_638495913131676341" xlink:to="cvac_StatementsLineItems_638495913131676341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="ifrs-full_RightofuseAssets_638495913131676341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets_638495913131676341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="ifrs-full_AdditionsToRightofuseAssets_638495913131676341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets_638495913131686339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="ifrs-full_DepreciationRightofuseAssets_638495913131686339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImpairmentOnRightOfUseAssets" xlink:label="cvac_ImpairmentOnRightOfUseAssets_638495913131686339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="cvac_ImpairmentOnRightOfUseAssets_638495913131686339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Foreigncurrencytranslationrightofuseassets" xlink:label="cvac_Foreigncurrencytranslationrightofuseassets_638495913131686339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="cvac_Foreigncurrencytranslationrightofuseassets_638495913131686339" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638495913131686339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="ifrs-full_RightofuseAssets_638495913131686339" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfRentalAgreements" xlink:label="cvac_NumberOfRentalAgreements_638495913131686339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="cvac_NumberOfRentalAgreements_638495913131686339" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightOfUseAssetsNumberOfExtensionOption" xlink:label="cvac_RightOfUseAssetsNumberOfExtensionOption_638495913131686339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="cvac_RightOfUseAssetsNumberOfExtensionOption_638495913131686339" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsLesseeOperatingLeaseRenewalTerm" xlink:label="cvac_IfrsLesseeOperatingLeaseRenewalTerm_638495913131686339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131676341" xlink:to="cvac_IfrsLesseeOperatingLeaseRenewalTerm_638495913131686339" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Fixed Assets - Carrying amounts of lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_LeaseLiabilities_638495913131696343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionsLeaseLiabilities" xlink:label="cvac_AdditionsLeaseLiabilities_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_AdditionsLeaseLiabilities_638495913131696343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_638495913131696343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_CashOutflowForLeases_638495913131696343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ForeignCurrencyTranslationLeaseLiabilities" xlink:label="cvac_ForeignCurrencyTranslationLeaseLiabilities_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_ForeignCurrencyTranslationLeaseLiabilities_638495913131696343" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_6384959131316963431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_LeaseLiabilities_6384959131316963431" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities_638495913131696343" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638495913131696343" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionalLeasePaymentsUponUsingExtensionOptions" xlink:label="cvac_OptionalLeasePaymentsUponUsingExtensionOptions_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_OptionalLeasePaymentsUponUsingExtensionOptions_638495913131696343" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Fixed Assets - Amounts recognized in the statement of operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets_638495913131696343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets_638495913131696343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImpairmentOnRightOfUseAssets" xlink:label="cvac_ImpairmentOnRightOfUseAssets_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_ImpairmentOnRightOfUseAssets_638495913131706341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_638495913131706341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_638495913131706341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_638495913131706341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeFromSubleasingRightofuseAssets" xlink:label="ifrs-full_IncomeFromSubleasingRightofuseAssets_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_IncomeFromSubleasingRightofuseAssets_638495913131706341" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LeasesExpenseRecognizedInProfitOrLoss" xlink:label="cvac_LeasesExpenseRecognizedInProfitOrLoss_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_LeasesExpenseRecognizedInProfitOrLoss_638495913131706341" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Assets held for sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetBookValueOfCmoEquipmentHeldForSale" xlink:label="cvac_NetBookValueOfCmoEquipmentHeldForSale_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_NetBookValueOfCmoEquipmentHeldForSale_638495913131706341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImpairmentOfAssetsHeldForSale" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_ImpairmentOfAssetsHeldForSale_638495913131706341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913131706341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638495913131706341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AssetsHeldForSaleNetBookValueSold" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_AssetsHeldForSaleNetBookValueSold_638495913131716341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AssetsHeldForSaleNetBookValueDirectSold" xlink:label="cvac_AssetsHeldForSaleNetBookValueDirectSold_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_AssetsHeldForSaleNetBookValueDirectSold_638495913131716341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DecreaseThroughClassifiedAsHeldForSale" xlink:label="cvac_DecreaseThroughClassifiedAsHeldForSale_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_DecreaseThroughClassifiedAsHeldForSale_638495913131716341" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="cvac_InventoriesTable_638495913131716341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638495913131716341" xlink:to="cvac_InventoriesLineItem_638495913131716341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials" xlink:label="ifrs-full_RawMaterials_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131716341" xlink:to="ifrs-full_RawMaterials_638495913131716341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131716341" xlink:to="cvac_IncreaseDecreaseInInventory_638495913131716341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131716341" xlink:to="ifrs-full_InventoryWritedown2011_638495913131716341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoryPilingForPandemicPreparednessAgreement" xlink:label="cvac_InventoryPilingForPandemicPreparednessAgreement_638495913131716341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131716341" xlink:to="cvac_InventoryPilingForPandemicPreparednessAgreement_638495913131716341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Other financial assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="DisclosureOfFinancialAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInvestments" xlink:label="ifrs-full_CurrentInvestments_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_CurrentInvestments_638495913131726342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DepositsHeldByThirdParties" xlink:label="cvac_DepositsHeldByThirdParties_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="cvac_DepositsHeldByThirdParties_638495913131726342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables_638495913131726342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Prepaid expenses and other current assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_InventoriesTable_638495913131726342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638495913131726342" xlink:to="cvac_InventoriesLineItem_638495913131726342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131726342" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638495913131726342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131726342" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_638495913131726342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131726342" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_638495913131726342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_638495913131726342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131726342" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_638495913131726342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638495913131726342" xlink:to="ifrs-full_CurrentPrepaidExpenses_638495913131736344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Equity - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131736344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131736344" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638495913131736344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638495913131736344" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638495913131736344" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638495913131736344" xlink:to="ifrs-full_OrdinarySharesMember_638495913131736344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638495913131736344" xlink:to="ifrs-full_PreferenceSharesMember_638495913131736344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131736344" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131736344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131736344" xlink:to="ifrs-full_NumberOfSharesAuthorised_638495913131736344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131736344" xlink:to="ifrs-full_ParValuePerShare_638495913131736344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638495913131736344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131736344" xlink:to="ifrs-full_NumberOfSharesIssued_638495913131736344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Equity - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131746342" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131746342" xlink:to="cvac_IfrsSaleOfStockAxis_638495913131746342" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638495913131746342" xlink:to="cvac_IfrsSaleOfStockDomain_638495913131746342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131746342" xlink:to="cvac_FollowOnPublicOfferingMember_638495913131746342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131746342" xlink:to="cvac_AtMarketOfferingProgramMember_638495913131746342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PublicOfferingOfCommonSharesMember" xlink:label="cvac_PublicOfferingOfCommonSharesMember_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131746342" xlink:to="cvac_PublicOfferingOfCommonSharesMember_638495913131746342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131746342" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" xlink:to="cvac_CommonSharesIssuedAndOutstanding_638495913131746342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_638495913131746342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises_638495913131746342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" xlink:to="cvac_ShareOptionExercises_638495913131746342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638495913131756341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders_638495913131756341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" xlink:to="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_638495913131756341" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131746342" xlink:to="cvac_CommonSharesIssuedAndOutstanding_638495913131756341" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Equity - Follow-on public offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131756341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131756341" xlink:to="cvac_IfrsSaleOfStockAxis_638495913131756341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638495913131756341" xlink:to="cvac_IfrsSaleOfStockDomain_638495913131756341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ClosingOfPublicOfferingOfCommonSharesMember" xlink:label="cvac_ClosingOfPublicOfferingOfCommonSharesMember_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131756341" xlink:to="cvac_ClosingOfPublicOfferingOfCommonSharesMember_638495913131756341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131756341" xlink:to="cvac_IfrsOverAllotmentOptionMember_638495913131756341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131756341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131756341" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131756341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131756341" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_638495913131766343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131756341" xlink:to="ifrs-full_WeightedAverageSharePrice2019_638495913131766343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131756341" xlink:to="ifrs-full_ProceedsFromIssuingShares_638495913131766343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131756341" xlink:to="ifrs-full_ShareIssueRelatedCost_638495913131766343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Equity - At-the-market offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131766343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131766343" xlink:to="cvac_IfrsSaleOfStockAxis_638495913131766343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638495913131766343" xlink:to="cvac_IfrsSaleOfStockDomain_638495913131766343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131766343" xlink:to="cvac_AtMarketOfferingProgramMember_638495913131766343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131766343" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131766343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638495913131766343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131766343" xlink:to="ifrs-full_ProceedsFromIssuingShares_638495913131766343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131766343" xlink:to="ifrs-full_NumberOfSharesIssued_638495913131776343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131766343" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_638495913131776343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131766343" xlink:to="ifrs-full_NumberOfSharesAuthorised_638495913131776343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Equity - Frame acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_3" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131776343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131776343" xlink:to="ifrs-full_BusinessCombinationsAxis_638495913131776343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638495913131776343" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913131776343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913131776343" xlink:to="ifrs-full_BusinessCombinationsMember_638495913131776343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsMember_638495913131776343" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913131776343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638495913131776343" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131776343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131776343" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913131776343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_638495913131776343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638495913131776343" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_638495913131776343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Equity - Exercises of share options under the VSOP plan and legacy program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsTable" xlink:label="cvac_StatementsTable_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="cvac_StatementsTable_638495913131786342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsTable_638495913131786342" xlink:to="cvac_IfrsPlanNameAxis_638495913131786342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameAxis_638495913131786342" xlink:to="cvac_IfrsPlanNameDomain_638495913131786342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OldVsopPlanMember" xlink:label="cvac_OldVsopPlanMember_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameDomain_638495913131786342" xlink:to="cvac_OldVsopPlanMember_638495913131786342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NewVsopPlanMember" xlink:label="cvac_NewVsopPlanMember_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameDomain_638495913131786342" xlink:to="cvac_NewVsopPlanMember_638495913131786342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LegacyPlanMember" xlink:label="cvac_LegacyPlanMember_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameDomain_638495913131786342" xlink:to="cvac_LegacyPlanMember_638495913131786342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_StatementsLineItems" xlink:label="cvac_StatementsLineItems_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsTable_638495913131786342" xlink:to="cvac_StatementsLineItems_638495913131786342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131786342" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913131786342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesHeldForTaxLiabilities" xlink:label="cvac_IfrsNumberOfSharesHeldForTaxLiabilities_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131786342" xlink:to="cvac_IfrsNumberOfSharesHeldForTaxLiabilities_638495913131786342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131786342" xlink:to="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_638495913131786342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131786342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131786342" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131786342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913131796344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_StatementsLineItems_638495913131786342" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913131796344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Share-based payments - Expense recognized for the share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131846345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131846345" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131846345" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131856374" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131856374" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131856374" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131856374" xlink:to="cvac_VirtualSharesProgramIMember_638495913131856374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131856374" xlink:to="cvac_VirtualSharesProgramIiMember_638495913131856374" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanStockOptionsMember" xlink:label="cvac_LongTermIncentivePlanStockOptionsMember_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131856374" xlink:to="cvac_LongTermIncentivePlanStockOptionsMember_638495913131856374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanRsusMember" xlink:label="cvac_LongTermIncentivePlanRsusMember_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131856374" xlink:to="cvac_LongTermIncentivePlanRsusMember_638495913131856374" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RsuSupervisoryBoardMember" xlink:label="cvac_RsuSupervisoryBoardMember_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131856374" xlink:to="cvac_RsuSupervisoryBoardMember_638495913131856374" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131846345" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131856374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638495913131856374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131856374" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638495913131856374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131866351" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131866351" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131866351" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131866351" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131866351" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131866351" xlink:to="cvac_VirtualSharesProgramIMember_638495913131866351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131866351" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913131866351" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131866351" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_638495913131866351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131866351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913131866351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131866351" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_6384959131318663511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_6384959131318663511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement_638495913131866351" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638495913131866351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638495913131866351" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_638495913131876342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_638495913131876342" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_638495913131876342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_638495913131876342" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913131876342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913131876342" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913131876342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913131876342" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TreasurySharesTransferred" xlink:label="cvac_TreasurySharesTransferred_638495913131876342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="cvac_TreasurySharesTransferred_638495913131876342" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes_638495913131876342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="cvac_ProvisionForEmployerTaxes_638495913131876342" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638495913131876342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131866351" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638495913131876342" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Share-based payments - Prior VSOP - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131886344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131886344" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131886344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131886344" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131886344" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131886344" xlink:to="cvac_VirtualSharesProgramIMember_638495913131886344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131886344" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131886344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131886344" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638495913131886344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131886344" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913131886344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131886344" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913131886344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131886344" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913131886344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638495913131886344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131886344" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638495913131886344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Share-based payments - New VSOP - Reconciliation of outstanding awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131896345" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131896345" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131896345" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131896345" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131896345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131896345" xlink:to="cvac_VirtualSharesProgramIiMember_638495913131896345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131896345" xlink:to="cvac_IfrsSaleOfStockAxis_638495913131896345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638495913131896345" xlink:to="cvac_IfrsSaleOfStockDomain_638495913131896345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131896345" xlink:to="cvac_ExerciseOfOptionsMember_638495913131896345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131896345" xlink:to="ifrs-full_RangeAxis_638495913131896345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131896345" xlink:to="ifrs-full_RangesMember_638495913131896345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131896345" xlink:to="ifrs-full_TopOfRangeMember_638495913131896345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131896345" xlink:to="ifrs-full_BottomOfRangeMember_638495913131896345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131896345" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_638495913131906343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131906343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913131906343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131906343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_6384959131319063431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_6384959131319063431" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_638495913131906343" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638495913131906343" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="cvac_ProvisionForEmployerTaxes_638495913131906343" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RemainingOptionLifeShareOptionsAwardsGranted" xlink:label="cvac_RemainingOptionLifeShareOptionsAwardsGranted_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="cvac_RemainingOptionLifeShareOptionsAwardsGranted_638495913131906343" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638495913131906343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638495913131906343" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsEmployerTaxesPayable" xlink:label="cvac_IfrsEmployerTaxesPayable_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131896345" xlink:to="cvac_IfrsEmployerTaxesPayable_638495913131916343" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131916343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131916343" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131916343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131916343" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131916343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131916343" xlink:to="cvac_VirtualSharesProgramIiMember_638495913131916343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131916343" xlink:to="cvac_IfrsSaleOfStockAxis_638495913131916343" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638495913131916343" xlink:to="cvac_IfrsSaleOfStockDomain_638495913131916343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638495913131916343" xlink:to="cvac_ExerciseOfOptionsMember_638495913131916343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131916343" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638495913131926346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131926346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638495913131926346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsEmployerTaxesPayable" xlink:label="cvac_IfrsEmployerTaxesPayable_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="cvac_IfrsEmployerTaxesPayable_638495913131926346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="cvac_ProvisionForEmployerTaxes_638495913131926346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913131926346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913131926346" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913131926346" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_638495913131926346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131916343" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_638495913131926346" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131936343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131936343" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131936343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131936343" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131936343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131936343" xlink:to="cvac_LongTermIncentivePlanMember_638495913131936343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131936343" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913131936343" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131936343" xlink:to="srt_TitleOfIndividualAxis_638495913131936343" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638495913131936343" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131936343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131936343" xlink:to="cvac_ChiefScientificOfficerMember_638495913131936343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131936343" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638495913131936343" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131936343" xlink:to="cvac_KeyEmployeesMember_638495913131936343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember_638495913131936343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131936343" xlink:to="srt_ChiefOperatingOfficerMember_638495913131936343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131936343" xlink:to="cvac_ChiefDevelopmentOfficerMember_638495913131946342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131936343" xlink:to="cvac_IfrsVestingAxis_638495913131946342" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingAxis_638495913131946342" xlink:to="cvac_IfrsVestingDomain_638495913131946342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638495913131946342" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638495913131946342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638495913131946342" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_638495913131946342" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638495913131946342" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_638495913131946342" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131936343" xlink:to="ifrs-full_RangeAxis_638495913131946342" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131946342" xlink:to="ifrs-full_RangesMember_638495913131946342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131946342" xlink:to="ifrs-full_BottomOfRangeMember_638495913131946342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131946342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131946342" xlink:to="ifrs-full_TopOfRangeMember_638495913131946342" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131936343" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted" xlink:label="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted_638495913131956341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" xlink:to="cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted_638495913131956341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_638495913131956341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_638495913131956341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_638495913131956341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_638495913131956341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_638495913131956341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_638495913131956341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_638495913131956341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_638495913131956341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_638495913131956341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131956341" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_638495913131956341" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131966346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913131966346" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913131966346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131966346" xlink:to="cvac_LongTermIncentivePlanMember_638495913131966346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913131966346" xlink:to="cvac_RestrictedStockUnitsMember_638495913131966346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" xlink:to="srt_TitleOfIndividualAxis_638495913131966346" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638495913131966346" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="cvac_ChiefScientificOfficerMember_638495913131966346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638495913131966346" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="cvac_KeyEmployeesMember_638495913131966346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember_638495913131966346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="srt_ChiefOperatingOfficerMember_638495913131966346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="cvac_ChiefDevelopmentOfficerMember_638495913131976344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="srt_ChiefFinancialOfficerMember_638495913131976344" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="cvac_ThenChiefExecutiveOfficerMember_638495913131976344" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913131966346" xlink:to="srt_ManagementMember_638495913131976344" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" xlink:to="cvac_IfrsPlanNameAxis_638495913131976344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameAxis_638495913131976344" xlink:to="cvac_IfrsPlanNameDomain_638495913131976344" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameDomain_638495913131976344" xlink:to="cvac_LongTermIncentivePlanMember_638495913131976344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" xlink:to="cvac_IfrsVestingAxis_638495913131976344" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingAxis_638495913131976344" xlink:to="cvac_IfrsVestingDomain_638495913131976344" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638495913131976344" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638495913131976344" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_638495913131976344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638495913131976344" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_638495913131976344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638495913131976344" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_638495913131986340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" xlink:to="ifrs-full_RangeAxis_638495913131986340" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913131986340" xlink:to="ifrs-full_RangesMember_638495913131986340" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131986340" xlink:to="ifrs-full_BottomOfRangeMember_638495913131986340" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913131986340" xlink:to="ifrs-full_TopOfRangeMember_638495913131986340" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913131966346" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913131986340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_638495913131986340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_638495913131986340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice" xlink:label="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice_638495913131996341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice_638495913131996341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_638495913131996341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_638495913131996341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_638495913131996341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_638495913131996341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage_638495913131996341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage_638495913131996341" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease" xlink:label="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease_638495913131996341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease_638495913131996341" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131996341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913131986340" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913131996341" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132006343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132006343" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132006343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132006343" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913132006343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913132006343" xlink:to="cvac_RestrictedStockUnitsMember_638495913132006343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913132006343" xlink:to="cvac_LongTermIncentivePlanMember_638495913132006343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132006343" xlink:to="cvac_IfrsPlanNameAxis_638495913132006343" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameAxis_638495913132006343" xlink:to="cvac_IfrsPlanNameDomain_638495913132006343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_6384959131320063431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameDomain_638495913132006343" xlink:to="cvac_LongTermIncentivePlanMember_6384959131320063431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132006343" xlink:to="srt_TitleOfIndividualAxis_638495913132006343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638495913132006343" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember_638495913132006343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" xlink:to="srt_ManagementMember_638495913132006343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638495913132016345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" xlink:to="cvac_KeyEmployeesMember_638495913132016345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" xlink:to="srt_ChiefExecutiveOfficerMember_638495913132016345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" xlink:to="srt_ChiefOperatingOfficerMember_638495913132016345" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638495913132016345" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132006343" xlink:to="cvac_FormerFrameEmployeesMember_638495913132016345" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132006343" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638495913132016345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638495913132016345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_638495913132016345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_638495913132016345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_638495913132026341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_638495913132026341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_638495913132026341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_638495913132026341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus" xlink:label="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus_638495913132026341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus_638495913132026341" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes_638495913132026341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="cvac_ProvisionForEmployerTaxes_638495913132026341" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsEmployerTaxesPayable" xlink:label="cvac_IfrsEmployerTaxesPayable_638495913132026341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="cvac_IfrsEmployerTaxesPayable_638495913132026341" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_638495913132026341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="ifrs-full_WeightedAverageSharePrice2019_638495913132026341" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913132026341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132016345" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913132026341" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132036345" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132036345" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132036345" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132036345" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913132036345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913132036345" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638495913132036345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132036345" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_638495913132036345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913132036345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913132036345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638495913132036345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_6384959131320363451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_6384959131320363451" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_638495913132036345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132036345" xlink:to="cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement_638495913132036345" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41010 - Disclosure - Share-based payments - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132046343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132046343" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132046343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132046343" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913132046343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913132046343" xlink:to="cvac_RestrictedStockUnitsMember_638495913132046343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132046343" xlink:to="cvac_IfrsPlanNameAxis_638495913132046343" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameAxis_638495913132046343" xlink:to="cvac_IfrsPlanNameDomain_638495913132046343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsPlanNameDomain_638495913132046343" xlink:to="cvac_LongTermIncentivePlanMember_638495913132046343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132046343" xlink:to="srt_TitleOfIndividualAxis_638495913132046343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638495913132046343" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132046343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638495913132046343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132046343" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638495913132046343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132046343" xlink:to="srt_ManagementMember_638495913132056344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132046343" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132056344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132056344" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638495913132056344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132056344" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638495913132056344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132056344" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_638495913132056344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage" xlink:label="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132056344" xlink:to="cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage_638495913132056344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132056344" xlink:to="ifrs-full_WeightedAverageSharePrice2019_638495913132056344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails" xlink:type="extended" xlink:title="41011 - Disclosure - Share-based payments - Restricted Stock Units expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132056344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132056344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132056344" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132066352" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132066352" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913132066352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913132066352" xlink:to="cvac_RestrictedStockUnitsMember_638495913132066352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638495913132056344" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132066352" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132066352" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638495913132066352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132066352" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638495913132066352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132066352" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638495913132066352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132066352" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638495913132066352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638495913132066352" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638495913132066352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Trade and other payables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638495913132066352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638495913132066352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherCurrentPayables_638495913132076346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638495913132076346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_ChangeInTradeAndOtherPayables_638495913132076346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638495913132076346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities and provisions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="cvac_IfrsOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisionsCurrent" xlink:label="cvac_ContractTerminationProvisionsCurrent_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="cvac_ContractTerminationProvisionsCurrent_638495913132076346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentProvisions_638495913132076346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision" xlink:label="ifrs-full_ShorttermOnerousContractsProvision_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_ShorttermOnerousContractsProvision_638495913132076346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisions" xlink:label="cvac_ContractTerminationProvisions_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="cvac_ContractTerminationProvisions_638495913132076346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisions_638495913132076346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions_638495913132076346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_Provisions_638495913132076346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Other liabilities and provisions - Movements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions_638495913132086347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="ifrs-full_Provisions_638495913132086347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_638495913132086347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_638495913132086347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_638495913132086347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="ifrs-full_ProvisionUsedOtherProvisions_638495913132086347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="ifrs-full_UnusedProvisionReversedOtherProvisions_638495913132086347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="ifrs-full_UnusedProvisionReversedOtherProvisions_638495913132086347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughReclassificationsProvisions" xlink:label="cvac_IncreaseDecreaseThroughReclassificationsProvisions_638495913132086347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="cvac_IncreaseDecreaseThroughReclassificationsProvisions_638495913132086347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions_6384959131320863471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="ifrs-full_Provisions_6384959131320863471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_638495913132086347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="ifrs-full_CurrentProvisions_638495913132086347" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_638495913132086347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="ifrs-full_NoncurrentProvisions_638495913132086347" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Other liabilities and provisions - Current and Non Current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="IfrsOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_OtherMiscellaneousNonCurrentLiabilities_638495913132096352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638495913132096352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PersonnelAccruedLiabilities" xlink:label="cvac_PersonnelAccruedLiabilities_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_PersonnelAccruedLiabilities_638495913132096352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants" xlink:label="ifrs-full_CurrentGovernmentGrants_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_CurrentGovernmentGrants_638495913132096352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OutstandingInvoicesCurrent" xlink:label="cvac_OutstandingInvoicesCurrent_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_OutstandingInvoicesCurrent_638495913132096352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfessionalFessCurrent" xlink:label="cvac_ProfessionalFessCurrent_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_ProfessionalFessCurrent_638495913132096352" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_638495913132096352" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilityCurrent" xlink:label="cvac_OtherLiabilityCurrent_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_OtherLiabilityCurrent_638495913132096352" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities_638495913132096352" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities" xlink:label="ifrs-full_OtherLiabilities_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_OtherLiabilities_638495913132096352" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_638495913132096352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_638495913132096352" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Other liabilities and provisions - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsOtherLiabilitiesAbstract_1" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_638495913132106345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_638495913132106345" xlink:to="ifrs-full_ClassesOfProvisionsAxis_638495913132106345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis_638495913132106345" xlink:to="ifrs-full_OtherProvisionsMember_638495913132106345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OnerousContractProvisionsMember" xlink:label="cvac_OnerousContractProvisionsMember_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherProvisionsMember_638495913132106345" xlink:to="cvac_OnerousContractProvisionsMember_638495913132106345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractTerminationProvisionsMember" xlink:label="cvac_ContractTerminationProvisionsMember_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherProvisionsMember_638495913132106345" xlink:to="cvac_ContractTerminationProvisionsMember_638495913132106345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_638495913132106345" xlink:to="cvac_GovernmentGrantsAxis_638495913132106345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsAxis_638495913132106345" xlink:to="cvac_GovernmentGrantsDomain_638495913132106345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638495913132106345" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638495913132106345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_638495913132106345" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_638495913132106345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638495913132106345" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_638495913132106345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="ifrs-full_UnusedProvisionReversedOtherProvisions_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638495913132106345" xlink:to="ifrs-full_UnusedProvisionReversedOtherProvisions_638495913132106345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_638495913132106345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638495913132106345" xlink:to="ifrs-full_ProvisionUsedOtherProvisions_638495913132106345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughReclassificationsProvisions" xlink:label="cvac_IncreaseDecreaseThroughReclassificationsProvisions_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638495913132106345" xlink:to="cvac_IncreaseDecreaseThroughReclassificationsProvisions_638495913132116346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638495913132106345" xlink:to="cvac_MaximumUnspentFundsReimbursable_638495913132116346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxTable" xlink:label="cvac_IncomeTaxTable_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_IncomeTaxTable_638495913132116346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxTable_638495913132116346" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132116346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132116346" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132116346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubsidiariesMember" xlink:label="ifrs-full_SubsidiariesMember_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132116346" xlink:to="ifrs-full_SubsidiariesMember_638495913132116346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxLineItems" xlink:label="cvac_IncomeTaxLineItems_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxTable_638495913132116346" xlink:to="cvac_IncomeTaxLineItems_638495913132116346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913132116346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_638495913132116346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_638495913132116346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_638495913132126348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_DeferredTaxExpenseIncome_638495913132126348" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_638495913132126348" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity" xlink:label="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity_638495913132126348" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure" xlink:label="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure_638495913132126348" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_DeferredTaxLiabilities_638495913132126348" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_ApplicableTaxRate_638495913132126348" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="ifrs-full_AverageEffectiveTaxRate_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="ifrs-full_AverageEffectiveTaxRate_638495913132126348" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfSolidarySurcharge" xlink:label="cvac_PercentageOfSolidarySurcharge_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="cvac_PercentageOfSolidarySurcharge_638495913132126348" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfTradeTax" xlink:label="cvac_PercentageOfTradeTax_638495913132126348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxLineItems_638495913132116346" xlink:to="cvac_PercentageOfTradeTax_638495913132126348" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income tax - Schedule of tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="ifrs-full_AccountingProfit_638495913132136344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638495913132136344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear_638495913132136344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_638495913132136344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards" xlink:label="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards_638495913132136344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:label="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913132136344" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities" xlink:label="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities_638495913132136344" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes" xlink:label="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_638495913132136344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes_638495913132136344" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NonDeductibleExpensesForTaxPurposes" xlink:label="cvac_NonDeductibleExpensesForTaxPurposes_638495913132146346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="cvac_NonDeductibleExpensesForTaxPurposes_638495913132146346" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes" xlink:label="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_638495913132146346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_NonDeductibleExpensesForTaxPurposes_638495913132146346" xlink:to="cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes_638495913132146346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_638495913132146346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_NonDeductibleExpensesForTaxPurposes_638495913132146346" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_638495913132146346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_638495913132146346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_638495913132146346" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913132146346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638495913132146346" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate_638495913132146346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638495913132136344" xlink:to="ifrs-full_ApplicableTaxRate_638495913132146346" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income tax - Schedule of deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638495913132146346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638495913132146346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638495913132146346" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_638495913132156355" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_638495913132156355" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IntangibleAssetsMember" xlink:label="cvac_IntangibleAssetsMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_IntangibleAssetsMember_638495913132156355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638495913132156355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="ifrs-full_RightofuseAssetsMember_638495913132156355" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember" xlink:label="ifrs-full_OtherAssetsMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="ifrs-full_OtherAssetsMember_638495913132156355" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsinventoriesMember" xlink:label="cvac_IfrsinventoriesMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_IfrsinventoriesMember_638495913132156355" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsprepaidExpensesAndOtherAssetsMember" xlink:label="cvac_IfrsprepaidExpensesAndOtherAssetsMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_IfrsprepaidExpensesAndOtherAssetsMember_638495913132156355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="ifrs-full_TradeReceivablesMember_638495913132156355" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_638495913132156355" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ShareBasedPaymentsMember" xlink:label="cvac_ShareBasedPaymentsMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_ShareBasedPaymentsMember_638495913132156355" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NonCurrentLeaseLiabilitiesMember" xlink:label="cvac_NonCurrentLeaseLiabilitiesMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_NonCurrentLeaseLiabilitiesMember_638495913132156355" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherNoncurrentLiabilitiesMember" xlink:label="cvac_IfrsOtherNoncurrentLiabilitiesMember_638495913132156355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_IfrsOtherNoncurrentLiabilitiesMember_638495913132156355" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_TradeAndOtherPayablesMember_638495913132166344" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentLeaseLiabilitiesMember" xlink:label="cvac_CurrentLeaseLiabilitiesMember_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_CurrentLeaseLiabilitiesMember_638495913132166344" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsOtherLiabilitiesMember" xlink:label="cvac_IfrsOtherLiabilitiesMember_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_IfrsOtherLiabilitiesMember_638495913132166344" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TaxLossesCarriedForwardsMember" xlink:label="cvac_TaxLossesCarriedForwardsMember_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_TaxLossesCarriedForwardsMember_638495913132166344" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember" xlink:label="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638495913132156355" xlink:to="cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_638495913132166344" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638495913132146346" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638495913132166344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638495913132166344" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_638495913132166344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember" xlink:label="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_638495913132166344" xlink:to="cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_638495913132166344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638495913132146346" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_638495913132176344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_DeferredTaxLiabilityAsset_638495913132176344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_638495913132176344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_638495913132176344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_638495913132176344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_638495913132176344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_638495913132176344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_638495913132176344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_6384959131321763441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_DeferredTaxLiabilityAsset_6384959131321763441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets_638495913132176344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_DeferredTaxAssets_638495913132176344" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities_638495913132176344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_DeferredTaxLiabilities_638495913132176344" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_638495913132176344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638495913132166344" xlink:to="ifrs-full_NetDeferredTaxAssets_638495913132176344" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Income tax - Schedule of unused tax losses carried forward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UnusedTaxLossesForCorporateIncomeTax" xlink:label="cvac_UnusedTaxLossesForCorporateIncomeTax_638495913132186342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_UnusedTaxLossesForCorporateIncomeTax_638495913132186342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UnusedTaxLossesForTradeTax" xlink:label="cvac_UnusedTaxLossesForTradeTax_638495913132186342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_UnusedTaxLossesForTradeTax_638495913132186342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_UnusedInterestCarryforward" xlink:label="cvac_UnusedInterestCarryforward_638495913132186342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_UnusedInterestCarryforward_638495913132186342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_638495913132186342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_638495913132186342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TemporaryDifferencesValuationOfDeferredTaxAssets" xlink:label="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets_638495913132186342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_TemporaryDifferencesValuationOfDeferredTaxAssets_638495913132186342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssets" xlink:label="ifrs-full_CurrentTaxAssets_638495913132186342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_CurrentTaxAssets_638495913132186342" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Earnings per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638495913132196355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares_638495913132196355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638495913132196355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638495913132196355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_638495913132196355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_638495913132196355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Disclosure of financial instruments and management of financial risks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_638495913132196355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable_638495913132196355" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskAxis" xlink:label="ifrs-full_ConcentrationsOfRiskAxis_638495913132196355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable_638495913132196355" xlink:to="ifrs-full_ConcentrationsOfRiskAxis_638495913132196355" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ifrs-full_ConcentrationsOfRiskMember_638495913132196355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ConcentrationsOfRiskAxis_638495913132196355" xlink:to="ifrs-full_ConcentrationsOfRiskMember_638495913132196355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanysLargestPrivateBankMember" xlink:label="cvac_GermanysLargestPrivateBankMember_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ConcentrationsOfRiskMember_638495913132196355" xlink:to="cvac_GermanysLargestPrivateBankMember_638495913132206350" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GermanLandesbankMember" xlink:label="cvac_GermanLandesbankMember_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GermanysLargestPrivateBankMember_638495913132206350" xlink:to="cvac_GermanLandesbankMember_638495913132206350" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_EuropeSLargestPrivateBankMember" xlink:label="cvac_EuropeSLargestPrivateBankMember_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ConcentrationsOfRiskMember_638495913132196355" xlink:to="cvac_EuropeSLargestPrivateBankMember_638495913132206350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable_638495913132196355" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638495913132206350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638495913132206350" xlink:to="ifrs-full_CarryingAmountMember_638495913132206350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638495913132206350" xlink:to="ifrs-full_AccumulatedImpairmentMember_638495913132206350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable_638495913132196355" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="ifrs-full_FinanceIncome_638495913132206350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="ifrs-full_InterestIncomeOnCashAndCashEquivalents_638495913132206350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain" xlink:label="ifrs-full_ForeignExchangeGain_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="ifrs-full_ForeignExchangeGain_638495913132206350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="ifrs-full_FinanceCosts_638495913132206350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="ifrs-full_ForeignExchangeLoss_638495913132206350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="ifrs-full_ForeignExchangeLoss_638495913132206350" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_InterestExpenseOnCash" xlink:label="cvac_InterestExpenseOnCash_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="cvac_InterestExpenseOnCash_638495913132216346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsConcentrationRiskPercentage" xlink:label="cvac_IfrsConcentrationRiskPercentage_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="cvac_IfrsConcentrationRiskPercentage_638495913132216346" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AllowanceForExpectedCreditLossOnFinancialAssets" xlink:label="cvac_AllowanceForExpectedCreditLossOnFinancialAssets_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_638495913132206350" xlink:to="cvac_AllowanceForExpectedCreditLossOnFinancialAssets_638495913132216346" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_638495913132216346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_638495913132216346" xlink:to="ifrs-full_MaturityAxis_638495913132216346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638495913132216346" xlink:to="ifrs-full_AggregatedTimeBandsMember_638495913132216346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638495913132216346" xlink:to="ifrs-full_NotLaterThanOneYearMember_638495913132216346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638495913132216346" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_638495913132216346" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanFiveYearsMember_638495913132216346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638495913132216346" xlink:to="ifrs-full_LaterThanFiveYearsMember_638495913132216346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_638495913132216346" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_638495913132226349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContractualCommitmentsUndiscountedCashFlows" xlink:label="cvac_ContractualCommitmentsUndiscountedCashFlows_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_638495913132226349" xlink:to="cvac_ContractualCommitmentsUndiscountedCashFlows_638495913132226349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_638495913132226349" xlink:to="ifrs-full_GrossLeaseLiabilities_638495913132226349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherLiabilitiesUndiscountedCashFlows" xlink:label="cvac_OtherLiabilitiesUndiscountedCashFlows_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_638495913132226349" xlink:to="cvac_OtherLiabilitiesUndiscountedCashFlows_638495913132226349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_638495913132226349" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_638495913132226349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_638495913132226349" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_638495913132226349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638495913132226349" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_638495913132226349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638495913132226349" xlink:to="srt_CurrencyAxis_638495913132226349" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_638495913132226349" xlink:to="currency_AllCurrenciesDomain_638495913132236349" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="currency_EUR_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638495913132236349" xlink:to="currency_EUR_638495913132236349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="currency_USD_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638495913132236349" xlink:to="currency_USD_638495913132236349" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF" xlink:label="currency_CHF_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638495913132236349" xlink:to="currency_CHF_638495913132236349" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP" xlink:label="currency_GBP_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638495913132236349" xlink:to="currency_GBP_638495913132236349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638495913132226349" xlink:to="ifrs-full_TypesOfRisksAxis_638495913132236349" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_638495913132236349" xlink:to="ifrs-full_TypesOfRisksMember_638495913132236349" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_638495913132236349" xlink:to="ifrs-full_CurrencyRiskMember_638495913132236349" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638495913132226349" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638495913132236349" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638495913132236349" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_638495913132236349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CashAndCashEquivalentsOneMember" xlink:label="cvac_CashAndCashEquivalentsOneMember_638495913132236349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_CashAndCashEquivalentsOneMember_638495913132236349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_TradeAndOtherReceivablesMember_638495913132246344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember_638495913132246344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_TradeAndOtherPayablesMember_638495913132246344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_TradeAndOtherPayablesOneMember_638495913132246344" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_TradeAndOtherPayablesTwoMember_638495913132246344" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638495913132236349" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember_638495913132246344" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638495913132226349" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638495913132246344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_638495913132246344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638495913132246344" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_638495913132246344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails" xlink:type="extended" xlink:title="41504 - Disclosure - Disclosure of financial instruments and management of financial risks - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_AverageForeignExchangeRate_638495913132256353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExchangeRateCurrencyNetExposure" xlink:label="cvac_ExchangeRateCurrencyNetExposure_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_ExchangeRateCurrencyNetExposure_638495913132256353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossBeforeTaxIfEurWeakened" xlink:label="cvac_ProfitLossBeforeTaxIfEurWeakened_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_ProfitLossBeforeTaxIfEurWeakened_638495913132256353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfEurWeakened" xlink:label="cvac_PercentageOfEurWeakened_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_PercentageOfEurWeakened_638495913132256353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossAfterTaxIfEurWeakened" xlink:label="cvac_ProfitLossAfterTaxIfEurWeakened_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_ProfitLossAfterTaxIfEurWeakened_638495913132256353" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfEurStrengthened" xlink:label="cvac_PercentageOfEurStrengthened_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_PercentageOfEurStrengthened_638495913132256353" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossBeforeTaxIfEurStrengthened" xlink:label="cvac_ProfitLossBeforeTaxIfEurStrengthened_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_ProfitLossBeforeTaxIfEurStrengthened_638495913132256353" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProfitLossAfterTaxIfEurStrengthened" xlink:label="cvac_ProfitLossAfterTaxIfEurStrengthened_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_ProfitLossAfterTaxIfEurStrengthened_638495913132256353" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfInterestHigher" xlink:label="cvac_PercentageOfInterestHigher_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_PercentageOfInterestHigher_638495913132256353" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetLossBeforeTax" xlink:label="cvac_NetLossBeforeTax_638495913132256353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_NetLossBeforeTax_638495913132256353" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Notes to the consolidated statements of cash flows - Financing activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:label="NotesToConsolidatedStatementsOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToConsolidatedStatementsOfCashFlowsAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_638495913132266350" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_638495913132266350" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_638495913132266350" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_638495913132266350" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_638495913132266350" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_638495913132266350" xlink:to="ifrs-full_LeaseLiabilitiesMember_638495913132266350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_638495913132266350" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_638495913132266350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_638495913132266350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities" xlink:label="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" xlink:to="cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities_638495913132266350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" xlink:to="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_638495913132266350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities" xlink:label="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" xlink:to="cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities_638495913132266350" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_638495913132266350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" xlink:to="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_638495913132266350" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_6384959131322663501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_638495913132266350" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_6384959131322663501" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Remuneration of the Company's key management personnel (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfKeyManagementPersonnelAbstract" xlink:label="DisclosureOfKeyManagementPersonnelAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfKeyManagementPersonnelAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132276347" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132276347" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132276347" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132276347" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132276347" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132276347" xlink:to="cvac_ManagementBoardMember_638495913132276347" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SupervisoryBoardMember" xlink:label="cvac_SupervisoryBoardMember_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132276347" xlink:to="cvac_SupervisoryBoardMember_638495913132276347" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132276347" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132276347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132276347" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638495913132276347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132276347" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_638495913132276347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638495913132276347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132276347" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638495913132276347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_638495913132286349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132276347" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_638495913132286349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Remuneration of the Company's key management personnel - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DisclosureOfKeyManagementPersonnelAbstract" xlink:label="cvac_DisclosureOfKeyManagementPersonnelAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132286349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfKeyManagementPersonnelAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132286349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132286349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132286349" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132286349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132336360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132286349" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132336360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember_638495913132336360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132336360" xlink:to="cvac_ManagementBoardMember_638495913132336360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SupervisoryBoardMember" xlink:label="cvac_SupervisoryBoardMember_638495913132336360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132336360" xlink:to="cvac_SupervisoryBoardMember_638495913132336360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExecutiveBoardMember" xlink:label="cvac_ExecutiveBoardMember_638495913132336360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132336360" xlink:to="cvac_ExecutiveBoardMember_638495913132336360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132336360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132286349" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132336360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913132346374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132336360" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913132346374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638495913132346374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913132346374" xlink:to="cvac_RestrictedStockUnitsMember_638495913132346374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132346374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132286349" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132346374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration" xlink:label="ifrs-full_AuditorsRemuneration_638495913132346374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132346374" xlink:to="ifrs-full_AuditorsRemuneration_638495913132346374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_638495913132346374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132346374" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_638495913132346374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913132346374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132346374" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_638495913132346374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132346374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132346374" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132346374" xlink:to="srt_TitleOfIndividualAxis_638495913132356361" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638495913132356361" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132356361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132356361" xlink:to="cvac_BaronJeanStephenneMember_638495913132356361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132356361" xlink:to="cvac_VincentStphenneMember_638495913132356361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638495913132356361" xlink:to="cvac_AntonyBlancMember_638495913132356361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132346374" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132356361" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638495913132356361" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_DietmarHoppMember_638495913132356361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_638495913132356361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_ClarentisSrlMember_638495913132356361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_BepharbelManufacturingS.aMember_638495913132356361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FranzWernerHaasMember" xlink:label="cvac_FranzWernerHaasMember_638495913132356361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_FranzWernerHaasMember_638495913132356361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AlexanderZehnderMember" xlink:label="cvac_AlexanderZehnderMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_AlexanderZehnderMember_638495913132366349" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_BarkerBiomedicalGmbhMember" xlink:label="cvac_BarkerBiomedicalGmbhMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_BarkerBiomedicalGmbhMember_638495913132366349" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CraigToomanMember" xlink:label="cvac_CraigToomanMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_CraigToomanMember_638495913132366349" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_RittershausRechtsanwaelteMember_638495913132366349" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_MariolaFotinMleczekMember" xlink:label="cvac_MariolaFotinMleczekMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_MariolaFotinMleczekMember_638495913132366349" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FlorianVonDerMlbeMember" xlink:label="cvac_FlorianVonDerMlbeMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_FlorianVonDerMlbeMember_638495913132366349" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_Dr.IngmarHrrMember" xlink:label="cvac_Dr.IngmarHrrMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_Dr.IngmarHrrMember_638495913132366349" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ImmaticsBiotechnologiesGmbhMember" xlink:label="cvac_ImmaticsBiotechnologiesGmbhMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_ImmaticsBiotechnologiesGmbhMember_638495913132366349" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurevacPrinterGmbhMember" xlink:label="cvac_CurevacPrinterGmbhMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_CurevacPrinterGmbhMember_638495913132366349" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_GridEuropeMember" xlink:label="cvac_GridEuropeMember_638495913132366349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638495913132356361" xlink:to="cvac_GridEuropeMember_638495913132366349" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132346374" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132376347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638495913132376347" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638495913132376347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638495913132376347" xlink:to="cvac_VirtualSharesProgramIMember_638495913132376347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132346374" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638495913132376347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638495913132376347" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638495913132376347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638495913132376347" xlink:to="ifrs-full_OrdinarySharesMember_638495913132376347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638495913132346374" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913132376347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913132376347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_638495913132386347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_RelatedPartyTransactionConsultingFees_638495913132386347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_638495913132386347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_IfrsContractualObligation_638495913132386347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_638495913132386347" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="ifrs-full_WeightedAverageSharePrice2019_638495913132386347" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfTravelCost" xlink:label="cvac_ReimbursementOfTravelCost_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_ReimbursementOfTravelCost_638495913132386347" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_638495913132386347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_638495913132386347" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_638495913132396348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_ExpenseRecognizedFromRelatedPartyTransaction_638495913132396348" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_638495913132396348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_638495913132396348" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638495913132396348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638495913132396348" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638495913132396348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="ifrs-full_NumberOfSharesIssued_638495913132396348" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_638495913132396348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_638495913132396348" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction" xlink:label="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction_638495913132396348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction_638495913132396348" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ExpensesToHandleFutureServiceAgreement" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_638495913132406346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_ExpensesToHandleFutureServiceAgreement_638495913132406346" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ServiceRenderedIssue" xlink:label="cvac_ServiceRenderedIssue_638495913132406346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638495913132376347" xlink:to="cvac_ServiceRenderedIssue_638495913132406346" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Business Combinations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132406346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_2" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132406346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638495913132406346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132406346" xlink:to="ifrs-full_BusinessCombinationsAxis_638495913132406346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638495913132406346" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132416366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132416366" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913132416366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132406346" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FairValueOfTotalConsiderationTransferred" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_FairValueOfTotalConsiderationTransferred_638495913132416366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_LiabilitiesIncurred_638495913132416366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_638495913132416366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ContingentConsiderationNumberOfPaymentsConsidered_638495913132416366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638495913132416366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638495913132416366" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsBusinessAcquisitionSharePrice" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_IfrsBusinessAcquisitionSharePrice_638495913132416366" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638495913132416366" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638495913132416366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638495913132416366" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_CashTransferred_638495913132426349" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_638495913132426349" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_AdditionalCashTransferred" xlink:label="cvac_AdditionalCashTransferred_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_AdditionalCashTransferred_638495913132426349" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ContingentConsiderationPercentageOfTotalConsideration_638495913132426349" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationNumberOfMilestones" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ContingentConsiderationNumberOfMilestones_638495913132426349" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638495913132426349" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_638495913132426349" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638495913132426349" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638495913132426349" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_638495913132426349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_638495913132426349" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638495913132436348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638495913132436348" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_638495913132436348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_638495913132436348" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913132436348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913132436348" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_638495913132436348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_638495913132436348" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer_638495913132436348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_EquityInterestsOfAcquirer_638495913132436348" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer_6384959131324363481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_EquityInterestsOfAcquirer_6384959131324363481" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ContingentConsiderationMaximumSharesIssuable" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_638495913132436348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ContingentConsiderationMaximumSharesIssuable_638495913132436348" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638495913132446348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638495913132446348" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_638495913132446348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_638495913132446348" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_638495913132446348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_638495913132446348" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_638495913132446348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_638495913132446348" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_ProvisionalFairValue" xlink:label="cvac_ProvisionalFairValue_638495913132446348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_ProvisionalFairValue_638495913132446348" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SigningSharePriceRepresenting10" xlink:label="cvac_SigningSharePriceRepresenting10_638495913132446348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_SigningSharePriceRepresenting10_638495913132446348" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_SigningSharePriceRepresenting40" xlink:label="cvac_SigningSharePriceRepresenting40_638495913132446348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_SigningSharePriceRepresenting40_638495913132446348" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638495913132456347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132416366" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638495913132456347" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails" xlink:type="extended" xlink:title="42002 - Disclosure - Business Combinations - Fair value recognized on acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132456347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_3" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132456347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638495913132456347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132456347" xlink:to="ifrs-full_BusinessCombinationsAxis_638495913132456347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132456347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638495913132456347" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132456347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913132456347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132456347" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913132456347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132456347" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638495913132466356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638495913132466356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638495913132466356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638495913132466356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638495913132466356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_638495913132466356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638495913132466356" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638495913132466356" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913132466356" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913132476349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638495913132476349" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638495913132476349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638495913132476349" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913132476349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638495913132476349" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638495913132476349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638495913132476349" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638495913132476349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132456347" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638495913132476349" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails" xlink:type="extended" xlink:title="42003 - Disclosure - Business Combinations - Goodwill recognized as a result of the acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132476349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_4" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132476349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132476349" xlink:to="ifrs-full_BusinessCombinationsAxis_638495913132486353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638495913132486353" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132486353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638495913132486353" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638495913132486353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638495913132476349" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132486353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132486353" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638495913132486353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132486353" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638495913132486353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638495913132486353" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_638495913132486353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638495913132486353" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638495913132486353" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638495913132486353" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638495913132486353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638495913132486353" xlink:to="ifrs-full_NonadjustingEventsMember_638495913132486353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_VirtualShareOptionPlanMember" xlink:label="cvac_VirtualShareOptionPlanMember_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638495913132486353" xlink:to="cvac_VirtualShareOptionPlanMember_638495913132496355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638495913132486353" xlink:to="ifrs-full_RangeAxis_638495913132496355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638495913132496355" xlink:to="ifrs-full_RangesMember_638495913132496355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913132496355" xlink:to="ifrs-full_BottomOfRangeMember_638495913132496355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638495913132496355" xlink:to="ifrs-full_TopOfRangeMember_638495913132496355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638495913132486353" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638495913132496355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions" xlink:label="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638495913132496355" xlink:to="cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions_638495913132496355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638495913132496355" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913132496355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20231231.xsd#cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638495913132496355" xlink:to="cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638495913132496355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DistributionCosts" xlink:label="ifrs-full_DistributionCosts_638495913132496355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638495913132496355" xlink:to="ifrs-full_DistributionCosts_638495913132496355" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645557120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CureVac N.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">P7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Friedrich-Miescher-Strasse 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">T&#252;bingen<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">72076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares, par value &#8364;0.12 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVAC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">223,988,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG AG Wirtschaftspr&#252;fungsgesellschaft<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Mannheim, Germany<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Friedrich-Miescher-Strasse 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">T&#252;bingen<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">72076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Alexander Zehnder<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">info@curevac.com<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589623999696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Other Comprehensive Income (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Operations and Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">&#8364; 53,758<span></span>
</td>
<td class="nump">&#8364; 67,420<span></span>
</td>
<td class="nump">&#8364; 102,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(124,366)<span></span>
</td>
<td class="num">(183,993)<span></span>
</td>
<td class="num">(238,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Selling and distribution expenses</a></td>
<td class="num">(3,912)<span></span>
</td>
<td class="num">(2,817)<span></span>
</td>
<td class="num">(1,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(115,724)<span></span>
</td>
<td class="num">(62,550)<span></span>
</td>
<td class="num">(815,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(91,758)<span></span>
</td>
<td class="num">(104,178)<span></span>
</td>
<td class="num">(100,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">9,151<span></span>
</td>
<td class="nump">37,932<span></span>
</td>
<td class="nump">67,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(1,356)<span></span>
</td>
<td class="num">(1,271)<span></span>
</td>
<td class="num">(1,210)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(274,207)<span></span>
</td>
<td class="num">(249,457)<span></span>
</td>
<td class="num">(412,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">16,731<span></span>
</td>
<td class="nump">4,009<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="num">(2,493)<span></span>
</td>
<td class="num">(3,707)<span></span>
</td>
<td class="num">(10,338)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">(259,969)<span></span>
</td>
<td class="num">(249,155)<span></span>
</td>
<td class="num">(412,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/ (expense)</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(260,167)<span></span>
</td>
<td class="num">(249,029)<span></span>
</td>
<td class="num">(411,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency adjustments</a></td>
<td class="nump">72<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">&#8364; (260,095)<span></span>
</td>
<td class="num">&#8364; (249,134)<span></span>
</td>
<td class="num">&#8364; (411,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share basic (in dollars per share)</a></td>
<td class="num">&#8364; (1.18)<span></span>
</td>
<td class="num">&#8364; (1.32)<span></span>
</td>
<td class="num">&#8364; (2.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Net loss per share diluted (in dollars per share)</a></td>
<td class="num">&#8364; (1.18)<span></span>
</td>
<td class="num">&#8364; (1.32)<span></span>
</td>
<td class="num">&#8364; (2.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644320288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">&#8364; 28,347<span></span>
</td>
<td class="nump">&#8364; 31,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">236,782<span></span>
</td>
<td class="nump">197,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">41,843<span></span>
</td>
<td class="nump">43,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DeferredTaxAsset', window );">Deferred tax assets</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">309,868<span></span>
</td>
<td class="nump">276,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Assets held for sale</a></td>
<td class="nump">2,419<span></span>
</td>
<td class="nump">10,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">24,801<span></span>
</td>
<td class="nump">23,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">14,326<span></span>
</td>
<td class="nump">6,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Contract assets</a></td>
<td class="nump">2,758<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">4,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">23,763<span></span>
</td>
<td class="nump">40,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Current tax assets</a></td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">402,452<span></span>
</td>
<td class="nump">495,797<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">478,381<span></span>
</td>
<td class="nump">584,029<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">788,249<span></span>
</td>
<td class="nump">860,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">26,879<span></span>
</td>
<td class="nump">23,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="nump">2,056,110<span></span>
</td>
<td class="nump">1,817,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(1,565,981)<span></span>
</td>
<td class="num">(1,305,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">516,941<span></span>
</td>
<td class="nump">533,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">36,819<span></span>
</td>
<td class="nump">37,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">48,100<span></span>
</td>
<td class="nump">72,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">84,919<span></span>
</td>
<td class="nump">170,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">5,005<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">48,033<span></span>
</td>
<td class="nump">73,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">37,400<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">50,717<span></span>
</td>
<td class="nump">40,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income taxes payable</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">44,580<span></span>
</td>
<td class="nump">34,759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">186,389<span></span>
</td>
<td class="nump">156,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">271,308<span></span>
</td>
<td class="nump">327,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 788,249<span></span>
</td>
<td class="nump">&#8364; 860,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644254448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Issued capital</div></th>
<th class="th"><div>Capital reserve</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Currency translation reserve</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">&#8364; 21,655<span></span>
</td>
<td class="nump">&#8364; 1,334,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (645,069)<span></span>
</td>
<td class="nump">&#8364; 57<span></span>
</td>
<td class="nump">&#8364; 711,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(411,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(411,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(411,716)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="num">(411,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">403,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,284)<span></span>
</td>
<td class="num">&#8364; (5,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">22,454<span></span>
</td>
<td class="nump">1,728,658<span></span>
</td>
<td class="num">(5,817)<span></span>
</td>
<td class="num">(1,056,785)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">688,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(249,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(249,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(249,029)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(249,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">65,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Share issuances and contingent consideration from business combination</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">18,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount', window );">Exercise of options / Settlement of share-based payment awards</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(3,440)<span></span>
</td>
<td class="nump">4,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Dec. 31, 2022</a></td>
<td class="nump">23,400<span></span>
</td>
<td class="nump">1,817,287<span></span>
</td>
<td class="num">(1,481)<span></span>
</td>
<td class="num">(1,305,814)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="nump">533,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,167)<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="num">(260,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">3,453<span></span>
</td>
<td class="nump">232,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SettlementOfShareBasedPaymentAwardsAmount', window );">Settlement of share-based payment awards</a></td>
<td class="nump">26<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
<td class="nump">&#8364; 1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Dec. 31, 2023</a></td>
<td class="nump">&#8364; 26,879<span></span>
</td>
<td class="nump">&#8364; 2,056,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,565,981)<span></span>
</td>
<td class="num">&#8364; (67)<span></span>
</td>
<td class="nump">&#8364; 516,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exercise of options or share based payment awards settled in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SettlementOfShareBasedPaymentAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based payment awards settled in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SettlementOfShareBasedPaymentAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Share-based payment expense (incl. deferred taxes)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644313552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">&#8364; (259,969)<span></span>
</td>
<td class="num">&#8364; (249,155)<span></span>
</td>
<td class="num">&#8364; (412,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile loss before tax to net cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="num">(16,731)<span></span>
</td>
<td class="num">(4,009)<span></span>
</td>
<td class="num">(10,103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance expense</a></td>
<td class="nump">2,493<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
<td class="nump">10,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">23,386<span></span>
</td>
<td class="nump">23,741<span></span>
</td>
<td class="nump">15,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment of property, plant and equipment</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">6,594<span></span>
</td>
<td class="nump">22,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="nump">11,981<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsTransferToAssetHeldForSale', window );">Impairment of assets held for sale</a></td>
<td class="nump">6,711<span></span>
</td>
<td class="nump">19,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Impairment of inventory</a></td>
<td class="nump">47,129<span></span>
</td>
<td class="nump">80,021<span></span>
</td>
<td class="nump">185,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expense</a></td>
<td class="nump">7,697<span></span>
</td>
<td class="nump">9,185<span></span>
</td>
<td class="nump">14,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(574,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Changes of provisions</a></td>
<td class="num">(25,842)<span></span>
</td>
<td class="num">(58,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangesInWorkingCapitalAbstract', window );"><strong>Working capital changes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Decrease / (increase) in asset held for sale</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease / (increase) in trade receivables and contract assets</a></td>
<td class="num">(8,082)<span></span>
</td>
<td class="nump">9,502<span></span>
</td>
<td class="num">(16,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease / (increase) in inventory</a></td>
<td class="num">(47,940)<span></span>
</td>
<td class="num">(47,851)<span></span>
</td>
<td class="num">(227,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets', window );">Decrease / (increase) in prepaid expenses and other assets</a></td>
<td class="nump">16,494<span></span>
</td>
<td class="nump">8,968<span></span>
</td>
<td class="num">(3,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities', window );">Receipts from grants from government agencies and similar bodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">(Decrease) / increase in trade and other payables and contract liabilities</a></td>
<td class="num">(29,984)<span></span>
</td>
<td class="num">(96,186)<span></span>
</td>
<td class="nump">179,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities', window );">(Decrease) / increase in other current financial and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Decrease / (increase) in deferred taxes</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(1,583)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="num">(3,891)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">15,852<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(4,606)<span></span>
</td>
<td class="num">(9,785)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="num">(267,887)<span></span>
</td>
<td class="num">(286,177)<span></span>
</td>
<td class="num">(733,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(52,320)<span></span>
</td>
<td class="num">(88,023)<span></span>
</td>
<td class="num">(124,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets</a></td>
<td class="num">(2,880)<span></span>
</td>
<td class="num">(5,199)<span></span>
</td>
<td class="num">(3,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisition of subsidiary, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="num">(55,200)<span></span>
</td>
<td class="num">(93,499)<span></span>
</td>
<td class="num">(127,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments on lease obligations</a></td>
<td class="num">(5,193)<span></span>
</td>
<td class="num">(4,221)<span></span>
</td>
<td class="num">(3,183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from the issuance of shares (net of transaction costs)</a></td>
<td class="nump">235,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions', window );">Payment on / proceeds from treasury shares/exercise of options</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="num">(30,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodValueNewIssues', window );">Proceeds from at-the-market offering program (net of transaction costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of the EIB loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flow provided by financing activities</a></td>
<td class="nump">230,893<span></span>
</td>
<td class="nump">63,173<span></span>
</td>
<td class="nump">344,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(92,194)<span></span>
</td>
<td class="num">(316,503)<span></span>
</td>
<td class="num">(516,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of currency translation gains on cash and cash equivalents</a></td>
<td class="num">(1,151)<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">495,797<span></span>
</td>
<td class="nump">811,464<span></span>
</td>
<td class="nump">1,322,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">&#8364; 402,452<span></span>
</td>
<td class="nump">&#8364; 495,797<span></span>
</td>
<td class="nump">&#8364; 811,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsTransferToAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsTransferToAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued other liability for up-front payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of proceed from issuing other equity instrument or exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from government grants and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650416288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationAbstract', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationTextBlock', window );">Corporate Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (CureVac or CV or the Company) is the parent company of CureVac Group (Group) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With in - house manufacturing capabilities and expertise we are an integrated biopharmaceutical company. We consider our manufacturing process an important part of our strategy that allows us to continuously improve our technology platform and maintain flexibility in clinical development and allow us to manufacture potential future commercial products. The close interaction of our technical development and research teams enables us to rapidly implement innovations and robustness to the manufacturing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were incorporated pursuant to the laws of the Netherlands as CureVac B.V. on April 7, 2020 to become a holding company for CureVac AG prior to our initial public offering. Pursuant to the terms of a corporate reorganization (the &#8220;Corporate Reorganization&#8221;), all of the outstanding shares in CureVac AG were contributed and transferred to CureVac B.V. in a capital increase in exchange for common shares of CureVac B.V. and, as a result, CureVac AG became a wholly-owned subsidiary of CureVac B.V. and then current shareholders of CureVac AG became the shareholders of CureVac B.V. Immediately following such exchange, and prior to the listing of our common shares on Nasdaq, we converted into a public company (naamloze vennootschap) under Dutch law pursuant to a Dutch notarial deed of amendment and conversion, following which our legal name became CureVac N.V. As part of our Corporate Reorganization, outstanding shares of all series in CureVac AG were exchanged for common shares in CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are registered in the commercial register at the Netherlands Chamber of Commerce under company number 77798031 (RSIN 861149336). Our principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 T&#252;bingen, Germany.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During fiscal 2023, dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, was the largest shareholder of CureVac. Together with its related parties, dievini held shares and voting rights in CureVac between appr. 37 &#8211; 43 % (prior year: 43 &#8211; 46 %) during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on corporate information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589676261136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SignificantAccountingPoliciesAbstract', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of preparation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and were authorized by the Management Board for presentation to the Supervisory Board on April 23, 2024. The Group&#8217;s consolidated financial statements are presented in Euros (EUR), which is also the parent company&#8217;s functional currency. Unless otherwise stated, the numbers are rounded to thousands of Euros, except per share amounts.Due to rounding, differences may arise when individual amounts or percentages are added together.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has prepared the consolidated financial statements on the basis that it will continue to operate as a going concern. No commercial products have been marketed yet as CureVac is still in the development phase. Hence, the Group is raising capital to perform research &amp; development activities and to advance its technologies up to a successful development and regulatory approval of its products. To reach its development and commercialization objectives, the Group will seek additional funding through collaboration or licensing agreements or other financing activities. While the Group&#8217;s business projections could be unfavorably affected by being unable to obtain funding or enter into collaboration or license agreements on acceptable terms, CureVac&#8217;s cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the financial statements. This anticipates, that for the foreseeable future the Group will continue to operate. Thus, no adjustments to the consolidated financial statements have been made related to the Group not being able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Details of the Group&#8217;s accounting policies, including changes thereto are described below. The accounting policies have been consistently applied to all years presented unless otherwise stated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of consolidation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsidiaries are entities controlled by the Group. The Group &#8220;controls&#8221; an entity when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The consolidated financial statements include the Company&#8217;s wholly-owned subsidiaries CureVac SE (until September 26, 2022: CureVac AG, Tuebingen, Germany), CureVac Inc. (Boston, Massachusetts, USA), CureVac Manufacturing GmbH (prior years: CureVac Real Estate GmbH, Tuebingen, Germany), CureVac Corporate Services GmbH (Tuebingen, Germany), CureVac RNA Printer GmbH (Tuebingen, Germany), CureVac Swiss AG (Basel, Switzerland &#8211; incorporated in 2021) and CureVac Belgium SA (Ottignies-Louvain-la-Neuve, Belgium &#8211; incorporated in 2022). Effective July 1, 2022, we acquired Frame Pharmaceuticals B.V., Amsterdam, Netherlands (Frame Pharmaceuticals), which was renamed to CureVac Netherlands B.V.; refer to Note 20 for additional information about this business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The fiscal year of all Group entities corresponds to the calendar year ending December&#160;31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Material accounting policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business combinations and goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Group determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Any contingent consideration to be transferred by the acquirer is recognized at fair value at the acquisition date. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of IFRS 9 Financial Instruments, is measured at fair value with the changes in fair value recognized in the statement of operations in accordance with IFRS 9. Other contingent consideration that is not within the scope of IFRS 9 is measured at fair value at each reporting date with changes in fair value recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred over the fair value of net identifiable assets acquired and liabilities assumed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;">After initial recognition, goodwill is measured at cost less any accumulated impairment losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Revenue from the sale of products and services is recognized when the Group transfers control to the customer. Control generally transfers when the customer gains the ability to direct the use of and obtain substantially all of the remaining benefits from the good or service. If the contract contains more than one performance obligation, the consideration which the Group expects to receive is allocated to each of the performance obligations, using the relative stand-along selling price method. Revenue is recognized at the amount of consideration that the Group is expected to receive in exchange for these goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group primarily generates revenue from its licensing and development agreements with its customers, which include collaboration partners for the development of mRNA medicines against a variety of targets in diseases and conditions. These arrangements contain multiple contractual promises, including (i) licenses, or options to obtain licenses to the Group&#8217;s mRNA technology, as well as related research and development technology services, (ii) delivery of products, and (iii) research and development services. Such arrangements provide for various types of payments to the Group, including upfront fees, funding of research and development services, payment for delivered products, development, regulatory and commercial milestone payments, license fees, and royalties on product sales, all of which may be satisfied at different points in time. Outlicensing agreements may be entered into with or without any further significant contractual obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Goods or services promised in collaborative arrangements are accounted for as separate performance obligations if such promises are distinct (i.e., if the customer can benefit from the good or service on its own or together with other resources readily available to it and if the promise is separately identifiable from other promises in the contract).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In determining whether contractual promises are separately identifiable, the Group considers whether:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It provides a significant service of integrating the goods or services with other goods or services that represent the combined output or outputs for which the other party has contracted.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One or more of the goods or services significantly modifies or customizes one or more of the other goods or services promised in the agreement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The goods or services the Group promised to transfer or to provide are highly interdependent or highly interrelated.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Based on these criteria, management evaluates whether the intellectual property (IP) licenses granted, and to which further research and development activities may apply under the terms of a collaboration agreement, are distinct from the unperformed obligations to the collaboration partner, considering the relevant facts and circumstances of each arrangement. Factors considered in this determination include the nature of the IP license, the stage of development of the IP license granted, the research capabilities of the partner, and the availability of mRNA technology research expertise in the general marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When an IP license is not considered to be distinct from research services, the Group generally recognizes revenue, including any upfront payment, attributable to the license on a straight-line basis, which reflects the performance of services by the Group towards satisfaction of the obligation, over the contractual or estimated performance period, which is typically from the effective date of the related collaboration agreement through to the estimated date of Marketing Authorization Application (MAA) or Biologics License Application (BLA) for a product developed under the agreement. The determination of the estimated date of MAA or BLA is a significant estimate given the uncertainty inherent in developing innovative pharmaceutical products and is based upon development plans with the customer, which are subject to change, clinical trials, and approval of regulatory authorities Changes in the estimated date of market entry could have a material impact on the amount and timing of revenue the Group records in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Sometimes an IP license is granted together with research and development services relating to the technology. In this case, the services are not considered distinct from the licenses and form a bundle for which revenue is recognized on a straight line basis over the time of services, as the services are determined predominant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When an IP license is considered to be distinct, the Group determines whether it provides the customer with either (1) a right to access the IP throughout the license period (for which revenue is recognized over the license period) or (2) a right to use the IP as it exists at the point in time that the license is granted (for which revenue is recognized at a point in time where the customer can first use and benefit from the license).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Some of the collaboration arrangements include rights and obligations that are considered outside the scope of a customer-vendor relationship as they are more akin to the activities that joint operators perform. CureVac decided that the nature of these types of activities is best reflected by applying joint arrangements accounting which, as the main effect, usually leads to revenue recognition at a later point in time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">If the transaction price in an agreement includes a variable amount, the Group estimates the amount of consideration to which the Group will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated deferred contract liability is updated at each reporting date to reflect the current facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Collaboration agreements may also provide a customer with the option to acquire additional goods or services. In these cases, the Group determines as to whether the customer was granted a material right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Product sales related to collaboration agreements include RNA products and are recognized over time as goods are produced because such goods have no alternative use. Otherwise, revenue for product sales is recognized at a point in time. In 2023 revenue for produced LNP batches were recognized on a point-in-time basis. No product revenue was recognized in 2022 and 2021. Revenue from certain research and development services, delivered as a distinct performance obligation under the collaboration agreements, are recognized over time as the services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A receivable is recognized when the consideration is unconditional and only the passage of time is required before payment is due. Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liability in the statements of financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group may present the following contract balances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contract assets&#8201;&#8212;&#8201;Represents the Group&#8217;s right to consideration in exchange for goods or services that the Group has transferred to the customer when that right is conditioned on something other than the passage of time</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trade receivables&#8201;&#8212;&#8201;Represents the Group&#8217;s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contract liabilities&#8201;&#8212;&#8201;Represents the Group&#8217;s obligations to transfer goods or services to a customer for which the Group has received consideration (or consideration is due) from the customer</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes revenue from contracts with customers relating to its core business. All other operating proceeds are presented as other operating income in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants from government agencies and similar bodies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects. Each grant agreement is assessed to determine whether there are elements of the supply of products from the group to the grantor that are recognized separately from the grant. For the supply of products, the standalone selling price is determined by reference to observed prices with other customers. The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If grant funds are received prior to qualifying expenses being incurred or assets purchased, they are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other operating income on a systematic basis over the period in which the corresponding expenses are incurred. If the funds reimburse purchased assets, the liability is reduced with a corresponding amount deducted from the asset&#8217;s carrying amount upon recording of the qualified asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">i) Financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial recognition and measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The classification of financial assets at initial recognition depends on the financial asset&#8217;s contractual cash flow characteristics and the Group&#8217;s business model for managing them. The Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component are measured at the transaction price determined under IFRS 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subsequent measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For purposes of subsequent measurement, financial assets are classified into four categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at amortized cost (debt instruments);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at fair value through other comprehensive income with recycling of cumulative gains and losses (debt instruments);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets designated at fair value through other comprehensive income with no recycling of cumulative gains and losses upon derecognition (equity instruments); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at fair value through profit or loss.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2021, 2022, and 2023, the Group only had the following financial assets to be measured at amortized cost:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash and cash equivalents</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trade receivables</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other financial assets</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in the statement of operations when the asset is derecognized, modified, or impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An allowance for expected credit losses (ECLs) is recognized for all debt instruments not held at fair value through profit or loss including contract assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12- months (a 12- month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For financial assets being due more than 30 days, a significant increase in credit risk is assumed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk but instead recognizes a loss allowance based on lifetime ECLs at each reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group considers a financial asset in default when contractual payments are 180&#160;days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ii) Financial liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s material financial liabilities consists of lease liabilities and trade payables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade payables at initial recognition are accounted for at fair value and subsequently at amortized costs. The material accounting policy information regarding accounting of leases is described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquired intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Acquired intangible assets are mainly comprised of software and licenses. Regarding the acquired intangible assets (i.e., technology and goodwill) in the business combination with Frame Pharmaceuticals, refer to Note 20.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated useful lives for each intangible asset class are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Software</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8 to 20 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the exception of goodwill, the Group does not have any intangible assets with indefinite useful lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and development costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research costs are expensed as incurred. Since our own development projects are mostly subject to regulatory approval and all studies are at an early phase, where the outcome of reaching the next phases is uncertain, the conditions for the capitalization of expenditures incurred prior to approval are not met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairments. These costs also comprise the costs for replacement parts, which are recognized at the time they are incurred, providing they meet the recognition criteria. All other repair and maintenance costs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Leasehold improvements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1 to 15 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technical equipment and machines:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 14 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment, furniture and fixtures:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 14 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated useful lives are reviewed regularly and revised if necessary. The depreciation method remained unchanged from 2021 through 2023. The residual values of the assets are generally considered to be zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of non-financial non-current assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At each reporting date, the Group assesses whether there is an indication that a non-financial asset may be impaired. If there is any indication of impairment (triggering event) or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of the asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case it is determined at the level of the cash-generating unit (CGU). If the carrying amount of an asset or CGU exceeds its recoverable amount, the asset or CGU is impaired and written down to its recoverable amount. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In principle, the recoverable amount has to be determined for each individual asset where such asset generates cash flows that are largely independent of those generated by other assets. Where it is not possible, the recoverable amount has been determined on the basis of a group of assets representing a cash generating unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In assessing whether the cash flows are largely independent, CureVac considers various factors, including how management manages the company activities and how the CureVac companies are linked in business operations. As management decisions are centralized on group level and the CureVac companies are closely linked in business operations, the Group operates as one cash-generating unit. Therefore, for the purpose of annual goodwill impairment testing in 2022 and 2023, goodwill was allocated at Group level. The recoverable amount for the Company&#8217;s cash-generating unit based on fair values less costs of disposal using market capitalization derived from public quotations of CureVac stock. Management believes that no reasonably foreseeable change in the price of CureVac stock would cause the carrying amount of our one cash-generating unit to exceed its recoverable amount.Impairment losses of continuing operations are recognized in the statement of operations in expense categories consistent with the function of the impaired asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal year 2021, impairment of EUR 22,810k were recognized. These pertained largely to machinery and technical equipment recorded as assets under construction and resulted from the partial impairment of production lines which were obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV, see Note 4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beginning in year 2022, goodwill is tested for impairment annually as of December 31 and when circumstances indicate that the carrying value may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For 2023, impairment was evaluated for goodwill by assessing the recoverable amount on Group level. Impairment losses relating to goodwill cannot be reversed in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There was no impairment of goodwill in 2023. However, there were impairments of technical equipment amounting to EUR 1,374k; refer to Note 4.1 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-current assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group classifies non-current assets as held for sale if their carrying amount is expected to be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expenses. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management is committed to the plan to sell the assets. Property, plant and equipment are not depreciated or amortized once classified as held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Right-of-use assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received as well as any estimated costs to be incurred by the lessee for dismantling and removing the underlying asset. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life, indicated below, and the lease term. Right-of-use assets are subject to impairment. Refer to the section above &#8220;Impairment of non-financial assets&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Land, Buildings and supply installations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1 to 15 years</p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 to 4 years</p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 to 5 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Lease liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in- substance fixed payments) less any lease incentives receivable and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments, or a change in the assessment to purchase the underlying asset. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount for the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Short-term leases and leases of low-value assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group applies the short-term lease recognition exemption to its short-term leases (i.e., leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption. Lease payments on short-term leases and leases of low-value assets are recognized as expenses on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventories are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Inventories are comprised of raw materials, work in progress, and finished goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in bringing each product to its present location and condition are accounted for, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raw materials: purchase cost on a first-in/first-out basis</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overhead based on normal operating capacity, but excluding borrowing costs</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and cash equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash on hand, bank balances on-demand, and short-term deposits with original maturities of three months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Onerous contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An onerous contract is a contract under which the unavoidable costs (i.e., the costs that the Group cannot avoid because it has the contract) of meeting the obligations under the contract exceed the economic benefits expected to be received under it. The unavoidable costs under a contract reflect the least net cost of exiting from the contract, which is the lower of the cost of fulfilling it and any compensation or penalties arising from failure to fulfil it. The cost of fulfilling a contract comprises the costs that relate directly to the contract (i.e., both incremental costs and an allocation of costs directly related to contract activities).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Group has a contract that is onerous, the present obligation under the contract is recognized and measured as a provision. However, before a separate provision for an onerous contract is established, the Group recognizes any impairment loss that has occurred on assets dedicated to that contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share-based payment awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Group operates several share-based payment programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">An equity-settled share-based payment award is accounted for by recognizing the related expense over the vesting period of the award, with a corresponding increase recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When a share-based payment award provides for different ways of settlement (i.e. cash versus shares) depending on the occurrence of contingent events, CureVac has the right to choose the manner of settlement and accounts the award based on this.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The related share-based payment expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Tax loss carryforwards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Tax loss carryforwards are examined by the German taxation authorities and may be adjusted. Furthermore, significant changes in the shareholder and company structure can lead to a reduction in the loss carryforwards under the current provisions of German tax law, which can be used to calculate the annual amount for offsetting against the future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. The amount of the expected tax liability or tax receivable reflects the amount, which represents the best estimation taken into account tax uncertainties. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Deferred income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Deferred tax assets are recognized for deductible temporary differences, the carry forward of unused tax credits and any unused tax losses to the extent that it is probable that future taxable income will allow the deferred tax asset to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">An operating segment is defined as a component of an entity for which discrete financial information is available and whose operating results are regularly reviewed by our Management Board as the Chief Operating Decision Maker (CODM). The Group operates as a single segment dedicated to the discovery and development of biotechnological applications and the CODM makes decisions about allocating resources and assessing performance based on the Group as a whole. Accordingly, the Group has determined it operates in one operating and reportable segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Significant accounting judgments, estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates, and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments and estimates in relation to assets, liabilities, contingent liabilities, uncertain tax position, revenues, and expenses. Management bases its judgments and estimates on historical experience and other various factors, which it believes to be reasonable under the circumstances, the result of which forms the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for. Actual results may differ from these estimates under different assumptions and conditions and may materially affect the financial results or the financial position reported in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Judgments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the process of applying the accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition and collaboration agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group applied the following judgments in determining the amount and timing of revenue from collaboration agreements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification and determination of the nature of performance obligations in collaboration and license agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group generates revenues from collaboration and license agreements under which the Group grants licenses to use, research, develop, manufacture, and commercialize candidates and products. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. If these promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in the Group accounting for all goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For these combined performance obligations, it must be assessed which of these promises is the predominant promise to determine the nature of the performance obligation. The Group determined that the research and development technology services for the grant of the license is the predominant promise within the (combined) performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Group shares the risks and benefits of a development project in such a way that the nature of the arrangement is not considered to be purely a customer-vendor-relationship, activities that are determined to be outside of a customer-vendor-relationship are accounted for in consideration of the principles of a joint operation accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, the promise of the research and development technology services for granting a license is accounted for as a performance obligation satisfied over time as the Group&#8217;s customer simultaneously receives and consumes the benefits from the Group&#8217;s performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition and collaboration agreements</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimation of variable consideration and assessment of the constraint when determining the amount of revenue of which to defer recognition</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s collaboration and license agreements comprise variable considerations which are contingent on the occurrence or non-occurrence of a future event (i.e., reaching a certain milestone). When determining the deferral of revenue in a collaboration and license agreement, the Group is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As there are usually only two possible outcomes (i.e., a milestone is reached or not), the Group has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which the Group will be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The most likely amount of these milestone payments (i.e., the full milestone payment) is only included in the transaction price if the occurrence of reaching a future milestone is highly probable. The Group has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has concluded that future milestone payments are fully constrained at each of the fiscal years. Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, regulatory approval, or achievement of a sales milestone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>Estimation of determination of date of market authorization application for revenue release over-time</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A significant amount of judgment given the uncertainty inherent in developing innovative pharmaceutical products is being used in the determination of the estimated date of the Marketing Authorization Application or Biologics License Applications. The group regularly reviews the timelines and changes are reflected in the release of revenue amount when they become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for non - current assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-current assets are classified as asset held for sale if their carrying amount will be recovered through a sale transaction rather than through continued use; the carrying value of such assets is measured at the lower of their previous carrying value and their fair value less costs to sell. In evaluating whether the criterion, for classification as assets held for sale, of a sale being highly probable, the Group considered that a plan to sell the assets was committed to and an active program to locate a buyer was initiated with an equipment reseller. By estimating the fair value less costs to sell the Group considered various indicative prices of expected auction proceeds quoted by the equipment reseller. Additionally, the Group estimated, whether the plan to sell the assets could be completed within one year from the date of classification and whether actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has multiple share-based payment programs. Significant estimates are included in the determination of the grant date fair value of the awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for onerous contract provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has entered into binding legal agreements for the supply of services by contract research organizations (CROs) to the Group for clinical trials of its first-generation COVID-19 vaccine candidate, CVnCoV. Such services are generally associated with the ongoing monitoring and care for enrolled participants in the clinical trials. Due to the discontinuation of the CVnCoV program, the remaining services, which the Group is obligated to procure, do not have a value for the Group anymore. In estimating the cost of the remaining services, judgment is required, particularly in estimating the number of participants completing the clinical trials, when measuring provisions for such contracts with clinical research organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for contract termination provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Contract termination provisions are established under certain conditions in the case of legal risks. Settlement and legal proceedings often raise complex issues and are subject to many uncertainties and complexities including, but not limited to, the facts and circumstances of each particular case. The outcome of any current or future proceedings cannot normally be predicted. The Group considers the need for accounting measures in respect of pending or future settlements for terminated contracts on the basis of the information available to its legal department and in close consultation with legal counsel acting for the Group. Where it is more likely than not that such settlement will result in an outflow of resources that is already reasonably estimable, a provision for settling terminated contracts is recorded in the amount of the present value of the expected cash outflows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for. The risk for the assessment regarding i) the deferral of upfront payments, ii) the cooperation between CureVac and GlaxoSmithKline Biologicals SA (GSK), and iii) the transfer pricing setup not to be accepted by the tax authorities is estimated to be between 10% and 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in accounting policies and disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New and amended standards and interpretations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has not early adopted any standards, interpretations, or amendments that have been issued but are not yet effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Standards issued but not yet effective</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following amendments will be adopted effective January 1, 2024, or at a later effective date:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 1: Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 7 and IFRS 7: Supplier Finance Arrangements</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IFRS 16: Lease Liability in a Sale and Leaseback</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 21: Lack of Exchangeability</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CureVac does not expect these standards to have an impact on the Group&#180;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589620921056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock', window );">Notes to the Consolidated Statements of Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the consolidated financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">The Group recognized the following revenues in 2021, 2022 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,128</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,197</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,425</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 102,990</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 67,420</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 53,758</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended December 31, 2023, the Company recognized revenues over-time (i) EUR 31,051k (2022: EUR 44,787k, 2021: EUR 79,827k) related to delivery of research and development services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below) and (ii) EUR 11,395k (2022: EUR 19,571k, 2021: EUR 22,706k) from those research and development services considered distinct within the agreements and recognized revenues at point-in-time (iii) EUR 11,312k (2022: EUR 3,062k, 2021: EUR 457k) related to delivery of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlaxoSmithKline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2020, the Group entered a collaboration with GSK for the research, development, manufacture and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. In addition to an equity investment of EUR 150,000k as part of the 2020 Private Investment, GSK made a non-refundable upfront cash payment of EUR 120,000k which was deferred upon receipt and recognized as a contract liability. Additionally, the Group is eligible to receive a one-time reimbursable payment of EUR 30,000k for manufacturing capacity reservation, upon certification of CureVac&#8217;s commercial scale manufacturing facility currently under construction in Germany as well as to receive development and regulatory milestone payments of up to EUR 320,000k, commercial milestone payments of up to EUR 380,000k and tiered royalties on product sales. GSK will fund R&amp;D activities incurred by CureVac related to the development projects covered by the collaboration. CureVac will be responsible for the research and development in collaboration with GSK up to the submission to authorities, after which GSK will be responsible, including commercialization. CureVac will be responsible for the manufacturing of the product candidates, including for commercialization, and will retain commercialization rights for selected countries for all product candidates. This contract consists of two performance obligations. Performance obligation one consists of a combined performance where CureVac grants its customer a license which is bundled with research and development services relating to the technology. The group accounts for this as a single obligation overtime. The second performance obligation consists of research and development project work which is recognized over-time. The upfront payment, attributable to the IP license, is being recognized straight-line from the effective date of the collaboration agreement through to the agreed estimated submission date for authority approval. In the year ended December 31, 2023, EUR 27,740k (2022: EUR 41,379k) in revenue was recognized under the collaboration agreement with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. In 2023, less revenue was released than originally anticipated, due to changes of the estimated project timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, in April 2021, the Group entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches (&#8220;GSK COVID Products&#8221;), such as the CureVac&#8217;s second-generation COVID-19 vaccine candidate, CV2CoV. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September 2021. Pursuant to the amendment in September 2021, CureVac and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. CureVac and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by CureVac, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the GSK COVID Agreement, GSK has paid CureVac an upfront payment of EUR 75,000k in 2021. Under the terms of the 2020 GSK Agreement, CureVac granted GSK a worldwide exclusive, sublicensable (subject to certain conditions) license under certain of our intellectual property relating to vaccines and antibodies encoded by our proprietary mRNA targeting certain selected pathogens, or GSK Program Products, and a non-exclusive license under certain LNP technology to develop, manufacture and commercialize a certain number of such GSK Program Products for use in connection with the infectious diseases targeted under the 2020 GSK Agreement. CureVac also granted GSK an exclusive option, after a certain date, to obtain exclusive licenses to develop, manufacture and commercialize CVnCoV and boosters for such vaccine. CureVac and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. CureVac and GSK will share all net profits generated from sales of GSK COVID Products, other than certain products defined in the agreement as &#8220;Combination Products&#8221;, under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. This contract consists of a bundled performance obligation where CureVac grants its customer a license which is bundle with research and development services relating to the technology. The group accounts for this as a single obligation overtime. For the equally shared development costs CureVac accounts for the GSK share as a research and development expense and reimbursements from GSK for CureVac&#8217;s share are offset against research and development expense. CureVac is eligible to receive tiered royalty payments ranging from a low-teen percentage to a mid-teen percentage of net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement, CureVac has the right to commercialize GSK COVID Products in Austria, Germany and Switzerland and if CureVac exercises such right, CureVac&#8217;s sales of GSK COVID Products, other than Combination Products will be subject to the profit share and CureVac will be required to pay GSK a high-teen percentage royalty on net sales of all Combination Products in such countries. In the year ended December 31, 2023, EUR 10,530k (2022: EUR 20,884k) in revenue was recognized under the GSK COVID Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Boehringer Ingelheim</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2014, the Group entered into an Exclusive Collaboration and License Agreement, which it refers to as the Boehringer Agreement, with Boehringer Ingelheim, whereby it granted Boehringer Ingelheim exclusive global rights for development and commercialization of its investigational therapeutic mRNA vaccine BI 1361849 (formerly CV9202) formulated with a legacy protamine technology. The Group received, in 2014, an upfront payment of EUR 30,000K, as well as, an option fee payment of EUR 5,000K and in 2018 an additional EUR 7,000K in development milestone payments, all of which are non-refundable and non-creditable in the event of expiry or termination of the agreement. In June 2021, Boehringer Ingelheim provided notice of its intention to terminate the Boehringer Agreement, with such termination to become effective on November 17, 2021. Upon termination of the Boehringer Agreement, the rights and licenses granted by the Group to Boehringer Ingelheim reverted back to the Group, provided that Boehringer Ingelheim has the right to sell off existing inventory of BI 1361849 for a certain period. In addition, Boehringer Ingelheim assigned to us all regulatory approvals or applications and grant us a non-exclusive, cost-free, perpetual and worldwide license to intellectual property held by Boehringer Ingelheim that has been used in the development, manufacture or commercialization of BI 1361849 or any other product developed under the Boehringer Agreement. As a result of the termination in 2021, the remaining contract liability, related to the upfront payment, EUR 14,003k was recognized over a shorter period through the termination date. In addition, the option fee payment of EUR 5,000k and the additional EUR 7,000k development milestone were recognized in 2021. Therefore, for the year ended December 31, 2023, EUR 0k (2022: EUR 0k, 2021: 26,003k) was recognized related to this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRISPR Therapeutics Development and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2017, we entered into a Development and License Agreement with CRISPR Therapeutics, which, as amended by amendments entered into in June 2020 and in October 2023, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. CureVac and CRISPR confirmed to stop working on two programs under the CRISPR Therapeutics Agreement and added three new programs. CRISPR Therapeutics has paid us an upfront one-time technology access fee of USD 3 million and certain additional amounts under the second amendment, which are recognized straight-line from the effective date of the collaboration agreement through to the date of market entry of a product developed under the agreement. In the year ended December 31, 2023, EUR 5,425k (2022: EUR 3,370k, 2021: EUR 919k) in revenue was recognized under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Genmab Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the Group entered into a Collaboration and License Agreement with Genmab, which we refer to as the Genmab Agreement, to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#8217;s proprietary antibody technology for the treatment of human diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, Genmab notified the Group of its intent to terminate the Genmab First Program under the Genmab Agreement effective in September 2023. Such termination did not terminate the Genmab Agreement in its entirety, but rather only with respect to certain license and exclusivity provisions related to the Genmab First Program. Under the Genmab Agreement, the Group further grants Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under CureVac&#8217;s mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In partial consideration for entering into the Genmab Agreement, in 2019 Genmab made a USD 20 million equity investment and paid us an upfront fee of USD 10 million, which was recognized through the date of market entry of a product developed under the agreement until August 2023 (no recognition from September 2023 onwards). In the year ended December 31, 2023, EUR 1,197k (2022: EUR 1,787k, 2021: 1,770k) in revenue was recognized under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period or upon termination of the agreement, when no services are provided anymore. Below is a summary of such payments and the related revenues recognized over-time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:24.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract liabilities at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized&#160;from&#160;upfront and milestone&#160;payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,089</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">USD 10,000 (EUR 8,937) *</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,192</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">USD 4,500 (EUR 3,947)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 770</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 107,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 92,680</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 67,828</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,787</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,051</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">*Translated at the currency exchange rate prevailing on the transaction date</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Contract balances:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,326</p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,758</p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 92,680</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Contract liabilities include advances received from the Group&#8217;s license and collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,580</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">More than one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,100</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 107,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 92,680</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are non-interest bearing and are generally settled within 30 to 45 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Group had two collaboration partners (2022: two) that owed 100% (2022: 100)% of all the receivables and contract assets outstanding. There were two collaboration partners (2022: one) with balances greater than 10% of the total amounts of receivable and contract assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The nature of expenses recognized in the functional categories of the statement of operations are as follows:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,159)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,734)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,891)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,641)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (139,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,398)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,874)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,425)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,672)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,992)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,295)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,850)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,948)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,085)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,918)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,986)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (238,195)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (183,993)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (124,366)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, cost of sales mainly decreased compared to the same period of 2022 due to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them (refer to Note 6 for further information). Additionally, in the prior year, the Company recognized a higher impairment of assets held for sale (refer to Note 5 for further information). Personnel expenses increased mainly due to increased workforce in the manufacturing organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,029)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,425)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (336)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (417)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (424)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,743)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,817)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (3,912)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, selling and distribution expenses increased compared to the same period of 2022. The increase was primarily attributable to higher personnel expenses mainly related to the satellite offices in Belgium and the US.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development (R&amp;D) expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">R&amp;D expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (232,292)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,982)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,126)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,733)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,267)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,259)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,539)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,666)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (539,786)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,587)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (347)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,069)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,287)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,291)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,591)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,252)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (815,907)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (62,550)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (115,724)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During the year ended December 31, 2023, research and development expenses increased significantly in comparison to the same period of 2022, as the prior period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">38,533k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group&#8217;s committed capacity at Novartis (see Note 3.8 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR 25,059k. The net effect of these two events resulted in an overall gain within the Third-party services category. The period of 2021 was largely impacted by the Group&#180;s CVnCoV program. These expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception through December 31, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from the German Federal Ministry of Education and Research (Bundesministerium f&#252;r Bildung und Forschung, or BMBF), the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.7 for more information on amounts recognized from this grant in the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period (refer to Note 10 for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">General and administrative expenses include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,996)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,306)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,853)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,353)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,875)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,669)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,920)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,160)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,360)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,821)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,703)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,508)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (100,402)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (104,178)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (91,758)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, general and administrative expenses decreased in comparison to the same period of 2022. The decrease was primarily attributable to less personnel expenses due to lower workforce in the corporate service functions. Others include mainly expenses for D&amp;O insurance and allocations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Expenses by nature</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nature of the expenses is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,655)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (99,924)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (113,422)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (278,542)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (121,873)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,767)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (708,636)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (67,905)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,381)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,356)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,232)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26,641)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,229)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,948)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,085)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,666)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,160)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,415)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,170)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,156,247)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (353,539)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (335,760)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We refer to Notes 3.2 - 3.5 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.7. Income from release of governmental contract liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the withdrawal of the EMA regulatory approval application for CVnCoV, in October 2021, CureVac recorded in 2021 &#8220;Income from release of governmental contract liabilities&#8221; amounting to EUR 574,502k, which is explained further below. There was no such event in 2022 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Advance Purchase Agreement with European Commission </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2020, CureVac entered into an Advance Purchase Agreement (APA) with the European Commission (EC), acting on behalf and in the name of all Member States of the European Union. The APA provided for the advance purchase by the Member States of 225 million doses of our SARS-CoV-2 vaccine. In order to support our accelerated efforts to develop a safe and effective vaccine, the APA provided support to our operations in the form of up-front payments. The first up-front payment of EUR 450 million was paid by the EC on behalf of the Member States and was included in contract liabilities as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The second up-front payment would have had been due after the submission of the interim data package to the EMA in view of obtaining EC marketing authorization for CVnCoV. The up-front payments were designed to support the development and prepare the commercial supply of the vaccine. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would return the unspent amount of the up-front payment. In the context of the APA, &#8220;spent&#8221; means either costs occurred, or commitments made in relation to the purpose as set out in the APA. CureVac demonstrated that the up-front payment was used in accordance with the contract and no repayment was required. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described above, CureVac recognized the consideration related to its delivery obligations, existing at the outset of the arrangement, as contract liabilities. Upon the automatic termination of the APA, the ability for CureVac to satisfy the contractual performance obligations of the arrangement ceased and the EC ceased to have the ability to exercise its rights for performance by the CureVac. As such, the substance of the arrangement changed from a revenue contract to that of a government grant. Due to the material magnitude of the amount, its non-recurring nature and to better enable comparability to past performance and predictability of future performance, CureVac recognized the EUR 450 million into income in an additional line item &#8220;Income from release of governmental contract liabilities&#8221; in the 2021 statement of operations. The &#8220;spent&#8221; amounts incurred by CureVac, and which demonstrate use of the up-front payment, have been included in &#8220;Research and development expenses&#8221; (refer to Note 3.4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, CureVac was required to transfer, upon EC&#8217;s request any raw material and primary components paid for with the up-front payment and not used as of the termination date. Should the EC request any raw material and primary components or should CureVac successfully sell some of these, an applicable portion of raw material, primary components or proceeds would be remitted to the EC. This agreement expired at the end of 2022 and an amount of EUR 4,114k was accrued as &#8216;other liabilities&#8217; as of December 31, 2022 for the related amount due to be remitted to the EC. As of December 31, 2023, the accrued amount of EUR 4,114k was paid to the EC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">German Federal Ministry of Education and Research </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company announced that the German Federal Ministry of Education and Research (Bundesministerium f&#252;r Bildung und Forschung), or BMBF, a German government-related entity,had established a grant to support the development and production of its COVID-19 vaccine candidates. In July 2020, CureVac applied for this grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2. The grant amounted up to EUR 252 million and the payments were contingent to reaching predefined milestones. Based on the terms and conditions of the arrangement, the Company assessed the arrangement as having two components: a grant component and a supply component which were separated. The amount attributed to the supply of future deliveries was determined based on the relative stand-alone selling price of the vaccine observed in similar arrangements and is presented in contract liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company reached all the predefined milestones for 2020. Due to the withdrawal of the EMA regulatory approval application for CVnCoV in October 2021, CureVac was not able to reach all predefined milestones in 2021. From 2020 to December 2021, CureVac received a total of EUR 196.3 million. In November 2021, CureVac notified BMG of the inability to supply CVnCoV, triggering the automatic termination of the supply agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with the rationale and treatment described above under the APA with the EC, the substance of the supply component of the BMBF arrangement changed from a revenue contract to that of a government grant and thus, consistent with the presentation of the contract liabilities under the APA, CureVac recognized the EUR 124 million in 2021 from the BMBF agreement as income in the line item &#8220;Income from release of governmental contract liabilities&#8221; and the corresponding expenses have been included in research and development expenses. The remaining amount of EUR 65 million, not related to the supply component, was reflected as grant income in &#8220;other operating income&#8221; in 2021. (Refer to Note 3.8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.8 Other operating income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Other operating income relates to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation for CMO/Materials transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,429</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 860</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,195</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grants and other reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,566</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,101</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 67,702</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,932</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,151</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac AG and GSK amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exited its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensation mainly consists of consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in &#8216;Compensation for CMO/Materials transfer&#8217; in other operating income during the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2023, 2022 and 2021 income from grants with government agencies and similar bodies resulted from the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">German Federal Ministry of Education and Research</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 3.7, in 2020 the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The Group recognized grant income of EUR 65,218k from this grant. As the grant ended in 2021, no such income was recognized in 2022 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, CureVac has been granted the positive research allowance notice by the German Federal Ministry of Education and Research for the years 2020 - 2026. The research allowance is an instrument that provides tax relief for research expenditure by companies subject to tax in Germany - regardless of size, legal form and sector - and is intended to create incentives to invest in R&amp;D. During the year ended December 31, 2023 the Group recognized EUR 3,064k for R&amp;D projects as other operating income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coalition for Epidemic Preparedness Innovations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Coalition for Epidemic Preparedness Innovations (CEPI) is an innovative partnership between public, private, philanthropic, and civil organizations, launched at the World Economic Forum in Davos in 2017, to develop vaccines to stop future epidemics. CEPI&#8217;s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (i.e., Disease X).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, CureVac entered into a partnership agreement worth up to USD 34,000k with CEPI to further develop CureVac&#8217;s The RNA Printer&#8482; prototype. Under the three-year partnership agreement, CureVac used its mRNA platform for the preclinical development of a Lassa virus vaccine (a high-priority disease on the World Health Organization R&amp;D list), a yellow fever vaccine and CureVac&#8217;s rabies virus vaccine. Funds are received semi-annually in advance, to cover costs for the next six&#160;months. These payments are allocated to the agreed and signed statements of work. Management concluded that the arrangement should be accounted for by analogy to IAS 20.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is required to use reasonable efforts to achieve certain development milestones and is responsible for conducting certain clinical trials. In the event of an infectious disease outbreak, where such outbreak can be addressed by a Lassa virus, SARS-CoV-2 or future vaccine developed under the agreement, CureVac must manufacture such vaccine for use in the area affected by the outbreak on economic terms that satisfy CEPI&#8217;s equitable access guidelines or otherwise allow CEPI or a third party to supply such vaccine in the affected area.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is required to grant certain approved manufacturers all necessary rights to use certain of CureVac&#8217;s pre-existing IP and IP developed under the CEPI Agreement to further develop CureVac&#8217;s automation solution and manufacture products for the treatment of certain diseases in geographic areas where there is an outbreak on economic terms that satisfy CEPI&#8217;s equitable access guidelines. CureVac must provide all necessary commercially reasonable support to such approved manufacturers to facilitate such efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac solely owns all IP developed under the CEPI Agreement but is required to obtain CEPI&#8217;s consent prior to exploiting any IP developed under the CEPI Agreement if such exploitation is in conflict with or goes against CEPI&#180;s mission or policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that CEPI terminates the agreement, CureVac will grant CEPI a license under CureVac&#8217;s background IP and IP developed under the agreement to, among other things, develop and use CureVac&#8217;s RNA Printer for use in treating certain infectious diseases and to manufacture products developed under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2020, CureVac and CEPI entered a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, CureVac recognized the reimbursement of approved expenses of EUR 3k (2022: EUR 42k; 2021: EUR 688k) as &#8220;other operating income&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, EUR 305k in grant funds received have been deferred and are presented within other liabilities (2022: EUR 309k). Following the completion of the partnership agreement of February 2019 between CureVac and CEPI in May 2022, CEPI requested a partial reimbursement of the unspent funds up to USD 1,000k. Those were reclassified from other liabilities to trade and other payables as of December 31, 2022. As of December 31, 2023, these unspent funds were repaid to CEPI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bill &amp; Melinda Gates Foundation (BMGF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BMGF finances, in the form of grants, various programs that CureVac operates for the development of vaccines, hence promoting and accelerating the development of CureVac&#8217;s technology platform. Through its equity investment, BMGF supports mainly the development of CureVac&#8217;s technology platform including the construction of a production plant in accordance with the GMP (Good Manufacturing Practice) standard on an industrial scale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2015, CureVac entered into a Global Access Commitments Agreement with the Bill &amp; Melinda Gates Foundation pursuant to which the Company is required to take certain actions to support the Bill &amp; Melinda Gates Foundation&#8217;s mission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2016, in connection with the Global Access Agreement, CureVac received a grant of USD 653k (EUR 614k) in funding for the development of a vaccine for picornaviruses. In November&#160;2017, also in connection with the Global Access Agreement, the company received two additional grants: an amount of USD 1,000k (EUR 852k) was received for the development of a universal influenza vaccine and an amount of USD 800k (EUR 673k) was received for a malaria vaccine. In August&#160;2019, the Company received a second payment for the universal influenza program amounting to USD 540k (EUR 486k). In November 2020, the Company received a third payment for the universal influenza program amounting to USD 322k (EUR 280k). In November and December 2020, the Company received further payment for the malaria program amounting to USD 1,449k (EUR 1,208k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023 CureVac recognized EUR 66k (2022: EUR 167k, 2021: EUR 488k) for services as other operating income. In addition, EUR 217k were repaid in 2023 to the Bill &amp; Melinda Gates Foundation due to the closure of one project. The grant is released on a cost occurred basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, EUR 1,430k in grant funds received have been deferred and presented within other liabilities (2022: EUR 1,712k).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of notes to consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649899504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsExplanatory', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Fixed Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4.1 Development of intangible assets and property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development of intangible assets and property, plant and equipment for the years ended December 31, 2023 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Advance</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Software</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Technology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,850</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,454</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (298)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,166)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (656)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,930</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,350</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,139</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated amortization and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,612</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,079</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,217)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,114)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,331)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,479</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,398</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 484</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,361</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,139</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,880</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,946)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,432)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,388)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,797)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,843</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,974</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,350</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,630</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated amortization and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,361</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,059</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,841)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,135)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,493)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,965</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,054</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,266</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,285</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Carrying amount</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,238</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,778</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,878</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,920</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,084</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,347</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As the Group operates as one cash-generating unit, for the purpose of impairment testing in 2023, goodwill was allocated at Group level. For the impairment test the market capitalization was compared to the Group&#8217;s equity; the Goodwill was covered by the exceeding amount. The market capitalization derived from public quotations of CureVac stock (Nasdaq Dec 29, 2023: USD 4.21). Based on this, CureVac has concluded, that there are no indications of potential impairment in the goodwill of its one cash-generating unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Other</b><span style="font-family:'Times New Roman Bold';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment,</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Technical</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">furniture</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">under</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and&#160;machines</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;fixtures</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">construction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 215,283</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,620</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,719)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,851)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,570)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,182)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,356)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,854)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,467</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 50,033</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,552</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 138,457</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 227,509</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated depreciation and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,019</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,394</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,884</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,083)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,938)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,038)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,747)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,710</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,617</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,415</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 826</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,568</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,509</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,873</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,825)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,235)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,165)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,537</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 54,941</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 178,990</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 274,205</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated depreciation and impairment charges </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,415</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,568</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,432</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,374</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,659)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,941)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,914</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,272</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,038</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,200</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,424</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Carrying amount</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 168,264</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 197,941</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,623</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,669</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,698</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 176,790</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 236,782</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2023, impairments of EUR 1,374k were recognized (2022: EUR 5,884k). These were recognized in cost of sales as they pertained to machinery and technical equipment recorded under assets under construction and resulted from the partial impairment of equipment which are obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV. In fiscal 2022, assets were reclassified as &#8216;assets held for sale&#8217; (Refer to Note 5 for additional information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group capitalized EUR 2,375k borrowing costs during fiscal 2023 (2022: EUR 2,291k, 2021: EUR 2,932k). The capitalization rate used to determine the amount of the borrowing costs eligible for capitalization during fiscal 2023 was a weighted average of 5.76% (2022: 5.78%, 2021: 7.17%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">4.2 Right-of-use assets and lease liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Set out below, are the carrying amounts of the Group&#8217;s right-of-use assets and the movements during the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-use&#160;assets</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Land&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,183</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 275</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,303</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,761</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions (new leases and reassessment of existing leases)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,988</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (352)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,772)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 39,574</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 319</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,950</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,843</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The most significant lease agreements that have been initiated relate to several buildings in T&#252;bingen, a building in Wiesbaden and Frankfurt am Main, a building in Amsterdam/Netherlands and a building in Boston/USA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The additions mainly relate to six rental agreements in T&#252;bingen (EUR 2,452k) and one rental agreement in Wiesbaden (EUR 510k). In addition, CureVac assessed one extension option of 5 years to be reasonably certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Below are the carrying amounts of lease liabilities and the movements during the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions (new leases and reassessment of existing leases)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,988</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,375</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,568)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,824</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,005</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,819</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A maturity analysis of lease liabilities is disclosed in Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following are the amounts recognized in the statement of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,772)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment expense / reversal of impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,218)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,375)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense relating to short-term leases (included in cost of sales)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (76)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense relating to leases of low-value assets (included in general and administrative expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from sub-leasing right-of-use assets presented in &#8220;other operating income&#8221;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Set out below, are the carrying amounts of the Group&#8217;s right-of-use assets and the movements of prior period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-use&#160;assets</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Land&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,129</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,244</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,639)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (316)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,053)</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (710)</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,183</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 275</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,303</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,761</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below are the carrying amounts of lease liabilities and the movements during the period 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,892</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,241</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,218</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,439)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,980</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,106</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A maturity analysis of lease liabilities is disclosed in Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There are no commitments for leases not yet commenced as of December 31, 2023. Commitments for leases not yet commenced as of December 31, 2022, related to two lease agreements of buildings in T&#252;bingen, Germany that have been signed in 2021 and one lease agreement of a building in Wiesbaden, Germany that has been signed in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Optional lease payments from using extension options not included in the measurement of the lease liability exist in a gross amount of EUR 39,325k.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589620930432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Assets held for sale</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">5. Assets held for sale</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO Equipment identified for sale had a gross book value of EUR 29,531k and was written down by EUR 19,064k (with the corresponding expense recognized in cost of sales) to EUR 10,467k, the fair value less anticipated costs to sell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">During fiscal year 2023 assets with a net book value of EUR 167k were classified as assets held for sale and assets held for sale with a net book value of EUR 1,505k were sold through direct sales and an external service provider, indicating the remaining assets held for sale&#8217;s carrying value might be further impaired. Based on fair value less costs of disposal calculations, and taking into account the most recent sales projections, including Q1 of 2024, the external service provider&#8217;s market expertise, and an assessment to date as prepared by management, the fair value at December 31, 2023 was lowered to EUR 2,419k by a decrease of EUR 6,711k (with the corresponding expense recognized in cost of sales). The assets held for sale have been valued taking into account the current market circumstances and demand for secondhand equipment for assets outside of warranty periods. Criteria for the determination of the fair value were defined based on certain sales scenarios and considering different sales campaigns, where valuation techniques applied have remained consistent to the prior year.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for non-current assets held for sale and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Section Presentation and disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS05_g30-42_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649921408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">6. Inventories</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials and supplies amounting to EUR 24,801k (December 31, 2022: EUR 23,989k), which are recoverable under the Company&#8217;s agreements with its collaboration partners. During the year ended December 31, 2023, the increase in inventory of EUR 811k is primarily due to purchases of raw material for R&amp;D collaborations and for stockpiling towards the PPA of EUR 62,082k. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Timelines related to the Pandemic Preparedness Agreement were ambitious with the aim of providing acute pandemic preparedness in Germany in the context of emerging COVID-19 variants. In 2023, CureVac identified a risk that necessary regulatory approvals needed to meet these timelines may not be achieved within the contractually agreed timeframe. After consultation with ZEPAI, CureVac applied for a timeline extension as foreseen under the agreement to avoid procurement of further substantial amounts of raw material at risk. As of December 31, 2023, it was considered unlikely that the extension would be granted. Additionally, a rapidly changing epidemiological environment did no longer prompt an acute pandemic threat. Accordingly, inventories which had been stockpiled as required by the PPA, were written down to their net realizable value. Ultimately, the extension was not granted, whereupon CureVac and GSK jointly decided to terminate the agreement. For more detailed information we refer to Note 21. In total, inventory in the amount of EUR 47,129k was written - off as of year-end including write-off of materials received as part of Gen1 commitments. The residual amount was consumed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expense recognized related to the write-offs, scraps and consumption are mainly included in &#8216;Cost of Sales&#8217;. In the year 2022 EUR 80,021k were written off.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650414384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Other financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherFinancialAssetsExplanatory', window );">Other financial assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">7. Other financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Other financial assets as of December 31, 2023 amounted to EUR 2,661k (2022: EUR 4,487k) mainly include deposits held by third parties in amount of EUR 1,936k (2022: EUR 1,936k) and other receivables in the amount of EUR 726k (2022: EUR 2,551k).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfOtherFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfOtherFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589620824720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory', window );">Prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Prepaid expenses and other current assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets of EUR 23,763k (2022: EUR 40,002k) include prepayments for future service agreements and material in the amount of EUR 1,075k (2022: EUR 4,507k), deferred charges of EUR 5,463k (2022: EUR 5,345k) and receivables of EUR 4,344k (2022: EUR 5,595k). For more details, refer to Note 3.8. As of December 31, 2023, we had tax receivables, mainly VAT refund claims, of EUR 12,881k in other current assets (2022: EUR 24,555k).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622992160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">9. Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">According to the Company&#8217;s articles of association, the Company&#8217;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a nominal value of EUR 0.12. As of December 31, 2023, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#8217; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#8217;s articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding in fiscal 2023 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2020</b></p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 180,460,565</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Follow-on public offering, incl. Greenshoe </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,750,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">910,163</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the at-the-market offering program </p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,908,493</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued to former shareholders of Frame Pharmaceuticals</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 858,496</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued for LTIP option exercises and RSU deliveries </p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,374</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2022 </b></p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 194,997,091</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the at-the-market offering program</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,218</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the public offering</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,027,028</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued for LTIP option exercises and RSU releases</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,338</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 223,988,675</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Refer to Note 21 for additional information on share transactions occurring after December 31, 2023. The share transactions which occurred in 2021, 2022 and 2023 are as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Follow-on public offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Company completed a follow-on public offering whereby it sold 5,000,000 common shares at a price of USD 90.00 per share. In addition, the underwriters exercised their option to purchase an additional 750,000 common shares at this same price less the underwriting discount. The aggregate proceeds, net of underwriting discounts, received by the Company from these transactions were EUR 426,652k. Offering costs for legal, accounting, printing and registration fees of EUR 22,590k were recognized as reduction to capital reserve against the proceeds from the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">At-the-market offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 17, 2021, CureVac filed a prospectus for an &#8220;at-the-market&#8221; (ATM) offering program to raise additional cash of up to USD 600 million. The program was activated in June 2022. Through December 31, 2022, CureVac has issued 6,908,493 shares and raised gross proceeds of USD 69,139k. In the first quarter of 2023, 1,748,218 shares were issued under the ATM program, raising USD 18,023k million in gross proceeds. Offering costs for legal, accounting, printing and registration fees were recognized as reduction to capital reserve against the proceeds from the offering. Following these issuances, the remaining value authorized for sale under the at - the - market program amounts to USD 513 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Follow-on public offering 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2023, the Company completed a follow - on public offering whereby it sold 27,027,028 common shares at a price of USD 9.25 per share. The aggregate proceeds, net of underwriting discounts, received by the Company from these transactions were EUR 219,832k. Offering costs for legal, accounting, printing and registration fees of EUR 14,580k were recognized as reduction to capital reserve against the proceeds from the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Frame Pharmaceuticals acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2022, CureVac entered into a Share Purchase Agreement (SPA) to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., a research company focused on advanced genomics and bioinformatics, based in Amsterdam, Netherlands. Under the SPA, the total consideration for the the purchase was up to EUR 34 million, conditioned on the meeting of certain development milestone payments. On the date of acquisition, July 1, 2022, CureVac issued 858,496 shares to the former shareholders of Frame Pharmaceuticals. Refer to Note 20 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercises of share options under the prior VSOP plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IPO in August 2020 triggered an exercise event under the set terms of the prior VSOP plan (see Note 10). In March 2021, CureVac received 759,677 shares from the old shareholders and transferred 390,023 shares to the participants of the old VSOP plan. CureVac withheld 369,654 shares equaling the amount to be paid for income tax and social security tax. A second triggering event, &#8220;liquidity after IPO&#8221; was met one year after IPO. In October 2021, CureVac received 765,223 shares from the old shareholders and transferred 523,897 shares to the participants of the VSOP plan. CureVac withheld 241,326 shares equaling the amount to be paid for income tax and social security tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third triggering event, again &#8220;liquidity after IPO&#8221;, was met on the second anniversary of the IPO. In December 2022, CureVac received 777,260 shares from the old shareholders. All shares were transferred to the participants of the prior VSOP plan and the portion of shares equaling the amount to be paid for income tax and social security tax were sold to pay for these taxes and social security amounts. In 2022, CureVac recorded a receivable for income tax and social security tax for former employees and received these amounts in Q1 2023. A fourth triggering event, again &#8220;liquidity after IPO&#8221;, was met on the third anniversary of the IPO. CureVac will receive 786,746 shares from the old shareholders and will transfer these to the participants of the old VSOP plan in March 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercises of share options under the new VSOP plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Participants of the new VSOP plan (see Note 10) were able to continue to exercise their options throughout the year of 2023. In 2023 69,246 shares (2022: 147,620 shares) were issued upon exercise of options and no options were forfeited (2022: 96,785).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622719104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2023, 2022, and 2021, the Group operated the following share-based plans for members of management and other key employees of the Group, as well as members of the supervisory board:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prior VSOP</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New VSOP &#8201;&#8212;&#8201;for US employees (from 2019 onwards)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">LTIP Stock Options </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">LTIP RSUs (from 2021 onwards)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">All programs were accounted for as equity-settled share-based payment awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Measurement of the grant date fair value is based on valuation techniques appropriate in the circumstances, such as Black Scholes option pricing models or a Monte Carlo simulation. Expected volatility, a key input to such models, was based on an evaluation of the historical volatilities of comparable listed biotech-companies over the historical period commensurate with the expected option life. Regarding the expected option life of the stock option programs, this was based on the assumptions that the beneficiary would exercise his option in equal installments from the date of the first time possible (taking into account lock-up and potential trading windows restrictions) until maturity. The risk-free interest was derived from German or US-Government bonds, as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expense recognized for share-based payments during the years ended December 31 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (624)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (572)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LTIP Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,472)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,944)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LTIP RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,072)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU Supervisory board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (566)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (478)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (652)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (14,939)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (9,184)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,697)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Prior VSOP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The development of the virtual shares in the Prior VSOP program granted to management and key employees was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the beginning of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,951,265</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,426,365</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,614,246</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34,859)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,091)</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised during the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,524,900)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (777,260)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,426,365</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,614,246</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,603,155</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,365,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,509,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,588,513</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">none</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">none</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">none</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IPO on August 14, 2020, triggered the right to exercise 10 % of the vested virtual shares at the end of the lock-up period, which ended on February 10, 2021. By March 10, 2021, the beneficiaries declared the exercise of all their exercisable 759,677 virtual shares and CureVac received 759,677 shares from their former major shareholders as of 2015, on that day. On March 11, 2021, CureVac transferred 390,023 shares to the exercising beneficiaries and withheld 369,654 (treasury) shares equal to the monetary value (approximately EUR 26 million) of the beneficiaries (wage) tax and social security obligations, which CureVac transferred to the relevant authorities on the exercising employee&#8217;s behalf in cash. The share price of CureVac on March 11, 2021, was EUR 69.69.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A second 10 % portion of the (vested) virtual shares became exercisable on the first anniversary after IPO i. e., on August 14, 2021, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were reached. The beneficiaries declared the exercise of their exercisable 765,223 virtual shares by October 18, 2021 and CureVac received 765,223 shares from the old shareholders on that day. On October 19, 2021, CureVac transferred 523,897 shares to the exercising beneficiaries and withheld 241,326 (treasury) shares equal to the monetary value (approximately EUR 8 million) of the beneficiaries (wage) tax and social security obligations, which CureVac transferred to the relevant authorities on the exercising employee&#180;s behalf in cash. The share price of CureVac on October 19, 2021, was EUR 34.56.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third 10 % portion of the (vested) virtual shares became exercisable on the second anniversary after IPO i. e., on August 14, 2022, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were again reached. The beneficiaries declared the exercise of their then exercisable 777,260 virtual shares by December 12, 2022 and CureVac received 777,260 shares from the old shareholders on that day. On December 14, 2022, CureVac transferred 777,260 shares to the exercising beneficiaries. The portion of shares equaling the amount to be paid for (wage) tax and social security obligations were sold to pay for these amounts. For former employees CureVac shows a receivable position equaling the amount to be paid for (wage) tax and social security obligations. The share price of CureVac on December 14, 2022, was EUR 6.96.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A fourth 10% portion of the (vested) virtual shares became exercisable on the third anniversary after IPO i. e., on August 14, 2023, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were again reached. The beneficiaries declared the exercise of their then exercisable 786,746 virtual shares by March 22, 2024 and CureVac received 786,746 shares from the old shareholders on that day. On March 26, 2024, CureVac transferred 786,746 shares to the exercising beneficiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Expense recognized in the statement of operations and other comprehensive income (loss)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The expense recognized for this share-based payment plan during the years ended December 31 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of Sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (624)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (131)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (10)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New VSOP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The number of awards in the New VSOP program granted to key employees developed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the beginning of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 349,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,108</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (99,696)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised during the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557,171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147,620)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69,246)</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 349,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,862</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,862</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof exercisable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The remaining life of the option awards as of December 31, 2023 is between 4.5 and 5.7 years (2022: range between 5.5 and 6.9 years).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021 multiple exercises happened throughout the year. In total 557,171 options were exercised with an average share price of USD 61.28. These exercises led to CureVac having to pay an amount of USD 493k employer taxes and to use USD 981k of the provision recorded in 2020.In 2022, a number of exercises were carried out throughout the year. In total, 147,620 options were exercised with an average share price of USD 16.81. These exercises led to CureVac having to pay an amount of USD 45k employer taxes and to use USD 51k of the provision recorded in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2023, a number of exercises were carried out throughout the year. In total, 69,246 options were exercised with an average share price of USD 9.90.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Expense recognized in the statement of operations and other comprehensive income (loss)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The expense recognized for employee services received during the years ended December 31, 2023, 2022, and 2021 is shown in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (349)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31)</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (188)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (572)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Term Incentive Plan (LTIP) - Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, CureVac granted 266,155 options to the former Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the company`s former Chief Business Officer (CBO) / Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan put in place by CureVac.Options will be settled in shares of CureVac.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the former CSO have an exercise price of EUR 10.04 per share option and an expiration date of July 14, 2030. The exercise price was based on value of the shares at entry date of the former CSO. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter . Exercise is contingent upon the stock price increasing by +20% from the grant date to the date of exercise, based on the 10-day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the former CSO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 57.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 50.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 11.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 10.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.07 - 1.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, 6,303 options granted to the former CSO had been exercised. No options granted to the former CSO had been exercised in 2023. As the former CSO left the Group as of July 14, 2023, all remaining unvested awards were subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the former CBO / CCO have been granted in 3 tranches vesting over <span style="-sec-ix-hidden:Hidden_QbGLvVS5SkqjgHf0Brd8Fg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span> to 3 years, with exercise prices applicable to future tranches being estimated. The exercise price of the first tranche is EUR 43.87 (USD 52.96), The exercise prices for future installments, 2021 and 2022, were estimated to be EUR 81.48 (USD 98.36) and EUR 81.65 (USD 98.57). For the second tranche the actual exercise price in fiscal year 2021 was determined to be EUR 33.07 (USD 39.92) and of the third tranche the actual exercise price in fiscal year 2022 was determined to be EUR 7.35 (USD 7.68). The tranches each have a term of 10 years. Exercise of all three tranches is contingent on a share price increase of 10 %, based on a <span style="-sec-ix-hidden:Hidden__sfsWKiKEkycy4zRfN1NDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span> - day VWAP at the time of each exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the former CBO/CCO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">First tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 48.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (actual 10-days VWAP before grant date, USD 81.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 67.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 52.96)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 43.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.07 - 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">Second tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 24.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (estimated by Monte Carlo simulation to be USD 98.36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (estimated by Monte Carlo simulation to be USD 98.36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.07 - 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">Third tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 20.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (estimated by Monte Carlo simulation to be USD 98.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (estimated by Monte Carlo simulation to be USD 98.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.07 - 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As the former CBO/CCO left the Company as of November 30, 2023, all remaining unvested awards were subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2021, CureVac granted 2,000 options to a key employee. Options granted to this key employee have an exercise price of EUR 77.73 (USD 88.16) per share option and an expiration date of February 28, 2031. The exercise price was based on the 30 - day volume - weighted average price (VWAP) of March 1 &#8211; March 31, 2021 of the shares. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +10%, based on the 10 - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (30-days VWAP after grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 77.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 88.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 77.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.08 - 0.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the former Chief Development Officer (CDO). Both grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the COO have an exercise price of EUR 70.92 (USD 84.03) per share option and an expiration date of July 2, 2026. The exercise price was based on the 20 - day VWAP of the shares at entry date of the COO. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the <span style="-sec-ix-hidden:Hidden_YzcivET66UycOOg4x0ArdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span> - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the COO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 17.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (20-day VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 56.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 84.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 70.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.099 &#8201;&#8211;&#8201; 0.903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted to the former CDO have an exercise price: EUR 46.16 (USD 54.79) per share option and an expiration date: August 2,2026. The exercise price was based on the 20 - days VWAP of the shares at entry date of the former CDO. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the 10 - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the former CDO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 17.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (20-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 41.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 84.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 46.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.075 &#8201;&#8211; &#8201;0.704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The former CDO has since left the company and, under the terms of his LTIP agreement, his options had expired as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 1, 2022, CureVac granted 9,500 options to a key employee. Options granted to this key employee have an exercise price of EUR 30.67 (USD 33.87) per share option and an expiration date of December 31, 2031. The exercise price was based on the 30 - day VWAP of January 1 &#8211; January 31, 2022 of the shares. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the 10 - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 14.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (30-days VWAP after grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 30.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 34.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 30.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.40 - 1.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The key employee has left the company and, under the terms of his LTIP agreement, his unvested options have been forfeited as of January 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted 130,000 supplemental options to the Company&#8217;s management board. 30,000 options were granted to the former CEO, and 25,000 <span style="-sec-ix-hidden:Hidden_tznxVCWtS0SW9reUKePQUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">options</span></span> <span style="-sec-ix-hidden:Hidden_-FWGuI_NEUqdXYeZrX373g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">were</span></span> <span style="-sec-ix-hidden:Hidden_hL-cJYxbn0-tJ6X_juFSYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">granted</span></span> to each of the CFO, former CSO, COO and former CBO/CCO. All grants were made at no cost under the terms of a new long-term incentive plan put in place by CureVac. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options granted to the management board have an exercise price of USD 19.35 per share option and an expiration date of March 1, 2032. The exercise price was based on the 10day VWAP as of March 1, 2022 + a performance criteria of 15%. The award has a vesting of 25% on each of Dec 31, 2022, Dec 31, 2023, Dec 31, 2024, Dec 31, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grants to the management board, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 4.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10 - day VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 15.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 19.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 18.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">73.87 - 86.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.34 - 3.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As the former CEO, former CSO and former CBO/CCO left the Group, in 2023, all of their remaining unvested awards were subject to accelerated vesting. As of December 31, 2023 none of these options had been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2022, CureVac granted 700 options to a key employee. Options granted to this key employee have an exercise price of EUR 17.45 (USD 19.28) per share option and an expiration date of March 31, 2032. The exercise price was based on the 10 - day VWAP of March 21 &#8211; March 31, 2022 of the shares. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the 10 - day VWAP at time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 6.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 19.28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On April 1, 2023, CureVac granted 144,379 options to the current CEO. All grants were made under the terms of the new long - term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of December 31, 2023, none of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the grant to the CEO, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Weighted average fair value per option</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';">3.55</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Weighted average share price (10-day VWAP before grant date)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';">6.12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Exercise price (USD </span><span style="font-family:'timesew Roman';">6.66</span><span style="font-family:'timesew Roman';">)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';">6.12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Expected volatility (%)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> 75.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Expected life (years)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> 3.39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Risk-free interest rate (%)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> 3.70</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expense recognized for employee services received under the LTIP &#8211; options during the year ended December 31, 2023, in an amount of EUR 2,944k (2022:EUR 5,564k) is mainly included in general and administration expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units (RSUs)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 24, 2021, the group awarded 10,956 RSUs to supervisory board members and on December 23, 2021, the group awarded 63,095 RSUs to the executive board and various key employees. These RSU awards vest over 3 years with <span style="-sec-ix-hidden:Hidden_XU_t8pnL4UiX_Hi9qILQtw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> vesting taking place each year on December 31. All RSU awards from 2021 had vested as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, on July 1, 2021, the group also awarded 4,691 special RSU awards. These special RSU awards vest over 12 months and are fully vested as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, as part of the LTIP program, the group awarded RSUs (RSU Award 2022) to senior executives as well as supervisory board members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022 the group awarded 225,888 RSU awards as part of the &#8220;LTIP - RSU Award 2022&#8221; to members of the supervisory board, executive board and various key employees. On November 30, 2022, the group awarded a further 7,633 RSU awards to key employees who joined the company during fiscal 2022. These RSU awards vest with one third vesting taking place each year on December 31, 2022, December 31, 2023 and December 31, 2024. <span style="-sec-ix-hidden:Hidden_QYgdAo6NHkmI49zrX7zMAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One third</span></span> of these RSU awards had vested as of December 31, 2022, one further third as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, on January 1, 2022, the group awarded 36,000 supplemental RSU awards to the former CEO. This RSU award vests over 12 months and is fully vested as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 31, 2022, the group also awarded 5,000 supplemental RSU awards to the COO and 30,000 supplemental RSU awards to the former CBO/CCO. These RSU awards vest in 2 tranches (50% on December 31 2022 and 50% on December 31, 2023). In order for the RSUs to settle and be delivered, the share price must reach 19.16 USD on or after vesting. As of December 31, 2023, all of these RSUs had vested but had not been settled or delivered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2022, the group awarded 89,655 RSU awards to former Frame employees to replace existing share-based payment awards of Frame Pharmaceuticals. These RSU awards vest with one third vesting taking place each year on June 30, 2023, June 30, 2024 and June 30, 2025. The RSU program is accounted for by recognizing the related expense over the vesting period of the award, with corresponding increases recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Group awarded 92,701 RSUs to the Supervisory Board members and 646,914 RSUs to the Executive Board and various key employees. On December 15, 2023, the group awarded a further 32,783 RSU awards to Supervisory Board members and key employees who joined the company during fiscal 2023. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified. <span style="-sec-ix-hidden:Hidden_11RqQzGybUSMAflcteDxJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One third</span></span> of these RSU awards had vested as of December 31, 2023. The RSU expense related to Supervisory Board members recognized during the year ended December 31, 2023, in an amount of EUR 652k (2022: EUR 478k) is included in other operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2023 the group also awarded 25,000 supplemental RSU awards to the COO. This RSU award vests with one third vesting taking place each year on December 31, 2023, December 31, 2024 and December 31, 2025. <span style="-sec-ix-hidden:Hidden_lI9qMg_ZoEa59Vg_AMB8SQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One third</span></span> of these RSU awards had vested as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the former CEO, former CSO and former CBO/CCO left the Group in 2023, all of their remaining unvested awards were subject to accelerated vesting. As a Supervisory Board member left the Group as of June 19, 2023, all remaining unvested awards were subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenses for employer taxes arising upon the delivery of RSUs are recognized in profit or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of Sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (331)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (240)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (909)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,719)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (269)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (383)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,753)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (705)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,108)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,072)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649933552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11. Trade and other payables</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Trade payables and other payables are all due within one year and include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,365</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Miscellaneous liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 73,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 48,033</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade and other payables are all due within one year. The prior year was highly impacted by received invoices of raw material suppliers before December 31, 2022. Thus, during the year ended December 31, 2023, Trade and other payables decreased by EUR 25,430k. Miscellaneous liabilities consist mainly of payroll-related taxes and social security liabilities of EUR 1,496k (2022: EUR 5,027k).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649898720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities and provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesAndProvisionsAbstract', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesAndProvisionsTextBlock', window );">Other liabilities and provisions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12. Other liabilities and provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract termination provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions (non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 61,320</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for onerous contracts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184</p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract termination provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,216</p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions (current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,922</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 37,400</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Provisions (current &amp; non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 63,242</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 37,400</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below are movements during the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 63,242</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 980</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">used (amounts charged against the provision)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,174)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">unused amounts reversed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,648)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,400</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,400</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for onerous contracts relates to CRO agreements and are expected to be settled within one year from December 31, 2023. All amounts recognized as of December 31, 2022 arose during 2021. During the year ended December 31, 2023, EUR 184k additional provisions were made, EUR 1,174k were utilized and EUR 748k were reversed. As described in Note 2, when initially measuring onerous contract provisions relating to CRO agreements, judgment was required in estimating the cost of the remaining services, particularly in estimating the number of participants completing the clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Contract termination provisions relate to amounts which the Company expects to pay out to settle its obligations under certain CMO contracts which it has terminated. All amounts recognized as of December 31, 2023 arose during 2021 and 2022 except for EUR 646k in additional provisions made in 2023 and EUR 18,000k reversed during the year. As described in Note 2, judgment is required in estimating these amounts. The amount of the outflow of resources to settle the obligations to which these provisions relate may vary from the provision amount recognized as of December 31, 2023 due to potential variability in the amount required to be paid to ultimately release the company from its remaining obligations under the CMO contracts, including as a result of arbitration decisions. In its final award rendered, the arbitration tribunal followed CureVac&#8217;s arguments and dismissed Rentschler&#8217;s claims in their entirety. The totality of Rentschler Biopharma SE related provision of EUR 6,900k was reversed as of December 31, 2023. Contract terminations provisions were reclassed from Provisions (non-current) into Provisions (current) due to an expected settlement within one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other liabilities include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other liabilities (non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel accrued liabilities (e.g. bonus, vacation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,543</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grants from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,735</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding invoices</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,081</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,116</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other liabilities (current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 40,491</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 50,717</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total other liabilities (current &amp; non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 40,510</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 50,717</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilitiesAndProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilitiesAndProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilitiesAndProvisionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other liabilities and provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilitiesAndProvisionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649878272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13. Income tax</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2023, the Group recorded a consolidated income tax expense of EUR 198k, in fiscal 2022 and 2021, the Group recorded a consolidated income tax benefit of EUR 126k and EUR 782k, respectively. The income tax expense in fiscal 2023 results from current income tax expenses (2022 income and 2021 expenses) of EUR 118k (2022: EUR 106k and 2021: EUR 1,033k) and deferred tax expenses (2022 income and 2021 income) of EUR 80k (2022: EUR 20k and 2021: EUR 1,815k), thereof from taxable temporary differences EUR 3,225k (2022: EUR 1,090k and 2021: EUR (1,540)k). In fiscal 2023, the Group further recorded deferred tax liabilities of EUR 0k (2022: EUR 20k and 2021: EUR 0k). In fiscal 2023 and 2022 an amount of EUR (2,094)k was accounted in equity. The basis for outside basis differences is EUR 168k (2022: EUR 1,120k and 2021: EUR 3,713k), which create a taxable outside base difference of EUR 8k (2022: EUR 56k and 2021: EUR 186k), which are indefinitely reinvested and associated with investments in subsidiaries, deferred tax liabilities have not been recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A reconciliation between actual income taxes and the expected tax benefit from the loss before tax multiplied by the Group&#8217;s applicable tax rate of 29.48% (15.0% corporate income tax, 0.825% solidary surcharge and 13.65% trade tax) is presented below for the years ended December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (412,498)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (249,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (259,969)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected tax benefit (based on statutory tax rate of 29.48% in 2023, 2022 and 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,626</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Recognition of tax loss carryforwards recognized in prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effects from differences between Group and local tax rates </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-recognition of tax loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (114,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (81,392)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-recognition of deferred tax assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,363)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Recognition of deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,717</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-deductible expenses for tax purposes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (706)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additions for local trade taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other effects</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,826)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,599</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Effective tax benefit / (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 782</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 126</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (198)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Deferred tax assets and deferred tax liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;01,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Recognized&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquired&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit&#160;and&#160;loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business&#160;combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTL</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,224)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,439)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,439)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,364)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,052)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,052)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non - current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Non-current )</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (118)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (67)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (152)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (142)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (137)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,498)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,490)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,490</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Taxes Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (84)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,194</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,777</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (6,583)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 01,2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Recognized in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquired in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit and loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTL</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,769)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,808)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (663)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,701)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,364)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,364)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (181)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,014)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non - current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (129)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (205)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (276)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,466)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Taxes Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,861</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,590)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (19)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,969</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (6,691)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Deferred Tax Assets for CureVac Corporate Services, which incurred a tax loss in the current or prior year, are recognized in the amount of EUR 1,172k as the company is expected to generate taxable profits due to its support function remuneration in the group (IAS 12.82).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following unused tax losses for which no deferred tax asset is recognized in the statement of financial position had been carried forward as of the end of the reporting periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Tax loss carryforwards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused tax losses for corporate income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,180,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,427,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,700,475</p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused tax losses for trade tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,175,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,419,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,685,517</p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused interest carryforward ("Zinsschranke")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac has tax losses in Germany and Netherlands that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose. In Germany and Netherlands tax losses carryforwards are unlimited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">DTA&#8217;s for temporary differences in the amount of EUR 20.9 million (2022: EUR 21.8 million) are not capitalized at year end 2023 because they are not recoverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pillar Two legislation has been enacted or substantively enacted in certain jurisdictions in which the Group operates. However, this legislation does not apply to the Group as its consolidated revenue is lower than EUR 750 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Current tax assets of EUR 5,201k (2022: 285k) consists of withholding tax receivables.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622764224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. Earnings per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated by dividing the consolidated net loss of CureVac by the weighted average number of shares outstanding in the fiscal period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted average number of shares outstanding in fiscal 2021, 2022 and 2023 was 186,012,586, 189,074,911 and 220,833,271, respectively. This has led to basic loss per share of EUR 2.21, EUR 1.32 and EUR 1.18 for fiscal 2021, 2022 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Diluted earnings per share is calculated using CureVac&#8217;s weighted-average outstanding common shares including the dilutive effect of share-based payment awards as determined under the treasury stock method. In periods when CureVac has a net loss, share-based payment awards are excluded from the calculation of earnings per share as their inclusion would have an antidilutive effect. Share options and RSUs of 1.217.526 and 1,788,206 as of December 31,2022 and 2023 respectively, were excluded from the computation of diluted weighted average number of shares because their effect would have been antidilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622547488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure of financial instruments and management of financial risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Disclosure of financial instruments and management of financial risks</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. Disclosure of financial instruments and management of financial risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is exposed to certain financial risks with respect to its assets and liabilities and the transactions associated with its business model. These risks generally relate to credit risks, liquidity risks and market risks (including currency risk, interest rate risk and price risk).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aim of risk management is to limit the potential negative impact on expected cash flows and take advantage of any opportunities that arise. As a result, the management of CureVac assesses at least once a year whether risks have changed and whether the measures in place to limit risk are still sufficient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Finance Income / Finance Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, finance income was EUR 16,731k (2022: EUR 4,009k, 2021: EUR 10,103k) and related mainly to interest income on cash investments EUR 15,411k (2022: EUR 1,733k, 2021: EUR 81k) and foreign exchange gains EUR 1,062k (2022: EUR 2,188k, 2021: EUR 10,092k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, finance expenses were EUR 2,493k (2022: EUR 3,707k, 2021: EUR 10,338k) and related mainly to foreign exchange losses EUR 2,272k (2022: EUR 1,319k, 2021: EUR 3,939k) and negative interest on cash of EUR 0k (2022: EUR 2,299k, 2021: EUR 6,793k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk is managed by CureVac&#8217;s finance department. Credit risk arises from cash and cash equivalents and other financial assets, including deposits with banks and financial institutions, as well as credit exposures to customers, including outstanding receivables and contract assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is exposed to bank default and concentration risk as its cash is concentrated at few financial institutions. Management distributed the cash to decrease concentration risk as of December 31, 2023, deciding to allocate 12% of the cash at one of Europe&#8217;s largest private bank, 7% at Germany&#8217;s largest private bank and 71% at a major German Landesbank; the remaining cash balance is maintained at other banks. The focused cash management structure with few banks allows enhanced bank risk supervision. The market capitalization of all banks mentioned above is regularly reviewed. Credit risk is further limited by investing only in liquid instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is also exposed to a credit risk for its receivables and contract assets. The risk of default is considered to be low because the structure of customers consists of reputable collaborating parties and government grantors. Receivables management and financial accounting incorporates monitoring of payments received and any overdue receivables. The risk of counterparty nonperformance is not material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amount of other financial assets recognized determines the maximum theoretical credit risk. As of the end of fiscal 2023, available funds are deposited at three reputable financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the loss allowance for the &#8220;expected credit losses&#8221; totaled to EUR 71k (2022: EUR 99k, 2021: EUR 105k), resulting in an effect recognized in fiscal 2023 in finance income EUR 248k (2022: EUR 57k, 2021: EUR 149k) and finance expense EUR 220k (2022: EUR 51k, 2021: EUR 71k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity risk</span> <span style="font-style:italic;font-weight:bold;">/ Capital management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of CureVac&#8217;s capital management, capital includes share capital and all other equity reserves attributable to the equity holders. The primary objective of CureVac&#8217;s capital management is to maximize the shareholder value through investment in the development activities of the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its business as an active research group, CureVac has historically relied almost exclusively on equity funding by its shareholders and lenders as a means of financing itself prior to successful development and sales of a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s finance department reviews the total amount of cash of the Group on a weekly basis. As part of this review, the finance department considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In meeting its financing objectives, the Group negotiates and enters into research cooperation agreements. In general, the aim is to maximize the financial resources available for further research and development projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac is not subject to externally imposed capital requirements. However, certain grant funds received may be required to be returned if qualifying costs are not incurred or are not incurred in accordance with the grant terms (see also Note 3.7. and Note 3.8.). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in Note 9, the Group has an at-the-market offering program through which, from time to time, may be able to raise additional capital through the issuance of common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No changes were made in the objectives, policies or processes for managing cash during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to safeguard liquidity, the Group invests funds not required immediately for operating purposes in call-deposit accounts with original maturities up to three months. Liquidity risks are therefore expected to be low. The Group does not enter into trading of financial instruments and monitors its risk of a shortage of funds using a liquidity planning tool.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, CureVac has relied on financing from shareholders, grant income and collaborators in order to ensure sufficient liquidity. Lack of external financial support could pose a risk of going concern. The liquidity management of CureVac ensures the availability of cash and cash equivalents for operational activities and further investments through appropriate budget planning.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ultimately, the responsibility for liquidity risk management lies with management, who has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. CureVac manages liquidity risks by holding appropriate reserves, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the maturity profile of the Group&#8217;s liabilities based on contractual undiscounted payments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt;1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual commitments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,269)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Note 4.2) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,656)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities and provisions (Note 12) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,117)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,117)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables (Note 11) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,033)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,033)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (146,673)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (23,581)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,821)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (193,075)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt; 1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;5years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,923)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,377)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (74,300)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Note 4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,247)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,693)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (54,723)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities and provisions (Note 12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41,447)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (103,753)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (73,463)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (73,463)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (172,080)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (112,356)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (21,803)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (306,239)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign currency risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. CureVac&#8217;s exposure to the risk of changes in foreign exchange rates relates primarily to the Group&#8217;s operating activities (when revenue or expense is denominated in a foreign currency) and the amounts held as cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For all CureVac entities except of CureVac Inc. and CureVac Swiss AG the functional currency is EUR. The functional currency of CureVac Inc. is the USD and of CureVac Swiss AG the CHF. CureVac SE&#8217;s exposure in foreign currency at the end of 2023 and 2022 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b>&#160;<b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">57,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">63,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total monetary assets in foreign currency </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">GBP</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total monetary liabilities in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b>&#160;<b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total monetary assets in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,566</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 113,664</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GBP</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total monetary liabilities in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,332</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the tables above, CureVac N.V. is exposed to a currency risk only in relation to the USD. Therefore, a foreign currency sensitivity analysis is only presented in respect to the net exposure in USD at fiscal year ends. CureVac&#8217;s net exposure in USD is the difference between monetary assets in USD and monetary liabilities in USD and developed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net exposure in USD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2022 (1 EUR= 1.0666 USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (1 EUR = 1.1050 USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">EUR </b><b style="font-weight:bold;">77,649</b><b style="font-weight:bold;">k from USD </b><b style="font-weight:bold;">82,822</b><b style="font-weight:bold;">k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR </b><b style="font-weight:bold;">72,015</b><b style="font-weight:bold;">k from USD </b><b style="font-weight:bold;">79,576</b><b style="font-weight:bold;">k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2023, if the EUR had weakened and conversely, had strengthened, 10 per cent against the US dollar, with all other variables held constant, pre-tax loss and post-tax loss would have been affected as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effect&#160;on&#160;pre-tax&#160;profit&#160;or&#160;loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effect&#160;on&#160;post-tax&#160;profit&#160;or&#160;loss</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strengthening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weakening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strengthening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weakening</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">31.12.2023 EUR against USD </b><b style="font-weight:bold;">10</b><b style="font-weight:bold;">% movement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,547</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (8,002)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,617</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5,644)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">31.12.2022 EUR against USD 10% movement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,628)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,085)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac did not have derivatives in 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest rate risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. CureVac&#8217;s exposure to the risk of changes in market interest rates relates primarily to CureVac&#8217;s cash and cash equivalents with floating interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If interest rates as of December 31, 2023 had been 1% higher while all other variables had remained the same, the net loss for the year (before and after tax) would have been EUR 4,025k (2022: EUR 4,959k) lower because the higher interest income would have been generated from floating rates on invested cash and cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair value measurement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized with the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Inputs use quoted prices in active markets for identical assets or liabilities</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs are inputs, other than quoted prices included in Level&#160;1, which are directly or indirectly observable</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs for the asset or liability that are not based on observable market data (unobservable inputs)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All financial instruments are measured at amortized cost at December 31, 2023 and December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The group measures assets held for sale at fair value less cost of disposals. For all short term liabilities and receivables the book value approximates the fair value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650892128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated statements of cash flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Notes to the consolidated statements of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Notes to the consolidated statements of cash flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16. Notes to the consolidated statements of cash flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in liabilities arising from financing activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;1,</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accrued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">in thousands of EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reclassification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Disposals</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Changes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Movements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Payment of lease liabilities (Note 4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,568)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,998)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,824</p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,568)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,998)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,986</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,375</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (57)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,824</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accrued</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">Exchange</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">in thousands of EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reclassification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Disposals</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Changes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Movements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Payment of lease liabilities (Note 4. 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,439)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,086</p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities from financing</b> <b style="font-weight:bold;">activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,892</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (6,439)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,241</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,218</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 174</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622500336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfCommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17. Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">No material contingent liabilities resulting from claims and legal proceedings exist as of December 31, 2023. Refer to Note 12 for provisions recognized for contract terminations. For contractual commitments, refer to Note 15.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfCommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfCommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589623314608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of the Company's key management personnel<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfKeyManagementPersonnelAbstract', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Remuneration of the Company's key management personnel</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18. Remuneration of the Company&#8217;s key management personnel</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Total remuneration of key management personnel</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Remuneration of the Company&#8217;s key management personnel was as follows :</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Remuneration of key management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 674</p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Termination benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 652</p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">15,771</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,212</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">9,756</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,147</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,928</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,326</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Out of the total remuneration, for Management Board EUR 1,551k (2022: EUR 852k, 2021: EUR 1,323k) and for the Supervisory Board EUR 158k (2022: EUR 0k, 2021: EUR 0k) are outstanding, as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In 2023, 105,260 RSUs were granted to the Supervisory Board and 207,481 RSUs and 144,379 options were granted to the Executive Board. During the year, 21,413 RSUs were transferred to the Supervisory Board and 139,027 RSUs were transferred to the Executive Board. No options were exercised from the Key Management Personnel. For more detailed information we refer to Note 10.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650325584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party disclosures</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">19. Related party disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parent and ultimate controlling party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As disclosed in Note 1, during fiscal 2023, dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, was the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between approximately 37-43 % during that period. dievini is thus the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer of shares from the former major shareholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 10, due to certain virtual share exercises under the Prior VSOP during the year 2023: 0 (2022:777,260) common shares were transferred to the Company by the former major shareholders, with no consideration paid in exchange, and all of these shares were subsequently transferred to fulfill obligations from option exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the majority shareholder of the Group, granted two convertible loans to the Group which were terminated in July 2020 and fully repaid in August 2020. Additionally, in 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Groups largest shareholder, purchased EUR 100,000k of the Group&#8217;s common shares at the price of USD 16 per share. In 2023 a total of EUR 1k (2022: EUR 58k) was paid to dievini Hopp BioTech Holding GmbH &amp; Co. KG as a reimbursement of travel cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immatics Biotechnologies GmbH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, a purchase agreement between CureVac Manufacturing GmbH and Immatics Biotechnologies GmbH was entered into. CureVac purchased technical equipment of containers which CureVac will use as a facility in the future. dievini held 16.7% of the shares in Immatics N.V. (Immatics) as of December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup>, 2023 per the Form 20-F of Immatics filed in March 2024. CureVac paid EUR 178k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key management personnel compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Referring to key management personnel compensation we refer to Note 18.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key management personnel transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Franz-Werner Haas</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was executed. In 2023 CureVac paid EUR 65k under this agreement. The payment was partially compensated by Franz-Werner Haas taking over his former company car for EUR 40k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alexander Zehnder</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR 51k during the month of March.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac, Antony also took over the role as Management Director at CureVac Belgium SA. He executed this function by using Clarentis SRL. As it relates to these services in 2023, CureVac paid EUR 85k in 2023 (2022: EUR 69k, 2021: EUR 0k). The amounts invoiced for this function/services are offset/deducted from his base compensation for his function on the Board of Management of CureVac. As Antony Blanc has left the company as of November 30, 2023, CureVac and Antony Blanc signed a settlement agreement as of September 26, 2023. Under this agreement CureVac incurred cost of EUR 107k for Clarentis SRL entity in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr. Ingmar H&#246;rr</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 573k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Florian von der M&#252;lbe</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 559k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consulting agreements between CureVac Printer GmbH and Florian von der M&#252;lbe related to the years 2022 to 2024 have been executed. In 2023 CureVac paid EUR 146k under such agreement related to 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mariola Fotin-Mleczek</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, a consulting agreement between CureVac and Mariola Fotin-Mleczek was made. In 2023 a total amount of EUR 2k (2022: EUR 20k) was paid. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 131k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barker BioMedical GmbH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was executed. Barker BioMedical GmBH is a wholly owned consulting company of Debra Barker, Supervisory Board member of CureVac. In 2023 CureVac paid EUR 14k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Craig Tooman</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Craig Tooman was executed. In 2023, CureVac paid EUR 5k under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ralf Clemens</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Q3 2023, a consulting agreement between CureVac and GRID EUROPE was executed. GRID EUROPE is a wholly owned consulting company of Ralf Clemens, who was a member of the supervisory board up to September 30, 2023. CureVac incurred EUR 23k under this agreement in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Indemnification Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s articles of association require it to indemnify its current and former managing directors and supervisory directors in relation to acts or omissions in the performance of their duties to the fullest extent permitted by law, subject to certain exceptions. We entered into indemnification agreements with all our managing directors and supervisory directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other related party transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Rittershaus Rechtsanwaelte</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since December 15, 2005, a consultant agreement is in place for an indefinite term with Rittershaus. The agreement can be terminated without notice by CureVac and with notice of three months to the end of the quarter by Rittershaus. In fiscal 2023, consulting fees of EUR 212k (2022: EUR 518k, 2021: EUR 757k) were paid to the Rittershaus. Additionally, EUR 16k were owed for services rendered in 2023 and paid in 2024. Prof. Dr. Christof Hettich is managing director of Rittershaus and was managing director at dievini until June 2022 as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2020, CureVac Manufacturing GmbH (formerly CureVac Real Estate GmbH) and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#8217;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Manufacturing GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Manufacturing GmbH terminated the commercial and supply agreement with BePharBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been recognized in provisions, based on estimate, as of December 31, 2021. In total an amount of EUR 4,016k was paid. Baron Jean St&#233;phenne, our Supervisory Board member, holds directly and indirectly 15.61% of BePharBel Manufacturing&#8217;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#233;phenne&#8217;s son, Vincent St&#233;phenne, holds 1.43% of BePharBel Manufacturing&#8217;s equity and is a managing director of BePharBel Manufacturing.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622013056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Business Combinations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">20. Business Combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination and Goodwill &#8211; Frame Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022 (&#8216;closing date&#8217;), CureVac acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#8216;Frame Pharmaceuticals&#8217; or &#8216;Frame&#8217;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling the identification of structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. In July 2022, Frame Pharmaceuticals was renamed CureVac Netherlands B.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the purchase price agreement (&#8216;SPA&#8217;) dated June 8, 2022, total consideration of up to EUR 32.0 million, subject to certain adjustments for vested and non-vested employee options of the acquiree plus an amount of EUR 1.56 million for the assumption of an outstanding obligation resulting from advisory services, was agreed. The consideration consisted of the transfer of shares in CureVac (&#8216;CureVac Shares&#8217;) and minor cash payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total consideration is split into three payments, two of which are contingent upon the achievement of defined milestones (contingent consideration). At the closing date, the consideration transferred was comprised of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">810,242</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11,040</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k) to former Frame shareholders. The respective share price of one CureVac Share was EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.63</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (&#8216;Closing Share Price&#8217;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">48,254</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">658</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k, valued at the Closing Share Price) as consideration for discharging the contractual obligations for the outstanding advisory agreements of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,560</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k before deducting strike prices. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">585</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, consisting of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">335</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k being the consideration for the settlement of the vested employee options, and an additional EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">250</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment of the remaining 50% of the total consideration is contingent upon the achievement of two milestones. A further 194,644 shares (representing 10% of EUR 32.0 million divided by the Signing Share Price) are issuable upon the achievement of a successful investigational new drug application filing for a product candidate of the Group that consists of at least one antigen based on frameshift-mutation identified by Frame&#8217;s algorithms; (&#8220;Milestone 1&#8221;) and a further 778,575 shares (representing 40% of EUR 32.0 million divided by the Signing Share Price) are issuable upon successful proof of mechanism in humans of that or another product candidate (&#8220;Milestone 2&#8221;). The fair value of these contingent payments was determined by considering the likelihood of the events occurring and totaled, based on the Closing Share Price, EUR 7,198k (Milestone 1: EUR 1,831k and Milestone 2: EUR 5,367k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consequently, the total consideration transferred for the business combination was determined to be EUR 19,481k, consisting of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">858,496</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11,697</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">585</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contingent consideration, classified as equity, with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,198</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k. The contingent consideration will be settled by the issuance of a maximum of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">973,236</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The contingent consideration of EUR 7,198k was valued by applying an estimated probability of the milestone being achieved to the payments due upon achievement. These probabilities were derived from third-party clinical development success rate studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, 89,655 restricted stock unit awards (RSUs) were issued to certain employees to replace existing share-based payment awards of Frame Pharmaceuticals. This element is accounted for as a separately from the business combination as an equity-settled share-based transaction according to IFRS 2 (see Note 10). The total fair value of the grant was determined to be EUR 1,218k and will be expensed in the functional cost category to which the award recipient&#8217;s costs are allocated (i.e., general and administrative expenses or research and development expenses) over the individual vesting periods for the 3 tranches, which run through June 30, 2023, June 30, 2024, and June 30, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The final fair values in accordance with IFRS 3 of the identifiable net assets as of the date of acquisition were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EUR thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;recognized&#160;on&#160;acquisition</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,592</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 206</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset (Technology)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,216</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 966</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 658</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,558</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 134</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities (net of deferred tax assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 406</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts Payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 540</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,018</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The technology intangible asset consists of a bioinformatical platform for cancer antigen discovery and validation for off-the-shelf and personalized cancer vaccines. The fair value of the technology of EUR 6,216k was determined by applying the replacement cost approach due to its early stage. The replacement cost was derived from historical costs incurred to create the technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Goodwill was recognized as a result of the acquisition as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consideration transferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,481</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,018)</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The goodwill is mainly attributable to the synergies and an assembled workforce as well as the strategic benefits to the Group. The goodwill is not deductible for tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions costs in relation to the business combination amounting to EUR 500k were expensed and recognized within general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated statements of profit or loss include the results of Frame Pharmaceuticals (meanwhile: CureVac Netherlands B.V.) since the acquisition date. From the date of acquisition through December 31, 2022 Frame Pharmaceuticals did not have any significant impact on the operating income or revenues of the Group. The same applies if the transaction had occurred at the beginning of the reporting period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649922208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">21. Subsequent events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, positive interim data from the ongoing Phase 2 clinical program assessing monovalent and bivalent modified vaccine candidates against COVID-19 in comparison with a licensed bivalent mRNA-based comparator vaccine were published. The tested vaccine candidates are being developed in collaboration with GSK. Results from the interim analysis showed that both vaccine candidates using CureVac&#8217;s proprietary second-generation mRNA backbone produced meaningful immune responses and favorable tolerability profiles across all tested doses, including the lowest tested dose. All three tested dose levels were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2024, the beneficiaries of the Prior VSOP plan declared their intent to exercise their exercisable shares. The shares became exercisable on the third anniversary after IPO (August 14, 2023), because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels had been reached. 786,746 virtual shares were exercised by March 22, 2024 and CureVac received 786,746 shares from the Prior VSOP holders on that day. On March 26, 2024, CureVac transferred 786,746 shares to the exercising beneficiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2024, the Company started a voluntary leaver program intended to align the workforce to the Company&#8217;s business scope and priorities. The business goal is to reduce 150 positions by year-end, including natural attrition. Unnecessary residual pandemic infrastructure is being adapted to significantly increase efficiency and performance while maintaining a strong focus on innovation and R&amp;D activities. For this program we anticipate costs in a range between EUR 2 and 3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, promising interim data from the ongoing Phase 2 part of the combined Phase 1/2 study of a seasonal influenza vaccine candidate were reported. The multivalent candidate was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains. Results from the planned interim analysis showed that the multivalent vaccine candidate boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose. The vaccine candidate was shown to have an acceptable safety and tolerability profile, with the majority of solicited adverse events reported as either grade 1 (mild) or grade 2 (moderate) within seven days of dosing. Among younger and older adults, geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across all tested dose levels. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across both age groups and tested dose levels. Targeted optimizations to further improve immune responses against influenza B strains will be assessed in an additional Phase 2 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, the Company entered into a co-development and licensing agreement with The University of Texas MD Anderson Cancer Center for the development of novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac&#8217;s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson&#8217;s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need. Both parties will contribute to the identification of differentiated cancer antigens based on whole genome sequencing, combined with long- and short-read RNA sequencing and cutting-edge bioinformatics followed by joint preclinical validation of the highest-quality cancer antigens and selection of the most promising clinical-lead candidates for conducting initial Phase 1/2 studies in appropriate clinical indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, Curevac and GSK entered into a Pandemic Preparedness Agreement with the Federal Republic of Germany. Timelines related to the Pandemic Preparedness Agreement were ambitious with the aim of providing acute pandemic preparedness in Germany in the context of emerging COVID-19 variants. In 2023, CureVac identified a risk that necessary regulatory approvals needed to meet these timelines may not be achieved within the contractually agreed timeframe. After consultation with ZEPAI, CureVac applied for a timeline extension as foreseen under the agreement to avoid procurement of further substantial amounts of raw material at risk. As of December 31, 2023, it was considered unlikely that the extension would be granted. Additionally, a rapidly changing epidemiological environment did no longer prompt an acute pandemic threat. Accordingly, inventories which had been stockpiled as required by the PPA, were written down to their net realizable value. Ultimately, the extension was not granted, whereupon CureVac and GSK jointly decided to terminate the agreement. Despite the termination, CureVac&#8217;s GMP IV manufacturing plant for the large-scale production of mRNA-based vaccines will be completed. Contingent upon regulatory approval, the facility is expected to be certified mid-2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, the Company announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate developed in collaboration with GSK. The H5N1 avian influenza virus is considered a potential future pandemic threat, able to cross species from its original bird host to humans. The monovalent vaccine candidate is based on CureVac&#8217;s proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen. Avian influenza represents latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2024, the Company had the first ruling in one of its CMO arbitration. In August 2022, Rentschler Biopharma SE initiated arbitration proceedings according to the procedural rules of the German Arbitration Institute against the Company. Rentschler&#8217;s claims are based on the assumption that certain agreements between Rentschler and CureVac Manufacturing GmbH (then: CureVac Real Estate GmbH) have been terminated due to the withdrawal of the EMA dossier for CVnCoV or alternatively that CureVac would have been obliged to terminate these agreements. CureVac&#8217;s position always was that the agreements had ended upon expiration of their term. We did not believe that there was a legal basis for Rentschler&#8217;s claims and therefore defended ourselves against these claims in written submissions and the oral hearing in October 2023. In its final award rendered, the arbitration tribunal followed CureVac&#8217;s arguments and dismissed Rentschler&#8217;s claims in their entirety. The totality of Rentschler Biopharma SE related provision was reversed as of December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589623295072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SignificantAccountingPoliciesAbstract', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of preparation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and were authorized by the Management Board for presentation to the Supervisory Board on April 23, 2024. The Group&#8217;s consolidated financial statements are presented in Euros (EUR), which is also the parent company&#8217;s functional currency. Unless otherwise stated, the numbers are rounded to thousands of Euros, except per share amounts.Due to rounding, differences may arise when individual amounts or percentages are added together.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has prepared the consolidated financial statements on the basis that it will continue to operate as a going concern. No commercial products have been marketed yet as CureVac is still in the development phase. Hence, the Group is raising capital to perform research &amp; development activities and to advance its technologies up to a successful development and regulatory approval of its products. To reach its development and commercialization objectives, the Group will seek additional funding through collaboration or licensing agreements or other financing activities. While the Group&#8217;s business projections could be unfavorably affected by being unable to obtain funding or enter into collaboration or license agreements on acceptable terms, CureVac&#8217;s cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the financial statements. This anticipates, that for the foreseeable future the Group will continue to operate. Thus, no adjustments to the consolidated financial statements have been made related to the Group not being able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Details of the Group&#8217;s accounting policies, including changes thereto are described below. The accounting policies have been consistently applied to all years presented unless otherwise stated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Basis of consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of consolidation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsidiaries are entities controlled by the Group. The Group &#8220;controls&#8221; an entity when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The consolidated financial statements include the Company&#8217;s wholly-owned subsidiaries CureVac SE (until September 26, 2022: CureVac AG, Tuebingen, Germany), CureVac Inc. (Boston, Massachusetts, USA), CureVac Manufacturing GmbH (prior years: CureVac Real Estate GmbH, Tuebingen, Germany), CureVac Corporate Services GmbH (Tuebingen, Germany), CureVac RNA Printer GmbH (Tuebingen, Germany), CureVac Swiss AG (Basel, Switzerland &#8211; incorporated in 2021) and CureVac Belgium SA (Ottignies-Louvain-la-Neuve, Belgium &#8211; incorporated in 2022). Effective July 1, 2022, we acquired Frame Pharmaceuticals B.V., Amsterdam, Netherlands (Frame Pharmaceuticals), which was renamed to CureVac Netherlands B.V.; refer to Note 20 for additional information about this business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The fiscal year of all Group entities corresponds to the calendar year ending December&#160;31.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory', window );">Business combinations and goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business combinations and goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Group determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Any contingent consideration to be transferred by the acquirer is recognized at fair value at the acquisition date. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of IFRS 9 Financial Instruments, is measured at fair value with the changes in fair value recognized in the statement of operations in accordance with IFRS 9. Other contingent consideration that is not within the scope of IFRS 9 is measured at fair value at each reporting date with changes in fair value recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred over the fair value of net identifiable assets acquired and liabilities assumed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;">After initial recognition, goodwill is measured at cost less any accumulated impairment losses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Revenue from the sale of products and services is recognized when the Group transfers control to the customer. Control generally transfers when the customer gains the ability to direct the use of and obtain substantially all of the remaining benefits from the good or service. If the contract contains more than one performance obligation, the consideration which the Group expects to receive is allocated to each of the performance obligations, using the relative stand-along selling price method. Revenue is recognized at the amount of consideration that the Group is expected to receive in exchange for these goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group primarily generates revenue from its licensing and development agreements with its customers, which include collaboration partners for the development of mRNA medicines against a variety of targets in diseases and conditions. These arrangements contain multiple contractual promises, including (i) licenses, or options to obtain licenses to the Group&#8217;s mRNA technology, as well as related research and development technology services, (ii) delivery of products, and (iii) research and development services. Such arrangements provide for various types of payments to the Group, including upfront fees, funding of research and development services, payment for delivered products, development, regulatory and commercial milestone payments, license fees, and royalties on product sales, all of which may be satisfied at different points in time. Outlicensing agreements may be entered into with or without any further significant contractual obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Goods or services promised in collaborative arrangements are accounted for as separate performance obligations if such promises are distinct (i.e., if the customer can benefit from the good or service on its own or together with other resources readily available to it and if the promise is separately identifiable from other promises in the contract).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In determining whether contractual promises are separately identifiable, the Group considers whether:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It provides a significant service of integrating the goods or services with other goods or services that represent the combined output or outputs for which the other party has contracted.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One or more of the goods or services significantly modifies or customizes one or more of the other goods or services promised in the agreement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The goods or services the Group promised to transfer or to provide are highly interdependent or highly interrelated.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Based on these criteria, management evaluates whether the intellectual property (IP) licenses granted, and to which further research and development activities may apply under the terms of a collaboration agreement, are distinct from the unperformed obligations to the collaboration partner, considering the relevant facts and circumstances of each arrangement. Factors considered in this determination include the nature of the IP license, the stage of development of the IP license granted, the research capabilities of the partner, and the availability of mRNA technology research expertise in the general marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When an IP license is not considered to be distinct from research services, the Group generally recognizes revenue, including any upfront payment, attributable to the license on a straight-line basis, which reflects the performance of services by the Group towards satisfaction of the obligation, over the contractual or estimated performance period, which is typically from the effective date of the related collaboration agreement through to the estimated date of Marketing Authorization Application (MAA) or Biologics License Application (BLA) for a product developed under the agreement. The determination of the estimated date of MAA or BLA is a significant estimate given the uncertainty inherent in developing innovative pharmaceutical products and is based upon development plans with the customer, which are subject to change, clinical trials, and approval of regulatory authorities Changes in the estimated date of market entry could have a material impact on the amount and timing of revenue the Group records in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Sometimes an IP license is granted together with research and development services relating to the technology. In this case, the services are not considered distinct from the licenses and form a bundle for which revenue is recognized on a straight line basis over the time of services, as the services are determined predominant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When an IP license is considered to be distinct, the Group determines whether it provides the customer with either (1) a right to access the IP throughout the license period (for which revenue is recognized over the license period) or (2) a right to use the IP as it exists at the point in time that the license is granted (for which revenue is recognized at a point in time where the customer can first use and benefit from the license).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Some of the collaboration arrangements include rights and obligations that are considered outside the scope of a customer-vendor relationship as they are more akin to the activities that joint operators perform. CureVac decided that the nature of these types of activities is best reflected by applying joint arrangements accounting which, as the main effect, usually leads to revenue recognition at a later point in time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">If the transaction price in an agreement includes a variable amount, the Group estimates the amount of consideration to which the Group will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated deferred contract liability is updated at each reporting date to reflect the current facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Collaboration agreements may also provide a customer with the option to acquire additional goods or services. In these cases, the Group determines as to whether the customer was granted a material right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Product sales related to collaboration agreements include RNA products and are recognized over time as goods are produced because such goods have no alternative use. Otherwise, revenue for product sales is recognized at a point in time. In 2023 revenue for produced LNP batches were recognized on a point-in-time basis. No product revenue was recognized in 2022 and 2021. Revenue from certain research and development services, delivered as a distinct performance obligation under the collaboration agreements, are recognized over time as the services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A receivable is recognized when the consideration is unconditional and only the passage of time is required before payment is due. Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liability in the statements of financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group may present the following contract balances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contract assets&#8201;&#8212;&#8201;Represents the Group&#8217;s right to consideration in exchange for goods or services that the Group has transferred to the customer when that right is conditioned on something other than the passage of time</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trade receivables&#8201;&#8212;&#8201;Represents the Group&#8217;s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contract liabilities&#8201;&#8212;&#8201;Represents the Group&#8217;s obligations to transfer goods or services to a customer for which the Group has received consideration (or consideration is due) from the customer</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes revenue from contracts with customers relating to its core business. All other operating proceeds are presented as other operating income in the statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Grants from government agencies and similar bodies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants from government agencies and similar bodies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects. Each grant agreement is assessed to determine whether there are elements of the supply of products from the group to the grantor that are recognized separately from the grant. For the supply of products, the standalone selling price is determined by reference to observed prices with other customers. The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If grant funds are received prior to qualifying expenses being incurred or assets purchased, they are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other operating income on a systematic basis over the period in which the corresponding expenses are incurred. If the funds reimburse purchased assets, the liability is reduced with a corresponding amount deducted from the asset&#8217;s carrying amount upon recording of the qualified asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">i) Financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial recognition and measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The classification of financial assets at initial recognition depends on the financial asset&#8217;s contractual cash flow characteristics and the Group&#8217;s business model for managing them. The Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component are measured at the transaction price determined under IFRS 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subsequent measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For purposes of subsequent measurement, financial assets are classified into four categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at amortized cost (debt instruments);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at fair value through other comprehensive income with recycling of cumulative gains and losses (debt instruments);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets designated at fair value through other comprehensive income with no recycling of cumulative gains and losses upon derecognition (equity instruments); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial assets at fair value through profit or loss.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2021, 2022, and 2023, the Group only had the following financial assets to be measured at amortized cost:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash and cash equivalents</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trade receivables</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other financial assets</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in the statement of operations when the asset is derecognized, modified, or impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of financial assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An allowance for expected credit losses (ECLs) is recognized for all debt instruments not held at fair value through profit or loss including contract assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12- months (a 12- month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For financial assets being due more than 30 days, a significant increase in credit risk is assumed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk but instead recognizes a loss allowance based on lifetime ECLs at each reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group considers a financial asset in default when contractual payments are 180&#160;days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ii) Financial liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s material financial liabilities consists of lease liabilities and trade payables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade payables at initial recognition are accounted for at fair value and subsequently at amortized costs. The material accounting policy information regarding accounting of leases is described below.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Acquired intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquired intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Acquired intangible assets are mainly comprised of software and licenses. Regarding the acquired intangible assets (i.e., technology and goodwill) in the business combination with Frame Pharmaceuticals, refer to Note 20.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated useful lives for each intangible asset class are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Software</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8 to 20 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the exception of goodwill, the Group does not have any intangible assets with indefinite useful lives.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and development costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research costs are expensed as incurred. Since our own development projects are mostly subject to regulatory approval and all studies are at an early phase, where the outcome of reaching the next phases is uncertain, the conditions for the capitalization of expenditures incurred prior to approval are not met.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairments. These costs also comprise the costs for replacement parts, which are recognized at the time they are incurred, providing they meet the recognition criteria. All other repair and maintenance costs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Leasehold improvements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1 to 15 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technical equipment and machines:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 14 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment, furniture and fixtures:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 14 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated useful lives are reviewed regularly and revised if necessary. The depreciation method remained unchanged from 2021 through 2023. The residual values of the assets are generally considered to be zero.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial non-current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of non-financial non-current assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At each reporting date, the Group assesses whether there is an indication that a non-financial asset may be impaired. If there is any indication of impairment (triggering event) or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of the asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case it is determined at the level of the cash-generating unit (CGU). If the carrying amount of an asset or CGU exceeds its recoverable amount, the asset or CGU is impaired and written down to its recoverable amount. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In principle, the recoverable amount has to be determined for each individual asset where such asset generates cash flows that are largely independent of those generated by other assets. Where it is not possible, the recoverable amount has been determined on the basis of a group of assets representing a cash generating unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In assessing whether the cash flows are largely independent, CureVac considers various factors, including how management manages the company activities and how the CureVac companies are linked in business operations. As management decisions are centralized on group level and the CureVac companies are closely linked in business operations, the Group operates as one cash-generating unit. Therefore, for the purpose of annual goodwill impairment testing in 2022 and 2023, goodwill was allocated at Group level. The recoverable amount for the Company&#8217;s cash-generating unit based on fair values less costs of disposal using market capitalization derived from public quotations of CureVac stock. Management believes that no reasonably foreseeable change in the price of CureVac stock would cause the carrying amount of our one cash-generating unit to exceed its recoverable amount.Impairment losses of continuing operations are recognized in the statement of operations in expense categories consistent with the function of the impaired asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In fiscal year 2021, impairment of EUR 22,810k were recognized. These pertained largely to machinery and technical equipment recorded as assets under construction and resulted from the partial impairment of production lines which were obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV, see Note 4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beginning in year 2022, goodwill is tested for impairment annually as of December 31 and when circumstances indicate that the carrying value may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For 2023, impairment was evaluated for goodwill by assessing the recoverable amount on Group level. Impairment losses relating to goodwill cannot be reversed in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There was no impairment of goodwill in 2023. However, there were impairments of technical equipment amounting to EUR 1,374k; refer to Note 4.1 for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory', window );">Non-current assets held for sale</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-current assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group classifies non-current assets as held for sale if their carrying amount is expected to be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expenses. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management is committed to the plan to sell the assets. Property, plant and equipment are not depreciated or amortized once classified as held for sale.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory', window );">Right-of-use assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Right-of-use assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received as well as any estimated costs to be incurred by the lessee for dismantling and removing the underlying asset. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life, indicated below, and the lease term. Right-of-use assets are subject to impairment. Refer to the section above &#8220;Impairment of non-financial assets&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Land, Buildings and supply installations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1 to 15 years</p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 to 4 years</p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 to 5 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Lease liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in- substance fixed payments) less any lease incentives receivable and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments, or a change in the assessment to purchase the underlying asset. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount for the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Short-term leases and leases of low-value assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group applies the short-term lease recognition exemption to its short-term leases (i.e., leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption. Lease payments on short-term leases and leases of low-value assets are recognized as expenses on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventories are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Inventories are comprised of raw materials, work in progress, and finished goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in bringing each product to its present location and condition are accounted for, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raw materials: purchase cost on a first-in/first-out basis</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overhead based on normal operating capacity, but excluding borrowing costs</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and cash equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash on hand, bank balances on-demand, and short-term deposits with original maturities of three months or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Onerous contracts</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Onerous contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An onerous contract is a contract under which the unavoidable costs (i.e., the costs that the Group cannot avoid because it has the contract) of meeting the obligations under the contract exceed the economic benefits expected to be received under it. The unavoidable costs under a contract reflect the least net cost of exiting from the contract, which is the lower of the cost of fulfilling it and any compensation or penalties arising from failure to fulfil it. The cost of fulfilling a contract comprises the costs that relate directly to the contract (i.e., both incremental costs and an allocation of costs directly related to contract activities).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Group has a contract that is onerous, the present obligation under the contract is recognized and measured as a provision. However, before a separate provision for an onerous contract is established, the Group recognizes any impairment loss that has occurred on assets dedicated to that contract.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share-based payment awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Group operates several share-based payment programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">An equity-settled share-based payment award is accounted for by recognizing the related expense over the vesting period of the award, with a corresponding increase recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">When a share-based payment award provides for different ways of settlement (i.e. cash versus shares) depending on the occurrence of contingent events, CureVac has the right to choose the manner of settlement and accounts the award based on this.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The related share-based payment expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Tax loss carryforwards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Tax loss carryforwards are examined by the German taxation authorities and may be adjusted. Furthermore, significant changes in the shareholder and company structure can lead to a reduction in the loss carryforwards under the current provisions of German tax law, which can be used to calculate the annual amount for offsetting against the future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. The amount of the expected tax liability or tax receivable reflects the amount, which represents the best estimation taken into account tax uncertainties. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Deferred income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Deferred tax assets are recognized for deductible temporary differences, the carry forward of unused tax credits and any unused tax losses to the extent that it is probable that future taxable income will allow the deferred tax asset to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for. The risk for the assessment regarding i) the deferral of upfront payments, ii) the cooperation between CureVac and GlaxoSmithKline Biologicals SA (GSK), and iii) the transfer pricing setup not to be accepted by the tax authorities is estimated to be between 10% and 50%.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">An operating segment is defined as a component of an entity for which discrete financial information is available and whose operating results are regularly reviewed by our Management Board as the Chief Operating Decision Maker (CODM). The Group operates as a single segment dedicated to the discovery and development of biotechnological applications and the CODM makes decisions about allocating resources and assessing performance based on the Group as a whole. Accordingly, the Group has determined it operates in one operating and reportable segment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant accounting judgments, estimates and assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Significant accounting judgments, estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates, and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments and estimates in relation to assets, liabilities, contingent liabilities, uncertain tax position, revenues, and expenses. Management bases its judgments and estimates on historical experience and other various factors, which it believes to be reasonable under the circumstances, the result of which forms the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#8217;s estimation, no provisions for uncertain tax treatments need to be accounted for. Actual results may differ from these estimates under different assumptions and conditions and may materially affect the financial results or the financial position reported in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Judgments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the process of applying the accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition and collaboration agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group applied the following judgments in determining the amount and timing of revenue from collaboration agreements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification and determination of the nature of performance obligations in collaboration and license agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group generates revenues from collaboration and license agreements under which the Group grants licenses to use, research, develop, manufacture, and commercialize candidates and products. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. If these promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in the Group accounting for all goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For these combined performance obligations, it must be assessed which of these promises is the predominant promise to determine the nature of the performance obligation. The Group determined that the research and development technology services for the grant of the license is the predominant promise within the (combined) performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Group shares the risks and benefits of a development project in such a way that the nature of the arrangement is not considered to be purely a customer-vendor-relationship, activities that are determined to be outside of a customer-vendor-relationship are accounted for in consideration of the principles of a joint operation accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, the promise of the research and development technology services for granting a license is accounted for as a performance obligation satisfied over time as the Group&#8217;s customer simultaneously receives and consumes the benefits from the Group&#8217;s performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition and collaboration agreements</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimation of variable consideration and assessment of the constraint when determining the amount of revenue of which to defer recognition</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s collaboration and license agreements comprise variable considerations which are contingent on the occurrence or non-occurrence of a future event (i.e., reaching a certain milestone). When determining the deferral of revenue in a collaboration and license agreement, the Group is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As there are usually only two possible outcomes (i.e., a milestone is reached or not), the Group has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which the Group will be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The most likely amount of these milestone payments (i.e., the full milestone payment) is only included in the transaction price if the occurrence of reaching a future milestone is highly probable. The Group has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has concluded that future milestone payments are fully constrained at each of the fiscal years. Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, regulatory approval, or achievement of a sales milestone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>Estimation of determination of date of market authorization application for revenue release over-time</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A significant amount of judgment given the uncertainty inherent in developing innovative pharmaceutical products is being used in the determination of the estimated date of the Marketing Authorization Application or Biologics License Applications. The group regularly reviews the timelines and changes are reflected in the release of revenue amount when they become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for non - current assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-current assets are classified as asset held for sale if their carrying amount will be recovered through a sale transaction rather than through continued use; the carrying value of such assets is measured at the lower of their previous carrying value and their fair value less costs to sell. In evaluating whether the criterion, for classification as assets held for sale, of a sale being highly probable, the Group considered that a plan to sell the assets was committed to and an active program to locate a buyer was initiated with an equipment reseller. By estimating the fair value less costs to sell the Group considered various indicative prices of expected auction proceeds quoted by the equipment reseller. Additionally, the Group estimated, whether the plan to sell the assets could be completed within one year from the date of classification and whether actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has multiple share-based payment programs. Significant estimates are included in the determination of the grant date fair value of the awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for onerous contract provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has entered into binding legal agreements for the supply of services by contract research organizations (CROs) to the Group for clinical trials of its first-generation COVID-19 vaccine candidate, CVnCoV. Such services are generally associated with the ongoing monitoring and care for enrolled participants in the clinical trials. Due to the discontinuation of the CVnCoV program, the remaining services, which the Group is obligated to procure, do not have a value for the Group anymore. In estimating the cost of the remaining services, judgment is required, particularly in estimating the number of participants completing the clinical trials, when measuring provisions for such contracts with clinical research organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting for contract termination provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Contract termination provisions are established under certain conditions in the case of legal risks. Settlement and legal proceedings often raise complex issues and are subject to many uncertainties and complexities including, but not limited to, the facts and circumstances of each particular case. The outcome of any current or future proceedings cannot normally be predicted. The Group considers the need for accounting measures in respect of pending or future settlements for terminated contracts on the basis of the information available to its legal department and in close consultation with legal counsel acting for the Group. Where it is more likely than not that such settlement will result in an outflow of resources that is already reasonably estimable, a provision for settling terminated contracts is recorded in the amount of the present value of the expected cash outflows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory', window );">Changes in accounting policies and disclosures</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in accounting policies and disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New and amended standards and interpretations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group has not early adopted any standards, interpretations, or amendments that have been issued but are not yet effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Standards issued but not yet effective</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following amendments will be adopted effective January 1, 2024, or at a later effective date:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 1: Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 7 and IFRS 7: Supplier Finance Arrangements</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IFRS 16: Lease Liability in a Sale and Leaseback</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 21: Lack of Exchangeability</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CureVac does not expect these standards to have an impact on the Group&#180;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for right of use assets.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for changes in accounting policies, accounting estimates and errors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Accounting policies<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS08_g7-31_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649711744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SignificantAccountingPoliciesAbstract', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory', window );">Schedule of estimated useful lives for intangible asset class</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Software</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8 to 20 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8 years</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory', window );">Schedule of estimated useful lives for property, plant and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Leasehold improvements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1 to 15 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Technical equipment and machines:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 14 years</p></td></tr><tr><td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment, furniture and fixtures:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 to 14 years</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory', window );">Schedule of estimated useful lives for right of use assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Land, Buildings and supply installations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1 to 15 years</p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 to 4 years</p></td></tr><tr><td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 to 5 years</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about estimated useful lives of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about estimated useful lives of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about estimated useful lives of right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589688040192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of revenue from contract with customers recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,128</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,197</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,425</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 102,990</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 67,420</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 53,758</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory', window );">Summary of upfront payments and related revenues recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:24.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract liabilities at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized&#160;from&#160;upfront and milestone&#160;payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,089</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">USD 10,000 (EUR 8,937) *</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,192</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">USD 4,500 (EUR 3,947)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 770</p></td></tr><tr><td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 107,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 92,680</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 67,828</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,787</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,051</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Schedule of contract balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,326</p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,758</p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 92,680</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory', window );">Schedule of contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,580</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">More than one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,100</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 107,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 92,680</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,159)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,734)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,891)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,641)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (139,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,398)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,874)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,425)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,672)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,992)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,295)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,850)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,948)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,085)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,918)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,986)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (238,195)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (183,993)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (124,366)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,029)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,425)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (336)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (417)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (424)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,743)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,817)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (3,912)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">R&amp;D expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (232,292)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,982)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,126)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,733)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,267)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,259)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,539)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,666)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (539,786)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,587)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (347)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,069)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,287)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,291)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,591)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,252)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (815,907)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (62,550)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (115,724)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">General and administrative expenses include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,996)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,306)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,853)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,353)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,875)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,669)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,920)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,160)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,360)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,821)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,703)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,508)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (100,402)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (104,178)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (91,758)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Schedule of nature of expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nature of the expenses is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,655)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (99,924)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (113,422)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (278,542)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (121,873)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,767)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (708,636)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (67,905)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,381)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,356)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,232)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26,641)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,229)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,948)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,085)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,666)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,160)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,415)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,170)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,156,247)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (353,539)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (335,760)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Schedule of other operating income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation for CMO/Materials transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,429</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 860</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,195</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grants and other reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,566</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,101</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 67,702</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,932</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,151</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about upfront payments and related revenues recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 120<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_120_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589623901824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of development of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Advance</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Software</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Technology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,850</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,454</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (298)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,166)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (656)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,930</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,350</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,139</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated amortization and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,612</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,079</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,217)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,114)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,331)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,479</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,398</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 484</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,361</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,139</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,880</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,946)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,432)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,388)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,797)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,843</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,974</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,350</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,630</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated amortization and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,361</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,059</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,841)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,135)</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,493)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,965</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,054</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,266</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,285</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Carrying amount</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,238</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,778</p></td></tr><tr><td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,878</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,920</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,084</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,347</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of development of property, plant and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Other</b><span style="font-family:'Times New Roman Bold';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment,</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Technical</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">furniture</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">under</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and&#160;machines</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;fixtures</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">construction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 215,283</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,620</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,719)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,851)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,570)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,182)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,356)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,854)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,467</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 50,033</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,552</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 138,457</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 227,509</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated depreciation and impairment charges</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,019</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,394</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,884</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,083)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,938)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,038)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,747)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,710</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,617</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,415</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 826</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,568</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Acquisition costs</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,509</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,873</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,825)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,235)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,165)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,537</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 54,941</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 178,990</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 274,205</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accumulated depreciation and impairment charges </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,415</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,568</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,432</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,374</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Disposals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,659)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,941)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,914</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,272</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,038</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,200</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,424</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Carrying amount</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 168,264</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">As of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 197,941</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,623</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,669</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,698</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 176,790</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 236,782</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Summary of carrying amounts of the Group's right-of-use assets and the movements during the period</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-use&#160;assets</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Land&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,183</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 275</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,303</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,761</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions (new leases and reassessment of existing leases)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,988</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (352)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,772)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34)</p></td></tr><tr><td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 39,574</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 319</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,950</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,843</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-use&#160;assets</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Land&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Buildings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vehicles</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,129</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,244</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,639)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (316)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,053)</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (710)</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,183</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 275</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,303</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,761</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock', window );">Summary of carrying amounts of lease liabilities and the movements during the period</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions (new leases and reassessment of existing leases)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,988</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,375</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,568)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,824</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,005</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,819</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,892</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,241</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,218</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,439)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,980</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,106</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock', window );">Summary of amounts recognized in the statement of operations related to leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,772)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment expense / reversal of impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,218)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,375)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense relating to short-term leases (included in cost of sales)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (76)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense relating to leases of low-value assets (included in general and administrative expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55)</p></td></tr><tr><td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from sub-leasing right-of-use assets presented in &#8220;other operating income&#8221;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of carrying amounts of lease liabilities and the movements during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease expense recognized in the statement of operations related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650325584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of total shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2020</b></p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 180,460,565</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Follow-on public offering, incl. Greenshoe </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,750,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">910,163</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the at-the-market offering program </p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,908,493</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued to former shareholders of Frame Pharmaceuticals</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 858,496</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued for LTIP option exercises and RSU deliveries </p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,374</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2022 </b></p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 194,997,091</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the at-the-market offering program</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,218</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued as part of the public offering</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,027,028</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issued for LTIP option exercises and RSU releases</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,338</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 223,988,675</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589651449936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock', window );">Schedule for expense recognized for the equity-settled programs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expense recognized for share-based payments during the years ended December 31 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (624)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (572)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LTIP Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,472)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,944)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LTIP RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,072)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU Supervisory board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (566)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (478)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (652)</p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (14,939)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (9,184)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,697)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember', window );">Prior VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of reconciliation of outstanding awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the beginning of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,951,265</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,426,365</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,614,246</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34,859)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,091)</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised during the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,524,900)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (777,260)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,426,365</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,614,246</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,603,155</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,365,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,509,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,588,513</p></td></tr><tr><td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">none</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">none</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">none</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory', window );">Schedule of share-based payments expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The expense recognized for this share-based payment plan during the years ended December 31 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of Sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (624)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (131)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (10)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of reconciliation of outstanding awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The number of awards in the New VSOP program granted to key employees developed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the beginning of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 349,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,108</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (99,696)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised during the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557,171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147,620)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69,246)</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 349,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,862</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,862</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereof exercisable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory', window );">Schedule of share-based payments expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The expense recognized for employee services received during the years ended December 31, 2023, 2022, and 2021 is shown in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (349)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31)</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (188)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (572)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember', window );">Former Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of inputs used in the measurement of the fair value at grant date</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 57.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 50.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 11.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 10.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.07 - 1.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">First tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 48.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (actual 10-days VWAP before grant date, USD 81.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 67.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 52.96)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 43.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.07 - 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">Second tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 24.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (estimated by Monte Carlo simulation to be USD 98.36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (estimated by Monte Carlo simulation to be USD 98.36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.07 - 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">Third tranche:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 20.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (estimated by Monte Carlo simulation to be USD 98.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (estimated by Monte Carlo simulation to be USD 98.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 81.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.07 - 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (30-days VWAP after grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 77.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 88.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 77.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.08 - 0.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 17.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (20-day VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 56.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 84.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 70.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.099 &#8201;&#8211;&#8201; 0.903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 17.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average share price (20-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 41.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price (USD 84.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">EUR 46.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.075 &#8201;&#8211; &#8201;0.704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 14.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (30-days VWAP after grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 30.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 34.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 30.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.40 - 1.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 4.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10 - day VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 15.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 19.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 18.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">73.87 - 86.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.34 - 3.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 6.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average share price (10-days VWAP before grant date)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD 19.28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">EUR 17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Weighted average fair value per option</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';">3.55</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Weighted average share price (10-day VWAP before grant date)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';">6.12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Exercise price (USD </span><span style="font-family:'timesew Roman';">6.66</span><span style="font-family:'timesew Roman';">)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">EUR&#160;</span><span style="font-family:'timesew Roman';">6.12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Expected volatility (%)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> 75.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Expected life (years)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> 3.39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">Risk-free interest rate (%)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';"> 3.70</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'timesew Roman';">%</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory', window );">Schedule of share-based payments expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of Sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (331)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (240)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (909)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,719)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (269)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (383)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,753)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (705)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,108)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,072)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expense recognized for employee services explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of expense recognized for the programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622479344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock', window );">Schedule of trade and other payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,365</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Miscellaneous liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 73,463</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 48,033</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular information pertaining to trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649891584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities and provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesAndProvisionsAbstract', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory', window );">Schedule of provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract termination provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions (non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 61,320</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for onerous contracts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184</p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract termination provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,216</p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions (current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,922</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 37,400</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Provisions (current &amp; non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 63,242</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 37,400</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Schedule of movements in provisions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 63,242</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 980</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">used (amounts charged against the provision)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,174)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">unused amounts reversed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,648)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,400</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,400</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesTableTextBlock', window );">Schedule of Other liabilities and provisions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other liabilities (non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel accrued liabilities (e.g. bonus, vacation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,543</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grants from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,735</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding invoices</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,081</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,116</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other liabilities (current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 40,491</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 50,717</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total other liabilities (current &amp; non-current)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 40,510</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 50,717</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular information pertaining to other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilitiesAndProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilitiesAndProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other provisions, contingent liabilities and contingent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS37_g84-92_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589643937760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of tax reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (412,498)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (249,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (259,969)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected tax benefit (based on statutory tax rate of 29.48% in 2023, 2022 and 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,626</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Recognition of tax loss carryforwards recognized in prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effects from differences between Group and local tax rates </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-recognition of tax loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (114,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (81,392)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-recognition of deferred tax assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,363)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Recognition of deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,717</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Non-deductible expenses for tax purposes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (706)</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additions for local trade taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other effects</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,826)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,599</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Effective tax benefit / (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 782</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 126</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (198)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Schedule of deferred taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;01,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Recognized&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquired&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit&#160;and&#160;loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business&#160;combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTL</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,224)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,439)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,439)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,364)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,052)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,052)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non - current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Non-current )</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (118)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (67)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (152)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (142)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (137)</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,498)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,490)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,490</p></td></tr><tr><td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Taxes Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (84)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,194</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,777</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (6,583)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 01,2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Recognized in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquired in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit and loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DTL</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,412)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,769)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,808)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (663)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,701)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,364)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,364)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (181)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,014)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non - current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Non-current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (129)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities (Current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (205)</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (276)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,466)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Taxes Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,861</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,590)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (19)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,969</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (6,691)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock', window );">Schedule of unused tax losses carried forward</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Tax loss carryforwards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused tax losses for corporate income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,180,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,427,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,700,475</p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused tax losses for trade tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,175,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,419,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,685,517</p></td></tr><tr><td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unused interest carryforward ("Zinsschranke")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644339808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure of financial instruments and management of financial risks (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Schedule of maturity profile of the financial liabilities based on contractual undiscounted payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt;1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual commitments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,269)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Note 4.2) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,656)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities and provisions (Note 12) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,117)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,117)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables (Note 11) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,033)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,033)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (146,673)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (23,581)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,821)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (193,075)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt; 1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;5years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;&#160;5&#160;years</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,923)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,377)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (74,300)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities (Note 4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,247)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,693)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (54,723)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities and provisions (Note 12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41,447)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (103,753)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (73,463)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (73,463)</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (172,080)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (112,356)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (21,803)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (306,239)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock', window );">Schedule of exposure in (foreign) currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b>&#160;<b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">57,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">63,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total monetary assets in foreign currency </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">GBP</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total monetary liabilities in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b>&#160;<b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total monetary assets in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,566</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 113,664</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GBP</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CHF</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total monetary liabilities in foreign currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,332</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net exposure in USD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2022 (1 EUR= 1.0666 USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (1 EUR = 1.1050 USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">EUR </b><b style="font-weight:bold;">77,649</b><b style="font-weight:bold;">k from USD </b><b style="font-weight:bold;">82,822</b><b style="font-weight:bold;">k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EUR </b><b style="font-weight:bold;">72,015</b><b style="font-weight:bold;">k from USD </b><b style="font-weight:bold;">79,576</b><b style="font-weight:bold;">k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMarketRiskExplanatory', window );">Schedule of other variables held constant, pre-tax loss and post-tax loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effect&#160;on&#160;pre-tax&#160;profit&#160;or&#160;loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effect&#160;on&#160;post-tax&#160;profit&#160;or&#160;loss</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strengthening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weakening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strengthening</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weakening</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">31.12.2023 EUR against USD </b><b style="font-weight:bold;">10</b><b style="font-weight:bold;">% movement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,547</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (8,002)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,617</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5,644)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">31.12.2022 EUR against USD 10% movement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,628)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,085)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about exposure to foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMarketRiskExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of market risk. [Refer: Market risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMarketRiskExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589680024240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated statements of cash flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Notes to the consolidated statements of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Schedule of changes in liabilities arising from financing activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;1,</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accrued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">in thousands of EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reclassification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Disposals</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Changes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Movements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Payment of lease liabilities (Note 4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,568)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,998)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,824</p></td></tr><tr><td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,568)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,998)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,986</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,375</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (57)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,824</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accrued</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">Exchange</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">in thousands of EUR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reclassification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Disposals</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Changes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Movements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Payment of lease liabilities (Note 4. 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,439)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,086</p></td></tr><tr><td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities from financing</b> <b style="font-weight:bold;">activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,892</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (6,439)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,241</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,218</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 174</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42,086</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589623497216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of the Company's key management personnel (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfKeyManagementPersonnelAbstract', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock', window );">Schedule of remuneration of company's key management personnel</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Management&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Supervisory&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Remuneration of key management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 674</p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Termination benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 652</p></td></tr><tr><td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">15,771</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,212</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">9,756</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,147</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,928</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,326</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of detailed information about remuneration of key management personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589621883968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Schedule of fair value recognized on acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EUR thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;recognized&#160;on&#160;acquisition</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,592</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 206</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset (Technology)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,216</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 966</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 658</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,558</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 134</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities (net of deferred tax assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 406</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts Payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 540</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,018</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock', window );">Schedule of goodwill recognized as a result of the acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consideration transferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,481</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,018)</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information pertaining to goodwill recognized as a result of the acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589621918432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Corporate Information (Details) - Dievini<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfVotingInterestsHeld', window );">Voting interests held</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfVotingInterestsHeld', window );">Voting interests held</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfVotingInterestsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests held in the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfVotingInterestsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_LargestShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_LargestShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644166720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SignificantAccountingPolicyLineItems', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">&#8364; 53,758,000<span></span>
</td>
<td class="nump">&#8364; 67,420,000<span></span>
</td>
<td class="nump">&#8364; 102,990,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsPropertyPlantAndEquipmentSalvageValue', window );">Residual values</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContractTerminationProvisions', window );">Contract termination provisions in prior year</a></td>
<td class="nump">37,216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermOnerousContractsProvision', window );">Provision for onerous contracts</a></td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">1,922,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsCapitalised', window );">Borrowing costs capitalized</a></td>
<td class="nump">&#8364; 2,375,000<span></span>
</td>
<td class="nump">&#8364; 2,291,000<span></span>
</td>
<td class="nump">&#8364; 2,932,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation', window );">Weighted average borrowing costs (as a percent)</a></td>
<td class="nump">5.76%<span></span>
</td>
<td class="nump">5.78%<span></span>
</td>
<td class="nump">7.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment to property, plant and equipment</a></td>
<td class="nump">&#8364; 1,374,000<span></span>
</td>
<td class="nump">&#8364; 5,884,000<span></span>
</td>
<td class="nump">&#8364; 22,810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill', window );">No impairment of goodwill</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SignificantAccountingPolicyLineItems', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp', window );">Estimated risk percentage for not accepting the transfer pricing set up</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SignificantAccountingPolicyLineItems', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp', window );">Estimated risk percentage for not accepting the transfer pricing set up</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SignificantAccountingPolicyLineItems', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">&#8364; 11,395,000<span></span>
</td>
<td class="nump">&#8364; 19,571,000<span></span>
</td>
<td class="nump">&#8364; 22,706,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContractTerminationProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contract termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContractTerminationProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of risk estimated for not accepting the transfer pricing setup.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsPropertyPlantAndEquipmentSalvageValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsPropertyPlantAndEquipmentSalvageValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2023-01-01<br> -Paragraph 26<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_26_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2023-01-01<br> -Paragraph 26<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_26_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermOnerousContractsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for onerous contracts. [Refer: Onerous contracts provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermOnerousContractsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589643850640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies - Estimated useful lives Intangible assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_SoftwareMember', window );">Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_SoftwareMember', window );">Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">Licenses | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives (in years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">Licenses | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_TechnologyMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives (in years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645453312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies - Property, plant and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesMember', window );">Technical equipment and machines: | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesMember', window );">Technical equipment and machines: | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives (in years)</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other equipment, furniture and fixtures: | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other equipment, furniture and fixtures: | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives (in years)</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589623952352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies - Estimated useful life of right-of-use assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=cvac_LandBuildingsAndSupplyInstallationsMember', window );">Land, Buildings and supply installations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Estimated useful lives of right-of-use assets (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=cvac_LandBuildingsAndSupplyInstallationsMember', window );">Land, Buildings and supply installations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Estimated useful lives of right-of-use assets (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Estimated useful lives of right-of-use assets (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Estimated useful lives of right-of-use assets (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=cvac_OtherEquipmentMember', window );">Other equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Estimated useful lives of right-of-use assets (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=cvac_OtherEquipmentMember', window );">Other equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Estimated useful lives of right-of-use assets (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=cvac_LandBuildingsAndSupplyInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=cvac_LandBuildingsAndSupplyInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=cvac_OtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=cvac_OtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644416608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 53,758<span></span>
</td>
<td class="nump">&#8364; 67,420<span></span>
</td>
<td class="nump">&#8364; 102,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_BE', window );">Belgium | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">47,128<span></span>
</td>
<td class="nump">62,263<span></span>
</td>
<td class="nump">74,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CH', window );">Switzerland | CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">5,425<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands | Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">&#8364; 1,787<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Boehringer Ingelheim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember', window );">Countries other than Belgium, Germany, Netherlands and Switzerland | Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589652157856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Additional Information (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>item</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 53,758<span></span>
</td>
<td class="nump">&#8364; 67,420<span></span>
</td>
<td class="nump">&#8364; 102,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 235,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding', window );">Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets', window );">Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember', window );">Research And Development Services Combined With Ip License Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,051<span></span>
</td>
<td class="nump">&#8364; 44,787<span></span>
</td>
<td class="nump">79,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,395<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
<td class="nump">22,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,312<span></span>
</td>
<td class="nump">3,062<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_BoehringerIngelheimMember', window );">Boehringer Ingelheim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OptionFeePayment', window );">Option Fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived', window );">Additional development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement', window );">Upfront Payment Revenue Recognized From Termination Of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsOptionFeePaymentIncludedInContractLiabilities', window );">Ifrs Option Fee Payment Included In Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities', window );">Development milestone payment included in contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_CrisprTherapeuticsMember', window );">CRISPR Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,425<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_GenmabMember', window );">Genmab | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Equity investment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember', window );">GSK [Member] | Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,740<span></span>
</td>
<td class="nump">41,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember', window );">GSK [Member] | GlaxoSmithKline COVID Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,530<span></span>
</td>
<td class="nump">20,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember', window );">GSK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="nump">&#8364; 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation', window );">Amount Eligible To Receive As One Time Reimbursable Payment For Manufacturing Capacity Reservation</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments', window );">Amount Eligible To Receive As Development And Regulatory Milestone Payments</a></td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AmountEligibleToReceiveAsCommercialMilestonePayments', window );">Amount Eligible To Receive As Commercial Milestone Payments</a></td>
<td class="nump">&#8364; 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember', window );">GSK [Member] | Belgium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 47,128<span></span>
</td>
<td class="nump">&#8364; 62,263<span></span>
</td>
<td class="nump">&#8364; 74,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional development milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionalDevelopmentMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AmountEligibleToReceiveAsCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount eligible to receive commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AmountEligibleToReceiveAsCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount eligible to receive development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payment included in contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsOptionFeePaymentIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Option fee payment included in contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsOptionFeePaymentIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OptionFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Option fee Payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OptionFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment revenue recognized from termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received or receivable by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_CrisprTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_CrisprTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsTypeOfArrangementAxis=cvac_GlaxosmithklineCovidAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsTypeOfArrangementAxis=cvac_GlaxosmithklineCovidAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644553776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">&#8364; 92,680<span></span>
</td>
<td class="nump">&#8364; 107,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">31,051<span></span>
</td>
<td class="nump">44,787<span></span>
</td>
<td class="nump">&#8364; 67,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">88,715<span></span>
</td>
<td class="nump">102,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">29,089<span></span>
</td>
<td class="nump">42,690<span></span>
</td>
<td class="nump">51,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember', window );">Boehringer Ingelheim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember', window );">Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable</a></td>
<td class="nump">8,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">2,383<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember', window );">CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront Payments Received Or Receivable</a></td>
<td class="nump">3,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">1,582<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">&#8364; 770<span></span>
</td>
<td class="nump">&#8364; 310<span></span>
</td>
<td class="nump">&#8364; 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments of the company included in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received or receivable by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649930928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Contract balances (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 14,326<span></span>
</td>
<td class="nump">&#8364; 6,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Contract assets</a></td>
<td class="nump">2,758<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 92,680<span></span>
</td>
<td class="nump">&#8364; 107,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649512256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Contract liabilities allocated to the remaining performance obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</a></td>
<td class="nump">&#8364; 92,680<span></span>
</td>
<td class="nump">&#8364; 107,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Contract liabilities allocated to the remaining performance obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</a></td>
<td class="nump">44,580<span></span>
</td>
<td class="nump">34,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">More than one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Contract liabilities allocated to the remaining performance obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</a></td>
<td class="nump">&#8364; 48,100<span></span>
</td>
<td class="nump">&#8364; 72,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 120<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589643836688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Cost of sales (Details) - Operative Expenses [Member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (113,422)<span></span>
</td>
<td class="num">&#8364; (99,924)<span></span>
</td>
<td class="num">&#8364; (94,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">(78,767)<span></span>
</td>
<td class="num">(121,873)<span></span>
</td>
<td class="num">(278,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(67,905)<span></span>
</td>
<td class="num">(39,501)<span></span>
</td>
<td class="num">(708,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(15,356)<span></span>
</td>
<td class="num">(9,381)<span></span>
</td>
<td class="num">(7,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(27,229)<span></span>
</td>
<td class="num">(26,641)<span></span>
</td>
<td class="num">(17,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment of equipment</a></td>
<td class="num">(8,085)<span></span>
</td>
<td class="num">(24,948)<span></span>
</td>
<td class="num">(22,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(8,170)<span></span>
</td>
<td class="num">(17,064)<span></span>
</td>
<td class="num">(14,415)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(335,760)<span></span>
</td>
<td class="num">(353,539)<span></span>
</td>
<td class="num">(1,156,247)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(37,734)<span></span>
</td>
<td class="num">(27,185)<span></span>
</td>
<td class="num">(22,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">(59,641)<span></span>
</td>
<td class="num">(88,891)<span></span>
</td>
<td class="num">(46,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(9,398)<span></span>
</td>
<td class="num">(32,331)<span></span>
</td>
<td class="num">(139,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(2,672)<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
<td class="num">(2,874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(4,850)<span></span>
</td>
<td class="num">(6,295)<span></span>
</td>
<td class="num">(3,992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment of equipment</a></td>
<td class="num">(8,085)<span></span>
</td>
<td class="num">(24,948)<span></span>
</td>
<td class="num">(22,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(1,986)<span></span>
</td>
<td class="num">(1,918)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (124,366)<span></span>
</td>
<td class="num">&#8364; (183,993)<span></span>
</td>
<td class="num">&#8364; (238,195)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589618096880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Selling and distribution expenses (Details) - Operative Expenses [Member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (113,422)<span></span>
</td>
<td class="num">&#8364; (99,924)<span></span>
</td>
<td class="num">&#8364; (94,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(15,356)<span></span>
</td>
<td class="num">(9,381)<span></span>
</td>
<td class="num">(7,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(27,229)<span></span>
</td>
<td class="num">(26,641)<span></span>
</td>
<td class="num">(17,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(8,170)<span></span>
</td>
<td class="num">(17,064)<span></span>
</td>
<td class="num">(14,415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(335,760)<span></span>
</td>
<td class="num">(353,539)<span></span>
</td>
<td class="num">(1,156,247)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember', window );">Selling and distribution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(3,425)<span></span>
</td>
<td class="num">(2,029)<span></span>
</td>
<td class="num">(1,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(424)<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (3,912)<span></span>
</td>
<td class="num">&#8364; (2,817)<span></span>
</td>
<td class="num">&#8364; (1,743)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645305552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Research and development (R&amp;D) expenses (Details) - Operative Expenses [Member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">&#8364; (78,767)<span></span>
</td>
<td class="num">&#8364; (121,873)<span></span>
</td>
<td class="num">&#8364; (278,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(113,422)<span></span>
</td>
<td class="num">(99,924)<span></span>
</td>
<td class="num">(94,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(27,229)<span></span>
</td>
<td class="num">(26,641)<span></span>
</td>
<td class="num">(17,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PatentsAndFeesToRegisterLegalRight', window );">Patents and fees to register a legal right</a></td>
<td class="num">(6,666)<span></span>
</td>
<td class="num">(3,813)<span></span>
</td>
<td class="num">(3,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(67,905)<span></span>
</td>
<td class="num">(39,501)<span></span>
</td>
<td class="num">(708,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(15,356)<span></span>
</td>
<td class="num">(9,381)<span></span>
</td>
<td class="num">(7,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(8,170)<span></span>
</td>
<td class="num">(17,064)<span></span>
</td>
<td class="num">(14,415)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(335,760)<span></span>
</td>
<td class="num">(353,539)<span></span>
</td>
<td class="num">(1,156,247)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">(19,126)<span></span>
</td>
<td class="num">(32,982)<span></span>
</td>
<td class="num">(232,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(43,267)<span></span>
</td>
<td class="num">(33,944)<span></span>
</td>
<td class="num">(33,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(8,539)<span></span>
</td>
<td class="num">(8,650)<span></span>
</td>
<td class="num">(4,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PatentsAndFeesToRegisterLegalRight', window );">Patents and fees to register a legal right</a></td>
<td class="num">(6,666)<span></span>
</td>
<td class="num">(3,813)<span></span>
</td>
<td class="num">(3,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(28,587)<span></span>
</td>
<td class="nump">20,499<span></span>
</td>
<td class="num">(539,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(7,287)<span></span>
</td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(2,252)<span></span>
</td>
<td class="num">(2,591)<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(115,724)<span></span>
</td>
<td class="num">&#8364; (62,550)<span></span>
</td>
<td class="num">&#8364; (815,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReversalOfProvisionForOnerousContracts', window );">Reversal of provision for onerous contracts</a></td>
<td class="nump">38,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsProvisionForLossOnContracts', window );">Estimated contract termination provisions</a></td>
<td class="nump">&#8364; 25,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsProvisionForLossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of provision for loss on contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsProvisionForLossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PatentsAndFeesToRegisterLegalRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for registering a legal right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PatentsAndFeesToRegisterLegalRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReversalOfProvisionForOnerousContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReversalOfProvisionForOnerousContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644097296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - General and administrative expenses (Details) - Operative Expenses [Member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (113,422)<span></span>
</td>
<td class="num">&#8364; (99,924)<span></span>
</td>
<td class="num">&#8364; (94,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(15,356)<span></span>
</td>
<td class="num">(9,381)<span></span>
</td>
<td class="num">(7,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(67,905)<span></span>
</td>
<td class="num">(39,501)<span></span>
</td>
<td class="num">(708,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and other professional services</a></td>
<td class="num">(10,160)<span></span>
</td>
<td class="num">(10,394)<span></span>
</td>
<td class="num">(9,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(27,229)<span></span>
</td>
<td class="num">(26,641)<span></span>
</td>
<td class="num">(17,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(8,170)<span></span>
</td>
<td class="num">(17,064)<span></span>
</td>
<td class="num">(14,415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(335,760)<span></span>
</td>
<td class="num">(353,539)<span></span>
</td>
<td class="num">(1,156,247)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(28,996)<span></span>
</td>
<td class="num">(36,765)<span></span>
</td>
<td class="num">(37,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(5,353)<span></span>
</td>
<td class="num">(5,853)<span></span>
</td>
<td class="num">(4,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(29,920)<span></span>
</td>
<td class="num">(27,669)<span></span>
</td>
<td class="num">(28,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and other professional services</a></td>
<td class="num">(10,160)<span></span>
</td>
<td class="num">(10,394)<span></span>
</td>
<td class="num">(9,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(13,821)<span></span>
</td>
<td class="num">(11,360)<span></span>
</td>
<td class="num">(8,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(3,508)<span></span>
</td>
<td class="num">(12,137)<span></span>
</td>
<td class="num">(11,703)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (91,758)<span></span>
</td>
<td class="num">&#8364; (104,178)<span></span>
</td>
<td class="num">&#8364; (100,402)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645517136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Operative Expenses (Details) - Operative expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (113,422)<span></span>
</td>
<td class="num">&#8364; (99,924)<span></span>
</td>
<td class="num">&#8364; (94,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">(78,767)<span></span>
</td>
<td class="num">(121,873)<span></span>
</td>
<td class="num">(278,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(67,905)<span></span>
</td>
<td class="num">(39,501)<span></span>
</td>
<td class="num">(708,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(15,356)<span></span>
</td>
<td class="num">(9,381)<span></span>
</td>
<td class="num">(7,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(27,229)<span></span>
</td>
<td class="num">(26,641)<span></span>
</td>
<td class="num">(17,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment of equipment</a></td>
<td class="num">(8,085)<span></span>
</td>
<td class="num">(24,948)<span></span>
</td>
<td class="num">(22,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PatentsAndFeesToRegisterLegalRight', window );">Patents and fees to register a legal right</a></td>
<td class="num">(6,666)<span></span>
</td>
<td class="num">(3,813)<span></span>
</td>
<td class="num">(3,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and other professional services</a></td>
<td class="num">(10,160)<span></span>
</td>
<td class="num">(10,394)<span></span>
</td>
<td class="num">(9,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(8,170)<span></span>
</td>
<td class="num">(17,064)<span></span>
</td>
<td class="num">(14,415)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (335,760)<span></span>
</td>
<td class="num">&#8364; (353,539)<span></span>
</td>
<td class="num">&#8364; (1,156,247)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PatentsAndFeesToRegisterLegalRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for registering a legal right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PatentsAndFeesToRegisterLegalRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=cvac_OperativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649559536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)<br> &#8364; in Thousands, $ in Thousands, item in Millions</strong></div></th>
<th class="th" colspan="12">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>EUR (&#8364;) </div>
<div>item</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="nump">&#8364; 574,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 574,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities', window );">Receipts from grants from government agencies and similar bodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsTypeOfArrangementAxis=cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember', window );">Advance Purchase Agreement with European Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement', window );">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentReceived', window );">Upfront Payment Received</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment', window );">Payment of accrued other liabilities of upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaximumGrantToBeReceived', window );">Maximum grant</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AccruedOtherLiabilityForUpFrontPayment', window );">Accrued other liability for up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities', window );">Compensation consist for set-up activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses', window );">Reimbursement of prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember', window );">German Federal Ministry of Education and Research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsRemainingGrantIncome', window );">Remaining grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaximumGrantToBeReceived', window );">Maximum grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 196,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember', window );">German Federal Ministry of Education and Research | Miscellaneous other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsRemainingGrantIncome', window );">Remaining grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaximumGrantToBeReceived', window );">Maximum grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PartnershipAgreementMaximumAmount', window );">Maximum amount under the partnership agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PartnershipAgreementTerm', window );">Term of the partnership agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PartnershipAgreementPeriodOfCostsToBeCovered', window );">Period for which the costs are to be covered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReimbursementOfApprovedExpenses', window );">Reimbursement of approved expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaximumUnspentFundsReimbursable', window );">Maximum unspent funds reimbursable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember', window );">Bill &amp; Melinda Gates Foundation (BMGF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities', window );">Receipts from grants from government agencies and similar bodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 614<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfAdditionalGrantsReceived', window );">Number of additional grants received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AmortizationOfGovernmentGrants', window );">Amortization of the grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RepaymentOfGrantReceivedFromGovernment', window );">Repayment of grant received from government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember', window );">Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities', window );">Receipts from grants from government agencies and similar bodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">&#8364; 486<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 852<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember', window );">Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities', window );">Receipts from grants from government agencies and similar bodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,208<span></span>
</td>
<td class="nump">$ 1,449<span></span>
</td>
<td class="nump">&#8364; 1,208<span></span>
</td>
<td class="nump">$ 1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 673<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AmortizationOfGovernmentGrants', window );">Amortization of the grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_BundesministeriumFurBildungUndForschungMember', window );">Bundesministerium fr Bildung und Forschung</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AccruedOtherLiabilityForUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued other liability for up-front payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AccruedOtherLiabilityForUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AmortizationOfGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of the grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AmortizationOfGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfGovernmentGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfGovernmentGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsRemainingGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of remaining grant income classified as other operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsRemainingGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaximumGrantToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum grant receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaximumGrantToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaximumUnspentFundsReimbursable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum unspent funds reimbursable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaximumUnspentFundsReimbursable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfAdditionalGrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional grants received by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfAdditionalGrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PartnershipAgreementMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount agreed under the partnership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PartnershipAgreementMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PartnershipAgreementPeriodOfCostsToBeCovered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which the costs are to be covered by the funds received under the partnership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PartnershipAgreementPeriodOfCostsToBeCovered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PartnershipAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the partnership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PartnershipAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment of accrued other liabilities of upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from government grants and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReimbursementOfApprovedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reimbursement of approved expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReimbursementOfApprovedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RepaymentOfGrantReceivedFromGovernment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayment of received government grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RepaymentOfGrantReceivedFromGovernment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsTypeOfArrangementAxis=cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsTypeOfArrangementAxis=cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_MiscellaneousOtherOperatingIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_MiscellaneousOtherOperatingIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_BundesministeriumFurBildungUndForschungMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_BundesministeriumFurBildungUndForschungMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644258496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Other operating income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransfer', window );">Compensation for CMO/Materials transfer</a></td>
<td class="nump">&#8364; 2,429<span></span>
</td>
<td class="nump">&#8364; 35,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CostOfReimbursementClaim', window );">Reimbursement claim</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SaleOfEquipment', window );">Sale of equipment</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherOperatingIncomeGovernmentGrants', window );">Grants and other reimbursements from government agencies and similar bodies</a></td>
<td class="nump">3,566<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">&#8364; 66,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MiscellaneousOtherOperatingIncomeOther', window );">Other</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Total</a></td>
<td class="nump">&#8364; 9,151<span></span>
</td>
<td class="nump">&#8364; 37,932<span></span>
</td>
<td class="nump">&#8364; 67,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CostOfReimbursementClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost of reimbursement claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CostOfReimbursementClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MiscellaneousOtherOperatingIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MiscellaneousOtherOperatingIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherOperatingIncomeGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other operating income recognized in relation to government agencies and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherOperatingIncomeGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SaleOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of equipment in operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SaleOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589621998720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Intangible assets (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,778<span></span>
</td>
<td class="nump">&#8364; 13,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,347<span></span>
</td>
<td class="nump">31,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_SoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,906<span></span>
</td>
<td class="nump">6,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">6,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,532<span></span>
</td>
<td class="nump">5,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,920<span></span>
</td>
<td class="nump">6,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_TechnologyMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,084<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_AdvancePaymentsIntangibleAssetMember', window );">Advance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative amortization and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,361<span></span>
</td>
<td class="nump">10,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,059<span></span>
</td>
<td class="nump">5,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,135)<span></span>
</td>
<td class="num">(3,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,285<span></span>
</td>
<td class="nump">12,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative amortization and impairment charges | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">5,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">820<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,841)<span></span>
</td>
<td class="num">(2,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative amortization and impairment charges | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,398<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,457<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,294)<span></span>
</td>
<td class="num">(1,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,054<span></span>
</td>
<td class="nump">6,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative amortization and impairment charges | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,139<span></span>
</td>
<td class="nump">23,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,880<span></span>
</td>
<td class="nump">24,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,388)<span></span>
</td>
<td class="num">(4,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,630<span></span>
</td>
<td class="nump">44,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,385<span></span>
</td>
<td class="nump">12,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,946)<span></span>
</td>
<td class="num">(2,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,797)<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
<td class="nump">12,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,930<span></span>
</td>
<td class="nump">10,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,432)<span></span>
</td>
<td class="num">(1,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,974<span></span>
</td>
<td class="nump">12,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,350<span></span>
</td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Goodwil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Advance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (11)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_AdvancePaymentsIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_AdvancePaymentsIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589674155328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Property, plant and equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">&#8364; 197,941<span></span>
</td>
<td class="nump">&#8364; 168,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">5,884<span></span>
</td>
<td class="nump">&#8364; 22,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">236,782<span></span>
</td>
<td class="nump">197,941<span></span>
</td>
<td class="nump">168,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsCapitalised', window );">Borrowing costs capitalized</a></td>
<td class="nump">&#8364; 2,375<span></span>
</td>
<td class="nump">&#8364; 2,291<span></span>
</td>
<td class="nump">&#8364; 2,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation', window );">Weighted average borrowing costs (as a percent)</a></td>
<td class="nump">5.76%<span></span>
</td>
<td class="nump">5.78%<span></span>
</td>
<td class="nump">7.17%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">&#8364; 17,757<span></span>
</td>
<td class="nump">&#8364; 21,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">14,623<span></span>
</td>
<td class="nump">17,757<span></span>
</td>
<td class="nump">&#8364; 21,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember', window );">Technical equipment and machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">37,416<span></span>
</td>
<td class="nump">40,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">40,669<span></span>
</td>
<td class="nump">37,416<span></span>
</td>
<td class="nump">40,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other equipment, furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">4,698<span></span>
</td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">137,631<span></span>
</td>
<td class="nump">101,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">176,790<span></span>
</td>
<td class="nump">137,631<span></span>
</td>
<td class="nump">101,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative Amortization And Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">29,568<span></span>
</td>
<td class="nump">47,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">12,432<span></span>
</td>
<td class="nump">13,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">5,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(5,941)<span></span>
</td>
<td class="num">(36,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">37,424<span></span>
</td>
<td class="nump">29,568<span></span>
</td>
<td class="nump">47,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative Amortization And Impairment | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">8,710<span></span>
</td>
<td class="nump">5,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">4,216<span></span>
</td>
<td class="nump">4,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">12,914<span></span>
</td>
<td class="nump">8,710<span></span>
</td>
<td class="nump">5,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative Amortization And Impairment | Technical equipment and machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">12,617<span></span>
</td>
<td class="nump">11,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">5,925<span></span>
</td>
<td class="nump">6,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(4,270)<span></span>
</td>
<td class="num">(9,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">14,272<span></span>
</td>
<td class="nump">12,617<span></span>
</td>
<td class="nump">11,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative Amortization And Impairment | Other equipment, furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">7,415<span></span>
</td>
<td class="nump">7,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1,659)<span></span>
</td>
<td class="num">(1,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">8,038<span></span>
</td>
<td class="nump">7,415<span></span>
</td>
<td class="nump">7,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember', window );">Cumulative Amortization And Impairment | Assets under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">22,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">22,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">227,509<span></span>
</td>
<td class="nump">215,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">54,873<span></span>
</td>
<td class="nump">89,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(8,165)<span></span>
</td>
<td class="num">(19,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">274,205<span></span>
</td>
<td class="nump">227,509<span></span>
</td>
<td class="nump">215,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">26,467<span></span>
</td>
<td class="nump">27,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(1,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">27,537<span></span>
</td>
<td class="nump">26,467<span></span>
</td>
<td class="nump">27,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Technical equipment and machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">50,033<span></span>
</td>
<td class="nump">51,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">9,171<span></span>
</td>
<td class="nump">9,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">7,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(5,090)<span></span>
</td>
<td class="num">(12,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">54,941<span></span>
</td>
<td class="nump">50,033<span></span>
</td>
<td class="nump">51,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Other equipment, furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">12,552<span></span>
</td>
<td class="nump">11,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">2,024<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="num">(1,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">12,736<span></span>
</td>
<td class="nump">12,552<span></span>
</td>
<td class="nump">11,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember', window );">Acquisition costs | Assets under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">138,457<span></span>
</td>
<td class="nump">124,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">43,126<span></span>
</td>
<td class="nump">76,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(1,358)<span></span>
</td>
<td class="num">(7,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(4,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">&#8364; 178,990<span></span>
</td>
<td class="nump">&#8364; 138,457<span></span>
</td>
<td class="nump">&#8364; 124,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2023-01-01<br> -Paragraph 26<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_26_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2023-01-01<br> -Paragraph 26<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_26_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment through classification as held for sale or inclusion in a disposal group classified as held for sale. [Refer: Disposal groups classified as held for sale [member]; Property, plant and equipment; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_CumulativeAmortizationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=cvac_GrossCarryingAmountOfAcquisitionCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589654126720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Right-of-use assets and lease liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the beginning</a></td>
<td class="nump">&#8364; 43,761<span></span>
</td>
<td class="nump">&#8364; 32,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">4,988<span></span>
</td>
<td class="nump">17,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(5,772)<span></span>
</td>
<td class="num">(5,053)<span></span>
</td>
<td class="num">&#8364; (3,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentOnRightOfUseAssets', window );">Impairment</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_Foreigncurrencytranslationrightofuseassets', window );">Foreign currency translation</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the end</a></td>
<td class="nump">&#8364; 41,843<span></span>
</td>
<td class="nump">43,761<span></span>
</td>
<td class="nump">32,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RightOfUseAssetsNumberOfExtensionOption', window );">Right of use assets, number of extension option | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsLesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cvac_TbingenMember', window );">Tbingen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">&#8364; 2,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfRentalAgreements', window );">Number of rental agreements | item</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cvac_WiesbadenMember', window );">Wiesbaden</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">&#8364; 510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfRentalAgreements', window );">Number of rental agreements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember', window );">Land and Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the beginning</a></td>
<td class="nump">&#8364; 41,183<span></span>
</td>
<td class="nump">31,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">4,788<span></span>
</td>
<td class="nump">14,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(5,264)<span></span>
</td>
<td class="num">(4,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentOnRightOfUseAssets', window );">Impairment</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_Foreigncurrencytranslationrightofuseassets', window );">Foreign currency translation</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the end</a></td>
<td class="nump">39,574<span></span>
</td>
<td class="nump">41,183<span></span>
</td>
<td class="nump">31,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the beginning</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the end</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other equipment, furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the beginning</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at the end</a></td>
<td class="nump">&#8364; 1,950<span></span>
</td>
<td class="nump">&#8364; 2,303<span></span>
</td>
<td class="nump">&#8364; 440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_Foreigncurrencytranslationrightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in right of use assets due to foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_Foreigncurrencytranslationrightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsLesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsLesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ImpairmentOnRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment on right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ImpairmentOnRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfRentalAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of rental agreements entered during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfRentalAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RightOfUseAssetsNumberOfExtensionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of extension option  under the right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RightOfUseAssetsNumberOfExtensionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cvac_TbingenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cvac_TbingenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cvac_WiesbadenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cvac_WiesbadenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650780960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Carrying amounts of lease liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at the beginning</a></td>
<td class="nump">&#8364; 42,086<span></span>
</td>
<td class="nump">&#8364; 28,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionsLeaseLiabilities', window );">Additions</a></td>
<td class="nump">4,988<span></span>
</td>
<td class="nump">17,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Accretion of interest</a></td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(2,218)<span></span>
</td>
<td class="num">&#8364; (1,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payments</a></td>
<td class="num">(7,568)<span></span>
</td>
<td class="num">(6,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ForeignCurrencyTranslationLeaseLiabilities', window );">Foreign currency translation</a></td>
<td class="num">(57)<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at the end</a></td>
<td class="nump">41,824<span></span>
</td>
<td class="nump">42,086<span></span>
</td>
<td class="nump">&#8364; 28,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">5,005<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">36,819<span></span>
</td>
<td class="nump">&#8364; 37,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OptionalLeasePaymentsUponUsingExtensionOptions', window );">Optional lease payments</a></td>
<td class="nump">&#8364; 39,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of addition of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ForeignCurrencyTranslationLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in lease Liabilities due to foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ForeignCurrencyTranslationLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OptionalLeasePaymentsUponUsingExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of optional lease payments arising upon exercise of extension options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OptionalLeasePaymentsUponUsingExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622670000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Amounts recognized in the statement of operations (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense of right-of-use assets</a></td>
<td class="num">&#8364; (5,772)<span></span>
</td>
<td class="num">&#8364; (5,053)<span></span>
</td>
<td class="num">&#8364; (3,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentOnRightOfUseAssets', window );">Impairment expense / reversal of impairment</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(2,218)<span></span>
</td>
<td class="num">(1,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases (included in cost of sales)</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to leases of low-value assets (included in general and administrative expenses)</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">&#8364; (66)<span></span>
</td>
<td class="num">&#8364; (39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeFromSubleasingRightofuseAssets', window );">Income from sub-leasing right-of-use assets presented in "other operating income"</a></td>
<td class="nump">&#8364; 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ImpairmentOnRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment on right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ImpairmentOnRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeFromSubleasingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income from subleasing right-of-use assets. Sublease is a transaction for which an underlying asset is re-leased by a lessee (&#8216;intermediate lessor&#8217;) to a third party, and the lease (&#8216;head lease&#8217;) between the head lessor and lessee remains in effect. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeFromSubleasingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644539120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NetBookValueOfCmoEquipmentHeldForSale', window );">Net book value Of CMO-Equipment held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 29,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentOfAssetsHeldForSale', window );">Impairment of assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Fair value less anticipated costs</a></td>
<td class="nump">&#8364; 2,419<span></span>
</td>
<td class="nump">&#8364; 10,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AssetsHeldForSaleNetBookValueSold', window );">Assets held for sale with a net book value sold</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AssetsHeldForSaleNetBookValueDirectSold', window );">Assets held for sale, net book value direct sold</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DecreaseThroughClassifiedAsHeldForSale', window );">Decrease through classified as held for sale</a></td>
<td class="nump">&#8364; 6,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AssetsHeldForSaleNetBookValueDirectSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value sold of assets held for direct sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AssetsHeldForSaleNetBookValueDirectSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AssetsHeldForSaleNetBookValueSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value sold of assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AssetsHeldForSaleNetBookValueSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DecreaseThroughClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in assets through classification as held for sale or inclusion in a disposal group classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DecreaseThroughClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ImpairmentOfAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss on assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ImpairmentOfAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NetBookValueOfCmoEquipmentHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net book value of CMO-Equipment held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NetBookValueOfCmoEquipmentHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649882000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InventoriesLineItem', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">&#8364; 24,801<span></span>
</td>
<td class="nump">&#8364; 23,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseInInventory', window );">Increase in inventory</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Raw materials write-off</a></td>
<td class="nump">47,129<span></span>
</td>
<td class="nump">&#8364; 80,021<span></span>
</td>
<td class="nump">&#8364; 185,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InventoryPilingForPandemicPreparednessAgreement', window );">Inventory piling for pandemic preparedness agreement</a></td>
<td class="nump">&#8364; 62,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseDecreaseInInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in inventory during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseDecreaseInInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InventoriesLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InventoriesLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InventoryPilingForPandemicPreparednessAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory piling for the pandemic preparedness agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InventoryPilingForPandemicPreparednessAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650933904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other financial assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Other financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Other current financial assets</a></td>
<td class="nump">&#8364; 2,661<span></span>
</td>
<td class="nump">&#8364; 4,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DepositsHeldByThirdParties', window );">Deposits held by third parties</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">&#8364; 726<span></span>
</td>
<td class="nump">&#8364; 2,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DepositsHeldByThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deposits held by third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DepositsHeldByThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645619552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InventoriesLineItem', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">&#8364; 23,763<span></span>
</td>
<td class="nump">&#8364; 40,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer', window );">Prepayments for compensation</a></td>
<td class="nump">4,344<span></span>
</td>
<td class="nump">5,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepayments for future service agreements and goods</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">4,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax', window );">Tax claims</a></td>
<td class="nump">12,881<span></span>
</td>
<td class="nump">24,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Current prepaid expenses</a></td>
<td class="nump">&#8364; 5,463<span></span>
</td>
<td class="nump">&#8364; 5,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InventoriesLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InventoriesLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589621837088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Overview and General Remarks (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Notional value per share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589644070288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Impact of share split (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding beginning</a></td>
<td class="nump">194,997,091<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="nump">180,460,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareOptionExercises', window );">Share option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StockIssuanceDuringPeriodForExistingShareholders', window );">Shares issued to former shareholders of Frame Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries', window );">Shares issued for LTIP option exercises and RSU deliveries</a></td>
<td class="nump">216,338<span></span>
</td>
<td class="nump">109,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding ending</a></td>
<td class="nump">223,988,675<span></span>
</td>
<td class="nump">194,997,091<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_FollowOnPublicOfferingMember', window );">Follow-on public offering, incl. Greenshoe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInNumberOfSharesOutstanding', window );">Capital Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,748,218<span></span>
</td>
<td class="nump">6,908,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_PublicOfferingOfCommonSharesMember', window );">Public offering of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">27,027,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CommonSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued and outstanding for during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CommonSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued for RSU deliveries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ShareOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share option exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ShareOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StockIssuanceDuringPeriodForExistingShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for existing shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StockIssuanceDuringPeriodForExistingShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_PublicOfferingOfCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_PublicOfferingOfCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650419248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Follow-on public offering (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 235,840<span></span>
</td>
<td class="nump">&#8364; 404,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_ClosingOfPublicOfferingOfCommonSharesMember', window );">Closing of public offering of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInNumberOfSharesOutstanding', window );">Capital increase (in shares) | shares</a></td>
<td class="nump">27,027,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="nump">&#8364; 219,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 426,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">&#8364; 14,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 22,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_IfrsOverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInNumberOfSharesOutstanding', window );">Capital increase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_ClosingOfPublicOfferingOfCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_ClosingOfPublicOfferingOfCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_IfrsOverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_IfrsOverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589674159632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - At-the-market offering (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Cash received from issuance of shares | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 235,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 404,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Cash received from issuance of shares | $</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748,218<span></span>
</td>
<td class="nump">6,908,493<span></span>
</td>
<td class="nump">6,908,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,000,000<span></span>
</td>
<td class="nump">513,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate gross proceeds receivable from issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AggregateGrossProceedsReceivableFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589621504480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Frame acquisition (Details) - Frame Pharmaceuticals B.V., Amsterdam, Netherlands<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred | &#8364;</a></td>
<td class="nump">&#8364; 19,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Shares issued for consideration | shares</a></td>
<td class="nump">858,496<span></span>
</td>
<td class="nump">858,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589623307136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Exercises of share options under the VSOP plan and legacy program (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Option </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsPlanNameAxis=cvac_OldVsopPlanMember', window );">Old VSOP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity', window );">Number of shares received</a></td>
<td class="nump">765,223<span></span>
</td>
<td class="nump">759,677<span></span>
</td>
<td class="nump">777,260<span></span>
</td>
<td class="nump">786,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesHeldForTaxLiabilities', window );">Number of shares held for payable of tax liabilities</a></td>
<td class="nump">523,897<span></span>
</td>
<td class="nump">390,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions', window );">Number of shares issued for exercise of stock options</a></td>
<td class="nump">241,326<span></span>
</td>
<td class="nump">369,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsPlanNameAxis=cvac_NewVsopPlanMember', window );">New VSOP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions', window );">Number of shares issued for exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,246<span></span>
</td>
<td class="nump">147,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Forfeiteded during the period | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsPlanNameAxis=cvac_LegacyPlanMember', window );">Legacy plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StatementsLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesHeldForTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares held for payable of tax liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesHeldForTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for exercise of stock options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares received from the participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsPlanNameAxis=cvac_OldVsopPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsPlanNameAxis=cvac_OldVsopPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsPlanNameAxis=cvac_NewVsopPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsPlanNameAxis=cvac_NewVsopPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsPlanNameAxis=cvac_LegacyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsPlanNameAxis=cvac_LegacyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645441360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Expense recognized for the share-based payments (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments</a></td>
<td class="num">&#8364; (7,697)<span></span>
</td>
<td class="num">&#8364; (9,184)<span></span>
</td>
<td class="num">&#8364; (14,939)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember', window );">Prior VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanStockOptionsMember', window );">LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments</a></td>
<td class="num">(2,944)<span></span>
</td>
<td class="num">(5,562)<span></span>
</td>
<td class="num">(12,472)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanRsusMember', window );">LTIP RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments</a></td>
<td class="num">(4,072)<span></span>
</td>
<td class="num">(3,108)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RsuSupervisoryBoardMember', window );">RSU Supervisory board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments</a></td>
<td class="num">&#8364; (652)<span></span>
</td>
<td class="num">&#8364; (478)<span></span>
</td>
<td class="num">&#8364; (566)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RsuSupervisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RsuSupervisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589653242144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 26, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 14, 2022</div></th>
<th class="th">
<div>Oct. 19, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 10, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Option </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Option </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Option </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember', window );">Prior VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RightToExercisePercentageOfVestedVirtualShares', window );">Right to exercise percentage of vested virtual shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions', window );">Number of shares issued for exercise of stock options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity', window );">Number of shares received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">777,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity', window );">Transfer from shareholders to company | shares</a></td>
<td class="nump">786,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TreasurySharesTransferred', window );">Treasury shares transferred | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProvisionForEmployerTaxes', window );">Provision for employer taxes | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Average share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 34.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 69.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember', window );">Former Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at the beginning of the period | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,614,246<span></span>
</td>
<td class="nump">6,426,365<span></span>
</td>
<td class="nump">7,951,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Forfeited during the period | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,091)<span></span>
</td>
<td class="num">(34,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the period | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777,260)<span></span>
</td>
<td class="num">(1,524,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at the end of the period | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,603,155<span></span>
</td>
<td class="nump">5,614,246<span></span>
</td>
<td class="nump">6,426,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement', window );">Thereof vested | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,588,513<span></span>
</td>
<td class="nump">5,509,886<span></span>
</td>
<td class="nump">6,365,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Thereof exercisable | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in the number of shares outstanding through transfer from shareholders to entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for exercise of stock options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares received from the participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options vested and expensed thereof in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProvisionForEmployerTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for employer taxes arising according to US regulations for future exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProvisionForEmployerTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RightToExercisePercentageOfVestedVirtualShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the right to exercise percentage of vested virtual shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RightToExercisePercentageOfVestedVirtualShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TreasurySharesTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TreasurySharesTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589621939568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Prior VSOP - Expenses (Details) - Prior VSOP - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales', window );">Cost of Sales</a></td>
<td class="num">&#8364; (9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses', window );">Selling and distribution expenses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">&#8364; (8)<span></span>
</td>
<td class="num">&#8364; (25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">46<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Total</a></td>
<td class="num">&#8364; (10)<span></span>
</td>
<td class="num">&#8364; (131)<span></span>
</td>
<td class="num">&#8364; (624)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in cost of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589643911072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - New VSOP - Reconciliation of outstanding awards (Details) - New VSOP<br> $ / shares in Units, &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="10">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>EUR (&#8364;) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Forfeiteded during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,246)<span></span>
</td>
<td class="num">(69,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,620)<span></span>
</td>
<td class="num">(557,171)<span></span>
</td>
<td class="num">(557,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement', window );">Thereof vested | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,942,000<span></span>
</td>
<td class="nump">88,464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Thereof exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,942<span></span>
</td>
<td class="nump">88,464<span></span>
</td>
<td class="nump">88,464<span></span>
</td>
<td class="nump">88,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProvisionForEmployerTaxes', window );">Provision for employer taxes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Average share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.90<span></span>
</td>
<td class="nump">$ 16.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsEmployerTaxesPayable', window );">Employer taxes payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RemainingOptionLifeShareOptionsAwardsGranted', window );">Remaining life of the options</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RemainingOptionLifeShareOptionsAwardsGranted', window );">Remaining life of the options</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsEmployerTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employer taxes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsEmployerTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options vested thereof in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProvisionForEmployerTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for employer taxes arising according to US regulations for future exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProvisionForEmployerTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RemainingOptionLifeShareOptionsAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining option life of share options awards granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RemainingOptionLifeShareOptionsAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_ExerciseOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_ExerciseOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589654248304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details) - New VSOP<br> $ / shares in Units, &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="7">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>EUR (&#8364;) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>EUR (&#8364;) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of awards exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="nump">69,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Average share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsEmployerTaxesPayable', window );">Employer taxes payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProvisionForEmployerTaxes', window );">Provision for employer taxes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="num">&#8364; (31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses', window );">Selling and distribution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Total</a></td>
<td class="num">&#8364; (19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseRecognizedForEmployeeServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized for employee services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseRecognizedForEmployeeServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsEmployerTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employer taxes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsEmployerTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProvisionForEmployerTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for employer taxes arising according to US regulations for future exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProvisionForEmployerTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_ExerciseOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_ExerciseOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589615081392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>Y </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2022 </div>
<div>Y </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>Y </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>Y </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>Y </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Scientific Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 57.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.04<span></span>
</td>
<td class="nump">$ 11.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.06%<span></span>
</td>
<td class="nump">62.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.82<span></span>
</td>
<td class="nump">1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Scientific Officer | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Scientific Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.48%<span></span>
</td>
<td class="nump">1.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | First tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 48.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.12<span></span>
</td>
<td class="nump">$ 81.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 43.87<span></span>
</td>
<td class="nump">$ 52.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.27%<span></span>
</td>
<td class="nump">62.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | First tranche | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | First tranche | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 24.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.48<span></span>
</td>
<td class="nump">$ 98.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 81.48<span></span>
</td>
<td class="nump">$ 98.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.27%<span></span>
</td>
<td class="nump">62.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.23<span></span>
</td>
<td class="nump">2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Second tranche | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Second tranche | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Third tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.65<span></span>
</td>
<td class="nump">$ 98.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 81.65<span></span>
</td>
<td class="nump">$ 98.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.27%<span></span>
</td>
<td class="nump">62.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66<span></span>
</td>
<td class="nump">2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Third tranche | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Third tranche | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.45<span></span>
</td>
<td class="nump">$ 19.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 77.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.91%<span></span>
</td>
<td class="nump">50.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.17%<span></span>
</td>
<td class="nump">72.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.16<span></span>
</td>
<td class="nump">2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.16<span></span>
</td>
<td class="nump">2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Key employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Key employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70.92<span></span>
</td>
<td class="nump">$ 84.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.95%<span></span>
</td>
<td class="nump">70.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Operating Officer | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.099%<span></span>
</td>
<td class="nump">0.099%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Operating Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.903%<span></span>
</td>
<td class="nump">0.903%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Development Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46.16<span></span>
</td>
<td class="nump">$ 84.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.13%<span></span>
</td>
<td class="nump">75.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Development Officer | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075%<span></span>
</td>
<td class="nump">0.075%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Development Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.704%<span></span>
</td>
<td class="nump">0.704%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember', window );">Former Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value per option</a></td>
<td class="nump">&#8364; 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="nump">6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="nump">&#8364; 6.12<span></span>
</td>
<td class="nump">$ 6.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | Y</a></td>
<td class="nump">3.39<span></span>
</td>
<td class="nump">3.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value per share of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefDevelopmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefDevelopmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589616511248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Long-Term Incentive Plan (LTIP) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>Option</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>Option </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Mar. 01, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>Option </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>Option </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>Option </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>Option</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>Option </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Option </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease', window );">Number of days increase related to percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Scientific Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice', window );">Threshold duration of volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage', window );">Percentage of increase in share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage', window );">Percentage of increase in share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease', window );">Number of days increase related to percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | First tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 43.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 81.65<span></span>
</td>
<td class="nump">$ 98.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 81.48<span></span>
</td>
<td class="nump">$ 98.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33.07<span></span>
</td>
<td class="nump">$ 39.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer | Third tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.35<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 77.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.28<span></span>
</td>
<td class="nump">$ 33.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice', window );">Threshold duration of volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage', window );">Percentage of increase in share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease', window );">Number of days increase related to percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice', window );">Threshold duration of volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage', window );">Percentage of increase in share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease', window );">Number of days increase related to percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Development Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage', window );">Percentage of increase in share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease', window );">Number of days increase related to percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | the Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="nump">144,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | Members of supervisory board | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in share price under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold duration of volume weighted average price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of days of VWAP based on which percentage of stock price increase is calculated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsVestingAxis=cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefDevelopmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefDevelopmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589652284128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>tranche </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (7,697)<span></span>
</td>
<td class="num">&#8364; (9,184)<span></span>
</td>
<td class="num">&#8364; (14,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Members of executive board and various key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,753)<span></span>
</td>
<td class="num">&#8364; (2,000)<span></span>
</td>
<td class="num">&#8364; (383)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement', window );">Number of tranches for vesting of RSUs granted | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus', window );">Minimum share price on or after vesting to settle and deliver the RSUs | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | Members of supervisory board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expenses from share-based payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 652<span></span>
</td>
<td class="nump">&#8364; 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | Members of executive board and various key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | Key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="nump">32,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | COO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | Chief Business Officer and Chief Commercial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | Former Frame employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,944<span></span>
</td>
<td class="nump">&#8364; 5,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | COO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Chief Business Officer and Chief Commercial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum share price on or after vesting to settle and deliver the RSUs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches for vesting of instruments granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645602032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details) - Former Chief Executive Officer Grant - Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at the beginning of the period</a></td>
<td class="nump">5,614,246<span></span>
</td>
<td class="nump">6,426,365<span></span>
</td>
<td class="nump">7,951,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(11,091)<span></span>
</td>
<td class="num">(34,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777,260)<span></span>
</td>
<td class="num">(1,524,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at the end of the period</a></td>
<td class="nump">5,603,155<span></span>
</td>
<td class="nump">5,614,246<span></span>
</td>
<td class="nump">6,426,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_OptionsGrantedToThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589653922880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Restricted Stock Units (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 22, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Jun. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options | Members of executive board and various key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | Members of executive board and various key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="nump">646,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units | LTIP Stock Options | Members of supervisory board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="nump">92,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsPlanNameAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645625792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Restricted Stock Units expense (Details) - Restricted Stock Units - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales', window );">Cost of Sales</a></td>
<td class="num">&#8364; (331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="num">(1,719)<span></span>
</td>
<td class="num">&#8364; (909)<span></span>
</td>
<td class="num">&#8364; (240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses', window );">Selling and distribution expenses</a></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="num">(1,753)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Total</a></td>
<td class="num">&#8364; (4,072)<span></span>
</td>
<td class="num">&#8364; (3,108)<span></span>
</td>
<td class="num">&#8364; (705)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in cost of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589620931184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">&#8364; 46,365<span></span>
</td>
<td class="nump">&#8364; 68,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Miscellaneous liabilities</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="nump">5,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">48,033<span></span>
</td>
<td class="nump">73,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangeInTradeAndOtherPayables', window );">Amount of decrease in trade and other payables</a></td>
<td class="nump">25,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Payroll-related taxes and social-security liabilities</a></td>
<td class="nump">&#8364; 1,496<span></span>
</td>
<td class="nump">&#8364; 5,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangeInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangeInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645509088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other liabilities and provisions (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsOtherLiabilitiesAbstract', window );"><strong>Other liabilities and provisions.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContractTerminationProvisionsCurrent', window );">Contract termination provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 61,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions (non-current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermOnerousContractsProvision', window );">Provision for onerous contracts</a></td>
<td class="nump">&#8364; 184<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContractTerminationProvisions', window );">Contract termination provisions</a></td>
<td class="nump">37,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions (current)</a></td>
<td class="nump">37,400<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total Provisions (current &amp; non-current)</a></td>
<td class="nump">&#8364; 37,400<span></span>
</td>
<td class="nump">&#8364; 63,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContractTerminationProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contract termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContractTerminationProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContractTerminationProvisionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contract termination provisions, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContractTerminationProvisionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount, including provisions for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermOnerousContractsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for onerous contracts. [Refer: Onerous contracts provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermOnerousContractsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589650551840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities and provisions - Movements (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesAndProvisionsAbstract', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Beginning balance</a></td>
<td class="nump">&#8364; 63,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">additions</a></td>
<td class="nump">980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">used (amounts charged against the provision)</a></td>
<td class="num">(1,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">unused amounts reversed</a></td>
<td class="num">(25,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Ending balance</a></td>
<td class="nump">37,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="nump">&#8364; 37,400<span></span>
</td>
<td class="nump">&#8364; 1,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 61,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilitiesAndProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilitiesAndProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount, including provisions for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649501760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities and provisions - Current and Non Current liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsOtherLiabilitiesAbstract', window );"><strong>Other liabilities and provisions.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherMiscellaneousNonCurrentLiabilities', window );">Other (e.g. license liabilities, Deferred Tax Liability)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities (non-current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelAccruedLiabilities', window );">Personnel accrued liabilities (e.g. bonus, vacation)</a></td>
<td class="nump">&#8364; 10,543<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Grants from government agencies and similar bodies</a></td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OutstandingInvoicesCurrent', window );">Outstanding invoices</a></td>
<td class="nump">36,081<span></span>
</td>
<td class="nump">28,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProfessionalFessCurrent', window );">Professional fees</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CurrentValueAddedTaxAndOtherTaxesPayables', window );">VAT and other taxes (real estate transfer taxes)</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilityCurrent', window );">Other</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities (current)</a></td>
<td class="nump">50,717<span></span>
</td>
<td class="nump">40,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Total other liabilities (current &amp; non-current)</a></td>
<td class="nump">50,717<span></span>
</td>
<td class="nump">40,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherOperatingIncomeGovernmentGrants', window );">Grants and other reimbursements from government agencies and similar bodies</a></td>
<td class="nump">&#8364; 3,566<span></span>
</td>
<td class="nump">&#8364; 440<span></span>
</td>
<td class="nump">&#8364; 66,394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CurrentValueAddedTaxAndOtherTaxesPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax and other taxes payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CurrentValueAddedTaxAndOtherTaxesPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherMiscellaneousNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other miscellaneous non-current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherMiscellaneousNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherOperatingIncomeGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other operating income recognized in relation to government agencies and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherOperatingIncomeGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OutstandingInvoicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current outstanding invoices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OutstandingInvoicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProfessionalFessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProfessionalFessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589621080112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other liabilities and provisions - Additional Information (Details) - 12 months ended Dec. 31, 2023<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesLineItems', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesLineItems', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaximumUnspentFundsReimbursable', window );">Maximum Unspent Funds Reimbursable | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=cvac_OnerousContractProvisionsMember', window );">Onerous Contract Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesLineItems', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=cvac_ContractTerminationProvisionsMember', window );">Contract Termination Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesLineItems', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseThroughReclassificationsProvisions', window );">Increase (decrease) through Reclassifications, Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfOtherLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfOtherLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseDecreaseThroughReclassificationsProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in provisions through reclassifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseDecreaseThroughReclassificationsProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaximumUnspentFundsReimbursable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum unspent funds reimbursable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaximumUnspentFundsReimbursable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=cvac_OnerousContractProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=cvac_OnerousContractProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=cvac_ContractTerminationProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=cvac_ContractTerminationProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589744006480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/ (expense)</a></td>
<td class="num">&#8364; (198)<span></span>
</td>
<td class="nump">&#8364; 126<span></span>
</td>
<td class="nump">&#8364; 782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense', window );">Deferred tax benefits (expense) from net operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Income tax expenses</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences', window );">Deferred tax (income) expenses on taxable temporary differences</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="num">(1,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity', window );">The amount of deferred tax assets related to items credited (charged) directly to equity</a></td>
<td class="num">(2,094)<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure', window );">Indefinetly reinvested and associated with invested in subsadiries, deferred tax liabilities have not been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">&#8364; 3,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">&#8364; 6,583<span></span>
</td>
<td class="nump">&#8364; 6,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">29.48%<span></span>
</td>
<td class="nump">29.48%<span></span>
</td>
<td class="nump">29.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Corporate income tax</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfSolidarySurcharge', window );">Percentage of solidary surcharge</a></td>
<td class="nump">0.825%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfTradeTax', window );">Percentage of trade tax</a></td>
<td class="nump">13.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="nump">&#8364; 56<span></span>
</td>
<td class="nump">&#8364; 186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets related to items credited (charged) directly to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfSolidarySurcharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of solidary surcharge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfSolidarySurcharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfTradeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of trade tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfTradeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649545360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax - Schedule of tax reconciliation (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Tax reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before tax</a></td>
<td class="num">&#8364; (259,969)<span></span>
</td>
<td class="num">&#8364; (249,155)<span></span>
</td>
<td class="num">&#8364; (412,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Expected tax benefit (based on statutory tax rate of 29.48% in 2023, 2022 and 2021)</a></td>
<td class="nump">76,626<span></span>
</td>
<td class="nump">73,426<span></span>
</td>
<td class="nump">121,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear', window );">Recognition of tax loss carryforwards recognized in prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Effects from differences between Group and local tax rates</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards', window );">Non-recognition of tax loss carryforwards</a></td>
<td class="num">(81,392)<span></span>
</td>
<td class="num">(69,724)<span></span>
</td>
<td class="num">(114,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities', window );">Non-recognition of deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626)<span></span>
</td>
<td class="num">(7,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities', window );">Recognition of deferred tax assets</a></td>
<td class="nump">3,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes', window );">Non-deductible expenses for tax purposes</a></td>
<td class="num">(706)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NonDeductibleExpensesForTaxPurposes', window );"><strong>Non-deductible expences for tax purposes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes', window );">Additions for local trade taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Other non-deductible expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other effects</a></td>
<td class="nump">1,599<span></span>
</td>
<td class="num">(2,826)<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Effective tax benefit / (expense)</a></td>
<td class="num">&#8364; (198)<span></span>
</td>
<td class="nump">&#8364; 126<span></span>
</td>
<td class="nump">&#8364; 782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">29.48%<span></span>
</td>
<td class="nump">29.48%<span></span>
</td>
<td class="nump">29.48%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NonDeductibleExpensesForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-deductible expenses for tax purposes abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NonDeductibleExpensesForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to additions or deductions for local trade taxes not deductible in determining taxable profit (tax loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of deferred tax assets or deferred tax liabilities (DTA/DTL).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of tax loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of tax loss carryforwards of prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-deductible expenses for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to recognition of deferred tax assets or deferred tax liabilities (DTA/DTL).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589620706816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax - Schedule of deferred taxes (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="num">&#8364; (84)<span></span>
</td>
<td class="nump">&#8364; 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquired in Business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">7,777<span></span>
</td>
<td class="nump">7,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(6,583)<span></span>
</td>
<td class="num">(6,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred Taxes Total</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">&#8364; 2,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember', window );">CureVac Corporate Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IntangibleAssetsMember', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(1,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquired in Business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(1,224)<span></span>
</td>
<td class="num">(1,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(1,224)<span></span>
</td>
<td class="num">(1,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(2,774)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="num">(665)<span></span>
</td>
<td class="num">(2,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(3,439)<span></span>
</td>
<td class="num">(2,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(3,439)<span></span>
</td>
<td class="num">(2,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_RightofuseAssetsMember', window );">Right of use-assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(12,364)<span></span>
</td>
<td class="num">(663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">312<span></span>
</td>
<td class="num">(11,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(12,052)<span></span>
</td>
<td class="num">(12,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(12,052)<span></span>
</td>
<td class="num">(12,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">90<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsinventoriesMember', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsprepaidExpensesAndOtherAssetsMember', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">62<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsCashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(1,014)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="num">(927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_ShareBasedPaymentsMember', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="num">(3,498)<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">3,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">3,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_NonCurrentLeaseLiabilitiesMember', window );">Lease liabilities (Non-current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">10,514<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">9,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">10,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">10,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsOtherNoncurrentLiabilitiesMember', window );">Other liabilities (Non-current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="num">(118)<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(67)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_TradeAndOtherPayablesMember', window );">Trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">42<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_CurrentLeaseLiabilitiesMember', window );">Lease liabilities (Current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="num">(152)<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsOtherLiabilitiesMember', window );">Other liabilities (Current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="num">(508)<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_TaxLossesCarriedForwardsMember', window );">Tax losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized profit and loss</a></td>
<td class="nump">3,122<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquired in Business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net balance</a></td>
<td class="nump">4,533<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">4,533<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember', window );">Netting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">10,490<span></span>
</td>
<td class="nump">11,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">&#8364; (10,490)<span></span>
</td>
<td class="num">&#8364; (11,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsinventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsinventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsprepaidExpensesAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsprepaidExpensesAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_ShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_ShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_NonCurrentLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_NonCurrentLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsOtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsOtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_CurrentLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_CurrentLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsOtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_IfrsOtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_TaxLossesCarriedForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_TaxLossesCarriedForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589620834240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income tax - Schedule of unused tax losses carried forward (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UnusedTaxLossesForCorporateIncomeTax', window );">Unused tax losses for corporate income tax</a></td>
<td class="nump">&#8364; 1,700,475<span></span>
</td>
<td class="nump">&#8364; 1,427,735<span></span>
</td>
<td class="nump">&#8364; 1,180,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UnusedTaxLossesForTradeTax', window );">Unused tax losses for trade tax</a></td>
<td class="nump">1,685,517<span></span>
</td>
<td class="nump">1,419,217<span></span>
</td>
<td class="nump">1,175,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UnusedInterestCarryforward', window );">Unused interest carryforward ("Zinsschranke")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Deferred tax assets, temporary differences</a></td>
<td class="nump">20,900<span></span>
</td>
<td class="nump">21,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TemporaryDifferencesValuationOfDeferredTaxAssets', window );">Temporary differences valuation of deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssets', window );">Current tax assets</a></td>
<td class="nump">&#8364; 5,201<span></span>
</td>
<td class="nump">&#8364; 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TemporaryDifferencesValuationOfDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of temporary differences valuation of deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TemporaryDifferencesValuationOfDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UnusedInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UnusedInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UnusedTaxLossesForCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses of corporate income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UnusedTaxLossesForCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UnusedTaxLossesForTradeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses of trade tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UnusedTaxLossesForTradeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of amount paid for current tax in respect of current and prior periods over the amount due for those periods. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589651382128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of shares outstanding</a></td>
<td class="nump">220,833,271<span></span>
</td>
<td class="nump">189,074,911<span></span>
</td>
<td class="nump">186,012,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share basic (in dollars per share)</a></td>
<td class="num">&#8364; (1.18)<span></span>
</td>
<td class="num">&#8364; (1.32)<span></span>
</td>
<td class="num">&#8364; (2.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares', window );">Dilutive share-based payment awards</a></td>
<td class="nump">1,788,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity&#8217;s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589652177120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure of financial instruments and management of financial risks (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">&#8364; 16,731<span></span>
</td>
<td class="nump">&#8364; 4,009<span></span>
</td>
<td class="nump">&#8364; 10,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income on cash investments</a></td>
<td class="nump">15,411<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
<td class="nump">10,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">2,493<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
<td class="nump">10,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">3,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InterestExpenseOnCash', window );">Interest on cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
<td class="nump">6,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AllowanceForExpectedCreditLossOnFinancialAssets', window );">Allowance for expected credit losses</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Loss Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">&#8364; 220<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
<td class="nump">&#8364; 71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConcentrationsOfRiskAxis=cvac_GermanysLargestPrivateBankMember', window );">Germany's largest private bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsConcentrationRiskPercentage', window );">Concentration of risk</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConcentrationsOfRiskAxis=cvac_GermanLandesbankMember', window );">German Landesbank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsConcentrationRiskPercentage', window );">Concentration of risk</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConcentrationsOfRiskAxis=cvac_EuropeSLargestPrivateBankMember', window );">Europe's largest private bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsConcentrationRiskPercentage', window );">Concentration of risk</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AllowanceForExpectedCreditLossOnFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for expected credit loss on financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AllowanceForExpectedCreditLossOnFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsConcentrationRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsConcentrationRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InterestExpenseOnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InterestExpenseOnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConcentrationsOfRiskAxis=cvac_GermanysLargestPrivateBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConcentrationsOfRiskAxis=cvac_GermanysLargestPrivateBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConcentrationsOfRiskAxis=cvac_GermanLandesbankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConcentrationsOfRiskAxis=cvac_GermanLandesbankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConcentrationsOfRiskAxis=cvac_EuropeSLargestPrivateBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConcentrationsOfRiskAxis=cvac_EuropeSLargestPrivateBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589643691840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContractualCommitmentsUndiscountedCashFlows', window );">Contractual commitments</a></td>
<td class="num">&#8364; (3,269)<span></span>
</td>
<td class="num">&#8364; (74,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(53,656)<span></span>
</td>
<td class="num">(54,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesUndiscountedCashFlows', window );">Other liabilities and provisions</a></td>
<td class="num">(88,117)<span></span>
</td>
<td class="num">(103,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade and other payables</a></td>
<td class="num">(48,033)<span></span>
</td>
<td class="num">(73,463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(193,075)<span></span>
</td>
<td class="num">(306,239)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContractualCommitmentsUndiscountedCashFlows', window );">Contractual commitments</a></td>
<td class="num">(3,269)<span></span>
</td>
<td class="num">(49,923)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(7,254)<span></span>
</td>
<td class="num">(7,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesUndiscountedCashFlows', window );">Other liabilities and provisions</a></td>
<td class="num">(88,117)<span></span>
</td>
<td class="num">(41,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade and other payables</a></td>
<td class="num">(48,033)<span></span>
</td>
<td class="num">(73,463)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(146,673)<span></span>
</td>
<td class="num">(172,080)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">1 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContractualCommitmentsUndiscountedCashFlows', window );">Contractual commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(23,581)<span></span>
</td>
<td class="num">(25,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesUndiscountedCashFlows', window );">Other liabilities and provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,286)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(23,581)<span></span>
</td>
<td class="num">(112,356)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Greater than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(22,821)<span></span>
</td>
<td class="num">(21,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesUndiscountedCashFlows', window );">Other liabilities and provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">&#8364; (22,821)<span></span>
</td>
<td class="num">&#8364; (21,803)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContractualCommitmentsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to contractual commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContractualCommitmentsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph IG31A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649845376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details) - Foreign currency risk<br> &#8364; in Thousands, &#163; in Thousands, SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">&#8364; 57,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 106,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Cash And Cash Equivalents, One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Total monetary assets in foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">58,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">13,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Trade and other payables, One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Trade and other payables, Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR | Total monetary liabilities in foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency</a></td>
<td class="nump">&#8364; 14,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | Total monetary assets in foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | Trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF | Cash And Cash Equivalents, One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF | Trade and other payables, Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">GBP | Trade and other payables, One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B8<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B8_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_CashAndCashEquivalentsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_CashAndCashEquivalentsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_MonetaryAssetsInForeignCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_MonetaryAssetsInForeignCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherPayablesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherPayablesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherPayablesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_TradeAndOtherPayablesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_MonetaryLiabilitiesInForeignCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_MonetaryLiabilitiesInForeignCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649477888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure of financial instruments and management of financial risks - Additional information (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>$ / &#8364;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>$ / &#8364;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Disclosure of financial instruments and management of financial risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Exchange rate | $ / &#8364;</a></td>
<td class="nump">1.1050<span></span>
</td>
<td class="nump">1.0666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExchangeRateCurrencyNetExposure', window );">Net exposure</a></td>
<td class="nump">&#8364; 72,015<span></span>
</td>
<td class="nump">&#8364; 77,649<span></span>
</td>
<td class="nump">$ 79,576<span></span>
</td>
<td class="nump">$ 82,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProfitLossBeforeTaxIfEurWeakened', window );">Pre-tax loss if EUR weakened</a></td>
<td class="num">&#8364; (8,002)<span></span>
</td>
<td class="num">&#8364; (8,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfEurWeakened', window );">Percentage of EUR weakened</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProfitLossAfterTaxIfEurWeakened', window );">Post-tax loss if EUR weakened</a></td>
<td class="num">&#8364; (5,644)<span></span>
</td>
<td class="num">&#8364; (6,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfEurStrengthened', window );">Percentage of EUR strengthened</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProfitLossBeforeTaxIfEurStrengthened', window );">Pre-tax loss if EUR strengthened</a></td>
<td class="nump">&#8364; 6,547<span></span>
</td>
<td class="nump">7,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProfitLossAfterTaxIfEurStrengthened', window );">Post-tax loss if EUR strengthened</a></td>
<td class="nump">&#8364; 4,617<span></span>
</td>
<td class="nump">4,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfInterestHigher', window );">Percentage of Interest higher</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NetLossBeforeTax', window );">Net loss before tax</a></td>
<td class="nump">&#8364; 4,025<span></span>
</td>
<td class="nump">&#8364; 4,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExchangeRateCurrencyNetExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents exchange rate net exposure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExchangeRateCurrencyNetExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NetLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent amount of Net loss before tax if interest rate 1% higher while all other variables had remained the same.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NetLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfEurStrengthened">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the Percentage of EUR strengthened.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfEurStrengthened</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfEurWeakened">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the Percentage of EUR weakened.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfEurWeakened</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfInterestHigher">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of Interest higher.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfInterestHigher</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProfitLossAfterTaxIfEurStrengthened">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the profit (loss) after tax expense or income if EUR strengthened.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProfitLossAfterTaxIfEurStrengthened</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProfitLossAfterTaxIfEurWeakened">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the profit (loss) after tax expense or income if EUR weakened.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProfitLossAfterTaxIfEurWeakened</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProfitLossBeforeTaxIfEurStrengthened">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the profit (loss) before tax expense or income if EUR strengthened.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProfitLossBeforeTaxIfEurStrengthened</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProfitLossBeforeTaxIfEurWeakened">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the profit (loss) before tax expense or income if EUR weakened.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProfitLossBeforeTaxIfEurWeakened</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622160832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated statements of cash flows - Financing activities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Notes to the consolidated statements of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">&#8364; 42,086<span></span>
</td>
<td class="nump">&#8364; 28,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="num">(7,568)<span></span>
</td>
<td class="num">(6,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities', window );">Disposals</a></td>
<td class="num">(2,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases</a></td>
<td class="nump">7,986<span></span>
</td>
<td class="nump">17,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities', window );">Paid Interest</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign Exchange Movements</a></td>
<td class="num">(57)<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">41,824<span></span>
</td>
<td class="nump">42,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Payment of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Notes to the consolidated statements of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">42,086<span></span>
</td>
<td class="nump">28,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="num">(7,568)<span></span>
</td>
<td class="num">(6,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities', window );">Disposals</a></td>
<td class="num">(2,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases</a></td>
<td class="nump">7,986<span></span>
</td>
<td class="nump">17,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities', window );">Paid Interest</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign Exchange Movements</a></td>
<td class="num">(57)<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">&#8364; 41,824<span></span>
</td>
<td class="nump">&#8364; 42,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from disposals that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from interest that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589622679728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of the Company's key management personnel (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ManagementBoardMember', window );">Management Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">&#8364; 3,757<span></span>
</td>
<td class="nump">&#8364; 3,067<span></span>
</td>
<td class="nump">&#8364; 3,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">6,689<span></span>
</td>
<td class="nump">12,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">9,928<span></span>
</td>
<td class="nump">9,756<span></span>
</td>
<td class="nump">15,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_SupervisoryBoardMember', window );">Supervisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">&#8364; 1,326<span></span>
</td>
<td class="nump">&#8364; 1,147<span></span>
</td>
<td class="nump">&#8364; 1,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ManagementBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ManagementBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_SupervisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_SupervisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589653826528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of the Company's key management personnel - Additional information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted</a></td>
<td class="nump">207,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ManagementBoardMember', window );">Management Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total remuneration</a></td>
<td class="nump">&#8364; 1,551<span></span>
</td>
<td class="nump">&#8364; 852<span></span>
</td>
<td class="nump">&#8364; 1,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_SupervisoryBoardMember', window );">Supervisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total remuneration</a></td>
<td class="nump">&#8364; 158<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted</a></td>
<td class="nump">105,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of share options expired</a></td>
<td class="nump">21,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ExecutiveBoardMember', window );">Executive Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted</a></td>
<td class="nump">144,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ExecutiveBoardMember', window );">Executive Board | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Remuneration of the Company's key management personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of share options expired</a></td>
<td class="nump">139,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ManagementBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ManagementBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_SupervisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_SupervisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ExecutiveBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ExecutiveBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589645761712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 10, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>loan</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionConsultingFees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 212<span></span>
</td>
<td class="nump">&#8364; 518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember', window );">Prior VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity', window );">Number of shares received | shares</a></td>
<td class="nump">786,746<span></span>
</td>
<td class="nump">777,260<span></span>
</td>
<td class="nump">765,223<span></span>
</td>
<td class="nump">759,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">777,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember', window );">Dietmar Hopp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionNumberOfLoansReceived', window );">Number of convertible loans | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember', window );">Dietmar Hopp | Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember', window );">Dievini Hopp BioTech holding GmbH &amp; Co. KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReimbursementOfTravelCost', window );">Reimbursement of travel cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember', window );">Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsContractualObligation', window );">Contractual obligation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction', window );">Expense recognized from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember', window );">BePharBel Manufacturing S.A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_FranzWernerHaasMember', window );">Franz-Werner Haas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction', window );">Expense recognized from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction', window );">Payment compensated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_AlexanderZehnderMember', window );">Alexander Zehnder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpensesToHandleFutureServiceAgreement', window );">Expenses to handle future service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BarkerBiomedicalGmbhMember', window );">Barker BioMedical GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction', window );">Expense recognized from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CraigToomanMember', window );">Craig Tooman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction', window );">Expense recognized from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_RittershausRechtsanwaelteMember', window );">Rittershaus Rechtsanwaelte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement', window );">Notice period for termination at the option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionConsultingFees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ServiceRenderedIssue', window );">Service rendered issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_MariolaFotinMleczekMember', window );">Mariola Fotin-Mleczek</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionConsultingFees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxAndSocialSecurityLiabilityReceivable', window );">Income tax and social security liability receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_FlorianVonDerMlbeMember', window );">Florian von der Mlbe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxAndSocialSecurityLiabilityReceivable', window );">Income tax and social security liability receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_Dr.IngmarHrrMember', window );">Dr. Ingmar Hrr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxAndSocialSecurityLiabilityReceivable', window );">Income tax and social security liability receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ImmaticsBiotechnologiesGmbhMember', window );">Immatics Biotechnologies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions', window );">Purchases of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CurevacPrinterGmbhMember', window );">CureVac Printer GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionConsultingFees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_GridEuropeMember', window );">Grid Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction', window );">Expense recognized from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember', window );">Baron Jean Stephenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember', window );">Vincent Stephenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember', window );">Antony Blanc | Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionConsultingFees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 85<span></span>
</td>
<td class="nump">&#8364; 69<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized during the period from related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseRecognizedFromRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpensesToHandleFutureServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses to handle future service agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpensesToHandleFutureServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares received from the participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncomeTaxAndSocialSecurityLiabilityReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax and social security liability receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncomeTaxAndSocialSecurityLiabilityReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reimbursed to the company in the form of kind from related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReimbursementOfTravelCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reimbursement of travel cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReimbursementOfTravelCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RelatedPartyTransactionConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consulting fees incurred as a part of related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RelatedPartyTransactionConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of notice for termination of the agreement at the option of the party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RelatedPartyTransactionNumberOfLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of loans received from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RelatedPartyTransactionNumberOfLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ServiceRenderedIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ServiceRenderedIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_FranzWernerHaasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_FranzWernerHaasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_AlexanderZehnderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_AlexanderZehnderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BarkerBiomedicalGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BarkerBiomedicalGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CraigToomanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CraigToomanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_RittershausRechtsanwaelteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_RittershausRechtsanwaelteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_MariolaFotinMleczekMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_MariolaFotinMleczekMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_FlorianVonDerMlbeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_FlorianVonDerMlbeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_Dr.IngmarHrrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_Dr.IngmarHrrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ImmaticsBiotechnologiesGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ImmaticsBiotechnologiesGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CurevacPrinterGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CurevacPrinterGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_GridEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_GridEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_VincentStphenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_AntonyBlancMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589643621792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Details) - Frame Pharmaceuticals B.v.Amsterdam Netherlands<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>Option </div>
<div>shares </div>
<div>item </div>
<div>Milestone </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FairValueOfTotalConsiderationTransferred', window );">Amount of fair value</a></td>
<td class="nump">&#8364; 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncurred', window );">Net amount of discharging contractual obligations</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">&#8364; 1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid', window );">Number of payments in which the total consideration is to be paid | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationNumberOfPaymentsConsidered', window );">Contingent consideration, Number of payments considered | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders', window );">Issuance and transfer of shares to former Frame shareholders | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders', window );">Value of shares issued to former Frame shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsBusinessAcquisitionSharePrice', window );">Closing Share Price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations', window );">Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations', window );">Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CashTransferredForSettlementOfVestedEmployeeOptions', window );">Consideration paid in cash for the settlement of the vested employee options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionalCashTransferred', window );">Additional cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationPercentageOfTotalConsideration', window );">Contingent consideration, Percentage of total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationNumberOfMilestones', window );">Contingent consideration, Number of milestones | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone', window );">Number of shares issued upon the achievement of the successful investigational new drug application filing | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone', window );">Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone', window );">Value of shares issued upon the achievement of the successful investigational new drug application filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone', window );">Number of shares issued upon successful proof of mechanism in humans | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone', window );">Percentage of consideration transferred upon successful proof of mechanism in humans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone', window );">Value of shares issued upon successful proof of mechanism in humans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total purchase price</a></td>
<td class="nump">&#8364; 34,000<span></span>
</td>
<td class="nump">&#8364; 19,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Aggregate consideration in shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,496<span></span>
</td>
<td class="nump">858,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Value of aggregate consideration in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Value of shares issued to former Frame shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationMaximumSharesIssuable', window );">Contingent Consideration, Maximum shares issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">973,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">RSUs issued to certain former employees | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Total fair value of the RSU grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement', window );">Number of tranches for vesting of RSUs granted | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transactions costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProvisionalFairValue', window );">Provisional fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SigningSharePriceRepresenting10', window );">Signing share price representing 10%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SigningSharePriceRepresenting40', window );">Signing share price representing 40%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">net deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionalCashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of additional cash transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionalCashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CashTransferredForSettlementOfVestedEmployeeOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash transferred in a business combination for the settlement of the vested employee options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CashTransferredForSettlementOfVestedEmployeeOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares issuable as contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationNumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestones to be achieved under the contingent consideration arrangement under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationNumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationNumberOfPaymentsConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of payments of total consideration under the business combination arrangement, that are subject to the achievement of defined milestones (contingent considerations).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationNumberOfPaymentsConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationPercentageOfTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total consideration transferred under the business combination, that are subject to the achievement of defined milestones (contingent considerations).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationPercentageOfTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fair value of total consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsBusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsBusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities net of deferred tax assets assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of payments in which the total consideration is to be paid under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches for vesting of instruments granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total consideration transferred under the business combination, upon the achievement of first milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total consideration transferred under the business combination, upon the achievement of second milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProvisionalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of provisional fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProvisionalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SigningSharePriceRepresenting10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents of signing share price representing 10%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SigningSharePriceRepresenting10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SigningSharePriceRepresenting40">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents of signing share price representing 40%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SigningSharePriceRepresenting40</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649503776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Fair value recognized on acquisition (Details) - Frame Pharmaceuticals B.V., Amsterdam, Netherlands<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate', window );">Non-current assets</a></td>
<td class="nump">&#8364; 6,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets (Technology)</a></td>
<td class="nump">6,216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate', window );">Current assets</a></td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfAcquiredReceivables', window );">Trade and other receivables</a></td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TotalAssetsRecognisedAsOfAcquisitionDate', window );">Total assets</a></td>
<td class="nump">7,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Non-current liabilities</a></td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities (net of deferred tax assets)</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Current liabilities</a></td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate', window );">Accounts Payables</a></td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Other current liabilities</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_LiabilitiesRecognisedAsOfAcquisitionDate', window );">Total liabilities</a></td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets acquired</a></td>
<td class="nump">&#8364; 7,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for current lease liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_LiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for total liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_LiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities net of deferred tax assets assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for non-current lease liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for other liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for right-of-use assets assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TotalAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for total assets assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TotalAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Current assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Current liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfAcquiredReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of receivables acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph h<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_h_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfAcquiredReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for non-current assets acquired in a business combination. [Refer: Non-current assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Non-current liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for technology-based intangible assets acquired in a business combination. [Refer: Technology-based intangible assets [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589649790128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Goodwill recognized as a result of the acquisition (Details) - Frame Pharmaceuticals B.V., Amsterdam, Netherlands - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred</a></td>
<td class="nump">&#8364; 19,481<span></span>
</td>
<td class="nump">&#8364; 34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net Assets acquired</a></td>
<td class="num">(7,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="num">&#8364; (12,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140589618276896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - VSOP - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2024</div></th>
<th class="th"><div>Mar. 22, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions', window );">Number of shares issued for exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity', window );">Number of shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity', window );">Beneficiaries declared the exercise of all their exercisable</a></td>
<td class="nump">786,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=cvac_VirtualShareOptionPlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DistributionCosts', window );">Distribution costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=cvac_VirtualShareOptionPlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DistributionCosts', window );">Distribution costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in the number of shares outstanding through transfer from shareholders to entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for exercise of stock options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares received from the participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to the distribution of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=cvac_VirtualShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=cvac_VirtualShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>165
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M]X.C,,1&&W6>0?%$OT;Z# ;;?Q"0,&# ,2T%C\E4Z[R9L$7S2F)HSC!H)\,
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M$-!/_,#NKQ#0QX2$(RT6]YH)3ZJ#Q4=>TC)E4V7F#<;&8>0-ZFP(\UTWL8D
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M U-&;MBS]P@!.2I$&J-A(>DP2Q$F'H A0U@4)NQ(]K&YB5)LI4:'&<B@IY1
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MB9.CV>SPU\7BZ& L_@ "* &3JQK6Z('R)DY!M+O*>>3 06WS2$EPX2/B+AR
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MW,(CD8'<-L2VB4>ZU=!;14_"L4K0N5#<#CTL *+UJCF(4-JP40#\O[)=L%Q
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M3WR.06\.^*DZV=EUS>K[6#=?QXN<.JYA@3L*(K,(-YPBHJPDL1R"39D)W*X
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M:VK*P+Q'(EN1]47XCE/ZD:27CRJ^"0S]_ 95STB3X/O<C;%>Y?+BV?)A'S$
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MHPZ,(,^*G]UEW# PYW"5R+AK9HL>N:Y0X<0(CNK7X4K ;U(%4%!V;' :"<'
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M_W*'7U(#/II\3C9QR!5";XCMH6&R@;FYKLH'+3AYI&6:L[S-^5'CPEE*$FI
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MA@D9]P4J$XRQ2@:9?=[QO BZ*#TY7W!IA9+N=BQ+HW?5^#6&95(R"1@TY/6
M3HC^,-JW05@I4$^=&0)^7Z%NN-PIF'%*$2Q$QEU+AX*S)4S A'B9D']D90%O
M/B9T5I'A_9YA$TTZELT:$_-SO-9+SF?H=2>*XN@;QW2WWH$]Y1GCG?T/ ;=O
MO/]@L.;_WX=BBS!9$12;AXMYQ]VQ#%>K^5$H,PV3"9H1LW Y\W'3+$SP\SAN
M@CZ7Y)*)%P"O? P4K\)5#"CF'X3-2'V:",>-IIQT3%BT':W".$%G232!Z?L
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M8<P6_>O3.M=L=);91<Y&3':.T^Z ]<#='7MT::S>&P,S:7[*+BI5UU9/A5P
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MDV,#K"\M]-"^<(+NJCW[!U!+ P04    " #TC)A87LF%5F4"  "@!0  &0
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M!4><: &>KR50;RYH@^X;Z]G_ %!+ P04    " #TC)A8V/-W=&L6  "W8@
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MJ+[LA:'N64[[L@!8<B5YD;.VZ?0%*O5/'\\0R=\TEQ#!:\ B*H@)8%^FEY=
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M/2=(!OH* +8MPPV!F'SC3;WGF\$K^[IC.BUV'@*-%5>4-FXQP!D\Z$419CF
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M<VAE971S+W-H965T,38N>&ULG551;]LV$/XK!Q4H6D"S)$I67-<VT+0=MH<
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MA>>QKNH2-X=0_90Y>=(9LL\.OUDA J/8KB[LZY7,5U[9%>D6ZJ'EE&==+1Z
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MYQ4'RO6NSFW*/J37K$#-(G0MMD6K)&,7./<G*[*C)7CL%.>45A'VUY97M9:
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M50J@TO_>DUC3GL^S/PW*;ZA60MT7MN6ZD8HK(ROR H*)G6WY47 $4?M":]B
M$P56[(?*)R66ZR"^, X@V(@:++RHF&1EU=LM&8_^S8NR3)>2%BLVFJ U1LG%
MCJ"QG"7J<,<F:, O3*Y1F_&F C<$EP2DU1EJ.JV4<=![RG.ET+U*&U4P-)^7
MM>>B"PK\H6976WEH [5R:-/AFK)6U*;F!;,#*4JFZIN.,M6_0SI=0$:W1<[7
MP%PVQ=]PE 2P0$8=Q6"YUZ"MN_8T(6N>YZCZ9C&6,XV;\8FBAQ5!*=UP\)'*
MG$!>Z%*4,2B-G+&4X@\#0.2AA4#[NP>+!^E,R7O !Q!W.T%RMN!E3FN+*[7%
ML8(J]R*DJE6J:*'K^]H)V$+*9 6R)__92EYF/-6% CWYZK(-_-T$:S6FY%>Q
M8\ #EJJ!1S I9P+D@FQB6=$#NJT.'IC"H^Q5*$K 4X!_0S2 %(N!:*&+$@.[
M$=>T#16-U_M:W('EVDY;\N7&P6K2O-VK-5BVM11YACJFJDVZ3'8Z5#EZ953O
MKIE<J!IE9!J.6!?RMJ-M&?2-KO[MENL:ZM^I7(!.@WSF &I/HV!$I*Y+UIU*
M;%0M\$Q4E5BKSR4#FY>X .;G0E1-!PFTQ>'7_P-02P,$%     @ ](R86%_D
M9M*. P  HP@  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULI5;;<M,P
M$/T5C9GAR?B6-$E+DAEZ8>"!F4Y+X5FQUK&FLF0DN6[^GI7DF!1"8. EUF7W
M[-F+=K/LE7XT-8 ESXV09A75UK87:6K*&AIJ$M6"Q)M*Z89:W.IM:EH-E'FE
M1J1%ELW2AG(9K9?^[%:OEZJS@DNXU<1T34/U[A*$ZE=1'NT/[OBVMNX@72];
MNH5[L _MK<9=.J(PWH T7$FBH5I%[_*+RZF3]P)?./3F8$V<)QNE'MWF(UM%
MF2,$ DKK$"A^GN *A'! 2./;@!F-)IWBX7J/_M[[CKYLJ($K);YR9NM5M(@(
M@XIVPMZI_@,,_IPYO%()XW])'V3S\XB4G;&J&9210<-E^-+G(0X'"HOL-PK%
MH%!XWL&09WE-+5TOM>J)=M*(YA;>5:^-Y+AT2;FW&F\YZMGU#=62RZTA+6"J
M:JIAF5K$=;=I.6!<!HSB-QAY03XI:6M#;B0#]A(@14(CJV+/ZK(XB7@-94(F
M>4R*K)B<P)N,7DX\WN2_O P8T^,8[G5<F):6L(JP_ WH)XC6KU_EL^SM"8;3
MD>'T%/I?,CR-D4\3\BO.L2-N2$E%V0EJ@9'-CC#^Q!D*$5L#*94T2G#F+R4V
M!J&,(:HB5YV&+[1T"DZN]R6/,O0)-+Y@(KMF@S90TIM!G<X:2Z5'YM(K5=R@
M:<>%*Y:0S_^",V!@<802*0C>^5HA/34D7\SB+"_B,_SBYCS.YM/X/,^#5)'%
MB\DD+N:HB]@M^+X@=HX+QJ5& (%<K'*OG9?!^1^A0U(W#W>D2)QMM\J32; ?
M-OF"8*L\0?%GJ]=<=,YY^%.:.N/<'W+P^M6BR.=OS1B\-_O@'<:J5$V#K6^(
M(I>EZ,8L,V<7.1"H*F0S1ON-:W*,M'2'O=<2VE/-#,&H,+"@L04Y*OC.M4>Q
M. E,IW<$.U7Y2!JPM4OK1SED& G6(,?*<=&E8TW%)RUB .#9,<:[2JLFU.80
M#]?1D?&1H*$%%.0ZN.N'1Z\ZP= V.DMQ$$C+?W(^(?<AN:T#-CY7=_</ONAS
MS/0\.2MF_C2/YXM%7&0S9P=OL5.!+U;L5B\K\3#+,:;IN#NJ:3L[NL.&6OCS
MB]A 23L#@ZM#"@_\W "\]#0YUJ32@\'1@-[Z\8A%ISIIPPP93\<)_"X,GA_B
M87Q_HGK+I7L[%:IFR?PL(CJ,Q+"QJO5C:*,L#C6_K/%?!&@G@/>54G:_<0;&
M_R7K[U!+ P04    " #TC)A8:BH<L]01   ^-   &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6R]6WN/VS82_RK$'GK8!12O);^S28 \FC1 VRN:MO<W
M+=&6;F71):EU]C[]S8.4*#^V2=$>$&1MBIP9#F=^\Z#\XJ#-O2V5<N+SKF[L
MRZO2N?WSVUN;EVHG[4CO50-/-MKLI(.O9GMK]T;)@A;MZMML/)[?[F357+UZ
M06,_F5<O=.OJJE$_&6';W4Z:QS>JUH>75^E5&/BYVI8.!VY?O=C+K?JDW*_[
MGPQ\N^VH%-5.-;;2C3!J\_+J=?K\S13GTX3?*G6PT6>!.UEK?8]?/A8OK\8H
MD*I5[I""A#\/ZJVJ:R0$8OSN:5YU+'%A_#E0?T][A[VLI55O=?WOJG#ERZOE
ME2C41K:U^UD?OE-^/S.DE^O:TO_BP',7XRN1M];IG5\,$NRJAO_*SUX/T8+E
MI0697Y"1W,R(I'PGG7SUPNB#,#@;J.$'VBJM!N&J!@_EDS/PM()U[M6[RN:U
MMJU10F_$IFIDDU>R%E5CG6E!^\X*V13 LH$SPN_#>::R]_;%K0-1D.!M[MF^
M8;;9!;9I)G[0C2NM^+8I5#$D< M[Z#:2A8V\R9ZD^$[E(S%)$Y&-L\D3]":=
M8B9$;_+_5@RSG9YGBS[XW.YEKEY>@9-991[4U:M__B.=C^^>V-2TV]3T*>I_
MWZ:>9IO.1N(O82T^J$896L5XA([]%FC^)G-16:$^[[55A7!:Y,HXP*03"H?*
ME8 F=@^P@/,JY&NM\NSK2JZKNG*5XN^N5,(9V5A)*$)S-9!SP(5(X?IU:V''
MUHJ=+E0]$K^4<'*>WY8EKA^!:0W+2#:CBLKQA 18_MY6\/W1KV MF'OE9XCK
MJLGKMJB:+2"",:K)>6H":G *]@(3D3*.T>J]J7+^>D/""%GM4)LT(5(P: RD
MJ:L="(,;W6L'PZBK1FTEPJ6H=F",<!0-ZA94!MO.I2W%!M#<:TC> X/B038.
MZ"(;V3P*O=]KX]J&->E*Z80$]FHD7L,R/ " S82X#D\\G":>"?X3L+)6TJ(,
ML"DI'I4TXE J6&J\@DH)DN:E;+8@'LH4'A-Y6 PT+2A+[&OPK'[/K#"P2.NJ
MNH; M-E4>06"C,1[,ALE/C:YWBEQVPU\"VIH4*YWK<$3018DDD(@$P!#:K<&
MU@&*$F^!H$HF=9  >K_^+-)YLIBD]^(:9F7/:6B:C,>K>UJ7\D@Z3M+QY/Z&
M=L4&A,8!+O9(QAO.W].&8Z+3J9H'&&6G(C*S9)H.>:7 ?3+@M4P]'W M"&9X
MXJQ3L06&GE RGF<#.EF2+I?',H]7&9K>5ZM(!>4>8%N>_'0U&3"<)(OQXICA
M9+*\J*23[0 ,(0\FGRVR([U,TN$93)+59.6I]WX1-!]4#J:+D\='RLE60V)P
MZ+ ?T,W;'@,&G\$GV2$*L7X,WO#/?RRS='%G.T45:B\-'?"0$OD83#-ZQV*A
MT/1! <@\R+K#64T.TJ,C8R!"2L :X*$MPAOAW%HV'IN&V%VYEH Q 0IP;#52
M"@!'<$R^AZ!'R8PR QZ0)EH'1/&S ;L $=>UA]X<$@2#X,.BC2X /0H6\K"P
M+E>XE*(#J\423K-OV&@&XH43&T@>S^]J)'[HT:FH(%15ZQ97H4T3.9"@4+!?
MR PO< ;+.&/RL*BB;0,!" \Z1P1/LV]P>D=<HGT1IG[;&DC$.SNHI=FB]0'2
M/^!"5$(B%M_@B@\*(F/S^.1<4M0BI?D2#.X_VOAUXGMXI"Q.NB-!C$)7HN"#
M(JUES6AFR<4PQK(2V:#(3#CH;#0<>8@7$<ACO,\=)@)D6*A\;UPU!175E,BA
M8$%)B[;=0R94827 M'U\S.6^<K*N_LL:Q]@#!LC4D!<,HG!K_4 "&[5M01L4
MBQ\@OU?%Z-CW-JVA?5" 8!]D,"5K142!,,(1.TY=!L8I:ZMC"Y5QP$<X(F/\
M0W/'?=(*V%:P;S9>6Q4 /FS]"&>@0)5+4#8=6*]?6-AY':^SCNS1J'WKD#6,
MUC7H!TT6-HB@$C*?+2C--'1B6TB G#8@T\^1T-&1#F%!YKEN&R*(<<GLD3PN
MT) .: H)(,->/G* 8D7XR$VY S N6A5K:*@-(J\,2OLH&MV <5 ZZ.VRT0Z$
M@PD@#"_,I3&/R%?N<"G2.(]_R%-OF^J_($ZA@,0.$SN?IGRN=NT./T- <54.
MBZ)SI<3&^ZY"?,7DU>(D]G?Y(*N:5+YIF\)2VN$1EOW'E4:IZ&0N =+K2XB"
MG#&TL1^1,M#6<!BQ(!O?]2D<R\V!D!ZFX.P:7(FM"B/58I@OK(X3D]G]3>+S
M.#YI.#NA-AO,JR,M4@K>Z4%T&7F7#U&<G"X'S&9' 7X:XN]1HL"+LV'0G:6#
MQ; /"+??#Y)LR.?>,G3$5OS>:VO?&O3=*!OML#0_695T8QS5P%ILB8<;ALFJ
M 978X# ,HQ!<VF%VRR&%CAPT3^;#<TI=@YM[TP?PQJ:)T.O_*&ID?)ET/L4G
MVX7C8'Q \9BX@(R@Q5&CVVV<-N(YX=Q"/:A:[]G)D2_G\][./\"R_4B\D0AT
M@+^#6D@BC/BN"^U7FKP$*($E28>6)<PJ 94 %?)0)%7H#_5.6TP@0*46", 3
M+$%8,>A :'*(S<[&^_$U'.:9AB7 ]+^Q42F)INJLJC>H4CQP#=$EST'B35L/
M]PNDK*QYN]*''#JGO=$%0"R?#"GAB03-QQH&$?*Q"(5"ZMAI$[<I(8]2][#E
MM03$)H]'8CR/PA@29(<_PR\$B)CCQ5PPZ9,-R,6PJDOZ(I,*WYIC:U&!:^.P
M#P]&]0KM+2-228![GW:A6<!,L _34+D:D!ESBC"&YEH@830!EA]*.X-UY0[;
M1:"3AL*^KT YT87$R,<O%*P/UY'!%ER)R A5L2(907T'%J*<-XO(2#I'\RKB
M/4'^KUU%T0QY*0Q#6%F"%74FGFLO$![E%D#=9PC RC<#F"(6Y6?<,VI8**M;
M0PKO@P>8;,A1.HXH2FRY8)\H_# KP:AH6]H5\E2?0?2&? YJ?,V)&L.'0?LP
M0>SO] %(FZ3KJ% VX*-8%[MW\A%S$;\TI"80)^%H,0ILQ.\M)&H;BL*YQCP$
M01*% MQ$@P,$,:=C&%8@G3 %63DEC*@DE@'CLQ77%N(FY5P_:C"AR6@Q(HWX
M;\O1#;D0(',.4,LTZ=DJ/MG2XY5[!F//?'ZIT>8I,3(:6.XZI#R455XF;'ZN
MVC%TP]\D*"+@N9%0D E90.@!>R!/9"4'2BA!96U+^Z/<9@>FSJ &VO]1^\:&
MKXEWLE !G&,3W>L:6Q<6E0C"YMP[06NA8-"E[\6P)+>7:G+2(,94LEO0OV*H
ME!O(H:4I^JY5K$3V/>N- P^R,XAJMX.< SP'# [%ZIW6AUMJT& 0>.;3HI!'
M^@(40@1L@Z(;&!6[-;"DF(F9$P&$/8[T;&;H+@K[ 'T7J\N=8\@JM&*QR;'9
MKP$$"Y^R/M&U#%A'F;U/4R6<HC:A*\8Z"3#8-_WV4$\U7 AJ2%>_BZ+A,$[Z
MT*B;"*7( ., F'C7\,D5%Q8AQ2<!H].$% K+A+[OU8L%>I0Y[2( 1;1[*,>P
MNX=Y>%T(RI5DM^NM9A<'>S:^6NLW>[[7QW($O">HPQ[L8Q<ASW8Q(BLBSXK@
MGE)%CY)Q+RPXG=R#CT#\IW*X+;;@ZN$81N)72&AW9*B)+X#M'D.JEPG9#ENV
M\:YJ9$_V&J>(AU+3$8(@  R5+:G:&8A!GV5><CSP+DOV\PQ !5RGW3WC[$8W
MVV>(?)$9<.>ZDVF WT')+(\]:3>O.=,D,I$\(4,=]'5@;E3$H4/!J;A0ND'1
M&5*-OCV,I0 (60?4\=[[B"BUJ7QV=5*&';7BV8PX^5KC1:*_1(28:<]2'>14
M?2<D:NZO0](:ZFZ4'1-+R]5ET16HSZE\&D_N_KZ_M;M+N44:AE*T@YG'Z&[>
MUMV=#/Y""1YA-I8[]V?^?QMM$>-+Y=TAD+B>)-E\=3.0*\WN+GX/\[^GKE>L
MU6L*K--1UA.[7B39;!I]AUIUMDSC@2P!^M' ;)+,9_,;\2_?BAE>R< 1<RLH
ML$MC;LMEDJ:+K]A+6/"+P=#:MT;A^+G/X9G$ DZ7R7@R^0HF80$?UG4ZG2?S
MQ>2KE)*N)LEX,;OY8VOZ"ZQ1G#7'K['&[*NM\7JZ2E;90"G39+)XXBRO%S!A
M//X#0T0#G"YBLK-DOAKP29/%,AZ839,%2O(5!G@]39/I@,T\2[+E/&8SCH]S
M/$D6L\D7V=WU8I),YU]C;V%!L+=%EHR7 _9IEDQF\Z$2EN-8"9/Q/,DFJU.#
M>^\O5 :7D1=&*\9G^DRW@%3BR"JT'JB<H69E%#?H#K&[/8!P"M%G4V-3DP*V
M[W5B<N!38^PJ'=_R4,]Q=-(CZ:CZ9DO74_PC4OYFR?I63,672Z=!)JI&^X3D
M^E J?(GE036\Z=# HH*WT3L(@,Z7.QW_H,F;[B::&P=6E*JF OEB<C2B9A:V
MG?H<R[$HL"NU'Z1?'YN<*Z8P\.D %8EX_8$/JVWR4+N$HZWH]LRW^<\\/R;N
MK>#73^_8T#?G6;W][GV?KWSZ]O3,HL/I>'F;\CW70>U"S7A,%.EBX:^+X\3D
MFJHPW5K@9F_$VXMYZFR1C.<IW_X!A,\RTL,)S8RG9.,9ZN$$%N+K@C29S<;A
M%C>=$#WV=,C.E,,^H<^CSBELMDR6$X;G8R$N8E$Z25:KM+M+GH\'>YA-^?IZ
M(3Z\^:G?$>^'=S.4+D;4<R*FTV0,U,Z)^!>>8?;E9Y@"%L[F<U8 *&,^G[+6
MGSBE ,IA%_CYZT[J2[EVQY0A8GN]+Y+58C4XIB5K=#$\IB[$<_X(?_[$@0'C
MR06;>HT=6GUH0M?"^2LOO)3K"]P?1[^-CBYVY5$H";=OA,/87//P"ULD).(*
M/SD#H,+B6X0$QJ!O0*I'"ZS@'Y&D]ZP:C[[1FT%(&[N-,?H0@KEPHQ%>:C@3
M9LXM]"C8=U(AE+F#@L!PQA@"5EXZ@O#<]_VX8=HAW8]GV \MGYSYI4A'XSE8
M&#R_\;#&7HY/TO%LS$_8;)+Y= 7Y&_4<D. 24]0,1@)EF@:91CJ+IRU6R6PQ
MCZ9UEN'.76-57+DAK5(64'K*>]7X$A-JM0=E+)7F^- ZT.,6IL.$!-Q%0.P5
M.37OZ9T5YPU$%-@#,0E7YOUMS /$<39'BJC8.7<2"W:PB6=.?O;W:0TU.5P_
M<J#&![UVM,;SDW3M=70&?Q=R?<MW;.  04HJ>AVF%21=-"%(?30CD/K4Z0_S
ME7^3JO'3I?$)&$4VZFK-H&0\95#^-V"L#]P&"0P OP#'KZ'Z&4=%VC29IS *
M:?@4"L..:':&Z!F:$$YG*Z0YSY8QS=5B"4DWY+E1C13@I:@*ZNO1D16*WH3
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M% F+F?)KI0!%96G-+6L[NQ/3P^=[4_%CK4V_E%Z4RFJ3#IMC-#%>!>Y3)>8
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M(96SVD?#U%'GFM!VL08!%MS#KQ? K_BVFZ8/7JZXAQZ'KZ/5LP!HP7)$\,:
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M\=[D_'&IT)9:6H#W<V-\_84.:'Y&]>Z_4$L#!!0    ( /2,F%@[6+QE70L
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M%I!R\-L@$7>E\\IFLDS$9^5S90L(ZCI^!X]&QL)8T=_6RC,XPG!ED&HD427
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M&85"*;84[@D5?DVQV<Z9X%4N">[H\P;B(E7]VS\^0QB@UCH%%E5J18Z)U'B
M&KS@C^F@';2)-==Y9&+=V-HX#J4=FKK.3;!T$<UB7D%JOC^+X,L-Z'"X"66X
M@TE2K>?&>"WZ'>"VNR4SG"K<Z.!?=Z. $(7^A(&8'SBVBB93,: I3EZY=3XM
ME:R ;X6Z/GKO>2:@<JI>A!K)0I?+L8<YA$0M7GY 02Z7R-Q)>X-^6!P,;.RH
M7#Y2/4>:T;A(-\S43I4UW-,.2P0QDFT.X>@^F7L #%N-<GNS=+"?(W8\C1/N
M]JX68_^4RRS.:+M[HB7BJZKBO4JL#\;VVH7!H<\?%[T/4R7BFC^_4;P@1,(W
MJFZU^\)W%SYL[;:'SX._\-63P^2_PM'AX')V(FSXY!8>O*GY,]?2>&]*_IDK
M8*&E#7B_,NC^X@,QZ+Y[WOX'4$L#!!0    ( /2,F%B/.N+D.0T  & @   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*5:;4\;N1;^*Q8KK5HI"1#H
MR^VV2(&R+7O%$L'"2O>;,^,DWGKLJ>TA9'_]?<ZQ9S*!P%;:+R69L8_/ZW.>
MX_3CROEO8:E4% ^5L>'3WC+&^L/^?BB6JI)AY&IE\6;N?"4COOK%?JB]DB5O
MJLS^^.#@[7XEM=T[^<C/IO[DHVNBT59-O0A-54F_/E7&K3[M'>ZU#Z[U8AGI
MP?[)QUHNU(V*M_74X]M^)Z74E;)!.RN\FG_:FQQ^.#VF];S@3JM5Z'T69,G,
MN6_TY:+\M'= "BFCBD@2)/[<JS-E# F"&M^SS+WN2-K8_]Q*_Y5MARTS&=29
M,W_J,BX_[;W?$Z6:R\;$:[?ZJK(];TA>X4S@?\4JK3W$XJ()T55Y,S2HM$U_
MY4/V0V_#^X-G-HSSAC'KG0YB+3_+*$\^>K<2GE9#&GU@4WDWE-.6@G(3/=YJ
M[(LG-\TLJ.^-LE&H>_P;/NY'B*67^T46<9I$C)\1<3@6E\[&91#GME3EMH!]
MZ-,I-6Z5.AV_*/&S*D;BZ' @Q@?CHQ?D'75&'K&\HW]C9!)QO%L$U<:'4,M"
M?=I#\@?E[]7>R<\_';X]^.4%!8\[!8]?DOYC"KXL8GPX$D_$B LK?I.V0;F1
M+X\'HG9!4QT(;:/RNA(ELD;,O:M$7"KA[,)INQ#3)3)=C$6!8W0AC:B]6WA9
M"1F""H&65,ZZ>VGH,&E+,=/Y2^5*/=>J%/>R**"D*/!:XQ@5A%P )D(49U=W
M%Y^'A_^!%J)P52V]#BC1E8Y+(871!:I>]65>_SX94O&5>;F,SG<'K)17HFYF
M1J,.RI'X X;@M/B,#E@\4V1!"2<9P%N9U#!&SAPDZU:3+S?_'8EK%5#@8>.B
MUG'22K,..HBP="O(B$L9Q<QAWXY#&W;96>/5G2Q^_NG]^/#=+X&<6GNM(H4G
MJ,+9<KA05F4=R&@@3@%,@S"L+9L"YU1*6@B;-T;HJFKP"OE8.S@L<"#F\AY6
MS Q\X QDS;31<4W[Y]K0FL*[@#_&M$XJ'?8.8%AAFI+T)#.!UGC;7S(2$]JS
M]$KU'PM#;@PI"C-">:RAYTU(GNT%KXM[=E'8Q!H+Z=C;T<V(S3B_'5'V7DI?
M+'/NTOL9_#/7A4;&8+>;\\.IUTB'NYNKJ:B-M AL81!FBHG2GB.&)(I.J ?E
M"PW=THO\E9T5EM@14O*DSSBKD)7:6N62EG&I?0DU+2K)!PJ?G",KQ,7T2KR:
M- O@MC@\3OCU>L""X U1*!\E>01%535()R_9W_?.--7&G)PFXO?1W:C5A5QB
M]/=&EQ3,[/*E1(TH1=U1%ISZ[]Z_';P[?BONM8\-RC;OYMBTQF//NO7KF'4\
M9O'ML5X5"G:5G; LI*N GKN7SI3P0/(+\K^4ZY&XZL+V=I!#U\J&Q3;,E?=/
MQ2,\)#QK26[9BO7.;#@C,+ H'I00Y:-D5UHN**,D@M,!%R=!23GAD/MZD0))
ME ',IE#M\5EB5Z(SJEP@G@@%D(+]5)/Y -$V6[HE"P>/:[8$]J%8Q>&;@XRX
MJ$]R^UI)/X0>_6JS,C8>.V6,GE>.Q*VU"$+@S()O=$FQA%ZEJG2!K7,O0_1-
M@8V*3DQX)DM9QV1A@(% 82!0-&LZ"QF"!%1S\J>RQ3I9HCS3.@M55TN@@R :
M1RG*XN!6CX8@Y@Y$A$*L+4%^8E/8?OVSK.I?/B=FE1T"JD35$3J_K\AI$:?6
M $*@; "6H@2D0"8LJ)[CBC+X_/8:[8:D'J$\C&$W(.(3>-NTO0L)F#+CQYH7
M^D1L:PIM8X8HE?GEX?X8UC7EFM[#4'C'68J>G1OTS[_E4Q!/1>15[2C54N@K
MM(:V1_46R@ (HA#@/#A8S+R3);L!\ Y5D)<@O .!0#A.@?PJP/^1"CDEJ<'F
MQHL_OUX-49.NJE("0T.*#'72'>V) - RGK[0IN(CW9\:"Q[-"$^:S1S\%'6D
M0F\[.&G'ZF\KQ!'L=1B8*1;>-75Z\[1M_$C;(4_O"(=,-EERUA*UCA-P=*'J
MF !=SE5,>;ZK$0Y2CV=/R+^HH#D7@D-'TFQY2=BN6B;5!AX,2"CL!+0@OTND
MDGB%A"U?"]<^&>,)'(,VKE[S*<CW0&(('AGE81<,1D.MJ+[6KD$I>%:5\11G
M4U '8J%<I8 *!7?]-@:9(R0@CSN=TX9ID\^3+D06O<83J0,RJ(="J3)URF=.
MRP74->JG!"S@&::T0%T6,G<3C!SOA! ;M4X[M7:?SD5'24&P0H^96J@V2-D!
M+RJ7]6%J]H_YB&R3?J'HJ:NCKO3?,H$WDFS>>(Z[KI!#1*&?T*\G7M^8MP*H
M >TR@4Z$AQ*V+!GS@3TM;#$N/0&_?KM35-NIQH$3,'J8J6S5LO'D$(:6!?@:
M/^=\IUJZ3;0E9_P?Z@$I??E93"RU<F#[&34$+\[X& 8P.KQ_!+:A$RBS1<S3
MKM;MJ6RW635U(6+#N:^$-?)XH9EII2[PF" W%I0'X08QCH[Z)DZI4R'3-E(M
M']N":ZD#X^MZD/ASPN$!.P6-KIE+:IH)<\N^U=V9Z@%M,1))I*G@&>F\&^!)
MU0;+!HG8&)E#6?IFT7=8.K\;IFB )":SRT><)UW'W>%X3%<@4/BB&0*VW=Z?
M.1AUZ/8#J^@J!RCH%GP^*4- AP)H*B['$L]3GG.6+/5B">>C'E&,)>^QBIK>
M*141]55R/ZN*TD?1SIK842A=DG+S+/%YE;NFE_*'; >=)!BR0 *1)ED8M1AL
MNC=K9Y \PV3$$I@\I,LH0<'>;$G^;F+$YZ$JB6AH<(-TB:4+2AUCN!\"0?["
MFXB^H+H ;2+;PA]Y!& Q_ XF1H7SV ;6IKMKRILJ]- >:VG%#PTIW(L4YS&F
M/Q"ZQ&Z0WAT@M%1%IY#*.DV-S*9:?7L!9.  9(P3Z49>L&Z891_#QK3EDU/T
M-AJ7F,1.MO&"S/A543,SX!H\9!=DWA=%O!$P]8>NE&&<]<K(3#]Y2O@G\83L
M$G&%VDW8G"9!6G  0:Q.Y*B@Y.K8;]T7!X=D3=H!DO)1/7"EX!S "\W=F[$3
MCD,W;YUTM)E,VJSE*<+K\"TQI3X/7S2&.LLZQ0 Y$K@JDLD5W:!" 1HN.Y=4
M<@V@C(S[Q5*K^YS"/5T] 1+W8D;JDG>#WU<T;_-02<T5=*!W,?&_\^GD8J,Z
MU#$Z4TW9G0X@B_GR5'**035 6$-XEQS=A8+2X=YI&FT /%ZU4-,VO-#,,&%9
M3DI9@:U$I@5>KHBP@DSP],)>@]+\[C/\5LVPM[W& ]&+S-F8*Y2<B(TU^ILR
MZPTIW>B\<HVAZ98XE67"/>E:I0&ZTP!1ZQ*;"_ "#K/"=Z1(!W/*8@QVEJU!
MJ2$2#!UI**SJF CC5G+1[8:,.*LHG*?LHZ.T)0KH^,8!8Q(FT&[P#M$5WVK0
M2>:%'OBC_8:63*>30<KS%?AEI :2^6JZ?[!(&9QG0#*(L2*C&D3]%KR<W$I'
M/_()SJ!TRBZ!;$1'-;6SFUS(M<Z8!N>4JM Y0Q&H2EO"C:WHCQ"K4.O\N%W$
M3>UQ._YR.147=X_Z* T<L6,)AMC3,,#][955"X@]JM!1LY84$6TSBJ-\AIJ
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MV0.;X]^STY?H:OX->>9B=!5_1'C@<EJ ]W.'#I._T '=?RHX^3]02P,$%
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M[]JVV%1P)F=OZ^X6>,U9F9_]XKI;D!_TO2,C7YS.L]>$8L"!LW]U0!U84;H
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MHYD709:4&(V>'O__C0+E*:[@_(G4B7BKH5OZWG?X^$(??XPPB"_P(_W[=W6
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MN$"3^A#L,%1'T5:*1^ _2%+@K-P)3.PHPWEL>7UBP/&5HT44!Z;B055%*8!
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MGYC;ZQI\ 9ZO:U"0Y ^< '.*:7DO_A]02P,$%     @ ](R86/Q5UJ'R @
MQP<  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULK55M3]LP$/XKIR"A
M34(D35_6E;82A4V;!%I%&?OL)I?&PK&#[5#Z[W=VVM"A-NP#7^*WN^>>>^([
MC]=*/YH<T<)+(:29!+FUY2@,39)CP<RY*E'22:9TP2PM]2HTI4:6>J="A'$4
M#<*"<1E,QWYOKJ=C55G!)<XUF*HHF-[,4*CU).@$NXT[OLJMVPBGXY*M<('V
M=SG7M H;E)07* U7$C1FD^"R,YH-G+TW>."X-GMS<)DLE7ITBY_I)(@<(128
M6(? :'C&*Q3" 1&-IRUFT(1TCOOS'?IWGSOELF0&KY3XPU.;3X)A "EFK!+V
M3JU_X#:?OL-+E##^"^O:=O U@*0R5A5;9V)0<%F/[&6KPY[#,#KB$&\=8L^[
M#N197C/+IF.MUJ"=-:&YB4_5>Q,Y+MU/65A-IYS\[/0R250E+9<KF"O!$XX&
M/MVSI4#S>1Q:BN#LPF2+-JO1XB-HG1ANE;2Y@6\RQ?1?@)"H-?SB';]9W(IX
MC<DY=#MG$$=QMP6OV^3;]7C=_\_W4)HU2.\PB"N4D2E9@I. *L&@?L9@>GK2
M&407+11[#<5>&_IT08675@)!98#&<KIZF$)E,*L$"+K#!J@8@4O+Y(K3GP)F
M#)5O(F@\E$Q[N-.381QU+^#8N%"973.-T 6KH!/!!IDV<,,3*DWBLK,;NN-X
M=WR/22Z54*O-GH$_:E&HWRC4_PB%2DV]2]O-&92"20M,IH!/%2^IJ=A#0K5'
M?4^H&Z3ND"N1 B\H]#.Z, 8Z7K;^OBX\8>*5B>=5L"2G>&:TE;FWM?]E<]2O
MMF>055IR6]'_<&X9?W'SMVXM&@\:C0<?H;%V7<_9T$E]#P]>P?98[RI+J9[!
MK.(BI<(U/G-3E:784!48RX1@KL6_U?H!<YY0(ZNU.:(HQ.ZP?URW<*^Y%JA7
M_@DQX-M(W6>;W>:5NJR;\ZMY_<3=,KTBPB P(]?H_ M=.%T_&_7"JM*WZJ6R
MU/C]-*>7%K4SH/-,*;M;N #-VSW]"U!+ P04    " #TC)A8:S.C0>X(  !P
M'@  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6S566UOVS@2_BN$%RB<
M!;<62;U0;1)@F^[VBKON!DE[B_LHV[0M5!*]E-PT_?7W#&5+<NLXR34+W'ZP
M+%+D<,AYYID9Z?3&NH_URIB&?2Z+JCX;K9IF_6(RJ6<K4V;U<[LV%9XLK"NS
M!DVWG-1K9[*YGU06$QD$\:3,\FIT?NK[+MWYJ=TT15Z92\?J35EF[O:5*>S-
MV4B,=AU7^7+54,?D_'2=+<VU:3ZL+QU:DT[*/"]-5>>V8LXLSD8_BQ>O1$ 3
M_(A_Y^:F'MPSVLK4VH_4>#L_&P6DD2G,K"$1&?X^F0M3%"0)>ORY%3KJUJ2)
MP_N=]%_]YK&9:5:;"UO\D<^;U=E(C]C<++)-T5S9FW^8[88BDC>S1>VO[&8[
M-ABQV:9N;+F=# W*O&K_L\_;@WC(!+F=(+W>[4)>R]=9DYV?.GO#'(V&-+KQ
M6_6SH5Q>D56N&X>G.>8UY[_9QM2LL:Q9&3:S56V+?)XU9LX6>955LSPK6-V@
M Y9H:C9^GTT+4Y^<3AHL3B(FL^U"K]J%Y!T+"<G>V:I9U>R7:F[F^P(FT+I3
M7>Y4?R6/2GQM9L^9$IS)0*HC\E1W%,K+4T]R%(=.H)4?'I9/_O6B7F<S<S:"
M ]7&?3*C\V<_B#AX>43[L-,^/";]_!K^.M\4AMD%O.63J3:&+9PM:2>- _@!
MK&:UA91Q-0;-[++*OWQMBW8KQQ=[]H.6@7K)OO<?)C3EU#B8\9MGL*J@B_3V
M_>;Q+Q^NV,>C+5#.,M^4=R[^YOJ?W7T2<IGJKAE++N-^S3#A0FKVQH &JMM'
M[_*5-2N75TOL\RVNQ<KDO58RYD&POSTA7W[3_LT E:[(JGG]Z/7?F*K,IEU3
M\"0)ABV=#%HB3=@UH/*E7>W1BUU<O;V^O.J:J4B[>\758.&(AS)BO].V'K^E
M ],.G=JNK=E[V\!]NVT&DJ=IKTN<0)F!:HHGD3[BE%'GE-%QIVQC'?GD9@UO
MK!JVSFY;*J7#=:;P!+-UV/N<\OAB3^643_7_8;MCVFB9(VHTMC+]_O-J5FP0
M"?XZ^3WU%7DVS8N\R7'$6<.NMOS8GW9+E9OC$B^VW/D0.N,M==WUI'=X3W.#
MAAPVOJ6],;;U\>01+$@L1W=2!B":P$-?!R'3FB<B8A'\']062A[#'V3* YT>
M)BP2HEH90_>B?Q%V'#;LWO+.A^O76-5/'),0S5.5G+ ?P0=1$C')E59;&MI=
M12IW1$*S0Q[M)BN>ALG)CRR5*<9%6N)$ _\C4OO:RQ.N HVQ/-8!.;FFK89^
M$1@BB,01'X\['X\?''@[P$TSD.?,',P2CHM[@E#*]QL' NL](#N$H_<NFWN/
M,?DGGP.R&"$S(MLK&;.+W<ZSNC;P%<F3(*%KI/MG0S?<-\X1.R2='9+'VV'/
M\8O"SCS=;G,\9ZAL <[9VCA?X,!DS$Z+?)E1R8!T=U/5N*T7.699!RIP#=+
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MV-+?KDPV-XX&X/G"VF;7H 6ZC\SG_P502P,$%     @ ](R86!;4?F)&"@
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M<& MJ<V9L&#?GV-!Z*$""\>F^6RJFD7Q<_EOJCV.\'Y_(50):[>5$RAAK?N
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MGXM,,,,OT *L5RJ6ISHVV",L<*?]]A%>&BA' N9+VS1E(G?&ER+/=0.8KAO
M.T61-AHB)Z'8(2%M6D(G(*'CMUJH$X*KDB!$_Y L5[!RK=30TH?)CQ9VW0/+
M+KCHIV/H!TY,(4":!HP=+X& _OR=R[DHCVJIA!U*(,(\KZ4@BB*8;*NE'K,#
M.DAW3T"S0=-J\2 M4(H@WTH."AYXJ>=K.H("TA*E7N+$<;LSC6.'8K_IS*N9
M:JI&>9'S1O2G&XOCQXWCQ[T=OY,2]O31Z?%VU1;R42N@D8[AT"9C^?^ A3J#
MK'5#VC<'EJH8J/W[L2B5AG+*H,XZ&1F-CX+#3Z& -9X(+IB*4DDQVYK\4R_
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MIEX&\P JW-".FP>Y^XY#/5/'5TJN?0N[/C>=!5!VVLAF %L%#1-]3]^&<S@
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M]0N[VC;I>Y"6QJJB<28&A9#U/W]M\G#@, K?<(@:AZCB71]4L7S@EL\F6NU
M.VM"<P]5J)4WD1/2%>7):GHKR,_.OMHU:L@%7XA<6($&N,Q@H]56N+P;N'SF
MBQQ-;Q)8.LXY!6D#?5=#1V] LPB^*&G7!C[+#+-C@(!X=F2CENQ==!;Q =,K
MB)D/41C%9_#B+OBXPHL_&/RIF&O$Y#2BD]"UV? 4IQYIQ*#>HC>[^,0&X<T9
MODG'-SF'/GLB269ECJ"6>Y:G2)Z'N?@TBL+X!O[O/V4]JE+?[7S^]@@OS>\]
MU5J3R,"BIHO**]$=7*0!\^,HK%Q9= /S@RLFE?PI+;5&:7MOV@%U(% 2M2H-
MI,UA!I@_)E9LE/R00(L8#_V(#8X(=(?7:&21A"$\*\OS4W9PP8O-#1S3COTH
M:5W/U+K?U;K_[EH7:HO4""E:(7]P/<^#OK?2=47?>GMK'*G?N2RIC4,CQS8!
M/,N$K;(U'H50&LS@DA>J=.S3-=<KVN K^EH8*M0:]^'TX)+Y;)CTH)256^NE
M<8NZPHGZ_B 9]1H"U VP6)" VX[0UNV^J5*S_'-?IO8.G*G/H*O/X-WU^4@?
M.8_^48D>2?5@<5JR#[A$RDL&S_P5_FCH?^],V?@(UVGGOY$>B_>,ZYR*J*3$
MG+[$J2[IU",8O%I=P4)1Z7W8\K12;P^&_G X A;Z_22&7S1W]V&I50$KDH26
M3A1TFU"F;=*-*$3.Z4NM,K<5^6'$Z(H.XSY\+:VQ9"/DBG2T52)U!B.?)0.(
M!WXX8D[K2S2N9B3\):)K+W&2T"^CCE$';_DKFBZZ<93L@_9#$D!MU>6>Z._K
M$)Y*8)>\)/23,8-^Z _9L.D^ZDW[4TV($/HL;!&:<T]=]N!@8BB01.GF(M=6
M27'U\-#M=J/7;3UQ[,WKN>T+:9K4##DNR36\&E(+TO4L5"^LVE3SQT)9FF:J
MQS6-CZB= ;U?*F7;A3N@&TAG_P)02P,$%     @ ](R86+*87#[G!P  #24
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MMETW]=LR6@\MV:[H8=/&X8A,Y =&<O"#U]N/JV^S$U>[)@&T:J(D;&;#P[&
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M!_@NH2$=;J5KOJTXVI>6YYC2[ !;V@V?-9\++T!YL9 NOGFT0OH*QCDF472
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M#ZEZYJP%(W=NSMM( U.C^RQ@3*?*&L!^+N$R&\$FZ ;_Y9]02P,$%     @
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M6<(/BA(&&X'DH:JP^'L/E#>I,W?. T]D7RHSX&9)C??P#.I7O1&ZY_8N!:F
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MBGAU@%+=2):71PI/3$J6EI<[@F/"=8#Z?<.8?+O1#33'6,M_ 5!+ P04
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M1ZNV(VAWGSWD0J(F,6L;:%?[X]=.,OF $(%J\4)BY]YCWV,?^]J,#Y1]YQ&
M0#_2).,3(Q)B^V":?!5!2O@]W4(FOZPI2XF01;8Q^98!"7.G-#%MRW+-E,29
M,1WG=4]L.J8[D<09/#'$=VE*V,\9)/0P,;#Q4K&(-Y%0%>9TO"4;6(+XMGUB
MLF16*&&<0L9CFB$&ZXGQ'C\$V%<.N<5?,1QXXQVI4)XI_:X*C^'$L%2/((&5
M4!!$/O8PAR112+(?_Y2@1M6F<FR^OZ#_G@<O@WDF'.8T^3L.130Q1@8*84UV
MB5C0PQ]0!C14>"N:\/P7'4I;RT"K'1<T+9UE#](X*Y[D1TE$PP&[9QSLTL$^
M=AB<<7!*!^=2AT'I,,B9*4+)>0B((-,QHP?$E+5$4R\YF;FW##_.U+@O!9-?
M8^DGII^I (X$12("-*<9ITD<$@$A6@KYD",L.*)K]&4+C*B1XN@WM( ]9#M
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M'F"(0 \Y5;]0FE/3=F_I+*/7;X4%KB*9;0]'PU;T4"?;#3"&XY'92N9#3R&
MTBB*)BMJQP4Q#HT5S-;34BDC;<Z3982D.5":"Z5Y4)H/I050&D719.V:C7;-
M5^CLZT)0,D?2'"C-A=(\*,V'T@(HC:)HLLP;S\O0N@['=OI05PM*<VJ:- Y@
M6.-^N]-7)!OWA^TA T4RTQSV!NU.'^HR06D419,5U1A-QB&GJ1X1$"-1LYT1
M@:(>$5 *#.H\06D.E.9":1Z4YD-I 91&4319U8WK9?1?(QR NF%0F@.EN5":
M!Z7Y4%H I5$4399YX[ 9>HOMR'  :H1!:8ZQ;W3Q<,!HFP>*9-:>#^LI4MG]
MO0$ J-<%I5$439938W<9>K_K.F/+/$H7+">4_XZ7+%+:4'K,R8*"&E%0F@NE
M>5":#Z4%4!I%T60A-RZ7,7J-[A]J;$%I#I3F0FD>E.9#:0&41E$T6>:-P65H
M+89CNW^HA06E.35MM\=N3^@ZG,13)#$'O9[5[OFA5A*41E$T>1I_8R:9>C/I
M\VJ>9_RF_S;\OKDXWE535/@%\R:O7XOI*BIYZ<FGRLM4>$(]_B-_E0ZT4!=*
M\Z T'TH+H#2*HLFB;?PJ4^]7W:RJV5@>8V2UT:U2GU#KJJ;M7FKZ"GE"+2DH
MS8/2?"@M@-(HBB;+L[&D3*T7<+FS2&QW7#6)8E:46;H5K3+VU+-/5JVY=U4=
M*E0+=9B@- ]*\Z&T $JC*)JLVL9A,O4.4RL2(,\QYMTVQB2>6$KPB>5)E&[F
MP][,R=4B9^S%2S#4CX+2'%-A--E[L:,++=2#TGPH+8#2*(HFJ[EQMTR]NT7G
M>4%VXH1G5=-T&J]G7,LT%>,#F^G7?T;A0Q3S:[;:]-(7=;**H:973=.')2ZT
M3 ]*\Z&T $JC*)HLXL;,,O5KN!Q=]$"B9RE':;.2(#X@9:BQ!:4YYOZBJ_U8
MQ866Z4%I/I060&D419.EW!A6IMZPFMS1^]L[\FG)\G#%UF4T5>L3ZEA!:0Z4
MYD)I'I3F0VD!E$91-%G'C5-F#E_!8#"A/AJ4YD!I+I3F06D^E!9 :11%DV7>
M^&CFH>5BQQ@,>LC),H;Z9#5-"HQMLSW;4)'*LH9MFT&1:FR,6R8#M/H!E$91
M-%E-C5UEZNVJ(TT&\B]YHY09U,>"TAPHS872/"C-A]("*(W6-+&,IFG'V_8I
M[S+46&.6WAKS69J$#UR4$VD-N)@N^[PT5COXI<>?*ELHS8'27"C-@])\*"V
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M=#0W+GAM;+V::W.;.!2&_XK&[73:F6Z-!!B<.IYI#'2S.]UF[,WN9V++-E-
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MRJ;M@0G!&,]N<MM8.'9FNQ3^_:Z=$+6T5"!%0KRT_KCGY)YCW_1VO)+J7A<
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M8(L/R@;@_EQBV]=,;!?9_FE(_P-02P,$%     @ ](R86(M<KT+;!   9Q4
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MF. DI@X# $?B) P(3"'J*$1'*7Q>Y3([6S.IOR-;X'S!03;1X>NC./5#APT
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M[9FH^^%ZH/BFZA#G7.E^LWI< TM!&(!^O^3ZL&X&9H'VOQ+3[U!+ P04
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MG"=H?3RJR:BFH)J*:AJJZ:AFH)J):A:JV:CFM-KK/!&'@XO=0$%+X5'-1[4
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M=7(HH<7RJ":CFH)J*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:W6G>.S'"O2"E
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M8++=\74E4W"\;Z8GL6B0 TT8CT>9FE&Z'UJFXI*I #/]V!_OP;XN5C+X"ZX
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MT%BK,1C5B9S'.\[C8RH/*U,7T[%=<_ H,&;>=&PO6KLRQ;:57IDT&GB@],0
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M($T OE\+H0\3\X&^V5_\"U!+ P04    " #TC)A8)B94^A(#   9"@  &0
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MZ;'CMKOJ5GKN'KO:M4VUBM>MHA/X7!0X@HFA,E0 7X 1'A[8@771A?B?Q#X
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M=F:[#?S[V4Z:]1%*F?JEM9U[CN\YUZ]!Q?BKR  D>BMR*H96)F5Y;=LBR:#
MXI*50-67&>,%EJK+Y[8H.>#4@(K<]APGM M,J!4/S-@CCP=L(7-"X9$CL2@*
MS-]'D+-J:+G6:F!*YIG4 W8\*/$<GD ^EX]<]>R6)24%4$$811QF0^O6O9[T
M=;P)^$6@$FMMI)6\,/:J._?IT')T0I!#(C4#5G]+&$.>:R*5QI^&TVJGU,#U
M]HK]N]&NM+Q@ 6.6_R:IS(969*$49GB1RRFK?D"CIZ?Y$I8+\XNJ.K;G6RA9
M",F*!JPR* BM__%;X\,:P T_ '@-P-L&!!\ _ ;@'PH(&D!@G*FE&!\F6.)X
MP%F%N(Y6;+IAS#1H)9]07?8GR=57HG ROJ=+H))Q @*=34!BDHMS=('NGJ?H
M[/0D\L/@YAPU#40H^IFQA< T%0-;JODUBYTT<XWJN;P/YG(]],"HS 2ZHRFD
MFP2V2KS-WEME/_+V,DX@N42^^PUYCN=W)#0^'.YUP">'P]T]:ORV%K[A\S^O
M19>Y-3CH!NOCX5J4.(&AI?:_ +X$*SX]<4/GILN88Y)-CD2V85K0FA;L8X^G
MN%+[00(G..^TK8:'!JX/P67L!9&CZK5<]Z,CRK^*KC:C)GM3^4^AO59H;Z_0
M>YJH<UV WH2D62GO78)KFMZ:E,C=EKMWJJ^6_TAD&ZZ$K2OAX>5'%2<2+MAL
MUN5+N.-+T'>]K1*/PYV%$#EF>V\LA-TH-^I%OM>&;8CIMV+ZGY2X*2LJB?HV
M1^I:1Z4Z;*$@"5+NE9A#2D$(A.<<0%V_LDMI?R>[T',B;TOIWER^N@:.1%;;
M9J_=9P7PN7D7")2P!97UY=".MD^/6W/C;HV/U).D?D'\HZG?,P^8SPD5*(>9
MHG0N^VI=\/J-4'<D*\VM^<*DNH--,U//*N Z0'V?,297'3U!^U"+_P)02P,$
M%     @ ](R86/%>U=)= @  6 8  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C0N>&ULK55=;]HP%/TK5BI5K;21[\!HB+3"INUA&J+K]FR2"['JV)EMH/WW
MLYT0\9%V3-H+N=>^Y_B<&WR3[KAXDB6 0L\597+BE$K58]>5>0D5E@-> ],[
M*RXJK'0JUJZL!>#"@BKJ!IZ7N!4FS,E2NS876<HWBA(&<X'DIJJP>+D'RG<3
MQW?V"PNR+I59<+.TQFMX /58SX7.W(ZE(!4P23A# E83YZ,_GL:FWA;\)+"3
M!S$R3I:</YGD:S%Q/",(*.3*,&#]V,(4*#5$6L;OEM/ICC3 PWC/_MEZUUZ6
M6,*4TU^D4.7$&3FH@!7>4+7@NR_0^K$"<TZE_46[IC;6Q?E&*EZU8*V@(JQY
MXN>V#P< /WH%$+2 X%) V )":[119FW-L,)9*O@."5.MV4Q@>V/1V@UAYBT^
M**%WB<:I[+LJ0: 589CE!%.$I00ET<T,%"94WJ+WZ-/C MU<7XW")+J[16V
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MM)*(P4K+O$FBLQ3MR=).%*]M<W[@2K=Z.RST80S"!.CU%>?J>6+Z?7^\IW\
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MA4_+L5NMHL\)TJ>'A$V1,!\$*\A#ZR@/K=OD@;,9"W="(*HDH))YJP2TZDD
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M+6'%7<7SA/*+J32Z[#_O"PGITSKT.5#&BJS4?=I(G\ZAS[&DJ6.U[M-%^O1
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M252^73!_QM*B ?]\GB3YYJ!PL'T(R>1_4$L#!!0    ( /2,F%B' \=H?04
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MVD-#M1#5(E2+42U!M135!*IEJ"91+4<UA6H%JI6HIE&M0C5#:?;G-+3MM>$
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M;I[_L!W@YW+UQ^YPOOPO4$L#!!0    ( /2,F%@@NE)/]!$  ,)/ 0 9
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M=R%]<YE&+ W.=;1'BFH:JNFH9J":B6H6JMF3EQM2CD<OUVG025U4\U#-1[4
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M,U$IX^7Y1]F1+"^.$-9,2I86S1A(!%P/4/<WC,G7CCZ5J$^AYO\"4$L#!!0
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M&ZM89[XL4";58G/M3(;-O'^D7?"^79W/OF6CO=W-_%Y(DQ0U$-[;O14P?BT
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M$D<+1@N49G+$H$Q I8G8 )3H5T;7E8Z2G"8D;P/**%VXQ_;2[07+^R:QP>1
MNHQ;EN-!EG_0\I(=$RDF4F/#<K 7]8D9S((H=/T>.8,9QGX416:&4<LP.I6A
M;'R L:9&$,Y!&.D-XIX:[I%!A+U*8# *O< S"X"=;1/CG%(*CJ3?@'8R-,2]
M%+T;GOK4,_!<:%VA=KH]_&ZLR-9J+;OMN>SS0)XE)9<I+Y- BU6M646Y.<,;
MZ.[F.?T3P62%<>\,C8>7^7]E<+<RN(.=E$F&Y%@9W'-FS5G1XG.A=67=]J=X
ML(6;W:2ISL%:R.;08"35+=<!-<_:KC9HG>#S/*<?? 8K' 8'BM"VP\3#+>:?
M8@4,E>8,,W(?Q#N9^SG1X@:MJY&##VBT[5WQ</-::P1UYV'4Q- KCJ)^"VZP
MNG3'>Z>-"6SLCPZ0V/:=>+CQK!NG[!DZ+;B-+IK--O;3#6;G[P#>^2_0$-NW
MPONT]HW"L7N U;8;Q,/MX$U5Y5E"5-"^-7I&'C5*M#.Y<^5&_AZ3X^SB]^UJ
M/O;.'4<!;*GOBF0+1]>EJ"\$VK?M?=2-OH7IO;]5]U3Z[F0+4U]R?25LF<GB
ME<-"0CI7H0P<5M\;U0-!*WV3,J="T$(_KD"6-Z8,Y.\+2L7;0$W0WM[-_@-0
M2P,$%     @ ](R86'(.FI4 #0  TGL  !D   !X;"]W;W)K<VAE971S+W-H
M965T.3 N>&ULM9UO;]NV%L:_BI !PPK,M4C][Y( K;F+%;C;+=IN][5B,XDP
M6_(D.6GOI[^2[9@B>7)L24=[L3K)X6,^QZ+XTS%%73\7Y=_5HY2U\VVSSJN;
MJ\>ZWKZ;SZOEH]RDU=MB*_/F+_=%N4GKYL?R85YM2YFN]HTVZSEWW7"^2;/\
MZO9Z_[M/Y>UUL:O762X_E4ZUVVS2\OL'N2Z>;Z[8U<LO/F</CW7[B_GM]39]
MD%]D_>?V4]G\-#^IK+*-S*NLR)U2WM]<O6?O!&-^VV(?\E<FGZO.:Z?U<E<4
M?[<_?%S=7+EME^1:+NM6(VW^>9(+N5ZW4DU'_CFJ7IW>M&W8??VB_J^]^\;-
M75K)1;'^;[:J'V^NXBMG)>_3W;K^7#S_)H^.@E9O6:RK_?^=YT-L%%PYRUU5
M%YMCXZ8'FRP__)M^.V:BTX"%KS3@QP;<;."_TL [-O N;> ?&^Q3/3]8V>=!
MI'5Z>UT6ST[91C=J[8M],O>M&_M9WG[P7^JR^6O6M*MO/^;+8B.=.OWFS)PO
MS6&UVJVE4]RWN9-E*5?MGV3E_"1DG6;KZDT3]NN?GYV??OPA]D+_ES?.\863
MY<[7QV)7I?FJNI[73=_:=Y@OC_WX<.@'?Z4?C#N_%WG]6#F_YBNYT@7FC:F3
M,_[B[ -'%85<OG4\]K/#7>X!'5I<WIP#S<7ES1GBQCM]3MY>SSO[.4&Y/;3U
MX;;MN>-=M4V7\N:J.3E4LGR25[<__L!"]Q<H+Y1B@DA,RYE_RIF/J=]^ELOB
M(<_^UQS$V[*XSVJG.3:==5&!Q^=!*]QKM:?+I]M9[%_/G[JIL6-XJ(<(M$L#
M#0<GP\&EAG_]9Y?5WR&?J$3?8^4@%G23QH+$-7)"])9:3L)33D(T)^^732;:
M\UAS?OJPJYJ_5I73C*6[+$_;F0=*$:K8-T4AD*+$2!#1&VH)BDX)BM $B<Z)
MWDFK2M;@\(@L&U'SGS$^@* D-,VBW1EH-CZ9C2\WN\[2NVS]RC")[8\M#&+/
M, Q%A0DS'*-]&N@X.3E.+G/\=3^/?RWJ= WY32PGC"7F^0\(XE%LN$WLDV0<
MJI1H+IBK.,5%?2QVI?PK73J+HMP695I+YTN3J6PI8=A Q?H.85(U0:6F)[(#
M?&P$21P;4R6.4DU0J>F)XRIQG! GCF+Z@(JX,:#PM^R=("(U/4$*41E*<\V1
M5:?Y0W;77$"\/H_@&KT/,%)8I5+3\Z=PE?EC1B8161X31ZDFJ-3TQ"GL93CW
M_B'KYN)_G>9+"68.HE2?66.1DHP%E9J>$D6]#,?>GB<K&U)9')OYH<1B0:6F
MYT=!+\.I=\AE 2[9>P3:L P<E8+J3?4\*5YF.#"?&UH  #/.36X$PP"O4X R
M4Z3,+D3ELQ<'S 9AT#84!MA&NS70-E=DS7&R_E066UG6WW]VMLWG?#A1R&9T
M;#<RKR'WN%[?<4"J)JC4]%PJN.9CX)J3PC6IFJ!2TQ.GX)KC<'WF/,-MFI[Q
M*#(''!06&*,-[\A0HPJ2.0[)_2;FHYA18 A,VT 4CZS""]ZSH<X5WG*\''ON
M(_9M$Y[O):97(,P^$@3>EZ%>%9%RG$@O+*KA*KU/"#;G>E9>IL!2KK"4XUAZ
M^13+@;HI=#@ 83QVS9H4WJVAMA5M<IPV]]^GMM^J[2HY0PX'4L D51-4:GH&
M%8?R>,S$2@2.Q\11J@DJ-3UQ"FHY#K7GSKH@R7JA-;,"<6'HF<-L"I+U%,EZ
M.,GVFUN/8MKITBH* $$SQB+7+/'C/1OJ7'&GA^+9N4_YV-KXE-W <@O&64>#
MP'LSU*V"10^'Q<MG$0\ 0M X& <8GP(>O<XB !P>_U,_RA+A";QY[X4 M"L!
MIJ!/3]&G-Z:XZI$65TG5!)6:GCB%LMZHXJH'%%?-!0 +_"UZ)V0*AO44PWJ4
MI57/!E0[/0#$6HLH\%X-=:T0UL,1]MQA0(JN'E ;M1,R!9%ZBD@]JJ4$N%#O
MW "U5#LW4T"GIZ#3PZ'S8_XD\[HH,_C;>;QU[X10J@DJ-7W%FD)8WQTQ3?FD
ME5=2-4&EIB=.$; _BH#QUKTS!W"R66VC>D<]'XJ1?<K5"K[-OQ8C S&6YRGP
MV%=X[.-X?.X8L,NDMDE2YJ52T_/16?^*5UPOK$+Z=DG5S@LITE*IZ7E12.OC
M2/NIE-LT6SGRVU;FE:SV0Z,X<VV%:_8^@Y 2,96:GD]%Q'XX9M(B74Y+JB:H
MU/3$*:CV1T&U;V,P\[FY+@.(FK'8+%#A/1GJ5-&RC]-RS^F(E)A]FYB;4&ON
MF@*9?87,_J@ZK0\LO04.A4NB!-Z3H?<H*,0-\"KMA;-28%=> <<710F\1T,=
M*S8-<#;]6J8KZ91R*;.G]&X-7Q3A&KUOS"!='$"EIN=/L6S 1\PO >4:V@6I
MFJ!2TQ.G@#@8!<0!L&[ -^_I (*2R!Q?4W!NH#@WP#FWW^02V+@;FK@+Q,R8
M;WX;@'=KJ.W.W5ZC*K.!79EEYLH1(,8Z @3>C:$V%5T&/=8,(/,%L(;5LDL*
MCU1J>EX4/ 8];MQ""Y"X4.\S),";]C$S!6X&"C<#'#<7:?6X/PDLVQ?M:L:G
M="WS5XX<4MHD51-4:GH>%94&R9B9E[2.2ZHFJ-3TFTX5Y(8XY)XY-X?0L@*7
MF:LNH+#8'&IX3X8Z57 ;XG#;;_(-[<HI<UWSMDH@:I9PR_@45!HJ*@U'+5D-
MH24%S#0*!5G'@<![,M2IPL@0Q\@+9^#0)D7++VEYE4I-3XO"SK!'>16=@$,(
M)TWF!(. 8V$*Z P5=(8X='YY3$LY:[=::<9[^GWSVJ2*R_2^B9ZT7$JEIJ>P
MLR/!F')I2+O[ "GQ4JGIB5/$&XXJEX8VF'J)=0\[$ 6LE<=[,M2IXM>0LEP:
M DL"/#\Q:V5 &(_-:R2!]VRH<T6<(5X'O6@/$URC]QB!UL#:NYA0O:F^2X<B
MRF@4448V*OJ)L3G- @BR1XC .S+4J +*" ?*2S<DL1D1,&P'08:G ,E(@62$
M@^2_93.;G@ B:W?;^J/(9\M=DX6\?@.:)ZUYDJH)*C4]FPI6HS$[946D*V1)
MU025FIXXA;,1CK/G3C VGC(WL"Y9@;"0FW>\XCT9ZE0Q;'3Q/ED7S*X1N'V
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M"D('X/Z4<_4\T<U,W^RF_P%02P,$%     @ ](R86*0MP536 @  GP@  !D
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M@@^[>@K=!14"R4!LA-6>/*?[L<)Q*K1AL%TIALG+J"MT]@!'9^E$:,,L=7T
M=#<"Q^BK$^GHN"T=!(K"=$PMN@X"/M9"/$6&,\OH89S!P[UHLXN3R9A,=*4?
M.NOF\X3XI'6]01N$EB"4)?;04%>RD;MDCRH@LE1>6])M=A JRS%J78E&[A+]
M.R=8JKR;#M,AA&Z8HS]&3X0V#+KWP?Y27^RG_63_&=_LJ&LRD+O)>))L($O7
MH+8,>K"";78PS49D W7=!7)W%\^1#3?DT=-DZ4[02&>"NLX$N3N3<<V('QY^
M6#-NLX.J\3M@YO=.)/5Q\!?,UVHC@(*LE&-PEBH<OC]AW=](MC6'E LF)2O-
MY8:H?I1K _5^Q9B\O]'GGNTY]_P_4$L#!!0    ( /2,F%B7@;Y,70D  -2#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;+W=;6_:2AH&X+]BL=4J
ME;H%OV"@)XET&L_;A]563;O[V2%#L&HPQW:25MH?OV/C,HQC!IS<RY<6"',-
M=I^8I]R9R>5SEO\HEE*6SL]5NBZN!LNRW'P:#HOY4J[BXF.VD6OUE466K^)2
MW<T?AL4FE_%]/6B5#KW1*!RNXF0]N+ZL'_N27U]FCV6:K.67W"D>5ZLX__59
MIMGSU< =_'[@:_*P+*L'AM>7F_A!WLKR^^9+KNX-=\I]LI+K(LG63BX75X,_
MW4\B"*L!]3/^G<CG8N^V4QW*79;]J.Z(^ZO!J'I%,I7SLB)B]=>3O)%I6DGJ
M=?S5H(/=G-7 _=N_=5H?O#J8N[B0-UGZG^2^7%X-I@/G7B[BQ[3\FCUSV1S0
MN/+F65K4?SK/S7-' V?^6)39JAFL7L$J66__CG\V)V)O@.<=&. U [Q3!_C-
M +\](#@P(&@&!*?.,&X&C$\=$#8#PE,'3)H!DU./8=H,F)XZPZP9,*O+8?OO
M5__C1W$97U_FV;.35\]66G6CKJ!ZM/HW3]95L=^6N?IJHL:5UU%2S-.L>,RE
MDRV<1;*.U_,D3IUD793YHZKJLG#B];V:<JUJO[IO/B]/BA^%\P]'59ZJJ[5Z
MR7DNU_-?]1><BTB6<9(6[P\^X^]_F_IA\(>:S_FVS!X+-5?Q03WJAG[[P5N:
MMQYY9]R_');JA%2'-9PW!_]Y>_#>H8.7\X^.[WYPO)'G.^3[5^>B>3WO.[";
M/MCWV\BY>-?%1'V8&TZ="W7@71#I ['/7ZJ#JTYKET5/M[RC)XKUP0Z?*-Z'
ML9THT0<Z?**&ZEMK]_WE[;Z_O!H/#N#5N?JO<Q,7R_K;:%[=D'\])D]Q6GUO
M==6L%:S>_#X5FW@NKP;JW:V0^9,<7%>O=_1'5\TBL0B)$21&D1A#8AR)"1!F
M5+*_JV2_UOTWOE/4EW7]=M%5X3ZRPI%8A,0($J-(C"$QCL0$"#,J/-A5>&"_
M5O_<;.M;=147BVV[\G[7KW05\M8+:Z_Z;\73]7@R"MW+X=-^A5IG[5NA2(P@
M,?KR9+BC<!R&YME@R#DY$A,@S*B]\:[VQJ?V"7^JBVA]@^@^X8/SK[7LJD"K
MVO=2BL0B)$:0&$5B#(EQ)"9 F%'.X:Z<PW,U"R&RPI%8A,0($J-(C"$QCL0$
M"#,J?+*K\ FX6=AZX[WW1\]KMPK6.?O6)Q(C2(PB,8;$.!(3(,RHS^FN/J<G
M-!3?\OA>UE?:K%S*W,GE7*J>XBZ5G1\]6,F^UUHD%B$Q@L0H$F-(C",Q <*,
M6I[M:GEVKFYBAJQP)!8A,8+$*!)C2(PC,0'"C IW1SJ'&8'[B0;<;RC<\7C4
MZBCLT_8M4JA&H!J%:@RJ<:@F4)I9JGN1H7M*:Y&5ZA*\RM:RC/-?3EP44EV&
M5?4N6D%?9^U:9^A['89J$50C4(U"-0;5.%03*,VL<1W;N=ZY6@X7&NA!M0BJ
M$:A&H1J#:ARJ"91FUKH.]EQKJO*:UL-_T7J,IU/?:_<>T&P.JA&H1CM.2&?X
M 9V50S6!TLPJU.&;>R1]Z_S 8A/_.OAIA1WL?6&%QG10C4 U"M485.-03: T
MLZ1UIN>.S]9$0(,^J!9!-0+5*%1C4(U#-8'2S%K7@9]K35M>TT2$+]\S_=FL
M'8G8Y^U=J]#0#JK1CA/BA5Z[JV+023E4$RC-+$*=R;E'0CEK#W'PARCL:N^+
M*S3$@VH$JE&HQJ :AVH"I9EUK;,\=WJV1@*:\4&U"*H1J$:A&H-J'*H)E&;6
MNL[Z7&O0\II&8O;RTXB@W45 LSJH1J :[3@;TTF[A8"F<%!-H#1SN8;.X;PC
M.=R1%N+;<]95@W:U[V45JD50C4 U"M485.-03: TLZYU:.>YYVHA/&AX!]4B
MJ$:@&H5J#*IQJ"90FEGK.KSSCBRZZ]U"-*#Q7^]6!V&?LW>=8M?281?3O3P9
MKM_J(* S<J@F4)I9?3I.\X[$:5T_'I$F\5V2)F4B3_X9"?LTO2^ST"P.JA&H
M1J$:@VH<J@F49A:Z3NR\X&PM!33*@VH15"-0C4(U!M4X5!,HS:QU'>5Y1];G
M]6\IMJ"Q'C(8!9-V6P&-XJ :@6JTXX1XH?\BWH!.RJ&:0&EF$>J,S;-G;-5>
M&7TWDX NGX-J$50C4(U"-0;5.%03*,VL:1W9>9.S-1'0& ^J15"-0#4*U1A4
MXU!-H#2SUG6,YQU9DV=M(M2E_5UG64,3NT:KEA#LWH9#?S1NO0U'T%D)5*-0
MC76=$=?UP["5(7'HM *EF;6H8S;/'K-M>XF>ZT/M9N]2A&9R4(U -0K5&%3C
M4$V@-'.+*IW>^:-S=1,^--&#:A%4(U"-0C4&U3A4$RC-K'6=Z/E'EN&]JINP
MH[W+VGT9%4S:84$$G9- -0K5&%3C4$V@-+-<=2CGVT.YIN%XRZI1^PR]:Q<:
MZ$$U M4H5&-0C4,U@=+,&M_;(O-\>V1B-\G$[I*)W283NT\F=J-,[$Z9V*TR
M_Q_IGZ_3/]^:N+RV_8 &?5 M@FH$JE&HQAK-:-NZ/O& SBI0FEFP.L+S[1%>
M]R<>M@6F=K!WL4*3/JA&H!J%:@RJ<:@F4)I9TCH0],^VS:8/#0JA6@35"%2C
M4(U!-0[5!$HS:UT'A?Y;-MP\V&] ,\%&,Z."<1".VA]X0-,^J$:A&NLZ(]YD
M-IFU.PEHCH?2S%+4.9YOS_&J7S;RFLVZ[6SO8H2NO8-J!*I1J,:@&H=J J69
MA:U#0?]L&VWZT*@0JD50C4 U"M485.-03: T\W=]Z*@P>,N&F^KZ?DOSKL*V
MLWT+&ZI%C>8:ZUA&8_.]F$#GI%"-034.U01*,PM6YWV!/>_;=AV]5Z;:U=[U
M"EVM!]4(5*-0C4$U#M4$2C/K6@>#P=FVV@R@ 2%4BZ :@6H4JC&HQJ&:0&EF
MK>N ,'C+5IN6I@.:!D*UJ-%<R^)9 IV10C4&U7C7V6C_0(Q 36E6X=[ON;-'
M=]7O.'W%-EEVM7<10K,[J$:@&H5J#*IQJ"90FEG7.N$+SK;?9@"-_J!:!-4(
M5*-0C4$U#M4$2C-K74=_P5OVVU27]VHNO^N5?[;+O6L;&O5!-=)H[OZ:T_8*
M7 J=DD$U#M5$U^F8Z-.QK<1AL92RC.(ROK[<J"OD/^/\05U G50NU*#1QXFJ
M^SQY6.[NE-E&F0/G+BO+;%7?7$K56N35$]37%UE6_KXS5/YSEO^HY[C^'U!+
M P04    " #TC)A8VHQ7WBH$  #S$P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Y-BYX;6RUF&UOHS@0Q[^*Q:Y6K;0-8!Y">DFDIN1T^V)/57N]>^W")* "
MSME.DY/NPY\-A *A-$C<FP3#S-\S/X8Q>'Z@[)5'  (=TR3C"RT28G>KZSR(
M("5\0G>0R2L;RE(BY)!M=;YC0,+<*4UT;!BNGI(XTY;S_-P#6\[I7B1Q!@\,
M\7V:$O;/"A)Z6&BF=CKQ&&\CH4[HR_F.;.$)Q//N@<F17JF$<0H9CVF&&&P6
MVIUYNS8MY9!;_!G#@=>.D4KEA=)7-?@1+C1#100)!$))$/GW!O>0)$I)QO%W
M*:I5<RK'^O%)_=<\>9G,"^%P3Y._XE!$"\W34 @;LD_$(SW\!F5"CM(+:,+S
M7W0H;0T-!7LN:%HZRPC2."O^R;$$47/ W@<.N'3 ESI8I8/5=L ?.-BE@WVI
M@U,ZY*GK1>XY.)\(LIPS>D!,64LU=9#3S[TEKSA3A?(DF+P:2S^Q]&,>))3O
M&2"Z09LX(UD0DP3%&1=L+RM"<$2R4$Z9R;I1XZ8=B_DK1S?H+@QC=>=SUZ)^
M51U<^2!(G/!K].V+9[GV+_(J^B.B>RY%^7?TM3&>ZT*FI +3@S+\51$^_B!\
M$Z.?-!,11^LLA+ IH$L6%1!\ K+"O8H^!!-DF=\1-K"%UL^/Z*H,_5I&JY_R
MZ CU_G)A/$C8'Q+Q\Y./KKY>=\BLA\37*=, :E459N6ZUO]985V544QK=T^K
M&NPMWY$ %IKLH!S8&VC+;U],U^B\=V.*^6.*K4<2:]P[N[IW=I_Z<GT,(I)M
M 3$B /W[29VN"C%SFJNI)>IM:4Y,PYGK;W76G6:&Z[I-.[\WMJ$81Q)K8'0J
MC$XOQM_E@@_'7?X0='$KO-T:CRDVS#:V#JNI:\]:T HKTZB;S9QIB^VZP\S#
M'L:562-1MTK4[4WT@<&-($<DGW>.XDW>Y0Y 7B%K]^8B<?<LI1O/,' K\2XK
M%WNMQ'LC&UHM(XDU($XKB--^B, "V05E,U2-\#.$A997@V-,S!; "VS\WIB&
MXAM)K('/J_!Y_?@H%X.*T#LO+\>U[1;##BO7\%K/J-\;VE"*(XDU*,XJBK.!
M12A7:\BV(OH(X^R"0NR=<^@J.Z;8>B2Q!FO3>'\)-P;WS<]XEY+UBG0=>]HB
M7EHY]>7 <-J+1G]X0UF.I=:$6?NB,8<W@$]IFF<T;=<\HVF>T;1GT_9*U!_?
M8)HCJ35IXG>:>$ C^)$)D+,(%,D/<&"=)'%'(S#:G:!_UJ&M8%2U]5AJ3>+O
MWTMF[RM]_K:8E^X+R ]I0+*4.SE;YQ5KX/9+8Y?5[/SY'_6+92RU@I]>V]Q(
M@6WS726. KK/1/%97YVM=J[N\OV:UOF5>7M?[#^]RQ3;83\)V\K/493 1DH:
MDZE\P%FQPU0,!-WE6R@O5 B:YH<1D!"8,I#7-Y2*TT!-4.WS+?\#4$L#!!0
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MM8%ZO^)*#KJ%#M#_6R']!5!+ P04    " #TC)A8@>^6S)<#  "'#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6R]5UV/FSH0_2L6E7I;Z>Z"^<XV
MB=0LK7H?5EKM]N/9&R8!+=A<VTF:?U\;6 *$T*V$^I+89N9XSAD\>.8'QI]%
M B#1SSRC8F$D4A8WIBG6">1$7+,"J'JR83PG4DWYUA0%!Q*73GEFVI;EFSE)
MJ;&<EVOW?#EG.YFE%.XY$KL\)_RX@HP=%@8V7A8>TFTB]8*YG!=D"X\@OQ7W
M7,W,!B5.<Z B911QV"R,C_@FPHYV*"V^IW 0K3'25)X8>]:3_^*%8>F(((.U
MU!!$_>WA%K),(ZDX_J]!C69/[=@>OZ!_+LDK,D]$P"W+?J2Q3!9&:* 8-F27
MR0=V^ (U(4_CK5DFRE]TJ&TM ZUW0K*\=E81Y"FM_LG/6HB6 _8O.-BU@]UW
M<"\X.+6#\UH'MW9P2V4J*J4.$9%D.>?L@+BV5FAZ4(I9>BOZ*=5Y?Y1</4V5
MGUP^0+ZCP$F9!+9!,@%TR_*"T.,_ CW#46U&U0N@4BU1 5PP2B%#[R*0),W$
M>W2%/GU[0._>O@D=W_WP'M4#E%+T-6$[06@LYJ94H>H-S74=UJH*R[X0%K;1
M':,R$>@3C2'N IB*8T/4?B&ZLD<1(UA?(P?_BVS+=@8"NGV]NSW@'KW>'8^P
M<9JT.26>>P'O[I24%2,\'E)X%$'7DQM1D#4L#%4P!/ ]&,NW;[!O?1A29TJP
M:"*PCG)NHYQ;HCN3OO!#^KI3ZCLE6#016$=?K]'7&WTS'Q/&Y94$GJ,GH+!)
MY>#QKT#\$D1_F_9+)_""N;EOBS)@9/D]HVC(:!8V1AT2?D/"'R7Q586?TNH=
M&6-1H7BMO7$8X!Z+T:W^-+43@754"1I5@M^DEG"XTE_9&!7DJ$_(H"K!F2JN
M8UD]5<Z-?#^<]7)[;H1M/W"&DQLV-,+QY#))!@]T>+;;;&:'O;@'C +/[\5]
M;H2]H/5B=.*>-7'/QN7?J7*T3P7CQ\M%?Q3B3XO2E&#11& =Z;!UNN98?ZGL
MUQM-)/&D:-%4:%V16W=)/$7MKU$Z9S]P>^=LR,COUX<A(]<?/F;8/M&P)ZES
M-4QG=\_N\S@W<H.PS^/<R/,O\3C=$?'X)?%BH:O]VM],[-A^/_(!*^SV/[]#
M5C:V>[&;K0XE![XM.SV!UFQ'976';U:;;O)CV4/UUE>ZRRP[GQ-,U:+>$;Y-
MJ4 9;!2D=1TH-7G5]543R8JR#WIB4G55Y3!1G3)P;:">;QB3+Q.]0=-[+W\!
M4$L#!!0    ( /2,F%@'4UI@+@0  %49   9    >&PO=V]R:W-H965T<R]S
M:&5E=#DY+GAM;+V976^C.!2&_XK%2+,STFS!0+XZ2:2F=+5ST5753G>O77 "
M*MBL;9)6VA^_-E"(:>)-5E9O$FQ\'ON\]C$',]]1]LQ3C 5X*7+"%TXJ1'GI
MNCQ.<8'X!2TQD7?6E!5(R"+;N+QD&"6U49&[ON>-W0)EQ%G.Z[H[MIS32N09
MP7<,\*HH$'M=X9SN%@YTWBKNLTTJ5(6[G)=H@Q^P>"SOF"RY'27)"DQX1@E@
M>+UPKN!E!&?*H&[Q9X9W?.\:*%>>*'U6A1_)PO'4B'".8Z$02/YM\37.<T62
MX_B[A3I=G\IP__J-_EOMO'3F"7%\3?._LD2D"V?J@ 2O496+>[K[';<.C10O
MICFO?\&N;>LY(*ZXH$5K+$=09*3Y1R^M$'L&OG_$P&\-_%,-@M8@.-4@; W"
M6IG&E5J'" FTG#.Z TRUEC1U48M96TOW,Z+F_4$P>3>3=F)YCXN*8(;J2:!K
M(%(,KFE1(O+Z"P?/^%5V1N0"D%,M0(D9IX3@'/P*KI(D4T8H!QEIUI]"?(FP
M0%G.OX+/GZ;!./PN[X*?*:TX(@F?NT*.6?7LQNWX5LWX_"/C@SZXI42D'-R0
M!"<ZP)7.=A[[;QZO?",QPO$%". WX'M^ &X>[\&7=JA?#PSO^G28_Y^PZ'08
M-,$TOX-NIH.:'AZ=:2Y8%@N<@ =!XV?P2#)Q<$:,'+417?(2Q7CAR)V&8[;%
MSO+S)SCVOA_2SR8LL@33] L[_<*:'EB-E$/ZAC;UM0F++,$T?4>=OB/C^ORC
M*IXP4\IF1*[42NG(P88A(H9QW\C8X$8U3CW>MDO?FX13.'>W^P(9>SU7($LP
M3:!Q)]#8*-!MO[Q6%+&#FA@)YRXMF[#($DQ3;M(I-_F@T)W8U-<F++($T_2=
M=OI.C2OS)Q4R#6![*A_2KF&,]^(5CD;#:'W?:#KR]3;1 5#@!UTCS859Y\+,
MZ,)#)>=]FW'*7H]'EQ%Q[NS;A$668)ITT.MS2.^#XJOMR)+$5FF1+9HN\EZB
M#BT$60O1HVPZ"+(#C;Q!C!F;Z![XO0>^W2=\R]M_Q$-OY(^]H3_&?L^>9TLT
M7:4^38?F/+U7B:>(84!+-=<<X)<R8T=T"MZG0C"$P5 FJ[FX+9HN4Y^-0V,R
MNKQYP7&ES@R.;]=FPMF;B=5,VQ9-5Z_/M>'HHW9LF_GUM55:9(NFB]SGZ]"<
ML)^_WXW?[W=A&$QFPT"VFIG;HNDJ];DY-*:FPT &_X#33RK,Z+,7G]6$W!9-
ME[5/R>'THR+<F/R?+;)-6F2+IHO<OS1 \UO#_WE6S]['>##S_,DPQJV^']BB
M-3JY>^?-!6:;^MR>@YA61#0'L5UM]VW@JCX1']2OU#>#^AR[QS0?'&X1V\A=
M$^1X+9'>Q40*QIHS_*8@:%F?:C]1(6A17Z88)9BI!O+^FE+Q5E ==%]2EO\"
M4$L#!!0    ( /2,F%@LVWU7HQ(  ($_ 0 :    >&PO=V]R:W-H965T<R]S
M:&5E=#$P,"YX;6R]W6MOV\BAQO&O0KC%H@5.8Y&ZV=G$0&S>R6&#9+L%SCM:
M'EM$*-(E*2=9[(<_E$R;&ID>2\"_9U]L;(?S&UW,)QSI$?GA>UE]JY=2-L:/
M55[4'T^637/__O2T7BSE*JW?E?>R:/_FMJQ6:=-^6]V=UO>53&^V@U;YJ34:
MS4Y7:5:<7'S8_NQS=?&A7#=Y5LC/E5&O5ZNT^GDI\_+[QQ/SY.D'7[*[9;/Y
MP>G%A_OT3GZ5S;_N/U?M=Z?/RDVVDD6=E851R=N/)Y_,]\E\NAFPW>+W3'ZO
M=[XV-G?ENBR_;;X);CZ>C#:W2.9RT6R(M/WC05[)/-]([>WX3X>>/,^Y&;C[
M]9/N;N]\>V>NTUI>E?F_LYMF^?'D[,2XD;?I.F^^E-]]V=VA[0U<E'F]_;_Q
M_7';J75B+-9U4ZZZP>TM6&7%XY_IC^Z!V!E@F:\,L+H!UJ$#QMV \:$#)MV
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M6P1=9(L>V'ZEC;6S?Q%%4*,(["B*=$NYPG DK["I2ATT7V(6Q0@"*Y*Y!!2
M1; =Y9H&8@**T99"$[9#?^I@,D3(ZGGLF@QZN/T.1D?N#(S+&N/2BO$1Y@W,
M'^!GLGJ'!@"?:U ;/*N_L?"6/7BX \^1.P->6,,+K?!^$Z(@6401;,H(EE\F
M]B6Q:K."R::R3"@K$P)='.<)(!1 \.*6]6!U.Y9AV&,8>C,\[X)TY-, N:I!
MKJP@?U?QO06. 5B89#9^0]BL3L9B6_4CH#>;=T.@(Y<&-6_6)*(S^^I-<J&B
M_[,"@YXX@[GXY]<D10]VPV-95=:6;5C^3= -=*Z<FK1::;OW3<N5B,Y^ 9//
MV&35OG)AH]5UU>^@$X4$!ZH^V9V8R/DK(@=.:1E#;<O>WO_1@^+U%OX\Q(MY
M=U <.34'!3>#@O_*TO\[QF)P"*R]'3T$N!=$@D78'0!'+LT!:(2*9TWDUX]$
MQ/46/XC$J42IK+5GY2)<=)%<0WMXC?CP[.KCT9AY.EF$W#)2H,Y32U I$SV-
MU-Q5)2>0I#!Q:7I,\E<*D^]X,0.WNQ]-=-[/,/T>T6O(%J_1+9Y=N-SO=DSA
M4"FYPFBL[4%$CK1%A:@O9_"BNY6[<FDB:O2,9Q<TES/Q)\HC*"8''2<'A,T@
M0*<BIK(6M@#.;GIS[!I"QFN4C/?M4B8]OSE2&W']&FF0GU,=X[TM9%PY-.DU
M4L:S:YF&D;D1%T<(@2J^D2AF]&2$/%%$$15B7R00'U7\JW9@F)\9?4$[7L"^
M>SPF+*KV<):HK=B: CF5/EY?^WBK>3#OY4#7$#]>HWX\N_PQ%[B9]YSS5'Z5
ML1@< J<RJK)F1@ZOR_\:,@HW,@K;9=2%'/3OP6WOVUC<E35#MH9^E[<KGR;O
M1HAANQ"SQIH6V2//H8X*VQ3R_HR)5.5A<9'"DK!&$;O_T4S[0FJY#!?+[O[G
MRJM)M5%2V*ZD1D61KZ0\"->I1*JLF?&A&Y]=N33)-A()VR62+3Y\"TBGPJJR
MUE[Y"S]8=DE>0UGA1EGA-Y75A1S-?LYC-SL:55\Q+;U55Y>[\FFB:B03MDNF
M3SK//Q8<YI*@,+E8-(RFKVW\>?\,;* :I$)A;V>XA@C"C0C"=A%T?SAP"CLI
M[9[<U ? UK#O5//@_LE-N CGJZ"+[,UZ)HQ&T&"[H*G##GF+RB ,IP*FLF:^
M#@]6O?!R#1&#&Q&#[2+&T3F"W<MH=.'7H;N&!L&-!L%V#=**S(]F9/Y OK"T
M2-M,R3:A]I7H5$-4UMHK;+7TL=];B=>0$7XC(WR[C/CX_+D]Y2+*)6'9>>J=
M7PRJ$%;>:1F\#N)4#536C-"T"A;=Q-654Y-;(P=\NQPH=[HF 3AK+.")#I"X
MRD%03E/\RIJQ1K'7S0A<^30Y-0F^;T_P&]FDTODHIN5)AU:?V4&5ZQFHD5F/
MZ.U^1K/#;]YP<.70!->ZBV7/WS\I]4.B\G HRL7P.8?=R&@J ^EX-RG;N')I
M<FFR<=^>C3_Q_,1$^=;"GG_;#8UFT\^_ ^QUH[DKGR:<)O_V[?GW,SMD:EGI
M3:Y,OQ&GVI7>*9$W^\<@*J<G%W[_MM; #;>-*Z<FJR9M]^UI^YNLYA=8.4W8
M_8&K5D.LKG%,X3=9O6_/ZC,JU27K\EV,)%]0PLB6)4R^#A)RFL7[_2P>]_ X
M3>&GK6O6D 4=]'5U%82+3)8WKNO2^DK\O;X(/FVJE_?I/^B3?X$2NH>FLYLE
M##0OKZB77V1^U)>VM[F4>:H_QI1 (JLJP._[/)?G+\I!_1\%UO\'4$L#!!0
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MFNL;T7R&SH\5F JN[),T7:[GD+166I0=&!64K&K?]*FKPQ; C]X !!T@^%M
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M2P96"4D97YGA-@Q,,IY)1^E]K1WZ,#)_,K!O>K#E2YZ4B4P6OHT'\SLNI^\
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=O+;MI &(;A6T&^@'C.ARK)JIMLJ]P
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MOGE8 M#;J]X>H+=7O3U ;Z]Z>X#>7O7V +V]ZNT!>GO5VP/T#JIW .@=5.\
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ](R86/N9\6CN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M](R86)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #TC)A8XB5@U)<&  !R'@  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M](R86,8RH?Q]!0  S!8  !@              ("!V@X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /2,F%@X.N"(E@8  /,?   8
M          " @8T4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " #TC)A80LY!<PT'  !!+P  &               @(%9&P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ](R86,6Q' 5Z"0  ;BX
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M965T.2YX;6Q02P$"% ,4    " #TC)A8?,-KQ,X$   9"P  &0
M    @(&EE@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M /2,F%@4C0?P8 4  '8+   9              " @:J;  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ ](R86%[)A59E @  H 4  !D
M             ("!0:$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #TC)A8\/!A*=,"  #"!@  &0              @('=HP  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( /2,F%B-M3AG^ D
M &\=   9              " @>>F  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ ](R86-CS=W1K%@  MV(  !D              ("!
M%K$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #TC)A8
M7#I%!!<#  !:!P  &0              @(&XQP  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( /2,F%@8.LO#:08   P1   9
M      " @0;+  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ ](R86!%6'(>/"P  *"X  !D              ("!IM$  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #TC)A87^1FTHX#  "C"
M&0              @(%LW0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( /2,F%AJ*ARSU!$  #XT   9              " @3'A  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ](R86+>&3\=>
M P  60P  !D              ("!//,  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #TC)A8]=9Z,6<"  "J!0  &0
M@('1]@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /2,
MF%@Z?VM$U ,  #P+   9              " @6_Y  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ ](R86/O5IPYJ#0  4B4  !D
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M=#(X+GAM;%!+ 0(4 Q0    ( /2,F%AK,Z-![@@  ' >   9
M  " @4%; 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M](R86!;4?F)&"@  MBH  !D              ("!9F0! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " #TC)A8'=[$$B8#  #M!P  &0
M            @('C;@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( /2,F%A$ %Z6U @  $PI   9              " @4!R 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ](R86)"NY5%0 @
M:04  !D              ("!2WL! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " #TC)A8.>[RWN(#  "<"@  &0              @('2
M?0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( /2,F%BR
MF%P^YP<   TE   9              " @>N! 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ ](R86'4FV#Y/!0  )1$  !D
M     ("!"8H! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2,F%C';Y>8& 4  -(:   9              "
M@5&< 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ](R8
M6+A0MC4# P  T@T  !D              ("!H*$! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " #TC)A8</U=@E$#  "W$   &0
M        @(':I $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( /2,F%@//EJ)3 ,  .H0   9              " @6*H 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ](R86 Z27_=3!   N1@
M !D              ("!Y:L! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " #TC)A8\*.OUY@,   ^CP  &0              @(%OL $
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( /2,F%CWV!?,
MR@4  +PL   9              " @3Z] 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ ](R86%_BN^%V @  B 8  !D
M ("!/\,! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #T
MC)A8%OS,O/D"  ! #   &0              @('LQ0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( /2,F%B+7*]"VP0  &<5   9
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M970U-"YX;6Q02P$"% ,4    " #TC)A87M:IY[D3  #D2P$ &0
M    @(%EX0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M /2,F%CJ?('"=@,  %,+   9              " @57U 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ ](R86%;(ELZN"@  5&0  !D
M             ("! OD! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " #TC)A8[(:0J4D,  #L9@  &0              @('G P( >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( /2,F%@R&D63H08
M &(K   9              " @6<0 @!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ ](R86%&1EGZP P  #@X  !D              ("!
M/Q<" 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #TC)A8
MJ$MOA; #  #X"P  &0              @($F&P( >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( /2,F%@F)E3Z$@,  !D*   9
M      " @0T? @!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ ](R86/]IC5KM @  M D  !D              ("!5B(" 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #TC)A8\5[5TET"  !8!@
M&0              @(%Z)0( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( /2,F%@)*: @K (  .H'   9              " @0XH @!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ ](R86"(%>NR)
M @  M@<  !D              ("!\2H" 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " #TC)A8"60S3%,$  #Q%0  &0
M@(&Q+0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( /2,
MF%@0^4AL?P0  !(=   9              " @3LR @!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ ](R86*'(LC3D P  KA,  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( /2,F%BD44M9$@,  !P*   9
M  " @3%/ @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
M](R86#30@"4:!P  D$0  !D              ("!>E(" 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " #TC)A8AP/':'T%  #R(P  &0
M            @('+60( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( /2,F%AKO\<@QQX  '*" @ 9              " @7]? @!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ ](R86!0LQ[N^&P
M>3T" !D              ("!?7X" 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    " #TC)A8(+I23_01  #"3P$ &0              @(%R
MF@( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( /2,F%C(
MKP%E"P,  -4)   9              " @9VL @!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ ](R86 1Q(167!0  ##<  !D
M     ("!WZ\" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2,F%CX!XO=/P0  %(1   9              "
M@87" @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ ](R8
M6/8KV['< P  D1(  !D              ("!^\8" 'AL+W=O<FMS:&5E=',O
M<VAE970X-RYX;6Q02P$"% ,4    " #TC)A8NCI%5MD$  #/%   &0
M        @($.RP( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0
M   ( /2,F%BC:7M&PP0  ,D3   9              " @1[0 @!X;"]W;W)K
M<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ ](R86'(.FI4 #0  TGL
M !D              ("!&-4" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q0
M2P$"% ,4    " #TC)A8 V3H9"H#  #X"@  &0              @(%/X@(
M>&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( /2,F%BD+<%4
MU@(  )\(   9              " @;#E @!X;"]W;W)K<VAE971S+W-H965T
M.3(N>&UL4$L! A0#%     @ ](R86)>TO#37!   <AL  !D
M ("!O>@" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " #T
MC)A8I< ;48<$  #S%@  &0              @('+[0( >&PO=V]R:W-H965T
M<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( /2,F%B7@;Y,70D  -2#   9
M          " @8GR @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#
M%     @ ](R86-J,5]XJ!   \Q,  !D              ("!'?P" 'AL+W=O
M<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " #TC)A8G/N)6^H#  !B
M$   &0              @(%^  , >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM
M;%!+ 0(4 Q0    ( /2,F%B![Y;,EP,  (</   9              " @9\$
M P!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ ](R86 =3
M6F N!   51D  !D              ("!;0@# 'AL+W=O<FMS:&5E=',O<VAE
M970Y.2YX;6Q02P$"% ,4    " #TC)A8+-M]5Z,2  "!/P$ &@
M    @('2# , >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4
M" #TC)A8*+7(W?D'   T,   &@              @(&M'P, >&PO=V]R:W-H
M965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " #TC)A8'\#'\\4#  !S#
M&@              @('>)P, >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q0
M2P$"% ,4    " #TC)A8+4"[+J@"  #]!@  &@              @(';*P,
M>&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " #TC)A8YD$,
MHUD#  !*$   &@              @(&[+@, >&PO=V]R:W-H965T<R]S:&5E
M=#$P-"YX;6Q02P$"% ,4    " #TC)A8*(&<<8L#  "/&   #0
M    @ %,,@, >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /2,F%B7BKL<P
M !,"   +              "  0(V P!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M /2,F%@G1:)45@<  %]$   /              "  >LV P!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #TC)A8\0BR^?("   ;/0  &@
M@ %N/@, >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #T
MC)A895'I;V8"  #K.@  $P              @ &800, 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     < !P ,P>   O1 ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>615</ContextCount>
  <ElementCount>519</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>164</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureCorporateInformation</Role>
      <ShortName>Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAccountingPolicies</Role>
      <ShortName>Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Notes to the consolidated financial statements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements</Role>
      <ShortName>Notes to the consolidated financial statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Assets held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSale</Role>
      <ShortName>Assets held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Other financial assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherFinancialAssets</Role>
      <ShortName>Other financial assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid expenses and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Other liabilities and provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions</Role>
      <ShortName>Other liabilities and provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTax</Role>
      <ShortName>Income tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Disclosure of financial instruments and management of financial risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks</Role>
      <ShortName>Disclosure of financial instruments and management of financial risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Notes to the consolidated statements of cash flows</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Notes to the consolidated statements of cash flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Remuneration of the Company's key management personnel</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnel</Role>
      <ShortName>Remuneration of the Company's key management personnel</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Related party disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</Role>
      <ShortName>Related party disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>12101 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies</Role>
      <ShortName>Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAccountingPoliciesTables</Role>
      <ShortName>Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Notes to the consolidated financial statements (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables</Role>
      <ShortName>Notes to the consolidated financial statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureFixedAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureShareBasedPayments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Other liabilities and provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables</Role>
      <ShortName>Other liabilities and provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Income tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTaxTables</Role>
      <ShortName>Income tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureIncomeTax</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Disclosure of financial instruments and management of financial risks (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables</Role>
      <ShortName>Disclosure of financial instruments and management of financial risks (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Notes to the consolidated statements of cash flows (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsTables</Role>
      <ShortName>Notes to the consolidated statements of cash flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlows</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Remuneration of the Company's key management personnel (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelTables</Role>
      <ShortName>Remuneration of the Company's key management personnel (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnel</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>32003 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureBusinessCombinations</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Corporate Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureCorporateInformationDetails</Role>
      <ShortName>Corporate Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureCorporateInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Accounting Policies - Estimated useful lives Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails</Role>
      <ShortName>Accounting Policies - Estimated useful lives Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Accounting Policies - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Accounting Policies - Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Accounting Policies - Estimated useful life of right-of-use assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails</Role>
      <ShortName>Accounting Policies - Estimated useful life of right-of-use assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Notes to the consolidated financial statements - Contract balances (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Contract balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40305 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Cost of sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Selling and distribution expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40308 - Disclosure - Notes to the consolidated financial statements - Research and development (R&amp;D) expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Research and development (R&amp;D) expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - General and administrative expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40310 - Disclosure - Notes to the consolidated financial statements - Operative Expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Operative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40312 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Other operating income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fixed Assets - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails</Role>
      <ShortName>Fixed Assets - Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Fixed Assets - Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Fixed Assets - Right-of-use assets and lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails</Role>
      <ShortName>Fixed Assets - Right-of-use assets and lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Fixed Assets - Carrying amounts of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails</Role>
      <ShortName>Fixed Assets - Carrying amounts of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Fixed Assets - Amounts recognized in the statement of operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails</Role>
      <ShortName>Fixed Assets - Amounts recognized in the statement of operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Assets held for sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails</Role>
      <ShortName>Assets held for sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureAssetsHeldForSale</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureInventories</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Other financial assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails</Role>
      <ShortName>Other financial assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureOtherFinancialAssets</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Equity - Overview and General Remarks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails</Role>
      <ShortName>Equity - Overview and General Remarks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Equity - Impact of share split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails</Role>
      <ShortName>Equity - Impact of share split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Equity - Follow-on public offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails</Role>
      <ShortName>Equity - Follow-on public offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Equity - At-the-market offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails</Role>
      <ShortName>Equity - At-the-market offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Equity - Frame acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails</Role>
      <ShortName>Equity - Frame acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Equity - Exercises of share options under the VSOP plan and legacy program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails</Role>
      <ShortName>Equity - Exercises of share options under the VSOP plan and legacy program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Share-based payments - Expense recognized for the share-based payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails</Role>
      <ShortName>Share-based payments - Expense recognized for the share-based payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails</Role>
      <ShortName>Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Share-based payments - Prior VSOP - Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails</Role>
      <ShortName>Share-based payments - Prior VSOP - Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Share-based payments - New VSOP - Reconciliation of outstanding awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails</Role>
      <ShortName>Share-based payments - New VSOP - Reconciliation of outstanding awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails</Role>
      <ShortName>Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41007 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails</Role>
      <ShortName>Share-based payments - Long-Term Incentive Plan (LTIP) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>41008 - Disclosure - Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails</Role>
      <ShortName>Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>41009 - Disclosure - Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails</Role>
      <ShortName>Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>41010 - Disclosure - Share-based payments - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails</Role>
      <ShortName>Share-based payments - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>41011 - Disclosure - Share-based payments - Restricted Stock Units expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails</Role>
      <ShortName>Share-based payments - Restricted Stock Units expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Trade and other payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails</Role>
      <ShortName>Trade and other payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureTradeAndOtherPayablesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Other liabilities and provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails</Role>
      <ShortName>Other liabilities and provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Other liabilities and provisions - Movements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails</Role>
      <ShortName>Other liabilities and provisions - Movements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Other liabilities and provisions - Current and Non Current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails</Role>
      <ShortName>Other liabilities and provisions - Current and Non Current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Other liabilities and provisions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails</Role>
      <ShortName>Other liabilities and provisions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTaxDetails</Role>
      <ShortName>Income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureIncomeTaxTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Income tax - Schedule of tax reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails</Role>
      <ShortName>Income tax - Schedule of tax reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Income tax - Schedule of deferred taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails</Role>
      <ShortName>Income tax - Schedule of deferred taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Income tax - Schedule of unused tax losses carried forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails</Role>
      <ShortName>Income tax - Schedule of unused tax losses carried forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureEarningsPerShare</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Disclosure of financial instruments and management of financial risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails</Role>
      <ShortName>Disclosure of financial instruments and management of financial risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails</Role>
      <ShortName>Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails</Role>
      <ShortName>Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>41504 - Disclosure - Disclosure of financial instruments and management of financial risks - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails</Role>
      <ShortName>Disclosure of financial instruments and management of financial risks - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Notes to the consolidated statements of cash flows - Financing activities (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails</Role>
      <ShortName>Notes to the consolidated statements of cash flows - Financing activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Remuneration of the Company's key management personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails</Role>
      <ShortName>Remuneration of the Company's key management personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Remuneration of the Company's key management personnel - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails</Role>
      <ShortName>Remuneration of the Company's key management personnel - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Related party disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails</Role>
      <ShortName>Related party disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureBusinessCombinationsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>42002 - Disclosure - Business Combinations - Fair value recognized on acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails</Role>
      <ShortName>Business Combinations - Fair value recognized on acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>42003 - Disclosure - Business Combinations - Goodwill recognized as a result of the acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails</Role>
      <ShortName>Business Combinations - Goodwill recognized as a result of the acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="cvac-20231231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>42101 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>104</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod, cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage, cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease, dei:CurrentFiscalYearEndDate, ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement -  cvac-20231231x20f.htm 9</Log>
  </Logs>
  <InputFiles>
    <File>cvac-20231231.xsd</File>
    <File>cvac-20231231_cal.xml</File>
    <File>cvac-20231231_def.xml</File>
    <File>cvac-20231231_lab.xml</File>
    <File>cvac-20231231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" original="cvac-20231231x20f.htm">cvac-20231231x20f.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvac-20231231x20f002.jpg</File>
    <File>cvac-20231231x20f004.jpg</File>
    <File>cvac-20231231x20f005.jpg</File>
    <File>cvac-20231231x20f006.jpg</File>
    <File>cvac-20231231x20f007.jpg</File>
    <File>cvac-20231231x20f009.jpg</File>
    <File>cvac-20231231x20f011.jpg</File>
    <File>cvac-20231231x20f013.jpg</File>
    <File>cvac-20231231x20f014.jpg</File>
    <File>cvac-20231231x20f016.jpg</File>
    <File>cvac-20231231x20f017.jpg</File>
    <File>cvac-20231231x20f019.jpg</File>
    <File>cvac-20231231x20f021.jpg</File>
    <File>cvac-20231231x20f023.jpg</File>
    <File>cvac-20231231x20f025.jpg</File>
    <File>cvac-20231231x20f026.jpg</File>
    <File>cvac-20231231x20f027.jpg</File>
    <File>cvac-20231231x20f028.jpg</File>
    <File>cvac-20231231x20f029.jpg</File>
    <File>cvac-20231231x20f030.jpg</File>
    <File>cvac-20231231x20f031.jpg</File>
    <File>cvac-20231231x20f032.jpg</File>
    <File>cvac-20231231x20f033.jpg</File>
    <File>cvac-20231231x20f034.jpg</File>
    <File>cvac-20231231x20f035.jpg</File>
    <File>cvac-20231231x20f036.jpg</File>
    <File>cvac-20231231x20f037.jpg</File>
    <File>cvac-20231231x20f038.jpg</File>
    <File>cvac-20231231x20f039.jpg</File>
    <File>cvac-20231231x20f041.jpg</File>
    <File>cvac-20231231x20f043.jpg</File>
    <File>cvac-20231231x20f044.jpg</File>
    <File>cvac-20231231x20f046.jpg</File>
    <File>cvac-20231231x20f047.jpg</File>
    <File>cvac-20231231x20f048.jpg</File>
    <File>cvac-20231231x20f050.jpg</File>
    <File>cvac-20231231x20f051.jpg</File>
    <File>cvac-20231231x20f052.jpg</File>
    <File>cvac-20231231x20f066.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="1340">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>172
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvac-20231231x20f.htm": {
   "nsprefix": "cvac",
   "nsuri": "http://www.curevac.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cvac-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvac-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvac-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvac-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvac-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvac-20231231x20f.htm"
     ]
    }
   },
   "keyStandard": 310,
   "keyCustom": 209,
   "axisStandard": 29,
   "axisCustom": 7,
   "memberStandard": 42,
   "memberCustom": 112,
   "hidden": {
    "total": 15,
    "http://www.curevac.com/20231231": 7,
    "http://xbrl.sec.gov/dei/2023": 5,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 3
   },
   "contextCount": 615,
   "entityCount": 1,
   "segmentCount": 164,
   "elementCount": 836,
   "unitCount": 16,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1340,
    "http://xbrl.sec.gov/dei/2023": 41
   },
   "report": {
    "R1": {
     "role": "http://www.curevac.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
     "longName": "00100 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition",
     "longName": "00200 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
     "longName": "00300 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AnQeJoI56kuDvOssY92e1Q",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AnQeJoI56kuDvOssY92e1Q",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:AdjustmentsForFinanceIncome",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.curevac.com/role/DisclosureCorporateInformation",
     "longName": "10101 - Disclosure - Corporate Information",
     "shortName": "Corporate Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:CorporateInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:CorporateInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.curevac.com/role/DisclosureAccountingPolicies",
     "longName": "10201 - Disclosure - Accounting Policies",
     "shortName": "Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements",
     "longName": "10301 - Disclosure - Notes to the consolidated financial statements",
     "shortName": "Notes to the consolidated financial statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.curevac.com/role/DisclosureFixedAssets",
     "longName": "10401 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSale",
     "longName": "10501 - Disclosure - Assets held for sale",
     "shortName": "Assets held for sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.curevac.com/role/DisclosureInventories",
     "longName": "10601 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.curevac.com/role/DisclosureOtherFinancialAssets",
     "longName": "10701 - Disclosure - Other financial assets",
     "shortName": "Other financial assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfOtherFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfOtherFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "10801 - Disclosure - Prepaid expenses and other current assets",
     "shortName": "Prepaid expenses and other current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.curevac.com/role/DisclosureEquity",
     "longName": "10901 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPayments",
     "longName": "11001 - Disclosure - Share-based payments",
     "shortName": "Share-based payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayables",
     "longName": "11101 - Disclosure - Trade and other payables",
     "shortName": "Trade and other payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions",
     "longName": "11201 - Disclosure - Other liabilities and provisions",
     "shortName": "Other liabilities and provisions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:OtherLiabilitiesAndProvisionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:OtherLiabilitiesAndProvisionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.curevac.com/role/DisclosureIncomeTax",
     "longName": "11301 - Disclosure - Income tax",
     "shortName": "Income tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShare",
     "longName": "11401 - Disclosure - Earnings per share",
     "shortName": "Earnings per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks",
     "longName": "11501 - Disclosure - Disclosure of financial instruments and management of financial risks",
     "shortName": "Disclosure of financial instruments and management of financial risks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlows",
     "longName": "11601 - Disclosure - Notes to the consolidated statements of cash flows",
     "shortName": "Notes to the consolidated statements of cash flows",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.curevac.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11701 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnel",
     "longName": "11801 - Disclosure - Remuneration of the Company's key management personnel",
     "shortName": "Remuneration of the Company's key management personnel",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures",
     "longName": "11901 - Disclosure - Related party disclosures",
     "shortName": "Related party disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.curevac.com/role/DisclosureBusinessCombinations",
     "longName": "12001 - Disclosure - Business Combinations",
     "shortName": "Business Combinations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.curevac.com/role/DisclosureSubsequentEvents",
     "longName": "12101 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Accounting Policies (Policies)",
     "shortName": "Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.curevac.com/role/DisclosureAccountingPoliciesTables",
     "longName": "30203 - Disclosure - Accounting Policies (Tables)",
     "shortName": "Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables",
     "longName": "30303 - Disclosure - Notes to the consolidated financial statements (Tables)",
     "shortName": "Notes to the consolidated financial statements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsTables",
     "longName": "30403 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.curevac.com/role/DisclosureEquityTables",
     "longName": "30903 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables",
     "longName": "31003 - Disclosure - Share-based payments (Tables)",
     "shortName": "Share-based payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesTables",
     "longName": "31103 - Disclosure - Trade and other payables (Tables)",
     "shortName": "Trade and other payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfTradeAndOtherPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfTradeAndOtherPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables",
     "longName": "31203 - Disclosure - Other liabilities and provisions (Tables)",
     "shortName": "Other liabilities and provisions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.curevac.com/role/DisclosureIncomeTaxTables",
     "longName": "31303 - Disclosure - Income tax (Tables)",
     "shortName": "Income tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables",
     "longName": "31503 - Disclosure - Disclosure of financial instruments and management of financial risks (Tables)",
     "shortName": "Disclosure of financial instruments and management of financial risks (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsTables",
     "longName": "31603 - Disclosure - Notes to the consolidated statements of cash flows (Tables)",
     "shortName": "Notes to the consolidated statements of cash flows (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelTables",
     "longName": "31803 - Disclosure - Remuneration of the Company's key management personnel (Tables)",
     "shortName": "Remuneration of the Company's key management personnel (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.curevac.com/role/DisclosureBusinessCombinationsTables",
     "longName": "32003 - Disclosure - Business Combinations (Tables)",
     "shortName": "Business Combinations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
     "longName": "40101 - Disclosure - Corporate Information (Details)",
     "shortName": "Corporate Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_lBS-kbj340mK__LFAXyYQg",
      "name": "cvac:PercentageOfVotingInterestsHeld",
      "unitRef": "Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "cvac:CorporateInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_lBS-kbj340mK__LFAXyYQg",
      "name": "cvac:PercentageOfVotingInterestsHeld",
      "unitRef": "Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "cvac:CorporateInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
     "longName": "40201 - Disclosure - Accounting Policies - Additional Information (Details)",
     "shortName": "Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:IfrsPropertyPlantAndEquipmentSalvageValue",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
     "longName": "40202 - Disclosure - Accounting Policies - Estimated useful lives Intangible assets (Details)",
     "shortName": "Accounting Policies - Estimated useful lives Intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IF3SAFyRDkmSY9vIIRwRsA",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IF3SAFyRDkmSY9vIIRwRsA",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
     "longName": "40203 - Disclosure - Accounting Policies - Property, plant and equipment (Details)",
     "shortName": "Accounting Policies - Property, plant and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_SzFXrlYIYkGJv5pgzyKXhQ",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_SzFXrlYIYkGJv5pgzyKXhQ",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
     "longName": "40204 - Disclosure - Accounting Policies - Estimated useful life of right-of-use assets (Details)",
     "shortName": "Accounting Policies - Estimated useful life of right-of-use assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_Q9fMN7T-y0m13lblbattaw",
      "name": "cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory",
       "cvac:DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_Q9fMN7T-y0m13lblbattaw",
      "name": "cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory",
       "cvac:DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
     "longName": "40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)",
     "shortName": "Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_5-Lg5t6vPU2ChcpJcmCALQ",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
     "longName": "40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)",
     "shortName": "Notes to the consolidated financial statements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding",
      "unitRef": "Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
     "longName": "40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)",
     "shortName": "Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails",
     "longName": "40304 - Disclosure - Notes to the consolidated financial statements - Contract balances (Details)",
     "shortName": "Notes to the consolidated financial statements - Contract balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
     "longName": "40305 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)",
     "shortName": "Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
     "longName": "40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)",
     "shortName": "Notes to the consolidated financial statements - Cost of sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw",
      "name": "cvac:PersonnelExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ",
      "name": "cvac:PersonnelExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails",
     "longName": "40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)",
     "shortName": "Notes to the consolidated financial statements - Selling and distribution expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw",
      "name": "cvac:PersonnelExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg",
      "name": "cvac:PersonnelExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
     "longName": "40308 - Disclosure - Notes to the consolidated financial statements - Research and development (R&D) expenses (Details)",
     "shortName": "Notes to the consolidated financial statements - Research and development (R&D) expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw",
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA",
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
     "longName": "40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)",
     "shortName": "Notes to the consolidated financial statements - General and administrative expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw",
      "name": "cvac:PersonnelExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg",
      "name": "cvac:PersonnelExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
     "longName": "40310 - Disclosure - Notes to the consolidated financial statements - Operative Expenses (Details)",
     "shortName": "Notes to the consolidated financial statements - Operative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw",
      "name": "cvac:PersonnelExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
     "longName": "40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)",
     "shortName": "Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2021_To_10_31_2021_a1WmAXnod02XXfLywgY6XA",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2021_To_10_31_2021_a1WmAXnod02XXfLywgY6XA",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails",
     "longName": "40312 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)",
     "shortName": "Notes to the consolidated financial statements - Other operating income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
     "longName": "40401 - Disclosure - Fixed Assets - Intangible assets (Details)",
     "shortName": "Fixed Assets - Intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
     "longName": "40402 - Disclosure - Fixed Assets - Property, plant and equipment (Details)",
     "shortName": "Fixed Assets - Property, plant and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w6XdbSqlp06NSNtoVAqCkQ",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails",
     "longName": "40403 - Disclosure - Fixed Assets - Right-of-use assets and lease liabilities (Details)",
     "shortName": "Fixed Assets - Right-of-use assets and lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails",
     "longName": "40404 - Disclosure - Fixed Assets - Carrying amounts of lease liabilities (Details)",
     "shortName": "Fixed Assets - Carrying amounts of lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:AdditionsLeaseLiabilities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails",
     "longName": "40405 - Disclosure - Fixed Assets - Amounts recognized in the statement of operations (Details)",
     "shortName": "Fixed Assets - Amounts recognized in the statement of operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails",
     "longName": "40501 - Disclosure - Assets held for sale (Details)",
     "shortName": "Assets held for sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "cvac:NetBookValueOfCmoEquipmentHeldForSale",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "cvac:NetBookValueOfCmoEquipmentHeldForSale",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.curevac.com/role/DisclosureInventoriesDetails",
     "longName": "40601 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails",
     "longName": "40701 - Disclosure - Other financial assets (Details)",
     "shortName": "Other financial assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:CurrentInvestments",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cvac:DisclosureOfOtherFinancialAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:CurrentInvestments",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cvac:DisclosureOfOtherFinancialAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "40801 - Disclosure - Prepaid expenses and other current assets (Details)",
     "shortName": "Prepaid expenses and other current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails",
     "longName": "40901 - Disclosure - Equity - Overview and General Remarks (Details)",
     "shortName": "Equity - Overview and General Remarks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails",
     "longName": "40902 - Disclosure - Equity - Impact of share split (Details)",
     "shortName": "Equity - Impact of share split (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "cvac:CommonSharesIssuedAndOutstanding",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA",
      "name": "cvac:CommonSharesIssuedAndOutstanding",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
     "longName": "40903 - Disclosure - Equity - Follow-on public offering (Details)",
     "shortName": "Equity - Follow-on public offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw",
      "name": "cvac:IncreaseInNumberOfSharesOutstanding",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
     "longName": "40904 - Disclosure - Equity - At-the-market offering (Details)",
     "shortName": "Equity - At-the-market offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_17_2021_To_9_17_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_jUlavD3NjEy-jk37WZ7FiQ",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails",
     "longName": "40905 - Disclosure - Equity - Frame acquisition (Details)",
     "shortName": "Equity - Frame acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A",
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
     "longName": "40906 - Disclosure - Equity - Exercises of share options under the VSOP plan and legacy program (Details)",
     "shortName": "Equity - Exercises of share options under the VSOP plan and legacy program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q",
      "name": "cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q",
      "name": "cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
     "longName": "41001 - Disclosure - Share-based payments - Expense recognized for the share-based payments (Details)",
     "shortName": "Share-based payments - Expense recognized for the share-based payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
     "longName": "41002 - Disclosure - Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)",
     "shortName": "Share-based payments - Prior VSOP - Development of the virtual shares in this program granted to management and key employees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_8_14_2023_To_8_14_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_c7I5rda9O0unxghjuyCeYA",
      "name": "cvac:RightToExercisePercentageOfVestedVirtualShares",
      "unitRef": "Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_14_2023_To_8_14_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_c7I5rda9O0unxghjuyCeYA",
      "name": "cvac:RightToExercisePercentageOfVestedVirtualShares",
      "unitRef": "Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
     "longName": "41003 - Disclosure - Share-based payments - Prior VSOP - Expenses (Details)",
     "shortName": "Share-based payments - Prior VSOP - Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q",
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q",
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
     "longName": "41004 - Disclosure - Share-based payments - New VSOP - Reconciliation of outstanding awards (Details)",
     "shortName": "Share-based payments - New VSOP - Reconciliation of outstanding awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g",
      "name": "ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
     "longName": "41005 - Disclosure - Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)",
     "shortName": "Share-based payments - New VSOP - Expense recognized in the statement of operations and other comprehensive income (loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog",
      "name": "ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q",
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
     "longName": "41006 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)",
     "shortName": "Share-based payments - Long-Term Incentive Plan (LTIP) - Inputs used in the measurement of the fair value at grant date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_1_1_2022_WZMCwy54QUmI6ryK9Caqbw",
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "unitRef": "Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_1_1_2022_WZMCwy54QUmI6ryK9Caqbw",
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "unitRef": "Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
     "longName": "41007 - Disclosure - Share-based payments - Long-Term Incentive Plan (LTIP) (Details)",
     "shortName": "Share-based payments - Long-Term Incentive Plan (LTIP) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
     "longName": "41008 - Disclosure - Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)",
     "shortName": "Share-based payments- Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_30_2022_To_11_30_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_YaepVSyZlU2heFMGLS9PMw",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
     "longName": "41009 - Disclosure - Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details)",
     "shortName": "Share-based payments - Former Chief Executive Officer Grant - Reconciliation of outstanding awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails",
     "longName": "41010 - Disclosure - Share-based payments - Restricted Stock Units (Details)",
     "shortName": "Share-based payments - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "Duration_3_1_2022_To_3_1_2022_y1_WCcSI20-05QOkXbljog",
      "name": "cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage",
      "unitRef": "Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails",
     "longName": "41011 - Disclosure - Share-based payments - Restricted Stock Units expense (Details)",
     "shortName": "Share-based payments - Restricted Stock Units expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA",
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA",
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails",
     "longName": "41101 - Disclosure - Trade and other payables (Details)",
     "shortName": "Trade and other payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfTradeAndOtherPayablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfTradeAndOtherPayablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails",
     "longName": "41201 - Disclosure - Other liabilities and provisions (Details)",
     "shortName": "Other liabilities and provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "cvac:ContractTerminationProvisionsCurrent",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "cvac:ContractTerminationProvisionsCurrent",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails",
     "longName": "41202 - Disclosure - Other liabilities and provisions - Movements (Details)",
     "shortName": "Other liabilities and provisions - Movements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "ifrs-full:Provisions",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails",
     "longName": "41203 - Disclosure - Other liabilities and provisions - Current and Non Current liabilities (Details)",
     "shortName": "Other liabilities and provisions - Current and Non Current liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "cvac:OtherMiscellaneousNonCurrentLiabilities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "cvac:OtherMiscellaneousNonCurrentLiabilities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails",
     "longName": "41204 - Disclosure - Other liabilities and provisions - Additional Information (Details)",
     "shortName": "Other liabilities and provisions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:AdditionalProvisionsOtherProvisions",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw",
      "name": "ifrs-full:AdditionalProvisionsOtherProvisions",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
     "longName": "41301 - Disclosure - Income tax (Details)",
     "shortName": "Income tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:IncomeTaxExpenseContinuingOperations",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails",
     "longName": "41302 - Disclosure - Income tax - Schedule of tax reconciliation (Details)",
     "shortName": "Income tax - Schedule of tax reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails",
     "longName": "41303 - Disclosure - Income tax - Schedule of deferred taxes (Details)",
     "shortName": "Income tax - Schedule of deferred taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails",
     "longName": "41304 - Disclosure - Income tax - Schedule of unused tax losses carried forward (Details)",
     "shortName": "Income tax - Schedule of unused tax losses carried forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:UnusedTaxLossesForCorporateIncomeTax",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:UnusedTaxLossesForCorporateIncomeTax",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
     "longName": "41401 - Disclosure - Earnings per share (Details)",
     "shortName": "Earnings per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails",
     "longName": "41501 - Disclosure - Disclosure of financial instruments and management of financial risks (Details)",
     "shortName": "Disclosure of financial instruments and management of financial risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:FinanceIncome",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails",
     "longName": "41502 - Disclosure - Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)",
     "shortName": "Disclosure of financial instruments and management of financial risks - Maturity profile of the group's financial liabilities based on contractual undiscounted payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:ContractualCommitmentsUndiscountedCashFlows",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ",
      "name": "cvac:ContractualCommitmentsUndiscountedCashFlows",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails",
     "longName": "41503 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)",
     "shortName": "Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_utQHB3ubf0qCXWhEgF-buQ",
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExposureToForeignCurrenciesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_utQHB3ubf0qCXWhEgF-buQ",
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExposureToForeignCurrenciesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails",
     "longName": "41504 - Disclosure - Disclosure of financial instruments and management of financial risks - Additional information (Details)",
     "shortName": "Disclosure of financial instruments and management of financial risks - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails",
     "longName": "41601 - Disclosure - Notes to the consolidated statements of cash flows - Financing activities (Details)",
     "shortName": "Notes to the consolidated statements of cash flows - Financing activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails",
     "longName": "41801 - Disclosure - Remuneration of the Company's key management personnel (Details)",
     "shortName": "Remuneration of the Company's key management personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
     "longName": "41802 - Disclosure - Remuneration of the Company's key management personnel - Additional information (Details)",
     "shortName": "Remuneration of the Company's key management personnel - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA",
      "name": "ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
      "unitRef": "Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA",
      "name": "ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
      "unitRef": "Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
     "longName": "41901 - Disclosure - Related party disclosures (Details)",
     "shortName": "Related party disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:RelatedPartyTransactionConsultingFees",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw",
      "name": "cvac:RelatedPartyTransactionConsultingFees",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
     "longName": "42001 - Disclosure - Business Combinations (Details)",
     "shortName": "Business Combinations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_UoCEidhqNkCfZfezQJra6Q",
      "name": "cvac:FairValueOfTotalConsiderationTransferred",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_UoCEidhqNkCfZfezQJra6Q",
      "name": "cvac:FairValueOfTotalConsiderationTransferred",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails",
     "longName": "42002 - Disclosure - Business Combinations - Fair value recognized on acquisition (Details)",
     "shortName": "Business Combinations - Fair value recognized on acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A",
      "name": "ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A",
      "name": "ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails",
     "longName": "42003 - Disclosure - Business Combinations - Goodwill recognized as a result of the acquisition (Details)",
     "shortName": "Business Combinations - Goodwill recognized as a result of the acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A",
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A",
      "name": "ifrs-full:GoodwillRecognisedAsOfAcquisitionDate",
      "unitRef": "Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.curevac.com/role/DisclosureSubsequentEventsDetails",
     "longName": "42101 - Disclosure - Subsequent events (Details)",
     "shortName": "Subsequent events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw",
      "name": "cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw",
      "name": "cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions",
      "unitRef": "Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvac-20231231x20f.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Loss before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "cvac_AccruedOtherLiabilityForUpFrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AccruedOtherLiabilityForUpFrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued other liability for up-front payment.",
        "label": "Accrued Other Liability for Up-front Payment",
        "terseLabel": "Additional depreciation expense",
        "verboseLabel": "Accrued other liability for up-front payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedImpairmentMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated impairment [member]",
        "terseLabel": "Loss Allowance"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r210",
      "r273",
      "r309",
      "r313",
      "r317",
      "r318"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails": {
       "parentTag": "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration transferred, acquisition-date fair value",
        "terseLabel": "Total purchase price",
        "verboseLabel": "Consideration transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination",
        "verboseLabel": "Transactions costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "cvac_AdditionalCashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdditionalCashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value, at acquisition date, of additional cash transferred as consideration in a business combination.",
        "label": "Additional Cash Transferred",
        "terseLabel": "Additional cash consideration"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AdditionalDevelopmentMilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdditionalDevelopmentMilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional development milestone payment received.",
        "label": "Additional Development Milestone Payments Received",
        "terseLabel": "Additional development milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional provisions, other provisions",
        "terseLabel": "additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "cvac_AdditionsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdditionsLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of addition of lease liabilities.",
        "label": "Additions, Lease Liabilities",
        "terseLabel": "Additions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Decrease / (increase) in inventory"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Decrease (Increase) In Non-current Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners",
        "terseLabel": "Decrease / (increase) in asset held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Decrease / (increase) in trade receivables and contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for deferred tax expense",
        "terseLabel": "Decrease / (increase) in deferred taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation and amortization"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Finance expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for finance income",
        "negatedLabel": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.",
        "label": "Adjustments For Increase Decrease In Other Current Financial And Other Liabilities",
        "terseLabel": "(Decrease) / increase in other current financial and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "(Decrease) / increase in trade and other payables and contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Changes of provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments to reconcile loss before tax to net cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "verboseLabel": "Share-based payment expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "cvac_AdjustmentsTransferToAssetHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdjustmentsTransferToAssetHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer to assets held for sale.",
        "label": "Adjustments Transfer To Asset Held For Sale",
        "terseLabel": "Impairment of assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AdvancePaymentsIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdvancePaymentsIntangibleAssetMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for advance payments, intangible asset.",
        "label": "Advance Payments [Member]",
        "terseLabel": "Advance payments"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AdvancedPurchaseAgreementWithEuropeanCommissionMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Advance Purchase Agreement with European Commission",
        "label": "Advance Purchase Agreement with European Commission"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AggregateGrossProceedsReceivableFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AggregateGrossProceedsReceivableFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of aggregate gross proceeds receivable from issuance of shares.",
        "label": "Aggregate Gross Proceeds Receivable From Issuing Shares",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r149",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r206",
      "r245",
      "r275",
      "r279"
     ]
    },
    "cvac_AlexanderZehnderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AlexanderZehnderMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Alexander Zehnder.",
        "label": "Alexander Zehnder [Member]",
        "terseLabel": "Alexander Zehnder"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AllowanceForExpectedCreditLossOnFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AllowanceForExpectedCreditLossOnFinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for expected credit loss on financial assets.",
        "label": "Allowance For Expected Credit Loss On Financial Assets",
        "terseLabel": "Allowance for expected credit losses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amortization"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "cvac_AmortizationOfGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AmortizationOfGovernmentGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of the grants.",
        "label": "Amortization of the Government Grants",
        "terseLabel": "Amortization of the grants"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AmountEligibleToReceiveAsCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AmountEligibleToReceiveAsCommercialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive commercial milestone payments.",
        "label": "Amount Eligible To Receive As Commercial Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive development and regulatory milestone payments.",
        "label": "Amount Eligible To Receive As Development And Regulatory Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion.",
        "label": "Amount Eligible To Receive As One Time Reimbursable Payment For Manufacturing Capacity Reservation"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AntonyBlancMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AntonyBlancMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Antony Blanc.",
        "label": "Antony Blanc [Member]",
        "terseLabel": "Antony Blanc"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "cvac_ArrangementsAndNonArrangementTransactionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ArrangementsAndNonArrangementTransactionsDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Non-arrangement Transactions [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r137",
      "r138",
      "r139",
      "r223",
      "r226"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Abstract",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AssetsHeldForSaleNetBookValueDirectSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AssetsHeldForSaleNetBookValueDirectSold",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value sold of assets held for direct sale.",
        "label": "Assets Held for Sale, Net Book Value Direct Sold",
        "terseLabel": "Assets held for sale, net book value direct sold"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AssetsHeldForSaleNetBookValueSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AssetsHeldForSaleNetBookValueSold",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value sold of assets held for sale.",
        "label": "Assets Held for Sale, Net Book Value Sold",
        "terseLabel": "Assets held for sale with a net book value sold"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_AtMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "AtMarketOfferingProgramMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to at the market offering program.",
        "label": "ATM Offering Program"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r298"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ]
    },
    "ifrs-full_AuditorsRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemuneration",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration",
        "terseLabel": "Total remuneration"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average effective tax rate",
        "terseLabel": "Corporate income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate",
        "terseLabel": "Exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "country_BE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "BE",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Belgium",
        "terseLabel": "Belgium"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_BarkerBiomedicalGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BarkerBiomedicalGmbhMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for barker biomedical GmbH member.",
        "label": "Barker BioMedical GmbH [Member]",
        "terseLabel": "Barker BioMedical GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_BaronJeanStephenneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BaronJeanStephenneMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Baron Jean Stephenne.",
        "label": "Baron Jean Stephenne [Member]",
        "terseLabel": "Baron Jean Stephenne"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Net loss per share basic (in dollars per share)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86"
     ]
    },
    "cvac_BepharbelManufacturingS.aMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BepharbelManufacturingS.aMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BePharBel Manufacturing S.A.",
        "label": "BePharBel Manufacturing S.A [Member]",
        "terseLabel": "BePharBel Manufacturing S.A"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_BillAndMelindaGatesFoundationBmgfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BillAndMelindaGatesFoundationBmgfMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_BoehringerIngelheimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BoehringerIngelheimMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Boehringer Ingelheim.",
        "label": "Boehringer Ingelheim",
        "terseLabel": "Boehringer Ingelheim"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingCostsCapitalised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingCostsCapitalised",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing costs capitalised",
        "terseLabel": "Borrowing costs capitalized"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r167",
      "r183",
      "r261",
      "r262",
      "r326"
     ]
    },
    "ifrs-full_BuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BuildingsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buildings [Member]",
        "terseLabel": "Buildings"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "cvac_BundesministeriumFurBildungUndForschungMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "BundesministeriumFurBildungUndForschungMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Bundesministerium fr Bildung und Forschung.",
        "label": "Bundesministerium fr Bildung und Forschung"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_BusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [member]",
        "terseLabel": "Business combinations"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for transactions or other events in which an acquirer obtains control of one or more businesses. Transactions sometimes referred to as 'true mergers' or 'mergers of equals' are also business combinations as that term is used in IFRS 3."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289"
     ]
    },
    "country_CH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CH",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland",
        "terseLabel": "Switzerland"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CHF": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CHF",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHF"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalReserve",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital reserve.",
        "terseLabel": "Capital reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_CapitalReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalReserveMember",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital reserve",
        "terseLabel": "Capital reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing capital reserves."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalisationRateOfBorrowingCostsEligibleForCapitalisation",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalisation rate of borrowing costs eligible for capitalisation",
        "terseLabel": "Weighted average borrowing costs (as a percent)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r60",
      "r96",
      "r101",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r199",
      "r210",
      "r211"
     ]
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA.",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]",
        "terseLabel": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r101",
      "r104",
      "r106",
      "r107",
      "r199",
      "r210",
      "r211"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents.",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r117",
      "r132"
     ]
    },
    "cvac_CashAndCashEquivalentsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CashAndCashEquivalentsOneMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for cash and cash equivalents, one.",
        "label": "Cash And Cash Equivalents, One [Member]",
        "terseLabel": "Cash And Cash Equivalents, One"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date",
        "verboseLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash flow provided by financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r118"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash flow provided by (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r118"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash flow provided by (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r109",
      "r118"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities",
        "negatedLabel": "Acquisition of subsidiary, net of cash acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "negatedLabel": "Payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash transferred",
        "terseLabel": "Cash payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "cvac_CashTransferredForSettlementOfVestedEmployeeOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CashTransferredForSettlementOfVestedEmployeeOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash transferred in a business combination for the settlement of the vested employee options.",
        "label": "Cash Transferred For The Settlement Of The Vested Employee Options",
        "terseLabel": "Consideration paid in cash for the settlement of the vested employee options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "cvac_ChangeInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ChangeInTradeAndOtherPayables",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in trade and other payables.",
        "label": "Change in Trade and Other Payables",
        "terseLabel": "Amount of decrease in trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ChangesInWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ChangesInWorkingCapitalAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Changes in Working Capital [Abstract]",
        "terseLabel": "Working capital changes"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ChiefBusinessOfficerAndChiefCommercialOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Business Officer and Chief Commercial Officer.",
        "label": "Chief Business Officer and Chief Commercial Officer"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ChiefDevelopmentOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ChiefDevelopmentOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Development Officer",
        "label": "Chief Development Officer"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "CEO"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer",
        "verboseLabel": "COO"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ChiefScientificOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ChiefScientificOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Scientific Officer.",
        "label": "Chief Scientific Officer"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ClarentisSrlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ClarentisSrlMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.",
        "label": "Clarentis SRL [Member]",
        "terseLabel": "Clarentis SRL"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r140",
      "r161"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r140",
      "r161"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r212",
      "r214",
      "r215"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r212",
      "r214",
      "r215"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "cvac_ClosingOfPublicOfferingOfCommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ClosingOfPublicOfferingOfCommonSharesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for closing of public offering of common shares.",
        "label": "Closing of public offering of common shares",
        "terseLabel": "Closing of public offering of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CoalitionForEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants related to Coalition for Epidemic Preparedness Innovations.",
        "label": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines.",
        "label": "Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for termination of exclusive collobaration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments made by entity, related party transactions",
        "terseLabel": "Settlement amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "cvac_CommonSharesIssuedAndOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CommonSharesIssuedAndOutstanding",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued and outstanding for during the period.",
        "label": "Common Shares Issued And Outstanding",
        "periodEndLabel": "Common shares issued and outstanding ending",
        "periodStartLabel": "Common shares issued and outstanding beginning"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CompensationForContractManufacturingOrganizationsTransfer",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.",
        "label": "Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Compensation for CMO/Materials transfer"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities",
        "terseLabel": "Compensation consist for set-up activities"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses",
        "terseLabel": "Reimbursement of prepayments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive income (loss)",
        "totalLabel": "Total comprehensive loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r36",
      "r122",
      "r124",
      "r130",
      "r260"
     ]
    },
    "ifrs-full_ConcentrationsOfRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ConcentrationsOfRiskAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of risk [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_ConcentrationsOfRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ConcentrationsOfRiskMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the concentrations of risk. It also represents the standard value for the 'Concentrations of risk' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in progress [Member]",
        "terseLabel": "Assets under construction"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ContingentConsiderationMaximumSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContingentConsiderationMaximumSharesIssuable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares issuable as contingent consideration in a business combination.",
        "label": "Contingent Consideration, Maximum Shares Issuable",
        "terseLabel": "Contingent Consideration, Maximum shares issuable"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ContingentConsiderationNumberOfMilestones": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContingentConsiderationNumberOfMilestones",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones to be achieved under the contingent consideration arrangement under the business combination.",
        "label": "Contingent Consideration, Number Of Milestones",
        "terseLabel": "Contingent consideration, Number of milestones"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ContingentConsiderationNumberOfPaymentsConsidered": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContingentConsiderationNumberOfPaymentsConsidered",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of payments of total consideration under the business combination arrangement, that are subject to the achievement of defined milestones (contingent considerations).",
        "label": "Contingent Consideration, Number Of Payments Considered",
        "terseLabel": "Contingent consideration, Number of payments considered"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ContingentConsiderationPercentageOfTotalConsideration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContingentConsiderationPercentageOfTotalConsideration",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total consideration transferred under the business combination, that are subject to the achievement of defined milestones (contingent considerations).",
        "label": "Contingent Consideration, Percentage Of Total Consideration",
        "terseLabel": "Contingent consideration, Percentage of total consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration recognised as of acquisition date",
        "verboseLabel": "Contingent consideration, fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "verboseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r145"
     ]
    },
    "cvac_ContractTerminationProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContractTerminationProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": {
       "parentTag": "ifrs-full_CurrentProvisions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contract termination provisions.",
        "label": "Contract Termination Provisions",
        "terseLabel": "Contract termination provisions",
        "verboseLabel": "Contract termination provisions in prior year"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ContractTerminationProvisionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContractTerminationProvisionsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": {
       "parentTag": "ifrs-full_NoncurrentProvisions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contract termination provisions, current.",
        "label": "Contract Termination Provisions, Current",
        "terseLabel": "Contract termination provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ContractTerminationProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContractTerminationProvisionsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for contract termination provisions.",
        "label": "Contract Termination Provisions [Member]",
        "terseLabel": "Contract Termination Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ContractualCommitmentsUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ContractualCommitmentsUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to contractual commitments.",
        "label": "Contractual Commitments, Undiscounted Cash Flows",
        "negatedLabel": "Contractual commitments"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CorporateInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CorporateInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Corporate Information"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CorporateInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CorporateInformationTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on corporate information.",
        "label": "Corporate Information [Text Block]",
        "terseLabel": "Corporate Information"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CostOfReimbursementClaim": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CostOfReimbursementClaim",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost of reimbursement claim.",
        "label": "Cost of reimbursement claim",
        "terseLabel": "Reimbursement claim"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of sales.",
        "negatedLabel": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r41"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for countries other than Belgium, Germany, Netherlands and Switzerland.",
        "label": "Countries Other Than Belgium, Germany, Netherlands and Switzerland [Member]",
        "terseLabel": "Countries other than Belgium, Germany, Netherlands and Switzerland"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CraigToomanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CraigToomanMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for craig tooman.",
        "label": "Craig Tooman [Member]",
        "terseLabel": "Craig Tooman"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CrisprMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CrisprMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR.",
        "label": "CRISPR",
        "terseLabel": "CRISPR"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CrisprTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CrisprTherapeuticsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR Therapeutics",
        "label": "CRISPR Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CumulativeAmortizationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CumulativeAmortizationAndImpairmentMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortization and impairment.",
        "label": "Cumulative Amortization And Impairment [Member]",
        "terseLabel": "Cumulative Amortization And Impairment",
        "verboseLabel": "Cumulative amortization and impairment charges"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CurevacCorporateServicesGmbhTuebingenGermanyMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to CureVac Corporate Services GmbH (Tuebingen, Germany).",
        "label": "CureVac Corporate Services GmbH (Tuebingen, Germany) [Member]",
        "terseLabel": "CureVac Corporate Services"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CurevacPrinterGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CurevacPrinterGmbhMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CureVac Printer Gmbh.",
        "label": "CureVac Printer GmbH [Member]",
        "terseLabel": "CureVac Printer GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency risk"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r220"
     ]
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current advances to suppliers",
        "terseLabel": "Prepayments for future service agreements and goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r126",
      "r260"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets Abstract",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "cvac_TotalAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets recognised as of acquisition date",
        "totalLabel": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Current assets; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_CurrentContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current contract assets",
        "terseLabel": "Contract assets",
        "verboseLabel": "Contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract assets. [Refer: Contract assets]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current government grants",
        "terseLabel": "Grants from government agencies and similar bodies"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current investments",
        "verboseLabel": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "cvac_CurrentLeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CurrentLeaseLiabilitiesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Lease liabilities (current portion).",
        "label": "Lease liabilities (Current)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for current lease liabilities assumed in a business combination.",
        "label": "Current Lease Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r128",
      "r260"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "cvac_LiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities recognised as of acquisition date",
        "totalLabel": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Current liabilities; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepayments and other current assets",
        "terseLabel": "Prepaid expenses and other assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current provisions",
        "terseLabel": "Provisions",
        "totalLabel": "Provisions (current)",
        "verboseLabel": "Current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_CurrentTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The excess of amount paid for current tax in respect of current and prior periods over the amount due for those periods. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax assets, current",
        "terseLabel": "Current tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods",
        "terseLabel": "Income tax expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "verboseLabel": "Income taxes payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "terseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r237"
     ]
    },
    "cvac_CurrentValueAddedTaxAndOtherTaxesPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "CurrentValueAddedTaxAndOtherTaxesPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current value added tax and other taxes payables.",
        "label": "Current Value Added Tax And Other Taxes Payables",
        "terseLabel": "VAT and other taxes (real estate transfer taxes)"
       }
      }
     },
     "auth_ref": []
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany",
        "terseLabel": "Germany"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The decrease in the number of shares outstanding through transfer from shareholders to entity.",
        "label": "Decrease In Number Of Shares Outstanding Through Transfer From Shareholders to Entity",
        "terseLabel": "Transfer from shareholders to company",
        "verboseLabel": "Beneficiaries declared the exercise of all their exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DecreaseThroughClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DecreaseThroughClassifiedAsHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The decrease in assets through classification as held for sale or inclusion in a disposal group classified as held for sale.",
        "label": "Decrease Through Classified As Held For Sale",
        "terseLabel": "Decrease through classified as held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through classified as held for sale, property, plant and equipment",
        "negatedLabel": "Assets held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment through classification as held for sale or inclusion in a disposal group classified as held for sale. [Refer: Disposal groups classified as held for sale [member]; Property, plant and equipment; Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "cvac_DeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax assets.",
        "label": "Deferred Tax Asset",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredTaxAssets",
        "terseLabel": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r49"
     ]
    },
    "cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to netting of tax in the DTA and DTL.",
        "label": "Deferred Tax Assets and Deferred Tax Liability, Netting [Member]",
        "terseLabel": "Netting"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)",
        "terseLabel": "Deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) recognised in profit or loss",
        "terseLabel": "Recognized profit and loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) relating to origination and reversal of temporary differences",
        "terseLabel": "Deferred tax (income) expenses on taxable temporary differences"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "negatedLabel": "Deferred tax liability",
        "terseLabel": "Deferred tax liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r49"
     ]
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability (asset)",
        "periodEndLabel": "Net balance",
        "periodStartLabel": "Net balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax relating to items credited (charged) directly to equity",
        "terseLabel": "Recognized Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax assets related to items credited (charged) directly to equity.",
        "label": "DeferredTaxAssetsRelatingToItemsChargedOrCreditedDirectlyToEquity",
        "terseLabel": "The amount of deferred tax assets related to items credited (charged) directly to equity"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DepositsHeldByThirdParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DepositsHeldByThirdParties",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deposits held by third parties.",
        "label": "Deposits Held By Third Parties",
        "verboseLabel": "Deposits held by third parties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedLabel": "Amortization and depreciation",
        "negatedTerseLabel": "Amortization and depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r41",
      "r133",
      "r221",
      "r228",
      "r232"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r62"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "calculation": {
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails": {
       "parentTag": "cvac_LeasesExpenseRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedLabel": "Depreciation expense",
        "negatedTerseLabel": "Depreciation expense of right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for business combinations and goodwill [text block]",
        "verboseLabel": "Business combinations and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for government grants [text block]",
        "terseLabel": "Grants from government agencies and similar bodies"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of non-financial assets [text block]",
        "terseLabel": "Impairment of non-financial non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income Taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets and goodwill [text block]",
        "terseLabel": "Acquired intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for measuring inventories [text block]",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Onerous contracts"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "cvac_DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for right of use assets.]",
        "label": "Description Of Accounting Policy For Right Of Use Assets Explanatory",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "verboseLabel": "Segment Reporting"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share-based payment awards"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected volatility (%)"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Expected life (years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate (%)"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "cvac_DietmarHoppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DietmarHoppMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.",
        "label": "Dietmar Hopp [Member]",
        "terseLabel": "Dietmar Hopp"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DieviniHoppBiotechHoldingGmbhCo.KgMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG.",
        "label": "Dievini Hopp BioTech holding GmbH &amp; Co. KG [Member]",
        "terseLabel": "Dievini Hopp BioTech holding GmbH &amp; Co. KG"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Net loss per share diluted (in dollars per share)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86"
     ]
    },
    "ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of all instruments on weighted average number of ordinary shares",
        "terseLabel": "Dilutive share-based payment awards"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity\u2019s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Significant accounting judgments, estimates and assumptions"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of basis of consolidation [text block]",
        "terseLabel": "Basis of consolidation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of business combinations [text block]",
        "terseLabel": "Business Combinations"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for business combinations."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination",
        "terseLabel": "Business Combinations",
        "verboseLabel": "Corporate Information"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of cash flow statement [text block]",
        "terseLabel": "Notes to the consolidated statements of cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting policies, accounting estimates and errors [text block]",
        "terseLabel": "Changes in accounting policies and disclosures"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for changes in accounting policies, accounting estimates and errors."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "verboseLabel": "Schedule of total shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Issued Capital and Reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "cvac_DisclosureOfCommitmentsAndContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfCommitmentsAndContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingent liabilities [text block]",
        "terseLabel": "Commitments and contingencies"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of deferred taxes [text block]",
        "verboseLabel": "Schedule of deferred taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [text block]",
        "terseLabel": "Schedule of fair value recognized on acquisition"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about estimated useful lives of intangible assets.",
        "label": "Disclosure Of Detailed Information About Estimated Useful Lives Of Intangible Assets, Explanatory",
        "terseLabel": "Schedule of estimated useful lives for intangible asset class"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about estimated useful lives of property, plant and equipment.",
        "label": "Disclosure Of Detailed Information About Estimated Useful Lives Of Property, Plant And Equipment, Explanatory",
        "terseLabel": "Schedule of estimated useful lives for property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about estimated useful lives of right of use assets.",
        "label": "Disclosure Of Detailed Information About Estimated Useful Lives Of Right Of Use Assets, Explanatory",
        "terseLabel": "Schedule of estimated useful lives for right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [text block]",
        "terseLabel": "Schedule of development of intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Schedule of development of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "cvac_DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of detailed information about remuneration of key management personnel.",
        "label": "Disclosure of Detailed Information of Remuneration of Key Management Personnel [Table Text Block]",
        "terseLabel": "Schedule of remuneration of company's key management personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of revenue from contract with customers recognized"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "terseLabel": "Notes to the Consolidated Statements of Operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent events"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expense recognized for employee services explanatory.",
        "label": "Disclosure of Expense Recognized For Employee Services Explanatory",
        "terseLabel": "Schedule of share-based payments expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "cvac_DisclosureOfExposureToForeignCurrenciesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfExposureToForeignCurrenciesTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about exposure to foreign currencies.",
        "label": "Disclosure Of Exposure To Foreign Currencies [Table Text Block]",
        "terseLabel": "Schedule of exposure in (foreign) currency"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [line items]",
        "terseLabel": "Disclosure of financial instruments and management of financial risks"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Disclosure of financial instruments and management of financial risks"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "cvac_DisclosureOfFixedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfFixedAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfFixedAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfFixedAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for fixed assets.",
        "label": "Disclosure Of Fixed Assets, Explanatory",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information pertaining to goodwill recognized as a result of the acquisition.",
        "label": "Disclosure Of Goodwill Recognized As A Result Of Acquisition, Explanatory [Table Text Block]",
        "terseLabel": "Schedule of goodwill recognized as a result of the acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfGovernmentGrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfGovernmentGrantsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Disclosure Of Government Grants [Line Items]",
        "terseLabel": "Notes to the consolidated financial statements"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfGovernmentGrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfGovernmentGrantsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of government grants.",
        "label": "Disclosure Of Government Grants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Schedule of inputs used in the measurement of the fair value at grant date"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of information about key management personnel [text block]",
        "terseLabel": "Remuneration of the Company's key management personnel"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets",
        "verboseLabel": "Fixed Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "cvac_DisclosureOfKeyManagementPersonnelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfKeyManagementPersonnelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Remuneration of the Company's key management personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMarketRiskExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMarketRiskExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of market risk [text block]",
        "terseLabel": "Schedule of other variables held constant, pre-tax loss and post-tax loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of market risk. [Refer: Market risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of material accounting policy information [text block]",
        "terseLabel": "Accounting Policies"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]",
        "terseLabel": "Disclosure of financial instruments and management of financial risks"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "verboseLabel": "Disclosure of financial instruments and risk management"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Subsequent events"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]",
        "terseLabel": "Assets held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current assets or disposal groups classified as held for sale [text block]",
        "terseLabel": "Non-current assets held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents of disclosure of notes to the consolidated financial statements.",
        "label": "Disclosure Of Notes To The Consolidated Financial Statements [Line Items]",
        "terseLabel": "Notes to the Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of notes to the consolidated financial statements.",
        "label": "Disclosure Of Notes To The Consolidated Financial Statements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of notes to consolidated financial statements.",
        "label": "Disclosure of Notes to Consolidated Financial Statements [Text Block]",
        "terseLabel": "Notes to the Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of reconciliation of outstanding awards"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "cvac_DisclosureOfOtherFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfOtherFinancialAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other financial assets.",
        "label": "Disclosure Of Other Financial Assets, Explanatory",
        "terseLabel": "Other financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfOtherLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfOtherLiabilitiesLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Disclosure of Other liabilities [Line Items]",
        "terseLabel": "Other liabilities and provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfOtherLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfOtherLiabilitiesTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to other liabilities.",
        "label": "Disclosure of Other liabilities [table]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfOtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfOtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular information pertaining to other liabilities.",
        "label": "Disclosure Of Other Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other liabilities and provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Schedule of nature of expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income [text block]",
        "terseLabel": "Schedule of other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]",
        "terseLabel": "Schedule of provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [text block]",
        "terseLabel": "Schedule of movements in provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid expenses and other current assets.",
        "label": "Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment",
        "verboseLabel": "Fixed Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "cvac_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of carrying amounts of lease liabilities and the movements during the period.",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Table Text Block]",
        "terseLabel": "Summary of carrying amounts of lease liabilities and the movements during the period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Summary of carrying amounts of the Group's right-of-use assets and the movements during the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]",
        "terseLabel": "Schedule of changes in liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]",
        "terseLabel": "Notes to the consolidated statements of cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party disclosures"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of research and development expense [text block]",
        "terseLabel": "Research and development costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "verboseLabel": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "terseLabel": "Income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "cvac_DisclosureOfTradeAndOtherPayablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfTradeAndOtherPayablesTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular information pertaining to trade and other payables.",
        "label": "Disclosure Of Trade And Other Payables [Table Text Block]",
        "terseLabel": "Schedule of trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [text block]",
        "terseLabel": "Schedule of contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [line items]",
        "terseLabel": "Contract liabilities allocated to the remaining performance obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the transaction price allocated to the remaining performance obligations in contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]",
        "terseLabel": "Related party disclosures",
        "verboseLabel": "Remuneration of the Company's key management personnel"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about upfront payments and related revenues recognized.",
        "label": "Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory",
        "terseLabel": "Summary of upfront payments and related revenues recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals, intangible assets other than goodwill",
        "negatedLabel": "Disposals"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedLabel": "Disposals"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_DistributionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DistributionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs relating to the distribution of goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r233"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "terseLabel": "Document and Entity Information",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cvac_Dr.IngmarHrrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "Dr.IngmarHrrMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dr. Ingmar Hrr.",
        "label": "Dr. Ingmar Hrr [Member]",
        "terseLabel": "Dr. Ingmar Hrr"
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EUR"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effect of currency translation gains on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r200"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83",
      "r136"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity.",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r29",
      "r121",
      "r123",
      "r137",
      "r138",
      "r139"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity And Liabilities Abstract",
        "terseLabel": "Equity and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityInterestsOfAcquirer",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity interests of acquirer",
        "terseLabel": "Value of shares issued to former Frame shareholders",
        "verboseLabel": "Value of aggregate consideration in shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "cvac_EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of risk estimated for not accepting the transfer pricing setup.",
        "label": "Estimated Risk Percentage For Not Accepting The Transfer Pricing Set Up",
        "terseLabel": "Estimated risk percentage for not accepting the transfer pricing set up"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_EuropeSLargestPrivateBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "EuropeSLargestPrivateBankMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Europe's largest private bank.",
        "label": "Europe's Largest Private Bank [Member]",
        "terseLabel": "Europe's largest private bank"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExchangeRateCurrencyNetExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExchangeRateCurrencyNetExposure",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents exchange rate net exposure",
        "label": "Exchange Rate Currency Net Exposure",
        "terseLabel": "Net exposure"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExecutiveBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExecutiveBoardMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for executive board of the entity's key management personnel.",
        "label": "Executive Board [Member]",
        "terseLabel": "Executive Board"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExerciseOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExerciseOfOptionsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of options.",
        "label": "Exercise of options"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of exercise of options or share based payment awards settled in cash.",
        "label": "Exercise of Options Settlement Of Share Based Payment Awards Amount",
        "terseLabel": "Exercise of options / Settlement of share-based payment awards"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "verboseLabel": "Exercise price of options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, share options granted",
        "terseLabel": "Exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_ExpenseByNature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseByNature",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses, by nature",
        "negatedTotalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in cost of sales.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets, In Cost of Sales",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails": {
       "parentTag": "cvac_ExpenseRecognizedForEmployeeServices",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails": {
       "parentTag": "cvac_ExpenseRecognizedForEmployeeServices",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails": {
       "parentTag": "cvac_ExpenseRecognizedForEmployeeServices",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Selling And Distribution Expenses",
        "verboseLabel": "Selling and distribution expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "totalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "verboseLabel": "Expenses from share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvac_ExpenseRecognizedForEmployeeServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExpenseRecognizedForEmployeeServices",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized for employee services.",
        "label": "Expense Recognized For Employee Services",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ExpenseRecognizedFromRelatedPartyTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExpenseRecognizedFromRelatedPartyTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized during the period from related party transaction.",
        "label": "Expense Recognized From Related Party Transaction",
        "terseLabel": "Expense recognized from related party transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails": {
       "parentTag": "cvac_LeasesExpenseRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense relating to leases of low-value assets for which recognition exemption has been used",
        "negatedLabel": "Expense relating to leases of low-value assets (included in general and administrative expenses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails": {
       "parentTag": "cvac_LeasesExpenseRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "negatedLabel": "Expense relating to short-term leases (included in cost of sales)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "cvac_ExpensesToHandleFutureServiceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ExpensesToHandleFutureServiceAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses to handle future service agreement.",
        "label": "Expenses To Handle Future Service Agreement",
        "terseLabel": "Expenses to handle future service agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Schedule of contract balances"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_FairValueOfAcquiredReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FairValueOfAcquiredReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of acquired receivables",
        "terseLabel": "Trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of receivables acquired in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "cvac_FairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "FairValueOfTotalConsiderationTransferred",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fair value of total consideration transferred.",
        "label": "Fair Value Of Total Consideration Transferred",
        "terseLabel": "Amount of fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance expenses",
        "terseLabel": "Finance expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "cvac_FinancialInstrumentsAndRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "FinancialInstrumentsAndRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Disclosure of financial instruments and management of financial risks"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_FlorianVonDerMlbeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "FlorianVonDerMlbeMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Florian von der Mlbe.",
        "label": "Florian von der Mlbe [Member]",
        "terseLabel": "Florian von der Mlbe"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to follow on public offering.",
        "label": "Follow-on public offering, incl. Greenshoe"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ForeignCurrencyTranslationLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ForeignCurrencyTranslationLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in lease Liabilities due to foreign currency translation.",
        "label": "Foreign Currency Translation, Lease Liabilities",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeGain",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain",
        "terseLabel": "Foreign exchange gains"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r68"
     ]
    },
    "ifrs-full_ForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange loss",
        "terseLabel": "Foreign exchange losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r68"
     ]
    },
    "cvac_Foreigncurrencytranslationrightofuseassets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "Foreigncurrencytranslationrightofuseassets",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in right of use assets due to foreign currency translation.",
        "label": "ForeignCurrencyTranslationRightOfUseAssets",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_FormerFrameEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "FormerFrameEmployeesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Frame employee's",
        "label": "Former Frame Employees [Member]",
        "terseLabel": "Former Frame employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "FramePharmaceuticalsB.v.AmsterdamNetherlandsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Frame Pharmaceuticals B.V., Amsterdam, Netherlands.",
        "label": "Frame Pharmaceuticals B.V., Amsterdam, Netherlands",
        "verboseLabel": "Frame Pharmaceuticals B.v.Amsterdam Netherlands"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_FranzWernerHaasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "FranzWernerHaasMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Franz-Werner Haas.",
        "label": "Franz-Werner Haas [Member]",
        "terseLabel": "Franz-Werner Haas"
       }
      }
     },
     "auth_ref": []
    },
    "currency_GBP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "GBP",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GBP"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvac_GenmabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GenmabMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Genmab.",
        "label": "Genmab [Member]",
        "terseLabel": "Genmab"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r244",
      "r264",
      "r267"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [member]",
        "terseLabel": "Geographical areas"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r244",
      "r264",
      "r267"
     ]
    },
    "cvac_GermanFederalMinistryOfEducationAndResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GermanFederalMinistryOfEducationAndResearchMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for German Federal Ministry of Education and Research.",
        "label": "German Federal Ministry of Education and Research"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_GermanLandesbankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GermanLandesbankMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for German Landesbank.",
        "label": "German Landesbank"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_GermanysLargestPrivateBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GermanysLargestPrivateBankMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Germany's largest private bank.",
        "label": "Germany's largest private bank"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_GlaxosmithklineCovidAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GlaxosmithklineCovidAgreementMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Collaboration Agreement With GlaxoSmithKline COVID Agreement.",
        "label": "GlaxoSmithKline COVID Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_GlaxosmithklineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GlaxosmithklineMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GlaxoSmithKline.",
        "label": "GSK [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Member]",
        "terseLabel": "Goodwil"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill recognised as of acquisition date",
        "totalLabel": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "ifrs-full_GovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GovernmentGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government grants",
        "terseLabel": "Grants received and deferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "cvac_GovernmentGrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GovernmentGrantsAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to government grants.",
        "label": "Government Grants [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_GovernmentGrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GovernmentGrantsDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to government grants.",
        "label": "Government Grants [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_GridEuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GridEuropeMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for related party Grid Europe, which is a wholly owned consulting company of Ralf Clemens, who was a member of the supervisory board.",
        "label": "Grid Europe [Member]",
        "terseLabel": "Grid Europe"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_GrossCarryingAmountOfAcquisitionCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "GrossCarryingAmountOfAcquisitionCostMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon.",
        "label": "Gross Carrying Amount of Acquisition Cost [Member]",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "negatedLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r276"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ]
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails": {
       "parentTag": "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsGoodwillRecognizedAsResultOfAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Identifiable assets acquired (liabilities assumed)",
        "negatedLabel": "Net Assets acquired",
        "totalLabel": "Net assets acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r272"
     ]
    },
    "cvac_IfrsBusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsBusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Ifrs Business Acquisition, Share Price",
        "terseLabel": "Closing Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails",
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for cash and cash equivalents.",
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsConcentrationRiskPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsConcentrationRiskPercentage",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "IFRS Concentration Risk, Percentage",
        "terseLabel": "Concentration of risk"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "IFRS Contractual Obligation",
        "terseLabel": "Contractual obligation amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsCostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsCostOfSalesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development milestone payment included in contract liabilities",
        "label": "IFRS Development Milestone Payment Included In Contract Liabilities",
        "terseLabel": "Development milestone payment included in contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsEmployerTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsEmployerTaxesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of employer taxes payable.",
        "label": "IFRS Employer Taxes Payable",
        "terseLabel": "Employer taxes payable"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative expenses",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsIncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsIncomeStatementLocationAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Ifrs Income Statement Location [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsIncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsIncomeStatementLocationDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Ifrs Income Statement Location [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Ifrs Increase Decrease In Prepaid Expense And Other Assets",
        "negatedLabel": "Decrease / (increase) in prepaid expenses and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsLesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsLesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Ifrs Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsMilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsMilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment received.",
        "label": "IFRS Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsNumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsNumberOfOperatingSegments",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Ifrs Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsNumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsNumberOfReportableSegments",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Ifrs Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsNumberOfSharesHeldForTaxLiabilities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsNumberOfSharesHeldForTaxLiabilities",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares held for payable of tax liabilities",
        "label": "IFRS Number Of Shares Held For Tax Liabilities",
        "terseLabel": "Number of shares held for payable of tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsNumberOfSharesIssuedForExerciseOfStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsNumberOfSharesIssuedForExerciseOfStockOptions",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for exercise of stock options",
        "label": "IFRs Number Of Shares Issued For Exercise Of Stock Options",
        "terseLabel": "Number of shares issued for exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares received from the participants.",
        "label": "IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity",
        "terseLabel": "Number of shares received"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsOptionFeePaymentIncludedInContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsOptionFeePaymentIncludedInContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Option fee payment included in contract liabilities",
        "label": "Ifrs Option Fee Payment Included In Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other liabilities and provisions."
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsOtherLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsOtherLiabilitiesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other liabilities (Current)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsOtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsOtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for other non-current assets.",
        "label": "Other liabilities (Non-current)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsOverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsOverAllotmentOptionMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsPlanNameAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "IFRS Plan Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsPlanNameDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "IFRS Plan Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsProductMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product",
        "terseLabel": "Product"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsPropertyPlantAndEquipmentSalvageValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsPropertyPlantAndEquipmentSalvageValue",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose).",
        "label": "Ifrs Property, Plant, and Equipment, Salvage Value",
        "terseLabel": "Residual values"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsProvisionForLossOnContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsProvisionForLossOnContracts",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of provision for loss on contracts.",
        "label": "Ifrs Provision For Loss on Contracts",
        "terseLabel": "Estimated contract termination provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsRemainingGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsRemainingGrantIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of remaining grant income classified as other operating income.",
        "label": "IFRS Remaining Grant Income",
        "terseLabel": "Remaining grant income"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsSaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsSaleOfStockAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "IFRS Sale of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsSaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsSaleOfStockDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "IFRS Sale of Stock [Domain]",
        "terseLabel": "IFRS Sale of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Ifrs Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of tax reconciliation"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage (as a percent)",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in share price under share-based payment arrangement.",
        "label": "IFRS Share-based Compensation Arrangement By Share-based Payment Award, Increase In Share Price, Percentage",
        "terseLabel": "Percentage of increase in share price"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsShareBasedPaymentArrangementTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "First tranche"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsShareBasedPaymentArrangementTrancheThreeMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Third tranche"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsShareBasedPaymentArrangementTrancheTwoMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Second tranche"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsSharePrice",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Ifrs Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Ifrs Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued other liability for up-front payment.",
        "label": "Ifrs Stock Issued During Period Value New Issues",
        "negatedLabel": "Proceeds from at-the-market offering program (net of transaction costs)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Ifrs Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of unused tax losses carried forward"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsThresholdDurationOfVolumeWeightedAveragePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsThresholdDurationOfVolumeWeightedAveragePrice",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold duration of volume weighted average price",
        "label": "IFRS Threshold Duration Of Volume Weighted Average Price",
        "terseLabel": "Threshold duration of volume weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsTypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsTypeOfArrangementAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "IFRS Type Of Arrangement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsVestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsVestingAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsVestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsVestingDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsinventoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsinventoriesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for inventories.",
        "label": "IFRSInventories [Member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IfrsprepaidExpensesAndOtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IfrsprepaidExpensesAndOtherAssetsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for prepaid expenses and other expenses.",
        "label": "IFRSPrepaid Expenses And Other Assets [Member]",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ImmaticsBiotechnologiesGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ImmaticsBiotechnologiesGmbhMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Immatics Biotechnologies Gmbh.",
        "label": "Immatics Biotechnologies Gmbh [Member]",
        "terseLabel": "Immatics Biotechnologies GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, goodwill",
        "terseLabel": "No impairment of goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment to property, plant and equipment",
        "verboseLabel": "Impairment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r57"
     ]
    },
    "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss",
        "negatedLabel": "Impairment of equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "cvac_ImpairmentOfAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ImpairmentOfAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss on assets held for sale.",
        "label": "Impairment of Assets Held for Sale",
        "terseLabel": "Impairment of assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ImpairmentOnRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ImpairmentOnRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails": {
       "parentTag": "cvac_LeasesExpenseRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment on right-of-use assets.",
        "label": "Impairment on Right-of-use Assets",
        "negatedLabel": "Impairment expense / reversal of impairment",
        "negatedTerseLabel": "Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeFromSubleasingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeFromSubleasingRightofuseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income from subleasing right-of-use assets",
        "terseLabel": "Income from sub-leasing right-of-use assets presented in \"other operating income\""
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income from subleasing right-of-use assets. Sublease is a transaction for which an underlying asset is re-leased by a lessee (\u2018intermediate lessor\u2019) to a third party, and the lease (\u2018head lease\u2019) between the head lessor and lessee remains in effect. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cvac_IncomeTaxAndSocialSecurityLiabilityReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncomeTaxAndSocialSecurityLiabilityReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax and social security liability receivable.",
        "label": "Income Tax and Social Security Liability Receivable",
        "terseLabel": "Income tax and social security liability receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax benefit/ (expense)",
        "negatedTotalLabel": "Effective tax benefit / (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r44",
      "r46",
      "r47",
      "r79",
      "r134",
      "r222"
     ]
    },
    "cvac_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.",
        "label": "Income tax [line Items]",
        "terseLabel": "Income tax"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of Income tax",
        "label": "Income tax [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid, classified as operating activities",
        "negatedLabel": "Income taxes paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInContingentConsiderationAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in contingent consideration asset (liability)",
        "negatedLabel": "Share issuances and contingent consideration from business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a contingent consideration asset (liability) relating to a business combination."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "cvac_IncreaseDecreaseInInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncreaseDecreaseInInventory",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in inventory during the period.",
        "label": "Increase (Decrease) In Inventory",
        "terseLabel": "Increase in inventory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through business combinations, deferred tax liability (asset)",
        "terseLabel": "Acquired in Business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "cvac_IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from disposals that the entity does not separately disclose in the same statement or note.",
        "label": "Increase Decrease Through Disposals Liabilities Arising from Financing Activities",
        "terseLabel": "Disposals"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities",
        "terseLabel": "Foreign Exchange Movements"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued on exercise of option",
        "terseLabel": "Exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities",
        "terseLabel": "Cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "cvac_IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from interest that the entity does not separately disclose in the same statement or note.",
        "label": "Increase Decrease Through Interest Liabilities Arising from Financing Activities",
        "terseLabel": "Paid Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "terseLabel": "Currency translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment",
        "terseLabel": "Currency translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "cvac_IncreaseDecreaseThroughReclassificationsProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncreaseDecreaseThroughReclassificationsProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in provisions through reclassifications.",
        "label": "Increase (decrease) through Reclassifications, Provisions",
        "terseLabel": "reclassified from accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment",
        "terseLabel": "Reclassifications"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill",
        "terseLabel": "Reclassifications"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Repurchase of common shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cvac_IncreaseInNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IncreaseInNumberOfSharesOutstanding",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in the number of shares outstanding.",
        "label": "Increase In Number Of Shares Outstanding",
        "terseLabel": "Capital Investment",
        "verboseLabel": "Capital increase (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "New leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r258"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "cvac_IntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "IntangibleAssetsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for intangible assets.",
        "label": "Intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r101"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r249",
      "r265"
     ]
    },
    "cvac_InterestExpenseOnCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "InterestExpenseOnCash",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest expense on cash.",
        "label": "Interest expense on cash",
        "terseLabel": "Interest on cash"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails": {
       "parentTag": "cvac_LeasesExpenseRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedLabel": "Interest expense on lease liabilities",
        "negatedTerseLabel": "Accretion of interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income on cash and cash equivalents",
        "terseLabel": "Interest income on cash investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "verboseLabel": "Interest received"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r64",
      "r235"
     ]
    },
    "cvac_InventoriesLineItem": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "InventoriesLineItem",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Line item",
        "terseLabel": "Inventories",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_InventoriesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "InventoriesTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_InventoryPilingForPandemicPreparednessAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "InventoryPilingForPandemicPreparednessAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory piling for the pandemic preparedness agreement.",
        "label": "Inventory Piling For Pandemic Preparedness Agreement",
        "terseLabel": "Inventory piling for pandemic preparedness agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InventoryWritedown2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoryWritedown2011",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "terseLabel": "Impairment of inventory",
        "verboseLabel": "Raw materials write-off"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r65"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "terseLabel": "Equity investment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r135",
      "r224"
     ]
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "verboseLabel": "Issuance of share capital (net of transaction costs)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital.",
        "terseLabel": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "cvac_KeyEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "KeyEmployeesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for key employees.",
        "label": "Key employees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, termination benefits",
        "terseLabel": "Termination benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_LandAndBuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LandAndBuildingsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land and buildings [Member]",
        "terseLabel": "Land and Buildings"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "cvac_LandBuildingsAndSupplyInstallationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LandBuildingsAndSupplyInstallationsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for land, buildings and supply installations.",
        "label": "Land, Buildings And Supply Installations [Member]",
        "terseLabel": "Land, Buildings and supply installations"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_LargestShareholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LargestShareholderMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac.",
        "label": "Largest Shareholder [Member]",
        "terseLabel": "Dievini"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "> 5 years",
        "terseLabel": "Greater than 5 years"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r173",
      "r275",
      "r278",
      "r280"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1 to 5 years"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r280"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "More than one year",
        "terseLabel": "More than one year"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities.",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "terseLabel": "Payment of lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r259"
     ]
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements",
        "terseLabel": "Leasehold improvements"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "cvac_LeasesExpenseRecognizedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LeasesExpenseRecognizedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsAmountsRecognizedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease expense recognized in profit or loss.",
        "label": "Leases Expense Recognized In Profit Or Loss",
        "negatedTotalLabel": "Total amount recognized in profit or loss"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_LegacyPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LegacyPlanMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for legacy plan.",
        "label": "Legacy plan",
        "terseLabel": "Legacy plan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r137",
      "r138",
      "r139",
      "r223",
      "r227"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfCashFlowsFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ifrs-full_LiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities incurred",
        "terseLabel": "Net amount of discharging contractual obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "cvac_LiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for total liabilities assumed in a business combination.",
        "label": "Liabilities Recognised As Of Acquisition Date",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LicencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LicencesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licence [Member]",
        "terseLabel": "Licenses"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LineItemsByFunctionMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line items by function [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r298"
     ]
    },
    "cvac_LongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LongTermIncentivePlanMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Long-Term Incentive Plan.",
        "label": "LTIP Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_LongTermIncentivePlanRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LongTermIncentivePlanRsusMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for long term incentive plan RSU.",
        "label": "Long Term Incentive Plan RSUs [Member]",
        "terseLabel": "LTIP RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_LongTermIncentivePlanStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "LongTermIncentivePlanStockOptionsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for long term incentive plan stock options.",
        "label": "Long Term Incentive Plan Stock Options [Member]",
        "terseLabel": "LTIP Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MaintenanceAndLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MaintenanceAndLeaseExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maintenance and lease expenses incurred by the company during the period.",
        "label": "Maintenance And Lease Expenses",
        "negatedLabel": "Maintenance and lease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_MajorCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers [member]",
        "terseLabel": "Customers"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "cvac_ManagementBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ManagementBoardMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for management board of the entity's key management personnel.",
        "label": "Management Board"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ManagementMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Members of supervisory board"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MariolaFotinMleczekMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MariolaFotinMleczekMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Mariola Fotin-Mleczek.",
        "label": "Mariola Fotin-Mleczek [Member]",
        "terseLabel": "Mariola Fotin-Mleczek"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]",
        "terseLabel": "Schedule of maturity profile of the financial liabilities based on contractual undiscounted payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r149",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r206",
      "r217",
      "r245",
      "r275"
     ]
    },
    "cvac_MaximumGrantToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MaximumGrantToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum grant receivable.",
        "label": "Maximum Grant To Be Received",
        "terseLabel": "Maximum grant"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MaximumUnspentFundsReimbursable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MaximumUnspentFundsReimbursable",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum unspent funds reimbursable.",
        "label": "Maximum Unspent Funds Reimbursable",
        "terseLabel": "Maximum unspent funds reimbursable"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MembersOfExecutiveBoardAndVariousKeyEmployeesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for person or persons designated as part of Executive board and various key employees.",
        "label": "Members of executive board and various key employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum share price on or after vesting to settle and deliver the RSUs.",
        "label": "Minimum Share Price on or After Vesting to Settle and Deliver the RSUs",
        "terseLabel": "Minimum share price on or after vesting to settle and deliver the RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating expense",
        "negatedLabel": "Other operating expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other operating income",
        "totalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvac_MiscellaneousOtherOperatingIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MiscellaneousOtherOperatingIncomeMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for other miscellaneous operating income.",
        "label": "Miscellaneous Other Operating Income [Member]",
        "terseLabel": "Miscellaneous other operating income"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MiscellaneousOtherOperatingIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MiscellaneousOtherOperatingIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income, classified as other.",
        "label": "Miscellaneous Other Operating Income, Other",
        "terseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MonetaryAssetsInForeignCurrencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MonetaryAssetsInForeignCurrencyMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Total monetary assets in foreign currency"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_MonetaryLiabilitiesInForeignCurrencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "MonetaryLiabilitiesInForeignCurrencyMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"This member stands for a type\n of market risk representing the\n risk that the fair value or future\n cash flows of a financial\n instrument will fluctuate\n because of changes in foreign\n exchange rates.\"",
        "label": "Total monetary liabilities in foreign currency"
       }
      }
     },
     "auth_ref": []
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "NL",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands",
        "terseLabel": "Netherlands"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NetBookValueOfCmoEquipmentHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NetBookValueOfCmoEquipmentHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net book value of CMO-Equipment held for sale.",
        "label": "Net Book Value Of Cmo Equipment Held For Sale",
        "terseLabel": "Net book value Of CMO-Equipment held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "verboseLabel": "Deferred Taxes Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities net of deferred tax assets assumed in a business combination.",
        "label": "Net Deferred Tax Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Deferred tax liabilities (net of deferred tax assets)",
        "verboseLabel": "net deferred tax liability"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NetLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NetLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent amount of Net loss before tax if interest rate 1% higher while all other variables had remained the same.",
        "label": "Net Loss Before Tax",
        "terseLabel": "Net loss before tax"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NewVsopPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NewVsopPlanMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for New VSOP Plan.",
        "label": "New VSOP Plan",
        "terseLabel": "New VSOP Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NonCurrentLeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NonCurrentLeaseLiabilitiesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for lease liabilities (non-current portion).",
        "label": "Lease liabilities (Non-current)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NonDeductibleExpensesForTaxPurposes": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NonDeductibleExpensesForTaxPurposes",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-deductible expenses for tax purposes abstract.",
        "label": "Non-Deductible Expenses For Tax Purposes",
        "terseLabel": "Non-deductible expences for tax purposes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total non-current assets",
        "totalLabel": "Total non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r127",
      "r260"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Assets",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
        "terseLabel": "Assets held for sale",
        "verboseLabel": "Fair value less anticipated costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "cvac_TotalAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets recognised as of acquisition date",
        "totalLabel": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for non-current assets acquired in a business combination. [Refer: Non-current assets; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for non-current lease liabilities assumed in a business combination.",
        "label": "Noncurrent Lease Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r27",
      "r129",
      "r260"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities Abstract",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "cvac_LiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities recognised as of acquisition date",
        "totalLabel": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Non-current liabilities; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current provisions",
        "terseLabel": "Provisions",
        "totalLabel": "Provisions (non-current)",
        "verboseLabel": "Non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-derivative financial liabilities, undiscounted cash flows",
        "negatedTotalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Within one year",
        "terseLabel": "Within one year",
        "verboseLabel": "Less than 1 year"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r163",
      "r164",
      "r173",
      "r275",
      "r280"
     ]
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the consolidated financial statements"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NotesToConsolidatedStatementsOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NotesToConsolidatedStatementsOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Notes to the consolidated statements of cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfAdditionalGrantsReceived": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfAdditionalGrantsReceived",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional grants received by the company.",
        "label": "Number Of Additional Grants Received",
        "terseLabel": "Number of additional grants received"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company.",
        "label": "Number Of Collaboration Partners That Owed Hundred Percent Of All Receivables And Contract Assets Outstanding",
        "terseLabel": "Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets.",
        "label": "Number Of Collaboration Partners With Balances Greater Than Ten Percent Of All Receivables And Contract Assets",
        "terseLabel": "Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of days of VWAP based on which percentage of stock price increase is calculated.",
        "label": "Number Of Days Of Vwap Calculate Percentage Of Stock Price Increase",
        "terseLabel": "Number of days increase related to percentage of stock price"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.",
        "label": "Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement",
        "terseLabel": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of instruments granted in share-based payment arrangement",
        "verboseLabel": "Number of instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureEquityFrameAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of instruments or interests issued or issuable",
        "terseLabel": "Shares issued for consideration",
        "verboseLabel": "Aggregate consideration in shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations",
        "terseLabel": "Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders",
        "terseLabel": "Issuance and transfer of shares to former Frame shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone",
        "terseLabel": "Number of shares issued upon the achievement of the successful investigational new drug application filing"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone",
        "terseLabel": "Number of shares issued upon successful proof of mechanism in humans"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSU's awarded",
        "verboseLabel": "RSUs issued to certain former employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r324"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested share-options outstanding",
        "periodEndLabel": "Outstanding at the end of the period",
        "periodStartLabel": "Outstanding at the beginning of the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r179",
      "r183"
     ]
    },
    "cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfPaymentsInWhichTotalConsiderationIsToBePaid",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of payments in which the total consideration is to be paid under the business combination.",
        "label": "Number Of Payments In Which The Total Consideration Is To Be Paid",
        "terseLabel": "Number of payments in which the total consideration is to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfRentalAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfRentalAgreements",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of rental agreements entered during the period.",
        "label": "Number Of Rental Agreements",
        "terseLabel": "Number of rental agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "terseLabel": "Thereof exercisable",
        "verboseLabel": "Number of awards exercisable"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedLabel": "Exercised during the period",
        "terseLabel": "Number of options exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options expiration",
        "negatedLabel": "Forfeited during the period",
        "terseLabel": "Number of share options expired",
        "verboseLabel": "Forfeiteded during the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options granted",
        "terseLabel": "Granted during the period",
        "verboseLabel": "Number of share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "cvac_NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options vested and expensed thereof in a share-based payment arrangement.",
        "label": "Number Of Share Options, Vested And Expensed Thereof, In Share-Based Payment Arrangement",
        "terseLabel": "Thereof vested"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options vested thereof in a share-based payment arrangement.",
        "label": "Number Of Share Options, Vested Thereof, In Share-Based Payment Arrangement",
        "terseLabel": "Thereof vested"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Number of shares authorized"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued for RSU deliveries.",
        "label": "Number of Shares Issued on Exercise of Options and RSU Deliveries",
        "terseLabel": "Shares issued for LTIP option exercises and RSU deliveries"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of tranches for vesting of instruments granted in a share-based payment arrangement.",
        "label": "Number Of Tranches For Vesting Of Instruments Granted In Share-Based Payment Arrangement",
        "terseLabel": "Number of tranches for vesting of RSUs granted"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OldVsopPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OldVsopPlanMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Old VSOP Plan.",
        "label": "Old VSOP Plan",
        "terseLabel": "Old VSOP Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OnerousContractProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OnerousContractProvisionsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for onerous contracts provisions.",
        "label": "Onerous Contract Provisions [Member]",
        "terseLabel": "Onerous Contract Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OperativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OperativeExpensesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for operating expenses incurred during the period.",
        "label": "Operative Expenses [Member]",
        "terseLabel": "Operative expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OptionFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OptionFeePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Option fee Payment received.",
        "label": "Option Fee payment"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OptionalLeasePaymentsUponUsingExtensionOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OptionalLeasePaymentsUponUsingExtensionOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsCarryingAmountsOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of optional lease payments arising upon exercise of extension options.",
        "label": "Optional Lease Payments Upon Using Extension Options",
        "terseLabel": "Optional lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OptionsGrantedToThenChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OptionsGrantedToThenChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).",
        "label": "Former Chief Executive Officer Grant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares [Member]",
        "terseLabel": "Common shares"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r303"
     ]
    },
    "ifrs-full_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r35",
      "r39",
      "r131"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Foreign currency adjustments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r39"
     ]
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Other financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other liabilities (current)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for other liabilities assumed in a business combination.",
        "label": "Other Current Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Miscellaneous liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "cvac_OtherCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherCustomersMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Other customers.",
        "label": "Others",
        "terseLabel": "Others"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OtherEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherEquipmentMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equipment [Member]",
        "label": "Other equipment :",
        "terseLabel": "Other equipment"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expense.",
        "label": "Other Expense",
        "negatedLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "totalLabel": "Total other liabilities (current &amp; non-current)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "cvac_OtherLiabilitiesAndProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherLiabilitiesAndProvisionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other liabilities and provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OtherLiabilitiesAndProvisionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherLiabilitiesAndProvisionsTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of other liabilities and provisions.",
        "label": "Other Liabilities and Provisions [Text Block]",
        "terseLabel": "Other liabilities and provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OtherLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to other liabilities.",
        "label": "Other Liabilities, Undiscounted Cash Flows",
        "negatedLabel": "Other liabilities and provisions"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OtherLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other current liabilities.",
        "label": "Other Liability, Current",
        "terseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_OtherMiscellaneousNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherMiscellaneousNonCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other miscellaneous non-current liabilities.",
        "label": "Other Miscellaneous Non-current Liabilities",
        "terseLabel": "Other (e.g. license liabilities, Deferred Tax Liability)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets.",
        "terseLabel": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities.",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other liabilities (non-current)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "cvac_OtherOperatingIncomeGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OtherOperatingIncomeGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other operating income recognized in relation to government agencies and similar bodies.",
        "label": "Other Operating Income, Government Grants",
        "verboseLabel": "Grants and other reimbursements from government agencies and similar bodies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other property, plant and equipment [Member]",
        "terseLabel": "Other equipment, furniture and fixtures",
        "verboseLabel": "Other equipment, furniture and fixtures:"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)",
        "negatedLabel": "Other effects"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "cvac_OutstandingInvoicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "OutstandingInvoicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current outstanding invoices.",
        "label": "Outstanding Invoices, Current",
        "terseLabel": "Outstanding invoices"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share",
        "verboseLabel": "Notional value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "cvac_PartnershipAgreementMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PartnershipAgreementMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount agreed under the partnership agreement.",
        "label": "Partnership Agreement, Maximum Amount",
        "terseLabel": "Maximum amount under the partnership agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PartnershipAgreementPeriodOfCostsToBeCovered": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PartnershipAgreementPeriodOfCostsToBeCovered",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which the costs are to be covered by the funds received under the partnership agreement.",
        "label": "Partnership Agreement, Period Of Costs To Be Covered",
        "terseLabel": "Period for which the costs are to be covered"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PartnershipAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PartnershipAgreementTerm",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the partnership agreement.",
        "label": "Partnership Agreement, Term",
        "terseLabel": "Term of the partnership agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PatentsAndFeesToRegisterLegalRight": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PatentsAndFeesToRegisterLegalRight",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for registering a legal right.",
        "label": "Patents And Fees To Register Legal Right",
        "negatedLabel": "Patents and fees to register a legal right"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables on social security and taxes other than income tax",
        "terseLabel": "Payroll-related taxes and social-security liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "cvac_PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment of accrued other liabilities of upfront payment.",
        "label": "Payment Of Accrued Other Liabilities Of Upfront Payment",
        "terseLabel": "Payment of accrued other liabilities of upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payments on lease obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total consideration transferred under the business combination, upon the achievement of first milestone.",
        "label": "Percentage Of Consideration Transferred Upon Achievement Of First Milestone",
        "terseLabel": "Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total consideration transferred under the business combination, upon the achievement of second milestone.",
        "label": "Percentage Of Consideration Transferred Upon Achievement Of Second Milestone",
        "terseLabel": "Percentage of consideration transferred upon successful proof of mechanism in humans"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PercentageOfEurStrengthened": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfEurStrengthened",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the Percentage of EUR strengthened.",
        "label": "Percentage of EUR Strengthened",
        "terseLabel": "Percentage of EUR strengthened"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PercentageOfEurWeakened": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfEurWeakened",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the Percentage of EUR weakened.",
        "label": "Percentage of EUR Weakened",
        "terseLabel": "Percentage of EUR weakened"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PercentageOfInterestHigher": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfInterestHigher",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of Interest higher.",
        "label": "Percentage of Interest Higher",
        "terseLabel": "Percentage of Interest higher"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PercentageOfSolidarySurcharge": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfSolidarySurcharge",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of solidary surcharge.",
        "label": "Percentage Of Solidary Surcharge",
        "terseLabel": "Percentage of solidary surcharge"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PercentageOfTradeTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfTradeTax",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of trade tax.",
        "label": "Percentage Of Trade Tax",
        "terseLabel": "Percentage of trade tax"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PercentageOfVotingInterestsHeld": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PercentageOfVotingInterestsHeld",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of voting equity interests held in the Entity.",
        "label": "Percentage of Voting Interests Held",
        "terseLabel": "Voting interests held"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PersonnelAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PersonnelAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel accrued liabilities.",
        "label": "Personnel Accrued Liabilities",
        "terseLabel": "Personnel accrued liabilities (e.g. bonus, vacation)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_PersonnelExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PersonnelExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses incurred by the company during the period.",
        "label": "Personnel Expenses",
        "negatedLabel": "Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreferenceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PreferenceSharesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityOverviewAndGeneralRemarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred shares",
        "terseLabel": "Preferred shares"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PrepaidCompensationForContractManufacturingOrganizationsTransfer",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of prepaid compensation for contract manufacturing organizations transfer.",
        "label": "Prepaid Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Prepayments for compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of proceed from issuing other equity instrument or exercise of options.",
        "label": "Proceed From Issuing Other Equity Instrument Or Exercise of Options",
        "terseLabel": "Payment on / proceeds from treasury shares/exercise of options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Cash received from issuance of shares",
        "verboseLabel": "Proceeds from the issuance of shares (net of transaction costs)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r263"
     ]
    },
    "ifrs-full_ProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [member]",
        "terseLabel": "Products and services"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r263"
     ]
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "negatedLabel": "Legal and other professional services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvac_ProfessionalFessCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProfessionalFessCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current professional fees.",
        "label": "Professional Fess, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r34",
      "r110",
      "r122",
      "r124",
      "r223",
      "r225",
      "r260",
      "r266"
     ]
    },
    "cvac_ProfitLossAfterTaxIfEurStrengthened": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProfitLossAfterTaxIfEurStrengthened",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the profit (loss) after tax expense or income if EUR strengthened.",
        "label": "Profit Loss after Tax If EUR Strengthened",
        "terseLabel": "Post-tax loss if EUR strengthened"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ProfitLossAfterTaxIfEurWeakened": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProfitLossAfterTaxIfEurWeakened",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the profit (loss) after tax expense or income if EUR weakened.",
        "label": "Profit Loss After Tax If EUR Weakened",
        "terseLabel": "Post-tax loss if EUR weakened"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r232",
      "r233",
      "r281",
      "r282"
     ]
    },
    "cvac_ProfitLossBeforeTaxIfEurStrengthened": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProfitLossBeforeTaxIfEurStrengthened",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the profit (loss) before tax expense or income if EUR strengthened.",
        "label": "Profit Loss Before Tax If EUR Strengthened",
        "terseLabel": "Pre-tax loss if EUR strengthened"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ProfitLossBeforeTaxIfEurWeakened": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProfitLossBeforeTaxIfEurWeakened",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the profit (loss) before tax expense or income if EUR weakened.",
        "label": "Profit Loss Before Tax If EUR Weakened",
        "terseLabel": "Pre-tax loss if EUR weakened"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r304"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [Member]",
        "terseLabel": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r249",
      "r265"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment recognised as of acquisition date",
        "terseLabel": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r272"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Equity interest held"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r82",
      "r125"
     ]
    },
    "cvac_ProvisionForEmployerTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProvisionForEmployerTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of provision for employer taxes arising according to US regulations for future exercises.",
        "label": "Provision for Employer Taxes",
        "verboseLabel": "Provision for employer taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision used, other provisions",
        "negatedLabel": "used (amounts charged against the provision)",
        "verboseLabel": "Provisions utilized"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "cvac_ProvisionalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ProvisionalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of provisional fair value.",
        "label": "Provisional Fair Value",
        "terseLabel": "Provisional fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Provisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Provisions",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Provisions (current &amp; non-current)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "cvac_PublicOfferingOfCommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "PublicOfferingOfCommonSharesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for public offering of common shares.",
        "label": "Public offering of common shares",
        "terseLabel": "Public offering of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Purchase of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases of goods, related party transactions",
        "terseLabel": "Purchases of related party"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r167",
      "r183",
      "r261",
      "r262",
      "r326"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r167",
      "r183",
      "r261",
      "r262",
      "r326"
     ]
    },
    "ifrs-full_RawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current raw materials",
        "verboseLabel": "Raw materials"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r311"
     ]
    },
    "ifrs-full_RawMaterialsAndConsumablesUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RawMaterialsAndConsumablesUsed",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials and consumables used",
        "negatedLabel": "Materials"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r232"
     ]
    },
    "cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from government grants and similar bodies.",
        "label": "Receipts from Government Grants Classified as Operating Activities",
        "verboseLabel": "Receipts from grants from government agencies and similar bodies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReceivablesFromTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables from taxes other than income tax",
        "terseLabel": "Tax claims"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]",
        "terseLabel": "Tax reconciliation"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ReimbursementOfApprovedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ReimbursementOfApprovedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reimbursement of approved expenses",
        "label": "Reimbursement of Approved Expenses",
        "terseLabel": "Reimbursement of approved expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount reimbursed to the company in the form of kind from related party transaction.",
        "label": "Reimbursement of Expense In The Form of Kind From Related Party Transaction",
        "terseLabel": "Payment compensated"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ReimbursementOfTravelCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ReimbursementOfTravelCost",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reimbursement of travel cost.",
        "label": "Reimbursement Of Travel Cost",
        "terseLabel": "Reimbursement of travel cost"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RelatedPartyTransactionConsultingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RelatedPartyTransactionConsultingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consulting fees incurred as a part of related party transaction.",
        "label": "Related Party Transaction, Consulting Fees",
        "terseLabel": "Consulting fees"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RelatedPartyTransactionNoticePeriodForTerminationOfAgreement",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of notice for termination of the agreement at the option of the party.",
        "label": "Related Party Transaction, Notice Period for Termination of Agreement",
        "terseLabel": "Notice period for termination at the option"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RelatedPartyTransactionNumberOfLoansReceived": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RelatedPartyTransactionNumberOfLoansReceived",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of loans received from a related party.",
        "label": "Related Party Transaction, Number of Loans Received",
        "terseLabel": "Number of convertible loans"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RemainingOptionLifeShareOptionsAwardsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RemainingOptionLifeShareOptionsAwardsGranted",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining option life of share options awards granted.",
        "label": "Remaining Option Life Share Options Awards Granted",
        "terseLabel": "Remaining life of the options"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RepaymentOfGrantReceivedFromGovernment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RepaymentOfGrantReceivedFromGovernment",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for repayment of received government grant.",
        "label": "Repayment of Grant Received From Government",
        "terseLabel": "Repayment of grant received from government"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedLabel": "Repayment of the EIB loan",
        "verboseLabel": "Amount paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ResearchAndDevelopmentServicesCombinedWithIpLicenseMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research and development services combined with Ip license.",
        "label": "Research And Development Services Combined With Ip License Member"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ResearchAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ResearchAndDevelopmentServicesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research and development services.",
        "label": "Research and development services [Member]",
        "terseLabel": "Research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency translation reserve",
        "terseLabel": "Currency translation reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r69",
      "r234"
     ]
    },
    "cvac_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Restricted stock Units",
        "label": "Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r234"
     ]
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total revenues",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenues",
        "verboseLabel": "Revenue recognized"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144"
     ]
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "negatedLabel": "Income from release of governmental contract liabilities",
        "verboseLabel": "Income from release of governmental contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue that was included in contract liability balance at beginning of period",
        "terseLabel": "Revenue recognized from upfront and milestones payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "cvac_ReversalOfProvisionForOnerousContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ReversalOfProvisionForOnerousContracts",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.",
        "label": "Reversal Of Provision For Onerous Contracts",
        "terseLabel": "Reversal of provision for onerous contracts"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RightOfUseAssetsNumberOfExtensionOption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RightOfUseAssetsNumberOfExtensionOption",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of extension option  under the right of use assets.",
        "label": "Right Of Use Assets, Number Of Extension Option",
        "terseLabel": "Right of use assets, number of extension option"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RightOfUseAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for right-of-use assets assumed in a business combination.",
        "label": "Right Of Use Assets Recognised As Of Acquisition Date",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RightToExercisePercentageOfVestedVirtualShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RightToExercisePercentageOfVestedVirtualShares",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the right to exercise percentage of vested virtual shares.",
        "label": "Right To Exercise Percentage Of Vested Virtual Shares",
        "terseLabel": "Right to exercise percentage of vested virtual shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "terseLabel": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r160"
     ]
    },
    "ifrs-full_RightofuseAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssetsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use-assets",
        "terseLabel": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk exposure associated with instruments sharing characteristic",
        "terseLabel": "Exposure in (foreign) currency"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "cvac_RittershausRechtsanwaelteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RittershausRechtsanwaelteMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Rittershaus Rechtsanwaelte , a related party.",
        "label": "Rittershaus Rechtsanwaelte [Member]",
        "terseLabel": "Rittershaus Rechtsanwaelte"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_RsuSupervisoryBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "RsuSupervisoryBoardMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for RSU supervisory board.",
        "label": "RSU Supervisory Board [Member]",
        "terseLabel": "RSU Supervisory board"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_SaleOfEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SaleOfEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sale of equipment in operating income.",
        "label": "Sale of equipment",
        "terseLabel": "Sale of equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedLabel": "Selling and distribution expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of expense recognized for the programs.",
        "label": "Schedule of Expense Recognized for the Programs [Table Text Block]",
        "terseLabel": "Schedule for expense recognized for the equity-settled programs"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of lease expense recognized in the statement of operations related to leases.",
        "label": "Schedule of Leases Expense Recognized In Profit Or Loss [Table Text Block]",
        "terseLabel": "Summary of amounts recognized in the statement of operations related to leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_SellingAndDistributionExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SellingAndDistributionExpensesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for selling and distribution expenses.",
        "label": "Selling and distribution expenses",
        "terseLabel": "Selling and distribution expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ServiceRenderedIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ServiceRenderedIssue",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of service rendered.",
        "label": "Service Rendered Issue",
        "terseLabel": "Service rendered issue"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_SettlementOfShareBasedPaymentAwardsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SettlementOfShareBasedPaymentAwardsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share based payment awards settled in cash.",
        "label": "Settlement Of Share Based Payment Awards , Amount",
        "terseLabel": "Settlement of share-based payment awards"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ShareBasedPaymentExpenseIncl.DeferredTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Share-based payment expense (incl. deferred taxes)",
        "label": "Share-based payment expense (incl. deferred taxes)",
        "terseLabel": "Share-based payment expense"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ShareBasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ShareBasedPaymentsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for share-based payments.",
        "label": "Share Based Payments [Member]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "cvac_ShareOptionExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ShareOptionExercises",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share option exercises.",
        "label": "Share Option Exercises",
        "terseLabel": "Share option exercises"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_ShorttermOnerousContractsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermOnerousContractsProvision",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": {
       "parentTag": "ifrs-full_CurrentProvisions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current onerous contracts provision",
        "verboseLabel": "Provision for onerous contracts"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provision for onerous contracts. [Refer: Onerous contracts provision]"
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "cvac_SignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_SignificantAccountingPolicyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SignificantAccountingPolicyLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Significant Accounting Policy [Line Items]",
        "verboseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_SignificantAccountingPolicyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SignificantAccountingPolicyTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of significant accounting policies.",
        "label": "Significant Accounting Policy [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83",
      "r136"
     ]
    },
    "cvac_SigningSharePriceRepresenting10": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SigningSharePriceRepresenting10",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents of signing share price representing 10%.",
        "label": "Signing Share Price Representing 10%",
        "terseLabel": "Signing share price representing 10%"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_SigningSharePriceRepresenting40": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SigningSharePriceRepresenting40",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents of signing share price representing 40%.",
        "label": "Signing Share Price Representing 40%",
        "terseLabel": "Signing share price representing 40%"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SoftwareMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for software.",
        "label": "Software [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Shareholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Other Comprehensive Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Financial Position"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_StatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "StatementsLineItems",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Statements Line Items",
        "terseLabel": "Fixed Assets",
        "verboseLabel": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_StatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "StatementsTable",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityExercisesOfShareOptionsUnderVsopPlanAndLegacyProgramDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Statements Table"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_StockIssuanceDuringPeriodForExistingShareholders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "StockIssuanceDuringPeriodForExistingShareholders",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityImpactOfShareSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period for existing shareholders.",
        "label": "Stock Issuance During Period For Existing Shareholders",
        "terseLabel": "Shares issued to former shareholders of Frame Pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [member]",
        "terseLabel": "Subsidiaries"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for entities that are controlled by another entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r81",
      "r83",
      "r136"
     ]
    },
    "cvac_SupervisoryBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "SupervisoryBoardMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for supervisory board of the entity's key management personnel.",
        "label": "Supervisory Board"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense",
        "terseLabel": "Deferred tax benefits (expense) from net operating loss carryforwards"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "cvac_TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to additions or deductions for local trade taxes not deductible in determining taxable profit (tax loss).",
        "label": "Tax Effect Of Expense Not Deductible In Determining Profit Loss Related To Additions Or Deductions For Local Trade Taxes",
        "negatedLabel": "Additions for local trade taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)",
        "negatedLabel": "Other non-deductible expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect of foreign tax rates",
        "negatedLabel": "Effects from differences between Group and local tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "cvac_TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of deferred tax assets or deferred tax liabilities (DTA/DTL).",
        "label": "Tax Effect Of Non-Recognition Of Deferred Tax Assets And Deferred Tax Liabilities",
        "terseLabel": "Non-recognition of deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TaxEffectOfNonRecognitionOfTaxLossCarryforwards",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of tax loss carryforwards.",
        "label": "Tax Effect Of Non-Recognition Of Tax Loss Carryforwards",
        "terseLabel": "Non-recognition of tax loss carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of tax loss carryforwards of prior year.",
        "label": "Tax Effect Of Non Recognition Of Tax Loss Carryforwards Prior Year",
        "negatedLabel": "Recognition of tax loss carryforwards recognized in prior years"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TaxEffectOnNonDeductibleExpensesForTaxPurposes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TaxEffectOnNonDeductibleExpensesForTaxPurposes",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-deductible expenses for tax purposes.",
        "label": "Tax Effect On Non-Deductible Expenses For Tax Purposes",
        "negatedLabel": "Non-deductible expenses for tax purposes"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to recognition of deferred tax assets or deferred tax liabilities (DTA/DTL).",
        "label": "Tax Effect On Recognition Of Deferred Tax Assets And Deferred Tax Liabilities",
        "verboseLabel": "Recognition of deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationsDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "negatedLabel": "Expected tax benefit (based on statutory tax rate of 29.48% in 2023, 2022 and 2021)"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "cvac_TaxLossesCarriedForwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TaxLossesCarriedForwardsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for tax losses carried forwards.",
        "label": "Tax Losses Carried Forwards [Member]",
        "terseLabel": "Tax losses carried forward"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TbingenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TbingenMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Tbingen.",
        "label": "Tbingen [Member]",
        "terseLabel": "Tbingen"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TechnicalEquipmentAndMachinesAndOtherEquipmentMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for technical equipment and machines and other equipment.",
        "label": "Technical equipment and machines [Member]",
        "terseLabel": "Technical equipment and machines"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TechnicalEquipmentAndMachinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TechnicalEquipmentAndMachinesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for technical equipment and machines.",
        "label": "Technical equipment and machines:"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TechnologyMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity.",
        "label": "Technology [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology-based intangible assets recognised as of acquisition date",
        "terseLabel": "Intangible assets (Technology)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for technology-based intangible assets acquired in a business combination. [Refer: Technology-based intangible assets [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "cvac_TemporaryDifferencesValuationOfDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TemporaryDifferencesValuationOfDeferredTaxAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of temporary differences valuation of deferred tax assets.",
        "label": "Temporary Differences Valuation Of Deferred Tax Assets",
        "terseLabel": "Temporary differences valuation of deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries]",
        "label": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVenture",
        "terseLabel": "Indefinetly reinvested and associated with invested in subsadiries, deferred tax liabilities have not been recognized"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ThenChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ThenChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dan Menichella, then Chief Executive Officer.",
        "label": "the Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ThirdPartyServiceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ThirdPartyServiceExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails": {
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOperativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for third party services during the period.",
        "label": "Third Party Service Expenses",
        "negatedLabel": "Third-party services"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r167",
      "r183",
      "r261",
      "r262",
      "r326"
     ]
    },
    "cvac_TotalAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TotalAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for total assets assumed in a business combination.",
        "label": "Total Assets Recognised As Of Acquisition Date",
        "totalLabel": "Total assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails",
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r302"
     ]
    },
    "cvac_TradeAndOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TradeAndOtherPayablesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails",
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for trade and other payables.",
        "label": "Trade and other payables",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_TradeAndOtherPayablesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TradeAndOtherPayablesOneMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade and other payables, One"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails": {
       "parentTag": "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsFairValueRecognizedOnAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables recognised as of acquisition date",
        "terseLabel": "Accounts Payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "cvac_TradeAndOtherPayablesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TradeAndOtherPayablesTwoMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade and other payables, Two"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksMaturityProfileOfGroupSFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables, undiscounted cash flows",
        "negatedLabel": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r280"
     ]
    },
    "cvac_TradeAndOtherReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TradeAndOtherReceivablesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeReceivablesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r213",
      "r273",
      "r298"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction price allocated to remaining performance obligations",
        "terseLabel": "Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_TreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasuryShares",
     "crdr": "debit",
     "calculation": {
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares.",
        "negatedLabel": "Treasury Shares"
       }
      },
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r239"
     ]
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://www.curevac.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury share",
        "terseLabel": "Treasury Shares"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "cvac_TreasurySharesTransferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "TreasurySharesTransferred",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares transferred.",
        "label": "Treasury Shares Transferred",
        "terseLabel": "Treasury shares transferred"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r172",
      "r205",
      "r207",
      "r208"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r172",
      "r205",
      "r207",
      "r208"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureRemunerationOfCompanySKeyManagementPersonnelAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsFormerChiefExecutiveOfficerGrantReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsExpenseDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_UnusedInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UnusedInterestCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unused interest carryforward.",
        "label": "Unused Interest Carryforward",
        "terseLabel": "Unused interest carryforward (\"Zinsschranke\")"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedProvisionReversedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedProvisionReversedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unused provision reversed, other provisions",
        "negatedLabel": "unused amounts reversed",
        "verboseLabel": "Reversed"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unused tax credits for which no deferred tax asset recognised",
        "terseLabel": "Deferred tax assets, temporary differences"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "cvac_UnusedTaxLossesForCorporateIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UnusedTaxLossesForCorporateIncomeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unused tax losses of corporate income tax.",
        "label": "Unused Tax Losses For Corporate Income Tax",
        "terseLabel": "Unused tax losses for corporate income tax"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_UnusedTaxLossesForTradeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UnusedTaxLossesForTradeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxScheduleOfUnusedTaxLossesCarriedForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unused tax losses of trade tax.",
        "label": "Unused Tax Losses For Trade Tax",
        "terseLabel": "Unused tax losses for trade tax"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment received.",
        "label": "Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment revenue recognized from termination of agreement.",
        "label": "Upfront Payment Revenue Recognized From Termination Of Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_UpfrontPaymentsIncludedInContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UpfrontPaymentsIncludedInContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments of the company included in contract liabilities.",
        "label": "Upfront Payments Included In Contract Liabilities",
        "terseLabel": "Upfront and milestones payments included in contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_UpfrontPaymentsReceivedOrReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UpfrontPaymentsReceivedOrReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments received or receivable by the company.",
        "label": "Upfront Payments Received Or Receivable",
        "terseLabel": "Upfront Payments Received Or Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLivesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, intangible assets other than goodwill",
        "terseLabel": "Remaining useful life",
        "verboseLabel": "Estimated useful lives (in years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, property, plant and equipment",
        "terseLabel": "Estimated useful lives (in years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "cvac_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for right of use assets.",
        "label": "Useful Life Measured As Period Of Time, Right Of Use Assets",
        "terseLabel": "Estimated useful lives of right-of-use assets (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations",
        "terseLabel": "Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders",
        "terseLabel": "Value of shares issued to former Frame shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone",
        "terseLabel": "Value of shares issued upon the achievement of the successful investigational new drug application filing"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone",
        "terseLabel": "Value of shares issued upon successful proof of mechanism in humans"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAccountingPoliciesEstimatedUsefulLifeOfRightOfUseAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "cvac_VincentStphenneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "VincentStphenneMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Vincent Stphenne.",
        "label": "Vincent Stephenne [Member]",
        "terseLabel": "Vincent Stephenne"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_VirtualShareOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "VirtualShareOptionPlanMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for virtual share option plan.",
        "label": "Virtual Share Option Plan [Member]",
        "terseLabel": "VSOP"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_VirtualSharesProgramIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "VirtualSharesProgramIMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program I.",
        "label": "Prior VSOP [Member]",
        "terseLabel": "Prior VSOP"
       }
      }
     },
     "auth_ref": []
    },
    "cvac_VirtualSharesProgramIiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "VirtualSharesProgramIiMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program II (New VSOP).",
        "label": "New VSOP"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopExpenseRecognizedInStatementOfOperationsAndOtherComprehensiveIncomeLossDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsNewVsopReconciliationOfOutstandingAwardsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsPriorVsopDevelopmentOfVirtualSharesInThisProgramGrantedToManagementAndKeyEmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, other equity instruments granted",
        "terseLabel": "Total fair value of the RSU grant"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "cvac_WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value per share of share options granted.",
        "label": "Weighted Average Fair Value Per Share At Measurement Date, Share Options Granted",
        "terseLabel": "Weighted average fair value per option"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEquityFollowOnPublicOfferingDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipRestrictedStockUnitsRsusDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price",
        "terseLabel": "Price per share",
        "verboseLabel": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsLongTermIncentivePlanLtipInputsUsedInMeasurementOfFairValueAtGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price, share options granted",
        "terseLabel": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "cvac_WiesbadenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.curevac.com/20231231",
     "localname": "WiesbadenMember",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsRightOfUseAssetsAndLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Wiesbaden.",
        "label": "Wiesbaden [Member]",
        "terseLabel": "Wiesbaden"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "23",
   "IssueDate": "2023-01-01",
   "Paragraph": "26",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2023-en-r&anchor=para_26_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "23",
   "IssueDate": "2023-01-01",
   "Paragraph": "26",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2023-en-r&anchor=para_26_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Accounting policies",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS08_g7-31_TI",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "116",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "h",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_h_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS03_g59-63_TI",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B8",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2023-03-23"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>173
<FILENAME>0001410578-24-000531-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-24-000531-xbrl.zip
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MI]2KW_ G4$XN8B\B(94KXI>:,R?R0>E-(H\0N3Q&?7WE23 @0G+-?84G!9<
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MTR"]\D&:P?(R5(\[?9"Q('Z<[G:XX__##I::"T@L^X#/ND2+JYB&N*@#:PF
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M'1R!,\"!CF<*>_^,?(+]0E[R!/Z)S<["Q5SWA_5MX2BW[80K=05I5NP!3(R
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M=<S#VTP;N(IRJFN7\C8H9V9-AR%X"GN>^$;C/",@"Q#7)Y =SL')=+I8"+J
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M3)M)A,[HFF?$^-T9Y>^J3M<0E$6&[FAOR=-?CI$EZ2]I2/[Z_P%02P,$%
M  @ ]8R86&9:(P,+&0  _X0! !4   !C=F%C+3(P,C,Q,C,Q7V-A;"YX;6SM
M75MSVSBR?C]5YS]P?1[.SH-C71Q/G)KLEFS'6=?&EE=V9O8\3=$D9.&$ C0
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M2*7[U@9(V1DCL;DMJG  X% B7<;1H0T*XA0>R]^8J@,N?D6#7K]?HC;RBA\
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M?6MX^W$-$^")9><1ATP:3[_BUQ<>$A,2RDS%WV;0F45<"\\CP%R0]@^;7@"
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M;2-W#A%G1>9FUIXG3]7P?DR?/4V?6H*1/]7=X8[Z#KRF]M.5QX)Q:D,>J4#
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MU22QK<2=[-G[3,FOM.]V(A];2<^9+UTT"4G8H0AMD+2C_O47 $F)E  0?(
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M^+!573(UGL\.(MUCB!A#<_?&Z?P[Q%%,]%7:G"AILR4,4QXSQ96:@;XX@;,
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M!PB(]!LZ8<C09"C2J0N0.]C-@$__W.<#"%?.6Q!CM*;_L#G?@1#,WZ7MW[U
M#^ W@8,Q>@%8#?I]$?$QWHY')WR3?B"0GWY\<WKZYBQAT?Y<RIAL9X)!],Z#
MJ^ULCN_7 SF7,$TSLS\P^-AHS8$B?U/A0,$;CPE=BQ >#MT"N&RD-RNP>JHK
M 'Q8B^,V!W1)8,)N_ 3>;,G0(KC<T5L5AF3OT2,-V=@Y@,EW,(#)QA3\*,P*
MZ/;E 2^;ET+:TK8'(SK4KN$HUW*4;,*C+TPDPE:@;>&PH4!D8/C(+<S-<H$0
MENS@(7#?+M#S.P_ 9/,F?^RV;/+ACZ0P ;E=$%T[9 G/](\9&9\"DPWM.T_
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MO['!6@!5N,('WE*VS#!PPAAO$L=8"5OXC0V6"*C"%C[PEK+E 40$>^!=.SB
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M0ZJK'0M6W+*@":J+':)M[5G0<IVAB;I\<-UN]39U9T7T4*OT*>H<+=Q4.H]
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M81*7/9W/R!7G-HB(C@7)$<^*K86L2.ULZ00TV/L%4EU#P/\61C98=;2A>+2
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M3!:DXW3)_5]MX;Z4(KKY/66CW8!L2AXO#]MTR:>/'?/I$%O=//@:4X2G\WN
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M"F" YBFL%TK"T?KHUCUGW(J8M$ZFGF]!]!;0_B:D,JIU#RMWMPVID$?W1O1
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M9:E&,AC87YV!W7R]L4L41H0VCF^\M%@!DN.TR!LEZ1$5R2,' R \7;+*J<_
M1VLZB24E\LJ .TZ7@6U4/B)I?P2^3VOE$4QI&4#X%-/?+9'V,N".V/5A$96/
M2-J' JCV.F:LHG,?7#FJS]DT)ICPRM@A!,?N8NJ0E(;<52RTXPXZ3] GPP!*
MNVTE_'#B)41T_-M@CO"*.62K^:S.3M[O^ZS8E"-_-^?("3R"?S8K:;*;>)2;
M6;O?2G 4Y@5LGUX\GY)J)UNVK$O?(4)(5DJ.\S+OD+"]<6=0-785U[H0*TL/
M&H;:#M82*[^@M2VNFQ(1+')*@,OQ\JGH@#@_'X_'%OE?FO..BY^.TK%$P41Q
M2)0#HEJZ40E3U+I8X6J1RMBN&&P9+CH>WTXGHXH9#-@QKD)VI6Y66(S52*^$
MCP;R?T;/  =47671NKQS7=+.>#&!ZN>Y!)L.R"M.=1>UM*!F@$Q&A"356#N@
M*5%M/"V;$KJK$_(2.3ZC#GT%;0T]L(+N/09K<O?U A"2BVZ GI,4.=GF77D0
MTW4'Y#*7V\8K8Z:!2;(-41114*5CY\$"U;':<D3A<#BF'+J=862G/NQI(,*K
MA5)?@SI5/2FHB%\?3,C?@IB:&3.H'P#9F\@7JGQ6[6[0*]V4U:HH]H';6WB_
M5>"QO)-!#VQ3SLH1TYXI%K@8.#0O(_EWMB07YL7R ;C4Q@'GT$T.=R&':H]B
MT(78X/2M@ZGV-ZZ=G_01YF]!N";G^4T<>.$#@*NG&(<B6WUI%X-^K@;<*47+
MD,^)2 U:@9GSLYHK:7QRD/Z4C#0B^[ IW] 6%Z$C:+^%+>?.I1.!!6$_M=RR
MNB?4LXF9#U#J_"GI9H</B,^6/8=/"2:6Z@O7K"I-.$.1XS-G<A[R$N^"4E]K
M?$)* KKGL%=!\'4RMFA"^FA%:4WMS.8B;2G_'^.G$'K0P>7LYC6UPA%508;W
MTK X&.E1\)-S06HGX[4R8Q03PYO7P0M'W3&9N[:XI8%8U(T&@Q@&BRG1!Y*[
MA7"1J'4V;?"2<[@J-GTP>! <+D! R!U-,+D4!@L:7G=/;@NTGJ&_^1;@)#Z.
MR",E"PI#\L\E!AZ,IG@&5FN$';RY@O,YP"!P 0T\(%@GU62HV6"&'H 7N^16
M2EI@-DI*-*&L&(7)M"%.502-$JD/DGT9$ZAI:F$&=D)9%M'\SSB,6.8K.19W
M[0HDD%RZ&@]LVB2H*F/-,>V#H!P*>(*F4 #$'4P;#E49*\:@SPQ+"L8&BQF:
M8KA((WN(L"8>"<>G$>D'^YXDV[OE:4S;+9L*1UV\==N8,WB);#DL?A^G@$8(
M4BS=I8,7P$.$8/3T YX'R=D8^9L( 59&D>N=;SYHE_S^M=YUI04L=7-W*U/>
M3J8(K,B%]#+[ J,E#)Y!>A;!(,Q=79^P$[A+TCSPMCU"]MAU1 8*:?-_(O+A
MF72-,==>W.7L7<K+QWKRTB4Y>G82Y9Q *B=*H7F7G/_4SLE0@+\/K)JLUSYT
MJ56&0/] A$\<FG/8LE-SWDD##G%@[P5SDJJ1UV13<6F6:2F+1.T[951U&Z$"
M!KK/TUTUUNG\$?G0([OY8XR3DYYW!)9TZ)3BU6UV*BAT2?(9=CP*;!FE=^TZ
M)7!UBY0$<M,1#8]$W_!B^K!([N "%=_0'I^,)8$.;T;9)",T'WGI-/0G<$2O
M9Q_<ZI*0O]2NR/*4M]\D)D9N*F[[P]MR?M7"05[TM?Z(QH,^=(G1G@&\/H4L
MU8)J853BG&XTIBW!)XV75PN28WF\BF6R4PCU^'!R/AY;5:36&GGBTDE+J$7D
M! M(-M.DQ(DX7TS4THJ(EA:D/!>JP4>T#_?E>XS(:1QMZ&N[$4&9/@?$"O"5
MK.C2?E9D<;?$Y0IH6\IF]GX*FA/H)*NVO+D5%2];9ZH(6TMYR3(%E-C(:6E%
M%<?6.<A!5-.#4]0K$41(&,PI:VA%/<%6#SX^GII(OZ89V=#+Z@82,,M60K6N
M5E2]:YL]2IA;NM$Q^U]2;8]>WDLO&8+F!KWG&K<\$;::%M^E$](*S?0?JO,\
M.[[P#1+%/@:=U/J6FQQE#;PY?)=,S!-Q6X-N8SV\$*.JVT7S%05I$.,=39W-
M>;?%C"GO8])MK(=#Y3AW\7XH.PP)*&X*B@JWU/J9]!_KV]_*\=8>Q47/O4R-
M(8M;K!F4-S?I<=;#(RFZ.@I+5=WJ;-KG=%L85!#N;).KMK699HUNTT$IMMJW
ML0S<2P>3N[-W@S!][EBVDY7TZ)0_G9@7RC#6& %.IDZNR.Q5FH-8Q<U7$-'@
M9C&W:@[4*1,[,4+4)(2E)HE'N A8_9L@NMW%)]\&^3QG:32&^@#&J[1V$WRA
M3A!+16(O-[Y"NK]"3UOB)JK*O;2B0]M% ?K)W*+#_NQ\?&:^GFUG#.<BK^=^
M0H,[+Q&FFU8$LC=</J^>EK,8/)$3!P2? 5XYP49Z::D\BA51#LKBF[^N5$;5
MTK7;^-2ZJ_B,;[,IK'G+MPU*R1[TK:\_'%,-%)X.S!1DL;")>U@1;*-=BL3X
M]R'22IP,G577N*6/1\QI50U*(A4Y4!S(BK"=#L5#D2P]DYI=UCRCPF6243W%
MEVE&]56:43U#U[QD]);&M"* J$-9JDZA/HB5H,+O11Q"^N#!)5H]I649PNH'
M53N#6Q$MI5O0VB%5'R3NP ZHLCU9_""IUDU'^?50NQC;E\H%PB@M RIL;\H>
M? 61^AKF-[8BY$LWC_FH&\I@SB-[0TZ2P(7TU=^0W(6908^@]\4)G.35Y%R3
M!QC^J)C>_.&PCGON YJ/YMG@([@#@#T2O-J"4&R'*13'DOR\I6TB$NIIS?R.
MMFP+ERB@"?MIJ=+IG$J.O-*\L(.EZ<8RQNU5.12B9NF>S@.XQ*\AZV*+MZI,
M)LNY9KEINU6^%7TQ[RUS1+7%2RZ6&CQ.J6\DO*-V@C"ZQ_#9B<"%$_ 9I-C'
M"F]2N=3MGKLLQ4AW@%4"P1U1+T#XI$#]PY;&'Z]4E*0]HA\BHIO4US'-BGVL
M(O&E7:SP:%00^%*$;#U)'(PW,%A,5B@.HHGKQJN8/>YP!=88T-J*E/0KA",8
M9F5:;U=K!V*JKI,/GS&Y)^V-(G]H2->$E@9,55 ?M9&F%\)7IL!P&UNC<FI>
M1S))Z=464X/+1=7M@V4E8,QSGDL?2X4A1Y\=$4ID0MK'#LU8(N)[U3IEN%C*
M,\EI=F +K6+)NK,N^*D,.W%8$_^4/Z: I03#LA<M]EI9H<;7Y_ >-GUPT]RF
M5= 3F*<!/R-=XKM7ZVY=2%$UQJJBV0>.WR ,X"*X_NDNG6 !/C-]5;0\>6VM
M"^FIN$AY./6"<<GN<HE"R8(L-K(N**;6?IHBTPL>%85+&IC);6M=Z$JCQ=5R
MX*2XQB3;G=,XSF1[YID1!0VMBR51H;D,H2ZRQ O&3FKIW)5BYY*^K(MUP1[J
M3"A#33<[)KZ/7NA&258?E027W!:3X!.Z_J;!'B8\]E0>PHH20+7851G5/L;B
M?'&BF,+,(MCI0P2?,8K7C]M&N7 R5O:([!R(BJ\;Q8[_+?#(W-0TL:N'5#6X
MYTQ/<,^;488980M#C;:*EF"TH C^6YCKX>]P'-$H'V^$@I&[0W,4Y_ <K5-$
MCR5^**/3A,CI)H3TM<ROB#"+N9K@,^")@GJ048/1;5'5MBC(W$_%1I9&'#5F
M=5&'*^)LJ:(]62PP6%"[Z(P0[8+L'&49UI(>MGB%>"*Y9P\6(W'\C"HZ+GX]
M'Y^=6^38:< \+F*6\O,KBNX("GA&+GC3 /P7<' )/R4]K/#&E$KH7L"V&!U+
M6;8/+M$<\TC<D"."?EVV+JL.8X4QOR)SJ^)H.\<K\]8H%X66^[I<[ N_FFIS
MU?RJ#6>PQ/G:"IW$'MH&2G7G;EQ1-9O=7?<2K58P*<J3O]U3<^&-CUZX-J%*
MW:W8[+6(1W5:],%1P:*(]JN,"G</06LKS@;->X( ==TVW?U"H\JK5K&C=4[<
M=M>K(A7ZL%*Y-9I5Q*'>$-:YC#6LZ2KTZ(.(E-*CFKC4'<XZW[4&T:E+FSXZ
MD5)G?E*2W-W0[ZJZ@0Z>L&[+#93"-G)3X-@/Q^*[^4KEEFY0UY2R49))%$X(
MBC!8W!"!Y[%2W7G39/CZ6][<"9\8N4(<,4J] WX4TD],_6'D(!_^R,2-XY<Y
M_-E2CTQS!M)=YQ#=ULZ?$+AO%^CY7;9\$H9DGW8,R;ZA7O,4%++'7:7^C*+V
M*6UJUL4BDBNF+TKA[BO%BRZ%C^?CLX_&?25UN<#%Q1QCOCU>B1C!?C*9"*P@
M/ 5J,X#-D?+RMQL1*=E/!JU*E4G) #9'RNMO#R)2LI\,VFHJDY(!;(Z4GR_N
M1:1D/QFTG50F)0/8TFOKC,P:9KJ1+ KGL*&ER=OMZ'TRQ'O RA)7(Z^I+0$X
M(HD4<\5RQV(COA3UKD_GX[%-E7[J\HJ+E:7LRYM>RC+A.4VM"*\1B^!>JCH'
M 5O9XCNTV*/ I"8M9U+>L_NC3<FUUO;1ID")/G*_;)6J]+7E-%06\PJ<[?/*
M;L[;PMES?G(^/K.J-(DV?G/Q'IZ>KU0S1%TR*SPQKSN,@3_[- "2U[/*NE@1
M:E2'':68#>]?E^LD=0C?]3/7A?D>@ L(KRO0G=/#BG"=QJ3G(*:!^E]0 "('
M;W).^=M@SY<MYD25WE;$RM3A2A4D-7(HR;"MP9R2CE8$HC3A2PE^79T3TG.Z
MK(<5515:.RT,G-*S%U21^KD>5I13:(WZ.<0LO3@V-I7<54KA:#J%)3D<[5!*
MG,31Q&AU3,7X*-K7/]>,*N1L0;3,*/!^A]$RA_?CTL&$+/3).L>- "%2!%VA
M-#89THH;G&XY;$(@0]&B7U%$]EITB8(0^="C\#Y&Y/\,U.E\&\Z:4B-83-P(
M/C/UL5I@Z/GAXS]L[E&$6#$/-P?!*-R"0$-!70+$:$ZAH%&@&2 C9PO)L02!
MTH=("6Y^4A%X.L_IZH>"F6>%>B!HTRELV=Z4X9;Z9BJ.8FGH:3MBLY=/6XTR
MEJIHREB4Y4I7'<<6?TZM95)3$BQ7UPW)0M$/<G8^'G^RR/_3O7QPZ6&KR.SE
M@)9)AJ"Y%<ZDFN*_QVL!AI;RKY5#LMHMO8UI++FIMT<Q\6V]J>IR3#=V9=R;
M'TT6WL=U25L%FO0A[U?P'/P6G^V%O;DTZ9C*"G]R%V*G@WCZBVIS82;D6J/0
M\6N+5-N#6^$9UR=$;9.K3]M:BN97\,)4S19WL08C6^'S[W+3:D K0WM45A5?
MQQ958VPKHA',[% UJ-6G#6H/V^OY'+C1='[)WK[8A6]DKV$\.%&;FYCFV:V(
MWS"HG;5-3T,^O0>PB@. 4YI=HM7:"3:/_P";7=V7>X!#% 3 K^;$^WCHQ,M/
MEA7F3Z?\MW#T VSR=5W6V;3'XK&;82<(J2,2!>$%B%X "!X >[OQWL'5/'.J
M0]FR(UX2T!9$O%FF5P'0DM>=Y=TL];%58_3^BZQRE"T]\JX#LNXWX0Q%CD\V
MPB+D):9PI;ZV.,G4)+G(4R4$7R=CBQZ>L15U:+0SFXNTCCCJ[6%Z@1SL2>*F
M^0VM\$55$,!=G#0?']WWS<>8'!S/,$1X4T)P44LK+.UU*"Y"J _7M4I'=S4/
M7Y7A+/'D5:> V&.GJ@@=DV>.?W6BMQQR^K";S^,2X2@">'6]6OMH \ %" C/
M):^V-AK3BCVE30EK1(T^;$CE",X(;C!@?[8@/-S1K/.^Z1<;+AV.0V!H(#E@
MKQRF+S8VVFL.QK+.R];%'G- A>,0E0:28:'[2[\@],)T._$\F(!T&\P17K%.
M5>VY!X^VUK3GOAGMP!G!'3R#H7<P] Z&WL'0.QAZCX^Q19OG^]=HZ'T_&'H[
M,O0.MMTN;+L:J'S]$[@Q?3JGA,;\=E:8+.I0F(^.I0=%6K#UX/X[P9C&O907
M.54?P-(RWDW4/G7D+66_%/(2/4&IKRT*8%4Y+_)9"=77R>*B5O3A?#P^LT@5
MU,YV+OH:SM('$$88NJQ(!W)_?"-4E508E+6V0CVL()3;<U6&E*5K;W!&#\[H
M]J1I$GN0S!?F#;5"6>$WMN+:TJ9,\-'L@^_F:TRI-9WG"D1])L0@F-\>NJ-R
MVZ.0X_4'M.*JU:94U"=%GR2'83)EX(77/]<0-Q:=&B,>G;.X 2V,N0ZWZ&UV
MWU:LTO:)E^#!QAVMZ< C;S?RX-HSX-I3?5)W1CE*MSX//D,O=GS!V[J"=D?C
MG)/@V-J^7ILGM#(D@Y_BLX3K&4HLC=RG7VN-8/X-7JD@"CE4AM?Q\ZYH4C@_
M'Y^=&[>HZ.(G%U<-YI,+!Z/@_P-.\!B!]1($LEKGXK8&32<-)'%K0!$CICN7
MXCL,7*(A/49EM!<T-'AM;8/P JQT4WT21"C87/A.X(HISFED\#K8!K4Y&%EZ
MD3N:^"KMCK8AOFJ(KWI%C"VJ1;^>C\>O+KXJ15J'*PW2;*)PZ<3A W"74>@$
M+P[1_25J26D7*YQJ=8)52C'3K:1<0?!,2/8;6J\O((H(#+\AWX/!XO/J:7F)
MWOYC(6:+>E\K_!YU^*..HA[>1"L'T\FE3-AO9(4_H2:U]W'1+?\7Y"KF8$+.
M+TX0SXEZ%-,W0A[?.I(+:ED7*VSR=>A?BIEN;MP0'?7/WP$. /[-<201%H*&
M5F1,U:&\ !\=MU(?_'0"@L'_!4OZC^1J*FAI18V].D06(:3'X/4#8')DK( '
M7<>GQX74Y"5L;45IN%J;B00I':\?8P<N9HC@%8@)S6EDQ>-]=>C+P44'67T'
M P)=^(A]"5TYK;HD[*=6"<M!1O?!]\4A$_C.#8I@\,4'[I_@ARSQ1-BXTXO0
M29M4ER"E0]'P"3N=X#O-V\5?_"?)Y5/8M%-:MWKK%**DXQ*#W]X&"ZK58XFN
MP6O5*7W;O35RL-%1DGE%4[W=,+V9!LA'"P*47-=0Z-0IX5N]0"H@I^.,3&*#
M[LEE*0)83GYQVTZIWNJU48R3!F)_QM"[CC%:2[;LPS:=$K?5F^$A+I;:Y(\Z
ME:V=L-DAE8W/^2&5;4AEVW= ?3H?OS^SR.O6<2I;BKZ68" <Q8[/( KO,5I@
M9W4K"PF2-+?"[U8GF4V*E:7+[])WPG K@Y?.&D;<Z&*E'MT?H>UD#\B"5,38
M]HFC)1NIM(\M9V2IJ"IPKH^KL3[O"KO_KR?GXS.;7BMNCY]</"UE\11[,'#P
M)CDE2GC+;VS% :D@JD7^\7&QE$M#DO>K2_(6V4,)%H7TP7 :1V'D!#1@)WUI
MBN$T!Y@^'<7:+)%/J!MF0<U<DVDKXUH1 ]5<5%JDB&ZG6CXQ,X?L5Q1!%]P#
M,KMW@W"N4/5T/EE@P,O5;6$\*Z*R6N)_,TH8XOLEP9-H._3=.,!_AU*QHQ7Q
M77HYN8^RJ:6:[C%WB'SU %P GW>YTRI+D]_?BC QS4N1C[GV5V()>D1V(DR#
M!QU_^N3#!:]02EEC*V+,6CPL!6CVH=S%)5JM8)08TQP/7&R2XUL@=Q)C5-5Q
MK(A\:U.WKDR!/HC'[P NE@3\R3/ S@(P3>\>$S7@[.3TDU 82GI9$937)NM+
M\-5_O,+54XQ#IH Q;)[INPNA0,T5-K8BIJ^U@U.(9@=OJ:,5F#D_)X'WB%SH
M^(_ C>F,V1O'F^3(YM0_J3. '5&!;1VGU7#7S<OKG_3Q$D ?S%X$\$_@T?NN
M8$OGL;):?SMB#EOB9#74^W 8WF.T1CBY\$Y? IK9!]>W-"H*A-%M, E#*K"1
MN*:1^@!V1$>V>4:JX]X'47@ Z\0;'4[G%PAC]$(NTR$SQ<,Y))I R'VY7B 7
M-4>S(Y*S32&I28@^2$S1H'H;AO&!K:.LL1TQI-K* 6[Q[ ,[[V/L+AWF=_N,
MD!=6OC"K#V!'=&NK9X$R[AU?G5*=Y3:X07@UG?\#!E45OH8#=LIKW::QAK3H
M2+</9^@W)_!\<!-'!.-'^H"+"Z2N(M6>G7)3HY&K$M+:GXY/9GR@E59IV5AZ
M:/"8Q&_7*4LT&I\D*!HJE'L1AP30,+Q$JZ?4+UBM2N[9R6&5W&S047[48ZF0
MRZ.8>E%<26];E"0>B-*05G$'2ROGEK*PJ/B(\;-4S=W+:>+!7ZT@EVP$6^);
MR\166GQ+AN# Y&* *'W1Y]2B0%A-C.<BK:>^S@K<DZOTRG%!'-&R'.'%V^>W
MDU48 >PYJZ\@6@+L$_5-7GRG\BA6!,)6%N-\?9[**%NZELL.IP-ELK*.D1O!
MDJA8)3S%@;"2,]R6V-<;!^+OCA_3ZP(5;QK !;WT19XL%!/S@Z?4^UH7PZK,
MV(J(]L' F+D[R07P-B#7KD/NEK2U+B*UQC+E(J;;P) 9I=-\0S+S[TOH+@]E
MZI:<-1?@WH'<=5=K&.N"3ZLMP5HXZ^8GC<Z#P8+ 4P!A'];L1_XN6F,0Z^)0
MJ_&R!L9=K<S<RV-3G/F04_<1^8+\2X_O25@\ 1"U.P.<SU:0K=L6)[$NWK7>
MJFZ1(MK?Q$CT *V"TOX<UL7$5I.3]@G214![AN/$_5<,0T;U70"G*+"]I)-U
M$:[5&*F H=5;/1$EBCP!=T%.,&YT?OM;O]JDUL78=G@4J%'(YJ.AKF#IG].^
M(.#NSHZ.Y4KKFT7A4FS.D;2S+W*XQFW_ "OM-\/BA$2.'D$4^6F\RG<B>L"[
M7JU]M '98[7<NV&=8>R+\*UX/:R#M/9'V3P/)N/)5U)98_LB:ZLQ1X*:(6O+
M/<#TE3YGP;7.5K"XE UD7Y!L*V:7,K0-&]&^0)^L>!3P,^\K=+8OV+55JUD>
M5;NN4-_6A-3N$H+G= N_@3B,MO VORZ53F!?[*O.NU$I.72+1WY'$;G*:@A%
M*\/:%SA;311:(8)5%^$:DM#N^/8%[FJ\X!J7C89[V2-P4>#I/#P.9NA4/HQ;
MULKI8>7QH2 7[8S;:2B+!G-8.U2P^P11$(:6)^A4*MJUDND@1R\LHOS[5%I5
M(*0IP=-YSD=U)<N_KS=8IU+3KJ6N*>I]D) <T!X!NF:H9 OC=2HGNB+N:F/?
M!U&IIF,)):3J,)T*1KLFR?I(]T$>KHFL1YLM$ND&B&6)+N(>G7*Y7<NE$GZ&
M+,Q?G)]P%:]V%2)$5;.J]>^46QJ,C=6P[<-BY&TP-.LF$\GMMY_)L1,I%$]1
M'ZA386C7W-@$[3Y(Q5YIQ:T^,HF^ (?2BJ)$E=5ZLM+6\)U*4+O6R?:)T95Q
MDNJ?[A*$-PC3> .R'1:D/X7G-HE;O. _(24S3;8S?J>BH=$PV0XU^K#GY.Y
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MAKAV1_P.)D TS4:>^+I#];AL63/$AR@+V^N;:8NRL&!+OVQI/Z\\3H_KJC7
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MFUYNB'FJMK%KY@Z]N$$7Q_BKP/:LO.)_KJ+G\*WI$EW=<B$S\E2ZQOE8-%O
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M==E.K'8ZVBV+=G=-M\CU[]'/GZHDM1DDOT0]AVHLCIU%0([<75N;2%GA.K6
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MB1BH_6#4W)K+7%L6"9=-"0$O N^C$_U&(7SZYNN>>VOU\S2M#MBMK4O6VIY
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M</>VSQ%.%P6< #Y"&^KCG-;N2SG4T1-B<!89D5H?KSV4A7ZD,8U>2V]ZTK(
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MMAO  /RQ+UBH/N\IQ>DBPZP9E'?9H"[T&%8\&>'<#@2L%AH+1*<NC71"D8K
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ME),S @,GPK1IQ@T*I,.@RH<V+2T+^.YV>X=%P+=X)Y ?-DC?U<@FM,<(2X?
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M[I(09X3F6@)I^A-="C*-$6WR*^>3YW38,&P.[95QK;PI:WI^N#R$&U=7V]P
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M>>L$6;H=I:9-4,8.(<:T5T68T60Q Y YX88:Z.?2IGJ7\@#9F?:""[$EYWQ
MB<>,$[D_C]/:"0EG)L_P--/-X/Q:?*2[-,BG=$@Q&Z[/KX^;_(PGU\<KC<D[
M[@&"[Q=_CPOX+\,H"M_XSW<5QDE\Y>Q9XO@LIO6H9+T>V(&Z4]IZP@M%<\S
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M V\LV:8W#CGO<18P&#L[6A+A^S/R[N5[SAIW3TH*D-4FH,@H5#?:''PG\H_
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M\E^<W?Z_DY0=(O@A!4/DW>7'#[??V\4"6RK2E]^L\:L%$_L>CH"EUU6K]>>
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M'1'C7"_9M>+/\U[(,:Z?#(/?R'%*A $IR%THDSZ0]$>)\W2$D,#&(0E$7_]
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MYM%6EUKF"YE$J0]<CLM5&,1)!.]0X2[P(0HW_&?H\F(Z.N'$V7XRUY[>M?3
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M8J[P\:#8$R]FP)T<#^)R"HW73-Y..3VKMKS_9-E8&3L%B1E# AR)8'F6Q>
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M7F$N/93'*\M_&\4WWUB2\E\(UKLH\,]+/PZE@1CNAEJDB+!Z$D .?8/5L0&
M8BN3*BED%*?$L!R[V392@8W L8J.XBFCC"LILW40]UDW3&7'3R3#Q/OLLH1B
M F/K-O;VE#SPW^Z]-3VF;&WT1<JZ+/-E'OHN-S(43A:A_Y@<KVG ^%33\*;*
M<%*(47:D?7*P'4@'.>:.U6J*0R1 VL>GGXF?L[,+L:YL4DQ'U;.DTGH:_JC8
MRXO-W$R%!/9!UY6IGLX&S/WJ[N%L@9[;R&^RT9BC]"!*1$+ L#R@?MT1 ^P
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MQ>G1"^2EL-I#P+X4<(+F"&L4I_2]NB,/H0<J,_C$M_K<3PS<X76?_"[@(1>
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M6A^Y[*2"+^/"@"[&7*KT<N)%/7[C>'#2K6EP84SE\<V^N*+9&3N6]+'!:1W
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MTY3'[[K)- :"ZKLP26/AP\DRSO+Q$K%'Z?-?\)]P,6&15 RSBN"XE\9/? U
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M@A[6]%?6P2+]'$"]8!,G]H1>D1^CNX LF1$T<*;1;SA:7,=A1%7!H#;3S$\
M"!M+; -&-VL3GX3+JN=XN72"=[I,5K. BCN[_]*]);7<IGB@N)B2N8__1*Y=
M3C::$5Q&9VOIRO%8P*_)=:SS-?@,RM_C/8_%=2-W0JC&[V#F"J5Z/5]?E*KQ
MBX?GR::U'VXVFQIDUH?TH&2A6-89N?LAN&QY1AX=;TXW'MHS"O!+S 2:Q1-9
MW@75O@V7>4\H1$XP73 *Z'[M$:ZF/MWLAWW*7X?+P"^(63@\2L&ENZ3["T4!
MW5!>T7X8J/QUN Q,5=I]<4S\.;@L^A+0:V3(U/LOY!4%/D_B2:,NJ.B?\1)[
M3G!%7&P=;W5F I>QW".1(L*?)V9\R_"3?;%E)ZDI*Y'*D"V3:MP&I#5VR\1O
M6USH'!\0_5Q.;S; !IVOM,R0:R<(WID:MV0&JW \L\ .]6^TS(QT@IM;^[V_
MWK[R!B@#/-'^%(A,FMKV4.% +>?5U"6H; @H639U:9*.!37GIBZQ6F.W%_@T
MIIKF*T9O='[I?8?9<H(_:M.M.FQ[)-\O5\Z4V6!8Q-/SBIX0S6B5C-<>D7?$
M\\C;V'^,7SP\'<]F** '9#-"*\9LC]C+Z"O%%HK,D"D<K45I!LX274[IOY.:
M 0WE*!JM/0)O?Z!@BND^F2ZC\8HK)]]]%P6_AF3%]'VNY,Z=Z3N]!,PI"<V8
MT.B+,"(]T[-EH^(QW6>G55TV-?X>#"8]!IAP@>:,H./9KSB(8L?CS>E%>K+
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M[L<AGQJ[@",>)8"YT9+IH@:9H/8=",6W:IO,1>-T+AF[+@?,?+1S[/KJ1'&
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M?O#WX0>J8_'*M??+54!>DS<ZJ_P*XC[P0%!':J7.!4VBVW8_R3P-]%CU-FO
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M7JK#5EAD(2NSOK+=<L;'Q?GIV5F74",7K3320IT=%M2T#4).K2!$V]^MTW_
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M#\@)I3B0-!\2$G39T+3:@&$LV(QS0)0DREDN:-^]7)(@PB'_,>60.'2ALNM
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M2U!"4N9OA5PDI%DM8?,%T?7NWR&7%6/YFM1A>1_/;MUXFEGLLF??Q)$=VH.
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M#TQAYC])U5'EW@<HY:J7-N-:VT96B\H\CXUC"=#;F@MC.2'N&RL4OJOCZ0\
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M'R.641.-'-\=H>QCAW0.:SX!H8#5\SKD0T#9"1HG>-0@\Y#IT23$'-JI40,
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M@88LNJ8S_)+%L5XSFTMUOMISF0JNU+&#HFY(G-D:Q!,2.5Y>VO9,+ E'<L^
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M."'6@4G/"PK+:V>%V0,2U::,BGY0MH?**9=9172[0]D^M.6Z50&H/K&2ZQ-
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M+4?:J\>@:L(!RRDS@##U&) I0BZOT<0,=YE;0'R$"7L, DMZU!MRU0H+%0$
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M&]7KNDT[63$T;T(F"^1?+S":W?Y TYC9 ,>S&9ZB0)*^IC=$;Q%A@@]F_")
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MM/#:*DC+W3[J5UX<49Z>=AB4<JB4 ;,.>PY5V"%481\P6,TP[E"%O=TJ[ <
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M?$3BL%1D0G-===<B_B]:BY/6<ETUH<U"P .4C9ZS9;/)B0&BTJ5KP*A-DX6
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M:ALZT!"+(WL\R_,N$^FR?>!T_DAO,6;1%3M<]P$6=Q[&VSG"/SP<Q-F1]+^
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MUT''$P3NLE)EL%XSRX#H5CGR>('-IXOQ^$\O3#U.]1)FJ+/D&+WFB3Z)C5;
MLL@N[>]R-&]EJPU[S1-)L32YSL+S[S[O/4R3V,=/ &?W;N5VE]=OWE9WE_F
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MQ6A=,PU7VSBK42%!<TUVYL!R[]I[[[).RH4@M )%T^&'99=8SWKMW09ZM>(
MBU2J*-AW[?U/B)/4"S.!XB>,%MA;3>JB&[G-[5.[JI8J$Y.LS%U'1)B,B N]
M.#Y\2G?>&B;,RPD"/>RCB\DX."D4-!V^6C;K,#%HF&UJ^MC''SDE"]/$SNG$
M(%&F.("1A[<[@]O $%;CGE!#: 92D-3A^<?"]"LVT,O@S*41(J,EO65CPGD.
M5R)XZ69[/$V3./$B&OVXK]><P4!>F%:YS=HL44@DB_,;%DR?K(9Q>\Z[>G)4
M/;FF\+(JEPLW%=DQFT !UD>40!\\976.'Q NE'*9SL<+#%B9+5J/5P;Q@].D
MTXZ3T2HZ5T;)=D<03<.$%O,&)^72Q3M>Z","B-'L)V9YDAOI+XC\ZAGX &Z.
MJ4U$C!"K_X4U$K@8"-763AXZG9/O(,O@D7KA]#6$"U:&NOK&0Z*%' A&E]86
M)?RZ0ZL53';^6R\ M]O=2H_S#=5X)>7&&0CQ].)C(![=2DY^ W"Q)*B,-P![
M"Y#M1)XP63&^>_/V(Y>!M;T&QS=Y- R$P1O8Q\'5:TH>0#^D#+<-K387<S9I
MG,8#(8,"" ;"Y[5S8!+Y: 5>O)_C*)@A'WKA#/@I?<07Z+W",+.J='7'2/(F
M/\"0N-(>& .!^-KY<_^3UJ8$1!*TB.!_04"]79QYF$4?F?YED#X2D#XXRY[6
MN)B(\+=R??.$T1KAG;MK^B.BMUW@>D*C+D&<3*)Q'-./+^%GJ!0=8"#TTP2,
MB2L(5O+O&:QWT3OQ='Z+,$8_8+2(LQ-5.(=DS1@_P,B+?/+;,5'/!E)E<,FH
M--K@F*D/)5TW*WC9R"W*!54^KYK$<7KB":UO/#B:"8.@ZXI&:+&=>TJQO_2R
M*)'/" 6QM%-+=(#!T:P5,";NCICV-.P7MY/H >'5=/Y/&,EN&UH-.!""&0+*
MQ!474]O2^ 7][D5!"![2A( [H\5(?5 ;C"#6LX3,]1N"S(VS%&J!2,X5.YSL
MO.J].TF>:=4+6AV$3O,L9K#:#8D'PO+G6C?K_#97+>4VC0DN<7R'5J_[2!JY
M4BE$A)-2*?F@H^*HKI1)82'&J8PB/\"_+=I#-;VS>"T4;F^[34J3HECK6W6Q
MW;Q P,2P[I(2KT/_J,)7-8LX4G*[R97*Y746(G)IO/DCE%%]>W-UTS6;I/3/
M(E [V>V[#?N O15X6GIXY?D@36@ZOOCVE\TOXU5,%DN!MWH$R1+@D*S3ZY./
M2HYB'S7::;:RLM4$B":^V%F_M\FR'[82RJL?]F;$"K;IG=;: 6%I_O('#^(_
MO3"EVT[Z4=*P<ACLRQ;G5V$P._9:M&__B%&ORJH9:@.#51>'#-JA/'@&@G@2
MD4W\*:5JV[I+(7FQC5[_T>2<RX_@]ADRB$#?EM!?GGX?$[(6N 5/'F1:&(5A
MW&6*5D3.4AFY;:8Z%-'[343,DF15"/(_LB<IZ4$<)Y >/(S>#M)L@R91G.!T
M%W:"\SBH?5@ ^07YERX#QW%YWD;TJ W@X@W@.@NE[2&.T^\\>%EU<8F7(FNW
M9#3*3MW/<)R<9X'+J@M,-1<K<S3'_E\IC"%]R^,%&MX%R]I.CK-'3?X^W#AJ
M9;3)9T%A)B@LR+J#>?E4_\PJ\E#'Z=@-?GVX/-7&S*NRV?0S'2=S)_!9=9'+
MY/5W+U[R7;W<=F7,WEF0,ER_3TY$9+NN;/%\*65!R#<Q TD2[N-+_R2?$0CN
M5^L0;0&8KKEF3&$8=VFB%1&[+E[Q"BH& =R]5KW-J&_L."/DY#91(^9<GM@G
M@'VJJP7SZ$O"&UL_D.-\T8>)B9(SY_;J?X4AL9DH8F>'$^X\3,X(XM"+RT=R
M^]<_UD25!'^PV<^\#Q#'R0&']@Z&A@<XSC?S6/7B?E+1)O/"/!28J&%8Q_EG
M"J%>W'22<GXHT$_G^([ST#A4Y[F$U>W4/ ,^B@*3<W/E"8Z3\@Q@Y;2TVJ^O
M-$D(D%''N(Y3T!A$.?'L<,(;F: %&*CU 66<KRS+H]#Q%"V"51Z :X?#WVA>
M9*:789_=+J8)FZ;S0JC#I[I\;2J#N4M5 [CDM-1[D<E*8A;@" @<BI=86H\W
M!'KJA"9GJ!UG'6?(V28V"7%I*3?,$-BH 9&<A&T/27J0.O">?+K)]@#/?AK!
M=;?.>3V&0"XYX7,>M3U$&3R/W@Z:2&^/3+*ZA"%GF?K5^PE7Z>J8:I.7<%ZF
MO[O&1@\4.6'L.+4X\SJ*IG3(/[##;S^3E6<BD!=7=* R[-<.,5 S)CD5VYY7
M]&#36:DF<]@)C9.OP*.*H6#1W;D:1?4,/P3B&D0JI[/5YQSYATNWV_X2Q \(
MTSA3,J64/N:]G)/=#:1;+Z;Y([/;O6-,_K3@YE+5.;Z[?#P/5#DA[3C_.(]+
M#^^2G=("31300CK4HU-T!HBN2:MP2Q,A%SJ3Q78<@R0>1P'Y3[I:[WY92J[!
M4+N(:["+]W+W^[$;XCP_1MLS'EWK&MZ1-T8;(CU]L\,TR#S"9K1SEUIR(N>J
MMOKFQ0P2\D>+XV7B9[!7$?DMO7ITJO.&+HZK7T7ZG EVG$^H,.%:G@G7@V8"
M1_J<"5;?I'@$R:?]R[QX/PO3G,P!?8N1RLB]MZPL9/NUO3Y0<CJ9.BOH)KG^
M85H]ECN<1D4X))/OOQ-+OO_W$7WP:$.?/,*'1X]0-/*.#[_DZ!=)_7YESP;P
M[#GZ^V"PBHIB;9W4Q78S[[JA'/U]H I?U2SB2,GM)E?NN\K1;P.;I/3//.-N
M)?LE1S\[);T-U&BGV<HB6A,@;EJ@SI+SVT SO?-9.R"Z3LYO,H0"[7*)1\G.
M.:X6O"\U2AGBFYNK]SW-15;#M_: Z,K\3\VTS0=[M!P]P,GVB=CX9!P%]#Q^
M3<\[U9BH-MP0**D1F3Z4&'BF02#3^1\QD#=L\@.X2R!-6%A54,"@.7L!_C)"
M(5ILJ<<PF!"U1PN899U4GU[;#.HN,PWB8U7] I,W.-LO_<2'& (36Z*AJS"!
M[8N^PC7!_=V'@( %X(9NZOC;V?IN0^"7 @)6%10PG*:8+&OI/W1IN_%"&EJI
M:-3DQQH"^W3!HJFH@>'@N<S#J;AY$.WK+FO:PZ"K5H#MD^'15Z08H]-F*'<)
MJ!T57?G^M?"1%_-U%!60K5"KH"^UH=PEE'94>E$9P*XH0O?XI \4NTH$F/=:
MM)XM)<=QEXEZ(=%6LL#D1'FG:994&:>,VF_]3?;(-FG:(+&K7H')0P/L!8!L
MK+,+R4_>-G/F*!X52 _E+ANUH]*+P@B9C.VF2.5QW.627DAZ4<V@#7DNA&D/
M@[;B [8[P"8!O6PWA][AQ#8_VRC@EUW9KLF/(C.(NZS3B(>V4@.U]#OOE;3/
M" 4_8!@>;Z2-R8<9IV%2_B0E;Z9=B=Y,RY]?O)?FQ2./_$Q?8H3F(S+%7.ZI
MR5Y_NK;'F)W]GEH?S%=142QCI2ZVFY'_ANZI?;BY>G]E.57XJF811TIN-[G2
MV3TU&]@DI7\6@=K)?KFGQKZ690,UVFFVLI'3!(B;%JBS>VHVT$SO?-8."(?O
MJ5E9TJ,/_*MG#(N#.J'19/!ZD/ZW8R>6FU1LC4=;B_AQQ[\(+&C>29OY5W%M
M21X;"O4> N/4@=!UPZTC=^DL?8W!7RD9Y7Y#H[KE?*!OW[RM^D"/ XY -J(K
MKLQ'HM;@/VF6QGF'U7A.EDS/8(TP_=T3(&H+.,[--@/98FKD91!W>DJ,9XLY
M:L\-_AZ@+1PUZR\+"PD)HE?G"!4?PA;ZF%$\BU@ML>D[EQJ\H+P.]O&DI1[%
MJ*'BQ=)2+!GB)/7"+!WO-!N9)JS@NRKKVI??_B-Y^_?6J4[<!RDMJ:X4,A:Z
M@YYI58S:B>#0PCX2F+;S]:)K<A):YH/.9&XR\<5&]M&B7FU<1=?)X^9YPRU*
M$K2:SC/Q&U3.:&NIYNOTR#SZ%I3,30Z\H+48 :H-'=&^D%ANFGKYZ5/N %)R
M3/L(97I]H1LLH[G!--6WG1#I\VINQQ*L('A ^/XGP#Z,"1BS!/G?=TOS*M74
M!G&!6_6ZK^QQ]"!D8..C_7;%J:33-(D3+PH(<B]+C-+%,C]=I87,LC9+%!+)
MXA>T"VX1XYC\N!?:Z0*M#YDR/P$?T[N:D\@$'_6-/CA6&H9.T[3;@]@,HJ<$
MP]>4"IC5CJQ;!Y9;#HETLC!HRI(9RAQV_^/7G>+VY\/_\_]02P,$%     @
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M!L'#9SI\Z?D'SSY8^/S8/^-.FQ$58 C(:R&%8#H_[L^0A"-X_@2\ZEGPYI_
MJ_[U[W\4($C__L< GO!+M$POM#___<L#&^^?)ZE%7T; TE=7__UK_SGB!3;X
MZY]__^.IG@[^_<\_A_\_W6IF2<&__Y'4U2_7"W3PW[\,P9%5$_$L^W<&M;W_
M%_[H/^'')]=(JFOK0O#;M$P07:!N?D=W \[3GZHD 7/W9WA!-[22CBH^/>[&
M&T1(K?K.3@P\%OX3J8-G+1[#^<S^5;XT<=?LHCGCU&7+62Q6?'UIK__Z90I&
M].M _4WL2./55%<4] D0'-*4JJ&U_.N7*OWW+U;DE9K=!M5M:<*ULBVS2^)F
MN:CT>2S'8W_]BR 8'I+X/_^</.)MG[BZ]Q<OCUP+WW&?'WC@V667HZ9MU' *
MZ^RBP&X:99G'\M$#1[_Q@T_;"W_!DDZ?EYVVAK*NY[<D0\@,+B),N4JL>:P0
M/6]M<M>G)<T0U $1/J\CZ U3 IL6")Z?=)$5A7*^EJUQN!L,!&+:E9U:^*3%
MZ$G1D-I%M(3A^%V?N!P*5]H)6!?DYR==UT5]772KLH;D\JU,4VI+,EGFL5+T
MI'-!=\&W'A*+4!0^&+I[S)=7S]:/'PBF#,H;U3UZKV)YGF70\]UG'6#,@'/T
M*1M:%9>>,XK@@,C#2STAB,93=ISH^NA/=W?#R(/S;<N46> 8C=!JAKI:@9XN
MF/M[AMZ29R.;1,]#U:DK5?(%_>6KA**"><5W0T/JAC\X#T,6IVQ*N[<)RPC'
M+:J"OO]@?TN/ZBSZ6&:2UT:NX[+VJ+E<\_V#_*/;_FZ$(]D]_"X$"V]D ]/=
MR>MH!)7@Y9+#^-:"(^W^,P2N%T:'3]QX4F%]9_GX_HQJKX9,CM&6"[D^1RN.
M5*S)?_W;P_Z$%O@)R/#8Z$(%-<.6@([F'0Q,QYME(T>>ZB(<?7@E/:\*07C7
MX5JP"4$7?3VTYZ%THZ<4Y/")&,\2M5XH)A ^>A@;N^!$ZKP[=T<MM45J@1AD
MMX-Y%^M6^Y'4T>IWQ%YX$CL6B?WY[_L*/?ID)US:!M%3F?*I;(WJ:%9JZLT
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M0^%U%O]DSZT5<,QH4)0CG+3<4< Q!+,&). (>D<U5==S GI.2KZXNVW9E ;
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M-Z#+A1XW KI2S"$8[<Y@.#<Q$N!>IE;,.?0BGPA*)\%70U:G+/M:+JL#!M5
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M$%1?G$$5K(!N[38).T7KNK[A"]-254:-H#A8KOT-1<.\[Q'D:'VQN.])/!Z
MS?P@8,\DU:;34)56T<NC+3DOYJ;%I=_80M<M'R^4WBVIQJY<[\%X+!^!$WW
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MA;D_0=\/CG!E@6%;CN $+Z<<<J;O HD5-FTKDG$HH.=W" =(ZIL9 =81)#
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M$*\D_4F#>36E?5:+_V[>P'6KY*HLUP&I#L8U%5O-^MDN=/83AKSAQVO8+Q!
MCY9>A2\RV.55T+*T$DP12#W?$17AJ+ R"CT/Z4?;A0MFU!6HNI'H]RC!AH-J
M/EN@53*_J$O--MLO- ;04?ZB M.W!' S'&$(AEZ\J"F\]!;3>MB)*3E>PQ>*
MP;;,<# N/8\Z [S@]6$Y@JUZ@CX +G!6AY!LJA0[OF\4<<[(K?Q22]2E*7S;
M5!Z?%'-NE"=GR9P9Y@TA<;%IP7Y@IO<S2+ .$%S?"78MT8<2XS1 \D727/BH
M6MGFY<G JAM5B'.LSR%Q;I@)]39_#(F&Z_I VI-HCPB\@4N;:6U5( -1S2#(
MB!G1!>@\RE<0<6:4*2"^X#; VIH8<F?+H_^?O?=N3EW9]D7_?Y]"-?<]^ZQ5
MSWA)9.:\9]?#((*))AC;MVY10FI 1@$4"/[TKT>W)$2RL0VV;.N<VFL:D%KJ
M[M^(/4(D=YVNE+3!+#4,G"8:6+'QJ9!(][FXAXGUA[=F/MW*AF4+"N6MI'6;
MH)8=F(BI<L*0A$R#M;7E:/QHKW+H/L#:Q2LSA)Z9^CFADXYP\>.@LW'I":$3
M]4/G[15(GH/.?'S;[#WPR0(?64G1?J,T'3\F \QAO@!THL=#)WHVZ+!^Z+!G
M@4YOH4\KU?MQ=J+>Q=CR>)8NB7R U94O !WV>.BP)X?.<]U.BOH<&1I,BE2&
M\H<$0J553:HA1=8DH8C?P2SH-OX3QKQ21T/7K=VM&,KM,'8S2<X>BT*JOZR4
ME<"9.]1QO6>RKE?MN-E^3XWF127WJ%#[D[(BV1DT4KM::OE:,M)-WES9Q5%)
M25SQ@4/7J0+G/YCIR2&HCPB]/PNN1]7AH)VL%C-LLJTO$\E^5+6#7,7VW8'T
M(;1/#NWMBN!!X-<]<9(;QN+-AV[QZ4F(F_7'1:$68(LUY-<!JQK^.E!_&+^.
MJR:GRRF)Y5>+1OJA/A@UY\&+.@_Y=8"AS67\T,:?_#YB"XUT0X9E;"'2BZ")
M7Q!_7L,S+R-+%8R2/ITZF+3RHMT:-AY*7=E,3I=\/Q*_>0RPB^?Y63KHV)GF
MN2#!98Z&Q'8:PX><*QP!B99L6<@PQX)MMI XMDQ!6PA(L5Q..(RN>O42VQKS
MN<DR,I7';2MW%V!'SE$ >6'2WUKC>Q]<<@KFN'BZ9MMP3R9?**V6U2Q=6UTI
M@B8Z-[0T>WR=K7;O^%ZR\?A4*.<3J/G5><[NPKQ=++Y4H&QG24/ '@1L3<#/
M582";LE:34'B$YJX<>S-TG0EIZ^2DT:AU1VS8F[5>@BPF7$4# ].-X3(89YF
M&PC_VS1DB)<LJH.QZV#)F7%9>%#8[DJ8=(9-N]R0K[\\HSHPVV\-D,,6X4<)
MO9MZ8EXS)]=/;/MQ5IU'K'1T=AM@X^\'"[T V'GO!.QAH2=(QM6X=W\E=BO-
M^%)))!_NY[6OKLY_O- + D2>"4/^()X6NY_F;UK=9JH;N1.[]W+$+)>#[-#Z
MP3PM"$'2[P/L2XZ*9>Z6'<23:-'M75U-LG*KV.IJ7UV=_RQ'11#@\CZE/B^C
MN:S)X .\DG4++UY))_7"0./-Z9>5D8.;_MA>YCN9F-G-=>?CB)[(+4J!#JP^
MT@-ZU.Q#I?_] ,JBWG3UD+FZ9V=WD50Y+EVC:NZK6XF?#J @:%A[VV4?CG;+
MZ8)"FC,7=(.?XLU296QFHRG6)R1H)5#6-'V^4<-1R6=K.2V7R["-6&LJE,U1
M;!(\%]1+<6^OGO>W!LVVEG-RT"2U'KL<C^HY5NUD\O'HC1Q_"FB3H2\!FL_5
M=;:ZZ<3\[72>#ZP]'&=*KL;K6A.P+2,+MX(HK@N &/7:,OYDH_:D<55(]-K7
MD[9R%SBC[9A8V[<MP-EP]-I6+:?%$>?'D5/B[JPX6BQ'9;$]-NI\99;0ZFQI
M<)V:?SDV%$P<'<N/V,VJ>D''T48+U*XFX]%,02EK0\5&VM,6OA(#+CY3,JT"
MCYX*9F,TTO)LZ\OI1J=?F.^)N[0OO"GM13=]/.J*A>JXV4QD>]U<]K$PK]0F
MYE/PRF-]']1!!-6178KII>>0FES*S^WPI_-)S7(_F;E+YH>92;*#8F:O^9@<
M+P+G;?IZ4I,6F#T.1ZES2<WSX.A5_*LW3D_9VTJYPS9B]=&MM*Q$AXUOBJ]
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MEOML,.>.;\*W=>GW@#F-G8.%]Z5P;B)]>5>)M<V4W./;MW>+PN!1*MY7 ^<
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M?^J[;[YL3S#'F+JP.G7!Y"]SETR43<0S'_R"I\>NCQ>^]<T3EVO&[O(6WS?
M3<C'-?OD+KD,4O>PV$V)XWNW@2!.1@9$=D1$7=&-WRY/<D<$_K<S''GT91(_
MB@X<Q:_Z7PZ7PU)#0][R,H)MZ?!,*B'H?S][3S^,_<3?21N%1JO&$%+ 2@M>
M5Z)+R2+C>'M:(-7?>-C$: (XWR0D_\[KH@WJ)7C&?A&Q6Q<,H[\:V/6[.Z.3
MZ38FR<:=%)5,N7_SPAM'V4B!TN[&&Y^2EC>6[R\XC64:&OJ;/,$BBHJ+;2IU
M,:X586JBW^X?+E!96'X+JX&6Y-[BT$EZ+?7I<_[Q7S1'!G$1.[M*-AA3Q)_%
M&-MH$8P?$;2IA2%,_QP:[[1K\0QS^+4-G2'H=-;__)+Q2YM(Q/NF*P-!471K
MH"]_G0E9+3223:=S,#:$+.)3]4&MO-#FN6&5O9^TI\,[K3W.52+$=[-#P^Y"
MM=%(1TRWS+17*H;>?Q,*SJ3B\34%[P'@/Y;DW\A/VY+G**C%%\OM3BO;P6*:
M:AHUOMYAFMU6NYO%?W0:#);OY%<N^M?@;Z;18OX:_?WO?W%)]D^CP'1*/.-3
M #SAG\UU&/PSEXG%/>%*UN,?((%_".4$01]HM+S7"ZDYD-2<U30;"AI"D0<?
M$=\KO4>KG'JL=-M&NJQ7[^)3;I%]"Q$GOSP19^OU;K;*M/AFHW6 =F- N%SB
M+^EOYCBJ9<Y.MAON#@)S0@VR!N=NOR/DFRT_ _$U)(_09'2#L<:(&<HFIC5F
MA02#07A<:9]ZXT/U;PFD!1YO+ DKN MIYX(U+5;"T_-W'ZX?4L5D19JQ:=Z^
M'BT>BS5PIBY>F&\>B?0(,L9=,/ B9U:*0H[[G3ENQQ T:H/M<%W+:-S:7/.A
MU"U.;1[U[UJ+0>*'JDY8:ZJWRX2]GH'S#HQ_CN-QEK=;##VE9X:&KCJ#'+R?
MD(&$1)V"9LL<W_X5D@!_V]#9&O[:^9FZ=(F7D6POZ(:?]=\7YNV^GJ7_V!4Z
M<ITN0[W]*TB1>%"E2'N,% 4*E@O::D>.3+*29D_O)VHW:LR>AE):5LK9-VGO
M09,C^_?C.2BW2WRU"M[R9K9^_RFB!%10.&]#4%2/,=#,EB& %8L7V61,V$>,
M$;*1^$?8R1_..U_)93^1AZZC![$MA+FD9H.9\)LYJX>7)R&'!?R\.GF<W[HQ
M%GSTOGHG\ZIEWER-S)&4K]ULT?T9T<.R7"26B<>3SS&-]^],\@CI=OX=</V@
MF@41ZKY=:)3:MU="<=[ED]7>77PQC@WDQDN^]IQMH%M!9.J7MY>?;%X&X*SE
MB-?\BU\*HD5V!9CK>C<8 7/5*1(AMEAB9(V1+9,1QX*!A_C[ Q'XK'&#+8OG
M?25$DT#22#"FACX7(1_"6)W>7T*A7-8P04]UGT\_1Q^8TR4_LJ-+.VYVZSUK
M@JZ:\532'D:7S>P+<_6%VX? /@;8U[8AFY(L$J,30UOV[PZ#[5+=& F:_$0^
MGPK1QZS?^7EJ5I(,9)K./U4L<3@__(R1-HA-(NFN6E;NS>3DNEAX$7X% [,!
M_+[C2$U&D*9@1-J83Y@FPKK>7D ^-]K%^4]P-U:BJ9N6H#S(TRU*O&_T9N-%
M1H]UDP_]B3GCBA-C,7IA*5)1-I7\9!K\L)7+X3\;1D=?:+YE0\-X/=&?2ZEN
MI"^56H_W.6ER]]*R=?[]KV@B^F< 26?:ZQ'SP=$OSTL41Y# FIU+F+CK3Y_D
M6_QBO2F8BUPKW8T^:OWK1:Z4O!Z_M/A%A">@K0+L<?]_XQDFQ:8X)I-.QQ@V
M,,%.@9)I#BA G$VQ\2O*4T%AT!*)-L0@X:^'LHC,KR',,-3[&U!'KL""H!N2
M@0>7K-,4-0MKJDZ"723>[C3JU;LD*Z>N[FZ>[I:M_M4&%3G7-Y%AZIJ&E"WK
MXBEC)1.MIWF;5[M5]C;:BEW'\B]9%UD%+04PXI@'-(9_ TQ/N;&,A@SO8:-!
ML&%\*AL-$#R.491XL=1O%FZN)19=3>:1U$WN=A5Y"2,!4Y0^<AD/:5D3H1)7
M[U6SW14JJ:Z1R*-.37QI';^VEO61R[Y71:NG2S8;J=3[O&"-N]G[=,\J\2^M
M>:BB??SF[>AW2727+W7T3(U-]O.W]])J.$L\O!1;$0S]+K#TLJT,\*H@*\X#
M?$O?'?&]5H.;7?&H$7^4A5QB)K OJ=:R-M3_/]$VT%P0+T5=#;TSQVBRH(Y=
M,!VDH.E8U_"?? 3VA,'JU3^ZP10$T935]6$ ?,_XM%_GR(YQ-I:A._N1BF]
MUGGCI=I8V3-D"^L=C$$<N<A $KBZ+)T9(/]W4]LP;?#RXE_P74":]"R(QL_B
M%8:HC:QH_3[7N[Y_ 9UTN*3$QA)Q2>BC=#+6CP_2F?X@,1CT4QPKBB@1&XAL
MW$F'HW=TQ/[M,IM<36M/HTFN,6S?WE4S9L=8]-D^NWUEY[$XK%50]*G;*W33
M0EYY?)K.X,KH]I5/1JZ;[UV5E&XR)5?0[2*KYM4LOG+GZ?U>ME"^7DGF1'TH
ML8O^:'#?KBR ,6Y?F3:6/:.3[$?XZ*1S/VY.&T8\>8.O=,<\+JQ@R^7NY+%
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M82(N]8?1= )3,DKV,T(\U8\.,D(ZD1K$A%1F9QMB%?[>UVVDCTD^G<E\ZA:
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M6ZL%HNE]JPE6I,F8.M:3(,(8OP:\BX8D$K1,B\/  VB*O1=T3$*@82S3"?#
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M<R-N2!%->F:N+=NAV _42-;.7H^EU<C6QPUT=S4;'C30Q@NI]J_?RI.955E
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M$,?04[0T&-Q8?U9:K2#%,@W=2WIEL@0CSY.V>Y_G1);L7?5C48,B9@_Z$?A
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MO;*6MNH3=23^-%ZE():!==S2L$G9;2L"A=CW A8<?G>C=_1HO4\^0("#45G
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M?%;&MN  GD=DEB;#I(4J5-<*R<XHVL]4O"AK^6L-J/:[GLN/]*.OAK8Y.?^
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MP[19=C" HG[_-7_@P3_S]32]1VL78S,E6Z25)?6=JNP.44_$AQHUC>X5)2A
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MCL>C]%/>HRF^RU#FFT/<L""M?DAR@#3M8-,T]W/]"'#8\P,L_F$!+"Z Q0<
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M!T'H4;MH,<W%-!^=7Q6K[T@*_2L&<FJE\ZW_((NXK-XQ[2>++/E/?_7VW3K
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M+ZA-$RM#\9<<+CQ4!LU,/D_;-4RRU[E[JKTN!KP8\+_"N89Y4IY@GN)*;>\
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M,V!*LDB1,)]0-1T+(V=IT Q:!KWW0/W%Y(T)AI4B4SK81:NG4"*!7Q1D^C0
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MFE]5Z7W6$V7R8RD?P#W&NV=L"'$;7=J7N$ID9Z1DE*[(FD8*>50.,U,69DC
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M*%H1LK<G$SCXX4IY=\T0%N&TBFDDMM>#"@-,/[U#%^, ,NK(8LZI*>+BCZW
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MR*QNS9]Y;,2%J2UO@Y$39S$D"+=]"@G]Y"#9F](WBA -+^SZ2[O0SK]4*L[
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MO&I9EDD7()?0 4)6K<Q]SQJV])HB)-JP7PE;?CF$:&SGB)D]04$]Q.R<X!D
M$B>@ VM<F */8=TORX["&FW5R7ZU6+45([Q;:E($)Y;=.*<&R;LP)37SL97(
MOCJ5R$XELC^E1#9O_VFO.AH8[X-ULVA^&$UPH)3-*O('>,/+G1D*(/)*;&P\
M<2B@[V$Y*)ZYO,AYN(,%VK2'Z@\$8'SUX.LO;_*88-GI;%,U/YSUG'4D3Y7+
M*^@EU^Z? UNU0M 8>LJPBJ.XLBA]4.\57X!UG?<;.W[1EI/#=%)(JI-33SHD
M)-%26SMHXI54 DZ0-AF/6:<<NXEQR^F8LW2D"FM1HY<IJ@VM63=I]2#K0T(>
MP-.4[=1!:(1HW<#UZF?-\PCQA$L[5#CN^WUW53/_0MY/AL^[BC"OFIE18BJJ
MP44-14=QHD^WJBG$V[C^N541Z;,$E5>5YL1>!VM<-=I!%J[WXI5<\O[6<XIL
M)82I@.ITB8ABK;<##OS/S<MY9[ \^A1O!F,;4_EB<0$=I+#P:\O]6L29A41%
M$'"\;F,4 4JGE5 ?L&/BE'!4"@?"3WM:-!O1J>9>J.R.X$Y"5U6B%T\791'@
M0EPGE3,"<CO*6":T'*9[&=D^:*:7O.*6]R2P\P'TR4>R#VQT%S/4+,[FX8'T
MET3\43""-_%V< CF):B%G,K6MCFG="AM#A.MUJYWWK'=0?V5?%2L"V'XD-Y3
M3Q0SV_U\7_'_3WL_0#770D74IQ16V<:84K$J3+16M;UFVLY4NNJM7C*7C.=D
M).T4"]>I!B_*E;W^>YIR$"W1R5HF;E#DBIK3B\O[WL_K-A>6H)BJ7$*1D9*V
MS8J:$6JU>,;-!+NN# "B7 ?Q\T;:BXO,X/.<LA4J89&\EW"3IL_,_$]#CB=
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M!H]]IWS:KX:?\>W;(@J>Z[T)&%3!K9@PY<0J<*(&$ZD=KS%K Y!:6*UBCX_
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M-:XQKP,#[Z&F[ RM%"+B$+=(<4#LZCF]Z(S3!=ZF]M1.]QV&.4I+9G<]+ZW
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M:,N;FCJ]0:X1]IR(C5)G8"%?$)H+D.]4M3Q.)4H?*L#L>8[Q327;WP?K5O:
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M<@7Z5S L7E6Q7GICS5NXOX$-!UU^W5^T'>^_PD-V0H >XK96JJ(B4:8$ZTR
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MQ/M2B+=D$I@<$/#3"HBF-*YZ>MR!V]5\GHP<3$ZGLU<(IH#P9!?$G;.ZJ 9
MBI<UY]:1\N>L".7=]IR!42EI.L$2H]M+$P.E[0#M.>OV"<N+",HC ]\+50([
M<3 /-8(.3N[I39A3 :^4VM,VK*]GS+*B1,VK.LIS;,D#6W5E/Z#U;>)$P69.
M+46AI3)^V87)"=[J@(J0 >_E*D5.&1-9 XK*5AONA_W*R!]9U)"/TS2MSJQ&
MLP4_RI_C<BZE'OY9[N3H8%J/Z9I#%MIU9L]F6(H8Z6PE2.*;IBD4*/4HP416
MR9UC-$DJ5;%F(@T 97"H2HWRA@.-3G1YJ;(AH0GLAA5#$7N[]X=D&87.B6<)
M&3Q72>C,5PF/&&9VQW+!2-07DMW3%U3S^5^22]^')^_70/$?K/[PUFJ+?$J)
MV.)2#U]?K!\K+]Z4G=?$_,VU!$MFVF)(2^13"7SG\+U;ROX9V597."-<Y [\
M/.=':LGJKG/Z&^<*:J(Q$7NVWB-"9>:X)!.P;A-!Z!LXY([-7W'$/SA*4#E*
MW19Y ;$K"?*Y+-''@49D-7&^1)44O7%AA(J;J<7WP: [7OFCQX)"[C5GL5F)
M9427(4$E9QL!#QVE,J/'>U\&:'S,)86+6QUNWLLE4^N)#U&W@"F*;F!2?E"+
MP,09^,_S@\6U>I9G*)-ID78=0W#WVD%_C !O%B-*3OQ F3UBNB#D%1^.Y$FR
M:PZ2KAT,\TU.=780#DBM2I207-X.M/.#&YF'SO0T)@DOX4G-!9%JREWLW N@
M9RU^601B$(\4E!\>+%ZU8=&1PU$LJO"-=AL\(0?NI%/"5?IXT>MYS*BR)2S4
MQ(P7:L/&[T(H&<,<[N/\^L<Q'BFV4W1L_$Q$515#T/F2>P'B7Y7!U=_WWJT%
MT2$9E&J3E"'9*';G]0#;?%X-UW278/7/,+5L=ZD8I_]VRXI>H3Z[^,3\/DY>
MXEV\Q%<?IV.X^#?RT3[*NNI7I[KJJ:[ZI]15WPTC_/ORDMIF&(:SWA#>/&[5
M\CS8GK91^P(H;C@<I,5CR2#M:33T/#G\'^Q4W\'-?&5I7O%]T2/5:Z44P94Y
MU@T>&EW\89O55ZJCUKIJ0GYR)D[KJ-R094O3;B;J-+L4G:REC4)M(A)=_F75
MC;6C5?Z5]N95V,MSQPF_QK%_;=7(%85I71(Z$%Q-N@U\=5XRF(*$LX;S^64
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MAK6['GW.TETUFNNIX<?)$JJL^N.'GS\L(@.-Z:<Q=P8Q"K0="9#T^WXG^5E
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M8=#]1 9'1LXPBC3&P33O[(QMVB#7#"AN,IN1!F-!H:HY&0YU[9PZ+Y\>8Z7
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M<C&WPX%H[FH*!0K#:,O5(OV5=#MS_FO.I=21E\^.F4%\FJ<A!?^W(XI:L22
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MFBLE_G+-W=Y!>V%)&*Y%9B#=<%K6"$G!9,CQ@%,)U/K>VN4Q4?5QXS*];E"
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M?)IBSFZ'UGR8\4['#<#%J[(ZJQH3THATC5"H#-RKMW37E2.?OJ UAF_>VK$
M8\8Z15:S3K029<=5W[\*CY2Z8-'QXJWV6!EQQ.=E]XOLMZ[,&6,OQV,?E#>G
MVC5._G,2GC!X W$N1)O$[^"!]NA(JBCF[#?Z2>LN\[/D_2 VVQN<K*F#@WE
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M>WZ>@6529O$TK.R\660K0<F2JP<0D>F&C/SVFDC$:QJ<*J=*VO9]L(B-P/2
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MMI;=]]5J5111U/(2K<^H$:Q=LCQI4LX(9(#MLH/I/9C>H>G-I"1X2KD?XEM
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M"AWISQ@F:S\\2L2,9[E4MBR9E )\*#0O/V?M(ON7][KN31/W'[7&L<_0-^5
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MDFCU)H*53.(WPTB,#!Z-^[%YKSCPD#P(5[":D6 N^09*>98'6S<U[#LF4-+
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MQG=U#QU/1 ]3J+$[FQ<2><3K#+&/OB2SS$]UD4_TTE<2^RRRJF[Z$8ZZ?'Z
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M2]R#,EQD@!E+?LH"9FCS><R-[V) CP/1B\2*>#JY]U]>>+Y$M2)\%LPS&*+
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MHI*5JVMJ(3M]++UZ\J]GT:FCDKDBZ(&_?N41T3[1]QR.GC8D&9X4:;ZM,RJ
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M(EF4,..NV[+?=# L-"[XX[+:E*(.R+J--?41)Z2#QX*F"&$\9Z$KNIM>2Q8
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M>$IWQ8:&BAB=1-2VJS#*(P[7%Q-%15C1S=8HPZ'_0LUKBY[H&BR]*AVO'()
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MM]K6](\ QAD%U;@NLSQLIP_CEO^607Z\E?[[1]\QGSP+G?($;'P>$(\LM*
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M'_QZEYLH@QO(W9$X+.]WL]E"L@E"-JGCR\I/DIBV2"8#967WGEE:'&:'&7=
MI![)G9]_^7[$WO"[ IU%LN!1-Y$,#[[(DR3DP0C<1_1[PSWC:!,W=>BR,'.3
MW)'Y@@N#:WN7RXL9=I[R(,FQ%_YE/AL#)E?$0:ML6M8P^;[?E$(+O)OA;9ZZ
M)34A-1%![CR$^/*PU!,(1N7)KS\D=YCK)*WDJ_HRPB<>PB%!MPY%<Z*E?-F[
M\_I.^$K^Z\V*3MQRB;X[AC/,;BQ3BP POAVABF'/@NL@19(.4X2,PU ^8!8V
M:QHC=4.70L6\&M,3_L+<3C(W\P'K[\F34?+KDQ^HTOGK#T_N[GQ@_#?!99 L
M<^!Q7Q*8K=I*SG@%AV2%,CUT-U@O:<'_8(YOS%IWW[K]">S[7-5F?1:=KX_]
M%?!LX/NH8C'/!*Q,*AV?G9R,[Y^<,+U]F+GZ,<>/W"V:^M\+F^B<.U"7I+7"
M0LJ4TX$KC4]'#T].[*+^REF6TQL&4!]-TZD'F?)M/H+@Y;,G6CX(-A&:((>[
M'$>RCN2M)S'3IK+#'TDV_T-YU?;Y?[\6QK#PCF8@QZ]O?ZGQ3#TY?4Q'Z]EC
M^1?^01JH>75UJ'-V'$]LXN_),8V7I[Y!-Q<>('.,<++XW'Z55ZM^4^VTIH=D
MW,SA%;)S2#I%66,,62,JJ$ CP\+OJHHABA(1>8 ]<AG:'63=*9^N3-"BSJK*
M"6#EW^!1H)2?JL$@^X^FD6KK,1$19K_!,XW8:\P,9\5EF5]RQ9K&"L\N/$>W
MB2OQN*D/N:G]+INEF\$]_)8(,#9AA;&6L# /42<6MZVK0R,""Q$;-[L9=D%:
M#U-.(NK3O44+<R />5R77VM=>I..8:./ NFXP4_&X%UCA^3.)1O]?OR$VRDY
M'"T[I XAQHS"JW+1N,)3?X@/?5?]?7]]<?RYR9S8)^A64FE0.>SWQ*7@X2%T
MH[;N'ABAV1V%0>B7K-ECN1F,#S<:'(KN)1$GP>,+TZ ^K*RBI[?/;"G5AZ?P
MEO**?B#OW!-IZ#H<\UU?C<I 7FUR665T0C%=N ])*X:7""DF;P5=RPRA093!
MRK)N]989*P#INNN*?77KD"]V4=@)_,HWB, =P$5!5/+24ESQ'E"O1BJ.*AY%
MGMBRS>:>L1(6\F56$]>AJ0IR.32B? ZQ:9V]#S>PM(FAI-%ED^Z3249[QPM.
MB^-HG#+>4?;D'$7>ZHA3(N?11_C4@T8I^@-LX0-1A#PGPC*J FD#^L :&L7$
M@YU^ZH@/R3!#K-&VX]OPG=CB\$9%WW6ZU2MSNR2B+ D]4C,";^#*T[9A"1/F
M),WA75.)BA,]M>;HB,$+O\+N/5I/!*P8$2@$W914 +)C&B6V$$WI&AV$U-P)
M9-NH1,6(3A=P$.K K[-C*MXYV%BO7?J.(2O<J-Y6'J\Z\%M9TNG\WPBO];N%
M07EHUP4C0!U>*RZ84VE;B(%L!(\^6#L0T(6SS&SZS@9NP#305'&OV#2J+%)*
ME,[,/)PS6;'(1?6 &C:7F,S$H_<:KCJ$-,>63<]9GW JK60?[/&^S!]G)O>0
MBAHI.>H/XX8UW^_:M<)*N";^ZC=8C#L[%N..Q;@;JVZ=34X^*VG !QQ*E/F@
MVG<&EAXMQRQ#!<Y\Z_/UNXYQCWV@?.8D^2F2PM3TIKKW@2+$'^31N8P#P;Z'
M)C0?!?>&#7BG;&(,KR"=B @8)@8]&T,:#,:+P(Q9P(%=N31O5DS10BF;$E,\
M/H?6D>Q,!0,NX%":,^TU0\U7.RJEB@DCP[34G*3(W>[TU&%<DA^S&NDDL<Z%
M"K^%6FP^YO5%M,P4PS0T!,9#$2DZEY&X;(J@43+;4X132,8!I^=CA%>Y+J/+
M2L\O :-F!=5PHB-L)(TCPNF?PB. 2U.OVF:.A4%ST-O7E/EFEY[LO*SMK=6;
M1U#N)82QQ.BS+#+U]OL'JF<?Q1$D>X9@N,IGLU:!*H8*C"J;N9LO$>BGF@!4
MX^(TI SES^"G#$U/1SQYX:YB]63U*% / *R1T=I-$<+,J$-#M"8/%X:A'D;<
M,B@WSPH3E33D2F YIZR9%M7A.BODV%]S*!X'![6$_!2T>:%0_\2F<"(N)%<W
MNQ@D;)/R;&DQB ESMP1CP@9+9,5X:G1[W\I_,XF27XN2-IY7,$?$0+A=;U9)
M4<Y=![+9%MV1[!C%*IU[WUH@H. #J67"GE(*%&\C9\;IQY*SG3XZG3QZL*__
M$O&7UXOLW7] <H!'V.2W 9L\/;$4:2PE(-# !44ME=F^(]JZ$7U9!X/(7@K.
MI38A@LFX@A6]'1N^S TF=ORY-1K:NK++5?![I&D4&T/!J=ZT%,*)G1/SD'J\
M.)FF!4*6L4-M[9J*:O[2T/CL^?U'VO<@,;\QH2%(P[8X.9+LC6Y5)^.S=).\
MT9K%X9H8.Z43C8/KV%?$-C\MI' 0&I<1O7:ZK4=F>-"+*I1&LK(F8F!// :"
M):7D4]1=9W NZNB4']"07?)!R'>".4=?SI'QLO_!<?GW+-LRDJ1+IVJ4>F88
M]!^&P_\A'P&FQZC6VZMR==G_,:,]%WL>ZN%WKLS4[)UL^MZ[P,27U:;D W[.
MFAT?[$+Z;F0Z]M&[B>ZY(5_!UXP[SB,*]DI:B7I0S:7RE*G>4\Y&,L%J5OM>
M9Z)2=G7X0SQ)6PP=R,8I9_V>]]$1?2+P#UYRB?;+!&0FX3J0S IY9NHFH201
MC[63INZNI,@S%<H*?<GQ:[.;I5F5=1!6%NTH0<G-RO7:53->/<+'B\%U\7D!
M29]DSG:'I0>3GZ*9-'$H'B))T:ZGPL0YI(2T^S$FR:^$"9UF95:(;MJL#AP!
MN)KX7I@/1-YM3E:&?D"+VK"95/LY=TMQ+-=MW]?%04)JY;(E9FC6<V J.<'.
M[7V([Z7$5_=Z-Z,@W:0M-%/K(Y$[O&MT\5/><3 A?#?*[NZX1$0Z.' -(E*O
MVH);./DE"NW,IFUVB$S1L_G707L(-[\MMR 4QR2'ZZYJF"FP^%/#OP&Z&%^C
M;J?CT-T^=2SS=D4J(3.,'BGX3AMC2"D#HNPV_F,.IO048YE$:FROO\TD[ODQ
MB7M,XMZTG_W!^6?NJ/A@'15V1C0/HD@W36T5 CS'D AWO<KC6>J*(2>BIMJ0
M_I)00-.R,N6H9[^\?//ZE\0TPW%2;0"U+TA8+J<;2_8LK1\%I26"\ML&^H?G
M?5LWV#OOX2%85QU[0TA&SC?1A^,LNFUH:__1;7XXD\!N 3/'/>Q,V2CR0H57
M# D/$<SM[63)^FAFTP=GDT?W/SE+<W[O8G+O])BE^5:R-&\-RX6Q!\.B-X$W
MXSS>IO#18 W\#NS)N[35O?]&R5_>IK7W?%@-C8UX1:X3IGS"]8P:!WTZJ[)-
MXPF'>E9C!SN'/,V./J.[7X.H \>\UVSE8GJ,2;+**?O-V <9K]N38?IYQPLY
M7+*)NLFT-+&_E2UKI)NM'FX&^X3&M*@O;9+\XG'!W)G&=5!IGF+)P:@+BQ N
M<^<[LHJTGKG"<%&^"+^7U>B(9C. 1,(%1PEJV%QB<+$F<<30ML2-"7(!RH+$
MT9ZT#3QOA1@F\\@1)HU .BQZ1 X_^$K;^'E&#%\Q4HM39[L(TV2]A<!J+A>S
MC3B:\Y+<#P/F^*EQOXA)5UNB80V\-OTA!YP<]?"OC=@<FH !W&"PF'!"C"6$
MPA'@<L!28RUOR(3]'G<DB<"4) %[,,4QT^RMW3Q#T@'F,&TKB<PBQ6)>QJBO
M!<$FO<*<^QT"SH=Z'1F(9P ]5N^1!1FIK22=S>" ]%V+#-_Q!"MIOH3@MEFM
M:TZ--O@ T>_P;J.D%C4 ^ .C 4SFCM<!+B@%!^'DAB]PM%G[4'=-T"6&4W;O
M+YEZR4PQ:&FHTZ,C@8E^J5"IA)HF#(@;4&'0\\KDZ[5\)X7B@<L+LLH,CDJK
MJG\F*GIQ7P\B^)!/SJNTD!!]_Y;?:,1]<8RXCQ'W32/NAP\F9X>*N%_V^C;5
M2G1B:'5L2T56"RZ*<X&!"J4KA4D51584\,+W)*M1>ZK5&$EP25ZP\KP@_0E<
M)]W4!GLP27[4H[KC+I)?+"7*/</M#M)P]J,UIGC!]#6'L.%VAL1G'TT<K4OO
M4\0^+BXF%_>/\?"W$@\_L?(>PQKAGLJ,-FK7 J21NN;.6+.G#M*(H 8Z;9,8
M7*E^HY<6N>I@G^!B8 D$SSAL+L@/(WNB=!=FE#BBFRB0["2=YIF ?Z;72XYX
M>%NNJB,=K9%OEYOIWM&O.?HU-]8!.9F</?B<?LTGY6!>E_GVSI.[PYU4ATO$
M[&S)U,XU\G$*BI%,<R<9'LRDH&CXB$LF#,M09GW;V<*)FNA6DF&H78JFDIG0
M0Q0ZU =D,1(#42!UBVK*+R1Y0N W8OD[X@:DWAL_?GDPO+!O9.VVJ]Y*Q.C9
M1Y/JZM[X),?KP='Q^H8<KY?@#,VHN!#V&>WTV 2H>+@X*;N<M $/*ESVTB'(
MSTMU1S?X%!\K$MP]"_!7\KT6#@X8ESQ-\^D_9X)??9.]%]PJZRIZ[>)1[RE[
M_-P#[AFYGG]NUVX,6^I=0)B7U10?.ZWK=)N @]8(I1H<E:[2<D&=O/C7RS=/
MR R)_H;1UO#RZ9^[</ A=.Y9P0TLV*H@N3WFIO$V=A'Z"HVD,B:UJ1?1VFAT
MJ/%=<@J2.',PH]H09K/3_D' /\'S>;B=LRT1 8:$?Z<V;NZXA#%CKG4#JZH)
MO<]?%@W7HV3\H$,WJSH4C<]%Z/-6")@04-O"Q%F+M&J7OMBFK<JFH59K-OM;
MU2GUJL4<6^-1-+"7/-4F(/R!ES*IS96$$HQ;CSJ!52I)&+ 8L[(B"QYI"!#P
MSW?!B7"/ - )=2J]W5:]J#,RHOS%6B6S*_K&;_*2.%CC>8/+S!H-#TV-5%!=
M."AL2>I>GONJ.$D^8Q^+YPL)>SEV9HE8=5S8+@4S(F84*PQ-1F]DD;=82\+V
M[SEAC_&GCO80+!8CP,DIKB>>%@<M A$LK]UZ"C/&0'O>];;-:II65>8JKN<V
M%;UZAA*J+UESFCVM0W-T;5YZXV:K HE T1Y*2;BM[9SRY?YHT6XVHB%CUX-,
MKF+\#PDW#9!?T[4(BQA"]ZSD70&&8(PEK:VRJ8 1<PUZM;WEP%19&/3+C"CG
M 3,5\JE>DS=+H&<OD(>Z=%B;,M\;G.Z4J<A: 2ECR9W[0> T&]<"GM<?<)>H
M0).I?Q'!J]*%7[(40*\L_SOU_^/A[8OX<MWNKO<R5ZG9J](X$+45=&"Q%DIK
M6U3PGFP:1D3YS50Z;.(JPX=&4TJ<#!YQ^6V6?^X?TR3'-,F^-,DA2CWH9[QS
MNVS;E:VQN_4F+[>>OR;/X,B2JOS .>ST^_2]I$B+,I;OQ+!B9(\1K<K(-='R
MKK8Y>ILS+F9'$AXU4R?F6ZYC6Y]%_/=M%"$%H\>>]&8#CS1$Z,^/D,FU]>"
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M*G=)_!P><R*?^G_733L7  @#;K!X"D\;!*'V+=J;*,)]:UG;A\>L[3%K>]M
M@"\+-A4&<Q8G=PRUJC#*4"VKAP/NPH!#A6@WI>Z\K%GBG>((:2KLPZ&1*3H"
MZ2,0>&1<14S<R-V4$%)XQ3O40096[$]T<2A'2;I&>4]IFN2'0H)['RL%-40K
M-R<TV=T;2:-$MEPZ:J'I3PJ5DE/J5K#=-?R7?5?US1!%V>W+P4GM7Y=8LIM8
MEJW_5 'W2= 'FB3S=BP,J5L+-&3LOD(^-'HJY_NL1R?[)D3-#)3$\X)?4V^
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M.PPVY65!$2"F#\4#'BLG0.B=T$7.O4=U6T%([NS?U2W@.*+VD2<V20B_B8^
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MW5@OHL\)04SS#,Y,F*)HXTE@)R7 GD"Y1K>:<[4V1-:A7J-9:H&)*VABDD>
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MN5FD-8.(HB"L;=N7_+1KWH;TS& =GSPS/^(%@[-W<F/3K;1N+.,B1]^UD/5
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MU00=<"Z@E.]CV%ELOBK[7;5T#[!&6XA<<'H4BJ?'"0S0HE""JW#X+5:A69:
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MB0:9:%2)('H QN@:P>4JHPGY3.S\]R3T'5PN?XUG\V?1NV1J]$P<O<;N8Z_
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M+-+R.AYI]VN3%9?+"FF$Q9Y/C#4/2LN_6]FAMCRFFD937!)8FY0(TEPNO1F
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MXARK")M_D,F#3+),VOU./9EK:^S*I3=OV #^O@E^.73;JS??X[_%^IHBY=Q
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M!Q,Q2L@;VOU9YZW7E_QZ/FYJQA&'^#HOA4UE![5+@UNRO(G-?.4LXIKM5(V
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M"=WRZU09EVV"7TAZ05JZWMD,/N,%8DY-N])G<S=8ZT[/<%#J0K_A[Z(A*5)
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M2[Q6V>"*=R"0N!^60/9;/YJB!$C+57< ==(;P*X=VGG"Q3I1:RUIY>S0-V1
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M.@Q*H!#3ULS@$:G3@4 *ZVHKD:CH6N_5YT?Q.:;<!,?NI2QR?,.XRT51*&/
MLD"/D4TOO17)WL=H,CM)/.F;PNT0Z1 ?-@[_4C$$FY;;9M**C2Q$-GYD8"O
M4FM=ZM-3YXDP"M5AF+<2V(9[)*>,&7.\ H][Q5@%%AGYHDD>)8T!J-Q]%CDE
M+ZG&<MT5%5V)^B#O$=CA?3N8$[.S6.6='298]N&'LMJ:DTDFP;S:\@$;'$IN
MY7/'P>45C(LDU[C3BW*D=!TT0ES,]Q_&)&ZG_*0^7^XVK'=NHTXC320]=;B
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MQITZQ*MV?<L?R/C<@6[IN?_CBIC]DKN"=%P<LRM"Z@*%,=9&-N2\X7:[3-@
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MY!FG2PGDQ&/'_/0FZJ7!$ZRHYZY%$BC]K#)S6B$-0:5JA)T=&RK!0@MN?ZV
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M32R]<B,K%B @N8&?!R:3EMQU@ED\+YYLOPKJ9$7UW98)T-N53!HS&\"[I5V
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M\(64MIL?RU@WW:_)K6IZG7#3R 4U4PSHW5F(5Y.']>/I&5X@?/Z6(H(\&[_
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M8P7R\?5!LF2;T"VH'9'%AA7[ILF%:FRNRF'"C!J3E062H'@+*K.&='Z3+&X
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M1\,+,DKF8T</YU]/M3'O!GGRG0Q=S"@-$K7ZE1N8J*"?4A75:-F&:>'>V'"
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M???=(+$M4&F\N05"@AZ%%\),P +RHRF^/O*R&&4%? @'DLU<+\UB7#5\-<V
M[>-8B0"&#_]%P4&V$@L/5XH/DA:1!)>"<1=^2-P8WX%Z"_#EEG4.K  _= /D
M[3P-V@R>"ZW67X#B!488RC6XB'"O8'?P0S]6K5@N/GRTQ)^9S["=/E(&!_MP
M!7CV+>N3B),H#$6@2WDPF8 V:PJ+]$.4G[R"_/.;*/X&K_#@]W^(7-;@EA4(
M'!::I"B,X#YRB!$69'W^F[M8OGQ]!E1\[7M"!BAO!._ 5)B;A\]',N'!$%W6
MTHW3$*9NP4;<X(:[:C"BJD2D9]F2WO!GYJ(B" \D64PU2RX*30+THGV(LEB=
MGSP&F!/L \I4+\B0)\,,HT3P.NB?D;4$DW@!BF]&^GY. $Q :"Z#X(%IF[BI
ML#TX6'$E[E4LJ'<.M\O!&2DBM.;NM;#"*(6S3ZTK@D'$?53Z"XMM)G(E]-B8
MH"&6B7BA_C!Y!4:.I>!##NHQYU4BGB22FZ61^H#E$7U2D%J&/2*?695 *RWY
M'.:1.W**-$W*GZA9_%WF>7,03W00=V4V-0?1W(C3.H@[DLN:<[C?.=0A;E&]
MZM$]5GW8ONH?;41I)A85DXQ*OOI3Z,KY-HI5-UO9D_/_@2$E6]J^0=NR?H&[
M8[\ Q]*LML8]UI6_A>])U[&;6]+<DF-(D/S1BX&^QUH%O6M((74GD&XELRS9
M(>TUC*@@@?I: A66^4O#@9O[=1+J^S,_5.I[E"5N.)6:>S3C_XHLCI*C0';4
MD9BC23<]]J*K+<&WAK8SVGTMQ3$=;FW/MCNTA]UZ=E7[H(+>M1&TQULKOAVQ
MC4;V:+Q[F/[:'EL]3JT_M@>]BE.KIY+R9>['TS/,OKBU5/Y&(]*.2E_I=NQN
MM^D&<I3ZRMCN[@Y.[(G5%1_3E#B!*YQ:U+6QD8$U45TZ=J_3E)/73'/IV(/A
MT32S/U]$,,?_RIQ+:F@/B_5\^J 1<D>EP0SLSKAQN!RE M.S1_UV+168]X7,
M?)V5WPC#NJ@P/7O<:QK7UTR'&=GM*M][/7480OYLY-FQ0!]O1<"./79VSW6.
MZ>R/^>A']6S-2KA;]121#2[,CZ-_C+KVF/I-U2A+;G]$<)PT .IR=S!H0&#N
M"Q!P*8* ZNC#J?7:3[B,'7U6;W2GQ7V!!IA3FYI3TY7C5#<O*_J[K?$/X0B$
MNM[<1([)@5$81V!<PA'H&' U$J;E;A !/=!F$ %98K]<K9@W"MQQQ 3^ 5-(
M<>8SJG"'J;P2P96?+6CW\*%_A3[^Y#*%AYM*[J9,KZE;/:V#:"JY#^0@FAMQ
M( ?15'+O]!QJX"<X^@*1+:H?UA=KGUBE1U.HW=!W4W'=5%P?,+G_8+U?4V"]
MS3TXH0+KIIYZ.WIHZJD/@I*.[#J=@E)]U.73!2?VL-4IA3/.^*,C+[)^2,SK
MA'.#.[)U>)-/<W2YP=WJ(I/#%.P/X%U'5 *U+Z95"S)N"J5JEF3<JW.&\0,8
MT6G44C6*U?W85K<B5[7F)-"H593.><0ZU6Y+*DZ#/QU!:GW/&39*UD%XAW=W
MI)V=X7#50PN[N_/Y<?6N7O'[[@N[^#2Z6MLCXI''1$%-]_/=TTG7'COE+M"'
M6.91N^:FW::Y*1]+T]RTNKGI O9&)<(ZK?[.V<1N6EHGL"!LB(CE3$8KQ/U7
M,Q6F9G9IY#:29BF3X_3SAM6[*V;J=TO53*-^N0UV)^^;NO-R)J.K*+<232S/
MS1)N*/K,?TZC8:O).'$#G+9N4,IM,T,!_"?1O4QU6VQW 6PI-=;9';7Z>3OK
MQ'*Q=746T".+"+89X21]SX>K 6^!&W#-+3>%Y05^2.TU4]F>E>>,K;BCQ3(0
M*>U<.H?]C8"S^-0OU1))ZF-+U^E+.MMG/JPE%J&XBE)?-KXV>K#*+M@7GS^N
M]%V5"UIIOVI3>](TBKY9F&Y.#[V#S5BBW'&&+W%3%@L_Q?HNSX6MI?ZC*2P<
M&[)R=T_> G@ !L$-4>U'Y9AZ#7?UBEV[ZYV^T40<R2(4J05*B/#H*?@-4$AZ
M$UG83)2:M!H3"FEAV'SU"KN:XP[)<:H 0&&1*>QN?/NC[61U<9SK_9GYS/!P
MLF]C=R&L3X66JRNGE<#7(.3HC4OWENZRG 3=!%F^AY3CQERLMW*R+4O#(NN>
MP;J#;_ZT:KZ+<YME,?6GU6V%:1&)!PJ261>(C5]G?ISH/JZXM(N/7]^_/H/#
MO((%VM;%U_ B^MK4 C:%'DWETTD=1%,+>" 'T=R( SF(IA9PI^=PF/&Z;?-Z
M]^/M/83BJ:;-:U,]>$(WXECZJ=6XVN:HJQ";:W,XN[+W9)*F3O'P*:3N!-(4
M+AXF:1W[A3L%C;\I;2R7!^VZH>.^$W::;B:R']MX5-&'ISG<(\BM']M.IS88
MWP=1;UU;(JU+^6'7'O<J4JE/]=CJ<6J]KMT95-0T'+/"<QIEB(T2Q'U\!E5]
MOYJSK;\.-++[W0I$CN-1@5S*_24.-1,P6AI9L;CR$S#7+-<*Q)4;6+1[C;"M
MBXYDCYQNHR+52T4:V(/!SDRM>FA(5<FZC?"L@V)D=0OE0%M1>*=M]\;C1D<Z
M0AVI TK2:&?FW0%RJB/"MCI!?<BQVX/=@^K5]M3J<6A#N[,[EE(/?:AIH'MZ
M#70[=G_L-)ZC4VR@V[$[_8K Z=$H34^, '.\8!W'V8=W *R/G.8-#3P@U? H
M2,!Q^O:0@+%6LJ .#)_ER?$?L"1^%@5!=$-H U1N'8M9(! 2 *NUX\T $8B!
M(%SX.IK1X[**.]D&'Z)#[\3\T!=-L7=3R=>4MI[2033%W@=R$,V-.)"#:(J]
M=WH.AVG?GGA!2%/LW11[-S?B&$ND:ERAV!1[-]>F*?;>YJ8TQ=Y-L7=3[-VP
MY$.\<*>@\3?%WL7-^E7<6I]4Q.'9Q=>1T^X@@.R[5Q]LZ_+\\^791?3UC.,,
M#"O[_&AR'TZH,=N>UWW"YUWC91^FCG!?)J<;8@QH%LSB:J,-G'I&<,<>CG:?
M=5?;4ZO'H3GV<%A1UG:T>M0*BP'MZ6BDYE&71VU-TEV[/6BP<PY.T=D)Y(4]
MZE2(F*/4?BZ%%X$E]Z[4.@0MO_:@[:#EUQZV'6GNM?MM9W?F7FTINRZJ4L\>
MCYIJ\IKI2F.[TSUI70E]2HU K8.R])!:\N[8[O5'C=Y4'[WI(:?<L]OH4SE*
M#>JE+/>TUO:@5/[S1N361%-R'-MI5T"XG.JQU>34QO:H-SHA50E&_A?VI(P\
MV< S29._)UEQ,O3Z(;7M#?Q0Z$Z^F&F,'8_Q/:7M@(\Q$DHV;[9LI/)IU;$/
MVG9[N'OF=TR'?[1G/P)%K7^TOJZ[<C^:2O:FDKVI9&\JV>^J9#=JNAX^^59^
M=FK_C$^49K: OY7&UG+&8E%1958L'3,+SK20PB+O*'ZA3L6H;EM]'0W=&@C%
MS#O]5EN=-)! */0>6UCH;;6M-HYK5H?=H\S\QZA^P\[1',X"]S;*TA<S_[N8
MFALEER/)I"C9?FA>954:Z1/UZ;7WB- #BG>#-._BY2Q=GI4<SX=.E_^)+X)9
MQ0LW*"2)RH\JS SL40\;#F/"O\/$3ZA%/7_E)DF$X.CP[(V?SK'C/;=FL,3W
MI0@3D=C6<FNL8MMR-\&OV]:B"M'/&,J#$X%'K'05HU0_13]4#RYD?QO];4OK
M0YM8@4%_B/Z0WXDG1)R@+W[ZYQ^\,B^%1;OI9I )O04W?A#08:9^FJ6"H"46
M<*!6DDV2U U3W!+</@5$H7\)>S;+TBP6>-1^-*5/T-CD\\<7N=-K?4#P.Q=(
M!@X37H1?FM/)02ZF&<S?@Q_X4S@0/(2G1>^0>WF!Y V\@L [8#?M+;<SOR#$
M6052>%J  ODF;C68Q[WA.7;#-YW.+AFGP="PA." ..K?_C(>#,<O#XRKOHUB
M(X7:MF[@?L3Z.B")(*DMHJD_\X&9+C[_?FY=NYZ'-RN_&!:'YJUGBRB,KMT
MJ/"YBL]CJ/[9Q%>?PK4D*H)#9&Y*]_/=Y:\MZX^Y#Z2GHOPB]*(I<F4@V(\+
MWXOAV5?GK=Y9'R8 O#%,7\K7;_,L2 18&W 7EY^*@+'[(%',_/%K/\Z2EO4J
M@@D9:\/]\+(XANG#38)/4*K ,ESKTQS9? ?.*YO> I>/%L";<,\FI5? O0.!
M MP>KN744IM!NWDV<?$S2G$X<\;R)6X*YZ+VV0]!/2)9!LLZSZXR8(B,K=-M
M69](>;J&(W-3UYK%T0*&FM'Q6BB4@ 7 2;C!+0A(V($8^5\(^IC'K_L_-\S<
M^-;JT_MZ<O6K)VRK(\Y/%:3B<@D[<@%<]ZOK88:N,WR)7"<"QB-2?&U"N1QG
M5WDN!U$0:H434.,V2#666X9L\T"HQF@2S$L,I(OD_AC8!6MK.#H](T;,%]<9
M],H !?^SE1YL+$NJQ!UB'5?BC'$=W!F,_,(-;MS;1"YS-&IU>CD?5-/"C;#Z
MK='HKU;^9ZX#%/2$[V?&CA6<&/RK(E*2_.P.< F#B3_:F92D9-<( KK6/!:S
M?_STER\?+RIKD.YDAE](]H'X!X%+NJ$F3]>$GUA'E,4]K=JL1KB>E'!]'Y+T
MC$*\\E>W*'A@%2*#Y:)4<4G<WD3Q-^3$(#C!//%018VK1"S+"7@01/%,H#1B
MF8!:,?!7^#CQ$!<&190W#W%$7UH5$S_R0Y(),#))(V#.5R)5OTU81T=!AV\
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M:<2:Y#+VHQCW09XU'P;R4QC;7RRR4)PMHBDPGC0"A=B=_B<+O;1E751,RQB
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M#XX- ^#DM+K-/K9UA]\=V[W^Z 34.IX(5>]::[MTJI#$44C^QNWVK&</G J
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M#=\QM[F&>P>4[8,:ZL:W%DS6Q5_!K0"2AQ]U\R$ZE@?W$L^0Q[(EGX!WP:6
M6PZW&Z](C"_ G]K,%D#_$$EB+A*VY9<HMB:^_/?*?B6P^ 3(A%\-;[X2J1Z=
M[Z( GH"_!,T N&[+^CV"W<(W@-I0]<()+&%JP=[!0<U$+$*Y1<B;K@1^G'B(
M_G%KI<*;AR!PKWRIB$S\R ]G>-Q P8DQ(_G;A#FE"SP,WP"[ GPEX>U/LP4"
M@?E)DA&;A',+(PL^"OPT#8C5XL/$T$)K+MP@G=^JY^' X >L*R6PPW#ZX@KV
M_4;Q'RN]B2QW">S']>;X/,&9^3$<N/I4;C^J=#05/>=D#A.&Q=WF.Z*V#[1!
MG]1!!6)69K*SV1E\?);,13 K[;F<1"* DJ?Y+&#^H,R!%B./%!X!<>1?^],,
MZ(FGEH@T6^+[734#F@#KJ\ V_HN_G0M@$;=$RLL +CJ\3,F'$&ZV7A[^$H6L
ML3TY#2#OYQF>P<-"WBJZNZAU3< &@F5$BG1QMHD[$Z"I(CWXBT461O!#W_/A
M(REU5M^G7H5TX.+YHAIWA=INF@*_HG-4HC;2MQ97'T?1[ S^#Z1/Z/E+DB9X
MNXD4].;^F<&5@YV'"?!UX^FB4'+E:C0[L02,CES2(NYEB:4/W!?V9!9'"T4:
MN:&@MQ%&U-1 U)MD(&;4+4SX^K\+_&@2N G((M?ZD 6IC[=%M+0NM**J'X>(
M'+9&_7U+23F'N@A*?0FDRH1BD*O_8(G,)[PL1F84$+F[6KY-(S0C$]@<%V]/
M+HQ2,@[QOL_P'J:W2-9P)]A13Z2-1K"4LY*!\$5&N;J8@.C+I2I2_MFGUXS-
M"/NSHG 6Y2U<7)!$0>9*I9?9A V?!S .)]NQXCJ;P6P]8A>\9 MEAC5HM^&T
M^H.75[S"E0OWZ?69@Y"4L>NE$8BG!>BA(5XTS-QSG)>6&R31-NM+"@L\<^BO
M"3 %LJ@/YJ:VFXMZ"!=5J5#&/>7JW+ON:>E>$F&N*L1X7?%^;*2]:D<!L7+M
MHGARQ-B_^Q4N C\%.O#@VW<D_@.Z?N=3T*I]4MM0SWXC;<J__^+_<S]@M^;D
MW.+D<DL>-$%D+=U![Z73[K4Z%DPK0/ZW!:(MD$>,SL $U6M60T"!B<D#"'Q/
MOK;;&JF7VJ@*]_YJLQJBAVVW>GI8J?-LPM%EE5./A#90;K>[*1#B)&,^1GH6
M/S;=[,C,=V2:E7Y7]1@NCQQ?J+9E\&_4Q5+IJFR ?4OO/P;8Q4K&W "3GOQ!
MG#!T[X&=1',E#N0@3AB<]W%.XC!3M;99]2EC;&W>E1,$U;HK.6\-P"[_64.4
MW>9:U.=:'# ,Y%W7IN80N2=Y2[8X\Y,&P;V+YH\)]?;QS_JP86ZW..L&U_9$
M^61-M8D#ODT-5&UQLSZI].CCJ)I[FA+*/1:!;%WWUAW:W7$%O$MSN@>,:[']
MZ0[LX:!_K%6-,/*'RKH**O&HC>!^5+94!RKMV=UV1>GMR1[;?B$HMCZVOCWJ
MGQ(P&!:VK)9G[8[/')7,K*]&U!G9HV&%S&Q.]Q@THL[0'@R.%K,51OZ-JE)1
M%Z*L5TQ5G'$M!9:H[)IGU9>$:Z(;C>U.M\YH72>J&SEM,*M[IZ4<G6_*'&WD
MZ'%I2: DC1LEZ4B5),>QNX,*J7,T2A)!GC;2=,_A[5W2Z["]>R=V?<]UOZ'L
MW9UKQW:Z%1C<QZQ%/3$PW[XE[L;EJCNQD_5N"W5Z6&ANF[=H@_W1MGOMSFX1
M_$Z+5K:!/CT26NG9SG"T">OOL;-TMLQ .;"RUO>A%RT$5VDB^(HLZ+S"DHP0
M84%<@G]*L4C="GPN?/?W6>OZ.M-835CV/HW=&YBCK.%_\^$<X>VRP*62>H((
MN49?XG()ZV6S'LM=N1T*EJ!^]-((2TXQS]"V+K)8?'4]>(>'EV0J$6^PI)[*
M\COMEP_=,?HY5O4OX#)2$2VL0A;&]H>]5E\7QCZ+Q0QF)!<IA\4$>>M-99EL
MV[J(%DM7(K!L>-!1<T!X#[45>,%3=JUJ,!SX"G;1C:>,JN53V2T\R[6ZU[#(
MYU2:&W--;AA92>;-^1LK\K" ''_)F]=I'2+A<\>(CTO"=(&Y\K'NCZQY/I&>
MC\]DAMNKJJN'K?$]BJ=72K:MJ5BIV.Z,\Y)MJM@NEVP/AJWA?0K%G9:U!3J>
M"0MQ&)"-PW8#V9@C,320C4\$V7@'4W@?6A\(QI#OLY).EV^L9ZY$K\KB:_^:
MX)_@FJ>W$O8)41I%?,484NIGY^_(I:W^^4JD F33519>)2"[0(JF^"<\]IR>
M>Q>XWZ/+!<C87PFV\95/V&F@@2;6Y3G(,>8 ^"APF93@I7!@DDCO+G^USJ]B
M(182%XZ^PD\O/GY]_]KXCK!LPE!*) 6 9]&-94:(2&#6U(\13RO_'3WY.TAW
MT(H3!G&40A5'RIC-Z>]ANRX^?$1D'@;S =::PBG1YW(_Q'<_32S\?WIRS4 $
MOY,HR3_E_?8)J%><P2L2QC!R04?%XP F#CNX(-0?X!Z"&:A^><LZ1Q@5V+\L
M2&WZCF1Y"+K+=>3S_EI1EF)Y+$%1B"3*8@_1V,ZUX YN;>/E^C#T*#GEH#@A
M0@E869AE,<D=F":B74AXLUN&($3LC<(7B "< Q$GC$3,\)NY:I6(]"Q;6J#]
M %VBXL-32]UO@EZMIO),B:!VKOHPX1&$C/ 7DRQ.A(*F@^U=NK>\D>JG3J?5
MUC_=DY;Q7BJ(N//1>AF^'K:$]<&$5,ZKD+#PB*:N8I>0^NAOK5S"H8K04P"&
MB0_K<Q$/#\&>;&,4NFT"&&-HO153 H?YP+ P!%3U9IIY>9!+]<TBT)97'UZ]
MK87&)F%W#D=E4X@QAL[FM+KW4=FV =EIMYP"R,ZH#+)S/V0?4-C6K8.!<:<F
M545%AF!@Y!!28K;$Y(P$3:])!.;#0=+16Y]S;?>M\:MYK&KZO9RM/1"<J4+5
M'Y3H9M!>06?*G]B2<KX0A*B!SB0E1)G'!0BV":\$A0V)QIN[X96P"#J7P*-]
M@IW4I,7HI1K'%M.C4:@AP*?G)G/XX!K^2;+@H"EL_\!@:B:5*&#=^YEVVY+9
MH$AFJR!@!D_\,3)3#&HMA051HIH.T .AN'(K2>H@R4AZFKZXWT%7#\7,3ZUG
MDJ2>[X^DSD/%L5*8V$1.K%(^/8BJJHBJG5,JR[RRT&L;;HSM:4I2R6;]3$T'
M<X%F(B8O6[[PG3*@%7_W^E-XU5JM(?[-_S/SIPJ7],)=^A1IV\?T/BLS9=?#
M%Z[(?6[:BC^A&'KY>(V:B[C9JZO^TI?Z@%ARRY4;8<U=8E>$R8D*/Y@(B#>+
M1I%6V)C-M:RW6UPWH@T)XFZ\.!2IXI:&=[ W-C01_*'Z8M#.M4R\P F"70-C
M#6X)7AN10//9SU@(34E'E+-&U%K36HFC[(J;0KS_]+$(;]^V)2CZ&4QBF4W@
MY!&HG+P#;/-<(_#H,G ]P?8AK$# 5: "!UC?_V?O6Y_;QI4]O^]?P9KSJ&27
MUNAA/3RYYU3YE4QFXL0;9S)[[Y=3$ E)G%"DA@\[GK]^NQL "4J4+=N41<JH
MW7LFED00Z'<W@/Y1%FI;V'J=G*%(6VD[#77<Y6/(D!^>;M%'64Z*5D?KY7_-
MUV-0J!/,$'D#02BB(5@<_ ?.6S3/IYH%3'69@\2XW(D?MKMY_BQ&%'2]%0,&
MG+LQM;"G=#\07 C"X"#KYTHO5W_H$U7H%S:M[B:,OLG:!NH?K _F&DF2J[Q=
M?4D!!]@B2/9EX_@,4P!OM@D>S!<^S^H&[RXNK?=?L;:B H5A1P]9J;?I>HH(
M40,YA'EG [3S8(0\O7PC;6IP]<8)<VC;CEK/C[GO 05RB!2MI!-#@KS*))2+
M61@E!Q!1S/705( D\( <21H7Z+^2;$EDI%7J+9$YH>N!24%CL#MV,EOJ&M^G
MY1!11'=\VL:!N7D(NX348* /\X5015KNG%'W[FL2E3'XQ2C$9O8XL1NL!*4^
MPK3,&.HE+H)=,U '7%TN$M+L6W$8!E2/ JN;=</?78GF+1]'*>I$)BXQV'T,
M8;7MK^[0;M/_C:AL!R0B*(58MOFG,M8-6).$K]@A:OD=Y'^""@I#\_>C5K>/
M2 =B+"MB'O7Q_WNWI[?@A3>@!0;J.ZBO0'3<-@!E1+P;_'WV<OR#("U2)7U4
M8J3;$>+O;!(YU@V[)39!4I4JD*VF[<]TS/Z,V9^IX?[,%<1JPAN)$P1H["BY
M=-7.10R>(M:+\6BS/X%J6E?P3;ZC88N=AE\XZ2\\\N'#*2GTU=<3ZP-'G?Z&
MGR$<2#8HDM$FL((8,Q:/8@FP1@3C A/_QI/<(+PZ_G+Q.F_\OD@CC(@(I$0T
M?X?)HQ.(N>_+_(HV27!/!?Z+J9<KX(2D8:3S ],IGA4 GP(*&,>9#4-&IPM\
M]N^#=CN/4([O].$NA6E O)$]Z _L8:>S9(MUQP?+R5<C]E#DL8._CX:Z;5V:
M&<PII7!907W!8(C0( /$V);[*%AFP*\1!X(C9";X>5&@QWT.9)ZVI5,@N9P5
M1C-_[W>R>L>.'" &A2((]\3A%.'R1%TD2QKEYI9"? -2IBH2\(()4(!B>/ A
MC-"9N$#(F1!Z!8;7@>.G=&"$8@.)D '/2^ <+F(GW,B2878Q'; 57!RN:0R!
M8H 5&[5SF!5L0$H(CPED?:J*/^#?,*"A"$=_6O!1ABEB/KB3)%PW1>\R=\!'
M!)B'2!LDL3#Z$34"B@&RLE)$P%-299!<WGR!IWUP01I,$,:XRTO.LY^;&5B
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M)L(=L'%$A@R#CLT1&!-_2J,N0L1 *JQ5 W'*&9C,PI@+/'GZ,\Q7PAR:L"L
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MZ5'JX:#5.7R9L%O+FZ#:#S??_ZP._ZS;.GRA>.<U8\11JV\840=&&(VH"2-
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MK-\"PC,G?,P;CR"$7+![B6J>IQKTY>]T783&D>B;O+QC):SQ+<),1IXS.[B
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MP#L,*'4H@#R=0!8S?QZ"%H 1%7K0LHYCTIR(8C1\*BJ+]4Y!*"+/I4[Y9US
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M4N+8ZY!D%#SH1F RI0*SM(&QYP RO7:K-S1-GY=J8XN=]$$?&#[4@0_M5M>
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M:*=A!'S%"7SF831E@?<7F:>6]5:;D*</2*R@(5$&I5E:WN_$MTEJJU,;)(I
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MEOH#:!V%Z!(9=10*(_WR$'VDZ*T?#Z''X;T!'IQ.QWAR#44*9"WV0-V9:)%
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M4^WZI+S7(>.S/FXR#=>>K0?AX<@PH@Z,:+>&AA.UX(11B7HPHMMN'0X,)VK
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M7B]-*=?]!BT?<9QJ^2WIEA24>L1[^O >]R>YITN.*JZ'7_DTUE\4U6[_C[[
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MWK+;S;\!-T_E=A\=2Y(*D_HM0$^T,'P+_NENJ2T@I:?2Z<=\7H(C\<$'7'5
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M'*X=N?%D]SP1U_86HXJA6&%7!E@/8/WE524P]3JK6/\G,P!4VHK4-R/);^K
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MJ1$40^=245<N*+K:S%$Y/0M7VT2.K+[&H6AM=#7;+LSKG;04CV&UF.#!>4I
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M_);:KN@QUOXUMLOL46.$5EG4?43)0V@?3#,LBS1#U+ZA'E$*'!;F;I-DJ(\
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M6K7[)-'QC%=BKK$% _8A@*L8KA&=5P'DKF#?>A=NM8'?\H\[KA*$N2.5^Y3
M'\S8L9H;FVOG@0":<;HTE1HY>A>V5B9Q-(G0&C:5KXR\VPI*:4;D50*9QE[U
MG?41GK'J=6KZK8_* J732"'].D&-2]BV>I[I_U5#]>UZ8Z#2",3F^E[>OULY
MCCB^]L^75MC">5@5GV0=U!VVSHYS.6?S92O",27L*N-20LJFT^BDL[@I'.77
MU)VP(@5 JBK"0M63J<#@((WI+PI5_A#S]=E/F?OU-3;3F)1]4"NQA9VP[P6Z
M$JM'\/<%K-NK*(F!\B_ANI0TINVPVD&]S<>B&PH<'X8\V#WX"0Y5F8-9#'\!
MAXJ&H![!V')2O4&;7C2Z<W///W[<W3U^7N1_E_G@ L8H7=,)U#T)MG!<A!*Q
M>]C9.SKXR0);C[,TSQUN-HA2T 4<;D15D9 -,V6.$ZT+FN,?M?E%N6BWMG$'
M61:8)TXJB(7$ERTPO3Q\HB#OM.TST >%?W#!^0CV2WC*2&3Q(-/#B()M6-*8
MD%*$(.W1@"P"MGZH9< "S9B>LP/*:? :'_3W, *S$K0^H.@R&>?F4;2\H5DE
M.R+0'D _93B63-%Z&,)?\&(@+-Y"4/ERHK4_@-2G0+\Z ^XXU'%>HI*7:"Q3
M<1B9<]]-]<5W?''SO?@4?B'7N%QJ/66YJH:3*,%FOUGN-E ,X2COEUG.NB?O
M3BY%;89+L,=/KJK^1 :PV5LX<)A+@CJL@)FXF0[*O$B'H'C=:JYN:KF:3'3L
M9E9I3VR2#;'_%6*8EKF!><"\$&DBP&^^,1@3GD&6Z3K$>VTN. _2[^=,Q&NH
M50GI%*Y$W_;W^*AN<+=/\=D59 3*X?$W1F#_32\=;SJ@ :!W*! DX-9G6]@P
M(FC.WYFB.P/-05P>G\\A$61ZPM ]EO>ZNI*I+DRY?XKX&_=:'7N7V!YN1*//
ME:W\-18Q+UDF=C'YF48&OR!T-6"JD!9J884JJ@UVFAC-\#(=M[!!Z1/CP23X
M9FWD >22+D>*FM-2N;+.$1\QV^Q>P^1W@=RNYI7-[(?@=(69O>XZP:YU$DW8
M>?CJ-Z#93+9FM]OK_7QR^#-\*9>=P=0'$2WQ>Y!O"#[ B95[W9 N#TWV.-SS
MD?NJG9=]7%.4?O;1(?);L+EC*0J7KKCO&,X #22;R& 1-WY+R(.E/*U%X)8;
M;:XX0#L&84=MA*:TL828@7QF5&;TMFFF\5OTC9D@#Y@/^2BBOGMS.>#K#"69
MCN,2264"(T;M1O7_+L<YV LC=9$9C%6VA[E+)3K%-+'E.=MVF][PMUXO6S!
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M0KB$F"\#%VQ=7U]W=(P>N\Y0_]SGKSGN7T[C5 VM+F 2C7,_D]\;!,B1CNK
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M!:KLGQB P=#^]N+\A3H&4[BK%>(SB[/V#;"5434'1>JYQ<!6MI/N1 JH!PV
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MQ3VG_-^5%THCHFB]P09K032#9.[_F+W@*80\*\K/OA^RHOLIAU<68Y!*QB6
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MAGONOT*,]_Y>1+ J] UPV0*,%-JKU]D0V3)YC:4DDSMZ3&*&G,9HSE#E)#D
M3$'83*4J+@5)2NA17/_ XY<.#_Q3F@%K&8-^:IK$Q*T8\(O34QF%5Y2-)P>&
MUR<UJ<7V6NX!L0BYX@L9)M.@^:[/^H<QJ;_&1+,I&_[L5DP1;APZ'@XBYW;3
MSR43(E;%>7ENLP8D;.E,D$PG+7.=BCTX$6OL:# I$)J,-JB=P\J>73M:FRFY
M:A\6[YLID@I[(50.P+?>DJG3RC3,9JXF/C_B\YR#$SIXM6/J1LYSK-SCJ2B+
MV^D.@8V)#A;O<E>'4)D&A196UGZ$MH>H1"J$"A_Q[J,[=;=ND:;K1MJ#,F$A
MG2'0)T3#!&=GA+"/Q#T,U[OM4Y&3A%0E?&IRA:G#([DZ9+4':2D!ZK J39D3
MC]H:*I66Z_\2U_+":?R9&+?\_G.O*WB9L['0U0>==Q>U^3_AP#.=%BE-T]%4
MB:F8@LOS;PGX.7PCKUS>7!9^.S&>.*;!LN#<"IAW<<>X&[YJ&*]"FD&Q!A&.
M[=8RY,CDP<QKIP"XX(NNG1$<=&FT#O=2SDW+.1A"^G>+8-Y8J4](;Q;=7O^[
MA/_(L*/J]L[@^W04(T;-BX&K>-7N[CI)'%3GVU=]781O01JMD8A"N(Y^P;3^
MI$R1H9<S7(&6MLNX@ZP#</."TD61K3KDDTH$L9C,Q:1^CJLD_A?3\XA!KVP@
M>&X]AD\0>R+A@8V.O[[E]A3!Y>AN16_G:]3([SWM=N-2]\3&P60%LAU&/ER_
MXTI5E*]C;C304*T1-.L*SI0Q$B9@D+A(E/-N:F()Y<LURXF7KG*."Z[["Y2]
M@"=/>$4#\#6%3NW<[GWYAF:$%$TYHX$+";$ *_'\KV@8N&5??H]2$9-O;AK[
MU22IY#1_2JJ1OU7Y+H_#N\&\XLH8MMI<6-$<B/8[F'S0OB74&*+F7K#1W>J/
MTCH<^A3<K9;@F'=5+UQOYL3U ?.GT!.<ZAN"WK5>NC' NV-N+IU"IJR#5 7?
M55F@/DGNHZ@+ZA!HM+/6DK6V#$OK&FM$QPTE=UX6ID%.B!G39ZCBX\)!XEND
M<G^GKR6,*RSG$I9MSB(>U1A[*LH0)2F3B!I.E6W2"+>O%"\2G2$\2*";M5;F
MFT%77%V(_Y-A_^[SACPQ0V/OCQN#=J,+JUOD8(I E2E66+-:E@[%__:7L4/O
MD19 [EOJ,AP<BG"$TGG\-'@E:CTR<I8\]W[390>N8\;KZL*V7 E7@==^@WD0
MS_/LN@/>KVZG0REY+4:N:6#Q-6Y3]&5)]LDOA+L@=1J9:?F5XU8XNL1;#%O<
M\L5BJ+.[9M!G4WSKC8,.-QB #0;@N6$ /-VOU08M<Z]IUS6MW'[;0^):>NB[
M38*%IYUN>G;MKL!'YRA,.W2F/0:PQOMW=G._RLYLA*O&]I4K!6?0#9YDZ9Q\
MQ45!OZAE^BM[ #Q>V><C,=?"8800U+NVCH^DLG8VKV5B/&L3' R\ F,)=EY-
MUN^;Q+=P@>>>(+\N.@=)I71IG 0+T;F!4FV+%^-DTGB(1CS +R[GGLK QFX?
M-QZVK#S]%9ZL5WS#$T]&.6!RH+<<YG-T^GRQ<L_R)[1 7G49(%\760FLLB:Y
M?B6+P*YV$BY":%TX*\'ZDO+<R/LVPUZ_LV$96IN2%%H+-M,@N2URD: .+RUX
M 8TC_1<U%"$3=*R.@H6:=.DX%/1A7&4N<A:.A]>'2'\]CHG'T=VU0*O$X?S%
M8",2>588$8*/K!TLL?/V=(*@%?Y"G<[@J]3PHIVP\,7KGZ[3=DA_U.AP'>2?
MP*[-L%> T2_\&+E4FBW1JX:'TB"L)ZMU8;^'>X@D<9;%-E&22RS#LD,]O%G[
M#+37!]$'2NQY[O6!-"$>?$1]L!;=]4L0@:#H8EN(8XV/+5=MD2G)B <?WIV_
M82 3-9(P=PN>)O+&(N-/-L@,-*XG+Y\4Q><7]348]5?7^A96I,TL'YR)*DLR
M. YXI0OIH*//>XF=F$)8/W@*E8ND$"-'Q6BHQKSEAC=S].UYCW:#QW)L#=;P
M*D5Z1/"E2UA,ID63MPJ7A;R/-!7_A4(1,Z9!BK10@?U*"3_QA[)04?<P77<\
MC.TZ/*D.C?(S-CSM]SZ,G,$=<,N4-S1HP@Z65&58"_6->Z9V5>$[1@)CAFMW
M\<]=<CTR?.^V 9&*# 7:NPE\B>)""8#WC_X2H?],BQXUV'JX_\'U(.A/]"%8
M0',() QG0N81@P[3BL)0A+^T<6A!&Y;%73RA(#BUF;3:E%6S$XC8ISG-D)RZ
MNRJ*A#9'@<4PTF*4T29Q\8 'Z7:*#Y%L)1QP<I_)*&6ZF<T?Q+E^2MM*DM<2
M(OJD1L(9)O1;%;2(/^Z:+B/,1)J)F@3NVC3Q\2N##C*'\,V[-Y%;&/2:&)&*
M^6LLJ$CTB7IZ B-7GW/>MP<\*'C'PE=T/9N;]: 25(2U=_3,VF6!F4$!\" S
M[DT=08[(08/AN20;>R+C."LUW2(,C#9A(81(YF-YH).N0 3@0F<?+DUVP"Z0
M/T=+EPDTAC<%CYB%FQ$.>/)$I+%PBOM'WE+K(QD03O(V3PU%=Q2<[S 2C)_"
M>BFH-L@LV1Y!NL=;ALH)#FK QGURM+<UW+:4.=O@CDVP(\/5M:&2DU-.ZE+2
M2H4)M7+?)UX'SO/N[^X?A"+G6>U8'CHQ-7!(I_/)52RD^/"473XX[4T.[Q-#
MW:C[N@VJ!ZGBD$HC67:4V^VU)$/7%'FQ J?Q;T4I]FD2WU7:*XI:\MDK7_M>
MX3UC8^%.:E2!!L%^ C13O81<]JF@:=B]!='\%5<=_HG]F]369]ZY1/OC-&BH
MJFH^93W$R?0@_U@SX\@J2[UX)5D;=HO >D+EW]N: K38C+V.XS3M9F6&LI<X
M@<@DN&6]W0+2IK"]MV#27NY)):E0YM0[5GJR<AH&AG?^\8+-D?BJ3(44@]/2
M*-Y,5OBK9'R,Y2*#X!-SJ,UC&$HAEB>Q$8JH#3EW'Z%SB#(K&A7S\Y'*OJ>-
M)?."S,LZ%OXMY]NJ\<4+9R-)B,B(?,LW%*38KKJU^EC[UGP]AO8<+2Q-SJ#_
MW4MX^V!8+,1N%':RN*^HJ"@!8F:!,T,4#&:_:* RTJ"4Z KVA^X>.YQ5F"6$
M^I'/YE9VL[U$^I:-L &X6R)**AI.URP0CU!8S\>J&HQ@X[=)BN1@:$N4($32
M5;)U:\W)6XV=PA4X3[6-IK>YY85M(AB84."QXXA@<M3)BS-(#+H,1M<*X72-
M#]%%8NN/TE@X+*=I*JV0KN%+Y -(XI(164XBV;QI,.[Q!=G?D9#N2W)K"AX4
M1H(RZIC!EC7%=OA(XEO0Q$9[4*[^H(L?+-H_T))X\2G3;^\,V+F-:\]P)]1T
M66-K&R%CU26-VG".3[<=&$\$6A<CXC=N#B6(N2U'#/M B<84FP%#AQ93^DM'
M/$O)1E1<>NA#@!#UXFP,3PXF-D%L!G'\_%J_:L?*^J*%Y&>YN)SN/@F<6%=*
MJ,J(O*(>.%"%.+LHW;+,2'33 (\%L2?_CGLA8Q#@"D[QO!;MU"(%G7HUY8(>
M&8<ZU>UO2>"WF5D]VF16-YG5YY99Y=NX:6>VPHJ+KN643G] X$&> /Z@":MS
MO?RFR,@0D^$!5TZ#A-!G$^-6.F=;\CD.W9.P\K4O*<B<[(VB&T_.@6@G:7)%
M?/(=Q<MB5S"O;3$B:P+!MD-G/O4$T[5J6UKZNF:Y(8^QS^54Y@6&R]Q[>N,E
M^0%IW.*LJ2'')VY3,LBG;H_=A%Q/<KH7T3I4R)/), 6#HJM)['D[-O=("XC&
M6X U_S4<)/2"&\"TL=@N7 U9<2#"-M:-*V[&,"LS*E_@-8SK1D"(7*O<63A8
MS5Q>I7Y088%&Y\1:3S4M@$,X-!>?$)2O,C:0WJU=XIC53?)E!B=5<!:/7#\U
M#6SK?^;YG&GD[:W<E9;S8,FYZR+BV?/1R@P:8A:KBFS$)YZP_!E=]1AP%P<_
MF'W/]@<-(:@!->@O(D'@%%]DC:\I6(6XRQ@FQ3CZVJK)[>:A!Q3?%%GB=(7N
M3H*,E6T;DE, PSMM;=>B6'5 A*8?TA*2J!$T:F\\VMH2IN.G4Y\&C<N]Z4Q?
M^R^*:7EG'\.QLM*%HUP\./<A9(_G5L"IB1JS;I"YFDXETS3.I8C(@#:Z8G0[
M'#0.(9>?T\K%63NOBJQNPO0] +2MX.C\ANBASJA4QY)+AXN<DN"D#D,E+3<"
M/"Q.?IL3M-^%F@U,P(PN]Z/K0*2V1]I^;O=0S5 Z0MC!/%IWS1;V"%-">:/\
MY+LY/,<':13*7*8WF"KWF1UQN[E9F.\=T+F%VPOWW6_T2M"%=J6%BV2YQ4.(
M\'C")1\^3R9  KV1O9V!***[EO%Q_YP]0<[YSL2F4&$PI"-3V)9<KJ/RT(A&
ME*,I3FO9RM->M>=/*>A6B1^1.8AW>U>H B?;]*VETU4CZ]CRP#DY@QU%P;E<
MH"E/_=0HC-$EA:LK\HYZMJ8'+Y%ZO%GA(YI+X_*$'] <NN^7KKM#@T#>#%J\
M>,TQZ32->J<9(@X.V\P;LQP[ +K.!_'@?\[>#<[<IVW<0'MKV+1W=8UDVJ_I
MO@_;6=#A2:D9#U_['0@*CA'!C57@VDCPJZ/I!JQ/)=$K.O3.OUH:W\5@+=4A
MAFO;O;0<>AU[D1&KH1*]YDLY\Q2O$50,. KZL85%RD'LU<-+!J-!OY:L*PS)
M!?SUIA'+."QA#- +^$2GX9U:"VK]4'\%,+LM7/H.I=FJ :LB'3Y%/K=9 [5N
M=&=[";-&!_^8B_?9H+@M1M'B+.[>(7=+YC"PTAX0RW(FQJ_PA0KX G+*RI0S
MIGT!>>V,V;_M0?2NEGI7N[%8>[]XI^>5GZBK:/>:IM93KM%^EX?WOI-$_2RF
MB%/=3675%8_0],1CK,0J)ZXQQB=57+L]BJL5R"G*MBJ.6RQO//V(?]G.E73A
M+P+$$ &>32DBXR_% \V*LKUO:%L0')4R?>Z'7,;9+'5O3N"+RE1]6IR$=5W;
MU52J=#TT\+7LO[L CEUIFU=IJEAO4TW!N!V,L=^OA ^X4IF2/%0\[<)R]ES$
MQAIP+AE>0J+#4%-CYO@=_&+PZGA_;[ EQY)R9%7%VS[=[E 54>"7U:W$V:+Z
MBC*MYV7NHSYK3/)_.1<' ?1<:RF+6U)8Q<+&4]X*7"_VEM9"P+>68N(C"9BR
MA7P?CS[/9X-?L4B'8TGK.6T?N%*5?(,D8*Y 5ZWRV2]')4,^B E8M"KJ!23K
M- Z!T"EZC^@?PYV!EUVJEYK!_I6!A6_/7ZEK&#DT0>@.#'E9;_VR1FK&.P1N
M4RED#>8O0Q'&%/'@+&2S#%8I"C&WC4[77>]NOLN9G/1&\D+@.,SB.QP'[A<8
M2R+6^9P8BL@B0ZJKL0-7>C38PIFOC4RT6<K='AJ#_6-7)]UJQN>B$-*^E-G9
MPNJS+\;F.]DA0Q7C>S("N'#G6"G0#B<Z&]5*(VR")&;&H'V9>$)<4K@$OM'T
MZ_$F_;I)OSY)^G6EBY07Y=W.WX;A(M!3]KN>@JQ^J)WM__[MN^%_A[Q,'Y@?
MZ?2*UV<=BO)G19%2B']-O7=_>("5O7#-NL$+/_L=&9_^S$OZXT,(:S&:BUV6
M4\GI)+Y;SY+^FC8-LD:TC'PG@\K35N;*L7(ZJAN827R>#?J0&R;^EZ%9LU>M
M<X@NSMZ$9=+6></%(M=K?_?%.ZD""C\X?O%WSMG#<QQ/%N4"SO%FQ!C9;3H$
ME2=!$G$&JR7#8^@6M:K'ELV3['-*'AT]@Z9'\<.RR)&QU#IX, X!$21)Z7)7
ML1\&&!FWM[<[53K:N2INUB32YP^A)32$=6>9]YY&J->E&A:Q*<IUW4$5C?V3
MV5+]ZW66P'QH35_M[QZ\MA2+,7@,_\]_7+Y,3^*7Z?#EY7B8'EP>'N\?7)[L
M'8TN#X].7HY&^PG\=>\_^.[G7YQ_.OMI;^]_?CG]^=/YI]-/Y_\\._WY+?SG
M/^2_WIY?O/G'^XM?Y$=/+VPPOL'>WL[ #G$ 8QR800YTE!_/+@:GW[__Y=/@
MI]./?S_[-/AX?O'WM65(\$B[F/JHF)>5*]IP375\K5SDJC]^9]R-*:.6Y%F9
M59^-\SU,[XH\T4H$+%"SVG \F8^$%)6)IZ1P+>"[J@2MXHN&$+HA*(V0""LH
M.O&>NU0,H"I4GXHF(SAVHH <@]]F.09W;.Y0[H@J#69)JS&B@%$UQTI\^#XE
M9A,&J>L8>2X+)NAK\N?87IS_X.*#R$@)W]H9O*=X$[)R=O4\;0R.G#V*H6M*
MT >C$-^ 5D^6POK -DAYO$:M1I90-)O.8LZD8ZL)1:)-806OA"F\\6(J,'+D
MP"XU9"2F@A6@L$%N4IH4W<4':(V)*9_Q3R'8NV=A2-*AP+:P3X-_@XZ'FCT-
M+E(:3#K8.]8LKI<-0Y@J=R?E1ZOTEC,10N)[RO<VQ\28C8!!9,&U*E2E- TX
MJ^!,DI5)FZ95K31,*I\HPG5[-D' -QRV^ BC6H]>0D&7V DM)6B8BD)[&?PF
MP_ %45GCL>7\'_P#S3,X_KW,M^TZHR0E7U'JX8=Q_IE_V=V$G1+;MRGW8)'!
MZ5;221O-*[@0R9RR948UUN30OQG,AY>YE#>C/L2SQ4,CJPJ[T@:O+\6J)K#D
M[S#_6@!-K.I$TQ" CX\$?$.(1.D@.FI5TL +5\P\Q&/V9740YJFS)AA!?=>S
M3K:^4++E?C?=05" #ML4B'" U8,;"-_.HW&W#TK \SD;RDKQ1JD!UW=*WC59
M"NFL9*SLZ=\N&F@DAC17\]HKN!>7:B8*9NK=G#J%C(BG95<9WU)6Q[G1K/+S
M 8?=[5D7C<VW(+E0OG1_B_+K)=;&\-3P6LNKE&O$\V*:Y5H0[*FO=+VV&TPW
M%4/>\7CWG1.>77 _=MXD[# *D[!R@-+)< 6+<7 -2HV4FBXZHYBY*K'H<='7
M:=9PON;:*=&D3O'5.N6,H:=$CDQ>74C0\VO+MNNSSYS(-7;/[UKAMT6G+#2/
MG*9ABZ=J<6UF*D)L>#$+-&\]CD'J%F.R^G!M30V5,JK.$"&=:7('M+S[3QN(
MQW4A&P])X;6[PL%>)+6[\F!:O>L8.<OCSRF:!GN[?VD'].75S"P!9X<O'[2,
M6=U++45.]9FX!>D+"O KLQ$^R*#M?64\>%$'QX>O7^WL@LDUF5"5 PQP_Z_^
MDV/]9'LP(7( LF&+JO:OZ'GJD?^M_#1\]O'.GGLVT<R3.4L4 XW5 =V=YE?P
MIT=9H9[A'YOAAP-_:0;.%0KW6)7#WL<>^5W0QW(HA)T0"MK@P#O>126#AE-]
MV_&U3.$7L&ZV<%DN]7&LI.4!H.8.[Y[TG_%H<)Z/=GR2O:.9?5:U-X#=E1HU
MO)]Z-D7#HB0[J6X=AWT:/IZ+;S1%]'*3(MJDB)Y;A=ZG=NW1+8*V^>851NF0
M2IK(I=L7IJ.0\!=EY*]!+4U&:%#';WLU-2D*"6$@R($#+760+.][Z&WJZ*SH
MSI>H CZ+B"@N4.&1%8>Y[7AR1^C^BOE6N/$K61)H_143LJ"$!D**H)S&[;0I
M^\P3<<^=:^'72T+:.A1P<7('8$@U!H*L%2Z&8E[+ADSP"@6R1LW@DK?$*\-@
MUHA,V7(OG-,(Z;FT<FM:5+6@RR0N3]9MD:<OR(3@[PEO+8_1K))CM*&($,.2
M'>>+F[^Z9SB5FPRDWSS!A?803@;W#59+2O_0U)=--H:],WAG)B[P?;PL*Q1^
M%[8#'_<W-NS:/HIK\&J#.VRE8Y$[7KW9HW<ENA^62D);']'>?SH_T;[:1]6^
MV"_L#$BLYB*Z3B9F-*M[B)V_[G<0^X,;9'3"A%A]-$?SEJTM;)*&_5I@;C#U
MYEL]>97QCNRXARF5'5-Y*D+7KV*AB@L>HPHHSC^[\!-AJ1O?BSO=$F^'161U
MD^FV]Q>U<&^O"1W:95S'B3 \"44$5FQ&KDBH[89L28$QE20QWV3\^W:_Q=SG
MG006,[D8D1,55SU<VKH61LTWWM/P(-U6ND7E>%6:+/#<_TCYL_'+XX.]D\M7
MQ\='EX='AP>7PX/=_<MAO+][DB2'NT<'A^W\V?[;LXLW'\\_?#I___/[=Q=G
M;W[Y>/[I_.SB<N_X>']O?[VYLWTXAGYX@_?O!GZ @_>??CS[./CTX^G/@[/_
M^>7\T_^:#]>373Y]", $IBXN7->G/S'\Y/L'6,U?XU+XMN#L?\3O_YE7],T#
MK"B3QV\$% ;Q]@&6\W0*H\#HY5N^]M&W>4H._D==RR7W'WWQ9/5[[IN++[W:
MQ)<V\:4E\24QWHX/QL.#X>CP\B 9G5P>OCP87\8O#PXOCT?CO<.3T7'Z:GP0
M&&\?3C]^.C^_/'SU\O#HU>-::;U"WZ$3<5B#\W-CEY*5>?#V[-WI+__X=/'V
M_)_G;\]^?GOZ\>/9Z<?3']#0/#PXV3]9KZ%Y@(8FCS :Z!@'?I"$VGI[]H_S
MG__GE[.?WWSC%N8XQA3:NFYNA"+44H'+R=!OV, \+4NB6$+[\FTZR7)B.WPR
MNVB]"_H47NTH/CA(AP=[E^.CX_'E87(ROCQY=9)<'A^.P-L]>G5R]&J_[=4>
M_G3ZZ>SC^>D_?GK_]OS=^9M3]!\O/I'+>/[#CY\N+A]99RY3.(<[ QWB(!CC
MX--[\&G/!CQ,X_+^[^#']_]X>_:1==$O%V?XV8>/[]^<G;W]AK713YI@_*E(
M7,T@B?*YASG]B9V,AU!2_6N\<8D?(LB0U==)&=]RB]V+^7":,4$^F(VGE,CY
M$R_P0SC);WSP_U.)9%X,X=F4OO$@SAY@B7_A),T'J9)_I-7L<-=V?6+LYR)_
MI/"#>]/Q_L[+MMTB1@KYNKOWME".]M*7+\<GKRX/A[O'EX=Q,KR,P=^[/!D>
MQ" 6PU?I0=*V4([>O/_YT\?W_[B VYQN\;>_?#R[?+EWN+=F5^AH9Z!#(TO#
M#>XAC8PE0F$&U1#M4)9/=]K2_#:K1A/.(:+/7A83*91%T4[F%%D;_O>:J$8K
M7R\XE'YUX'S&+_:.ME+&G>X=)?)?OLF1+4&,*%/HBPB:S2O>7&?I&'Z1CN:4
M:7P_A@L?(7QOSM[S&_RWWKD,KO_6N_?;$;$VS](2"QA2(MI-@VX;'FD!;\BE
MV \?F_BU']FUG[FU[TEAHO^]_+?$(R0H&/\%SFJ:KR4I8F*%OCCG;#+5@@0$
M'+YL<YCJP'U+ "V3O$VY[)'HT^!BKWNV99 Q=21V>8IX,,AJA%ULIYB/_C>M
M8^+1OX9X!+D7! ]1#;!TAXG&="1S+0S T;NR5*JW7&'-A(B,J:&PN#/HZ-[W
MJZ]:0FJ]I:2<NI *9%IY-0TJ4LHBIM,YEIW66LO3=P0<DAEY3^08\/ST[QZZ
M4+#@5\2(@KE^ZAG%HD_,2;!:"'M2&&6+HEK: A>W2J&1P/Y59%_[SLV\$+)<
M_I!4.X-GT,#(,1M&"Q7($M6!I-E7TD9(>PP)-3"==!)<NV>4QN<N1,I0$O5I
MA\B5S@T<(!61UZ1[,N$!)X@KRS/CC?PN.[J==K/@%=66:Y?E]-XWBGD]V>0D
M-CF))\>\?H6-]WV'C?>3TR,.YQX68A;*@P!_>F-U@M=;CL9L?>;@^\"28Q.B
MFF$?6]Q@(B>MD+<XJZZ5;DWK]NB_$VSY7:<]ZB^L9_4JL-&]$8U0M4''@0TZ
M[K-!D;E[98V;A=:$LG0ZE&AJ^#S]C<DVF&>Z FGO>K@CU(,_Q:4S4#N+KV@]
M?Y=A^\YJN;2)H@'0U77^[N,%-6)"&@PR9\Y/+[[7HBMN8,L-E(("7G-;<,O'
MO6VT)*CB2E"!M'MI3J^"8;+!6,G=1SSC;E&2%'XXH6;?\U*:) A.F'MV.2+S
M&M:NBMDZH>\$79R:387Y#N<NTZ\'6_O;BW>$(:'!&PCBRY8NKI*G6&6T)%IU
MJVS'R@NOW2ACZ6<UJUW!M*]N"R<F% ,H(<3R1Y#HCA?&<]A',,YCMU;F./)2
M(K5=4;97CBIW#I:LGI?G&56]*2N?,Q7K5+M/PU'3T>"ZCL!8K(3JE1HK%BV6
M>3,<IP5M#\211TL:LRDD1NC:&>9R;UE9B+Y'M3%"=H"[B%NW3(=822D#<I]F
MW%-Q=;,LDA[V@C]FIM_8KBDCR5D7,-+<CQ'#K8ZY29M!\G50"(@TFW8+H:5O
MEBU*$RX/K!EP3GTP9+^HV\"ZNI3D=^WUK.XJF$F$I,B< QQ<@R-"U>BJ<]F9
MS_)K8N -O3_O-C$/A%]B6,7K^10=_[(L2L\ D97@E!E!Q@TMLT3Z?$@Y1Y<!
M;;DZJ.\S+[9?ZF 7U^88-6YD7#IFRA" =&?48W7OHS?X<9YK^Q@NN*!WLI\4
MAGNX4 .',I]QH3&X,W0.!M)>O+[FMIQ[!\HECFUA,I .NG,NT+XHJ(SD?7D5
MYU;YX9>1#3@!(YY_Q7F,K3?O+]YOXV.EHT++MB(%A-V_X8,KAF2_*^-I>EN4
MGZ7GPIK.3<>..J<S\L4CV@]<5]W55ZZ^N;?2ZLS)2-]V+W)FN;S9,8MB!\I)
MS-TPD4N&]&M-]]@\=Q90-8=[EYHOWDD,(T\GTBI7?VU#%A,X>\3V @?OFIB\
M[!/AMB?[\K4VM#1/P4I<J8:0((G:,N[<]ZW/FO;_YZ+&J]ZQ;; 9UKK=A+)6
M.K!TAB"*!9+D2V>6DP"X_BK='#*6^BURI5!L]]&MBI4<;@;"]5-%#7-?#86H
MIV#>U4)P08^K_)(HI+R6!PE3HG!8?;?(3%N7ROY;UN$^2UG6?_SWQY2;C*$:
MFTWB_&_?9>N+_9LF.RY:&G%1I.>$P'T,)8)( (,Z'+![TZ1=!Q1]?7S,ET\I
MT35U>AB<?Q)CHZ.PG&L3)<"K!$\@,]G57,+#H*!H)A5<#E0")0;CO,X\RQ4[
M%6)*P.+C"OP&JX'C3H7_RG#MR*\"$YYJ!><E>*I5RGU=J) K[+V>36<3.HHP
MMBE1WS-1CS#;C^<3FKTTI^,CVEK5-6FSCL '2C7ZUJ61=#<ME9HOT7BNAPE>
M0GHID.*XSKAK@32C@,?Z%D*@Z,;CUWSWN)5F$Q^[34PG]!CRZ;XK*#T =XMM
MS>DDK9(^*N@%T#X72E>=V^M*<RU-B]->7VE^%5^)=54FW!,CY5"^AN4C846#
MVTU(+=W=2)QH=89>6";VC3;?M'.B<C\M(=;K<%U:T0N*DBY58;"?Y$8<(&>Q
M- 0_#5PZIN$@/J>^>Q0IS&^QQU5?PY:8-I78><CCLT+K&WOK.20>%E8-H1;G
M*(0YR)&]F=''J*FUBQ=0=R*HR722C=DTQH<U>VTQ,=SB:T7M8!#3 9CO?T\#
M+E VA_=?#][N4'WOX%W,003]^Z\I^^7V$'9K[DX35%7S'\@Z9/>0&&2X<;E(
M86*'AOQ!&CR))+XA1(Q9SN6JU-$.BSXI/ %W4)*2W.66LT#K]I$^A;IU48FX
M-B]"T9ISU($ M?8\M/:(XB P:.V"V?A8BMK]/D=:,BQ!!_\:-OX:,5LVW7P,
M,'*.\[B,Y]Q]AQ*J<RWPST:>XI<($^9#$%DBE(ES#H+Y+LS8FE5[XCG+Z%M+
M:>WO;E):FY36MY32>M.1TCJM:TSVF X[&I'YF%ZA4D53^@,?YE.OCM]EY71]
M":Q@JT&#U^D+^,LH_2O27=V6\0R^\_<//_TP./UA\&L&.@DL\W%=S<K_^L_]
MH_W7X$)<55?@:4XF_$G$3;V3%"/[J.5*/W=19.8J&L/<X=X ^V*>4.N>U?SO
M6'@-DU5\J@..GU(#3/N:5B!0 FU!-/X! H-(UY)Y% U=)JO'#^"&@9UCXQ0L
M)^PU_NX%LG5Y$..S.AAO.PZ& ?\^PY0N1ACIZ@?W5\B:9;S-#JYL$(N#[%ES
MBGM&&;\^>XN2MG=R<+BM,?EB1,1(83=Y,B9@.#=IJ5TI0=2\9)&[3T:L&CV.
M# JM'$P:A%Q V$N 65E:/XCNMP9/4Z)\/Q#PP='^R>CD(+W<W1^?7!Z>'%&9
M$OS/X<OCD]UD;V_756D:$/#Q1U!^Y4V:8!'D[O'#LFV$4UMT[!CX>[PS^']U
M//_? Y^@52K!]U9'7O\A*MOVX]U7N\/=T>7P.#V\/$S'KRZ'!R>'EWL'+X<O
MCU\=[!_LC3M$YO04KR&7TW':C_O5H.@]J!0]D&87$3L%EQZ';W)27GWS#)Y6
M=Q.#IO>/AT5<)G3CNQ:V$MO_"31E#'[Q]V51P8"CP1MPA*\&,*%/!0XD&OQ]
M$L^KP<7HNIA,IFF&09 ?,53QYKH$&Z:870\^D</%7"3Q!(Q="E]4@PK,ODHB
M$A)9\$;0*-6FY4%WFB#;Q[? [NF+@SZ=3X )['2LD;I*6L?+^\BV(8PM[XI7
MNQS]BG00\"O.U1,?>' 7>;2RQ2AWKT&ID"#' WAAMN%[V@8P6?[O/(>)G4A
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M(B4(]%RJM,9DOMJ5N;N<C722*L163*&5,"G$*@(K'TT@>J+VBIMB$ CL+F8
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M:D=2C3OE\!83M\).AJ2?N+%RF3(]%!AS_&]43EF2Q:7).'&,C1IB5FE<8A\
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M2'6AY%BAD/4%?C'=]3MU!46+E+*['8E<K-LFW&R6:^$?]UV7&L0":YZ0B:"
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M%&-S)VVC?C?JMZU^M4PFPJYLR,81UA$0U_ 4ZT^6B[#[+IVZ-#5'C@L=NKY
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MT,I6,J/XZHK0!5-L)_GB#FY:HBA>A OH]1;9:]:6D"XG2UN!^*XO<I2U7V*
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MTYV L@S]G:VV[CJ_/.W1_SM@.!U/S1*9/#5!,4TZ!8K,=W86M4(AN,O&7+B
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M%,^F6L0$-"LB,*R>/ 29NA7*2(@*MBD&Q+<Z75_F!QIW+WK<?!_Z8%,E B+
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MDJ?2;)WV=A$CY<U9>62(O9]2NBI"EF]/:]>W,-S35@9HB(_=P7_RP/+*&@7
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MV.S4! E#I,6BS+ADUX))<:%=^(?&W=*A#2=;H9!L @S$+"V!'',+N6.$S)#
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M/HD%T/ HP#9,BR6Y9FX.PD7S3&LTWP[%%[$]ZATTCJT"F-UD$J,4[5W:E]C
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M4F:D7!!0[;&HF8=5+EE+\H0)Y3W]?@[+HT3)?'D(+_F@8VYF6EB=6D[D8\9
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MJQJ&_P<8![[[_&)/7XB<C(8+E>.O]-V9YSO1,Q73"9]MD.??(6 &?U^ZLFA
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M]WTYX&2Z!D:8_S%RD8M8ZJ$*,G=?73R4\<';!J\L**H\A@Z<.#4403(\=16
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M0KQ>6WN#-5T><+.K#.]4#B/D6+<QP0@XM,1W![1PD = 8$!91!$FR"*"7'F
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MWP?^_*VL^U29*!<MLLJCVVF,;B=(?!=QW+(FVFKTM!.H"2"N8U_.JDK-9O,
M[JL'@Z YR1\K)IM7!3]"R/'K[?(OCCGV?]Q9KS4"64-HI%L-PS1:F%AN'I<'
MD314 2% T)&@BQ1SS<$Z:>>)/.QX(UGYXKCC^V0%WC=#:"0V"+ZWJ5'Z %X>
M$2&6E7A@>9'&7W5DLQ1Z?/J*UZ;D3AW7B-ZF((D;/8Y!/IG+%YJ;FS+O/7$
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M WKZ^0=&4$%495O2GXQ]3X_>0G0+2V>ERQ<T]U-S, ^72DC7,>3<D-XTP[T
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MZ#FN;KA)^OO?Z<F#XCD6X=W_I/#_-NNF_0HA RH@_\S[<UMM[PWO>K5V[>K
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M[#>OG_/I"6=<]QSXM/)@>M)GN^@X:/;QNQ,#"+GKN7[WPO0MH]EO$&$P-?5
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MJ!-"C0/JD:,_ 9MX KX\<IO@[<HLEG9 ).S4] CELB>%&PM,)\(X.>HZQ,W
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M'=-D0HZ>HH@L(0K)GDPA.!-1WX1P/ 0V<V[ FB77AJ@BB/&+)H3Z+3FVR9:
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MLFMCXTZ?#PN-H_S\;-D!'O_<NR*-O.5=N!^#Q[3>ZZX2CQ%E4D@;X4I#R3C
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MD#V,PT!YK^OT5/35<A>!B-:H4]6T<$%4*1L;.OK-Z0@V6H',(QN6]^XH%>:
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M=7 -<X!"(MOYN_*^C2SG6Z. 8*W0$7Z-&GNQ/!Y[%$OU/FQ(2-/U^/-HN@4
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M;T/.;QYR3J=>%W-._U',^>VBR*^0F)$3TDUO0FRRWZ8-D,[)GN5HHR4S5C;
M/MY6$184HPG\GZ@!LQ3DX=<7V861X?-LID>FOH:)SJA,NL*R9IC;Q.Y+@A-E
M38IB))8=JBX\3JH,"%73FS>L[ *M9$B3FS"*BE<'A5FQR36!FL!DJ)(MU8P
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M4U&*&>9ID ):$P@ .[0?<Z@A01!AZ:J6#S[;-SO0.JD.=+V/:K@Z4]>&MS0
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M!B*39&\C[8$"\NB9$9]UA>;LT$^X',+S6JFG&VRIHG5=5^@YXBC/35\+.&(
M>B#*K\&.N++YK)SD1C5\ _D;/2LK'X'\H>N1,H(>ZVL4QC5GZUE'R WX$0]
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M7CM5[ES>,LW/%SBO;C)SOEKB9":/Y]M^9OT;RQ0YX&H8JX+:Q#P,_>O ;$E
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M2[(\=2,3= (/TX )&*G/<!&0CU7@GNWC6(!Q$ TBU2G#:ZZSQZ CG-#>;KT
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M)Y%5]:D/C%\P(@$@Q97FX+>_D4^?K6<+0$GL7OAHX& [L08_ R1Z@)$LH*J
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MQG3[$[H]&5$.^]VWP#_6=)>L##&>BRI:GR2CL\QV>9%T1-XGIOZXM\S0'J?
MFM\/^$DR/ASV4SJHP!X56":8?]]X7WK7#!%\\71)YL34W[=@"601-A6&\'O4
M-O&3.A^%C>>HA\<^G*@.NGI0S5P)\Y,0L+XM#0FBJZ][NX+[<.DS2]>M-33
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M[<^3YN)*#M/!IO),=ISH'$-$#HT,'6'P"714]RGPNBJBNU'PO.IRN/J,:A<
M4BEH%M=D(T]SS>&FG^O2R8XY_TCJ[9NH-B6;=7Z];O+:0$TN&2G .&8!<X?P
MX[8LVM\_$X5=9GWD0!FV+J/]C5RJT]D!X(^[# .869)YV<E1]X8R&1G*,#X"
MO"SD"L*G0^_ER*J!K_9-UY;W''4QD_BN#9O(1.;#K4+GN8?77DZR"-\;3%<\
MSV X([?:IF!*]5*.A<4W3N8E0*?7 B[I[K*++@)G>*;NKF<<"RWT=QQQ*A_4
MI+7% $XGS$H[!F8297F?1FP/'9 ^Y85H*K:H(N\*LM4-9+5E82@*G= GZC"(
M.A43111B*,!P4QB5^"M;+Q;^_KR$-OCZQ$PU833$?=B=!* ( ]C^\*[. _!*
M'12. F8#^&@70M[)=JCJY<?X];.LAUUFV4-B+L.@"WB*847AS2F*-.L[6^'$
MMY]'T?897,$^& (Y$CC3RARYVBB('4397V%P$*TR"D*[NSN5[WM7%'1Y!$B4
M-"SM(%+<A>7@[[8>7B!!Q^K.%$6<4 P6N?_U5N*OHF5-$T]NK"5:2- D^6]X
MJ(^0*X'.#,!SIKZ+#LQ"(?[,*U[ B7XI?:RH6Q,P138\0,A9AJ%Z868"^_16
M+=R$MXB(#;#+%\,X2'B-Z/#2TK, .[SS^GA.)(49F,]N+[WAI7L.B"+BG[?7
M#:!H( +N$_>8AU.7I1%'/=EY]C@V?G3!"S#L115HJ$$)!FE00J#P\+??:%!(
M']:<1K1!I'FD3-909I'>'"B<HC(-L<\-M'H!S!2K%!OO]DS!UMB>>^HV1VZO
MX5AWGQG^FYO ZFRU4'*NU->*%E8DUUR1G3@LO.9T,EQP48?U&U.AO"IF&QDC
MCW?G#)[O]$?ZI A]6.)$VOS?4*YV8?,75)GXY*#?5@&L1\<0<IC%<"2NJ8==
M,O*?R>S.^GYR,?.-+ (04Q8L.5]I+[IRD3-:$WR<H?A"<_@['DD]X9'4N7BD
MQA!ZA\[W1;RZ"DJT:@PGM>(3A[7<*+SE]A7BDH8/']J</19C".=U% [&#UBA
MG-RT&]M&(/*!/M:G[H+6DS9, UT?7[\Z/$\)3:!_H (646[OM4#S':1XF0YH
M-'!(\H_LW)R!B8*GN:)>-F>Z+YM;L1\R]TZRYVD;[U?+/;Q)-93^=%,E9\UW
MAN[/+=F4,JM-J$I%QGT[V>,4F3":CO*BSW(=A(U)]AK)%EVJ(1N%@.?)U8KU
MY>8R;4T &*>3)R*Y?^]N.8; ]R(<^[L-@:?FX8X\R7O^&F);%W7@@3VC=5E@
M,D,F/\MH3$^FW$%KP<S7-T)K9C.;+@E:5O!F=3T2N/(X5V3@^>D7$\Z[(TRG
M@%G:H)YK\>I$VK1ZK2Y)U.'U^]0)N_2$$(K >T9+?KPT *P>UE> :WIXM^B%
MNA(N3$6;[M+;]V)]2HJC6$,DOLC?OFRX+WUP'R$=1OM^?Q_A AA>+-3FK5:2
M'? Y=E%85>N:NRV\^^#GS!CN5S;<UFR;O%QAZQ/=SU>8!7!KDB>:D%Q8KF-R
MO4':@RD5Y!MBE6=2Y&8QG!&%)@?/3M/'731@\/_ @8E265Z0XUU2\0V*<83W
M)'Z(][_/;+D 9R0G!+W4,YT")V\+;E-1S#S>N1'/.-\1ZUE[TQQS02G;*S":
MD:[D83(#><(8NXJ"C@GV*L&4BB!59Q5"UI9;9]LR^[S+--<_?I'I4P7)GHHR
M-(3W)RFOR/4NF?VY7.]4_M>2Y9.VVWJCE*7NW&EPU672;."E227UWBX2YV:!
M!LNTZLLFF\.#R;25SK5*=C;_]M(\?[[[Y.'NDV_-$?S [CN-^H;>^G)7:V8+
MR4&WHG7UX3OS/<^]^^UML4K.-],F/L@.R35?<LR.V881!YH^/DK_4B!Z=Y)B
MM])%',\L#(YD*\->N>%4L-4EBUC%DG*P^Y7,I"C9UMK7R.E\VF[XV?FHOX:2
M0IYL_G2LO6XZ%?=4)N[MY==^@+<,@;!70L=.<5W<P*V!,=#6F7?R%FM8CA>5
M*VC.WI2QU+=JI1;33::TY7*:F>2[TX4*K\Z?Z/QWPXFV']A_JU!:M%QG,N*Q
M/MDG27UI37+O1-9W[#\_==EN6L[X'#ENYL9Z>ECSDE!\F=0Q 1YN-N/VK6=3
MNK(AZ)&:YOCB<.!HG0E>I2K7V^V^5>I,52$H\,;0'MKS6;)G.6WHHI],LPW+
M?3LK59)?*^D%S?_=(=9%DES/@$YO(<Z,KSIZ?T:U-6:Y*(HI85,MZ^]6<Y%?
MTPS%;W=<^%3MG232B&S4R8H_532CB&G.HC NYPA ))(X(1)/LM'"XHS4[L[/
M6_)=IKZ\&R[IE@NO^EFSA&7*NUINX:VSJ#HMC,_JX3TCF":$BK$D+$GR46KM
M1'15]^N4["#BDAUQR8ZSE^RX2A&.&[^$\%9 9E>*6,3PA:D!F<E8#6I=F;Q:
MH/@L2>QJW22&:G)BX]4BQQ6[>:^-2:'O39TZ>/C#RP=W=?'@ X;E9KTQ>"DP
M.WBU*4^YY;!?8HR+WT!8MFVV5UV,54WFW*I;SRY+^AJY@RGBU,G_2^KJ1IKP
MB+N.0YAOS_5*(9W5!LERD_:'BV:IMH8&$?XCA+/]T)2HI/(-S\_RLCNJ61J!
M=R5#$4CA:&0^1XRZ=JI)<<U&=L@4JAR=)]:P/MKSD0L?5RJ!WC%XO\(PJQ+M
M-:@I?";]?.3*8:1JH8,9O)IDN=7&&ZQ;:3B2>3YR0@[,R6)0K7)DJ<HZ*P;8
M717X]O3SD5J+ZT!NM+@<D??T;') )"MM6-/M:$G;I9E5EF0_P)>.1Y/I'-99
M35@X]&A->,.R^L0F-^::HTHU.[:8HIYJ"]3Q/CDK76D/EMT<M]2&7 ;#5SE6
M4P3Z>&3'S9:&4K/9YE6)PHDU+?M,&HX\6GW1UX59MCWC^$#-C1JBM.#GVS48
M>;1Z.JFL?<%V79P93(/\ILJ3[: M)(_?GAT+$Z]=*RA<-<L'9*ZPR8D=%HP\
MWB>^FE,W&][2.:9=F_5+LR5N-V#C^Z.1TH J3>H]O\CER%E+E3T_66TJ8.31
MDNJI['9:R952O#SL>8"P5K579L'(HR6)Z[;$<G1!Y*K> !.PQ4C@/=BU^^CM
M@23(U:TS4#A_Z\OI]$S(CHRHQ_&S%7&9QMR9XHS6'$W\=A5>:&RMP\ZN3T>6
M:M2F493Z/L\D#;;MRRG"J;;!R*-Y%G2I,]OV? ;W4^,Z5<U[,RL#WW[,32:9
MT@2K,6<TOSX74V,F-VFD%"%]O*2U@$W43<>IX"K5DRA5E:K;.ALVX'LZ,MD<
M<ZU@,$[CXM1=5Q2RU)6Z;-AF[.E(H[4:CZ8;QN-5?E!<^TF+X7NPJ=_1DK;.
MS+%TLJIR@R6[36ID'?C^\)G'/"('3CT['5@TONQV!V6U;N5LP$Z9XR7E1+VY
MH%LS'R>U E:IXXH]DMK@D<=#2SA=&Q>2P .N;AE-(9Q@6>)8&$4^&DHYNL:L
MY62-9^99.C?!N2$Y6<.A1^NWM6:OW"L):4ZL^YYFEF4YH-MPZ-$&2-U4N9O3
M!BU\65-U,U,E[0;@*.(4E,ZXJEQ61;O!JUYSVY+2^5*FOH;Z\V@HTR#+4W*I
M!%HQ8]JM"6##:9&%0X]FT"[[V?0H&$SX7*8P+#:G_@+"+G$*SR;4P"*+!6S#
M,9TVMYW+!"F7P6Q/H)1=74RJVTEASC?3C#4=9%;R$NXL=;Q=F]H07W5-J<Q5
MM;)5&&L*V1R@IQZCCT-Y@YE9TSEYS,IF8;4*<OTV''H\V4U6GQ6EVEC4!@(N
MCU>90D[@P=@30#G$VX(VXNL*OMS02LV;N.T&0!4P]$@*U@L>+W4&NL:KI>:\
MUV+&3C^+AAZM:]XJS;?+3*N)JU5M+GN;5:Z-K^'0HW4)R=IFW/:GFJ962+\M
M#C.<JZ&AQ^LR6OD%ETV5ICPYJN>D&L:S; /L[ D('I,S2L<]P><'BZEOC3*%
M:A:N*WD\@S)X:RG3$XM\-5-OV,N!I92=-AQZ/(,10\C]0J<@<7)E47#9NC0N
M9,%L3^"UJ7+6@AAIC(:-JEFJE?-J9!8\]@2X]E?>DNYY+1JO\ATIM5!2M,&"
MR9X +3T85[?+1K#E_(IF!M;6)]>#-AQZ1(2@M)I._-G6 ZI%JN?FR=46;Z_A
MT*,MX&:K =Y>UCOXTBX/%*QJ5/0 /?5X"[1@. NV>M?4F%K>=363-^4I(,()
M.,HLTNW JN K;5EL5U9X9<FKH@*''DW6\YS%-LWP#I[K=VI)5FAD,OH:#CV:
M+,EQOI[>+-M:ERL)'49;+(,2L$).@%QKW2%SCJO(N+PT"TVYT[>7 1IZ- &B
MDY343<]S-'_8QD=FH5^;VVCHT02RZY[2]-NM%MZLFJU6-[.>CVDT],1N+=T:
M%BQ8FU?)J=@GM:(^+RIH[)'J:F1FC$BGN!0P6NAV94@Y8R$##+$3D-RAAFE:
M\]P^SIBK^I*<$[JB*'#HT5.)0B83D'10YXI4.PELP:R2U]'0(PEONJG:9ELJ
ML1R93:9M;#V>+]0V''JT7?B06DQ=DZ9X)I59;=1IMFR'3SW:+H^KM<$3BCZN
M<HK<5S/5[H1%3SW>+BE)*/768COFU.*VV%<:=KW'H2TXWJ[!.(,W):Q.<,5-
M4TOBE< J&V#L":4PPR9\371(4<,$W"MDAWV^W$9#CZ= $*5QQL:,/$X:-;_+
M6;[73H*5G4!Z8SS)5-T,-<6-B3;O=Y6!49N"QY[ V7ZGN$QS+:>,,_5F<=#'
M*+VKL7#HL5'F!O9F+G?'?+%/"TJKT'()Z#><0L04-<EA*U+-XVK/D3+^IMG=
M%L'>GD#$;@OP>-H=+G YW?'21;[17'70T*,9K%(*U>W/EQJ_7"8W^9$FFD6:
MA4./9U"U4DDZT\4R?+7+I ?NL)3J!V /3B!B94[F6BMUTN0'ON;I^6R2D@$<
MD"=,V*+-62UNEK'PG%M.%1;+]* %1>R$#:N)%C?S*$O5E@+7)>JNT9A7T 1.
M2&/%Z>+U#D?R@WYGJO8&@BN[X+$G,%F3ETZ#$B1+6UIY(\]Z<K'E*'#HT60%
MD6@.*YE,2I-3K%$N#L>C3'$-AQY-EFD3$I]5>EFM.C"IRIPN3Y=%]-3CR3:Q
MHA^LEH,I/T@NK$P&,.0H$XX]D@5@QHI9H[#NX$U]J(^SV%Q4H"R<T" ,T^S-
MVTU?QV6\L)#6^?F@O%90*>XC?ZNXQK&)O@UPV5P5&\I6F8\<]-0CZ&#*6*I1
M&2\[7& 2LZ'&#[%!'@T]VBZJ)RY5KZ77M"+12H[934GG2#2!H^UJ&4YIE#:*
M6P[;C+B<RI!&>=J&0X^W:Y'$RH5-:>'AAI3&DH 6%7^#'GN\75ZZNVG[K=Y2
MRY5<QE=:38?O@+&G=%A1K!H=S^!Y0VD.!JEY9CW%VG#HL2'1+NA>:E+):%BC
M/1^MUK37VJ*G'L_6(@-FL* Z,C\8I5(5=FH-H'*F3BBQ]4*;9B=Y*ZT59^:T
MEJ*WZ\)2@9&CHZ%>BEW[HCI/\MT%E^8Q5QE66#3TB KY"=Y<# MC&Y>QYJR1
M\MAF!L@M=0+ "ZT^GF(=5>/]XJ:JMP(^QQ? T!- VYMU)^*&GP-_1K7J1<]K
M.(TQ*U GP'/"9ARN@O$-7+:8OM;*%/TFX!CJP*!]0SWY/^Q.?7 RE%?=Z*2E
M.2NH&YCKX,J>RVW@!6[4H>3'+HQ<3>7RXH38C/EJP]ED6A47'[#KXYK/I\>A
M<#/Q(R&[DFB#MWN.+U\J;/_6*@7TSP1:<R)<])E+$;PRJ1<.#U1/U%7IN!DG
MG"F1R#^] *2:GF@JJ-2TB*8?Q7/A@:@7/$0W\.%G\(XX^MJG-M3NG6B>^>=+
M>-;A[*4\E:@A'!D>2(INU#75/6?/U)?#J6\B:?GYXL]/G=_-$ T$?WQC^/=2
M0/085#]$H[SLB:HN3\MF&)4'CV<GP Q]W+>7H8J=;07.JS0I7FU;QEQ>U6I"
M=WUQ\'EG6#TL.[T[R46GKA@J#&N[\C^['P[?RH!71:>Y\%A0"H\3=P?7Z)@5
M%M_>?1 >LJ)/GAS%XN@D^/ @]OA8U7-V$XM>2(3+]*;[10)9A?5BH[/L\-C\
MW_5<]60,K%&"9Z)K1[2C!U/IGVGJ?P\W+9K";@,/CC\/7@E/6V9 @G<;N?L=
M@X_^)SS*AA>F?WN*'!WKHQ?OAHH35*!<OO"1\EF$\" #X/_^ZTT_0 GR)\[$
MA+@!0J1_$G1,B!L@!)"(9$R(&R $D(A81]P"(6*)N!%"Q!)Q(X2()>)&"!%+
MQ(T0(I:(&R%$+!$W0HA8(FZ$$$ BR)@0YR/$?ST'A@0O&?Z[\.6:5[<F_0=;
M<]'0V_6X 2[YZ'#B*GOPNZC7=V&$5S7%9V_"I['&36/$Y^S*Q7GEZ-;6JX?G
M8<F[XW_WI^CWP /?G.)WL <Q'\1\<!4^2+]!);R&AVS85Q7"WPX(;Y_PMP;Y
MKWIKGZWV_X3/W^XI';I%4?)'Y#<2]@:VWU:GB=UM_IOAA+]0MQS+=T5XR3CL
MLOGWF=C@XL[1K3$]_>F$_PCN=:V9MQ8=^7S4_UZ0]_EB_Q'JU\(.\VY,_>](
M_=Z^25A,_^](?]C#;:WJ>DS][TC]J*98C/WO=W;NF/H]RQ.?"?X[G9Y][;)_
M_B-)LCR;73G4H3YU]^#/NWL;P*V7EKX:GMVA G. V]7S>3F?O?:S12HB-^;Z
MRSE@872'X=3ZSAR/N;E5ON?2R5ET5[P1G\81%Q/C6T#D;TK&;R3',;V_%[V_
MAYJ^&"B3-TBT=W/O^]R$Z]%N7WR9L1]KUU9$TQ>=(!'>,"?OX9SCXN;^)_)?
M@GI2(/O"E6FCBOLYT7$"V 0$-8%B)<DW?%WTY&E>MAU94L-+ZJ@0OAO^;$[+
MABVJ#HJ3@-^*CN6ZSQZS+V][XH_-V8'_F0/N9U3.=G]E7D!=2F2W.7M^+QZ^
M+0K//;YB=U@3/<:CL4YE;"L.GLMO5^7%$&Q)ZB-5<9]/H@FK"??FHKF;RO,R
MN3U)J"4E5^]QA:G6;&46VWIIE.FL8)52\L<O@GQ@R./F%_<0;;I)=^7JF76Q
MW'Y4;A^_@L[:)-F-GD6.&6LE.'V&+TY$P5$IGFPZ?]YK]V/"B_6SL[JY[.&X
MP<P(O;BL2W,3%@ZF@?#B#V3R5'^P.Q'>2[K8MR."$&,(\BZRE6['@XK)%Y,O
M5H!7-%RC[,I6=.3X[#O1PQ>3Y+(A,YTY7RQD5F.VB:<+VI\WL?V81J0T9ISO
MK+J.5O0%?M1J>E2F \U96- OPR1C??C)69^Q1#Z12(]>U"VZ:Y,\F5(VO;E&
MYH+1M85F/AJ,["2?,;ABR^HU]57?68LL%!K@!)+40SIYW.OFKL^=]S$F6"$1
M98^''>O<^&CY'HZ6+XP9;VK >3L0<J9HE.21/;FUF-F:7'=PHM],T>4/]6C:
M"]4>@GISP$+*/.N[JBF#Y5G&1#71YCPW*=ZFZ^LZ5\.PU QONO.1D"V#KU<5
M(8E"5P\T15U.V=^6/,2'63$P7#C<)2TW1K'>+P[P0<K$25'!.9O_B)UR<71(
MRVJV92C+)<?,:UAJ//3X\0RVRJ)__*)?: A^O^CPQ1)28AF_L/)_O#NP\]Z%
M@L^K7G'+8X,RDZ*"F;NP/A+/OKB ;V777O1'?I>3M4$]T^=4CVJN@8 S/WXQ
M#]2K/LN="WBL[6,D.*NVWWV\Z]=:L'UC4\OT>::WE(*>FJK5.S>M[;OU5DT?
MC'F."P3=QX0F.2C($ S2Z!B;9KZ6,Q"CP;5/9CZ;R%\ZGRU&\D,DKRU'A1G=
MGDPUM6O4F$W&5D7MIB,QPD2C<LM.;J0%'4;)!M:2"XHP$H,"R/0#G:3/'D#^
MO&AQ7G5MRP6$B-,0/S<-$4+%7]\;*VXU^+N7D?? 265&I,4BTS"U0:V3J^)T
MTAQ0L"$Y1),'BB*.P.3ONSG&O<TP;BS$=R;$UPO4?DB29SJ3ME4]V>*K4X6;
M#[O]_#+# DF&"8H/22IUQY(<)RC>/%6^(9S&Y+MK\L7:\+))BJUQH3)ETFM%
MRRV'-CT:D#U-_<@QQX?4H[\LM*S>1.QSS=PDWYDO*]IV!0U=F*U(9HZ/*&/M
M^,GIBK%\GC\\]2$1,AJ*-B+T;)^K#C:<K?8J-+M (D3"<WZ".;Z_]O>7REWL
MR!*$274&)HT">(DOD\3X*?H_SG:\:?2YU8!7V90<673EO!S^/XJP]QS1=&>R
M\RYLZ_CC>K69E73<3X_;V8HP=E-+14C!.!B3O.#%W-L2@/B(\WL<<<9$CHD<
M$SDF\E<A<NPKWEDLYQPV'& $\-X3QMRF,LU*K:KL<,PF*8XH!I=J[!H8<S#6
M<\J:.U^LYUO"P:TG.1UA_KVEP>1\QY%-*4AX4#YT!"3WF1'S:7&&SZL_'0<=
MOG#0H2%[W$8">DF1\^H,:"Z4(/">",2XV6LS>F9!:=AH;.8&V(#.SQ4AC:Y8
MWF\MA1L--MP-',2GRC%Y8_+&Y(W)&Y/W"Y#W<UO!Q*;XIV8?7-Z&G@R<0EDK
M%[AJ5Z;(_D+H.JDVL*&)WQC1]YR<$!;O?KUE+ZKL#;8=$39,$:*(A_"'L,KW
MN3I;W4(NP^^[79VWI^GQ>I]B' 4P;FKY@)5O$.1>W:T+UXB[.<@[4_2A9^>Z
MC?6DV,&9+F[Q^;&RL(AK5RRVBI/%D&?&*ZY;G6<"3S;X"=L6,E&Y<2I]JD+C
M&1O<W59(^+:.RF)\^#;X\.+UH=QF%)"UUK"@B;722IENJK7):'UED"A4:JU>
MD,^6\$'?+O:&]"SEYM< )&@$$AGJ5&F7^P:)S[,58BSXYEAPNAZ4:[2ZS?FL
MAN.R.RR3 K.I#XUK6PMS2IFJ=DFB--5FJMM4?E+*CB$0O%+BZ2OAP*%M<,3<
ML;$0 \3GEHGRQ*;6%:GN@@_Z[65]73;QTN+:#8RV*4]+#BC6UHK";!((<M$<
M]*%'\5KEIQ@D8I"(0>)STO9D:NB+09_T-"9P1P[6:V/9[K4MBUJAOU6]\;K+
MBVN]L27KPVJF#5$#9N,1IZ*R7PDRKNE?G,[#BY'A/I%AN]A.]<IXS'-B.5G-
MJ&Q0"YAKJWR9KC4TF1XDM656<EOK5$%61.@6H#N?] -!G>I[=LC0MYYK"9^I
M/GDF^OD?U0.SD^#AR2,/)$1$^"TB? +P6T+=DSXAS<$S91=LQ_F.4N[VZOBG
M5RO[K%;;WVW5MU#&XZO2^HN6/?HN%(N%,29M3-I[(^V7*J#S;HK=?T)4F/-4
M$4U?=(($\9 (\YR^2(Y3W'3NSAI5YL+'J2N9/? AGSSCO#E(E=Y ::;6Z0'?
M91NY:;M5GZ1+UPX?+'K3J8<Y5H934YZXKE=2Y5ZO+1 $3$)*/ERT2^QM\?1M
MY1_%PGT_POUB I'=*Y.!-!IO^)PRLHFA:"WJN6M'][/N**\O[4F5$PVWH"G)
MJMQH( E'S=\8^KCN\#U+^"5=\IN6T[AN2DSDF,@QD6^/R'&[IB]K+;%C35BV
MVG2='U2V@YZI$R-]]I$."^^Q<(K; *?+'$%PF+K):[1%MAUK#2T<=*L,?V (
M\@NU7#JD27R.^;GGF-_@/NK5XR+-:EVC>UHIPV,":24Q =LVZQ^Y=G&X]O?@
MBUWHXJ4MK_;QXBKO23.K)7(3%M(!PLM#ZN05C#N)K-]F0"26Z+N5Z!>#(;)-
M>Z:\*>%:4!BE^]M2J6*,/M1']X-B[4PTH\E;KJE5A4T>'R:KP_$&B34-6ZNE
M+QGZO%MU&POG/0OGZ>M->J%%"D-VE.?]Z1";C; 1F__09>B/2F;&,/+U?#*U
MY);4TNMJRG)@BT@RF1^_Z/1K_5/O22YC[1J7YXG)]Q6TXN>FD<1:\4 KZD83
M%S9VTN$&]72ONY1[0J/WH8;A'U1F32&9KWK]DHM7VQ6-[U9;F=RD#3>00$?L
M>.I4@OY72/.Y6(OPSPYHQ[V8HI=\R9+^]Q_P^E@3.4,S"DMO7N-EMK-LCMDM
M54BM!8(*.XZ3Q"7[%-\<A\<'E+&HWWPD[$/R3F#)Y+JRKA"XT<7LC$ZRP[Z%
MY!WU)2>(8W?[KN4]%N_OEG\0$SDF<DSDF,A?)>4HML;.'N3YD 55FI,UPUU(
M 2^6+,;>.DVKQBK0@H(1'NJ!HHYKJ'RX[_;GQ7/B7E=QKZOO 3.W&M^Y>)G^
MM87SK$IY8TVL+M)$:Y3*F0+P">FXUU7<3B4^\(NI]L5U=$S>F+PQ>6\,<^/.
M5'=C.)_=/[^XQ9ON\4:]*-=]7M1Z\XT5Y,2QPD*+-^Y,%7>FBCM3G02YKU\-
M]NJQ GW36*^<?'6*8^U@Y,G;C$KGKMUS)M?6FKJQ60BX;YO)46;%+!82</^3
M85$8^F3&VGW7A+[1R$ ,#]\7'E[,'YGK<X6H-%B7ZV[;V=K(6-O,YNK-ZRJ=
MN<W54CC?S*=R1#[5&Z;T-L0(&O6CR:2_'$9\GJ400\'WAH+3][:(0J6MSP=\
M76.JC;4KY=)$*WUM6T':N(%5R^H&[],TN<$*> <8-! '7KRK]950(&XX<W%X
MV ? 8KZ)^>:[\TW<K2:V.MYE=;2W2U.:K1E/DXEQD\IK;2ZO7[M24WJ<<<K>
MH%+BFG77L:;8>&6MD+% 1#VOF=^UF[KU;*E_?]^M9M]+"/"/Z]UQ/YK;T&)Q
M)YO/7_5GFC#??AL^^]@^)OY7D_R8UC&M8UK'H/X9Q+^MECP?VH;[3PTYU:.'
M^CK9'C?!\#=7V..Z):UOKJWOF3(Y>G:NVUA/BAV<Z>(6GQ\K"^M#5?7>$W!)
MN<O*T!TV#;Q:"YQFP6X1>7<M$"DABK>DX_X^W_R.<"S>[\_$R&U& 5EK#0N:
M6"NME.FF6IN,KGT"VUODVG6BTJ]R/MD9-,8E07?Z;2CC-)+QS"7K4\<J/);Q
M+R'CIU,L7*/5;<YG-1R7W6&9%)A-?6A<6XG/NR/6]VLE7BN22P+K;_R:X;-0
MP!F4:I6,Y3N6[UB^WZK#=Q]'S_+$IM85J>Z"#_KM97U=-O'2XMIM.$O#:7;
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M]>O_P#\[V91T672@XIE'@K57(E# 0K5#X/C_7D152&!=LK.3:)(^..8(Q;N
M45&*,IHW^O=_#J?_J LQ"?BYSC\[A7>PKGFH8DBD^Q09FSBRJ&'B#+SZ'U%?
MBX&[4Z_IG^0^'?B?O=*$.Y%(_DRG_S?Q^"/<CZ/--,0-=K!ED:;%='GF_1-^
M:_<14I*[SRQ7A:3_QY'#&FCPV4^>BNCB6?;EB/+LH(DZT-=B8NY V?Q/KYD[
M922CGP&3 9'3_SW4Z=%'/W[UH)I"T )%W?3<O980?QU0]R6N?+JGIS9+W&G6
M1=)J!,PX&/*#DDVNW'2OM5': @$#"^AM^Y'9>8=RJMR@AP_\CKLM%J0<ZRL"
M>3Q2GQ<K_>3<S>(Y*]5M-K,9UM?6 HH?/AW9S'5<9M#%&2ZGFJUYUIOEBBH<
M>?1,-;LI]?S2>(T/UG9^NQCDEE036 #0U7HZ<E#5L@6[U2WQ3+'5QIBU/N]M
MU@)]_/;\>-49C[?&B)>+$I6>6.UTEVN#D4=OK^/5DMV>U4=X-3,JS<"BJX4U
M"T8>O;WC:1M*33F!MLP7ZQ-2[\Y7JB(D!?SYR-'6I0=!MM[DQ&6SM& :]0FK
MM\%(\OE(.UM?5]+K":95LX97KJ\WHDK D4<KFC4FTU*ETL+Y0=4L%FAQ$BRG
M:S#RF$:%GJ62YDC@EB.VJW<K'H$UX3./5J0N^\-V,BL6M.:V8GG!MF7C.3B2
M.%K2I.\%;'4@9'@5QP=RA:DO4[6UP!PO?L8G\10[G"SQ:LNW\X-@BHW&;2%U
M/+)5$EU@?PI+K3G\_^Q]67/BRK+N^_T5Q#IQ;NP= 7TT#VN?NR($B'D&,;TH
MA!!": (-"/'K;Y6$W79#NST !KM>.MQ02%65^>5469G5%CZ:BET7;#UW/#+(
MX\W=NB-L3:9;B1L<MM7*N:[,'X_D?&W2%(:<8Q9H%?>KJ[7!=2*9/][Z.M^2
M\A6/]; -V>6;@^9TL%'A,X\V5"D4YN'65AI20<7KXS"'*61# )MT_/I>IRAP
M M/EL/9R.VOO! 4+0C 4/QZ*RRT^OYX0'3'F2M-F+]]4QST=#CV:*L\M2';3
M4&*I'><;M<4BZHG]+AQZ--?:;+CMBHQC2>7-.,]+$:Z&6O+48YJR'FWMEV)^
M@1'MHE%7E[J:#R-H8)P@@+*KU RU*,436]F2<JG9]Y.A1Y.5:MYVPU?[&ZRP
MV^8'ZMR<[>TN''J,TKI<V@HF8TNVTI/LGM1CAK@.AQZQ:C"HRIUI6*R)9<O3
M&+$[[ EEL+'D\5SY 1[';FW:QC2B%>Z&H<KTEV "U D:-+8R3[<;IJB%Y8X5
M#>EB#M+@!*:G@J#M1^V")]GKL#;W.',QVH"A)Q#0Z=05=JC.0\RH$]TJFV/"
M&A ^8.C1LAQ[M6A9$W(A;D)E1!C"SJVWP- 3:%E.QQ2W+_<66-QKYL?L''!$
M68=#CTA08S6-+;6K0],.*+DVZ0G[!9<\]8A?\+U7F.\ VV+E02G&-F*.H>&R
M3H P1RLTM6ILJR*![PM:R5U7PR%XZ@D4FB-O34U4I2L:L90C+(%6F(T AQ[-
MU8G8,5WB/$R*.T)5,PM[Q^\E3SUB%]YKB/F6[^[,MMF3<WD&7Y(-'0X]VM<Q
M425S5M>=2F%G81"]<%HM#"-@-1_/5>CU\[9@U$BL'XNC[7+GMFA-D(D3D&UC
M@3S,!7L&VVP+7FTPMOMD%>C)$X"IJ!VQK'6;D3B*\=5\2K0+S1J8P E^#>S2
MS%!+G8Y$5 >]7&=9F]9R8 (G^+7=*=DY-M?H277;G$WR1KV\@HKZ!+_6[,ZD
MN9UKN&07NG6\KE-<7>C*Q E^]8=$K4SOA:FIZ4&S)"P5H6 +<.BQ))JUB^.Y
M06O S]C5P@D>LQ4\>>H1M70F]L6ZH6M8O.FM[8J+*W. +>($"F)MR0_7_'YN
M$E2]/",J8E"AP= 3*-C3[:"UTQ8[D;':]E8C9YU*'NSK"7X5RD5RK(7&WJSK
MNS&W".P5%B6%:8^&DI.]$5:VJXZ9(XVNH"Y[;+,OR.0)=AD6\_1LX1DM<=.L
M KTD"549J TP]&A9=M/AFT109"6B/@]G]2 7+SI)^9RCIZ[VP[@:B"M35 1^
MKRMS1M;8ATH[O\QUU5I[ V6WPPKE#EZ/MY5.OA<="H3\0@)R$!..+2U,0RJ6
MNS@5\48M&7HD![8NBRV,9;LM;OQ #BN58CX.(IA$=LQ93:52:Y8D18KSY<%D
M6"\VVZN').1?U&$1&U@VIH=8P7-*Z\J"JS C 09WCI61BT_"'5Y=8W5NU58:
M%:I*2@\9),^'[K;K:-4UK;FH,1KIZ<)JTV<?3K%_L86&NJ^-%R4):\]VO853
M]>/I4CC$\9\/%2LSHMZO;<I8?9IO-"VW5O1YL ,G8&@+77A)O5 2R]5Q;[@1
MIT2W"(:>@.$8KZHX,_<IR:9G$]F85)RX 99U H:2(QA,;EXNF.WFF&KMZ]'0
M@)QU @6QWJM0O7*0EPBA7[8FJPK=I<"R?J( N+HPEF X81KJ2'XXD^MLH:C,
M\-U4JK>\'=^I^=A(B&0X%$^C#^ 7VEP(_C2:N-:Q0^I1'2HMGXB2=CP8Z0KB
M;&9M*4Z049QY$BM:PSC!TPC<,^?_-X$6&7\:9GF(DS+\Q(\&J]I,,C9U;[7:
MRI7-.CH.?Q8-7[5</_2T]J*H!8IA:?.JD\9?8 7OF1L&#]/MP,D*SEQ\F*JX
M@_-7 M>+_WJ@UBP?"I%#S9IF6QT!&\+4.O,">+'FJ\H:O#KP0NUVTN^3 .QC
M+"(-PJNN92EK7_O[X8^G;X79FX=X!'1LU=0A?@B])($")0S<AP_2,$'RR;-@
MPI,X_F',<6 @\!XF=G@AGB[S=3FO%/:#9%]*VG[BK3]Y/@Q,+BPW>MBUA__G
MX"G&WVGD)0+[],>@QR$*E;SX8:@R\UTK#+0+1T!.8S(9"+Y\[3G@SX#5AP^Y
MJ!?K9")"7(D0_ \:1X2X 4( 1"!"W (A$")NA! ($3=""(2(&R$$0L2-$ (A
MXD8(@1!Q(X3@?U O%DQ#A'@;(=YXF_>/D8VKK/HWC\WD76O^]%G<&S;FHF&&
M[[DK?])>WW-7_J1*ON>N(%Y!O'(SO,*]E&EY,A/_%7OT_!@J275/TM+?N-\_
M;T4@)KMK)KO+74&\\AZGY*YWY?4>PN^VYTI.PY\D]F]WK !^-/,,\."*9FTU
MN#3X$L7Q<R=5P_=Q*1Z7_#DW.J\C@[\<WWR^A$9\@_@&\<TY'(OG7L-CHEH6
MN@YGJ].(:(]D!N*;6[;];Y)O[O+LX)/9!9GU-RMJ/Y\SD#"]=0,LJ0D'%X3L
MK^]&^D7H.480>AHB_7<C?5J="-']>YC.Y]D59!PCX_@FA2$RCG^G(CZI,.'-
MJ[\GUV/O20,BDOY^M8HS/UL9443&3R-CZ,S3+*+[0>5=J&!DE_YBEWYB#Z^W
MX?]?2:5'-_2!A$O*08I2[]_G$W67-4_?(^J._SVK\/MDPG]$..9#PX(3\K^R
MID/D?\'$23?$5M2EX6B(#;XE&Z2[L3!V,'2+>.!;\H#J.G[@A4FE:<0![[:(
M[Y@#!FZ0GME]V!#^['X9QG.? /[]4.WLKW\$=1,:Z;74C.KZ\,S".)_E^]EK
M/YN3>Q!HM]8#\CEPSR2B$-$0T1#1$-$0T;XZT:C/Z2?^'J+=^N'X+PWCTY[P
M-<4)%2_.X$DC'^(> HH7%Q*?R%R_M$:[</<S/.T)6U \+P:K%))>48*JAG9H
MP9Y616WM::J1%NZU7;"5?OJW,Z\^MB%*FEIZKN__\IC'EK,GOFPOGACU!6#3
M']I>GFBA^=M:P;\TT'P,C!X>%8J55JT4>:1H#Y7"OC%61<+Z2*OIWT[D1#\W
M1W,$'I,;C*D9\F@9*-ZD%L/V'[";&YLE6.)$-[?;=]\1\A#RM*<O>,P<_OF=
M,V\>0M/@SZ0@Q.-W#Z]BQ4736M*&5+>5G85MU9SM?J3C]%N0*07M#4EM!KS$
M8!A7]2>S@5C4 3*IO_ZA\2S/GNHTC9")D'D_R/SY@P1^OQU\>'Y=5LID?ZK4
MI1%N%R;+TM8I3C[2 /4M<"2*7:=>$LIMC*@WRLO6MM)N&X*<].C!\2S%(S@B
M.'X5.!:>G-A4'? KW=/\!WN5F\6M]JKD4J9!#GK"T%/7D7PM>]6;:UI(#AU3
M(H29/>JP1:J?AUHQ:?1.96GJ5*?W;X[#*^=3(1P^PV% K9HNU5\3$L'JN\'2
M) KQ1+@27N0Q%KF3F3XTZ[L]N2R[JKXJ0?\.]A<D<#I+<"\!Y@Y/Z1Z#1SB1
M1H_ VY+NQ.@@[AXBS1<6%K\VCR*>-8\B;DUVG#',5*3&2J4#-DF**^0JY]?K
MJR7]$>OY$5B)\3Y8*LY@"=A(7^9#'WK5?L&U9X:3M@9_B\RJSFEB[9AU%BOD
MI&J!VN:E_;@K<S F1;+LY?0[ C8"]JT"^_U1K(K0-IF=;C;%<-R.ME(@]2GB
M(_;ZQ8 _%EEVE2^:K%1O,+OFH,;-5A7889KZZQ\^R^(8@CZ"_O>#_AO#9.UY
MO;8J!KFEJ=37!I87&E6]^!%_XV)X#XD>;H]47L9LRIY*PK#0;W<C@'<&^"99
MED%X1WC_UGA_,0ZW690:3<ZO=K!<7MUR_'::4]F;U.LSC9+)_JBG2W9K51_I
M6J$P6$&]SOWU#\MD6?:",;LO!/3;RS!"0'\*],9F4EI0W=G<-/HV,&#YM:&8
M'SDNOA@@EVXMQJ8](H_5-Y[6&JOL?A! #QM&!3D^RQ OJ=Z[21][B  F]8,R
M2\V:P]W/^& W[C-][/A6\M<OD/(GF0-7B!-?YO+]]R,H).*_OK?FN.=H4%%3
M/4WQM8-J2A9@+ QM+O@5('%+KM<'\O8MVHG%F#RQM)L#DS"QBE(L-R4LK\L\
M# ,!:Q'GCW33OQ'Z[Q7]OXAS),WOG)Y(FM^/PW]^T2WOJLZ2X*V=.%(&"T'6
MU1;C1D!T T^?QK(<C2/9?;^%DA#6+^_SGQ^3D; 2Z6%QI9NY*<_7!;;)MP80
MD]#9I]DLS1X[^__^4BE 1<-?N\#K1RE =W%\@,3*3>?]/*+I+4)H'W37*\N9
MA])F.,MSDM@K$I8.1!!,ZL&S.'=\S^Q\A@%"*T+K3:'UEL(W[T&S2 [*.HXM
M JGM5?&(XRN%D!0@FBF8AI^EN>/;, C.",Y?%,Z?G:#S+@Q7.N%:&8G+JED.
M1\MERYW2XTFBD>&-MBQ+(HV,(/P-(7SE$-R[H*OL76LV* ZD42A[TWD'*[AL
M%T*7^^L?*DO2#(+N?2;4(.A>(*+V'HA))A[J576%F1LAXEALU&N.YXEVA%$S
MG,]R](LF[KWER/0T]1!I5)7SWI:[5^%P6^>B]YWF\G7)\KUE]3T'/JI.>M#R
MRX'+P%,<?Z%Y?LES[=.VX)LB):XJBO.HGI,,?VB0<\GD'#^2<1Q&2M@L0Z/Z
M6C<.<21X;X(JR#*^'Z?V,J(5< 68R0D96UYT"XN C]98H3 MTX7Y0)RT="AC
MN=_)V#M-.OFR-6&.A.P7R#HHA)ZG.6J<"2#?6XEL0 D(KPZ@?F*[BT^V$!!M
M$6T1;9'S?KOFY.<<<_[&K&QI@;A3EXJC:T5C >Q+H'2U-SGI##[8!DPW\D2"
MJI8+I#%=:+H.2<?\]0^)JA!\"VF )/U;S\GNA[;?7-*?_4CM8I(X6 @Z(]?6
M*TPA-,*(K>ZT,NW"K87';B^*XKLY<4N;FKS8+R_M> )V-Z%?BF02SZ9_I-U/
M[J.E\HE[,U=N'_]<2)% 2,W=<&9I-RBE7MR:"U?-O3F9=<8,>'VHU2=-SR;,
M34<0]4"@U$"_5MUX/C\N..& ,DVC6AF7M^*ZNX*V)9ET6&&R%'.JH.5]-$E%
MZ$;HOOF#8['/D?ZX7!8E(YSCC4*K:*ZWUVKB8BPZ%=S4S(F9\^.6ZDSDVM2+
M(/JIY$(L1IXJ?870C]"/T/_^R)/1V ]XH4F7L/)6;H[G6(L=1==2^$.^[J_"
MS2K&%+74+X>D&+7B+H0\D]Z-.9GR@2"/((\@__;<A7*-P_(M@8HP8E+J=X8D
M07NC:S6CT7T^+S(E7#&9H3/A2+/.S+<)U&$W&I++4O17,N[/'5%$4+Y+*.]7
M^[E5FTXE4:G2==X0XD;,7,N@YN>309\;D1%F+(U2J8%ME.TX,:B3AC8$FZ6Q
MX_I@SS%WA[DE\)G&LV<F?_]M!&#"*HP8_F0(0(B?')$!S)<Q'OD@HR[!,S4?
M[-#YXH>?O3-?_3+?LU)#5ZDL].5.L!!=$5T171%=$5UOP.[_,G2]LR/G]%2Y
MICBAXL49/)M)3Y+O\13YZ]QK^8K-40OIXXRMECYC?_R,\Y_R5NKS8:G2-7>B
MK<>K97$W)@;\M2)!_#0:AB'98[%^N"Y85)_)4T5=QFEXRDMG28I#U_P0\.X9
M>.\_@!6*FW:]PJT"K)['G5G5Z]1U]UJG,=Q6'.29HM'%%-I2QTMW4_.7$00F
MK%2&9UGBN%8*0B9"YATA\ZV'HV) \[J,+<61E&<F>]YK5>5KM2/']L'8F+1C
M0VJSBSS'MY?XLIWH209>U<1)&J$1H?%KH/'%<\OV>.13V+*CF_6-J31B;!F/
MO&LI1=)Q"X94]1S1*.UG?L?V#(86( HY>(:2Y2[9:?=>87A;%Z:_&0R%J2EO
M.EVJ*8UJ^]' L?")M;B6TBK3/9>R]%I-U!JMF<*X7;783N "SQPI-HN=:$ET
MU\>-1P7TGY ;'1O>0[CZ&UR ^I0H4VZZC)4&(_*F,B#G=;W;:!69#]7N?;(7
M;Q%*];E U0MY>8J-%)4(9O1B38==&6=@Q(G*4M0%+6F$7(3<&T7N!^X)<+.N
M0Y<*IIBCXG5UM;3'1OXSD)V;],CZ?L%8$K%HY%RV4I-L-4%VTO^0YU\R-A"R
M$;*_)K+?&.8J%1T_W$CF2JKOYQ76E9MD(_>Q9GGO@W/;9DH:(S4PK#Y2*<:B
M!&]=2>"<U-GG:51?XDO &=6/N*.L#R2*GXA*RVYC\FY->^*HR0WZ&VT@MP8?
MZV'X/E%I-HFR;FR]NEC7:O5VS["DD2) 49D472>S)']<=/T.TW$.496?A+C/
M))SKY\/=W&'(71<'1O3[WG+_GIWKGXMI@+WH::JK.X:OS9.#MH41M#WX^5N4
MSWQ9#(B.H/>E,F5QG-+<5L,]4#XL=+O)+'?).G (]G=MJB/R(:E]NU+[E1D)
M]7C(]JTE43,W94NU6M@TU#L?J@)_=A&]Z/:;$T:8Q)AMQK/6F"2;(3SS8).\
MA2QVHB43PCC*;[@_C)_=(S\_%BM^M<?B59&7[&EURF\GOBSN$RQ"7YW.<B=:
M '^MG(B'MG(H(>(>HK7_^:+]8[Y(%L1[>C1NFB-,D(J*9&H=8N;GPCKC=(#'
MQL$4"#R+<<>UU5 ;5 36KPG6&XK-O _,^%AJ#E9*22JTG$7,8I8ZQ!,P4W_]
MPV=Y\O@&'0(S O/7!/.GYSJ\!\$Q[NGMIM#0Q+H\FAAYUAJUE@F"DT0'AD,(
M1@C^?@B^;M#M7<@5AH.])HE8),7%N;@*E5ZG($40N3"N1F4QI'SO-=$%0??\
MV2WO@9A6C',-Q>@UI+;>V%;:RUE-;G4AQ)+&)DR6I8Y+A?[[?G-;+MK\\E[%
MPW$!XUMNFG37IZ2(:HAJ=T2U[WW<=7?^\<7ZGSE2K[/%>V(1"W'6;!J!#1A<
MEW$^\:%1$:D[ASD2SK\K_W[+5/O>POG\N0B7$IZV[>7*E8!1L=QP+81:6U]'
MJP@*S^3ZP$O2\Y[S$6ZNG^1G!W2NWI/F3ZUQ46^+3^UM\2DI$F1[']-MMRF+
MFT*S/%K3YKXA7*L<J3^GQ:8IYF1QI'?JTL:Q+6\4@1V'F1%<ECU9W^F,;6F0
M!$ 2X)M(@/?G7<3]FHW)\;Z/M>G13#5K,Z]F7*N/3L6?#R<N5QF(<>RKQ:6N
MQ(U6%TH(*NE2Q^ 7[ER%1 02$=]$1+PQ6M4?+4HMNS#NFN5=>XVWE;@YZEW+
M<EA0M+UCJ%Y-4IQ.SE*=EM1MZ% N) 5:*?Q462DD%I!80&+A0BDBY+)E$6I9
MUC CPJK%H!'IF'^U9K836Y?+VQPO$M%@%D^V<K F!2@...!(G*R=CH3!.5-'
MD#"X2V'0W6\<=1$Q@:GATS99-+MBT;I6O=JE[*^+1C>_QI1HSL6J0<9$+K'M
MDQZ9?)9F3L5"/]XB\[K@_$,_S,?6I8!O_."\'2\_[S+H$;2^QPWPV]B&S[X)
MC(B/B(^(CXB/B(^(__4K0IQU&UYOT/YN/V[PS/]40T_RZQSCWP(&;N\RUG4;
MP5S'L3[Q97OQQ(4K  _N_$?T^E"K3YJ>39B;CB#J@4"I@7ZMR!H]4_8>S\1-
MC!DUZA;6&+>F55T&&TX 'YW)4LRI [BO$EA#T$;0_CBT/U#SH,^1_KA<%B4C
MG..-0JMHKK?7.GO76#M2S!H_PNJ-AB5P=J4ET5T(?>JO?V@LBY''A4L0]!'T
M$?3?W_2TL1_P0I,N8>6MW!S/L18[BJZEZDNBJ3/;OL";&SXLY:?K]72.)ZJ>
M27)M:)I >$=X1WC_^&%YN<9A^99 11@Q*?4[0Y*@O=&U<F>*BJ(REEC@I+@[
MFND]K#(-FXE>YV#W BY+T<BFOWS("@']AH"^7^WG5FTZE42E2M=Y0X@;,7,M
M0WO:UB=\<;Q8FGTET)DUEW-K%0$",CD()]@LC9V_<^OG%5T0P-O@$LY7DO3[
M29#O5>J<?';UD+PUZ7'&8%]YTIGS'-USQ3KN.4$UM^SO9A\11(]@2QR0P5)Q
M#A<9\Z$/0P]^P;5GAI-LT-LJ*W>*3LUE>E4SKG8YM[>.XU$]D@%UB+_^H6G\
MBUP"1VA':/^T^)\YEP5C5+%EL3#F*+>XPA;.AW+L+R8-\K7:+&RUQ:TX6G"M
MO5PO,QH,'I!I752<1?( R0,D#]X3%)S6UVW+F 0#R6@Y:VM6*$<-XR:%@.[+
MU8[8&UH2$>)L(,N,7(T3DX!)&I\07[+Q"1("2 A<+%+8KM:[\701UZ2XL>NT
M:@IK4<N/G A<#/SRJH!W<IA7PA@JUB,5T[5A3X#@Y_[ZAR*S^,EK. C]]YGU
MAM#_%/T#>DR58S^G87:K7VDL6EZ[:=PD2B?"N$4PYF@A*ALCW_:MG2J%78C2
MI!\2E>78ET[U[[D T9=MB'03\NCVSB[_<X6:TC<NEVXY,/FN^M2-3J.P4!O6
M&HLGM:'.#4>4* +Q126]E([=BZ]3_OVS^JDB3-\[IF\H_/@NS-<D85DF<4P5
MZUU7:XT<K.?8 L0\S$/,8OQQE; O"GNDVY$<N-^PX[O 'W'1K-<WJUNSCV_Y
M?HLQEIVM#L&?=&OBB.-"/PC\"/P(_#<2;GP7Z!5FM]$Q:A]([>6X4O,[6WRA
M1!#T,$,Q2Y (]-\N01&!_OQ1QG>!<U_IC:29.JJ;.;O"CS>*Q?ELHI%A!)'+
MXLR+Z+RW9,6>ID():RS #%'2(CJQ_#+2Y)9C@[_IO3" 3=H6FN>7/-<^;<>\
M19*M&IV0GYD,A1$A7>@Q<GFL;(&902<9C)>\W8B@CZ!_3]"_H1#B=40#OF<I
M#(NPHEG>=V/<XFL^W]2A:*!@0=&OTN$*B0;D6-QC*/$R0@!P!YC)"6G 2E2N
MYA?F2[-L%<B(:AD#LYY( YC7>,%8!!(&2!C<D3"X;FCQRD) "ZG*I#6;X29!
M56BNN.A1737Q%I*@)$E?LOG\]Q,$*+_QAF3"V2./U['B!_NVY"MZF15M>:CZ
MFE+0)V8"V:33XM?.<[QH:WMT2/+:QB@WW3'VW(U^$5M\!;9 7(&X OE"7RDP
M\O:FU;]U@_C*2*_)_)3%PI(?%>NV:T@LL*F8)"'K^,P$)69\<S&"E,NGI>O<
M,%<@Y7(UI_J,PM^H4EC1P+"9&<[9<GLUI_)R(1'^B4/]HO2_F\2?M&G!BVWB
MTHX&8)\32J8M]D@\F_Z1=C<X5W_!;YLHA%H*OJJ4XLV)M7/F%>V"?9<>$1NS
M7E^.!ZO06?>'UVI/6-J-)N%DAKO2:+V(0T'1IHVE(!-LTOF S=+DA5N/(]@C
MV']AV+\_ITC&2AMJ)ZJTU-_.)P(;1C/>O%:5=%RV%6KAB#*FZ;8YJ^=Z%CY+
MQ *5U$_@J5/G"D@L(+& Q,(%(FC;'8;EZX-5 RO@S0JS'JG#O7,M$R&:Z(MV
M1-8U,]<NZN5<7%5+1A?*@K1C DM>N/,XD@5(%GP+6?!B9I%9T7I]8Q[VQ5R%
M* 7+@MWLL=<JWBX$_0TO57T,RQFY^K:]7D][\T0&P+0@ELOR)^H3("'P\7 G
M$@)W*02$T*0I2^MCIJ;'S75;B>B9>*W6)UVS0]EZ/]"D-C_@S'Z)5(H='8(U
MZ;3 4ED".[Z]^!RM=Y@:!)]I/'MF\O??1@ FK,)XYD^& (3XR1$9P'P9XY$/
M,NH2/!-, FS1^<*;G[XUMR#2;K+*P@WL##KD0RR"6 2Q"&(1Q"*(1;YQ\9?S
M[<R=)2*DN08UQ0D5+\[@V4R:7X!R"^[SAN%7;+182!]G;+7T&?OC9YP_.8!L
M[V.Z[39E<5-HED=KVMPWA&L%$L21,S"6$<%@_6+9%T;!8F=-!)G@87( EV7Q
M4S$_%.]#D/T&D'W_P7[<K]F8'._[6)L>S52S-O-JQK4"^<:VL*.F\:(CA3NG
MNY "(V\5$TA3R6$>@U^P*_*W*"6.('PO$'[C(7Q_M"BU[,*X:Y9W[37>5N+F
MZ$-%?M[4=RBV'5M>36I28=!94CK?"WQ)A[AE_OJ'S5+XJ8 ^@BV"[5>&[8OG
MY>2R91%J6=8P(\*JQ: 1Z9A_K?RYIFMUNU0#\T4F[P^7E-D?=5H1A"L'*VM]
MR1YAJ&3&UP=K=[]QU$7$!*:&3]MDT>R*1>M:B6C=W&Q5<%O52-QXCMT7)W7#
MSR>@2LZU^2S-O%2R[@Z/M(^Z>CTA-SJ9_MH'!M^@-L^G1-0BSMO9Y#(?8[&<
M$X 8&X[JUH<Z?CS9B[>(,UL/S6$'+ZW$NMW;!ZJEJ<M^5R8Q&%VCL@1^02L!
M81YA_LMA_OTAN2!GC+M*8$ZQ^MZ,1Z)*SM?1AWH.O%,F^!/+,X-2-9(VJWE<
M+HE13$@1E E)%S#^1".@KRD3D A (N#R(3U<7*V4P-_1HM&HMJ@8>!1-[B/N
MS'MQKU1S[6VG34]%FW#;4UF-67XM0-S#VKM9@G^IC!_"_=?#_9<N(/-M,WR0
M<'\:2S+K[F(_&>?,0HWOZ?EH. WVGR%\C9H:R:UZ-,7B_%X.9_.@, L21RRI
M]T)D*?*X_/D=9EH=@D@_"8'RJ[[(D=&YM06B)Z+G7:EZ1#Y$/F26?;;/_>)Y
M?"?D\7RM[DZP..ZRJ_&R5I\5/U0%]G'F#;#PGJ:ZNF/XVCQY\\((VA[\_$V&
M8,%CZEQAQTI*<T:4O'J#Q6P=TBEM?L%2Z-P>G=M_ 8R?W?4Z/Q:K[=QDW.CG
M6&P46IM5/@B['2O!8N*4_0&,7^&L_Z%M,3KH_]J1O_]\T2+!7^1T_SW=P[M2
M6.V)9:&-*4HIMZWPS>F^+<@D 8_V\4OVTD,81QC_&AB_I=/\]\B @<$8JU:Y
MLI+J)5W#A%TIIPH1E %4DM[#'E^>^Z)B *$>H?YN#O#? _75V-M3N<G$,LL3
MC!E6V4;;HA-U#RMD9AF:1U#_XE!'Q_??X/@>R?/SG]F_1]X.Q]HL-^G/.+,P
MWJQ]<3R4:;8+Y2V,#=$GJY/?8X^6:_0X_:;>X>WVC/JR9XF(WM^+WHB\R&:X
M2Q_P\AWF<O.*F.\(A2&68XI^,-):TSJMRR0)'<9+.HM(&B!A?\_D/:Z)?U/D
M1<+^_)D%%Q?&^5R]&83%?5O,:<WULCMC.N0B$<;0FWQ1&M]SFL'--0"]J1C7
MC1U=HCX@-]0'Y%,2&\K#FNF+:BF6XOI^N.Z03K_5NE;50*JI]7%O%NY%PF_-
M-RVL6\,Z0$12:3Y#EL=/)6.=L?L/D@U(-GQWV?#^A(@ZO;6TDH'YYJ;2V!+^
M+-SZN6N50C.,NBAHT\ R1Q6M,MP)5:63CZ#L@!5'82+$J<MU7U5V(%&!1,7-
M1=!H=>9UN6:^9!HV$;ELH[N;#J\E'Z)YKEL5PE'1W.ABO;K3F]1\+D#YP, B
MXQAYJJ8;$@](/"#Q<.$;6V)YO\[M5E81Z]>\[KP^Z!%8>*UBCQ6E7FU2EMDU
M1^MJ:T+5+)'-)V*!2RJB8!?N-_H=Q<)O,FZ06+A+L5!RY5VKP.T(D6A%C+9;
M^_:&OI96']/Y0L>M$#NS7]_6IE:A4)N)2<0 !E5)-DL1?PH9W'J:#GSFB_U&
M'TB841(:GK6=Z%67F09\O\)-[T\1K)]P-H<HABB&*(8HABAV(8I]<C6#CU#L
M_@^M3S6+)+[,.?29Y<H?';J;RJ"Y;GL-_)PGM/W*3)(H LM)3"Z:;EU-;?0*
MU_*W.A;'BZYMU"1BQHK-\<X8CS3@;S'PA); L_Q)=^N+Q$H08FX9,>\_M]R&
M1:],\^'<9.2UK6.K><_BKI7S,"?T.*2ETEBR^66^;.V&TU)?@(B"][>Q+$&]
MU&P&(0HAZ@HZZ%7'>_'&VM+L%FN+95R>>?/AIK'!KP6CPGJ=\S!-ULP^3O#-
M&;F=5IM="",&ED$@3]R-1BA"*+HJBEX\!=M6]5*UL"^PDE%IY\K2%-M2DVNU
M_5QWZONM,:5&ID%1@XK*:69K%T'TP(J$&)YE21+AYUQ'6]\:/T&/QKK;E>*)
M1G^PX8N\QNBS:_%YW-^R@UYN/#)SA=T<F[<HWUPE?)Y4^V.X+,&<O][?)P<P
M?I]8?[Y@QKWB];[N<5V\"^@9PQ0KHYQWYN;,,IFP/\35EM#O$=?">6M:=L(.
M19:E0BF8B9$<#L0"L ;9))&<S;+T5VD_C[!P,UAX?P""FC5J8CZT,:FLKHO=
M@KHND,:UL*+W\ GE=/&%-"+8W4 I;?850X!8H=(,BDLVB$18^9Y8>6-H@5E&
M^7:[H5;,7!WW&R57S6'>M4(+2A I>!1(MJD-FT;!U.UR!4N4"0.K .$DTB4(
M'Q?#QXM!@W(0C.("K0W%$%/H(K?+3>O#:^'"UN+AIBFL-$G3<Y2MM994?9[@
M @8-@.9@R NV$[Q79-QX:8%K(T/:$\(0*P_Z4EP6IAW9P#NZ<*WD;V$Z;Y?,
M_6"$V4VMV9GV_4T-3S@X"0?P[,D2;U\IQ0'=R_^9Z/+25CP(@+.L%UV,^6@&
M_#DK^3/C^:R_L=88T^JW G<H; KFM=(I2(VC-E17-\RZT1_)/5T<TBT@@+@D
M3D%E&>)4V/T+73^Y]M$5PM3Y,/7^>,=XT2X0&ZU 8X:DK!JMQ7(V4:\5[R@%
M/6$TDVA-M,MY=]00ZET'IC!QAX0+ACEU5(PPAS!W YA[8]S$CX8>.QX4NN)F
M.357>=?A'?E:0*N5QEMF5HH]B5F(W%+2M$Z("1!H24H&PW_Q&]<(9U\!9R_&
M7\B)6)S61+4E%4JY_*Q(5"-R>BWCL2E5^=PL[\^DS1BC2_7-<KC=)HH,QE]8
M)LOR7_SR\K43-Q#"?HNP>LX-RI6<U,$8O,,W\SVF,8^OA00_6$BSR;S"BG%5
MG=%+9FN9E00),(Y#D  *W)^J_R2QG/\)%$#<?QZ&MD(;$$6]F8OW9V0IPP%O
M"?[&N>/H$&P'<."IJI-9&'"[X=47,ILQ?EX@AZ$AP"W7;G#*\!,_&JQJ,\G8
MU+W5:BM7-NL;:N_;4CQ/%O?Y>4XSIP;6]A>FL*MBQ'(7_:Z=J)F)-$_+>.FK
M]]H\\R\8&OW[&MM+/-M>0NZ:\XI6\59UL8]3 [NO%,O$]B,'"A?97KO3TJT.
M6S0WR\)(8_:+LB1$\"R.XTYL[[]_9 9+S=>.MMEPP-[X >1D'[S$SRA^!EC5
M<0;.10$.[#P3N!D[=6:]. /V.A,\^+L9[6&.R2.!FI@#X@!ED8$&!L!'^A_U
MB?F0/ !8#Z$5@,$+S[7AZS)K!>@J\,"?X((S^OEXH+74948!<W=GOFMI@9:9
MAQJ<&OQU9 3+N:=$X '@5_ 3L2F M^BP?(,+9[U>>^X6? W^L,#,DYD "F8*
M0Z?@#G]DGH&<R#[,_V&WH,%D+ PP8[ ]225IYC^'(4O-FB>/@MN7?,7^)_,O
MP&A@X6!Z+1=,E4X&0-4(7PR7Z:3L _[W[Q^?(]8 .V3*0-&O,ZJR3NHH0';X
M"M(L[WJ>&P$KI  8VR\<5@?P=A)(06.SMC#&6(B;E6LZBV:)K75U6/>&9.D3
M<FKV\/0$-SY@0P_^YXF*^$JBZVU[Z1$5L]@MKG@S)O6*7!YL:16+DAI"_/$9
MDIE<)L6OLE'XLXW"97,[GJVD&KW#VE4Q9BNXK%2+'SER>]M&60RO;E?^C)(,
MO%@IZ(NMK6$"W"B>/#;2#M+[)U!3^056J&5"/Y70<R 2/1O(Z$3\I550'H3A
MKRRK 5/:@ 8\E$J_//0$.T= YBF9U):&$A#X%8JNP8>_DFCKT--D5RO6NJN^
M5@:::X9->5(JM<=G%Q74FXCV2*;DK3VPG^W%<T**AZTJN=[SP8]DS1%/Z%I0
M^CN%77@5R2 KM*^1-&624"O_8(\3R/[[05!<>AO?+B4^>1L]VJ@(BW90E(CU
M:.J.M779UX5D&X_C9?_]($8NO8UOER&?O(U,N.3%[IJW1+M2L>?^W _$/=A&
M]@=^G*[UWP=#!'X.=\%P0N7@(LZ-[3__"_YY,%%42U,\&$]8'NR+Q]@ -"W2
M: *.8?]]D0B "FP;S7LP; CJR7%^:MB4<O">SOIAWLF__^?I]'^&.'*J:[G>
MWP]QC"?K6J:1 R():>A:;N9IBIE3%N#5?RM6I,3^89T<]X.@'K)9_GZ,A<"=
MR- _..Z_,S__A/MQM)FVLLL]V;)# "5G:8O@[_17#Q\EL8^'SUP_L27_]K2T
M0AE\]K.G)G0)W/7EB/*+;4D^"<,HF:4'(?1?@W;A5$7OM'J7 [%A_>=IJ.;P
M$3!/81 "ZI@"1"3PM1]C ,H_3ZC[.ZY\OJ>G-DMY/ NK4_5>L.<#R6;]N=G/
M-2NSH LA_U?ZML>1E1(Q'Q%TZ(L$7C3<>9WL*$17)HY'\HMNR9CTE+;8GH72
M>%3R!(K4Y:1)[?.1X_I^U^,6FZFXV:NE[H)OKPPUDLGC9U;+7<E>:8V6E!,7
M7H<=\#O=@2.IHWEVPZ$7[NL=L6VW:]9J1M7VC""3QV\?JA6.**UEUPR'$M.M
M[K;LR(//Y'X=&>LV+O<G:URLQU1ILLH3]3(ER-3Q/$-VXHRVW3"2<GX]FC7B
M<H=1(IDZGN<<BQIN6(QK6%_SPG4I6M8% S[S:)Y]X/FU\; M8T:Y:I SIFO7
M!#CR:)Z.51MV^AO)%LNYW5+F>]&J$$0R+6._CEQ/1-:7=CO79$A.Z,E<."K:
MNLP<CR3%Y;XVWS9U,=Q7E'RAE%_TNUV9.9ZG&+!,9=&@5V9AL&USL4J&.3.2
MV>-G<KB6HU?L:F76:PUO%^;7]&S5E;GCD;3"N@13FL5F89L3!Y-6L9!S!)D[
MWL^":P6"$0J.J,S[VF3,.41Q!I]Y-,]%:5)C)V8E$-N5A3[3FMB:V0HR?_SV
M<ET.R;Q#-\3V<%-:EM>L%T\C,/*8FD!J$'E*9[#R;"DM['8QC#9PY-';J]U2
M/[]W=W6)H7)">YT;3^JU2,:QX]=W>S0Q5FMQ3C+:]J*K*JOU1M=/@=/LV8VP
M'FX76+WKR'M,=*L#L'CR^)D;:SJ/J+P_$]O<UMV,NO26=2&#'HUT"J-XL<VO
M<2FTNH9!S8=E>M(]Q4QF%QLKXJP,8%S%E(G3W7MXM7N*F;JR)F*YV887"8D(
M)I/ D\M%_12+"$5J7>AB^Y64&^SK,T)2VR(>G6*1R Y'MF*7!T!%$55^/-R3
M%'Z2G'VO+);GFF:997<S*S4ENBU/]9-;WZIUP=N*]9QI>^1X[!=6-:,<G=KZ
M6DS6C*!2\<1<*90$I:-V:!:./.*1O<;:SH+9%+"RFEO7:6"022XDYQ&/Z(6Z
M8A/;L8AI ,8*8ZJ.-XE.R=I)+&O4:!CVQ?ID*'76JZT0B@(8>?1V)_2BNI O
M>E*.*H@SIB[L]ZOHE%1NV"5CJ,ZXCK0)+5%@F6VQ[NNGF(E02GUOVVJ96)D:
MTWLZ;^9G(_T4,[6*.%4SFQ53JCO%6E.<JEI8ZIZ2H,T\MJ?W:X,2-=WM#8;=
MTF#0.RG#A)#K=/2!*YAAU&_D%Q:>(X8GV:Y(1'1EP+F22+3G9>"<6TZ?/RF9
MW%P'W]K\4#>!$3)QVE&#PA8GV6Y44]?M^H0:2*.)+<WS&J',93CR:$5J1R,+
MZUIA)!)TI^WG^%:UV7XJPWXQ.M/?S>0Z6R@J,WPWE>HM;\=W:CXV$B(9#B52
M8QW\0IL+P9]&DU>H''Q<E_3$(13U@\CTX <Y=Y$#SOM#I!&&12W8="MC&4IR
M#&)H_OG//6[_^ 6\MJ\%&3<,,C/-<J-L$O4-DO#'LQJO_D-X(XEB'B*O?L;[
MS>;"D;:[U=*#FT.8(PD]@QFZ\[^3U3T[\CI+:.)$$V[5<GW@@[87W5 !#!PD
M)FGU9T18F('%)SSB+L BA&0-XFYM*4X2S4X]O&35\KC?:/9P8S;!<EH\98#5
M7%EUA5^@\=)0@-6,!IS'-9AEX(7:>5VVWY+X&>L]=R*33MROY,;DJ/+1KTO/
MJ8%/9REK7_O[X8^G,X,9WP??#CH):NI</+BQB=.EA('[\$'J<B6?/'/,GAQU
M'\8<.UF!]S"QPPOQ=.6ORY-GJ!\D]](-CR>>SY/G P;W%@ U#[OV\/\</.C_
M._5B([!/?W0@#\1(7OPP5(%'+V&@7=B;/"U7DX&OYXPGSO^'TSPP$A'B!@C!
M_.!>K 2*"($0\;T(@1!Q(X1 B+@10B!$W @A$")NA!  $2^6WT*$>!LAWGC?
M^8]^W/56#9WPHXC4E?H/O"P,+GQ(_,==>>,FJ*X%/_Q_?[%_O7-#2/('S7YJ
M#03N%1OV4C+]TQAF>@4AC;5]J*\4 LO7 \ME[+A/Y_^&XLP/?._,SW:A"%'^
M\I2_ATU G' /,B"Y?HRP?U:*7Z%4\'4V 9D^" 0?$'MW[!H\5A="HA%QQ2-7
M#+6EH5H:8@K$%#^9XO&")^**<UM1=\P5 S=0+!1(NGDPO(+.:8CD^-_OX!Z*
M4L^\%[F&2(E(B4B)2'G5:,SY2?D^,^&S2WB]H@#U\P;<YRLZ#1GXLY=_9MGS
M"<NYCP)E)ULPI+<+?JGW!P^W!&?^:YEH2N('=27'F6:(;>)X- E;#/.1ZB*_
M7G(XU1JXJY6Z#&N:HM:T,%HUO&G'AU?PB+_^H? LSEVP./0M@./8J[BZ'X%@
M=298/83 #G#*KX,ZA37W E9OU^>#GJ"4!/PC-6A> 2>RU178\3XNB7;5-8:B
M$CC>1 =PHO[ZASA1[PAA"6'I)K'TJM+/6V)3X9B<X6*$+/9KFS%'MJD+*ZP"
MRU<WW'HS,9D27S X=;/I%N#E72:I*88A?76E^"?"V-7Z#;T"%D6QO9R:0SS$
M<MWF2%[W+(W7(2PX8,>1698YU6/HSB+ PJ' HY_YEP.>D%SG]@\%+Q-9YC\6
MM@3"+( 7D-,Q_[Z'8,3%';?;@>>U2V!^T"^3ZT5:"+%='V.VQFB?R\VQ_OPC
M:NZ1D0?N*Z =;"=47QL(:VED19PVV Q*DS(L0@%=M"S+G6IQ<(_L_IYR"0@7
MU\#%+XY5V3-KF)=C?$RI,FZCW*,"EON(?GL;'B)\Y.4V9'L@;KIJJSIL8:[:
MB  >H(^%G6I'@-!PEVA(:HX0YU" WX5^U\WNO#%I=O9"UV\32]PH9ZV'G;IG
M&LN*WH@$7Q)MJ*:A!9[E7U33]WFN4M36'MB[M**4MEMKCJ]]&4?[2Y^:0'3^
MZT:-C6L9X4^Y]Q7P[O=E=N!67,4LM%9295<5]H0BR"RTPNDLP1PWA3B?U_G9
M6/@L6P2!YE8L]#>"983%CM>A]RLQU]"#;@W'HE$(BW "$QVGCTNU(Z@@J%P+
M*J\ZV0@WZG XRXF1V(\<TLHST<[AKZAM:KN-)[5\11-CT78J'M7I%K$N !#S
MUS\D?=S" @'H:YUG? : SNX_O9'GI0T]MKS=.I#J@[5'+%6)YB2H-#AH8;'L
MBUQ_!\<7/]N4H8C&G42D;EF/7=9/@HW7GS36:Z< ;B^DER(@K9U/&GQ3!"K+
M:<J56:U*+_6T7C6>Q4^$9N_T8.X;(@'%9A']OC?]/C>V?L<&X7M42:M#8%5+
MM.MB6.T;8F$F;:4Y5"7<*U3)?4;32ZZG@;EEU-#S-$>-,X&G.+Z54.C+>'>7
MCZI_XKW<6\3P#5F3!P9_X.\G[.T].H?*@T   \&S3T@&T</*/J^/%F:=MS9^
MA5ECN*K+/#0RR>/D3Q08^5X8N[2=@[@ <<$WY8+30=(;YH)[MYG/HS [U7C1
M;_#*6HI-0M(&LA;V%K!Y'3"ER1=/K>\@IOJ*J[U%34ULF=3T)/%L^L?9K_G>
MSKH?C.RS+.Y4#202H'SNAK WU W _(;N?GS8WC;YOFE$S%(V-U34+"YF(V:"
M7_A&5;X7T^,.+;2EW+X4L@/.-\U)TK,2FM1\EF:/I<0=(^>S#"B$H/,BZ)>4
M%V\7R(M=?UG&#*9L2DU]L%\ONY=%CC(S5E9^[>RD4&6'DVIW:U*[!#D40 [.
M(]@@V-P:;%Z5_E*JS.-)LY5GQ8WLTD&S-S0"^\)JJ-%O8IQ,Q!96T"-<9:?;
M:JXM0# Q,.;+TZ=N=B X?:1J(8+3;^%4S[E!N9*3.AB#=_AFOL<TYO&%U<G"
M:) M?3*I8H;-59QRW9ZMJDG?=BXIQL)1?[K<GGAL_Y-T;?WG8>BAV^[-L/'%
MV]\F/ 2[W!X8:9!T)O:#Q$<V%@ S3G#H!:WHGG;H6!PLE2"S5+9:9J9I3L8
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M\59UL8]3 [NO%,O$]HKM[=U>1\W3L;*5;%-4EU&7MAL$O'A-)4EY],7ZN-V
M3+\^UQ\,F6_'];?6X!Y;S=9FK2V.Q#K>J.5JG8XD-"+ ]<P%&MQ_0NS@9X_7
M1_OL?S(>+)KM*U9RN?EQP#WX&A<WQVXH5_6L#?(^=VF?:%A\<7EZ(2OB/?VA
MF4YHS24ICL3"@L*LELT:,[XK4]" 8$]40SZ?^? M;(4OSL@WU.B\6JCB'CVW
MEJ8MNMUI3.5RG06L=L)<H-'Y;01R'FI,_ SB.,<Y[LC<1T[NK<5ZWE,<I; 9
MN'[46]7$ME0?V_MI)3?5A;0X"IYEB>-+,G?MZ=ZF779S&W&OIMK'L&"J=('4
MRT%DCN9\>9;K\;6Y$@$L4+!0$(&_6-7D_K!P$Y;<]V/]FZR1Y9MR?FQB=$YB
M1I-V=^B(#3:ID<7\KD;6?85^#GN1]@!+.G&X&7_I>D$.[)7]4';R7X:C6N$\
MO1>HPI9L[B+C@ZTZ4[5)%!"Z:61>W$![O-R9,N' [4,6A!R87OXLN=YH::C+
MP^U/.#=QI]E)EY^*XN<US0&^VOP$?NOZH-+4BJ,J5E?"36>T[?A1]U"0"S]Q
MT_E^^/DV+;8OCH2+FV>70X)>+H?5CAD.)'O?W$^W456:2EV !!AY.ZZ7?#]
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M8T>@8M\K=E]\$1"13FE$_?7OG#0VJ=DNN\STU*E5F28"<XY^S#&> 2DH7L=
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MQ,F;6^-2F+,@<'F(9B9,LE:@&[D9"K<F$:>I$^[DKWB8"X:GH]#_64J6K]J
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MEW GBN-M=/Z;Y 2RAM->-MO--;?(&P.WC:E-2I5A>P]4 A@93R3.HP&^>]%
MXBNF"1X% O>0-W@/ZM1E\P9$U79JO)S#U3;;;R-LCW4J20:^(=0"_C S*DZ>
M@'D\D3CXK]^(=;<P2E<?]=%Z-D F&%6TG>=S,&\F4CS[C?]VS!0@GI>O=_RA
M2$>J)VB^/_'-8&)/\/T +0 6I(1Y3:C4]EL21<D6+&4,>]DES?1N-!GE55E\
ML;+[=G,CBT8L)XTM%X[)"C9WK^W?1TW0),<?K#5YZ>6#44;C-9P2Y0]AOZ!W
M@N^5*P+IIMY3VYS13-L/9]X1WHQP@A1$J8>II%HOEX0"TF7+GPYO/E[J[(.4
MZ':>R*PWFSFGN*RP;O;=ND0U8:$SBKX/ \D!])I;$ /8G,2X=O9] #S@PH@H
MA2HQ:;5%>:BZM=K:QH5ZMCULWBU1/H;*T_.%$M@5.+U2#L!I&G"W<!2C3U)$
MP$?6O"++G(K491<;VSG2@0BY-/IT$B,IJK_PAQ5%RC(0+7^(FS\9R;*WX9H8
M3A4+H[B]F8S^H+.=MKTST8)_@%AN#% -_M21P',/Z68IPS4^),IY-*]2@![#
M3;F&7UN8) 2K-7.IPH(C%ZXA&>RFPJX!Z5[J&3@6)6>JV#$;5L\$(J5!/)P#
M4@93S6U_='LX^5V6+4F& ]O@7#Z(UQ*/0'%.?LO''PUA> ZA5P)4GG ZX8%Q
MA$A"EQQ]=7NQ_B#69B/<:@BT"3W'J*SD-'!QR9M02PEM9-@UOY!4/#_!9@2$
M7<?).)D\.:8S6DX(9@0](0U068O'>$$(YRC'(9<$$Y4#I&,9 @ %_M%$NAC>
M\=>EFG]WW]%O!>/CX-2WDQ0K+EE&<+(&@?: GU%+#%)FIPE'@^#Q)'TLR>'@
MLSVX*7_.H^@*D9)]ACT%I)97##L89QG)[5;^MO[./7J6S,D3PMNYE74CUI;F
M3N#G8ZEXZ%M&HRXGP=A-N,GV7!(<-Q F/IC\AZ/_')QX^I]A_\3^9CK57\>%
MSH"0%J] 4[FSDP)O3WUE.X=_?ML#VLH;]('*C9931E2ZR2*5#=\N+KV2T'C)
M^:%'6&HK<+M?_N14;<9I_#*;J,W8-3)3$ZG>,)53_@3$^6.*L:VT2FIZU&BS
MF4%+%9J5:FNC HM)GK*6@),T" #F6[V((G!");Q@Z4^#!&%;"5A>/VJ#UUFF
M*T^/"U5VW '\GBAS=87DQ9]0JI#LIOJ"(K99:;$<UE%UV*KG/^'A? +)<*8E
M5DMUS.353)\MK@L$5;&GS&M5S?L(J;[ B#$9R)^]4W7O"A8^+RHW.8!^/S(]
M$_EL>;@KD<SL +S?)SW%X=1+UFIX1\U,^NUI*JEUF#4(WD@ZCB5.C)+=SC.=
M*!8P/0L0B3L!+M-E43T39]E_8^Z6>V5Q;G*]Y4I>5N:XYSEG1+!]10"6RJRK
M&XB(<7RO*M=:C?YX+C.OG?9' N"[!:&"V<W4!L8E4F!Q7SZ@C;F6.)R'&F:_
MJ*W8<D5&W7ZCC X&=*G'?W).PWFD8<JTW?4FSV!LN;HRR5JYQO9%.'6'BOMG
M#D<N6VA/H-$X5$YG\KXOY!+&@M2>CR?NAVI*6.YN!U&_)<'1$/#/ 7+J'F X
M7(<--FY_O+L30_P?D%CHT466-1KA_C&GYG[-(T*>%]Z:W..]<J8G5-72C%%=
MCM:)\;287>?@4!#LA&V,_)@[].U?S!H?GMO=.G6<>"MU# >EWT/R.+$?&K_%
MX!\)C:MSPVO4^&H:S6>0U1)"UX-/KIWOREGVC/5J%;:=IH;=[,KCVO[4D)<K
M8NXB>WQ#JEP\>SS/L7E"&A;1!=4KR#K"5V@=9H^?\.,CR?WD\3?+)-Z0Q!<-
MF&E*:K-(+;-@^<8LF5:6--]J>[#^A(Y3B:^>2?PZ5'M_)M%6*J[8QNT$AW =
M@RK;JQ0]@Z.IB'B2^MF9Q)-]PH K%ZX2H$?>-*GH)Y*HYPDC']D]&K3#QP*0
MI$9T@L9$8U!C?[<;S"](+G\YL&Q TZ(*ZA=*I4*;^%(#=2S]U'T"0NL3G@</
M]/T>7]F:@@M3+"8\O_/G<(HQ68+S$X0@!3-6S&WMA "T=C"_ ,0]C&Z#Y8@P
M#*WYHP8T<#F(?[AM? "6$3A;C@F9SA^- /X6J@8SN"@H"P_W &;D@ESHQ::H
MD2,JZ"+:#0!)NT 92+8-A'^L&,$<OSW,,;BAS_8S_;1\VJY_;_6ARDABZGA2
M4,H8FLFUDJ*^:: XT?R#@(+9\;4(-$:.5X*!+?5)!VYM9G]GHPF$U@OQQJR&
M]OIKUS8X"9%7YM0NHPD=F('$<5MB%&[$X3X&2>N 52#1=$GRE3Z<4R%9#E D
M8'U+23/G/A.#KTJV [ZPG74!S$GP3;@$?S+#;E5Q(#+:.G:48[UP?C45=99>
MD!GJX[3>(0VJH];+.18U.#J1S)UE5E41J&[+]?>V;D6#XJ(Z5<OO9!]KIX?Y
M+,R9NT[U&VD5GU?GRQGG9F8S[^4F]4C!A.,_/@+>\!1[5IN%OE*;M9O0L8]@
M_Q5G=*0>,SH>,SK>F-'Q\4$-5QF]\"%'; N5MYW1$)8'V7N90A A )'OMNN-
M&!R <#O?#(:JQ4;=]U]<V06N+X01!G&F(LN^;\;OFE-BP)H!0[9;A0WB62!\
M^G;,U+-EQ?ZV)2E0<ACZRS\QJ?K.UN&I\C;NO6 .B1J% ,D@***V:,G;H*@!
MWK8&=/7.L-4UL6N;<_B'T&ZM#$G-#RLU&U5:RTU:-H6*_FD\-?C0%Q-$X5EK
MY+C :'8?9Z5CLD!&G/5)0^:EUX5A=F/FT7RG8.K,S. G9!/63=%Q,G4\%CXR
M9+L@1Q,/[9@_D6OG0_UL*A4D#<+?=/A51>']NN\3#2Y!&KN']QA%-0P4&12R
M^#R3U[@*="MI].09RC./8NZ/[%* >G6VX@5)LQ6NIZW\>(HSG4J7S<'>/V4"
M-\^')HKZD?PD1]B4=+IB=U!8-V1[.&;;RVYJ/$2ZC9Q/(Q((2_*$_Q_22%JX
MP/$)#HW"LQU(MW$PSLUWYQ1_1K0_:AP*D#]R30,:4W M. T.?/X48^#OIB]>
MOKJ%=_1U;#RJI]$4$!&(\ M!#3Y0U5%5#0P-=9A0!!'%&EC9W16^HJT+C@G+
M-*ZO:C%T'YL6/4:R?@^S&(VYUFY+_3&G.^AZH2 KOI7Z;&O*Q91M2U_UBW,E
M6T%)@DCJ"7&Z5B58I$HFX_@K,GX7RO8KT.G]ZG:>4)),,I6IJSJ#X>5Z*5EP
M6_#4$$_$*?IEN_>*NKV1JOT*=/F,LDV4S:%<+="B6C>\ADLL:Z[GP70[@<43
M^,LA]GF4[6W<:P96H5NG%+R?:7Y;S<?W]'SH<_L6@S<,V%UKPT/<D%TCS;^M
MT#O,'%U%];]1*?8>SM7G.+,IY:01A^<WU03?[="UZI\@%5Q$\^?*K;ZP4!F;
ME<Q2FI%6A([TH9N=2L5Q\D3!Y5N:'W@#FG90Z;1O!E[14L]CKFB [MRT@N:^
MR5D%*7@W_\@?MKOPZRAQ;?M?"^L4GW\QK'_Q^?.(+6&:1O1S\5&1TGO?!5X6
MIMXD?:Z9:RFJDXR8/7BQJ/P&2%P3"WL7&?!-UW*F9Y3-0-9?$LV=#=&TZ 5O
M"1#\'F%D2,4A:652X:1R2Q9-IMDAE+N+>5/ZII,:)IR16LY.5K*QJ:!E![IA
M%!E/$2];EM?=,)].D1!&'/[.X QRVC;50=SC>>&[TE0&>*T;)*G ZS5.[/#!
MVQSFE@*MY*L.Q]R.;H4_;Y-7^YUZL _,9S?3#<YZ_0 JK-V-E%3BOBPEV-EG
MPCG0ZRBCK[4JE^^OL^JR+V4JVFU]/,=#DOEY@V)1GBBC;+>813J4[%=1XZ\(
MXM]0,_V^+V5XO-\V4\VA;'9C<XLFU9AW5#95KM[8IZ8HJ[G4IJZJJ#4F2[5M
M=P,;7#$B%2?Q%]V07X>UU/,]!"(H!9&00"UX5S)0D61>6.^1I)4?LYK3'178
MMHLGK)6UJ'+2JR1!@ ,!R0*'<-J2\4:M:KCW>6 %'$DL!H4P_HE_(SC$92SP
M)]DO4SA)(!F=5/6ZGJVQ+JL0"\]:35 *!#V&>4R;:-M]VH!7GD@*K,/\F' $
M;SQJF85Y?62W6RR_:@DY0TQ*!/-2Q= ]"<?KA&!7<\7Z%"%JZH:4,I-5'T7Z
MTT*VC^'CS@8X[#1P$:CC<KY?+QV\W@F>2##]?)3 I3'%H\*(3_+)$9' R!&?
MP+$1E1I+!):21!0GG\]+IV4=Q]*98E]=BSG.3/,%?@@!V"#HRN&5_033+TS1
M:9Y5=$_J+P;)-B-[X$KB: 9[R>C32]P=<0L&$VEU44]6<W#LX]'3Q0;;PZO&
MNL212'<\I0I9LL T@XEPAU<*F<RPI;HJ ^Y)CN7L;):2*1E<>?1T=+YQ2BB#
MX:I+KZJUU"Q-#I<>N/+HZ6IQD"DUK?224PJ#6MTBW'*W*(\2QU/EJ6ZWE\LN
MD0RWT#M%#D4-B0)7$L=7FGT:.++Y?AY=5Q31ZN -+55B1LGC*]>JX54WV4*#
M6U03!4?VG!9'0C3\HRN=(E[OVAU]P*Y;G+!*I8?]4M,;I8ZO+&3'S*HTZ!<X
M)24/QPN5KFI+9D1MK[SNE/?7Y-(^->V]A"7;I*'/914I3YM2JFTD\NG08D ?
M3F2<5Z[SSX"QB\^&_Y!GC:%/02D;$I2&1>4^MSOD#0 :MXZN'9,,&'$? ?I$
MQ48A1$\(*I,'GO(<&"=83A5$U&%CP+;.+EHH(&Y0$ZO[]_4==[ 4/B!_4*,'
MJX%BJK3>"]A#]]Y_3AR6:'H2B+S\T'I[&S_UY8)W /H1L$]L; )C]]O?3A_X
M:5M'XM=\P!H2C9_;TN_HAW_.P E11<W>)["6PR<&? =$X]<@H/@]45:2N%_=
M$16B!+QSB%L77@8)^-=_]__P1R_\#!K-YQ7PKJ^ HU%'>&C_YW]I,D7_\QQU
M[1EHVE$9R6=?^9TU*(UMNFMK#H\PP!X<\9,XHA:E!7PW"?L'_@^&_Q/^!M41
MU][3-G_[61_8]!$S#0]H$?O7@Y,>G 0YR4?D]6/N6!AOQ!ZL\6"-+6NTVMQ.
M?^#8._3'Z>I/Z)KMZD[/[PZ^Y+P&Y/X7'C2%C<EALB%L7@J[FGG_J A$H(@M
M.0Y$?+&/W=D8[Z_]1JGMJL3#>,-_D= [E&&.)BBEG_"*%39L*W;8H&$:_B=!
M7:DC"5-#6;CPM&@.MF)N*?![2G",(RB6X.KP8,+O [==80KW)*WQ0#&TA:FI
M0:<U@'R#_9;0#]9-4=+ IV#W8E488\4RO*69,5O172VHY(Z!\$<2X"8O3?@1
MC/%A"PITAA5C[OJ'<?[#@IL%QTO;MX>%F+L5A(N>*C:(IJ#([6ZJ!"ZUW]!B
M^4I* U=)?N<*7#@2M+KXERW#1/_>?>8^CKO?6RH9-@P1);_LP;].BI80+E]3
M)A*L9Y<!+T0AQJEKMBZ\KURW>Q?P8#R :CM8K7]$:=NNOLW7\T&F?BP9T@3L
M.3Q=\TQ7$W>92WB3\-: DOYI9PQV<_&:Y@=@N_.>J.%BA]_A*! GSK1M!6[8
MWPZOPN4$C4F!<,0T\.H(B(1@&#,W8?TS/(]T+-Y?.8B&1-.#[66V S;2?^M?
M,=@1J($8R/'/+(/.4$NQ561B29#?@A8%?^E 5?LGEOY+YB6@=XR8[[L@>4@F
MP^?UL6G 1E+^@&\#&;Q4G!^, A2FDNC"QD'(Q(8MM;8]=3G3"M$#;+\^O ,>
MFX9[M0WQZ;[3H,129L[A+#(0VN*TOAHQ%PK:/UC[+ 7+V>\1]($=3L3O,?'-
M,!JJ&]X.PV/[P^%IL H2O%S8Z@!KYH6@UCXR_7X/ N\Z9O1!T('@?W+0IX#N
M+&MXS:[G@ I:#APK>J_P>5CH*KP+13R%/B7QU_"T]XS?WOTA,T_ ]D3IS>AW
M!+H%OX.>#IB<?[.=8L\MVE[*CVU3<QWIPKT5)SV0X$+H!;T3S7S7"O/' ]]1
MZD&(.R $]430#T+< 2$>$G$GA$@])5(/0MP!(1X2<2>$ !+QZN29!R$^1H@/
M3@-[TVN]WJJI*/UT]5$X;RF#/]X#:OY*?_@[SE#_S_]B)/K/\;\?G';TNI\6
M!F.A1&#S%2QK5L18U'I^Q_L#TX]GVHN?S@N!A_*U>0%_\,*Y>('\ZKR0^*.I
MV@_S> TQ>!T_Y4YWY:WDQLV9G^5:@390OXHZ_))\\%9(_^"#'\,'EQVA>BD^
M^)Q)O/5(Y?W"MS-Q]*V7%/ENYXKG[FKV,WA([.]+8;QB^Q !^!8B8(?:UUG/
M)?N-<NQ=.T=7L1R7UX(^I/ TMQ@V=A!V<SGBW'I/Y?/Y89DM@A^Y/YEJ$YX@
M;SL\]U^OLX=OW%.<*1N5[?T5L\$F@V<]QX7M"*-,@TQCJ[5EJ.U\6<*M:=$S
M>LU1 K84D/@QBLNOAP"]$ 3_. %ZWO)T"0$:">JB.+3K157JI-;%MJEB2EN^
M)P$J99J\F76)+K?NDY79,,,,AR(#!(CXZU\L@3T$Z-V9@Q\G0,]KB2XA0!5W
MO!H6TAV+6RP;98SG^6(Q<5<6J-+6**8WQQ+J8E02^F(SLS09:(%(V [TFOQ\
M@?1,5%__90*I2_J8WUR<+^I0*J$\U]:5<GLD9S*<TM>+C$U5$;?^)P,$SB[/
MO5RQ6E$<JZ*26@4A"CH_SPO>B( >93)U/!GB? ;Q:\K&Q5-";\E&+'$ -WVQ
MV1K7<!LC,>G2?6^RG-3;:#DE,".3(7K#Y"W\QN?282)UQAH(KJ-*R*HSMLS<
M<)YJ ND [B)]W$K_D(W+ILGNP6Y<U V,!()/N;7)/,7UT'5&QU@Y.RDWR;OR
M V?2LJ6/UT81Q9M<+<<@;A);,D RH!]X/$3TC_W 6X=/QPUSC\CPD9L\KRM9
M,0VY(UEZT8 ' ,I2@J S^\!(H7:@6KE-WMIP$DLV:*3AH&@OG_J3 ?=GUPX:
M[QIKO8OHW$)992R:K@WJ:WF4A%XEAL>)BSJ6WT:>'JG*/_,YWRM/TWR=\(B:
MD^%X8,!XD\_HA<U=6=N:WLN,-AQ90?%I0\/DF37R3"A/P ]-QI/D0YP>B<N+
M>ZSO%2>W6BZC35)D.5W4%O5&<I8DK;L2)T)RQM*8K7.JI%".D1WW^J45Q+$"
MSBL>IXE7#]*^0!YSV\+_PP/21R+S3\6[9;N16-=4,4=KW?R86R17'I>I%U)K
MYJ[$NKL6B859INNJ*R;'J0RNY@9T<T1"KS.%GD ^_.'B<?-<YI=W)O?$ W$:
M<F79;8BHDE=PND.DS31W5T'9K,NGI-RPVT?S2K-.F!4\72Q#3$;@1";B&'H\
M=OTA((^$YMD$9-:JSDU\-$RQDCWMT<H"&Z[J=U4<,FTU>M6"CO11I42.S2RK
MY=D\M!_ +23BZ.M)BZ^9U@1.8JS]'&SR$3J^.[-YPP::>] =Y_(]@9K8X\(T
M9,)0:XP9=E)>T+B KH7FF%_R1$&:W)77.4&D!,\:O0[:9DR4DK,]7)C*HY1_
M@DX>3P)X9&;>G^C\X>)U+M_U9?&B+$/&&E5.4]?)UF95TQ%D/;^K I6^,NL4
MEIE:5I6LGC52BN#I60:(%_!:B=0E?=;O)%ZG$Y\_7+S.Y?F^+%YZ)]$KYH@J
MK2(%:[4JHXEB&KLKG[=23_1R4K.Q8MVTDL[FZ\5-OPWA]X'/2R8OX/%>M]_V
MM::ICNGPVI?JF_MH]_@%,2020%F(I@L!_^Y#6[RZ'5=WA-5E?SSC2LD56B^R
MZU0!&_'%[%UE@ZSTVN@WI(F%(IU.K8],B^7TI#FB_"-Z(DXG3A;Q/(3E,R ;
M#V%YU:UMJF)!*EBS,MO&B([>YK-Y?'E75E*83JH>.^4+J#N?47FJEZ>*=1D(
M"ZP#C6/4R0/#AZQ\!H3D(2N?0C"^'UEIU#/):D;-YE62ZR#-I=0WW#8T+,"C
M3,7)$P/*?YUH6H]@Y?][ /9\G8F<;TPIVP^D)N#_ (>>QAQX]NH!DML>0)V@
M2;P%A60:(1Q',@#?XQ((=2]B#.#$KJL@["S((0GJ.0[=_QS@ZVWW :(\F];O
M2%[WUA7B^N&^Z,H2$L#W^>.%?_.:QZ_MR,>DGG!B-\@A>B^X$['D$T7])[;[
M\9^_3FPF!)#>V[(#@.C@6X<0T>%G;V (AG2!HPPN1I2]W@[XW\2.!/^/CTTM
MJ!7^MU//G,3%@#^_.LW!!RJ' / 9TP?7MK<<RN^C#+[$E8=[>FJS=N/9%LQ
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MD#@OMDKBQ.Z@+#PLRR$)^CGPS?\< /ILM04$EC2MWY%*V%M7""2$^]I!EI
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M/(#%9PSQM5D]]O-A/<=(YLPFK94X;-3DVK.6V\POAHY69FZ&9&[XRX+6FO=
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M$T>9+TZSGI*/,)6(7I+>3T[R87X6DWS$5MA@1&;MC^904\@)<&G@*RLV_'^
MZ7G$CT\M3Z'%T1)R95;[:6COYSSV5;GG_0;0?R,P..YT-^>=0R54SOWSZ=.
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M(<\;A_L.#9)E+X;VOE(G+"[8R31K3B =:JXG,Q&RO&&+NQB2F,CF"]F14ZG
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M:B\Q'*_HK%OP*X4BW9QR5^0'E/:L,V'$PD27BAP_&'N%?EWU ;XQ7NX':PY
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M,?SUX5"UC%6G@N()PES'25$7^769!K6[GSYI?*5VZ8]K)K'CFDD\MF8R_:Z
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M[>WGK2+_.$](PG_^^B^9O-64XADE"B6>B1^"R<0[$L3&\NM5X;Y\+7 )@.L
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M/8>G*X;5#7LE3H2E5%7CI08AS4U(\0X),SY>4SRWH0((@0SKI^))PS@S#-T
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M#:(\E.BN)(TAMA)A^%ZMQ/LML)"!XX]R%-:]3FDS*I>6_&HN3^!VO^!B@9J
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MFO-:=<**M;Q$Y3NQ"8GMLE\Q)&MXE87^W:8K\@O8.3"-:,[2"VAM/21[M"[
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M0],;2XG* JDUQF.X!<7"SHP&2KN5]&5,RPU4%JHCIEK7(VZ[&&[S6+D,UG5
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M]5S+CF<9/>5L0S1WY3 4)]#L%0B<NF7G\:4MNVL(E[J @$".(B!>G_',H#W
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MI5$/N('$7([MY@5 P';K^<YQT]F2XN:;7G:0D]7"P(_Y0!"P3VSE'=2ZGIC
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M7GLP,SJ]3+X-'2F4QH[42$GP=L!A0P-BNDW(=D("SQ8<P$_'2(!%2[ZP (F
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M8SE[4-FH0",DP"$3/,*Q7.F\_O"[!O.5(0^^>>X+P< 57[3MOE.XOTUX!!"
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MVK.\I0.ZV"W)\L?4LAL3."^\8UC;YU;SK&UUTI,=IK%%.I\98(*RF'8S@90
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M)N3QE;RAL/3:\LJL1M3LH="O]%<BA) _>L\Y:=>7L_2TK*1V=)D3A%JOUO'
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M:ZL,9%AW_D:9#]=P\HT2LIUP%E+PL[/@'?^W&2];B36ONE+"L!(S%^R-4D(
MTI^ T*TVG+0'R"%M3,.&WWBRJH)O7-CXYDB)J23PKNW/XQ/ UCD'"Y)UJ)3^
MXZ5-\&'" M?:3XD<N$.?%_QP*_V/_7)7QWAYLZ_<*N$#QX)_30OHN@7(N;]%
M$9A8\_D!ABF!ZX'=3$ U7(=-:-Y"TL$=UI(>+!J\AJ2#10#Z .(:&C -P +
MI_//S]]3\B\_"0J?Q&O04MB)A:2*"=X.: :_]'^05BZP-"KL"7RZC@P$;$_P
M@#\AG1/@JF#)@'H2$ XX-3'\JJP+3_[;[C_H>K)M)S+%0"A<W3=;$+UC+T*
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M// G,Y!GQUO_M@2,Z@_%I),PC"8^(EM/EN?>XU"JJ"N*L#31+_</[S+@K<X
M7578A@E"-7<A-+DIV);N?D$(CGYSD@#U9D3I-?#-Z:!<RW 7YIG8^\=[)M)&
M;MA@9O:#\^S!S.R?C(C$3?+)SMX!(@*.^%F(>&ZH28"(@"-^%B*>&_$2("+@
MB)^%B,0-^^1<A0 1 4?\+$0D;N*!CK@$1 0<<2&(P!SQY!2/ !$!1_PL1 0<
M<2&("#CB0A#QW!2O !$!1_PL1 0*X@.Q\/)SL&_.F'YW>_;?8]CO%30??RY1
M&!#"CR&$8.![0 @O2 L%A/!#".&Y;,A/@$% !\_G  *!\',(X7,'6 >$<"5
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MWQEBA^TL(DL[,ZMUMN;T0C"QW3:15+R/;_GJ9HJ):+4N[R2P8V*Q4#1Y?O*
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M&>M"\ $ @=4=+D_UJRL.A>]GK)#MY^K5_3[&JR?ITM=9(]A?AU LWD!CTM@
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MI\8O]["09U\.3W#DW- 4A<<&$A9A88)?_4M0-L+.=/:92MUP,?<@TJ_#@2.
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MTC)^@JK)$VAA"61Q*&+^Z,ZDKV#+[K&YV*'/"U ,]@)(R87@'-N&]1IPE-Y
M4*J'N4%V=K,CS3$)]3L=3 _=R1YT"**=,;W<=?Q%UF@TVJE<Q"C&K\<<Z52W
MFNY)?'POH41-= ,RLL%(-I#XL;Y?@>)9+"HLYTR9*EO.^1=%V(2@:':.7^OM
M@8BV(J)]DV^8 3H]!2 _0)LGE4*:K9$N:O;K]GLMZJ-!6J!Z.Y_N/OEHWJ<J
M0Z #PYP)MLE@$36S3$';"$BQOC>QW)&!F@\QQ$@<E L;]^A)X:082C:/)<(0
MS2*]<B4TD;%VH>W"*&%ZMNM4DQT>(>)[QB>MQ> .W;883;?@5 SF%:\:=KH*
M6DZOIW?TL7Z=LO)LX11ACNZ:<+M!O<2V9WQNL0TOY5G'RMVUSEN^2;;QFI9O
M9*--TG^WH!M=!TJDM87GY,E!:=W5RN-!1-)2B\3PKKXM9O-&$8;663-\+3U5
M8CYL(W (+VN2:W>L;+P.3  8]B>HPZ;327MECVTS051,?X/5\5A#\J]-*UB1
MB3BO[$M9MAJ/I"OE55GBX0@=%[FL9$YK(950R9A7^4XDUE4[0K[(O6&BXCNA
MU9[LTTVQFJFP]G@2DZ1LN22)X/5$?%IB7$V!\'-"8IOKL^-8 FUZ@VQVD9';
MQ79/^_*D8WF<J);6^VB/S<5:O7UBT#:6.0S[9-RG<O(OYW"0T]T*I,.)2#AM
M[7CQ/L=;Q?A;,.2<$&PC< Z01-HB^B+D?B:5-OV:?,<.]KEJ?AA."P8I9?6K
MGR#HT#=.!?:AYMIPWG(X\P#*TFW&27O\- U]<L- !6EN9LBFA:5U"5F6T^?>
MMXVFUTXAVE?PNU"P#OVH;,V2%:9B:X@6X\#A?:0HEWIF.(N:,\'((N5!_Z_.
M3>;F&\:_>;.W;.BIWF1_4M=&.1I';835,F]:T#L?+J$C/)_:8.C4NR!=5U5(
M,4/VT5XN\<./=AITMD-KI.BT=;]Z>!IMVR_)BDTN@WD!-#RR1*)3TH/M.]M$
M3G<\Q;:03TM/>D(:,SZD PUB".8:_7(^'$DSF)E$&5.4"&VQ)?Q;R#E,&')%
MDE.28N)W8O>(>EA(P(0MZ29B%%@XIG_;,&V![H6<M\36E.F:/(>=AL"KA!U
ML17&E43W]!@@-[JMG((#P",A.MH O^FI!G.,HF\P"Z\1V%53<O.AML:#C+%@
MB3/DS":@<'83R6XWW0AY+:F=8@JZ@I_K'B4&@UDRA(W@=MAV#V+B&QN8?1UR
MB[C-^(]0EPW,]1(F9 R30:E!?SD@ TV@,2_21.CZ2Q:+Y3IU2PE]& MD.51
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ML&.VLL"4P(X]EB)N-$,&"!XSX# "T7'LH8D=F2A&D^%.EEZ$_+S!3)$&)?:
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M2<B FK^;FH]'PU\B.U%U,=BS"IKPX4:>*U1CXXTH0EOF^ 49<$\$!?WKMJ&
MY%@Q_N5%*QX[@HQ01*H@:\!U'WW<Y+)H],5![D<J(YK(@!,*PM2W",__-(K6
M4?(#:1J/L<*$SP@5;I(R83"A#_G^]U >Y5]/]()ZB1?BK^:64XQVZBJ&[LSA
M?4_05JM[MKK,6?6+1N('5K@<P. ?QXN$JUQE'3:F/,>VRY5-NUB\E3*/5+8<
M*U1NF,PQ!AS$8M\6B^UA L\<:;LQ*4 C@ /"?/$E9FH6.Q*S4U[8S[5J9#N[
MW8X@R92.A1*Q\\#K(0!JH"7^%Q%:"40@19=7UCU6:_Q2))T(Q%A="J?+Y?YF
M$2Y7K-$^NT9"BPPM]A>(GS^&X+LMIQ?7@'?D*6CI8ZZU[2'<".M;(9R;W7;$
M"+8Y%KD&'V\ORW:TWWJN])LA)S]IOPS0,LZ+'P1=H=.BPZZ/*B0!1OJ(&* 8
MNC D% Z_T\ KUG P:EPR["DC+)>*>W9C(I-3':3=@=MPX=CBPU61I$L(;<'A
MN*NT&Z3%*$B 49H:.IS;.)R\GP#ZS)D\L<*J;;GMX.G)$;I9[W$5DQ$4./%N
MS53S'YH:YMA_#M3-1,@W$:<B60AD_H?+_ ["4)">%OIW>>W>'+2BT5ZXN-!C
MB?Q@*"6@:U4R%8HGS_W:0.A_M-!_#$LG4C\?O9?ZJEX1%O;@]KX^7D=RU3"6
M^CY52X'4?X74C_E+?7VXG[,+OCE9J/QJT:@:S<80)M!\AM3W"'@LKJ%^:\*H
M" [=R:8*4<69C=U7YPP0%M"DCXU.1.6Y>#\7LYPK9FG9V$20#9H2=%2!>5)(
M[M;YDY(Q"='^071+KC_E1I<4>8$4>:;KA[)OZ+@$>D2$E!)) T)I!SAC2/(T
M<'DD#?DI;>XNC&A?VY#'U_URFF^;T)^E,?$4D>6]/1V\0:!=)VU/4LI.[N6F
MY<&&U\J=\@![8LE0).W3&)+YTZ.E/Z4_Y!6BY?5U!B\U[T^:2-ZU5G9IN!SQ
MN49I/X]F[QNV#=9]*.4__ H&#1YY/4#6AR'K,;5\@BUQEXQSJ_V$']0'V])M
M*S-I U_%0]&$7]//;SIC!](#K:#!'303?2Q"YCW5X^8*QNYA?]%SV/^!:J"=
M" .Z.Y7='K$,BOG5QX^]9#9HJ.VN,))VO6H\C_\I-UKA'I1AI$.QE(]4>)""
M# YA_;Q*A^ 0UA>+!_95TN%UCKVOXSZ8[K>3PFTSPX;+\UV]48C&8ALX9!5/
MA6+I\]/KWU8FZQY%<0('=*3& S\D2"M?AM;B2:>V R$ZWH6!#%^])(A:H9D9
M]J+L[G;!EBOY7*J1VY#C5(GTN?WS?36P0?U?H!6#^K^+E#@OJ6%93Q.R:<Y5
M;6'/D_P&7]E&=].+K?_#X H$3B!P%.IY^_;:"$$C<Z?),IR^H!U20X%Q=-&B
MZJ/"L95R4^QWAV5[$1YT]N$^RX5KR]9CX=COJ\IS6U'YDC!#>CV.W7K20]9#
M=CU/DKU6A:VLVFIPKO.B\LJ/4'*-(HOV"WO2^8Q$U_.>G6]F%G*TKW=W^Y@R
MDC %IY/1$!>]6.?SVNI,G^2_'Y'E_28);77ODJV"D-[VU%BQ+(8W7'4G/I$P
MV]!.IC85@U".LZ/YS\.T"C+\9$R/W>W<A.FAZ-$IVG>*?PXCP0[96!@B0Y+%
MGO(@(IY)&U'WN=!OE<RQ@BPM/,89CB(;4IB.]A0560/,G/2(=1+0#(P'PA1N
M2S+ZKFZ Y>-A@Q=WFJ,G-D9MO;1LC,Q.FQ>V;;&@27$4R[QYZ-F'TWJQT%;C
MG6)IR,IUBQL8,;-D\JW7R^^G8XCP5C>&<_BVB-TKZY'N<S6M<3^45[S!5LWU
MM+L/U].=/B;T5#J4B/M4_T!8R)#)!"I,N.*"((41-A@1)O-GN],SG<EV,HEA
MGHS@=8Z7D#F^!J+C3='625,0 1VF-0(.V;N/?:S1,C" C&UGY3 U51!%Z(?J
M)+#(Y&\38<K'A*WLCJ."?+-: FFH2@WQL&O3>%?E&8M+7F20D\YX+^5"N\-P
MS)\F0DQ=QSP489UB"YIF.RNY8*: D2"/]A(J'Q"-CB4W=A*%Z3&/EK%J2(#^
M\8![D.,OHWVOD*].^[R,9@.-'S2&^DXVAI';.<FU<W[C,ITYN=3H170.NN2.
MK9[8FNA498HZ3%RCXWYV@%7:L9$4=P)!PXPC>2GCU1T*)>$6DY0&"8JBBT1=
M_"G?H)L0M-A&AC/32I PI6!^,4BC?G<-9(XV%#0)!C2&)&/2CL+=O>@O1B>3
MT\!"/PPF(2>_@(J79!3N\2S_1S?Y_ T$[TE!)D2L8'9<03?Z%(0G<MBANC)M
MZY0%\>&$'C.& <W4Z7QA'WD<W^_;MX.U4N3E=EBW!O.=F>#@B.&Y*+:<-;@S
MM P;2-'0[>F,-@R/LB%GH+#W8XP>Z_-^%3\.6?$,,+["V2;)8+9),-ODF=DF
M ATG(HXFP^CHME=GTXMP>='>#M?I=2VWP?*)_8.^[7#E?&+UA31OEGJ-5F]J
M5'/"?>J^!9+LX97=G= 5LFFAWY.+9GIWE]L(VTUKQ)T_L]_+-L.U5KK-5I=L
M95>?[WJW<FL4/;]R/[H=F'N[%UW(JE$L<>W)7C,VH]CYE9:B3.L;JR4M=H-;
ME.B.N5)RWQK%SZ_,MTNKHEI/9_BPT:A9=Y.2/+[/C!+G5T9OIXEVNCSJ+^S>
M6DGVQ=VBO]J,DN=7LJO)H)8<Y=H+>9E*&^'[9+/6;XU2YU?&=NRX7"S)W&(5
M3^VW'(?:1F4Z2I]?6>N.HLV[=;7#R\GTKE)+C8?[*(8\>WZI4-DM]MOAHLKG
M<CUN4M[>\?(47^J#SU'M7IW/16[+#]1>85B0(\O;NQ;HH[-+9ZG"6%PLUO<]
ME4]%EG9^R9DLOM0'3Y4IO\]P;&O-H[M$*E?8CN1D-#.*^" JTU8L,6-K91[%
M)VRB>=<MYB5,>CZ88OGRL%7B[,BBR$6U^K;=2XPX?*D/JFIWD>XRN9"+B^HJ
MW]@)R51*@ 7XX$I>WD?,5&<=965K9HO5[MBZNYV.(C[($FX7*PF--JB'FGRE
M8^A%Q>JV_-@D,TT*P[O,M-"3%^OUF)UPP_%VXT?\:F0XOVNMYBPO-U;<Y%:9
M8E;?^!$_=Y>:=79<I\9S<J>0$=+96RW=\A#_@\%@3\\*<F8 ?5,D9R)K)]X
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M\$#$[^!Z,=VRHO51J]6K3F\KC9:6U9<6.4T'7!_QX_K?R@K)(Z<3NB5LO;*
M^1-.8>D3C![/!=3+^;B\[84!(RCH^*'B!%DN'W2%[7NDB2+.[=IJ4^+#]Y-R
M+35.MO41.7!+BK]^3E D]\F^R\5N/(B-_'"!<I:<?8<XB2]92PB+VF#1:*YF
M9KA0+23@]#JI)8WYUI+^=F&2S_-2+FRC@?'QXV0%[5'Z,8Y,Q1I.>M'BVEA4
M-YF[_,9(]ZP,Z<J!985/A[MK-CTRM/V=R32%75"_<15F0\#MWD)2J$3*:!)I
MY>?2\&L9?K^>JQ6VK:JL73?%GE 8AH4"Z:T#&=C8;U\]2H#'^"9) @,A*.KX
M$2*%&!"$$=[O;+0JW*9W)]76K+SN2Z5,NEC)*BUHP 4&Q&]E/[R@GB,(7/QN
M%D@0N'B!+'F'_,AHLVB]U>QF%]QM:Y(K1R.Q;G@#7?E ?OC,;_\-@Q5/UW1X
MVMHY5;M!/<?GUG-<E3T3"*B7^D]E3[=(6H'FEL%[Y!?^P5;/.Z)C267SS7O^
M+BN%^<0D=W]?C]XW&_P&FH*2^C/6IRFZCZQR!ZH\[";]Z2TW_WG0<^RT1369
MY/+"QF/?TAW4.IRB9.2'AX.=<<XFG:DTEG79;:L)LSR6BF#!1]*]7816H@8C
M8$*8(HV19%.$?G([4N>_QCPGT3ZI<*T^F80Q48;-&5(FY((E,DQH8@^=HMQ'
M8>H6@?#I2(/S80:>A7_.2)J+;A[_<ANB:>A ?P#>PT$5W[D$V?;=KEAGS5LV
MEUCG1XU$O3H9M1X[_+IX.$?".X &\..,VE#I!"'3@E\-71!G9*J,I3,R)BPD
M&,H.D[TP113/9W?1MWCFRLPP1>H&H4 ZOT"FQ2=TZ(>!H#'M*7U\TU"9HJY+
M9&X#;.'8"8W.!S&0:2N62\O>+KI?U4"7$(>W=ZZ[WO9AJ1EL=<(R3^Q-3]M<
MTC2]BY>3571Q<6BB>R^6NK?"+MEB4;J^C??MXGUU\=.;Z#IJ@?30%6Q+=[^@
M/73)-R_NLYOZB#:[J>1-*FBS>XGM7(-NKA>)E_1--,#+Q739=<37=7?977Q8
MQ.&3XWO/[?7Q;KGOWMMS;'<!>WLCZ5Y6@.AD="6=.D=K,#^,/B]LPQ],H=<>
M[PI"6IZ0EL??@4DGG@X/)!]UPBO=(ZOX1+<:)26<;*Z1VDN,HX-I+;\VRO4,
M;4,;28=BJ<C'Y?*>->D_GZD@JIYY&%6_?/WVY<+B@B7#V=Z9/P/1\&'1;G:N
M#>QM=9O@BY7V?(M6"[G=W=!^M/[![K]^,T/C2;O8#4)]J&%\30#XT%3<[V&9
M!)FXE\JF!R'<1XL%,-SQLWVDTXB/MU:HF4_P.UEKK;+AF=3M;)Q>N%PHEC@?
M"!ODXCXL%S=U,P:RR:B"K"D[1K L0Q[;- IMZ21;8.XTA!^#3#J=62/9.G4,
M@\,WNK' ]"*2.7P;I$ G''H/3&]&4UEDQDA#$\B].$\K8LFPI,D7[_LUW<)T
M*-D8R?!J,J%9V#)+VUCJ)C*_*:?2/0Y#-P_I'X9&S,!KU9\8M*Y"D;HS.SU(
M%[[4_2&P15(.8%W0#0\"CD*F<QAV7S!TU7,SECW40M(D8A$MZ9<>0ZFL^4##
M-ST9PWM3S,5.[14;HTUGTDCWZ\G,'__&V?-:I@6=17F8E@Y\XLG P<1+3#8O
MF'%^PWR?-(#LNTX2YPCT/_Z'#/F&G.'2T#$+PP!V13=)!E2Q)>2D72%C1ZXB
ME,0\("7F3Q4)&K88%/2+R=D&Z@LBXR$I)GO3O_D+JP@8#?HP-PEKN6$ R8\.
M 75'@>>12(B3B4;(L&_ND>5(V.H 63,3UM -=$>4$S:O19A@(JO8IL'[I,/N
M82*$0#@8+T['SR(#Z-=(@YFF3B;5(\U,>!VDI$%2RD[1P)%\\1LE1A>=W+%@
M4<F!1:2FP2N<YQEHJ1N>6?7'D>7>\:_?H-I.@^YO5W1?.Y^57P,)9V"N>=N%
M;), UF\:ZU2SV#"ZL]J+<'[-K] Z/3:X%A6[&/38NK&>N,Z9NOM):>='6?=)
M:Y6+W# =>VRBE0T5#FA-VUZ.O\GH*&M,1< T;.R 16,AAF:6,"?*, U.5H'%
M!5IW03A0F^K "YB)3<1PC*A@H4EJ@0Q]BMF;6"*F"9>HNJ;37H9$OHZ=QH;X
M>PES-Y+<^AXH]Y&(D,/FS!0;/:;%Y!K]<CX<28-NQXR.E8MLPGQA&%0L,(HL
M4JE^?&:[G@F3)O#.Y4!&AQ<05;"TQXILSI!$90-^F_7(&@R0 K #"6-'P3)'
MHLM0% %[3=26("LI=JHW3-L1MP<0N8##M*SL3&Q(F3-] \4I,RQB8%J\WTMM
M C)'&@.31I+_F #4I2$C"]!C8NVE26&JLL@:8-,,N'9C'3\,7XMM-?P>D.[X
M89CSL/14;8UHA*4.RHP@8B*L\2ZH-:G@9U$1036* M>(!J@4 5N!#I DL/="
MCI)QJWL4O"F,*<\E-TP&[ID9"'F_9A0 HTFQ,,8 W<!H2?R];5+(>I!WP+M;
M^W7$M4Q50.^F<T.VP?>.DMCK8M"$HB=M*BI(,,!1GCT0DM%C/<7'YDT?':K(
MQ=QHP($!"V'HKG>:#OU_)UG?@^\.52>Z\<OUT#W[<K+-'''6IRA,D\H""-E?
M@K(1=J8;#TK=<(><Z:^#EP^08.(WJ=1_F>.? (\S8$)!BP=D)P4K]*[3DA7G
MNV<RVPY>+'WY>4AY( .C1Q3\G\!@FL7Z[C_=1LY7R<+?F,BPV:+\XY7ISE?8
M6B/\A"V&'"WV,0\*5O FNQ^CRE.8^@'KD6GS3^N]5VA)[F.)_\7*IR88XLQ1
M/=3\ M]4E+' /YIT36P>&$R_TVB2N7;@U2@"J??#A&\0@8MU ';JT!89(O9'
MG!^<C[1^"UN=;BDI_1N_2P0#T7N58V=BY\  GT'#T#=,D+Z$EYARL\'\F;&G
M-A9\D1BQ:J-_A<B#8+J6B Q+ (&&=:)JJV!K$G&YUA5;/6[G8'-C.]M="T@T
M1<9&M 2RV)&88)^.$0+W5A")YGJAQTH?.C(;7&+5$GO#GMRT(UHX$DO/^<PC
M3FMTQ'%@UL7 R#M^.#JM=5T3I#G>.M[2XU;<T8WMRX9E"TH'UM(@?A^,<G,<
MUBB_65F3^T2?'60[]^9\JN>GXXW782W7"R\M<"WC-6+YCY_;F)#7F67L:R()
M>ZN\0Q'X!TL7%W0=QX[LK,>]3&;;\4DL'=DOU.1N7ABG#3VG;_[X-YE*A)(^
MQW>9-=V@BT+'X:3O(]6P#G%SA%!B!,<N[NFL WQ9@-&78;1A6R8  R^K2QU,
M-^L*SBBY9H8M;,RN79W'8L_:^2(Y9>RSZ:'!+OF=U=RQPW*N4<Q.GT"R@]R#
M=>>11<[[J-# MITD[&Z8QD&F)4*.7'-Q[JFH^&2T)[QH3WPJV@UQK^S;MWR'
M5^>"PNG-64HSIV]$>QY!^;:)RMJG(#\R%ROA;JHP6N0:4CISGRZ6BO=/<;B#
M?">HZ/ V2/03-?5-D5 ?[9D#WT<CY?0&F-\"43T:\1^PO8&5V<%/(TI3HC7S
MQ%0E#SA&CYT].T\\>"2'P*HI8L>('MT CB"A/*I=#Y=,=8$$DO&C#(@C(R82
M9QG7O#%!0NZP$13&Z_ Z%YI@V20H!X%ON/*&Z6D:EI<FT<08(;($8A>O2T*J
M+.);)X9@8N=>Q#<B>"-UWP1)6%ITAYZ0D@+'7"B9,6@"2$2:N',/H1 ZA< 7
MB8^1&#RH=/(X"*%C_Q?3LF@3KI<U\'!I;!G?WOZ?H"[_R3- /6L'( 6(FL]D
M\P#W#2)'9$1Y":&S0P!;8#!!3\'^L3:@\3\S/!VET1Q'/D0CGRH?CH]MPP;)
M79Y ./'$&A/RFW-'/5UL5>["_3H;;EG-WKC&Q=N;$T423KPJEIV'J"ZD4/#*
M2!3[(!P2'N'02\>KO7VE.^R%5['9Z&ZPV8BKS!__GD^))LC^ <CIZLM3S,22
M^>+M4*\HO6(QGAK<QS$O;Z:?CAEETMEM4H)XQR)=D7.-?2]9[F"Q?9Z)Q):W
MHH#$^#:)G,'24'%#:5@W477QLEC:$@MMUT>@>2LLO.B/D;\YO!E;VM&#>":6
M7G"<"T2?8B-M+YS'E*@]2J/7;M!+M17+#9EY+B0'K$!$P@DK++#&ABY(AY-\
MY!B?,$4A!@M*G8AHYR?(45K@F% EHN";;8,9E!IA2+6H*E4P>(4D^2AKID^T
M#!PZC81WGHB:60_6?K[9L:Z3@!.L;*QC.&$C &PS-Z (JR/+/UT0S?P< UYX
MFPP$6Y;TE_,HUDNB8 !I'W0(=$\D1^GD.O"K1;1T#A@)$V11/>07EPO1D".!
MA# 'A4MH ?)#HDQV+H&OBIR(\@'QD/Y%,FG-,R7SUB+,GY@1I+\@=T*_X? W
M.JEE1'^YF3$3'@,6+?%:\;[PAF^8C KZ;Z?;6"88='(;6%WXW8#4$#-%NHHL
M2"- $-+%@1.RI#Z1Y0L<%TU'>LX<4*31R!Y&SPZ;8")"$O7\'WF;PT"'N.%Y
M/-ATC[4B8@WXQSL=?%,-?EQ6]K L_[<3I@.B +4/7Y-()W*1Y #@R<4YZR&1
MXF?I$5,;%D<(OM6Q=%?E/<TF Y%-;(/@758Q#4%$_RP:? ;UX_9(%< 8.?%\
M&G\%@I4D8I-AV>.*+2*7+D/B>FU@$GBE@@4+)PSIL!/.5]V,!,4"D6=3 ]$3
MIX3)@(%[-/;CL%D7;3$?U?),1I/(264F1\\HY\AK:'$$Y$,]K\"W8?,0*2?)
M";^3S:>9!7J U72-S6.IAVL:/DP28,MC96,:TZ2PI8,QC=^R//8-?^IL=HCF
M$*CP#Q&@8 39$P$L:2KH)>^N#^^$[#@V-TQ$,B,O._D=H@XP+=3 ]",9]M0+
M,/K^0T()DRD"]\8/1H0X#V:X#^ E>8*=0RC3)'+G%.S>O L1=0H2X:H9PNH,
MS@N3]\-B:$F<9:M$!DCX>\I<A$IF\G2&@8^% )8 $KE'0Z!IL\"YH,P!_&2I
M8.D1.^?@5\E.#2E]XN-+/FA:2C^P=^SI@NS3(/]-TXAX4]/0T60@JU,P\83I
M)F98$6"-C%4Z(/MX"X6W;8'9&$82>!_> _[N*60JMN;X%PLK(W1 D.=,OR-S
M 2)80H57V. $QGFX![(: FW/32J<\3Z:2N[CPPHLV(,I0L>Z1NJ1B$F%R?L@
MA5S[2*8H)0?-L5P@+I:[7@\"OT]:01T$C0AA8B0 *7:J#V55T_5LFP;4U2")
MN-.94R$%L"L@B=2O8.L?LILBP+2(P(/=8;;!RU:(1G$J>%S:>_;QH,,$3$P8
M5K9Y?)N S3-:>K*6J1DH D4?_/"E]W$8"\Y*W,R=X^[ (_![ $93;[X/8PO;
M+3<,!5+T&#9S687$,PS97%";T!L1F-H*J1N@B%]#58GFV DZ9DY$+$A("QQ
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M+#]K7'?G[/URFDGZD:M)-==*K'0]V;)8=W9;R .NFLM?TD_B92_MU!IANK5
MV<14 DNQ)YGRR%%JG,P:2L[O\*8?K-MYCRNA\]6(%'G#1^UP*,*FR<1[Z>"V
M/0WA#%BCE#5^?R_P2Y+A$H%_@!0P/6#X!BZVJ8,D0G8=!E<>AFU//A]9C=^
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M RY[GHWO5G$+K:B/\61__EPKQSI)4:<5H:BIO$C@EEHT;4U]W?#'K**[I4.
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M(S<F5)1?VG[\*+SX>K9(:JJTG^G-M._G'VR#E:56CL\-.IPM&=9&/K<;P\,
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MU@EI!4-&[X0-R4>N3R_HD[2;U'_NX\.PS7Y0%Z"@>#.EL1RL;Y1?7SC;6=,
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MKXQ%VP9QGQKJ0DG;6]@F$";LR3D[.N?0G8ES,=]M)=5 ZK "6O"2##;B2Y$
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MD!>4GI9772B@19YI)Q %;+2CT['615R$W"7DA!R=4S,A?YR2_BFEB&!)*4#
MU"Y(H>6\1Z/P=RC )TSB%YS3=LCQ$F31Z! +>>L*=(D/@9&B !NOD#^%<O[D
M-)EX\?O,C'H01\A!C.+E$NCBL/60%X;.#Z\C,ZZP6Q'HS+!&4NZ_:XB<*X<,
M!,P(1H- Y\!O(6K( ",D%@J889)&\(_RG%QI;^UG6KM8.-!I%N/WKL091M1#
M-G*-SD]!W2TB?R4#^;=<?*/^$(GH1P&2Z(JMM0@I".U)R)A5@Z]JH&U*@;8I
MI(P"G8S^/"J' OR9H*1;Z(I$!6U9"-QDU_=/.0$[HXLMFJLK-6AYY*]YT4PR
M_@,3D_U?(CE.*&!(J?5@&Q+AX_C[O&A?=OY'7\*9_I2B3T1ZR:, R%.$]<JO
M:?O5]MFOCCC^%D^@9:91%)"9B*:" LYZ?L#_D+.8;3T>X85?9JP8W?PU]4]G
M@OZ],Z5Z_I !,P67VY;NL>K:E:X87W0\>7,YV=[RN_3[C..!OVG!_+L9,D'3
M"4;'<$L4\)H,745I0:QT(4-[!4AL170YIK-Q'L^$./[-'^B^Q.@_>P3TMP?D
M$NNJR P%@&HR8&1,OWU GY>(0$Y#%A]"$,_\()X::(L)_$9-"_)/J/[.#20-
MJ>9JW3A#6PN3Y;?W'F.?T9/.J"'PT)5B6/G0P3W0Q?I/,_=%(3T+_@L[;Y+^
M%0?3W_@^N[CZ@]F?^/ZMUZ\P_HXD!Z[9CX38@@YO@Y#W6D%-A6BQE)_!]PO?
MOXN^S.AY_=D'S^V8D_V_/E_3%KG$TD83?=ZJ!R.5F2B7>% \LZUGVCUR=&TV
MEKEGT5?FI/Q3"P5"JP(65\ C-&-UB'&6^A@%K&QM%YR49_9Y!"28"3]R7,V0
M]UXXFNR]>'P>9+U&.>[E=/;^LE&W_)E[0?*.RL]7#3%^FY>:DQ-,1/^ZT%+R
M4L<<-J3%GEZOA$(ZB\Y*IG8%X"6ND6Q0K&G%ZP]6HRJ+R>ZH2:1;8ZG .CY:
MA-)+E!<:*AMGB]J7Z??JQ$)S2&\#]RE),C<R,TES"\LSJEM#+_?FRHKL)6<?
M+%@.%<ZPK<=P=E$&B_MNK^';1*NISCX5( V=9\M0&Q&84]3X5%]WY *O=,]O
MQ"?X&CW<=R,M+GS51.H]Q@D;U:H1D1^G1U2/&.+5BE( ,<&:^=U[Q.58"C.R
M"7Q,PB(;>(V^.XD3$I#E.8IETK"R@;GP:1^ZH+(H$^R1P0K]JI(,OH=$9/YM
M0[)/[LL#OH3RGM=>0^6ZI&Z/[5:]$_<ET>]LJ*]M:CYF.Z)]^8+P80YK+*GL
M+.-ZC10;;,?P<+V ..$=8PK>IW2D)>^$0F^XN54@2WF1A!<=<.+%V6XG=<\C
MX'DG7?94T:O1_:RX1PG/\913KPG/??AQNB(54-]*Z&,-==+5WTH0VM ;PYPU
ME#B/27[<RT.+_6C>&/L+D\=^STUUW%$M'7]8R0IOV&YWJ\U7DTR#=\JY(XB9
M5Q_,.(K=/;=N/0Y/RU)7+"KHAV9TZ:E^@MND,Z2H"O4-KI^;*.6?#YD!<L<^
MN=>VY4Q77ZCC-@\;<GI#<PQ'7,G<7<T*!G)4/-W-J*HP95R33'AN5(@[.2A\
M;XTPVP+1-;F7>/ALW_=PF[#8-PFVN*EPO?/CDS6RY&-Q#B BCW\(C:Q5PV"R
MHYRB]AV"S:Q868*&_!&>>VV $HV#"$N_DZ[2/CY(;\OBM^]4E/&<K^ &">S
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MW!@(X!D/Z&K3-/%JT[3\:JMVDG5]#F$\Q7E.O@N"W_PEUFAKZ+I9#4;*C&C
MXCH:H,DM=G:,Z+C:I^V"7NW3<AZ(.F0TAJ$! 8J8,=)3,,X4$/_;5BU?#RK
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MM0U&U29<[(S-?1MBN\/"&0L#,?K$;XQ-_MS@DF9-KD%\7MA2$!+*'7GQPBU
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M]RJMD.-\P045 ]0'&\G< MM.//HS76UL,A2]G7TV['@<'I-HO33_R4*&?^"
MU6$Y-BB*;S64*'=,[F2E$*+%5GR/!PW@\NNXHR DQ)+<FG+CJ8BB+9)Y#!SV
MHI6&-T1KI!A\T\8V[0V)U*=[V"3R&15<5!>'>CF1^XGM"<DE8<)C/M1E@?J-
M<</M1@R[W_%Z;"T^LMSDGW]RO/J!%T7J15(/IPU:JJO3M?JY$[= !Q5,'HF*
MC3PUU*T^6-KJO[G1S@*ZZT4UPJLP<->@Q=%H;<9RK#:[R)'>VH[QO5',QR^$
M>?W\BV4+B,M"-@_K9QLNS^:LN(*.TNT8 EA#_&.R"NMHG9@YN";SK*!4QYX-
M:J]A[*JD,(Z'C<$$2K./(<8)> <N)%\JYI<?E(EO*P*<?4@1SQE+:LP*MKZ8
MGZIFG6K:V.!?7_+5UKJW8F?P\^(G3LHH>*DT4 T!T7H>V9 FD3W]LV":[AV-
MQ </&A&KOF5$[**-D/RH60VTJJX"7 U[Z$LT0_SC4/TVR1>NZ3O*\,,MC2.[
M<-33\=W2U7)XP*6 SB8SC:ELK''0P@M9F-=4!/R3GOT #U:Q(USR<L4_/54I
MB(W"ZQ7)LQJ^G3AA3I_17L[MT4+=^@=RCA8%#W#&8#K4\KO=[&$"7_C>X4!Q
MKVL9A1-XY#9#J:;=QE\U7'@VUV;'-%,6:NTP5%FYL.!):YIVG6H\'+<3IZ$5
M:Z)V46@PO2V42$ KVQA@XNE68EHCE^6,I=?QR&=]V:N-:O<H>P1%@(A^PXV+
M^A'F3*F@H% E:AQF_=#05=*%8*KJ2.B]DH/5U'H:(<T("L]@\]Y4>_Q87*NE
M9KSJM'0H(U<?N81?N);Q@^APUD28F)G0I=A+73GK(DX[]F&\^89H(%0;+^PS
M?J#% 5Z_^.N6Z,E&_XP/ GM8YK6I@4A.,Y,B@PY0GC1AHK E0$" RE^_E7#Q
MQX">YHM_E2'^Y:,NHBL''N<YLRY]=UB<W7XT+?U>@BKB/<L*'7]^S)OHT%@8
MR[,8AFQ2T] X>$[<^J9->;%'[4?*J6\COK2E!>&"]G)V"^PLH]:M+E-26<,#
M>+,=5EUU[EO]KA"@SG@?3Q]%9UF\"KT#48KR@O8%A=Q<K/><6._4U)A5?/+4
MZ ED)3>]5\N+9[!(9;!%I%<:MU*KI(3F9?B-]G?J3%AN-$CG0I+&Z[#Y#RT\
MX^-#[F7R(>[N#!G<E#<4:X0-/^YZ1NL3L$NVO X?!-IGMK\S*<Q#'2:/(*]G
M;HZSV_-PL^TX0$QE;8U#SPH2B1LUJ/P7"V:]>(9*)^I7&XVC&(/=VH[2]%BB
M-'O/REN-YZ-AX;&CJW&?WYK+G_J.=]*'M39W\](D6K:JWTJ[XQ>LPUP2'7KE
MM5@? .&Q\4%FD.IONS8E:?CYCF9"+QY*MZ]T'^-B1[S5=>IBE/W T7U5U)B%
M":]?N$)3.F93*:8FOX[[6\1">P1-6KRX_I=HQNZIQ!I\48</./Z./>^?*3F.
M%YNW85A)MKVD"XSJEV/\1&H$SIJI/UX3FBHMME;1EB&4%I+PGN.V>%<XL)@(
M$HM?GNC61O(,;H])'>R:27_<46&JC1QC!NY)?TB-\6D\NB@-%&1?V9H6=L4R
MYJJ,VW!\U$;?$1;>?><FECA2H"3CRU/K>3_,C]JQ#LG*LL81YU9UX:&G'' T
M:826T"G$6VWGA[Z ]N0J/\U*+Y?\Q'3WMQ],3(>\1"""HVJ;^W@YT)"NR*RJ
M**$.;78'/%9*YUL./@92SDZ) 3LUY%O!HH4OSDBG:?5;T8"!CE,T0']N]B+V
M:(L(9IU1%2Z7K=6./2T_+.3:9<H0K6&>51(3I2%#::L(J:Y4T_9]PB;Y<3K!
MF>MO[47_HX_7^'Y=:VW)MZ5OZ970E$G:)W<Z.['%8KV? -F07K@H$OQIVN,G
M<H6[/),_EZ$+O)CP9YW3&0WP)H1GHA[H@U"^I\#30<PBV=9T)!9+)AIXD-U=
M1YB@WU>*4,3<=GY[!C3W LF,!GP:!Z(!:0WCET=BS67OO0E7I G3D7DK^G[_
M)^^5DV'9IAK>]=!L47Y@.1E0Z!"O\VD<[_LRV]>'5!&61W:0:=" ,M(>U%R?
MNB"##+!% [8"CXDWB1Q*FOHX5B+^]O7?KPJ'?AM2Z\*[ WF$!G20(IG_?LG2
M\+\75&#90JNBS%1$KB3QMQ?<CWO^]E@M0['VGY43^O543/&W1V18@[^"#:E?
MA5[_E<:0P=RX6TX%(2=9DS2)'+E??'Z>1'XKOX$U*^WA.1H(7XUFD'P\O)W
M=>\#'402QZS B-;IE)KU!4\E5F(&PDH6/DUX)SI[PN)]IZNPB\O&_;*-*")\
MF&T]:\;L!F@BGD(J]-S6U3M<P=C<,6GM+5F_=Z%J,&!M5Y@P>]I*D"]SY2L:
M4'YON'^,O1#',^ V#G8>-C8UBSI<)E #9;60MN%[8C-KTUD1T1O]OL76ID:
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M0J3$G1H2T?C$+1P[S]R ?-@89NQR]^QP 7Y'X*SCH%06YGPQP]E4MIG"&D[
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M\\^NVI45*^VC 3\R469R5U/-_@=3T6H%FJ$!'WJ0?IM@H:NV$1%GR8S$?6C
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M84^\/)DBL3B@BF&&$^!.(<6$YW'__5X.;10>;UL8GW#64U:F9$U1^ZAK +$
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M,0\UO#OC=_.LV6.TB$&']&V8:C80:Z%XT;$3$[KJ#4KW]X"78S*)?>*T=,@
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M>H$"_&//\EL*.Q[A O.D*  !:YFPJ=T+B1JU]GU98E%+LWC;3B ;]DPQC+-
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MZRO@ ,1[[>;[O!O,Z L"OV%A_(G"[WW(%9MC?>"U'\\H^R$M#3OZ9]>D.K$
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MAY8PQR=%&WZV73OJUV<4)A\&N3%7[Y4SS*N[U&MD5>FXZ121.!YG%AJS<3*
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M!,8FP03YTL*=MFF^ NBK,HUUL*+CUX:"=AS?M=ZH='6\@4AM?_FE'^_]TW/
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M[$J6!6M>'FUCIO/>R$"K5;I4/69C,<:'9SJUX+?'BLLT<_??:--G]'/U/8F
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M.#<$?%UN-%8YR[%K4+*;!T6*MTAM3*QJNE*,'ODJP3[&*=Q6CGSE 2!<D90
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MI#4M)7N88D6\MI.8E,<60+KJ[O(6NK]KO!<TFF%FFO+R>4]0O9K7X<]WZTZ
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M[,0J@7FEYU1)V1=2 FM,+39]^'_:4/Y0/^TJ"B+B)2DF=&IIH_\&4$L#!!0
M   ( /6,F%A04R82!.   .;X   8    8W9A8RTR,#(S,3(S,7@R,&8P,#0N
M:G!G[+MW7%/=MBX<!$1 >N\*(@H"TCL1%1 0D-Z)2B="Z!TB(KT)""A(DR8U
MTCL1Z0(BO1,ZTA-J@)0O[_GV/F>_[SWG[G//_>YW[Q]W)?/WRUJ9<ZTYQAQC
M/,\8F<%/XY< M)IJ&FH HBL  !'A!<#/ 1X!B*]<^>--.$@(;])KI*0D)*04
M9&17KUVGN'Z=DH*2DHJ:GI:*FHZ:DI*6F9:.@9&)B>DZ#0LK,R,K/2,3XQ\W
M(2(FC"$A)2<E)6>DHJ1B_!\^\-\ =->('(GMB(EX 5?HB(CIB/!= !["/$F)
M_N4 _.T@ND*8XU6R:^04E(0.=;2 *T3$Q%=(B/^8->';8,+W !(Z4OJ;8BI7
M&?1>D/&Z,XJ')N5=XWM8U<&D/X*\)?'2XPTY!3,+*QL[_VV!.W<%):6D963E
MY!\]5E53?Z*A:6!H9&QB:F9N8VMG[^#HY.SIY>WCZ^<?$/8V/"(R*CHF.>5]
M:EKZAX\9G_,+"HN*OY245M?4UM4W-#8U?^_LZN[I[>O_,3HV/C$Y-3TSN[RR
MNK:^L?E[:QMU>'1\<GJ&/K_X0RXB #'1WX]_5RXZ@EQ72$B(2<C^D(OHBN\?
M'>A(2&^*7:57T2-[X<[ *QYZC?%A4EY5!SF?A#Z2Z:7'" 7S+<EE?M0?HOV+
M9/\YP=[\ER3[5\'^3:Y9P'5B(L+B$=,!@ "LP>>8.X#_6HL)_.!B$#1:H+6]
M"\@E=RQ]MCUY)@-UB(YM7YA['P3/LLJ]$G/G?[PU\<0J"[<A!3KCH5WLWJV^
M)AG>58U/['].=K#]5*JQ\K9%-SQ,[.9FGCCV?W 7ZB1<-7SI:'(Q^7[><&6]
M[D0.)58B*!$OX"2YB]G+0^$!D7@ ),O]>-,"#R#O" ZQ?"^M7YW[U.W:C4\G
ML'P<<9!1"[IC";HWL,"N3;WL:KU0L=9/U<!J=^N*RO!O\#)\^FRE*!Y9ME(<
M?0QB4GM1G6H\LW_K==]7RWN9#URI?_FSP4;!+ZZ%7B<B>4HLTO%:Y<#ZIQV[
M9 Z_O/%1RSBZDJTLOKO#I&NE:;=\^4>*5298W_S.YU:^@X?_%<W\KVSYC5G"
MN<D.?4_&:VQ^&:9FKMQQK?12^'VO,(&C_X5MC(::D6G<%76W.\3]&-_+AUHD
M.3/<Y",.*&[XW>DPUC><> !C_"^B T,,&7*NBSWU<(=;?.H6BB6*=7_V8T)/
M'\]RC/);/*!V/N.()I&'^3,V)83%U*F=XRN$"0W3:],2>IRR/^!]]_*@H5[W
MFE+;SA8DW)IMO%5T*4L98=GNH@O*$%/.]_H&&/M*^B;TF]%E+O7WT"SJCP6=
M1>IO.0KX2(<-3+Y\#B5EU'OP7VD\Z:#:Q^P\WX=G1R]UVVVX,V';TLUQL6S+
M2=,0@ZV(ZVZ![%A@C1C'D^NRASXB@U!?SI#4\[S+8-Q/7W/?J,+)/)&+D$*W
M,Y_9!"T-B(?.2L)B=O:\#ZP!:)?(.80B7M(-]^;HH2I1=:Y/_R"'/8;R\?2R
M8< +O24ZX8+1BW?-\8#-C2!N%4%#L>ERA41^M?VQ*=4:W;J<OI.,?S&6__D%
M%DHD>$+W 5F0:*U6(@,Z8D##C)RN5S)_T/-WJ9QD9OVZFHC.B(G#"U5_X&NX
M,R0"2"]J/JR&TH;-=MQ0\:%JD0:VM%Z?2&3"C8&N*[*49DD8H1(RJ0Y7O>@&
M-L0WIUS=#88YK#?:O\-D!/C@8(GQ.Y46W^",00(H\4F+1,J=4_EYMT^:PK>O
MC^ !K?(QV\XINH8OQV)K5%09#6CU5!D!_]"(TLO0"<./TZY5DG:E/"5_LE>Q
M]C&*2X>6D]HY!W-[$GBT609=*EW% Z(^XP$X=2L!7%LQ#FQ%"O#$ Y"9IGC
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MF\-@!I;QF'O0(&;Y^(U:PO;D$YW1)R00O:1W <9UG@3/[<,#@-@P/CQ@!/:
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MZI85540.=199*L62]ZV3VZ%ICI]C2!CU5 %,PX25XL/@ :?7"5BHUN;UUPL
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MIG5(7))_B74?;VU==&'2\/.KSB=!"Y>.F(>9CY#M*<LN<JEUPJ[K-H?#7O,
MGH==)DH![3WO2WT4D+(F\5W?WVR?'%J!YM67:,(SH'L,U$VK"&[3NOF 3JG*
M6/M=0U,S/MKR[(1!2@9+YF(D:"5R=ZA,N@:Y<0&E]W.42PZ^B;.?FV>]1"WX
MGY9=B';2)$(IO-!+R-/RAEDO1PJ+1_*ZC,\/C5Y\L'/36#;/X=F+705&UE3
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MIP\=<=^9B25-I]#3];&\SV-^^3"%:<[S6XOBP!+H[4&0:)Z.Z+W9J:&9FI_
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M;9:0H"^"N\D/+ZT@X)!]/(!%9'+VPO($^I=5,F+"MAZD6P9KX6@'@H=?U>-
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MEB&U[V#(L5$B/+-A GKHG+4':RLJEFPLBUTEDXD9 14JZ6MJPWR-[+,C@_$
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MU0\3&=R+@E__=)>UE.;OH4W1\.B8"5J9^;.],/[E]B"%$9 6+L\-@;T"PU!
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M@(_"1N!FCWNBGI%+".DT.L42:1C"/97MPM?5LVZ3?4K$^:N66/SN@R<OU1<
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MQ,73G46%4 ,EX1O)-N<MUT,,-:4$S;V^-/9[M[6C1M,8: ),!X.<QP(:#W^
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MX.:0;C,0DW28@Z*0@)YC=0_2_Q_>WC.LR:[=%HVB8@$BTKM2!02D20M$1;J
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M:5)86/G&3#V^\:D,2A9-TPF^B=M2M)Z^MV4O]R;4(1&@#-_],?BK*7N_]((
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MZQ>YCSZ@)+'X>F<&Q=6J&*T!XN$Z<#"8S*V9^4/B/!5&_NM94][D@271_9G
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M"Y#NB&KS&%:!W"%=[%.OL*'O7-'M?5JFOT5"[AL0_\GX]QI<5+DR;4TZ];!
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M X$R1R):W>*_'$K!4Q+?;J.8Y&>4RC*/]\VK4)](XOK^<6]0%2J%93F.F""
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M3'L=.I,[7GXMP? S7F2BNYH[R\EBXYO8E-%;GGZG8?4"97D9U:1C]WAY%]B
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MR,1C4PQ9%"K.9+_LR0JK2D37.3D_M(G+K=K^QQEC[Q_QE()=)R)>R_U^+(Q
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M5IXJ@W\;U [<";"L6.US&-.W/H&4E+J6UY^X3V-+P-6M/6*.-P^FFP@/S *
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M_^+-;>9('MT(G<3F;EE9V5*SK%Q9A$]G+*^+'-30(H05H5Q?Y[23>))^+X?
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M)M3T?,OLH:./%=)4%LKS,MDH=QSN(]H82G9L(+9P&+1ION$SS$R57X]?6OY
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M9,O<'CD2;LY?A158\6=:[3RKVO;QC,MM; QZ)*5R.XGZR36@T,ORR!UFB)U
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MO(D4%<CL5;&,+ H!PN@VTSFVI1&1'\;EQ-9_]=4]41FJQ WA6YX/[S_1%#4
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M DN7%M/AZV?1S8_L:?=AGD@MWS(O6PT[9+)>NERI*2;G+\V/TJNTD4@8M4,
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M=Y-(<NV.9B,^W<+JB81+#_]8N08\4"^&7@-.*1H*$3F6?K.D_$%I2KL#WG=
MQA?.*$1'B3P3MF=?$?$>?5H@/@268C0<9*D5]+VORC')U%6-#2PP#TTW$OH#
METUZ+BA7"3Z\P [4.TP4Z<DL*^.5][!^%,RT847&&:90!ZC[99%3<?_,->##
M"#M.94J0O2/Y!3*#8<ID][3ORX,%U;@W,9TA(XH,4MO@O?@0_).,WF5*":&
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M?7_?=5XX ?QN)35HYSX4)( L1OE@]-HIHDXG00(HWS5(Q*@]0J"^.-W\4U;
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M/69JB2:6?J/.)>^8V-[K0IC5U!P[(6=<L:MH#R69[WE<4,YHG:A2]-L2Z C
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ML%C:#9Z0LTJB2]]6D3,;G%&F_J2]HD(P*D]%TE0#:-&<6LM[AP'G$C]4?*I
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M4'*ST7V=/7D,H/)^/SNO[NK*VH-OY2[+"("1(I=C-Y$OMY;P>PI[YY3E31\
M/G]P0_3/<LSHD>2D]E8J4EEF#UQX /AV=#8MRFHW3D'8ZNHB"K.50O0? /*\
M$4^?/HUY?<0'-/I=H_:^M.X(].3$&D3VPW)H"_0;)_UZ!?J#^\0\N +-8Y<8
M <MG:LM@4)PS=]PMD<#].[[W+R/>;#5>+W/&Z,EJ-8=,+7IS?)=X1'2LMMS9
M47*HEYCX0S1S7<M=/2.]OMHN=[;?.]"=H:+9,T%I>91P>]8P"ZP@-16@E'8^
M>B.1#=U<>ZXPP?T L/%3D1_6'J_>BMW6:Z>ZJ8//PU07J+N?$:E---S"$PU$
MW#//]LU(@F.W$PU)9-(%J-8,?E0']QM_,ZU) -G*9BLMU#"JE\G[&;*X%@F%
MH1WR,W"W0I=U'-JG[(=-*%F\(6^"]NW&:^74ORWZQ*XAIC7SG/.$C@5)<?C$
M#A3V7!C(FH[ NA'R#/'M+QA\Q V<7P\CMF1]759BU[1;R/HP)4<-!!H^ ;7?
MUYL,YT)LJ9XZGOI&YARE;.BGM=+EEY.J"I0NJ@OB-U QR57ZDR[Z',8F1R\<
MVPNU[A66U/G%W BA).Y;*,7O@I:[ZB\G%O)J=1=4G=O>4] ,8UC-VM;V(;H9
MV_@&T=XV4'?;>Y()3\HI"$2/J4:;V@J+>4,N ?J$>N6"L[Y.4\"PLUG#%.H(
M<I10BTS]\&&"E>03NQV#X<1X"(\LB"!P>>M5WI,S\;>ROHHMSL-C66S6(M6Q
MK._'K6158>,U=7?O4.[W"N\D\19ZQ$L($X@@&D/CYVU/=>I.#UP0:W-?7#Z;
M4F+Y_4C,]I\&)180F ,S-+U2$++>IP/ ]DE(@)?4>7$)[Q?OR-']SLX8>P1$
MAX!7W1-"\W1_<%#V2<%GEE"':8DH)H^S&6F8CB*^1YO+@B;!@J';NNQJO%%0
M:/DN"- P/N=<65MF!M%(I4ZXT"^H7_^B2?0U4#9R9.K^D0^9J7>BEGJ 8C&4
M8#K":U0F&PY8N1-6EQI<&\LBT"OR5.=,]8>-)5U \??2!:)3D"VU^,_>G)F>
M,_)0B@BTE]$!%94S'+B7S35V@FA09' 0+B,GE,0G0D[+@=VF=J-Q\%4!QJS1
M.0UU'\/^Y@, Y\_2 9W8=?-<0&C,]F1&0L6?I"VP*F\_*=@(CI1Z0\2DL0&+
M*OA<0NN>VC.3NQSZT^!WL4:YA8O9C!GD7G6\<*_W?B$T!7?%M;:,^.>G>8J0
M<K1DW:3S6FMUW*V"FE%:H;!+E.O.>__;.(US>=+MSOIF\<)JBG(;E^_&N424
M]*$T]%[B2KK31YY-F+_;7_'=5R[Z,5]=5>X,C5CUEJF(4<) \*27?RRE^K+;
M^#[E>O"<H!3]8\SX;+^K'E#+9(!\8$%_Z1ZM14V3R+4M*TX&&[X$!D.S;8N6
MJF[#./]&<TN2$AY^RE%@6)O/<%&)^EJ@!G!708\]_#LF!I6<ZYY_^N2FR5[_
MA3:)8_/%:HO_5X'G#P!#<D(]YOO"&FM@2X3D@JG6^Z[,OHUIVY(UUR)3\8I\
M/E=>5[:&1=W=X]<3<B#K+)9)9C7]X:D4A0^WD0'E83IPP]4XBI'5J%Y2OI&B
M :@OM30WM+5CTK $:&;D$Z5-0*?L[_@ Z.QB#E2U KVY7!51.S1HI2LMC%I+
M(EPRJQN_UAHFESQ)1'?0 @GW["\9F+II.T(N*_)C2AW6*V(F[I$X=Z)?'@ [
M M<SWWW<>]*AD2QV-4D15@\ ,V?N>7[5L=2;<YCX93%7+>D01;=.OX,_U4U9
M,>$<V?R"/R.OS6,V1_UM3>72PWO5NK>F<1_DWD)ARE#G8B6:YJIX-G"Q5&S@
M8"-Q1^?S7M4VSZG?,WPU\I'N^JP%Q-\C>;7^7;90IHRN0U>!&*< ^5L]M8GI
MA*2+_'\$O)3^5VG]O'M^GO4516;&9ITUB(7>T4$Z0AJC=W$#':(* FC%)I3%
M^J&V4JIK)(_<H+&?[Y<&;M55^"3MG3R;^-GR8<A)E4_'+[XU/FKOO71FP565
M5RG;QT0HW.L.F>-?4Y?NF_ZBG4,G[4MQM9%7>=>>#P#1PKNO"CQ$$8J$ CV3
M+1<Q0I2I[W*^5BFH*ZYHWGP"U;@[4RRV=/&#^5\_Z^MBCD1OWV4I<$MV/@#"
MI[U%^W35VEG'K_VQN#:A*-SMW?0[.E5#?=Y?21]>X##'F42;,=DI<H*3U^ZK
ME3GO=G;O7YT14:!%$F8"I[_@5P=NU7'Q=QQEKR,:L1\;E3TJ)WPB1PS>0>-O
M->50^% .=C\?^'30T+AF32]90WAQBLILTES.NV+R_C1DZHRO4M9QG2V@;#[M
MP;?XZ."7/U4*- 3.NSY)FVLNS]VH8"R@7?PO3;-KY-Z$:A,XELID&"N>DYEX
MYE1H.SES_$C99$G?XJ$4Y\=4''"/C !3.FNK%\8\ &:O#%MG[JGF@&8.\?6)
M%FQ1\G^]<DF^JGY'?-JBOK_4_G'77.&^NX -]4*\]O4Q/FT%/+5UV[$:!W->
M&O:M[$#DO+WL]? -U-SUY&L9%%3FZ0R:N;UHOPTA?POZN/&/?51KG]3N^FR:
M"<3>Y@]X^!K.5GP;#FHZ'[;9?1Q]J.-Z#LN2>P$S0T6]33@Z/)WK_'9;W!Z<
M3D;5K<#2@A3\-F,(21QC8_+$^5;2*K0*[B!?#F=^S *R28M+QD'=ZK;RK0([
M*,S#WSUF!MEDQA)#=?\PR^_V*<V//WNEQ'^.\>5J8=(]?O67O1]%4=@!Z?CX
MLV)I6T7?D9(*O'^*P_(D!HY=D-_$0IM0D8"S"LN#CXY-@T=)9_?7^Z]#CP<Q
M?WNJ6'Q1[X7B]4\9O! 3?>E&*\'."'?7]W<@2;,QUJ9O$+>44?)GKWXDU<]
MR)W XV+%6_Y$(!;XK924G'CC%8EA@OI/S,EIA=0UZ@LMKZ/I\36Z##HC-MNF
M\"-L%:X-G-R?-.O34;C]RODW66:_1?.%/V@>4BOE;!M?WG1/>YW^$N,3>817
MB4V5HSW=M$R*&C^Z'#Y[-7J0WY[UW9Y@UI7^61-6X%%^]#F%V](>=RWXJ9#
M4$\M2:?U_2T 0UJAS8%/W0S36;VG(EHQG*KSN#N=%^ F\.E(X0@\&\#T &#N
M>P L4JS>\\=,]/AII\UGE4^--!P341PID%)/_ $0#QTK2?M_MX"_C3[VWT>)
M#:J[N%@;O8MVL7.96KV71+;>\S:?KBT2YM#<+1AO=B @?FU(S6XJ;\0YPEUA
M7M/R46\;]0I]CM_&^9#@ME%;[/@X&_\X/4#6/^>%7@29UH2+N/]LA0"K@^V7
M%=X_*W6';P%-L]("Q3-^ .#/C!,MC<2A/0,?"WUJI7->U93#U_1E9G1"[=_W
M75;&%7#V?OFW'1"R/VY:J]VZNN?3_2P<E<;3;++Z^U/1LY[X'$'%R[X]?\Q]
M0^HF63;:.BL-R7BKGGO9I(7! OO7%5YASD-(NKSZ/YQ+%:E^..I]7JDQ/"Q+
M_CXD6YTN(*%O/C^YI89Q*\<93)&)BT42OOHBY.W-G79)N3Q8$\FQ^;M(:\:Y
M=M_J$[VS/7O ^A>C[)P03Q4>^SC" G6M,TWST1WN<L4G^Z?[?NX%.VIU8'63
MI5/R%;Z2/9Q<:K9]X-?"J8BH+4,5EZ9"32B^CDFSLK_+O37_.J^VIT+WVV_[
MF, J8!S[?!_-]Q1.Z=F]]UWR>Q==,B_85']_I"Z^@E,DKR"I3S83V7"?EGB[
MHE^K\VNWNYO>ZAOL9=T;R-SS$@SFJ0<<0_OF"NCCU8W2.R(K:O=SJI7H&VXR
M!'7&YR0EJZW&5)LJ[*0F#!.%0Z2G JH,H3,7;D6?K*A$'-.CXYV:T_?43..'
M2:JP V4,7Q$-?2B'WY;FY_09*JY4T.ZK352"+@QD6^936U(HG#M%9J_=EPL\
MWH\(U Z*D=:2PE25AFQ>J.O$7)U)=I_*G-:,WRG^51?W6?#Q[YI=&;SYA=_"
M'%TOV7#V]X'W9"AOSC"/*TFMK86^^<41]WT=H,^97AU "\NP5#'B=>\# "\Y
MB%-9?%Q9C,!I:%1-.">W0)*K:>XO,<NV7K,96/:5O@1&Y/Q/[!5"R>KM] 9(
M4>>7<\!Z\<J,?.6K44<HPC7X,A7@8C'<BTE_2UN5S?7A>\A[^#<\-RU;SW23
M^PC)6#F&LAUSIX0!X[5G=X6<+!\4UK/]Z U34/Z7+N,!5-_"Q66;ZL*4FIRG
MYIB?*X8Q )$PAU&6A.D!S:B/FZWPH*Y)PKER<V*?R$D-*SO&Y'[#IRJMDWLJ
MA][S1[.'>3&PL,+=\51>_WEHA[\O(]O:,2W4RNRU5EM?TDO+V@3Y[]29A)C1
MUO@>\ +?[9ZXR':!DX+,P8)>UK?^+J0W )<\7ET%DW<!F_/!LH9C,T&DGW2C
MEW?'>X4 #P"]V>Z\VR+Q> <'IR]8L>-2C]K7B5*PX<=PJV.S?FGQ03[CNWO5
M&!-'/-,3G>8??CNWN_-'"F_B+D.0=C&0CA^>QWAT6$I;V*&X;+RN5Z_=B-;-
M8"$7F&5 M7VLE'L@^5,NK$Q/F#GJ8ZYFI;W099"+P/RP/N:=+0[;*>S9F)F9
M$N-3=S/GHA]R&>($PZ0]$OV\@_',\0UVE>Y#VL6?3]7H,UW-@F"KU.+ T,;Z
MU(-4G&-DLM6>:@5GXDJC4R7IVNGZH4L8[\?WWVYR3%HR*S*>J>P7(B*@TT]2
MO0)=C6?B,<FVO]&,%#@N#'T!8^HT+A3*;4AB^44.'3FKB\ZT$D 5"E8SU"M%
MC&ST1Y#%.V"?']_XMY_D\6N_DYER%GXKMJ\?(]?8K4$A').'&6E;1K:(>"K5
M,0/J2RDY;%W)^>DBQKIQDS?:3CU'+<?Q>#(J K;A#Q^YM=MDNNHSV7?D,R*=
M1G"S85A%_,7-\(&:0L"U?W'A:K=K[I=JU5ME"L[<_UYFT?\LJJX0AM\BRKRX
MK/$:,L_Z;-BPF#KSOW]T"7)!VZ(4H2N02$D3["P;^0VJF.W=?CPJ!U:KGP"H
MQZ;V>/L*BL1A+5!VM3#>9FW>%5(ZSY7PK=%.F*BI@X&:\,EEY6YYKG]^T[-N
M%Q(-_H(7GKJ3F)-X57P_*CFF@Z. GG+1G&;T L;ZT;6!<L&1W)6BL[R.,OJ5
M%8Z75Z[\HPTG5;M'\@2^AI'M#(OV(4?\#2!C0C7X,1OC>N,5S'PQ,9JV!XD3
M4TOT%*'E6KIW:2#<79"F)1/ZDW[5/2&P+*6=DCK9MN[(RP(Y\:NEZ.A"VZHS
M3)K9#E-\FY%U2@Q":;)L[(A4S]M+X3U]?N15#]BK6%9(KD"FK@M]$-^7%=#\
M=<_9V##S8JG^F4E'ZGMM!PP 3TD YLEM-Q.])X/@5;<,KX,"?:T%^X^^$(X6
M-A25W*'\K2'<\B1Y=\;(!=AP);X\ -^A\5+$!>(C!\#)+L>E_O.UE2U!.,5!
M?=FD4%PT4QT13;BY:;\W;;U[U4E1CBD9:.[M/! .AI _ZZU6IOW\\L6'4FP
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M2G$J-+!W)ZE=BW0F)VW)@\"VY G,KP>;]FDK.:^)UOALN"O&MD>(] _Y;AX
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MHM2P>$_?KV;_A%I. 9.(7H'$!.]R^K:ES>PFV[5LUN=(.YP5J,W3*GHY+_$
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MRK!K]X.T@(32W4I*(RDB)2*A=$DS#$/'T-T- @I2TMT]=(,T##+T4 (.SH#
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M>HLJ&9>8LI^;#I?!!2"; YN0U2*C*YLR-P*G"QN3;Y7\]8(SZRS,.Y4>;U;
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M#=KLC_0O=^)O.S?B_P@S'F$I4+.)M^XED#ZC7M1F0;%C@U3$1RT]R//H9PQ
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M86&QQ5V!'#%"+:I>/$ZG--'?ML"VMZ/]1K_&AI@4:UK_M=#6ZLI-_;=9WCT
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M!&;Z0,U'A95B3Y:*HGW.'AR.VU.I= >_"SY]!&IQ3:D0G\ID>!(S+ *I@.@
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M^ #RLM,/,,:_O",[FY<NN'2@;'[,7;;-*#>=\^<#EXJG,=IJ(M1YDM3O9\\
M/GCENM:,/D>UEAGES/1)B")AMDNP86H=$RRL+VN3*^KA(32<\27:M.'J%P@1
MW)M4L$TGD4I!6!XN>XE--=A%1$B'I*2[JO36IKDMW-N+3(NY2F@,06*9.VU[
M6PH-*AO?8BUBI_<)TSL;]1%@WV5]@IL9U>XVMK&-G>34 V*1\_-M>#UXMN3/
M]OT(.FMN,[:NT#U4.Y(\\C*%!I!R_)'Y[@3( _>5:;-E>S/O)F8J%.%QQH.K
M=<_OX<^2&F!%#H+Y>MF=#3SPG#7FS:[LZ5_K9!L[LMR:_JTG3@O.ELSBZ?[<
M*9SD-W"V?B0;3RQE?ZKX9I[)ILZ@VH14TH^DC03-@.I#<Q\][;"#-QE>*?IP
M;.3OGZZY>5\?;Q\._!G)Q)Q?YBAX^E&3?J6\&>(7FM6<!U&_ZZ@T55'2MN2Q
M_F*!68Q'@8) _;HS9OJ&R;Q;H%Z/(ORO UUJ2/#L0.%ZZV!I;[U)G57[[D?F
M5\ODG^H<QP,!@.#CLO;C&"3B'."C 6*]E?7YQR8_?TW?#B;LI[3#P[^&] ]?
M@[8C"[.7]WDO#=U.&ZC DXLG5SLQ6B*3_KOB=1"U_5W_G!#43IY-R)N=O^\5
M7H3]3OTPAR(''V74PKF6O+!K-7:;6/BKBM#-PV;(+;89[%-H6ISZBC"VU#QP
MP5#Q8$@;\ <N0.:*#*5Y=<VQ,>O(L=:[_$7M_F\&-O^#?RE^FWF!O\!O2'J=
M^A3#HDCS.G4<#LD7;O?!CN:$8S@D(;;9__OHPFJ5=#G1J@_$2-%NZZB;O+5Q
M$I4\(-:7>?AV%DJ+S$6NCR3W\7CW4*4R*V<2EI =-$0M3%0A6+T'Y[1)ZE/>
MTG/7+ =?C[LI4Y5H(;),V='F7!L'*I1'C]WXBFLY74J@6&<SYK4'8* 36L@K
M,[WF.T_3#;T_G/UJ^40<6N;-!&2_[D?7%Q=5V<$&C,8U(: $)1!'*<3LV^9F
MT!GT;:WFFV\.8>')26TL\X*96",O6,%1,O$$)M!_?,;>87@:K#->I?Q.MAHB
MD:R1.,%96&IC-?JR;C72#1G]( B[W\_,0^9Y1.QOA%>2[_7._JL\S<SXU>)>
M6.,X>)1@(4ZCRD;CMMC\V9[=<LT$:%01/::P997=E ],]*R9*9YNV+5[TIHZ
M;[>CRH'Z](.MJ%9*W9^AA%<-0&3TA&4=!<Y$.C=!_RTAX$VAN"CCD_NW"HID
M_EE>IF%/M&[(T09D,;8UG0-R)&+XE@6P5W_;D-=7F:E@<<9QQ@V8KQ'&S%NF
M-/3/)W2NUW>NI6O.L"4 7*7SM,Q1/:15*_\8YE5J3U>)I'UE#02/8:T)@6NO
M8TFLJ"ZMN4G+PJ/K%V>*R26RU9'[A6:!6C1\S>K=C9#1$G=BJRO.Y:6UM\DQ
MOW1Q3!^S]%"+<*JI^1QSKYPQ1FJC"7HQE<H:9.'ZV=V?.<8S$*'ON(@?H@HC
M,6SZ/&_3TI_,VN[]7SUEJ7L:0/,]9C68FHE#.9[1,MC#,?L,)P>1$V7AM&)5
MXU#>AY"UOP8B-#B,:#6^J\^0>6<UE _Q-1Z9(N&?4.,3]Q39<PYPUE&]=IH/
M&?V^\^Y^LT:87R=]*_ODKZ4&4$SHK@_.L'YV?N^6G-N4"\KPYBH&W.!AB?G]
M_G*TGVE-3ET$=9H!^.0^[-+!L'6'$63.>-)FM:T=-;0B:&#I)-E;=_WJP;Y0
M9*-8ZD.J44 0%K.S^GE11PM10B9 -+H.MFNW5_74?0R%']V:W;Q@"."@]SV5
MQ=98_S;MO@<KYP  FBUZZM\<@N9]F3=6*\L-U15*RR"/WX)K/MQBUVRI;!+Y
MK<Y'\:1IC0"EG@%;QQO;;0X+7"&?_L*Q"CX<];8+=N'HK>-[PC)H$%5 2>"R
M&\F^*NWDT2_HF1))\]K":4:/[=WX#_O*HZ]Z;P0Z.-@;L*3JY]X#!+(*")ZL
M;? !-$!)YP"F8A+%D0\U9LFM4I3O,^$SBV'VO27B\31$<O-+T-5O"_&7>?E_
M5/#\QZTI:OFN7L\].UC?1A)/KY//B;P8W?25C4P,5$3$8^=DM3$4N]^+9"2[
MG#QMF&FT#OD;TJZF#.[_H%BH4K'W6LC7%87HIQKC4^/JKKNX69?M1J6MI@5L
MP;0-A<F&S8T\:KN>]]_N)KU4%&X%^F>&?5Z <6F: !5N[.Q"B\%6YX ?>-FS
M(>+I4=F_AB9PH8[LFK]HGN_$@Y!Y:9XOKB]2.A6H$CC_R F0A2)#/0MPC:LV
M<$^?(]L:=R3\'>2GC69' 4_3ZMWZ\4FR'.%A[.HY "..#)6V_U%7N9B[7M&$
MD>?@TB4]*EN67^-U7EXF.0:2-%8I2XS5AZ\"P64#_M6;W(^P\_,+@X%@OLF"
M1Y.[9GQ'*#>ZN75SU!U![F,X54$+4;2#YPP7:D6Z0"4G[Q-Y40',:?4@KK4X
MVFC^>, GP>P4/?L3_S-"CF6T9#N)$-YF6N)CX%,E*YZIV914()LD(FEC+/5D
M3_Z!WS!IM4L>EGR7P\'2>@^_*\-0[7ZGR; $4-DZ5C]L\V3]+SW-(#47H46.
MB[QZGQQ5 /<!SPV[>DT6LE(0HAF/-NAXO6+JO]QEUQ&/T<3+S>/!HRZR<!O2
M_6QTDI-CS:Q?M67?LZ35!CU]B&NBVL%X>"J4P\60+3A/.=*&J ZZCHTTCMF6
M@UP(_?8*CI'N!=4?E&;-W)Z?/+_G@/R9M1\CP41H4I4,9"?42M4JJ[JXJ+&O
M8MR0;^B^A_Q0:FR!*S>*JG,!R%7PB(Q;;@]^HCK+/>F @T,P"?<>,+S,(>(>
M"T(&!QR6H-1J TI4WRFZIVAG<BSTLZ%*>VA)Y7X\<_RWID0_TXT*?!@A?#WL
M;3^MJ&?V1L,Y8-Z5._,4GT_@46#?2/"/O#-K*Y[ E .Y;L43+"5\^UD_'LH!
M3($,W,6\ GDY4<%P%E-*IR*V$4F-=PG]-C)50B_6Q]E( ](?'X9>[?VHQJD9
M ,XG?>V%4*^LM[_-7EQ[,QBE\&)R%HLWS'F= *AE[6.K;[K.IL])G9$,^!V!
MG"_=?F[?]&\I:?U+*X1I0#_UH'L0DLWEN\<=$9%Y9<&/P5PJB&GJQ[)X^XGZ
M5O0%OI20K! \%K.'C!(G'+-[N,=V7C*5(Y]E7CUC4]D(0RCV#5P%4+>0]8[0
MQ-V]I/ R<-8F8^58HG]#U'7K>7M#,8(NM>3!C,W(N\6TV&\BU.P+U?T"5U5?
M'2ZQY!JL3C:HC3;ERZ#JRNV^L7-^UFVMNYPT#CU2HE)",\\:OV:!X79'^&79
M_\!K_MJS3%5T>%#. ?4IKAW!]ON]S+&H)99(IZ@RART$Q_LR+S98A/G42ZIL
M+\/6PC3#9LY%A\'OG+Q,0-OZ568L3Z<6]72HQEVP'=A;J<'R*TI:[6?\=-W>
M4]13W<0=6B$ZAB!Y-?9?M=_J^JM*I#I9HDJIA]L4B,'6&))';!6YNE\15F;,
MA!NFR;RZN>E5.BF(^/FN7/7]31V,B ]B1'=M[O/$_[O&(WP)H77#QQ:#J*0X
MK2#9S@'=MZL9-3>ALLK)>-P";E]1T&M8B"G5NISF3)A6<$XZZD1VTRJ:C^CQ
M3GEX255W9LFRO0VE'*[L*H./&@F*C?EDH*O*IR+9U?<<B-"2(OMWJLZBN!L7
M>WQ4 S6)/W[8&(<'3 A1K1VL/'2.>4//FO)&6OSD0KF+H3**? PJ!DMMM\*J
MHWQ#<-*O,> 0#4</_;3WK-;+*&I@:IL)4,+_Y-8/+ Q*4,GB:+^C)3=]!?MX
MMA.AQ:KZH8E4M?_^/D+:4^0],V_P)'E_9:_L3'Q.$[)R:F8'9X%WRVHE/8/P
M-03Y?OCFD?JL_44M P#;PU_<*DJ*1LJ]A*](QI])(X [>J9VOQ1_S:ZH[ML'
M/<3#?C;KP[V7$JR>)/E7+"P8*@G_G.4,:6U*/Q(Y!\C*OGWP?AJJ$$_=(4G]
MF23Q0H2<0)S<[CX3]X#ORFK:.1GZ=EGK/_4+N=,IU+_2?X?7"EA!N7014OX6
M%O[Z3'#)9S>PI B18S,O5FCYO:ZP/(CDYXZ"D/1^\P*H 06!59]^KWY] 5&"
M,)LCK:)TE^Q?52G]:L"I[6TT)P6V]RJ(W+'XQO (41(7UP<R(Z\OYZKJC1^"
M=M%-.+#/?HEX+D1Y84X*O<WEDL1%1/?J4QD#@<F GR)D/H)AI;_=W*% (I29
MP'=//^%1\D&/83)>XT%RL&+=_9&5. [GK=X]!FTIA10GLKO^GA*:\S4B>A9G
M0V*;IPXN^#4Q;ZL]6Q\^H0^)2Q/).AD92V^FYJP$Q</Y1$E#L+!_JZ83E0V+
M3QP@,:PCU7?;BSKUBQ"#DC'B]/LB&O'C\@\<9N!>^W1;CIQSMS3O5N-T2K&;
M&3Z6&5O_HA;"ZG7?T83\I39FD?FBX+>,--5F/X3'_-LYUA)1UTLM'-]MLV"#
M^W4QO4L/S_@KS5"/K0?M<=^WN,PJ>/F2VK;L_LZ&\QD':2_6M6S0M82,UFN<
MR'<25*M)IG?U*XSL&;DC^#LUL[HZ>KSC"K'J,[S8!SO<$U5,"V]X;'F#[8&'
MV(.0<#?KH?Z7\G_?Q<Y)Q%E%6I &NJ(99HJF&HT<T@FT9H3-RDKQYN3O$B?I
MQJ)>PU??T%WYQLFU.0JX$RG3E$%@1"=5^:'V))6H\U70RLUN;\('Y;(-M#XC
MFO<_S(#8*?Q&_OVV_*U%6W&ZACSTHU*$2?PTJW)CE^Z9'8WY]=@",UZ:_;[G
MO+?U MD,KU6DJ<?KW<MT#K_,3T!K"VB1)8[,X,!M?KK6"W6(^JZO*1W@@8D?
MUHF?V*?"I%^:4RQ'I=L;Y%(NZ8@9J''LG@/<^=0:)/_D++$X&/OE<<;U?-(7
MM"[4B_^U,!!2$@P8.@DH9#TX5.N+:+].M9(G<?I!V2E117V"!$7@+&?\_M@T
M:/"41]V4S:]+MGJ(<I+4AWX[L[T$!5Q:ILIP4.UECC.#E?1E^R<K1;DPBC@T
MU$(4+3NFS,ZPA!_- 977%-\,K0IEQJ[%O0%/>7UD%G2*?=Z4I15;_@NODC?7
M9QOUX5_4;'EX<9^2U;BAY-L"[7AEHU0JHT((+U_GG WQ]0J.(D-4KDXHG"F:
M\TB.R$E2IB.P:HXIC4FSE>D#;^GQYP(?[?SZR)P331?)0F(_CFECOO%:&=<<
M$L7_M]&K[;;6AYI1OB%CD>ZZT=Q1[MM "RPS/4K0I542Y%E43_9>\6?$PI(C
M'#Q[U.-\GGLTHX8>/1Z39B&FWQ,RR.6",L2]T:EV_A2C:6Q^>B'P=C4<6Z<I
MCL>.\C/^?[;W=V-+A'&XTWA3L8:;D*^GUI#UV,C:H* [G[:/PJ9=9@Z__('?
M*$:Z5SDRWC-)\:HQ#LIBN/YD=NJ;0:(!YHY[AK=HU6W'^8O,Z[#16;K79JQ5
M>]HHS!5IZ$F0D]CI7,9AZ0.9H"&^?HNIZJ[M(?@;Y.@.;M) "N6A7/9*FYYL
M1?&/O@:[O_*T-3P288%Y<7S25?^S)@6:YOU?&4)//:W(@\&>WO1(-I@MH_3C
M8,7/J-#D31N>DP+%$HE4XZ+@/"TRD"# :^.%?>JR9-SD!' @AX%1;]E?[-WS
M,0VK%F-.[\S</63_$WJ=ZK=>_!D3^;7Y5W"N59?AY:/G?.LOC0@@CD6?FC$E
M4H6'Y"J3KG97M(>S $]  4T]18,8/*!G3*+)PU(_6/'^HU+G1$<N[Y4PQ^2M
MM;#;A4]S.;^4:EZO3T_PPF7_RTL&_ U^0H:0@HV)YX!D*]T,TTE9]Q=#=T&/
MY@Y+0S760M"A72]VTWJU^PX&?M[HH?RP7:-8$ OZU&UAF#Y'0<_Q/TL[NS<K
M_32-JW-U\G[.F5Y+K,K5L5X-TJ7$?-H(5/M67;^ED>-5+;OV I8.$S-#7D_F
M<C"^S (3_&<"'(B6F&Q<PIH/G*E.+==._;%+6Z&7=#T(56HS5=P">>F79#.\
M7%KGO2*6^61/\<KS@6Y0PO/VDEZU2,,*F./^?7"40L6SYAF*N59MV,Z!=(O@
M+5?]#NV@:)? 3JYJIW&*6B'99:(R).K6L$&CQRWG6HR^":9J!N");_"B[E>N
M9B;/=9X#KE&>$4",9+^IOJ;HF_4-QK?L_C1&2+\.@75FP/ZN.*]TV-=H=)AG
MYQ.ARZAZXNRI<XN\XSW_Y59&5CF7 .I%T>.@QXDEF2GA$[MCOL^M6DVU^4V7
M!0!@6^:=T1*R^@'^SB$Y4OU?1&==N>"[[J$;L%4ND;S,SGM$:-^L+!0L$=\P
M^GS8@LB1\W%!!QY5A]<H-[U%=L?]SH2KTHN&8Q\:1<D^ ,#@G4AJ\E0/O]2,
MG_+]&:6O5^^^-+'=Y-ZKRVZ?AE(->J0&T,L(R>=S_<CX?J,M6I-L3N"#GMW(
MKZ^/UR,Y)H%=BU"Y3T>%[1ZG5**;J?75-(/ BY(?F?,ZQ"/Y27J):].I.>[4
M%1? T*;&[\<.FG)3V$'./YGZ'<(NEQ0-P+P\!ZPPD;)ZJIF\N:&(!B$&U285
MT@,(1[E7ER7A1E3KO50'4<T7S=\YY\:OFP#C0)U1>KTMT-Y292"W5GXI[",L
MKB>[4!&8/AG2A+'V[-Q,0,R\/33K*;#B6AZ;/QG(/@<D=/!X\<LV9_6HM#"T
MY+66+OY2K?V+^#P*O8FQKJM\9?TS[4"/1#5M-?/6!/@"!EH90T33P4H&ZF!!
M/$A>+^Q,FWHCYNA[":\58]DEX6S5@)@KL)?^K7ZWN8 9C@<OWYKU@%F_?0_P
M_C]+E?[[[7<0SMBF03@')*(9&Y ,/1]M;,A!($X''R1!(;*H+2?*Q7NH0M#_
M6OU /2CDYO?@OE#4TA6*.;!K5+&;QU",)(X@;$8:T: UEW5@G\YL9E72=+".
M:E27XQJ;-HJBJ-U=(<6X1%E90F/,;?GDZ[0?ZSE<8_L-1-%F!I]_4?^LOD&1
M(,WU+K'XY"DW3U2T:939%+]M<8P+CJR/JIE?;)PZ+;;NLL#;?W(-6W [[-.Y
MB#,>SG(FCH_4GJF*5'9?P2'N&4V*3.[L*8N^+T%])^UQB<.ZZ%J%=+@ +,8!
M6A\^Q6CYD) ] HD"[(=.'%MS+7S(>/RV_N2S*9FJZMG5R".K_3#79H47E[X(
M!;7& .\&2>WW5E-3'I G"@:5]Q,J(I5:+!9?G<:_#07]&=YTSLPSF0LX!WS6
MK4PDI?/ZW=ETNG]QYC6(YBMG!?FP\EXMX1E-C<#\T0B(O_NUK6BA'*N.]R*W
M!D8\PA L2@E>9L9XT8,KP6A6K6NP>O.Y2$CY9G:(:K$_*QEN6].DZGW-4<]-
MZ+:@:[>*:<QB%Z'CU47X[G,=[.0#IT35;'3\'X-(:6A4>5>42HE[-7!R3VB1
MZ\WBYA[GW?X^-W%Y*N<*7I=VC57C..7V:#@0?,;?%&<^W:90CM#WAMZFM3Q0
MB==WL/@FY';)8<@NI8J.:_2Y^T6&#6LEE@]$BV-(^XA/DQ5__+GP]MZ8#H&)
M/)([JZ&+P+,\"Q[51V)I3(J7V"_G^6"Z+W!NS(DHUQO%FNM\(1<>#CQ.>/J&
M+DXS^W@>45%A-9X?K@H/;R_?+).DWCBE7P$F*>TG@"XK06M?:"S1@^7Q6VD5
MFTV2L_AUSL^_-D(^=VYG.$#[!*Z2D[0$81H#_+Q3PJ3+6%'5)BOU^UG2?@</
M D1.UYZ< R1#O;*$$H=J-T309A?+ B%:=3MQ7T"%Q0K$WW:BXL]Q7+]M?WOX
MY1M)BKBN8-]-5O/8+QAY(/7TG[(S=;([B>$7^CI%XA/Y^;!I#<FC(A3LX&%D
M(&R=-DLE*L?*T]:U5F.F9=[,]I 69&2J+<!.>49BGWO9=HW4T\WMXX7=>8XO
M"01A1:?3I7.\]](%(7DS">]%WP^\_7:UQFT-HGS8%!M1:5"^96F%O1_VW*@B
MC-!]ZO<2&?;(PV0B]MV1/'4ZU%/3(@=-]PN:/:W>UX\H&2O7!22?&3[U'F?*
M<1,)H##ZC/]__VF2*2[$K\A0)/\F5%W*YT;>#0Z:FY 0!\>[4LL.X>\7E?H,
M&S1H>5S5+E^+2W-\5D"A):$3*'3+PQIH!N/@RDW+XW&5HI7J:RKH4MNVK*!'
M96*N=3 ^&P,F>AHNJ2#P=K8D]:AOFQCA,\CS"T6URL'.)T\N1SMOR/LC/:_9
M@J9,F>*EV$% $^".!'61*\Q_I0I3''F/#"XS\KSJ_>]&W,;DK??N9BY?7+T;
MGT(YXXW?!78>5KM>[)7^!-QSB9-L*T"[M5^(]X%:/G?8RX@H]L(+0Q0)?,<'
M"WU2CU/*A3,C%=GDP]+2::O*NY>NMMD1.TZZ'<4FVF3=X<$TN?!GI>3GC,\6
M*[$_=QSH"KXTGP.L<;%L;BD;TIV7.A 7T]A.1@/(PW;$_JQBL$K3<Z5C%4=I
M3$>$79I,&+)TA)OQ75=@RD;)D\!L'$DN/EJ2O+V"RE\Q1-)M<HN&G?&AC9:.
MUG*KJU+ O'!/$?['3M*WN=343%/IJC^5?F2F)S%WHUF6R/#5S :. .6QY$J1
M!,.1(4U"BV_ ,R01J6 =C,M>.1R+Y9>=.OQZ?=#_HP,L%=?;A/HJ6YU<,KF,
MR905:4J7+EU]]G/@P$V1QH6S2IW[7UTR8*WM!J3<B]E_96Y"=H<"*MJT?#._
MU 5S^^UF(4FB_>%OH?TYWD,,\SS. ?*_H,7B_Y(!/)__+U!+ P04    " #U
MC)A8 %&^64R6  #BM   &    &-V86,M,C R,S$R,S%X,C!F,# V+FIP9^R\
M=UQ3W[8ONBB* H)4E:ITI$E76FQTD=Y+E X1D-Z)@HITZ0("2@L]TJ5&>N\E
M]-Y[J %"\O+;>Y_SV_OL<\^[]]WWWOV\=_<B\X^L.><8XSLSUQC?,=?X@!O'
MS0,W5124%0 "0@ @P/\!N"G@&4!$2/C'!W\1XS]7KEVY0DQ\A92$Y.HU<E)R
M<C)2,K(;%-0W;U!049"1W:2_245#2T='1TYYZS8][6UJ6CK:/X00$.'G$%^Y
M?N7*==H;9#=H_X<OW&^ ZAJ!,1$]$0$;0$A%0$1%@&L!6/%V7B'XRP7\[2(@
MQ-MXE>3:=5(R_("*FP A 1$1(3'1'U;C>_WQ_0 QU17J>\)/KM)HOB9A<Z85
M>1_]XQK[TY)&.JW!?0Y1<Y? ZZ3TMV[?8>#DXN;AO2\F+B'Y\)'4L^?R"HI*
MRBK:.KIZ^@:&1A:65M8VMG;VKF[N'IY>WCY!'SY^"OX<$AH3&Q>?D/@U*3DC
M,RL[!Y:;EU]:5EY16?6KNJ:IN:6UK;VCLVMH>&1T##D^,;FPN+2\LKJVOK&)
M.C@\.CXY19^=_X&+ " B^+?K/\5%A<=%2$Q,1$SR!RX"0L\_!E 17[DG?)7Z
MB2;):V<:-I'WUVB?1O\H:;S.+JJU3V?N,DA*SR&VP(GZ ]I?D/WW 0O\OX3L
MWX']B6L2("<BP/]X1%0 "+C4S@CE ?[:%MS[([#7]V?S!%/S(.9C)[Q^"2%%
MUH^@NX$W/X&>0I2T4Q5MN2[)^<QY%I#B=KEPB<153QT]C_>+9)2T=AJ;1I:K
MJWUOMK^T=7YC8KE-A)PLMV>PFTANT_RFD['[55.>-I3T?M&G/+O\Z[W932;7
MN"#>'DS;T0$'Z<YZ>>5CX<IY?#FTFO+W/M)J/K[R1Z-301J4UX\(\?^(J^]-
M:Y1Z\[KJ;=>! B5+4D'Y),1%)RY^^-=?I/)DO"/E2T.!H\2BKBI;4&1R[+CZ
M;2><C"4,F:AR33O>NTGS/CIVP/JSGW^&B5I6*_.4Z&99MX,]^<OLY<_42^0$
MMR=]SO72^AQ<#<?7O)+O.Z8DUU2,'H^-7>PV'+F):<I;NUWY-YO^OM'U>2$6
M*8+G7]O75$QQ]D[15997A:RFN4AM1Q!81*[=SO-C7_)G;:=WG=ZX12DRU;G<
MSS10)_(<30)A?_>DD;E W4;.S%?:\Q&V3'[TY#XDO6(4N^03RE/8]P[_4U3L
M1<C1[.\6N,.FY]1E6Y,(]R<,>]\FU-F<%C%\^>;!+?X6)A4YH/^@R"R!168T
M)Z-N)G(U% Z;F]JLE#BMC"D\J:(J+%&I9[YM275\M5#'(5-"3=R-5M.P1O)S
M^=[-5G>N5(]$7H@S9^&*BTRUQL) T$"HAX/)2TTU^7K#;'F;=:.3]$7_^S?4
M5:M5NZ\?F*<23*+-87=.KY;SV,&LJ>)LZ'AJ<VAU7'N9RT74^#Z$B@OVS !$
M'",^ 3\<"@RF9B=Z$B42KW&&VO;ICH0'4OZ@-9Q<6M5?:<C&XZLW;DE@X#R)
MM_$6CES2_C9EE*OEV4'U+<HI7AG#HUQE^0)VFZ]S IJ4)T^KQ<^3;]0'AWS?
MD$R.WT[33<U2D^F[ZI$1'OM^^SZ$;-R=C]&WUF/N2@N$WR'<RL"2M6.XK.*<
MII?%4753'3^=AR<C%/@O6ZX0_-7P&UAM]9=G#L0._*62\KIWN/<)J]7),:_V
MH\+=;_.[^1OO5(G^\!HQ?O$CCGQ9]"ZS[.;22Q?\4F6]EI%G<(UXU,LK&VLG
MN5Z3&D^KJ>&(W\/ _TBC6TV_K60*6>A[*[IHH"B+ ]P%?$P5!>JTO_9$<WR2
MF/TXPERT*7L#\C*@SZ1=D"MJC%?*;LJI$7;.RNVGA7I!C4XQ'2U?&RX7,'XY
MNE!QP[5@^L9+/4-VK<&IH)7"%[!W3X@M3^%:E8,P%&NK$VL_5UY^QZ2H0>=K
MV#-_#H_%9_:LJ_)WF7[>(0F*;?6IJQ'_V-H\K6KAP+%+6 XG37@E1>C\3?=#
M5>@CRVAV^9@73NX:9*]>69[^+IXP'PX-MX#P.6U@U?=DI QE,G5'\L2&$\5C
MJI3AJA>=.R?J7_TX\]'^,+2#O\4B61B<T=XH_X:CQ BGJ)QY7#?3S]W)_&+:
M*_>%WX=V#5;<T+MHB3:;W6*0B%]<1F*JS2Y,?D4>=E\H##H*2+P9'YP''CZZ
MD7QJ*KW G;A8X #10197.-N\/=6KA#L0WR_]:46QPW#U2WX9P2]4\L[RT!OK
M>N/VTBK?BHNR<A5+5H4V2(97EW/ 9CUR\VC";MG[R,7^^&[UY,>TL3FE8@?&
M\N*4^KV"R;5(/^KA.MEL]'#KR4:^">7-G#(_4!GW"(?%<H(>M3?G3Y=K9ZBY
M(AN,1WU-[*)@-&Q3'08+9E3S?AVE-VH]7&15<_A@(N:!IU0.:1Y['KOX;C?,
M*'O)M*B<SZ.[ D85]2#JZ8RS_&XZ)._9\LS4,W=ZUY7^V^[]Q3=<^+5.9D<+
M-N8.9.VL'.:Q!7<XBXZ,Q'TGBAN@T8>%D[.(##11(S*9OBZ-#56J['PE(C5B
M)%%O,N*[]2R'0-7;$,)%+8+I[Y:[>>YJZLVG/OI-QPTHTVTLRXA-G;_*R9Y&
MS/BTV@KU8.\G1B"6O7M>4!C\M!4V.57G1%<N7&>WDLGQBLYDS?:(9?1]L9_<
ML/@,Y-D(5ZBXFJ#R"GT&G?"+H9PVP6M;<W(5A<X:3KH.Q\?JW=E'9V?&,3G:
M1L*G7-E9=*D[F1&SEUI^,Z,)IZO[M:HA3F*J M**8\=\4#(3KU4^ <&3251+
MC-%MIH[H#F4!UJ],Y&LPYBNLU.5+&>A=$.6<Z20.:))UR"Y,]L1P!-RM+E.(
MSW+E#[O_240)P=/,&F=!E'RN]D8@@<><'G5MX5[&XR"JZ('<';06V"[!YYM]
M8L(7TXQO^?VWWU+F$FN4Y*E@:GRP<HC5=O[HKMA@J894L=(+"8>+^D15@6V_
M^L6P0ELSA@849<B1.K5L97#B<,[86HE=5ZWYZJ0\48\'(&C@?H?97IUU<]+<
M3+X0;-::9UP<:\-AQMHP!BL9+11)ZKGWDC/ZE%#51:D-LI$2<4N]]D'2MD#.
M@WGYU:=%*SB@-KI]X66Z<DE-3>0JA,^[V.(B5IFZ##X0':U34J(FIX\L0BPT
M&"7U<^1Q<N0+.-0YY>O5UGH>>9HI;WJ!(C#RN8GH#_0X0*-\F/I0P3@G4H%Z
M8J(C;"V>*$Y:>5KQI=IK2')Q>N8&@NK'/GV9,_>G5P-LJ;#R^AC;(J?PK(!-
MK9:"V_M*) .G\!QL-\5&2F>46S,U<Z90FYR3F:S];;<P1HAB>6C7+)_^RG>E
M.'9_'7(=Q5NWLZI]?>R<A(1:9HLUM;)23E(.(0ZZTT<OSX6\3=VKLNO@S0&L
ME?OJ;?Z2ZD.[0E>*L[^KN7K2]4['GAUR#%Z)V^->;?[)85$DO?1Q-CF->Y\Y
MISJ_,WO]EKZ^JG<8LB+RU=TNCO L2YL2\2V0S>>>,F_EU?PX0XF(1G4-2ACA
M3QGE^3 A6D@R?::/7V-675_";BBJ>U7QYR=B#Z;0+O'A7)A<"%PV-3+_UW7%
M&U*T#H490^OQBY-5#HS^NU[B13U5/IPYJ9D0GS@6NE^H'@DCTYV*J6!?A8_A
M(4Q9,8-G[W]SLT=*Z>V%EL/);6>EL8VHA#)OBX4P-2:U[ ILG@A_69))SZKI
M[[I0B5?4;RD)ZV?>".CQF!O;/M?X,GCW2:6(%!TS@E1U1F)82\>XUL QGF*%
MIHV)]_@.76:;F;%8O?LQ GIH(](Y^?%;K(]C_910&00C&W]4.MO>ET8UQ(ER
M"@V@F][R3(9/@>7KH0]F5)WX2]I%;ALV1<=TZ%0&G-XI"& <V76755^H.Y44
M,9V&-LD7L]4=T',[I=&Y^ ) ^RN^]6<.9"]BOG[I>I=?K5G]9)-@9^AKLG^A
MM4CE0%Y$TC#5^XHH+=GKG;W4;:[^:3B [Q":/D][8/-R+&]48J>^/NU\;Q>$
M(=L[TUYHQ6;Z+PK=F)N%2,D&A[+J7<\CB_"8G^LC^QDS4=CUAHC5C>(JP=6&
MLOST"7J0XX73>!%V @> 6+3.TD_'1/6VF-3<S92S+6KY?ZL2O-2(.X./C6U
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M$1%.#3"Q^HPNT>W&&A\?5,PE=3/%YQZ\5"Z2-"J0GH!D@2$!#$+I++>&Q7
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M?^NXF-7-8U/JL9-A3ZAHRH4HW?7^Z)G<#6Y(M9F@Y.@,-TN>[4Y1.X;[YZA
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M9WYG#M1Z0U$K4FE(3\!'A\R*DZ!-HHSI'*G]N\&=CJ^@WF$*2Q&<Q'0N&%3
M8Z0L/]$UV76B7W50##GQF#X-Y>LNPKCG>QU07IE<3XY9+X7HB<Q.SUZF6KL+
M.^B'B@=(.G$_VN83EW%=3,EUFZ$2E[8]!J.5N0:*Q77+]:G;HN\0A[&\9?S.
MGO/D7%^J2;U &6M\YNV3%M2;*V!!/UR17)%B+\ )M^,N2DS:?D4S8)U2[^DP
M+6DA[=HG%[]HQCXBH^[JX/^C=Y$CYE09Q95*[I,\F6M'K558P,9+%L_]12J2
MTFABS+U(O9GE'HH[A;-HMP"&UMY)GP194=657@<#N=QDO\_L+G6/8A#]W9@.
M[%C$S$9YPLX4U&=+X=@$WGFZMSGR,5[IRCON=]>WCN!<%36HHO:0(]E[=<;4
M@E4YXA<O:BQ]BTAINUJN-Y) ]?M5@I^C'#.+8.\8M8R->Y\<%TQ=%^P!F%I*
M>:*!!8.=.^U,R6!=#X0(%&HS(]B3G=S8'3\<XZEJ[!FZ/G<(.Y\^(>7K?".C
MNM@A?FGM-O8#11+L)FV7=FXUG$# V?2#C_A%H2?=DO.ZE'N^&8!"AHD[.#U)
M7KO0UO@Y2I6\*QUQVVC*,/#CX.)7IE\D9(<VC_IIL7E\CW@%9/U] \P-Z[D?
M-C8I=T[!W.!9J:,SY0W])=O%6PRBM<3R=_C; 4HM>S)9E6$-"@='BW2;V?$)
MMCI$$U+N/@KV_DW%C-'YY$G?LI/#_:YA"UI#I6F3JIZWU3Q7;QBA?7]L2A@M
M4_+G[%B$ER,A3-%<P[<UZ9%WN+WFHML#I+02F)^H'(S2D;?I6BDWI:RDIE76
MI_4KX("B;1]_6DT3Q<I_KV,87@<=W%#/P[KWZ*M_QP$=XG*PLX&K$?]9Z<S_
MHL9T&@)=6F4]I3PL#$7^Z1GP?03)IA&7PV<:A)JJ)8@:Z'T)R5/UE9=-O^*T
MMIUVT[LB_NC4?%6=7FR;$, Q).C6^Y1=/+YK.^%!JR?Y6NZY#D/PQZ,==9VA
M8][O;#A ;5J@F-V\.+^9_$-479:[=BOD3RFZO,IO<$".U7V=U3T>6-7\;L-:
M_G:?T<4"+%A<B*1YP3>%0#",C"22<(VGL3N0,?<1]V$K9,.,]><@W&EWY]Z$
MJ]_Z*;7P--C\PY/^Q[2O2(?&YV9 \8R,%["#?'>NT10/MH<^-V.^O8K54Y4O
MK0&[. CIN>A#R>H>></"),IB'H[M&J]G!2XL)=S)>A2=Z7XW5_;W8JF,\GYD
M$[:YJ48OB7#"CL$Z"YEX+9%:D8\WXKV5\^$M_M\Q2GN]/EQMV U,[E_TF4!&
MPVIB'VU:H55"8&H0JPQCKM1Z,2.F?#^1_44O^Z4G%T3B'ULR%LV''R4K/R%6
MLNI;G'\?E":L);^_]2R4\7,/C8J@& [8[C2#!$?/SCD[9(=P?"M9*W(KU[FP
M3^_I#8!]TJL0SZCL=IQ-+A,$W=A V2=[9/R,]H1-B:?6[H(XU*K8F;&;ASLZ
M175$&48"[T)'XPQFU'R=+IH/5 7WA.L/JQN2BH-IS6&3:NY81$XO"TO8:*/_
M;/IRP\KX4IWD?GHSEN97J)KDQ5.>Q;G*2;6G^E729;7"-.5KW!6JF7X"^ZOO
M\YK]+2#.-+\-O[^'<]K>Y;X;][ER=--7WS!46&]K-'Z/&YX4_O:A 4_N4.C*
MJ&WYT47B="@#1;#50BK;U(OAC >&QKP&F?S&MARQG:=<\!AU[61A!3[ZZ=39
M-4N+V_)/[W=>H34/U^+AR:0U?_>7&K:-(]:SJS \^91:Y8,-0)<9TK4QZT0*
M_]DIU?^B1N';@D =4EX$GXW)0]")6+G7.. MWMZ.[^24GVFZ(?/J-]7(H\@'
MQ[LZ.=[HQNW,!THQG)%[];<\Q %?3O D_7T,-,+?&<6.53X- 6TU@2^O-@@Q
M\QVR\.<]-.?E489[(I(N0(2:,&TRPS[>BV[W@,_C^$2@OP5TQ()?EWT1=50F
ME@9T$P<,^.+9P^].4%O).OS#>:O3&M07I'9>S(KUAU<SLNXGH8.Q09/IV*O*
M6#%HD\TBZSFE/11]AQL])DOK;UYUB*@/'L4;?KCCW_%_KB!SBPZ1>KDM5Q",
M)RR0785V#%? /1SP_=\ _8,Z\2AY5H,BS-[>ZV,3$.8"["(!6A!%45Z25( P
MY+$86Z<[Z ]$.(!F1QT'$''@ (;V+*<:V[\BH,Q?P!.JR8OHTUN?LKSK)+,Z
MV44[3J)%I9D2.*\JBZ\BZ 37@EHZ2GHY("?N#Q7ONHMOL-#C@&BP(@Z /X0>
M$9A9H&RP"I]QP-8,* D.1U&[!%.T:7KX#6"2,.5#YRW(%$R?^H7"'C8 ;SHB
M&&.+':S%8\+G87MXS0QP>2C?7U<GE5X^:H<1<7:>CL6RHC+_;HI]_=\6\&.T
MQ7\EZ6^+8&GPCQV@<D<\Q$WH!1K:5C"H.,8'E;X8-Z3_^]M_ISC_2/,X=*X/
M>T*O"-Z?/5ATNF7$']NUJ7M0N!Q5 YG8:FFX@P\T2S;8+1RPSE5?B<BK>_ -
M%J/6.7<:@P.&7KW51P?6^)-@G^0=@_JJ0_]\P"[=UL1L\Q.EBE)3C[/C3C6?
M>7HBMO=K@:$=H')P#E@M&B PP0&?LRQKP_GH&*59?=;Y4E'<&/]6[-KQ=_)^
M.?6S];G3P<S^6*R/Y.6179P&$>8,M)8)G5.(^J,/!YP.YF@^ICQ<Q@%I$?BD
MET'F;]U)\@#H;[-L_^RUH@7P">S?"UW])YES_[,B_Q,[_Y^3R5PHT\QZD7FF
MO?D0-**(7<?J<OZWJR [K938[3C<(\7O6%N\(ZF&<Z-3+^37Y8CM"M](;!EU
MK;RX6;6; =I!'#%=\JW@ "8_0Q2HA=?X0E_3V?:E7M?<Z5LXAM@=XPH6^(JB
MIR&<>>A[N%UI!L<R7;R!?4!-Q.C:7-0X%<R<"QV6RA6C;'9HYN&DHJV7&>ZJ
MV?.-,'A2T+KQ1]94;[W:B]=S73TUH.#Y]U+7A:P%YTP$^=9>/7CPD%:_<=$K
MY4'Q92>/$.=Y+39X8USN1M?/3E^EFJB+_B,]C*-/$0[8D5S:&O*PIZ\,&W]B
M7Q? +8[?@ZP!=Z5ML-3&'T^HY*,NK_XBY6M+L(E(J2T2PES' 4E'&IT'D_:#
MS<TX@ "\[*,&V[F%(AQ\CYVF62H_0?V\!(HS%2^+,+K6.O8, :FY<!2=7@B"
MG)JO.;?(;A5]_A)5))2"6'-EJ*;0-S7R\L+$(_A83= V)^7[;;F=+' ;SXP.
M+T'%U)L8_?2A>M\G*+G8Q; GKEF;$I,?2-#?OTC(9>9B((<9Q>N3LS\6II;K
MA_9L?M8\BQ:HC0=%P9? BA\6>]0D$KCN0VH&<4#B?-27]GT)BE*7QM[&$Q_X
M(0;\XUQ6WJ]Y?^X$GD82V=UV\WK&0\T\HYP[_C,DX'RL[E%D5)$!.NCE)SPG
MJ@T]Z=.,2Z:?AF'.]=<?,O7?^-J>_*%B,VUKY9+]X%L_5YN5Z$I+LV*9$>SP
MDB5[DB>C7KOE+W'Q/[1'>]0XH+T'M,NZ9D@'7P2CSX(OFS%;;.\>]8>P'JC7
M*>, ,_R(=7&4UP;8UD\)!\3X+ZJ?[R?B@"?PL'853%48#ICEA08?@][,LYZJ
MX(!%< Q>< /QY7.>#7E5"/]/TV<<I"QN[K8C.?L&+%>'D6DS&T6-V\+1L8SQ
ML7<?3 M_\6'-EJBG6;I2F5?@5:N2 .%-/CA4+=55V@G=^](FDOO.O?/BN[.9
MS_J@-'N>HI9N_*=K[+EL-<*T_A\-G[FEPDLZ/[;PJ]W6G:CP-5NRS0A=E6J*
M;MC(_B,2W#DE^8A8UL<O]U8?ZR6@_Q5CB/?P&:#S4_55R'"=  Y@:XC"(\1'
MKW7"NO;%?DP$%0Y UD!%P7:+DIC8:!Q "^*"\B!.D\X1/8OK&:%8#:E_BN.P
MA71,I 1T%X$-A$Q!_LF-YF,$\4HYU<_/A"ZY2*Y /_\[']GZ6IS^!!_,[?W5
M#^'C%!8K0FB>3Q70A5[&A9.\[)GNU[F3]K%J5WH$*I:<&>:#S((O! *&*UF9
MCJA@FP+,B>%O+%CM*TC(7#*CI.ZM^T:V3]8AL*2Z>%#00.CV/1 VC Z%;.QE
M;)U<:TFEGOO=9HM1*;LNL/9Y_BG)K*<L(0%2AJK=I\"4RE?TY&GU'#6T?1J\
M"S5"#K'7AZF4J:D8P$;H:6]1__YHX?U DH[DR_6^*Y9>L5BY11S@>CZ28#DH
M3PMH_K41A!1ZS34W,(_<_3GJOB/YHOX;$5W]RM#S \*WU\@5O(N^NXA0/-GE
M6T.$!#".8HQ1B!:IE[$_T% ]R32:P%EOS).8RM!A)9F.D7O\TVD$9D')]1D;
M6.XA\3U:.X\ [I'=0@Q=EH%_F&KHPY.Y'H';T7QT_+I)BEU9[EN/6?9TW65?
M]LL/[PH=DWTM+'3XTBW>LE/!_F3TZPG=H5X22EH_6"G-GV^1/.U!3?U^Q6Y!
M[E.+,"S'J6;&UZYM#7/&I-ANO_18\?0BK[93[7W]$'X'/P^L3&G#OD[-IRR#
MIULY,^8/0G,X"3P=G4M"0(*V1)OCRX86^@KDD41\%!]8/N5O^M1'AA%KV]]Z
M.R'/W^D8)>IP@_T;&Z6+%V&=ID"=0^:L?0/S<!T86@A67_CL7G"K[A/G@^FL
M7\)<K:RU[AJU+YW3*L(*O!9/%],_%M7IY4"<*-47'1CZ7Y;$2^QXK;+:?CGM
M3S8D*0\X(C@*N?U0UBZFFXFJ/*8C6B&3_^"!KN:F\KQ^#Y+UCKAW@.2X?.8F
M<F@C4>YNK%+UD+B PF 50;UQ=X4.C4)M')V'HW]C/D-.K60+:Q!6H+H>'>WN
MO&@\PW59C&%U.G&CMQ9QO1UF\[66\* %\SL9. ^IX)-'A+;,/!6R"H%%SGD=
MLCQX+$BB]?V+Z.[]?J.S;BR-<3^%L6'O I2J<TFG:M_C!_3&3'N\R\[;* H:
M-WN1FS0'E.U<];?F=[,M<HVFE>U0;&#63HZ;O0]BE!BW"YNY;4.>/'X9H-!Y
M^SO%^9Q.:6UE\BKC+\ZJ]ZF<\1Q7+"PO%J+,ZR_O&T.^.CED_*J*YP[4I60J
M^5:0MWS3-P@LYW6YMK\7YJ>Y?] O3/E9=,IDHY6$ZBRX>^3:49,B8G,TK-C/
ML&%(3F#<#LL\ZN1P5*#F,_<X11$Q(D"L(/QY7-Z6II_TZK4OE0_[58#ST *P
MO42RI;+ 2H]>25T8J4P?K6A)4RYWM0S!;!V1$CHDS\00'6;FQ*0,"G=@U%*J
M(_K\W/;U(;'SF;'?V#U=RUG&&T=9E2@C:)/PCUD[/"<U;CNMFLR)<=S)IA\2
M@*?P4%90$7QFBI^<#O<9(!GD>#4_"):S2SX-8Q_A]U.4#-M;JTAL%_HN$;[?
M>@(N%>^6#_38XW]XK\HYW+QZCLA/"S5;A1*<5)UQ>ED>JF:TVK?WM'ZT**Z5
M\!8I=?^K;TJ$!8[\GN0#)"/E^H%^5U&SV07HOBVEL3IMT.=C7GZSG;2ND[&]
M%[^_"*YCLBD)ELT?/6*7B]]S^_?G=_()-@-TJGB0=_^_HAAJG@8C93?SKRIS
M Z2 56^/GL>!NDP(N7">38Q"4RZSLFS!"B@<!Y1'(#]S_AKTXQ.=M+/@%?R>
MSI_(\@-4TW"I7F&#'6!E8FT[C5EGX.]))J8,L7X6Y#6/]Y1$/_>00W5Z",%^
MKT!=R_U?CXQD+6O.A(3D&E*PH\TR?*3"D9*LC+V;&>?>")!@6BVM;I&H:MT8
M?*'D9V7"P8'U%-.#XE4+\$N,P&5"8?GZ_(B?B=[YX2<&>];I-N@4J,V_QA^R
MXH(IHTE23_C@9EQ5BJUE=4JV>2B3D2['952?4045&EWW.UV@# Y@0TU?B*D)
M0LI);KQ5Z$C<7 L]B;H1T(YTO=\)A^0YI?TT4*R+0C,ZG^L/ZWEXG/N7>YS\
M;'<BMKA.JT*GXTN@K;^.?DG?.*B,='3:!;O@ -$#?BBC!>I&X7V=I5-$_<8I
M>X<;8@+RNY+ ;\NW]I19K;6S$7.+KAQ1MM8\J@%:N%/IY!'S%'IT_TB%;_UU
M_/RK(@9A?/JD>1 O6MB565="@_^2C$E:.9TK S=?C-YSLX"DG1S61)_%FCC6
M7["N(TEW,K?T$X0PO"X9EAAUDF/X]]Q"^^4)?RL[S:A.XX.2P6>?74VDZX2I
MSVJQGG+W4(G;.TM"USABPSA'MV,Y^F$QRY1:P:NLT7#1NP4B/^]WO=4)O^E_
M#3Z4?[CW&4$L(XZBOQ6S.&Y@[W7F3J9+>H8#;-V<CS&M?@F@#Z/?]K6099>L
M9Y=K,RO?W/GRO</%L+;8 DS#TH+1%I;93Q,I=V<3;#O,=2C _#ZM3>N%5A3,
M8O>^>@@KJ7C_)ZG@^-SFM?&.\4#L3;\\V:A3XW'LG6*1AJOCX5<"?GX+P ?R
M?9M-Y077%Y(J<2N'ZEC*Q:1S@OVM185HE- STV<O8M\4?/Q5_@5[0'+$/CQP
M)#Z*7(L*K+/+0Y.TT)\WQ MV9C[T^HJ)Y79[/<TZU+"&]EZZE%X$?9H?+5^=
M2H_Q]0#)B%#D0W_L\AT7QDI%6E':Z*N$H0[!^:!KBR^9TM1!#HI&(E-U8)MS
M45A&*-]FU.?_EPA5D= -.[MBKRC584N/2.G:W'D;L_P[[S@"W/>=P[[%Z6U?
M2KGJ+*X)).0XR-U)F]5)X+9=P0>H8/(LEVNR$3Z")?L-?><#W0O!(]:_U'0V
MKB*U(F[V<MW^%!$W'Q6WS))$%T+2U$]E,J-*['%2^T-'I+K^LR*C\#T+H5J"
M/LKN;\@W/PT^JW0)G!5!V?L_67S(HY\>VDV+VK66G0L3[S[;@=6,N9,E%:7W
M!"H[IB9S80^H [1W^424&0SOS(354O?TN"C+*HN/(YIV%%A)9K:TE>DJ>K.W
M$V(-IE6B.VIIJ1]S<Y;]UGC$%!JH_BEY-_V$%U[H["3>\D"92;1M^+GEW?LU
M:SS&,HZMO LEZH:M#?4&VJWSF=F/6@VG,J8R+O#.-C:CE@_\T0A;(M"3[/#E
M@FU6U89ULM@\HN>S\\J!PMK&[RV3#X.R=4/R;'$Q$CSK/@5$@91+)L<\.EFQ
MWXS4'22E-LQMD8YBJRG&6<=FF;R,N\E&"A<Y)5+JOV3^"Y)HEKK@=$9W!#T_
M#,8!C^E60?309=LH;/WP6?*%.A5B^5L4^L>9Z)D\#JCK'\7:W)*GU3]X/_ ?
MW:H[B!P'+#N7X0!W''!$8S9EQKG?CU5D!)V"\7M"?*?B4G_!$Q-R'XKLA&X\
M>,B'>6(J%X0#[HZ<IZ^9M+J=4V*"M#>AJ0&_75F%L'-F%&,R_C;[>T\&WJ3A
M )VZD36EC)=!IQ;\[6@="F59OE&0#6AB30E]?>&)$WWWW,W9^Y69>?&K"OBT
MU&Z#X83Y/-W)T);=6TLOPDB'F#W^CH;/_$D?R8J6]J^BHJ8_2>)ZP;^G\%FB
M7'_'AJ^UEC]=@%'=38V[%\<SK>-V9RO*GGJ6)R=&)X3:4+A!7N,.:IB[X;X*
M#]$MP_V Q,)UJ;'X$]OM'Z/S,61Y#NP&RV\WGY@_7CX<&:D!?3RJIU2*4JLH
MJ535)'W&]EG'NU&'1^C](37)HR(C'L**WG#7=L$>X[[]<C)7AB@1<7:T>LDR
M15(A#J#P4E7;1WQRFR$=H^*,"+S?NO9NVX!IS]RGQ/REO]J;P<>TB!*WO<J*
MM1-_V.1,4$7[EX;7KP<2VEQD[3:RQEN]Q1<-ICBGNRN-/WY\'D.I\,8RJL@H
MX]U]PPUZ!H_^4H,IHVWRO.6G>>4T"41$X6GJ10*1\18YW@B+TJJR0V._=)N/
M%K.S,*)8O=SOURS+JI(7&4/NAJP%R^D4OJOSGM^15?#/)QETVW!BV#FZ4*QU
MR"YFN"+"C/ 4"$=-%@\^IE-(M*P) H=).P=T_YRYEMC+/AP@&M66&?QT6"#\
M$[-$'SM'H+[P5,:><X?%^TZ6"I]0 'Z9#OG)/?%CG.,P\,R"\,4:]&)B3=8N
M6.FG5/!4;T0)8JIJQTSE[-?17#BVPC$4R+/(,K!S$#4TF#(L[ZUYYD3:9G)>
M"?0OZ:W_Z<FDE?Z-"2B2G'_& 3.L75G_?)#9$'"9*\>OG&%(>7U#^TU=;93[
M=JYW*/N@;)CGR3FRW*N]Y63VQGY;9N',EWOE'SJK+GHQ]V4[?^,3Y3W3L5V,
M<N&L?>+!'2?!%9&.]I$3EM]OY>)1)FI)=0)7/F5=;NPM(^9W3M,S]AU?EHPG
MAA?"27V]NV$SB&E-(D+XNA'=:4B%KZFH6A6D8"IQ@@ER'KM.HF4?O+7-M]T_
ML;3 YD79O%5@3T6Y,Z/PH/^7JQ/5LH+L17J M/[:Q$M#F7ZJ[;%HHZH):,IZ
M0%':&NW!&[["XY0AOEH<P(G<W73 L*$E<_R$AHG>526/K%_IW:+$.,O>.CN%
M/\](XL\C5N<O+FD+-4SM(WP_$CNNOS/N)\LO(*X0[D +E31'N9=49']N44U6
M][QT8S69"V]@1]LL',,F99X53=HI*>A:QZY!3S7\>M&D9T%+[3NY)X?3ZV#*
MI-O%%BG&[M.B Y]U]J%SH'=[X'N;YZU81*XJ-&]6/=>LR^7TEL@M#XR:OR,E
M9YXA+]*OH J,)ED^:V=ZO:_E]E;S),8TH L'@.(3DTY!(5 GH2MV,6(^"HEY
M6Y;0[J<%3G?.Z;L#[/DB4K"DE+RQIV9D&DGKIQ.@#/WV$?V!9N[&5L,V;%%Z
MZNC2B]5".$.HG K?L1J6>XH!A*&E5$R6-]5NTJ_,2[.LJ%;VP@%N'['NVRQ7
M+G,"6/P>QSSD=U_?WC-Y5YD<>IGVU/_J7GS40#*F/?,.GGQ\-82[H*#05?>%
MAUOB/SAWJNV%Q&U."P)>7(82/R!F"NI@2T!(-% $C#0(H'5E)&*GY>H7]A_[
MDG62B4%PP(MO!["IZ!VPOY\$.O4[1F]_V:?OO0?WA]32)HPJ$0YP1I9<4MJ?
MR3B:&A/O"5C,G8]?NG(NOF!QJ[9K, KSJL>:(H\&JXO6/>38AW;%=E0F!+=A
MIJ7R=SO8SUE]T(@E_<8"^,?S_-XWEC4#@L:GM\A%S)W.5M>0 Z?PJBW1EC3F
M$I19B'?6ID;(]NZ7S+Q-V6M'=P]N^%D[Q0WU;!C;%:6O8Z)&#IA.*M7,+H:A
MM%#=501S5)_/GAR%W\M?:(O%7[MAHAN2'/*^P+JVS$/663/$B] .=-B\<7^P
M&5_M8'%GM(7T?/IMFN<!6_Z^K,XFHP'BU_5^FS]*K'T(:F4=&/[$*-9T@/!)
ME3^%7?HEG:M!W.EVRO5O*I4VWB=1IET6B?ZBN*"%?!_0!;Z98C!0["?L+7B1
M^M [(3M*@ #DB26$/N6;@YR^N"IR&R,F?',++9>+M>Y]0"?28[)?(=<]>&K*
M.HV/1#XD<?]0/3_[YSM^/O"?[RH UW1JT'*Z5RRV#C]@ +*(&FH80$?C (Z+
MEO3C!2%L$/A69/R9TRU\V-/" 92; 1._0;OQ.* %P4&7O9"J*0:BVO )SQU2
MM'-GV@X;#?S)0=E59F^L-&;\B^J3;I8N^W@T^/KUAYTJTIE'F]'A\TL"R=*B
MJ*?8BW:/R=D\3V^HE8,K_T]C92Z_"H=Q4BFB0-#]'PNI4/FP9B0#"P+B*Y!4
MJ[J>/3RC]^2N5K;!@T9BEGIYCV3XISJ^?#32:-\_X=.D_,JOE&V?</T8I3N9
MX0T<BAROWBDH"+>Z;NT[&3B10R%)F88![2<XH.0V9W]L^%KOU,KN5-_T:GWG
M4!MO97*>#=\Q\OEPC7H%@FCU!QC8:!-Y&3_"7^DQVEJL-S0S<[E<@VCQEVRI
MK*D>X1=\71.KR9 :/#&CPE[XFHZSH_.V+D>DSUA;/2KGAM52M:&XP4KR+EE*
MRE5Z'&!#P"1]Y=7[J>@V=9;CF !:Y<PMJ1M%JYE6[N[^KL36C9FIM"%7]XY_
M/+8BNL/CVD\'ED?KG2^/Y0E6P6Q/&<(/%5_;/(R>M5*PXI<(^MCU1=+%V8AW
M5=)Y\W0*M7%2Y"1M;,&MSFLO"B7WF-E8+IRIGYKQJ#]E'Y&!0KPODRHGK2ZX
MZIT+))16.-Q?95[^J*P6,#]V%S#'HF@S3$R410K<";Y^H5PS#4C<SU=3?SG,
M+85-<?#.:\4CIRY,>]-@_(#]KL.=R;?*Q3>9PI&)(5YAW(:V.U.E.RL6$XV%
M0F()S%N,,(3>Q5Z^KP?]W\[H(.^._[]%LAC$_G@__Q%NU"L[XL"D?O=ZH(Y-
MO>/@8R;HB3L2<]&) _P&+U/Q6N0.H'/BXYK_ZOB_HX/\ Q4IX8.GD;Q'_UR)
MP"H>@$P3L3+E;MJ7PP>#G!G YWW+*ZQTU I8# E!I;<HMN!3A..+WJD,U2"'
M6Z6*!U$C-&@D[<LK 53?S--$F;6RC^H3,X:QUR^EO[Q*(!+(5)B<W!O=Q '=
MRSZ([87],S_(4E9=;5C/L-@704YR.?U8K"%\51+Z&[*C<M _4=7TK)F5_(VU
MVY1G7JPW+_LWEIO0N;L![IONYSE/ @UDR!WK-R[ZUTK/A$8PST)=;WVUUBX[
MO;<+3]A;Q0%D5_Q %V#L8,Q6S4?D>S])]S*5*H?D^&F!WI:@PL=1\V986&10
M^@^HW5QHQ'[!@OO.:%:&K(4&R+SD6/_U(0ASQ27@%[SWJK6'M35_CXMAI+)L
M)WRXU(0T%UNF:5MYO N51C7XRLCH&0=[N.C''JPW^/O5/X<UDR=29VDJ#'4M
MW\_@M3;W 4BT]<0BV [!HPYB,U(SNWO%*P:O X43/+D!TDOJRW2HM3_K GW*
MU<Q<>7K88J?.'<=Q1^,W.(#8<"-R9^3R(3RSW2)O_H>W_6P'!LG6(7QGQ88A
M8)L=I7QT8#H7?=#^#F$!_BPG&BA=T.T+O3'QJ\-!.2I9,3?"11%#1K=Q@MA7
M?[],68X>2"KIC[?XV+]X?").AQH5+32961S1C\$!HB=^DL0KM/?LO[CZ3T%C
M2N5NH4#;E(L1<B2)SY!'ER:1SVDRC:M/2/BKSZ/!LE[MOP/NHJ'YS* 6*;6V
M1'<,F]69B4\!Q6W?('!11= 2F' =>O.(MSP"JAZF41KGYGRH *V+&#7P"=UH
M7HO_OF/J*E2- Z)7K4U( HM(^,E3'QVIS0KMC?K,G+/&Z$Y@N-$%A9B[*$N&
ML>A[E@N"A>/8W57^@T)9?TH+4Y)V'/#>*+A1B*;PRNSATSK.0J'/*^^V&,^E
ML)G)!UT7/%T)]^/'2J+1%2I>A;!;W7Q-A:S3. !>SUJ41HQJ2$3=:DH.0&3V
MKAF:MO\B.LUT6E1@_LIRPPG9B(]&)*V>^W/AJ_ON1\MVR7UFX\*+TO',)#G'
MQ/Y/D;-T9PT@TGWW&;D4^+-SX[N]F=_F+3Y/JBH+]D+3UE%[DQ8+F^BJ1LK\
MJ6>U.D,$22I120LX("'LS&\NN-[/GD(^($Z-6IVFE2TX8J2 =_W))M_AVB+K
M)\H@/Z?"=32;-.330=FLZ"'WNGP J/4KY\LLX;=@^JA1!W2 XI$-X:I@$</7
MZXB@V:C,&;_T5>5]9.N0%V,[@\+/\.>:+ZC?4LZ&-.BS1O<O@+]KJL0^CU%H
MC/YM]7H@: "Y6GV'F.53PR[ZUB(7"M0T0[JI.">C<9FL]?+E>M]LP'<B]%@=
M>ZB][@.X4TB ^I'PTC3UV\R(T%%?^"$8/NM9KBD?D!#PT O6KC[)1OD^X.&^
M54,1 *6 R+GI)Y**<I;QJI52ZMYYQ/(M,G[[C_^HDS\^-3O1SSR:W73=/(V+
M/#++\J:BAKS?$QQP!1^%HJ((+@41)RH+4$O6R1KUCXD#7HJM^@)"'P0MIYQ<
MEF-ACT#G/+$=6);,>MURKO/T+#'MNVG27RV2[] ;9&ELL#$5\.+A+*9K:?QQ
MJMKO]7=E'470/T^&: GZ_OGHY^+9HB(F=H\:BOR .+_A9R:EOU('QJ)4,:"\
M"QL !]3HXP!JS!?MA;A&,1?@N@(YP5Y0LA7=OC1K;H4_Q:D1NG0R_#Q[)3'8
M;8===R0^\]?(ZQAESLEF"AKG)LNW2G?:[*]C>:;-UJDVD,DFMR2IILB>-UR\
MZ&@$FE;%'<(?+W'X0T(R:M.DJ;BF$K J<^Y%4-E^B4>.]+R<-RI'Y]2E9V?U
MJZ+7\2SEUMKPSAN!\DN*OBXR2*[CI+"S6!B[XNECBA:%Z]S2$-??T)MBJHRJ
M:L],&?RJSDW*ZI.]:2H&]/D;Z1)/+1U= V<>P=DS*F!?%WE[U<IW2B$O4^EJ
M39J*M3\6D!!_<ZI5F]FM\IR1J!>3"@.SSAC-H%T6WLQ;#RS%/(Q/*N'QM.:L
M%ZZMRG:9?Z4I_[:O<),C:\_I0/5 Z6AC$*9<=06?+J1 4Z!>6I(S8N41IVJ6
MCOZ-_TT&<;1'!NV 9^*9QC?0.0 71N,) OMSZ/%N>@]RTBL"SVF7H:V4G>E=
M0I>K ?##AS4\&8@XBG=_*7:MF2,TL)OL'2BI'6:OYDB(68$S<.O@PX^MW"'E
M2U>3BB9^3^H,Q_'BIWNWW]B$1QD=05YE*]Y0I^OY9CTY=*IF=%JC"E<8E!QK
M<=.4]V[](Y QJS>#SICP;G4&>DF,K$2&^(GBW5!;_R42S[/5?!V@NFA3/%%2
M23\^ )^_H"#% 3?_K Y$"O_)6, _F=K^4BNH@1B-:=)54#!7<+E_Z=K @=_@
MOQ#3V'("")9:";H6BS6/0BO?PP%IZF>A:^O?*8+^X^US?9 \X,:Z'_,,!\BD
M'])"FY0I,0?0GO_M;WMT3 T:CUBG:C;^[<7)/]9+YQN-HH>.(!?#0Y.SRI'0
M"2UHMFDQ>#%\=6JA/<3$'=O_-<!6\;@0TC\Q%'?!A0.(,F^H3R(_2HYFGY8=
MGALF+]IQNE8OFR^G+7\;J:1WRIV;,N(6DLFCOC1X?VE?\S;LJ#AE(?YG+3IL
MX>M72V8%FJC,H$N^L]UPV2*EQF,[_[5C=^\+!M'<ABZG7<6Y&H<X'^M4B,W-
M*;HZ96K*Q]\),/F]M/I'*LI\[&>\55Q3TVB^DQU4$)[Q4!_M$'!P32F7472F
MR4R\5#[?(>5;33Z:FS0_WL-*H[L4'*:$9+)/2$._!\2OZIZG74W._@2CFPB0
M2N]Z=,)F4#A,I0?N079*"S6R@@/P(8MLL29=&S5Z=*^'_(W;9?/'-P''[0W7
MP*T%VY,'Z1,0Q3 %-.7"\XBGY2<[KO>8)V8BH?SZ!?IK9Q$V8+I'<I'=@ZR#
M3(\"/Y'P9;[DTXM+3TE [,LI@#]C5'.\5)53M$>+ETK+PO:4[VWZ E(Q_E>\
M$K(O7MM^,2TUM)5$)LS/JW$44,E=>&/=U\ 5K.&.[OV?A3*O&QC8*>67$#7&
MQXD*L_RZJQ^AOW1616UNMVCU[+IM;JT9TJ'H=!TJORQS[T/!AT_<3-^RQ=V*
MAY1W*JM*3L'-41$-C.B$MMDV_?*1.$<)R<=\T=-YZ\T;_14^5P(<-Y)3Q\)R
MI^SI1<7K5\H##;*U PNE]-?U@XX'%Z&D&U(_31$.%9$NLF0\W,?P'QVB2:O.
M\5+=<U&.N6=F/ OGWC(+^A13,%G^4W5DV;HK@@'+:.RGBW;-7]=F2TD([[7A
M96J5"M2(:@_:5@LPZ"=.*.LF[K!(YOKKD39(ZO(SO-MIDDQ!C61)/UR 32/:
MOWY%G@@@:5[" 2QPI AIWV'&R1RF?Y7RYEL-37P8'</ ^_,O*A[6DQC]VE^M
M@FU61@Y.CT]SMKR!$8O\! TAC,MOF E GPX?/[QFZR2P].LIC)T<[W*,,$'P
M$=:)6@T'U7F;("O7ZH1&-N[+)OUSO>I+L072U%0$_-?R_BD5IUD#:Z8*V+5J
MTT?7+^S">+VIO?V$(3"7\+SC*GLM.Q4F%(G4/;39B;+/H22;7EJEE#$\N:=^
M!.] )R3G)?2>V&$E+M4W!2GS-VQHARY45/>=#A5[CH^AV]!\\?:@XP)"%P&G
MYT'C4I18M@8->";"(BRF*HV[JK^KD_SK*6/P,;S?R]'Q3JKX[!_OC3!@-9W.
MS89I. [@4CVP&?Z#.XQ _P_VWCHNJJ]=&Q\$Q2!$6F)40*25[A&5%D9 .D:E
M04"Z&4) 20%IZ<Z1[N[N&KH;AAY@XIWGG.><I[[/J=]Y__A]/N\?^Y^U]UYK
M[;WBNJY[W>M>HD B:(LB='6U&:H(0T<V,C$]:<0Q,M\8'%IW>6-B(=<L'K(Z
MLH9"-6>;>[;7VBFWALR7(+0&5,/&'QD3\Y07C]:Z,I7!J#+6- SY_M@IK99H
M@"JM7#=3&JQM%(^ 40I6"3($P<?VK(P16$!G55,U\^M,B[*J>0FJ.S3G>X5>
M@15/ ^(O]"E4WFG_-PE#CMJ8U5FHZ$[K/E%,U8NXK)<=SFQ+(6'2MD!$F@<I
M#NSB00AN"(:]D4>RQY8V24LY6)[%2O=P+?Z*A\B6BIPE337F":^U\DZ/9,S.
MR+$5Y5DLZAD$)Z&&GX)1]W"E!&5@*'A\<)*<G!5SLP\+Z-#LA^9K'6X$+F !
ME^1[.-BL+[MDO9#%54Q2*;VQ% OPO[<$O2+ Z3<?.RS@Z#VTU1\!0M\PP@*:
M:Z#(?- $I_/)ZT,HZAL4YFIZ##[ 27YFCT1I3V,LX"YU,TZ9WXG" FZL8P$K
MN?^8U[^7?!\+,#@>6DN9!V+D+@6#KOK^KI8J?Y3;^Y+% =(&+.#X,:9A/:4'
M5 M"11Q;,7F.0;2Q@+^M)FDS&#\"!Z5__GOA9XH,J.'K11ST G<7M%%1USC"
MT,-@\\]=BZ:XN#Z55 3 *6>(GI6D1_UZ1H,/4C@&!8..^7'_RF ;-0!Z\&2U
M+9\G<_F2[TBN1[D\LW;N7]R+E$5;@YX- *S-#)BKAB=9,9WE=0T!8%Z.O/@+
M#J=>/S^_T5Q]"P[GSQJ*9ICQD_(AISL+UTV!#"^2+5]-M8@V'"11[MV795;M
M'.WT-3YA>/]#[NW:ZJV\IL##U9'4B;>$>^1R'^6E"#<8ONT;G,F9&+3R;RKE
M/IMW_^Y>ZSY5V62ZL#!@F<>X?V"JHG.^0#'!(U!3'F=5M=A*4_\Q$$"4#&7O
M,69OOR]%2,#869\0YS:N*2#'7SR9#R^:RJ]M^E0<]U-%VCYDQ^MO/:#J%?_&
M0>H*UGIX^0#'E&#_B5NI]X9XW^IB5QW4^V*!M&:\R --JEX7,WG^GJ#'.DU*
MF\(9D"R;HW FP:I1.E7>IR^K7!-TW+GS@E/H?N5:Q.WN1U,X*890A5V2H\BQ
M@(]W</U!"T:#QA5J41#NEY#IQ7!$<:SGPKVC3+.>J&SG=15^ %PQF)=U*S!3
M.@.]_<L"5U$=W:ZG<N^].OG(C4D'[4\)3XF*,XV>,^4^*1&7QP* MM :M(4"
MK]D?A<3,[GG20=>]7\FONK?@311UJ?D=U]FVCB(0$4C?QH>C0]YX?*XW]K&
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MU,9/B7GTQJPXZT7PN>J=-SK-TL;U@SUC9"*:B1J>2^W.BN17"DV>ZQ@$9T#
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MNHKS;A(J:%"$H0:(*T/G"CXT888%]%^[GSL>?3C2;$4+Z%_HFU^6QI$/]5V
MT2=!IW#DU+DQTKOQP5'-Z,'Z\>F^WNWOAO[R@7,V7=$HV2S/:$BAD?!$:'-+
MU:'L/)3G1';Y%SA6O(XW-_+"]) G>7?MP!6X#T(4-;)[<#54EG^3+S3OVJ]\
MY&BB<O(("W"UDZR&#5#A^&ZOND^+!LVCJX?H(%@@U/)P9A!"NB-D(()8+T8_
M7:\?4)BDW("_<OV)AR)>'+YF!+WML>U-O*J0S9B=*D$===%2')%IQS#H=^@H
M]F5<.AY7&6YP ;4:$)@B\[SM*5)SJ#G[ -'1+][G(K>:I$&FAW!=661#]NN/
M4$X=FZ"5ET_+3.!5-#M'IKD24[E7]I#$4R1K)-PH@9:1-N-QI-QT 1O#;:8T
M6$;7![;5C^9FD_VHQ2=#1[0,INQ>IRSU[I?%0_WH;^E-8AXWKTV06$#+;UE+
M3X&F[Y^'/Q!+@W\1HAWT<!KPQH";/PQ%P<AT^QKL.Z<4YE&PI D*NHN$QPMR
MDXSH]>%:*_Y:DB[4S@VAG#D'-$G9* [_77"OTTMX1!)HIK9S=9Y&E6)\_WH4
M&#]DK+[3[WG3PVH%.KO;7H40UZ$.+.2/$;]S8&09R+CT4<:K!I9<;[IZ>!_U
M:H(D;85+9_5]S:9-PB*SX0C%EXPMC@+2B,E?,/UC6,._KC0Z^V80TM]U9!TI
M']=<+#BMZM^'F@'#+K  .H^W99_=)6YU1Y>4&G83%H9C9M"$E.OO-8T1&<L&
M94?.'3_,$MX8L;7-S?^6U"_77I_& A[/3<W(\/\N+RP/ 7=8O.\PF6XT-W T
MP5R@/;O/H=.!RXK(J,Y29.OY#8<!.K;/6K8L8R0O,"N17EF6A^R;J)M+GCS+
M0_Z<XJ",MG5MG:?#X(6(IN_3%Y]<!88U-VE0NIV:CJ*?&TBW/_NQA2GYA %=
M)8Q0BY>? ^H*S0;W*-\;10W?1:&1B2OAR+?UGD4[R\'2 BU:]EB ^-0Z>/@N
MCD&&(WW%:9=$"O>S9O(M:BJ_LEU&O[CN0E5?)2!_ P#XWAS')%R=>8,T<DV!
MFKMC"-305O'-OB11QQ<G$.HZH'3=]5[CVSO-S*>P6B\\I /29EDC$#^[IYA)
M2)7HP\;K:M.MVT!_#RL$3FN7(F<[W91#'T96\87S^R25A.EA7DYMB=]G*2=K
MP\W  K?S10&W /G+]!SV>4'N/(Y>-J?7W:MS%N^WEM+/;.)1Y1#8G+PTA>9V
MX*II&Q"ANGB&P;_2A^Y%]WEU04KM7:YVICH7>,HYEG.!GOY?"\*KJL7%2"_7
M2-&GG@4[6$ (%E V']ZY2.\B>:W[4] G[7)TR(BO=G^Z>)RUU",S>3/+;;VH
M4%!PY!\@@>(0!Q=N3]J#OJ61R5"^_X"WQ3:N(I?Z'P5BP0]#]F$!S.&=D/.[
M*7^R$0Z,C#;)-?)B 3U,1[%HWYP_N6N=.#C JKI!?B#(,(JGG>>B%[@,3?S3
MCKU,5.JS]*)M'=<)1P[+%[8W<Y*7Q:]S9BA<,4^MFU6M>_<R?R4HYJD&[7H8
M(S8.6ZY,DO*Y<W(LW:2O>RB$KHRR5D^8.D\?>S\*;:L2*5;()@^9XC<(B,X=
M3Y-4"!I"G4E)4ZC'^1-F43#^)$(+(7A0WQD9L(#?CDV88)V3E+\RC;D)^4#7
MY!"':+\B+.!49^K77UO6+ODZ2"_)^C"-LF>@TE(<QVQ#<1S+4FOP;\<LOJN(
M'B1CD3'<PB.8<..X9'_P)3)RRYW0V3UOJ]:@I-!2(P%V[C\_E<RUGU'E<-NH
M>VYO>NO.DG-!0DK(Z2Z,I#NF3/?EH5%,YZ"<":\1X#8!D(>6EI!RDT)SG)NI
MO>5]J*AMB*E[UD#=@GR-D/.N53G?FJQC$;)Q.%3&\EZ,9< X5W'JI981LQ9K
M#OV1&K05DK&->3S&.*!=/A&I6-/R2A#\B,FGY;%PI\21 51:<47<,#'WIXW#
MN9L JX3 3!7,(9+DC9O$14C1D[I*,\?;=-U5M61]YA2]W0=Q>N5?D\$Y-W)=
M%+4'0_/T+0R,>\88;+B,(ZJ\T '-7Y-KEIN6*-O&OH;<3S6YK:RPZ>L5#=FE
M>JKE;V"N#9%VU^^0%A,\MPV^=--:T_@MSS3 U,-$[<P2'ZX*5E-*#[K4F'4V
M"53[6W^H%<C?.4Q!)@RHH=V1.6B/6$P4OF]3^Q_&*)G:(WR1(4WQ#D_O\#MH
M]8#G E3DH/X*1\84+]5G9N1HFE-)=(*V0,MTP1AWT-HS+."K-<_E'A;P(Y7$
MZ_^E_T_2B?_=35N ^A/[%9%:[C\$;L+O\B*O.NKZ6L%%M0:H4J&4!36O1MLT
M>UN>7*B/'I1+*.\J-WYK<[5DDN;\+/I<6.#J-408,]YTU^#XQ2H#-_'H*Q^!
MV\-VW9)[U>=;GB7;$++V2\OV$:U\Q84 C"T6X-.4-33JPB>L)?ZZ1</)7ZD^
M"PL@M-$%OO!]'Z"J[M/]X8O4&>5Y4S,HF PEC1B%&\C=:LA)5?1GC==,[Y5L
M0)-.-K(60>XA4U003C66!>9JB>Y]3MV@UM7:WP>DMA#"J V[OA?TURW;+%=7
M&:<H+.!I@+W_N;NR:,?EN1<8MCB,ILI6(G(F$U=-[R//TY"EU2#,9:HNYE@V
M[?!D70D(8RW_:)/;FK&OP>WE$IY[IC8]90NI? <#DRFI9W%T[ UMH)0?%C\H
MS-4,YXS93J%'N:"#UF+<DYR7CY_2Q#\=GJ]<.GM*)0YM)EURU^RN+8[R3(/T
M&>9I#WUT)8,C]#I5QJ_](+\I^Y%#RS!_S&.=2\;'(UP"TOAW3V2OVW'#IZL?
MA _1]1O,5U&@G.(]G,+<N92Q;T9Z&"5])FKXE0+&S6)]ZXYK7DHJ$!=D[/D]
MA'46AWS&SE5R<,JE28<U$_#EM,U J&T4M$62FR"E]NB7%:-;PW="H-_4\&OA
MEA[]WH6\E*2)I?Z=GX5Y;*YY/!,Y2."C866.?7TZS)V+K#<[<%@PC%M3O,O<
MHL06<\2%*ICVN'?]PD,,05 RIVTF[^GVE<PY3PA.#WQ'V@L"<#RL6:"Z-U>?
MDG.9%*=\:\"RQ]U:QW)@'MV+D^B2G$B1:QZ7JI5ZQ+R\]16CMQ;U.,_]/,?#
M]<?KX4WX"XW72'-$TTLD>+G[U//65$^P6';29<PR%M"X/X?QJW ,2GL) ! "
M2,8KCN/F.BL%X#JR59<7(+T>81O"R&(+KS/9^F0L@+OOJEJ=RU*[#'$>[9AG
M05[4D%1N(F]D[4VZNZ]J(1I='&$HL;_?[E3YX['KT^C?^1DU D=57>#0,@_Y
M)LS@F(Z<N)CUC#J(0Z\:(\B8['<$"QNPU]$V9C2W%"H]Q ( Z-=,/1RFPOZW
MMY4\5/?7ZA?!]6N89RBI&F3TRFZ2P8<1W?!YG6;P5:[/DB=8[< R,KV.QQ](
MPHUYZE),+,IB5/+MNXTUH=S*$/@B7 H+F(1UC!:%MT/Y-[  :K1'^%8,XM*$
M^M)\#&('F1I(7K]^BI*T).8]['#^L1^#<*5R#WSRR,L$>$@6GCXU?&;0VKJH
M6%)55O']8Z4/E?"JBG?^+4 !Y74RQ"\,GYA(W,UFXZKL,D6@GS7!D#4H13_6
MJ!(R]2X]B&-$_,=_)3K;_V=2P*'6]E _N6*%0;)+93QC9,_T)_/%"9NQCU@)
M?I'QL#*;@*.1WL.0*(MMAP.WQ78)D&)=;%LM8_Q*T2V>>[IZ=.X.E0G:F8&N
MC,83+2^*%3^8VKP$X <=)^;&+.R81:HGD<UHO+\NQFO^N.<V+D(SZ)(U8*R0
M4J9753,1U,[Y=NY2U4L3/JDXXG#WV0!E23N./;QS>\=WNMC<=,SLXHQIF<0I
M?R[+02].' "- -'N.2<"6PLW<82!J:WIG*0*)P8M#>S_.I#+VA %:$V6Y^H2
M.([IQ?V90%($K(=>GT(%TKWY^_^RVS"%BI;.V=SDA4JA7>F-^,?@!H#UB![T
MC\*#XDVK_+\;_PLWWGZ-NOO 3B',_/3O)3] [:D_]Q.7+.E((=7"$%X:QMM/
M4J3Q2HX"N\)]HSS$QE/4QYC,/<3L6?O"E I2EFS./4F7#60AF6X!*58%VF!3
M5P)GP3(V^<?1SAQL>](>P4>)YRZ-"+VQ'3B!*F2+E?N(9X K]X)!V_/:^0S6
M6S;GJ^4JKDQFP*!I ^;I&T:W!;ADT^1V$89%YW-1I,"/H0LH-/CI< 5:MNUA
MIFA8M#-+]!XK!Z<LT(>AY53@#-QZ"+=7.&*7RD%&F83G_WI6+:[;[]74#$Y;
M76B4(>0G2[CLKQ-H7R]MH'9I&)O!*> 3R3K!;H1K.Y>!8"1<T1%CV9.21:80
M)5,JL_OD>6_I+U^)4,G&FPAPQQ %"L2>H)&],4R?*):R\,K+&[W81KF?_!#]
MV\KH?3AD>-WGBG:/7A3M5'D;-> 5]77%@^HQB^Y<;'+!(:0HO.L(11NWK.OB
MD"_;)WL!&BG;VN'H+V^"@YH?)MQP+#'J0G(O.X"Z)^>@-"CR)P<0<O/IBUC*
MT_M=R^P<G860 2"'&D?7J%/2'=@UKMTB9E3TB ^[PO&T_#9<$D:^86BJ1$ _
MBH4,T$4>;!\*:ZVRS@N>;7\E>^I5- BZVUELZ9,.$QVY/D0RN=$RFGYSR@F,
M'>!OO#!R][=M!"'+EA<#J0JODI;<2_D80FC,?Z'%2.U](+S(KO.4(^?OJG+\
M)U0^%G.?IC;BPJ^VW+P FA%#XE5J]6.])V\W>9A#M..NHR LX2N]MLHTS^8O
MW#UB#C<-#WD';Q4(YIOPK4/Z&" #>XV:8HM!$-JSIN\7)B+3TUM;,\'@[XT0
M$WN4TA7)Q.:IIOP2)!"^V*ZDI;5UGOV6;%.OB>R5A'93CAHD>= EQ-.]]^17
MX\F9FP,BWH NYHY:#C#R$@O0- ;>1>JJ'B77666:OZ,]9!4&SDL?]+OC0>P]
MGB-M/B+ZVE2V*^-BEH?B'1UD'IJ_F-H2Q9M^#[S72&D.NG=J4Z:=6]WT$]_>
M8_>DUY,P/:RUS@(-8>JAT@=:Z>J$(_1C4YS1H#:7V.\LB> =I.<S&"K^PDL_
M=N 2-^UYFB,^_HG#_]5%*/&7K<P5*$4L /@<"ZB&)AF](V0XBL7( T.:]BA!
M&#](8D:65X3'WRV1[/BV ^ZP>A.Z77OX(?G.T*2M*)PF\$C#4%_^3B\TV)YR
M^QP4ZU0&KR/N+>M\%[&#1ZE'=+K1F":VYZ4ZIMQ_'GX7!40$E.0@#8A?ZTU:
M"10Y*U:/QW97A"F:43$]E>HALGLBC-_D-HLT7P*1Z+B4O9QT</>#9EK42A9P
M6JXH:DWK#EE_M8EX:<Q^1X/^P7/+[CT/]Q4QJM%#K@/!4,91)5$XI"Q/*SW6
M:TW\0U3#I?B50^9H(Q/2[TWI[_*R>KFEDJK:"I^WSV8-JVGBC,*<W9*32@R,
MMC03(C<7L !8;,Z*ISJ]UXV?:3R&IG1BL_HBH(:IQ>NIOCE=I;'8%5C;U_K?
MPV>ZEPZ7ASS<Y;.4X6^;]"/Y'ZN9:;)3$\W*BAL^J8&1NXB!:Y"6,,NKITED
M95.P\IGR^1+?\\$-]>0975HZ(YKF'<&I7V;0^_5*R_-,X+#>I6 &R15Y+N:8
M>:/[\D\H(U2FZ6^I1=9TNG:Z9@Y+LB*CVD0I1 7\K[(32=(8\QCJ?V<&Q;)=
MZ%D3#ML.+[TO%- J7SFO6IJ]=$"%LL0OL[,^_.%UMM"[72W#H;L[434Q<V@_
MY26$XGX(;*M.(*::[$"]L"7^&5LY0.N.7 NQB5'*$='V>S8_XPU+YM %'RGG
M9#-\3/T%W'?16;CN#X4,:'S8%*%G:+XO^VCR\^3H[-[))Y>J7(>%3&NUX9 S
MQK.9P!Q1E;7$IC.,:6C<RK.5G?SR1ZM9"6/9LRRC?=9)<EL2SU)/BS-Z04JH
M>UC $]E Z!Z##1:0/EF_^5]= GI[]!KSQ@[7/!%H\%YA$_(+%G 7%=$Q(DV)
M"G/'^_ON_9^K7Z__LOKUZ+K^[*$ZU7B?-'#A\3"W>-VW"MI)2V?6WIIOG749
MMG- @]1CCBD,D8?1<*.0BR"QNW2488BLL_%C1JO"ZG4:*--PT*>:A2FQ/UH2
M* \P^@?SM5Q_P46\)GKE)H_"OSJ=9'83TM)*Y)D!TA.,I(5-U27]O;.+^GE>
M?#<)S;I7GU[-524\*,&WX,W\SR+]EONAWT /PM=5WW_Y-S^,/SSQE>TVP7T9
MJ3USLU32!\B4:UXS#*=Y!0->E/0$A'/$!Q/^XD+E ER-*M@ T: DCDB]BT-$
M%Q*YTC?O?;FU!=E:#4+?R>7AM#JC,ZVJ]16+H_^8'HW/X2D%B^AWL;D78IW%
M8^>E"U+'R"X8BT-"^T:S(!<_]"\,PE&'QR#!+5B9N/8U#U*LG?-XND/0WVYN
M8Z",$3HG[J4%8Y]J,H*0S5!9<;PO'<_ 4,31Z*'=PB<;R<G;X@,8KG]OZH^A
MA5"D8[\]]*,_16[D=5_+ZQYI0KXO4R3*IL+>C(-,%X';>^^1;HHA4,KRW-7+
MH#[H5T8AF19$95;*U7K*K@'_;YIJ,86?L>A:7,M?T9BXT!:TU@/1]4W]:R^"
M.*HKD(]7^RKQQ'G<<#V#(O$=Z4!![@@68!Q.M_.VR4*1@9</I0:N#V^1*F);
MCX,7#V?PU&"R!>Q_U?HVO'U#C:Y/60H'YNU]MG84J][_O+]>5_-C^;'_O3I/
M "S7@^_ZT;9&2.1N;4=G:EO4S?QO:MMUD;+K!CW+-GA(:(L&1B,X2W=Z[6.F
M='_HF6$/2LF3D=S?UC'!)2"U\0)ICDQA"E_UN$FPZA^<QU/C>0AIOJQ;;MHK
MRMLEI=P,6K-B[PN@4GG.URU!<PH>1W-L#Q$C#1418=%429G:TH;FP#<ACI*9
M9ZQSDUF45T_QV5O71RIH=B<:%L_6O, )IG%S"YKMBO/;E.D0[L;B96D*S6*7
MOQ]K_RTXH< ,V<8>#<SJRM+#YW24YA+>6*=]KR?#')J)4U]WR.92GE=U0BZ9
MO7!RYO=[G!0@]OHB)5XYVL7/*\[WF"A2ID-;;DN*@=@S1I'4/*" Y/ 41+D:
MM$L<OVPIX*6UB 4\A88;+O ;3Z&T$5<N7H_0C2M"1S>_/M2#__XH$K'V9)TL
M<6.FC,"G6;AH@+#5@&',0]TXKV-I-YRD,G1E5I]W#J+7VY>;T;T454\:+UB
MJO_@;=E*&G96-^"N..&HI'"HG:*<()*FNPU_*?C;JCX9K\L"3.&RJ7ODE3V5
M$)/C:EMIFG [J]I9U[-?]TY4IYCA:$.L?^ZL_(SD5-4\VMI#SUY/_%/FROJS
M&5;F1*>Z.BLQ[88'6Y%NC#G05.W=A+#*LBT^%S>A(\$DDRN[@>=ATLZ_Q/WU
MCG7I&>=6B^2AA&VS7&+OFB!X8G3 ^]!/LO=V1O<C;ML9184<TMT&?+ ?M#4
M>:[LVZM5"U$G=)R-KV?8,X^5"6Z=K/^*FK"SW8YZO_B^/E(HM#C;;,&FO#16
MV-SU<NA:+]ES5ST@1=MSX-+UUQ!?)JQ/7O"P( 2B,1E3NIBV/]5$^GCTX:;\
M&']P.%D<RE RR29SP/&)-/\G@*;3Z/.^7[&[/ML:=,T+C)/BCIRB$'_._=,&
M:F7>'9B[P%)E@NJR8C,%K;[Z-Q6?(>:E3_4ZBQU7ZT6+\+1)GD\U)PFK@_+3
M0@E]Y8WV%]]6):.M;;YA.*K'/XRS''$7L)S>'NFPFPK?>"*D3OS+VY.=D;'J
MQ.%@P#!N:;^(.P\^XL8=ZW957%D9:]JTXT4QC+IC?$2J/(KB=-RU#.63']=H
ME:TF29<G65?Q>:1N$V=-NWFKIB"<P%S>J+:A,]A]Q;P<"R#:GE+9"MA1BXF>
MT?].:TL/G=?[$&$@0AWJ(74K&Q[BMI&>X">])C ZUY1@B-G^O!9N$3;6X3:9
M KUY5@QSMW(G^$13_"0I>A1TX$MBNZ\@K%,"8:QUWHO=;KR*51-L';>\$%0X
MUPB+M3/?+X*5C8'Y9@06\9&O6P07V":*44(25_#9;<WGYM1",-JRR'6]'J*0
M)KZ;S4M+IP.N31V'Q-L8BJ/ULX!8BA_F^Q34S]LX#LV^_LY,%'+NW#.I*0BU
M?%='[>N^^]U_]3NW1X^B:S]?@ =ZA==5@/(,/9@EDGS@RFW"3M'#0?49SYO7
M$W"CEDTE2<1>0?,:U=2#WDP,[AR&@6?&,C.*)H.N>QI4&P?99SG,O.)<J#%O
MPDFP@&E1W)"2+G(=ZDBY?,B$PUX'C$D#W7\@U5$E*X&H;^M8 (3I*F52!(I8
MQE!>,@6G!W%<TI__WPNTMP9!LFFBOF/NX&:-K[A:<6IV8P'X&$YD^!(.9SDK
M("1WN->2)N^%<MEI7.(>TGB)X3E(3IV:@B!4'<P]6)8<I$V=QTW4U6DYWUIZ
M$]KK8 $EFWL)3:161?7F*]?O%IXE"6E/]_+RGS+E 4_&PZ\W<_0F<HQDU78\
MGQ[KRRJ6U2:/ZM[)\6=VU_[&<^_^'9DN6@;AT\+P/XBNDLO9\_?HW.PE:3:\
MNTCE06X.\@.'K8IJI+8I7*OJ>L^FM_O/>],,6;NN9"/$0?=1H (7:+-BL?FY
M(7B87+4A<F,"9MQ38WQ?ENEY]YVO<S/;"><]Y9;W0G5FW\<,T@IPF"73<,]
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M*!&N0/S%U?(%$S-=@I7&*VX&#PI.3K$?$YPU2]1=O2,<P +NU).N#)&Z%-G
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MA=;E-FZ:N=U3 *-#;5-"Y^<E$SSI"65!/_D._C<3':Z#O;XGT4XT\Y86.+J
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M]HA$L6:2\A1<G)._=KV-!%%9;.QI]M9>A5C<>':I,)KTG>BGCHK<U_#HX7L
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M?&P;MYM-EN;UV7+*I&1)WZ#\,U1<0@HUB-( )PXT1Q-M[#N0UNF/$%/(MZA
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M6ZN>[/H(%O$)R6+FN@@W3B:;/>]0JA$'O&<AC]3;MHA[!MW6C<YL84"SCGL
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M>2VX7%DDY I5847GU'BTV]+OMOI9D[_UX"C#)<AR!Z.84'C&:B!FB*T7\']
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MZP!>S[Y.HF,V?3M,.GF!30OM"^I+D]3#3=S;\C_W=X["YH][0-\H4103VV@
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M;ICO<YL/*QM3'?EN%^?J.$L#WP9A]_<XFCSV92>,=@WGRM@?3,?69<(==B&
M%OFRPT,6JPT1#@;JY.6%=-GA]P#]]"_Y<@Z$(#/Q)M#X'!$E-/MPM=8 /'VV
MZJ*L@,EN.P/\;U9H_WTL@.]+<>.\C)2&!_3< ["1H"F@+-9G7_&B+H&.MJ2W
MQR_7HS+2;8]QPX%%'YR0' :9-@@PM*X05G\1-<EO0H18Z!+2X878VF?IEU%$
M4^DXRQVG,"QEX:W,-T,QP;#U/OJG" =H.P4$$3$[7Y:<]DGK=?(=;4S+W!*'
M%!H68ZVO.FS]0AU!YP5/,1YW/<8S,=C+H!*\!-GY2<MLO=QTYAL5WS]4,"/J
MC<C%R47;E23^4ZKY]9"1O8J12K"WU]Q)96WAP/)$QUP1^L_>.F-W. A..%\G
MB*%&.7+DX^1-UT6:8\@RKA3U3T!@B\?E)1B\6]8*>Y0EWPLQ"6=&&&4CFM?L
MMQ(]7*!T%M?6=J\8.9]KTAYS+5"!DMQ$0V"W&;Y>N;;7K=$SLTE.V?@2BH<I
M[@,SGW#D&\ %#*JU";L?C6?)&]1#4G,Q?IUAE7.-?*7X0@S%+GSC3/X6CV]_
M!$U"18U@[]JA<XFFIT^YT;(._GBVH-K0@?SJH^1YEVMY (K</8!6 M2Q?BL!
M,0C MV[RG>6ZR.<X;2[2K/'&H[[VZ8_JV?PVWA=EQ]DK_E+1WMS!XCO7:LR2
MZ&$X:NQDH 3Z;9L_FB?-VN4G(%>9E2BMNVBB9\0P3>"P[I;YJ+/?_M%#-KL'
M]#<7/&3S/X\AL0?\TU-(#J$!&\93 ?M+H+@LN?BM(IMJYA8EH2];<8?A/SY\
M+,?)+56L6MED8V4E<J"Z*A:/,/CZH=%9N#':/3#ZZ]@QNWFRE2#5$2,*MIZ$
M:IFW)K-/P@^@S&:7!>C*6M6]"9?BQWC\/8"KGI6F69LE^(C5"B>5525"_AO.
M-ECIPYQ-@N!N(E&<Q:";YF0ZG_+74_HG@5LF*2 E1<-0HS%RE-L+382/NN-/
MFAFCP:D"1#]O>F:G-TZR%XO(VU2R ?R$=)(&9 D)(]O5,MU:-<\ DJY=2=LG
MAY)1MJ6A5P<!NGUK](GS=<\\UR"[62OF<OBNX3T@ML+#4T=;-DEYX&,O3TI6
MGT#+L3.NE[\B\Z?7L:O'NL;B2?> -9)9P6_U-.XGCB*](F6V0@?Y.[:R_B>"
M1\XF**PO/ F6Z-]J>V%'D8T2>I^)?/P<@FQ<5^D;BGUYEM@(%D/@,X(#G^A8
MU1]+&&\>KYR#7UE_ ^;3$S>@OB"YT[\L<TP;UQ'J6=))ZO'ZIJ#8&!M"M&Z)
MK#T' Q'@U=+(W?4Y_LC,ZKUD2B\J[X$5^O,=?_N.I-"=GV\)&Q]^1QMW+[)V
M3].3"ZBDO%BS=FTQ!WSSX[)?5)&VIU=QC\E08R3LIB\Y0VBB>_9D:^LY$_QG
MAS8MPYS 7+$P(,.V"ZA6H (#FX1UBS[7K<I00WQ;R+J2!/5$7*B0Z-3-\=_X
M#.DE6^5+#@YZ3Z_9*BG_GIE4AO/WC$?9:Z=TW@.PYB<**B'L4M"<!I1U#A]X
MC\<UO1?N4H@SL.>-:((\V7L:Y]!%;/$^[ZN%GC:T$PE.:U%3F_I]6_]0+]11
M3Q$@SN6MD)HR#397?'H"&7;9-M/Z;,.+^=39K[ELD-&^W(BNR6QLI735C^9^
MY:;'Z\HJ?4INWE@_2/^3>?SW0<;M4=KR6ZP4Z5PXV54BG//B+:)^#7<_,@!A
M")$/\P5Q5URWAGR^V'FM$:3TDVDCOF%N=\G?SG_I%$$'L@[ C'90F6FQ>T6!
MNMU5)]9+@$GE)$F_=$."P.UNXOF"-(&JD2$E?\+O*DN\%+F6<CAX.6)0<'O\
MG$4)9D[D#P3O\+_:;G>:$)RKH90DG<KE#;]:7Q X;Q A_2>O+ OP#;@'8'#?
M Q)4UAP>O'+ 'Z_<]@^O_&=QPS?_SRD@N#62ZT_9*/9O92/0W\M&U]A9^**E
M168#Z^]30,TKMWNU;\_9NJ293KJKY#R>)4:EI=H)-&I%_<(O?73D'! 3G^;\
M5BGND)'WP]G'Z82K7(!^-M:V_0C2_VO>"$L'5PE@A0_YN\N]C"AK%R^59O;)
MY[O3C.!:IBR24-V@!."1-\'T%=G&+ULWCGM  &MA/J^N3+W@?NTH$W-EH"AU
M%JHR2>.S10/B4Z1XM*B,H/^K+P-Q %:$=31)FV)]5$V877" [('U"=773:[I
MN [_2ZW=- #N:UYBX08[5G'-UG>>\'E/-;W.GN:#8<8^IX@=PF]YAX'$A3:K
M#\J\_)WGK<$=D<K[SYR-7 M#(OM] DD.:\KCL['P]_X[&W>HQ \GK2Y7)A,3
MI^ZI>9]Y,&Z?S*+%IO)Z#RSJ_$ "U(36D'@3J -/V13W?.9R@/0&0DGV5+BG
M!0:(FUE*T.JKG=Z\2KYZIWM JS6!-E'<(]#99)YC#VR72 /%+!-:@/+$G>6W
M&JHJ#>*6?4-,04:ZF<KCY1A<QTQ'6_@+3]GJ]+.$94_3!*JOX5_ODC;\Z68<
MVD@\&W:$8A@DF[[>IJG? YXKBN!FJMK.0UZ8#WQR>G8'V\ZFXTR'%WZV1QKE
M#ED^5XIE8QVA>Q,3)M 7GL^N[[A$-Z]?L^;MUH:%D-C69<'KQ@*N!JM:,/UP
M!^HD^[Z FR\GNBZ3P6D_"7QI#)_?'E7M9LCW3KELY>7,27+33^%=W !+O^5P
M'M*:N)1/\!Q \W6"M<DCFTD>6)+Z I"%<\) %3#@"&N_]6&XQ9[[J2-!5*_=
MCFA_Y;'>'A+VP =WB]T]7*0Z!5[_VS.C_R:@T5U\R/@V( ";.S3/6D*$0;=#
MD-:PKKXVO'%?J=P>)P?/Z_2-]P.^CEWBGN"&(Y+A\'$8E5+B;H^_V-W,2C7H
M4QLVXE@#KIT"U06Z%._IQ$QYZLLMB5+8I3?[M^X07=8?A)3ZRDWGSCYP/A">
M&08T?%OX>T$RB8DHYN;B#)P?IG25>4&/D%U;0?/EK843Q.<L(@+>S#TC7IHW
M?,%%18>)I73]SI443_]_W6$M,YL<%P% \-WA6*^72W.J87A^L/+@>B]8;\UI
M$^B_BYWJF'<SMTA/^9_G<.&?.<SP,(<YQ (ZY<W_VI]<^F=_\M_6.TBQ9TJ\
M(SX&>Q=[,5XE2?6JZ,5'Y#[FE1SQO5I7BY5@A3T8H&=3:B'4:KRF=4=5 64]
MUJI1I4:OML 1A2%*FN*M>7&!$J/=+TYI,F)W%2S3I"AMM359AY&WDYQB"C,5
MX)I2G\CO5$\RWA(/4/\X=#B:#384Z(BFIM(9OAI@Z)2WV4Q0MQ<?W1E0Y5 N
MYAQ@?(&)5CLV[#).\'6 =/ 7/U>XZMQ5VPX=_O,3OL_TA@UQI_4(ZZKB!$F<
M0?3NIT]N%SV*V0*&I>OC.O+L8_@NY<N?5PW1Z]FG?G=\C3;C9R/(_,DTX0Y>
M]V)L":U5PCI-<&53H?N%),KA_FN9-&LSBP4TXO)*K[W"5I=ET"!"4S^ [2AF
M*<CE,I0SRWJ1CX@TS'I>O*_\H;,?EO%SV2"392EP^]A)=_:.M!7?ZAY 35^T
MZ8\2FK)VQIS#:I;P#>0YE]=48RH9QP< =HQIGX$%$(_8'<+>9'*-)3U]1]$H
M7CJ1GH;A5SG$TG,J#_+,7"MS#/@EAQB[#+^.X56J$N0*IT%/74(&+!7/5RO^
M['2O.C++N$O"43VZ 19CH6HLWR4]B4^3!M:;O/1(W(V9@<2\'&U,_#9VC#46
M?.DTF>.*=_6"5KDK?0E#/(4WODIJ*RHQXUO19K^CH&)X ^M-C2"GB<R8/S."
MP\A"]WQ$8BEK]J#OR$)FFB!P=KM+[<M+Q)#"@M,7-UM'XKW%VTVG%;))FM#$
MY""U9?^#J#/ZVDT)B4D>($UI?60+R,IX4RW%PP[KNN?NDFQC5@UG2=_'3=Q&
M,X8%%U]3D2?D+N3^?]3V5F%Q==W68 $)$B DN 5W=X)#"!Z"!M=@ 8*[0]#@
M$C2A"M= 07 KW"TX%%Y8\"JT@ (Z[SG?W]_IOCC=3_]]+N;E?O9>:Z\Y]I0Q
MY@906*#<X#6/@%(=T-V?OTX>.@JC<B%&&<!M"Y^$XE2IB=M]^PSZM@ )1^HM
M4BAZ5+$] D3_1&?KY+)9;FH9ECD] ER4_Y[_#JN^_TX?_[]CC+EX*<IYQUQ%
M=C.QJ&.$"XH0K(W 2KIT(3%"GJ@9+X]&YS(QCRJ2[Z%W*I3SR])*!H^ ZNQB
M.NT0E25-6YQ@$N:3&5JHM>U9[7[.+4,:<?V_RH4LG] ^%17GH<>^<5,R OR3
MI)NXP?^=Q%>T2V+#U_[%9@VL_,<_]S;_"S_J ]+W/[N1_Z@'A*AR$+0)U=P/
M]+X,ZI%?5H+FJ$$Y'<V7-',P<ZI=XY 8:>STK\\R*5Y33(Z;"KTJ/9/\,66.
M=Z^_FZ3GF! _^BN0T'S'##C'L!J74%'N1I&V^Z3\Q@U:F+K!YK*N,GPN]\S?
M7S?)DT47AROFS#(SO.L"+//]7&K^JTVZ21F#S8I;LOC'PJRHUYANN[EY&ZCF
M4S6NL*$/.6\%J)\3D!^J?ZM++8!I[;VH -PU'RKQ_>14:\Y #P%M#\QT7Y9^
M3^+-K6MFHM^Z+%MJBK+T8#W%5NBZ*YT'7C^+:%-GZ0ILM[@_R2[,XK8<"(K(
M_97\?,P*W.$N0U@-[JSAY3[BJ@;;?1I3T GU>=X9Z16UHPE:4XF0-B273%N+
MOOEAZ],36-U\$*#GQ7C\<3. 4@=4EPKB/O(3[2ZL^F1DM.^?F.9E3\UC,"(N
M$J!?@:/WJO>>^2H8CBH%66IPX$5"INA>GFV]DBM;6F/]O*K:39"EN%:Y/_VK
M=_J*^(;7PT3!)J9\<O2CY6LNQ:56G+HDE#?PC,R]<%Q[X[6%]&G#FQF\7S?3
M5NAFT:6EJKD_))P(6S.HHB2>[7=,.!HX$IHD3">)Y@^N]C\7<+O;L-XBWU?N
MJD_(7K]NYL""P[ZS&,G'91,/\4G5[BL<8:C#N4*\7$4#\YPDO<?EW#@DW8F(
M3U-VCCA_W,VE>;9])5*)H@)T;]S.$IKF'JUYMBF==$'];V?5RQ5*KO&MP%9_
M0Q1B!W%P-(3)7(7ZE^&XD^> ,!::V+&YAR^9;IH^')CBQYC-G#/'Y#/AK@RF
M1UQ'>^:J;9%^=?1P^%757TN4F\7C[E?92E/'V_T((!$)\[65ILH-:VC[1EB3
MAJ*X *>.[FOP].EZ^,39K>V19]DV.TA/4#<P$M_KK<,U7"*4J?!GJ@PK1)9M
MEIG<OS+*\-ELOW"X#.J8F:,%0J'_;TAS_UO&S$V,E@DS=9,4RU\]T.YGFEHN
M.:>6YUI7/>O$>IARK$8.S/3F+$1Y$>"9'0 @0!?XT^E$]\Y(_^BX0+527_G>
MA=:!*H'E_?D8ZQQ%"C3'/5[ H2-B 78,2JAVX=[Z[?D'*O6LJX:P+EE>V6WV
M9;R_)I8=S 7J/?,&\72GHRD:?"E%V+/OQ-OP/9#<:?NSZ_J[6"@R';%&^\1L
M7SPXLV 5"=*;=1I?T=.3"7S#GRF]LA#K2]9GY!(MC1.H-NT5,/1Q[A'0X&S%
MW\ECNLR/6(_W,%4*<RF$VPWD\B%C3UXS-<.;[R3>^3_UXLH#WB-D:9+\$(^
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M'7LI<.1%S,60K=.9T\>QP8.^G*-:-5E:VI!NM6;D?Q(#_K/80?5/HO3^7\0
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M?4J-"KE'^Y]N$7OQ=;<K^V&K/ (,D_Z(Y37D8X5)ZKC!'P&PG?2QQI-;[[+
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M'LO6IFRTW"GTE%P_"=674B*98XV3^=3%L+J1RY4"$KSGEW9Y?WG1T)'>4<:
M;15!E,JHV8*JT D+4^)X;AM85>'["+CZ^KN^+4'UO!MJT5CW=?='%9102]%W
M[_<' D"@-1*!H.KQIF&<#J0H'2Y93Q+ 3-TGN?+L)KE\WU(L!\-GN'[7BN?D
M0N_+#'7U_NL&1WX_0=$/6#/2E$BE]_"UI#V>7$O:3.S<:\C*7L;IWYM:]2K%
M=7Y*-I?&F=&08;VU#B1XWS 4J'6?%_PZD!$.G_<"HR^K. F/>4]Q_]QGQ'31
ME-!?[$WFX*RD"MC&<</SR)/X,I0?*MT^-1*>=>,_.AA2KP>V;LJ X,YHX\;H
M*6.8YG&F !U^(_2/:5OE'P'8MADRGB2 ]J3H$_^%&4=RA6>%#HD :K3W_=1E
M/($>6^90@JV0WE6KWE;GR@U'*^D6WL7C>*)"WMS$GP'/CH@&9.KYH2&;V#.U
M-7OW/-+&U#0-%Y']"1W+BC/=U.-4SO(,F!Q!BOZZ;;*%WW@"!['^[OVE0?LZ
MIKWSF]Q'P+[;60!-PX#)W_=%?0&.@2J%G4HREC9V>GU>D"#<$1&WW@)]UH=B
M%;M11O=(8>D@OUMN#<]OW?F/+$+[1ED8ETXZ;O\N,QLHZ@+KA+)K\\ITBULG
MM9]R^M%R+GI5Y R [^0<<TP'0!X;N3+#V3%<F4,_B7Z_<#QX]R#D-'08/^T)
MF\O6*F<;5G'^"T71M2BU6935SZ4_D*<XY7\R.5CM>3%[@5W AA.!PT= O?P@
M!SCL(GU")*18T<U<0\$&OZVMG]BM[7[W+:!I8;Z8$W@92<V,)][ MGC89U5+
MWN*QD+YTEMO_"!@L?SO.VCM.<M;)[AC33*=/!M^#^?1KQ-XZW>^FP"?5SJIX
M: 8TI K?,,M'R;Q;6*%2Y-<T7I2SC>3.3US%6=%C>H9S":O:W)?YY7'_L=1C
MNW3J@4\UIG0S.%;Y#7E<UN#XH5D(PDX+&0>O[&K-C M4@I\,X N^C_/J-5HK
M.4H+E9WL"+K0#.NN5H,U]>*3;9&%-LA@(R-MTY1GDYD.75@SMM&Q>[VW];2[
M+7?:7W9(>C-D=HLDQ4M3=B-T8"YA];Q$G];P8O9S(ENR*1H \5T7KR=)6K!Z
M91+XY9V9X<FVVFN6ZB;X2_MKD':DVP8WZZ;+%T\P[B>(P[Z_]1LJ-XE3U\+9
MZ^IOEM&OI"IHS"/WU8,&UJ&^DS?(AZO@ -\#F3A:O M'SF.KG@6>M+7B&A%H
MR8-I8[6K[_:""FWO:2*8\L:,UFO4Y8DCM=/%X3QDL_G7%P2Z!IX''?T_1YTQ
M?[?(H <.0"^V8"N%@YM!Q]0Z:TZHR8ABI,N=?-:*0K$XX1+%W'G8S8(@3(KQ
M*@:^^I!2LFK8NN*PH+BVE*:YDO\EHY<:T06>,M%U7U809%2A'!IR+_[VJG36
M_\.]8I+=]9<QSNIU-[@[$N,*]!9@/!@VB(I >V@HMM_LA";.OXBS<0Q;!>N"
M]LS=K(CGU>\? <](GZ5"'P&^:Y8?3C)7@GWV:4F#9=01:=I(EU=%A+X9/1,2
M2X6BG#LQVQ0Z/R[[_372[[0V:(_::$+VCT,&(&&_D$2;N3);+,4($9+61T $
M\&%>0BQK] [,C4F&>QA[H<$[5_%0KM%&ME "Z0O>VOIC? 5,N(*D6/==WVEO
M!(M5&W?+$#\"/LG0'$HSS0BMDI(T_W8FA1Y.9+'96J;4@-KY]\V];ABK';#K
MA^A2E6+98 +4+0GH&=)%B?60\N='(>:@,Z43:56,JUSGD%]<_*?>H"U#&LZD
MK1]0KE%8)7D55V;NO$>T+:KR6"%2U\*5_1=T4(#$2Y\F7M!D,1XB7"[NEJ8O
M7M-27S-7^&$FKBD%?MI]V!G3:E;HYK'IB#57C'-NO#)>2P QCKWL1RP< V0?
M ;%8&G^_7]N/ ,I;])EW337:=%&OZ^[[,&X^Y"Z[+1_J9UH\%,HOMGCX9>\N
M)5V5,,/$B#T;4LX&DX)%49^1;IOX.GVMDV%<:>]F/@I.3*WE6Q168SJN!1/Y
MKD(84*_A>U^+XHY.*Q8'?;;W)##P8%4H>;A(-D*TN[4T2CB%T][_!PM.'V_M
M%;!9JL(%PU?F/3)D4YVUU]\\2^A>8-7)";6W<D=L87T-?H=(_/+?M0_2B.O_
M@S2/3M, "^9#AF^I8VP]CRS,XF: K^[3F\J=4Y\,RD0&&%-[F%$@''L?I!8@
M=)\H@5_SC$P6[=\;U"_(4;X#]@JAG82'J6E"59@:IX2&=]YIDLEZ--0.C:O_
MFUGBMDXD&4#V-W3$'RWS^[A[F:7@Y-2&:4@ ".*L$=Z3(8;@[H-(>#SOXI9'
M*\6.$C]F+"'"#V,!.S*V!#'!G(C+ICCC_K6W/O-&V5%LW!-Z;(CDEBNP.QC]
M_@<$<!""'2B_)7$LK]O<D:0S2^EH<68MY+N1<FB&9$/[]*\<@KU:H"17/1C+
M1!-KHI/\)\ICPP VRR7-L)H-/M5>6WB?"I4""7I."(9RKDF*D1SYDP)SOO4$
M7$8&W@"Z[ :%=W#@RWT/[,A+T5A)!29^I)UJTO#TSQ<GYU04Y\9382P=!7QO
MSMR#_J#-_J\?-BAX= ZEC6J:L$,)/*#%9;NV!HL%)Z[/IPZ"V# &(43(PP'Q
MO;Y.VD]K[%'SN$[T3CDCG)JN6KV$[P-^/#O'1H5L37[-#'EQV<':=YIGX/O>
M.W']?2*S3?.S[XEGBHZ_VYF+D-<:R 98E?MY;V/MOE&?'KR0^S</T&Q#A>*$
MLKE2)F)-!H[72>A91:3:,"_T-_(SJ9^_=GHM__GG=V/7 S=HJ%3;1FD"CS0]
MBAM^&G.R=78JC/LAU>:5J.=K5&5+->-&Z1<>:2H4%WP]JGJ7C,PHJ*!?J,+7
M[L#M9L'E7],*]M64_36Q8A]F::00I;V=Z"N.-,11LX.8,V["7<PI:FAG"Y95
M2X= -OC3\'VCPT\^=<M*0@M?R;T!>5RR4H?9]\7M@K#)5X&2LX%BFPD"N,.\
MZ7(9?E^PARP<S08U$8U)&U(<KU%BCFZ5\H1R4M]- IL_ )*7!JUD:8SOI%!O
M$:0M" T3^*TO4(,,^7&$N^3VC)]Z^+5D&<"=<W_D9JN+%D_RO;3D*G+W7+D)
M/A#[.:%YIFH';T;9O^TI#!(IWXPQ*5T/./A7SY^AA8=[FS]^B/B8I@02A.1'
M: P$,R&O$;0]#QRD5U=0X8Z?C8U7O9'Z)MM[+207U&/#1+\2QM#H_$&J-UN;
MX%"47\G#%% 4 0070*&?@ND:&\/P?.B+DD;46P8"?F.]JD:%A/?1$C<DB)S#
M\-<C_J8C.J2D\][>8?,;U0*3]-08/_3GO0E_-KK^4M_+EWV;=X]([$P(7*Y"
ML2*8(Z,34#(VF_@R>HT+PF1M=7,V*6B1ULMMOI([WJG\AV;'\-->0N1?=+!-
M$IY94W-\H9?SONB:5D[V%??_\K_ RSO30%U$4P_HN?UM=&1APQU77<R)S0^;
M;X32IWOF;Q;"'N8["=HM$?(]I%#:R/K#@+K=K]89?A$6%N%AH&* .7)\*]=A
M@A?S4ZM9^7VX2/L!\YPK0:K(=AA0P"&S6X/:42O0$!'=NVIL\O<3D(//, ^]
M6M=QA5B>^]A0N5 [55?V06@R^];QC[@#Y3:?S+O0?<#22/1Z^JR,*OU.G_U.
M)A W<W/O;V@.&SYBG/INK&P1]TZE_93E]?D7XQ8QL3RE#H[(?34%8KQ_?%G>
M$$)?VS'K&5<9)'Y])WZER_EJ?G5 \."I_3Q6DKEQ4C>T!;ZB-5Y]GQN9H^I:
M(M\UG$> /],@0Q4HBNPL0-JC=-RV')W>N708#\VIY^R=5D\-_IZCA3Z_&PS!
M%OH.IK1_D&CI_&;*Y0VA25V5S"9)6MEPGI"8;^HRQ_#=ZO))\("9T@M+F6L[
M+4#[,CDFPL6@ $DT0RU?6EAB(4+OKF^-8>KS91RNW\B^-\/^6W[%YT\BB*YC
M\@@*4&)!TJ5Y^TV9_#?Z9*13HPS/8_OE&,^%2S_47V>H*1OY1A"14,&PZ F*
M#?^?6[__8#?ZTW[N_UX.A6ZA/?5_[8JP/&7IPGF]FZL H",O_B]5EG< #V5=
MHA\Z97F8Z4^F+XK_S8=Y$1\K$FO$AB82/^U$,2[^[TO8L3$S8@'J>=YY_W4N
MY'_,AM1]F3B+]O>B_S$9>IFS"UU=W%AS-GW2ZU7&I[39Y?],N5G6Z:MS -$&
MTR )^FCHF^%-O<>*\XZ5R\CB,_GWI=OJ#P_?T"Y$PSOM04]]3V$A,9*X)6;*
MM_-1?Z&_.89 <Q7?W[2DI71=D+GALJ.W;-A@&T\6Q7D6L.E<O.D2)4,>+#-I
M5V;JL/9JYNB-@H<C7ZH?6A=Y\+UC)+RI[Q% @C3? O?<'9/I-]=,22JY,XI\
M/%(]?4E'RX?1O1M&6\]>9C26*N3#+S!X/=),'PSYMB3LR%:E,+K:D[%75")+
M=@X>X8T'$4LS/$RLOY"F1Q*N;6E"T@801>)H[@8#9RI1BP$O2JH"O>&G?9,8
M]L'8,Q\1U*V03*M2!8_*/^B75NT[[D<^+X&?*&ZK'$.<0@ 94)C8EA2-")Z,
M:JTYQT,7[<MV*031ILTVA#I:]XN$6B'Q:,5P1_@U-(CS($46]W](D/?_U=!?
MYFP\<*!(X. !)_'YT;[;S_I3QFJ[?6-YOT ?'3L*0B7C_L83OQ9Z._&6'5\8
M_-%4(*W"6CI9^/B "$+^#"*Z$D):;=[="YPLO)%S*U79,Q[J(DPX[@^H(L:^
M.861'4W*](&A!#W28G,GW.^3-AL$EJ$5MDK?"U*#GGJ%$';:AF"@].<[&QJ.
MA4:#-15MXH^9E3X&<<X3&&&I8GK08" ]\@*%?^LKPZ]R27.MJ;R'-'FV#MQF
M%_Y_&$F$]KCT?P!02P,$%     @ ]8R86)C%ETIL7P  T&@  !@   !C=F%C
M+3(P,C,Q,C,Q>#(P9C P.2YJ<&>\NW=8D]^V+1R:=)#>000$*2*]2!7I8D"!
MT"-%6J1)"Q":"$BD"$@1D(YT(KT(A(ZB]*9!2NC%0$*-$.#RV_ON<^[99]_[
MW>\^SSDK[_SK;7/D77.N,=::Z_+'Y1+@NH&.O@Z B!@ (+KZ 2[G %H $F+B
MOXZK1GIUD%&0D9&2DE&1DU^CH*&BH:&FHJ:FI6.\3DO'0$=-?9WU.@,3,PL+
M"PT]&SLK,SLC,POS7P\A(KFZAY2,DHR,DIF6FI;Y_W>[[ (P4!!U$W.0$-T$
M$#,0D3 07?8!^*[\)"/Z6P/\ST9$?.7C-7(*2BKJJPL:KP.(B4A(B$E)_O+Z
MZFSHU7D *0,9([^4YC4F$WORFS[,TI')!10"]VN[61Z/8P5E'%Z\I*1B96/G
MX!2Z)2QR6U163EY!44E9ZX&VCJZ>OL$34S-SD(6EE:/3,V<75S=W7S__@$!H
M4'#4J^B8V-=Q\)34=VGI&9GOLPJ+BDL^EI:55]35-S0V-;>TMO7T]O4/#'[Y
M.C0Q.34],_OC)PJ]O+*ZMKZQN;6-VS\X/#H^P?\Y_0L7$8"$Z!_M7^)BN,)%
M3$I*0DK^%RXBXL"_+F @)>.7NL:H:4)N[\-T4SJ2@OE^<D%M-Z6 S&,LB\.+
M<2I605FT$.XO:']#]G\'[.7_$[)_ _;ON%  &A*BJX]'P@!0!YR;_)*)/S#0
MXW&G?I\RP^&2^BK!4.J899_DXA<KP\7$=>@CZWXP'860M'K&E^1@7PT^QVOD
M!<,<O(W[S?V+J&4N-X*"V]+M1P6!0<')OTI3K!F87D*VN?2IYWHP)Q^8\VI$
MB(>9'SM'L,+=DC6[G]*WEH@S.[TE[P!(,'>+\B:6;KH%UFC\D@YQCN#1YG^J
MG&/2PI"#TZ#6OJ7),2P!8#;1_F\S+1]BFP<XY5U=+HO@*# #/K:;CU;V$H#*
MHKZ&Q<T?W][U%%3WPW#(G5 NG4.6P7,N7<%WWE?T+D-AANJQC7',<U+-Y-(Z
MA+OYNB38WF5,>M+* ,YF@:VY&>LQO.,V0_<M19 ^ G*HPW90&#?EH:/1TRG2
MBK=$O]F+O030-;CZD[B5Z*H$/DU;MWQ!M[)K%%KK_H:GBHINJ:R"'L%,DYOY
M4_7V$7?.;?5J  R-B^U2DZEOGH69JSQ*3[9\<(#J<1)%BGQY?"_53G<Y/%%-
M$2?Y>[AXYT0&6+S]Q(:B-(TA]EN.2Z);F#H!BL2%]W6CN3Y(;ZG(V$M_%4G4
M4)L:"MLZ1KQ(75&(.=R+&7>7AMIF/XQ+XQR>I@#V,A-]OQCU<3LY'G<?P__:
M"932>);UY7O@+G6.A]Q:L]I=_/ME20I\T;)18M.F;+7%G!6**<)C^M.C>UD_
M)AH<<2XKNVG+HQ1;P )7^0 $V8H V8'ENY4U;I#,-60E5 P]"[]@&R[Z*O\Y
MI.+S7)WB#X? I3'RR0N&\\+VVY*]&!D;W)U&CZ*&%7L%B83ORC,Q&6<&!.D9
M?S$/^<$!*X]Y3*\'G'UQW1%C@^C=^]G<FP&F/JSF&LAZP)GSJ3;M00YF'M4>
MM:+;A22!J>)[L;L;O2@:3K_UL%J7F8^/:TM$?(<&YR@/;O+904NG GI9<?3'
MNOOE[O&GT<PF&F3_34:A]P4QNHB:^>D?'N_FM7P6AR'<YBFN2:RN)2W:79W=
MI%2T'[3ZP[4RAX*>K:2_6:+GL$1)OO(J##S3:M$]()]?CU )-,>%-L-5:+$'
MVMB/'R4;*PU7W1[0MU2WV)]4'C[N-_@QY[DM8!PNB@.^N@34A_?RO>(LLG-]
M.8YX!I3T2ZWDZ8QP[FCE\";.B>P'&#UT$M(C/R@=U^!^5("%]'!^+) X&DGP
M$IK*:2@)$IZI'L4B>S,X9;: I0,S1C,J_C4U<,!ZNR3VY '6CYXUS3E]:)6U
M:\=L+XP-ZGX)L+WXT3)Y,^42H'2@M][6J[FE$1\: FK"+J3*8;JH/3RC$^\1
M@3D)/G@T>I&=<!^;7N"PG^GWM5YJ;@]L"G.XU\F[8Q]+^*RDGA;F:*/<T=<R
M]%9_&);H^]Z\>T@TK7H]K+1;13UJY)FY1>59N=7(7%X)F$[M'AZR+-=5/_$L
M>3WAVM*WB0X>/NB(%)CVHN\A?;SDM6M4_H@6CP$2WUS(S%"M[X#]>;71+JR9
M<<UO'S9@86 MI@K[6E8(/Z9/IQ(IC/CO, Z"K=0Y9$T=56^,MWU6V2V/+ U_
M#LV2RI1X6_OT7O,0M#_4>C$'- !NB.VY!%S?O 0P\0UF>;1;5=>A#)_/\,=F
M9VQVA1B38>@6T<!H<9C",E>U*@;\Q-\P\,#IA@$0L#H[<]PKCTT3\!S3X,U$
M1,CR44.+5F)BT5YTWS[R4(WJ=EA_O>.9YWCOVEF1W"F1&SM\8D%E]P>\]:@K
MGUKV'XDRH2?'OZ0P0@IFDC^X[,&Z \SFOR,@$LZ)3UT^Z0I1)\;/]BK;*&@6
M3;O\\%:FF5UH/"#'*(WVA\>&'V'5/P19_*;C8VZMU#E62[TU7!ODH?-ILG$&
M>1,1V\F;]'-C0!X5)W0(>44M.Z1H+G>8%]L8(@$V2MP=,4OG4/I5*@?LY^5M
MQ.E$^Y3:ED&?Q9,D3\+W>4A,4Y<2V[+D_@3Y&7X<;L\<F0CA'$F3RT QF$?Q
MWFRH?[=C%EB%9$8^66SO'UQ@_APYJ.I>757N0VP0P>S_B[[Q$069#NJ8R<B6
M3W[ZO1"SR4--;69CHO]B(Y,P6*O"N'RXZ882O", ;.^C>XE4W+L$N"+Y=,],
M[Q1? N@)1D$?K;MEQ4JJ2*LZ$^_Y@(N_*PTB2F"!N)T^.WG<[&"U&'HQ1NZK
M"L]ZUPFY:22;S]R<XJ@LT0@T=6"1 >EJ%-Y[ZIRP9 3I:FH"&?K[^P=2) T;
MZSQ)LCJ+F::1?\N_-L[,?2ZVAB2_& YG\U,-'CDQP8^&EUO=/\N:T&;WR?T@
MMFUA6FQRS>-[/O%"*8\K@P-<)-_^'R# =\,F\_;-+GC"9P>/$*4[ZWPHWPN#
MT=[:.0S?S*=J+$^+JBA")U2,<8V\+6G-(NPN-BT#[M?ZM#72R;O4,7DHM\_\
M$*:3MYNTIL.1=YY52F8NGSQ,E5(B))++A=WH1PV^@NE=\. $])X*5C=^SPO\
MX=S10\EJ%*UW(WZ6 Z?5%8Y]#PUSY>\#51YHW5V*P=C$]O*Q;7/*#>$=^^ID
ME=/*YKA'H.]#&&Q,UT295LMV<P>K[:X/:,T]MMN?#RL[;A.M\OU3$0E6XIC?
M>9 ]![4,2%$\1NA#:I>#T\O*EFAJ10)^_5@]G7I'(U((!_Q7VLN@"91"NLX<
M)^WW/BP9K!?7NW0)B"'XKWQ0Z'^S4H3>P5]_G44^L!0,/W4QJ8=?S$""D--Z
M\BVCQI 1@N;9/:A8WTN&T&=B50(4E3(TQN3)>*TN:A?$SZ$PB?EM%^C<<Z<O
MGL&@*>^:'V^E!,M(O/?LP(5AP[RDV(L2LJ,/K[[Y,/R*=W&$'XF,W12]P0^*
MSP+D9H)=OS*?.OO.46MPN[SNO(MW[.6LX@S%G%9_'_TD>M!P=FJ^6[#<H?!P
M(N]Q[K9<O6;+U\]P7#B*O*>3<IP@56UKZ%D'33R]E3@A4OR]6LR[F.[7[.C%
M3>PEX$T[#W82'1A-, F2'J[8CN,9D^;I-_03WM+@<\<K+#M'K[0(I>JW,?[Q
M:$QK4:HX0;+!9$JA<;*&"3J*B.S"VB6^^Y!UR=><MLCN<)1 ]TPN;XIUB-@<
MAU/NE)Y>  !=:],9AZ:69 D;S97%V14)UD'B*O7%0<Y:G7<1/7#2T"WNG@=T
M2D^^".3 _V0?YY 2+/!0C4M 1B1AY_UXN"N0 P]>6H\+=T0/&_9E/+XG(%<5
M\L5D#)0"35U!OND4)'CB SVJH>I/Q@K.-*X9_FBB:XSVBL#TB$W_D3ET4#\R
MN02TJ:?I?:#591,I:C%YG-\E5Q6@^).7O7;4X" )CJ3AZC?1*G?;Y_*P&LUT
MXCE/"+:C<TMY&;2M*B8ZE>;:DHW> =++*7H&9?0@7@N87@+B;A6\/@HQ-IEN
M$>;9F;C&E=JM"OG:*4J0R1E9$,#^.9.O)J+KIU/I4H8OXGUPZD!<6D- Q>^V
M^-MQ*V^?[G)SKA4]^=&H$RXPT3>6  UUCYD'N2R.'0JR:]R>ZH=]]';K6@45
M0GO&M9D!)O]U1M1+<'QCDX%>K[\$4&Q);7_CQ>MM^WQ%),#XSWS<L[P&:+EZ
M48=L#CW4PH9?#'@P=S=U&T,OSO>EQ5:0\/JMT]'!'3Y***@7Y=$,ET0G%\_4
M%-"OZJCAJ+==2:;:U<^LH: ^SF+SNUNGKZ3U-&AP2U3'^-4#AD<^+=<(8BN8
MP">SZLZC3*XD_6X?H1FZT[>LH342F = IM3(K#-BR@>?'N"[_&G(/VH#@$9/
M]11WX/[,1#B^-\AG5]TU \EU1,]IB8^A%,^^4/7(3%V+QWI#AX-U$SI)H7/+
MH-X=:UL(" YD<-NO[B_IBXKVF2P)O:T-@ UB%X\#<5>/2*Q6L<91/XY]C)Q<
MN6N5OT&A0_M"&?F[!$=V8Q8F50(9UT1[@$W/8&_.^^=3&H_-F(F&H6S=Z1<4
MV.'<9.*B8BKI']OSPU!AC'S<)8#:$(UZ1=0Y16?JV!&J]N@J6YP]5+X$]/S
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M;T\9[SE'J [!7\[L<\VY[MY(?A:C39,8>R-JX>,P0(*Y5S1"?Y/NMF%D4C#
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M$L"N)ASN? GPA Y01SY3;'GET:W+0XDHO +-*XV]>#VS(#G-!FJW(4W3 9#
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M=@>]UOQ*-M,AC6&7K=+A<V2$XN9MXNBM1PCI$GVS[)R%JL.MQPGL(IJNT$L
M1@);TBF*)QUTC3J# !U]2FLO.'S@!_21B^0P,!H<<R$^+7<_=B KH?GG^$&.
M!SN[:N7V!+S/R:]X_TG>.YJCJ@3@\,].)F'X<X_#\WN]6=_#;L'_"'UN[7C?
MGM(=Z= Y?02,4>/>#EALX.Z\T=(<O]6K'\-W=S\P@@CA;\WE%[I#:H]L9W8N
MOEO CA(A647 \ZC:W<I@CW&Y]?D4*R$)@OUNMY=B!UD.,$G=";K]5KQY+EZ%
M[E']\AD,'>>8W]6KNS0*+"RG7FO\#G,ZP"?PA.?58RF?!HJ/>A)=2=;WR D2
MLX>C2;.Y-[+8T_NVJ#UK[G7^ G%>$6>8D=L2/4?9IR<RX/,:D5A"HYF2^H?0
MQ)N:XQI7SLRGD2J8[&@D\9]_4 E7CX?=:@I4-AMY+Q?!H/P]D_0,I'[V!)\Z
M8(XRM6*+>4Z#!8NP,0U^0,M\X8L.697WMG89BKXY*OQTP&W"NE]A,0'<+'"E
M_>E_VG'1TV\%<DK$QNPV>,1^SPJI2D\;?9(*UC0U1FEY^G*[Q[)_89'[3^N$
M<G$W5JIAPV>/8(*UG23]/M")E6Y40L9(,^N$?>T6?G:2=#_D#-3/UZ2]%_6[
M'>@TBT19+30AE5VQ0^;D).6P8..;L;__G('P2 M<+.'F#D0AOLHTVL-65X2<
MP_T,SOK=5:_[!J.JV'K2-9@M5K?7BPIOM\]'VUWPL<Y\/FOF+H7O "6B)%\4
M^V#KQ%:+YJA[/4+\L:-LPX=-CGT7C!LV[W[&0"X5SJTYWCVNXN:?UGMMB>Y>
M<[(=PWN]U+>YSQ-7S%\]DMG_]&4)OM<I?3$:C.RO=A_9NV#<\ILSU&74>OXV
MABARQ-<J["Z> A:$IJ85LYJQ6S'^E/RL"6F!_;)2T$^LHKXB5X*(1KHA2'@8
MR1HL_;8>5#Z73^]2W+*9C?:C%3,[3X>%^ 9ZD&8857V[G1S[O>[:2I[5*5_/
M8OU+2_S08M_%S9DUW+5*"$/,_*I1H9P J4-K]MX//-"ERHUU0:2U ;M0&7*\
MDZ#*5+DA>.TPWR47A<\;5,=^#7SLVB1LVB(_J3.A%^9G$X#HIV?D&L2Q%@GM
MURU06@Q5!9'+G4M#O;JS F-4%.CB(%3GT0+[0W?1,7=]P1^0#;,$IH,N!3#G
M(<?SC3S@FSXVP7DMOGGN _B$0GJ,5SHO;AF,-?1BU@U?H7VB\7F:=\ RP[]6
M8K_VD.44\4SX=;MBKHVHG)C_%<-YM9J%TT,N?>"CDTVB1&VA2#.">4N]8I),
M&]]6?>[0K]&UQ0$'P#_ONU:OQ4-7NJ7D-UIAYQ]E]XZJ66\!#=YDS8\$V1>%
MN8?MA"95R.[%-:4 5Q<'9EX<]B;*V-KF5GK 6 K>"S[9A QT<A <L>2#'1).
M=6D>NSFPXQ-%?=.3I5F'!>)09HZ&RI,W;>5_(BL;J=[H.NO*!8=4(OKV]E7=
M(,//<"ZO86I#DE43RU/^:6HG:[;7XE;.U4%_3.)?A/O@Y1@+9&L:96-N,8YO
M^JN<F8PV:M-./(R,H@O=UO:>%\M^4BY[S)K^]O$D^W]4D_SY%+P,76???G%B
MD:_5Z8_4J:&U[;:%4E!'_AKQ[BZ!5@3T_OV#'3-)C^@EZ#.C\191S5U:7P<1
MG3K0_/. )5QJC]'0/4/=]7A)$GQG;S^G%TK<F5: IMUIO[2EYKW@"PK%8=AY
MI:M"WC6Y]5GQG,Y4E9:L:YL1N84=];T+_(TX^3R6H^RJMWKYE219(]'.<R5/
MEG4ROXN[65630V5L,OZ$6Z5D6N" -9,C_ZG$TG/!]U%A!&/ZOZ2=_]*(2@&S
M_>!&X1X$RR8?0VP?CX!^=E\ZV#D$]*G)=N)V6 (>-+.@."'' ^D%S00;[5BX
M,WZ\V<+7%0I9+^\D(@0$92+Z.1[J%MX=!@3Q1<'D5KP29W+9L.T7C%,P2<="
MFS=SV1W:WBF?GD<TGK)Y,+Q$48R::C_6_81XKR*$O;?"FXJPG'='7A_&Q'MR
M&H:VS(,?]56]'>"HZ]80#\D"7 '))UV'6XD BO<,M0$L!^$8IM$!^K]KA\W*
M-Z\:(M?>HDV=9K_G\31FAX*6PR.]\E/O6HUF'*^WN6H/!7-/KQ?1 C\6TJXE
MRNS#X7N/HHRC"]J:$Y=929F3M8C5.8ORH?!1FR161$LA_">/&.6M#^\;K-QD
M81B<];'*%>F 2]1($FZIHSEPK(':/IYK3($M+*MJ[/@/.-]CV^F15!S7P\^X
MC%B^<_/*CP7^K\(;%SHWY&C[&Q3N9GZ,$XX_LF2^>^[^_#-;]:@*/@A7WW4)
M8/G-GVHP([X0R"<7OR_Z,':L?+W-2+?;RG])_-.?%[PINMV('#7YL)YC7DD<
M$[2^6\$'"NZK6'B:>_U;^ZFWCV4P",.S,AKAK5D*>X2=[Y_)H-P?:69Z!KT0
M '$,W9-1FGQUHHNTN[K'ZN'<X><.;,%HAM17.1=#W/E\495R4YI<[9.8]SKF
M-019?"4:^2:8Q@H9*\>^5VU!\_MYVK'<-/ 9\^:WFS%/ML4*9AZ;9RF9\TP&
M1HE:X/,>(DF&/L?G[:9&64&D%4GOWCBI$0;C(6YE8<?#G=]\49JH,@L+:%(O
MA6.@<I7["XXD3<.?/>&D47-F4>>K82OC)_165FB/BYO=+#V#90]FA!7/-Q[.
M6CZKL@8/",:8)=/[R[TK&^%C5(B& IUM1T3(92.G$BE*R%5WN+*IM9F?_"U*
M>RS\F ?H;)9@C7+,1'$56R80\U04V%I\K$4 0A-E=]M#8K8KCUDVD-<1'T!8
MORMM3I(;]K(S\GTFMPA+W#*2SAI:I)LRL"N4HG1M@F++!@J_ \GBRHVA9BQ7
M,/A8&W()Z+KCUC;<5._B%?A,=-A+A(:=&V=E'0V[!*#WKO^"<<T@/_G+.4_<
M2F6=Y<GX,?M9,U@X1LDX)F'JKMI 1;27:ZO=9KPY"WI1^F_U&F5][X5_/'F[
M:QP**5[FN<+P?QN5_VPD?/UA0@W8Q%C_BD4GJ[F:#92TC]T5J6@&]K(72\EA
MNC+]XW4/PLSV3G.S/2I_?G4+H@)ZW>@=6+D!QX.6V7JKZ=%YF"?%^"A;[.XH
M:4=#K;Z*-UL"]_E\%Q7@!$$?AN*C:S>LMG9+;PXDWD:_'!",C\\ZL2BQ=- G
MG_>F&(9QX=J\R/&3_6&T26B=S#M'UI"^D'*,Q'M6Q4":U;=*B,]5R>D3B^$+
M^^^NAW!3D5I=N?R/I$K$/2Z(RUPUWNPEY3W:E\2$,FXN*& % _2/_7+19H1.
M$MK>ZM!0L$ 82IA7!1]X"0!K_34!ZIV3O\<H3#%LI3N%DL]P*T7U>"SI90ZT
MHJ1^F+]E+ZL:/!7\V^I#!9?'_+L4JQM_O=%<-TY%I@3::Y!M-"-N/R5>PN[J
MHM$UTW%+A&1-\OK% 'E/&V;Q=2<'OO"L)]#FZWF&UW#5*S_;#V0O%IC.ZV'V
M2WRLNF@D_(+3FD+ACUBE5<HWX:=Z5^+I*=6&BBWVK'=!8;*D;L:O,N2'$[O0
MF"?OTAAGNHK<<K58OS(L,,OL4,'X"PEM#26?B;4$+RX*S$70/T^!@9<,HV?"
MZ* QUAS=MXR4]\U=7^]$6H73A#^O1-()JG'A6XOL7'EO1K:W2LZPRM?193<[
M)#2QGN4!MR_8)AO?B?D3ZP^2)FK["J/;MO:#LCP.C_M>, 6 ]FOR>B]$)F @
M1Y[UY+(Y=_E=$O+F-##)(H\8F&2B*<$]>5R51NA^SCQJZ@""O'X5EL/9V8J[
MF(RJBJ#!&C%P[X5ZW0R(ZL)Z@\P:OK/:G&C&/V[!VV=^IQRM*O^'XDQT8 -?
MQ"Z':"B5$&(B-ZB2>Y60>4O?\5<5EUJLW TEA"(26]-<DK/%EM08M/]CE3/#
M$#=0\#'ZC<7DFN[6>OZ7XDTWZ+TT&L.."IW!@G&++"_X(<90S7;*8''>L>&B
M\9.@.0<IPS:M[] =95E_'9^L=HO3VY5'P[>W3,+Z7P,51V5[-KQNI5W;!9H
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M>Y]4*PQ\4M^T.0V)&@SS0D*PNQ=#YMF&4R6OHUKN X> )49NB!W.^ROFM6Z
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M55 'C/M^/ML#N$,%LO"W%UC6GQ#K%#2)G;%5ZE&=)9=A.9[(=Q1T2]U'J/O
M+>FDTEJLU@C4U1O<!4E%:4?-@7PNV<JE1&Z2_$[!#EPGUX:4,:VT+68ZMBU7
MHS_ .RIJXM=KZ5YC;U$36(SU['[XA8#Z2P>$9-#B;SOWB'1[ZKH1*[2?+>*/
M1ZX=G=W-ZB'*.3_.%5[M,!>RQQ>FYMH>AOMME65/9Y\8?#5'[HM8JGN%MG\#
M.N!_9%>T_C*I/5,"QP)6$IA>R/\@J6=01/] V-TI/[24:O/9E/6<ME=>M@R'
M^83*T+>2B"\>E6[&4RNAKX>E7,5<+A]@;MC_?)(0:P&I^D:A*_?^%NTRR#"4
MTI_7C6_< ^PO*M>O^GH3SXSC\^J&9!NK[_7XY](40\S2SD%NV<NTFX N#ZO.
M;G>WZB1'FG4JML *W6R"K-MH#\L6D4'+MO4?2%GX=VX2;SV5HUA6^!\,=BTX
MW2[Y[-FI\<7KUAX@F%NU/V*6+-\\T;TQU3!4<XS@.O%6+#52!0X+<H.]?=U?
M4;'LXJ'P!%!INLP$4UZ]..O[G#*FB;?@#XNE1&[K4;Q3OAB2(KWNW#6/:;K^
MV[W%U;LQ99J=SHNAXI[]WN\7V H5I+[QV*X=;"[7O.\'5V3\1N\B95TGQ6 H
MG:V7NPQB5CBS-HR'SAY5NJGY Y^WZ#7K,^%E7$?=)%_*H2/#;FF!G6ZF7"J6
MSK9\[A@O-AVN36J9X66"W)G2L>9UU/0(7\G5Z:UC"5BI]>[09<-J:0GJIPTP
M=34"PFXW/RV'^P"+RQ"-,!"I2353!&*,=CC!\D=U+[9$8&S98?OV]]R?FY#8
M%*BWP%]LJP]<FCD!7=-&:.[;UC=[@%P>P';+/]-!_M,-X7\[A#C'?\+,8\B,
M$_DN]P8]LL-807]<24%:Q-U%[.EH%UY]-V;V-95]W\?WP,((838]"][B/Z8=
M9V\^P)9['%<+S!%(.+%;@0BCZ#H\OD0O(]CPQPL>M>UYP:MU_V#XRP?84@:0
M*JQ#[7G._R.QS!8N_0AXVR*R*[LM %Q60D?!1I:G1\UQ,=M<[,JF$1' 1$0N
M-91V8>A!XG7F8>A#C:?3XB/*ML:^9W8T-W>R9-F69MO6]+5+=(AX" 5(MB$V
MQCPQR$<X]JV0&A*K)4PGQ*^TCC2H=&"JBUHP;/,7ZBHVXQ2^Q7Q#KJ@_4YGK
M2QIB6:DEOOB>L(D5HZOLV"$TZ$O!8$P,V#]SY41Z#"P-/="0#/==B(@'W!,I
M+% -^'5]Y,P-UGC95ZR"R?&LQ/1XP.4/):PLIGGAQ[\GS&4:1, K/8UDN4I$
M6\H27+,-CN+,I"M>3T5F]I59/C535GI7&21M(7;UDW22B8D>VP<5189FT<P)
M&W)^!G3F>*6!#?T4(<L)=FZ"-W#C(8MCN'M3N<SE-#V/*_-%<16&TX?=J8:-
MKI-V-EI+_*%F#RMMS&?D^!6*HA@^.6V];J5ZP>C9K(,PDN. U;.<[(I4^\=*
MN<"(&^1TKX3B"@M$5[?,MJ28'Q5$5(I]5C$3D[XB%1QD:@@THBI-0(G,$F+B
MA8%Q7 FN6O?EYX+;HU_Y#U-,H7);O;1RND<Y?5%>,&\\;@+B$-X>_/Z5).[<
M6]IA[X7<#:V+B5V%Z")Q!^Y"1C<.3T;'&<3YY'!WR;.2>TR0"0R^ #S=*]]8
MT>;+S11YHC%TG-115_H^UOCLR?L%.Z-?H=P*<Y2:"%R#XK9"AEF.]?6QT<3D
MW;N%CD8E:XIHY^6@M6#X<(F6&!JJTI!=_69!-Z>P@$M*U'9GD$(MA_+L_YVH
MA_5*5$U:6K^63)F-XX2C,5O7L;Q8[@+4P;"EY6HG.X#;"-YYMP@O[D$NFPCJ
MLJ .T'_#K6D5)08:9S>Q?,K11\="G>$"=&>[ZJ%;P]B"E*E6N7>'#V#S;EX2
MO_I<QC.B&_&88F>;T8D$6?9#E&&E+RQ$O>2+;4\NS;#4C8ZZ)Q2'9[4!>$/Z
MV''F>FQ_'/X5?-S(X?B5WO57!\@K<TN>UK\'2%XBS.R&H7>YS;A&COVWV5O_
ML8R/OMYI]:5]]EU<%:8#]:D=J>"8*F>A=>43]NK?6#5%F4CH'1]63"Q4;&/J
MF,CWF@&GM,1RT[9B=EHWZLK8\4]+CAS4/0!-@1ZX<]F$?Z2F* QC\3"EQHQB
MI^VWI .,WP.\F7G,L", $R9<>J/*78:5GK^^0X0B0D<7OV/)SZF:AC7!X,;(
M[:8;=-=JJ=%@"A=-G!ZVH[4XX#D!+K-?3/&=NZ:""PVQ[KO\^4 _*7WJ@IJE
M2X^[X-K!C#T Q[$DKQBT!=V#R'_^Z/TUV78?=Q3%W"<V))I:-72B?D!: MGW
M4N S_M$'NA^AK._*Q*F7N74K"=;:@3M:"+6&M ),B^B=I*D;K3H]:L:[M1#^
MQ4%N)VKTVR^HZ B1RD[3W3RDA.?;\@"\W)ODR;S5#J^4#[N/D4?L>Z4_$4)#
M/<37^A($[7=[EX]01D*CLPX6>LXR7O$FUN[*LDTOUSOG>?*5^91,7K7+.<PS
M;/<,L_(Y=KX%[UR[&ZLZAD60U3HTOK]T7LE]^=(R$/,6&/^P&;<'B->HJL-.
M63GYZ@#-YU3=LM.H,_%(5D;HP#5#PNJCE)F.QG:566;5X[(QYC 3&"^[/N^]
MD9+E4&D>B'S 0J.JYX,I 8747MIKRH.K-7#>'+R]G]S7,K>ULO/(2:@00KLP
M#-L.Y*]4,-K]7I/P$64$V,G)5)FI0G@5HIJO(F3X2XVQ'AHCF6TNJ3N*UW&[
MO@[HV#W ;"Z<&UP<EVK9^ Y43SLLQ;1D6>^Y[XZ5HG2272C8=M^M=(C"NROB
M@O<0[[9'70H9-A3':C6;H'PC#'#J XR:<[ NOKN*>CHU;-]5WRY\N0?8^.SO
M\\USS;[]1,OGA+!G9NQ/+3BY:O/"V;*'_,CZ!A4* !G5")VB?7I:@W4M/D1^
M/D^+2S]Z]P=./I)>6 J[Y<4=:Q*FD_U972C+\++@W5#1P2*+\J=GRFK6Y.C
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M+%*D'4H#EQC^V /8:,7ZU9 <ZOC^GHA;&;2)@1FK 2TQ'P72V W(&Y%L F=
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MBB>%=:,]>>Q@XMG$\Y8$7H&4>Q?$J-QY(:WFR5:IU;6ZNB3?1UGU'"]DC+]
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M9I'OZ@*&^4QCE6!T'-BG54^OP:I%<OWA5?E?7)1>F!:_8P5E[K:*KVCMB2+
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MRFK;=,&W .QTO5(5\1E*WB(K_E)A%MRF_D^_1*AO4;4U<.TM?$__/5$?024
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M(O7:'B'<#R(S8A,EBFLUSKVP^ISUE<%!(FN0[(4-5>E"+V$EOQJD&O3PZ$T
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M/UR"[\?NP*L1L_&$/R_\W8F-"$RW*AV6'7X!(R&;H+,'7_$+1* IGV:ELR<
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MT]0G 5/I.W4XCE*K'7^:K^M<EP2M0$>10_"27R?IK->S__3NMB9+!.]JD&W
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MUJ]IW 5F9-@0%/0A>I><CCA19]H<EH+I]QPR[7%:4[.;]6K.DIJ[M"ZXZC\
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M40+780\ '(T.NC/V.:O901)P9RQ"Z Y7D.[RJ,J+@&;A8.:E<EC4 Z!\ZK8
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M+JW>F77;.>P?2PKXBB!9)P9EZP(-<+/VT^X/9GZA2LP:WG0>1(<2I=R1TF$
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M>0"8R%WIJ"\5;=.>H6G5V/*G2<T2A2FT2WF5)*R;4/#K\4?I]^K73=D_S;?
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M"AN[QJ$(J_OW=0T/@ SH[7X<L8JFDUJH$HTPGA3,U$9E48PV(Y2596KN?JU
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MT?PO26UU4 '%>KOD^NEQ%-OQ,E%=D15;>>M%=:4RY^%%#+G>M<%KJ5R$A@I
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M#7N) ZZURWI3R&10R54)F[S7?TIQSJR*"BL^>\,J_7F*%I_\)KU?MEWT3VU
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M_]\<!/((M!3/?\*1>=(9\?(K-!13[?]"'O OY!E;Z8&*Y6ZD.?@6QF=L@_E
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M/6,7,5 E#AB\T2_V(I%LX/@_B]7%QA:0[T]P0GEDVO+;Q\=\13=';)^^1&"
M'+L@)7STH!>]!%7SG."+@2H@"=#N_K _C*:XPUL-8YI+B=$BAE$B2$HK%99M
M43=E]%NC4F&)1G^+VB>(!1/H:DP+>/PU-_S=2P*S?HX55((ZY"_@K7YOIU?J
M@7K]AXWW;2X]>#7?RU5GI=AD]#]F@/=H(8D*GS%E_6>02%"APFYK% !,?,GK
M0Z'0Q8;<.&(IM7<5-S79,@\)_S<90'$W=![_"$6FTD64/P1Z(-6*WD/F!%Z
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M$*V_YHC&IX#-4FVK(^+PL@W#*?#9"_Z]$NXZ=WB)_]HI@/"TA%1#B&\05*?
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M5!?NLG,>M@D?HTI-7P=-5!$80?R;N/'-GFR7$42B<F[RM=9G!E0"H0(UUJ=
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M0Y+"\[TKD<4EO0C,DJ>-6$/VPG:L?L3&3)I:U=*2PZH0_&4S7&ND? ^J,#N
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M7O4!A8E?&?UP*T\CP#A.E\B-U-:+-MAZXYHJ=<=_FU__*VK?)7\"4$L#!!0
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MR0E@O-?B;]H37<V:*7!_QX[SMB9Y9V6\-FKY17&KA5Y)\Y/+KJS3*X/R%O)
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M!@#T5.++HA&O[4 CF"WDM6^XJ%E5^W F&P-%I5DF2)W?E(VG\8TRJ:>/:L'
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M&\]G69ZC+GP_G'W8[4"EK^:S:)F$DPZ_#4:3#C;I/ALW?(;*:6R6^_U6X7S
M$+H'*SE9.7S">4D4&L)34^W(,:K5^B'AF4:[.V(\)+:;O#'1"J7\T6M9?<WZ
M1LUX78U4:EY+6BB)<-+Q(-]6.W5";"O=9I3N<&*J:*UX2/*2VF+Y];=457+
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MWZ6&E.F$-.*QVA/63FUE='[:VE"OL8F2:Y(XU]9IZ72'V:?=[2E3"R3KQU&
MWX/*YL0S!UO[R#/H8YDPJ+%^GRY&3[+J;5U+5=MT&D2D2*>ZD_O>-&.0IZ;F
MC/915)1!BONLEF-F*ZI3ON\]@:N=<<]!/A0!EUXZG7G*;<HU8Z2<YB+L/E?Z
M=9 7^^5Q4@9"S.E03S&Y36KF.ZQ9JV6.?=K(C?\]]N?+B5(YV)&;UQ;-3,J7
M=SL:FLL]I<S<1Q58H=SV11\>&K!\U $PX_VSN.WK&=7;S#C *QUEA[]G P"
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M):>.?)1R?;H)F@QJ.^M]].89?)+ZRE&[\<PPTT-XSZD$DFC. &PEH.O#BGE
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M]>ZXQ2@Y^BDF<@^7JBE>K+I@E_?=NYS,\WF&.-7UPZ:A/L4BSCU.U[",B76
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MC[(YG[1-^%\#*X(-S#4NZ'@B?[*#,#I9DOO__+W"_^.(^3W['U!+ P04
M" #UC)A8U:;WNH]Z  "5C   &    &-V86,M,C R,S$R,S%X,C!F,#$W+FIP
M9\2[=UA3W]<G&II(C4BO44%!$9$F4@,B7:0I'6)!*1$0:0%" BB]B0@H2%%
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M"0)Q;G[A[^+2\@IY:WMGE[('[!_\XQ<#B(GAO[9_Z1?/L5^,S,Q,S*S_^,7
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M%L$K7Z[?5,QM-Q_\GD.,'#^O&4!V:X=R,Z,G)Q(#O:2G;#3SVEKY1E!R5#^
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MKP +$)QY[-:DO;$[ZWCY.MAZ$^8&GU"$3XAOO%7 !5U5/M]:((Q1)F^NBW]
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M)P2O"V&*=WK'0S3 *8V;..,-ZEBMT+@+TY*A"5 P)]C>HO']8":)-5KEUV1
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M*FRUYC%9 5/M/KGP4QO3A1B5_5J2^HQ%"ZU(6_)C^L48JU.W^A1W.=GPJ->
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M +K,KY2_\&]T%T")M!Q7EUE.VQUP)JTI!^TQ(!PCYS55U2\VL-OA:--$Z)[
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MJ7;!;$CGD0+VQ=R^ZR/W7#X=&Z5!/V,$J0*]JP@)4IEL2W_,XZ(G73Y#[I%
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MGC#<5M@O*=V7#%H-+J+)!N<1.B;;+)')#2.8NOJ0UE4?T%;:\'>6^"]%'<(
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MQ1X^_4;*>:52<B@/\5U:Z3P6"9E1.-F;-UO!L9L9XWSO/#Y-) "%GIL_!M\
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M"8]I3]I.&R5YO$M&+#F*_+&\M-;B6_'^-IPL&+NZ"\+L2ZEME.]$@?LK6$'
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M9U35%M8+?6[N7!(%L2%:GGHP^FH/*S*L-L72*FUQ0'D6P"7=?&U?-B!WLT;
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M]=QP@0,'-"88$F2E[6>T\TGZ8J)IWEQIMO-XI]THQ1:-MR2]W6Z/5+T4([R
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MQ,]_6(K@K>/'';4N+_S8V= SUZS$?'^_>@DPYG()_@6SP52BB-UHG6]6.O@
M?\ 7G]6@+3V"AH,$T4P_F]#&+6=A!:2D[DECQF\\OJB743\[<<LH]EJ3IOOU
M\X91(23FH5&SN<FI@R4<))+-B+F?BMK"UWO[D9?O@G^]DQ@K.H4U6?I0+U68
MMG/L<?=!=FPHT %3OF0+Q"I >UH"!"QNEW!OFEV)+7*=12'B.4?_UL*QM-=2
MO\0G#?#YOA?K[>6_.&-^A1^9371+NFUPRK.S[(4"H,W-N<)71.9!PH!XY]Z*
M'J)M=("%Y!>4&J26N-V3S1&WH/_S_$O\ 7FA-XX2(U3A*SK@,>_8Z-3"U)N1
MC3]? E*ZR/)B@%'J5&',,9N-;H,WW _]X58:;C]ZLC/2>/LB8*IQS[9U>WD"
M'A_Y%P;%'"HP;<FS86P\2;8I>DH5JZA.\SG+MX!A0=P1?=:W:]L@! VQR<_%
M::^U472^S*'#E!VP(V/]8+G&I(_DG#<N 3=]K1>ZI3D[,IQR.11)9TY!?/U"
M669R;7&@LP;Z-TNTA@8YUE:QO:^!3%L:SQ196#UU8/J#+B#M=B4(3]%?106#
MP.=K;UF>.(5_!(D-BR#WE,R>ZZ\$\O>^N@0XNQ(BS-@D#O95^9R?&"3O?X4J
M4$-[GB7Z1I4L-&\'L:/C,I9N3&@I;<D8QB]I9M</#Z,'NLL*PV$N[@/SL*P.
M:>SSR0Y.4T>TX[BT.LG=9\Y]Z3\*#)HRC_J=ISZ&>$+%H,%#3?W9+!0[K[=S
MAIGWT9< 9, V?4I;R_T24)A.QA=;R)*L<Z![*<;M43;2.-V _/XZ!YR$U=?U
M=7&]MS6?L=M-7]^3 S_Q#3Z]@H2#V\/E+\6WITO?-$N<9A;8WIS)]VQN=U#R
M!F@[L#YOA8M#1]?YN\7@2JJLG-XL-Q16G'7.UA:^-O5,M.J$+LOS_W'TJ;)0
M=*.&/LXO6<8,IR8.NP1\\;\$X%H:#\O4\J9W0>#>DROA456)W8K:J"_#//=-
M48@R.-MZ,$&6OZTQ%5IR!JF-/X)%YAQH@A2L];#7VH%(;FSB CD\Y<$I@:?N
MN=JT/;@W L-^2LKDK-:=<R#ML/#'TJ?_$?7')9U3)K$_$US F@MR?'*L[^_<
M-^Q_Y+=5_E)V.JN6DKLZEP".M6^X5K4+_C\U7V7Q?]1\"O0\_U3NJ%3FE/#M
M?HZTXCG7BWL,8],MSHS$@-.<7I8;0:R^1209KIKZ-'=KA/$LSNMINJ$_%LPP
MGC 5=_P;N\I[7D0/80[H]7X6$I!(M7,GQ9:CS;5+ .4U\"-+H;!+@,O"NWFQ
MF<7Q7V#* 9\2;>^!&['!W >%&C-M-TN2,*,N#;21AO6,'+2?&:^)\&GX=.1K
M?/U\=1?^F>%BIOZ]"OKLC\)?@Z7]4SS'A?]>]_O?ED&IZ1]11?CXK\JZH36?
MH#ALZFE>^0O8<L MQP0^<*?"TMO<&6E8& 2?3UM&7XM834H1'S7.#U5G'^_2
M"_.O-&JU5JO'^"!5H4A7SGH&=?#K?$_"Q9(3ZJ%+0(^*+_!<;P<,;K9XEF3_
M56>F28&6.^S7+I$)D-BR.G-YE^_=4E"*OZ80*32\X6 G8N3 X\5RT-:J[P=5
M5^8VCRW!G_W&;FOM.IIHHKY*RNYCM);OCK'17*&JI]D\$V9U:8$*&)CXHR!\
MF8Z$;Y'"6KP$H5:*V-"U?FGX=8>H:=1_ EV45.2 >S@1 JWYO!*$SJ=E-=;O
M&U;[4-4@AAOI$?(P:97C-K[(;1/-=^9^FC8:\'96D\U.;=D0)P@" F_YBL@I
M:WE,/%T4@(A0F:18;\S$?RZUVC39+.NFJE7CB_U^=E2ZH-<PTW&C<.#[XWNO
M)%(\6SNMG?VFTU>CQW$1%E]??WJ#T/KY8^X7C!P;.'X)6*)K;.\4J<M0M*TE
M@-:_PG@N>P<C;ZG*R+@]Y$S;.RV''&!^6<GHM:"&6_M8$G?>E2T30>;1%W$Y
M2]!(Q,TXL890!SJ]F/2R>FZMAW(P#*U)EPV3BO;-0W6)#K6R;7FI3V/U_*[R
M2X--3:O"$\W[=T%N8R F3Z;ZPR>'#_%=E*7.X"3+/YTFC=%[4"K1<DU:!<_T
M'M1P4;0?FL%"AZ)%5DF>M!TPX-0\[<1;57Q=9*,_*7FR'69;BBE$#XN1R(FL
MZZ1DSV\GZKZ _ )&,-_7H<5XD'R9_LR>N'P='N:+F.UF^8'P0^UL^SC5QB_5
M*,J'BN\!R;/G64@M2%04O:$I3A]Y-0ICA9,=E EN=M^_>"-#L,$[34JZ?UOD
M_LQ>7E%5TII!DYX*%2E/@=@X%Z'I\[<L*L(O?DZFNR2Y6&;S7#,/7\+6C4PL
M:)2#*RT<9V(]94NI- =?2EWK\,!4G[_8E.9->XJ*&7,Z^^X:0I$4_JO4(\;+
MOC#D6_7#=\VOT9TY*EMG+,I;\O=J)NX="MUG;P2:,5"392"S),W8=TPHYF*.
M8H-A"6(Y$;^?MR6O 5N6*<]B>))$OC(;V\S\ 9;?00>B&,/1FK,Y)EJV+MJM
MQ3> I=\/#NY^G(WKLD$)KV9I.YZZGF0GI)LK\CJ- B"*DIX#5&&&B\AL--$^
MQ$GYTVW3S),B . G7&PMAGEJ*L)F!.ED+G==U="6EBV]&ON..>6>OLX\,IF4
MU"O?]6VL(4\7U>1=2XJ!>@V3,61LQR_ @/8-)BT)J2\&3>N(@N\^>W-!R5NR
MH95?9ECS<X^+Q#CC'I5^T.2EZV/K5UJL%N,:,S\C/5!D/4SWI97C]<[9I]<5
M7A"[9DR):2^=>K\6\F1S&/\NY-5R]OM\;CD>O"D#GQA#S8>#I "YL&OM49N)
M/'9KX1XT[-1JAM-Y$Q4O6UK9&'Q-/+_XXZDN!3@9H(TM>NB++UZ[K0*SI$/P
M2N=?D]FYK0,]--'./<P"X_6:6J+ZFM%)^-C03>"M+=9+@..\;7'ZPDC[7,M]
MV<%\]+QLI?;K/.1>UC$UA07J5S%EW3/B9Z>J@0ZCK/!&G^I3IMWK^4UI9N<*
MS"D(W\Q+0!_GTB7@;-G2:O95:)&P57'4%4[KHTXNW*O,O\[()_'7G'5KXY#8
M$5%98AX<A8J78,*AU>-7>%7PQ4L -O;J:LO94Q.JA3=P9Q08ISIUQ4>NV'+B
M2P#>+UFY2P [K;_"ES6LDCO,B>5HNC-+UZVEXRB@E]&Y\1+P^UCO5;2Y4#AW
M@@DF1:$JWSK>B\7<9-612.^H_"&Y!>;JW3D:>XY6KZ_R3W>P@0<%41=^>K0:
M:Q^/H>4CEX H<I3: 7V[B@/& *<FQX#KH#R%C%KG_<_E&N=CEH^'F+_R%3[_
M@:7^R$Q8"OVWR!_\Y?O?^2NA17]"4@-P2GD<'^_K,T"QY5\4!U+.2VRMS+2C
M\N$PS"%N<T2U]F9SUUE1=ID'ANTM19<@ 1\K%6)J%&([V,'=_"4C+F+ZA)L#
M7RWD%,5'G')N@!10++WF7!^79$Z%JHJSE!&M^P3J*S.F,JW</Z%41T&1Y]0/
M;@,> ) YNHCFU!D:=M(O-YG?0=+K;__N(SW@_G_N3@657P((;O]K;\LEX!2P
M^2?'*=*+_;5=]^_Q^.=-)N=8M'U/('E?4G3T!L,NR83A4IAWA7<<H9.DT@#K
M,J*P3]/3W,A)+TV<URS3.!0UV9.N58!ZY&"I(<S^Y*%3GCPAQF'N-,->>-TG
MJ74%6SY&=:#ZU4])35FYF/!8W'1(T[6E:F?M/H[9P4?0M67!+2'V_2Y$G"6B
MA:N\I,?/\]6+5$Z$Z"3U1*()1E21X\A<O_ FOYC:C+,U=F?13?ZFK],:>OW)
M:N.\QR"EC<4L-4RRQXH,?"OKMOF[3[:)^57.I8"<I3X1J^VWN9.O8]*]!9';
M7^$9WE*[#$L2$7F#+F,%,:ZS;^QFI<IQ(BBRE.47L5XW9D%JO!SVI KTFW8C
MG]]Z*NJK/EF92&;7\_@"-*L<*?-LK2HF*0:QH8X_^%%/%-18JHW/K8S#L*RH
M_:A7?4.H0<8+A&CL@OE>0XX&+34=29)FXBV/V><=C9&=DG7V%-S=0F3WD\6.
M:@]RMP_(/+<M@NA0[="PBK[ZM ^K,*UUKD9*SSC5A4K9T@&7Z9*"O<=H\3*U
M5 /OZ]=YBM_D>O!*PDJ*/./RDMAG8F*6Q0"4P;H1#$]DQ^7F'N1_X'Q,+*+)
M^+S-'IFVRY[K2SQ[0;8EJ+T1(IOA/==UYJXR,;?;O5A-BX"DW/B)8Y'PWQWY
MZ%9\SR_G.5ZBEJ])'QC1V1-$XMTX465@,!7%>_SFX6D+^4R;\4)O)PU.VJDI
MBG-"5H']V>TPRU*8"PJZ$[K83K#8V58?J*Q/ZY/JV;2_;?90PUSQK#!E4:04
MW)W97(BM=KS805W@JV)ZT)TF;KL!Y;$TRJE:2,"-KY0XZE]N(0HO6? QJ@ZO
M.FOOKNL!1$=YKJ<>P<P;ZS0=GD.DN@?HPVB9REY:Y<MX.!ZHR+2/*C#D((7Y
M?RQ-%)*-3> :YL+GAP7SC1X3EW?I(2I)EXO%(CUGJ9 ZA4Z@OED?%W.>O/C_
MT/I!"0&8\[;"I88)ID@3"0#2$,?71'I/)O)X7SZC\E#?523CQN=*WZ^SGZ@N
M1!>%A*74.^NJ7:<CHA[ 7 *67T4MELN8S:S)[(M#:KIF(3.0S,+".'7DAH&V
M?GK-H5J^*.'*BHD,4HAE(YO.A@GWD:EN>-ST" 9 ^^P:<!P_=DAXOT>._<5H
M$HY9'DB'0>\O-TVA:OKE]4,A^X4AF?4)Z-,(FF>OJY,=Y1TYP4)MYS7[2*[@
M8L=CN(_Y.W?EUZ(,23W&+@NT6*[XUJ)*RB\T?,W;P/L@RSN2/=#K53JW/4.M
M-8DI:3D:U)B<\V@)!#\LOV2TM2"2,HCE/U21VVT^4BT^-QV@GD*KV)T7//]X
M$;C]3583O=YGS16'FZX:%[!?>CZ @J>*-DG1L446I9B"WE/_U+FI35\'XA*%
MU#):K'BN1&]T+C(GH<P4X>*W<\E_V7-6+U!WSSUS\@D\9 =+[W?<S'0VAWH>
MF^",NN9BMM(4CL8[LQPU1O*?]-"O',P)[/OX-%M>+&\^RCW)A9L=Q+@.7@+4
MQ!&8?)R*$#D83H]\!9ZBWP7IC;[[O;ILZ9S>J;PI$GL%7,%!]@Q8-HBEC0I1
MY9LK*FI7;52V*OY\A5X,!KCFQH,JP8[-JLDEHK\QD[%X!_Z&5 !.]<$O<,*(
M[[M_MDQY,-]0G#(BXL++;=U0!\_Y"99"%M+96WKA1?M3^$D;A<94])11)M1V
MIH.-!5/_5VG =- 5#_V90?_ZSTGS=\ V?N7NSBL/=45L!U<FRH'[=27+?T^;
M_XULK.#=HCG$B$L 7!QGU(V[XL\#;9=+P'8=>*(UYQWP@-\"_#MRNJIP\B'G
MQSY.9?Q(QGT2G1=\-5I'F<CS(#P<? RM!;4-?@52C^FD2LL>(M4_OO B+?"X
MQ444 S*8D<4KV^S7\BL(L4Z84^J4SC%?"J)50:TIW'F<BNCX6+'%4(O79DU4
M;XD97785?8J^;L[G>-OJW>F:(R& >J63'*1<:NI;)$1IZ2B,<'3T.W;( ]@%
MRU(8101-+HE4[L%\SQM^:'3G'@UHI.?6I(TVQ.GLE[@-&<8M$:IW'7W<L_16
MWJ@8ASF.6))LW-1I WT>F$EO.0KMM;/8(+4-F7_6[VCJ(V_V5\-8^3\:QLK^
MN2,,EMRYF%L[X+G$@B^K715;]2C<(.$D+-#LMS'[W9&YE_-%SYE@[_>V"Z1_
MVYHN3DG)?C[> T_.L=&$Q-55H. %*P>TT#<M0L%A&WP;^PA\:X!> +(:B*DH
M-A;;*7@SWF-4E;E97MB\]^QY:G[42963QKA,YN?_4*]\34(PFX@J6'MN.=VN
MAX^7L^%"ZS7XMKR0 Y"L;KUIZHA6K_H@KV%-X>W'C:IA1_TL?TB6V*R]>YI
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M=@TAL@6.RA8%99BL5A'"0GO7C\+T=G,/V?3GS1P&,18:BRV)NYYWFPXL6%)
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M&JY1@+I,ZVVI.54G(E4_Q;Z@L'Q'K-H^>\TSZ6&1!^H>68CAJC@F]M,29KY
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M?X+HC=H$W5&_J_1^+^9WFYW(I1IRF:F&3Y&Q,>UG%QG:72XCU@P>5C2[23#
MRJ@$3<O^?'VJ)M#WQ%K)EO$:IK&?H[NUMJ[%>!FLP(HWP]N^B/^0JQP:*GNM
MF3,VOIK_G;@))_1G,<6GCVXK"LU ")&A5!F8^E2Z\:CA0M[NE["?/^^ZD+%Y
M]\^$3GWDG,N6%YD]<ELSRU\DG>-()Q]K3#..@,_U?JDQFC$6OA.D^@.C%A'5
ME V]@)&463+[^-7SZ,VCFJ9+SJN5:RKLBV^YWE/+[MJ)6F0YC8H/Q>>IGKW^
MR*&,O?@8ZZJ0WAX A@LST?Q5DVC4K:DV"N_\^1(^SIY@].XXV\V4TX? ,-V9
M9]1'VQ*JW[MT' S:;Q>;/<B7"7(ZY9.%@P_?;99QC,SL*Q@6>%'QUZU-(8Y9
M^#E)0CDQ,OWRF%:^>9SA,2:%N-^\U\=0 SMR*FP6UW(J"6U+F&+Z95BMK=F%
M :'^50OJ0VW.![S\]C/'T2_ W _$MV8.)TYJ%;CK':VN?.98F_G@?J['#;Y#
M4@2SYI.\EG7XC9=SH8NX CG>9(=9=S-!,AKGR&[;90/WK/Y='3B9.%_/KWZ9
M=H=XW>]901S0\WTKWLSPZDF!!;.<M56Z:L7[DMU>6NZBSCMI(Q4%W<AFR[Q!
M-[L[.\8TUNN&5W3^ZKH#F-L.2K3<\#C/T[[X\[6M+CD'HFT:>E9M <AC?#ZD
MJ4JDW^'RH9=%%1T #M24L=L>X%T,1 B5C.XNX=E]46!^@N$H,%E[ *PUW?(]
M[23FR 7E6D$'O6B9U8BS@<2\2:MM=5H>YM!."$J%/,)P4[5(4CL\SK-A=X.4
M_XV@.(([\O)9PD<U!5UUQ^\2!>,?ZPCISWT(VT8)R'DOU@8(B8+9]:IS$J47
M0[9'=O8;OR1%6-'K^"NO FMC=AF@V:FNVLY/MZ#CW_E!-CAC725BT],*TW\8
M1ZG2L[$.>(L] 'L6 P8EF\&4$@8HPJ?UUB:H<5WZBPA'AA_V:-IW]B]PT]0O
M2>?5H-32@053H;<]B9>&ZI@F/X'7HL;@V!JXR :)'C=O?@0\_8S!7E#N='V,
M^:1"0C"6:@JFPJ9(B)UCXW#L<[K;?6_]91OZ RCR(/%M- YFD9-3K%-E51@H
MWCCS5?X:G*1*RK0"ELU[H9OO(X(5&%ZH4'*Z:!-E3,[; UR9:P"26FJC%?S_
M4"VS?ZC60B])(O9T60\F*6 [:M[\,/K/J6#)/C^X 9X&N1TP&*PW [$59?Y0
ML*/P'1;&V)49$P0AYU,T(+30M=3\MR4QI"_A<T+CH00%TY4[JTGN%*@-SGR'
M_4\.)J(*/#_->,)QAWT_]C8!Q5<H+MQ.R#@X*$2NA&H\U@)\O@,KK _9*5_Y
MOCN\5,_*2LZ#'A"K6_4+A=C)51IC=0YXUAZ 22%X/RMMM7]2.%X/QL']X N,
M0.'+[A%S(C,MV!%-*&&$#3(&461+3\FXW $S]"<>'7=@(&CSZ_XA81H!?08]
M'0?SJTV&YZ&@Y$#&!*$:23-,NZ8'A6US?_"0R;<7*G>)85CQ47^J 73H''GC
M^\GO5A7&6L72+<OA3 I>".JH/'3>U^)_HMY_NPB9[Q\3UOU]3(A<%QZ&[_<5
MVQF3O\4&+@4>-,3$9^&5)'PG6D)7Y=ZI_]U 3%,F<8[%5O[-3O!6\D#!RFQ0
MXQ-TZ@A$^231D(:Y3#F[8.(8+%'']EWA;D^9&,L8Y%1<0VZ[':'\,L1EU;2B
M%7+47L:OR@TG*RN09USKK7%=O&(>%++FN#77-"^Q?(/O["85=L/ 4"B*)2I
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M*0QCE?O3@N3CW9T*>W+_"F>A/ $I7=U4>0OEB9]Q,VY0&=&CVX(,=VYD8?8
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M;G_S%"_?["GGQ/%=VFK!A.P5N_-L)WZNEWB4N[2(_5S8T-EYZJ4O<3+]X<^
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MVBMU!;68J&XIK' [H2_Y6VVWL!"_8QC&ZAM1J-61XY</N&_%867 5 WRL;'
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MKZKAX_*$E&E8Z0J1SW%M4YZ+'/!A&+[VB7A?A9PP^&(\#V794H/W=32Y4^U
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MU<]]\&3SS^KTW#K=J0E:#)SM $\\39"+A$$%/GC[7>)=:OH.E%]@"6C[80_
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M?$&& ]=I A+QU:"/JTBZY\W%4UZ.7*H+;!L=/D))PJ"^_D'XI\V@*<;0(Q+
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M#K,N'+"6*U<?$-P: )(=4%7=$E$FMU@K?J+7T=:U5_^U3L*/BARRI0V?";,
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M+UKFT"?-]@4QV&+T>1::^GHO>"? ]Q(K,CAQ [KV8_7A+7Y[+;:!KGY4VYU
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M6S*ST!P)8A^?_I=Y]O^7H/TS]S]02P,$%     @ ]8R86'2NF"Y$6   .V<
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M30W;Z=]+T*<!GD708:;[BA=%UN;R?$^)8A,-P*>K-3]]?IM;XOK3GY/*V[G
M0^A8S2HD88:E@:3B^FAU;!T.=&9"Y#:HK!J%KF=M2M/CS8\&T%/X/=H&-<@F
M SX_+_\,!+R:NM]>>D3CC$:@/N:NGK?%"I9/J4*9>]EV+ SEX7<OP$\2Y/F3
M!R*S:O34[WMM9L[O"_)WIWZ/Q_(H\P(Y#H^-O&D)(7#?Y&)0_F8JP8))D0^G
MGB##VK55)_.2/ND'NG&F)N4\7&,J<1U >RC5Q'^CIP(:0 KB4?*M[DC7;"Z\
M'EN.;7'-CH&038LZ Z_>XC]2R!0/&RZ'K=I;<077::42)N^*R1DD-NX*CD:*
MEWD9!:D5Y=UJ4M.S*;/_S%EZ6Z_?7T<Q7-#2Y-V_IL-%[)0*I&X$PTW^)"'K
M\OIKGZ!3XNFLM6'"-)L#V2P'\SK [6A%I<E/Q\ ;5[31O4E9[CN\@FW<H^N]
M#:UFNA<8T1)'(J2W-VF *+ 3D&55H]\[3XP">G$^\'UI2I)<UY*,6L%F2O*-
M.R]J"#/BF4!!ZB!6;-M#P&?Y%+XCM.0$4*:3H;/_"N0I%( 47X4"Y$8I^EZ>
MGK>E/F3>;O2]"]'/V \"AD_RAF)$89/&$:K5Z[G5GU-/#![NO2E8@9S$H,@R
M!^+C9G/=(B35M,]76NLKN54>>OIT]BI*;M:5E;:0-YN#H#$@-@2H9M0CO+%\
M)*ZAH>6-,S<90!6:H(Y)<Q%G0S$B9(>IEIN#MG;=GR;JV.]<^"+L4(W.J;]!
M3&L!G2)>!0EDM&N6?Q1DMSH?)B;5M%URB7<BN,6@^?,/F^3^0&8--]\XE=26
M4YVKQHH/S/5.),T[Z)$#LA&FA^CY+R26ZIK*R"N57@J50O&#5F2#'2<B2\>Z
M?)&;U?*52?<)L;&IP/'B-\Z8%\EXAWCL44CL5QJ@=;C3S"O[8V/A9$#HUC2X
M70,D=WD*I<K*ZG6C5[)2*.M"+<B96!6Y5B^,/.\:=!WU8/CXF?NA=N&:A1BF
M6F)\^L'YMH_P/L7@3L=JIZ<ZJ8V!''L7T8&09_O':W _Q4_(CNEK&(]5TP B
MU&YI85+^TV)=E<=#AO<\Y-^*QI5N!@TZ*YKJ)9PBGS_0<9T$O2U&7+\UU'TS
M6"NCO>D!6]=<BF8O8H.XVCRC0,[!]QK;9#5E$9-F9[OEW\(?7#]MD*@I?P+S
MC2BRUI('Y[U5V1!IVU 7P5!NVWU*P>C\4Y6AM#94&3J\7O^3>4C>-WMX<*]6
M^IF3KJ,)PYHY*6G#>!"<]* JFJ)%;&FD<I-.J[_-G9E]69/P2.<H,(5#\GX=
M;U061[T(<9< "7U 7'^C/M3/+R:N9>"YW-6$?N\%XB3#;(A''(1'E# 3#_@I
M+ZZT8FB #4_=Q>I9;N17:0%B7X%+@6J52-58\4&!?,IKURU QAEYD6Z8=+<O
M^FR2]ON]N-+K';N5N"YHF=Q($&^'5_2^<TD7K.#.&7.!:TU'&J7]DZ$.IYB<
M-2T 8F@-\ELB4S.6?T:Q+M8G?Z7T3>SJS5/RBZ?*OK]V-WO_/:L"@\XSG\>R
M_+@Y)-=>I?KIOLDKG7>=?=X.(82W$NW:V/5@?PSOJ./0=C5"60SD=?*JM"!2
M;2NA!3LQW SE1;=G>TS9C%DLZETBQ7:&#0C8308T3TMW$)QFU*/5W<MLN=11
M-]A4BQ\[]HJIIRY%4[^:W3MCVX,Y7L-&$/]V-2VQ9NI8!R) J(DB0_8F@(41
MM\F1WMGD# \A?B*KR1XW]"H,Q>0K9=:1",>,2W#?B)"%7V-NP<!L&FF (^5H
M1O?]"NJ;.N>1!YO.\C7YCAIB6K>+N;W87-,RI0?>?1[QFK6J=[!=QL;4R^^\
M(AI%$FB Z$S&RM&U\&_6.I'6 _LV0X[,CWSN=,0@V/+A.;9#?CI-U*3\\ZZE
M&_I?S(T&0;?)Q7,07E3+1;@B_O ;8T?CNK.G\,1K=]V]Y8Q5%)Z1B&[FG61K
M&B ?Z6#I^] O_1YV)+3Q^5DC[^&,G808('N]!LD1$L-M.X@<99AF(4B570Z)
M*H*$8[_,1B!%W:U6*I?E?A8M+\1.19Z="W8B&3X;JY.6.]"B2!*SXD''*29C
M%77L&]M<(9[0,W62\KV3F!H^N=RDIW*M;F*<;.\D.1<1W,35*T2EF5*?_).X
MT;/</=2U(-Q-Y,.P@>?6!C%E.)\%Y7 P(T6*Q$RF)V1<>3D&:WX%GEC3:"%2
M$9CP3&P-[)(@MJSP??+6ZMG$LS_Y AXIKF=QD($0XDO;(F&9^RL"#:TU/V_=
MQ1UW.0#!W7$MDY6)'Y%='[])I!L?7%[,:[_P/..F;98B^6UD3$5_&%5@K.2R
MM$3#HRJ%]0HGZ72T92W9FLZ+(FB "MYPD>;*Q,F(+X\(6@8N\?7B*U1-BN)P
M6F.07TI5.&M])5<E1XY'66/(==QK"BM9JRB_70(H,.UJ(WXC/+PF+K_A57U)
M:TB0A5I>G+NO-K I@0-A3/Y"$K# %0GOPX)5;TWT,1)AS?4:A&F7%NB7R!C5
M7K[<C!FI2\'>XH^[I7^=TRO<L%=LLD5&%[E/AI>QO+9^+CO_A>&6]%$R$ \Y
MXI81]Z0T?J7O<'HINH.YM"N[Q3+ %LCR \J&L"\F0UMPXL!03+_/HFQW(5?X
MD?KOR;W!T%8TXVWRQDX\&?H>_I:[!S7Q6)7DV>@F9)P;U(!=2\('<]_S.K/-
M?4E",#GHEE)+U,LE32:UV6\4A2%YTE@<(4%98_)!S5/^:X_8\Y[-RY=IU!^?
MZP4V3MY?SE#*N#6!/J&J)8:.1\',T'SP_'GG6'QUN3-.M=IZ_>B$"K.Q3]-W
MW-2/IBBMKNT2>4):LQX3X>TS/O?$<IN;ZQB)3M&B*&1VP1H,IL3[%NO<#R#7
M-=, _'Z*=5G<63RN528%LEPG/LORU(O3$Z,DQ"N7@LQJK-1.!K=,VVY)/;[<
M%3]CT#<T_05ZBZ)&%KE'''<P9<T/#/%[7(=8C4Z/2;AK?LLK%".0U2R>%^U]
M3S#V8^>#ZMJ.#;$O;Y9*W,\\$*T(X64_+$%PXV?)QA2^=XVZO<)FG8Y&T8TW
MS1N=LKRM*#?I@9$5(:U#%,(]\YC_,B9;$W?DT17@J0ZE,%MPN<C:83 :#FN1
MEAZ6R:0!(!4US[]L',^Y&N^S[A!'W-UQ(Z*?JE57I.NNVUA'&Z<HC83W7.:9
M4+UE-I-23 , ?M$ /)23Q(TVX&1LNQ4\L].==?"$D_'#TV\XB31 W-'5R=UU
MH$CXNN\IOQ 9\Q3"Y^$6YJAW#EIZL(T0 ?S,:SP]\ZQ0Y9\ JU;N!G8LMSDA
M3,FG\*CH4*>&"N':#!J@<.28G)S!"GO.RQ)[-=M,M@,0Y3SI04I_3-'/\@AB
MQ-N"J2+W/$.%>#9Y=!!!E:Z:VH@ZK:E9Q!3X)<4#82R7=(5D4Y6*!G=3;XCE
M7,*3?8VG6W&76F<=W#W@KZ5AZ>FO0K2*N 5V;(CM"026$;2G9X6K3')O3-^O
MF_#YATO'! R+^!.< H'MV*>313.@&E)(9C)OW!GT/6NIA#>?[HI*WLW YJ_6
M@KX0PUHLEC-<!\5QK>=:O/,+79Q":Q8;'#NROCC$S<?Y>]SPDYB^<+NC7ZJ^
MI_#Y70!#2:0Y60[?H-A<ZQ_NX;4P.7%';H:(='O IA.]G9-2>H5[IO,7)$J:
M?Q I1QVR]0\G5,9M53]\GDJZAN=[O0+K+RH_X(W$ A$N>&66+AI L)L<=/OG
MW>@JHV0/K29T'D:!PDM?E?#0;85,KE7/$_6A,9TYPR?>$94;H1P4W4$_+C,N
M?;F%+0^IMJW6\OBB<T;FDD4E-A4)+[ N&Q.[32#9PU>Z-PCVEQKM5Z8\K_K4
M2;ZW;A+:#EC+]5'"-6YPJGXHO7S^*426*=26RD,VSB8K-VID"I3&=@^5A&WH
M4V=M?U 8\#I QA_JXB<SZCR4$K[RUN3E.-NKP5R#%JKV4PK<%;VV%:W&O'Q^
MC'4J9,<8T@GI198_F:AV9 2AOBXP?J[WAWL-\24SP,Q[!9;WX5--WP_]NO'%
M_F=SI_7[N$^3;PH"&!]I,]A+*^2\<FB6BO>B\ID8_&2)%%V]DBD<+N+5TS)3
M>T5A\=XVW%_K"_Z6J>S/KA4W+#%:OPJH#JH8MC16X2T<7O,Q;DY,-.[M9PW%
MFUR_Z]GF6V[9T[*R=2 Y2SGQF08H![V,PVM*B!U!YM7:_AXL*"3^(=SV^'3I
M<@:P^7.GOD=K?,3OTP _1SIF0#DO86? UG1%Q%X$7N=<5L@F[!Q=\X$2HUN>
M@AQ-=.7895+G',5*,F*TPGZ?8XY8?Z5ZB2F_0I5LQ7]^$^DW-&C8L79\?+$C
M/)N)_)&N0VS/?/^I5_@A._[N[X' Q*BFYP](RQELS]ZS'</HJ;3YCECVM/V>
M%(SNO4_6*RL:H%E1Y.#&T!_NM93V9'$T^R\%L.FYS1)C6JBCOB\M>X VD8[I
M7NQ3M2EW;T-NZ)U"X06>G!W@F?T9GS)D-?AHOUY'LAMNQ'KL[;?@ 0Q?E76B
MJ(VYH60/" TI[05R7KJ&O/>'@_)U]/G^KZOHV/PY_O5'D'!4IIF-Z1]OYNE0
M1<ASB.Z%;O>KAC6KKTQ]GJ#ZT:_ZN1"'+,=T$/^SQ,<4R=#?(WT0U0O<F*FU
MO?I[:OGC2VSA]]FT'#,@Y,MS2QL^N(QEUYSTR-'E':WW>!,1T6_GAS.@9,/W
MH \X4U/#EG&#TMX$SLL26HA#5Y#@LRQ"1^[?EI#X>U*#RI<:@ZSHDT8U[.',
M_I<3Z/!LAS5XAYI<57CQ_-V)AV%)]BPG%18=KQ^KY1!_>!'S<D6A0..SI:'@
M$7J  OY_HUL)K .I%MM8>Q&;.D0XS- 7]!\K3//7 Y3 &K&2OED2Y(CY2S"=
M7I';H;H=95AS=-6(!5NNY?7YD>(2J2'%9X%'$5]Y958OV[X48#O?]^)9'R%?
ML^/. ,M7Q:];D$E((^8D.6J&<TC-=\2OL^E"!SOA@O93]XT$C*8KE7E,:<O'
MPZ]P9;-DNZS4?LAC^QVO<79U @OBQC#H.!FY2 ,8VL#J'@]V.9Z;DGW,\ZFY
M5!4<$U1-:G60QOEV%LO5/.]F"-V5Y-T(LF KL+QZ9QZMFJ,*6%'(?L+Y_X%I
MH:5@DY!PWU/;'D[H"26V],B.&:GS&U P@B/+FEQ%2KA)3MR'N069/)NTXQ#A
M/KVT85.&<"7KW"/EM# 9C*#/%GOHCJ9@ND\VM_H7S49DL8#Q]O8?$F':X6T9
MA@MR+S<]GP=Y7TQX2P.X D57Z$04I9XSU_#8(]@&IV$0_ &2SC]TQJ7'0IO/
M8>'@PNWQJB?4:9ZJDU6@G'07%UT9Z4]L[FMKF*-DYY96D?W)Y:3>C[/&"V9G
M6@*Z?Z@,H>$&^,7D.;CG_<%W![(B9^P);$\@^;E,($@IT2AY#CV5;"9N7COU
M>E4^$W'$4Z<V8^NCC%W6%../F=,,/!FZ3XT;7.V174%^2ZW5]5[*46J.19=-
MGJ=3;UQ=\M13+"*'$F4@I,4J6+'$0:_RC8CC'-7ER; +"=87I6\0G>T*47&H
MHQZJB=E3/4GO1?>8&S;M\UN@=))E0J*^)RCS-PDMM/59BI_<NP_1S_B)$:/(
M#5'%EH>:G(?L[_0MFGJ62/C&=Y28^Q_8,>D.R"ST)X#%0:H41>UV="[<V!Q+
M;$CK.YN+,!'X9E.)$")19@60DC]F3M2$>Y0HO^.O-QTT1<L>UH*.)7!2Q'"J
M_6O=L=@JN_7-;*L;6AOV:6OQC10FXCO $5MEP.(3O?@8A7?W# 4M&/XK.PGO
M50((6EEF &Q/,?Q^:6GXG\U*(+[<^8DP_22,_\9X7Z&\P+'2$D2;IG5'H]$L
M\8@<@)W?1*;I=LGFCNDQ"C,Q#\"V%@,OL=XA#"'D0XC6#J_M(KZ:7U-$3*JU
M:X1EJN-L#F2?@AC($"W92>633_1B_L/9_LD2MW*SG^CFSZ-;H2(4T)?AD\3\
MB->M7KK/O[S3_-4H*># 2\B:DB"DA=7K!!2M9!WA;DC)WD@U.-XH7;'C" AZ
MCHNCXC[E[,!):9WL!Q*^@@P$#._A%Y \>;6%"!.W:6'-Z'OP+5X6? [M198@
M@=NSCI:@<6T. B#)>&;6$Z:@>_U7N@YCGU8U\O(\8-4-7]$KG+X4.L!P\=GS
MHSQ&I[;"8FQ9_WXA&>G[,?1?Z<9O$_+,LX-_R# XJ!Y,QSQQPF4BY,D'>.7G
M:1G%Z,BSO:W[=R)TPKV??I"T>;=BF5Y^\#$'\)58^Q'T09R25$.6/]"GJ)!F
MZC["K]$ UX:LJ#9)!!5F9Y9H,;%WQJN=Q^)YW&!+_>/KF!-5H4[@HR7W:T>8
M\$[ANP44V \YV7@C!='R?[/PB.X#?\JI85T8$64[=G;!MWJX>+==Z#,/=P"X
MS"J%S(%7J?ZL'OL\@ZXOIG!-VAM15#YWW*3GI[&;_HF>F8!6#M9@'.I CA_)
M"+<>7HL!4!28QC_^'Z"^8CL- )O=T\@2I0%PKVW*;.A+A?WE!3I/ Z#5WQV9
M':^BFN^VH+:;4"G!%7#(FAT-</( C]V?PWYM&+%@'#04!%C^9V,PLTQ9WSJH
ML7 VP?M;:']G-$0JPH<[=O=QK5-8 7A:JY6M?4@!(=G,[2NS12MK>XCBSB>J
MH]<]/P7SM:0O'JMO&+VA*: 3(TA6R@/RZT#YUEE&=^21D9L^HC7&)TX]>>B4
M@"QGW\^G<BR4.,"0C*,+FW)95S7*) )E[T](M^Z@2]BN;/:'3H*?(O3F%+EU
M&JWL0)&<"<IK:Q*;NVA]-B];5E!,2PVI(W)MT35OK.A^$O*7[@K[(<P,,JKD
M=XMY+(#O6W.0J0"K-7F Y=-?H#_(YA#3$9>&-\I#Z/AY22?>9=S1$DQM#XK9
M\IHX-8IA)%LH;C .!NZV!=( Z^LD[8TF.A_:]CC)S1EBJL;.J-;CPL4#L78(
M/SCY#O(D4X!)<O*4O"K#VO\6,?YD0O.HB@W*Z_[GJ-7>PHE_7E(+5J]_6K2Q
M>L4=)1H@.80X>_@(NN"PHL#@^C_QP$P?CNFO<MQI:%]EY9>O)LU&O6'?0M_8
M++FTFGE%0ROLIW>2'\SIJ1@,\QM'^VE=/_/,*6YT.V#=YJ-I'EGEVEM="# \
MVVYPR?X*WJ $M([@*^;E,R\P/_N:5/EU9CKZ^(DW"JOT;%^#=0).],WO^!./
M#IW==AX]^S96A^U;8>;HFK1FJFN]7)$YT][CW ]%\=?4W^9GD+S&V[FO !DA
MASF$:LK-A5]G94(:@YUKO>+ $A0YO-X595;8+&QS.\I!;^S'M=&F?E YPUXL
M<7<N/+_-:62[_RC%H7JH0J0^37W6#6^T&3J&O4H#./6SVI(E\$IYZ0_06?P7
MOZB$U&1Y@R;0?5PT "OUJV*1O7 #Z:5/?8_3KS(1__E,4,7^J0/)2?B%CKG#
M(B1+*M6>MS\D[N-2[_1L,:/>9,S5!%LZ+%DY/X^AYP 5(_SJ12[#DQ<U.WL!
M8;]?^>@?LV#K!5=YM6*YX<9S8Q4?5H9/NVL_D_!XF1<H/U8'F3A^B8[I[YKZ
M)P27QFKZIV"FQ)WW1'"KP K642-)_S6J7&B&!Q6IBS,]D*W3:(1R+I@ ']P1
MF/D_P/7?5N^UTT /AT!2PF%@1; <?'8]F!XMF_/ _4UW0.]A+.K[+$*#!K@C
MLF=3&T-$_Q,>_%NT_;-)&Q^8(OOVE=?EYCXBM(I[985)UT[RBAU;Q#A"R;(!
M+0,YX@TK62YJNW$]S9.3;@F*XBI9[\30_> H*-&J7Z!MWFQ=I@G$4H,[4S21
MM!C-]9A'@6^[8VW[0/?'[)?^B"RCP9]RU:&O_1_(OL')'%@A+,G>Q%"/;;3H
ML>3K1TN_)"2\F<_U0':CQ! &I+1FWD_PL$MI!C5L40^LN('EN$8@"\61^#TM
M4^E)E_1;+YGVU9&[ A>!DF[0"K:UZ9 Y@R*'90+OT4ZQC*Y'I@_?V."@I=B$
M-8PL0B+RUK!JQ.##C,7+\=.1%KPS%-CWV0AP67YS,#I4 ZF5W.+A^Y"KWK4C
M_5(I#<"Y3P/L&)-0D91[Q,=?-UJ"'B^K\_407S^@BK"Q/E&BN!SFJ$+"-#+\
M*M931A=ZOZ]R%EWQ?QJ<[%"8O>)H,^2A?&E=H%V6ZP<[^@W6PWC@/3$^6>G[
M9SF"NV5RP^=&FS*X0;NV6E5+,=C:PXCU<U65X0O?AY](,T\4*<[D+/KI7S>;
M%:-<U#]N/$J4JP4-M<6SJ4$;D;HD<$Q)HCOR:(APV_S,6?'OX.'0VRC1(H0B
M"8)O-@XFL&^M*RV9GL#<G-/4]7& $K-:Q1,B,)KZ>#N@ #AF2ZP(T9'FCQ?@
M ?0R@1*'ZV]_< ^*&PVOS/?06__80_P0AG <B1^IM8G>0A\M[EZN*IU1*DQY
MW>4Q9;*B.(^>/-UQ(XQP/8%8.;1046" >FCN_H%PQE?M9U;9=MY;-R(-(+RS
M[A746D%$;"A_>[/[SL@E @4S9VJ'BCF10QQSIV,[J]AJT_T_R@R/U2I' R6A
M33/G*HGM2>\AZ%4!@R55"\Q [(8#R\<5D,00V*.7HZAD/='4G6!5!*(& 8.V
M='J](,2T=7N_P*)II93<]E?",X%]1]_LJ![90D>@1++)6;G0(F'TA]6;\40S
M1ZTN8^GMN-\E+7BL.3F!CN'4@F"O0F-OOI34WD=C]:1J7":%K[R&Q-N6(+U2
M>Q5+.ED7$"/Q<<^<FMV@@\<V=:,9R,F6HPNCW(>]N_M=3D!U/19&W>Z=3;+.
M!S(-@)<N1#M 5&V"[*OA@T"&ST%\#M$'L@L81KAEY7IO]G.;/AJ@TK@)&BT"
MDB!!HT^06I/@#Y5?3=[4G/@!^X&=T$AXDLF_].C@Q";90F7\OQ9]GW:'HI3D
M$I?8<ZMWT"D5"5-ZY6\=?@VXO::DVY[SP;$)=46U6;4HCOKK7>6Y'=/S)E5<
M\EM=UBU<'!(W^\M+^L)OFH"6!U8QU]$ WP5"MTL,"+/K)K,"]4R%Y =;PYRS
MK?<W&98S-F>\PZ /=U"C=Z9I@.[4X*I_RDF3F"-D@X.KV.8$AF6,9 +DX&+Y
MQ4SG()P[MNI(_9+)\L:EOG->ZPF'U_O 2]T@3#;&J/RP\D-=7<34@;S7JZD
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M+]F[S#P2W/=%#_23Y0FKI<C^##B._GF=]0OLYOVSYUT6P"E,H%>_OY[:0@/
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MWW00'UI7=MB?'-(L@48D&7'L#Z@L*D\!=YX1CZ"X*#9XK>U7-M#S@6Z>QCU
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M@H<![@P-YH,: ?28,CH4%  Q0++<^LZ:3'1G_+@Z?;LG)9TIB39G!4GJC0B
MATC2!9M//2Y9]HS< GD8AC38/$A4#(9,]UEKK'G%=$7$+0SA+X$I%K"APW;!
M=*WW-U2\IYJ6N29UP3F:\*_56+HP9J(] PU)+@MVC)L=&;^87G3M BUB 2^!
M(A(EIJD9#^R5@ !4I:30](N;2<=*=[%B>X>G2><&/KO0;KE,7B@+1NIR2XWW
ME3,.$BG#FTX,;M2^7SGA#(!839] @DE?X6VLL2$$:^PW+B,0PW?-'#OH>U&R
M$Q4EGI14=7</GY:%ZZ>QHI[#C%#6 :T[YE@)QB!$/)FR2-W*OF(6TIRK)QB
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MQT$6'!FQG\3EV6;=ZI'^M&O(XY3[CX0:RC:CNCN4-P1-W 7N/4PY\ODX>R:
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M@Y?\+#AI9QZHL,FR^^!"4=K B2V0BZ>D,?*POWHX73\MQNE=M:<*H3DZ27U
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M2&?OS(+$17>:S"N>B38#6F[>7!/H%H*O2H2J;T8A45[ZN,LL.C7B%1(JG#O
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MSAM3YCT2/9+=K^</O] 3LVOI[7\#NB<,^JMF3_^,T%N#_P502P,$%     @
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MN0;,:X#]Z\U,.TF@L&@OM[KBQJ(./4?#3EAV_(F3OCD3*^Y8;>0)A&]V^[T
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M7D,O;[63L_C,R%#8U34"KN7XM^=3W9K?EQL/@2]GKYA_RIO)L_CONH#Y!R4
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M34]4ER.?;&?6@1=T=OM)>$\J1Q/VJV0\)&L2';U;T.Q>+VIRL8P VV!7I@.
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M268#.@\.&-1^0M:@:*$?C56$HZ6@8>?L[GS@,@A<F&V 6A(+"N!6U!(X**@
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M"?V]N1I)B4H3H"+B?CJH0VG+*BM$9YH!$6FU4-9*4[5 _,I9@\1FC<O:0NF
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M#W,S/<8H4I\X3&9]LZZ*V$*ZGL@*LVFLHP/.4.9"[S9YGT^$W*0\H'Z!'UD
MLDRO$([ =S0QUV0RY1=X\1UUY2>@?L^OS\V(::+"L2<5 _?NG[&HJUY%8#";
M]U^V#*!.ZM_NJ Z&)&@]C#4_EXZ/L_4R[(*,U<8O0/TTR6J#=$"50>$LW'BX
M2%TDM.;EQ<?V*]%9)@>@=8HSA81\0J(#")NW9YK*@0UK56#4FI$>2@I_%TV1
M.48']%>BJ6159.L3#P/AH5\OQCOU.<]V5'L^HF&T=Q2JR>VZ.^.,(7:B P3Z
MC>Y/@M<@G^X_N[5\TF8QKR4KBD$XNF=<)V?SH'ZB+WF2'.,3 M%3$-PLA#N"
MF0J.(SE"=Q\G)YE<N"54"%8Y:(LYKWK^:6(&F]\T2<\K)4E'_F?6U-=$C"([
M4];N -)D)(XQL(_#0_*/(I<C4=S4SW0 @TF.P"UQ2TG0#_J!^^K[C@8S/,P>
M\M7*>5HU=PPXK;Y^.W,E]J%!KLV#5&Q.LN!)Q]?R)%IEKU*L(CX1Z@NL>)1"
M._'.9VAR"[SW _TS3JFCF$]F'S1:J-T#_B4!"M0R8\RT(5':O>6X8F\0KEQU
MKO+577-"@K+$Q([3BC42HUZM(+*^#]G_-?"% OD]E)"I5&?J8;TMK:YO@ 1
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MW>Q]7_\=V$'H(6*2*\R2)!.EM;T0'W4!:=<;[I([$7Y0]672@MU$4<Y=[@@
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M[V Z_VZ[INV0&Z59/W)A V6U\V@*[IA5K[71)EM!D'G9KBP4V D]H:]9Z!.
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M!%&12N02CXN2\9('7GA:'>^6_;-<.7[RNN7_[V\(_B^NZ*//_P502P,$%
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M! 0%?C7"Q,)XAI6-DXV-4X";BUO@OWS0&P'> TS/F5M8F*0 9EXF%EXF>BL
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MQ%4.*28-&8F6+K$3T%]"IR_S[TFHVB<#6QL_/' =;0@1V !:V!-TI.V)%]8
M9.(@[7YIRN'BO++V^H$FS;!"V#"XG"-2N0C>-G6X 00-=-MQ4=1*-!XN-UL/
M8>Z]D.OX!E0WL?*C3FW_(DFW&7ZT'!EQ17_9Q)Q8"AY:FZF3&L1^!KRCCDZ\
M'"VA*=(ZP3P-*J3W*^19\]2T_),%9I:&'Z=42JI#Z !K%>A<.@]2GJ*/,] G
MGL.#$3N0*//P5W%#UQQSH7=/(._6@Y<3SW+:&(KI6F+D"7(SE>WCAL%3K,>'
MU]VVZ8 @Z:5,HL50V4VCY:$;U><[8RM9YL8L5B ZI!;B$9+C#(2;)'>U+O#%
MU&U\B.2=>+:<S(&0ID[OHRV75@T<2.&,-RI&4L 9CN2*#)Q<_?4;L;.?,3%Y
M+7?#X9-WSXF,KT4"O=10FLP*'1#0Y%;9C2@O*5P>Q0Q9@%..QLRSF31_7+YT
MF,.<K%#E%@)F5Y?'@ULXKN&+4L;-N^0,U8<Z[9)]+0HZ%Q)L5ZQZ (&[VO^#
M<CON_FOF]3S.QI_N[Y:T>#+3+<9]TFZ:0),=PJS/S;Q N(^ENGAQS\+L^'75
M?=L7OY_K&S9B+6,\*MA.&L>"0FG'5R8E1KTF+ED[28*J5,T#LE]OVK4K=9BO
MYJ7SR)(2]Q4"+I,J<4\('*^WE=P+HFR?[AK=P9=]1DX'?G25;"]507_OP]Y!
M9Y+\]:O[)5P\#UA/W=E4L%9]*;8!-"XD$\FG6+JDJ/$PD28L_##)#W186R@^
M?:HXW_;@938%7:EK?B7D86M%ZKL&4>AX6Z*F]+"RGM2(0I+YTNJZ-5NU7'_G
M)RW7U)7OI])Y1#!@.W H39IP:G1'@JFXF.5C&$>UA^LWI.=O6V6QB%O$HT69
MP1/'8E0>WKUV]M%SX:/M&F?,3['T-!RE]=*82&J%T*C[^+10H<1 '.?ML9"\
MUB2]$[%]5^/NL)E&$1U(/L)!Y7WL$LRGU=6*+.LGUK)*I/0LYU(T8IR''=)Y
M+F+0]DAFTCML='@+];HN/]2\M;7?S#?DV?D/N1I0E443$Z,EHI&Y5LJQ,)4(
M_@&M1E"\H38 -7T-MW$+D90EL*V7!&*#7#<43#:?1/K<3'YRF>>SN+WFB&(,
MV-8P=.H(Q5K];J'#+I]SU,'Q[%G5.!U"YAN@2MU]R1K+:&8J$FV'#$M3'E*6
M,[#03O!5OFE0'[\Y<;-23V0YQ\CG'#EY@R9)N81?:.[COII.@NB'ZPWB3H:<
MBRGT^R+Y$6EL)?^OLJ0[6(AV:@G)23E%SJ8,G&SM(_J?R@F,4I[3>R#_W;TK
M_?!8Y)[^-6I> &3&D'.Q,EFP(EPFO<:37)QW^PW^68Q5V*G7-.EE9^<[U(\!
M^H7.Q.34BI1':4?V ZY8M=Y3"D3U>G5YK97Q1P+D.Y&SKK#3#D+FGQQWE0S=
MU&[+M^BQL$[Z<7]O\YIP^/^$6:-2T YPMH!;!.&8.J6\)5XS)TGQH1V+TX_+
M^>M>M$X^VCKYZ-(C#I0362<2(&4PR%BR&Y\S86F,O<@>5T)<&"WWB:TKTI'U
M.A5;\?Q%>FCC4=1M:IJZTJ?OC@U2[UK,G_2%*$?,AIC_6%[LBQ#4B@]..&&W
MCQGP-.(X/ET$,:\:V:E7,DL>6[801MB-$MX?$O'H["INJ-K@H@.=>[B-W2(Z
ML&WEK?R?XC9_54R\J[%KJJT5\O:?'C;!71LI[]K%#[VQLWONNV*N;,018TG[
M*LG\3GMPNU;??^T,QG!+D!WI,2=BZ_V3T*FU]S9M))<.')J;'IB1 _.>$';7
M<[IWXW/,=)1.K+!3Y\!, DN#\_"I],/"N.V;ZDK/O!5@4VZ]'+L%58AUQ7Y3
M?@*<IAT%(3,8%QWH+ZCX==*()2\S$CCU_W*1T]QH%7T2EN'VV"//?'SR)SR_
M,N&)V0DZX*7719&[UN!#S5*7]\#!CT)MY$'--:'K7[BI]4W#6>%4B0Q3MMBY
MB=\(F)<]@/][Z[,#LB/V0](CA<B[0?SRF;TY#QN7S3QB(RMSG(A71BK'E/<[
M%1_]-/U6^?;*K)>(X.:#J1:D@&H,[9@V=HW_KE!RZ4]+JPDG[TQ5,PO[];5<
MCK-O6 X],O7"\S>9]Z0B7F</;D?U 8Z[A@<J2AL,>B6,.$&/98&TO?D@#5.&
MMMG4A-925^!48:MHWX66%(EK+6T-9Z/N#;-GNS>PS+\FNL]MM_E),%#?+)E6
MI<QU_,6HCVEZQ93"H,;&3AO@.&!I2)$_0 <6K3%@/#\=0.G^N:HEUJ!(X*%(
M34K6#K?56BD?]V[.98MX!/0-8U(=Z0 H;N'^P%F%LH32!.)2X?H)7Z:;3R0$
M>(?3Y#XB<=KEWYY>KE,MTA=91CT] "ZZ"Q=R&+1L4X.J&2O=:!N@-6J:T':M
M&[:9E@1,&>_BN@8F"Y?W45CIP,K GZO]'"X,R,&72=.!#']+.M!H2*OW&@N<
M'CZ;4<VK!\1?]_50P$!L-!R8VP3N:K']BR+Y> 84:2TS2''TP-*!PR2IE5;P
MDXH8G']?V8GSW+/8J[9=>[Z%":2N&1=%HR%3<Y*+CVWNQ(2NTZ[1I*[J>\OI
M\P\NMST+\!TI+^)O3MAM *GR>+CX"^QZ$\5@0QJEZS]?\UBFHL.<$TB\[C,I
M" %(%\Z_>WQ%_AIF_WI7W2G;S_$?]XXA),[]UJFQR#+Q]X&.I2DR@KG$F0Y
MB'2 +.@]0&TC'\3!_NHLX/6[*Z->QL&-( ^]!5WJ#F61:=M8?9$.-*!3)3WA
M4Y#>H-.6T'#]<K20L9-0B35OE=9F7H#?S.7\,JI)GTE$=FE-V+J*FGXS-D@S
M27"!=HJDE@M-:54UKTL<ETW%/7LDSLKJTNOQ*LW9$.O3LD@373+UYLPO7^6_
M_21&BODCRW[DE9EE \#[/[X4I*W4B]A?V1N*CZ\Y @L+$HH\E<[\;RMR8O<(
M":^RED=KK(@EMO;Y5O"\\C0OO?\5LNG<R7*B(!$'I>7$L6=^/:^6A>0:EG^X
M'NEBWE6H[J0XN7"TUAA&/NN91.2;+R<T18H4R9@)G%M[Z\#"\><@<I\4I@.Q
M6VU3&Q:,,*A9_6^E&):%C3'%YG<]GQ1?VW\I$37(_LP/L5Z^8'%@3_WQ'>Z'
MU _/I(9VY*@%CT5JRF+FCSO#3[;H\:IKBJ7O%B.(;P==5)!,5]W<\YIR)\06
M&UJ(>=]B#9]?9XT>9GG[ GYFE@[8TP&.Y09A0GRKI%S]D"WA9,[[A/ZE&AMT
M0L7DTX#F;^QZKN?'@C2#_VY.. E-!Z3:4%0X0QTL/AC7W15>E(OXBY.GF(89
M/,^#O/MR>XIWHJAMW#)"T!LA@WUKNRBG1!/4#*?NTP'*(3BAN#<2F %CC1?A
M4XQ6&COH@.B?:ZN+Z8?_]$36_^SQHBD>TM.^%B,]P:3?"E([>M]WPLU',X,.
MGOKWE$N*KQD2(+%1-.%=[E4LU;35E!RS)2YJJ?;US*&XCO(7E5-E#R81XCZB
MN2TH@26BSOU(_7R7JP]WSQG=X;F=O*1YH>/30U)@>2T/WU5LE,L%U;3-=8O'
MYS>#%D26+%6;$$+.:?($Z?%E<D-VP1+JF=W-C3+XEQL_WUR<H>2Q3&:Y2\FA
M=(!(O.$85[-YY9LZ8VR!@71SW(3E^)3%A 1DUX;[]73IK597P(OI9A<J@(6%
MY:6^%DBB"V_8MDM.R\Z]CHT?*B[2'#]+)KV'M_Z\];5;TF^3B4/CO#4"KXI=
MKQ1$OW:='[0G^;H%]'\4$GJ3,MP>I#0CIF-8J;)19L2!#% ?7!@,@."^RPX7
M>^GR,&T5$S?H@.E0$)L?]U\%!%;=<2;5HZ5!!=\;FPM]$6AZ9S@U89VFM#GV
MLC^YJJGGA\B# M&[\PECONL^GJ;O6PB&;1?T9]K<V*VD%N&;AT^B9X]WX#'.
MTZ C3I*G\ FI^<O)ELDJ.ZV/LTO?SV5IAA5[9K/Y[%&^.=HXCB2>=0OT4_E2
MTC^@+1@Q^KN",7U/@9'R<<C044E)9#/M4 WA37)89D+E^;$/8@X(,YYRO_BZ
MZ+.\M1G12=<%P,TWE[3X_C4)4L'X79A]\\;.._VP(<X^2'DC B8AJK+V<Y2_
M,-_+T<<)^[0R27,U(FU&MM*OD^2&3X"SKZB.S7_!J6T(.F.,BDKJZ@]FGKK:
M>>,!P)1F %6,]$0*D,1P"8EYT,I6(XLEXCO9[RJLM1[*GT_;+,WRU/54,?L]
MEUM"L%)NX1=:+SU]=VTXJ\[A\,DH-CO$<FZLEH2&._BH;06RL;+$TEGUB@Q-
M.FUTSF52MTD.]%MCZ$]=\[4"-6O\>A(N6J-0Q?^HBMC%XV^$#XCH21P^Q8)S
MAD=H'A]5/YG1]@FZ<G]@\&OSYCI7F1>/EY?X/A]'8-7[,[N ZXI%C5OKE, 4
M:<9@1#' ,- 1Q7UKK$G]0M410Z=.KIO&(EW[/WH"S;SP^RVF%1>%/!9-^,:^
MGW-^:,TFQ[ES=ZP0_6K[LDIG><*@B]B#"/6JC4/7OSW8YM:2#"086V!.?BDO
M3VRA6843WW,1I\I/-T[L5MB"PYQ'AM85!ZN045.;9RW@&"J:%FI5!G>'!0=)
M: L8L;N]5M?.@1KK(8U'-AX/%1X3B<-AFS.I>@57O+-<"AXV^=I?L1SK?3F3
M</%K35J(Z-;4V)F9I@HTIU>^NK_SR8TP0=,UH^;LWR@M1SLTG+-(MC+AJD'*
MLOB?\NQAHWDNTE['"J'31WR++@?VVDKZK%U6'I]G9%+MI\_^9V+ZK\MS$.A1
M51WI_(R:OQR\PEHONU>JDK/^P]JB<#7J C6E/,_-BTOL,0XNZ/0N)TWUQXJW
MF\!-+9'9/!&)\U9TH$/,C9T.V#VT(GVQ1+8@#N6N7HDO[VXY<<^V8E(LYMN!
M8C4L/*:<>MW<0IZEC:S:&BUT^;S:5^V&+#<1FHSTP9G%S" -<G6@#\XM3%T)
M)\?-<W]DNG1XX[40OCNV[EV0TIM##'VG#46V31TFY;:!CRC+V>$#TTJF]WVE
MJJMJ+?)PU8ZQFT'KK*O&6X]>.+#459*JL7)%/L8#,Z-2JF,.'M[9#T^HL5LH
M1M<%.E]O:M#HUSRVU!>(7;O'?6],=7,""_:J/Z".Z4M&-$X==4I3($0,*<_A
MB5$%A5M6NBJ;EMKPYVVW+N2)9?;^%/]@:HM/Q-ZIB77>A4E]?M7\PHE=(*9%
MM^J>@$Z&3X(1QZ7M)2W)5]@@782Z12S%A$&#%&I%M_K"1?F@\+8&^?*8Y?E5
MW[<7]Q,GIY:ISOV+_^5,W=&@3EHPQ=^OL:N1+'TT_/&G]""L$<.\379EF24G
M?\'#<:!6Q:.E\&:KZ:M8AZ_\\X%Y>N_&7PZI( BU.,-7Q6L; 2IPG%PJR]U*
MSSC]JD<O;(&P=NQWA-^V8AB83UV5 &[&,U+UB.VHY["F[EA6KTCBJ]&@RXJ1
MX(/E&L[M8VYO M0^_3!;N9B LALE?V1V.!']^C) '67U$N@+G>2H'E#WSW<V
MIU7G6I/BUKL>[Q]..M@B;L3>B\O:X/-/_D&*QTNW@ 1W)D#&!  =6]86RS<Y
M1GXH]?ZB)DE'I/U2#I1KFB.D001:L0+![]3W?-B]F#GX,+LFSO.,V/-CG=^N
MDD6![<B_)T%X%(,+G36G W\(3D:\_N/)WR.6S>6Z0?E(T8GR^LK(Y;&KX9%/
M#A7ML&=75D8.LH8=&#WUENW^U:"L_H-QD6RN&8S[S_TNIA5(H1QMG)HGH=J4
MT^XYNM,[WK0Q_6R9I];C<L,._T:Z>"J=1XW4PR#VW$M^SX?6RIR[NY,B3XA^
M:U9^=BCU8XR!;T>+O]H4+\5V*.!J40]V38@X9)@\-G5[P)6ER[/P?D* ;6C'
MBA5HC<DC0P:%?4)0?%5,,<S1/3&HJ_'QZ75GA9_,]_UBY()*"6[! 6HHLQ5K
M?I)+D6*$L5#"ZJB+:$AL&.4#G@/2'*29FYDBIJ03&C9ZC$^#^X6F+.D+%LX!
M1=SIWXG67_4+W3_3*"I[2E_\E )[O]ZT73_'8^WG"5/BZOP^J&6RLM\VR&TP
M=G+IX.<'G+OXUL<EL1_X1\LH; 3%%B2_YQ(JX')><0:KXEQ7B)V=1FDATWR0
M'!1"T^T3AM>[T8',E<^R@IW01[PS?4*SMO,,C3W@N1%EZO$]0)7 W596Q$H8
M4SOQ^OG]F;R"$-_9K)_MY=HZ[S]I1J"K5E11N^$+.CLT/&5E\ZMBY.0%AV$D
MOQ-XES2$QCI!NVEA+KHT6C(9L0/+I5 @[GOA# T?3@>0?/L#Y,1Z>!WXRN\M
M0!*0^'+U)W3@^L4L.@ W /VY]ET0O(#;?T6%M="!OHC 1:K^X8_3YV17[J#Z
M(#\V<+*1*FYO)D6^U&-0KD5/DEZUG @IX,[-0_5_(KA_/_TH)T/6OP!I'V=_
MKC?O5MVQ&7N70'[JM<A3J$OD8YEU#]3]"0\I-H2T-P$BC+XX\"0F67:@W/9<
MSUQ[OS?O^'PG12Z3Q()#2D!;L*NBB%;PX0XL@E=Y4_IA.S;H#2B^:D> H4S_
M!<@'1!,T^]II&J3$HJL>,DEYI#-C<V?7R@K\8UVWOMWG>U=Q86H]DLR#%8KW
MRB!=F6Q?:$G0%-Y\^,F1["MICK+M\-L;:A\SJ*2<E7?QG(H4E8PGNKS0N&?!
M-6XUV/+\"!"R\%9795NV:4J$#C0[8KMRX;R.M)-5P=YA%O47%16.M9#<ET\Q
M)W:LZ;=> ;TT?H ?2J__7!\V[S";9*/WF'7#Y.GT(=!@(46)%)\'79Z';I2!
M5T,?FD MUO14DZ,'@HR')DOACJE\&O98E_&>0'M[P??=GEUY7:63,TSA[V<]
M@A_"CIDB85T)N^9K/VO6AL=<JDN&WND97&E^ZF,$@NVQ +KI,]E X'E&:#,Q
M"@?/7TSF_!^:X<$%P G&>B3?8A+DSHAIMX$WS@*ZGMK<P7EC(D$6DUY4+]U&
M9J_U=-E>,_E*G.9NOW32Y)'&<[D>L /RH*/Y2,>K'1=;W5K,ZK9_UY,K7F52
M5T]#B<$_I &O'@\D"^P$(WR$6U,F>)H;N*H'O HL;':%,S%',A?619C:-YP
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M'H:&2*;*H4(92AO!8SB"K,*#]D,A!#JPED<R_ -0-:Y8]_T1Q1KLJ.=F^>A
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M^J;EA@L; (K^L**;_''\-VNO++9$K\&7<1?.F\+_Z'C093#3 HT?Q1/01P=
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MG//]GNLZUW7.^?W.^?U^?SR?OS[7?3V?Y_K<]_UZ/_?SW"24>6?G\.48UOH
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MT*<_0"27!1K>YCLHDL9ZJJ9R?*\'\HO7'J/VC. ,ZWKW5 )Y^)QW6I*[%F[
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MJ.?#?"G59*04>%Z)+S)6)Q#.C\,\8EZ[E<!_U3E&_=C3QPRZBT VN/")12$
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M0[(>_2A@Q.<.4*\<*2';QD&/N/1S-D\#3CX*R?_%5@0NG\Y\_[N"ZP]XM(K
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M,WP(@D9;MB!^GU$$ZYX4=STHZ55-_\RP1Q<7J54?LDR+LYUI3UB*F*FO.J+
M%MX!D,9NAW6VH,7GJ7PYN._Y/3D$Q,J)3DJQ8VL5F*4+([<.KK:\Y\U0*\1L
MI-3<0R:2QRR9WD8&\J=P_<*W+*Q@6K>X9Y6X[PX,"N, 3_X;3Y^Z$IFJD/WW
M80,NSE#)_];XOV,KG N*NX@2CH8X*$[-B%G;(L,@OL0$11E2/W/8B??[O'*Y
ML"S4Z#M DB<$+JE,YQ;\-^ 'X_0$"8VUDQ#.AU,U6*3X[I'=L 8@=&/MZ-WE
M48)_Q,,5[,*^*=A#79.97_*ZMA[Y_DE*,>E[-X#:6]E1BD"C4-*3^M)I2?N'
M]GN9''.3+C%P9BU6K\%GED]NA>5F*XU56$6B;FEV;^EG$2,69$-;&4@50ZI"
M)2F$[B.OG9OJN $$EHLW9;U=^OE$J&'(Z]<NPO@IBFV^/ /97$I6EOXF _C
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MPKM@1,ILD9;HB/4L.[[G;7R/2RC:UD:U<6QH<V?<*:W)7U2.8WN\LP/\V6,
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M(]S/X]6.*=%0.#EMM3UC48PI@D:(I/!F/"TI4^F9/03R+>Z=-PUIYD+Y0LX
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M5Z'M.4']R-_E5\'&'1F2R\GP;F(S-XJY <&(-6V.)"_NK*1^$(I)QF=[ !
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MFU%01PZE+5<=G.NTYFP=Z:KX]8[^Y9W_?FZ]C2#:@1S'0["Y\;?1O(@3@H:
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MB_<$T,T\U(&];X@0I0"^KO*NB#SS0(.:GR*%(IOC-@YBDY]@5_^3K0*1GW:
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M5-.?:CL9K'8=A5[33U4)2AKVF-!/N^V[+PO.+I$.,IB+C/"NN<A@P#%(]J[
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M*H5-;2W#00<[E6%>C4(+QE 'H0T\#\1BY*MMDL@,V'2?L\HZD!1<"X:%]MM
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M$76*X>J7.\Q*A5\C\)D!V>M-?4-WI3:V)<$[7YY@61<5!%'%O'J"/0X5]O(
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MJBB(Y(; J^F5UXZB/W@I]N5P=R#]Q*I2F*(KC8W4YO?&60A2$W3H%P#LHD/
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M^I;FDV/BI486?)JSF#!;Y3U<P]]Z97_HBO6BE V5*+T.>MXD%U1K4S7*ZC@
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M ZDLS^SY:);T.XM?<LFNY4CB *83AOR?YS,FCM>PRH,)6K2U0CUL2A&"^I.
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M;[C=09>LQ&()<("S6_64AL19D>],C-X0:..1QGS._YO?_B]>A_1B]]'W^OX
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M>5)9]$!2Z.Q9E_,/1[5+&9X_IV=:Q5BM7*G;\^Y'N>\<(2(D1;?S-O  ) O
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MGDH7:FG@!],Z!B#)-H^$^7D[4L9P'&#UDZVJ^(#M%)KKXA%8&WT#);\8&KX
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MB'(LK1J?(1NG-B4Z+;J6YQ;V%C,_U@=V>0%<5,;<ES3%G#I<G$!:"J<&?F;
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MV^0Y_[NAZ8-P"G#,FL)U#H!= L6Y4K5B;''<0PD!/T'&'FON@\+)-8[C@,'
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M$O25\3N.S38#!YA_JL<1I?Z5<Q^A]K"*1R&@C8D?F9$+9'$'Q\)(LXT3ELK
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M6!\LH%=QND3@$X3%/?M@$[JQN_ C9^'QUT@QP>0<,)/O4792QG0.B'Y"AZ'
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M2>P<0.N!H.$4Z[7M^ 2Q'NU,*I*9J;+.#+=0>9=JLGLY R?/1H;!1I(LA[C
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MZISI1$$[<TBQQ%@9W!#Q=O[8^6>/DS9\,<8-AJUGQ6I,:Y&CZK!*["$XR;:
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M5IL GP^HJ4 =<'KB\M5]9;[*-J(/V.@\RX1;HDRF:IOYH+#\"SIN<V&OY)Q
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M='3,96VS_D!R'M/R$I0@LCI^';I?Y_3Q/LA;_G;B-)!;WRBJKYIT')#8B=9
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M'PU'KOX;N/M_>",Z__;_ %!+ P04    " #UC)A8Z0ZT<ZRN  "6PP  &
M &-V86,M,C R,S$R,S%X,C!F,#(X+FIP9^R\=UB3:Y<^&HH@79!>5:H@($A1
MJH)T 1'I)2K2#:$(A!H5Z4U00*G2!%$("*%#I(,(2(V$$A)Z3Z@!0OAE[V_F
MS'Q[9O8WYYP_SWG(NGBO*T_>9Y5[K76O\%Z<_3Z; UPPU#70!5!0 @ 4Y!_
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M<]<735@4@5UY7$39N7)?:3Z+5LB^0:%-(3R*-FV& =1+S\)36"E0S-&&"O7
MS2!C+P]SHVT=[.]-'.S,3/:QW_CQ,35FX5'VU4N!/1R]$.C!FVJ\2618(/@9
MRJ&KHFR">NV"8>6W6&*E-L5A<HG7GO1S('+?.Q@*1#JA5BI8+ A3&'6^3N-"
M^]D?XDE/ZS(7+[G4O;(\*=VA@%LO>(=YZ!)Z, B"8=[M.*.FK-(MG>SJ*91:
M.M[$)V;V]G6^E+Q[NUK(1U-^]065:J#Y'"',00RJHLX7M*G]59^5H4^JJKU
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M9W0&L(,?7VRJVX>? <R'5V!J8^'J$*6..R.*UOMT_N?A3W326A*8%';23LX
M353"X-"]"E,,L.<+3'"2H(5=WK"$3F4F??:H-*Q(;0[H.M@0R*)G\")*T&S
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M10E72#69)CAR)FH5(24+7YQ[]X*%&)#S5R\HFJ3I3IF%E!QZ(.0M;]"GY>C
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MK9\P/Y?HV14@*$@N81PM2U\^>J1X^/QVZ%_4>\YUN1 =43.'T^_V_+FMP4!
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MJS*3?];]R57M682&3R9#RA2S/<F"X-!,7_C$Q7XT[C"3SH(L#A 0'\V_;%3
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MOYUD 6^I.044=K @[\N_[[ CA,A9X2AOUWI-=:$&!R6B/SZDRP0MD5HX4MY
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MT%L<Y2Q(MRYBW[J69GFH;85ANGRWXO81]!H6!45W#66@"1/FBJ^Q%RA"SL$
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M7WE58I/F#UWCA'.K'#GTKJ)R$>^L4JH8E_#,\*?YC88TQ]Q:LO>N3P(CB!=
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MM+-T&W0+>S]\L0H*@E*'+WWI+;.?ANL"_(D$JE 3@V/=2CWE!?(:R@65]S=
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M>]5JQE$Y0CF=[W0:V^]GO74>IA+X5@)9^S(Y=KC:MQP::,G=Q]@Q'@JOHV6
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M1X]T,_425G:_VK];W?3*OAUA>]33K\H7O]0WWWU0=(1\]+GTJ,#VS]SX#T"
MD6G:O(E))36IF/Z+JGJM-3$]G9F[\?.A*)N_ R9/,KI*LW?39N4GB/-BP\E$
M=!28AK&/F4H,^G^&NEX U"\M=TEP9D I66"&!L2<*,[0>11[HD^GKB+KOF:F
M/(V?S]LCE@P$I6'Y-'NJ4[=TP#C-1R_6(F>*)Y^T2-P6TY%*%!6T/1O:A!=8
M3OZ&9,2 +,$2#'#Y[$86I%*O2]J?DWX+-%9GYX6_;F'\YN1ODF:R>-;68.%
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MO/;Y;_"SN0S],]Y\<<6M]&X(Z 4FVX+A3*7._"5=^"2',F0G>02\:X>$&D<
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M[=Q- 4N;J8^$@W4[/AC5741,EY2N1"_/!*C'+0&@ *S^AP#T-V%F^[$@<-
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MJ;TY9>XAZW7< 9?S.G=G8*PQ(R,6M3>YFU=AG GC]YPZ'1Y #2QD]:Q8$.@
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MIV""9<RF\]*MLVLG?MP+WZ#G\R!QEMRN)D:U\Z.HS+FC1UXD'9;W7_5N">B
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M0U7Q9R*WHM<[9T*F8^H 3_OYXM)M<.:_7V,S-86*?8@S#Q?&3LKKK0@)!M
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MC2;";8WFT#4:<*8LR;MA%BEC-7,99VW8^KTSI'2VB=-G^.=8XT<A!Y'*M&X
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MDR93JDT3<R<:^SI#>DC2L=,?6'"IW^[-EM1L84S<46[RJ5SRPW<761)NI<A
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MJ+]M_T+V\GJ6:&(1X/F<OA*/*,%H-.':;Z;:(:^^::X)UYZ?IL.++]_8^)>
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MR #_'+G2]17E-TJO&_"*Z_D<,)NUP,[ :'S25Y]"[T$ VP6<SPO:V72Q/82
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M,W]@=V]556@7:QKAVC/!UMF$"P?R=(QU3L@K'L%4Q!!P=Y>/Q-TW=KKQK6F
M>ZBVAI)<[R%"\2 /CNUF%151<')HM;K&>(XEOMN']I\Q)J9L231"RF#-.BJ&
MNV]JF4B$MB8[5IJTN$B25W+2JD[YVS;>S\/,]W%[TE2Z"\&'9PY3HC=-0+1=
MR,F7J>$9U'4;4X+97FJH!X_[F+J*J,91H>0'5R]K7J#M+T).^1"1A?0N!B!>
MGLK:LNB4=J"&-+!=%.(S_3)^F2#:T/E.R;F!CVECFI]DLYM'5W5/FF"NY86+
MA[^GG:6^XNS*D<KT<^N$YXSD^D2SV'88F1_T6XRUZ\;L5NE*^IK@I5L[ ATY
MQ5?:,)S>^3IJY6?N[B^MCW&M@*^NK5;P?^[VG->#I+^T_J8!*=N,/+;[@2[N
MR^WT24L=@]^'O8_ZIGOCW87"$$V\E[]UEPI]#"9>0&>?1PHZP]F-\4;:5W&<
MXPE),0KW!;[?K EZ4'M4]&$76#Y6(ZC)!$.B(MFZ&54FW8S9B]"M[]'6R:2=
MZ>,UKT^T*7>='A#+L%5/9_&X?EJ(LED$L68 SY[ZDNG[:)":TN*RV-8T[02D
M.D6$M2IBZ/3PLUN5%LFW8MZD<_6>E%W#+5(&J6UXZ,A; B:B?(7K@S"X.U<*
M)/K* W9/FIQ6.RW]V2;2[Z"7T 4O%9H)S![!-!@D20UN2EB$'.H*$QQPJJCN
M]RB[P@"JHJ=^-%Z UWI9Y]0!_JG\) C1<L>1=H[Z< HE>';2C,\UI4!<.%RJ
MJM>C%BJ/'6G=AW_X\+/<[=DH9GO_9*(K69J CJD_Z,N*W^JM52RDUC2V$PI-
M+ 9ON+]^'Y4/D5)EN3W-I4MO?:*++1Z4VS!X5;#\OMKF7>N,$#/QYN!E+8C;
MI^7<K-<A5Y2-Y_8&6=)8J6,$S,@*Q8+:1JA3*KA/T^=J'I&;\<N0VJ=LPF-D
M^3!.4]+?$V;F&TN))1O,$H^R-@G$=-"YQPP;$MV]JEL1*]#V;DY433OAB6Y1
M"6A1]J:GJ\_>[QP7PV_&*2><ECA6:#UUO+5TRD&$PDM5\<0'/KI+,B4?GL$%
MHH^92!*]H8E)YU0.,6V>6'RUCL[#N'+A+*9B&\9<OM2+#DKV+\G-]O^L'J3!
M;Z9W!KK,;L56' ^Y?(N)Q4\.^2(%V&E-%ZB8(>'8IC3.:C<=)-<J>-:(>:9M
MS$Z48F)GJ:FD,#TR_U!EMF\H85D99MXG<9<X<_3%MTROG 'QT-J.R:YB5X&0
M('G$S:$-03G%%36QRXI$V4&%%._HR'8.I:F=R.FR$,.K;75 H*P!XB%IDY).
M#GT[]?G1Q*&ZY9KW$[Y@4;9]MKISCOXMD/(M^D4H12%*A/I$(M9NE(1M04><
M<IO8[YWJ;M.G\,CLA4 -Q*CR$VY(2953]:;S6-*1O2SQBWH0RUX8C^\M"IJ:
M.*7C8HI=]Q QK^N]7]Y<0O\2>>X6US!G]\LU]C$&L,BO(J5.W+J(':F>2=GN
MBO6[)49L33W>;"H\AHL[_B(^^IN1A,2\G@#_X%IY\(W)R=E]Z94#'@HS"3(*
M[U-LZ-N&1YQAN6*RTQ,C] 485]#W"5X&4%9KCA3J+W?PDD"/5Z40#E7ML5CH
M&&":=[0G25P8J(60H9//M[$A=TB2E91-STZTOO\F&\'/L3?JRN4/J0F'A)%O
M3RM-BM]E7L'!7X>>>YOL*S2:YKF.%B5#B$<A8=HJA%3'E2_B)TIBSU>Z7AL;
MQBL,GS:P^5;*FW!VOE^JEHOR@(IR+0@:Q$55YT1)#VW4(9OBC8]G&&C9V5^6
M<CH2(@8P\0+%.VW:/:PXB69AVZK#4U=+-?96[*]='[?O%^IRZRS?J)NZ],E,
MM)-]RVO_#Z4+]/DV?2+L$-4$/[*;2C-)=T084#TSW8:V*R/I':Z$Q3--:M-U
MG6.C:IG&0O1#W\/C^X,=ARGM) 9 J?D4:_I=75>K9]EY0)[WN<9C#_&.J,>W
M1 NB HC7U].Y_/X,<OYNS%LF7RWSVR,_P/%SZFX<+RK;M;I8PJ3VR.26XE<&
M\ @[R0!HDKKPY]Z3GZCUHVW"89'3GWII]KNEDL)W2OT8@-?E!Z? 7KS1"V-%
M/-K-USV&4"%//-,]Y!LT+=+,CL\M-X4UFV09YVEW1W^.8#D29]2.(*?$!6$G
MN+-V4\L"8<TE=C1-\G1K[?9%P\ ,TX=2'P5-OU&&TD-_C(:Q3'JH,FUZ'#VR
MQ[B!?PL[B:'*N,30SI#RIPZ_GY(7%C.!D:[UG'5F +?<>97>AJB<,SX1DY.R
M#N._'M0+WX'ZSMIC:^WQFH7>D'V.;J>0+B/M'!2>%X,C_,$(L+*I %,BL)OI
M7*6#P<!9%G%"$D:U7I#>"SNLRQK47,^,!?>7=+-UFDQU91_B]*;QT82>VI)P
MR9KXUUMA,4I+LKW=Q(=DV4EXK'; 9&SX+4.R<V:FKT.M\:W<NSUJ)16GM#\>
M2FRU>3C'"01V&@0%^%I0"JGXG 5(Z7(A0<>Z<3LTA RS-@H)B4Z4&SJ\=&L+
MT3GL/"I]_8&!D^\$98U:0X"\$->-Q2_'SLS7\PY)]KWO[3^7LK'!R_LRKG;!
MD^WXY7U:5UCGCU\;4+.7/RX1,/I9KL^0.]/LB-YW?YEN"R*,S[>2DD+M)71'
M*_FR?SDUYRB<!F=M(PA=J'-;-?90:+@="T2](ZDX6I.9*6\'ZD_1P<>]GW:3
MP  XYE*&RC6:3ZL&O)B-;CXPYW)6VZW@0 6?MZ07V+AP>5*%=X[3DDS\F!TO
MU(S_,-)N@5VMTT/'0?'^""<JGCQ%, L.$EP0%R<5)4Y*1XS[>==<^)Q$?\PR
M]4Q=FL5EV!_+3D#QNU="RPQ;HV7-^E7E%5L?8[@DJA.;N0NBB-()E_+CAD>?
MC!H!P<%@WW7[$GKMF8Z!?-!MA"#U"WD*K[@D=I.L.W&M3]L\PQ7+_?U>47J2
M_43Q;I[-\J6$4M&XBX<"9. 7M^&3&D2-@J >$&+8NN 3[V@T$IE-RZ!PFTV3
MAP'*;.KYLX*63OLW+/0@QM<7*JQ\KMB;^;!H\+XSX$O8ZP<=8TVD6N9M25/2
MR,>+DG?LZ-TICW#[WGXT1?IX%4^,R;XA*HF(-NL#;)O[:B'-$Q65;<6D&H)&
M<ZH"\L 7?#<S-7<.>UC%MN;Z6.N="#5@ECU6T\L_+5"&>;TZ8FJ4P/> =APF
M8G)O'$;16F@=N7R9XYAI%<T3QC&/K$"UFFHTZ+)1VPLP80JUS(1 ;U4T]0*Q
M\ U</L/G)'K69>;F,Z,6("C4?N&QCX_UX1X'?;7.>NVY6W$J;6EOG_P,4C7-
MLQT=UW>5'U :N\06P1K'^D!KTEMMJRH' 4^>A+0P@%$SPO'R9$I(U^MJI?+R
MN+A"N2ZR8<UN7-^>P*=Y\_DTP\^[10S !<:#N#A4%NTT>[574<WD;IF]U5,/
M@F^2O@C/Y54F08GQ)U#3N^CO'?!1!C %C?*V[^:AFC05?IP[7-T_C XE/A+*
M<?6(I]2\;7B</^ER_PRVK'OG+,*5W$TTG<*$T-F"FQY;"1].S5G8$^BDH7R^
MI$W$Z+/%FOKU&,\(8.=DQ.H$SH)P"75 ]Y"[^-%@6'^MFL_!YE &8%$9\.+5
MR),#$HX.L7JL_EO021_B%S)3D 2UK:E>\ZEWH88)J98N659+_QJHX'=8<JSR
MF[-D_F.PDK10/KID^T'OU81BNSQ%@QX]U:B:R]0Q*[=#M\,B,3Q!)Q#N)-C2
M!EF@52L[5%L-33M;DGBIMVS4RI8(Q+^$)Y]&Y&H*+D9L%\%QI:W<M*N[F=I:
MQ_KI+9.<)V7'I#<- \[HQ2":4*_O1 .![@_S;$=^?(%[^G#P=GGR737B_Z ;
MP05K+&"UDMS#)O; WWHFK8IL8DOMGD(/][?:33[3L;>NJD[Q+K]:'#H\></_
MP<G9I4H".AKGTV*&.W,MTK*?9@G'$QW)*ZK2MG8F':]"'[)8W7G]XLK70_Q@
MP>\[&>-'* ^923&(D-R;9GB#7V_!6$=V<F)$@]) 7FE1C/"_'#(5R^-J=R$3
M4:I*YZ[M<2FN>5%$S!!Z1[AT@[<!G8YQLTJ&13;H[E6N%49&:I\52\OXZCEC
MUR+RG<QS1M/ @ABO)S[%T?OC?$+SHN1]9MF/7R4&A ,1L^0UPGWT))K/59>?
MY%BE]HHF[((;/=^'@.YFR<1Z&HVUW[')/',QQNN!9U_5REYZ3Y 6%9N)D.O7
MABJ@\('PYFK1[:&<W&XX)23D9KS3";[;44F/NZ6?ZD&L>F%"CD&#CII]=,B\
MN@\[_VQ$N2*?F_"A@4>=JMW33>X=%RM&0V>/Q*C$9-<E4URHD5,0L?DTB>"6
M;>\?IMDP.2OAK/%W]X3I^Z+M/9\7X[ZU]$Q.$EGK@ #.,6+=\Z [G<U6Y%F1
MZ0>94 OCA[EV(PVE9@\Y#E4H22;LM4A[ET+M)SQ/DZ F@DE[+L*,U8XZT33.
M5EQB4U:H?\W=AJ]#I$,R0XE><HY/1KX!%^AN88@A31!5R $-E.J85,GZ_2#D
M5MFYW'VN*CY)2>6RT_%G\9_33=,I((J"R;)>^:9_0HA%-/B*PP1N?@[M_9"S
MI+C!]=T1Z?Z4K;<4/VI6X"3FV6.2208UK/74\.)V1:RKU)M#U:\\"I>G8XXM
M?5?>\R3]YZR'%PKB5$M>:7.0EZ\]JM%L$H!D>]N!874<$[G0;V<,]3D]ZWYI
M^#;.W^.T*A-%=3.)4C'CEQ,CR*I[.X8?J=)BJ)[C H>+KH[IB_*49%SL PKL
MEY_XBU+084&BAJYD3?H^JK0]I@J+4!WR+Q_<C?Z>(*-Q2BMCU"0QF?N^;+MF
MJWM//9<ONQEYH@D3#78.]/<2JHL1V7+YS8?#KU*7;JW>3%/B33 ZU7$4]_ 5
MCM4-V,Z+6(.,O&W%,@#NH#U4Z6;A_*WJK*%WD=Z*M(U7*B(8&EM<Y91CJMY>
M/O-_/?PJ7]0#OB8M$,%'D/!DRB87(?#P(%%>TG;XO 2R5D@+TEHG%0&0HJ&4
M$U3;[,J8R4C#=W/C:BR+PA+7,<,? K\\#S_L*?),6>B!@15)8,EA<F4/K$D&
MJVU>.&R/Z[SCGN6VW5R*.\L1_WK$2OE!D-41E]/H=)ETKM>U*@R 995JC8^,
MY3)F7]PTIP9<H??T>125NZ:):'0]_N W6JD[F#4%'3;#8R-K;Q91G[&G(IL2
MJ$\KW:U2Q#_*%]9G!+SA-K-(3%!ZA^U]=(7UQ2(#*-%XMH&)5J*9A2[:]"$N
M].K#?:L#UUKVKGO>.'8I.%30DL4'<*[21$ZF8=BFR2(3K[T],]MS&8 [-!1K
M'N<:[9TZ[I+XSGM63"=_/D^&>1*&0U..DEU:X.'CDH.U$I,K^YL.E]X22UBT
M6/2I>*BXW*C2[7%(Z=NUG^A;3^/<1U1AP^Z- M ]0:*^O,W]/\86Q3DJ]G0T
M:UWO=GW(LF1BU*O\+D0N:+X;<*Y/RGBBBTRFG""IYY!V;$@Q5;G4R.;'=N4_
M!))][+(+Y2HYR,C\)I=I9IU]*@YO=M.TQ8,471D 3WWW0P; IA,3\^CTG1U]
M/Z?1GIQS@=O8[%X]B#;7L#[^'.W8)^JC:H^%N[C'Z=N%(=_&ORH0%>P+XCM2
M&W8>?12A2)+$0/HK3>HJ1Q*X#HW^<$O:KJWT3_LH5\FES<R-V,+K+9U66Q?C
M8R*(2^W&UXH0%*.JD<W#:+54D>8ALOV7!]MW=IK$EJZ4O(RY _$+,F#Q84Y9
MZ^8(:O=_U4W$$Y#1N(W09/=,PYMB%='\95FS*9,7BLN;OUW;>\:'Z9F_?. =
M ^ &=>6+/[P9QNHN+C3$8ZQ:9S56>/^JM$R+2)&@EVQGF>*(-)X!A'FOA*;4
MI182QA$Z)0E-^O*/?QKR9DJP"FUU8;53*/XRS%WUO#16$OI+M$6K5ECHY.?0
MV1;_#RFM'UQ2/W ^6/K><G8G4^'' 3)J]!;%9@CJ!N%&G"JN+.L7:,*IY\+5
M A8_1OSP$W46'#CQ0T3T9TSYA@,?TT^D( -PYMJ+<"\C30[B:_N]H9P51(A5
MGX(=;KGCR7Y#QV:F+U,17_J03O!085@CDL^7J6RQ9NQ,\UI@ODU]38V?(ERZ
M"R][\;(/\]<V8':H;B$"V!K%(Y>D25B\691J-]]\82','1?X,@5A[9^4(S?;
M[AE=8S,)G!9DYM?I7M(DU:],3M!DA>3*N:@&F/*NRFGV>1:,JUQGZE:7<EO$
M]H$(@&I/^;P;K6U-#B 491(@[+[ZC8EO=]7/2!2,@6FI<:;AY"7R.?5+>7N(
MW=HWR(ZO)E>&S1I==W2HO/B5R.RW5P9K%;+=/1Y>>D/,J?SL9**J<%!O5E#'
MLZ\>!29E8")%FJ2;0YIJ$>?$EIOQ^":;D25&=79;"_--5(D_C21?R+K\9 J[
MYU(74!&==39]CJ)U)_=.><FS,W>#1>->O+>6Q@"6WV289V$B]$8H!\UO"L)'
M?;;N;A5+\&U<H&@%Y<C7E8\^ 7P,)*2?$HEF9-22/*F_]7$02\3YP;(.]+X1
MA;?9"\+WWTL*0.\PBYM\S9'3U-[X.;D&TP=S7'=^XE-;8Z$B2*;"Z<)GLQTA
M'+[/: L^YAT!$M^2(2<.)O 8'<F(7\^M%PYJ9 "<08>I18J\KIA1Z^J%^017
M>;_<!:^N;N:BOE-MS$^ !D'T^[ET+I2:V3 <'_J1I(O%V]O!6O =.J;ED<82
MM<BRT3&!QVL\^MVVHK>R.:W 6NO$Q>X;T?IM?+:%KL;%CQI6<'9X[(#M]4O0
ME6IO$OW:=)I54"PD4,@ \,)PZ I2?297GJYWL_G:-;OBI%(AR1Q'(R%7;6,E
M$P? 37.0=C"M:X7@$^S]UM[!&A\6F>8^Y[06T0D__O78\G NY$&QLFQPW/68
M!FQ%KYZX)AX^$ME$%\86>"_6P1S)5L4W;WIFXSK0"V8/(N$GG_1Z0!5.I;L(
M;73Z09LF1AXV#Z'X:$?S8/-Q5'A3&F]MVG(?#LKS8^'%3GR\Q#,A"8/*6 YC
MH5O#GC '4+N&R\ZI.3O#%XZ;%\@"X64ZXB8K1"'$F1RW!(.<VA9:JZ[-7,&/
MERPGVJ=2-CS@)L+C\7XW[M^_U_+=E/MSZ<L653^(GZC7!_^(.@/ 3Z )/9+8
M.''P$>K0O/HF;KSX@WN'3'W_1NI%D]S;K@]GZH>T55P2Q]^3H$MU>,Q>W\CS
M@S ;[,9TCP8#N#F\J!7YPWX^(*[UDA$R\J:,4(F>)'-G@!@?@(V^<[7H_< &
MAS*G5P]"I:>P_HC9E$QAA+N%C4)*5^'S5?UD0<<G/]/<\S.>:#^\O/OZD0S"
M FQ Z!<($X)]X#&2F[!S8L%"K*>KJY=*B:7^YAL-L9KP41SZ+I1+K<YLJJMX
M:H*;W?=>@1RT&*'CPI)]X5"-7+( SX,]-249(4*-.;"WL9893P[(_/>&1!K_
MYV=&J&6CK,LZ^UM\'7*6S$@EHWCXBWI(?;P.-LR[8W:@Z-;G*I]X!:%*@>CV
M;Z+;UK7F>A"H+XIRG,057K9R(-]A<4AX(M0CJ"G;-Z+;(D'GPAG$N_-]LPJ9
MTDRE$6'VNV':3 0HRWP09 !.T_=YF+U06##JGK!04O%>K/]D_JF7[YZ<BV$5
MV\;VK%]A?4:%4Z2H#O@QQ=9JSWZXMSU,,$/J4W76>J6\IF-T5?C1TJZS7:ZZ
MHO36H /41[@(J2R"V.-O*T:HL_:<+I9)!/: $Q5;\1>>3]X^%K71L.BX:0 @
M1MX'-4QPJB)#_5%/BHX/;<1RC!F+5@Q5AV:L(EV4593?WAI2J0K_NCA>5BNQ
M(^PKBY]Y2UBLTV5'\?LF._3][/]03W;XF>QL1#D45ZQ=X-?Z>"UB>U\$0,-3
MC4%XL$*.>4/.P6^^*'>0;:KG(*T\5^/]^%HUU6WS:L*RGKZD9\&DG-+RE0>:
M/S>F()=\:R@0$B1<V[70]^WE 80!7I;H2>NT4^1R*['31XR-]%Y6]O*ZP-89
MR FFZ(7X'15?V?/48$@4,;U.ZZ?_$1(UR;[26_W]N<EG?O>XZH:JKNV&Z0KD
M-#EP-61\8P [S!>P82^(MW;NO6V9N;XL_^[5UNCT/$P/W#K,9 '*29) LZ+X
M@KB22>'#)KOECSQ-'SO3W:[:L:\#P''+T]J RE"UJ0@%1E((GPJT;CDU\J/]
MXX*_9!"D>JW(H<_DO.G3BXE8N,4 MA#, (V[$R7[8DE(/%>S(@>5$UW^"EN6
M_U96AZM9.+'N.>>Q]A#SX&(3(Y-#;*<+(<,!%(]$BB.5,]O7_LJ.:MJQ-%=%
M;UNB31G\C.A>JR,\_'MBTNK+U_?R,<W6:U(%P/Q#'JJ%3)DZL8>K80Y\79U'
M\RV]*%BPK)3!?Y8N]%2FMR YI:BWILR8U%+)) 8066Y>L."Y6[Y9U^ [<7+D
M6U3SNX-:VU@P4X7LX*&/=A4;*?60&(B*266I"7^H1<VCBT_W5/C3,NH1/0Q@
M$@4Y\$B1U\9-R2#_AZN_]]; $D+',_?KMG=YEX]?.-OIQ:^L$=M.$0 Y<F($
M@F_-09+5%S9-4E;HAR7-]8M:Y)M>QAE\;KWB\O.D_1'T QW99*KK#@M-A0HC
M=!_T3?JRT6EHVR/A>R]GH-S8Y5IXZ(3BS3./GS8 UKU@PG=B,9_@34/8<EFB
M]%6R8FB!]YE$G\#,.5QM!<6'AS=)2DW[]D:K;!]-EL3;F':06DY0?(%[)"!+
M</#_QLX^<ONS2W1&N.45%FD SZJSV)N;?E!@RO +BH/F3^*??8ZP]CC>FNS5
M?N24T:V$$X>6#2^([9=0:_!EI2A0_2:Y^#L)1J'H@D4-89.Y2@WAUDQY+.I>
M@ZSLOM-S2FUNFRDRS-,>7'2V2E+8N=J^G'"UD8P^M6N#ZZ/&Y:XI[)J6FR%&
M:]%959H_IPKAM$N[P71!A"4U.I_:;15K73%0'GFG8@#?7R[D@:^UO))W^YJ$
M)%#?QJRV;@G"-BWKI4#2R@6ST'D/5W_6IM79\V./9SM^[#^SM;6=5OXJ8(?;
M]\ L 1)1:^L12. \">=C>VO5O[Y[U4C^_H<$C>@/)W-6N)1>'_*];Q#(:@#X
M2C>AAMN^0+CJCPQ3A^R)/LWTH_WO[ZKN%"+- ]#%F=[[N2H?)CK$MJ'"A%'-
M$'8;4_P\OH)L%9RKGS^O?#VA6+7WI^IE/4G)%UW/8]ZPEON#+OZDGZ2RY]#.
MDH\G1][?X'1I'#^:?-D4:N' ?M77:ADP>7'[3NMDP4JH(%1IYK/9"UBI$Q7Y
MA;ZOEPZA/IA <7RH&*J4;JX4MB36*M\N"9^*.;?0MB+K[Q^Q?1G$6EA\Y5+R
MK6R:> D)&[Y\)]8^S!)E'V;>NSQM6[;SQ@;UHROH<</IX_6;FOR+4$ZZJ&)3
MC>S7M\W"L^$*]Z=Y.OR*',N_OY.Y(J MTS '%+5& *NH%\C2[& R<_.:^Y3E
M$$WGHP.N,.:]5%C04"/]!\_YATR;3WX,ZUPP4^WF">ITY!\LJ#TC'N_YD7IN
M1:]<_;# ]MY1>S.QXM8Y$Z[:#U%K$VGEBZI76#5)FPW"BB!$V>]*%R;M%I?W
M+;U\,?BNII3'-O7UZO?OQI*KQFKM",-=U#KLA>.)X.9>-QPVA&8@]K$XT:)'
MT0YG2RRM^98HJAR<H*RL[.GX'BQJAS-W3E%UD6R^ >?[(>8D&HX%K9N:[YKL
M(;:D;$P'PTI21+U]_/#">U*..=63Y&Y#:FOBNT#>E[UZ>%#M;;;+VK+()K94
ME]UH\?-GQY],<5K^1#ZF3IHZ23ZL21&@(AM3;CH7]RYEE(9/K)PV $H#$A,"
M.Q^]_!MZ^?_7P0_RE\.Z4-]@O&Y)Z015RK96FC)\#UE^E8AH<]W/E*3[X3;]
MU4+]<7)1Y.3$P8J:H@5N5[NK+!,//>/R:Y^D[QKO>:(^5V1_C?H>;WIXT::B
M'BLO[])+'%J@:T+VC4OM%$Q<C[*$[:$YD7R:WWXL1&@6G?WHH,_3+7F@H.A%
MVX'F4Z+"P-)"?1KQ>!1'<RD?2^)$1+&C[$>:^5!9S1;QR-WSIS22:C+;&VAW
MF7&Y:'8&$()!,X"@"?HN<F/NK^^8QV3^KR><K(LL2XI7X?EN*(D-9P"-$R"0
MQK#N;C. Q7XG:F51DW!&F<BU&T$@@T?KB1,-?&$T^5WD#H4!;/[ZE8-W3DSY
MB<*;\2DZWY^\.^ZZ7W/IX1!:^(2FMXYPQ-H*U=0;LF+( !#F(#,NRMP%S:]$
M] ]?FMG>553IN8O690#/L>;T=>1F"X24L@ =CZ53,X<OZ6),OJ\S-ZAQ)I:.
M2BC)7?:#6EQ7I$E5QVYF,H#Z$\6^K73!1EG#I_06\<:;&]NZ+N]['0/_9 &*
M5QM UD%VR8:?7@<&);^94[5&(1O=<QF /W2'$/N'5TM2$%C6C#\G_^S$[^;I
MO Z&.[T,8((O@"T,.^^7]L2-G=557L+Y^.M9R5WWT#]<5H8(PKX(&MQN +E'
M[,U3V[L0E5Z9OXU)6+8;\[MOOP<D0^'E0O>MZ>S[5RNF\[QI<;VV^VP>Y6"?
M7;[*82<SZ<7K&G\L2!RUD;Z_45:*->^WB#)G_(__*:(L<;6!AW\QM"=B"]X,
M*3.,6!_SH@\)E*V^?Q/_<-]EINTA)$VU,@J*<0$S!+J]L= FU=PN58A^L\I_
M>D(V1X/MA,.9>YCOVWT16XIT8?M6R$0IF"V077\H/JOVYNX.=(?, +!Y].86
MO\"?2+2MM>MN!ZV[H/MB:/L(\66QY,_5H.SZJPP@-(D<MKD$1M;& !SK0ZF6
M!'8,+U6JXTJ=S'U)^1JG2>_UHDN7'>S9#OHG5;25OB(KL)XNF+M95950GX=S
MG9WQ'K!.I?<XJ@X&01!'L>5$'B.G08_ZKCB=1GCTI63N5F/'J8/N,7U!ZNYV
MSW7WE7R.&<<Z)#9SI?N&8IW/F8@JM&2N6^-B<G8*'6TW#*M[KWEW.F.;<*9=
MF?Y=%16+]?JB'A),[Q[DL>D$6$,R:9ZDM)H\NWE*LD"G]\,C$4I2J5HGG!XH
M?W_"]3']X'9$5D%3H&>60TOV#T/7('(\RYK4>O0.3QW]U<]Z?K)U>*T:V0W&
MMAATM)*LGJ::/7 ?'?2]@ICS^=Y>!(_ZIW:AV0B XB_;K TE9UXGPUI3V4U+
M2V,F&K93HVE)R;Q'><=U:LYQ-.T4)RH(8(6694?G_NZ;SCUG8HXD[O8;%'?6
MPI9CIXT?,@#Q563UW0H&$'L7\P/R[<GQ_\[WI7G?S2A1MZ3%;:?(_,YY&-IS
M,'F*3&DM@-U_1_J##J?\T;F[>^I3C(N?)R96?LQ7L[X$.K ?.I9_#3 WX/O/
M!M,:O 4:C.%'P,E7)QPCS4F##"!,M9TEQ3$V3V[\.OSI#O9:ZRSKZ?:&0OBH
M?A,.&XYQ[G2YW/]H?L/!T?A>]T@95=C*23JJV!)(V,>V;5T/@O6COCN4 '):
M71;-F R)6+EGNER:8R=G11<M3<&_(J;:ZH7'S')^NLV<YL8 E@HS?3'65 RA
M6Y :K!\HU>HAU7_IF6'_]"=;NV-^-EE;Y!C:@>WJ"$!V-AJD$85#Q7YR6MX#
M\=K/\S\</"O>QK^N8]6/_ GQ8 #7L5M76+N0I/!%Z#I[+0-H\&$ !Z!XWB'D
MG( ? WBR0N=?+P0#MJ8=\^_>W;,"_77LUQA+/;^!VMX[CIP\ ];H0%F0PH%+
ML#\-W&%Z-=TT5B0ID\ZMXT)_ZH.B'F0 >-C%7CV(&K)1NH !]"BL,0"F"=H)
MWD9<4^Z=?H6O.LU<H)5RJW[,U#?(YEWF617\GV0=QF+"@Y*N["M[=^C)(:?[
MI[>M"\WM&C-#V^3]#U0;U]BL=B_9KVQMO*7O5E+-=R/!TJI;BIP D^C AI8L
MO$"W#4)YA'S]=[-DMIN6(".]]%L=T&(T9G8(OD.9P)N:'B,/*..^GUV6@)/0
MUW0XS]X$\S.<R@!4#(<@-^A=L6OBKG]1!"V&_U/8,<< 8A,8O*,%_>[G0I'?
MI&UW@D5JE"9#;ZEG "A;S,HH,L0_E2_P)H5K":R:2M.HX<J)M46-W1TX*7/G
M\ X]T!DL5AYT_H5'YAMAP]#23%I;$M)I ME=,+%)Q#2FI!A,Y=ZI>!W\XP)H
M+=??TD.#KIU!0[[)7.3ZA'0QW(I5_[,IR!_:T189L06Z7W93(3/:I7^RQ/<G
M[767(W0_[;#^3]8-_J=U6S7X4='/O?!KW2SSJN$TOYP!!J#U3XUK\#\T7E&U
M!RMKVW^P2LUI<60FB[6%>VL>ZRD_(1$0=G+1]2B+2^X9=T4Z_PK8^^=@@U#2
M03.Z5/U"1MWGV5<2_.(&.6](EK[L7%8?\K16!RM+%A"RH)N;S0Q@77$!1665
M9@"\AC397W^XTH/)0TZ*HFBF@8,&UI0-LRU*_9HB-6P8OKT_^4=L"!+O2$71
M0W8M& #PDP$0W!>YGE5H"/LT=>JRYTI6O#%QUKR6?S"0TT<ZR_H36"PLMU$S
M[F%";[J%3"U>7AV:[;G]3M[P>+.V@5:1:;YMUABT9RKHM.^!30*\B1/6Y(\@
MC3J,J]5(5@H-:]>\F-9LTWXNL> .MIF&FD+[*7@H#9X%:W%U@9_LS!O^?+HJ
M0?5VA&4;>:^/Q8+2O&.[@6_.#SZU3G%YI'%5_VP287^1@+NQNXK!R374*VR<
M+_'Z_6B2M5&OFKT]U3N6VU2^[)E!S*QMFLUPS/>L3TW#V/1>/2%QA4A;5)/6
MRR#Q%-R$O:_0O>F:JT[&2JM)S E[_2!-T!!=V;Y[Y?*0%O^@8+^<124,I2(+
M[GUF?/P,Q^TD@&D T#KX:OG1%=;0+SL*=U.@S2MLOF$7DQ8X-2X\PSN.VV^E
M1D7U"E9,?^+S\W@UYZ5%J/OV-R48C8(CW=^:P ^Y#W7@W8=ZU]_F>G1]E%S(
MP#MNW!LWZG?]:GS]P>7+7!>W#V"@M29Y-,VPJ;JDVG$(=IEOT<ODHXU^?NPG
MN^<#//N7/P0[7UY,ME[=9)IX1WBB2_L,/AP_Z)BJ/;*M#+;,-6W01@MHI\]G
MC-)U,AC  ^1)("E")GW/?S7^U%7L\D! >E0&1)R)2"6]P[D9$8#,?S%.<.F;
M&/D+ X79R+;GD.7!O/Q_WOQK,71RK<>.@X,=XGH=*2A,,;1LU$%A0=:D9H+[
MQZ50/Y&]24>%XTYQ61]QKIMMPW"7F87J<KUMKC]6K8Z[MD])LN=]<O*-_">U
M[Q)DF',SP*K>#!6C">'M&0#WR(+_^W)4$Z5X'!8:\N)\HHCZ.T3S3X!54TV@
M"1DK+D#-*G"8US(:*/0VL;]=D]1M49R ,PCOXB8UQ05PZXE'6I9-;+&.(K%J
M=$OG6A4K:EBAZ_:KSC*-O4[AWV36]SS1Z8H@0:BVVYNT76$HWF5Q8FW]+O-$
M+IH)[!,H-+*[-Y-^.*B. 4 O/-'9_L^FYE6D@G7V"@.H<>1G .Q01["(95Z*
M)#C7\+D]FYODN,+:HVK]!.Q!W5C,[%SO[U/TQ'<-?+EH<KL!]*!H"*ET8V5K
M6Y5I9>"/N0,5*%ZU$87)"U7?RB+V4SK5<M^65*VPOL^5@T[U0B$S[L&ZBIC9
M&<B;; -"S5R<C.?39??,A=5E/Q2.;T>E=PZM!8)EL*;N-*VI(AMAR%W\5HHN
M6@&_^]ZL5.=PQ!J::K+" &JA*H:TXYL,8!SRYI<TY#?ANW\K?&@]#P>628-?
MS>6Z]&_2$Z ;+: ;M_87G=+IA%@G/Z#WY(RDQ1KX87_73N?9 6$IU_?>#3\?
M+N*!P#=S9=:I_U0.Q2MBZ"3:'Z*1?R]:;FT*;A;5;=3LOWD 3LO6)^2#'J ;
M-E4#'1V:=LZAG/T-^&=AI.0)!N ;Y!S[>\2#TS^@92<H+AF]CMX@%P#;Q&;8
MC'LH%4V&.I+H;V\>#^FM]),ZV?PPOE*M7%1TT=0BTMI%7$7K_;/W<@9&%9FX
M\=3NH(QZ-3!+R%.*X$:?-J0IQ@HA>RP9P,D-Y*=BR'<,9%779#>H S/[@SY-
M=QD!:V\_ Y@:#,K92MG*P2-;)GBI8:VX.R'+&7VCIC+6Y[0BMNW-P)@,?E7G
M]I;)V>"4YS@?ZY[M)93F^U3S5V[<K@:C]H_-,@,[5*W3:$ART4?2&EZJ!CU7
M>, M*7OL2,#S">$W"A)1"6=(,Y^)$E/.Y;FCOH>'?#V(:NT;FSW:^FY7XD5[
M6R248G7X*9D?Z8L1>)VU'W-YPLM5=_"%QV8M!N[<E2M,1I3(>1PU?Q<XR))6
M%^*9HMBVLH<:;%76?T_-;Z:N.LZ SP.TY:S-5)4!!(*$7>= 1%:A/M+SPUA;
M]G4#UUSMVV>U>[?"12A.54+,_6K3XGQDEXA:'?(]*A2&)2+,W' F;A;CQS/L
MU9YR/D%71A<H7_";[&$M,7<\GHZX-Z1M2\[4[UN2RPAKP*6^6D_R*?G("].I
M>B'T$LEQOB,$VO+,G]MQ]%\?02 TBMRKO6AGL;5VVJSX%:I!%MF@/C6W>N+5
MP+)S#)%;:O7LW/&3.TI=/687=S1:*K4Z46&*,Z3=K#I*6?S,T/CRN7BC+5&5
M@WJM[O@[0QNNM383/-YFH?4<T43MLX=1?@_%LXZ>>'3?BDNC?>S9E]?J2RX0
M=24]2. /9%LM:CE%'C.%4]QD7<V8HNN K?A1+XA9Q7N1GZ&O !,#OBM,_]6P
MA-'/@>P4*T5W*K2T9@!Q+Y$;[9C7Z>S7S T OO]JA+W/ @D"8-4/G6KDVG0;
MM/SGS;\404Q/H4<.P_A]@YN)-PG=2V@.:O:"2*>+B8>F\ZN?L<R;*H?W:3^=
M\[1'EF.:B+=:H:45'_%H#IO.CVYGEH;8?4D.29IQB5TJ3SY@JT!6(.?;1H%A
M-W2D"0=+"68\QH3H6]<_540?[57]4!$O6>GM^TWBFV75V3BC;NV(XIU35*XV
M,L*<;!B-\/#0*1F;3ZJ^4^-HU^:J6F^N_3HS02]3K.,AS*Q7;Z_OOO+)3N<U
MJ^HT,5V"T8>XDNK6YD/( YO;A=D,X*ON*+T*O9K.A8+BF;'(.2&0F06]I8%-
M[SF7 P-(O].]NPUBNTR9=*YW($#__WS*"=X&W,\70H]&$[CTIS6HUKWE]I?!
M?2R#'/M_X]))=\4]B^%^S.IO'^1)7C4._RRT;=TS8&''EI\O?ANA@>S>UD9M
M-B%#U*%<,*.G2>/GN'98:;+]L?I7;)!M&4'0[UBSH>/#JPR@%$_[#K:!"QM<
M6YN)="K\%PNJTZ<'@HE;+P)*W,U<Y $1,XGN[)=,D_ /H^VT,P"$!A5,T/WC
M[T%HO8J<X*3SSY>9;X0_YEJB(E6T._ZLX5<L<+ UHOR@*Z$@MEW'R6PWU[!2
M$- W:7?^HH-OF 8-/+G/WF\_= E"0E_6.5GQ%MPXYJ"SO;_K7OM?ZD8V:N0B
MNVM_6Q-_#[Y )X?@'5W(]V[E?Z<"BA<9@,Z.F^W@07"O'J%;K/!E%\4UX_+F
MSPK 19VX^#2)]0@#^(1LK-/-F\>09U 6M+G?K?O][ZQ/!BGZLCL,/>K4D7LT
M^C;'.%*YA9=GWWB=[%RUK-OI=O/<O./%+='M)VX]6&OJ\CCQN#( Q8-LS"0C
M=P%%!D 2PX L]UH0>)N^EP'0F2NIUJ./K MW:^RW! @()$V?)D"CH_!TPV](
M-KH(-?D">>:53T"FH_VHH8RB9%Q)B/C/B.W87_WG/-A_W+[,6ZXS .H&["/=
MN3;*6=EFY&.[W;>VX9]5\G()4;E7$Q,2ZRN6DLWTHZC3OTAU.(I](Y9S/O'L
M7N+4J+*QEU&4GP_WUY$CO+T'3R]&3&O?(BDP@&M4/!XM,B\P1*E^I"*WW?+\
MS3Z"36^"4") ^W+[CJ:$!#PK0(>_(9 -A9YK)W"*+UY.6%AN5Q"XF=;X^-FC
M64U#QVOD 6ON]S2NXI[R --ST,.^743B!Y[]B@A]3U6%LW-SG:'BK77B$<!7
MLM<B')]JC% ?<BUZ+6BK1E\Y>J?M&^RN-.3BJF(HY@#-[%;.0K5&Y+H.SP+6
M(9H!5)2_5LL/1\,=0@^>?::3'_4DKT&F578,W'V<D92;_:JQ$;I<Y'VO O.S
M$S-&KTLF;=KMKG>)EDGQZ_5Q3].BA)3YZZ^<;1.?_L]/8'X[A1%K:;:*J^TW
M*CX?++?\ -A4F[)&[='E< -A;B;Y'<XY6>/%]T7/6L?*EVO!\4>?ZS9NS9[Q
MT]Y 6Y*AH8\F!.<$JA6*[RFJ=@S3/DXZZ7EW><9WNU'%9RD^E:3-F ^DBM1)
M3DWOT[7Z>\=0(.,L]Q2K0^&2#*()BJFMIVZQ1[W;Z 2"GDWP5%BSB'*+@-63
MI$^6;39/C<S];#F)" =YJC7-YCH2JTZW7%W'+(HLZHE!:7(3W"#]- ;!U_/?
M=H@S-9;^#,P2A#356MX \(:22A&&#. L2%;K>7]MRI"W!.@V&W27A,)?+^=C
M IET8R<9LLN"HE/-P/IR&/X"),.2(-YJ1(9X#5QA!3DKNT8S<IT'N8.'@BEL
M6R\!IG BB"C9Z/P=YGIB9O^O?)CXIPOY\XY*@T6J5,D$8NJ(U^5!2%\A*&'[
MD0%TM]/"J-9J&<BO)T=WO]4YOKLI;OE^=?#D@$7"U8!-$/WAY4#ELS_I^K_5
MHU(P&%3B%A>I(.)DE<1P]^@UNLMF"K@YD]R0:ZO(HW2^?D*TT5<(D?6!X)Q6
MD.4K ]'X)7%<SAJT%OMG<1#N=IK1@\Q^0AM+9#(3=(+_HR+D'_Y9&?!Y&7X*
M<$-]IZ_!_I $P:X:=&L+&@>NV=>,&",*EX?%%FK<_<^A_3H'=\X!V8WT*@1O
MRV?>+OZ%F(=4V>E$_DD8^D>0LL<B-"6&=<K-9I!^Z#_+@A0B!46CH;XB0VZ;
M&TH&L%9\I'6O:/<36%L5!>;&3]:4E0[=#AU3)Y[E<Q$27[R^0E.$BR)['L-V
MU@08 *_M!!\#^/FX?EMZM>AB?3]7:/K<EVKW.[V0,&?;;%U!7&_,,=<3T'(%
M>@Z(U-E'VR#K8LET6@M(%'O_W7LLL\&C0&LNL/I.;4ITTK'?D7-22*HHYOL*
M!A_@.T4/+@$SZS6&"O*-O[R=O)NY\!FYM0FI8J74WP*3284!-("P_5_9$T_\
MW1[$L@E<SL^[7Z'E:Y!M-A2=57%-ETIJ[O;$=RK;BCQ*L+^PU%9UDDTMQU:7
MAP'$VQLQ +019IW;;G K:CT1FG=7??YL?<?J 9F,]!__D5W7GKE&;9D2.T-)
M(S& )PJJ@>K=3<*OLCJ;K9\YI\Q,&HI/#@MRWRQ1CQL1_7F%]7,O3(AV:3>_
MUA,/C]0:#_'PS)R?SUFPHEC9F78&?TLFMT=W;3[3^_2I^]S>0"7R&4+:&U(D
MOG,VRIN:DVA68G.)/)P;OR:1QUEUA+NJ+>@E$\[<T8* PIDT.AX<U#:Y^5%^
MW6M.ZYY6:I/<D8+P$TS<FNU>-APW ET9  <#N"NF03"+N*\--H3]]"H\T4E$
M<.-PY>!DM I'V,\;EJ.%@'_JGTYR+5-(.BZMVYU)^=YPSO6/?)?-KYVYP43M
M8:TW=^1*]UVT^SPH80R_$[]?TRJ^F+98!.Z1#+"W^5?N4B:F[,\EIE2[\-^[
M=M?D569?+EKM+Y^""0DFUMH@9J6" 0CW@\06Q$YW];=LYZ]9@QNIT1S) '3L
MZ3MP,KC9(AG UL+$YB@R^A_L,VRUM.]/O/[7MU\Z#(!&@>\0,:UO(>&*&7KY
MLC>0%:"9WXCD45K!^C?93B1>!L, TL#B$5A)!1.%S0 4VOA-*#:_XS/R?V+^
M[^/Y!Q/GFG;YD!::_NM$[SP-^08-^O@\[7<)T]CFY-XCEJ\^04=!*[\Q^T-T
M*_\[_#,8TDL8F+%68+D<I;D_H=:161U[RXB:2VILA6(S=V[Q12FKKR_:FW^Y
M6&Y@JO:Q);IK;O+!:O-ESEQ*90#D?"^,%]F()X?MLJ*A*VN@TZ3/B)O@CEGL
MWJ%-3#E64OCAL[!P,@,@'SH%6YM!;BENH>[]O9#A;S(OD,UZ7Y#=;\!2@)D)
M_/3'(3$Z"HI_0&VB!V-1FUN8U@1HY/BIZ#W1_IO,]!1PI7=#[+>P4_2S8!]E
M!K&/K@L#2&  ;RB#_&0-F@)$$-GCOT9G !J_G@E[6"NX>6L9 *:3KHJ\:47W
MIH;1SG,(T+90=!.ZRZBJ=?/$7UW[JX;?;!$@_W>AE5H^FJ"NF7VD>Y/#_J*^
M_Q:UAD"-D\&B/5=40$W#EIC4H*/_/JZQ_U5<,URM:)PLX4(8P<3HT8J@6]*#
M\MS'1D7[69;O(R^N35#=S"(AZSJ+4"J/N]#M02?B=PQO/4KXYDD#XZM)]:B9
MH 9S6"S8@090AZ%S 4-(DB1HE=.8?(L>5@<ZML?4C&( FX&%(Q=C!.B!)F"M
M4MF@K>=M(VG^:+!]J,#B(?^01?R2Q<ZM++TB!-J#)92YS-3";D!Z8(,MQ713
M@[-JE+/5U,OI 6]C4YJIRG"'RK9FELN%=\*N,'L_OZVT-H,',#&$WT>$,M6Z
MD)IH]*QOUJ)T]?!^=*7?\0]II^L#/XAR;DU2BBR,J<1<MPK=O:QFY>6#WO+W
M3=D=2KR^WRLZ%J-_K/4L?77/A]F3#9OH4]O!.)D\NZ[26WBB\I3YP#*A^%.E
MP^J/RU_,]WDFF%TN_^8*%=5F*EJPP@6A"+O'5K>GFZ^,-CV.6E6: [JEGIR)
M.)E4IL;[82SZ""[:K /JHO$^ZN@.G+U+]QWVM:]%F[A2G^Z)G&"$M7?&XKFI
M2Q[&\+( 3?F@]O**E_&.MLI<I I#_1; ?YI_RE^Z+:";#^'<1SN3->^I\5S1
M VXGYG;59ZS[7B_KJ:BI;_NNU+PX\^+TY.V=X_^2SO.3G(M)-<U34\XY688'
M$SP0^@79*[RZQ0(IE[2>.1!M(N%K"6K<]YBC=F;JU]!/$2:DBJZUJ9"9<&AL
MK8K4QX/%HBEB[S_[+A/%3<^=J1KKZLM^D.=DR2H)O>?%M)D$DAIQ <A&)^85
MHDYQNW4;.Z ![G*\)UC,1[>L._H80 &\$%#_FZ/I@YOG&4"<9>7.*__<.=3J
M ;"8>:&M"R$A$ GKJ>1\L 7F?OV[LVD2) *Y>@86R+ME?=P!W@+=$D/7A]/R
M$]#53<@]XI&K4* 3.I'/ ")@K\T-^/O\GO[;N8K$"HP-^;7P Q+[ ;:]O]"M
MG91,B\ 9[OJ#)3H]8JN-H)Y?2'U("<'66N8X.IK<P==I?7,G*AV_Q3?D==]V
MV/#K^.N#^Y<*88G=4T$Y&W0(]=0Z+'[C./]/9&E]B?<H7-RA<'3<'A.![JRI
M#6EX\>JD@'3(E\F#)^$1*.&B>M'%'E>2*TX>UPXD!V42!!]M"DG>D/@HZ3F4
M_F/#3?8%U8+, W^QK3.X1$GQSM173!(P';PU<(C\+MD @+A]I6))LR;DRZ^]
M_6@0Q>AR>Z,H=1R<DFB7SI)@<Z=Q'V2\=>4BL+X@.XO9>S>-BRR]M(;O6!%W
M>^A>_3A>--O5FVWVN5S$<O8)W@?*@@Q@,'JKJR< "]O1F/</?3O))CPC4J.C
M/$-Q7<\7V1(V+BP8P3R.LDD2]>);9SD ;-C]\T][R;%\]&Z-\>/4FCM3T^2A
MK%L!-X3/R!H1G>Y.AC_AN<#V,W0V\6LW_]+Z%=8GU&3*V=Y:@X+%!&2C<1[N
MKO T ;9@)^DN8J"=_T-3Y&6@K \EDWHG'V&\B_)>V>_K/*Y9+AM2;G(W.^[8
MJQC?X>G8'1GWX;OI7&\WD"/G.]Y3ZS>O8M4@0N[50Z_XDY.]G"J.9MSQK:B.
MVG,@QBB7 ;A @L5/DS#-@? 6NDK58]?U8=4.FR+I&->*"[YRMYCTF)^.U[\$
M8R#M6N/KRW,7- 2N-')8Z&YH+KG_^.VDX<@.?'L&\^V)MH\^U:70=L&\0^[H
M%>;$E 4DGA.S;K=^4O:NY0,K0[%[<K(F*9? :JD/WST<^]MKW8$(#%R":VG;
M86060PJ=V):'_/;JS\\7X,=*"518^K?I;P2>P[.C'?2^"*$-\G ^-#]].E%\
M_.PNRJ3F-/RO"G5J@W=TDQ_[K=".5M(C#7][=0PQ^+?9VIOT0Z,,P"#S'_^A
MSV7$PH_0N[/&T@) W 5"J_1L [S(?.9!X OZ_%^^"*Z,0[KT+7<)_$.P2(20
MTY@:T/SX,+>-7JGVU=)37:?4"77+$4-)REE">?$7YZ9:;W]&>+#=7%!_66-?
MMP,19P!-NM0..D* OL.'_/V6G\+/OX"\[P1]%02=0>1LAR3]XA>[BR#8U05!
M26@@.9E&5=RER/SI7G;II S]1S/R) WY'3H@5PF2EA48+9R\0E-9B<+,?D&N
M%%^*G.2*NA-U^M-UR/9=V27]OGQ7#'E:8(K6"1E]'3L-B]T*^\V4-GV# 7Q%
M2?Q+Y_C^Z1MDX;#]+\:RB::?IV[2A39;86N3F,WAS#]NT9]R,W<><M/R00!S
MB@%<*9D :5 =<E6Z#4/JKE<&&1K8BNM;(']^$QAB\%>/_K/@3\0CF,A1N8(V
M"ER[JOP4><M^Y%2G;LY6[V[5"[HE^'A>(W-MX6O=OU9A%?K'*AC^<0N[:6Y(
MF9'8LIZBWZ2_OX,!J: _B"C,NA1!"%DBW8SA\WTV-'NY-\'WZO"%[\[FH3_:
MMK%L(#*'DN'T)^#-4W98/I^5F4;1& [T-;5G\L?>T[D?.\S4Z(;34!H8;@MF
M&Y"FLX I#'*:PR!+!E#40^7;Q09FE/*@CNVM9'KN#60:#+0JL8JB"R()$[L
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M(./TCP9U32E%1R@L.J0C_&&'W.#<./O$4;/ZWJSAY6@50.[5E\DJ,9=Z(+S
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M^T-($OF6@B']GBUNZPO\0?@Q(]"H4-<<Q(=[4^D8T[<RJ=ZN].ULYNDVG_
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M0>*R=/JHHM.%0U:.H4G[?V@E+]B.- T[?M]ZE>;XJ>R(8NV]-B]E9-]=-@>
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M[DYJS2)S%>X2Z0JTQ-BCS6\G\OM5MKELKKP]]U7DS-N&ESF;I?SD36A@&33
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M_,EJX@[O?A@^IF.6HQ8DT#5FY:@Z2.0Y4,G'=??7UG9W][^+]Y5\]O9#G+'
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M"G._\\A 94YX\2U/K2G&;+I FU9R'P6/M5+K8D7??.A1[/XE=C0C7HI&L5^
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M)VKP;C%^W^]T)]@L\RWY,HKGO,M/6;0U>+AS/,P4D.69502W('/$;B."$)J
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M2>O>];89"YZQCP?6P[L9B)NVNK]]=^%G4[;!T2BZ%4W29$TUEX24>%)AFHT
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M&LR-T9Z\63)B'>?PZ<[!W2>RP_UY5RE 9S#A,SGB $PZI,;?A/)L=,5:-F9
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M>[F;AP;Z?[L$^-@9M3^AN$/'<_"'#<3J'2B'1S#_) 6HJ14V!:^Q+W3NEF2
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MEN ($H"'7!U<7ROWZZOEJ]4-Z1,6+]?%H]YI[.2S(V*N/<0H2EQQT1]\[,6
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MBQ2>2EVYB@,_\*N(F1&H^:;\.O-0=Z0QT?[3,/A+=[)-G&2&2HVWYYBWQ(!
MIOKFYZ39IQ ]$0H0261]#>>;(8N>//I0:ZI1WI5EH5KZ1>5B_F[YPS^<(_A$
M/A/*".+1-GA]9XB =!C,-GYB;VNW-,#5*Y+/.[MU0J-=O R*S^PHL^K:4ZVV
M)AQVZ8(44<S&0]V8,_>T&MD>25. FH8*@U<1VGLFA#.OW<5$<%_C7D.7;5V2
M8WQW"_GVZ%6FTDR"YDFD+UUYOO:+\4A73^FNX+9&662L?XZP(9XN3B6'K^>Z
M7<B/'H$7)<[31X4]!-]1 -1941]MR)S\:A[O<A.]9O2;#'X%ZW-'4H5SIB,'
M!(BP:4^,0KN("^I:/$_SSEVVXID([?IN1/5Z7NE**DSH:/-;@I*99K"'U3GW
M]0=>GA:ZMII-[S_-K]UZ>"ZH'/MAAFF(+$JPN(K;3>+6+[;NK5)8M9E(,U%2
M7.Y*,]Y1:?W3*O<<@]CGJ_USG"JVR96D3E48-0)7&".VZ2Q!<8*69)%6P7WA
M( H \D6T(7+T+1S_L@6]THOOR\9(2Y>9F(380:64'WF=2P. Q43+*:C6*IZ4
M?SQ/P$?PTR*J\%75]:'LDC#;RG&9BX47U .>OIK::JX*)F9.\_Z[O/[J[[R^
M_!_Q^M\.TF5B\G[3?R>= IQ7^1#^!;1Y@4@=,7L0!3!4"22?^;,Y-N!M;GN&
MU4X*("'?@=QIIZZ%3F8,)8-_.)2G;]\P(JN<4%)3JE[+:L#Q3-8MK\]8^+U\
M;5U*J- F!8B@ -S:YOC .=+79G_O8@^RQ*'+6M;%![DHR7C7)-^OUJPMN4IK
MCMD8K162FGY+T] V!5CSO"#U6=_YE'7+#_+ZC[DP4SAX=0\]&P=E;>.!QQBT
MX@K+ZNI%1]=?%GN-B*=)QTD^G[]^&QGH-<>H3%.)]A:%+W90 $'E 3I"M>50
MZ!4JW[9#JSYW'1NR?G+\UDBS"]L]QG9,*[AWD! /9?NHK?1F"67XLM5D9OF>
M\J ^Q\+439>^WBLO@L>3B/2X\61M+8Q=F5'W#*OK^$YB73%&PU_*98+A>[34
MR(*3* "R<""2)0@QGFC&\D6<9T9A*?-B[%+ WO(K$],N1CJ%J89RMN'D5G>Z
M#((@WJI;3*4!7Y2G\O4I5LN!M\ 4W-5D=JA3]%+\A#S;>9]&-AJ7CXM%,+?=
M$,++"B)DJ,5$+7959GN*)&^=#3E4>1)]T>"*T^)Q+^V=#P=68!SB0ZXD;C8^
M-!![ID6+(7IMQ_V6"3NC[;113<OY:J4G)%3S/)L63;HIZ7F+&C;OV"RA"<1#
M<-01F[HQ>GKT5D/R@08>"6H^$?2QU_$)S<;UOWU9C'=;"RQ8RI4FY*$17'8.
M1/7Q59F:PS)53ZV>8%0[^XM3]$_T@OSFN4?<>'=S0ONQ>2+AGTO+II<<SXJQ
M95ZK:GA>^/!@2 V^$/"E^.FR7?JR.]U$.*.1")1)^]SC*?<Q'V:#*8:8HJUW
M',YX9@K =3B&C L_ 8>UCZ,\,VK+)I?JLYYTS'R="=)+"V(WL%SV0+++A:H$
MSI6=]&9(4,%]_L :\5[O?9!#'<T'4=@B9(J[4RBY$IL7HUD4A:, YGB^EZ^6
M4V>_WPD.JU*2;=J)U3@^G^LS%*%3WPL%D<6(2GC6Y!@,@G?"0ZAL?9BW9CT0
MZ&7ZJG>")Y?F+M,&-M4UR4% 4X'E7?'QR&_Q! OL;&>%D"-\'/-Y$BY_??PV
M(0&]IMMITA!]RJ4J2W5_R#?O>]1'C=V*&FWF GM"8+LM6V:0?$Z@B].1EBHW
MK1RS,R0#P&O0W$08^?U)[S9MP:'V[-;F[-['?&9E2^_J?@H EJ4"JWC= 34B
ML9ZT*47;SVNWNH48^(R8/9GRUW*@&IHS6U=/S*1.UX.=>@HP>!MYX<]"TEOC
MN\,WH,EJ[2\:#T\A)1##BE"#5$0KV&B_8"M9ASJKKR!Z09^,(@<->/=ZMR93
M&8C)_'D["R#R(YACY5Q]FYAD[M):JJ?SHPLBQNE1$I$IH6/=]]$;'@YV,XCG
M*ZZJB\6?AO=.5$,LA56*H<<KBA$WD?M2!_6DR"D*H']Y/[XMBQ0YF(U1K:C]
MA.AJ;6+?'6O<DM_3S(TIZ 1O:G0B$K;=9OZAN;_!FVJ#&W_NE8(_FQXA,VC9
M]N<^^4_WV7_!@Q<JB9[#"X2B&5H[5MBA39!'?]XZK6^<&L+OL6$8;"C\_X0.
M(N9-;G[1D#>\I_XZ2><1M2+AXDT$<"F*<,V8 M0Y;_9%]^AE7K.+.7J+$=Q;
MK:ZR\I2Z#J_%X/(PD)3:/-9E,/O=,GGGNO<C,G(9RWNK4T<ZSC) KRF8 EJ[
M*L,[A](5O&J3+28N<W4*%,"U$]-W)3,W@#WKO/;JTEA;;H4$*=>5D,T>G6Y"
MB$.3Y T\-6>$8<9^A\/WQFG,SKAM:UN5?6-()7H1#N7;70ZOM[&.^:^=9O;U
M#RNQ?L1I:\C&Z-DKL?>A'-J#K'.+T5;T9?(XX"O#'!,?0H_5"KX;U'M?DRDL
MVJXAF?LP^]",*$%XB0]>-!G65GSKS@'7/5FU+.3XQM4B'%W%99CH]GGI@[C.
M2@Q^;[4>#[(9]0\S.M^&:WTR<_:;[+:L%R/]9]:L+GB(&8V,*KZVDDJV2[=E
M[PQW9<DFE]Z2S'$)88*P1!)2H\\3DQS?@6D)MO+T<*6+..*YYZ^&93 U-L*E
M]&:-).G;,+\725CUO7Q&)<,[R(D3Y"5B/^AFS&'QEC*-D[)K*>DA:#WOR^#N
M,4030DE/C!$#IO,X1QX/%VQ2'/@!*9B^<TZJX5Z2]K6+E6W3V >HMLA^>%&K
M&P>IE"BA2@&^5(=J4H!A]]()<CO['N2'.VV/>[_5(3WX._AYP2J5,?B172-D
M7!-'$>_U2</[6;K_D5IT'Q'N<J%&N$YRCQ1RFZ_"M1^>MT;CP45=O"*8>XD2
MYE06[%(ZR?I(@C0[]B^W4AT*&8C>L4<,_'IY40K]K2M4LC%V4A:=6274E4 N
M;0\\_5?ZGE:?A]]3.US<'U&1G>@>Z215$Y?/_J+OO[T:^;?0)8CTBY<_4:/R
M<MISX)K;9/_HW\',3Q<*L/&$NGKU@TJ""E2@?](FY7=UB<_(S3*NT=I"%;^/
MPOG**,. [;U\]J\I"11 0-OE=>@5/&].<:QW?EWTVJBX\24FI6]65+3#_+D7
ML:VT#-HC#.NJ24$2Q"29%'11%.!K0S#I6I+0U2?0LY-^#BGSTZYJ/)4JUTKE
MXZ$>>^%NGO[XYEXEVP%A0@8IM>#F]2]! BHI<]Z)NN>&0B6+;5'PZ -F^+='
M2:>.2TW#<K-)5Y#K:IOO-JA1[F.K"WF)[/IRL'@-TWACX-5Z$CJQBW2A8+<*
MJ1T^3+;9S\W[HU:C25K8P.3"$=G!%M,WO!Z ^%?=VL6GL,O \HW\[2W^_7']
M I-]_ND4#:=**VAK)IF>ZE DWT$)#S\'G>\)S78]-BG7 A*SFK/ZOKU[%<9^
M]520ZN >!;AIN?&GCGME5WV R?O0RBSX=YV:?N&?^)ATJ4$TRN9DQ,#9E\ZQ
MJM_GV8Y"KHP_#^4EE+PA6N<YVFT<-46_\<LNJO)P029COSR'?,V7O^(S<-6=
M;JSZ7YA!?.Y%1EQ=#>8/_O#O5&VLI()0MSD;71E6MP[4;E(!/*T'Y2EI43.F
MK;X7L$5[V/*5?R-RMJ&BI70>-"4);<!M)!'!1PO*8;E,N.MCW%=1 ]$UE;XR
M!['WN!BMSYPM#*(3D&S(9[]/RE9.T&&?"WPDLZJB_VZRUY4EL(C[V&,^"33[
MV7.7Z(9:S[4L[@:.:AN4A?+C"C?BRW+'[3.^"*99AV;>2J_, L^Y.KQ.[AHO
M^ <OB/XN3E^$;37OCE& M 4$!7#\=71>QFK0&;H!(<IO&2V*A/ROZMXSK*FM
M:Q<.HJ(44>F@1 4$J2I56E1$!#:&HH"TJ$B-- 'IB2*(4@4$%"4@14 (D=Z)
M]-Y+I$/H31)J@)1OX;.?=[O+>=[WN\[Y<<Z/=5VL13+7FF/><XS['FO.$1KH
MW#L:*!SR-N(0(/A7(^:^_E2X?X^R?WF3T-Z&'5GT!D/_*\:.]NFI(QXB]?_3
MKA9^:5LH638\6;J1+ ",[?P6QAK#4T #1>?U(9>-@V@@#5D?V?_1HL(_#@L_
M8MP49R+!\GI>WR:?)N9<6<F>8O;! \=Z!N<63 S2%?-U_<MMY(39M(]JW5UJ
MC;TTBGJA[HNE@5@6)IUVZ0# #W7_>H+[1(D+I8$2G0BJ'A3[9N3\601DVL.;
M!B(G! 5@ETVJ +-V&^7A:KTQ*Z\GAS$1%F#BN07YY#'<C;)"VV))?.>YXTAB
MK\7K7QOMRR[F$AOZT#7@J_W60.])G9"[>]7PTS75I.0J& WT<H-03 %MLNZM
MP/L13+ZNO:JRPXOY=D4&@SFH[JR=Z=/#VY;<P%3HN_L-;WNM+Y-)T"&@<ZW-
MW4J-]9Z6DQ5&QX=_7VW1;=#I>!CWY7^]>UI3@7UQ'3QD,FL*\4>(Q!_EY]$?
M%IVO.]&T:M(35)C)[?'TBHL[-2LHTP(WHS/<;;;A5#R,[*R#;7]/6=D:7R=R
M4;;$UFZ1BDV:::#7A7,4&LB)F$(].0JG^N.PVQ1L0U46!89<7P<XKS]"AP8Z
M<1*RP0*,(_(;Y#H",GI-^%45=TR\''V='EO0*5^T1?/6GM,.*82ZQT%:Q<-.
M+O9VIO#(BJ5?\,Q.^VQ9,+%V!9V/'X4+4\_C$O=;SPN_,7-!8\AAA@8ZN)C9
MF)NNE0#+(AOMF2>4@]%8)P#%B:^PJ[G0\$6>#_:_A8\%?XLG1]!  <4F-%!2
MX>K/Q\7X4D(*1S7T2;6GC(QP7"="-,.;K:QYAN=U='PCN])$JWJVC(:I1XM@
MC9<:\0L/$!C'IS$[1=BFO=E@$4P<Q.#_Q/OSGWFR+E40LMF:$$0) "++W.:?
M5'3M"3+/+J1IXS(-M-T"F8J8C>@K$_F9X:V)K%K8U>^1'X5H@<@YI$D:2,BF
MC@;:W-V/$_8_$ K(YGM$" 6!7<_AQ9JDD$6\I9JHUQIHH$I 0[-CY2X[;9[<
MVN';,?0([/"%_/3_F%%3#2_ZVLL_PAJXZ4/[GO*Z5[UGB'Z,,O/J&)F+CSOJ
M8Z4:"U\MWN&]62CT(H%S7"G*Q^Y1_-C>TO G:_0"9(VMD ;*"2$OIIGV(*>%
MX320.=?.P*KE<\<(W&EZZE43)XJ/!F"J8.P=&=8=.COLY@J8ZB]*0:A+#%)"
MH!,127KJ'.>?[[LIBPM[EVB@1FR=U![O*G++9*N,"!V,H*I0SR*_XP"7E-?%
M4-C]#WM<C&I5Q:M(DQ/CX;AM;UB LB8>S#1,^CQW=]C)ZY7C"O_W&V\."?/=
M79MP:_=K5P<]( F888G"@3+MT#L]Y[O<F=[=B+8K9F8:+M[6/+WT9#_M%&]^
M9^(KPTCOGW?$8#I6ATVIVC$T$,4;\'_SN;!DV9W1/3BR^0G@.#"F2 JGV'R>
MU'8ZE>O/(L?_7R+G9]+CO\VYSL["?KBKL*9/)NZ<FL36[TK_6 3&_A(D\V_Y
MXI^'V-QX!)BG0GV"E5/C09HVH^D[#J+@M7!HI1=IV5V\*J(8[6,QQ)]S+W:@
MW05L6#L<W[Z4W+7+&$QJI?*&-&#7QW!4,B-D,J,"&#F5%>3J-TP"#61".)VV
M+;6N6DS1:%>J745.^ZBDDQ-B4VB@AW60W2M9@UGK0^-; 403LG-%?\42LK#H
M]:F#.P)\-[*]C;P #Z<^!=M9!1I$'((;O/XJL]*6]@7J2 -),YKQO3><=7'I
M+BP?]8W(M\6$8G^]LPZ)@1A=!SON>\_EP9=6IN&T?*V#+H%*+T3 ;0/O' 6J
M\5DW V7%FH>=2.>-.TZT.1M[X>U+UNK-!\NI&EV W_?3))[]#PLE#AIQ.9N(
MV,V&<SQDY^$6$=PXM?VE[&7E9SMITUJ_C*'!5N?A!]JO8WC5YI-0T)XJ+4I5
M6H]$(21(WE7[BRK:+EO-9<L'=F6"LV6B:95W1O/4?12\'6LW7T"QP7N$;T*.
M+\0IHG/0DZ9Z$X.(EC6.,JGHF?N^$5&I&S)TNSP#L:700+G=M/1:"%,UFDNQ
MPOLQD]NC*TX7SXPF^N*@%^($6AG]/'A!457W*578Z8^>2&H-<D]S:<%WU%M]
M)WXG>FL3< <UI5W*WUY0SR-KH.0U[\W+G=LM".RGM9^O:AY#TQ<C N>3@RD7
MJ1:7)2'3CGD *J\@-\Z:;#YW]7[1()?R*$"0]>C](,?9,^%P1.G%M=MW)<CC
MR2JA-2<#+I);QO T4$\JQU8<F6V5>HT?N%U.$;;%A%14U0$X=.0.=E#UTEH-
M$EVXUSBD-=D!&4E?(W?_(#B1P^=IH.'Q76W5RN2LV:4>J;;N#YA;6&G81W!/
M??!:YY /]99-,'9I>#=XH^)G;P 1./2XDP9B5*HWK?/<DW_HI^[^ #)V81?3
MMI;OM,.%AU1+-2>^#T*S\Q<8+3:N:4;B63>'H!0_S)ILCO> 8>'G,7LV$]F"
MKKHWD'<W@C6%"6B]C\R;JV9]O7>MAWJA39N7+K^HZ=*+<KA@_G1@-]"/80\@
M%LW6T-WU#S30-4RBV#SX>S22+'ECL!AB^6$566X\10.-BNY*%P=AIQU>TD"\
MY,ZN+Z)5CI7GR.T\91LAZ[([+I0[QG]Q]UE>/__U 6_@0@,=F<V*Y%1MEG*E
MU/Z1=[WP1]Y5?W1NQ< F9_V_DQSY .N.J^%N0!8\7-K,O@2N3DPA1ZA) 0H\
MA:I M:7\!AAY[@\C1X-Q5L$W]](7=*WW3=^ETW'EA.6B+?T:;BJ('),(/"]N
MB092G,PJ(8V64SD;7V];0ARBTP< 66$?0?@TCQ788>"C;AJ1]<F @^+(K>-P
M K3[FP0,Q0TV=U=T("9Q1<S,'2#X/3[LQ1I+L<]IH#,2\M1*P!ETJ<.R$XZ,
M(!\L?#\QM=R]*;R7C/GY$+AI_='$[P74([N<(E]V]FTD\_-Z7SP_A*BV%80,
MLA".UN15'#NH.V;W+N>)=._A4E;28WG (3Z%D(]"R#K.XP7[A=#NN:XR0MP2
M5/TKHK!GVZ3;:EY*HD7='[^--Y&D!JW>@[)8&7\\Q-MO.Z8?[#!F6KCH)XHM
MXHMB( MDTD#/A0&6@I$A">WI%+\\1PP.8SF_!WLEZ>CU,:P\MW%T"R,'K<*:
M3%>!_<:/([\;.BW<Z^W,Y]'+E#>Z"[<MPZIYCUQZV\AVDS$\:K8J;[Y@T0_H
M.0L C0W)QM\;3X,-'QU\!C",IZJW(5/3-!!1=OWN%=5=BOH39/:51#*%+$#5
M0.ZF1R,[(\CQL%E$D*=4G4U]%7?OIBO#8%B?#SEIN(@J6VPF7%T+(8OIT-M&
M@&U.:^9TREM$(JRQEC4==R]NS EG:6)+J+Z-!F'B=TV<#;5TI&ZTLAL(C!?/
M,?)1XOW<3UW[BY]CF-M>26")#2.ZFA"M.H,+=$R4^,247"?N;?IDJ5PW%+_<
M)2XN+WUX0V"@:I70_JV<,!NC4!S5I6G'%N(5;G%&]W0V5%^1%X.<P+ NEM7Q
M%OX(2C=??&/94HGJY[<E]L(C(W<&^D$:8K>PB]VPQ>\9Y-;$_<W^XT#<R-:[
MRO'+:<3E.:IG.@60>0-9[+J'D'^<IK25_JL,@!_ 7K[L+^G]]4+6>N]6KR1"
M87Q5-WTYEG(,.?,.TZU(_D$IQ$Z7 M08A\920S@V[G'M]6X@XR$*4^,[[(UD
M%W*JIP2['LP7J1*X+RW\Y/<8XL G"OV"^:A"*WU3I)ZJ1W^5,.NN/Y."O81.
M<KCS.)["LRW_WO5GO8(]&FA);W9_A3H[#030^]W^A\'D.FJJV$X<9+]H 99:
MR&_5229"]U9I(+2A2!(C]8]3C5\:N1LL<@#['QH%87Z]T.?U7\WO;TCXG]P,
M)HCH#^R,^#3V"=D=_:D3[8>$G44,@-<@M8"V:Z; IQ72J>KC6VNJV_[(Z<?8
M6JDN(B] *?@A2<?TP3NB'K M1BB%&YZ5<UU)P@YQ3CLC01&RW%C,B?) R8..
M.@PC3STLVUUM,-E8[MVVS,>JM7VSZ'>,WYXI@^<L[F$N8APIT>\;(S!R(I9;
MPHLN9$T+ 8NI/2' 3U( YV<!.*Y/0N[3V+5+*8O.+ESD8!?PI&K>NB1R+A@Y
MCJ38*_^*'E@YN"WP?PR3C#]:R54':;#=&EP_+OR93U;H[[&?GE_PS4RW\5YH
MK\40CQ;7ZU/I8J77AC<R;7\7]7\)NKL[+[8 3AWE C#LO:,TT(HPQ@"0S[[I
M2[M@L7K(VOFZ740&Z3:@"7I99R;:?Z(M#9 EP/B^T0C%+J$Q:[%5$I@"[$0B
M<NT(,8[B7DC5QX5]1)9"9W925CSEJ1IND)55BE"B&< -=ZHIXOO[X;;);SHY
MD+CB38Y%]S^=]@?00)[IBUCIEG;L-.P5<"/L>80EJD#7NQN6!6[^27I@UZAU
MD+5[T=0*P'%VP>=:=EFW@+@2U9:X.2=/?6$&2,5MK:K077Y^@)<6\9'AZY#K
M@!(AEU"__#\N:@#F]]CET"_RHU^K.!7HP&T<M4QJ/77KPO\O*1+4 "L 9/U;
M0.,N12'/6JA95.Y! ?+P6R*U5'B-8UJ6=!Y.I8%,R=!U2,83R X'\+S5X"8-
M9CW_HH$SS\:"!DI7CWH:3M5*(:SZQBB.,](<GC4KKGW$)7,.CFK>W@ A'0>)
M#7-6?;<+?9F,>18;3@XP\XU!<DT">+=^-]A!$;(9LLGQNL=O@0"G:J)> %-H
M:@<'-S.JQNR<]V:E^$3,F:.1UR:0HW;(0,0MJGX;=AR.#(9]  A%.53AO]N)
M)_;WQ,]\&,(#,32^9H8!NKQ?M40]>%<\A+)  P52;<E3$<AI S"Q<2URH@"@
MV$3RUL]D_\;J,A<P4&!#&NBK#W+>#G;IK\K&JS1N+P&JMD"RH6HH.!$1H7ME
MP'QI@RY>_<?5$V^P<-8=,&!,S"-JX>:*;^">,;*)!@(Z++R)>8-/W.%"#C?M
MC0&3,1+@M<Q8M3I; +V>U'\M:]\&#TI1-98Z=XE(RE&QVJP1Y"/L#A@#6:H'
M K8@!@ZXH\@PL,&<9PA572&"D&@.#/5>+KGI/V>18$+DIY2D"K\4LCJQ*&)B
M*4P)FD<P?'TLW[-X@&I7-3:^6-W9<I%5AFXSC:.3K$J$DL]3#W?Y7IOQ8C#(
M"UYNI(PN\H'1CIJ*:F%UH;L'; ]H_=VO?%8=YMJ.H*S!YU:'I6I,&B-\69*'
M;'E]=V/:%(,^"#IC1*M,F:F/C-)BFS6X;NL_-5*U>9W9D:/W*E!F&&Z5-0I.
M?&N4C*Q5(=\ C Z,!I640N59Q0M3&(N!F5:/"-N,!W=4;2#ED-:6V#E@7A&X
MJ!H)W?N9*.9M(ALUT!1X%'P$R0;[*G%#%!C]<78_ZZ!U3"7#EK42U1> /AUR
MVFOT[^X-H+PO?4A ,]?1@"(FPNXBZE%'<;YTZ9Z?(<?MXG@M1YH=NX]&KSX3
M[%!]#T[PW"GT-JCNN!3E=#NK3+4VX*O"EROM//UI(FGM62':DPB-WH([8(>0
MO4;JCHQ?D=0J>&\:-S>WH:GB9;,"2&E!Z7K8Y@I%W=MF^"&5N+^9W&MNA2[=
MW#-QDNM50?OE,>W6I5=R]<SV3QH%TMPF3>Y.C+OOH*SMN)0/>=:;EVBOV<P0
ME]2]SU)0U+-S5/6_=9IC%SE@BU3<ZR;G4]Z'TT#[Q/D;;(??0]U;F"P]7@?=
MY7"B@5:#(9,HZCED5Q8P?7SU_F5:\."[U1W @QX",#;GO@%>5@,FQGO(4H<3
MY7 )ZZ_W6('EP6HZ.4@"^'A[WK$@C_1!2NR=];3;ES4.E+A\#[Y<TZ=EO^6G
MM_KH"N(RRN[EQ_EF(=FL$!I(8&5(E+6HGC*UOP7\WWA9-]A]C,I7AOY[E5X4
M#31_..=WTPT@7YTW13/HO3S3*1[;<R[#($KKS:$["$$; V/M[L0H^?]Z#[+
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MWKM9U64 >1"R.-GM'@V.<F=2R E%CDH^S]WM.MS.<2HZ%>89N7&P]_<I;'O
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M9Q,;PSH#SW<OKZ!9J.E?1M&%E564E-/WFI?9'W6-LY'E4&?C;CC<AA37<+>
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M(Q+\8?X[6^AM]7>N#&NK=FTC?.%X=HD+F,'553_/&S7EE8F$W4.'YT;.33V
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M?K1@MNHF/PLW"V8Y_ QF/^#G5A#QG3JR9GU4ZI(4_.0VF,'PZ71 R)L@JE:
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M(W1[$P*2"4_J0; ']]\WI$+;L]^B=J:'2T%C[$/Q17L67+4)X9,;YEI@ZHT
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MY&H;"DBZ7K,W\Z&!T)IO(QY@#QUWS7ME8.3K$L@M(.0)32Z^I3IA.NWCZVZ
M4*=.&>3YCKI]?X>Z*=A+\?[GWS"FBM2$?42ZP0NH(1KP8[JU?#7((Y%RJOW<
M9*W!WQX_#0=6OIEO#45R5"1F%/T-A#+]Z!KX-_O(5-/A:)RQ6=9,1W-*JS,^
M=/I-48JNM-P&FH9A)Y'X)21>4*#9<NL!'Z$2LH9J(JNT 5TT\@-0"EB\9&!'
MV\?* 5$#U<[8TC5+1O2A[( S? 0%51*5P%Q(#L"3VB_#9'^->'\":_(/8/7_
M:; _6FCSHT3Q&M_&!A<.3:([7YYYH+ 'K+V;-LMN%!#7<79R:?$&TT8$G L)
MX%U+<3HQE'2N!KW.]VF. A)G:C8$9D&]"[T$EMA@ZL/\&7=C/'$I9%:X(NJ=
MJR@%U$A'.L]AQ:AFZ+3 N4,X]SD,EZ V6DH!*4*^0'M_3%*5WB^(BUFJ "S^
M;#\>_87L/ 7996_O@H0R:G?>>.[+V%.@!M-VO?J7N*P=60C^+*@Q650XCJ(W
M*V*[5^XT4?Z>T^"HP?/(XES)\;2'6=X<"M>9-CD8J; P@%X9PWPY]Z^EU"[K
M*Y=TVM.=<C320_=00+G)I6%2/!YS#X?JA;H4OM9E'W=!+E6O.6CBKHU+#=U]
M.3,X9=!KS[JETFFB<I.]::#_M;L2=>!DI;<_R#+._H*=YYSM?9(_!(@%JMIT
MXMT%?OX&/P[II8!6\[6_H\>/ \7^A"T$8:G7GW\?^K>?G=O\)!B9(/;8'Y1]
M,8$&,)(Q$_1EB%GB86QXW6=3L(5UBAC>YY>$(S[0$]>]25)M(5ZG@)XGD"&=
ML98 O R#7_\$3(ZHZD(ZK$K-YUGRC4O %G2%+OCE!88]IX!V!E"M=)Z0=2UI
M00KH$0MD\S(L?0L+D%NL.1Y<ZNA$7O3=X[O^?^VSP#?5OMO_M:&@?OLIZO9_
M96+^<C>4$"G!/F.99J*SK'LE*;^$\,!RYD:]_GYQ!?GGD[E'C]ZPG\Z.SW9X
M^"RO\;'Y1/S23!<Z;1[RYT=AJL%KA17 YKA.H( (Y+$I1:*@#>#P.N 4$!D@
MZCA,/2)K$S+;4[4)]R/'3:)GB? 9M]4?O9J$/;E.,%YN-2*?:%\%[Q)0,8@)
M2\=BLB<0.^^0T TEH5B&.N1::=4(*=]I&[T$$_BZ<6^YRMH6>:=OLR3=R]!2
MW9EWQX#68OBD7T*K<^=.M+YLRKS-GX>^]FN7 /=P5+\>O0D& GST,EG,!S]V
MD^RFLJJHBO<$%@R));S?0?^'>V  F\\W*4]U]/PL\F!!XOFHZG8*3,3DHFTC
MJ]C"MXKK*B*H):Z#,1_Z1N@8)";T=F79%\4NI DD&2,U>F3KP=\--"17<6'/
MDC(8@3U] DI@A*,H(+?HGW_.5)-C(O_ETOL'$#]^IRA:A!9-E,LNW;W[[[.,
M3.NFRQ30GTA+G_U?S_T3D?F^&?Y)&*K^C9"TQP'1_2[[(W1#2$<Z?SQ:"))>
M\Q="XKP>,AA%5H+YH1<_(O"7+5$TY U5HLJ&M.LL6;X$N090+673&=U%>9HL
M)GP:\=WW,?PG@<=^3^!)^'\C\#R29]0X<[YY![-X-X5O#)8%VM[+IOS1G67S
MC:.(80C@'.8UHJ7<@AB-QIH"*W0%OT-%GE<D7B:^49-G>C7\OZD- 0+,16GW
MO?*?3>IM%F R;MH#L,,,&"1]50 J!O(H9)=GCR$@]MQ;&;%1A )R25M J*]A
MB'YK8Q-[06:TV^4-NC_[*3=V @S1=%/ANU)5[_H-YFL*!& B60MH'H3R,Q31
M;\X9TN;U'(I>URQ $6C:B/7VA:T/<*KJR(;[BYYZFM[G+@NF#+PB#2R4Y^,Q
M'SS?<I\O;1E=BC(8++[5;@1F"P\2NT>K_5&_L$!YI%*/*"89#<1)V=3=,H1M
M12#62% #6)4=L=Y-'W8>W@0\6=0"LK6">(?*L-PV! 89^M0--H.0L442@V;G
MP4W '.#S)VK^J^\2HH719NV[%ZOX@(<DD^WQGO]]]$_Y-7S_N^(,!L#7GT)^
M(D3Y(%=*0K#">_W<U=AZ\^]JN%!<I#3(=)0$"5Y/C*YTKO#93@36\\'8%H%Y
MW0*[$;++C 'P28;H258HL<&BON!:_/E1U>WSX]EW$,W:D&V A@Y&]$%Y(=,9
M8,)^Q/+MU1I$:_L:NF,="TSA+-&6="_/GS^;NN<(@6$;L+4P*SZ2&WJ="3OB
MYD<X#QBN>#BY:FSW")X,#"PTA%0&C&/<<8@L#]O>1&@,S,7[DUX3_U&_6D<'
M(0I\7L/WM\</66ZH"FYG/7MSW=(<_&Z!U</G$5$@[.!=.S0]Q'+UB*L$-C9M
M@A DH=73X)\CFX\PLJDZ+JH2(MQV;>60-/0=N0N1.Q8HRV6A5U4Z@6:6J2>G
MI>L.RT1L*M&/'M+G,G*EW[=UM".V\#U6>-L4%S9Z#H<T^G33*-L<<3)K$X<2
MLTPCOK\X[7'Y=+ 1]<PPU:/@&7?9]IPJ3XW<XHJB-RI6MFRMC &=$=[7B4$Z
MF<C#<T:UG*<Z-VWYHB]>G"S<@%3F[IO=S&*-T\TMR6G\5 ]2CMZ5V ;@/=2A
MA@+:P@J3/0064#E\.T@R7FP]9'EC7^W$V-'Q7 I(*2JM?<U_*P^UTX* -".Y
MZY'KY^J<A4GGP4R=\DQX-6+==]S:I%M2!LPE&H+?^("'MO?NY?>E'ZL&YGHH
M[>7W/S4F/3.B@$8LG*_,7?TIY@B+FF207D$J (3O3%@Z3)H%7'40_ %"*_**
MH09!?6--N&YLZRN$Q%(X/_90=15"VK1L05NP:X:,P_S6OMJ==M,G1PO:CU-
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MH#?N.Y_CZ,SBH^<K;T\'[C#1]/L0-\/)^+BCHEHVN72[\WRD+<7_]KGOZCZ
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MEN1;.)NU.  )VV3?[?K\@CU50204>IHK 8$1)S^N>HZJN[)7+:V]!0N#))9
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M=<_;]-&V%[+@ !%7;3OO%)6CE@U0AY=SG;OU\G @$*D]X2I#WO[=L?G*<E)
M+C_12?@G8L!AY'B S \#Y]'C8"0C= Y"O$Q3.[9J\?O.\YQ8W2G\%;0#/E!
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MFY2A5IFZC-.V7*'-,HSVHD."MX?4\CT61I^$C=K3L<]2O9KW!Q7*BS:E5ZN
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MX,'=W5V"!W<9= ;W&8(,,,"7WW]WO[W9B]U]NZIO2IXZW?V\YYSJ[N>5YVW
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M)'7ICCZ5Q*!GZN2Z\HGDL554"7K3U=0 @U+U/VEVM*)C"=X]OJS-W[,?^2,
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MO=G7.]HA;Y<DY?-.EAKI&@RD+]L8"EK+^#CHO7_%2-'J7^0LK*QSY'ZH?=.
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M#")/U(? ZS[M;$2BR=/K189I#"+,/:-P6/K7 (*/?"<1GZJ9GP'N3F(@AAJ
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M1TQ0,Y^^B5*AL9Y'**'CE5KO9:<&CV[8_E(J$GC0*W<4+>SC4PLNC]"Q^=A
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MI:.D=P8UY9\#?G@8G@,ZTL\!G/Y$AM@(34P)<7H+2);MCO_41TDT5D8+.%B
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MI)F0S2K4]^:P-=,_>U843,,4Y?[8<[5='UJ80HWMY?$9O8;VOT@26W;=Z_^
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M^>HY@(#N%<"1&&&1]MK1EUQ8VSPOT?'UU2[9)II9H5F1'PPW:0BU["<JA',
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MO&#@K)7%H/]>F9LHQ=W ).!-.IV2$2CKE<1O=)X!!7=U5XL4BMWZ0'&2%$E
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MF!KS<4)J"YZVK2DD @<$2F6BN,/ ]=](+0NA,0AV$Q4]XP2;/B^V.BW?I&
M&_+"TV7:8MO?U-,LLM/;N1 AK=($QL>$L_4U8/DZ;N ;YLD,I/_->[HEER*
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M;=A?\'.@6/^EEM(Q >"C]]^2OP@]__D?4$L#!!0    ( /6,F%BYSKC7V5(
M /!4   8    8W9A8RTR,#(S,3(S,7@R,&8P,S,N:G!GG+IU5%Q-LSZZ<;?@
M[@%"<"? 0 CN'CS!)4 (#@.#0R8X 1*"![>!!/?@">X$9W!GT,$O[WN^<\Z]
M:_W^N/?V[%IKUMZ[>U7MKJ[GJ>I^F'U8 8A5%544 114 $!Y_ $/\X \@(:*
M^L_UV- ?+PQL# QT= Q<+"Q,;'Q<?'P\7#P\ L(GQ 2$)(1X>,04Q"2D9.3D
MY/A$E%049%1/R,C)_AD$!>VQ#SH&#@8&#AD!'@'9_^?VT &08 /]:$_04%@
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M:Z569],*[][Q[?=6J6^H@L@GK%I^]F3_Y.@:H=US*=N]9ISCFUW_\]1V9(4
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M",P!'P+UWC-43PMO\EC[AL"M^)5AD5L3PA#:^U'_?)-\.+M8D,I$;OB7]0?
M,5Y]9N&>]/@@.[+&V5RTDX_ESY1W'^6E@@X'(R(*'E1P/.GXQ'C'?5?T=) U
MHR;$V.@N<6$F"=E^,5][7#.C]A0Z;).@4,1[;^NZVBI@\0NAM%(8B]#3&SOR
M4BMK8)M@.V4V]9G+OXD[_^W,6'T9#)83S159;#E1\Y5WX[LOB?(Z>QJ2Y7/S
M$FP[#G8[?M$UT1R8K#_IA?<A-9PTDE!H*%!G=44QH@CS9ME>_0%89FGSORL
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M], "!;4*P44C8":W#LA =_?2YTWBB8;<@@TV;R2V6@-963UB/"SX$&GQT0\
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MG$Y&<!UD9(ZQ/FXV3'D-.*N%H'@'_- :V.8V^@6A:W%'H/4F(3W4DGY+53\
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MSS:Y85\GA='<6%^_%^=.$\67]DRC+.'^^CI]54('O9(7WV]H*$9&.-@8:O.
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MY0?I65Z'IE^.GCZ=?05Z@F-T(/.VP["_SA#:L\YOQM&[&B8F,5P'T/=8K3I
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M*Z?^ T"JHYD&T[P$,JM!K5UFQ'/CWO8B (41<[ NK,"3XQR):C!H;Q=)+ST
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MCJ$\S+/*I7+0\_OC$^\Y^ES'7_L\ME1GW22@BM0BG=(7!J5,M@:P79E><Y0
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MT&_Q[0\,"?O$>@39*KL 3LO)X3Q+4Y-"3'ZB^J*<.TY2OSVPEP>QV#M'*/Y
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MM_4FS8'G!/1T,T6!%7AFN3&6AERYS[0H.II*Y$W!BQJIV]]-"C))G.ZJQT9
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MQ4_V$9!C![S]8_X-S"M-9_T(P#+H?7E#GO,(Z$C..DV^DY&Z^%L;YU2U AK
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M8L,QDK,W'(X;^K^H&R1$8/R(T=,&D[,TL%N%ADH"Q:#9M\SJK:P3)%UQSM-
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M@-:L8O#_.(06R+ =Y9,BR,^'.O%G\T#_VI#YTJE6-)Y,*!" ;0'Y2?RP_U$
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M@$WO4.%RG%C=U;"DMH0)=L2E)A14S<>%1'1ZIC$>:HA!S/R4'P#^NK-S%@^
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M :EGD8;CVNEUDY8< B+YR>E;OZW!$XI3FAKN4?_=M8+_\WB" MWVET[PHSZ
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MJP(4K8[*)IKT**E+/V#NT#UM5-._1M6!OXI=(JOY8B[TBJM?FAAH\G&I'/P
M0#V/0RH<"OC-"+G!!^:?XF$P2TQ[.H5>XUUYI1%4F'B=O2&,OQJ8B<>6')#$
MZB$=NBOX/'%;;R89A6A>)D!F]_31V)GNGOZ9&>ETT*.10$."\TX+(PMCK,[>
MT3E/SR&#I&#'!SES7%-<3-MDJ *RJ(C4>)1LMESTPGY\,MA_F!3A_Q:\3^#*
M\=9XIL$#92MQ,2! 186"V IY\@"07X^T!V4#X% 6H;VW^/M 9J89$NWY^(E@
MM$5Z+<?YH[0F0'V2^A_XKO\7@?HP]Y\ 4$L#!!0    ( /6,F%AA7Z)\JFX
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M@&V%V]GD-U?C"V<0TO8^>B^&)<5@ 6.$LM:L^88M"8D<*2;P2],EG(V.,WE
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M41M#4+V^9M%JB;56'NR#ZPX2IC<VJ7E8:?25V=U@@S"]R<04G,9;.<;WB_O
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M<K&2%"2GZL;]T\L988IHA$6IH7KY:^ILWTL&#<?0O#*6_0;X+].FY%F JO1
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M/]5R5?61$9+EAWF")*N%-F\(0D5%QN,%FE2\>PC<4GA:[(\@BT9H>UC8M]P
MF31[2"G%[7,+B8MW61\VPA/?K#3DQ*2*1#F)NT=H[&JOAN H17%!TVE1/VZ
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M]WPL>W_Z!OCC*NU@[)-7C'9U-T :VJ66GT77&=P _VH85?<)[2\0T6CM,-Y
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M P0HN17K3PJS.Y/>"6?G69\E2I:<CM;?)D62#;UB9H2E>/H6ET]^XU>28F1
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M*+9OI)4;XZI,=,"M3#I7+FY7:YV'R*ZGEA@37BZP>#YN7[OO,>LV?88Z3VZ
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MX_.YZ6-P?0\Y4/V?/(%+W;',(%&"DNLC&U_38.'4SSDF'8\&?4/*0<[%X#>
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M& PO6Y$1;US&&4Q"'O$K_<^+<]TM]BE@8J-G?C#LUGMM*?/S _<_[.T;Y\L
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M0A8<IA_7U]")HWCY4N.(')&M9=@EP"3%N04X202\C3OK #D&,L[N>+C<98Z
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M5^]HOX7F!1RYOTE'+0LIX)I()<]_]M-987@]]7 +SM=!7*3G4#64*_EK^JR
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MB8%7M0 -!<V-_VJHZ 3<>-<-Z]S4^"L1<9(0]J^&5<(M).4IZ%\52G1G*B"
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M9460?3;H40\55MH!2$8IX7D#4C" 0U]OSLAJ;MP,O$0PGR!5/$'N[Z,U *9
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MYO#NZQP/$,-#2+#VB),A( )SS9#;9Q$ ZOQO""*P4GU_!0%[O2L <Z'O,';
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MGXR9__;^M:X/%!>'THM1W(DI#1SO[O=U97DA7N7U$\ZW3[Y,D29F)7_^U/%
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M/@^M=#)=JA_V:YO]G>02?M9:HRYVFS[U>%_B&&)5J>I]W4445[!Y(444@.:
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MXR_@A<^TZUR+#S2V/3AB<,_BD;&G3QSQ;P_)%7A(H4?/GVK)LOA_\7[.'8/
M:''?SEJ8>"/C$6Y\!H!_UV6D\/4[&$\31YFXLT01G.[BG ([J6VG'<CD50_X
M0SXP)_S(:'_MLM*/"/QA!_Y$)/\ O^M-4*G8GZQ2>MS4$T2GA@S>M)-<I'$S
MEP-HXR:R9/!'Q><$CP& WM.M*O@7XMR1;9? 2MGUG6J5"HGL)XFCT98TKQ3;
MO*T4Y 8G ]ZWWFC1 PP5(XQ7)VOP[^*EE</-%\/4WL.2TZFK">$/C$KDKX$
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MZ<H[BFY._&*<>HI ?,G@>1?^%F_$C=P!?+_*O1@2(@ZJ >S>M>;>"D_XN?\
M$4#K]O7K]*]"GN[@Q,D4'F'& *\>LOWLC-+WK%>.^03R?O/G7D@]JS+[R-0D
M6=9Y%5#\R)_$:?=:?/<6WE@>1,3DYZFJ-S)+9-OL@'EQM> ]SZUR2T/=PT%I
M)%MG%O>>>-RRA<*6Z 5GGQ"9M19[)#<3@$.Y^ZM0W&I3:A;FSAB,MT_5^RUK
M:!I:Z?Y7GPXC _>,>K-6*1Z?*HQ;J;E."VF"1R10F<R-OFQUJ[IND7X$LZE@
M9&SY;?PBNQ@N+*RC0^4(RQYVCC%,=TN;PM&=L..,5JXQY3RY8N=W=:'.V=DT
M5[N?J>&P.":V_P#A';93(9U$9F7DCJ:M'R(D+NH;;T)IL9%U*LKNQ!^XI[5R
MM6+^L2J?"[&?>S:=H]K#$S[92=BJH[U1U;0-6-G(\5VRN1D8]*W+ZPB:UD"P
MK)==0S=J8ES.^G)#-+M<#&<5G;K8Z(8B<4GU\S%T/1#8FWN[I_M,Z]SVKIO,
M EE8R[97Y7;5.RN0D0C=<S#[PQPPJ2PN[::YD21#$YY7/I4M7)K2E5O*1>=)
M;9 \9)DQG![TZPE6[82RQ^4Q[GUIS.<JJH6'8D]:BG#"0+(XACC&0/6FE8\Z
M2]VUM1PTZQFD9D;YL\@51U31T:1'%R1$.B+ZU;L9B-P2(*I_C[FHKB ES*K;
M3_=?O522Z&D*LT]62Z2[B%X H.WG=WJ9&Q*&)W^Q[523S+8*V =W!9:M@)IL
M?V@C?DY://2LVKG-.U[GFG[.\F_XF?$KT^V+G\J\U\ 75O:^(_'TSLRL-;<
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M*MD+IH9(-BE2N7([TZSTE9KNVS&&C1OQ)JY#9R02)<-(0A&"!WK2ANHH)H\
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M-?_T5A>[:! G]S-=F?8T//"!<L:NAU"BD<''77%W1[7;FHDU-^+S5N#8&5+
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M\"I6I\0:^P[Y.72//4(YYIU9O%@/;/F#10;W5-<5F$&]V^24W+Z0_<F%R6=
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MUS!@4_3UBB"DFX.8%'V'O>Y1S?DFE5_/*UCEQ;Z=$63YS9<9N,RCZ>!),2*
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M>4)H=>7@2HJ8^Q[,T/C^?9]BCY\&/]B^\G,H7:F5>' (0D6J5_Y.5,N@? Q
MM%RYH;]CR73Z.XQP#M<5P'B42JS%/I47I$<\--YR,V-ITL&Q=Q$"LXD Q-/B
M)6<+JT39TOJ4#DG6;O6.I,18D]I(M@.I'JG=7>'C&'3RT/%\H=ZG!+S.REV;
MR'>B$M81_E)=3&%93 2FQ2T+6.1NV><6Q,=RAW"T6952VN'G7.=5(J#O/2FU
MES]M%YGPJ*-Q\V7B*J^X.YD[-9#3"R284YQX0IPWY&Y#G([E+L=J"=T8R+(R
MJOFUQBQU+/'W#N,?.3RZD'X7P)NU &^)=\W G-?M+KVI,RN5)/2\<,L3N[F%
M$"UVGXM%MM\B#"T"L)B"F3ELRG>NY<JDP;B<SEW!*;9IK+X.NB<SR37/F<91
MB=TP*IF5_#&CV%I"!'=D]!%P9JX;;;FE[U<:;2.RYYAT9>B^*^38(NU/R+R6
MI(JAC$V9_9F"4A5-_6E.7>8TJM>]V#?6I5Y)8M$BX/WI?$+/G].[I-,2N!?9
MOJJ/+"6G0OY49*V6(/QDYV6%\+PYFXI'OM]:-!J,[ MI%UB$HNA< ZQ=S2&B
M>:D\]F>TOQ!.GZ3NZZP$%;DDZ99\>RU>NV'?Q4\X%NNO%?&M(/5?IYHMRNW1
MFGR@\E/)YS"_4!ZE(.<>^<NS&G-H@3Y.LPECZGNM](_KNO%7)B1]$R+.K@VL
MQHGO7F00]'W^JGPVHE2VB(0#(_[5!KW_$X&N[\JA=%6[@B^&; Z.M$UT=@B*
M=LSJ,7C94 WG8OU6=LGG'C9]0HWO!LZ]3_[A[F%Q[!$5?*$&&Y[=7V C'R?=
M)&3S92'.B^\"5OX5<L']BJG9!!%0YU@7V_4<<%4@8$)ESNO9RUJ6XQ1L.I*T
M,F$T1^F(2Q")]W+LNZS/ ZK8,)$[TCASO#3V&9(A>,P:<\&D9A[2.A(!]M-:
MGIJ'<8-HH*]6"L,*T2=1N]W'>X6VX*]!KNM#$23RI;/_IIVQLBG,N(I[M?J;
M^;74J]F'Q=P'BJ])&8L2*T8$J#X&G#L!T0;ZH9$5,5<A@1-@["NY#HHL;'X.
M?H 43D.]\)?606R11T0 -Y4U&&W %/K5'73CC>B&M]7+)IQW(%\CQNW3O(UP
M^++AP4U!> >Z 7\Y'1D?O5*F:M$F4>R<"MRJG9&NELKW%R"%787@B^%7H29\
MP8@5*VB&C*?,N/WQ*YDW\SP2PGA6IN4<$I>%5P- =8+!2PC*B5>D&6!,M60U
M049"R>O8J[E9M)V>1Q4R;22[]/&R35AX\]E#C-,*$'.#:]JU6/+Q.VG'$M+T
M[6BG)0*&IZC7-?!*',L5YPP&P-[B+*PPN(-*GH_M3?#UMR13Y-LODIH5J(5\
M_$*A!O98"ETE@04:*P!CD[)H(8&6&FVL!T:*A1U47,5^)JE/PWJOP"YOSL9'
MOR#P53< =!TO7G/H6)?=- &B]8"A*9,FZ!_(HL)W,K2CE[WZ)D-DAO"L',L%
MX%77L(-"#5)WDV-%Q7;UV>]9EDL_MB30#*#O$0$_2R[B=;V6+B&6/P OMII^
M/D_0'NN-?GG%S*I;[P630(BB]U\5Q3G#4$5D?(=C_Q@U*^ G.Z<EM.Y0Z%EP
MJINK)W)C;RV.O/:GGM79Q-*?$60Z8R,-(,"*-+20T-@72N9DH(^%65@1Z@[?
M;501]8H5(@:\_)$(H);=9X*8F3F5%%CK->H4'31+;QL'_NGN7JP:$L;85;B5
M9K$MI^GEGC>XELV((/#1H0U@/TE=JTF:708)H9[EECUOO6>+2;W>%'P1-ES&
ML>8B3T)L&5D7+.14D!_>5[^].$0]F?SU:"D<?*65'U,^ZYI LU6UQ=SY L>D
M?6AQNGYL??[V$#83NF)%Z!NW;VX8?W9;7")#79DRB%;!B,SI/[E#Y=_M5KGX
MYQ<;O\#L(.H^#(MAF$'M.(\V0J5J+=9K>],Z(220S7E9BJFKP (_O:9UZT>#
MEVM^GC!%VJN7E:42;*O *^VW(8%2W%;<[IFS<<>?A5-Y=<P7J<]S=)>BEM'K
M<)]^'UT+^P5@VLU24*W,:).)L]5Q?ZYY+G0NV??J5.0\X>?P K1P=\QEM#\_
MNGU8/#W[^5H;<[LX]J'+T@QBSJ3WI#"%U[>,?\7ZTDQ0!4Z;J8;Z]\^67CG_
M1P="D]7U.IJ717J9647X0HSAOTH)UZ ..&/KVPQ/9W4F-R\W]I=D"F$RXY9Q
M]EEFX_Q5<81M[:\.(2;J2"ZV;F@A,KDPNA62NSW:7^\F7UV2T&9QAPA@QBN^
MRKU3QE[B/NO_XF"?1R6O$AN'++/4RGI4/[&[6M5 !%C>] P_&YTSS'0.PMV:
MML;V'ZDAH(<-C3A+,[LPJ;* 9\T75S3';0U?OCZLD,-([5(O+S$X27SY\:5+
MN?&]6M2TH^RPBXUB75@',S9^(7GW69R]^I"!RZ=3]V.*BB]3QR4!CLHM/A^Y
M;P>1<99?'UO1"+=1?-PX62;0^(&^VY[KPA0_"CQ[>7(.=?QI.>B&9KGP.V"M
MOB3T0;[C.'O!6B):2G^TE:48ZBD)_-:2F']9BM(L8QQ"&TP#ZT1,"(]7U%V?
MJ/@8V/C+\[NPK;5#*@;8E=:;-\GNWU9[XCK!UK'>9IJ*6G_SN;6U1F&BJ*F.
M,C\!^JW/4'=Q^4CQAL5O"!-AV((IUK?$59?OU_7H?*?5IUU7XX\F^S ZG:,N
MUSM\6TR:J7DH8M='8V[Y\=EB=([M8%&98'W6GG*M9R^B?Y4^L2=[A T[=N0N
MJTL,,W\WBQ:)/WX"7D%2V]F\ 4E!E7VE"^\@G*3DW'[C.]X&B55%=Q=Q:=X@
MZ4"%0\-JI/'R.2K(MLM#NO4H.J=.)O_Q/ K6VO_KG/773E8#_U&V*\[C4T\;
MOPY<55I"$0%Q%8?,MGG. ,G"8G JZ\"(\A8X;%&A'4-_5AY>(J)0'H^2=[!Y
MY]BF@BGL;"XO.C.IRKTO*56[^2H*T6:(9T;'E^0MNJ8MUEUL0$P\8[0#=E):
M/?KU-""S4L%8PN5,5TZGJ2F>O?&=D'B5L,E5GY+L,6'*G!<*R5>#C065$I8=
M>Q8T4&Z$%JK/!?49S_-FB_3TK;QMVA5,WP<"L;!BK&IW^_76=H/*I6]\XD&N
M$WW:@(JBH6MM&:,/,NV_O/D"@QZS'>Q.]0"YH'*]"B[;=[:5VXO![U,,,UK%
M,CFGVEW+O-+45LQC%Z+2OU/CIE'MUECPYT"]_U'+N;\SP;!Q?,)#*)4G(IF0
MTZC(XC&F4CD3FL68)*>&R#QIFU/.(AV8D*D,Y31BMCFL'$8YMR$Y;W+(<<(L
MPNNW]X?WE_=]K_?]"^[KNJ_K_ER?[_W#MVJ%S-@%/*I.IZ^6BSZ>1N+>KK8:
M:S"VAI(10/C5BX -93W2A@T@Q$)M%,HA^G2/RT!!_)B/2+6:6OPT""*2X9G<
M2%]K-D:-ZR%V 8LVFDQN$=XGZ3;HQU.DX(I,,T'K*QE4IC1_*0%&H3[?EMON
MDXX.3R-C$V+TDM! ";\AW,^L(DJ<_2!APM%=N'$I4.<7JCW"$.=%X;NS?T$[
MD^Z70B6<ABN"">0YJB( -)TW),FSB4RN+1BK\R&Y#=U1/5O9E/JSER(UR%N.
M)YS*8= /L$(1<>)Z/_"POQK+W[X46\V+VMG7P$=QE^UZEY>(]=0$"/%Y&>:<
MO)B PLFM:SBO.K[5*[\\#_>UU*N>AS)E]R^[B7R,E',-:V[B<'@[D.'2GYYS
MFD5MQN*(?@\F22] =_C&EDI! 9EVX6.:?[]=-%2@#PWJLG/I6\RTR5Y_7Q/,
M381F!%MEC ?A4Q4^C8+:=R"_;R6PI9-0Y]3U]7N^-W6&.<XC"S%R*\M#(#:L
MK255QCJ[6X5:SRJ2:I/(/7ZB1%:M('GVS,?(1,J.'N+M<KE'K<[/]R=G?B3S
M3B(/<T%L'H48]FR/3/W^+&MGF5O#C(^_2\9 ?LX-HJG,OCW(/WSX7SUN5UEE
MVLH2&PP CK7E@(3&34H*SY$"P(R"AD^ZU>H(WZ[@\4/D.E(*\(@665O$BAJ@
M;U[MA[R?\NYOP:7DS<U5J^H^S\.CB+:@J)DCZDHY 43G;Z>'L3<\;-F'Q$K&
M&)9P)Y/S/?&A!T(8M=+O#L36A'S&2:-"DUH2Q6\^PZ!)5OU&QXOWK*:OEGNJ
M^KG5:T$>3_T[X:HYB>QN6B$\JC7A?)S?)#%-D_P#IU+)S4LB:]_OP=;-LSJL
MNAMG-?.A-ZA/>&9M&+M88%.>M-Y\KD*[FY7^!:,C^<N/"+2]W44.Q:'/#^ .
M&EGX;KC<S\H*^ HE]*_A,. 4N"I;^R0B9N!"C$ENR-AI_MW"L XXZRZ)U8F5
M'I4[G&'B\FA!M=KW%]">.S=R:F1(.C=$)-KFNS=*2[^3-B/(+)U#RK'6(9%'
MS=CSQ[L@356(XA=L)Z!).6A1%/W(("!V/TJ,D?+ XZHD^[*A<4:UMH13!=%F
MXXEB8^$4NC_Q&@;X$A\A1-BXU+?6429+=CLM>^1*;;*^@]EKD89PV,H?C<3M
MK%N4+V5>*8]N7X\6&-$9:F@](=<ZI)H,,G<XO]7^]NP=#R] 0OMAM723&/F(
MZU.0;S?>FF4$XDY,V#VL<2EJ3I-"N1#B@D_3GPC>52F@E!Q\<?1\&G=N9P:6
MYIA@DVT<7'TBS]\+0KG]W>?KT0WSBNAK;YJ/F?9?BCJPWW/?/<74H+-G\XL*
M3/Q*QU<CA%D;DCUI CCHAP17YO>*>G2_H,G+RLMSOW8!OMEK!R"FW%B7<$8U
M_<_:#RNQS-H1:\%]]S#/?[C?;'P]Z-+-:O81"M&'7P<PFXG.C'M?Q5%BW:.W
M175]>=DC/9F=?!%;KO\F/$5+VPA,'/FQ\5F%'@P+R >-E9FQ.X2XB\3S0V .
M?]!=!S\!\I&="R]9AC$#E+,*K6XX.<VQ_[!1P6BGASQXPP3JK8?'@$^;UKS+
MR\N,%!UBL0,I)-54-,YQNS36-7?,^URW<<DR4$!OIA&C01N=V<8;;VW.G)B_
M.8AX_Z>OLKJMY>(QU<+KH@!! 'I?L>.TDYSIVS?)G?^3BB)B =&S)DJQG@"R
M>J":U1+T2FL)*[8Z;))&%Z;V13"DW\=?B00] "I"L\K&DP/A[*7:ZXLFWO[
M)CJ*K\->/N"VTX-4I/8I5:/ZGWE+Z2C<]-AX,#]0+(V?&,B$4A_RCB<>N3%M
MEAH/RZ""-8)3]NG#9^(H>Y0_ZJ<@]%A]NAZ/TNZN;-E_\N)$WIUUDGA$KTMW
M+KM!AF'X_5-V^%3)53@3&;-2?'WD>;I%';1*2GTBESI/2/\Y@5;\RHB4HJOQ
M-SN::\\74B0&9+P*- "=T88/46-&^R=I]:;<2S9_@YX:,Q$Z1] GHY:O<9A4
MEO7ZA[/W!(18$E2Q_0)I7 )YQ3MK!=**@<=&LL$Y;LE+5VB^<%ND[9=%N%:$
M2E@S@RY$YR>"7RP4O4\O]DMMG5+HNR'Y'M=+%8Y2JP0[&2.96$JUQ20V738L
M!M>Q3DHDDQY#=>X>\C,D;W>8%G0_?<*5Q.MBP1BSCW78!L1D_(>2SZ7@%BE$
MB3;-I%SCYY"-5&2H^>9%,/8OL'25,\6U5=>16>KF/CR(T-N04K$_,W8O#.C"
MWP5,YC%,#H?Y<&"M>?E=)ZJZ#&(MS13E2)PD'$PAC12&W 4@_6)K5D:26B\Z
M/%!Z;+;0\-H=E;YU&C18%'W*^>B;X(R@,*4,]V"#64-X^Z9W"6G^OJ%=]"(Y
MLA+1>*N*O*K@.EEX)R&9?H9?U.Q^8!D\&RHZ3?\2:/,B-H3WE!7Z5QO>B78V
M4W=PLWP&6551'S_ N9DI)7\UH03&2S\8*S6"@3=%:/"_<=P@S3NR*Q(4'=<Y
M^/<*5Y_V78 $G,2_[S#P&\RNXAB;,2HL-P9:W:LLQ]&31@[VMOI4&KERS='5
M3#YP*E.\X^;:YL!U!4WF=!T"BR42S SL97O *W9Q4+VP8CO@Z11FM]8Z]=3V
M[\FI8R(9Q73A%7H5ESF]PACLEW"P4O*9OA7B@E7#RJ G.\.Y7H*]A-]?:%8
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MO0<;!Q\'!Y^2F)"8\G\L#YT <CP,'XQ$+ P6 "8Y!A8YQD,/@/FOGS@8_R:
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ML)D_^76+LC(:P/ZH%*=@GVJ(A8&R_9R0)BHPY//ML()L*ROWA&WI$U=3:%3
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M)FHJ.E9O>)T\<4ON7"YIL?_Y5#V;!?=/U=&H1D--I#(VB-X'0T?@*+4*&!=
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MB(+4-UW,Y"H'(#/DU%W 5)6<J(GL_%U?D@K;7B4)<\JX06M:C8Q[(C;LBIZ
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M_4DWM>YSV#%R7WRCFOHS';-B^*\%*Y1SS1NHPX3D^'N7Q/Q2 V[HRO[J:2:
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M#H2N_M1;T_CV<LO9RPY3:R:AN2[VI$SF"?A%0KA?^D'ZBV.G']H!43<]FYA
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M5_E#N3&"'E!N_Y[H1]F.Q3UU.N/%XY&3<GW+YH';-RI_2S=DBY&GV2A9I \
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MN4\'C39!&>XWF8!+X1_L&]JAPXB##-Y-PQRD]A(4I<2('IRSX*P*QN9KD9B
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MH-)C OK2SYE 6 [M7&G^=%\"+J'F->-4_ZU[DM$Y- 7VW>QAG:"/\.*V((?
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M3LF5^ELVFX\]/^?&RMSUA0MML^/X:+*4>\F/HPQZ2H4D8]@H-V[R;WFE$;\
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M-S#$D'[.O 3YZI@'%'>!19[[92\$?YP:HY0C_"GLI@G5EZ&KMAV7_>\H[0:
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MOY]V[S6O+AN*Z&$&E!L]U;Z!9(8FC_L6^&%TM<R:) @A8%9(0+]NI9OPT&B
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M!<I?D=RF=C$!&=\$9+_TH>C!@7/U'2.!A\'A6:.:8,)A:.=+74D" \!)K>T
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M-1S+^\NEB/^B$"9(S.$0VXUPX"J)8TWI*4?O\^QG2.E6B3=*MB+1U-;@SZ2
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M"?<;^X@HSVW=P.G=E 9!7CL)2_?=!O+L)/I!W3!I5.-0U>[SZ9;BL4O7O!B
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MD!SS$XOMT.^,EU>;7%U<Q]'T,!<G)KW';3T]!!2?]I]!=*K'<W\"4$L#!!0
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M5U;7UC<V\?M_#PX)1\3CDW_XH@'0T?Q'^]_RQ4GEBY:>GHZ>Z1^^:&C]_QG
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M4[**,2O;*3=M7NEX![RK(OG9?).):@(.G@N0$#&1P3U[9_2U%_RWXC5T7[O
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MZPF[J?CSXB&3/FS ='TL2$8)GA4,W5\B]%6%/"'N?$4GA@9#V*.BGU>B1J-
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M[!GE&ZH%JT6:S<5GA<_VV)_>>ES;2\0V(@;$]Z5:*0!( E+U#[&(7/H#<W@
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M<BQA.9,[4C\=PR56/8QMLMOF&% ?J'Y^3U;B=H.U:HA!T1Z3G>VI7DX9"T0
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MAT<U, MQ#6A;T[5Y",<X23>C'0?;Z["TK2]H)T#]$G7VE\-5VFH?+F?)C+<
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M'K1MI[G<)^.(PFAWFRS[:/%%R6V2=Q';XXU30-O)"R3=&N36D_"IK^=#3:2
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M "(=_R4U2X!RDCG&O&7L(6G&+W_"_B34F%5S:CPCGB.61K2(,%W#0T,/[I=
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M/*X*[OCTHT!O3?_RM7K,_T08DJ:?1(U!@4C1]Q41!5K&J.-$N,HI0&SVR2D
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M]>B&6]53D_< =91NDCTG9*.+IV]RR-G(!M6E]:6(=U(*M<4\P0IP:T)-^Y;
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M/R1Y8?9_;B<P_A^(MW \,(X>L]K C[=Y66+LX1ZO!%P)H<@.B<ES1*B4@#[
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M%=0=/]H1K@:!744UQZ<8F6MS^$6/3[-P\\<9C6Q=GWY0;NIV+ ^XI8T,"Y2
M&L;-IVP-XLRC[BX[UM@NRG[IR0Z[&^8*?-"773=SJAUM?=GA-P\J^3\7,X[\
MY[I&HY6TUA$S?-S4QX5#:T)UNZO-Z/8!=JZ2?X_TT =[IYN#_V+:E<"KT+M5
M8 B'J87@<0B6M@_] 6V_$5J)?_:[5R+Z*W5BDSRR'7:)+#>$E.ZV?#+>9KB&
M^=E9?'BD?"/X^_535J(YZ9_S=0[]+GF7]'L[7BSJO;T@OV$\VK-3"*9<5YKW
MX+F4.9I_8T@OZ+Q;_B$#>L#+G#"($4C%VO+5<)FAP*E,X2K"?HULC*/D:;2=
MJ9P:*S>J$2I/A./40HQE*[W&NIW];_RZ;JX >7ADER4JPGLHUF\9H-8R:-;K
M6IVJ:B=0B.PP( JRQ*:WS7%!WM-#)&EH K(>8]E)S]0<_1] KXGE')7H][O8
M/>+(YQ+>)9F-V!"C".I&HS+:MK$<&\$IT;85]BC!WS=KX3]X_D BQ3PAX2?W
MLV!BK%+PE\$@T(99;7W=<'7SSX7$-5 FO S]V8,VY':YK&);ZYC;'ZV?=1=T
MJBE)^YJM_='Y3XB^,.G=.ZG.?6P<G[3FPU TF=XD)F*\3_XAB:"'^>,1.ZL5
MQ#UZ4@F*YL'K1'U&HIU4C ^AQRD/N^\*-.@%]@_Y?XT57Q#^UL#J\SG<T&%E
MOZC_HYG?%%EBH%CN[Y#>^]RZCIFX7&?RRZ'B W3XR5),-+]_]58J[V>_$MY<
M.9QJDF<667F@G+1:%]7M;ZO]3N ^;1;B..7?%%LK"&_QSTCA;Q-"'+6=(J*+
M555)=\,DJG/</UX&CLOP#^[[=R]5)JS]^)Q#URK9'S0 _,N^THX =;![%=Y<
M0F/V325+$5]:D^GM:3@_[O7J!MS6]K3MCP;*@IA0*H8(S[>YNK8B'TSK<U(3
M]K>Q6$^S W$:2M_)S0IX?G]!3MDZN,)T!JXT-UN"MI\+"F^^W5\$]AJDZ>I[
MBR)ML 0T9H;$CNXP.0H*W^-PL].OQCF+MYK93\C0"+H@FG%&S_IFY>_5&5@.
M*5OCIK25F5RSG\W74[V B?5MA5W^99\3/.$AL\_D&U9+H'Y!F:DJK?CXCGX0
ME>@J$A5KPSV*XE3^W55 [GNO(<2J56BPM&XC$"YM<,.1F<)5DB"HYJ77-E_9
MP^K5ZTR4PXVBQF)+05VB+=\C%KU67,!*C91KE/%1-"HWSCE.2?U[JFHVIMY)
M?HSO:B33HT8JE)])Y!PPKB17U"]3ECE\W$E9SV>M=.^9N27_V+"^+N-GO=+B
MF6C)J\4&+X=1/-<,1-L3G2K3;++I303;A]>%JW[631A_Y8"\.D*_G"P,CYY/
M&$2DK9UZ*4"N$,VXQ'C][_^:FNG191W_:?^G."]22.A5DJF[UE ,Z\"GD(N1
M@D6]_]YR\*]M!]T0HC#Y+?DU-L&U68V)@$)W0!@=S (R*A+5)NY5W"F(7I!'
M3H P<8>B^*,MS4)'EK2Q?,\W)Q_N7J+>L1^KDS0@\M%^7.39E5A7RS!S",OH
MCT&B'6^"7Q(]*D]B39=%7;8SM-N@HUR];0T_('<SG\R#9-1+Y!5Z ZO. "WY
M=71028^7\USJG9+'M66=,I$P;"SEHL(9(#+1:&4V*LL4SD@4/HPDW#CASO(M
MV#(1>7%/.D#/%S77UJMK3,BIZ=U'N%H_I!'-"1?:V$<.@]6(?/U!FV0IWVR!
M"$]:H:66LL1^KM^<L":NNHN \UKCC.19-_171?JC KDIHV5$*=-@W>'WR?V/
M:U(D?R@_4.G(]0.U0C!#.TUI3YE/[NP5B_'=:E;_+E" S)JC7-W ,M\Y S1K
M%M[P6*Z :IXKMS2\7$1F5\[XP=7>\B=WRP^HJG^>5]X+BVT03.DXZ>'F2R;/
M<-3"#D3<%[^["1_24JXMJP=V-S W]7>"6T&4JZ=8V>A\,I]?\I!$]/B$VL4&
M6L>S<^O$N39+-[3-5UU6>DDDX70A+7G;R%CERK^3\^DP*&2.F^RN%MH@[S.K
MHHH1W+F2=9?TED=^<5^&5-%=K77 BHR@W#TW9J)0%@)M>TU'Q#9J@^@B\Z!G
M5R,\E._PEWXKRAV+_,3#?8"0TA\IDC'-/.E3F_O,IS#5:TO<.,P;/X#<GNZ
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MP6ZO"XF..V$/BLX 1/?PC[3DGIJ4%;TNCULO]R"XL5PWZ2T[!7OO\@J4$J_
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MX<>Q.BFL>54=4V#IM(551IEB1A-CYH_Q5:ZY+6<\LC63.[.KV#[LT<.<1OV
M)F1/W%3RL%X#80P^GW%K9<OL?9#&=@B='[M[T[R@F-/(-#"-TVFHX/@MWURB
MZN_3KV< VUH0M4.)4X41@O+%[6GS<W*'2HS%:0&9UQ',F;;<Q)7[U:;+I>5.
ML>)"_7D@+UUI1UY=0U_=?#>*\BQ_<!'.]T! ?LMBO%TM4I6)4!'U:Z)FNEGL
MC<<GQ_B0>.M(UZ;Y_!TAE]F0[ML:HAHOM=%2'><.-/7HQ Y!,G:22U.G<KP?
M_/W"1]HA- A,@%.N:;X]327I@YE_O-&$"/(\']]L<]5USV7C%G5N8!^)RZ$E
M_Y9J9"C!MX4@) .^-5_<FT4IF]2290K%BVZIZ73C [\X>V.W^!]8_]4(:J3F
M'!<0/B3/@@ICS@ !$/&1]<?3%[@>\+ERON_]&Y2H W@!6!7D [@/UWMD4'?S
M,*0;$Z,64C?W5;SD/9)?E$[5]5)EB[_FHI;9@=_TT%/7P#\+#?O]L*HN5C+F
M7L-"Y9^9N4@\+896OY) &R,F@@);OO:H0M1-L7F\:C\.X(SS.X!,3K6Y@3.I
M*DJKRVO*:DNX7R(P\8M>RB3#FV_&#T;<B8F4&NYG!411LHH_P6S\646ML$38
MO+%(CXWE,91A:P+X&-_R=*C.>7[FE<.7XT .$E>5G59D?F;V]XO4/;0OK9:H
MHZ$JGK(%7T 8G4-A2BHJ:+<C^S7M31]2LUERNFA?HJ\CUZ_ND@I!@V\D_T$6
MFY04,B"YF ([-TOJR>.4V]-M^<3(PRE0YM_=Y=$!O1O60ED&3(4D-8T!\AW\
MHLLR4.MZ>?AONHZT57&R=CZ8W0H%=G0KG58'\^]S:7:":;'BY(0,&DIU)27,
M854LGXODZ&26"2<I^-1+^^2D&U6C'C[YD\#C[KJ[4 ^5(%UT@I?;-\?XMZ2!
M(LN5)NHN%,V\!V>\_NPA3^%, .^++QP+8SNO;AQVUIPZQ;4>R])>*.$1K+M9
M_D$^]J/2#+@CD N_G.N8OYXVFA2Z-=E*9_'\=HYJX]CJFT:ZQ]193,<[XIOF
MXAT@!B)R7BY.V;I@SFQ25SI-):8H]V9Q4_RU?GWA+;5/P[VN^-J6/-_,^6>H
M5Y*=;KVQD@&K5.5>5T/C'DE9] =#8;8+NC'Z'"8"044"#[7L "YOU[9>!8KJ
M2?K8:-YL39Y]_RN:P"FK<ME7\Q-4N(BHV7JX-Q-0VN:"8I:XQG?9+LYA<=AC
M<45/(*>ZQ@LXO9%3J*SBV^L_N%11,3.Y-JZ^BA%>.0.P!@[O6,_[(UC4!VWK
M_+5#C*:[6NTS/P3\GI&.PA6N)5>J\]1'*V!\NIA"%4M^86+V=[UD6K'@-[AK
M8Z4K0)VU6F]'I=_[U6Z1@H@XY=RBU3&K.\/VPP<T'C5E&5[:C,%WP[.*XHC
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M%(T^_G8,LO*3VI@(F1UJY":_&\"/JCD+# $=%(%*C;KX$[\GDS; 9T![J&#
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M(#&%]BR#V^>UXM;8II93)+/9[WUXA3 VR\U@V[&,!Y]>:I8"3,\TE?]1\.X
M)8RP/->U!E@[,2 TA!&J-F9 GKRU8O@F?29^AU[Q\"LAB1X(/FP9^O.#H_O9
M!9NNX=\$C"0"UA,$AY"&QMO>3*E9WQFDXRO];J5J$G>F'$9MGSZ#1M(9YZ#*
ME28FP)H_;FKO]GJ&X1!?[1+F=YN1/%S*0W2146G>B47-WX_2%1;S\(8?1CY:
M*5XFX(9>[^>$^-CJKM/A&PJ(B<A IR!XR=RU3LJ;:\$FS1\7X#27<ZJ0N#P
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MB UK;#I?@FK)QE17/Z:FN/-/L^1XH.[MX=G<Z;N1FAW./+*PI?Y7PM4%]F<
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M>"9&/$#<IOLR%3K,@@1@2EHN@WY:(-HQ;*#. BYXXNX>CD,D?V"GZI<+)D*
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M'@>5GC@"A1/E$4H2A>YF_-)538CO8WI@^L\)')<IS:M.<A2_%9YY$36"M$C
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M*#Q(^4\CJ^'<?(=S=N$'09/Y'Q0FYAD$9XQ*_DK9!0;;6TX1IDG>PE4]SU;
MC[I0ZV:O%5;KXWUKSNMF!&$+K: )P6U]G]2\.;X_1B4X:8R]735-[B?<P RM
MOX8*>Q3:]PLWQGRL5"AOJNLRS7"_66RF5.UVNUFE%P)_EF]E6'C#M3!W[R=Y
MDO;[B/K[6>B&8;5U]<VH,Y,'V NX8Q#C!NMWI4$-X/F'JE%&7\O%FO8W?B2
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MW/-X:D_V.,EHM;G!,QQ_+:=.YC]]70.1IO\+4$L#!!0    ( /6,F%@W#[T
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MGVEA8A<MUZBXPT&[4_V'2SK@\=DI5AP-/5L'/3XC$_*U>^E9N]FK*M<_'&M
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M?,UQOH\-_M99&%QK.1 _ R8B\WOR?LE$ZM95;G=?V[N&+EJ9,+A[T _ZMJ?
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M#G-S\R*T"WU>/3>!MLP<"B.@=,"RS1&.L&Y-P9";R_S%Z4!G-QY)VI1+X*R
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M2E%!36@5:@H=>(DY0CE%-"F<^W*F!*TB[\GS*]G6]8=H$L=:O"\V!W2CW4=
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M);CJFG::,3H2W%3OE T$(\_.-B8SBNL*I3""L$3Y "+7?F$=9^G (?\NAG3
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M",2&513JJ%FN0TR<6DV5I^*5:8?1P/W"[<B42RN^"W=_ZR1<O4'L]%JR;\C
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M\3/Q'^9JQS9$EL20"#VU-KZE;.>67 3K0* X<7"&8Y,VV.S-_-G34*7"T+\
M8;7\MN-3@_:7B;<)4*C]_J3;SV$NVBM'\JVT&I_';2U9%9%O4D3\L;E6X,)^
M/3]+6>3]4[K;:TV;G>7< /[Q$H7Z"6%S7U'D8EOVL<DP?G/D2_D+(@2>T)-:
M5!TJ-#?#K^@8&4Z1TO<%F/;T_W!Z:Z,?*,WTC6XF\9 $VTG D7ENN5G7Y\2C
M+VUU'ATW;KIH>1RU! C\,; ++D)_]%$&[%#EL'I58%3C:.C=EF^.!HL2V,6;
M%P+:.=V2NBUFD"/MK9W)Y1<NWVO8DN^<I7,(B"@M]J?PA'D=@+4IW4=YY>KV
M\[22*<5>N21 GB$,RKL,:?%P[&U_H&DA-77:U0LZA;!X+++Z)C$G)!+<@V?"
MARB&K;=<X@'O9QZ#"O#B15 U<#W]DLNV5%GW5 G+/BT(2%1<RCIK/1AF(_&Q
M97TCYQ!*@1_: &@#ZR[I>,?=ZN=UL6:\,HY5C"J^05O@_VK+?SF7_,N79D0
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MB?=L$3*;/IE=EQJ<Q[+9> &LEWC@R#PHR9)*J6_W=XEN=FIV6DB0K6/]D!5
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M%7_S$F1-Q^17QY]1/2F[.[$@>EO=[N]O&A R5['EJ#B5?+C]DH3Q"[6>KUI
MQU5P6B4!96S0X0M ZCY+:",@3*N#&SX%X^OG)8W4W]<CC)J=/8Y^:(A#=!8Y
MPKI1G84&A/HSUAC8WX"CA?I6S7=:]3FH!;@R\WF&]O/(D6XL87WYEA:SZI[%
M^@]T]:H]TM@=_,0'AC"8]L:O^X _ >\-#L:S3V+1N@B6A5!&W*-JGWF.9UQ+
M&.0>V9-)3R%DC1>)1DY!RN6U*\T\%_7_47E7XNC2QJ@^(/K:HRGNH(-\TH!
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M53HWS&3S:= >"A1(2]]LEIPY,HN.@Y)?9SE]0<;D[O"9=ZPU@?]>(^\4Z07
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M_. 6F74L<;#7F&'8_9Y"+9=!>QYR9GH(7O+C4\.)K&]HPFG8P3VQ*YZV*$X
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M7@!^:#FN[<2]3D0+)\*M06DIZ.%BJ]=5J3MPI)P7@,7=\*8#;D5IMZ6*/5A
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MTT$DF&!T4,Y@17LG<?I>U:7TJ68]<"93YP50X2[F7MYER9!:M=V4]@+PU*=
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M/6J@9#ZREW8N?==&T:)TXYWF[41]JJ,?6I:/B-)H*L67YX4UJQ:%-D4[-UX
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M/E3LVO+:)I7XHL#QAV':-;*_R9 9++.AJ1;B&,>)Z"99SX2:_Y45?Y5S.**
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M@/LKROP-5,/THD@NTQ>6_ZJR1.2U-,8%'$!F9BECV*R30S>81ZU>5[+MZG@
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M[U/X!&VD%@9U> ,FZLNAVJ>9!+M@>Y.";.H=]N@Z#Z<*_7M8$N/^R1J#Z*/
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M5*IQ=;E7B6]9#?OYOYP=*?/VKF%RQ;3/-%%LPQ2,1L7 AE5QLS7 WS_PURQ
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MU$1RU=.;54S4DM7UM*5-)Q;;4<U9P6-E=T<: [/!H(WLR_K\'&^=<)'XR.F
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MG<>E)+2]I%_J5>\+6U"P4;E;$21Q6(R9"QKT!0%*2@L/@([(=VPV->.HNP=
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M*P3V'3+8P"ZK>MV9M>5%H=^JE32"$?)NF O)W@]BG5HT;!GFU*\-2KU,?[Y
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MXP_M 8U,>TXNL/FO*BNQ4SNR02-<:.H)W"QU;HZ]_I]HS4-#8<F[N2_7 __
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M^J_I@NA C<J_V.."Q:^_=;7<8F;?D/QQ$0X9@*M\'BXCOIT!$G*[R/H!$^0
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MW/2\O6O=G"7[EJ/&BOI;ST57V7".]%_/:BM"7+.!?M["G,W!<^M[DF=R=["
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M#E',5ZZ_RDY)N7_QV=']=K2_RBN9BX+B3B\W!R>KOPJXZ6Y1SKHFMB5-AVN
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MKK!J(E*"-KT:MW/J2=&X':\1KG+"DK#>VM=KR8A^;C-&_' C[N')HJGZ?+C
MC:CYR0C613UL0SGYMD1%G:Z&DB4@OC)2U^O2+T/KVC_?8+".=-$XP\*W)LS5
M3D3[YA?X:)N^D5!MQZB=),RV>G_!O@B2EJ5!S9FC34_>F1=W-!O%C_PD'C77
M8DDGL%"QTZ]5J9E*#69XH,F?KBZ3M3E:>S-J&&425C^9F!O;Q)JYS9=G7D%W
M\7R@_H@L[?<3MZNSSDRM>)^IJG1=C6/HY)MBL 0BWSZ8>HF(.543R3LD?@1<
M8,(]MECNE ,4!TQK!H:H#C'WQ2UO1%:H M0=MI'T\H*/ +>F5O_ZQH>R#AK9
M&[*#HJ[#:] !%_.-W3^B8+8LM%Q68 $1[BA-<>U'5S.(\O)%BPL1A,3;P:CT
M[?%!<?"*TN8N.M7 RA<,M)2BNZO)"XEVV=CO1]Y].0\HK1SQT_;ZN%9LGEBB
M-><,B#"/S30Z'#S4W&UQ^UNJ=YP6Z4TJ2#)++/MZ.\,DS) _O]&?F"F1*KC=
MEC7N^_&G3'Y^_T2#=$&>"5086,;!?29#K$'*4(FGSC=IU3J,>20-=U[L$L/K
MG!,'Y5@51>]S3IX!N%Y.!.K]AY@;*S$[RR(SY9C14H235_BU:P[NML3GU6^N
M!W:D]EI\I:4),54-R?$$(>VU9Z(R)LVGV*ES1PV5!OH^@M4!J$UO?!Z8)89#
M7J.(%;8S^^R=E!U,Z]PGZ*^5CP=-@N5&AZOR+X]D*(WZQ3D_=HN-^T_3:0SJ
MZVY=@ T#5:?L9<Z58O"\OLM)'^MK%*E69HB S16&/P%=X^]RC4_OS5>WVION
M>_N>^!KPUKLK^(QQ9^5RFP@9QK(%@5'+!Z]]LE_0I;W1&W#.T9WZ[XF!S/\_
M,4B1D<V9\IZ_$'/F\LYQ:B'34I<)Q-B(L/0IG+N][KG^O=MH;QYPR@E<Z__H
MF( !-E@5$UG>(_7NYB PLG48\4G7<+38:W.36]/7SF 3Y#%0W\HRL4[>.X:K
MD>R^UO-16T](;LF-+O',3GDVV'Q]T>>;&"+B#Z=Z&R#1^/LPB&?G.N/U.&K/
M%:&Z"\JF>FO6R,RQB.#)W97X]&$;BRL^(K$?EP(\6J/0LJYO_'/C>AWZ"+#!
MC10C0JB=,/SBW$U/OQ)C@[9!W[I+ )J2S60/X"G+C4K)16X+F1QWOK"K,UT#
MXI5<S"5-^R$VR-:$YP-$>WZ5LKR6?_N-(=J7Q9M8[8NP;>F?Z0J<((<0U(OR
M1X!=A85XG>-HAF.M1D.DQ@"QXV[>7.5NQI5C@6UE2T1V<%$9VIJH&/3L*6O(
M!SP"I%>&^;YVR/:ULIY&S_[L?=C3Z-97##\O'^#+?BBQQZ,6!LFXB%W#\*G&
M2Y5B];1&G0]&X[CRZAD0\R-WPJU%*[8T4@!J-F+AA0KZDA!6IT.JYSCN^E>-
M_*-(ZZOX)+:9AP+Q_C)CG=G)).>JTQRJBZ_;E\6K<U7]QI\NI7G[=48_!^->
M5PX/87+SQL1AECN!,1F1O^MUXLZSGP1+&PHLWYDUSL4I#-P'T*/OZT-'+ZE:
M9F/3)=_-+'_V$46WR_YT=OR**R!KJ+X%VM!B3E]@RX0:9\1 !39*OAKM+UXQ
M0#.'K8GW-ZJJ3^+145JRA.M7_<1E0E#F0FF5-@U^!NEAS7RRXY<I[KO,!?2+
M_<Z#JS3-.#)(4+?78W7Z/[P7?+#5<E(6;.%GU5Q<[C59TN7*$716!&XB?__]
MJ/7)+VG<#J925AL BZBR07-IQ!CQ/U>@A0630:JZ:*#=P?'.ZC*:<46M]'RZ
MPCJU.^JY)+.O" <'OA@A(8[\S94&-G,E09.NN60(.;#'8447%C"V7#\-G>KT
MY(>XT+JG,]Z"#\\Z?TJ5DJ_-U5%  _7:2_7]N<:NOS/ W(&B2/>4C+HYA0]4
M_/8(5-V[]S/UMO3GFS]3BX)O0;7FVP1)02>?)2",S@?[SL!SGT296;!3?;L<
M"ZN22QX+TG.I++I0:9(\XVVY$G:^$8,XV![8HY4FN]N_/[C5IYI=7MDXO)%B
MNPLQ%E7U7JU[^U 61/TF>+.;ZN&ECE4K<<I5_:PTHP5R6#E<-PC-"#QQR'>*
MEP8/T.M!@GMPVX2!)> E&?1#^\H8^DAJC^)?Z1*9]V.!+^2AZ8Q#^G^#K(>G
MD_5:JS>0[Z;,IC?]1_A&BN(W$YTEC?O3,!=V)V_>:_U<7-11[?3\\J*RU5B?
M</$#4Y-JL,',SYE#3(9;X^^#JX$E @_VF\4YA2EB=7C&LT4$MYZ\A>ZL9&GR
MAV,?1G/1^G\/+<R01B]+<.H@QUQGR%*['NPR?[SOQ ^V^3ML*:#]@2GBP?[E
MY):77$Y>@9.ST-'V!(T[\XF0UF15$]E/GO$513W(Y\WXPZP&%]U#IH%]R99Z
MPY 5I[K=1X X$Y+/T7C9,&FT0=8+6EC::,W7WAVCGAI";(T^U\;3%83*=/I4
MYC;_W(EE-N?*QL''+M ZOJI(C>F?!EH%'S[%8K.CMVQ#BZ\G-O_9,)N)>!:3
MRK";G!-T=\V.66UYEF=QI(YDK4 CXI $Q,%0&TP]=@0J1A#U.:^M4@I$8^.Y
MYZJ9V5MMZ]2'CM\ WCG=^,_GVK#YP\5)%2I]4@YT(F%TB2-W4@$'XK%@OU=*
MI?658?8X>?Z'&$C>4^;L\D55$:WWLI_BEK8MQZRR.BN&$75]0YX$)O+)9,]=
MG"PM!T9R):KL5[!\. 9:+G0-'%-X\>1&L_F/["Z4HNNWO]),?&'V8+9.I!K_
M0>!GF8KY<U%/"AATX)X_L:\JD&>MTLT\=LF<*T3P_BZVWV O+^AAE-CCU0/U
M"U(+4 -7*'X"ESZG/2RG9=&KL:;P&(Z:7[VS"&O),?U;,4"U^V37"?N&M]YG
M/:Q$7O8B.,2<S<J-$+_MKS=Y[>7EZUJ;=@V7>[9RQ7*TIPHLO'%YWJ(O;"8<
MB,G?L<Q4"\VXV/$G2X"O]D7@+X)^YU"-)QN;+>.EN#KLM.L[X2?.Q:JJ3JK4
MA6F;POS)._OT\IV_(IDL/F*F.ST+_;TZ'WS"D1?Z__^,M!E,>&DHA_BR7@%F
MB)3QEUM\OKOC;]6NN:J.OFK]=7#'X[_M \K5.;O]1GOS-1OFFR2*[.S;X\&H
M[/H>CP#\:DXBW6QTY'/[DE/OZ&S5VO1/P^<X/>75XJNQ/6R)P*3J0[CX GX
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M; ]U+GEP319333LG>DH02!C#<=4])[B*@GDEB@V+U*RVX)SXOO=2['(" =)
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MDXC@82$6%UD1Q@.+NAH7_[\) %!+ P04    " #UC)A85R]@7Z(I  "Z+
M&    &-V86,M,C R,S$R,S%X,C!F,#0W+FIP9YUY>3S4W]OW1X@LB2PA)*(L
M*86R32E[R%[$5+(U(?MN1")K"-]LDWT=DV7L9LB6*+O)6&=D)S-B#,;,,]_O
M<S_W_5ON[_UZGN?,Y_W7.7-]KO<YUSGG?5T?V@_:/'#*0$=?!V X!@ ,]!]
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MVQS5TTNQ0==4NN)9HG>OZ#%A^^-A),Y DXT/VQ3)<!Y%]Z4%T*95R28+SD[
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M$!RW7ON\16QZH+"D+Z."E\\J;WCG0B!40=EVT.]U?QKP2H%ZG6$=.J4*I=
M6^C<(@T0,J]\<&GIX$>H$YB(.#-. Y[1 ,8[A6!U_H;<H/8EC0:%G"GCJX/P
MEV@&J),"USJ4"]]$%*DOQG[(O=6SY&^-Y1)985SCVH2#J-!-]-8VG9W8E,V?
M]J?^M_UM$_(S!$ #!N%S5"8T>21I4J']7"3)MH!^9/SECO.#3XQ2!S^X#M;0
M"_I'R!+ZT*._*"+2-/G#!K"B10LP8=LU$K; =0)C*Q>R.GW1A!2(N$\#WA@0
MN"@',S1@WI#^6B!HCC0!HP$@TMS>/K0GX_!II^"A;[U&R/B?7H#^R0M,QC3=
M\AGRH4<QO+Z,!K!.C@[$Y_MOAPP$+<.!4.M_=*/@$&)" V"''H<4](*]/@W@
M2)L7V]]MH0'M&73+(%Q**R,-T&R DNGALG!+M%$ICG&$1$]IIRSIW<=K2U)?
MA;XP.?*C$WI/5: .8*72\ HLVGE3SR,F\'N.6\EJ:5>)>TVK]B5B&[#YB\7Z
M5A,KBE>>4%..=.G6OK ^9KW)TEA4"H>/C,Q>E,!)W*^ W38;^MMR#1V,DF^E
MM&K.?RDA/WAF5@CAB=)F+?AH&GYIC*[2G)!<,;YM88:&#W6RBC]_.-29_B \
MTJ+Z>^LLF3Z1=='1UUM>-Z"2O97Z=Z+48/" 2;B!Q4J)E1$DW_B[23YZ87\E
M*#!$QKC" I]5OVEW8;J-0 .Z5+!I/67%<\W31B5?'018;WC:Y7C;,X]>ATL8
M*F/=OLXTJI5DW73V'LM<A90P""5_[K#,N YOVR+OUF/6'!->II\WSJS9:?@^
MH]"6*(R_%E#\RPUD3%@UU',_>U1^M+]M_L-:@S#5;=,JJCI&D0T.R5R$U\DJ
M@KL:L286+_RK2GKL-4=:52I<L<J5-=K\\#_,%O(9$U]C/I O?^[]+';6:41=
M_F:64>[<M['S3C.+:(?40:6LC,OG+RLVNY4@TB<V)Y9''J\&/V+6LRS.:%P4
M<-O834U?A:=,YAY:;FU]')4K:6E*?AK!>_E7+P H/N\.%-L4^4CN[:+RU8V&
M2'.8%]9&AIZ-MPZYD_/Q$!.J?T-GU0YV+3+OK%' 2/9[\QE4M/"\6((-#4B$
MN@C6+<9MH+@A5L'G^M]D)RT<"!VHHM2&?$%G'U)'5#GK4&=J1KN$7H;;=BT_
MUSK.SA5TR.EEX1PY6QS9IH2Q1E=H9).B5)5<@R\69DODNQYM^H8>O)N;CE,3
M?CMX[.(D#1#/I"\'&SGR(3$<4D^,JH))8N2J'Z8)US.V?PO61$N:NC0@U(VN
M'^-7$/*53?2TEX8_"#@)CJI9$[H+<1,'K6R<X*F<Q'FO9Q[(M>FF6\>YU:76
M^,TU[5>Y+W\[^; POQ#KY=D&'_<[,O&KTXW%2B93^HZ%#ZZ%/M=]'#,0 #R;
MD'Z5@".DO_?H4PG3VI*N\K15N?H!OACO^TP&Q&VO_6#;V+1M8Q#*I63U7AIB
M)S^8KL3U-DR2G 5?W[,2O5)-%P?%,QJY,,X>]IE[V3RSX9E[6U&86?$Q=1%'
MZ;<+44HO69/A4Y?.;72N@Z5"! E<K_*3\%'1B9(LMG5CEZ53;DXG23%^55TH
M"D[:B XNLZ=()R"<4O##[D6&@D4WG<)5^@='VBAN0I[Y"T:NHO8Y&%W,=_JD
M*1\5MV$/T2;K99L[IMHAN";:Y/\"4$L#!!0    ( /6,F%B+;!BVJ"H  / L
M   8    8W9A8RTR,#(S,3(S,7@R,&8P-#@N:G!GG7D).)3_V^^(HFS924Q%
M44B+)=M(0I)DG1A,DBS3F,K.F,F>=4+X18PUNRD9LLQ,69,DZX08,V1?9BQC
M,#A^[SGO__V_[_F?ZSWGW,_S>:[KN9[E^GZ^S_W<G_N^O_N_]B< QV\;FQH#
M. X! !P'&V!_%& (X#QTZ._]P+@.]L,\AP]S<1T^QLU]A(?O&!\?[S%>7GX!
MX>/\ D("O+S'Q8\+B8B*B8GQ"4I(BHM*"HN*B?[]$@[.@V>X#A\]?/BH*#\O
MO^C_L^U_!@CQ<(@ !CDYS@ ."7%P"G'LMP* !^,\S/%O!OA?QG'H8(Q'N'F.
M'N,]N %_''"(@Y/S$!?GWZ,^N!IZ<!W )718^/1E@R,BEB[<9YZ)7@E+SN.1
MN_'ABYA5+UW^ZL/GX4>/B4M(2ITX>TY!\?P%-74-S6M:VH8WC8Q-;IG>MK:Q
MM0/?MW=P?>3VV-W#T\O'U\\_(# H."(R*CKF96Q<2NKKM/2,O]YDYA<4%KTK
M+BDMJ_Y8@Z^M^U3?T-S2VM;>\;7S6U__P. 0^=?P")4V.?5G>F9V;IZQNK:^
MP=QD;6W_S8L#P,GQ[_8O>0D=\#K$Q<7)Q?TW+XY# 7_?(,1U^/3E(\(&EMPN
MST3.7 GC$;V1G/?ARU&YJU9TL8?/>X^)RZM1SS+^IO9OS/[OB(7_?S'[!['_
MX#4"X./D./AXG$( ?<"N=7Z<(N!? :?*BM^Y%2A!117M9E?,%U(F?2 .[6Y^
MLM1@<'$FJPY"GXDC<K(=&= X>?H-]O6?ZO6Z@PTQFQGBXR42.1>D-U."51=N
M]#5!YD.O3E 2G848*]$7-Y9$;,VZE(Q4GHH*R=^7TLDHJ4IM)BJ^9Z1'P<KG
M4MY45!EXC+TNE;LV"_N#B0:IL/Q*!5_FJ-#="K<5XHS?=I>P@E?U56Q?AZXH
M;VP/7<QC;-(.L?59%G#J-64X'B$:E/Q-M\E$_.C4L=H-4Q4GXB:*8!<Y.M88
M#-N4Q\Z'(IY-5IXAMZ7O2:?XGZA@O+%2B3EL0O 56R5@DI">5(OX$X@8I*E*
M='%IXAE8J6I^I)*W[5?.D09H#$FJR9"F.ESGQ$@;O>F79?#\X85/T.27SA>\
MZQT;E?944&&/IPO&BE@*VUB#7JA4((Z9SGA)UVS1U/SIP=GZM"9C_%2ZS,_K
M!KJN^!#HXA8-+0YCCJ3 MFO?T)1X_@K%V/4["EW9!]04Y%4&.4TU.H6VUCW"
M^OPJP67O V# >.(5%B)HHO+JEUC.>>U=5C4H>.JBR3A;*9;1T4Z18>LVT&=:
MEJ"M#D]D50:OZOVHNP"/'E<U)W2[2WRO:AP=W-A)AC]O!)&W@% [:&R3J0N5
M_]@*>%!!?$B\E&AO8235AJR;P(U@[M$S7B(-J?L 89@X2CFI_0NN$N^DYU\^
M$=J^KMZ&O#NT=R5PE.G'$$R\B%"&&@VXC*L9R,KJA$YR!U1=N* IJ652NZN#
M2B@QNNUU97YI>Z]X=$2\SIVF=X9L_?ZUA?OS\%N%P-9B A0'VL4V8R) 0J.?
M=[B0P<^<(YS$'N9I&?FZZVEI-5\)O6=I)/8FU])(%/"O0'::_1;(]9!HF],U
MJ?]Y'W 2ALF?0]/?ZRJ5W?$^'?OG#.Q&<(ELVH:;:*6GCZH!Q>SJE#X/4II!
M3F@RF\2\=);KA2.URKR";V:Z)6&>!#W!$$YO%-&+/^.DYGXB12'QDH--NF[:
M28+;3:D)8+*OM:E1L6PZ^^(^P.Z\IOQ  X5ABKI%5Y5@*Y'QE)$K+:V7/Y-^
MR=U.[[-?^];(=XRQI'DP)BGV>3JY#7IL?1_ #W&$C#7M QZ1I;YBNI(_1JQ
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M7_NQ H^6Y/KVT%(4)?;)(K6NNO])5,5MX4LIX@"!X6ZA/GZ]9>$AT\H*CWU
M<T/O/J!><W?72Y_J.+L/^)VUMX>W-G=O>RXLW/[M1C&?^)TE4/0[_$"3W>;E
MBA&_ZF;(](..4U:'$"RP@_[FN7T J=N$K50)W$E%4X:JWOH6Y0HXLJ_UOOR?
MY^'-[2H:0SJ!!D*YGW\_]VK[CV@.3D,&L6+<J#(76TQ3#2Q$O+1;HWGA&G<.
MOYI\F]I'L&NR9F;A?S[^Z;N%-"CVLH")-F;8]*U-VP-7&#^4M-:)Y(O2.2I4
M!"\4-K)<7N!1JT]_N? J-P?!1R&-*'N+[@-\_7'>+"F<F5M($+5\'\"E$(GG
MD?@>4&.Q'K0[2"KRT>?<$(Q$"9INZ&FVOY]O2/O9FA&<UKGV MBRYEM5UP;%
M"[Y8EXZLZ=_@H*D\O"&N)*-RI_HR:#(,0DGOZF*LSKNY*Y$6IH-WP7%[(R%O
M5"9S-'- SNH/[%'Y]19B7K**@R"@-(9_I,.3QOM76)Q22]A1_?%-L;6,1711
M(*:%(K$G]XM5 $EU'#0T4:[^L"6*I5K^.A95\1MXD_);R_.P^IAJT_;'>PSC
MY,+NJ7$ON]KJ29VSK\^SR\:B"V!ED-C%9;GZR/64<WR"D]"<S)4XW?,T3")%
M" \\,4N4&\K]D U?ZC<?EXN^!'I\#?<1!+"86,#&B(L$ROZI4M/L4GAS.L!X
MN3+'0-204MPSA1VWV>U<12:I6NX#4JO[]1<E-Y9 IX:L;_9Y+[^73Y%,B#^N
M6ZO4MG%6COFA_^A)F<L+(LR$>H;@"W431E[TFA5]-V<HAQ=D+W+J)&[2V=@]
MKC(JO^A&UMLLL[L9"ZMZRB1!$Q&'P3)%>1P.XKN5DTJ/IU626\_C\ANJ-:8Y
MTQY<:P\&OR.KTFEK%D--"L4PNQ,03].2YH]_G;U>?1'=I <KJ:S>OI8 DE5C
MV&I-U_E_R-&N/+;Q1U=-ZQ03$F7L?<;*(-E )K94*9M(/_>FQ*G+1Q4[?>OY
MJ-LIE.WL6^YO^GAS<IL:*[D0PS.^6VR&3_8^>U1JMWDF%4O;MB,OJ1W45,L@
M<9;_:'-#R8!Z"&OPXJE;<6\$^1OU6Q+ O2W4'TE75[^;SM\ISC1B^124?K6O
MU@:J,=9++&NT=)>AFJ0>[W00^@2NU1[]&%&'?A)!B[90_;HJ0&VGJ *=-\R8
M7EDT&R"?^FR391DOOT.W=&<433ZOW:"' >XMH+8G"/[.DGDV_?8>14#-7_YU
M5@Z)H+L+,UZ>W@=DT4][Y#?J;&.54=\"H&) FG-5CBIQYUR:S^FF6.>K\6G<
M)X'4;?!P^/29I_(WT.-53]A:O5^!\I^3(F\'%H^R]?N6BI-LUC;SOG[_;J2Q
MG+*4VU#W>\ZCD)-3%"]W3#'_Q3^01!M1^N1P?M(TWR7:Q#$<E';6R$<U&:'\
MPENQZ,.":4W:KR&<X3>DQ<YYM@K#C]$T@%3P(/,]=Q;NG:%;'?8E<K.N3N!B
ME#""@:@?7PZ$(?_=S$'.DF2.A$UBA-B6#&0&4;F.L9XID.#7LYA</,J8.K=X
MQ(NI.IQ.;LT18F71L'RLCVV;H O$^U;3?>Z(U$[0>-.@U:!G,?N*_TYVF[5)
M%8G.9/<4ET_WA&O#-W!+(@P0#:*5%VX-3%-^>4/?.880JF N5/;A0:[(0-A0
MD>=%Q#DB/;@EHUO_TU8LVE-:GW,!I=*KZS<QW:<NF4UL96H\OCGP*J+NE7:.
M]N#*L!*56%_ 5B%/#0BC^3IIO',(.#R?9G9M5.>ICNS&^AVF./DN3KW)6GMW
M*)E3:+W[[M\29XUI+!\?VD)G59_<71(GDWK8>/<ND"#=:#-<WPMR']%D71J8
M-]V?'=F0/M8;P@>N0/4_PKP8O]+!WL+L2N([_Y'[-?2,^.S=TDP@+7Q'S[;F
MFMC2?Z;2]P$MK:NH-HF]<*5W5>Y4+#MU11!-?@W=YJG*?'&UR;#R"Y4@O&G3
MT#.\)'>ELZ[J<!"E&3MRM04HL1&?K6DD$KO4_QVM_O3R6W H;4F["TS_4>16
M\EUET3TJQ=.T?5#O+JP#=0BIP J9L!"B.+',6L^7.W?*=CZ$A)WKQ1HXBA'Q
M2]3%RL4],CIY_9K^(JX$O#V:4=<_/(K0R5DS$@4'K75T$Y5V"_&)@LPW?6PQ
M@?@0U1CY^*YZ(L1?L3H'JW$Y;OOFR1<FP5M*[4 @VS)O;R!=7]!UL,;EW?BE
M5SJC(O)FN\V4<5PE>#G)I\.A/:LQ@Q"*FAQH;TE1@U9/-8&A\=\=%/-K==__
MU_Y7X:GC!E-6 P$\?09GY."/K3B#3UBX5/:DH,X(1H!D&57U5#/"W3F\H,@M
MKJ'TPAK__AS,;&7FHKX;-&:/CSXX3@K*8V4NM&GWW5*I*B:Z3G\NR'_ I!&]
M61&T>,'([<3Q&!I:<&P? #]02..&#&:KQK2+'G%Q=^*HI$SY..EQ!D(6>9\!
MQ:QGGY@TI!,6SR-X<JY*-;YRO0*GE45_:%C:5D)YZ[5!3-PI*X.XU>0-?E'+
M6X?B%',%.0?04XLU/3M']""[!;I!!5ZHHPR+<)=&SE8)\8BN.K=3P&P+:&Y9
M)H:=G?YF'_"@H])BQ(Y?6Y7?0&Z8L\144>AW/A]NL('6E$"1T!4X4G4NNSZ_
M"O=AWNTO#]?+KV?O,E.'1K.@W"#YV1/,#%=JHW2/ODU_Q23D9?/;\YS<F>OS
M$WO\(YY8>I0G6</N/%S)6-R4[X%.SE3.QCC86:#F@Z277Q&L4^'=2$&&A.F]
MUKNO$1ZU^-]_]A3>@*E,HDO\CXQ%3*U>8]U)WS9DXLY12 ]\$B>,;B4M,K[Q
MI9K^F7SR1O]B2*C2TI:HVA/)(U9:1YJN,A_>;YMIM3L61Z&_NGT-</+!,TL(
MOW8:U=[&TZ389#[XE^Z/)&D.*+>NKON%+/,5:?_^#;VAN OI-1E]GF"S=[J6
ME+^^ALUPY7H/=WBM@)!;.ZTHT=XJ-*SR3%!-5Y "_&KW%;4'V51,]P:NX/KG
M-E1H8#D-T2:CP"SK5SM?U%LXE$@:;L]-7]W-N73WNJZ[+GD<)!%O%V.(-W\.
M"]JX3B*F# A)@88KJ(K?V 2!Q;NR!)Y^O]J4!G)>N9&H70S/?VUQ69]S^MD0
M;G#!1'0[;MXX;@1L4#]HRCE >P?12?1&VN:RR#2%YGV 9&#YG0&BS&]6U\V<
MK9GJID_)O(H*N;\%Q58.LA&B\@+P^&-"S0!;6B%*>-@@T=GVP3[@.K?8*C#1
M-]ND_9G7^*4!]K,RAQ[!EZ O?L60NY9P^.:#D_Z3A!#P8EW>"%*?A:/A^ UH
MO"21CK-- :^<'1V#B X:( N<NJ]?G-72EOP^X+1MGWD':<&=A;7K VLR1%HW
MB<?I1=-%[^9\8)J]"8;N/%O9&(MF8N#NZ[TSK)TVM+!NJ 1&!EY<=UY>V]==
MZ4G,-:##7T3/:TSPT9 /TVMF*Z!R96ZKPRI(=*&@]%X?Z!0C!^]":\3P>P;+
M=(W,I3,+8J4,SF+)R<Z$'16VY0!1@7UM#?^^V*'?6[9]B1PFE]>^TFJ-(4AO
M*:R&H+"!9F,H<%TWVF+YLM^_UP1.[DN7N*!<2-OG9<10POO MTF6=25?V0NI
M V% ?-)?MQ;>Z?FB:X8*>%BV9;/+H^<&[T':QS*FN?6+GC]<N-?R,\W1[#9O
MR**?2ZD=SD&-/E=/J*P?9JMQ[AWGYPB/4G&7/BGPQ\AW\"O[/"EZY_,)U133
M^_"^,Q8EDE4-^ )M/\]VWVS:4/JBFYU(L=6]4H8"KG224D-JES&;($<NJIL?
M9+.E[@W'J[]>XQ1;);?$XUZBU%GQ"!I<EK=<3\22)#)NY.'?#*D_0UPC-VD6
ML=('#,KNMZ"/R7Q+S7T@6!FX#UALR!_3#?$\?A0&QYF=O"S8>&+BJ5YY9^N$
MTL/RTF_E]^QZ T"C2K23LK89#9>:SX/3^M_B'7%=#7KMNHN.&QUJ\XJXIRS#
M28J,V22&!7<Z7/G@P]XWB*.R0!?Q_EI7\#3QB\R10'4ZL-5,[['%*-D8&?E7
MB<;7B\_^VGF+OKW#\*EQK]*J\M)LPOUFKITWOI?WC=@\AV"A+3WRX^9TK__O
MJPV/JI4OZR8VE\CW!7MS<Y0BC]#M2C4(RB.Z(1LUPR$UKP[\#":#(=BQM'9
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M;# B_ R^AEZ;Y>X96/=AY/.KK6\HYA$E_[(K5K<M VZ\=G0JK.@1VP=$OV
M=X41HBC3^WLG=\M7D/?].(J0EQEZO>_?COQ^4:)Q2[LRY$=>"<33__GOL1_I
M=.,K?;>> G"76,!BCV 9<FS[&YQ)N5F9ERK*]:1:2/3EI'6?CJST[4SC1'N#
M@01(W-BHT=I5-#57UV0?<#.K#9ARX G\'#3];?EQ178*H2RN0&2FG@13:D2+
MM%"'05*!V7ZQ#]=21KT>%5?"T2W7 S%[L9IQ^O*5&#$6]$XO2MDS1W-@X].B
M#20T7,E>0+==00Z8'1SWWH]/B^N1%>';LY3;YAX]XO_,S!YT;K<,QY8IYMV%
M4M&Q2RIWXH\GIPE^[SBF+P*]#LYD/^_SQ8JRO/BE+8<*>H>K'GX"HRH_1+BN
MER>X:7:)^;MIM;\->K?8]",([:$JI!T-/-ITST"*^VA?QC]/.#9&U^C=PA")
M<;'1#!]Y^+%%$:Q7\9M@^NWOIZ\-8-1DR,DT"6C-79(;7*65<DSWWJO6HK'W
M;SF&/K*O[MA06"UWG$QNL:"TD,8K;5QA]YYKD_&!14O6+2,O"(UF2NY1R3/)
M+WAXVGV<X3N@^1S1/B0(J9[/2J= ZL--DM\_[5#0%:"]==%24"POM/;TMOYG
M_D8AMF*<_ZE/_>_XXZ=_S/,93%.;67JFZT1;C?S,5$+(L?GR3C;*;]>UE3%2
MBWD6D&NP)A8Y^0.!]J*O>?TLN'TE#10$-9<VW?0GOMQX/N]3;MM^]8_=X)B"
M][==^P)Z+2>HO-)+XYDZ$:-+FF7D<*)KN(N"]7Q  H-5*P]A037V:B]=)!,=
M'P@M.:G[NKVFFAWE,1B#-=0NKYA4$[L^Y+AHV;2:=D*\ZWI5U"'$F:N3/9S#
MK#7S\&][]E9#YV_VG#3'7 4VAY:WPY?7Y_:NS?[TW/8)])(^^^B*]A,(B6E2
M&4QN9= \:D)"2+QI(5V>D2FCFNPZ3 ,F>(U@U0-EU=.P@KH-7"/\Z1F*.2%9
M83&/]^9WK"I2*V5MR[RV$3-HN;GGL;<E@[3Q$A^?9;*(1\BKNU5P%=)$"!X\
MH#K1MUC<V)#L4A?%V_CA,\!F7J-$-D(L<5*?%Q)(;M'</CO9 '$V=DTNN/8D
MY,1Z\??\+4V0=F;$6UL3#PK4< J:H FFB/KI";:#)?@1N0Y>G4?>> $/(;+>
M\. ^/GD)N\9SBAU1W$<T9Q7OR)NYYWG4HDX2!E8>1B]Q&DPS1(/^Q/01\^DY
MD;KJU 69:^9G/X=?RGE4K!RXXL@*_+3VKF%W6PEKFSW88M?BLH?3*5F3KX0I
ME4-[UM076MA!B!)GMJT]FBH#]^X;)PM5O#5I!.&7Q68:]AII&%[6.].,NZGW
M?TY;)*MTK,BAT5Z;3T5>7] 4S?HX-LI81B$R^Q-O'S6OJ4_U!X\V+*T^PO(B
M30KG2T-AGH55L260VHOP0Y/<Y/'&^35,]/C)@1^$<E:J;=T.'WE*V7]LT.3.
M#KE@*'#PL/TJ: Q1B0?/>Z8W8 0(^?-+156X EA1SQLT7%#L7!J"*G-N9DG8
M<W/SLR,$,N,[X7M71^3^GL  4O% ;9IT9$LG=K"'8,<B/3_>]._P)XVA@]>Q
M(];4JLI)%9V;0S62!T'VIW?4;SO</D#EQ7S!^*?2)5T(@T+3C*Q:0:KZ4!.5
MKJ-!0;@CLJ;Z#3F#"U0%[N@$!,S'1V>$[. YM..W&&!'&'5*(WBO@W+R7_$!
M%'&9FN+_+RKU3Q#<'_X?4$L#!!0    ( /6,F%B5CY"[(8L  #Z1   8
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M$>8*M?<CLY_?\$,WV;O.XNU\;(Z<"#1<J"88[KL=RV1I(,/<5J)CG2?EI<U
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M%T&X#8HS</9)^5GM0A9% DGV*S,4S=@7;:HNH+,BS-T,HR>^YD6'AV<^ZAX
M;N!(M%'"7OLUQU[3%%9^$QV)NA1: MF4=?V2(&?@RZ "1@?(TCQ??!G_>Y_O
MK3#=<R4OW7*KQBLAXFK"V6!2$@S _Q/\FOD)K .XAL :%NK":D\.HH)WP<\4
MZ!?._BL!?FON\ ,8JC]9$^AB-FXB8&UDK%?(PYMS%\!TSBM3L<5L.+!]9-#Y
M+/MT9R2F[$(F$'GU>W5FHK[XJ^^A<2LW5!X6VLIB/OC<=OPH?>O\I7,4GEV$
M\.F3.*M+XZ_-[Y*D2Z^^+"#E6?MM$H?%N)K&BRJ9!7:OD[VRKPGG8#-*:.^+
MRU0,@.76[3^_OX;F"Z(TRS" _:+*2J^1:X)YV(P0JM2BTR^30>ID\IJZZ#O\
M5+M:1%9U./+?P[:OK=Q2\DPJ'WBW_E"N3XB='W\&;CSZUY""YD8UBN5@ (6A
M:._-+9<R1G4?A\K$9XAS-U3?C<AO,ULSWY#S^M>Z]!$TDHQ:O 4,A-TGL:A(
M>H<[=_"FN?=L^'BBWD$,D6*+4]TBVMXAPGL?3+SKN6S95TSIK,U960M51?BN
M*3<@F$W%$<^R7PO^HM7G%+L0[,TFMD2FM],\_QL6&('VH,< J/Q)#_I7[=MF
M!"J\)=F^S$674A EN@5<0]>H$$FK'R,W/]4YS-I2/4<2R6D,J*>YCW%>9UQ&
MWDI#?)B(@AS?SWVPW'4%L1A'#P65.)FM:S^+-U_^C3QG@=]QG:8PXB_8,%:!
M98+'8/=S)@^.9)7R0)%]8;8?:(YO9U+2W$_SP_7;Z_R.FJZSME2[K>:I>$SA
MFMJO;L$YP-^P.1(YJ$+.OBM;,^Y#F0S\RARJSM,'+*</CL&9/E:,ED]4(XW:
MTB ^]G.?:9;UC\$:J(?(U*+%A?F=M)#TK_3/1S66H:2*E@T"+E(]DE#C[M$S
MR4BV?+5WW:\S5Z=@<<>9CMW\5)?;VV^8DDZ!AR[?YG:76'^T?'S^<X%TB6RI
MM:$R"0-XJQ]YR+8#&>K9*6X[!IW)A[.YO#E<$D:EGJ7=Z(WC)*B#BT0X<W_H
M*GLJ/?T(QZ-2P>).'H[NG^?A6<T&]6NYZ4>Q196"XJZ2A(<P7E2L.K_J.E=A
MG;#\[EVVK(Q;#DKRAQ 7L?1U%"C@_.?[M?JV$$X@B9?;S1KOKTIXAY+R)_Y9
M9F"LR]K>\G7V%N7$=*:A&/]+8N%A\_3PAY3.IE\S/"PU\RJ&*=-]0'((7JN:
M$PP@I)8WLIA:3$BXB+/X:;/QI<;H,5NVT=2SS_'CF[')73:RTZ[E16#T*.QQ
M@E:M($W8P;RPY# S?FO<R64T9'6(Y]$3KE?NK^Z]QQ<Y!@NIR@X^85 ;ISRW
M>GLS-VYJ!.:C;/ML- Q>5'=KONX)K#WQ/:2_"DBKH;ZB,]FR#I6ZJBQTV31-
M>J9,$B-,%T!F!4.$KV8PD]4\I")(*%(XZWS.L&&,<_)DS>4RLTA]!0,@=U4?
M])DE^NE1'RQ:I+I9GZI;>J*Y")08':&@2GN]'I%W=Z.JK#Z8"QH]?V_3\B2\
M'+!AW_KM6O<)8P^DH\U),B:)([)L+IOGE/L%.0EQ8*EQ&'IR^11GO&V_OE)"
M"'QP>%TYQ%1@BCY-24"E]BSX'5M./@4+7_QF<2"@2N7(#Y3B4$]EWILR(KN-
MZ/&;X_Y-4GOUXY.!81S2SGF*G7.(\PH^GYW\+#M ' &W&#>:!K$ \ !G2I0/
ML-B!3SO,\Z0XRB=!<H]R<K&D' .@?[O=.F%B#&LH0F5O^+[6\RM1O8A'C>C?
M)9__S>YL##WC$E$7PFM::YEZS/)[Q3@R>!!\^FP!-F-C-2EMW+[9N/IZ6?\2
M-<PC.1!GSFFW0Y#O#XOD"".%!VC4\143OE)UV.&=)%4[ <X]KF^&\?JF7MI$
MMT"@EB#ER**D [N/^8>E/"YS-TR_6T5'$[^(F;O=(GG39]"2?OHO'%3=IAVL
MQC)FNH,)3Y++UYU<O]=-:C;]?L0L_E+DT'0.-<@0:;?I4O_^(%YS=@FR4NHA
MSB%ZO:[*OC4RON/N2NW=DE"Q,;UK:G(3<WO9-/HMHXQ:>" $&>V(A%R6G&Q5
M>_VP[+I4BL&54$,N.\FY\TC5<>& UJV>^64S%?Z9"P:-#W[\V:\8SUVXM+TL
MGI+<&!O+[WHPR\3]O2].9N:[]WWCD3; JYYYD/ 1L%%R$:Q >*<H6+(_9FA6
M'9 =:>\'*UFSO'^4F]_#%VCP'M+;YC3X0/M#ZYQ.T/>'^#.]3UN2FV,O,R21
M3IZQQ_"R?MA/@^"7@\!E[DJ1SG-3]%2^^4# 3Q+GU;)E(@R@CW#B;F!<[!*I
M*F6]LFR#D!T@I!VHBAG0P&IT7W;T7YK]K^;&#?OAYE,^]LD(,#! LN\XJ2/C
M+D#6MV).NI;(2-/)?)VSRH$RD (8Q-(1E3$S@@%4X]RA:]%W0?>DC;>O82=Y
MM[^"]Z/1/+&OXL$>Q(L#INW/QK]4L?!US73#&%L%EI&55HT3917TO ]B%KCW
MP;I0A\FM\59FYX2.A^Y??U>.7&56;/FGRV3$>X*9NR5W)W0[%>9NJL^M'@PZ
M36<@DJBNO:QRB-QX\UXGQT7H'D'V*S\%TYT<?SJHR12_&::[@%R04WO?+X?F
M?EOJS8-0UU4K74:L?)&*G6XI766&'S7#$ &,+WKTGCW1E6&A.I.B,C,HY9C:
M6"P+\J4<J[0*^>A32.5SV;03Z]Q64S7.[VV^6W/K='[KI!(OKI 1:#S<QBC+
M:.?"GQ)1\_55@-4W"3S=CK0;W][&>X+O4:I4S>BW":4RI$?9:M<DL,]NG!]@
MJY2M=6=1Y,P\;D<SXPX#&3 /T5K-PNV@UO4-/SW)SY,W4]3S>FIJ&(!=+RQ!
MBE_0I'6TPJ;^9^9JW ,VI\I:>0!42UYZM+FT$/_R,:[M*63UZEHI8/M@K&RD
M$(E^\+@JQI40?MW*W#-"'!4-K.8GK5IK_I4LB"-]6;-:/E+WTW^M@?1SHRC]
MS,=:K@I*297!BD R2S\Y"$%/+IJ;WQA=+W%:^5=(2"]7]);Y_6A"J,F P) H
M-'*5+FK.ABBA:F#CUFCH-5(0K3 !FS%">[> 59/$3T0K_Z(Z(UAI[9/6J>Q@
M8WB4NE;%9SG8C(,E3X[;,:]'A+)>]--J<7 M.U'F+^7>4?ICK'A#U-P80&VM
M*<#_3SY5K [O2 4&,*F*WJW4OTOJD94KALUX@MDR;O^6B5K-H4&[S>Q'*XAX
M\SE>A-Q(N1A2S_.#=DE:[M?SVP)P,]L;(,^3GPV'^4&D &3+>BP%LLDDH3.+
M#/ZB^%3;O04HO81D/+%?_^TN7UJ\6-.8-Z!1LK#6V/:IRI11?,MQ3J(QWDC8
M!B]<M(T>JANX*HAO:>6$2*FWXWDN K_N6RTNENTHRTC3&JPZ/^TQR&!+6EW+
MI1--W[LS76V51DY4F/LU&4R([E<]([=GB?UMAFCQU9PYS"1"])E4Q5F)]V_]
M$!1[<OCRR'SP V<V&[4#2XPS.GO-4@T[E(5H*/Z]OG>\IP?*XB:I@_/B2>>G
M0-=V.PB.%M!8MR4)-7?^M''&6W7M5$" \3*K(O@U9 I]'^4^"14I;2]P]FSI
MR6:[;[G]C/X,6>.-T..?U.^I.QV@6I%UD.L.X(Q& X96VAXYS?T1J:FS2\J+
M!CVRE((*_<B>=I3I$7>S"N> &/,7:[ZN4E76;S1[._*3;YM&]]G NYB<Q%A%
M_3H>2!82)J.]<LB>)P5C]<S.]Y*#7,+UMC\Y+#*/B+$>;*W._CU;CKH1-0OO
M'-+Y0ZT<+<'-EE.96L/)G]^YA\^[5QD)A<I. _?C*A//F43[E)0)-*;FKX'Z
M(VN468K4&,#V-GK.95<1S?$K*\L1RRRGTX0*_XM!;KBP99I- ,\FC6>D?5%^
MYAC O[-+?R0^G_T7L73$$DO2?\02RT7-*Z^(H6T(;?2+R^R+15AFD,*:]O6]
M15@]9/,8[D"O5'CG"]ZV,G)";^N/90UKHS$ ]2EF#>0+#*!;+!\[,A[:L,XD
MZS$&$ =1QP J'J%*79N*,  2^8BS*N;N[%)4WX;E['U;LA"+WM!@9A.DMM&D
M8/E#8K_Y3.T7D))>J5PJO<*'8ARUYG0]>2L9;PZRUJ:(K>^GN8QG>-+MGY<.
M_9:L!""+<U&:"*9:4;-7'1.:#%SZ_146]JRKNXL* W<Q?TCHWCB?-L*IIT]]
M0.%^(5UUU/1'^1".U.V>GQGW&JQ:E"!03H1\KF L']Q<E/"(*N;YO1O#W>#[
MJ%>94?&J3Z3V>ENDYU?"NR!2KY+/GFE)"U]6_BD>[^DDHU\:-M*ZK+HEME V
MU7_(0U@FE59[W7@EWQ<=HISW>,%'].8$]LE,NRN(P,2DMK][*6O9KZJ?ZNAN
M__R @W/?X/K:(DB[5^BKX:?2@\E)U'H)=:OQ757;.@:@<D-_\_W?P1.)1A!C
MM++$:C@R]SIWO \#6 8>S@9K7/]AWE17;1;4(UC7%9OD$K:EN@E-GV5(*"9T
M6XY_-6G(.;5JE2J&NV^#)"]^J7%6LH64-A]&AQ7XKWW)MN)]O'?ZR^.#3K^O
M:'8/1-MV:3O%..)D#/ETMG5".3?EWO?X2THT"P0G]>MI3QI(:JM<5[UX8VK-
M.1;I7E4M4$4?5;*5$ZL/"7]@#(@S#<E7=X9!VW2MM#PT^9JP:F[$ -C>9DMU
MKXG(RMKQ,Z1LQ8Z3AN"Z=68RP";(+.O,UN2)&%!28VW[$15KK:2/4 \"!/MN
M4+#;13 "^"?F)=M+5<+<>&UK,&_P&)C!['+-C7B7A(AM,\U.+JAT5E[>+QD#
MZ 22'AV)WG4X7#_BVL %X[7\29'0EBTS,V;_FI4WT^,A[J!/2A66GW_EL.SN
MHZY.)Q%561(S^.?\& ?E,8EFVOTXJ%433I <%\[1"$-"M,FSKWTC3RN)!>3\
M\Q;!!.IB/6,?"[5R59F+C/J$YRX8S6KTWUX!L1TI8",UH),*@NYE2F]2*LCT
MW-AG%[=O4L2T/<&UW6Y7W0*H$Q[GK:\#8[K%NC6UHIT;_C[T6E[%SY;"%V"X
MP7S="(+.L5Z/IP*%@+D=;?YCJ[(V+^-M<,<Q^3+2H5=<@IJH.[-#%#(6&ASF
M-%$[%-I<(=[T[8T<">^% /.?_-C.N<)N"@03]P!KD@W0^T3;H,F?HM;/[?#?
MR[;\O.@FPBN1\6:12ZS/?:%.P0 L0P.N8V]K6HRW8G'Y,(  JU@,0-7AJP+Z
M._!*2=:K0 %=@-V1R0_^0!K*'&* S"ZJT572_:(+,A-Z@4=),40)@#TL:8Q%
MA11B %Y3%5/F.FRWTK K3<\WP!!]E# J!D5Z.\6, )V!*H,'.=%<I;$W!Y"Y
M_2XL],1A )2:O7<^8H=))ZD.MYE Q2N&F;N;RJ*9VX)6O[L"U LTY92HIK(H
MB?Q^KI?=,?@5Q7O()@8P+[NN/8[8@S"LY16_+I0\BLD(RX#8&SAIVQ_X9T<T
M\][EOX&"5OUME;[:0TR&Z8)@A&?<1%G^9XK^;=U-Y4'>)_KMC_>S"<]OYRT4
MBZ)BGY];[RBY,S\.?BR06S)04EJX9WNJTO6.V1EU]21^*O/!&R>(=]5-EFF7
M%]>:L[70$Z6:;$O&VE-9LM1&KOZA .80>4:W*NFEIO1 VE;O]W>[,,)]%/.)
MK>-57/XY>(X^G>$[:("SH=(6P?Q^0NT$/]^[R"4+82T#N*V*\KJ7#(XS\$AR
MWK<+I+='::L.2$+Y6CD2@BMS^H.'Y?GD>1#!!:6/P\:GY;XHRQ#>O##NSZY:
MQ0#@N98WQM,V^4%'2E(&[<KZ2P>HSL]<'6%VTE[3\.4OM1NPFFU4@GGV57?
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MJF[$05=\JD8"D'\P -&;LN#RP6"[AJL%H?AF3[_6P'<R\PTWO*M/"<*\.C$
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MKB%.J4F ;FTOIIMK1%.>M4<U(<0 'L*A0"O^I'D-Y7JV&:<(/<$EDR<3@DF
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M17H8"(_O)<_4)61;DEW,'Y>D_X]ZT^)"BHGD<&A?;_8F:H8BY=,!XW(P=UV
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MP[L^S,[XV;=[EA]#]Y4T+>X'LF."BU%[;!L)\WU<3>H5EB=MY^::8/GGS$B
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M9"(OV5?>11+K$0>(PD"-?]/9&S':,7='@ >ST P_/]A9GK9R@ SHC"""X=R
M46(6,\2)-2+[\"0O2 GEZ#@H5)4$"+76!!VV0!-]F]MIGIB@CV-<]["FW05H
MW',=(8M+(JWU]O^DM#N1 "S!B /%=]D-1JW-]'L-EOY;.69<8.?T1]VU)(")
M"&,?+FW)-=I3Z"*V6P+7#Q-JJ7YK?<O*(WI\E7)H=/QYVP4*+"()>%2$Y!JY
M4T7L2&)_E,O+Q>_VDVHLXB@$(YS[484CL\JCBUKS_N>@A8K+IVH/==Z^W>9S
M6JVGC0/'[,RNM(M^K[$?%70^9O@4C:IV5938DN7H$]Z57AE]Z7;3[7X4+9Q"
M 16U/Q *I7=ML"C8RB?<6!GALID'JG2\!D=T$%YO/:H?6TR0AI>R:/B^H#B.
M_S[0]Y#C])9Q^GTK.8KA)C#A!W3I3!7;@C D9,(K'Z#5YS>K^X*\O%>.?ZR+
M0_3.K$B KJ/X0\DUZV!F:!0H50'_@8"!AEM\4O0XG]Q(O:$4G&D;]'!(B2'*
M,I,W.RI7SN=&MN'"6QU67HMO5*G1GPR\HVT??R;RBM3DG^K3##)*7AE^>I7+
M:%<:SF_3[(-A7%[=ATYB20 R<>(TJQ9J;6@-_4P7V'N@2 +@Q/*"V=8G9115
M2V&F@X+R*B^=O5AM:M\<_-A*P4F2'?^:,EEI[M8[XDI$T'RG(K\6NYRBBHD\
M)^F'P><&+8=-GVD^N&'3)7136E(H^5V%N>*8\\((2E5_F5N:L5;)BXWG_)1/
MJ*?KC:9$0MI5(RGWY/CWK?'S$E@T\NVU9%[C$IITU]I?EF&OD/<PL,7C]_(&
MA0U3@N&7]JG\WBP@$Z?)/N9>>(B[JWTR75!66)T)\]*M9;C VT.MKSDX,5?:
M%&'.LB 1N6,75K7340YJ6&O3@Q'(TK,?D7 4][Q<P+6QI4Q:G'6)/8M 6]'4
M0*$#Q/I5A3?7PJ'D)NA\H)#'HL75F19WIR/1>VUJ;) H;89S\QVY)BT%06^%
M!DUV!):75KKR7FX0+PQZ%D($S!\PQT][\$+RJ]?S*1AO2K<6MKY]<]'79^<9
M%*64!SMU$9@94$</3'VQ>S1, FS5(,3)'L4G^1M^:-,6MB=ZF$Q,&+@?07@*
MW8V".MH -SD'S+/3 XS6K^,8!UJ^!6J/@ODN"IEDO$M(BCK?HG:8E_WFNT?%
MF"F9B%-J$S>*S97YX3@RC_+J.LNO_0%L*2+>"E8)IB3L)O]9Z(!LMHT[H2N%
M;M4B7B$8"$ED)G/9H(4$R.]L+"Y$A/:"9C9.@=6KS7MC05KTQKB1Q1C:=AZ5
M^CK[78-WY<XG^C ]\\_^&;D_KMQ<O1OF8^>[L06A"4!;ZV*,VG>L-O>U.96]
MKQFYB@712+5;T& 1N*>2[GD-&/,N]WT7ZZ3WWHR;'#I[3PS*'^0O[>CX492D
M=<[W_UC&K":R'TQ?:>A\?FUYV>B=O2(34E!>P-8KP-7+KZ#+#;S:Q743J+ZQ
M,BBR=].T44 KH?,*@Y_[_64J(XII([V*ET_/GCY6N779S(;("*&]/M''4)8R
MS!7S^Y7-'3]$I@W:*)+#SS7:Z-*17*)HTU*K3_%4;%@I>,O[-*G84O%KSA7M
M%*=;\NEN[L]HLRX5O>PO%,X6;N/_VJD]7&3?Q%V!+!5>K.*J+-X./$7^)O(,
M-I@6X\9[5CL[@Q3[^1A^_E@+.Y3<F:>N"-@1-M?9L^;=_\7J 64$^-/X,?TE
MQ,-K! RD'J)RI@7MEB #5:!1!IEJUND?*LB7$_9A18N*MTB CW]8;Y[)' MY
MD['@[%V%T\Y]T&X%@;;CP.)X<QYEY:&AQ#CEYTVE#KZ2964GX4V6^K71)2*\
MZ?/(>#*/=9" +*PM.8<_&6.YV2S>0/@"6MHR^9-&'H* 05_2XD[&F^<16<4+
M;L"6D_+C0"AF/AO_T8@5%7<+YW$&'FD#ARCYN$,3]\4N \&;E9=S,SM]%X,2
MRJ[#U]T[ GN!K; ;&B5MQ*C>$A7!DJDT-GS!+JJ1LU^A7@,=$2+$E33>/]7[
M.Z9:WO(M?] 61)/V487'ZZ.C(0E'CSL_6Y%O\ HX*;C#:6?^\<%L4)6-F^V<
M]Z>)X5D\'V85L3"-;1RUE<IV_DH!3+T-;7VCX*.'X0GS+)Z5T[C^1-:Q5E_T
MQ=?3T?&F:VBE'C/C%B?;VS'5:BSQ^ZD8&I&%@?<)2 U3[A1Y^%I@%[=8$+]#
MX(W2C52]_N^]U@JI/QK31?L&),[M!;,-RXL[B^#54)5T3UKV5>\YY2%@1 Z<
MW'.D<%;S2)+SS4X-Y[(FK0W@>".B#2Q?Q_$EJ=R\.^!NINW'?7L*P^^!9.]S
M]]]<<*P'45(&'?N?3XQ_DS7 %NUQ1?NT(:!E]G_X:&U+">@B]-^\<*?UU[!C
M%@BLZ*3@!O37](VMT]M9A]E1V+@,*C&Y(:7SW[WZV&(#AI0=?@ H<879T</4
M'V>A15#-_$:5(T-R< G5(P$0(1!S+V(>,;Q1[NB%G+Q0">-"I''<>).*- D0
MT$8"3,_'G_I006M0),#._._CH+91G?1#1'R#%&J/?:X7I<$,0>UW[J\JQ:YS
M.+_+'*M%X$V1^'O9]H-3YFDI\%'6G-O=[NGZF8N'B]*WN,[MJ<S=NG##0@J,
M-\9(Q<F#4*;KZB8;IZ\N?N$]F5BJU!^!VC<: L,LIK]/,=E,NWR4)BPH2+$
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MPR2[[.K1HC-Q)"SE$4U5_<"#]>-(119?%U:K87#I1#\)(!HG@!L3XGF(=D&
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MTF( N\N(9H*5;3I% VVB^(CDI0+,05N=2[EP1F3&D!H]/W'[HW@T\IS?F>0
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MJN3 1 1+=Y>61BT6O2\R0MG)?^LW_7$^C)F-UA'0(<38;_/_T@3JWH6725&
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M**C<EAIQZ/D*2)LE IE]1E?ZL"/SO^0=X,J^ '_W2'1[AWFM\$',]2KY_P;
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MCWG8NJKY+SX=:#N*]0 8X[T\@X5WT":L3CQZ^@/WH^I,^["=1]5_">M7;1X
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M*FL;W"9<Z;OU%W%;9JQHR>W1>#-7MAHXW;M$5+_E+;L_SE#S^[8"2-E17XL
M?J6F88?OS7OLVPH/^1^ ]RH;#PSSONF<BCL3) @<J[F+^9IL"W#-]\ AW^AZ
M4C\VI4X=Y./6YOIE3U_\!FD_*^E5X-K-$A9@E>\#:\G6I9=IV!+G^)9)O:;6
M3%!#9R6N 63C3'R=^#I.:8S6.2S7RO;&),PI/=I+"DM=,4P#_<46$51\$E+X
M7W7T7:A7?)*N[K\GL2\W-__/A^#+OX?@.CQOC1O)ZO51>0V((^LBP16(VQU5
M>T)S7^G# 95%8V7)(+(QDOWD"]X?1;(&[OG(KWI[OM;0>G';R)@Y=>*:"$W*
M<A;;7(/-GVYVBA9M+ASKJW6-EZ>-7[:GV]2+^BC+4D:Z\/*W/UD>@LJOB<G]
M()Q[KW.?.+Z,K&-U!=-P*]>\H;.V4?K5[C(A,"PSOB[GF:3N8O*)J3XT&F2]
M<RO Y.ZEW;J8]+M$^\J B]P7W,Y9H@ U4\5:YF]C/K=>CNW\%A^AM<=).O39
MUB7-PS4M\?4]LGC(I&@\JW0/:)**+9%"&&4 0?^8B32TFB'Z^"N2%S6DO\AZ
MD[OB/-XZ>5R6T-[@Z:)3_W1;/8' UQR68(-QKQU/XA4$"5%FJ#OG:UM:B@W+
MR<6?XY]WCPUZIXO'7KD+:UJK,%N(AM4[<T[GF<(8L9U"7,)4T73)H'O[)<KL
M+^9,,V1+8-\3E92MK=-UJU5U%\]75;!4-"[#KJ=+F(M<&:NP+;/V.HXUD<Z2
MOM+W<TX%#)HG;,?J.WIO+B*&G)V65#)#*,0X6N+HZ9)Q)'V^\/),D.R.1QA,
M6G!4J1C$7JH;"4UI/>U[KIOLHX%LI0N9J_E#'AZ^144KO4%_<5G<QN'S45"9
M.2B[,NYPY.=+E:6N1D[&U9\3G#:UN!]38$?F5(RBYT?6CB2;ZC>4-&_,:UAE
M4B\2V^3*K. G6]NR:08S3.:9H!1&EBUAF%RUIMG*.5;#'+Y"_?K9\UW2RA"L
MW@24_4,=@867M7 ?&/ULWXO<IMW/JT%;FTL+Z5,<0\_CD\*V@,&V:$:XF;LR
M4_.C( 6_D2;(A477OJ"!^>K\NZ5&& ]2%F[?DT72PN*<YV&'E@K7)^U)?\*Q
MJXI^RXK@]A?%SK=J*DQ\Q=M).N<6$3EUFM)K2/]4+-J9.S@^H2F=[ILX&M(;
MU)RTS]OMS//JEXAYFP<R;:5JM57J1F3)!)CRXAL&]0GX$#L8++3XDRI'F\G.
M0'<P4^P!$-K?T\KPXF;>>Y.<3F^MTYB]X V;96RKE]8QB5TA:1%\O\>/+AA8
MLZM)7O>D(CQ&1F1&2$]NDXV!]_5!1]C-G_5GA L#I-)/R;8 %Q40+:3[ZA]7
M"F[^X@\$0Z4KTY.GP34E1!2?B-P#Q/DF.JPZJ6,_!MC,;SX 4.DEAKV7>_$#
M18 !JV&GRDGO3T7Z^OV-#%?:@[U&(X)AW@4R/UX1'CKTQQO5.+J42FNU)0L9
M/NNS(Q4^QR<'T+)SA+/:Q4![6YQ@-XJ&>%4K?[R[CZ0OTOC!$PX:TL9\0DR\
MB>*!QLV3NY.&%,-6$T=1YK8$+L-V<S7A0QD,[]Z0UB;DC*X:7<+;UT?[1E'[
M8+E(Z#G8,AB](N<4QU?9$U6OO.E/,\1)=*U5M<,4FM]?- B.^F"M39T1E56N
M%:B=<FA$^ #XFH?L[JY_1T>!%.!>T>U)UC'=E/7!N@Y?C;XE1EUY /3 F'DJ
M*D*+Y?TO#*4V;&:V</>.VAM9T$B!;+L&=B6K?]YH(0QT3A>X1*%ST9O"UV'K
M)<EE7#*NFGV@-:!/#=1= ?&R=+0(-+]'0!MI_^(3F*-?G*,*CAER)*#_\[VQ
MP%O&T66[#MTU8/"Y*H6/<*-B-"9R5&.<*6+SLY5B'_ )N''Z 0"&A<_7Z(PA
MH0R(EPDTE.+4-VN-?GE"\M[21VFB6F9D!TMM%F-T)'[T^T "@9_G'-/XM(XX
MPJND+:J]9-92(3+OQ*35QMNM5+'W1S= LH+1+D*FWWU*_6K%6\NLKFOK4TR\
M<>=?#YA^ B]KLSF=C'O1$D5J<TSJ9;Y=0^8F9K$_%=BX[LUW?$M,3K+GQZ4<
M<?MI)FG_93CU"4=OC_7<P><C4P"/"O&O$W0@U+,HSVDZ8<%5D6\L-&$; 6L\
MDS@4J$FKIZ]3W00]V]W/4!G#<V1_ (C<0-XC_(+02'5^[#WO]7BAS5.U7>"R
MFJIMO"!<]J=S=L^X4,G1EX#&4=&60<E/GJ"3FD0X/Y,Y6KW>Y-)MK2VI/WSC
M T?@D&NI\X*TJT_)JT^PY!A93(%L+?]3 NUYZ3<_*<BO^%)K3(9+J'6(%D3"
MO8/9(4%7O9Z0[IR7(3T/ -+Y-M&)$*%+&"AB2QK@F*GLB1\2H'?K@F"H>@#H
M/TFDK=W:XKBTR@S&,$+L3A]($7I-#B*OI]Q>$E.?6$7RT$7Z_#ZRJ[ ,>?D&
MS[JR(9XIX L[6B-[L_S*I/K/4 IWN&<AZ5M57-YAZQO/;>:ZYK!M'TJ#@@$L
M):F,#D=#>BI$7;O2D-EP4$"[U(KC?C*!F$@PVZH,&\FSP^&W5B2[M+[==KAO
M[3=5L#Z8:ASR!UX\9V7(B%##8),8!L1\+WI!K>&?ZB 5AFHK95]+Y5NJ]IIU
MA/W=)8$:@8:^C/C"O[7BN$68:_VMWP+DG^-S7/QR[ &P@6OR # @NL)B_9\/
M'">>/DIWO$ L<9K'_1#.?]'&!&^=])Y2?[HH8IIZ%6T$%VWC'8="N9AO1)50
MJZB==SAV'X_6R,2[Q^W!C2%+)5SU86XS$A*.T>94.XTSTWM4D82M]DXF_Z1H
M45NSY%UZ0@$F\Y^,C)K3(T^A8FTGGXH_BDVJ@2X/ !RK(6J>JV/"VX'MMZW#
M5OC$5L;##H/97W%,HGS1U2=KR>T49O6'MI1G7IQR,NGAQ=HZ<,'J^OE0-CNS
MFOP2+P@BK-ZN+)K@/U;L/R_%?9>LD>'U8\/PK?)QZ+HJV5RNO%/=8$OEN8"J
M82OX;=I/B_06 W[]T<& \>9ACH-D#$V:!JR6JPCQ<T_5\ J32>["\9A@O(V6
MR-^^I55:N96##IFI>R*$3J63L;&ER-#S9^ND)S8UV#>_( 2EE'YI)+??QK/8
M9P5Y[M8U(.:QC!\[@BUDJ(N4=!4M5J^D2DE!+W![:$O!?9HEMPIZ]>#ZJGVA
MXK+7(2HBJ368=[1/R3^3?>E>:IE86^ZYXK0 X5MR-^T^ -Q.9)SKZ] 5$;IK
MHQ?>\KF6G%O+0B<;J>)N=QR,7<MXNE)U$]SG). ,A1,0WR_1PV-]&:+T17J$
M:[(]_3S_^B'[X6]W#B1DM0%^=FTVDI=RSI&"&N,Y+[;?AN"'(-1V"7 K@MI6
M]\_+O%I UHC@K"=TZ<QK;0E&\R'(<,NHYE3R'_C6EU:_@[#L"(ZB10JLIN/2
MFWFS>K#I+R)Y/MCK)C@N4NZSC*],GFW4-BK_7B&L22U,L2VQUKGD8[,(.,*;
M*U-EP]SLA$AJLH$9C*'$S70Z?ITB&ITE^S,$K 3EM'K^\VW]GKE)/-2QY5\@
M'KJ##X#*NLA-)/C#)'5BIGR7XP0YK+B@SIEE\"982!/$&.8SE3\*S88JB >;
MEZVT8AK)*+8*8J ]_\ ML';/>!?2@@]#9O;K5R6M*S55)P]CIY<)>(\/OV+$
M$%<UW2I0/,FS0B/J'-@U +^?<3KSSB0HOQ_U6B1L_)'!E7<X.T,#6<&%2%GI
M[*LF5MW*\7+L<[CAX2>SJ.0)L+,Y204Y> 535+"IA<].J>I7GX+7R[GMB_K,
M(N.'-!RZ24;NAV+MX--5+D5LG*N @*5V^5ME^%#7$E]HSM39-R[&3LQ-P*F1
M;8'?8.;S,4XN3GZT>-4P>:5FY]AX0[[IK_GUC1'&4[J"H]@\3%^N$$R#'MW%
M @/(F=7^X',:4N]0_MFUAL[NGM?@G0S(A?NTS6P:]O=C1IK0SL<D(W&%CLA2
MG+3YU"5E\7 E=ZMA]T;/.;)F<MZ:-[Q)G L>W2WO8XO@NE2H;GB.[8$=;!>2
MF7C0AH5\ZYNG9^VX%Y+PSMCC:A&,?>%:ERC.!2[<HOB<\FF7@6"I+<$RB7>Y
M1]F;!'%N.>6H*C4<14IB57;DPU9N=3GO5N!0/:],>!6",^!E7KGJ3V48M[+R
M0_8+^/"8<G?:/GOIZB)FX%<@!BLOD/(*7^[WB\D6BU*]]'S'0HE;\$1.Y(=O
MSO)ZO]8S:<82XQN33/_,?X_[\;-^NDGQ 8"N2!2/EA/R"<Q@2'LT!4>0HC;
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MTSRHR=AW87M7S=XF^.VA:(&CL4DU2Y7C$0XS]:Y^+XF_%/38W\5Z1+_PCUO
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MP!H)Y8L= #4>LZ-=3:#J$7VPN# Q._G/%:FF$RV2YZ@FI;R/_B67_?\ </\
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ME&+4ET/-F^#?C%GD<&P,7\/S'<:X_P <?"?QUK&AW&G6FEXE;@N#\K"OJU9
MHW#)'>I%N=X#*<!:\/\ LZ@I<T8V/1]M4:LV?"WP[^#/CKPE\1[35]3\+W']
MFVELR;T(/S>U>Y+K<1MVE>VN(Y >8VC.1^E>Z-.UP>'.<\YZ5)(NY0/+B^NP
M5V5:4:TN:1C3;@N4\"EUJS:(.ZS0CU>,BO._BO/ ]O&Z.94(SE5)K[ >PANK
M<QW4$4ZGU054/A?P^\?EOI%HZ]]R4Z-"-*:DF*HY5(N)\)_LTS0GQAXL<R>4
M"0%,@*@\>]?0B7"1XS+']2PKTG5/ 7AB:8Q)H-M:*W)>W7:6JA+\*O#;HO\
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M7B&"W_T>\=5Z8D'%<W%^TEXJUR:TB;4A$HN$ :,8SR.*\%M?&DD(*%!=(?\
MEE(,XK4TW6_LFMZ:MO;K'Y\\; ,N0.1FO/BIM:LT<FWHC]R?"<SW/AC299#N
M=[6-F/J2HHJ/P6Q;PCHI/!-G$3C_ '!17K+8Q/C+_@H7;//XC\,XP%"')/UK
MY)FM!)(SP^7"3@%R <?A7US_ ,%"2AU[PVKR%,QGH>O-?(QN$DLY(HT\J16
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MD\Y\>),^A"XHOF)E<+XK$XO5S^2CP"0L!-.Q1VV<[E"V*5K2BX;QM'@U G9
MH<9A7X0&<Y>[,ESIL\$8%U+HNWXMTG-,V[E>5NOVQ38MM;LYG#FS4C(0-LGF
M>2ZRL/_F8:.?A#>_ 8N@2W>0TK8A5:K R4_ARWH\8GB.P^!+4Z5YB)2\1$'Q
M4')L16KP*Q-/7X1_DL(W!>)FJHB&Y8Z7C>U8-Y/B-.&Q..O&L_LIMC*&F.,'
M$8&FYDSR/ G7GS8L!SLTU?)=?3XM-S-R#['.UGS#[F/2//=J![E@;<W.GM3(
M/-6KA8\+[;W,Q-@K7TJ"7G.DCED7O6UYV) 1A;UN_VX,=2HEWGP['5^S#HSV
M:735J."JN<]XKN3IG<N9>0W/=_365:H;DE"L)II"T@92]KJ+>QPK108+5PC=
M-2S593<6+7BG0OS\-3K\.#);OCBJ:^]0;$V6"@W_MHHH>SNQNZ9Q]&-P^>_,
M'9W,=H>V88&@I2[9SIY/;71 9*ESYO!2+^S]RETXR"SQ"-;2@-1/FN&+H;C=
MNS-]6@$[+-.'=))"*H>"ZQMK+5*Y3(/C01PL&L&QFLV(0H_"G#(<;H.;R_"%
M/;N-/( ,.N?$O5U ;J(2Q@CM'@$JXX(N:;'#Q-&Q[:LFZ0N93 V>P -( [%!
M*_K[2J=GFU:0^'3K+M^7N^$IWMB<SK)./F'_<R/>#K-**JJM);/]4F3)Y_W=
MWWB+ Q^NJ]*RPKE4(\]PM$LJI6A"> NT6TN8B3?*/05IPD^D/KH0O-A/<?-P
MH -F*.LSI<O0E2XC/T'==P) )VLA:I*>W,DD$MN'HV7') \MZ+@0%"HW+3HD
M>3.Z3]]HZ6M5[^DI:YKT6 >/J*N]^#TTZ9=(+M6^I05K,04=L&G&;[@^2RRG
MF<"8\23YCW1 !<Q7Y69%68D ^R]'_<ZV8225HDV=CY!"Y14A%38<(0D,E&Y(
M6C.O(&K!2E.^PKI3U;=-U=,J4M/KH"5Y;Z@^2'7#]RK(:.CA!TZ,MUN2)EQ9
M,7M7XDQE4*)0FLSGH@ZLY;A^18L#WX=':V23#M+^".,CJ67Q+W;G!_/NF"2"
M&HT,K<\NJ7-_OI,T-G5;\=R%T/Q\CYPZ]V_R1HF746";@.$MU=.#M\YW =9J
MAV(,F,!IP^EHT8=8GIWL=39S-8V#.V@::&OBU[XR8N],-NKCM;2L1<KACPN(
MN>SH-9 PU?6 O51W4*9!F^12^2A?1#@FR)W\;HL!"^)_VREL9I-F]Z9H>8TF
M5HVK?EE("Y)'\6X:JUI.#']/9>GUI[5M]+:UZ_KE45,+QT\-Q7G$!1+%%:Y9
MP21TWBR[6=E$R4>Q=*Z.4W$?7$I%4[U "Y=LV;WKBX1@F-S%8.F&Z Z#T.K;
M>.E%-2]UD>JKU+7(I\B4WY== ?\#LN)HQV>.A08532D1!<.AJF%IV^+5%?*/
M1)P3'IV"M3M01^N:9FQJQ8X^JAJX?Q,!?(CS0; 14^_#G8R .^:'_%3QU73J
M2*M5/-*G[.=>F)38W\YA"4%P7(,2F9#D-IVYSV?'1<N9*66S$!59E-^UF95/
M>VTP3+B796EG/<N20HS=B5=7+Q6)V88VZ&BFVK(8RVTF1*K;_/I4@CX;W),I
M-B H["I=#KVD^([-Z;G*>7]["RQ'O6*$_&3Q"\4,S89[@=-W3%E/P0LO65E+
MI""[E'H,% ::(AH@F [^Y]":D1SNK@3.%8N]J9S\G]..7%/ (6V"&J7DHU3-
MDOCBK)/B8P]Q*9X*<0W.MOC[<B,*I[>3=2*[;GI<;634HSGC:*%:'E:]^O4Z
M$#I $AM9=&3Z3IFMF#^B;\W"56A)S]=;L6_!2BZF<>0"DTE4./]S/9@590I<
MN_DVT#FD8Q[O*Q,^AFG-X?@ND]("W'T<!*M"GSO0>WXU_OS-5=&O?V==4ZA6
MA%?>611I\&\L3N2T.,#WPB#YUE]?[(9=G!C:EPE3_2MRUEJG#EAU^@1.FXJV
M(Y^_2\F3(V>TM36,3#1GFHUQ2A7G_BJ,6(EN3;Q9ATLG<L&C&>@ 0477Q;-8
M1'/3NGK8Y?)ZR(?5#7UH%*6@?;+%EP>Y%AN;<#WQU&,1=R_*ZJL1>YFP!F.N
MSC$/<IB/9V6F^-_8L 8])%J[S@L4X&WR_L'H2^6- '?MP2)+=7.BHQ#)LA_N
M_J"6[TJ_1SK0 ^4^6C4=,58]06$G"'SN+7[ /.D9XA\6J0,UDD$D&\\[D8G8
M'A!I)SS756WT!BCD&&.;A,K1)=HSK#2^_W[[D5\YQVJ:/>NTGE]K3U0!"J6<
MW]'MB&:5_ [N<R-T=C9RK/0J0)+38[15+I(72)QOK_10H+B2::& ;K4Y<!.S
M$+AB<Z5: NOC,:[S-F,+R0FK466B'A*S X'%L%+)3&M1B$"GRC-M4D@A#2<Q
M8G .AC<D,)[XQL#D6IXU^&QHZ8I@P#3".':(R //G)_GV[>%S0/63_PUO5&P
M9WJ2]G*=]18T9YTKTX#:(V<W%T0M_3+0XJXV6II&9H05S&8+ D:R'C6Y#L+Y
MD6*)1DM:5AO8#7ERDO9UBPWACP?J\;)1^58V^DW-G!A;F5G]]T^<G<O'@),O
M&'W]E:>8AU4'2SC3"QDS+1YHP21Z3T[93/J]S) NEX?W3,9%&XPVSH;4!:7+
M]6:J<4Z.[Z8)"@W,>_F)W#.3?+0NM<6:YB_U)J7LI+HK4\:J Q4UIW,40T(9
M:GTXZ?L4]K-?@<G7GO9 YMV.9-CP<Y-<(I-@CVTO;TPS[U64O[U9U)S9DW2I
M9/S8I >P):.[N16K\^P<6!64*5>;\>NV#\J,I\6:YKAXC[]H_*W%#OWXPS]I
M;G$WC&"7Q80ZH7'1]*#HCE&. C6:O<ZZ,7WA[DY+$;PAUWJT&,>/3,<(*?:9
M%<*99_=!A/Y+IPAPC"5XBN$O@>X7:0@6&066Y(:F[[XL,9%[:JG>UADN(;YN
M&UK*:H6.3_QB#<FS27G9=<;?DTFG^Z@&W&XEI#BNASKC8 ^7@%83<"[KC]Y
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M!7:DWDF% G=B,B4*C@O\9D63M7P"V@3&.Q7$#Y1'$D(.D7ZA=(!NG+FH^;T
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M-_X-[\0C6=F[$$UV!OKH_P%02P,$%     @ ]8R86-F&+:C:K@  <J\  !@
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M%PWC' 8L]1@X>P-Z>7Q#Y).HV9;[0&FL_G8Y0T)8I)R>MG5ZTG7R"X7T+\F
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MK.,8A:YPD6J:2C>TCN$-,K6:;!\,",R7?2BL78]_RP6*OX.@",7/['-L01A
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M,GC03>);G2KO_5WR,4#="Z>GU&?RKS3Q-,D=O+(>$C4M@=>E6?A-<3Z-X[\
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M&TI.-K,N6/C:_/CZPMBD(C69<!4/>OH 70:3%?+>GZ7J+^--.NGFM1YEPN5
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MN%W)N&UNO.:VZF5]#M=/N-VH0KZDDX^E7Q_JC_O?TK T.7.J6P_O9S^1K?\
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MR.*D?"UH5(3<.IHS>-HKUA#8137<K @?(0I^M5+#1)Q&UW??OKW+.-Q^6/\
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M^1EMP8D=!T+@=6]^O%3SJUDRE!IZHY7X;?%*UM[J#3]-\''3+F]O?)GCC+[
MV=I;<>",<\=:]-\:^,Y?"?B6;2H;-;KR@C&9Y"N[<H/2N,T/0],TV\L9!?((
M[:0.H8MD8-=/\4=/TOXGW-I)'>QV#6\807-M<;)7X'WCWQ1=/=BM9G.>(/C9
M'X7T^WN+G1+FYW72[4MY 69FZ <5T/BWXIZKX7U<6ILK;#01S".8G>H=0V"1
M]?TK@+[X!WMQ'"\/B74+L1.'C5IT;:PZ'\J[;XE?"FY\9^(X[Y+F6./[+#$^
MQ@02J 9^N:N-B&>RZM)^YB'^U_2L]?O5-?3>:L8'9OZ575OFK4SCL6 ::WS
M@]:3/3-&[O4%"LS<8]>:"VW)/;K3%?.<_+S22,&4YZ8YI@>/VNK#3/VP'G89
MC3PRI/\ W\-3_#ZZ&I?$KXM3E5^;4+8CZ&'->#=%EV58E,_[MQ<541 PZ%HD
MI07IV 61;I!:6I#N9FF0D%H6I(5%NA>$I;L[EEBDFR_=70^__YOG[1SW,??,
M7#/7>7[V=%>5+-K E%,7GYM]0?M*-!\H+%L9_I@S>EWC[K9\0[XU\$RY=;U.
M[TRJ_SVN-Z?DQ/_2!/6+$-U45*OK36B'[@/BA0Q:*7!?)R!XXOWT@"I7@4_V
M'?.!G4YJ:=-JO9^D":>R[H=^UKU7R8<ZCIO@[,-:7V%""B^JB;83^Z??[H-W
M@ZRY]F0O3+[!6Y8$B]DL7NRI')ON1EZ.3^!R%,H-#]A"2>Q90!C/N_=2I]LV
M7[!.;UD^3%1^HHCW'Y RNOB*6\J$\*#MT*^]%KC4FM5PO[.LX!?5[C*J) SP
ML2M 3:&6!R@CX]87OJB7[$+C)-92#WBYPJZUPUS3E'BZY^U*2DW?2#J\QC)5
M&Q-_ (C9%!RW??,>3[#ZJ3\,DT+! %*7\<II"C7&8,>P;3;))_!K51*6'ON*
MU:?$5MIV6%:6+\).LB(^L+-0)*:(O_JOTW4E$=Y\=*T^^D1 WGS;18,0 K#1
M\**V&I(3?]/;$$_>)8#.$<.6T7KREE7@0"5/58'>P1[U[EUUGHEJRT+F())E
MI^MKTK1F8?.)I@R?K.+/&.$)VXF_ GQ/A<S/\\SI.74FV(4N"LF/5/EURY_+
M[4EDL<S_IMK,+&/K&4.-A').FB9^_M3^GMT[ '#&A[Z,[*30#K5;V-29*#FM
MU;Z'& Q7P'I3#Q=)_1[#Q"L?-K8.NR)]&XP:X@RJ+Y4$/OA-V%\4K?TYJZ#^
MC>$/)Z)<>0-EH[:6MXW@%7]BO:U4WQO)XJW<Q!.%)DG\3D5!,)O;[2>CS].#
M$(9G9C22VNLQ?XX<E.KO2EJ63?3;G/*V!(0S&^+8#^($^_>$Z)&%2/0([F7<
M2&<&<=6DJUZRFX)(8#AS8/![G#Q?L;:-YK(,QI7L(0[R8^)#!1Q&"FB>U8[*
MN9^TIH?O?C8?')2S(/$SFS'GGE9$LSI*KX]"CCM1>KWF=$CK6./B!U6 W[Y_
M@BMC;LIFWJP(8>"UHB'=95@^1R\'U9L^-JSY@&XPY#H.B#_-Y%.P$?X ^+NF
M/; (<$A3N?QC\V+'Y16<&0-X ,A?E[%%YKS2)0O$$!^GA-RA&F'( 8Y=APVO
MFBZC9]O7DUT_QSDRKA]CP>P:5O"[ T.VE0< P3:$_O/%C.]D5B%WHMLJ?%L0
M6;(\^2KJZ[[&/AO8J+P&X[I5XI"M5ZSKITL7Z^C?7HP/2W^6.3DF^+N9;S8U
M(>7H,^+OO(KM \ MW&0+4J\?9M^V<Z5=<GFPQ($ZN%8)._KNF,UA0_\V#J@Z
M#]LR5//-W/8CG\A&3=@U]SG1,C'  WBPVF9'AB*N*3PCW"8?ES1XR&IB/7H)
M+TC,T@K@3:':I!;D'9+X]OD)[0/ JO!83X7AH\//I$W:)1J1#01_&JO,2>?G
MP+BAUEL;&9<7I>25A\Z#0RMVND^X-6MP!%?C;W=&47L,:=J4RKY;BT^_HRH/
MO0UFI8@.7!Q7Y":#DV8<G\N049V6G5^?=Q^3Q*Q@LT*/@HT8(Q%\6AC)74=5
MQZSX;4^QJ0C3/C9=#PI+P^*%)G_U0W.83U=FQLK<_VH1L>%P3UE4289B";CH
MT,:'?3FI+I?ZQG]V7F ^OO)4A/MTI4$$!MC&58$7M*^BO]!?:7W'!)V5F-HU
M-H<P])P0E? ZA?:*S@8ZKL:01?C_6^!47S'V]=#*62">VENSFW&-(SPG ^Y\
MS0D]9O]INZ_AH-_I")9/(W;^X(?9>,)9C<S^(%3ZMI+GR=BL4LQ@CI:9AVSI
MR7=NC#,<,CHGPV!<$N&Y:\T>3?<OW;E2VH,!E_"&!QZ1.MXID"A:\A9<D;R2
M6YOB9P+7K90+77V"8&6X5DNNYF'Y>CO9<RFLY\5E+YH"T9Y^R?E/< 2R(T"0
M@';*-5-JCA_<R)I7FOM 3J_HHM;'G??)E;>[XUNPH<;R V!6!'A8\XV\[WXH
M[ 'P&;KG;_)B,(E&$-<],6+"X@BZXF\[_@ @A8(0Q_C_]\%^BW'+Y?51X0,@
MSWUQ:&=GV[\7!>4:O/7 >0 P,C09K?G:.) FD!G,-@W)*5%;2>P9T?JU<A#-
M+T(,)D@XB-(*YO?$\93$+/MR,I_;715:9@72<=/SEC5\+!)T@+B8$N5G_)JZ
MR#1.+VR)YCK./LQ\2G/Z@\*-") NK*$W&\%"$4#F/Z4V.JX'LH"H3P T6,@+
M&QI2 0:+\@ZK<HKSJ>74]<E#>]+;IGP SFV;-XKF>:29@3H7!0SF2W2;$QD3
M=X/S1(C,,N;N17)1_,-]TOA./W;T:5:3:>(Z1"6OJR\SN!">C%7[O6&EJ'>.
M2KN?!O0 "$KTX1N%6#:*F!1YEJTK$Z.Y'5Z"#P08_(A/$##P4H[1VT;9O_EA
MNU4MN'H"N&,RF\,X#0*2IWEAIJ?M^Y:EM%9EC#$SQ.16YHX1H)PC0ZG5D9GL
M9:..509H?N1N?CTLV"8?6#6 N"1\>H+L-R*[A1SEPW)Y/".[*,I*](3DRO0&
M-L<DNMGB=8F_[@*@J\A5A60AS3.P^*W# P";$VU\\OX0]H/3(2U+?QL=/KY3
MX07^B40TVMTX^^@>I<0Q8.@.S[)OFY7AK\-AE\ %OI/1>C98VDE!\V2]XA/=
MZ5.U.+^@H)A(K2.2/RMXP2Y%VP+0W YGM,$@&C$QP;VM8/_QA02LO<P2C.^C
MN6(<;94[\(HYYX)^P*CWY%H[WU/EW+XN]'CF0'-"M"?T2U)OH)\D*K"-N6 5
M93Y-X[("#%W@-R*<M3E8YC#AE3,],9V@Z!O\[H(1W#K0/PBY?W^);,4\42&T
MJ;G^$NYA5UEG1KXOOTE\<Y,]TU'@Z:$R1W_S:::G^G7VP%/C;6'M%!^=NZ1F
M,A_%\>]*+FWUMICWA$DN5F1!)G.Q6\&&4:R0EX8]HEEI'MH@T=%F0<]VX'1J
MQTI@/4SWB"1]A=ZT(%V>5FME]# [RGCSLGZ*,*QEZ8^PZ%2;VP&V@9Y0JY?K
M3N8 XKM)+)CBND?ITF09C.,#.-H,Z0E=U#V<#$D?CZ8VHY.;I'OU\<[C.5:-
MVTH+=?= 'I!S>EC^/3.KV*>Y&$2(ATG%NU]Z3;N.DVUC\5-@I^OLFP]^XQGX
MEPE'F X*$#Q_>]1HKBJ';Z9 JM-66=D+.;8&9JC=,0H$5J1W3<7?R/L(>3IT
MI=Q/AXB>M.'^P_8])ECL;O'-MKU#_H,=(P4HF5F3?&,&Q03'PMAE;0_1S4LO
M"W-"<']GI1::,FTA:";MTM;Y6NV-]=D5=_/7V[I\)!XOB<ZX&YM1D!_IE&N^
M99+*5/N0&R5QW!L&,TXT@7L<@4PYLIIS72NEC?H:$W&/H7GJ_Q-8V1+-*_LM
M9OMH3VKHM[,L_7//9.$ %9\G8(J=/YP0.%$2CQ4B2@M,VNB694!NVVA:VL%:
M:+!HX](M1BB?7^"C<&3?6)(*B^"+[/1O9&AT)MS1T6XM^?O\2N<MN3]-V);F
M\DU?#-M_:;[#Q"\,SV5VPV[?!:O'0^X23BUK[..Z[[?G_\[=W;6>G"'S[$N-
M^H2B$%/-7Q]?HMEL(_COEB.9UTSZZO/KUVQ;?)/?H\7?"N2]1"85W\K11-GU
MA_8YU#"2)Q0]C_.\! L6QJO))0=Y'6C@QW'*\"7W@ZTBE*G=4?RRIG#GTB&=
M5++9HI4TZHA?_?P$ENS#WKKTFP4%LQ[2&C#HV"QK!5E_#+?"+Y^PI>LWXF1[
M%@[<'1V4P1AG7*1 R&E#R/O32V5?4F!_37-O&+SKR_E^BZOYGYA-:J_#"^DT
M6O$Q0ITU$YT:X"O;NN,#SC]"]_<'&VRCC*_JYK@U_U5,J&H.(L,.PP_*DHN*
MR4)E'P">VMX'^D:!7SG65JFN_&\^E@T5&PR;O%R!)T/5X'(#+A*6IC2_YJ>[
M!+NM1"L7@F!A8-LIX&%M_'U;^0/@/Q6#Q5W2^Y;NEK-AS%63(Z(:NG?9BSC'
M#[YJ\O OMW00Z<ZOGE6[;O+U-;HB04I=(6*6'@!K.4G%H%H@!U$WW#0Z/9G!
MFF>P!T#HHIMJ]+.$K[B/MB).(3?J>YGZIS4+L*O0$B+71^.WAIJ#R[D.^G?6
M.G%%J0Q*O7G*UG67,JU@A<%^AD"/II:ZZ%?SQ_&I+8Y,][I?)<Z$[-$-^M^5
MY3;I1U6WV\440BCB)NEM?>:?VQ!YCG^)3T8]^VW/4D^V(#67C^V!W;91.T+L
M(T<1]*@=U0K1])UX])+@WSQV>]Q)#>HXM&6:_C.T7Z%:I4B(I^[IT"?)^O$X
MQI"J$_Q:;9+95E?CGI2@];].<<K"VMD4H ->V'//G:]KH47#^_/>U"VW3!!6
M>/,=[29E?O2J_DVB*C<$WIOTI@0NW/<N8(#!C-AD^\4V6VK-%(?KM$6E'MO-
M31]PK:(A5H4WFXID+1QSMZKA2=K!M6Q$F!L54\HVQ#$@0\XDJ!B-X!0]E1CU
M Z%^9V63#!>Y%<E;\;EBE,,D>R3DZN/BQ=B>-KIO.Z!C?Z-5GZR-Q<O)U0=0
M(]I3)]*:?\W/6V+=/ )L#*YH#; !+KS;4S(O2.6WS1:A<4%8N_ O.I0^R^10
M7)2D"/4B(8OZ6]_Q>H<ABEAFQ?)#;)_2?$;"VCWHK@A$XB/P%M^B&^I9*RZ'
MJHS?>V?FWNYZN[,)!/JWJ8N*?4-+/M8:U]"& +0WG$T;1']0Y7(]&7C!M'NZ
M4<GW 'BS!2)%"4"Z"RUR];ATN2QTPNY%I6V./7H> (>J_E$TO"=TJ,F]VT]6
M3#+QN9^)6W?Q?J=>W73Z<4[YZ+DQ3M44+UIC\ ?$UCOD$(.C.#O,G82S%TN;
M@3Z=,,.D3H_P%Z^W7B<]BYD=QO997CVX9+5'>36#<3Q!&&7%)0-K=(H^H6ID
MX!6F;; C4_#IJ+H]I;2R\A*+3O _4?\;71^=2_A&3['G\#6ES,@US6^_(> X
MWIU-'R=3W+8#__+"AD9?G#OG8DK1L3Y@4,4Z2"AUQ>05"\-Q1:OLKTI@)E&7
M<U^*KS]NV)Z!Q!)!PIRGQ9)#]*TF*GL<7$GKIWC1,[#Z#XHI]=0^_U(),TM=
MR 9EWD'8G-:E$!N6> @^O&#V2"KK$_EY^B@2TTO<75&1P["N^P]F'[=43)^>
M;!H"V?UD$.CFP4-D6Q-IAU-XU1#=PK\*&/=K4M!ZM$<BS4OV;!\3OZRL<_+C
ML!"PV>7Z/R94P9"[RR!_]H#$98:2-U>('XYE,_ %[SP-V9S3QN[<YG9W4X?*
MX8^/JVRU-U-W&>&FK5]QQ:SU(RHVW,$$TZQ)4BH%PVS%A\@.4@R?X"Z'\<+!
MQ1I<3@=39^N._'[ILFS IGHCN3A;NH[FQV[@)Y;17VV"9D1:V>1T,*(22K2*
MF0^+['I/>5<)[-JW&8$X6P(TE*.V>S3+*+(E-6!Z "5UJ!BV'@;9E5X\0J3"
M6[LAUC)<%=+87XRB5VWZ>.>/&TY?Z9 0![K55E&@!_)[/0#"D,\\- ;8<4UK
MYYA^!%>%D@G=L@WXF-P\OR4_FHN?5\B>\_16=3^AL:,P^D!U>N6W=5N\6&7
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M#]N?_(]W?EYF2^_-/R09,<]LR)XX>?D_[/]0)G8R5-^0[*") \X UM)F:\T
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M1'$(.* #R"MG8DOE:F;@(0#-X^/ND##R$7F$0RZE=4"("5D^.UT>WHY"#3J
MX2_L+1=Q)8733"4[Z<5.1D)E%:<4TS,.-0&HMP:!/^3+&P%B=9,3"M3[(FVT
M3S:U)7M4L)IL:-IY*-4;):N4>E61=T5[CPW,HS")_5<WQ."+9"7O7N-X]7CU
M2O*+JFNEJI7\B$1>W4K8H#&;G>O$=S+1J5>O!H:=(D9C[F6/@F6MYQ5XK+J@
MFA:5;O<4-30%3B><UFX3=(Z?V@HX>SOAN'?6S8X]?-D%LG$?7XYZ%+WRQ=;E
MK[#HA._K-.?5B12[?;<]*UO4"1M6NXK8L.<X5"$N_+G9S'NHA5C%?[NJ,/%M
MD2B8A0ED.4OU$935K'0$_($"/K6)LTJ-6"L<U"!LX''_?H^Z8-R+=1K!*74$
MO_;!LEF-)E$@?P"XN)% 9I8(3!VV"3^ST$Y?MO0HX@2<+1$ =_=@Z&;P L5R
MHK*?YKUY\]!EW7*3@M1A?CA[?DVLP6S[%WA1(H-3[]DS[:YQ%KU\Y@-L2O]7
M4P'<$?XO:$\+[G?X95<+\XG<7\E1.SNI6T$,IAK<.5QWV-+E_?H<W@G=86,G
M4$A1L>#\QQ(U5',I?K'1E-WN_Q<6(ZI<R+A+LD"#LGV+B:Y7]*]M##ZC:RIN
M:ZE AK@B. T,%9"OE85+>OK#P/N/X+8RP-WLAK@CW$H-&%$AN=W9SG->[D=)
MX%BDSB%L%[F*>.?E;"CAL'PCO>FV:J[_.-WFMI1OSW)+6*I%Z%XGA6&Z0[XX
M (LVG$DFOV75@ ,9UEXSF-)#1BS:B>#V%#@7.FR.Z^.LX)AJ<?PHW^]3ZW*_
M?>S_SG!U&1DV8Q%FI[6H,&[G^M]SD)YGT)KW->;/S'^<CD^<3DN]P?C8;4Y=
M%H,#E8(-*H0%;=VK>EI^5.ZV/UJOM4T=LGIHGF2"(:,QK5SBPN>%M1/*$$R'
M98X]>:FW+\V'BFKAV9A!J&;R[LGHUZ0_"32(*)],7]8)]V!T%;KW^G$\:)7Y
M--/<UMUOTEZ$NN2C8"G9WGV3M>42WH0JVR]3%'6H=;M>5* V";LKT0. V8&^
M5#/$N28.YYF+RE>\&-;VG@PEUFY052_]5Z)UF)M\Q0DZ1^?>WO()8TS.<5BI
M;+$R+53UF9ZW>^ZLRLK_'J)E;KY=SNT'+.XAHM542#FYE(@#"A@"$+! $>4S
MQ:1;8K'\NE:VQ,*]R,D?J[K&!:@<YMGE[V4_"2"OP9126KG'39RIG?&)?W*8
M2M!"5#_.",*LP56:K+P:BD&<%&5E3NJ H3VU2J?+\1Q;37.F0!WR<NNH'A>@
M? 43=-+]0+Q_L/G7?,;DIV]I/?951"GLNK,1[G,G7_Q=-8ITZ46;K6:M;JR6
M?5FP2!9+A4SGIW*/8;E E]*GGV6 _=8J["MI> 36=@L33^GU(PRF\]?>J-$T
M"69*FHG4#<DH^]=C?TK%JVOP)5]R*]$;4/KWO2Q-0Y5<\*P$HZJSII6G8/K$
MVV '8=W=,OX/XWPH ]GZKM9"MLJG.6%\I$[?[^-[>.K9H6*39O9F^[SW,_?J
M$'".^<KB#W)XC_2<_3)ZQ>[SBL*-H(^0^07!;-FL:X,'S6>N,[[K@OZW.^MD
M0\9S!?"Y\KX1J,<S'XUE\'1P!\5+.;[$.DP9:5RE0!*)+QSZV.9A$I=V>9?V
M_^Q.FT"+RC]>>;D?_@#FGR'U&FM@7E?8JMS,X \%#:P]] [+*'7!S?Q2J]G_
MV)VJ><"XVQS&417]N.,U(4]@O]0I9+@<ED<."!+R'?[D6#!*\"'+GXMJ)H\:
M4[D7UEDSN4*@91^#2G*39Z-<M%?5X#U778H1 JXY:M(BX+0\UDYWPTD_/C)1
MS02U*B=Q(M.*K2Z=F/&G@5H!Y'S"!3WREMIL,C8Q3NJEM:<;)7LTZ87:I6J,
M;F%$1V1;,=;VIRWM'YZ\IQ89N-V&N&,_@Y?X:/SP"\JHV@:8HX4C^%%RM[Q<
M$( E1!\(\>4)>&?'M:IP2P># !R6Y2HQ$6Y$@ 7?+7?TV*TK(!(=_SSG-&\R
M /V8B,2V3M.[ #)2H B PY%&11>][[*"^'.Q@MG37 @$H%25YC0D'.&!Q3]6
MG>!W)W)K!5BCWD9O$AOXERJG8P,8[E@;'C=@?H/2K1]]ILC*#TEHF+ 3?_U7
MPSTB(][R-/-9U-?:\SR9B8E(]59Y^#O! LSU9*1_8PM$7(?D =!0A'E90TY<
M4,2-+EP@P);14 [1^?;JDXKEL-7YZAHQ&V%B222QWQ[OR9!0\U%.YA=E 0$4
MTXS_$874EH3,P[__!U!+ P04    " #UC)A8\^-MG2HE   _)@  &    &-V
M86,M,C R,S$R,S%X,C!F,#8V+FIP9YV:9U137=3G0Q/IO2@E2A$4 >D]$7D0
M 0$1::%+-U*E!"E1$) .(E4@2!&E13K20D=!0&KHD !2%$@H(4!(AN==[[PS
M'^9=:V;VO?O3.?>N_3MGG?W?^ZY+F:&L -@-[NO?!U!1 P!4%Q> ,@_0 =!0
M4_][7QCMQ4UWF8Z.EI:.D9[^TF5F1F9F)D8F)A963G865@Y6)B9V7G8.+FX>
M'AYF-CY^7FY^3FX>[G]?0D5S\0PM'0,='0,W"Q,+]_^S43H!')<!KE0B-%0B
M &H.*AH.*DHO '@1)QW5?QC@/XV*^B+&2_27&1B9+B8TL .HJ6AHJ&EI_HWZ
M8C3\8AQ RT''>5U.^Q*7J1.]B!^W_.NTCY=%[]5T\3P>PXDI//6/9&#DY>._
M<E7\AH3DS5N*2LHJJFKJ.O_HWM=[H&]@]L3<PM+*&N+LXNKF[N'Y[$5 8% P
M+.1EU)OHF-BW<?'OTM]G9&9EY^06%9>4?BK[_*6\MJZ^H;&I^5M+=T]O7__
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M:#K!]7HQ5%[@OL:KO9YY>@HWW8"$<?#OY:2'*"ZP!Y#I1Y,%3O=3#6/:MQW
M[1ZA^ ?PPZNG"?Q;I^,9"^IN;7O5!V&^"2<V^Z#T,Y8)\B41OY/%\)\GD6SS
M(#N>:5D>(IOEF$WQ'7ID& ,/.#_87NB\$B0 >TNGOC)Q0_5$%NM1DT<!\#(2
MC@Z1=M^^-K9&%Q7PK\?%7!%[]"3%%QJ%E_A+ :RP<6=!]YBM0JK5,B^3LBB
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M:0SI:--?:>1^QQW'!2!XMZ),?QU)V4$ZO^.EI_(J;C_<[+.]9!L50RL8S).
M?\?4BGACKQK3;1%Y:L1X(KUN%OE.()BQ9],7RD5XAFM(B:0 W)=CK\KD\V5
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M42Q_Q7#CFR]O$>%&8PTS;??G(K*#=,)#N)^G:I[\\!->&528T@7XD+CQ+!1
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M=8+J$\;O:+?Q>^_8M 'C^T>U>Z,9=H )CS%^4RUSZUE4 \ Q8X3",57Q'$B
M:TZ=?R)_W38L[BD6<Q9.;CM8$UW)."U+N*T,*DI5 )RUY=M1!+YM%;"YYYCE
M0*,%H!IJ6(';!8I 7NV0"]L*+R!0/V/W"6 WVC7L#B94E#9&H6.S)('LCT_
M)?7=+&[!F.\1;=WE]L3.XA0:0K#4+G<<R=)\>?C[\ &ZD&:8&"=?/\4AHWG*
M;;<>YJ8!]'$PPQ&>H?9XH;9RN^N_I<;4#M$7[Q;ZMBIYZMQ]$S:8@E7)FZW9
M!.8WQ$]DMS**2H7(V&23:YAA=^Y,V,8IU0MZC*'+(I?%-J9;G:MX.R."WS!1
M'>S>D:__,S-^+:@^V6.B_:=Q3&3OZ,5S]-:7 0;C72:U <?%6^\KL08CU3?0
MY?6$<Z$:A:332*47]-06H%C&C6'L2W%\)(']8F7,03/;PQZ@%[8 C6$9OC'I
MG>\,[*^2@^)H0%+FD3WV??5\%/2HD;=[1T$] 4D4S!\'<%%8;SRZC#@#*%2L
M<G$D,V7T!FFB2ZHL4;3IH+W9.+\Q\4T JPY0W''OEO!%8VBHV2)Z;0=CE4&"
M/( */*_NB*H&EJK+# R&&;&65-%TZ_V;7RNR/06 M7;MJ&:K0CW@D(F"^% '
M9V<VI %<[!WQ"E=U1^]X/I%BPI#CY71<W=A7511D62'DC$'M-)4N[M$UU +*
M_CE)]7?;]1] C5-8@Y#T"L4%:77J!)_>W:5GS.P#MP[R54.'?"^20M!"LW#^
M8W7H Q@O=<\3X@.TN.S@37/?M$_GTM+(>8%[-M>6K#W!VU@BN9+!DI7'<6O$
M;@QO:N[YQHV]YL[^X8!2==!Y_5NWLJ4"4+.X)?;\GKQHV'^KT_<@ -Z2#:ZM
M6*"#S2<2MVTO?V=HZ\MV&GS*&^\2Y.;!;5TSS#V&O/GYK;;]W2+^-..^!V?+
M/>^[/!BW^]USWQ_ANH]CY>Z_8(_#GN_PQ)_M;/V4LX0,;EE4XG$RN73)^K/+
M/1)[U@B?>]%G5]2SRKC/5"UX$(UNQDJ6>8Q<2*IPONNNO#VT7E$Q(F3I@N?,
MJZX;:[S(O:&T1HS6BA:O0Q7 T;T19*TW'DV _(1T(GE<+?OAH=_J+**#*VO8
M!,N]9F7?VSK^/U!+ P04    " #UC)A8TJ_"<*$(  #9,P  &    &-V86,M
M,C R,S$R,S%X97@Q,F0R+FAT;>U;;7/;-A+^*SAW>G%F1%*OCD,YGI%E>:*Y
MQ,XX2N_R$2)!$6>08 %0LN[7WRY O5IIG;9NY)=,+(G  E@ ^^RS"Y(G__"\
M09[2/&(Q>3_Z^('$,BHSEAL2*48-E,ZX2<E(%@7-R4>F%!>"G"D>3Q@AC;I_
MY#>:';_N>:<GT%>_:B3SD+2#)ORO-]ND_C9L=<+F&_+I(SG\,NJ_MM+G5_W1
MUT\#-^RG+V<?AGURX 7!OUO](#@?G;N*ME]OD)&BN>:&RYR*(!A<'I"#U)@B
M#(+9;.;/6KY4DV!T':0F$^U 2*F9'YOXX/0$2^"3T?CT)&.&DBBE2C/S[N#+
MZ,([!@G#C6"G)\'BV\F.93P_/8GYE&@S%^S=04;5A.>>D478JA>F"RT#J-Z2
MN?5F/#9IV*C7?^X6-(YY/O$$2TS8\8^/5T6*3])EF713"Q43U/ IP[[7>HT$
MHRH<2Y-VMP?8U;)8M$MD;KR$9ES,PU<CGC%-+MF,7,N,YJ]JK@2^-5,\>=6U
MTIK_CT'7,#W#;HU'!9] YZBK*^!Y#*81MMZV_0X(N34)09[8/[\!GT?^&[<\
MXPU%9LQ.>2Q%#)6#VY2/N2&-IM\\"<:PEL6#:;[2$K5"Z<4X4ZY!"\'-/$QY
M#%,#@7_^=-RLM[HG 0H^D%X1+")36XK]UG+U!]>CX<6PWQL-KR[)V5<R>C\@
M_??#P06Y&%[V+OO#W@=R=0$2@VN TO7G+[W+$1E=D<^#OFW2JC>AWC;[W+L^
MZUT./GM7__DP^$IZ_1'4/-P>?/=<F_7Z7VT2>V(!WX!+O6/U&M;()P[^E9%_
ML:P4M$8BI@Q/YL2DU(3[M!R&C@4C8ZEBIMX=U ] 4R$JU[:\U@6-JFMHH> O
M7@SC7%BSX3=!A:K=0IW Q.NB4UR#B(K*FJQA@0_NSE)NF(=CL#"7,T6AR#G&
MCM_HW.WVKUPY#WRQD5EH-["[1@QNK(9O%VEK(C].GR%)Z901Q::<S8";3<HU
MH7E>4@&%A50&Z)I<2)619MV[(#(A_5*Q7VA$+OU??-C_M^WN:DH![F5@3>#%
M(/?-(%OM71;0_'$6N5NA,ZIMD$BR.;F!U1(,PLF:L\S*)&,)X^82XE 8@/(<
M+'9.RMRHDH&B$&3:(!5LE9(,KA0':TYH!$6*R Q""R.=W!V!G$5,:ZKF*)+1
M&P;CKO6IH2P&96!(@;R$8Z! Q!5$QB &L;(&3<#4"&QZE!)=XL>J_8R!$W>=
MX 0RKB&"PZ5VL;1BNF"151#[+4 U&<,TP;)@4<;S]65X =^C!U_KT8"/D83G
M8-Z(E)4YUP!Y( [5:JV>YPD0!L7L WY'HHRA3X#,FNW6 &Y<B3DIP.(1K AB
M2!Z7:*R H+>&!L#'-JVIH40I0  @* $G=CAM]8FH3DDBY$PO\2FS GT$Q1*G
M-*A86\.87FAR1]47F#UZF+7W#6:CE4WB;C;>='6%HBJN1T*02<+A\E"_M@8[
M)%0QBPNP<X[[#29,F,:]YSK%%BB6 1\B)^)US'4DI(: S3*EDL(!I% R8C$4
M:W((D(@9 ,S9_> V2FD^8:0')'1="I!HM*C7Z!PRIT6C$[LK=\DQ@<L=,+%_
M@DRUAE<'(=3EW@,E&P,E,!#.<P/%4(UA:_@<0-DZ\EL[X/,$4'E(7^\9+,^9
MAM4# [51V^^CIX8!941+??\F&-F-&2"A&LG%BK)4T $P$9H6DAM(L=SV@PG^
MBA;7J=4=[ &TJF"Q@D>MXERLX<"/H(B6@L?V[%678\UC3A5'[;F+9RW3Y]A-
MJ3'&M)Y(VX#44J'4#+0QP+O8J*!H:J6@2-\P)ZO!*E:%%B[R70_8X=>8H2"0
M++1G\?,AU2>,W_%^X_?>W'0'QO=GM7NC&3S E,?(WU3+W%H6U0!PS!BA<$)5
MO  2X)I39Y\8O^X:%GV*Q9R%DW,'&Z)K&:>-$FZK"16E*@#.VL;;402V;16P
MN>>$Y1!&"T UU+ "W06*0%[MD MNA1= U"_8?0+8C?8-NX,I%:7E*#1LEB20
M_?$IF*3>SN*6$?,]V-9=[D[L+$ZA(9"E=KGC6);FV\/?)QZ@2VF&B7'R^Z<X
M9+Q(N:WK86X90!\',QSA!6J/%VIK=[O^6VI,[1!]\7ZA;Z>2Y\[<[\(&4[ J
M>;,U=X'Y'?R)T:V,HE(A,NY&DQN885MW)FSCE.IE>(S499'+8LOI5N>*;^=$
M\!LFJH/=+?G:GYO&\X+JDSTFZCR-8R)[1R]>H+>V(ACDNTQJ X:+=][7N :9
MZCO"Y<V$<ZD:A:332*67X:DM0+&,&\/8MWA\+"'ZQ<J8@V:VAT- +[@ C;0,
MWYCT+CP#^[7DH#A.("GSR![[OGXY"GK4R-N_HZ">@"0*UH\#N"CL-QY=1IP!
M%*JH<GDD,V/T!L-$EU390-&F@_9FX^+&Q'<!K#I <<>].^B+QM!0LR5[[09C
ME4&"/( *+*_F E4-4:HN,Y@PK(B=2<6F.^_?/"]F>P( V[.#FIW0@O@Q4< -
M-3!T9ND,H&+OAE>8JKG0CN=3*:8,X[N<3JJ;^JIB0)850LX9U,Y2Z3B/;B 6
M$/;G U1_O\W^ =0XAST(2:]07)!FNT;P(=U]>KX,'WZUP'MW@,_.'BRP7_7B
M7( 722%HH5FX^+&NQQ$,GKKG"O&A6;0!,*W-1W+K*[Q6#^1BR=KSM7=<R)9;
M< BH6K2/@69^[E;*5>!H%+?$GLR3G^KVW_KB/" XJSX#'6P^5$AV.8G?FE6G
MX1]UOCTK@P]FXVE_;O[>F6V8U9VG2.]I9RO,_]%M1H_W@_=X8W__X/8^JZW[
M6R?;3SE+R,62=:Y<)O<,]VE!J^ZMB3UA&J>,^TS5DF!H=#-1LLQC)!FIP@6P
MUU[%V*RHJ ;/3 3/F5==+US!^BL@5<GZ&R#;[Y84$ EY8\@+;CR:0!03TJGD
M<64*Q\=^<^6 7%G=AK#NG17[$LSI_P%02P,$%     @ ]8R86(R9OT#"!0
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MU%#:_JX/>"GY1F!.O%K2@,<N7HR.DNP<<EM(<P^<@_4QYQZ=[5&4>19K VV
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MC!5H]\(;],H_7 _]?3/_"U!+ P04    " #UC)A8IRROH%($  "(#P  &
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M*J:&Z4KOJ7D+67[#5O51F\S:3-85.WUQZ^64L$H]+5+_:B(3/=KH3Q$''Z1
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MC/@2!45><2]39RN>UCRG^Y;C3!YQA-()UYMIUP!$L]Z^!GN:-Y#$/(V->4G
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M%3059 \KEN;"*^1"P4"XV?\)YKF(NV+4>PAPY2'S9O#ABS X^C]02P,$%
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M^P$SN#X+@51C-SOP;1K"):I^8E)$A/>]+EB/[!8U'-RI5PY/#$+W16HY IN
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MABTO+/TXG!^G4B3^&#'&C^,!&:>UW&B;KU.(N3&]]TN^,VZ_*3!)XL,/GL<
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MJ=#,H)PD_ 6J]#H%^<M>HH16XR$%^-Q>_#U,KX+W6IE"OC)33A/2!?-3RC0
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M<\>9+OF*!'VZP%7?QI#^]SEQ?+Z,^9$3NNK:Q,/#\N%7%R<^8L_S#[7G7Y/
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M[G;-9GM]_:-I=M%LUQWYHL4_^ =02P,$%     @ ]8R86/]+;3(''@  \;L
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M*2G--KM_ :S/</,&23;H#(2/ FF18@L,&<O$15\3^));62Q65 U>:#69@!C
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M\ZVF#AKMZRR=/;R'#/Z9%K/TY?\#4$L! A0#%     @ ]8R86)?WZ.-<,0
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M,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ ]8R86*G]$VFDF@  ;N(+ !4
M             ( !$IT! &-V86,M,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0
M   ( /6,F%@:BSFWA1D) "+<4P 5              "  >DW @!C=F%C+3(P
M,C,Q,C,Q>#(P9BYH=&U02P$"% ,4    " #UC)A8,K;^#H8@ 0#B40$ &
M            @ &A40L 8W9A8RTR,#(S,3(S,7@R,&8P,#(N:G!G4$L! A0#
M%     @ ]8R86%!3)A($X   YO@  !@              ( !77(, &-V86,M
M,C R,S$R,S%X,C!F,# T+FIP9U!+ 0(4 Q0    ( /6,F%@N1/@SR=\  .3J
M   8              "  9=2#0!C=F%C+3(P,C,Q,C,Q>#(P9C P-2YJ<&=0
M2P$"% ,4    " #UC)A8 %&^64R6  #BM   &               @ &6,@X
M8W9A8RTR,#(S,3(S,7@R,&8P,#8N:G!G4$L! A0#%     @ ]8R86$!P1ASY
M<@  'GP  !@              ( !&,D. &-V86,M,C R,S$R,S%X,C!F,# W
M+FIP9U!+ 0(4 Q0    ( /6,F%B8Q9=*;%\  -!H   8              "
M 4<\#P!C=F%C+3(P,C,Q,C,Q>#(P9C P.2YJ<&=02P$"% ,4    " #UC)A8
M*Q !W*-N  !G?   &               @ 'IFP\ 8W9A8RTR,#(S,3(S,7@R
M,&8P,3$N:G!G4$L! A0#%     @ ]8R86/%T\J:1J0  =[0  !@
M     ( !P@H0 &-V86,M,C R,S$R,S%X,C!F,#$S+FIP9U!+ 0(4 Q0    (
M /6,F%@O6W#" 4<  &)1   8              "  8FT$ !C=F%C+3(P,C,Q
M,C,Q>#(P9C Q-"YJ<&=02P$"% ,4    " #UC)A8E*FPP>).  #Q5P  &
M            @ ' ^Q  8W9A8RTR,#(S,3(S,7@R,&8P,38N:G!G4$L! A0#
M%     @ ]8R86-6F][J/>@  E8P  !@              ( !V$H1 &-V86,M
M,C R,S$R,S%X,C!F,#$W+FIP9U!+ 0(4 Q0    ( /6,F%@'25"MBMX  %SL
M   8              "  9W%$0!C=F%C+3(P,C,Q,C,Q>#(P9C Q.2YJ<&=0
M2P$"% ,4    " #UC)A8=*Z8+D18   [9P  &               @ %=I!(
M8W9A8RTR,#(S,3(S,7@R,&8P,C$N:G!G4$L! A0#%     @ ]8R86"9R>6J8
M4@  5UP  !@              ( !U_P2 &-V86,M,C R,S$R,S%X,C!F,#(S
M+FIP9U!+ 0(4 Q0    ( /6,F%@YB2DRUE<  /IF   8              "
M :5/$P!C=F%C+3(P,C,Q,C,Q>#(P9C R-2YJ<&=02P$"% ,4    " #UC)A8
MFZ76/8O.  #VV@  &               @ &QIQ, 8W9A8RTR,#(S,3(S,7@R
M,&8P,C8N:G!G4$L! A0#%     @ ]8R86)*M0]\ZA   IIP  !@
M     ( !<G84 &-V86,M,C R,S$R,S%X,C!F,#(W+FIP9U!+ 0(4 Q0    (
M /6,F%CI#K1SK*X  );#   8              "  >+Z% !C=F%C+3(P,C,Q
M,C,Q>#(P9C R."YJ<&=02P$"% ,4    " #UC)A8<C7'?]MY  !ID   &
M            @ '$J14 8W9A8RTR,#(S,3(S,7@R,&8P,CDN:G!G4$L! A0#
M%     @ ]8R86!RNU6K-<P  <HX  !@              ( !U2,6 &-V86,M
M,C R,S$R,S%X,C!F,#,P+FIP9U!+ 0(4 Q0    ( /6,F%@+DW6(V(P  #&I
M   8              "  =B7%@!C=F%C+3(P,C,Q,C,Q>#(P9C S,2YJ<&=0
M2P$"% ,4    " #UC)A8*BCKC]-5  "T5@  &               @ 'F)!<
M8W9A8RTR,#(S,3(S,7@R,&8P,S(N:G!G4$L! A0#%     @ ]8R86+G.N-?9
M4@  \%0  !@              ( ![WH7 &-V86,M,C R,S$R,S%X,C!F,#,S
M+FIP9U!+ 0(4 Q0    ( /6,F%A%YHM0"WH  $B%   8              "
M ?[-%P!C=F%C+3(P,C,Q,C,Q>#(P9C S-"YJ<&=02P$"% ,4    " #UC)A8
M85^B?*IN  !F>0  &               @ $_2!@ 8W9A8RTR,#(S,3(S,7@R
M,&8P,S4N:G!G4$L! A0#%     @ ]8R86'/6NSG1A0  VX@  !@
M     ( !'[<8 &-V86,M,C R,S$R,S%X,C!F,#,V+FIP9U!+ 0(4 Q0    (
M /6,F%@OZJ>CJ$P  $)5   8              "  28]&0!C=F%C+3(P,C,Q
M,C,Q>#(P9C S-RYJ<&=02P$"% ,4    " #UC)A8\B@N$$]5  #26   &
M            @ $$BAD 8W9A8RTR,#(S,3(S,7@R,&8P,S@N:G!G4$L! A0#
M%     @ ]8R86 +YJT35B0  >Y4  !@              ( !B=\9 &-V86,M
M,C R,S$R,S%X,C!F,#,Y+FIP9U!+ 0(4 Q0    ( /6,F%A0_\"N1?P  ,X%
M 0 8              "  91I&@!C=F%C+3(P,C,Q,C,Q>#(P9C T,2YJ<&=0
M2P$"% ,4    " #UC)A8OK4T"30@  #L(@  &               @ $/9AL
M8W9A8RTR,#(S,3(S,7@R,&8P-#,N:G!G4$L! A0#%     @ ]8R86#</O0"<
M2@  5U   !@              ( !>88; &-V86,M,C R,S$R,S%X,C!F,#0T
M+FIP9U!+ 0(4 Q0    ( /6,F%AHA>/!N0@! $<, 0 8              "
M 4O1&P!C=F%C+3(P,C,Q,C,Q>#(P9C T-BYJ<&=02P$"% ,4    " #UC)A8
M5R]@7Z(I  "Z+   &               @ $ZVAP 8W9A8RTR,#(S,3(S,7@R
M,&8P-#<N:G!G4$L! A0#%     @ ]8R86(ML&+:H*@  \"P  !@
M     ( !$@0= &-V86,M,C R,S$R,S%X,C!F,#0X+FIP9U!+ 0(4 Q0    (
M /6,F%B5CY"[(8L  #Z1   8              "  ? N'0!C=F%C+3(P,C,Q
M,C,Q>#(P9C U,"YJ<&=02P$"% ,4    " #UC)A8ZA< Q3:4  !,E@  &
M            @ %'NAT 8W9A8RTR,#(S,3(S,7@R,&8P-3$N:G!G4$L! A0#
M%     @ ]8R86-F&+:C:K@  <J\  !@              ( !LTX> &-V86,M
M,C R,S$R,S%X,C!F,#4R+FIP9U!+ 0(4 Q0    ( /6,F%CSXVV=*B4  #\F
M   8              "  </]'@!C=F%C+3(P,C,Q,C,Q>#(P9C V-BYJ<&=0
M2P$"% ,4    " #UC)A8;#<&7<\(  ",-@  &               @ $C(Q\
M8W9A8RTR,#(S,3(S,7AE>#$R9#$N:'1M4$L! A0#%     @ ]8R86-*OPG"A
M"   V3,  !@              ( !*"P? &-V86,M,C R,S$R,S%X97@Q,F0R
M+FAT;5!+ 0(4 Q0    ( /6,F%B,F;] P@4  -89   8              "
M ?\T'P!C=F%C+3(P,C,Q,C,Q>&5X,3-D,2YH=&U02P$"% ,4    " #UC)A8
M%NPJZIX%  #W&   &               @ 'W.A\ 8W9A8RTR,#(S,3(S,7AE
M>#$S9#(N:'1M4$L! A0#%     @ ]8R86)JG+6\5 P  1 <  !@
M     ( !RT ? &-V86,M,C R,S$R,S%X97@Q-60Q+FAT;5!+ 0(4 Q0    (
M /6,F%BG+*^@4@0  (@/   8              "  19$'P!C=F%C+3(P,C,Q
M,C,Q>&5X,35D,BYH=&U02P$"% ,4    " #UC)A8#[ V(C-"  !TA@( &
M            @ &>2!\ 8W9A8RTR,#(S,3(S,7AE>#1D-3 N:'1M4$L! A0#
M%     @ ]8R86/.P9:]2"@  W(   !@              ( !!XL? &-V86,M
M,C R,S$R,S%X97@T9#4Q+FAT;5!+ 0(4 Q0    ( /6,F%B:MSTV@!(  'JQ
M   8              "  8^5'P!C=F%C+3(P,C,Q,C,Q>&5X-&0U,BYH=&U0
M2P$"% ,4    " #UC)A8DL>[X^P2  !VBP  &               @ %%J!\
M8W9A8RTR,#(S,3(S,7AE>#1D-3,N:'1M4$L! A0#%     @ ]8R86.4G9"-F
M#0  <(8  !@              ( !9[L? &-V86,M,C R,S$R,S%X97@T9#4T
M+FAT;5!+ 0(4 Q0    ( /6,F%B$1[KS^!@  +.M   8              "
M 0/)'P!C=F%C+3(P,C,Q,C,Q>&5X-&0U-2YH=&U02P$"% ,4    " #UC)A8
M#X>4,B $  "W(   %P              @ $QXA\ 8W9A8RTR,#(S,3(S,7AE
M>#AD,2YH=&U02P$"% ,4    " #UC)A8_TMM,@<>  #QNP  &
M    @ &&YA\ 8W9A8RTR,#(S,3(S,7AE>#DW9#$N:'1M4$L%!@     [ #L
*"Q   ,,$(     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>cvac-20231231x20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:cvac="http://www.curevac.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvac-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_IVeKC3yvOEugAiflyH3c3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WHDQrxvJz065lEPIjGIWuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_wEcN7ca8EkmDto9rHIMXqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_4y9Rq2Ban029PexLw4uVTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_SzFXrlYIYkGJv5pgzyKXhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_yHk0L5C8gEyXoJw8KYw3Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_dLLTUG3nUkmNAeblyIfEfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_h5bEzTVa3EyxXxcQh-dg1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_n816zTthhUCd928-Xo9B2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WdwXgqTk-0Gz8-5HXgSqZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IF3SAFyRDkmSY9vIIRwRsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_TechnologyMember_hH9UPyIPlEOolWMJj-UurA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember__BM_BXDhyESvodEXrE5DVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember_ihjeHuLIPk2tQ0IJ5csIrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_7ob2rXhv0ECk61hyXNe7kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR__hXio1aUh0yPowZRVEGPEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_OFTLAOtsqkSihsTZpVXK2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tiOKflb2S0qu7_rAt0WFJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_UfCOEGrffUq3abl-fRhxig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DxjsavysM0WLv8Lp8ri1eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_XId6JMRHbEi7pWfMUdRyfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_4BI6yad6zEGqAQHMGJ0Ssw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_sFnkjvJ1RUWEpsQY3dM6qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryLiabilitiesInForeignCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_1QMTkTTsdkCGavOTm0os4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryAssetsInForeignCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_Ju4vpITtT02dIgHA1CnNWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_utQHB3ubf0qCXWhEgF-buQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_kxVp_wCgNE6FvnLLR-syMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:CashAndCashEquivalentsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_yLPRccYMQ0WEes48TIb4Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:CashAndCashEquivalentsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DolE5C86p0ekLVQ3PMh3_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_bODM9rD0EUC2RC277AOZlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_ov6PyZWWUUy6kIErGoPNSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_w0ZgcmzTPkCXLtNWBXC5iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_RmJ2ciRZdEmmfIdFfjBrGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_xdnpZEJ2mEWa4sCfDXRnOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_uhnmPrBIeEi3fuQMts_BCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryLiabilitiesInForeignCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_qzSBjM_s00e_a6TyWqLnUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryAssetsInForeignCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_2hwJbQ3UHEG7HHhakH5QdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:MonetaryAssetsInForeignCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_lmEX-wi5LEW5VEf6oyObmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_XKseGYdQ5U21PwXtFPcggA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_rxt_fxShG0i6GkUMgTzphQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FHdyYMNB7Eq_o5tMRVitmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_k9Skiw6h_kq4wMDfbW6Y1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_BptK40MzA0KOKdTRAaFA1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_v2qH86-io02_ESJqX83O4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_4U9TKa-8kku0qyyWYuN66g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_8jM0YpsBR0yMEEEdxZY0HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_kyYUjNgs7UmP0QeRDTa87w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_MqFywxdSdU-VC2yfCNoI7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_VRui_vZPnUujh6ZiBB2PSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_BjoLbqhzlEu6HrZ0ubsedQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_yBPoJBQs-0OaTLvr_QnFFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_dQAt4xUTeEa7rdqV3nh2dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8UvD_28teUGxzHNuaZqFzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_BtRutl2rT0KKDhuHIfebvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_EJnK4qeQukWwruVzej1OHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3-k7Yjy3h0SK1bXLY0SdIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_zGcglSxVGUO78S8LUIsdFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_EHc6gwQXD0SOYI6THi9OXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_q_oIdOGpA0Sek6pDPz5Now">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_M57Dz1YMN0mNMaEnjl265w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_a1WmAXnod02XXfLywgY6XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BundesministeriumFurBildungUndForschungMember_Bwm_0zYqGkqkxhjgUSGCYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BundesministeriumFurBildungUndForschungMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_pZPakGLA-kuhoS52uwEr1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:GlaxosmithklineCovidAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_ifrs-full_MajorCustomersAxis_cvac_OtherCustomersMember_1iVbqSw630CraOQMAg_n6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">cvac:CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_SxzE48-JZ0GVSklXpGPGZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_7Ew6bGtW7U-tbNE2PXrHEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_oqWek3tQ0kWMDoro7ubGQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_5-Lg5t6vPU2ChcpJcmCALQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_RMBBdxirVU2J7HBkSJTreA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_d3CfPh5Ro06AwvuG4ee_dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_axX3OEHMmkqd9Ok2GiGCCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ETMXkobFKEy02hSV09o2aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Z1OBdDkToEK9908Tmo7-Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_eY2mumkXxUm95YVOlQS_oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:GlaxosmithklineCovidAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_Fzr32Hw5zkuxkQLHVRVGAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_iy1v_ExV0UmIJE_JDCu52A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_9-AN-Kf0kE-sEE04nCFBVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ye3SzgaAhUuYYFA2QScpkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_BNdhSUOAIEaFWRVUEBmbrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_0BY17joY10aei1gwG_rArQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WsnVoqdta0SqDA9Z3Yh5sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_LlIbA19tekq2L6F9XYlTsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_aZBsDHmyoEK9afaiu5dSRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_MM2GgEv-80-KyXB__YMNuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_rZxpRnG9XUK0LeJgU3D9Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8zx9Bh4e0kKH3oVw23ubCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_5WdzkEBG3U2RD2KTauKIHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_8MAty4A8qE6RjZSge37rBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_tqNpKUkXKE2OcFOuv70evw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_beG4kI-_-EObUq60yy9jHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WxiupYvXpUCZcGSWCISs4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_b7TNjQEttE2_PmjG1h3w9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Oxw0JrIpY0G78r49kJmAPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember__cAQp-UsNEC2DWQx2cXz0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_wkd5UtMjWEm5jn5jyWXGGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_8_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ImmaticsBiotechnologiesGmbhMember_8VKq2e-Yh0aBVCNKzz4EmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ImmaticsBiotechnologiesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_H9754yeGbUCITGZy_i1eNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_KF0KEZ_P60OBG3llY8c9rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_vx00BKTjL0C1MH6pWcVznA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_kHeRSiduSE-H2FthCmMR7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GxtzQ5W2qkKKhXTjunpSVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__0Fq4xEc5USvdYA7uwb9kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_5cbrQ8MBFkim2wo7LQxZVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_EGzp-xjlD0SJrQdKTR20uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GVJksEcFyUyKzVpP3nSNNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_K5vleFi0skqHLv2sbuvs-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_swVr7XTCQEqhZkjBon9n_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3YEDZJEcNUCF-BbD2Iw3ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w6XdbSqlp06NSNtoVAqCkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_XfOC2qeC50iUajLNfhbYcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iLzT9AM5F0Gv_MXd0N7WwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GJ80BNA4w02YFSPV325rWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_gVeKYMrm2kqPAEgtA4ctgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ES83sXGGEUiud1LCNDkpvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_SWfFNmCXQkGxOp1OayMWRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3hNl2cG_e0iw0IDtLwg0sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_3Ozy5OoM_EqCMGWp5kzLAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ySJm0_yzS0O5WbckJbrJig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_6hwBOOLcHk-K1sLFoc-0rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GttWyC5eVEu0a5D8x-ZKVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_jiGBndkblk6uSV1cNASR2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4bLJEBum0UGcpDQCcpC3iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_K_aG3SZaKUW1mCYhFvnDYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_8byNOjFo4ki3TRAVrcpw_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_uEHNJFwr3EmVaCzLXcE2lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_i7EfMlh5iUKmaxl0vc-mog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iEt59g_0hEWUB6Yz9rNI_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OXWs40hPgkKqkaLy0hyWrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_HKdVFHQkxEmgyjhDxX2T9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ADqOKH8jt0KB1nbIrPKgoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_yqlv57v0OEG1_brdVqLq1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_vIgFICzC7UiHO-GUZ0v4Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_SHbUU420-U6-wZvoecLRCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_vuDrG59udk6_pmg0jdRl8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_17_2021_To_9_17_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_jUlavD3NjEy-jk37WZ7FiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_npuKWKdpoUWvxgvLp2wwtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Xs37kP1MXEWQ-qdRg_8D7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_Sw6Kjo1tDE-BHe-dTLqX0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_H5V7XcidSEeqvZO0kZROGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_x6s2vBxPH0OH-sUVuKrR1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_uxFGoa7hQEWcuDdN_uz3Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LegacyPlanMember_RGbEltV_HESu23rxrqMUeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LegacyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_ZqrduP_DhU-c-0DXXjhxKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_QddTv344JkOsFwJFGAPjQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_s1OUV32MXEmc3KvzrvgpIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MWzGNMmG1E6v3rQ9gBnpSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_Cfres-mG-kGSfXOFxQdxag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_jh1w8gRbgEipnv2Kd3Q7zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_QqhHzWTUTUWo9mtYyqyW5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ExecutiveBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_uKCC8GofE0G_GEmvlAEeTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_NUSNjsD8UEOnZi8loJYDVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_ExerciseOfOptionsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wMo5XPBJDEWL4EzQFfN9nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:ExerciseOfOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WpDGmX1BBk-irWX_MsZINg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_Emv5VFNkOkeu9n01IcUiDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_xxYCQu-d0kOvAqnbd6uzjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_15_2023_To_12_15_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_zcNwztHf20yUPCFfBpK37A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="Duration_9_30_2023_To_9_30_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_hmgAXRtQi0mLk9qz8iijtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_HaxPqM7xIEqQzOqccUnD3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_30_2022_To_11_30_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_YaepVSyZlU2heFMGLS9PMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-30</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_ixs-47BeUUyl1kn1TalbNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_EaL8v88MnEKSvl3GFfmHuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_Fl_UlTw2MEicwzSFEfSNiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hcC_vpIE1k--3Sn_jsbP0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_MQ4SgOseWki-M9I2hpt9zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_Ufa1a3hx1k2ehDCG8MEN5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_I9QppcopR0ywsK2v4mo-QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_uxxE4wcx60S5_hvy1sXzRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_ObBmT6n8TkOKFE0nU935Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_IedADyrcS0Sk1puAhMSxsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ExecutiveBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_x7oTzwEM40qM38yhmGMObg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_hizFCmgkaE2aderOvs1LNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_kk4sEIFbXE6LU2RSZnpNkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_b9BiLH-CyUWgD-n-MYvg5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_ZF2N9tkLFEaK095giq-KlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_eimyXQngAkWRK3ARVfDZJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_-yi3-Too5kCsgm19jUEi9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3uG-xQGBjk2UUp8qg_geog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_cDlmM3W2jEmSkYOD4grJhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_SNfgVOPHpkOAwFRDrPaxfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_tEkPhB01qkqTdfn3O75Wzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_syES-Ei1DUW-SeNDoWBa7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_TsCUi_lxRUSo6j60ua4lmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_amLMRVfn1Ee2t3F85rOj6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_Auk54leS0kegyMpOaw5bEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Fo_xNC8x2E2Nw6expsmq5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CxYy2LPXFkaLHvgdxKLbYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_taOkSa3SjUyVQqMwIn0Hjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_smPSOhfL00esXI2_6xMXmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_TpCSNwbGR06S0oUDZgjo1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_e3XuayV2tk6ysYr-TQ-BSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hlhg1JNAsESzQBLYmwp6xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1FJQlhWUMk6KNwscC81P8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_lxNwvrDKd0-QyYtez9i4Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3xb5m9-bNEqJh9Hoo7pWKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_4a0nsTyeT0WWO6mJkY9WFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1teDHrsx_kWaav_Zvx6nuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_9EPi2cugF02lQJNpQpyZfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_-ENPqM9es0SNp-ig-Xj1tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_2Z6ov_rV6UGba_ri3U2OrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_t4-RJZpgr0CDzvIjX0yH7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_jb5qNe6RhUGF9vZAO08FkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_pTI2ycYZxUCgYp1XaojMCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JTWgO7w8WUSANCdQPMb8Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hhtxzsBDiUKB449PVvTqJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JgayIPr0HUqHcsGqQ4Msdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_t4jMo4Sp2U27gxThk2CyYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_AZk_qPQ4MUWJzWTnl1YlfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_glkxLuCSRUCQqGxSgDm4sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nbvH9kC4i0CT5CljgxvX-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8G-l7cSohE2wypqHd_nGtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_rK-mQvhP6k6rDG5s_W9Crw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_Pu91BJKoY0yyQ7jXhJKbDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_jspXe4LQ_UyibQFOKeFBYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Oueb9u3QfkWqN8BPX_v-xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_xc2cFeX11U6brkADl8elRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_AvgaG-0jnkaft9oN3wJb5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_cyOGw2ND4EOXxVCS45Rnhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_xwxmUcynR0KOedEqXVH6mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_ZRIYWuzzT0SCY6jmM6q8Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_Z4th35GQN0yb98iIcO_pdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_lt3cWNU5H0SMaF3fADwXfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_41JFXgAYbU-2g4bnHFwsiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_mT3WIF4M9k-HrxxK03IB1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RsuSupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_uMKK0Q6dEUmdlqOP5j56rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_jRMpo2_Z7EeshW9iq1ZxOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_D1vacamOH0G3JMpcUfj14g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_8rng1PMUlky5RzxNm--ypw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RsuSupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_hGO4w4NtCUa_4_aoaCmHzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_-tPgLvVPd0iGi29T4BoBUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_bAEfKq92c0ycQbava4HefQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RsuSupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_8RFzGrzUeE6P9-Pt00WG7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_NkdF9lVGbUq5xwUCOH7yAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_jpnt_Qkh80SEH5rLvclaIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_WZMCwy54QUmI6ryK9Caqbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_FRvDHd6gz0-TIgKz3l7NTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_UBWp1OUhsESfo0wo4zeF7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_eThCk2awTUa5-6f7LEuCSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_bx2x9QVGwUKRwb9RkD06sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_LeF6mzlRgUqn4uUTYSSTkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_-_-inCxASkiTTlbNRKnG9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember__tOhjBnh-k-Pzhm_-oubRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_wHx_7Z9Dg0my8RqwuxGOxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_nrIihK8t60Kg6c5Z8quIzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_rkGlJwdXYkifsZbvBkjdoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MlAIV3j9EESYEfc4Yj76xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember__36EPFnJpUGaQzWSL7tMWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_-SG7NEQ-8E-ah1y5uSU_bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8C3Nwu6XF0Oi2St2MLlLAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_RpHUMDrg-UiGjsQj8CQEXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_b_PVXi45TkWmP1ML_7DnkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_2d_godOeNkaEasgWMSZ_jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_WR0SFBa4b0qDmHaXvC4SwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_whZRjt-4FU-yl6yGweVnzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_0VcWnDDzFUyC5BwrczrKvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_dzqCRSdTaUyCKSftygGc5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lwBDHWf6DkiDBz3u8cOGuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_s8xXd8c1h0mpJ1IehtKt5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3ZjP9sOEAEuMEnQiZZAC6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_HPKAQE4Je0CJX_Y06wwKhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_KQB5gpktAESb-bTOPIdFnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_Jd9TaF_3MUmPThwO_m8oKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AnQeJoI56kuDvOssY92e1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_S1JWhNByVkO_gfsU5FZiQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_47DGLZoJlUGG58WY5poswg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_N9GQJX-VN0-QtPUbM25Rww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_KyV7Slh2JkqGlclN0ZugPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_rkeQ49L4e06MJK-fI2BJhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_PZFJd68wgkCqXp4YW2TkiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:AdvancePaymentsIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_vwFy4tKujEGvLRYO8xC60g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_sopM0fRxjEGXBD4cfhAb-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_x2jtrAGjukm-Q3NjjwN9zA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_RPtNKWdi7kep-OWhPRdbZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_YQ7OFau-40655Qsd3p7mHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_KQcN-T4_jUa6vvQqtTmIxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Y2yquS5opE-ddUHuqsYCSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_C0Yd0VHbrESYa5VTH7JK-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_5g69MJCNR0qupo7-cCBilg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_YWA7IRvytUCV0dt4jLtEeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_nwphsrqbPkGFkMezYtJrvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_z3m9cMNGJkyyuC_pOxiLYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xyqNnfW_P0-d5WX8yyxmQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hjZQJLPupkuissku-yiCaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_2nV73AJ870mDjh_tkOBisg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_BR9esw-0g0WSTYUwmmFSEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_b0HAzOV390aY5p51-Rkqhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_VWLXKKbGpUq7QH7ui7XDUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_uqcVVb-EwESwn3lB6wxn9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w8rxm3hBy0y_-Ae1ZVWKlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_t-iXQatkZ0KzkyWEc3dpwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_-ZhyaL6E9kaT3dKgQLND6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_budjsnBG90KFg41r2z8BQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_N2Zm5geGpE2tjfPniK-XXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_MKSIOOU_xkyo8xpkv2OyHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_8o2ZYCj_7EKP52vUoSck2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_XS4wMvPP1k64ztgaiLo9AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_qNgj2Z_Q3k6Magi__mK2Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_RcuGyuNGcUqdgPvzwcxZHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_8V8uLdfk1k6k9TaP2157vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_bMA8T5tG6ES2FAnIC7DkfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_WlD6qYqQ-UChT6kij1OauQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_dPvTMfFzZkqhDReqmruC2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_Ay6fLSJ51ketqazQXPf5hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_ZZaNrVakd0WQ7KvFCMu6Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_2NV8EZlD8UGXJFNTR3SpMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_vPbCsfbl10GjVuhXwSETZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_xceMST2sskiZALYanrkx6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_HeRhz1br2kW9XGBq3W35TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_2z_v-2cIV0GPSwrqAp-RhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_0jknVHupLEyMHv6EAT-P4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_KOCTqYugQU-Xp2Dma3UX4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_FgRE2Czx-0e3kuw6SVMj_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_brACGjFlf0yYmlE-IZbkqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_BxdZ_fqI90qVPvPxCxQ8Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_N6uLOUQcWEa4CDo-FoW1jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_AdgiqRdnnUCyfzTbCUw3EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_WoU5OY8q9UmNGItiCh3wFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_q0E1iqjsuEivVAPEk_0CQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_K70FGvuxREqsUGGoFXb3Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WJuDdMd_AEOjhVaYyZzKtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_sPUZgy8alUm9DrExIlqZxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_NwLw6YbSN0CNCMJtsJh-lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__QCZpl7FCECVWYoHf5mRiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_q7WO6vvez0OVGaUlPRtXNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_AMhqZjayEkyLFJUXTSfqhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_y_Uiw0kSbEuybbOsAdT54w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_nNMExjPVFE-feDhtK4OSgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServicesGmbhTuebingenGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_bZP5vsKUxUWOPhfDrg8I3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_dpBYHdH2n0euqcNEgHxmzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_Fr_u4k8C4EyZbX93eTH8iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_6IbdDCUU1k2phHbdFhwJZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_J-pJWtADOEeUxcm-wYpInA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_8P9AJYdqkUuBYi1IlF81dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_5ly2YlnqS0GPhMxtaYcLWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WbbYak-BQUGFoFXANHb7Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_mdiFR6M0iEGRWxBYIMdEcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_iav8T9jxJ02hwX0kprs5wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__OUzUplfMke4OyytxLopmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_TXI_swpSqEWRqNR403cl4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_XYmGcuw_GUu29m7J0DC8FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_LXDETgWXhUW-6PMmcfMtQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_RRVoksyfikayCq6qHVsupQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_1Cz5tMIDUE64OdcnvtgS2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_CL_42NO980yFn3bMpoksBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_3qNBdkGOC0S9Pb4g2-0A6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_tiHq0sjs80K57XqBzMQLJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_bOuXDQXtgECvVjIJJiEBBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsinventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_fOnOhohTI0aH7chs7hxlhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_VwP1ZgmTKEqT0Qondxniqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:TaxLossesCarriedForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:NonCurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsprepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:IfrsOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_USje2-QFJEy2AJRt3OvR5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cvac:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pgKJujKGq0Gc4IGKg7SH9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_5Z0-f_Nn2Uep_e7zqZA6_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZFq3H-aADUWbi48lz1-J3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_2n8B9LUx5UueVjJYl4z0CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dj_kuij1ukqB0BZd5Wb8cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_y1C8YKr28UeNst5nGOjNFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_a0Kr79sWk0Obs3Ohp5ui0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:SupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:SupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:SupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_2doude3lg0OUQmpYjlR9-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_ep4tnexH0kyFY8VzHHJmYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_lFP2_XAYDUudX-fY-YAD1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:CumulativeAmortizationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_GrkJ0r-6s0aI6oLGR4t78A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_tg5uf0hf90mOvis2DMD5YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_WuUc_xWmdUqMzpKJ1_OlaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_D4XaHP_XzUyH3j-sKKjh5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_cqxmGMVGW0W7n02ag0EpUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_xFpumxL9VU6TqcyTi7LMRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_j_FuUitGzU-WI673yfsjoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">cvac:GrossCarryingAmountOfAcquisitionCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">cvac:OnerousContractProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_51kbfHiK10CFR5dmzP024Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsVestingAxis">cvac:IfrsShareBasedPaymentArrangementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_8YeTvYg7kUKynLYBgt67GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_oC7hV09GIUK4KIsK7e8ZoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_B2bOhJ54KEOrUvEAltnJrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:OtherEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_vnP_GndeskmGccGmbmXP2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:OtherEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_BsheSwtJGU-hU30WhGx3GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:LandBuildingsAndSupplyInstallationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_Q9fMN7T-y0m13lblbattaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">cvac:LandBuildingsAndSupplyInstallationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_HfoXp3Ph3E6zl6AvXTfb-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2021_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_Uqq6tqDywUKR7NfMQRtxqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:GlaxosmithklineCovidAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember__SZm_EveFkuat9TplxJ75w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2017_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_HShGdT13tU-b1m7Ylf054A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:CrisprTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_IkXEAQpU6E-CCqDrHRQ4QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b8EFZRIMq0WCtvwfKe4gIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_nC4KCpY88UGym-D27dL6Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_fV8dgKI9A0qDluOP4s-fcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_VDgvtxQGnUWTC1YHHYEPSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_UNDEvAgHeEiRXFi1vbQ4Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_1VRD647OiE6jHdJLTQ7IRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_Zy-68Enju0iBz6gYRoHmDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2I2dxZFv7Eyci3--WSWO7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_14_2023_To_8_14_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_c7I5rda9O0unxghjuyCeYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="Duration_8_14_2022_To_8_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_vhVPWZE6FE-yd2_OHphj6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-14</startDate>
            <endDate>2022-08-14</endDate>
        </period>
    </context>
    <context id="Duration_8_14_2020_To_8_14_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_WwopKLYhAkmX30Ihq8HcEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fUKrlVf3Qk6qjGa7_xKIlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-MBxnDM6-U6QBuGgHl5BEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_gLfbS6LG906Sox56_2muhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WckCf34PZUGzza4sNjwFMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4ms1oi7d0EywO8ZNbgPv5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_tDcuRfOZHUis6pxE_-4Qjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_f2yWNH0RhECkx-pihStCXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:RittershausRechtsanwaelteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_RnuhJALUXEW6OjzFID5ePg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_qPHpyi8B6kOFRUh0cCyRZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:MariolaFotinMleczekMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CurevacPrinterGmbhMember_gCs4iaZl0UyakTfPuIOiJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:CurevacPrinterGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_QN5vMskJz0SjqLv-t82qVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_adrBhWYBcUKP4xl56ZYvMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:MariolaFotinMleczekMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_3YpDQRUP7U-XcUYi-sII5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_xCV0b46ewUWBBkAiRGRUnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:RittershausRechtsanwaelteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember__huxDT93sUCUvh-o5CwH7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DieviniHoppBiotechHoldingGmbhCo.KgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_AeWpyZ9BY0qX-7I4dJeLCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DieviniHoppBiotechHoldingGmbhCo.KgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_lDAMCnCC90O3RpaIsg3kZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_6nW0xhgNC0mT9D42Qi4zog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_rNMx4zueSkOBF5WSJkSlXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_wxgIcShrNEKq5nN0HbJ7vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_5b14ql9RFEezFsOggnD0RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_GFLhPP5AWUCAjFvKMkszFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_I_69X6Df9k6Te3sWPj6hwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_Wh8p0VKIT0O3NgVdxK2fOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2016_To_11_30_2016_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_WgEgi6NaVEWkMFit_-JGNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_HRF1MwVKgUu89NEIRuzDvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_z_oev7deRk-jsRWTlzMzkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_lBS-kbj340mK__LFAXyYQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_34HbkgDTrEKqkuExas5krQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_s0o811r3yEWWO5MCpwlyaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_PqOHXw2W70SLtVHUTZnIIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2019_To_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_v2GiAszp-UioMADTqx2Ctg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_nQQb4IPGNkaNHOnRJ9HnPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_cieCTs_Zuk2PWdYu7Wy6ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mZrACg5Qy0atlIzvQ-sFZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:OptionsGrantedToThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_WiesbadenMember_qqZmF0WHQk-CQHfo53QZ7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvac:WiesbadenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_TbingenMember_qUeXimjzQ0KjqUiReUdC4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvac:TbingenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b2Vp5VUFV0ur7dOqZSCNYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_dBuLkJzR8UGZKxJeLbvRJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tieFmpdel06r1eZXxqI5EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_L61lR4DVa0KvyH4imXbLGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_CwZYI28sy0a1k2hv3Y76Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_XKUaAnV49EWl3jd-hAE8eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_UkHTlmAHJkSss_TraYDEdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2020_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zETrLnvnJU-bFHQhtWzRHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_wT00lKBxs0KIgm-oIxqE4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_0NzIZ6BiH0K-Yg0H0gY9Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:ClosingOfPublicOfferingOfCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_IfrsOverAllotmentOptionMember_riZy2Z4KG0Gk8otdZzKN2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:IfrsOverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:ClosingOfPublicOfferingOfCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_pq40A99Zy0-J899Hpgyiuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">cvac:ContractTerminationProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_TsjaEu7n40i6mOR_moJurg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:MariolaFotinMleczekMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FlorianVonDerMlbeMember_SIwLkqeJIE-s7t_ZN4MKdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:FlorianVonDerMlbeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_Dr.IngmarHrrMember_wYrvLaDbgEqiqWSPHKS2gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:Dr.IngmarHrrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_21_2022_To_3_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_M7yeLt7eC0yDiQxH3rlo7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_PublicOfferingOfCommonSharesMember_aEkH7sfkH02lkeyEWiOvdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:PublicOfferingOfCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_bhT-Hm2SaEu5uUt9fXRzGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_29_2023_To_12_29_2023_SuqeE38xXUK8RRKDLZ3EOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_xeuiIWVNGkapjrX-CNiEZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_y1_WCcSI20-05QOkXbljog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_qO3ooGZGqE-1SoyY1Zy6eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JtGHYH8FrEKyyYF5zBuS5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tGMjQ13Y6kWsrsTpWJqw_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_38uXsNcfl0e1xpuxCmbyTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_cvac_IfrsIncomeStatementLocationAxis_cvac_MiscellaneousOtherOperatingIncomeMember_cpxyNogu7kOQwMXm7EojUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:MiscellaneousOtherOperatingIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_qyWBhjwBlkKQHtJUuv5N4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_q_UBt-6xnEai2whg5OLb5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">cvac:OperativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_mp2AzJFe_U2GzM3aVT9NMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_A6it69ifLUeKRgdoAQT4iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2024_To_3_22_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LzXStsEX10Sllgbp-IfhBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_YmO0AmylMUGXyDkvXeCLlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:NewVsopPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_12_2022_To_12_12_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_RQ8a6WZN30er9veT-GsPsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_sAMF0EDzsUqQ8PpTkE7KMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:NewVsopPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_18_2021_To_10_18_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_NU3QWXFiZkS0exKI1Z5L4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-18</startDate>
            <endDate>2021-10-18</endDate>
        </period>
    </context>
    <context id="Duration_3_10_2021_To_3_10_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_D2yuVO9FDUOmQ5j1k8A3bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-10</startDate>
            <endDate>2021-03-10</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsPlanNameAxis">cvac:OldVsopPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_3vgagNoi6kSQIXzMaP-lig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wK1DnDLSIkWj7Emo6TjbNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_Tj5GLbNT3kSBwyxRAfJfVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_2ruopNpg1EOnMxTf_GiPBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanysLargestPrivateBankMember_TPfvCFqo80y0z7BFfC2YKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">cvac:GermanysLargestPrivateBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanLandesbankMember_x_lULUcrc0GPG1twEsc5vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">cvac:GermanLandesbankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_EuropeSLargestPrivateBankMember_grNAnpFTY0ubOJ1E3t9yiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">cvac:EuropeSLargestPrivateBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_UoCEidhqNkCfZfezQJra6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_AlexanderZehnderMember_mQ65pe5XS02CILSpyMNi-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:AlexanderZehnderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_GridEuropeMember_6WJlWjlo_kuCilFMPK6nQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:GridEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FranzWernerHaasMember_3KoWd6cW3kiWfRndyVReUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:FranzWernerHaasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_FnDpFAjGGkeAyPEcOA6zCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:CraigToomanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_1aQ3jbYg70uyuJDLyM2Akw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_03V4AWHHaUicJNVRIZQgJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BarkerBiomedicalGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_LRyErr-s70-iTcECgyji4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_WZbR2KdIsEWpAKkVfjG6Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_8DK6e_LQPUG6vKafYfDvgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dzLDR4-bwEyHrc4xbtFT-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ao6gXG47qEqwSYLU3wAumQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_26_2024_To_3_26_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8MhaP9inOEWOlUmUTvRFIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="Duration_3_26_2024_To_3_26_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_rczlzRLESEmjal2oPh8nsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:VirtualShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="Duration_12_14_2022_To_12_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_AYQqGHS96EG_31uhHqhopg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-19</startDate>
            <endDate>2021-10-19</endDate>
        </period>
    </context>
    <context id="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-11</startDate>
            <endDate>2021-03-11</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_UJYAD019cUGBDnGIwVIvFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_m_1pv_Rp7ES0m0oWmWkw9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_oFHjPsrbYU-V2V22lqobCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_lgx14Yi8EUGXWrkRb0K3Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember___lz1oR3-k2v1ISygb7bPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_oXIlxEKLg0uXPK0YY9JWaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2014_To_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_uR8Rb-zZ-0W5xnOW1rqrfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_pfMi8wn3EkWe1O0Rx8uvnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsTypeOfArrangementAxis">cvac:AdvancedPurchaseAgreementWithEuropeanCommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_tranche_maOPN1bXI0mZlNy5N3Q2hA">
        <measure>cvac:tranche</measure>
    </unit>
    <unit id="Unit_Standard_loan_B2W9DgI1ukyKELWFZzXYow">
        <measure>cvac:loan</measure>
    </unit>
    <unit id="Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>iso4217:EUR</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">
        <measure>cvac:Y</measure>
    </unit>
    <unit id="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">
        <measure>cvac:Option</measure>
    </unit>
    <unit id="Unit_Standard_GBP_NKJzu3jWTEavxop33-TfZw">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_Milestone_ymq4eXsZYUanqqY0KpCtNg">
        <measure>cvac:Milestone</measure>
    </unit>
    <unit id="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">
        <measure>cvac:item</measure>
    </unit>
    <unit id="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_thtYd9HVPUa-ZcLIAcALtA">
        <measure>cvac:segment</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tc_hFpLeDz9YUK4KnNE2nA8hQ_15_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tc_RtpAsUGZL0mr7w4j7TxIAg_16_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tc_TZKVgll6zESCgS2c-SADCw_17_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tc_j4caA6F4FU2syRaCZNgrFw_18_1">0001809122</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tc_wHclw8sDgk-56K3JdLdgEA_19_1">false</dei:AmendmentFlag>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tGMjQ13Y6kWsrsTpWJqw_Q"
      id="Hidden_QbGLvVS5SkqjgHf0Brd8Fg">P1Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_tieFmpdel06r1eZXxqI5EQ"
      id="Hidden__sfsWKiKEkycy4zRfN1NDQ">P10D</cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease>
    <cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      id="Hidden_YzcivET66UycOOg4x0ArdA">P10D</cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MWzGNMmG1E6v3rQ9gBnpSg"
      decimals="INF"
      id="Hidden_tznxVCWtS0SW9reUKePQUQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">25000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_ZqrduP_DhU-c-0DXXjhxKw"
      decimals="INF"
      id="Hidden_-FWGuI_NEUqdXYeZrX373g"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">25000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_Cfres-mG-kGSfXOFxQdxag"
      decimals="INF"
      id="Hidden_hL-cJYxbn0-tJ6X_juFSYQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">25000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_xeuiIWVNGkapjrX-CNiEZQ"
      decimals="4"
      id="Hidden_XU_t8pnL4UiX_Hi9qILQtw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0033</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_xeuiIWVNGkapjrX-CNiEZQ"
      decimals="4"
      id="Hidden_QYgdAo6NHkmI49zrX7zMAA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0033</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="4"
      id="Hidden_11RqQzGybUSMAflcteDxJA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0033</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="4"
      id="Hidden_lI9qMg_ZoEa59Vg_AMB8SQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0033</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_ybuNXXrT9UOk6OXd2dsi_Q">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_IwnvCfL0YkSpfXnShCK-Zw">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_YlWjtI7jKUSr8IoLX4p1wA">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_Z7G6Kdq08EuJgwjGMd_puw">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_trOVu1PZHUGpuEe_XRwb5w">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_kAdnupYkmU2rqzfd8ilIAA">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_ZrwE2YLXiEmtsQBgsgdDMQ">001-39446</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_OHSVBaGvUE6LWX4wh3biOQ">CureVac N.V.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_2xu4sUNWtkeBP476uf2xPA">P7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_2rgnb3k-8UmIlYs6kJGFPA">Friedrich-Miescher-Strasse 15</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_YOWqhw9o3U6Z_ksq1Gkrwg">72076</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_ef4N5_vd7U-_dHRjYCdkXg">T&#xfc;bingen</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_GNPaswCR8U2jn_JwCH6Jhg">DE</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw"
      id="Narr_z9t65RzvSEmUL0V2R3J3DQ">Alexander Zehnder</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw"
      id="Narr_EcH_PFQJd0eBkv-7QCVy-Q">Friedrich-Miescher-Strasse 15</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw"
      id="Narr_kaK4mYmsSUaK7Ur5DeTMcQ">72076</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw"
      id="Narr_N8Hu0-KN_EathUAY8WtHEQ">T&#xfc;bingen</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw"
      id="Narr_6eXDHTo9M06_DVYdyfq5Zw">DE</dei:EntityAddressCountry>
    <dei:ContactPersonnelEmailAddress
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_-4STONLX60i7BXQzXxR_Bw"
      id="Narr_UgEWRO1qBEeO4jiaC5qa0g">info@curevac.com</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tc_8wfEsfmrx0Gh2WZYkePIOg_1_0">Common shares, par value &#x20ac;0.12 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_6oJFeWDCc0ixwHw9vthxjA">CVAC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_M7f3xFBqhU66sGfXIIDs-A">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="INF"
      id="Tc_NNbkZggg50mmX96y96Y13Q_1_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">223988675</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_Tpi7U8EepEm3rCNUd6y9Lw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_RroQN4RTkUSxGkdAHXHLPw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_yk-lY5OtB0eMsu5jBIu-pg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_VQrU2lU0o0WYqRG3VHQe7g">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr__8dygCuLoESknhMn3rGG0A">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_PUUtPRNycUKXJVFxhib19A">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_IAg3E86dY0KyLtk8nrg7zQ">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_EHPvzg6mtk2jk0unaG5iHw">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_pfyRfD9wfU-Ps-OYNjduMw">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_b3g3PMa-skSPvBSoS-0BeA">false</dei:EntityShellCompany>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_CO7TZPt7bki__iE1IHrCYw">1021</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_Dp4uzXDHnUePGZv6D5HpqA">KPMG AG Wirtschaftspr&#xfc;fungsgesellschaft</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_EFiAjEe_jUChj3VhrFYnPw">Mannheim, Germany</dei:AuditorLocation>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_PMS8uamPG06EoJ4i5QL5fQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">102990000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_reLhFVtv106EzvYF47r0pg_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">67420000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_rJGTOvl97EuA2OKBclUQhQ_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">53758000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_0IRPlnx7mU-QjKSib0DdUg_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">238195000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_Am3D5S6ll0iyzJaKBM7iVA_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">183993000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_BWFnkJEaWkSy0_TgUw0dbg_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">124366000</ifrs-full:CostOfSales>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_1y4s9Xc0gESZtTY4yZbDOA_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1743000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_fv9vmVHQRUaxcXIkEj6mPA_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2817000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_NZ0ht4cNUU-pAi2eOpjEWA_6_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3912000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_cdpnFo5IcUyspkJHm6MhGw_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">815907000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_aqryNoanm0OMnZwvLWZrBQ_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">62550000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_YJjE3piWuEG9kGxL7d6jFQ_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">115724000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_X396aTzMyk-On4jv4vNnPQ_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">100402000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_7pwAhBgEn0y1dNvf3ovgEA_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">104178000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_6R1sUeZ--kWGapIhBGLA4Q_8_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">91758000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_HO9RkhdWcUeLONaf_je2MA_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">574502000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_5Xt12yclvkim0sPLK6PU2w_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">67702000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_jmPqkaWTcUWsEAzG0Y84gw_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37932000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_4AtDkLRK-0atJt3Yx4-0uQ_10_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9151000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_qVgt5m3djU67kXRHqSGINg_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1210000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_B4Un2win1kCDSFpEKuMU8w_11_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1271000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_F7zJdHCf3kqDA7Wjq9h86Q_11_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1356000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_UxHVVikYFEep3pe4b9cU2w_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-412263000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_JYGE8h6U80OfoAsLb4y71Q_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249457000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_zDuEkeVsOE2B7vj07UZlow_12_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-274207000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_Q58WronV2UuuTxPDqVIXnA_13_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10103000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_ETShN1oNNEayX_FLvsWnRA_13_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4009000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_A7dn9cGWKE2Rscy8gaI4-Q_13_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">16731000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_kyXdp46UZ02FpeUDqyVo9Q_14_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10338000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_wcBz17VrJ0GtHHQvLVOpfg_14_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3707000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_t1nGyJawS0aS25NrBbeDfQ_14_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2493000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_kBiMC_FR40iVLxC18iaSCQ_15_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-412498000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_mS6DSOIN0U-SWRe08HDdfQ_15_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249155000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_ogeDG7jPFkeYc-H8_xCiFA_15_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-259969000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_JtfNjGy_10OvL00rntWLeg_16_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-782000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc__gX0Qn66RU2B3UGfJxlHPA_16_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-126000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_XL_JdU_zD0q0fvkBUGo8fQ_16_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">198000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_mTs3OizpeEeyaBeCCJmyQg_17_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-411716000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_8fIk3_0MZ0C7YTPvzX3GZw_17_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249029000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_lS8WLy39vkemu58vQelhSQ_17_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-260167000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_valqUtf2N0qcBg_90UW8CA_20_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-91000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_YE4Ju4rmmES5UEMxyuhbHw_20_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-105000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_1hGwZoUfyU2FloBW_hc_hw_20_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">72000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_ia5rT6QyK0qAHnTSH1C18A_21_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-411807000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_8Wje0eJ9NkaFbW1U6mVvDg_21_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249134000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_b1Zwj6X-r0ita4rxK7wrQw_21_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-260095000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="2"
      id="Tc_aB0cfEG2iE2T2L3bx3aQ3Q_22_4"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-2.21</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="2"
      id="Tc_aB0cfEG2iE2T2L3bx3aQ3Q_22_4_2"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-2.21</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="2"
      id="Tc_i-hchxS41kaEeZ_w71gJRg_22_6"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-1.32</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="2"
      id="Tc_i-hchxS41kaEeZ_w71gJRg_22_6_2"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-1.32</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="2"
      id="Tc_aUetIiLEOEiEjaI5jMbnVw_22_8"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-1.18</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="2"
      id="Tc_aUetIiLEOEiEjaI5jMbnVw_22_8_2"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-1.18</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_qveFr0uNSUWNHMtVfdDs4g_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">31778000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_6kWiX3pez069iWibHb9JIg_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28347000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_EfAbT2QkqkiEexreMViNYw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">197941000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_5duFXUHQwk6Ptli7eAWrmg_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">236782000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_fzUQZ1vG7EmM199QG6pJbA_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">43761000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_S_U70h3woEqvNFL9kdREbw_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41843000</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_uRXFUgfUH0CUXPieEHylfg_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1666000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_S0kKSzWcmUG9-e5siprYDg_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1702000</ifrs-full:OtherNoncurrentAssets>
    <cvac:DeferredTaxAsset
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_WvqPxDJsjEWLqabeQBJCUg_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1297000</cvac:DeferredTaxAsset>
    <cvac:DeferredTaxAsset
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_R_08S60Dc0eL5FUZd5vvXg_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1194000</cvac:DeferredTaxAsset>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_IlhFo9NaT0-TPFGIw9CESg_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">276443000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_WFjKRxGlGEWY9OpKW5TBsA_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">309868000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_5T4-Zl0JZEmGLqo0AwHm0g_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10467000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_tO4VR4OPGUqOdXXiM3WZ7Q_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2419000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_2IG0qMJPPkOdajtVudfvyA_13_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23989000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_xZmrDIp3IESPmtR6u8Ep7w_13_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24801000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_eysxGcbZTkew3Z4LafriZQ_14_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6295000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_2-lCK-o9-0-zaL0XrVDETQ_14_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14326000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_FNnQoJq9T0K0i2jrE4HS5Q_15_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2707000</ifrs-full:CurrentContractAssets>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_0MzB2Mu_JEe1LxW7nnE1yQ_15_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2758000</ifrs-full:CurrentContractAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_fPcEEZSq8kmN9o0G4Tr5eQ_16_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4487000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_KE_XNKb6pE-ogXboyaXSzA_16_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2661000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_AWheY8DEFkKcUGTn7394gg_17_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40002000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_DkqQAxcREUuiHTxm8qD3bQ_17_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23763000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_IB7eUCR0bUuMlpXhwFWmoA_18_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">285000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_ucGF63shjEKbSF4_evBUZg_18_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5201000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_YMvaCzcUIUiqMUiYGkWV5w_19_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">495797000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_L-DQLaKiTUKtM5undoIk7A_19_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">402452000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_KZ6MJgrVF0i9Nm7ZZAFzHQ_20_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">584029000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_yczDW4XdVEumIEzPtm-ZxA_20_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">478381000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_qB0zI89hh0-4wMWppRfwjg_21_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">860472000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_ybfJ7raVY0-cp6KMuPLPlw_21_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">788249000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_gPFe1f6IVkWqyaCJ45uh1A_24_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23400000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_YqwAT2YThUiyJ_1_SMiZwg_24_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26879000</ifrs-full:IssuedCapital>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_cTnt3KqAm0-WxFD5PyY-sw_25_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1817287000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_SQzOlhHWPkuPRwThXLLpsg_25_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2056110000</ifrs-full:CapitalReserve>
    <ifrs-full:TreasuryShares
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_S6fkH6WNv0aZhgCSMGBWXg_26_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1481000</ifrs-full:TreasuryShares>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_WNAtm_AU1kWFS5tIhiG3yw_27_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1305814000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_8sZRgDKS_UCTPlNc6rLqfA_27_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1565981000</ifrs-full:RetainedEarnings>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_91XGuBfbh0-5UMfgrIYcpw_28_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-139000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_KPyYK-ChME2gkW8cI1M_2Q_28_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-67000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_wPc7XFXYzEOCgUK7CnOjkw_29_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">533253000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_oyJ83VTBokqcM19cQmrsRw_29_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">516941000</ifrs-full:Equity>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_SxbsKgGDD0eE9Z3Lsk_0sw_31_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37106000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_PJfnJtFv1Uii9ZPQCeG8_Q_31_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">36819000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_azwS-B66tEmnBN29Ep8bww_32_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">72549000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_YhnjxlSE4kOOEyN5pMgbyw_32_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">48100000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentProvisions
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_mzrsfQ_shkuxnq_EhD0jSA_33_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">61320000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_oDcyPSLMLkqnWQP3CmY6yA_34_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_3Klj9LBq_0qlrSWzXAE6Dw_35_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">170994000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_yAgXqvCTU06bs-kx7C6zuw_35_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">84919000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_iVRA3-if8U2PNRkWyWK1UQ_37_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4980000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_IGc-WXcnREaVVEU-tlJrdQ_37_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5005000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_5tZWFicCtkO5eIP6mUj6yA_38_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">73463000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_bdudxceiz0iAa-xIkK0rVA_38_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">48033000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_1AP1DMVzKkefuRk3tXmpSw_39_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1922000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_0QDMmchsK0mIdI711TC65g_39_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37400000</ifrs-full:CurrentProvisions>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_ny9lbsULyU-NpFA-0aFBeQ_40_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40491000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_ulIlTRZ4T0SCowIXbyiQGg_40_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">50717000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_OhG77VIolEqWhwLgN3Uofg_41_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">610000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_KUDqzC_-tUq2OZ5ptSroDQ_41_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">654000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_E1nA8fWkwUGSxJHbFgpLPA_42_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">34759000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_Q9xAfL-LdUug4DQa2FW3DQ_42_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">44580000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_T1XNDZJBJEGtcqilcAbNPg_43_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">156225000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_p1hg4aFLQU2NHwA6zRN3mw_43_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">186389000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_IgKe89Y4WkCYuqQzWBwa4g_44_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">327219000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_KcgJUUuZgUyixGt5U3SxgA_44_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">271308000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_THE32kqrT0SpWCXRbgTRlQ_45_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">860472000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_oa6Y0zx5xU6NmPob6OLRcA_45_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">788249000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AnQeJoI56kuDvOssY92e1Q"
      decimals="-3"
      id="Tc_nTmagA4fCk-8HzNSdc8q4g_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">21655000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_S1JWhNByVkO_gfsU5FZiQQ"
      decimals="-3"
      id="Tc_aRKmPq40tESqJ0LdIGEjjQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1334704000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_KQB5gpktAESb-bTOPIdFnA"
      decimals="-3"
      id="Tc_39_xq3hImE2KjeMs2mqnAg_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-645069000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_Jd9TaF_3MUmPThwO_m8oKg"
      decimals="-3"
      id="Tc_6CEs8VKSL0GIYG-cdHSoGg_4_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">57000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA"
      decimals="-3"
      id="Tc_uca6GGCvaE-73Oc8sX-Ofw_4_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">711347000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dj_kuij1ukqB0BZd5Wb8cQ"
      decimals="-3"
      id="Tc_D4m-tnnKbEqTwtUz2u5hag_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-411716000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_8Uy90qnIOUCPOjSt63hyXA_5_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-411716000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_y1C8YKr28UeNst5nGOjNFw"
      decimals="-3"
      id="Tc_Cp2amuh_RkSfYbrIL7N1aw_6_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-91000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_8KrI9re5B0KjKZfv8Z7xRg_6_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-91000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dj_kuij1ukqB0BZd5Wb8cQ"
      decimals="-3"
      id="Tc_7ocGcS014EGGNLGc2cktfQ_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-411716000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_y1C8YKr28UeNst5nGOjNFw"
      decimals="-3"
      id="Tc_ffxC9zVc-EGyzZ3DBUAk6g_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-91000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_UKBxZKPvCUexd13tBrEiPQ_7_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-411807000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA"
      decimals="-3"
      id="Tc_Bu06EDd-7keB-Ej3HnMOJA_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15789000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc__Iodufop9kWdL29nPDQQ7w_8_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15789000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8G-l7cSohE2wypqHd_nGtQ"
      decimals="-3"
      id="Tc_huj4j_QbpUGU5DAQRcjznQ_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">109000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA"
      decimals="-3"
      id="Tc__2SXce2MT0yHF1aqAXA0Zg_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3077000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_A9bmgF8rA02Jnne_48vjZg_9_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3186000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8G-l7cSohE2wypqHd_nGtQ"
      decimals="-3"
      id="Tc_G_lEsrXDsE2BJwBQmlZImA_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">690000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA"
      decimals="-3"
      id="Tc_qDlbXw-DT0mVGVxZlmSLKQ_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">403372000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_62rfI4MKJ0eT3J7IsBgKtg_10_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">404062000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Zh8Muum82Um5vu9KcldZUA"
      decimals="-3"
      id="Tc_-SjBWjjos0GkZprnzbGh0A_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-28284000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nbvH9kC4i0CT5CljgxvX-A"
      decimals="-3"
      id="Tc_Rdj2DX7jjU6VxB1q1IAolg_11_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-5817000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_WvZ0jLZ3E0WsKTs3DPuktQ_11_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-34101000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3ZjP9sOEAEuMEnQiZZAC6Q"
      decimals="-3"
      id="Tc_TwOSEiFYEEOON1jF4fTPSw_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22454000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_HPKAQE4Je0CJX_Y06wwKhA"
      decimals="-3"
      id="Tc_nq32YJsZvEeRNOQzXQzRbA_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1728658000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_dzqCRSdTaUyCKSftygGc5A"
      decimals="-3"
      id="Tc_zy0DQHqof0mPSFGeVpmMSw_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-5817000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lwBDHWf6DkiDBz3u8cOGuQ"
      decimals="-3"
      id="Tc_XxiBZO-fpUePAqI8cGcEcQ_12_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1056785000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_s8xXd8c1h0mpJ1IehtKt5w"
      decimals="-3"
      id="Tc_HZZaSHuWxkaUOTWJhO0lLQ_12_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-34000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_aRUugoQ9EUS8Z0S3GkLS6w_12_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">688476000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3ZjP9sOEAEuMEnQiZZAC6Q"
      decimals="-3"
      id="Tc_RCapSEntkUGH8s8NCLpFVg_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22454000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_HPKAQE4Je0CJX_Y06wwKhA"
      decimals="-3"
      id="Tc_ffP-QT4qFkWXlNm9NthJkQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1728658000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_dzqCRSdTaUyCKSftygGc5A"
      decimals="-3"
      id="Tc_UAC9baOxk0qdPHDrp-13sw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-5817000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lwBDHWf6DkiDBz3u8cOGuQ"
      decimals="-3"
      id="Tc_Ejh97SeXu0C-WbdimDfydg_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1056785000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_s8xXd8c1h0mpJ1IehtKt5w"
      decimals="-3"
      id="Tc_h7EeRslB5UqQfUTDQ0e9Xw_4_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-34000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_wQaelAA7mUCgJxNxylryNQ_4_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">688476000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZFq3H-aADUWbi48lz1-J3Q"
      decimals="-3"
      id="Tc_MTysRwZYlkiO1F5B4OvwOA_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249029000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_NgEh7jAGpEW-J_tuIB3GDA_5_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249029000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_2n8B9LUx5UueVjJYl4z0CA"
      decimals="-3"
      id="Tc_xG_pHMfmIE2Ji7MZIyni4w_6_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-105000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_xFQpWFnYhEigEoqtqz0-RA_6_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-105000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZFq3H-aADUWbi48lz1-J3Q"
      decimals="-3"
      id="Tc_kP4qgA8ztEKyypqRPDkvsQ_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249029000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_2n8B9LUx5UueVjJYl4z0CA"
      decimals="-3"
      id="Tc_kZJlBz33h0aTmXjmV2dBbA_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-105000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_pR_9vRy3YEKmIB1KalouGQ_7_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249134000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA"
      decimals="-3"
      id="Tc_N-6MazUpCUaGmpOWi7tSwA_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7539000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_VhRiBo0xDUaNjtNxIJGJsA_8_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7539000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ"
      decimals="-3"
      id="Tc_DspC-OT87k2c2opT7g8iag_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">829000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA"
      decimals="-3"
      id="Tc_ahW3V1LTKUyiWib3ckBhXw_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">65552000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_luWN4X-bOUCWRmZCFhnPUA_9_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">66381000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ"
      decimals="-3"
      id="Tc_3HjxkBQ2b02_Ji5uZlNdHw_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-103000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA"
      decimals="-3"
      id="Tc_Zzz6RixDAkuA0zpzIC97gQ_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-18978000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_eimAMolq402H2XrIPLAs0A_10_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-19081000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xP4I_dIKHU2msvR3OFvyuQ"
      decimals="-3"
      id="Tc_mKOr-W7rIUuGob7LUKMxWw_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14000</cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount>
    <cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_m9wv3YKFf0m9dcg5KM2jsA"
      decimals="-3"
      id="Tc_a0_ADO5P4k6thtu3KFPSVg_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-3440000</cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount>
    <cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_8DK6e_LQPUG6vKafYfDvgw"
      decimals="-3"
      id="Tc_C-GGBfkEG06u4JvUNJ6rjA_11_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4336000</cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount>
    <cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_j0mFzwI4rUaXw62scsee1w_11_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">910000</cvac:ExerciseOfOptionsSettlementOfShareBasedPaymentAwardsAmount>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_whZRjt-4FU-yl6yGweVnzQ"
      decimals="-3"
      id="Tc_SZb65vP3JEut5_H0vXZgmg_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23400000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_0VcWnDDzFUyC5BwrczrKvA"
      decimals="-3"
      id="Tc_xwC5ff8oOECbPe-FvFwGmg_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1817287000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_b_PVXi45TkWmP1ML_7DnkQ"
      decimals="-3"
      id="Tc_Hh1n4mRorky-D55oXzCrEw_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1481000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_2d_godOeNkaEasgWMSZ_jg"
      decimals="-3"
      id="Tc_d7xT-_IdDUWcld37HgpPLA_12_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1305814000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_WR0SFBa4b0qDmHaXvC4SwQ"
      decimals="-3"
      id="Tc_szF7QLNjUkODlfnn9bQIpw_12_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-139000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_g7KZNHop-UG5CA0dDXVi6w_12_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">533253000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_whZRjt-4FU-yl6yGweVnzQ"
      decimals="-3"
      id="Tc_jnrA-bZJu0K12ysP_T2a8Q_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23400000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_0VcWnDDzFUyC5BwrczrKvA"
      decimals="-3"
      id="Tc_L0vcWxcuhkujN9EMf0D-BQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1817287000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_b_PVXi45TkWmP1ML_7DnkQ"
      decimals="-3"
      id="Tc_-ekGiXXPhU2_FFEzwENU3w_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1481000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_2d_godOeNkaEasgWMSZ_jg"
      decimals="-3"
      id="Tc_fp7Cs407mUmRbbYkqIH6kQ_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1305814000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_WR0SFBa4b0qDmHaXvC4SwQ"
      decimals="-3"
      id="Tc_QKvEFsRVcE21zFrA3K4zAA_4_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-139000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_c2IyADG6hUC-EKRUubOtBg_4_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">533253000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pgKJujKGq0Gc4IGKg7SH9Q"
      decimals="-3"
      id="Tc_x2l3AVnpZkqwutibTDs7Yw_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-260167000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_PajIgtHbmEWAaKWMkcyxzQ_5_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-260167000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_5Z0-f_Nn2Uep_e7zqZA6_g"
      decimals="-3"
      id="Tc_N_H4SuSR9EmkuUl97YjwrA_6_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">72000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_yBqHrCL4rEmoR3a88GZAwQ_6_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">72000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pgKJujKGq0Gc4IGKg7SH9Q"
      decimals="-3"
      id="Tc__Mgbyt1mgE-jikbab5SX5A_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-260167000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_5Z0-f_Nn2Uep_e7zqZA6_g"
      decimals="-3"
      id="Tc_3tr56iUuy0CkaxPeuEe8Gw_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">72000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_4DZ77CT-yEaWkf_cksgduA_7_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-260095000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg"
      decimals="-3"
      id="Tc_yb-6NXkPNUGRfxIiw4TB6g_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7697000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_QdOylNGhrk-vE6GsLj3RZA_8_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7697000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2I2dxZFv7Eyci3--WSWO7Q"
      decimals="-3"
      id="Tc_Sq6IPGlhB06QnMTkQXjRrg_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3453000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg"
      decimals="-3"
      id="Tc_nvPSmkYKPEGQFVspwXmm3A_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">232387000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_TqmgG5kogkqB8FyWCAl8oQ_9_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">235840000</ifrs-full:IssueOfEquity>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2I2dxZFv7Eyci3--WSWO7Q"
      decimals="-3"
      id="Tc_OpFQgrT3Hk2qOmh9DtfL4A_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_ewoYmgMz_0-CJ8KHnbq7fg"
      decimals="-3"
      id="Tc_X3v1S6lK2Ua6EisMhRgc-Q_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1261000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_Zy-68Enju0iBz6gYRoHmDw"
      decimals="-3"
      id="Tc_DbP0M_PSrkGxUBNUqB5wZA_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1481000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_JOZzjq-t4kqUncnBXNEJzw_10_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">246000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_8C3Nwu6XF0Oi2St2MLlLAA"
      decimals="-3"
      id="Tc_JhbpO-WBWUqGjLCgoPnGmg_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26879000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_RpHUMDrg-UiGjsQj8CQEXQ"
      decimals="-3"
      id="Tc_fyS1zHn3_kuE2BUNQ8_yeQ_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2056110000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember__36EPFnJpUGaQzWSL7tMWg"
      decimals="-3"
      id="Tc_OnCJR6I7q0mRrAUR4A-Sig_11_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1565981000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_-SG7NEQ-8E-ah1y5uSU_bQ"
      decimals="-3"
      id="Tc_w126yYUOak6jvlOTia5AgA_11_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-67000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_UYsFzaHNlEyUXx2BIsKVnQ_11_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">516941000</ifrs-full:Equity>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_LyYhAbnB_EmN3e7hbWZ5xQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-412498000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_XqWe2NObZUqc_Dt4WDNQFw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249155000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_T4Wd2JbzfkWM2f9scCcG9w_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-259969000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc__oX1-de53EKzygiwFZRoBw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10103000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_HI0EcCs2y0OFOAe3jua5mg_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4009000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_IFjyBx5BqUSzHLmH47Af0Q_6_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">16731000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_Ew0q2opSpESl5FcHKVZ49g_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10338000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_H_f062Kfa0G9NKkZSlazzg_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3707000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_i-n6hMsok0WGYilX4W_UsA_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2493000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_x5tVQNxOxUymq7LjHcqaaA_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15674000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_eVxD_2FTc0S6z6ya95Lhww_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23741000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_S-YXnd-ljUOUjH5q4ukBHQ_8_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23386000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_bQ-0JaNeYEGDmFuR_Y0dQg_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22810000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_QEijHxhs_0-3JzYUYU6KTQ_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6594000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_tqgyKTRD_UKmWjxf3CPVnA_9_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2466000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_c955qYQ6e0aIyr7RnB53qQ_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-587000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_OowYQf7isE6ft8OLbmO_SA_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-11981000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_v2yBT_SezEiFeEnMs7t9Bw_10_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-3477000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <cvac:AdjustmentsTransferToAssetHeldForSale
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_urj-z1ZHlUKuEEQMRZC5Gw_11_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19064000</cvac:AdjustmentsTransferToAssetHeldForSale>
    <cvac:AdjustmentsTransferToAssetHeldForSale
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_9mY0yGxlQUuqvgLc_Wh_Ig_11_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6711000</cvac:AdjustmentsTransferToAssetHeldForSale>
    <ifrs-full:InventoryWritedown2011
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_SjTgmL5mq0e0VbvpvUvQmw_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">185832000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_ZUqowEjIKkSeCSnBiOceDg_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">80021000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_c5I_zKU160GF9bwJdjieGw_12_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">47129000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_3PF-HCx4B0GRvM1yScH6zw_13_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14956000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_JftGZ_pd7kCPUcAgM6DJvA_13_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9185000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_pRQpLx1YLE6VUZYjFQWajg_13_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7697000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_4E220jxI2Ue_YSr79eDiSA_14_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">574502000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_mR-SimIklkK3aCJzbya6kg_15_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-58799000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_0xJw-SaI5UOpG7iQ0bz1_g_15_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-25842000</ifrs-full:AdjustmentsForProvisions>
    <cvac:AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_EctPo7J6qEioZEhsXItKIg_17_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1337000</cvac:AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_TjVhIxalI0O6phqVFLE95w_18_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-16682000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_03r99611NEWSHgA9iu_7LQ_18_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9502000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_YBsBOvCeSkCLJhfdhfrbiw_18_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-8082000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_oOrboWaJSkmhNshBTEmUQQ_19_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-227460000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_YAkFYk50iEOZIu70m_7l7A_19_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-47851000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_I9e1lz1ffUSUJhIQfXeVpg_19_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-47940000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_Qlp4xMXUdE2jg8_BL14iEw_20_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3118000</cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets>
    <cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_E7BCNk_7jk2dyLEtV2mW7Q_20_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-8968000</cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets>
    <cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_RQ1RkG63jUataoieYjw4ow_20_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-16494000</cvac:IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_pftm3WOFKka8oY_K6r-nwg_21_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">93531000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_yhbfgoq26k2c5O-JBRM9KQ_22_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">179316000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_ZBpc8DwJ-kSQm66W8yZkpQ_22_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-96186000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_hQ5s6GF8ykiFsdyCHBUfKQ_22_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-29984000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_8lcjMh-jSEiNwls6B93S1A_23_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-20000</cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_zNGGebl9fEao3h0jSj9NTw_24_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1583000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_XyvBxxRYKEm2_NbDHMr1hA_24_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_rFRUct6dDkaFX3q4kLJWAw_24_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-115000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_WTZxt9mwo0KaGhkFP_oZvA_25_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">502000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_-_WljoKblkO2vG4KgpK28Q_25_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">128000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_c-E4JY6OBkGtSxdlqdD5uw_25_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3891000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_ldA7zHyQwECPpD4J-aU95Q_26_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">81000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_dmGYOGY9qEGJhoKBt1OCpw_26_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1790000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_jxAjHgPGYkehrfgffNczMA_26_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15852000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_ZCSDhjbESEWHncxg2NtN1Q_27_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9785000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_ZlhkJuCd1kmk7lqiH6L39A_27_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4606000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_00pWYmSxskCrA_WEU4fCqw_27_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2375000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_k5OnnA-5o0iK4T7mvUc01w_28_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-733128000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_S4fRvgKaakWWUe51PCNZoQ_28_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-286177000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_-tVWhck-CUylY95_TkGt6g_28_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-267887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_gM8WIj5jVUu4epsm1PZt1A_30_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">124222000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_ife3ndJ8a0Sy8CaDWz0fdw_30_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">88023000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_jqdAOKZEfUOqD5nCxpD8tQ_30_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">52320000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_qk_4JWkU102W8EOWFbALjQ_31_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3679000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_3R-ZvL2ECEi84BKOGhw-Tg_31_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5199000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_-fJdItPEz0ir69hQ_Vh2Cw_31_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2880000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_2fwzt6sdfUql2hryeYgkYw_32_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">277000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_Gf7VzDdzXkCT42ll0yX2Gw_33_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-127901000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_6gGvmbXrcUK7nG0Wuq-ixg_33_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-93499000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_mUH6kvmPyUyJXGHNNEQBeQ_33_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-55200000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_fgltxFxSrU-Fr8Q2-BnocQ_35_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3183000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_uNDmo-J1a0OtQR74EuevLQ_35_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4221000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_SuqcbZS6IkmKx6fO9mj8jg_35_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5193000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_WOVUaOY4XUiNioU9lxQnEQ_36_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">404062000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_wgJFKbo0okKlGksiFKA81Q_36_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">235840000</ifrs-full:ProceedsFromIssuingShares>
    <cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_cxNY5ZWoqEKZ1gvDQ3YNtw_37_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-30915000</cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions>
    <cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_rtuxeRaVHkm6Z2VdbNH0oA_37_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">910000</cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions>
    <cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_CSo9zvDPv0ur5v7h1xG-MQ_37_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">246000</cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions>
    <cvac:IfrsStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_1lXhpmscT0uJlv7MHbiB5w_38_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-66484000</cvac:IfrsStockIssuedDuringPeriodValueNewIssues>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_nBKuAzDGo0GTYvxvEuV-UQ_39_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">25000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_AGXHXceAU0aoXScBTWxS8A_40_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">344964000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_Uee74yd6tUqYvrEts4TLAA_40_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">63173000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_JXTESQjRbkK0SsILPgIllQ_40_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">230893000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_LLuCTJHcfka_Q553bKY-Cw_41_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-516065000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_07Vp8bvN_Ee8Q1HZZ_WNyg_41_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-316503000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_0rbSUXPywkGfZHToiIzKCA_41_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-92194000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_uMb3CHO-50GD4R57sJsotA_42_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4936000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_13ysMu2grEu1KO1LLGr7jQ_42_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">836000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_s43hpS4xskSAGLouCCqiQQ_42_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1151000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA"
      decimals="-3"
      id="Tc_HUtZNR6aQk-ZpDWiS4ynjQ_43_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1322593000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_uNIdDPv7H0GHQEdT8tqG2A_43_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">811464000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_zPChOYLzukWLbingWmx2Bg_43_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">495797000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_dY7U1g8B70KZceoxis-tDA_44_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">811464000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_05jq1wle50m1tptOgknKPg_44_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">495797000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_ZXVYYIoxA0GClws4uC_dMA_44_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">402452000</ifrs-full:CashAndCashEquivalents>
    <cvac:CorporateInformationTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_r6PH5N7q1UGBeCKzNjZrdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Corporate Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac N.V. (CureVac or CV or the Company) is the parent company of CureVac Group (Group) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;With in - house manufacturing capabilities and expertise we are an integrated biopharmaceutical company. We consider our manufacturing process an important part of our strategy that allows us to continuously improve our technology platform and maintain flexibility in clinical development and allow us to manufacture potential future commercial products. The close interaction of our technical development and research teams enables us to rapidly implement innovations and robustness to the manufacturing process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We were incorporated pursuant to the laws of the Netherlands as CureVac B.V. on April 7, 2020 to become a holding company for CureVac AG prior to our initial public offering. Pursuant to the terms of a corporate reorganization (the &#x201c;Corporate Reorganization&#x201d;), all of the outstanding shares in CureVac AG were contributed and transferred to CureVac B.V. in a capital increase in exchange for common shares of CureVac B.V. and, as a result, CureVac AG became a wholly-owned subsidiary of CureVac B.V. and then current shareholders of CureVac AG became the shareholders of CureVac B.V. Immediately following such exchange, and prior to the listing of our common shares on Nasdaq, we converted into a public company (naamloze vennootschap) under Dutch law pursuant to a Dutch notarial deed of amendment and conversion, following which our legal name became CureVac N.V. As part of our Corporate Reorganization, outstanding shares of all series in CureVac AG were exchanged for common shares in CureVac N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We are registered in the commercial register at the Netherlands Chamber of Commerce under company number 77798031 (RSIN 861149336). Our principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 T&#xfc;bingen, Germany.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During fiscal 2023, dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, was the largest shareholder of CureVac. Together with its related parties, dievini held shares and voting rights in CureVac between appr. 37 &#x2013; 43 % (prior year: 43 &#x2013; 46 %) during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.&lt;/p&gt;</cvac:CorporateInformationTextBlock>
    <cvac:PercentageOfVotingInterestsHeld
      contextRef="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_lBS-kbj340mK__LFAXyYQg"
      decimals="2"
      id="Narr_QBgYVnBMuECGp0asCcJ__w"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.37</cvac:PercentageOfVotingInterestsHeld>
    <cvac:PercentageOfVotingInterestsHeld
      contextRef="As_Of_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_z_oev7deRk-jsRWTlzMzkA"
      decimals="2"
      id="Narr_q5yOOdqvsEyZzjbYvZv5rQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.43</cvac:PercentageOfVotingInterestsHeld>
    <cvac:PercentageOfVotingInterestsHeld
      contextRef="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_s0o811r3yEWWO5MCpwlyaw"
      decimals="2"
      id="Narr_AZpmYp3tJkai7DvO97_slQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.43</cvac:PercentageOfVotingInterestsHeld>
    <cvac:PercentageOfVotingInterestsHeld
      contextRef="As_Of_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_34HbkgDTrEKqkuExas5krQ"
      decimals="2"
      id="Narr_JUz8QWspwkaJmKR2lqDw1Q"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.46</cvac:PercentageOfVotingInterestsHeld>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_z08GPT4NXkK0SYqRGX7bXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and were authorized by the Management Board for presentation to the Supervisory Board on April 23, 2024. The Group&#x2019;s consolidated financial statements are presented in Euros (EUR), which is also the parent company&#x2019;s functional currency. Unless otherwise stated, the numbers are rounded to thousands of Euros, except per share amounts.Due to rounding, differences may arise when individual amounts or percentages are added together.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has prepared the consolidated financial statements on the basis that it will continue to operate as a going concern. No commercial products have been marketed yet as CureVac is still in the development phase. Hence, the Group is raising capital to perform research &amp;amp; development activities and to advance its technologies up to a successful development and regulatory approval of its products. To reach its development and commercialization objectives, the Group will seek additional funding through collaboration or licensing agreements or other financing activities. While the Group&#x2019;s business projections could be unfavorably affected by being unable to obtain funding or enter into collaboration or license agreements on acceptable terms, CureVac&#x2019;s cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the financial statements. This anticipates, that for the foreseeable future the Group will continue to operate. Thus, no adjustments to the consolidated financial statements have been made related to the Group not being able to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Details of the Group&#x2019;s accounting policies, including changes thereto are described below. The accounting policies have been consistently applied to all years presented unless otherwise stated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsidiaries are entities controlled by the Group. The Group &#x201c;controls&#x201d; an entity when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The consolidated financial statements include the Company&#x2019;s wholly-owned subsidiaries CureVac SE (until September 26, 2022: CureVac AG, Tuebingen, Germany), CureVac Inc. (Boston, Massachusetts, USA), CureVac Manufacturing GmbH (prior years: CureVac Real Estate GmbH, Tuebingen, Germany), CureVac Corporate Services GmbH (Tuebingen, Germany), CureVac RNA Printer GmbH (Tuebingen, Germany), CureVac Swiss AG (Basel, Switzerland &#x2013; incorporated in 2021) and CureVac Belgium SA (Ottignies-Louvain-la-Neuve, Belgium &#x2013; incorporated in 2022). Effective July 1, 2022, we acquired Frame Pharmaceuticals B.V., Amsterdam, Netherlands (Frame Pharmaceuticals), which was renamed to CureVac Netherlands B.V.; refer to Note 20 for additional information about this business combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The fiscal year of all Group entities corresponds to the calendar year ending December&#160;31.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Material accounting policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business combinations and goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The Group determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Any contingent consideration to be transferred by the acquirer is recognized at fair value at the acquisition date. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of IFRS 9 Financial Instruments, is measured at fair value with the changes in fair value recognized in the statement of operations in accordance with IFRS 9. Other contingent consideration that is not within the scope of IFRS 9 is measured at fair value at each reporting date with changes in fair value recognized in the statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred over the fair value of net identifiable assets acquired and liabilities assumed).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;After initial recognition, goodwill is measured at cost less any accumulated impairment losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Revenue from the sale of products and services is recognized when the Group transfers control to the customer. Control generally transfers when the customer gains the ability to direct the use of and obtain substantially all of the remaining benefits from the good or service. If the contract contains more than one performance obligation, the consideration which the Group expects to receive is allocated to each of the performance obligations, using the relative stand-along selling price method. Revenue is recognized at the amount of consideration that the Group is expected to receive in exchange for these goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group primarily generates revenue from its licensing and development agreements with its customers, which include collaboration partners for the development of mRNA medicines against a variety of targets in diseases and conditions. These arrangements contain multiple contractual promises, including (i) licenses, or options to obtain licenses to the Group&#x2019;s mRNA technology, as well as related research and development technology services, (ii) delivery of products, and (iii) research and development services. Such arrangements provide for various types of payments to the Group, including upfront fees, funding of research and development services, payment for delivered products, development, regulatory and commercial milestone payments, license fees, and royalties on product sales, all of which may be satisfied at different points in time. Outlicensing agreements may be entered into with or without any further significant contractual obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Goods or services promised in collaborative arrangements are accounted for as separate performance obligations if such promises are distinct (i.e., if the customer can benefit from the good or service on its own or together with other resources readily available to it and if the promise is separately identifiable from other promises in the contract).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;In determining whether contractual promises are separately identifiable, the Group considers whether:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;It provides a significant service of integrating the goods or services with other goods or services that represent the combined output or outputs for which the other party has contracted.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;One or more of the goods or services significantly modifies or customizes one or more of the other goods or services promised in the agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The goods or services the Group promised to transfer or to provide are highly interdependent or highly interrelated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Based on these criteria, management evaluates whether the intellectual property (IP) licenses granted, and to which further research and development activities may apply under the terms of a collaboration agreement, are distinct from the unperformed obligations to the collaboration partner, considering the relevant facts and circumstances of each arrangement. Factors considered in this determination include the nature of the IP license, the stage of development of the IP license granted, the research capabilities of the partner, and the availability of mRNA technology research expertise in the general marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;When an IP license is not considered to be distinct from research services, the Group generally recognizes revenue, including any upfront payment, attributable to the license on a straight-line basis, which reflects the performance of services by the Group towards satisfaction of the obligation, over the contractual or estimated performance period, which is typically from the effective date of the related collaboration agreement through to the estimated date of Marketing Authorization Application (MAA) or Biologics License Application (BLA) for a product developed under the agreement. The determination of the estimated date of MAA or BLA is a significant estimate given the uncertainty inherent in developing innovative pharmaceutical products and is based upon development plans with the customer, which are subject to change, clinical trials, and approval of regulatory authorities Changes in the estimated date of market entry could have a material impact on the amount and timing of revenue the Group records in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Sometimes an IP license is granted together with research and development services relating to the technology. In this case, the services are not considered distinct from the licenses and form a bundle for which revenue is recognized on a straight line basis over the time of services, as the services are determined predominant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;When an IP license is considered to be distinct, the Group determines whether it provides the customer with either (1) a right to access the IP throughout the license period (for which revenue is recognized over the license period) or (2) a right to use the IP as it exists at the point in time that the license is granted (for which revenue is recognized at a point in time where the customer can first use and benefit from the license).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Some of the collaboration arrangements include rights and obligations that are considered outside the scope of a customer-vendor relationship as they are more akin to the activities that joint operators perform. CureVac decided that the nature of these types of activities is best reflected by applying joint arrangements accounting which, as the main effect, usually leads to revenue recognition at a later point in time. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;If the transaction price in an agreement includes a variable amount, the Group estimates the amount of consideration to which the Group will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated deferred contract liability is updated at each reporting date to reflect the current facts and circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Collaboration agreements may also provide a customer with the option to acquire additional goods or services. In these cases, the Group determines as to whether the customer was granted a material right.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Product sales related to collaboration agreements include RNA products and are recognized over time as goods are produced because such goods have no alternative use. Otherwise, revenue for product sales is recognized at a point in time. In 2023 revenue for produced LNP batches were recognized on a point-in-time basis. No product revenue was recognized in 2022 and 2021. Revenue from certain research and development services, delivered as a distinct performance obligation under the collaboration agreements, are recognized over time as the services are provided.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A receivable is recognized when the consideration is unconditional and only the passage of time is required before payment is due. Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liability in the statements of financial position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group may present the following contract balances:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Contract assets&#x2009;&#x2014;&#x2009;Represents the Group&#x2019;s right to consideration in exchange for goods or services that the Group has transferred to the customer when that right is conditioned on something other than the passage of time&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Trade receivables&#x2009;&#x2014;&#x2009;Represents the Group&#x2019;s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Contract liabilities&#x2009;&#x2014;&#x2009;Represents the Group&#x2019;s obligations to transfer goods or services to a customer for which the Group has received consideration (or consideration is due) from the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognizes revenue from contracts with customers relating to its core business. All other operating proceeds are presented as other operating income in the statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grants from government agencies and similar bodies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects. Each grant agreement is assessed to determine whether there are elements of the supply of products from the group to the grantor that are recognized separately from the grant. For the supply of products, the standalone selling price is determined by reference to observed prices with other customers. The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If grant funds are received prior to qualifying expenses being incurred or assets purchased, they are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other operating income on a systematic basis over the period in which the corresponding expenses are incurred. If the funds reimburse purchased assets, the liability is reduced with a corresponding amount deducted from the asset&#x2019;s carrying amount upon recording of the qualified asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;i) Financial assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Initial recognition and measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The classification of financial assets at initial recognition depends on the financial asset&#x2019;s contractual cash flow characteristics and the Group&#x2019;s business model for managing them. The Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component are measured at the transaction price determined under IFRS 15.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Subsequent measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"&gt;For purposes of subsequent measurement, financial assets are classified into four categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets at amortized cost (debt instruments);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets at fair value through other comprehensive income with recycling of cumulative gains and losses (debt instruments);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets designated at fair value through other comprehensive income with no recycling of cumulative gains and losses upon derecognition (equity instruments); or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets at fair value through profit or loss.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In fiscal 2021, 2022, and 2023, the Group only had the following financial assets to be measured at amortized cost:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in the statement of operations when the asset is derecognized, modified, or impaired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment of financial assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;An allowance for expected credit losses (ECLs) is recognized for all debt instruments not held at fair value through profit or loss including contract assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12- months (a 12- month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For financial assets being due more than 30 days, a significant increase in credit risk is assumed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk but instead recognizes a loss allowance based on lifetime ECLs at each reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group considers a financial asset in default when contractual payments are 180&#160;days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ii) Financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group&#x2019;s material financial liabilities consists of lease liabilities and trade payables. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade payables at initial recognition are accounted for at fair value and subsequently at amortized costs. The material accounting policy information regarding accounting of leases is described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquired intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Acquired intangible assets are mainly comprised of software and licenses. Regarding the acquired intangible assets (i.e., technology and goodwill) in the business combination with Frame Pharmaceuticals, refer to Note 20.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated useful lives for each intangible asset class are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Software&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Licenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;8 to 20 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technology&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;8 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;With the exception of goodwill, the Group does not have any intangible assets with indefinite useful lives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research costs are expensed as incurred. Since our own development projects are mostly subject to regulatory approval and all studies are at an early phase, where the outcome of reaching the next phases is uncertain, the conditions for the capitalization of expenditures incurred prior to approval are not met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairments. These costs also comprise the costs for replacement parts, which are recognized at the time they are incurred, providing they meet the recognition criteria. All other repair and maintenance costs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leasehold improvements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;1 to 15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technical equipment and machines:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 14 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other equipment, furniture and fixtures:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 14 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated useful lives are reviewed regularly and revised if necessary. The depreciation method remained unchanged from 2021 through 2023. The residual values of the assets are generally considered to be zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of non-financial non-current assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At each reporting date, the Group assesses whether there is an indication that a non-financial asset may be impaired. If there is any indication of impairment (triggering event) or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of the asset&#x2019;s or CGU&#x2019;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case it is determined at the level of the cash-generating unit (CGU). If the carrying amount of an asset or CGU exceeds its recoverable amount, the asset or CGU is impaired and written down to its recoverable amount. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In principle, the recoverable amount has to be determined for each individual asset where such asset generates cash flows that are largely independent of those generated by other assets. Where it is not possible, the recoverable amount has been determined on the basis of a group of assets representing a cash generating unit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing whether the cash flows are largely independent, CureVac considers various factors, including how management manages the company activities and how the CureVac companies are linked in business operations. As management decisions are centralized on group level and the CureVac companies are closely linked in business operations, the Group operates as one cash-generating unit. Therefore, for the purpose of annual goodwill impairment testing in 2022 and 2023, goodwill was allocated at Group level. The recoverable amount for the Company&#x2019;s cash-generating unit based on fair values less costs of disposal using market capitalization derived from public quotations of CureVac stock. Management believes that no reasonably foreseeable change in the price of CureVac stock would cause the carrying amount of our one cash-generating unit to exceed its recoverable amount.Impairment losses of continuing operations are recognized in the statement of operations in expense categories consistent with the function of the impaired asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In fiscal year 2021, impairment of EUR 22,810k were recognized. These pertained largely to machinery and technical equipment recorded as assets under construction and resulted from the partial impairment of production lines which were obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV, see Note 4.1.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Beginning in year 2022, goodwill is tested for impairment annually as of December 31 and when circumstances indicate that the carrying value may be impaired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For 2023, impairment was evaluated for goodwill by assessing the recoverable amount on Group level. Impairment losses relating to goodwill cannot be reversed in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;There was no impairment of goodwill in 2023. However, there were impairments of technical equipment amounting to EUR 1,374k; refer to Note 4.1 for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group classifies non-current assets as held for sale if their carrying amount is expected to be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expenses. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management is committed to the plan to sell the assets. Property, plant and equipment are not depreciated or amortized once classified as held for sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received as well as any estimated costs to be incurred by the lessee for dismantling and removing the underlying asset. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life, indicated below, and the lease term. Right-of-use assets are subject to impairment. Refer to the section above &#x201c;Impairment of non-financial assets&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Land, Buildings and supply installations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1 to 15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vehicles&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3 to 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in- substance fixed payments) less any lease incentives receivable and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments, or a change in the assessment to purchase the underlying asset. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount for the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Short-term leases and leases of low-value assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applies the short-term lease recognition exemption to its short-term leases (i.e., leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption. Lease payments on short-term leases and leases of low-value assets are recognized as expenses on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Inventories are comprised of raw materials, work in progress, and finished goods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs incurred in bringing each product to its present location and condition are accounted for, as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Raw materials: purchase cost on a first-in/first-out basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overhead based on normal operating capacity, but excluding borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash on hand, bank balances on-demand, and short-term deposits with original maturities of three months or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Onerous contracts&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;An onerous contract is a contract under which the unavoidable costs (i.e., the costs that the Group cannot avoid because it has the contract) of meeting the obligations under the contract exceed the economic benefits expected to be received under it. The unavoidable costs under a contract reflect the least net cost of exiting from the contract, which is the lower of the cost of fulfilling it and any compensation or penalties arising from failure to fulfil it. The cost of fulfilling a contract comprises the costs that relate directly to the contract (i.e., both incremental costs and an allocation of costs directly related to contract activities).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Group has a contract that is onerous, the present obligation under the contract is recognized and measured as a provision. However, before a separate provision for an onerous contract is established, the Group recognizes any impairment loss that has occurred on assets dedicated to that contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Share-based payment awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The Group operates several share-based payment programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;An equity-settled share-based payment award is accounted for by recognizing the related expense over the vesting period of the award, with a corresponding increase recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;When a share-based payment award provides for different ways of settlement (i.e. cash versus shares) depending on the occurrence of contingent events, CureVac has the right to choose the manner of settlement and accounts the award based on this.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The related share-based payment expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tax loss carryforwards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Tax loss carryforwards are examined by the German taxation authorities and may be adjusted. Furthermore, significant changes in the shareholder and company structure can lead to a reduction in the loss carryforwards under the current provisions of German tax law, which can be used to calculate the annual amount for offsetting against the future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. The amount of the expected tax liability or tax receivable reflects the amount, which represents the best estimation taken into account tax uncertainties. Based on management&#x2019;s estimation, no provisions for uncertain tax treatments need to be accounted for.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Deferred tax assets are recognized for deductible temporary differences, the carry forward of unused tax credits and any unused tax losses to the extent that it is probable that future taxable income will allow the deferred tax asset to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;An operating segment is defined as a component of an entity for which discrete financial information is available and whose operating results are regularly reviewed by our Management Board as the Chief Operating Decision Maker (CODM). The Group operates as a single segment dedicated to the discovery and development of biotechnological applications and the CODM makes decisions about allocating resources and assessing performance based on the Group as a whole. Accordingly, the Group has determined it operates in one operating and reportable segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant accounting judgments, estimates and assumptions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates, and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments and estimates in relation to assets, liabilities, contingent liabilities, uncertain tax position, revenues, and expenses. Management bases its judgments and estimates on historical experience and other various factors, which it believes to be reasonable under the circumstances, the result of which forms the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#x2019;s estimation, no provisions for uncertain tax treatments need to be accounted for. Actual results may differ from these estimates under different assumptions and conditions and may materially affect the financial results or the financial position reported in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Judgments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the process of applying the accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue recognition and collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applied the following judgments in determining the amount and timing of revenue from collaboration agreements:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identification and determination of the nature of performance obligations in collaboration and license agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group generates revenues from collaboration and license agreements under which the Group grants licenses to use, research, develop, manufacture, and commercialize candidates and products. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. If these promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in the Group accounting for all goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For these combined performance obligations, it must be assessed which of these promises is the predominant promise to determine the nature of the performance obligation. The Group determined that the research and development technology services for the grant of the license is the predominant promise within the (combined) performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Group shares the risks and benefits of a development project in such a way that the nature of the arrangement is not considered to be purely a customer-vendor-relationship, activities that are determined to be outside of a customer-vendor-relationship are accounted for in consideration of the principles of a joint operation accounting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result, the promise of the research and development technology services for granting a license is accounted for as a performance obligation satisfied over time as the Group&#x2019;s customer simultaneously receives and consumes the benefits from the Group&#x2019;s performance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue recognition and collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Estimation of variable consideration and assessment of the constraint when determining the amount of revenue of which to defer recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group&#x2019;s collaboration and license agreements comprise variable considerations which are contingent on the occurrence or non-occurrence of a future event (i.e., reaching a certain milestone). When determining the deferral of revenue in a collaboration and license agreement, the Group is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As there are usually only two possible outcomes (i.e., a milestone is reached or not), the Group has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which the Group will be entitled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The most likely amount of these milestone payments (i.e., the full milestone payment) is only included in the transaction price if the occurrence of reaching a future milestone is highly probable. The Group has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has concluded that future milestone payments are fully constrained at each of the fiscal years. Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, regulatory approval, or achievement of a sales milestone.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;Estimation of determination of date of market authorization application for revenue release over-time&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant amount of judgment given the uncertainty inherent in developing innovative pharmaceutical products is being used in the determination of the estimated date of the Marketing Authorization Application or Biologics License Applications. The group regularly reviews the timelines and changes are reflected in the release of revenue amount when they become effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for non - current assets held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Non-current assets are classified as asset held for sale if their carrying amount will be recovered through a sale transaction rather than through continued use; the carrying value of such assets is measured at the lower of their previous carrying value and their fair value less costs to sell. In evaluating whether the criterion, for classification as assets held for sale, of a sale being highly probable, the Group considered that a plan to sell the assets was committed to and an active program to locate a buyer was initiated with an equipment reseller. By estimating the fair value less costs to sell the Group considered various indicative prices of expected auction proceeds quoted by the equipment reseller. Additionally, the Group estimated, whether the plan to sell the assets could be completed within one year from the date of classification and whether actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for share-based payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has multiple share-based payment programs. Significant estimates are included in the determination of the grant date fair value of the awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for onerous contract provisions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has entered into binding legal agreements for the supply of services by contract research organizations (CROs) to the Group for clinical trials of its first-generation COVID-19 vaccine candidate, CVnCoV. Such services are generally associated with the ongoing monitoring and care for enrolled participants in the clinical trials. Due to the discontinuation of the CVnCoV program, the remaining services, which the Group is obligated to procure, do not have a value for the Group anymore. In estimating the cost of the remaining services, judgment is required, particularly in estimating the number of participants completing the clinical trials, when measuring provisions for such contracts with clinical research organizations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for contract termination provisions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract termination provisions are established under certain conditions in the case of legal risks. Settlement and legal proceedings often raise complex issues and are subject to many uncertainties and complexities including, but not limited to, the facts and circumstances of each particular case. The outcome of any current or future proceedings cannot normally be predicted. The Group considers the need for accounting measures in respect of pending or future settlements for terminated contracts on the basis of the information available to its legal department and in close consultation with legal counsel acting for the Group. Where it is more likely than not that such settlement will result in an outflow of resources that is already reasonably estimable, a provision for settling terminated contracts is recorded in the amount of the present value of the expected cash outflows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Current income tax&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#x2019;s estimation, no provisions for uncertain tax treatments need to be accounted for. The risk for the assessment regarding i) the deferral of upfront payments, ii) the cooperation between CureVac and GlaxoSmithKline Biologicals SA (GSK), and iii) the transfer pricing setup not to be accepted by the tax authorities is estimated to be between 10% and 50%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Changes in accounting policies and disclosures&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New and amended standards and interpretations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has not early adopted any standards, interpretations, or amendments that have been issued but are not yet effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Standards issued but not yet effective&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following amendments will be adopted effective January 1, 2024, or at a later effective date:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IAS 1: Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IAS 7 and IFRS 7: Supplier Finance Arrangements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IFRS 16: Lease Liability in a Sale and Leaseback&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IAS 21: Lack of Exchangeability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;CureVac does not expect these standards to have an impact on the Group&#xb4;s consolidated financial statements.&lt;/p&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_WtQh0Wnqs0uMcjH5wAO1hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and were authorized by the Management Board for presentation to the Supervisory Board on April 23, 2024. The Group&#x2019;s consolidated financial statements are presented in Euros (EUR), which is also the parent company&#x2019;s functional currency. Unless otherwise stated, the numbers are rounded to thousands of Euros, except per share amounts.Due to rounding, differences may arise when individual amounts or percentages are added together.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has prepared the consolidated financial statements on the basis that it will continue to operate as a going concern. No commercial products have been marketed yet as CureVac is still in the development phase. Hence, the Group is raising capital to perform research &amp;amp; development activities and to advance its technologies up to a successful development and regulatory approval of its products. To reach its development and commercialization objectives, the Group will seek additional funding through collaboration or licensing agreements or other financing activities. While the Group&#x2019;s business projections could be unfavorably affected by being unable to obtain funding or enter into collaboration or license agreements on acceptable terms, CureVac&#x2019;s cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the financial statements. This anticipates, that for the foreseeable future the Group will continue to operate. Thus, no adjustments to the consolidated financial statements have been made related to the Group not being able to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Details of the Group&#x2019;s accounting policies, including changes thereto are described below. The accounting policies have been consistently applied to all years presented unless otherwise stated.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_T5lc3F2RTkSxzEUgiHRJkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsidiaries are entities controlled by the Group. The Group &#x201c;controls&#x201d; an entity when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The consolidated financial statements include the Company&#x2019;s wholly-owned subsidiaries CureVac SE (until September 26, 2022: CureVac AG, Tuebingen, Germany), CureVac Inc. (Boston, Massachusetts, USA), CureVac Manufacturing GmbH (prior years: CureVac Real Estate GmbH, Tuebingen, Germany), CureVac Corporate Services GmbH (Tuebingen, Germany), CureVac RNA Printer GmbH (Tuebingen, Germany), CureVac Swiss AG (Basel, Switzerland &#x2013; incorporated in 2021) and CureVac Belgium SA (Ottignies-Louvain-la-Neuve, Belgium &#x2013; incorporated in 2022). Effective July 1, 2022, we acquired Frame Pharmaceuticals B.V., Amsterdam, Netherlands (Frame Pharmaceuticals), which was renamed to CureVac Netherlands B.V.; refer to Note 20 for additional information about this business combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The fiscal year of all Group entities corresponds to the calendar year ending December&#160;31.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_6kU3LzyZHkKMry3gtG2jOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business combinations and goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The Group determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Any contingent consideration to be transferred by the acquirer is recognized at fair value at the acquisition date. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of IFRS 9 Financial Instruments, is measured at fair value with the changes in fair value recognized in the statement of operations in accordance with IFRS 9. Other contingent consideration that is not within the scope of IFRS 9 is measured at fair value at each reporting date with changes in fair value recognized in the statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred over the fair value of net identifiable assets acquired and liabilities assumed).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;After initial recognition, goodwill is measured at cost less any accumulated impairment losses.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_5gbQSr8_Dk6pkr98gj0OEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Revenue from the sale of products and services is recognized when the Group transfers control to the customer. Control generally transfers when the customer gains the ability to direct the use of and obtain substantially all of the remaining benefits from the good or service. If the contract contains more than one performance obligation, the consideration which the Group expects to receive is allocated to each of the performance obligations, using the relative stand-along selling price method. Revenue is recognized at the amount of consideration that the Group is expected to receive in exchange for these goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group primarily generates revenue from its licensing and development agreements with its customers, which include collaboration partners for the development of mRNA medicines against a variety of targets in diseases and conditions. These arrangements contain multiple contractual promises, including (i) licenses, or options to obtain licenses to the Group&#x2019;s mRNA technology, as well as related research and development technology services, (ii) delivery of products, and (iii) research and development services. Such arrangements provide for various types of payments to the Group, including upfront fees, funding of research and development services, payment for delivered products, development, regulatory and commercial milestone payments, license fees, and royalties on product sales, all of which may be satisfied at different points in time. Outlicensing agreements may be entered into with or without any further significant contractual obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Goods or services promised in collaborative arrangements are accounted for as separate performance obligations if such promises are distinct (i.e., if the customer can benefit from the good or service on its own or together with other resources readily available to it and if the promise is separately identifiable from other promises in the contract).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;In determining whether contractual promises are separately identifiable, the Group considers whether:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;It provides a significant service of integrating the goods or services with other goods or services that represent the combined output or outputs for which the other party has contracted.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;One or more of the goods or services significantly modifies or customizes one or more of the other goods or services promised in the agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The goods or services the Group promised to transfer or to provide are highly interdependent or highly interrelated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Based on these criteria, management evaluates whether the intellectual property (IP) licenses granted, and to which further research and development activities may apply under the terms of a collaboration agreement, are distinct from the unperformed obligations to the collaboration partner, considering the relevant facts and circumstances of each arrangement. Factors considered in this determination include the nature of the IP license, the stage of development of the IP license granted, the research capabilities of the partner, and the availability of mRNA technology research expertise in the general marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;When an IP license is not considered to be distinct from research services, the Group generally recognizes revenue, including any upfront payment, attributable to the license on a straight-line basis, which reflects the performance of services by the Group towards satisfaction of the obligation, over the contractual or estimated performance period, which is typically from the effective date of the related collaboration agreement through to the estimated date of Marketing Authorization Application (MAA) or Biologics License Application (BLA) for a product developed under the agreement. The determination of the estimated date of MAA or BLA is a significant estimate given the uncertainty inherent in developing innovative pharmaceutical products and is based upon development plans with the customer, which are subject to change, clinical trials, and approval of regulatory authorities Changes in the estimated date of market entry could have a material impact on the amount and timing of revenue the Group records in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Sometimes an IP license is granted together with research and development services relating to the technology. In this case, the services are not considered distinct from the licenses and form a bundle for which revenue is recognized on a straight line basis over the time of services, as the services are determined predominant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;When an IP license is considered to be distinct, the Group determines whether it provides the customer with either (1) a right to access the IP throughout the license period (for which revenue is recognized over the license period) or (2) a right to use the IP as it exists at the point in time that the license is granted (for which revenue is recognized at a point in time where the customer can first use and benefit from the license).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Some of the collaboration arrangements include rights and obligations that are considered outside the scope of a customer-vendor relationship as they are more akin to the activities that joint operators perform. CureVac decided that the nature of these types of activities is best reflected by applying joint arrangements accounting which, as the main effect, usually leads to revenue recognition at a later point in time. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;If the transaction price in an agreement includes a variable amount, the Group estimates the amount of consideration to which the Group will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated deferred contract liability is updated at each reporting date to reflect the current facts and circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Collaboration agreements may also provide a customer with the option to acquire additional goods or services. In these cases, the Group determines as to whether the customer was granted a material right.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Product sales related to collaboration agreements include RNA products and are recognized over time as goods are produced because such goods have no alternative use. Otherwise, revenue for product sales is recognized at a point in time. In 2023 revenue for produced LNP batches were recognized on a point-in-time basis. No product revenue was recognized in 2022 and 2021. Revenue from certain research and development services, delivered as a distinct performance obligation under the collaboration agreements, are recognized over time as the services are provided.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A receivable is recognized when the consideration is unconditional and only the passage of time is required before payment is due. Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liability in the statements of financial position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group may present the following contract balances:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Contract assets&#x2009;&#x2014;&#x2009;Represents the Group&#x2019;s right to consideration in exchange for goods or services that the Group has transferred to the customer when that right is conditioned on something other than the passage of time&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Trade receivables&#x2009;&#x2014;&#x2009;Represents the Group&#x2019;s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Contract liabilities&#x2009;&#x2014;&#x2009;Represents the Group&#x2019;s obligations to transfer goods or services to a customer for which the Group has received consideration (or consideration is due) from the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognizes revenue from contracts with customers relating to its core business. All other operating proceeds are presented as other operating income in the statements of operations.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_MbE6eT_jhUqN_qgDGJR4FA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grants from government agencies and similar bodies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects. Each grant agreement is assessed to determine whether there are elements of the supply of products from the group to the grantor that are recognized separately from the grant. For the supply of products, the standalone selling price is determined by reference to observed prices with other customers. The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If grant funds are received prior to qualifying expenses being incurred or assets purchased, they are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other operating income on a systematic basis over the period in which the corresponding expenses are incurred. If the funds reimburse purchased assets, the liability is reduced with a corresponding amount deducted from the asset&#x2019;s carrying amount upon recording of the qualified asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_1gpPUxi8nEmejdyh6IK5yQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;i) Financial assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Initial recognition and measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The classification of financial assets at initial recognition depends on the financial asset&#x2019;s contractual cash flow characteristics and the Group&#x2019;s business model for managing them. The Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component are measured at the transaction price determined under IFRS 15.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Subsequent measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"&gt;For purposes of subsequent measurement, financial assets are classified into four categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets at amortized cost (debt instruments);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets at fair value through other comprehensive income with recycling of cumulative gains and losses (debt instruments);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets designated at fair value through other comprehensive income with no recycling of cumulative gains and losses upon derecognition (equity instruments); or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;financial assets at fair value through profit or loss.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In fiscal 2021, 2022, and 2023, the Group only had the following financial assets to be measured at amortized cost:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in the statement of operations when the asset is derecognized, modified, or impaired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment of financial assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;An allowance for expected credit losses (ECLs) is recognized for all debt instruments not held at fair value through profit or loss including contract assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12- months (a 12- month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For financial assets being due more than 30 days, a significant increase in credit risk is assumed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk but instead recognizes a loss allowance based on lifetime ECLs at each reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group considers a financial asset in default when contractual payments are 180&#160;days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ii) Financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group&#x2019;s material financial liabilities consists of lease liabilities and trade payables. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade payables at initial recognition are accounted for at fair value and subsequently at amortized costs. The material accounting policy information regarding accounting of leases is described below.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_kKiOgBSCg02kvzakYWmvMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquired intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Acquired intangible assets are mainly comprised of software and licenses. Regarding the acquired intangible assets (i.e., technology and goodwill) in the business combination with Frame Pharmaceuticals, refer to Note 20.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated useful lives for each intangible asset class are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Software&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Licenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;8 to 20 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technology&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;8 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;With the exception of goodwill, the Group does not have any intangible assets with indefinite useful lives.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_U8a8-hZsxUeUeGC3VXjqvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Software&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Licenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;8 to 20 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technology&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;8 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IF3SAFyRDkmSY9vIIRwRsA"
      id="Narr_BE7o92UqtECHAT-k2uksLA">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_SoftwareMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WdwXgqTk-0Gz8-5HXgSqZg"
      id="Narr_JSJ3wbQxQkOGF7gzt3FmCA">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_n816zTthhUCd928-Xo9B2w"
      id="Narr_7XnC16SbgkyPm4UMR8ekzA">P8Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_LicencesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_h5bEzTVa3EyxXxcQh-dg1Q"
      id="Narr__0YCT1SI80C9xrb5bu7w4A">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_TechnologyMember_hH9UPyIPlEOolWMJj-UurA"
      id="Tc_eZQzr3udf0mwpEfDhLYuEA_3_2">P8Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_gPK-zIfPBEKYFJjcmPjYlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research costs are expensed as incurred. Since our own development projects are mostly subject to regulatory approval and all studies are at an early phase, where the outcome of reaching the next phases is uncertain, the conditions for the capitalization of expenditures incurred prior to approval are not met.&lt;/p&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_Pbtkyp1Us020Fy5DJmRwrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairments. These costs also comprise the costs for replacement parts, which are recognized at the time they are incurred, providing they meet the recognition criteria. All other repair and maintenance costs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leasehold improvements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;1 to 15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technical equipment and machines:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 14 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other equipment, furniture and fixtures:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 14 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated useful lives are reviewed regularly and revised if necessary. The depreciation method remained unchanged from 2021 through 2023. The residual values of the assets are generally considered to be zero.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_gHPvM-qNlEeYHjEjWplc8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leasehold improvements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;1 to 15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technical equipment and machines:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 14 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other equipment, furniture and fixtures:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 to 14 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_SzFXrlYIYkGJv5pgzyKXhQ"
      id="Narr_Oi1qwRFM4ESiy7nsxyDC4Q">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_4y9Rq2Ban029PexLw4uVTQ"
      id="Narr_coYQpGkBeUiypJowebydVQ">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_dLLTUG3nUkmNAeblyIfEfQ"
      id="Narr_JIxID085CUOvOikV0BAVvw">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_yHk0L5C8gEyXoJw8KYw3Kg"
      id="Narr_comUzR9oDk6HS16WNty7Fg">P14Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_wEcN7ca8EkmDto9rHIMXqw"
      id="Narr_XdVCH1o3XEKu09tl16AeDw">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_WHDQrxvJz065lEPIjGIWuQ"
      id="Narr_IVbAIYVrIkajB2XTdVLtJg">P14Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <cvac:IfrsPropertyPlantAndEquipmentSalvageValue
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="0"
      id="Narr_f0gSpQlpPkKdJVtSkfRoPw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</cvac:IfrsPropertyPlantAndEquipmentSalvageValue>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_DRKo6uCtjES-vPEOqH_BOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of non-financial non-current assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At each reporting date, the Group assesses whether there is an indication that a non-financial asset may be impaired. If there is any indication of impairment (triggering event) or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of the asset&#x2019;s or CGU&#x2019;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case it is determined at the level of the cash-generating unit (CGU). If the carrying amount of an asset or CGU exceeds its recoverable amount, the asset or CGU is impaired and written down to its recoverable amount. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In principle, the recoverable amount has to be determined for each individual asset where such asset generates cash flows that are largely independent of those generated by other assets. Where it is not possible, the recoverable amount has been determined on the basis of a group of assets representing a cash generating unit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing whether the cash flows are largely independent, CureVac considers various factors, including how management manages the company activities and how the CureVac companies are linked in business operations. As management decisions are centralized on group level and the CureVac companies are closely linked in business operations, the Group operates as one cash-generating unit. Therefore, for the purpose of annual goodwill impairment testing in 2022 and 2023, goodwill was allocated at Group level. The recoverable amount for the Company&#x2019;s cash-generating unit based on fair values less costs of disposal using market capitalization derived from public quotations of CureVac stock. Management believes that no reasonably foreseeable change in the price of CureVac stock would cause the carrying amount of our one cash-generating unit to exceed its recoverable amount.Impairment losses of continuing operations are recognized in the statement of operations in expense categories consistent with the function of the impaired asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In fiscal year 2021, impairment of EUR 22,810k were recognized. These pertained largely to machinery and technical equipment recorded as assets under construction and resulted from the partial impairment of production lines which were obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV, see Note 4.1.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Beginning in year 2022, goodwill is tested for impairment annually as of December 31 and when circumstances indicate that the carrying value may be impaired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For 2023, impairment was evaluated for goodwill by assessing the recoverable amount on Group level. Impairment losses relating to goodwill cannot be reversed in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;There was no impairment of goodwill in 2023. However, there were impairments of technical equipment amounting to EUR 1,374k; refer to Note 4.1 for additional information.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_AheVyckymEeU2JcsgEPfJw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22810000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_FPullIuzD0GPTaPm66gk2A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_245TIN92bECXts4LlGOaEQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1374000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_TlLiOCP7IUGGRzrOnJSYKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group classifies non-current assets as held for sale if their carrying amount is expected to be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expenses. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management is committed to the plan to sell the assets. Property, plant and equipment are not depreciated or amortized once classified as held for sale.&lt;/p&gt;</ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
    <cvac:DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_oEdZSYxJ_02Qvz05S10_NA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received as well as any estimated costs to be incurred by the lessee for dismantling and removing the underlying asset. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life, indicated below, and the lease term. Right-of-use assets are subject to impairment. Refer to the section above &#x201c;Impairment of non-financial assets&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Land, Buildings and supply installations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1 to 15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vehicles&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3 to 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:DescriptionOfAccountingPolicyForRightOfUseAssetsExplanatory>
    <cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_SBTZDvsbgkyOw4Avjm5m5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Land, Buildings and supply installations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1 to 15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vehicles&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3 to 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfRightOfUseAssetsExplanatory>
    <cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_Q9fMN7T-y0m13lblbattaw"
      id="Narr_m8s-LClxc0Gt5WpF-qU2pw">P1Y</cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_LandBuildingsAndSupplyInstallationsMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_BsheSwtJGU-hU30WhGx3GA"
      id="Narr_GyGIs8_7PUynBxco2YFf0Q">P15Y</cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_oC7hV09GIUK4KIsK7e8ZoA"
      id="Narr_EvV5pTxQ6ECgDtw54FlHuA">P3Y</cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_8YeTvYg7kUKynLYBgt67GA"
      id="Narr_M8eRbLuj90m7H8iq7rVvlg">P4Y</cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_vnP_GndeskmGccGmbmXP2A"
      id="Narr_N_N5PZlCLkyMtPkr-LO6qw">P2Y</cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_cvac_OtherEquipmentMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_B2bOhJ54KEOrUvEAltnJrA"
      id="Narr_FroxxU0WlEeBsEYv3B5OdA">P5Y</cvac:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_1hRDglRq30mHpVOSkvhDuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in- substance fixed payments) less any lease incentives receivable and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments, or a change in the assessment to purchase the underlying asset. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount for the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Short-term leases and leases of low-value assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applies the short-term lease recognition exemption to its short-term leases (i.e., leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption. Lease payments on short-term leases and leases of low-value assets are recognized as expenses on a straight-line basis over the lease term.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_Tnd53Csth0q6t2_forfrtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Inventories are comprised of raw materials, work in progress, and finished goods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs incurred in bringing each product to its present location and condition are accounted for, as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Raw materials: purchase cost on a first-in/first-out basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overhead based on normal operating capacity, but excluding borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_chk7Wx3lJUqegCZz_JM_ww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash on hand, bank balances on-demand, and short-term deposits with original maturities of three months or less.&lt;/p&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_STlyy1tmbEyK6DbWMAMl5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Onerous contracts&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;An onerous contract is a contract under which the unavoidable costs (i.e., the costs that the Group cannot avoid because it has the contract) of meeting the obligations under the contract exceed the economic benefits expected to be received under it. The unavoidable costs under a contract reflect the least net cost of exiting from the contract, which is the lower of the cost of fulfilling it and any compensation or penalties arising from failure to fulfil it. The cost of fulfilling a contract comprises the costs that relate directly to the contract (i.e., both incremental costs and an allocation of costs directly related to contract activities).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Group has a contract that is onerous, the present obligation under the contract is recognized and measured as a provision. However, before a separate provision for an onerous contract is established, the Group recognizes any impairment loss that has occurred on assets dedicated to that contract.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_UHxHXHGJwkaENdD2YZROWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Share-based payment awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The Group operates several share-based payment programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;An equity-settled share-based payment award is accounted for by recognizing the related expense over the vesting period of the award, with a corresponding increase recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;When a share-based payment award provides for different ways of settlement (i.e. cash versus shares) depending on the occurrence of contingent events, CureVac has the right to choose the manner of settlement and accounts the award based on this.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The related share-based payment expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Group_uD0V0ZAsJ0Gp9x0Gos3Icg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tax loss carryforwards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Tax loss carryforwards are examined by the German taxation authorities and may be adjusted. Furthermore, significant changes in the shareholder and company structure can lead to a reduction in the loss carryforwards under the current provisions of German tax law, which can be used to calculate the annual amount for offsetting against the future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. The amount of the expected tax liability or tax receivable reflects the amount, which represents the best estimation taken into account tax uncertainties. Based on management&#x2019;s estimation, no provisions for uncertain tax treatments need to be accounted for.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Deferred tax assets are recognized for deductible temporary differences, the carry forward of unused tax credits and any unused tax losses to the extent that it is probable that future taxable income will allow the deferred tax asset to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Current income tax&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#x2019;s estimation, no provisions for uncertain tax treatments need to be accounted for. The risk for the assessment regarding i) the deferral of upfront payments, ii) the cooperation between CureVac and GlaxoSmithKline Biologicals SA (GSK), and iii) the transfer pricing setup not to be accepted by the tax authorities is estimated to be between 10% and 50%.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_MWDWGZhnPUOjwmjP1FXNVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;An operating segment is defined as a component of an entity for which discrete financial information is available and whose operating results are regularly reviewed by our Management Board as the Chief Operating Decision Maker (CODM). The Group operates as a single segment dedicated to the discovery and development of biotechnological applications and the CODM makes decisions about allocating resources and assessing performance based on the Group as a whole. Accordingly, the Group has determined it operates in one operating and reportable segment.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <cvac:IfrsNumberOfReportableSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="INF"
      id="Narr_SCapgVV-sUG_d4zRl0p-dQ"
      unitRef="Unit_Standard_segment_thtYd9HVPUa-ZcLIAcALtA">1</cvac:IfrsNumberOfReportableSegments>
    <cvac:IfrsNumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="INF"
      id="Narr_HK7q48A2PEGZm82kl5c7bQ"
      unitRef="Unit_Standard_segment_thtYd9HVPUa-ZcLIAcALtA">1</cvac:IfrsNumberOfOperatingSegments>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_cm7pzYxFaEyUwjOjIa21wA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant accounting judgments, estimates and assumptions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates, and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments and estimates in relation to assets, liabilities, contingent liabilities, uncertain tax position, revenues, and expenses. Management bases its judgments and estimates on historical experience and other various factors, which it believes to be reasonable under the circumstances, the result of which forms the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. CureVac assesses whether it is likely that a tax authority will accept an uncertain tax treatment. Based on management&#x2019;s estimation, no provisions for uncertain tax treatments need to be accounted for. Actual results may differ from these estimates under different assumptions and conditions and may materially affect the financial results or the financial position reported in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Judgments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the process of applying the accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue recognition and collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applied the following judgments in determining the amount and timing of revenue from collaboration agreements:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identification and determination of the nature of performance obligations in collaboration and license agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group generates revenues from collaboration and license agreements under which the Group grants licenses to use, research, develop, manufacture, and commercialize candidates and products. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. If these promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in the Group accounting for all goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For these combined performance obligations, it must be assessed which of these promises is the predominant promise to determine the nature of the performance obligation. The Group determined that the research and development technology services for the grant of the license is the predominant promise within the (combined) performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Group shares the risks and benefits of a development project in such a way that the nature of the arrangement is not considered to be purely a customer-vendor-relationship, activities that are determined to be outside of a customer-vendor-relationship are accounted for in consideration of the principles of a joint operation accounting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result, the promise of the research and development technology services for granting a license is accounted for as a performance obligation satisfied over time as the Group&#x2019;s customer simultaneously receives and consumes the benefits from the Group&#x2019;s performance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue recognition and collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Estimation of variable consideration and assessment of the constraint when determining the amount of revenue of which to defer recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group&#x2019;s collaboration and license agreements comprise variable considerations which are contingent on the occurrence or non-occurrence of a future event (i.e., reaching a certain milestone). When determining the deferral of revenue in a collaboration and license agreement, the Group is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As there are usually only two possible outcomes (i.e., a milestone is reached or not), the Group has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which the Group will be entitled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The most likely amount of these milestone payments (i.e., the full milestone payment) is only included in the transaction price if the occurrence of reaching a future milestone is highly probable. The Group has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has concluded that future milestone payments are fully constrained at each of the fiscal years. Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, regulatory approval, or achievement of a sales milestone.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;Estimation of determination of date of market authorization application for revenue release over-time&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant amount of judgment given the uncertainty inherent in developing innovative pharmaceutical products is being used in the determination of the estimated date of the Marketing Authorization Application or Biologics License Applications. The group regularly reviews the timelines and changes are reflected in the release of revenue amount when they become effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for non - current assets held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Non-current assets are classified as asset held for sale if their carrying amount will be recovered through a sale transaction rather than through continued use; the carrying value of such assets is measured at the lower of their previous carrying value and their fair value less costs to sell. In evaluating whether the criterion, for classification as assets held for sale, of a sale being highly probable, the Group considered that a plan to sell the assets was committed to and an active program to locate a buyer was initiated with an equipment reseller. By estimating the fair value less costs to sell the Group considered various indicative prices of expected auction proceeds quoted by the equipment reseller. Additionally, the Group estimated, whether the plan to sell the assets could be completed within one year from the date of classification and whether actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for share-based payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has multiple share-based payment programs. Significant estimates are included in the determination of the grant date fair value of the awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for onerous contract provisions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has entered into binding legal agreements for the supply of services by contract research organizations (CROs) to the Group for clinical trials of its first-generation COVID-19 vaccine candidate, CVnCoV. Such services are generally associated with the ongoing monitoring and care for enrolled participants in the clinical trials. Due to the discontinuation of the CVnCoV program, the remaining services, which the Group is obligated to procure, do not have a value for the Group anymore. In estimating the cost of the remaining services, judgment is required, particularly in estimating the number of participants completing the clinical trials, when measuring provisions for such contracts with clinical research organizations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting for contract termination provisions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract termination provisions are established under certain conditions in the case of legal risks. Settlement and legal proceedings often raise complex issues and are subject to many uncertainties and complexities including, but not limited to, the facts and circumstances of each particular case. The outcome of any current or future proceedings cannot normally be predicted. The Group considers the need for accounting measures in respect of pending or future settlements for terminated contracts on the basis of the information available to its legal department and in close consultation with legal counsel acting for the Group. Where it is more likely than not that such settlement will result in an outflow of resources that is already reasonably estimable, a provision for settling terminated contracts is recorded in the amount of the present value of the expected cash outflows.&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <cvac:EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ao6gXG47qEqwSYLU3wAumQ"
      decimals="2"
      id="Narr_m4RGqbUNAEWU585W7NAwdA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp>
    <cvac:EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dzLDR4-bwEyHrc4xbtFT-A"
      decimals="2"
      id="Narr_2lV3L7R4VUS42M-Kr6EGTQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.50</cvac:EstimatedRiskPercentageForNotAcceptingTransferPricingSetUp>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_ddOKYpbuRUKe48w28s-akQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Changes in accounting policies and disclosures&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New and amended standards and interpretations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has not early adopted any standards, interpretations, or amendments that have been issued but are not yet effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Standards issued but not yet effective&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following amendments will be adopted effective January 1, 2024, or at a later effective date:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IAS 1: Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IAS 7 and IFRS 7: Supplier Finance Arrangements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IFRS 16: Lease Liability in a Sale and Leaseback&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IAS 21: Lack of Exchangeability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;CureVac does not expect these standards to have an impact on the Group&#xb4;s consolidated financial statements.&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory>
    <cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_eXNajj7K5E23MRE8ailPlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Notes to the consolidated financial statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.1 Revenue from contract with customers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;The Group recognized the following revenues in 2021, 2022 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 74,298&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Germany &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Boehringer Ingelheim &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 919&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 102,990&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 67,420&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 53,758&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the fiscal year ended December 31, 2023, the Company recognized revenues over-time (i) EUR 31,051k (2022: EUR 44,787k, 2021: EUR 79,827k) related to delivery of research and development services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below) and (ii) EUR 11,395k (2022: EUR 19,571k, 2021: EUR 22,706k) from those research and development services considered distinct within the agreements and recognized revenues at point-in-time (iii) EUR 11,312k (2022: EUR 3,062k, 2021: EUR 457k) related to delivery of products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;GlaxoSmithKline&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In July 2020, the Group entered a collaboration with GSK for the research, development, manufacture and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. In addition to an equity investment of EUR 150,000k as part of the 2020 Private Investment, GSK made a non-refundable upfront cash payment of EUR 120,000k which was deferred upon receipt and recognized as a contract liability. Additionally, the Group is eligible to receive a one-time reimbursable payment of EUR 30,000k for manufacturing capacity reservation, upon certification of CureVac&#x2019;s commercial scale manufacturing facility currently under construction in Germany as well as to receive development and regulatory milestone payments of up to EUR 320,000k, commercial milestone payments of up to EUR 380,000k and tiered royalties on product sales. GSK will fund R&amp;amp;D activities incurred by CureVac related to the development projects covered by the collaboration. CureVac will be responsible for the research and development in collaboration with GSK up to the submission to authorities, after which GSK will be responsible, including commercialization. CureVac will be responsible for the manufacturing of the product candidates, including for commercialization, and will retain commercialization rights for selected countries for all product candidates. This contract consists of two performance obligations. Performance obligation one consists of a combined performance where CureVac grants its customer a license which is bundled with research and development services relating to the technology. The group accounts for this as a single obligation overtime. The second performance obligation consists of research and development project work which is recognized over-time. The upfront payment, attributable to the IP license, is being recognized straight-line from the effective date of the collaboration agreement through to the agreed estimated submission date for authority approval. In the year ended December 31, 2023, EUR 27,740k (2022: EUR 41,379k) in revenue was recognized under the collaboration agreement with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. In 2023, less revenue was released than originally anticipated, due to changes of the estimated project timelines.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Additionally, in April 2021, the Group entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches (&#x201c;GSK COVID Products&#x201d;), such as the CureVac&#x2019;s second-generation COVID-19 vaccine candidate, CV2CoV. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September 2021. Pursuant to the amendment in September 2021, CureVac and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. CureVac and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by CureVac, GSK or jointly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Under the GSK COVID Agreement, GSK has paid CureVac an upfront payment of EUR 75,000k in 2021. Under the terms of the 2020 GSK Agreement, CureVac granted GSK a worldwide exclusive, sublicensable (subject to certain conditions) license under certain of our intellectual property relating to vaccines and antibodies encoded by our proprietary mRNA targeting certain selected pathogens, or GSK Program Products, and a non-exclusive license under certain LNP technology to develop, manufacture and commercialize a certain number of such GSK Program Products for use in connection with the infectious diseases targeted under the 2020 GSK Agreement. CureVac also granted GSK an exclusive option, after a certain date, to obtain exclusive licenses to develop, manufacture and commercialize CVnCoV and boosters for such vaccine. CureVac and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. CureVac and GSK will share all net profits generated from sales of GSK COVID Products, other than certain products defined in the agreement as &#x201c;Combination Products&#x201d;, under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. This contract consists of a bundled performance obligation where CureVac grants its customer a license which is bundle with research and development services relating to the technology. The group accounts for this as a single obligation overtime. For the equally shared development costs CureVac accounts for the GSK share as a research and development expense and reimbursements from GSK for CureVac&#x2019;s share are offset against research and development expense. CureVac is eligible to receive tiered royalty payments ranging from a low-teen percentage to a mid-teen percentage of net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement, CureVac has the right to commercialize GSK COVID Products in Austria, Germany and Switzerland and if CureVac exercises such right, CureVac&#x2019;s sales of GSK COVID Products, other than Combination Products will be subject to the profit share and CureVac will be required to pay GSK a high-teen percentage royalty on net sales of all Combination Products in such countries. In the year ended December 31, 2023, EUR 10,530k (2022: EUR 20,884k) in revenue was recognized under the GSK COVID Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Boehringer Ingelheim&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In August 2014, the Group entered into an Exclusive Collaboration and License Agreement, which it refers to as the Boehringer Agreement, with Boehringer Ingelheim, whereby it granted Boehringer Ingelheim exclusive global rights for development and commercialization of its investigational therapeutic mRNA vaccine BI 1361849 (formerly CV9202) formulated with a legacy protamine technology. The Group received, in 2014, an upfront payment of EUR 30,000K, as well as, an option fee payment of EUR 5,000K and in 2018 an additional EUR 7,000K in development milestone payments, all of which are non-refundable and non-creditable in the event of expiry or termination of the agreement. In June 2021, Boehringer Ingelheim provided notice of its intention to terminate the Boehringer Agreement, with such termination to become effective on November 17, 2021. Upon termination of the Boehringer Agreement, the rights and licenses granted by the Group to Boehringer Ingelheim reverted back to the Group, provided that Boehringer Ingelheim has the right to sell off existing inventory of BI 1361849 for a certain period. In addition, Boehringer Ingelheim assigned to us all regulatory approvals or applications and grant us a non-exclusive, cost-free, perpetual and worldwide license to intellectual property held by Boehringer Ingelheim that has been used in the development, manufacture or commercialization of BI 1361849 or any other product developed under the Boehringer Agreement. As a result of the termination in 2021, the remaining contract liability, related to the upfront payment, EUR 14,003k was recognized over a shorter period through the termination date. In addition, the option fee payment of EUR 5,000k and the additional EUR 7,000k development milestone were recognized in 2021. Therefore, for the year ended December 31, 2023, EUR 0k (2022: EUR 0k, 2021: 26,003k) was recognized related to this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CRISPR Therapeutics Development and License Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In November 2017, we entered into a Development and License Agreement with CRISPR Therapeutics, which, as amended by amendments entered into in June 2020 and in October 2023, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. CureVac and CRISPR confirmed to stop working on two programs under the CRISPR Therapeutics Agreement and added three new programs. CRISPR Therapeutics has paid us an upfront one-time technology access fee of USD 3 million and certain additional amounts under the second amendment, which are recognized straight-line from the effective date of the collaboration agreement through to the date of market entry of a product developed under the agreement. In the year ended December 31, 2023, EUR 5,425k (2022: EUR 3,370k, 2021: EUR 919k) in revenue was recognized under this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Genmab Collaboration and License Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the Group entered into a Collaboration and License Agreement with Genmab, which we refer to as the Genmab Agreement, to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#x2019;s proprietary antibody technology for the treatment of human diseases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2023, Genmab notified the Group of its intent to terminate the Genmab First Program under the Genmab Agreement effective in September 2023. Such termination did not terminate the Genmab Agreement in its entirety, but rather only with respect to certain license and exclusivity provisions related to the Genmab First Program. Under the Genmab Agreement, the Group further grants Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under CureVac&#x2019;s mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In partial consideration for entering into the Genmab Agreement, in 2019 Genmab made a USD 20 million equity investment and paid us an upfront fee of USD 10 million, which was recognized through the date of market entry of a product developed under the agreement until August 2023 (no recognition from September 2023 onwards). In the year ended December 31, 2023, EUR 1,197k (2022: EUR 1,787k, 2021: 1,770k) in revenue was recognized under this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period or upon termination of the agreement, when no services are provided anymore. Below is a summary of such payments and the related revenues recognized over-time:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:24.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract liabilities at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized&#160;from&#160;upfront and milestone&#160;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 30,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;USD 10,000 (EUR 8,937) *&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;USD 4,500 (EUR 3,947)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,582&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 107,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 92,680&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 67,828&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,787&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,051&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;*Translated at the currency exchange rate prevailing on the transaction date&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Contract balances:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,758&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 92,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Contract liabilities include advances received from the Group&#x2019;s license and collaboration agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;More than one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 107,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 92,680&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade receivables are non-interest bearing and are generally settled within 30 to 45 days.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, the Group had two collaboration partners (2022: two) that owed 100% (2022: 100)% of all the receivables and contract assets outstanding. There were two collaboration partners (2022: one) with balances greater than 10% of the total amounts of receivable and contract assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;The nature of expenses recognized in the functional categories of the statement of operations are as follows:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.2 Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,159)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,734)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,891)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (139,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,331)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,398)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,874)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,425)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,672)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,992)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,295)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,850)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,948)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,085)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,918)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,986)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (238,195)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (183,993)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (124,366)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, cost of sales mainly decreased compared to the same period of 2022 due to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them (refer to Note 6 for further information). Additionally, in the prior year, the Company recognized a higher impairment of assets held for sale (refer to Note 5 for further information). Personnel expenses increased mainly due to increased workforce in the manufacturing organization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.3 Selling and distribution expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,029)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,425)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (45)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (336)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (417)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (424)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,743)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,817)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,912)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, selling and distribution expenses increased compared to the same period of 2022. The increase was primarily attributable to higher personnel expenses mainly related to the satellite offices in Belgium and the US.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.4 Research and development (R&amp;amp;D) expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (232,292)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,982)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,126)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,733)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,259)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,539)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,666)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (539,786)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,587)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (347)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,069)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,287)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,291)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,591)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,252)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (815,907)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (62,550)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (115,724)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;During the year ended December 31, 2023, research and development expenses increased significantly in comparison to the same period of 2022, as the prior period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;38,533k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group&#x2019;s committed capacity at Novartis (see Note 3.8 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR 25,059k. The net effect of these two events resulted in an overall gain within the Third-party services category. The period of 2021 was largely impacted by the Group&#xb4;s CVnCoV program. These expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception through December 31, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from the German Federal Ministry of Education and Research (Bundesministerium f&#xfc;r Bildung und Forschung, or BMBF), the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.7 for more information on amounts recognized from this grant in the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period (refer to Note 10 for further details).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.5 General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,393)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,996)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,306)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,853)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,353)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,875)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,669)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,920)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,160)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,360)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,703)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,137)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,508)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (100,402)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (104,178)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (91,758)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, general and administrative expenses decreased in comparison to the same period of 2022. The decrease was primarily attributable to less personnel expenses due to lower workforce in the corporate service functions. Others include mainly expenses for D&amp;amp;O insurance and allocations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.6 Expenses by nature&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The nature of the expenses is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (94,655)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (99,924)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (113,422)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (278,542)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (121,873)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,767)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (708,636)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,501)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67,905)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,528)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,381)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,356)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,232)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26,641)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,229)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,948)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,085)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,666)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,160)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,415)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,170)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,156,247)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (353,539)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (335,760)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We refer to Notes 3.2 - 3.5 for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.7. Income from release of governmental contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the withdrawal of the EMA regulatory approval application for CVnCoV, in October 2021, CureVac recorded in 2021 &#x201c;Income from release of governmental contract liabilities&#x201d; amounting to EUR 574,502k, which is explained further below. There was no such event in 2022 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Advance Purchase Agreement with European Commission &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 30, 2020, CureVac entered into an Advance Purchase Agreement (APA) with the European Commission (EC), acting on behalf and in the name of all Member States of the European Union. The APA provided for the advance purchase by the Member States of 225 million doses of our SARS-CoV-2 vaccine. In order to support our accelerated efforts to develop a safe and effective vaccine, the APA provided support to our operations in the form of up-front payments. The first up-front payment of EUR 450 million was paid by the EC on behalf of the Member States and was included in contract liabilities as of December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The second up-front payment would have had been due after the submission of the interim data package to the EMA in view of obtaining EC marketing authorization for CVnCoV. The up-front payments were designed to support the development and prepare the commercial supply of the vaccine. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would return the unspent amount of the up-front payment. In the context of the APA, &#x201c;spent&#x201d; means either costs occurred, or commitments made in relation to the purpose as set out in the APA. CureVac demonstrated that the up-front payment was used in accordance with the contract and no repayment was required. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As described above, CureVac recognized the consideration related to its delivery obligations, existing at the outset of the arrangement, as contract liabilities. Upon the automatic termination of the APA, the ability for CureVac to satisfy the contractual performance obligations of the arrangement ceased and the EC ceased to have the ability to exercise its rights for performance by the CureVac. As such, the substance of the arrangement changed from a revenue contract to that of a government grant. Due to the material magnitude of the amount, its non-recurring nature and to better enable comparability to past performance and predictability of future performance, CureVac recognized the EUR 450 million into income in an additional line item &#x201c;Income from release of governmental contract liabilities&#x201d; in the 2021 statement of operations. The &#x201c;spent&#x201d; amounts incurred by CureVac, and which demonstrate use of the up-front payment, have been included in &#x201c;Research and development expenses&#x201d; (refer to Note 3.4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, CureVac was required to transfer, upon EC&#x2019;s request any raw material and primary components paid for with the up-front payment and not used as of the termination date. Should the EC request any raw material and primary components or should CureVac successfully sell some of these, an applicable portion of raw material, primary components or proceeds would be remitted to the EC. This agreement expired at the end of 2022 and an amount of EUR 4,114k was accrued as &#x2018;other liabilities&#x2019; as of December 31, 2022 for the related amount due to be remitted to the EC. As of December 31, 2023, the accrued amount of EUR 4,114k was paid to the EC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;German Federal Ministry of Education and Research &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2020, the Company announced that the German Federal Ministry of Education and Research (Bundesministerium f&#xfc;r Bildung und Forschung), or BMBF, a German government-related entity,had established a grant to support the development and production of its COVID-19 vaccine candidates. In July 2020, CureVac applied for this grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2. The grant amounted up to EUR 252 million and the payments were contingent to reaching predefined milestones. Based on the terms and conditions of the arrangement, the Company assessed the arrangement as having two components: a grant component and a supply component which were separated. The amount attributed to the supply of future deliveries was determined based on the relative stand-alone selling price of the vaccine observed in similar arrangements and is presented in contract liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reached all the predefined milestones for 2020. Due to the withdrawal of the EMA regulatory approval application for CVnCoV in October 2021, CureVac was not able to reach all predefined milestones in 2021. From 2020 to December 2021, CureVac received a total of EUR 196.3 million. In November 2021, CureVac notified BMG of the inability to supply CVnCoV, triggering the automatic termination of the supply agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Consistent with the rationale and treatment described above under the APA with the EC, the substance of the supply component of the BMBF arrangement changed from a revenue contract to that of a government grant and thus, consistent with the presentation of the contract liabilities under the APA, CureVac recognized the EUR 124 million in 2021 from the BMBF agreement as income in the line item &#x201c;Income from release of governmental contract liabilities&#x201d; and the corresponding expenses have been included in research and development expenses. The remaining amount of EUR 65 million, not related to the supply component, was reflected as grant income in &#x201c;other operating income&#x201d; in 2021. (Refer to Note 3.8).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.8 Other operating income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Other operating income relates to:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation for CMO/Materials transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reimbursement claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Grants and other reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 67,702&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,932&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,151&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022, CureVac AG and GSK amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exited its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensation mainly consists of consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in &#x2018;Compensation for CMO/Materials transfer&#x2019; in other operating income during the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2023, 2022 and 2021 income from grants with government agencies and similar bodies resulted from the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;German Federal Ministry of Education and Research&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed in Note 3.7, in 2020 the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The Group recognized grant income of EUR 65,218k from this grant. As the grant ended in 2021, no such income was recognized in 2022 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2024, CureVac has been granted the positive research allowance notice by the German Federal Ministry of Education and Research for the years 2020 - 2026. The research allowance is an instrument that provides tax relief for research expenditure by companies subject to tax in Germany - regardless of size, legal form and sector - and is intended to create incentives to invest in R&amp;amp;D. During the year ended December 31, 2023 the Group recognized EUR 3,064k for R&amp;amp;D projects as other operating income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Coalition for Epidemic Preparedness Innovations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Coalition for Epidemic Preparedness Innovations (CEPI) is an innovative partnership between public, private, philanthropic, and civil organizations, launched at the World Economic Forum in Davos in 2017, to develop vaccines to stop future epidemics. CEPI&#x2019;s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (i.e., Disease X).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2019, CureVac entered into a partnership agreement worth up to USD 34,000k with CEPI to further develop CureVac&#x2019;s The RNA Printer&#x2122; prototype. Under the three-year partnership agreement, CureVac used its mRNA platform for the preclinical development of a Lassa virus vaccine (a high-priority disease on the World Health Organization R&amp;amp;D list), a yellow fever vaccine and CureVac&#x2019;s rabies virus vaccine. Funds are received semi-annually in advance, to cover costs for the next six&#160;months. These payments are allocated to the agreed and signed statements of work. Management concluded that the arrangement should be accounted for by analogy to IAS 20.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac is required to use reasonable efforts to achieve certain development milestones and is responsible for conducting certain clinical trials. In the event of an infectious disease outbreak, where such outbreak can be addressed by a Lassa virus, SARS-CoV-2 or future vaccine developed under the agreement, CureVac must manufacture such vaccine for use in the area affected by the outbreak on economic terms that satisfy CEPI&#x2019;s equitable access guidelines or otherwise allow CEPI or a third party to supply such vaccine in the affected area.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac is required to grant certain approved manufacturers all necessary rights to use certain of CureVac&#x2019;s pre-existing IP and IP developed under the CEPI Agreement to further develop CureVac&#x2019;s automation solution and manufacture products for the treatment of certain diseases in geographic areas where there is an outbreak on economic terms that satisfy CEPI&#x2019;s equitable access guidelines. CureVac must provide all necessary commercially reasonable support to such approved manufacturers to facilitate such efforts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac solely owns all IP developed under the CEPI Agreement but is required to obtain CEPI&#x2019;s consent prior to exploiting any IP developed under the CEPI Agreement if such exploitation is in conflict with or goes against CEPI&#xb4;s mission or policies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that CEPI terminates the agreement, CureVac will grant CEPI a license under CureVac&#x2019;s background IP and IP developed under the agreement to, among other things, develop and use CureVac&#x2019;s RNA Printer for use in treating certain infectious diseases and to manufacture products developed under the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2020, CureVac and CEPI entered a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, CureVac recognized the reimbursement of approved expenses of EUR 3k (2022: EUR 42k; 2021: EUR 688k) as &#x201c;other operating income&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, EUR 305k in grant funds received have been deferred and are presented within other liabilities (2022: EUR 309k). Following the completion of the partnership agreement of February 2019 between CureVac and CEPI in May 2022, CEPI requested a partial reimbursement of the unspent funds up to USD 1,000k. Those were reclassified from other liabilities to trade and other payables as of December 31, 2022. As of December 31, 2023, these unspent funds were repaid to CEPI.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Bill &amp;amp; Melinda Gates Foundation (BMGF)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;BMGF finances, in the form of grants, various programs that CureVac operates for the development of vaccines, hence promoting and accelerating the development of CureVac&#x2019;s technology platform. Through its equity investment, BMGF supports mainly the development of CureVac&#x2019;s technology platform including the construction of a production plant in accordance with the GMP (Good Manufacturing Practice) standard on an industrial scale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2015, CureVac entered into a Global Access Commitments Agreement with the Bill &amp;amp; Melinda Gates Foundation pursuant to which the Company is required to take certain actions to support the Bill &amp;amp; Melinda Gates Foundation&#x2019;s mission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2016, in connection with the Global Access Agreement, CureVac received a grant of USD 653k (EUR 614k) in funding for the development of a vaccine for picornaviruses. In November&#160;2017, also in connection with the Global Access Agreement, the company received two additional grants: an amount of USD 1,000k (EUR 852k) was received for the development of a universal influenza vaccine and an amount of USD 800k (EUR 673k) was received for a malaria vaccine. In August&#160;2019, the Company received a second payment for the universal influenza program amounting to USD 540k (EUR 486k). In November 2020, the Company received a third payment for the universal influenza program amounting to USD 322k (EUR 280k). In November and December 2020, the Company received further payment for the malaria program amounting to USD 1,449k (EUR 1,208k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023 CureVac recognized EUR 66k (2022: EUR 167k, 2021: EUR 488k) for services as other operating income. In addition, EUR 217k were repaid in 2023 to the Bill &amp;amp; Melinda Gates Foundation due to the closure of one project. The grant is released on a cost occurred basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2023, EUR 1,430k in grant funds received have been deferred and presented within other liabilities (2022: EUR 1,712k).&lt;/p&gt;</cvac:DisclosureOfNotesToConsolidatedFinancialStatementsTextBlock>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_IFouQAZpqUiqSovtbYyINQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 74,298&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Germany &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Boehringer Ingelheim &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 919&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 102,990&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 67,420&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 53,758&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_tqNpKUkXKE2OcFOuv70evw"
      decimals="-3"
      id="Tc_MfLAw8co30G2QMnTBe6N2w_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">74298000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_BNdhSUOAIEaFWRVUEBmbrQ"
      decimals="-3"
      id="Tc_vSKntqhg60mpA8GaHYuJFw_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">62263000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_RMBBdxirVU2J7HBkSJTreA"
      decimals="-3"
      id="Tc_xI1A3gnE4U6Pys6DY-LXfQ_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">47128000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_5WdzkEBG3U2RD2KTauKIHw"
      decimals="-3"
      id="Tc_e2ARdi8dGU2_VsThKeYUVg_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26003000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8zx9Bh4e0kKH3oVw23ubCw"
      decimals="-3"
      id="Tc_oqTVUh85CkixmDMjmSQpfw_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1770000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_9-AN-Kf0kE-sEE04nCFBVw"
      decimals="-3"
      id="Tc_5w8qB93B9EKtiHLdqxSBTw_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1787000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_oqWek3tQ0kWMDoro7ubGQA"
      decimals="-3"
      id="Tc_LSKQVQPwXUOhvgXjkrhNWQ_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1197000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_8MAty4A8qE6RjZSge37rBg"
      decimals="-3"
      id="Tc_hXJRYo4nmES-2cA46TxdPA_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">919000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ye3SzgaAhUuYYFA2QScpkg"
      decimals="-3"
      id="Tc_NPkGfcboU0iCycUoUA-mlA_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3370000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_5-Lg5t6vPU2ChcpJcmCALQ"
      decimals="-3"
      id="Tc_ZhrMfn34rU68kbVvsSJUPw_11_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5425000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_GeographicalAreasAxis_cvac_CountriesOtherThanBelgiumGermanyNetherlandsAndSwitzerlandMember_ifrs-full_MajorCustomersAxis_cvac_OtherCustomersMember_1iVbqSw630CraOQMAg_n6w"
      decimals="-3"
      id="Tc_OQ8fMuYHM02FdpdWtbCelg_13_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_F67rk625S0CKRXA0xBDoAQ_14_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">102990000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_mSngo5i0R0ystLIGl-9Eeg_14_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">67420000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_m9ws-S-hF0mwDHySRDzybQ_14_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">53758000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_axX3OEHMmkqd9Ok2GiGCCw"
      decimals="-3"
      id="Narr_iagVXZ_M8UaS63dLTvwmOw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">31051000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WsnVoqdta0SqDA9Z3Yh5sQ"
      decimals="-3"
      id="Narr_Rlkn2Lm3TUGA3EcHs-zFjw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">44787000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember_WxiupYvXpUCZcGSWCISs4A"
      decimals="-3"
      id="Narr_WCTCSylmFkufPyggQ82HpA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">79827000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ETMXkobFKEy02hSV09o2aw"
      decimals="-3"
      id="Narr_L6kawoZOiEuOtrNhHYJLtw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11395000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_LlIbA19tekq2L6F9XYlTsg"
      decimals="-3"
      id="Narr_DzuYELJ08EOuQJnIY5mIHA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19571000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_b7TNjQEttE2_PmjG1h3w9Q"
      decimals="-3"
      id="Narr_1PIUHvpDUkSoNiWR3LRvaA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22706000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_d3CfPh5Ro06AwvuG4ee_dw"
      decimals="-3"
      id="Narr_AUCoNEXAj0uTx6VBJ9I4Ag"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11312000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_0BY17joY10aei1gwG_rArQ"
      decimals="-3"
      id="Narr_i8xgRSJ5u06M6rJNcw9kMQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3062000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_beG4kI-_-EObUq60yy9jHQ"
      decimals="-3"
      id="Narr_y3hesRd2iEyhqLiKALKzfw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">457000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_7_1_2020_To_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b2Vp5VUFV0ur7dOqZSCNYg"
      decimals="-3"
      id="Narr_uuvTrs27rk-LLTfspUgh_w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">150000000</ifrs-full:ProceedsFromIssuingShares>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA"
      decimals="-3"
      id="Narr_PzMUYFjEa0eknV1Blk-RFQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">120000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation
      contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA"
      decimals="-3"
      id="Narr_fdngwfUmh0CNDro7LTF4YQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">30000000</cvac:AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation>
    <cvac:AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments
      contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA"
      decimals="-3"
      id="Narr_bIEvY7SyIUKrSCjXcOufNg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">320000000</cvac:AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments>
    <cvac:AmountEligibleToReceiveAsCommercialMilestonePayments
      contextRef="As_Of_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_K1YMq0Ml4EKUCrw5NVgUiA"
      decimals="-3"
      id="Narr_JmJ9A_lldEutp8qN5DrWnw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">380000000</cvac:AmountEligibleToReceiveAsCommercialMilestonePayments>
    <cvac:NumberOfPerformanceObligations
      contextRef="Duration_7_1_2020_To_7_31_2020_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b2Vp5VUFV0ur7dOqZSCNYg"
      decimals="INF"
      id="Narr_MxT3sbVLpUeBcUSNAKaRKw"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">2</cvac:NumberOfPerformanceObligations>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_7Ew6bGtW7U-tbNE2PXrHEQ"
      decimals="-3"
      id="Narr_TEW_0r7Ll0GoJydnNBMytw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">27740000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_iy1v_ExV0UmIJE_JDCu52A"
      decimals="-3"
      id="Narr_9CSGCp0ATkeX8C3c4rMEhw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41379000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_4_30_2021_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_Uqq6tqDywUKR7NfMQRtxqw"
      decimals="-3"
      id="Narr_3IyDDuom3UqZW9jxcOWhTg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">75000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_pZPakGLA-kuhoS52uwEr1w"
      decimals="-3"
      id="Narr_9xYep9YZNkexvUVeOm2ZOg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10530000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_GlaxosmithklineCovidAgreementMember_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_eY2mumkXxUm95YVOlQS_oA"
      decimals="-3"
      id="Narr_pLTM9EMEKk27lcixsaSLfQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20884000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_IkXEAQpU6E-CCqDrHRQ4QA"
      decimals="-3"
      id="Narr_SDILTMEiNEqDvYOBK3S3Lg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">30000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:OptionFeePayment
      contextRef="Duration_8_1_2014_To_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_uR8Rb-zZ-0W5xnOW1rqrfQ"
      decimals="-3"
      id="Narr_zILOH24IYkWuZVPamMAv8w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5000000</cvac:OptionFeePayment>
    <cvac:AdditionalDevelopmentMilestonePaymentsReceived
      contextRef="Duration_8_1_2014_To_8_31_2014_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_uR8Rb-zZ-0W5xnOW1rqrfQ"
      decimals="-3"
      id="Narr_YllUD57LXU2PiHFcbHkC5A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7000000</cvac:AdditionalDevelopmentMilestonePaymentsReceived>
    <cvac:UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_UNDEvAgHeEiRXFi1vbQ4Ng"
      decimals="-3"
      id="Narr_W4oC6MSCRUWzENHzETA5YA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14003000</cvac:UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement>
    <cvac:IfrsOptionFeePaymentIncludedInContractLiabilities
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_Tj5GLbNT3kSBwyxRAfJfVQ"
      decimals="-3"
      id="Narr_pl7tj6eUa0iWxx8kWzgv_w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5000000</cvac:IfrsOptionFeePaymentIncludedInContractLiabilities>
    <cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_Tj5GLbNT3kSBwyxRAfJfVQ"
      decimals="-3"
      id="Narr_nUKwOW_36U-o56PWWtdyrg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7000000</cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_UNDEvAgHeEiRXFi1vbQ4Ng"
      decimals="-3"
      id="Narr_icw2KySuYUWzh0gDxkKmHw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember_MM2GgEv-80-KyXB__YMNuw"
      decimals="-3"
      id="Narr_tyH57qhOoUSaNhEGO1HtAg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_BoehringerIngelheimMember__cAQp-UsNEC2DWQx2cXz0Q"
      decimals="-3"
      id="Narr_bHjSIs94fkqCsSjNEbdpuw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26003000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_11_30_2017_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_HShGdT13tU-b1m7Ylf054A"
      decimals="-6"
      id="Narr_J7nF-EGGJk-RELzBRU1CEQ"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">3000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Z1OBdDkToEK9908Tmo7-Sg"
      decimals="-3"
      id="Narr_SS726DfhHECc_cWEZHz_vg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5425000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_aZBsDHmyoEK9afaiu5dSRQ"
      decimals="-3"
      id="Narr_3-7XsUXtYUKaglSubymL6A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3370000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_cvac_CrisprTherapeuticsMember_Oxw0JrIpY0G78r49kJmAPQ"
      decimals="-3"
      id="Narr_kiNyD8U8w0GLIHpmveC20g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">919000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2019_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember__SZm_EveFkuat9TplxJ75w"
      decimals="-6"
      id="Narr_jtFgZqe1ykaEpbrjmq2srw"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">20000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_12_31_2019_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember__SZm_EveFkuat9TplxJ75w"
      decimals="-6"
      id="Narr_IEZNVC1L_UCyaP6zPMZHiA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_SxzE48-JZ0GVSklXpGPGZA"
      decimals="-3"
      id="Narr_ME4ZQmrmIkiMgfKgSPIXdA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1197000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_Fzr32Hw5zkuxkQLHVRVGAQ"
      decimals="-3"
      id="Narr_-aRb6CDx3kyROKzo4Slv5A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1787000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_CollaborationAndLicenseAgreementMember_srt_CounterpartyNameAxis_cvac_GenmabMember_rZxpRnG9XUK0LeJgU3D9Fg"
      decimals="-3"
      id="Narr_ZSHT778WSEG9aK2KFusIlg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1770000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_5G8AUmQg2kqy96_P5DvqdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:24.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract liabilities at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized&#160;from&#160;upfront and milestone&#160;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 30,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;USD 10,000 (EUR 8,937) *&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;USD 4,500 (EUR 3,947)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,582&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 107,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 92,680&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 67,828&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,787&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,051&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b8EFZRIMq0WCtvwfKe4gIw"
      decimals="-3"
      id="Narr_8n30FeBV-EKPRLu-GV8-BA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">220000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_nC4KCpY88UGym-D27dL6Fg"
      decimals="-3"
      id="Tc_TFYUABimN0WR_S4T6DsQcA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">102804000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_b8EFZRIMq0WCtvwfKe4gIw"
      decimals="-3"
      id="Tc_SPhex_Xng0m0N-iv_UJe_g_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">88715000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_EJnK4qeQukWwruVzej1OHA"
      decimals="-3"
      id="Tc_2iTA2fTVBUa1vC1LrnwrBQ_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">51728000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_dQAt4xUTeEa7rdqV3nh2dg"
      decimals="-3"
      id="Tc_2JbZeDN3V0GcCE8S3VGaCQ_5_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42690000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_VRui_vZPnUujh6ZiBB2PSA"
      decimals="-3"
      id="Tc_QUfYT1XL8UOS-IqeFG8vDg_5_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">29089000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_HfoXp3Ph3E6zl6AvXTfb-g"
      decimals="-3"
      id="Narr_Jea8Tf89BUqdf9jfS757JA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">30000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_EHc6gwQXD0SOYI6THi9OXg"
      decimals="-3"
      id="Tc_jIpFMdlLX0CiF-artEZ46A_6_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14003000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg"
      decimals="-3"
      id="Narr_GOB91vcpXU60qIB1IbdNXA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg"
      decimals="-3"
      id="Narr_SQaYkG7SAkWa54auJh-xfw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8937000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_fV8dgKI9A0qDluOP4s-fcA"
      decimals="-3"
      id="Tc_q_M8ZNPLWkGLIvorktvXTA_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3575000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_sOkfjVgLD0SDRC2GCDVCeg"
      decimals="-3"
      id="Tc_yPsef0xOl06x0UOtN1k8ew_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2383000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3-k7Yjy3h0SK1bXLY0SdIA"
      decimals="-3"
      id="Tc_dyGE6rJmW0KyCAwVC-VjaA_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1787000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_8UvD_28teUGxzHNuaZqFzg"
      decimals="-3"
      id="Tc_0G8_ZuPu60GwOPleEE7F3w_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1787000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_BjoLbqhzlEu6HrZ0ubsedQ"
      decimals="-3"
      id="Tc_yeTzfgfWuEySAgySEKwCXw_7_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1192000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw"
      decimals="-3"
      id="Narr_Ti2oxCceIk2jNDXC_Dyqpw"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">4500000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw"
      decimals="-3"
      id="Narr_nVQuKS3dhUGXU-dqJ0Bh4g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3947000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_VDgvtxQGnUWTC1YHHYEPSQ"
      decimals="-3"
      id="Tc_ohGi8gH3w0KRpXbjOSzsVg_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">929000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_q0-20TAGSky_X8b96Cd-Aw"
      decimals="-3"
      id="Tc_x6s7J1jJFkmBzTLtEKaZRw_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1582000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_zGcglSxVGUO78S8LUIsdFQ"
      decimals="-3"
      id="Tc_9fw2a9G7iEKeYqXx6vuowA_8_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">310000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_BtRutl2rT0KKDhuHIfebvQ"
      decimals="-3"
      id="Tc_4-ocebYaq0-Oalfiv4X5sw_8_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">310000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_yBPoJBQs-0OaTLvr_QnFFA"
      decimals="-3"
      id="Tc_1rIUZLdnmkeCwtH3CnaGyg_8_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">770000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_CZ3BRhpvpkWS9sN4DW6Ouw_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">107308000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_B3BM_VrsykqZYqVcKKY7Wg_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">92680000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_XgEoocaX10WVhK_ij38Ukg_9_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">67828000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_EkrAfLMm8U6WQAf-xp4HVA_9_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">44787000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_LNHYLl-S3kex0CdpJvhlCA_9_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">31051000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_pI19jb36WEeXKFp6cO4Z0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,758&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 92,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_UYAdhzzVOkidkySM2ifOww_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6295000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_2MRNU2V98kiGS9GrKvlgWw_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14326000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc__4lSMT49EU2aw08C6j2iZA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2707000</ifrs-full:CurrentContractAssets>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_aFdMNsq-WkyNBJs-Wv9Pgw_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2758000</ifrs-full:CurrentContractAssets>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_Pnq1UKNXgEq2oxeAv812xA_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">107308000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_Aib7YnxJIkS19i4BRdNvzQ_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">92680000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_R0lLaepF4k6jPR9KKZ-ltA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;More than one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 107,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 92,680&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A"
      decimals="-3"
      id="Tc_oLj14qB7LUuJUwNg2cTxoA_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">34759000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ"
      decimals="-3"
      id="Tc_kApRhjcUtEapWTqmt1_mTQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">44580000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember_ihjeHuLIPk2tQ0IJ5csIrg"
      decimals="-3"
      id="Tc_R4BOCE7ZkkK9P5UuzlLiMA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">72549000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearMember__BM_BXDhyESvodEXrE5DVA"
      decimals="-3"
      id="Tc_F2t6KzOWY0KQnkQlZ5iaHA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">48100000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_yzdTvQcjp0KWAzIjoSHZ6w_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">107308000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_5CoyuMfTqkagHzjWc9XRIg_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">92680000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <cvac:NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="INF"
      id="Narr_5pMKwyxcI0auW7EOH382Mw"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">2</cvac:NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding>
    <cvac:NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="INF"
      id="Narr_CrBxiFaFGkaxkxS2WE2llw"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">2</cvac:NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding>
    <cvac:NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="INF"
      id="Narr_BQA5YNBJ8UyHts5cnsMzLQ"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">2</cvac:NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets>
    <cvac:NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="INF"
      id="Narr_UbrmoUbpGkqBEwVv-aubUw"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">1</cvac:NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Group_LwtXsnMciUCqqZu7eH8ELA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,159)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,734)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,891)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (139,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,331)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,398)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,874)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,425)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,672)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,992)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,295)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,850)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,948)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,085)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,918)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,986)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (238,195)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (183,993)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (124,366)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,029)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,425)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (45)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (336)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (417)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (424)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,743)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,817)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,912)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (232,292)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,982)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,126)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,733)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,259)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,539)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,666)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (539,786)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,587)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (347)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,069)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,287)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,291)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,591)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,252)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (815,907)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (62,550)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (115,724)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,393)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,996)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,306)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,853)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,353)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,875)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,669)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,920)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,160)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,360)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,703)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,137)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,508)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (100,402)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (104,178)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (91,758)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_AZx7f0emFUmAlTMe7BpaQQ_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22159000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_p7cNWxPmbUS6D3PGZRNRBg_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">27185000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_IlzhbjJXTkGcRCGiEN7Xsg_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37734000</cvac:PersonnelExpenses>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_4saV7DxKHE6sWyvvr993IQ_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">46250000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_RF8t3Y-6qUOIl0E2HtXDtg_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">88891000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_W5rjb2KIJECdVfpA9Ud2Aw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">59641000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_BGnS-DlM2EyNRIpSiUmOww_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">139975000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_03If7Ooh4ky4M9X_PUKENw_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">32331000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_o047g8-oBkGbaVQhjfXFsw_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9398000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_F9jq5mRFNUe02PjgRV8Wng_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2874000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_vSUKL9_58E68pajVbA0W_A_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2425000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_-pI5_S3ZXkS2ulDnzHBB2A_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2672000</cvac:MaintenanceAndLeaseExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_9NmwIXdgGk21ogzLnOYYlQ_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3992000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_fm6XkLBMJUi0l27pUSLsAA_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6295000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_iygTgcCf_0Snh0OaxqiL3w_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4850000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_1eS2IU-2XkuLIasgJcNFtw_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22810000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_VLgX9Ofvnk2a3kdIBSi4Xg_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24948000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_WV0KiE6EnEKHW8ORkIXTsQ_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8085000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_I07WFhKOLUKxJGTK4O7Ugg_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">135000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_6G9f-nKiEkyoBuNJqly0KQ_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1918000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_106ZB72Uxkmu6_Sz90_8iA_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1986000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_YmzOqZoILE-5IqOZrAtpVA"
      decimals="-3"
      id="Tc_sK45siVg8k6wHgZtG39mHA_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">238195000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_ve5zNvVA4kePv7gWBHUMqA"
      decimals="-3"
      id="Tc_-SWgJ1H93Eqp7ICrg9iZXg_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">183993000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_LQojJQ5FBU20mQqfqVJuzQ"
      decimals="-3"
      id="Tc_vu9F9QdDf06aN0kl7AbBWg_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">124366000</ifrs-full:ExpenseByNature>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA"
      decimals="-3"
      id="Tc_u8f3oop4gkK5wg-yKu7eWw_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1369000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg"
      decimals="-3"
      id="Tc_nTfaK9gE-U6e5BaRSAEePg_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2029000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg"
      decimals="-3"
      id="Tc_l6nxgMwJvku-xQ2AmbB4tA_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3425000</cvac:PersonnelExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA"
      decimals="-3"
      id="Tc_CbArIvCJ_Ua7iicCP_QzZg_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg"
      decimals="-3"
      id="Tc_JOaPzJwhhki4k7Y1dFNa4w_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">35000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg"
      decimals="-3"
      id="Tc_qxKgvTw4qk-QFBJQ1omslw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">45000</cvac:MaintenanceAndLeaseExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA"
      decimals="-3"
      id="Tc_wO7LDLIUd0yHgwPjd8piGQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">86000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg"
      decimals="-3"
      id="Tc_BhOEKn3zzUyUJn8aX-o-BA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">336000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg"
      decimals="-3"
      id="Tc_FQ0B8lZ5jUOEdPEsfucRog_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">18000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA"
      decimals="-3"
      id="Tc_QhCU2O_hCkOjrJm-0jV57w_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">287000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg"
      decimals="-3"
      id="Tc_TTaggNPNXUWGt1Q7DUX4cQ_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">417000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg"
      decimals="-3"
      id="Tc_yt_h6PlfIUmq-IUmnUm-Fg_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">424000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_kKSwHlPV_UWJEfZZwSiDlA"
      decimals="-3"
      id="Tc_zo8uAdR31UeV74ht0elIaQ_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1743000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_D5Cl4d4iIEGDDckiRv5vXg"
      decimals="-3"
      id="Tc_GYx-XZTPwUqJFoSVLJXQaA_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2817000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_4LWWF3wA7067wum8bir7xg"
      decimals="-3"
      id="Tc_ZBWBgebFnUmd1-Q6ebA4fQ_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3912000</ifrs-full:ExpenseByNature>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_azF26qTB5UC_8NloPoffuw_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">232292000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_L0KUjZutm0KXgt62OfwMdA_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">32982000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_nMF-ghd2Tk6eyKlphKxW7A_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19126000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_Lyi0gi4KOUm1iLFDb9Fg2g_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">33733000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_rmfwUYiSzUSBZeqabWpcjw_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">33944000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_PpIjBu49XEmVYG-wlW2zgA_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">43267000</cvac:PersonnelExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_oJHFW2AIWEGk1zsxyluPkg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4259000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_wVjFChlyekCC1-Z09jYNsw_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8650000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_hXSIdjyqREe2-9YDxTtGdg_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8539000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_UYP3sLnd5EGwQq9Mv6lIqA_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3199000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_EyMCn0TbPE2k_pNePMF_GA_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3813000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_Cq42S9HAQ02nJdYNRS4F2w_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6666000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_56-eW5OweE2we8jUCgvVRw_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">539786000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_eKPKasBx0Eir8uJTe_mm_g_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-20499000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_y6A9fMvhBkiwtMIvWIkGyw_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28587000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_jOFTo8LWeEaSkhpXF2hhLg_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">347000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_cSGilp7fZ0u9TwLuKpeujA_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1069000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_p7uu8uYXhkKieoyHYsZwSw_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7287000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_5m5SjAbIMk68lAcJSXZyjg_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2291000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_6Xhu7MUdAE6bQeroHwoJxA_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2591000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_pkMlKGlvkEaIdF9HB5jrnQ_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2252000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_RB_yq3jVRU6oqzAtVzlpIw"
      decimals="-3"
      id="Tc_bpmQaEVHoEuy4B9ylzKivA_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">815907000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_nKLecuVsZ0ymYH0WNLMfUA"
      decimals="-3"
      id="Tc_MH85bdyhlU6rgljqapbGdg_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">62550000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_gpxkKaqy3EupayhGRztKqA"
      decimals="-3"
      id="Tc_9Kusb-6P0EKeIVIq7NGMgQ_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">115724000</ifrs-full:ExpenseByNature>
    <cvac:ReversalOfProvisionForOnerousContracts
      contextRef="As_Of_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_q_UBt-6xnEai2whg5OLb5Q"
      decimals="-3"
      id="Narr_rYFdEAaVb0iAU2YWonnK-Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">38533000</cvac:ReversalOfProvisionForOnerousContracts>
    <cvac:IfrsProvisionForLossOnContracts
      contextRef="As_Of_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_q_UBt-6xnEai2whg5OLb5Q"
      decimals="-3"
      id="Narr_IFjl0-Z5T0ygIFKEfeH27Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">25059000</cvac:IfrsProvisionForLossOnContracts>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"
      decimals="-3"
      id="Tc_hi6H4x8qcEWNpm88c_zgjg_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37393000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"
      decimals="-3"
      id="Tc_2U94WxfzXkOxfZgFfJUnpQ_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">36765000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"
      decimals="-3"
      id="Tc_fBz_rxHR70yVnpbn6DW-NQ_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28996000</cvac:PersonnelExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"
      decimals="-3"
      id="Tc_iZwMiiQ5vUKKT7IptitUGQ_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4306000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"
      decimals="-3"
      id="Tc_89pAP-qyckyIg3Vy_jddyQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5853000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"
      decimals="-3"
      id="Tc_K2KE8VCH7kaJfKO89ydS-g_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5353000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"
      decimals="-3"
      id="Tc_m3YKzqePK0KIJYPpwQceLA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28875000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"
      decimals="-3"
      id="Tc_Dk2DFw4AS0Ckvqqz3M84aQ_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">27669000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"
      decimals="-3"
      id="Tc_yU-Cgxr74EOEdd8_XVpI8Q_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">29920000</cvac:ThirdPartyServiceExpenses>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"
      decimals="-3"
      id="Tc_dpZrGQXa60-vehf6LlP3Xw_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9230000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"
      decimals="-3"
      id="Tc_jSdeSrmaSUS9rV8zSzVLiA_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10394000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"
      decimals="-3"
      id="Tc_nCC26czCQkeylT0-VCfqag_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10160000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"
      decimals="-3"
      id="Tc_ODHCc5e1wEiIf25qJ0q9Wg_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8895000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"
      decimals="-3"
      id="Tc_PEs2DO2gzEq0VhHO2MN1Zw_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11360000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"
      decimals="-3"
      id="Tc_d1AYXowyVkmESXxVn4DvnA_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">13821000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"
      decimals="-3"
      id="Tc_Qzzp5FH0sEWfGl7IfWkRiQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11703000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"
      decimals="-3"
      id="Tc_hksEAnwwKEWllkoq1ee_0Q_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12137000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"
      decimals="-3"
      id="Tc_L0cmU6urDEmmBZcU8ZUnPg_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3508000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_-eHaCq1KLEerm1nyMllXZg"
      decimals="-3"
      id="Tc_dRZcSZVDTE-LC5W7s58r7A_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">100402000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_tFly0SzQD0W1kIjoNfNYrA"
      decimals="-3"
      id="Tc_8rOy2b5Mn0arFRa9IWBxzQ_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">104178000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_y6_RcPnjvUOdmoxsuvgEbg"
      decimals="-3"
      id="Tc_0IoZLKxL2kGP79LsvGlD8A_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">91758000</ifrs-full:ExpenseByNature>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_PCXqPT01rk6y5AkVera5AA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The nature of the expenses is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (94,655)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (99,924)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (113,422)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (278,542)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (121,873)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,767)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (708,636)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,501)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67,905)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,528)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,381)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,356)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,232)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26,641)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,229)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,948)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,085)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,666)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,160)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,415)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,170)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,156,247)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (353,539)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (335,760)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_WQo6Cuk8CUahC9gcyQOCBw_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">94655000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_F6CmkqMOjkOOQFicKoVijw_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">99924000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_eVPjcw9weEW8f4s_AkFkAA_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">113422000</cvac:PersonnelExpenses>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_VkGXgeYV7kChGe9OHGNqeQ_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">278542000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_AlrSSCNVhkazwvu3fNUEUQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">121873000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_E2hEHGk8V0y09hhdIHgoGw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">78767000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_YpvUnJ3_wE-J9-1I-j-_kA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">708636000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_3VV9FxPCZUSQOjwcf493eA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">39501000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_kvYSCbak3UKHPmhHseOJGw_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">67905000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_khvHydw370aLuJ0Uh0GZqg_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7528000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_Sxs49JphN0OOLoRnHsRXSg_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9381000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_Q-g_7cZEwEKDxtuuHXSbzg_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15356000</cvac:MaintenanceAndLeaseExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_LmlkFQP-yUOR9aHwmNg6sA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17232000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_7peIeNcsjEWf56Rnh882Qw_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26641000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_AJW1N4tuzUOV-vwzklXFKg_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">27229000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_Qs0amL_q3keSxjcGnku_fg_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22810000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_KyKQV6TeB0uQ1YK3NpIjQg_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24948000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_8p1NvQxugkixIj7XiD7BzQ_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8085000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_3YWQxAw4IUO0HHsau5uyHA_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3199000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_ypzOqwA8okuo11-Un9hIwg_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3813000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_czdBMFL0yEumePBdZ8Kvww_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6666000</cvac:PatentsAndFeesToRegisterLegalRight>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_2NF2FQQ4_kuHTRbElTwt1A_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9230000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_gyWyTx4PNk2geGeQ1JNlwA_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10394000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_VshZIlK4LEmscIvHRCVkAw_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10160000</ifrs-full:ProfessionalFeesExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_QhH9Dj3meUCTPSnLqOOpFw_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14415000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_Z7oUGLYve0WkIMg1tJTVUg_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17064000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_KvF54vMtNU-UT9cr3mpeYg_11_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8170000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_VIONu1zcAEOVvlgiu_mnDQ"
      decimals="-3"
      id="Tc_2-ObkWeYYkapvdaWNYN31A_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1156247000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_1yYSxl06JE2jZGv1CqWQlg"
      decimals="-3"
      id="Tc_PXV4gpBCyEG20X5V0ADLqQ_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">353539000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_cvac_OperativeExpensesMember_Tnpah0clc0aoLchlW8OiOw"
      decimals="-3"
      id="Tc_a10nLrmj-EeUuGT_uGk8-g_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">335760000</ifrs-full:ExpenseByNature>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_10_1_2021_To_10_31_2021_a1WmAXnod02XXfLywgY6XA"
      decimals="-3"
      id="Narr_REjB00mQYUulfd5skFLFtQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">574502000</ifrs-full:RevenueFromGovernmentGrants>
    <cvac:NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement
      contextRef="Duration_11_1_2020_To_11_30_2020_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_dBuLkJzR8UGZKxJeLbvRJQ"
      decimals="-6"
      id="Narr_LYy43hTYyku8fyvAtBAKyg"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">225000000</cvac:NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement>
    <cvac:UpfrontPaymentReceived
      contextRef="Duration_11_1_2020_To_11_30_2020_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_dBuLkJzR8UGZKxJeLbvRJQ"
      decimals="-6"
      id="Narr_NPIhA8vyQUONkAwqLstrpA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">450000000</cvac:UpfrontPaymentReceived>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_UkHTlmAHJkSss_TraYDEdw"
      decimals="-3"
      id="Narr_7myTAuk3-EOfwfR_CWUYUA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</cvac:MaximumGrantToBeReceived>
    <cvac:UpfrontPaymentReceived
      contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_1VRD647OiE6jHdJLTQ7IRQ"
      decimals="-6"
      id="Narr_Dhj0Uix9hUKHEe6D0DQu9w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">450000000</cvac:UpfrontPaymentReceived>
    <cvac:AccruedOtherLiabilityForUpFrontPayment
      contextRef="As_Of_12_31_2022_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_pfMi8wn3EkWe1O0Rx8uvnQ"
      decimals="-3"
      id="Narr_D47IKXH8SkGfHxIKCbJP9g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4114000</cvac:AccruedOtherLiabilityForUpFrontPayment>
    <cvac:PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment
      contextRef="As_Of_12_31_2023_cvac_IfrsTypeOfArrangementAxis_cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_PqOHXw2W70SLtVHUTZnIIg"
      decimals="-3"
      id="Narr_9MAI3pvdoU-QHSMEqJRh_w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4114000</cvac:PaymentOfAccruedOtherLiabilitiesOfUpfrontPayment>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_7_31_2020_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zETrLnvnJU-bFHQhtWzRHA"
      decimals="-6"
      id="Narr_IzPzINZXL0y7Y633SC2xXA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">252000000</cvac:MaximumGrantToBeReceived>
    <cvac:IfrsMilestonePaymentReceived
      contextRef="Duration_1_1_2020_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_3vgagNoi6kSQIXzMaP-lig"
      decimals="-5"
      id="Narr_RJ3w0sTvwEWACEJ7xD5ulQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">196300000</cvac:IfrsMilestonePaymentReceived>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BundesministeriumFurBildungUndForschungMember_Bwm_0zYqGkqkxhjgUSGCYQ"
      decimals="-6"
      id="Narr_DJ4uyUegi0m-d-7qEMA5CQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">124000000</ifrs-full:RevenueFromGovernmentGrants>
    <cvac:IfrsRemainingGrantIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_qyWBhjwBlkKQHtJUuv5N4g"
      decimals="-6"
      id="Narr_yrerR5t5lkin5m2AtUTkrw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">65000000</cvac:IfrsRemainingGrantIncome>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_TqJ5BJYuh06EybXTGE1AUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation for CMO/Materials transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reimbursement claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Grants and other reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 67,702&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,932&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,151&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_vjBdfCmUCkaI8cxojxWGzQ_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">35393000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_yQI4W9EsgUi8EB4mpWS2lQ_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2429000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CostOfReimbursementClaim
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_rhX8xOI5U0eMp132Wqnl5w_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">610000</cvac:CostOfReimbursementClaim>
    <cvac:CostOfReimbursementClaim
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_EEu1yMFiPk6VKQxjG1zlEQ_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">860000</cvac:CostOfReimbursementClaim>
    <cvac:SaleOfEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_sr6lXJFDOESpwShIqyW8lw_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">785000</cvac:SaleOfEquipment>
    <cvac:SaleOfEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_UOO3uVGb8kGj7FVD60MG0A_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1195000</cvac:SaleOfEquipment>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_SIRG2U9QAU-3TTZtjrWEag_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">66394000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_c0bARPuaeEKCaxpq6xx-Sw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">440000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_7QEfF3onkE-MYbLTilEHXw_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3566000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_6aJQSjirSkeU2YRo3jEPhA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1308000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_YpZj_x17Y02-zzujkleRrg_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">704000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_fwuP64Es1k-31ZEsuk7jqg_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1101000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_WIaGeK5hhE-ZqX6mp4QZxw_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">67702000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_yX9--gqDpkucuflsmvgUXw_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37932000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_7an2u6XyL0uqXHuVQSIwdQ_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9151000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_UJYAD019cUGBDnGIwVIvFQ"
      decimals="-3"
      id="Narr_mnRmtZIAJEK3c-QBlrsPVg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20500000</cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities>
    <cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_UJYAD019cUGBDnGIwVIvFQ"
      decimals="-3"
      id="Narr_rqBSUa2raUu1duZTq94tEg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12000000</cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_qyWBhjwBlkKQHtJUuv5N4g"
      decimals="-3"
      id="Narr_bozyeBVIf0i9y2AAYiha3g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">65218000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_M57Dz1YMN0mNMaEnjl265w"
      decimals="-3"
      id="Narr_W8r3ht3CfUeqTnGv2eo7xw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_q_oIdOGpA0Sek6pDPz5Now"
      decimals="-3"
      id="Narr_5pJfqLjp30SPF0FHYg9X5Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:RevenueFromGovernmentGrants>
    <cvac:IfrsRemainingGrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_cvac_IfrsIncomeStatementLocationAxis_cvac_MiscellaneousOtherOperatingIncomeMember_cpxyNogu7kOQwMXm7EojUQ"
      decimals="-3"
      id="Narr_iGKXWq3_oU2oUyZfpIJXyw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3064000</cvac:IfrsRemainingGrantIncome>
    <cvac:PartnershipAgreementMaximumAmount
      contextRef="As_Of_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_nQQb4IPGNkaNHOnRJ9HnPw"
      decimals="-3"
      id="Narr_fS33VVTaAES9Rog0arsmBA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">34000000</cvac:PartnershipAgreementMaximumAmount>
    <cvac:PartnershipAgreementTerm
      contextRef="Duration_2_1_2019_To_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_v2GiAszp-UioMADTqx2Ctg"
      id="Narr_d5codZSJVEuJevyvPmV23g">P3Y</cvac:PartnershipAgreementTerm>
    <cvac:PartnershipAgreementPeriodOfCostsToBeCovered
      contextRef="Duration_2_1_2019_To_2_28_2019_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_v2GiAszp-UioMADTqx2Ctg"
      id="Narr_Eujj5ZQ7oUahUnQFXuSjmg">P6M</cvac:PartnershipAgreementPeriodOfCostsToBeCovered>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_0NzIZ6BiH0K-Yg0H0gY9Ww"
      decimals="-3"
      id="Narr_NCxt92rpR0emRnPc1Sy8Sg"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">8300000</cvac:MaximumGrantToBeReceived>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_wT00lKBxs0KIgm-oIxqE4Q"
      decimals="-3"
      id="Narr_8oH0Ff4arUqkWoPPgoaREg"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">15300000</cvac:MaximumGrantToBeReceived>
    <cvac:ReimbursementOfApprovedExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_XKUaAnV49EWl3jd-hAE8eg"
      decimals="-3"
      id="Narr_GPY91mQyJ0-i7IqRvCawjg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3000</cvac:ReimbursementOfApprovedExpenses>
    <cvac:ReimbursementOfApprovedExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_lDAMCnCC90O3RpaIsg3kZA"
      decimals="-3"
      id="Narr_0uw8oEE9akWllHdagmjDxA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42000</cvac:ReimbursementOfApprovedExpenses>
    <cvac:ReimbursementOfApprovedExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_6nW0xhgNC0mT9D42Qi4zog"
      decimals="-3"
      id="Narr_CMMrhNAy4kG2s5bZqU_XwQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">688000</cvac:ReimbursementOfApprovedExpenses>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_xc2cFeX11U6brkADl8elRw"
      decimals="-3"
      id="Narr_DjFKcta51EWAbhra_CQfqA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">305000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_cyOGw2ND4EOXxVCS45Rnhg"
      decimals="-3"
      id="Narr_d2OMUwwOUkWi5q6cy-E6jw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">309000</ifrs-full:GovernmentGrants>
    <cvac:MaximumUnspentFundsReimbursable
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_XKUaAnV49EWl3jd-hAE8eg"
      decimals="-3"
      id="Narr_UTWdvUU6-06ePQn_ncMHCA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">1000000</cvac:MaximumUnspentFundsReimbursable>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2016_To_11_30_2016_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_WgEgi6NaVEWkMFit_-JGNA"
      decimals="-3"
      id="Narr_ifvjgCscVkGo-G2wEGAbrA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">653000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2016_To_11_30_2016_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_WgEgi6NaVEWkMFit_-JGNA"
      decimals="-3"
      id="Narr_iIvGBN9mD0Sh60DRVYlbGQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">614000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:NumberOfAdditionalGrantsReceived
      contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_L61lR4DVa0KvyH4imXbLGw"
      decimals="INF"
      id="Narr_I5xQNzNyaUylZldsj4l5pg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">2</cvac:NumberOfAdditionalGrantsReceived>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_Wh8p0VKIT0O3NgVdxK2fOQ"
      decimals="-3"
      id="Narr_3gfLb3JJe0up5TEge1mOrg"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">1000000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_Wh8p0VKIT0O3NgVdxK2fOQ"
      decimals="-3"
      id="Narr_jS3NemFyUU2vvAueOq8obQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">852000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_I_69X6Df9k6Te3sWPj6hwQ"
      decimals="-3"
      id="Narr_6xfdq14eg0OKwY_EIZCG6g"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">800000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2017_To_11_30_2017_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_I_69X6Df9k6Te3sWPj6hwQ"
      decimals="-3"
      id="Narr_RF-okWMCPUibcxPTPS21Mg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">673000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_8_1_2019_To_8_31_2019_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_GFLhPP5AWUCAjFvKMkszFg"
      decimals="-3"
      id="Narr_juJxEznQnUeJAMbluDJ6jA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">540000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_8_1_2019_To_8_31_2019_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_GFLhPP5AWUCAjFvKMkszFg"
      decimals="-3"
      id="Narr_Ryd3yDNaKU672xjXf1FOEA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">486000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_5b14ql9RFEezFsOggnD0RA"
      decimals="-3"
      id="Narr_DRaMBpxOZEyHBTF6km8JDg"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">322000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_5b14ql9RFEezFsOggnD0RA"
      decimals="-3"
      id="Narr_gJ_cKfJ1ekqzrzPnVUs6Ow"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">280000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_wxgIcShrNEKq5nN0HbJ7vg"
      decimals="-3"
      id="Narr_NA6PMqOAC0ybdP8CPHpBDw"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">1449000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_12_1_2020_To_12_31_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_rNMx4zueSkOBF5WSJkSlXw"
      decimals="-3"
      id="Narr_QzGK2hxdO0WBX2wUHrnRnQ"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">1449000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_11_1_2020_To_11_30_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_wxgIcShrNEKq5nN0HbJ7vg"
      decimals="-3"
      id="Narr_pP8G009jmE2AJXTINrJ-vw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1208000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_12_1_2020_To_12_31_2020_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_rNMx4zueSkOBF5WSJkSlXw"
      decimals="-3"
      id="Narr_J9bGcpowuk2dhdQNuBhYVw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1208000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <cvac:AmortizationOfGovernmentGrants
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_m_1pv_Rp7ES0m0oWmWkw9w"
      decimals="-3"
      id="Narr_VoLHP6S57kqqd9bDSdjimg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">66000</cvac:AmortizationOfGovernmentGrants>
    <cvac:AmortizationOfGovernmentGrants
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_oFHjPsrbYU-V2V22lqobCg"
      decimals="-3"
      id="Narr_UdsAS8e9uE2ZOCZl8XLt5w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">167000</cvac:AmortizationOfGovernmentGrants>
    <cvac:AmortizationOfGovernmentGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_lgx14Yi8EUGXWrkRb0K3Jg"
      decimals="-3"
      id="Narr_VoHRdi_yFUmXpXphf5TorQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">488000</cvac:AmortizationOfGovernmentGrants>
    <cvac:RepaymentOfGrantReceivedFromGovernment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fUKrlVf3Qk6qjGa7_xKIlw"
      decimals="-3"
      id="Narr_Y2NM2JudgkmG-krjFZIC1Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">217000</cvac:RepaymentOfGrantReceivedFromGovernment>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2023_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_AvgaG-0jnkaft9oN3wJb5w"
      decimals="-3"
      id="Narr_iMn1Xi5bp0KGEEGSDtQ-cQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1430000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2022_cvac_GovernmentGrantsAxis_cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_xwxmUcynR0KOedEqXVH6mg"
      decimals="-3"
      id="Narr_qQpATKjZikeEsKsMBqHlww"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1712000</ifrs-full:GovernmentGrants>
    <cvac:DisclosureOfFixedAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_K7CDab1xZUKNrx9PJs0WAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Fixed Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;4.1 Development of intangible assets and property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The development of intangible assets and property, plant and equipment for the years ended December 31, 2023 and 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Advance&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands of EUR)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Software&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Licenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technology&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Goodwill&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,331)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (298)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,166)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (656)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,385&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,930&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,350&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,139&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated amortization and impairment charges&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,079&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,217)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,114)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,331)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,479&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,398&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 484&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,361&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,946)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,432)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,388)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,797)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,843&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,974&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,350&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,630&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated amortization and impairment charges&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,841)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,135)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,493)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,965&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,054&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,266&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,285&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Carrying amount&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,878&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,920&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,084&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,347&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As the Group operates as one cash-generating unit, for the purpose of impairment testing in 2023, goodwill was allocated at Group level. For the impairment test the market capitalization was compared to the Group&#x2019;s equity; the Goodwill was covered by the exceeding amount. The market capitalization derived from public quotations of CureVac stock (Nasdaq Dec 29, 2023: USD 4.21). Based on this, CureVac has concluded, that there are no indications of potential impairment in the goodwill of its one cash-generating unit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;Other&lt;/b&gt;&lt;span style="font-family:'Times New Roman Bold';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment,&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technical&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;furniture&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;under&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands of EUR)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Buildings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;machines&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;fixtures&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;construction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 215,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Assets held for sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,719)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,851)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,570)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,182)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,584)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,356)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,854)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,652)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,467&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 50,033&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,552&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 138,457&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 227,509&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated depreciation and impairment charges&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,083)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,938)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,688)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,038)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,747)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,710&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,617&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,415&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 826&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 29,568&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,090)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,825)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,235)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,165)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 27,537&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 54,941&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,736&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 178,990&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 274,205&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated depreciation and impairment charges &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,617&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,415&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,659)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,941)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,914&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,272&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,038&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,200&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,424&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Carrying amount&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 168,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 137,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 197,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,623&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,669&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,698&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 176,790&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 236,782&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In fiscal 2023, impairments of EUR 1,374k were recognized (2022: EUR 5,884k). These were recognized in cost of sales as they pertained to machinery and technical equipment recorded under assets under construction and resulted from the partial impairment of equipment which are obsolete due to the withdrawal of the EMA regulatory approval application for CVnCoV. In fiscal 2022, assets were reclassified as &#x2018;assets held for sale&#x2019; (Refer to Note 5 for additional information).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group capitalized EUR 2,375k borrowing costs during fiscal 2023 (2022: EUR 2,291k, 2021: EUR 2,932k). The capitalization rate used to determine the amount of the borrowing costs eligible for capitalization during fiscal 2023 was a weighted average of 5.76% (2022: 5.78%, 2021: 7.17%).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;4.2 Right-of-use assets and lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Set out below, are the carrying amounts of the Group&#x2019;s right-of-use assets and the movements during the period:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use&#160;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Land&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Buildings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vehicles&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,183&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 275&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,303&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 43,761&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions (new leases and reassessment of existing leases)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,264)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (352)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,772)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 39,574&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 319&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,950&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,843&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The most significant lease agreements that have been initiated relate to several buildings in T&#xfc;bingen, a building in Wiesbaden and Frankfurt am Main, a building in Amsterdam/Netherlands and a building in Boston/USA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The additions mainly relate to six rental agreements in T&#xfc;bingen (EUR 2,452k) and one rental agreement in Wiesbaden (EUR 510k). In addition, CureVac assessed one extension option of 5 years to be reasonably certain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Below are the carrying amounts of lease liabilities and the movements during the period:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions (new leases and reassessment of existing leases)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,568)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,824&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,005&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A maturity analysis of lease liabilities is disclosed in Note 15.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following are the amounts recognized in the statement of operations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation expense of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,772)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment expense / reversal of impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (710)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,218)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,375)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expense relating to short-term leases (included in cost of sales)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (76)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (70)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expense relating to leases of low-value assets (included in general and administrative expenses)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (66)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (55)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income from sub-leasing right-of-use assets presented in &#x201c;other operating income&#x201d;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Set out below, are the carrying amounts of the Group&#x2019;s right-of-use assets and the movements of prior period:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use&#160;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Land&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Buildings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vehicles&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,639)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (316)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (710)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (710)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,183&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 275&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,303&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 43,761&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Below are the carrying amounts of lease liabilities and the movements during the period 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,892&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,439)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;A maturity analysis of lease liabilities is disclosed in Note 15.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;There are no commitments for leases not yet commenced as of December 31, 2023. Commitments for leases not yet commenced as of December 31, 2022, related to two lease agreements of buildings in T&#xfc;bingen, Germany that have been signed in 2021 and one lease agreement of a building in Wiesbaden, Germany that has been signed in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Optional lease payments from using extension options not included in the measurement of the lease liability exist in a gross amount of EUR 39,325k.&lt;/p&gt;</cvac:DisclosureOfFixedAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_Afz_EtJO3UiQomhevLL_Sw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Advance&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands of EUR)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Software&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Licenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technology&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Goodwill&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,331)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (298)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,166)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (656)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,385&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,930&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,350&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,139&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated amortization and impairment charges&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,079&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,217)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,114)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,331)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,479&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,398&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 484&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,361&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,946)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,432)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,388)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,797)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,843&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,974&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,350&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,630&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated amortization and impairment charges&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,841)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,135)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,493)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,965&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,054&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,266&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,285&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Carrying amount&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,878&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,920&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,084&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,347&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_t4-RJZpgr0CDzvIjX0yH7g"
      decimals="-3"
      id="Tc_L5cslTEFdkOP9jzMHY9Rvg_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12626000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_2Z6ov_rV6UGba_ri3U2OrQ"
      decimals="-3"
      id="Tc_-VBfMnqT00m6f1lGqMchnw_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10259000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_jb5qNe6RhUGF9vZAO08FkA"
      decimals="-3"
      id="Tc_3k6ZDRvSrkGu_UYPOt39Rg_4_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">965000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_t4jMo4Sp2U27gxThk2CyYA"
      decimals="-3"
      id="Tc_hYWYp5U9mEGPoTOlvVrwaA_4_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23850000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img"
      decimals="-3"
      id="Tc_3MlEL--7f0OshY_BIiblKg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1433000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_cqxmGMVGW0W7n02ag0EpUA"
      decimals="-3"
      id="Tc_8eiBPmgqqE6hL-7ZXtUZfQ_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4208000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_j_FuUitGzU-WI673yfsjoQ"
      decimals="-3"
      id="Tc_zespjVYuSEekWM9VEit3Ow_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6350000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_xFpumxL9VU6TqcyTi7LMRA"
      decimals="-3"
      id="Tc_SMPLlWZUEEy_lu-_O2WFew_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12463000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"
      decimals="-3"
      id="Tc__bk3CqRCYkyR6gByoqEyGg_5_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24454000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img"
      decimals="-3"
      id="Tc_Jf18aG6NnkWLRCK045nW3w_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2331000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_cqxmGMVGW0W7n02ag0EpUA"
      decimals="-3"
      id="Tc_fl68pil5PUKdgEhXSVDq9A_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1537000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_PZFJd68wgkCqXp4YW2TkiQ"
      decimals="-3"
      id="Tc_uqFPoTbaVEOCbDRhqJkzvw_6_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">298000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"
      decimals="-3"
      id="Tc_mNgkY1lBVEKWxEpiTJ4Ajw_6_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4166000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img"
      decimals="-3"
      id="Tc_RuZMKOBcl0u8ZQBJ_Zs7qg_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">656000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_PZFJd68wgkCqXp4YW2TkiQ"
      decimals="-3"
      id="Tc_xJdBcPKerE6x5aY360cLAw_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-656000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ct2TePjfpkeMr01VO74Img"
      decimals="-3"
      id="Tc_ZOTQ6l9j3k-YZnCW-W4Dhg_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"
      decimals="-3"
      id="Tc_ZbWrFIkIFEKSe32Vj_Sr7Q_8_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_TpCSNwbGR06S0oUDZgjo1Q"
      decimals="-3"
      id="Tc_oGbjXU6ZvESKh9ytemUbAQ_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12385000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CxYy2LPXFkaLHvgdxKLbYw"
      decimals="-3"
      id="Tc_FJLPTyDBH0WVpGTX4f7sDw_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12930000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_smPSOhfL00esXI2_6xMXmQ"
      decimals="-3"
      id="Tc_h3gdipHc3kip6Kz7DbHBZw_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6350000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_taOkSa3SjUyVQqMwIn0Hjg"
      decimals="-3"
      id="Tc_z7tk5W3ApkG_fby_eGnWVQ_9_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12463000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_e3XuayV2tk6ysYr-TQ-BSQ"
      decimals="-3"
      id="Tc_LFVzitZwSUawlNz2MXK9QQ_9_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g"
      decimals="-3"
      id="Tc_e4LNke4W5kqBcsPw7Fegaw_9_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">44139000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JTWgO7w8WUSANCdQPMb8Hg"
      decimals="-3"
      id="Tc_jTddt-ro9Ei7tawMJ7ITTQ_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5965000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_pTI2ycYZxUCgYp1XaojMCQ"
      decimals="-3"
      id="Tc_BsYDlqpbKEamsFkg5KeNNQ_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4647000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_AZk_qPQ4MUWJzWTnl1YlfA"
      decimals="-3"
      id="Tc_Gzy04IE11E-ixDk4o2Qrow_11_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10612000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw"
      decimals="-3"
      id="Tc_pFS0HzUiV0GvDtcfoPaEbA_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1730000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_ep4tnexH0kyFY8VzHHJmYA"
      decimals="-3"
      id="Tc_rbkmOUosnkK_xD0X5KXZxA_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2865000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_lFP2_XAYDUudX-fY-YAD1Q"
      decimals="-3"
      id="Tc_9mmDMD57qEq3qtSkgqWpaA_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">484000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"
      decimals="-3"
      id="Tc_O_5DKtVHs0KQJkUSKP9CbQ_12_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5079000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw"
      decimals="-3"
      id="Tc_mmkmFqthLUeARqOZAz3F7w_13_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2217000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_ep4tnexH0kyFY8VzHHJmYA"
      decimals="-3"
      id="Tc_1-55wJwJ10mS-p9l2AXVow_13_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1114000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"
      decimals="-3"
      id="Tc_Hh2LmsjcyUaHo6pzrOoLAg_13_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3331000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_OKMk4TkH9U-_2o5-_-zOMw"
      decimals="-3"
      id="Tc_wo0UAi3tZkaKj81PY7Cn_w_14_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"
      decimals="-3"
      id="Tc_8TUmMGeMuUakThxoyCaZgA_14_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_lxNwvrDKd0-QyYtez9i4Cw"
      decimals="-3"
      id="Tc_CQkOlmxj_0upn5Y9v6jjcw_15_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5479000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hlhg1JNAsESzQBLYmwp6xQ"
      decimals="-3"
      id="Tc_oJRhpEL70UOD7C1D7TX7lQ_15_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6398000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1FJQlhWUMk6KNwscC81P8w"
      decimals="-3"
      id="Tc_cxsyoLBlmUu442x-F0Rftw_15_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">484000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA"
      decimals="-3"
      id="Tc_8Z9rItWJHEOMsrod-Zvovw_15_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12361000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_TpCSNwbGR06S0oUDZgjo1Q"
      decimals="-3"
      id="Tc_7sqJXsXOm0KLyrOFpP1Dsw_17_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12385000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CxYy2LPXFkaLHvgdxKLbYw"
      decimals="-3"
      id="Tc_TjCQM1JVKEu2RWNZH_lrVQ_17_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12930000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_smPSOhfL00esXI2_6xMXmQ"
      decimals="-3"
      id="Tc_hSYAuuLHUkG2q1-VxuLmuA_17_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6350000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_taOkSa3SjUyVQqMwIn0Hjg"
      decimals="-3"
      id="Tc_HXdBWAHuzkmkgb583KCRdA_17_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12463000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_e3XuayV2tk6ysYr-TQ-BSQ"
      decimals="-3"
      id="Tc_kAxRiwRqsEywC3w43nUU_g_17_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g"
      decimals="-3"
      id="Tc_RS4qR934BkmkkcGdV4oZ3w_17_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">44139000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ"
      decimals="-3"
      id="Tc_kdAR8QIep0ePDXZusmjS3A_18_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">201000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw"
      decimals="-3"
      id="Tc_v08ySrrQo0WRSZMzc1oKNg_18_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2679000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ"
      decimals="-3"
      id="Tc_snYCQPo_UU2S7j5Eqa87OQ_18_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2880000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ"
      decimals="-3"
      id="Tc_LvEvVlD5IE6hjTf4SE_HDQ_19_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1946000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw"
      decimals="-3"
      id="Tc_KblfovmMrUeHFZRuwWkqrg_19_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4432000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_rkeQ49L4e06MJK-fI2BJhg"
      decimals="-3"
      id="Tc_4o3BhRHAfUyAN2seQr4B_g_19_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ"
      decimals="-3"
      id="Tc_1LEEBU619EWgs84-LNC08g_19_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6388000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_Ug13HvLc90-T2QMAs1vPMQ"
      decimals="-3"
      id="Tc_FEcZHi5jNE6ISXikqXxMbA_20_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-6797000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_HPmIn0t770ayTMaGuX-Jiw"
      decimals="-3"
      id="Tc_ov8njsUfV0OnkiZaYYfIsQ_20_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6797000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_-yi3-Too5kCsgm19jUEi9A"
      decimals="-3"
      id="Tc_J_e_vPWT30KLui-E39QE1w_22_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3843000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_b9BiLH-CyUWgD-n-MYvg5Q"
      decimals="-3"
      id="Tc_t2N3Rvv8rkuqHUa_6Mfb1Q_22_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17974000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_eimyXQngAkWRK3ARVfDZJA"
      decimals="-3"
      id="Tc_YPJL8bwPFUa6bhtuYftqCg_22_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6350000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_ZF2N9tkLFEaK095giq-KlA"
      decimals="-3"
      id="Tc_tPIuTE8D9UiyCGlOTVZQRQ_22_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12463000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_Auk54leS0kegyMpOaw5bEw"
      decimals="-3"
      id="Tc_EF17ec9RW0S0E_X4wQjERw_22_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40630000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_lxNwvrDKd0-QyYtez9i4Cw"
      decimals="-3"
      id="Tc_545aXI1Fd0mTyvjoDjESHA_24_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5479000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hlhg1JNAsESzQBLYmwp6xQ"
      decimals="-3"
      id="Tc_-y7_HM61Lkq4oODC_bYC5Q_24_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6398000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1FJQlhWUMk6KNwscC81P8w"
      decimals="-3"
      id="Tc_ry6j5JtVFEWTct9F3GXrzg_24_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">484000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA"
      decimals="-3"
      id="Tc_sBsNqlkV_USWGISarRkHVA_24_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12361000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ"
      decimals="-3"
      id="Tc_x1ysCY7z40OBHKJkKAzXKw_25_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">820000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg"
      decimals="-3"
      id="Tc_FgaOzuFwr0mdhs6fb_xdqg_25_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3457000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_2doude3lg0OUQmpYjlR9-w"
      decimals="-3"
      id="Tc_460X-bu7xEOEaVFomClVxQ_25_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">782000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA"
      decimals="-3"
      id="Tc_BlOG_bENfkCtrJ6V88PujQ_25_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5059000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ"
      decimals="-3"
      id="Tc_EthjrErtS0ShP1ybmIkgIA_26_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1841000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg"
      decimals="-3"
      id="Tc_hEd47oA77E-Oc0_7ILTTfQ_26_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3294000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA"
      decimals="-3"
      id="Tc_SqZ9nd9RpUCv0monSnYz_g_26_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5135000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_ON7yRiseRECL78Q0ikeDPQ"
      decimals="-3"
      id="Tc_kIKNsVTxNU-i2m76MzW1cA_27_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2493000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_CiOss_xw1k-awU8a4ZY7Qg"
      decimals="-3"
      id="Tc_6Ceq3j8CbUKN1RzHO6g7WA_27_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2493000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_SNfgVOPHpkOAwFRDrPaxfw"
      decimals="-3"
      id="Tc_x3GEdjGaFk6NqNX9wCRPvw_29_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1965000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3uG-xQGBjk2UUp8qg_geog"
      decimals="-3"
      id="Tc_HT31obYvYUi3OcJataAbGw_29_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9054000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_cDlmM3W2jEmSkYOD4grJhw"
      decimals="-3"
      id="Tc_UbfYH_kJPkCAbwx1mUfSmg_29_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1266000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Fo_xNC8x2E2Nw6expsmq5Q"
      decimals="-3"
      id="Tc_CsKxUJe6o0OpYhNfSUz5CA_29_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12285000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_JgayIPr0HUqHcsGqQ4Msdg"
      decimals="-3"
      id="Tc_l-YkUhOwfEeBNTUGRNgJdQ_31_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6661000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_hhtxzsBDiUKB449PVvTqJA"
      decimals="-3"
      id="Tc_ABZ63v2ZKka42wnxfGapbA_31_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5612000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_glkxLuCSRUCQqGxSgDm4sQ"
      decimals="-3"
      id="Tc_XL3JVUYV_0KQknsnhh_LHw_31_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">965000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_tV7LRNl6G0-jNcJUCe8hUA_31_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">13238000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_9EPi2cugF02lQJNpQpyZfA"
      decimals="-3"
      id="Tc_sCvoMGO_1k2VTiicsV8o6g_32_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6906000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_3xb5m9-bNEqJh9Hoo7pWKQ"
      decimals="-3"
      id="Tc_2R6aVxsIXE-pPBQlu_Ieag_32_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6532000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_1teDHrsx_kWaav_Zvx6nuA"
      decimals="-3"
      id="Tc_O1iIeUjkN0KysOk9z5IE6g_32_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5866000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_4a0nsTyeT0WWO6mJkY9WFA"
      decimals="-3"
      id="Tc_p4h6VMRzmE2SaOeqAftmxA_32_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12463000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_AdvancePaymentsIntangibleAssetMember_-ENPqM9es0SNp-ig-Xj1tA"
      decimals="-3"
      id="Tc_hnQP-cWVeEWUBu_b661AAg_32_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_coJkUiG4PUqqUXLUpGLlkA_32_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">31778000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_SoftwareMember_amLMRVfn1Ee2t3F85rOj6Q"
      decimals="-3"
      id="Tc_1ZfIvnc91U2u0q7Zblh9MQ_33_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1878000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_LicencesMember_tEkPhB01qkqTdfn3O75Wzw"
      decimals="-3"
      id="Tc_SSt2DGno30SQRznrZEZW9g_33_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8920000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_TechnologyMember_TsCUi_lxRUSo6j60ua4lmg"
      decimals="-3"
      id="Tc_E3p_LfZjqUCJXLk0ZUUYQQ_33_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5084000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-full_GoodwillMember_syES-Ei1DUW-SeNDoWBa7Q"
      decimals="-3"
      id="Tc_ZXcyXMHR7E6XJor_OWsc6g_33_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12463000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_rVrenyNaq0-Dru8yqPUgrQ_33_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28347000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <cvac:IfrsSharePrice
      contextRef="Duration_12_29_2023_To_12_29_2023_SuqeE38xXUK8RRKDLZ3EOw"
      decimals="2"
      id="Narr_IIEGWwHHZE2Z9px7uktwdA"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">4.21</cvac:IfrsSharePrice>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_bBuAwn4bMkOcWuJEkePdCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;Other&lt;/b&gt;&lt;span style="font-family:'Times New Roman Bold';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment,&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Technical&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;furniture&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;under&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands of EUR)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Buildings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;machines&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;fixtures&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;construction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 215,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Assets held for sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,719)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,851)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,570)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,182)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,584)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,356)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,854)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,652)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,467&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 50,033&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,552&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 138,457&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 227,509&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated depreciation and impairment charges&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,083)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,938)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,688)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,038)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,747)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,710&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,617&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,415&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 826&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 29,568&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition costs&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,090)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,825)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,235)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,165)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 27,537&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 54,941&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,736&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 178,990&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 274,205&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated depreciation and impairment charges &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,617&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,415&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,659)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,941)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,914&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,272&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,038&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,200&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,424&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Carrying amount&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 168,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;As of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 137,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 197,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,623&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,669&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,698&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 176,790&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 236,782&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_uEHNJFwr3EmVaCzLXcE2lw"
      decimals="-3"
      id="Tc_nenA90_L6kei_WhtarYJyQ_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">27272000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_i7EfMlh5iUKmaxl0vc-mog"
      decimals="-3"
      id="Tc_UtOq34qT9U6008IsYbTEDg_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">51974000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_K_aG3SZaKUW1mCYhFvnDYQ"
      decimals="-3"
      id="Tc_2DQnKFAGO02KLGhNvHOOiA_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11494000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_8byNOjFo4ki3TRAVrcpw_w"
      decimals="-3"
      id="Tc_rdeeu3VnkU2AbmWP7D4SBg_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">124543000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_t4jMo4Sp2U27gxThk2CyYA"
      decimals="-3"
      id="Tc__X0woYbgVkKxz3hGocgjFQ_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">215283000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_D4XaHP_XzUyH3j-sKKjh5Q"
      decimals="-3"
      id="Tc_Id52pnkK70C-UIC4vBUzXQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">377000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w"
      decimals="-3"
      id="Tc_XE77jBDk7UKL6xMTJ8bjHA_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9710000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA"
      decimals="-3"
      id="Tc_u2R1mWc9_0m4mZUAVCSOQw_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2760000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w"
      decimals="-3"
      id="Tc_be4_3SWRgUmNjKWgeCCTjA_8_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">76773000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"
      decimals="-3"
      id="Tc_hoJy0ZR2B0KqreNXc7zTtQ_8_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">89620000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w"
      decimals="-3"
      id="Tc_706B2hmMTk2k0HaDGMU0Bg_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6719000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w"
      decimals="-3"
      id="Tc__xInh29lxEWaTfA_gcN6ow_9_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">50851000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"
      decimals="-3"
      id="Tc_wAjE5VDjgk-Z99KA7M9NTw_9_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">57570000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_D4XaHP_XzUyH3j-sKKjh5Q"
      decimals="-3"
      id="Tc_ztQpjlnduUqVbB8UERD2lg_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1182000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w"
      decimals="-3"
      id="Tc_E3TGg10ftUOrI1w89HCu3A_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12584000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA"
      decimals="-3"
      id="Tc_HPupaWEhIkGuWhhNoZ5XYg_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1732000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w"
      decimals="-3"
      id="Tc_HazolbTDTUWu_rZdP0Co7Q_10_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4356000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"
      decimals="-3"
      id="Tc_Uk1ugIcj0kqAw870WRMXdg_10_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19854000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_HAOk6xgkMEuXOwvUtUS42w"
      decimals="-3"
      id="Tc_EocEEdwK-UisVi3dUk8nsw_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7652000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qfFLM8sIP0-Bcv89vZ-c7w"
      decimals="-3"
      id="Tc_GfQCft9wp0CCZG5CdTEYNg_11_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-7652000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_OdKJjDt-hkaKpi0BALIgDA"
      decimals="-3"
      id="Tc_61Tvt6QwrE24IGC3iZfegg_12_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">30000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_LqYFf4QbdkiSmL6x9piakg"
      decimals="-3"
      id="Tc_tfAg6_Jpj0a2e2iylQZHZQ_12_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">30000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_gVeKYMrm2kqPAEgtA4ctgQ"
      decimals="-3"
      id="Tc_9BXCnuT4kkiIHXGvEpQjgg_13_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26467000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ES83sXGGEUiud1LCNDkpvg"
      decimals="-3"
      id="Tc_ifPH1kekYk-syNcnY_JZrw_13_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">50033000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iLzT9AM5F0Gv_MXd0N7WwQ"
      decimals="-3"
      id="Tc_V9Ksjuqjy0acFSGu3EwNyQ_13_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12552000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GJ80BNA4w02YFSPV325rWw"
      decimals="-3"
      id="Tc_gs9BE6F1ak6VnY83kK6dvQ_13_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">138457000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g"
      decimals="-3"
      id="Tc_9dYTS8W3w0ihiFFL0qavXw_13_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">227509000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_HKdVFHQkxEmgyjhDxX2T9w"
      decimals="-3"
      id="Tc_9ZwVuu3R70SupCl4S6B4Dg_15_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5348000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ADqOKH8jt0KB1nbIrPKgoQ"
      decimals="-3"
      id="Tc_8vETB6DiQ0a5lcXhoqJshw_15_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11726000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iEt59g_0hEWUB6Yz9rNI_A"
      decimals="-3"
      id="Tc_0ztXiYOyiUO7fB89Oh1hOg_15_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7135000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OXWs40hPgkKqkaLy0hyWrQ"
      decimals="-3"
      id="Tc_3noCiUIrnEiFzbsPmri65A_15_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22810000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_AZk_qPQ4MUWJzWTnl1YlfA"
      decimals="-3"
      id="Tc_G5Ro4lgJJEeLNba6oQcDOA_15_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">47019000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_-ZhyaL6E9kaT3dKgQLND6A"
      decimals="-3"
      id="Tc_KdA4KCB_Z0Wac2tb5fp5uQ_16_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4445000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA"
      decimals="-3"
      id="Tc_-YR3Kzf6lU2fL-o7HJUmcQ_16_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6999000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w"
      decimals="-3"
      id="Tc_Om6Fe6UL00KWc46l4ArpHQ_16_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1950000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"
      decimals="-3"
      id="Tc_kM2GgivrKEKeJKORilUWaA_16_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">13394000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA"
      decimals="-3"
      id="Tc_dhDt2PAgSUG4l88aMvIuzA_17_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3830000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_KyV7Slh2JkqGlclN0ZugPw"
      decimals="-3"
      id="Tc_fQSMY6AYy0mkybNX33MuuQ_17_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2054000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"
      decimals="-3"
      id="Tc_HsIR71IE9UmZIZ9vYs_EzQ_17_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5884000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_-ZhyaL6E9kaT3dKgQLND6A"
      decimals="-3"
      id="Tc_qMW0AUDaUkeP2bs-uK6nPA_18_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1083000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_E8bQn5FCkE-4ypIjhmXiBA"
      decimals="-3"
      id="Tc_q1XUMTjaFUCNnfy70lcV1A_18_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9938000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w"
      decimals="-3"
      id="Tc_y1rgOMALeEK_WYiB7lWNhA_18_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1688000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_KyV7Slh2JkqGlclN0ZugPw"
      decimals="-3"
      id="Tc_AVTzeUE0wUyDdEjuaRPCUw_18_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24038000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"
      decimals="-3"
      id="Tc_eDy-LaiRLUOgLvHOhbJ_NQ_18_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">36747000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FDnsuqUkjUKzdH7o_M3L-w"
      decimals="-3"
      id="Tc_nURPv1RED0u17kMitmiteg_19_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">18000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_lmO0_xp5rEWM8TSqeT_NTg"
      decimals="-3"
      id="Tc_mmr-GHt6c0-VpAueOgpwjw_19_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">18000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_3Ozy5OoM_EqCMGWp5kzLAw"
      decimals="-3"
      id="Tc_sd5EMkE-_EWgPKUqnmlrWw_20_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8710000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ySJm0_yzS0O5WbckJbrJig"
      decimals="-3"
      id="Tc_HsdVYo8HTEyyscDhgayLNQ_20_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12617000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_SWfFNmCXQkGxOp1OayMWRw"
      decimals="-3"
      id="Tc_f45mx64RJUanP-lcnNUQLg_20_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7415000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3hNl2cG_e0iw0IDtLwg0sQ"
      decimals="-3"
      id="Tc_VYmg_Gv-9E2wTbyYv_tp3A_20_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">826000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA"
      decimals="-3"
      id="Tc_h_spDiQBp0awd8yci3y2-Q_20_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">29568000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_gVeKYMrm2kqPAEgtA4ctgQ"
      decimals="-3"
      id="Tc_5bazr96yM06WLKl0LXNZIg_22_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26467000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ES83sXGGEUiud1LCNDkpvg"
      decimals="-3"
      id="Tc_e7mwakJ9W0KLLlA8mHNU5Q_22_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">50033000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_iLzT9AM5F0Gv_MXd0N7WwQ"
      decimals="-3"
      id="Tc_FEkg6vSA9kq9uFBZppZd1g_22_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12552000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GJ80BNA4w02YFSPV325rWw"
      decimals="-3"
      id="Tc_Daac6lEC8UyQWbgR0HZuMQ_22_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">138457000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_zjzdlJZZUEaI5K9iAyLy6g"
      decimals="-3"
      id="Tc_ZOgY9DXfhkSatg6p8-oJHA_22_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">227509000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg"
      decimals="-3"
      id="Tc_HPDnJo6RIkyIQ8oRpyyWKw_23_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">551000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw"
      decimals="-3"
      id="Tc_BJJbuNOEvEWf8Nz_KG6e1g_23_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9171000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw"
      decimals="-3"
      id="Tc_gs_IPERVlU2u17t__6_Iyw_23_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2024000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ"
      decimals="-3"
      id="Tc__jC1P-0rF064ygwc0geVRA_23_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">43126000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ"
      decimals="-3"
      id="Tc_YAXN26kWfEaqiBOslxcUuQ_23_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">54873000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg"
      decimals="-3"
      id="Tc_LPLCfcLlp0yYJVg8VW4EEQ_24_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw"
      decimals="-3"
      id="Tc_JUAhG310cEKQoeNWn0RnmA_24_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5090000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw"
      decimals="-3"
      id="Tc_w8wbRSkIvkS1v9SN6ihPvg_24_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1825000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ"
      decimals="-3"
      id="Tc_a6xqg04ztUOhXHJsPv1faw_24_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1235000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ"
      decimals="-3"
      id="Tc_zHRWUbcWKk-mH9Xqal8s7g_24_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8165000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GYPd985RoEK1rntI-hSxbg"
      decimals="-3"
      id="Tc_jLPu9bk6402u5CR6_GXavw_25_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">533000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_kd_AiWHm_ECX84oDj0fnRw"
      decimals="-3"
      id="Tc_1z7400w0DkGzQy1l9Js9Mg_25_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">828000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw"
      decimals="-3"
      id="Tc_7U4-JsCdhkGlC3w4NiTkKg_25_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_OIKQyZfyJUyLxPNJa7l4hQ"
      decimals="-3"
      id="Tc_eu4HYNbb1k24H58DfR4Qcw_25_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1358000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ"
      decimals="-3"
      id="Tc_TzOUsagG7Em_VcseaCgYkw_25_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_ZKpOliYtTUiNnplbCGwLiw"
      decimals="-3"
      id="Tc_9HWgJ_9Z70uFswDKmoiU7w_26_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-13000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_T5X4Gys-e0mNSHLfNrOMiQ"
      decimals="-3"
      id="Tc_iI40Di00bkud7GOjd4B_Cw_26_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-13000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GxtzQ5W2qkKKhXTjunpSVA"
      decimals="-3"
      id="Tc_FxWYuYb1oUWpfyuAaeZLhA_27_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">27537000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__0Fq4xEc5USvdYA7uwb9kQ"
      decimals="-3"
      id="Tc_1_ma4fnE_0egmkbK-Rl1bA_27_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">54941000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_vx00BKTjL0C1MH6pWcVznA"
      decimals="-3"
      id="Tc_wYgfOw3Kek-ODgG-yIcFiQ_27_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12736000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_kHeRSiduSE-H2FthCmMR7g"
      decimals="-3"
      id="Tc_AtSq9UIs00-i-KvOppZRdQ_27_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">178990000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_GrossCarryingAmountOfAcquisitionCostMember_Auk54leS0kegyMpOaw5bEw"
      decimals="-3"
      id="Tc_QkP4mgSteUO9T8kSF3aDPg_27_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">274205000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_3Ozy5OoM_EqCMGWp5kzLAw"
      decimals="-3"
      id="Tc_EWnTihw260SDGsAWtfxlYA_29_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8710000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_ySJm0_yzS0O5WbckJbrJig"
      decimals="-3"
      id="Tc_ivCx4ZyfPUuxnQfUtiBlDA_29_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12617000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_SWfFNmCXQkGxOp1OayMWRw"
      decimals="-3"
      id="Tc__ymnm_jYJUCTPh4g9RtsUg_29_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7415000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3hNl2cG_e0iw0IDtLwg0sQ"
      decimals="-3"
      id="Tc_MolQQ4L0sE6BsVh4kSWPNw_29_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">826000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Qzqncfw6tke1ZO3DkQEDlA"
      decimals="-3"
      id="Tc_Q-bjCoNIwEqrnmSEYKisBw_29_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">29568000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w8rxm3hBy0y_-Ae1ZVWKlw"
      decimals="-3"
      id="Tc_mgukVP1FjEKmRztclechSQ_30_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4216000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_t-iXQatkZ0KzkyWEc3dpwQ"
      decimals="-3"
      id="Tc_sYlrktFIwUqjdyGFEwy2Uw_30_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5925000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A"
      decimals="-3"
      id="Tc_aI-OvPO5ZEm2oOZ_cy79pA_30_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2291000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA"
      decimals="-3"
      id="Tc_iJcw_NKwZ0yBz_ubdtCbtQ_30_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12432000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_Pu91BJKoY0yyQ7jXhJKbDw"
      decimals="-3"
      id="Tc_iCr6K8Cx7UaMb2FrKL70mg_31_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1374000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA"
      decimals="-3"
      id="Tc_IO-YXLS-70WulqjBtuQPlg_31_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1374000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w8rxm3hBy0y_-Ae1ZVWKlw"
      decimals="-3"
      id="Tc_QUuIREGAO0aaF-vH9MZzOA_32_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_t-iXQatkZ0KzkyWEc3dpwQ"
      decimals="-3"
      id="Tc_Ti6ijNGHjUKFge0AxF-cAw_32_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4270000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A"
      decimals="-3"
      id="Tc_jXrz4-YYlkGY06VI7LOl5A_32_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1659000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA"
      decimals="-3"
      id="Tc_VXeb-YSb8kCXqpsEXV_57Q_32_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5941000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_1Ejjatsx5EiLIN4yYKiM8A"
      decimals="-3"
      id="Tc_-dHEBPACV0-6DstWeNZK5g_33_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-9000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_QkKofzYX-kCJ9RgBwVZtzA"
      decimals="-3"
      id="Tc_B-KMtuDzOE-eMphQb6P3fg_33_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-9000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_GVJksEcFyUyKzVpP3nSNNg"
      decimals="-3"
      id="Tc_4MeS1rbuzE2sNdqN0QJ0Pg_34_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12914000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_K5vleFi0skqHLv2sbuvs-Q"
      decimals="-3"
      id="Tc_iiKEAeZtlkWHeHVxAIaPBw_34_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14272000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_5cbrQ8MBFkim2wo7LQxZVQ"
      decimals="-3"
      id="Tc_wd-QIAuWDkqgEKIxgM4ddA_34_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8038000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_EGzp-xjlD0SJrQdKTR20uA"
      decimals="-3"
      id="Tc_HaKIM4lkQkWpINY4JlE7BA_34_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_cvac_CumulativeAmortizationAndImpairmentMember_Fo_xNC8x2E2Nw6expsmq5Q"
      decimals="-3"
      id="Tc_X5BCPoH2xkSKvJZlCCJbEg_34_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37424000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_SHbUU420-U6-wZvoecLRCQ"
      decimals="-3"
      id="Tc_Pl89EomiJU2b7EMXxiXWeg_36_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">21924000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_vuDrG59udk6_pmg0jdRl8g"
      decimals="-3"
      id="Tc_d2gyu5UFXUm9hBGlxVZFSA_36_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40248000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_yqlv57v0OEG1_brdVqLq1g"
      decimals="-3"
      id="Tc_Cpp-r0e_ekS129Mb3vZIMQ_36_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4359000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_vIgFICzC7UiHO-GUZ0v4Yw"
      decimals="-3"
      id="Tc_pPKzviZ4Wki44THc8ekNxw_36_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">101733000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_ySv7TR-XWk-Cxd0dN4skjw_36_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">168264000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_jiGBndkblk6uSV1cNASR2w"
      decimals="-3"
      id="Tc_NZGnuP43GUCFtbEw_uTECQ_37_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17757000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4bLJEBum0UGcpDQCcpC3iw"
      decimals="-3"
      id="Tc_gR1Y4nQ1fUW27xTaFqzHiA_37_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37416000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_6hwBOOLcHk-K1sLFoc-0rg"
      decimals="-3"
      id="Tc_atwa1wtUmkeVMiCkgmGH0Q_37_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5137000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_GttWyC5eVEu0a5D8x-ZKVg"
      decimals="-3"
      id="Tc_meyVqMAjeUeg-4meNh4KdQ_37_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">137631000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_AZdOFkzTW0mMeMPZSsqJ1Q_37_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">197941000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_w6XdbSqlp06NSNtoVAqCkQ"
      decimals="-3"
      id="Tc_3e84q4QgikKiSW_RgEV5NQ_38_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14623000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_XfOC2qeC50iUajLNfhbYcw"
      decimals="-3"
      id="Tc_FtRAWbU5eEmGBoWLAKQneg_38_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40669000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_swVr7XTCQEqhZkjBon9n_w"
      decimals="-3"
      id="Tc_JFXv6bFyrU6fE8hUeePu0A_38_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4698000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_3YEDZJEcNUCF-BbD2Iw3ZQ"
      decimals="-3"
      id="Tc_MUI9-bBsbUqX05FKqhVvvg_38_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">176790000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_stfUbYdH7EyIcb5h6vlkHg_38_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">236782000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_EzBd-ekZi0OsfkAxI02hxw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1374000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_EmPNglP7DkqhCWe6zfGUAw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5884000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:BorrowingCostsCapitalised
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_tLqpl06ifEqjoknfMF7JQg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2375000</ifrs-full:BorrowingCostsCapitalised>
    <ifrs-full:BorrowingCostsCapitalised
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_r2HkDQDj9ky3gH_GTv5c0w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2291000</ifrs-full:BorrowingCostsCapitalised>
    <ifrs-full:BorrowingCostsCapitalised
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_l69cvjsb4Ui1DHCgfvme0A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2932000</ifrs-full:BorrowingCostsCapitalised>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="4"
      id="Narr_CaSxa7frHUi3H5se354k3w"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0576</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="4"
      id="Narr_r5iHAfOtDU2pWZoXepGsgA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0578</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="4"
      id="Narr_6uh9EQp9lEmHHmdsdstEzA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0717</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Group_XSLMR1ibY0-eyZ6TabHjQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:33.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use&#160;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Land&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Buildings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vehicles&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,183&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 275&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,303&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 43,761&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions (new leases and reassessment of existing leases)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,264)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (352)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,772)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 39,574&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 319&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,950&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,843&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use&#160;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Land&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Buildings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vehicles&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,639)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (316)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (710)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (710)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,183&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 275&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,303&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 43,761&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_4U9TKa-8kku0qyyWYuN66g"
      decimals="-3"
      id="Tc_dQeFQ67kkEeMl05cirZPsQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41183000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_BptK40MzA0KOKdTRAaFA1A"
      decimals="-3"
      id="Tc_3NQA7XzyFEmIoiVEatnrYg_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">275000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_v2qH86-io02_ESJqX83O4g"
      decimals="-3"
      id="Tc_C79Iq8pqYk6F9Ci8cqqQCw_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2303000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_DEOhZkV1u0-QMW_pRle9gw_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">43761000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg"
      decimals="-3"
      id="Tc_tvY4SeTApUWlw8eTqTFYGQ_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4788000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_GrkJ0r-6s0aI6oLGR4t78A"
      decimals="-3"
      id="Tc_w1Wr-q3OTEqQcNIVN0ocLw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">200000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_8W-lpVPKrkihHgLwAsUEmQ_6_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4988000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg"
      decimals="-3"
      id="Tc_SS_7ToHoakCNjUHxIAz2aA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5264000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_GrkJ0r-6s0aI6oLGR4t78A"
      decimals="-3"
      id="Tc_W0ynrP5zjE-LgtQJ10wWug_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">156000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_uqcVVb-EwESwn3lB6wxn9g"
      decimals="-3"
      id="Tc_JxqrUNsaeEyEmnHr4PQD0Q_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">352000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_Uq5XlrxptUKTpr2hcU58Ug_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5772000</ifrs-full:DepreciationRightofuseAssets>
    <cvac:ImpairmentOnRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg"
      decimals="-3"
      id="Tc_8Nxs3i9MEEmnnM_HbJI5hg_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1100000</cvac:ImpairmentOnRightOfUseAssets>
    <cvac:ImpairmentOnRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_NP20IlEmKEuISiECbUvUdg_8_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1100000</cvac:ImpairmentOnRightOfUseAssets>
    <cvac:Foreigncurrencytranslationrightofuseassets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember__KD5Au0xS06viWz--d0Sdg"
      decimals="-3"
      id="Tc_Er0Gs9gWfkK9lqsH6p01cg_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-33000</cvac:Foreigncurrencytranslationrightofuseassets>
    <cvac:Foreigncurrencytranslationrightofuseassets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_PIyfSL9apUyk2UeT_euRfA_9_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-34000</cvac:Foreigncurrencytranslationrightofuseassets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_k9Skiw6h_kq4wMDfbW6Y1g"
      decimals="-3"
      id="Tc_BRy5XP5AOU-zFu7T8skkYg_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">39574000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_rxt_fxShG0i6GkUMgTzphQ"
      decimals="-3"
      id="Tc_abijlBpnxUuc7VYIQvk4xg_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">319000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_FHdyYMNB7Eq_o5tMRVitmg"
      decimals="-3"
      id="Tc_LSM08_2yl0Cgw1c7ZvI-OA_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1950000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_fiL3NgYYI0im8HnGKmbjIw_10_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41843000</ifrs-full:RightofuseAssets>
    <cvac:NumberOfRentalAgreements
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_TbingenMember_qUeXimjzQ0KjqUiReUdC4g"
      decimals="INF"
      id="Narr_ym8pQkDDsUORmsWRm7pQWA"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">6</cvac:NumberOfRentalAgreements>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_TbingenMember_qUeXimjzQ0KjqUiReUdC4g"
      decimals="-3"
      id="Narr_XzNqqoPbzka9HDTZ7BuAfg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2452000</ifrs-full:AdditionsToRightofuseAssets>
    <cvac:NumberOfRentalAgreements
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_WiesbadenMember_qqZmF0WHQk-CQHfo53QZ7w"
      decimals="INF"
      id="Narr_uAhMI4K9bkuJFxJNltGa0A"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">1</cvac:NumberOfRentalAgreements>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvac_WiesbadenMember_qqZmF0WHQk-CQHfo53QZ7w"
      decimals="-3"
      id="Narr_D0VAkyMhrU2YOOTaiN-qSw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">510000</ifrs-full:AdditionsToRightofuseAssets>
    <cvac:RightOfUseAssetsNumberOfExtensionOption
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="INF"
      id="Narr_7soaQe8Eq0iGN-wHPFgTBQ"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">1</cvac:RightOfUseAssetsNumberOfExtensionOption>
    <cvac:IfrsLesseeOperatingLeaseRenewalTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_iKUsxr25qkmIgMu1FiI4qA">P5Y</cvac:IfrsLesseeOperatingLeaseRenewalTerm>
    <cvac:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Group_gh1fkl4ob0yAPF6hUC3i7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions (new leases and reassessment of existing leases)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,568)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,824&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,005&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,892&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,439)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_J1a4onlnpUujgNXlytBGKg_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42086000</ifrs-full:LeaseLiabilities>
    <cvac:AdditionsLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_pIsM3246TEax4q6vh87iRA_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4988000</cvac:AdditionsLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_hpXhLicIi0CXK7JjgAJfRQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2375000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_TvJVd9_ue0GGTrp_Tuobiw_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7568000</ifrs-full:CashOutflowForLeases>
    <cvac:ForeignCurrencyTranslationLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_odjw9CjepE2AdQxHpThgcQ_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-57000</cvac:ForeignCurrencyTranslationLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_GIeiOjaA60GWCxoD4XZXtQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41824000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_D6_KFjQ1I0CuCSzG9uye0A_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5005000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_-Uw8ENdE00e3TG4rhi_C-g_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">36819000</ifrs-full:NoncurrentLeaseLiabilities>
    <cvac:ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Group_SzcK8yTu-Eu0JN95XYaWSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation expense of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,772)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment expense / reversal of impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (710)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,218)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,375)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expense relating to short-term leases (included in cost of sales)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (76)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (70)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expense relating to leases of low-value assets (included in general and administrative expenses)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (66)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (55)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income from sub-leasing right-of-use assets presented in &#x201c;other operating income&#x201d;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:ScheduleOfLeasesExpenseRecognizedInProfitOrLossTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_gVVxjInyP0mTEIJFmXm51A_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3901000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_oRPcB5yavUmkEchwQ5mL2g_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5053000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_0jbpkJOEWEK1LJ-JPPUALw_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5772000</ifrs-full:DepreciationRightofuseAssets>
    <cvac:ImpairmentOnRightOfUseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_6PuldUUywECf40lNm7ib9Q_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">710000</cvac:ImpairmentOnRightOfUseAssets>
    <cvac:ImpairmentOnRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_ICI1r5dlhkmEoQZy4--PfA_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1100000</cvac:ImpairmentOnRightOfUseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_CqToswRjJEOUKXmzZH-ZgA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1729000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_kc5C3gGtwkWd9Gb-R9Jdaw_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2218000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_sk_BXk05-U6WYOQVnEL7RQ_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2375000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_KgTHMeDWI0KauqPWvPswQw_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">119000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_gGGuIPkuTUmzMzZvwIUZUQ_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">76000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_zJmtIxH1bEe9ixEUtL1tMg_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">70000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_KBs_FuR1ik6m8ZUwxh2KmA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">39000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_ca6Bvm5FtEixoAurWJVx2w_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">66000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_LRiDL5ebs0-Ms4A9HRSR8w_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">55000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:IncomeFromSubleasingRightofuseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_3jtruc42_UqPyf4AmRB_gA_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">51000</ifrs-full:IncomeFromSubleasingRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_MqFywxdSdU-VC2yfCNoI7A"
      decimals="-3"
      id="Tc_tnk8O1cVkkqzuFQpHb6SDg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">31547000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_8jM0YpsBR0yMEEEdxZY0HQ"
      decimals="-3"
      id="Tc_yKzAtP5pWUeiqEXTBLOzjA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">142000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_kyYUjNgs7UmP0QeRDTa87w"
      decimals="-3"
      id="Tc_4IJ3hJU5J0aUi9XW9gCqGQ_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">440000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_Q6eBG0sst0-hvpVaNsQquA_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">32129000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ"
      decimals="-3"
      id="Tc_WnH4T6xNC0mstKjM7uFCcA_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14834000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_tg5uf0hf90mOvis2DMD5YQ"
      decimals="-3"
      id="Tc_v2cmyOiyk0aY8bqXDaJptw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">231000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_WuUc_xWmdUqMzpKJ1_OlaA"
      decimals="-3"
      id="Tc_lUxCPRu8uEOv3_NdfxLJxg_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2179000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_EM3ERRevWEWekDrsaor9vQ_6_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17244000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ"
      decimals="-3"
      id="Tc_Y3ymH2bGfUa9f1t713BkGw_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4639000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_tg5uf0hf90mOvis2DMD5YQ"
      decimals="-3"
      id="Tc_X_YyEkJUxEi-Hlbrp0EjGw_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">98000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_WuUc_xWmdUqMzpKJ1_OlaA"
      decimals="-3"
      id="Tc_IiXOstB73kmFPUKpAFjKkQ_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">316000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_llc9wDtYWUux_KDb_JPM3w_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5053000</ifrs-full:DepreciationRightofuseAssets>
    <cvac:ImpairmentOnRightOfUseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ"
      decimals="-3"
      id="Tc_J_XQSJR_OkCMPEtEQ27f1A_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">710000</cvac:ImpairmentOnRightOfUseAssets>
    <cvac:ImpairmentOnRightOfUseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc__4alOeP6sUqEf8LtcrYQgg_8_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">710000</cvac:ImpairmentOnRightOfUseAssets>
    <cvac:Foreigncurrencytranslationrightofuseassets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_cP34yhvpAkmFMUpRDd0bgQ"
      decimals="-3"
      id="Tc_CQ78heJICUqioSo4uibCaw_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">151000</cvac:Foreigncurrencytranslationrightofuseassets>
    <cvac:Foreigncurrencytranslationrightofuseassets
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_VaJFntROA0KmtLMgJHcDlw_9_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">151000</cvac:Foreigncurrencytranslationrightofuseassets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_4U9TKa-8kku0qyyWYuN66g"
      decimals="-3"
      id="Tc_JjJwxlqAk0as_a9YrTZVPA_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41183000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_VehiclesMember_BptK40MzA0KOKdTRAaFA1A"
      decimals="-3"
      id="Tc_bWGzgD1YLkeAMYaVfIvt2g_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">275000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfAssetsAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_v2qH86-io02_ESJqX83O4g"
      decimals="-3"
      id="Tc_0XpPhKViukaaYGlNQt3IHA_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2303000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_tIjQQstunEi-sc5-yp30Iw_10_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">43761000</ifrs-full:RightofuseAssets>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_EvvBnjQSs0apuSh_tMEeGQ_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28892000</ifrs-full:LeaseLiabilities>
    <cvac:AdditionsLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_fcpt0K-wpUG6ZZkgzgRRHw_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17241000</cvac:AdditionsLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_i-H-m9M3A0W-7F_cB-8VIw_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2218000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_5opMwmMCA0SEg84r3eFQ9A_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6439000</ifrs-full:CashOutflowForLeases>
    <cvac:ForeignCurrencyTranslationLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_4p2laoScQUe4StJ-B7PD7w_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">174000</cvac:ForeignCurrencyTranslationLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_RRKA-wnmqES1B-bqsoe0rA_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42086000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_Q2My9glY8EOklv9ZThUohA_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4980000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_anomI2d0xkyQqHEBcf07aw_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37106000</ifrs-full:NoncurrentLeaseLiabilities>
    <cvac:OptionalLeasePaymentsUponUsingExtensionOptions
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_hCGaaRXo8UCfSx1QCESCEQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">39325000</cvac:OptionalLeasePaymentsUponUsingExtensionOptions>
    <ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_zFHSCHcR3EqjgHJ6VMxADw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Assets held for sale&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;In 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO Equipment identified for sale had a gross book value of EUR 29,531k and was written down by EUR 19,064k (with the corresponding expense recognized in cost of sales) to EUR 10,467k, the fair value less anticipated costs to sell.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;During fiscal year 2023 assets with a net book value of EUR 167k were classified as assets held for sale and assets held for sale with a net book value of EUR 1,505k were sold through direct sales and an external service provider, indicating the remaining assets held for sale&#x2019;s carrying value might be further impaired. Based on fair value less costs of disposal calculations, and taking into account the most recent sales projections, including Q1 of 2024, the external service provider&#x2019;s market expertise, and an assessment to date as prepared by management, the fair value at December 31, 2023 was lowered to EUR 2,419k by a decrease of EUR 6,711k (with the corresponding expense recognized in cost of sales). The assets held for sale have been valued taking into account the current market circumstances and demand for secondhand equipment for assets outside of warranty periods. Criteria for the determination of the fair value were defined based on certain sales scenarios and considering different sales campaigns, where valuation techniques applied have remained consistent to the prior year.&lt;/p&gt;</ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <cvac:NetBookValueOfCmoEquipmentHeldForSale
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_bYVRs52Zrk6qygZx760DZQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">29531000</cvac:NetBookValueOfCmoEquipmentHeldForSale>
    <cvac:ImpairmentOfAssetsHeldForSale
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_t4__rOb4ZU-rL0vqWseViw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19064000</cvac:ImpairmentOfAssetsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_IGXR47s-4U2C3UlCo9UDEQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10467000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <cvac:AssetsHeldForSaleNetBookValueSold
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr__eKq45xxCk238LCLr86iGQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">167000</cvac:AssetsHeldForSaleNetBookValueSold>
    <cvac:AssetsHeldForSaleNetBookValueDirectSold
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_I8b5FigfGEOk6Udj_G4tlQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1505000</cvac:AssetsHeldForSaleNetBookValueDirectSold>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_DhlSAVI5SUOJVVvz_4_hfg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2419000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <cvac:DecreaseThroughClassifiedAsHeldForSale
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_EVGSrCZB8keY-6uGamX2dA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6711000</cvac:DecreaseThroughClassifiedAsHeldForSale>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_Xi-9GfONZUibh_cN9Lc1LA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Inventories&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The inventories include only raw materials and supplies amounting to EUR 24,801k (December 31, 2022: EUR 23,989k), which are recoverable under the Company&#x2019;s agreements with its collaboration partners. During the year ended December 31, 2023, the increase in inventory of EUR 811k is primarily due to purchases of raw material for R&amp;amp;D collaborations and for stockpiling towards the PPA of EUR 62,082k. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Timelines related to the Pandemic Preparedness Agreement were ambitious with the aim of providing acute pandemic preparedness in Germany in the context of emerging COVID-19 variants. In 2023, CureVac identified a risk that necessary regulatory approvals needed to meet these timelines may not be achieved within the contractually agreed timeframe. After consultation with ZEPAI, CureVac applied for a timeline extension as foreseen under the agreement to avoid procurement of further substantial amounts of raw material at risk. As of December 31, 2023, it was considered unlikely that the extension would be granted. Additionally, a rapidly changing epidemiological environment did no longer prompt an acute pandemic threat. Accordingly, inventories which had been stockpiled as required by the PPA, were written down to their net realizable value. Ultimately, the extension was not granted, whereupon CureVac and GSK jointly decided to terminate the agreement. For more detailed information we refer to Note 21. In total, inventory in the amount of EUR 47,129k was written - off as of year-end including write-off of materials received as part of Gen1 commitments. The residual amount was consumed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expense recognized related to the write-offs, scraps and consumption are mainly included in &#x2018;Cost of Sales&#x2019;. In the year 2022 EUR 80,021k were written off.&lt;/p&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <ifrs-full:RawMaterials
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_FmEUobXRK02A1nGn7EhvEg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24801000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_u81tq42gZ0CfA5NH9PFj0g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23989000</ifrs-full:RawMaterials>
    <cvac:IncreaseDecreaseInInventory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_c8pdUV0rRESLef5YQ4IorQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">811000</cvac:IncreaseDecreaseInInventory>
    <cvac:InventoryPilingForPandemicPreparednessAgreement
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_gjh5EOdvdEmhq9ek037-pw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">62082000</cvac:InventoryPilingForPandemicPreparednessAgreement>
    <ifrs-full:InventoryWritedown2011
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_PBDqY4e5cUmEFLEhP9XVBg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">47129000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_5PFOZzZ_30C9wzZtjbpx0w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">80021000</ifrs-full:InventoryWritedown2011>
    <cvac:DisclosureOfOtherFinancialAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_1l3f0tk1LEax9mz8LmGlNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Other financial assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Other financial assets as of December 31, 2023 amounted to EUR 2,661k (2022: EUR 4,487k) mainly include deposits held by third parties in amount of EUR 1,936k (2022: EUR 1,936k) and other receivables in the amount of EUR 726k (2022: EUR 2,551k).&lt;/p&gt;</cvac:DisclosureOfOtherFinancialAssetsExplanatory>
    <ifrs-full:CurrentInvestments
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_dJLKcsFwf0eUfyd88IceUA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2661000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_qwutj0HrnkadKls2H43Rog"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4487000</ifrs-full:CurrentInvestments>
    <cvac:DepositsHeldByThirdParties
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_nSRslSY3CkWIlGnt8qqnlQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1936000</cvac:DepositsHeldByThirdParties>
    <cvac:DepositsHeldByThirdParties
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_PBxm_UIZxUqup4BdVGWqrA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1936000</cvac:DepositsHeldByThirdParties>
    <ifrs-full:OtherReceivables
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_RfZYMPzsJk6bWmQw6xc0Tw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">726000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_nsvzKBJZXkec23qgKoX9Og"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2551000</ifrs-full:OtherReceivables>
    <cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_PkekTGcw90WmfP8xLLJt1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Prepaid expenses and other current assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other current assets of EUR 23,763k (2022: EUR 40,002k) include prepayments for future service agreements and material in the amount of EUR 1,075k (2022: EUR 4,507k), deferred charges of EUR 5,463k (2022: EUR 5,345k) and receivables of EUR 4,344k (2022: EUR 5,595k). For more details, refer to Note 3.8. As of December 31, 2023, we had tax receivables, mainly VAT refund claims, of EUR 12,881k in other current assets (2022: EUR 24,555k).&lt;/p&gt;</cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_1ZgqOPnfCUWUfMD-aiRdWQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23763000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_0Qo9BdI0pUWrLviHOD8hhg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40002000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_gtwcvPuseEqCpoI0DjGlbw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1075000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_OLe-LwdHsECOUJO088-QFA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4507000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_vZum8BI7DE-m8ZkfJY9Okg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5463000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_g91rDLrGQ0Kf2UqPNc7Mfg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5345000</ifrs-full:CurrentPrepaidExpenses>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_qpUmqYWcEkej_TFR1rGkJA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4344000</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_DhaRRmjPZUSjgSH7p1wVbg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5595000</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_yF6HE7k0sUSMv_jrKLycYg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12881000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_zUw7NXPoVkaimEkknwDgwQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24555000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_ImtZU1CtokaCkFhKtxxaDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Overview&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;According to the Company&#x2019;s articles of association, the Company&#x2019;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a nominal value of EUR 0.12. As of December 31, 2023, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#x2019; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#x2019;s articles of association.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The number of shares issued and outstanding in fiscal 2023 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 180,460,565&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Follow-on public offering, incl. Greenshoe &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5,750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;910,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2021 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued as part of the at-the-market offering program &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,908,493&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued to former shareholders of Frame Pharmaceuticals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 858,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued for LTIP option exercises and RSU deliveries &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2022 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 194,997,091&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued as part of the at-the-market offering program&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,748,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued as part of the public offering&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,027,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued for LTIP option exercises and RSU releases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 223,988,675&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Refer to Note 21 for additional information on share transactions occurring after December 31, 2023. The share transactions which occurred in 2021, 2022 and 2023 are as described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Follow-on public offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2021, the Company completed a follow-on public offering whereby it sold 5,000,000 common shares at a price of USD 90.00 per share. In addition, the underwriters exercised their option to purchase an additional 750,000 common shares at this same price less the underwriting discount. The aggregate proceeds, net of underwriting discounts, received by the Company from these transactions were EUR 426,652k. Offering costs for legal, accounting, printing and registration fees of EUR 22,590k were recognized as reduction to capital reserve against the proceeds from the offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At-the-market offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 17, 2021, CureVac filed a prospectus for an &#x201c;at-the-market&#x201d; (ATM) offering program to raise additional cash of up to USD 600 million. The program was activated in June 2022. Through December 31, 2022, CureVac has issued 6,908,493 shares and raised gross proceeds of USD 69,139k. In the first quarter of 2023, 1,748,218 shares were issued under the ATM program, raising USD 18,023k million in gross proceeds. Offering costs for legal, accounting, printing and registration fees were recognized as reduction to capital reserve against the proceeds from the offering. Following these issuances, the remaining value authorized for sale under the at - the - market program amounts to USD 513 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Follow-on public offering 2023&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2023, the Company completed a follow - on public offering whereby it sold 27,027,028 common shares at a price of USD 9.25 per share. The aggregate proceeds, net of underwriting discounts, received by the Company from these transactions were EUR 219,832k. Offering costs for legal, accounting, printing and registration fees of EUR 14,580k were recognized as reduction to capital reserve against the proceeds from the offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Frame Pharmaceuticals acquisition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 8, 2022, CureVac entered into a Share Purchase Agreement (SPA) to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., a research company focused on advanced genomics and bioinformatics, based in Amsterdam, Netherlands. Under the SPA, the total consideration for the the purchase was up to EUR 34 million, conditioned on the meeting of certain development milestone payments. On the date of acquisition, July 1, 2022, CureVac issued 858,496 shares to the former shareholders of Frame Pharmaceuticals. Refer to Note 20 for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercises of share options under the prior VSOP plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The IPO in August 2020 triggered an exercise event under the set terms of the prior VSOP plan (see Note 10). In March 2021, CureVac received 759,677 shares from the old shareholders and transferred 390,023 shares to the participants of the old VSOP plan. CureVac withheld 369,654 shares equaling the amount to be paid for income tax and social security tax. A second triggering event, &#x201c;liquidity after IPO&#x201d; was met one year after IPO. In October 2021, CureVac received 765,223 shares from the old shareholders and transferred 523,897 shares to the participants of the VSOP plan. CureVac withheld 241,326 shares equaling the amount to be paid for income tax and social security tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A third triggering event, again &#x201c;liquidity after IPO&#x201d;, was met on the second anniversary of the IPO. In December 2022, CureVac received 777,260 shares from the old shareholders. All shares were transferred to the participants of the prior VSOP plan and the portion of shares equaling the amount to be paid for income tax and social security tax were sold to pay for these taxes and social security amounts. In 2022, CureVac recorded a receivable for income tax and social security tax for former employees and received these amounts in Q1 2023. A fourth triggering event, again &#x201c;liquidity after IPO&#x201d;, was met on the third anniversary of the IPO. CureVac will receive 786,746 shares from the old shareholders and will transfer these to the participants of the old VSOP plan in March 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercises of share options under the new VSOP plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Participants of the new VSOP plan (see Note 10) were able to continue to exercise their options throughout the year of 2023. In 2023 69,246 shares (2022: 147,620 shares) were issued upon exercise of options and no options were forfeited (2022: 96,785).&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw"
      decimals="INF"
      id="Narr_EPtB9tP-TEK2-HT_DhqQMA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_Sw6Kjo1tDE-BHe-dTLqX0g"
      decimals="INF"
      id="Narr_dihUyWBzmU66FxqenRAbZA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_szgl50mPNUakBk7gzS1jkw"
      decimals="2"
      id="Narr_MPWn6Yhb9k2MaUaT36kptg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">0.12</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_Sw6Kjo1tDE-BHe-dTLqX0g"
      decimals="INF"
      id="Narr_7_l2rU1GWkiYSJzNRPqkBQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">0</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_5ouEwXM_v0yAlU6QCx9kkA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 180,460,565&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Follow-on public offering, incl. Greenshoe &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5,750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;910,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2021 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued as part of the at-the-market offering program &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,908,493&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued to former shareholders of Frame Pharmaceuticals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 858,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued for LTIP option exercises and RSU deliveries &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2022 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 194,997,091&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued as part of the at-the-market offering program&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,748,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued as part of the public offering&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,027,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issued for LTIP option exercises and RSU releases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 223,988,675&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_12_31_2020_weQNB6gv8EuEjNt9Otl0jA"
      decimals="INF"
      id="Tc_ecwrKnXM6UOEVpuUwd4Ixg_1_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">180460565</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IncreaseInNumberOfSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_pq40A99Zy0-J899Hpgyiuw"
      decimals="INF"
      id="Tc_uVpFMSvKLEq3ym5R9Y2_xA_2_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">5750000</cvac:IncreaseInNumberOfSharesOutstanding>
    <cvac:ShareOptionExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="INF"
      id="Tc_VMAl3pVhM0ukg4-u0TlPSA_3_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">910163</cvac:ShareOptionExercises>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="INF"
      id="Tc_N_Y6BK8HR0anqbp5EaDwuQ_4_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">187120728</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_bhT-Hm2SaEu5uUt9fXRzGw"
      decimals="INF"
      id="Tc_YWd0pTw-A0WWw8KZfgP_iQ_5_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">6908493</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:StockIssuanceDuringPeriodForExistingShareholders
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="INF"
      id="Tc_IpNLY7l1WUqkSKSuGb6qRw_6_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">858496</cvac:StockIssuanceDuringPeriodForExistingShareholders>
    <cvac:NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="INF"
      id="Tc_lpB0PwKwzkC43WBCMggF5A_7_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">109374</cvac:NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="INF"
      id="Tc_zkohPBrMUkitW6zdsKie5g_8_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">194997091</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember___lz1oR3-k2v1ISygb7bPw"
      decimals="INF"
      id="Tc_RhcHOzaSPUGImQymEnKqzw_9_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">1748218</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_PublicOfferingOfCommonSharesMember_aEkH7sfkH02lkeyEWiOvdA"
      decimals="INF"
      id="Tc__Hu1v7rGg0ifiIVdq1Ag-Q_10_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">27027028</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="INF"
      id="Tc_DntSvQSQyUqGnYuS1kQ8kg_11_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">216338</cvac:NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="INF"
      id="Tc_4MstNagF2kSEXS-EWEtL5A_12_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">223988675</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IncreaseInNumberOfSharesOutstanding
      contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA"
      decimals="INF"
      id="Narr_msG4CyzzpUiuEcyQXuOe8Q"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">5000000</cvac:IncreaseInNumberOfSharesOutstanding>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA"
      decimals="2"
      id="Narr_c2_rpLggUk-Ogu1bsF6tFA"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">90.00</ifrs-full:WeightedAverageSharePrice2019>
    <cvac:IncreaseInNumberOfSharesOutstanding
      contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_IfrsOverAllotmentOptionMember_riZy2Z4KG0Gk8otdZzKN2A"
      decimals="INF"
      id="Narr_e-1NQF7HqU6qunenEzLEyA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">750000</cvac:IncreaseInNumberOfSharesOutstanding>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA"
      decimals="-3"
      id="Narr_Jwf8ve0PCEyaqek2Gf1j4g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">426652000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="Duration_2_1_2021_To_2_28_2021_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember__246cdeW1k6kOKJcH-VEKA"
      decimals="-3"
      id="Narr_IvEActDn40WsolN3Y7oTQg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22590000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_9_17_2021_To_9_17_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_jUlavD3NjEy-jk37WZ7FiQ"
      decimals="-3"
      id="Narr_SiRJkB_PSECYRkcQLMRzkA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">600000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_H5V7XcidSEeqvZO0kZROGA"
      decimals="INF"
      id="Narr_jl3xvkbAGkCXEIyH48LshA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">6908493</ifrs-full:NumberOfSharesIssued>
    <cvac:AggregateGrossProceedsReceivableFromIssuingShares
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember___lz1oR3-k2v1ISygb7bPw"
      decimals="-3"
      id="Narr_IZhw5NN2TkCfXSh75lTAyQ"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">69139000</cvac:AggregateGrossProceedsReceivableFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_npuKWKdpoUWvxgvLp2wwtg"
      decimals="INF"
      id="Narr_vijVmn-d1UaWMgNRPXbpgA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">1748218</ifrs-full:NumberOfSharesIssued>
    <cvac:AggregateGrossProceedsReceivableFromIssuingShares
      contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_oXIlxEKLg0uXPK0YY9JWaA"
      decimals="-3"
      id="Narr_hASuyzGA1EKMxo6NKNEXdw"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">18023000</cvac:AggregateGrossProceedsReceivableFromIssuingShares>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_12_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_H5V7XcidSEeqvZO0kZROGA"
      decimals="-6"
      id="Narr_KCWcMkJjAkuU9m4bhIDyFg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">513000000</ifrs-full:NumberOfSharesAuthorised>
    <cvac:IncreaseInNumberOfSharesOutstanding
      contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw"
      decimals="INF"
      id="Narr_eFrsjEwNLESB8ZVDxwUSwQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">27027028</cvac:IncreaseInNumberOfSharesOutstanding>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw"
      decimals="2"
      id="Narr_cpFEG4eZI0q8WHgm-aL9mA"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">9.25</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw"
      decimals="-3"
      id="Narr_98eSE-NCqEaPj5Biv9aRSw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">219832000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_ClosingOfPublicOfferingOfCommonSharesMember_MpnwPNaMB0GC-xvqQMApnw"
      decimals="-3"
      id="Narr_siLudS2s3U-UTn8Ksx79jg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14580000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_51kbfHiK10CFR5dmzP024Q"
      decimals="-6"
      id="Narr_jN0WXyusnUe-gxohsK03mw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">34000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_ObBmT6n8TkOKFE0nU935Fw"
      decimals="INF"
      id="Narr_qojuy7XPBk2pMpvjUuCjjw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">858496</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw"
      decimals="INF"
      id="Narr_wByHZDzoG0GTHomAjnaf6Q"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">759677</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:IfrsNumberOfSharesHeldForTaxLiabilities
      contextRef="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw"
      decimals="INF"
      id="Narr_KW2WAiknn0-YHD2pCGlULw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">390023</cvac:IfrsNumberOfSharesHeldForTaxLiabilities>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_8_1_2020_To_8_31_2020_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_xnekGZLNs0iRvzBgocLmbw"
      decimals="INF"
      id="Narr_mYHyPgsZbESvV7bZ-VPFLw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">369654</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q"
      decimals="INF"
      id="Narr_RmxXIpiDL06445m3dhykeA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">765223</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:IfrsNumberOfSharesHeldForTaxLiabilities
      contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q"
      decimals="INF"
      id="Narr_p3i5A57COkmA12KOJ5HuRg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">523897</cvac:IfrsNumberOfSharesHeldForTaxLiabilities>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_10_1_2021_To_10_31_2021_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_nPplSSeXbUmt0yqi-xaR7Q"
      decimals="INF"
      id="Narr_3KoZgMH9dkOnwPu4vNuwww"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">241326</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_mp2AzJFe_U2GzM3aVT9NMA"
      decimals="INF"
      id="Narr_FKRXcqkAsEeoJBAex4m-XQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">777260</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_OldVsopPlanMember_A6it69ifLUeKRgdoAQT4iw"
      decimals="INF"
      id="Narr_7mzT7Z3t_kKDfxgnzL0KtA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">786746</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_YmO0AmylMUGXyDkvXeCLlQ"
      decimals="INF"
      id="Narr_tw-5GpP8E0a4K0EVID-T8g"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">69246</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_sAMF0EDzsUqQ8PpTkE7KMQ"
      decimals="INF"
      id="Narr_388rQvlhukikNAD8SsuzFA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">147620</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LegacyPlanMember_RGbEltV_HESu23rxrqMUeQ"
      decimals="INF"
      id="Narr_g0fMmOmDNEuEi4qwrxf08w"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_NewVsopPlanMember_sAMF0EDzsUqQ8PpTkE7KMQ"
      decimals="INF"
      id="Narr_Nkz6eCfxX0-XhHDX12bTzQ"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">96785</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_J15S6nmpgk-KhQe7Sn3GBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Share-based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December 31, 2023, 2022, and 2021, the Group operated the following share-based plans for members of management and other key employees of the Group, as well as members of the supervisory board:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Prior VSOP&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;New VSOP &#x2009;&#x2014;&#x2009;for US employees (from 2019 onwards)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;LTIP Stock Options &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;LTIP RSUs (from 2021 onwards)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;"&gt;All programs were accounted for as equity-settled share-based payment awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Measurement of the grant date fair value is based on valuation techniques appropriate in the circumstances, such as Black Scholes option pricing models or a Monte Carlo simulation. Expected volatility, a key input to such models, was based on an evaluation of the historical volatilities of comparable listed biotech-companies over the historical period commensurate with the expected option life. Regarding the expected option life of the stock option programs, this was based on the assumptions that the beneficiary would exercise his option in equal installments from the date of the first time possible (taking into account lock-up and potential trading windows restrictions) until maturity. The risk-free interest was derived from German or US-Government bonds, as appropriate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expense recognized for share-based payments during the years ended December 31 is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (624)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (572)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;LTIP Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,472)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,944)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;LTIP RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (705)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,108)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,072)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSU Supervisory board&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (566)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (478)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (652)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (14,939)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (9,184)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,697)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prior VSOP&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The development of the virtual shares in the Prior VSOP program granted to management and key employees was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.27%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the beginning of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,951,265&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,426,365&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,614,246&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34,859)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,091)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised during the period &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,524,900)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (777,260)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the end of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,426,365&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,614,246&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,603,155&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,365,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,509,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,588,513&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;none&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;none&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;none&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The IPO on August 14, 2020, triggered the right to exercise 10 % of the vested virtual shares at the end of the lock-up period, which ended on February 10, 2021. By March 10, 2021, the beneficiaries declared the exercise of all their exercisable 759,677 virtual shares and CureVac received 759,677 shares from their former major shareholders as of 2015, on that day. On March 11, 2021, CureVac transferred 390,023 shares to the exercising beneficiaries and withheld 369,654 (treasury) shares equal to the monetary value (approximately EUR 26 million) of the beneficiaries (wage) tax and social security obligations, which CureVac transferred to the relevant authorities on the exercising employee&#x2019;s behalf in cash. The share price of CureVac on March 11, 2021, was EUR 69.69.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A second 10 % portion of the (vested) virtual shares became exercisable on the first anniversary after IPO i. e., on August 14, 2021, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were reached. The beneficiaries declared the exercise of their exercisable 765,223 virtual shares by October 18, 2021 and CureVac received 765,223 shares from the old shareholders on that day. On October 19, 2021, CureVac transferred 523,897 shares to the exercising beneficiaries and withheld 241,326 (treasury) shares equal to the monetary value (approximately EUR 8 million) of the beneficiaries (wage) tax and social security obligations, which CureVac transferred to the relevant authorities on the exercising employee&#xb4;s behalf in cash. The share price of CureVac on October 19, 2021, was EUR 34.56.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A third 10 % portion of the (vested) virtual shares became exercisable on the second anniversary after IPO i. e., on August 14, 2022, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were again reached. The beneficiaries declared the exercise of their then exercisable 777,260 virtual shares by December 12, 2022 and CureVac received 777,260 shares from the old shareholders on that day. On December 14, 2022, CureVac transferred 777,260 shares to the exercising beneficiaries. The portion of shares equaling the amount to be paid for (wage) tax and social security obligations were sold to pay for these amounts. For former employees CureVac shows a receivable position equaling the amount to be paid for (wage) tax and social security obligations. The share price of CureVac on December 14, 2022, was EUR 6.96.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A fourth 10% portion of the (vested) virtual shares became exercisable on the third anniversary after IPO i. e., on August 14, 2023, because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels were again reached. The beneficiaries declared the exercise of their then exercisable 786,746 virtual shares by March 22, 2024 and CureVac received 786,746 shares from the old shareholders on that day. On March 26, 2024, CureVac transferred 786,746 shares to the exercising beneficiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expense recognized in the statement of operations and other comprehensive income (loss)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The expense recognized for this share-based payment plan during the years ended December 31 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of Sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (45)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (624)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (131)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (10)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;New VSOP&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The number of awards in the New VSOP program granted to key employees developed as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the beginning of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 906,595&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 349,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (99,696)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised during the period &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (557,171)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (147,620)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69,246)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the end of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 349,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,862&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,862&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof exercisable &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The remaining life of the option awards as of December 31, 2023 is between 4.5 and 5.7 years (2022: range between 5.5 and 6.9 years).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2021 multiple exercises happened throughout the year. In total 557,171 options were exercised with an average share price of USD 61.28. These exercises led to CureVac having to pay an amount of USD 493k employer taxes and to use USD 981k of the provision recorded in 2020.In 2022, a number of exercises were carried out throughout the year. In total, 147,620 options were exercised with an average share price of USD 16.81. These exercises led to CureVac having to pay an amount of USD 45k employer taxes and to use USD 51k of the provision recorded in 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2023, a number of exercises were carried out throughout the year. In total, 69,246 options were exercised with an average share price of USD 9.90.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expense recognized in the statement of operations and other comprehensive income (loss)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The expense recognized for employee services received during the years ended December 31, 2023, 2022, and 2021 is shown in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (349)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (188)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (572)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Long-Term Incentive Plan (LTIP) - Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 16, 2020, CureVac granted 266,155 options to the former Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the company`s former Chief Business Officer (CBO) / Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan put in place by CureVac.Options will be settled in shares of CureVac.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Options granted to the former CSO have an exercise price of EUR 10.04 per share option and an expiration date of July 14, 2030. The exercise price was based on value of the shares at entry date of the former CSO. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter . Exercise is contingent upon the stock price increasing by +20% from the grant date to the date of exercise, based on the 10-day VWAP at time of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the grant to the former CSO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 57.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (10-days VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 50.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 11.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 10.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.07 - 1.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2022, 6,303 options granted to the former CSO had been exercised. No options granted to the former CSO had been exercised in 2023. As the former CSO left the Group as of July 14, 2023, all remaining unvested awards were subject to accelerated vesting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Options granted to the former CBO / CCO have been granted in 3 tranches vesting over &lt;span style="-sec-ix-hidden:Hidden_QbGLvVS5SkqjgHf0Brd8Fg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt; to 3 years, with exercise prices applicable to future tranches being estimated. The exercise price of the first tranche is EUR 43.87 (USD 52.96), The exercise prices for future installments, 2021 and 2022, were estimated to be EUR 81.48 (USD 98.36) and EUR 81.65 (USD 98.57). For the second tranche the actual exercise price in fiscal year 2021 was determined to be EUR 33.07 (USD 39.92) and of the third tranche the actual exercise price in fiscal year 2022 was determined to be EUR 7.35 (USD 7.68). The tranches each have a term of 10 years. Exercise of all three tranches is contingent on a share price increase of 10 %, based on a &lt;span style="-sec-ix-hidden:Hidden__sfsWKiKEkycy4zRfN1NDQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10&lt;/span&gt;&lt;/span&gt; - day VWAP at the time of each exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the grant to the former CBO/CCO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;First tranche:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 48.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (actual 10-days VWAP before grant date, USD 81.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 67.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 52.96)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 43.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.07 - 1.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;Second tranche:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 24.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (estimated by Monte Carlo simulation to be USD 98.36)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (estimated by Monte Carlo simulation to be USD 98.36)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.07 - 1.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;Third tranche:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 20.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (estimated by Monte Carlo simulation to be USD 98.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (estimated by Monte Carlo simulation to be USD 98.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.07 - 1.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As the former CBO/CCO left the Company as of November 30, 2023, all remaining unvested awards were subject to accelerated vesting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 1, 2021, CureVac granted 2,000 options to a key employee. Options granted to this key employee have an exercise price of EUR 77.73 (USD 88.16) per share option and an expiration date of February 28, 2031. The exercise price was based on the 30 - day volume - weighted average price (VWAP) of March 1 &#x2013; March 31, 2021 of the shares. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +10%, based on the 10 - day VWAP at time of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 0.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (30-days VWAP after grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 77.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 88.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 77.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.08 - 0.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the former Chief Development Officer (CDO). Both grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Options granted to the COO have an exercise price of EUR 70.92 (USD 84.03) per share option and an expiration date of July 2, 2026. The exercise price was based on the 20 - day VWAP of the shares at entry date of the COO. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the &lt;span style="-sec-ix-hidden:Hidden_YzcivET66UycOOg4x0ArdA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10&lt;/span&gt;&lt;/span&gt; - day VWAP at time of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;For the grant to the COO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 17.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (20-day VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 56.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 84.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 70.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.099 &#x2009;&#x2013;&#x2009; 0.903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Options granted to the former CDO have an exercise price: EUR 46.16 (USD 54.79) per share option and an expiration date: August 2,2026. The exercise price was based on the 20 - days VWAP of the shares at entry date of the former CDO. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the 10 - day VWAP at time of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;For the grant to the former CDO, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 17.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (20-days VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 41.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 84.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 46.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.075 &#x2009;&#x2013; &#x2009;0.704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The former CDO has since left the company and, under the terms of his LTIP agreement, his options had expired as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 1, 2022, CureVac granted 9,500 options to a key employee. Options granted to this key employee have an exercise price of EUR 30.67 (USD 33.87) per share option and an expiration date of December 31, 2031. The exercise price was based on the 30 - day VWAP of January 1 &#x2013; January 31, 2022 of the shares. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the 10 - day VWAP at time of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the relevant grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 14.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (30-days VWAP after grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 30.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 34.87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 30.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.40 - 1.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The key employee has left the company and, under the terms of his LTIP agreement, his unvested options have been forfeited as of January 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 1, 2022, CureVac granted 130,000 supplemental options to the Company&#x2019;s management board. 30,000 options were granted to the former CEO, and 25,000 &lt;span style="-sec-ix-hidden:Hidden_tznxVCWtS0SW9reUKePQUQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;options&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_-FWGuI_NEUqdXYeZrX373g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;were&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_hL-cJYxbn0-tJ6X_juFSYQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;granted&lt;/span&gt;&lt;/span&gt; to each of the CFO, former CSO, COO and former CBO/CCO. All grants were made at no cost under the terms of a new long-term incentive plan put in place by CureVac. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The options granted to the management board have an exercise price of USD 19.35 per share option and an expiration date of March 1, 2032. The exercise price was based on the 10day VWAP as of March 1, 2022 + a performance criteria of 15%. The award has a vesting of 25% on each of Dec 31, 2022, Dec 31, 2023, Dec 31, 2024, Dec 31, 2025. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the grants to the management board, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 4.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (10 - day VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 15.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 19.35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 18.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;73.87 - 86.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.34 - 3.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As the former CEO, former CSO and former CBO/CCO left the Group, in 2023, all of their remaining unvested awards were subject to accelerated vesting. As of December 31, 2023 none of these options had been exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 1, 2022, CureVac granted 700 options to a key employee. Options granted to this key employee have an exercise price of EUR 17.45 (USD 19.28) per share option and an expiration date of March 31, 2032. The exercise price was based on the 10 - day VWAP of March 21 &#x2013; March 31, 2022 of the shares. The award vests over a period of four years, with 25% vesting after 12 months and the rest in 1/36 monthly installments thereafter. Exercise is contingent to a share price increase of +20%, based on the 10 - day VWAP at time of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the grant to the key employee, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 6.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (10-days VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 19.28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On April 1, 2023, CureVac granted 144,379 options to the current CEO. All grants were made under the terms of the new long - term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of December 31, 2023, none of the options were exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;For the grant to the CEO, a Monte Carlo simulation has been used to measure the fair value at the grant date. The inputs used in the measurement of the fair value at grant date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Weighted average fair value per option&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;EUR&#160;&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;3.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Weighted average share price (10-day VWAP before grant date)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;EUR&#160;&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;6.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Exercise price (USD &lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;6.66&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;EUR&#160;&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;6.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Expected volatility (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt; 75.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt; 3.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt; 3.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expense recognized for employee services received under the LTIP &#x2013; options during the year ended December 31, 2023, in an amount of EUR 2,944k (2022:EUR 5,564k) is mainly included in general and administration expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Long-Term Incentive Plan (LTIP) - Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 24, 2021, the group awarded 10,956 RSUs to supervisory board members and on December 23, 2021, the group awarded 63,095 RSUs to the executive board and various key employees. These RSU awards vest over 3 years with &lt;span style="-sec-ix-hidden:Hidden_XU_t8pnL4UiX_Hi9qILQtw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one third&lt;/span&gt;&lt;/span&gt; vesting taking place each year on December 31. All RSU awards from 2021 had vested as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, on July 1, 2021, the group also awarded 4,691 special RSU awards. These special RSU awards vest over 12 months and are fully vested as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2022, as part of the LTIP program, the group awarded RSUs (RSU Award 2022) to senior executives as well as supervisory board members.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022 the group awarded 225,888 RSU awards as part of the &#x201c;LTIP - RSU Award 2022&#x201d; to members of the supervisory board, executive board and various key employees. On November 30, 2022, the group awarded a further 7,633 RSU awards to key employees who joined the company during fiscal 2022. These RSU awards vest with one third vesting taking place each year on December 31, 2022, December 31, 2023 and December 31, 2024. &lt;span style="-sec-ix-hidden:Hidden_QYgdAo6NHkmI49zrX7zMAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;One third&lt;/span&gt;&lt;/span&gt; of these RSU awards had vested as of December 31, 2022, one further third as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, on January 1, 2022, the group awarded 36,000 supplemental RSU awards to the former CEO. This RSU award vests over 12 months and is fully vested as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 31, 2022, the group also awarded 5,000 supplemental RSU awards to the COO and 30,000 supplemental RSU awards to the former CBO/CCO. These RSU awards vest in 2 tranches (50% on December 31 2022 and 50% on December 31, 2023). In order for the RSUs to settle and be delivered, the share price must reach 19.16 USD on or after vesting. As of December 31, 2023, all of these RSUs had vested but had not been settled or delivered.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 1, 2022, the group awarded 89,655 RSU awards to former Frame employees to replace existing share-based payment awards of Frame Pharmaceuticals. These RSU awards vest with one third vesting taking place each year on June 30, 2023, June 30, 2024 and June 30, 2025. The RSU program is accounted for by recognizing the related expense over the vesting period of the award, with corresponding increases recorded in equity. The expense is based on the fair value determined at the grant date of the award and the number of awards expected to vest. The fair value remains unchanged after grant date. Once the award has vested, there is no reversal of expense related to the award.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 31, 2023, the Group awarded 92,701 RSUs to the Supervisory Board members and 646,914 RSUs to the Executive Board and various key employees. On December 15, 2023, the group awarded a further 32,783 RSU awards to Supervisory Board members and key employees who joined the company during fiscal 2023. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified. &lt;span style="-sec-ix-hidden:Hidden_11RqQzGybUSMAflcteDxJA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;One third&lt;/span&gt;&lt;/span&gt; of these RSU awards had vested as of December 31, 2023. The RSU expense related to Supervisory Board members recognized during the year ended December 31, 2023, in an amount of EUR 652k (2022: EUR 478k) is included in other operating expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 30, 2023 the group also awarded 25,000 supplemental RSU awards to the COO. This RSU award vests with one third vesting taking place each year on December 31, 2023, December 31, 2024 and December 31, 2025. &lt;span style="-sec-ix-hidden:Hidden_lI9qMg_ZoEa59Vg_AMB8SQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;One third&lt;/span&gt;&lt;/span&gt; of these RSU awards had vested as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the former CEO, former CSO and former CBO/CCO left the Group in 2023, all of their remaining unvested awards were subject to accelerated vesting. As a Supervisory Board member left the Group as of June 19, 2023, all remaining unvested awards were subject to accelerated vesting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Expenses for employer taxes arising upon the delivery of RSUs are recognized in profit or loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of Sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (331)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (240)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (909)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,719)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (383)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,753)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (705)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,108)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,072)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_9XtP8dJCpU2E-YcSdhOx_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expense recognized for share-based payments during the years ended December 31 is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (624)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (572)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;LTIP Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,472)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,944)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;LTIP RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (705)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,108)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,072)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSU Supervisory board&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (566)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (478)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (652)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (14,939)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (9,184)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,697)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ"
      decimals="-3"
      id="Tc_CP6B1xyrnkSGKe2rhIwnWQ_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-624000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg"
      decimals="-3"
      id="Tc_JCQaoDu4VUyX6LjZCAZZdA_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-131000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="-3"
      id="Tc_LSl8AWp13kq_JcXdQCvoAQ_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-10000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="-3"
      id="Tc_WFIMLitrLk6lL-4HmapGcw_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-572000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_o-OArYcutke-xTbroFZp7Q_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">95000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="-3"
      id="Tc_jevRmbynI02QUNFA-u51vA_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-19000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_8RFzGrzUeE6P9-Pt00WG7A"
      decimals="-3"
      id="Tc_launymV-mUqixCr99NYOyg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-12472000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_hGO4w4NtCUa_4_aoaCmHzQ"
      decimals="-3"
      id="Tc_NmWC_zU6L02hPl1gjr_wog_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-5562000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanStockOptionsMember_uMKK0Q6dEUmdlqOP5j56rQ"
      decimals="-3"
      id="Tc_4etbebEOUkei8tnDbWXJxA_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2944000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_NkdF9lVGbUq5xwUCOH7yAQ"
      decimals="-3"
      id="Tc_Vyd4qoK9Okud5b7C2kFY9Q_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-705000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_-tPgLvVPd0iGi29T4BoBUA"
      decimals="-3"
      id="Tc_jVa7eFZVX0GiQO4oL2BIKw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-3108000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanRsusMember_jRMpo2_Z7EeshW9iq1ZxOg"
      decimals="-3"
      id="Tc_hRPWMHm-X0iJ6boDElGEGQ_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-4072000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_bAEfKq92c0ycQbava4HefQ"
      decimals="-3"
      id="Tc_f-e3aEnWT0SAo08gDW2chg_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-566000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_8rng1PMUlky5RzxNm--ypw"
      decimals="-3"
      id="Tc_XijTHvCNDkerWr_iIdotDA_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-478000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RsuSupervisoryBoardMember_mT3WIF4M9k-HrxxK03IB1g"
      decimals="-3"
      id="Tc_LO3WFeQPxEuBiBDGOIzXSw_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-652000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_rBynXPefr0-TTNX-hIKBfQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-14939000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_chfMwEhaH0upj8G8WG8IOg_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-9184000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_POC5MCkDGk6UT-QveXnuSQ_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-7697000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      id="Tb_QjrzYGqHlkGfLHoUfpv-cA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.27%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the beginning of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,951,265&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,426,365&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,614,246&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34,859)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,091)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised during the period &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,524,900)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (777,260)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the end of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,426,365&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,614,246&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,603,155&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,365,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,509,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,588,513&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;none&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;none&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;none&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_xxYCQu-d0kOvAqnbd6uzjQ"
      decimals="INF"
      id="Tc_fsgDMNEHoEK579HDQ6QXmA_2_2"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">7951265</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw"
      decimals="INF"
      id="Tc_XU0Ppm6wx0G8TaaxaukyAg_2_4"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">6426365</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g"
      decimals="INF"
      id="Tc_TdyxG_YNRU-pyxU4jkr7xQ_2_6"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">5614246</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA"
      decimals="INF"
      id="Tc_6rT1jUnMVEKAypHqjmZOoA_4_4"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">34859</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg"
      decimals="INF"
      id="Tc_2unfQMZ6d0yGw6Q6YC9uKQ_4_6"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">11091</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mZrACg5Qy0atlIzvQ-sFZQ"
      decimals="INF"
      id="Tc_lpdeRRf71Ema_1ca-9i5BA_5_2"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">1524900</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA"
      decimals="INF"
      id="Tc_KRrmOkaIkEiTyfXst6ihEQ_5_4"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">777260</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw"
      decimals="INF"
      id="Tc_F0PjmSFj_EOZrH8ZKbgx_g_6_2"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">6426365</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g"
      decimals="INF"
      id="Tc_4k2l7c70t0ig_G0hwJ_xsw_6_4"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">5614246</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_Emv5VFNkOkeu9n01IcUiDw"
      decimals="INF"
      id="Tc_JSuAj5usSUmXKB0LlkVsjA_6_6"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">5603155</ifrs-full:NumberOfOutstandingShareOptions>
    <cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mZrACg5Qy0atlIzvQ-sFZQ"
      decimals="INF"
      id="Tc_dEjZEUGuf0GFGDQ4IuQc3w_7_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">6365422</cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_a5077tN8zkmmEFYSzgtHNA"
      decimals="INF"
      id="Tc_thvIox4v6kGP9wR4JXA0Bg_7_4"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">5509886</cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg"
      decimals="INF"
      id="Tc_pCMzmjCmdUWBumXr7y7b2w_7_6"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">5588513</cvac:NumberOfShareOptionsVestedAndExpensedThereofInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_mcD830Tj8kylOqlRoRZJWw"
      decimals="INF"
      id="Tc_j55KzHHTV0-9M7XId1miLg_8_2"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_PApXO-6mMEOG4Pju7zQK3g"
      decimals="INF"
      id="Tc_3sBGapBm2ky2h1GaTaWUBg_8_4"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_Emv5VFNkOkeu9n01IcUiDw"
      decimals="INF"
      id="Tc_9-zMHHrBAU6_Uk7tqSRzkQ_8_6"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <cvac:RightToExercisePercentageOfVestedVirtualShares
      contextRef="Duration_8_14_2020_To_8_14_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_WwopKLYhAkmX30Ihq8HcEQ"
      decimals="2"
      id="Narr_9M5wl4zBDkicbvlZw40ntw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:RightToExercisePercentageOfVestedVirtualShares>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_3_10_2021_To_3_10_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_D2yuVO9FDUOmQ5j1k8A3bw"
      decimals="INF"
      id="Narr_YhU7i224S0O0ki-5IMeMnA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">759677</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_3_10_2021_To_3_10_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_D2yuVO9FDUOmQ5j1k8A3bw"
      decimals="INF"
      id="Narr_NfQe9hJwpESu5dI3IuACkA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">759677</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA"
      decimals="INF"
      id="Narr_pTbohJf3ZkqciuC17uKyxg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">390023</cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:TreasurySharesTransferred
      contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA"
      decimals="INF"
      id="Narr_A16k_AHwrUCcntAX9iZfng"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">369654</cvac:TreasurySharesTransferred>
    <cvac:ProvisionForEmployerTaxes
      contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA"
      decimals="-6"
      id="Narr_omatLzW7mUiDHg8DC2chGg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26000000</cvac:ProvisionForEmployerTaxes>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_3_11_2021_To_3_11_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_yPBkTAaQxkqP0pgGeuqMNA"
      decimals="2"
      id="Narr_H6GkULc44UOUqsJ4VqJkQQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">69.69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:RightToExercisePercentageOfVestedVirtualShares
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="2"
      id="Narr_eWLu5D1hGUqhU8yWun2YBQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:RightToExercisePercentageOfVestedVirtualShares>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_10_18_2021_To_10_18_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_NU3QWXFiZkS0exKI1Z5L4Q"
      decimals="INF"
      id="Narr_FuYfUxQfcU2vcP-zwkU9pQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">765223</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_10_18_2021_To_10_18_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_NU3QWXFiZkS0exKI1Z5L4Q"
      decimals="INF"
      id="Narr_k6b-9FmKl0un43IjSYkPCQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">765223</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ"
      decimals="INF"
      id="Narr_6-utdyqKG0SBGykuUrHY9A"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">523897</cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:TreasurySharesTransferred
      contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ"
      decimals="INF"
      id="Narr_tkhoMmNAY0q3j9KSpkZmVQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">241326</cvac:TreasurySharesTransferred>
    <cvac:ProvisionForEmployerTaxes
      contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ"
      decimals="-6"
      id="Narr_mUFnJCYMp0qxSaUXXb0FyQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8000000</cvac:ProvisionForEmployerTaxes>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_10_19_2021_To_10_19_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_943SY1zuSU-q-GFBhmPbQQ"
      decimals="2"
      id="Narr_N4QMIaWPBUaAN89Kon5uwA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">34.56</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:RightToExercisePercentageOfVestedVirtualShares
      contextRef="Duration_8_14_2022_To_8_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_vhVPWZE6FE-yd2_OHphj6g"
      decimals="2"
      id="Narr_ImwhryUaE0me2T1tW0vZtw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:RightToExercisePercentageOfVestedVirtualShares>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_12_12_2022_To_12_12_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_RQ8a6WZN30er9veT-GsPsQ"
      decimals="INF"
      id="Narr_5W9TPOeXnkW0asZsNjJ_fg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">777260</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_12_12_2022_To_12_12_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_RQ8a6WZN30er9veT-GsPsQ"
      decimals="INF"
      id="Narr_3PwT5mTBgUyCJZlS-rm9FQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">777260</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_12_14_2022_To_12_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_AYQqGHS96EG_31uhHqhopg"
      decimals="INF"
      id="Narr_BhopSudEKEas_r6_tdNb6A"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">777260</cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_12_14_2022_To_12_14_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_AYQqGHS96EG_31uhHqhopg"
      decimals="2"
      id="Narr_vR1itbL7w0ys4aygLwWyVg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">6.96</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:RightToExercisePercentageOfVestedVirtualShares
      contextRef="Duration_8_14_2023_To_8_14_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_c7I5rda9O0unxghjuyCeYA"
      decimals="2"
      id="Narr_-uAKCvE2AkyEcfjY8ahBHQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:RightToExercisePercentageOfVestedVirtualShares>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LzXStsEX10Sllgbp-IfhBQ"
      decimals="INF"
      id="Narr_sYQgY0fzWk2OJbbKjGzubQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">786746</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LzXStsEX10Sllgbp-IfhBQ"
      decimals="INF"
      id="Narr_mYHrzEz3rUi9fazlDbkDxA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">786746</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_3_26_2024_To_3_26_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8MhaP9inOEWOlUmUTvRFIA"
      decimals="INF"
      id="Narr_5d64Y9qUQECcEX2QBrEDnQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">786746</cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      id="Tb_uG-GhwUd6kOYYjaHviKQZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The expense recognized for this share-based payment plan during the years ended December 31 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of Sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (45)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (624)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (131)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (10)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="-3"
      id="Tc_cTjLrkVNi0OpqStaGl5tnA_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-9000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ"
      decimals="-3"
      id="Tc_W4YqFMq5CU2xl-hpjHyaAQ_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-25000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg"
      decimals="-3"
      id="Tc_8qpqSs47CEaopfDxtZlKOw_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-8000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="-3"
      id="Tc_a28D1l3e-0-tGg1G7PXCJg_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-6000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ"
      decimals="-3"
      id="Tc_uXqkn4zr4EmWb0mHxG_MUA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-369000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg"
      decimals="-3"
      id="Tc_J9Q8Kd-7BES9PfpA6l5W7w_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-45000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="-3"
      id="Tc_CFuJ5wyyv0KbpQIhXMTe0w_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">46000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ"
      decimals="-3"
      id="Tc_T9WnR8-NG06kpvfuL-nWcw_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-230000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg"
      decimals="-3"
      id="Tc_5BYIKpaYkUS7l8FKi0LMmg_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-78000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="-3"
      id="Tc_G6yQnD6wY0-03xouuemkPg_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-41000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_4sQv_UuOWkaGGZKEIuOWUQ"
      decimals="-3"
      id="Tc_FXBIsrLGzUGCwDgq2WYgcA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-624000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg"
      decimals="-3"
      id="Tc_xMMLigGLw0iMkT_IQaISHw_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-131000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="-3"
      id="Tc_liI6GQajSEKZrhVnYX4bMg_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-10000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      id="Tb_AzBlJU1_QUSjRuQGqZtlKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The number of awards in the New VSOP program granted to key employees developed as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the beginning of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 906,595&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 349,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (99,696)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised during the period &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (557,171)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (147,620)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69,246)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at the end of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 349,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,862&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,862&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereof exercisable &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wK1DnDLSIkWj7Emo6TjbNQ"
      decimals="-3"
      id="Tc_2kBCMk-0-0CbAqm-Pl9sbA_2_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">906595000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw"
      decimals="-3"
      id="Tc_osjBFV12302d5-TdTmHvAg_2_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">349424000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog"
      decimals="-3"
      id="Tc_UbIbZL01-kWDpZz1HBxJ9w_2_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">102108000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_BFFANs7Q-EKSXYD2JUbJag_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">99696000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="-3"
      id="Tc_Rl-zrsjFXUC-FLMzPjZVIg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">557171000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_v6SGIvuLW0CPKXvfiQYkAg_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">147620000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="-3"
      id="Tc_Pt4SBMdLl0OvuGwN4ESB-g_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">69246000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw"
      decimals="-3"
      id="Tc_JqeNwy5dikyntOsmImiw9A_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">349424000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog"
      decimals="-3"
      id="Tc_xzbRd6cOr0GvwxvIHwE99A_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">102108000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WpDGmX1BBk-irWX_MsZINg"
      decimals="-3"
      id="Tc_HBqugzxp3EmjhGyoZ9NjrQ_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">32862000</ifrs-full:NumberOfOutstandingShareOptions>
    <cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="-3"
      id="Tc_z5HO9-ToHkWL7bOP1HRO4w_7_2"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">88464000</cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_lXYhJHiB_Ei5crTVJ954eQ_7_4"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">59942000</cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="-3"
      id="Tc_P2oWZ_UvXEO5MeDbMICPkw_7_6"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">32862000</cvac:NumberOfShareOptionsVestedThereofInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw"
      decimals="-3"
      id="Tc_2F-xqv1vxEGMlgLwhGJXRQ_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">88464000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog"
      decimals="-3"
      id="Tc_McmpJLenCkaqginp6UKoBQ_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">59942000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <cvac:RemainingOptionLifeShareOptionsAwardsGranted
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_gLfbS6LG906Sox56_2muhw"
      id="Narr_4jsS4tnEAEqoX2R2bbhAFw">P4Y6M</cvac:RemainingOptionLifeShareOptionsAwardsGranted>
    <cvac:RemainingOptionLifeShareOptionsAwardsGranted
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-MBxnDM6-U6QBuGgHl5BEw"
      id="Narr_gcnuXv-tU0uQWai1OKWdOA">P5Y8M12D</cvac:RemainingOptionLifeShareOptionsAwardsGranted>
    <cvac:RemainingOptionLifeShareOptionsAwardsGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4ms1oi7d0EywO8ZNbgPv5w"
      id="Narr_CVw7fXMgT0ercfpu8Ieudw">P5Y6M</cvac:RemainingOptionLifeShareOptionsAwardsGranted>
    <cvac:RemainingOptionLifeShareOptionsAwardsGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_WckCf34PZUGzza4sNjwFMA"
      id="Narr_US-wqnMHyU-vontMCcaqog">P6Y10M24D</cvac:RemainingOptionLifeShareOptionsAwardsGranted>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="INF"
      id="Narr_I4_IhLTJjEKaN-zyEKLfgg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">557171</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="2"
      id="Narr_fYpSGSXe_EW_x7HdBzRySQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">61.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:IfrsEmployerTaxesPayable
      contextRef="As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wK1DnDLSIkWj7Emo6TjbNQ"
      decimals="-3"
      id="Narr_g1J6ROoH2Ua78p6OabgtRA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">493000</cvac:IfrsEmployerTaxesPayable>
    <cvac:ProvisionForEmployerTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_HRF1MwVKgUu89NEIRuzDvg"
      decimals="-3"
      id="Narr_LVO04ktNbUO8fR8RDCLToQ"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">981000</cvac:ProvisionForEmployerTaxes>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsSaleOfStockAxis_cvac_ExerciseOfOptionsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_wMo5XPBJDEWL4EzQFfN9nw"
      decimals="INF"
      id="Narr_S7bh73hnaUG8Sp8dqgovkw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">147620</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="2"
      id="Narr_mZpZEQWy1E-9M2n-X2WSGQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">16.81</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:IfrsEmployerTaxesPayable
      contextRef="As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_kWXEgMhNiUCC87rngF6xog"
      decimals="-3"
      id="Narr_3Zx4ikUQg0id_j8NWxEyLw"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">45000</cvac:IfrsEmployerTaxesPayable>
    <cvac:IfrsEmployerTaxesPayable
      contextRef="As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KAbaQ9zpskKfI45nWc48Hw"
      decimals="-3"
      id="Narr_jujo1AjepEKC9ncC5XYxoQ"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">51000</cvac:IfrsEmployerTaxesPayable>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="INF"
      id="Narr_qHL-5b_bCkS0eMvp0NdGnQ"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">69246</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="2"
      id="Narr_FY3J1kO0l0CHze4DE0AITQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">9.90</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      id="Tb_EJwBl2mMkkmiFQFtP9dPng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The expense recognized for employee services received during the years ended December 31, 2023, 2022, and 2021 is shown in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (349)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (188)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (572)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="-3"
      id="Tc_e9VapVmxfUe-bMNFWlE1rQ_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-349000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_97nhJiWWC06aceyWZ9WYQw_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">69000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="-3"
      id="Tc_1lJGYMJq4EqZZtnidqZJRw_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-31000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="-3"
      id="Tc_f5nBCOdxJk6t7wtuROZBNw_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-188000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_XHgZxRYnXUmtm6y3TY7vmw_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="-3"
      id="Tc_GQQYlu8se0G7E-xghrRQzQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-35000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_NJgEZ4KejECGqsKASjI9dg_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="-3"
      id="Tc_ILNCNmma7kukm7cA83LCNA_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_NyLKS_gCCUiXmIAs8M-uOw"
      decimals="-3"
      id="Tc_XUP_WKL3vEey-rluHP07pQ_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-572000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_V9XwfvfOS0K7cA_oA4WZ5g"
      decimals="-3"
      id="Tc_CFqlMoXZwk2ERvdpijW5hw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">95000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_a7uNfp7UW0yCm1EgDfKQ6Q"
      decimals="-3"
      id="Tc_SAyS3_rHVE28CAc3ra2OgA_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-19000</cvac:ExpenseRecognizedForEmployeeServices>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="INF"
      id="Narr_h16zoZEEs0mNQJ4RroRV_A"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">266155</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_jh1w8gRbgEipnv2Kd3Q7zQ"
      decimals="INF"
      id="Narr_a9aAf_EQ1kSIcUNdlEdbaQ"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">266156</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_MlAIV3j9EESYEfc4Yj76xA"
      decimals="2"
      id="Narr_wRHSsvcvU0SoGpte1oqG3A"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">10.04</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      id="Narr_EkzMI72F9UOQTzkYFTeOhQ">P4Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="2"
      id="Narr_5LhJWmRmf06i8Wocj-zjXQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.25</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="2"
      id="Narr_fEk7n5xOn0izN5uZ4CSe7Q"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.20</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage>
    <cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      id="Narr_g5-JDbCT3UOQbnuzdEfc6g">P10D</cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lAb_IMNJZEqsHSSH2TNYcg"
      id="Group_dDIDNyJK5kiORGNPsPB6Og">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 57.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (10-days VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 50.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 11.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 10.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.07 - 1.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;First tranche:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 48.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (actual 10-days VWAP before grant date, USD 81.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 67.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 52.96)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 43.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.07 - 1.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;Second tranche:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 24.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (estimated by Monte Carlo simulation to be USD 98.36)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (estimated by Monte Carlo simulation to be USD 98.36)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.07 - 1.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;Third tranche:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 20.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (estimated by Monte Carlo simulation to be USD 98.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (estimated by Monte Carlo simulation to be USD 98.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 81.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.07 - 1.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 0.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (30-days VWAP after grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 77.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 88.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 77.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.08 - 0.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 17.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (20-day VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 56.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 84.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 70.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.099 &#x2009;&#x2013;&#x2009; 0.903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 17.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average share price (20-days VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 41.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price (USD 84.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;EUR 46.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.075 &#x2009;&#x2013; &#x2009;0.704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 14.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (30-days VWAP after grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 30.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 34.87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 30.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.40 - 1.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 4.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (10 - day VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 15.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 19.35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 18.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;73.87 - 86.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.34 - 3.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per option&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 6.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average share price (10-days VWAP before grant date)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD 19.28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;EUR 17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Weighted average fair value per option&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;EUR&#160;&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;3.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Weighted average share price (10-day VWAP before grant date)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;EUR&#160;&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;6.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Exercise price (USD &lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;6.66&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;EUR&#160;&lt;/span&gt;&lt;span style="font-family:'timesew Roman';"&gt;6.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Expected volatility (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt; 75.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt; 3.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt; 3.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'timesew Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="2"
      id="Narr_369zwdq-PUCU0HZwexOHZw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">57.40</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="2"
      id="Narr_B2dUjzvbTUalYcUHWHSCIA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">50.01</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="2"
      id="Narr_YRbyjLezhUWJWFgH1Qiewg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">11.90</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="2"
      id="Narr_sDD8AvQSzE6AExUdKaAvew"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">10.04</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="4"
      id="Tc_EAMHzSVkO0uDlBeJHVKTmA_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.6206</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_tNkSBGGxN06ycHwLqGsGwQ"
      decimals="INF"
      id="Tc_JCjPXm9avUqmHiemGSCR-w_5_2"
      unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">1.82</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_BR9esw-0g0WSTYUwmmFSEQ"
      decimals="4"
      id="Narr_ElEAflM0ekSJz0hw1HkykQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0007</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_2nV73AJ870mDjh_tkOBisg"
      decimals="4"
      id="Narr_N1qmRgh3AUCVEEo1Bj5tVw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0148</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_NUSNjsD8UEOnZi8loJYDVg"
      decimals="INF"
      id="Narr_2DCtRqW_5k-ZQmRy5SBDIw"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">6303</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_uKCC8GofE0G_GEmvlAEeTw"
      decimals="INF"
      id="Narr_ToCipSMftUeHAtX_GZACng"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JtGHYH8FrEKyyYF5zBuS5w"
      id="Narr_ZxvFr5Ih50iGQSzDehMyzA">P3Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_11_16_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_rkGlJwdXYkifsZbvBkjdoA"
      decimals="2"
      id="Narr_rsVxgJiktEGcAnmhiwvOpA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">43.87</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_11_16_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_rkGlJwdXYkifsZbvBkjdoA"
      decimals="2"
      id="Narr_gGpdQCG2vkOvGOcdqfwOOg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">52.96</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_-_-inCxASkiTTlbNRKnG9Q"
      decimals="2"
      id="Narr_mA5QK1NMSk2kLf5wK7rlow"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">81.48</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_-_-inCxASkiTTlbNRKnG9Q"
      decimals="2"
      id="Narr_u4Anla7Vw0eIzF3Z7XWeYg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">98.36</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_UBWp1OUhsESfo0wo4zeF7Q"
      decimals="2"
      id="Narr_AIb0kT8rFUeJKymzlWMtLw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">81.65</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_UBWp1OUhsESfo0wo4zeF7Q"
      decimals="2"
      id="Narr_kCxnAwJo8ky1Y-Y2RsT2iA"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">98.57</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_LeF6mzlRgUqn4uUTYSSTkQ"
      decimals="2"
      id="Narr_3RcrAYNd10mfj0aHIm46uQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">33.07</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2021_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_LeF6mzlRgUqn4uUTYSSTkQ"
      decimals="2"
      id="Narr_TFKwhclE5EascV1QZ2g0-w"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">39.92</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_FRvDHd6gz0-TIgKz3l7NTQ"
      decimals="2"
      id="Narr_1BP2-PXc7kCYCQeIVbnU1A"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">7.35</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_12_31_2022_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_FRvDHd6gz0-TIgKz3l7NTQ"
      decimals="2"
      id="Narr_GPeestl6Ek2pGX7V6tDbWg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">7.68</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_38uXsNcfl0e1xpuxCmbyTw"
      id="Narr_ApkSzU33MEmnG0IGPdE5IQ">P10Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_38uXsNcfl0e1xpuxCmbyTw"
      decimals="2"
      id="Narr_oJPZcUixoE2Eufsg4phvXw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"
      decimals="2"
      id="Narr_X6L3rcVVzUqdnRUUpwy7Tg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">48.27</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"
      decimals="2"
      id="Narr_O8_PkiFMdkWdom8WATp9bQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">81.03</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"
      decimals="2"
      id="Narr_ztR6cezj7kmokW41YQSh2Q"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">67.12</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"
      decimals="2"
      id="Narr_q57cW_DNZ0-CsT6kz8SWGw"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">52.96</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"
      decimals="2"
      id="Narr_vmHUsr8K00ycxPzcoGo8bg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">43.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"
      decimals="4"
      id="Tc_1KCppi_b_0qS2rCvHgTm7Q_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.6227</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_bdiRbai2IkW3TTggHidVmA"
      decimals="INF"
      id="Tc_7YzNj3ODMUyjPDjCQj-V6w_5_2"
      unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">1.78</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hjZQJLPupkuissku-yiCaw"
      decimals="4"
      id="Narr_osF9Sv57rkyt0OJfcOJYBg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0007</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xyqNnfW_P0-d5WX8yyxmQQ"
      decimals="4"
      id="Narr_eU5yzCMTMUiF2uFsLoxU_w"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0150</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"
      decimals="2"
      id="Narr_IVuRYcqWFEOVxundSn42_g"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">24.36</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"
      decimals="2"
      id="Narr_i61Gn-lTQ0GB3__zizp0BQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">98.36</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"
      decimals="2"
      id="Narr_OyOfPtvWZE64M0Scm_0cFg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">81.48</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"
      decimals="2"
      id="Narr_WtrSNIWy2EGJ0cj0x-b9TQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">98.36</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"
      decimals="2"
      id="Narr_vG3rFbzUskSwnxYRYuwAzQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">81.48</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"
      decimals="4"
      id="Tc_qVqflbKpwE-43nxqvWcH_w_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.6227</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_kQH_Sa2DsU-H2ZnTF7IXuw"
      decimals="INF"
      id="Tc_m0IpS_AVEUuD5g7zMLEHVg_5_2"
      unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">2.23</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_YWA7IRvytUCV0dt4jLtEeg"
      decimals="4"
      id="Narr_Q8n_BjGdfUOpnlF63uAOqw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0007</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheTwoMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_5g69MJCNR0qupo7-cCBilg"
      decimals="4"
      id="Narr_QrF3rh67lkqa3I-8vaAfgg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0150</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"
      decimals="2"
      id="Narr_U8Trx90CLkeI0srANloX_Q"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">20.01</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"
      decimals="2"
      id="Narr_Omi6ezzaDkW18NdD3o3G4w"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">98.57</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"
      decimals="2"
      id="Narr__QaqIqNtfkqrX7V61lE-Wg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">81.65</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"
      decimals="2"
      id="Narr_YQdOesAmN0KOIyTIAEoMUg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">98.57</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"
      decimals="2"
      id="Narr_NPSdz2MrAE25cyPN4dmTOw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">81.65</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"
      decimals="4"
      id="Tc_A5Trh88OOkiovL1aAduaRg_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.6227</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_7tgF-pO7t0WGQ3cwif1Cog"
      decimals="INF"
      id="Tc_5-31TNWgx0GF5oFxE5DtGA_5_2"
      unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">2.66</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_z3m9cMNGJkyyuC_pOxiLYw"
      decimals="4"
      id="Narr_ybVj_TW9_E-nGP9AnmPraw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0007</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_12_1_2020_To_12_1_2020_cvac_IfrsVestingAxis_cvac_IfrsShareBasedPaymentArrangementTrancheThreeMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_nwphsrqbPkGFkMezYtJrvw"
      decimals="4"
      id="Narr_dFDCFmj6xUCG-eH5enzUaA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0150</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="INF"
      id="Narr_rYFLjLEep0ajcFxkKpskoQ"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">2000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_nrIihK8t60Kg6c5Z8quIzg"
      decimals="2"
      id="Narr_-aUg33L_iUSTCbEh8DvdJA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">77.73</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_nrIihK8t60Kg6c5Z8quIzg"
      decimals="2"
      id="Narr_3cX4XtnJz0-zjIWdzSbekw"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">88.16</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      id="Narr_kPwskKesd0eRPws3VYVPYg">P4Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="2"
      id="Narr_KeZjZq0dPEKk-S2BuqjkYA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.25</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="2"
      id="Narr_asNgyZMOCEaxMNu8TtCE9Q"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage>
    <cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      id="Narr_CyYR27D2SEa-YVLqt3vV_Q">P10D</cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="2"
      id="Narr_yU8axQyL70K_HnE_L-1hWg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">0.65</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="2"
      id="Narr_t1-DTzm6gkaw31MYefYwJw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">77.73</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_jpnt_Qkh80SEH5rLvclaIw"
      decimals="2"
      id="Narr_jLW-f9VTcUCX4VR85lsekg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">88.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="2"
      id="Narr_tSlGKro8UUm74KlhEncu0g"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">77.73</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="4"
      id="Tc_q7u8NnfRe0OiOEQYPA5D7w_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.7300</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_S01oNnDxLkqeG-XfqClPtw"
      decimals="2"
      id="Tc_0I393VrhUkumkgwfOezwpw_5_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">2.15</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_C0Yd0VHbrESYa5VTH7JK-g"
      decimals="4"
      id="Narr_jKtfYAKFGEudS1y923_Oug"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0008</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Y2yquS5opE-ddUHuqsYCSg"
      decimals="4"
      id="Narr_H8KxpSdgVU2pg3OfWktz6A"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0049</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="INF"
      id="Narr_T-9SDwhe_0qq4opfNtgg1g"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">20000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"
      decimals="INF"
      id="Narr_TpUKYadcSE27PjnOUAUk2A"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">30000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember__tOhjBnh-k-Pzhm_-oubRQ"
      decimals="2"
      id="Narr_6BDFBdrJJ0uNgGMXxx4LIA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">70.92</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember__tOhjBnh-k-Pzhm_-oubRQ"
      decimals="2"
      id="Narr_vVzcP8OPw0WzAjdaqOE3jQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">84.03</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      id="Narr_AHBJh6qi_0uyd1NReDR74A">P20D</cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      id="Narr_Aay5oHzcHUS2URL02r0akw">P4Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="2"
      id="Narr_xXMoj0lcWUi48BrKUsZnig"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.25</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="2"
      id="Narr_yqZBMJ3O8EiP_kIojdezMw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.20</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="2"
      id="Narr_oFGBD5Zew0Gn_IfmFgO6AA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">17.56</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="2"
      id="Narr_s9wFEIJqc0yHWlZZFfOyug"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">56.51</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="2"
      id="Narr_EsUIaWOf4UGzgm4lHifDlg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">84.03</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="2"
      id="Narr_YgaaedEW90-mqhgEirKunA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">70.92</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="4"
      id="Tc_DV1IWoU_zEKpgy6CYm-e7w_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.7095</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      decimals="1"
      id="Tc_8Bm4c_7-5Ua7hctyfB0LMw_5_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">4.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_KQcN-T4_jUa6vvQqtTmIxA"
      decimals="5"
      id="Narr_S0otEMl0mE2nXUlF5hHS0Q"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.00099</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_YQ7OFau-40655Qsd3p7mHw"
      decimals="5"
      id="Narr_4awXyc402kW2cRs1qisyOw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.00903</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_wHx_7Z9Dg0my8RqwuxGOxw"
      decimals="2"
      id="Narr_X9grP2K-Vk684IparK5YHQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">46.16</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_wHx_7Z9Dg0my8RqwuxGOxw"
      decimals="2"
      id="Narr_v3KSA-lvqESvFhb1pmkDHg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">54.79</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_mDWb9JlJy0eNUrfctEFH-g"
      id="Narr_RQlzUfn4BUyK1AiBCvmsIg">P20D</cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw"
      id="Narr_31wR9Hup6kCIEvqLNfd-8g">P4Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw"
      decimals="2"
      id="Narr_c5ATAxYFsUOXPzCkF_mjIQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.25</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw"
      decimals="2"
      id="Narr_ICz8EX16CEqHE9MizkrzSA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.20</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage>
    <cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_xXK3Ss7iWESVXwFbjdGYLw"
      id="Narr_HzOBr8O3DUCcTFj7lAy3fQ">P10D</cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"
      decimals="2"
      id="Narr_pw0dN1j2Z0qjUXKpZQ-R1Q"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">17.56</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"
      decimals="2"
      id="Narr_RFp3cXF90UW4_vV6TRBVQQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">41.81</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"
      decimals="2"
      id="Narr_WMpccKMsX0y6nuVh_7B5GQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">84.03</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"
      decimals="2"
      id="Narr_5lrCU29RcUaN1FqB3r5raQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">46.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"
      decimals="4"
      id="Tc_7jPIY9CzfE2A8y8dld47rg_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.7513</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_S3tox9lOkEi7fb-le7aGRg"
      decimals="1"
      id="Tc_VnxJ2NL_Tkuxja3Dkt-oMQ_5_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">4.6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_RPtNKWdi7kep-OWhPRdbZw"
      decimals="5"
      id="Narr_j7zyaVp3O0q4hKr73u2JYw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.00075</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_x2jtrAGjukm-Q3NjjwN9zA"
      decimals="5"
      id="Narr_BaP1BUFie0O63LR9FqoYmQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.00704</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      decimals="INF"
      id="Narr_eVmliQYuVk2ddZB68jYp8w"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">9500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_bx2x9QVGwUKRwb9RkD06sQ"
      decimals="2"
      id="Narr_lnA15SsAwUyzGKrfV1yyMw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">30.67</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_bx2x9QVGwUKRwb9RkD06sQ"
      decimals="2"
      id="Narr_KdKhkB2gW0mwuCVY3c3wRA"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">33.87</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      id="Narr_8Rao5uNpfky_StQRFzHjTw">P30D</cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      id="Narr_sXpDll66UEiwkgljfYD57Q">P4Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA"
      decimals="2"
      id="Narr_6vpNUKaYNUyYwC_sxM5LIg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.25</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage
      contextRef="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA"
      decimals="2"
      id="Narr_UfQoDjX4-kST-wbpW8O7gQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.20</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage>
    <cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease
      contextRef="Duration_1_1_2022_To_1_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_TwV2i5qbQ0ekqqLTm3RYmA"
      id="Narr_3be-ebFnb0mpPTsVBvjU_A">P10D</cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      decimals="2"
      id="Narr_BXgOwAY-8kWiag28J9nqRQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">14.31</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      decimals="2"
      id="Narr_xaYKmDlzV0yEBhLEIYwDkw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">30.67</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      decimals="2"
      id="Narr_dKZF2Y60cUSLk0zjHaZ5dQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">34.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_1_1_2022_To_1_1_2022_WZMCwy54QUmI6ryK9Caqbw"
      decimals="2"
      id="Narr_83JwmovxXEK6yK3jAiZy1w"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">30.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      decimals="4"
      id="Tc_-S5QYpKRKU21Ww-8z6Pi_Q_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.7217</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_ysfZaovc4EeLb3UOmRZgmA"
      decimals="INF"
      id="Tc_Qzbj6XHK0kqu1lBa1Dgi_w_5_2"
      unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">2.16</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_sopM0fRxjEGXBD4cfhAb-w"
      decimals="4"
      id="Narr_yHKmwLjkTkWSOIezlyxWaw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0040</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_vwFy4tKujEGvLRYO8xC60g"
      decimals="4"
      id="Narr_jmCGxEB5fESM9vJOnynRbw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0115</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A"
      decimals="INF"
      id="Narr_9rNAShnTckS6xPeeQAhFeg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">130000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_s1OUV32MXEmc3KvzrvgpIg"
      decimals="INF"
      id="Narr_cQ7Rq9fcGEGXXZKtvzBaZg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">30000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_QddTv344JkOsFwJFGAPjQA"
      decimals="INF"
      id="Narr_eTmVhE_FhkaGQSZfuFYMgw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">25000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg"
      decimals="2"
      id="Narr_3LoLbhctnUiC8qf9ru6Lyg"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">19.35</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Narr_WmqWPFe6HUe-IAlC8oZlcQ">P10D</cvac:NumberOfDaysOfVwapCalculatePercentageOfStockPriceIncrease>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_3_1_2022_To_3_1_2022_y1_WCcSI20-05QOkXbljog"
      decimals="2"
      id="Narr_tITvYS2EmUCkboizACqnXQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.25</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A"
      decimals="2"
      id="Narr_a3H4BQ8LREarvhbs3Aw7zw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">4.86</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A"
      decimals="2"
      id="Narr_-LJPHGTHEkKDRDexexsv1A"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">15.07</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_3_1_2022_qj6a8qNT30aZ38oUt-7WNg"
      decimals="2"
      id="Narr_GozJjRpBK0iF9S5NPbZxJA"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">19.35</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_V-qrIbNMWkSpAxsTT17_-A"
      decimals="2"
      id="Narr_-MopLh2Nv0uvjq1qh1t-Wg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">18.37</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_VWLXKKbGpUq7QH7ui7XDUQ"
      decimals="4"
      id="Narr_8SdagxVS2UyMbHDgjI-Wvg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.7387</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_b0HAzOV390aY5p51-Rkqhg"
      decimals="4"
      id="Narr_delOaki8fUe68UFu6K54dw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.8609</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_3_1_2022_To_3_1_2022_y1_WCcSI20-05QOkXbljog"
      decimals="INF"
      id="Tc_27y6XM7HKESQnE5HaIJO6g_5_2"
      unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">2.33</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_VWLXKKbGpUq7QH7ui7XDUQ"
      decimals="4"
      id="Narr_OopRCwL34UaNJUW43Ld-Vg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0234</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_b0HAzOV390aY5p51-Rkqhg"
      decimals="4"
      id="Narr_HHobAb-DBEm5Ob4UaH8Rfw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0321</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="INF"
      id="Narr_P5vdUy0dhku-gGRouu-6bQ"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">700</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_eThCk2awTUa5-6f7LEuCSQ"
      decimals="2"
      id="Narr_1e9U2qIijU2RHkegkJtg7w"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">17.45</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="As_Of_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_eThCk2awTUa5-6f7LEuCSQ"
      decimals="2"
      id="Narr_e-VB75OwwU6UpXXxXLYVPw"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">19.28</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      id="Narr_zChIeXXb-0mcL27gLW7dTw">P10D</cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      id="Narr_k027aOwVFEuoQBBDrIb2Zw">P4Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="2"
      id="Narr_9lv_Fy3DC0-Uh4G66BAr9A"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.25</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="2"
      id="Narr_b1HRsXyGmkGURTrHtOU5eg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.20</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharePricePercentage>
    <cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice
      contextRef="Duration_3_21_2022_To_3_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_M7yeLt7eC0yDiQxH3rlo7g"
      id="Narr_8I_0SlUleEeyaLzjLJrGBA">P10Y</cvac:IfrsThresholdDurationOfVolumeWeightedAveragePrice>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="2"
      id="Narr_o2EjXR-fXkaDTOugOR24lw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">6.81</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="2"
      id="Narr_UDNqozGWgky3bz16pvDKiQ"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">17.45</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="2"
      id="Narr_0BmescjZ10Ox2hP97DumgQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">19.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="2"
      id="Narr_eBp1e2f40kmaVcj2Z6iVrg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">17.45</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="4"
      id="Tc_5P1nCs914kOoB_6G_BPAKg_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.5091</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="2"
      id="Tc_VtRckBWZ_EqapG9ND2AOvw_5_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">2.16</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_RuzDxl1kO0W5aGdy_pqXOA"
      decimals="4"
      id="Tc_4Y8Yq20QiUm1NqGpx54z8w_6_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0267</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_x6s2vBxPH0OH-sUVuKrR1A"
      decimals="INF"
      id="Narr_jOy9_rjqek-NH9Mt49PuBw"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">144379</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"
      decimals="2"
      id="Narr_PgsECSJe6UCC2D-lST2xrw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">3.55</cvac:WeightedAverageFairValuePerShareAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"
      decimals="2"
      id="Narr_0AiGZDlnjUS1RpfDUpGVXA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">6.12</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"
      decimals="2"
      id="Narr_vfe1RGIl0kSToLxyGyNTXQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">6.66</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"
      decimals="2"
      id="Narr__nWntDouvUii0Wp0uNnBuw"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">6.12</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"
      decimals="4"
      id="Tc_i_FytkJlFUayP0mAdBwdSg_4_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.750</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"
      decimals="INF"
      id="Tc_YZm-QqwN20S4VUi2laqzSg_5_2"
      unitRef="Unit_Standard_Y_-FfHeMht8UynrzuX8kt9EA">3.39</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_GBh2JihlxESJsAwzQoCOQw"
      decimals="4"
      id="Tc_9KmWe_JYG0iSYBi451ijXQ_6_2"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0370</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_LRyErr-s70-iTcECgyji4w"
      decimals="-3"
      id="Narr_IppPB7oDA0aFsJwLeZ6r7Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2944000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_WZbR2KdIsEWpAKkVfjG6Ow"
      decimals="-3"
      id="Narr_SCLfYLE88UexUdF4u5RwIw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5564000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_I9QppcopR0ywsK2v4mo-QQ"
      decimals="INF"
      id="Narr_zFvdutR8T0mMyYmQbcfQAw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">10956</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_24_2021_To_6_24_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_uxxE4wcx60S5_hvy1sXzRQ"
      decimals="INF"
      id="Narr_VvUk99Oro0SWdPJmg-FXvA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">63095</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_qO3ooGZGqE-1SoyY1Zy6eA"
      id="Narr_nF9SOqGbV0qKgV0ws_tPOQ">P3Y</cvac:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_7_1_2021_To_7_1_2021_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_Ufa1a3hx1k2ehDCG8MEN5w"
      decimals="INF"
      id="Narr_I7lgL7lPN0SpC56yzrLVFg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">4691</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_EaL8v88MnEKSvl3GFfmHuw"
      decimals="INF"
      id="Narr_kCxm3ygW2UmcYldQMISGPA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">225888</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_11_30_2022_To_11_30_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_YaepVSyZlU2heFMGLS9PMw"
      decimals="INF"
      id="Narr_wctcBEvMfke8O3yOYP3kdw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">7633</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_1_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_MQ4SgOseWki-M9I2hpt9zg"
      decimals="INF"
      id="Narr_YGCoDLh9WE2iQF7YcsR-Fg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">36000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_Fl_UlTw2MEicwzSFEfSNiw"
      decimals="INF"
      id="Narr_ZPPOlHCItESKIV40wEnwFQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">5000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_31_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_hcC_vpIE1k--3Sn_jsbP0g"
      decimals="INF"
      id="Narr_I6szy2ow8EuFNDfalTKPoA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">30000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_cieCTs_Zuk2PWdYu7Wy6ag"
      decimals="INF"
      id="Narr_MW7TvQk7Ck-jMeeri2-Txw"
      unitRef="Unit_Standard_tranche_maOPN1bXI0mZlNy5N3Q2hA">2</cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement>
    <cvac:MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus
      contextRef="As_Of_1_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_CwZYI28sy0a1k2hv3Y76Ig"
      decimals="2"
      id="Narr_wso67wc1q0WQbEP5tHBsiQ"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">19.16</cvac:MinimumSharePriceOnOrAfterVestingToSettleAndDeliverRsus>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_7_1_2022_To_7_1_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_ixs-47BeUUyl1kn1TalbNg"
      decimals="INF"
      id="Narr_9Gs_rqTwwUmFNscaIfn6Ew"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">89655</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_uxFGoa7hQEWcuDdN_uz3Xg"
      decimals="INF"
      id="Narr_g58-LWWsD0q18b_FV1MNdw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">92701</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_3_31_2023_To_3_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_HaxPqM7xIEqQzOqccUnD3A"
      decimals="INF"
      id="Narr_3nRu5tIMwUiS0N9tGUYw5A"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">646914</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_12_15_2023_To_12_15_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_zcNwztHf20yUPCFfBpK37A"
      decimals="INF"
      id="Narr_cnJaDD47702be_4rBgwRoQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">32783</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_12_31_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_41JFXgAYbU-2g4bnHFwsiw"
      decimals="-3"
      id="Narr_BysEvyepH0yqwdj_B0valQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">652000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_12_31_2022_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ManagementMember_D1vacamOH0G3JMpcUfj14g"
      decimals="-3"
      id="Narr_1QQMrx1jAU26D3Z5jSP4sQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">478000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_9_30_2023_To_9_30_2023_cvac_IfrsPlanNameAxis_cvac_LongTermIncentivePlanMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_hmgAXRtQi0mLk9qz8iijtg"
      decimals="0"
      id="Narr_KI3KjUeuUUqk47_k_SzIAA"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">25000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      id="Tb_UoYjbvyDbUemgRI65xRhBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of Sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (331)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (240)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (909)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,719)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (383)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,753)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (705)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,108)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,072)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="-3"
      id="Tc_Q13KPV2ooUOE1A6QcBLm_g_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-331000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ"
      decimals="-3"
      id="Tc_-Lu2Ow567kSiSXJs508Cjw_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-240000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q"
      decimals="-3"
      id="Tc_xkx-ryDNlkmIA_c6c-ZV5Q_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-909000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="-3"
      id="Tc_OnS5ak8XSEiYjo1goFapFQ_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1719000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ"
      decimals="-3"
      id="Tc_4I4oyb7y80SnLyXZXs6Fyw_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-82000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q"
      decimals="-3"
      id="Tc_PuaYSOdjRk2aUbOZKIZeEg_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-199000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="-3"
      id="Tc_Jaegf7xXQUa9vX5VldI2uw_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-269000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ"
      decimals="-3"
      id="Tc_MnqoTnZFIkmMnTYNhPk1Ug_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-383000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q"
      decimals="-3"
      id="Tc_gujyzJavtEmhHo8zE4UwKQ_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2000000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="-3"
      id="Tc_3Ohex6btI0aufJdFtFkVAQ_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1753000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_j2xP_c13IESW0k_rfPFXqQ"
      decimals="-3"
      id="Tc_GFflu1pChkShp2Z3TtAj_g_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-705000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_YhMjYp47PkSjB5hkvevG5Q"
      decimals="-3"
      id="Tc_s-mIsUgGf0mxm0rfXhy6xQ_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-3108000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="-3"
      id="Tc_ZXLBgR_fPUmRwcbYRh70xQ_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-4072000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_BxkQ6wnpR0G5UgzDinbS-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11. Trade and other payables&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Trade payables and other payables are all due within one year and include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Miscellaneous liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 48,033&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade and other payables are all due within one year. The prior year was highly impacted by received invoices of raw material suppliers before December 31, 2022. Thus, during the year ended December 31, 2023, Trade and other payables decreased by EUR 25,430k. Miscellaneous liabilities consist mainly of payroll-related taxes and social security liabilities of EUR 1,496k (2022: EUR 5,027k).&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <cvac:DisclosureOfTradeAndOtherPayablesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_4k_uzUssxEu1DY9TU_UmPQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Miscellaneous liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 48,033&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfTradeAndOtherPayablesTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_YbKTwu6NNUWDGuGbpcC0Ag_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">68246000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_UeY6hxWKd0yQNCHxlV0FxQ_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">46365000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_tnThSGeJO0aepNDegKiG-Q_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5217000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_2m7NFnOSA0S5-uBtEBhpvg_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1668000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_dQ53-KDsckeKzMHNf7EguQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">73463000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_fPJz1a8szUqnUWrdi9wFCA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">48033000</ifrs-full:TradeAndOtherCurrentPayables>
    <cvac:ChangeInTradeAndOtherPayables
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_bV5YICbYvEuA5tCteUUqOw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">25430000</cvac:ChangeInTradeAndOtherPayables>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_TNWY1EaHbkea1syO-l9t2Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1496000</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_jB38XwHcIE-xW81yyf0HWQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5027000</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <cvac:OtherLiabilitiesAndProvisionsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_KZnpuMa2tUG5iJzIf4yN7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Other liabilities and provisions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Provisions include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract termination provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 61,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provisions (non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 61,320&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for onerous contracts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract termination provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provisions (current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,922&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,400&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Provisions (current &amp;amp; non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,242&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,400&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Below are movements during the period:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,242&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;used (amounts charged against the provision)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,174)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;unused amounts reversed&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,648)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,400&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The provision for onerous contracts relates to CRO agreements and are expected to be settled within one year from December 31, 2023. All amounts recognized as of December 31, 2022 arose during 2021. During the year ended December 31, 2023, EUR 184k additional provisions were made, EUR 1,174k were utilized and EUR 748k were reversed. As described in Note 2, when initially measuring onerous contract provisions relating to CRO agreements, judgment was required in estimating the cost of the remaining services, particularly in estimating the number of participants completing the clinical trials. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract termination provisions relate to amounts which the Company expects to pay out to settle its obligations under certain CMO contracts which it has terminated. All amounts recognized as of December 31, 2023 arose during 2021 and 2022 except for EUR 646k in additional provisions made in 2023 and EUR 18,000k reversed during the year. As described in Note 2, judgment is required in estimating these amounts. The amount of the outflow of resources to settle the obligations to which these provisions relate may vary from the provision amount recognized as of December 31, 2023 due to potential variability in the amount required to be paid to ultimately release the company from its remaining obligations under the CMO contracts, including as a result of arbitration decisions. In its final award rendered, the arbitration tribunal followed CureVac&#x2019;s arguments and dismissed Rentschler&#x2019;s claims in their entirety. The totality of Rentschler Biopharma SE related provision of EUR 6,900k was reversed as of December 31, 2023. Contract terminations provisions were reclassed from Provisions (non-current) into Provisions (current) due to an expected settlement within one year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Other liabilities include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other liabilities (non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel accrued liabilities (e.g. bonus, vacation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,543&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grants from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding invoices&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other liabilities (current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,491&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 50,717&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total other liabilities (current &amp;amp; non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,510&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 50,717&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:OtherLiabilitiesAndProvisionsTextBlock>
    <ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_5NFprLLw802xJLWot5sLlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract termination provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 61,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provisions (non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 61,320&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for onerous contracts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract termination provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provisions (current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,922&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,400&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Provisions (current &amp;amp; non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,242&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,400&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory>
    <cvac:ContractTerminationProvisionsCurrent
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_7zSoasSnRUqX8G6ig702wQ_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">61320000</cvac:ContractTerminationProvisionsCurrent>
    <ifrs-full:NoncurrentProvisions
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_cSsXIc1oFkSbLDqola5WTA_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">61320000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:ShorttermOnerousContractsProvision
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_yiuhcPMNREupVwIq22dCYg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1922000</ifrs-full:ShorttermOnerousContractsProvision>
    <ifrs-full:ShorttermOnerousContractsProvision
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_wF-8G13dgkSNs-R-fQd43g_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">184000</ifrs-full:ShorttermOnerousContractsProvision>
    <cvac:ContractTerminationProvisions
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_K-YP1CCuRUG03rPmfNPCvw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37216000</cvac:ContractTerminationProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_LeieRS1Ft0-x2paVBUZquQ_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1922000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_ZE6VJhwNUkC7mhRlES6A5A_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37400000</ifrs-full:CurrentProvisions>
    <ifrs-full:Provisions
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_B6zfYGqJYkO-7LRfOA0uIQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">63242000</ifrs-full:Provisions>
    <ifrs-full:Provisions
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_4H-3ni08cE-Sa9tD_KaWtw_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37400000</ifrs-full:Provisions>
    <ifrs-full:DisclosureOfOtherProvisionsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_zR41z5k6yk25vV23X4xT4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,242&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;used (amounts charged against the provision)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,174)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;unused amounts reversed&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,648)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,400&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherProvisionsExplanatory>
    <ifrs-full:Provisions
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_Ce4_svI3M0Ci7jnIZI6qow_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">63242000</ifrs-full:Provisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_Ww8tvodn6UKAyGKYVSNfwg_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">980000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_IcmMRzk_zEyntWJEO7HKmA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1174000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_55FuOOfKKEGoTnuXhk5teQ_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">25648000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:Provisions
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_FZnaaLmqV0GbyUebBQERLA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37400000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_p6qQ604R9EGyspC-d91ZOA_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">37400000</ifrs-full:CurrentProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw"
      decimals="-3"
      id="Narr_Qgqbk_I0rEe0L7pXNWXXVA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">184000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw"
      decimals="-3"
      id="Narr_k9OGrU3M4U2cE9gQNdnRDw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1174000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_OnerousContractProvisionsMember_qdVJvJ85iEum2wCukXJThw"
      decimals="-3"
      id="Narr_ixpy8e5v2E2cFxsZ_eC07A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">748000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw"
      decimals="-3"
      id="Narr_JTYmlz3t2kumUt9Rtzqq0A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">646000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw"
      decimals="-3"
      id="Narr_J6eooGg_GU2hhDaoBXWPUw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">18000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <cvac:IncreaseDecreaseThroughReclassificationsProvisions
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_cvac_ContractTerminationProvisionsMember_dAshWBNxWkKGHllRjDiRbw"
      decimals="-3"
      id="Narr_Y0dIN6ublU6i4_3oItTeAA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6900000</cvac:IncreaseDecreaseThroughReclassificationsProvisions>
    <cvac:DisclosureOfOtherLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_Awl0GECeHEmDZQnnmT7Cqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other liabilities (non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel accrued liabilities (e.g. bonus, vacation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,543&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grants from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding invoices&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other liabilities (current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,491&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 50,717&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total other liabilities (current &amp;amp; non-current)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,510&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 50,717&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:DisclosureOfOtherLiabilitiesTableTextBlock>
    <cvac:OtherMiscellaneousNonCurrentLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_FbsOtnjieE2zHlpKj4YKuw_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19000</cvac:OtherMiscellaneousNonCurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_3pPp_GkXRUGVDrBacpaKFg_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19000</ifrs-full:OtherNoncurrentLiabilities>
    <cvac:PersonnelAccruedLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_5G45pjHFKUibigb9xOMtRQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7778000</cvac:PersonnelAccruedLiabilities>
    <cvac:PersonnelAccruedLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_wWlDzoKaA0a7_01vGXnVAQ_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10543000</cvac:PersonnelAccruedLiabilities>
    <ifrs-full:CurrentGovernmentGrants
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_iD0N48eiVEqhrVHv74mUDA_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2021000</ifrs-full:CurrentGovernmentGrants>
    <ifrs-full:CurrentGovernmentGrants
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_4VtJ3vBzMU6VUSGXzg-XjQ_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1735000</ifrs-full:CurrentGovernmentGrants>
    <cvac:OutstandingInvoicesCurrent
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc__gtfi-j7-UaCHbTPFJOcTA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28146000</cvac:OutstandingInvoicesCurrent>
    <cvac:OutstandingInvoicesCurrent
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_k5X2t1C3M060I99XEKMz_Q_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">36081000</cvac:OutstandingInvoicesCurrent>
    <cvac:ProfessionalFessCurrent
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_2wrlMw2EwkWsgzrkFpVVJQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1344000</cvac:ProfessionalFessCurrent>
    <cvac:ProfessionalFessCurrent
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_lSTRCV6Uy0qaZZD06jcwEQ_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1116000</cvac:ProfessionalFessCurrent>
    <cvac:CurrentValueAddedTaxAndOtherTaxesPayables
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_uWNXrtgUJUCnaK4dIdAS-g_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">924000</cvac:CurrentValueAddedTaxAndOtherTaxesPayables>
    <cvac:CurrentValueAddedTaxAndOtherTaxesPayables
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_WxVowDD47E6VgW2LsKvAAQ_9_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1042000</cvac:CurrentValueAddedTaxAndOtherTaxesPayables>
    <cvac:OtherLiabilityCurrent
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_Jn_s1Bz5JUOiP6SUWbLwwg_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">278000</cvac:OtherLiabilityCurrent>
    <cvac:OtherLiabilityCurrent
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_h65ZqFJWiUKP_OJFde9HmQ_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">200000</cvac:OtherLiabilityCurrent>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_SXpkMGYwXkessy2IzqMnWg_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40491000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_J6QAYPjcjkGFUG9NmhH1gw_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">50717000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_hwFPeHW9KkC7K8iIoDa_Zg_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40510000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_-tUQSlOStU-7GI9Wx5vCdA_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">50717000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_JwKNKbgjW0uda0xjj62bwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13. Income tax&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In fiscal 2023, the Group recorded a consolidated income tax expense of EUR 198k, in fiscal 2022 and 2021, the Group recorded a consolidated income tax benefit of EUR 126k and EUR 782k, respectively. The income tax expense in fiscal 2023 results from current income tax expenses (2022 income and 2021 expenses) of EUR 118k (2022: EUR 106k and 2021: EUR 1,033k) and deferred tax expenses (2022 income and 2021 income) of EUR 80k (2022: EUR 20k and 2021: EUR 1,815k), thereof from taxable temporary differences EUR 3,225k (2022: EUR 1,090k and 2021: EUR (1,540)k). In fiscal 2023, the Group further recorded deferred tax liabilities of EUR 0k (2022: EUR 20k and 2021: EUR 0k). In fiscal 2023 and 2022 an amount of EUR (2,094)k was accounted in equity. The basis for outside basis differences is EUR 168k (2022: EUR 1,120k and 2021: EUR 3,713k), which create a taxable outside base difference of EUR 8k (2022: EUR 56k and 2021: EUR 186k), which are indefinitely reinvested and associated with investments in subsidiaries, deferred tax liabilities have not been recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;A reconciliation between actual income taxes and the expected tax benefit from the loss before tax multiplied by the Group&#x2019;s applicable tax rate of 29.48% (15.0% corporate income tax, 0.825% solidary surcharge and 13.65% trade tax) is presented below for the years ended December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Loss before tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (412,498)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (249,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (259,969)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected tax benefit (based on statutory tax rate of 29.48% in 2023, 2022 and 2021)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Recognition of tax loss carryforwards recognized in prior years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Effects from differences between Group and local tax rates &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Non-recognition of tax loss carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (114,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69,724)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (81,392)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Non-recognition of deferred tax assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,363)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (626)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Recognition of deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,717&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Non-deductible expenses for tax purposes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (706)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Additions for local trade taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (176)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (330)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other non-deductible expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other effects&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,826)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective tax benefit / (expense)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 782&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 126&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (198)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Deferred tax assets and deferred tax liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;01,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recognized&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Acquired&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit&#160;and&#160;loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&#160;combination&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTA&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,224)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,224)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (665)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,439)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,439)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,364)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,052)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,052)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non - current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Non-current )&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Non-current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (118)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (152)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (142)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (508)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (137)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,498)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,490)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Taxes Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (84)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,194&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,777&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,583)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 01,2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recognized in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Acquired in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit and loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business combination&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTA&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,769)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,808)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (663)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,701)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,364)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,364)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (181)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,609&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non - current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Non-current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Non-current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (129)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (205)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (276)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,590)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,466)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Taxes Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,861&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,590)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (19)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,969&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,691)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Deferred Tax Assets for CureVac Corporate Services, which incurred a tax loss in the current or prior year, are recognized in the amount of EUR 1,172k as the company is expected to generate taxable profits due to its support function remuneration in the group (IAS 12.82).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following unused tax losses for which no deferred tax asset is recognized in the statement of financial position had been carried forward as of the end of the reporting periods:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tax loss carryforwards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unused tax losses for corporate income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,180,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,427,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,700,475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unused tax losses for trade tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,175,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,419,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,685,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unused interest carryforward ("Zinsschranke")&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac has tax losses in Germany and Netherlands that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose. In Germany and Netherlands tax losses carryforwards are unlimited.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;DTA&#x2019;s for temporary differences in the amount of EUR 20.9 million (2022: EUR 21.8 million) are not capitalized at year end 2023 because they are not recoverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pillar Two legislation has been enacted or substantively enacted in certain jurisdictions in which the Group operates. However, this legislation does not apply to the Group as its consolidated revenue is lower than EUR 750 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Current tax assets of EUR 5,201k (2022: 285k) consists of withholding tax receivables.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_CYuX-KDHa0yXKLdWAAhtvw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">198000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_GLDgm4iSfEqzBgb4BJ7Iog"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-126000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_YBExezxE4kaKAa9awPtlzQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-782000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_UyM4V6Oemk67lfDXjSTW-Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">118000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_F65YYHxI_EGBSubJDj-x1g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">106000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_vXo0clyk2USGWUa2h97Hfg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1033000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_7cshXY1gi0CuX_wzpCH3lw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">80000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_Dfx5OG1KC0yft28CVFJGDw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_Qm0CgcRdWUanO8hJ7iQ4Zg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1815000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_fK39PEa-L0mkYUh1iI5mhg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3225000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_19EJwW9op0aCuoNdSi4z5w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1090000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_oMXmNGc_VkCpdlI7poWB1A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1540000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_m6mcYE1wik6R-MZ657lhZg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_HsgfifTM1kS5ZeyqsTeVUg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_Dq1t8OpDmECS1OrurREgjg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
    <cvac:Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_LpIB_RSxJkuLIRO9ZZ1ztg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2094000</cvac:Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity>
    <cvac:Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_3uRyM8yf5kiwwjXQjBSK_g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">168000</cvac:Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity>
    <cvac:Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_yf9neI0GC02UyG0zEG-gAg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1120000</cvac:Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure>
    <cvac:Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_ERqr_-n3EkCxH6dLm4r1gg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3713000</cvac:Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_2NV8EZlD8UGXJFNTR3SpMQ"
      decimals="-3"
      id="Narr_s7mG9lDdxEevUqcOBkDmEw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_KOCTqYugQU-Xp2Dma3UX4g"
      decimals="-3"
      id="Narr_4pM1MgZN-EWW_O7_LewleA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">56000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_SubsidiariesMember_FgRE2Czx-0e3kuw6SVMj_w"
      decimals="-3"
      id="Narr_lnWvcLORy02Fkk5Y1LwWKA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">186000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:ApplicableTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="4"
      id="Narr_fQ-Y_q9KcUin2CP9AkjCsw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.2948</ifrs-full:ApplicableTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="2"
      id="Narr_y7jt-S6rg02Zd8TvQpa3Iw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.150</ifrs-full:AverageEffectiveTaxRate>
    <cvac:PercentageOfSolidarySurcharge
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="5"
      id="Narr_z-AfO1xMMkmih1jr2Os9YQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.00825</cvac:PercentageOfSolidarySurcharge>
    <cvac:PercentageOfTradeTax
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="4"
      id="Narr_cHa4AYCQT0agGwBkkNDtfg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.1365</cvac:PercentageOfTradeTax>
    <cvac:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_eGJ8cKQLUkq_dYm4ygwGMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Loss before tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (412,498)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (249,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (259,969)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected tax benefit (based on statutory tax rate of 29.48% in 2023, 2022 and 2021)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Recognition of tax loss carryforwards recognized in prior years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Effects from differences between Group and local tax rates &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Non-recognition of tax loss carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (114,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69,724)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (81,392)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Non-recognition of deferred tax assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,363)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (626)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Recognition of deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,717&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Non-deductible expenses for tax purposes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (706)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Additions for local trade taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (176)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (330)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other non-deductible expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other effects&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,826)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective tax benefit / (expense)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 782&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 126&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (198)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <ifrs-full:AccountingProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_A4LRjFnFVkqvVodRAQT9_w_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-412498000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_hvArTo27xku77frvgUdVCw_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-249155000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_V49kepUc00asC-BBDHnshg_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-259969000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="4"
      id="Narr_dPnm3jY-rUWvA7Yel6TVZQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.2948</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="4"
      id="Narr_9ecVc0Gv6UuLawAgzapIEg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.2948</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="4"
      id="Narr_c2K8spcK00qOJEbVVSNLUw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.2948</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_NLr2nwCrT027oagj_mDsnQ_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-121584000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_pQlryqhp3EKoEHrEGhFmkQ_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-73426000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_Q05T3l8X-E2BNp300-mZzQ_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-76626000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_vtVdSnR0RESg8U_U_GXXSg_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-327000</cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwardsPriorYear>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_K4kD0-n-lkW8aqzofqMm_g_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">8000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_72XekMyJ3EKdaqPGHdSEnA_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_YOSxZQNSD0ajSuttcOZLOQ_6_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2000</ifrs-full:TaxEffectOfForeignTaxRates>
    <cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_OXFopvAAJ0m2_IYVfpLMng_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-114999000</cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards>
    <cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_0IJgoHRY_UGCbnh0aaeVsw_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-69724000</cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards>
    <cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_An9cXz3LZUyn-8viQAqSkw_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-81392000</cvac:TaxEffectOfNonRecognitionOfTaxLossCarryforwards>
    <cvac:TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_SfGDrS4370uyRfYlM72gTQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-7363000</cvac:TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities>
    <cvac:TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_Jd3qxAEXt06hSl_Nusd7Rw_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-626000</cvac:TaxEffectOfNonRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities>
    <cvac:TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_aGHvjTfdg0erO4tdUcgouQ_9_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3717000</cvac:TaxEffectOnRecognitionOfDeferredTaxAssetsAndDeferredTaxLiabilities>
    <cvac:TaxEffectOnNonDeductibleExpensesForTaxPurposes
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_h4wr7EH6qk67Ft_D67DENw_10_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">119000</cvac:TaxEffectOnNonDeductibleExpensesForTaxPurposes>
    <cvac:TaxEffectOnNonDeductibleExpensesForTaxPurposes
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_dWgOQwt7VE2unAtlZMryew_10_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">706000</cvac:TaxEffectOnNonDeductibleExpensesForTaxPurposes>
    <cvac:TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_TLxQBNB8r0KxXQXdfIA0ig_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">176000</cvac:TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes>
    <cvac:TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_5YQyPpRivkOMVlDgfZ9w-Q_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">330000</cvac:TaxEffectOfExpenseNotDeductibleInDeterminingProfitLossRelatedToAdditionsOrDeductionsForLocalTradeTaxes>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_bRHwNIxrNE-UiH2fCbyEsg_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">101000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_xNmdZnpgf0KpYlLnaLtHVw_13_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1845000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_Vji-1JxwCUqA0Ot6GesrIg_13_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2826000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_Rc-RDly9mU6mzrnCeGtokg_13_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1599000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Tc_N_5SmR1VykeJXQ7ysOzBug_14_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-782000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_LZ6SRiO52k-SVMhky7NMQQ_14_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-126000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_DSAAuKLrZ0yFdi8kAz74hA_14_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">198000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_9c7kfuKhX0-XhHK3Dk9PVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;01,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recognized&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Acquired&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit&#160;and&#160;loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&#160;combination&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTA&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,224)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,224)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (665)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,439)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,439)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,364)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,052)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,052)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non - current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Non-current )&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Non-current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (118)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (152)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (142)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (508)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (137)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,498)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,490)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Taxes Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (84)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,194&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,777&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,583)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 01,2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recognized in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Acquired in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit and loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business combination&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTA&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;DTL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,412)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,769)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,808)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (663)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,701)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,364)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,364)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (181)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,609&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non - current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Non-current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Non-current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (129)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities (Current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (205)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (276)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,590)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,466)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Taxes Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,861&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,590)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (19)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,969&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,691)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg"
      decimals="-3"
      id="Tc_aBG681UXeUit3EpdZXEbgg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1412000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_sPUZgy8alUm9DrExIlqZxg"
      decimals="-3"
      id="Tc_nHmw2OvuG0G5252dnobdOg_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">188000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_2z_v-2cIV0GPSwrqAp-RhA"
      decimals="-3"
      id="Tc_maDql4I2tUCR_gGRHRSVtg_5_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1224000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_2z_v-2cIV0GPSwrqAp-RhA"
      decimals="-3"
      id="Tc_zT7B8iRQXkWhDCE6gswrpA_5_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1224000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ"
      decimals="-3"
      id="Tc_6lVkhXH0AUGAqskpK7YXDA_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2774000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_N6uLOUQcWEa4CDo-FoW1jw"
      decimals="-3"
      id="Tc_uUdj737wQkyJqC-AfieZXQ_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-665000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_xceMST2sskiZALYanrkx6Q"
      decimals="-3"
      id="Tc_R1WPxsd4gESfKtYgskGT_Q_6_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-3439000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_xceMST2sskiZALYanrkx6Q"
      decimals="-3"
      id="Tc_Rc67bcVCH0aQHVc2nEPx2Q_6_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3439000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw"
      decimals="-3"
      id="Tc_Y3FLMGSOCE6QrgdNOIuEIQ_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-12364000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_BxdZ_fqI90qVPvPxCxQ8Cw"
      decimals="-3"
      id="Tc_19xjbz_hWUidIeyGaMOk2A_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">312000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_vPbCsfbl10GjVuhXwSETZQ"
      decimals="-3"
      id="Tc_CjPL3y0g7kevrFoS4KZhkw_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-12052000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_vPbCsfbl10GjVuhXwSETZQ"
      decimals="-3"
      id="Tc_OWAg_vuVZkiYVHW-tseERQ_7_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12052000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA"
      decimals="-3"
      id="Tc_az5nhTyJi02zSv6Cgsy7Dg_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-90000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_AdgiqRdnnUCyfzTbCUw3EA"
      decimals="-3"
      id="Tc_1aWuBP4USUe3-wfp3HKyFA_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">90000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_q7WO6vvez0OVGaUlPRtXNw"
      decimals="-3"
      id="Tc_zO0hXKKnV0OJSNp1O7fJ0g_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">52000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_bOuXDQXtgECvVjIJJiEBBQ"
      decimals="-3"
      id="Tc_7KQV_fSxMEefU8vWTgj28g_11_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">52000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_bOuXDQXtgECvVjIJJiEBBQ"
      decimals="-3"
      id="Tc_m4c0yEjC0kWZpkyAFATn7A_11_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">52000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA"
      decimals="-3"
      id="Tc_g799CB7bWESmkku-wVT9AQ_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-47000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_brACGjFlf0yYmlE-IZbkqQ"
      decimals="-3"
      id="Tc_PeLz3dbJVEa-TFUQD48yfg_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">62000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_RRVoksyfikayCq6qHVsupQ"
      decimals="-3"
      id="Tc_qZN_9MtWwUSZ02XbpmgsQA_12_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_RRVoksyfikayCq6qHVsupQ"
      decimals="-3"
      id="Tc_TY4Lxq1sAkqaYiFplQHUpg_12_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q"
      decimals="-3"
      id="Tc_SNFag8xaYkSVrMiB8WVT-Q_13_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1428000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_tiHq0sjs80K57XqBzMQLJg"
      decimals="-3"
      id="Tc_I8dfQ_l3x0S0w9bLSFyBFg_13_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1428000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_tiHq0sjs80K57XqBzMQLJg"
      decimals="-3"
      id="Tc_u1H0dTX5GkujsLJX_VTV5Q_13_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1428000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA"
      decimals="-3"
      id="Tc_sJvMehruh0SL3_MLiyScng_14_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1014000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_AMhqZjayEkyLFJUXTSfqhA"
      decimals="-3"
      id="Tc_Syx4YD-n10KdNAWbbLoDng_14_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1003000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ"
      decimals="-3"
      id="Tc_bnz7AYEHyU66rCbG225deA_14_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-11000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ"
      decimals="-3"
      id="Tc_L1XtKWWlkEmHy2VJe5XHrQ_14_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_HcFzi1lAdEqkEtXJTDmEjQ"
      decimals="-3"
      id="Tc_eMJndYy13UWuF0Q__Cz_rA_14_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA"
      decimals="-3"
      id="Tc_HeUHViCqcEiCL7EXrzetuQ_17_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10514000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WJuDdMd_AEOjhVaYyZzKtA"
      decimals="-3"
      id="Tc_o5ZLIsoKEU2Z9pdVSe-iKw_17_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-14000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_3qNBdkGOC0S9Pb4g2-0A6A"
      decimals="-3"
      id="Tc_S1esw5hi5km1fJjkZuy3-w_17_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10500000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_3qNBdkGOC0S9Pb4g2-0A6A"
      decimals="-3"
      id="Tc_vPM9xWB9jUmfdY0LR5r4ug_17_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10500000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA"
      decimals="-3"
      id="Tc_GUklFo36YUCYkB35N7CWMg_18_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">51000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_NwLw6YbSN0CNCMJtsJh-lA"
      decimals="-3"
      id="Tc_bhxfP_Oa7Ei3wQ8Zp8PA4g_18_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-118000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_0jknVHupLEyMHv6EAT-P4w"
      decimals="-3"
      id="Tc_p2bD1EeK_0O45T_Q2ZxVBQ_18_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-67000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_0jknVHupLEyMHv6EAT-P4w"
      decimals="-3"
      id="Tc_717-RIpFyEKSYlmmyt-Nmw_18_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">67000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA"
      decimals="-3"
      id="Tc_v2vEahXnjUqhd1aGHdJDiQ_21_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1345000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_y_Uiw0kSbEuybbOsAdT54w"
      decimals="-3"
      id="Tc_pFuStwutKkSpMX2XwrpktQ_21_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-152000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_VwP1ZgmTKEqT0Qondxniqg"
      decimals="-3"
      id="Tc_W8VgMS8LBkqMJ3r7-jtDqg_21_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1193000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_VwP1ZgmTKEqT0Qondxniqg"
      decimals="-3"
      id="Tc_wR7uNE2_D06rU6ARoXuiMQ_21_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1193000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew"
      decimals="-3"
      id="Tc_0wtAWnvcw0WlzLd57QizqQ_22_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-184000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_WoU5OY8q9UmNGItiCh3wFQ"
      decimals="-3"
      id="Tc_FDd8Mbr5uUCLjarTe7RJhQ_22_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_HeRhz1br2kW9XGBq3W35TQ"
      decimals="-3"
      id="Tc_zLTEQU9PmEOx6yyjxFlyMQ_22_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-142000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_HeRhz1br2kW9XGBq3W35TQ"
      decimals="-3"
      id="Tc_B-qfygeQ5kaXB7Q5rpda8A_22_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">142000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw"
      decimals="-3"
      id="Tc_Y4VXeJc9MkigIsAoXuQ77g_23_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">420000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__QCZpl7FCECVWYoHf5mRiw"
      decimals="-3"
      id="Tc_XyTYU04LGEmFZ9_VqLUqSQ_23_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-508000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w"
      decimals="-3"
      id="Tc_Mm9ehNdpE0OuLujHkIN2Og_23_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-88000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w"
      decimals="-3"
      id="Tc_djAGZJtGdEeyXMTRYLA4aA_23_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">49000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_JfZ9eeO4FEiosYueceke2w"
      decimals="-3"
      id="Tc_caltuI94p0S_QK0MGbfUUw_23_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">137000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw"
      decimals="-3"
      id="Tc_4S99_2fWfUiFYQaG3cC3Mg_24_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1411000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_q0E1iqjsuEivVAPEk_0CQw"
      decimals="-3"
      id="Tc_4MvYj5HoaUSunVKszngY4g_24_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3122000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_1Cz5tMIDUE64OdcnvtgS2A"
      decimals="-3"
      id="Tc_9g-BDp7MP0u2uAhfIQ_S-g_24_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4533000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_1Cz5tMIDUE64OdcnvtgS2A"
      decimals="-3"
      id="Tc_NhiPu_ukME2MRAh2ixO0Vg_24_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4533000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ"
      decimals="-3"
      id="Tc_nx_b9xX9tUyULXIg9s1bsg_25_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3994000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_K70FGvuxREqsUGGoFXb3Ig"
      decimals="-3"
      id="Tc_9-CABrykQEewZKF9FjhAew_25_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-3498000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_CL_42NO980yFn3bMpoksBA"
      decimals="-3"
      id="Tc_zL51qIckkEikVkSyYnvJGg_25_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">496000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_CL_42NO980yFn3bMpoksBA"
      decimals="-3"
      id="Tc_kBflKx_nYE6IJN2ORLvxLg_25_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">496000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_fOnOhohTI0aH7chs7hxlhQ"
      decimals="-3"
      id="Tc_e4ig74cwX0emHn9pjbqHig_26_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10490000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_fOnOhohTI0aH7chs7hxlhQ"
      decimals="-3"
      id="Tc_vRcJQTkuJkqs4BMppOilBg_26_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10490000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_euQ-jIMNi0KZo2kyvKCy6g_27_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1278000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_kXS-c1vXzkKVzLSVSQVA7A_27_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-84000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_jGtf0-VXTU23h3mNoGimeg_27_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1194000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_3SG-4mBhX0qC6CRILOQ4sA_27_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7777000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_GqVqFoG6RE2Ou6FLjQheUg_27_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6583000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_rK-mQvhP6k6rDG5s_W9Crw"
      decimals="-3"
      id="Tc_6LE4-bXb1UGMMMPEftTYcg_5_9"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1412000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg"
      decimals="-3"
      id="Tc_zUEeNR6WFU2pLVv7QktXNw_5_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1412000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IntangibleAssetsMember_fpp-8UsE4kOc_kes2uyFmg"
      decimals="-3"
      id="Tc_EL5ADEy70k2i9pak6v69dA_5_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1412000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_MKSIOOU_xkyo8xpkv2OyHQ"
      decimals="-3"
      id="Tc_8VOH0Hf_5E2KDjLd4irViw_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-5000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_Fr_u4k8C4EyZbX93eTH8iw"
      decimals="-3"
      id="Tc_k2d5fPdIZ0OTKM7A_l4Eyw_6_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2769000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ"
      decimals="-3"
      id="Tc_ahlA9G0TskG04DtZMQkQDg_6_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2774000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ"
      decimals="-3"
      id="Tc_uKkjmoVZ4Em1OZr_jGxnlQ_6_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">34000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_PropertyPlantAndEquipmentMember_kDKKOxRhkk2MLkxPHl2hdQ"
      decimals="-3"
      id="Tc_6G5Abu0ehkyobH1jsIp2FQ_6_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2808000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_N2Zm5geGpE2tjfPniK-XXA"
      decimals="-3"
      id="Tc_cYe4Hl3MdUeHxgbmskOYSw_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-663000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_dpBYHdH2n0euqcNEgHxmzg"
      decimals="-3"
      id="Tc_Y2EkUzGh00KqUQlbJxHdFA_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-11701000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw"
      decimals="-3"
      id="Tc__5stfYUXvEittEDiT1V4Xw_7_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-12364000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_RightofuseAssetsMember_v7eVyKLEEEWRnAyaTEvPSw"
      decimals="-3"
      id="Tc_MjVnQdYGqEyHRRz3nU7Gfg_7_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12364000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_6IbdDCUU1k2phHbdFhwJZQ"
      decimals="-3"
      id="Tc_iVadYp7zC0CgfYswDhP1MQ_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-90000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA"
      decimals="-3"
      id="Tc_GyDtQsdK8kGqKj0zNE4SxA_8_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-90000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_OtherAssetsMember_YEnc1HIkxEyO0rTqRHXAnA"
      decimals="-3"
      id="Tc_LC7oNLC9jU-2d1HHC2jgYg_8_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">90000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_dPvTMfFzZkqhDReqmruC2g"
      decimals="-3"
      id="Tc_-kz0CeTWZUKvb7STf4j8_A_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-9000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsinventoriesMember_TXI_swpSqEWRqNR403cl4w"
      decimals="-3"
      id="Tc_pRI76V4HqkKZNzUzlYYRCA_11_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_budjsnBG90KFg41r2z8BQw"
      decimals="-3"
      id="Tc_l5MaQ60PCkO0UulrbXfQKQ_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">97000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_bZP5vsKUxUWOPhfDrg8I3A"
      decimals="-3"
      id="Tc_XTGVNz_XW0aTi8TnTnQB_g_12_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-144000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA"
      decimals="-3"
      id="Tc_Ny-a0vEd20qI0RO22TRa9w_12_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-47000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TradeReceivablesMember_78C97B9FLkOzv_t5_iOtmA"
      decimals="-3"
      id="Tc_7NJpBg9Kc0O4-6K1ejqDxw_12_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">47000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_8V8uLdfk1k6k9TaP2157vA"
      decimals="-3"
      id="Tc_9dJPVEDb-UWuasQrVH9aag_13_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-181000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_mdiFR6M0iEGRWxBYIMdEcQ"
      decimals="-3"
      id="Tc_Af7TIcysAkmv6IrqXTlP5Q_13_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1609000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q"
      decimals="-3"
      id="Tc_M3Z_ABpQikazBC4xgzgLaQ_13_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1428000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsprepaidExpensesAndOtherAssetsMember_w1dZA3DuJ0Ka7pFTISw52Q"
      decimals="-3"
      id="Tc_OIDkh8L0IU6vV2PJ-q8pCg_13_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1428000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_Ay6fLSJ51ketqazQXPf5hw"
      decimals="-3"
      id="Tc_rtBBnxXW4ku0j9eeSd9A-g_14_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-87000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_XYmGcuw_GUu29m7J0DC8FQ"
      decimals="-3"
      id="Tc_aYwlpGxYqU-wujWDHJs3Ug_14_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-927000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA"
      decimals="-3"
      id="Tc_oQ6Pk-kPXE2SRPpogo15Lg_14_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1014000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsCashAndCashEquivalentsMember_7qXXY3wo6Uy8ebl5X0-YpA"
      decimals="-3"
      id="Tc_uZLSH8TvxE-NxIKYy-MJyw_14_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1014000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_RcuGyuNGcUqdgPvzwcxZHA"
      decimals="-3"
      id="Tc_RHJJ5KuxIEusTHRy4oZPdg_17_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">622000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_WbbYak-BQUGFoFXANHb7Vw"
      decimals="-3"
      id="Tc_DBn-xSsn5ki6k1ltpJsNow_17_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9892000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA"
      decimals="-3"
      id="Tc_GSJYiQ3oWkOlUaqLY4gc2Q_17_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10514000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_NonCurrentLeaseLiabilitiesMember_QYf4cSqtJEaTdnPKlO1xgA"
      decimals="-3"
      id="Tc_VSV4phClr0CNajtNqsfSvA_17_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10514000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_bMA8T5tG6ES2FAnIC7DkfA"
      decimals="-3"
      id="Tc_07UgCtJOikmM55_TJ0vsbA_18_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-129000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_iav8T9jxJ02hwX0kprs5wA"
      decimals="-3"
      id="Tc_jJn35ow6SE2-ziK-uHM57w_18_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">180000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA"
      decimals="-3"
      id="Tc_-vsG7nA7d0e7-sB5rwws0A_18_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">51000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA"
      decimals="-3"
      id="Tc_JFL86pOiJk-ZUIBub6xmeg_18_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">84000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherNoncurrentLiabilitiesMember_IIavYbNl50q7tDG9wediFA"
      decimals="-3"
      id="Tc_M64GEFe8502eGYrwDO224Q_18_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">33000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_ZZaNrVakd0WQ7KvFCMu6Bw"
      decimals="-3"
      id="Tc_6lkjWB1h00atfLOFoCd60g_21_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">156000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_LXDETgWXhUW-6PMmcfMtQA"
      decimals="-3"
      id="Tc_M-jNIYNgCUaaGOeC38tgNQ_21_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1189000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA"
      decimals="-3"
      id="Tc_D1bWb9__jUy_cOTLWYeUQA_21_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1345000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_CurrentLeaseLiabilitiesMember_aKi3h9yRqUWra6RliUXeNA"
      decimals="-3"
      id="Tc_WQQ2nZrwt0mDU2T8xwPFzg_21_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1345000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_8o2ZYCj_7EKP52vUoSck2g"
      decimals="-3"
      id="Tc_Es74sqshZUOElU2pJ-AS_w_22_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-23000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_J-pJWtADOEeUxcm-wYpInA"
      decimals="-3"
      id="Tc_nDkJ6bU_Tk-4L9gop5ixAQ_22_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-161000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew"
      decimals="-3"
      id="Tc_7Gpinpnejkmj88LbkzbxuA_22_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-184000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TradeAndOtherPayablesMember_sscaxV8wWkC87wmwk-roew"
      decimals="-3"
      id="Tc_zvgztu9BHkuDOwBWCilFWw_22_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">184000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_WlD6qYqQ-UChT6kij1OauQ"
      decimals="-3"
      id="Tc_WT0qkSOMWUGfUq1R4UO-Cw_23_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember__OUzUplfMke4OyytxLopmg"
      decimals="-3"
      id="Tc_aeQIn7e78UaiiW55FdQA-w_23_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">400000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw"
      decimals="-3"
      id="Tc_KfWV61s1vEmILIThCzm8kw_23_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">420000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw"
      decimals="-3"
      id="Tc_PU4MWpM08Eq6LsHBJBw-Yg_23_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">625000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_IfrsOtherLiabilitiesMember_Mtfl6v_qYkCHBwpuoR9eHw"
      decimals="-3"
      id="Tc_i8nxbOo0Q0-EvFKMYyVsyQ_23_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">205000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_XS4wMvPP1k64ztgaiLo9AQ"
      decimals="-3"
      id="Tc_4RDt93HpTUeOka25FdJvxg_24_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">294000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_8P9AJYdqkUuBYi1IlF81dg"
      decimals="-3"
      id="Tc_2meTWX1mFUyBJK8TZvNLHw_24_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-276000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_8P9AJYdqkUuBYi1IlF81dg"
      decimals="-3"
      id="Tc_3xlBOA8M0k6mHck2vFvoGg_24_9"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1393000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw"
      decimals="-3"
      id="Tc_bH7upELfKk-xnDKipQZyqg_24_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1411000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_TaxLossesCarriedForwardsMember_n8jekqBnXkSnUKTiaP_DWw"
      decimals="-3"
      id="Tc_sAouS4o4gkiO7kuVn5RjTA_24_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1411000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2021_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_qNgj2Z_Q3k6Magi__mK2Lw"
      decimals="-3"
      id="Tc_E0yH-85SmEiCeTLX87P0jA_25_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2769000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_5ly2YlnqS0GPhMxtaYcLWg"
      decimals="-3"
      id="Tc_HlpiEtKXDEeBocc_ioVyaA_25_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2815000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_5ly2YlnqS0GPhMxtaYcLWg"
      decimals="-3"
      id="Tc_V0G7I3odoky9FdglKHx58w_25_7"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1590000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ"
      decimals="-3"
      id="Tc_2otOJbDo2UutJnKuunSk0Q_25_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3994000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_ShareBasedPaymentsMember_rcQnkXYBQkC0-CVHRbJGKQ"
      decimals="-3"
      id="Tc_tVvC7oSkSEytAeBxRJmXwA_25_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3994000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_USje2-QFJEy2AJRt3OvR5Q"
      decimals="-3"
      id="Tc_FqG5Mzg2TU6cmE66aiOgJQ_26_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11466000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_cvac_DeferredTaxAssetsAndDeferredTaxLiabilityNettingMember_USje2-QFJEy2AJRt3OvR5Q"
      decimals="-3"
      id="Tc_fhOsJ9nxyUaE2saQ-XV_FA_26_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11466000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_gecJPuZG2UCLwesvxNB8zg_27_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2861000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_4kp1ibTytEKBjM1xCJBHyA_27_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_IyA2RBVQykOSxPKhdGDv-w_27_7"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-1590000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_1SxUq2DcvUWQ5XGPcvgZaA_27_9"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-19000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_T8ozrOdIpkGU-g27PVPzIw_27_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1278000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_cJtg9Wp8AUCLtK-xe1pW9g_27_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7969000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_F6HwetmY4k2AybMRkZpPUA_27_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6691000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServicesGmbhTuebingenGermanyMember_nNMExjPVFE-feDhtK4OSgg"
      decimals="-3"
      id="Narr_1cnf2f6c5kWwTQWfoRTADQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1172000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <cvac:TemporaryDifferencesValuationOfDeferredTaxAssets
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Narr_zn4N7cMQEkm6MFBOLe8HSQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</cvac:TemporaryDifferencesValuationOfDeferredTaxAssets>
    <cvac:TemporaryDifferencesValuationOfDeferredTaxAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_rL38fYZXlE6LZhadPNvtHw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</cvac:TemporaryDifferencesValuationOfDeferredTaxAssets>
    <cvac:TemporaryDifferencesValuationOfDeferredTaxAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_IbmP5sHOuEOtkTDVtlpP3g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</cvac:TemporaryDifferencesValuationOfDeferredTaxAssets>
    <cvac:IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_IUYQ3_9DmE-0Zg2CsWJxlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tax loss carryforwards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unused tax losses for corporate income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,180,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,427,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,700,475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unused tax losses for trade tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,175,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,419,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,685,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unused interest carryforward ("Zinsschranke")&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:IfrsSummaryOfOperatingLossCarryforwardsTableTextBlock>
    <cvac:UnusedTaxLossesForCorporateIncomeTax
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_1wffuUWj202H4CxdVqSAtQ_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1180227000</cvac:UnusedTaxLossesForCorporateIncomeTax>
    <cvac:UnusedTaxLossesForCorporateIncomeTax
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_bqJe-g-xk0iUECTxolOy1g_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1427735000</cvac:UnusedTaxLossesForCorporateIncomeTax>
    <cvac:UnusedTaxLossesForCorporateIncomeTax
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_T-u2V5vokEqt9hnLeEiZPw_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1700475000</cvac:UnusedTaxLossesForCorporateIncomeTax>
    <cvac:UnusedTaxLossesForTradeTax
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_gvXerF_-RUyiPsm0hz-01A_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1175846000</cvac:UnusedTaxLossesForTradeTax>
    <cvac:UnusedTaxLossesForTradeTax
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_UDCyKT7nRUKZz4PpA87Qog_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1419217000</cvac:UnusedTaxLossesForTradeTax>
    <cvac:UnusedTaxLossesForTradeTax
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_xIvrk90mC0K_OL5lfurTfw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1685517000</cvac:UnusedTaxLossesForTradeTax>
    <cvac:UnusedInterestCarryforward
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_LDbmcQd9W02yVBCQv2rnhg_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2879000</cvac:UnusedInterestCarryforward>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-5"
      id="Narr_r1L4jVPZFk6YJRdH-XNiHw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20900000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-5"
      id="Narr_GYqeEENL1kSoVjRcYDOs1g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">21800000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:CurrentTaxAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_FucMfEB2yk2pmf4_u2lugg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5201000</ifrs-full:CurrentTaxAssets>
    <ifrs-full:CurrentTaxAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_o7_8aWiw7kOOYVj0gTyp6g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">285000</ifrs-full:CurrentTaxAssets>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_BsrR9_z2mEG7DAW2ckhbSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14. Earnings per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Earnings per share is calculated by dividing the consolidated net loss of CureVac by the weighted average number of shares outstanding in the fiscal period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average number of shares outstanding in fiscal 2021, 2022 and 2023 was 186,012,586, 189,074,911 and 220,833,271, respectively. This has led to basic loss per share of EUR 2.21, EUR 1.32 and EUR 1.18 for fiscal 2021, 2022 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Diluted earnings per share is calculated using CureVac&#x2019;s weighted-average outstanding common shares including the dilutive effect of share-based payment awards as determined under the treasury stock method. In periods when CureVac has a net loss, share-based payment awards are excluded from the calculation of earnings per share as their inclusion would have an antidilutive effect. Share options and RSUs of 1.217.526 and 1,788,206 as of December 31,2022 and 2023 respectively, were excluded from the computation of diluted weighted average number of shares because their effect would have been antidilutive.&lt;/p&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="0"
      id="Narr_ft4879ykCUqauc4AzVDwtg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">186012586</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="0"
      id="Narr_SwvtTWN3HkGONDNZharf1w"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">189074911</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="0"
      id="Narr_hiswsaqsOEWTgEBMOuWNoQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">220833271</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="2"
      id="Narr_SzfnR9XRMUez2eIXMJcsDg"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-2.21</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="2"
      id="Narr_sz2BzUCnXEC8GIvVc6oIXA"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-1.32</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="2"
      id="Narr_XGL7312URUSXiJTmUIqY-w"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">-1.18</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="0"
      id="Narr_1s4mB-Y7bEiZmIqNewuyog"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">1788206</ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_v_SZS6UNNEWzHvoUyGwcJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15. Disclosure of financial instruments and management of financial risks&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;General information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac is exposed to certain financial risks with respect to its assets and liabilities and the transactions associated with its business model. These risks generally relate to credit risks, liquidity risks and market risks (including currency risk, interest rate risk and price risk).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The aim of risk management is to limit the potential negative impact on expected cash flows and take advantage of any opportunities that arise. As a result, the management of CureVac assesses at least once a year whether risks have changed and whether the measures in place to limit risk are still sufficient.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Finance Income / Finance Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, finance income was EUR 16,731k (2022: EUR 4,009k, 2021: EUR 10,103k) and related mainly to interest income on cash investments EUR 15,411k (2022: EUR 1,733k, 2021: EUR 81k) and foreign exchange gains EUR 1,062k (2022: EUR 2,188k, 2021: EUR 10,092k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, finance expenses were EUR 2,493k (2022: EUR 3,707k, 2021: EUR 10,338k) and related mainly to foreign exchange losses EUR 2,272k (2022: EUR 1,319k, 2021: EUR 3,939k) and negative interest on cash of EUR 0k (2022: EUR 2,299k, 2021: EUR 6,793k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Credit risk is managed by CureVac&#x2019;s finance department. Credit risk arises from cash and cash equivalents and other financial assets, including deposits with banks and financial institutions, as well as credit exposures to customers, including outstanding receivables and contract assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac is exposed to bank default and concentration risk as its cash is concentrated at few financial institutions. Management distributed the cash to decrease concentration risk as of December 31, 2023, deciding to allocate 12% of the cash at one of Europe&#x2019;s largest private bank, 7% at Germany&#x2019;s largest private bank and 71% at a major German Landesbank; the remaining cash balance is maintained at other banks. The focused cash management structure with few banks allows enhanced bank risk supervision. The market capitalization of all banks mentioned above is regularly reviewed. Credit risk is further limited by investing only in liquid instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac is also exposed to a credit risk for its receivables and contract assets. The risk of default is considered to be low because the structure of customers consists of reputable collaborating parties and government grantors. Receivables management and financial accounting incorporates monitoring of payments received and any overdue receivables. The risk of counterparty nonperformance is not material.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amount of other financial assets recognized determines the maximum theoretical credit risk. As of the end of fiscal 2023, available funds are deposited at three reputable financial institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, the loss allowance for the &#x201c;expected credit losses&#x201d; totaled to EUR 71k (2022: EUR 99k, 2021: EUR 105k), resulting in an effect recognized in fiscal 2023 in finance income EUR 248k (2022: EUR 57k, 2021: EUR 149k) and finance expense EUR 220k (2022: EUR 51k, 2021: EUR 71k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity risk&lt;/span&gt; &lt;span style="font-style:italic;font-weight:bold;"&gt;/ Capital management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the purpose of CureVac&#x2019;s capital management, capital includes share capital and all other equity reserves attributable to the equity holders. The primary objective of CureVac&#x2019;s capital management is to maximize the shareholder value through investment in the development activities of the Group.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on its business as an active research group, CureVac has historically relied almost exclusively on equity funding by its shareholders and lenders as a means of financing itself prior to successful development and sales of a marketable product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group&#x2019;s finance department reviews the total amount of cash of the Group on a weekly basis. As part of this review, the finance department considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In meeting its financing objectives, the Group negotiates and enters into research cooperation agreements. In general, the aim is to maximize the financial resources available for further research and development projects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac is not subject to externally imposed capital requirements. However, certain grant funds received may be required to be returned if qualifying costs are not incurred or are not incurred in accordance with the grant terms (see also Note 3.7. and Note 3.8.). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As described in Note 9, the Group has an at-the-market offering program through which, from time to time, may be able to raise additional capital through the issuance of common shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;No changes were made in the objectives, policies or processes for managing cash during the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In order to safeguard liquidity, the Group invests funds not required immediately for operating purposes in call-deposit accounts with original maturities up to three months. Liquidity risks are therefore expected to be low. The Group does not enter into trading of financial instruments and monitors its risk of a shortage of funds using a liquidity planning tool.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Historically, CureVac has relied on financing from shareholders, grant income and collaborators in order to ensure sufficient liquidity. Lack of external financial support could pose a risk of going concern. The liquidity management of CureVac ensures the availability of cash and cash equivalents for operational activities and further investments through appropriate budget planning.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Ultimately, the responsibility for liquidity risk management lies with management, who has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. CureVac manages liquidity risks by holding appropriate reserves, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The table below summarizes the maturity profile of the Group&#x2019;s liabilities based on contractual undiscounted payments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;lt;1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&#160;to&#160;5&#160;years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;gt;&#160;5&#160;years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual commitments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,269)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Note 4.2) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (53,656)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities and provisions (Note 12) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,117)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,117)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables (Note 11) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,033)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,033)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (146,673)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (23,581)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,821)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (193,075)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;lt; 1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&#160;to&#160;5years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;gt;&#160;5&#160;years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual commitments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,923)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,377)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (74,300)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Note 4.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,247)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,693)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (54,723)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities and provisions (Note 12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,447)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (103,753)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables (Note 11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (73,463)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (73,463)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (172,080)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (112,356)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (21,803)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (306,239)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Foreign currency risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. CureVac&#x2019;s exposure to the risk of changes in foreign exchange rates relates primarily to the Group&#x2019;s operating activities (when revenue or expense is denominated in a foreign currency) and the amounts held as cash and cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;For all CureVac entities except of CureVac Inc. and CureVac Swiss AG the functional currency is EUR. The functional currency of CureVac Inc. is the USD and of CureVac Swiss AG the CHF. CureVac SE&#x2019;s exposure in foreign currency at the end of 2023 and 2022 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&#160;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;57,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;63,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;CHF&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary assets in foreign currency &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;GBP&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;CHF&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary liabilities in foreign currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;  &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&#160;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary assets in foreign currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,566&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 113,664&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GBP&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CHF&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary liabilities in foreign currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,332&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As shown in the tables above, CureVac N.V. is exposed to a currency risk only in relation to the USD. Therefore, a foreign currency sensitivity analysis is only presented in respect to the net exposure in USD at fiscal year ends. CureVac&#x2019;s net exposure in USD is the difference between monetary assets in USD and monetary liabilities in USD and developed as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net exposure in USD&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;2022 (1 EUR= 1.0666 USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023 (1 EUR = 1.1050 USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;77,649&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k from USD &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;82,822&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;72,015&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k from USD &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;79,576&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2023, if the EUR had weakened and conversely, had strengthened, 10 per cent against the US dollar, with all other variables held constant, pre-tax loss and post-tax loss would have been affected as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect&#160;on&#160;pre-tax&#160;profit&#160;or&#160;loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect&#160;on&#160;post-tax&#160;profit&#160;or&#160;loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strengthening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weakening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strengthening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weakening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;31.12.2023 EUR against USD &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;10&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;% movement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,547&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (8,002)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,617&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5,644)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;31.12.2022 EUR against USD 10% movement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,628)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,085)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac did not have derivatives in 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Interest rate risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. CureVac&#x2019;s exposure to the risk of changes in market interest rates relates primarily to CureVac&#x2019;s cash and cash equivalents with floating interest rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If interest rates as of December 31, 2023 had been 1% higher while all other variables had remained the same, the net loss for the year (before and after tax) would have been EUR 4,025k (2022: EUR 4,959k) lower because the higher interest income would have been generated from floating rates on invested cash and cash equivalents. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair value measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized with the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Inputs use quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs are inputs, other than quoted prices included in Level&#160;1, which are directly or indirectly observable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs for the asset or liability that are not based on observable market data (unobservable inputs)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All financial instruments are measured at amortized cost at December 31, 2023 and December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The group measures assets held for sale at fair value less cost of disposals. For all short term liabilities and receivables the book value approximates the fair value.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_pz3Jr-vqtkOKPwSSl1SJDQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">16731000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_E7zxk3vWYk-PzY-i1BJ4Jg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4009000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_yWv3w5MAq0-0xDHpNqjVrg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10103000</ifrs-full:FinanceIncome>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_F50yBYMc1kyJUxkGOfo91Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15411000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_qPeH84va106jwu0SFkcf7g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1733000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_kMcivfaNWUephxMLb8IIMQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">81000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:ForeignExchangeGain
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_tLiizCrtvUKVlJrcVYbBBQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1062000</ifrs-full:ForeignExchangeGain>
    <ifrs-full:ForeignExchangeGain
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_iUcPuSdU2k6IMdvIJp1qFA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2188000</ifrs-full:ForeignExchangeGain>
    <ifrs-full:ForeignExchangeGain
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_iUsed17LYkC22Hq5bEZIPA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10092000</ifrs-full:ForeignExchangeGain>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_sHWWQX4V7EiZo19NoBIUqw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2493000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_EEGXNoRzgkqumyrwPmm2cw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3707000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_RU4h1i8GiEeVHgbFQnFQ1g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">10338000</ifrs-full:FinanceCosts>
    <ifrs-full:ForeignExchangeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_R14YZ7bQKEOmpHpDXm3nmg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2272000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:ForeignExchangeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_Zcn3UL__F0msx69D2bdCew"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1319000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:ForeignExchangeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_3o8L-oNFxk2E5tYRpLrLUw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3939000</ifrs-full:ForeignExchangeLoss>
    <cvac:InterestExpenseOnCash
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_ms8od68D9UGegXsXn7XoSA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</cvac:InterestExpenseOnCash>
    <cvac:InterestExpenseOnCash
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_8VyP733vLUeO4H46LfvFZQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2299000</cvac:InterestExpenseOnCash>
    <cvac:InterestExpenseOnCash
      contextRef="Duration_1_1_2021_To_12_31_2021_kvXbjUJ5x0OIEy7H1_aIDA"
      decimals="-3"
      id="Narr_mh04dIMVSUCNdkQnsliOQw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6793000</cvac:InterestExpenseOnCash>
    <cvac:IfrsConcentrationRiskPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_EuropeSLargestPrivateBankMember_grNAnpFTY0ubOJ1E3t9yiQ"
      decimals="2"
      id="Narr_xtKvVBruI0Otzgxpja2SxQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.12</cvac:IfrsConcentrationRiskPercentage>
    <cvac:IfrsConcentrationRiskPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanysLargestPrivateBankMember_TPfvCFqo80y0z7BFfC2YKQ"
      decimals="2"
      id="Narr_F412yhw3r0u5IpWF9sK7sA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.07</cvac:IfrsConcentrationRiskPercentage>
    <cvac:IfrsConcentrationRiskPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_ConcentrationsOfRiskAxis_cvac_GermanLandesbankMember_x_lULUcrc0GPG1twEsc5vQ"
      decimals="2"
      id="Narr_bKOnzGh4XEa4EVsuTxdrzA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.71</cvac:IfrsConcentrationRiskPercentage>
    <cvac:AllowanceForExpectedCreditLossOnFinancialAssets
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_nCEC00hXPUmd6-yvWqc29w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">71000</cvac:AllowanceForExpectedCreditLossOnFinancialAssets>
    <cvac:AllowanceForExpectedCreditLossOnFinancialAssets
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_uSMywn47P0ypBK663mGdUA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">99000</cvac:AllowanceForExpectedCreditLossOnFinancialAssets>
    <cvac:AllowanceForExpectedCreditLossOnFinancialAssets
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Narr_qIQKPVWNNEGgmRZIRbHX8A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">105000</cvac:AllowanceForExpectedCreditLossOnFinancialAssets>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_ZRIYWuzzT0SCY6jmM6q8Kw"
      decimals="-3"
      id="Narr_13V-evk5UUWmTfWBH07TuQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">248000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_Z4th35GQN0yb98iIcO_pdA"
      decimals="-3"
      id="Narr_NgOIMiyUqkmQSFPVj_F7_Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">57000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_lt3cWNU5H0SMaF3fADwXfA"
      decimals="-3"
      id="Narr_NTFHSqvWsU-mcpbtDR_IdA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">149000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_ZRIYWuzzT0SCY6jmM6q8Kw"
      decimals="-3"
      id="Narr_HXm85k2lXEOPM4XESYpvZg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">220000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_Z4th35GQN0yb98iIcO_pdA"
      decimals="-3"
      id="Narr_39SSm4aqcEWeNjTQF5seaQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">51000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_lt3cWNU5H0SMaF3fADwXfA"
      decimals="-3"
      id="Narr_HBCvGcYmb0mth1Z9vLkpCQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">71000</ifrs-full:FinanceCosts>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_CHUGFXssIUGHettfIcO9RA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;lt;1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&#160;to&#160;5&#160;years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;gt;&#160;5&#160;years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual commitments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,269)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Note 4.2) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (53,656)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities and provisions (Note 12) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,117)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,117)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables (Note 11) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,033)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,033)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (146,673)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (23,581)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,821)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (193,075)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;lt; 1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&#160;to&#160;5years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&amp;gt;&#160;5&#160;years&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual commitments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,923)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,377)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (74,300)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities (Note 4.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,247)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,693)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (54,723)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other liabilities and provisions (Note 12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,447)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (103,753)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables (Note 11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (73,463)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (73,463)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (172,080)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (112,356)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (21,803)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (306,239)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <cvac:ContractualCommitmentsUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ"
      decimals="-3"
      id="Tc_2Se7KjZlpUWrP5YuIVGLYA_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3269000</cvac:ContractualCommitmentsUndiscountedCashFlows>
    <cvac:ContractualCommitmentsUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_9UozcO8T2UKMY66eT1OZkw_3_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3269000</cvac:ContractualCommitmentsUndiscountedCashFlows>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ"
      decimals="-3"
      id="Tc_7QKTV9_1VE2imjYpwyE6MA_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7254000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_jspXe4LQ_UyibQFOKeFBYw"
      decimals="-3"
      id="Tc_NpZT_jsWrEeuigng9fygCA_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23581000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Oueb9u3QfkWqN8BPX_v-xw"
      decimals="-3"
      id="Tc_YS_3TWNiOEaPAm2s8k9OhA_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22821000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_-a4Hab1Y8k6Ja-fZzIx6iQ_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">53656000</ifrs-full:GrossLeaseLiabilities>
    <cvac:OtherLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ"
      decimals="-3"
      id="Tc_SpniZedu60ei_EIIdj90lA_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">88117000</cvac:OtherLiabilitiesUndiscountedCashFlows>
    <cvac:OtherLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_xLjdGP0CY066_OK1nh4qUg_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">88117000</cvac:OtherLiabilitiesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ"
      decimals="-3"
      id="Tc_rigUll7b-kCpB7ex5HFA8A_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">48033000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_lo-9Mn0G70qMqkE4HWbwMw_6_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">48033000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_NXmz5w7ge0ygmva76jthrQ"
      decimals="-3"
      id="Tc_xzyFvo5Py0q3jvuXCMoVHg_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">146673000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_jspXe4LQ_UyibQFOKeFBYw"
      decimals="-3"
      id="Tc_sFaFU-F-D0i9bhsKFbVz1Q_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23581000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Oueb9u3QfkWqN8BPX_v-xw"
      decimals="-3"
      id="Tc_z2Mpz2pcMUWLx58s-0UJuA_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">22821000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_7022TWiyUUS-wqwLn3_zfQ_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">193075000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <cvac:ContractualCommitmentsUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A"
      decimals="-3"
      id="Tc_839Rhr_pPEGJ8JDsz-Ip3w_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">49923000</cvac:ContractualCommitmentsUndiscountedCashFlows>
    <cvac:ContractualCommitmentsUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g"
      decimals="-3"
      id="Tc_YQGCEr6qhkm-UlW2gPticQ_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">24377000</cvac:ContractualCommitmentsUndiscountedCashFlows>
    <cvac:ContractualCommitmentsUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_WTFXdwvym0qOtBlHvmn7Zg_3_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">74300000</cvac:ContractualCommitmentsUndiscountedCashFlows>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A"
      decimals="-3"
      id="Tc_RpU8fU_6VEqCS7QuVjk7pg_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7247000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g"
      decimals="-3"
      id="Tc_IXuA-Gzrukqoy0NJxSkMkw_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">25693000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA"
      decimals="-3"
      id="Tc_fT4Z_TcfzEG4vk6M40CnZw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">21783000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_mJCM3b9-d0-KTOUhkOTTwQ_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">54723000</ifrs-full:GrossLeaseLiabilities>
    <cvac:OtherLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A"
      decimals="-3"
      id="Tc_qPhHsNzcz0q64vYLMeKCvQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41447000</cvac:OtherLiabilitiesUndiscountedCashFlows>
    <cvac:OtherLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g"
      decimals="-3"
      id="Tc_KG5Y9pqYXk6K28K8e-wvJA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">62286000</cvac:OtherLiabilitiesUndiscountedCashFlows>
    <cvac:OtherLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA"
      decimals="-3"
      id="Tc__qPITBnQAE2htWYLHF0Erg_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20000</cvac:OtherLiabilitiesUndiscountedCashFlows>
    <cvac:OtherLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_NvLW3HkD6EaKwCptCK-8rg_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">103753000</cvac:OtherLiabilitiesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A"
      decimals="-3"
      id="Tc_e5Ap34FcJ02r3zbUXprakw_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">73463000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_I6CEAnNlg0ifs_GWB0O2mw_6_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">73463000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_Jh1Fs4yTXUmNjcNsrQZW9A"
      decimals="-3"
      id="Tc_4z_ZHDoIYEWyQOK61-cuDg_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">172080000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_2LmR5SYx-km9tsXdISik1g"
      decimals="-3"
      id="Tc_okUiJFp5ZUKFow8VkI54qQ_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">112356000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_1cjsErMkPEy2PaM2QL0BKA"
      decimals="-3"
      id="Tc_VwSV_qmMHUiLDIjoyMe6QA_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">21803000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_byD--wYXpUWNiiPpphP24w_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">306239000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <cvac:DisclosureOfExposureToForeignCurrenciesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Group_wdgJQwWiiECmTvPfPoUEXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&#160;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;57,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;63,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;CHF&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary assets in foreign currency &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;GBP&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;CHF&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary liabilities in foreign currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;  &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&#160;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary assets in foreign currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,566&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 113,664&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GBP&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CHF&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total monetary liabilities in foreign currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,332&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net exposure in USD&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;2022 (1 EUR= 1.0666 USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023 (1 EUR = 1.1050 USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;77,649&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k from USD &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;82,822&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;72,015&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k from USD &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;79,576&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfExposureToForeignCurrenciesTableTextBlock>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_utQHB3ubf0qCXWhEgF-buQ"
      decimals="-3"
      id="Tc_KCQxwyi6jUeSlh9Q9xzBnA_2_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">57061000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_Ju4vpITtT02dIgHA1CnNWQ"
      decimals="-3"
      id="Tc_lLt-Bxh5I0SXbSrGjzUsKQ_2_4"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">63052000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_kxVp_wCgNE6FvnLLR-syMQ"
      decimals="-3"
      id="Tc_WlLEHM9g_0ylGQxbOjpgkA_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">221000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_CashAndCashEquivalentsOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_yLPRccYMQ0WEes48TIb4Rw"
      decimals="-3"
      id="Tc_ENcMfIYU0kqMo2kSxP7rXQ_3_4"
      unitRef="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q">205000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR__hXio1aUh0yPowZRVEGPEA"
      decimals="-3"
      id="Tc_C4CiCyQZpEi3HeUVbBFXGA_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1550000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherReceivablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_7ob2rXhv0ECk61hyXNe7kg"
      decimals="-3"
      id="Tc_00Iay9-ZwEmqmqtgjtJZEA_4_4"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">1713000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_1QMTkTTsdkCGavOTm0os4w"
      decimals="-3"
      id="Tc_oiC9sB1wK0OBJIHqy7Kb9w_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">58832000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_4BI6yad6zEGqAQHMGJ0Ssw"
      decimals="-3"
      id="Tc_MeQo9WLIr0itY7sMe992dw_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">13991000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_XId6JMRHbEi7pWfMUdRyfA"
      decimals="-3"
      id="Tc_CTUrolPpgE2nLjjLurOx7w_6_4"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">15460000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DxjsavysM0WLv8Lp8ri1eA"
      decimals="-3"
      id="Tc_euJedYaO0kKGsaRDB3HOIA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">54000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_UfCOEGrffUq3abl-fRhxig"
      decimals="-3"
      id="Tc_6oZ8eix5_ES-PtXVCNROXw_7_4"
      unitRef="Unit_Standard_GBP_NKJzu3jWTEavxop33-TfZw">47000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_OFTLAOtsqkSihsTZpVXK2g"
      decimals="-3"
      id="Tc_gzy3ty5nMEq935jHf2xDEA_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tiOKflb2S0qu7_rAt0WFJA"
      decimals="-3"
      id="Tc_8sWRw-_b9EytFcpnr5esVQ_8_4"
      unitRef="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q">2000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_sFnkjvJ1RUWEpsQY3dM6qA"
      decimals="-3"
      id="Tc_72yQ24f1IkSf9nIgaJWITg_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14047000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_XKseGYdQ5U21PwXtFPcggA"
      decimals="-3"
      id="Tc_sXMff2AeC0mhqvKTxf1G2A_2_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">106566000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_lmEX-wi5LEW5VEf6oyObmA"
      decimals="-3"
      id="Tc_nIkRMBd18EGZGEIid3oYjw_2_4"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">113664000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_2hwJbQ3UHEG7HHhakH5QdQ"
      decimals="-3"
      id="Tc_a_dAXYySYkmW2iGLcYh7AQ_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">106566000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryAssetsInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_qzSBjM_s00e_a6TyWqLnUg"
      decimals="-3"
      id="Tc_3yz1cdfOXU2W6H03sd14wg_4_4"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">113664000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_xdnpZEJ2mEWa4sCfDXRnOg"
      decimals="-3"
      id="Tc_o6W21ydoFEerwhNWtQtvFQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26232000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_RmJ2ciRZdEmmfIdFfjBrGQ"
      decimals="-3"
      id="Tc_1KMniw3nhEaCpRC5bm5nNg_5_4"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">27979000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_w0ZgcmzTPkCXLtNWBXC5iA"
      decimals="-3"
      id="Tc_Bu_eSotEUUumWaXdkZzpNA_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">87000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesOneMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_ov6PyZWWUUy6kIErGoPNSw"
      decimals="-3"
      id="Tc_nJCM5PDKGku9Z4YG11QFrQ_6_4"
      unitRef="Unit_Standard_GBP_NKJzu3jWTEavxop33-TfZw">77000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_DolE5C86p0ekLVQ3PMh3_w"
      decimals="-3"
      id="Tc_s1ViKmr4PE-rXKB0cq40nw_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">13000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_TradeAndOtherPayablesTwoMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_bODM9rD0EUC2RC277AOZlA"
      decimals="-3"
      id="Tc_0HWZzV5t80qJ8tsTwWLtBA_7_4"
      unitRef="Unit_Standard_CHF_H3rxliNSZ0ezl7lzFuTA2Q">13000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_MonetaryLiabilitiesInForeignCurrencyMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_uhnmPrBIeEi3fuQMts_BCw"
      decimals="-3"
      id="Tc_OkaYH6KGkk2nBcaQCIi7nA_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">26332000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="4"
      id="Narr_SD6GWYEa6kqVgXC7B6n-Lw"
      unitRef="Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A">1.0666</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="4"
      id="Narr_gO_RbTvFbEekmzUsYLJkVA"
      unitRef="Unit_Divide_USD_EUR_MBWJDtmpsEScw9OEoL6f2A">1.1050</ifrs-full:AverageForeignExchangeRate>
    <cvac:ExchangeRateCurrencyNetExposure
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr_iNqmiClWrU27XIAFllNQdg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">77649000</cvac:ExchangeRateCurrencyNetExposure>
    <cvac:ExchangeRateCurrencyNetExposure
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Narr__yF4axFIbUCKlAKu8xMhLQ"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">82822000</cvac:ExchangeRateCurrencyNetExposure>
    <cvac:ExchangeRateCurrencyNetExposure
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_b-OFVU3nk0evnVaeLfjvAA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">72015000</cvac:ExchangeRateCurrencyNetExposure>
    <cvac:ExchangeRateCurrencyNetExposure
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Narr_l_CVOOeLvUus_FakGnKS4Q"
      unitRef="Unit_Standard_USD_KPRtK-k9QE-LzaSIvwJcPQ">79576000</cvac:ExchangeRateCurrencyNetExposure>
    <cvac:PercentageOfEurStrengthened
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="2"
      id="Narr_T40oVljj4E6jb5tZRXI61Q"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:PercentageOfEurStrengthened>
    <ifrs-full:DisclosureOfMarketRiskExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_MCKV3MNf0E630oM7VQjMpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect&#160;on&#160;pre-tax&#160;profit&#160;or&#160;loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect&#160;on&#160;post-tax&#160;profit&#160;or&#160;loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strengthening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weakening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strengthening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weakening&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;31.12.2023 EUR against USD &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;10&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;% movement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,547&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (8,002)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,617&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5,644)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;31.12.2022 EUR against USD 10% movement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,628)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,085)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfMarketRiskExplanatory>
    <cvac:PercentageOfEurWeakened
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="2"
      id="Narr_xNQfTjLM5Uyi64er3FuUyw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:PercentageOfEurWeakened>
    <cvac:ProfitLossBeforeTaxIfEurStrengthened
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_b6Kkxebps0mrd9ALragGfA_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6547000</cvac:ProfitLossBeforeTaxIfEurStrengthened>
    <cvac:ProfitLossBeforeTaxIfEurWeakened
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_sslkHezKa0OjIpPBUHYCNw_3_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-8002000</cvac:ProfitLossBeforeTaxIfEurWeakened>
    <cvac:ProfitLossAfterTaxIfEurStrengthened
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_l4Ih2-7If0uiiPwpW9eSbg_3_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4617000</cvac:ProfitLossAfterTaxIfEurStrengthened>
    <cvac:ProfitLossAfterTaxIfEurWeakened
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_306OphxVTUyfcj5YdTzItA_3_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-5644000</cvac:ProfitLossAfterTaxIfEurWeakened>
    <cvac:PercentageOfEurWeakened
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="2"
      id="Narr_6HFJNXlyHE6M7607-ApDgw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:PercentageOfEurWeakened>
    <cvac:ProfitLossBeforeTaxIfEurStrengthened
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_QqMLUpk61EaHa1ko_9EHfg_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7059000</cvac:ProfitLossBeforeTaxIfEurStrengthened>
    <cvac:ProfitLossBeforeTaxIfEurWeakened
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_ZgFhi9eUAk-bdPLAt_2adw_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-8628000</cvac:ProfitLossBeforeTaxIfEurWeakened>
    <cvac:ProfitLossAfterTaxIfEurStrengthened
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_oCmnbmzi_kiZOb5sZ2Wbbw_4_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4978000</cvac:ProfitLossAfterTaxIfEurStrengthened>
    <cvac:ProfitLossAfterTaxIfEurWeakened
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_2Z3lTGwlnE-uOD-d3Leu3w_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-6085000</cvac:ProfitLossAfterTaxIfEurWeakened>
    <cvac:PercentageOfInterestHigher
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="2"
      id="Narr_XPGHdeZ4ZUiw2s8dW_dF3w"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.01</cvac:PercentageOfInterestHigher>
    <cvac:NetLossBeforeTax
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_Osj5sG5c5Ue1WHWRxYi3oQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4025000</cvac:NetLossBeforeTax>
    <cvac:NetLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_-5EBMiOBvECjF7b_NbSoow"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4959000</cvac:NetLossBeforeTax>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_H_McRjxbqkS0qjikrZc6JA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;16. Notes to the consolidated statements of cash flows&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Changes in liabilities arising from financing activities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;1,&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accrued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Paid&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in thousands of EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash&#160;flows&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Disposals&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Movements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Payment of lease liabilities (Note 4.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,568)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,998)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,824&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities from financing activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,568)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,998)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,986&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,375&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (57)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,824&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accrued&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Paid&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;b style="font-weight:bold;"&gt;Exchange&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in thousands of EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash&#160;flows&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Disposals&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Movements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Payment of lease liabilities (Note 4. 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,439)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,086&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities from financing&lt;/b&gt; &lt;b style="font-weight:bold;"&gt;activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,892&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,439)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,241&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,218&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 174&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_4y9DAroZA0C5BTsFw-B73g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;1,&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accrued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Paid&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in thousands of EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash&#160;flows&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Disposals&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Movements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Payment of lease liabilities (Note 4.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,568)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,998)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,824&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities from financing activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,568)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,998)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,986&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,375&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (57)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,824&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accrued&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Paid&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;b style="font-weight:bold;"&gt;Exchange&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in thousands of EUR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash&#160;flows&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Disposals&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Movements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Payment of lease liabilities (Note 4. 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,439)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,086&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities from financing&lt;/b&gt; &lt;b style="font-weight:bold;"&gt;activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,892&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,439)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,241&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,218&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 174&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42,086&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_hizFCmgkaE2aderOvs1LNA"
      decimals="-3"
      id="Tc_FiwMgrqXjUCHs-ydxFi88g_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42086000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ"
      decimals="-3"
      id="Tc_I81JXTvP8kqygWoMimy83A_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-7568000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <cvac:IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ"
      decimals="-3"
      id="Tc_gjOg5HWSZkWvVxS86RONBA_4_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2998000</cvac:IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ"
      decimals="-3"
      id="Tc_LCsXa9Y-DEGYcMqMZXJFVw_4_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7986000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ"
      decimals="-3"
      id="Tc_NCEnravM60efnt5pNZBNMQ_4_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2375000</cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_WqRoCyjp50uizxMA7knBYQ"
      decimals="-3"
      id="Tc_uwpGJVjj602fZZC1hbpihw_4_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-57000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2023_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_x7oTzwEM40qM38yhmGMObg"
      decimals="-3"
      id="Tc_gFXbW3cEFU6UATPdHMNomQ_4_18"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41824000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_M5CqQ8hh20yA64xT9tcP7Q_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42086000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_UlPkuYIzLkGGuMJ2xBq4TQ_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-7568000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <cvac:IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_gj4LqbjpykeVKMwhyyTtwg_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-2998000</cvac:IncreaseDecreaseThroughDisposalsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_RuhHknfuc0-jO8qFNeB9DA_5_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7986000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_x5ThmmEL9Ee0bVIRryAvcw_5_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2375000</cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Tc_V31nMpzuIEG-vqmcS1rf6Q_5_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-57000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2023_K-otGH-UP061P9MBR6LdyQ"
      decimals="-3"
      id="Tc_kscN7SiN9kWKMoZwvQOhAg_5_18"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">41824000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2021_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_kk4sEIFbXE6LU2RSZnpNkA"
      decimals="-3"
      id="Tc__xEWceRYVUiKDd_Bw_C0zw_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28892000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A"
      decimals="-3"
      id="Tc__ikjHTqvOkCgQ8ZthBDs9Q_4_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-6439000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A"
      decimals="-3"
      id="Tc_C6hbZsufx0K3rluNtalXyg_4_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17241000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A"
      decimals="-3"
      id="Tc_N6y0aErfEk6bXd8ChRcY5Q_4_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2218000</cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_TddXvSD-D0yPIQKKWxr37A"
      decimals="-3"
      id="Tc_K8VYr3ixY0W8XIoGGK8NsA_4_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">174000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2022_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_LeaseLiabilitiesMember_hizFCmgkaE2aderOvs1LNA"
      decimals="-3"
      id="Tc_IUG-q3xwzUuCIx3KJXrmRw_4_18"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42086000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2021_tR50QvjarEiSTq9D9e6gbw"
      decimals="-3"
      id="Tc_cMd4QQCAdEqNCxYhLOPitw_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">28892000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_BBVlGjIQmUO9yOCeHDdyhA_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-6439000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_IPOevQtd_EiS69_lh5jv7w_5_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">17241000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_Q7ByCKxmIEuGONnKdt2cMg_5_14"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2218000</cvac:IncreaseDecreaseThroughInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Tc_3uKAnydQ-06lzw0FLe1Vpg_5_16"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">174000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="As_Of_12_31_2022_Uz2AV0GTSUyGAZP_i1PgAA"
      decimals="-3"
      id="Tc_hcg-Ff8Vdkmy_I3NgScuXQ_5_18"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">42086000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_95QJp9J70ES68En72T3r7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;17. Commitments and contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;No material contingent liabilities resulting from claims and legal proceedings exist as of December 31, 2023. Refer to Note 12 for provisions recognized for contract terminations. For contractual commitments, refer to Note 15.&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_r3T8_NBaX0mvJgA4k41atQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;18. Remuneration of the Company&#x2019;s key management personnel&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Total remuneration of key management personnel&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Remuneration of the Company&#x2019;s key management personnel was as follows :&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Supervisory&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Supervisory&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Supervisory&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remuneration of key management&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,098&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Termination benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15,771&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1,212&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9,756&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1,147&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,928&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,326&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Out of the total remuneration, for Management Board EUR 1,551k (2022: EUR 852k, 2021: EUR 1,323k) and for the Supervisory Board EUR 158k (2022: EUR 0k, 2021: EUR 0k) are outstanding, as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In 2023, 105,260 RSUs were granted to the Supervisory Board and 207,481 RSUs and 144,379 options were granted to the Executive Board. During the year, 21,413 RSUs were transferred to the Supervisory Board and 139,027 RSUs were transferred to the Executive Board. No options were exercised from the Key Management Personnel. For more detailed information we refer to Note 10.&lt;/p&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <cvac:DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Group_-a-3UIxTKk2FWG9kg4Ly3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Supervisory&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Supervisory&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Supervisory&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remuneration of key management&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,098&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Termination benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15,771&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1,212&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9,756&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1,147&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,928&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,326&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfDetailedInformationOfRemunerationOfKeyManagementPersonnelTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA"
      decimals="-3"
      id="Tc_OO-hWAHxu0SNEKVRZ1QhsQ_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3098000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w"
      decimals="-3"
      id="Tc_VxFwEkAUKkmjAkTU1bQw2w_5_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">646000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA"
      decimals="-3"
      id="Tc_fe7JJkDgC0edR069D8-Jnw_5_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3067000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ"
      decimals="-3"
      id="Tc_BVjLNn0VaU-vj0tNHyV1ag_5_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">669000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg"
      decimals="-3"
      id="Tc__7OH19kh2Umz7-UCS9lA2g_5_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3757000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA"
      decimals="-3"
      id="Tc_4k59ujFy7UG5G1OHW2Ar4A_5_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">674000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg"
      decimals="-3"
      id="Tc_UQNQr6Yd5UCgrxa-6zRcPA_6_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1871000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA"
      decimals="-3"
      id="Tc_c58OF2ZO7E-cPN9a4fQ5fQ_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">12673000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w"
      decimals="-3"
      id="Tc_w7bQH5HaE0mAXo0MnHHeBg_7_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">566000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA"
      decimals="-3"
      id="Tc_9CyuiImoc0Gk_0WUdA-FrA_7_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6689000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ"
      decimals="-3"
      id="Tc_-1rtvMPqfU-bqyMJNsaX9g_7_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">478000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg"
      decimals="-3"
      id="Tc_3R6tikYJvE2TbXBqDtWciw_7_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA"
      decimals="-3"
      id="Tc_Q-bfxwxDTkq_CxH_AyQuPg_7_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">652000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA"
      decimals="-3"
      id="Tc_XjzwaPWBhECBBpjfdRdplw_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">15771000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w"
      decimals="-3"
      id="Tc_6TpFB3uAEkSWTI9MYftznA_8_4"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1212000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA"
      decimals="-3"
      id="Tc_xKmeCuozTkGHPeJOAer2JA_8_6"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9756000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ"
      decimals="-3"
      id="Tc_G895cncFfUOAMARpcDvFqQ_8_8"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1147000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg"
      decimals="-3"
      id="Tc_6er4xNP91U2cySh1Ioc48w_8_10"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">9928000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA"
      decimals="-3"
      id="Tc_2EFtBplQ-USBSup9ngJrJw_8_12"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1326000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:AuditorsRemuneration
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_0wJPpKjkG0GI4GQA9Ip0vg"
      decimals="-3"
      id="Narr_niXGamqBm0-a9Vdbx2Vnng"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1551000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_NQf7rU9Wjk2L2g9R1B6TzA"
      decimals="-3"
      id="Narr_y3syXisTUEKnprp-mi5PFg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">852000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ManagementBoardMember_ELCzHJjouk-ghnzYnOSsHA"
      decimals="-3"
      id="Narr_AV7dqeQ8REKEIbpqHike4w"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1323000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA"
      decimals="-3"
      id="Narr_7TJvrAG9xU6PZtoivNJiSA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">158000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_X412Udi-q0KNynQ7QHgkiQ"
      decimals="-3"
      id="Narr_AwAHbmuhzk2WB3APtNbzYw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_WuGty63JgE2DJrYojw4-_w"
      decimals="-3"
      id="Narr_0kw7PI2ErUKiWf043596JA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</ifrs-full:AuditorsRemuneration>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA"
      decimals="0"
      id="Narr_vCYEDODVKUutm04bE5jrPw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">105260</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_BLnC6daC2EauxSmFL-6xMA"
      decimals="0"
      id="Narr_JpslkfIHHEOCHkx9kfTGsg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">207481</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_IedADyrcS0Sk1puAhMSxsg"
      decimals="0"
      id="Narr_xxPedGY5xEKwgStoqvIydA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">144379</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_SupervisoryBoardMember_o_-k7DY99UG7Hj2vZFtzoA"
      decimals="0"
      id="Narr_VxpWvh8P3069gCX5dbuJrQ"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">21413</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ExecutiveBoardMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitsMember_QqhHzWTUTUWo9mtYyqyW5g"
      decimals="0"
      id="Narr_uZE8ygBMqEiWZ5Jz-6mF2g"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">139027</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_RYpbc8X8-k6bGuF8wrTcQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;19. Related party disclosures&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Parent and ultimate controlling party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As disclosed in Note 1, during fiscal 2023, dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, was the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between approximately 37-43 % during that period. dievini is thus the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Transfer of shares from the former major shareholders&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed in Note 10, due to certain virtual share exercises under the Prior VSOP during the year 2023: 0 (2022:777,260) common shares were transferred to the Company by the former major shareholders, with no consideration paid in exchange, and all of these shares were subsequently transferred to fulfill obligations from option exercises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Dietmar Hopp&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), the majority shareholder of the Group, granted two convertible loans to the Group which were terminated in July 2020 and fully repaid in August 2020. Additionally, in 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Groups largest shareholder, purchased EUR 100,000k of the Group&#x2019;s common shares at the price of USD 16 per share. In 2023 a total of EUR 1k (2022: EUR 58k) was paid to dievini Hopp BioTech Holding GmbH &amp;amp; Co. KG as a reimbursement of travel cost.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Immatics Biotechnologies GmbH&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2023, a purchase agreement between CureVac Manufacturing GmbH and Immatics Biotechnologies GmbH was entered into. CureVac purchased technical equipment of containers which CureVac will use as a facility in the future. dievini held 16.7% of the shares in Immatics N.V. (Immatics) as of December 31&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt;, 2023 per the Form 20-F of Immatics filed in March 2024. CureVac paid EUR 178k under this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Key management personnel compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Referring to key management personnel compensation we refer to Note 18.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Key management personnel transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Franz-Werner Haas&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was executed. In 2023 CureVac paid EUR 65k under this agreement. The payment was partially compensated by Franz-Werner Haas taking over his former company car for EUR 40k.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Alexander Zehnder&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR 51k during the month of March.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Antony Blanc&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac, Antony also took over the role as Management Director at CureVac Belgium SA. He executed this function by using Clarentis SRL. As it relates to these services in 2023, CureVac paid EUR 85k in 2023 (2022: EUR 69k, 2021: EUR 0k). The amounts invoiced for this function/services are offset/deducted from his base compensation for his function on the Board of Management of CureVac. As Antony Blanc has left the company as of November 30, 2023, CureVac and Antony Blanc signed a settlement agreement as of September 26, 2023. Under this agreement CureVac incurred cost of EUR 107k for Clarentis SRL entity in 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Dr. Ingmar H&#xf6;rr&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 573k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Florian von der M&#xfc;lbe&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 559k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Consulting agreements between CureVac Printer GmbH and Florian von der M&#xfc;lbe related to the years 2022 to 2024 have been executed. In 2023 CureVac paid EUR 146k under such agreement related to 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Mariola Fotin-Mleczek&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2022, a consulting agreement between CureVac and Mariola Fotin-Mleczek was made. In 2023 a total amount of EUR 2k (2022: EUR 20k) was paid. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the exercise of the Prior VSOP award in December 2022, CureVac had a receivable position of EUR 131k as per year-end for the income tax and social security liability. CureVac has received the money in February 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Barker BioMedical GmbH&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was executed. Barker BioMedical GmBH is a wholly owned consulting company of Debra Barker, Supervisory Board member of CureVac. In 2023 CureVac paid EUR 14k under this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Craig Tooman&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In Q1 2023, a consulting agreement between CureVac SE and Craig Tooman was executed. In 2023, CureVac paid EUR 5k under this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Ralf Clemens&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In Q3 2023, a consulting agreement between CureVac and GRID EUROPE was executed. GRID EUROPE is a wholly owned consulting company of Ralf Clemens, who was a member of the supervisory board up to September 30, 2023. CureVac incurred EUR 23k under this agreement in 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Indemnification Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s articles of association require it to indemnify its current and former managing directors and supervisory directors in relation to acts or omissions in the performance of their duties to the fullest extent permitted by law, subject to certain exceptions. We entered into indemnification agreements with all our managing directors and supervisory directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other related party transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Rittershaus Rechtsanwaelte&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since December 15, 2005, a consultant agreement is in place for an indefinite term with Rittershaus. The agreement can be terminated without notice by CureVac and with notice of three months to the end of the quarter by Rittershaus. In fiscal 2023, consulting fees of EUR 212k (2022: EUR 518k, 2021: EUR 757k) were paid to the Rittershaus. Additionally, EUR 16k were owed for services rendered in 2023 and paid in 2024. Prof. Dr. Christof Hettich is managing director of Rittershaus and was managing director at dievini until June 2022 as well.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;BePharBel Manufacturing S.A.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2020, CureVac Manufacturing GmbH (formerly CureVac Real Estate GmbH) and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#x2019;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Manufacturing GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Manufacturing GmbH terminated the commercial and supply agreement with BePharBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been recognized in provisions, based on estimate, as of December 31, 2021. In total an amount of EUR 4,016k was paid. Baron Jean St&#xe9;phenne, our Supervisory Board member, holds directly and indirectly 15.61% of BePharBel Manufacturing&#x2019;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#xe9;phenne&#x2019;s son, Vincent St&#xe9;phenne, holds 1.43% of BePharBel Manufacturing&#x2019;s equity and is a managing director of BePharBel Manufacturing.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_LubxZHBTrUqvPK1aaaII3Q"
      decimals="INF"
      id="Narr_I1KYRHnhw0WZTuj1LeOczA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">0</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember__ckqIZsOIkeT7yISok1iSg"
      decimals="INF"
      id="Narr_w-w0xzFDaEur6OVFAS3oTA"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">777260</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:RelatedPartyTransactionNumberOfLoansReceived
      contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_tDcuRfOZHUis6pxE_-4Qjg"
      decimals="INF"
      id="Narr_8hO_LvvrW0WFtASBwzBKYA"
      unitRef="Unit_Standard_loan_B2W9DgI1ukyKELWFZzXYow">2</cvac:RelatedPartyTransactionNumberOfLoansReceived>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Xs37kP1MXEWQ-qdRg_8D7g"
      decimals="-3"
      id="Narr_1Y9jhRAQ6EKe7R4amvBWTg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">100000000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_IVeKC3yvOEugAiflyH3c3g"
      decimals="INF"
      id="Narr_DYv6rOnDOEWsO0EVAgb--A"
      unitRef="Unit_Divide_USD_shares_HM4fRSdgZkuNNys2cODSZQ">16</ifrs-full:WeightedAverageSharePrice2019>
    <cvac:ReimbursementOfTravelCost
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember__huxDT93sUCUvh-o5CwH7Q"
      decimals="-3"
      id="Narr_fhvBkN_MoE6PaUaeLm2G5A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1000</cvac:ReimbursementOfTravelCost>
    <cvac:ReimbursementOfTravelCost
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_AeWpyZ9BY0qX-7I4dJeLCg"
      decimals="-3"
      id="Narr_ySmgoNc5mUOModUxmppQRg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">58000</cvac:ReimbursementOfTravelCost>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_8_1_2023_To_8_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ImmaticsBiotechnologiesGmbhMember_8VKq2e-Yh0aBVCNKzz4EmA"
      decimals="3"
      id="Narr_HqCM5ywRz0m3n3X4oscagg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.167</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions
      contextRef="Duration_8_1_2023_To_8_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ImmaticsBiotechnologiesGmbhMember_8VKq2e-Yh0aBVCNKzz4EmA"
      decimals="-3"
      id="Narr_MOiPKfvHO06hmtDEHiifMw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">178000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <cvac:ExpenseRecognizedFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FranzWernerHaasMember_3KoWd6cW3kiWfRndyVReUQ"
      decimals="-3"
      id="Narr_-3fnveGJLkOzR23jJNKVDQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">65000</cvac:ExpenseRecognizedFromRelatedPartyTransaction>
    <cvac:ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FranzWernerHaasMember_3KoWd6cW3kiWfRndyVReUQ"
      decimals="-3"
      id="Narr_qyaw_PqfpE-V9CS_Pzc2rA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">40000</cvac:ReimbursementOfExpenseInFormOfKindFromRelatedPartyTransaction>
    <cvac:ExpensesToHandleFutureServiceAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_AlexanderZehnderMember_mQ65pe5XS02CILSpyMNi-g"
      decimals="-3"
      id="Narr_du9paQ0b_0mmXyWQ72A5Xw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">51000</cvac:ExpensesToHandleFutureServiceAgreement>
    <cvac:IfrsContractualObligation
      contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_2ruopNpg1EOnMxTf_GiPBQ"
      decimals="-3"
      id="Narr_yvJoA-2fCkuSFxP9bHDPcg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">100000</cvac:IfrsContractualObligation>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_RnuhJALUXEW6OjzFID5ePg"
      decimals="-3"
      id="Narr_l5LUDwlm8kKxuOPW608qsA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">85000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_QN5vMskJz0SjqLv-t82qVw"
      decimals="-3"
      id="Narr_FwO46RM0R0OMK-sL6CUiTw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">69000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_3YpDQRUP7U-XcUYi-sII5w"
      decimals="-3"
      id="Narr_ZLIIalEtTkO3d2t1E0XDKg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">0</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:ExpenseRecognizedFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_1aQ3jbYg70uyuJDLyM2Akw"
      decimals="-3"
      id="Narr_11MyD1_Gu0WEq7bkHfRplQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">107000</cvac:ExpenseRecognizedFromRelatedPartyTransaction>
    <cvac:IncomeTaxAndSocialSecurityLiabilityReceivable
      contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_Dr.IngmarHrrMember_wYrvLaDbgEqiqWSPHKS2gQ"
      decimals="-3"
      id="Narr_egSxEuuFY0-yHgenvJK5yA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">573000</cvac:IncomeTaxAndSocialSecurityLiabilityReceivable>
    <cvac:IncomeTaxAndSocialSecurityLiabilityReceivable
      contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_FlorianVonDerMlbeMember_SIwLkqeJIE-s7t_ZN4MKdg"
      decimals="-3"
      id="Narr_a-KZYOo5HEqojlp3znF-9A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">559000</cvac:IncomeTaxAndSocialSecurityLiabilityReceivable>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CurevacPrinterGmbhMember_gCs4iaZl0UyakTfPuIOiJg"
      decimals="-3"
      id="Narr_UZb0KeXSYk6o6mnGJ4oD6g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">146000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_qPHpyi8B6kOFRUh0cCyRZA"
      decimals="-3"
      id="Narr_mtYXMgOr_kyLCqChPFvgWQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_adrBhWYBcUKP4xl56ZYvMQ"
      decimals="-3"
      id="Narr_J0SmsFg6XUeabMdCAF3wOw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:IncomeTaxAndSocialSecurityLiabilityReceivable
      contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_MariolaFotinMleczekMember_TsjaEu7n40i6mOR_moJurg"
      decimals="-3"
      id="Narr_nCO9sjlrq0a0zwN0Hzwy_g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">131000</cvac:IncomeTaxAndSocialSecurityLiabilityReceivable>
    <cvac:ExpenseRecognizedFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_03V4AWHHaUicJNVRIZQgJw"
      decimals="-3"
      id="Narr_k347H2oRwkuKisaEis1FDQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">14000</cvac:ExpenseRecognizedFromRelatedPartyTransaction>
    <cvac:ExpenseRecognizedFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_FnDpFAjGGkeAyPEcOA6zCA"
      decimals="-3"
      id="Narr_4iVY8UCZB0eg86yPQ5huVQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5000</cvac:ExpenseRecognizedFromRelatedPartyTransaction>
    <cvac:ExpenseRecognizedFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_GridEuropeMember_6WJlWjlo_kuCilFMPK6nQQ"
      decimals="-3"
      id="Narr_i5Ibjpt7OEmsJyjsDS-brQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">23000</cvac:ExpenseRecognizedFromRelatedPartyTransaction>
    <cvac:RelatedPartyTransactionNoticePeriodForTerminationOfAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_f2yWNH0RhECkx-pihStCXQ"
      id="Narr_XMIbW1dn8k6ZXNxGBDrGng">P3M</cvac:RelatedPartyTransactionNoticePeriodForTerminationOfAgreement>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      decimals="-3"
      id="Narr_t1fcjJzHB0K519JIqIdErA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">212000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2022_To_12_31_2022_QkdHeHrjKES14TmSaDG2vg"
      decimals="-3"
      id="Narr_Rfz9PcKAJ0ubf4ddBIHdcQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">518000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_xCV0b46ewUWBBkAiRGRUnA"
      decimals="-3"
      id="Narr_Ib6KHvz3U0C4QUz6WRrpCQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">757000</cvac:RelatedPartyTransactionConsultingFees>
    <cvac:ServiceRenderedIssue
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_RittershausRechtsanwaelteMember_f2yWNH0RhECkx-pihStCXQ"
      decimals="-3"
      id="Narr_YhdHwVMiX0WzCKDZ-9arlQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">16000</cvac:ServiceRenderedIssue>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_a0Kr79sWk0Obs3Ohp5ui0Q"
      decimals="-3"
      id="Narr_QA0FMMAlrUuLE7f449L35Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3900000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_wkd5UtMjWEm5jn5jyWXGGw"
      decimals="-3"
      id="Narr_xntuBxmgGUe3p6YqLiCeMQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">4016000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_KF0KEZ_P60OBG3llY8c9rg"
      decimals="4"
      id="Narr_lusTJ-qd8UyPyTSS21HoOw"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.1561</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_H9754yeGbUCITGZy_i1eNA"
      decimals="4"
      id="Narr_Asr66n9NO0uSDDpOu93w7w"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.0143</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_Eq0m47RIC0uxVd61vji5GQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;20. Business Combinations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Combination and Goodwill &#x2013; Frame Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective July 1, 2022 (&#x2018;closing date&#x2019;), CureVac acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#x2018;Frame Pharmaceuticals&#x2019; or &#x2018;Frame&#x2019;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling the identification of structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. In July 2022, Frame Pharmaceuticals was renamed CureVac Netherlands B.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the purchase price agreement (&#x2018;SPA&#x2019;) dated June 8, 2022, total consideration of up to EUR 32.0 million, subject to certain adjustments for vested and non-vested employee options of the acquiree plus an amount of EUR 1.56 million for the assumption of an outstanding obligation resulting from advisory services, was agreed. The consideration consisted of the transfer of shares in CureVac (&#x2018;CureVac Shares&#x2019;) and minor cash payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The total consideration is split into three payments, two of which are contingent upon the achievement of defined milestones (contingent consideration). At the closing date, the consideration transferred was comprised of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Issuance and transfer of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;810,242&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares (EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;11,040&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k) to former Frame shareholders. The respective share price of one CureVac Share was EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;13.63&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; (&#x2018;Closing Share Price&#x2019;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Issuance and transfer of further &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;48,254&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares (EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;658&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k, valued at the Closing Share Price) as consideration for discharging the contractual obligations for the outstanding advisory agreements of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1,560&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k before deducting strike prices. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payment of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;585&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k in cash, consisting of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;335&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k being the consideration for the settlement of the vested employee options, and an additional EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Payment of the remaining 50% of the total consideration is contingent upon the achievement of two milestones. A further 194,644 shares (representing 10% of EUR 32.0 million divided by the Signing Share Price) are issuable upon the achievement of a successful investigational new drug application filing for a product candidate of the Group that consists of at least one antigen based on frameshift-mutation identified by Frame&#x2019;s algorithms; (&#x201c;Milestone 1&#x201d;) and a further 778,575 shares (representing 40% of EUR 32.0 million divided by the Signing Share Price) are issuable upon successful proof of mechanism in humans of that or another product candidate (&#x201c;Milestone 2&#x201d;). The fair value of these contingent payments was determined by considering the likelihood of the events occurring and totaled, based on the Closing Share Price, EUR 7,198k (Milestone 1: EUR 1,831k and Milestone 2: EUR 5,367k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Consequently, the total consideration transferred for the business combination was determined to be EUR 19,481k, consisting of:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Issuance and transfer of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;858,496&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; CureVac shares with a fair value of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;11,697&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payment of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;585&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k in cash, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Contingent consideration, classified as equity, with a fair value of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;7,198&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k. The contingent consideration will be settled by the issuance of a maximum of further &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;973,236&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; CureVac shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The contingent consideration of EUR 7,198k was valued by applying an estimated probability of the milestone being achieved to the payments due upon achievement. These probabilities were derived from third-party clinical development success rate studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, 89,655 restricted stock unit awards (RSUs) were issued to certain employees to replace existing share-based payment awards of Frame Pharmaceuticals. This element is accounted for as a separately from the business combination as an equity-settled share-based transaction according to IFRS 2 (see Note 10). The total fair value of the grant was determined to be EUR 1,218k and will be expensed in the functional cost category to which the award recipient&#x2019;s costs are allocated (i.e., general and administrative expenses or research and development expenses) over the individual vesting periods for the 3 tranches, which run through June 30, 2023, June 30, 2024, and June 30, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The final fair values in accordance with IFRS 3 of the identifiable net assets as of the date of acquisition were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EUR thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;recognized&#160;on&#160;acquisition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,592&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible asset (Technology)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 966&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,558&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 134&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities (net of deferred tax assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 406&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts Payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 540&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The technology intangible asset consists of a bioinformatical platform for cancer antigen discovery and validation for off-the-shelf and personalized cancer vaccines. The fair value of the technology of EUR 6,216k was determined by applying the replacement cost approach due to its early stage. The replacement cost was derived from historical costs incurred to create the technology.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill was recognized as a result of the acquisition as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,018)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Goodwill&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The goodwill is mainly attributable to the synergies and an assembled workforce as well as the strategic benefits to the Group. The goodwill is not deductible for tax purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions costs in relation to the business combination amounting to EUR 500k were expensed and recognized within general and administrative expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated statements of profit or loss include the results of Frame Pharmaceuticals (meanwhile: CureVac Netherlands B.V.) since the acquisition date. From the date of acquisition through December 31, 2022 Frame Pharmaceuticals did not have any significant impact on the operating income or revenues of the Group. The same applies if the transaction had occurred at the beginning of the reporting period.&lt;/p&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <cvac:FairValueOfTotalConsiderationTransferred
      contextRef="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_UoCEidhqNkCfZfezQJra6Q"
      decimals="-5"
      id="Narr_LeiY5vaFi0e701OYEAxVJw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">32000000.0</cvac:FairValueOfTotalConsiderationTransferred>
    <ifrs-full:LiabilitiesIncurred
      contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_51kbfHiK10CFR5dmzP024Q"
      decimals="-4"
      id="Narr_GGb9KepAXESDue24OJdb7g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1560000</ifrs-full:LiabilitiesIncurred>
    <cvac:NumberOfPaymentsInWhichTotalConsiderationIsToBePaid
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_KoHRjwbtFEaJntckzVMOGA"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">3</cvac:NumberOfPaymentsInWhichTotalConsiderationIsToBePaid>
    <cvac:ContingentConsiderationNumberOfPaymentsConsidered
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_1iRoVbDjdkCIFIL9EC7cow"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">2</cvac:ContingentConsiderationNumberOfPaymentsConsidered>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_i4ln780I5U-4gh7uupmnmQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">810242</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_EVWlMrQqWEG-cS5DMIEzbQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11040000</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders>
    <cvac:IfrsBusinessAcquisitionSharePrice
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="2"
      id="Narr_vg-R52tGukqmL-KuWMri5Q"
      unitRef="Unit_Divide_EUR_shares_YiuWZUloEEagyYYdV6HXmQ">13.63</cvac:IfrsBusinessAcquisitionSharePrice>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_36BnKWdw60e5OIUvgE090Q"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">48254</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_t8oTBwODcEGb5q4HomBFJg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">658000</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations>
    <ifrs-full:LiabilitiesIncurred
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_r-lDNK_Z7EKS69C8MfSRRA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1560000</ifrs-full:LiabilitiesIncurred>
    <ifrs-full:CashTransferred
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_kOvhu3NQ4EC5hRxMNXojNA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">585000</ifrs-full:CashTransferred>
    <cvac:CashTransferredForSettlementOfVestedEmployeeOptions
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_0prpt2NFjEORdLWkPM2orA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">335000</cvac:CashTransferredForSettlementOfVestedEmployeeOptions>
    <cvac:AdditionalCashTransferred
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_eKkWz0lefE-OD2FK4bwccw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">250000</cvac:AdditionalCashTransferred>
    <cvac:ContingentConsiderationPercentageOfTotalConsideration
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="2"
      id="Narr_nSlDWdg540afEAaJ2f8ssA"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.50</cvac:ContingentConsiderationPercentageOfTotalConsideration>
    <cvac:ContingentConsiderationNumberOfMilestones
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_1-K2Jv-rgE20RIJwRGGLdA"
      unitRef="Unit_Standard_Milestone_ymq4eXsZYUanqqY0KpCtNg">2</cvac:ContingentConsiderationNumberOfMilestones>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_cAMt0_cBgEazjnK1xhLx_Q"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">194644</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone>
    <cvac:PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="2"
      id="Narr_4Nd-9IIVwk-IJt_zBveaQg"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.10</cvac:PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone>
    <cvac:SigningSharePriceRepresenting10
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-5"
      id="Narr_ChLSc1topkCOE5RpIu3VQw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">32000000.0</cvac:SigningSharePriceRepresenting10>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_XDnYsWQ33U-Gko46DWZd6Q"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">778575</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone>
    <cvac:PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="2"
      id="Narr_D3YdVmoJakuWLYNbv1CK-g"
      unitRef="Unit_Standard_pure_oeDJQjSeGEmPb0Z93UFOXg">0.40</cvac:PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone>
    <cvac:SigningSharePriceRepresenting40
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-5"
      id="Narr_oZzj0kEPfkmEqkOKrPOZ_g"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">32000000.0</cvac:SigningSharePriceRepresenting40>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_yS9uf8lyiUCgIWwEnISIWA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7198000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_IXQquHZp_ECOHzj3BYOuug"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1831000</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_Icy752qzfEWNWxHLQAfRWA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5367000</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_WOmRTa_dyUK5D_dyIOQ-UA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19481000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="0"
      id="Narr_WgzxfFLPA0-IjyNOF344wQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">858496</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_acnFPAZU30yLk0IJDC8OCw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">11697000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:CashTransferred
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_vg6issjmnkuj7EwferReXg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">585000</ifrs-full:CashTransferred>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_JIPcVTZIuk-WSz-V02-MpQ"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7198000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <cvac:ContingentConsiderationMaximumSharesIssuable
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="INF"
      id="Narr_13vjUuDPAki3VoTyz4l_dQ"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">973236</cvac:ContingentConsiderationMaximumSharesIssuable>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_tTX7QFa9xUm4GIc-w2KycA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7198000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ"
      decimals="INF"
      id="Narr_MnOYZiqEr0KsvgTz-N9SVA"
      unitRef="Unit_Standard_Option_RoHpO_sSREaxRcFnd5e4Ag">89655</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Narr_KgVEiehWnEWOZoyirZ1Ljg"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">1218000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ"
      decimals="INF"
      id="Narr_5zzRLWvlGEiR-otWjys62A"
      unitRef="Unit_Standard_item_69ZZVK88n0eAAmS-n_u2jw">3</cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_lUJnAt2aY0aamtuvJ_ZDTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EUR thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;recognized&#160;on&#160;acquisition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,592&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible asset (Technology)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 966&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,558&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 134&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities (net of deferred tax assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 406&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts Payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 540&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_ZV8XFX30gE2zx-8KHvOqwQ_2_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6592000</ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_FscUwDYRWUiapOTTr6jLQg_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">206000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <cvac:RightOfUseAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_5ySFNnJMuUSlwGAwkHKL-g_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">170000</cvac:RightOfUseAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_ctLPmAPk9UC2Z_IMchS5hw_5_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6216000</ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_tyRSZr-FH0mUeHGGkavK3w_6_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">966000</ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:FairValueOfAcquiredReceivables
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_d8mKHYW_U0SUm6j4cI4WwA_7_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">658000</ifrs-full:FairValueOfAcquiredReceivables>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_5ReQH2ch1EmZm1dyEpPFrQ_8_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">308000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <cvac:TotalAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_dhbfXmt5MESJJZQzRLuMSA_9_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7558000</cvac:TotalAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_pDOBroCb0EmGyMOHSkwOiQ_10_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">134000</ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_c9Qt3N_QQUKgLJOQnBoptQ_11_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">114000</cvac:NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_clcjuMqwHE-YfIM8b7Ro_Q_12_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">20000</cvac:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_5p0ta-cnWkOPqhs-FKF6Lg_13_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">406000</ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_JtZfU3GvrkKwAXDwr9UtAA_14_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">55000</cvac:CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_zvjmJ0Rmm0uNscUaFZ-aFw_15_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">346000</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <cvac:OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_QJ2wUXdMv0ivVdHA9GJBlQ_16_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">5000</cvac:OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:LiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_Anh3NQPTBk2LQfCI314T-w_17_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">540000</cvac:LiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_uEPYEXBd-E6fCYYN3YPOEw_18_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7018000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <cvac:ProvisionalFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ"
      decimals="-3"
      id="Narr_BRXyGN0sL0C6vD_O6NKf_Q"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">6216000</cvac:ProvisionalFairValue>
    <cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_YcHTLay7Q0e9Nx5VuGYKkQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,018)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Goodwill&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_OHl-7PvemU6b3WgMDvrINA_2_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">19481000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc_0jnWuxKx6EGJRjxeqkiRTw_3_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">7018000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="As_Of_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_kAcakkz4fEKMKiQ81IpJ9A"
      decimals="-3"
      id="Tc__E5QqePD6EyinQqB-hdTSw_4_2"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">-12463000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_GFRm5SGHZ0iNt2Wr4sHsEQ"
      decimals="-3"
      id="Narr_4iNtlskymUGO_wSfO9VN7A"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">500000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_1_1_2023_To_12_31_2023_69YswTjJbUiqKrjjv_Hqpw"
      id="Tb_gnt0-eXtRk-DvEqev9br2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;21. Subsequent events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2024, positive interim data from the ongoing Phase 2 clinical program assessing monovalent and bivalent modified vaccine candidates against COVID-19 in comparison with a licensed bivalent mRNA-based comparator vaccine were published. The tested vaccine candidates are being developed in collaboration with GSK. Results from the interim analysis showed that both vaccine candidates using CureVac&#x2019;s proprietary second-generation mRNA backbone produced meaningful immune responses and favorable tolerability profiles across all tested doses, including the lowest tested dose. All three tested dose levels were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2024, the beneficiaries of the Prior VSOP plan declared their intent to exercise their exercisable shares. The shares became exercisable on the third anniversary after IPO (August 14, 2023), because certain minimum trading volumes of the CureVac N.V. shares and liquidity levels had been reached. 786,746 virtual shares were exercised by March 22, 2024 and CureVac received 786,746 shares from the Prior VSOP holders on that day. On March 26, 2024, CureVac transferred 786,746 shares to the exercising beneficiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2024, the Company started a voluntary leaver program intended to align the workforce to the Company&#x2019;s business scope and priorities. The business goal is to reduce 150 positions by year-end, including natural attrition. Unnecessary residual pandemic infrastructure is being adapted to significantly increase efficiency and performance while maintaining a strong focus on innovation and R&amp;amp;D activities. For this program we anticipate costs in a range between EUR 2 and 3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2024, promising interim data from the ongoing Phase 2 part of the combined Phase 1/2 study of a seasonal influenza vaccine candidate were reported. The multivalent candidate was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains. Results from the planned interim analysis showed that the multivalent vaccine candidate boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose. The vaccine candidate was shown to have an acceptable safety and tolerability profile, with the majority of solicited adverse events reported as either grade 1 (mild) or grade 2 (moderate) within seven days of dosing. Among younger and older adults, geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across all tested dose levels. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across both age groups and tested dose levels. Targeted optimizations to further improve immune responses against influenza B strains will be assessed in an additional Phase 2 study.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2024, the Company entered into a co-development and licensing agreement with The University of Texas MD Anderson Cancer Center for the development of novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac&#x2019;s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson&#x2019;s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need. Both parties will contribute to the identification of differentiated cancer antigens based on whole genome sequencing, combined with long- and short-read RNA sequencing and cutting-edge bioinformatics followed by joint preclinical validation of the highest-quality cancer antigens and selection of the most promising clinical-lead candidates for conducting initial Phase 1/2 studies in appropriate clinical indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2022, Curevac and GSK entered into a Pandemic Preparedness Agreement with the Federal Republic of Germany. Timelines related to the Pandemic Preparedness Agreement were ambitious with the aim of providing acute pandemic preparedness in Germany in the context of emerging COVID-19 variants. In 2023, CureVac identified a risk that necessary regulatory approvals needed to meet these timelines may not be achieved within the contractually agreed timeframe. After consultation with ZEPAI, CureVac applied for a timeline extension as foreseen under the agreement to avoid procurement of further substantial amounts of raw material at risk. As of December 31, 2023, it was considered unlikely that the extension would be granted. Additionally, a rapidly changing epidemiological environment did no longer prompt an acute pandemic threat. Accordingly, inventories which had been stockpiled as required by the PPA, were written down to their net realizable value. Ultimately, the extension was not granted, whereupon CureVac and GSK jointly decided to terminate the agreement. Despite the termination, CureVac&#x2019;s GMP IV manufacturing plant for the large-scale production of mRNA-based vaccines will be completed. Contingent upon regulatory approval, the facility is expected to be certified mid-2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2024, the Company announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate developed in collaboration with GSK. The H5N1 avian influenza virus is considered a potential future pandemic threat, able to cross species from its original bird host to humans. The monovalent vaccine candidate is based on CureVac&#x2019;s proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen. Avian influenza represents latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2024, the Company had the first ruling in one of its CMO arbitration. In August 2022, Rentschler Biopharma SE initiated arbitration proceedings according to the procedural rules of the German Arbitration Institute against the Company. Rentschler&#x2019;s claims are based on the assumption that certain agreements between Rentschler and CureVac Manufacturing GmbH (then: CureVac Real Estate GmbH) have been terminated due to the withdrawal of the EMA dossier for CVnCoV or alternatively that CureVac would have been obliged to terminate these agreements. CureVac&#x2019;s position always was that the agreements had ended upon expiration of their term. We did not believe that there was a legal basis for Rentschler&#x2019;s claims and therefore defended ourselves against these claims in written submissions and the oral hearing in October 2023. In its final award rendered, the arbitration tribunal followed CureVac&#x2019;s arguments and dismissed Rentschler&#x2019;s claims in their entirety. The totality of Rentschler Biopharma SE related provision was reversed as of December 31, 2023.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions
      contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw"
      decimals="INF"
      id="Narr_7BR5f491zkm7yjFb9roCow"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">786746</cvac:IfrsNumberOfSharesIssuedForExerciseOfStockOptions>
    <cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_3_22_2024_To_3_22_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_3EwqtfY6V0WBSYsjgoDgbw"
      decimals="INF"
      id="Narr_8rzB9Zr0pEytPy0ZICOGBg"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">786746</cvac:IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity
      contextRef="Duration_3_26_2024_To_3_26_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_rczlzRLESEmjal2oPh8nsg"
      decimals="INF"
      id="Narr_1jcJ-T8F_kCOd9AY9GHGYw"
      unitRef="Unit_Standard_shares_sO26qQcUZUiPu1n-149jEA">786746</cvac:DecreaseInNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity>
    <ifrs-full:DistributionCosts
      contextRef="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_N9GQJX-VN0-QtPUbM25Rww"
      decimals="-6"
      id="Narr_U95KUzJTZU-q4h_XWwwcqA"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">2000000</ifrs-full:DistributionCosts>
    <ifrs-full:DistributionCosts
      contextRef="Duration_3_1_2024_To_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_VirtualShareOptionPlanMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_47DGLZoJlUGG58WY5poswg"
      decimals="-6"
      id="Narr_lfSyw8acX0eoliCOzU7ISw"
      unitRef="Unit_Standard_EUR_XzW_k3dG_0yHUtdnjvQ5Zg">3000000</ifrs-full:DistributionCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
